FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Lai, JP
   Wang, FS
   Hung, CM
   Wang, CJ
   Huang, CJ
   Kuo, YR
AF Lai, Jui Pin
   Wang, Feng Sheng
   Hung, Chun Min
   Wang, Ching Jen
   Huang, Chun Jen
   Kuo, Yur Ren
TI Extracorporeal Shock Wave Accelerates Consolidation in Distraction
   Osteogenesis of the Rat Mandible
SO JOURNAL OF TRAUMA INJURY INFECTION AND CRITICAL CARE
LA English
DT Article
DE Shock wave; Osteogenesis; Mandibular distraction; Bone regeneration
ID BONE REGENERATION; SEGMENTAL DEFECT; EXPRESSION; MODEL;
   MECHANOTRANSDUCTION; THERAPY; RABBITS; CELLS; VEGF
AB Background: One of major limitations of applying distraction osteogenesis for craniofacial skeleton hypoplasia is the long duration for bony consolidation. This study investigated whether extracorporeal shock wave therapy (ESWT) could accelerate bony consolidation in distraction osteogenesis of the rat mandible.
   Methods and Materials: An L shape osteotomy was performed unilaterally in the hemimandible of Sprague Dawley rats. An internal distracter was employed to create a 7 mm distraction gap in the mandible. One hundred twenty rats were divided into three groups. The distraction zone of the mandible was received no treatment as controls (group I). Group II received ESWT (500 impulses at 14 kV) at 2 weeks postoperatively. Group III treated with 500 ESW impulses at 21 kV at 2 weeks postoperatively.
   Results: Dual energy X ray absorptiometry and material testing showed that optimal dosage of ESWT in group II significantly increased mineral density and enhanced biomechanical strength of the bone tissue. In histomorphological analysis, the mandibular tissue in group II showed intense osteoblastic cell recruitment, new bone formation, and vascularization. The osteoblasts in the distracted zone in group II indicated significantly strong immunoreactivities for proliferating cell nuclear antigen, vascular endothelial growth factor, and bone morphogenetic protein 2, when compared with other groups.
   Conclusion: Optimal dosage of ESWT was beneficial for accelerating facial skeleton consolidation and bone regeneration in the distracted rat mandible tissue. The mechanism was presumably associated with the up regulation of neovascularization, cell proliferation, and osteogenic growth factor expression in bone microenvironment.
C1 [Lai, Jui Pin; Hung, Chun Min; Kuo, Yur Ren] Chang Gung Univ Coll Med, Kaohsiung Med Ctr, Chang Gung Mem Hosp, Dept Plast & Reconstruct Surg, Kaohsiung 83305, Taiwan.
   [Wang, Feng Sheng; Hung, Chun Min; Kuo, Yur Ren] Chang Gung Univ Coll Med, Kaohsiung Med Ctr, Chang Gung Mem Hosp, Dept Med Res, Kaohsiung 83305, Taiwan.
   [Wang, Ching Jen] Chang Gung Univ Coll Med, Kaohsiung Med Ctr, Chang Gung Mem Hosp, Dept Orthoped, Kaohsiung 83305, Taiwan.
   [Huang, Chun Jen] Chang Gung Univ Coll Med, Kaohsiung Med Ctr, Chang Gung Mem Hosp, Dept Clin Pathol, Kaohsiung 83305, Taiwan.
C3 Chang Gung Memorial Hospital; Chang Gung University; Chang Gung Memorial
   Hospital; Chang Gung University; Chang Gung University; Chang Gung
   Memorial Hospital; Chang Gung Memorial Hospital; Chang Gung University
RP Kuo, YR (通讯作者)，Chang Gung Univ Coll Med, Kaohsiung Med Ctr, Chang Gung Mem Hosp, Dept Plast & Reconstruct Surg, 123 Ta Pei Rd, Kaohsiung 83305, Taiwan.
EM t1207816@ms22.hinet.net
RI Hung, Chun Min/G 3849 2010
CR Ashinoff RL, 2004, ANN PLAS SURG, V52, P585, DOI 10.1097/01.sap.0000123023.28874.1e
   Birnbaum K, 2002, ARCH ORTHOP TRAUM SU, V122, P324, DOI 10.1007/s00402 001 0365 4
   Chen YJ, 2004, J ORTHOP RES, V22, P526, DOI 10.1016/j.orthres.2003.10.005
   Cho BC, 2002, J CRANIOFAC SURG, V13, P465, DOI 10.1097/00001665 200205000 00019
   Eckardt H, 2003, J ORTHOP RES, V21, P335, DOI 10.1016/S0736 0266(02)00159 6
   HIZAROV GA, 1998, BASIC LIFE SCI, V48, P323
   HIZAROV GA, 1989, CLIN ORTHOP RELAT R, V238, P263
   HIZAROV GA, 1989, CLIN ORTHOP RELAT R, V238, P249
   Ikeda K, 1999, J TRAUMA, V47, P946, DOI 10.1097/00005373 199911000 00024
   KARAHARJU EO, 1993, CLIN ORTHOP RELAT R, P38
   KARAHARJUSUVANTO T, 1990, J CRANIO MAXILL SURG, V18, P280, DOI 10.1016/S1010 5182(05)80431 7
   KARP NS, 1992, ANN PLAS SURG, V29, P2, DOI 10.1097/00000637 199207000 00002
   Li G, 2002, J ORTHOP RES, V20, P779, DOI 10.1016/S0736 0266(01)00166 8
   Li G., 2004, Current Opinion in Orthopaedics, V15, P325, DOI [10.1097/01.bco.0000134434.61307.4e, DOI 10.1097/01.BCO.0000134434.61307.4E]
   Maier M, 2003, CLIN ORTHOP RELAT R, P237, DOI 10.1097/01.blo.0000030173.56585.8f
   Martini L, 2006, J TRAUMA, V61, P1198, DOI 10.1097/01.ta.0000203575.96896.34
   McCarthy JG, 2002, PLAST RECONSTR SURG, V110, P1704, DOI 10.1097/00006534 200212000 00013
   McCarthy JG, 2001, PLAST RECONSTR SURG, V107, P1812, DOI 10.1097/00006534 200106000 00029
   MCCARTHY JG, 1992, PLAST RECONSTR SURG, V89, P1, DOI 10.1097/00006534 199289010 00001
   MEHRAR BJ, 1990, PLASTIC SURG, V1, P668
   Narasaki Kazuto, 2003, J Orthop Sci, V8, P474, DOI 10.1007/s00776 003 0664 4
   Raschke MJ, 1999, BONE, V24, P81, DOI 10.1016/S8756 3282(98)00158 6
   Rauch F, 2000, BONE, V26, P619, DOI 10.1016/S8756 3282(00)00283 0
   Rhee ST, 2005, ANN PLAS SURG, V55, P207, DOI 10.1097/01.sap.0000164576.10754.aa
   Richards M, 1998, CLIN ORTHOP RELAT R, pS191
   Rompe JD, 2001, CLIN ORTHOP RELAT R, P102, DOI 10.1097/00003086 200106000 00014
   Seebach C, 2004, J ORTHOP RES, V22, P472, DOI 10.1016/j.orthers.2003.08.018
   Sen C, 2006, INT ORTHOP, V30, P272, DOI 10.1007/s00264 005 0048 9
   Shimazaki A, 2000, J BONE JOINT SURG BR, V82B, P1077, DOI 10.1302/0301 620X.82B7.9948
   Tong L, 2003, PLAST RECONSTR SURG, V111, P211, DOI 10.1097/01.PRS.0000033180.01581.9A
   Trebinjac Suad, 2005, Bosn J Basic Med Sci, V5, P27
   Wang CJ, 2008, ARCH ORTHOP TRAUM SU, V128, P879, DOI 10.1007/s00402 008 0663 1
   Wang FS, 2003, BONE, V32, P387, DOI 10.1016/S8756 3282(03)00029 2
   Williams BE, 2005, ARCH ORAL BIOL, V50, P497, DOI 10.1016/j.archoralbio.2004.10.008
NR 34
TC 32
Z9 33
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0022 5282
EI 1529 8809
J9 J TRAUMA
JI J. Trauma Injury Infect. Crit. Care
PD NOV
PY 2010
VL 69
IS 5
BP 1252
EP 1258
DI 10.1097/TA.0b013e3181cbc7ac
PG 7
WC Critical Care Medicine; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine; Surgery
GA 678VK
UT WOS:000284110100056
PM 20404761
DA 2025 08 17
ER

PT J
AU Gasser, JA
   Ingold, P
   Venturiere, A
   Shen, V
   Green, JR
AF Gasser, Jurg A.
   Ingold, Peter
   Venturiere, Andrea
   Shen, Victor
   Green, Jonathan R.
TI Long term protective effects of zoledronic acid on cancellous and
   cortical bone in the ovariectomized rat
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE osteoporosis; bone loss; bisphosphonate; single dose; zoledronic acid
ID 3 AND 5 YEAR TREATMENT; PAGETS DISEASE; POSTMENOPAUSAL OSTEOPOROSIS;
   INTRAVENOUS ALENDRONATE; MECHANICAL STRENGTH; MEVALONATE PATHWAY; ILIAC
   CREST; IN VITRO; BISPHOSPHONATES; MINERALIZATION
AB Current bisphosphonate therapies effectively prevent bone loss in postmenopausal women. We studied the effect of a single intravenous dose of ZOL in ovariectomized rats. Protection from bone loss was dose dependent, lasting for up to 32 weeks, supporting the rationale for an annual intravenous dosing regimen of ZOL for treatment of postmenopausal osteoporosis.
   Introduction: Once yearly dosing with zoledronic acid (ZOL) 5 mg can increase BMD and reduce fracture rate in postmenopausal women with low BMD. The primary objective of this study was to determine the duration of bone protective effects of a single dose of ZOL in ovariectomized rats, an animal model of postmenopausal osteopenia. Secondary objectives were to determine the effects on bone turnover and mechanical properties.
   Materials and Methods: Female Wistar rats (10 per group) received single intravenous doses of ZOL 0.8, 4, 20, 100, or 500 mu g/kg, alendronate 200 mu g/kg, or isotonic saline 4 days before bilateral ovariectomy. Sham operated controls were pretreated with saline. Mass and density of cancellous and cortical bone (pQCT) were measured at 4 wk intervals for 32 wk. Bone architecture (mu CT), bone formation dynamics (fluorochrome label based histomorphometry), and biomechanical strength in compression testing were also assessed at 32 wk.
   Results: Ovariectomy associated BMD loss was significantly attenuated for 32 wk by ZOL >= 4 mu g/kg for total BMD, ZOL >= 20 mu g/kg for cortical BMD, and ZOL >= 4 mu g/kg for cancellous BMD (p < 0.01 versus ovariectomized controls). Alendronate 200 mu g/kg was of equivalent potency to ZOL 20 mu g/kg. Ovariectomy associated decreases in trabecular architectural parameters were dose dependently attenuated by ZOL. Alendronate 200 mu g/kg was equivalent to ZOL 20 mu g/kg. The bone resorption marker TRACP56 indicated transient suppression of elevated osteoclast activity by ZOL relative to OVX rats even at the lowest dose of 0.8 mu g/kg, whereas at 100 500 mu g/kg, the effect was significant relative to the OVX control for the entire duration of the study of 32 wk. Bone formation parameters were not significantly affected by ZOL 20 mu g/kg but were significantly reduced by ZOL 100 500 mu g/kg. Alendronate 200 mu g/kg was equivalent to ZOL 100 mu g/kg. ZOL produced dose related improvements in bone strength parameters after ovariectomy. Alendronate 200 mu g/kg was of similar potency to ZOL 20 mu g/kg.
   Conclusions: The duration and magnitude of the bone protecting effect of a single intravenous dose of ZOL in ovariectomized rats is dose dependent and lasts for up to 32 wk. Compared with alendronate, ZOL shows 10 fold higher potency in preventing bone loss. These data support the use of an annual intravenous ZOL dosing regimen for the treatment of osteoporosis.
C1 [Gasser, Jurg A.; Ingold, Peter; Venturiere, Andrea; Green, Jonathan R.] Novartis Inst Biomed Res, CH 4002 Basel, Switzerland.
   [Shen, Victor] Skele Tech, Seattle, WA USA.
C3 Novartis
RP Gasser, JA (通讯作者)，Novartis Inst Biomed Res, WKL 125 10 15, CH 4002 Basel, Switzerland.
EM juerg.gasser@novartis.com
RI Gasser, Juerg/AAT 5389 2020; Gasser, Jurg A./AAT 5389 2020
OI Gasser, Jurg A./0000 0002 0106 364X
CR Adami S, 2002, CLIN EXP RHEUMATOL, V20, P55
   AMIN D, 1992, J LIPID RES, V33, P1657
   Binkley N, 1998, J BONE MINER RES, V13, P1775, DOI 10.1359/jbmr.1998.13.11.1775
   Black DM, 2007, NEW ENGL J MED, V356, P1809, DOI 10.1056/NEJMoa067312
   Boivin GY, 2000, BONE, V27, P687, DOI 10.1016/S8756 3282(00)00376 8
   Burr DB, 2003, BONE, V33, P960, DOI 10.1016/j.bone.2003.08.004
   CASEY PJ, 1995, SCIENCE, V268, P221, DOI 10.1126/science.7716512
   Durchschlag E, 2006, J BONE MINER RES, V21, P1581, DOI 10.1359/JBMR.060701
   Fisher JE, 1999, P NATL ACAD SCI USA, V96, P133, DOI 10.1073/pnas.96.1.133
   Gasser J.A., 1995, BONE S, V17, P145
   Gasser JA, 2005, J BONE MINER METAB, V23, P90, DOI 10.1007/BF03026331
   Glatt M, 2004, OSTEOPOROSIS INT, V15, P707, DOI 10.1007/s00198 004 1588 3
   GREEN JR, 1994, J BONE MINER RES, V9, P745
   Hornby SB, 2003, CALCIFIED TISSUE INT, V72, P519, DOI 10.1007/s00223 002 2015 4
   Hosking D, 2007, J BONE MINER RES, V22, P142, DOI 10.1359/JBMR.061001
   HUGHES DE, 1995, J BONE MINER RES, V10, P1478
   HUGHES DE, 1989, J CLIN INVEST, V83, P1930, DOI 10.1172/JCI114100
   LOWIK CWGM, 1988, J BONE MINER RES, V3, P185
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Luckman SP, 1998, J BONE MINER RES, V13, P1668, DOI 10.1359/jbmr.1998.13.11.1668
   ODOHERTY DP, 1995, J BONE MINER RES, V10, P1094
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Rogers MJ, 2004, CALCIFIED TISSUE INT, V75, P451, DOI 10.1007/s00223 004 0024 1
   Roschger P, 2001, BONE, V29, P185, DOI 10.1016/S8756 3282(01)00485 9
   SATO M, 1991, J CLIN INVEST, V88, P2095, DOI 10.1172/JCI115539
   Selander KS, 1996, MOL PHARMACOL, V50, P1127
   Thomsen JS, 1999, BONE, V25, P561, DOI 10.1016/S8756 3282(99)00212 4
   TURNER CH, 1993, BONE, V14, P595, DOI 10.1016/8756 3282(93)90081 K
   Vasikaran SD, 1995, BONE, V17, P517, DOI 10.1016/8756 3282(95)00400 9
   ZIMOLO Z, 1995, J CLIN INVEST, V96, P2277, DOI 10.1172/JCI118283
   Zoehrer R, 2006, J BONE MINER RES, V21, P1106, DOI 10.1359/JBMR.060401
NR 31
TC 85
Z9 101
U1 0
U2 4
PU AMER SOC BONE & MINERAL RES
PI WASHINGTON
PA 2025 M ST, N W, STE 800, WASHINGTON, DC 20036 3309 USA
SN 0884 0431
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD APR
PY 2008
VL 23
IS 4
BP 544
EP 551
DI 10.1359/JBMR.071207
PG 8
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 282TL
UT WOS:000254590000011
PM 18072878
OA Bronze
DA 2025 08 17
ER

PT J
AU Liang, J
   Bao, AL
   Ma, HY
   Dong, W
   Li, WH
   Wu, X
   Li, HY
   Hou, HY
   Chen, YQ
   Fu, JL
   Shao, C
AF Liang, Jing
   Bao, Ai li
   Ma, Hong yu
   Dong, Wei
   Li, Wei hua
   Wu, Xi
   Li, Han yu
   Hou, Hai yan
   Chen, Ya qiong
   Fu, Jia lin
   Shao, Chao
TI Prevention of polycystic ovary syndrome and postmenopausal osteoporosis
   by inhibiting apoptosis with Shenling Baizhu powder compound
SO PEERJ
LA English
DT Article
DE Shenling Baizhu powder compound; Aromatic hydrocarbon receptor (AHR);
   Polycystic ovary syndrome (POCS); Postmenopausal osteoporosis (PMO);
   Cell apoptosis
ID IN VITRO; RECEPTOR; ACTIVATION; ETIOLOGY
AB Objective. Shenling Baizhu powder (SBP) has been shown to reverse the abnormal expression of the aromatic hydrocarbon receptor (AHR) mediated by air pollution. Our study aimed to understand the main ingredient of SBP and investigate its action mechanism in preventing polycystic ovary syndrome (POCS) and postmenopausal osteoporosis (PMO). Methods. The active ingredients of SBP with the highest binding affinity to AHR were screened using a Chinese medicine database, and their binding mechanism was simulated using molecular dynamics simulation (MDS). Rutin was utilized to treat ovarian granulosa cell lines and osteoblast cell lines. The cell lines were treated with a gradient of rutin concentration (0.01 mmol/L, 0.05 mmol/L and 0.1 mmol/L) to find the optimal drug dose. PCR was used to detect AHR and apoptosis related proteins, and WB to detect the expression of AHR, caspase 3 and cleaved caspase 3. Finally, the CCK 8 cell proliferation assay detected the proliferation of cells. Results. We obtained Rutin through the Chinese medicine database, and dynamics simulation determined its binding sites. Ovarian granulosa cell lines and osteoblast cell lines were treated with Rutin. RT PCR and western blotting revealed that the expression of apoptosis associated protein Bcl 2 was elevated, and the expression of AHR, Bax, caspase 3 and PARP were decreased. CCK 8 results showed accelerated proliferation in both cell types. Conclusion. Rutin, the main ingredient of SBP compound, works by binding to AHR, which can improve POCS and PMO by inhibiting cell apoptosis and by promoting cell proliferation.
C1 [Liang, Jing; Bao, Ai li; Dong, Wei; Li, Wei hua; Wu, Xi; Li, Han yu; Fu, Jia lin; Shao, Chao] China Acad Chinese Med Sci, Guanganmen South Area Hosp, Dept Gynecol, Beijing, Peoples R China.
   [Ma, Hong yu] Hebei Gen Hosp, Dept Tradit Chinese Med, Shijiazhuang, Hebei, Peoples R China.
   [Hou, Hai yan; Chen, Ya qiong] Chinese Peoples Armed Police Force, Dept Obstet & Gynecol, Characterist Med Ctr, Tianjin, Peoples R China.
C3 China Academy of Chinese Medical Sciences
RP Shao, C (通讯作者)，China Acad Chinese Med Sci, Guanganmen South Area Hosp, Dept Gynecol, Beijing, Peoples R China.
EM cso38205714510@163.com
RI li, wei/IUQ 2973 2023; Ma, Hongyu/MTF 0612 2025; dong, wei/KVA 6898 2024
FU National Natural Science Foundation of China [82104921]; Science and
   Technology Innovation Project of the Chinese Academy of Traditional
   Chinese Medicine (The CACMS Fund) [CI2021A02405]; Project of Guanganmen
   Hospital, China Academy of Traditional Chinese Medicine [Y2019 14];
   Project of Hebei Administration of Traditional Chinese Medicine
   [2018077]
FX This work was supported by the National Natural Science Foundation of
   China (Grant number 82104921) , the Science and Technology Innovation
   Project of the Chinese Academy of Traditional Chinese Medicine (The
   CACMS Fund, Grant number CI2021A02405) , the Project of Guanganmen
   Hospital, China Academy of Traditional Chinese Medicine: Y2019 14, and
   the Project of Hebei Administration of Traditional Chinese Medicine:
   2018077. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR [Anonymous], 2020, ACOG PRACTICE B, V136, P638, DOI [10.1097/AOG.0000000000004069, DOI 10.1097/AOG.0000000000004069]
   Arceo Mendoza R, 2021, ENDOCRIN METAB CLIN, V50, P167, DOI 10.1016/j.ecl.2021.03.009
   Banjabi AA, 2022, ENVIRON SCI POLLUT R, V29, P6943, DOI 10.1007/s11356 021 16186 2
   Chen YS, 2022, DIS MARKERS, V2022, DOI 10.1155/2022/9082576
   Collier TA, 2020, METHODS MOL BIOL, V2073, P311, DOI 10.1007/978 1 4939 9869 2_17
   Esser C, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113603
   Feng Z, 2020, EVID BASED COMPL ALT, V2020, DOI 10.1155/2020/4121483
   Gao K, 2021, LIFE RES, V4, P17, DOI [10.53388/life2021 0401 0401, DOI 10.53388/LIFE2021 0401 0401]
   Goodarzi MO, 2011, NAT REV ENDOCRINOL, V7, P219, DOI 10.1038/nrendo.2010.217
   Hildebrand PW, 2019, TRENDS BIOCHEM SCI, V44, P902, DOI 10.1016/j.tibs.2019.06.004
   Hu T, 2017, J NUTR BIOCHEM, V47, P21, DOI 10.1016/j.jnutbio.2017.04.012
   Huo MX, 2022, MOLECULES, V27, DOI 10.3390/molecules27072293
   Jahan S, 2016, J OVARIAN RES, V9, DOI 10.1186/s13048 016 0295 y
   Johnston CB, 2020, MED CLIN N AM, V104, P873, DOI 10.1016/j.mcna.2020.06.004
   Kang XR, 2022, FRONT AGING NEUROSCI, V14, DOI 10.3389/fnagi.2022.880794
   Lane NE, 2006, AM J OBSTET GYNECOL, V194, pS3, DOI 10.1016/j.ajog.2005.08.047
   Li J, 2018, HUM REPROD, V33, P617, DOI 10.1093/humrep/dey027
   Lin SY, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16234816
   Lins TLBG, 2021, THERIOGENOLOGY, V173, P64, DOI 10.1016/j.theriogenology.2021.07.018
   Liu C, 2020, MEDIAT INFLAMM, V2020, DOI 10.1155/2020/5918587
   Liu XW, 2021, EUR J HISTOCHEM, V65, DOI 10.4081/ejh.2021.3195
   Liu XW, 2018, EXPERT OPIN DRUG DIS, V13, P23, DOI 10.1080/17460441.2018.1403419
   Lu LX, 2022, DIS MARKERS, V2022, DOI 10.1155/2022/4416637
   Ma YY, 2017, BBA MOL BASIS DIS, V1863, P1904, DOI 10.1016/j.bbadis.2016.12.021
   Ma YM, 2022, DIS MARKERS, V2022, DOI 10.1155/2022/3843954
   Mahendra VP, 2020, MOL BIOL REP, V47, P2811, DOI 10.1007/s11033 020 05393 8
   Mazerska Z, 2016, PHARMACOL THERAPEUT, V159, P35, DOI 10.1016/j.pharmthera.2016.01.009
   Merlo E, 2019, TOXICOL LETT, V312, P45, DOI 10.1016/j.toxlet.2019.05.006
   Moran C, 2019, CURR NEUROL NEUROSCI, V19, DOI 10.1007/s11910 019 0973 4
   Naruse M, 2002, ENDOCRINOLOGY, V143, P3575, DOI 10.1210/en.2002 220003
   Ong CP, 2021, LIFE RES, V4, P6, DOI [10.53388/life2021 0121 601, DOI 10.53388/LIFE2021 0121 601]
   Pan MX, 2021, J INTEGR MED JIM, V19, P428, DOI 10.1016/j.joim.2021.07.004
   Paquet E, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/183918
   Qu SQ, 2019, PHYTOTHER RES, V33, P2056, DOI 10.1002/ptr.6391
   Rio D.C., 2010, COLD SPRING HARBOR P, V6, DOI [10.1101/pdb.prot5439, DOI 10.1101/PDB.PROT5439]
   Rutkowska AZ, 2016, FERTIL STERIL, V106, P948, DOI 10.1016/j.fertnstert.2016.08.031
   Schraufnagel DE, 2019, CHEST, V155, P409, DOI 10.1016/j.chest.2018.10.042
   Tang KR, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/9701285
   Tao PY, 2022, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.825330
   Vandenberg LN, 2009, ENDOCR REV, V30, P75, DOI 10.1210/er.2008 0021
   Vogel CFA, 2020, REDOX BIOL, V34, DOI 10.1016/j.redox.2020.101530
   Vogel CFA, 2019, CHEMOSPHERE, V220, P993, DOI 10.1016/j.chemosphere.2018.12.178
   Wang SB, 2020, J ETHNOPHARMACOL, V257, DOI 10.1016/j.jep.2020.112887
   Wang XY, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.642685
   Weng WD, 2022, GENES BASEL, V13, DOI 10.3390/genes13050806
   Wu WD, 2018, J ALLERGY CLIN IMMUN, V141, P833, DOI 10.1016/j.jaci.2017.12.981
   Xi SY, 2016, J ETHNOPHARMACOL, V190, P1, DOI 10.1016/j.jep.2016.05.055
   Xuan ZD, 2022, FRONT NEUROL, V13, DOI 10.3389/fneur.2022.889106
   Yan DY, 2022, NUCLEIC ACIDS RES, V50, pD1238, DOI 10.1093/nar/gkab1011
   Yang QY, 2015, HUM REPROD, V30, P1964, DOI 10.1093/humrep/dev123
   Yang YT, 2018, LIFE SCI, V209, P409, DOI 10.1016/j.lfs.2018.08.014
   Ye H, 2011, NUCLEIC ACIDS RES, V39, pD1055, DOI 10.1093/nar/gkq1165
   Zhang D, 2022, PHYTOMEDICINE, V104, DOI 10.1016/j.phymed.2022.154205
   Zhang Q, 2022, FRONT NEUROL, V13, DOI 10.3389/fneur.2022.833922
   Zhang YP, 2018, BIOMED PHARMACOTHER, V102, P1025, DOI 10.1016/j.biopha.2018.03.158
NR 55
TC 4
Z9 7
U1 0
U2 15
PU PEERJ INC
PI LONDON
PA 341 345 OLD ST, THIRD FLR, LONDON, EC1V 9LL, ENGLAND
SN 2167 8359
J9 PEERJ
JI PeerJ
PD OCT 28
PY 2022
VL 10
AR 13939
DI 10.7717/peerj.13939
PG 17
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 5Z6OA
UT WOS:000880089200004
PM 36325179
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Dias, MD
   Menezes, GPR
   Tavares, FOM
   Leite, KLD
   Tenorio, JD
   Esteves, JC
   Prado, R
   Maia, LC
AF Dias, Millene de Oliveira
   Menezes, Gabriel Pereira Ribeiro
   Tavares, Fernanda Oliveira Miranda
   Leite, Karla Lorene de Franca
   Tenorio, Jefferson da Rocha
   Esteves, Jonatas Caldeira
   Prado, Roberto
   Maia, Lucianne Cople
TI Influence of the use of bisphosphonates on the development of
   postextraction sequelae: Scoping review with mapping evidence of
   in vivo studies
SO JOURNAL OF DENTISTRY
LA English
DT Article
DE Osteonecrosis; Bisphosphonates; Tooth extraction; Zoledronic acid;
   Alendronate
ID MEDICATION RELATED OSTEONECROSIS; MECHANISM; JAWS
AB Objective: To map the current scientific landscape regarding the association/causality of medication related osteonecrosis of the jaw (MRONJ) after tooth extraction under bisphosphonate (BF) therapy to identify knowledge gaps and guide future research. Data: This review used the PCC strategy (P = Patient; C = Concept; C = Context). Sources: The MEDLINE/PubMed, Scopus, Web of Science/Clarivate Analytics, and gray literature databases were used. Study selection: Searches were conducted by two independent reviewers until April 2024. Studies involving prior BF use and tooth extraction in humans or animals were included. Among the 176 studies, 73 (41.4 %) were in animals, and 103 (58.5 %) were in humans. Brazil led in animal studies (n = 14; 19.1 %), while Italy led in human studies (n = 14; 13.6 %). Zoledronic acid was the most cited BF (79.4 % in animals; 34.9 % in humans), with intravenous administration being most frequent (38.3 % in animals; 35.9 % in humans). The mandible was the main extraction site (n = 36 in animals; n = 41 in humans). In 91.7 % of the animal studies, sequelae compatible with osteonecrosis signs and symptoms were observed, with bone necrosis being most common (n = 39; 53.4 %). In humans, 93.2 % of studies presented 239 sequelae, with bone necrosis (n = 53; 22.1 %) being the most cited. The main location of sequelae was the mandible (n = 36 in animals; n = 41 in humans). Conclusions: Animal studies highlighted bone exposure, notably using murine models, with a significant Brazilian contribution. In human studies, bone necrosis was the main sequela of MRONJ, which has been reported by researchers in the Italy. Clinical significance: These findings underscore the importance of careful consideration and monitoring of patients who have a history of bisphosphonate use and who are undergoing tooth extraction, highlighting the potential risk of MRONJ.
C1 [Dias, Millene de Oliveira; Menezes, Gabriel Pereira Ribeiro; Tavares, Fernanda Oliveira Miranda; Leite, Karla Lorene de Franca; Maia, Lucianne Cople] Univ Fed Rio de Janeiro, Sch Dent, Dept Pediat Dent & Orthodont, Rodolpho Paulo Rocco St 325, Rio De Janeiro, RJ, Brazil.
   [Tenorio, Jefferson da Rocha] Univ Fed Rio de Janeiro, Sch Dent, Dept Oral Pathol & Diag, Rio De Janeiro, RJ, Brazil.
   [Esteves, Jonatas Caldeira] Univ Estado Rio De Janeiro, Sch Dent, Dept Oral Surg, Rio De Janeiro, RJ, Brazil.
   [Prado, Roberto] Univ Fed Rio de Janeiro, Sch Dent, Dept Oral Surg, Rio De Janeiro, RJ, Brazil.
   [Maia, Lucianne Cople] IQVIA Brazil, Sao Paulo, Brazil.
C3 Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de
   Janeiro; Universidade do Estado do Rio de Janeiro; Universidade Federal
   do Rio de Janeiro
RP Maia, LC (通讯作者)，Univ Fed Rio de Janeiro, Sch Dent, Dept Pediat Dent & Orthodont, Rodolpho Paulo Rocco St 325, Rio De Janeiro, RJ, Brazil.; Maia, LC (通讯作者)，IQVIA Brazil, Sao Paulo, Brazil.
EM rorefa@terra.com.br
RI ; TENORIO, JEFFERSON/NMJ 4477 2025; Menezes, Gabriel/O 5535 2018; leite,
   karla/GPX 3607 2022; Maia, Lucianne/E 9938 2011; Esteves,
   Jonatas/B 8909 2014
OI de Oliveira Dias, Millene/0000 0003 0163 0146; Leite,
   Karla/0000 0002 0113 6810; Maia, Lucianne/0000 0003 1026 9401; Tavares,
   Fernanda/0000 0001 9746 1708; TENORIO, JEFFERSON/0000 0002 6986 9148;
   Menezes, Gabriel/0000 0002 3937 0960; 
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior   Brasil
   (CAPES) [001]; Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro
   (FAPERJ) [E 26/202.037/2021 (267002)]
FX Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior   Brasil
   (CAPES) , Finance Code 001; Fundacao de Amparo a Pesquisa do Estado do
   Rio de Janeiro (FAPERJ) grant numbers [E 26/202.037/2021 (267002) ] .
CR Abughazaleh K, 2011, DM DIS MON, V57, P231, DOI 10.1016/j.disamonth.2011.03.011
   Akashi M, 2018, ORAL MAXILLOFAC SURG, V22, P59, DOI 10.1007/s10006 017 0667 5
   Bornmann L, 2014, EMBO REP, V15, P1228, DOI 10.15252/embr.201439608
   Cremers S, 2019, BRIT J CLIN PHARMACO, V85, P1052, DOI 10.1111/bcp.13867
   Drake MT, 2008, MAYO CLIN PROC, V83, P1032, DOI 10.4065/83.9.1032
   Hampson G, 2012, INT J WOMENS HEALTH, V4, P455, DOI 10.2147/IJWH.S24783
   Ishimaru M, 2022, J ORAL MAXIL SURG, V80, P714, DOI 10.1016/j.joms.2021.12.007
   Jackson C, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0246441
   Khan AA, 2015, J BONE MINER RES, V30, P3, DOI 10.1002/jbmr.2405
   Lombard T, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/8768162
   Otto S, 2018, CANCER TREAT REV, V69, P177, DOI 10.1016/j.ctrv.2018.06.007
   Otto S, 2012, J CRANIO MAXILL SURG, V40, P303, DOI 10.1016/j.jcms.2011.05.003
   Peters MDJ, 2015, INT J EVID BASED HEA, V13, P141, DOI 10.1097/XEB.0000000000000050
   Reszka AA, 2004, MINI REV MED CHEM, V4, P711
   Rodan Gideon A., 2002, Current Molecular Medicine (Hilversum), V2, P571, DOI 10.2174/1566524023362104
   Ruggiero SL, 2022, J ORAL MAXIL SURG, V80, P920, DOI 10.1016/j.joms.2022.02.008
   Rupel K, 2014, ORAL ONCOL, V50, P1049, DOI 10.1016/j.oraloncology.2014.08.016
   Song SS, 2022, PHARMACOL THERAPEUT, V237, DOI 10.1016/j.pharmthera.2022.108168
   Soutome S, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 96480 8
   Tricco AC, 2018, ANN INTERN MED, V169, P467, DOI 10.7326/M18 0850
NR 20
TC 4
Z9 4
U1 2
U2 7
PU ELSEVIER SCI LTD
PI London
PA 125 London Wall, London, ENGLAND
SN 0300 5712
EI 1879 176X
J9 J DENT
JI J. Dent.
PD SEP
PY 2024
VL 148
AR 105051
DI 10.1016/j.jdent.2024.105051
EA JUL 2024
PG 8
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA A9D8E
UT WOS:001285478100001
PM 38763386
DA 2025 08 17
ER

PT J
AU Wang, L
   Huang, MJ
   Liu, B
   Zhang, ZM
   Zheng, XC
   Yan, B
   Chen, TY
   Jin, DD
   Bai, XC
AF Wang, Liang
   Huang, Min jun
   Liu, Bin
   Zhang, Zhong min
   Zheng, Xiao chen
   Yan, Bo
   Chen, Tian yu
   Jin, Da di
   Bai, Xiao chun
TI Could heterotopic ossification be prevented by varying dietary n 3/n 6
   polyunsaturated fatty acid ratio: A novel perspective to its treatment?
SO MEDICAL HYPOTHESES
LA English
DT Article
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; BONE FORMATION; DOCOSAHEXAENOIC
   ACID; COX 2 INHIBITORS; BETA CATENIN; CYCLOOXYGENASE 2; EXPRESSION;
   CELECOXIB; N 3; INDOMETHACIN
AB Heterotopic ossification (HO) is a common complication following with musculoskeletal trauma and surgical procedures. It usually decreases joint mobility and eventually causes loss of joint function. Despite nonsteroidal anti inflammatory drugs (NSAIDs), the inhibitor of cyclooxygenase(COX), have been proven to prevent HO effectively via prostaglandin E2 synthesis regulation and modulation of tissue responsiveness to pro inflammatory signaling, HO prevention is still a matter of debate for clinicians to avoid the side effect of NSAIDs. Interestingly, it is suggested that PGE2 production and pro inflammatory microenvironment in body could be modified by varying the ratio of the precursor fatty acids in the diet. On account of the effect of dietary (n 6)/(n 3) PUFAs ratio on both COX metabolism and pro inflammatory cytokines mediated biological responsiveness, we hypothesized lowering dietary (n 6)/(n 3) PUFAs ratio may not only directly reduce the substrate of COX 2 and COX 2 activity, but also partially ameliorate tissue inflammatory responsiveness to cytokines correlated with HO development, exerting an inhibitory effect on PGE2 synthesis to prevent HO formation. The negative role of lowering dietary (n 6)/(n 3) PUFAs ratio on angiogenesis, cytokines induced apoptosis, inflammatory responsiveness and osteogenesis could also contribute to its action on HO development. If our hypothesis is proved to be corrected, it could be an innovative method to treat HO. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Wang, Liang; Huang, Min jun; Zhang, Zhong min; Zheng, Xiao chen; Yan, Bo; Chen, Tian yu; Jin, Da di; Bai, Xiao chun] So Med Univ, Dept Orthopaed, Affiliated Hosp 3, Guangzhou 510665, Guangdong, Peoples R China.
   [Wang, Liang; Huang, Min jun; Zhang, Zhong min; Zheng, Xiao chen; Yan, Bo; Chen, Tian yu; Jin, Da di; Bai, Xiao chun] So Med Univ, Orthopaed Res Inst, Guangzhou 510665, Guangdong, Peoples R China.
   [Liu, Bin] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Spine Surg, Guangzhou 510630, Guangdong, Peoples R China.
   [Bai, Xiao chun] So Med Univ, Sch Basic Med Sci, Dept Cell Biol, Guangzhou 510515, Guangdong, Peoples R China.
C3 Southern Medical University   China; Southern Medical University  
   China; Sun Yat Sen University; Southern Medical University   China
RP Jin, DD (通讯作者)，So Med Univ, Orthopaed Res Inst, Guangzhou 510665, Guangdong, Peoples R China.
EM jindadi@yahoo.cn; baixc15@smu.edu.cn
RI Wang, Liang/ADN 3248 2022; Yan, Bo/AFQ 7025 2022; Chen,
   Tianyu/AAT 6554 2020
CR Atkinson TG, 1997, LIPIDS, V32, P293, DOI 10.1007/s11745 997 0036 x
   Bedi A, 2012, AM J SPORT MED, V40, P854, DOI 10.1177/0363546511434285
   Board TN, 2007, J BONE JOINT SURG BR, V89B, P434, DOI 10.1302/0301 620X.89B4.18845
   Boudrault C, 2010, NEUROCHEM INT, V56, P585, DOI 10.1016/j.neuint.2009.12.022
   Caplan AI, 2011, J ORTHOP RES, V29, P1795, DOI 10.1002/jor.21462
   Caughey GE, 2010, COMPLEMENT THER MED, V18, P171, DOI 10.1016/j.ctim.2010.05.032
   Cipriano CA, 2009, J AM ACAD ORTHOP SUR, V17, P689, DOI 10.5435/00124635 200911000 00003
   Cullen N, 2009, J HEAD TRAUMA REHAB, V24, P69, DOI 10.1097/HTR.0b013e31819a8fcc
   Dilling CF, 2010, J BONE MINER RES, V25, P1147, DOI 10.1359/jbmr.091031
   Evans KN, 2012, J ORTHOP TRAUMA, V26, pE204, DOI 10.1097/BOT.0b013e31825d60a5
   Fransen M, 2004, Cochrane Database Syst Rev, pCD001160, DOI 10.1002/14651858.CD001160.pub2
   Genêt F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023129
   Gislason GH, 2006, CIRCULATION, V113, P2906, DOI 10.1161/CIRCULATIONAHA.106.616219
   Gravaghi C, 2011, J NUTR BIOCHEM, V22, P360, DOI 10.1016/j.jnutbio.2010.03.003
   Horia E, 2007, CARCINOGENESIS, V28, P809, DOI 10.1093/carcin/bgl183
   Hurst S, 2009, LIPIDS, V44, P889, DOI 10.1007/s11745 009 3347 x
   Kaplan FS, 2004, J AM ACAD ORTHOP SUR, V12, P116, DOI 10.5435/00124635 200403000 00007
   Karunakar MA, 2006, J BONE JOINT SURG BR, V88B, P1613, DOI 10.1302/0301 620X.88B12.18151
   Kirsch T, 2006, CURR OPIN RHEUMATOL, V18, P174, DOI 10.1097/01.bor.0000209431.59226.46
   Kruger MC, 2010, PROG LIPID RES, V49, P438, DOI 10.1016/j.plipres.2010.06.002
   Lim K, 2009, MOL CANCER THER, V8, P3046, DOI 10.1158/1535 7163.MCT 09 0551
   Lin L, 2010, BONE, V46, P425, DOI 10.1016/j.bone.2009.08.057
   Mayorek N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012715
   Mori Trevor A, 2004, Curr Atheroscler Rep, V6, P461, DOI 10.1007/s11883 004 0087 5
   Moyad MA, 2005, UROL ONCOL SEMIN ORI, V23, P28, DOI 10.1016/j.urolonc.2005.01.016
   Narayanan BA, 2004, CARCINOGENESIS, V25, P2443, DOI 10.1093/carcin/bgh252
   Ou YS, 2012, MED SCI MONITOR, V18, pBR247, DOI 10.12659/MSM.882901
   Poulsen RC, 2007, EXP BIOL MED, V232, P1275, DOI 10.3181/0704 MR 100
   Rapuano BE, 2008, ARCH ORTHOP TRAUM SU, V128, P333, DOI 10.1007/s00402 007 0436 2
   Romanò CL, 2004, J ARTHROPLASTY, V19, P14, DOI 10.1016/S0883 5403(03)00279 1
   Salari P, 2008, MED SCI MONITOR, V14, pRA37
   Saudan M, 2007, J BONE JOINT SURG BR, V89B, P155, DOI 10.1302/0301 620X.89B2.17747
   Schurch B, 1997, ARCH PHYS MED REHAB, V78, P687, DOI 10.1016/S0003 9993(97)90074 5
   Simon AM, 2002, J BONE MINER RES, V17, P963, DOI 10.1359/jbmr.2002.17.6.963
   Solomon SD, 2005, NEW ENGL J MED, V352, P1071, DOI 10.1056/NEJMoa050405
   Spencer L, 2009, EUR J CANCER, V45, P2077, DOI 10.1016/j.ejca.2009.04.026
   Vasileiadis GI, 2011, ORTHOPEDICS, V34, P467, DOI 10.3928/01477447 20110427 23
   Watkins BA, 2000, J NUTR, V130, P2274, DOI 10.1093/jn/130.9.2274
   Watkins BA, 1996, J BONE MINER RES, V11, P1321
   Wei D, 2010, DIABETES, V59, P471, DOI 10.2337/db09 0284
   Welting T J M, 2011, Eur Cell Mater, V22, P420
   Wen ZH, ONCOGENE IN PRESS
   Xue DT, 2010, MED HYPOTHESES, V74, P330, DOI 10.1016/j.mehy.2009.08.038
   Xue DT, 2011, INT ORTHOP, V35, P3, DOI 10.1007/s00264 009 0886 y
   Yang SP, 1998, J CELL PHYSIOL, V176, P342, DOI 10.1002/(SICI)1097 4652(199808)176:2<342::AID JCP12>3.0.CO;2 5
   Zhang XP, 2002, J CLIN INVEST, V109, P1405, DOI 10.1172/JCI200215681
NR 46
TC 5
Z9 6
U1 0
U2 8
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1 3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306 9877
EI 1532 2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PD JAN
PY 2013
VL 80
IS 1
BP 57
EP 60
DI 10.1016/j.mehy.2012.10.012
PG 4
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA 071QO
UT WOS:000313609500014
PM 23159103
DA 2025 08 17
ER

PT J
AU Bleskestad, IH
   Bergrem, H
   Hartmann, A
   Godang, K
   Goransson, LG
AF Bleskestad, Inger H.
   Bergrem, Harald
   Hartmann, Anders
   Godang, Kristin
   Goransson, Lasse G.
TI Fibroblast growth factor 23 and parathyroid hormone after treatment with
   active vitamin D and sevelamer carbonate in patients with chronic kidney
   disease stage 3b, a randomized crossover trial
SO BMC NEPHROLOGY
LA English
DT Article
DE Active vitamin D; Chronic kidney disease; Fibroblast growth factor 23;
   FGF23; Phosphate binder; Parathyroid hormone; PTH; Sevelamer carbonate
ID DIALYSIS OUTCOMES; DIETARY PHOSPHATE; PHOSPHORUS; MORTALITY; FGF 23;
   METABOLISM; TARGET; FGF23; PTH
AB Background: Fibroblast growth factor 23 (FGF23) is a phosphaturic hormone that is secreted from bone and serum level increases as renal function declines. Higher levels of FGF23 are associated with increased mortality in hemodialysis patients and in patients with chronic kidney disease (CKD) stage 2 4. The use of active vitamin D and phosphate binders as recommended in international guidelines, may affect the level of FGF23 and thereby clinical outcome. We investigated the effects of a phosphate binder and active vitamin D on the serum levels of intact FGF23 (iFGF23) and intact parathyroid hormone (iPTH) in patients with CKD stage 3b (glomerular filtration rate (GFR) 30 44 ml/min/1.73 m(2)).
   Methods: Seven women and 14 men were included, mean age 65.6 +/  12.2 years. They were randomized in a 1:1 ratio to receive one of two treatment sequences. Group 1 (the alphacalcidol sevelamer carbonate group): alphacalcidol 0.25 mu g once daily for two weeks followed by sevelamer carbonate 800 mg TID with meals for two weeks after a two week washout period. Group 2 (the sevelamer carbonate alphacalcidol group): vice versa. Nineteen patients completed the study. The 25 hydroxyvitamin D level at baseline was 97.6 +/  25.0 nmol/l.
   Results: There were no treatment effects on the iFGF23 and iPTH levels overall. In group 1 the iFGF23 level was higher after treatment with alphacalcidol compared with sevelamer carbonate (mean 105.8 +/  41.6 vs. 79.1 +/  36.5 pg/ml, p = 0.047 (CI: 0.4 52.9), and the iPTH level was lower (median: 26.5, range: 14.6 55.2 vs. median 36.1, range 13.4 106.9 pg/ml, p = 0.011). In group 2 the iFGF23 level increased non significantly after treatment with sevelamer carbonate and throughout the washout period.
   Conclusions: In this crossover trial with alphacalcidol and sevelamer carbonate in patients with CKD stage 3b, the levels of iFGF23 were not significantly different after the two treatments. However, in the group of patients initiating therapy with sevelamer carbonate the iFGF23 levels seemed to increase while this response was mitigated in the group of patients given alphacalcidol followed by sevelamer carbonate. This may have therapeutic implications on choice of first line therapy. The number of patients is small and this conclusion is in part based on subgroup analysis. It is therefore important that these results are confirmed in larger studies.
C1 [Bleskestad, Inger H.; Bergrem, Harald; Goransson, Lasse G.] Stavanger Univ Hosp, Dept Med, Stavanger, Norway.
   [Hartmann, Anders] Univ Oslo, Rikshosp, Nephrol Sect, Oslo Univ Hosp,Dept Med, N 0027 Oslo, Norway.
   [Godang, Kristin] Univ Oslo, Rikshosp, Dept Med, Sect Endocrinol,Oslo Univ Hosp, N 0027 Oslo, Norway.
C3 Stavanger University Hospital; University of Oslo; National Hospital
   Norway; University of Oslo; National Hospital Norway
RP Bleskestad, IH (通讯作者)，Stavanger Univ Hosp, Dept Med, Stavanger, Norway.
EM inger.hjoerdis.bleskestad@sus.no
FU Shire; Pfizer; Novartis; Eli Lilly; Amgen; Roche; Genzyme; Swedish
   Orphan; Abbot
FX IHB has received lecture fees or travel funding from Shire, Pfizer,
   Novartis and Eli Lilly. HB has received travel funding from Amgen and
   Roche. LGG has received lecture fees or travel funding from Genzyme,
   Novartis, Amgen, Swedish Orphan and Abbot.
CR Altman DG, 1999, PRACTICAL STAT MED R, P467
   Antoniucci DM, 2006, J CLIN ENDOCR METAB, V91, P3144, DOI 10.1210/jc.2006 0021
   Berndt T, 2007, P NATL ACAD SCI USA, V104, P11085, DOI 10.1073/pnas.0704446104
   Berndt T, 2009, PHYSIOLOGY, V24, P17, DOI 10.1152/physiol.00034.2008
   Burnett SAM, 2006, J BONE MINER RES, V21, P1187, DOI 10.1359/JBMR.060507
   Dallal G.E., 2008, The little handbook of statistical practice
   Dusso AS, 2011, KIDNEY INT, V79, P715, DOI 10.1038/ki.2010.543
   Evenepoel P, 2010, CLIN J AM SOC NEPHRO, V5, P1268, DOI 10.2215/CJN.08241109
   Ferrari SL, 2005, J CLIN ENDOCR METAB, V90, P1519, DOI 10.1210/jc.2004 1039
   Gonzalez Parra E, 2011, NEPHROL DIAL TRANSPL, V26, P2567, DOI 10.1093/ndt/gfr144
   Gutierrez O, 2005, J AM SOC NEPHROL, V16, P2205, DOI 10.1681/ASN.2005010052
   Gutiérrez OM, 2008, NEW ENGL J MED, V359, P584, DOI 10.1056/NEJMoa0706130
   Isakova T, 2008, J AM SOC NEPHROL, V19, P615, DOI 10.1681/ASN.2007060673
   Isakova T, 2011, JAMA J AM MED ASSOC, V305, P2432, DOI 10.1001/jama.2011.826
   Isakova T, 2011, NEPHROL DIAL TRANSPL, V26, P584, DOI 10.1093/ndt/gfq419
   Ito N, 2007, J BONE MINER METAB, V25, P419, DOI 10.1007/s00774 007 0779 3
   Kidney Disease: Improving Global Outcomes (KDIGO) CKD MBD Work Group, 2009, Kidney Int Suppl, pS1, DOI 10.1038/ki.2009.188
   Komaba H, 2010, KIDNEY INT, V77, P232, DOI 10.1038/ki.2009.414
   Kuro o M, 2010, PEDIATR NEPHROL, V25, P583, DOI 10.1007/s00467 009 1260 4
   Levey AS, 1999, ANN INTERN MED, V130, P461, DOI 10.7326/0003 4819 130 6 199903160 00002
   Nishi H, 2005, NEPHRON CLIN PRACT, V101, pC94, DOI 10.1159/000086347
   Nishida Y, 2006, KIDNEY INT, V70, P2141, DOI 10.1038/sj.ki.5002000
   Oliveira RB, 2010, CLIN J AM SOC NEPHRO, V5, P286, DOI 10.2215/CJN.05420709
   Savica Vincenzo, 2008, Nutr Metab Cardiovasc Dis, V18, pe39, DOI 10.1016/j.numecd.2008.03.003
   Senn S, 2002, CROSS OVER TRIALS CL, P42
   Shimada T, 2004, J BONE MINER RES, V19, P429, DOI 10.1359/JBMR.0301264
   Slatopolsky E, 2011, KIDNEY INT, V79, pS3, DOI 10.1038/ki.2011.23
   Tentori F, 2008, AM J KIDNEY DIS, V52, P519, DOI 10.1053/j.ajkd.2008.03.020
   Tentori F, 2009, NEPHROL DIAL TRANSPL, V24, P963, DOI 10.1093/ndt/gfn592
   Vervloet MG, 2011, CLIN J AM SOC NEPHRO, V6, P383, DOI 10.2215/CJN.04730510
   Yamazaki Y, 2002, J CLIN ENDOCR METAB, V87, P4957, DOI 10.1210/jc.2002 021105
NR 31
TC 14
Z9 14
U1 0
U2 26
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471 2369
J9 BMC NEPHROL
JI BMC Nephrol.
PD JUN 28
PY 2012
VL 13
AR 49
DI 10.1186/1471 2369 13 49
PG 8
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Urology & Nephrology
GA 015EK
UT WOS:000309428100001
PM 22742720
OA Green Accepted, gold
DA 2025 08 17
ER

PT J
AU Neto, JRB
   Neto, PD
   Sales, FAM
   da Silva, EE
   Ladeira, LO
   Freire, VN
   Caetano, EWS
AF Bezerra Neto, Joao Rufino
   de Lima Neto, Pedro
   Matos Sales, Francisco Adilson
   da Silva, Edelma Eleto
   Ladeira, Luiz Orlando
   Freire, Valder Nogueira
   Santos Caetano, Ewerton Wagner
TI Phosphate group vibrational signatures of the osteoporosis drug
   alendronate
SO JOURNAL OF RAMAN SPECTROSCOPY
LA English
DT Article
DE Infrared spectroscopy; Raman spectroscopy; alendronate; osteoporosis
   drug; density functional theory calculations
ID ANALYTIC 2ND DERIVATIVES; IN VITRO; BONE; DENSITY; RAMAN; MECHANISMS;
   ENERGY; BISPHOSPHONATES; ADSORPTION; MODES
AB The infrared (IR) and Raman spectra of the osteoporosis drug alendronate in the monosodium trihydrate alendronate crystal were measured. In order to interpret them, density functional theory (DFT) calculations for the solvated alendronate molecule were performed following the structural features revealed by X ray data. A comparison between the DFT calculated IR and Raman of the converged species and the measured spectra unveils relevant phosphate group signatures in the 400 1400cm( 1) wavenumber range, especially IR absorption bands at 1015, 1049, 1067, 1131, 1177, and 1235cm( 1), which were related to CP and OP bond length stretching, and Raman lines at 449, 661, and 969cm( 1), involving phosphate scissors and bond length vibrations. A comparison with experimental data of alendronate incorporated into hydroxyapatite (HAP) indicates that, for wavenumbers below 1500cm( 1), the interaction of alendronate with HAP does not affect significantly the alendronate vibrational spectra, while for the 1600 3000cm( 1) interval the interaction with HAP changes the normal mode wavenumbers by about  100cm( 1). Copyright (c) 2014 John Wiley & Sons, Ltd.
C1 [Bezerra Neto, Joao Rufino; de Lima Neto, Pedro] Univ Fed Ceara, Dept Quim Analit & Fis Quim, BR 60440900 Fortaleza, Ceara, Brazil.
   [Matos Sales, Francisco Adilson; Freire, Valder Nogueira] Univ Fed Ceara, Dept Fis, BR 60440900 Fortaleza, Ceara, Brazil.
   [da Silva, Edelma Eleto] Univ Fed Itajuba, BR 35900373 Itabira, MG, Brazil.
   [Ladeira, Luiz Orlando] Univ Fed Minas Gerais, Dept Fis, BR 31340550 Belo Horizonte, MG, Brazil.
   [Santos Caetano, Ewerton Wagner] Inst Fed Educ Ciencia & Tecnol Ceara, BR 60040531 Fortaleza, Ceara, Brazil.
C3 Universidade Federal do Ceara; Universidade Federal do Ceara;
   Universidade Federal de Itajuba; Universidade Federal de Minas Gerais;
   Instituto Federal do Ceara (IFCE)
RP Caetano, EWS (通讯作者)，Inst Fed Educ Ciencia & Tecnol Ceara, Av 13 Maio 2081, BR 60040531 Fortaleza, Ceara, Brazil.
EM ewcaetano@gmail.com
RI ; Ladeira, Luiz/AAJ 4918 2021; Sales, Francisco/E 1391 2014; De
   Lima Neto, Pedro/F 2440 2012; Freire, Valder/D 1136 2013; Silva,
   Edelma/GLQ 5926 2022; Caetano, Ewerton/A 2284 2015
OI Matos Sales, Francisco Adilson/0000 0001 9447 0887; Freire,
   Valder/0000 0001 7867 3908; De Lima Neto, Pedro/0000 0002 1613 4797;
   Ladeira, Luiz Orlando/0000 0002 4935 6070; Eleto da Silva,
   Edelma/0000 0002 1498 9134; Caetano, Ewerton/0000 0002 1021 6927
FU CNPq INCT [Nano(Bio)Simes project] [573925/2008 9]; CAPES PROCAD; CNPq
   [307843/2013 0, 550579/2012 5]; CNPq FUNCAP [159900/2010 7]
FX V.N.F., L.O.L., and P.L. N. are senior researchers from the Brazilian
   National Research Council (CNPq) and would like to acknowledge the
   financial support received through the Brazilian Research Agencies
   CNPq INCT [Nano(Bio)Simes project 573925/2008 9] and CAPES PROCAD. E. W.
   S. C. received financial support from CNPq projects 307843/2013 0 and
   550579/2012 5; F. A. M. S. received a Pos Doc fellowship from
   CNPq FUNCAP, project 159900/2010 7. The authors would like to
   acknowledge the CENAPAD UFC computer processing time allocated for their
   Gaussian 09 calculations. We also give special thanks to M. S. Alves and
   Prof. A. P. Ayala for helping us with the Raman measurements.
CR Amarie S, 2012, BEILSTEIN J NANOTECH, V3, P312, DOI 10.3762/bjnano.3.35
   [Anonymous], MARVIN SKETCH 6 1 4
   [Anonymous], 2007, ASSESSMENT OSTEOPORO
   [Anonymous], VIBRATIONAL ENERGY D
   Biczysko M, 2010, J CHEM THEORY COMPUT, V6, P2115, DOI 10.1021/ct100212p
   Boanini E, 2012, J PHYS CHEM C, V116, P15812, DOI 10.1021/jp304472s
   Cremers SCLM, 2005, CLIN PHARMACOKINET, V44, P551, DOI 10.2165/00003088 200544060 00001
   Cremers S, 2011, BONE, V49, P42, DOI 10.1016/j.bone.2011.01.014
   Cukrowski I, 2007, BONE, V41, P668, DOI 10.1016/j.bone.2007.05.008
   desAza PN, 1997, CHEM MATER, V9, P916
   FRANCIS MD, 1969, SCIENCE, V165, P1264, DOI 10.1126/science.165.3899.1264
   Frisch M.J., 2009, Gaussian 09, P201
   Hofstetter B, 2012, J BONE MINER RES, V27, P995, DOI 10.1002/jbmr.1572
   HOHENBERG P, 1964, PHYS REV B, V136, pB864, DOI 10.1103/PhysRevB.7.1912
   Howard AA, 2010, J PHYS CHEM A, V114, P6803, DOI 10.1021/jp101267w
   Iafisco M, 2008, LANGMUIR, V24, P4924, DOI 10.1021/la703381h
   Jamróz MH, 2013, SPECTROCHIM ACTA A, V114, P220, DOI 10.1016/j.saa.2013.05.096
   Jansen JP, 2011, SEMIN ARTHRITIS RHEU, V40, P275, DOI 10.1016/j.semarthrit.2010.06.001
   JOHNSON BG, 1994, J CHEM PHYS, V100, P7429, DOI 10.1063/1.466887
   JOHNSON BG, 1993, CHEM PHYS LETT, V216, P133, DOI 10.1016/0009 2614(93)E1238 C
   Juillard A, 2010, BONE, V47, P895, DOI 10.1016/j.bone.2010.07.018
   Kawai M, 2011, NAT REV DRUG DISCOV, V10, P141, DOI 10.1038/nrd3299
   KOHN W, 1965, PHYS REV, V140, P1133, DOI 10.1103/PhysRev.140.A1133
   Kourkoumelis N, 2012, J BIOL PHYS, V38, P623, DOI 10.1007/s10867 012 9276 6
   Li DD, 2013, MATER RES BULL, V48, P2201, DOI 10.1016/j.materresbull.2013.02.049
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   MELTON LJ, 1992, J BONE MINER RES, V7, P1005, DOI 10.1002/jbmr.5650070902
   Melton LJ, 1998, J BONE MINER RES, V13, P1915, DOI 10.1359/jbmr.1998.13.12.1915
   Morris MD, 2011, CLIN ORTHOP RELAT R, V469, P2160, DOI 10.1007/s11999 010 1692 y
   Negrea D, 2010, J OPTOELECTRON ADV M, V12, P1194
   PARR RG, 1989, DENSITY FUNCTIONAL T
   Pascaud P, 2012, BIOMED MATER, V7, DOI 10.1088/1748 6041/7/5/054108
   Paschalis EP, 2011, CLIN ORTHOP RELAT R, V469, P2170, DOI 10.1007/s11999 010 1751 4
   Penel G, 1998, CALCIFIED TISSUE INT, V63, P475, DOI 10.1007/s002239900561
   Rosen CJ, 2006, NAT CLIN PRACT RHEUM, V2, P35, DOI 10.1038/ncprheum0070
   Rosen CJ, 2008, CELL METAB, V7, P7, DOI 10.1016/j.cmet.2007.12.004
   Rossi B, 2009, J RAMAN SPECTROSC, V40, P453, DOI 10.1002/jrs.2150
   Russell RGG, 2007, ANN NY ACAD SCI, V1117, P209, DOI 10.1196/annals.1402.089
   Stratmann RE, 1997, J CHEM PHYS, V106, P10175, DOI 10.1063/1.474047
   Tomasi J, 2005, CHEM REV, V105, P2999, DOI 10.1021/cr9904009
   Ulian G, 2013, AM MINERAL, V98, P752, DOI 10.2138/am.2013.4315
   Becerril NV, 2013, J AUST CERAM SOC, V49, P112
   Vega D, 1996, ACTA CRYSTALLOGR C, V52, P2198, DOI 10.1107/S0108270196006105
   Zhao Y, 2008, THEOR CHEM ACC, V120, P215, DOI 10.1007/s00214 007 0310 x
   Zvereva EE, 2011, J PHYS CHEM A, V115, P63, DOI 10.1021/jp108057p
NR 45
TC 19
Z9 19
U1 1
U2 45
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0377 0486
EI 1097 4555
J9 J RAMAN SPECTROSC
JI J. Raman Spectrosc.
PD SEP
PY 2014
VL 45
IS 9
BP 801
EP 806
DI 10.1002/jrs.4559
PG 6
WC Spectroscopy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Spectroscopy
GA AP6RR
UT WOS:000342205800013
DA 2025 08 17
ER

PT J
AU Kähkönen, TE
   Ivaska, KK
   Jian, M
   Büki, KG
   Väänänen, HK
   Härkönen, PL
AF Kahkonen, T. E.
   Ivaska, K. K.
   Jian, M.
   Buki, K. G.
   Vaananen, H. K.
   Harkonen, P. L.
TI Role of fibroblast growth factor receptors (FGFR) and FGFR like 1
   (FGFRL1) in mesenchymal stromal cell differentiation to osteoblasts and
   adipocytes
SO MOLECULAR AND CELLULAR ENDOCRINOLOGY
LA English
DT Article
DE Mesenchymal stromal cell; Osteoblast; Adipocyte; Fibroblast growth
   factor; Fibroblast growth factor receptor; Fibroblast growth factor
   receptor like 1
ID STEM CELLS; HUMAN PREADIPOCYTES; KEY REGULATOR; MICE; THERAPY; PATHWAY;
   BETA; MSCS
AB Fibroblast growth factors (FGF) and their receptors (FGFRs) regulate many developmental processes including differentiation of mesenchymal stromal cells (MSC). We developed two MSC lines capable of differentiating to osteoblasts and adipocytes and studied the role of FGFRs in this process. We identified FGFR2 and fibroblast growth factor receptor like 1 (FGFRL1) as possible actors in MSC differentiation with gene microarray and qRT PCR. FGFR2 and FGFRL1 mRNA expression strongly increased during MSC differentiation to osteoblasts. FGF2 treatment, resulting in downregulation of FGFR2, or silencing FGFR2 expression with siRNAs inhibited osteoblast differentiation. During adipocyte differentiation expression of FGFR1 and FGFRL1 increased and was down regulated by FGF2. FGFR1 knockdown inhibited adipocyte differentiation. Silencing FGFR2 and FGFR1 in MSCs was associated with decreased FGFRL1 expression in osteoblasts and adipocytes, respectively. Our results suggest that FGFR1 and FGFR2 regulate FGFRL1 expression. FGFRL1 may mediate or modulate FGFR regulation of MSC differentiation together with FGFR2 in osteoblastic and FGFR1 in adipocytic lineage. (C) 2017 Elsevier B.V. All rights reserved.
C1 [Kahkonen, T. E.; Ivaska, K. K.; Jian, M.; Buki, K. G.; Vaananen, H. K.; Harkonen, P. L.] Univ Turku, Inst Biomed, Turku, Finland.
C3 University of Turku
RP Kähkönen, TE (通讯作者)，Univ Turku, Finland Inst Biomed, Turku, Finland.
EM tesilv@utu.fi
RI Ivaska, Kaisa/G 1406 2012
OI Ivaska, Kaisa/0000 0001 7482 7623
FU European Union 6th framework project (EXERA) [LSHB CT 2006 037168];
   Academy of Finland; Sigrid Juselius, University of Turku; Ida Montin
   foundations
FX Cell lines were created and their initial characterization was done in
   European Union 6th framework project (LSHB CT 2006 037168, EXERA). The
   further work was supported by Academy of Finland, Sigrid Juselius,
   University of Turku and Ida Montin foundations.
CR Beenken A, 2009, NAT REV DRUG DISCOV, V8, P235, DOI 10.1038/nrd2792
   Catela C, 2009, DIS MODEL MECH, V2, P283, DOI 10.1242/dmm.002287
   Chamberlain G, 2007, STEM CELLS, V25, P2739, DOI 10.1634/stemcells.2007 0197
   COFFIN JD, 1995, MOL BIOL CELL, V6, P1861, DOI 10.1091/mbc.6.12.1861
   Debiais F, 1998, J BONE MINER RES, V13, P645, DOI 10.1359/jbmr.1998.13.4.645
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Du XL, 2012, J CELL PHYSIOL, V227, P3731, DOI 10.1002/jcp.24083
   Hutley L, 2004, DIABETES, V53, P3097, DOI 10.2337/diabetes.53.12.3097
   Hutley LJ, 2011, MOL CELL ENDOCRINOL, V339, P165, DOI 10.1016/j.mce.2011.04.012
   Marie PJ, 2012, GENE, V498, P1, DOI 10.1016/j.gene.2012.01.086
   May T, 2004, NUCLEIC ACIDS RES, V32, P5529, DOI 10.1093/nar/gkh887
   Miraoui H, 2009, J BIOL CHEM, V284, P4897, DOI 10.1074/jbc.M805432200
   Newell FS, 2006, FASEB J, V20, P2615, DOI 10.1096/fj.05 5710fje
   Ng F, 2008, BLOOD, V112, P295, DOI 10.1182/blood 2007 07 103697
   Niu TH, 2015, HUM MOL GENET, V24, P4710, DOI 10.1093/hmg/ddv144
   Ornitz DM, 2015, WIRES DEV BIOL, V4, P215, DOI 10.1002/wdev.176
   Patel NG, 2005, J CLIN ENDOCR METAB, V90, P1226, DOI 10.1210/jc.2004 1309
   Peister A, 2004, BLOOD, V103, P1662, DOI 10.1182/blood 2003 09 3070
   Silva PN, 2013, J BIOL CHEM, V288, P17859, DOI 10.1074/jbc.M112.440677
   Tang XL, 2015, MOL CELL ENDOCRINOL, V413, P78, DOI 10.1016/j.mce.2015.06.013
   Tarkkonen KM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049970
   Trueb B, 2003, J BIOL CHEM, V278, P33857, DOI 10.1074/jbc.M300281200
   Trueb B, 2011, CELL MOL LIFE SCI, V68, P951, DOI 10.1007/s00018 010 0576 3
   Valta MP, 2006, ENDOCRINOLOGY, V147, P2171, DOI 10.1210/en.2005 1502
   White KE, 2005, AM J HUM GENET, V76, P361, DOI 10.1086/427956
   Widberg CH, 2009, AM J PHYSIOL ENDOC M, V296, pE121, DOI 10.1152/ajpendo.90602.2008
NR 26
TC 32
Z9 37
U1 0
U2 30
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0303 7207
J9 MOL CELL ENDOCRINOL
JI Mol. Cell. Endocrinol.
PD FEB 5
PY 2018
VL 461
IS C
BP 194
EP 204
DI 10.1016/j.mce.2017.09.015
PG 11
WC Cell Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Endocrinology & Metabolism
GA FV1GJ
UT WOS:000424309100020
PM 28923346
DA 2025 08 17
ER

PT J
AU Gonzalez Suarez, E
   Jacob, AP
   Jones, J
   Miller, R
   Roudier Meyer, MP
   Erwert, R
   Pinkas, J
   Branstetter, D
   Dougall, WC
AF Gonzalez Suarez, Eva
   Jacob, Allison P.
   Jones, Jon
   Miller, Robert
   Roudier Meyer, Martine P.
   Erwert, Ryan
   Pinkas, Jan
   Branstetter, Dan
   Dougall, William C.
TI RANK ligand mediates progestin induced mammary epithelial proliferation
   and carcinogenesis
SO NATURE
LA English
DT Article
ID HORMONE REPLACEMENT THERAPY; HUMAN BREAST TUMORS; GLAND DEVELOPMENT;
   TRANSGENIC MICE; MEDROXYPROGESTERONE ACETATE; OSTEOCLAST
   DIFFERENTIATION; OSTEOPROTEGERIN LIGAND; CELL FUNCTION; RECEPTOR;
   EXPRESSION
AB RANK ligand (RANKL), a TNF related molecule, is essential for osteoclast formation, function and survival through interaction with its receptor RANK(1,2). Mammary glands of RANK and RANKL deficient mice develop normally during sexual maturation, but fail to form lobuloalveolar structures during pregnancy because of defective proliferation and increased apoptosis of mammary epithelium(3). It has been shown that RANKL is responsible for the major proliferative response of mouse mammary epithelium to progesterone during mammary lactational morphogenesis(4), and in mouse models, manipulated to induce activation of the RANK/RANKL pathway in the absence of strict hormonal control, inappropriate mammary proliferation is observed(5,6). However, there is no evidence so far of a functional contribution of RANKL to tumorigenesis. Here we show that RANK and RANKL are expressed within normal, pre malignant and neoplastic mammary epithelium, and using complementary gain of function (mouse mammary tumour virus (MMTV) RANK transgenic mice) and loss of function (pharmacological inhibition of RANKL) approaches, define a direct contribution of this pathway in mammary tumorigenesis. Accelerated pre neoplasias and increased mammary tumour formation were observed in MMTV RANK transgenic mice after multiparity or treatment with carcinogen and hormone (progesterone). Reciprocally, selective pharmacological inhibition of RANKL attenuated mammary tumour development not only in hormone and carcinogen treated MMTV RANK and wild type mice, but also in the MMTV neu transgenic spontaneous tumour model. The reduction in tumorigenesis upon RANKL inhibition was preceded by a reduction in pre neoplasias as well as rapid and sustained reductions in hormone and carcinogen induced mammary epithelial proliferation and cyclin D1 levels. Collectively, our results indicate that RANKL inhibition is acting directly on hormone induced mammary epithelium at early stages in tumorigenesis, and the permissive contribution of progesterone to increased mammary cancer incidence is due to RANKL dependent proliferative changes in the mammary epithelium. The current study highlights a potential role for RANKL inhibition in the management of proliferative breast disease.
C1 [Gonzalez Suarez, Eva; Jacob, Allison P.; Jones, Jon; Miller, Robert; Erwert, Ryan; Dougall, William C.] Amgen Inc, Dept Hematol Oncol Res, Seattle, WA 98119 USA.
   [Roudier Meyer, Martine P.; Branstetter, Dan] Amgen Inc, Dept Pathol, Seattle, WA 98119 USA.
   [Pinkas, Jan] Amgen Inc, Dept Hematol Oncol Res, Cambridge, MA 02139 USA.
C3 Amgen; Amgen; Amgen
RP Dougall, WC (通讯作者)，Amgen Inc, Dept Hematol Oncol Res, Seattle, WA 98119 USA.
EM dougallw@amgen.com
RI Gonzalez Suarez, Eva/L 6298 2014
OI Gonzalez Suarez, Eva/0000 0003 0858 8171; Dougall,
   William/0000 0001 9487 251X
CR Aldaz CM, 1996, CARCINOGENESIS, V17, P2069, DOI 10.1093/carcin/17.9.2069
   Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593
   Asselin Labat ML, 2010, NATURE, V465, P798, DOI 10.1038/nature09027
   Aupperlee Mark, 2005, Breast Dis, V24, P37
   Beleut M, 2010, P NATL ACAD SCI USA, V107, P2989, DOI 10.1073/pnas.0915148107
   Brisken C, 1998, P NATL ACAD SCI USA, V95, P5076, DOI 10.1073/pnas.95.9.5076
   Cao YX, 2001, CELL, V107, P763, DOI 10.1016/S0092 8674(01)00599 2
   Cardiff RD, 2000, ONCOGENE, V19, P968, DOI 10.1038/sj.onc.1203277
   Chlebowski RT, 2003, JAMA J AM MED ASSOC, V289, P3243, DOI 10.1001/jama.289.24.3243
   Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412
   Fata JE, 2000, CELL, V103, P41, DOI 10.1016/S0092 8674(00)00103 3
   Fernandez Valdivia R, 2009, DEV BIOL, V328, P127, DOI 10.1016/j.ydbio.2009.01.019
   Gonzalez Suarez E, 2007, MOL CELL BIOL, V27, P1442, DOI 10.1128/MCB.01298 06
   Greendale GA, 2003, J NATL CANCER I, V95, P30, DOI 10.1093/jnci/95.1.30
   GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578
   Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb 2007 8 5 r76
   Hewitt SC, 2002, CANCER RES, V62, P2798
   Hofseth LJ, 1999, J CLIN ENDOCR METAB, V84, P4559, DOI 10.1210/jc.84.12.4559
   Holmberg L, 2008, JNCI J NATL CANCER I, V100, P475, DOI 10.1093/jnci/djn058
   Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540
   Ismail PM, 2003, STEROIDS, V68, P779, DOI 10.1016/S0039 128X(03)00133 8
   Joshi PA, 2010, NATURE, V465, P803, DOI 10.1038/nature09091
   Klijn JGM, 2000, STEROIDS, V65, P825, DOI 10.1016/S0039 128X(00)00195 1
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Landis MW, 2006, CANCER CELL, V9, P13, DOI 10.1016/j.ccr.2005.12.019
   Luo JL, 2007, NATURE, V446, P690, DOI 10.1038/nature05656
   Van Poznak C, 2006, J CLIN PATHOL, V59, P56, DOI 10.1136/jcp.2005.026534
   WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0
NR 28
TC 464
Z9 502
U1 0
U2 46
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 0028 0836
EI 1476 4687
J9 NATURE
JI Nature
PD NOV 4
PY 2010
VL 468
IS 7320
BP 103
EP +
DI 10.1038/nature09495
PG 7
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 674YF
UT WOS:000283786900044
PM 20881963
DA 2025 08 17
ER

PT J
AU Della Porta, G
   Campardelli, R
   Cricchio, V
   Oliva, F
   Maffulli, N
   Reverchon, E
AF Della Porta, Giovanna
   Campardelli, Roberta
   Cricchio, Vincenzo
   Oliva, Francesco
   Maffulli, Nicola
   Reverchon, Ernesto
TI Injectable PLGA/Hydroxyapatite/Chitosan Microcapsules Produced by
   Supercritical Emulsion Extraction Technology: An In Vitro Study
   on Teriparatide/Gentamicin Controlled Release
SO JOURNAL OF PHARMACEUTICAL SCIENCES
LA English
DT Article
DE controlled release; drug delivery systems; microencapsulation; PLGA;
   supercritical fluids
ID PLGA BASED MICROPARTICLES; DRUG DELIVERY SYSTEMS; PARATHYROID HORMONE;
   POSTMENOPAUSAL WOMEN; ACID) MICROSPHERES; BONE REGENERATION; FLUID
   EXTRACTION; OSTEOPOROSIS; DEGRADATION; MECHANISMS
AB Supercritical emulsion extraction (SEE) is proposed as a green and effective strategy for the fabrication of chitosan covered poly lactic co glycolic acid (chi PLGA) injectable microcapsules for the controlled release of teriparatide (THA) and teriparatide/gentamicin sulfate (THA/Gen). These formulations can be used for locally bone pathologies treatment or in complex fracture healing of aged patients. Several oil water (o w) and water oil water (w o w) emulsions were processed by SEE to produce multifunctional microcapsules containing hydroxyapatite (HA) within a poly lactic co glycolic acid (PLGA) matrix (up to 24 mg/g) and with both THA (0.45 mg/g) and Gen (up to 9 mg/g). Chitosan coating was also successfully added, as external layer (0.4 mu m). SEE fabricated microcapsules showed good encapsulation efficiency (up to 90%) for all the drugs tested and a mean size ranging between 1.4 (+/  0.4) mu m and 2.2 (+/  0.5) mu m. Different drug amounts loaded and microcapsules compositions assured a controlled drug release over a wide range of times and concentrations, as in vitro monitored in PBS medium at 37 degrees C for 15/20 days. HA embedded into the biopolymer structure delayed the THA release profile; chitosan coating strongly reduced the initial drug "burst" release. In addition, the coencapsulation of both THA and Gen, which have very different water solubility, accelerated the release profile of the less water soluble drug. No drugs degradation was also monitored after the SEE manufacturing. Apparent drug diffusivities (D) were calculated by fitting of the release profiles. In the case of Gen, D ranged between 2.9 x 10( 8) and 1.6 x 10( 9) cm(2)s( 1) if the drug was entrapped in simple PLGA or in the chitosan coated microcapsules, respectively. In the case of THA, the calculated values ranged between 8.1 x 10( 9) and 7.4 x 10( 10) cm(2)s( 1) when the drug was entrapped in PLGA/HA microcapsules or in the chitosan coated ones, respectively. These mass transfer values are consistent with the different release behaviors observed and confirmed the possibility of multicomponent microcapsules fabrication by SEE. (C) 2016 American Pharmacists Association (R). Published by Elsevier Inc. All rights reserved.
C1 [Della Porta, Giovanna; Campardelli, Roberta; Cricchio, Vincenzo; Reverchon, Ernesto] Univ Salerno, Dept Ind Engn, I 84084 Salerno, Italy.
   [Oliva, Francesco] Univ Roma Tor Vergata, Sch Med, Dept Orthoped & Traumatol, Rome, Italy.
   [Maffulli, Nicola] Univ Salerno, Fac Med & Surg, Dept Musculoskeletal Med & Surg, I 84081 Salerno, Italy.
C3 University of Salerno; University of Rome Tor Vergata; University of
   Salerno
RP Della Porta, G (通讯作者)，Univ Salerno, Dept Ind Engn, I 84084 Salerno, Italy.
EM gdellaporta@unisa.it
RI della Porta, Giovanna/G 7751 2012; Maffulli, Nicola/A 1839 2014;
   Reverchon, Ernesto/F 6809 2011; Della Porta, Giovanna/G 7751 2012;
   Oliva, Francesco/AAC 2030 2019; Campardelli, Roberta/AAE 1182 2021
OI Della Porta, Giovanna/0000 0002 1426 0159; Oliva,
   Francesco/0000 0002 7473 0271; 
CR Aspenberg P, 2010, J BONE MINER RES, V25, P404, DOI 10.1359/jbmr.090731
   Baldino L, 2014, J SUPERCRIT FLUID, V90, P27, DOI 10.1016/j.supflu.2014.03.002
   Borden M, 2003, BIOMATERIALS, V24, P597, DOI 10.1016/S0142 9612(02)00374 5
   Bukata Susan V, 2010, Curr Osteoporos Rep, V8, P28, DOI 10.1007/s11914 010 0006 3
   Campardelli R, 2015, J SUPERCRIT FLUID, V101, P193, DOI 10.1016/j.supflu.2015.01.030
   Campardelli R, 2014, J SUPERCRIT FLUID, V92, P93, DOI 10.1016/j.supflu.2014.05.012
   Coppola C, 2015, TRANSL MED UNISA, V12, P47
   Cosman F, 2010, J CLIN ENDOCR METAB, V95, P151, DOI 10.1210/jc.2009 0358
   Crank J, 1979, MATH DIFFUSION
   Daddona PE, 2011, PHARM RES DORDR, V28, P159, DOI 10.1007/s11095 010 0192 9
   Della Porta G, 2010, J PHARM SCI US, V99, P1484, DOI 10.1002/jps.21920
   Dempster DW, 2001, J BONE MINER RES, V16, P1846, DOI 10.1359/jbmr.2001.16.10.1846
   Díez Peña E, 2002, CHEM PHARM BULL, V50, P1201, DOI 10.1248/cpb.50.1201
   Dunne M, 2000, BIOMATERIALS, V21, P1659, DOI 10.1016/S0142 9612(00)00040 5
   Eswaramoorthy R, 2012, ACTA BIOMATER, V8, P2254, DOI 10.1016/j.actbio.2012.03.015
   Faisant N, 2002, EUR J PHARM SCI, V15, P355, DOI 10.1016/S0928 0987(02)00023 4
   Falco N, 2013, INT J PHARMACEUT, V441, P589, DOI 10.1016/j.ijpharm.2012.10.039
   Fredenberg S, 2011, INT J PHARMACEUT, V415, P34, DOI 10.1016/j.ijpharm.2011.05.049
   Gopferich A, 1997, J CONTROL RELEASE, V44, P271, DOI 10.1016/S0168 3659(96)01533 7
   Habraken WJEM, 2006, J BIOMAT SCI POLYM E, V17, P1057, DOI 10.1163/156856206778366004
   Hamdy RC, 2002, SOUTHERN MED J, V95, P567, DOI 10.1097/00007611 200206000 00001
   Ho ML, 2008, J CONTROL RELEASE, V128, P142, DOI 10.1016/j.jconrel.2008.02.012
   Hodsman AB, 2005, ENDOCR REV, V26, P688, DOI 10.1210/er.2004 0006
   Hoyer H, 2010, DRUG DEV IND PHARM, V36, P31, DOI 10.3109/03639040903059342
   Ignjatovic N, 2013, MAT SCI ENG C MATER, V33, P943, DOI 10.1016/j.msec.2012.11.026
   Jacobson JA, 2011, TISSUE ENG PT A, V17, P389, DOI [10.1089/ten.tea.2010.0115, 10.1089/ten.TEA.2010.0115]
   Janes KA, 2001, ADV DRUG DELIVER REV, V47, P83, DOI 10.1016/S0169 409X(00)00123 X
   Jiang T, 2010, ACTA BIOMATER, V6, P3457, DOI 10.1016/j.actbio.2010.03.023
   KENT GN, 1985, CLIN SCI, V68, P171, DOI 10.1042/cs0680171
   Kim IY, 2008, BIOTECHNOL ADV, V26, P1, DOI 10.1016/j.biotechadv.2007.07.009
   Klose D, 2006, INT J PHARMACEUT, V314, P198, DOI 10.1016/j.ijpharm.2005.07.031
   Kluge J, 2009, J SUPERCRIT FLUID, V50, P327, DOI 10.1016/j.supflu.2009.05.010
   Lanao RPF, 2011, BIOMATERIALS, V32, P8839, DOI 10.1016/j.biomaterials.2011.08.005
   Liu X, 2007, BIOMATERIALS, V28, P4124, DOI 10.1016/j.biomaterials.2007.05.034
   Morley Paul, 2005, Expert Opin Drug Deliv, V2, P993, DOI 10.1517/17425247.2.6.993
   Nakazawa T, 2005, BONE, V37, P711, DOI 10.1016/j.bone.2005.06.013
   Porta GD, 2008, BIOTECHNOL BIOENG, V100, P1020, DOI 10.1002/bit.21845
   Prior S, 2000, INT J PHARM, V196, P115, DOI 10.1016/S0378 5173(99)00448 2
   Proos ER, 2008, PHARM RES, V25, P1387, DOI 10.1007/s11095 008 9544 0
   Puig Domingo M, 2008, EUR J ENDOCRINOL, V159, P653, DOI 10.1530/EJE 08 0269
   Qi XP, 2008, ACTA BIOMATER, V4, P1837, DOI 10.1016/j.actbio.2008.05.009
   Rane SS, 2012, J PHARM ANA, V2, P136, DOI 10.1016/j.jpha.2011.12.001
   Sansdrap P, 1997, J CONTROL RELEASE, V43, P47, DOI 10.1016/S0168 3659(96)01469 1
   Santo IE, 2015, J PHARM SCI US, V104, P3842, DOI 10.1002/jps.24595
   Sato M, 2005, BIOMATERIALS, V26, P1349, DOI 10.1016/j.biomaterials.2004.04.044
   Shekunov BY, 2006, PHARM RES DORDR, V23, P196, DOI 10.1007/s11095 005 8635 4
   Siegel RA, 2012, ADV DEL SCI TECHNOL, P19, DOI 10.1007/978 1 4614 0881 9_2
   Siepmann J, 2005, BIOMACROMOLECULES, V6, P2312, DOI 10.1021/bm050228k
   Siepmann J, 2001, ADV DRUG DELIVER REV, V48, P229, DOI 10.1016/S0169 409X(01)00116 8
   Stevens B, 2008, J BIOMED MATER RES B, V85B, P573, DOI 10.1002/jbm.b.30962
   Tashjian AH, 2006, J BONE MINER RES, V21, P354, DOI 10.1359/JBMR.051023
   Versypt ANF, 2013, J CONTROL RELEASE, V165, P29, DOI 10.1016/j.jconrel.2012.10.015
   Virto MR, 2007, BIOMATERIALS, V28, P877, DOI 10.1016/j.biomaterials.2006.09.045
   Waller J, 1997, J Med Syst, V21, P33, DOI 10.1023/A:1022839308196
   Wang M, 2003, BIOMATERIALS, V24, P2133, DOI 10.1016/S0142 9612(03)00037 1
   Wei GB, 2004, BIOMATERIALS, V25, P345, DOI 10.1016/S0142 9612(03)00528 3
   Werner P, 2005, OSTEOPOROSIS INT, V16, P115, DOI 10.1007/s00198 004 1750 y
   Xiao W, 2016, MAT SCI ENG C MATER, V60, P324, DOI 10.1016/j.msec.2015.11.039
NR 58
TC 34
Z9 34
U1 1
U2 80
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0022 3549
EI 1520 6017
J9 J PHARM SCI US
JI J. Pharm. Sci.
PD JUL
PY 2016
VL 105
IS 7
BP 2164
EP 2172
DI 10.1016/j.xphs.2016.05.002
PG 9
WC Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology &
   Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy; Chemistry
GA DT8UD
UT WOS:000381770300017
PM 27290629
DA 2025 08 17
ER

PT J
AU Liu, YJ
   Zong, Y
   Shan, HJ
   Lin, YW
   Xia, WY
   Wang, N
   Zhou, LH
   Gao, YS
   Ma, X
   Jiang, CL
AF Liu, Yingjie
   Zong, Yang
   Shan, Haojie
   Lin, Yiwei
   Xia, Wenyang
   Wang, Nan
   Zhou, Lihui
   Gao, Youshui
   Ma, Xin
   Jiang, Chaolai
TI MicroRNA 23b 3p participates in steroid induced osteonecrosis of the
   femoral head by suppressing ZNF667 expression
SO STEROIDS
LA English
DT Article
DE MicroRNA 23b 3p; ZNF667; SONFH; Gene regulation
ID OSTEOGENIC DIFFERENTIATION; OSTEOBLASTS
AB Background: Clinical treatment with high dose of steroid hormone causes steroid induced osteonecrosis of the femoral head (SONFH), whereas the internal regulation mechanism remains elusive. Numerous studies have reported that microRNAs participated in the development of SONFH through modulating gene expression. The aim of the current study was to clarify the function of microRNA 23b 3p (miR 23b 3p) and ZNF667 in SONFH.
   Experimental design: Bioinformatics prediction and luciferase reporter system were utilized to confirm the target relation between miR 23b 3p and ZNF667. To examine the function of miR 23b 3p in vivo, rat SONFH models were established by specific inducers. The morphological changes, plasma viscosity, blood lipid, and inflammatory cytokines were measure by corresponding experiments.
   Results: MiR 23b 3p and ZNF667 was negatively correlated in SONFH patient tissues, miR 23b 3p was downregulated, while ZNF667 was up regulated. MiR 23b 3p targeted ZNF667, the expression level of ZNF667 was suppressed by miR 23b 3p activation whereas strengthened by miR 23b 3p inhibition. SONHF rats with overexpressed miR 23b 3p displayed alleviated symptoms, including reduced plasma viscosity, declined blood lipids, decreased levels of pro inflammatory cytokines and improved bone integrality. Moreover, elevation of ZNF667 reversed the repression of SONFH induced by miR 23b 3p overexpression.
   Conclusions: We found that miR 23b 3p played a protective role in SONFH by targeting ZNF667, which provided a novel reference for SONFH prevention and therapy.
C1 [Liu, Yingjie; Zong, Yang; Shan, Haojie; Lin, Yiwei; Xia, Wenyang; Gao, Youshui; Ma, Xin; Jiang, Chaolai] Shanghai Jiao Tong Univ Affiliated Peoples Hosp 6, Dept Orthopaed Surg, Shanghai 200233, Peoples R China.
   [Wang, Nan] Zhengzhou Univ, Dept Emergency, Affiliated Hosp 1, Zhengzhou 450052, Henan, Peoples R China.
   [Zhou, Lihui] Xiangshan First Peoples Hosp, Dept Orthopaed Surg, Ningbo 315700, Zhejiang, Peoples R China.
C3 Shanghai Jiao Tong University; Zhengzhou University
RP Ma, X; Jiang, CL (通讯作者)，Shanghai Jiao Tong Univ Affiliated Peoples Hosp 6, Dept Orthopaed Surg, Shanghai 200233, Peoples R China.
EM drmx330@126.com; bakehim@alumni.sjtu.edu.cn
RI yang, hailong/GXH 9625 2022; GAO, YOUSHUI/U 8349 2019
FU National Natural Science Foundation of China [81873993]; Foundation of
   Shanghai Health and Family Planning Commission [201740190]
FX This work was funded by the National Natural Science Foundation of China
   (81873993) and Foundation of Shanghai Health and Family Planning
   Commission (201740190).
CR Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092 8674(04)00045 5
   Chen LC, 2012, NEURO ONCOLOGY, V14, P1026, DOI 10.1093/neuonc/nos122
   Cui LQ, 2016, INT ORTHOP, V40, P267, DOI 10.1007/s00264 015 3061 7
   De Petro G, 1998, CANCER RES, V58, P2234
   Dong Yu lei, 2015, Zhongguo Yi Xue Ke Xue Yuan Xue Bao, V37, P152, DOI 10.3881/j.issn.1000 503X.2015.02.004
   Fang SH, 2019, EUR REV MED PHARMACO, V23, P9761, DOI 10.26355/eurrev_201911_19539
   Fang SH, 2019, DRUG DES DEV THER, V13, P45, DOI 10.2147/DDDT.S178698
   Fulciniti M, 2016, BLOOD CANCER J, V6, DOI 10.1038/bcj.2015.106
   Gao YC, 2020, INT J BIOL SCI, V16, P543, DOI 10.7150/ijbs.35256
   Grossi Ilaria, 2018, Microrna, V7, P156, DOI 10.2174/2211536607666180629155025
   Gu CX, 2016, SCI REP UK, V6, DOI 10.1038/srep38491
   Ham O, 2012, BIOMATERIALS, V33, P4500, DOI 10.1016/j.biomaterials.2012.03.025
   Hildebrand J, 2011, J INVEST DERMATOL, V131, P20, DOI 10.1038/jid.2010.268
   Jiang L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111653
   Jiang LD, 2020, J CELL PHYSIOL, V235, P979, DOI 10.1002/jcp.29013
   Kubo T, 2016, J ORTHOP SCI, V21, P407, DOI 10.1016/j.jos.2016.03.008
   Lagos Quintana M, 2001, SCIENCE, V294, P853, DOI 10.1126/science.1064921
   Li BL, 2013, CELL PHYSIOL BIOCHEM, V32, P1729, DOI 10.1159/000356607
   Li G, 2020, CELL CYCLE, V19, P551, DOI 10.1080/15384101.2020.1717043
   Li PF, 2016, GENE, V591, P69, DOI 10.1016/j.gene.2016.06.045
   Meng WX, 2019, J BIOMED SCI, V26, DOI 10.1186/s12929 019 0506 0
   Petek D, 2019, EFORT OPEN REV, V4, P85, DOI 10.1302/2058 5241.4.180036
   Powell C, 2010, AUTOIMMUN REV, V9, P721, DOI 10.1016/j.autrev.2010.06.007
   Shi CG, 2015, J MOL ENDOCRINOL, V54, P325, DOI 10.1530/JME 14 0314
   Sun Q, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 1841 5
   Tian L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075885
   Tian Y, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/8298193
   Xie Y, 2018, EUR REV MED PHARMACO, V22, P4053, DOI 10.26355/eurrev_201807_15393
   Yuan D, 2013, BIOMED REP, V1, P534, DOI 10.3892/br.2013.124
   Yue J, 2018, GENE, V651, P126, DOI 10.1016/j.gene.2018.01.057
   Zhang HS, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1555
   Zhao DW, 2012, BONE, V50, P325, DOI 10.1016/j.bone.2011.11.002
   Zhu R, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 1614 1
NR 33
TC 13
Z9 15
U1 0
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0039 128X
EI 1878 5867
J9 STEROIDS
JI Steroids
PD NOV
PY 2020
VL 163
AR 108709
DI 10.1016/j.steroids.2020.108709
PG 7
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA OD5HG
UT WOS:000579883100006
PM 32730776
DA 2025 08 17
ER

PT J
AU Mauro, M
   Radovic, V
   Armstrong, D
AF Mauro, Marina
   Radovic, Vladimir
   Armstrong, David
TI Improvement of lumbar bone mass after infliximab therapy in Crohn's
   disease patients
SO CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
LA English
DT Article
DE bone mass; Crohn's disease; infliximab; osteopenia; osteoporosis
ID INFLAMMATORY BOWEL DISEASE; NECROSIS FACTOR ALPHA; POPULATION BASED
   COHORT; MINERAL DENSITY; ULCERATIVE COLITIS; MAINTENANCE INFLIXIMAB;
   RHEUMATOID ARTHRITIS; FRACTURE RISK; OSTEOCLASTOGENESIS; OSTEOPOROSIS
AB BACKGROUND: Patients with Crohn's disease (CD) have a high risk of developing osteoporosis, but the mechanisms underlying bone rnass loss are unclear. Elevated proinflammatory cytokines, such as turnout necrosis factor alpha (TNF alpha), have been implicated in the pathogenesis of bone resorption.
   AIM: To assess whether suppression of TNF alpha with infliximab treat ment has a beneficial effect on lumbar bone mass.
   METHODS: Adult CD patients who had received infliximab treatment, and who underwent lumbar densitometric evaluation before and during treatment, were selected. Adult CD patients who had never received infliximab treatment were selected as controls. Information regarding age, sex, weight, duration of CD, use of gluco corticoids and bisphosphonates, and signs of disease activity between both densitometric measurements were collected.
   RESULTS: Data from 45 patients were analyzed. The control group (n=30, mean [ +/  SD] 26.7 +/  9 years of age) had a significantly higher increase in body weight between both evaluations (6.26% +/  8%) than the infliximab group (n=15, 30.6 +/  13 years), which had an increase of 0.3% +/  7.4%. There was a strong correlation between the final weight and lumbar bone mineral content (BMC) in both groups. The inflix imab group had a significant increase in lumbar bone area (4.15 +/  6.6%), BMC (12.8% +/  13.6%) and bone mineral density (8.13% +/  7.7%) between both evaluations (interval 22.6 +/  11 months) compared with the control group. The increase in BMC in patients who had received infliximab treatment was significant when compared with control patients who had received glucocorticoids (n=8) or had evidence of disease activity (n=13).
   CONCLUSION: Infliximab therapy improved lumbar bone mass independent of nutritional status. This finding suggests that TNF alpha plays a role in bone loss in CD.
C1 McMaster Univ, Div Gastroenterol, Intestinal Dis Res Program, Hamilton, ON, Canada.
C3 McMaster University
RP Armstrong, D (通讯作者)，McMaster Univ, Med Ctr, Div Gastroenterol, HSC 2F55, 1200 Main St W, Hamilton, ON L8N 3Z5, Canada.
EM armstro@mcmaster.ca
OI Armstrong, David/0000 0003 2487 1479
CR Abreu MT, 2006, J CLIN GASTROENTEROL, V40, P55, DOI 10.1097/01.mcg.0000190762.80615.d4
   Andreassen H, 1999, AM J GASTROENTEROL, V94, P824, DOI 10.1111/j.1572 0241.1999.00866.x
   Bernstein CN, 2000, ANN INTERN MED, V133, P795, DOI 10.7326/0003 4819 133 10 200011210 00012
   Bernstein CN, 2003, AM J GASTROENTEROL, V98, P1797, DOI 10.1016/S0002 9270(03)00441 6
   Bernstein CN, 2003, GASTROENTEROLOGY, V124, P795, DOI 10.1053/gast.2003.50106
   Bernstein M, 2005, AM J GASTROENTEROL, V100, P2031, DOI 10.1111/j.1572 0241.2005.50219.x
   Bjarnason I, 1997, GUT, V40, P228, DOI 10.1136/gut.40.2.228
   Card T, 2004, GUT, V53, P251, DOI 10.1136/gut.2003.026799
   Franchimont N, 2004, ALIMENT PHARM THER, V20, P607, DOI 10.1111/j.1365 2036.2004.02152.x
   Fuller K, 2002, ENDOCRINOLOGY, V143, P1108, DOI 10.1210/en.143.3.1108
   Gilbert L, 2000, ENDOCRINOLOGY, V141, P3956, DOI 10.1210/en.141.11.3956
   Habtezion A, 2002, INFLAMM BOWEL DIS, V8, P87, DOI 10.1097/00054725 200203000 00003
   Hanauer SB, 2002, LANCET, V359, P1541, DOI 10.1016/S0140 6736(02)08512 4
   Jahnsen J, 1997, GUT, V40, P313, DOI 10.1136/gut.40.3.313
   Komatsu M, 2001, CLIN CHEM, V47, P1297
   Lam J, 2000, J CLIN INVEST, V106, P1481, DOI 10.1172/JCI11176
   LANFRANCHI GA, 1992, LANCET, V339, P1053, DOI 10.1016/0140 6736(92)90573 L
   LUKERT BP, 1994, RHEUM DIS CLIN N AM, V20, P629
   Martin JP, 1999, EUR J GASTROEN HEPAT, V11, P537, DOI 10.1097/00042737 199905000 00012
   Mauro M, 2007, BONE, V40, P1610, DOI 10.1016/j.bone.2007.02.026
   Mauro M, 2007, BONE, V40, P1290, DOI 10.1016/j.bone.2007.01.002
   MOTLEY RJ, 1988, GUT, V29, P1332, DOI 10.1136/gut.29.10.1332
   MURCH SH, 1991, GUT, V32, P913, DOI 10.1136/gut.32.8.913
   Oelzner P, 1999, RHEUMATOLOGY, V38, P841, DOI 10.1093/rheumatology/38.9.841
   PIGOT F, 1992, DIGEST DIS SCI, V37, P1396, DOI 10.1007/BF01296010
   Pollak RD, 1998, AM J GASTROENTEROL, V93, P1483
   Robinson RJ, 1998, DIGEST DIS SCI, V43, P2500, DOI 10.1023/A:1026650719552
   Ryan BM, 2004, ALIMENT PHARM THER, V20, P851, DOI 10.1111/j.1365 2036.2004.02097.x
   Sands BE, 2004, NEW ENGL J MED, V350, P876, DOI 10.1056/NEJMoa030815
   Schulte C, 1998, INFLAMM BOWEL DIS, V4, P268, DOI 10.1002/ibd.3780040403
   Siffledeen JS, 2004, INFLAMM BOWEL DIS, V10, P220, DOI 10.1097/00054725 200405000 00007
   SILVENNOINEN JA, 1995, GUT, V37, P71, DOI 10.1136/gut.37.1.71
   Sylvester FA, 2002, J BONE MINER RES, V17, P695, DOI 10.1359/jbmr.2002.17.4.695
   Udagawa N, 2002, ARTHRITIS RES, V4, P281, DOI 10.1186/ar431
   Vestergaard P, 2002, AM J EPIDEMIOL, V156, P1, DOI 10.1093/aje/kwf007
   Vestergaard P, 2000, GUT, V46, P176, DOI 10.1136/gut.46.2.176
   Zhang YH, 2001, J BIOL CHEM, V276, P563, DOI 10.1074/jbc.M008198200
NR 37
TC 31
Z9 32
U1 0
U2 1
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2291 2789
EI 2291 2797
J9 CAN J GASTROENTEROL
JI Can. J. Gastroenterol. Hepatol.
PD OCT
PY 2007
VL 21
IS 10
BP 637
EP 642
DI 10.1155/2007/216162
PG 6
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Gastroenterology & Hepatology
GA 222WK
UT WOS:000250328300003
PM 17948133
OA Green Submitted, gold, Green Published
DA 2025 08 17
ER

PT J
AU Byrum, ML
   Pondenis, HC
   Fredrickson, RL
   Wycislo, KL
   Fan, TM
AF Byrum, M. L.
   Pondenis, H. C.
   Fredrickson, R. L.
   Wycislo, K. L.
   Fan, T. M.
TI Downregulation of CXCR4 Expression and Functionality After Zoledronate
   Exposure in Canine Osteosarcoma
SO JOURNAL OF VETERINARY INTERNAL MEDICINE
LA English
DT Article
DE Aminobisphosphonate; Cell chemotaxis; Pattern of metastases
ID BREAST CANCER; APPENDICULAR OSTEOSARCOMA; PULMONARY METASTASES;
   BISPHOSPHONATES INHIBIT; MEVALONATE PATHWAY; PHASE I; ACID; BONE; CELLS;
   PRENYLATION
AB BackgroundThe establishment and progression of metastases remains the life limiting factor for dogs diagnosed with osteosarcoma (OS). The pattern of metastases is likely regulated through interactions between chemokine receptors and chemokines, and perturbations in these signaling cascades responsible for cytoskeletal organization and directional migration have the potential to alter metastatic cell trafficking behaviors.
   HypothesisZoledronate will impair directional migration of OS cells through downregulation of chemokine (C X C motif) receptor 4 (CXCR4) expression and functionality.
   SamplesNineteen archived tumor specimens and plasma from 20 dogs with OS.
   MethodsProspectively, the expressions of CXCR4 were studied in OS cell lines and spontaneous tumor samples. The effect of zoledronate on CXCR4 expression and functionality was investigated by characterizing responses in 3 OS cell lines. In 19 OS specimens and 20 dogs with OS, changes in CXCR4 expression and circulating CXCR4 concentrations were characterized in response to zoledronate therapy respectively.
   ResultsAll canine OS cells express CXCR4, and zoledronate reduces CXCR4 expression and functionality by 27.7% (P < .0001), through augmented proteasome degradation and reduced prenylation of heterotrimeric G proteins in 33% of tumor cell lines evaluated. In OS bearing dogs, zoledronate reduces CXCR4 expressions by 40% within the primary tumor compared to untreated controls (P = .03) and also decreases the circulating concentrations of CXCR4 in 18 of 20 dogs with OS.
   Conclusions and clinical importanceZoledronate can alter CXCR4 expression and functionality in OS cells, and consequent perturbations in CXCR4 intracellular signaling cascades might influence patterns of metastases.
C1 [Byrum, M. L.; Pondenis, H. C.; Fan, T. M.] Univ Illinois, Dept Vet Clin Med, Urbana, IL 61801 USA.
   [Fredrickson, R. L.] Univ Illinois, Vet Diagnost Lab, Urbana, IL 61801 USA.
   [Wycislo, K. L.] Univ Illinois, Dept Pathobiol, Urbana, IL 61801 USA.
   Univ Illinois, Comparat Oncol Res Lab, Urbana, IL 61802 USA.
   [Fan, T. M.] Univ Illinois, Vet Teaching Hosp, Urbana, IL 61802 USA.
C3 University of Illinois System; University of Illinois Urbana Champaign;
   University of Illinois System; University of Illinois Urbana Champaign;
   University of Illinois System; University of Illinois Urbana Champaign;
   University of Illinois System; University of Illinois Urbana Champaign;
   University of Illinois System; University of Illinois Urbana Champaign
RP Fan, TM (通讯作者)，Dept Vet Clin Med, 1008 West Hazelwood Dr, Urbana, IL 61802 USA.
EM t fan@illinois.edu
RI Wycislo, Kathryn/AAN 3317 2021
OI Wycislo, Kathryn/0000 0002 3074 6044; Fan, Timothy/0000 0003 2510 7050;
   Pondenis, Holly/0000 0003 1708 3570
FU NIH HHS [T35 OD011145] Funding Source: Medline
CR Berenson JR, 2001, SEMIN ONCOL, V28, P25
   BRODEY RS, 1969, CLIN ORTHOP RELAT R, P54
   Busillo JM, 2007, BBA BIOMEMBRANES, V1768, P952, DOI 10.1016/j.bbamem.2006.11.002
   Chatterjee S, 2014, ADV CANCER RES, V124, P31, DOI 10.1016/B978 0 12 411638 2.00002 1
   Coleman R, 2014, LANCET ONCOL, V15, P997, DOI 10.1016/S1470 2045(14)70302 X
   Denoyelle C, 2003, BRIT J CANCER, V88, P1631, DOI 10.1038/sj.bjc.6600925
   Dong F, 2009, CLIN CANCER RES, V15, P2588, DOI 10.1158/1078 0432.CCR 08 2356
   Endo Munoz L, 2010, CANCER RES, V70, P7063, DOI 10.1158/0008 5472.CAN 09 4291
   Fan TM, 2008, J VET INTERN MED, V22, P602, DOI 10.1111/j.1939 1676.2008.0089.x
   Farese JP, 2004, IN VITRO CELL DEV AN, V40, P113, DOI 10.1290/1543 706X(2004)040<0113:TEOTBA>2.0.CO;2
   Fernandis AZ, 2002, J BIOL CHEM, V277, P18111, DOI 10.1074/jbc.M200750200
   Fournier PG, 2010, NEOPLASIA, V12, P571, DOI 10.1593/neo.10282
   Galsky MD, 2014, CLIN CANCER RES, V20, P3581, DOI 10.1158/1078 0432.CCR 13 2686
   Gibbs JB, 1997, ANNU REV PHARMACOL, V37, P143, DOI 10.1146/annurev.pharmtox.37.1.143
   Heaney ML, 1998, J LEUKOCYTE BIOL, V64, P135, DOI 10.1002/jlb.64.2.135
   Higgins JB, 1996, CELL SIGNAL, V8, P433, DOI 10.1016/S0898 6568(96)00071 X
   Im KS, 2017, VET COMP ONCOL, V15, P315, DOI 10.1111/vco.12165
   Kim SY, 2008, CLIN EXP METASTAS, V25, P201, DOI 10.1007/s10585 007 9133 3
   Labrinidis A, 2010, INT J CANCER, V127, P345, DOI 10.1002/ijc.25051
   Labrinidis A, 2009, CLIN CANCER RES, V15, P3451, DOI 10.1158/1078 0432.CCR 08 1616
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Malvoisin E, 2011, ANAL BIOCHEM, V414, P202, DOI 10.1016/j.ab.2011.03.022
   Marrari Y, 2007, BIOCHEMISTRY US, V46, P7665, DOI 10.1021/bi700338m
   Murphy PM, 2001, NEW ENGL J MED, V345, P833, DOI 10.1056/NEJM200109133451113
   Oldham WM, 2008, NAT REV MOL CELL BIO, V9, P60, DOI 10.1038/nrm2299
   Ory B, 2008, J CELL MOL MED, V12, P928, DOI 10.1111/j.1582 4934.2008.00141.x
   PAGET S, 1989, CANCER METAST REV, V8, P98
   Poirier V J, 2003, Vet Comp Oncol, V1, P207, DOI 10.1111/j.1476 5810.2003.00026.x
   Richert MM, 2009, ONCOL REP, V21, P761, DOI 10.3892/or_00000282
   Selmic LE, 2014, J VET INTERN MED, V28, P554, DOI 10.1111/jvim.12313
   SPODNICK GJ, 1992, J AM VET MED ASSOC, V200, P995
   Spugnini EP, 2009, J SMALL ANIM PRACT, V50, P44, DOI 10.1111/j.1748 5827.2008.00635.x
   Thurnher M, 2012, CLIN CANCER RES, V18, P3524, DOI 10.1158/1078 0432.CCR 12 0489
   Weiss HM, 2008, DRUG METAB DISPOS, V36, P2043, DOI 10.1124/dmd.108.021071
   Wolfe TD, 2011, CLIN EXP METASTAS, V28, P377, DOI 10.1007/s10585 011 9377 9
   Wong D, 2014, BMC UROL, V14, DOI 10.1186/1471 2490 14 12
   Zhan YZ, 2015, J CELL MOL MED, V19, P1614, DOI 10.1111/jcmm.12536
   Zlotnik A, 2008, J PATHOL, V215, P211, DOI 10.1002/path.2350
NR 38
TC 11
Z9 11
U1 0
U2 6
PU WILEY BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0891 6640
EI 1939 1676
J9 J VET INTERN MED
JI J. Vet. Intern. Med.
PD JUL AUG
PY 2016
VL 30
IS 4
BP 1187
EP 1196
DI 10.1111/jvim.14257
PG 10
WC Veterinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Veterinary Sciences
GA DS3UQ
UT WOS:000380708600032
PM 27251585
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Marycz, K
   Kolankowski, J
   Grzesiak, J
   Hecold, M
   Rac, O
   Teterycz, H
AF Marycz, Krzysztof
   Kolankowski, Jakub
   Grzesiak, Jakub
   Hecold, Mateusz
   Rac, Olga
   Teterycz, Helena
TI Application of Gold Nanoparticles of Different Concentrations to Improve
   the Therapeutic Potential of Autologous Conditioned Serum: Potential
   Implications for Equine Regenerative Medicine
SO JOURNAL OF NANOMATERIALS
LA English
DT Article
ID PLATELET RICH PLASMA; MESENCHYMAL STEM CELLS; IN VITRO; GROWTH;
   PROLIFERATION; OSTEOBLASTS; MECHANISMS; TENDONS; HORSES; BONE
AB The aim of this work was to evaluate the effect of different concentrations of gold nanoparticles (AuNPS) on equine platelet morphology, ultrastructure as well as secretion of bone morphogenetic protein 2 (BMP 2), vascular endothelial growth factor (VEGF), gelsolin (GSN), and tumor necrosis factor alpha (TNF alpha.). The gold nanoparticles, with an average diameter of 20 nm, were incubated with whole anticoagulated blood at 1%, 5%, and 10% w/v for 24 hours. We showed that the application of gold nanoparticles at all the tested concentrations led to platelet activation; however, 5% of AuNPS resulted in the secretion of elevated levels of GSN and VEGF, while the concentration of TNF alpha. was the lowest. The data indicate that this method may be considered a promising tool for improving the currently used in clinical practice commercially available autologous conditioned serum (ACS) isolation systems for the treatment of equine osteoarthritis.
C1 [Marycz, Krzysztof; Kolankowski, Jakub; Grzesiak, Jakub] Wroclaw Univ Environm & Life Sci, Electron Microscopy Lab, PL 51631 Wroclaw, Poland.
   [Grzesiak, Jakub] EIT Wroclaw Res Ctr, Dept Biotechnol, PL 54066 Wroclaw, Poland.
   [Hecold, Mateusz] Warsaw Univ Life Sci, Fac Vet Med, Dept Large Anim Dis Clin, PL 02776 Warsaw, Poland.
   [Rac, Olga; Teterycz, Helena] Wroclaw Univ Technol, Fac Microsyst Elect & Photon, PL 50372 Wroclaw, Poland.
C3 Wroclaw University of Environmental & Life Sciences; Warsaw University
   of Life Sciences; Wroclaw University of Science & Technology
RP Marycz, K (通讯作者)，Wroclaw Univ Environm & Life Sci, Electron Microscopy Lab, PL 51631 Wroclaw, Poland.
EM krzysztofmarycz@interia.pl
RI Grzesiak, Jakub/ABB 6774 2020; Rac Rumijowska, Olga/D 4885 2017; Marycz,
   Krzysztof/A 2249 2017
OI Rac Rumijowska, Olga/0000 0002 8740 6817; Teterycz,
   Helena/0000 0002 5598 2983; 
FU Wroclaw Centre of Biotechnology, programme The Leading National Research
   Centre (KNOW)
FX The project was supported by Wroclaw Centre of Biotechnology, programme
   The Leading National Research Centre (KNOW), for years 2014 2018.
CR Anitua E, 2009, CELL PROLIFERAT, V42, P162, DOI 10.1111/j.1365 2184.2009.00583.x
   Baltzer AWA, 2009, OSTEOARTHR CARTILAGE, V17, P152, DOI 10.1016/j.joca.2008.06.014
   Bogdanov AA, 2015, BIOCONJUGATE CHEM, V26, P39, DOI 10.1021/bc5005087
   Boopathi S, 2012, J ANAL METHODS CHEM, V2012, DOI 10.1155/2012/348965
   Browning SR, 2012, J BONE JOINT SURG AM, V94, pe172
   BRUST M, 1994, J CHEM SOC CHEM COMM, P801, DOI 10.1039/c39940000801
   Carofino B, 2012, ARTHROSCOPY, V28, P711, DOI 10.1016/j.arthro.2011.09.013
   Chauhan A, 2011, INT J NANOMED, V6, P2305, DOI 10.2147/IJN.S23195
   Cho HS, 2011, KOREAN J LAB MED, V31, P212, DOI 10.3343/kjlm.2011.31.3.212
   Creeper F, 2012, ORAL DIS, V18, P494, DOI 10.1111/j.1601 0825.2011.01897.x
   Daniel MC, 2004, CHEM REV, V104, P293, DOI 10.1021/cr030698+
   de Mos M, 2008, AM J SPORT MED, V36, P1171, DOI 10.1177/0363546508314430
   Faraday MX., 1997, PHILOS T ROY SOC LON, V147, P145, DOI [10.1098/rstl.1857.0011, DOI 10.1098/RSTL.1857.0011]
   Frisbie DD, 2007, AM J VET RES, V68, P290, DOI 10.2460/ajvr.68.3.290
   Frizziero A, 2013, BRIT MED BULL, V105, P169, DOI 10.1093/bmb/lds016
   García Martínez O, 2012, J ORAL MAXIL SURG, V70, P1558, DOI 10.1016/j.joms.2011.06.199
   Gawaz M, 2004, CARDIOVASC RES, V61, P498, DOI 10.1016/j.cardiores.2003.11.036
   GIERSIG M, 1993, LANGMUIR, V9, P3408, DOI 10.1021/la00036a014
   Goldring M B, 2000, Curr Rheumatol Rep, V2, P459, DOI 10.1007/s11926 000 0021 y
   Graziani F, 2006, CLIN ORAL IMPLAN RES, V17, P212, DOI 10.1111/j.1600 0501.2005.01203.x
   Guidetti GF, 2012, NANOMED NANOTECHNOL, V8, P1329, DOI 10.1016/j.nano.2012.04.001
   Hoppe CE, 2006, LANGMUIR, V22, P7027, DOI 10.1021/la060885d
   Huang CJ, 2006, J ELECTROCHEM SOC, V153, pD193, DOI 10.1149/1.2358103
   Jo CH, 2012, AM J SPORT MED, V40, P1035, DOI 10.1177/0363546512437525
   Juan ML, 2011, NAT PHOTONICS, V5, P349, DOI [10.1038/nphoton.2011.56, 10.1038/NPHOTON.2011.56]
   Kakudo N, 2008, PLAST RECONSTR SURG, V122, P1352, DOI 10.1097/PRS.0b013e3181882046
   Marycz K., 2014, J CELL SCI THERAPY, V5
   Marycz K, 2012, J ANIM VET ADV, V11, P4324
   Mazzocca AD, 2012, AM J SPORT MED, V40, P1742, DOI 10.1177/0363546512452713
   Mishra A, 2009, TISSUE ENG PART C ME, V15, P431, DOI 10.1089/ten.tec.2008.0534
   Mohammed FS, 2013, ACS SUSTAIN CHEM ENG, V1, P826, DOI 10.1021/sc400028t
   Murthy VS, 2004, J AM CHEM SOC, V126, P5292, DOI 10.1021/ja038953v
   Nicpon J, 2014, KAFKAS UNIV VET FAK, V20, P345, DOI 10.9775/kvfd.2013.10105
   Nishino J, 2008, J NANOMATER, V2008, DOI 10.1155/2008/592838
   Prokopovic V. Z., 2012, POLYM ADVAN TECHNOL, V25, P1342
   Rahme K, 2013, RSC ADV, V3, P6085, DOI 10.1039/c3ra22739a
   Roffi A, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/692913
   Song JY, 2009, PROCESS BIOCHEM, V44, P1133, DOI 10.1016/j.procbio.2009.06.005
   Sun WF, 2005, J PHYS CHEM B, V109, P20854, DOI 10.1021/jp055109d
   Sun XP, 2005, J COLLOID INTERF SCI, V288, P301, DOI 10.1016/j.jcis.2005.02.079
   Thanh NTK, 2014, CHEM REV, V114, P7610, DOI 10.1021/cr400544s
   Ullah MH, 2011, J MATER SCI, V46, P6988, DOI 10.1007/s10853 011 5667 5
   Visser LC, 2010, TISSUE ENG PT A, V16, P1021, DOI [10.1089/ten.tea.2009.0254, 10.1089/ten.TEA.2009.0254]
   Vogel JP, 2006, PLATELETS, V17, P462, DOI 10.1080/09537100600758867
   Wang CH, 2008, J PHYS D APPL PHYS, V41, DOI 10.1088/0022 3727/41/19/195301
   Wang HS, 2005, MATER CHEM PHYS, V94, P449, DOI 10.1016/j.matchemphys.2005.05.005
   Wehling P, 2007, BIODRUGS, V21, P323, DOI 10.2165/00063030 200721050 00004
   Wen SH, 2013, COLLOID SURFACE A, V419, P80, DOI 10.1016/j.colsurfa.2012.11.052
NR 48
TC 8
Z9 8
U1 0
U2 21
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1687 4110
EI 1687 4129
J9 J NANOMATER
JI J. Nanomater.
PY 2015
VL 2015
AR 521207
DI 10.1155/2015/521207
PG 9
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Materials Science
GA CO1CL
UT WOS:000358890400001
OA hybrid, Green Submitted
DA 2025 08 17
ER

PT J
AU Marupanthorn, K
   Tantrawatpan, C
   Kheolamai, P
   Tantikanlayaporn, D
   Manochantr, S
AF Marupanthorn, Kulisara
   Tantrawatpan, Chairat
   Kheolamai, Pakpoom
   Tantikanlayaporn, Duangrat
   Manochantr, Sirikul
TI MicroRNA treatment modulates osteogenic differentiation potential of
   mesenchymal stem cells derived from human chorion and placenta
SO SCIENTIFIC REPORTS
LA English
DT Article
ID HUMAN BONE MARROW; STROMAL CELLS; OSTEOBLAST DIFFERENTIATION;
   EXPRESSION; RUNX2; OSTERIX; INDUCTION; CAPACITY; MARKERS; BMP2
AB Mesenchymal stem cells (MSCs) are important in regenerative medicine because of their potential for multi differentiation. Bone marrow, chorion and placenta have all been suggested as potential sources for clinical application. However, the osteogenic differentiation potential of MSCs derived from chorion or placenta is not very efficient. Bone morphogenetic protein 2 (BMP 2) plays an important role in bone development. Its effect on osteogenic augmentation has been addressed in several studies. Recent studies have also shown a relationship between miRNAs and osteogenesis. We hypothesized that miRNAs targeted to Runt related transcription factor 2 (Runx 2), a major transcription factor of osteogenesis, are responsible for regulating the differentiation of MSCs into osteoblasts. This study examines the effect of BMP 2 on the osteogenic differentiation of MSCs isolated from chorion and placenta in comparison to bone marrow derived MSCs and investigates the role of miRNAs in the osteogenic differentiation of MSCs from these sources. MSCs were isolated from human bone marrow, chorion and placenta. The osteogenic differentiation potential after BMP 2 treatment was examined using ALP staining, ALP activity assay, and osteogenic gene expression. Candidate miRNAs were selected and their expression levels during osteoblastic differentiation were examined using real time RT PCR. The role of these miRNAs in osteogenesis was investigated by transfection with specific miRNA inhibitors. The level of osteogenic differentiation was monitored after anti miRNA treatment. MSCs isolated from chorion and placenta exhibited self renewal capacity and multi lineage differentiation potential similar to MSCs isolated from bone marrow. BMP 2 treated MSCs showed higher ALP levels and osteogenic gene expression compared to untreated MSCs. All investigated miRNAs (miR 31, miR 106a and miR148) were consistently downregulated during the process of osteogenic differentiation. After treatment with miRNA inhibitors, ALP activity and osteogenic gene expression increased over the time of osteogenic differentiation. BMP 2 has a positive effect on osteogenic differentiation of chorion  and placenta derived MSCs. The inhibition of specific miRNAs enhanced the osteogenic differentiation capacity of various MSCs in culture and this strategy might be used to promote bone regeneration. However, further in vivo experiments are required to assess the validity of this approach.
C1 [Marupanthorn, Kulisara] Chiangmai Rajabhat Univ, Fac Agr Technol, Dept Agr Technol & Dev, Chiangmai 50330, Thailand.
   [Tantrawatpan, Chairat; Kheolamai, Pakpoom; Tantikanlayaporn, Duangrat; Manochantr, Sirikul] Thammasat Univ, Fac Med, Dept Preclin Sci, Div Cell Biol, Pathum Thani 12120, Thailand.
   [Tantrawatpan, Chairat; Kheolamai, Pakpoom; Tantikanlayaporn, Duangrat; Manochantr, Sirikul] Thammasat Univ, Ctr Excellence Stem Cell Res, Pathum Thani 12120, Thailand.
C3 Chiang Mai Rajabhat University; Thammasat University; Thammasat
   University
RP Manochantr, S (通讯作者)，Thammasat Univ, Fac Med, Dept Preclin Sci, Div Cell Biol, Pathum Thani 12120, Thailand.; Manochantr, S (通讯作者)，Thammasat Univ, Ctr Excellence Stem Cell Res, Pathum Thani 12120, Thailand.
EM bsirikul@gmail.com
RI Tantikanlayaporn, Duangrat/AAB 3358 2021; Kheolamai,
   Pakpoom/R 8575 2019; Marupanthorn, Kulisara/JPA 3856 2023; Manochantr,
   Sirikul/AAX 7324 2021
OI Marupanthorn, Kulisara/0000 0002 4647 6237; Tantikanlayaporn,
   Duangrat/0000 0002 1197 4957
FU Program Management Unit for Human Resources & Institutional Development,
   Research and Innovation, Office of National Higher Education Science
   Research and Innovation Policy Council, Thailand; Center of Excellence
   in Stem Cell Research, Thammasat University
FX This work was supported by a research grant from the Program Management
   Unit for Human Resources & Institutional Development, Research and
   Innovation, Office of National Higher Education Science Research and
   Innovation Policy Council, Thailand, and Center of Excellence in Stem
   Cell Research, Thammasat University.
CR Afzal F, 2005, J CELL PHYSIOL, V204, P63, DOI 10.1002/jcp.20258
   Ankrum JA, 2014, NAT BIOTECHNOL, V32, P252, DOI 10.1038/nbt.2816
   Baglìo SR, 2013, GENE, V527, P321, DOI 10.1016/j.gene.2013.06.021
   Bianco P, 2008, CELL STEM CELL, V2, P313, DOI 10.1016/j.stem.2008.03.002
   Cava C, 2019, COMPUT MATH METHOD M, V2019, DOI 10.1155/2019/9029351
   Cheng P, 2013, J BONE MINER RES, V28, P1180, DOI 10.1002/jbmr.1845
   Dazzi F, 2006, BLOOD REV, V20, P161, DOI 10.1016/j.blre.2005.11.002
   De Biase P, 2005, INJURY, V36, P43, DOI 10.1016/j.injury.2005.07.034
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   FRIEDENSTEIN AJ, 1970, CELL TISSUE KINET, V3, P393, DOI 10.1111/j.1365 2184.1970.tb00347.x
   Fröhlich LF, 2019, CELLS BASEL, V8, DOI 10.3390/cells8020121
   Gao J, 2011, J CELL BIOCHEM, V112, P1844, DOI 10.1002/jcb.23106
   Garnero P, 2014, BONE, V66, P46, DOI 10.1016/j.bone.2014.05.016
   Gomathi K, 2020, LIFE SCI, V245, DOI 10.1016/j.lfs.2020.117389
   Heo JS, 2016, INT J MOL MED, V37, P115, DOI 10.3892/ijmm.2015.2413
   Horak M, 2016, DEV BIOL, V410, P1, DOI 10.1016/j.ydbio.2015.12.013
   Hu LF, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020360
   Kmiecik G, 2015, STEM CELL REV REP, V11, P570, DOI 10.1007/s12015 014 9569 1
   Komori T, 2006, J CELL BIOCHEM, V99, P1233, DOI 10.1002/jcb.20958
   Li HL, 2013, STEM CELL RES, V10, P313, DOI 10.1016/j.scr.2012.11.007
   Li Y, 2018, CURR STEM CELL RES T, V13, P362, DOI 10.2174/1574888X13666180403163456
   Lin ZW, 2014, EXP THER MED, V7, P625, DOI 10.3892/etm.2013.1464
   Manochantr S, 2013, INTERN MED J, V43, P430, DOI 10.1111/imj.12044
   Manochantr S, 2017, STEM CELLS INT, V2017, DOI 10.1155/2017/7257628
   Manochantr S, 2015, NEUROL RES, V37, P545, DOI 10.1179/1743132815Y.0000000019
   Marupanthorn K, 2017, INT J MOL MED, V39, P654, DOI 10.3892/ijmm.2017.2872
   Matas J, 2019, STEM CELL TRANSL MED, V8, P215, DOI 10.1002/sctm.18 0053
   Mattar P, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00560
   Mueller SM, 2001, J CELL BIOCHEM, V82, P583, DOI 10.1002/jcb.1174
   Na K, 2007, BIOMATERIALS, V28, P2631, DOI 10.1016/j.biomaterials.2007.02.008
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Nancarrow Lei R, 2017, CURR STEM CELL RES T, V12, P601, DOI 10.2174/1574888X12666170608124303
   Nishimura R, 2008, J BONE MINER METAB, V26, P203, DOI 10.1007/s00774 007 0824 2
   Oskowitz AZ, 2008, P NATL ACAD SCI USA, V105, P18372, DOI 10.1073/pnas.0809807105
   Osyczka AM, 2009, CONNECT TISSUE RES, V50, P270, DOI 10.1080/03008200902846262
   Peng SP, 2016, MOL MED REP, V14, P623, DOI 10.3892/mmr.2016.5335
   Petite H, 2000, NAT BIOTECHNOL, V18, P959, DOI 10.1038/79449
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Ryoo HM, 1997, MOL ENDOCRINOL, V11, P1681, DOI 10.1210/me.11.11.1681
   Ryoo HM, 2006, GENE, V366, P51, DOI 10.1016/j.gene.2005.10.011
   Saliminejad K, 2019, J CELL PHYSIOL, V234, P5451, DOI 10.1002/jcp.27486
   Sarugaser R, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006498
   Shen CY, 2019, CELL BIOSCI, V9, DOI 10.1186/s13578 019 0281 3
   Sinha KM, 2013, J CELL BIOCHEM, V114, P975, DOI 10.1002/jcb.24439
   Stenderup K, 2003, BONE, V33, P919, DOI 10.1016/j.bone.2003.07.005
   Svedbom A, 2019, OSTEOPOROSIS INT, V30, P1745, DOI 10.1007/s00198 019 05064 w
   Tian LJ, 2017, GENE, V627, P32, DOI 10.1016/j.gene.2017.06.002
   Vega A, 2015, TRANSPLANTATION, V99, P1681, DOI 10.1097/TP.0000000000000678
   Vemuri MC, 2011, METHODS MOL BIOL, V698, P3, DOI 10.1007/978 1 60761 999 4_1
   Wang JC, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1309 7
   Wang YX, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 1153 1
   Westhauser F, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0212799
   Xu JH, 2015, AM J TRANSL RES, V7, P2527
   Xu XM, 2012, ONCOL LETT, V4, P339, DOI 10.3892/ol.2012.714
   Yoshida CA, 2002, NAT GENET, V32, P633, DOI 10.1038/ng1015
   Zheng LL, 2017, J CELL PHYSIOL, V232, P182, DOI 10.1002/jcp.25406
NR 56
TC 10
Z9 10
U1 0
U2 7
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD APR 7
PY 2021
VL 11
IS 1
AR 7670
DI 10.1038/s41598 021 87298 5
PG 17
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA RN5MS
UT WOS:000640395800034
PM 33828198
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Ehrhart, NP
   Eurell, JA
   Constable, PD
   Gaddy, D
   Nicholas, RW
AF Ehrhart, NP
   Eurell, JA
   Constable, PD
   Gaddy, D
   Nicholas, RW
TI The effect of host tissue irradiation on large segment allograft
   incorporation
SO CLINICAL ORTHOPAEDICS AND RELATED RESEARCH
LA English
DT Article
ID BONE MORPHOGENETIC PROTEIN 2; RADIATION INDUCED IMPAIRMENT;
   MESSENGER RNA; FRACTURE; DIFFERENTIATION; OSTEOINDUCTION; EXPRESSION;
   OSTEOBLAST; SURGERY; GRAFTS
AB Therapeutic radiation delivered to bone and the adjacent local tissues before allograft limb salvage surgery has been associated with poor graft incorporation and higher numbers of clinical complications. Our objective was to determine the effect of preoperative radiation therapy on specific histologic, molecular and structural parameters of large segment, bone allograft incorporation in a canine model. Skeletally mature dogs received a total of 0, 25, or 50 Gy of radiation to the foreleg (radius and ulna) delivered in 2 Gy fractions during a 5 week period before reconstruction of a 3.5 cm defect in the radius. The dogs were sacrificed at postoperative day 150. Nondestructive four point bending was done on the harvested allograft host bone immediately after euthanasia and specimens were compared using biomechanical, histomorphometric, immunohistochemical, and in situ reverse transcription polymerase chain reaction techniques. Preoperative irradiation significantly impaired allograft incorporation as determined by radiographic healing scores, histomorphometry, and frequency of nominions. Biochemical differences included diminished bone morphogenetic protein 2 and bone morphogenetic protein 4 protein levels and messenger ribonucleic acid expression. Vascular endothelial growth factor expression was not altered. These data suggest that bone morphogenetic protein 2 and bone morphogenetic protein 4 signaling at the allograft host junction is altered after preoperative fractionated radiation and provides a plausible albeit partial mechanistic explanation for radiation mediated delays in allograft incorporation.
C1 Colorado State Univ, Anim Canc Ctr, Dept Clin Sci, Ft Collins, CO 80523 USA.
   Univ Illinois, Coll Vet Med, Dept Vet Biosci, Urbana, IL 61801 USA.
   Univ Illinois, Coll Vet Med, Dept Vet Clin Med, Urbana, IL 61801 USA.
   Univ Arkansas Med Sci, Dept Orthopaed Surg, Ctr Orthopaed Res, Little Rock, AR 72205 USA.
C3 Colorado State University System; Colorado State University Fort
   Collins; University of Illinois System; University of Illinois
   Urbana Champaign; University of Illinois System; University of Illinois
   Urbana Champaign; University of Arkansas System; University of Arkansas
   Medical Sciences
RP Colorado State Univ, Anim Canc Ctr, Dept Clin Sci, 300 W Drake St, Ft Collins, CO 80523 USA.
EM nicole.ehrhart@colostate.edu
CR Abe E, 2000, J BONE MINER RES, V15, P663, DOI 10.1359/jbmr.2000.15.4.663
   Arnold M, 1998, RADIOTHER ONCOL, V48, P259, DOI 10.1016/S0167 8140(98)00039 5
   Bauer TW., 2000, CLIN ORTHOP RELAT R, V371, P10
   Bouletreau PJ, 2002, PLAST RECONSTR SURG, V109, P2384, DOI 10.1097/00006534 200206000 00033
   BRAS J, 1990, AM J OTOLARYNG, V11, P244, DOI 10.1016/0196 0709(90)90084 9
   BROWN RK, 1991, J ORTHOP RES, V9, P876, DOI 10.1002/jor.1100090614
   Chen D, 1998, J CELL BIOL, V142, P295, DOI 10.1083/jcb.142.1.295
   Cook SD, 1996, CLIN ORTHOP RELAT R, P29, DOI 10.1097/00003086 199603000 00005
   DELLOYE C, 1992, CLIN ORTHOP RELAT R, P273
   EMERY SE, 1994, J BONE JOINT SURG AM, V76A, P540, DOI 10.2106/00004623 199404000 00008
   EURELL JA, 1995, J HISTOTECHNOL, V17, P45
   Goldberg V M, 1993, Semin Arthroplasty, V4, P58
   GRIFFITHS HJ, 1995, SKELETAL RADIOL, V24, P283
   Howard BK, 1998, ARCH OTOLARYNGOL, V124, P985, DOI 10.1001/archotol.124.9.985
   Ikeda S, 2000, INT J RADIAT BIOL, V76, P403, DOI 10.1080/095530000138745
   KIRKERHEAD CA, 1995, VET SURG, V24, P408, DOI 10.1111/j.1532 950X.1995.tb01352.x
   Lin PP, 1998, CANCER AM CANCER SOC, V82, P2356, DOI 10.1002/(SICI)1097 0142(19980615)82:12<2356::AID CNCR9>3.3.CO;2 L
   LOPEZ MJ, 1999, MECH TESTING BONE BO
   Mahajan A, 2000, Surg Oncol Clin N Am, V9, P503
   MARKBREITER LA, 1989, J ORTHOP RES, V7, P178, DOI 10.1002/jor.1100070204
   Okubo Y, 2000, INT J ORAL MAX SURG, V29, P62, DOI 10.1034/j.1399 0020.2000.290114.x
   PELKER R R, 1984, Journal of Orthopaedic Research, V2, P90, DOI 10.1002/jor.1100020114
   Pelker RR, 1997, CLIN ORTHOP RELAT R, P267
   ROSEN V, 1989, CONNECT TISSUE RES, V20, P313, DOI 10.3109/03008208909023902
   Spector JA, 2001, AM J PHYSIOL CELL PH, V280, pC72, DOI 10.1152/ajpcell.2001.280.1.C72
   Stevenson S, 1997, J BONE JOINT SURG AM, V79A, P1
   STRAW RC, 1992, J ORTHOPAED RES, V10, P434, DOI 10.1002/jor.1100100316
   Street J, 2002, P NATL ACAD SCI USA, V99, P9656, DOI 10.1073/pnas.152324099
   Suit, 1994, Cancer Control, V1, P592
   Temple WJ, 1997, ANN SURG ONCOL, V4, P586, DOI 10.1007/BF02305541
   Valcourt U, 1999, EXP CELL RES, V251, P264, DOI 10.1006/excr.1999.4584
   Wozney JM, 1998, CLIN ORTHOP RELAT R, P26
   Wurzler KK, 1998, J CRANIOFAC SURG, V9, P131
   Yasko A W, 1997, Cancer Treat Res, V90, P127
NR 34
TC 6
Z9 7
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0009 921X
EI 1528 1132
J9 CLIN ORTHOP RELAT R
JI Clin. Orthop. Rel. Res.
PD JUN
PY 2005
IS 435
BP 43
EP 51
DI 10.1097/01.blo.0000165732.64757.bb
PG 9
WC Orthopedics; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics; Surgery
GA 932MC
UT WOS:000229556800010
PM 15930920
DA 2025 08 17
ER

PT J
AU Shen, ZH
   Zeng, DF
   Wang, XY
   Ma, YY
   Zhang, X
   Kong, PY
AF Shen, Zhao Hua
   Zeng, Dong Feng
   Wang, Xiao Yan
   Ma, Ying Ying
   Zhang, Xi
   Kong, Pei Yan
TI Targeting of the leukemia microenvironment by c(RGDfV) overcomes the
   resistance to chemotherapy in acute myeloid leukemia in biomimetic
   polystyrene scaffolds
SO ONCOLOGY LETTERS
LA English
DT Article
DE endosteal niche; Opn; three dimensional culture system; c(RGDfV)
ID HEMATOPOIETIC STEM CELL; BONE; OSTEOPONTIN; NICHE; REGULATOR; ALPHA
AB The bone marrow microenvironment provides a relative sanctuary from cytotoxic drugs for leukemia cells. The present niche models concentrate on a two dimensional (2D) co culture system in vitro, which does not imitate the in vivo environment, while the 3D scaffolds are more reflective of this. Osteopontin (Opn) secreted by bone marrow osteoblasts, may participate in protecting leukemia cells from apoptosis by binding to its receptor v3, which can be expressed on the surface of the leukemia MV4 11 cell line. However, the association between the Opn/v3 axis and leukemia cells is unknown. In the present study, experiments were conducted on 3D polystyrene scaffolds coated with osteoblasts and leukemia cells. The cells were exposed to cyclo(Arg Gly Asp d Phe Val) [c(RGDfV)] (35 nmol/ml), which blocks v3, for a period of 24 h. Cytarabine was applied 24 h later. The adhesion, migration and apoptosis rates, and the cell cycle of the leukemia cells were analyzed after incubation for 24 and 48 h. In contrast to the 2D culture system, the stromal cells in the scaffolds secreted significantly more alkaline phosphatase and Opn (P<0.05). c(RGDfV) disrupted the adhesion and migration between the tumor cells and the matrix, induced the leukemia cells to leave the protective microenvironment and increased their sensitivity to cell cycle dependent agents (P<0.05). In summary, the data certified that the 3D scaffolds are suitable for the growth of cells, and that c(RGDfV) inhibits the adhesion and migration abilities of leukemia cells in the endosteal niche. Therefore, blocking the function of Opn may be beneficial in the treatment of acute myeloid leukemia.
C1 [Shen, Zhao Hua; Zeng, Dong Feng; Ma, Ying Ying; Zhang, Xi; Kong, Pei Yan] Third Mil Med Univ, Xinqiao Hosp, Dept Hematol, 183 Xinqiao St, Chongqing 400037, Peoples R China.
   [Shen, Zhao Hua; Wang, Xiao Yan] Cent S Univ, Xiangya Hosp 3, Dept Gastroenterol, Changsha 410013, Hunan, Peoples R China.
C3 Army Medical University; Central South University
RP Kong, PY (通讯作者)，Third Mil Med Univ, Xinqiao Hosp, Dept Hematol, 183 Xinqiao St, Chongqing 400037, Peoples R China.
EM peiyankong@aliyun.com
RI Wang, Xiaoyan/M 7442 2018; shen, zhaohua/HLH 7953 2023
FU National Natural Science Foundation, the Key Discipline of Medical
   Science of China [81000195]
FX This study was supported by a grant from the National Natural Science
   Foundation, the Key Discipline of Medical Science of China (grant no.
   81000195).
CR Balduino A, 2005, CELL TISSUE RES, V319, P255, DOI 10.1007/s00441 004 1006 3
   Bissell MJ, 2003, CURR OPIN CELL BIOL, V15, P753, DOI 10.1016/j.ceb.2003.10.016
   Breslin S, 2013, DRUG DISCOV TODAY, V18, P240, DOI 10.1016/j.drudis.2012.10.003
   Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040
   Courter D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009633
   Eliasson P, 2010, J CELL PHYSIOL, V222, P17, DOI 10.1002/jcp.21908
   Haylock DN, 2006, BRIT J HAEMATOL, V134, P467, DOI 10.1111/j.1365 2141.2006.06218.x
   HIJIYA N, 1994, BIOCHEM J, V303, P255, DOI 10.1042/bj3030255
   KASSEM M, 1991, APMIS, V99, P269, DOI 10.1111/j.1699 0463.1991.tb05149.x
   Kluza E, 2010, NANO LETT, V10, P52, DOI 10.1021/nl902659g
   Lane SW, 2009, BLOOD, V114, P1150, DOI 10.1182/blood 2009 01 202606
   Lee CY, 2008, BRIT J HAEMATOL, V141, P736, DOI 10.1111/j.1365 2141.2008.07082.x
   Locatelli F, 2007, HAEMATOLOGICA, V92, P872, DOI 10.3324/haematol.11479
   Meads MB, 2008, CLIN CANCER RES, V14, P2519, DOI 10.1158/1078 0432.CCR 07 2223
   Méndez Ferrer S, 2010, NATURE, V466, P829, DOI 10.1038/nature09262
   Mitjans F, 2000, INT J CANCER, V87, P716, DOI 10.1002/1097 0215(20000901)87:5<716::AID IJC14>3.0.CO;2 R
   Moqattash S, 1998, P SOC EXP BIOL MED, V219, P8
   Nilsson SK, 2005, BLOOD, V106, P1232, DOI 10.1182/blood 2004 11 4422
   Paraguassú Braga FH, 2003, CELL DEATH DIFFER, V10, P1101, DOI 10.1038/sj.cdd.4401279
   Rodríguez JP, 2004, J CELL BIOCHEM, V93, P721, DOI 10.1002/jcb.20234
   Saito Y, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000349
   SCHOFIELD R, 1978, BLOOD CELLS, V4, P7
   Tabe Y, 2004, BLOOD, V103, P1815, DOI 10.1182/blood 2003 03 0802
   Visnjic D, 2004, BLOOD, V103, P3258, DOI 10.1182/blood 2003 11 4011
NR 24
TC 11
Z9 11
U1 1
U2 11
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792 1074
EI 1792 1082
J9 ONCOL LETT
JI Oncol. Lett.
PD NOV
PY 2016
VL 12
IS 5
BP 3278
EP 3284
DI 10.3892/ol.2016.5042
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA ED4RR
UT WOS:000388838900036
PM 27899994
OA Green Submitted, Green Published, gold
DA 2025 08 17
ER

PT J
AU Hokugo, A
   Kanayama, K
   Sun, ST
   Morinaga, K
   Sun, YJ
   Wu, QQ
   Sasaki, H
   Okawa, H
   Evans, C
   Ebetino, FH
   Lundy, MW
   Sadrerafi, K
   McKenna, CE
   Nishimura, I
AF Hokugo, Akishige
   Kanayama, Keiichi
   Sun, Shuting
   Morinaga, Kenzo
   Sun, Yujie
   Wu, QingQing
   Sasaki, Hodaka
   Okawa, Hiroko
   Evans, Courtney
   Ebetino, Frank H.
   Lundy, Mark W.
   Sadrerafi, Keivan
   McKenna, Charles E.
   Nishimura, Ichiro
TI Rescue bisphosphonate treatment of alveolar bone improves extraction
   socket healing and reduces osteonecrosis in zoledronate treated mice
SO BONE
LA English
DT Article
DE Bisphosphonates; Osteonecrosis of the jaw; BRONJ; MRONJ; Drug
   displacement; Prophylaxis
ID MEDICATION RELATED OSTEONECROSIS; INDUCE OSTEONECROSIS; JAW; DISEASE;
   ASSOCIATION; PREVALENCE; MECHANISMS; ANALOGS; CELLS; ONJ
AB Bisphosphonate (BP) related osteonecrosis of the jaw, previously known as BRONJ, now referred to more broadly as medication related osteonecrosis of the jaw (MRONJ), is a morbid condition that represents a significant risk for oncology patients who have received high dose intravenous (IV) infusion of a potent nitrogen containing BP (N BP) drug. At present, no clinical procedure is available to prevent or effectively treat MRONJ. Although the pathophysiological basis is not yet fully understood, legacy adsorbed N BP in jawbone has been proposed to be associated with BRONJ by one or more mechanisms. We hypothesized that removal of the preadsorbed N BP drug common to these pathological mechanisms from alveolar bone could be an effective preventative/therapeutic strategy. This study demonstrates that fluorescently labeled BP preadsorbed on the surface of murine maxillo cranial bone in vivo can be displaced by subsequent application of other Bps. We previously described rodent BRONJ models involving the combination of N BP treatment such as zoledronate (ZOL) and dental initiating factors such as tooth extraction. We further refined our mouse model by using gel food during the first 7 days of the tooth extraction wound healing period, which decreased confounding food pellet impaction problems in the open boney socket. This refined mouse model does not manifest BRONJ like severe jawbone exposure, but development of osteonecrosis around the extraction socket and chronic gingival inflammation are clearly exhibited. In this study, we examined the effect of benign BP displacement of legacy N BP on tooth extraction wound healing in the in vivo model. Systemic IV administration of a low potency BP (lpBP: defined as inactive at 100 mu M in a standard protein anti prenylation assay) did not significantly attenuate jawbone osteonecrosis. We then developed an intra oral formulation of lpBP, which when injected into the gingiva adjacent to the tooth prior to extraction, dramatically reduced the osteocyte necrosis area. Furthermore, the tooth extraction wound healing pattern was normalized, as evidenced by timely closure of oral soft tissue without epithelial hyperplasia, significantly reduced gingival inflammation and increased new bone filling in the extraction socket. Our results are consistent with the hypothesis that local application of a rescue BP prior to dental surgery can decrease the amount of a legacy N BP drug in proximate jawbone surfaces below the threshold that promotes osteocyte necrosis. This observation should provide a conceptual basis for a novel strategy to improve socket healing in patients treated with BPs while preserving therapeutic benefit from anti resorptive N BP drug in vertebral and appendicular bones.
C1 [Hokugo, Akishige; Kanayama, Keiichi; Sun, Shuting; Morinaga, Kenzo; Sun, Yujie; Wu, QingQing; Sasaki, Hodaka; Okawa, Hiroko; Evans, Courtney] UCLA, Sch Dent, Weintraub Ctr Reconstruct Biotechnol, Los Angeles, CA 90095 USA.
   [Hokugo, Akishige] UCLA, Dept Surg, Div Plast & Reconstruct Surg, Regenerat Bioengn & Repair Lab,David Geffen Sch M, Los Angeles, CA 90095 USA.
   [Kanayama, Keiichi] Asahi Univ, Sch Dent, Dept Periodontol, Gifu 5010296, Japan.
   [Sun, Shuting; Ebetino, Frank H.; Lundy, Mark W.; Sadrerafi, Keivan] Bio Vinc LLC, Pasadena, CA 91107 USA.
   [Morinaga, Kenzo] Fukuoka Dent Coll, Dept Oral Rehabil, Sect Implantol, Fukuoka, Fukuoka 8140175, Japan.
   [Sun, Yujie] Capital Med Univ, Beijing Stomatol Hosp, Dept Dent Implant Ctr, Sch Stomatol, Beijing 10050, Peoples R China.
   [Wu, QingQing] Chongqing Med Univ, Stomatol Hosp, Dept Oral Implantol, Chongqing Key Lab Oral Dis & Biomed Sci, Chongqing 400015, Peoples R China.
   [Sasaki, Hodaka] Tokyo Dent Coll, Dept Oral & Maxillofacial Implantol, Tokyo 1010061, Japan.
   [Okawa, Hiroko] Tohoku Univ, Div Mol & Regenerat Prosthodont, Grad Sch Dent, Sendai, Miyagi 9808575, Japan.
   [McKenna, Charles E.] Univ Southern Calif, Dana & David Dornsife Coll Letters Arts & Sci, Dept Chem, Los Angeles, CA 90089 USA.
   [Nishimura, Ichiro] UCLA, Sch Dent, Weintraub Ctr Reconstruct Biotechnol, Box 951668 CHS B3 087, Los Angeles, CA 90095 USA.
C3 University of California System; University of California Los Angeles;
   University of California System; University of California Los Angeles;
   Asahi University; Fukuoka Dental College (FDC); Capital Medical
   University; Chongqing Medical University; Tokyo Dental College; Tohoku
   University; University of Southern California; University of California
   System; University of California Los Angeles
RP Sun, ST (通讯作者)，Bio Vinc LLC, Pasadena, CA 91107 USA.; McKenna, CE (通讯作者)，Univ Southern Calif, Dana & David Dornsife Coll Letters Arts & Sci, Dept Chem, Los Angeles, CA 90089 USA.; Nishimura, I (通讯作者)，UCLA, Sch Dent, Weintraub Ctr Reconstruct Biotechnol, Box 951668 CHS B3 087, Los Angeles, CA 90095 USA.
EM shuting.sun@biovinc.com; mckenna@usc.edu; inishimura@dentistry.ucla.edu
RI ; Sun, Shuting/N 1807 2014
OI Sun, Shuting/0000 0002 3635 9029; 
FU NIH/NIDCR [1R43DE025524, 2R44DE025524, R01DE022552, R21DE023410];
   NIH/NCRR [C06RR014529]; USC College of Letters, Arts and Sciences
FX This work was supported by NIH/NIDCR grants 1R43DE025524, 2R44DE025524,
   R01DE022552, R21DE023410, by NIH/NCRR grant C06RR014529 and by the USC
   College of Letters, Arts and Sciences. We thank the UCLA Translational
   Pathology Core Laboratory (TPCL) for histopathological specimen
   preparation. We also thank Dr. Matthew J. Schibler, UCLA CNSI for the
   technical support for confocal microscopy.
CR Aftimos V, 2014, INT J DENT, V2014, DOI 10.1155/2014/869067
   Aghaloo T, 2015, ORAL MAXIL SURG CLIN, V27, P489, DOI 10.1016/j.coms.2015.06.001
   Aghaloo TL, 2014, J ORAL MAXIL SURG, V72, P702, DOI 10.1016/j.joms.2013.09.008
   Aghaloo TL, 2011, J BONE MINER RES, V26, P1871, DOI 10.1002/jbmr.379
   Aguirre JI, 2012, J BONE MINER RES, V27, P2130, DOI 10.1002/jbmr.1669
   Allen MR, 2011, ODONTOLOGY, V99, P8, DOI 10.1007/s10266 010 0153 0
   Bauss F, 2002, J RHEUMATOL, V29, P2200
   Coxon FP, 2001, J BIOL CHEM, V276, P48213, DOI 10.1074/jbc.M106473200
   de Molon RS, 2015, J BONE MINER RES, V30, P1627, DOI 10.1002/jbmr.2490
   Devlin H, 2018, BRIT DENT J, V224, DOI 10.1038/sj.bdj.2017.1001
   Diab DL, 2013, THER ADV MUSCULOSKEL, V5, P107, DOI 10.1177/1759720X13477714
   Duan X, 2010, J BONE MINER RES  S1, V25, pS347
   Ebetino F. H., 2017, PCTUS2017035169
   Ebetino FH, 2011, BONE, V49, P20, DOI 10.1016/j.bone.2011.03.774
   El Rabbany M, 2017, J AM DENT ASSOC, V148, P584, DOI 10.1016/j.adaj.2017.04.002
   Elsayed R, 2018, BONE, V110, P141, DOI 10.1016/j.bone.2018.01.030
   Fedele S, 2010, AM J MED, V123, P1060, DOI 10.1016/j.amjmed.2010.04.033
   Ferlito S, 2011, J ORAL MAXIL SURG, V69, pE1, DOI 10.1016/j.joms.2010.10.055
   FRANCIS MD, 1980, J NUCL MED, V21, P1185
   Hadaya D, 2019, J ORAL MAXIL SURG, V77, P71, DOI 10.1016/j.joms.2018.08.010
   Hansen T, 2007, VIRCHOWS ARCH, V451, P1009, DOI 10.1007/s00428 007 0516 2
   Hokugo A, 2013, BONE, V53, P59, DOI 10.1016/j.bone.2012.11.030
   Hokugo A, 2010, J BONE MINER RES, V25, P1337, DOI 10.1002/jbmr.23
   Hutcheson A, 2014, J ORAL MAXIL SURG, V72, P1456, DOI 10.1016/j.joms.2014.02.036
   Jha S, 2015, J BONE MINER RES, V30, P2179, DOI 10.1002/jbmr.2565
   Kalyan S, 2015, J TRANSL MED, V13, DOI 10.1186/s12967 015 0568 z
   Kang B, 2013, J BONE MINER RES, V28, P1631, DOI 10.1002/jbmr.1894
   Kashemirov BA, 2008, BIOCONJUGATE CHEM, V19, P2308, DOI 10.1021/bc800369c
   Kawamoto T, 2003, ARCH HISTOL CYTOL, V66, P123, DOI 10.1679/aohc.66.123
   Khan AA, 2015, J BONE MINER RES, V30, P3, DOI 10.1002/jbmr.2405
   Khosla S, 2007, J BONE MINER RES, V22, P1479, DOI 10.1359/JBMR.0707ONJ
   Landesberg R, 2011, ANN NY ACAD SCI, V1218, P62, DOI 10.1111/j.1749 6632.2010.05835.x
   Lin TC, 2014, OSTEOPOROSIS INT, V25, P1503, DOI 10.1007/s00198 014 2624 6
   Mark DB, 2014, CIRC CARDIOVASC QUAL, V7, P508, DOI 10.1161/CIRCOUTCOMES.114.000977
   McGowan K, 2018, ORAL DIS, V24, P527, DOI 10.1111/odi.12708
   Montefusco V, 2008, LEUKEMIA LYMPHOMA, V49, P2156, DOI 10.1080/10428190802483778
   Nicolatou Galitis O, 2015, OR SURG OR MED OR PA, V120, P699, DOI 10.1016/j.oooo.2015.08.007
   Oizumi T, 2016, BIOL PHARM BULL, V39, P1549, DOI 10.1248/bpb.b16 00041
   Park S, 2015, J BIOL CHEM, V290, P17349, DOI 10.1074/jbc.M115.652305
   Pratt G, 2007, BRIT J HAEMATOL, V138, P563, DOI 10.1111/j.1365 2141.2007.06705.x
   Ruggiero SL, 2014, J ORAL MAXIL SURG, V72, P1938, DOI 10.1016/j.joms.2014.04.031
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Russmueller G, 2016, SCI REP UK, V6, DOI 10.1038/srep31604
   Schiodt M, 2014, OR SURG OR MED OR PA, V117, P204, DOI 10.1016/j.oooo.2013.10.010
   Shibahara T, 2018, J ORAL MAXIL SURG, V76, P2105, DOI 10.1016/j.joms.2018.04.009
   Soundia A, 2018, OR SURG OR MED OR PA, V126, P537, DOI 10.1016/j.oooo.2018.08.005
   Sun ST, 2016, BIOCONJUGATE CHEM, V27, P329, DOI 10.1021/acs.bioconjchem.5b00369
   Sun YJ, 2016, J BIOL CHEM, V291, P20602, DOI 10.1074/jbc.M116.735795
   Taguchi A, 2019, J BONE MINER METAB, V37, P886, DOI 10.1007/s00774 019 00990 5
   Topaloglu G, 2017, J CRANIO MAXILL SURG, V45, P1158, DOI 10.1016/j.jcms.2017.05.003
   Tseng HC, 2015, ONCOTARGET, V6, P20002, DOI 10.18632/oncotarget.4755
   van Beek ER, 1998, BONE, V23, P437, DOI 10.1016/S8756 3282(98)00120 3
   Vandone AM, 2012, ANN ONCOL, V23, P193, DOI 10.1093/annonc/mdr039
   Yamaguchi K, 2010, J ORAL MAXIL SURG, V68, P889, DOI 10.1016/j.joms.2009.04.048
   Zandi M, 2017, J CRANIO MAXILL SURG, V45, P157, DOI 10.1016/j.jcms.2016.10.015
   Zustin J, 2014, IN VIVO, V28, P125
   2018, AM J PATHOL, V188, P2318, DOI DOI 10.1016/J.AJPATH.2018.06.019
   2012, PHARMACOEPIDEM DR S, V21, P810, DOI DOI 10.1002/PDS.3292
   2013, INT J EXP PATHOL, V94, P65, DOI DOI 10.1111/IEP.12007
   2010, J ORAL MAXILLOFAC SU, V68, P2232, DOI DOI 10.1016/J.JOMS.2010.05.003
NR 60
TC 29
Z9 30
U1 1
U2 29
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD JUN
PY 2019
VL 123
BP 115
EP 128
DI 10.1016/j.bone.2019.03.027
PG 14
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA HY1PW
UT WOS:000467890000014
PM 30926440
OA Green Accepted, Green Submitted
DA 2025 08 17
ER

PT J
AU Galea, GL
   Meakin, LB
   Sugiyama, T
   Zebda, N
   Sunters, A
   Taipaleenmaki, H
   Stein, GS
   van Wijnen, AJ
   Lanyon, LE
   Price, JS
AF Galea, Gabriel L.
   Meakin, Lee B.
   Sugiyama, Toshihiro
   Zebda, Noureddine
   Sunters, Andrew
   Taipaleenmaki, Hanna
   Stein, Gary S.
   van Wijnen, Andre J.
   Lanyon, Lance E.
   Price, Joanna S.
TI Estrogen Receptor α Mediates Proliferation of Osteoblastic Cells
   Stimulated by Estrogen and Mechanical Strain, but Their Acute
   Down regulation of the Wnt Antagonist Sost Is Mediated by
   Estrogen Receptor β
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID BREAST CANCER CELLS; INHIBITS ADIPOCYTE DIFFERENTIATION; MESENCHYMAL
   STEM CELLS; ER ALPHA; GENE EXPRESSION; CORTICAL BONE; IN VIVO;
   OSTEOGENIC RESPONSE; POSTMENOPAUSAL WOMEN; SIGNALING PATHWAYS
AB Mechanical strain and estrogens both stimulate osteoblast proliferation through estrogen receptor (ER) mediated effects, and both down regulate the Wnt antagonist Sost/sclerostin. Here, we investigate the differential effects of ER alpha and  beta in these processes in mouse long bone derived osteoblastic cells and human Saos 2 cells. Recruitment to the cell cycle following strain or 17 beta estradiol occurs within 30 min, as determined by Ki 67 staining, and is prevented by the ER alpha antagonist 1,3 bis(4 hydroxyphenyl) 4 methyl 5 [4 (2 piperidinylethoxy)phenol] 1H pyrazole dihydrochloride. ER beta inhibition with 4 [2 phenyl 5,7 bis(trifluoromethyl)pyrazolo[1,5 beta]pyrimidin 3 yl]phenol (PTHPP) increases basal proliferation similarly to strain or estradiol. Both strain and estradiol down regulate Sost expression, as does in vitro inhibition or in vivo deletion of ER alpha. The ER beta agonists 2,3 bis(4 hydroxyphenyl) propionitrile and ERB041 also down regulated Sost expression in vitro, whereas the ER alpha agonist 4,4',4 '' [4 propyl (1H) pyrazol 1,3,5 triyl]tris phenol or the ER beta antagonist PTHPP has no effect. Tamoxifen, a nongenomic ER beta agonist, down regulates Sost expression in vitro and in bones in vivo. Inhibition of both ERs with fulvestrant or selective antagonism of ER beta, but not ER alpha, prevents Sost down regulation by strain or estradiol. Sost down regulation by strain or ER beta activation is prevented by MEK/ERK blockade. Exogenous sclerostin has no effect on estradiol induced proliferation but prevents that following strain. Thus, in osteoblastic cells the acute proliferative effects of both estradiol and strain are ER alpha mediated. Basal Sost down regulation follows decreased activity of ER alpha and increased activity of ER beta. Sost down regulation by strain or increased estrogens is mediated by ER beta, not ER alpha. ER targeting therapy may facilitate structurally appropriate bone formation by enhancing the distinct ligand independent, strain related contributions to proliferation of both ER alpha and ER beta.
C1 [Galea, Gabriel L.; Meakin, Lee B.; Sugiyama, Toshihiro; Zebda, Noureddine; Lanyon, Lance E.; Price, Joanna S.] Univ Bristol, Sch Vet Sci, Bristol BS40 5DU, Avon, England.
   [Sunters, Andrew] Univ London, Royal Vet Coll, London NW1 0TU, England.
   [Taipaleenmaki, Hanna; Stein, Gary S.; van Wijnen, Andre J.] Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA.
   [Taipaleenmaki, Hanna; Stein, Gary S.; van Wijnen, Andre J.] Univ Massachusetts, Sch Med, Ctr Canc, Worcester, MA 01655 USA.
C3 University of Bristol; University of London; University of London Royal
   Veterinary College; University of Massachusetts System; University of
   Massachusetts Worcester; University of Massachusetts System; University
   of Massachusetts Worcester
RP Galea, GL (通讯作者)，Univ Bristol, Sch Vet Sci, Southwell St, Bristol BS2 8EJ, Avon, England.
EM gabriel.galea@bristol.ac.uk
RI ; Galea, Gabriel/I 9374 2019; Meakin, Lee/H 7726 2019; van Wijnen,
   Andre/AAG 3578 2019
OI Meakin, Lee/0000 0002 2161 9414; Galea, Gabriel/0000 0003 2515 1342;
   Sugiyama, Toshihiro/0000 0001 5551 1340; van Wijnen, Andre
   J./0000 0002 4458 0946; 
FU Wellcome Trust; National Institutes of Health Grant [R01AR049069]
FX This work was supported by the Wellcome Trust. This work was also
   supported in part by National Institutes of Health Grant R01AR049069 (to
   A. v. W.). Recipients of veterinary integrated training fellowships from
   the Wellcome Trust.
CR Aguirre JI, 2007, J BIOL CHEM, V282, P25501, DOI 10.1074/jbc.M702231200
   Ahdjoudj S, 2002, J BONE MINER RES, V17, P668, DOI 10.1359/jbmr.2002.17.4.668
   Almeida M, 2013, J CLIN INVEST, V123, P394, DOI 10.1172/JCI65910
   Almeida M, 2010, J BONE MINER RES, V25, P769, DOI 10.1359/jbmr.091017
   Ardawi MSM, 2012, OSTEOPOROSIS INT, V23, P1789, DOI 10.1007/s00198 011 1806 8
   Armstrong VJ, 2007, J BIOL CHEM, V282, P20715, DOI 10.1074/jbc.M703224200
   Barou O, 1998, AM J PHYSIOL ENDOC M, V274, pE108, DOI 10.1152/ajpendo.1998.274.1.E108
   Bartella V, 2012, BREAST CANCER RES TR, V134, P569, DOI 10.1007/s10549 012 2090 9
   Becker K. A., 2005, CELL BIOL HDB LAB MA, P103
   Becker KA, 2010, J CELL PHYSIOL, V222, P103, DOI 10.1002/jcp.21925
   Bord S, 2001, J CLIN ENDOCR METAB, V86, P2309, DOI 10.1210/jc.86.5.2309
   Börjesson AE, 2011, P NATL ACAD SCI USA, V108, P6288, DOI 10.1073/pnas.1100454108
   Bradford PG, 2010, PHYSIOL BEHAV, V99, P181, DOI 10.1016/j.physbeh.2009.04.025
   Braidman IP, 2001, J BONE MINER RES, V16, P214, DOI 10.1359/jbmr.2001.16.2.214
   Callewaert F, 2010, J BONE MINER RES, V25, P124, DOI 10.1359/jbmr.091001
   Cao LH, 2003, J CELL BIOCHEM, V89, P152, DOI 10.1002/jcb.10486
   Cardoso L, 2009, J BONE MINER RES, V24, P597, DOI 10.1359/JBMR.081210
   Case N, 2008, J BIOL CHEM, V283, P29196, DOI 10.1074/jbc.M801907200
   Chang EC, 2006, ENDOCRINOLOGY, V147, P4831, DOI 10.1210/en.2006 0563
   Cheng MZ, 2002, J BONE MINER RES, V17, P593, DOI 10.1359/jbmr.2002.17.4.593
   Chung CJ, 2007, AM J ORTHOD DENTOFAC, V132, pU13, DOI 10.1016/j.ajodo.2007.02.049
   Compton DR, 2004, J MED CHEM, V47, P5872, DOI 10.1021/jm049631k
   Cooke AL, 2008, J CLIN ONCOL, V26, P5227, DOI 10.1200/JCO.2007.15.7123
   Damien E, 1998, J BONE MINER RES, V13, P1275, DOI 10.1359/jbmr.1998.13.8.1275
   Damien E, 2000, J BONE MINER RES, V15, P2169, DOI 10.1359/jbmr.2000.15.11.2169
   Dupont S, 2000, DEVELOPMENT, V127, P4277
   Ellies DL, 2006, J BONE MINER RES, V21, P1738, DOI 10.1359/JBMR.060810
   Emerton KB, 2010, BONE, V46, P577, DOI 10.1016/j.bone.2009.11.006
   Galea GL, 2011, FEBS LETT, V585, P2450, DOI 10.1016/j.febslet.2011.06.019
   Ghule PN, 2007, J CELL PHYSIOL, V213, P9, DOI 10.1002/jcp.21119
   Ghule PN, 2011, J CELL PHYSIOL, V226, P1149, DOI 10.1002/jcp.22440
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Hagino H, 2005, BONE, V36, P444, DOI 10.1016/j.bone.2004.12.013
   Harrington WR, 2003, MOL CELL ENDOCRINOL, V206, P13, DOI 10.1016/S0303 7207(03)00255 7
   Hawse JR, 2008, MOL ENDOCRINOL, V22, P1579, DOI 10.1210/me.2007 0253
   Hong L, 2011, STEM CELLS DEV, V20, P925, DOI 10.1089/scd.2010.0125
   Hong L, 2009, J STEROID BIOCHEM, V114, P180, DOI 10.1016/j.jsbmb.2009.02.001
   Il Mödder U, 2011, J BONE MINER RES, V26, P27, DOI 10.1002/jbmr.128
   Ivanova MM, 2011, FASEB J, V25, P1402, DOI 10.1096/fj.10 169029
   Jessop HL, 2004, J BONE MINER RES, V19, P938, DOI 10.1359/jbmr.2004.19.6.938
   Jessop HL, 2002, BONE, V31, P186, DOI 10.1016/S8756 3282(02)00797 4
   Jessop HL, 2001, J BONE MINER RES, V16, P1045, DOI 10.1359/jbmr.2001.16.6.1045
   Jin WJ, 2012, OSTEOPOROSIS INT, V23, P2469, DOI 10.1007/s00198 011 1859 8
   Kallio A, 2008, MOL CELL ENDOCRINOL, V289, P38, DOI 10.1016/j.mce.2008.03.005
   Keller H, 2005, BONE, V37, P148, DOI 10.1016/j.bone.2005.03.018
   Khalid O, 2008, ENDOCRINOLOGY, V149, P5984, DOI 10.1210/en.2008 0680
   Kietz S, 2004, BIOCHEM BIOPH RES CO, V320, P76, DOI 10.1016/j.bbrc.2004.05.132
   Kim JH, 2011, BMB REP, V44, P452, DOI 10.5483/BMBRep.2011.44.7.452
   Kousteni S, 2001, CELL, V104, P719, DOI 10.1016/S0092 8674(02)08100 X
   Krause C, 2010, J BIOL CHEM, V285, P41614, DOI 10.1074/jbc.M110.153890
   Krum SA, 2008, EMBO J, V27, P535, DOI 10.1038/sj.emboj.7601984
   Kudwa AE, 2003, J NEUROENDOCRINOL, V15, P978, DOI 10.1046/j.1365 2826.2003.01089.x
   Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252
   Kushner PJ, 2000, J STEROID BIOCHEM, V74, P311, DOI 10.1016/S0960 0760(00)00108 4
   Lanyon L, 2001, J BONE MINER RES, V16, P1937, DOI 10.1359/jbmr.2001.16.11.1937
   Lanyon LE, 2007, CLIN REV BONE MINER, V5, P234, DOI 10.1007/s12018 008 9011 9
   Lee K, 2003, NATURE, V424, P389, DOI 10.1038/424389a
   Lee KCL, 2004, J ENDOCRINOL, V182, P193, DOI 10.1677/joe.0.1820193
   Leskelä HV, 2006, BONE, V39, P1026, DOI 10.1016/j.bone.2006.05.003
   Li Y, 2012, J BONE MINER RES, V27, P1263, DOI 10.1002/jbmr.1574
   Lindberg K, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2865
   Lindberg MK, 2003, MOL ENDOCRINOL, V17, P203, DOI 10.1210/me.2002 0206
   Maran A, 2006, BONE, V39, P523, DOI 10.1016/j.bone.2006.03.006
   Matthews Jason, 2003, Mol Interv, V3, P281, DOI 10.1124/mi.3.5.281
   McCarthy TL, 2011, GENE, V479, P16, DOI 10.1016/j.gene.2011.02.002
   Meyers MJ, 2001, J MED CHEM, V44, P4230, DOI 10.1021/jm010254a
   Mödder UI, 2011, J BONE MINER RES, V26, P373, DOI 10.1002/jbmr.217
   Monroe DG, 2003, J CELL BIOCHEM, V90, P315, DOI 10.1002/jcb.10633
   Moustafa A, 2012, OSTEOPOROSIS INT, V23, P1225, DOI 10.1007/s00198 011 1656 4
   Niziolek PJ, 2012, BONE, V51, P459, DOI 10.1016/j.bone.2012.05.023
   Noble BS, 2003, AM J PHYSIOL CELL PH, V284, pC934, DOI 10.1152/ajpcell.00234.2002
   Ogita M, 2008, ENDOCRINOLOGY, V149, P5713, DOI 10.1210/en.2008 0369
   Okazaki R, 2002, ENDOCRINOLOGY, V143, P2349, DOI 10.1210/en.143.6.2349
   Omoto Y, 2003, ONCOGENE, V22, P5011, DOI 10.1038/sj.onc.1206787
   Padhi D, 2011, J BONE MINER RES, V26, P19, DOI 10.1002/jbmr.173
   PEAD MJ, 1988, J BONE MINER RES, V3, P647
   Pettersson K, 2000, ONCOGENE, V19, P4970, DOI 10.1038/sj.onc.1203828
   Quaedackers ME, 2001, ENDOCRINOLOGY, V142, P1156, DOI 10.1210/en.142.3.1156
   Robling AG, 2008, J BIOL CHEM, V283, P5866, DOI 10.1074/jbc.M705092200
   Roosa SMM, 2011, J BONE MINER RES, V26, P100, DOI 10.1002/jbmr.193
   Rozen S, 2000, Methods Mol Biol, V132, P365
   Saika M, 2001, ENDOCRINOLOGY, V142, P2205, DOI 10.1210/en.142.6.2205
   Sakai D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024847
   Sawakami K, 2006, J BIOL CHEM, V281, P23698, DOI 10.1074/jbc.M601000200
   Saxon LK, 2007, AM J PHYSIOL ENDOC M, V293, pE484, DOI 10.1152/ajpendo.00189.2007
   Saxon LK, 2012, ENDOCRINOLOGY, V153, P2254, DOI 10.1210/en.2011 1977
   Saxon LK, 2011, BONE, V49, P184, DOI 10.1016/j.bone.2011.03.683
   Sen B, 2008, ENDOCRINOLOGY, V149, P6065, DOI 10.1210/en.2008 0687
   Sen B, 2009, J BIOL CHEM, V284, P34607, DOI 10.1074/jbc.M109.039453
   Setchell KDR, 2005, AM J CLIN NUTR, V81, P1072
   Sevetson B, 2004, J BIOL CHEM, V279, P13849, DOI 10.1074/jbc.M306249200
   Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522
   Silvestrini G, 2007, J MOL HISTOL, V38, P261, DOI 10.1007/s10735 007 9096 3
   Sims NA, 2002, BONE, V30, P18, DOI 10.1016/S8756 3282(01)00643 3
   Somjen D, 2011, J STEROID BIOCHEM, V125, P226, DOI 10.1016/j.jsbmb.2011.03.006
   Stauffer SR, 2000, J MED CHEM, V43, P4934, DOI 10.1021/jm000170m
   Stossi F, 2004, ENDOCRINOLOGY, V145, P3473, DOI 10.1210/en.2003 1682
   Sugiyama T, 2008, BONE, V43, P238, DOI 10.1016/j.bone.2008.04.012
   Sugiyama T, 2010, ENDOCRINOLOGY, V151, P5582, DOI 10.1210/en.2010 0645
   Sunters A, 2010, J BIOL CHEM, V285, P8743, DOI 10.1074/jbc.M109.027086
   Taku K, 2011, MATURITAS, V70, P333, DOI 10.1016/j.maturitas.2011.09.001
   Tong JS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015408
   Tu XL, 2012, BONE, V50, P209, DOI 10.1016/j.bone.2011.10.025
   Turner CH, 1998, BONE, V22, P463, DOI 10.1016/S8756 3282(98)00041 6
   van der Eerden BCJ, 2004, J ENDOCRINOL, V180, P457, DOI 10.1677/joe.0.1800457
   Waters KM, 2001, J CELL BIOCHEM, V83, P448, DOI 10.1002/jcb.1242
   Williams C, 2008, ONCOGENE, V27, P1019, DOI 10.1038/sj.onc.1210712
   Windahl SH, 2013, J BONE MINER RES, V28, P291, DOI 10.1002/jbmr.1754
   Windahl SH, 2001, J BONE MINER RES, V16, P1388, DOI 10.1359/jbmr.2001.16.8.1388
   Woo SM, 2011, J BONE MINER RES, V26, P2634, DOI 10.1002/jbmr.465
   Xie H, 2011, J BONE MINER RES, V26, P156, DOI 10.1002/jbmr.169
   Yu LC, 2011, BONE, V49, P1131, DOI 10.1016/j.bone.2011.08.016
   Zaman G, 1997, J BONE MINER RES, V12, P769, DOI 10.1359/jbmr.1997.12.5.769
   Zaman G, 2000, BONE, V27, P233, DOI 10.1016/S8756 3282(00)00324 0
   Zaman G, 2010, BONE, V46, P628, DOI 10.1016/j.bone.2009.10.021
   Zhang J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035736
   Zhao CY, 2010, J BIOL CHEM, V285, P39575, DOI 10.1074/jbc.R110.180109
   Zhao LZ, 2007, BRAIN RES, V1172, P48, DOI 10.1016/j.brainres.2007.06.092
   Zhao YY, 2009, EXP MOL MED, V41, P478, DOI 10.3858/emm.2009.41.7.053
NR 119
TC 92
Z9 116
U1 0
U2 23
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 3996 USA
EI 1083 351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD MAR 29
PY 2013
VL 288
IS 13
BP 9035
EP 9048
DI 10.1074/jbc.M112.405456
PG 14
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA 116DG
UT WOS:000316862200023
PM 23362266
OA Green Published
DA 2025 08 17
ER

PT J
AU Stefanska, K
   Nemcova, L
   Blatkiewicz, M
   Zok, A
   Kaczmarek, M
   Pienkowski, W
   Mozdziak, P
   Piotrowska Kempisty, H
   Kempisty, B
AF Stefanska, Katarzyna
   Nemcova, Lucie
   Blatkiewicz, Malgorzata
   Zok, Agnieszka
   Kaczmarek, Mariusz
   Pienkowski, Wojciech
   Mozdziak, Paul
   Piotrowska Kempisty, Hanna
   Kempisty, Bartosz
TI Expression Profile of New Marker Genes Involved in Differentiation of
   Human Wharton's Jelly Derived Mesenchymal Stem Cells into Chondrocytes,
   Osteoblasts, Adipocytes and Neural like Cells
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE Wharton's jelly; mesenchymal stem cells; RNA seq; MSC; differentiation
ID LEUKOCYTE PROTEASE INHIBITOR; UMBILICAL CORD; STROMAL CELLS;
   BONE MARROW; IN VITRO; PROTEINASE INHIBITOR; IDENTIFICATION; BLOOD;
   RECONSTRUCTION
AB Wharton's jelly (WJ) contains mesenchymal stem cells (MSCs) exhibiting broad immunomodulatory properties and differentiation capacity, which makes them a promising tool for cellular therapies. Although the osteogenic, chondrogenic and adipogenic differentiation is a gold standard for proper identification of MSCs, it is important to elucidate the exact molecular mechanisms governing these processes to develop safe and efficient cellular therapies. Umbilical cords were collected from healthy, full term deliveries, for subsequent MSCs (WJ MSCs) isolation. WJ MSCs were cultivated in vitro for osteogenic, chondrogenic, adipogenic and neurogenic differentiation. The RNA samples were isolated and the transcript levels were evaluated using NovaSeq platform, which led to the identification of differentially expressed genes. Expression of H19 and SLPI was enhanced in adipocytes, chondrocytes and osteoblasts, and NPPB was decreased in all analyzed groups compared to the control. KISS1 was down regulated in adipocytes, chondrocytes, and neural like cells compared to the control. The most of identified genes were already implicated in differentiation of MSCs; however, some genes (PROK1, OCA2) have not yet been associated with initiating final cell fate. The current results indicate that both osteo  and adipo induced WJ MSCs share many similarities regarding the most overexpressed genes, while the neuro induced WJ MSCs are quite distinctive from the other three groups. Overall, this study provides an insight into the transcriptomic changes occurring during the differentiation of WJ MSCs and enables the identification of novel markers involved in this process, which may serve as a reference for further research exploring the role of these genes in physiology of WJ MSCs and in regenerative medicine.
C1 [Stefanska, Katarzyna; Blatkiewicz, Malgorzata] Poznan Univ Med Sci, Dept Histol & Embryol, PL 60781 Poznan, Poland.
   [Stefanska, Katarzyna] Celliv 3 SA, PL 61623 Poznan, Poland.
   [Nemcova, Lucie] Czech Acad Sci, Inst Anim Physiol & Genet, Libechov 27721, Czech Republic.
   [Zok, Agnieszka] Poznan Univ Med Sci, Div Philosophy Med & Bioeth, PL 60806 Poznan, Poland.
   [Kaczmarek, Mariusz] Poznan Univ Med Sci, Dept Canc Immunol, PL 61866 Poznan, Poland.
   [Kaczmarek, Mariusz] Greater Poland Canc Ctr, Dept Canc Diagnost & Immunol, Gene Therapy Lab, PL 61866 Poznan, Poland.
   [Pienkowski, Wojciech] Poznan Univ Med Sci, Div Perinatol & Womens Dis, PL 60535 Poznan, Poland.
   [Mozdziak, Paul] North Carolina State Univ, Prestage Dept Poultry Sci, Raleigh, NC 27695 USA.
   [Piotrowska Kempisty, Hanna] Poznan Univ Med Sci, Dept Toxicol, PL 60631 Poznan, Poland.
   [Piotrowska Kempisty, Hanna] Nicolaus Copernicus Univ Torun, Inst Vet Med, Dept Basic & Preclin Sci, PL 87100 Torun, Poland.
   [Kempisty, Bartosz] Nicolaus Copernicus Univ Torun, Inst Vet Med, Dept Vet Surg, PL 87100 Torun, Poland.
   [Kempisty, Bartosz] Wroclaw Med Univ, Dept Human Morphol & Embryol, Div Anat, PL 50368 Wroclaw, Poland.
   [Kempisty, Bartosz] Univ Hosp, Dept Obstet & Gynecol, Brno 60177, Czech Republic.
   [Kempisty, Bartosz] Masaryk Univ, Brno 60177, Czech Republic.
   [Kempisty, Bartosz] North Carolina State Univ, Physiol Grad Fac, Raleigh, NC 27695 USA.
C3 Poznan University of Medical Sciences; Czech Academy of Sciences;
   Institute of Animal Physiology & Genetics of the Czech Academy of
   Sciences; Poznan University of Medical Sciences; Poznan University of
   Medical Sciences; Wielkopolskie Centrum Onkologii; Poznan University of
   Medical Sciences; North Carolina State University; Poznan University of
   Medical Sciences; Nicolaus Copernicus University; Nicolaus Copernicus
   University; Wroclaw Medical University; University Hospital Brno;
   Masaryk University Brno; North Carolina State University
RP Kempisty, B (通讯作者)，Nicolaus Copernicus Univ Torun, Inst Vet Med, Dept Vet Surg, PL 87100 Torun, Poland.; Kempisty, B (通讯作者)，Wroclaw Med Univ, Dept Human Morphol & Embryol, Div Anat, PL 50368 Wroclaw, Poland.; Kempisty, B (通讯作者)，Univ Hosp, Dept Obstet & Gynecol, Brno 60177, Czech Republic.; Kempisty, B (通讯作者)，Masaryk Univ, Brno 60177, Czech Republic.; Kempisty, B (通讯作者)，North Carolina State Univ, Physiol Grad Fac, Raleigh, NC 27695 USA.
EM kempistybartosz@gmail.com
RI Nemcova, Lucie/G 7125 2014; Kaczmarek, Mariusz/G 2853 2014; Stefanska,
   Katarzyna/MTB 9619 2025; Blatkiewicz, Małgorzata/C 8192 2018;
   Blatkiewicz, Malgorzata/C 8192 2018
OI Stefanska, Katarzyna/0000 0002 8814 4935; Kaczmarek,
   Mariusz/0000 0002 6282 3251; mozdziak, paul/0000 0002 1575 3123;
   Blatkiewicz, Malgorzata/0000 0001 5506 2397; Nemcova,
   Lucie/0000 0002 2594 3369
FU Polish Ministry of Science and Higher Education [0070/DW/2018/02];
   National Institute of Food and Agriculture [NC7082]; National Institute
   of Food and Agriculture; Ministry of Education, Youth and Sports of the
   Czech Republic; Operational Program Research, Development and Education
   [CZ.02.1.01/0.0/0.0/15_003/0000460]; Ministry of Science and Higher
   Education [0070/DW/2018/02]
FX This research was funded by the Polish Ministry of Science and Higher
   Education, grant number 0070/DW/2018/02, and by the National Institute
   of Food and Agriculture, grant number NC7082. The APC was funded by the
   National Institute of Food and Agriculture. This work was supported by
   the Ministry of Education, Youth and Sports of the Czech Republic,
   Operational Program Research, Development and Education, project
   "EXCELLENCE in molecular aspects of the early development of
   vertebrates" (grant number CZ.02.1.01/0.0/0.0/15_003/0000460) and the
   Ministry of Science and Higher Education (grant number 0070/DW/2018/02).
CR Adapala VJ, 2011, J INFLAMM LOND, V8, DOI 10.1186/1476 9255 9 15
   Ansari AS, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/2406462
   Arutyunyan I, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/6901286
   Bader GD, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471 2105 4 2
   Benjamini Y, 2017, BIOSTATISTICS, V18, P91, DOI 10.1093/biostatistics/kxw030
   Binder BYK, 2014, TISSUE ENG PT A, V20, P1156, DOI [10.1089/ten.tea.2013.0487, 10.1089/ten.TEA.2013.0487]
   Budna J, 2017, ZYGOTE, V25, P331, DOI 10.1017/S096719941700020X
   Cabrera Pérez R, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1450 3
   Cao BR, 2020, FEBS OPEN BIO, V10, P2656, DOI 10.1002/2211 5463.13002
   Cheng YC, 2015, NEURAL DEV, V10, DOI 10.1186/s13064 015 0055 5
   Choi BD, 2016, MOL MED REP, V14, P1241, DOI 10.3892/mmr.2016.5381
   Cui XY, 2004, J BIOL CHEM, V279, P25858, DOI 10.1074/jbc.M313505200
   da Rosa NN, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24065852
   da Silva C, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21114104
   Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb 2003 4 9 r60
   Derfoul A, 2006, STEM CELLS, V24, P1487, DOI 10.1634/stemcells.2005 0415
   Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635
   Dogan A, 2018, ADV EXP MED BIOL, V1079, P1, DOI 10.1007/5584_2018_175
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Farr JN, 2018, J BONE MINER RES, V33, P720, DOI 10.1002/jbmr.3351
   Fresno C, 2013, BIOINFORMATICS, V29, P2810, DOI 10.1093/bioinformatics/btt487
   Goesmann A, 2002, BIOINFORMATICS, V18, P124, DOI 10.1093/bioinformatics/18.1.124
   Golkar Narenji A, 2022, GENES BASEL, V13, DOI 10.3390/genes13020242
   Huang YP, 2016, SCI REP UK, V6, DOI 10.1038/srep28897
   JACOBY AS, 1993, EUR J BIOCHEM, V218, P951, DOI 10.1111/j.1432 1033.1993.tb18452.x
   Jiang ZJ, 2023, J NEUROSCI, V43, P3807, DOI 10.1523/JNEUROSCI.1494 22.2023
   Karagianni M, 2013, CYTOTHERAPY, V15, P76, DOI 10.1016/j.jcyt.2012.11.001
   Karahuseyinoglu S, 2007, STEM CELLS, V25, P319, DOI 10.1634/stemcells.2006 0286
   Lacaná E, 2002, J BIOL CHEM, V277, P32947, DOI 10.1074/jbc.M202841200
   Lecorguillé M, 2022, J CLIN ENDOCR METAB, DOI 10.1210/clinem/dgac553
   Li K, 2019, J CELL PHYSIOL, V234, P20925, DOI 10.1002/jcp.28697
   Liang WC, 2016, SCI REP UK, V6, DOI 10.1038/srep20121
   Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656
   Lizarazo Fonseca Liliana, 2023, Regen Ther, V24, P11, DOI 10.1016/j.reth.2023.05.005
   Lorenzo P, 1998, J BIOL CHEM, V273, P23463, DOI 10.1074/jbc.273.36.23463
   Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059 014 0550 8
   Lyons FG, 2019, ADV EXP MED BIOL, V1169, P243, DOI 10.1007/978 3 030 24108 7_13
   Manna C, 2023, VET RES COMMUN, V47, P2229, DOI 10.1007/s11259 023 10098 x
   Mansour RN, 2023, GENES BASEL, V14, DOI 10.3390/genes14040909
   Martin M., 2011, EMBNET J, V17, P10, DOI DOI 10.14806/EJ.17.1.200
   Martin Rendon E, 2008, VOX SANG, V95, P137, DOI 10.1111/j.1423 0410.2008.01076.x
   Michael GJ, 2011, NEUROGENETICS, V12, P295, DOI 10.1007/s10048 011 0294 5
   Morganstein DL, 2010, CELL RES, V20, P434, DOI 10.1038/cr.2010.11
   Ngan ESW, 2007, BBA MOL CELL RES, V1773, P536, DOI 10.1016/j.bbamcr.2007.01.013
   Ohlsson S, 1997, BIOL CHEM, V378, P1055, DOI 10.1515/bchm.1997.378.9.1055
   Oliver L, 2013, STEM CELLS, V31, P800, DOI 10.1002/stem.1336
   Pesarini JR, 2018, BIOMED PHARMACOTHER, V108, P914, DOI 10.1016/j.biopha.2018.09.083
   Potier E, 2007, TISSUE ENG, V13, P1325, DOI 10.1089/ten.2006.0325
   Roforth MM, 2013, BIOCHEM BIOPH RES CO, V440, P768, DOI 10.1016/j.bbrc.2013.10.006
   Rucinski M, 2008, INT J MOL MED, V22, P553, DOI 10.3892/ijmm_00000055
   Saidi S, 2011, CYTOKINE, V53, P347, DOI 10.1016/j.cyto.2010.11.021
   Schulze J, 2011, J BONE MINER RES, V26, P704, DOI 10.1002/jbmr.269
   Sobieszczuk DF, 2010, GENE DEV, V24, P206, DOI 10.1101/gad.554510
   Stefanska K, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms241210023
   Stelcer E, 2022, ONCOL LETT, V23, DOI 10.3892/ol.2022.13240
   Subramanian A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127992
   Taherpour A, 2022, GENE, V833, DOI 10.1016/j.gene.2022.146586
   Tong CK, 2011, CELL BIOL INT, V35, P221, DOI 10.1042/CBI20100326
   Vidács DL, 2022, PIGM CELL MELANOMA R, V35, P38, DOI 10.1111/pcmr.13012
   Wang HS, 2004, STEM CELLS, V22, P1330, DOI 10.1634/stemcells.2004 0013
   Weiss ML, 2008, STEM CELLS, V26, P2865, DOI 10.1634/stemcells.2007 1028
   Wood IS, 2009, BIOCHEM BIOPH RES CO, V384, P105, DOI 10.1016/j.bbrc.2009.04.081
   Wu Y, 2022, BONE JOINT RES, V11, P503, DOI 10.1302/2046 3758.117.BJR 2021 0358.R2
   Yan L., 2023, Draw Venn Diagram by "ggplot2
   Zhang WT, 2023, MATER TODAY BIO, V18, DOI 10.1016/j.mtbio.2022.100528
   Zhang X, 2011, J CELL BIOCHEM, V112, P1206, DOI 10.1002/jcb.23042
   Zheng X, 2022, BIOENGINEERED, V13, P6880, DOI 10.1080/21655979.2022.2044274
   Zhong QQ, 2017, EXP BIOL MED, V242, P250, DOI 10.1177/1535370216672747
   Zhou YY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 09234 6
   Zhu X, 2022, FRONT CELL NEUROSCI, V15, DOI 10.3389/fncel.2021.768711
NR 70
TC 5
Z9 5
U1 1
U2 10
PU MDPI
PI BASEL
PA MDPI AG, Grosspeteranlage 5, CH 4052 BASEL, SWITZERLAND
SN 1661 6596
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD AUG
PY 2023
VL 24
IS 16
AR 12939
DI 10.3390/ijms241612939
PG 21
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA Q3TW0
UT WOS:001056786000001
PM 37629120
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Ge, QH
   Zhang, HW
   Hou, JX
   Wan, LF
   Cheng, WZ
   Wang, XY
   Dong, D
   Chen, CZ
   Xia, J
   Guo, J
   Chen, XL
   Wu, XW
AF Ge, Quanhu
   Zhang, Hongwei
   Hou, Jixue
   Wan, Longfei
   Cheng, Wenzhe
   Wang, Xiaoyi
   Dong, Dan
   Chen, Congzhe
   Xia, Jie
   Guo, Jun
   Chen, Xueling
   Wu, Xiangwei
TI VEGF secreted by mesenchymal stem cells mediates the differentiation of
   endothelial progenitor cells into endothelial cells via paracrine
   mechanisms
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE endothelial progenitor cells; mesenchymal stem cells; endothelial cells;
   differentiation; vascular endothelial growth factor
ID IN VITRO DIFFERENTIATION; NITRIC OXIDE SYNTHASE; BONE MARROW CELLS;
   GROWTH FACTOR; ANGIOGENESIS; DISEASE; SUPERFAMILY; EXPRESSION;
   EXPANSION; THERAPY
AB Stem cell therapy is a promising treatment strategy for ischemic diseases. Mesenchymal stem cells (MSCs) and endothelial progenitor cells (EPCs) adhere to each other in the bone marrow cavity and in in vitro cultures. We have previously demonstrated that the adhesion between MSCs and EPCs is critical for MSC self renewal and their multi differentiation into osteoblasts and chondrocytes. In the present study, the influence of the indirect communication between EPCs and MSCs on the endothelial differentiation potential of EPCs was investigated, and the molecular mechanisms underlying MSC mediated EPC differentiation were explored. The effects of vascular endothelial growth factor (VEGF), which is secreted by MSCs, on EPC differentiation via paracrine mechanisms were examined via co culturing MSCs and EPCs. Reverse transcription quantitative polymerase chain reaction and western blot analysis were used to detect the expression of genes and proteins of interest. The present results demonstrated that co culturing EPCs with MSCs enhanced the expression of cluster of differentiation 31 and von Willebrand factor, which are specific markers of an endothelial phenotype, thus indicating that MSCs may influence the endothelial differentiation of EPCs in vitro. VEGF appeared to be critical to this process. These findings are important for the understanding of the biological interactions between MSCs and EPCs, and for the development of applications of stem cell based therapy in the treatment of ischemic diseases.
C1 [Ge, Quanhu; Zhang, Hongwei; Hou, Jixue; Wan, Longfei; Cheng, Wenzhe; Wang, Xiaoyi; Dong, Dan; Chen, Congzhe; Xia, Jie; Guo, Jun; Wu, Xiangwei] Shihezi Univ, Sch Med, Affiliated Hosp 1, Dept Gen Surg, 107 North 2nd Rd, Shihezi 832002, Xinjiang, Peoples R China.
   [Chen, Xueling] Shihezi Univ, Sch Med, Dept Immunol, 107 North 2nd Rd, Shihezi 832002, Xinjiang, Peoples R China.
   [Wu, Xiangwei] Shihezi Univ, Sch Med, Lab Translat Med, Shihezi 832002, Xinjiang, Peoples R China.
C3 Shihezi University; Shihezi University; Shihezi University
RP Wu, XW (通讯作者)，Shihezi Univ, Sch Med, Affiliated Hosp 1, Dept Gen Surg, 107 North 2nd Rd, Shihezi 832002, Xinjiang, Peoples R China.; Chen, XL (通讯作者)，Shihezi Univ, Sch Med, Dept Immunol, 107 North 2nd Rd, Shihezi 832002, Xinjiang, Peoples R China.
EM xuelingch@hotmail.com; wxwshz@126.com
RI dong, Dong/JFJ 3808 2023; Xia, Jie/K 8226 2014
FU National Natural Science Foundation of China [31271458]; Science and
   Technology Program of Xinjiang Production and Construction Corps
   [2014AB047]; Scientific Research Foundation for the Returned Overseas
   Chinese Scholars; Ministry of Human Resources and Social Security of the
   People's Republic of China [RSLX201201]; Shihezi University Youth
   Science and Technology Research and Development Program, Basis and
   Application Research Project [20142RKXYQ20]
FX The present study was supported by the National Natural Science
   Foundation of China (grant no. 31271458), the Science and Technology
   Program of Xinjiang Production and Construction Corps (grant no.
   2014AB047), the Scientific Research Foundation for the Returned Overseas
   Chinese Scholars, the Ministry of Human Resources and Social Security of
   the People's Republic of China (grant no. RSLX201201) and the Shihezi
   University Youth Science and Technology Research and Development
   Program, Basis and Application Research Project (grant no.
   20142RKXYQ20).
CR Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964
   Asahara T, 1999, EMBO J, V18, P3964, DOI 10.1093/emboj/18.14.3964
   Bianco P, 2008, CELL STEM CELL, V2, P313, DOI 10.1016/j.stem.2008.03.002
   Bost F, 2002, BIOCHEM J, V361, P621, DOI 10.1042/0264 6021:3610621
   Cao X, 2011, P NATL ACAD SCI USA, V108, P1609, DOI 10.1073/pnas.1015350108
   Cepko CL, 1996, P NATL ACAD SCI USA, V93, P589, DOI 10.1073/pnas.93.2.589
   da Silva ML, 2016, BLOOD, V128, P277, DOI 10.1182/blood 2015 10 677054
   FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0
   FRIEDENSTEIN AJ, 1970, CELL TISSUE KINET, V3, P393, DOI 10.1111/j.1365 2184.1970.tb00347.x
   Gehling UM, 2000, BLOOD, V95, P3106
   Geng YJ, 2006, FUTUR CARDIOL, V2, P585, DOI 10.2217/14796678.2.5.585
   Glaser DE, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166663
   Guo SF, 2010, CELL PHYSIOL BIOCHEM, V26, P679, DOI 10.1159/000322335
   Gupta K, 1997, EXP CELL RES, V230, P244, DOI 10.1006/excr.1996.3421
   Horwitz EM, 2002, P NATL ACAD SCI USA, V99, P8932, DOI 10.1073/pnas.132252399
   Jiang YH, 2002, EXP HEMATOL, V30, P896, DOI 10.1016/S0301 472X(02)00869 X
   Kim SW, 2006, STEM CELLS, V24, P1620, DOI 10.1634/stemcells.2005 0365
   Kinnaird T, 2004, CIRC RES, V94, P678, DOI 10.1161/01.RES.0000118601.37875.AC
   Lenti M, 2007, J VASC SURG, V45, P32, DOI 10.1016/j.jvs.2006.08.032
   Li HY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016767
   Liu Z, 2007, AM J PHYSIOL HEART C, V293, pH1760, DOI 10.1152/ajpheart.01408.2006
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Mayer H, 2005, J CELL BIOCHEM, V95, P827, DOI 10.1002/jcb.20462
   Morrison SJ, 1997, CELL, V88, P287, DOI 10.1016/S0092 8674(00)81867 X
   NEWMAN PJ, 1990, SCIENCE, V247, P1219, DOI 10.1126/science.1690453
   Oswald J, 2004, STEM CELLS, V22, P377, DOI 10.1634/stemcells.22 3 377
   Quirici N, 2001, BRIT J HAEMATOL, V115, P186, DOI 10.1046/j.1365 2141.2001.03077.x
   Reyes M, 2001, BLOOD, V98, P2615, DOI 10.1182/blood.V98.9.2615
   Ribatti D, 2007, LEUKEMIA RES, V31, P439, DOI 10.1016/j.leukres.2006.10.014
   Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0
   Saigawa T, 2004, CIRC J, V68, P1189, DOI 10.1253/circj.68.1189
   Shah NM, 1996, CELL, V85, P331, DOI 10.1016/S0092 8674(00)81112 5
   Tashiro K, 2008, J GENE MED, V10, P498, DOI 10.1002/jgm.1171
   Tateishi Yuyama E, 2002, LANCET, V360, P427, DOI 10.1016/S0140 6736(02)09670 8
   Vasa M, 2001, CIRC RES, V89, pE1, DOI 10.1161/hh1301.093953
   Wu XW, 2010, CELL STEM CELL, V7, P571, DOI 10.1016/j.stem.2010.09.012
   Xia J, 2016, CELL BIOL INT, V40, P407, DOI 10.1002/cbin.10579
   Xu J, 2008, J CELL MOL MED, V12, P2395, DOI 10.1111/j.1582 4934.2008.00266.x
   Zachary I, 2003, BIOCHEM SOC T, V31, P1171
   Zaniboni A, 2015, AM J PHYSIOL CELL PH, V309, pC320, DOI 10.1152/ajpcell.00049.2015
   Zhang HW, 2014, MOL CELL BIOCHEM, V397, P235, DOI 10.1007/s11010 014 2191 3
   Zhang Meng, 2015, Zhonghua Yi Xue Za Zhi, V95, P1253
   Ziche M, 1997, J CLIN INVEST, V99, P2625, DOI 10.1172/JCI119451
NR 43
TC 124
Z9 136
U1 6
U2 40
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791 2997
EI 1791 3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD JAN
PY 2018
VL 17
IS 1
BP 1667
EP 1675
DI 10.3892/mmr.2017.8059
PG 9
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Research & Experimental Medicine
GA FT8WG
UT WOS:000423433300211
PM 29138837
OA hybrid, Green Submitted, Green Published
DA 2025 08 17
ER

PT J
AU Morii, T
   Ohtsuka, K
   Ohnishi, H
   Mochizuki, K
   Satomi, K
AF Morii, Takeshi
   Ohtsuka, Kouki
   Ohnishi, Hiroaki
   Mochizuki, Kazuo
   Satomi, Kazuhiko
TI Inhibition of Heat shock Protein 27 Expression Eliminates Drug
   Resistance of Osteosarcoma to Zoledronic Acid
SO ANTICANCER RESEARCH
LA English
DT Article
DE Osteosarcoma; drug resistance; zoledronic acid; heat shock protein 27
ID BREAST CANCER CELLS; S PHASE ARREST; OSTEOGENIC SARCOMA; IN VITRO;
   APOPTOSIS; HSP27; BISPHOSPHONATES; DOXORUBICIN; ACTIVATION; GROWTH
AB Background: Although zoledronic acid (ZOL) has been reported to show anti tumour effects on various malignant tumours, few studies have reported the molecular mechanisms of resistance to ZOL. Materials and Methods: A drug resistant cell line was developed by repeatedly treating human osteosarcoma cell line HOS with ZOL. Expression status of drug resistance related molecules including ATP binding cassette (ABC) and heat shock protein 27 (HSP27) was confirmed in order to analyse molecular mechanisms of the drug resistance. Results: Repeated treatment with ZOL induced drug resistance with down regulation of apoptosis in the resistant cell line. Although ABC expression was down regulated, up regulation of HSP27 in the resistant cell line was confirmed. The resistance was overcome by HSP27 silencing. Conclusion: Resistance to ZOL in osteosarcoma cells may be induced by a molecular mechanism different from conventional efflux pump based resistance. Upregulation of HSP27 expression may play a role in the development of ZOL resistance in HOS cells.
C1 [Morii, Takeshi; Mochizuki, Kazuo; Satomi, Kazuhiko] Kyorin Univ, Dept Orthoped Surg, Fac Med, Tokyo 1618611, Japan.
   [Ohtsuka, Kouki; Ohnishi, Hiroaki] Kyorin Univ, Dept Clin Lab Med, Fac Med, Tokyo 1618611, Japan.
C3 Kyorin University; Kyorin University
RP Morii, T (通讯作者)，Kyorin Univ, Dept Orthoped Surg, Fac Med, 6 20 2 Shinkawa, Tokyo 1618611, Japan.
EM t morii@ks.kyorin u.ac.jp
RI Morii, Takeshi/S 7980 2019; Ohnishi, Hiroaki/NGR 7827 2025
FU Ministry of Education, Science, Sports and Culture of Japan
FX We are grateful to Ms. Mizuho Kosuge and Ms. Miyuki Murayama for their
   skilful technical assistance and to Ms. Minako Oshiro for her skilful
   secretarial assistance. This investigation was supported in part by a
   Grant in Aid for Scientific Research from the Ministry of Education,
   Science, Sports and Culture of Japan.
CR Aapro M, 2008, ANN ONCOL, V19, P420, DOI 10.1093/annonc/mdm442
   Concannon CG, 2003, APOPTOSIS, V8, P61, DOI 10.1023/A:1021601103096
   Dass CR, 2007, MOL CANCER THER, V6, P3263, DOI 10.1158/1535 7163.MCT 07 0546
   Duan ZF, 2009, CANCER CHEMOTH PHARM, V63, P1121, DOI 10.1007/s00280 008 0843 2
   Evdokiou A, 2003, BONE, V33, P216, DOI 10.1016/S8756 3282(03)00223 0
   Gottesman MM, 2002, ANNU REV MED, V53, P615, DOI 10.1146/annurev.med.53.082901.103929
   Green JR, 2003, CANCER, V97, P840, DOI 10.1002/cncr.11128
   Havasi A, 2008, J BIOL CHEM, V283, P12305, DOI 10.1074/jbc.M801291200
   Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710
   Heymann D, 2005, BONE, V37, P74, DOI 10.1016/j.bone.2005.02.020
   Horie N, 2007, BRIT J CANCER, V96, P255, DOI 10.1038/sj.bjc.6603548
   Ibrahim A, 2003, CLIN CANCER RES, V9, P2394
   Iguchi T, 2007, INT J ONCOL, V31, P285
   Kang SH, 2008, BMC CANCER, V8, DOI 10.1186/1471 2407 8 286
   Kars MD, 2007, ANTICANCER RES, V27, P4031
   Kubista B, 2006, J ORTHOP RES, V24, P1145, DOI 10.1002/jor.20129
   Labrinidis A, 2009, CLIN CANCER RES, V15, P3451, DOI 10.1158/1078 0432.CCR 08 1616
   Marina N, 2004, ONCOLOGIST, V9, P422, DOI 10.1634/theoncologist.9 4 422
   MCALLISTER RM, 1971, CANCER AM CANCER SOC, V27, P397, DOI 10.1002/1097 0142(197102)27:2<397::AID CNCR2820270224>3.0.CO;2 X
   Mehlen P, 1996, J BIOL CHEM, V271, P16510, DOI 10.1074/jbc.271.28.16510
   Morioka H, 2003, EXP CELL RES, V287, P166, DOI 10.1016/S0014 4827(03)00137 X
   Ory B, 2008, J CELL MOL MED, V12, P928, DOI 10.1111/j.1582 4934.2008.00141.x
   Ory B, 2007, MOL PHARMACOL, V71, P333, DOI 10.1124/mol.106.028837
   Rajkumar T, 2008, ANTI CANCER DRUG, V19, P257, DOI 10.1097/CAD.0b013e3282f435b6
   Romani AA, 2009, BIOCHEM PHARMACOL, V78, P133, DOI 10.1016/j.bcp.2009.04.004
   Rondeaux P, 1997, IN VITRO CELL DEV AN, V33, P655
   Russell RGG, 1999, BONE, V25, P97, DOI 10.1016/S8756 3282(99)00116 7
   Schwartz CL, 2007, J CLIN ONCOL, V25, P2057, DOI 10.1200/JCO.2006.07.7776
   Shao L, 2003, BIOCHEM PHARMACOL, V66, P2381, DOI 10.1016/j.bcp.2003.08.033
   Shi P, 2008, CHINESE MED J PEKING, V121, P1975, DOI 10.1097/00029330 200810020 00005
   Spugnini EP, 2009, J SMALL ANIM PRACT, V50, P44, DOI 10.1111/j.1748 5827.2008.00635.x
   Susa M, 2009, ANTICANCER RES, V29, P1879
   Takeshita H, 1996, J BONE JOINT SURG AM, V78A, P366, DOI 10.2106/00004623 199603000 00007
   Tsuruta M, 2008, ONCOL REP, V20, P1165, DOI 10.3892/or_00000125
   Uozaki H, 1997, CANCER AM CANCER SOC, V79, P2336, DOI 10.1002/(SICI)1097 0142(19970615)79:12<2336::AID CNCR7>3.0.CO;2 J
   Yuasa T, 2007, CURR MED CHEM, V14, P2126
NR 36
TC 31
Z9 33
U1 0
U2 0
PU INT INST ANTICANCER RESEARCH
PI ATHENS
PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU KALAMOU RD KAPANDRITI, PO BOX 22,
   ATHENS 19014, GREECE
SN 0250 7005
EI 1791 7530
J9 ANTICANCER RES
JI Anticancer Res.
PD SEP
PY 2010
VL 30
IS 9
BP 3565
EP 3571
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 665BI
UT WOS:000283009400048
PM 20944138
DA 2025 08 17
ER

PT J
AU Hosonuma, M
   Sakai, N
   Furuya, H
   Kurotaki, Y
   Sato, Y
   Handa, K
   Dodo, Y
   Ishikawa, K
   Tsubokura, Y
   Negishi Koga, T
   Tsuji, M
   Kasama, T
   Kiuchi, Y
   Takami, M
   Isozaki, T
AF Hosonuma, Masahiro
   Sakai, Nobuhiro
   Furuya, Hidekazu
   Kurotaki, Yutaro
   Sato, Yurie
   Handa, Kazuaki
   Dodo, Yusuke
   Ishikawa, Koji
   Tsubokura, Yumi
   Negishi Koga, Takako
   Tsuji, Mayumi
   Kasama, Tsuyoshi
   Kiuchi, Yuji
   Takami, Masamichi
   Isozaki, Takeo
TI Inhibition of hepatocyte growth factor/c Met signalling abrogates joint
   destruction by suppressing monocyte migration in rheumatoid arthritis
SO RHEUMATOLOGY
LA English
DT Article
DE hepatocyte growth factor; c Met; rheumatoid arthritis; chemokines
ID MACROPHAGE INFLAMMATORY PROTEIN 1 ALPHA; C MET; SKG ARTHRITIS; M CSF;
   ANTIBODY; DIFFERENTIATION; IDENTIFICATION; OSTEOCLASTS; SUBSTITUTE;
   EXPRESSION
AB Objectives. To determine the expression of hepatocyte growth factor (HGF) in RA biological fluids, the role of HGF in monocyte migration and the therapeutic effect of the c Met inhibitor savolitinib in an arthritis model mice.
   Methods. HGF/c Met expression in serum, SF and synovial tissues (STs) obtained from RA patients and controls, as well as RA fibroblast like synoviocytes (FLSs), was evaluated by ELISA and immunostaining. To determine the function of HGF in RA SF, we preincubated RA SF with a neutralizing anti HGF antibody and measured the chemotactic ability of a human acute monocytic leukaemia cell line (THP 1). Additionally, examinations were conducted of SKG mice treated with savolitinib for 4 weeks.
   Results. HGF levels in serum from RA patients were significantly higher than those in the controls and were decreased by drug treatment for 24 weeks. Additionally, the HGF level in SF from RA patients was higher than that in SF from OA patients. HGF and c Met expression was also noted in RA STs. Stimulation of RA FLSs with TNF alpha increased HGF/c Met expression in a concentration dependent manner, and c Met signal inhibition suppressed production of fractalkine/CX3CL1 and macrophage inflammatory protein 1 alpha/CCL3. When HGF was removed by immunoprecipitation, migration of THP 1 in RA SF was suppressed. In SKG mice, savolitinib significantly suppressed ankle bone destruction on mu CT, with an associated reduction in the number of tartrate resistant acid phosphatase positive osteoclasts.
   Conclusion. HGF produced by inflammation in synovium of RA patients activates monocyte migration to synovium and promotes bone destruction via a chemotactic effect and enhanced chemokine production.
C1 [Hosonuma, Masahiro; Furuya, Hidekazu; Tsubokura, Yumi; Kasama, Tsuyoshi; Isozaki, Takeo] Showa Univ, Dept Med, Div Rheumatol, Sch Med,Shinagawa Ku, 1 5 8 Hatanodai, Tokyo 1428666, Japan.
   [Hosonuma, Masahiro; Handa, Kazuaki; Dodo, Yusuke; Tsuji, Mayumi; Kiuchi, Yuji] Showa Univ, Dept Pharmacol, Div Med Pharmacol,Sch Med, Shinagawa Ku, Tokyo, Japan.
   [Hosonuma, Masahiro; Sakai, Nobuhiro; Kurotaki, Yutaro; Sato, Yurie; Handa, Kazuaki; Dodo, Yusuke; Negishi Koga, Takako; Takami, Masamichi] Showa Univ, Dept Pharmacol, Sch Dent, Shinagawa Ku, Tokyo, Japan.
   [Hosonuma, Masahiro; Sakai, Nobuhiro; Kurotaki, Yutaro; Sato, Yurie; Handa, Kazuaki; Dodo, Yusuke; Ishikawa, Koji; Negishi Koga, Takako; Tsuji, Mayumi; Kiuchi, Yuji; Takami, Masamichi] Showa Univ, Parmacol Res Ctr, Shinagawa Ku, Tokyo, Japan.
   [Kurotaki, Yutaro] Showa Univ, Sch Dent, Dept Special Needs Dent, Ota Ku,Div Community Based Comprehens Dent, Tokyo, Japan.
   [Sato, Yurie] Showa Univ, Sch Dent, Div Dent Persons Disabil, Ota Ku, Tokyo, Japan.
   [Handa, Kazuaki; Dodo, Yusuke; Ishikawa, Koji] Showa Univ, Dept Orthopaed Surg, Sch Med, Shinagawa Ku, Tokyo, Japan.
   [Negishi Koga, Takako] Univ Tokyo, Int Res & Dev Ctr Mucosal Vaccines, Inst Med Sci,Div Mucosal Barriol, Minato Ku, Tokyo, Japan.
C3 Showa University; Showa University; Showa University; Showa University;
   Showa University; Showa University; Showa University; University of
   Tokyo
RP Isozaki, T (通讯作者)，Showa Univ, Dept Med, Div Rheumatol, Sch Med,Shinagawa Ku, 1 5 8 Hatanodai, Tokyo 1428666, Japan.
EM t.isozaki@med.showa u.ac.jp
RI Ishikawa, Koji/ABC 4850 2020; Dodo, Yakubu/KBD 4114 2024
OI Tsuji, Mayumi/0000 0001 8005 9069; Hosonuma,
   Masahiro/0000 0002 5861 7543; Ishikawa, Koji/0000 0003 3689 5662; 
FU Ministry of Education, Culture, Sports, Science and Technology of Japan
   (MEXT); Grants in Aid for Scientific Research [20K17431, 20K09963]
   Funding Source: KAKEN
FX This work was supported by the Private University Research Branding
   Project of the Ministry of Education, Culture, Sports, Science and
   Technology of Japan (MEXT) to Showa University.
CR Adamopoulos IE, 2006, BIOCHEM BIOPH RES CO, V350, P478, DOI 10.1016/j.bbrc.2006.09.076
   ARNETT FC, 1988, ARTHRITIS RHEUM US, V31, P315, DOI 10.1002/art.1780310302
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   CHAPPARD D, 1983, BASIC APPL HISTOCHEM, V27, P75
   Chintalacharuvu SR, 2005, IMMUNOL LETT, V100, P202, DOI 10.1016/j.imlet.2005.03.012
   FERRACINI R, 1995, ONCOGENE, V10, P739
   Firestein GS, 2003, NATURE, V423, P356, DOI 10.1038/nature01661
   Gómez Reino JJ, 2012, ANN RHEUM DIS, V71, P382, DOI 10.1136/annrheumdis 2011 200302
   Gong RJ, 2008, CURR OPIN INVEST DR, V9, P1163
   Grandaunet B, 2011, ARTHRITIS RHEUM US, V63, P662, DOI 10.1002/art.30163
   Gron KL, 2019, ARTHRITIS RHEUMATOL, V71, P1997, DOI 10.1002/art.41031
   Hanyuda M, 2003, RHEUMATOLOGY, V42, P1390, DOI 10.1093/rheumatology/keg391
   Hasegawa T, 2019, NAT IMMUNOL, V20, P1631, DOI 10.1038/s41590 019 0526 7
   Hashimoto M, 2010, J EXP MED, V207, P1135, DOI 10.1084/jem.20092301
   Hoshino Negishi K, 2019, ARTHRITIS RHEUMATOL, V71, P222, DOI 10.1002/art.40688
   KASAMA T, 1995, J CLIN INVEST, V95, P2868, DOI 10.1172/JCI117993
   Keller KK, 2011, CLIN EXP RHEUMATOL, V29, P536
   Keller KK, 2013, RHEUMATOL INT, V33, P1127, DOI 10.1007/s00296 012 2500 7
   Kim KW, 2015, AM J PATHOL, V185, P3011, DOI 10.1016/j.ajpath.2015.07.017
   Koch AE, 1996, ARTHRITIS RHEUM, V39, P1566, DOI 10.1002/art.1780390917
   KOCH AE, 1994, J CLIN INVEST, V93, P921, DOI 10.1172/JCI117097
   Lee DH, 2015, IMMUNOTARGETS THER, V4, P35, DOI 10.2147/ITT.S37409
   Matsunawa M, 2006, ARTHRITIS RHEUM, V54, P3408, DOI 10.1002/art.22208
   Nagashima M, 2001, J RHEUMATOL, V28, P1772
   NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0
   Nishikawa K, 2010, J CLIN INVEST, V120, P3455, DOI 10.1172/JCI42528
   Okamatsu N, 2017, BIOCHEM BIOPH RES CO, V491, P614, DOI 10.1016/j.bbrc.2017.07.154
   Okunishi K, 2007, J IMMUNOL, V179, P5504, DOI 10.4049/jimmunol.179.8.5504
   Redlich K, 2002, J CLIN INVEST, V110, P1419, DOI 10.1172/JCI200215582
   Sakaguchi N, 2003, NATURE, V426, P454, DOI 10.1038/nature02119
   Shibasaki S, 2015, FEBS OPEN BIO, V5, P341, DOI 10.1016/j.fob.2015.04.008
   Shibasaki S, 2014, SPRINGERPLUS, V3, DOI 10.1186/2193 1801 3 554
   Tanaka Y, 2018, MOD RHEUMATOL, V28, P58, DOI 10.1080/14397595.2017.1337056
   Taylor RM, 2012, LAB INVEST, V92, P1398, DOI 10.1038/labinvest.2012.108
   Trusolino L, 2010, NAT REV MOL CELL BIO, V11, P834, DOI 10.1038/nrm3012
   Tsunemi S, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4252
   Tsunemi S, 2010, CLIN IMMUNOL, V136, P197, DOI 10.1016/j.clim.2010.03.428
   YUKIOKA K, 1994, J RHEUMATOL, V21, P2184
   Zhang G, 2018, EUR REV MED PHARMACO, V22, P6625, DOI 10.26355/eurrev_201810_16137
NR 39
TC 11
Z9 11
U1 0
U2 7
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1462 0324
EI 1462 0332
J9 RHEUMATOLOGY
JI RHEUMATOLOGY
PD JAN
PY 2021
VL 60
IS 1
BP 408
EP 419
DI 10.1093/rheumatology/keaa310
PG 12
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA PV5TL
UT WOS:000610050100069
PM 32770199
DA 2025 08 17
ER

PT J
AU Mukherjee, M
   Das, AS
   Das, D
   Mukherjee, S
   Mitra, S
   Mitra, C
AF Mukherjee, M
   Das, AS
   Das, D
   Mukherjee, S
   Mitra, S
   Mitra, C
TI Effects of garlic oil on postmenopausal osteoporosis using
   ovariectomized rats:: Comparison with the effects of lovastatin and
   17β estradiol
SO PHYTOTHERAPY RESEARCH
LA English
DT Article
DE bone loss; garlic oil; 17 beta estradiol; lovastatin; ovariectomy
ID BONE RESORPTION; IN VITRO; MODEL; DIFFERENTIATION; OSTEOCLASTS;
   ACTIVATION; MECHANISM; WOMEN
AB The purpose of this study was to examine the antiosteoporosis effects of garlic oil in an ovariectomized (Ovx) rat model of osteoporosis and to compare its efficacy with lovastatin (a synthetic hypocholesterolemic drug) and 17 beta estradiol (a potent antiosteoporotic agent). Animals were divided into five groups: sham operated control, ovariectomized, ovariectomized supplemented with lovastatin, ovariectomized supplemented with garlic oil and ovariectomized supplemented with 17 beta estradiol. In our study, the development of a high rate of bone turnover and osteoporosis in the ovariectomized animals were confirmed by significant alterations of serum alkaline phosphatase activity, serum tartrate resistant acid phosphatase activity, urinary excretion of calcium, phosphate, hydroxyproline and urinary calcium to creatinine ratio, when compared with the sham operated control group. Supplementation of these animals with either garlic oil or lovastatin or 17 beta estradiol, in addition to their hypocholesterolemic effect, could counterbalance all these changes. The results revealed that all three compounds significantly protected the hypogonadal bone loss as reflected by higher bone densities and higher bone mineral contents than the ovariectomized group of animals. The results emphasize that, like 17 beta estradiol, the hypocholesterolemic compounds garlic oil and lovastatin are also effective in suppressing bone loss owing to estrogen deficiency and their efficacy in the order of lower to higher is garlic < lovastatin < 17 beta estradiol. Copyright (c) 2006 John Wiley & Sons, Ltd.
C1 Presidency Coll, Dept Physiol, Kolkata 700073, W Bengal, India.
   Indian Inst Chem Biol, Drug Dev Div, Kolkata 700032, W Bengal, India.
C3 Presidency University, Kolkata; Council of Scientific & Industrial
   Research (CSIR)   India; CSIR   Indian Institute of Chemical Biology
   (IICB)
RP Mitra, C (通讯作者)，14 17A,Golf Club Rd, Kolkata 700033, W Bengal, India.
EM chandan_mitrapresi@yahoo.com
RI Mukherjee, Sandip/Y 7336 2019; Das, Asankur/N 3988 2013
OI Mukherjee, Sandip/0000 0003 4176 3496; 
CR Adeniyi K. O., 1993, Acta Physiologica Hungarica, V81, P95
   [Anonymous], J BONE MINERAL RES
   [Anonymous], PRACTICAL BIOCH CLIN
   [Anonymous], J BIOL CHEM
   [Anonymous], BIOCH J
   Arjmandi BH, 1996, J NUTR, V126, P161, DOI 10.1093/jn/126.1.161
   Armstrong K, 2000, MED DECIS MAKING, V20, P308, DOI 10.1177/0272989X0002000307
   AUGUSTI KT, 1973, INDIAN J EXP BIOL, V11, P239
   Bergman I, 1970, Clin Chim Acta, V27, P347, DOI 10.1016/0009 8981(70)90355 4
   BRANCA F, 2001, ANN NUTR METAB, V45, P219
   Christiansen C, 1990, Osteoporos Int, V1, P35, DOI 10.1007/BF01880414
   CHRISTIANSEN C, 1987, Lancet, V1, P1105
   CUMMINGS SR, 1993, LANCET, V341, P72, DOI 10.1016/0140 6736(93)92555 8
   Delmas PD, 2002, LANCET, V359, P2018, DOI 10.1016/S0140 6736(02)08827 X
   Fanelli SL, 1998, RES COMMUN MOL PATH, V102, P163
   Fisher JE, 1999, P NATL ACAD SCI USA, V96, P133, DOI 10.1073/pnas.96.1.133
   GERTZ BJ, 1994, J BONE MINER RES, V9, P135
   GHOSH MN, 1984, FUNDAMENTALS EXPT PH, P155
   Gupta Navneet Kumar, 1996, Indian Journal of Experimental Biology, V34, P851
   Halleen JM, 2003, J BONE MINER RES, V18, P1908, DOI 10.1359/jbmr.2003.18.10.1908
   HANSEN MA, 1991, BMJ BRIT MED J, V303, P961, DOI 10.1136/bmj.303.6808.961
   HOLICK MF, 1998, HARRISONS PRINCIPLES, V2, P2217
   Horn Ross PL, 2000, CANCER CAUSE CONTROL, V11, P289, DOI 10.1023/A:1008995606699
   Hui S L, 1990, Osteoporos Int, V1, P30, DOI 10.1007/BF01880413
   KALU DN, 1991, BONE MINER, V15, P175, DOI 10.1016/0169 6009(91)90124 I
   KALU DN, 1991, BONE MINER, V14, P175, DOI 10.1016/0169 6009(91)90021 Q
   Li XD, 2003, BONE, V33, P652, DOI 10.1016/S8756 3282(03)00239 4
   Li XX, 2002, BIOL PHARM BULL, V25, P738, DOI 10.1248/bpb.25.738
   LINDSAY R, 1977, CLIN ENDOCRINOL, V6, P87, DOI 10.1111/j.1365 2265.1977.tb01999.x
   Maeda T, 2001, BIOCHEM BIOPH RES CO, V280, P874, DOI 10.1006/bbrc.2000.4232
   Mathew Biju C., 1996, Indian Journal of Experimental Biology, V34, P337
   Mukherjee M, 2004, PHYTOTHER RES, V18, P389, DOI 10.1002/ptr.1448
   Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946
   Mundy GR, 1996, BRIT J OBSTET GYNAEC, V103, P32
   MYBURGH KH, 1989, J APPL PHYSIOL, V66, P14, DOI 10.1152/jappl.1989.66.1.14
   NATH RL, 1990, PRACTICAL BIOCH CLIN, P94
   NORDIN BEC, 1975, CURR MED RES OPIN S3, V3, P28
   Riis BJ, 1996, BRIT J OBSTET GYNAEC, V103, P9
   SODIMU O, 1984, EXPERIENTIA, V40, P78, DOI 10.1007/BF01959111
   STEPAN JJ, 1999, ENZYME TESTS DIAGNOS, P162
   TRIPATHI KD, 2003, ESSENTIALS MED PHARM, P578
   VAES G, 1988, CLIN ORTHOP RELAT R, P239
   Woo JT, 2000, J BONE MINER RES, V15, P650, DOI 10.1359/jbmr.2000.15.4.650
   YEH JK, 1993, AM J PHYSIOL, V264, P182
NR 44
TC 19
Z9 21
U1 0
U2 4
PU WILEY BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0951 418X
EI 1099 1573
J9 PHYTOTHER RES
JI Phytother. Res.
PD JAN
PY 2006
VL 20
IS 1
BP 21
EP 27
DI 10.1002/ptr.1795
PG 7
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 006NX
UT WOS:000234905300005
PM 16397916
DA 2025 08 17
ER

PT J
AU Chen, LJ
   Wang, SQ
   Zhou, YM
   Wu, XS
   Entin, I
   Epstein, J
   Yaccoby, S
   Xiong, W
   Barlogie, B
   Shaughnessy, JD
   Zhan, FH
AF Chen, Lijuan
   Wang, Siqing
   Zhou, Yiming
   Wu, Xiaosong
   Entin, Igor
   Epstein, Joshua
   Yaccoby, Shmuel
   Xiong, Wei
   Barlogie, Bart
   Shaughnessy, John D.
   Zhan, Fenghuang
TI Identification of early growth response protein 1 (EGR 1) as a
   novel target for JUN induced apoptosis in multiple myeloma
SO BLOOD
LA English
DT Article
ID TRANSCRIPTION REGULATORY FACTORS; DOMINANT NEGATIVE INHIBITOR; C JUN;
   CELL APOPTOSIS; CANCER CELLS; HUMAN SURVIVIN; EXPRESSION; GENE;
   PROLIFERATION; ACTIVATION
AB Tumor bone marrow microenvironment interactions in multiple myeloma (MM) are documented to play crucial roles in plasma cell growth/survival. In vitro coculture of MM cells with osteoclasts supported cell survival and significantly down regulated JUN expression. JUN expression in myeloma cells from late stage and high risk MM was significantly lower than in plasma cells from healthy donors, monoclonal gammopathy of undetermined significance, smoldering MM, and low risk MM; patients with low JUN expressing MM cells had earlier disease related deaths. JUN overexpression in MM cells induced cell death and growth inhibition and up regulated expression of early growth response protein 1 (EGR 1), whose low expression also carried unfavorable clinical implications. EGR 1 knockdown in MM cells abrogated JUN overexpression induced MM cell death and growth inhibition, indicating that EGR 1 acts directly downstream of JUN. JUN modulates myeloma cell apoptosis through interacting with EGR 1, which down regulates Survivin and triggers caspase signaling. Importantly, high JUN or EGR 1 expression was associated with improved outcome in Total Therapy 3, in which bortezomib is given throughout therapy, versus Total Therapy 2, in which bortezomib is given only at relapse. Consistently, JUN or EGR 1 knockdown in cultured MM cells enhanced their resistance to bortezomib, demonstrating the crucial role of low JUN/EGR 1 expression in MM resistance to bortezomib. (Blood. 2010;115:61 70)
C1 [Zhan, Fenghuang] Univ Utah, Huntsman Canc Inst, Sch Med, Div Hematol,BMT Myeloma Program, Salt Lake City, UT 84132 USA.
   [Chen, Lijuan; Wang, Siqing; Zhou, Yiming; Wu, Xiaosong; Entin, Igor; Epstein, Joshua; Yaccoby, Shmuel; Xiong, Wei; Barlogie, Bart; Shaughnessy, John D.; Zhan, Fenghuang] Univ Arkansas Med Sci, Myeloma Inst Res & Therapy, Donna D & Donald M Lambert Lab Myeloma Genet, Little Rock, AR 72205 USA.
   [Chen, Lijuan] Nanjing Med Univ, Affiliated Hosp 1, Dept Hematol, Jiangsu Prov Hosp, Nanjing, Peoples R China.
C3 Utah System of Higher Education; University of Utah; Huntsman Cancer
   Institute; University of Arkansas System; University of Arkansas Medical
   Sciences; Nanjing Medical University
RP Zhan, FH (通讯作者)，Univ Utah, Huntsman Canc Inst, Sch Med, Div Hematol,BMT Myeloma Program, 30 North 1900 East, Salt Lake City, UT 84132 USA.
EM shaughnessyjohn@uams.edu; fenghuang.zhan@hsc.utah.edu
RI Chen, lijuan/GYA 3236 2022; Zhong, Wenzhao/C 3388 2008; Zhou,
   Yiming/AAK 3059 2021
FU National Institutes of Health [PO1 CA55819, RO1 CA113992]; Nancy and
   Stephen Grand Philanthropic Fund; Multiple Myeloma Research Foundation
FX This work was supported by National Institutes of Health PO1 grant
   CA55819 (to B. B., J. D. S., and J. E.), National Institutes of Health
   RO1 CA113992 (to J. E.), the Fund to Cure Myeloma, the Nancy and Stephen
   Grand Philanthropic Fund, and the Multiple Myeloma Research Foundation
   (to I. E. and S. Y.). We thank Lei Shi, Yan Xiao, and Hongqing Zhu for
   assistance.
CR Ahmed MM, 2004, CURR CANCER DRUG TAR, V4, P43, DOI 10.2174/1568009043481704
   Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897 917
   ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092 8674(88)90143 2
   ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092 8674(87)90611 8
   Bailey S, 2001, LEUKEMIA, V15, P391, DOI 10.1038/sj.leu.2402039
   Barlogie B, 2008, CANCER AM CANCER SOC, V112, P2720, DOI 10.1002/cncr.23487
   Barlogie B, 2007, BEST PRACT RES CL HA, V20, P761, DOI 10.1016/j.beha.2007.09.005
   Barlogie B, 2007, BRIT J HAEMATOL, V138, P176, DOI 10.1111/j.1365 2141.2007.06639.x
   Colla S, 2007, BLOOD, V109, P4470, DOI 10.1182/blood 2006 11 056747
   Das M, 2007, P NATL ACAD SCI USA, V104, P15759, DOI 10.1073/pnas.0707782104
   Epstein Joshua, 2003, Hematol J, V4, P310, DOI 10.1038/sj.thj.6200313
   Gibbs JD, 2008, LEUKEMIA, V22, P1909, DOI 10.1038/leu.2008.189
   Gibbs J, 2008, ONCOGENE, V27, P98, DOI 10.1038/sj.onc.1210627
   Harada T, 2001, NAT CELL BIOL, V3, P453, DOI 10.1038/35074516
   Hideshima T, 2003, BLOOD, V101, P1530, DOI 10.1182/blood 2002 08 2543
   Hoffmann E, 2008, J BIOL CHEM, V283, P12120, DOI 10.1074/jbc.M800583200
   Hurt EM, 2006, CANCER BIOL THER, V5, P1154, DOI 10.4161/cbt.5.9.3001
   Hyun T, 2000, BLOOD, V96, P3560, DOI 10.1182/blood.V96.10.3560.h8003560_3560_3568
   Jia L, 2008, PROSTATE, V68, P427, DOI 10.1002/pros.20716
   Kajiguchi T, 2006, CANCER SCI, V97, P540, DOI 10.1111/j.1349 7006.2006.00199.x
   KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483
   Kaufmann K, 2001, J NEUROL SCI, V189, P83, DOI 10.1016/S0022 510X(01)00562 7
   Kaufmann K, 2002, J CELL BIOCHEM, V85, P381, DOI 10.1002/jcb.10145
   Kolbus A, 2000, MOL CELL BIOL, V20, P575, DOI 10.1128/MCB.20.2.575 582.2000
   Kyle RA, 2004, NEW ENGL J MED, V351, P1860, DOI 10.1056/NEJMra041875
   Levkovitz Y, 2001, J NEUROSCI, V21, P5893, DOI 10.1523/JNEUROSCI.21 16 05893.2001
   Levkovitz Y, 2001, J NEUROSCI, V21, P45, DOI 10.1523/JNEUROSCI.21 01 00045.2001
   Liu CT, 1998, CANCER GENE THER, V5, P3
   Lu AP, 2002, J BIOL CHEM, V277, P31364, DOI 10.1074/jbc.M201060200
   Lucerna M, 2006, CANCER RES, V66, P6708, DOI 10.1158/0008 5472.CAN 05 2732
   Mitsiades CS, 2006, EUR J CANCER, V42, P1564, DOI 10.1016/j.ejca.2005.12.025
   Nair P, 1997, J BIOL CHEM, V272, P20131, DOI 10.1074/jbc.272.32.20131
   Podar K, 2007, CANCER RES, V67, P1680, DOI 10.1158/0008 5472.CAN 06 1863
   Ronski K, 2005, CANCER AM CANCER SOC, V104, P925, DOI 10.1002/cncr.21262
   Satoh K, 2001, CANCER, V92, P271, DOI 10.1002/1097 0142(20010715)92:2<271::AID CNCR1319>3.0.CO;2 0
   Shaughnessy JD, 2007, BLOOD, V109, P2276, DOI 10.1182/blood 2006 07 038430
   Shaughnessy JD, 2007, BRIT J HAEMATOL, V137, P530, DOI 10.1111/j.1365 2141.2007.06586.x
   Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383
   Shin S, 2001, BIOCHEMISTRY US, V40, P1117, DOI 10.1021/bi001603q
   SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092 8674(88)90485 0
   Thiel G, 2002, J CELL PHYSIOL, V193, P287, DOI 10.1002/jcp.10178
   Virolle T, 2001, NAT CELL BIOL, V3, P1124, DOI 10.1038/ncb1201 1124
   Wagner M, 2008, INT J CANCER, V122, P1278, DOI 10.1002/ijc.23183
   Xiong W, 2008, BLOOD, V112, P4235, DOI 10.1182/blood 2007 10 119123
   Yaccoby S, 2004, CANCER RES, V64, P2016, DOI 10.1158/0008 5472.CAN 03 1131
   Yamamoto H, 2008, CANCER SCI, V99, P1709, DOI 10.1111/j.1349 7006.2008.00870.x
   Yu J, 2002, BRIT J CANCER, V87, P91, DOI 10.1038/sj.bjc.6600421
   Zhan F, 2006, BLOOD, V108, P2020, DOI 10.1182/blood 2005 11 013458
   Zhang JY, 2007, CANCER RES, V67, P3827, DOI 10.1158/0008 5472.CAN 06 4017
NR 49
TC 73
Z9 77
U1 1
U2 9
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006 4971
EI 1528 0020
J9 BLOOD
JI Blood
PD JAN 7
PY 2010
VL 115
IS 1
BP 61
EP 70
DI 10.1182/blood 2009 03 210526
PG 10
WC Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Hematology
GA 541CE
UT WOS:000273389600013
PM 19837979
OA Bronze, Green Published
DA 2025 08 17
ER

PT J
AU Strugnell, SA
   Sprague, SM
   Ashfaq, A
   Petkovich, M
   Bishop, CW
AF Strugnell, Stephen A.
   Sprague, Stuart M.
   Ashfaq, Akhtar
   Petkovich, Martin
   Bishop, Charles W.
TI Rationale for Raising Current Clinical Practice Guideline Target for
   Serum 25 Hydroxyvitamin D in Chronic Kidney Disease
SO AMERICAN JOURNAL OF NEPHROLOGY
LA English
DT Article
DE Chronic kidney disease; Secondary hyperparathyroidism; Vitamin D
   insufficiency; 25 Hydroxyvitamin D; Extended release calcifediol; Bone
   turnover markers
ID EXTENDED RELEASE CALCIFEDIOL; VITAMIN D SUPPLEMENTATION; SECONDARY
   HYPERPARATHYROIDISM; D INSUFFICIENCY; D DEFICIENCY; MORTALITY; RISK;
   ERGOCALCIFEROL; CALCIFICATION; CALCIUM
AB Background: Vitamin D repletion is recommended for secondary hyperparathyroidism (SHPT) and associated vitamin D insufficiency (VDI) in chronic kidney disease (CKD), but optimal levels of serum total 25 hydroxyvitamin D remain undefined. Clinical practice guidelines target sufficiency, whereas recent data indicate that higher levels are required to control the elevation of intact parathyroid hormone (iPTH) as CKD advances. This secondary analysis of 2 randomized controlled trials seeks to identify the minimum level of mean serum 25 hydroxyvitamin D required to control SHPT arising from VDI in stage 3 or 4 CKD. Methods: Adult subjects (n = 429) with SHPT, VDI, and stage 3 or 4 CKD were stratified by stage and treated daily with either extended release calcifediol (ERC) or placebo in 2 identical, parallel, randomized, double blind studies. After treatment for 26 weeks, all subjects were ranked by the level of serum total 25 hydroxyvitamin D and divided into quintiles in order to examine the relationships between the degree of vitamin D repletion and the associated changes in plasma iPTH, serum bone turnover markers, calcium, phosphorus, intact fibroblast growth factor 23 (FGF23) and vitamin D metabolites, estimated glomerular filtration rate (eGFR), and urine calcium: creatinine (Ca:Cr) ratio. Results: Progressive increases in serum 1,25 dihydroxyvitamin D and reductions in plasma iPTH and serum bone turnover markers were observed as mean posttreatment serum 25 hydroxyvitamin D rose from 13.9 ng/mL (in Quintile 1) to 92.5 ng/mL (in Quintile 5), irrespective of CKD stage. Mean serum calcium, phosphorus and FGF23, eGFR, and urine Ca: Cr ratio (collectively " safety parameters") did not significantly change from Quintile 1. Suppression of iPTH and bone turnover markers was not observed until serum 25 hydroxyvitamin D rose to at least 50.8 ng/mL (Quintile 3). Conclusion: ERC therapy produced exposure dependent reductions in plasma iPTH and bone turnover markers only when mean serum total 25 hydroxyvitamin D reached at least 50.8 ng/mL, indicating that current targets for vitamin D repletion therapy in CKD are too low. Gradual elevation of mean serum 25 hydroxyvitamin D to 92.5 ng/mL was not associated with significant adverse changes in safety parameters. (c) 2019 S. Karger AG, Basel
C1 [Strugnell, Stephen A.; Ashfaq, Akhtar; Bishop, Charles W.] OPKO Hlth Inc, Div Renal, 4400 Biscayne Blvd, Miami, FL 33139 USA.
   [Sprague, Stuart M.] NorthShore Univ HealthSyst, Dept Med, Evanston, IL USA.
   [Petkovich, Martin] Queens Univ, Dept Biomed & Mol Sci, Kingston, ON, Canada.
C3 NorthShore University Health System; Queens University   Canada
RP Strugnell, SA (通讯作者)，OPKO Hlth Inc, Div Renal, 4400 Biscayne Blvd, Miami, FL 33139 USA.
EM sstrugnell@opko.com
OI Sprague, Stuart/0000 0002 3330 0179
FU Renal Division of OPKO Health, Inc.
FX These studies were supported by the Renal Division of OPKO Health, Inc.
CR Agarwal R, 2016, NEPHROL DIAL TRANSPL, V31, P706, DOI 10.1093/ndt/gfw080
   Al Aly Z, 2007, AM J KIDNEY DIS, V50, P59, DOI 10.1053/j.ajkd.2007.04.010
   [Anonymous], 2017, CLIN J AM SOC NEPHRO, DOI [10.2215/CJN.10791016, DOI 10.2215/CJN.10791016]
   BIKLE DD, 1992, ENDOCR REV, V13, P765, DOI 10.1210/er.13.4.765
   Chlebowski RT, 2008, JNCI J NATL CANCER I, V100, P1581, DOI 10.1093/jnci/djn360
   Cunningham J, 2011, CLIN J AM SOC NEPHRO, V6, P913, DOI 10.2215/CJN.06040710
   de Boer IH, 2011, CLIN J AM SOC NEPHRO, V6, P2141, DOI 10.2215/CJN.02640311
   DeLuca HF, 2011, ARCH BIOCHEM BIOPHYS, V505, P226, DOI 10.1016/j.abb.2010.10.012
   Durup D, 2015, J CLIN ENDOCR METAB, V100, P2339, DOI 10.1210/jc.2014 4551
   DUSSO A, 1988, KIDNEY INT, V34, P368, DOI 10.1038/ki.1988.190
   Eknoyan G, 2003, AM J KIDNEY DIS, V41, pS1, DOI 10.1016/S0272 6386(03)00111 2
   Ennis JL, 2016, J NEPHROL, V29, P63, DOI 10.1007/s40620 015 0186 0
   González EA, 2004, AM J NEPHROL, V24, P503, DOI 10.1159/000081023
   Holick MF, 2005, SEMIN DIALYSIS, V18, P266, DOI 10.1111/j.1525 139X.2005.18402.x
   Holick MF, 2011, J CLIN ENDOCR METAB, V96, P1911, DOI [10.1210/jc.2011 0385, 10.1210/jc.2011 1193]
   Hollis BW, 2005, J NUTR, V135, P317, DOI 10.1093/jn/135.2.317
   HUGHES MR, 1976, J CLIN INVEST, V58, P61, DOI 10.1172/JCI108459
   Jia X, 2007, BRIT J NUTR, V98, P593, DOI 10.1017/S0007114507725163
   Jones G, 2008, AM J CLIN NUTR, V88, p582S, DOI 10.1093/ajcn/88.2.582S
   Kalantar Zadeh K, 2009, CLIN J AM SOC NEPHRO, V4, P1529, DOI 10.2215/CJN.02140309
   Kidney Disease: Improving Global Outcomes (KDIGO) CKD MBD Update Work Group, 2011, KIDNEY INT SUPPL, V2017, P1
   Kidney Disease: Improving Global Outcomes (KDIGO) CKD MBD Work Group, 2009, Kidney Int Suppl, pS1, DOI 10.1038/ki.2009.188
   Levin A, 2007, KIDNEY INT, V71, P31, DOI 10.1038/sj.ki.5002009
   Mehrotra R, 2009, KIDNEY INT, V76, P977, DOI 10.1038/ki.2009.288
   Melamed ML, 2008, ARCH INTERN MED, V168, P1629, DOI 10.1001/archinte.168.15.1629
   Navaneethan SD, 2011, AM J KIDNEY DIS, V58, P536, DOI 10.1053/j.ajkd.2011.04.028
   Nigwekar Sagar U, 2014, Bonekey Rep, V3, P498, DOI 10.1038/bonekey.2013.232
   Pilz S, 2011, NEPHROL DIAL TRANSPL, V26, P3603, DOI 10.1093/ndt/gfr076
   Ravani P, 2009, KIDNEY INT, V75, P88, DOI 10.1038/ki.2008.501
   Ritter CS, 2012, J STEROID BIOCHEM, V130, P73, DOI 10.1016/j.jsbmb.2012.01.010
   Rodbro LL, 2018, OSTEOPOROSIS INT, V29, P2211, DOI 10.1007/s00198 018 4602 x
   Ross AC, 2011, J CLIN ENDOCR METAB, V96, P53, DOI 10.1210/jc.2010 2704
   Shardlow A, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen 2017 016528
   SHEPARD RM, 1980, ARCH BIOCHEM BIOPHYS, V202, P43, DOI 10.1016/0003 9861(80)90404 X
   Sprague SM, 2017, EXPERT REV ENDOCRINO, V12, P289, DOI 10.1080/17446651.2017.1347501
   Sprague SM, 2016, AM J NEPHROL, V44, P316, DOI 10.1159/000450766
   Sprague SM, 2014, AM J NEPHROL, V40, P535, DOI 10.1159/000369939
   Stolzenberg Solomon RZ, 2010, AM J EPIDEMIOL, V172, P81, DOI 10.1093/aje/kwq120
   Tomiyama C, 2010, J BONE MINER RES, V25, P499, DOI 10.1359/jbmr.090735
   Torres U, 2016, VITAMIN D CHRONIC KI
   Towler DA, 2011, CIRC RES, V108, P1378, DOI 10.1161/CIRCRESAHA.110.234419
   Tuohimaa P, 2004, INT J CANCER, V108, P104, DOI 10.1002/ijc.11375
   Visser M, 2006, AM J CLIN NUTR, V84, P616, DOI 10.1093/ajcn/84.3.616
   West SL, 2015, J INTERN MED, V278, P19, DOI 10.1111/joim.12361
   Zisman AL, 2007, AM J NEPHROL, V27, P36, DOI 10.1159/000098561
NR 45
TC 53
Z9 55
U1 0
U2 4
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH 4009 BASEL, SWITZERLAND
SN 0250 8095
EI 1421 9670
J9 AM J NEPHROL
JI Am. J. Nephrol.
PY 2019
VL 49
IS 4
BP 284
EP 293
DI 10.1159/000499187
PG 10
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Urology & Nephrology
GA HT2DF
UT WOS:000464372700004
PM 30878999
DA 2025 08 17
ER

PT J
AU Wu, YX
   Wang, XY
   Zhang, YX
   Wen, ZH
   Li, YY
   Zhang, KH
   Gosar, N
   Li, QL
   Mao, J
   Gong, SQ
AF Wu, Yaxin
   Wang, Xiangyao
   Zhang, Yuxiao
   Wen, Zhihao
   Li, Yuanyuan
   Zhang, Kehan
   Gosar, Nuerlan
   Li, Qilin
   Mao, Jing
   Gong, Shiqiang
TI Proanthocyanidins Ameliorate LPS Inhibited Osteogenesis of PDLSCs by
   Restoring Lysine Lactylation
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE periodontitis; lysine; proanthocyanidins; bone regeneration
ID STEM CELLS; LACTATE; DIFFERENTIATION; REPAIR; GENE; PERIODONTITIS
AB Periodontitis is a bacteria induced inflammatory disease characterized by the progressive destruction of periodontal supporting tissues. Periodontal ligament stem cells (PDLSCs) are capable of differentiating into osteoblasts, which is an important stem cell source for endogenous periodontal tissue regeneration. Lysine lactylation (Kla) is a novel post translational modification of proteins that is recently thought to be associated with osteogenic differentiation. Here, we found that lactylation levels are reduced both in the periodontal tissue of rats with periodontitis and lipopolysaccharide (LPS) stimulated human PDLSCs. Proanthocyanidins were able to promote the osteogenesis of inflamed PDLSCs by restoring lactylation levels. Mechanistically, proanthocyanidins increased lactate production and restored the lactylation levels of PDLSCs, which recovered osteogenesis of inflamed PDLSCs via the Wnt/beta catenin pathway. These results provide evidence on how epigenetic regulation by pharmacological agents influence the osteogenic phenotype of stem cells and the process of periodontal tissue repair. Our current study highlights the valuable potential of natural product proanthocyanidins in the regenerative engineering of periodontal tissues.
C1 [Wu, Yaxin; Wang, Xiangyao; Zhang, Yuxiao; Wen, Zhihao; Li, Yuanyuan; Zhang, Kehan; Gosar, Nuerlan; Li, Qilin; Mao, Jing; Gong, Shiqiang] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Stomatol, Wuhan 430030, Peoples R China.
   [Wu, Yaxin; Wang, Xiangyao; Zhang, Yuxiao; Wen, Zhihao; Li, Yuanyuan; Zhang, Kehan; Gosar, Nuerlan; Li, Qilin; Mao, Jing; Gong, Shiqiang] Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Stomatol, Wuhan 430033, Peoples R China.
C3 Huazhong University of Science & Technology; Huazhong University of
   Science & Technology
RP Mao, J; Gong, SQ (通讯作者)，Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Stomatol, Wuhan 430030, Peoples R China.; Mao, J; Gong, SQ (通讯作者)，Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Stomatol, Wuhan 430033, Peoples R China.
EM yaxinwu@163.com; d202380929@hust.edu.cn; m202372648@hust.edu.cn;
   kqys_wzh@163.com; lyy13486378721@163.com; 15987879508@163.com;
   gaosaer0606@163.com; qilinli@tjh.tjmu.edu.cn; maojing@hust.edu.cn;
   gsq@hust.edu.cn
RI Zhang, Yu Xiao/G 7407 2019; Gong, Shi qiang/HGB 7742 2022; Li,
   Yuanyuan/LXV 3727 2024; li, qilin/HHD 0423 2022
OI Mao, Jing/0000 0001 6353 9992; Gong, Shi qiang/0000 0001 9796 4081; Li,
   Qilin/0000 0001 7715 7848; 
FU Natural Science Foundation of Hubei Province; Tongji Medical College,
   Huazhong University of Science and Technology
FX All authors are grateful for the technical assistance from the
   Experimental Medicine Center, Tongji Hospital, Tongji Medical College,
   Huazhong University of Science and Technology.
CR Akaberi M, 2016, PHYTOTHER RES, V30, P540, DOI 10.1002/ptr.5570
   Arora P, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23074038
   Cheng MS, 2021, CELLS TISSUES ORGANS, V209, P227, DOI 10.1159/000511702
   Dannewitz B, 2021, BUNDESGESUNDHEITSBLA, V64, P931, DOI 10.1007/s00103 021 03373 2
   Delgado Calle J, 2011, BONE, V49, P830, DOI 10.1016/j.bone.2011.06.006
   Deng J, 2023, BMC MED GENOMICS, V16, DOI 10.1186/s12920 023 01726 1
   Eleuterio E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071101
   Ghani QP, 2003, WOUND REPAIR REGEN, V11, P439, DOI 10.1046/j.1524 475X.2003.11608.x
   Hagihara H, 2021, CELL REP, V37, DOI 10.1016/j.celrep.2021.109820
   Hassan MQ, 2007, MOL CELL BIOL, V27, P3337, DOI 10.1128/MCB.01544 06
   Herrera D, 2022, J CLIN PERIODONTOL, V49, P4, DOI 10.1111/jcpe.13639
   Jiahui H, 2020, INFLAMMATION, V43, P892, DOI 10.1007/s10753 019 01175 y
   Huang XF, 2020, J TRANSL MED, V18, DOI 10.1186/s12967 020 02664 7
   Icard P, 2018, DRUG RESIST UPDATE, V38, P1, DOI 10.1016/j.drup.2018.03.001
   Kwak SC, 2020, NUTRIENTS, V12, DOI 10.3390/nu12103164
   Li JJ, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287 020 02123 6
   Li LP, 2020, NAT METAB, V2, P882, DOI 10.1038/s42255 020 0267 9
   Li W, 2022, J DENT RES, V101, P802, DOI 10.1177/00220345211070222
   Liberti MV, 2016, TRENDS BIOCHEM SCI, V41, P211, DOI 10.1016/j.tibs.2015.12.001
   Liu XC, 2016, CURR STEM CELL RES T, V11, P593, DOI 10.2174/1574888X11666160429122858
   Liu Z, 2023, J PERIODONTAL RES, V58, P1300, DOI 10.1111/jre.13186
   Loeffler J, 2018, TRENDS ENDOCRIN MET, V29, P99, DOI 10.1016/j.tem.2017.11.008
   Lv XY, 2023, EXPERT REV MOL MED, V25, DOI 10.1017/erm.2022.42
   Milovanova TN, 2008, MOL CELL BIOL, V28, P6248, DOI 10.1128/MCB.00795 08
   Nichols JA, 2010, ARCH DERMATOL RES, V302, P71, DOI 10.1007/s00403 009 1001 3
   Padumadasa C, 2016, BMC COMPLEM ALTERN M, V16, DOI 10.1186/s12906 016 1335 2
   Pan LH, 2022, PHARMACOL RES, V181, DOI 10.1016/j.phrs.2022.106270
   Pandkar MR, 2023, TRANSL ONCOL, V37, DOI 10.1016/j.tranon.2023.101758
   Peres MA, 2019, LANCET, V394, P249, DOI 10.1016/S0140 6736(19)31146 8
   Queiroz A, 2021, WORLD J STEM CELLS, V13, P605, DOI 10.4252/wjsc.v13.i6.605
   Rabinowitz JD, 2020, NAT METAB, V2, P566, DOI 10.1038/s42255 020 0243 4
   Rattigan YL, 2012, EXP CELL RES, V318, P326, DOI 10.1016/j.yexcr.2011.11.014
   Rauf A, 2019, BIOMED PHARMACOTHER, V116, DOI 10.1016/j.biopha.2019.108999
   Reik W, 2007, NATURE, V447, P425, DOI 10.1038/nature05918
   Schulze Späte U, 2015, J CLIN ENDOCR METAB, V100, P2425, DOI 10.1210/jc.2014 4180
   Seo BM, 2004, LANCET, V364, P149, DOI 10.1016/S0140 6736(04)16627 0
   Shen J, 2003, MOL ENDOCRINOL, V17, P743, DOI 10.1210/me.2002 0122
   Slots J, 2017, PERIODONTOL 2000, V75, P7, DOI 10.1111/prd.12221
   Sun C, 2017, INT J MOL MED, V39, P1548, DOI 10.3892/ijmm.2017.2971
   Sun LH, 2023, NAT COMMUN, V14, DOI 10.1038/s41467 023 42025 8
   Tour G, 2012, J DENT RES, V91, P789, DOI 10.1177/0022034512452430
   Vaid M, 2016, INT J ONCOL, V48, P624, DOI 10.3892/ijo.2015.3286
   Wieczfinska J, 2020, CURR PHARM DESIGN, V26, P2876, DOI 10.2174/1381612826666200406093257
   Wu JH, 2023, ADV SCI, V10, DOI 10.1002/advs.202301300
   Yang KY, 2017, NUTR REV, V75, P642, DOI 10.1093/nutrit/nux028
   Yang LY, 2018, BIOMED RES INT UK, V2018, DOI 10.1155/2018/8584136
   Yin X, 2015, J DENT RES, V94, P1487, DOI 10.1177/0022034515599772
   Yu J, 2021, GENOME BIOL, V22, DOI 10.1186/s13059 021 02308 z
   Zahra K, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00159
   Zhang D, 2019, NATURE, V574, P575, DOI 10.1038/s41586 019 1678 1
   Zhang RP, 2011, J BIOL CHEM, V286, P41083, DOI 10.1074/jbc.M111.258715
   Zhao J, 2022, CELL DEATH DIS, V13, DOI 10.1038/s41419 022 05051 w
NR 52
TC 17
Z9 18
U1 5
U2 32
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
SN 1661 6596
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD MAR
PY 2024
VL 25
IS 5
AR 2947
DI 10.3390/ijms25052947
PG 18
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA KV9Q4
UT WOS:001182859400001
PM 38474198
OA gold
DA 2025 08 17
ER

PT J
AU Koefoed, M
   Ito, H
   Gromov, K
   Reynolds, DG
   Awad, HA
   Rubery, PT
   Ulrich Vinther, M
   Soballe, K
   Guldberg, RE
   Lin, ASP
   O'Keefe, RJ
   Zhang, XP
   Schwarz, EM
AF Koefoed, M
   Ito, H
   Gromov, K
   Reynolds, DG
   Awad, HA
   Rubery, PT
   Ulrich Vinther, M
   Soballe, K
   Guldberg, RE
   Lin, ASP
   O'Keefe, RJ
   Zhang, XP
   Schwarz, EM
TI Biological effects of rAAV caAlk2 coating on structural allograft
   healing
SO MOLECULAR THERAPY
LA English
DT Article
DE allograft; recombinant adeno associated virus; bone morphogenetic
   protein
ID MEDIATED GENE THERAPY; BONE FORMATION; IN VIVO; MICROCOMPUTED
   TOMOGRAPHY; CLINICAL APPLICATIONS; STEM CELLS; REGENERATION; VECTORS;
   REPAIR; TRANSPLANTATION
AB Structural bone allografts often fracture due to their lack of osteogenic and remodeling potential. To overcome these limitations, we utilized allografts coated with recombinant adeno associated virus (rAAV) that mediate in vivo gene transfer. Using beta galactosidase as a reporter gene, we show that 4 mm murine femoral allografts coated with rAAV LacZ are capable of transducing adjacent inflammatory cells and osteoblasts in the fracture callus following transplantation. While this LacZ vector had no effect on allograft healing, bone morphogenetic protein signals delivered via rAAV caAlk2 coating induced endochondral bone formation directly on the cortical surface of the allograft by day 14. By day 28 there was evidence of remodeling of the new woven bone and massive osteoclastic resorption of the cortical surface of the rAAV caAlk2 coated allografts only. Micro CT analysis of rAAV LacZ  vs rAAV caAlk2 coated allografts after 42 days of healing demonstrated a significant increase in new bone formation (0.67 +/  0.21 vs 2.49 +/  0.40 mm(3); P < 0.005). Furthermore, the 3D micro CT images of femurs grafted with rAAV Alk2 coated allografts provided the first evidence that complete bridging of bone around a cortical allograft is possible. These results indicate that cell free, rAAV coated allografts have the potential to revitalize in vivo following transplantation.
C1 Univ Rochester, Med Ctr, Ctr Musculoskeletal Res, Rochester, NY 14642 USA.
   Aarhus Univ Hosp, Dept Orthoped, DK 8000 Aarhus, Denmark.
   Georgia Inst Technol, Inst Bioengn & Biosci, Atlanta, GA 30332 USA.
C3 University of Rochester; Aarhus University; University System of
   Georgia; Georgia Institute of Technology
RP Schwarz, EM (通讯作者)，Univ Rochester, Med Ctr, Ctr Musculoskeletal Res, 601 Elmwood Ave,Box 665, Rochester, NY 14642 USA.
EM Edward_Schwarz@URMC.Rochester.edu
RI ; Gromov, Kirill/AAM 2270 2020; Mostafa, Taymour/H 6834 2019; Awad,
   Hani/G 6976 2014
OI Gromov, Kirill/0000 0002 8114 5193; Soballe, Kjeld/0000 0001 8872 9856;
   Awad, Hani/0000 0003 2197 2610
CR Baltzer AWA, 2004, GENE THER, V11, P344, DOI 10.1038/sj.gt.3302195
   BERREY BH, 1990, J BONE JOINT SURG AM, V72A, P825, DOI 10.2106/00004623 199072060 00005
   Bonadio J, 1999, NAT MED, V5, P753, DOI 10.1038/10473
   BURCHARDT H, 1987, ORTHOP CLIN N AM, V18, P187
   Chen Y, 2003, GENE THER, V10, P1345, DOI 10.1038/sj.gt.3301999
   Chen Y, 1997, P NATL ACAD SCI USA, V94, P12938, DOI 10.1073/pnas.94.24.12938
   Childs LM, 2001, J BONE JOINT SURG AM, V83A, P1789, DOI 10.2106/00004623 200112000 00004
   DELUCA JV, 1987, T ORTHOP RES SOC, V11, P376
   Duvall CL, 2004, AM J PHYSIOL HEART C, V287, pH302, DOI 10.1152/ajpheart.00928.2003
   Einhorn TA, 2003, J BONE JOINT SURG AM, V85A, P82, DOI 10.2106/00004623 200300003 00014
   Einhorn TA, 1998, CLIN ORTHOP RELAT R, pS7
   Gafni Y, 2004, GENE THER, V11, P417, DOI 10.1038/sj.gt.3302197
   Gafni Y, 2004, MOL THER, V9, P587, DOI 10.1016/j.ymthe.2003.12.009
   Garbuz DS, 1998, ORTHOP CLIN N AM, V29, P199, DOI 10.1016/S0030 5898(05)70318 7
   Gazit D, 1999, J GENE MED, V1, P121, DOI 10.1002/(SICI)1521 2254(199903/04)1:2<121::AID JGM26>3.0.CO;2 J
   Gerber HP, 1999, NAT MED, V5, P623, DOI 10.1038/9467
   Goater J, 2000, J RHEUMATOL, V27, P983
   Guldberg RE, 2003, IEEE ENG MED BIOL, V22, P77, DOI 10.1109/MEMB.2003.1256276
   Guldberg Robert E, 2004, Birth Defects Res C Embryo Today, V72, P250, DOI 10.1002/bdrc.20016
   Ito H, 2005, NAT MED, V11, P291, DOI 10.1038/nm1190
   Lieberman JR, 2002, J BONE JOINT SURG AM, V84A, P1032, DOI 10.2106/00004623 200206000 00022
   Lieberman JR, 2002, MOL THER, V6, P141, DOI 10.1006/mthe.2000.0663
   LORD CF, 1988, J BONE JOINT SURG AM, V70A, P369, DOI 10.2106/00004623 198870030 00008
   Luk KDK, 2003, BIOCHEM BIOPH RES CO, V308, P636, DOI 10.1016/S0006 291X(03)01429 3
   Moutsatsos IK, 2001, MOL THER, V3, P449, DOI 10.1006/mthe.2001.0291
   Rabinowitz JE, 2000, VIROLOGY, V278, P301, DOI 10.1006/viro.2000.0707
   Schwarz EM, 2000, CLIN ORTHOP RELAT R, pS31, DOI 10.1097/00003086 200010001 00005
   Stevenson S, 1999, ORTHOP CLIN N AM, V30, P543, DOI 10.1016/S0030 5898(05)70107 3
   Stevenson S, 1996, CLIN ORTHOP RELAT R, P86
   Stevenson S, 1997, J BONE JOINT SURG AM, V79A, P1
   SUMMERS BN, 1989, J BONE JOINT SURG BR, V71, P677, DOI 10.1302/0301 620X.71B4.2768321
   Tiyapatanaputi P, 2004, J ORTHOP RES, V22, P1254, DOI 10.1016/j.orthres.2004.03.017
   Turgeman G, 2001, J GENE MED, V3, P240
   Xiao X, 1998, J VIROL, V72, P2224, DOI 10.1128/JVI.72.3.2224 2232.1998
   Yaszemski MJ, 1996, BIOMATERIALS, V17, P175, DOI 10.1016/0142 9612(96)85762 0
   Younger E M, 1989, J Orthop Trauma, V3, P192, DOI 10.1097/00005131 198909000 00002
   Zhang DH, 2003, J BONE MINER RES, V18, P1593, DOI 10.1359/jbmr.2003.18.9.1593
   Zhang XP, 2002, J CLIN INVEST, V109, P1405, DOI 10.1172/JCI200215681
NR 38
TC 89
Z9 108
U1 0
U2 6
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 1525 0016
EI 1525 0024
J9 MOL THER
JI Mol. Ther.
PD AUG
PY 2005
VL 12
IS 2
BP 212
EP 218
DI 10.1016/j.ymthe.2005.02.026
PG 7
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
   Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
   Experimental Medicine
GA 954CV
UT WOS:000231132600006
PM 16043092
OA hybrid
DA 2025 08 17
ER

PT J
AU Yamada, S
   Ganno, T
   Ohara, N
   Hayashi, Y
AF Yamada, Shizuka
   Ganno, Tomoko
   Ohara, Naoko
   Hayashi, Yoshihiko
TI Chitosan monomer accelerates alkaline phosphatase activity on human
   osteoblastic cells under hypofunctional conditions
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A
LA English
DT Article
DE chitosan monomer; osteoblast; microgravity; interferon gamma receptor;
   alkaline phosphatase
ID NITRIC OXIDE PRODUCTION; WATER SOLUBLE CHITOSAN; IN VITRO;
   GENE EXPRESSION; BONE; TISSUE; PROLIFERATION; WEIGHT
AB Chitosan is a natural polyaminosaccharide that is extensively applied as an antitumor and antirheumatic drug. However, there are few reports about its effects on hypofunctional osteoblasts in vitro. We investigated the biological characteristics of a human osteoblastic cell line (NOS 1 cells) that was cultured with a chitosan monomer containing medium under simulated microgravity conditions. After 7 days of cell incubation under the conventional conditions, the flasks were transferred to a microgravity simulator for 3 days. In the 0.005% chitosan monomer supplemented group, the marker enzyme of biological mineralization, the alkaline phosphatase (ALP) activity, was significantly higher compared with the control group (p < 0.05). A cDNA microarray was performed to investigate the effects on the mRNA level by chitosan monomer, and the fluorescent signal was analyzed. The interferon gamma (IFN gamma) receptor gene was detected with a signal ration of 2.2. The slight increase of IFN gamma receptor expression was confirmed after 3 days of incubation according to RT PCR analysis. Western blot analysis also showed the increased expression of IFN gamma receptor. These results suggest that a supra low concentration of chitosan monomer may increase the ALP activity of osteoblastic cells through the IFN gamma receptor at the early phase of cell culture and recover the activity for biological mineralization under the hypofunctional condition. (c) 2007 Wiley Periodicals, Inc.
C1 Nagasaki Univ, Grad Sch Biomed Sci, Dept Cardiol, Nagasaki 852, Japan.
C3 Nagasaki University
RP Yamada, S (通讯作者)，Nagasaki Univ, Grad Sch Biomed Sci, Dept Cardiol, Nagasaki 852, Japan.
EM shiduka@nagasaki u.ac.jp
CR Aksungur P, 2004, J CONTROL RELEASE, V98, P269, DOI 10.1016/j.jconrel.2004.05.002
   Bacabac RG, 2004, BIOCHEM BIOPH RES CO, V315, P823, DOI 10.1016/j.bbrc.2004.01.138
   Basso N, 2005, BONE, V36, P173, DOI 10.1016/j.bone.2004.09.016
   Basso N, 2002, BONE, V30, P347, DOI 10.1016/S8756 3282(01)00678 0
   Carey LE, 2005, BIOMATERIALS, V26, P5002, DOI 10.1016/j.biomaterials.2005.01.015
   Choi BK, 2001, INT J ANTIMICROB AG, V18, P553, DOI 10.1016/S0924 8579(01)00434 4
   FLEET JC, 1994, J BONE MINER RES, V9, P1565
   Grewal TS, 2000, FASEB J, V14, P523, DOI 10.1096/fasebj.14.3.523
   Ho MH, 2005, BIOMATERIALS, V26, P3197, DOI 10.1016/j.biomaterials.2004.08.032
   Hoemann CD, 2005, OSTEOARTHR CARTILAGE, V13, P318, DOI 10.1016/j.joca.2004.12.001
   HOTTA T, 1992, ACTA PATHOL JAPON, V42, P595
   Hughes Fulford M, 2003, ADV SPACE RES SERIES, V32, P1585, DOI 10.1016/S0273 1177(03)90399 1
   Ikeda T., 2002, BIOINDUSTRY, V19, P22
   Jeong HJ, 2000, INT J IMMUNOPHARMACO, V22, P923, DOI 10.1016/S0192 0561(00)00055 2
   Kelly HM, 2004, INT J PHARMACEUT, V274, P167, DOI 10.1016/j.ijpharm.2004.01.019
   Kim SB, 2004, BIOMATERIALS, V25, P5715, DOI 10.1016/j.biomaterials.2004.01.022
   Kunisada T, 1997, ACTA MED OKAYAMA, V51, P135
   Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293
   LEVY DE, 1995, SEMIN VIROL, V6, P181, DOI 10.1006/smvy.1995.0023
   Lin C, 2005, J BIOL CHEM, V280, P36784, DOI 10.1074/jbc.M506462200
   Lisignoli G, 2004, J CELL PHYSIOL, V198, P388, DOI 10.1002/jcp.10427
   Matsunaga T, 2006, J BIOMED MATER RES A, V76A, P711, DOI 10.1002/jbm.a.30588
   Meininger CJ, 2000, BIOCHEM BIOPH RES CO, V279, P234, DOI 10.1006/bbrc.2000.3912
   Muzzarelli RAA, 1998, CARBOHYD POLYM, V36, P267, DOI 10.1016/S0144 8617(98)00008 3
   NOVICK D, 1990, Patent No. 0369413
   Ohara N, 2004, BIOMATERIALS, V25, P1749, DOI 10.1016/j.biomaterials.2003.08.022
   Park DJ, 2005, J CRANIO MAXILL SURG, V33, P50, DOI 10.1016/j.jcms.2004.05.011
   PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003 2697(77)90043 4
   Senel S, 2004, ADV DRUG DELIVER REV, V56, P1467, DOI 10.1016/j.addr.2004.02.007
   TAKIUCHI H, 1994, JPN J UROL, V85, P584
   VantHof RJ, 1997, J BONE MINER RES, V12, P1797, DOI 10.1359/jbmr.1997.12.11.1797
   Woodgate DE, 2003, CURR THER RES CLIN E, V64, P248, DOI 10.1016/S0011 393X(03)00058 4
   Xu HHK, 2005, BIOMATERIALS, V26, P1337, DOI 10.1016/j.biomaterials.2004.04.043
   Yamada S, 2003, J BIOMED MATER RES A, V66A, P500, DOI 10.1002/jbm.a.10009
NR 34
TC 17
Z9 17
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1549 3296
EI 1552 4965
J9 J BIOMED MATER RES A
JI J. Biomed. Mater. Res. Part A
PD NOV
PY 2007
VL 83A
IS 2
BP 290
EP 295
DI 10.1002/jbm.a.31234
PG 6
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA 218AV
UT WOS:000249989300005
PM 17415763
DA 2025 08 17
ER

PT J
AU Park, JK
   Byun, JY
   Park, JA
   Kim, YY
   Lee, YJ
   Oh, JI
   Jang, SY
   Kim, YH
   Song, YW
   Son, J
   Suh, KH
   Lee, YM
   Lee, EB
AF Park, Jin Kyun
   Byun, Joo Yun
   Park, Ji Ah
   Kim, Yu Yon
   Lee, Ye Ji
   Oh, Jeong In
   Jang, Sun Young
   Kim, Young Hoon
   Song, Yeong Wook
   Son, Jeewoong
   Suh, Kwee Hyun
   Lee, Young Mi
   Lee, Eun Bong
TI HM71224, a novel Bruton's tyrosine kinase inhibitor, suppresses B cell
   and monocyte activation and ameliorates arthritis in a mouse model: a
   potential drug for rheumatoid arthritis
SO ARTHRITIS RESEARCH & THERAPY
LA English
DT Article
DE B cells; Btk inhibitor; Inflammation; HM71224; Monocytes; Rheumatoid
   arthritis; Osteoclast
ID SYSTEMIC LUPUS ERYTHEMATOSUS; RITUXIMAB; EFFICACY; TEC; THERAPY; TUMOR;
   EXPRESSION; INDUCTION; PROTEIN; SAFETY
AB Background: Bruton's tyrosine kinase (Btk) is critical for activation of B cells and myeloid cells. This study aimed to characterize the effects of HM71224, a novel Btk inhibitor, both in vitro and in a mouse model of experimental arthritis.
   Methods: The kinase inhibition profile of HM71224 was analyzed. The in vitro effects of HM71224 on B cells and monocytes were analyzed by examining phosphorylation of Btk and its downstream signaling molecules, along with cytokine production and osteoclast formation. The in vivo effects of HM71224 were investigated in a mouse model of collagen induced arthritis (CIA).
   Results: HM71224 irreversibly bound to and inhibited Btk (IC50 = 1.95 nM). The compound also inhibited the phosphorylation of Btk and its downstream molecules such as PLC gamma 2, in activated Ramos B lymphoma cells and primary human B cells in a dose dependent manner. Furthermore, HM71224 effectively inhibited the production of tumor necrosis factor (TNF) alpha, interleukin (IL) 6, and IL 1 beta by human monocytes, and osteoclast formation by human monocytes. Finally, HM71224 improved experimental arthritis and prevented joint destruction in a murine model of CIA.
   Conclusions: HM71224 inhibits Btk in B cells and monocytes and ameliorates experimental arthritis in a mouse model. Thus, HM71224 is a potential novel therapeutic agent for rheumatoid arthritis in humans.
C1 [Park, Jin Kyun; Park, Ji Ah; Lee, Ye Ji; Song, Yeong Wook; Lee, Eun Bong] Seoul Natl Univ, Coll Med, Dept Internal Med, Div Rheumatol, 101 Daehank No, Seoul 03080, South Korea.
   [Byun, Joo Yun; Kim, Yu Yon; Oh, Jeong In; Jang, Sun Young; Kim, Young Hoon; Suh, Kwee Hyun; Lee, Young Mi] Hanmi Pharm Co Ltd, Hanmi Res Ctr, 550 Dongtangiheung Ro, Hwaseong Si 18469, Gyeonggi Do, South Korea.
   [Son, Jeewoong] Hanmi Pharm Co Ltd, 45 Bangi Dong, Seoul 138724, Gyeonggi Do, South Korea.
C3 Seoul National University (SNU); Hanmi Pharmaceutical; Hanmi
   Pharmaceutical
RP Lee, EB (通讯作者)，Seoul Natl Univ, Coll Med, Dept Internal Med, Div Rheumatol, 101 Daehank No, Seoul 03080, South Korea.; Lee, YM (通讯作者)，Hanmi Pharm Co Ltd, Hanmi Res Ctr, 550 Dongtangiheung Ro, Hwaseong Si 18469, Gyeonggi Do, South Korea.
EM leeym@hanmi.co.kr; leb7616@snu.ac.kr
RI Park, Kyung Woo/AAX 3046 2020; Kim, Young Hoon/E 5614 2012; Lee,
   YoungMi/JCF 0461 2023; Lee, Eun/J 5594 2012
OI Lee, Yeji/0000 0003 2175 0049; Park, Jin Kyun/0000 0003 2167 9393; 
FU Hanmi Research Center, Hanmi Pharm. Co. Ltd., Seoul, Korea
FX HM71224 (produced by Hanmi Pharmaceutical Co.) is also referred to as
   LY3337641 (Eli Lilly and Company). Funding was provided by Hanmi
   Research Center, Hanmi Pharm. Co. Ltd., Seoul, Korea.
CR Aalipour A, 2014, THER ADV HEMATOL, V5, P121, DOI 10.1177/2040620714539906
   [Anonymous], N ENGL J MED
   Audo R, 2014, ARTHRITIS RHEUMATOL, V66, pS168, DOI 10.1002/art.38666
   Bishop GA, 2001, CURR OPIN IMMUNOL, V13, P278, DOI 10.1016/S0952 7915(00)00216 8
   Bowie AG, 2008, NAT REV IMMUNOL, V8, P911, DOI 10.1038/nri2436
   Brand DD, 2007, NAT PROTOC, V2, P1269, DOI 10.1038/nprot.2007.173
   Chang BY, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3400
   Chatzidionysiou K, 2011, ANN RHEUM DIS, V70, P1575, DOI 10.1136/ard.2010.148759
   Christensen SR, 2005, J EXP MED, V202, P321, DOI 10.1084/jem.20050338
   Clavel C, 2008, ARTHRITIS RHEUM US, V58, P678, DOI 10.1002/art.23284
   Cohen SB, 2006, ARTHRITIS RHEUM US, V54, P2793, DOI 10.1002/art.22025
   Di Paolo JA, 2011, NAT CHEM BIOL, V7, P41, DOI 10.1038/NCHEMBIO.481
   Edwards JCW, 2001, RHEUMATOLOGY, V40, P205, DOI 10.1093/rheumatology/40.2.205
   Edwards JCW, 2004, NEW ENGL J MED, V350, P2572, DOI 10.1056/NEJMoa032534
   Finnegan A, 2012, AUTOIMMUNITY, V45, P353, DOI 10.3109/08916934.2012.665526
   Firestein GS, 2003, NATURE, V423, P356, DOI 10.1038/nature01661
   GENEVIER HC, 1994, EUR J IMMUNOL, V24, P3100, DOI 10.1002/eji.1830241228
   Humphries LA, 2004, J BIOL CHEM, V279, P37651, DOI 10.1074/jbc.M311985200
   Hussain A, 2011, FEBS J, V278, P2001, DOI 10.1111/j.1742 4658.2011.08134.x
   Jefferies CA, 2003, J BIOL CHEM, V278, P26258, DOI 10.1074/jbc.M301484200
   Jongstra Bilen J, 2008, J IMMUNOL, V181, P288, DOI 10.4049/jimmunol.181.1.288
   Kim SY, 2010, NAT REV RHEUMATOL, V6, P165, DOI 10.1038/nrrheum.2009.279
   Kitanaka A, 1998, BLOOD, V91, P940, DOI 10.1182/blood.V91.3.940.940_940_948
   Köprülü AD, 2009, CRIT REV IMMUNOL, V29, P317, DOI 10.1615/CritRevImmunol.v29.i4.30
   Koivuniemi R, 2006, SCAND J RHEUMATOL, V35, P273, DOI 10.1080/03009740600556258
   Marron TU, 2010, CLIN IMMUNOL, V137, P74, DOI 10.1016/j.clim.2010.06.011
   Ng KP, 2007, ANN RHEUM DIS, V66, P1259, DOI 10.1136/ard.2006.067124
   Ramos Casals M, 2009, LUPUS, V18, P767, DOI 10.1177/0961203309106174
   Satterthwaite AB, 2000, IMMUNOL REV, V175, P120, DOI 10.1034/j.1600 065X.2000.017504.x
   Shinohara M, 2014, BONE, V60, P8, DOI 10.1016/j.bone.2013.11.025
   Specks U, 2013, NEW ENGL J MED, V369, P417, DOI 10.1056/NEJMoa1213277
   Stone JH, 2010, NEW ENGL J MED, V363, P221, DOI 10.1056/NEJMoa0909905
   Tai YT, 2012, BLOOD, V120, P1877, DOI 10.1182/blood 2011 12 396853
   Terrier B, 2010, ARTHRITIS RHEUM US, V62, P2458, DOI 10.1002/art.27541
   Turner NC, 2015, NEW ENGL J MED, V373, P209, DOI 10.1056/NEJMoa1505270
   Wang JM, 2014, EUR J IMMUNOL, V44, P1130, DOI 10.1002/eji.201344030
   Wang QT, 2011, INT ARCH ALLERGY IMM, V155, P205, DOI 10.1159/000321185
   Xu DG, 2012, J PHARMACOL EXP THER, V341, P90, DOI 10.1124/jpet.111.187740
   Zhao XY, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2478
   Zorn CN, 2009, CELL SIGNAL, V21, P79, DOI 10.1016/j.cellsig.2008.09.010
NR 40
TC 70
Z9 72
U1 0
U2 35
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1478 6354
EI 1478 6362
J9 ARTHRITIS RES THER
JI Arthritis Res. Ther.
PD APR 18
PY 2016
VL 18
AR 91
DI 10.1186/s13075 016 0988 z
PG 9
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA DK2GI
UT WOS:000374732200002
PM 27090981
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU He, ZH
   Zou, JT
   Chen, X
   Gong, JS
   Chen, Y
   Jin, L
   Liu, YW
   Rao, SS
   Yin, H
   Tan, YJ
   Wang, Z
   Du, W
   Li, HM
   Qian, YX
   Wang, ZX
   Wang, YY
   Wan, TF
   Luo, Y
   Zhu, H
   Chen, CY
   Xie, H
AF He, Ze Hui
   Zou, Jing Tao
   Chen, Xia
   Gong, Jiang Shan
   Chen, Ya
   Jin, Ling
   Liu, Yi Wei
   Rao, Shan Shan
   Yin, Hao
   Tan, Yi Juan
   Wang, Zun
   Du, Wei
   Li, Hong Ming
   Qian, Yu Xuan
   Wang, Zhen Xing
   Wang, Yi Yi
   Wan, Teng Fei
   Luo, Yi
   Zhu, Hao
   Chen, Chun Yuan
   Xie, Hui
TI Ångstrom scale silver particles ameliorate collagen induced and
   K/BxN transfer arthritis in mice via the suppression of inflammation and
   osteoclastogenesis
SO INFLAMMATION RESEARCH
LA English
DT Article
DE Rheumatoid arthritis; & Aring;ngstrom scale silver particles;
   Inflammation; Osteoclastogenesis; Low toxicity
ID MAGNETIC NANOPARTICLES; RHEUMATOID ARTHRITIS; SIZE; CYTOTOXICITY
AB Objective Nanoparticles (NPs) hold a great promise in combating rheumatoid arthritis, but are often compromised by their toxicities because the currently used NPs are usually synthesized by chemical methods. Our group has previously fabricated & Aring;ngstrom scale silver particles (Ag & Aring;Ps) and demonstrated the anti tumor and anti sepsis efficacy of fructose coated Ag & Aring;Ps (F Ag & Aring;Ps). This study aimed to uncover the efficacy and mechanisms of F Ag & Aring;Ps for arthritis therapy.Methods We evaluated the efficacy of F Ag & Aring;Ps in collagen induced arthritis (CIA) mice. We also compared the capacities of F Ag & Aring;Ps, the commercial AgNPs, and the clinical drug methotrexate (MTX) in protecting against K/BxN serum transfer arthritis (STA) mice. Moreover, we evaluated the effects of F Ag & Aring;Ps and AgNPs on inflammation, osteoclast formation, synoviocytes migration, and matrix metalloproteinases (MMPs) production in vitro and in vivo. Meanwhile, the toxicities of F Ag & Aring;Ps and AgNPs in vitro and in vivo were also tested.Results F Ag & Aring;Ps significantly prevented bone erosion, synovitis, and cartilage damage, attenuated rheumatic pain, and improved the impaired motor function in mouse models of CIA or STA, the anti rheumatic effects of which were comparable or stronger than AgNPs and MTX. Further studies revealed that F Ag & Aring;Ps exhibited similar or greater inhibitory abilities than AgNPs to suppress inflammation, osteoclast formation, synoviocytes migration, and MMPs production. No obvious toxicities were observed in vitro and in vivo after F Ag & Aring;Ps treatment.Conclusions F Ag & Aring;Ps can effectively alleviate arthritis without notable toxicities and their anti arthritic effects are associated with the inhibition of inflammation, osteoclastogenesis, synoviocytes migration, and MMPs production. Our study suggests the prospect of F Ag & Aring;Ps as an efficient and low toxicity agent for arthritis therapy.
C1 [He, Ze Hui; Zou, Jing Tao; Chen, Xia; Gong, Jiang Shan; Chen, Ya; Jin, Ling; Liu, Yi Wei; Rao, Shan Shan; Yin, Hao; Tan, Yi Juan; Wang, Zun; Du, Wei; Li, Hong Ming; Qian, Yu Xuan; Wang, Zhen Xing; Wang, Yi Yi; Wan, Teng Fei; Luo, Yi; Zhu, Hao; Chen, Chun Yuan; Xie, Hui] Cent South Univ, Xiangya Hosp, Movement Syst Injury & Repair Res Ctr, Dept Orthoped, Changsha, Hunan, Peoples R China.
   [He, Ze Hui; Zou, Jing Tao; Gong, Jiang Shan; Chen, Ya; Jin, Ling; Liu, Yi Wei; Rao, Shan Shan; Yin, Hao; Tan, Yi Juan; Li, Hong Ming; Qian, Yu Xuan; Wang, Zhen Xing; Wang, Yi Yi; Wan, Teng Fei; Luo, Yi; Zhu, Hao; Chen, Chun Yuan; Xie, Hui] Hunan Key Lab Angmed, Changsha 410008, Hunan, Peoples R China.
   [He, Ze Hui; Zou, Jing Tao; Gong, Jiang Shan; Chen, Ya; Jin, Ling; Liu, Yi Wei; Rao, Shan Shan; Yin, Hao; Tan, Yi Juan; Li, Hong Ming; Qian, Yu Xuan; Wang, Zhen Xing; Wang, Yi Yi; Wan, Teng Fei; Luo, Yi; Zhu, Hao; Chen, Chun Yuan; Xie, Hui] Cent South Univ, Angmed Res Ctr, Changsha 410008, Hunan, Peoples R China.
   [Chen, Xia; Rao, Shan Shan; Wang, Zhen Xing; Chen, Chun Yuan; Xie, Hui] Cent South Univ, Xiangya Hosp, Natl Clin Res Ctr Geriatr Disorders, Changsha, Hunan, Peoples R China.
   [Wang, Zun] Cent South Univ, Xiangya Sch Nursing, Changsha, Hunan, Peoples R China.
   [Du, Wei] Cent South Univ, Xiangya Hosp, Dept Rehabil, Changsha 410008, Hunan, Peoples R China.
C3 Central South University; Central South University; Central South
   University; Central South University; Central South University
RP Chen, CY; Xie, H (通讯作者)，Cent South Univ, Xiangya Hosp, Movement Syst Injury & Repair Res Ctr, Dept Orthoped, Changsha, Hunan, Peoples R China.; Chen, CY; Xie, H (通讯作者)，Hunan Key Lab Angmed, Changsha 410008, Hunan, Peoples R China.; Chen, CY; Xie, H (通讯作者)，Cent South Univ, Angmed Res Ctr, Changsha 410008, Hunan, Peoples R China.; Chen, CY; Xie, H (通讯作者)，Cent South Univ, Xiangya Hosp, Natl Clin Res Ctr Geriatr Disorders, Changsha, Hunan, Peoples R China.
EM xiangyahezehui@csu.edu.cn; zjt2077@csu.edu.cn; chenxia85@csu.edu.cn;
   jiangshangong@csu.edu.cn; 1843754999@qq.com; jinl0213@csu.edu.cn;
   liuywxy@csu.edu.cn; 15526458167@163.com; 168111045@csu.edu.cn;
   767862086@qq.com; wang_zun@csu.edu.cn; wdznxy2016@csu.edu.cn;
   hominglee0309@163.com; qyx0110@csu.edu.cn; wangzx@csu.edu.cn;
   yiyiwang@csu.edu.cn; tengfeiw@csu.edu.cn; luo_yi@csu.edu.cn;
   1378368322@qq.com; chency19@csu.edu.cn; huixie@csu.edu.cn
RI Zhu, Hao/L 5114 2013; Wang, Zhenxing/GXM 9798 2022; Xie,
   Hui/AAF 8152 2020; wang, zun/ABE 8516 2021; He, Zehui/F 1876 2014; RAO,
   SHANSHAN/MVW 9829 2025; Chen, Chun Yuan/T 1367 2017
OI XIE, HUI/0000 0002 8526 2637; Chen, Chun Yuan/0000 0001 7808 533X
FU This work was supported by the Special Funding for the Construction of
   Innovative Provinces in Hunan (Grant Nos. 2019SK2301), the Science and
   Technology Innovation Program of Hunan Province (Grant Nos. 2022RC1211),
   the China National Postdoctoral Program f [2019SK2301]; Special Funding
   for the Construction of Innovative Provinces in Hunan [2022RC1211];
   Science and Technology Innovation Program of Hunan Province [BX2021383];
   China National Postdoctoral Program for Innovative Talents
   [2023CXQD001]; Central South University Innovation Driven Research
   Programme [2023JJ10094]; Hunan Province Natural Science Foundation of
   China [2021zzts0342, 2022ZZTS0239]; Hunan Provincial Innovation
   Foundation for Postgraduate
FX This work was supported by the Special Funding for the Construction of
   Innovative Provinces in Hunan (Grant Nos. 2019SK2301), the Science and
   Technology Innovation Program of Hunan Province (Grant Nos. 2022RC1211),
   the China National Postdoctoral Program for Innovative Talents (Grant
   Nos. BX2021383), the Central South University Innovation Driven Research
   Programme (Grant Nos. 2023CXQD001), the Hunan Province Natural Science
   Foundation of China (Grant No. 2023JJ10094), and the Hunan Provincial
   Innovation Foundation for Postgraduate (Grant Nos. 2021zzts0342,
   2022ZZTS0239). We especially thank Professor Fu Bin Li (Shanghai Jiao
   Tong University) for providing T cell receptor (TCR) transgenic KRN
   mice.
CR Auréal M, 2021, BIOMOLECULES, V11, DOI 10.3390/biom11010048
   Avalos A, 2014, J APPL TOXICOL, V34, P413, DOI 10.1002/jat.2957
   Brand DD, 2007, NAT PROTOC, V2, P1269, DOI 10.1038/nprot.2007.173
   Burrage PS, 2006, FRONT BIOSCI LANDMRK, V11, P529, DOI 10.2741/1817
   Chen CY, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aba0942
   Corrado A, 2021, ARTHRITIS RES THER, V23, DOI 10.1186/s13075 021 02562 3
   Deng YQ, 2022, J MATER CHEM B, V10, P5454, DOI 10.1039/d2tb00336h
   Fatima F, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171222
   Fukui S, 2022, ARTHRITIS RHEUMATOL, V74, P1139, DOI 10.1002/art.42093
   Guo XM, 2016, ACS APPL MATER INTER, V8, P3092, DOI 10.1021/acsami.5b10352
   Han Y, 2021, ARTHRITIS RES THER, V23, DOI 10.1186/s13075 021 02619 3
   Hu XL, 2020, BRAIN BEHAV IMMUN, V88, P507, DOI 10.1016/j.bbi.2020.04.030
   Hu XK, 2020, THERANOSTICS, V10, P7710, DOI 10.7150/thno.45858
   Jeong M, 2021, MOL PHARMACEUT, V18, P539, DOI 10.1021/acs.molpharmaceut.0c00295
   Jin YY, 2022, CELL DISCOV, V8, DOI 10.1038/s41421 022 00382 6
   Kalashnikova I, 2020, THERANOSTICS, V10, P11863, DOI 10.7150/thno.49069
   Kuang XW, 2022, J COLLOID INTERF SCI, V616, P189, DOI 10.1016/j.jcis.2022.02.050
   Lefèvre S, 2009, NAT MED, V15, P1414, DOI 10.1038/nm.2050
   Levescot A, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI141008
   Li CH, 2022, EXPERT OPIN DRUG DEL, V19, P883, DOI 10.1080/17425247.2022.2094364
   Li YF, 2022, ACTA BIOMATER, V152, P406, DOI 10.1016/j.actbio.2022.08.054
   Li YY, 2023, ADV THER GERMANY, V6, DOI 10.1002/adtp.202200100
   Liu RH, 2019, ANN RHEUM DIS, V78, P1524, DOI 10.1136/annrheumdis 2019 215543
   Liu YJ, 2017, ACS NANO, V11, P10539, DOI 10.1021/acsnano.7b05908
   Liu ZZ, 2021, AUTOPHAGY, V17, P2766, DOI 10.1080/15548627.2020.1839286
   Means N, 2022, MOL ASPECTS MED, V83, DOI 10.1016/j.mam.2021.100993
   Miethling Graff R, 2014, TOXICOL IN VITRO, V28, P1280, DOI 10.1016/j.tiv.2014.06.005
   Mohammadinejad R, 2019, AUTOPHAGY, V15, P4, DOI 10.1080/15548627.2018.1509171
   Monach Paul A, 2008, Curr Protoc Immunol, VChapter 15, DOI 10.1002/0471142735.im1522s81
   Müller Ladner U, 2005, NAT CLIN PRACT RHEUM, V1, P102, DOI 10.1038/ncprheum0047
   Park JS, 2022, ARTHRITIS RES THER, V24, DOI 10.1186/s13075 022 02941 4
   Park MVDZ, 2011, BIOMATERIALS, V32, P9810, DOI 10.1016/j.biomaterials.2011.08.085
   Smolen JS, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/nrdp.2018.1
   Smolen JS, 2016, LANCET, V388, P2023, DOI 10.1016/S0140 6736(16)30173 8
   Smolen JS, 2003, NAT REV DRUG DISCOV, V2, P473, DOI 10.1038/nrd1109
   Tsoi KM, 2016, NAT MATER, V15, P1212, DOI [10.1038/NMAT4718, 10.1038/nmat4718]
   Wang D, 2019, NAT REV RHEUMATOL, V15, P581, DOI 10.1038/s41584 019 0275 x
   Wang ZX, 2019, ADV FUNCT MATER, V29, DOI 10.1002/adfm.201808556
   Wei KV, 2020, NATURE, V582, P259, DOI 10.1038/s41586 020 2222 z
   Wu HH, 2020, THERANOSTICS, V10, P10092, DOI 10.7150/thno.44865
   Yin H, 2021, THERANOSTICS, V11, P8152, DOI 10.7150/thno.55334
   Zeng C, 2018, ENVIRON TOXICOL, V33, P1221, DOI 10.1002/tox.22628
   Zhai ZQ, 2022, ARTHRITIS RHEUMATOL, V74, P427, DOI 10.1002/art.41963
   Zhang M, 2022, MATER TODAY BIO, V14, DOI 10.1016/j.mtbio.2022.100223
   Zhang SC, 2018, COLLOID SURFACE B, V170, P224, DOI 10.1016/j.colsurfb.2018.06.016
NR 45
TC 2
Z9 2
U1 1
U2 11
PU SPRINGER BASEL AG
PI BASEL
PA PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND
SN 1023 3830
EI 1420 908X
J9 INFLAMM RES
JI Inflamm. Res.
PD NOV
PY 2023
VL 72
IS 10 11
BP 2053
EP 2072
DI 10.1007/s00011 023 01778 0
EA OCT 2023
PG 20
WC Cell Biology; Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Immunology
GA W5OH9
UT WOS:001081613400001
PM 37816881
DA 2025 08 17
ER

PT J
AU Hong, JM
   Shin, JK
   Kim, JY
   Jang, MJ
   Park, SK
   Lee, JH
   Choi, JH
   Lee, SM
AF Hong, Jeong Min
   Shin, Jun Kyu
   Kim, Jeom Yong
   Jang, Min Jung
   Park, Sun Kyu
   Lee, Jong Hoon
   Choi, Jung Hyo
   Lee, Sun Mee
TI BST106 Protects against Cartilage Damage by Inhibition of Apoptosis and
   Enhancement of Autophagy in Osteoarthritic Rats
SO BIOLOGICAL & PHARMACEUTICAL BULLETIN
LA English
DT Article
DE osteoarthritis; BST106; apoptosis; autophagy; matrix metalloproteinase
ID CHONDROCYTES IN VITRO; ARTICULAR CARTILAGE; MATRIX METALLOPROTEINASES;
   CHRYSANTHEMUM ZAWADSKII; OXIDATIVE STRESS; SUBCHONDRAL BONE; CELL DEATH;
   MODEL; DEGRADATION; DISEASE
AB Chrysanthemum zawadskii var. latilobum (CZ) has been used as a traditional medicine in Asian countries for the treatment of inflammatory diseases. Recently, CZ extract was shown to inhibit differentiation of osteoclasts and provide protection against rheumatoid arthritis. The aim of this study was to investigate the molecular mechanisms of BST106, the ethanol extract of CZ, for cartilage protection in monosodium iodoacetate (MIA) induced osteoarthritis (OA), particularly focusing on apoptosis and autophagy. BST106 (50, 100, and 200 mg/kg) was orally administered once daily to MIA induced OA rats. Swelling, limping, roentgenography, and histomorphological changes were assessed 28d after MIA injection. Biochemical parameters for matrix metalloproteinase (MMP), apoptosis, and autophagy were also assessed. BST106 ameliorated the severity of swelling and limping after MIA injection. Roentgenographic and histomorphological examinations revealed that BST106 reduced MIA induced cartilage damage. BST106 decreased MIA induced increases in MMP 2 and MMP 13 mRNA levels. Increased levels of serum cartilage oligomeric matrix protein and glycosaminoglycan release were attenuated by BST106. Furthermore, BST106 suppressed the protein expression of proapoptotic molecules and increased the protein expression of autophagosome  and autolysosome related molecules. These findings indicate that BST106 protects against OA induced cartilage damage by inhibition of the apoptotic pathway and restoration of impaired autophagic flux.
C1 [Hong, Jeong Min; Shin, Jun Kyu; Lee, Sun Mee] Sungkyunkwan Univ, Sch Pharm, 2066 Seobu Ro, Suwon 16419, Gyeonggi Do, South Korea.
   [Kim, Jeom Yong; Jang, Min Jung; Park, Sun Kyu; Lee, Jong Hoon; Choi, Jung Hyo] GREENCROSS WellBeing Corp, Res Inst, Seongnam 13595, South Korea.
C3 Sungkyunkwan University (SKKU)
RP Lee, SM (通讯作者)，Sungkyunkwan Univ, Sch Pharm, 2066 Seobu Ro, Suwon 16419, Gyeonggi Do, South Korea.
EM sunmee@skku.edu
RI Kim, Song Yi/JAC 5358 2023
FU National Research Foundation of Korea (NRF)   Ministry of Education,
   Science, and Technology in Korea (MEST) [2012R1A5A2A28671860]; NRF  
   MEST in Korea [NRF 2016H1A2A1909480]
FX This research was supported by the National Research Foundation of Korea
   (NRF) Grant funded by the Ministry of Education, Science, and Technology
   in Korea (MEST; 2012R1A5A2A28671860). Jeong Min Hong received 'Global
   Ph.D. Fellowship Program' support (NRF 2016H1A2A1909480) from NRF funded
   by the MEST in Korea.
CR Ansari MY, 2017, BIOMED PHARMACOTHER, V96, P198, DOI 10.1016/j.biopha.2017.09.140
   Brizuela Nilda Y, 2007, Rev Fac Cien Med Univ Nac Cordoba, V64, P9
   Caramés B, 2015, ARTHRITIS RHEUMATOL, V67, P1568, DOI 10.1002/art.39073
   Caramés B, 2012, ANN RHEUM DIS, V71, P575, DOI 10.1136/annrheumdis 2011 200557
   Caramés B, 2010, ARTHRITIS RHEUM US, V62, P791, DOI 10.1002/art.27305
   Cetrullo S, 2016, BBA GEN SUBJECTS, V1860, P1181, DOI 10.1016/j.bbagen.2016.03.002
   Chaitanya GV, 2010, CELL COMMUN SIGNAL, V8, DOI 10.1186/1478 811X 8 31
   Charlier E, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17122146
   Dai T, 2017, INFLAMM RES, V66, P1075, DOI 10.1007/s00011 017 1087 6
   Eskelinen EL, 2009, BBA MOL CELL RES, V1793, P664, DOI 10.1016/j.bbamcr.2008.07.014
   Gu DR, 2013, EVID BASED COMPL ALT, V2013, DOI 10.1155/2013/509482
   Guzman RE, 2003, TOXICOL PATHOL, V31, P619, DOI 10.1080/01926230390241800
   Han S, 2002, ARCH PHARM RES, V25, P170, DOI 10.1007/BF02976559
   Huang WZ, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/6341919
   Hwang HS, 2015, INT J MOL SCI, V16, P26035, DOI 10.3390/ijms161125943
   Hyttinen JMT, 2013, BBA MOL CELL RES, V1833, P503, DOI 10.1016/j.bbamcr.2012.11.018
   Ishiguro Naoki, 2002, Nagoya J Med Sci, V65, P73
   Jackson MT, 2014, ARTHRITIS RHEUMATOL, V66, P1525, DOI 10.1002/art.38401
   Jain A, 2010, J BIOL CHEM, V285, P22576, DOI 10.1074/jbc.M110.118976
   Jiang LP, 2013, J ORTHOP RES, V31, P364, DOI 10.1002/jor.22250
   KATO T, 1987, ARCH INT PHARMACOD T, V285, P288
   Kelly S, 2013, OSTEOARTHR CARTILAGE, V21, P1327, DOI 10.1016/j.joca.2013.07.002
   Kim AR, 2016, EVID BASED COMPL ALT, V2016
   Kim HA, 2000, J RHEUMATOL, V27, P455
   Kim JK, 2012, EVID BASED COMPL ALT, V2012, DOI 10.1155/2012/730907
   Kim Y, 2012, J FUNCT FOODS, V4, P474, DOI 10.1016/j.jff.2012.02.007
   Kirkegaard K, 2004, NAT REV MICROBIOL, V2, P301, DOI 10.1038/nrmicro865
   Lee HS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036221
   Lee JH, 2004, J ETHNOPHARMACOL, V95, P425, DOI 10.1016/j.jep.2004.08.023
   Lee SW, 2008, ARTHRITIS RHEUM US, V58, P790, DOI 10.1002/art.23220
   Lee SW, 2004, ARTHRITIS RHEUM US, V50, P534, DOI 10.1002/art.20052
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Link TM, 2003, RADIOLOGY, V226, P373, DOI 10.1148/radiol.2262012190
   Murphy G, 2002, ARTHRITIS RES THER, V4, DOI 10.1186/ar572
   Na JY, 2012, J GINSENG RES, V36, P242, DOI 10.5142/jgr.2012.36.3.242
   Nuttall ME, 2000, J ORTHOPAED RES, V18, P356, DOI 10.1002/jor.1100180306
   Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200
   Poole AR, 2001, CLIN ORTHOP RELAT R, pS26, DOI 10.1097/00003086 200110001 00004
   Rannou F, 2016, SEMIN ARTHRITIS RHEU, V45, pS18, DOI 10.1016/j.semarthrit.2015.11.007
   SANDY JD, 1978, BIOCHIM BIOPHYS ACTA, V543, P536, DOI 10.1016/0304 4165(78)90308 2
   Sasaki H, 2012, ARTHRITIS RHEUM US, V64, P1920, DOI 10.1002/art.34323
   Settle S, 2010, ARTHRITIS RHEUM US, V62, P3006, DOI 10.1002/art.27596
   Shlopov BV, 1997, ARTHRITIS RHEUM US, V40, P2065, DOI 10.1002/art.1780401120
   Singh RP, 2005, CARCINOGENESIS, V26, P845, DOI 10.1093/carcin/bgi014
   Song B, 2017, MOL MED REP, V16, P3958, DOI 10.3892/mmr.2017.7064
   Takayama K, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/s13075 014 0482 4
   Tang Q, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.453
   VANDERSLUIJS JA, 1992, J ORTHOPAED RES, V10, P58, DOI 10.1002/jor.1100100107
   Vilím V, 2002, OSTEOARTHR CARTILAGE, V10, P707, DOI 10.1053/joca.2002.0819
   Vuppalapati KK, 2015, J BONE MINER RES, V30, P2249, DOI 10.1002/jbmr.2575
   Wang ZM, 2016, BIOMED PHARMACOTHER, V83, P763, DOI 10.1016/j.biopha.2016.06.050
   Webb GR, 1997, OSTEOARTHR CARTILAGE, V5, P427, DOI 10.1016/S1063 4584(97)80047 7
   Wei YL, 2017, CELL PHYSIOL BIOCHEM, V42, P319, DOI 10.1159/000477387
   Wu TY, 2011, AAPS J, V13, P1, DOI 10.1208/s12248 010 9239 4
   Xie XW, 2017, CHEMMEDCHEM, V12, P1157, DOI 10.1002/cmdc.201700349
   Yeom MJ, 2003, BIOL PHARM BULL, V26, P1472, DOI 10.1248/bpb.26.1472
   Yu L, 2010, NATURE, V465, P942, DOI 10.1038/nature09076
NR 57
TC 7
Z9 9
U1 2
U2 6
PU PHARMACEUTICAL SOC JAPAN
PI TOKYO
PA 2 12 15 SHIBUYA, SHIBUYA KU, TOKYO, 150 0002, JAPAN
SN 0918 6158
J9 BIOL PHARM BULL
JI Biol. Pharm. Bull.
PD AUG
PY 2018
VL 41
IS 8
BP 1257
EP 1268
DI 10.1248/bpb.b18 00207
PG 12
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA GP4YP
UT WOS:000440878600020
PM 29794403
OA gold
DA 2025 08 17
ER

PT J
AU Kim, YG
   Sohn, DH
   Zhao, XY
   Sokolove, J
   Lindstrom, TM
   Yoo, B
   Lee, CK
   Reveille, JD
   Taurog, JD
   Robinson, WH
AF Kim, Yong Gil
   Sohn, Dong Hyun
   Zhao, Xiaoyan
   Sokolove, Jeremy
   Lindstrom, Tamsin M.
   Yoo, Bin
   Lee, Chang Keun
   Reveille, John D.
   Taurog, Joel D.
   Robinson, William H.
TI Role of Protein Phosphatase Magnesium Dependent 1A and Anti Protein
   Phosphatase Magnesium Dependent 1A Autoantibodies in Ankylosing
   Spondylitis
SO ARTHRITIS & RHEUMATOLOGY
LA English
DT Article
ID BONE MORPHOGENETIC PROTEINS; DISEASE ACTIVITY; AUTOIMMUNE;
   DIFFERENTIATION; PROGRESSION; CRITERIA; HLA B27; CLASSIFICATION;
   PATHOGENESIS; ASSOCIATION
AB ObjectiveAlthough ankylosing spondylitis (AS) is driven by immune mediated processes, little is known about the presence and role of autoantibodies in this disease. This study was undertaken to investigate whether autoantibodies occur in and are involved in AS.
   MethodsWe performed human protein microarray analysis of sera derived from patients with AS or other autoimmune disorders to identify autoantibodies associated specifically with AS, and identified autoantibody targeting of protein phosphatase magnesium dependent 1A (PPM1A) in AS. We performed enzyme linked immunosorbent assay (ELISA) analysis of sera from 2 independent AS cohorts to confirm autoantibody targeting of PPM1A, and to assess associations between levels of anti PPM1A antibodies and AS disease severity or response to anti tumor necrosis factor (anti TNF) therapy (as measured by Bath AS Disease Activity Index [BASDAI] score). Levels of anti PPM1A antibodies were also evaluated in sera from rats transgenic for HLA B27 and human (2) microglobulin. The expression of PPM1A was assessed by immunohistochemistry in synovial tissue samples from patients with AS, rheumatoid arthritis, or osteoarthritis. The role of PPM1A in osteoblast differentiation was investigated by gene knockdown and overexpression.
   ResultsAS was associated with autoantibody targeting of PPM1A, and levels of anti PPM1A autoantibodies were significantly higher in patients with more advanced sacroiliitis and correlated positively with BASDAI score after treatment with anti TNF agents. The levels of anti PPM1A autoantibodies were also higher in the sera of transgenic rats that are prone to develop spondyloarthritis than in those that are not. PPM1A was expressed in AS synovial tissue, and PPM1A overexpression promoted osteoblast differentiation, whereas PPM1A knockdown suppressed it.
   ConclusionAnti PPM1A autoantibodies are present in AS, and our findings suggest that PPM1A may contribute to the pathogenic bone ankylosis characteristic of AS.
C1 [Kim, Yong Gil; Sohn, Dong Hyun; Zhao, Xiaoyan; Sokolove, Jeremy; Lindstrom, Tamsin M.; Robinson, William H.] Stanford Univ, Stanford, CA 94305 USA.
   [Kim, Yong Gil; Sohn, Dong Hyun; Zhao, Xiaoyan; Sokolove, Jeremy; Robinson, William H.] VA Palo Alto Hlth Care Syst, Palo Alto, CA USA.
   [Kim, Yong Gil] Univ Ulsan Coll, Seoul, South Korea.
   [Kim, Yong Gil; Yoo, Bin; Lee, Chang Keun] Asan Med Ctr, Seoul, South Korea.
   [Yoo, Bin; Lee, Chang Keun] Univ Ulsan, Seoul, South Korea.
   [Reveille, John D.] Univ Texas Hlth Sci Ctr Houston, Houston, TX 77030 USA.
   [Taurog, Joel D.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA.
C3 Stanford University; US Department of Veterans Affairs; Veterans Health
   Administration (VHA); VA Palo Alto Health Care System; University of
   Ulsan; University of Ulsan; Asan Medical Center; University of Ulsan;
   University of Texas System; University of Texas Health Science Center
   Houston; University of Texas System; University of Texas Southwestern
   Medical Center
RP Kim, YG (通讯作者)，Univ Ulsan, Coll Med, Div Rheumatol, 388 1 Pungnap Dong, Seoul 138736, South Korea.
EM bestmd2000@amc.seoul.kr; wrobins@stanford.edu
RI ; Kim, TaeHeon/KIC 2380 2024
OI Robinson, William/0000 0003 4385 704X; KIM,
   YONG GIL/0000 0002 8029 7355; 
FU NIH (National Heart, Lung, and Blood Institute Proteomics Center)
   [N01 HV 00242]; NIH (National Institute of Arthritis and Musculoskeletal
   and Skin Diseases) [R01 AR 063676]; Department of Veterans Affairs;
   National Research Foundation of Korea [NRF 2013R1A1A1009271]; Arthritis
   Foundation [5119]
FX Supported by the NIH (National Heart, Lung, and Blood Institute
   Proteomics Center grant N01 HV 00242 and National Institute of Arthritis
   and Musculoskeletal and Skin Diseases grant R01 AR 063676 to Dr.
   Robinson) and by the Department of Veterans Affairs (funding to Dr.
   Robinson). Dr. Kim's work was supported by the National Research
   Foundation of Korea (NRF 2013R1A1A1009271). Dr. Sohn is recipient of an
   Arthritis Foundation Postdoctoral Fellowship (award 5119).
CR ALTMAN R, 1986, ARTHRITIS RHEUM US, V29, P1039, DOI 10.1002/art.1780290816
   Ambarus C, 2012, CURR OPIN RHEUMATOL, V24, P351, DOI 10.1097/BOR.0b013e3283534df4
   Appel H, 2009, ARTHRITIS RHEUM US, V60, P3257, DOI 10.1002/art.24888
   ARNETT FC, 1988, ARTHRITIS RHEUM US, V31, P315, DOI 10.1002/art.1780310302
   Bodnár N, 2012, JOINT BONE SPINE, V79, P63, DOI 10.1016/j.jbspin.2011.03.010
   Braun J, 2011, ANN RHEUM DIS, V70, pI97, DOI 10.1136/ard.2010.140541
   Braun J, 2008, ARTHRIT RHEUM ARTHR, V59, P1270, DOI 10.1002/art.24001
   Chen HA, 2010, J RHEUMATOL, V37, P2126, DOI 10.3899/jrheum.100200
   Colbert RA, 2004, CURR MOL MED, V4, P21, DOI 10.2174/1566524043479293
   Criswell LA, 2005, AM J HUM GENET, V76, P561, DOI 10.1086/429096
   Duan XY, 2006, J BIOL CHEM, V281, P36526, DOI 10.1074/jbc.M605169200
   EGHTEDARI AA, 1976, ANN RHEUM DIS, V35, P155, DOI 10.1136/ard.35.2.155
   Francois RJ, 2006, ANN RHEUM DIS, V65, P713, DOI 10.1136/ard.2005.037465
   GARRETT S, 1994, J RHEUMATOL, V21, P2286
   HAMMER RE, 1990, CELL, V63, P1099, DOI 10.1016/0092 8674(90)90512 D
   Heiland GR, 2012, ANN RHEUM DIS, V71, P572, DOI 10.1136/annrheumdis 2011 200216
   Kokabu S, 2010, J BONE MINER RES, V25, P653, DOI 10.1359/jbmr.090736
   Lin X, 2006, CELL, V125, P915, DOI 10.1016/j.cell.2006.03.044
   Liu X, 2009, J RHEUMATOL, V36, P1136, DOI 10.3899/jrheum.080796
   Lories R, 2011, NAT REV RHEUMATOL, V7, P700, DOI 10.1038/nrrheum.2011.156
   Lories RJU, 2005, J CLIN INVEST, V115, P1571, DOI 10.1172/JCI23738
   Maksymowych WR, 2009, CURR OPIN RHEUMATOL, V21, P313, DOI 10.1097/BOR.0b013e32832af481
   Maurer K, 1979, Vital Health Stat 11, P1
   Paniagua RT, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar2940
   Park MC, 2008, SCAND J RHEUMATOL, V37, P200, DOI 10.1080/03009740701774941
   Reuter S, 2009, ANN NY ACAD SCI, V1171, P436, DOI 10.1111/j.1749 6632.2009.04731.x
   Robinson WH, 2013, NAT REV RHEUMATOL, V9, P267, DOI 10.1038/nrrheum.2013.14
   Schett G, 2010, BEST PRACT RES CL RH, V24, P363, DOI 10.1016/j.berh.2010.01.005
   Schett G, 2009, ADV EXP MED BIOL, V649, P114
   Sieper J, 2002, ANN RHEUM DIS, V61, P8
   Strovel ET, 2000, J BIOL CHEM, V275, P2399, DOI 10.1074/jbc.275.4.2399
   Tani Y, 1997, CLIN EXP RHEUMATOL, V15, P295
   Taurog JD, 2012, ARTHRITIS RHEUM US, V64, P2518, DOI 10.1002/art.34480
   Tran TM, 2006, ARTHRITIS RHEUM US, V54, P1317, DOI 10.1002/art.21740
   van der Heijde D, 2006, ARTHRITIS RHEUM US, V54, P2136, DOI 10.1002/art.21913
   van Duivenvoorde LM, 2012, ARTHRITIS RHEUM US, V64, P3210, DOI 10.1002/art.34600
   van Tubergen A, 2003, ANN RHEUM DIS, V62, P215, DOI 10.1136/ard.62.3.215
   VANDERLINDEN S, 1984, ARTHRITIS RHEUM, V27, P361
   VEYS EM, 1973, ANN RHEUM DIS, V32, P493, DOI 10.1136/ard.32.6.493
   Wang D, 1999, J BONE MINER RES, V14, P893, DOI 10.1359/jbmr.1999.14.6.893
   Wright C, 2012, MOL CELL PROTEOMICS, V11, DOI 10.1074/mcp.M9.00384
   Yamaguchi A, 2000, ENDOCR REV, V21, P393, DOI 10.1210/er.21.4.393
   Zolnierowicz S, 2000, BIOCHEM PHARMACOL, V60, P1225, DOI 10.1016/S0006 2952(00)00424 X
NR 43
TC 30
Z9 34
U1 0
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 2326 5191
EI 2326 5205
J9 ARTHRITIS RHEUMATOL
JI Arthritis Rheumatol.
PD OCT
PY 2014
VL 66
IS 10
BP 2793
EP 2803
DI 10.1002/art.38763
PG 11
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA AQ4DZ
UT WOS:000342744300016
PM 24980965
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Ji, LM
   Gao, J
   Kong, RN
   Gao, Y
   Ji, XF
   Zhao, DB
AF Ji, Lianmei
   Gao, Jie
   Kong, Ruina
   Gao, Ying
   Ji, Xiaofan
   Zhao, Dongbao
TI Autophagy exerts pivotal roles in regulatory effects of
   1α,25 (OH)2D3 on the osteoclastogenesis
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE 1 alpha,25 (OH)(2)D 3; Osteoporosis; Osteoclast; Autophagy; RANKL
AB As an active form of vitamin D 3, 1 alpha,25 (OH)(2)D 3 has a positive therapeutical effect on osteoporosis. However, 1 alpha,25 (OH)(2)D 3 can not only promote the osteoclastogenesis, but also inhibit the proliferation of osteoclast precursors (OCPs). Autophagy is regulated by 1 alpha,25 (OH)(2)D 3 and is considered to promote the osteoclastogenesis. Nevertheless, the role of 1 alpha,25 (OH)(2)D 3 in OCPs' autophagy remains unknown. Our study aims to explore whether the effect of 1 alpha,25 (OH)(2)D 3 on osteoclastogenesis is related to its regulation in autophagy. The results showed that 1 alpha,25 (OH)(2)D 3 exhibited a direct inhibitory effect on the autophagy activity and the proliferation of OCPs derived from bone marrow derived macrophages (BMMs), which was reversed by the overexpression of autophagy related gene. In presence of RANKL, the autophagy capacity of OCPs and the differentiation from OCPs into mature osteoclasts were significantly enhanced by 1 alpha,25 (OH)(2)D 3, while the suppression of autophagy with spautin 1 or 3 MA downregulated the osteoclastogenesis capacity. In summary, 1 alpha,25 (OH)(2)D 3 can directly suppress OCPs autophagy, which negatively regulates the proliferation of OCPs without RANKL. 1 alpha,25 (OH)(2)D 3 can indirectly upregulate the autophagy response of OCPs, thereby enhancing the osteoclasts formation in presence of RANKL. Therefore, our study found that 1 alpha,25 (OH)(2)D 3 had a dual effect on osteoclastogenesis by regulating autophagy, suggesting that some drugs targeting autophagy may act as an effective supplement of 1 alpha,25 (OH)(2)D 3 in treating osteoporosis. (C) 2019 Elsevier Inc. All rights reserved.
C1 [Ji, Lianmei; Gao, Jie; Kong, Ruina; Gao, Ying; Ji, Xiaofan; Zhao, Dongbao] Second Mil Med Univ, Shanghai Changhai Hosp, Dept Rheumatol & Immunol, 168 Changhai Rd, Shanghai 200433, Peoples R China.
C3 Naval Medical University
RP Zhao, DB (通讯作者)，Second Mil Med Univ, Shanghai Changhai Hosp, Dept Rheumatol & Immunol, 168 Changhai Rd, Shanghai 200433, Peoples R China.
EM DBgzss02@yeah.net
FU National Natural Science Foundation of China [81471607]
FX We thank Dr. Wang Zheng (Children's National Medical Centre; Washington
   DC, USA) for reviewing the article. This work was supported by The
   National Natural Science Foundation of China (81471607).
CR Chung YH, 2014, J CELL PHYSIOL, V229, P1963, DOI 10.1002/jcp.24646
   Datta HK, 2008, J CLIN PATHOL, V61, P577, DOI 10.1136/jcp.2007.048868
   DeSelm CJ, 2011, DEV CELL, V21, P966, DOI 10.1016/j.devcel.2011.08.016
   Gu JH, 2015, J STEROID BIOCHEM, V152, P25, DOI 10.1016/j.jsbmb.2015.04.003
   Hu F, 2016, CELL PHYSIOL BIOCHEM, V38, P2219, DOI 10.1159/000445577
   Ke DS, 2018, BIOCHEM BIOPH RES CO, V497, P890, DOI 10.1016/j.bbrc.2018.02.164
   Kim JH, 2014, J CELL BIOL, V204, P1063, DOI 10.1083/jcb.201308102
   Li RL, 2017, OBESITY, V25, P561, DOI 10.1002/oby.21757
   Li RF, 2014, J HISTOCHEM CYTOCHEM, V62, P879, DOI 10.1369/0022155414551367
   Lin NY, 2016, ANN RHEUM DIS, V75, P1203, DOI 10.1136/annrheumdis 2015 207240
   Lin NY, 2013, ANN RHEUM DIS, V72, P761, DOI 10.1136/annrheumdis 2012 201671
   Lu XM, 2009, BIOCHEM BIOPH RES CO, V390, P494, DOI 10.1016/j.bbrc.2009.09.123
   RAISZ LG, 1972, SCIENCE, V175, P768, DOI 10.1126/science.175.4023.768
   Saiki S, 2011, AUTOPHAGY, V7, P176, DOI 10.4161/auto.7.2.14074
   Sato M, 2007, BONE, V40, P293, DOI 10.1016/j.bone.2006.09.007
   Schwartz Z, 2001, BIOMATERIALS, V22, P731, DOI 10.1016/S0142 9612(00)00241 6
   Shen QQ, 2018, CELL PHYSIOL BIOCHEM, V51, P1751, DOI 10.1159/000495678
   Tavera Mendoza LE, 2017, P NATL ACAD SCI USA, V114, pE2186, DOI 10.1073/pnas.1615015114
   Wang LP, 2006, BIOMATERIALS, V27, P3716, DOI 10.1016/j.biomaterials.2006.02.022
   Wang XZ, 2016, SCI REP UK, V6, DOI 10.1038/srep24225
   Wang XF, 2015, AUTOPHAGY, V11, P1998, DOI 10.1080/15548627.2015.1091551
   Wei HL, 2017, J STEROID BIOCHEM, V168, P71, DOI 10.1016/j.jsbmb.2017.02.007
   Xiu Y, 2014, J CLIN INVEST, V124, P297, DOI 10.1172/JCI66947
   Yang LN, 2017, MOL MED REP, V16, P7080, DOI 10.3892/mmr.2017.7408
NR 24
TC 25
Z9 29
U1 0
U2 12
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0006 291X
EI 1090 2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD APR 16
PY 2019
VL 511
IS 4
BP 869
EP 874
DI 10.1016/j.bbrc.2019.02.114
PG 6
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA HT5TK
UT WOS:000464626000023
PM 30850163
DA 2025 08 17
ER

PT J
AU Dideriksen, K
   Boesen, AP
   Reitelseder, S
   Couppé, C
   Svensson, R
   Schjerling, P
   Magnusson, SP
   Holm, L
   Kjaer, M
AF Dideriksen, Kasper
   Boesen, Anders P.
   Reitelseder, Soren
   Couppe, Christian
   Svensson, Rene
   Schjerling, Peter
   Magnusson, S. Peter
   Holm, Lars
   Kjaer, Michael
TI Tendon collagen synthesis declines with immobilization in elderly
   humans: no effect of anti inflammatory medication
SO JOURNAL OF APPLIED PHYSIOLOGY
LA English
DT Article
DE tendon unloading; tendon reloading; tendon mechanical properties;
   ibuprofen; scleraxis
ID HUMAN PATELLAR TENDON; SKELETAL MUSCLE; MECHANICAL PROPERTIES;
   PROTEIN SYNTHESIS; ACHILLES TENDON; GENE EXPRESSION; GROWTH HORMONE;
   IN VIVO; TERM IMMOBILIZATION; CONNECTIVE TISSUE
AB Nonsteroidal anti inflammatory drugs (NSAIDs) are used as pain killers during periods of unloading caused by traumatic occurrences or diseases. However, it is unknown how tendon protein turnover and mechanical properties respond to unloading and subsequent reloading in elderly humans, and whether NSAID treatment would affect the tendon adaptations during such periods. Thus we studied human patellar tendon protein synthesis and mechanical properties during immobilization and subsequent rehabilitating resistance training and the influence of NSAIDs upon these parameters. Nineteen men (range 60 80 yr) were randomly assigned to NSAIDs (ibuprofen 1,200 mg/day; Ibu) or placebo (Plc). One lower limb was immobilized in a cast for 2 wk and retrained for 6 wk. Tendon collagen protein synthesis, mechanical properties, size, expression of genes related to collagen turnover and remodeling, and signal intensity (from magnetic resonance imaging) were investigated. Tendon collagen synthesis decreased (P < 0.001), whereas tendon mechanical properties and size were generally unchanged with immobilization, and NSAIDs did not influence this. Matrix metalloproteinase 2 mRNA tended to increase (P < 0.1) after immobilization in both groups, whereas scleraxis mRNA decreased with inactivity in the Plc group only (P < 0.05). In elderly human tendons, collagen protein synthesis decreased after 2 wk of immobilization, whereas tendon stiffness and modulus were only marginally reduced, and NSAIDs had no influence upon this. This indicates an importance of mechanical loading for maintenance of tendon collagen turnover. However, reduced collagen production induced by short term unloading may only marginally affect tendon mechanical properties in elderly individuals.
   NEW & NOTEWORTHY In elderly humans, 2 wk of inactivity reduces tendon collagen protein synthesis, while tendon stiffness and modulus are only marginally reduced, and NSAID treatment does not affect this. This indicates that mechanical loading is important for maintenance of tendon collagen turnover and that changes in collagen turnover induced by short term immobilization may only have minor impact on the internal structures that are essential for mechanical properties in elderly tendons.
C1 [Dideriksen, Kasper; Boesen, Anders P.; Reitelseder, Soren; Couppe, Christian; Svensson, Rene; Schjerling, Peter; Magnusson, S. Peter; Holm, Lars; Kjaer, Michael] Univ Copenhagen, Inst Sports Med Copenhagen, Dept Orthoped Surg M, Bispebjerg Hosp,Fac Hlth & Med Sci, DK 1168 Copenhagen, Denmark.
   [Dideriksen, Kasper; Boesen, Anders P.; Reitelseder, Soren; Couppe, Christian; Svensson, Rene; Schjerling, Peter; Magnusson, S. Peter; Holm, Lars; Kjaer, Michael] Univ Copenhagen, Ctr Hlth Aging, Fac Hlth & Med Sci, DK 1168 Copenhagen, Denmark.
   [Reitelseder, Soren; Holm, Lars] Univ Copenhagen, Inst Biomed Sci, Fac Hlth & Med Sci, DK 1168 Copenhagen, Denmark.
   [Couppe, Christian; Magnusson, S. Peter] Bispebjerg Hosp, Dept Phys Therapy, Musculoskeletal Rehabil Res Unit, Copenhagen, Denmark.
C3 University of Copenhagen; Copenhagen University Hospital; Bispebjerg
   Hospital; University of Copenhagen; University of Copenhagen; University
   of Copenhagen; Copenhagen University Hospital; Bispebjerg Hospital
RP Dideriksen, K (通讯作者)，Bispebjerg Hosp, Inst Sports Med Copenhagen, Bldg 8,1st Floor,Bispebjerg Bakke 23, DK 2400 Copenhagen NV, Denmark.
EM kasperjuel@hotmail.com
RI Holm, Lars/G 8181 2017; Svensson, Rene B./AGZ 3181 2022; Magnusson,
   Stig/AAN 1631 2020; Schjerling, Peter/F 6194 2011; Holm,
   Lars/AAI 1320 2020; Magnusson, Stig Peter/AAN 1631 2020; Kjaer,
   Michael/W 6842 2019
OI Holm, Lars/0000 0002 4392 9616; Svensson, Rene B/0000 0002 1607 5379;
   Kjaer, Michael/0000 0002 4582 8755; Magnusson, Stig
   Peter/0000 0002 4308 5484; Schjerling, Peter/0000 0001 7138 3211
FU Danish Dairy Research Foundation; Danish Council for Independent
   Research [09 073587]; Center for Healthy Aging (The Nordea Foundation);
   Lundbeck Foundation [R198 2015 207] Funding Source: researchfish; Novo
   Nordisk Fonden [NNF16OC0022846, NNF14OC0012491] Funding Source:
   researchfish
FX Funding is gratefully acknowledged from the Danish Dairy Research
   Foundation, the Danish Council for Independent Research (09 073587), and
   the Center for Healthy Aging (The Nordea Foundation). Arla Foods
   Ingredients P/S provided the Lacprodan whey protein.
CR Almeida Silveira MI, 2000, EUR J APPL PHYSIOL, V81, P252
   Andersen MB, 2011, J APPL PHYSIOL, V110, P1549, DOI 10.1152/japplphysiol.00037.2010
   Arruda EM, 2007, AM J PHYSIOL REG I, V292, pR983, DOI 10.1152/ajpregu.00483.2006
   Aspenberg P., 1985, J APPL PHYSL 1985, V107, P399, DOI DOI 10.1152/JAPPLPHYSI0L.91563.2008
   Boesen AP, 2014, J APPL PHYSIOL, V116, P192, DOI 10.1152/japplphysiol.01077.2013
   Boesen AP, 2013, J PHYSIOL LONDON, V591, P6039, DOI 10.1113/jphysiol.2013.261263
   Carroll CC, 2011, J APPL PHYSIOL, V111, P508, DOI 10.1152/japplphysiol.01348.2010
   Carroll CC, 2008, J APPL PHYSIOL, V105, P1907, DOI 10.1152/japplphysiol.00059.2008
   Carroll CC, 2012, AM J PHYSIOL REG I, V302, pR990, DOI 10.1152/ajpregu.00659.2011
   Christensen B, 2008, J APPL PHYSIOL, V105, P420, DOI 10.1152/japplphysiol.00201.2008
   Christensen B, 2011, J APPL PHYSIOL, V110, P137, DOI 10.1152/japplphysiol.00942.2010
   Christensen B, 2008, J APPL PHYSIOL, V105, P1845, DOI 10.1152/japplphysiol.90445.2008
   Couppe C, 2008, J APPL PHYSIOL, V105, P805, DOI 10.1152/japplphysiol.90361.2008
   Couppé C, 2012, CLIN BIOMECH, V27, P949, DOI 10.1016/j.clinbiomech.2012.06.003
   Couppé C, 2009, J APPL PHYSIOL, V107, P880, DOI 10.1152/japplphysiol.00291.2009
   de Boer MD, 2007, J PHYSIOL LONDON, V585, P241, DOI 10.1113/jphysiol.2007.142828
   de Boer MD, 2007, J PHYSIOL LONDON, V583, P1079, DOI 10.1113/jphysiol.2007.135392
   Dideriksen K, 2016, EXP GERONTOL, V82, P8, DOI 10.1016/j.exger.2016.05.009
   Doessing S, 2010, J PHYSIOL LONDON, V588, P341, DOI 10.1113/jphysiol.2009.179325
   Farup J, 2014, SCAND J MED SCI SPOR, V24, P788, DOI 10.1111/sms.12083
   Hansen M, 2009, J APPL PHYSIOL, V106, P1385, DOI 10.1152/japplphysiol.90935.2008
   Heinemeier KM, 2009, J APPL PHYSIOL, V106, P178, DOI 10.1152/japplphysiol.91092.2008
   Hirose T, 2008, J APPL PHYSIOL, V104, P170, DOI 10.1152/japplphysiol.00463.2006
   Holm L, 2014, AM J PHYSIOL ENDOC M, V306, pE1330, DOI 10.1152/ajpendo.00084.2014
   Kinugasa R, 2010, J APPL PHYSIOL, V109, P870, DOI 10.1152/japplphysiol.00384.2010
   Kjaer M, 2013, J APPL PHYSIOL, V115, P879, DOI 10.1152/japplphysiol.00120.2013
   Kongsgaard M, 2007, ACTA PHYSIOL, V191, P111, DOI 10.1111/j.1748 1716.2007.01714.x
   Kubo K, 2004, BRIT J SPORT MED, V38, P324, DOI 10.1136/bjsm.2003.005595
   Langberg H, 2002, J PHYSIOL LONDON, V542, P985, DOI 10.1113/jphysiol.2002.019141
   Langberg H, 2003, J PHYSIOL LONDON, V551, P683, DOI 10.1113/jphysiol.2003.046094
   Magnusson SP, 2003, ACTA PHYSIOL SCAND, V177, P185, DOI 10.1046/j.1365 201X.2003.01048.x
   Majima T, 1996, J ORTHOP RES, V14, P377, DOI 10.1002/jor.1100140306
   Matsumoto F, 2003, ARCH PHYS MED REHAB, V84, P662, DOI 10.1016/S0003 9993(03)04834 7
   Miller BF, 2005, J PHYSIOL LONDON, V567, P1021, DOI 10.1113/jphysiol.2005.093690
   Nielsen RH, 2014, J APPL PHYSIOL, V116, P42, DOI 10.1152/japplphysiol.01084.2013
   Petersen SG, 2011, MED SCI SPORT EXER, V43, P425, DOI 10.1249/MSS.0b013e3181f27375
   Reeves ND, 2005, J APPL PHYSIOL, V98, P2278, DOI 10.1152/japplphysiol.01266.2004
   Reeves ND, 2003, J PHYSIOL LONDON, V548, P971, DOI 10.1113/jphysiol.2002.035576
   SAVOLAINEN J, 1988, AM J PHYSIOL, V254, pR897, DOI 10.1152/ajpregu.1988.254.6.R897
   Seynnes OR, 2009, J APPL PHYSIOL, V107, P523, DOI 10.1152/japplphysiol.00213.2009
   Suetta C, 2009, J APPL PHYSIOL, V107, P1172, DOI 10.1152/japplphysiol.00290.2009
   Trappe TA, 2013, J APPL PHYSIOL, V115, P909, DOI 10.1152/japplphysiol.00061.2013
   Tsai WC, 2010, J ORTHOP RES, V28, P487, DOI 10.1002/jor.21009
   Uchida H, 2005, J BIOMECH, V38, P791, DOI 10.1016/j.jbiomech.2004.05.009
   VISSER JJ, 1990, EUR J APPL PHYSIOL O, V61, P453, DOI 10.1007/BF00236067
NR 45
TC 27
Z9 32
U1 0
U2 3
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 8750 7587
EI 1522 1601
J9 J APPL PHYSIOL
JI J. Appl. Physiol.
PD FEB
PY 2017
VL 122
IS 2
BP 273
EP 282
DI 10.1152/japplphysiol.00809.2015
PG 10
WC Physiology; Sport Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Physiology; Sport Sciences
GA EN2GY
UT WOS:000395829200006
PM 27932679
OA Green Published
DA 2025 08 17
ER

PT J
AU Seki, I
   Takai Imamura, M
   Kohara Tanaka, T
   Shirae, S
   Sasano, M
   Matsuno, H
   Aono, H
AF Seki, Iwao
   Takai Imamura, Miwa
   Kohara Tanaka, Tomomi
   Shirae, Satoshi
   Sasano, Minoru
   Matsuno, Hiroaki
   Aono, Hiroyuki
TI Concomitant Treatment with Etanercept and Tacrolimus Synergistically
   Attenuates Arthritis Progression via Inhibition of Matrix
   Metalloproteinase 3 Production and Osteoclastogenesis in Human TNF α
   Transgenic Mice
SO MEDIATORS OF INFLAMMATION
LA English
DT Article
ID TUMOR NECROSIS FACTOR; ANTIGEN INDUCED ARTHRITIS; KAPPA B ACTIVITY;
   RHEUMATOID ARTHRITIS; T CELLS; IMMUNOGENICITY; SAFETY; DAMAGE;
   ACTIVATION; EFFICACY
AB In the present study, we investigated the effects and mechanisms of action of a combined treatment with etanercept, a soluble tumor necrosis factor receptor (p75) Fc fusion protein, and tacrolimus, a calcineurin inhibitor on the progression of arthritis in human tumor necrosis factor alpha (TNF alpha) transgenic (hTNF Tg) mice. Single drug treatments with etanercept and tacrolimus attenuated the clinical signs but not the radiographic changes associated with the development of arthritis in mice. On the contrary, combined treatment significantly suppressed the radiographic progression and also improved the clinical signs. The combined treatment exhibited synergistic effects of the two drugs in reducing the serum matrix metalloproteinase 3 level and the number of peripheral CD11b(high) osteoclast precursor cells. Moreover, tacrolimus inhibited the cytokine induced osteoclast differentiation in synergy with etanercept in an in vitro assay. Interestingly, tacrolimus did not inhibit the production of antidrug antibodies (ADAs) against etanercept in the hTNF Tg mice. This result implies that the synergistic effects of etanercept and tacrolimus are not due to secondary effects derived from the suppression of ADA production by tacrolimus but are due to their primary effects. These findings suggest that concomitant treatment with etanercept and tacrolimus may be one of preferable treatment options to control disease activities for patients with rheumatoid arthritis, especially for those with bone resorption.
C1 [Seki, Iwao; Takai Imamura, Miwa; Kohara Tanaka, Tomomi; Shirae, Satoshi; Sasano, Minoru; Aono, Hiroyuki] AYUMI Pharmaceut Corp, Res & Dev Dept, Shimogyo Ku, 8F Shijyo Karasuma FT Sq,20 Naginatahoko Cho, Kyoto 6008008, Japan.
   [Matsuno, Hiroaki] Matsuno Clin Rheumat Dis, 7187 2 Kureha Cho, Toyama, Toyama 9300138, Japan.
RP Seki, I (通讯作者)，AYUMI Pharmaceut Corp, Res & Dev Dept, Shimogyo Ku, 8F Shijyo Karasuma FT Sq,20 Naginatahoko Cho, Kyoto 6008008, Japan.
EM iwao.seki@ayumi pharma.com; pepetan@kcn.jp; tomomikohara@gmail.com;
   shirae@yo.rim.or.jp; minoru.sasano@ayumi pharma.com; info@toyama ra.com;
   hiroyuki.aono@ayumi pharma.com
CR Arnoult C, 2017, J IMMUNOL, V199, P418, DOI 10.4049/jimmunol.1601246
   Asahara H, 1995, BIOCHEM MOL BIOL INT, V37, P827
   Bond M, 1999, BIOCHEM BIOPH RES CO, V264, P561, DOI 10.1006/bbrc.1999.1551
   Collantes E, 1998, ANN RHEUM DIS, V57, P738, DOI 10.1136/ard.57.12.738
   Crotty S, 2011, ANNU REV IMMUNOL, V29, P621, DOI 10.1146/annurev immunol 031210 101400
   Dichamp I, 2007, J RHEUMATOL, V34, P1976
   Dore RK, 2007, CLIN EXP RHEUMATOL, V25, P40
   Kaneshiro S, 2017, MOD RHEUMATOL, V27, P42, DOI 10.1080/14397595.2016.1181315
   KEFFER J, 1991, EMBO J, V10, P4025, DOI 10.1002/j.1460 2075.1991.tb04978.x
   Kitahama M, 2013, MOD RHEUMATOL, V23, P788, DOI 10.1007/s10165 012 0745 3
   Koizumi K, 2009, J IMMUNOL, V183, P7825, DOI 10.4049/jimmunol.0803627
   Kontoyiannis D, 1999, IMMUNITY, V10, P387, DOI 10.1016/S1074 7613(00)80038 2
   Krieckaert CL, 2012, ANN RHEUM DIS, V71, P1914, DOI 10.1136/annrheumdis 2012 201544
   Li P, 2004, ARTHRITIS RHEUM, V50, P265, DOI 10.1002/art.11419
   McInnes IB, 2017, LANCET, V389, P2328, DOI 10.1016/S0140 6736(17)31472 1
   Migita K, 2005, IMMUNOL LETT, V98, P194, DOI 10.1016/j.imlet.2004.11.014
   Mitoma H, 2005, GASTROENTEROLOGY, V128, P376, DOI 10.1053/j.gastro.2004.11.060
   Motomura H, 2014, INT J RHEUM DIS, V17, P747, DOI 10.1111/1756 185X.12227
   Nakano K, 2007, RHEUMATOLOGY, V46, P597, DOI 10.1093/rheumatology/kel356
   Nam JL, 2017, ANN RHEUM DIS, V76, P1108, DOI 10.1136/annrheumdis 2016 210713
   Naniwa T, 2009, RHEUMATOL INT, V29, P1287, DOI 10.1007/s00296 009 0845 3
   Schett G, 2001, ARTHRITIS RHEUM, V44, P2888, DOI 10.1002/1529 0131(200112)44:12<2888::AID ART477>3.0.CO;2 3
   Singh JA, 2016, ARTHRITIS RHEUMATOL, V68, P1, DOI 10.1002/art.39480
   Smolen JS, 2016, LANCET, V388, P1984
   Smolen JS, 2017, ANN RHEUM DIS, V76, P960, DOI 10.1136/annrheumdis 2016 210715
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takeuchi T, 2018, MOD RHEUMATOL, V28, P48, DOI 10.1080/14397595.2017.1332471
   Uster S, 2018, BONE, V107, P56, DOI 10.1016/j.bone.2017.10.020
   van Meurs J, 1999, ARTHRITIS RHEUM US, V42, P2074, DOI 10.1002/1529 0131(199910)42:10<2074::AID ANR7>3.0.CO;2 5
   van Schouwenburg PA, 2013, NAT REV RHEUMATOL, V9, P164, DOI 10.1038/nrrheum.2013.4
   Zhang YH, 2001, J BIOL CHEM, V276, P563, DOI 10.1074/jbc.M008198200
   Zwerina J, 2004, ARTHRITIS RHEUM, V50, P277, DOI 10.1002/art.11487
NR 32
TC 2
Z9 3
U1 0
U2 0
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 0962 9351
EI 1466 1861
J9 MEDIAT INFLAMM
JI Mediat. Inflamm.
PD DEC 17
PY 2019
VL 2019
AR 4176974
DI 10.1155/2019/4176974
PG 12
WC Cell Biology; Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Immunology
GA KY1JG
UT WOS:000522327700001
PM 31949424
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Li, KC
   Chang, YH
   Yeh, CL
   Hu, YC
AF Li, Kuei Chang
   Chang, Yu Han
   Yeh, Chia Lin
   Hu, Yu Chen
TI Healing of osteoporotic bone defects by baculovirus engineered bone
   marrow derived MSCs expressing MicroRNA sponges
SO BIOMATERIALS
LA English
DT Article
DE Osteoporosis; Bone defect; MicroRNA; miR 214; BMP2; miRNA sponge
ID STEM CELLS; CHONDROGENIC DIFFERENTIATION; OSTEOGENIC DIFFERENTIATION;
   HYBRID BACULOVIRUS; MIR 214 PROMOTES; OVARIAN CANCER; BETA CATENIN;
   TARGETS; GROWTH; BMP 2
AB Fractures associated with osteoporosis are a worldwide health problem. To augment osteoporotic bone healing, we aimed to develop a cell/gene therapy approach in combination with miRNA manipulation. We unraveled aberrant overexpression of miR 140* and miR 214 in the bone marrow derived MSCs isolated from ovariectomized (OVX) rats (OVX BMSCs). To suppress the miRNA levels, we constructed hybrid baculovirus vectors expressing miRNA sponges to antagonize miR 140* or miR 214. Engineering OVX BMSCs with the hybrid vectors persistently attenuated the cellular miR 140*/miR 214 levels, which promoted the OVX BMSCs osteogenesis and augmented the ability of OVX BMSCs to repress osteoclast maturation in vitro. Notably, suppressing miR 214 exerted more potent osteoinductive effects. In the osteoporotic rat models with a critical size bone defect at the femoral metaphysis, implanting the OVX BMSCs ectopically expressing BMP2 failed to heal the defect, which underscored the difficulty to heal osteoporotic bone defects. Nonetheless, allotransplantation of the miR 214 sponges expressing OVX BMSCs healed the defect and ameliorated the bone quality (density, trabecular number, trabecular thickness and trabecular space) at 4 weeks post implantation. Co expressing BMP2 and miR 214 sponges in OVX BMSCs further synergistically substantiated the healing. The baculovirus engineered OVX BMSCs that expressed miR 214 sponge, with or without BMP2 expression, thus paved a new avenue to the treatment of osteoporotic bone defects. (C) 2015 Published by Elsevier Ltd.
C1 [Li, Kuei Chang; Yeh, Chia Lin; Hu, Yu Chen] Natl Tsing Hua Univ, Dept Chem Engn, Hsinchu 300, Taiwan.
   [Chang, Yu Han] Chang Gung Mem Hosp, Ctr Tissue Engn, Taoyuan 333, Taiwan.
   [Chang, Yu Han] Chang Gung Mem Hosp, Dept Orthopaed, Taoyuan 333, Taiwan.
C3 National Tsing Hua University; Chang Gung Memorial Hospital; Chang Gung
   Memorial Hospital
RP Hu, YC (通讯作者)，Natl Tsing Hua Univ, Dept Chem Engn, Hsinchu 300, Taiwan.
EM ychu@mx.nthu.edu.tw
RI Hu, Yu Chen/E 7825 2012; Yeh, Chun Hung/JDM 9927 2023
FU National Tsing Hua University [104N2050E1, 103N2758E1]; CGMH Intramural
   Project [CMRPG3E0441, CMRPG3E0061, CMRPG3E0062, CMRPG3B1542]; Ministry
   of Science and Technology, Taiwan [101 2628 E 007 009 MY3,
   101 2923 E 007 002 MY3, MOST 103 2221 E 007 093 MY3]
FX This work was supported by the National Tsing Hua University (Toward
   World Class University Project 104N2050E1 and NTHUCGMH Joint Research
   Program 103N2758E1), CGMH Intramural Project (CMRPG3E0441, CMRPG3E0061,
   CMRPG3E0062, CMRPG3B1542) and Ministry of Science and Technology
   (101 2628 E 007 009 MY3, 101 2923 E 007 002 MY3 and MOST
   103 2221 E 007 093 MY3), Taiwan.
CR Ahmed MI, 2014, J CELL BIOL, V207, P549, DOI 10.1083/jcb.201404001
   Airenne KJ, 2013, MOL THER, V21, P739, DOI 10.1038/mt.2012.286
   Aurora AB, 2012, J CLIN INVEST, V122, P1222, DOI 10.1172/JCI59327
   Bellido M, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3103
   Buechli ME, 2013, STEM CELLS DEV, V22, P1288, DOI 10.1089/scd.2012.0411
   Cao L, 2012, BIOMATERIALS, V33, P5076, DOI 10.1016/j.biomaterials.2012.03.069
   Chen CY, 2011, MOL PHARMACEUT, V8, P1505, DOI 10.1021/mp100368d
   Chen HL, 2010, BIOCHEM BIOPH RES CO, V394, P921, DOI 10.1016/j.bbrc.2010.03.076
   Chen Y, 2007, J BIOL CHEM, V282, P526, DOI 10.1074/jbc.M602700200
   Clark EA, 2014, STEM CELLS, V32, P1074, DOI 10.1002/stem.1623
   Deal C, 2009, NAT CLIN PRACT RHEUM, V5, P20, DOI 10.1038/ncprheum0977
   Hill CR, 2014, BONE, V62, P10, DOI 10.1016/j.bone.2014.01.019
   Ho YC, 2005, J GENE MED, V7, P860, DOI 10.1002/jgm.729
   Hwang S, 2014, FEBS LETT, V588, P2957, DOI 10.1016/j.febslet.2014.05.048
   Joglekar MV, 2007, TRENDS ENDOCRIN MET, V18, P393, DOI 10.1016/j.tem.2007.10.001
   Karlsen TA, 2014, STEM CELLS DEV, V23, P290, DOI 10.1089/scd.2013.0209
   Kim KM, 2014, CURR OPIN PHARMACOL, V16, P133, DOI 10.1016/j.coph.2014.05.001
   Li H, 2009, J CLIN INVEST, V119, P3666, DOI 10.1172/JCI39832
   Li KC, 2015, ADV HEALTHC MATER, V4, P948, DOI 10.1002/adhm.201400773
   Lian JB, 2012, NAT REV ENDOCRINOL, V8, P212, DOI 10.1038/nrendo.2011.234
   Liao YH, 2014, BIOMATERIALS, V35, P4901, DOI 10.1016/j.biomaterials.2014.02.055
   Lin CY, 2015, BIOMATERIALS, V50, P98, DOI 10.1016/j.biomaterials.2015.01.052
   Lin CY, 2014, TISSUE ENG PT A, V20, P1392, DOI [10.1089/ten.tea.2013.0314, 10.1089/ten.TEA.2013.0314]
   Lin CY, 2013, BIOMATERIALS, V34, P9401, DOI 10.1016/j.biomaterials.2013.08.051
   Lin CY, 2012, BIOMATERIALS, V33, P7422, DOI 10.1016/j.biomaterials.2012.06.083
   Lin CY, 2012, BIOMATERIALS, V33, P3682, DOI 10.1016/j.biomaterials.2012.02.007
   Lin CY, 2011, BIOMATERIALS, V32, P6505, DOI 10.1016/j.biomaterials.2011.05.059
   Lin CY, 2010, BIOMATERIALS, V31, P3222, DOI 10.1016/j.biomaterials.2010.01.030
   Mbalaviele G, 2005, J CELL BIOCHEM, V94, P403, DOI 10.1002/jcb.20253
   Muruganandan S, 2013, STEM CELLS, V31, P2172, DOI 10.1002/stem.1450
   Nakamura Y, 2011, MOL CELL BIOL, V31, P3019, DOI 10.1128/MCB.05178 11
   Oliver RA, 2013, OSTEOPOROSIS INT, V24, P2581, DOI 10.1007/s00198 013 2345 2
   Ono M, 2011, J BONE MINER RES, V26, P193, DOI 10.1002/jbmr.205
   Osako MK, 2010, CIRC RES, V107, P466, DOI 10.1161/CIRCRESAHA.110.216846
   Salingcarnboriboon RA, 2010, J CELL PHYSIOL, V224, P743, DOI 10.1002/jcp.22176
   Seeliger C, 2014, J BONE MINER RES, V29, P1718, DOI 10.1002/jbmr.2175
   Sehic A, 2011, PHYSIOL GENOMICS, V43, P488, DOI 10.1152/physiolgenomics.00248.2010
   Shi KK, 2013, BONE, V55, P487, DOI 10.1016/j.bone.2013.04.002
   Staines KA, 2012, J ENDOCRINOL, V214, P241, DOI 10.1530/JOE 12 0143
   Sugatani T, 2013, J CELL BIOCHEM, V114, P1217, DOI 10.1002/jcb.24471
   Sung LY, 2014, NAT PROTOC, V9, P1882, DOI 10.1038/nprot.2014.130
   Sung LY, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gkt442
   Takahashi Naoyuki, 2007, V135, P285
   Tanaka K, 2012, BONE, V51, P158, DOI 10.1016/j.bone.2012.04.017
   van Balkom BWM, 2013, BLOOD, V121, P3997, DOI 10.1182/blood 2013 02 478925
   van Mil A, 2012, CARDIOVASC RES, V93, P655, DOI 10.1093/cvr/cvs003
   van Wijnen AJ, 2013, CURR OSTEOPOROS REP, V11, P72, DOI 10.1007/s11914 013 0143 6
   Wang XG, 2013, NAT MED, V19, P93, DOI 10.1038/nm.3026
   Wang Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034641
   Watanabe T, 2008, DEV DYNAM, V237, P3738, DOI 10.1002/dvdy.21787
   Xia HP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044206
   Xu CX, 2012, J BIOL CHEM, V287, P34970, DOI 10.1074/jbc.M112.374611
   Xu ZY, 2014, BIOCHEM BIOPH RES CO, V449, P190, DOI 10.1016/j.bbrc.2014.04.140
   Yang H, 2008, CANCER RES, V68, P425, DOI 10.1158/0008 5472.CAN 07 2488
   Yang J, 2011, FEBS LETT, V585, P2992, DOI 10.1016/j.febslet.2011.08.013
   Yao W, 2010, J BONE MINER RES, V25, P190, DOI 10.1359/jbmr.090719
   Zhao CY, 2015, RNA BIOL, V12, P343, DOI 10.1080/15476286.2015.1017205
NR 57
TC 90
Z9 100
U1 0
U2 51
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142 9612
EI 1878 5905
J9 BIOMATERIALS
JI Biomaterials
PD JAN
PY 2016
VL 74
BP 155
EP 166
DI 10.1016/j.biomaterials.2015.09.046
PG 12
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA CV9MH
UT WOS:000364610800014
PM 26454414
DA 2025 08 17
ER

PT J
AU Lee, LR
   Peacock, L
   Lisowski, L
   Little, DG
   Munns, CF
   Schindeler, A
AF Lee, Lucinda R.
   Peacock, Lauren
   Lisowski, Leszek
   Little, David G.
   Munns, Craig F.
   Schindeler, Aaron
TI Targeting Adeno Associated Virus Vectors for Local Delivery to Fractures
   and Systemic Delivery to the Skeleton
SO MOLECULAR THERAPY METHODS & CLINICAL DEVELOPMENT
LA English
DT Article
ID BONE MORPHOGENETIC PROTEIN 2; GENE THERAPY; IN VIVO; TRANSGENE
   EXPRESSION; AAV DJ; PROMOTER; CELLS; SEROTYPES; LINEAGE; TISSUE
AB A panel of 18 recombinant adeno associated virus (rAAV) variants, both natural and engineered, constitutively expressing Cre recombinase under the cytomegalovirus early enhancer/chicken beta actin (CAG) promoter, were screened for their ability to transduce bone in Ai9 fluorescent reporter mice. Transgenic Cre induced tdTomato expression served as a measure of transduction efficiency and alkaline phosphatase (AP) activity as an osteoblastic marker. Single injections of AAV8, AAV9, and AAV DJ into midshaft tibial fractures yielded robust tdTomato expression in the callus. Next, the bone cell specific promoters Sp7 and Col2.3 were tested to restrict Cre expression in an alternate model of systemic delivery by intravenous injection. Although CAG promoter constructs packaged into AAV8 produced high levels of tdTomato in the bone, liver, heart, spleen, and kidney, bone specific promoter constructs restricted Cre expression to osseous tissues. AAV variants were further tested in vitro in a human osteoblast cell line (hFOB1.19), measuring GFP reporter expression by flow cytometry after 72 h. AAV2, AAV5, and AAV DJ showed the highest transduction efficiency. In summary, we produced AAV vectors for selective and high efficiency in vivo gene delivery to murine bone. The AAV8 Sp7 Cre vector has significant practical applications for inducing gene deletion postnatally in floxed mouse models.
C1 [Lee, Lucinda R.; Peacock, Lauren; Little, David G.; Schindeler, Aaron] Childrens Hosp Westmead, Orthopaed Res & Biotechnol Unit, Westmead, NSW, Australia.
   [Lee, Lucinda R.; Little, David G.; Munns, Craig F.; Schindeler, Aaron] Univ Sydney, Fac Hlth & Med, Discipline Child & Adolescent Hlth, Sydney, NSW, Australia.
   [Lisowski, Leszek; Schindeler, Aaron] Univ Sydney, Fac Med & Hlth, Childrens Med Res Inst, Translat Vectorol Grp, Sydney, NSW 2006, Australia.
   [Lisowski, Leszek] Biol Threats Identificat & Countermeasure Ctr, Mil Inst Hyg & Epidemiol, PL 24100 Pulawy, Poland.
   [Munns, Craig F.] Childrens Hosp Westmead, Inst Endocrinol & Diabet, Westmead, NSW, Australia.
C3 NSW Health; The Children's Hospital at Westmead; University of Sydney;
   Sydney Childrens Hospitals Network; University of Sydney; Children's
   Medical Research Institute   Australia; University of Sydney; Military
   Institute of Hygiene & Epidemiology (MIHE); NSW Health; Sydney Childrens
   Hospitals Network; The Children's Hospital at Westmead; University of
   Sydney
RP Schindeler, A (通讯作者)，Childrens Hosp Westmead, Orthopaed Res & Biotechnol Unit, Kids Res, Locked Bag 4001, Westmead, NSW 2145, Australia.
EM aaron.schindeler@sydney.edu.au
RI ; Lisowski, Leszek/AAU 2228 2020; Munns, Craig/A 8719 2015
OI Lisowski, Leszek/0000 0002 4772 8651; Schindeler,
   Aaron/0000 0002 7757 6281; Lee, Lucinda/0000 0002 9094 7171; Munns,
   Craig/0000 0001 5898 5808
FU Care 4 Brittle Bones Foundation; Sticks and Stones Foundation of
   Australia; Australian Government Research Training Program (RTP)
   scholarship; Australian National Health and Medical Research Council
   (NHMRC) [APP1108311]; Paediatrio organization
FX This work was supported by funding from the Care 4 Brittle Bones
   Foundation, the Sticks and Stones Foundation of Australia, and the
   Paediatrio organization. L.R.L. was supported by an Australian
   Government Research Training Program (RTP) scholarship. L.L. was
   supported by a project grant from the Australian National Health and
   Medical Research Council (NHMRC; APP1108311). The authors wish to thank
   Dr Laurence Cantrill for assistance with the DMi8 microscope.
CR Asokan A, 2010, NAT BIOTECHNOL, V28, P79, DOI 10.1038/nbt.1599
   Breitbach M, 2018, CELL STEM CELL, V22, P262, DOI 10.1016/j.stem.2018.01.008
   Brown BD, 2007, NAT BIOTECHNOL, V25, P1457, DOI 10.1038/nbt1372
   Bulaklak K, 2017, CURR OPIN PHARMACOL, V34, P56, DOI 10.1016/j.coph.2017.07.001
   Chen Y, 2004, BIOCHEM BIOPH RES CO, V317, P675, DOI 10.1016/j.bbrc.2004.03.098
   Chen Y, 2003, GENE THER, V10, P1345, DOI 10.1038/sj.gt.3301999
   Chen Y, 2002, BIOCHEM BIOPH RES CO, V298, P121, DOI 10.1016/S0006 291X(02)02394 X
   Choi JH, 2014, MOL BRAIN, V7, DOI 10.1186/1756 6606 7 17
   Meirelles LDS, 2006, J CELL SCI, V119, P2204, DOI 10.1242/jcs.02932
   Dacquin R, 2002, DEV DYNAM, V224, P245, DOI 10.1002/dvdy.10100
   Dalkara D, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005708
   El Hoss J, 2012, J BONE MINER RES, V27, P68, DOI 10.1002/jbmr.528
   Gao GP, 2004, J VIROL, V78, P6381, DOI 10.1128/JVI.78.12.6381 6388.2004
   Ginn SL, 2018, J GENE MED, V20, DOI 10.1002/jgm.3015
   Grieger JC, 2005, J VIROL, V79, P9933, DOI 10.1128/JVI.79.15.9933 9944.2005
   Grimm D, 2008, J VIROL, V82, P5887, DOI 10.1128/JVI.00254 08
   HARRIS SA, 1995, J BONE MINER RES, V10, P178
   Lakhan R, 2015, GENE THER, V22, P721, DOI 10.1038/gt.2015.40
   Lerch TF, 2012, STRUCTURE, V20, P1310, DOI 10.1016/j.str.2012.05.004
   Lieberman JR, 1998, J ORTHOP RES, V16, P330, DOI 10.1002/jor.1100160309
   Lisowski L, 2014, NATURE, V506, P382, DOI 10.1038/nature12875
   Liu F, 2004, INT J DEV BIOL, V48, P645, DOI 10.1387/ijdb.041816fl
   Lu XH, 2006, J BIOL CHEM, V281, P6297, DOI 10.1074/jbc.M507804200
   Luk KDK, 2003, BIOCHEM BIOPH RES CO, V308, P636, DOI 10.1016/S0006 291X(03)01429 3
   Madisen L, 2010, NAT NEUROSCI, V13, P133, DOI 10.1038/nn.2467
   Marijanovic I, 2003, CROAT MED J, V44, P412
   MIYAZAKI J, 1989, GENE, V79, P269
   Moreno AM, 2018, MOL THER, V26, P1818, DOI 10.1016/j.ymthe.2018.04.017
   Müller CW, 2017, J TISSUE ENG REGEN M, V11, P1122, DOI 10.1002/term.2015
   Musgrave DS, 1999, BONE, V24, P541, DOI 10.1016/S8756 3282(99)00086 1
   Nam HJ, 2007, J VIROL, V81, P12260, DOI 10.1128/JVI.01304 07
   NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378 1119(91)90434 D
   Parmiani G, 1998, GENE THER, V5, P863, DOI 10.1038/sj.gt.3300692
   Qiao C, 2011, GENE THER, V18, P403, DOI 10.1038/gt.2010.157
   Ran FA, 2015, NATURE, V520, P186, DOI 10.1038/nature14299
   ROSSERT J, 1995, J CELL BIOL, V129, P1421, DOI 10.1083/jcb.129.5.1421
   Strobel B, 2015, HUM GENE THER METHOD, V26, P147, DOI 10.1089/hgtb.2015.051
   Tabebordbar M, 2016, SCIENCE, V351, P407, DOI 10.1126/science.aad5177
   Ulrich Vinther M, 2005, BONE, V37, P751, DOI 10.1016/j.bone.2005.07.021
   Virk MS, 2008, BONE, V42, P921, DOI 10.1016/j.bone.2007.12.216
   Wang LL, 2016, BLOOD, V128, DOI 10.1182/blood.V128.22.2316.2316
   Yazici C, 2011, MOL THER, V19, P1416, DOI 10.1038/mt.2010.294
   Zachos T, 2007, MOL THER, V15, P1543, DOI 10.1038/sj.mt.6300192
   Zhang C, 2008, P NATL ACAD SCI USA, V105, P6936, DOI 10.1073/pnas.0710831105
   Zincarelli C, 2008, MOL THER, V16, P1073, DOI 10.1038/mt.2008.76
   Zinn E, 2015, CELL REP, V12, P1056, DOI 10.1016/j.celrep.2015.07.019
NR 46
TC 20
Z9 22
U1 1
U2 9
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
EI 2329 0501
J9 MOL THER METH CLIN D
JI Mol.Ther. Methods Clin. Dev.
PD DEC 13
PY 2019
VL 15
BP 101
EP 111
DI 10.1016/j.omtm.2019.08.010
PG 11
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA JV7XB
UT WOS:000502573100010
PM 31649959
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Sakaida, K
   Omori, K
   Nakayama, M
   Mandai, H
   Nakagawa, S
   Sako, H
   Kamei, C
   Yamamoto, S
   Kobayashi, H
   Ishii, S
   Ono, M
   Ibaragi, S
   Yamashiro, K
   Yamamoto, T
   Suga, S
   Takashiba, S
AF Sakaida, Kyosuke
   Omori, Kazuhiro
   Nakayama, Masaaki
   Mandai, Hiroki
   Nakagawa, Saki
   Sako, Hidefumi
   Kamei, Chiaki
   Yamamoto, Satoshi
   Kobayashi, Hiroya
   Ishii, Satoki
   Ono, Mitsuaki
   Ibaragi, Soichiro
   Yamashiro, Keisuke
   Yamamoto, Tadashi
   Suga, Seiji
   Takashiba, Shogo
TI The Fungal Metabolite (+) Terrein Abrogates Ovariectomy Induced Bone
   Loss and Receptor Activator of Nuclear Factor κB Ligand Induced
   Osteoclastogenesis by Suppressing Protein Kinase C α/βII Phosphorylation
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE (+) terrein; ovariectomy; osteoporosis; RANKL; PKC
ID INHIBITOR; TERREIN; DIFFERENTIATION; OSTEOPOROSIS; EXPRESSION;
   INDUCTION; SECRETION
AB Osteoporosis is a common disease characterized by a systemic impairment of bone mass and microarchitecture that results in fragility fractures. Severe bone loss due to osteoporosis triggers pathological fractures and consequently decreases the daily life activity and quality of life. Therefore, prevention of osteoporosis has become an important issue to be addressed. We have reported that the fungal secondary metabolite (+) terrein (TER), a natural compound derived from Aspergillus terreus, has shown receptor activator of nuclear factor kappa B ligand (RANKL) induced osteoclast differentiation by suppressing nuclear factor of activated T cell 1 (NFATc1) expression, a master regulator of osteoclastogenesis. TER has been shown to possess extensive biological and pharmacological benefits; however, its effects on bone metabolism remain unclear. In this study, we investigated the effects of TER on the femoral bone metabolism using a mouse ovariectomized osteoporosis model (OVX mice) and then on RANKL signal transduction using mouse bone marrow macrophages (mBMMs). In vivo administration of TER significantly improved bone density, bone mass, and trabecular number in OVX mice (p < 0.01). In addition, TER suppressed TRAP and cathepsin K expression in the tissue sections of OVX mice (p < 0.01). In an in vitro study, TER suppressed RANKL induced phosphorylation of PKC alpha/beta II, which is involved in the expression of NFATc1 (p < 0.05). The PKC inhibitor, GF109203X, also inhibited RANKL induced osteoclastogenesis in mBMMs as well as TER. In addition, TER suppressed the expression of osteoclastogenesis related genes, such as Ocstamp, Dcstamp, Calcr, Atp6v0d2, Oscar, and Itgb3 (p < 0.01). These results provide promising evidence for the potential therapeutic application of TER as a novel treatment compound against osteoporosis.
C1 [Sakaida, Kyosuke; Kamei, Chiaki; Kobayashi, Hiroya; Yamamoto, Tadashi; Takashiba, Shogo] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Pathophysiol Periodontal Sci, Okayama, Japan.
   [Omori, Kazuhiro; Nakagawa, Saki; Sako, Hidefumi; Yamamoto, Satoshi; Yamashiro, Keisuke] Okayama Univ Hosp, Dept Periodont & Endodont, Okayama, Japan.
   [Nakayama, Masaaki] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Microbiol, Okayama, Japan.
   [Mandai, Hiroki] Gifu Univ Med Sci, Fac Pharm, Dept Pharm, Gifu, Japan.
   [Ishii, Satoki] Okayama Univ, Grad Sch Nat Sci & Technol, Div Appl Chem, Okayama, Japan.
   [Ono, Mitsuaki] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Mol Biol & Biochem, Okayama, Japan.
   [Ibaragi, Soichiro] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Oral & Maxillofacial Surg, Okayama, Japan.
C3 Okayama University; Okayama University; Okayama University; Okayama
   University; Okayama University; Okayama University
RP Omori, K (通讯作者)，Okayama Univ Hosp, Dept Periodont & Endodont, Okayama, Japan.
EM kazu@cc.okayama u.ac.jp
RI Mandai, Hiroki/B 5378 2009; Omori, Kazuhiro/LGZ 8114 2024; Yamashiro,
   Keisuke/B 2455 2011; Takashiba, Shogo/C 9830 2010
OI Takashiba, Shogo/0000 0002 4712 6829
FU Japan Society for the Promotion of Science, Ryobi Memorial Foundation
   [19K10108, 20K18509]; Wesco Scientific Promotion Foundation;
   Grants in Aid for Scientific Research [21K09842, 20K18509, 21K21087,
   19K10108] Funding Source: KAKEN
FX This study was supported by a Grant in Aid for Scientific Research (C)
   (no. 19K10108, to KO) and Young Investigator (B) (no. 20K18509, to SN)
   from the Japan Society for the Promotion of Science, Ryobi Memorial
   Foundation, and Wesco Scientific Promotion Foundation (to KO and HM).
CR Aaron S., 2010, BMC MUSCULOSKEL DIS, V11, P105, DOI [10.1186/1471 2474 11 105, DOI 10.1186/1471 2474 11 105]
   Arakawa M, 2008, J ANTIBIOT, V61, P442, DOI 10.1038/ja.2008.60
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003 2697(76)90527 3
   Burge R, 2007, J BONE MINER RES, V22, P465, DOI [10.1359/jbmr.061113, 10.1359/JBMR.061113]
   Chen Xiao, 2018, Cell Physiol Biochem, V51, P2858, DOI 10.1159/000496039
   Choi SW, 2012, EVID BASED COMPL ALT, V2012, DOI 10.1155/2012/810563
   Crotti TN, 2008, J CELL PHYSIOL, V215, P636, DOI 10.1002/jcp.21344
   Hagino H, 2021, OSTEOPOROSIS INT, V32, P2011, DOI 10.1007/s00198 021 05927 1
   Horibe K, 2013, IMMUNOLOGY, V140, P344, DOI 10.1111/imm.12146
   Kim B, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 26974 5
   Kumar RA, 2018, INT IMMUNOPHARMACOL, V65, P348, DOI 10.1016/j.intimp.2018.10.016
   Kwak HB, 2010, BONE, V46, P724, DOI 10.1016/j.bone.2009.10.042
   Lee JC, 2008, J ENDODONT, V34, P433, DOI 10.1016/j.joen.2008.01.015
   Lee JM, 2012, J IMMUNOL, V189, P5284, DOI 10.4049/jimmunol.1003738
   Lin HX, 2019, EVID BASED COMPL ALT, V2019, DOI 10.1155/2019/2705263
   Liu YS, 2007, NAT REV IMMUNOL, V7, P202, DOI 10.1038/nri2035
   Ma XJ, 2014, BIOCHEM BIOPH RES CO, V445, P282, DOI 10.1016/j.bbrc.2014.01.145
   Mandai H, 2014, BIOORGAN MED CHEM, V22, P5338, DOI 10.1016/j.bmc.2014.07.047
   Matsuo K, 2008, ARCH BIOCHEM BIOPHYS, V473, P201, DOI 10.1016/j.abb.2008.03.027
   Matsuoka K, 2014, J BONE MINER RES, V29, P1522, DOI 10.1002/jbmr.2187
   Miyazaki T, 2000, J CELL BIOL, V148, P333, DOI 10.1083/jcb.148.2.333
   Nakagawa S, 2020, INT IMMUNOPHARMACOL, V83, DOI 10.1016/j.intimp.2020.106429
   Nasu I., 2016, RONEN SHIKA IGAKU, V31, P39, DOI [10.11259/jsg.31.39, DOI 10.11259/JSG.31.39]
   Negishi Koga T, 2009, IMMUNOL REV, V231, P241, DOI 10.1111/j.1600 065X.2009.00821.x
   Omori K, 2004, J BIOL CHEM, V279, P6643, DOI 10.1074/jbc.M311688200
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Raistrick H, 1935, BIOCHEM J, V29, P606, DOI 10.1042/bj0290606
   Schröder K, 2019, FREE RADICAL BIO MED, V132, P67, DOI 10.1016/j.freeradbiomed.2018.08.036
   Shibahara T, 2018, J ORAL MAXIL SURG, V76, P2105, DOI 10.1016/j.joms.2018.04.009
   Shimada Sugawara M, 2015, SCI REP UK, V5, DOI 10.1038/srep09620
   Shin J, 2014, MOL CELLS, V37, P747, DOI 10.14348/molcells.2014.0220
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Tevlin R, 2014, JOVE J VIS EXP, DOI 10.3791/52056
   THOMPSON DD, 1995, BONE, V17, pS125, DOI 10.1016/8756 3282(95)00285 L
   Wakchoure S, 2009, PROSTATE, V69, P652, DOI 10.1002/pros.20913
   Xiao ZF, 2018, ARTHRITIS RES THER, V20, DOI 10.1186/s13075 018 1701 1
   Xu LJ, 2018, CALCIFIED TISSUE INT, V103, P400, DOI 10.1007/s00223 018 0428 y
   Yamamoto S, 2018, HELIYON, V4, DOI 10.1016/j.heliyon.2018.e00979
   Yao J, 2015, J CELL PHYSIOL, V230, P1235, DOI 10.1002/jcp.24858
   Yoneda T, 2017, J BONE MINER METAB, V35, P6, DOI 10.1007/s00774 016 0810 7
   Yoneda T, 2010, J BONE MINER METAB, V28, P365, DOI 10.1007/s00774 010 0162 7
   Zaidi M, 2007, NAT MED, V13, P791, DOI 10.1038/nm1593
NR 43
TC 3
Z9 3
U1 0
U2 8
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD JUN 8
PY 2021
VL 12
AR 674366
DI 10.3389/fphar.2021.674366
PG 14
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA SV8TP
UT WOS:000664090900001
PM 34168561
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Cai, XJ
   Wang, Z
   Wang, CY
   Hj, Z
   Ni, JJ
   Xu, YY
   Zhu, LY
   Fu, TH
   Li, FZ
   Chen, SS
   Zhou, JS
   Yang, GY
AF Cai, Xinjun
   Wang, Zeng
   Wang, Congyao
   Hj, Zhou
   Ni, Jianjun
   Xu, Yingying
   Zhu, Liyan
   Fu, Tianhong
   Li, Fanzhu
   Chen, Sangsang
   Zhou, Jianshe
   Yang, Gaoyi
TI In Vitro and In Vivo Evaluation of Cationic Liposomes
   Containing Zoledronic Acid as Anticancer Agent
SO LATIN AMERICAN JOURNAL OF PHARMACY
LA English
DT Article
DE anti tumor efficacy; cationic liposomes; neutral liposomes; zoledronic
   acid
ID CANCER PATIENTS; DRUG DELIVERY; BISPHOSPHONATES; CELLS;
   PHARMACODYNAMICS; PHARMACOKINETICS; CHEMOTHERAPY; METASTASIS; APOPTOSIS;
   GROWTH
AB Zoledronic acid (ZOL) is a potent amino bisphosphonate used for the treatment of bone metastases with recently reported antitumor activity. However, its short plasma half life as well as rapid uptake and accumulation within bone limits the use of ZOL as an antitumor agent. Cationic liposomes have a propensity for localizing in newly formed tumor vessels, improved anti tumor efficacy associated with impaired function of the tumor microvasculature. At present study, we aim to proposed new delivery systems cationic liposomes to slow ZOL metabolize, so as to improve its effect on tumors. The antiproliferative effects of ZOL loaded cationic liposomes (ZOL CLPs), ZOL loaded neutral liposomes (ZOL NLPs), and free ZOL in the human lung adenocarcinoma A549 cell lines were evaluated by MTT assay. The advantage of ZOL CLPs over ZOL NLPs and free ZOL with regard to antitumor activity in vivo was evaluated in a lung tumor bearing mouse model. The particle size, zeta potential, and entrapment efficiency (EE%) of the ZOL CLPs were observed as 106.76 +/  1.94 nm, +42.37 +/  2.60 mV, and 38.54 +/  0.99%, respectively. The antiproliferative effects experiment in vitro, the IC50 of ZOL CLPs, ZOL NLPs and free ZOL were 6.38 +/  1.66, 66.92 +/  3.75, and 184.65 +/  12.31 mu g/mL, respectively. Compared with the control group, the tumor inhibition rate of ZOL CLPs group, ZOL NLPs group, free ZOL group were 48.18, 36.66, and 2.10%, respectively. Immunohistochemical study showed that the expression of VEGF protein and COX 2 protein were high in control group, medium in ZOL group, low in ZOL NLPs group, and lower in ZOL CLPs group. In conclusion, the ZOL CLPs is a tumor targeting liposomes which has significant antitumor activity against adenocarcinoma A549 cell lung cancer.
C1 [Cai, Xinjun; Ni, Jianjun; Xu, Yingying] Integrated Chinese & Western Med Hosp Zhejiang Pr, Dept Pharm, Hangzhou 310003, Zhejiang, Peoples R China.
   [Wang, Zeng] Zhejiang Canc Hosp, Dept Pharm, Hangzhou 310022, Zhejiang, Peoples R China.
   [Wang, Congyao; Zhou, Jianshe] First Peoples Hosp Xiaoshan, Dept Pharm, Hangzhou 311200, Zhejiang, Peoples R China.
   [Hj, Zhou; Chen, Sangsang] Zhejiang Univ, Coll Pharmaceut Sci, Inst Pharmacol & Toxicol, Hangzhou 310003, Zhejiang, Peoples R China.
   [Zhu, Liyan; Fu, Tianhong] Integrated Chinese & Western Med Hosp Zhejiang Pr, Dept Pathol, Hangzhou 310003, Zhejiang, Peoples R China.
   [Li, Fanzhu] Zhejiang Chinese Med Univ, Coll Pharmaceut Sci, Hangzhou 310053, Zhejiang, Peoples R China.
   [Yang, Gaoyi] Integrated Chinese & Western Med Hosp Zhejiang Pr, Dept Ultrasoud, Hangzhou 310003, Zhejiang, Peoples R China.
C3 Zhejiang Cancer Hospital; Zhejiang University; Zhejiang Chinese Medical
   University
RP Li, FZ (通讯作者)，Zhejiang Chinese Med Univ, Coll Pharmaceut Sci, Hangzhou 310053, Zhejiang, Peoples R China.
EM heat.hz@163.com
RI Li, FanZhu/AFV 1744 2022; Ni, Jianjun/AFW 0120 2022; Wang,
   zhenyu/HGB 1461 2022
FU Health Science and technology program of Hangzhou [2011A308];
   Traditional Chinese Medicine Scientific Research Fund Program of
   Zhejiang [2012ZA101, 2015ZA148]; Hospital Pharmacy Research Program of
   Zhejiang Pharmaceutical Association [2011ZYY11]; Medicine and Health
   Care Studies Program of Zhejiang [2014KYB036]; Public welfare Technology
   Application Studies Program of Zhejiang [2015C33286]
FX The authors gratefully acknowledge the financial support from the Health
   Science and technology program of Hangzhou (No 2011A308), Traditional
   Chinese Medicine Scientific Research Fund Program of Zhejiang (No
   2012ZA101, NO2015ZA148), Hospital Pharmacy Research Program of Zhejiang
   Pharmaceutical Association (No 2011ZYY11), Medicine and Health Care
   Studies Program of Zhejiang (No 2014KYB036), and Public welfare
   Technology Application Studies Program of Zhejiang (2015C33286).
CR Abu Lila AS, 2009, J CONTROL RELEASE, V137, P8, DOI 10.1016/j.jconrel.2009.02.023
   AUGUSTIN HG, 1994, BIOESSAYS, V16, P901, DOI 10.1002/bies.950161208
   Caraglia M, 1999, ADV EXP MED BIOL, V472, P187
   Caraglia M, 2010, EXPERT OPIN PHARMACO, V11, P141, DOI 10.1517/14656560903485664
   Chen TL, 2002, J CLIN PHARMACOL, V42, P1228, DOI 10.1177/009127002762491316
   Daubiné F, 2007, J NATL CANCER I, V99, P322, DOI 10.1093/jnci/djk054
   Dipali SR, 1996, J PHARM PHARMACOL, V48, P1112, DOI 10.1111/j.2042 7158.1996.tb03904.x
   Heyes J, 2006, J CONTROL RELEASE, V112, P280, DOI 10.1016/j.jconrel.2006.02.012
   Iwamoto T, 2013, BIOL PHARM BULL, V36, P715, DOI 10.1248/bpb.b12 01102
   Lee MV, 2001, CANCER RES, V61, P2602
   Lv HT, 2006, J CONTROL RELEASE, V114, P100, DOI 10.1016/j.jconrel.2006.04.014
   Marra M, 2011, NANOMED NANOTECHNOL, V7, P955, DOI 10.1016/j.nano.2011.03.004
   Obata Y, 2010, J CONTROL RELEASE, V142, P267, DOI 10.1016/j.jconrel.2009.10.023
   Ran S, 2002, CANCER RES, V62, P6132
   Riebeling C, 2002, BRIT J CANCER, V87, P366, DOI 10.1038/sj.bjc.6600476
   Salzano G, 2011, INT J PHARMACEUT, V403, P292, DOI 10.1016/j.ijpharm.2010.10.046
   Scheper MA, 2009, SUPPORT CARE CANCER, V17, P1553, DOI 10.1007/s00520 009 0710 7
   Shipman CM, 1997, BRIT J HAEMATOL, V98, P665, DOI 10.1046/j.1365 2141.1997.2713086.x
   Skerjanec A, 2003, J CLIN PHARMACOL, V43, P154, DOI 10.1177/0091270002239824
   Sommer K, 2001, INT J ONCOL, V18, P1145
   Streith S, 2004, INT J CANCER, V110, P117, DOI 10.1002/ijc.20083
   WEIDNER N, 1993, AM J PATHOL, V143, P401
   Wu J, 2007, INT J PHARMACEUT, V337, P329, DOI 10.1016/j.ijpharm.2007.01.003
NR 23
TC 4
Z9 5
U1 0
U2 7
PU COLEGIO FARMACEUTICOS PROVINCIA DE BUENOS AIRES
PI LA PLATA
PA DEPT CIENTIFICO, CALLE 5 NO 966, LA PLATA, 00000, ARGENTINA
SN 0326 2383
J9 LAT AM J PHARM
JI Lat. Am. J. Pharm.
PY 2015
VL 34
IS 6
BP 1239
EP 1245
PG 7
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA CR7ZG
UT WOS:000361570200027
DA 2025 08 17
ER

PT J
AU Zhang, J
   Wu, JK
   Lin, XY
   Liu, XL
AF Zhang, Jian
   Wu, Jiankun
   Lin, Xiuya
   Liu, Xueli
TI Platelet rich Fibrin Promotes the Proliferation and Osteo /odontoblastic
   Differentiation of Human Dental Pulp Stem Cells
SO CURRENT STEM CELL RESEARCH & THERAPY
LA English
DT Article
DE Platelet rich fibrin; immature apical foramen; apical periodontitis;
   pulp regeneration; notch signaling; osteogenesis
ID PERMANENT TEETH; GROWTH FACTORS; THERAPY; TISSUE
AB Background Pulp regeneration is a promising strategy that promotes the continued development of young permanent teeth with immature apical foramen. Platelet rich fibrin (PRF) was found to stimulate the proliferation and differentiation of osteoblasts, but its effects on osteoblast/odontoblast differentiation of human dental pulp stem cells (hDPSCs) are unknown. Methods The hDPSCs were isolated and identified using known surface markers by flow cytometry. The CCK 8 assay and the expression of Ki67 and PCNA were used to examine hDPSC proliferation. After 7 days of culture in an osteo /odontoblastic induction medium with various concentrations of liquid PRF (0, 10% and 20%), the early stage of osteogenesis intracellular alkaline phosphatase (ALP) was checked. After 21 days of culture, matrix mineralization was checked using Alizarin Red S and quantified. The mRNA and protein levels of osteo /odontoblastic genes, including RUNX2, DSPP, DMP1 and BSP, were measured by qRT PCR. The notch signal was checked by Western blot to analyze three key proteins (Notch 1, Jagged 1 and Hes 1). Results PRF treated groups showed higher expression of Ki 67 and PCNA, higher ALP activity, and the higher dose showed a stronger induction. PRF promoted osteo /odontoblastic differentiation of hDPSCs indicated by elevated protein levels and mRNA levels of the expression of osteo /odontoblastic markers. The three key proteins in Notch signaling showed an increase compared with the control group and increased as the PRF concentration increased. Conclusion PRF can promote the proliferation and osteo /odontoblastic differentiation of hDPSC, which may be through the Notch signaling pathway.
C1 [Zhang, Jian; Wu, Jiankun; Lin, Xiuya; Liu, Xueli] Cangzhou Cent Hosp, Dent Clin, 16 Xinhua West Rd, Cangzhou 061000, Hebei, Peoples R China.
RP Zhang, J (通讯作者)，Cangzhou Cent Hosp, Dent Clin, 16 Xinhua West Rd, Cangzhou 061000, Hebei, Peoples R China.
EM czszxyyzj@126.com
RI liu, xueli/LVR 7450 2024
CR Banyatworakul P, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 90906 z
   Chandran Vidya, 2014, Int J Clin Pediatr Dent, V7, P213, DOI 10.5005/jp journals 10005 1268
   Chen MYH, 2012, INT ENDOD J, V45, P294, DOI 10.1111/j.1365 2591.2011.01978.x
   de Carvalho LAC, 2020, ACTA HISTOCHEM, V122, DOI 10.1016/j.acthis.2020.151636
   Hang K, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1286 x
   Strauss FJ, 2018, CLIN ORAL IMPLAN RES, V29, P6, DOI 10.1111/clr.13275
   Kang YH, 2011, TISSUE ENG PT A, V17, P349, DOI 10.1089/ten.TEA.2010.0327
   Kargarpour Z, 2020, ANTIOXIDANTS BASEL, V9, DOI 10.3390/antiox9060560
   Kobayashi E, 2016, CLIN ORAL INVEST, V20, P2353, DOI 10.1007/s00784 016 1719 1
   Kumar V, 2014, CASE REP DENT, V2014, DOI 10.1155/2014/673127
   Li CZ, 2021, STEM CELLS INT, V2021, DOI 10.1155/2021/5560872
   Liu JN, 2010, CURR TOP DEV BIOL, V92, P367, DOI [10.1016/S0070 2153(10)91012 7, 10.1016/S0070 2153(10)92012 7]
   Liu YP, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/3295756
   Miron RJ, 2017, TISSUE ENG PART B RE, V23, P83, DOI [10.1089/ten.TEB.2016.0233, 10.1089/ten.teb.2016.0233]
   Naik Balaram, 2013, J Conserv Dent, V16, P284, DOI 10.4103/0972 0707.114344
   Niapour A, 2019, BIOTECHNOL LETT, V41, P873, DOI 10.1007/s10529 019 02687 1
   Saoud TM, 2016, J ENDODONT, V42, P57, DOI 10.1016/j.joen.2015.09.015
   Shah R, 2017, EUR J PROSTHODONT RE, V25, P64, DOI 10.1922/EJPRD_01690Shah09
   Thanasrisuebwong P, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21145153
   Tian Y, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.2
   VanDussen KL, 2012, DEVELOPMENT, V139, P488, DOI 10.1242/dev.070763
   Verma UP, 2017, J INT SOC PREV COMMU, V7, P227, DOI 10.4103/jispcd.JISPCD_429_16
   Wang J, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.112
   Wang X, 2019, STEM CELLS INT, V2019, DOI 10.1155/2019/2402916
   Wu CL, 2012, AUST DENT J, V57, P207, DOI 10.1111/j.1834 7819.2012.01686.x
   Xie Z, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22168991
   Zhou S, 2019, CELL MOL LIFE SCI, V76, P1653, DOI 10.1007/s00018 019 03017 4
   Ziouti F, 2019, STEM CELLS INT, V2019, DOI 10.1155/2019/5150634
NR 28
TC 7
Z9 7
U1 0
U2 6
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y 2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1574 888X
EI 2212 3946
J9 CURR STEM CELL RES T
JI Curr. Stem Cell Res. Ther.
PY 2023
VL 18
IS 4
BP 560
EP 567
DI 10.2174/1574888X17666220704092411
PG 8
WC Cell & Tissue Engineering; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA J0PH2
UT WOS:001006706900013
PM 35794740
DA 2025 08 17
ER

PT J
AU Peng, SY
   Liu, Y
   Bao, XH
   Wang, L
   Zhang, FY
   Wang, F
   Wang, WJ
AF Peng, Shan Ying
   Liu, Yang
   Bao, Xu hong
   Wang, Lin
   Zhang, Fu ying
   Wang, Feng
   Wang, Wen jie
TI Inhibition of 5 lipoxygenase and cyclooxygenase 2 pathways by
   pain relieving plaster in macrophages
SO PHARMACEUTICAL BIOLOGY
LA English
DT Article
DE Pain relieving plaster; COX 2; 5 LOX; NF kappa B; inflammation
ID NF KAPPA B; NITRIC OXIDE; EXPRESSION; CELLS; INFLAMMATION; OSTEOBLASTS;
   INDUCTION; COX 2; INOS
AB Context: Pain relieving plaster (PRP) is a traditional Chinese medicine (TCM) that has been widely used with satisfactory results in the treatment of some diseases related to inflammation, such as bruises, chronic arthritis.
   Objective: The mechanisms underlying the anti inflammatory actions of PRP are investigated in this study for the first time.
   Materials and methods: The anti inflammatory effects of PRP extracts were evaluated in lipopolysaccharide (LPS) or calcium ionophore A23187 treated murine peritoneal macrophages (PMs). Tumor necrosis factor alpha alpha (TNF alpha alpha), interleukin 1 beta beta (IL 1 beta beta), prostaglandin E(2) (PGE(2)), and leukotrienes B(4) (LTB(4)) were evaluated by ELISA assays. Reverse transcriptase polymerase chain reaction (RT PCR) and western blot analysis were used to detect the expression of cyclooxygenase 2 (COX 2) and 5 lipoxygenase (5 LOX). Nuclear factor kappa B (NF kappa kappa B)  DNA binding activity was determined by gel mobility shift assay.
   Results: PRP extracts were found to inhibit the production of TNF alpha alpha, IL 1 beta beta, and PGE(2), reduce the expressions of COX 2 at the mRNA and protein levels induced by LPS, and reduced the production of LTB(4) induced by A23187. Furthermore, PRP extracts significantly attenuated LPS induced NF kappa kappa B  DNA binding activity.
   Discussion and conclusion: The anti inflammatory effects of PRP possibly are related to reduction of inflammatory cytokines (TNF alpha alpha and IL 1 beta beta), inducible inflammatory enzyme (COX 2), and its metabolite PGE(2) via NF kappa kappa B signal pathway. Moreover, PRP extracts also notably inhibited the production of LTB(4), indicating that PRP inhibited the 5 LOX pathway, which may be the other mechanism for its anti inflammatory action.
C1 [Peng, Shan Ying; Liu, Yang; Wang, Lin; Zhang, Fu ying; Wang, Feng; Wang, Wen jie] Chinese Acad Med Sci, Inst Mat Med, Dept Pharmacol, Beijing 100050, Peoples R China.
   [Peng, Shan Ying; Liu, Yang; Wang, Lin; Zhang, Fu ying; Wang, Feng; Wang, Wen jie] Peking Union Med Coll, Beijing 100021, Peoples R China.
   [Bao, Xu hong] Tibet Cheezheng Tibetan Med Co Ltd, Lanzhou, Peoples R China.
C3 Chinese Academy of Medical Sciences   Peking Union Medical College;
   Institute of Materia Medica   CAMS; Chinese Academy of Medical Sciences
     Peking Union Medical College; Peking Union Medical College
RP Wang, WJ (通讯作者)，Chinese Acad Med Sci, Inst Mat Med, Dept Pharmacol, 1 Xian Nong Tan St, Beijing 100050, Peoples R China.
EM wwenj@imm.ac.cn
FU National Key Technology R&D Program of China [2007BAI31B04]
FX This work was supported by a grant (Grant No. 2007BAI31B04) from
   National Key Technology R&D Program of China.
CR Andreakos E, 2004, IMMUNOL REV, V202, P250, DOI 10.1111/j.0105 2896.2004.00202.x
   BAI H, 2009, J BEIJING U TRADIT C, V16, P1
   Boscá L, 2005, TOXICOLOGY, V208, P249, DOI 10.1016/j.tox.2004.11.035
   DU ZH, 2007, MOD J INTEGR CHIN TR, V16, P1586
   Flamand N, 2006, J BIOL CHEM, V281, P129, DOI 10.1074/jbc.M506513200
   Griscavage JM, 1996, P NATL ACAD SCI USA, V93, P3308, DOI 10.1073/pnas.93.8.3308
   Harris GK, 2006, J NUTR, V136, P1517, DOI 10.1093/jn/136.6.1517
   HE CY, 2008, J TRADIT CHIN ORTHOP, V20, P9
   Huang H, 2008, J GASTROEN HEPATOL, V23, pS50, DOI 10.1111/j.1440 1746.2007.05284.x
   Huang L, 2004, ARTERIOSCL THROM VAS, V24, P1783, DOI 10.1161/01.ATV.0000140063.06341.09
   Kim JB, 2007, BIOL PHARM BULL, V30, P2345, DOI 10.1248/bpb.30.2345
   LEE SJ, 2010, CARDIOVASC IN PRESS
   LEE SJ, CARDIOVASC RES, V88, P352
   Leone S, 2007, CURR TOP MED CHEM, V7, P265, DOI 10.2174/156802607779941341
   李茂星, 2004, [中药材, Journal of Chinese Medicinal Materials], V27, P222
   Liu Yang, 2009, Yaoxue Xuebao, V44, P863
   Martel Pelletier J, 2004, ARTHRITIS RHEUM US, V50, P3925, DOI 10.1002/art.20632
   Maxis K, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar2092
   Notoya M, 2006, EUR J PHARMACOL, V534, P55, DOI 10.1016/j.ejphar.2006.01.028
   Raynauld JP, 2009, ANN RHEUM DIS, V68, P938, DOI 10.1136/ard.2008.088732
   Shen F, 2002, ACTA PHARMACOL SIN, V23, P762
   Vidal C, 2007, J PHARMACOL EXP THER, V320, P108, DOI 10.1124/jpet.106.110361
   Wang MT, 2007, CANCER METAST REV, V26, P525, DOI 10.1007/s10555 007 9096 5
   Wang YZ, 2008, BMC COMPLEM ALTERN M, V8, DOI 10.1186/1472 6882 8 51
   Willoughby DA, 2000, LANCET, V355, P646, DOI 10.1016/S0140 6736(99)12031 2
   XU RM, 2004, CHIN J TRAD W MED, V5, P12
   YAN ZW, 2008, MED INNOV CHINA, V5, P64
   Yu G, 2010, BIOORG MED CHEM LETT, V20, P2168, DOI 10.1016/j.bmcl.2010.02.040
   Zaitsu M, 2000, BLOOD, V96, P601
   ZHAO K, 2010, CAP MED, V14, P49
   ZHEN Y, 2006, CHIN J INTEGR TRAD W, V12, P152
NR 31
TC 11
Z9 14
U1 2
U2 14
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69 77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1388 0209
J9 PHARM BIOL
JI Pharm. Biol.
PD JUL
PY 2011
VL 49
IS 7
BP 716
EP 726
DI 10.3109/13880209.2010.544043
PG 11
WC Plant Sciences; Medical Laboratory Technology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Medical Laboratory Technology; Pharmacology & Pharmacy
GA 772YX
UT WOS:000291275300007
PM 21639685
OA Bronze
DA 2025 08 17
ER

PT J
AU Ren, YL
   Weeks, J
   Xue, TM
   Rainbolt, J
   Bentley, KLD
   Shu, Y
   Liu, YT
   Masters, E
   Cherian, P
   Mckenna, CE
   Neighbors, J
   Ebetino, FH
   Schwarz, EM
   Sun, ST
   Xie, C
AF Ren, Youliang
   Weeks, Jason
   Xue, Thomas
   Rainbolt, Joshua
   Bentley, Karen L. de Mesy
   Shu, Ye
   Liu, Yuting
   Masters, Elysia
   Cherian, Philip
   Mckenna, Charles E.
   Neighbors, Jeffrey
   Ebetino, Frank H.
   Schwarz, Edward M.
   Sun, Shuting
   Xie, Chao
TI Evidence of bisphosphonate conjugated sitafloxacin eradication of
   established methicillin resistant S. aureus infection with
   osseointegration in murine models of implant associated osteomyelitis
SO BONE RESEARCH
LA English
DT Article
ID STAPHYLOCOCCUS AUREUS; CORTICAL BONE; IN VIVO; BIOFILM; SUSCEPTIBILITY;
   EXCHANGE; MICE
AB Eradication of MRSA osteomyelitis requires elimination of distinct biofilms. To overcome this, we developed bisphosphonate conjugated sitafloxacin (BCS, BV600072) and hydroxybisphosphonate conjugate sitafloxacin (HBCS, BV63072), which achieve "target and release" drug delivery proximal to the bone infection and have prophylactic efficacy against MRSA static biofilm in vitro and in vivo. Here we evaluated their therapeutic efficacy in a murine 1 stage exchange femoral plate model with bioluminescent MRSA (USA300LAC::lux). Osteomyelitis was confirmed by CFU on the explants and longitudinal bioluminescent imaging (BLI) after debridement and implant exchange surgery on day 7, and mice were randomized into seven groups: 1) Baseline (harvested at day 7, no treatment); 2) HPBP (bisphosphonate control for BCS) + vancomycin; 3) HPHBP (hydroxybisphosphonate control for HBCS) + vancomycin; 4) vancomycin; 5) sitafloxacin; 6) BCS + vancomycin; and 7) HBCS + vancomycin. BLI confirmed infection persisted in all groups except for mice treated with BCS or HBCS + vancomycin. Radiology revealed catastrophic femur fractures in all groups except mice treated with BCS or HBCS + vancomycin, which also displayed decreases in peri implant bone loss, osteoclast numbers, and biofilm. To confirm this, we assessed the efficacy of vancomycin, sitafloxacin, and HBCS monotherapy in a transtibial implant model. The results showed complete lack of vancomycin efficacy while all mice treated with HBCS had evidence of infection control, and some had evidence of osseous integrated septic implants, suggestive of biofilm eradication. Taken together these studies demonstrate that HBCS adjuvant with standard of care debridement and vancomycin therapy has the potential to eradicate MRSA osteomyelitis.
C1 [Ren, Youliang; Weeks, Jason; Xue, Thomas; Rainbolt, Joshua; Bentley, Karen L. de Mesy; Shu, Ye; Liu, Yuting; Masters, Elysia; Schwarz, Edward M.; Xie, Chao] Univ Rochester, Med Ctr, Ctr Musculoskeletal Res, Rochester, NY 14642 USA.
   [Ren, Youliang; Weeks, Jason; Xue, Thomas; Rainbolt, Joshua; Bentley, Karen L. de Mesy; Shu, Ye; Liu, Yuting; Masters, Elysia; Schwarz, Edward M.; Xie, Chao] Univ Rochester, Med Ctr, Dept Orthopaed, Rochester, NY 14642 USA.
   [Bentley, Karen L. de Mesy] Univ Rochester, Med Ctr, Dept Pathol, Rochester, NY 14642 USA.
   [Bentley, Karen L. de Mesy] Univ Rochester, Med Ctr, Ctr Adv Res Technol, Rochester, NY 14642 USA.
   [Cherian, Philip; Ebetino, Frank H.; Sun, Shuting] BioVinc LLC, Pasadena, CA 91107 USA.
   [Mckenna, Charles E.] Univ Southern Calif, Dept Chem, Los Angeles, CA 90089 USA.
   [Neighbors, Jeffrey] Penn State Univ, Dept Pharmacol, Hershey, PA 17033 USA.
   [Ebetino, Frank H.] Univ Rochester, Dept Chem, Rochester, NY 14642 USA.
C3 University of Rochester; University of Rochester; University of
   Rochester; University of Rochester; University of Southern California;
   Pennsylvania Commonwealth System of Higher Education (PCSHE);
   Pennsylvania State University; Penn State Health; University of
   Rochester
RP Xie, C (通讯作者)，Univ Rochester, Med Ctr, Ctr Musculoskeletal Res, Rochester, NY 14642 USA.; Xie, C (通讯作者)，Univ Rochester, Med Ctr, Dept Orthopaed, Rochester, NY 14642 USA.; Sun, ST (通讯作者)，BioVinc LLC, Pasadena, CA 91107 USA.
EM shuting.sun@biovinc.com; chao_xie@urmc.rochester.edu
RI ; liu, Yuting/AAK 4042 2020
OI , Thomas Xue/0009 0002 9118 3764; Cherian, Philip/0000 0002 1070 6483;
   Masters, Elysia/0000 0002 9981 624X; de Mesy Bentley,
   Karen/0000 0003 0176 1111
FU This work was supported by grants from the National Institutes of Health
   (SBIR R44 AI125060, NIAMS P50 AR072000, and NIAMS P30 AR069655). We
   would like to thank the members of the Histology, Biochemistry amp;
   Molecular Imaging Core in the Center for Muscu [SBIR R44 AI125060, NIAMS
   P50 AR072000, NIAMS P30 AR069655]; National Institutes of Health;
   Biochemistry amp; Molecular Imaging Core in the Center for
   Musculoskeletal Research; Electron Microscopy Core at the University of
   Rochester, NY; National Institute of Allergy and Infectious Diseases
   [R44AI125060] Funding Source: NIH RePORTER
FX This work was supported by grants from the National Institutes of Health
   (SBIR R44 AI125060, NIAMS P50 AR072000, and NIAMS P30 AR069655). We
   would like to thank the members of the Histology, Biochemistry &
   Molecular Imaging Core in the Center for Musculoskeletal Research.
   Additionally, we would like to thank the Electron Microscopy Core at the
   University of Rochester, NY.
CR Adjei Sowah E, 2021, ANTIBIOTICS BASEL, V10, DOI 10.3390/antibiotics10060732
   Amorena B, 1999, J ANTIMICROB CHEMOTH, V44, P43, DOI 10.1093/jac/44.1.43
   Bentley KLD, 2017, J BONE MINER RES, V32, P985, DOI 10.1002/jbmr.3055
   BUCHHOLZ HW, 1984, CLIN ORTHOP RELAT R, P96
   Cheng AG, 2009, FASEB J, V23, P3393, DOI 10.1096/fj.09 135467
   Cremers S, 2019, BRIT J CLIN PHARMACO, V85, P1052, DOI 10.1111/bcp.13867
   de Mesy Bentley Karen L, 2018, JBJS Case Connect, V8, pe8, DOI 10.2106/JBJS.CC.17.00154
   Ebetino FH, 2022, BONE, V156, DOI 10.1016/j.bone.2021.116289
   Farrell Kristen B, 2018, Bone Rep, V9, P47, DOI 10.1016/j.bonr.2018.06.007
   Guo Y, 2013, ANTIMICROB AGENTS CH, V57, P855, DOI 10.1128/AAC.01003 12
   Ishikawa M, 2017, J BIOMED MATER RES A, V105, P3413, DOI 10.1002/jbm.a.36189
   JENSEN KLD, 1992, ULTRASTRUCT PATHOL, V16, P51, DOI 10.3109/01913129209074550
   Kourbatova EV, 2005, AM J INFECT CONTROL, V33, P385, DOI 10.1016/j.ajic.2005.06.006
   Lawson MA, 2010, J BIOMED MATER RES B, V92B, P149, DOI 10.1002/jbm.b.31500
   Li D, 2008, J ORTHOP RES, V26, P96, DOI 10.1002/jor.20452
   Li D, 2010, ANN NY ACAD SCI, V1192, P84, DOI 10.1111/j.1749 6632.2009.05210.x
   Masters EA, 2022, NAT REV MICROBIOL, V20, P385, DOI 10.1038/s41579 022 00686 0
   Masters EA, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008988
   Masters EA, 2019, BONE RES, V7, DOI 10.1038/s41413 019 0061 z
   Melchior MB, 2006, J VET MED B, V53, P326, DOI 10.1111/j.1439 0450.2006.00962.x
   Metsemakers WJ, 2021, J BONE JOINT SURG AM, V103, P4, DOI 10.2106/JBJS.20.01214
   Morgenstern M, 2021, J ORTHOP RES, V39, P136, DOI 10.1002/jor.24804
   Moriarty TF, 2022, NAT REV DIS PRIMERS, V8, DOI 10.1038/s41572 022 00396 0
   Nishitani K, 2015, J ORTHOP RES, V33, P1311, DOI 10.1002/jor.22907
   Parvizi J, 2019, J ARTHROPLASTY, V34, pS1, DOI 10.1016/j.arth.2018.09.038
   Prabhakara R, 2011, INFECT IMMUN, V79, P5010, DOI 10.1128/IAI.05571 11
   Ren YL, 2022, FRONT CELL INFECT MI, V12, DOI 10.3389/fcimb.2022.910970
   Saeed K, 2019, J ORTHOP RES, V37, P1007, DOI 10.1002/jor.24229
   Schwarz EM, 2021, J ORTHOP RES, V39, P227, DOI 10.1002/jor.24616
   Schwarz EM, 2019, J ORTHOP RES, V37, P997, DOI 10.1002/jor.24293
   Sedghizadeh PP, 2017, J MED CHEM, V60, P2326, DOI 10.1021/acs.jmedchem.6b01615
   Sun ST, 2021, BRIT J PHARMACOL, V178, P2008, DOI 10.1111/bph.15251
   Thammavongsa V, 2013, SCIENCE, V342, P863, DOI 10.1126/science.1242255
   Thurlow LR, 2011, J IMMUNOL, V186, P6585, DOI 10.4049/jimmunol.1002794
   Trombetta RP, 2019, EUR CELLS MATER, V37, P431, DOI 10.22203/eCM.v037a26
   Trombetta RP, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11020094
   Trombetta RP, 2018, MSPHERE, V3, DOI 10.1128/mSphere.00422 18
   Varrone JJ, 2014, J ORTHOP RES, V32, P1389, DOI 10.1002/jor.22672
   Wang H, 2020, J BONE MINER RES, V35, P343, DOI 10.1002/jbmr.3889
   Wang H, 2018, PHARMACEUTICS, V10, DOI 10.3390/pharmaceutics10030154
   Xie C, 2012, J ORTHOP RES, V30, P325, DOI 10.1002/jor.21500
   Xing LP, 2020, BONE, V138, DOI 10.1016/j.bone.2020.115492
   Yokogawa N, 2018, J ORTHOP RES, V36, P1590, DOI 10.1002/jor.23801
   Zhang XP, 2005, J BONE MINER RES, V20, P2124, DOI 10.1359/JBMR.050806
NR 44
TC 15
Z9 15
U1 3
U2 18
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 2095 4700
EI 2095 6231
J9 BONE RES
JI Bone Res.
PD OCT 18
PY 2023
VL 11
IS 1
AR 51
DI 10.1038/s41413 023 00287 4
PG 13
WC Cell & Tissue Engineering
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA W4CR8
UT WOS:001091126600001
PM 37848449
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Liang, LL
   Sun, CH
   Zhang, RT
   Han, SW
   Wang, JG
   Ren, N
   Liu, H
AF Liang, Linlin
   Sun, Chunhui
   Zhang, Ruitong
   Han, Shuwei
   Wang, Jingang
   Ren, Na
   Liu, Hong
TI Piezotronic effect determined neuron like differentiation of adult stem
   cells driven by ultrasound
SO NANO ENERGY
LA English
DT Article
DE Rat bone marrow mesenchymal stem cells; Localized electrical signals;
   Piezotronic effect; PVDF nanopillar array; Neural differentiation
ID OSTEOBLASTS PROLIFERATION; ELECTRICAL STIMULATION; NANOGENERATOR; FILMS;
   PIEZOELECTRICITY; NANOPARTICLES; MEMBRANES; GRAPHENE; PROMOTES; PLATFORM
AB Electrical stimulation is an efficient approach to inducing neural differentiation of stem cells. However, most demonstrations of conventional electrical stimulation for the regulation of stem cell differentiation generally involve three components an electrical signal generator, conductive culture substrate, and pair of lines, which limits its use in clinical applications for neural degeneration treatments. Herein, we proposed a facile method to generate localized electrical signals on the surface of a piezoelectric poly (vinylidene fluoride) (PVDF) film with a well designed nanopillar array driven by ultrasound irradiation based on a piezotronic effect, which proved to induce neuronal differentiation of rat bone marrow mesenchymal stem cells (rBMSCs) without any biological or chemical neural inducing factors. The assessment of rBMSCs on the surface of the PVDF nanopillar array at the gene and protein levels confirmed that rBMSCs could differentiate into neuron like cells. This demonstration provides a practical approach for the regulation of adult stem cells to differentiate into neurons, which will be a great achievement to overcome the shortage of neural stem cells in the adult human body and realize the autologous stem cell treatment of neurodegeneration. This work creates a new therapeutic avenue for contactless, controlled neuroregenerative therapies.
C1 [Liang, Linlin; Sun, Chunhui; Wang, Jingang; Ren, Na; Liu, Hong] Univ Jinan, Collaborat Innovat Ctr Technol & Equipment Biol D, Inst Adv Interdisciplinary Res iAIR, Jinan 250022, Peoples R China.
   [Liu, Hong] Shandong Univ, State Key Lab Crystal Mat, 27 Shandanan Rd, Jinan 250100, Shandong, Peoples R China.
   [Zhang, Ruitong] Shandong Univ, Sch Basic Med Sci, Key Lab Infect & Immun Shandong Prov, Key Lab Expt Teratol,Minist Educ,Cheeloo Med Coll, Jinan 250012, Shandong, Peoples R China.
   [Zhang, Ruitong] Shandong Univ, Sch Basic Med Sci, Dept Immunol, Cheeloo Med Coll, Jinan 250012, Shandong, Peoples R China.
   [Han, Shuwei] Shandong Univ, Ctr Orthopaed, Cheeloo Coll Med, Jinan 250012, Shandong, Peoples R China.
C3 University of Jinan; Shandong University; Shandong University; Shandong
   University; Shandong University
RP Wang, JG; Ren, N (通讯作者)，Univ Jinan, Collaborat Innovat Ctr Technol & Equipment Biol D, Inst Adv Interdisciplinary Res iAIR, Jinan 250022, Peoples R China.; Liu, H (通讯作者)，Univ Jinan, Inst Adv Interdisciplinary Res iAIR, Jinan 250022, Peoples R China.
EM chm_wangjg@ujn.edu.cn; bio_renn@ujn.edu.cn; hongliu@sdu.edu.cn
RI Liang, Linlin/HNJ 2746 2023; Liu, Hong/D 7288 2019
OI Sun, Chunhui/0000 0002 3197 6642; 
FU Project of "20 items of University" of Jinan [2018GXRC031]; National
   Natural Science Foundation of China [51972148]; Major Innovation
   Projects in Shandong Province [2018YFJH0503]; Natural Science Foundation
   of Shandong Province [ZR2020KE056]
FX This work was financially supported by the Project of "20 items of
   University" of Jinan (2018GXRC031) , National Natural Science Foundation
   of China (51972148) , Major Innovation Projects in Shandong Province
   (2018YFJH0503) , and Natural Science Foundation of Shandong Province
   (ZR2020KE056) .
CR Bianco P, 2001, NATURE, V414, P118, DOI 10.1038/35102181
   Bolonduro OA, 2020, NANO RES, V13, P1253, DOI 10.1007/s12274 020 2682 3
   Cao HQ, 2009, ADV DRUG DELIVER REV, V61, P1055, DOI 10.1016/j.addr.2009.07.009
   Chen P, 2021, NANO ENERGY, V86, DOI 10.1016/j.nanoen.2021.106123
   Cheng Y, 2020, NANO ENERGY, V69, DOI 10.1016/j.nanoen.2019.104411
   Damaraju SM, 2017, BIOMATERIALS, V149, P51, DOI 10.1016/j.biomaterials.2017.09.024
   Ding R, 2017, NANO ENERGY, V37, P126, DOI 10.1016/j.nanoen.2017.05.010
   Farrar D, 2011, ADV MATER, V23, P3954, DOI 10.1002/adma.201101733
   Gao Y, 2007, NANO LETT, V7, P2499, DOI 10.1021/nl071310j
   Griffin M, 2018, INT J NANOMED, V13, P6123, DOI 10.2147/IJN.S167637
   Griffin MF, 2019, MAT SCI ENG C MATER, V105, DOI 10.1016/j.msec.2019.110085
   Gu XS, 2014, BIOMATERIALS, V35, P6143, DOI 10.1016/j.biomaterials.2014.04.064
   Guan QB, 2018, NANO ENERGY, V51, P333, DOI 10.1016/j.nanoen.2018.06.060
   Guo WB, 2016, ACS NANO, V10, P5086, DOI 10.1021/acsnano.6b00200
   Han SW, 2020, NANO ENERGY, V72, DOI 10.1016/j.nanoen.2020.104688
   He LM, 2021, BIOMATERIALS, V268, DOI 10.1016/j.biomaterials.2020.120585
   Huang YJ, 2012, SMALL, V8, P2869, DOI 10.1002/smll.201200715
   Jiang LM, 2020, NANO ENERGY, V77, DOI 10.1016/j.nanoen.2020.105131
   Jin L, 2018, NANO ENERGY, V50, P632, DOI 10.1016/j.nanoen.2018.05.068
   Katsouras I, 2016, NAT MATER, V15, P78, DOI [10.1038/NMAT4423, 10.1038/nmat4423]
   Kelzenberg MD, 2010, NAT MATER, V9, P239, DOI [10.1038/NMAT2635, 10.1038/nmat2635]
   Kim TH, 2013, BIOMATERIALS, V34, P8660, DOI 10.1016/j.biomaterials.2013.07.101
   Lee YS, 2011, ACTA BIOMATER, V7, P3877, DOI 10.1016/j.actbio.2011.07.013
   Li SR, 2017, NAT MATER, V16, P953, DOI [10.1038/NMAT4954, 10.1038/nmat4954]
   Li YC, 2019, NANOMATERIALS BASEL, V9, DOI 10.3390/nano9070952
   Lin QF, 2017, ACS NANO, V11, P5113, DOI 10.1021/acsnano.7b02124
   Liu HJ, 2020, SCIENCE, V369, P292, DOI 10.1126/science.abb3209
   Liu J, 2014, STEM CELLS, V32, P1843, DOI 10.1002/stem.1682
   Liu L, 2020, ADV FUNCT MATER, V30, DOI 10.1002/adfm.201910108
   Lu LJ, 2020, NANO ENERGY, V78, DOI 10.1016/j.nanoen.2020.105251
   Manchineella S, 2016, ACS APPL MATER INTER, V8, P22849, DOI 10.1021/acsami.6b06403
   Marino A, 2015, ACS NANO, V9, P7678, DOI 10.1021/acsnano.5b03162
   Mavrokefalos A, 2012, NANO LETT, V12, P2792, DOI 10.1021/nl2045777
   Nakamura M, 2013, CELL RES, V23, P70, DOI 10.1038/cr.2012.171
   Nguyen LH, 2015, ADV DRUG DELIVER REV, V88, P53, DOI 10.1016/j.addr.2015.05.007
   Ren XH, 2018, NANO ENERGY, V50, P562, DOI 10.1016/j.nanoen.2018.06.002
   Ren XH, 2017, NANO ENERGY, V35, P233, DOI 10.1016/j.nanoen.2017.03.047
   Ren XH, 2016, ACS APPL MATER INTER, V8, P26190, DOI 10.1021/acsami.6b04497
   Ritzau Reid KI, 2020, ADV FUNCT MATER, V30, DOI 10.1002/adfm.202003710
   Sadtler K, 2016, NAT REV MATER, V1, DOI 10.1038/natrevmats.2016.40
   Surmenev RA, 2021, NANO ENERGY, V79, DOI 10.1016/j.nanoen.2020.105442
   Tai GP, 2018, BURNS TRAUMA, V6, DOI 10.1186/s41038 018 0123 2
   Tang QQ, 2012, ANNU REV BIOCHEM, V81, P715, DOI 10.1146/annurev biochem 052110 115718
   Tang W, 2015, ACS NANO, V9, P7867, DOI 10.1021/acsnano.5b03567
   Tian JJ, 2019, NANO ENERGY, V59, P705, DOI 10.1016/j.nanoen.2019.02.073
   Tomaskovic Crook E, 2020, CELLS BASEL, V9, DOI 10.3390/cells9030658
   Tropel P, 2006, STEM CELLS, V24, P2868, DOI 10.1634/stemcells.2005 0636
   Tsui KH, 2014, ADV MATER, V26, P2805, DOI 10.1002/adma.201304938
   Wang WJ, 2010, POLYMER, V51, P3575, DOI 10.1016/j.polymer.2010.05.021
   Wang Y, 2012, ADV MATER, V24, P4285, DOI 10.1002/adma.201200846
   Williams AR, 2011, CIRC RES, V109, P923, DOI 10.1161/CIRCRESAHA.111.243147
   Wu SC, 2010, BIOMATERIALS, V31, P631, DOI 10.1016/j.biomaterials.2009.09.089
   Zhang RT, 2021, NANO ENERGY, V87, DOI 10.1016/j.nanoen.2021.106192
   Zhang RT, 2020, NANOSCALE, V12, P18305, DOI 10.1039/d0nr02765k
   Zhang XD, 2019, ADV FUNCT MATER, V29, DOI 10.1002/adfm.201900372
   Zhang XH, 2016, ACS NANO, V10, P7279, DOI 10.1021/acsnano.6b02247
   Zhang Y, 2011, ADV MATER, V23, P3004, DOI 10.1002/adma.201100906
   Zhu ZC, 2006, POLYMER, V47, P7881, DOI 10.1016/j.polymer.2006.09.047
NR 58
TC 36
Z9 37
U1 11
U2 166
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2211 2855
EI 2211 3282
J9 NANO ENERGY
JI Nano Energy
PD DEC
PY 2021
VL 90
AR 106634
DI 10.1016/j.nanoen.2021.106634
EA OCT 2021
PN B
PG 11
WC Chemistry, Physical; Nanoscience & Nanotechnology; Materials Science,
   Multidisciplinary; Physics, Applied
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science;
   Physics
GA WO6AB
UT WOS:000712534000004
DA 2025 08 17
ER

PT J
AU Wang, XH
   Schröder, HC
   Schlossmacher, U
   Neufurth, M
   Feng, QL
   Diehl Seifert, B
   Müller, WEG
AF Wang, Xiaohong
   Schroeder, Heinz C.
   Schlossmacher, Ute
   Neufurth, Meik
   Feng, Qingling
   Diehl Seifert, Baerbel
   Mueller, Werner E. G.
TI Modulation of the Initial Mineralization Process of SaOS 2 Cells by
   Carbonic Anhydrase Activators and Polyphosphate
SO CALCIFIED TISSUE INTERNATIONAL
LA English
DT Article
DE Bone metabolism; Carbonic anhydrase; Quinolinic acid; SaOS 2 cell;
   Ca carbonate; Suberites domuncula extract
ID INTRACELLULAR CALCIUM PHOSPHATE; QUINOLINIC ACID; INORGANIC
   POLYPHOSPHATE; THERAPEUTIC APPLICATIONS; ISOZYME II; BONE; BICARBONATE;
   EXPRESSION; BIOMINERALIZATION; HYDROXYAPATITE
AB Ca phosphate/hydroxyapatite (HA) crystals constitute the mineral matrix of vertebrate bones, while Ca carbonate is the predominant mineral of many invertebrates, like mollusks. Recent results suggest that CaCO3 is also synthesized during early bone formation. We demonstrate that carbonic anhydrase driven CaCO3 formation in vitro is activated by organic extracts from the demosponge Suberites domuncula as well as by quinolinic acid, one component isolated from these extracts. Further results revealed that the stimulatory effect of bicarbonate (HCO3 ( )) ions on mineralization of osteoblast like SaOS 2 cells is strongly enhanced if the cells are exposed to inorganic polyphosphate (polyP), a linear polymer of phosphate linked by energy rich phosphodiester bonds. The effect of polyP, administered as polyP (Ca2+ salt), on HA formation was found to be amplified by addition of the carbonic anhydrase activating sponge extract or quinolinic acid. Our results support the assumption that CaCO3 deposits, acting as bio seeds for Ca carbonated phosphate formation, are formed as an intermediate during HA mineralization and that the carbonic anhydrase mediated formation of those deposits is under a positive negative feedback control by bone alkaline phosphatase dependent polyP metabolism, offering new targets for therapy of bone diseases/defects.
C1 [Wang, Xiaohong; Schroeder, Heinz C.; Schlossmacher, Ute; Neufurth, Meik; Mueller, Werner E. G.] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Inst Physiol Chem, ERC Adv Investigator Grant Res Grp, D 55128 Mainz, Germany.
   [Feng, Qingling] Tsinghua Univ, Sch Mat Sci & Engn, Adv Mat Lab, Beijing 100084, Peoples R China.
   [Diehl Seifert, Baerbel] NanotecMARIN, D 55128 Mainz, Germany.
C3 Johannes Gutenberg University of Mainz; Tsinghua University
RP Wang, XH (通讯作者)，Johannes Gutenberg Univ Mainz, Univ Med Ctr, Inst Physiol Chem, ERC Adv Investigator Grant Res Grp, Duesbergweg 6, D 55128 Mainz, Germany.
EM wang013@uni mainz.de; wmueller@uni mainz.de
RI ; Neufurth, Meik/N 4297 2015; Müller, W./AAR 8651 2020
OI Muller, Werner E.G./0000 0002 8223 3689; Neufurth,
   Meik/0000 0002 2383 6412; Schroder, Heinz C./0000 0003 0992 6427; 
FU ERC Advanced Investigator Grant [268476 BIOSILICA]; Deutsche
   Forschungsgemeinschaft [Schr 277/10 3]; European Commission [604036,
   286059, 268476, 311848]; International Human Frontier Science Program
FX W. E. G. M. is a holder of an ERC Advanced Investigator Grant (268476
   BIOSILICA). This work was supported by grants from the Deutsche
   Forschungsgemeinschaft (Schr 277/10 3), the European Commission
   ("Bio Scaffolds Customized Rapid Prototyping of Bioactive Scaffolds,''
   604036; Industry Academia Partnerships and Pathways "CoreShell,''
   286059; "MarBioTec*EU CN*,'' 268476; and "BlueGenics,'' 311848), and the
   International Human Frontier Science Program.
CR Alvarez L, 2001, J HISTOCHEM CYTOCHEM, V49, P1045, DOI 10.1177/002215540104900812
   An Z, 2009, ACTA CRYSTALLOGR E, V65, pM1501, DOI 10.1107/S1600536809045541
   Andrade LR, 2012, HEARING RES, V292, P14, DOI 10.1016/j.heares.2012.07.003
   BACHRA BN, 1963, ARCH BIOCHEM BIOPHYS, V103, P124, DOI 10.1016/0003 9861(63)90018 3
   Beniash E, 2011, WIRES NANOMED NANOBI, V3, P47, DOI 10.1002/wnan.105
   Bentov S, 2010, J STRUCT BIOL, V171, P207, DOI 10.1016/j.jsb.2010.04.007
   Berg JT, 2004, J HISTOCHEM CYTOCHEM, V52, P1101, DOI 10.1369/jhc.4a6266.2004
   Bhakuni D.S., 2005, Bioactive Marine Natural Products
   BILTZ RM, 1977, CLIN ORTHOP RELAT R, P279, DOI 10.1097/00003086 197711000 00040
   Boonrungsiman S, 2012, P NATL ACAD SCI USA, V109, P14170, DOI 10.1073/pnas.1208916109
   BOSKEY AL, 1973, J PHYS CHEM US, V77, P2313, DOI 10.1021/j100638a011
   CARTER ND, 1984, FEBS LETT, V165, P197, DOI 10.1016/0014 5793(84)80168 4
   Casey JR, 2009, AM J PHYSIOL CELL PH, V297, pC1091, DOI 10.1152/ajpcell.00177.2009
   de Brito Ashurst I, 2009, J AM SOC NEPHROL, V20, P2075, DOI 10.1681/ASN.2008111205
   Dey A, 2010, NAT MATER, V9, P1010, DOI [10.1038/nmat2900, 10.1038/NMAT2900]
   FOGH J, 1977, JNCI J NATL CANCER I, V59, P221, DOI 10.1093/jnci/59.1.221
   Gilis M, 2013, J STRUCT BIOL, V183, P441, DOI 10.1016/j.jsb.2013.05.018
   Gregory CA, 2004, ANAL BIOCHEM, V329, P77, DOI 10.1016/j.ab.2004.02.002
   Hofmann LC, 2013, J EXP BOT, V64, P899, DOI 10.1093/jxb/ers369
   Ilies M, 2002, J MED CHEM, V45, P504, DOI 10.1021/jm011031n
   Ilies M, 2004, CRC ENZYM INHIB SER, P317
   Leyhausen G, 1998, J BONE MINER RES, V13, P803, DOI 10.1359/jbmr.1998.13.5.803
   LINDSEY AE, 1990, P NATL ACAD SCI USA, V87, P5278, DOI 10.1073/pnas.87.14.5278
   Lindskog S, 1997, PHARMACOL THERAPEUT, V74, P1, DOI 10.1016/S0163 7258(96)00198 2
   MAGID E, 1968, BIOCHIM BIOPHYS ACTA, V151, P236, DOI 10.1016/0005 2744(68)90178 2
   Mahamid J, 2011, J STRUCT BIOL, V174, P527, DOI 10.1016/j.jsb.2011.03.014
   Mahamid J, 2010, P NATL ACAD SCI USA, V107, P6316, DOI 10.1073/pnas.0914218107
   MANN S, 1983, PROC R SOC SER B BIO, V218, P415, DOI 10.1098/rspb.1983.0048
   Mikami T, 2006, ANTICANCER RES, V26, P1153
   Müller WEG, 2007, CALCIFIED TISSUE INT, V81, P382, DOI 10.1007/s00223 007 9075 4
   Müller WEG, 2014, ACTA BIOMATER, V10, P450, DOI 10.1016/j.actbio.2013.08.025
   Müller WEG, 2013, FEBS OPEN BIO, V3, P357, DOI 10.1016/j.fob.2013.08.004
   Müller WEG, 2013, BIOMATERIALS, V34, P8671, DOI 10.1016/j.biomaterials.2013.07.096
   Müller WEG, 2013, CHEM EUR J, V19, P5790, DOI 10.1002/chem.201204412
   Müller WEG, 2011, ACTA BIOMATER, V7, P2661, DOI 10.1016/j.actbio.2011.03.007
   Müller WEG, 2004, INT REV CYTOL, V235, P53, DOI 10.1016/S0074 7696(04)35002 3
   Nudelman F, 2010, NAT MATER, V9, P1004, DOI 10.1038/NMAT2875
   Omelon S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005634
   Pastorekova S, 2004, J ENZYM INHIB MED CH, V19, P199, DOI 10.1080/14756360410001689540
   Pavlov E, 2010, J BIOL CHEM, V285, P9420, DOI 10.1074/jbc.M109.013011
   Peters A, 2007, SOLID STATE IONICS, V178, P67, DOI 10.1016/j.ssi.2006.12.004
   Pisam M, 2002, CELL TISSUE RES, V310, P163, DOI 10.1007/s00441 002 0622 z
   POSNER AS, 1954, EXPERIENTIA, V10, P424, DOI 10.1007/BF02318507
   POSNER AS, 1978, METAB BONE DIS RELAT, V1, P179, DOI 10.1016/0221 8747(78)90057 7
   POSNER AS, 1969, PHYSIOL REV, V49, P760, DOI 10.1152/physrev.1969.49.4.760
   POYART CF, 1975, RESP PHYSIOL, V25, P89, DOI 10.1016/0034 5687(75)90053 5
   Purkerson JM, 2005, AM J PHYSIOL REG I, V288, pR1256, DOI 10.1152/ajpregu.00735.2004
   Querido W, 2011, MICROSC ACTA SB, V20B, P1
   Rao NN, 2009, ANNU REV BIOCHEM, V78, P605, DOI 10.1146/annurev.biochem.77.083007.093039
   Raz S, 2002, BIOL BULL US, V203, P269, DOI 10.2307/1543569
   Reinhard J F Jr, 1994, Adv Pharmacol, V30, P85, DOI 10.1016/S1054 3589(08)60173 8
   Rey C, 1996, CONNECT TISSUE RES, V35, P343, DOI 10.3109/03008209609029210
   ROOS A, 1981, PHYSIOL REV, V61, P296, DOI 10.1152/physrev.1981.61.2.296
   Sachs L., 1999, Angewandte Statistik
   Sadan O, 2012, EXP NEUROL, V234, P417, DOI 10.1016/j.expneurol.2011.12.045
   Salge T, 2009, ANADOLU U J SCI TECH, V10, P45
   Sarma AS, 1993, BIOACTIVE MARINE NAT
   Schmitt BM, 2000, J NEUROSCI, V20, P6839, DOI 10.1523/JNEUROSCI.20 18 06839.2000
   Schröder HC, 2005, J BIOMED MATER RES B, V75B, P387, DOI 10.1002/jbm.b.30322
   Schröder HC, 2002, MAR BIOTECHNOL, V4, P546, DOI 10.1007/s10126 002 0028 7
   SEBASTIAN A, 1994, NEW ENGL J MED, V330, P1776, DOI 10.1056/NEJM199406233302502
   Sei Y, 1998, NEUROSCI LETT, V241, P180, DOI 10.1016/S0304 3940(97)00980 4
   Shinohara C, 2007, J HARD TISSUE BIOL, V16, P115
   Slowinski E.J., 2009, Chemical Principles in the Laboratory, V9th
   SLY WS, 1983, P NATL ACAD SCI BIOL, V80, P2752, DOI 10.1073/pnas.80.9.2752
   Supuran CT, 2008, CURR PHARM DESIGN, V14, P603, DOI 10.2174/138161208783877884
   Supuran CT, 2008, NAT REV DRUG DISCOV, V7, P168, DOI 10.1038/nrd2467
   Supuran CT, 2000, EXPERT OPIN THER PAT, V10, P575, DOI 10.1517/13543776.10.5.575
   Wang HX, 2013, CRIT REV ONCOL HEMAT, V85, P1, DOI 10.1016/j.critrevonc.2012.05.004
   Wang XH, 2012, SOFT MATTER, V8, P9501, DOI 10.1039/c2sm25889g
   Wiens M, 2010, CALCIFIED TISSUE INT, V87, P513, DOI 10.1007/s00223 010 9408 6
   Wiens M, 2010, BIOMATERIALS, V31, P7716, DOI 10.1016/j.biomaterials.2010.07.002
   WILBUR KM, 1955, BIOL BULL US, V108, P359, DOI 10.2307/1538521
   Xie BQ, 2010, P NATL ACAD SCI USA, V107, P22369, DOI 10.1073/pnas.1017493108
   Zhu Z, 2010, MOLECULES, V15, P4695, DOI 10.3390/molecules15074695
NR 75
TC 45
Z9 46
U1 1
U2 30
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0171 967X
EI 1432 0827
J9 CALCIFIED TISSUE INT
JI Calcif. Tissue Int.
PD MAY
PY 2014
VL 94
IS 5
BP 495
EP 509
DI 10.1007/s00223 013 9833 4
PG 15
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA AF0OS
UT WOS:000334414500004
PM 24374859
DA 2025 08 17
ER

PT J
AU Liu, J
   Han, XL
   Qu, LJ
   Du, BC
AF Liu, Jian
   Han, Xueliang
   Qu, Lianjun
   Du, Bencai
TI Identification of key ferroptosis related biomarkers in steroid induced
   osteonecrosis of the femoral head based on machine learning
SO JOURNAL OF ORTHOPAEDIC SURGERY AND RESEARCH
LA English
DT Article
DE Steroid induced osteonecrosis of the femoral head; Ferroptosis; Immune;
   Machine learning
ID MTOR; OSTEOPENIA; ACTIVATION; GENES; CELLS
AB BackgroundThis study was aimed to identify key ferroptosis related biomarkers in steroid induced osteonecrosis of the femoral head (SONFH) based on machine learning algorithm.MethodsThe SONFH dataset GSE123568 (including 30 SONFH patients and 10 controls) was used in this study. The differentially expressed genes (DEGs) were selected between SONFH and control groups, which were subjected to WGCNA. Ferroptosis related genes were downloaded from FerrDb V2, which were then compared with DEGs and module genes. Two machine learning algorithms were utilized to identify key ferroptosis related genes, and the underlying mechanisms were analyzed by GSEA. Correlation analysis between key ferroptosis related genes and immune cells was analyzed by Spearman method. The drug gene relationships were predicted in CTD.ResultsTotal 2030 DEGs were obtained. WGCNA identified two key modules and obtained 1561 module genes. Finally, 43 intersection genes were identified as disease related ferroptosis related genes. After LASSO regression and RFE SVM algorithms, 4 intersection genes (AKT1S1, BACH1, MGST1 and SETD1B) were considered as key ferroptosis related gene. The 4 genes were correlated with osteoclast differentiation pathway. Twenty immune cells with significant differences were obtained between the groups, and the 4 key ferroptosis related genes were correlated with most immune cells. In CTD, 41 drug gene relationship pairs were finally obtained.ConclusionsThe 4 key ferroptosis related genes, AKT1S1, BACH1, MGST1 and SETD1B, were identified to play a critical role in SONFH progression through osteoclast differentiation and immunologic mechanisms. Additionally, all the 4 genes had good disease prediction effect and could act as biomarkers for the diagnosis and treatment of SONFH.
C1 [Liu, Jian; Han, Xueliang; Qu, Lianjun; Du, Bencai] Sunshine Union Hosp, Dept Orthoped, 9000 Yingqian Rd, Weifang 261000, Shandong, Peoples R China.
RP Du, BC (通讯作者)，Sunshine Union Hosp, Dept Orthoped, 9000 Yingqian Rd, Weifang 261000, Shandong, Peoples R China.
EM ben96fag@163.com
CR Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556
   Bernhard ME, 2021, J ARTHROPLASTY, V36, P1352, DOI 10.1016/j.arth.2020.10.019
   Borghi SM, 2018, J NUTR BIOCHEM, V53, P81, DOI 10.1016/j.jnutbio.2017.10.010
   Charoentong P, 2017, CELL REP, V18, P248, DOI 10.1016/j.celrep.2016.12.019
   Chen C, 2015, J EXP MED, V212, P73, DOI 10.1084/jem.20140643
   Chen X, 2021, J EXP MED, V218, DOI 10.1084/jem.20210518
   Davis AP, 2021, NUCLEIC ACIDS RES, V49, pD1138, DOI 10.1093/nar/gkaa891
   Hänzelmann S, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471 2105 14 7
   Hirschhorn T, 2019, FREE RADICAL BIO MED, V133, P130, DOI 10.1016/j.freeradbiomed.2018.09.043
   Jiang B, 2019, Arxiv, DOI arXiv:1911.07681
   Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27
   Kohl M, 2011, METHODS MOL BIOL, V696, P291, DOI 10.1007/978 1 60761 987 1_18
   Langfelder P, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471 2105 9 559
   Laplante M, 2009, J CELL SCI, V122, P3589, DOI 10.1242/jcs.051011
   Li J, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419 020 2298 2
   Li SY, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.702661
   Liu C, 2022, OXID MED CELL LONGEV
   Liu F, 2017, J RES MED SCI, V22, DOI 10.4103/1735 1995.200273
   Liu Y, 2016, STEM CELLS, V34, P2157, DOI 10.1002/stem.2392
   Ma J, 2019, BIOMED RES INT
   MANOLAGAS SC, 1995, BONE, V17, pS63, DOI 10.1016/8756 3282(95)00180 L
   Meyer D., 2019, Package 'e1071'
   Migliorini F, 2022, LIFE BASEL, V12, DOI 10.3390/life12020179
   Migliorini F, 2023, SURG J R COLL SURG E, V21, P85, DOI 10.1016/j.surge.2021.12.004
   Migliorini F, 2021, EXPERT OPIN BIOL TH, V21, P423, DOI 10.1080/14712598.2021.1862790
   Mou YH, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045 019 0720 y
   Quaranta M, 2021, BRIT MED BULL, V137, P98, DOI 10.1093/bmb/ldaa044
   Radke S, 2006, J ORTHOP RES, V24, P945, DOI 10.1002/jor.20097
   Reichert CO, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21228765
   Sadile F, 2016, BRIT MED BULL, V118, P35, DOI 10.1093/bmb/ldw010
   Sherman BT, 2022, NUCLEIC ACIDS RES, V50, pW216, DOI 10.1093/nar/gkac194
   Smyth GK, 2005, STAT BIOL HEALTH, P397, DOI 10.1007/0 387 29362 0_23
   Song Y, 2017, BONE, V101, P104, DOI 10.1016/j.bone.2017.05.002
   Sun F, 2022, BIOCHEM BIOPH RES CO, V602, P149, DOI 10.1016/j.bbrc.2022.02.112
   Sun YT, 2020, BIOMED PHARMACOTHER, V127, DOI 10.1016/j.biopha.2020.110108
   Tang Y, 2015, BIOSYSTEMS, V127, P67, DOI 10.1016/j.biosystems.2014.11.005
   Towheed TE, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004257.pub2
   van der Jagt D, 2015, J AM ACAD ORTHOP SUR, V23, P69, DOI 10.5435/JAAOS D 14 00431
   Völkers M, 2013, CELL CYCLE, V12, P3579, DOI 10.4161/cc.26822
   von Mering C, 2003, NUCLEIC ACIDS RES, V31, P258, DOI 10.1093/nar/gkg034
   Xian LL, 2012, NAT MED, V18, P1095, DOI 10.1038/nm.2793
   Yoon BH, 2019, J ARTHROPLASTY, V34, P163, DOI 10.1016/j.arth.2018.09.005
   Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118
   Yu ZF, 2015, INT J MOL MED, V36, P1264, DOI 10.3892/ijmm.2015.2340
   Zhang HY, 2014, INT IMMUNOPHARMACOL, V20, P95, DOI 10.1016/j.intimp.2014.02.016
   Zhang QY, 2018, CHINESE MED J PEKING, V131, P2589, DOI 10.4103/0366 6999.244111
   Zhao J, 2022, BMC MUSCULOSKEL DIS, V23, DOI 10.1186/s12891 022 04994 7
   Zhou N, 2023, NUCLEIC ACIDS RES, V51, pD571, DOI 10.1093/nar/gkac935
NR 48
TC 4
Z9 5
U1 0
U2 15
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1749 799X
J9 J ORTHOP SURG RES
JI J. Orthop. Surg. Res.
PD APR 29
PY 2023
VL 18
IS 1
AR 327
DI 10.1186/s13018 023 03800 x
PG 12
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA E5TS7
UT WOS:000976171400001
PM 37120553
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Hoseinzadeh, S
   Atashi, A
   Soleimani, M
   Alizadeh, E
   Zarghami, N
AF Hoseinzadeh, Saghar
   Atashi, Amir
   Soleimani, Masoud
   Alizadeh, Effat
   Zarghami, Nosratollah
TI MiR 221 inhibited adipose tissue derived mesenchymal stem cells
   bioengineered in a nano hydroxy apatite scaffold
SO IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY ANIMAL
LA English
DT Article
DE Adipose tissue derived mesenchymal stem cells; Osteogenic
   differentiation; Scaffold; Anti miR 221
ID OSTEOGENIC DIFFERENTIATION; MICRORNAS; BIOGENESIS; EXPRESSION;
   MECHANISM; REPAIR
AB The repair of skeletal defects is the main goal of bone tissue engineering. Recent literature highlighted various regulatory roles of microRNAs in stem cell fate determination. In addition, the role of porous hydroxyapatite/polycaprolacton (nHA/PCL) as a bioactive scaffold which enhances adipose tissue derived mesenchymal stem cells (AT MSCs) growth and osteogenic differentiation has been proved. The aim of the present study was to investigate the synergistic potential of both down regulating miR 221 and nHA/PCL scaffold seeding in osteogenic potential of AT MSCs. After isolation and characterization of AT MSCs, the transfection of anti miR 221 was performed into the cells using lipofectamine 2000 and the transfected cells were seeded into a synthesized nHA/PCL scaffold. The DAPI staining confirmed the presence of AT MSCs on nHA/PCL scaffold. Quantitative expression of osteoblast marker genes, Runx2, and osteocalcin of the transfected cells in the scaffold were evaluated. Interestingly, significant upregulation of transcribed Runx2 and osteocalcin genes (P < 0.01) were observed in miR 221 inhibited nHA/PCL seeded cells. Also, alkaline phosphatase activity (ALP) was significantly higher (P < 0.01) in miR 221 inhibited AT MSCs seeded on nHA/PCL than those seeded on nHA/PCL or transfected with anti miR 221, individually. The results of this combination suggest a valuable method for enhancing osteogenesis in AT MSCs. This method could be applicable for gene cell therapy of bone defects.
C1 [Hoseinzadeh, Saghar; Alizadeh, Effat; Zarghami, Nosratollah] Tabriz Univ Med Sci, Fac Adv Med Sci, Dept Med Biotechnol, Tabriz, Iran.
   [Atashi, Amir; Soleimani, Masoud] Tarbiat Modares Univ, Dept Hematol, Fac Med Sci, Tehran, Iran.
   [Alizadeh, Effat; Zarghami, Nosratollah] Tabriz Univ Med Sci, Umbil Cord Stem Cell Res Ctr UCSRC, Tabriz, Iran.
C3 Tabriz University of Medical Science; Tarbiat Modares University; Tabriz
   University of Medical Science
RP Zarghami, N (通讯作者)，Tabriz Univ Med Sci, Fac Adv Med Sci, Dept Med Biotechnol, Tabriz, Iran.; Zarghami, N (通讯作者)，Tabriz Univ Med Sci, Umbil Cord Stem Cell Res Ctr UCSRC, Tabriz, Iran.
EM Zarghami@tbzmed.ac.ir
RI ; Zarghami, Nosratollah/A 7821 2017; Atashi, Amir/B 1715 2017; Alizadeh,
   Effat/L 7235 2017
OI atashi, Amir/0000 0002 3889 5642; Zarghami,
   Nosratollah/0000 0002 4236 4537; Alizadeh, Effat/0000 0002 7481 0896
FU Umbilical Cord Stem Cell Research Center (UCSRC), Tabriz University of
   Medical Sciences, Tabriz, Iran [5/104/577]
FX The present work is part of an MSc thesis supported financially (Grant
   No. 5/104/577) by The Umbilical Cord Stem Cell Research Center (UCSRC),
   Tabriz University of Medical Sciences, Tabriz, Iran. Also, we thank
   Tarbiat Modares University for providing technical assistance.
CR Ahn HH, 2009, TISSUE ENG PT A, V15, P1821, DOI 10.1089/ten.tea.2008.0386
   Alizadeh E, 2015, CHEM BIOL DRUG DES
   Alizadeh E., 2014, ARTIF CELL NANOMED B, V30, P1, DOI DOI 10.3109/21691401.2014.928778
   Alizadeh E, 2014, CHEM BIOL DRUG DES
   Arnsdorf EJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005388
   Bakhshandeh B, 2012, BIOTECHNOL LETT, V34, P1579, DOI 10.1007/s10529 012 0934 3
   Bakhshandeh B, 2012, MOL BIOL REP, V39, P7569, DOI 10.1007/s11033 012 1591 2
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092 8674(04)00045 5
   Bauersachs J, 2011, CIRC RES, V109, P334, DOI 10.1161/CIRCRESAHA.110.228676
   Bentwich I, 2005, FEBS LETT, V579, P5904, DOI 10.1016/j.febslet.2005.09.040
   BRUDER SP, 1994, J CELL BIOCHEM, V56, P283, DOI 10.1002/jcb.240560303
   Cai X, 2012, OSTEOGENESIS ADIPOSE
   Chastain SR, 2006, J BIOMED MATER RES A, V78A, P73, DOI 10.1002/jbm.a.30686
   Chen LA, 2010, J BONE MINER RES, V25, P2447, DOI 10.1002/jbmr.133
   D'Antò V, 2016, J TISSUE ENG REGEN M, V10, pE147, DOI 10.1002/term.1768
   Dong SW, 2012, BIOCHEM BIOPH RES CO, V418, P587, DOI 10.1016/j.bbrc.2012.01.075
   Elfick APD, 2002, BIOMATERIALS, V23, P4463, DOI 10.1016/S0142 9612(02)00163 1
   Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108
   Gómez Barrena E, 2015, BONE, V70, P93, DOI 10.1016/j.bone.2014.07.033
   Guntur AR, 2012, BONE, V50, P54, DOI 10.1016/j.bone.2011.09.036
   Habraken WJEM, 2007, ADV DRUG DELIVER REV, V59, P234, DOI 10.1016/j.addr.2007.03.011
   Hassan MI, 2014, J NANOMATERIALS
   Hassan MQ, 2010, P NATL ACAD SCI USA, V107, P19879, DOI 10.1073/pnas.1007698107
   Hellmich C, 2003, BIOMECH MODEL MECHAN, V2, P21, DOI [10.1007/s10237 002 0025 9, 10.1007/S10237 002 0025 9]
   Hench LL, 1998, J SOL GEL SCI TECHN, V13, P245, DOI 10.1023/A:1008643303888
   Hu R, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.176099
   Inose H, 2009, P NATL ACAD SCI USA, V106, P20794, DOI 10.1073/pnas.0909311106
   Itoh T, 2010, J BIOL CHEM, V285, P27745, DOI 10.1074/jbc.M110.105080
   Javazon EH, 2004, EXP HEMATOL, V32, P414, DOI 10.1016/j.exphem.2004.02.004
   Kim YJ, 2009, J BONE MINER RES, V24, P816, DOI 10.1359/JBMR.081230
   Koh W, 2010, BMC GENOMICS, V11, DOI 10.1186/1471 2164 11 S1 S6
   Le Blanc K, 2005, CYTOTHERAPY, V7, P36, DOI 10.1080/14653240510018118
   Luo JY, 2010, J BIOL CHEM, V285, P29588, DOI 10.1074/jbc.M110.130518
   OHGUSHI H, 1989, ACTA ORTHOP SCAND, V60, P334, DOI 10.3109/17453678909149289
   Osathanon T, 2014, TISSUE ENG REGEN MED, V11, P239, DOI 10.1007/s13770 014 0015 x
   Parker AM, 2007, CYTOTHERAPY, V9, P637, DOI 10.1080/14653240701508452
   Poinern GE, 2009, ULTRASON SONOCHEM, V16, P469, DOI 10.1016/j.ultsonch.2009.01.007
   Prante C, 2006, STEM CELLS, V24, P2252, DOI 10.1634/stemcells.2005 0508
   Reiser J, 2005, POTENTIAL MESENCHYMA
   Schaap Oziemlak AM, 2010, STEM CELLS DEV, V19, P877, DOI 10.1089/scd.2009.0112
   Schindeler A, 2006, J BONE MINER RES, V21, P1331, DOI 10.1359/JBMR.060603
   Serra T, 2013, ACTA BIOMATER, V9, P5521, DOI 10.1016/j.actbio.2012.10.041
   Shor L, 2007, BIOMATERIALS, V28, P5291, DOI 10.1016/j.biomaterials.2007.08.018
   Undale AH, 2009, MAYO CLIN P
   Van Damme An, 2002, Current Gene Therapy, V2, P195
   Vats A, 2002, CLIN OTOLARYNGOL, V27, P227, DOI 10.1046/j.1365 2273.2002.00579.x
   Venugopal J, 2010, PHILOS T R SOC A, V368, P2065, DOI 10.1098/rsta.2010.0012
   Wang YY, 2010, POLYM DEGRAD STABIL, V95, P207, DOI 10.1016/j.polymdegradstab.2009.11.023
   Wutticharoenmongkol P, 2007, BIOMACROMOLECULES, V8, P2602, DOI 10.1021/bm700451p
   Xin XJ, 2007, BIOMATERIALS, V28, P316, DOI 10.1016/j.biomaterials.2006.08.042
   Zuk PA, 2002, MOL BIOL CELL, V13, P4279, DOI 10.1091/mbc.E02 02 0105
NR 51
TC 27
Z9 29
U1 0
U2 22
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1071 2690
EI 1543 706X
J9 IN VITRO CELL DEV AN
JI In Vitro Cell. Dev. Biol. Anim.
PD APR
PY 2016
VL 52
IS 4
BP 479
EP 487
DI 10.1007/s11626 015 9992 x
PG 9
WC Cell Biology; Developmental Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Developmental Biology
GA DJ6UX
UT WOS:000374349800011
PM 26822432
DA 2025 08 17
ER

PT J
AU Campbell, JJ
   Bader, DL
   Lee, DA
AF Campbell, J. J.
   Bader, D. L.
   Lee, D. A.
TI Mechanical loading modulates intracellular calcium signaling in human
   mesenchymal stem cells
SO JOURNAL OF APPLIED BIOMATERIALS & BIOMECHANICS
LA English
DT Article
DE mesenchymal stem cells; calcium signaling; mechanical loading; alginate
   hydrogels; mechanotransduction; cell deformation
ID ACTIVATED PROTEIN KINASE; OSCILLATORY FLUID FLOW; GENE EXPRESSION; CA2+
   OSCILLATIONS; CHONDROCYTES; DIFFERENTIATION; COMPRESSION; MATRIX;
   DEFORMATION; OSTEOBLAST
AB Mesenchymal stem cells (MSCs) are a promising cell source for tissue engineered connective tissue repair strategies. Additionally, increasing evidence confirms the role of the mechanical environment in maintaining tissue homeostasis, with calcium signaling implicated as a mediator in mechanotransduction pathways. Spontaneous intracellular calcium signaling was observed in a subset of MSCs embedded within 4% alginate hydrogel constructs, measured by a Ca2+ indicator fluo 4 in conjunction with confocal laser scanning microscopy. By the use of pair wise analysis, it was shown that distinct populations of MSCs up regulated and down regulated the frequency of calcium transients with the application of a 20% static uniaxial compressive strain of 20 min duration, delivered after a 20 min unstrained period. Calcium transients in control specimens were monitored throughout two unstrained 20 min periods. These values were statistically significant (p<0.05) by chi(2) test of independence. This dual response indicator highlights the heterogeneous nature of MSC populations, which may have important implications for their successful use in cell therapies.
C1 [Campbell, J. J.; Bader, D. L.; Lee, D. A.] Queen Mary Univ London, Sch Engn & Mat Sci, Med Engn Div, London E1 4NS, England.
C3 University of London; Queen Mary University London
RP Lee, DA (通讯作者)，Queen Mary Univ London, Sch Engn & Mat Sci, Med Engn Div, Mile End Rd, London E1 4NS, England.
EM D.A.Lee@qmul.ac.uk
OI Lee, David/0000 0001 7646 4643
FU EPSRC [EP/E046975/1] Funding Source: UKRI; Engineering and Physical
   Sciences Research Council [EP/E046975/1] Funding Source: researchfish
CR Bootman MD, 2001, J CELL SCI, V114, P2213
   BUSCHMANN MD, 1995, J CELL SCI, V108, P1497
   Campbell JJ, 2006, BIORHEOLOGY, V43, P455
   CARTER DR, 1988, J ORTHOP RES, V6, P736, DOI 10.1002/jor.1100060517
   CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092 8674(95)90408 5
   Conget PA, 1999, J CELL PHYSIOL, V181, P67, DOI 10.1002/(SICI)1097 4652(199910)181:1<67::AID JCP7>3.0.CO;2 C
   D'Andrea P, 2000, BIORHEOLOGY, V37, P75
   Fickert S, 2003, OSTEOARTHR CARTILAGE, V11, P790, DOI 10.1016/S1063 4584(03)00167 5
   Foreman MA, 2006, J CELL PHYSIOL, V206, P664, DOI 10.1002/jcp.20521
   Gomez P, 2001, CELL CALCIUM, V29, P137, DOI 10.1054/ceca.2000.0173
   Guilak F, 1999, J ORTHOPAED RES, V17, P421, DOI 10.1002/jor.1100170319
   Huang CYC, 2004, STEM CELLS, V22, P313, DOI 10.1634/stemcells.22 3 313
   Jaiswal RK, 2000, J BIOL CHEM, V275, P9645, DOI 10.1074/jbc.275.13.9645
   Kamioka H, 2006, J BONE MINER RES, V21, P1012, DOI 10.1359/JBMR.060408
   Kawano S, 2006, CELL CALCIUM, V39, P313, DOI 10.1016/j.ceca.2005.11.008
   Kawano S, 2003, CELL CALCIUM, V34, P145, DOI 10.1016/S0143 4160(03)00069 1
   Kawano S, 2002, CELL CALCIUM, V32, P165, DOI 10.1016/S0143416002001240
   Knight MM, 2003, AM J PHYSIOL CELL PH, V284, pC1083, DOI 10.1152/ajpcell.00276.2002
   Knight MM, 2002, BBA GEN SUBJECTS, V1570, P1, DOI 10.1016/S0304 4165(02)00144 7
   Knight MM, 2001, BBA GEN SUBJECTS, V1526, P141, DOI 10.1016/S0304 4165(01)00118 0
   Lagar'kova MA, 2006, B EXP BIOL MED+, V141, P112, DOI 10.1007/s10517 006 0108 1
   Lee DA, 1997, J ORTHOP RES, V15, P181, DOI 10.1002/jor.1100150205
   Li YJ, 2004, J ORTHOP RES, V22, P1283, DOI 10.1016/j.orthres.2004.04.002
   Muraglia A, 2000, J CELL SCI, V113, P1161
   Pingguan Murphy B, 2006, J CELL PHYSIOL, V209, P389, DOI 10.1002/jcp.20747
   Riddle RC, 2006, AM J PHYSIOL CELL PH, V290, pC776, DOI 10.1152/ajpcell.00082.2005
   Roberts SR, 2001, J APPL PHYSIOL, V90, P1385, DOI 10.1152/jappl.2001.90.4.1385
   Salasznyk RM, 2005, STEM CELLS DEV, V14, P608, DOI 10.1089/scd.2005.14.608
   Simmons CA, 2003, J BIOMECH, V36, P1087, DOI 10.1016/S0021 9290(03)00110 6
   Solursh M, 1983, CARTILAGE, V2, P121
   Toma C, 2002, CIRCULATION, V105, P93, DOI 10.1161/hc0102.101442
   Xiao GZ, 2002, J BONE MINER RES, V17, P101, DOI 10.1359/jbmr.2002.17.1.101
   You J, 2001, J BIOL CHEM, V276, P13365, DOI 10.1074/jbc.M009846200
NR 33
TC 30
Z9 39
U1 0
U2 13
PU WICHTIG PUBLISHING
PI MILAN
PA 72/74 VIA FRIULI, 20135 MILAN, ITALY
SN 1722 6899
EI 1724 6024
J9 J APPL BIOMATER BIOM
JI J. Appl. Biomater. Biomech.
PD JAN APR
PY 2008
VL 6
IS 1
BP 9
EP 15
PG 7
WC Biophysics; Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biophysics; Engineering; Materials Science
GA 299AB
UT WOS:000255727100002
PM 20740441
DA 2025 08 17
ER

PT J
AU Pan, T
   Hua, MH
   Lv, N
AF Pan, T.
   Hua, M.  H.
   Lv, N.
TI NSC1122002, a TRAF binding domain inhibitor, inhibits collagen induced
   arthritis in a mouse model
SO CLINICAL AND EXPERIMENTAL RHEUMATOLOGY
LA English
DT Article
DE NSC1122002; TRABID; JMJD2D; IL 12; IL 23; collagen induced arthritis
ID EPIGENETIC REGULATION; IL 12; DEUBIQUITINASE; INNATE; UBIQUITINATION;
   INTERLEUKIN 12; EXPRESSION; REGULATORS; THERAPY; KINASE
AB ObjectiveDysregulation of IL 12 and IL 23 is related to many autoimmune diseases including arthritis. The production of IL 12 and IL 23 were reported to be under the control of JMJD2D, whose activity and stability were promoted by the TRAF binding domain (TRABID), a deubiquitinating enzyme that epigenetically modulated inflammatory gene expression. NSC1122002 is a novel inhibitor of TRABID, and this study aimed to examine the effects of NSC1122002 on the expression of IL 12 and IL 23 both in vitro and in vivo in the context of collagen induced arthritis, consequently to evaluate its potential as a drug candidate for treating inflammatory disease. MethodsBone marrow cells were isolated to detect the effect of NSC1122002 on the development of innate immune cells and other precursor cells. Primary macrophages and osteoclasts were used to examine the impact of NSC1122002 on cytokine expression. Collagen induced arthritis was established to determine the function of NSC1122002 in vivo.ResultsNSC112200 did not affect the development of innate immune cells, primary osteoclast, and haematopoietic stem cells. NSC112200 specifically downregulated the expression of IL 12 and IL 23 through promoting degradation of JMJD2D by directly inhibited the deubiquitinating activity of TRABID. Besides, NSC112200 significantly suppressed the induction of CIA in mice.ConclusionOur findings provided new insight into the pathological mechanism and intervention method for arthritis therapy and identified that NSC112200 could be a potential drug for treating autoimmune diseases.
C1 [Pan, T.; Hua, M.  H.; Lv, N.] Nanjing Med Univ, Rheumatol Dept, Wuxi Peoples Hosp 2, Wuxi, Peoples R China.
   [Lv, N.] Nanjing Med Univ, Rheumatol Dept, Wuxi Peoples Hosp 2, 68 Zhongshan Rd, Wuxi 214002, Peoples R China.
C3 Nanjing Medical University; Nanjing Medical University
RP Lv, N (通讯作者)，Nanjing Med Univ, Rheumatol Dept, Wuxi Peoples Hosp 2, 68 Zhongshan Rd, Wuxi 214002, Peoples R China.
EM lvna4140@163.com
CR Accari SL, 2015, INT REV CEL MOL BIO, V319, P165, DOI 10.1016/bs.ircmb.2015.07.003
   Afonina IS, 2016, NAT IMMUNOL, V17, P227, DOI 10.1038/ni.3388
   Barker N, 2009, NATURE, V457, P608, DOI 10.1038/nature07602
   Bautista Herrera L, 2018, CLIN EXP MED, V18, P229, DOI 10.1007/s10238 017 0475 0
   Berry WL, 2013, CANCER RES, V73, P2936, DOI 10.1158/0008 5472.CAN 12 4300
   Chen L, 2019, J ETHNOPHARMACOL, V236, P63, DOI 10.1016/j.jep.2019.02.039
   Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092 8674(00)00126 4
   Dhaouadi T, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0194883
   Evans PC, 2001, BIOCHEM J, V357, P617, DOI 10.1042/0264 6021:3570617
   Fernando MDA, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004117
   Gaffen SL, 2014, NAT REV IMMUNOL, V14, P585, DOI 10.1038/nri3707
   Giannini D, 2020, CLIN EXP RHEUMATOL, V38, P387, DOI 10.55563/clinexprheumatol/3uj1ng
   Greaney SK, 2020, CANCER IMMUNOL RES, V8, P246, DOI 10.1158/2326 6066.CIR 19 0359
   Jin J, 2016, NAT IMMUNOL, V17, P259, DOI 10.1038/ni.3347
   Kim L, 2005, J IMMUNOL, V174, P4178, DOI 10.4049/jimmunol.174.7.4178
   Koh J, 2019, CLIN CANCER RES, V25, P4026, DOI 10.1158/1078 0432.CCR 18 3458
   Kroenke MA, 2008, J EXP MED, V205, P1535, DOI 10.1084/jem.20080159
   Langrish CL, 2004, IMMUNOL REV, V202, P96, DOI 10.1111/j.0105 2896.2004.00214.x
   Loures MAR, 2019, EXPERT REV CLIN IMMU, V15, P303, DOI 10.1080/1744666X.2019.1564039
   Shi Tong, 2012, BMC Chemical Biology, V12, P4, DOI 10.1186/1472 6769 12 4
   Teng MWL, 2015, NAT MED, V21, P719, DOI 10.1038/nm.3895
   Tran H, 2008, GENE DEV, V22, P528, DOI 10.1101/gad.463208
   Trinchieri G, 2003, NAT REV IMMUNOL, V3, P133, DOI 10.1038/nri1001
   Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597
   Wcislo Dziadecka D, 2016, POSTEP HIG MED DOSW, V70, P1198
   Wen HT, 2008, BLOOD, V111, P1797, DOI 10.1182/blood 2007 08 106443
   Wertz IE, 2004, NATURE, V430, P694, DOI 10.1038/nature02794
   Whetstine JR, 2006, CELL, V125, P467, DOI 10.1016/j.cell.2006.03.028
   Young LC, 2013, BIOCHEM CELL BIOL, V91, P369, DOI 10.1139/bcb 2012 0054
   Yu J. s., 2020, STEMEDICINE, V1, pe49, DOI [DOI 10.37175/STEMEDICINE.V1I4.49, 10.37175/stemedicine.v1i4.49]
   Zhang PJ, 2018, CELL REP, V23, P823, DOI 10.1016/j.celrep.2018.03.078
   Zhou HL, 2004, NATURE, V427, P167, DOI 10.1038/nature02273
   Zhou L, 2007, MOL CELL BIOL, V27, P2698, DOI 10.1128/MCB.00788 06
   Zhu YN, 2012, MOL CELL, V46, P408, DOI 10.1016/j.molcel.2012.05.011
NR 34
TC 2
Z9 2
U1 0
U2 3
PU CLINICAL & EXPER RHEUMATOLOGY
PI PISA
PA VIA SANTA MARIA 31, 56126 PISA, ITALY
SN 0392 856X
EI 1593 098X
J9 CLIN EXP RHEUMATOL
JI Clin. Exp. Rheumatol.
PD SEP
PY 2022
VL 40
IS 9
BP 1718
EP 1725
PG 8
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA 6E4FD
UT WOS:000883334500015
PM 34936549
DA 2025 08 17
ER

PT J
AU Abdel Maged, AE
   Gad, AM
   Wandan, SA
   Azab, SS
AF Abdel Maged, Amany E.
   Gad, Amany M.
   Wandan, Sara A.
   Azab, Samar S.
TI Efficacy and safety of Ramucirumab and methotrexate co therapy in
   rheumatoid arthritis experimental model: Involvement of angiogenic and
   immunomodulatory signaling
SO TOXICOLOGY AND APPLIED PHARMACOLOGY
LA English
DT Article
DE Adjuvant Induced Arthritis; Rats; Ramucirumab; Immune Response
ID COLLAGEN INDUCED ARTHRITIS; NF KAPPA B; OSTEOCLAST DIFFERENTIATION;
   RECEPTOR; PATHOGENESIS; APOPTOSIS; GROWTH; RAT; EXPRESSION; ADJUVANT
AB Rheumatoid arthritis (RA) is a chronic and progressive autoimmune inflammatory disease associated with irreversible joint destruction that leads to permanent motor disability and compromised quality of life. However, the main cause of RA is still unknown though stimulation of immune system and cells plays pivotal role in disease development and progression. Ramucirumab (RAM) is the monoclonal antibody against VEGF  receptor. This study aimed to investigate and evaluate the therapeutic effect of RAM with or without Methotrexate (MTX) against adjuvant induced arthritis in rats. Complete Freund's adjuvant (CFA) induced arthritic rats were treated for three consecutive weeks with MTX or RAM alone and MTX RAM co therapy. Arthritic score, gait score, ankle diameter, paw thickness, angiogenic, inflammatory cytokines, bone erosion markers, and apoptotic markers were assessed to evaluate the anti arthritic effect. RAM monotherapy exhibited anti inflammatory, anti angiogenic and anti apoptotic effects similar to MTX alone to treat RA in the current study. Furthermore, RAM alone had a protective effect on bone and cartilage health better than standard anti rheumatic agent MTX. Interestingly, combined therapy of MTX and RAM produced significant differences in comparison with MTX or RAM monotherapy in all tested parameters. Moreover, the current study proved that MTX RAM co therapy has a synergistic effect.
C1 [Abdel Maged, Amany E.] NORCB, Cairo, Egypt.
   [Gad, Amany M.] Natl Org Drug Control & Res NODCAR, Dept Pharmacol, Cairo, Egypt.
   [Wandan, Sara A.; Azab, Samar S.] Ain Shams Univ, Fac Pharm, Dept Pharmacol & Toxicol, Cairo, Egypt.
C3 National Organization for Drug Control & Research (NODCAR); Egyptian
   Knowledge Bank (EKB); Ain Shams University
RP Azab, SS (通讯作者)，Ain Shams Univ, Fac Pharm, Pharmacol & Toxicol Dept, Cairo 11566, Egypt.
EM samar_saad_azab@pharma.asu.edu.eg
RI ; Gad, Amany/AAB 5425 2019
OI Azab, Samar/0000 0002 0253 8280; Gad, Amany/0000 0002 6175 184X
CR Abd Allah ARA, 2014, INT IMMUNOL, V26, P325, DOI 10.1093/intimm/dxt075
   Abdel Daim MM, 2015, IMMUNOPHARM IMMUNOT, V37, P126, DOI 10.3109/08923973.2014.998368
   Abdel Maged AE, 2018, TOXICOL APPL PHARM, V356, P65, DOI 10.1016/j.taap.2018.07.014
   Akhavani MA, 2007, SCAND J RHEUMATOL, V36, P83, DOI 10.1080/03009740701305704
   Asquith DL, 2009, EUR J IMMUNOL, V39, P2040, DOI 10.1002/eji.200939578
   Axmann R, 2009, ARTHRITIS RHEUM US, V60, P2747, DOI 10.1002/art.24781
   Azab SS, 2008, CANCER CHEMOTH PHARM, V62, P893, DOI 10.1007/s00280 008 0679 9
   Azizi G, 2014, INT J RHEUM DIS, V17, P369, DOI 10.1111/1756 185X.12280
   Bancroft JD, 2008, Theory and practice of histological techniques
   Bingham CO, 2002, J RHEUMATOL, V29, P3
   Bondeson J, 2000, J RHEUMATOL, V27, P2078
   Bowes J, 2008, RHEUMATOLOGY, V47, P399, DOI 10.1093/rheumatology/ken005
   Casak SJ, 2015, CLIN CANCER RES, V21, P3372, DOI 10.1158/1078 0432.CCR 15 0600
   Catrina AI, 2002, ANN RHEUM DIS, V61, P934, DOI 10.1136/ard.61.10.934
   Cho ML, 2006, J IMMUNOL, V176, P5652, DOI 10.4049/jimmunol.176.9.5652
   Choy E, 2012, RHEUMATOLOGY, V51, pV3, DOI 10.1093/rheumatology/kes113
   Danks L, 2002, ANN RHEUM DIS, V61, P916, DOI 10.1136/ard.61.10.916
   Dhaouadi Tarak, 2007, Tunis Med, V85, P991
   Falcon BL, 2016, PHARMACOL THERAPEUT, V164, P204, DOI 10.1016/j.pharmthera.2016.06.001
   Firestein GS, 2003, NATURE, V423, P356, DOI 10.1038/nature01661
   FIRESTEIN GS, 1995, J CLIN INVEST, V96, P1631, DOI 10.1172/JCI118202
   Fuchs CS, 2014, LANCET, V383, P31, DOI 10.1016/S0140 6736(13)61719 5
   Gaffen Sarah L, 2009, Curr Rheumatol Rep, V11, P365
   Garon EB, 2014, LANCET, V384, P665, DOI 10.1016/S0140 6736(14)60845 X
   Helyes Z, 2001, BRIT J PHARMACOL, V134, P1571, DOI 10.1038/sj.bjp.0704396
   Isomäki P, 2015, RHEUMATOLOGY, V54, P1103, DOI 10.1093/rheumatology/keu430
   Iwamoto T, 2008, FEBS J, V275, P4448, DOI 10.1111/j.1742 4658.2008.06580.x
   Jones DH, 2002, ANN RHEUM DIS, V61, P32, DOI 10.1136/ard.61.suppl_2.ii32
   Kaneko Y, 2016, ANN RHEUM DIS, V75, P1917, DOI 10.1136/annrheumdis 2015 208426
   Kemanetzoglou E, 2017, CURR NEUROL NEUROSCI, V17, DOI 10.1007/s11910 017 0742 1
   Kishimoto T, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1916
   Krause A, 2002, J IMMUNOL, V169, P6610, DOI 10.4049/jimmunol.169.11.6610
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lu J, 2000, J IMMUNOL, V164, P5922, DOI 10.4049/jimmunol.164.11.5922
   Lubberts E, 2004, ARTHRITIS RHEUM US, V50, P650, DOI 10.1002/art.20001
   Lubberts E, 2008, CYTOKINE, V41, P84, DOI 10.1016/j.cyto.2007.09.014
   Ma XX, 2013, BIOMED REP, V1, P177, DOI 10.3892/br.2012.42
   Makarov SS, 2001, ARTHRITIS RES, V3, P200, DOI 10.1186/ar300
   Mapp PI, 2012, NAT REV RHEUMATOL, V8, P390, DOI 10.1038/nrrheum.2012.80
   McInnes IB, 2011, NEW ENGL J MED, V365, P2205, DOI 10.1056/NEJMra1004965
   MIKOLAJEW M, 1969, ANN RHEUM DIS, V28, P35, DOI 10.1136/ard.28.1.35
   Mohamed AM, 2008, MALAYS J MED SCI, V15, P4
   Nagashima M, 2002, LAB INVEST, V82, P981, DOI 10.1097/01.LAB.0000022220.44511.40
   Nakahara H, 2003, ARTHRITIS RHEUM US, V48, P1521, DOI 10.1002/art.11143
   Nataraj NB, 2013, CLIN EXP IMMUNOL, V171, P155, DOI 10.1111/cei.12009
   O'Brien W, 2016, ARTHRITIS RHEUMATOL, V68, P2889, DOI 10.1002/art.39837
   O'Shea JJ, 2010, SCIENCE, V327, P1098, DOI 10.1126/science.1178334
   Paleolog E M, 1998, Angiogenesis, V2, P295, DOI 10.1023/A:1009229508096
   PANAYI GS, 1995, BRIT MED BULL, V51, P462, DOI 10.1093/oxfordjournals.bmb.a072973
   Paulos CM, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1944
   PEARSON CM, 1956, P SOC EXP BIOL MED, V91, P95, DOI 10.3181/00379727 91 22179
   Pedersen M, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar2022
   Pope RM, 2002, NAT REV IMMUNOL, V2, P527, DOI 10.1038/nri846
   Rubbert Roth A, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2666
   Sato K, 2006, J EXP MED, V203, P2673, DOI 10.1084/jem.20061775
   Smolen JS, 2007, LANCET, V370, P1861, DOI 10.1016/S0140 6736(07)60784 3
   Smolen JS, 2003, NAT REV DRUG DISCOV, V2, P473, DOI 10.1038/nrd1109
   Snekhalatha U, 2013, Z RHEUMATOL, V72, P375, DOI 10.1007/s00393 012 1083 8
   Sode J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100361
   Stuebgen JP, 2008, MUSCLE NERVE, V37, P281, DOI 10.1002/mus.20924
   Tak PP, 2000, ARTHRITIS RHEUM US, V43, P2619, DOI 10.1002/1529 0131(200012)43:12<2619::AID ANR1>3.0.CO;2 V
   Tak PP, 2000, ARTHRITIS RES, V2, P229, DOI 10.1186/ar92
   Taylor PC, 2002, ARTHRITIS RES THER, V4, pS99, DOI 10.1186/ar582
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Wang Y, 2013, INFLAMMATION, V36, P1460, DOI 10.1007/s10753 013 9687 y
   Wild R, 2000, MICROVASC RES, V59, P368, DOI 10.1006/mvre.1999.2233
   Yang XXO, 2007, J BIOL CHEM, V282, P9358, DOI 10.1074/jbc.C600321200
NR 67
TC 22
Z9 23
U1 0
U2 9
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0041 008X
EI 1096 0333
J9 TOXICOL APPL PHARM
JI Toxicol. Appl. Pharmacol.
PD OCT 1
PY 2019
VL 380
AR 114702
DI 10.1016/j.taap.2019.114702
PG 13
WC Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy; Toxicology
GA IW0IR
UT WOS:000484646100015
PM 31398424
DA 2025 08 17
ER

PT J
AU Bashir, A
   Mak, Y
   Sankaralingam, S
   Cheung, J
   Mc Gowan, NWA
   Grigoriadis, AE
   Fogelman, I
   Hampson, G
AF Bashir, A
   Mak, Y
   Sankaralingam, S
   Cheung, J
   Mc Gowan, NWA
   Grigoriadis, AE
   Fogelman, I
   Hampson, G
TI Changes in RANKL/OPG/RANK gene expression in peripheral mononuclear
   cells following treatment with estrogen or raloxifene
SO STEROIDS
LA English
DT Article
DE RANKL; RANK; OPG; mononuclear cells; estrogen
ID HORMONE REPLACEMENT THERAPY; POSTMENOPAUSAL WOMEN; RANK LIGAND; BONE
   LOSS; CIRCULATING OSTEOPROTEGERIN; OSTEOCLAST FORMATION; RECEPTOR
   ACTIVATOR; MECHANISM; CYTOKINES; RESORPTION
AB The RANKL/OPG/RANK pathway is the key mediator of osteoclastogenesis. Mononuclear cells may be implicated in post menopausal osteoporosis. The effect of estrogen or raloxifene on bone resorption and the expression of RANKL/OPG/RANK in peripheral blood mononuclear cells (PBMCs) was examined. Twenty nine women with post menopausal osteoporosis were treated with estrogen (HRT) or raloxifene for 12 months. Bone mineral density (BMD) was measured at baseline and at 12 months at the spine and hip. Serum C terminal telopeptide (CTX) and OPG were measured at baseline and at 1, 3, 6 and 12 months. PBMCs were isolated from 17 women and changes in RANKL, OPG and RANK mRNA were determined. The effects of estrogen or raloxifene in PBMCs in vitro were also assessed. BMD increased following treatment (lumbar spine % change mean [S.E.M.]: 4.3% [0.9], p < 0.00 1). Serum CTX decreased (6 months:  43.7% [6.0], p < 0.0001). Serum OPG declined gradually (12 months:  26.4% [4.4], p < 0.001). RANKL, OPG and RANK gene expression decreased (6 months: RANKL 50.0% [24.8] p < 0.00 1, OPG: 21.7% [28] p < 0.001, RANK: 76.6% [10.2] p = 0.0 15). Changes in OPG mRNA correlated with changes in BMD (r =  0.53, p = 0.027) and CTX (r = 0.7, p = 0.0044). Down regulation in RANKL, OPG, RANK mRNA and reduction in bone resorption was also seen in vitro. These results suggest that the expression of RANKL/OPG/RANK in PBMCs are responsive to the slowing in bone tumover/remodeling associated with treatment with estrogen or raloxifene. Further confirmatory studies are needed. (c) 2005 Elsevier Inc. All rights reserved.
C1 St Thomas Hosp, Dept Chem Pathol, London SE1 7EH, England.
   Kings Coll London, Guys Hosp, Dept Craniofacial Dev, London SE1 9RT, England.
   Guys Hosp, Osteoporosis Screening & Res Unit, London SE1 9RT, England.
C3 Guy's & St Thomas' NHS Foundation Trust; University of London; King's
   College London; Guy's & St Thomas' NHS Foundation Trust; Guy's & St
   Thomas' NHS Foundation Trust
RP Hampson, G (通讯作者)，St Thomas Hosp, Dept Chem Pathol, 5th Floor,N Wing,Lambeth Palace Rd, London SE1 7EH, England.
EM geeta.hampson@kcl.ac.uk
OI Grigoriadis, Anita/0000 0003 3434 201X
CR Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593
   Bernard Poenaru O, 2001, OSTEOPOROSIS INT, V12, P769, DOI 10.1007/s001980170054
   Cenci S, 2000, J CLIN INVEST, V106, P1229, DOI 10.1172/JCI11066
   Cenci S, 2003, P NATL ACAD SCI USA, V100, P10405, DOI 10.1073/pnas.1533207100
   Chesnut CH, 1997, AM J MED, V102, P29, DOI 10.1016/S0002 9343(96)00387 7
   Cheung J, 2003, J ENDOCRINOL, V177, P423, DOI 10.1677/joe.0.1770423
   COHENSOLAL ME, 1993, J CLIN ENDOCR METAB, V77, P1648, DOI 10.1210/jc.77.6.1648
   Eghbali Fatourechi G, 2003, J CLIN INVEST, V111, P1221, DOI 10.1172/JCI200317215
   Erben RG, 1998, AM J PHYSIOL ENDOC M, V274, pE476
   Ettinger B, 1999, JAMA J AM MED ASSOC, V282, P637, DOI 10.1001/jama.282.7.637
   HEANEY LG, 1994, EUR RESPIR J, V7, P1527, DOI 10.1183/09031936.94.07081527
   Hofbauer LC, 2000, J BONE MINER RES, V15, P2, DOI 10.1359/jbmr.2000.15.1.2
   Hofbauer LC, 2004, CLIN ENDOCRINOL, V60, P214, DOI 10.1046/j.1365 2265.2003.01969.x
   Hofbauer LC, 1999, ENDOCRINOLOGY, V140, P4367, DOI 10.1210/en.140.9.4367
   Jevon M, 2002, J ENDOCRINOL, V172, P673, DOI 10.1677/joe.0.1720673
   Khosla S, 2002, J CLIN ENDOCR METAB, V87, P1443, DOI 10.1210/jc.87.4.1443
   Khosla S, 2002, J CLIN ENDOCR METAB, V87, P1550, DOI 10.1210/jc.87.4.1550
   MANOLAGAS SC, 1995, NEW ENGL J MED, V332, P305, DOI 10.1056/NEJM199502023320506
   MASUZAWA T, 1994, J CLIN INVEST, V94, P1090, DOI 10.1172/JCI117424
   MATTHEWS JNS, 1990, BMJ BRIT MED J, V300, P230, DOI 10.1136/bmj.300.6719.230
   Pacifici R, 1996, J BONE MINER RES, V11, P1043
   PACIFICI R, 1991, P NATL ACAD SCI USA, V88, P5134, DOI 10.1073/pnas.88.12.5134
   Riggs BL, 2002, ENDOCR REV, V23, P279, DOI 10.1210/er.23.3.279
   Roggia C, 2001, P NATL ACAD SCI USA, V98, P13960, DOI 10.1073/pnas.251534698
   Saika M, 2001, ENDOCRINOLOGY, V142, P2205, DOI 10.1210/en.142.6.2205
   Shalhoub V, 2000, BRIT J HAEMATOL, V111, P501, DOI 10.1046/j.1365 2141.2000.02379.x
   Shevde NK, 1996, BLOOD, V87, P2683, DOI 10.1182/blood.V87.7.2683.bloodjournal8772683
   Shevde NK, 2000, P NATL ACAD SCI USA, V97, P7829, DOI 10.1073/pnas.130200197
   Srivastava S, 2001, J BIOL CHEM, V276, P8836, DOI 10.1074/jbc.M010764200
   Tan KB, 1997, GENE, V204, P35, DOI 10.1016/S0378 1119(97)00509 X
   Taranta A, 2002, BONE, V30, P368, DOI 10.1016/S8756 3282(01)00685 8
   Torgerson DJ, 2001, JAMA J AM MED ASSOC, V285, P2891, DOI 10.1001/jama.285.22.2891
   Yano K, 1999, J BONE MINER RES, V14, P518, DOI 10.1359/jbmr.1999.14.4.518
NR 33
TC 32
Z9 43
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0039 128X
EI 1878 5867
J9 STEROIDS
JI Steroids
PD DEC 1
PY 2005
VL 70
IS 13
BP 847
EP 855
DI 10.1016/j.steroids.2005.04.011
PG 9
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA 984YV
UT WOS:000233344200001
PM 16005483
DA 2025 08 17
ER

PT J
AU Williams, SA
   Maecker, HL
   French, DM
   Liu, JF
   Gregg, A
   Silverstein, LB
   Cao, TC
   Carano, RAD
   Dixit, VM
AF Williams, Samuel A.
   Maecker, Heather L.
   French, Dorothy M.
   Liu, Jinfeng
   Gregg, Andrew
   Silverstein, Leah B.
   Cao, Tim C.
   Carano, Richard A. D.
   Dixit, Vishva M.
TI USP1 Deubiquitinates ID Proteins to Preserve a Mesenchymal Stem Cell
   Program in Osteosarcoma
SO CELL
LA English
DT Article
ID LOOP HELIX PROTEINS; UBIQUITIN PROTEASOME PATHWAY; FANCONI ANEMIA
   PATHWAY; OSTEOBLAST DIFFERENTIATION; RETINOBLASTOMA PROTEIN; GROWTH
   ARREST; IN VIVO; CANCER; GENE; MICE
AB Inhibitors of DNA binding (IDs) antagonize basic helix loop helix (bHLH) transcription factors to inhibit differentiation and maintain stem cell fate. ID ubiquitination and proteasomal degradation occur in differentiated tissues, but IDs in many neoplasms appear to escape degradation. We show that the deubiquitinating enzyme USP1 promotes ID protein stability and stem cell like characteristics in osteosarcoma. USP1 bound, deubiquitinated, and thereby stabilized ID1, ID2, and ID3. A subset of primary human osteosarcomas coordinately overexpressed USP1 and ID proteins. USP1 knockdown in osteosarcoma cells precipitated ID protein destabilization, cell cycle arrest, and osteogenic differentiation. Conversely, ectopic USP1 expression in mesenchymal stem cells stabilized ID proteins, inhibited osteoblastic differentiation, and enhanced proliferation. Consistent with USP1 functioning in normal mesenchymal stem cells, USP1 deficient mice were osteopenic. Our observations implicate USP1 in preservation of the stem cell state that characterizes osteosarcoma and identify USP1 as a target for differentiation therapy.
C1 [Williams, Samuel A.; Gregg, Andrew; Silverstein, Leah B.; Dixit, Vishva M.] Genentech Inc, Dept Physiol Chem, San Francisco, CA 94080 USA.
   [Maecker, Heather L.] Genentech Inc, Dept Translat Oncol, San Francisco, CA 94080 USA.
   [French, Dorothy M.] Genentech Inc, Dept Pathol, San Francisco, CA 94080 USA.
   [Liu, Jinfeng] Genentech Inc, Dept Bioinformat, San Francisco, CA 94080 USA.
   [Cao, Tim C.; Carano, Richard A. D.] Genentech Inc, Dept Biomed Imaging, San Francisco, CA 94080 USA.
C3 Roche Holding; Roche Holding USA; Genentech; Roche Holding; Genentech;
   Roche Holding USA; Roche Holding; Genentech; Roche Holding USA; Roche
   Holding; Genentech; Roche Holding USA; Roche Holding; Roche Holding USA;
   Genentech
RP Dixit, VM (通讯作者)，Genentech Inc, Dept Physiol Chem, 1 DNA Way, San Francisco, CA 94080 USA.
EM dixit@gene.com
RI ; dixit, vishva/A 4496 2012
OI Liu, Jinfeng/0000 0002 0343 8222; Maecker, Heather/0000 0002 5378 1141;
   Williams, Samuel/0000 0003 2642 3039
CR Bounpheng MA, 1999, FASEB J, V13, P2257, DOI 10.1096/fasebj.13.15.2257
   Ciarapica R, 2009, ONCOGENE, V28, P1881, DOI 10.1038/onc.2009.56
   Cohn MA, 2007, MOL CELL, V28, P786, DOI 10.1016/j.molcel.2007.09.031
   D'Andrea AD, 2010, NEW ENGL J MED, V362, P1909, DOI 10.1056/NEJMra0809889
   Di Fiore R, 2009, J CELL PHYSIOL, V219, P301, DOI 10.1002/jcp.21667
   Dupont S, 2009, CELL, V136, P123, DOI 10.1016/j.cell.2008.10.051
   FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0
   Funato N, 2001, MOL CELL BIOL, V21, P7416, DOI 10.1128/MCB.21.21.7416 7428.2001
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092 8674(00)81683 9
   Huang TT, 2006, NAT CELL BIOL, V8, P339, DOI 10.1038/ncb1378
   IAVARONE A, 1994, GENE DEV, V8, P1270, DOI 10.1101/gad.8.11.1270
   KASTAN MB, 1991, CANCER RES, V51, P6304
   Kenner L, 2004, J CELL BIOL, V164, P613, DOI 10.1083/jcb.200308155
   Kim D, 1999, MOL CELL BIOL, V19, P8240
   Kim JM, 2009, DEV CELL, V16, P314, DOI 10.1016/j.devcel.2009.01.001
   Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504
   Lasorella A, 2001, ONCOGENE, V20, P8326, DOI 10.1038/sj.onc.1205093
   Lasorella A, 2006, NATURE, V442, P471, DOI 10.1038/nature04895
   LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092 8674(91)90620 E
   Luo XJ, 2008, LAB INVEST, V88, P1264, DOI 10.1038/labinvest.2008.98
   Lyden D, 1999, NATURE, V401, P670, DOI 10.1038/44334
   Maeda Y, 2004, J CELL BIOCHEM, V93, P337, DOI 10.1002/jcb.20154
   Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429 440.2000
   Matsumoto T, 1998, CANCER LETT, V129, P61, DOI 10.1016/S0304 3835(98)00080 9
   Miller CW, 1996, CANCER GENET CYTOGEN, V86, P136, DOI 10.1016/0165 4608(95)00216 2
   Nielsen GP, 1998, AM J PATHOL, V153, P159, DOI 10.1016/S0002 9440(10)65556 3
   Nijman SMB, 2005, MOL CELL, V17, P331, DOI 10.1016/j.molcel.2005.01.008
   Nishimori H, 2002, ONCOGENE, V21, P8302, DOI 10.1038/sj.onc.1206025
   Oestergaard VH, 2007, MOL CELL, V28, P798, DOI 10.1016/j.molcel.2007.09.020
   Oh JH, 2006, CLIN ORTHOP RELAT R, P216, DOI 10.1097/01.blo.0000188063.56091.69
   Ozaki T, 2003, CANCER GENET CYTOGEN, V140, P145, DOI 10.1016/S0165 4608(02)00685 4
   PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092 8674(94)90482 0
   Parmar K, 2010, STEM CELLS, V28, P1186, DOI 10.1002/stem.437
   Peng Y, 2004, J BIOL CHEM, V279, P32941, DOI 10.1074/jbc.M403344200
   Peng Y, 2003, J CELL BIOCHEM, V90, P1149, DOI 10.1002/jcb.10744
   Perk J, 2005, NAT REV CANCER, V5, P603, DOI 10.1038/nrc1673
   Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945
   Prabhu S, 1997, MOL CELL BIOL, V17, P5888, DOI 10.1128/MCB.17.10.5888
   Roa S, 2008, P NATL ACAD SCI USA, V105, P16248, DOI 10.1073/pnas.0808182105
   Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905
   Sharff KA, 2009, J BIOL CHEM, V284, P649, DOI 10.1074/jbc.M806389200
   Soignet SL, 1998, NEW ENGL J MED, V339, P1341, DOI 10.1056/NEJM199811053391901
   Stock C, 2000, GENE CHROMOSOME CANC, V28, P329, DOI 10.1002/1098 2264(200007)28:3<329::AID GCC11>3.0.CO;2 F
   Suh JH, 2008, BIOCHEM BIOPH RES CO, V367, P97, DOI 10.1016/j.bbrc.2007.12.100
   Tang N, 2008, CLIN ORTHOP RELAT R, V466, P2114, DOI 10.1007/s11999 008 0335 z
   Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007
   Tupler R, 2001, NATURE, V409, P832, DOI 10.1038/35057011
   WEINTRAUB H, 1994, GENE DEV, V8, P2203, DOI 10.1101/gad.8.18.2203
   Yan Y, 1997, GENE DEV, V11, P973, DOI 10.1101/gad.11.8.973
   Yokota Y, 2002, J CELL PHYSIOL, V190, P21, DOI 10.1002/jcp.10042
   Zhang PM, 1997, NATURE, V387, P151, DOI 10.1038/387151a0
NR 51
TC 221
Z9 251
U1 3
U2 30
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 0092 8674
EI 1097 4172
J9 CELL
JI Cell
PD SEP 16
PY 2011
VL 146
IS 6
BP 917
EP 929
DI 10.1016/j.cell.2011.07.040
PG 13
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 825GB
UT WOS:000295258100014
PM 21925315
OA Bronze
DA 2025 08 17
ER

PT J
AU McCanless, JD
   Jennings, LK
   Cole, JA
   Bumgardner, JD
   Haggard, WO
AF McCanless, Jonathan D.
   Jennings, Lisa K.
   Cole, Judith A.
   Bumgardner, Joel D.
   Haggard, Warren O.
TI In vitro differentiation and biocompatibility of mesenchymal stem
   cells on a novel platelet releasate containing injectable composite
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A
LA English
DT Article
DE platelet releasate; tricalcium phosphate; alginate; osteochondrogenesis;
   mesenchymal stem cell
ID GROWTH FACTORS; UP REGULATION; TGF BETA; BONE; PROLIFERATION; ULCERS;
   GENE; RICH
AB Underlying changes in subchondral and cancellous bone precede joint degeneration in spinal discs, knees, hips, and other joints. We hypothesize that an early bone remodeling intervention therapy may alleviate or postpone the later manifestation of joint failure. Utilization of a novel biomaterial for injection deliverability to the underlying subchondral and cancellous bone during the onset of osseous changes, before severe cartilaginous damage, is proposed. In this preliminary study, we introduced novel platelet releasate containing alginate/calcium phosphate composites for this intervention therapy and evaluated them in vitro through mesenchymal stem cell biocompatibility and induction of osteochondral differentiation. DNA quantification and gene expression profiles suggested mesenchymal stem cells were directed along an osteochondral differentiation pathway, more specifically, to the immature nonhypertrophic chondrocyte phenotype. These conclusions were based on reduced mitogenic activity, a rapid upregulation followed by suppression of Runx2 transcription factor mRNA, sustained upregulation of Sox9 transcription factor mRNA and the absence of late marker expressions for both mature articular chondrocytes and osteoblasts over the course of 14 days. Initial findings in regard to the use of these materials for bone remodeling were positive and support the execution of future studies evaluating the inflammatory and angiogenic aspects of the materials. In this study, we have considered one of the many aspects of the endochondral ossification process; neovascularization and resorption of bone with an irregular physiology need to be evaluated. (C) 2011 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 100A: 220 229, 2012.
C1 [McCanless, Jonathan D.; Bumgardner, Joel D.; Haggard, Warren O.] Univ Memphis, Dept Biomed Engn, Herff Coll Engn, Memphis, TN 38152 USA.
   [Jennings, Lisa K.] Univ Tennessee, Hlth Sci Ctr, Coll Med, Dept Internal Med, Memphis, TN 38163 USA.
   [Jennings, Lisa K.] Univ Tennessee, Hlth Sci Ctr, Vasc Biol Ctr Excellence, Memphis, TN 38163 USA.
   [Cole, Judith A.] Univ Memphis, Dept Biol Sci, Coll Arts & Sci, Memphis, TN 38152 USA.
   [Bumgardner, Joel D.] Univ Tennessee, Hlth Sci Ctr, Sch Dent, Memphis, TN 38163 USA.
   [Bumgardner, Joel D.] Univ Tennessee, Hlth Sci Ctr, Dept Plast Surg, Sch Med, Memphis, TN 38163 USA.
C3 University of Memphis; University of Tennessee System; University of
   Tennessee Health Science Center; University of Tennessee System;
   University of Tennessee Health Science Center; University of Memphis;
   University of Tennessee System; University of Tennessee Health Science
   Center; University of Tennessee System; University of Tennessee Health
   Science Center
RP Haggard, WO (通讯作者)，Univ Memphis, Dept Biomed Engn, Herff Coll Engn, Memphis, TN 38152 USA.
EM whaggrd1@memphis.edu
CR Adams MA, 2006, SPINE, V31, P2151, DOI 10.1097/01.brs.0000231761.73859.2c
   Amstein C., 1985, Surface and Interfacial Aspects of Biomedical Polymers
   Anitua E, 2005, J ORTHOP RES, V23, P281, DOI 10.1016/j.orthres.2004.08.015
   Bancroft LW, 2004, RADIOL CLIN N AM, V42, P73, DOI 10.1016/S0033 8389(03)00165 9
   Beamer B, 2010, HSS J, V6, P85, DOI [10.1007/s11420 009 9129 4, DOI 10.1007/S11420 009 9129 4]
   Benneker LM, 2005, SPINE, V30, P167, DOI 10.1097/01.brs.0000150833.93248.09
   Brandt K D., 2000, Diagnosis and nonsurgical management of osteoarthritis
   Carrino JA, 2006, OSTEOARTHR CARTILAGE, V14, P1081, DOI 10.1016/j.joca.2006.05.011
   Cheng AX, 2010, J BONE MINER RES, V25, P2404, DOI 10.1002/jbmr.174
   Danielpour D, 1989, GROWTH FACTORS, V2, P61, DOI 10.3109/08977198909069082
   Dennis J E, 1992, Cell Transplant, V1, P23
   Ehrenfreund Kleinman T., 2006, Scaffolding in Tissue Engineering, P27
   El Sharkawy H, 2007, J PERIODONTOL, V78, P661, DOI 10.1902/jop.2007.060302
   Fellah BH, 2008, BIOMATERIALS, V29, P1177, DOI 10.1016/j.biomaterials.2007.11.034
   Ferro F, 2010, TISSUE ENG PT A, V16, P3657, DOI [10.1089/ten.tea.2009.0750, 10.1089/ten.TEA.2009.0750]
   Goldring SR, 2008, RHEUM DIS CLIN N AM, V34, P561, DOI 10.1016/j.rdc.2008.07.001
   Gordon S, 2005, NAT REV IMMUNOL, V5, P953, DOI 10.1038/nri1733
   HAGGARD WO, 2011, US PROVISIONAL PATEN
   Hudis M., 1974, Techniques and applications of plasma chemistry, P113
   Kalfas I H, 2001, Neurosurg Focus, V10, pE1
   Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534 5807(02)00157 0
   Kim YJ, 2006, GENE, V366, P145, DOI 10.1016/j.gene.2005.08.021
   Klinger MHF, 1997, ANAT EMBRYOL, V196, P1, DOI 10.1007/s004290050075
   KNIGHTON DR, 1990, SURG GYNECOL OBSTET, V170, P56
   KNIGHTON DR, 1986, ANN SURG, V204, P322, DOI 10.1097/00000658 198609000 00011
   Kolar P, 2010, TISSUE ENG PART B RE, V16, P427, DOI [10.1089/ten.teb.2009.0687, 10.1089/ten.TEB.2009.0687]
   Lefebvre Veronique, 2005, Birth Defects Research, V75, P200, DOI 10.1002/bdrc.20048
   Lennon DP, 2001, J CELL PHYSIOL, V187, P345, DOI 10.1002/jcp.1081
   Marie PJ, 2008, ARCH BIOCHEM BIOPHYS, V473, P98, DOI 10.1016/j.abb.2008.02.030
   MCCANLESS JD, 2010, 56 ANN M ORTH RES SO
   MCCANLESS JD, 2011, SPINE PHILA PA  0209
   Mehta S, 2008, J ORTHOP TRAUMA, V22, P433, DOI 10.1097/BOT.0b013e31817e793f
   Murakami S, 2000, P NATL ACAD SCI USA, V97, P1113, DOI 10.1073/pnas.97.3.1113
   Ng F, 2008, BLOOD, V112, P295, DOI 10.1182/blood 2007 07 103697
   Oida T, 2010, J IMMUNOL METHODS, V362, P195, DOI 10.1016/j.jim.2010.09.008
   Provot S, 2005, BIOCHEM BIOPH RES CO, V328, P658, DOI 10.1016/j.bbrc.2004.11.068
   Provot S, 2006, DEVELOPMENT, V133, P651, DOI 10.1242/dev.02258
   Remedios A, 1999, VET CLIN N AM SMALL, V29, P1029, DOI 10.1016/S0195 5616(99)50101 0
   Shankaran H, 2007, BMC SYST BIOL, V1, DOI 10.1186/1752 0509 1 48
   STEED DL, 1992, DIABETES CARE, V15, P1598, DOI 10.2337/diacare.15.11.1598
   Sun H, 2008, TRANSPL P, V40, P2645, DOI 10.1016/j.transproceed.2008.07.096
   Wang Li, 2011, Sheng Wu Gong Cheng Xue Bao, V27, P233
   WEN Q, 2011, J CELL MOL MED  0810
   Whitelaw MA, 2000, ADV AGRON, V69, P99
   Worster AA, 2000, AM J VET RES, V61, P1003, DOI 10.2460/ajvr.2000.61.1003
   Xia B, 2011, BIOLOGICALS, V39, P217, DOI 10.1016/j.biologicals.2011.04.004
   Yamashita S, 2009, EXP CELL RES, V315, P2231, DOI 10.1016/j.yexcr.2009.03.008
NR 47
TC 6
Z9 8
U1 0
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1549 3296
EI 1552 4965
J9 J BIOMED MATER RES A
JI J. Biomed. Mater. Res. Part A
PD JAN
PY 2012
VL 100A
IS 1
BP 220
EP 229
DI 10.1002/jbm.a.33256
PG 10
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA 857SV
UT WOS:000297740800026
PM 22042623
DA 2025 08 17
ER

PT J
AU Jung, SM
   Lee, J
   Baek, SY
   Lee, J
   Jang, SG
   Hong, SM
   Park, JS
   Cho, ML
   Park, SH
   Kwok, SK
AF Jung, Seung Min
   Lee, Jaeseon
   Baek, Seung Ye
   Lee, Juhyun
   Jang, Se Gwang
   Hong, Seung Min
   Park, Jin Sil
   Cho, Mi La
   Park, Sung Hwan
   Kwok, Seung Ki
TI Ethyl pyruvate ameliorates inflammatory arthritis in mice
SO INTERNATIONAL IMMUNOPHARMACOLOGY
LA English
DT Article
DE Ethyl pyruvate; Pyruvate; Rheumatoid arthritis; T helper 17 cells; HMGB1
ID ACUTE LUNG INJURY; RAW 264.7 CELLS; REPERFUSION INJURY; SIGNALING
   PATHWAY; IMPROVES SURVIVAL; P38 MAPK; IN VITRO; HMGB1; MODEL; RELEASE
AB Objectives: Ethyl pyruvate (EP) is the ethyl ester of pyruvate and has antioxidative and anti inflammatory effects. This study aimed to evaluate the therapeutic effect of EP in inflammatory arthritis and to identify the underlying mechanisms.
   Methods: Mice with collagen induced arthritis (CIA) were treated with the vehicle control or EP at 20 mg/kg, and clinical and histological analyses were performed on the animals. The differentiation of murine CD4 + T cells into T helper 17 (Th17) cells in the presence of EP was investigated in vitro. The effects of EP on osteoclastogenesis were determined by staining for tartrate resistant acid phosphatase, and measuring the mRNA levels of osteoclastogenesis related genes. The expression of high mobility group box 1 (HMGB1) was evaluated after EP therapy using immunohistochemical staining and Western blotting.
   Results: EP significantly improved the clinical and histological features of arthritis in CIA mice. EP suppressed the differentiation of CD4 + T cells into Th17 cells, and inhibited the expression of ROR gamma t. The generation of osteoclasts and osteoclastogenic markers from murine and human monocytes was significantly reduced in the presence of EP. The expression of HMGB1 in the synovium was significantly lower in CIA mice treated with EP, compared to control CIA mice. During osteoclastogenesis, HMGB1 release from monocytes was inhibited in the presence of EP.
   Conclusions: EP attenuated synovial inflammation and bone destruction in the experimental arthritis model through suppression of IL 17 and HMGB 1. The data suggests that EP could be a novel therapeutic agent for the treatment of inflammatory arthritis, such as rheumatoid arthritis.
C1 [Jung, Seung Min] Yonsei Univ, Coll Med, Dept Internal Med, Div Rheumatol, Seoul, South Korea.
   [Park, Sung Hwan; Kwok, Seung Ki] Catholic Univ Korea, Seoul St Marys Hosp, Dept Internal Med, Div Rheumatol,Coll Med, 222 Banpodaero, Seoul 06591, South Korea.
   [Lee, Jaeseon; Baek, Seung Ye; Lee, Juhyun; Jang, Se Gwang; Hong, Seung Min; Park, Jin Sil; Cho, Mi La; Park, Sung Hwan; Kwok, Seung Ki] Catholic Univ Korea, Coll Med, Catholic Inst Med Sci, Rheumatism Res Ctr, Seoul, South Korea.
C3 Yonsei University; Yonsei University Health System; Catholic University
   of Korea; Seoul St. Mary's Hospital; Catholic University of Korea
RP Kwok, SK (通讯作者)，Catholic Univ Korea, Seoul St Marys Hosp, Dept Internal Med, Div Rheumatol,Coll Med, 222 Banpodaero, Seoul 06591, South Korea.
EM seungki73@catholic.ac.kr
RI Jung, SeungHyun/HTS 1049 2023
OI Jung, Seung Min/0000 0003 3465 2181
FU Basic Science Research Program through the National Research Foundation
   of Korea (NRF)   Ministry of Education, ICT and Future Planning
   [2015R1A2A2A01003886]
FX LThis research was supported by the Basic Science Research Program
   through the National Research Foundation of Korea (NRF) funded by the
   Ministry of Education, ICT and Future Planning (2015R1A2A2A01003886).
CR Algieri F, 2016, BIOCHEM PHARMACOL, V103, P53, DOI 10.1016/j.bcp.2015.12.022
   ANDRAE U, 1985, TOXICOL LETT, V28, P93, DOI 10.1016/0378 4274(85)90015 3
   Bennett Guerrero E, 2009, J CARDIOTHOR VASC AN, V23, P324, DOI 10.1053/j.jvca.2008.08.005
   Brand DD, 2007, NAT PROTOC, V2, P1269, DOI 10.1038/nprot.2007.173
   Brand KA, 1997, FASEB J, V11, P388, DOI 10.1096/fasebj.11.5.9141507
   Burmester GR, 2017, LANCET, V389, P2338, DOI 10.1016/S0140 6736(17)31491 5
   Cai BL, 2009, J MOL MED, V87, P423, DOI 10.1007/s00109 009 0441 8
   Chen Y, 2013, RHEUMATOLOGY, V52, P1739, DOI 10.1093/rheumatology/ket134
   Cheng Y, 2017, BBA MOL BASIS DIS, V1863, P354, DOI 10.1016/j.bbadis.2016.11.012
   Chung KY, 2008, TRANSPL P, V40, P2136, DOI 10.1016/j.transproceed.2008.06.040
   Cruz RJ, 2011, J SURG RES, V165, P151, DOI 10.1016/j.jss.2009.07.008
   Deretic V, 2013, NAT REV IMMUNOL, V13, P722, DOI 10.1038/nri3532
   Fink MP, 2007, J INTERN MED, V261, P349, DOI 10.1111/j.1365 2796.2007.01789.x
   Gardella S, 2002, EMBO REP, V3, P995, DOI 10.1093/embo reports/kvf198
   Ha YM, 2011, BIOCHEM PHARMACOL, V82, P769, DOI 10.1016/j.bcp.2011.06.041
   Hauser B, 2005, CRIT CARE MED, V33, P2034, DOI 10.1097/01.CCM.0000178177.03979.CE
   He Z, 2012, SCAND J IMMUNOL, V76, P483, DOI 10.1111/j.1365 3083.2012.02759.x
   Jang HJ, 2012, ANTIOXID REDOX SIGN, V17, P878, DOI 10.1089/ars.2011.3994
   Kim HS, 2008, FREE RADICAL BIO MED, V45, P950, DOI 10.1016/j.freeradbiomed.2008.06.009
   Kim YM, 2016, INT IMMUNOPHARMACOL, V41, P98, DOI 10.1016/j.intimp.2016.11.002
   Kung CW, 2011, J SURG RES, V167, pE323, DOI 10.1016/j.jss.2011.01.006
   Lee SE, 2002, BONE, V30, P71, DOI 10.1016/S8756 3282(01)00657 3
   Li XT, 2002, ENDOCRINOLOGY, V143, P3105, DOI 10.1210/en.143.8.3105
   Li Y, 2015, J SURG RES, V196, P136, DOI 10.1016/j.jss.2015.02.042
   Lin YL, 2015, EXP THER MED, V9, P1537, DOI 10.3892/etm.2015.2290
   Liu J, 2009, NEUROCHEM INT, V54, P106, DOI 10.1016/j.neuint.2008.10.009
   Lu B, 2014, P NATL ACAD SCI USA, V111, P3068, DOI 10.1073/pnas.1316925111
   Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200
   McInnes IB, 2011, NEW ENGL J MED, V365, P2205, DOI 10.1056/NEJMra1004965
   Miossec P, 2009, NEW ENGL J MED, V361, P888, DOI 10.1056/NEJMra0707449
   MONTGOMERY CM, 1956, J BIOL CHEM, V221, P359
   Musumeci D, 2014, PHARMACOL THERAPEUT, V141, P347, DOI 10.1016/j.pharmthera.2013.11.001
   Ponpuak M, 2015, CURR OPIN CELL BIOL, V35, P106, DOI 10.1016/j.ceb.2015.04.016
   SALAHUDEEN AK, 1991, J CLIN INVEST, V88, P1886, DOI 10.1172/JCI115511
   Schett G, 2012, NAT REV RHEUMATOL, V8, P656, DOI 10.1038/nrrheum.2012.153
   Shen M, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/461536
   Shi Y, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/295081
   Shin JH, 2014, NEUROSCI LETT, V558, P159, DOI 10.1016/j.neulet.2013.11.006
   Sims CA, 2001, CRIT CARE MED, V29, P1513, DOI 10.1097/00003246 200108000 00003
   Smolen JS, 2016, LANCET, V388, P1984
   Song MC, 2004, J PHARMACOL EXP THER, V308, P307, DOI 10.1124/jpet.103.056622
   Su FH, 2007, ARCH SURG CHICAGO, V142, P166, DOI 10.1001/archsurg.142.2.166
   Su XF, 2011, MEDIAT INFLAMM, V2011, DOI 10.1155/2011/807142
   Tan YH, 2015, J TRAUMA ACUTE CARE, V78, P784, DOI 10.1097/TA.0000000000000588
   Tang DL, 2010, J CELL BIOL, V190, P881, DOI 10.1083/jcb.200911078
   Tawadrous ZS, 2002, SHOCK, V17, P473, DOI 10.1097/00024382 200206000 00006
   Tsoyi K, 2009, MOL PHARMACOL, V76, P173, DOI 10.1124/mol.109.055137
   Tsung A, 2005, TRANSPLANTATION, V79, P196, DOI 10.1097/01.TP.0000151681.07474.2E
   Ulloa L, 2002, P NATL ACAD SCI USA, V99, P12351, DOI 10.1073/pnas.192222999
   Wang GZ, 2013, J THORAC DIS, V5, P706, DOI 10.3978/j.issn.2072 1439.2013.08.69
   WILLEMS JL, 1978, FEBS LETT, V86, P42, DOI 10.1016/0014 5793(78)80094 5
   Woo YJ, 2004, J THORAC CARDIOV SUR, V127, P1262, DOI 10.1016/j.jtcvs.2003.11.032
   Yang H, 2015, MOL MED, V21, pS6, DOI 10.2119/molmed.2015.00087
   Yang RK, 2016, J INFLAMM LOND, V13, DOI 10.1186/s12950 016 0144 1
   Zeng JY, 2007, ANESTHESIOLOGY, V107, P630, DOI 10.1097/01.anes.0000281898.01966.1e
   Zhang YJ, 2009, J TRAUMA, V66, P1355, DOI 10.1097/TA.0b013e31817d0568
   Zhou LA, 2007, NAT IMMUNOL, V8, P967, DOI 10.1038/ni1488
   Zhu QT, 2017, MOL MED REP, V15, P1272, DOI 10.3892/mmr.2017.6118
NR 58
TC 13
Z9 14
U1 0
U2 8
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1567 5769
EI 1878 1705
J9 INT IMMUNOPHARMACOL
JI Int. Immunopharmacol.
PD NOV
PY 2017
VL 52
BP 333
EP 341
DI 10.1016/j.intimp.2017.09.027
PG 9
WC Immunology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology; Pharmacology & Pharmacy
GA FL3FK
UT WOS:000414108100045
PM 28987932
DA 2025 08 17
ER

PT J
AU Cheng, T
   Wang, MJ
   Chen, ZW
   Eisenberg, RA
   Zhang, Y
   Zou, YH
   Deng, YS
   Wang, M
   Zhou, L
AF Cheng Tao
   Wang Mingjun
   Chen Zhiwei
   Eisenberg, Robert A.
   Zhang Yu
   Zou Yaohong
   Deng Yingsu
   Wang Mian
   Zhou Ling
TI Tartrate resistant acid phosphatase 5b is a potential biomarker for
   rheumatoid arthritis: a pilot study in Han Chinese
SO CHINESE MEDICAL JOURNAL
LA English
DT Article
DE tartrate resistant acid phosphatase 5b; rheumatoid arthritis; Chinese;
   osteoclast; biologic agent
ID SERUM MARKER; REVISED CRITERIA; BONE METABOLISM; ISOFORM 5B;
   CLASSIFICATION; RECEPTOR; DISEASE
AB Background Bone damage around the joints is one of the major pathophysiological mechanisms that leads to rheumatoid arthritis (RA) chronic disability. Serum tartrate resistant acid phosphatase 5b (TRACP 5b) is secreted by osteoclasts, its activity can be used as a clinically relevant bone resorption marker. The aim of this study was to test whether the measurement of serum levels of TRACP 5b in patients with RA would correlate with measures of disease activity and with responses to therapy.
   Methods Fifty six patients were randomly assigned to receive recombinant human cytotoxic tlymphocyte associated antigen 4 immunoglobulin (RhCTLA4 Ig), infliximab or methotrexate (MTX). The clinical and serologic indicators of RA activity were evaluated at baseline and at 24 weeks. Serum TRACP 5b was measured by Enzyme linked lmmunosorbent Assay (ELISA) at 0, 12 and 24 weeks. Hand X rays were obtained at baseline.
   Results At baseline, the levels of TFtACP 5b correlated with the severity of X ray damage, disease duration (r=0.332, P=0.012), and tender joint count (r=0.408, P=0.002). The 24 weeks values of TRACP 5b for RhCTLA4 Ig group and infliximab group differed significantly from the baseline values in each group (P < 0.05; P < 0.05), whereas only the value for RhCTLA4 Ig group differed significantly from the 24 weeks value for the MTX group (P < 0.01). Considering the two biologics treated groups together, the TRACP 5b levels at 24 weeks differed significantly from the baseline values only in those patients who reached an ACR70 level (P < 0.05).
   Conclusions Measurement of serum TRACP 5b in RA patients reflects clinical and radiological measures of disease activity, treatment with certain biologics, and degree of response to therapy. TRACP 5b should be investigated further as a potential biomarker to predict response to therapy, including slowing of radiographic progression.
C1 [Cheng Tao; Wang Mingjun; Chen Zhiwei; Deng Yingsu] Soochow Univ, Affiliated Hosp 1, Dept Rheumatol, Suzhou 215000, Jiangsu, Peoples R China.
   [Zhou Ling] Soochow Univ, Affiliated Hosp 1, Dept Nephrol, Suzhou 215000, Jiangsu, Peoples R China.
   [Eisenberg, Robert A.] Univ Penn, Dept Rheumatol, Philadelphia, PA 19104 USA.
   [Zhang Yu] Subei Peoples Hosp, Dept Hematol, Yangzhou 225001, Jiangsu, Peoples R China.
   [Zou Yaohong] Wuxi First Peoples Hosp, Dept Rheumatol, Wuxi 214043, Jiangsu, Peoples R China.
   [Wang Mian] Cent South Univ, Sch Publ Hlth, Changsha 410083, Hunan, Peoples R China.
C3 Soochow University   China; Soochow University   China; University of
   Pennsylvania; Central South University
RP Zhou, L (通讯作者)，Soochow Univ, Affiliated Hosp 1, Dept Nephrol, 188 Shizi St, Suzhou 215000, Jiangsu, Peoples R China.
EM zl66060@163.com
RI zhou, ling/MTC 2736 2025
FU Shanghai CP Guojian Pharmaceutical Co, Ltd, China
FX This work was supported by Shanghai CP Guojian Pharmaceutical Co, Ltd,
   China.
CR ARNETT FC, 1988, ARTHRITIS RHEUM US, V31, P315, DOI 10.1002/art.1780310302
   Axmann R, 2008, ANN RHEUM DIS, V67, P1603, DOI 10.1136/ard.2007.080713
   Durez P, 2007, ARTHRITIS RHEUM US, V56, P3919, DOI 10.1002/art.23055
   Firestein GS, 2003, NATURE, V423, P356, DOI 10.1038/nature01661
   Gerdhem P, 2004, J BONE MINER RES, V19, P386, DOI 10.1359/JBMR.0301244
   Goronzy JJ, 2005, IMMUNOL REV, V204, P55, DOI 10.1111/j.0105 2896.2005.00245.x
   Gravallese EM, 1998, AM J PATHOL, V152, P943
   Halleen JM, 2000, J BONE MINER RES, V15, P1337, DOI 10.1359/jbmr.2000.15.7.1337
   Hannon RA, 2004, BONE, V34, P187, DOI 10.1016/j.bone.2003.04.002
   HOCHBERG MC, 1992, ARTHRITIS RHEUM, V35, P498, DOI 10.1002/art.1780350502
   Janckila AJ, 2002, CLIN CHIM ACTA, V320, P49, DOI 10.1016/S0009 8981(02)00026 8
   Janckila AJ, 2001, CLIN CHEM, V47, P74
   Janckila AJ, 2008, J BONE MINER RES, V23, P1287, DOI 10.1359/JBMR.080329
   Kim N, 2005, J EXP MED, V202, P589, DOI 10.1084/jem.20050978
   Kremer JM, 2008, ARTHRITIS RHEUM, V58, P953, DOI 10.1002/art.23397
   Lee CK, 2004, ARTHRITIS RHEUM US, V50, P3831, DOI 10.1002/art.20637
   Lee SP, 2001, J BIOL CHEM, V276, P29826, DOI 10.1074/jbc.M101822200
   Mose S, 2003, ANTICANCER RES, V23, P2783
   Schett G, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2110
   STEINBROCKER O, 1949, JAMA J AM MED ASSOC, V140, P659, DOI 10.1001/jama.1949.02900430001001
   Suematsu Ayako, 2007, Mod Rheumatol, V17, P17
   Terpos E, 2003, INT J CANCER, V106, P455, DOI 10.1002/ijc.11247
   Tsai SH, 2007, MAYO CLIN PROC, V82, P917, DOI 10.4065/82.8.917
   YAZIJI H, 1995, AM J CLIN PATHOL, V104, P397
   Zhao SA, 2011, CHINESE MED J PEKING, V124, P3058, DOI 10.3760/cma.j.issn.0366 6999.2011.19.019
NR 25
TC 12
Z9 14
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0366 6999
EI 2542 5641
J9 CHINESE MED J PEKING
JI Chin. Med. J.
PD AUG 20
PY 2014
VL 127
IS 16
BP 2894
EP 2899
DI 10.3760/cma.j.issn.0366 6999.20140670
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA AY3OD
UT WOS:000347491900003
PM 25131223
OA gold
DA 2025 08 17
ER

PT J
AU Zhang, WT
   Lee, WY
   Siegel, DS
   Tolias, P
   Zilberberg, J
AF Zhang, Wenting
   Lee, Woo Y.
   Siegel, David S.
   Tolias, Peter
   Zilberberg, Jenny
TI Patient Specific 3D Microfluidic Tissue Model for Multiple Myeloma
SO TISSUE ENGINEERING PART C METHODS
LA English
DT Article
ID HU MODEL; CELLS; GROWTH; EXPANSION
AB In vitro culturing of primary multiple myeloma cells (MMC) has been a major challenge as this plasma cell malignancy depends on the bone marrow environment for its survival. Using a microfluidic platform to emulate the dynamic physiology of the bone marrow microenvironment, we report here a new approach for culturing difficult to preserve primary human MMC. The system uses a three dimensional ossified tissue to mimic the tumor niche and recapitulate interactions between bone marrow cells and osteoblasts (OSB). To this end, the human fetal OSB cell line hFOB 1.19 was cultured in an eight chamber microfluidic culture device to facilitate the seeding of mononuclear cells from bone marrow aspirates from three multiple myeloma patients. Optical microscopy, used for real time monitoring of mononuclear cell interactions with the ossified tissue, confirmed that these are drawn toward the OSB layer. After 3 weeks, cocultures were characterized by flow cytometry to evaluate the amount of expansion of primary MMC (with CD138(+) and CD38(+) CD56(+) phenotypes) in this system. For each of the three patients analyzed, bone marrow mononuclear cells underwent, on an average, 2 to 5 expansions; CD38(+) CD56(+) cells underwent 1 to 3 expansions and CD138(+) cells underwent 2.5 to 4.6 expansions. This approach is expected to provide a new avenue that can facilitate: (1) testing of personalized therapeutics for multiple myeloma patients; (2) evaluation of new drugs without the need for costly animal models; and (3) studying the biology of multiple myeloma, and in particular, the mechanisms responsible for drug resistance and relapse.
C1 [Zhang, Wenting; Lee, Woo Y.; Tolias, Peter] Stevens Inst Technol, Hoboken, NJ 07030 USA.
   [Siegel, David S.] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Hackensack, NJ 07601 USA.
   [Zilberberg, Jenny] Hackensack Univ, Med Ctr, Dept Res, Hackensack, NJ 07601 USA.
C3 Stevens Institute of Technology; Hackensack University Medical Center;
   Hackensack University Medical Center
RP Zilberberg, J (通讯作者)，Hackensack Univ, Med Ctr, Jurist Res Bldg,Room 350,40 Prospect Ave, Hackensack, NJ 07601 USA.
EM jzilberberg@hackensackumc.org
RI Zhang, Wenting/AAU 5182 2020
OI Zilberberg, Jenny/0000 0002 4139 2616
FU Center for Healthcare Innovation at the Stevens Institute of Technology;
   John Theurer Cancer Center at Hackensack university Medical Center
FX This research was supported jointly by the Center for Healthcare
   Innovation at the Stevens Institute of Technology and the John Theurer
   Cancer Center at Hackensack university Medical Center.
CR Calimeri T, 2011, LEUKEMIA, V25, P707, DOI 10.1038/leu.2010.300
   Damiano JS, 1999, BLOOD, V93, P1658, DOI 10.1182/blood.V93.5.1658
   Groen RWJ, 2011, HAEMATOL HEMATOL J, V96, P1653, DOI 10.3324/haematol.2010.038133
   Kirshner J, 2008, BLOOD, V112, P2935, DOI 10.1182/blood 2008 02 142430
   Lee JH, 2008, BIOMED MICRODEVICES, V10, P489, DOI 10.1007/s10544 007 9157 0
   Lee JH, 2011, TISSUE ENG PART C ME, V17, P39, DOI 10.1089/ten.TEC.2010.0285
   Lee JH, 2012, BIOMATERIALS, V33, P999, DOI 10.1016/j.biomaterials.2011.10.036
   Neri P, 2012, CURR CANCER DRUG TAR, V12, P776, DOI 10.2174/156800912802429337
   Rajkumar SV, 2013, AM J HEMATOL, V88, P225, DOI 10.1002/ajh.23390
   Roodman GD, 2011, BONE, V48, P135, DOI 10.1016/j.bone.2010.06.016
   Roodman GD, 2010, J BONE MINER METAB, V28, P244, DOI 10.1007/s00774 009 0154 7
   Wells AD, 1997, J CLIN INVEST, V100, P3173, DOI 10.1172/JCI119873
   Yaccoby S, 1999, BLOOD, V94, P3576, DOI 10.1182/blood.V94.10.3576.422k01_3576_3582
   Yaccoby S, 1998, BLOOD, V92, P2908, DOI 10.1182/blood.V92.8.2908.420a32_2908_2913
   Yaccoby S, 2002, BLOOD, V100, P4162, DOI 10.1182/blood 2002 03 0939
   Yata K, 2004, LEUKEMIA, V18, P1891, DOI 10.1038/sj.leu.2403513
   Zlei M, 2007, EXP HEMATOL, V35, P1550, DOI 10.1016/j.exphem.2007.06.016
NR 17
TC 68
Z9 85
U1 0
U2 26
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1937 3384
EI 1937 3392
J9 TISSUE ENG PART C ME
JI Tissue Eng. Part C Methods
PD AUG
PY 2014
VL 20
IS 8
BP 663
EP 670
DI 10.1089/ten.tec.2013.0490
PG 8
WC Cell & Tissue Engineering; Cell Biology; Engineering, Biomedical;
   Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Engineering; Materials Science
GA AN3XF
UT WOS:000340521300006
PM 24294886
DA 2025 08 17
ER

PT J
AU Xie, PP
   Xue, W
   Qi, WY
   Li, Y
   Yang, L
   Yang, ZJ
   Shi, AX
AF Xie, Panpan
   Xue, Wei
   Qi, Wenyuan
   Li, Yang
   Yang, Lei
   Yang, Zhaojun
   Shi, Aixin
TI Safety, Tolerability, and Pharmacokinetics of Ibuprofenamine
   Hydrochloride Spray (NSAIDs), a New Drug for Rheumatoid Arthritis and
   Osteoarthritis, in Healthy Chinese Subjects
SO DRUG DESIGN DEVELOPMENT AND THERAPY
LA English
DT Article
DE ibuprofenamine hydrochloride spray; tolerability; safety;
   pharmacokinetics
ID CHRONIC KNEE PAIN; TRANSDERMAL DELIVERY; TOPICAL IBUPROFEN;
   PHARMACODYNAMICS; STRATEGIES; DESIGN
AB Background: Ibuprofenamine hydrochloride spray is novel transdermal nonsteroidal anti inflammatory drugs (NSAIDs), under clinical development for the treatment of Rheumatoid Arthritis and Osteoarthritis as a novel transdermal drug.
   Methods: A single and multiple ascending dose study investigated the safety, tolerability and pharmacokinetics of ibuprofenamine hydrochloride in healthy Chinese subjects. A total of 34 subjects (single dose study: 34 subjects and multiple dose study: 20 subjects) were involved in the trial. In the single dose study, subjects were assigned to one of the four groups received 35, 70, 140, 280 mg. In the 70 mg and 140 mg treatment groups, subjects received one dose on the first day and twice a day from day 6 to 12. The starting dose was determined considering the no observed adverse effect level based on preclinical studies, and the dose escalations in subsequent cohorts were decided based on safety, tolerability, and pharmacokinetic data from previous dose cohorts.
   Results: After a single dose, both ibuprofenamine and ibuprofen plasma exposure showed a more than dose proportional increase across a dose range of 35 280 mg. After multiple dosing, both ibuprofenamine and ibuprofen steady state exposure increased obviously more than dose proportional manner across the evaluated dose range (twice a day for 7 days) resulted in obvious accumulation. Single or multiple doses of ibuprofenamine hydrochloride were generally well tolerated and no obvious skin irritation was observed.
   Conclusion: Ibuprofenamine hydrochloride exhibited a safety and pharmacokinetic profile that supports its future investigation as a potential therapeutic for Rheumatoid Arthritis and Osteoarthritis.
C1 [Xie, Panpan; Xue, Wei; Qi, Wenyuan; Li, Yang; Yang, Lei; Shi, Aixin] Beijing Hosp, Clin Trial Ctr, Natl Ctr Gerontol, Beijing 100730, Peoples R China.
   [Xie, Panpan; Xue, Wei; Qi, Wenyuan; Li, Yang; Yang, Lei; Shi, Aixin] Chinese Acad Med Sci, Inst Geriatr Med, Beijing 100730, Peoples R China.
   [Xie, Panpan; Xue, Wei; Qi, Wenyuan; Li, Yang; Yang, Lei; Shi, Aixin] Beijing Key Lab Drug Clin Risk & Personalized Med, Beijing 100730, Peoples R China.
   [Yang, Zhaojun] Xin Chen Taifei Med Technol Co LTD, Res & Dev Dept, Tianjin 300221, Peoples R China.
C3 Beijing Hospital; Chinese Academy of Medical Sciences   Peking Union
   Medical College
RP Shi, AX (通讯作者)，1 Dahua Rd, Beijing, Peoples R China.
EM aixins0302@126.com
RI Qi, Wenyuan/OBO 2369 2025
FU Xin Chen Taifei Biochemical Technology Co. Ltd, Tianjin, China; Xin Chen
   Taifei Biochemical Technology Co. Ltd; Good Publication Practice
FX The study was funded by Xin Chen Taifei Biochemical Technology Co. Ltd,
   Tianjin, China. The authors thank all the volunteers who participated in
   this study, as well as all the investigators, site staff, and operations
   staff who participated in the study. Additionally, the authors thank
   Rundong pharmaceutical R&D (Shanghai) Co. Ltd of medical writing for
   providing medical writing assistance, which was funded by Xin Chen
   Taifei Biochemical Technology Co. Ltd, in accordance with Good
   Publication Practice guidelines.
CR Al Hanbali OA, 2019, ACTA PHARMACEUT, V69, P197, DOI 10.2478/acph 2019 0016
   Bjarnason I, 2007, ALIMENT PHARM THER, V26, P95, DOI 10.1111/j.1365 2036.2007.03348.x
   Bjarnason I, 2018, J PHARM PHARMACOL, V70, P223, DOI 10.1111/jphp.12827
   CAMPBELL J, 1994, J ACCID EMERG MED, V11, P178
   Derry S, 2008, COCHRANE DB SYST REV, V4
   García Rayado G, 2018, EXPERT REV CLIN PHAR, V11, P1031, DOI 10.1080/17512433.2018.1516143
   Gu RL, 2016, DRUG METAB PHARMACOK, V31, P51, DOI 10.1016/j.dmpk.2015.08.005
   Irvine J, 2018, DRUG DEV IND PHARM, V44, P173, DOI 10.1080/03639045.2017.1391838
   KIVISTO KT, 1994, EUR J CLIN PHARMACOL, V46, P345
   Lewis F, 2018, CLIN PHARM DRUG DEV, V7, P684, DOI 10.1002/cpdd.423
   Liu WH, 2017, EUR J PHARM SCI, V96, P530, DOI 10.1016/j.ejps.2016.10.024
   Mikulak SA, 1998, J PHARM PHARMACOL, V50, P153, DOI 10.1111/j.2042 7158.1998.tb06170.x
   N'Da DD, 2014, MOLECULES, V19, P20780, DOI 10.3390/molecules191220780
   Park I, 2008, PHARM RES DORDR, V25, P1052, DOI 10.1007/s11095 007 9470 6
   Prausnitz MR, 2008, NAT BIOTECHNOL, V26, P1261, DOI 10.1038/nbt.1504
   Tiso RL, 2010, PAIN PHYSICIAN, V13, P457
   Underwood M, 2008, BMJ BRIT MED J, V336, P138, DOI 10.1136/bmj.39399.656331.25
   Yeomans ND, 2018, ALIMENT PHARM THER, V47, P1453, DOI 10.1111/apt.14610
NR 18
TC 12
Z9 13
U1 1
U2 5
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300 008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1177 8881
J9 DRUG DES DEV THER
JI Drug Des. Dev. Ther.
PY 2021
VL 15
BP 629
EP 638
DI 10.2147/DDDT.S294849
PG 10
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA QR5UW
UT WOS:000625283400001
PM 33628011
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Cicione, C
   Muiños López, E
   Hermida Gómez, T
   Fuentes Boquete, I
   Díaz Prado, S
   Blanco, FJ
AF Cicione, Claudia
   Muinos Lopez, Emma
   Hermida Gomez, Tamara
   Fuentes Boquete, Isaac
   Diaz Prado, Silvia
   Blanco, Francisco J.
TI Effects of Severe Hypoxia on Bone Marrow Mesenchymal Stem Cells
   Differentiation Potential
SO STEM CELLS INTERNATIONAL
LA English
DT Article
ID REDUCED OXYGEN TENSION; MODELING PO(2) DISTRIBUTIONS; GENE EXPRESSION;
   IN VITRO; OSTEOGENIC DIFFERENTIATION; HEMATOPOIETIC COMPARTMENT; STROMAL
   CELLS; PROLIFERATION; CHONDROGENESIS; EXPANSION
AB Background. The interests in mesenchymal stem cells (MSCs) and their application in cell therapy have resulted in a better understanding of the basic biology of these cells. Recently hypoxia has been indicated as crucial for complete chondrogenesis. We aimed at analyzing bone marrow MSCs (BM MSCs) differentiation capacity under normoxic and severe hypoxic culture conditions. Methods. MSCs were characterized by flow cytometry and differentiated towards adipocytes, osteoblasts, and chondrocytes under normoxic or severe hypoxic conditions. The differentiations were confirmed comparing each treated point with a control point made of cells grown in DMEM and fetal bovine serum (FBS). Results. BM MSCs from the donors displayed only few phenotypical differences in surface antigens expressions. Analyzing marker genes expression levels of the treated cells compared to their control point for each lineage showed a good differentiation in normoxic conditions and the absence of this differentiation capacity in severe hypoxic cultures. Conclusions. In our experimental conditions, severe hypoxia affects the in vitro differentiation potential of BM MSCs. Adipogenic, osteogenic, and chondrogenic differentiations are absent in severe hypoxic conditions. Our work underlines that severe hypoxia slows cell differentiation by means of molecular mechanisms since a decrease in the expression of adipocyte , osteoblast , and chondrocyte specific genes was observed.
C1 [Cicione, Claudia; Muinos Lopez, Emma; Hermida Gomez, Tamara; Blanco, Francisco J.] INIBIC Hosp Univ A Coruna, Div Rheumatol, La Coruna 15006, Spain.
   [Cicione, Claudia; Muinos Lopez, Emma; Hermida Gomez, Tamara; Fuentes Boquete, Isaac; Diaz Prado, Silvia; Blanco, Francisco J.] Hosp Univ A Coruna, CIBER BBN Cellular Therapy Area, La Coruna 15006, Spain.
   [Cicione, Claudia; Muinos Lopez, Emma; Hermida Gomez, Tamara; Blanco, Francisco J.] Hosp Univ A Coruna, Catedra Bioiberica Univ A Coruna, La Coruna 15006, Spain.
   [Fuentes Boquete, Isaac; Diaz Prado, Silvia] INIBIC Univ A Coruna, Dept Med, La Coruna 15006, Spain.
   [Blanco, Francisco J.] Univ Santiago de Compostela, Dept Med, La Coruna, Spain.
   [Blanco, Francisco J.] Hosp Univ A Coruna, Osteoarticular & Aging Res Lab, La Coruna 15006, Spain.
C3 Complejo Hospitalario Universitario A Coruna; Universidade da Coruna;
   Instituto de Investigacion Biomedica de A Coruna (INIBIC); CIBER  
   Centro de Investigacion Biomedica en Red; CIBERBBN; Complejo
   Hospitalario Universitario A Coruna; Complejo Hospitalario Universitario
   A Coruna; Universidade da Coruna; Instituto de Investigacion Biomedica
   de A Coruna (INIBIC); Universidade de Santiago de Compostela; Complejo
   Hospitalario Universitario A Coruna
RP Díaz Prado, S (通讯作者)，Hosp Univ A Coruna, CIBER BBN Cellular Therapy Area, C As Xubias S N, La Coruna 15006, Spain.
EM silvia.maria.diaz.prado@sergas.es; fblagar@sergas.es
RI Cicione, Claudia/AAD 9053 2020; Blanco Garcia, Francisco J/C 3192 2014;
   DÍAZ PRADO, SILVIA/ABH 6665 2020; Gomez, Tamara/D 2972 2019; Fuentes
   Boquete, Isaac Manuel/C 8865 2015; LOPEZ, EMMA/G 1433 2016; Blanco,
   Francisco/C 3192 2014
OI Hermida Gomez, Tamara/0000 0001 7405 4595; Blanco Garcia, Francisco
   J/0000 0001 9821 7635; Diaz Prado, Silvia/0000 0001 9776 2180; cicione,
   claudia/0000 0003 1351 3641
FU Servizo Galego de Saude, Xunta de Galicia [PS07/84]; Catedra Bioiberica
   de la Universidade da Coruna; Instituto de Salud Carlos III [CIBER BBN
   CB06 01 0040]; Ministerio Ciencia e Innovacion [PLE2009 0144]; Fondo
   Investigacion Sanitaria [PI 08/2028]; FEDER (European Community); Fondo
   de Investigacion Sanitaria, Spain; Rheumatology Spanish Foundation,
   Spain
FX This study was supported by Grants from Servizo Galego de Saude, Xunta
   de Galicia (PS07/84), Catedra Bioiberica de la Universidade da Coruna
   and Instituto de Salud Carlos III CIBER BBN CB06 01 0040, Ministerio
   Ciencia e Innovacion PLE2009 0144 and Fondo Investigacion Sanitaria PI
   08/2028 with participation of funds from FEDER (European Community);
   Tamara Hermida Gomez is the beneficiary of a Contract from Fondo de
   Investigacion Sanitaria (2008), Spain. Emma Muinos Lopez is supported by
   the Rheumatology Spanish Foundation, Spain. The authors would like to
   thank P. Filgueira and M. J. Sanchez for technical assistance.
CR Barlow S, 2008, STEM CELLS DEV, V17, P1095, DOI 10.1089/scd.2007.0154
   Carrancio S, 2008, EXP HEMATOL, V36, P1014, DOI 10.1016/j.exphem.2008.03.012
   Chow DC, 2001, BIOPHYS J, V81, P675, DOI 10.1016/S0006 3495(01)75732 3
   Chow DC, 2001, BIOPHYS J, V81, P685, DOI 10.1016/S0006 3495(01)75733 5
   D'Ippolito G, 2006, BONE, V39, P513, DOI 10.1016/j.bone.2006.02.061
   Djouad F, 2005, ARTHRITIS RES THER, V7, pR1304, DOI 10.1186/ar1827
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Dos Santos F, 2010, J CELL PHYSIOL, V223, P27, DOI 10.1002/jcp.21987
   Ezashi T, 2005, P NATL ACAD SCI USA, V102, P4783, DOI 10.1073/pnas.0501283102
   Fehrer C, 2007, AGING CELL, V6, P745, DOI 10.1111/j.1474 9726.2007.00336.x
   Fink T, 2004, STEM CELLS, V22, P1346, DOI 10.1634/stemcells.2004 0038
   Genbacev O, 2000, PLACENTA, V21, pS45, DOI 10.1053/plac.1999.0523
   Giaccia AJ, 2004, GENE DEV, V18, P2183, DOI 10.1101/gad.1243304
   GRANT JL, 1963, ANN INTERN MED, V58, P801, DOI 10.7326/0003 4819 58 5 801
   Grayson WL, 2006, J CELL PHYSIOL, V207, P331, DOI 10.1002/jcp.20571
   Holzwarth C, 2010, BMC CELL BIOL, V11, DOI 10.1186/1471 2121 11 11
   Hombach Klonisch S, 2008, J MOL MED, V86, P1301, DOI 10.1007/s00109 008 0383 6
   Hung SP, 2012, J ORTHOP RES, V30, P260, DOI 10.1002/jor.21517
   Johnstone B, 1998, EXP CELL RES, V238, P265, DOI 10.1006/excr.1997.3858
   Kanichai M, 2008, J CELL PHYSIOL, V216, P708, DOI 10.1002/jcp.21446
   Koay EJ, 2008, OSTEOARTHR CARTILAGE, V16, P1450, DOI 10.1016/j.joca.2008.04.007
   Lasala GP, 2011, CARDIOVASC REVASCULA, V12, P29, DOI 10.1016/j.carrev.2010.01.001
   Lavrentieva A, 2010, CELL COMMUN SIGNAL, V8, DOI 10.1186/1478 811X 8 18
   Lee JS, 2010, STEM CELLS, V28, P1099, DOI 10.1002/stem.430
   Lennon DP, 2001, J CELL PHYSIOL, V187, P345, DOI 10.1002/jcp.1081
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Malladi P, 2006, AM J PHYSIOL CELL PH, V290, pC1139, DOI 10.1152/ajpcell.00415.2005
   Michiels C, 2002, FREE RADICAL BIO MED, V33, P1231, DOI 10.1016/S0891 5849(02)01045 6
   Minguell JJ, 2000, BRAZ J MED BIOL RES, V33, P881, DOI 10.1590/S0100 879X2000000800003
   Muraglia A, 2000, J CELL SCI, V113, P1161
   Mylotte LA, 2008, STEM CELLS, V26, P1325, DOI 10.1634/stemcells.2007 1072
   Ohnishi S, 2007, STEM CELLS, V25, P1166, DOI 10.1634/stemcells.2006 0347
   Papandreou I, 2006, CELL METAB, V3, P187, DOI 10.1016/j.cmet.2006.01.012
   Parrinello S, 2003, NAT CELL BIOL, V5, P741, DOI 10.1038/ncb1024
   Pasquinelli G, 2007, ULTRASTRUCT PATHOL, V31, P23, DOI 10.1080/01913120601169477
   Pittenger Mark F., 2008, V449, P27, DOI 10.1007/978 1 60327 169 1_2
   Potier E, 2007, BONE, V40, P1078, DOI 10.1016/j.bone.2006.11.024
   Ren HY, 2006, BIOCHEM BIOPH RES CO, V347, P12, DOI 10.1016/j.bbrc.2006.05.169
   RICHLER C, 1970, DEV BIOL, V23, P1, DOI 10.1016/S0012 1606(70)80004 5
   Robins JC, 2005, BONE, V37, P313, DOI 10.1016/j.bone.2005.04.040
   Rydén M, 2003, BIOCHEM BIOPH RES CO, V311, P391, DOI 10.1016/j.bbrc.2003.10.010
   Sakaguchi Y, 2005, ARTHRITIS RHEUM US, V52, P2521, DOI 10.1002/art.21212
   Salim A, 2004, NAT BIOTECHNOL, V22, P804, DOI 10.1038/nbt0704 804
   SAMBROOK J, 1989, MOL CLONING LAB MANU, V1
   Satija NK, 2009, J CELL MOL MED, V13, P4385, DOI 10.1111/j.1582 4934.2009.00857.x
   Sato M, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3735
   SCHOFIELD R, 1978, BLOOD CELLS, V4, P7
   Semenza GL, 2001, CELL, V107, P1, DOI 10.1016/S0092 8674(01)00518 9
   Simon MC, 2008, NAT REV MOL CELL BIO, V9, P285, DOI 10.1038/nrm2354
   Talks KL, 2000, AM J PATHOL, V157, P411, DOI 10.1016/S0002 9440(10)64554 3
   Valorani MG, 2010, CELL TISSUE RES, V341, P111, DOI 10.1007/s00441 010 0982 8
   van Oorschot AAM, 2011, J CELL MOL MED, V15, P2723, DOI 10.1111/j.1582 4934.2011.01270.x
   Wang DW, 2005, J CELL PHYSIOL, V204, P184, DOI 10.1002/jcp.20324
   Wang SN, 2010, STEM CELL RES, V4, P117, DOI 10.1016/j.scr.2009.12.002
NR 54
TC 77
Z9 82
U1 0
U2 20
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1687 966X
EI 1687 9678
J9 STEM CELLS INT
JI Stem Cells Int.
PY 2013
VL 2013
AR 232896
DI 10.1155/2013/232896
PG 11
WC Cell & Tissue Engineering
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA 218KF
UT WOS:000324430600001
PM 24082888
OA Green Published, gold, Green Submitted
DA 2025 08 17
ER

PT J
AU Devogelaer, JP
   Adler, RA
   Recknor, C
   See, K
   Warner, MR
   Wong, M
   Krohn, K
AF Devogelaer, Jean Pierre
   Adler, Robert A.
   Recknor, Chris
   See, Kyoungah
   Warner, Margaret R.
   Wong, Mayme
   Krohn, Kelly
TI Baseline Glucocorticoid Dose and Bone Mineral Density Response with
   Teriparatide or Alendronate Therapy in Patients with
   Glucocorticoid induced Osteoporosis
SO JOURNAL OF RHEUMATOLOGY
LA English
DT Article
DE GLUCOCORTICOIDS; BONE MINERAL DENSITY; TERIPARATIDE; ALENDRONATE;
   OSTEOPOROSIS
ID PARATHYROID HORMONE TREATMENT; CONTROLLED CLINICAL TRIAL; VERTEBRAL
   FRACTURE; ADVERSE EVENTS; DOUBLE BLIND; RISEDRONATE; MECHANISMS;
   PREVENTION; EPIDEMIOLOGY; MANAGEMENT
AB Objective. This post hoc analysis studied the effect of baseline glucocorticoid dose on the 18 month bone mineral density (BMD) response to teriparatide 20 mu g/day or alendronate 10 mg/day in 387 patients with glucocorticoid induced osteoporosis (GIO) from a randomized, double blind trial.
   Methods. Lumbar spine (LS), femoral neck (FN), and total hip (TH) BMD were measured at baseline and 18 months. Mean baseline glucocorticoid dose was categorized as low (<= 5 mg/day), medium (> 5 and < 15 mg/day), or high (>= 15 mg/day).
   Results. Baseline LS, FN, and TH BMD were similar between groups, and between glucocorticoid dose categories within each group. LS BMD increases at the low, medium, and high glucocorticoid doses were 8.1%, 6.6%, and 4.6%, respectively, with teriparatide, and 3.6%, 2.8%, and 2.3% with alendronate. Analyzed as a continuous variable, higher glucocorticoid doses had a negative, but nonsignificant, effect on the percentage increase in LS BMD in both groups. Glucocorticoid dose did not significantly affect FN or TH BMD increases in either group. Across the 3 glucocorticoid dose categories, the overall LS BMD increases were different for both treatments combined (p = 0.033), but the relative differences between the treatment groups were not different (interaction, p = 0.52).
   Conclusion. Teriparatide and alendronate increased LS and hip BMD across a range of baseline glucocorticoid doses. LS BMD increases with teriparatide were greater in the low dose category than in the high dose category. Overall LS BMD increases were significantly greater with teriparatide compared with alendronate, which may reflect the respective anabolic and antiresorptive mechanisms of action. Clinical Trial Registry Number: NCT00051558. (First Release Nov 15 2009; J Rheumatol 2010;37:141 8; doi:10.3899/jrheum.090411)
C1 [Devogelaer, Jean Pierre] Univ Catholique Louvain, B 1200 Brussels, Belgium.
   [Adler, Robert A.] McGuire VA Med Ctr, Richmond, VA USA.
   [Recknor, Chris] United Osteoporosis Ctr, Gainesville, GA USA.
   [See, Kyoungah; Warner, Margaret R.] Eli Lilly & Co, Indianapolis, IN 46285 USA.
   [Krohn, Kelly] Lilly USA LLC, Indianapolis, IN USA.
C3 Universite Catholique Louvain; Hunter Holmes McGuire Veterinary Affairs
   Medical Center; Eli Lilly; Lilly USA LLC
RP Devogelaer, JP (通讯作者)，St Luc Univ Hosp, Arthrit Unit, UCL 5390,Ave Hippocrate 10, B 1200 Brussels, Belgium.
EM devogelaer@uclouvain.be
FU Lilly USA, LLC
FX Lilly USA, LLC, sponsored this clinical trial.
CR Adachi JD, 2001, ARTHRITIS RHEUM US, V44, P202, DOI 10.1002/1529 0131(200101)44:1<202::AID ANR27>3.0.CO;2 W
   Adler RA, 2008, OSTEOPOROSIS, VOLS I AND II, 3RD EDITION, P1135
   Boivin GY, 2000, BONE, V27, P687, DOI 10.1016/S8756 3282(00)00376 8
   Canalis E, 2007, OSTEOPOROSIS INT, V18, P1319, DOI 10.1007/s00198 007 0394 0
   Canalis E, 2007, NEW ENGL J MED, V357, P905, DOI 10.1056/NEJMra067395
   Cohen S, 1999, ARTHRITIS RHEUM, V42, P2309, DOI 10.1002/1529 0131(199911)42:11<2309::AID ANR8>3.0.CO;2 K
   Crawford BAL, 2003, J CLIN ENDOCR METAB, V88, P3167, DOI 10.1210/jc.2002 021827
   Curtis JR, 2006, ARTHRIT RHEUM ARTHR, V55, P420, DOI 10.1002/art.21984
   Devogelaer JP, 2006, RHEUM DIS CLIN N AM, V32, P733, DOI 10.1016/j.rdc.2006.09.001
   Eastell R, 2000, OSTEOPOROSIS INT, V11, P331, DOI 10.1007/s001980070122
   Emkey R, 2003, ARTHRITIS RHEUM, V48, P1102, DOI 10.1002/art.10861
   Hoes JN, 2007, ANN RHEUM DIS, V66, P1560, DOI 10.1136/ard.2007.072157
   Jilka RL, 1999, J CLIN INVEST, V104, P439, DOI 10.1172/JCI6610
   Jilka RL, 2007, BONE, V40, P1434, DOI 10.1016/j.bone.2007.03.017
   Lane NE, 2000, J BONE MINER RES, V15, P944, DOI 10.1359/jbmr.2000.15.5.944
   Lane NE, 1998, J CLIN INVEST, V102, P1627, DOI 10.1172/JCI3914
   Lane NE, 2006, J BONE MINER RES, V21, P466, DOI 10.1359/JBMR.051103
   Mazziotti G, 2006, TRENDS ENDOCRIN MET, V17, P144, DOI 10.1016/j.tem.2006.03.009
   McDonough AK, 2008, CURR OPIN RHEUMATOL, V20, P131, DOI 10.1097/BOR.0b013e3282f51031
   Reid DM, 2001, CALCIFIED TISSUE INT, V69, P242, DOI 10.1007/s00223 001 1060 8
   Russell RGG, 2007, ANN NY ACAD SCI, V1117, P209, DOI 10.1196/annals.1402.089
   Saag KG, 2007, NEW ENGL J MED, V357, P2028, DOI 10.1056/NEJMoa071408
   Saag KG, 1998, NEW ENGL J MED, V339, P292, DOI 10.1056/NEJM199807303390502
   Sosa M, 2008, EUR J INTERN MED, V19, P51, DOI 10.1016/j.ejim.2007.08.005
   van Staa TP, 2006, CALCIFIED TISSUE INT, V79, P129, DOI 10.1007/s00223 006 0019 1
   Van Staa TP, 2000, J BONE MINER RES, V15, P993, DOI 10.1359/jbmr.2000.15.6.993
   Wallach S, 2000, CALCIFIED TISSUE INT, V67, P277, DOI 10.1007/s002230001146
   FORTEO PRODUCT LABEL
   FOSAMAX PRODUCT LABE
NR 29
TC 42
Z9 45
U1 2
U2 2
PU J RHEUMATOL PUBL CO
PI TORONTO
PA 920 YONGE ST, SUITE 115, TORONTO, ONTARIO M4W 3C7, CANADA
SN 0315 162X
J9 J RHEUMATOL
JI J. Rheumatol.
PD JAN
PY 2010
VL 37
IS 1
BP 141
EP 148
DI 10.3899/jrheum.090411
PG 8
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA 545PZ
UT WOS:000273749900022
PM 19918047
OA Bronze
DA 2025 08 17
ER

PT J
AU Polak, SJ
   Rustom, LE
   Genin, GM
   Talcott, M
   Johnson, AJW
AF Polak, S. J.
   Rustom, L. E.
   Genin, G. M.
   Talcott, M.
   Johnson, A. J. Wagoner
TI A mechanism for effective cell seeding in rigid, microporous substrates
SO ACTA BIOMATERIALIA
LA English
DT Article
DE Bone; Porosity; Cell seeding; Scaffold; Microstructure
ID CALCIUM PHOSPHATE SCAFFOLDS; MESENCHYMAL STEM CELLS; BONE;
   HYDROXYAPATITE; OSTEOINTEGRATION; OSTEOINDUCTION; BIOMATERIALS;
   CHONDROCYTES; OSTEOBLASTS; MORPHOLOGY
AB Seeding cells into porous ceramic substrates has been shown to improve outcomes in surgical repair of large bone defects, but the physics underlying cellular ingress into such scaffolds remains elusive. This paper demonstrates capillary forces as a novel, yet simple, self loading or self seeding mechanism for rigid, microporous substrates. Capillary forces were found to draw cells through a microporous network with interconnections smaller than the diameter of the cells in suspension. Work here emphasizes CaP based bone scaffolds containing both macroporosity (>100 mu m) and microporosity (5 50 mu m); these have been shown to improve bone formation in vivo as compared to their macroporous counterparts and also performed better than microporous scaffolds containing BMP 2 by some measures of bone regeneration. We hypothesize that capillary force driven self seeding in both macro  and micropores may underlie this improvement, and present a mathematical model and experiments that support this hypothesis. The cell localization and penetration depth within these two dimensional substrates in vitro depends upon both the cell type (size and stiffness) and the capillary forces generated by the microstructure. Additional experiments showing that cell penetration depth in vitro depends on cell size and stiffness suggest that microporosity could be tailored to optimize cell infiltration in a cell specific way. Endogenous cells are also drawn into the microporous network in vivo. Results have important implications for design of scaffolds for the healing of large bone defects, and for controlled release of drugs in vivo. (C) 2013 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
C1 [Polak, S. J.; Rustom, L. E.] Univ Illinois, Dept Bioengn, Urbana, IL 61801 USA.
   [Genin, G. M.] Washington Univ, Sch Med, Dept Mech Engn & Mat Sci, St Louis, MO USA.
   [Genin, G. M.] Washington Univ, Sch Med, Dept Neurol Surg, St Louis, MO USA.
   [Talcott, M.] Washington Univ, Sch Med, Div Comparat Med, St Louis, MO USA.
   [Johnson, A. J. Wagoner] Univ Illinois, Dept Mech Sci & Engn, Urbana, IL 61801 USA.
C3 University of Illinois System; University of Illinois Urbana Champaign;
   Washington University (WUSTL); Washington University (WUSTL); Washington
   University (WUSTL); University of Illinois System; University of
   Illinois Urbana Champaign
RP Johnson, AJW (通讯作者)，Univ Illinois, Dept Mech Sci & Engn, 1206 W Green St, Urbana, IL 61801 USA.
EM spolak2@illinois.edu; rustom2@illinois.edu; genin@wustl.edu;
   mtalcott@wustl.edu; ajwj@il linois.edu
RI Wagoner Johnson, Amy/C 3472 2008; Johnson, Amy/C 3472 2008
OI Wagoner Johnson, Amy/0000 0001 8396 3803; Genin, Guy/0000 0003 3612 4729
FU University of Illinois at Urbana Champaign (UIUC) College of Engineering
   Roy J. Carver Fellowship program; UIUC Support for Under Represented
   Groups in Engineering (SURGE) Fellowship Program; NSF Grant CMMI
   [09 00184 ARRA]; NSF Grant DMR [1106165]; Direct For Mathematical &
   Physical Scien; Division Of Materials Research [1106165] Funding Source:
   National Science Foundation; Div Of Civil, Mechanical, & Manufact Inn;
   Directorate For Engineering [0900184] Funding Source: National Science
   Foundation
FX Fellowship assistance was awarded to S.J.P. by the University of
   Illinois at Urbana Champaign (UIUC) College of Engineering Roy J. Carver
   Fellowship program and the UIUC Support for Under Represented Groups in
   Engineering (SURGE) Fellowship Program. The research was supported in
   part by NSF Grants CMMI No. 09 00184 ARRA and DMR No. 1106165. The PMMA
   microspheres that generated the nominally 10 mu m diameter micropores
   were kindly donated by Tetsuya Okano at Sekisui Plastics Co., Ltd.
   (Japan).
CR Alexander B, 2012, J R SOC INTERFACE, V9, P1774, DOI 10.1098/rsif.2011.0880
   Annaz B, 2004, J MICROSC OXFORD, V215, P100, DOI 10.1111/j.0022 2720.2004.01354.x
   Carragee EJ, 2011, SPINE J, V11, P471, DOI 10.1016/j.spinee.2011.04.023
   Cordell JM, 2009, J MECH BEHAV BIOMED, V2, P560, DOI 10.1016/j.jmbbm.2009.01.009
   DACULSI G, 2009, ADV MAT FUNDAMENTALS
   Darling EM, 2008, J BIOMECH, V41, P454, DOI 10.1016/j.jbiomech.2007.06.019
   Furlani D, 2009, MICROVASC RES, V77, P370, DOI 10.1016/j.mvr.2009.02.001
   Habibovic P, 2006, J BIOMED MATER RES A, V77A, P747, DOI 10.1002/jbm.a.30712
   Habibovic P, 2005, BIOMATERIALS, V26, P3565, DOI 10.1016/j.biomaterials.2004.09.056
   Harkins WD, 1919, J AM CHEM SOC, V41, P499, DOI 10.1021/ja01461a003
   Hing KA, 2005, J MATER SCI MATER M, V16, P467, DOI 10.1007/s10856 005 6988 1
   Hing KA, 2005, INT J APPL CERAM TEC, V2, P184, DOI 10.1111/j.1744 7402.2005.02020.x
   Hing KA, 2004, J BIOMED MATER RES A, V68A, P187, DOI 10.1002/jbm.a.10050
   Hochmuth RM, 2000, J BIOMECH, V33, P15, DOI 10.1016/S0021 9290(99)00175 X
   HOCHMUTH RM, 1993, BIOPHYS J, V64, P1596, DOI 10.1016/S0006 3495(93)81530 3
   Hoelzle DJ, 2008, ACTA BIOMATER, V4, P897, DOI 10.1016/j.actbio.2008.02.018
   Hoelzle DJ, 2011, J BIOMECH ENG T ASME, V133, DOI 10.1115/1.4005173
   Hollister SJ, 2011, TISSUE ENG PART B RE, V17, P459, DOI [10.1089/ten.TEB.2011.0251, 10.1089/ten.teb.2011.0251]
   Jones WR, 1999, J BIOMECH, V32, P119, DOI 10.1016/S0021 9290(98)00166 3
   LeGeros Racquel Z., 2008, P153, DOI 10.1007/978 1 59745 239 7_8
   LeGeros RZ, 2008, CHEM REV, V108, P4742, DOI 10.1021/cr800427g
   Levengood SKL, 2010, ACTA BIOMATER, V6, P3283, DOI 10.1016/j.actbio.2010.02.026
   Levengood SKL, 2010, BIOMATERIALS, V31, P3552, DOI 10.1016/j.biomaterials.2010.01.052
   Lu JX, 1999, J MATER SCI MATER M, V10, P111, DOI 10.1023/A:1008973120918
   Michna S, 2005, BIOMATERIALS, V26, P5632, DOI 10.1016/j.biomaterials.2005.02.040
   Mouton P.R., 2002, Principles and practices of unbiased stereology: An introduction for bioscientists
   Ohtsubo S, 2003, HISTOL HISTOPATHOL, V18, P153, DOI 10.14670/HH 18.153
   PARK J, 2009, BIOCERAMICS PROPERTI, P177
   Polak SJ, 2011, ACTA BIOMATER, V7, P1760, DOI 10.1016/j.actbio.2010.12.030
   Shekaran A, 2011, J BIOMED MATER RES A, V96A, P261, DOI 10.1002/jbm.a.32979
   Simon JL, 2007, J BIOMED MATER RES A, V83A, P747, DOI 10.1002/jbm.a.31329
   Stoll T, 2004, MATERIALWISS WERKST, V35, P198, DOI 10.1002/mawe.200400738
   TINGBEALL HP, 1993, BLOOD, V81, P2774
   Toma C, 2009, CIRC RES, V104, P398, DOI 10.1161/CIRCRESAHA.108.187724
   Woodard JR, 2007, BIOMATERIALS, V28, P45, DOI 10.1016/j.biomaterials.2006.08.021
   Yang L, 2008, BMC SYST BIOL, V2, DOI 10.1186/1752 0509 2 68
   Zhou Z, 2008, MATER SCI POLAND, V26, P505
NR 37
TC 53
Z9 56
U1 1
U2 54
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1742 7061
EI 1878 7568
J9 ACTA BIOMATER
JI Acta Biomater.
PD AUG
PY 2013
VL 9
IS 8
BP 7977
EP 7986
DI 10.1016/j.actbio.2013.04.040
PG 10
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA 188QD
UT WOS:000322207700038
PM 23665116
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Shikama, Y
   Nagai, Y
   Okada, S
   Oizumi, T
   Shimauchi, H
   Sugawara, S
   Endo, Y
AF Shikama, Yosuke
   Nagai, Yasuhiro
   Okada, Satoru
   Oizumi, Takefumi
   Shimauchi, Hidetoshi
   Sugawara, Shunji
   Endo, Yasuo
TI Pro IL 1β accumulation in macrophages by alendronate and its prevention
   by clodronate
SO TOXICOLOGY LETTERS
LA English
DT Article
DE Bisphosphonates; Macrophages; Interleukin 1beta
ID NITROGEN CONTAINING BISPHOSPHONATES; ENCODING MEVALONATE KINASE;
   PERIODIC FEVER SYNDROME; NECROSIS FACTOR ALPHA; ACUTE PHASE RESPONSE;
   IN VITRO; HISTIDINE DECARBOXYLASE; INFLAMMATORY ACTIONS; MOUSE
   MACROPHAGE; MICE
AB Nitrogen containing bisphosphonates (NBPs), anti bone resorptive drugs, exhibit inflammatory side effects (fever, jaw osteomyelitis or osteonecrosis, etc.). We previously reported that in mice: (i) a single intraperitoneal injection of alendronate (an NBP, 40 mu mol/kg or less) induces various inflammatory reactions, (ii) these effects, which are minimal in IL 1 deficient mice, can be prevented by co administration of clodronate (a non NBP, 40 mu mol/kg or less), and (iii) alendronate increases IL 1 beta in tissues (liver, spleen, and lung), but strangely not in blood. Here, we found the following in mice. (a) The IL 1 beta in tissues is pro IL 1 beta. (b) Unlike LPS, alendronate induces minimal activation of caspase 1 (pro IL 1 beta processing enzyme). (c) The tissue pro IL 1 beta elevations are largely absent in macrophage depleted mice. (d) In vitro, 100 mu M alendronate directly stimulates RAW 264 cells (murine macrophage like cells) to produce pro IL 1 beta, and 1 mu M clodronate inhibits this effect. These results suggest that in mice: (i) the major pro IL 1 beta producing cells in response to alendronate are macrophages, (ii) alendronate directly stimulates them to produce pro IL 1 beta, but the release of mature IL 1 beta is below detectable levels due to insufficient activation of caspase 1, and (iii) clodronate inhibits the pro IL 1 beta production by acting directly on macrophages, although the in vivo mechanism may differ from the in vitro one. (C) 2010 Elsevier Ireland Ltd. All rights reserved.
C1 [Shikama, Yosuke; Shimauchi, Hidetoshi] Tohoku Univ, Grad Sch Dent, Div Periodontol & Endodontol, Aoba Ku, Sendai, Miyagi 9808575, Japan.
   [Shikama, Yosuke; Nagai, Yasuhiro; Okada, Satoru; Oizumi, Takefumi; Sugawara, Shunji; Endo, Yasuo] Tohoku Univ, Grad Sch Dent, Div Mol Regulat, Aoba Ku, Sendai, Miyagi 9808575, Japan.
   [Shikama, Yosuke] Tokushima Univ Hosp, Clin Res Ctr Diabet, Tokushima 7708503, Japan.
C3 Tohoku University; Tohoku University; Tokushima University
RP Shikama, Y (通讯作者)，Tohoku Univ, Grad Sch Dent, Div Periodontol & Endodontol, Aoba Ku, 4 1 Seiryo Machi, Sendai, Miyagi 9808575, Japan.
EM shikama thk@umin.ac.jp
OI Nagai, Yasuhiro/0009 0004 8373 2908
FU Japan Society for the Promotion of Science [21390529]; Grants in Aid for
   Scientific Research [21390529] Funding Source: KAKEN
FX This work was supported by a grant from the Japan Society for the
   Promotion of Science (21390529). We are grateful to Dr. Robert Timms for
   editing the manuscript.
CR ADAMI S, 1987, CALCIFIED TISSUE INT, V41, P326, DOI 10.1007/BF02556671
   AUSTYN JM, 1981, EUR J IMMUNOL, V11, P805, DOI 10.1002/eji.1830111013
   Deng X, 2007, INT IMMUNOPHARMACOL, V7, P152, DOI 10.1016/j.intimp.2006.09.009
   Deng X, 2006, TOXICOL APPL PHARM, V213, P64, DOI 10.1016/j.taap.2005.09.005
   Dinarello CA, 2006, AM J CLIN NUTR, V83, p447S
   Drenth JPH, 1999, NAT GENET, V22, P178, DOI 10.1038/9696
   Endo Y, 1999, BRIT J PHARMACOL, V126, P903, DOI 10.1038/sj.bjp.0702367
   Houten SM, 1999, NAT GENET, V22, P175, DOI 10.1038/9691
   Lazarovici TS, 2009, J ORAL MAXIL SURG, V67, P850, DOI 10.1016/j.joms.2008.11.015
   Lipton Allan, 2007, Support Cancer Ther, V4, P92, DOI 10.3816/SCT.2007.n.003
   MACAROL V, 1994, AM J OPHTHALMOL, V118, P220, DOI 10.1016/S0002 9394(14)72902 2
   Makkonen N, 1999, EUR J PHARM SCI, V8, P109, DOI 10.1016/S0928 0987(98)00065 7
   Mandey SHL, 2006, ARTHRITIS RHEUM US, V54, P3690, DOI 10.1002/art.22194
   Mönkkönen H, 2006, BRIT J PHARMACOL, V147, P437, DOI 10.1038/sj.bjp.0706628
   Mönkkönen H, 2001, PHARMACEUT RES, V18, P1550, DOI 10.1023/A:1013026313647
   MONKKONEN J, 1990, PHARMACOL TOXICOL, V66, P294
   Oizumi T, 2009, BASIC CLIN PHARMACOL, V104, P384, DOI 10.1111/j.1742 7843.2008.00374.x
   Pelegrin P, 2008, J IMMUNOL, V180, P7147, DOI 10.4049/jimmunol.180.11.7147
   Roelofs AJ, 2006, CLIN CANCER RES, V12, p6222S, DOI 10.1158/1078 0432.CCR 06 0843
   Rogers Michael J., 2000, Cancer, V88, P2961, DOI 10.1002/1097 0142(20000615)88:12+<2961::AID CNCR12>3.0.CO;2 L
   Ruggiero SL, 2004, J ORAL MAXIL SURG, V62, P527, DOI 10.1016/j.joms.2004.02.004
   Sauty A, 1996, BONE, V18, P133, DOI 10.1016/8756 3282(95)00448 3
   SHIKAMA Y, INNATE IMMU IN PRESS
   SIRIS ES, 1993, LANCET, V341, P436, DOI 10.1016/0140 6736(93)93029 Z
   Sugawara S, 1998, BRIT J PHARMACOL, V125, P735, DOI 10.1038/sj.bjp.0702151
   Thiebaud D, 1997, CALCIFIED TISSUE INT, V61, P386, DOI 10.1007/s002239900353
   Töyräs A, 2003, EUR J PHARM SCI, V19, P223, DOI 10.1016/S0928 0987(03)00108 8
   VANROOIJEN N, 1994, J IMMUNOL METHODS, V174, P83
   Yamaguchi K, 2000, BRIT J PHARMACOL, V130, P1646, DOI 10.1038/sj.bjp.0703460
   Yamaguchi K, 2006, BBA MOL BASIS DIS, V1762, P269, DOI 10.1016/j.bbadis.2005.11.010
NR 30
TC 24
Z9 25
U1 0
U2 4
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378 4274
J9 TOXICOL LETT
JI Toxicol. Lett.
PD NOV 30
PY 2010
VL 199
IS 2
BP 123
EP 128
DI 10.1016/j.toxlet.2010.08.013
PG 6
WC Toxicology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Toxicology
GA 683RV
UT WOS:000284493800003
PM 20804833
DA 2025 08 17
ER

PT J
AU Zhang, C
   Xu, XX
   Trotter, TN
   Gowda, PS
   Lu, Y
   Suto, MJ
   Javed, A
   Murphy Ullrich, JE
   Li, J
   Yang, Y
AF Zhang, Chao
   Xu, Xiaoxuan
   Trotter, Timothy N.
   Gowda, Pramod S.
   Lu, Yun
   Suto, Mark J.
   Javed, Amjad
   Murphy Ullrich, Joanne E.
   Li, Juan
   Yang, Yang
TI Runx2 Deficiency in Osteoblasts Promotes Myeloma Resistance to
   Bortezomib by Increasing TSP 1 Dependent TGFβ1 Activation and
   Suppressing Immunity in Bone Marrow
SO MOLECULAR CANCER THERAPEUTICS
LA English
DT Article
ID GROWTH FACTOR BETA; TGF BETA; MULTIPLE MYELOMA; ANTITUMOR IMMUNITY;
   CELLS; PATHOGENESIS; GEMCITABINE; INHIBITION; SURVIVAL; CANCER
AB Multiple myeloma is a plasma cell malignancy that thrives in the bone marrow (BM). The proteasome inhibitor bortezomib is one of the most effective first line chemotherapeutic drugs for multiple myeloma; however, 15% to 20% of high risk patients do not respond to or become resistant to this drug and the mechanisms of che moresistance remain unclear. We previously demonstrated that multiple myeloma cells inhibit Runt related transcription factor 2 (Runx2) in pre and immature osteoblasts (OB), and that this OB Runx2 deficiency induces a cytokine rich and immunosup pressive microenvironment in the BM. In the current study, we assessed the impact of OB Runx2 deficiency on the outcome of bortezomib treatment using OB Runx2(+/+) and OB Runx2( / ) mouse models of multiple myeloma. In vitro and in vivo experiments revealed that OB Runx2 deficiency induces multiple myeloma cell resistance to bortezomib via the upregulation of immunosuppressive myeloid derived suppressor cells (MDSCs), downregulation of cytotoxic T cells, and activation of TGF(31 in the BM. In multiple myeloma tumor bearing OB Runx2( / ) mice, treatment with SRI31277, an antagonist of thrombospondin 1 (TSP 1) mediated TGF(31 activation, reversed the BM immuno suppression and significantly reduced tumor burden. Further more, treatment with SRI31277 combined with bortezomib alleviated multiple myeloma cell resistance to bortezomib induced apoptosis caused by OB Runx2 deficiency in cocultured cells and produced a synergistic effect on tumor burden in OB Runx2( / ) mice. Depletion of MDSCs by 5 fluorouracil or gemcitabine similarly reversed the immunosuppressive effects and bortezomib resistance induced by OB Runx2 deficiency in tumor bearing mice, indicating the importance of the immune environment for drug resistance and suggesting new strategies to overcome bortezomib resistance in the treatment of multiple myeloma.
C1 [Zhang, Chao; Li, Juan] Sun Yat Sen Univ, Dept Hematol, Affiliated Hosp 1, 58 Zhongshan Er Rd, Guangzhou, Peoples R China.
   [Zhang, Chao; Xu, Xiaoxuan; Trotter, Timothy N.; Gowda, Pramod S.; Lu, Yun; Murphy Ullrich, Joanne E.; Yang, Yang] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA.
   [Suto, Mark J.] Southern Res, Birmingham, AL USA.
   [Suto, Mark J.; Javed, Amjad; Murphy Ullrich, Joanne E.; Yang, Yang] Univ Alabama Birmingham, ONeal Comprehens Canc Ctr, Birmingham, AL 35294 USA.
   [Javed, Amjad] Univ Alabama Birmingham, Sch Dent, Dept Oral & Maxillofacial Surg, Birmingham, AL 35294 USA.
C3 Sun Yat Sen University; University of Alabama System; University of
   Alabama Birmingham; University of Alabama System; University of Alabama
   Birmingham; University of Alabama System; University of Alabama
   Birmingham
RP Li, J (通讯作者)，Sun Yat Sen Univ, Dept Hematol, Affiliated Hosp 1, 58 Zhongshan Er Rd, Guangzhou, Peoples R China.; Yang, Y (通讯作者)，Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA.
EM 13719209240@163.com; yangyang@uabmc.edu
OI Zhang, Chao/0000 0002 7863 0737
FU National Institutes of Health (NIH) [R01CA151538, R01CA175012,
   AR062091]; International Myeloma Foundation Senior Award; American
   Society of Hematology (ASH) Bridge Grant Award; UAB CCSG grant [P30
   CA013148]; International Program for Ph.D. Candidate, Sun Yat Sen
   University, China; Alabama Drug Discovery Alliance; NIH [P30CA013148,
   1S10OD021697, P30 AR048311, P30 AI27667]; National Institute of
   Arthritis and Musculoskeletal and Skin Diseases [R01AR062091] Funding
   Source: NIH RePORTER
FX The authors thank Dr. Fenghuang Zhan for the generous gift of 5TGM1 Luc
   multiple myeloma cells. We thank the UAB Animal Imaging Core for
   assistance with mouse bioluminescence imaging (NIH P30CA013148, NIH
   1S10OD021697) , the UAB Histomorphometry and Molecular Analysis Core for
   tissue processing, and the UAB Flow Cytometry Core for aid in flow
   experiments (NIH P30 AR048311, NIH P30 AI27667) . This work was
   supported by National Institutes of Health (NIH) grants R01CA151538 (Y.
   Yang) , R01CA175012 (J.E. Murphy Ullrich, M.J. Suto, and Y. Yang) , and
   AR062091 (A. Javed) ; an International Myeloma Foundation Senior Award
   (Y. Yang) , an American Society of Hematology (ASH) Bridge Grant Award
   (Y. Yang) , UAB CCSG P30 CA013148 grant (Y. Yang) , an International
   Program for Ph.D. Candidate, Sun Yat Sen University, China (C. Zhang) ,
   and support from the Alabama Drug Discovery Alliance (J.E.
   Murphy Ullrich and M.J. Suto) . A previous version of this article was
   edited by Dr. Erin Thacker.
CR Adhami MD, 2015, J BONE MINER RES, V30, P71, DOI 10.1002/jbmr.2321
   Amend SR, 2016, JOVE J VIS EXP, DOI 10.3791/53936
   Anderson KC, 2011, ANNU REV PATHOL MECH, V6, P249, DOI 10.1146/annurev pathol 011110 130249
   Brunen D, 2013, CELL CYCLE, V12, P2960, DOI 10.4161/cc.26034
   Caja F, 2015, J IMMUNOTOXICOL, V12, P300, DOI 10.3109/1547691X.2014.945667
   Candolfi M, 2011, NEOPLASIA, V13, P947, DOI 10.1593/neo.11024
   Ciccolini J, 2016, CANCER CHEMOTH PHARM, V78, P1, DOI 10.1007/s00280 016 3003 0
   D'Souza S, 2011, BLOOD, V118, P6871, DOI 10.1182/blood 2011 04 346775
   De Veirman K, 2019, CANCER LETT, V442, P233, DOI 10.1016/j.canlet.2018.11.002
   Di Lernia G, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020552
   Di Marzo L, 2016, ONCOTARGET, V7, P60698, DOI 10.18632/oncotarget.10849
   Faccio R, 2011, ANN NY ACAD SCI, V1237, P71, DOI 10.1111/j.1749 6632.2011.06244.x
   Frassanito MA, 2016, LEUKEMIA, V30, P640, DOI 10.1038/leu.2015.289
   Gallina G, 2006, J CLIN INVEST, V116, P2777, DOI 10.1172/JCI28828
   Giuliani N, 2005, BLOOD, V106, P2472, DOI 10.1182/blood 2004 12 4986
   Jiang Y, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.162
   Kanterman J, 2014, CANCER RES, V74, P6022, DOI 10.1158/0008 5472.CAN 14 0657
   Kariminik A, 2017, CYTOKINE, V95, P64, DOI 10.1016/j.cyto.2017.02.011
   Kawano Y, 2017, CURR CANCER DRUG TAR, V17, P806, DOI 10.2174/1568009617666170214102301
   Kumar R, 2017, NAT COMMUN, V8, DOI 10.1038/s41467 017 00068 8
   Kumar SK, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.46
   Le HK, 2009, INT IMMUNOPHARMACOL, V9, P900, DOI 10.1016/j.intimp.2009.03.015
   Lee CR, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19030869
   Li MO, 2006, ANNU REV IMMUNOL, V24, P99, DOI 10.1146/annurev.immunol.24.021605.090737
   Liu S, 2018, MOL MED REP, V17, P699, DOI 10.3892/mmr.2017.7970
   Lu AL, 2016, AM J PATHOL, V186, P678, DOI 10.1016/j.ajpath.2015.11.003
   Marvel D, 2015, J CLIN INVEST, V125, P3356, DOI 10.1172/JCI80005
   Matsumoto T, 2011, BONE, V48, P129, DOI 10.1016/j.bone.2010.05.036
   Moon JR, 2019, INT J ONCOL, V54, P2117, DOI 10.3892/ijo.2019.4776
   Murphy Ullrich JE, 2018, MATRIX BIOL, V68 69, P28, DOI 10.1016/j.matbio.2017.12.009
   NEWTON I, 1994, PESTIC SCI, V41, P187, DOI 10.1002/ps.2780410304
   Prete A, 2018, CLIN CANCER RES, V24, P6078, DOI 10.1158/1078 0432.CCR 18 0693
   Raab MS, 2009, LANCET, V374, P324, DOI 10.1016/S0140 6736(09)60221 X
   Roodman GD, 2009, LEUKEMIA, V23, P435, DOI 10.1038/leu.2008.336
   Ruan J, 2013, BONE, V57, P10, DOI 10.1016/j.bone.2013.07.024
   Sawant A, 2013, CANCER RES, V73, P6609, DOI 10.1158/0008 5472.CAN 13 0987
   Shi ML, 2011, NATURE, V474, P343, DOI 10.1038/nature10152
   Suto MJ, 2020, ACS MED CHEM LETT, V11, P1130, DOI 10.1021/acsmedchemlett.9b00540
   Sweetwyne MT, 2012, MATRIX BIOL, V31, P178, DOI 10.1016/j.matbio.2012.01.006
   Syed V, 2016, J CELL BIOCHEM, V117, P1279, DOI 10.1002/jcb.25496
   Thirukkumaran CM, 2019, BLOOD ADV, V3, P797, DOI 10.1182/bloodadvances.2018025593
   Vaidya Anuradha, 2015, Syst Synth Biol, V9, P1, DOI 10.1007/s11693 015 9161 2
   Vincent J, 2010, CANCER RES, V70, P3052, DOI 10.1158/0008 5472.CAN 09 3690
   Vodenkova S, 2020, PHARMACOL THERAPEUT, V206, DOI 10.1016/j.pharmthera.2019.107447
   Wesolowski R, 2013, J IMMUNOTHER CANCER, V1, DOI 10.1186/2051 1426 1 10
   Xu XX, 2020, CANCER RES, V80, P1036, DOI 10.1158/0008 5472.CAN 19 0284
   Yu KM, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002470
   Zaal EA, 2017, CANCER METAB, V5, DOI 10.1186/s40170 017 0169 9
   Zeng HJ, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.248
   Zhou Q, 2011, BLOOD, V117, P4501, DOI 10.1182/blood 2010 10 310425
NR 50
TC 7
Z9 8
U1 0
U2 5
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106 4404 USA
SN 1535 7163
EI 1538 8514
J9 MOL CANCER THER
JI Mol. Cancer Ther.
PD FEB
PY 2022
VL 21
IS 2
BP 347
EP 358
DI 10.1158/1535 7163.MCT 21 0310
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA YX4LM
UT WOS:000754076900001
PM 34907087
OA Green Submitted, Bronze, Green Accepted
DA 2025 08 17
ER

PT J
AU Ozel, L
   Ata, P
   Ozel, MS
   Toros, AB
   Kara, M
   Unal, E
   Canbakan, M
   Erdogrul, G
   Aktas, GE
   Titiz, MI
AF Ozel, L.
   Ata, P.
   Ozel, M. S.
   Toros, A. B.
   Kara, M.
   Unal, E.
   Canbakan, M.
   Erdogrul, G.
   Aktas, G. E.
   Titiz, M. I.
TI Risk Factors for Osteoporosis After Renal Transplantation and Effect of
   Vitamin D Receptor Bsm I Polymorphism
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 22nd Congress of the Spanish Liver Transplantation Society (SETH)
CY OCT 29 30, 2010
CL Madrid, SPAIN
SP Spanish Liver Transplantat Soc (SETH)
ID BONE MINERAL DENSITY; CYCLOSPORINE A; DISEASE; MECHANISMS
AB Objective. Rapid loss of vertebral or hip mineral density after renal transplantation is a major complication which occurs within 6 12 months. The aim of this study was to evaluate risk factors contributing to bone disease in the early stage after renal transplantation and the effect of vitamin D receptor (VDR) gene polymorphisms.
   Methods. We prospectively followed for up to 12 months 44 patients (29 men and 15 women) with end stage renal disease who underwent kidney transplantation. All patients received prednisone with either cyclosporine (CsA)/mycophenolate mofetil (MMF) or tacrolimus (Tac)/MMF therapy. Spine, hip, and whole body bone mineral density (BMD) was measured at 12 months after transplantation. According to World Health Organization recommendations, Our patients were categorized as normal, osteopenic, or osteoporotic BMD levels. VDR alleles were genotyped as BB, Bb, or bb by polymerase chain reactions based on polymorphism at the Bsm I restriction site.
   Results. Forty six percent of patients were normal, 43% osteopenic, and 11% osteoporotic. Significant risk factors for osteoporosis among renal transplant recipients were younger age and pretransplant high intact parathyroid hormone (iPTH) levels. (P values .045 and .027, respectively). According to polymorphic group categorization, posttransplant serum Ca was significantly higher in patients with BB or Bb genotype than in those with bb genotype (P = .012). Although there was no statistical significance regarding iPTH levels, it was higher among Bb+BB than the bb genotype group. Also, first year BMD analysis after transplantation according to Bsm I polymorphism showed significant differences in femur BMD levels according to the dual classification of polymorphism (P < .05). The BMD levels in the bb group was higher than in the Bb+BB group.
   Conclusions. Although high pretransplant iPTH levels and younger age enhanced posttransplant bone loss, functionally different alleles of the VDR gene may modulate bone turnover during the first year after renal transplantation.
C1 [Ozel, L.; Kara, M.; Unal, E.; Erdogrul, G.; Titiz, M. I.] Haydarpasa Numune Hosp, Dept Gen Surg & Transplantat 1, Istanbul, Turkey.
   [Ozel, M. S.] Haydarpasa Numune Hosp, Genet Dis Res Ctr, Mol Genet Lab, Dept Orthoped & Traumatol, Istanbul, Turkey.
   [Canbakan, M.] Haydarpasa Numune Hosp, Dept Nephrol, Istanbul, Turkey.
   [Aktas, G. E.] Haydarpasa Numune Hosp, Dept Nucl Med, Istanbul, Turkey.
   [Toros, A. B.] Istanbul Training & Res Hosp, Dept Internal Med, Istanbul, Turkey.
C3 Istanbul Haydarpasa Numune Training & Research Hospital; Istanbul
   Haydarpasa Numune Training & Research Hospital; Istanbul Haydarpasa
   Numune Training & Research Hospital; Istanbul Haydarpasa Numune Training
   & Research Hospital; Istanbul Training & Research Hospital
RP Ozel, L (通讯作者)，Haydarpasa Numune Hosp, Dept Gen Surg & Transplantat 1, Istanbul, Turkey.
EM drleylaozel@gmail.com
RI ATA, PINAR/AAC 9967 2020; Aktas, Gul/R 1776 2019
OI ATA, PINAR/0000 0002 6688 2347; Unal, Ethem/0000 0003 4056 4874; Ege
   Aktas, Gul/0000 0003 4880 2275; 
CR Canalis E, 1996, J CLIN ENDOCR METAB, V81, P3441, DOI 10.1210/jc.81.10.3441
   Cunningham J, 2005, TRANSPLANTATION, V79, P629, DOI 10.1097/01.TP.0000149698.79739.EF
   DELPOZO E, 1995, BONE, V16, pS271, DOI 10.1016/S8756 3282(95)80097 2
   Eknoyan G, 2003, AM J KIDNEY DIS, V41, pS1, DOI 10.1016/S0272 6386(03)00111 2
   Epstein S, 1996, J BONE MINER RES, V11, P1
   FERRARI S, 1995, LANCET, V345, P423, DOI 10.1016/S0140 6736(95)90404 2
   GROTZ WH, 1995, NEPHROL DIAL TRANSPL, V10, P2096
   HRUSKA KA, 1995, NEW ENGL J MED, V333, P166, DOI 10.1056/NEJM199507203330307
   HUSTMYER FG, 1994, J CLIN INVEST, V94, P2130, DOI 10.1172/JCI117568
   MELLITUS H, 1994, LANCET, V344, P949
   Mikuls TR, 2003, TRANSPLANTATION, V75, P49, DOI 10.1097/00007890 200301150 00009
   MORRISON NA, 1994, NATURE, V367, P284, DOI 10.1038/367284a0
   ORCEL P, 1989, J BONE MINER RES, V4, P387
   Sperschneider H, 2003, NEPHROL DIAL TRANSPL, V18, P874, DOI 10.1093/ndt/gfg029
   TORREGROSA JV, 1995, NEPHROL DIAL TRANSPL, V10, P111, DOI 10.1093/ndt/10.supp6.111
   Torres A, 1996, KIDNEY INT, V50, P1726, DOI 10.1038/ki.1996.492
   Torres A, 2002, J AM SOC NEPHROL, V13, P551, DOI 10.1681/ASN.V132551
   Weisinger JR, 2006, CLIN J AM SOC NEPHRO, V1, P1300, DOI 10.2215/CJN.01510506
NR 18
TC 12
Z9 12
U1 1
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0041 1345
EI 1873 2623
J9 TRANSPL P
JI Transplant. Proc.
PD APR
PY 2011
VL 43
IS 3
BP 858
EP 862
DI 10.1016/j.transproceed.2011.02.075
PG 5
WC Immunology; Surgery; Transplantation
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC Immunology; Surgery; Transplantation
GA 754MZ
UT WOS:000289860300045
PM 21486615
DA 2025 08 17
ER

PT J
AU Rashidi, H
   Ellis, MJ
   Cartmell, SH
   Chaudhuri, JB
AF Rashidi, Hassan
   Ellis, Marianne J.
   Cartmell, Sarah H.
   Chaudhuri, Julian B.
TI Simvastatin Release from Poly(lactide co glycolide) Membrane Scaffolds
SO POLYMERS
LA English
DT Article
DE PLGA; membrane; scaffold; statin; controlled release; bone tissue
   engineering
ID BIOMATERIAL OG PLG; FORMATION IN VITRO; HMG COA REDUCTASE;
   BONE FORMATION; STATINS; CELLS; COMPACTIN; RATS; DIFFERENTIATION;
   CERIVASTATIN
AB Statins, a group of potent inhibitors of 3 hydroxy 3 methylglutaryl Coenzyme A reductase in cholesterol biosynthesis pathway, have been widely used as a cholesterol lowering drug. The plieotrophic effect of statins on bone metabolism in long term usage has been begun to be studied during recent years and several in vitro and in vivo studies have demonstrated the ability of statins to promote expression of bone morphogenetic protein 2 (BMP 2), inhibition of osteoclast differentiation and reduction of osteoporotic fractures risk. The high liver specificity and low oral bioavailability of statins, leading to poor peripheral distribution, are the main obstacles to benefit anabolic effects of hydrophobic statins on bone formation. Therefore, developing new administration roots for direct delivery to achieve optimum concentration in the bone microenvironment is of interest. Here we present and compare two approaches of combining statins with bone tissue engineering scaffolds. Simvastatin was combined with a poly(lactide co  glycolide) (PLGA) membrane scaffold for diffusion controlled release by dissolving simvastatin (dis sim) in the membrane casting dope, and for degradation controlled release by covalently bonding saponifiedsimvastatin (sap sim) to the PLGA in the spinning dope. Rheological and concentration dependent membrane morphology changes were observed with saponifiedsimvastatin, suggesting ester bond cleavage and covalent bonding of the statin to the PLGA, but not with dissolved simvastatin. Dissolved simvastatin membranes showed a logarithmic decay release profile while the saponifiedsimvastatin membranes showed constant release. It can be concluded that the covalent bonding of simvastatinto PLGA scaffolds is showing potential for use as a controlled releasescaffold for bone tissue engineering.
C1 [Rashidi, Hassan; Ellis, Marianne J.; Chaudhuri, Julian B.] Univ Bath, Dept Chem Engn, Ctr Regenerat Med, Bath BA2 7AY, Avon, England.
   [Cartmell, Sarah H.] Univ Manchester, Ctr Mat Sci, Sch Mat, Manchester M13 9PL, Lancs, England.
C3 University of Bath; University of Manchester
RP Chaudhuri, JB (通讯作者)，Univ Bath, Dept Chem Engn, Ctr Regenerat Med, Bath BA2 7AY, Avon, England.
EM mgxhr@nottingham.ac.uk; M.J.Ellis@bath.ac.uk;
   sarah.cartmell@manchester.ac.uk; J.B.Chaudhuri@bath.ac.uk
RI Rashidi, Hassan/D 2572 2009; Chaudhuri, julian/F 5032 2012; cartmell,
   sarah/J 8506 2012; Rashidi, Hassan/N 9313 2014; Cartmell,
   Sarah/J 8506 2012
OI Rashidi, Hassan/0000 0002 9682 8288; cartmell,
   sarah/0000 0001 6864 0846; Rashidi, Hassan/0000 0001 8078 6688; Ellis,
   Marianne/0000 0003 4155 0853
FU Marie Curie
FX We would like to thank Fernando Acosta in the Department of Chemical
   Engineering and Ursula Potter in the Centre for Electron Optical Studies
   for their technical assistance, and Marie Curie for funding.
CR Bauer DC, 2003, OSTEOPOROSIS INT, V14, P273, DOI 10.1007/s00198 002 1323 x
   Benoit DSW, 2006, BIOMATERIALS, V27, P6102, DOI 10.1016/j.biomaterials.2006.06.031
   Buehler J, 2001, BONE, V29, P176, DOI 10.1016/S8756 3282(01)00484 7
   Canalis E, 1996, BONE, V18, P517, DOI 10.1016/8756 3282(96)00080 4
   Crawford DT, 2001, J BONE MINER RES, V16, pS295
   Ellis MJ, 2007, BIOTECHNOL BIOENG, V96, P177, DOI 10.1002/bit.21093
   Garrett IR, 2000, J BONE MINER RES, V15, pS225
   Garrett IR, 2002, ARTHRITIS RES, V4, P237, DOI 10.1186/ar413
   Garrett IR, 1999, J BONE MINER RES, V14, pS180
   Gasser JA, 2001, J BONE MINER RES, V16, pS295
   Jadhav SB, 2006, J PHARM PHARMACOL, V58, P3, DOI 10.1211/jpp.58.1.0002
   Maeda T, 2003, ENDOCRINOLOGY, V144, P681, DOI 10.1210/en.2002 220682
   Maeda T, 2001, BIOCHEM BIOPH RES CO, V280, P874, DOI 10.1006/bbrc.2000.4232
   Maritz FJ, 2001, ARTERIOSCL THROM VAS, V21, P1636, DOI 10.1161/hq1001.097781
   Mulder M., 1992, BASIC PRINCIPLES MEM
   Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946
   Phillips BW, 2001, BIOCHEM BIOPH RES CO, V284, P478, DOI 10.1006/bbrc.2001.4987
   Piskin E, 2009, J BIOMED MATER RES A, V90A, P1137, DOI 10.1002/jbm.a.32157
   Shearer H, 2006, TISSUE ENG, V12, P2717, DOI 10.1089/ten.2006.12.2717
   Sugiyama M, 2000, BIOCHEM BIOPH RES CO, V271, P688, DOI 10.1006/bbrc.2000.2697
   von Stechow D, 2003, BMC MUSCULOSKEL DIS, V4, DOI 10.1186/1471 2474 4 8
   Whang K, 2000, J BONE MINER RES, V15, pS225
   Whang KM, 2005, J BIOMED MATER RES A, V74A, P237, DOI 10.1002/jbm.a.30309
   Whang KM, 2005, J BIOMED MATER RES A, V74A, P247, DOI 10.1002/jbm.a.30370
   Woo JT, 2000, J BONE MINER RES, V15, P650, DOI 10.1359/jbmr.2000.15.4.650
   Yang SF, 2001, TISSUE ENG, V7, P679, DOI 10.1089/107632701753337645
   Yao W, 2001, J BONE MINER RES, V16, pS294
NR 27
TC 8
Z9 10
U1 0
U2 19
PU MDPI AG
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
SN 2073 4360
J9 POLYMERS BASEL
JI Polymers
PD DEC
PY 2010
VL 2
IS 4
BP 709
EP 718
DI 10.3390/polym2040709
PG 10
WC Polymer Science
WE Science Citation Index Expanded (SCI EXPANDED)
SC Polymer Science
GA V27GH
UT WOS:000208601200020
OA Green Submitted, gold, Green Published
DA 2025 08 17
ER

PT J
AU Chang, JF
   Kuo, HL
   Liu, SH
   Hsieh, CY
   Hsu, CP
   Hung, KC
   Wang, TM
   Wu, CC
   Lu, KC
   Lin, WN
   Hung, CF
   Ko, WC
AF Chang, Jia Feng
   Kuo, Hsiao Ling
   Liu, Shih Hao
   Hsieh, Chih Yu
   Hsu, Chih Ping
   Hung, Kuo Chin
   Wang, Ting Ming
   Wu, Chang Chin
   Lu, Kuo Cheng
   Lin, Wei Ning
   Hung, Chi Feng
   Ko, Wen Chin
TI Translational Medicine in Uremic Vascular Calcification: Scavenging ROS
   Attenuates p Cresyl Sulfate Activated Caspase 1, NLRP3 Inflammasome and
   Eicosanoid Inflammation in Human Arterial Smooth Muscle Cells
SO LIFE BASEL
LA English
DT Article
DE Caspase 1; COX2; cPLA2; IL 1 beta; inflammasome; NLRP3; p cresyl
   sulfate; pyroptosis; reactive oxygen species; uremic vascular
   calcification
ID ALKALINE PHOSPHATASE; OXIDATIVE STRESS; MECHANISMS; EVENTS; TOXINS
AB We formerly proved that uremic vascular calcification (UVC) correlates tightly with oxidative elastic lamina (EL) injury and two cell fates (apoptosis and osteocytic conversion) in smooth muscle cells (SMC) of chronic kidney disease (CKD) patients and eliminating p cresyl sulfate (PCS) activated intracellular ROS ameliorates the MAPK signaling pathway in a human arterial SMC (HASMC) model. Nonetheless, whether ROS scavenger attenuates PCS triggered inflammasome activation and eicosanoid inflammation in the UVC process remains unknown. Patients with lower extremity amputation were categorized into CKD and normal control group according to renal function. We used immunohistochemistry stain to analyze UVC in arterial specimens, including oxidative injury (8 hydroxy 2' deoxyguanosine (8 OHdG) and internal EL disruption), cytosolic phospholipase A2 (cPLA2), cyclooxygenase 2 (COX2), interleukin 1 beta (IL 1 beta), caspase 1 and NLRP3. To simulate the patho mechanism of human UVC, the therapeutic effects of ROS scavenger on PCS triggered inflammatory pathways was explored in a HASMC model. We found CKD patients had higher circulating levels of PCS and an increase in medial arterial calcification than the check control group. In CKD arteries, the severity of UVC corresponded with expressions of oxidative EL disruption and 8 OHdG. Furthermore, coupling expressions of cPLA2 and COX2 were accentuated in CKD arteries, indicative of eicosanoid inflammation. Notably, tissue expressions of IL 1 beta, caspase 1 and NLRP3 were enhanced in parallel with UVC severity, indicative of inflammasome activation. From bedside to bench, ROS scavenger attenuates PCS activated expressions of cPLA2/COX2, procaspase 1 and NLRP3 in the HASMC model. UVC as an inevitable outcome is predictive of death in CKD patients. Nonetheless, UVC remain pharmacoresistant despite the evolution of treatment for mineral parathyroid hormone vitamin D axis. Beyond the mineral dysregulation, the stimulation of pro oxidant PCS alone results in eicosanoid inflammation and inflammasome activation. Concerning the key role of Caspase 1 in pyroptosis, cell fates of HASMC in uremic milieu are not limited to apoptosis and osteogenesis. In view of this, reducing ROS and PCS may act as a therapeutic strategy for UVC related cardiovascular events in CKD patients.
C1 [Chang, Jia Feng; Hsieh, Chih Yu] En Chu Kong Hosp, Dept Internal Med, Div Nephrol, New Taipei 237414, Taiwan.
   [Chang, Jia Feng] Taipei Med Univ, Dept Internal Med, Div Nephrol, Shuang Ho Hosp, New Taipei 23561, Taiwan.
   [Chang, Jia Feng] Yuanpei Univ Med Technol, Dept Nursing, Hsinchu 30015, Taiwan.
   [Chang, Jia Feng; Hsieh, Chih Yu] Renal Care Joint Fdn, New Taipei 220, Taiwan.
   [Chang, Jia Feng] Armfulcare Hosp, Dept Internal Med, Taoyuan 32049, Taiwan.
   [Chang, Jia Feng; Hung, Kuo Chin] Min Sheng Gen Hosp, Dept Med, Div Nephrol, Taoyuan 330, Taiwan.
   [Kuo, Hsiao Ling] En Chu Kong Hosp, Dept Internal Med, Div Rheumatol, New Taipei 237414, Taiwan.
   [Liu, Shih Hao] En Chu Kong Hosp, Dept Internal Med, Div Pathol, New Taipei 237414, Taiwan.
   [Hsu, Chih Ping] Yuanpei Univ Med Technol, Dept Biotechnol & Pharmaceut Technol, Hsinchu 30015, Taiwan.
   [Hsu, Chih Ping] Yuanpei Univ Med Technol, Dept Med Lab Sci & Biotechnol, Hsinchu 30015, Taiwan.
   [Wang, Ting Ming] Natl Taiwan Univ Hosp, Dept Orthopaed Surg, Taipei 100229, Taiwan.
   [Wu, Chang Chin] En Chu Kong Hosp, Dept Orthopaed Surg, New Taipei 237414, Taiwan.
   [Lu, Kuo Cheng] Taipei Tzu Chi Hosp, Buddhist Tzu Chi Med Fdn, Dept Med, Div Nephrol, New Taipei 231405, Taiwan.
   [Lin, Wei Ning] Fu Jen Catholic Univ, Coll Med, Grad Inst Biomed & Pharmaceut Sci, New Taipei 24205, Taiwan.
   [Hung, Chi Feng; Ko, Wen Chin] Fu Jen Catholic Univ, Sch Med, New Taipei 24205, Taiwan.
   [Ko, Wen Chin] Cathay Gen Hosp, Dept Cardiovasc Ctr, Div Cardiac Electrophysiol, Taipei 106, Taiwan.
C3 Taipei Medical University; Shuang Ho Hospital; National Taiwan
   University; National Taiwan University Hospital; Buddhist Tzu Chi
   General Hospital; Taipei Tzu Chi Hospital; Fu Jen Catholic University;
   Fu Jen Catholic University; Cathay General Hospital
RP Ko, WC (通讯作者)，Fu Jen Catholic Univ, Sch Med, New Taipei 24205, Taiwan.; Ko, WC (通讯作者)，Cathay Gen Hosp, Dept Cardiovasc Ctr, Div Cardiac Electrophysiol, Taipei 106, Taiwan.
EM cjf6699@gmail.com; eckdr.kuo@gmail.com; 01393@km.eck.org.twtm;
   cyh0817@tmu.edu.tw; hsucp@mail.ypu.edu.tw; corey926@gmail.com;
   dtorth76@yahoo.com.tw; dtorth65@yahoo.com.tw; kuochenglu@gmail.com;
   081551@mail.fju.edu.tw; skin@mail.fju.edu.tw; wck@cgh.org.tw
RI Ko, Wen chin/ABI 3879 2020; Hsieh, Chih Yu/GWQ 8343 2022; Hung,
   Chi Feng/AAL 4977 2021; Chang, Jia Feng/AAW 1326 2020
OI Hung, Kuo Chin/0000 0001 9023 8925; Hung, Chi Feng/0000 0003 3478 5451;
   Chang, Jia Feng/0000 0002 9903 7473; Hsieh, Chih Yu/0000 0001 9770 6779;
   Wang, Ting Ming/0000 0002 2263 5993; Lin, Wei Ning/0000 0003 3205 871X
FU Ministry of Science and Technology [MOST 1092628 B 385 001]; En Chu Kong
   Hospital [ECKH_W11005]; Cathay General Hospital [CGH MR A11012]; Renal
   Care Joint Foundation
FX This work was financially supported by Ministry of Science and
   Technology (MOST 1092628 B 385 001), the En Chu Kong Hospital
   (ECKH_W11005), and the Cathay General Hospital (CGH MR A11012). This
   research was also funded by the Renal Care Joint Foundation.
CR Boini KM, 2017, CELL PHYSIOL BIOCHEM, V44, P152, DOI 10.1159/000484623
   Chang JF, 2021, TOXINS, V13, DOI 10.3390/toxins13070479
   Chang JF, 2021, DIAGNOSTICS, V11, DOI 10.3390/diagnostics11020286
   Chang JF, 2020, TOXINS, V12, DOI 10.3390/toxins12080472
   Chang JF, 2020, FRONT MED LAUSANNE, V7, DOI 10.3389/fmed.2020.00102
   Chang JF, 2020, FRONT MED LAUSANNE, V7, DOI 10.3389/fmed.2020.00078
   Chang JF, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20184393
   Chang JF, 2018, J CLIN MED, V7, DOI 10.3390/jcm7090266
   Chen PC, 2021, DIAGNOSTICS, V11, DOI 10.3390/diagnostics11071254
   De Vriese AS, 2017, J AM SOC NEPHROL, V28, P1675, DOI 10.1681/ASN.2017020201
   Durham AL, 2018, CARDIOVASC RES, V114, P590, DOI 10.1093/cvr/cvy010
   Falconi CA, 2021, FRONT PHYSIOL, V12, DOI 10.3389/fphys.2021.686249
   Feng YS, 2020, FRONT CELL NEUROSCI, V14, DOI 10.3389/fncel.2020.00155
   Glorieux G, 2021, NEPHROL DIAL TRANSPL, V36, P998, DOI 10.1093/ndt/gfab004
   He Y, 2016, TRENDS BIOCHEM SCI, V41, P1012, DOI 10.1016/j.tibs.2016.09.002
   Hénaut L, 2018, TOXINS, V10, DOI 10.3390/toxins10060218
   Hung KC, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21228712
   [姜华 Jiang Hua], 2017, [中国科学. 生命科学, Scientia Sinica Vitae], V47, P125
   Kattoor AJ, 2019, ANTIOXIDANTS BASEL, V8, DOI 10.3390/antiox8070218
   Lekawanvijit S, 2016, AM J PHYSIOL RENAL, V311, pF52, DOI 10.1152/ajprenal.00348.2015
   London GM, 2013, KIDNEY INT SUPPL, V3, P442, DOI 10.1038/kisup.2013.92
   Mackenzie IS, 2009, HYPERTENSION, V54, P409, DOI 10.1161/HYPERTENSIONAHA.109.133801
   Rossi MN, 2019, FRONT CELL DEV BIOL, V7, DOI 10.3389/fcell.2019.00252
   Roumeliotis S, 2020, FRONT MED LAUSANNE, V7, DOI 10.3389/fmed.2020.00154
   Schoppet M, 2008, KIDNEY INT, V73, P989, DOI 10.1038/ki.2008.104
   Sun Y, 2018, FRONT BIOSCI LANDMRK, V23, P348, DOI 10.2741/4595
   Tada S, 2004, AM J PHYSIOL HEART C, V287, pH905, DOI 10.1152/ajpheart.00647.2003
   Vaziri ND, 2004, SEMIN NEPHROL, V24, P469, DOI 10.1016/j.semnephrol.2004.06.026
   Yamada S, 2012, J BONE MINER RES, V27, P474, DOI 10.1002/jbmr.539
   Yeh JC, 2018, J CLIN MED, V7, DOI 10.3390/jcm7110439
   Zhang XL, 2020, ARTERIOSCL THROM VAS, V40, P751, DOI 10.1161/ATVBAHA.119.313414
   Zhao MM, 2011, KIDNEY INT, V79, P1071, DOI 10.1038/ki.2011.18
NR 32
TC 7
Z9 7
U1 2
U2 9
PU MDPI
PI BASEL
PA MDPI AG, Grosspeteranlage 5, CH 4052 BASEL, SWITZERLAND
EI 2075 1729
J9 LIFE BASEL
JI Life Basel
PD MAY
PY 2022
VL 12
IS 5
AR 769
DI 10.3390/life12050769
PG 15
WC Biology; Microbiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Life Sciences & Biomedicine   Other Topics; Microbiology
GA 1O9TJ
UT WOS:000801664500001
PM 35629435
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Baniwal, SK
   Little, GH
   Chimge, NO
   Frenkel, B
AF Baniwal, Sanjeev K.
   Little, Gillian H.
   Chimge, Nyam Osor
   Frenkel, Baruch
TI Runx2 controls a feed forward loop between androgen and
   prolactin induced protein (PIP) in stimulating T47D cell proliferation
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
ID NEGATIVE BREAST CANCER; DISEASE FLUID PROTEIN 15; INDUCIBLE PROTEIN;
   OSTEOBLAST DIFFERENTIATION; GENE EXPRESSION; BONE METASTASIS; RECEPTOR;
   TRANSCRIPTION; PROSTATE; TUMOR
AB Prolactin Induced Protein (PIP) is a small polypeptide expressed by breast and prostate cancer (BCa, PCa) cells. However, both the regulation of PIP expression and its function in cancer cells are poorly understood. Using BCa and PCa cells, we found that Runx2, a pro metastatic transcription factor, functionally interacts with the Androgen Receptor (AR) to regulate PIP expression. Runx2 expression in C4 2B PCa cells synergized with AR to promote PIP expression, whereas its knockdown in T47D BCa cells abrogated basal as well as hormone stimulated PIP expression. Chromatin immunoprecipitation (ChIP) assays showed that Runx2 and AR co occupied an enhancer element located similar to 11kb upstream of the PIP open reading frame, and that Runx2 facilitated AR recruitment to the enhancer. PIP knockdown in T47D cells compromised DHT stimulated expression of multiple AR target genes including PSA, FKBP5, FASN, and SGK1. The inhibition of AR activity due to loss of PIP was attributable at least in part to abrogation of its nuclear translocation. PIP knockdown also suppressed T47D cell proliferation driven by either serum growth factors or dihydrotestosterone (DHT). Our data suggest that Runx2 controls a positive feedback loop between androgen signaling and PIP, and pharmacological inhibition of PIP may be useful to treat PIP positive tumors. J. Cell. Physiol. 227: 2276 2282, 2012. (C) 2011 Wiley Periodicals, Inc.
C1 [Baniwal, Sanjeev K.; Little, Gillian H.; Chimge, Nyam Osor; Frenkel, Baruch] Univ So Calif, Keck Sch Med, Inst Med Genet, Los Angeles, CA 90033 USA.
   [Baniwal, Sanjeev K.; Frenkel, Baruch] Univ So Calif, Keck Sch Med, Dept Orthopaed Surg, Los Angeles, CA 90033 USA.
   [Little, Gillian H.; Chimge, Nyam Osor; Frenkel, Baruch] Univ So Calif, Keck Sch Med, Dept Biochem, Los Angeles, CA 90033 USA.
   [Little, Gillian H.; Chimge, Nyam Osor; Frenkel, Baruch] Univ So Calif, Keck Sch Med, Dept Mol Biol, Los Angeles, CA 90033 USA.
C3 University of Southern California; University of Southern California;
   University of Southern California; University of Southern California
RP Baniwal, SK (通讯作者)，Univ So Calif, Keck Sch Med, Inst Med Genet, 2250 Alcazar St,CSC 240, Los Angeles, CA 90033 USA.
EM baniwal@usc.edu; frenkel@usc.edu
FU National Institute of Health [DK071122 DK071122S1, CA 109147, AR047052,
   SC CTSI UL1 RR03986]
FX Contract grant sponsor: National Institute of Health RO1 and NCRR
   grants;Contract grant numbers: DK071122 DK071122S1, CA 109147, AR047052,
   and SC CTSI UL1 RR03986.
CR Akech J, 2010, ONCOGENE, V29, P811, DOI 10.1038/onc.2009.389
   Bae SC, 2004, ONCOGENE, V23, P4336, DOI 10.1038/sj.onc.1207286
   Baniwal SK, 2010, MOL CANCER, V9, DOI 10.1186/1476 4598 9 258
   Baniwal SK, 2009, MOL ENDOCRINOL, V23, P1203, DOI 10.1210/me.2008 0470
   Blanchard A, 2009, CAN J PHYSIOL PHARM, V87, P859, DOI 10.1139/Y09 077
   Blyth K, 2005, NAT REV CANCER, V5, P376, DOI 10.1038/nrc1607
   Blyth K, 2010, BLOOD CELL MOL DIS, V45, P117, DOI 10.1016/j.bcmd.2010.05.007
   BUNDRED NJ, 1990, EUR J CANCER, V26, P1145, DOI 10.1016/0277 5379(90)90273 V
   Cameron ER, 2004, ONCOGENE, V23, P4308, DOI 10.1038/sj.onc.1207130
   Caputo E, 2000, J BIOL CHEM, V275, P7935, DOI 10.1074/jbc.275.11.7935
   Carsol JL, 2002, MOL ENDOCRINOL, V16, P1696, DOI 10.1210/me.16.7.1696
   CASSONI P, 1995, INT J CANCER, V60, P216
   Chia KM, 2011, NEOPLASIA, V13, P154, DOI 10.1593/neo.101324
   Chiu WWC, 2003, J REPROD IMMUNOL, V60, P97, DOI 10.1016/S0165 0378(03)00084 6
   Chua CW, 2009, CLIN CANCER RES, V15, P4322, DOI 10.1158/1078 0432.CCR 08 3157
   Clark JW, 1999, BRIT J CANCER, V81, P1002, DOI 10.1038/sj.bjc.6690799
   Doane AS, 2006, ONCOGENE, V25, P3994, DOI 10.1038/sj.onc.1209415
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Ellison G, 2002, J CLIN PATHOL MOL PA, V55, P294, DOI 10.1136/mp.55.5.294
   Gaubin M, 1999, J IMMUNOL, V162, P2631
   Gonzalez LO, 2008, BMC CANCER, V8, DOI 10.1186/1471 2407 8 149
   HAAGENSEN DE, 1990, ANN NY ACAD SCI, V586, P161, DOI 10.1111/j.1749 6632.1990.tb17804.x
   HAAGENSEN DE, 1980, AM J OBSTET GYNECOL, V138, P25, DOI 10.1016/0002 9378(80)90007 1
   Hall RE, 1998, BRIT J CANCER, V78, P360, DOI 10.1038/bjc.1998.499
   Hassan MI, 2009, CELL MOL LIFE SCI, V66, P447, DOI 10.1007/s00018 008 8463 x
   Javed A, 2005, P NATL ACAD SCI USA, V102, P1454, DOI 10.1073/pnas.0409121102
   Jia L, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003645
   Kayed H, 2007, BRIT J CANCER, V97, P1106, DOI 10.1038/sj.bjc.6603984
   Kilbey A, 2007, CANCER RES, V67, P11263, DOI 10.1158/0008 5472.CAN 07 3016
   Kim JH, 2008, MOL CELL, V31, P510, DOI 10.1016/j.molcel.2008.08.001
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Migliaccio A, 2000, EMBO J, V19, P5406, DOI 10.1093/emboj/19.20.5406
   MURPHY LC, 1987, J BIOL CHEM, V262, P15236
   Naderi A, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2858
   Ni M, 2011, CANCER CELL, V20, P119, DOI 10.1016/j.ccr.2011.05.026
   Ning YM, 1999, J BIOL CHEM, V274, P30624, DOI 10.1074/jbc.274.43.30624
   Onodera Y, 2010, CANCER SCI, V101, P2670, DOI 10.1111/j.1349 7006.2010.01742.x
   Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092 8674(00)80259 7
   Phillips Jennifer E., 2008, V433, P333, DOI 10.1007/978 1 59745 237 3_20
   Pratap J, 2006, CANCER METAST REV, V25, P589, DOI 10.1007/s10555 006 9032 0
   Pratap J, 2005, MOL CELL BIOL, V25, P8581, DOI 10.1128/MCB.25.19.8581 8591.2005
   Pratap J, 2003, CANCER RES, V63, P5357
   Robinson JLL, 2011, EMBO J, V30, P3019, DOI 10.1038/emboj.2011.216
   Sandelin A, 2004, NUCLEIC ACIDS RES, V32, pD91, DOI 10.1093/nar/gkh012
   Shin KJ, 2006, P NATL ACAD SCI USA, V103, P13759, DOI 10.1073/pnas.0606179103
   SHIU RPC, 1985, J BIOL CHEM, V260, P1307
   Shore P, 2005, J CELL BIOCHEM, V96, P484, DOI 10.1002/jcb.20557
   Thomas DM, 2004, J CELL BIOL, V167, P925, DOI 10.1083/jcb.200409187
   Tian W, 2004, CANCER SCI, V95, P491, DOI 10.1111/j.1349 7006.2004.tb03238.x
   WICK MR, 1989, HUM PATHOL, V20, P281, DOI 10.1016/0046 8177(89)90137 8
   Zaidi SK, 2007, P NATL ACAD SCI USA, V104, P19861, DOI 10.1073/pnas.0709650104
NR 51
TC 48
Z9 53
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0021 9541
EI 1097 4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD MAY
PY 2012
VL 227
IS 5
BP 2276
EP 2282
DI 10.1002/jcp.22966
PG 7
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA 879ZS
UT WOS:000299373900053
PM 21809344
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Diomede, F
   Merciaro, I
   Martinotti, S
   Cavalcanti, MFXB
   Caputi, S
   Mazzon, E
   Trubiani, O
AF Diomede, F.
   Merciaro, I.
   Martinotti, S.
   Cavalcanti, M. F. X. B.
   Caputi, S.
   Mazzon, E.
   Trubiani, O.
TI miR 2861 IS INVOLVED IN OSTEOGENIC COMMITMENT OF HUMAN PERIODONTAL
   LIGAMENT STEM CELLS GROWN ONTO 3D SCAFFOLD
SO JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS
LA English
DT Article
DE miR 2861; RUNX2; hydroxyapatite; human periodontal ligament stem cells;
   osteogenic differentiation
ID MICRORNA CONTROL; IN VITRO; BIOMATERIALS; EXPRESSION; THERAPY; ASSAY;
   RUNX2
AB miR 2861 endorsing osteoblast differentiation through the overexpression of Runt related transcription factor 2 (RUNX2) protein has been recently described. In this study we evaluated: the performance of living construct, composed by human Periodontal Ligament Stem Cells (hPDLSCs) and 3D scaffold (EXg), and the behaviour of miR 2861/RUNX2 expression pathway on the osteogenic commitment. Human PDLSCs were seeded with and without EXg scaffold and cultured under basal and osteogenic conditions. Morphological features, adhesiveness and differentiation abilities were analysed using scanning electron and confocal laser scanning microscopy. Time course of RUNX2, ALP, OPN and miR 2861 were evaluated through RT PCR analysis. Our results highlighted that the osteogenic differentiation was mostly obvious in the hPDLSCs, grown onto 3D scaffold in presence of osteoinductive medium. Moreover, the overexpression of miR 2861 and RUNX2 in hPDLSCs cultured in presence of EXg under osteogenic and standard conditions was demonstrated. In synthesis, the increased expression of miR 2861/RUNX2 provides new insights regarding miRNA signaling network in the presence of scaffold providing an additional method to evaluate the performance of biomaterial in bone regeneration.
C1 [Diomede, F.; Merciaro, I.; Trubiani, O.] Univ G dAnnunzio, Lab Stem Cells & Regenerat Med, Chieti, Italy.
   [Martinotti, S.] Univ G dAnnunzio, Dept Pharm, Chieti, Italy.
   [Cavalcanti, M. F. X. B.] Lorraine Univ, Fac Med, CNRS UL IMoPA, UMR 7365, Vandoeuvre Les Nancy, France.
   [Cavalcanti, M. F. X. B.] Lorraine Univ, Fac Med, FR UL CNRS INSERM, Vandoeuvre Les Nancy, France.
   [Cavalcanti, M. F. X. B.] Cruzeiro do Sul Univ, Postgrad Dept, Sao Paulo, SP, Brazil.
   [Caputi, S.] Univ G dAnnunzio, Dept Med Oral & Biotechnol Sci, Chieti, Italy.
   [Mazzon, E.] IRCCS, Ctr Neurolesi Bonino Pulejo, Messina, Italy.
C3 G d'Annunzio University of Chieti Pescara; G d'Annunzio University of
   Chieti Pescara; Universite de Lorraine; Centre National de la Recherche
   Scientifique (CNRS); CNRS   Institute for Engineering & Systems Sciences
   (INSIS); Universite de Lorraine; Institut National de la Sante et de la
   Recherche Medicale (Inserm); G d'Annunzio University of Chieti Pescara;
   IRCCS Bonino Pulejo
RP Trubiani, O (通讯作者)，Univ G dAnnunzio Chieti, Dept Med Oral & Biotechnol Sci, Lab Stem Cells & Regenerat Med, Via Vestini 31, I 66100 Chieti, Italy.
EM oriana.trubiani@unich.it
RI Martinotti, Stefano/LSK 3931 2024; Merciaro, Ilaria/AAQ 4025 2020;
   Cavalcanti, Marcos/MCJ 5870 2025; Diomede, Francesca/AAL 6840 2020;
   Mazzon, Emanuela/AAL 4334 2020
OI MARTINOTTI, Stefano/0000 0001 7672 891X; mazzon,
   emanuela/0000 0002 5073 717X; DIOMEDE, Francesca/0000 0002 0384 6509;
   Cavalcanti, Marcos/0000 0003 0334 3423; 
CR Bae YJ, 2012, HUM MOL GENET, V21, P2991, DOI 10.1093/hmg/dds129
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092 8674(04)00045 5
   Dangaria SJ, 2009, DIFFERENTIATION, V78, P79, DOI 10.1016/j.diff.2009.03.005
   Diomede F, 2016, EUR CELLS MATER, V32, P181, DOI 10.22203/eCM.v032a12
   Diomede F, 2014, INT ENDOD J, V47, P864, DOI 10.1111/iej.12230
   Eleuterio E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071101
   Feng JL, 2009, GENE, V437, P14, DOI 10.1016/j.gene.2009.01.017
   Gregory CA, 2004, ANAL BIOCHEM, V329, P77, DOI 10.1016/j.ab.2004.02.002
   Gronthos S, 2000, P NATL ACAD SCI USA, V97, P13625, DOI 10.1073/pnas.240309797
   Hagen JW, 2008, CELL CYCLE, V7, P2327, DOI 10.4161/cc.6447
   Hu R, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.176099
   Ivanovski S, 2006, ORAL DIS, V12, P358, DOI 10.1111/j.1601 0825.2006.01253.x
   Kobayashi T, 2008, P NATL ACAD SCI USA, V105, P1949, DOI 10.1073/pnas.0707900105
   LANGER R, 1993, SCIENCE, V260, P920, DOI 10.1126/science.8493529
   Li ZY, 2009, J BIOL CHEM, V284, P15676, DOI 10.1074/jbc.M809787200
   Lian JB, 2012, NAT REV ENDOCRINOL, V8, P212, DOI 10.1038/nrendo.2011.234
   Liao HT, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/321549
   Luzi E, 2012, NUCLEIC ACID THER, V22, P103, DOI 10.1089/nat.2012.0344
   Manescu A, 2016, J PERIODONTAL RES, V51, P112, DOI 10.1111/jre.12289
   Orciani M, 2008, J CELL BIOCHEM, V105, P905, DOI 10.1002/jcb.21887
   Ortega FJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009022
   Petrovic L, 2006, INT J ORAL MAX IMPL, V21, P225
   Pratap J, 2003, CANCER RES, V63, P5357
   Ryoo HM, 2006, GENE, V366, P51, DOI 10.1016/j.gene.2005.10.011
   Salvadè A, 2007, CYTOTHERAPY, V9, P427, DOI 10.1080/14653240701341995
   Sonoyama W, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000079
   Teplyuk NM, 2009, J CELL BIOCHEM, V107, P144, DOI 10.1002/jcb.22108
   Trubiani O, 2008, J BIOMED MATER RES A, V87A, P986, DOI 10.1002/jbm.a.31837
   Trubiani O, 2016, CELL SIGNAL, V28, P1631, DOI 10.1016/j.cellsig.2016.07.012
   Trubiani O, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287 015 0253 4
   Trubiani O, 2015, TISSUE ENG PART C ME, V21, P52, DOI [10.1089/ten.tec.2014.0024, 10.1089/ten.TEC.2014.0024]
   Trubiani O, 2010, EUR CELLS MATER, V20, P72
   Varkonyi Gasic E, 2007, PLANT METHODS, V3, DOI 10.1186/1746 4811 3 12
   Cavalcanti MFXB, 2015, PHOTOMED LASER SURG, V33, P610, DOI 10.1089/pho.2014.3864
   Yang P, 2013, BMC MUSCULOSKEL DIS, V14, DOI 10.1186/1471 2474 14 318
NR 35
TC 45
Z9 46
U1 0
U2 8
PU BIOLIFE SAS
PI SILVA MARINA (TE)
PA VIA S STEFANO 39 BIS, 64029 SILVA MARINA (TE), ITALY
SN 0393 974X
EI 1724 6083
J9 J BIOL REG HOMEOS AG
JI J. Biol. Regul. Homeost. Agents
PD DEC
PY 2016
VL 30
IS 4
BP 1009
EP 1018
PG 10
WC Endocrinology & Metabolism; Immunology; Medicine, Research &
   Experimental; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Immunology; Research & Experimental
   Medicine; Physiology
GA EI5XT
UT WOS:000392570300008
PM 28078846
DA 2025 08 17
ER

PT J
AU Fillatreau, S
AF Fillatreau, Simon
TI B cells and their cytokine activities implications in human diseases
SO CLINICAL IMMUNOLOGY
LA English
DT Article
DE B cell; Cytokine; Inflammation; Autoimmunity; Monocyte
ID MYELIN OLIGODENDROCYTE GLYCOPROTEIN; RHEUMATOID ARTHRITIS PATIENTS;
   REMITTING MULTIPLE SCLEROSIS; CENTRAL NERVOUS SYSTEM;
   TUMOR NECROSIS FACTOR; CEREBROSPINAL FLUID; DEPLETION THERAPY;
   CLINICAL RESPONSE; T CELLS; OSTEOCLAST DIFFERENTIATION
AB B cells are the only cell type that can give rise to antibody producing cells, and the only cell type whose selective depletion can, today, lead to an improvement of a wide range of immune mediated inflammatory diseases, including disorders not primarily driven by autoantibodies. Here, I discuss this paradoxical observation, and propose that the capacity of B cells to act as cytokine producing cells explains how they can control monocyte activity and subsequently disease pathogenesis. Together with current data on the effect of anti CD20 B cell depleting reagents in the clinic, this novel knowledge on B cell heterogeneity opens the way for novel safer and more efficient strategies to target B cells. The forthcoming identification of disease relevant B cell subsets is awaited to permit their monitoring and specific targeting in a personalized medicine approach. (C) 2017 The Author. Published by Elsevier Inc.
C1 [Fillatreau, Simon] INSERM, U1151, CNRS, UMR 8253,INEM, Paris, France.
   [Fillatreau, Simon] Univ Paris 05, Sorbonne Paris Cite, Fac Med, Paris, France.
   [Fillatreau, Simon] Hop Necker Enfants Malad, AP HP, Paris, France.
   [Fillatreau, Simon] Deutsch Rheuma Forschungszentrum Berlin DRFZ, Leibniz Inst, Berlin, Germany.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   Universite Paris Cite; Centre National de la Recherche Scientifique
   (CNRS); CNRS   National Institute for Biology (INSB); Universite Paris
   Cite; Assistance Publique Hopitaux Paris (APHP); Universite Paris Cite;
   Hopital Universitaire Necker Enfants Malades   APHP
RP Fillatreau, S (通讯作者)，INEM, Team Immun Hlth & Dis 16, 14 Rue Maria Helena Vieira da Silva, F 75993 Paris 14, France.
EM simon.flllatreau@inserm.fr
FU European Research Council [ERC PREG LAB 647696]; AXA Chair in
   Translational Immunology, Agence Nationale de la recherche
   [ANR 16 CE18 0007 01]; Infect ERA project ABIR [031A403]; Deutsche
   Forschungsgemeinschaft [TRR130, Fl 1238/1 2]; Bundesministerium fur
   Bildung and Forschung [BMBF Neu2 16GW0069]; Agence Nationale de la
   Recherche (ANR) [ANR 16 CE18 0007] Funding Source: Agence Nationale de
   la Recherche (ANR)
FX The S.F. team is supported by a European Research Council grant ERC
   PREG LAB 647696, an AXA Chair in Translational Immunology, Agence
   Nationale de la recherche (ANR 16 CE18 0007 01), the Infect ERA project
   ABIR (031A403), the Deutsche Forschungsgemeinschaft (TRR130, Fl
   1238/1 2), the Bundesministerium fur Bildung and Forschung (BMBF Neu2
   16GW0069).
CR Adlard NJ, 2014, ANN RHEUM DIS, V73, pA28, DOI 10.1136/annrheumdis 2013 205124.65
   Amara K, 2017, J AUTOIMMUN, V81, P34, DOI 10.1016/j.jaut.2017.03.004
   [Anonymous], NEUROTHERAPEUTICS
   Audo R, 2014, ARTHRITIS RHEUMATOL, V66, pS168, DOI 10.1002/art.38666
   Bankó Z, 2017, J IMMUNOL, V198, P1512, DOI 10.4049/jimmunol.1600218
   Bar Or A, 2010, ANN NEUROL, V67, P452, DOI 10.1002/ana.21939
   Barr TA, 2012, J EXP MED, V209, P1001, DOI 10.1084/jem.20111675
   Boumans MJH, 2012, ANN RHEUM DIS, V71, P108, DOI 10.1136/annrheumdis 2011 200198
   Brändle SM, 2016, P NATL ACAD SCI USA, V113, P7864, DOI 10.1073/pnas.1522730113
   Brink M, 2013, ARTHRITIS RHEUM US, V65, P899, DOI 10.1002/art.37835
   Cambridge G, 2003, ARTHRITIS RHEUM US, V48, P2146, DOI 10.1002/art.11181
   Cambridge G, 2014, J AUTOIMMUN, V50, P67, DOI 10.1016/j.jaut.2013.12.002
   Carter NA, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3736
   Carter NA, 2011, J IMMUNOL, V186, P5569, DOI 10.4049/jimmunol.1100284
   Carter NJ, 2010, DRUGS, V70, P1545, DOI 10.2165/11204560 000000000 00000
   Chiu YG, 2017, EXPERT OPIN BIOL TH, V17, P119, DOI 10.1080/14712598.2017.1263614
   Correale J, 2008, ANN NEUROL, V64, P187, DOI 10.1002/ana.21438
   Correale J, 2007, ANN NEUROL, V61, P97, DOI 10.1002/ana.21067
   Cross AH, 2006, J NEUROIMMUNOL, V180, P63, DOI 10.1016/j.jneuroim.2006.06.029
   Crotty S, 2011, ANNU REV IMMUNOL, V29, P621, DOI 10.1146/annurev immunol 031210 101400
   Cunningham Rundles C, 2005, NAT REV IMMUNOL, V5, P880, DOI 10.1038/nri1713
   de Masson A, 2015, BLOOD, V125, P1830, DOI 10.1182/blood 2014 09 599159
   Doorenspleet ME, 2014, ANN RHEUM DIS, V73, P756, DOI 10.1136/annrheumdis 2012 202861
   Duddy M, 2007, J IMMUNOL, V178, P6092, DOI 10.4049/jimmunol.178.10.6092
   Edwards JCW, 2004, NEW ENGL J MED, V350, P2572, DOI 10.1056/NEJMoa032534
   Ehrhardt GRA, 2005, J EXP MED, V202, P783, DOI 10.1084/jem.20050879
   El Behi M, 2017, BRAIN, V140, P967, DOI 10.1093/brain/awx008
   Emery P, 2006, ARTHRITIS RHEUM, V54, P1390, DOI 10.1002/art.21778
   Emery P, 2011, ANN RHEUM DIS, V70, P2063, DOI 10.1136/ard.2010.148015
   Ettinger R, 2005, J IMMUNOL, V175, P7867, DOI 10.4049/jimmunol.175.12.7867
   Fillatreau S, 2002, NAT IMMUNOL, V3, P944, DOI 10.1038/ni833
   Fillatreau Simon, 2007, Expert Rev Clin Immunol, V3, P565, DOI 10.1586/1744666X.3.4.565
   Fillatreau S, 2015, CURR OPIN PHARMACOL, V23, P1, DOI 10.1016/j.coph.2015.04.006
   Firestein GS, 2017, IMMUNITY, V46, P183, DOI 10.1016/j.immuni.2017.02.006
   Genain CP, 1999, NAT MED, V5, P170, DOI 10.1038/5532
   Grützke B, 2015, ANN CLIN TRANSL NEUR, V2, P119, DOI 10.1002/acn3.155
   Hamel KM, 2014, ARTHRITIS RHEUMATOL, V66, P60, DOI 10.1002/art.38207
   Hartung Hans Peter, 2010, Ther Adv Neurol Disord, V3, P205, DOI 10.1177/1756285610371146
   Hauser SL, 2008, NEW ENGL J MED, V358, P676, DOI 10.1056/NEJMoa0706383
   Heine G, 2014, EUR J IMMUNOL, V44, P1615, DOI 10.1002/eji.201343822
   Hogan VE, 2012, ANN RHEUM DIS, V71, P1888, DOI 10.1136/annrheumdis 2011 201115
   Ireland SJ, 2014, JAMA NEUROL, V71, P1421, DOI 10.1001/jamaneurol.2014.1472
   Isaacs JD, 2013, ANN RHEUM DIS, V72, P329, DOI 10.1136/annrheumdis 2011 201117
   Iwaki Egawa S, 2005, ANN RHEUM DIS, V64, P1094, DOI 10.1136/ard.2004.032847
   Iwata Y, 2011, BLOOD, V117, P530, DOI 10.1182/blood 2010 07 294249
   James EA, 2014, ARTHRITIS RHEUMATOL, V66, P1712, DOI 10.1002/art.38637
   Kala M, 2010, EXP NEUROL, V221, P136, DOI 10.1016/j.expneurol.2009.10.015
   Kamburova EG, 2013, AM J TRANSPLANT, V13, P1503, DOI 10.1111/ajt.12220
   Kappos L, 2011, LANCET, V378, P1779, DOI 10.1016/S0140 6736(11)61649 8
   Keystone E, 2009, ANN RHEUM DIS, V68, P216, DOI 10.1136/ard.2007.085787
   Krumbholz M, 2006, BRAIN, V129, P200, DOI 10.1093/brain/awh680
   Kuhn KA, 2006, J CLIN INVEST, V116, P961, DOI 10.1172/JCI25422
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lal P, 2011, ARTHRITIS RHEUM US, V63, P3681, DOI 10.1002/art.30596
   Lalive PH, 2006, P NATL ACAD SCI USA, V103, P2280, DOI 10.1073/pnas.0510672103
   Lampropoulou V, 2008, J IMMUNOL, V180, P4763, DOI 10.4049/jimmunol.180.7.4763
   Larousserie F, 2006, J PATHOL, V209, P360, DOI 10.1002/path.1995
   Leandro MJ, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar3908
   Lee SK, 2012, IMMUNITY, V37, P880, DOI 10.1016/j.immuni.2012.10.010
   Li R, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab4176
   LINK H, 1977, SCAND J CLIN LAB INV, V37, P397, DOI 10.3109/00365517709091498
   Lino AC, 2016, IMMUNOL REV, V269, P130, DOI 10.1111/imr.12374
   Liu BS, 2014, EUR J IMMUNOL, V44, P2121, DOI 10.1002/eji.201344341
   McInnes IB, 2017, LANCET, V389, P2328, DOI 10.1016/S0140 6736(17)31472 1
   McInnes IB, 2011, NEW ENGL J MED, V365, P2205, DOI 10.1056/NEJMra1004965
   Meednu N, 2016, ARTHRITIS RHEUMATOL, V68, P805, DOI 10.1002/art.39489
   Miyazaki Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105421
   Miyazaki Y, 2014, CLIN IMMUNOL, V151, P127, DOI 10.1016/j.clim.2014.02.001
   Molnarfi N, 2013, J EXP MED, V210, P2921, DOI 10.1084/jem.20130699
   Montalban X, 2017, NEW ENGL J MED, V376, P209, DOI 10.1056/NEJMoa1606468
   Ngo VN, 1999, J EXP MED, V189, P403, DOI 10.1084/jem.189.2.403
   O'Neill SK, 2007, J IMMUNOL, V179, P5109, DOI 10.4049/jimmunol.179.8.5109
   Olalekan SA, 2015, EUR J IMMUNOL, V45, P988, DOI 10.1002/eji.201445036
   Onal M, 2012, J BIOL CHEM, V287, P29851, DOI 10.1074/jbc.M112.377945
   Ota Y, 2016, ARTHRITIS RES THER, V18, DOI 10.1186/s13075 016 0957 6
   Petereit HF, 2008, ACTA NEUROL SCAND, V117, P399, DOI 10.1111/j.1600 0404.2007.00958.x
   Piccio L, 2010, ARCH NEUROL CHICAGO, V67, P707, DOI 10.1001/archneurol.2010.99
   Rantapää Dahlqvist S, 2003, ARTHRITIS RHEUM, V48, P2741, DOI 10.1002/art.11223
   Rasmussen TK, 2016, DAN MED J, V63
   Ries S, 2014, EUR J IMMUNOL, V44, P1251, DOI 10.1002/eji.201343683
   Ritchie AM, 2004, J IMMUNOL, V173, P649, DOI 10.4049/jimmunol.173.1.649
   Rosengren S, 2011, RHEUMATOLOGY, V50, P603, DOI 10.1093/rheumatology/keq337
   SCHLUESENER HJ, 1987, J IMMUNOL, V139, P4016
   Sellam J, 2013, ARTHRITIS RHEUM US, V65, P2253, DOI 10.1002/art.38023
   Shen P, 2015, NAT REV IMMUNOL, V15, P441, DOI 10.1038/nri3857
   Shen P, 2014, NATURE, V507, P366, DOI 10.1038/nature12979
   Silverman GJ, 2003, ARTHRITIS RHEUM US, V48, P1484, DOI 10.1002/art.10947
   Spadaro M, 2016, NEUROL NEUROIMMUNOL, V3, DOI 10.1212/NXI.0000000000000257
   Storch MK, 1998, ANN NEUROL, V43, P465, DOI 10.1002/ana.410430409
   Tak PP, 2008, ARTHRITIS RHEUM US, V58, P61, DOI 10.1002/art.23178
   Tak PP, 2012, ARTHRITIS RHEUM US, V64, P360, DOI 10.1002/art.33353
   van Vollenhoven RF, 2011, ARTHRITIS RHEUM US, V63, P1782, DOI 10.1002/art.30372
   Váncsa A, 2013, J RHEUMATOL, V40, P565, DOI 10.3899/jrheum.111488
   Vermeulen N, 2011, INFLAMM BOWEL DIS, V17, P1291, DOI 10.1002/ibd.21508
   von Büdingen HC, 2008, EUR J IMMUNOL, V38, P2014, DOI 10.1002/eji.200737784
   Vos K, 2007, ARTHRITIS RHEUM, V56, P772, DOI 10.1002/art.22400
   Wheater G, 2011, OSTEOPOROSIS INT, V22, P3067, DOI 10.1007/s00198 011 1607 0
   Wilson TJ, 2012, J IMMUNOL, V188, P4741, DOI 10.4049/jimmunol.1102651
   Yamada H, 2008, ANN RHEUM DIS, V67, P1299, DOI 10.1136/ard.2007.080341
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Yellin M, 2012, ARTHRITIS RHEUM US, V64, P1730, DOI 10.1002/art.34330
   Yoshizaki A, 2012, NATURE, V491, P264, DOI 10.1038/nature11501
NR 102
TC 50
Z9 57
U1 0
U2 7
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 1521 6616
EI 1521 7035
J9 CLIN IMMUNOL
JI Clin. Immunol.
PD JAN
PY 2018
VL 186
SI SI
BP 26
EP 31
DI 10.1016/j.clim.2017.07.020
PG 6
WC Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology
GA GA5FZ
UT WOS:000428359800006
PM 28736271
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Marques, LM
   Alves, MM
   Eugénio, S
   Salazar, SB
   Pedro, N
   Grenho, L
   Mira, NP
   Fernandes, MH
   Montemor, MF
AF Marques, L. M.
   Alves, M. M.
   Eugenio, S.
   Salazar, S. B.
   Pedro, N.
   Grenho, L.
   Mira, N. P.
   Fernandes, M. H.
   Montemor, M. F.
TI Potential anti cancer and anti Candida activity of Zn derived
   foams
SO JOURNAL OF MATERIALS CHEMISTRY B
LA English
DT Article
ID ZINC OXIDE NANOPARTICLES; SIMULATED PHYSIOLOGICAL CONDITIONS; IN VITRO
   DEGRADATION; REACTIVE OXYGEN; CANCER CELLS; PERMEABILITY TRANSITION;
   INDUCE APOPTOSIS; DRUG DELIVERY; MG ALLOYS; BIOMATERIALS
AB Zinc (Zn) derived foams have been prepared from an alkaline electrolyte solution by galvanostatic electrodeposition under different conditions. A detailed physico chemical characterization was performed by Raman spectroscopy, X ray diffraction (XRD) and scanning electron microscopy (SEM). A pioneer application of these foams in medical implant related applications was investigated. The in vitro behaviour of these Zn derived foams in simulated physiological conditions was studied. The results revealed that the presence of zinc oxide was important enough to change the in vitro behaviour of these materials. The potential of these Zn derived foams in inhibiting bone cancer cell proliferation   osteoscarcoma cells   and important pathogenic fungi responsible for implant related infections   Candida albicans   was examined. Furthermore, the foams were evaluated for cytocompatibility with normal human osteoblasts. The results obtained allowed us to conclude that Zn derived foams have an interesting potential for anti cancer and anti Candida activity, targeted for bone related implant applications, suggesting that this novel material may have potential for further clinical studies.
C1 [Marques, L. M.; Alves, M. M.; Eugenio, S.; Montemor, M. F.] Univ Lisbon, Dept Engn Quim, CQE, Inst Super Tecn, Ave Rovisco Pais, P 1049001 Lisbon, Portugal.
   [Salazar, S. B.; Pedro, N.; Mira, N. P.] Univ Lisbon, Inst Bioengn & Biociencias, Dept Bioengn, Inst Super Tecn,iBB, Ave Rovisco Pais, P 1049001 Lisbon, Portugal.
   [Grenho, L.; Fernandes, M. H.] Porto, Fac Med Dent, Lab Bone Metab & Regenerat, P 4200393 Porto, Portugal.
   [Fernandes, M. H.] Univ Porto, LAQV REQUIMTE, Porto, Portugal.
C3 Universidade de Lisboa; Universidade de Lisboa; Universidade do Porto;
   Universidade do Porto
RP Marques, LM (通讯作者)，Univ Lisbon, Dept Engn Quim, CQE, Inst Super Tecn, Ave Rovisco Pais, P 1049001 Lisbon, Portugal.
EM luisasmarques@gmail.com
RI Salazar, Sara/R 7341 2018; Mira, Nuno/E 2965 2012; Grenho,
   Liliana/I 4540 2015; Marques, L.M/NDS 6514 2025; Alves,
   Marta/E 9716 2015; Fernandes, Maria Helena/K 6917 2014; Fernandes,
   Maria/K 6917 2014; Alves, Marta M./E 9716 2015; MONTEMOR,
   FATIMA/D 8976 2012; Eugénio, Sónia/B 2254 2013; Eugenio,
   Sonia/B 2254 2013
OI Salazar, Sara/0000 0002 4867 8975; Mira, Nuno/0000 0001 7556 0385;
   Grenho, Liliana/0000 0001 9476 2839; Fernandes, Maria
   Helena/0000 0001 9391 9574; Aparicio Pedro, Nuno
   Alexandre/0000 0001 9292 5729; Alves, Marta M./0000 0002 9679 4022;
   MONTEMOR, FATIMA/0000 0001 7835 6814; Marques, L.M./0000 0002 0807 240X;
   Eugenio, Sonia/0000 0002 1386 5236
FU Fundacao para a Ciencia e Tecnologia (FCT) [RECI/QEQ QIN/0189/2012,
   UID/QUI/00100/2013]; iBB Institute for Bioengineering and Biosciences
   from FCT [UID/BIO/04565/2013]; Programa Operacional Regional de Lisboa
   [007317]; European Union [POCI/01/0145/FEDER/007265]; National Funds
   (FCT/MEC, Fundacao para a Ciencia e Tecnologia and Ministerio da
   Educacao e Ciencia) [PT2020 UID/QUI/50006/2013];  [SFRH/BPD/76646/2011];
   Fundação para a Ciência e a Tecnologia [SFRH/BPD/76646/2011] Funding
   Source: FCT
FX We would like to express our gratitude to the Fundacao para a Ciencia e
   Tecnologia (FCT) for the funding under the contracts
   RECI/QEQ QIN/0189/2012 and UID/QUI/00100/2013. Funding received by
   iBB Institute for Bioengineering and Biosciences from FCT
   (UID/BIO/04565/2013) and from Programa Operacional Regional de Lisboa
   2020 (Project No. 007317) is also acknowledged. Financial support also
   from the European Union (FEDER funds POCI/01/0145/FEDER/007265) and
   National Funds (FCT/MEC, Fundacao para a Ciencia e Tecnologia and
   Ministerio da Educacao e Ciencia) under the Partnership Agreement PT2020
   UID/QUI/50006/2013 is also acknowledged. The author Marta Alves thanks
   the FCT for providing financial support towards SFRH/BPD/76646/2011.
CR Agarwal R, 2015, ADV DRUG DELIVER REV, V94, P53, DOI 10.1016/j.addr.2015.03.013
   Akhtar MJ, 2012, INT J NANOMED, V7, P845, DOI 10.2147/IJN.S29129
   Alves MM, 2017, ACS APPL MATER INTER, V9, P28157, DOI 10.1021/acsami.7b02320
   Alves MM, 2017, RSC ADV, V7, P28224, DOI 10.1039/c6ra28542b
   Alves MM, 2017, MAT SCI ENG C MATER, V70, P112, DOI 10.1016/j.msec.2016.08.071
   Alves MM, 2016, J MATER CHEM B, V4, P4754, DOI 10.1039/c6tb00797j
   Banoriya D, 2017, MATER TODAY PROC, V4, P3534, DOI 10.1016/j.matpr.2017.02.244
   Buerki Thurnherr T, 2013, NANOTOXICOLOGY, V7, P402, DOI 10.3109/17435390.2012.666575
   Cheng H, 2017, DRUG DISCOV TODAY, V22, P1336, DOI 10.1016/j.drudis.2017.04.021
   Choi SW, 2016, ACS BIOMATER SCI ENG, V2, P494, DOI 10.1021/acsbiomaterials.5b00395
   Choy WS, 2015, YONSEI MED J, V56, P460, DOI 10.3349/ymj.2015.56.2.460
   Circu ML, 2008, FREE RADICAL RES, V42, P689, DOI 10.1080/10715760802317663
   De Berardis B, 2010, TOXICOL APPL PHARM, V246, P116, DOI 10.1016/j.taap.2010.04.012
   Eugénio S, 2016, INT J HYDROGEN ENERG, V41, P14370, DOI 10.1016/j.ijhydene.2016.01.142
   Gervais Benjamin, 2016, Case Studies in Engineering Failure Analysis, V5 6, P30, DOI 10.1016/j.csefa.2015.12.001
   Guo DD, 2013, TOXICOL IN VITRO, V27, P731, DOI 10.1016/j.tiv.2012.12.001
   Györgyey A, 2013, MAT SCI ENG C MATER, V33, P4251, DOI 10.1016/j.msec.2013.06.020
   Hanley C, 2008, NANOTECHNOLOGY, V19, DOI 10.1088/0957 4484/19/29/295103
   Hassan HFH, 2017, CLIN EXP PHARMACOL P, V44, P235, DOI 10.1111/1440 1681.12681
   Jiang DM, 2001, J BIOL CHEM, V276, P47524, DOI 10.1074/jbc.M108834200
   Johnson Melissa D., 2001, Curr Infect Dis Rep, V3, P450, DOI 10.1007/BF03160470
   Jones LC, 2017, WOODH PUBL SER BIOM, P17, DOI 10.1016/B978 0 08 100286 5.00002 0
   Khamlich S, 2013, J SOLID STATE ELECTR, V17, P2879, DOI 10.1007/s10008 013 2206 0
   Ko SK, 2014, NAT CHEM, V6, P885, DOI [10.1038/NCHEM.2021, 10.1038/nchem.2021]
   Koshy ST, 2016, CURR OPIN BIOTECH, V40, P1, DOI 10.1016/j.copbio.2016.02.001
   Lange GA, 2015, J ELECTROANAL CHEM, V737, P85, DOI 10.1016/j.jelechem.2014.10.025
   Li Y, 2011, CRYST RES TECHNOL, V46, P305, DOI 10.1002/crat.201000673
   Liou GY, 2010, FREE RADICAL RES, V44, P479, DOI 10.3109/10715761003667554
   Lyndon JA, 2014, J CONTROL RELEASE, V179, P63, DOI 10.1016/j.jconrel.2014.01.026
   Momodu DY, 2015, ELECTROCHIM ACTA, V151, P591, DOI 10.1016/j.electacta.2014.11.015
   Montemor MF, 2014, SURF COAT TECH, V258, P17, DOI 10.1016/j.surfcoat.2014.06.031
   Moon SH, 2016, TOXICOL REP, V3, P430, DOI 10.1016/j.toxrep.2016.03.008
   Moos PJ, 2010, CHEM RES TOXICOL, V23, P733, DOI 10.1021/tx900203v
   Nair S., 2008, J MATER SCI MATER M, V20, P235
   Owens GJ, 2016, PROG MATER SCI, V77, P1, DOI 10.1016/j.pmatsci.2015.12.001
   Pacchioni G, 2003, CHEMPHYSCHEM, V4, P1041, DOI 10.1002/cphc.200300835
   Paino IMM, 2016, ACS APPL MATER INTER, V8, P32699, DOI 10.1021/acsami.6b11950
   Petrochenko PE, 2014, TOXICOL IN VITRO, V28, P1144, DOI 10.1016/j.tiv.2014.05.004
   Plowman BJ, 2015, CHEM COMMUN, V51, P4331, DOI 10.1039/c4cc06638c
   Puljak L, 2006, BBA MOL BASIS DIS, V1762, P404, DOI 10.1016/j.bbadis.2005.12.008
   Qiao YQ, 2014, BIOMATERIALS, V35, P6882, DOI 10.1016/j.biomaterials.2014.04.101
   Raggatt LJ, 2010, J BIOL CHEM, V285, P25103, DOI 10.1074/jbc.R109.041087
   Ramage G, 2006, FEMS YEAST RES, V6, P979, DOI 10.1111/j.1567 1364.2006.00117.x
   Rasmussen JW, 2010, EXPERT OPIN DRUG DEL, V7, P1063, DOI 10.1517/17425247.2010.502560
   Saini M, 2015, WORLD J CLIN CASES, V3, P52, DOI 10.12998/wjcc.v3.i1.52
   Saptarshi S., 2015, NANOMEDICINE, V10, P1
   Shen CC, 2013, TOXICOL SCI, V136, P120, DOI 10.1093/toxsci/kft187
   Shinagawa T, 2017, CRYST GROWTH DES, V17, P3826, DOI 10.1021/acs.cgd.7b00396
   Sithole J, 2012, APPL SURF SCI, V258, P7839, DOI 10.1016/j.apsusc.2012.04.073
   Song B, 2017, CRYST GROWTH DES, V17, P3548, DOI 10.1021/acs.cgd.7b00494
   Song WH, 2010, TOXICOL LETT, V199, P389, DOI 10.1016/j.toxlet.2010.10.003
   Taccola L, 2011, INT J NANOMED, V6, DOI 10.2147/IJN.S16581
   Tavares SR, 2014, J PHYS CHEM C, V118, P19106, DOI 10.1021/jp504051z
   Tsukimoto M, 2005, J BIOL CHEM, V280, P2653, DOI 10.1074/jbc.M411072200
   Wahab R, 2016, SCI REP UK, V6, DOI 10.1038/srep19950
   Walley M. B. K., 2016, HARVARD ORTHOPAEDIC, V17, P68
   World Health Organization, 2011, Global Health and Aging
   Wudarczyk J, 1999, ARCH BIOCHEM BIOPHYS, V363, P1, DOI 10.1006/abbi.1998.1058
   Xia T, 2008, ACS NANO, V2, P2121, DOI 10.1021/nn800511k
   Yang XY, 2017, CHEM SOC REV, V46, P481, DOI 10.1039/c6cs00829a
   Yoo Chae Kyung, 2016, Maxillofac Plast Reconstr Surg, V38, P17, DOI 10.1186/s40902 016 0062 4
   Zhang Y, 2013, CURR MOL MED, V13, P1633, DOI 10.2174/1566524013666131111130058
   1963, BR MED J, P264
NR 63
TC 7
Z9 7
U1 1
U2 17
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2050 750X
EI 2050 7518
J9 J MATER CHEM B
JI J. Mat. Chem. B
PD MAY 14
PY 2018
VL 6
IS 18
BP 2821
EP 2830
DI 10.1039/c7tb02726e
PG 10
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA GF8FY
UT WOS:000432205900018
PM 32254235
DA 2025 08 17
ER

PT J
AU Su, N
   Villicana, C
   Zhang, C
   Lee, J
   Sinha, S
   Yang, A
   Yang, F
AF Su, Ni
   Villicana, Cassandra
   Zhang, Carl
   Lee, Jeehee
   Sinha, Sauradeep
   Yang, Andrew
   Yang, Fan
TI Aspirin synergizes with mineral particle coated macroporous scaffolds
   for bone regeneration through immunomodulation
SO THERANOSTICS
LA English
DT Article
DE mineral particles; osteogenesis; bone resorption
ID BIPHASIC CALCIUM PHOSPHATE; TISSUE REGENERATION; CELLS
AB Rationale: Mineral particles have been widely used in bone tissue engineering scaffolds due to their osteoconductive and osteoinductive properties. Despite their benefits, mineral particles can induce undesirable inflammation and subsequent bone resorption. Aspirin (Asp) is an inexpensive and widely used anti inflammatory drug. The goal of this study is to assess the synergistic effect of Asp and optimized mineral particle coating in macroporous scaffolds to accelerate endogenous bone regeneration and reduce bone resorption in a critical sized bone defect model.
   Methods: Four commonly used mineral particles with varying composition (hydroxyapatite v.s. tricalcium phosphate) and size ( nano v.s. micro) were used. Mineral particles were coated onto gelatin microribbon (mu RB) scaffolds. Macrophages (Mf) were cultured on gelatin mu RB scaffolds containing various particles, and Mf polarization was assessed using PCR and ELISA. The effect of conditioned medium from Mf on mesenchymal stem cell (MSC) osteogenesis was also evaluated in vitro. Scaffolds containing optimized mineral particles were then combined with varying dosages of Asp to assess the effect in inducing endogenous bone regeneration using a critical sized cranial bone defect model. In vivo characterization and in vitro cell studies were performed to elucidate the effect of tuning Asp dosage on Mf polarization, osteoclast (OC) activity, and MSC osteogenesis.
   Results: Micro sized tricalcium phosphate (mTCP) particles were identified as optimal in promoting M2 Mf polarization and rescuing MSC based bone formation in the presence of conditioned medium from Mf. When implanted in vivo, incorporating Asp with mTCP coated mu RB scaffolds significantly accelerated endogenous bone formation in a dose dependent manner. Impressively, mTCP coated mu RB scaffolds containing 20 mu g Asp led to almost complete bone healing of a critical sized cranial bone defect as early as week 2 with no subsequent bone resorption. Asp enhanced M2 Mf polarization, decreased OC activity, and promoted MSC osteogenesis in a dosage dependent manner in vivo. These results were further validated using in vitro cell studies.
   Conclusions: Here, we demonstrate Asp and mineral particle coated microribbon scaffold provides a promising therapy for repairing critical sized cranial bone defects via immunomodulation. The leading formulation supports rapid endogenous bone regeneration without the need for exogenous cells or growth factors, making it attractive for translation. Our results also highlight the importance of optimizing mineral particles and Asp dosage to achieve robust bone healing while avoiding bone resorption by targeting Mf and OCs.
C1 [Su, Ni; Lee, Jeehee; Yang, Fan] Stanford Univ Sch Med, Dept Orthopaed Surg, Stanford, CA 94305 USA.
   [Villicana, Cassandra; Zhang, Carl; Sinha, Sauradeep; Yang, Andrew; Yang, Fan] Stanford Univ Sch Med, Dept Bioengineering, Stanford, CA 94305 USA.
C3 Stanford University; Stanford University
RP Yang, F (通讯作者)，Stanford Univ, Dept Orthopaed Surg & Bioengn, Sch Med, 240 Pasteur Dr,Biomed Innovat Bldg,Room 1254, Palo Alto, CA 94304 USA.
EM fanyang@stanford.edu
RI Lee, Jeehee/JXW 9775 2024; Su, Ni/GWC 2671 2022
OI Su, Ni/0000 0002 6207 596X; Villicana, Cassandra/0000 0003 2106 1913
FU NIH [R01DE024772, R01AR074502, R01CA276872]; Stanford Maternal and
   Children's Health Institute Postdoctoral Fellowship; National Science
   Foundation [ECCS 2026822]; Stanford Bio X doctoral fellowship; EDGE
   Fellowship; NIH Stanford Biotechnology Training Grant [T32GM141819];
   Stanford Chem H O'Leary Thiry Graduate Fellowship; Bioengineering REU
   program
FX The authors would like to thank the following funding sources, including
   the NIH R01DE024772 (F. Y.), R01AR074502 (F. Y.), R01CA276872 (F. Y.),
   Stanford Maternal and Children's Health Institute Postdoctoral
   Fellowship (N. S.), National Science Foundation Predoctoral Fellowship
   (C. V.), Stanford Bio X doctoral fellowship (C. V.), the EDGE Fellowship
   (C. V.), the NIH Stanford Biotechnology Training Grant T32GM141819 (C.
   V.), Stanford Chem H O'Leary Thiry Graduate Fellowship (C.V.), and
   Bioengineering REU program (C. Z. and A. Y.). SEM imaging was performed
   at the Stanford Nano Shared Facilities (SNSF), supported by the National
   Science Foundation under award ECCS 2026822.
CR Alhamdi JR, 2019, BIOMATERIALS, V196, P90, DOI 10.1016/j.biomaterials.2018.07.012
   Bai L, 2018, ACTA BIOMATER, V76, P344, DOI 10.1016/j.actbio.2018.06.023
   Bouler JM, 2017, ACTA BIOMATER, V53, P1, DOI 10.1016/j.actbio.2017.01.076
   Cao Y, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287 015 0200 4
   Chen LJ, 2021, INFLAMMATION, V44, P278, DOI 10.1007/s10753 020 01331 9
   Chen XN, 2020, ACTA BIOMATER, V103, P318, DOI 10.1016/j.actbio.2019.12.019
   Conrad B, 2022, BIOMATER ADV, V140, DOI 10.1016/j.bioadv.2022.213050
   Diez Escudero A, 2018, ADV HEALTHC MATER, V7, DOI 10.1002/adhm.201700867
   Eliaz N, 2017, MATERIALS, V10, DOI 10.3390/ma10040334
   Fang XQ, 2018, J BIOMED MATER RES B, V106, P1739, DOI 10.1002/jbm.b.33982
   Fasolino I, 2020, NANOMATERIALS BASEL, V10, DOI 10.3390/nano10091743
   Fellah BH, 2007, J MATER SCI MATER M, V18, P287, DOI 10.1007/s10856 006 0691 8
   Han LH, 2016, J BIOMED MATER RES A, V104, P1321, DOI 10.1002/jbm.a.35715
   Humbert P, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00663
   Jeong J, 2019, BIOMATER RES, V23, DOI 10.1186/s40824 018 0149 3
   Jin SS, 2019, ACS NANO, V13, P6581, DOI 10.1021/acsnano.9b00489
   Julier Z, 2017, ACTA BIOMATER, V53, P13, DOI 10.1016/j.actbio.2017.01.056
   Koons GL, 2020, NAT REV MATER, V5, P584, DOI 10.1038/s41578 020 0204 2
   Lange T, 2009, BIOMATERIALS, V30, P5312, DOI 10.1016/j.biomaterials.2009.06.023
   Levingstone TJ, 2019, NANOMATERIALS BASEL, V9, DOI 10.3390/nano9111570
   Li SP, 2023, FRONT BIOENG BIOTECH, V11, DOI 10.3389/fbioe.2023.1105248
   Liang H, 2019, ACS APPL MATER INTER, V11, P41758, DOI 10.1021/acsami.9b16848
   Limami Y, 2021, EUR J PHARM SCI, V158, DOI 10.1016/j.ejps.2020.105679
   Liu HF, 2023, ACS APPL MATER INTER, DOI 10.1021/acsami.2c19767
   Liu QY, 2022, BIOMATER ADV, V134, DOI 10.1016/j.msec.2021.112578
   Liu Y, 2011, NAT MED, V17, P1594, DOI 10.1038/nm.2542
   Liu YT, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 10720 4
   Mahon OR, 2020, BIOMATERIALS, V239, DOI 10.1016/j.biomaterials.2020.119833
   Maruyama K, 2022, J INNATE IMMUN, V14, P207, DOI 10.1159/000518953
   Mestres G, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120381
   Ooms EM, 2003, BIOMATERIALS, V24, P989, DOI 10.1016/S0142 9612(02)00438 6
   Rahman FA, 2016, J PERIODONTOL, V87, P837, DOI 10.1902/jop.2016.150610
   Ramesh N, 2018, J BIOMED MATER RES B, V106, P2046, DOI 10.1002/jbm.b.33950
   Rana N, 2022, ACTA BIOMATER, V141, P440, DOI 10.1016/j.actbio.2021.12.027
   Sabokbar A, 2001, J MATER SCI MATER M, V12, P659, DOI 10.1023/A:1011267005465
   Shi JW, 2020, J CELL PHYSIOL, V235, P2599, DOI 10.1002/jcp.29164
   Sinha S, 2023, ADV HEALTHC MATER, V12, DOI 10.1002/adhm.202202147
   Su N, 2022, Advanced Materials, V35
   Su N, 2022, BIOMATERIALS, V286, DOI 10.1016/j.biomaterials.2022.121604
   Subramaniam S, 2016, BIOMATERIALS, V74, P99, DOI 10.1016/j.biomaterials.2015.09.044
   Velard F, 2013, ACTA BIOMATER, V9, P4956, DOI 10.1016/j.actbio.2012.09.035
   Wang J, 2020, J BIOMED MATER RES A, V108, P1305, DOI 10.1002/jbm.a.36903
   Wang YP, 2022, REGEN BIOMATER, V9, DOI 10.1093/rb/rbac003
   Wang YP, 2022, BIOMATERIALS, V285, DOI 10.1016/j.biomaterials.2022.121538
   Xiao DQ, 2020, ACTA BIOMATER, V106, P22, DOI 10.1016/j.actbio.2019.12.034
   Yuan MT, 2018, INT J MOL MED, V42, P1967, DOI 10.3892/ijmm.2018.3801
   Zhang YF, 2019, FRONT CHEM, V7, DOI 10.3389/fchem.2019.00682
NR 47
TC 9
Z9 9
U1 2
U2 19
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1838 7640
J9 THERANOSTICS
JI Theranostics
PY 2023
VL 13
IS 13
BP 4512
EP 4525
DI 10.7150/thno.85946
PG 14
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA U6MO0
UT WOS:001085926200014
PM 37649612
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Susantitaphong, P
   Vadcharavivad, S
   Susomboon, T
   Singhan, W
   Dumrongpisutikul, N
   Jakchairoongruang, K
   Eiam Ong, S
   Praditpornsilpa, K
AF Susantitaphong, Paweena
   Vadcharavivad, Somratai
   Susomboon, Teerada
   Singhan, Wanchana
   Dumrongpisutikul, Netsiri
   Jakchairoongruang, Ketsuda
   Eiam Ong, Somchai
   Praditpornsilpa, Kearkiat
TI The effectiveness of cinacalcet: a randomized, open label study in
   chronic hemodialysis patients with severe secondary hyperparathyroidism
SO RENAL FAILURE
LA English
DT Article
DE Cinacalcet; chronic hemodialysis; severe secondary hyperparathyroidism
ID PARATHYROID HORMONE SECRETION; CLINICAL PRACTICE GUIDELINE;
   CALCIUM SENSING RECEPTOR; PERSISTENT HYPERPARATHYROIDISM; BONE DISORDER;
   GLAND VOLUME; HYPERPLASIA; SENSIPAR/MIMPARA; CALCIFICATION; PATHOGENESIS
AB Background: Secondary hyperparathyroidism (SHPT) is associated with high incidences of cardiovascular disease, bone fracture, and mortality. This study was conducted to demonstrate the effectiveness of cinacalcet treatment on chronic kidney disease mineral bone disorder (CKD MBD) markers in chronic hemodialysis patients with severe SHPT. Methods: In phase 1, 30 adult HD patients were randomized to cinacalcet or control groups for 12 weeks to explore the achievement of >30% reduction of iPTH. In phase 2, 45 patients were participated to further explore the effect of cinacalcet on CKD MBD parameters for 24 week follow up and 12 additional weeks after cinacalcet discontinuation. Results: In phase 1, the baseline serum iPTH levels were not different [1374 (955, 1639) pg/mL in the control group vs. 1191 (1005, 1884) pg/mL in the cinacalcet group], the percentage of patients achieving iPTH target were significantly higher in the treatment group [80% vs. 13%, p = .001]. In phase 2, the significant reductions of iPTH, FGF 23, tartrate resistant acid phosphatase 5b, and slightly decreased size of parathyroid gland and stabilized vascular calcification were observed at 24 week follow up and markedly rebounded after discontinuation of cinacalcet. Conclusions: The effectiveness of cinacalcet were still obviously demonstrated even in chronic HD patients with severe SHPT. In addition, the improvements of bone markers and FGF 23, and stabilization of vascular calcification were observed. Therefore, cinacalcet can provide salutary effects on CKD MBD in severe SHPT and might be an initially effective PTH lowering therapy prior to surgical parathyroidectomy as well as an alternative treatment in the patients unsuitable for surgery.
C1 [Susantitaphong, Paweena; Eiam Ong, Somchai; Praditpornsilpa, Kearkiat] Chulalongkorn Univ, Div Nephrol, Dept Med, Fac Med,King Chulalongkorn Mem Hosp, Bangkok 10330, Thailand.
   [Vadcharavivad, Somratai; Susomboon, Teerada; Singhan, Wanchana] Chulalongkorn Univ, Dept Pharm Practice, Bangkok, Thailand.
   [Dumrongpisutikul, Netsiri; Jakchairoongruang, Ketsuda] Chulalongkorn Univ, Dept Radiol, Fac Med, Bangkok, Thailand.
C3 Chulalongkorn University; Chulalongkorn University; Chulalongkorn
   University
RP Susantitaphong, P (通讯作者)，Chulalongkorn Univ, Div Nephrol, Dept Med, Fac Med,King Chulalongkorn Mem Hosp, Bangkok 10330, Thailand.
EM pesancerinus@hotmail.com
RI ; Praditpronsilpa, Kearkiat/AFT 5058 2022
OI Vadcharavivad, Somratai/0000 0001 5080 7070; 
FU Thailand research fund Career Development Grant, Thailand [RSA5880067];
   Metabolic Bone Disease in CKD Patients Research Unit, Faculty of
   Medicine, Chulalongkorn University, Thailand
FX This work was supported by Thailand research fund Career Development
   Grant #RSA5880067, Thailand and the Metabolic Bone Disease in CKD
   Patients Research Unit, Faculty of Medicine, Chulalongkorn University,
   Thailand. Cinacalcet was used in this study was granted from Kyowa Hakko
   Kirin (Thailand) Company.
CR Apetrli M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0187025
   Bouma de Krijger A, 2014, NEPHROL DIAL TRANSPL, V29, P88, DOI 10.1093/ndt/gft456
   Cernaro V, 2014, EXPERT OPIN INV DRUG, V23, P1459, DOI 10.1517/13543784.2014.962652
   Djukanovic L, 2016, NEPHRON, V132, P168, DOI 10.1159/000443848
   Eknoyan G, 2003, AM J KIDNEY DIS, V41, pS1, DOI 10.1016/S0272 6386(03)00111 2
   Faul C, 2011, J CLIN INVEST, V121, P4393, DOI 10.1172/JCI46122
   Fukagawa M, 2006, KIDNEY INT, V70, pS3, DOI 10.1038/sj.ki.5001594
   Fukagawa M, 2013, THER APHER DIAL, V17, P247, DOI 10.1111/1744 9987.12058
   FUKUDA N, 1993, J CLIN INVEST, V92, P1436, DOI 10.1172/JCI116720
   Gogusev J, 1997, KIDNEY INT, V51, P328, DOI 10.1038/ki.1997.41
   Greeyiroj P, 2018, NEPHRON, V139, P197, DOI 10.1159/000487546
   Indridason OS, 1996, KIDNEY INT, V50, P1663, DOI 10.1038/ki.1996.483
   Ketteler M, 2018, ANN INTERN MED, V168, P422, DOI 10.7326/M17 2640
   Kidney Disease: Improving Global Outcomes (KDIGO) CKD MBD Work Group, 2009, Kidney Int Suppl, pS1, DOI 10.1038/ki.2009.188
   Komaba H, 2010, CLIN J AM SOC NEPHRO, V5, P2305, DOI 10.2215/CJN.02110310
   Leifheit Nestler M, 2016, NEPHROL DIAL TRANSPL, V31, P1088, DOI 10.1093/ndt/gfv421
   Liao SL, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/8175898
   Lindberg JS, 2005, J AM SOC NEPHROL, V16, P800, DOI 10.1681/ASN.2004060512
   Lorenz K, 2015, LANGENBECK ARCH SURG, V400, P907, DOI 10.1007/s00423 015 1344 5
   Martin KJ, 2004, AM J KIDNEY DIS, V43, P558, DOI 10.1053/j.ajkd.2003.12.003
   MCCARRON DA, 1982, KIDNEY INT, V22, P662, DOI 10.1038/ki.1982.227
   Meola M, 2009, NEPHROL DIAL TRANSPL, V24, P982, DOI 10.1093/ndt/gfn654
   Messa P, 2008, CLIN J AM SOC NEPHRO, V3, P36, DOI 10.2215/CJN.03591006
   Moe SM, 2006, EUR J CLIN INVEST, V36, P51, DOI 10.1111/j.1365 2362.2006.01665.x
   Moe SM, 2007, ADV CHRONIC KIDNEY D, V14, P3, DOI 10.1053/j.ackd.2006.10.005
   Moe SM, 2005, KIDNEY INT, V67, P760, DOI 10.1111/j.1523 1755.2005.67139.x
   Palmer SC, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001436
   Reams BD, 2015, BMC NEPHROL, V16, DOI 10.1186/s12882 015 0174 6
   Rodriguez M, 2005, AM J PHYSIOL RENAL, V288, pF253, DOI 10.1152/ajprenal.00302.2004
   Rodriguez M, 2002, KIDNEY INT, V61, pS155, DOI 10.1046/j.1523 1755.61.s80.26.x
   Sterrett JR, 2007, CLIN NEPHROL, V68, P10
   Takahashi H, 2014, J CLIN ENDOCR METAB, V99, pE652, DOI 10.1210/jc.2013 4050
   Taniguchi M, 2006, KIDNEY INT, V70, P363, DOI 10.1038/sj.ki.5001549
   Tominaga Y, 1997, SEMIN SURG ONCOL, V13, P87, DOI 10.1002/(SICI)1098 2388(199703/04)13:2<87::AID SSU4>3.0.CO;2 Y
   Ureña Torres PA, 2013, NEPHROL DIAL TRANSPL, V28, P146, DOI 10.1093/ndt/gfs356
   Yamada S, 2015, THER APHER DIAL, V19, P367, DOI 10.1111/1744 9987.12292
   Zhang Q, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048070
NR 37
TC 21
Z9 22
U1 0
U2 9
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0886 022X
EI 1525 6049
J9 RENAL FAILURE
JI Ren. Fail.
PD JAN 1
PY 2019
VL 41
IS 1
BP 326
EP 333
DI 10.1080/0886022X.2018.1562356
PG 8
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Urology & Nephrology
GA HU6IP
UT WOS:000465383800001
PM 31014177
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Lee, YC
   Cheng, CJ
   Huang, M
   Bilen, MA
   Ye, XC
   Navone, NM
   Chu, K
   Kao, HH
   Yu Lee, LY
   Wang, ZX
   Lin, SH
AF Lee, Yu Chen
   Cheng, Chien Jui
   Huang, Miao
   Bilen, Mehmet A.
   Ye, Xiangcang
   Navone, Nora M.
   Chu, Khoi
   Kao, Hsin Hsin
   Yu Lee, Li Yuan
   Wang, Zhengxin
   Lin, Sue Hwa
TI Androgen depletion up regulates cadherin 11 expression in prostate
   cancer
SO JOURNAL OF PATHOLOGY
LA English
DT Article
DE PCa; androgen receptor; cadherin 11; bone metastasis; osteoblast
ID BONE; CELLS; METASTASIS; MODEL; MICE
AB Men with castration resistant prostate cancer (PCa) frequently develop metastasis in bone. The reason for this association is unclear. We have previously shown that cadherin 11 (also known as OB cadherin), a homophilic cell adhesion molecule that mediates osteoblast adhesion, plays a role in the metastasis of PCa to bone. Here, we report that androgen deprivation therapy up regulates cadherin 11 expression in PCa. In human PCa specimens, immunohistochemical staining showed that 22/26 (85%) primary PCa tumours from men with castration resistant PCa expressed cadherin 11. In contrast, only 7/50 (14%) androgen dependent PCa tumours expressed cadherin 11. In the MDA PCa 2b xenograft animal model, cadherin 11 was expressed in the recurrent tumours following castration. In the PCa cell lines, there is an inverse correlation between expression of cadherin 11 and androgen receptor (AR), and cadherin 11 is expressed in very low levels or not expressed in AR positive cell lines, including LNCaP, C4 2B4 and VCaP cells. We showed that AR likely regulates cadherin 11 expression in PCa through an indirect mechanism. Although re expression of AR in the AR negative PC3 cells led to the inhibition of cadherin 11 expression, depletion of androgen from the culture medium or down regulation of AR by RNA interference in the C4 2B4 cells or VCaP cells only produced a modest increase of cadherin 11 expression. Promoter analysis indicated that cadherin 11 promoter does not contain a typical AR binding element, and AR elicits a modest inhibition of cadherin 11 promoter activity, suggesting that AR does not regulate cadherin 11 expression directly. Together, these results suggest that androgen deprivation up regulates cadherin 11 expression in prostate cancer, and this may contribute to the metastasis of PCa to bone. Our study suggests that therapeutic strategies that block cadherin 11 expression or function may be considered when applying androgen ablation therapy. Copyright (C) 2010 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
C1 [Lin, Sue Hwa] Univ Texas MD Anderson Canc Ctr, Dept Mol Pathol, Unit 89, Houston, TX 77030 USA.
   [Navone, Nora M.; Chu, Khoi; Lin, Sue Hwa] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA.
   [Wang, Zhengxin] Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA.
   [Yu Lee, Li Yuan] Baylor Coll Med, Dept Med, Houston, TX 77030 USA.
   [Cheng, Chien Jui] Taipei Med Univ & Hosp, Dept Pathol, Taipei, Taiwan.
C3 University of Texas System; UTMD Anderson Cancer Center; University of
   Texas System; UTMD Anderson Cancer Center; University of Texas System;
   UTMD Anderson Cancer Center; Baylor College of Medicine; Taipei Medical
   University; Taipei Medical University Hospital
RP Lin, SH (通讯作者)，Univ Texas MD Anderson Canc Ctr, Dept Mol Pathol, Unit 89, 1515 Holcombe Blvd, Houston, TX 77030 USA.
EM slin@mdanderson.org
FU National Institutes of Health [CA111479, P50 CA 140388]; US Department
   of Defense [PC093132]
FX This work was supported in part by National Institutes of Health Grant
   Nos CA111479 and P50 CA 140388, US Department of Defense Grant No.
   PC093132 and an award from the Prostate Cancer Foundation.
CR Best CJM, 2005, CLIN CANCER RES, V11, P6823, DOI 10.1158/1078 0432.CCR 05 0585
   Bolton EC, 2007, GENE DEV, V21, P2005, DOI 10.1101/gad.1564207
   Cheng CJ, 2007, MOL CANCER RES, V5, P675, DOI 10.1158/1541 7786.MCR 06 0306
   Chu K, 2008, MOL CANCER RES, V6, P1259, DOI 10.1158/1541 7786.MCR 08 0077
   Furr BJA, 1996, UROLOGY, V47, P13, DOI 10.1016/S0090 4295(96)80003 3
   Korenchuk S, 2001, IN VIVO, V15, P163
   Lira CBB, 2008, PROTEIN EXPRES PURIF, V61, P220, DOI 10.1016/j.pep.2008.06.007
   Park SI, 2008, CANCER RES, V68, P3323, DOI 10.1158/0008 5472.CAN 07 2997
   Pettaway CA, 1996, CLIN CANCER RES, V2, P1627
   Pishvaian MJ, 1999, CANCER RES, V59, P947
   Rosenbaum E, 2003, EXPERT OPIN PHARMACO, V4, P875, DOI 10.1517/14656566.4.6.875
   Tamura D, 2008, INT J ONCOL, V33, P17
   Wu TT, 1998, INT J CANCER, V77, P887, DOI 10.1002/(SICI)1097 0215(19980911)77:6<887::AID IJC15>3.0.CO;2 Z
   Ye XC, 2007, FRONT BIOSCI, V12, P3273, DOI 10.2741/2311
NR 14
TC 29
Z9 36
U1 0
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0022 3417
EI 1096 9896
J9 J PATHOL
JI J. Pathol.
PD MAY
PY 2010
VL 221
IS 1
BP 68
EP 76
DI 10.1002/path.2687
PG 9
WC Oncology; Pathology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Pathology
GA 595RD
UT WOS:000277629100008
PM 20191612
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Anders, E
   Dahl, S
   Svensson, D
   Nilsson, BO
AF Anders, Emma
   Dahl, Sara
   Svensson, Daniel
   Nilsson, Bengt Olof
TI LL 37 induced human osteoblast cytotoxicity and permeability occurs
   independently of cellular LL 37 uptake through clathrin mediated
   endocytosis
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Antimicrobial peptide (AMP); Cathelicidin; Clathrin; Host defense
   peptide (HDP); Innate immunity; Osteoblast
ID ANTIMICROBIAL PEPTIDE LL 37; GINGIVAL CREVICULAR FLUID; HUMAN
   CATHELICIDIN; APOPTOSIS; DEFENSE; PROTEIN; HEAVY; CELLS; SKIN
AB The host defense peptide LL 37 is cytotoxic for bacteria but it has also been reported to reduce host cell viability through an intracellular mechanism. LL 37 evoked cytotoxicity may be involved in the loss of bone tissue in periodontitis which is an inflammatory disease characterized by high concentrations of LL 37 observed locally in the periodontal tissue at the inflammation process. Here, we showed that LL 37 reduced human osteoblast like MG63 cell viability assessed by the 3 (4,5 dimethylthiazol 2 y1) 2,5diphenyltetrazolium bromide (MTT) assay and increased plasma membrane permeability determined by measuring intracellular Ca2+ levels and lactate dehydrogenase (LDH) release. Treatment with chlorpromazine, a well recognized inhibitor of clathrin mediated endocytosis, reduced cellular uptake of synthesized LL 37 b y about 30% assessed by Western blotting and ELISA, while filipin, an inhibitor of caveolin mediated endocytosis, had no effect. The chlorpromazine induced attenuation of LL 37 uptake was not associated with modulation of LL 37 induced cytotoxicity and LL 37 evoked plasma membrane permeability. Clathrin heavy chain 2 is a major protein of the polyhedral coat of coated pits and vesicles encoded by clathrin heavy chain like 1 gene. Down regulation of clathrin heavy chain like 1 gene activity by siRNA reduced uptake of LL 37 but did not affect LL 37 induced cytotoxicity and permeability. Thus, we show, using both a pharmacological approach and knockdown of clathrin heavy chain like 1 expression, that LL 37 induced MG63 cell cytotoxicity and permeability occurs independently of LL 37 uptake via clathrin mediated endocytosis. (C) 2018 Elsevier Inc. All rights reserved.
C1 [Anders, Emma; Dahl, Sara; Svensson, Daniel; Nilsson, Bengt Olof] Lund Univ, Dept Expt Med Sci, BMC D12, SE 22184 Lund, Sweden.
C3 Lund University
RP Nilsson, BO (通讯作者)，Lund Univ, Dept Expt Med Sci, BMC D12, SE 22184 Lund, Sweden.
EM bengt olof.nilsson@med.lu.se
RI Svensson, Daniel/C 6279 2014
OI Svensson, Daniel/0000 0001 6670 2142; Nilsson,
   Bengt Olof/0000 0003 2337 8412; Bodahl, Sara/0000 0002 2829 7497
FU Alfred Osterlund Foundation; Swedish Dental Society; Royal Physiographic
   Society; Gyllenstiernska Krapperupsstiftelsen; Sigurd and Elsa Goljes
   Minne Foundation
FX This study was supported by grants from The Alfred Osterlund Foundation,
   The Swedish Dental Society, The Royal Physiographic Society, The
   Gyllenstiernska Krapperupsstiftelsen and the Sigurd and Elsa Goljes
   Minne Foundation. The authors wish to thank Professor Birgitta Agerberth
   for kindly providing an LL 37 antibody and Mrs Katarzyna Kawka for
   excellent technical assistance.
CR Barlow PG, 2010, AM J RESP CELL MOL, V43, P692, DOI 10.1165/rcmb.2009 0250OC
   Brodsky FM, 2012, ANNU REV CELL DEV BI, V28, P309, DOI 10.1146/annurev cellbio 101011 155716
   Burton MF, 2009, NAT PROD REP, V26, P1572, DOI 10.1039/b912533g
   Choi KY, 2012, J INNATE IMMUN, V4, P361, DOI 10.1159/000336630
   Ciornei Cristina D, 2006, BMC Cardiovasc Disord, V6, P49, DOI 10.1186/1471 2261 6 49
   Esk C, 2010, J CELL BIOL, V188, P131, DOI 10.1083/jcb.200908057
   Jönsson D, 2012, J PERIODONTAL RES, V47, P330, DOI 10.1111/j.1600 0765.2011.01436.x
   LARRICK JW, 1995, INFECT IMMUN, V63, P1291, DOI 10.1128/IAI.63.4.1291 1297.1995
   Liu SH, 2001, EMBO J, V20, P272, DOI 10.1093/emboj/20.1.272
   Mader JS, 2011, J IMMUNOTHER, V34, P229, DOI 10.1097/CJI.0b013e318207ecdf
   Mansour SC, 2014, TRENDS IMMUNOL, V35, P443, DOI 10.1016/j.it.2014.07.004
   McMahon HT, 2011, NAT REV MOL CELL BIO, V12, P517, DOI 10.1038/nrm3151
   Nizet V, 2001, NATURE, V414, P454, DOI 10.1038/35106587
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Puklo M, 2008, ORAL MICROBIOL IMMUN, V23, P328, DOI 10.1111/j.1399 302X.2008.00433.x
   Säll J, 2013, J INNATE IMMUN, V5, P290, DOI 10.1159/000346587
   Sorensen OE, 2001, BLOOD, V97, P3951, DOI 10.1182/blood.V97.12.3951
   Svensson D, 2017, BIOCHEM BIOPH RES CO, V493, P71, DOI 10.1016/j.bbrc.2017.09.072
   Svensson D, 2016, BIOCHEM J, V473, P87, DOI 10.1042/BJ20150798
   Tang X, 2015, J IMMUNOL, V195, P1191, DOI 10.4049/jimmunol.1402845
   Turkoglu O, 2017, CLIN ORAL INVEST, V21, P763, DOI 10.1007/s00784 016 1834 z
   Wakeham DE, 2005, P NATL ACAD SCI USA, V102, P7209, DOI 10.1073/pnas.0502058102
   WANG LH, 1993, J CELL BIOL, V123, P1107, DOI 10.1083/jcb.123.5.1107
   Yamasaki K, 2006, FASEB J, V20, P2068, DOI 10.1096/fj.06 6075com
   Yoshio H, 2003, PEDIATR RES, V53, P211, DOI 10.1203/01.PDR.0000047471.47777.B0
   Zhang ZF, 2008, J LEUKOCYTE BIOL, V84, P780, DOI 10.1189/jlb.0208086
NR 26
TC 24
Z9 24
U1 0
U2 26
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0006 291X
EI 1090 2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD JUN 18
PY 2018
VL 501
IS 1
BP 280
EP 285
DI 10.1016/j.bbrc.2018.04.235
PG 6
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA GI4VX
UT WOS:000434370400041
PM 29729269
DA 2025 08 17
ER

PT J
AU Xie, F
   Wu, CF
   Zhang, Y
   Yao, XS
   Cheung, PY
   Chan, ASC
   Wong, MS
AF Xie, F
   Wu, CF
   Zhang, Y
   Yao, XS
   Cheung, PY
   Chan, ASC
   Wong, MS
TI Increase in bone mass and bone strength by Sambucus williamsii
   HANCE in ovariectomized rats
SO BIOLOGICAL & PHARMACEUTICAL BULLETIN
LA English
DT Article
DE Sambucus williamsii; ovariectomized rat; bone mineral density; bone
   strength OPG; RANKL
ID HORMONE REPLACEMENT THERAPY; RESORPTION IN VITRO; KAMPO FORMULAS;
   PHYTOESTROGENS; PREVENTION; ESTROGEN; GENISTEIN; VIVO
AB Herbal Sambucus williamsii HANCE (SWH) is a folk medicine with a long history of safe use for treatment of bone fractures and joint diseases in China. The present study was designed to investigate if SWH extract could be used for treatment of postmenopausal osteoporosis. SWH extracts (30 or 60 mg/100 g body weight/d) were orally administrated to four months old ovariectomized (OVX) rats for 3 months. SWH extracts did not alter weight gain and uterus weight in OVX rats. SWH extracts significantly increased serum Ca levels (p<0.05, vs. OVX control group) as well as decreased urinary Ca excretion (p<0.01, vs. OVX control group) in OVX rats. The upregulation of serum alkaline phosphatase, serum osteocalcin as well as urinary deoxypyridinoline levels by OVX was suppressed by treatment with SWH extracts in rats (p<0.05, vs. OVX control group). SWH extract increased the stiffness of femur at both dosage (p<0.05, vs. OVX control group) and increased tibial bone mineral density at 60 mg/100 g body weight/d (p<0.05, vs. OVX control group) in OVX rats. Our results indicate that orally administrated SWH extracts can decrease urinary calcium excretion and bone turnover rate in OVX rats, resulting in positive effects on biomechanical strength of bone and bone mineral density. This study is the first to report that SWH could be considered as a potential candidate for management of postmenopausal osteoporosis. Then in vitro experiments were performed to determine the potential molecular mechanism of the anti osteoporotic effect of SWH. Results suggested that chloroform fraction and ethyl acetate fraction of SWH can inhibit osteoclastogenesis osteoclast by modulating the expression of osteoprotegrin (OPG) and receptor activator of NFKB ligand (RANKL) mRNA in osteoblastic UMR 106 cells. Both of them increased OPG mRNA and decreased RANKL mRNA expression, resulting in a dose dependent increase in OPG/RANKL mRNA ratio (p<0.01, vs. vehicle treated). Taken together, SWH treatment can effectively suppress the OVX induced increase in bone turnover and its effects might be mediated by a decrease in osteoclastogenesis.
C1 Shenyang Pharmaceut Univ, Dept Pharmacol, Shenyang 110016, Peoples R China.
   Hong Kong Polytech Univ, Dept Appl Biol & Chem Technol, Inst Mol Technol Drug Discovery & Synth, Open Lab Chirotechnol, Hong Kong, Hong Kong, Peoples R China.
   Chinese Med & Mol Pharmacol, State Key Lab, Shenzhen 518057, Peoples R China.
C3 Shenyang Pharmaceutical University; Hong Kong Polytechnic University
RP Yao, XS (通讯作者)，Shenyang Pharmaceut Univ, Dept Pharmacol, Shenyang 110016, Peoples R China.
EM yaoxinsheng@hotmail.com; bcmswong@polyu.edu.hk
RI Wong, Man Sau/F 2059 2015; Chan, Ash/JPY 2777 2023
OI Wong, Man Sau/0000 0002 0729 8618; 
CR Ahmadiani A, 1998, J ETHNOPHARMACOL, V61, P229, DOI 10.1016/S0378 8741(98)00043 9
   Allen MJ, 2003, VET CLIN PATH, V32, P101, DOI 10.1111/j.1939 165X.2003.tb00323.x
   Anderson JJB, 1998, P SOC EXP BIOL MED, V217, P345, DOI 10.3181/00379727 217 44243
   Arjmandi BH, 1998, AM J CLIN NUTR, V68, p1364S, DOI 10.1093/ajcn/68.6.1364S
   Beral V, 1999, J Epidemiol Biostat, V4, P191
   Body JJ, 2002, BONE, V30, p75S
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   *CHIN MAT MED STAT, 2000, CHIN BENC, P545
   Davison S, 2003, CLIN ENDOCRINOL, V58, P249, DOI 10.1046/j.1365 2265.2003.01774.x
   DEMPSTER DW, 1995, BONE, V16, P157, DOI 10.1016/8756 3282(95)80027 N
   FORREST SM, 1985, CALCIFIED TISSUE INT, V37, P51, DOI 10.1007/BF02557679
   Garnero P, 1997, ENDOCRIN METAB CLIN, V26, P913, DOI 10.1016/S0889 8529(05)70287 5
   Glazier MG, 2001, ARCH INTERN MED, V161, P1161, DOI 10.1001/archinte.161.9.1161
   Hans D, 1997, BAILLIERE CLIN RHEUM, V11, P495, DOI 10.1016/S0950 3579(97)80017 9
   Ibarreta D, 2001, APMIS, V109, P161, DOI 10.1034/j.1600 0463.2001.090301.x
   Ishida H, 1998, BIOL PHARM BULL, V21, P62, DOI 10.1248/bpb.21.62
   KAJI H, 2003, PHARM MED, V21, P69
   KALU DN, 1991, BONE MINER, V15, P175, DOI 10.1016/0169 6009(91)90124 I
   Kang HJ, 2002, INT J GYNECOL OBSTET, V79, P195, DOI 10.1016/S0020 7292(02)00297 7
   Kleerekoper M, 1998, ENDOCRIN METAB CLIN, V27, P441, DOI 10.1016/S0889 8529(05)70015 3
   LI CY, 1997, CHIN J OSTEOPOROSIS, V3, P67
   Li H, 1998, BIOL PHARM BULL, V21, P1322, DOI 10.1248/bpb.21.1322
   Li HY, 1998, BIOL PHARM BULL, V21, P594, DOI 10.1248/bpb.21.594
   Li HY, 1999, BIOL PHARM BULL, V22, P391, DOI 10.1248/bpb.22.391
   Lin YP, 1993, CHIN J ORTHOPAEDIC T, V6, P8
   Liu HD, 1996, CHIN J OSTEOPOROSIS, V2, P62
   LIU W, 1991, Fitoterapia, V62, P83
   Milbury PE, 2002, MECH AGEING DEV, V123, P997, DOI 10.1016/S0047 6374(01)00383 9
   MITLAK BH, 1994, J BONE MINER RES, V9, P119
   NAKAMURA T, 2002, BONE OSAKA, V16, P167
   Nelson HD, 2002, JAMA J AM MED ASSOC, V288, P872, DOI 10.1001/jama.288.7.872
   Ososki AL, 2003, PHYTOTHER RES, V17, P845, DOI 10.1002/ptr.1364
   Persson I, 1999, CANCER CAUSE CONTROL, V10, P253, DOI 10.1023/A:1008909128110
   Ringe JD, 2004, RHEUMATOL INT, V24, P189, DOI 10.1007/s00296 004 0454 0
   RODRIGUEZ C, 1995, AM J EPIDEMIOL, V141, P828, DOI 10.1093/oxfordjournals.aje.a117518
   Saarinen NM, 2000, NUTR CANCER, V36, P207, DOI 10.1207/S15327914NC3602_10
   Santell RC, 1997, J NUTR, V127, P263, DOI 10.1093/jn/127.2.263
   SOMCHIT J, 1999, J MED ASS THAI, V82, P1268
   Toda T, 1999, BIOL PHARM BULL, V22, P1193, DOI 10.1248/bpb.22.1193
   Ward WE, 2001, BRIT J NUTR, V86, P499, DOI 10.1079/BJN2001429
   Watts NB, 2003, CLIN GERIATR MED, V19, P395, DOI 10.1016/S0749 0690(02)00069 1
   Yin J, 1993, MODERN STUDY CLIN AP, P382
   Yu S, 1999, Chin J Dent Res, V2, P7
   Zakay Rones Z, 1995, J Altern Complement Med, V1, P361, DOI 10.1089/acm.1995.1.361
NR 44
TC 41
Z9 47
U1 0
U2 14
PU PHARMACEUTICAL SOC JAPAN
PI TOKYO
PA 2 12 15 SHIBUYA, SHIBUYA KU, TOKYO, 150 0002, JAPAN
SN 0918 6158
EI 1347 5215
J9 BIOL PHARM BULL
JI Biol. Pharm. Bull.
PD OCT
PY 2005
VL 28
IS 10
BP 1879
EP 1885
DI 10.1248/bpb.28.1879
PG 7
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 975RY
UT WOS:000232680800012
PM 16204939
OA Bronze
DA 2025 08 17
ER

PT J
AU Yuan, SS
   Wei, YP
   Jiang, WT
   Sun, F
   Li, SQ
   Li, QQ
   Song, ZM
   Liu, ZT
   Mo, YQ
   Wang, XK
   Li, N
   Lv, P
   She, SP
   Wang, C
   Zhang, Y
   Wang, Y
   Hu, WJ
AF Yuan, Shasha
   Wei, Yiping
   Jiang, Wenting
   Sun, Fei
   Li, Siqi
   Li, Qingqing
   Song, Zhanming
   Liu, Zhongtian
   Mo, Yaqian
   Wang, Xuekang
   Li, Ning
   Lv, Ping
   She, Shaoping
   Wang, Cui
   Zhang, Yu
   Wang, Ying
   Hu, Wenjie
TI CCR2 is a potential therapeutic target in peri implantitis
SO JOURNAL OF CLINICAL PERIODONTOLOGY
LA English
DT Article
DE bone loss; chemokine; dental implant(s); immunity; inflammation
ID CONSENSUS REPORT; COMPLICATIONS; EXPRESSION; CYTOKINE; HEALTH
AB Aim: CCR2 plays important roles in many inflammatory and bone metabolic diseases, but its specific role in periodontitis is unknown. In the present study, we aimed to explore the role of CCR2 in the progression of periodontitis and evaluate the effect of cenicriviroc (CVC) on periodontitis.Materials and methods: The expression of CCR2 was studied in patients with periodontitis and in ligation induced murine model of periodontitis. The role of CCR2 in promoting inflammation and bone resorption in periodontitis was evaluated in Ccr2( / ) mice and wild type mice. The effect of CVC in the prevention and treatment of periodontitis was evaluated by systemic and local medication. Microcomputed tomography, haematoxylin and eosin staining, tartrate resistant acid phosphatase staining, quantitative real time polymerase chain reaction, enzyme linked immunosorbent assay, and flow cytometry were used for histomorphology, molecular biology, and cytology analysis, respectively.Results: In this study, we demonstrated that CCR2 was highly expressed in human and murine periodontitis and that CCR2 deficiency was associated with decreased inflammatory monocyte and macrophage infiltration and inflammatory mediators, osteoclast number and alveolar bone resorption. Prevention and treatment with CVC significantly reduced the severity of periodontitis, regardless of whether it was administered systemically or locally.Conclusions: CCR2 plays an important role in the development and progression of periodontitis, and CVC is a potential drug for the prevention and treatment of periodontitis.
C1 [Yuan, Shasha; Wei, Yiping; Jiang, Wenting; Sun, Fei; Li, Siqi; Wang, Cui; Hu, Wenjie] Peking Univ, Beijing Key Lab Digital Stomatol, Natl Engn Lab Digital & Mat Technol Stomatol, Dept Prosthodont,Natl Clin Res Ctr Oral Dis,Sch &, Beijing, Peoples R China.
   [Yuan, Shasha] Nankai Univ, Tianjin Stomatol Hosp, Hosp Stomatol, Dept Periodontol, Tianjin, Peoples R China.
   [Li, Qingqing; Song, Zhanming; Liu, Zhongtian; Mo, Yaqian; Wang, Xuekang; Li, Ning; Lv, Ping; Zhang, Yu; Wang, Ying] Peking Univ, Sch Basic Med Sci, Dept Immunol, Beijing, Peoples R China.
   [Li, Qingqing; Song, Zhanming; Liu, Zhongtian; Mo, Yaqian; Wang, Xuekang; Li, Ning; Lv, Ping; Zhang, Yu; Wang, Ying] Peking Univ, NHC Key Lab Med Immunol, Beijing, Peoples R China.
   [Lv, Ping; Wang, Ying] Peking Univ, Ctr Human Dis Genom, Beijing, Peoples R China.
   [She, Shaoping] Peking Univ, Peoples Hosp, Hepatol Inst, Beijing Key Lab Hepatitis C & Immunotherapy Liver, Beijing, Peoples R China.
   [Hu, Wenjie] NHC Res Ctr Engn & Technol Computerized Dent, Beijing, Peoples R China.
   [Wang, Ying] Peking Univ, Sch Basic Med Sci, Dept Immunol, 38 Coll Rd, Beijing, Peoples R China.
   [Wang, Ying] Peking Univ, NHC Key Lab Med Immunol, 38 Coll Rd, Beijing, Peoples R China.
   [Hu, Wenjie] Peking Univ, Beijing Key Lab Digital Stomatol, Natl Engn Lab Digital & Mat Technol Stomatol, Dept Prosthodont,Natl Clin Res Ctr Oral Dis,Sch &, 22 Zhongguancun South St, Beijing, Peoples R China.
C3 Peking University; Tianjin Medical University; Nankai University; Peking
   University; Peking University; Peking University; Peking University;
   Peking University; Peking University; Peking University
RP Wang, Y (通讯作者)，Peking Univ, Sch Basic Med Sci, Dept Immunol, 38 Coll Rd, Beijing, Peoples R China.; Wang, Y (通讯作者)，Peking Univ, NHC Key Lab Med Immunol, 38 Coll Rd, Beijing, Peoples R China.; Hu, WJ (通讯作者)，Peking Univ, Beijing Key Lab Digital Stomatol, Natl Engn Lab Digital & Mat Technol Stomatol, Dept Prosthodont,Natl Clin Res Ctr Oral Dis,Sch &, 22 Zhongguancun South St, Beijing, Peoples R China.
EM yw@bjmu.edu.cn; huwenjie@pkuss.bjmu.edu.cn
RI Liu, Zhongtian/ABE 5037 2021
OI Wei, Yiping/0000 0002 8517 3757; Li, Siqi/0000 0002 0048 0820
FU Peking University Clinical Scientist Program
FX No Statement Availabler No Statement Available
CR Al Aali KA, 2018, CLIN IMPLANT DENT R, V20, P410, DOI 10.1111/cid.12597
   Ambade A, 2019, HEPATOLOGY, V69, P1105, DOI 10.1002/hep.30249
   Anstee QM, 2020, CONTEMP CLIN TRIALS, V89, DOI 10.1016/j.cct.2019.105922
   Arciola CR, 2018, NAT REV MICROBIOL, V16, P397, DOI 10.1038/s41579 018 0019 y
   Berglundh T, 2018, J CLIN PERIODONTOL, V45, pS286, DOI 10.1111/jcpe.12957
   Binder NB, 2009, NAT MED, V15, P417, DOI 10.1038/nm.1945
   Deng S, 2020, J PERIODONTOL, V91, P671, DOI 10.1002/JPER.18 0748
   Derks J, 2015, J CLIN PERIODONTOL, V42, pS158, DOI 10.1111/jcpe.12334
   Dionigi C, 2020, J CLIN PERIODONTOL, V47, P1466, DOI 10.1111/jcpe.13370
   Festing Michael F W, 2002, ILAR J, V43, P244
   Fretwurst T, 2020, CLIN ORAL IMPLAN RES, V31, P274, DOI 10.1111/clr.13568
   Fujihara R, 2014, J PERIODONTAL RES, V49, P508, DOI 10.1111/jre.12131
   Ghassib I, 2019, CLIN IMPLANT DENT R, V21, P190, DOI 10.1111/cid.12694
   Hajishengallis E, 2014, J DENT RES, V93, P231, DOI 10.1177/0022034513507956
   Heitz Mayfield LJ, 2018, CLIN ORAL IMPLAN RES, V29, P351, DOI 10.1111/clr.13307
   Hentenaar DFM, 2021, J CLIN PERIODONTOL, V48, P590, DOI 10.1111/jcpe.13423
   Irshad M, 2013, J PERIODONTAL RES, V48, P647, DOI 10.1111/jre.12051
   Jiang WT, 2022, J CLIN PERIODONTOL, V49, P1203, DOI 10.1111/jcpe.13699
   Kim JH, 2009, J IMMUNOL, V183, P1862, DOI 10.4049/jimmunol.0803007
   Lang NP, 2000, CLIN ORAL IMPLAN RES, V11, P146, DOI 10.1034/j.1600 0501.2000.011S1146.x
   Pirih FQ, 2015, J PERIODONTAL RES, V50, P519, DOI 10.1111/jre.12234
   PRODJOSUDJADI W, 1995, KIDNEY INT, V48, P1477, DOI 10.1038/ki.1995.437
   Raghu H, 2017, ANN RHEUM DIS, V76, DOI 10.1136/annrheumdis 2016 210426
   Renvert S, 2017, CLIN ORAL IMPLAN RES, V28, P1127, DOI 10.1111/clr.12927
   Roccuzzo M, 2018, CLIN ORAL IMPLAN RES, V29, P331, DOI 10.1111/clr.13287
   Schwarz F, 2015, PERIODONTOL 2000, V68, P168, DOI 10.1111/prd.12064
   Serbina NV, 2006, NAT IMMUNOL, V7, P311, DOI 10.1038/ni1309
   Shen ZS, 2021, CELL MOL IMMUNOL, V18, P2224, DOI 10.1038/s41423 020 0500 1
   Sima C, 2013, PERIODONTOL 2000, V63, P80, DOI 10.1111/prd.12032
   Singh S, 2021, INT IMMUNOPHARMACOL, V101, DOI 10.1016/j.intimp.2021.107598
   Venza I, 2010, J PERIODONTOL, V81, P99, DOI 10.1902/jop.2009.090358
   Wang CW, 2021, THERANOSTICS, V11, P6703, DOI 10.7150/thno.57775
   Yao Y, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.664871
   Zhao BH, 2012, J EXP MED, V209, P319, DOI 10.1084/jem.20111566
   Zhu SP, 2021, J CELL PHYSIOL, V236, P7211, DOI 10.1002/jcp.30375
NR 35
TC 5
Z9 5
U1 4
U2 25
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0303 6979
EI 1600 051X
J9 J CLIN PERIODONTOL
JI J. Clin. Periodontol.
PD MAR
PY 2024
VL 51
IS 3
BP 354
EP 364
DI 10.1111/jcpe.13916
EA DEC 2023
PG 11
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA IC8M1
UT WOS:001127024000001
PM 38111083
DA 2025 08 17
ER

PT J
AU Tsuboi, E
   Asakawa, Y
   Hirose, N
   Yanoshita, M
   Sumi, C
   Takano, M
   Onishi, A
   Nishiyama, S
   Kubo, N
   Kita, D
   Tanimoto, K
AF Tsuboi, Eri
   Asakawa, Yuki
   Hirose, Naoto
   Yanoshita, Makoto
   Sumi, Chikako
   Takano, Mami
   Onishi, Azusa
   Nishiyama, Sayuri
   Kubo, Naoki
   Kita, Daiki
   Tanimoto, Kotaro
TI The role of semaphorin 3A on chondrogenic differentiation
SO IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY ANIMAL
LA English
DT Article
DE Semaphorin3A; Cartilage; Endochondral ossification; Cartilage substrate;
   ATDC5
ID CELL LINE; ENDOCHONDRAL OSSIFICATION; HYALURONAN; GROWTH; IV;
   NEUROPILIN; CARTILAGE; RECEPTOR; PLEXIN; FAMILY
AB Osteoblast derived semaphorin3A (Sema3A) has been reported to be involved in bone protection, and Sema3A knockout mice have been reported to exhibit chondrodysplasia. From these reports, Sema3A is considered to be involved in chondrogenic differentiation and skeletal formation, but there are many unclear points about its function and mechanism in chondrogenic differentiation. This study investigated the pharmacological effects of Sema3A in chondrogenic differentiation. The amount of Sema3A secreted into the culture supernatant was measured using an enzyme linked immunosorbent assay. The expression of chondrogenic differentiation related factors, such as Type II collagen (COL2A1), Aggrecan (ACAN), hyaluronan synthase 2 (HAS2), SRY box transcription factor 9 (Sox9), Runt related transcription factor 2 (Runx2), and Type X collagen (COL10A1) in ATDC5 cells treated with Sema3A (1,10 and 100 ng/mL) was examined using real time reverse transcription polymerase chain reaction. Further, to assess the deposition of total glycosaminoglycans during chondrogenic differentiation, ATDC5 cells were stained with Alcian Blue. Moreover, the amount of hyaluronan in the culture supernatant was measured by enzyme linked immunosorbent assay. The addition of Sema3A to cultured ATDC5 cells increased the expression of Sox9, Runx2, COL2A1, ACAN, HAS2, and COL10A1 during chondrogenic differentiation. Moreover, it enhanced total proteoglycan and hyaluronan synthesis. Further, Sema3A was upregulated in the early stages of chondrogenic differentiation, and its secretion decreased later. Sema3A increases extracellular matrix production and promotes chondrogenic differentiation. To the best of our knowledge, this is the first study to demonstrate the role of Sema3A on chondrogenic differentiation.
C1 [Tsuboi, Eri; Asakawa, Yuki; Hirose, Naoto; Yanoshita, Makoto; Sumi, Chikako; Takano, Mami; Onishi, Azusa; Nishiyama, Sayuri; Kubo, Naoki; Kita, Daiki; Tanimoto, Kotaro] Hiroshima Univ, Dept Orthodont & Craniofacial Dev Biol, Grad Sch Biomed & Hlth Sci, 1 2 3 Kasumi,Minami Ku, Hiroshima 7348553, Japan.
C3 Hiroshima University
RP Hirose, N (通讯作者)，Hiroshima Univ, Dept Orthodont & Craniofacial Dev Biol, Grad Sch Biomed & Hlth Sci, 1 2 3 Kasumi,Minami Ku, Hiroshima 7348553, Japan.
EM hirose@hiroshima u.ac.jp
FU Hiroshima University
FX Open Access funding provided by Hiroshima University.
CR ATSUMI T, 1990, CELL DIFFER DEV, V30, P109, DOI 10.1016/0922 3371(90)90079 C
   Behar O, 1996, NATURE, V383, P525, DOI 10.1038/383525a0
   Chen H, 1997, NEURON, V19, P547, DOI 10.1016/S0896 6273(00)80371 2
   Chen HY, 2014, J BONE MINER RES, V29, P2653, DOI 10.1002/jbmr.2287
   Goldring MB, 2006, J CELL BIOCHEM, V97, P33, DOI 10.1002/jcb.20652
   Hayashi M, 2019, CELL METAB, V29, P627, DOI 10.1016/j.cmet.2018.12.021
   Hayashi M, 2012, NATURE, V485, P69, DOI 10.1038/nature11000
   Kajii TS, 2018, BIOMED REP, V9, P253, DOI 10.3892/br.2018.1128
   Kaneko S, 2006, NAT MED, V12, P1380, DOI 10.1038/nm1505
   Kolodkin AL, 1997, CELL, V90, P753, DOI 10.1016/S0092 8674(00)80535 8
   KOLODKIN AL, 1993, CELL, V75, P1389, DOI 10.1016/0092 8674(93)90625 Z
   Kumanogoh A, 2002, NATURE, V419, P629, DOI 10.1038/nature01037
   Mackie EJ, 2008, INT J BIOCHEM CELL B, V40, P46, DOI 10.1016/j.biocel.2007.06.009
   Magee C, 2001, BIOCHEM J, V360, P667, DOI 10.1042/0264 6021:3600667
   Nagata K, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 022 33744 5
   Nakatani S, 2007, BIOL PHARM BULL, V30, P433, DOI 10.1248/bpb.30.433
   Nishimura R, 2012, J BIOL CHEM, V287, P33179, DOI 10.1074/jbc.M111.337063
   Ono K, 2021, COMMUN BIOL, V4, DOI 10.1038/s42003 021 01848 1
   Sekido Y, 1996, P NATL ACAD SCI USA, V93, P4120, DOI 10.1073/pnas.93.9.4120
   Serini G, 2003, NATURE, V424, P391, DOI 10.1038/nature01784
   Shukunami C, 1997, J BONE MINER RES, V12, P1174, DOI 10.1359/jbmr.1997.12.8.1174
   Sumi C, 2018, MEDIAT INFLAMM, V2018, DOI 10.1155/2018/5703651
   Suzuki A, 2005, BBA MOL CELL RES, V1743, P57, DOI 10.1016/j.bbamcr.2004.08.007
   Takahashi T, 2001, NEURON, V29, P429, DOI 10.1016/S0896 6273(01)00216 1
   Winberg ML, 1998, CELL, V95, P903, DOI 10.1016/S0092 8674(00)81715 8
   Woods A, 2007, J BIOL CHEM, V282, P23500, DOI 10.1074/jbc.M700680200
   Yamaguchi Y, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0201839
   Yazdani U, 2006, GENOME BIOL, V7, DOI 10.1186/gb 2006 7 3 211
   Yonashiro R, 2009, MOL BIOL CELL, V20, P4524, DOI 10.1091/mbc.E09 02 0112
   Yoshida S, 2016, J DENT RES, V95, P1282, DOI 10.1177/0022034516653085
   Yoshioka Y, 2015, HISTOCHEM CELL BIOL, V144, P167, DOI 10.1007/s00418 015 1325 3
   Zhou YP, 2008, TRENDS BIOCHEM SCI, V33, P161, DOI 10.1016/j.tibs.2008.01.006
NR 32
TC 2
Z9 2
U1 1
U2 5
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1071 2690
EI 1543 706X
J9 IN VITRO CELL DEV AN
JI In Vitro Cell. Dev. Biol. Anim.
PD JUN
PY 2024
VL 60
IS 6
BP 609
EP 615
DI 10.1007/s11626 024 00909 z
EA MAY 2024
PG 7
WC Cell Biology; Developmental Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Developmental Biology
GA L5C1W
UT WOS:001220298400001
PM 38727898
OA hybrid
DA 2025 08 17
ER

PT J
AU Martel Pelletier, J
   Tat, SK
   Pelletier, JP
AF Martel Pelletier, J.
   Tat, S. Kwan
   Pelletier, J.  P.
TI Effects of chondroitin sulfate in the pathophysiology of the
   osteoarthritic joint: a narrative review
SO OSTEOARTHRITIS AND CARTILAGE
LA English
DT Article; Proceedings Paper
CT 13th World Congress of the Osteoarthritis Research Society International
CY SEP 18 21, 2008
CL Rome, ITALY
SP Osteoarthritis Res Soc Int, Bioiberica
DE Chondroition sulfate; Articular tissues; Cartilage; Synovial membrane;
   Subchondral bone
ID SUBCHONDRAL BONE OSTEOBLASTS; COLLAGEN INDUCED ARTHRITIS;
   FACTOR KAPPA B; HYALURONIC ACID; ARTICULAR CHONDROCYTES;
   GENE EXPRESSION; METABOLIC FATE; GLUCOSAMINE SULFATE; CARTILAGE;
   INTERLEUKIN 1 BETA
AB Objective: Osteoarthritis is a chronic disease characterized by irreversible damage to joint structures, including loss of articular cartilage, inflammation of the synovial membrane, and alterations in the subchondral bone. Symptomatic slow acting drugs for osteoarthritis have been proposed as treatment because of their excellent safety profile. This review summarizes some data relating to the mechanisms of action of chondroitin sulfate in the pathophysiology of osteoarthritic joint tissues.
   Methods: Peer reviewed articles obtained using pre defined search criteria and published in the PubMed database are summarized. In addition, a relevant in press paper is included.
   Results: Chondroitin sulfate belongs to the group of glycosaminoglycans and is a major component of articular cartilage. The effect of chondroitin sulfate in patients with osteoarthritis is possibly the result of the stimulation of the synthesis of proteoglycans and the decrease in catabolic activity of chondrocytes by inhibiting the synthesis of proteolytic enzymes and other factors that contribute to cartilage matrix damage and cause the death of these cells. Chondroitin sulfate was also shown to exert anti inflammatory activity. In addition, it acts on osteoarthritic subchondral bone osteoblasts by modulating the osteoprotegerin/receptor activator of NF kappa B ligand ratio in favor of reduced bone resorption. It is noteworthy to mention that a head to head comparison of the effects of chondroitin sulfate of different origins and levels of purity on human osteoarthritic cartilage revealed the existence of a disparity in effects.
   Conclusion: The positive effects of chondroitin sulfate on the pathophysiology of osteoarthritis are possibly due to its contribution to a proper balance between anabolism/catabolism in the articular tissues. (C) 2010 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
C1 [Martel Pelletier, J.; Tat, S. Kwan; Pelletier, J.  P.] Univ Montreal Hosp Res Ctr CRCHUM, Notre Dame Hosp, Osteoarthritis Res Unit, Montreal, PQ H2L 4M1, Canada.
C3 Universite de Montreal
RP Martel Pelletier, J (通讯作者)，Univ Montreal Hosp Res Ctr CRCHUM, Notre Dame Hosp, Osteoarthritis Res Unit, 1560 Sherbrooke St E, Montreal, PQ H2L 4M1, Canada.
EM jm@martelpelletier.ca
RI Pelletier, Jean Pierre/AAG 2896 2019; Martel Pelletier,
   Johanne/AAG 2928 2019
CR Albertini R, 2000, INT J MOL MED, V6, P129
   BAICI A, 1984, CHEM BIOL INTERACT, V51, P1, DOI 10.1016/0009 2797(84)90015 2
   BAICI A, 1990, CELL TISSUE RES, V259, P567, DOI 10.1007/BF01740785
   Bassleer CT, 1998, OSTEOARTHR CARTILAGE, V6, P196, DOI 10.1053/joca.1998.0112
   Campo GM, 2004, FREE RADICAL RES, V38, P601, DOI 10.1080/10715760410001694017
   Campo GM, 2003, ARTHRITIS RES THER, V5, pR122, DOI 10.1186/ar748
   Campo GM, 2003, FREE RADICAL RES, V37, P257, DOI 10.1080/1071576021000046640
   Caraglia M, 2005, EXP MOL MED, V37, P476, DOI 10.1038/emm.2005.58
   Chan PS, 2006, J RHEUMATOL, V33, P1329
   Chan PS, 2005, AM J VET RES, V66, P1870, DOI 10.2460/ajvr.2005.66.1870
   Chan PS, 2005, OSTEOARTHR CARTILAGE, V13, P387, DOI 10.1016/j.joca.2005.01.003
   Cho SY, 2004, BIOL PHARM BULL, V27, P47, DOI 10.1248/bpb.27.47
   Chou MM, 2005, EXP BIOL MED, V230, P255
   Clegg DO, 2006, NEW ENGL J MED, V354, P795, DOI 10.1056/NEJMoa052771
   CONTE A, 1991, ARZNEIMITTEL FORSCH, V41 2, P768
   CONTE A, 1995, ARZNEIMITTEL FORSCH, V45 2, P918
   CONTE A, 1991, DRUG EXP CLIN RES, V17, P27
   Couchourel D, 2009, ARTHRITIS RHEUM US, V60, P1438, DOI 10.1002/art.24489
   Jomphe C, 2008, BASIC CLIN PHARMACOL, V102, P59, DOI 10.1111/j.1742 7843.2007.00158.x
   Li BH, 1999, J ANAT, V195, P101, DOI 10.1046/j.1469 7580.1999.19510101.x
   Maneiro Emilia, 2001, Revista Espanola de Reumatologia, V28, P12
   Martel Pelletier J., 2007, OSTEOARTHRITIS, P15
   Martel Pelletier J., 2005, Arthritis and Allied Conditioned:A textbook of Rheumatology, P2199
   Monfort J, 2005, DRUG EXP CLIN RES, V31, P71
   NISHIKAWA H, 1985, ARCH BIOCHEM BIOPHYS, V240, P146, DOI 10.1016/0003 9861(85)90017 7
   NISHIKAWA H, 1988, ARCH BIOCHEM BIOPHYS, V266, P201, DOI 10.1016/0003 9861(88)90251 2
   Omata T, 1999, ARZNEIMITTELFORSCH, V49, P577
   Orth MW, 2002, EQUINE VET J, V34, P224
   PALMIERI L, 1990, ARZNEIMITTELFORSCH, V40 1, P319
   Ronca F, 1998, OSTEOARTHR CARTILAGE, V6, P14, DOI 10.1016/S1063 4584(98)80006 X
   SEIBEL MJ, 1989, J RHEUMATOL, V16, P964
   SOWERS M, 1991, ARTHRITIS RHEUM, V34, P36, DOI 10.1002/art.1780340106
   Tat SK, 2008, CLIN EXP RHEUMATOL, V26, P295
   Tat SK, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2325
   Tat SK, 2010, J RHEUMATOL, V37, P656, DOI 10.3899/jrheum.090696
   Uebelhart D, 1998, OSTEOARTHR CARTILAGE, V6, P6, DOI 10.1016/S1063 4584(98)80005 8
   Verbruggen G, 1977, Acta Rhumatol Belg, V1, P75
   Verges J, 2004, OSTEOARTHR CARTILAGE, V12, P194
   Volpi N, 2002, OSTEOARTHR CARTILAGE, V10, P768, DOI 10.1053/joca.2002.0824
   Wang L, 2002, CLIN EXP RHEUMATOL, V20, P669
NR 40
TC 67
Z9 76
U1 0
U2 24
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1063 4584
EI 1522 9653
J9 OSTEOARTHR CARTILAGE
JI Osteoarthritis Cartilage
PD JUN
PY 2010
VL 18
SU 1
BP S7
EP S11
DI 10.1016/j.joca.2010.01.015
PG 5
WC Orthopedics; Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC Orthopedics; Rheumatology
GA 622LG
UT WOS:000279664700002
PM 20399897
OA Bronze
DA 2025 08 17
ER

PT J
AU Nam, JS
   Jagga, S
   Sharma, AR
   Lee, JH
   Park, JB
   Jung, JS
   Lee, SS
AF Nam, Ju Suk
   Jagga, Supriya
   Sharma, Ashish Ranjan
   Lee, Joon Hee
   Park, Jong Bong
   Jung, Jun Sub
   Lee, Sang Soo
TI Anti inflammatory effects of traditional mixed extract of medicinal
   herbs (MEMH) on monosodium urate crystal induced gouty arthritis
SO CHINESE JOURNAL OF NATURAL MEDICINES
LA English
DT Article
DE Gout; Monosodium urate crystals; Inflammation; Chondrocyte; Oriental
   medicine
ID HUMAN ARTICULAR CARTILAGE; ANTI DIURETIC ACTIVITIES; IN VITRO;
   MONOHYDRATE CRYSTALS; INHIBITORY ACTIVITY; MATRIX DEGRADATION;
   ALISMATIS RHIZOMA; CHINESE MEDICINE; QUALITY CONTROL; ANIMAL MODEL
AB Korean oriental medicine prescription is widely used for the treatment of gouty diseases. In the present study, we investigated anti inflammatory effects of modified Korean herbal formulation, mixed extract of medicinal herbs (MEMH), and its modulatory effects on inflammatory mediators associated with gouty arthritis. Both in vitro and in vivo studies were carried out to assess the anti inflammatory efficacy of MEMH on monosodium urate (MSU) crystals induced gouty inflammation. MSU crystals stimulated human chondrosarcoma cell line, SW1353, and human primary chondrocytes were treated with MEMH in vitro. The expression levels of pro inflammatory mediators and metalloproteases were analyzed. The effect of MEMH on NF kappa B signaling pathway in SW1353 cells was examined. Effect of MEMH on the mRNA expression level of pro inflammatory mediators and chemotactic factor from human monocytic cell line, THP 1, was also analyzed. The probable role of MEMH in the differentiation process of osteoblast like cells, SaOS 2, after MSU treatment was also observed. To investigate the effects of MEMH in vivo, MSU crystals induced ankle arthritic model was established. Histopathological changes in affected joints and plasma levels of pro inflammatory mediators (IL 1 beta and TNF alpha) were recorded. MEMH inhibited NF kappa B signaling pathway and COX 2 protein expression in chondrocytes. MSU induced mRNA expressions of pro inflammatory mediators and chemotactic cytokines were suppressed by MEMH. In MSU crystals induced ankle arthritic mouse model, administration of MEMH relieved inflammatory symptoms and decreased the plasma levels of IL 1 beta and TNF alpha. The results indicated that MEMH can effectively inhibit the expression of inflammatory mediators in gouty arthritis, demonstrating its potential for treating gouty arthritis.
C1 [Nam, Ju Suk; Jagga, Supriya; Sharma, Ashish Ranjan; Park, Jong Bong; Lee, Sang Soo] Hallym Univ, Chuncheon Sacred Heart Hosp, Inst Skeletal Aging & Orthoped Surg, Chunchon 24252, Gangwon Do, South Korea.
   [Jung, Jun Sub] Hallym Univ, Coll Med, Inst Nat Med, Chucheon 24252, Gangwon Do, South Korea.
   [Lee, Joon Hee] Hana Oriental Clin, Chucnheon 24433, Gangwon Do, South Korea.
C3 Hallym University; Hallym University
RP Lee, SS (通讯作者)，Hallym Univ, Chuncheon Sacred Heart Hosp, Inst Skeletal Aging & Orthoped Surg, Chunchon 24252, Gangwon Do, South Korea.
EM 123sslee@gmail.com
RI Sharma, Ashish/W 4816 2019; Lee, Sang Soo/LTD 5070 2024; Jagga,
   Supriya/HDM 9580 2022; jagga, supriya/AAW 5176 2020
OI jagga, supriya/0000 0003 2915 8154
FU National Research Foundation of Korea (NRF)   Ministry of Education
   [2014R1A1A4A03009388, 2014R1A1A2055560]; Korea Health Industry
   Development Institute (KHIDI)   Ministry of Health &Welfare, Republic of
   Korea [HI12C1265]; Hallym University
FX This work was supported by Basic Science Research Program through the
   National Research Foundation of Korea (NRF) funded by the Ministry of
   Education (Nos. 2014R1A1A4A03009388 & 2014R1A1A2055560), a grant of the
   Korea Health Technology R&D Project through the Korea Health Industry
   Development Institute (KHIDI), funded by the Ministry of Health
   &Welfare, Republic of Korea (No. HI12C1265), and Hallym University
   Research Fund.
CR Ahn Sangwoo, 2011, [Korea Journal of Oriental Medicine, 한국한의학연구원논문집], V17, P17
   Ahn YM, 2012, J ETHNOPHARMACOL, V141, P780, DOI 10.1016/j.jep.2012.02.021
   Amaral FA, 2012, ARTHRITIS RHEUM US, V64, P474, DOI 10.1002/art.33355
   Bae H, 2012, J ETHNOPHARMACOL, V142, P41, DOI 10.1016/j.jep.2012.04.009
   Brennan FM, 2008, J CLIN INVEST, V118, P3537, DOI 10.1172/JCI36389
   Castrejon I, 2015, RHEUMATOL INT, V35, P1127, DOI 10.1007/s00296 014 3189 6
   Chen DQ, 2014, J ETHNOPHARMACOL, V157, P114, DOI 10.1016/j.jep.2014.09.022
   Chen LY, 2013, J ETHNOPHARMACOL, V150, P545, DOI 10.1016/j.jep.2013.08.063
   Chhana A, 2013, J RHEUMATOL, V40, P2067, DOI 10.3899/jrheum.130708
   Chhana A, 2011, ANN RHEUM DIS, V70, P1684, DOI 10.1136/ard.2010.144774
   Choi DW, 2002, TOXICOLOGY, V181, P581, DOI 10.1016/S0300 483X(02)00487 0
   Choi MK, 2013, J ETHNOPHARMACOL, V147, P662, DOI 10.1016/j.jep.2013.03.065
   Choi MJ, 2015, EVID BASED COMPL ALT, V2015, DOI 10.1155/2015/873185
   Choi SI, 2006, J ETHNOPHARMACOL, V106, P279, DOI 10.1016/j.jep.2005.12.018
   Cronstein BN, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1908
   Dalbeth N, 2009, ANN RHEUM DIS, V68, P1290, DOI 10.1136/ard.2008.094201
   Dalbeth N, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3913
   Debas HT, 2006, DIS CONTROL PRIORITI
   Feng YL, 2014, J ETHNOPHARMACOL, V154, P386, DOI 10.1016/j.jep.2014.04.017
   Funk JL, 2006, ARTHRITIS RHEUM US, V54, P3452, DOI 10.1002/art.22180
   Habiboallah G, 2008, J ETHNOPHARMACOL, V120, P335, DOI 10.1016/j.jep.2008.09.011
   Harre U, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3508
   Hoffman BE, 2010, J CELL PHYSIOL, V222, P695, DOI 10.1002/jcp.21994
   Hsu HY, 1986, ORIENTAL MATERIA MED, P451
   Ke RD, 2010, CARBOHYD POLYM, V80, P31, DOI 10.1016/j.carbpol.2009.10.063
   Khan S, 2014, J ETHNOPHARMACOL, V152, P478, DOI 10.1016/j.jep.2014.01.028
   Khan S, 2013, J ETHNOPHARMACOL, V145, P626, DOI 10.1016/j.jep.2012.12.001
   Kim CK, 2011, J ETHNOPHARMACOL, V137, P396, DOI 10.1016/j.jep.2011.05.036
   Kodithuwakku ND, 2015, J ETHNOPHARMACOL, V163, P278, DOI 10.1016/j.jep.2015.01.013
   Kodithuwakku ND, 2013, J ETHNOPHARMACOL, V150, P1071, DOI 10.1016/j.jep.2013.10.016
   Koo HJ, 2006, J ETHNOPHARMACOL, V103, P496, DOI 10.1016/j.jep.2005.08.011
   Lao L, 2015, OSTEOARTHR CARTILAGE, V23, P2102, DOI 10.1016/j.joca.2015.06.007
   Largo R, 2003, OSTEOARTHR CARTILAGE, V11, P290, DOI 10.1016/S1063 4584(03)00028 1
   Lee HS, 2009, OSTEOARTHR CARTILAGE, V17, P91, DOI 10.1016/j.joca.2008.05.010
   Lee SS, 2012, BIOMATERIALS, V33, P4251, DOI 10.1016/j.biomaterials.2012.03.005
   Lee YP, 2012, EVID BASED COMPL ALT, V2012, DOI 10.1155/2012/650809
   LICHTENSTEIN L, 1956, AM J PATHOL, V32, P871
   Liu R, 2004, ARTHRITIS RHEUM, V50, P247, DOI 10.1002/art.11486
   Liu YF, 2014, EVID BASED COMPL ALT, V2014, DOI 10.1155/2014/406816
   Martillo MA, 2014, CURR RHEUMATOL REP, V16, DOI 10.1007/s11926 013 0400 9
   Nanjundaiah SM, 2013, EVID BASED COMPL ALT, V2013, DOI 10.1155/2013/518094
   Nishimura A, 1997, J LEUKOCYTE BIOL, V62, P444, DOI 10.1002/jlb.62.4.444
   Oh YC, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472 6882 14 242
   Orlowsky EW, 2014, BMC MUSCULOSKEL DIS, V15, DOI 10.1186/1471 2474 15 318
   Peng YJ, 2012, FREE RADICAL BIO MED, V52, P765, DOI 10.1016/j.freeradbiomed.2011.12.003
   Reddy AM, 2004, PLANTA MED, V70, P823, DOI 10.1055/s 2004 827230
   Riss T.L., 2004, CELL VIABILITY ASSAY
   Schlesinger N, 2010, POSTGRAD MED, V122, P157, DOI 10.3810/pgm.2010.03.2133
   Schwabl H, 2015, J ETHNOPHARMACOL, V167, P108, DOI 10.1016/j.jep.2014.10.033
   Seo UK, 2005, J ETHNOPHARMACOL, V97, P101, DOI 10.1016/j.jep.2004.10.022
   Shin JS, 2009, J ETHNOPHARMACOL, V124, P397, DOI 10.1016/j.jep.2009.05.036
   Smith SM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026908
   Stehlik C, 2009, ARTHRITIS RHEUM US, V60, P3524, DOI 10.1002/art.24961
   Tew SR, 2008, METHODS, V45, P2, DOI 10.1016/j.ymeth.2008.01.006
   Umamaheswari M, 2009, J ETHNOPHARMACOL, V124, P646, DOI 10.1016/j.jep.2009.05.018
   Williamson EM, 2001, PHYTOMEDICINE, V8, P401, DOI 10.1078/0944 7113 00060
   Wu XH, 2015, J ETHNOPHARMACOL, V162, P362, DOI 10.1016/j.jep.2015.01.012
   Xu Y, 2013, REJUV RES, V16, P364, DOI 10.1089/rej.2013.1439
   Yao XJ, 2012, INT IMMUNOPHARMACOL, V14, P454, DOI 10.1016/j.intimp.2012.07.024
   Zhang GW, 2010, J ETHNOPHARMACOL, V128, P433, DOI 10.1016/j.jep.2010.01.032
   Zhang RX, 2009, J ETHNOPHARMACOL, V121, P366, DOI 10.1016/j.jep.2008.11.018
   Zhao FL, 2015, J ETHNOPHARMACOL, V168, P1, DOI 10.1016/j.jep.2015.03.035
   Zhao YY, 2013, J ETHNOPHARMACOL, V149, P35, DOI 10.1016/j.jep.2013.06.031
NR 63
TC 16
Z9 19
U1 2
U2 44
PU CHINESE JOURNAL NATURAL MEDICINES
PI NANJING
PA 24, TONGJIA XIANG, NANJING, 210009, PEOPLES R CHINA
SN 2095 6975
EI 1875 5364
J9 CHIN J NAT MEDICINES
JI Chin. J. Nat. Med.
PD AUG
PY 2017
VL 15
IS 8
BP 561
EP 575
DI 10.3724/SP.J.1009.2017.00561
PG 15
WC Integrative & Complementary Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Integrative & Complementary Medicine; Pharmacology & Pharmacy
GA FJ5LX
UT WOS:000412794100001
PM 28939019
DA 2025 08 17
ER

PT J
AU Ab Kadir, R
   Ariffin, SHZ
   Wahab, RMA
   Senafi, S
AF Ab Kadir, Ruzanna
   Ariffin, Shahrul Hisham Zainal
   Wahab, Rohaya Megat Abdul
   Senafi, Sahidan
TI Molecular characterisation of human peripheral blood stem cells
SO SOUTH AFRICAN JOURNAL OF SCIENCE
LA English
DT Article
ID HUMAN HEMATOPOIETIC CELLS; OSTEOCLAST DIFFERENTIATION; PROGENITOR CELLS;
   T CELL; GENE; EXPRESSION; IDENTIFICATION; THERAPY; SAP
AB Peripheral blood mononucleated cells consist of haematopoietic stem cells (HSCs) and mesenchymal stem cells (MSCs). To date there is no well defined isolation or characterisation protocol of stem cells from human adult peripheral blood mononucleated cells. Our aim in this study was to isolate and characterise mononucleated cells from human peripheral blood. Peripheral blood mononucleated cells were isolated using the Ficoll Paque density gradient separation method and cultured in complete medium. After 4 days of culture, adherent and suspension mononucleated cells were separated and cultured for 14 days in an in vitro culture selection. Stem cells in the isolated mononucleated cells were characterised using a multidisciplinary approach which was based on the expression of stern cell markers, morphology and the capacity to self renew or proliferate and differentiate into specialised cells. Reverse transcription polymerase chain reaction was used to identify the expression of an HSC marker (signalling lymphocytic activation molecule family member 1, SLAMF1) and a MSC marker (CD105). Results revealed that adherent mononucleated cells were positive for MSC markers, whereas mononucleated cells in suspension were positive for HSC markers. The isolated adherent and suspension mononucleated cells were able to maintain their stem cell properties during in vitro culture by retaining their capacity to proliferate and differentiate into osteoclast and osteoblast cells, respectively, when exposed to the appropriate induction medium. The isolated mononucleated cells consisted of suspension HSCs and adherent MSCs, both of which have the capability to proliferate and differentiate into mature cells. We have shown that suspension HSCs and adherent MSCs can be obtained from an in vitro culture of peripheral blood mononucleated cells.
C1 [Ab Kadir, Ruzanna; Ariffin, Shahrul Hisham Zainal; Senafi, Sahidan] Natl Univ Malaysia, Sch Biosci & Biotechnol, Fac Sci & Technol, Bangi, Selangor, Malaysia.
   [Wahab, Rohaya Megat Abdul] Natl Univ Malaysia, Fac Dent, Dept Orthodont, Bangi, Selangor, Malaysia.
C3 Universiti Kebangsaan Malaysia; Universiti Kebangsaan Malaysia
RP Ariffin, SHZ (通讯作者)，Natl Univ Malaysia, Sch Biosci & Biotechnol, Fac Sci & Technol, Bangi 43600, Selangor Darul, Malaysia.
EM hisham@ukm.my
RI Wahab, Rohaya/K 7077 2019; ARIFFIN, SHAHRUL/K 7071 2019
FU Ministry of Higher Education, Malaysia [FRGS/1/2011/SG/UKM/02/13,
   UKM DD 03 FRGS0030 2010]; Ministry of Science, Technology and Innovation
   (MOSTI), Malaysia [09 05 MGI GMB002]; Department of Fishery Malaysia
   [STGL 007 2010/9]; National University of Malaysia
   [UKM OUP KPB 33 170/2011, UKM GUP 2011 093]
FX This study was supported by grants from the Ministry of Higher
   Education, Malaysia (FRGS/1/2011/SG/UKM/02/13 and
   UKM DD 03 FRGS0030 2010), the Ministry of Science, Technology and
   Innovation (MOSTI), Malaysia (09 05 MGI GMB002), the Department of
   Fishery Malaysia (STGL 007 2010/9) and the National University of
   Malaysia (UKM OUP KPB 33 170/2011 and UKM GUP 2011 093).
CR Alhadlaq A, 2004, STEM CELLS DEV, V13, P436, DOI 10.1089/scd.2004.13.436
   Ariffin SHZ, 2010, CELL COMMUN SIGNAL, V8, DOI 10.1186/1478 811X 8 29
   Arslan Ö, 2007, TRANSFUS APHER SCI, V37, P179, DOI 10.1016/j.transci.2007.08.002
   Barber RD, 2005, PHYSIOL GENOMICS, V21, P389, DOI 10.1152/physiolgenomics.00025.2005
   Bhatia M, 1998, NAT MED, V4, P1038, DOI 10.1038/2023
   Bobis S, 2006, FOLIA HISTOCHEM CYTO, V44, P215
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Duff SE, 2003, FASEB J, V17, P984, DOI 10.1096/fj.02 0634rev
   Engel P, 2003, NAT REV IMMUNOL, V3, P813, DOI 10.1038/nri1202
   Feng X, 2001, J CLIN INVEST, V107, P1137, DOI 10.1172/JCI12040
   Gaebel R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015652
   Guo YL, 2003, STEM CELLS, V21, P15, DOI 10.1634/stemcells.21 1 15
   Hentze H, 2007, TRENDS BIOTECHNOL, V25, P24, DOI 10.1016/j.tibtech.2006.10.010
   HISHAM ZAS, 2005, SAINS MALAYS, V34, P21
   HISHAM ZAS, 2005, ASIA PAC J MOL BIOL, V13, P1
   Howie D, 2002, BLOOD, V100, P2899, DOI 10.1182/blood 2002 02 0445
   Kartsogiannis V, 2004, MOL CELL ENDOCRINOL, V228, P79, DOI 10.1016/j.mce.2003.06.002
   Kent DG, 2009, BLOOD, V113, P6342, DOI 10.1182/blood 2008 12 192054
   Kiel MJ, 2005, CELL, V121, P1109, DOI 10.1016/j.cell.2005.05.026
   Larochelle A, 1996, NAT MED, V2, P1329, DOI 10.1038/nm1296 1329
   Li Z, 2006, J CELL PHYSL, V290, P1248
   Matsuo K, 2008, ARCH BIOCHEM BIOPHYS, V473, P201, DOI 10.1016/j.abb.2008.03.027
   Peichev M, 2000, BLOOD, V95, P952, DOI 10.1182/blood.V95.3.952.003k27_952_958
   Shi ZQ, 2004, GENE, V343, P117, DOI 10.1016/j.gene.2004.08.009
   Sidorenko SP, 2003, NAT IMMUNOL, V4, P19, DOI 10.1038/ni0103 19
   Tögel F, 2007, DEV DYNAM, V236, P3321, DOI 10.1002/dvdy.21258
   Valenti MT, 2008, BONE, V43, P1084, DOI 10.1016/j.bone.2008.07.252
   Wang NH, 2004, J EXP MED, V199, P1255, DOI 10.1084/jem.20031835
   Weissman IL, 2001, ANNU REV CELL DEV BI, V17, P387, DOI 10.1146/annurev.cellbio.17.1.387
   Wognum AW, 2003, ARCH MED RES, V34, P461, DOI 10.1016/j.arcmed.2003.09.008
   Yazid MD, 2010, CANCER CELL INT, V10, DOI 10.1186/1475 2867 10 42
NR 31
TC 3
Z9 3
U1 0
U2 6
PU ACAD SCIENCE SOUTH AFRICA A S S AF
PI LYNWOOD RIDGE
PA PO BOX 72135, LYNWOOD RIDGE 0040, SOUTH AFRICA
SN 0038 2353
J9 S AFR J SCI
JI S. Afr. J. Sci.
PD MAY JUN
PY 2012
VL 108
IS 5 6
BP 67
EP 73
DI 10.4102/sajs.v108i5/6.939
PG 7
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 003RI
UT WOS:000308628600014
OA gold
DA 2025 08 17
ER

PT J
AU Gruening, M
   Neuber, S
   Nestler, P
   Lehnfeld, J
   Dubs, M
   Fricke, K
   Schnabelrauch, M
   Helm, CA
   Müller, R
   Staehlke, S
   Nebe, JB
AF Gruening, Martina
   Neuber, Sven
   Nestler, Peter
   Lehnfeld, Jutta
   Dubs, Manuela
   Fricke, Katja
   Schnabelrauch, Matthias
   Helm, Christiane A.
   Mueller, Rainer
   Staehlke, Susanne
   Nebe, J. Barbara
TI Enhancement of Intracellular Calcium Ion Mobilization by Moderately but
   Not Highly Positive Material Surface Charges
SO FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY
LA English
DT Article
DE human osteoblasts; calcium ion signaling; titanium surface modification;
   amino polymer; polyelectrolyte multilayer; zeta potential; surface
   charge; wettability
ID CELL CYCLE ARREST; PLASMA POLYMERIZATION; PROTEIN ADSORPTION;
   FUNCTIONAL GROUPS; FOCAL ADHESION; TITANIUM; PROLIFERATION;
   BIOMATERIALS; CHEMISTRY; TOPOGRAPHY
AB Electrostatic forces at the cell interface affect the nature of cell adhesion and function; but there is still limited knowledge about the impact of positive or negative surface charges on cell material interactions in regenerative medicine. Titanium surfaces with a variety of zeta potentials between  90 mV and +50 mV were generated by functionalizing them with amino polymers, extracellular matrix proteins/peptide motifs and polyelectrolyte multilayers. A significant enhancement of intracellular calcium mobilization was achieved on surfaces with a moderately positive (+1 to +10 mV) compared with a negative zeta potential ( 90 to  3 mV). Dramatic losses of cell activity (membrane integrity, viability, proliferation, calcium mobilization) were observed on surfaces with a highly positive zeta potential (+50 mV). This systematic study indicates that cells do not prefer positive charges in general, merely moderately positive ones. The cell behavior of MG 63s could be correlated with the materials' zeta potential; but not with water contact angle or surface free energy. Our findings present new insights and provide an essential knowledge for future applications in dental and orthopedic surgery.
C1 [Gruening, Martina; Staehlke, Susanne; Nebe, J. Barbara] Rostock Univ, Dept Cell Biol, Med Ctr, Rostock, Germany.
   [Neuber, Sven; Nestler, Peter; Helm, Christiane A.] Ernst Moritz Arndt Univ Greifswald, Inst Phys, Soft Matter & Biophys, Greifswald, Germany.
   [Lehnfeld, Jutta; Mueller, Rainer] Univ Regensburg, Inst Phys & Theoret Chem, Colloid & Interface Chem, Regensburg, Germany.
   [Dubs, Manuela; Schnabelrauch, Matthias] INNOVENT eV, Dept Biomat, Jena, Germany.
   [Fricke, Katja] Leibniz Inst Plasma Sci & Technol eV INP, Greifswald, Germany.
   [Nebe, J. Barbara] Univ Rostock, Fac Interdisciplinary, Dept Sci & Technol Life Light & Matter, Rostock, Germany.
C3 University of Rostock; Universitat Greifswald; University of Regensburg;
   Leibniz Institut fur Plasmaforschung und Technologie; University of
   Rostock
RP Nebe, JB (通讯作者)，Rostock Univ, Dept Cell Biol, Med Ctr, Rostock, Germany.; Nebe, JB (通讯作者)，Univ Rostock, Fac Interdisciplinary, Dept Sci & Technol Life Light & Matter, Rostock, Germany.
EM barbara.nebe@med.uni rostock.de
RI Helm, Christiane A./C 5000 2015; Helm, Christiane/C 5000 2015; Mueller,
   Rainer/JBJ 1897 2023
OI Helm, Christiane A./0000 0001 5181 1688; 
FU Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)  
   Collaborative Research Center (CRC) [1270/1 ELAINE   299150580]; Fonds
   der Chemischen Industrie (FCI); Chemiefonds Fellowship
FX This project was supported by the Deutsche Forschungsgemeinschaft (DFG,
   German Research Foundation)   Collaborative Research Center (CRC) 1270/1
   ELAINE   299150580. JL was supported by the Fonds der Chemischen
   Industrie (FCI) with the Chemiefonds Fellowship.
CR Abalymov A, 2020, ACS APPL MATER INTER, V12, P38862, DOI 10.1021/acsami.0c06641
   Ahn HH, 2014, INT J MOL SCI, V15, P2075, DOI 10.3390/ijms15022075
   Akter F., 2016, Tissue Engineering Made Easy, V1st
   Altankov G, 2003, MATERIALWISS WERKST, V34, P1120, DOI 10.1002/mawe.200300699
   Anselme K, 2010, P I MECH ENG H, V224, P1487, DOI 10.1243/09544119JEIM901
   Antonini V, 2014, COLLOID SURFACE B, V113, P320, DOI 10.1016/j.colsurfb.2013.09.020
   Arias CJ, 2016, LANGMUIR, V32, P5412, DOI 10.1021/acs.langmuir.6b00784
   Bacakova L, 1996, BIOMATERIALS, V17, P1121
   Bacakova L, 2011, BIOTECHNOL ADV, V29, P739, DOI 10.1016/j.biotechadv.2011.06.004
   Blagosklonny MV, 2011, AGING US, V3, P94, DOI 10.18632/aging.100281
   Boraschi Diaz I, 2017, FRONT PHYS LAUSANNE, V5, DOI 10.3389/fphy.2017.00012
   Brunot C, 2007, BIOMATERIALS, V28, P632, DOI 10.1016/j.biomaterials.2006.09.026
   Cao C, 2015, J BIOMAT SCI POLYM E, V26, P600, DOI 10.1080/09205063.2015.1049044
   CHAKKALAKAL DA, 1989, J MATER RES, V4, P1034, DOI 10.1557/JMR.1989.1034
   Chang HY, 2014, J PHYS CHEM C, V118, P14464, DOI 10.1021/jp504662c
   Chen SC, 2018, COLLOID SURFACE B, V164, P58, DOI 10.1016/j.colsurfb.2018.01.022
   CLOVER J, 1994, BONE, V15, P585, DOI 10.1016/8756 3282(94)90305 0
   Cohen M, 2004, CHEMBIOCHEM, V5, P1393, DOI 10.1002/cbic.200400162
   Czekanska EM, 2014, J BIOMED MATER RES A, V102, P2636, DOI 10.1002/jbm.a.34937
   De Aza PN, 2003, BIOMATERIALS, V24, P1437, DOI 10.1016/S0142 9612(02)00530 6
   Devgan S, 2019, MATER CHEM PHYS, V233, P68, DOI 10.1016/j.matchemphys.2019.05.039
   Dhowre HS, 2015, NANOMEDICINE UK, V10, P849, DOI [10.2217/NNM.14.222, 10.2217/nnm.14.222]
   Eichler M, 2011, BIOMATERIALS, V32, P9168, DOI 10.1016/j.biomaterials.2011.08.063
   El Ghannam AR, 2004, J BIOMED MATER RES A, V68A, P615, DOI 10.1002/jbm.a.20051
   Felgueiras HP, 2018, WOODH PUBL SER BIOM, P1, DOI 10.1016/B978 0 08 100803 4.00001 2
   Fernández Yagüe M, 2019, NANOMED NANOTECHNOL, V18, P1, DOI 10.1016/j.nano.2019.02.005
   Ferrari M, 2019, COLLOID INTERFAC, V3, DOI 10.3390/colloids3020048
   Ferraris S, 2018, FRONT BIOENG BIOTECH, V6, DOI 10.3389/fbioe.2018.00060
   Finke B, 2007, BIOMATERIALS, V28, P4521, DOI 10.1016/j.biomaterials.2007.06.028
   Finke B, 2014, LANGMUIR, V30, P13914, DOI 10.1021/la5019778
   Fritsche A, 2009, J MATER SCI, V44, P5544, DOI 10.1007/s10853 009 3776 1
   Gentleman MM, 2014, INT MATER REV, V59, P417, DOI 10.1179/1743280414Y.0000000038
   Goldenberg NM, 2010, CANCER RES, V70, P1277, DOI 10.1158/0008 5472.CAN 09 2905
   Gruening M., 2020, AM J BIOMED SCI RES, V9, P4, DOI [10.34297/AJBSR.2020.09.001341, DOI 10.34297/AJBSR.2020.09.001341]
   Guo SS, 2018, ACS APPL MATER INTER, V10, P7882, DOI 10.1021/acsami.8b00666
   Hanawa T, 2019, FRONT BIOENG BIOTECH, V7, DOI 10.3389/fbioe.2019.00170
   Heo WD, 2006, SCIENCE, V314, P1458, DOI 10.1126/science.1134389
   Hernandez Montelongo J, 2017, MAT SCI ENG C MATER, V71, P718, DOI 10.1016/j.msec.2016.10.064
   Hoene A, 2010, ACTA BIOMATER, V6, P676, DOI 10.1016/j.actbio.2009.09.003
   Iwai R, 2013, BIOMATERIALS, V34, P9096, DOI 10.1016/j.biomaterials.2013.08.027
   Kato T, 2008, ORAL MICROBIOL IMMUN, V23, P158, DOI 10.1111/j.1399 302X.2007.00405.x
   Katzur V, 2012, J COLLOID INTERF SCI, V366, P179, DOI 10.1016/j.jcis.2011.09.029
   Kennedy SB, 2006, BIOMATERIALS, V27, P3817, DOI 10.1016/j.biomaterials.2006.02.044
   Kidambi S, 2004, J AM CHEM SOC, V126, P16286, DOI 10.1021/ja046188u
   Koch F, 2018, INT J NANOMED, V13, P6717, DOI 10.2147/IJN.S173702
   Kokubo T, 2015, FRONT BIOENG BIOTECH, V3, DOI 10.3389/fbioe.2015.00176
   Krajewski A, 1998, BIOMATERIALS, V19, P637, DOI 10.1016/S0142 9612(97)00153 1
   Kumar PS, 2019, JMIR Biomed Eng, V4, DOI [10.2196/13237, DOI 10.2196/13237]
   Labelle D, 2007, CELL PROLIFERAT, V40, P866, DOI 10.1111/j.1365 2184.2007.00477.x
   Lee G, 2018, J IND ENG CHEM, V62, P341, DOI 10.1016/j.jiec.2018.01.014
   LEE JH, 1994, BIOMATERIALS, V15, P705, DOI 10.1016/0142 9612(94)90169 4
   Lehnfeld J, 2020, LANGMUIR, V36, P5880, DOI 10.1021/acs.langmuir.0c00625
   Lesny P, 2006, J MATER SCI MATER M, V17, P829, DOI 10.1007/s10856 006 9842 1
   Liao TQ, 2010, BIOTECHNOL PROGR, V26, P1705, DOI 10.1002/btpr.471
   Liu Q, 2002, BIOMATERIALS, V23, P3103, DOI 10.1016/S0142 9612(02)00050 9
   Liu ZM, 2009, J MATER SCI MATER M, V20, P2317, DOI 10.1007/s10856 009 3806 1
   Mecke A, 2005, LANGMUIR, V21, P10348, DOI 10.1021/la050629l
   Metwalli E, 2006, J COLLOID INTERF SCI, V298, P825, DOI 10.1016/j.jcis.2006.03.045
   Metwally S, 2019, MAT SCI ENG C MATER, V104, DOI 10.1016/j.msec.2019.109883
   Moerke C, 2018, J CELL SCI, V131, DOI 10.1242/jcs.207001
   Moerke C, 2017, ACS APPL MATER INTER, V9, P10461, DOI 10.1021/acsami.6b16430
   Mohamad HS, 2019, LANGMUIR, V35, P15491, DOI 10.1021/acs.langmuir.9b01787
   Muderrisoglu C, 2018, ADV MATER INTERFACES, V5, DOI 10.1002/admi.201800452
   Müller R, 2006, BIOMATERIALS, V27, P4059, DOI 10.1016/j.biomaterials.2006.03.019
   Muller FL, 2007, FREE RADICAL BIO MED, V43, P477, DOI 10.1016/j.freeradbiomed.2007.03.034
   Nebe B, 2007, BIOMOL ENG, V24, P447, DOI 10.1016/j.bioeng.2007.07.004
   Nebe JB, 2019, POLYMERS BASEL, V11, DOI 10.3390/polym11061004
   Nestler P, 2012, J PHYS CHEM B, V116, P1234, DOI 10.1021/jp208837m
   Nikkhah M, 2012, BIOMATERIALS, V33, P5230, DOI 10.1016/j.biomaterials.2012.03.079
   NORDE W, 1991, Journal of Biomaterials Science Polymer Edition, V2, P183
   OLSSON J, 1995, COLLOID SURFACE B, V5, P161, DOI 10.1016/0927 7765(95)01212 2
   OTTER M, 1988, J ORTHOP RES, V6, P346, DOI 10.1002/jor.1100060306
   Padial Molina M, 2011, ACTA BIOMATER, V7, P771, DOI 10.1016/j.actbio.2010.08.024
   Pommerenke H, 2002, J BONE MINER RES, V17, P603, DOI 10.1359/jbmr.2002.17.4.603
   Ponsonnet L, 2003, MAT SCI ENG C BIO S, V23, P551, DOI 10.1016/S0928 4931(03)00033 X
   Ravenscroft Chang MS, 2010, BIOMATERIALS, V31, P602, DOI 10.1016/j.biomaterials.2009.09.084
   Rebl H, 2016, MAT SCI ENG C MATER, V69, P1116, DOI 10.1016/j.msec.2016.08.016
   Rebl H, 2012, ACTA BIOMATER, V8, P3840, DOI 10.1016/j.actbio.2012.06.015
   Rebl H, 2010, ADV ENG MATER, V12, pB356, DOI 10.1002/adem.200980070
   Rico P, 2009, TISSUE ENG PT A, V15, P3271, DOI 10.1089/ten.TEA.2009.0141
   Schulz A, 2018, J MATER SCI MATER M, V29, DOI 10.1007/s10856 018 6113 x
   Secchi AG, 2007, J BIOMED MATER RES A, V83A, P577, DOI 10.1002/jbm.a.31007
   SHELTON RM, 1988, BIOMATERIALS, V9, P24, DOI 10.1016/0142 9612(88)90065 8
   Sjaastad MD, 1997, BIOESSAYS, V19, P47, DOI 10.1002/bies.950190109
   Skalak R., 1986, ELECTROMECHANICAL EF
   Staehlke S, 2019, CELL BIOL INT, V43, P22, DOI 10.1002/cbin.11073
   Staehlke S, 2018, CELL BIOSCI, V8, DOI 10.1186/s13578 018 0220 8
   Staehlke S, 2015, BIOMATERIALS, V46, P48, DOI 10.1016/j.biomaterials.2014.12.016
   Terzi MY, 2016, MOL BIOL REP, V43, P1213, DOI 10.1007/s11033 016 4065 0
   Tryoen Tóth P, 2002, J BIOMED MATER RES, V60, P657, DOI 10.1002/jbm.10110
   von der Mark K, 2013, PROG MATER SCI, V58, P327, DOI 10.1016/j.pmatsci.2012.09.002
   Webb K, 1998, J BIOMED MATER RES, V41, P422, DOI 10.1002/(SICI)1097 4636(19980905)41:3<422::AID JBM12>3.0.CO;2 K
   Wennerberg A, 2009, CLIN ORAL IMPLAN RES, V20, P172, DOI 10.1111/j.1600 0501.2009.01775.x
   Zimmerman E, 2002, BIOPHYS J, V82, P1848, DOI 10.1016/S0006 3495(02)75535 5
   Zou WJ, 2015, J BONE MINER METAB, V33, P615, DOI 10.1007/s00774 014 0627 1
NR 95
TC 20
Z9 20
U1 2
U2 25
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 2296 4185
J9 FRONT BIOENG BIOTECH
JI Front. Bioeng. Biotechnol.
PD SEP 8
PY 2020
VL 8
AR 1016
DI 10.3389/fbioe.2020.01016
PG 18
WC Biotechnology & Applied Microbiology; Engineering, Biomedical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Engineering
GA NW2BO
UT WOS:000574815400001
PM 33015006
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Akchurin, O
   Sureshbabu, A
   Doty, SB
   Zhu, YS
   Patino, E
   Cunningham Rundles, S
   Choi, ME
   Boskey, A
   Rivella, S
AF Akchurin, Oleh
   Sureshbabu, Angara
   Doty, Steve B.
   Zhu, Yuan Shan
   Patino, Edwin
   Cunningham Rundles, Susanna
   Choi, Mary E.
   Boskey, Adele
   Rivella, Stefano
TI Lack of hepcidin ameliorates anemia and improves growth in an
   adenine induced mouse model of chronic kidney disease
SO AMERICAN JOURNAL OF PHYSIOLOGY RENAL PHYSIOLOGY
LA English
DT Article
DE chronic kidney disease; adenine; growth delay; hepcidin; anemia
ID CHRONIC RENAL FAILURE; BODY MASS INDEX; IRON STATUS;
   PARATHYROID HORMONE; GENE EXPRESSION; SHORT STATURE; CHILDREN;
   INFLAMMATION; UREMIA; MICE
AB Growth delay is common in children with chronic kidney disease (CKD), often associated with poor quality of life. The role of anemia in uremic growth delay is poorly understood. Here we describe an induction of uremic growth retardation by a 0.2% adenine diet in wild type (WT) and hepcidin gene (Hamp) knockout (KO) mice, compared with their respective littermates fed a regular diet. Experiments were started at weaning (3 wk). After 8 wk, blood was collected and mice were euthanized. Adeninefed WT mice developed CKD (blood urea nitrogen 82.8 +/  11.6 mg/dl and creatinine 0.57 +/  0.07 mg/dl) and were 2.1 cm shorter compared with WT controls. WT adenine fed mice were anemic and had low serum iron, elevated Hamp, and elevated IL6 and TNF alpha. WT adenine fed mice had advanced mineral bone disease (serum phosphorus 16.9 +/  3.1 mg/dl and FGF23 204.0 +/  115.0 ng/ml) with loss of cortical and trabecular bone volume seen on microcomputed tomography. Hamp disruption rescued the anemia phenotype resulting in improved growth rate in mice with CKD, thus providing direct experimental evidence of the relationship between Hamp pathway and growth impairment in CKD. Hamp disruption ameliorated CKD induced growth hormone insulin like growth factor 1 axis derangements and growth plate alterations. Disruption of Hamp did not mitigate the development of uremia, inflammation, and mineral and bone disease in this model. Taken together, these results indicate that an adenine diet can be successfully used to study growth in mice with CKD. Hepcidin appears to be related to pathways of growth retardation in CKD suggesting that investigation of hepcidin lowering therapies in juvenile CKD is warranted.
C1 [Akchurin, Oleh; Sureshbabu, Angara; Zhu, Yuan Shan; Patino, Edwin; Cunningham Rundles, Susanna; Choi, Mary E.; Boskey, Adele; Rivella, Stefano] Weill Cornell Med, New York, NY USA.
   [Doty, Steve B.; Boskey, Adele] Hosp Special Surg, 535 E 70th St, New York, NY 10021 USA.
   [Rivella, Stefano] Univ Penn, Childrens Hosp, Philadelphia, PA 19104 USA.
C3 Cornell University; Weill Cornell Medicine; University of Pennsylvania;
   Pennsylvania Medicine; Childrens Hospital of Philadelphia
RP Akchurin, O (通讯作者)，Weill Cornell Med, New York Presbyterian Phyllis & David, Komansky Ctr Childrens Hlth, 505 East 70th St HT 376, New York, NY 10021 USA.
EM oma9005@med.cornell.edu
RI Patino, Edwin/ABD 3834 2020; Akchurin, Oleh/HLG 7742 2023; Rivella,
   Stefano/A 1597 2010
OI Akchurin, Oleh/0000 0002 3745 5418; Patino, Edwin/0000 0002 0828 4269;
   Rivella, Stefano/0000 0002 0938 6558
FU National Institutes of Health/National Center for Advancing
   Translational Sciences [UL1TR00457]; National Institute of Diabetes and
   Digestive and Kidney Diseases [R01 DK 095112, R01 DK 57661]; Weill
   Cornell Medicine
FX This work was supported in part by the National Institutes of
   Health/National Center for Advancing Translational Sciences Grant
   UL1TR00457 awarded to the Clinical and Translational Science Center,
   Weill Cornell Medicine (to O. Akchurin and Y. S. Zhu), and National
   Institute of Diabetes and Digestive and Kidney Diseases Grants
   R01 DK 095112 (to S. Rivella) and R01 DK 57661 (to M. E. Choi).
CR Abraham AG, 2014, PEDIATR NEPHROL, V29, P1231, DOI 10.1007/s00467 014 2768 9
   Aeberli I, 2009, INT J OBESITY, V33, P1111, DOI 10.1038/ijo.2009.146
   Agarwal R, 2006, KIDNEY INT, V69, P1259, DOI 10.1038/sj.ki.5000164
   Akchurin OM, 2015, BLOOD PURIFICAT, V39, P84, DOI 10.1159/000368940
   Akchurin OM, 2014, CLIN J AM SOC NEPHRO, V9, P1519, DOI 10.2215/CJN.01150114
   Al Uzri A, 2013, J PEDIATR US, V163, P736, DOI 10.1016/j.jpeds.2013.03.016
   Amato A, 2010, INT J OBESITY, V34, P1772, DOI 10.1038/ijo.2010.204
   ARNOLD WC, 1983, KIDNEY INT, V24, P205, DOI 10.1038/ki.1983.145
   Atkinson MA, 2015, PEDIATR NEPHROL, V30, P635, DOI 10.1007/s00467 014 2991 4
   Ayestaran FW, 2016, PEDIATR NEPHROL, V31, P1121, DOI 10.1007/s00467 016 3321 9
   Bamgbola OF, 2011, KIDNEY INT, V80, P464, DOI 10.1038/ki.2011.179
   BENDICH A, 1950, J BIOL CHEM, V183, P267
   Carvalho C, 2011, CLIN NEPHROL, V76, P90, DOI 10.5414/CN107018
   de Almeida JC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140062
   CHANTLER C, 1974, PEDIATR RES, V8, P109, DOI 10.1203/00006450 197402000 00007
   Cheung WW, 2014, J AM SOC NEPHROL, V25, P119, DOI 10.1681/ASN.2013040432
   Claramunt D, 2015, AM J PHYSIOL RENAL, V309, pF57, DOI 10.1152/ajprenal.00051.2015
   Cobo A, 1996, MINER ELECTROL METAB, V22, P192
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Dutta S, 2016, LIFE SCI, V152, P244, DOI 10.1016/j.lfs.2015.10.025
   Farquharson C, 2013, PEDIATR NEPHROL, V28, P547, DOI 10.1007/s00467 012 2271 0
   FINE RN, 1994, J PEDIATR US, V124, P374, DOI 10.1016/S0022 3476(94)70358 2
   Gao Y, 2015, J CLIN INVEST, V125, P3681, DOI 10.1172/JCI81860
   Gardenghi S, 2014, BLOOD, V123, P1137, DOI 10.1182/blood 2013 08 521625
   HANNA JD, 1995, KIDNEY INT, V47, P1374, DOI 10.1038/ki.1995.193
   Hörl WH, 2013, NAT REV NEPHROL, V9, P291, DOI 10.1038/nrneph.2013.21
   Kikuchi H, 2016, CLIN EXP NEPHROL
   Kim A, 2014, BLOOD, V123, P1129, DOI 10.1182/blood 2013 08 521419
   Ku E, 2016, CLIN J AM SOC NEPHRO, V11, P832, DOI 10.2215/CJN.08250815
   Lane PH, 2005, ADV CHRONIC KIDNEY D, V12, P372, DOI 10.1053/j.ackd.2005.07.009
   Lu JL, 2014, J AM SOC NEPHROL, V25, P2088, DOI 10.1681/ASN.2013070754
   Ma LJ, 2003, KIDNEY INT, V64, P350, DOI 10.1046/j.1523 1755.2003.00058.x
   Mahan JD, 2006, PEDIATR NEPHROL, V21, P917, DOI 10.1007/s00467 006 0020 y
   McDonald SP, 2004, NEW ENGL J MED, V350, P2654, DOI 10.1056/NEJMoa031643
   Molinos I, 2006, KIDNEY INT, V70, P1955, DOI 10.1038/sj.ki.5001949
   Nicolas G, 2002, P NATL ACAD SCI USA, V99, P4596, DOI 10.1073/pnas.072632499
   Oikonomidou PR, 2016, OSTEOPOROSIS INT, V27, P1559, DOI 10.1007/s00198 015 3412 7
   Padeh S, 2011, J PEDIATR US, V159, P832, DOI 10.1016/j.jpeds.2011.04.012
   Park CH, 2001, J BIOL CHEM, V276, P7806, DOI 10.1074/jbc.M008922200
   Patel NM, 2010, KIDNEY INT, V77, P715, DOI 10.1038/ki.2009.551
   Pereira RA, 2015, NEPHROL DIAL TRANSPL, V30, P1718, DOI 10.1093/ndt/gfv133
   PHILIPS FS, 1952, J PHARMACOL EXP THER, V104, P20
   RAO DS, 1993, NEW ENGL J MED, V328, P171, DOI 10.1056/NEJM199301213280304
   Rodig NM, 2014, PEDIATR NEPHROL, V29, P1987, DOI 10.1007/s00467 014 2812 9
   Ruifrok AC, 2001, ANAL QUANT CYTOL, V23, P291
   Runolfsdottir HL, 2016, AM J KIDNEY DIS, V67, P431, DOI 10.1053/j.ajkd.2015.10.023
   Santana AC, 2013, NEPHROL DIAL TRANSPL, V28, P1140, DOI 10.1093/ndt/gfs569
   Sasu BJ, 2010, BLOOD, V115, P3616, DOI 10.1182/blood 2009 09 245977
   SCHAEFER F, 1994, J CLIN ENDOCR METAB, V78, P1298, DOI 10.1210/jc.78.6.1298
   Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73
   Seikaly MG, 2003, PEDIATR NEPHROL, V18, P796, DOI 10.1007/s00467 003 1158 5
   Seikaly MG, 2006, PEDIATR NEPHROL, V21, P793, DOI 10.1007/s00467 006 0040 7
   Singh L, 2016, BONE, V85, P29, DOI 10.1016/j.bone.2016.01.014
   Sun CC, 2013, NEPHROL DIAL TRANSPL, V28, P1733, DOI 10.1093/ndt/gfs584
   Sun CC, 2012, AM J HEMATOL, V87, P392, DOI 10.1002/ajh.23110
   Taft RA, 2006, TRENDS GENET, V22, P649, DOI 10.1016/j.tig.2006.09.010
   Tamura M, 2009, HISTOCHEM CELL BIOL, V131, P483, DOI 10.1007/s00418 009 0557 5
   Tonshoff B, 1997, ENDOCRINOLOGY, V138, P938, DOI 10.1210/en.138.3.938
   Troib A, 2016, NEPHROL DIAL TRANSPL, V31, P1270, DOI 10.1093/ndt/gfv373
   Troutt JS, 2013, J CLIN LAB ANAL, V27, P504, DOI 10.1002/jcla.21634
   Ulinski T, 2000, PEDIATR NEPHROL, V14, P589, DOI 10.1007/s004670000361
   Waller SC, 2005, KIDNEY INT, V67, P2338, DOI 10.1111/j.1523 1755.2005.00339.x
   Weiss G, 2003, KIDNEY INT, V64, P572, DOI 10.1046/j.1523 1755.2003.00099.x
   Wong H, 2006, KIDNEY INT, V70, P585, DOI 10.1038/sj.ki.5001608
   YOKOZAWA T, 1986, NEPHRON, V44, P230, DOI 10.1159/000183992
   YOKOZAWA T, 1984, J NUTR SCI VITAMINOL, V30, P245, DOI 10.3177/jnsv.30.245
   Zaritsky J, 2009, CLIN J AM SOC NEPHRO, V4, P1051, DOI 10.2215/CJN.05931108
NR 67
TC 43
Z9 50
U1 0
U2 13
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 1931 857X
EI 1522 1466
J9 AM J PHYSIOL RENAL
JI Am. J. Physiol. Renal Physiol.
PD NOV 1
PY 2016
VL 311
IS 5
BP F877
EP F889
DI 10.1152/ajprenal.00089.2016
PG 13
WC Physiology; Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Physiology; Urology & Nephrology
GA EE5KU
UT WOS:000389646700006
PM 27440777
OA Bronze, Green Published
DA 2025 08 17
ER

PT J
AU Nam, SY
   Yoou, MS
   Kim, HM
   Jeong, HJ
AF Nam, Sun Young
   Yoou, Myoung Schook
   Kim, Hyung Min
   Jeong, Hyun Ja
TI Efficacy of proline in the treatment of menopause
SO EXPERIMENTAL BIOLOGY AND MEDICINE
LA English
DT Article
DE Proline; menopause; estrogen receptor; estradiol; MCF 7 cells; MG 63
   cells
ID ESTROGEN RECEPTOR; IN VITRO; BONE; PROLIFERATION; PLACENTA; MODEL;
   DIFFERENTIATION; OSTEOPOROSIS; EXTRACTS; THERAPY
AB The amino acids in the placenta have multiple functions; however, the therapeutic effects of proline remain poorly for relief postmenopausal symptoms. The aim of present study was to evaluate the effects of proline in the treatment of menopause using in vitro and in vivo models. We assessed the therapeutic effects and regulatory mechanisms of proline by using MCF 7 estrogen dependent cells, MG63 osteoblast cells, and ovariectomized mice model. An in vivo study was carried out in eight week old sham and ovariectomized group. The ovariectomized mouse was further subdivided into two groups administered orally with 17 beta estradiol or proline (10 mg/kg/day) for eight weeks. Proline significantly increased cell proliferation and Ki 67 levels in MCF 7 cells and enhanced cell proliferation, alkaline phosphatase activity, extracellular signal regulated kinase phosphorylation, and glutamyl prolyl tRNA synthetase activation in MG63 cells. The estrogen receptor beta and estrogen response elements luciferase activity were significantly increased by proline in MCF 7 and MG63 cells. In ovariectomized mice, oral administration of proline (10 mg/kg/day) for eight weeks significantly reduced body and vaginal weights. Proline also significantly increased serum estradiol and alkaline phosphatase levels, whereas serum luteinizing hormone was decreased by proline. In addition, detailed microcomputed tomography analysis showed that the proline notably enhanced bone mineral density, trabecular bone volume, and trabecular number in ovariectomized mice. Those findings implied that proline can be a promising candidate for the treatment of menopause.
C1 [Nam, Sun Young; Yoou, Myoung Schook; Kim, Hyung Min] Kyung Hee Univ, Dept Pharmacol, Coll Korean Med, Seoul 130701, South Korea.
   [Jeong, Hyun Ja] Hoseo Univ, Dept Food Technol, Asan 336795, Chungnam, South Korea.
   [Jeong, Hyun Ja] Hoseo Univ, Inflammatory Dis Res Ctr, Asan 336795, Chungnam, South Korea.
C3 Kyung Hee University; Hoseo University; Hoseo University
RP Kim, HM (通讯作者)，Kyung Hee Univ, Dept Pharmacol, Coll Korean Med, Seoul 130701, South Korea.; Jeong, HJ (通讯作者)，Hoseo Univ, Dept Food Technol, Asan 336795, Chungnam, South Korea.; Jeong, HJ (通讯作者)，Hoseo Univ, Inflammatory Dis Res Ctr, Asan 336795, Chungnam, South Korea.
EM hmkim@khu.ac.kr; hjjeong@hoseo.edu
FU Ministry of Trade, Industry and Energy(MOTIE) through the Special
   Education program for Industrial Convergence
FX This research was supported by the Ministry of Trade, Industry and
   Energy(MOTIE) through the Special Education program for Industrial
   Convergence (2015).
CR Auro K, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5708
   Biswas TK, 2001, ACTA PHARMACOL SIN, V22, P1113
   Buckler Helen, 2005, J Br Menopause Soc, V11, P61, DOI 10.1258/136218005775544525
   Cho Peter, 2004, Implant Dent, V13, P79, DOI 10.1097/01.ID.0000116456.76235.BC
   Chu TLH, 2013, INT IMMUNOPHARMACOL, V16, P414, DOI 10.1016/j.intimp.2013.04.031
   Cruzat VF, 2014, J INT SOC SPORT NUTR, V11, DOI 10.1186/s12970 014 0061 8
   Datta P, 2004, J PHARMACEUT BIOMED, V34, P1091, DOI 10.1016/S0731 7085(03)00654 X
   DUBUC PU, 1985, P SOC EXP BIOL MED, V180, P468
   Fu SW, 2014, NUTR RES, V34, P467, DOI 10.1016/j.nutres.2014.05.003
   Hamdy RC, 2010, REV ENDOCR METAB DIS, V11, P229, DOI 10.1007/s11154 009 9118 4
   Han NR, 2013, NUTRITION, V29, P1381, DOI 10.1016/j.nut.2013.04.016
   Hong HT, 2002, J ETHNOPHARMACOL, V79, P143, DOI 10.1016/S0378 8741(01)00371 3
   Jennings A, 2016, J BONE MINER RES, V31, P326, DOI 10.1002/jbmr.2703
   Ji ZN, 2006, GYNECOL ENDOCRINOL, V22, P578, DOI 10.1080/09513590600924345
   김현진, 2003, [Korean Journal of Dermatology, 대한피부과학회지], V41, P1612
   Kolta S, 2003, J CLIN DENSITOM, V6, P251, DOI 10.1385/JCD:6:3:251
   Lee CH, 2012, EUR J PHARMACOL, V676, P26, DOI 10.1016/j.ejphar.2011.12.001
   Lindh Åstrand L, 2015, HUM REPROD, V30, P848, DOI 10.1093/humrep/dev017
   Lobo RA, 2014, CLIMACTERIC, V17, P540, DOI 10.3109/13697137.2014.933411
   Micevych P, 2008, BRAIN RES REV, V57, P470, DOI 10.1016/j.brainresrev.2007.06.009
   Mori Okamoto J, 2004, J ETHNOPHARMACOL, V92, P93, DOI 10.1016/j.jep.2004.02.006
   Nelson HD, 2008, LANCET, V371, P760, DOI 10.1016/S0140 6736(08)60346 3
   OBER WB, 1979, B NEW YORK ACAD MED, V55, P591
   Odo S., 2013, Food and Nutrition Sciences, V4, P222
   Panay Nick, 2013, Menopause Int, V19, P59, DOI 10.1177/1754045313489645
   김민호, 2014, [CELLMED, 셀메드], V4, P14, DOI 10.5667/tang.2014.0020
   Raucci A, 2008, J CELL PHYSIOL, V215, P442, DOI 10.1002/jcp.21323
   Riggs BL, 1998, J BONE MINER RES, V13, P763, DOI 10.1359/jbmr.1998.13.5.763
   Rimoldi G, 2007, ENVIRON HEALTH PERSP, V115, P62, DOI 10.1289/ehp.9367
   SANCHEZGUERRERO J, 1995, ANN INTERN MED, V122, P430, DOI 10.7326/0003 4819 122 6 199503150 00005
   Shim MK, 2012, J GINSENG RES, V36, P169, DOI 10.5142/jgr.2012.36.2.169
   STEINBERG KK, 1991, JAMA J AM MED ASSOC, V266, P1362
   Torricelli P, 2002, BIOMED PHARMACOTHER, V56, P492, DOI 10.1016/S0753 3322(02)00287 1
   Vadlamudi RK, 2001, J BIOL CHEM, V276, P38272
   Wu GY, 2011, AMINO ACIDS, V40, P1053, DOI 10.1007/s00726 010 0715 z
   Young SM, 2010, ECOL FOOD NUTR, V49, P467, DOI 10.1080/03670244.2010.524106
   Zaid SSM, 2010, BMC COMPLEM ALTERN M, V10, DOI 10.1186/1472 6882 10 82
   Zhang CF, 2014, J BIOMED SCI, V21, DOI 10.1186/1423 0127 21 30
   Zheng X, 2016, J MED FOOD, V19, P1
NR 39
TC 6
Z9 7
U1 1
U2 6
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1535 3702
EI 1535 3699
J9 EXP BIOL MED
JI Exp. Biol. Med.
PD MAR
PY 2016
VL 241
IS 6
BP 611
EP 619
DI 10.1177/1535370216629011
PG 9
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA DG6NS
UT WOS:000372203100006
PM 26830682
OA Green Published
DA 2025 08 17
ER

PT J
AU Turi, GK
   Donovan, V
   DiGregorio, J
   Criscitelli, TM
   Kashan, B
   Barrientos, S
   Balingcongan, JR
   Gorenstein, S
   Brem, H
AF Turi, George K.
   Donovan, Virginia
   DiGregorio, Julie
   Criscitelli, Theresa M.
   Kashan, Benjamin
   Barrientos, Stephan
   Balingcongan, Jose Ramon
   Gorenstein, Scott
   Brem, Harold
TI Major Histopathologic Diagnoses of Chronic Wounds
SO ADVANCES IN SKIN & WOUND CARE
LA English
DT Article
DE granulomatosis with polyangiitis; histopathology; vasculitis; wound care
ID DIABETIC FOOT OSTEOMYELITIS; CUTANEOUS VASCULITIS UPDATE; CLINICAL
   APPROACH; MANAGEMENT; INFECTIONS; BONE; CLASSIFICATION; PATHOGENESIS;
   ANTIBIOTICS
AB OBJECTIVE: The presence of a chronic wound can result in significant morbidity/mortality. Understanding the pathological alterations of wound tissue that are refractory to standard wound therapy is essential for effective wound management and healing. The authors describe 4 wound etiologies, specifically, acute osteomyelitis, chronic osteomyelitis, primary vasculitis, and secondary type vasculitis.
   SETTING: A tertiary care hospital.
   DESIGN: A retrospective review of 1392 wound operations performed during a 24 month period at a tertiary care hospital was conducted. Tissue specimens reviewed included soft tissue infections of the lower extremity, sacrum, hip/pelvis, trunk, perineum, and buttocks.
   MAIN RESULTS: Acute osteomyelitis is defined as bone tissue with a predominance of polymorphonuclear leukocytes, evidence of osteoclast bone resorption with scalloping of the cortical bone edges, and bone detritus. Chronic osteomyelitis is defined as bone tissue with a significant amount of fibrosis surrounding devitalized tissue and heavy infiltration of lymphocytes and plasma cells. Primary type vasculitis is defined primarily as inflammation and necrosis of blood vessel walls. In cutaneous lesions of granulomatosis with polyangiitis, ulceration with numerous inflammatory granulomas is seen in the papillary dermis. Secondary vasculitis is defined by vessel wall infiltration by inflammatory cells and fibrinoid necrosis of the small vessel wall.
   CONCLUSIONS: Pathologies of these 4 types of wounds can complicate standard algorithms designed for diagnosis and treatment, and accurate diagnosis through histopathologic analysis can help tailor targeted treatment.
C1 [Turi, George K.] Winthrop Univ Hosp, Pathol, Mineola, NY 11501 USA.
   [Turi, George K.] SUNY Stony Brook, Sch Med, Pathol, Stony Brook, NY 11794 USA.
   [Donovan, Virginia] Winthrop Univ Hosp, Dept Pathol, Mineola, NY 11501 USA.
   [Donovan, Virginia] SUNY Stony Brook, Sch Med, Stony Brook, NY 11794 USA.
   [DiGregorio, Julie] Winthrop Univ Hosp, Res & Clin Trials, Mineola, NY 11501 USA.
   [Criscitelli, Theresa M.] Winthrop Univ Hosp, Perioperat Procedural Dept, Adm, Mineola, NY 11501 USA.
   [Kashan, Benjamin] Nassau Univ, Med Ctr, Oceanside, NY USA.
   [Barrientos, Stephan] Brody Sch Med, Vidant Med Ctr, Greenville, NC USA.
   [Balingcongan, Jose Ramon] Winthrop Univ Hosp, Dept Surg, Div Wound Healing & Regenerat Med, Mineola, NY 11501 USA.
   [Gorenstein, Scott] Winthrop Univ Hosp, Dept Surg, Mineola, NY 11501 USA.
   [Brem, Harold] SUNY Stony Brook, Dept Surg, Sch Med, Stony Brook, NY 11794 USA.
   [Brem, Harold] Winthrop Univ Hosp, Div Wound Healing & Regenerat Med, Mineola, NY 11501 USA.
C3 Winthrop University Hospital; State University of New York (SUNY)
   System; Stony Brook University; Winthrop University Hospital; State
   University of New York (SUNY) System; Stony Brook University; Winthrop
   University Hospital; Winthrop University Hospital; Winthrop University
   Hospital; Winthrop University Hospital; State University of New York
   (SUNY) System; Stony Brook University; Winthrop University Hospital
RP Turi, GK (通讯作者)，Winthrop Univ Hosp, Pathol, Mineola, NY 11501 USA.; Turi, GK (通讯作者)，SUNY Stony Brook, Sch Med, Pathol, Stony Brook, NY 11794 USA.
OI Gorenstein, Scott/0000 0002 6545 675X
FU National Institute of Diabetes and Digestive and Kidney Diseases of the
   National Institutes of Health [K24DK090135]
FX The authors have disclosed that research reported in this article was
   supported by the National Institute of Diabetes and Digestive and Kidney
   Diseases of the National Institutes of Health under award number
   K24DK090135. The content is solely the responsibility of the authors and
   does not necessarily represent the official views of the National
   Institutes of Health.
CR Attinger CE, 2006, PLAST RECONSTR SURG, V117, p72S, DOI 10.1097/01.prs.0000225470.42514.8f
   Berendt AR, 2008, DIABETES METAB RES, V24, pS145, DOI 10.1002/dmrr.836
   Brem H, 2007, J CLIN INVEST, V117, P1219, DOI 10.1172/JCI32169
   Brem H, 2006, PLAST RECONSTR SURG, V117, p193S, DOI 10.1097/01.prs.0000225459.93750.29
   Brown Gregory, 2003, Ostomy Wound Manage, V49, P42
   Calhoun JH, 2005, INFECT DIS CLIN N AM, V19, P765, DOI 10.1016/j.idc.2005.07.009
   Carek PJ, 2001, AM FAM PHYSICIAN, V63, P2413
   Carlson JA, 2006, AM J DERMATOPATH, V28, P486, DOI 10.1097/01.dad.0000246646.45651.a2
   Carlson JA, 2005, AM J DERMATOPATH, V27, P504, DOI 10.1097/01.dad.0000181109.54532.c5
   Chen K R., 2011, HISTOPATHOLOGY CUTAN
   Chen KR, 2008, AM J CLIN DERMATOL, V9, P71, DOI 10.2165/00128071 200809020 00001
   Comarmond C, 2014, AUTOIMMUN REV, V13, P1121, DOI 10.1016/j.autrev.2014.08.017
   Conterno LO, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004439.pub3
   Conterno LO, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004439.pub2
   Davis JS, 2005, INTERN MED J, V35, pS79, DOI 10.1111/j.1444 0903.2005.00982.x
   Davis WA, 2006, DIABETOLOGIA, V49, P2634, DOI 10.1007/s00125 006 0431 0
   GENTRY LO, 1990, ANTIMICROB AGENTS CH, V34, P40, DOI 10.1128/AAC.34.1.40
   Golinko Michael S, 2008, J Am Coll Surg, V207, pe1, DOI 10.1016/j.jamcollsurg.2008.09.018
   Golinko MS, 2009, J AM COLL SURGEONS, V209, P254, DOI 10.1016/j.jamcollsurg.2009.04.012
   Gross WL, 2000, RHEUMATOLOGY, V39, P245, DOI 10.1093/rheumatology/39.3.245
   Hatzenbuehler J, 2011, AM FAM PHYSICIAN, V84, P1027
   Hobizal KB, 2012, DIABET FOOT ANKLE, V3, DOI 10.3402/dfa.v3i0.18409
   HUNT JA, 1992, DIABETIC MED, V9, P749
   Jeffcoate WJ, 2004, CLIN INFECT DIS, V39, pS115, DOI 10.1086/383272
   Jennette JC, 2013, CLIN EXP NEPHROL, V17, P603, DOI 10.1007/s10157 013 0869 6
   Johnston BL, 2007, CAN J INFECT DIS MED, V18, P115, DOI 10.1155/2007/968523
   Kirshen Carly, 2006, Adv Skin Wound Care, V19, P506, DOI 10.1097/00129334 200611000 00011
   Korantzopoulos P, 2004, CARDIOLOGY, V102, P7, DOI 10.1159/000076995
   Lavery LA, 2007, DIABETES CARE, V30, P270, DOI 10.2337/dc06 1572
   Lipsky BA, 1997, CLIN INFECT DIS, V25, P1318, DOI 10.1086/516148
   Lázaro Martínez JL, 2014, DIABETES CARE, V37, P789, DOI 10.2337/dc13 1526
   Mustoe TA, 2006, PLAST RECONSTR SURG, V117, p35S, DOI 10.1097/01.prs.0000225431.63010.1b
   Restrepo Santiago, 2003, Ear Nose Throat J, V82, P100
   SAPICO FL, 1984, REV INFECT DIS, V6, pS171
   Senneville E, 2006, CLIN INFECT DIS, V42, P57, DOI 10.1086/498112
   Seror R, 2006, MEDICINE, V85, P54, DOI 10.1097/01.md.0000200166.90373.41
   Smith K, 2016, BMC MICROBIOL, V16, DOI 10.1186/s12866 016 0665 z
   Spellberg B, 2012, CLIN INFECT DIS, V54, P393, DOI 10.1093/cid/cir842
   Sunderkötter C, 2006, EUR J DERMATOL, V16, P114
   Werdin Frank, 2009, Eplasty, V9, pe19
   WHEAT LJ, 1986, ARCH INTERN MED, V146, P1935, DOI 10.1001/archinte.146.10.1935
NR 41
TC 7
Z9 7
U1 0
U2 17
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1527 7941
EI 1538 8654
J9 ADV SKIN WOUND CARE
JI Adv. Skin Wound Care
PD AUG
PY 2016
VL 29
IS 8
BP 376
EP 382
DI 10.1097/01.ASW.0000484665.45022.b3
PG 7
WC Dermatology; Nursing; Surgery
WE Science Citation Index Expanded (SCI EXPANDED); Social Science Citation Index (SSCI)
SC Dermatology; Nursing; Surgery
GA DS2RL
UT WOS:000380631100008
PM 27429243
DA 2025 08 17
ER

PT J
AU Wang, LJ
   Chen, ZG
   Chen, D
   Kan, B
   He, YF
   Cai, HQ
AF Wang, Lijuan
   Chen, Zhigang
   Chen, Dong
   Kan, Bo
   He, Yangfang
   Cai, Hanqing
TI Farnesyl diphosphate synthase promotes cell proliferation by regulating
   gene expression and alternative splicing profiles in HeLa cells
SO ONCOLOGY LETTERS
LA English
DT Article
DE farnesyl diphosphate synthase; cell proliferation; RNA sequencing;
   differentially expressed genes; alternative splicing
ID NITROGEN CONTAINING BISPHOSPHONATES; DECREASED IFIT2 EXPRESSION;
   PYROPHOSPHATE SYNTHASE; BONE FORMATION; MESSENGER RNA; CANCER
   PROGRESSION; OSTEOPOROSIS; INHIBITION; IDENTIFICATION; PROTEIN 2
AB Farnesyl diphosphate synthase (FDPS), an essential enzyme involved in the mevalonate pathway, is implicated in various diseases, including multiple types of cancer. As an RNA binding protein (RBP), FDPS is also involved in transcriptional and post transcriptional regulation. However, to the best of our knowledge, transcriptome wide targets of FDPS still remain unknown. In the present study, FDPS expression patterns in pan cancer were analyzed. In addition, it was investigated how FDPS overexpression (FDPS OE) regulates the transcriptome in HeLa cells. FDPS OE increased the proliferation rate in HeLa cells by MTT assay. Using transcriptome wide high throughput sequencing and bioinformatics analysis, it was found that FDPS upregulated the expression levels of genes enriched in cell proliferation and extracellular matrix organization, including the laminin subunit gamma 2, interferon induced proteins with tetratricopeptide repeats 2 and matrix metallopeptidase 19 genes. According to alternative splicing (AS) analysis, FDPS modulated the splicing patterns of the bone morphogenic protein 1, semaphorin 4D, annexin A2 and sirtuin 2 genes, which are enriched in the cell cycle and DNA repair, and are related to cell proliferation. To corroborate the FDPS regulated transcriptome findings, FDPS was overexpressed in human osteosarcoma cells. Differentially expressed genes and regulated AS genes in the cells were both validated by reverse transcription quantitative PCR. The results suggested that, as an emerging RBP, FDPS may serve an important role in transcriptome profiles by altering gene expression and regulating AS. FDPS also affected the cell proliferation rate. These findings broaden the understanding of the molecular functions of FDPS, and the potential of FDPS as a target in therapy should be investigated.
C1 [Wang, Lijuan; He, Yangfang; Cai, Hanqing] Second Hosp Jilin Univ, Dept Endocrinol, Changchun 130021, Jilin, Peoples R China.
   [Chen, Zhigang; Chen, Dong] ABLife BioBigData Inst, Wuhan 430075, Hubei, Peoples R China.
   [Kan, Bo] Second Hosp Jilin Univ, Dept Clin Lab, Changchun 130021, Jilin, Peoples R China.
   [Cai, Hanqing] Second Hosp Jilin Univ, Dept Endocrinol, 218 Ziqiang St, Changchun 130021, Jilin, Peoples R China.
C3 Jilin University; Jilin University; Jilin University
RP Cai, HQ (通讯作者)，Second Hosp Jilin Univ, Dept Endocrinol, 218 Ziqiang St, Changchun 130021, Jilin, Peoples R China.
EM caihq@mail.jlu.edu.cn
CR Abate M, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 14495 6
   Anderson PH, 2007, J STEROID BIOCHEM, V103, P601, DOI 10.1016/j.jsbmb.2006.12.084
   Asharani PV, 2012, AM J HUM GENET, V90, P661, DOI 10.1016/j.ajhg.2012.02.026
   Beaudreuil J, 2000, BONE, V27, P161, DOI 10.1016/S8756 3282(00)00305 7
   Bouterfa HL, 2000, ANTICANCER RES, V20, P2761
   Castello A, 2015, TRENDS ENDOCRIN MET, V26, P746, DOI 10.1016/j.tem.2015.09.012
   Castello A, 2012, CELL, V149, P1393, DOI 10.1016/j.cell.2012.04.031
   Chatrikhi R, 2019, CELL REP, V28, P2795, DOI 10.1016/j.celrep.2019.08.022
   Chen J, 2015, ONCOGENE, V34, P1, DOI 10.1038/onc.2013.570
   Chen LJ, 2018, CELL PHYSIOL BIOCHEM, V45, P15, DOI 10.1159/000486219
   Ciubean AD, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0225776
   Climente González H, 2017, CELL REP, V20, P2215, DOI 10.1016/j.celrep.2017.08.012
   Coxon FP, 2003, CALCIFIED TISSUE INT, V72, P80, DOI 10.1007/s00223 002 2017 2
   Dhar MK, 2013, NEW BIOTECHNOL, V30, P114, DOI 10.1016/j.nbt.2012.07.001
   Dunford JE, 2008, J MED CHEM, V51, P2187, DOI 10.1021/jm7015733
   Fagoonee S, 2017, ONCOTARGET, V8, P10007, DOI 10.18632/oncotarget.14318
   Fan X, 2013, GENE, V528, P21, DOI 10.1016/j.gene.2013.06.027
   Fontalis A, 2020, BONE, V136, DOI 10.1016/j.bone.2020.115336
   Fujiwara T, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.213
   FULLER K, 1993, J EXP MED, V178, P1733, DOI 10.1084/jem.178.5.1733
   Gao F, 2017, MOL MED REP, V15, P3969, DOI 10.3892/mmr.2017.6544
   Garg M, 2014, EXPERT OPIN THER TAR, V18, P979, DOI 10.1517/14728222.2014.934814
   Grainger DJ, 1999, OSTEOPOROSIS INT, V9, P398, DOI 10.1007/s001980050163
   Grgurevic L, 2011, BIOCHEM BIOPH RES CO, V408, P26, DOI 10.1016/j.bbrc.2011.03.109
   Han YX, 2020, MOL GENET GENOM MED, V8, DOI 10.1002/mgg3.1366
   Ishimoto K, 2010, BIOCHEM J, V429, P347, DOI 10.1042/BJ20091511
   Janckila AJ, 2001, CLIN CHEM, V47, P74
   Jara P, 2015, AM J PHYSIOL LUNG C, V308, pL511, DOI 10.1152/ajplung.00043.2014
   Jing YX, 2019, CELL MOL BIOL, V65, P66, DOI 10.14715/cmb/2019.65.7.12
   Jobke B, 2014, BONE, V59, P37, DOI 10.1016/j.bone.2013.10.024
   Kamimura Mikio, 2019, Osteoporos Sarcopenia, V5, P57, DOI 10.1016/j.afos.2019.06.001
   Kang MH, 2017, ONCOGENE, V36, P1745, DOI 10.1038/onc.2016.327
   Kavanagh KL, 2006, P NATL ACAD SCI USA, V103, P7829, DOI 10.1073/pnas.0601643103
   Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb 2013 14 4 r36
   Kimura T, 2009, CELL CALCIUM, V45, P264, DOI 10.1016/j.ceca.2008.11.005
   LaFleur J, 2015, BONE, V78, P174, DOI 10.1016/j.bone.2015.04.022
   Li HL, 2014, ONCOL REP, V32, P2118, DOI [10.3892/or_xxxxxxxx, 10.3892/or.2014.3447]
   Li XD, 2018, ENDOCRINOLOGY, V159, P260, DOI 10.1210/en.2017 00794
   Liang PH, 2002, EUR J BIOCHEM, V269, P3339, DOI 10.1046/j.1432 1033.2002.03014.x
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Marini F, 2008, CURR MED RES OPIN, V24, P2609, DOI [10.1185/03007990802352894, 10.1185/03007990802352894 ]
   Martínez Glez V, 2012, HUM MUTAT, V33, P343, DOI 10.1002/humu.21647
   Mazur CM, 2019, BONE RES, V7, DOI 10.1038/s41413 019 0070 y
   Nagy A, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 84787 5
   Negishi Koga T, 2011, NAT MED, V17, P1473, DOI 10.1038/nm.2489
   Notarnicola M, 2004, ONCOLOGY BASEL, V67, P351, DOI 10.1159/000082918
   Ohsugi T, 2017, ONCOTARGET, V8, P100176, DOI 10.18632/oncotarget.22122
   Olmos JM, 2012, PHARMACOGENOMICS J, V12, P227, DOI 10.1038/tpj.2010.88
   Raj T, 2018, NAT GENET, V50, P1584, DOI 10.1038/s41588 018 0238 1
   Rauwel B, 2020, J BONE MINER RES, V35, P753, DOI 10.1002/jbmr.3943
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Seshacharyulu P, 2019, ONCOGENE, V38, P5265, DOI 10.1038/s41388 019 0791 9
   Shen H, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 017 0107 3
   Sherman EJ, 2019, J BIOL CHEM, V294, P17188, DOI 10.1074/jbc.AC119.010419
   Shinoda K, 2020, CHEM COMMUN, V56, P1365, DOI 10.1039/c9cc09298f
   Paiva KBS, 2014, ARCH BIOCHEM BIOPHYS, V561, P74, DOI 10.1016/j.abb.2014.07.034
   Su WY, 2019, ONCOTARGETS THER, V12, P8139, DOI 10.2147/OTT.S220698
   Sugiyama M, 2000, BIOCHEM BIOPH RES CO, V271, P688, DOI 10.1006/bbrc.2000.2697
   Tang ZF, 2019, NUCLEIC ACIDS RES, V47, pW556, DOI 10.1093/nar/gkz430
   Terpos E, 2018, BLOOD CANCER J, V8, DOI 10.1038/s41408 018 0075 6
   Therneau T. M., 2022, CALCULATING SAMPLESS
   Trost Z, 2010, BONE, V46, P72, DOI 10.1016/j.bone.2009.09.015
   Tu YF, 2019, BMC IMMUNOL, V20, DOI 10.1186/s12865 019 0292 1
   Vuong CK, 2016, NAT REV NEUROSCI, V17, P265, DOI 10.1038/nrn.2016.27
   Waller DD, 2019, CRIT REV BIOCHEM MOL, V54, P41, DOI 10.1080/10409238.2019.1568964
   Wang E, 2020, TRENDS CANCER, V6, P631, DOI 10.1016/j.trecan.2020.04.011
   Wang L, 2013, INT J ONCOL, V43, P1095, DOI 10.3892/ijo.2013.2030
   Wiemer AJ, 2009, ANTI CANCER AGENT ME, V9, P526, DOI 10.2174/187152009788451860
   Woo IS, 2010, NEUROSCI LETT, V474, P115, DOI 10.1016/j.neulet.2010.03.021
   Xia H, 2017, BBA GENE REGUL MECH, V1860, P911, DOI 10.1016/j.bbagrm.2017.07.004
   Xie C, 2011, NUCLEIC ACIDS RES, V39, pW316, DOI 10.1093/nar/gkr483
   Yang J, 2013, INT J BIOCHEM CELL B, V45, P657, DOI 10.1016/j.biocel.2012.12.016
NR 73
TC 3
Z9 3
U1 2
U2 12
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792 1074
EI 1792 1082
J9 ONCOL LETT
JI Oncol. Lett.
PD APR
PY 2023
VL 25
IS 4
AR 145
DI 10.3892/ol.2023.13731
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 9Z4MJ
UT WOS:000951116600001
PM 36936029
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Humby, F
   Lewis, M
   Ramamoorthi, N
   Hackney, JA
   Barnes, MR
   Bombardieri, M
   Setiadi, AF
   Kelly, S
   Bene, F
   DiCicco, M
   Riahi, S
   Rocher, V
   Ng, N
   Lazarou, I
   Hands, R
   van der Heijde, D
   Landewé, RBM
   van der Helm van Mil, A
   Cauli, A
   McInnes, I
   Buckley, CD
   Choy, EH
   Taylor, PC
   Townsend, MJ
   Pitzalis, C
AF Humby, Frances
   Lewis, Myles
   Ramamoorthi, Nandhini
   Hackney, Jason A.
   Barnes, Michael R.
   Bombardieri, Michele
   Setiadi, A. Francesca
   Kelly, Stephen
   Bene, Fabiola
   DiCicco, Maria
   Riahi, Sudeh
   Rocher, Vidalba
   Ng, Nora
   Lazarou, Ilias
   Hands, Rebecca
   van der Heijde, Desiree
   Landewe, Robert B. M.
   van der Helm van Mil, Annette
   Cauli, Alberto
   McInnes, Iain
   Buckley, Christopher Dominic
   Choy, Ernest H.
   Taylor, Peter C.
   Townsend, Michael J.
   Pitzalis, Costantino
TI Synovial cellular and molecular signatures stratify clinical response to
   csDMARD therapy and predict radiographic progression in early rheumatoid
   arthritis patients
SO ANNALS OF THE RHEUMATIC DISEASES
LA English
DT Article
ID TISSUE MACROPHAGES; SMALL JOINTS; PATHOGENESIS; EROSION; DISEASE
AB Objectives To unravel the hierarchy of cellular/molecular pathways in the disease tissue of early, treatment naive rheumatoid arthritis (RA) patients and determine their relationship with clinical phenotypes and treatment response/outcomes longitudinally.
   Methods 144 consecutive treatment naive early RA patients (<12 months symptoms duration) underwent ultrasound guided synovial biopsy before and 6 months after disease modifying antirheumatic drug (DMARD) initiation. Synovial biopsies were analysed for cellular (immunohistology) and molecular (NanoString) characteristics and results compared with clinical and imaging outcomes. Differential gene expression analysis and logistic regression were applied to define variables correlating with treatment response and predicting radiographic progression.
   Results Cellular and molecular analyses of synovial tissue demonstrated for the first time in early RA the presence of three pathology groups: (1) lympho myeloid dominated by the presence of B cells in addition to myeloid cells; (2) diffuse myeloid with myeloid lineage predominance but poor in B cells nd (3) pauci immune characterised by scanty immune cells and prevalent stromal cells. Longitudinal correlation of molecular signatures demonstrated that elevation of myeloid and lymphoid associated gene expression strongly correlated with disease activity, acute phase reactants and DMARD response at 6 months. Furthermore, elevation of synovial lymphoid associated genes correlated with autoantibody positivity and elevation of osteoclast targeting genes predicting radiographic joint damage progression at 12 months. Patients with predominant pauci immune pathology showed less severe disease activity and radiographic progression.
   Conclusions We demonstrate at disease presentation, prior to pathology modulation by therapy, the presence of specific cellular/molecular synovial signatures that delineate disease severity/progression and therapeutic response and may pave the way to more precise definition of RA taxonomy, therapeutic targeting and improved outcomes.
C1 [Humby, Frances; Lewis, Myles; Barnes, Michael R.; Bombardieri, Michele; Kelly, Stephen; Bene, Fabiola; DiCicco, Maria; Riahi, Sudeh; Rocher, Vidalba; Ng, Nora; Lazarou, Ilias; Hands, Rebecca; Pitzalis, Costantino] Queen Mary Univ London, Barts & London Sch Med & Dent, William Harvey Res Inst, Ctr Expt Med & Rheumatol, London, England.
   [Ramamoorthi, Nandhini; Setiadi, A. Francesca; Townsend, Michael J.] Genentech Inc, Biomarker Discovery OMNI, San Francisco, CA 94080 USA.
   [Hackney, Jason A.] Genentech Inc, Bioinformat & Computat Biol, San Francisco, CA 94080 USA.
   [Barnes, Michael R.] William Harvey Res Inst, Ctr Translat Bioinformat, London, England.
   [van der Heijde, Desiree; van der Helm van Mil, Annette] Leiden Univ, Med Ctr, Dept Rheumatol, Leiden, Netherlands.
   [Landewe, Robert B. M.] AMC, Amsterdam Rheumatol Ctr, Amsterdam, Netherlands.
   [Landewe, Robert B. M.] Zuyderland MC, Dept Rheumatol, Heerlen, Netherlands.
   [Cauli, Alberto] Univ Cagliari, Cagliari, Italy.
   [McInnes, Iain] Univ Glasgow, Inst Infect Immun & Inflammat, Glasgow, Lanark, Scotland.
   [Buckley, Christopher Dominic] Univ Birmingham, Birmingham, W Midlands, England.
   [Choy, Ernest H.] Cardiff Univ, Sch Med, Inst Infect & Immun, Cardiff, S Glam, Wales.
   [Taylor, Peter C.] Kennedy Inst Rheumatol, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Oxford, England.
C3 University of London; Queen Mary University London; Roche Holding; Roche
   Holding USA; Genentech; Roche Holding; Roche Holding USA; Genentech;
   University of London; Queen Mary University London; Leiden University;
   Leiden University Medical Center (LUMC); Leiden University   Excl LUMC;
   University of Amsterdam; Academic Medical Center Amsterdam; University
   of Cagliari; University of Glasgow; University of Birmingham; Cardiff
   University; University of Oxford; Kennedy Institute for Rheumatology
RP Pitzalis, C (通讯作者)，Queen Mary Univ London, Barts & London Sch Med & Dent, William Harvey Res Inst, Ctr Expt Med & Rheumatol, London, England.; Townsend, MJ (通讯作者)，Genentech Res & Early Dev, Biomarker Discovery OMNI, San Francisco, CA 94080 USA.
EM townsend.michael@gene.com; c.pitzalis@qmul.ac.uk
RI ; McInnes, Iain/ACS 0958 2022; humby, frances/GSE 3706 2022; LANDEWE,
   ROBERT/ABD 7388 2021; van der Heijde, Désirée/I 6774 2019; Kelly,
   Stephen/GZH 1668 2022; Lewis, Myles/AAW 2453 2021; Buckley,
   Christopher/AAN 6378 2021; Buckley, Christopher Dominic/AAN 6378 2021
OI Taylor, Peter/0000 0001 7766 6167; Bombardieri,
   Michele/0000 0002 3878 5216; Lewis, Myles J/0000 0001 9365 5345;
   Townsend, Michael/0000 0003 0240 4562; Pitzalis,
   Costantino/0000 0003 1326 5051; Hackney, Jason/0000 0002 5922 563X; van
   der Helm   van Mil, Annette/0000 0001 8572 1437; Humby,
   Frances/0000 0003 1280 9133; Buckley, Christopher
   Dominic/0000 0001 6924 6402
FU Barts and The London School of Medicine and Dentistry Charity [523/819];
   Arthritis Research UK, Experimental Arthritis Treatment Centre [20];
   Medical Research Council, Pathobiology of Early Arthritis Cohort (PEAC)
   Grant; Medical Research Council (MRC) [MR/K015346/1]; Arthritis Research
   UK (ARUK) [20670]; MRC [G0800648, MR/K015346/1] Funding Source: UKRI;
   Medical Research Council [G0800648, MR/K015346/1, HDR 9004] Funding
   Source: researchfish
FX This study was funded by Barts and The London School of Medicine and
   Dentistry Charity (grant number: 523/819); Arthritis Research UK
   (http://dx.doi.org/10.13039/501100000341), Experimental Arthritis
   Treatment Centre Grant n: 20; Medical Research Council
   (http://dx.doi.org/10.13039/501100000265), Pathobiology of Early
   Arthritis Cohort (PEAC) Grant; Medical Research Council (MRC) and
   Arthritis Research UK (ARUK) for their joint funding of Maximizing
   Therapeutic Utility in Rheumatoid Arthritis (MATURA) [grant numbers
   MR/K015346/1, 20670, respectively].
CR Bottini N, 2013, NAT REV RHEUMATOL, V9, P24, DOI 10.1038/nrrheum.2012.190
   Brown PM, 2016, NAT REV RHEUMATOL, V12, P731, DOI 10.1038/nrrheum.2016.175
   Bueno R, 2016, NAT GENET, V48, P407, DOI 10.1038/ng.3520
   Cascao R, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3168
   Dalbeth N, 2009, ANN RHEUM DIS, V68, P279, DOI 10.1136/ard.2008.096024
   Davison A., 2003, Statisticial Computing and Statistical Graphics Newsletter, V13, P6
   Dennis G, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/ar4555
   Dharmapatni AASSK, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3294
   Gravallese Ellen M, 2017, Trans Am Clin Climatol Assoc, V128, P24
   Greisen SR, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/s13075 014 0434 z
   Haringman JJ, 2005, ANN RHEUM DIS, V64, P834, DOI 10.1136/ard.2004.029751
   HOCHBERG Y, 1990, STAT MED, V9, P811, DOI 10.1002/sim.4780090710
   Houseman M, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3734
   Humby F, 2009, PLOS MED, V6, P59, DOI 10.1371/journal.pmed.0060001
   Jones JD, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/ar4552
   Kelly S, 2015, ANN RHEUM DIS, V74, P611, DOI 10.1136/annrheumdis 2013 204603
   Khandpur R, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005580
   Kraan MC, 2002, ARTHRITIS RHEUM US, V46, P2034, DOI 10.1002/art.10556
   Kraan TCTMV, 2003, ARTHRITIS RHEUM US, V48, P2132, DOI 10.1002/art.11096
   Mandelin AM, 2018, ARTHRITIS RHEUMATOL, V70, P841, DOI 10.1002/art.40453
   McInnes IB, 2017, LANCET, V389, P2328, DOI 10.1016/S0140 6736(17)31472 1
   Meednu N, 2016, ARTHRITIS RHEUMATOL, V68, P805, DOI 10.1002/art.39489
   Musters A, 2018, J IMMUNOL, V201, P417, DOI 10.4049/jimmunol.1800421
   Naredo E, 2008, ANN RHEUM DIS, V67, P1017, DOI 10.1136/ard.2007.082560
   Orange DE, 2018, ARTHRITIS RHEUMATOL, V70, P690, DOI 10.1002/art.40428
   Pitzalis C, 2013, CURR OPIN RHEUMATOL, V25, P334, DOI 10.1097/BOR.0b013e32835fd8eb
   Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007
   Smith GCS, 2014, AM J EPIDEMIOL, V180, P318, DOI 10.1093/aje/kwu140
   van Baarsen LGM, 2010, ARTHRITIS RHEUM US, V62, P1602, DOI 10.1002/art.27415
   YANNI G, 1994, ANN RHEUM DIS, V53, P39, DOI 10.1136/ard.53.1.39
NR 30
TC 228
Z9 236
U1 0
U2 26
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0003 4967
EI 1468 2060
J9 ANN RHEUM DIS
JI Ann. Rheum. Dis.
PD JUN
PY 2019
VL 78
IS 6
BP 761
EP 772
DI 10.1136/annrheumdis 2018 214539
PG 12
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA IC6HN
UT WOS:000471072800024
PM 30878974
OA Green Published, Green Accepted, hybrid, Green Submitted
DA 2025 08 17
ER

PT J
AU Yoldi, G
   Pellegrini, P
   Trinidad, EM
   Cordero, A
   Gomez Miragaya, J
   Serra Musach, J
   Dougall, WC
   Muñoz, P
   Pujana, MA
   Planelles, L
   González Suárez, E
AF Yoldi, Guillermo
   Pellegrini, Pasquale
   Trinidad, Eva M.
   Cordero, Alex
   Gomez Miragaya, Jorge
   Serra Musach, Jordi
   Dougall, William C.
   Munoz, Purificacion
   Pujana, Miguel Angel
   Planelles, Lourdes
   Gonzalez Suarez, Eva
TI RANK Signaling Blockade Reduces Breast Cancer Recurrence by Inducing
   Tumor Cell Differentiation
SO CANCER RESEARCH
LA English
DT Article
ID MAMMARY GLAND DEVELOPMENT; STEM CELL; EPITHELIAL CELLS; EXPRESSION;
   MOUSE; PROLIFERATION; MODEL; METASTASIS; OSTEOCLAST; CARCINOMA
AB RANK expression is associated with poor prognosis in breast cancer even though its therapeutic potential remains unknown. RANKL and its receptor RANK are downstream effectors of the progesterone signaling pathway. However, RANK expression is enriched in hormone receptor negative adenocarcinomas, suggesting additional roles for RANK signaling beyond its hormone dependent function. Here, to explore the role of RANK signaling once tumors have developed, we use the mouse mammary tumor virus Polyoma Middle T (MMTV PyMT), which mimics RANK and RANKL expression patterns seen in human breast adenocarcinomas. Complementary genetic and pharmacologic approaches demonstrate that therapeutic inhibition of RANK signaling drastically reduces the cancer stem cell pool, decreases tumor and metastasis initiation, and enhances sensitivity to chemotherapy. Mechanistically, genome wide expression analyses show that anti RANKL therapy promotes lactogenic differentiation of tumor cells. Moreover, RANK signaling in tumor cells negatively regulates the expression of Ap2 transcription factors, and enhances the Wnt agonist Rspo1 and the Sca1 population, enriched in tumor initiating cells. In addition, we found that expression of TFAP2B and the RANK inhibitor, OPG, in human breast cancer correlate and are associated with relapse free tumors. These results support the use of RANKL inhibitors to reduce recurrence and metastasis in breast cancer patients based on its ability to induce tumor cell differentiation. (C) 2016 AACR.
C1 [Yoldi, Guillermo; Pellegrini, Pasquale; Trinidad, Eva M.; Cordero, Alex; Gomez Miragaya, Jorge; Munoz, Purificacion; Gonzalez Suarez, Eva] IDIBELL, Bellvitge Biomed Res Inst, Canc Epigenet & Biol Program, Barcelona, Spain.
   [Serra Musach, Jordi; Pujana, Miguel Angel] IDIBELL, Catalan Inst Oncol, Breast Canc & Syst Biol Lab, Program Canc Therapeut Resistance ProCURE, Barcelona, Spain.
   [Dougall, William C.] Amgen Inc, Therapeut Innovat Unit, Seattle, WA USA.
   [Planelles, Lourdes] UAM Cantoblanco, Ctr Nacl Biotecnol CSIC, Madrid, Spain.
   [Pellegrini, Pasquale] Gladstone Inst, San Francisco, CA USA.
   [Dougall, William C.] QIMR Berghofer Med Res Inst, Dept Immunol Canc & Infect, Herston, Qld, Australia.
   [Cordero, Alex] Northwestern Univ, Dept Neurol Surg, Feinberg Sch Med, Chicago, IL 60611 USA.
C3 Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); University of
   Barcelona; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL);
   Institut Catala d'Oncologia; University of Barcelona; Amgen; Consejo
   Superior de Investigaciones Cientificas (CSIC); CSIC   Centro Nacional
   de Biotecnologia (CNB); University of California System; University of
   California San Francisco; The J David Gladstone Institutes; QIMR
   Berghofer Medical Research Institute; Northwestern University; Feinberg
   School of Medicine
RP González Suárez, E (通讯作者)，Bellvitge Biomed Res Inst IDIBELL, Ave Gran Via Hospitalet 199 203, Barcelona 08908, Spain.
EM egsuarez@idibell.cat
RI Casanovas, Alex/AAA 8157 2020; Yoldi, Guillermo/AAA 8668 2019; Pujana,
   Miguel Angel/N 3127 2014; Pujana, Miquel Angel/AAG 4983 2021; Trinidad,
   Eva/B 3222 2016; Gonzalez Suarez, Eva/L 6298 2014
OI Cordero Casanovas, Alejandro/0000 0002 2224 7122; Dougall,
   William/0000 0001 9487 251X; Gomez Miragaya, Jorge/0000 0003 1801 4681;
   Trinidad Alvarez, Eva Maria/0000 0001 6090 5205; planelles,
   lourdes/0000 0001 7599 5389; Pujana, Miguel Angel/0000 0003 3222 4044;
   Gonzalez Suarez, Eva/0000 0003 0858 8171; Pellegrini,
   Pasquale/0000 0002 6196 4191
CR Anderson SM, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1653
   Bar Eli M, 1999, CANCER METAST REV, V18, P377, DOI 10.1023/A:1006377309524
   BARCELLOSHOFF MH, 1989, DEVELOPMENT, V105, P223
   Batts TD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027841
   Beleut M, 2010, P NATL ACAD SCI USA, V107, P2989, DOI 10.1073/pnas.0915148107
   Bogachek MV, 2014, CANCER CELL, V25, P748, DOI 10.1016/j.ccr.2014.04.008
   Bosher JM, 1996, ONCOGENE, V13, P1701
   Buchwalter G, 2013, CANCER CELL, V23, P753, DOI 10.1016/j.ccr.2013.04.026
   Cai CG, 2014, GENE DEV, V28, P2205, DOI 10.1101/gad.245142.114
   Cordero A, 2016, STEM CELLS, V34, P1027, DOI 10.1002/stem.2271
   Cyr AR, 2015, ONCOGENE, V34, P436, DOI 10.1038/onc.2013.569
   Dontu G, 2005, J MAMMARY GLAND BIOL, V10, P75, DOI 10.1007/s10911 005 2542 5
   Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803
   Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412
   Fata JE, 2000, CELL, V103, P41, DOI 10.1016/S0092 8674(00)00103 3
   Gee JMW, 1999, J PATHOL, V189, P514, DOI 10.1002/(SICI)1096 9896(199912)189:4<514::AID PATH463>3.0.CO;2 9
   Gonzalez Suarez E, 2007, MOL CELL BIOL, V27, P1442, DOI 10.1128/MCB.01298 06
   González Suárez E, 2016, FEBS J, V283, P2018, DOI 10.1111/febs.13645
   González Suárez E, 2011, CLIN TRANSL ONCOL, V13, P222, DOI 10.1007/s12094 011 0646 5
   Gonzalez Suarez E, 2010, NATURE, V468, P103, DOI 10.1038/nature09495
   GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954
   Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008
   Jäger R, 2003, MOL CANCER RES, V1, P921
   Joshi PA, 2015, STEM CELL REP, V5, P31, DOI 10.1016/j.stemcr.2015.05.012
   Lee GY, 2007, NAT METHODS, V4, P359, DOI 10.1038/NMETH1015
   Li XX, 2008, JNCI J NATL CANCER I, V100, P672, DOI 10.1093/jnci/djn123
   Lim E, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2560
   Lin EY, 2003, AM J PATHOL, V163, P2113, DOI 10.1016/S0002 9440(10)63568 7
   Maglione JE, 2001, CANCER RES, V61, P8298
   Malanchi I, 2012, NATURE, V481, P85, DOI 10.1038/nature10694
   McPherson LA, 2002, J BIOL CHEM, V277, P45028, DOI 10.1074/jbc.M208924200
   McPherson LA, 2007, J SURG RES, V138, P71, DOI 10.1016/j.jss.2006.07.002
   Palafox M, 2012, CANCER RES, V72, P2879, DOI 10.1158/0008 5472.CAN 12 0044
   Pasquale P, 2013, STEM CELLS, V31, P1954, DOI 10.1002/stem.1454
   Pfitzner BM, 2014, BREAST CANCER RES TR, V145, P307, DOI 10.1007/s10549 014 2955 1
   Santini D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019234
   Schramek D, 2010, NATURE, V468, P98, DOI 10.1038/nature09387
   Scibetta AG, 2010, CELL CYCLE, V9, P4525, DOI 10.4161/cc.9.22.13746
   Sleeman KE, 2007, J CELL BIOL, V176, P19, DOI 10.1083/jcb.200604065
   Smalley MJ, 2010, METHODS MOL BIOL, V633, P139, DOI 10.1007/978 1 59745 019 5_11
   Span PN, 2004, J CLIN ONCOL, V22, P691, DOI 10.1200/JCO.2004.01.072
   Tallman MS, 1997, NEW ENGL J MED, V337, P1021, DOI 10.1056/NEJM199710093371501
   Tanos T, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005654
   Vaillant F, 2008, CANCER RES, V68, P7711, DOI 10.1158/0008 5472.CAN 08 1949
   Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140 6736(05)17947 1
   Woodfield GW, 2010, GENE CHROMOSOME CANC, V49, P948, DOI 10.1002/gcc.20807
   Zhang J, 2003, DEV BIOL, V256, P127, DOI 10.1016/S0012 1606(02)00119 7
NR 47
TC 50
Z9 55
U1 0
U2 12
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106 4404 USA
SN 0008 5472
EI 1538 7445
J9 CANCER RES
JI Cancer Res.
PD OCT
PY 2016
VL 76
IS 19
BP 5857
EP 5869
DI 10.1158/0008 5472.CAN 15 2745
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA DZ1UD
UT WOS:000385625500029
PM 27480274
OA Green Submitted
DA 2025 08 17
ER

PT J
AU Hoffman, MD
   Benoit, DSW
AF Hoffman, Michael D.
   Benoit, Danielle S. W.
TI Agonism of Wnt β catenin signalling promotes mesenchymal stem cell (MSC)
   expansion
SO JOURNAL OF TISSUE ENGINEERING AND REGENERATIVE MEDICINE
LA English
DT Article
DE mesenchymal stem cells; hydrogel biomaterials; 6 bromoindirubin 3
   ' oxime; proliferation; pluripotency; regenerative medicine
ID MARROW STROMAL CELLS; GLYCOGEN SYNTHASE KINASE 3; OSTEOGENIC
   DIFFERENTIATION; GROWTH FACTOR; SELF RENEWAL; CHONDROGENIC
   DIFFERENTIATION; PROLIFERATION; PLURIPOTENCY; INHIBITION; HYDROGELS
AB Promoting mesenchymal stem cell (MSC) proliferation has numerous applications in stem cell therapies, particularly in the area of regenerative medicine. In order for cell based regenerative approaches to be realized, MSC proliferation must be achieved in a controlled manner without compromising stem cell differentiation capacities. Here we demonstrate that 6 bromoindirubin 3' oxime (BIO) increases MSC beta catenin activity 106 fold and stem cell associated gene expression similar to 33 fold, respectively, over untreated controls. Subsequently, BIO treatment increases MSC populations 1.8 fold in typical 2D culture conditions, as well as 1.3 fold when encapsulated within hydrogels compared to untreated cells. Furthermore, we demonstrate that BIO treatment does not reduce MSC multipotency where MSCs maintain their ability to differentiate into osteoblasts, chondrocytes and adipocytes using standard conditions. Taken together, our results demonstrate BIO's potential utility as a proliferative agent for cell transplantation and tissue regeneration. Copyright (C) 2013 John Wiley & Sons, Ltd.
C1 [Benoit, Danielle S. W.] Univ Rochester, Med Ctr, Dept Biomed Engn, Rochester, NY 14627 USA.
   Univ Rochester, Med Ctr, Dept Chem Engn, Rochester, NY 14627 USA.
   Univ Rochester, Med Ctr, Dept Orthopaed, Rochester, NY 14627 USA.
   Univ Rochester, Med Ctr, Ctr Musculoskeletal Res, Rochester, NY 14627 USA.
C3 University of Rochester; University of Rochester; University of
   Rochester; University of Rochester
RP Benoit, DSW (通讯作者)，Univ Rochester, Med Ctr, Dept Biomed Engn, 207 Robert B Goergen Hall,Box 270168, Rochester, NY 14627 USA.
EM benoit@bme.rochester.edu
RI ; Benoit, Danielle/HKV 4384 2023
OI Benoit, Danielle/0000 0001 7137 8164; 
FU Orthopaedic Research and Education Foundation/Musculoskeletal Transplant
   Foundation (OREF/MTF); Rochester/Finger Lakes Eye and Tissue Bank
   (RETB/FLETB); National Institutes of Health (NIH; T32, Training in
   Orthopaedic Research) [NIH T32AR053459]
FX Funding was received from the Orthopaedic Research and Education
   Foundation/Musculoskeletal Transplant Foundation (OREF/MTF), the
   Rochester/Finger Lakes Eye and Tissue Bank (RETB/FLETB) and the National
   Institutes of Health (NIH; T32, Training in Orthopaedic Research; Grant
   No. NIH T32AR053459, to MDH). The authors also wish to thank Dr Tori
   Matthews and Teresa Sherman for their assistance in plasmid isolation,
   as well as Dr Yufeng Dong for human primer development, Dr Jennifer
   Jonason and Dr Tzong jen Sheu for transfection troubleshooting, and Dr
   James McGrath for use of laboratory equipment.
CR Awad HA, 2007, TISSUE ENG, V13, P1973, DOI 10.1089/ten.2006.0107
   Ball SG, 2007, J CELL BIOL, V177, P489, DOI 10.1083/jcb.200608093
   Banfi A, 2000, EXP HEMATOL, V28, P707, DOI 10.1016/S0301 472X(00)00160 0
   Baxter MA, 2004, STEM CELLS, V22, P675, DOI 10.1634/stemcells.22 5 675
   BECKER AJ, 1963, NATURE, V197, P452, DOI 10.1038/197452a0
   Benoit DSW, 2008, NAT MATER, V7, P816, DOI 10.1038/nmat2269
   Benoit DSW, 2007, ADV FUNCT MATER, V17, P2085, DOI 10.1002/adfm.200700012
   Benoit DSW, 2007, J BIOMED MATER RES A, V81A, P259, DOI 10.1002/jbm.a.31292
   Benoit DSW, 2007, BIOMATERIALS, V28, P66, DOI 10.1016/j.biomaterials.2006.08.033
   Benoit DSW, 2006, BIOMATERIALS, V27, P6102, DOI 10.1016/j.biomaterials.2006.06.031
   Benoit DSW, 2006, TISSUE ENG, V12, P1663, DOI 10.1089/ten.2006.12.1663
   Benoit DSW, 2005, ACTA BIOMATER, V1, P461, DOI 10.1016/j.actbio.2005.03.002
   Bilechele Travis L., 2008, V468, P99, DOI 10.1007/978 1 59745 249 6_8
   Bilkovski R, 2010, J BIOL CHEM, V285, P6170, DOI 10.1074/jbc.M109.054338
   Bonab MM, 2006, BMC CELL BIOL, V7, DOI 10.1186/1471 2121 7 14
   BONEWALD LF, 1994, J CELL BIOCHEM, V55, P350, DOI 10.1002/jcb.240550312
   Bork S, 2010, AGING CELL, V9, P54, DOI 10.1111/j.1474 9726.2009.00535.x
   Bowers RR, 2008, CELL CYCLE, V7, P1191, DOI 10.4161/cc.7.9.5815
   Brack AS, 2007, SCIENCE, V317, P807, DOI 10.1126/science.1144090
   Bruder SP, 1997, J CELL BIOCHEM, V64, P278, DOI 10.1002/(SICI)1097 4644(199702)64:2<278::AID JCB11>3.0.CO;2 F
   Chen SB, 2006, P NATL ACAD SCI USA, V103, P17266, DOI 10.1073/pnas.0608156103
   Elisseeff J, 2005, Orthod Craniofac Res, V8, P150, DOI 10.1111/j.1601 6343.2005.00335.x
   Fairbanks BD, 2009, BIOMATERIALS, V30, P6702, DOI 10.1016/j.biomaterials.2009.08.055
   Fierro F, 2007, CELL PROLIFERAT, V40, P355, DOI 10.1111/j.1365 2184.2007.00438.x
   Fre S, 2009, P NATL ACAD SCI USA, V106, P6309, DOI 10.1073/pnas.0900427106
   Jaiswal N, 1997, J CELL BIOCHEM, V64, P295, DOI 10.1002/(SICI)1097 4644(199702)64:2<295::AID JCB12>3.3.CO;2 6
   Kashyap V, 2009, STEM CELLS DEV, V18, P1093, DOI 10.1089/scd.2009.0113
   Kasten P, 2008, EUR CELLS MATER, V16, P47, DOI 10.22203/eCM.v016a06
   Kelly KF, 2011, CELL STEM CELL, V8, P214, DOI 10.1016/j.stem.2010.12.010
   Krause U, 2010, P NATL ACAD SCI USA, V107, P4147, DOI 10.1073/pnas.0914360107
   Kwon C, 2011, NAT CELL BIOL, V13, P1244, DOI 10.1038/ncb2313
   Lin CC, 2009, PHARM RES DORDR, V26, P631, DOI 10.1007/s11095 008 9801 2
   Lin Gibson S, 2004, BIOMACROMOLECULES, V5, P1280, DOI 10.1021/bm0498777
   Liu GZ, 2009, J CELL BIOL, V185, P67, DOI 10.1083/jcb.200810137
   Luu HH, 2007, J ORTHOP RES, V25, P665, DOI 10.1002/jor.20359
   Mackay AM, 1998, TISSUE ENG, V4, P415, DOI 10.1089/ten.1998.4.415
   Masckauchan T. Nestor H., 2005, Angiogenesis, V8, P43, DOI 10.1007/s10456 005 5612 9
   McBeath R, 2004, DEV CELL, V6, P483, DOI 10.1016/S1534 5807(04)00075 9
   Meijer L, 2003, CHEM BIOL, V10, P1255, DOI 10.1016/j.chembiol.2003.11.010
   Murphy JM, 2003, ARTHRITIS RHEUM US, V48, P3464, DOI 10.1002/art.11365
   Nuttelman CR, 2006, J BIOMED MATER RES A, V76A, P183, DOI 10.1002/jbm.a.30537
   Ogawa T, 2010, J BIOMAT SCI POLYM E, V21, P609, DOI 10.1163/156856209X434638
   Pevsner Fischer M, 2007, BLOOD, V109, P1422, DOI 10.1182/blood 2006 06 028704
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Polychronopoulos P, 2004, J MED CHEM, V47, P935, DOI 10.1021/jm031016d
   Reinhold MI, 2006, J BIOL CHEM, V281, P1381, DOI 10.1074/jbc.M504875200
   REZNIKOFF CA, 1973, CANCER RES, V33, P3231
   Rodrigues M, 2010, STEM CELL RES THER, V1, DOI 10.1186/scrt32
   Roobrouck VD, 2008, EXP CELL RES, V314, P1937, DOI 10.1016/j.yexcr.2008.03.006
   Sato N, 2004, NAT MED, V10, P55, DOI 10.1038/nm979
   SAWHNEY AS, 1993, MACROMOLECULES, V26, P581, DOI 10.1021/ma00056a005
   Shahdadfar A, 2005, STEM CELLS, V23, P1357, DOI 10.1634/stemcells.2005 0094
   Shea CM, 2003, J CELL BIOCHEM, V90, P1112, DOI 10.1002/jcb.10734
   Sineva GS, 2010, BIOL CELL, V102, P549, DOI 10.1042/BC20100016
   Stewart A, 2010, J CELL PHYSIOL, V223, P658, DOI 10.1002/jcp.22064
   Tang J, 2010, BIOMATERIALS, V31, P2470, DOI 10.1016/j.biomaterials.2009.12.006
   Tang QQ, 2012, ANNU REV BIOCHEM, V81, P715, DOI 10.1146/annurev biochem 052110 115718
   Tseng AS, 2006, CHEM BIOL, V13, P957, DOI 10.1016/j.chembiol.2006.08.004
   Tsutsumi S, 2001, BIOCHEM BIOPH RES CO, V288, P413, DOI 10.1006/bbrc.2001.5777
   Vougogiannopoulou K, 2008, J MED CHEM, V51, P6421, DOI 10.1021/jm800648y
   Wagner W, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002213
   Wakitani S, 2002, OSTEOARTHR CARTILAGE, V10, P199, DOI 10.1053/joca.2001.0504
   Wen J, 2010, REPRODUCTION, V139, P1039, DOI 10.1530/REP 09 0539
   Wu QQ, 2008, J BONE MINER RES, V23, P552, DOI 10.1359/JBMR.071115
   Xie C, 2007, TISSUE ENG, V13, P435, DOI 10.1089/ten.2006.0182
   Yi F, 2011, NAT CELL BIOL, V13, P762, DOI 10.1038/ncb2283
   Ying QL, 2008, NATURE, V453, P519, DOI 10.1038/nature06968
   Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526
   Yu JY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017557
   Zhang DZ, 2011, ELECTRON J QUAL THEO, P1
   Zhao L, 2009, CALCIFIED TISSUE INT, V84, P56, DOI 10.1007/s00223 008 9189 3
NR 72
TC 34
Z9 41
U1 0
U2 18
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1932 6254
EI 1932 7005
J9 J TISSUE ENG REGEN M
JI J. Tissue Eng. Regen. Med.
PD NOV
PY 2015
VL 9
IS 11
BP E13
EP E26
DI 10.1002/term.1736
PG 14
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell
   Biology; Engineering, Biomedical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology; Engineering
GA CV8GQ
UT WOS:000364520300013
PM 23554411
OA Green Accepted
DA 2025 08 17
ER

PT J
AU El Sheikh, A
   Khired, Z
AF El Sheikh, Azza
   Khired, Zenat
TI Interactions of Analgesics with Cisplatin: Modulation of Anticancer
   Efficacy and Potential Organ Toxicity
SO MEDICINA LITHUANIA
LA English
DT Article
DE cisplatin; analgesics; acetaminophen; non steroidal anti inflammatory
   drugs; morphine; cytotoxicity
ID LOW DIRECT CYTOTOXICITY; NF KAPPA B; IN VITRO; INDUCED NEPHROTOXICITY;
   MOLECULAR MECHANISMS; CANCER CELLS; OSTEOSARCOMA; INHIBITION; ASPIRIN;
   DRUGS
AB Cisplatin (CDDP), one of the most eminent cancer chemotherapeutic agents, has been successfully used to treat more than half of all known cancers worldwide. Despite its effectiveness, CDDP might cause severe toxic adverse effects on multiple body organs during cancer chemotherapy, including the kidneys, heart, liver, gastrointestinal tract, and auditory system, as well as peripheral nerves causing severely painful neuropathy. The latter, among other pains patients feel during chemotherapy, is an indication for the use of analgesics during treatment with CDDP. Different types of analgesics, such as acetaminophen, non steroidal anti inflammatory drugs (NSAIDS), and narcotic analgesics, could be used according to the severity of pain. Administered analgesics might modulate CDDP's efficacy as an anticancer drug. NSAIDS, on one hand, might have cytotoxic effects on their own and few of them can potentiate CDDP's anticancer effects via inhibiting the CDDP induced cyclooxygenase (COX) enzyme, or through COX independent mechanisms. On the other hand, some narcotic analgesics might ameliorate CDDP's anti neoplastic effects, causing chemotherapy to fail. Concerning safety, some analgesics share the same adverse effects on normal tissues as CDDP, augmenting its potentially hazardous effects on organ impairment. This article offers an overview of the reported literature on the interactions between analgesics and CDDP, paying special attention to possible mechanisms that modulate CDDP's cytotoxic efficacy and potential adverse reactions.
C1 [El Sheikh, Azza] Princess Nourah Bint Abdulrahman Univ, Basic Hlth Sci Dept, Riyadh 11671, Saudi Arabia.
   [El Sheikh, Azza] Minia Univ, Dept Pharmacol, Fac Med, El Minia 61511, Egypt.
   [El Sheikh, Azza] Jazan Univ, Dept Surg, Fac Med, Jazan 45142, Saudi Arabia.
C3 Princess Nourah bint Abdulrahman University; Egyptian Knowledge Bank
   (EKB); Minia University; Jazan University
RP El Sheikh, A (通讯作者)，Princess Nourah Bint Abdulrahman Univ, Basic Hlth Sci Dept, Riyadh 11671, Saudi Arabia.; El Sheikh, A (通讯作者)，Minia Univ, Dept Pharmacol, Fac Med, El Minia 61511, Egypt.
EM aaelsheikh@pnu.edu.sa; zkherd@jazanu.edu.sa
RI khired, zenat/M 2553 2017; El Sheikh, Azza/GQQ 4455 2022
OI Khired, Zenat/0000 0002 8728 5381; 
FU Deanship of Scientific Research at Princess Nourah bint Abdulrahman
   University [240/S/39]
FX FundingThis research was funded by Deanship of Scientific Research at
   Princess Nourah bint Abdulrahman University, grant number 240/S/39.
CR Abd El Kader M, 2020, ACTA HISTOCHEM, V122, DOI 10.1016/j.acthis.2020.151534
   Abd Rashid N, 2021, BIOMED PHARMACOTHER, V144, DOI 10.1016/j.biopha.2021.112328
   Alves SR, 2020, J INORG BIOCHEM, V205, DOI 10.1016/j.jinorgbio.2019.110984
   Arai Y, 2005, DIGEST DIS SCI, V50, P1641, DOI 10.1007/s10620 005 2909 x
   Arora M, 2020, LIFE SCI, V251, DOI 10.1016/j.lfs.2020.117631
   Atashbar S, 2022, J BIOCHEM MOL TOXIC, V36, DOI 10.1002/jbt.22934
   Awad DS, 2014, PHARM BIOL, V52, P182, DOI 10.3109/13880209.2013.821665
   Aytaç P, 2022, ANTI CANCER AGENT ME, V22, P1340, DOI 10.2174/1871520621666210623093550
   Barbosa J, 2021, PHARMACEUTICALS BASE, V14, DOI 10.3390/ph14020097
   Barbosa J, 2020, PHARMACEUTICALS BASE, V13, DOI 10.3390/ph13070149
   Boland JW, 2018, BRIT J PHARMACOL, V175, P2726, DOI 10.1111/bph.13903
   Brenner GB, 2020, CELLS BASEL, V9, DOI 10.3390/cells9030551
   Broadfield LA, 2019, PROSTATE, V79, DOI 10.1002/pros.23755
   Caglar S, 2021, CELL BIOCHEM BIOPHYS, V79, P729, DOI 10.1007/s12013 021 00984 z
   Cetin D, 2016, CYTOTECHNOLOGY, V68, P1361, DOI 10.1007/s10616 015 9896 3
   Chai J, 2011, PEPTIC ULCER DIS, P437
   Chen Y, 2020, DALTON T, V49, P5192, DOI 10.1039/d0dt00424c
   Cheng QQ, 2014, CHEM COMMUN, V50, P7427, DOI 10.1039/c4cc00419a
   Dasari S, 2014, EUR J PHARMACOL, V740, P364, DOI 10.1016/j.ejphar.2014.07.025
   Drozdzal S, 2021, PHARMACOL RES PERSPE, V9, DOI 10.1002/prp2.817
   Dugbartey GJ, 2016, TOXICOLOGY, V371, P58, DOI 10.1016/j.tox.2016.10.001
   El Sheikh AAK, 2021, CARDIOVASC TOXICOL, V21, P553, DOI 10.1007/s12012 021 09646 1
   El Sheikh AAK, 2020, SCI PHARM, V88, DOI 10.3390/scipharm88010014
   Endo H, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.550
   Eroglu N, 2021, SUPPORT CARE CANCER, V29, P1859, DOI 10.1007/s00520 020 05670 z
   Fan CC, 2020, REDOX BIOL, V34, DOI 10.1016/j.redox.2020.101571
   Fazzio LE, 2021, VET SCI, V8, DOI 10.3390/vetsci8020030
   Frejborg E, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21239246
   Gentilin E, 2019, TRENDS MOL MED, V25, P1123, DOI 10.1016/j.molmed.2019.08.002
   Ghlichloo I, 2021, NONSTEROIDAL ANTIINF, P1
   Dehkordi NG, 2021, INFLAMMOPHARMACOLOGY, V29, P49, DOI 10.1007/s10787 020 00765 9
   Ghosh S, 2019, BIOORG CHEM, V88, DOI 10.1016/j.bioorg.2019.102925
   Grande F, 2021, MOLECULES, V26, DOI 10.3390/molecules26133940
   Greene SN, 2010, CANCER CHEMOTH PHARM, V65, P549, DOI 10.1007/s00280 009 1061 2
   Gunjal PM, 2015, J OVARIAN RES, V8, DOI 10.1186/s13048 015 0141 7
   Guo JF, 2021, PEERJ, V9, DOI 10.7717/peerj.11591
   Hall AJ, 2006, PROSTAG LEUKOTR ESS, V75, P9, DOI 10.1016/j.plefa.2006.04.006
   He B, 2009, CLIN CANCER RES, V15, P5803, DOI 10.1158/1078 0432.CCR 09 0811
   Heidarian E, 2021, ARCH PHYSIOL BIOCHEM, V127, P112, DOI 10.1080/13813455.2019.1620785
   Honma S, 2013, EUR J PHARMACOL, V715, P181, DOI 10.1016/j.ejphar.2013.05.023
   Hopkins HL, 2016, CURR OPIN SUPPORT PA, V10, P119, DOI 10.1097/SPC.0000000000000204
   Ibrahim MA, 2021, CHEM BIOL INTERACT, V338, DOI 10.1016/j.cbi.2021.109402
   Jiang W, 2020, AGING US, V12, P611, DOI 10.18632/aging.102644
   Jin SX, 2020, ANGEW CHEM INT EDIT, V59, P23313, DOI 10.1002/anie.202011273
   Karalis Theodoros T, 2020, Matrix Biol Plus, V6 7, P100031, DOI 10.1016/j.mbplus.2020.100031
   Karatopuk DU, 2010, TURK J GASTROENTEROL, V21, P146, DOI 10.4318/tjg.2010.0073
   Khan P, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 53134 0
   Kim M, 2021, BIOMOL THER, V29, P205, DOI 10.4062/biomolther.2020.108
   Klobucki M, 2019, SCI REP UK, V9, DOI 10.1038/s41598 018 36571 1
   Kozlowska AK, 2017, J CANCER, V8, P537, DOI 10.7150/jca.15989
   Kumar A, 2012, MOL CELL BIOCHEM, V371, P43, DOI 10.1007/s11010 012 1421 9
   Landgraf V, 2019, ANTICANCER RES, V39, P3633, DOI 10.21873/anticanres.13511
   Li H, 2018, FRONT CELL NEUROSCI, V12, DOI 10.3389/fncel.2018.00139
   Li LM, 2021, INT J NANOMED, V16, P5513, DOI 10.2147/IJN.S322688
   Li WJ, 2021, CLIN CHIM ACTA, V522, P36, DOI 10.1016/j.cca.2021.08.007
   Liao D, 2015, CLIN CANCER RES, V21, P5349, DOI 10.1158/1078 0432.CCR 15 0198
   Liu FF, 2021, CLIN TRANSL MED, V11, DOI 10.1002/ctm2.548
   Loren P, 2021, PHARMACEUTICALS BASE, V14, DOI 10.3390/ph14060491
   Ma ZY, 2021, BIOCHEM PHARMACOL, V188, DOI 10.1016/j.bcp.2021.114523
   Machkalyan Gayane, 2016, J Mol Signal, V11, P4, DOI 10.5334/1750 2187 11 4
   Maher DP, 2019, ANESTH ANALG, V128, P1013, DOI 10.1213/ANE.0000000000004058
   Makovec T, 2019, RADIOL ONCOL, V53, P148, DOI 10.2478/raon 2019 0018
   Matsumoto R, 2016, SCI REP UK, V6, DOI 10.1038/srep34625
   McSweeney KR, 2021, CANCERS, V13, DOI 10.3390/cancers13071572
   Menale C, 2015, PHARM RES DORDR, V32, P362, DOI 10.1007/s11095 014 1467 3
   Michalska M, 2018, ANTICANCER RES, V38, P1369, DOI 10.21873/anticanres.12360
   Mirzaei S, 2021, MOLECULES, V26, DOI 10.3390/molecules26082382
   Mu QC, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.709324
   Naruse T, 2007, BIOMED PHARMACOTHER, V61, P338, DOI 10.1016/j.biopha.2007.02.011
   Neuwelt A, 2009, NEOPLASIA, V11, P1003, DOI 10.1593/neo.09688
   Neuwelt AJ, 2014, PEDIATR BLOOD CANCER, V61, P120, DOI 10.1002/pbc.24602
   Nilsen OG, 2001, PHARMACOL TOXICOL, V89, P265, DOI 10.1034/j.1600 0773.2001.d01 158.x
   O'Brien AJ, 2015, BIOCHEM J, V469, P177, DOI 10.1042/BJ20150122
   Okamoto K, 2021, DRUG METAB PHARMACOK, V41, DOI 10.1016/j.dmpk.2021.100417
   Okamoto K, 2021, TOXICOL IN VITRO, V74, DOI 10.1016/j.tiv.2021.105155
   Okamoto K, 2020, EUR J PHARMACOL, V884, DOI 10.1016/j.ejphar.2020.173339
   Oun R, 2018, DALTON T, V47, P6645, DOI 10.1039/c8dt00838h
   Özdemir Ö, 2021, Z NATURFORSCH C, V76, P329, DOI 10.1515/znc 2020 0093
   Özgürbüz U, 2019, GENE, V718, DOI 10.1016/j.gene.2019.144030
   Pathak Rakesh K, 2014, Angew Chem Int Ed Engl, V53, P1963, DOI 10.1002/anie.201308899
   Petruzzella E, 2018, CHEM SCI, V9, P4299, DOI 10.1039/c8sc00428e
   Poradowski D, 2019, J VET RES, V63, P399, DOI 10.2478/jvetres 2019 0051
   Qi LY, 2019, CHEM RES TOXICOL, V32, P1469, DOI 10.1021/acs.chemrestox.9b00204
   Ravera M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20123074
   ROSENBERG B, 1965, NATURE, V205, P698, DOI 10.1038/205698a0
   SADZUKA Y, 1994, BIOCHEM PHARMACOL, V48, P453
   Shahid F, 2018, EUR J PHARMACOL, V827, P49, DOI 10.1016/j.ejphar.2018.03.009
   Shiiba M, 2017, ONCOL REP, V37, P2025, DOI 10.3892/or.2017.5480
   Shriwas O, 2020, APOPTOSIS, V25, P233, DOI 10.1007/s10495 020 01591 8
   Sohail N, 2019, ENVIRON SCI POLLUT R, V26, P25301, DOI 10.1007/s11356 019 05704 y
   Soriano Hernandez AD, 2015, ONCOL LETT, V10, P2574, DOI 10.3892/ol.2015.3580
   Stankovic JSK, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21207753
   Suemasu S, 2012, BIOCHEM PHARMACOL, V84, P1470, DOI 10.1016/j.bcp.2012.09.016
   Sun SX, 2007, CURR MED RES OPIN, V23, P1859, DOI 10.1185/030079907X210561
   Tamasi G, 2010, J INORG BIOCHEM, V104, P799, DOI 10.1016/j.jinorgbio.2010.03.010
   Tchounwou Paul B, 2021, J Exp Pharmacol, V13, P303, DOI 10.2147/JEP.S267383
   Ulubas B, 2003, DRUG CHEM TOXICOL, V26, P259, DOI 10.1081/DCT 120024841
   Walker C, 2018, INT J RHEUMATOL, V2018, DOI 10.1155/2018/1302835
   Wang Q, 2020, CHEM COMMUN, V56, P13017, DOI 10.1039/d0cc05184e
   Wu FY, 2021, MED SCI MONITOR, V27, DOI 10.12659/MSM.928205
   Wu YJJ, 2013, ANTICANCER RES, V33, P2391
   Xing L, 2021, J CONTROL RELEASE, V331, P460, DOI 10.1016/j.jconrel.2021.01.037
   Yamakawa N, 2010, BIOL PHARM BULL, V33, P398, DOI 10.1248/bpb.33.398
   Yao JQ, 2016, ONCOL REP, V36, P3363, DOI 10.3892/or.2016.5183
   Yildirim Muzeyyen, 2010, Kulak Burun Bogaz Ihtis Derg, V20, P173
   Yu L, 2011, MOL PHARMACOL, V79, P608, DOI 10.1124/mol.110.069393
   Zhao HY, 2021, GENES DIS, V8, P320, DOI 10.1016/j.gendis.2020.11.006
   Zhao MY, 2020, THORAC CANCER, V11, P3117, DOI 10.1111/1759 7714.13619
   Zhou PH, 2019, J BIOL CHEM, V294, P16908, DOI 10.1074/jbc.RA119.011009
   Zhu FS, 2010, J DIGEST DIS, V11, P34, DOI 10.1111/j.1751 2980.2009.00411.x
   Zou ZG, 2021, BRIT J CANCER, V125, P826, DOI 10.1038/s41416 021 01499 3
NR 111
TC 10
Z9 10
U1 5
U2 32
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
SN 1010 660X
EI 1648 9144
J9 MEDICINA LITHUANIA
JI Med. Lith.
PD JAN
PY 2022
VL 58
IS 1
AR 46
DI 10.3390/medicina58010046
PG 12
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA YN5HU
UT WOS:000747290400001
PM 35056355
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Fan, JB
   Park, H
   Tan, S
   Lee, M
AF Fan, Jiabing
   Park, Hyejin
   Tan, Steven
   Lee, Min
TI Enhanced Osteogenesis of Adipose Derived Stem Cells with Noggin
   Suppression and Delivery of BMP 2
SO PLOS ONE
LA English
DT Article
ID BONE MORPHOGENETIC PROTEIN 2; COMBINATORIAL GENE THERAPY; IN VITRO;
   STROMAL CELLS; DIFFERENTIATION; EXPRESSION; COMPLICATIONS; OSTEOBLAST;
   INDUCE; MATRIX
AB Bone morphogenetic proteins (BMPs) are believed to be the most potent osteoinductive factors. However, BMPs are highly pleiotropic molecules and their supra physiological high dose requirement leads to adverse side effects and inefficient bone formation. Thus, there is a need to develop alternative osteoinductive growth factor strategies that can effectively complement BMP activity. In this study, we intrinsically stimulated BMP signaling in adipose derived stem cells (ASCs) by downregulating noggin, a potent BMP antagonist, using an RNAi strategy. ASCs transduced with noggin shRNA significantly enhanced osteogenic differentiation of cells. The potency of endogenous BMPs was subsequently enhanced by stimulating ASCs with exogenous BMPs at a significantly reduced dose. The level of mineralization in noggin shRNA treated ASCs when treated with BMP 2 was comparable to that of control shRNA treated cell treated with 10 fold more BMP 2. The complementary strategy of noggin suppression + BMP 2 to enhance osteogenesis was further confirmed in 3D in vitro environments using scaffolds consisting of chitosan (CH), chondroitin sulfate (CS), and apatite layer on their surfaces designed to slowly release BMP 2. This finding supports the novel therapeutic potential of this complementary strategy in bone regeneration.
C1 [Fan, Jiabing; Park, Hyejin; Tan, Steven; Lee, Min] Univ Calif Los Angeles, Div Adv Prosthodont, Los Angeles, CA 90024 USA.
   [Lee, Min] Univ Calif Los Angeles, Dept Bioengn, Los Angeles, CA USA.
C3 University of California System; University of California Los Angeles;
   University of California System; University of California Los Angeles
RP Lee, M (通讯作者)，Univ Calif Los Angeles, Div Adv Prosthodont, Los Angeles, CA 90024 USA.
EM leemin@ucla.edu
RI ; Fan, Jinjiang/C 2010 2009; Fan, Jiabing/J 6581 2015
OI Papadopoulos, Vassilios/0000 0002 1183 8568; Fan,
   Jinjiang/0000 0003 3102 4833; 
FU National Institutes of Health [R01 AR060213, R21 DE021819];
   International Association for Dental Research; Academy of
   Osseointegration
FX This work was supported by the National Institutes of Health grants R01
   AR060213 and R21 DE021819, the International Association for Dental
   Research, and the Academy of Osseointegration. The funders had no role
   in study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Abe E, 2000, J BONE MINER RES, V15, P663, DOI 10.1359/jbmr.2000.15.4.663
   Aghaloo T, 2007, MOL THER, V15, P1872, DOI 10.1038/sj.mt.6300270
   Cahill KS, 2009, JAMA J AM MED ASSOC, V302, P58, DOI 10.1001/jama.2009.956
   Carlisle Elliot, 2005, Spine J, V5, p240S, DOI 10.1016/j.spinee.2005.02.014
   Chou YF, 2005, J BIOMED MATER RES B, V75B, P81, DOI 10.1002/jbm.b.30261
   Devlin RD, 2003, ENDOCRINOLOGY, V144, P1972, DOI 10.1210/en.2002 220918
   Estes BT, 2010, NAT PROTOC, V5, P1294, DOI 10.1038/nprot.2010.81
   Fan JB, 2010, ACTA BIOMATER, V6, P1178, DOI 10.1016/j.actbio.2009.08.042
   Gazzerro E, 2003, BONE, V32, P111, DOI 10.1016/S8756 3282(02)00948 1
   Gazzerro E, 1998, J CLIN INVEST, V102, P2106, DOI 10.1172/JCI3459
   Groppe J, 2002, NATURE, V420, P636, DOI 10.1038/nature01245
   Hannallah D, 2004, J BONE JOINT SURG AM, V86A, P80, DOI 10.2106/00004623 200401000 00013
   Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284
   Hu JL, 2012, J BIOMED MATER RES A, V100A, P1680, DOI 10.1002/jbm.a.34115
   James AW, 2011, STEM CELLS DEV, V20, P427, DOI 10.1089/scd.2010.0082
   James AW, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007120
   Kilgore ML, 2009, J BONE MINER RES, V24, P2050, DOI [10.1359/JBMR.090523, 10.1359/jbmr.090523]
   Koh JT, 2008, J DENT RES, V87, P845, DOI 10.1177/154405910808700906
   Kuwahara K, 2011, TISSUE ENG PT A, V17, P2955, DOI 10.1089/ten.tea.2011.0290
   LANGER R, 1993, SCIENCE, V260, P920, DOI 10.1126/science.8493529
   Lee M, 2009, BIOMATERIALS, V30, P6094, DOI 10.1016/j.biomaterials.2009.07.046
   Levi B, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011177
   Li ZS, 2005, BIOMATERIALS, V26, P3919, DOI 10.1016/j.biomaterials.2004.09.062
   Luginbuehl V, 2004, EUR J PHARM BIOPHARM, V58, P197, DOI 10.1016/j.ejpb.2004.03.004
   McKay B, 2002, SPINE, V27, pS66, DOI 10.1097/00007632 200208151 00014
   Paine Saunders S, 2002, J BIOL CHEM, V277, P2089, DOI 10.1074/jbc.M109151200
   Park H, 2013, CARBOHYD POLYM, DOI DOI 10.1016/J.CARBP0L.2013.05.023
   Reddi AH, 1998, NAT BIOTECHNOL, V16, P247, DOI 10.1038/nbt0398 247
   SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092 8674(92)90316 5
   Smucker JD, 2006, SPINE, V31, P2813, DOI 10.1097/01.brs.0000245863.52371.c2
   Stafford DA, 2011, DEVELOPMENT, V138, P1005, DOI 10.1242/dev.051938
   Sun Yubo, 2012, Open Rheumatol J, V6, P24, DOI 10.2174/1874312901206010024
   Takayama K, 2009, J BONE MINER METAB, V27, P402, DOI 10.1007/s00774 009 0054 x
   Wan DC, 2007, J BIOL CHEM, V282, P26450, DOI 10.1074/jbc.M703282200
   Warren SM, 2003, NATURE, V422, P625, DOI 10.1038/nature01545
   Wu XB, 2003, J CLIN INVEST, V112, P924, DOI 10.1172/JCI200315543
   Xiao GZ, 2002, J BONE MINER RES, V17, P101, DOI 10.1359/jbmr.2002.17.1.101
   Zara JN, 2011, TISSUE ENG PT A, V17, P1389, DOI [10.1089/ten.TEA.2010.0555, 10.1089/ten.tea.2010.0555]
   Zhang D, 2013, BIOMATERIALS, V34, P3962, DOI 10.1016/j.biomaterials.2013.02.029
   Zhao M, 2005, J CELL BIOCHEM, V95, P1, DOI 10.1002/jcb.20411
   Zhu W, 2006, BONE, V39, P61, DOI 10.1016/j.bone.2005.12.018
NR 41
TC 67
Z9 74
U1 0
U2 24
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD AUG 15
PY 2013
VL 8
IS 8
AR e72474
DI 10.1371/journal.pone.0072474
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 204OU
UT WOS:000323378000098
PM 24124589
OA Green Submitted, Green Published, gold
DA 2025 08 17
ER

PT J
AU Hillstrom, HJ
   Soeters, R
   Miranda, M
   Backus, SI
   Hafer, J
   Gibbons, M
   Thaqi, I
   Lenhoff, M
   Hannan, MT
   Endo, Y
   Sculco, T
   Lane, J
AF Hillstrom, H. J.
   Soeters, R.
   Miranda, M.
   Backus, S. I.
   Hafer, J.
   Gibbons, M.
   Thaqi, I.
   Lenhoff, M.
   Hannan, M. T.
   Endo, Y.
   Sculco, T.
   Lane, J.
TI Effect of increased serum 25(OH)D and calcium on structure and function
   of post menopausal women: a pilot study
SO ARCHIVES OF OSTEOPOROSIS
LA English
DT Article
DE Recommended serum 25(OH)D levels; Muscle cross sectional area; Postural
   sway; Isometric strength; Muscle fatigue; Functional task times
ID VITAMIN D SUPPLEMENTATION; LOWER EXTREMITY FUNCTION; PHYSICAL
   PERFORMANCE; MUSCLE STRENGTH; PARATHYROID HORMONE; D DEFICIENCY; FALLS;
   ASSOCIATION; OSTEOPOROSIS; FRACTURES
AB The purpose was to determine if increasing serum 25(OH)D and calcium in postmenopausal women increased skeletal muscle size, strength, balance, and functional task performance while decreasing muscle fatigue. PCSA of the vastus lateralis increased and ascent of stairs time decreased after 6 months of increased serum 25(OH)D. Purpose The Institute of Medicine recommends >= 20 ng/ml of serum 25 hydroxyvitamin D [25(OH)D] for bone and overall health. Serum 25(OH)D levels have been associated with physical performance, postural sway, and falls. The purpose of this study was to determine if increasing postmenopausal women's serum 25(OH)D levels from 20 30 ng/ml to 40 50 ng/ml improved skeletal muscle size, strength, balance, and functional performance while decreasing skeletal muscle fatigue. Methods Twenty six post menopausal women (60 85 years old) with baseline serum 25(OH)D levels between 20 and 30 ng/ml were recruited. Oral over the counter (OTC) vitamin D3 and calcium citrate were prescribed to increase subjects' serum 25(OH)D to levels between 40 and 50 ng/ml, serum calcium levels above 9.2 mg/dl, and PTH levels below 60 pg/ml, which were confirmed at 6 and 12 weeks. Outcome measures assessed at baseline and 6 months included muscle physiological cross sectional area (PCSA), muscle strength, postural balance, time to perform functional tasks, and muscle fatigue. Repeated measures comparisons between baseline and follow up were performed. Results Nineteen subjects completed the study. One individual could not afford the time commitment for the repeated measures. Three individuals did not take their vitamin D as recommended. Two subjects were lost to follow up (lack of interest), and one did not achieve targeted serum 25(OH)D. Vastus lateralis PCSA increased (p= 0.007) and ascent of stair time decreased (p= 0.042) after 6 months of increasing serum 25(OH)D levels from 20 30 ng/ml to 40 50 ng/ml. Isometric strength was unchanged. Anterior posterior center of pressure (COP) excursion and COP path length decreased (p< 0.1) albeit non significantly, suggesting balance may improve from increased serum 25(OH)D and calcium citrate levels. Conclusions Several measures of muscle structure and function were sensitive to elevated serum 25(OH)D and calcium levels indicating that further investigation of this phenomenon in post menopausal women is warranted.
C1 [Hillstrom, H. J.; Soeters, R.; Miranda, M.; Backus, S. I.; Hafer, J.; Gibbons, M.; Thaqi, I.; Lenhoff, M.; Endo, Y.; Sculco, T.] Hosp Special Surg HSS, Leon Root Mot Anal Lab, LRMALab, 535 East 70th St, New York, NY 10021 USA.
   [Hafer, J.] Univ Massachusetts, Dept Kinesiol, Biomech Lab, Totman Rm 110,30 Eastman Lane, Amherst, MA 01003 USA.
   [Hannan, M. T.] Harvard Med Sch, Hebrew SeniorLife, Inst Aging Res, 1200 Ctr St, Boston, MA 02115 USA.
   [Lane, J.] HSS, Metab Bone Dis Serv, 535 East 70th St, New York, NY USA.
C3 University of Massachusetts System; University of Massachusetts Amherst;
   Harvard University; Harvard University Medical Affiliates; Hebrew
   SeniorLife; Harvard Medical School
RP Hillstrom, HJ (通讯作者)，Hosp Special Surg HSS, Leon Root Mot Anal Lab, LRMALab, 535 East 70th St, New York, NY 10021 USA.
EM HillstromH@HSS.edu
RI Lane, Joseph/F 8011 2011
OI Hillstrom, Howard/0000 0002 6440 1917; Hafer,
   Jocelyn/0000 0002 4178 8872; Backus, Sherry/0000 0002 5308 352X
FU Orthopaedic Chief of Staff Funds
FX The Orthopaedic Chief of Staff Funds were used to conduct this pilot
   project at HSS
CR Akdeniz S, 2016, J PHYS THER SCI, V28, P1272, DOI 10.1589/jpts.28.1272
   Anek A., 2015, Journal of the Medical Association of Thailand, V98, P26
   Annema W, 2018, J CLIN LAB ANAL, V32, DOI 10.1002/jcla.22328
   [Anonymous], 2018, VITAMIN D FACT SHEET, P2018
   [Anonymous], 2018, VITAMIN D TEST KIT D, P2018
   [Anonymous], 1999, EUROPEAN RECOMMENDAT
   [Anonymous], 2011, DIETARY REFERENCE IN
   Barber L, 2009, J BIOMECH, V42, P1313, DOI 10.1016/j.jbiomech.2009.03.005
   Bischoff HA, 2003, J BONE MINER RES, V18, P343, DOI 10.1359/jbmr.2003.18.2.343
   Bischoff Ferrari HA, 2015, OSTEOPOROSIS INT, V26, P2793, DOI 10.1007/s00198 015 3194 y
   Bischoff Ferrari HA, 2004, AM J CLIN NUTR, V80, P752
   Bischoff Ferrari HA, 2004, JAMA J AM MED ASSOC, V291, P1999, DOI 10.1001/jama.291.16.1999
   Cangussu LM, 2015, OSTEOPOROSIS INT, V26, P2413, DOI 10.1007/s00198 015 3151 9
   Dam TTL, 2009, OSTEOPOROSIS INT, V20, P751, DOI 10.1007/s00198 008 0749 1
   Dhaliwal R, 2018, CONTEMP CLIN TRIALS, V65, P39, DOI 10.1016/j.cct.2017.11.015
   Dhesi JK, 2004, AGE AGEING, V33, P589, DOI 10.1093/ageing/afh209
   Dhesi JK, 2002, J BONE MINER RES, V17, P891, DOI 10.1359/jbmr.2002.17.5.891
   Fielding RA, 2017, J NUTR HEALTH AGING, V21, P936, DOI 10.1007/s12603 017 0936 x
   Gao LH, 2015, ACTA PHARMACOL SIN, V36, P1065, DOI 10.1038/aps.2015.55
   Gerdhem P, 2005, OSTEOPOROSIS INT, V16, P1425, DOI 10.1007/s00198 005 1860 1
   Grimnes G, 2017, CLIN ENDOCRINOL, V87, P20, DOI 10.1111/cen.13353
   Hassani A, 2006, J ELECTROMYOGR KINES, V16, P661, DOI 10.1016/j.jelekin.2005.11.006
   HOLICK MF, 1989, LANCET, V2, P1104
   Iolascon G, 2015, AGING CLIN EXP RES, V27, pS23, DOI 10.1007/s40520 015 0405 5
   Kuchuk NO, 2009, J CLIN ENDOCR METAB, V94, P1244, DOI 10.1210/jc.2008 1832
   LeBoff MS, 2008, OSTEOPOROSIS INT, V19, P1283, DOI 10.1007/s00198 008 0582 6
   Manson JE, 2016, NEW ENGL J MED, V375, P1817, DOI 10.1056/NEJMp1608005
   Matheï C, 2013, AGE AGEING, V42, P186, DOI 10.1093/ageing/afs186
   Murad MH, 2011, J CLIN ENDOCR METAB, V96, P2997, DOI 10.1210/jc.2011 1193
   Petroni ML, 2019, NUTRIENTS, V11, DOI 10.3390/nu11061302
   Pfeifer M, 2000, J BONE MINER RES, V15, P1113, DOI 10.1359/jbmr.2000.15.6.1113
   Rosendahl Riise H, 2017, J HUM NUTR DIET, V30, P3, DOI 10.1111/jhn.12394
   Saito K, 2016, J BONE MINER METAB, V34, P547, DOI 10.1007/s00774 015 0695 x
   Sato Y, 2005, CEREBROVASC DIS, V20, P187, DOI 10.1159/000087203
   Shardell M, 2009, J GERONTOL A BIOL, V64, P69, DOI 10.1093/gerona/gln007
   Smith LM, 2017, J STEROID BIOCHEM, V173, P317, DOI 10.1016/j.jsbmb.2017.03.015
   Snijder MB, 2006, J CLIN ENDOCR METAB, V91, P2980, DOI 10.1210/jc.2006 0510
   Suzuki T, 2008, J BONE MINER RES, V23, P1309, DOI 10.1359/JBMR.080328
   Visser M, 2003, J CLIN ENDOCR METAB, V88, P5766, DOI 10.1210/jc.2003 030604
   Walrand S, 2016, GERIATR PSYCHOL NEUR, V14, P127, DOI 10.1684/pnv.2016.0599
   Wicherts IS, 2007, J CLIN ENDOCR METAB, V92, P2058, DOI 10.1210/jc.2006 1525
NR 41
TC 2
Z9 2
U1 0
U2 4
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 1862 3522
EI 1862 3514
J9 ARCH OSTEOPOROS
JI Arch. Osteoporos.
PD OCT 3
PY 2020
VL 15
IS 1
AR 154
DI 10.1007/s11657 020 00814 4
PG 10
WC Endocrinology & Metabolism; Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Orthopedics
GA NW1BU
UT WOS:000574743500001
PM 33009959
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Rahman, MS
   Spitzhorn, LS
   Wruck, W
   Hagenbeck, C
   Balan, P
   Graffmann, N
   Bohndorf, M
   Ncube, A
   Guillot, PV
   Fehm, T
   Adjaye, J
AF Rahman, Md Shaifur
   Spitzhorn, Lucas Sebastian
   Wruck, Wasco
   Hagenbeck, Carsten
   Balan, Percy
   Graffmann, Nina
   Bohndorf, Martina
   Ncube, Audrey
   Guillot, Pascale V.
   Fehm, Tanja
   Adjaye, James
TI The presence of human mesenchymal stem cells of renal origin in amniotic
   fluid increases with gestational time
SO STEM CELL RESEARCH & THERAPY
LA English
DT Article
DE Amniotic fluid; Kidney; Renal progenitor cells; SIX2; Mesenchymal stem
   cells; Albumin endocytosis; Third trimester
ID ACUTE KIDNEY INJURY; NEPHRON PROGENITORS; URINE; DIFFERENTIATION;
   EXPRESSION; BIOINFORMATICS; EPIDEMIOLOGY; PERSPECTIVES; GENERATION;
   CONTRIBUTE
AB Background: Established therapies for managing kidney dysfunction such as kidney dialysis and transplantation are limited due to the shortage of compatible donated organs and high costs. Stem cell based therapies are currently under investigation as an alternative treatment option. As amniotic fluid is composed of fetal urine harboring mesenchymal stem cells (AF MSCs), we hypothesized that third trimester amniotic fluid could be a novel source of renal progenitor and differentiated cells.
   Methods: Human third trimester amniotic fluid cells (AFCs) were isolated and cultured in distinct media. These cells were characterized as renal progenitor cells with respect to cell morphology, cell surface marker expression, transcriptome and differentiation into chondrocytes, osteoblasts and adipocytes. To test for renal function, a comparative albumin endocytosis assay was performed using AF MSCs and commercially available renal cells derived from kidney biopsies. Comparative transcriptome analyses of first, second and third trimester derived AF MSCs were conducted to monitor expression of renal related genes.
   Results: Regardless of the media used, AFCs showed expression of pluripotency associated markers such as SSEA4, TRA 1 60, TRA 1 81 and C Kit. They also express the mesenchymal marker Vimentin. Immunophenotyping confirmed that third trimester AFCs are bona fide MSCs. AF MSCs expressed the master renal progenitor markers SIX2 and CITED1, in addition to typical renal proteins such as PODXL, LHX1, BRN1 and PAX8. Albumin endocytosis assays demonstrated the functionality of AF MSCs as renal cells. Additionally, upregulated expression of BMP7 and downregulation of WT1, CD133, SIX2 and C Kit were observed upon activation of WNT signaling by treatment with the GSK 3 inhibitor CHIR99201. Transcriptome analysis and semiquantitative PCR revealed increasing expression levels of renal specific genes (e.g., SALL1, HNF4B, SIX2) with gestational time. Moreover, AF MSCs shared more genes with human kidney cells than with native MSCs and gene ontology terms revealed involvement of biological processes associated with kidney morphogenesis.
   Conclusions: Third trimester amniotic fluid contains AF MSCs of renal origin and this novel source of kidney progenitors may have enormous future potentials for disease modeling, renal repair and drug screening.
C1 [Rahman, Md Shaifur; Spitzhorn, Lucas Sebastian; Wruck, Wasco; Graffmann, Nina; Bohndorf, Martina; Ncube, Audrey; Adjaye, James] Heinrich Heine Univ, Med Fac, Inst Stem Cell Res & Regenerat Med, Moorenstr 5, D 40225 Dusseldorf, Germany.
   [Hagenbeck, Carsten; Balan, Percy; Fehm, Tanja] Heinrich Heine Univ Dusseldorf, Med Fac, Dept Obstet & Gynaecol, Moorenstr 5, D 40225 Dusseldorf, Germany.
   [Guillot, Pascale V.] UCL, Inst Womens Hlth, Maternal & Fetal Med Dept, London WC1E 6HX, England.
C3 Heinrich Heine University Dusseldorf; Heinrich Heine University
   Dusseldorf; University of London; University College London
RP Adjaye, J (通讯作者)，Heinrich Heine Univ, Med Fac, Inst Stem Cell Res & Regenerat Med, Moorenstr 5, D 40225 Dusseldorf, Germany.
EM james.adjaye@med.uni duesseldorf.de
RI ; Rahman, Md Shaifur/MZQ 5575 2025; Rahman, Md Shaifur/HKM 5370 2023;
   Hagenbeck, Carsten/AAG 4292 2021
OI Fehm, Tanja/0000 0002 4926 0108; Graffmann, Nina/0000 0002 1229 0792;
   Hagenbeck, Carsten/0000 0002 9890 5435; Guillot, Pascale
   V/0000 0002 3796 1572; Rahman, Md Shaifur/0000 0002 4306 6224; 
FU Medical Faculty, Heinrich Heine University, Dusseldorf, Germany; German
   Academic Exchange Service [DAAD 91607303]
FX JA and TF acknowledge support from the Medical Faculty,
   Heinrich Heine University, Dusseldorf, Germany. In addition, JA and MSR
   acknowledge support from the German Academic Exchange Service
   (DAAD 91607303).
CR Al Awqati Q, 2002, KIDNEY INT, V61, P387, DOI 10.1046/j.1523 1755.2002.00164.x
   Arcolino FO, 2016, J AM SOC NEPHROL, V27, P2762, DOI 10.1681/ASN.2015060664
   Bharadwaj S, 2013, STEM CELLS, V31, P1840, DOI 10.1002/stem.1424
   Bohndorf M, 2017, STEM CELL RES, V25, P18, DOI 10.1016/j.scr.2017.10.004
   Bussolati B, 2015, NAT REV NEPHROL, V11, P695, DOI 10.1038/nrneph.2015.126
   Buzhor E, 2013, AM J PATHOL, V183, P1621, DOI 10.1016/j.ajpath.2013.07.034
   Cananzi M, 2012, ORGANOGENESIS, V8, DOI 10.4161/org.22426
   Casiraghi F, 2016, NAT REV NEPHROL, V12, P241, DOI 10.1038/nrneph.2016.7
   Combes AN, 2017, KIDNEY INT, V17, P30763
   De Coppi P, 2007, NAT BIOTECHNOL, V25, P100, DOI 10.1038/nbt1274
   Depping R, 2012, CELL PHYSIOL BIOCHEM, V29, P223, DOI 10.1159/000337603
   Eyre J, 2007, AM J PHYSIOL RENAL, V292, pF674, DOI 10.1152/ajprenal.00272.2006
   Freedman BS, 2015, BIOMARK INSIGHTS, V10, P153, DOI [10.4137/BMIMI.S20054, 10.4137/BMI.S20054]
   Gautier L, 2004, BIOINFORMATICS, V20, P307, DOI 10.1093/bioinformatics/btg405
   Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb 2004 5 10 r80
   Georgas KM, 2011, DEV DYNAM, V240, P1600, DOI 10.1002/dvdy.22640
   Guillot PV, 2007, STEM CELLS, V25, P646, DOI 10.1634/stemcells.20060208
   Hamza AH, 2017, RENAL FAILURE, V39, P67, DOI 10.1080/0886022X.2016.1244080
   Hauser PV, 2010, AM J PATHOL, V177, P2011, DOI 10.2353/ajpath.2010.091245
   Hendry C, 2011, PEDIATR NEPHROL, V26, P1395, DOI 10.1007/s00467 010 1750 4
   Higgins JPT, 2004, MOL BIOL CELL, V15, P649, DOI 10.1091/mbc.E03 06 0432
   Hoste EAJ, 2008, CRIT CARE MED, V36, pS146, DOI 10.1097/CCM.0b013e318168c590
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Kanehisa M, 2017, NUCLEIC ACIDS RES, V45, pD353, DOI 10.1093/nar/gkw1092
   Kellum JA, 2008, SCAND J CLIN LAB INV, V68, P6, DOI 10.1080/00365510802144813
   Kim EY, 2016, SKELET MUSCLE, V6, DOI 10.1186/s13395 016 0103 9
   Kobayashi A, 2014, STEM CELL REP, V3, P650, DOI 10.1016/j.stemcr.2014.08.008
   Lam AQ, 2014, J AM SOC NEPHROL, V25, P1211, DOI 10.1681/ASN.2013080831
   Lang R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053980
   Little MH, 2016, CELL DEATH DISCOV, V2, DOI 10.1038/cddiscovery.2016.53
   Little MH, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a008300
   Loukogeorgakis SP, 2017, STEM CELLS, V35, P1663, DOI 10.1002/stem.2553
   Metsuyanim S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006709
   Moschidou D, 2013, CURR STEM CELL RES T, V8, P73, DOI 10.2174/1574888X11308010009
   Musah S, 2017, NAT BIOMED ENG, V1, DOI 10.1038/s41551 017 0069
   Park JS, 2012, DEV CELL, V23, P637, DOI 10.1016/j.devcel.2012.07.008
   Perin L, 2007, CELL PROLIFERAT, V40, P936, DOI 10.1111/j.1365 2184.2007.00478.x
   Perin L, 2017, PEDIATR NEPHROL, P1
   Perin L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009357
   Qin DN, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt458
   Romagnani P, 2011, CONTRIB NEPHROL, V170, P228, DOI 10.1159/000325702
   Rosenblum ND, 2008, SEMIN FETAL NEONAT M, V13, P125, DOI 10.1016/j.siny.2007.10.005
   Rosner M, 2012, EUR J CLIN INVEST, V42, P677, DOI 10.1111/j.1365 2362.2011.02622.x
   Saidi RF, 2014, INT J TRANSPLANT MED, V5, P87
   Schedl A, 2007, NAT REV GENET, V8, P791, DOI 10.1038/nrg2205
   Schutgens F, 2016, EUR J PHARMACOL, V790, P12, DOI 10.1016/j.ejphar.2016.06.059
   Sedrakyan S, 2012, J AM SOC NEPHROL, V23, P661, DOI 10.1681/ASN.2011030243
   Siegel N, 2010, HUM MOL GENET, V19, P3320, DOI 10.1093/hmg/ddq236
   Siegel N, 2009, REPROD BIOMED ONLINE, V19, P838, DOI 10.1016/j.rbmo.2009.09.015
   Spitzhorn LS, 2017, STEM CELLS INT, V2017, DOI 10.1155/2017/5932706
   SUTHERLAND GR, 1972, NATURE, V239, P231, DOI 10.1038/239231a0
   Taguchi A, 2014, CELL STEM CELL, V14, P53, DOI 10.1016/j.stem.2013.11.010
   Tojo A, 2012, INT J NEPHROL, V2012, DOI 10.1155/2012/481520
   Tong GX, 2009, MODERN PATHOL, V22, P1218, DOI 10.1038/modpathol.2009.88
   Underwood Mark A, 2005, J Perinatol, V25, P341, DOI 10.1038/sj.jp.7211290
   Veceric Haler Z, 2017, STEM CELLS INT, V2017, DOI 10.1155/2017/7304643
   Wang H, 2013, J AM SOC NEPHROL, V24, P1263, DOI 10.1681/ASN.2012060596
   Xia Y, 2013, NAT CELL BIOL, V15, P1507, DOI 10.1038/ncb2872
   Xinaris C, 2016, J AM SOC NEPHROL, V27, P1400, DOI 10.1681/ASN.2015030316
   Zagoura DS, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.93
   Zeisberg M, 2006, NEPHROL DIAL TRANSPL, V21, P568, DOI 10.1093/ndt/gfk010
   Zhang DY, 2014, GENES DIS, V1, P8, DOI 10.1016/j.gendis.2014.07.001
   Zhang YY, 2008, J UROLOGY, V180, P2226, DOI 10.1016/j.juro.2008.07.023
   Zhou T, 2011, J AM SOC NEPHROL, V22, P1221, DOI 10.1681/ASN.2011010106
NR 64
TC 16
Z9 18
U1 0
U2 4
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1757 6512
J9 STEM CELL RES THER
JI Stem Cell Res. Ther.
PD APR 25
PY 2018
VL 9
AR 113
DI 10.1186/s13287 018 0864 7
PG 17
WC Cell & Tissue Engineering; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA GE1AF
UT WOS:000430948100001
PM 29695308
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Foroni, C
   Milan, M
   Strina, C
   Cappelletti, M
   Fumarola, C
   Bonelli, M
   Bertoni, R
   Ferrero, G
   Maldotti, M
   Takano, E
   Andreis, D
   Venturini, S
   Brugnoli, G
   Petronini, PG
   Zanoni, V
   Pritzker, L
   Pritzker, K
   Parissenti, A
   Santini, D
   Fox, SB
   Bottini, A
   Generali, D
AF Foroni, Chiara
   Milan, Manuela
   Strina, Carla
   Cappelletti, Mariarosa
   Fumarola, Claudia
   Bonelli, Mara
   Bertoni, Ramona
   Ferrero, Giuseppina
   Maldotti, Mara
   Takano, Elena
   Andreis, Daniele
   Venturini, Sergio
   Brugnoli, Giulia
   Petronini, Pier Giorgio
   Zanoni, Vanessa
   Pritzker, Laura
   Pritzker, Kenneth
   Parissenti, Amadeo
   Santini, Daniele
   Fox, Stephen B.
   Bottini, Alberto
   Generali, Daniele
TI Pure anti tumor effect of zoledronic acid in na⟨ve bone only metastatic
   and locally advanced breast cancer: proof from the "biological window
   therapy"
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE Zoledronic acid; Breast cancer; Circulating tumor cells; Ki67; Window
   therapy
ID CIRCULATING TUMOR CELLS; NEOADJUVANT CHEMOTHERAPY; DISEASE PROGRESSION;
   APOPTOSIS; BISPHOSPHONATES; MECHANISMS; EXPRESSION; SURVIVAL;
   PROLIFERATION; MITOCHONDRIA
AB The study investigated the anti tumour effect of zoledronic acid (ZA) administered alone in a biological window therapy in na < ve bone only metastatic and locally advanced breast cancer (LABC) patients. 33 patients with LABC (Group 1) and 20 patients with a first diagnosis of bone metastasis only (Group 2) received 4 mg single dose of ZA, 14 days (biological window) before starting any treatment. In Group 1, Ki67, CD34, p53/bcl 2 and caspase 3 expression along with the adenosine triphosphate (ATP) levels and RNA disruption index were evaluated as markers of tumor growth in tumour specimens obtained before and after ZA administration (basal, day 14). In Group 2, the total enumeration of circulating tumour cells (CTCs), and of M30+ve CTCs along with the soluble marker of cell death (M30/M65) were carried out as markers of tumor dissemination at baseline, at 48 h and day 14th. In Group 1, there was a significant reduction in Ki67, CD34, bcl 2 expression after 14 days ZA based treatment (p = 0.0032; p = 0.0001, p < 0.00001 respectively). ZA showed a significant increase of RNA disruption (p < 0.0076). In Group 2, we observed a significant reduction of CTCs number after 48 h (p = 0.0012), followed by a significant rebound at 14 days (p = 0.012). The apoptotic CTCs/M30+ve and M65 levels significantly increased under treatment (p = 0.018 and p = 0.039 respectively) after drug administration when compared to the baseline. These results are the first prospective in vivo data showing the direct pure anti tumour effect (either on the tumour cell or on CTCs) of ZA.
C1 [Foroni, Chiara; Milan, Manuela; Strina, Carla; Cappelletti, Mariarosa; Maldotti, Mara; Andreis, Daniele; Brugnoli, Giulia; Zanoni, Vanessa; Bottini, Alberto; Generali, Daniele] AO Ist Ospitalieri Cremona, US Terapia Mol & Farmacogen, UO Multidisciplinare Patol Mammaria, I 26100 Cremona, Italy.
   [Fumarola, Claudia; Bonelli, Mara; Petronini, Pier Giorgio] Dipartimento Med Sperimentale, I 43125 Parma, Italy.
   [Bertoni, Ramona; Ferrero, Giuseppina] AO Ist Ospitalieri Cremona, UO Anat Patol, I 26100 Cremona, Italy.
   [Takano, Elena; Fox, Stephen B.] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia.
   [Takano, Elena; Fox, Stephen B.] Univ Melbourne, Melbourne, Vic, Australia.
   [Venturini, Sergio] Univ Bocconi, CERGAS, I 26100 Milan, Italy.
   [Pritzker, Laura; Pritzker, Kenneth] Rna Diagnost Inc, Toronto, ON, Canada.
   [Parissenti, Amadeo] Laurentian Univ, Sudbury, ON P3E 2C6, Canada.
   [Santini, Daniele] Univ Campus Biomed Roma, Rome, Italy.
C3 Peter Maccallum Cancer Center; University of Melbourne; Bocconi
   University; Laurentian University; University Campus Bio Medico   Rome
   Italy
RP Generali, D (通讯作者)，AO Ist Ospitalieri Cremona, US Terapia Mol & Farmacogen, UO Multidisciplinare Patol Mammaria, Viale Concordia 1, I 26100 Cremona, Italy.
EM daniele.generali@gmail.com
RI ; Fox, Stephen/G 9719 2016; Andreis, Daniele/J 8333 2016; Venturini,
   Sergio/U 7029 2017
OI Santini, Daniele/0000 0002 9118 3337; Fox, Stephen/0000 0002 7648 8896;
   Maldotti, Mara/0000 0002 3299 9053; Andreis,
   Daniele/0000 0001 6686 5662; GENERALI, DANIELE/0000 0003 2480 3855;
   Venturini, Sergio/0000 0002 6574 3337
FU Associazione Ricerca in Campo Oncologico Onlus, Cremona, Italy
FX This study was partly funded by Associazione Ricerca in Campo Oncologico
   Onlus, Cremona, Italy
CR Aft R, 2012, CRIT REV ONCOL HEMAT, V82, P233, DOI 10.1016/j.critrevonc.2011.05.009
   Archer CD, 2003, BRIT J CANCER, V89, P1035, DOI 10.1038/sj.bjc.6601173
   Bottini A, 2001, BRIT J CANCER, V85, P1106, DOI 10.1054/bjoc.2001.2048
   Braun S, 2000, NEW ENGL J MED, V342, P525, DOI 10.1056/NEJM200002243420801
   Brenner C, 2006, ONCOGENE, V25, P4744, DOI 10.1038/sj.onc.1209609
   Candé C, 2002, BIOCHIMIE, V84, P215, DOI 10.1016/S0300 9084(02)01374 3
   Chang J, 2000, CANCER AM CANCER SOC, V89, P2145, DOI 10.1002/1097 0142(20001201)89:11<2145::AID CNCR1>3.3.CO;2 J
   Chen TL, 2002, J CLIN PHARMACOL, V42, P1228, DOI 10.1177/009127002762491316
   Clézardin P, 2005, CANCER TREAT REV, V31, pS1, DOI 10.1016/j.ctrv.2005.09.002
   Coleman RE, 2010, BRIT J CANCER, V102, P1099, DOI 10.1038/sj.bjc.6605604
   Coleman R, 2012, JNCI J NATL CANCER I, V104, P1059, DOI 10.1093/jnci/djs263
   Coleman RE, 2011, NEW ENGL J MED, V365, P1396, DOI 10.1056/NEJMoa1105195
   Coleman RE, 2011, BONE, V49, P71, DOI 10.1016/j.bone.2011.02.003
   COME PC, 1982, J CLIN ULTRASOUND, V10, P233, DOI 10.1002/jcu.1870100506
   Cristofanilli M, 2004, NEW ENGL J MED, V351, P781, DOI 10.1056/NEJMoa040766
   Cristofanilli M, 2006, SEMIN ONCOL, V33, pS9, DOI 10.1053/j.seminoncol.2006.03.016
   Cummings J, 2005, BRIT J CANCER, V92, P532, DOI 10.1038/sj.bjc.6602363
   Dowsett M, 2011, JNCI J NATL CANCER I, V103, P1656, DOI 10.1093/jnci/djr393
   Fehm T, 2012, BMC CANCER, V12, DOI 10.1186/1471 2407 12 308
   Fumarola C, 2005, J CELL PHYSIOL, V204, P155, DOI 10.1002/jcp.20272
   Garrido C, 2006, CELL DEATH DIFFER, V13, P1423, DOI 10.1038/sj.cdd.4401950
   Gnant M, 2012, CANCER TREAT REV, V38, P407, DOI 10.1016/j.ctrv.2011.09.003
   Gnant M, 2011, LANCET ONCOL, V12, P631, DOI 10.1016/S1470 2045(11)70122 X
   Gnant M, 2009, NEW ENGL J MED, V360, P679, DOI 10.1056/NEJMoa0806285
   Jagdev SP, 2001, BRIT J CANCER, V84, P1126, DOI 10.1054/bjoc.2001.1727
   Kingsley LA, 2007, MOL CANCER THER, V6, P2609, DOI 10.1158/1535 7163.MCT 07 0234
   Kunzmann V, 2000, BLOOD, V96, P384
   Kuroda J, 2004, CANCER SCI, V95, P186, DOI 10.1111/j.1349 7006.2004.tb03202.x
   Leist M, 1999, EXP CELL RES, V249, P396, DOI 10.1006/excr.1999.4514
   Lin JH, 1996, BONE, V18, P75, DOI 10.1016/8756 3282(95)00445 9
   Manders K, 2006, BMC CANCER, V6, DOI 10.1186/1471 2407 6 179
   Nakopoulou L, 2001, PATHOBIOLOGY, V69, P266, DOI 10.1159/000064337
   Neville Webbe HL, 2006, TUMOR BIOL, V27, P92, DOI 10.1159/000092489
   Ottewell PD, 2008, JNCI J NATL CANCER I, V100, P1167, DOI 10.1093/jnci/djn240
   Ottewell PD, 2009, MOL CANCER THER, V8, P2821, DOI 10.1158/1535 7163.MCT 09 0462
   Rossi E, 2010, CLIN CANCER RES, V16, P5233, DOI 10.1158/1078 0432.CCR 10 1449
   Santini D, 2003, CLIN CANCER RES, V9, P2893
   Sceneay J, 2013, CANCER METAST REV, V32, P449, DOI 10.1007/s10555 013 9420 1
   Solomayer EF, 2012, ANN ONCOL, V23, P2271, DOI 10.1093/annonc/mdr612
   Winter MC, 2013, CLIN CANCER RES, V19, P2755, DOI 10.1158/1078 0432.CCR 12 3235
   Zoccoli A, 2012, EXPERT OPIN THER TAR, V16, pS119, DOI 10.1517/14728222.2012.656092
NR 41
TC 14
Z9 14
U1 0
U2 6
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167 6806
EI 1573 7217
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD FEB
PY 2014
VL 144
IS 1
BP 113
EP 121
DI 10.1007/s10549 014 2840 y
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA AB2VD
UT WOS:000331649300011
PM 24469643
DA 2025 08 17
ER

PT J
AU Chen, YMF
   Braun, BJ
   Menger, MM
   Ronniger, M
   Falldorf, K
   Histing, T
   Nussler, AK
   Ehnert, S
AF Chen, Yangmengfan
   Braun, Benedikt J.
   Menger, Maximilian M.
   Ronniger, Michael
   Falldorf, Karsten
   Histing, Tina
   Nussler, Andreas K.
   Ehnert, Sabrina
TI Intermittent Exposure to a 16 Hz Extremely Low Frequency Pulsed
   Electromagnetic Field Promotes Osteogenesis In Vitro through Activating
   Piezo 1 Induced Ca<SUP>2+</SUP> Influx in Osteoprogenitor Cells
SO JOURNAL OF FUNCTIONAL BIOMATERIALS
LA English
DT Article
DE electromagnetic field; bone; piezo 1; calcium ions; osteoprogenitor
   cells
ID CALCIUM; BONE
AB Exposure to extremely low frequency pulsed electromagnetic fields (ELF PEMF) is supposed to simulate local EMF generated during mechanical stimulation of bone and may therefore be used to improve bone regeneration. This study aimed at optimizing the exposure strategy and investigating the underlying mechanisms of a 16 Hz ELF PEMF, previously reported to boost osteoblast function. Comparing influences of daily continuous (30 min every 24 h) and intermittent (10 min every 8 h) exposure to the 16 Hz ELF PEMF on osteoprogenitor cells revealed that the intermittent exposure strategy enhanced the 16 Hz ELF PEMF effects regarding cell numbers and osteogenic function. Gene expression of piezo 1 and related Ca2+ influx were significantly increased in SCP 1 cells with the daily intermittent exposure. Pharmacological inhibition of piezo 1 with Dooku 1 largely abolished the positive effect of the 16 Hz ELF PEMF exposure on osteogenic maturation of SCP 1 cells. In summary, the intermittent exposure strategy enhanced the positive effects of 16 Hz continuous ELF PEMF exposure in terms of cell viability and osteogenesis. This effect was shown to be mediated by an increased expression of piezo 1 and related Ca2+ influx. Thus, the intermittent exposure strategy is a promising way to further optimize the therapeutic effects of the 16 Hz ELF PEMF regarding fracture healing or osteoporosis.
C1 [Chen, Yangmengfan; Braun, Benedikt J.; Menger, Maximilian M.; Histing, Tina; Nussler, Andreas K.; Ehnert, Sabrina] Univ Tubingen, Siegfried Weller Inst, BG Trauma Ctr Tubingen, Dept Trauma & Reconstruct Surg, Schnarrenbergstr 95, D 72076 Tubingen, Germany.
   [Ronniger, Michael; Falldorf, Karsten] Sachtleben GmbH, Haus Spectrum UKE, Martinistr 64, D 20251 Hamburg, Germany.
C3 Eberhard Karls University of Tubingen
RP Ehnert, S (通讯作者)，Univ Tubingen, Siegfried Weller Inst, BG Trauma Ctr Tubingen, Dept Trauma & Reconstruct Surg, Schnarrenbergstr 95, D 72076 Tubingen, Germany.
EM sabrina.ehnert@gmail.com
RI Falldorf, Karsten/AAJ 1118 2020; Chen, Yangmengfan/AHC 5544 2022;
   Menger, Maximilian M/HHZ 8483 2022; Ehnert, Sabrina/AAE 8163 2019
OI Ronniger, Michael/0000 0003 4992 9761; Falldorf,
   Karsten/0000 0001 9487 7097; Ehnert, Sabrina/0000 0003 4347 1702
FU Chinese Scholarship Council
FX ELF PEMF devices were provided by Sachtleben GmbH. Y.C. received support
   from the Chinese Scholarship Council to cover his living expenses.
CR ANTONSSON EK, 1985, J BIOMECH, V18, P39, DOI 10.1016/0021 9290(85)90043 0
   Blair H. C., 2007, V45, P539
   Case N, 2008, J BIOL CHEM, V283, P29196, DOI 10.1074/jbc.M801907200
   Chen YMF, 2021, BIOENGINEERING BASEL, V8, DOI 10.3390/bioengineering8110167
   Chen YMF, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22137036
   Danciu TE, 2003, FEBS LETT, V536, P193, DOI 10.1016/S0014 5793(03)00055 3
   Ehnert S, 2019, J CLIN MED, V8, DOI 10.3390/jcm8122028
   Ehnert S, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 14983 9
   Ehnert Sabrina, 2015, Bone Rep, V3, P48, DOI 10.1016/j.bonr.2015.08.002
   Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200
   Görlach A, 2015, REDOX BIOL, V6, P260, DOI 10.1016/j.redox.2015.08.010
   Graham SJL, 2009, DIFFERENTIATION, V77, P239, DOI 10.1016/j.diff.2008.10.013
   Greer R B 3rd, 1993, Orthop Rev, V22, P1087
   Henriksen Z, 2006, CELL CALCIUM, V39, P435, DOI 10.1016/j.ceca.2006.01.012
   Ivancsits S, 2005, MUTAT RES GEN TOX EN, V583, P184, DOI 10.1016/j.mrgentox.2005.03.011
   Ivancsits S, 2003, INT ARCH OCC ENV HEA, V76, P431, DOI 10.1007/s00420 003 0446 5
   Jin Jing, 2008, Ther Clin Risk Manag, V4, P269
   Jin XJ, 2014, CELL MOL LIFE SCI, V71, P2165, DOI 10.1007/s00018 013 1483 1
   JOHNSON M, 1977, B AM PHYS SOC, V22, P43
   Kaestner L, 2020, ADV EXP MED BIOL, V1131, P625, DOI 10.1007/978 3 030 12457 1_25
   Li XH, 2019, ELIFE, V8, DOI 10.7554/eLife.49631
   Liu H, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aau9087
   Petecchia L, 2015, SCI REP UK, V5, DOI 10.1038/srep13856
   Raghuwanshi S, 2020, FEBS J, V287, P5411, DOI 10.1111/febs.15329
   Romanello M, 2001, BIOCHEM BIOPH RES CO, V285, P1226, DOI 10.1006/bbrc.2001.5325
   Shen B, 2021, NATURE, V591, P438, DOI 10.1038/s41586 021 03298 5
   Spadaro JA, 2002, CALCIFIED TISSUE INT, V70, P496, DOI 10.1007/s00223 001 1001 6
   Sun WJ, 2019, ELIFE, V8, DOI 10.7554/eLife.47454
   Sun ZC, 2016, SCI REP UK, V6, DOI 10.1038/srep21774
   Wang H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091730
   Wang LJ, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 019 14146 6
   Wildemann B, 2021, NAT REV DIS PRIMERS, V7, DOI 10.1038/s41572 021 00289 8
   WOO SLY, 1981, J BONE JOINT SURG AM, V63, P780, DOI 10.2106/00004623 198163050 00013
   Yoneda M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20194960
   Ziegler P, 2019, J CLIN MED, V8, DOI 10.3390/jcm8112008
NR 35
TC 8
Z9 11
U1 5
U2 22
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2079 4983
J9 J FUNCT BIOMATER
JI J. Func. Biomater.
PD MAR
PY 2023
VL 14
IS 3
AR 165
DI 10.3390/jfb14030165
PG 13
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA A9ED3
UT WOS:000958068100001
PM 36976089
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Lin, CH
   Chang, CK
   Shih, CW
   Li, HY
   Chen, KY
   Yang, WS
   Tsai, KS
   Wang, CY
   Shih, SR
AF Lin, C.  H.
   Chang, C.  K.
   Shih, C.  W.
   Li, H.  Y.
   Chen, K.  Y.
   Yang, W.  S.
   Tsai, K.  S.
   Wang, C.  Y.
   Shih, S.  R.
TI Serum fibroblast growth factor 23 and mineral metabolism in patients
   with euthyroid Graves' diseases: a case control study
SO OSTEOPOROSIS INTERNATIONAL
LA English
DT Article
DE Fibroblast growth factor 23; Graves' disease; Osteoporosis; Phosphorus
ID BONE; DIAGNOSIS; THERAPY
AB A Summary This study investigated the alterations of mineral metabolism in patients with Graves' disease (GD) who achieved euthyroidism. They had higher fibroblast growth factor 23 (FGF23) and phosphorus as compared with healthy subjects. Serum FGF23 was negatively correlated with serum phosphorus. These indicated abnormal mineral metabolism even after 1.6 years of euthyroid status.
   Introduction FGF23 is involved in the mineral homeostasis, especially the regulation of serum phosphorus. Graves' disease (GD) is associated with accelerated bone turnover, hyperphosphatemia, and elevated serum FGF23. Evidence suggested that serum FGF23 decreased after a 3 month treatment of GD. However, it remains unclear whether serum FGF23, serum phosphorus, and other markers of mineral metabolism will be normalized after euthyroid status achieved.
   Methods A total of 62 patients with euthyroid GD and 62 healthy control subjects were enrolled, and the median duration of euthyroid status was 1.6 years. Endocrine profiles including thyroid function test, autoantibodies, serum FGF23, and bone turnover markers were obtained and compared between the two groups.
   Results Euthyroid GD patients had significantly higher serum FGF23 and phosphorus, and lower 25 hydroxyvitamin D (25(OH)D) and intact parathyroid hormone (iPTH) levels as compared with the control group. Serum FGF23 was significantly and negatively correlated with phosphorus level after adjusted for age, gender, calcium, iPTH, and 25(OH)D in the euthyroid GD group.
   Conclusion Serum phosphorus and FGF23 levels remain higher in GD patients even after euthyroid status has been achieved for a median of 1.6 years. Serum FGF23 was negatively correlated with serum phosphorus in euthyroid GD patients. Underlying mechanisms warrant further investigations.
C1 [Lin, C.  H.] Natl Taiwan Univ Hosp, Dept Internal Med, Div Endocrinol & Metab, Hsin Chu Branch, Hsinchu, Taiwan.
   [Chang, C.  K.] Taipei City Hosp, Dept Internal Med, Div Endocrinol & Metab, Ren Ai Branch, Taipei, Taiwan.
   [Shih, C.  W.] Taipei City Hosp, Zhongxing Branch, Dept Ophthalmol, Taipei, Taiwan.
   [Li, H.  Y.; Yang, W.  S.; Tsai, K.  S.; Wang, C.  Y.; Shih, S.  R.] Natl Taiwan Univ Hosp, Dept Internal Med, Div Endocrinol & Metab, 1,Sect 1,Ren Ai Rd, Taipei 10051, Taiwan.
   [Chen, K.  Y.] Ansn Clin, Hsinchu, Taiwan.
   [Yang, W.  S.; Tsai, K.  S.; Wang, C.  Y.; Shih, S.  R.] Natl Taiwan Univ, Coll Med, Dept Internal Med, Taipei, Taiwan.
   [Tsai, K.  S.] Natl Taiwan Univ Hosp, Dept Lab Med, Taipei, Taiwan.
   [Shih, S.  R.] Natl Taiwan Univ Hosp, Ctr Antiaging & Hlth Consultat, Taipei, Taiwan.
C3 National Taiwan University; National Taiwan University Hospital; Taipei
   City Hospital; Taipei City Hospital; National Taiwan University;
   National Taiwan University Hospital; National Taiwan University;
   National Taiwan University; National Taiwan University Hospital;
   National Taiwan University; National Taiwan University Hospital
RP Shih, SR (通讯作者)，Natl Taiwan Univ Hosp, Dept Internal Med, Div Endocrinol & Metab, 1,Sect 1,Ren Ai Rd, Taipei 10051, Taiwan.; Shih, SR (通讯作者)，Natl Taiwan Univ, Coll Med, Dept Internal Med, Taipei, Taiwan.; Shih, SR (通讯作者)，Natl Taiwan Univ Hosp, Ctr Antiaging & Hlth Consultat, Taipei, Taiwan.
EM srshih@ntu.edu.tw
RI ; Li, Ling Yu/ABD 1618 2020; Wu, Chih Hsing/Q 3314 2019; Cheng,
   TY/X 1695 2019
OI Lin, Chia Hung/0000 0001 8995 7420; SHIH,
   SHYANG RONG/0000 0001 7424 1358; TSAI, KEH SUNG/0000 0001 8528 1566; Li,
   Hung Yuan/0000 0001 9644 2855; Chen, kuan yu/0000 0002 9493 5741; WANG,
   CHIH YUAN/0000 0002 6742 3935
FU Liver Disease Prevention and Treatment Research Foundation, Taiwan;
   National Taiwan University Hospital [107 S3859]; National Taiwan
   University; Wong Yuan Endocrine Fund in Taiwan
FX This work was financially supported by Liver Disease Prevention and
   Treatment Research Foundation, Taiwan, National Taiwan University
   Hospital (grant number: 107 S3859), National Taiwan University and
   Wong Yuan Endocrine Fund in Taiwan.
CR Alcalde AI, 1999, ENDOCRINOLOGY, V140, P1544, DOI 10.1210/en.140.4.1544
   [Anonymous], 2016, Williams textbook of endocrinology, DOI DOI 10.1016/C2013 0 15980 6
   Bhattoa Harjit Pal, 2018, EJIFCC, V29, P117
   Brandt F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066711
   Burch HB, 2015, JAMA J AM MED ASSOC, V314, P2544, DOI 10.1001/jama.2015.16535
   Cardoso LF, 2014, ARQ BRAS ENDOCRINOL, V58, P452, DOI 10.1590/0004 2730000003311
   Cho SW, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144599
   Chong WH, 2011, ENDOCR RELAT CANCER, V18, pR53, DOI 10.1530/ERC 11 0006
   Ercolano MA, 2013, THYROID RES, V6, DOI 10.1186/1756 6614 6 11
   Holick MF, 2007, NEW ENGL J MED, V357, P266, DOI 10.1056/NEJMra070553
   Hung CS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112355
   Ishiguro M, 2010, BIOCHEM J, V427, P161, DOI 10.1042/BJ20090671
   Lucidarme N, 2000, J PEDIATR US, V137, P56, DOI 10.1067/mpd.2000.106219
   Ma WY, 2013, DIABETES CARE, V36, P1660, DOI 10.2337/dc12 1452
   Minisola S, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.44
   Mirza F, 2015, EUR J ENDOCRINOL, V173, pR131, DOI 10.1530/EJE 15 0118
   MOSEKILDE L, 1977, LANCET, V1, P806
   Olauson H, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003975
   Pantazi H, 2000, J CLIN ENDOCR METAB, V85, P1099, DOI 10.1210/jc.85.3.1099
   Park SE, 2007, CLIN ENDOCRINOL, V66, P854, DOI 10.1111/j.1365 2265.2007.02824.x
   Pathak JL, 2016, CALCIFIED TISSUE INT, V98, P596, DOI 10.1007/s00223 016 0116 8
   Pedro ABB, 2011, NEUROIMMUNOMODULAT, V18, P45, DOI 10.1159/000311519
   Salvatore D., 2016, Williams Textbook of Endocrinology, V13th, P334
   Sanders J, 1999, J CLIN ENDOCR METAB, V84, P3797, DOI 10.1210/jc.84.10.3797
   Cabral HWS, 2016, REV ASSOC MED BRAS, V62, P368, DOI 10.1590/1806 9282.62.04.368
   Silver J, 2012, ADV EXP MED BIOL, V728, P92, DOI 10.1007/978 1 4614 0887 1_6
   Smith TJ, 2016, NEW ENGL J MED, V375, P1552, DOI 10.1056/NEJMra1510030
   Vestergaard P, 2003, THYROID, V13, P585, DOI 10.1089/105072503322238854
   Yamashita H, 2005, J CLIN ENDOCR METAB, V90, P4211, DOI 10.1210/jc.2004 2498
   Yu TY, 2017, SCI REP UK, V7, DOI 10.1038/srep39777
   Zhou M, 2019, CURR OSTEOPOROS REP, V17, P97, DOI 10.1007/s11914 019 00507 z
NR 31
TC 6
Z9 6
U1 0
U2 5
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0937 941X
EI 1433 2965
J9 OSTEOPOROSIS INT
JI Osteoporosis Int.
PD NOV
PY 2019
VL 30
IS 11
BP 2289
EP 2297
DI 10.1007/s00198 019 05116 1
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA JU7HI
UT WOS:000501843100014
PM 31384956
DA 2025 08 17
ER

PT J
AU Wang, YX
   Ding, XY
   Zhang, F
   Xie, XR
   Yang, C
   Wang, ZM
   Cai, XD
   Li, QL
   Li, LJ
   Chen, XZ
   Dai, FR
   Zhang, SY
AF Wang, Yexin
   Ding, Xuyang
   Zhang, Feng
   Xie, Xinru
   Yang, Chen
   Wang, Zhiming
   Cai, Xiaodong
   Li, Qilin
   Li, Lingjie
   Chen, Xuzhuo
   Dai, Fengrong
   Zhang, Shanyong
TI Ultrasmall Cu2I2 nanoclusters trigger
   metabolic epigenetic reprogramming and endogenous antioxidant systems
   for alleviating osteoarthritis
SO CHEMICAL ENGINEERING JOURNAL
LA English
DT Article
DE Nanoclusters; Metabolic epigenetic regulation; ROS; Osteoarthritis;
   Osteoclast
ID INHIBITS OSTEOCLASTOGENESIS; TEMPOROMANDIBULAR JOINT; DNA METHYLATION
AB Temporomandibular joint (TMJ) osteoarthritis (OA) affects millions of people worldwide, characterized by imbalance metabolism, excess reactive oxygen species (ROS), aberrant epigenetic alterations and so on. Currently, analgesics and anti inflammatory drugs are mainly used for treatment, but they only alleviate symptoms. Here, we designed a ultrasmall copper based nanoclusters agent (copper iodide coordination, Cu2I2), which exhibited remarkable ROS scavenging activities. And the antioxidant properties of Cu2I2 nanoclusters (Cu2I2 NCs) were achieved by activating the nuclear factor erythroid 2 related factor 2 (Nrf2) pathway. Excitingly, Cu2I2 NCs exhibited excellent metabolic epigenetic regulation property via reprogramming energy metabolism to inhibit S adenosylmethionine (SAM) production metabolic pathway and contributing to the global hypomethylation mediated by Dnmt3a. Then, the expression of anti osteoclastogenic genes was upregulated. Consistent with in vitro observations, Cu2I2 NCs efficiently alleviated subchondral bone destruction of TMJ OA in rats. Altogether, this study not only provides a novel nanoclusters agent for TMJ OA treatment that can activate endogenous antioxidant systems, but also reveals the significance and feasibility of therapeutic strategies to break the bridge between metabolic and epigenetic regulation.
C1 [Wang, Yexin; Xie, Xinru; Li, Qilin; Chen, Xuzhuo; Zhang, Shanyong] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Shanghai Key Lab Stomatol, Coll Stomatol,Sch Med,Dept Oral Surg,Narl Clin Res, Shanghai 200011, Peoples R China.
   [Wang, Yexin; Xie, Xinru; Li, Qilin; Chen, Xuzhuo; Zhang, Shanyong] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Shanghai Res Inst Stomatol, Coll Stomatol,Sch Med, Shanghai 200011, Peoples R China.
   [Ding, Xuyang; Dai, Fengrong] Chinese Acad Sci, Fujian Inst Res Struct Matter, State Key Lab Struct Chem, Fuzhou 350002, Fujian, Peoples R China.
   [Zhang, Feng; Yang, Chen; Wang, Zhiming; Cai, Xiaodong; Li, Lingjie] Shanghai Jiao Tong Univ, Dept Histoembryol Genet & Dev Biol, Shanghai Key Lab Reprod Med, Key Lab Cell Differentiat & Apoptosis,Sch Med,Chin, Shanghai 200025, Peoples R China.
C3 Shanghai Jiao Tong University; Shanghai Jiao Tong University; Chinese
   Academy of Sciences; Fujian Institute of Research on the Structure of
   Matter, CAS; Shanghai Jiao Tong University
RP Chen, XZ; Zhang, SY (通讯作者)，Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Shanghai Key Lab Stomatol, Coll Stomatol,Sch Med,Dept Oral Surg,Narl Clin Res, Shanghai 200011, Peoples R China.; Chen, XZ; Zhang, SY (通讯作者)，Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Shanghai Res Inst Stomatol, Coll Stomatol,Sch Med, Shanghai 200011, Peoples R China.; Dai, FR (通讯作者)，Chinese Acad Sci, Fujian Inst Res Struct Matter, State Key Lab Struct Chem, Fuzhou 350002, Fujian, Peoples R China.; Li, LJ (通讯作者)，Shanghai Jiao Tong Univ, Dept Histoembryol Genet & Dev Biol, Shanghai Key Lab Reprod Med, Key Lab Cell Differentiat & Apoptosis,Sch Med,Chin, Shanghai 200025, Peoples R China.
EM lingjie@shsmu.edu.cn; cxzzxcaa@126.com; dfr@fjirsm.ac.cn;
   zhangshanyong@126.com
RI ; Wang, Zhiming/LTF 0266 2024; Chen, Xuzhuo/ACC 3813 2022; Li,
   Qilin/AAO 9403 2021; Cai, Xiaodong/JCN 5605 2023; Dai,
   Feng Rong/A 5963 2012
OI Ding, Xu Yang/0009 0002 9477 1166; Wang, Zhiming/0009 0001 0131 8139; 
FU National Natural Science Foundation of China [82301108, 82370979];
   National Key R&D & D Pro gram of China [2021YFA1100400]; China
   Postdoctoral Science Foundation [2023M732281]; Frontiers Science Center
   of Cellular Homeostasis and Human Diseases
FX This work was supported by the National Natural Science Foundation of
   China (Nos. 82301108, and 82370979) , the National Key R&D & D Pro gram
   of China (No: 2021YFA1100400, to LL) , Frontiers Science Center of
   Cellular Homeostasis and Human Diseases (to LL) , China Postdoctoral
   Science Foundation (No. 2023M732281)
CR Cardoneanu A, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24010171
   Chen K, 2019, THERANOSTICS, V9, P1634, DOI 10.7150/thno.30206
   Chen XZ, 2022, THERANOSTICS, V12, P3251, DOI 10.7150/thno.70623
   Chen XZ, 2021, CHEM ENG J, V415, DOI 10.1016/j.cej.2021.128939
   Cheng L, 2017, ADV FUNCT MATER, V27, DOI 10.1002/adfm.201702928
   Derwich M, 2021, PHARMACEUTICALS BASE, V14, DOI 10.3390/ph14030219
   Domazetovic V, 2017, CLIN CASES MINER BON, V14, P209, DOI 10.11138/ccmbm/2017.14.1.209
   Evans CH, 2014, NAT REV RHEUMATOL, V10, P11, DOI 10.1038/nrrheum.2013.159
   Fang L, 2023, ADV SCI, V10, DOI 10.1002/advs.202300698
   Feng XL, 2023, BIOCHEM PHARMACOL, V218, DOI 10.1016/j.bcp.2023.115895
   Guan ZJ, 2022, ANGEW CHEM INT EDIT, V61, DOI 10.1002/anie.202209725
   Hu WH, 2022, FASEB J, V36, DOI 10.1096/fj.202101717R
   Huang YY, 2019, CHEM REV, V119, P4357, DOI 10.1021/acs.chemrev.8b00672
   Ishii K, 2009, NAT MED, V15, P259, DOI 10.1038/nm.1910
   Izawa N, 2019, J BONE MINER RES, V34, P1143, DOI 10.1002/jbmr.3689
   Kameoka S, 2010, DENTOMAXILLOFAC RAD, V39, P441, DOI 10.1259/dmfr/37174063
   Krenn V, 2006, HISTOPATHOLOGY, V49, P358, DOI 10.1111/j.1365 2559.2006.02508.x
   Lai WF, 2020, ADV MATER, V32, DOI 10.1002/adma.201906872
   Li BC, 2021, J CELL MOL MED, V25, P4902, DOI 10.1111/jcmm.16514
   Li HY, 2024, ADV SCI, V11, DOI 10.1002/advs.202305363
   Li YQ, 2024, BIOMATERIALS, V305, DOI 10.1016/j.biomaterials.2023.122449
   Lima FGGP, 2024, J ORAL REHABIL, V51, P775, DOI 10.1111/joor.13635
   Liu ST, 2023, BIOMATERIALS, V295, DOI 10.1016/j.biomaterials.2023.122030
   Loughlin J, 2015, NAT REV RHEUMATOL, V11, P7, DOI 10.1038/nrrheum.2014.189
   Luo Q, 2022, SMALL, V18, DOI 10.1002/smll.202107401
   Ma FN, 2019, BIOCHEM BIOPH RES CO, V519, P430, DOI 10.1016/j.bbrc.2019.09.022
   Maor GL, 2015, TRENDS GENET, V31, P274, DOI 10.1016/j.tig.2015.03.002
   Mu J, 2021, MICROCHIM ACTA, V188, DOI 10.1007/s00604 021 05011 9
   Nishikawa K, 2015, NAT MED, V21, P281, DOI 10.1038/nm.3774
   Ouanounou A, 2017, J CAN DENT ASSOC, V83
   Peng GT, 2022, SMALL, V18, DOI 10.1002/smll.202107816
   Pritzker KPH, 2006, OSTEOARTHR CARTILAGE, V14, P13, DOI 10.1016/j.joca.2005.07.014
   Rafaniello C, 2016, PHARMACOL RES, V104, P108, DOI 10.1016/j.phrs.2015.12.026
   Reynard LN, 2017, SEMIN CELL DEV BIOL, V62, P57, DOI 10.1016/j.semcdb.2016.04.017
   Rohatgi N, 2023, NAT COMMUN, V14, DOI 10.1038/s41467 023 41629 4
   Sanin DE, 2018, IMMUNITY, V49, P1021, DOI 10.1016/j.immuni.2018.10.011
   Shi J, 2017, J DENT RES, V96, P888, DOI 10.1177/0022034517707515
   Solier S, 2023, NATURE, V617, P386, DOI 10.1038/s41586 023 06017 4
   Song Y, 2023, ADV MATER, V35, DOI 10.1002/adma.202210895
   Tanaka E, 2008, J DENT RES, V87, P296, DOI 10.1177/154405910808700406
   Vissers C, 2019, ADV DRUG DELIVER REV, V148, P239, DOI 10.1016/j.addr.2019.02.007
   Wang XD, 2015, J DENT RES, V94, P666, DOI 10.1177/0022034515574770
   Wang YX, 2019, J CELL PHYSIOL, V234, P10432, DOI 10.1002/jcp.27711
   Wang Y, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 020 20869 8
   Wu ZM, 2024, MOL CELL, V84, P34, DOI 10.1016/j.molcel.2023.10.006
   Xue ZQ, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 13051 2
   Yoshida M, 2018, COORDIN CHEM REV, V355, P101, DOI 10.1016/j.ccr.2017.07.016
   Yu B, 2024, ADV SCI, V11, DOI 10.1002/advs.202307798
   Yu P, 2023, ADV MATER, V35, DOI 10.1002/adma.202303299
   Zhang HT, 2022, ADV SCI, V9, DOI 10.1002/advs.202202039
   Zhang LW, 2020, THERANOSTICS, V10, P6638, DOI 10.7150/thno.44793
   Zhu XB, 2019, ANN RHEUM DIS, V78, P1420, DOI 10.1136/annrheumdis 2018 214940
NR 52
TC 1
Z9 1
U1 15
U2 34
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 1385 8947
EI 1873 3212
J9 CHEM ENG J
JI Chem. Eng. J.
PD OCT 1
PY 2024
VL 497
AR 154568
DI 10.1016/j.cej.2024.154568
EA AUG 2024
PG 15
WC Engineering, Environmental; Engineering, Chemical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering
GA D7W9P
UT WOS:001298261700001
OA hybrid
DA 2025 08 17
ER

PT J
AU Glorieux, FH
   Devogelaer, JP
   Durigova, M
   Goemaere, S
   Hemsley, S
   Jakob, F
   Junker, U
   Ruckle, J
   Seefried, L
   Winkle, PJ
AF Glorieux, Francis H.
   Devogelaer, Jean Pierre
   Durigova, Michaela
   Goemaere, Stefan
   Hemsley, Sarah
   Jakob, Franz
   Junker, Uwe
   Ruckle, Jon
   Seefried, Lothar
   Winkle, Peter J.
TI BPS804 Anti Sclerostin Antibody in Adults With Moderate Osteogenesis
   Imperfecta: Results of a Randomized Phase 2a Trial
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE ANTI SCLEROSTIN ANTIBODY; CLINICAL TRIALS; DXA; OSTEOGENESIS IMPERFECTA;
   WNT
ID BONE MINERAL DENSITY; PLACEBO CONTROLLED TRIAL; BRTL/+ MOUSE MODEL;
   INTRAVENOUS PAMIDRONATE; BISPHOSPHONATE THERAPY; ORAL BISPHOSPHONATES;
   POSTMENOPAUSAL WOMEN; FRACTURE RATE; CHILDREN; HISTOMORPHOMETRY
AB This 21 week, open label, phase 2a trial aimed to evaluate the pharmacodynamics and safety of multiple, escalating infusions of BPS804, a neutralizing, anti sclerostin antibody, in adults with moderate osteogenesis imperfecta (OI). Patients received BPS804 (three escalating doses each separated by 2 weeks [5, 10, and 20 mg/kg]) or no treatment (reference group). The primary efficacy endpoints were mean changes from baseline to day 43 in: procollagen type 1 N terminal propeptide (P1NP), procollagen type 1 C terminal propeptide (P1CP), bone specific alkaline phosphatase (BSAP), osteocalcin (OC), and type 1 collagen cross linked C telopeptide (CTX 1). Mean change from baseline to day 141 in lumbar spine areal bone mineral density (aBMD) was also assessed. BPS804 safety and tolerability were assessed every 2 weeks. Overall, 14 adults were enrolled (BPS804 group: n = 9, mean age 30.7 years, mean aBMD Z score  2.6; reference group, n = 5, mean age 27.4 years, mean aBMD Z score  2.2). In the BPS804 group, P1NP, P1CP, BSAP, and OC were increased by 84% (p< 0.001), 53% (p = 0.003), 59% (p< 0.001), and 44% (p = 0.012), respectively, versus baseline (reference: P1NP, +6% [p = 0.651]; P1CP, +5% [p = 0.600]; BSAP,  13% [p = 0.582]; OC,  19% [p = 0.436]). BPS804 treatment downregulated CTX 1 by 44% from baseline (reference:  7%; significance was not tested for this biomarker), and increased aBMD by 4% (p = 0.038; reference group: +1%; p = 0.138). BPS804 was generally well tolerated. There were 32 adverse events reported in nine patients; none was suspected to be treatment related. There were no treatment related fractures. BPS804 stimulates bone formation, reduces bone resorption, and increases lumbar spine aBMD in adults with moderate OI. This paves the way for a longerterm, phase 3 trial into the efficacy, safety, and tolerability of BPS804 in patients with OI. (C) 2017 American Society for Bone and Mineral Research.
C1 [Glorieux, Francis H.; Durigova, Michaela] Shriners Hosp Children, Res Ctr, 1003 Decarie Blvd, Montreal, PQ H4A 0A9, Canada.
   [Glorieux, Francis H.; Durigova, Michaela] McGill Univ, Montreal, PQ, Canada.
   [Devogelaer, Jean Pierre] Catholic Univ Louvain, St Luc Univ Hosp, Brussels, Belgium.
   [Goemaere, Stefan] Ghent Univ Hosp, Ghent, Belgium.
   [Hemsley, Sarah; Junker, Uwe] Novartis Inst BioMed Res, Basel, Switzerland.
   [Jakob, Franz; Seefried, Lothar] Univ Wurzburg, Orthoped Ctr Musculoskeletal Res Expt & Clin Oste, Dept Orthoped, Wurzburg, Germany.
   [Ruckle, Jon] Pacific Pharma Grp, Tacoma, WA USA.
   [Winkle, Peter J.] Anaheim Clin Trials, Anaheim, CA USA.
C3 McGill University; Universite Catholique Louvain; Cliniques
   Universitaires Saint Luc; Ghent University; Ghent University Hospital;
   Novartis; University of Wurzburg
RP Glorieux, FH (通讯作者)，Shriners Hosp Children, Res Ctr, 1003 Decarie Blvd, Montreal, PQ H4A 0A9, Canada.
EM glorieux@shriners.mcgill.ca
RI ; Seefried, Lothar/AAU 2169 2021; Jakob, Franz/D 8526 2015
OI Seefried, Lothar/0000 0003 1154 3388; 
FU Novartis Institutes for BioMedical Research, Basel, Switzerland;
   Shriners of North America; Mereo BioPharma
FX This research was funded by Novartis Institutes for BioMedical Research,
   Basel, Switzerland, and the Shriners of North America. Medical writing
   support was provided by Noelle L O'Regan, PhD, of PharmaGenesis London,
   London, UK, and was funded by Mereo BioPharma.
CR Adami S, 2003, J BONE MINER RES, V18, P126, DOI 10.1359/jbmr.2003.18.1.126
   Bardai G, 2016, OSTEOPOROSIS INT, V27, P3607, DOI 10.1007/s00198 016 3709 1
   Basel D, 2009, GENET MED, V11, P375, DOI 10.1097/GIM.0b013e3181a1ff7b
   Biggin A, 2015, HORM RES PAEDIAT, V83, P183, DOI 10.1159/000369582
   Bishop N, 2016, J BONE MINER RES, V31, P699, DOI 10.1002/jbmr.2835
   Bradbury LA, 2012, OSTEOPOROSIS INT, V23, P285, DOI 10.1007/s00198 011 1658 2
   CHARNAS LR, 1993, NEUROLOGY, V43, P2603, DOI 10.1212/WNL.43.12.2603
   Cheung MS, 2008, REV ENDOCR METAB DIS, V9, P153, DOI 10.1007/s11154 008 9074 4
   Chevrel G, 2006, J BONE MINER RES, V21, P300, DOI 10.1359/JBMR.051015
   Chevrel G., 2004, ORPHANET ENCY
   Cosman F, 2016, NEW ENGL J MED, V375, P1532, DOI 10.1056/NEJMoa1607948
   Devogelaer JP, 2012, J BONE MINER RES, V27
   Devogelaer JP, 2011, J BONE MINER RES S1, V26
   DiMeglio LA, 2006, J BONE MINER RES, V21, P132, DOI 10.1359/JBMR.051006
   Gatti D, 2005, J BONE MINER RES, V20, P1323, DOI 10.1359/JBMR.050312
   Glorieux FH, 2000, J BONE MINER RES, V15, P1650, DOI 10.1359/jbmr.2000.15.9.1650
   Glorieux FH, 2000, J PEDIATR ENDOCR MET, V13, P989
   Glorieux FH, 2008, BEST PRACT RES CL RH, V22, P85, DOI 10.1016/j.berh.2007.12.012
   Hegazy A, 2016, J PEDIATR ORTHOPED, V36, P757, DOI 10.1097/BPO.0000000000000552
   Kok DHJ, 2007, EUR J PEDIATR, V166, P1155, DOI 10.1007/s00431 006 0399 2
   Lewiecki EM, 2014, THER ADV MUSCULOSKEL, V6, P48, DOI 10.1177/1759720X13510479
   Li M, 2011, CHINESE MED J PEKING, V124, P3049, DOI 10.3760/cma.j.issn.0366 6999.2011.19.017
   McClung MR, 2014, NEW ENGL J MED, V370, P412, DOI 10.1056/NEJMoa1305224
   Meier RPH, 2012, ACTA ORTHOP, V83, P548, DOI 10.3109/17453674.2012.729183
   Nicolaou N, 2012, J CHILD ORTHOP, V6, P21, DOI 10.1007/s11832 011 0380 0
   ORWOLL ES, 1993, J BONE MINER RES, V8, P693
   Rauch F, 2000, BONE, V26, P581, DOI 10.1016/S8756 3282(00)00269 6
   Roschger A, 2014, BONE, V66, P182, DOI 10.1016/j.bone.2014.06.015
   Shapiro JR, 2010, CALCIFIED TISSUE INT, V87, P120, DOI 10.1007/s00223 010 9383 y
   Shapiro JR, 2003, CALCIFIED TISSUE INT, V72, P103, DOI 10.1007/s00223 001 1055 5
   SILLENCE DO, 1979, J MED GENET, V16, P101, DOI 10.1136/jmg.16.2.101
   Sinder BP, 2014, OSTEOPOROSIS INT, V25, P2097, DOI 10.1007/s00198 014 2737 y
   Sinder BP, 2015, BONE, V71, P115, DOI 10.1016/j.bone.2014.10.012
   Sinder BP, 2013, J BONE MINER RES, V28, P73, DOI 10.1002/jbmr.1717
   Trejo P, 2017, J BONE MINER RES, V32, P1034, DOI 10.1002/jbmr.3071
   Vasanwala RF, 2016, J BONE MINER RES, V31, P1449, DOI 10.1002/jbmr.2805
   Wheater G, 2013, J TRANSL MED, V11, DOI 10.1186/1479 5876 11 201
   Winkler DG, 2005, J BIOL CHEM, V280, P2498, DOI 10.1074/jbc.M400524200
NR 38
TC 113
Z9 128
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD JUL
PY 2017
VL 32
IS 7
BP 1496
EP 1504
DI 10.1002/jbmr.3143
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA EZ0FB
UT WOS:000404375300012
PM 28370407
OA Bronze
DA 2025 08 17
ER

PT J
AU Shen, C
   Jiang, LF
   Long, XW
   Dahl, KN
   Meng, Q
AF Shen, Chong
   Jiang, Lifang
   Long, Xuwei
   Dahl, Kris Noel
   Meng, Qin
TI Cells with Higher Cortical Membrane Tension Are More Sensitive to Lysis
   by Biosurfactant Di rhamnolipids
SO ACS BIOMATERIALS SCIENCE & ENGINEERING
LA English
DT Article
DE cortical membrane tension; rhamnolipid; biosurfactant; myofibroblast;
   mechanosensitivity
ID MYOFIBROBLASTS; SCAR
AB Tissue and cellular stiffening is associated with pathologies including fibrosis and cancer. Healthy cells also exhibit a wide range of membrane cortical tensions, which have been studied in the field of mechanobiology. Here, we quantify the mechanosensitivity of the lysis agent the di rhamnolipid (RHA), which is a bacterially produced biosurfactant. RHA exhibited selective lysis correlated strongly with cortical membrane tension in osteoblasts, smooth muscle cells, fibroblasts, epithelial cells, and erythrocytes. Reducing cortical membrane tension by cytoskeleton inhibitors (cytochalasin D and nocodazole) or osmotic regulators (sucrose, polyethylene glycol, and nonionic surfactants) attenuated the RHA toxicity. The selective toxicity of RHA toward human chronic myeloid leukemia K562 cells over healthy blood cells suggests a potential therapy for blood cancer. Targeted killing of myofibroblasts transformed from either fibroblasts or epithelial cells indicates its antifibrotic effect. Combined, these studies showed the potential for specific targeting of cells with differential mechanical properties rather than chemical or biological pathways.
C1 [Shen, Chong; Jiang, Lifang; Long, Xuwei; Meng, Qin] Zhejiang Univ, Coll Chem & Biol Engn, 38 Zheda Rd, Hangzhou 310027, Zhejiang, Peoples R China.
   [Dahl, Kris Noel] Carnegie Mellon Univ, Dept Chem Engn, Doherty Hall 2100C 5000 Forbes Ave, Pittsburgh, PA 15213 USA.
C3 Zhejiang University; Carnegie Mellon University
RP Meng, Q (通讯作者)，Zhejiang Univ, Coll Chem & Biol Engn, 38 Zheda Rd, Hangzhou 310027, Zhejiang, Peoples R China.
EM mengq@zju.edu.cn
RI Dong, Cheng/KVY 6050 2024; Long, Xuwei/GLU 2908 2022
OI Dong, Cheng/0000 0002 7760 4692; 
FU NSFC (National Natural Science Foundation of China) [21776242]; NSF
   (National Science Foundation) [1634888]; Div Of Civil, Mechanical, &
   Manufact Inn; Directorate For Engineering [1634888] Funding Source:
   National Science Foundation
FX We gratefully acknowledge financial support for this study from the NSFC
   (National Natural Science Foundation of China, no. 21776242) and the NSF
   (National Science Foundation, no. 1634888 to KND).
CR Arauz J, 2013, J APPL TOXICOL, V33, P970, DOI 10.1002/jat.2788
   Boal D., 2012, MECH CELL, V2 ed.
   Butcher DT, 2009, NAT REV CANCER, V9, P108, DOI 10.1038/nrc2544
   Christova N, 2013, APPL BIOCHEM BIOTECH, V170, P676, DOI 10.1007/s12010 013 0225 z
   GARNER WL, 1993, J INVEST DERMATOL, V101, P875, DOI 10.1111/1523 1747.ep12371710
   Guo Q, 2012, LAB CHIP, V12, P1143, DOI 10.1039/c2lc20857a
   Hale JP, 2011, BIOPHYS J, V101, P1921, DOI 10.1016/j.bpj.2011.08.053
   Hochmuth RM, 2000, J BIOMECH, V33, P15, DOI 10.1016/S0021 9290(99)00175 X
   Ince TA, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8419
   Jiang LF, 2014, APPL MICROBIOL BIOT, V98, P10187, DOI 10.1007/s00253 014 6065 0
   LeBleu VS, 2013, NAT MED, V19, P1047, DOI 10.1038/nm.3218
   Lopez JI, 2011, INTEGR BIOL UK, V3, P910, DOI 10.1039/c1ib00043h
   Piljac G., 1998, COMP IMMUNOL MICROB, V21, P5
   Ribeiro AJS, 2014, CELL MOL BIOENG, V7, P544, DOI 10.1007/s12195 014 0358 3
   Rosenbluth MJ, 2006, BIOPHYS J, V90, P2994, DOI 10.1529/biophysj.105.067496
   Schaefer A, 2015, J CELL SCI, V128, P2221, DOI 10.1242/jcs.163055
   Schneider DI, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082402
   Shen C, 2016, SCI REP UK, V6, DOI 10.1038/srep37553
   Shi JH, 2013, ARCH DERMATOL RES, V305, P341, DOI 10.1007/s00403 013 1314 0
   Sosale NG, 2015, BLOOD, V125, P542, DOI 10.1182/blood 2014 06 585299
   Sotirova AV, 2008, CURR MICROBIOL, V56, P639, DOI 10.1007/s00284 008 9139 3
   Tinevez JY, 2009, P NATL ACAD SCI USA, V106, P18581, DOI 10.1073/pnas.0903353106
   Togo T, 1999, J CELL SCI, V112, P719
   Togo T, 2000, MOL BIOL CELL, V11, P4339, DOI 10.1091/mbc.11.12.4339
   Tomasek JJ, 2002, NAT REV MOL CELL BIO, V3, P349, DOI 10.1038/nrm809
   Wyss K, 2012, J BIOMECH, V45, P882, DOI 10.1016/j.jbiomech.2011.11.030
   Yang T, 2013, CELL PHYSIOL BIOCHEM, V31, P863, DOI 10.1159/000350104
   Zheng Y, 2013, LAB CHIP, V13, P2464, DOI [10.1039/c3lc50355k, 10.1039/c31c50355k]
NR 28
TC 5
Z9 7
U1 1
U2 27
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 2373 9878
J9 ACS BIOMATER SCI ENG
JI ACS Biomater. Sci. Eng.
PD JAN
PY 2020
VL 6
IS 1
BP 352
EP 357
DI 10.1021/acsbiomaterials.9b01305
PG 11
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA KC8NV
UT WOS:000507429200031
PM 33463232
DA 2025 08 17
ER

PT J
AU Alvarez Soria, MA
   Herrero Beaumont, G
   Sánchez Pernaute, O
   Bellido, M
   Largo, R
AF Alvarez Soria, M. A.
   Herrero Beaumont, G.
   Sanchez Pernaute, O.
   Bellido, M.
   Largo, R.
TI Diacerein has a weak effect on the catabolic pathway of human
   osteoarthritis synovial fibroblast  : comparison to its effects on
   osteoarthritic chondrocytes
SO RHEUMATOLOGY
LA English
DT Article
DE osteoarthritis; cytokines and inflammatory mediators; extracellular
   matrix; synovium; non steroidal anti inflammatory drugs
ID NF KAPPA B; HUMAN ARTICULAR CHONDROCYTES; NECROSIS FACTOR ALPHA;
   PROSTAGLANDIN E 2; RHEUMATOID ARTHRITIS; CLINICAL PHARMACOKINETICS;
   CELL PROLIFERATION; ENDOTHELIAL CELLS; NITRIC OXIDE; EXPRESSION
AB Objectives. Synoviocytes play a crucial role in the inflammatory response leading to structural damage in OA. Our aim was to assess the effects of diacerein and NSAIDs on cellular responses of synoviocytes associated with inflammation and structural integrity of cartilage in OA.
   Methods. The effects of diacerein, celecoxib, diclofenac, meloxicam and indomethacin on prostaglandin (PG) E2 production, cyclo oxygenase 2 (COX 2) protein expression, nitrite levels, presence of MMP 1 and  13, and activation of nuclear factor kappa B (NF kappa B) were studied on stimulated OA synoviocytes and chondrocytes.
   Results. Diacerein and NSAIDs inhibited IL 1 beta stimulated NF kappa B activation in synoviocytes and chondrocytes except indomethacin in synoviocytes. Diacerein further increased COX 2 protein expression and PGE2 synthesis in synoviocytes stimulated with IL beta 1, while no effect was observed on stimulated chondrocytes. NSAIDs diminished until almost basal levels PGE2 release in both cells and, surprisingly, these drugs also diminished COX 2 protein expression both in synoviocytes and chondrocytes. With regard to structural mediators, diacerein decreased MMP 13 levels in synoviocytes but did not modify MMP 1 presence. NSAIDs induced a significant increase in MMP 1 levels in both cell types and in MMP 13 levels in chondrocytes.
   Conclusions. Diacerein does not seem to reduce but rather increase inflammatory mediators in synoviocytes, while it does not overall affect chondrocyte inflammatory profile.
C1 [Alvarez Soria, M. A.; Herrero Beaumont, G.; Sanchez Pernaute, O.; Bellido, M.; Largo, R.] Autonomous Univ Madrid, Fdn Jimenez Diaz, Dept Rheumatol, Bone & Joint Res Unit, E 28040 Madrid, Spain.
C3 Autonomous University of Madrid
RP Largo, R (通讯作者)，Autonomous Univ Madrid, Fdn Jimenez Diaz, Dept Rheumatol, Bone & Joint Res Unit, Avenida Reyes Catolicos 2, E 28040 Madrid, Spain.
EM rlargo@fjd.es
RI Sanchez Pernaute, Olga/AAG 2811 2021; Largo, Raquel/B 2949 2009
OI Largo, Raquel/0000 0001 6525 2944; Herrero Beaumont,
   Gabriel/0000 0002 3241 991X; Alvarez Soria/0000 0001 5665 2970
CR Alvarez Soria MA, 2006, ANN RHEUM DIS, V65, P998, DOI 10.1136/ard.2005.046920
   Alvarez Soria MA, 2007, RHEUMATOL INT, V27, P911, DOI 10.1007/s00296 007 0328 3
   Benito MJ, 2005, ANN RHEUM DIS, V64, P1263, DOI 10.1136/ard.2004.025270
   Berenbaum F, 2004, CURR OPIN RHEUMATOL, V16, P616, DOI 10.1097/01.bor.0000133663.37352.4a
   Berenbaum F, 1996, EXP CELL RES, V222, P379, DOI 10.1006/excr.1996.0047
   Billinghurst RC, 1997, J CLIN INVEST, V99, P1534, DOI 10.1172/JCI119316
   Clemett D, 2000, DRUGS, V59, P957, DOI 10.2165/00003495 200059040 00017
   Dougados M, 2001, ARTHRITIS RHEUM US, V44, P2539, DOI 10.1002/1529 0131(200111)44:11<2539::AID ART434>3.0.CO;2 T
   Faour WH, 2001, J BIOL CHEM, V276, P31720, DOI 10.1074/jbc.M104036200
   FARAHAT MN, 1993, ANN RHEUM DIS, V52, P870, DOI 10.1136/ard.52.12.870
   Fidelix TS, 2006, COCHRANE DB SYST REV, V25, DOI DOI 10.1002/14651858.CD005117.PUB2
   Goldring MB, 2004, CLIN ORTHOP RELAT R, pS37, DOI 10.1097/01.blo.0000144484.69656.e4
   Guicheux J, 2002, J CELL PHYSIOL, V192, P93, DOI 10.1002/jcp.10121
   Guilak F, 2004, CLIN ORTHOP RELAT R, P17, DOI 10.1097/01.blo.0000131233.83640.91
   Hardy MM, 2002, ARTHRITIS RHEUM, V46, P1789, DOI 10.1002/art.10356
   He W, 2002, J RHEUMATOL, V29, P546
   HUSKISSON EC, 1995, J RHEUMATOL, V22, P1941
   Inoue H, 2002, ARTERIOSCL THROM VAS, V22, P1415, DOI 10.1161/01.ATV.0000028816.13582.13
   Kida Y, 2005, CYTOKINE, V29, P159, DOI 10.1016/j.cyto.2004.10.009
   Kojima F, 2003, ARTHRITIS RHEUM, V48, P2819, DOI 10.1002/art.11261
   Konttinen YT, 2000, ARTHRITIS RES, V2, P348, DOI 10.1186/ar111
   Largo R, 2004, ANN RHEUM DIS, V63, P1197, DOI 10.1136/ard.2003.011163
   Largo R, 2003, OSTEOARTHR CARTILAGE, V11, P290, DOI 10.1016/S1063 4584(03)00028 1
   Legendre F, 2007, CLIN EXP RHEUMATOL, V25, P546
   Martin G, 2003, INFLAMMATION, V27, P233, DOI 10.1023/A:1025040631514
   Mengshol JA, 2001, NUCLEIC ACIDS RES, V29, P4361, DOI 10.1093/nar/29.21.4361
   Mor A, 2005, CLIN IMMUNOL, V115, P118, DOI 10.1016/j.clim.2004.12.009
   Nicolas P, 1998, CLIN PHARMACOKINET, V35, P347, DOI 10.2165/00003088 199835050 00002
   Nishimura M, 2002, ORAL SURG ORAL MED O, V94, P328, DOI 10.1067/moe.2002.124106
   OBERBAUER R, 1993, CLIN PHARMACOKINET, V24, P428, DOI 10.2165/00003088 199324050 00007
   Palombella VJ, 1998, P NATL ACAD SCI USA, V95, P15671, DOI 10.1073/pnas.95.26.15671
   Pelletier JP, 1998, J RHEUMATOL, V25, P2417
   PELLETIER JP, 2001, ETIOPATOGENESIS OSTE, P1969
   Pham H, 2008, J CELL PHYSIOL, V214, P96, DOI 10.1002/jcp.21167
   Pham T, 2004, ANN RHEUM DIS, V63, P1611, DOI 10.1136/ard.2003.019703
   Pillinger MH, 2003, J IMMUNOL, V171, P6080, DOI 10.4049/jimmunol.171.11.6080
   REGINATO AM, 1994, ARTHRITIS RHEUM, V37, P1338, DOI 10.1002/art.1780370912
   Sanchez C, 2003, BIOCHEM PHARMACOL, V65, P377, DOI 10.1016/S0006 2952(02)01485 5
   Tak PP, 2001, J CLIN INVEST, V107, P7, DOI 10.1172/JCI11830
   Takada Y, 2004, ONCOGENE, V23, P9247, DOI 10.1038/sj.onc.1208169
   Takahashi HK, 2002, J IMMUNOL, V168, P4446, DOI 10.4049/jimmunol.168.9.4446
   Tamura T, 2002, EUR J PHARMACOL, V448, P81, DOI 10.1016/S0014 2999(02)01898 8
   Tamura T, 2001, OSTEOARTHR CARTILAGE, V9, P257, DOI 10.1053/joca.2000.0383
   Tanabe T, 2002, PROSTAG OTH LIPID M, V68 9, P95, DOI 10.1016/S0090 6980(02)00024 2
   TODD PA, 1988, DRUGS, V35, P244, DOI 10.2165/00003495 198835030 00004
   Turck D, 1996, BRIT J RHEUMATOL, V35, P13
   Verbruggen G, 2006, RHEUMATOLOGY, V45, P129, DOI 10.1093/rheumatology/kei171
   Vincenti MP, 2001, ARTHRITIS RES, V3, P381, DOI 10.1186/ar331
   WILKINSON LS, 1992, ARTHRITIS RHEUM US, V35, P1179, DOI 10.1002/art.1780351010
   Yaron M, 1999, OSTEOARTHR CARTILAGE, V7, P272, DOI 10.1053/joca.1998.0201
   YOSHIDA H, 1992, LIFE SCI, V50, pPL195, DOI 10.1016/0024 3205(92)90432 O
NR 51
TC 27
Z9 27
U1 0
U2 8
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1462 0324
J9 RHEUMATOLOGY
JI RHEUMATOLOGY
PD MAY
PY 2008
VL 47
IS 5
BP 627
EP 633
DI 10.1093/rheumatology/ken116
PG 7
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA 293DQ
UT WOS:000255315700014
PM 18375401
OA Bronze
DA 2025 08 17
ER

PT J
AU Martelli, G
   Bloise, N
   Merlettini, A
   Bruni, G
   Visai, L
   Focarete, ML
   Giacomini, D
AF Martelli, Giulia
   Bloise, Nora
   Merlettini, Andrea
   Bruni, Giovanna
   Visai, Livia
   Focarete, Maria Letizia
   Giacomini, Daria
TI Combining Biologically Active β Lactams Integrin Agonists with
   Poly(L lactic acid) Nanofibers: Enhancement of Human Mesenchymal Stem
   Cell Adhesion
SO BIOMACROMOLECULES
LA English
DT Article
ID SMOOTH MUSCLE CELLS; HUMAN BONE MARROW; OSTEOGENIC DIFFERENTIATION;
   RGD GLYCOPROTEINS; HUMAN OSTEOBLASTS; EXPRESSION; PROLIFERATION;
   SCAFFOLDS; BIOFUNCTIONALIZATION; ALPHA(V)BETA(3)
AB Regulating stem cell adhesion and growth onto functionalized biomaterial scaffolds is an important issue in the field of tissue engineering and regenerative medicine. In this study, new electrospun scaffolds of poly(L lactic acid) (PLLA), as bioresorbable polymer, and beta lactam compounds agonists of selected integrins, as functional components with cell adhesive properties, are designed. The new beta lactam PLLA scaffolds contribute significantly in guiding protein translation involved in human bone marrow mesenchymal stem cells (hBM MSC) adhesion and integrin gene expression. Scanning electron microscopy, confocal laser scanning microscopy, and Western Blot analyses reveal that GM18 PLLA shows the best results, promoting cell adhesion by significantly driving changes in focal adhesion proteins distribution (beta(1) integrin and vinculin) and activation (pFAK), with a notable increase of GM18 targets subunits integrin gene expression, alpha(4) and beta(1). These novel functionalized submicrometric fibrous scaffolds demonstrate, for the first time, the powerful combination of selective beta lactams agonists of integrins with biomimetic scaffolds, suggesting a designed rule that could be suitably applied to tissue repair and regeneration.
C1 [Bloise, Nora; Visai, Livia] Univ Pavia, UdR INSTM, CHT, DMM,Biochem Unit, I 27100 Pavia, Italy.
   [Bloise, Nora; Visai, Livia] IRCCS, Ist Clin Sci Maugeri SpA, Dept Occupat Med Toxicol & Environm Risks, I 27100 Pavia, Italy.
   [Martelli, Giulia; Merlettini, Andrea; Focarete, Maria Letizia; Giacomini, Daria] Univ Bologna, Dept Chem Giacomo Ciamician, I 40126 Bologna, Italy.
   [Bruni, Giovanna] Univ Pavia, Dept Chem, Chem Phys Sect, I 27100 Pavia, Italy.
C3 University of Pavia; University of Pavia; Istituti Clinici Scientifici
   Maugeri IRCCS; University of Bologna; University of Pavia
RP Visai, L (通讯作者)，Univ Pavia, UdR INSTM, CHT, DMM,Biochem Unit, I 27100 Pavia, Italy.; Visai, L (通讯作者)，IRCCS, Ist Clin Sci Maugeri SpA, Dept Occupat Med Toxicol & Environm Risks, I 27100 Pavia, Italy.; Focarete, ML (通讯作者)，Univ Bologna, Dept Chem Giacomo Ciamician, I 40126 Bologna, Italy.
EM livia.visai@unipv.it; marialetizia.focarete@unibo.it
RI Martelli, Giulia/AAU 4288 2020; Focarete, Maria/JAC 8889 2023; Bruni,
   Giovanna/B 5685 2014; Bloise, Nora/M 5699 2016; Visai,
   Livia/R 7397 2017; Focarete, Maria Letizia/B 2369 2009
OI Martelli, Giulia/0000 0001 7563 4954; Visai, Livia/0000 0003 1181 3632;
   Focarete, Maria Letizia/0000 0002 0458 7836
FU University of Bologna; Italian Ministry of Education, University and
   Research (PRIN 2015 project) [20157WVVSEH]; Italian Ministry of
   Education, University and Research
FX This research was supported by the University of Bologna (D.G., G.M.,
   and M.L.F.) and the Italian Ministry of Education, University and
   Research (D.G.) (PRIN 2015 project 20157WVVSEH). This research was also
   supported by a grant of the Italian Ministry of Education, University
   and Research to the Department of Chemistry "Giacomo Ciamician" of the
   University of Bologna (D.G., G.M., and M.L.F.), and the Department of
   Molecular Medicine of the University of Pavia (N.B. and L.V.) under the
   initiative "Dipartimenti di Eccellenza (2018 2022)".
CR Abbasian M, 2019, INT J BIOL MACROMOL, V134, P673, DOI 10.1016/j.ijbiomac.2019.04.197
   Altankov G, 1996, J BIOMED MATER RES, V30, P385, DOI 10.1002/(SICI)1097 4636(199603)30:3<385::AID JBM13>3.0.CO;2 J
   Argentati C, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20215337
   Arnaout MA, 2007, CURR OPIN CELL BIOL, V19, P495, DOI 10.1016/j.ceb.2007.08.002
   Bacáková L, 2004, PHYSIOL RES, V53, pS35, DOI 10.33549/physiolres.930000.53.S35
   Bacáková L, 2000, J BIOMED MATER RES, V49, P369, DOI 10.1002/(SICI)1097 4636(20000305)49:3<369::AID JBM10>3.0.CO;2 W
   Bacakova L, 2011, BIOTECHNOL ADV, V29, P739, DOI 10.1016/j.biotechadv.2011.06.004
   Bachmann M, 2019, PHYSIOL REV, V99, P1655, DOI 10.1152/physrev.00036.2018
   Bae D, 2014, BIOMATERIALS, V35, P916, DOI 10.1016/j.biomaterials.2013.10.031
   Baiula M, 2016, J MED CHEM, V59, P9721, DOI 10.1021/acs.jmedchem.6b00576
   Balcioglu HE, 2015, J CELL SCI, V128, P1316, DOI 10.1242/jcs.156950
   Barczyk M, 2010, CELL TISSUE RES, V339, P269, DOI 10.1007/s00441 009 0834 6
   Bays JL, 2017, CELL MOL LIFE SCI, V74, P2999, DOI 10.1007/s00018 017 2511 3
   Beachley V, 2010, PROG POLYM SCI, V35, P868, DOI 10.1016/j.progpolymsci.2010.03.003
   Bennett JH, 2001, ARCH ORAL BIOL, V46, P229, DOI 10.1016/S0003 9969(00)00114 X
   Bernardo ME, 2007, J CELL PHYSIOL, V211, P121, DOI 10.1002/jcp.20911
   Biggs MJP, 2010, NANOMED NANOTECHNOL, V6, P619, DOI 10.1016/j.nano.2010.01.009
   Bloise N, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19103212
   Brooke G, 2008, STEM CELLS DEV, V17, P929, DOI 10.1089/scd.2007.0156
   Ceccarelli G, 2013, BIORESEARCH OPEN ACC, V2, P283, DOI 10.1089/biores.2013.0016
   Chambard JC, 2007, BBA MOL CELL RES, V1773, P1299, DOI 10.1016/j.bbamcr.2006.11.010
   Clarke SA, 2001, J BIOMED MATER RES, V57, P84, DOI 10.1002/1097 4636(200110)57:1<84::AID JBM1145>3.0.CO;2 5
   Cristofaro F, 2018, NANOSCALE, V10, P8689, DOI 10.1039/c8nr00677f
   DELCOMMENNE M, 1995, J BIOL CHEM, V270, P26794, DOI 10.1074/jbc.270.45.26794
   Desgrosellier JS, 2010, NAT REV CANCER, V10, P9, DOI 10.1038/nrc2748
   Di Benedetto A, 2015, STEM CELL RES, V15, P618, DOI 10.1016/j.scr.2015.09.011
   Docheva D, 2007, J CELL MOL MED, V11, P21, DOI 10.1111/j.1582 4934.2007.00001.x
   Dolci LS, 2016, J PHYS D APPL PHYS, V49, DOI 10.1088/0022 3727/49/27/274003
   El Amin SF, 2002, J ORTHOPAED RES, V20, P20, DOI 10.1016/S0736 0266(01)00062 6
   Fahimipour F, 2019, DENT MATER, V35, P990, DOI 10.1016/j.dental.2019.04.004
   Galletti P, 2011, CURR MED CHEM, V18, P4265, DOI 10.2174/092986711797200480
   Galletti P, 2014, EUR J MED CHEM, V83, P284, DOI 10.1016/j.ejmech.2014.06.041
   Giacomini D, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 02943 2
   Greiner A, 2007, ANGEW CHEM INT EDIT, V46, P5670, DOI 10.1002/anie.200604646
   Gronthos S, 2001, BONE, V28, P174, DOI 10.1016/S8756 3282(00)00424 5
   GRZESIK WJ, 1994, J BONE MINER RES, V9, P487, DOI 10.1002/jbmr.5650090408
   Gualandi C, 2016, MACROMOL BIOSCI, V16, P1533, DOI 10.1002/mabi.201600061
   Gualandi C, 2012, EUR POLYM J, V48, P2008, DOI 10.1016/j.eurpolymj.2012.09.016
   GUAN JL, 1990, CELL, V60, P53, DOI 10.1016/0092 8674(90)90715 Q
   Guan M, 2012, NAT MED, V18, P456, DOI 10.1038/nm.2665
   Hall JE, 2011, INT REV CEL MOL BIO, V288, P185, DOI 10.1016/B978 0 12 386041 5.00005 4
   Hamidouche Z, 2009, P NATL ACAD SCI USA, V106, P18587, DOI 10.1073/pnas.0812334106
   HAYASHI Y, 1990, J CELL BIOL, V110, P175, DOI 10.1083/jcb.110.1.175
   Hoon JL, 2016, CELLS BASEL, V5, DOI 10.3390/cells5020017
   Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092 8674(02)00971 6
   Ivaska J, 2010, CELL TISSUE RES, V339, P111, DOI 10.1007/s00441 009 0857 z
   Kafi MA, 2020, REGEN BIOMATER, V7, P141, DOI 10.1093/rb/rbz034
   Karimi F, 2018, ADV HEALTHC MATER, V7, DOI 10.1002/adhm.201701324
   Kechagia JZ, 2019, NAT REV MOL CELL BIO, V20, P457, DOI 10.1038/s41580 019 0134 2
   Keselowsky BG, 2004, BIOMATERIALS, V25, P5947, DOI 10.1016/j.biomaterials.2004.01.062
   Klim JR, 2012, ACS CHEM BIOL, V7, P518, DOI 10.1021/cb2004725
   Koh HS, 2008, BIOMATERIALS, V29, P3574, DOI 10.1016/j.biomaterials.2008.05.014
   Kumar S, 2007, FASEB J, V21, P3917, DOI 10.1096/fj.07 8275com
   Kundu AK, 2009, TISSUE ENG PT A, V15, P273, DOI 10.1089/ten.tea.2008.0055
   Lee JW, 2004, BIOMATERIALS, V25, P1901, DOI 10.1016/j.biomaterials.2003.08.037
   Lee ST, 2010, BIOMATERIALS, V31, P1219, DOI 10.1016/j.biomaterials.2009.10.054
   Ley K, 2016, NAT REV DRUG DISCOV, V15, P173, DOI 10.1038/nrd.2015.10
   Li ZH, 2016, EXP CELL RES, V349, P85, DOI 10.1016/j.yexcr.2016.10.001
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Marklein RA, 2010, ADV MATER, V22, P175, DOI 10.1002/adma.200901055
   Mehta PD, 2010, EUR J MED CHEM, V45, P5541, DOI 10.1016/j.ejmech.2010.09.035
   MIKOS AG, 1994, BIOMATERIALS, V15, P55, DOI 10.1016/0142 9612(94)90197 X
   Mitra SK, 2006, CURR OPIN CELL BIOL, V18, P516, DOI 10.1016/j.ceb.2006.08.011
   MOONEY DJ, 1995, J CELL SCI, V108, P2311
   Nakayamada S, 2003, J BIOL CHEM, V278, P45368, DOI 10.1074/jbc.M308786200
   Olivares Navarrete R, 2008, P NATL ACAD SCI USA, V105, P15767, DOI 10.1073/pnas.0805420105
   Olivares Navarrete R, 2015, BIOMATERIALS, V51, P69, DOI 10.1016/j.biomaterials.2015.01.035
   Patel DM, 2013, STEM CELLS INT, V2013, DOI 10.1155/2013/496218
   Pérez Tanoira R, 2015, J MATER SCI MATER M, V26, DOI 10.1007/s10856 015 5568 2
   Pertici V, 2018, CURR MED CHEM, V25, P2385, DOI 10.2174/0929867325666171129133120
   Petrie TA, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001002
   Prowse ABJ, 2011, STEM CELL RES, V6, P1, DOI 10.1016/j.scr.2010.09.005
   Rodda AE, 2016, J MATER CHEM B, V4, P7314, DOI 10.1039/c6tb02444k
   Saino E, 2011, EUR CELLS MATER, V21, P59, DOI 10.22203/eCM.v021a05
   Schneider GB, 2001, J DENT RES, V80, P1540, DOI 10.1177/00220345010800061201
   Schwab EH, 2013, INT J MED SCI, V10, P1846, DOI 10.7150/ijms.6908
   Seo CH, 2011, BIOMATERIALS, V32, P9568, DOI 10.1016/j.biomaterials.2011.08.077
   Shekaran A, 2011, J BIOMED MATER RES A, V96A, P261, DOI 10.1002/jbm.a.32979
   Sohni A, 2013, STEM CELLS INT, V2013, DOI 10.1155/2013/130763
   Stephanopoulos N, 2019, BIOCONJUGATE CHEM, V30, P1915, DOI 10.1021/acs.bioconjchem.9b00259
   Tayalia P, 2009, ADV MATER, V21, P3269, DOI 10.1002/adma.200900241
   Thevenot P, 2008, TISSUE ENG PART C ME, V14, P319, DOI 10.1089/ten.tec.2008.0221
   Tolomelli A, 2017, CANCERS, V9, DOI 10.3390/cancers9070078
   Topal T, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 30939 z
   Vachon Pierre H, 2011, J Signal Transduct, V2011, P738137, DOI 10.1155/2011/738137
   Veinberg G, 2014, CURR MED CHEM, V21, P393
   Wang LP, 2006, BIOMATERIALS, V27, P3716, DOI 10.1016/j.biomaterials.2006.02.022
   Wang MY, 2012, AGING CELL, V11, P500, DOI 10.1111/j.1474 9726.2012.00813.x
   Weyts FAA, 2002, J CELL BIOCHEM, V87, P85, DOI 10.1002/jcb.10278
   Wohlrab S, 2012, BIOMATERIALS, V33, P6650, DOI 10.1016/j.biomaterials.2012.05.069
   Yang G, 2018, PROG POLYM SCI, V81, P80, DOI 10.1016/j.progpolymsci.2017.12.003
   Yeo GC, 2019, P NATL ACAD SCI USA, V116, P2042, DOI 10.1073/pnas.1812951116
   Yoo HS, 2009, ADV DRUG DELIVER REV, V61, P1033, DOI 10.1016/j.addr.2009.07.007
   Zhu JX, 2013, J BIOMED NANOTECHNOL, V9, P1757, DOI 10.1166/jbn.2013.1661
NR 94
TC 21
Z9 21
U1 0
U2 21
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1525 7797
EI 1526 4602
J9 BIOMACROMOLECULES
JI Biomacromolecules
PD MAR
PY 2020
VL 21
IS 3
BP 1157
EP 1170
DI 10.1021/acs.biomac.9b01550
PG 14
WC Biochemistry & Molecular Biology; Chemistry, Organic; Polymer Science
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry; Polymer Science
GA KT6UV
UT WOS:000519150600011
PM 32011862
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Su, Y
   Zhang, F
   Wu, L
   Kuang, HX
   Wang, QH
   Cheng, GH
AF Su, Yang
   Zhang, Fan
   Wu, Lun
   Kuang, Haixue
   Wang, Qiuhong
   Cheng, Genhong
TI Total withanolides ameliorates imiquimod induced psoriasis like skin
   inflammation
SO JOURNAL OF ETHNOPHARMACOLOGY
LA English
DT Article
DE Datura metel L.; Total withanolides; Treg/Th17 axis; Psoriasis;
   Traditional Chinese medicine
ID REGULATES IMMUNE RESPONSES; METEL L.; CHEMOKINES; CELLS; CYTOTOXICITY;
   INHIBITION; PROGRAM; FLOWER; LEAVES
AB Ethnopharmacological relevance: Datura metel L. has been used as an anesthetic in clinic for more than 1800 years in China, and the main efficacy of D. metel L. flower is relieving asthma and cough, relieving spasm and relieving pain. From 1978 to 1980, Datura metel L. was used as an anesthetic agent and occasionally cured psoriasis patients during anesthesia clinically, and our group confirmed that the effective portion is total withanolides (YWS). Moreover, the new drug "Datura metel L. capsule" composed of YWS has since been approved and used for the treatment of more than 3,000 psoriasis patients, with efficacy and cure rates greater than 90% and 65%. However, the immunological mechanism has not been elucidated.
   Aim of the study: Nowadays, although total withanolides from Datura metel L. have a better clinical efficacy in the treatment of psoriasis, there is a lack of overall understanding of the mechanism of their treatment, especially about some immune cells and proteins closely related to psoriasis and their relationship in executive function and biological significance. This study focused on investigating the mechanism of psoriasis treatment by YWS and determined the biochemical processes in the treatment of psoriasis based on Treg/Th17 axis cell mediated bidirectional immunoregulatory functions, which provides an important scientific basis for understanding the mechanism underlying the treatment of psoriasis by YWS.
   Materials and methods: The effects of YWS on the lesion pathology of IMQ induced psoriasis mice and the underlying molecular mechanism were assessed directly using HE staining, the PASI score and the animal body mass. We also investigated the effects of YWS on the Treg/Th17 axis and their critical functions in psoriasis pathogenesis via molecular biological methods. Finally, we performed differential proteomics analysis on skin in IMQ induced psoriasis mice to clarify the effect of YWS by incorporates mass spectrometry bioinformatics and annotated the functions and pathways associated with the differential proteins through GO enrichment, KEGG pathway analysis and PPI networks analysis, respectively.
   Results: YWS regulated the imbalance of the Treg/Th17 axis. And proteomic analysis showed that YWS up regulated 46 and down regulated 37 proteins. According to the bioinformatics analysis, the improvement of Treg/Th17 imbalance may be the key immunological mechanism of YWS in the treatment of psoriasis by up regulating the butyrate metabolism pathway, down regulating leukocyte migration, inhibiting the phagocytic function of natural killer cells, suppressing osteoclast differentiation and interfering with chemokine activity, and the critical proteins involved are Lyn, HMGCS2, ABAT, ITG beta 2, PRKC beta, MMP9, NCF1, JUN beta, and Hck.
   Conclusion: This research clarified that the improvement of the imbalance of the Treg/Th17 axis may be the key immunological mechanism of YWS in the treatment of psoriasis through metabolic pathways and influencing key proteins. The results not only expand the therapeutic targets and approaches for the treatment of psoriasis, which is a challenging and complex disease, but also deepens the understanding of the mechanism of YWS in the treatment of psoriasis and other important conditions to open up a new way of thinking for research on YWS in the treatment of psoriasis.
C1 [Su, Yang; Zhang, Fan; Kuang, Haixue] Heilongjiang Univ Chinese Med, Chinese Acad Sci, Minist Educ, Sch Pharm,Key Lab Med Mat,Key Lab Basic & Appl Re, Harbin 150040, Peoples R China.
   [Wu, Lun] Heilongjiang Univ Chinese Med, Inst Tradit Chinese Med, Harbin 150040, Peoples R China.
   [Wang, Qiuhong] Guangdong Pharmaceut Univ, Sch Tradit Chinese Med, Guangzhou 511400, Peoples R China.
   [Cheng, Genhong] Univ Calif Los Angeles, Fac Microbiol & Immunogenet, Los Angeles, CA 90095 USA.
C3 Heilongjiang University of Chinese Medicine; Chinese Academy of
   Sciences; Heilongjiang University of Chinese Medicine; Guangdong
   Pharmaceutical University; University of California System; University
   of California Los Angeles
RP Wu, L; Kuang, HX (通讯作者)，24 Heping Rd, Harbin, Heilongjiang, Peoples R China.
EM wulun2012@163.com; 3182207925@qq.com
OI Wu, Lun/0009 0009 4815 933X
FU National Natural Science Foundation of China [81603416]; University
   Nursing Program for Young Scholars with Creative Talents in Heilongjiang
   Province [UNPYSCT 2016207]; Outstanding Innovative Talents Project of
   Heilongjiang University of Traditional Chinese Medicine  Young Academic
   Leaders Project [2018RCD12]; Outstanding youth of project by Natural
   Science Foundation of Heilongjiang Province of China by Heilongjiang
   Provincial Department of Education [YQ2019H028]; Traditional Chinese
   Medicine Inheritance and Innovation the "Hundred Thousand Ten Thousand
   Project" Talent Project Chief Scientist of Qihuang Project; Traditional
   Chinese Medicine Inheritance and Innovation the "Hundred Thousand Ten
   Thousand Project" Talent Project (Qihuang Project) QiHuang Scholar;
   Outstanding youth of project by Natural Science Foundation of
   Heilongjiang Province of China [YQ2020H030]
FX This research was funded by the National Natural Science Foundation of
   China (Grant No. 81603416) by National Natural Science Foundation of
   China, and the University Nursing Program for Young Scholars with
   Creative Talents in Heilongjiang Province (Grant No. UNPYSCT 2016207),
   the Outstanding Innovative Talents Project of Heilongjiang University of
   Traditional Chinese Medicine  Young Academic Leaders Project (Grant No.
   2018RCD12), and the Outstanding youth of project by Natural Science
   Foundation of Heilongjiang Province of China (Grant No. YQ2019H028) by
   Heilongjiang Provincial Department of Education, The Outstanding youth
   of project by Natural Science Foundation of Heilongjiang Province of
   China (YQ2020H030), by Traditional Chinese Medicine Inheritance and
   Innovation the "HundredThousand Ten Thousand Project" Talent
   Project Chief Scientist of Qihuang Project and by Traditional Chinese
   Medicine Inheritance and Innovation the "Hundred Thousand Ten Thousand
   Project" Talent Project (Qihuang Project) QiHuang Scholar.
CR Ahmadi M, 2019, J CELL PHYSIOL, V234, P3985, DOI 10.1002/jcp.27207
   Alebiowu G., 2007, Journal of Herbal Pharmacotherapy, V7, P1, DOI [10.1300/J157v07n01_01, 10.1080/J157v07n01_01]
   Ben Mkaddem S, 2017, NAT COMMUN, V8, DOI 10.1038/s41467 017 00294 0
   Borish Larry C., 2003, Journal of Allergy and Clinical Immunology, V111, pS460
   Capriotti L, 2018, EUR J DERMATOL, V28, P457, DOI 10.1684/ejd.2018.3357
   Chen XQ, 2017, BIOCHEM PHARMACOL, V142, P111, DOI 10.1016/j.bcp.2017.06.136
   Chen YF, 2019, ARTIF CELL NANOMED B, V47, P757, DOI 10.1080/21691401.2019.1577877
   Dunphy SE, 2017, CLIN IMMUNOL, V177, P43, DOI 10.1016/j.clim.2015.10.004
   Eckert N, 2019, IMMUNOL REV, V289, P62, DOI 10.1111/imr.12746
   Gang L., 1979, ACTA CHIN MED PHARM, V21
   Garcet S, 2018, J ALLERGY CLIN IMMUN, V142, P1010, DOI 10.1016/j.jaci.2018.05.039
   Gavin MA, 2007, NATURE, V445, P771, DOI 10.1038/nature05543
   Green A, 2020, BRIT J DERMATOL, V182, P714, DOI 10.1111/bjd.18227
   Guo R, 2018, PHYTOCHEMISTRY, V155, P136, DOI 10.1016/j.phytochem.2018.08.005
   Habtemariam S, 1997, PLANTA MED, V63, P15, DOI 10.1055/s 2006 957594
   Hui WP, 2019, INT IMMUNOPHARMACOL, V68, P226, DOI 10.1016/j.intimp.2019.01.018
   Ivanov II, 2006, CELL, V126, P1121, DOI 10.1016/j.cell.2006.07.035
   Jayaprakasam B, 2003, LIFE SCI, V74, P125, DOI 10.1016/j.lfs.2003.07.007
   [井佳楠 Jing Jianan], 2016, [中草药, Chinese Traditional and Herbal Drugs], V47, P3513
   Kuang HX, 2008, ARCH PHARM RES, V31, P1094, DOI 10.1007/s12272 001 1274 6
   Li S.J., 2016, EFFECTS XIAOYIN MIXT
   Li TT, 2019, MOLECULES, V24, DOI 10.3390/molecules24142596
   Mahil SK, 2016, SEMIN IMMUNOPATHOL, V38, P11, DOI 10.1007/s00281 015 0539 8
   Ming L., 1983, HARBIN MED J, V100
   Peltonen S, 2007, BRIT J DERMATOL, V156, P466, DOI 10.1111/j.1365 2133.2006.07642.x
   Poh AR, 2017, CANCER CELL, V31, P563, DOI 10.1016/j.ccell.2017.03.006
   Qi X.L, 2017, EFFECT QINGRE LIANGX
   Richmond JM, 2019, IMMUNOL REV, V289, P186, DOI 10.1111/imr.12762
   Ritchlin CT, 2017, NEW ENGL J MED, V376, P957, DOI 10.1056/NEJMra1505557
   Sakaguchi S, 2006, IMMUNOL REV, V212, P8, DOI 10.1111/j.0105 2896.2006.00427.x
   Sang Ngern M, 2016, BIOORG MED CHEM LETT, V26, P2755, DOI 10.1016/j.bmcl.2016.04.077
   Scheinecker C, 2020, J AUTOIMMUN, V110, DOI 10.1016/j.jaut.2019.102376
   Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73
   Su Y, 2017, CLIN EXP IMMUNOL, V190, P40, DOI 10.1111/cei.12998
   Su Y, 2017, BIOORGAN MED CHEM, V25, P4917, DOI 10.1016/j.bmc.2017.07.042
   [孙敏 Sun Min], 2016, [中国皮肤性病学杂志, The Chinese Journal of Dermatovenereology], V30, P1233
   Tang L, 2006, ANTIPSORIATIC PROPER
   Palomino DCT, 2015, EINSTEIN SAO PAULO, V13, P469, DOI 10.1590/S1679 45082015RB3438
   Villarino AV, 2017, NAT IMMUNOL, V18, P374, DOI 10.1038/ni.3691
   Wang XY, 2019, CHEM BIODIVERS, V16, DOI 10.1002/cbdv.201900004
   Wang Y. L., 2013, 2013 Abstracts IEEE International Conference on Plasma Science (ICOPS), DOI 10.1109/PLASMA.2013.6633252
   Wu J.Y, 2012, EXPRESSION SIRT1 COM
   Yang B.Y, 2005, STUDIES CHEM CONSTIT
   Yang BY, 2019, MOLECULES, V24, DOI 10.3390/molecules24112157
   Yang BY, 2014, STEROIDS, V87, P26, DOI 10.1016/j.steroids.2014.05.003
   Yang BY, 2010, ARCH PHARM RES, V33, P1143, DOI 10.1007/s12272 010 0802 4
   Yang LR, 2018, J CHROMATOGR B, V1083, P284, DOI 10.1016/j.jchromb.2018.02.022
   Zhang WJ, 2016, BIOCHEM PHARMACOL, V105, P66, DOI 10.1016/j.bcp.2016.02.001
   Zhang X, 2016, PRELIMINARY STUDY SY
NR 49
TC 17
Z9 17
U1 1
U2 33
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378 8741
EI 1872 7573
J9 J ETHNOPHARMACOL
JI J. Ethnopharmacol.
PD MAR 1
PY 2022
VL 285
AR 114895
DI 10.1016/j.jep.2021.114895
PG 12
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA 2Q0GY
UT WOS:000820109100004
PM 34875348
DA 2025 08 17
ER

PT J
AU Gao, L
   Kuraji, R
   Zhang, MJ
   Martinez, A
   Radaic, A
   Kamarajan, P
   Le, C
   Zhan, L
   Ye, CC
   Rangé, H
   Sailani, MR
   Kapila, YL
AF Gao, Li
   Kuraji, Ryutaro
   Zhang, Martin Jinye
   Martinez, April
   Radaic, Allan
   Kamarajan, Pachiyappan
   Le, Charles
   Zhan, Ling
   Ye, Changchang
   Range, Helene
   Sailani, M. Reza
   Kapila, Yvonne L.
TI Nisin probiotic prevents inflammatory bone loss while promoting
   reparative proliferation and a healthy microbiome
SO NPJ BIOFILMS AND MICROBIOMES
LA English
DT Article
ID LIGATURE INDUCED PERIODONTITIS; LACTOBACILLUS RHAMNOSUS GG; SALIVARY
   MICROBIOTA; ORAL MICROBIOME; HOST RESPONSE; BREVIS CD2; THERAPY;
   REUTERI; DISEASE; LOZENGES
AB Dysbiosis of the oral microbiome mediates chronic periodontal disease. Realignment of microbial dysbiosis towards health may prevent disease. Treatment with antibiotics and probiotics can modulate the microbial, immunological, and clinical landscape of periodontal disease with some success. Antibacterial peptides or bacteriocins, such as nisin, and a nisin producing probiotic, Lactococcus lactis, have not been examined in this context, yet warrant examination because of their biomedical benefits in eradicating biofilms and pathogenic bacteria, modulating immune mechanisms, and their safety profile in humans. This study's goal was to examine the potential for nisin and a nisin producing probiotic to abrogate periodontal bone loss, the host inflammatory response, and changes in oral microbiome composition in a polymicrobial mouse model of periodontal disease. Nisin and a nisin producing Lactococcus lactis probiotic significantly decreased the levels of several periodontal pathogens, alveolar bone loss, and the oral and systemic inflammatory host response. Surprisingly, nisin and/or the nisin producing L. lactis probiotic enhanced the population of fibroblasts and osteoblasts despite the polymicrobial infection. Nisin mediated human periodontal ligament cell proliferation dose dependently by increasing the proliferation marker, Ki 67. Nisin and probiotic treatment significantly shifted the oral microbiome towards the healthy control state; health was associated with Proteobacteria, whereas 3 retroviruses were associated with disease. Disease associated microbial species were correlated with IL 6 levels. Nisin or nisin producing probiotic's ability to shift the oral microbiome towards health, mitigate periodontal destruction and the host immune response, and promote a novel proliferative phenotype in reparative connective tissue cells, addresses key aspects of the pathogenesis of periodontal disease and reveals a new biomedical application for nisin in treatment of periodontitis and reparative medicine.
C1 [Gao, Li; Kuraji, Ryutaro; Martinez, April; Radaic, Allan; Kamarajan, Pachiyappan; Le, Charles; Zhan, Ling; Ye, Changchang; Range, Helene; Kapila, Yvonne L.] Univ Calif San Francisco UCSF, Sch Dent, Orofacial Sci Dept, San Francisco, CA 94143 USA.
   [Gao, Li] Sun Yat Sen Univ, Guanghua Sch Stomatol, Hosp Stomatol, Dept Periodontol,Guangdong Prov Key Lab Stomatol, Guangzhou, Peoples R China.
   [Kuraji, Ryutaro] Nippon Dent Univ Tokyo, Dept Life Sci Dent, Tokyo, Japan.
   [Kuraji, Ryutaro] Nippon Dent Univ Tokyo, Dept Periodontol, Sch Life Dent Tokyo, Tokyo, Tokyo, Japan.
   [Zhang, Martin Jinye; Sailani, M. Reza] Oralome Inc, 1700 4th St,Byers Hall Suite 214, San Francisco, CA USA.
   [Ye, Changchang] Sichuan Univ, West China Sch Stomatol, Dept Periodontol, Natl Clin Res Ctr Oral Dis,State Key Lab Oral Dis, Chengdu, Peoples R China.
   [Range, Helene] Univ Paris Cite, Fac Hlth, Dept Periodontol,PaCeMM,FHU,Hop Rothschild,APHP, URP2496 Orofacial Pathol,Imaging & Biotherapies L, Paris, France.
C3 University of California System; University of California San Francisco;
   Sun Yat Sen University; Nippon Dental University; Nippon Dental
   University; Sichuan University; Assistance Publique Hopitaux Paris
   (APHP); Sorbonne Universite; Hopital Universitaire Rothschild   APHP;
   Universite Paris Cite; Hopital Universitaire Hotel Dieu   APHP
RP Kapila, YL (通讯作者)，Univ Calif San Francisco UCSF, Sch Dent, Orofacial Sci Dept, San Francisco, CA 94143 USA.
EM ykapila@dentistry.ucla.edu
RI Zhang, Martin/AAF 2206 2019; Rangé, Hélène/KFB 1287 2024; Ye,
   Changchang/ABF 9535 2021; Kuraji, Ryutaro/M 6002 2017; Kapila,
   Yvonne/AAG 5418 2021; Radaic, Allan/J 5354 2018
OI Range, Helene/0000 0002 4761 0805; Zhang, Martin
   Jinye/0000 0003 0006 2466; Kamarajan, pachiyappan/0009 0007 8413 5082;
   Radaic, Allan/0000 0002 0899 9061
FU NIH [R01 DE025225]; AAP Sunstar Innovation grant; Chinese Scholarship
   Council; National Institute of Dental and Craniofacial Research
   [R01DE025225] Funding Source: NIH RePORTER
FX This study was supported by an NIH R01 DE025225 grant and AAP Sunstar
   Innovation grant to Y.L.K. L.G. was supported by a grant from the
   Chinese Scholarship Council.
CR Abbas AA, 2019, CELL HOST MICROBE, V25, P719, DOI 10.1016/j.chom.2019.04.001
   Albuquerque Souza E, 2019, J PERIODONTAL RES, V54, P115, DOI 10.1111/jre.12608
   [Anonymous], 1978, World Health Organ Tech Rep Ser, P1
   Becker Daniel E, 2013, Anesth Prog, V60, P188, DOI 10.2344/0003 3006 60.4.188
   Becker Daniel E, 2013, Anesth Prog, V60, P111, DOI 10.2344/0003 3006 60.3.111
   BENJAMINI Y, 1995, J ROY STAT SOC B, V57, P289, DOI 10.1111/j.2517 6161.1995.tb02031.x
   Chandrapati S, 2002, MOL MICROBIOL, V46, P467, DOI 10.1046/j.1365 2958.2002.03163.x
   Chukkapalli SS, 2014, INFECT IMMUN, V82, P1959, DOI 10.1128/IAI.01511 14
   Cunha E, 2021, PEERJ, V9, DOI 10.7717/peerj.11626
   Cunha E, 2018, BMC VET RES, V14, DOI 10.1186/s12917 018 1692 9
   Dominy SS, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aau3333
   Foureaux RD, 2014, J PERIODONTOL, V85, P975, DOI 10.1902/jop.2013.130356
   Ganther S, 2021, PLOS PATHOG, V17, DOI 10.1371/journal.ppat.1009311
   Gao L, 2020, NPJ BIOFILMS MICROBI, V6, DOI 10.1038/s41522 020 0120 7
   Garcia VG, 2016, J PERIODONTAL RES, V51, P26, DOI 10.1111/jre.12274
   Gatej SM, 2018, J CLIN PERIODONTOL, V45, P204, DOI 10.1111/jcpe.12838
   Ghyselinck J, 2020, INT J PHARMACEUT, V587, DOI 10.1016/j.ijpharm.2020.119648
   Gough R, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.01186
   Guder A, 2000, BIOPOLYMERS, V55, P62, DOI 10.1002/1097 0282(2000)55:1<62::AID BIP60>3.3.CO;2 P
   Hajishengallis G, 2012, NAT REV MICROBIOL, V10, P717, DOI 10.1038/nrmicro2873
   Hill C, 2014, NAT REV GASTRO HEPAT, V11, P506, DOI 10.1038/nrgastro.2014.66
   HOWELL TH, 1993, J CLIN PERIODONTOL, V20, P335, DOI 10.1111/j.1600 051X.1993.tb00369.x
   Hurst A., 1981, Adv Appl Microbiol, V27, P85, DOI DOI 10.1016/S0065 2164(08)70342 3
   Ikram S, 2019, J INVESTIG CLIN DENT, V10, DOI 10.1111/jicd.12393
   Ince G, 2015, J PERIODONTOL, V86, P746, DOI 10.1902/jop.2015.140612
   Iniesta M, 2012, J CLIN PERIODONTOL, V39, P736, DOI 10.1111/j.1600 051X.2012.01914.x
   Invernici MM, 2018, J CLIN PERIODONTOL, V45, P1198, DOI 10.1111/jcpe.12995
   Jaffar N, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159466
   Jepsen K, 2016, PERIODONTOL 2000, V71, P82, DOI 10.1111/prd.12121
   Kajwadkar R, 2017, J ENDODONT, V43, P989, DOI 10.1016/j.joen.2017.01.034
   Kapila YL, 2021, PERIODONTOL 2000, V87, P11, DOI 10.1111/prd.12398
   Kapoor Anoop, 2012, Dent Res J (Isfahan), V9, P505
   Kesavalu L, 2007, INFECT IMMUN, V75, P1704, DOI 10.1128/IAI.00733 06
   Khasenbekova Zhanagul, 2013, Cent Asian J Glob Health, V2, P109, DOI 10.5195/cajgh.2013.109
   Kim J, 2006, ODONTOLOGY, V94, P10, DOI 10.1007/s10266 006 0060 6
   Ko Y, 2020, J PERIODONTAL IMPLAN, V50, P171, DOI 10.5051/jpis.2020.50.3.171
   Kobayashi R, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 00623 9
   Kristensen M, 2020, J CYST FIBROS, V19, P553, DOI 10.1016/j.jcf.2020.04.007
   Kuang XY, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/6498932
   Kudo Y, 2016, GENES ENVIRON, V38, DOI 10.1186/s41021 016 0042 z
   KUFF EL, 1988, ADV CANCER RES, V51, P183, DOI 10.1016/S0065 230X(08)60223 7
   Kuraji R, 2020, ORAL DIS, V26, P1292, DOI 10.1111/odi.13328
   Kuru BE, 2017, J PERIODONTOL, V88, P1115, DOI 10.1902/jop.2017.170213
   Kushkevych I, 2020, J CLIN MED, V9, DOI 10.3390/jcm9082347
   Laleman I, 2015, J CLIN PERIODONTOL, V42, P1032, DOI 10.1111/jcpe.12464
   Laleman I, 2015, QUINTESSENCE INT, V46, P255, DOI 10.3290/j.qi.a33182
   Lee JK, 2015, ORAL DIS, V21, P705, DOI 10.1111/odi.12332
   Linden GJ, 2013, J CLIN PERIODONTOL, V40, pS8, DOI [10.1111/jcpe.12064, 10.1902/jop.2013.1340010]
   Liu TH, 2018, FOOD FUNCT, V9, P4916, DOI 10.1039/c8fo01303a
   Lu HY, 2019, J CLIN PERIODONTOL, V46, P1094, DOI 10.1111/jcpe.13177
   Maekawa T, 2014, J PERIODONTAL RES, V49, P785, DOI 10.1111/jre.12164
   Malone ET, 2021, FRONT CELL INFECT MI, V11, DOI 10.3389/fcimb.2021.671968
   Mayanagi G, 2009, J CLIN PERIODONTOL, V36, P506, DOI 10.1111/j.1600 051X.2009.01392.x
   Messora MR, 2016, ARCH ORAL BIOL, V66, P108, DOI 10.1016/j.archoralbio.2016.02.014
   Messora MR, 2013, J PERIODONTOL, V84, P1818, DOI 10.1902/jop.2013.120644
   Meurman JH, 2007, ORAL DIS, V13, P443, DOI 10.1111/j.1601 0825.2007.01386.x
   Montero E, 2017, J CLIN PERIODONTOL, V44, P708, DOI 10.1111/jcpe.12752
   Morales A, 2018, J APPL ORAL SCI, V26, DOI 10.1590/1678 7757 2017 0075
   Murphy F. A, 1999, VET VIROLOGY, V3rd
   Nackaerts O, 2008, J CLIN PERIODONTOL, V35, P1048, DOI 10.1111/j.1600 051X.2008.01333.x
   Nibali L, 2015, VIRULENCE, V6, P223, DOI 10.4161/21505594.2014.986407
   Oliveira LFF, 2017, J PERIODONTOL, V88, P197, DOI 10.1902/jop.2016.160217
   Parvaneh K, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/897639
   Paster BJ, 2001, J BACTERIOL, V183, P3770, DOI 10.1128/JB.183.12.3770 3783.2001
   Pazzini CA, 2017, ARCH ORAL BIOL, V79, P30, DOI 10.1016/j.archoralbio.2017.02.017
   Radaic A, 2020, J ORAL MICROBIOL, V12, DOI 10.1080/20002297.2020.1809302
   Rana S, 2020, MICROB PATHOGENESIS, V142, DOI 10.1016/j.micpath.2020.104105
   Rickard AH, 2003, TRENDS MICROBIOL, V11, P94, DOI 10.1016/S0966 842X(02)00034 3
   Ricoldi MST, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179946
   Rivera MF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057178
   Brito EM, 2006, RES MICROBIOL, V157, P752, DOI 10.1016/j.resmic.2006.03.005
   Santiago Rodriguez TM, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864 015 1781 0
   Schmitter T, 2018, J ORAL MICROBIOL, V10, DOI 10.1080/20002297.2018.1502027
   Shin JM, 2016, J APPL MICROBIOL, V120, P1449, DOI 10.1111/jam.13033
   Shin JM, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.00617
   Shrestha D, 2015, J PERIODONTOL, V86, P418, DOI 10.1902/jop.2014.140408
   Staab B, 2009, J CLIN PERIODONTOL, V36, P850, DOI 10.1111/j.1600 051X.2009.01459.x
   Szkaradkiewicz AK, 2014, ARCH IMMUNOL THER EX, V62, P495, DOI 10.1007/s00005 014 0277 y
   Tankou SK, 2018, ANN NEUROL, V83, P1147, DOI 10.1002/ana.25244
   Tatakis Dimitris N, 2005, Dent Clin North Am, V49, P491, DOI 10.1016/j.cden.2005.03.001
   Tekce M, 2015, J CLIN PERIODONTOL, V42, P363, DOI 10.1111/jcpe.12387
   Teughels W, 2007, J DENT RES, V86, P1078, DOI 10.1177/154405910708601111
   Todaro G J, 1976, Hamatol Bluttransfus, V19, P357
   Toiviainen A, 2015, CLIN ORAL INVEST, V19, P77, DOI 10.1007/s00784 014 1221 6
   Nguyen T, 2020, PERIODONTOL 2000, V82, P173, DOI 10.1111/prd.12324
   Tsubura S, 2009, EUR J CLIN MICROBIOL, V28, P1353, DOI 10.1007/s10096 009 0790 9
   Twetman S, 2009, ACTA ODONTOL SCAND, V67, P19, DOI 10.1080/00016350802516170
   Vivekananda M R, 2010, J Oral Microbiol, V2, DOI 10.3402/jom.v2i0.5344
   Welch JLM, 2016, P NATL ACAD SCI USA, V113, pE791, DOI 10.1073/pnas.1522149113
   Wu LJ, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.01082
   Zahradnik RT, 2009, J APPL MICROBIOL, V107, P682, DOI 10.1111/j.1365 2672.2009.04243.x
   Zhang Y, 2019, VIRUS GENES, V55, P381, DOI 10.1007/s11262 019 01658 y
   Zhang Y, 2017, VIRUS GENES, V53, P823, DOI 10.1007/s11262 017 1505 4
   Zheng DP, 2020, CELL RES, V30, P492, DOI 10.1038/s41422 020 0332 7
NR 94
TC 26
Z9 29
U1 1
U2 30
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
EI 2055 5008
J9 NPJ BIOFILMS MICROBI
JI npj Biofilms Microbomes
PD JUN 7
PY 2022
VL 8
IS 1
AR 45
DI 10.1038/s41522 022 00307 x
PG 14
WC Biotechnology & Applied Microbiology; Microbiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Microbiology
GA 1X5MN
UT WOS:000807497800001
PM 35672331
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Gupta, D
   Savva, J
   Li, X
   Chandler, JH
   Shelton, RM
   Scheven, B
   Mulvana, H
   Valdastri, P
   Lucas, M
   Walmsley, AD
AF Gupta, Dhanak
   Savva, Jill
   LI, Xuan
   Chandler, James H.
   Shelton, Richard M.
   Scheven, Ben A.
   Mulvana, Helen
   Valdastri, Pietro
   Lucas, Margaret
   Walmsley, A. Damien
TI TRADITIONAL MULTIWELL PLATES AND PETRI DISHES LIMIT THE EVALUATION OF
   THE EFFECTS OF ULTRASOUND ON CELLS IN VITRO br
SO ULTRASOUND IN MEDICINE AND BIOLOGY
LA English
DT Article
DE Ultrasound; Saos 2 cells; Osteogenic differentiation; Bone; Standing
   waves; Experimental reproducibility
ID INTENSITY PULSED ULTRASOUND; LOW FREQUENCY ULTRASOUND; OSTEOGENIC
   ACTIVITY; CANCER CELLS; STIMULATION; OSTEOBLAST; STRESS;
   DIFFERENTIATION; EXPOSURE
AB Ultrasound accelerates healing in fractured bone; however, the mechanisms responsible are poorly understood. Experimental setups and ultrasound exposures vary or are not adequately characterized across stud ies, resulting in inter study variation and difficulty in concluding biological effects. This study investigated exper imental variability introduced through the cell culture platform used. Continuous wave ultrasound (45 kHz; 10, 25 or 75 mW/cm2, 5 min/d) was applied, using a Duoson device, to Saos 2 cells seeded in multiwell plates or Petri dishes. Pressure field and vibration quantification and finite element modelling suggested formation of complex interference patterns, resulting in localized displacement and velocity gradients, more pronounced in multiwell plates. Cell experiments revealed lower metabolic activities in both culture platforms at higher ultrasound inten sities and absence of mineralization in certain regions of multiwell plates but not in Petri dishes. Thus, the same transducer produced variable results in different cell culture platforms. Analysis on Petri dishes further revealed that higher intensities reduced vinculin expression and distorted cell morphology, while causing mitochondrial and endoplasmic reticulum damage and accumulation of cells in sub G1 phase, leading to cell death. More defined experimental setups and reproducible ultrasound exposure systems are required to study the real effect of ultrasound on cells for development of effective ultrasound based therapies not just limited to bone repair and regeneration. (E mail: d.gupta@bham.ac.uk) (c) 2022 The Author(s). Published by Elsevier Inc. on behalf of World Federation for Ultrasound in Medicine & Biology.
C1 [Gupta, Dhanak; Shelton, Richard M.; Scheven, Ben A.; Walmsley, A. Damien] Univ Birmingham, Sch Dent, Birmingham, England.
   [Savva, Jill; LI, Xuan; Lucas, Margaret] Univ Glasgow, Ctr Med & Ind Ultrason, James Watt Sch Engn, Glasgow, Scotland.
   [Chandler, James H.; Valdastri, Pietro] Univ Leeds, Sch Elect & Elect Engn, Sci & Technol Robot Med STORM Lab UK, Leeds, England.
   [Mulvana, Helen] Univ Strathclyde, Dept Biomed Engn, Glasgow, Scotland.
   [Gupta, Dhanak] Univ Birmingham, Inst Clin Sci, Coll Med & Dent Sci, Sch Dent, 5 Mill Pool Way, Birmingham B5 7EG, England.
C3 University of Birmingham; University of Glasgow; University of Leeds;
   University of Strathclyde; University of Birmingham
RP Gupta, D (通讯作者)，Univ Birmingham, Inst Clin Sci, Coll Med & Dent Sci, Sch Dent, 5 Mill Pool Way, Birmingham B5 7EG, England.
EM d.gupta@bham.ac.uk
RI Valdastri, Pietro/A 2840 2010; Lucas, Margaret/B 3198 2010; Gupta,
   Dhanak/AAH 8376 2019; Chandler, James/AAI 8039 2020; Mulvana,
   Helen/A 1924 2013; Mulvana, Helen/ACH 0017 2022; Walmsley,
   Anthony/V 8585 2018; Valdastri, Pietro/AAG 1706 2019
OI Valdastri, Pietro/0000 0002 2280 5438; Chandler,
   James/0000 0001 9232 4966; Lucas, Margaret/0000 0002 3625 9714; Gupta,
   Dhanak/0000 0002 6493 1600; Mulvana, Helen/0000 0002 5058 0299; Li,
   Xuan/0000 0002 5655 8631; 
FU Engineering and Physi  cal Sciences Research Council [EP/R045291/1];
   EPSRC [EP/R045291/1] Funding Source: UKRI
FX Acknowledgments  This work is funded by the Engineering and Physi  cal
   Sciences Research Council and part of the Ultrasurge Project under Grant
   EP/R045291/1. We thank Dr. Yao Jiang, School of Biomedical Sciences,
   University of Birmingham for assisting with flow cytometry.
CR Aliabouzar M, 2018, BIOTECHNOL BIOENG, V115, P495, DOI 10.1002/bit.26480
   Angle SR, 2011, ULTRASONICS, V51, P281, DOI 10.1016/j.ultras.2010.09.004
   Azuma Y, 2001, J BONE MINER RES, V16, P671, DOI 10.1359/jbmr.2001.16.4.671
   Gao QH, 2017, J ENDODONT, V43, P1130, DOI 10.1016/j.joen.2017.02.022
   Gao QH, 2016, J ENDODONT, V42, P425, DOI 10.1016/j.joen.2015.12.019
   Ghorayeb SR, 2013, J THER ULTRASOUND, V1, DOI 10.1186/2050 5736 1 12
   Hasegawa T, 2009, J BONE JOINT SURG BR, V91B, P264, DOI 10.1302/0301 620X.91B2.20827
   HECKMAN JD, 1994, J BONE JOINT SURG AM, V76A, P26, DOI 10.2106/00004623 199401000 00004
   Hensel K, 2011, ULTRASOUND MED BIOL, V37, P2105, DOI 10.1016/j.ultrasmedbio.2011.09.007
   Huang W, 2015, INT J ORAL MAX SURG, V44, P929, DOI 10.1016/j.ijom.2015.03.001
   Imai Y, 2014, INT J ORAL MAX SURG, V43, P367, DOI 10.1016/j.ijom.2013.07.746
   Leskinen JJ, 2012, ULTRASOUND MED BIOL, V38, P777, DOI 10.1016/j.ultrasmedbio.2012.01.019
   Li JM, 2018, CELL PHYSIOL BIOCHEM, V45, P1350, DOI 10.1159/000487561
   Maddi A, 2006, BONE, V39, P283, DOI 10.1016/j.bone.2006.01.162
   Man J, 2012, J BONE MINER METAB, V30, P602, DOI 10.1007/s00774 012 0368 y
   Man J, 2012, J ENDODONT, V38, P608, DOI 10.1016/j.joen.2012.01.015
   McCormick SM, 2006, ANN BIOMED ENG, V34, P436, DOI 10.1007/s10439 005 9057 5
   Naruse K, 2003, J BONE MINER RES, V18, P360, DOI 10.1359/jbmr.2003.18.2.360
   National Institute for Health and Care Excellence (NICE), 2019, EXOGEN ULTR BON HEAL
   Padilla F, 2014, ULTRASONICS, V54, P1125, DOI 10.1016/j.ultras.2014.01.004
   Patel US, 2015, J THER ULTRASOUND, V3, DOI 10.1186/s40349 015 0028 5
   Pelicano H, 2004, DRUG RESIST UPDATE, V7, P97, DOI 10.1016/j.drup.2004.01.004
   Reher P, 1997, ULTRASOUND MED BIOL, V23, P1251, DOI 10.1016/S0301 5629(97)00031 8
   Reher P, 1998, EUR J CANCER, V34, P1962, DOI 10.1016/S0959 8049(98)00238 X
   Sant'Anna EF, 2005, J ORTHOP RES, V23, P646, DOI 10.1016/j.orthres.2004.09.007
   Scheven BA, 2009, ARCH ORAL BIOL, V54, P185, DOI 10.1016/j.archoralbio.2008.09.008
   Scheven BA, 2007, ULTRASOUND MED BIOL, V33, P1475, DOI 10.1016/j.ultrasmedbio.2007.03.010
   Sena K, 2011, ULTRASONICS, V51, P639, DOI 10.1016/j.ultras.2011.01.007
   Sun JS, 2001, J BIOMED MATER RES, V57, P449, DOI 10.1002/1097 4636(20011205)57:3<449::AID JBM1188>3.0.CO;2 0
   Sura H, 2001, J MATER SCI MATER M, V12, P997, DOI 10.1023/A:1012873402275
   Uddin SMZ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073914
   Wang JW, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00600
   Wu YQ, 2018, ONCOTARGETS THER, V11, P5621, DOI 10.2147/OTT.S176744
   Xiang JY, 2014, J ULTRAS MED, V33, P1755, DOI 10.7863/ultra.33.10.1755
   Xiao DG, 2016, ULTRASONICS, V68, P150, DOI 10.1016/j.ultras.2016.02.017
   Young MJR, 2003, US Patent, Patent No. [US6565520B1, 6565520]
   Yue Y, 2013, CELL PROLIFERAT, V46, P320, DOI 10.1111/cpr.12035
NR 37
TC 7
Z9 7
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0301 5629
EI 1879 291X
J9 ULTRASOUND MED BIOL
JI Ultrasound Med. Biol.
PD SEP
PY 2022
VL 48
IS 9
BP 1745
EP 1761
DI 10.1016/j.ultrasmedbio.2022.05.001
EA AUG 2022
PG 17
WC Acoustics; Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI EXPANDED)
SC Acoustics; Radiology, Nuclear Medicine & Medical Imaging
GA 3Y6IC
UT WOS:000843825800005
PM 35760602
OA Green Published, Green Accepted
DA 2025 08 17
ER

PT J
AU Choudhary, S
   Sun, QL
   Mannion, C
   Kissin, Y
   Zilberberg, J
   Lee, WY
AF Choudhary, Saba
   Sun, Qiaoling
   Mannion, Ciaran
   Kissin, Yair
   Zilberberg, Jenny
   Lee, Woo Y.
TI Hypoxic Three Dimensional Cellular Network Construction Replicates Ex
   Vivo the Phenotype of Primary Human Osteocytes
SO TISSUE ENGINEERING PART A
LA English
DT Article
DE primary human osteocytes; hypoxia; bone tissue engineering;
   microfluidics; sclerostin; 3D culture
ID PROSTATE CANCER; MULTIPLE MYELOMA; GENE EXPRESSION; OXYGEN TENSION;
   ANIMAL MODELS; SCLEROSTIN; ESTABLISHMENT; LINE; DIFFERENTIATION;
   OSTEOBLASTS
AB Osteocytes are deeply embedded in the mineralized matrix of bone and are nonproliferative, making them a challenge to isolate and maintain using traditional in vitro culture methods without sacrificing their inimitable phenotype. We studied the synergistic effects of two microenvironmental factors that are vital in retaining, ex vivo, the phenotype of primary human osteocytes: hypoxia and three dimensional (3D) cellular network. To recapitulate the lacunocanalicular structure of bone tissue, we assembled and cultured primary human osteocytic cells with biphasic calcium phosphate microbeads in a microfluidic perfusion culture device. The 3D cellular network was constructed by the following: (1) the inhibited proliferation of cells entrapped by microbeads, biomimetically resembling lacunae, and (2) the connection of neighboring cells by dendrites through the mineralized, canaliculi like interstitial spaces between the microbeads. We found that hypoxia synergistically and remarkably upregulated the mature osteocytic gene expressions of the 3D networked cells, SOST (encoding sclerostin) and FGF23 (encoding fibroblast growth factor 23), by several orders of magnitude in comparison to those observed from two dimensional and normoxic culture controls. Intriguingly, hypoxia facilitated the self assembly of a nonproliferating, osteoblastic monolayer on the surface of the 3D networked cells, replicating the osteoblastic endosteal cell layer found at the interface between native bone and bone marrow tissues. Our ability to replicate, with hypoxia, the strong expressions of these mature osteocytic markers, SOST and FGF23, is important since these (1) could not be significantly produced in vitro and (2) are new important targets for treating bone diseases. Our findings are therefore expected to facilitate ex vivo studies of human bone diseases using primary human bone cells and enable high throughput evaluation of potential bone targeting therapies with clinical relevance.
C1 [Choudhary, Saba] Stevens Inst Technol, Dept Biomed Engn Chem & Biol Sci, Hoboken, NJ 07030 USA.
   [Sun, Qiaoling; Lee, Woo Y.] Stevens Inst Technol, Dept Chem Engn & Mat Sci, 1 Castle Point Hudson, Hoboken, NJ 07030 USA.
   [Mannion, Ciaran] Hackensack Univ, Dept Pathol, Med Ctr, Hackensack, NJ USA.
   [Kissin, Yair] Insall Scott Kelly Inst Orthopaed & Sports Med, New York, NY USA.
   [Kissin, Yair] Hackensack Univ, Med Ctr, Hackensack, NJ USA.
   [Kissin, Yair] Lenox Hill Hosp, New York, NY 10021 USA.
   [Zilberberg, Jenny] Hackensack Univ, John Theurer Canc Ctr, Med Ctr, Hackensack, NJ USA.
C3 Stevens Institute of Technology; Stevens Institute of Technology;
   Hackensack University Medical Center; Hackensack University Medical
   Center; Northwell Health; Hackensack University Medical Center
RP Lee, WY (通讯作者)，Stevens Inst Technol, Dept Chem Engn & Mat Sci, 1 Castle Point Hudson, Hoboken, NJ 07030 USA.
EM wlee@stevens.edu
OI Zilberberg, Jenny/0000 0002 4139 2616
FU National Institute of Arthritis and Musculoskeletal and Skin Diseases of
   the National Institutes of Health [1R21AR065032]; National Science
   Foundation [DMR 1409779]
FX Research in this publication was supported by grants from (1) the
   National Institute of Arthritis and Musculoskeletal and Skin Diseases of
   the National Institutes of Health under Award Number 1R21AR065032 to
   W.Y.L. and J.Z. and (2) the National Science Foundation (DMR 1409779) to
   W.Y.L. and J.Z. The content is solely the responsibility of the authors
   and does not necessarily represent the official views of the National
   Institutes of Health and the National Science Foundation.
CR Bodine PVN, 1996, ENDOCRINOLOGY, V137, P4592, DOI 10.1210/en.137.11.4592
   Bonewald LF, 1999, J BONE MINER METAB, V17, P61, DOI 10.1007/s007740050066
   Bonewald LF, 2011, J BONE MINER RES, V26, P229, DOI 10.1002/jbmr.320
   Boukhechba F, 2009, J BONE MINER RES, V24, P1927, DOI [10.1359/JBMR.090517, 10.1359/jbmr.090517]
   Brunetti G, 2011, ANN NY ACAD SCI, V1237, P19, DOI 10.1111/j.1749 6632.2011.06196.x
   Chen DF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065940
   Clarke BL, 2014, MATURITAS, V78, P199, DOI 10.1016/j.maturitas.2014.04.016
   Clinkenbeard EL, 2014, J BONE MINER RES, V29, P361, DOI 10.1002/jbmr.2049
   Compton JT, 2014, J BONE JOINT SURG AM, V96A, P1659, DOI 10.2106/JBJS.M.01096
   Couzin Frankel J, 2014, SCIENCE, V346, P28, DOI 10.1126/science.346.6205.28
   Dallas SL, 2010, ANN NY ACAD SCI, V1192, P437, DOI 10.1111/j.1749 6632.2009.05246.x
   Domcke S, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3126
   Feng S, 2015, ONCOTARGET, V6, P17291, DOI 10.18632/oncotarget.4174
   Franz Odendaal TA, 2006, DEV DYNAM, V235, P176, DOI 10.1002/dvdy.20603
   García Fontana B, 2014, OSTEOPOROSIS INT, V25, P645, DOI 10.1007/s00198 013 2462 y
   Genetos DC, 2010, J CELL BIOCHEM, V110, P457, DOI 10.1002/jcb.22559
   Gillet JP, 2013, JNCI J NATL CANCER I, V105, P452, DOI 10.1093/jnci/djt007
   Gross TS, 2001, J APPL PHYSIOL, V90, P2514, DOI 10.1152/jappl.2001.90.6.2514
   Gu YX, 2015, J MATER CHEM B, V3, P3625, DOI 10.1039/c5tb00421g
   Hartung Thomas, 2008, Parkinsonism Relat Disord, V14 Suppl 2, pS81, DOI 10.1016/j.parkreldis.2008.04.003
   Hirao M, 2007, J BONE MINER METAB, V25, P266, DOI 10.1007/s00774 007 0765 9
   Horvath P, 2016, NAT REV DRUG DISCOV, V15, P751, DOI 10.1038/nrd.2016.175
   Hutmacher DW, 2009, J CELL MOL MED, V13, P1417, DOI 10.1111/j.1582 4934.2009.00853.x
   Jucker M, 2010, NAT MED, V16, P1210, DOI 10.1038/nm.2224
   Kale S, 2000, NAT BIOTECHNOL, V18, P954, DOI 10.1038/79439
   Kato Y, 1997, J BONE MINER RES, V12, P2014, DOI 10.1359/jbmr.1997.12.12.2014
   Kato Y, 2001, J BONE MINER RES, V16, P1622, DOI 10.1359/jbmr.2001.16.9.1622
   Li AG, 2008, MOL CANCER RES, V6, P21, DOI 10.1158/1541 7786.MCR 07 0280
   Pajevic Paola Divieti, 2013, Curr Biotechnol, V2, P179
   Rhrissorrakrai K, 2015, BIOINFORMATICS, V31, P471, DOI 10.1093/bioinformatics/btu611
   Sandberg R, 2005, P NATL ACAD SCI USA, V102, P2052, DOI 10.1073/pnas.0408105102
   Shanks Niall, 2009, Philos Ethics Humanit Med, V4, P2, DOI 10.1186/1747 5341 4 2
   Stern AR, 2012, BIOTECHNIQUES, V52, P361, DOI 10.2144/0000113876
   Sun Q., 2017, BONE IN PRESS
   Sun QL, 2015, BONE RES, V3, DOI 10.1038/boneres.2015.26
   Suvannasankha A, 2015, ONCOTARGET, V6, P19647, DOI 10.18632/oncotarget.3794
   Trojani C, 2005, BIOMATERIALS, V26, P5509, DOI 10.1016/j.biomaterials.2005.02.001
   Vazquez M., 2012, Eur. Cells Mater, V24, P7
   Woo SM, 2011, J BONE MINER RES, V26, P2634, DOI 10.1002/jbmr.465
   Yang Y., 2008, Front. Med. China, V2, P239, DOI DOI 10.1007/S11684 008 0045 7
   Yavropoulou MP, 2012, BONE, V51, P153, DOI 10.1016/j.bone.2012.04.016
   Zahm AM, 2008, BONE, V43, P25, DOI 10.1016/j.bone.2008.03.010
   Zhong H, 1999, BIOCHEM BIOPH RES CO, V259, P523, DOI 10.1006/bbrc.1999.0815
NR 43
TC 19
Z9 22
U1 0
U2 20
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1937 3341
EI 1937 335X
J9 TISSUE ENG PT A
JI Tissue Eng. Part A
PD MAR
PY 2018
VL 24
IS 5 6
BP 458
EP 468
DI 10.1089/ten.tea.2017.0103
PG 11
WC Cell & Tissue Engineering; Cell Biology; Engineering, Biomedical;
   Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Engineering; Materials Science
GA FY1GZ
UT WOS:000426561200009
PM 28594289
OA Green Published
DA 2025 08 17
ER

PT J
AU Woodward, JKL
   Neville Webbe, HL
   Coleman, RE
   Holen, I
AF Woodward, JKL
   Neville Webbe, HL
   Coleman, RE
   Holen, I
TI Combined effects of zoledronic acid and doxorubicin on breast cancer
   cell invasion in vitro
SO ANTI CANCER DRUGS
LA English
DT Article
DE adhesion; bisphosphonate; breast cancer; cytotoxic drug; invasion;
   metastatic bone disease; mevalonate pathway; migration
ID NITROGEN CONTAINING BISPHOSPHONATES; BONE METASTASES; INDUCE APOPTOSIS;
   CARCINOMA; PROSTATE; ADHESION; INHIBIT; COMBINATION; ALENDRONATE;
   PACLITAXEL
AB The bisphosphonate zoledronic acid and the cytotoxic drug doxorubicin induce synergistic levels of apoptosis in breast cancer cells. As zoledronic acid and doxorubicin have been shown to reduce cell invasion and migration, we have investigated if these drugs also act synergistically on breast cancer invasion in vitro. MCF7 cells were treated with 0.05 mu M doxorubicin/4 h followed by 1 or 10 mu M zoledronic acid/24 h (or the reverse sequence). To study invasion, MCF7 cells were either grown on Transwell membranes coated with Matrigel or in a 24 well plate. Cells were treated sequentially using the above drug combinations, prior to starting the invasion assays for 48 h. Cell growth and death were also assessed under the same conditions. We found that invasion of MCF7 cells treated with zoledronic acid and doxorubicin was significantly reduced when compared with control, but the effect was dependent on drug sequence. At 1 mu M, zoledronic acid significantly reduced invasion only if cells were pre treated with doxorubicin, but cell growth was unaffected. For 10 mu M zoledronic acid, invasion was reduced when administered before or after the doxorubicin, but this dose of zoledronic acid caused a significant reduction in MCF7 growth. Apoptosis was not induced by any of the drug doses and combinations. We conclude that pre treatment with 0.05 mu M doxorubicin followed by 1 mu M zoledronic acid reduces invasion when cells were grown on Matrigel. For 10 mu M zoledronic acid, pre  or post doxorubicin also reduces invasion, but for this combination inhibition of cell growth may contribute to the reduction in invasion observed.
C1 Univ Sheffield, Sch Med, Acad Unit Clin Oncol, Div Genom Med, Sheffield S10 2RX, S Yorkshire, England.
C3 University of Sheffield
RP Woodward, JKL (通讯作者)，Univ Sheffield, Sch Med, Acad Unit Clin Oncol, Div Genom Med, D Floor,Beech Hill Rd, Sheffield S10 2RX, S Yorkshire, England.
EM j.k.woodward@sheffield.ac.uk
OI Holen, Ingunn/0000 0002 8759 6913
FU Breast Cancer Now [2002:288] Funding Source: Medline
CR AMIN D, 1992, J LIPID RES, V33, P1657
   Benbow U, 1999, CLIN CANCER RES, V5, P203
   Bezzi M, 2003, J BIOL CHEM, V278, P43603, DOI 10.1074/jbc.M308114200
   Boissier S, 2000, CANCER RES, V60, P2949
   Boissier S, 1997, CANCER RES, V57, P3890
   Brown JE, 2004, ENDOCR RELAT CANCER, V11, P207, DOI 10.1677/erc.0.0110207
   Chen TL, 2002, J CLIN PHARMACOL, V42, P1228, DOI 10.1177/009127002762491316
   Chirgwin JM, 2000, CRIT REV EUKAR GENE, V10, P159, DOI 10.1615/CritRevEukarGeneExpr.v10.i2.50
   Coleman RE, 2004, BREAST, V13, pS19, DOI 10.1016/j.breast.2004.09.004
   Denoyelle C, 2003, BRIT J CANCER, V88, P1631, DOI 10.1038/sj.bjc.6600925
   Dunford JE, 2001, J PHARMACOL EXP THER, V296, P235
   Fromigue O, 2000, J BONE MINER RES, V15, P2211, DOI 10.1359/jbmr.2000.15.11.2211
   Green JR, 2001, SEMIN ONCOL, V28, P4, DOI 10.1053/sonc.2001.24154
   Jagdev SP, 2001, BRIT J CANCER, V84, P1126, DOI 10.1054/bjoc.2001.1727
   Käkönen SM, 2003, CANCER AM CANCER SOC, V97, P834, DOI 10.1002/cncr.11132
   Magnetto S, 1999, INT J CANCER, V83, P263, DOI 10.1002/(SICI)1097 0215(19991008)83:2<263::AID IJC19>3.0.CO;2 T
   Neville Webbe HL, 2005, INT J CANCER, V113, P364, DOI 10.1002/ijc.20602
   Neville Webbe HL, 2003, PALLIATIVE MED, V17, P539, DOI 10.1191/0269216303pm800ra
   Orr FW, 2000, J PATHOL, V190, P310, DOI 10.1002/(SICI)1096 9896(200002)190:3<310::AID PATH525>3.0.CO;2 P
   Oxford G, 2003, CANCER LETT, V189, P117, DOI 10.1016/S0304 3835(02)00510 4
   Rogers Michael J., 2000, Cancer, V88, P2961, DOI 10.1002/1097 0142(20000615)88:12+<2961::AID CNCR12>3.0.CO;2 L
   Rogers Michael J., 2003, Current Pharmaceutical Design, V9, P2643, DOI 10.2174/1381612033453640
   SATO M, 1991, J CLIN INVEST, V88, P2095, DOI 10.1172/JCI115539
   Senaratne SG, 2000, BRIT J CANCER, V82, P1459, DOI 10.1054/bjoc.1999.1131
   Shipman CM, 1997, BRIT J HAEMATOL, V98, P665, DOI 10.1046/j.1365 2141.1997.2713086.x
   Sliva D, 2001, CANCER INVEST, V19, P783, DOI 10.1081/CNV 100107739
   Stearns ME, 1996, INVAS METAST, V16, P116
   Terzis AJ, 1997, BRIT J CANCER, V75, P1744, DOI 10.1038/bjc.1997.298
   van Beek E, 1999, BIOCHEM BIOPH RES CO, V264, P108, DOI 10.1006/bbrc.1999.1499
   vanderPluijm G, 1996, CANCER RES, V56, P1948
   vanderPluijm G, 1996, J CLIN INVEST, V98, P698, DOI 10.1172/JCI118841
   Virtanen SS, 2002, CANCER RES, V62, P2708
   Vogt U, 2004, ONCOL REP, V12, P1109
   Wang F, 2003, J ASIAN NAT PROD RES, V5, P121, DOI 10.1080/1028602021000054973
   Westerlund A, 1997, CLIN EXP METASTAS, V15, P318, DOI 10.1023/A:1018481617275
   Witters LM, 2003, AM J CLIN ONCOL CANC, V26, pS92, DOI 10.1097/00000421 200308002 00011
NR 36
TC 41
Z9 44
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106 3261 USA
SN 0959 4973
J9 ANTI CANCER DRUG
JI Anti Cancer Drugs
PD SEP
PY 2005
VL 16
IS 8
BP 845
EP 854
DI 10.1097/01.cad.0000175582.01446.6f
PG 10
WC Oncology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Pharmacology & Pharmacy
GA 964GR
UT WOS:000231867800007
PM 16096432
DA 2025 08 17
ER

PT J
AU Yu, T
   You, XM
   Zhou, HC
   He, WB
   Li, ZH
   Li, B
   Xia, J
   Zhu, H
   Zhao, YG
   Yu, GR
   Xiong, Y
   Yang, YF
AF Yu, Tao
   You, Xiaomeng
   Zhou, Haichao
   He, Wenbao
   Li, Zihua
   Li, Bing
   Xia, Jiang
   Zhu, Hui
   Zhao, Youguang
   Yu, Guangrong
   Xiong, Yuan
   Yang, Yunfeng
TI MiR 16 5p regulates postmenopausal osteoporosis by directly targeting
   VEGFA
SO AGING US
LA English
DT Article
DE osteoporosis; osteogenesis; bone mass density; miR 16 5p; VEGFA
ID MESENCHYMAL STEM CELLS; OSTEOGENIC DIFFERENTIATION; ADIPOGENIC
   DIFFERENTIATION; BIOINFORMATICS; IDENTIFICATION; OSTEOBLAST; MICRORNA;
   GENES; SHIFT; TP53
AB In this study, we used bioinformatics tools, and experiments with patient tissues and human mesenchymal stem cells (hMSCs) to identify differentially regulated genes (DEGs) and microRNAs (miRNAs) that promote postmenopausal osteoporosis. By analyzing the GSE56815 dataset from the NCBI GEO database, we identified 638 DEGs, including 371 upregulated and 267 downregulated genes, in postmenopausal women with low bone density. Enrichment and protein protein interaction network analyses showed that TP53, RPS27A, and VEGFA were the top three hub genes with the highest degree of betweenness and closeness centrality. TargetScanHuman and DIANA software analyses and dual luciferase reporter assays confirmed that miR 16a 5p directly targets the 3'UTR of VEGFA. Postmenopausal patients with osteoporosis showed higher miR 16 5p and lower VEGFA levels than those without osteoporosis (n=10 each). VEGFA levels were higher in miR 16 5p knockdown hMSCs and were reduced in miR 16 5p overexpressing hMSCs. mRNA expression of osteogenic markers, ALP, OCN, and RUNX2, as well as calcium deposition based on Alizarin red staining, correlated inversely with miR 16 5p levels and correlated positively with VEGFA levels. These findings suggest that miR 16 5p suppresses osteogenesis by inhibiting VEGFA expression and is a promising target for postmenopausal osteoporosis therapy.
C1 [Yu, Tao; Zhou, Haichao; He, Wenbao; Li, Zihua; Li, Bing; Xia, Jiang; Zhu, Hui; Zhao, Youguang; Yu, Guangrong; Yang, Yunfeng] Tongji Univ, Tongji Hosp, Dept Orthoped Surg, Sch Med, Shanghai 200065, Peoples R China.
   [You, Xiaomeng] Harvard Med Sch, Brigham & Womens Hosp, Dept Orthoped Surg, Boston, MA 02115 USA.
   [Xiong, Yuan] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Orthoped, Wuhan 430022, Peoples R China.
C3 Tongji University; Harvard University; Harvard Medical School; Harvard
   University Medical Affiliates; Brigham & Women's Hospital; Huazhong
   University of Science & Technology
RP Yang, YF (通讯作者)，Tongji Univ, Tongji Hosp, Dept Orthoped Surg, Sch Med, Shanghai 200065, Peoples R China.; Xiong, Y (通讯作者)，Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Orthoped, Wuhan 430022, Peoples R China.
EM xiongyuanmed@163.com; yangyunfeng1051@126.com
RI Xiong, Yuan/AAQ 3642 2021; Li, Zihua/HJI 7616 2023; Yang,
   Yunfeng/JLM 4147 2023
OI Li, Zihua/0000 0002 6087 7459; Xiong, Yuan/0000 0003 1090 9288
FU National Science Foundation of China [31600754, 81472144]
FX This study was supported by the National Science Foundation of China
   (Grant Nos.31600754 and 81472144).
CR Agarwal V, 2015, ELIFE, V4, DOI 10.7554/eLife.05005
   Alberti C, 2018, NAT METHODS, V15, P283, DOI [10.1038/NMETH.4610, 10.1038/nmeth.4610]
   [Anonymous], 2016, ENCYCL GIS, DOI DOI 10.1007/978 3 319 23519 6_703 2
   Artigas N, 2017, CELL DEATH DIFFER, V24, P2022, DOI 10.1038/cdd.2017.113
   Behr B, 2011, STEM CELLS, V29, P286, DOI 10.1002/stem.581
   Burge R, 2007, J BONE MINER RES, V22, P465, DOI [10.1359/jbmr.061113, 10.1359/JBMR.061113]
   Cai BL, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 0403 6
   Cai X, 2018, OSTEOPOROSIS INT, V29, P2041, DOI 10.1007/s00198 018 4575 9
   Cao Z, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097098
   Carbonell P, 2016, NAT PROD REP, V33, P925, DOI 10.1039/c6np00018e
   Castaño IM, 2019, TISSUE ENG PT A, V25, P24, DOI 10.1089/ten.tea.2017.0460
   Charoenpanich A, 2014, TISSUE ENG PT A, V20, P67, DOI [10.1089/ten.tea.2013.0006, 10.1089/ten.TEA.2013.0006]
   Duan LJ, 2018, CELL PHYSIOL BIOCHEM, V51, P1087, DOI 10.1159/000495489
   Francis M, 2019, BIOMETALS, V32, P111, DOI 10.1007/s10534 018 00162 4
   Gu ZG, 2014, BIOINFORMATICS, V30, P2811, DOI 10.1093/bioinformatics/btu393
   Hausser J, 2014, NAT REV GENET, V15, P599, DOI 10.1038/nrg3765
   Henshall DC, 2016, LANCET NEUROL, V15, P1368, DOI 10.1016/S1474 4422(16)30246 0
   Hu K, 2016, J CLIN INVEST, V126, P509, DOI 10.1172/JCI82585
   Hui SY, 2019, SPINE J, V19, P1584, DOI 10.1016/j.spinee.2019.05.003
   Jia F, 2016, GENET TEST MOL BIOMA, V20, P398, DOI 10.1089/gtmb.2015.0282
   Kocijan R, 2016, J CLIN ENDOCR METAB, V101, P4125, DOI 10.1210/jc.2016 2365
   Lee KH, 2019, J TRANSL MED, V17, DOI 10.1186/s12967 019 2129 3
   Li GQ, 2019, EUR REV MED PHARMACO, V23, P4599, DOI 10.26355/eurrev_201906_18037
   Li HQ, 2014, BIOMARKERS, V19, P553, DOI 10.3109/1354750X.2014.935957
   Li ZQ, 2018, ACTA BIOCH BIOPH SIN, V50, P273, DOI 10.1093/abbs/gmy006
   Liu YQ, 2012, J CLIN INVEST, V122, P3101, DOI 10.1172/JCI61209
   Ma M, 2016, AGING CLIN EXP RES, V28, P1067, DOI 10.1007/s40520 015 0509 y
   Mangul S, 2019, NAT BIOTECHNOL, V37, P324, DOI 10.1038/s41587 019 0053 y
   McClung MR, 2019, LANCET DIABETES ENDO, V7, P899, DOI 10.1016/S2213 8587(19)30346 8
   Oliver F, 2012, DIFFERENTIATION, V83, P10, DOI 10.1016/j.diff.2011.08.008
   Paraskevopoulou MD, 2016, NUCLEIC ACIDS RES, V44, pD231, DOI 10.1093/nar/gkv1270
   Qian GF, 2019, MOL MED REP, V20, P3202, DOI 10.3892/mmr.2019.10570
   Qiao L, 2018, EUR REV MED PHARMACO, V22, P5804, DOI 10.26355/eurrev_201809_15906
   Qiu J, 2018, MOL MED REP, V17, P6301, DOI 10.3892/mmr.2018.8713
   Sang S, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/3173547
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI [10.1093/nar/gky1131, 10.1093/nar/gkac1000]
   Teufel A, 2015, J HEPATOL, V62, P712, DOI 10.1016/j.jhep.2014.10.036
   Toti P, 2013, ARCH ORAL BIOL, V58, P912, DOI 10.1016/j.archoralbio.2013.02.013
   Vijayakumar R, 2016, J LOCAL GLOBAL HLTH, V2016, DOI [DOI 10.5339/JLGHS.2016.2, 10.5339/jlghs.2016.2]
   Walter W, 2015, BIOINFORMATICS, V31, P2912, DOI 10.1093/bioinformatics/btv300
   Wang WW, 2017, EUR REV MED PHARMACO, V21, P5534, DOI 10.26355/eurrev_201712_13989
   Wang ZQ, 2012, INTRACTABLE RARE DIS, V1, P81, DOI 10.5582/irdr.2012.v1.2.81
   Xie WG, 2015, MED SCI MONITOR, V21, P1333, DOI 10.12659/MSM.894111
   Yan GM, 2019, BMC WOMENS HEALTH, V19, DOI 10.1186/s12905 019 0808 0
   You L, 2016, CELL PHYSIOL BIOCHEM, V39, P253, DOI 10.1159/000445621
NR 46
TC 44
Z9 50
U1 1
U2 19
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
SN 1945 4589
J9 AGING US
JI Aging US
PD MAY 31
PY 2020
VL 12
IS 10
BP 9500
EP 9514
DI 10.18632/aging.103223
PG 15
WC Cell Biology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Geriatrics & Gerontology
GA LU4HS
UT WOS:000537718700046
PM 32427128
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Takahashi, S
   Toyoda, A
   Sekiyama, Y
   Takagi, H
   Nogawa, T
   Uramoto, M
   Suzuki, R
   Koshino, H
   Kumano, T
   Panthee, S
   Dairi, T
   Ishikawa, J
   Ikeda, H
   Sakaki, Y
   Osada, H
AF Takahashi, Shunji
   Toyoda, Atsushi
   Sekiyama, Yasuyo
   Takagi, Hiroshi
   Nogawa, Toshihiko
   Uramoto, Masakazu
   Suzuki, Ryuichiro
   Koshino, Hiroyuki
   Kumano, Takuto
   Panthee, Suresh
   Dairi, Tohru
   Ishikawa, Jun
   Ikeda, Haruo
   Sakaki, Yoshiyuki
   Osada, Hiroyuki
TI Reveromycin A biosynthesis uses RevG and RevJ for stereospecific
   spiroacetal formation
SO NATURE CHEMICAL BIOLOGY
LA English
DT Article
ID MODULAR POLYKETIDE SYNTHASES; MYXOBACTERIUM SORANGIUM CELLULOSUM;
   EPIDERMAL GROWTH FACTOR; EUKARYOTIC CELL GROWTH; GENE CLUSTER;
   SACCHAROPOLYSPORA ERYTHRAEA; SACCHAROMYCES CEREVISIAE; OXIDATIVE
   CYCLIZATION; ENZYMATIC DOMAINS; OKADAIC ACID
AB Spiroacetal compounds are ubiquitous in nature, and their stereospecific structures are responsible for diverse pharmaceutical activities. Elucidation of the biosynthetic mechanisms that are involved in spiroacetal formation will open the door to efficient generation of stereospecific structures that are otherwise hard to synthesize chemically. However, the biosynthesis of these compounds is poorly understood, owing to difficulties in identifying the responsible enzymes and analyzing unstable intermediates. Here we comprehensively describe the spiroacetal formation involved in the biosynthesis of reveromycin A, which inhibits bone resorption and bone metastases of tumor cells by inducing apoptosis in osteoclasts. We performed gene disruption, systematic metabolite analysis, feeding of labeled precursors and conversion studies with recombinant enzymes. We identified two key enzymes, dihydroxy ketone synthase and spiroacetal synthase, and showed in vitro reconstruction of the stereospecific spiroacetal structure from a stable acyclic precursor. Our findings provide insights into the creation of a variety of biologically active spiroacetal compounds for drug leads.
C1 [Takahashi, Shunji; Sekiyama, Yasuyo; Takagi, Hiroshi; Nogawa, Toshihiko; Uramoto, Masakazu; Suzuki, Ryuichiro; Koshino, Hiroyuki; Kumano, Takuto; Panthee, Suresh; Osada, Hiroyuki] RIKEN Adv Sci Inst, Dept Biol Chem, Saitama, Japan.
   [Toyoda, Atsushi] Natl Inst Genet, Comparat Genom Lab, Shizuoka, Japan.
   [Dairi, Tohru] Hokkaido Univ, Fac Engn, Sapporo, Hokkaido 060, Japan.
   [Ishikawa, Jun] Natl Inst Infect Dis, Dept Bioact Mol, Tokyo, Japan.
   [Ikeda, Haruo] Kitasato Univ, Kitasato Inst Life Sci, Kanagawa, Japan.
   [Sakaki, Yoshiyuki] Toyohashi Univ Technol, Aichi, Japan.
C3 RIKEN; Research Organization of Information & Systems (ROIS); National
   Institute of Genetics (NIG)   Japan; Hokkaido University; Japan
   Institute for Health Security (JIHS); National Institute of Infectious
   Diseases (NIID); Kitasato University; Toyohashi University of Technology
RP Takahashi, S (通讯作者)，RIKEN Adv Sci Inst, Dept Biol Chem, Saitama, Japan.
EM hisyo@riken.jp
RI Panthee, Suresh/H 2754 2013; Nogawa, Toshihiko/ABG 2652 2020; Osada,
   Hiroyuki/AAY 6254 2020; Dairi, Tohru/A 5448 2012; Takahashi,
   Shunji/N 6921 2015; Koshino, Hiroyuki/N 7948 2015; Nogawa,
   Toshihiko/C 4095 2017; Sekiyama, Yasuyo/F 2561 2017; Kumano,
   Takuto/ABC 3242 2020
OI Panthee, Suresh/0000 0003 4021 7936; Dairi, Tohru/0000 0002 3406 7970;
   Sekiyama, Yasuyo/0000 0002 7057 0864; Kumano,
   Takuto/0000 0002 9240 4074; Koshino, Hiroyuki/0000 0002 0954 9839;
   Nogawa, Toshihiko/0000 0003 1270 5270; 
FU Naito Foundation; RIKEN; Ministry of Education, Culture, Sports, Science
   and Technology of Japan; Grants in Aid for Scientific Research
   [21580104, 22108010, 22108006] Funding Source: KAKEN
FX We thank T. Shimizu for discussions on spiroacetal formation; K. Wierzba
   for reading this paper; T. Nakamura for mass analysis; N. Dohmae for
   MALDI TOF and N terminal sequencing; and E. Oowada for technical
   assistance. We thank all the technical staff of the Sequence Technology
   Team at RIKEN Genomic Sciences Center for their assistance. This work
   was supported in part by the Naito Foundation, the Strategic Programs
   for R&D of RIKEN, a Grant in Aid for Creative Scientific Research and a
   Grant in Aid for Scientific Research (C) from the Ministry of Education,
   Culture, Sports, Science and Technology of Japan.
CR AGTARAP A, 1967, J AM CHEM SOC, V89, P5737, DOI 10.1021/ja00998a062
   Aparicio JF, 1996, GENE, V169, P9, DOI 10.1016/0378 1119(95)00800 4
   Benach J, 2002, BIOCHEMISTRY US, V41, P14659, DOI 10.1021/bi0203684
   BEVITT DJ, 1992, EUR J BIOCHEM, V204, P39, DOI 10.1111/j.1432 1033.1992.tb16603.x
   Bhatt A, 2005, ANGEW CHEM INT EDIT, V44, P7075, DOI 10.1002/anie.200501757
   BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283
   Bisang C, 1999, NATURE, V401, P502, DOI 10.1038/46829
   BURG RW, 1979, ANTIMICROB AGENTS CH, V15, P361, DOI 10.1128/AAC.15.3.361
   Caffrey P, 2003, CHEMBIOCHEM, V4, P654, DOI 10.1002/cbic.200300581
   Cui ZF, 1996, J BIOL CHEM, V271, P14712, DOI 10.1074/jbc.271.25.14712
   DONADIO S, 1992, GENE, V111, P51, DOI 10.1016/0378 1119(92)90602 L
   Frank B, 2007, CHEM BIOL, V14, P221, DOI 10.1016/j.chembiol.2006.11.013
   Gallimore AR, 2006, CHEM BIOL, V13, P453, DOI 10.1016/j.chembiol.2006.01.013
   HAYDOCK SF, 1995, FEBS LETT, V374, P246, DOI 10.1016/0014 5793(95)01119 Y
   Hertweck C, 2009, ANGEW CHEM INT EDIT, V48, P4688, DOI 10.1002/anie.200806121
   Höltzel A, 1998, J ANTIBIOT, V51, P699
   Ikeda H, 1999, P NATL ACAD SCI USA, V96, P9509, DOI 10.1073/pnas.96.17.9509
   ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006 291X(89)92189 X
   Ishikawa J, 1999, FEMS MICROBIOL LETT, V174, P251, DOI 10.1016/S0378 1097(99)00150 0
   Jing H, 2002, STRUCTURE, V10, P1453, DOI 10.1016/S0969 2126(02)00840 7
   Keatinge Clay A, 2008, J MOL BIOL, V384, P941, DOI 10.1016/j.jmb.2008.09.084
   Keatinge Clay AT, 2006, STRUCTURE, V14, P737, DOI 10.1016/j.str.2006.01.009
   KOSHINO H, 1992, J ANTIBIOT, V45, P1420, DOI 10.7164/antibiotics.45.1420
   Kwan DH, 2008, CHEM BIOL, V15, P1231, DOI 10.1016/j.chembiol.2008.09.012
   Li WL, 2008, J BIOL CHEM, V283, P28607, DOI 10.1074/jbc.M804279200
   MACKINTOSH C, 1990, FEBS LETT, V277, P137, DOI 10.1016/0014 5793(90)80828 7
   Mayerhofer LE, 1998, ARCH MICROBIOL, V169, P339, DOI 10.1007/s002030050580
   Miyamoto Y, 2002, J BIOL CHEM, V277, P28810, DOI 10.1074/jbc.M203827200
   Muguruma H, 2005, CLIN CANCER RES, V11, P8822, DOI 10.1158/1078 0432.CCR 05 1335
   Niggemann J, 2005, EUR J ORG CHEM, V2005, P5013, DOI 10.1002/ejoc.200500425
   Oliynyk M, 2003, MOL MICROBIOL, V49, P1179, DOI 10.1046/j.1365 2958.2003.03571.x
   OSADA H, 1991, J ANTIBIOT, V44, P259, DOI 10.7164/antibiotics.44.259
   Paterson I, 2009, CHEM ASIAN J, V4, P594, DOI 10.1002/asia.200800445
   Persson B, 2009, CHEM BIOL INTERACT, V178, P94, DOI 10.1016/j.cbi.2008.10.040
   Reid R, 2003, BIOCHEMISTRY US, V42, P72, DOI 10.1021/bi0268706
   Shafqat N, 2003, BIOCHEM J, V376, P49, DOI 10.1042/BJ20030877
   Sheppeck JE, 1997, J ORG CHEM, V62, P387, DOI 10.1021/jo961633s
   Shimizu T, 2000, ORG LETT, V2, P2153, DOI 10.1021/ol0060634
   Shimizu T, 2005, ORG LETT, V7, P5573, DOI 10.1021/ol052039k
   Staunton J, 2001, NAT PROD REP, V18, P380, DOI 10.1039/a909079g
   TAKAHASHI H, 1992, J ANTIBIOT, V45, P1414, DOI 10.7164/antibiotics.45.1414
   Takahashi H, 1997, ONCOL RES, V9, P7
   Tanaka Y, 2002, J ANTIBIOT, V55, P904, DOI 10.7164/antibiotics.55.904
   UBUKATA M, 1994, J CHEM SOC CHEM COMM, P1877, DOI 10.1039/c39940001877
   Weissman KJ, 2005, NAT REV MICROBIOL, V3, P925, DOI 10.1038/nrmicro1287
   WITKOWSKI A, 1991, J BIOL CHEM, V266, P18514
   Woo JT, 2006, P NATL ACAD SCI USA, V103, P4729, DOI 10.1073/pnas.0505663103
   Yano A, 2008, P NATL ACAD SCI USA, V105, P15541, DOI 10.1073/pnas.0805354105
NR 48
TC 73
Z9 80
U1 0
U2 41
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013 1917 USA
SN 1552 4450
EI 1552 4469
J9 NAT CHEM BIOL
JI Nat. Chem. Biol.
PD JUL
PY 2011
VL 7
IS 7
BP 461
EP 468
DI 10.1038/NCHEMBIO.583
PG 8
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA 785TF
UT WOS:000292252100014
PM 21642985
DA 2025 08 17
ER

PT J
AU Ehnes, DD
   Price, FD
   Shrive, NG
   Hart, DA
   Rancourt, DE
   zur Nieden, NJ
AF Ehnes, D. D.
   Price, F. D.
   Shrive, N. G.
   Hart, D. A.
   Rancourt, D. E.
   zur Nieden, N. J.
TI Embryonic stem cell derived osteocytes are capable of responding to
   mechanical oscillatory hydrostatic pressure
SO JOURNAL OF BIOMECHANICS
LA English
DT Article
DE Embryonic stem cell; Mechanotransduction; Osteoblast; Beta catenin;
   Nitric oxide synthetase
ID NITRIC OXIDE SYNTHASE; FLOW SHEAR STRESS; GENE EXPRESSION;
   BONE FORMATION; IN VITRO; BETA CATENIN; OSTEOGENIC DIFFERENTIATION;
   SIGNAL TRANSDUCTION; ENDOTHELIAL CELLS; STRAIN
AB Osteoblasts can be derived from embryonic stem cells (ESCs) by a 30 day differentiation process, whereupon cells spontaneously differentiate upon removal of LIF and respond to exogenously added 1,25 alpha(OH)(2) vitamin D 3 with enhanced matrix mineralization. However, bone is a load bearing tissue that has to perform under dynamic pressure changes during daily movement, a capacity that is executed by osteocytes. At present, it is unclear whether ESC derived osteogenic cultures contain osteocytes and whether these are capable of responding to a relevant cyclic hydrostatic compression stimulus. Here, we show that ESC osteoblastogenesis is followed by the generation of osteocytes and then mechanically load ESC derived osteogenic cultures in a compression chamber using a cyclic loading protocol. Following mechanical loading of the cells, iNOS mRNA was upregulated 31 fold, which was consistent with a role for iNOS as an immediate early mechanoresponsive gene. Further analysis of matrix and bone specific genes suggested a cellular response in favor of matrix remodeling. Immediate iNOS upregulation also correlated with a concomitant increase in Ctnnb1 and Tcf7l2 mRNAs along with increased nuclear TCF transcriptional activity, while the mRNA for the repressive Tcf7l1 was down regulated, providing a possible mechanistic explanation for the noted matrix remodeling. We conclude that ESC derived osteocytes are capable of responding to relevant mechanical cues, at least such that mimic oscillatory compression stress, which not only provides new basic understanding, but also information that likely will be important for their use in cell based regenerative therapies. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Ehnes, D. D.; zur Nieden, N. J.] Univ Calif Riverside, Dept Cell Biol & Neurosci, Riverside, CA 92521 USA.
   [Ehnes, D. D.; zur Nieden, N. J.] Univ Calif Riverside, Stem Cell Ctr, Coll Nat & Agr Sci, Riverside, CA 92521 USA.
   [Price, F. D.; Rancourt, D. E.; zur Nieden, N. J.] Univ Calgary, Alberta Childrens Hosp Res Inst, Calgary, AB T2N 4N1, Canada.
   [Shrive, N. G.; Hart, D. A.] Univ Calgary, McCaig Inst Bone & Joint Hlth, Calgary, AB T2N 4N1, Canada.
C3 University of California System; University of California Riverside;
   University of California System; University of California Riverside;
   University of Calgary; University of Calgary
RP zur Nieden, NJ (通讯作者)，Univ Calif Riverside, Dept Cell Biol & Neurosci, 1113 Biol Sci Bldg, Riverside, CA 92521 USA.
EM nicole.zurnieden@ucr.edu
FU Alberta Innovates Health Solutions and its predecessor; Alberta Heritage
   Foundation for Medical Research; Killam Trust
FX The authors would like to acknowledge the financial support from Alberta
   Innovates Health Solutions and its predecessor, the Alberta Heritage
   Foundation for Medical Research, through a postdoctoral fellowship for
   NzN, a Youth Researcher Summer Fellowship for FDP and a Senior
   Scholarship for DER. NGS was supported by the Killam Trust. We are
   further deeply grateful to Kent Paulsen for servicing the compression
   chamber setup and providing excellent technical assistance. We would
   also like to express our sincere thanks to Irving Weissman (Stanford
   University) for providing the LEF/TCF Gfp reporter cell line.
CR Adams DJ, 1997, J BIOMECH, V30, P671, DOI 10.1016/S0021 9290(97)00004 3
   Adyshev DM, 2014, AM J RESP CELL MOL, V50, P409, DOI 10.1165/rcmb.2013 0292OC
   Aguirre J, 2001, AM J PATHOL, V158, P247, DOI 10.1016/S0002 9440(10)63963 6
   Armour KE, 2001, ENDOCRINOLOGY, V142, P760, DOI 10.1210/en.142.2.760
   Armour KJ, 2001, ARTHRITIS RHEUM, V44, P2790, DOI 10.1002/1529 0131(200112)44:12<2790::AID ART466>3.0.CO;2 X
   Bacabac RG, 2004, BIOCHEM BIOPH RES CO, V315, P823, DOI 10.1016/j.bbrc.2004.01.138
   Bakker AD, 2013, CALCIFIED TISSUE INT, V92, P228, DOI 10.1007/s00223 012 9670 x
   Bertin A, 2015, HISTOCHEM CELL BIOL, V143, P431, DOI 10.1007/s00418 014 1289 8
   Bilousova G, 2011, STEM CELLS, V29, P206, DOI 10.1002/stem.566
   Bonewald LF, 2008, BONE, V42, P606, DOI 10.1016/j.bone.2007.12.224
   Bonewald LF, 2011, J BONE MINER RES, V26, P229, DOI 10.1002/jbmr.320
   Bourne S, 2004, TISSUE ENG, V10, P796, DOI 10.1089/1076327041348293
   Buttery LDK, 2001, TISSUE ENG, V7, P89, DOI 10.1089/107632700300003323
   Chen BPC, 2001, PHYSIOL GENOMICS, V7, P55, DOI 10.1152/physiolgenomics.2001.7.1.55
   Chen JC, 2015, J BIOMECH ENG T ASME, V137, DOI 10.1115/1.4029551
   Compton JT, 2014, J BONE JOINT SURG AM, V96A, P1659, DOI 10.2106/JBJS.M.01096
   Cuzzocrea S, 2003, ENDOCRINOLOGY, V144, P1098, DOI 10.1210/en.2002 220597
   Damaraju S, 2014, TISSUE ENG PT A, V20, P3142, DOI [10.1089/ten.tea.2014.0026, 10.1089/ten.TEA.2014.0026]
   Das Gupta V, 2012, OSTEOPOROSIS INT, V23, P2635, DOI 10.1007/s00198 012 1957 2
   Davis LA, 2008, CELL MOL LIFE SCI, V65, P2658, DOI 10.1007/s00018 008 8042 1
   Dawson JI, 2013, CYTOTHERAPY, V15, P242, DOI 10.1016/j.jcyt.2012.09.004
   Ding HW, 2012, J CELL SCI, V125, P5564, DOI 10.1242/jcs.081703
   Du YH, 2008, CIRCULATION, V117, P1045, DOI 10.1161/CIRCULATIONAHA.107.748236
   Dunn J, 2014, J CLIN INVEST, V124, P3187, DOI 10.1172/JCI74792
   Ehrlich PJ, 2002, OSTEOPOROSIS INT, V13, P688, DOI 10.1007/s001980200095
   Feng JQ, 2006, NAT GENET, V38, P1310, DOI 10.1038/ng1905
   Galli C, 2010, J DENT RES, V89, P331, DOI 10.1177/0022034510363963
   Gosgnach W, 2000, AM J PHYSIOL CELL PH, V279, pC1880, DOI 10.1152/ajpcell.2000.279.6.C1880
   Guo DY, 2010, PROTEOMICS, V10, P3688, DOI 10.1002/pmic.201000306
   Johnson DL, 1996, AM J PHYSIOL ENDOC M, V271, pE205, DOI 10.1152/ajpendo.1996.271.1.E205
   JONES DB, 1991, BIOMATERIALS, V12, P101, DOI 10.1016/0142 9612(91)90186 E
   Kamel MA, 2010, BONE, V47, P872, DOI 10.1016/j.bone.2010.08.007
   Kang HK, 2008, INT J MOL MED, V21, P539
   Kapur S, 2003, BONE, V32, P241, DOI 10.1016/S8756 3282(02)00979 1
   Klein Nulend J, 2012, EUR CELLS MATER, V24, P278, DOI 10.22203/eCM.v024a20
   Klein Nulend J, 2013, BONE, V54, P182, DOI 10.1016/j.bone.2012.10.013
   KLEINNULEND J, 1995, FASEB J, V9, P441, DOI 10.1096/fasebj.9.5.7896017
   Kramer J, 2000, MECH DEVELOP, V92, P193, DOI 10.1016/S0925 4773(99)00339 1
   Li F, 2012, BMC CELL BIOL, V13, DOI 10.1186/1471 2121 13 35
   Lin CW, 2009, J BONE MINER RES, V24, P1651, DOI [10.1359/JBMR.090411, 10.1359/jbmr.090411]
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Majima T, 2000, J Orthop Sci, V5, P503, DOI 10.1007/s007760070030
   McCormick SM, 2001, P NATL ACAD SCI USA, V98, P8955, DOI 10.1073/pnas.171259298
   Myers KA, 2007, J BIOSCI BIOENG, V103, P578, DOI 10.1263/jbb.103.578
   Nguyen H, 2006, CELL, V127, P171, DOI 10.1016/j.cell.2006.07.036
   Norvell SM, 2004, CALCIFIED TISSUE INT, V75, P396, DOI 10.1007/s00223 004 0213 y
   Ochiai Shino H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099534
   Ott CE, 2009, J BONE MINER RES, V24, P1247, DOI [10.1359/JBMR.090206, 10.1359/jbmr.090206]
   Ozawa N, 2004, HYPERTENS RES, V27, P93, DOI 10.1291/hypres.27.93
   Papachristou DJ, 2009, BIOESSAYS, V31, P794, DOI 10.1002/bies.200800223
   Pereira L, 2006, MOL CELL BIOL, V26, P7479, DOI 10.1128/MCB.00368 06
   Phillips BW, 2001, BIOCHEM BIOPH RES CO, V284, P478, DOI 10.1006/bbrc.2001.4987
   Pitsillides AA, 1995, FASEB J, V9, P1614, DOI 10.1096/fasebj.9.15.8529841
   Poole KES, 2005, FASEB J, V19, P1842, DOI 10.1096/fj.05 4221fje
   Qin YX, 1998, J ORTHOPAED RES, V16, P482, DOI 10.1002/jor.1100160414
   RANJAN V, 1995, AM J PHYSIOL HEART C, V269, pH550, DOI 10.1152/ajpheart.1995.269.2.H550
   Robling AG, 2001, J EXP BIOL, V204, P3389
   Robling AG, 2008, J BIOL CHEM, V283, P5866, DOI 10.1074/jbc.M705092200
   Robling AG, 2009, CRIT REV EUKAR GENE, V19, P319, DOI 10.1615/CritRevEukarGeneExpr.v19.i4.50
   Rubin C, 1996, J BONE JOINT SURG AM, V78A, P1523, DOI 10.2106/00004623 199610000 00010
   RUBIN CT, 1984, J BONE JOINT SURG AM, V66A, P397, DOI 10.2106/00004623 198466030 00012
   Santos A, 2010, BIOCHEM BIOPH RES CO, V391, P364, DOI 10.1016/j.bbrc.2009.11.064
   Sauer H, 2011, J CELL PHYSIOL, V226, P1642, DOI 10.1002/jcp.22495
   Smalt R, 1997, AM J PHYSIOL ENDOC M, V273, pE751, DOI 10.1152/ajpendo.1997.273.4.E751
   Sottile V, 2003, CLONING STEM CELLS, V5, P149, DOI 10.1089/153623003322234759
   Tasevski V, 2005, BIOCHEM CELL BIOL, V83, P96, DOI 10.1139/O04 124
   Tatsumi S, 2007, CELL METAB, V5, P464, DOI 10.1016/j.cmet.2007.05.001
   Thaler JD, 2014, BIOL SEX DIFFER, V5, DOI 10.1186/s13293 014 0014 6
   Trettner S, 2014, OSTEOPOROSIS INT, V25, P1255, DOI 10.1007/s00198 013 2566 4
   Trettner S, 2011, METHODS MOL BIOL, V690, P135, DOI 10.1007/978 1 60761 962 8_9
   Tu XL, 2012, BONE, V50, P209, DOI 10.1016/j.bone.2011.10.025
   Umemura Y, 1997, J BONE MINER RES, V12, P1480, DOI 10.1359/jbmr.1997.12.9.1480
   Vazquez M, 2014, FRONT ENDOCRINOL, V5, DOI 10.3389/fendo.2014.00208
   Watanuki M, 2002, J BONE MINER RES, V17, P1015, DOI 10.1359/jbmr.2002.17.6.1015
   zur Nieden NI, 2005, BMC DEV BIOL, V5, DOI 10.1186/1471 213X 5 1
   zur Nieden NI, 2003, DIFFERENTIATION, V71, P18, DOI 10.1046/j.1432 0436.2003.700602.x
   zur Nieden NI, 2007, MOL ENDOCRINOL, V21, P674, DOI 10.1210/me.2005 0438
   zur Nieden NI, 2010, TOXICOL APPL PHARM, V247, P91, DOI 10.1016/j.taap.2010.05.010
NR 78
TC 8
Z9 12
U1 0
U2 13
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0021 9290
EI 1873 2380
J9 J BIOMECH
JI J. Biomech.
PD JUL 16
PY 2015
VL 48
IS 10
BP 1915
EP 1921
DI 10.1016/j.jbiomech.2015.04.015
PG 7
WC Biophysics; Engineering, Biomedical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biophysics; Engineering
GA CN5HG
UT WOS:000358459800032
PM 25936968
DA 2025 08 17
ER

PT J
AU Tang, XF
   Gao, YY
   Chen, YH
   Li, XX
   Yu, P
   Ma, ZT
   Liu, RH
AF Tang, Xiufeng
   Gao, Yingying
   Chen, Yuheng
   Li, Xiaoxi
   Yu, Ping
   Ma, Zitong
   Liu, Renhui
TI Evaluation of the effect of CaD on the bone structure and bone metabolic
   changes in senile osteoporosis rats based on MLP ANN methods
SO FOOD & FUNCTION
LA English
DT Article
ID POSTMENOPAUSAL WOMEN; OSTEOBLASTS; IGF 1; MASS; DIFFERENTIATION;
   FRACTURES; MIXTURE; NETWORK; PATHWAY; HEALTH
AB Senile osteoporosis (SOP) is a related disease of systematic degenerative changes in bones during natural aging. Increasing age is an important factor in its pathogenesis. This experiment was to evaluate the comprehensive effect of calcium with vitamin D3 (CaD) on SOP based on multilayer perception (MLP) artificial neural network (ANN) methods. 15 month old male Sprague Dawley rats were administered CaD for 2 months, while 3 , 6 , 9 , 12 , 15  and 17 month old rats were used as the mature or aging control groups. We detected the bone mass and bone mineral density (BMD), performed biomechanical testing and measured micro CT properties to evaluate the degree of osteoporosis. Levels of alkaline phosphatase (ALP) and tartrate resistant acid phosphatase (TRACP), and the ratio of ALP to TRACP both in serum and bone were measured for the evaluation of the bone turnover rate. The bone mRNA and protein expression of ATP6v0d2, IGF 1, BMP2, M CSF, Wnt5a and TGF beta 1 were detected by western blotting (WB), immunofluorescence (IF) and quantitative real time polymerase chain reaction (qRT PCR) for evaluating bone metabolism in the bone microenvironment. The MLP ANN model was constructed and used to evaluate the importance of related parameters and the comprehensive action of CaD. Our data showed that bone mass, BMD, maximal load, ultimate displacement, ALP and TRACP in serum and tibia, and the protein and mRNA expressions of ATP6v0d2, IGF 1, BMP2, M CSF, Wnt5a and TGF beta 1 in tibia reached a peak in 6 m rats, and then were gradually decreased with the increase of age to the lowest in 17 m rats. This study demonstrated the degeneration of the bone structure and bone metabolism in SOP rats during the aging process of rats aged 3 to 17 months. CaD could effectively increase bone mass and bone strength, alleviate the degradation of the bone microstructure and rebalance bone remodeling. In addition, the MLP model was a comprehensive method for evaluating the effects of drugs on SOP, which provided a new direction for future drug and nutrition evaluation.
C1 [Liu, Renhui] Capital Med Univ, Sch Tradit Chinese Med, 10 Xitoutiao, Beijing 100069, Peoples R China.
   Beijing Key Lab TCM Collateral Dis Theory Res, 10 Xitoutiao, Beijing 100069, Peoples R China.
C3 Capital Medical University
RP Liu, RH (通讯作者)，Capital Med Univ, Sch Tradit Chinese Med, 10 Xitoutiao, Beijing 100069, Peoples R China.
EM tangxf927@126.com; yingying1039@163.com; angela2155110@163.com;
   lixiaoxi0314@163.com; 373718234@qq.com; mzt199511@163.com;
   gzblrh45@ccmu.edu.cn
RI zitong, Ma/LFS 4594 2024
FU National Natural Science Foundation of China [81673993, 81873115];
   Planned Project on Beijing Traditional Chinese Medicine inheritance of
   "3+3 Programme" of the Beijing Chinese Medicine Administration Bureau
   [2012 SZ C 42]
FX This work was supported by grants from the National Natural Science
   Foundation of China (No. 81673993 and 81873115) and the Planned Project
   on Beijing Traditional Chinese Medicine inheritance of "3+3 Programme"
   of the Beijing Chinese Medicine Administration Bureau (No.
   2012 SZ C 42).
CR Aguiar FS, 2016, MED BIOL ENG COMPUT, V54, P1751, DOI 10.1007/s11517 016 1465 1
   Akbar MA, 2017, MOL MED, V23, P57, DOI 10.2119/molmed.2016.00170
   Almeida M, 2017, PHYSIOL REV, V97, P135, DOI 10.1152/physrev.00033.2015
   Ashpole NM, 2016, J BONE MINER RES, V31, P443, DOI 10.1002/jbmr.2689
   Atkinson HF, 2019, BMC MUSCULOSKEL DIS, V20, DOI 10.1186/s12891 019 2547 7
   Baschant U, 2016, HAEMATOLOGICA, V101, P1499, DOI 10.3324/haematol.2016.144808
   Briggs AM, 2016, GERONTOLOGIST, V56, pS243, DOI 10.1093/geront/gnw002
   Chapurlat RD, 2007, J BONE MINER RES, V22, P1502, DOI 10.1359/JBMR.070609
   Chawalitpong S, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 23912 3
   Chen M, 2011, IMMUNOLOGY, V132, P376, DOI 10.1111/j.1365 2567.2010.03392.x
   Cheng SY, 2011, OSTEOPOROSIS INT, V22, P2575, DOI 10.1007/s00198 011 1596 z
   Chung HJ, 2017, J NAT PROD, V80, P434, DOI 10.1021/acs.jnatprod.6b00964
   Ciubean AD, 2018, CLIN INTERV AGING, V13, P2465, DOI 10.2147/CIA.S190440
   Ebrahimpour R, 2011, MACH VISION APPL, V22, P421, DOI 10.1007/s00138 009 0232 9
   Engelke K, 2008, J CLIN DENSITOM, V11, P123, DOI 10.1016/j.jocd.2007.12.010
   Gamsjaeger S, 2011, J BONE MINER RES, V26, P12, DOI 10.1002/jbmr.180
   Gao ST, 2018, BMC MUSCULOSKEL DIS, V19, DOI 10.1186/s12891 018 2066 y
   Hu ZB, 2018, EXP THER MED, V16, P811, DOI 10.3892/etm.2018.6220
   Hyun SY, 2017, MOL CELLS, V40, P550, DOI 10.14348/molcells.2017.0019
   Içer S, 2006, EXPERT SYST APPL, V31, P406, DOI 10.1016/j.eswa.2005.09.037
   Iwamoto I, 2004, GYNECOL ENDOCRINOL, V19, P97, DOI 10.1080/09513590412331284389
   Jao HY, 2016, FOOD FUNCT, V7, P4753, DOI 10.1039/c6fo00852f
   Johnston BD, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/635023
   Karsenty G, 2010, J CLIN ENDOCR METAB, V95, P4795, DOI 10.1210/jc.2010 1030
   Khosla S, 2017, LANCET DIABETES ENDO, V5, P898, DOI 10.1016/S2213 8587(17)30188 2
   Kim T, 2010, BIOCHEM BIOPH RES CO, V403, P73, DOI 10.1016/j.bbrc.2010.10.117
   Krajisnik D, 2014, J PHARM SCI US, V103, P1085, DOI 10.1002/jps.23869
   Lee SS, 2012, BIOMATERIALS, V33, P4251, DOI 10.1016/j.biomaterials.2012.03.005
   Lee SH, 2006, NAT MED, V12, P1403, DOI 10.1038/nm1514
   Li M, 2016, J ETHNOPHARMACOL, V185, P120, DOI 10.1016/j.jep.2016.03.023
   Liu JM, 2008, J BONE MINER METAB, V26, P159, DOI 10.1007/s00774 007 0799 z
   Liu RH, 2015, EVID BASED COMPL ALT, V2015, DOI 10.1155/2015/184802
   Lizneva D, 2018, MATRIX BIOL, V71 72, P70, DOI 10.1016/j.matbio.2018.05.001
   Maeda K, 2012, NAT MED, V18, P405, DOI 10.1038/nm.2653
   Odén A, 2013, CALCIFIED TISSUE INT, V92, P42, DOI 10.1007/s00223 012 9666 6
   Ouyang YC, 2014, NEUROCOMPUTING, V135, P171, DOI 10.1016/j.neucom.2013.12.037
   Paccou J, 2012, JOINT BONE SPINE, V79, P78, DOI 10.1016/j.jbspin.2011.06.002
   Park KH, 2011, J PINEAL RES, V51, P187, DOI 10.1111/j.1600 079X.2011.00875.x
   Park So Young, 2018, [Journal of Bone Metabolism, 대한골대사학회지], V25, P195
   Pietschmann P, 2007, EXP GERONTOL, V42, P1099, DOI 10.1016/j.exger.2007.08.008
   Raisz LG, 2003, ENDOCRIN METAB CLIN, V32, P15, DOI 10.1016/S0889 8529(02)00055 5
   Santibanez Juan F, 2012, Biomol Concepts, V3, P429, DOI 10.1515/bmc 2012 0015
   Segredo Morales E, 2018, INT J PHARMACEUT, V543, P160, DOI 10.1016/j.ijpharm.2018.03.034
   Shuai B, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132104
   Sims NA, 2015, FRONT ENDOCRINOL, V6, DOI 10.3389/fendo.2015.00041
   Song Shuang hong, 2015, Yaoxue Xuebao, V50, P154
   Springo Z, 2015, J CEREBR BLOOD F MET, V35, P527, DOI 10.1038/jcbfm.2014.256
   Sugiyama Toshihiro, 2017, Front Endocrinol (Lausanne), V8, P46, DOI 10.3389/fendo.2017.00046
   Wang AG, 2015, EXPERT SYST APPL, V42, P7601, DOI 10.1016/j.eswa.2015.06.012
   Wen SZ, 2016, SCI REP UK, V6, DOI 10.1038/srep36313
   Yamashita T, 2012, WORLD J ORTHOP, V3, P175, DOI 10.5312/wjo.v3.i11.175
   Yang Y, 2017, J ETHNOPHARMACOL, V201, P91, DOI 10.1016/j.jep.2017.02.033
   Yuan X., 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/6869452
   Zeng Yuqing, 2017, Zhongguo Zhen Jiu, V37, P473, DOI 10.13703/j.0255 2930.2017.05.005
   Zhu CT, 2017, EUR REV MED PHARMACO, V21, P5230, DOI 10.26355/eurrev_201711_13846
   Zur Y, 2017, BIOCHEM J, V474, P2601, DOI 10.1042/BCJ20170276
NR 56
TC 14
Z9 15
U1 1
U2 19
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2042 6496
EI 2042 650X
J9 FOOD FUNCT
JI Food Funct.
PD DEC 1
PY 2019
VL 10
IS 12
BP 8026
EP 8041
DI 10.1039/c9fo01322a
PG 16
WC Biochemistry & Molecular Biology; Food Science & Technology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Food Science & Technology
GA KD1PE
UT WOS:000507643700036
PM 31763639
DA 2025 08 17
ER

PT J
AU Klop, C
   Welsing, PMJ
   Elders, PJM
   Overbeek, JA
   Souverein, PC
   Burden, AM
   van Onzenoort, HAW
   Leufkens, HGM
   Bijlsma, JWJ
   de Vries, F
AF Klop, C.
   Welsing, P. M. J.
   Elders, P. J. M.
   Overbeek, J. A.
   Souverein, P. C.
   Burden, A. M.
   van Onzenoort, H. A. W.
   Leufkens, H. G. M.
   Bijlsma, J. W. J.
   de Vries, F.
TI Long term persistence with anti osteoporosis drugs after fracture
SO OSTEOPOROSIS INTERNATIONAL
LA English
DT Article
DE Epidemiology; Fracture prevention; Osteoporosis; Persistence;
   Therapeutics
ID RANDOMIZED CONTROLLED TRIAL; POSTMENOPAUSAL WOMEN; MEDICATION ADHERENCE;
   ORAL BISPHOSPHONATES; SECONDARY PREVENTION; VERTEBRAL FRACTURE; RISK;
   THERAPY; NONADHERENCE; EXPOSURE
AB A Summary Long term persistence with anti osteoporosis drugs and determinants for discontinuation among fracture patients were examined. Persistence was 75.0 and 45.3 % after 1 and 5 years, respectively. Those aged >= 80 years were at increased risk of early discontinuation. Within 1 year after discontinuation, 24.3 % restarted therapy, yet 47.0 % persisted for 1 year.
   Introduction The risk of osteoporotic fracture can effectively be reduced with use of anti osteoporosis drugs. However, little is known about persistence with these drugs after fracture where subsequent fracture risk is high. The aims were to determine long term persistence with anti osteoporosis drugs among fracture patients, including its determinants, and to describe restart and subsequent persistence.
   Methods A cohort study was conducted within the Dutch PHARMO Database Network. Patients aged >= 50 years (n = 961) who received anti osteoporosis drugs within 1 year after fracture, but not in the preceding year, were included (2002 2011). Persistence (defined as the proportion on treatment) and the proportion restarting after discontinuation were estimated using Kaplan Meier analyses. Time dependent Cox regression was used to identify determinants of non persistence including age, sex, initial dosage regime, fracture type, comorbidities, and drug use.
   Results Persistence with anti osteoporosis drugs was 75.0 % (95 % confidence interval (CI) 72.0 77.7) and 45.3 % (95 % CI 40.4 50.0) after 1 and 5 years, respectively. A significant determinant of non persistence was age >= 80 years (reference 50 59 years: adjusted hazard ratio [adj. HR] 1.65; 95 % CI 1.15 2.38). This effect was not constant over time (<= 360 days following initiation: adj. HR 2.07; 95 % CI 1.27 3.37; >360 days: adj. HR 1.08; 95 % CI 0.62 1.88). Within 1 year after discontinuation, 24.3 % (95 % CI 20.1 29.2) restarted therapy, yet 47.0 % persisted for 1 year.
   Conclusions This study identified suboptimal persistence with anti osteoporosis drugs among fracture patients. Major target groups for measures aimed to improve persistence may be those aged > 80 years and those restarting therapy.
C1 [Klop, C.; Souverein, P. C.; Burden, A. M.; Leufkens, H. G. M.; de Vries, F.] Univ Utrecht, Utrecht Inst Pharmaceut Sci, Div Pharmacoepidemiol & Clin Pharmacol, Utrecht, Netherlands.
   [Welsing, P. M. J.; Bijlsma, J. W. J.] Univ Med Ctr, Dept Rheumatol & Clin Immunol, Utrecht, Netherlands.
   [Welsing, P. M. J.] Univ Med Ctr, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands.
   [Elders, P. J. M.] Vrije Univ Amsterdam, Med Ctr, Dept Gen Practice & Elderly Care, Amsterdam, Netherlands.
   [Overbeek, J. A.] PHARMO Inst Drug Outcomes Res, Utrecht, Netherlands.
   [Burden, A. M.; van Onzenoort, H. A. W.; de Vries, F.] Maastricht Univ, Med Ctr, Dept Clin Pharm & Toxicol, NL 6200 MD Maastricht, Netherlands.
   [de Vries, F.] Southampton Gen Hosp, MRC Lifecourse Epidemiol Unit, Southampton SO9 4XY, Hants, England.
   [van Onzenoort, H. A. W.] Radboud Univ Nijmegen, Med Ctr, Dept Pharm, NL 6525 ED Nijmegen, Netherlands.
C3 Utrecht University; Utrecht University; Utrecht University Medical
   Center; Utrecht University; Utrecht University Medical Center; Vrije
   Universiteit Amsterdam; Maastricht University; University of
   Southampton; Radboud University Nijmegen
RP de Vries, F (通讯作者)，Univ Utrecht, Utrecht Inst Pharmaceut Sci, Div Pharmacoepidemiol & Clin Pharmacol, Utrecht, Netherlands.
EM f.devries@uu.nl
RI ; van Onzenoort, Hein/A 1730 2016; Burden, Andrea/B 3004 2016; de Vries,
   Frank/E 4934 2011; Overbeek, Jetty/AAG 1770 2019
OI Elders, Petra/0000 0002 5907 7219; Burden, Andrea/0000 0001 7082 8530;
   de Vries, Frank/0000 0003 3837 8319; Souverein,
   Patrick/0000 0002 7452 0477; van Onzenoort, Hein/0000 0002 3272 2898;
   Overbeek, Jetty/0000 0003 0935 5193
FU Netherlands Organization for Health Research and Development [ZonMw]
   [113101007]
FX This study was supported by a research grant from The Netherlands
   Organization for Health Research and Development [ZonMw; grant number
   113101007].
CR [Anonymous], 2008, Knowl. Inf. Systeme., DOI DOI 10.1002/14651858.CD001155.PUB2
   [Anonymous], ARTHRITIS CARE RES, DOI DOI 10.1002/ACR.21563
   Balasubramanian A, 2013, INT J GEN MED, V6, P839, DOI 10.2147/IJGM.S36944
   Boudou L, 2011, OSTEOPOROSIS INT, V22, P2099, DOI 10.1007/s00198 011 1638 6
   Brookhart MA, 2007, AM J MED, V120, P251, DOI 10.1016/j.amjmed.2006.03.029
   Burden AM, 2012, OSTEOPOROSIS INT, V23, P1075, DOI 10.1007/s00198 011 1645 7
   Buurma H, 2008, J CLIN PHARM THER, V33, P17, DOI 10.1111/j.1365 2710.2008.00878.x
   Confavreux CB, 2012, EUR J ENDOCRINOL, V166, P735, DOI 10.1530/EJE 11 0959
   Cramer JA, 2007, OSTEOPOROSIS INT, V18, P1023, DOI 10.1007/s00198 006 0322 8
   Curtis JR, 2013, BONE, V55, P1, DOI 10.1016/j.bone.2013.03.003
   Dehamchia Rehailia N, 2014, OSTEOPOROSIS INT, V25, P2409, DOI 10.1007/s00198 014 2774 6
   Eekman DA, 2014, OSTEOPOROSIS INT, V25, P701, DOI 10.1007/s00198 013 2481 8
   Ganda K, 2014, OSTEOPOROSIS INT, V25, P1345, DOI 10.1007/s00198 013 2610 4
   Gardarsdottir H, 2010, J CLIN EPIDEMIOL, V63, P422, DOI 10.1016/j.jclinepi.2009.07.001
   Geers HCJ, 2011, ANN PHARMACOTHER, V45, P576, DOI 10.1345/aph.1P607
   Gibson Smith D, 2014, OSTEOPOROSIS INT, V25, P2555, DOI 10.1007/s00198 014 2799 x
   Grymonpre R, 2006, MED CARE, V44, P471, DOI 10.1097/01.mlr.0000207817.32496.cb
   Hadji P, 2012, OSTEOPOROSIS INT, V23, P223, DOI 10.1007/s00198 011 1535 z
   Hiligsmann M, 2013, OSTEOPOROSIS INT, V24, P2907, DOI 10.1007/s00198 013 2364 z
   Huntjens KMB, 2010, OSTEOPOROSIS INT, V21, P2075, DOI 10.1007/s00198 010 1178 5
   Kanis JA, 1999, J ENDOCRINOL INVEST, V22, pXX
   Kothawala P, 2007, MAYO CLIN PROC, V82, P1493, DOI 10.4065/82.12.1493
   Lau HS, 1997, J CLIN EPIDEMIOL, V50, P619, DOI 10.1016/S0895 4356(97)00040 1
   Li L, 2012, MENOPAUSE, V19, P33, DOI 10.1097/gme.0b013e318221bacd
   Lindsay R, 2001, JAMA J AM MED ASSOC, V285, P320, DOI 10.1001/jama.285.3.320
   Lo JC, 2006, OSTEOPOROSIS INT, V17, P922, DOI 10.1007/s00198 006 0085 2
   McHorney CA, 2007, CURR MED RES OPIN, V23, P3137, DOI 10.1185/030079907X242890
   Meijer WM, 2008, CURR MED RES OPIN, V24, P3217, DOI 10.1185/03007990802470241
   Montori VM, 2011, AM J MED, V124, P549, DOI 10.1016/j.amjmed.2011.01.013
   Morin SN, 2014, J BONE MINER RES, V29, P1675, DOI 10.1002/jbmr.2204
   National Institute for Clinical Excellence (NICE), 2008, SYST REV CLIN EFF PR
   Netelenbos JC, 2011, OSTEOPOROSIS INT, V22, P1537, DOI 10.1007/s00198 010 1372 5
   Ojeda Bruno S, 2011, OSTEOPOROSIS INT, V22, P1821, DOI 10.1007/s00198 010 1414 z
   Peeters G, 2014, PHARMACOEPIDEM DR S, V23, P1303, DOI 10.1002/pds.3703
   Penning van Beest FJA, 2006, CLIN THER, V28, P236, DOI 10.1016/j.clinthera.2006.01.002
   Roerholt C, 2009, OSTEOPOROSIS INT, V20, P299, DOI 10.1007/s00198 008 0651 x
   Ross S, 2011, VALUE HEALTH, V14, P571, DOI 10.1016/j.jval.2010.11.010
   Salter C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0083552
   Schuit SCE, 2004, BONE, V34, P195, DOI 10.1016/j.bone.2003.10.001
   Sewerynek E, 2013, ARCH MED SCI, V9, P288, DOI 10.5114/aoms.2013.34575
   Shu ADH, 2009, AM J MANAG CARE, V15, P417
   Solomon DH, 2012, ARCH INTERN MED, V172, P477, DOI 10.1001/archinternmed.2011.1977
   Ström O, 2015, OSTEOPOROSIS INT, V26, P315, DOI 10.1007/s00198 014 2900 5
   Stuurman Bieze AGG, 2014, OSTEOPOROSIS INT, V25, P1807, DOI 10.1007/s00198 014 2659 8
   Van Boven JFM, 2011, PW WETENSCHAPPELIJK, V5, pa1132
   van Boven JFM, 2013, J BONE MINER METAB, V31, P562, DOI 10.1007/s00774 013 0440 2
   van Geel TACM, 2009, ANN RHEUM DIS, V68, P99, DOI 10.1136/ard.2008.092775
   Vrijens B, 2012, BRIT J CLIN PHARMACO, V73, P691, DOI 10.1111/j.1365 2125.2012.04167.x
NR 48
TC 45
Z9 49
U1 0
U2 6
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0937 941X
EI 1433 2965
J9 OSTEOPOROSIS INT
JI Osteoporosis Int.
PD JUN
PY 2015
VL 26
IS 6
BP 1831
EP 1840
DI 10.1007/s00198 015 3084 3
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA CK6AV
UT WOS:000356311100020
PM 25822104
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Li, BH
   Zhang, BL
   Wang, XZ
   Zeng, ZQ
   Huang, ZQ
   Zhang, L
   Weiar, F
   Ren, XB
   Yang, LL
AF Li, Baihui
   Zhang, Bailu
   Wang, Xuezhou
   Zeng, Ziqing
   Huang, Ziqi
   Zhang, Lin
   Weiar, Feng
   Ren, Xiubao
   Yang, Lili
TI Expression signature, prognosis value, and immune characteristics of
   Siglec 15 identified by pan cancer analysis
SO ONCOIMMUNOLOGY
LA English
DT Article
DE Siglec 15; prognosis; cancer Immunity; pathway; multi omics
   Bioinformatics
ID OSTEOCLAST DIFFERENTIATION; SURVIVAL; LIGANDS; CLASSIFICATION;
   CARCINOMAS; ANTIBODIES; RECEPTORS; THERAPY; PD L1; CELLS
AB Sialic acid binding immunoglobulin like lectin 15 (Siglec 15) is considered a novel anti tumor target comparable to programmed cell death 1 ligand 1(PD L1). However, little is known about Siglec 15. Our study aims to understand its expression signature, prognosis value, immune infiltration pattern, and biological function using multi omic bioinformatics from public databases and verify them in lung cancer patients. Integrated analysis of The Cancer Genome Atlas and Genotype Tissue Expression portals showed Siglec 15 was overexpressed across cancers. Genetic and epigenetic alteration analysis was performed using cBioportal and UALCAN, showed Siglec 15 was regulated at the genetic and epigenetic levels. Survival estimated using Kaplan Meier plotter indicated high Siglec 15 expression correlated with favorable or unfavorable outcomes depending on the different type and subtype of cancer. Components of immune microenvironment were analyzed using CIBERSORT, and the correlation between immune cells and Siglec 15 was found to be distinct across cancer types. Based on Gene Set Enrichment Analysis, Siglec 15 was implicated in pathways involved in immunity, metabolism, cancer, and infectious diseases. Lung cancer patients with positive Siglec 15 expression showed significantly short survival rates in progression free survival concomitant with reduced infiltration of CD20 + B, and dendritic cells by immunohistochemistry. Quantitative real time PCR results indicated the overexpression of Siglec 15 was correlated with activation of the chemokine signaling pathway. In conclusion, Siglec 15 could serve as a vital prognostic biomarker and play an immune regulatory role in tumors. These results provide us with clues to better understand Siglec 15 from the perspective of bioinformatics and highlight the importance of Siglec 15 in many types of cancer.
C1 [Li, Baihui; Zhang, Bailu; Wang, Xuezhou; Zeng, Ziqing; Huang, Ziqi; Zhang, Lin; Weiar, Feng; Ren, Xiubao; Yang, Lili] Tianjin Med Univ Canc Inst & Hosp, Dept Immunol, Tianjin, Peoples R China.
   [Li, Baihui; Zhang, Bailu; Wang, Xuezhou; Zeng, Ziqing; Huang, Ziqi; Zhang, Lin; Weiar, Feng; Ren, Xiubao; Yang, Lili] Natl Clin Res Ctr Canc, Tianjin, Peoples R China.
   [Li, Baihui; Zhang, Bailu; Wang, Xuezhou; Zeng, Ziqing; Huang, Ziqi; Zhang, Lin; Weiar, Feng; Ren, Xiubao; Yang, Lili] Key Lab Canc Prevent & Therapy, Tianjin, Peoples R China.
   [Li, Baihui; Zhang, Bailu; Wang, Xuezhou; Zeng, Ziqing; Huang, Ziqi; Zhang, Lin; Weiar, Feng; Ren, Xiubao; Yang, Lili] Tianjins Clin Res Ctr Canc, Tianjin, Peoples R China.
   [Li, Baihui; Zhang, Bailu; Wang, Xuezhou; Zeng, Ziqing; Huang, Ziqi; Zhang, Lin; Weiar, Feng; Ren, Xiubao; Yang, Lili] Key Lab Canc Immunol & Biotherapy, Tianjin, Peoples R China.
   [Ren, Xiubao] Tianjin Med Univ Canc Inst & Hosp, Dept Biotherapy, Tianjin, Peoples R China.
C3 Tianjin Medical University; Tianjin Medical University
RP Ren, XB; Yang, LL (通讯作者)，Huanhuxi Rd, Tianjin 300060, Peoples R China.
EM renxiubao@tjmuch.com; yanglill@tjmuch.com
OI Yang, Lili/0000 0003 4274 4617
FU National Natural Science Foundation of China [81974246, 81572265];
   National Key Technology RD Program [2018YFC1313400]; Key Projects of
   Tianjin Health Industry [15KG145]
FX This work was supported by a grant from the National Natural Science
   Foundation of China [No.81974246 & 81572265];National Key Technology R&D
   Program [No.2018YFC1313400];Key Projects of Tianjin Health Industry
   [No.15KG145].
CR Anastasiadi D, 2018, EPIGENET CHROMATIN, V11, DOI 10.1186/s13072 018 0205 1
   Angata T, 2007, GLYCOBIOLOGY, V17, P838, DOI 10.1093/glycob/cwm049
   [Anonymous], 2018, NAT REV DRUG DISCOV, V17, P854, DOI 10.1038/nrd.2018.210
   [Anonymous], 2019, BLOOD CANCER J, DOI DOI 7310.1038/s41408 019 0233 5
   Barkal AA, 2019, NATURE, V572, P392, DOI 10.1038/s41586 019 1456 0
   Bellone S, 2018, CLIN CANCER RES, V24, P3282, DOI 10.1158/1078 0432.CCR 17 1805
   Boyd CR, 2009, J IMMUNOL, V183, P7703, DOI 10.4049/jimmunol.0902780
   Briard JG, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 03245 5
   Cao GC, 2019, SIGNAL TRANSDUCT TAR, V4, DOI 10.1038/s41392 019 0045 x
   Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159 8290.CD 12 0095
   Chandrashekar DS, 2017, NEOPLASIA, V19, P649, DOI 10.1016/j.neo.2017.05.002
   Chang LY, 2017, J PROTEOME RES, V16, P3929, DOI 10.1021/acs.jproteome.7b00625
   Cogdill AP, 2017, BRIT J CANCER, V117, P1, DOI 10.1038/bjc.2017.136
   Demaria O, 2019, NATURE, V574, P45, DOI 10.1038/s41586 019 1593 5
   Deng M, 2016, BMC BIOINFORMATICS, V17, DOI 10.1186/s12859 016 0917 9
   Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205
   Gettinger S, 2018, J CLIN ONCOL, V36, P1675, DOI 10.1200/JCO.2017.77.0412
   Gobbini E, 2018, EUR J CANCER, V96, P17, DOI 10.1016/j.ejca.2018.03.015
   Godfrey J, 2019, BLOOD, V133, P2279, DOI 10.1182/blood 2018 10 879015
   Gupta S, 2019, MODERN PATHOL, V32, P1344, DOI 10.1038/s41379 019 0269 x
   Hamid O, 2019, ANN ONCOL, V30, P582, DOI 10.1093/annonc/mdz011
   Hegde PS, 2020, IMMUNITY, V52, P17, DOI 10.1016/j.immuni.2019.12.011
   Hiruma Y, 2013, BONE, V53, P87, DOI 10.1016/j.bone.2012.11.036
   Hiruma Y, 2011, BIOCHEM BIOPH RES CO, V409, P424, DOI 10.1016/j.bbrc.2011.05.015
   Horn L, 2018, NEW ENGL J MED, V379, P2220, DOI 10.1056/NEJMoa1809064
   Hudak JE, 2014, NAT CHEM BIOL, V10, P69, DOI [10.1038/nchembio.1388, 10.1038/NCHEMBIO.1388]
   Imperato S, 2019, CELLS BASEL, V8, DOI 10.3390/cells8020137
   Ishida Kitagawa N, 2012, J BIOL CHEM, V287, P17493, DOI 10.1074/jbc.M111.324194
   Jandus C, 2014, J CLIN INVEST, V124, P1810, DOI 10.1172/JCI65899
   Jandus P, 2019, BLOOD, V134, P1941, DOI 10.1182/blood.2019001705
   Jia L, 2018, CANCER BIOL MED, V15, P116, DOI 10.20892/j.issn.2095 3941.2017.0086
   Kameda Y, 2013, J BONE MINER RES, V28, P2463, DOI 10.1002/jbmr.1989
   Kataoka K, 2016, NATURE, V534, P402, DOI 10.1038/nature18294
   Kondratova M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 12270 x
   Macauley MS, 2014, NAT REV IMMUNOL, V14, P653, DOI 10.1038/nri3737
   McDonald KA, 2019, ANN SURG ONCOL, V26, P2191, DOI 10.1245/s10434 019 07338 3
   Miyazaki K, 2012, J IMMUNOL, V188, P4690, DOI 10.4049/jimmunol.1100605
   Murugesan G, 2021, GLYCOBIOLOGY, V31, P44, DOI 10.1093/glycob/cwaa048
   Nagy A, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 29514 3
   Newman AM, 2019, NAT BIOTECHNOL, V37, P773, DOI 10.1038/s41587 019 0114 2
   Otto JE, 2017, CANCER CELL, V32, P542, DOI 10.1016/j.ccell.2017.10.014
   Pan CX, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045 020 00862 w
   Park JH, 2018, NEW ENGL J MED, V378, P449, DOI 10.1056/NEJMoa1709919
   Pecuchet N, 2017, ANN ONCOL, V28, P1597, DOI 10.1093/annonc/mdx162
   Pellegrino A, 2004, CANCER LETT, V207, P221, DOI 10.1016/j.canlet.2003.10.036
   Poh A, 2020, CANCER DISCOV, V10, P7, DOI 10.1158/2159 8290.CD NB2019 136
   Radvanyi L, 2013, CLIN CANCER RES, V19, P5541, DOI 10.1158/1078 0432.CCR 13 1054
   Rankin LC, 2018, IMMUNITY, V49, P201, DOI 10.1016/j.immuni.2018.08.008
   Ren XB, 2019, CANCER BIOL MED, V16, P205, DOI 10.20892/j.issn.2095 3941.2018.0141
   Ru BB, 2019, BIOINFORMATICS, V35, P4200, DOI 10.1093/bioinformatics/btz210
   Sharma P, 2017, CELL, V168, P707, DOI 10.1016/j.cell.2017.01.017
   Stanczak MA, 2018, J CLIN INVEST, V128, P4912, DOI 10.1172/JCI120612
   Stuible M, 2014, J BIOL CHEM, V289, P6498, DOI 10.1074/jbc.M113.494542
   Takamiya R, 2013, GLYCOBIOLOGY, V23, P178, DOI 10.1093/glycob/cws139
   Tanyi JL, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao5931
   Thorsson V, 2019, IMMUNITY, V51, P411, DOI [10.1016/j.immuni.2019.08.004, 10.1016/j.immuni.2018.03.023]
   Tokunaga R, 2018, CANCER TREAT REV, V63, P40, DOI 10.1016/j.ctrv.2017.11.007
   van de Wall S, 2020, TRENDS IMMUNOL, V41, P274, DOI 10.1016/j.it.2020.02.001
   Wang BQ, 2011, J CANCER RES CLIN, V137, P1525, DOI 10.1007/s00432 011 1010 4
   Wang J, 2019, NAT MED, V25, P656, DOI 10.1038/s41591 019 0374 x
   Wei L, 2018, BIOINFORMATICS, V34, P1615, DOI 10.1093/bioinformatics/btx812
   Yang X, 2018, NEW ENGL J MED, V379, DOI 10.1056/NEJMc1808251
   Zhang Y, 2016, JAMA ONCOL, V2, P1403, DOI 10.1001/jamaoncol.2016.2450
   Zhao S, 2018, CANCER BIOL MED, V15, P290, DOI 10.20892/j.issn.2095 3941.2018.0047
   Zou WP, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad7118
NR 65
TC 74
Z9 81
U1 3
U2 43
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 2162 402X
J9 ONCOIMMUNOLOGY
JI OncoImmunology
PY 2020
VL 9
IS 1
AR 1807291
DI 10.1080/2162402X.2020.1807291
PG 11
WC Oncology; Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Immunology
GA NL3XG
UT WOS:000567352500001
PM 32939323
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Musacchio, E
   Priante, G
   Valvason, C
   Baggio, B
   Sartori, L
AF Musacchio, E.
   Priante, G.
   Valvason, C.
   Baggio, B.
   Sartori, L.
TI EICOSAPENTAENOIC ACID MODULATES CYA INDUCED PROINFLAMMATORY CYTOKINE
   OVER EXPRESSION IN OSTEOBLASTIC CELLS IN VITRO
SO JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS
LA English
DT Article
DE cyclosporin A; eicosapentaenoic acid; osteoblasts; osteopenia
ID POLYUNSATURATED FATTY ACIDS; MESSENGER RNA EXPRESSION;
   C VIRUS REPLICATION; CYCLOSPORINE A; HEPATITIS C; TRANSPLANTATION;
   OSTEOPOROSIS; METABOLISM; MECHANISMS; THERAPY
AB Several adverse outcomes are reported in subjects undergoing long term Cyclosporin A (CyA) treatment. Severe osteopenia has been described in clinical and experimental reports, while beneficial effects of n 3 polyunsaturated fatty acids (PUFAs) on bone metabolism are recognized. In the present study we investigated the effects of n 3 versus n 6 PUFAs on osteoblastic cells treated with CyA, evaluating the expression of interleukin (IL) 1 beta, interleukin 6 (IL 6), inducible nitric oxide synthase (iNOS), and cyclooxygenase 2 (COX 2) in two different experimental protocols and the production of IL 6, IL 1 beta, and tumor necrosis factor alpha (TNF alpha) in cells challenged simultaneously with CyA and eicosapentaenoic acid (EPA) for 48h. IL 1 beta and IL 6 up regulation, induced by CyA, was counteracted by the addition of EPA in both protocols; on the contrary, arachidonic acid (AA) magnified CyA the effects. COX 2 and iNOS levels were not modified by CyA treatment. These in vitro results, that substantiate clinical reports of CyA induced osteopenia, demonstrate a beneficial effect of EPA on CyA altered cytokine profile, opening new perspectives in the non pharmacological management of adverse outcomes in CyA treated patients.
C1 [Musacchio, E.; Priante, G.; Valvason, C.; Baggio, B.] Univ Padua, Dept Med DIMED, Nephrol Unit, I 35128 Padua, Italy.
C3 University of Padua
RP Musacchio, E (通讯作者)，Univ Padua, Dept Med DIMED, Nephrol Unit, Via Giustiniani 2, I 35128 Padua, Italy.
EM estella.musacchio@unipd.it
RI Priante, Giovanna/V 4729 2019
OI Musacchio, Estella/0000 0001 9811 9103; PRIANTE,
   Giovanna/0000 0002 1870 4466
CR Baggio B, 2005, TRANSPLANTATION, V80, P1349, DOI 10.1097/01.tp.0000179152.57167.c1
   Baggio B, 2005, J NEPHROL, V18, P362
   BOREL JF, 1977, IMMUNOLOGY, V32, P1017
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003 2697(76)90527 3
   Calder PC, 1996, P NUTR SOC, V55, P737, DOI 10.1079/PNS19960069
   Calder PC, 2003, LIPIDS, V38, P343, DOI 10.1007/s11745 003 1068 y
   Campistol JM, 2010, TRANSPL P, V42, pS21, DOI 10.1016/j.transproceed.2010.09.015
   Campistol JM, 2005, TRANSPL INT, V18, P1028, DOI 10.1111/j.1432 2277.2005.00163.x
   CLOVER J, 1994, BONE, V15, P585, DOI 10.1016/8756 3282(94)90305 0
   CVETKOVIC M, 1994, TRANSPLANTATION, V57, P1231, DOI 10.1097/00007890 199404270 00016
   Das UN, 2000, NUTRITION, V16, P386, DOI 10.1016/S0899 9007(00)00262 8
   Ebeling PR, 2009, J CLIN ENDOCR METAB, V94, P1483, DOI 10.1210/jc.2009 0205
   Encarnacion MMD, 2011, AM J PHYSIOL RENAL, V300, pF1142, DOI 10.1152/ajprenal.00064.2011
   Epstein S., 1990, CALCIFIED TISSUE INT, V49, P232
   Gedaly R, 2008, TRANSPL INT, V21, P867, DOI 10.1111/j.1432 2277.2008.00699.x
   Iwami D, 2011, INT IMMUNOPHARMACOL, V11, P384, DOI 10.1016/j.intimp.2010.11.035
   James MJ, 2000, AM J CLIN NUTR, V71, p343S, DOI 10.1093/ajcn/71.1.343s
   JILKA RL, 1992, SCIENCE, V257, P88, DOI 10.1126/science.1621100
   KAHAN BD, 1989, NEW ENGL J MED, V321, P1725
   Liu JP, 2011, TRANSPL INFECT DIS, V13, P24, DOI 10.1111/j.1399 3062.2010.00556.x
   Long E, 2009, TRANSPLANTATION, V88, P1050, DOI 10.1097/TP.0b013e3181bb7913
   Mandal CC, 2010, BIOCHEM BIOPH RES CO, V402, P602, DOI 10.1016/j.bbrc.2010.10.063
   Marcén R, 2007, TRANSPL P, V39, P2256, DOI 10.1016/j.transproceed.2007.07.073
   Mariee AD, 2011, RENAL FAILURE, V33, P66, DOI 10.3109/0886022X.2010.541584
   Mazziotti G, 2010, AM J MED, V123, P877, DOI 10.1016/j.amjmed.2010.02.028
   McLean Robert R, 2009, Curr Osteoporos Rep, V7, P134
   Musacchio E, 2007, CONNECT TISSUE RES, V48, P34, DOI 10.1080/03008200601056528
   Orchard TS, 2010, AM J CLIN NUTR, V92, P1452, DOI 10.3945/ajcn.2010.29955
   Priante G, 2005, CLIN SCI, V109, P177, DOI 10.1042/CS20040369
   Priante G, 2002, CLIN SCI, V102, P403, DOI 10.1042/CS20010213
   Rahman MM, 2009, J CELL MOL MED, V13, P1833, DOI 10.1111/j.1582 4934.2009.00649.x
   SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904
   Schroeder A, 2006, BMC MOL BIOL, V7, DOI 10.1186/1471 2199 7 3
   Watkins BA, 2003, PROSTAG LEUKOTR ESS, V68, P387, DOI 10.1016/S0952 3278(03)00063 2
   Wawrzynowicz Syczewska M, 2007, TRANSPL INT, V20, P808, DOI 10.1111/j.1432 2277.2007.00508.x
   Yaqoob P, 2007, BRIT J NUTR, V98, pS41, DOI 10.1017/S0007114507832995
   ZENKE G, 1993, ANN NY ACAD SCI, V685, P330, DOI 10.1111/j.1749 6632.1993.tb35882.x
NR 37
TC 1
Z9 1
U1 0
U2 2
PU BIOLIFE SAS
PI SILVA MARINA (TE)
PA VIA S STEFANO 39 BIS, 64029 SILVA MARINA (TE), ITALY
SN 0393 974X
EI 1724 6083
J9 J BIOL REG HOMEOS AG
JI J. Biol. Regul. Homeost. Agents
PD OCT DEC
PY 2012
VL 26
IS 4
BP 663
EP 670
PG 8
WC Endocrinology & Metabolism; Immunology; Medicine, Research &
   Experimental; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Immunology; Research & Experimental
   Medicine; Physiology
GA 071OD
UT WOS:000313603200009
PM 23241116
DA 2025 08 17
ER

PT J
AU Laurenti, M
   Lamberti, A
   Genchi, GG
   Roppolo, I
   Canavese, G
   Vitale Brovarone, C
   Ciofani, G
   Cauda, V
AF Laurenti, Marco
   Lamberti, Andrea
   Genchi, Giada Graziana
   Roppolo, Ignazio
   Canavese, Giancarlo
   Vitale Brovarone, Chiara
   Ciofani, Gianni
   Cauda, Valentina
TI Graphene Oxide Finely Tunes the Bioactivity and Drug Delivery of
   Mesoporous ZnO Scaffolds
SO ACS APPLIED MATERIALS & INTERFACES
LA English
DT Article
DE mesoporous zinc oxide; graphene oxide; bioactivity; drug delivery;
   biocompatibility; bone tissue engineering
ID IN VIVO; MEMBRANES; SEPARATION; NANOFLOWERS; GROWTH; CELLS
AB Mesoporous zinc oxide (ZnO) scaffolds coated with drop cast graphene oxide (GO) flakes are proposed to be a novel bilayer system featuring bioactivity, biocompatibility, and promising loading/release properties for controlled drug delivery systems. The high surface area ZnO scaffolds show clear apatite deposition, but their particular surface chemistry and topography prevent the formation of a continuous coating, resulting in micrometric crystalline apatite aggregates after 28 days in simulated body fluid (SBF). When gentamicin sulfate (GS) is considered as a model molecule, pure ZnO scaffolds also show functional GS loading efficiency, with fast in vitro release kinetics driven by a simple diffusion mechanism. Strikingly, the bioactivity and GS delivery properties of mesoporous ZnO are efficiently triggered by drop casting GO flakes atop the mesoporous scaffold surface. The resulting ZnO@GO bilayer scaffolds show the formation of a uniform apatite coating after 28 days in SBF and demonstrate a biocompatible behavior, supporting the culture of SaOS 2 osteoblast like cells. Moreover, the GO coating also leads to a barrier layer effect, preventing fast GS release, particularly in the short time range. This barrier effect, coupled with the existence of nanopores within the GO structure, sieves drug molecules from the mesoporous ZnO matrix and allows for a delayed release of the GS molecule. We, thus, demonstrated a new generation ZnO@GO bilayer system as effective multifunctional and biocompatible scaffold for bone tissue engineering.
C1 [Laurenti, Marco; Lamberti, Andrea; Roppolo, Ignazio; Canavese, Giancarlo; Vitale Brovarone, Chiara; Cauda, Valentina] Politecn Torino, Dept Appl Sci & Technol, Cso Duca Abruzzi 24, I 10129 Turin, Italy.
   [Genchi, Giada Graziana; Ciofani, Gianni] Ist Italiano Tecnol, Smart Biointerfaces, Viale Rinaldo Piaggio 34, I 56025 Pisa, Italy.
   [Ciofani, Gianni] Politecn Torino, Dept Mech & Aerosp Engn, Cso Duca Abruzzi 24, I 10129 Turin, Italy.
C3 Polytechnic University of Turin; Istituto Italiano di Tecnologia   IIT;
   Polytechnic University of Turin
RP Cauda, V (通讯作者)，Politecn Torino, Dept Appl Sci & Technol, Cso Duca Abruzzi 24, I 10129 Turin, Italy.
EM valentina.cauda@polito.it
RI Lamberti, Andrea/Z 4829 2019; Cauda, Valentina/W 6630 2019; Ciofani,
   Gianni/D 3761 2009; Roppolo, Ignazio/LIG 3543 2024; Genchi, Giada
   Graziana/AAD 9095 2022; Brovarone, Chiara/G 9630 2012
OI Ciofani, Gianni/0000 0003 1192 3647; Roppolo,
   Ignazio/0000 0001 7602 4015; Genchi, Giada Graziana/0000 0002 2154 7991;
   Lamberti, Andrea/0000 0003 4100 9661
CR Barui AK, 2012, NANOSCALE, V4, P7861, DOI 10.1039/c2nr32369a
   Cardoso MV, 2017, J CLIN PERIODONTOL, V44, P950, DOI 10.1111/jcpe.12736
   Cote LJ, 2009, J AM CHEM SOC, V131, P1043, DOI 10.1021/ja806262m
   Doadrio AL, 2004, J CONTROL RELEASE, V97, P125, DOI 10.1016/j.jconrel.2004.03.005
   Erickson K, 2010, ADV MATER, V22, P4467, DOI 10.1002/adma.201000732
   Feng LY, 2013, ADV MATER, V25, P168, DOI 10.1002/adma.201203229
   Han WX, 2017, ACS APPL MATER INTER, V9, P29526, DOI 10.1021/acsami.7b07990
   Hu M, 2013, ENVIRON SCI TECHNOL, V47, P3715, DOI 10.1021/es400571g
   Huang HB, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3979
   Huang HB, 2013, CHEM COMMUN, V49, P5963, DOI 10.1039/c3cc41953c
   Huang K, 2014, ANGEW CHEM INT EDIT, V53, P6929, DOI 10.1002/anie.201401061
   Huang L, 2015, J PHYS CHEM LETT, V6, P2806, DOI 10.1021/acs.jpclett.5b00914
   Hung WS, 2014, CHEM MATER, V26, P2983, DOI 10.1021/cm5007873
   Kasten P, 2005, BIOMATERIALS, V26, P5879, DOI 10.1016/j.biomaterials.2005.03.001
   Kent NW, 2018, J BIOMED MATER RES B, V106, P21, DOI 10.1002/jbm.b.33809
   Koinuma M, 2012, J PHYS CHEM C, V116, P19822, DOI 10.1021/jp305403r
   Kokubo T, 2006, BIOMATERIALS, V27, P2907, DOI 10.1016/j.biomaterials.2006.01.017
   Laurenti M, 2016, RSC ADV, V6, P76996, DOI 10.1039/c6ra17319e
   Laurenti M, 2018, MATERIALS, V11, DOI 10.3390/ma11020314
   Laurenti M, 2017, NANOMATERIALS BASEL, V7, DOI 10.3390/nano7110374
   Laurenti M, 2015, ADV MATER, V27, P4218, DOI 10.1002/adma.201501594
   Lin LC, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9335
   Lu ZZ, 2010, J PHYS CHEM C, V114, P820, DOI 10.1021/jp9091078
   Ma JX, 2017, MEMBRANES BASEL, V7, DOI 10.3390/membranes7030052
   Mi BX, 2014, SCIENCE, V343, P740, DOI 10.1126/science.1250247
   Murillo G, 2017, ADV MATER, V29, DOI 10.1002/adma.201605048
   Park JK, 2010, ADV MATER, V22, P4857, DOI 10.1002/adma.201002255
   Sacco A, 2012, PHYS CHEM CHEM PHYS, V14, P16203, DOI 10.1039/c2cp42705b
   Shruti S, 2013, ACTA BIOMATER, V9, P4836, DOI 10.1016/j.actbio.2012.09.024
   Vasudevan S, 2012, RSC ADV, V2, P5234, DOI 10.1039/c2ra20270k
   Wang GS, 2016, CHEM ENG J, V289, P150, DOI 10.1016/j.cej.2015.12.072
   Wang WT, 2014, CHEM COMMUN, V50, P13089, DOI 10.1039/c4cc05295a
   Wers E, 2015, APPL SURF SCI, V353, P200, DOI 10.1016/j.apsusc.2015.06.146
   Xiong HM, 2013, ADV MATER, V25, P5329, DOI 10.1002/adma.201301732
   Xu C, 2013, CARBON, V62, P465, DOI 10.1016/j.carbon.2013.06.035
   Zhu P, 2016, ADV MATER INTERFACES, V3, DOI 10.1002/admi.201500494
NR 36
TC 37
Z9 37
U1 2
U2 60
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1944 8244
EI 1944 8252
J9 ACS APPL MATER INTER
JI ACS Appl. Mater. Interfaces
PD JAN 9
PY 2019
VL 11
IS 1
BP 449
EP 456
DI 10.1021/acsami.8b20728
PG 8
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Materials Science
GA HH2PR
UT WOS:000455561200046
PM 30525399
DA 2025 08 17
ER

PT J
AU Monteiro, CF
   Custódio, CA
   Mano, JF
AF Monteiro, Catia F.
   Custodio, Catarina A.
   Mano, Joao F.
TI Bioengineering a humanized 3D tri culture osteosarcoma model to assess
   tumor invasiveness and therapy response
SO ACTA BIOMATERIALIA
LA English
DT Article
DE 3D in vitro tumor model; Osteosarcoma; Human platelet lysates;
   Co culture; Drug screening
ID MESENCHYMAL STEM CELLS; IN VITRO; OSTEOCYTE DIFFERENTIATION; MATRIX
   STIFFNESS; DRUG DELIVERY; DOXORUBICIN; SPHEROIDS; STROMA; NANOPARTICLES;
   RESISTANCE
AB To date, anticancer therapies with evidenced efficacy in preclinical models fail during clinical trials. The shortage of robust drug screening platforms that accurately predict patient's response underlie these misleading results. To provide a reliable platform for tumor drug discovery, we herein propose a rel evant humanized 3D osteosarcoma (OS) model exploring the potential of methacryloyl platelet lysates (PLMA) based hydrogels to sustain spheroid growth and invasion. The architecture and synergistic cell microenvironment interaction of an invading tumor was recapitulated encapsulating spheroids in PLMA hydrogels, alone or co cultured with osteoblasts and mesenchymal stem cells. The stem cells alignment toward OS spheroid suggested that tumor cells chemotactically attracted the surrounding stromal cells, which supported tumor growth and invasion into the hydrogels. The exposure of established models to doxorubicin revealed an improved drug resistance of PLMA based models, comparing with scaffold free spheroids. The proposed OS models highlighted the feasibility of PLMA hydrogels to support tumor in vasion and recapitulate tumor stromal cell crosstalk, demonstrating the potential of this 3D platform for complex tumor modelling. Statement of significance Cell invasion mechanisms involved in tumor progression have been recapitulated in the field of 3D in vitro modeling, leveraging the great advance in biomimetic materials. In line with the growing interest in human derived biomaterials, the aim of this study is to explore for the first time the potential of methacryloyl platelet lysates (PLMA) based hydrogels to develop a humanized 3D osteosarcoma model to assess tumor invasiveness and drug sensitivity. By co culturing tumor spheroids with human osteoblasts and human mesenchymal stem cells, this study demonstrated the importance of the synergistic tumor cell microenvironment interaction in tumor growth, invasion and drug resistance. The established 3D os teosarcoma model highlighted the feasibility of PLMA hydrogels as a relevant 3D platform for complex tumor modelling. (c) 2021 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
C1 [Monteiro, Catia F.; Custodio, Catarina A.; Mano, Joao F.] Univ Aveiro, CICECO Aveiro Inst Mat, Dept Chem, Campus Univ Santiago, P 3810193 Aveiro, Portugal.
C3 Universidade de Aveiro
RP Custódio, CA; Mano, JF (通讯作者)，Univ Aveiro, CICECO Aveiro Inst Mat, Dept Chem, Campus Univ Santiago, P 3810193 Aveiro, Portugal.
EM catarinacustodio@ua.pt; jmano@ua.pt
RI Custodio, Catarina/N 3290 2016; Mano, João/A 4418 2009; Custódio,
   Catarina/N 3290 2016; Monteiro, Catia/KLD 2983 2024
OI Custodio, Catarina/0000 0003 2967 700X; Monteiro,
   Catia/0000 0001 6140 5990; 
CR Abarrategi A, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/3631764
   Aiyelabegan HT, 2017, BIOMED PHARMACOTHER, V88, P956, DOI 10.1016/j.biopha.2017.01.136
   Alfranca A, 2015, CELL MOL LIFE SCI, V72, P3097, DOI 10.1007/s00018 015 1918 y
   Arai K, 2013, PROTEOMICS, V13, P2351, DOI 10.1002/pmic.201300053
   Baek N, 2016, ONCOTARGETS THER, V9, P7207, DOI 10.2147/OTT.S112566
   Baek NamHuk, 2016, Drug Des Devel Ther, V10, P2155, DOI 10.2147/DDDT.S108004
   Benton G, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123312
   Brancato V, 2018, ACTA BIOMATER, V75, P200, DOI 10.1016/j.actbio.2018.05.055
   Charoen KM, 2014, BIOMATERIALS, V35, P2264, DOI 10.1016/j.biomaterials.2013.11.038
   Chatzinikolaidou M, 2016, DRUG DISCOV TODAY, V21, P1553, DOI 10.1016/j.drudis.2016.06.024
   Chen FM, 2016, PROG POLYM SCI, V53, P86, DOI 10.1016/j.progpolymsci.2015.02.004
   Chen WJ, 2014, JOVE J VIS EXP, DOI 10.3791/51639
   Chow T, 2021, TISSUE ENG PART B RE, V27, P514, DOI [10.1089/ten.teb.2020.0254, 10.1089/ten.TEB.2020.0254]
   Corre I, 2020, CELLS BASEL, V9, DOI 10.3390/cells9040976
   Cortini M, 2019, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.00814
   Cortini M, 2017, CANCER LETT, V405, P90, DOI 10.1016/j.canlet.2017.07.024
   Cortini M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166500
   Díaz ECG, 2019, ACTA BIOMATER, V99, P18, DOI 10.1016/j.actbio.2019.08.020
   Duan XP, 2009, CANCER AM CANCER SOC, V115, P13, DOI 10.1002/cncr.24013
   Duchi S, 2013, J CONTROL RELEASE, V168, P225, DOI 10.1016/j.jconrel.2013.03.012
   Eilenberger C, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 41273 3
   Ferreira LP, 2018, BIOMATERIALS, V185, P155, DOI 10.1016/j.biomaterials.2018.09.007
   Ferreira LP, 2017, BIOTECHNOL J, V12, DOI 10.1002/biot.201700079
   Fitzgerald KA, 2015, J CONTROL RELEASE, V215, P39, DOI 10.1016/j.jconrel.2015.07.020
   Folkesson E, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 68441 0
   Fong ELS, 2016, BIOMATERIALS, V108, P197, DOI 10.1016/j.biomaterials.2016.08.052
   Fontanella R, 2016, CANCER LETT, V370, P100, DOI 10.1016/j.canlet.2015.10.018
   Gkretsi V, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00145
   Han XW, 2019, ONCOL LETT, V17, P2592, DOI 10.3892/ol.2019.9905
   Harrison DJ, 2018, EXPERT REV ANTICANC, V18, P39, DOI 10.1080/14737140.2018.1413939
   Harrison DJ, 2017, CURR TREAT OPTION ON, V18, DOI 10.1007/s11864 017 0464 2
   Hattinger CM, 2019, EXPERT OPIN EMERG DR, V24, P153, DOI 10.1080/14728214.2019.1654455
   Horvath P, 2016, NAT REV DRUG DISCOV, V15, P751, DOI 10.1038/nrd.2016.175
   Jiang TM, 2019, BIOMATERIALS, V188, P130, DOI 10.1016/j.biomaterials.2018.10.015
   Junttila MR, 2013, NATURE, V501, P346, DOI 10.1038/nature12626
   Kalimuthu S, 2018, INT J MED SCI, V15, P1051, DOI 10.7150/ijms.25760
   Kundu B, 2019, ACS APPL MATER INTER, V11, P14548, DOI 10.1021/acsami.8b22724
   Lambert AW, 2017, CELL, V168, P670, DOI 10.1016/j.cell.2016.11.037
   Lazennec G, 2016, BBA REV CANCER, V1866, P290, DOI 10.1016/j.bbcan.2016.10.004
   Levinger I, 2014, ADV CANCER RES, V121, P383, DOI 10.1016/B978 0 12 800249 0.00009 3
   Lintz M, 2017, J BIOMECH ENG T ASME, V139, DOI 10.1115/1.4035121
   Lu HX, 2018, SMALL, V14, DOI 10.1002/smll.201702858
   Luca AC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059689
   Luetke A, 2014, CANCER TREAT REV, V40, P523, DOI 10.1016/j.ctrv.2013.11.006
   Mc Garrigle MJ, 2016, EUR CELLS MATER, V31, P323, DOI 10.22203/eCM.v031a21
   McCoy MG, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 45535 y
   Meazza C, 2016, EXPERT REV ANTICANC, V16, P543, DOI 10.1586/14737140.2016.1168697
   Millard M, 2017, INT J NANOMED, V12, P7993, DOI 10.2147/IJN.S146927
   Mirabello L, 2009, CANCER AM CANCER SOC, V115, P1531, DOI 10.1002/cncr.24121
   Molina ER, 2020, TISSUE ENG PART B RE, V26, P249, DOI 10.1089/ten.teb.2019.0302
   Monteiro CF, 2020, ADV SCI, V7, DOI 10.1002/advs.201902398
   Monteiro CF, 2019, ADV THER GERMANY, V2, DOI 10.1002/adtp.201800108
   Mullen CA, 2013, J MECH BEHAV BIOMED, V28, P183, DOI 10.1016/j.jmbbm.2013.06.013
   Neto AI, 2015, BIOMATER SCI UK, V3, P581, DOI 10.1039/c4bm00411f
   Santos SCND, 2018, TISSUE ENG PART B RE, V24, P454, DOI [10.1089/ten.teb.2018.0008, 10.1089/ten.TEB.2018.0008]
   Oliveira MS, 2014, TOXICOL LETT, V224, P380, DOI 10.1016/j.toxlet.2013.11.023
   Pavlou M, 2019, ACTA BIOMATER, V96, P247, DOI 10.1016/j.actbio.2019.07.011
   Huong PT, 2019, CANCERS, V11, DOI 10.3390/cancers11020240
   Puls TJ, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 31138 6
   Qiao B, 2015, DRUG DES DEV THER, V9, P969, DOI 10.2147/DDDT.S77116
   NguyenThai QA, 2015, J GENE MED, V17, P87, DOI 10.1002/jgm.2826
   Rimann M, 2014, J BIOTECHNOL, V189, P129, DOI 10.1016/j.jbiotec.2014.09.005
   Villegas MR, 2015, ACS APPL MATER INTER, V7, P24075, DOI 10.1021/acsami.5b07116
   Russell S, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 15325 5
   Sackett SD, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 28857 1
   Santos SC, 2018, ADV HEALTHC MATER, V7, DOI 10.1002/adhm.201800849
   Shi YF, 2017, NAT REV DRUG DISCOV, V16, P35, DOI 10.1038/nrd.2016.193
   Shologu N, 2016, DRUG DISCOV TODAY, V21, P1521, DOI 10.1016/j.drudis.2016.06.001
   Tchoryk A, 2019, BIOCONJUGATE CHEM, V30, P1371, DOI 10.1021/acs.bioconjchem.9b00136
   Techavichit P, 2016, BMC CANCER, V16, DOI 10.1186/s12885 016 2909 6
   Tesfamariam B, 2016, PHARMACOL THERAPEUT, V157, P112, DOI 10.1016/j.pharmthera.2015.11.005
   Valkenburg KC, 2018, NAT REV CLIN ONCOL, V15, P366, DOI 10.1038/s41571 018 0007 1
   Wagner Eric R., 2011, Sarcoma, V2011, P325238, DOI 10.1155/2011/325238
   Wu Q, 2014, CANCER LETT, V347, P159, DOI 10.1016/j.canlet.2014.03.013
   Wu VM, 2017, ACS APPL MATER INTER, V9, P25887, DOI 10.1021/acsami.7b08108
   Yang F, 2013, CELL PHYSIOL BIOCHEM, V32, P1072, DOI 10.1159/000354507
   Zhang J, 2013, PHARMACOL THERAPEUT, V137, P200, DOI 10.1016/j.pharmthera.2012.10.003
   Zhang ZL, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0194016
   Zheng Y, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 0780 x
NR 79
TC 41
Z9 41
U1 8
U2 49
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1742 7061
EI 1878 7568
J9 ACTA BIOMATER
JI Acta Biomater.
PD OCT 15
PY 2021
VL 134
BP 204
EP 214
DI 10.1016/j.actbio.2021.07.034
EA OCT 2021
PG 11
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA WK8FE
UT WOS:000709956300004
PM 34303015
DA 2025 08 17
ER

PT J
AU Harcke, HT
   Stevenson, KL
   Kecskemethy, HH
   Bachrach, SJ
   Grissom, LE
AF Harcke, H. Theodore
   Stevenson, Kimberly L.
   Kecskemethy, Heidi H.
   Bachrach, Steven J.
   Grissom, Leslie E.
TI Fracture after bisphosphonate treatment in children with cerebral palsy:
   the role of stress risers
SO PEDIATRIC RADIOLOGY
LA English
DT Article
DE Bisphosphonates; Cerebral palsy; Fractures; Stress risers; Children
ID PEDIATRIC REFERENCE DATA; OSTEOGENESIS IMPERFECTA; PAMIDRONATE
   TREATMENT; DISTAL FEMUR; BONE DENSITY; DISCONTINUATION; OSTEOPENIA;
   OSTEOPOROSIS; ADOLESCENTS; THERAPY
AB In the nonambulatory cerebral palsy (CP) population with a prior history of fracture, the use of pamidronate is not always effective in preventing further fractures.
   To test the hypothesis that when fractures occur after cyclic pamidronate, they will be at the proximal or distal end of a pamidronate band.
   Retrospective review of our CP patient database revealed 53 children who had received one or more complete courses of pamidronate therapy (five cycles over 12 months). Medical records were screened to identify children who had sustained a fracture or fractures after completing treatment.
   Of 53 patients treated with pamidronate, only 14 sustained fractures after treatment. Radiographs were available for 11 patients, showing 19 fractures. Sixty three percent of these fractures were located at a junction with pamidronate bands but not within the bands.
   We propose stress risers as the mechanism for fractures that have occurred where bone mineral density abruptly changes as a result of cyclic administration of pamidronate. We show a theoretical example of how alternative dosing might reduce the ratio and therefore decrease the chance of formation of a stress riser.
C1 [Harcke, H. Theodore; Stevenson, Kimberly L.; Kecskemethy, Heidi H.; Bachrach, Steven J.; Grissom, Leslie E.] Alfred I duPont Hosp Children, Wilmington, DE 19899 USA.
C3 Nemours Alfred I. duPont Hospital for Children
RP Harcke, HT (通讯作者)，Alfred I duPont Hosp Children, POB 269, Wilmington, DE 19899 USA.
EM tharcke@nemours.org
OI Kecskemethy, Heidi/0000 0002 4508 184X; Harcke, Howard
   T/0000 0003 0908 1911
CR Alford JW, 2007, J TRAUMA, V63, P647, DOI 10.1097/01.ta.0000221042.09862.ae
   Andiran N, 2008, J PEDIATR ENDOCR MET, V21, P63
   Aspenberg P, 2009, IBMS BONEKEY, V6, P465
   Bachrach SJ, 2006, J CLIN DENSITOM, V9, P167, DOI 10.1016/j.jocd.2005.11.003
   Bachrach SJ, 2010, DEV MED CHILD NEUROL, V52, P837, DOI 10.1111/j.1469 8749.2010.03676.x
   Bishop NE, 1996, J BONE JOINT SURG BR, V78B, P349, DOI 10.1302/0301 620X.78B3.0780349
   Gandrud LM, 2003, J PEDIATR ENDOCR MET, V16, P887
   Grissom LE, 2003, PEDIATR RADIOL, V33, P226, DOI 10.1007/s00247 003 0865 1
   Harcke HT, 1998, PEDIATR RADIOL, V28, P241, DOI 10.1007/s002470050341
   Henderson RC, 2002, J PEDIATR US, V141, P644, DOI 10.1067/mpd.2002.128207
   Henderson RC, 2002, AM J ROENTGENOL, V178, P439, DOI 10.2214/ajr.178.2.1780439
   Hernandez CJ, 2008, BONE, V42, P1014, DOI 10.1016/j.bone.2008.02.001
   Ing Lorenzini K, 2009, DRUG SAFETY, V32, P775, DOI 10.2165/00002018 200932090 00002
   Marx RE, 2005, J ORAL MAXIL SURG, V63, P1567, DOI 10.1016/j.joms.2005.07.010
   MILLER F, 1995, COMPLICATIONS PEDIAT
   Neviaser AS, 2008, J ORTHOP TRAUMA, V22, P346, DOI 10.1097/BOT.0b013e318172841c
   Plotkin H, 2006, DEV MED CHILD NEUROL, V48, P709, DOI 10.1017/S0012162206001526
   Rauch F, 2006, J CLIN ENDOCR METAB, V91, P1268, DOI 10.1210/jc.2005 2413
   Rauch F, 2007, BONE, V40, P821, DOI 10.1016/j.bone.2006.11.020
   SHAW NJ, 1994, ARCH DIS CHILD, V71, P235, DOI 10.1136/adc.71.3.235
   Staheli L, 2006, PRACTICE PEDIAT ORTH, P267
   Steelman J, 2003, J PEDIATR US, V142, P417, DOI 10.1067/mpd.2003.137
   Ward KA, 2007, OSTEOPOROSIS INT, V18, P1137, DOI 10.1007/s00198 007 0330 3
   Whyte MP, 2003, NEW ENGL J MED, V349, P457, DOI 10.1056/NEJMoa023110
   Zemel BS, 2009, J CLIN DENSITOM, V12, P207, DOI 10.1016/j.jocd.2009.01.005
NR 25
TC 12
Z9 12
U1 0
U2 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0301 0449
J9 PEDIATR RADIOL
JI Pediatr. Radiol.
PD JAN
PY 2012
VL 42
IS 1
BP 76
EP 81
DI 10.1007/s00247 011 2198 9
PG 6
WC Pediatrics; Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pediatrics; Radiology, Nuclear Medicine & Medical Imaging
GA 876SR
UT WOS:000299128500010
PM 21877116
DA 2025 08 17
ER

PT J
AU Wang, JA
   Tian, C
   Cao, ZG
AF Wang, Jianan
   Tian, Chao
   Cao, Zhengguo
TI One Pot Synthesis Bodipy Nano Precipitations for Prostate Cancer
   Treatment
SO JOURNAL OF BIOMATERIALS AND TISSUE ENGINEERING
LA English
DT Article
DE One Pot; Bodipy; Photodynamic Therapy; Prostate Cancer
ID TUMOR TARGETED DELIVERY; OSTEOBLAST PROMOTION; CALCIUM SUPPLEMENT;
   NANOPARTICLES; THERAPY; ROS; ICG
AB Here in this study, we proposed a polystyrene maleic anhydride (PSMA) stabilized Bodipy nanoparticles (PB NPs) in a one pot approach for the photodynamic therapy (PDT) of prostate cancer. The nanoparticle formed by precipitation method was then employed to treat PC 3 cells and PC 3 tumor bearing nude mice model. It was shown that this platform showed promising anticancer performance than free bodipy with reduced side effects.
C1 [Wang, Jianan; Tian, Chao; Cao, Zhengguo] Yuebei Peoples Hosp, Dept Urol, Shaoguan 512000, Guangdong, Peoples R China.
C3 Shantou University
RP Cao, ZG (通讯作者)，Yuebei Peoples Hosp, Dept Urol, Shaoguan 512000, Guangdong, Peoples R China.
RI Yin, Minghao/E 9611 2015
OI Yin, Minghao/0000 0002 6226 2394
CR Abbad S, 2015, INT J NANOMED, V10, P305, DOI 10.2147/IJN.S73971
   Aghajanzadeh M, 2020, DRUG DEV IND PHARM, V46, P846, DOI 10.1080/03639045.2020.1757698
   Ahmad J, 2020, CURR PHARM DESIGN, V26, P1181, DOI 10.2174/1381612826666200214110645
   Bauleth Ramos T, 2020, J CONTROL RELEASE, V323, P398, DOI 10.1016/j.jconrel.2020.04.025
   Borodziuk A, 2020, NANOTECHNOLOGY, V31, DOI 10.1088/1361 6528/aba975
   Cai WL, 2020, MAT SCI ENG C MATER, V112, DOI 10.1016/j.msec.2020.110900
   Chen DP, 2019, BIOMATERIALS, V221, DOI 10.1016/j.biomaterials.2019.119422
   Chen H, 2020, J CONTROL RELEASE, V323, P635, DOI 10.1016/j.jconrel.2020.04.021
   Chen SQ, 2020, CARBOHYD POLYM, V230, DOI 10.1016/j.carbpol.2019.115613
   Dong CH, 2020, NANOSCALE, V12, P5587, DOI 10.1039/c9nr10735e
   Duangrat R, 2020, CANCER SCI, V111, P3164, DOI 10.1111/cas.14548
   Fang XL, 2020, J DRUG DELIV SCI TEC, V57, DOI 10.1016/j.jddst.2020.101662
   Huang L, 2021, BIOMATERIALS, V268, DOI 10.1016/j.biomaterials.2020.120557
   Jiang GY, 2020, ADV OPT MATER, V8, DOI 10.1002/adom.202001119
   Kim MW, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.00133
   Li J, 2010, J CONTROL RELEASE, V142, P416, DOI 10.1016/j.jconrel.2009.11.008
   Li Y, 2020, J CONTROL RELEASE, V325, P100, DOI 10.1016/j.jconrel.2020.06.025
   Lo PC, 2020, CHEM SOC REV, V49, P1041, DOI 10.1039/c9cs00129h
   Lu BB, 2020, ACS BIOMATER SCI ENG, V6, P4106, DOI 10.1021/acsbiomaterials.0c00762
   Luesakul U, 2018, CARBOHYD POLYM, V181, P841, DOI 10.1016/j.carbpol.2017.11.068
   Prieto Montero R, 2020, PHOTOCHEM PHOTOBIOL, V96, P458, DOI 10.1111/php.13232
   Qi F, 2021, J INORG BIOCHEM, V218, DOI 10.1016/j.jinorgbio.2021.111394
   Rastogi RP, 2010, BIOCHEM BIOPH RES CO, V397, P603, DOI 10.1016/j.bbrc.2010.06.006
   Sui CX, 2021, BIOCONJUGATE CHEM, V32, P318, DOI 10.1021/acs.bioconjchem.0c00694
   Tao S, 2021, J CONTROL RELEASE, V329, P121, DOI 10.1016/j.jconrel.2020.11.059
   Wang CP, 2020, SMALL, V16, DOI 10.1002/smll.202004829
   Wang C, 2021, SMALL, V17, DOI 10.1002/smll.202007953
   Wang C, 2020, INT J NANOMED, V15, P4049, DOI 10.2147/IJN.S237156
   Wang CL, 2021, NANO TODAY, V38, DOI 10.1016/j.nantod.2021.101140
   Wang JW, 2020, THERANOSTICS, V10, P8591, DOI 10.7150/thno.45142
   Wang TT, 2020, BIOMATER SCI UK, V8, P118, DOI 10.1039/c9bm01546a
   Wang YP, 2019, CARBOHYD POLYM, V203, P203, DOI 10.1016/j.carbpol.2018.09.035
   Wang YZ, 2016, COLLOID SURFACE B, V148, P533, DOI 10.1016/j.colsurfb.2016.09.037
   Wu FS, 2020, ACS BIOMATER SCI ENG, V6, P5230, DOI 10.1021/acsbiomaterials.0c00684
   Wu YC, 2020, BIOMATER SCI UK, V8, P949, DOI 10.1039/c9bm01662g
   Yang XY, 2020, J CONTROL RELEASE, V323, P333, DOI 10.1016/j.jconrel.2020.04.027
   Yu K, 2020, POLYMER, V200, DOI 10.1016/j.polymer.2020.122585
   Zeng ZL, 2021, ADV MATER, V33, DOI 10.1002/adma.202007247
   Zhang XX, 2019, DRUG DELIV, V26, P129, DOI 10.1080/10717544.2018.1564403
   Zhang XB, 2020, MED RES REV, V40, P1754, DOI 10.1002/med.21669
   Zhang Y, 2021, CANCER IMMUNOL IMMUN, V70, P3217, DOI 10.1007/s00262 021 02917 4
   Zhang YH, 2020, CHEM COMMUN, V56, P10317, DOI 10.1039/d0cc02045a
NR 42
TC 0
Z9 0
U1 1
U2 23
PU AMER SCIENTIFIC PUBLISHERS
PI VALENCIA
PA 26650 THE OLD RD, STE 208, VALENCIA, CA 91381 0751 USA
SN 2157 9083
EI 2157 9091
J9 J BIOMATER TISS ENG
JI J. Biomater. Tissue Eng.
PD AUG
PY 2022
VL 12
IS 8
BP 1537
EP 1541
DI 10.1166/jbt.2022.3070
PG 5
WC Cell & Tissue Engineering
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA 1N5SL
UT WOS:000800715300002
DA 2025 08 17
ER

PT J
AU Mora, S
   Puzzovio, M
   Giacomet, V
   Fabiano, V
   Maruca, K
   Capelli, S
   Nannini, P
   Lombardi, G
   Zuccotti, GV
AF Mora, Stefano
   Puzzovio, Maria
   Giacomet, Vania
   Fabiano, Valentina
   Maruca, Katia
   Capelli, Silvia
   Nannini, Pilar
   Lombardi, Giovanni
   Zuccotti, Gian Vincenzo
TI Sclerostin and DKK 1: two important regulators of bone metabolism in
   HIV infected youths
SO ENDOCRINE
LA English
DT Article
DE Sclerostin; DKK 1; HIV infection; Bone mineral density
ID IMMUNODEFICIENCY VIRUS INFECTION; VITAMIN D METABOLISM; MINERAL DENSITY;
   FRACTURE RISK; TENOFOVIR; CHILDREN; MASS; TURNOVER; MARKERS; WEIGHT
AB Reduced bone mineral density (BMD) and altered bone metabolism are common findings in HIV infected patients. Increased bone formation has been described both in HIV infected adults and children. Wnt ligands promote bone formation by stimulating osteoblast differentiation and their survival. Sclerostin and dickkopf factor 1 (DKK 1), Wnt antagonists, are important negative regulators of bone formation. We studied 86 HIV infected patients whose ages ranged from 5.7 to 27.9 years. Patients were all on antiretroviral therapy, but seven who were na < ve to treatment. Bone alkaline phosphatase (BAP), sclerostin, and DKK 1 were measured in serum by enzyme immunoassay. BMD was measured by dual energy X ray absorptiometry at the lumbar spine and in the whole skeleton. Biochemical indexes were also measured in 143 healthy controls (age range 4.5 27.4 years). HIV infected patients had lower than normal BMD (spine P < 0.005, and whole skeleton P < 0.03). BAP measurements were significantly higher in HIV infected patients than controls (P a parts per thousand currency sign 0.05). Sclerostin and DKK 1 concentrations were markedly lower than in controls (P a parts per thousand currency sign 0.0006, and P a parts per thousand currency sign 0.03, respectively). The serum concentration of both analytes of patients na < ve to antiretroviral treatment was not different from that of treated patients. No correlations were found between sclerostin, DKK 1, and bone mineral measurements. Our data confirm the alteration of bone metabolism pathways in HIV infected individuals. The lower concentration of Wnt antagonists is consistent with the increased bone formation markers.
C1 [Mora, Stefano; Puzzovio, Maria; Maruca, Katia; Capelli, Silvia] IRCCS San Raffaele Sci Inst, Div Genet & Cell Biol, Lab Pediat Endocrinol, I 20132 Milan, MI, Italy.
   [Giacomet, Vania; Nannini, Pilar] Univ Milan, Dept Pediat, L Sacco Hosp, Milan, Italy.
   [Fabiano, Valentina; Zuccotti, Gian Vincenzo] Univ Milan, Dept Pediat, Osped Bambini V Buzzi, Milan, Italy.
   [Lombardi, Giovanni] IRCCS Ist Ortoped Galeazzi, Lab Expt Biochem & Mol Biol, Milan, Italy.
C3 Vita Salute San Raffaele University; IRCCS Ospedale San Raffaele;
   University of Milan; Luigi Sacco Hospital; University of Milan; IRCCS
   Istituto Ortopedico Galeazzi
RP Mora, S (通讯作者)，IRCCS San Raffaele Sci Inst, Div Genet & Cell Biol, Lab Pediat Endocrinol, Via Olgettina 60, I 20132 Milan, MI, Italy.
EM mora.stefano@hsr.it
RI , Vania/M 5350 2017; Zuccotti, Gianvincenzo/H 8572 2017; Fabiano,
   Valentina/H 8818 2017; Giacomet, Vania/AAM 1411 2020; Maruca,
   Katia/AAN 5117 2020; Lombardi, Giovanni/I 2414 2012; FABIANO,
   VALENTINA/H 8818 2017
OI , Vania/0000 0002 0892 9039; Zuccotti, Gianvincenzo/0000 0002 2795 9874;
   Lombardi, Giovanni/0000 0002 8365 985X; FABIANO,
   VALENTINA/0000 0001 6449 1724
CR Aeberli D, 2011, JOINT BONE SPINE, V78, P422, DOI 10.1016/j.jbspin.2011.02.015
   Amrein K, 2012, J CLIN ENDOCR METAB, V97, P148, DOI 10.1210/jc.2011 2152
   Ardawi MSM, 2011, J BONE MINER RES, V26, P2812, DOI 10.1002/jbmr.479
   Aukrust P, 1999, J CLIN ENDOCR METAB, V84, P145, DOI 10.1210/jc.84.1.145
   Baron R, 2007, ENDOCRINOLOGY, V148, P2635, DOI 10.1210/en.2007 0270
   Bedimo R, 2012, AIDS, V26, P825, DOI 10.1097/QAD.0b013e32835192ae
   Butler JS, 2013, J ORTHOP RES, V31, P218, DOI 10.1002/jor.22196
   Cacciari E, 2006, J ENDOCRINOL INVEST, V29, P581, DOI 10.1007/BF03344156
   Ellies DL, 2006, J BONE MINER RES, V21, P1738, DOI 10.1359/JBMR.060810
   Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551
   Lewiecki EM, 2008, OSTEOPOROSIS INT, V19, P1369, DOI 10.1007/s00198 008 0689 9
   Li J, 2006, BONE, V39, P754, DOI 10.1016/j.bone.2006.03.017
   MacDonald BT, 2007, BONE, V41, P331, DOI 10.1016/j.bone.2007.05.009
   Madeddu G, 2004, Q J NUCL MED MOL IM, V48, P39
   Mallon PWG, 2010, CURR OPIN INFECT DIS, V23, P1, DOI 10.1097/QCO.0b013e328334fe9a
   Mondy K, 2003, CLIN INFECT DIS, V36, P482, DOI 10.1086/367569
   Mora S, 2004, J CLIN ENDOCR METAB, V89, P24, DOI 10.1210/jc.2003 030767
   Mora S, 2001, AIDS, V15, P1823, DOI 10.1097/00002030 200109280 00011
   Mora S, 2007, AIDS, V21, P1129, DOI 10.1097/QAD.0b013e32810c8ccf
   Mora Stefano, 2010, Front Biosci (Elite Ed), V2, P1265
   Morvan F, 2006, J BONE MINER RES, V21, P934, DOI 10.1359/JBMR.060311
   Panayiotopoulos A, 2013, REV ENDOCR METAB DIS, V14, P119, DOI 10.1007/s11154 013 9246 8
   Poole KES, 2005, FASEB J, V19, P1842, DOI 10.1096/fj.05 4221fje
   Siberry GK, 2012, AIDS RES HUM RETROV, V28, P247, DOI 10.1089/aid.2011.0064
   Stellbrink HJ, 2010, CLIN INFECT DIS, V51, P963, DOI 10.1086/656417
   Sutherland MK, 2004, BONE, V35, P828, DOI 10.1016/j.bone.2004.05.023
   Tan BM, 2001, J PEDIATR US, V139, P447, DOI 10.1067/mpd.2001.117005
   TANNER JM, 1976, ARCH DIS CHILD, V51, P170, DOI 10.1136/adc.51.3.170
   Vigano A, 2010, ANTIVIR THER, V15, P1053, DOI 10.3851/IMP1650
NR 29
TC 12
Z9 12
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1355 008X
EI 1559 0100
J9 ENDOCRINE
JI Endocrine
PD AUG
PY 2015
VL 49
IS 3
BP 783
EP 790
DI 10.1007/s12020 015 0527 8
PG 8
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA CN3NJ
UT WOS:000358333300027
PM 25596857
DA 2025 08 17
ER

PT J
AU Fernandes, H
   Mentink, A
   Bank, R
   Stoop, R
   van Blitterswijk, C
   de Boer, J
AF Fernandes, Hugo
   Mentink, Anouk
   Bank, Ruud
   Stoop, Reinout
   van Blitterswijk, Clemens
   de Boer, Jan
TI Endogenous Collagen Influences Differentiation of Human Multipotent
   Mesenchymal Stromal Cells
SO TISSUE ENGINEERING PART A
LA English
DT Article
ID EMBRYONIC STEM CELLS; EXTRACELLULAR MATRIX; ASCORBIC ACID; OSTEOGENIC
   DIFFERENTIATION; IN VITRO; BONE; ACTIVATION; THERAPY; MICROENVIRONMENT;
   OSTEOBLASTS
AB Human multipotent mesenchymal stromal cells (hMSCs) are multipotent cells that, in the presence of appropriate stimuli, can differentiate into different lineages such as the osteogenic, chondrogenic, and adipogenic lineages. In the presence of ascorbic acid, MSCs secrete an extracellular matrix mainly composed of collagen type I. Here we assessed the potential role of endogenous collagen synthesis in hMSC differentiation and stem cell maintenance. We observed a sharp reduction in proliferation rate of hMSCs in the absence of ascorbic acid, concomitant with a reduction in osteogenesis in vitro and bone formation in vivo. In line with a positive role for collagen type I in osteogenesis, gene expression profiling of hMSCs cultured in the absence of ascorbic acid demonstrated increased expression of genes involved in adipogenesis and chondrogenesis and a reduction in expression of osteogenic genes. We also observed that matrix remodeling and anti osteoclastogenic signals were high in the presence of ascorbic acid. The presence of collagen type I during the expansion phase of hMSCs did not affect their osteogenic and adipogenic differentiation potential. In conclusion, the collagenous matrix supports both proliferation and differentiation of osteogenic hMSCs but, on the other hand, presents signals stimulating matrix remodeling and inhibiting osteoclastogenesis.
C1 [Fernandes, Hugo; Mentink, Anouk; van Blitterswijk, Clemens; de Boer, Jan] Univ Twente, Dept Tissue Regenerat, NL 7500 AE Enschede, Netherlands.
   [Bank, Ruud] Univ Groningen, Univ Med Ctr Groningen, Stem Cell & Tissue Engn Grp, Med Biol Sect, NL 9713 AV Groningen, Netherlands.
   [Stoop, Reinout] TNO KvL BioSci, Leiden, Netherlands.
C3 University of Twente; University of Groningen; Netherlands Organization
   Applied Science Research
RP de Boer, J (通讯作者)，Univ Twente, Dept Tissue Regenerat, Postbus 217, NL 7500 AE Enschede, Netherlands.
EM j.deboer@tnw.utwente.nl
RI ; Fernandes, Hugo/H 6192 2014
OI de Boer, Jan/0000 0001 9188 9324; Fernandes, Hugo/0000 0002 4574 7648;
   van Blitterswijk, Clemens/0000 0003 2371 4615; ,
   Reinout/0000 0002 8773 8248
FU Senter/Novem
FX The authors would like to thank Huipin Yuan for providing the scaffolds
   and Jessica Dijkstra for excellent technical assistance. The research by
   H.F., A.M., and J.d.B. was sponsored by a grant from Senter/Novem.
CR ADAMS JC, 1993, DEVELOPMENT, V117, P1183
   Ahlmann E, 2002, J BONE JOINT SURG AM, V84A, P716, DOI 10.2106/00004623 200205000 00003
   Arrington ED, 1996, CLIN ORTHOP RELAT R, P300, DOI 10.1097/00003086 199608000 00037
   Atala A, 2006, LANCET, V367, P1241, DOI 10.1016/S0140 6736(06)68438 9
   Aubin JE, 1998, BIOCHEM CELL BIOL, V76, P899, DOI 10.1139/bcb 76 6 899
   Bank RA, 1997, J CHROMATOGR B, V703, P37, DOI 10.1016/S0378 4347(97)00391 5
   Bank RA, 1996, ANAL BIOCHEM, V240, P167, DOI 10.1006/abio.1996.0346
   Barry FP, 2004, INT J BIOCHEM CELL B, V36, P568, DOI 10.1016/j.biocel.2003.11.001
   Bi YM, 2007, NAT MED, V13, P1219, DOI 10.1038/nm1630
   Bruder SP, 1998, J ORTHOPAED RES, V16, P155, DOI 10.1002/jor.1100160202
   Bruder SP, 1999, CLIN ORTHOP RELAT R, pS68
   Caplan AI, 2005, TISSUE ENG, V11, P1198, DOI 10.1089/ten.2005.11.1198
   Chang Y, 2008, OSTEOARTHR CARTILAGE, V16, P1403, DOI 10.1016/j.joca.2008.03.018
   Chen XD, 2007, J BONE MINER RES, V22, P1943, DOI 10.1359/JBMR.070725
   Choi KM, 2008, J BIOSCI BIOENG, V105, P586, DOI 10.1263/jbb.105.586
   De Boer J, 2006, TISSUE ENG, V12, P2927
   de Bruijn J D, 1999, Adv Dent Res, V13, P74
   Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb 2003 4 9 r60
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Duque G, 2009, STEM CELLS, V27, P550, DOI 10.1634/stemcells.2008 0886
   Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044
   Fashena Sarah J., 2000, Nature Cell Biology, V2, pE225, DOI 10.1038/35046654
   Fernandes H, 2009, TISSUE ENG PT A, V15, P3857, DOI 10.1089/ten.tea.2009.0011
   FRANCESCHI RT, 1992, J BONE MINER RES, V7, P235
   GEESIN JC, 1991, ARCH BIOCHEM BIOPHYS, V289, P6, DOI 10.1016/0003 9861(91)90434 K
   GORDON MY, 1988, BRIT J HAEMATOL, V70, P1, DOI 10.1111/j.1365 2141.1988.tb02425.x
   Jaiswal N, 1997, J CELL BIOCHEM, V64, P295, DOI 10.1002/(SICI)1097 4644(199702)64:2<295::AID JCB12>3.3.CO;2 6
   KAO WWY, 1976, ARCH BIOCHEM BIOPHYS, V173, P638, DOI 10.1016/0003 9861(76)90301 5
   Lin TM, 2005, STEM CELLS DEV, V14, P92, DOI 10.1089/scd.2005.14.92
   Macchiarini P, 2008, LANCET, V372, P2023, DOI 10.1016/S0140 6736(08)61598 6
   Mandelin J, 2006, BONE, V38, P769, DOI 10.1016/j.bone.2005.10.017
   Mauney JR, 2004, BIOMATERIALS, V25, P3233, DOI 10.1016/j.biomaterials.2003.10.005
   Moore KA, 2006, SCIENCE, V311, P1880, DOI 10.1126/science.1110542
   Ott HC, 2008, NAT MED, V14, P213, DOI 10.1038/nm1684
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Postovit LM, 2006, STEM CELLS, V24, P501, DOI 10.1634/stemcells.2005 0459
   Pozzi M, 1998, J CELL BIOL, V142, P587
   PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403
   Siddappa Ramakrishnaiah, 2007, Curr Stem Cell Res Ther, V2, P209, DOI 10.2174/157488807781696267
   Siddappa R, 2008, P NATL ACAD SCI USA, V105, P7281, DOI 10.1073/pnas.0711190105
   Solchaga LA, 2005, J CELL PHYSIOL, V203, P398, DOI 10.1002/jcp.20238
   SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191
   TORII Y, 1994, J NUTR SCI VITAMINOL, V40, P229, DOI 10.3177/jnsv.40.229
   Xiao GZ, 1997, MOL ENDOCRINOL, V11, P1103, DOI 10.1210/me.11.8.1103
   YOSHIDA K, 1994, MECH DEVELOP, V45, P163, DOI 10.1016/0925 4773(94)90030 2
   ZUCKERMAN KS, 1985, J CLIN INVEST, V75, P970, DOI 10.1172/JCI111798
NR 46
TC 54
Z9 63
U1 0
U2 9
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1937 3341
EI 1937 335X
J9 TISSUE ENG PT A
JI Tissue Eng. Part A
PD MAY
PY 2010
VL 16
IS 5
BP 1693
EP 1702
DI 10.1089/ten.tea.2009.0341
PG 10
WC Cell & Tissue Engineering; Cell Biology; Engineering, Biomedical;
   Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Engineering; Materials Science
GA 589SG
UT WOS:000277173100021
PM 20038205
OA Green Submitted
DA 2025 08 17
ER

PT J
AU Choi, SY
   Ryu, HM
   Oh, EJ
   Choi, JY
   Cho, JH
   Kim, CD
   Kim, YL
   Park, SH
AF Choi, Soon Youn
   Ryu, Hye Myung
   Oh, Eun Joo
   Choi, Ji Young
   Cho, Jang Hee
   Kim, Chan Duck
   Kim, Yong Lim
   Park, Sun Hee
TI Dipeptidyl peptidase 4 inhibitor gemigliptin protects against vascular
   calcification in an experimental chronic kidney disease and vascular
   smooth muscle cells
SO PLOS ONE
LA English
DT Article
ID ARTERIAL MEDIAL CALCIFICATION; OXIDATIVE STRESS; OSTEOBLASTIC
   DIFFERENTIATION; PHOSPHATIDYLINOSITOL 3 KINASE; IN VITRO; PHOSPHATE;
   CATENIN; RUNX2; AKT; ACTIVATION
AB Although dipeptidyl peptidase 4 inhibitors, a class of antidiabetic drugs, have various pleiotropic effects, it remains undetermined whether gemigliptin has a beneficial effect on vascular calcification. Therefore, this study was performed to evaluate the effect of gemigliptin on vascular calcification in a rat model of adenine induced chronic kidney disease and in cultured vascular smooth muscle cells. Gemigliptin attenuated calcification of abdominal aorta and expression of RUNX2 in adenine induced chronic kidney disease rats. In cultured vascular smooth muscle cells, phosphate induced increase in calcium content was reduced by gemigliptin. Gemigliptin reduced phosphate induced PiT 1 mRNA expression, reactive oxygen species generation, and NADPH oxidase mRNA expression (p22(phox) and NOX4). The reduction of oxidative stress by gemigliptin was associated with the downregulation of phospho PI3K/AKT expression. High phosphate increased the expression of frizzled 3 (FDZ3) and decreased the expression of dickkopf related protein 1 (DKK 1) in the Wnt pathway. These changes were attenuated by gemigliptin treatment. Gemigliptin restored the decreased expression of vascular smooth muscle cells markers (alpha SMA and SM22 alpha) and increased expression of osteogenic makers (CBFA1, OSX, E11, and SOST) induced by phosphate. In conclusion, gemigliptin attenuated vascular calcification and osteogenic trans differentiation in vascular smooth muscle cells via multiple steps including downregulation of PiT 1 expression and suppression of reactive oxygen species generation, phospho PI3K/AKT, and the Wnt signaling pathway.
C1 [Choi, Soon Youn; Ryu, Hye Myung; Oh, Eun Joo; Choi, Ji Young; Cho, Jang Hee; Kim, Chan Duck; Kim, Yong Lim; Park, Sun Hee] Kyungpook Natl Univ, Sch Med, Div Nephrol, Daegu, South Korea.
   [Choi, Soon Youn; Ryu, Hye Myung; Oh, Eun Joo; Choi, Ji Young; Cho, Jang Hee; Kim, Chan Duck; Kim, Yong Lim; Park, Sun Hee] Kyungpook Natl Univ, Sch Med, Dept Internal Med, Daegu, South Korea.
   [Choi, Soon Youn; Kim, Yong Lim] Kyungpook Natl Univ, Dept Biomed Sci, Plus Biomed Convergence Program BK21, Daegu, South Korea.
   [Choi, Soon Youn; Ryu, Hye Myung; Kim, Chan Duck; Kim, Yong Lim; Park, Sun Hee] Kyungpook Natl Univ, Cell & Matrix Res Inst, Daegu, South Korea.
C3 Kyungpook National University (KNU); Kyungpook National University
   (KNU); Kyungpook National University (KNU); Kyungpook National
   University (KNU)
RP Park, SH (通讯作者)，Kyungpook Natl Univ, Sch Med, Div Nephrol, Daegu, South Korea.; Park, SH (通讯作者)，Kyungpook Natl Univ, Sch Med, Dept Internal Med, Daegu, South Korea.; Park, SH (通讯作者)，Kyungpook Natl Univ, Cell & Matrix Res Inst, Daegu, South Korea.
EM sh park@knu.ac.kr
RI Park, Sun Hee/LMN 0033 2024; Kim, Yong Lim/AGK 3172 2022; Choi, Soon
   Youn/AHC 8865 2022; Cho, Jang hee/ABD 3534 2020; Kim,
   Hyoungnae/JXN 1329 2024
FU Korea Health Technology R & D Project through Korea Health Industry
   Development Institute (KHIDI) [HI15C0001, HI13C1232]; Ministry of Health
   & Welfare, Republic of Korea
FX This study was supported by a grant from the Korea Health Technology R &
   D Project through the Korea Health Industry Development Institute
   (KHIDI) (HI15C0001; HI13C1232), funded by the Ministry of Health &
   Welfare, Republic of Korea (www.khidi.or.kr) (YLK, CDK). The funders had
   no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Al Aly Z, 2011, KIDNEY INT, V79, P1044, DOI 10.1038/ki.2010.548
   Barbieri M, 2013, ATHEROSCLEROSIS, V227, P349, DOI 10.1016/j.atherosclerosis.2012.12.018
   Byon CH, 2008, J BIOL CHEM, V283, P15319, DOI 10.1074/jbc.M800021200
   Cai T, 2016, EXP CELL RES, V345, P206, DOI 10.1016/j.yexcr.2016.06.007
   Chinda K, 2013, INT J CARDIOL, V167, P451, DOI 10.1016/j.ijcard.2012.01.011
   Clempus RE, 2007, ARTERIOSCL THROM VAS, V27, P42, DOI 10.1161/01.ATV.0000251500.94478.18
   Ellmark SHM, 2005, CARDIOVASC RES, V65, P495, DOI 10.1016/j.cardiores.2004.10.026
   Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200
   Ghosh Choudhury N, 2002, J BIOL CHEM, V277, P33361, DOI 10.1074/jbc.M205053200
   Hwang HJ, 2015, MOL CELL ENDOCRINOL, V405, P25, DOI 10.1016/j.mce.2015.01.025
   Hwang HJ, 2014, MOL CELL ENDOCRINOL, V392, P1, DOI 10.1016/j.mce.2014.04.017
   Jono S, 2006, J BONE MINER METAB, V24, P176, DOI 10.1007/s00774 005 0668 6
   Jono S, 2000, CIRC RES, V87, pE10, DOI 10.1161/01.RES.87.7.e10
   Kim SH, 2016, EUR J PHARMACOL, V788, P54, DOI 10.1016/j.ejphar.2016.06.016
   Koska J, 2015, DIABETES VASC DIS RE, V12, P154, DOI 10.1177/1479164114562411
   Li XW, 2006, CIRC RES, V98, P905, DOI 10.1161/01.RES.0000216409.20863.e7
   Lim S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035007
   London GM, 2003, NEPHROL DIAL TRANSPL, V18, P1731, DOI 10.1093/ndt/gfg414
   Manivannan J, 2013, MOL CELL BIOCHEM, V378, P9, DOI 10.1007/s11010 013 1588 8
   Manrique C, 2016, CARDIOVASC DIABETOL, V15, DOI 10.1186/s12933 016 0414 5
   Martínez Moreno JM, 2012, AM J PHYSIOL RENAL, V303, pF1136, DOI 10.1152/ajprenal.00684.2011
   Min HS, 2014, LAB INVEST, V94, P598, DOI 10.1038/labinvest.2014.50
   Mizobuchi M, 2009, J AM SOC NEPHROL, V20, P1453, DOI 10.1681/ASN.2008070692
   Mody N, 2001, FREE RADICAL BIO MED, V31, P509, DOI 10.1016/S0891 5849(01)00610 4
   de Oca AM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089525
   Muteliefu G, 2009, NEPHROL DIAL TRANSPL, V24, P2051, DOI 10.1093/ndt/gfn757
   Persy V, 2009, TRENDS MOL MED, V15, P405, DOI 10.1016/j.molmed.2009.07.001
   Picatoste B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078330
   Qin SF, 2003, BIOCHEMISTRY US, V42, P2995, DOI 10.1021/bi0205911
   Rong S, 2014, CELL PHYSIOL BIOCHEM, V34, P2049, DOI 10.1159/000366400
   Scirica BM, 2013, NEW ENGL J MED, V369, P1317, DOI 10.1056/NEJMoa1307684
   Shah Z, 2011, VASC PHARMACOL, V55, P2, DOI 10.1016/j.vph.2011.03.001
   Shanahan CM, 2011, CIRC RES, V109, P697, DOI 10.1161/CIRCRESAHA.110.234914
   Shimomura A, 2014, J AM SOC NEPHROL, V25, P1954, DOI 10.1681/ASN.2013090967
   Sutra T, 2008, FREE RADICAL RES, V42, P789, DOI 10.1080/10715760802400766
   Tang Y, 2016, MOL NEUROBIOL, V53, P1181, DOI 10.1007/s12035 014 9070 5
   Terawaki Y, 2014, CARDIOVASC DIABETOL, V13, DOI 10.1186/s12933 014 0154 3
   Villa Bellosta R, 2009, ARTERIOSCL THROM VAS, V29, P761, DOI 10.1161/ATVBAHA.108.183384
   Vittone F, 2012, DIABETOLOGIA, V55, P2267, DOI 10.1007/s00125 012 2582 5
   Wang WJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093447
   White WB, 2013, NEW ENGL J MED, V369, P1327, DOI 10.1056/NEJMoa1305889
   Yamada S, 2012, J BONE MINER RES, V27, P474, DOI 10.1002/jbmr.539
   Yao L, 2015, AM J NEPHROL, V41, P28, DOI 10.1159/000370250
   Yoshida T, 2013, J VASC RES, V50, P512, DOI 10.1159/000355263
   Yoshiko Y, 2007, MOL CELL BIOL, V27, P4465, DOI 10.1128/MCB.00104 07
   Zhan JK, 2015, INT J CARDIOL, V189, P188, DOI 10.1016/j.ijcard.2015.04.086
   Zhao MM, 2011, KIDNEY INT, V79, P1071, DOI 10.1038/ki.2011.18
   Zhu DX, 2015, J CELL MOL MED, V19, P165, DOI 10.1111/jcmm.12373
   Zhu DX, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019595
NR 49
TC 17
Z9 18
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD JUL 7
PY 2017
VL 12
IS 7
AR e0180393
DI 10.1371/journal.pone.0180393
PG 18
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA FA5DZ
UT WOS:000405464100059
PM 28686724
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Li, JJ
   Fu, LL
   Lu, Q
   Guo, SL
   Chen, S
   Xia, T
   Wang, M
   Chen, LW
   Bai, Y
   Xia, HB
AF Li, Jiaojiao
   Fu, Liangliang
   Lu, Qian
   Guo, Shuling
   Chen, Si
   Xia, Ting
   Wang, Min
   Chen, Liangwen
   Bai, Yi
   Xia, Haibin
TI Comparison of the osteogenic potential of fibroblasts from different
   sources
SO TISSUE & CELL
LA English
DT Article
DE Osteogenic potential; Different origins; Fibroblasts; HGFs
ID BONE REGENERATION; PROTEIN; ACTIVATION; PATHWAY; OSTERIX; HEALTH; CELLS
AB Objective: With the growing interest in the role of fibroblasts in osteogenesis, this study presents a comparative evaluation of the osteogenic potential of fibroblasts derived from three distinct sources: human gingival fibroblasts (HGFs), mouse embryonic fibroblasts (NIH3T3 cells), and mouse subcutaneous fibroblasts (L929 cells). MC3T3 E1 pre osteoblast cells were employed as a positive control for osteogenic behavior. Design: Our assessment involved multiple approaches, including vimentin staining for cell origin verification, as well as ALP and ARS staining in conjunction with RT PCR for osteogenic characterization. Results: Our findings revealed the superior osteogenic differentiation capacity of HGFs compared to MC3T3 E1 and NIH3T3 cells. Analysis of ALP staining confirmed that early osteogenic differentiation was most prominent in MC3T3 E1 cells at 7 days, followed by NIH3T3 and HGFs. However, ARS staining at 21 days demonstrated that HGFs produced the highest number of calcified nodules, indicating their robust potential for latestage mineralization. This late stage osteogenic potential of HGFs was further validated through RT PCR analysis. In contrast, L929 cells displayed no significant osteogenic differentiation potential. Conclusions: In light of these findings, HGFs emerge as the preferred choice for seed cells in bone tissue engineering applications. This study provides valuable insights into the potential utility of HGFs in the fields of bone tissue engineering and regenerative medicine.
C1 [Li, Jiaojiao; Fu, Liangliang; Lu, Qian; Guo, Shuling; Chen, Si; Xia, Ting; Wang, Min; Chen, Liangwen; Bai, Yi; Xia, Haibin] Wuhan Univ, Sch & Hosp Stomatol, State Key Lab Oral & Maxillofacial Reconstruct & R, Hubei Key Lab Stomatol,Key Lab Oral Biomed,Minist, Wuhan 430079, Peoples R China.
C3 Wuhan University
RP Bai, Y; Xia, HB (通讯作者)，Wuhan Univ, Sch & Hosp Stomatol, Dept Dent Implantol, 237 Luoyu Rd, Wuhan 430079, Hubei, Peoples R China.
EM bai_yi@whu.edu.cn; xhaibin@whu.edu.cn
RI Wang, Min/Q 1064 2019; Xia, Haibin/Q 1085 2019
FU National Natural Science Foundation China [82071095, 32370816]
FX This work was supported by the National Natural Science Foundation China
   [grant numbers 82071095, 32370816] .
CR Akiyama N, 2023, J MATER CHEM B, V11, P6225, DOI 10.1039/d3tb00905j
   ANDERSON HC, 1989, LAB INVEST, V60, P320
   Barczyk MM, 2009, J DENT RES, V88, P621, DOI 10.1177/0022034509339291
   Chen FG, 2018, CONNECT TISSUE RES, V59, P223, DOI 10.1080/03008207.2017.1353085
   Cho Y, 2017, J DENT RES, V96, P555, DOI 10.1177/0022034516686745
   Claes L, 2012, NAT REV RHEUMATOL, V8, P133, DOI 10.1038/nrrheum.2012.1
   Fernandes CJD, 2017, MOL CELL BIOCHEM, V436, P111, DOI 10.1007/s11010 017 3083 0
   Dan HX, 2014, BIOMATERIALS, V35, P113, DOI 10.1016/j.biomaterials.2013.09.074
   Fadl A, 2023, CELLS BASEL, V12, DOI 10.3390/cells12162021
   Ghaemi SR, 2019, ADV HEALTHC MATER, V8, DOI 10.1002/adhm.201900595
   Gomes RN, 2021, NPJ REGEN MED, V6, DOI 10.1038/s41536 021 00153 z
   He XD, 2020, MOL MED REP, V22, P4551, DOI 10.3892/mmr.2020.11576
   Jung RE, 2009, CLIN ORAL IMPLAN RES, V20, P162, DOI 10.1111/j.1600 0501.2008.01634.x
   Kuburich NA, 2022, SEMIN CANCER BIOL, V86, P816, DOI 10.1016/j.semcancer.2021.12.006
   Lekic PC, 1997, CRIT REV ORAL BIOL M, V8, P253, DOI 10.1177/10454411970080030201
   Maehata Y, 2006, MATRIX BIOL, V25, P47, DOI 10.1016/j.matbio.2005.09.001
   MATTHEWS CJ, 1992, FERTIL STERIL, V57, P990
   Mostafa NZ, 2011, OPEN DENT J, V5, P139, DOI 10.2174/1874210601105010139
   Omar O, 2019, J CLIN PERIODONTOL, V46, P103, DOI 10.1111/jcpe.13068
   Patel KD, 2020, ACTA BIOMATER, V108, P97, DOI 10.1016/j.actbio.2020.03.012
   Plikus MV, 2021, CELL, V184, P3852, DOI 10.1016/j.cell.2021.06.024
   Rabel K, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 96526 x
   Ren YR, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms232314987
   Rutherford RB, 2002, TISSUE ENG, V8, P441, DOI 10.1089/107632702760184709
   Shui CX, 2002, J CELL PHYSIOL, V193, P164, DOI 10.1002/jcp.10157
   Tai GP, 2005, BIOCHEM BIOPH RES CO, V333, P1116, DOI 10.1016/j.bbrc.2005.05.195
   Tal H, 2008, CLIN ORAL IMPLAN RES, V19, P295, DOI 10.1111/j.1600 0501.2007.01424.x
   Tony JB, 2022, J FUNCT BIOMATER, V13, DOI 10.3390/jfb13040194
   Wang YJ, 2021, J AGR FOOD CHEM, V69, P2576, DOI 10.1021/acs.jafc.0c06466
   Wu H, 2023, BIOMATERIALS, V293, DOI 10.1016/j.biomaterials.2022.121990
   Wu JJ, 2022, NANO RES, V15, P9169, DOI 10.1007/s12274 022 4591 0
   Yu FC, 2011, BIOSCI TRENDS, V5, P46, DOI 10.5582/bst.2011.v5.2.46
   Zhang C, 2017, ONCOTARGET, V8, P113543, DOI 10.18632/oncotarget.22708
   Zhang JL, 2021, J LEUKOCYTE BIOL, V110, P485, DOI 10.1002/JLB.3MA0321 739R
   Zhang WH, 2017, BRAZ J MED BIOL RES, V50, DOI [10.1590/1414 431X20176272, 10.1590/1414 431x20176272]
   Zhao Q, 2019, NANO LETT, V19, P5904, DOI 10.1021/acs.nanolett.9b01459
   Zou YC, 2016, CONNECT TISSUE RES, V57, P200, DOI 10.3109/03008207.2015.1127916
NR 37
TC 0
Z9 0
U1 1
U2 11
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1 3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0040 8166
J9 TISSUE CELL
JI Tissue Cell
PD JUN
PY 2024
VL 88
AR 102358
DI 10.1016/j.tice.2024.102358
EA MAR 2024
PG 8
WC Anatomy & Morphology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Anatomy & Morphology; Cell Biology
GA C5Q5Y
UT WOS:001289912000001
PM 38537379
DA 2025 08 17
ER

PT J
AU Bozic, D
   Grgurevic, L
   Erjavec, I
   Brkljacic, J
   Orlic, I
   Razdorov, G
   Grgurevic, I
   Vukicevic, S
   Plancak, D
AF Bozic, Darko
   Grgurevic, Lovorka
   Erjavec, Igor
   Brkljacic, Jelena
   Orlic, Iva
   Razdorov, Genadij
   Grgurevic, Ivica
   Vukicevic, Slobodan
   Plancak, Darije
TI The proteome and gene expression profile of cementoblastic cells treated
   by bone morphogenetic protein 7 in vitro
SO JOURNAL OF CLINICAL PERIODONTOLOGY
LA English
DT Article
DE BMP1; BMP7; PCPE1; periodontal regeneration; proteomic analysis; tooth
   cementum
ID HUMAN OSTEOGENIC PROTEIN 1; ROOT SHEATH CELLS; OSTEOBLAST
   DIFFERENTIATION; EXTRACELLULAR MATRIX; GROWTH; IDENTIFICATION;
   MINERALIZATION; RECEPTORS; ROLES; REGENERATION
AB Aim: Regenerative periodontal therapy is often unpredictable and limited. Cementum regeneration is necessary for the proper repair of a periodontal ligament. The precise mechanism how bone morphogenetic protein 7 (BMP7) induces differentiation and mineralization of cementoblasts remains undetermined. The purpose of this study was to evaluate the effect of BMP7 on early proteome and gene expression profile of cementoblastic OCCM. 30 cells in vitro.
   Materials and Methods: Immortalized murine cementoblasts (OCCM. 30) were exposed to BMP7 and evaluated for: (1) proliferation; (2) mineralization; (3) early proteome profile using liquid chromatography mass spectrometry (LC MS); and (4) gene expression by quantitative RT PCR.
   Results: Bone morphogenetic protein 7 increased the cell proliferation at 24 h and 48 h, while higher doses suppressed the cell proliferation at 48 h. BMP7 induced the mineralization of cementoblasts following 8 days of therapy. Using LC MS we identified 1117 proteins from the cell lysate. Many belonged to extracellular matrix formation such as PCPE1, collagens, annexins and integrin receptors. RT PCR analyses revealed a BMP7 dose dependent upregulation of BMP1, TGF beta 1, osterix, osteoprotegerin, procollagen I and II, PCPE1, and noggin, while BMP6 and chordin expression were decreased. The high BMP7 dose down regulated most of the genes 24 h following therapy.
   Conclusion: Bone morphogenetic protein 7 promotes differentiation and mineralization of cementoblasts via inducing PCPE1 and BMP1 responsible for processing of type I collagen.
C1 [Grgurevic, Lovorka; Erjavec, Igor; Brkljacic, Jelena; Orlic, Iva; Razdorov, Genadij; Vukicevic, Slobodan] Univ Zagreb, Lab Mineralized Tissues, Sch Med, Ctr Translat & Clin Res, Zagreb 10000, Croatia.
   [Bozic, Darko; Plancak, Darije] Univ Zagreb, Sch Dent Med, Dept Periodontol, Zagreb 10000, Croatia.
   [Grgurevic, Ivica] Dubrava Univ Hosp, Dept Internal Med, Zagreb, Croatia.
C3 University of Zagreb; University of Zagreb; University of Zagreb, School
   of Dental Medicine; University of Zagreb
RP Grgurevic, L (通讯作者)，Univ Zagreb, Lab Mineralized Tissues, Sch Med, Ctr Translat & Clin Res, Salata 11, Zagreb 10000, Croatia.
EM lgrgurev@mef.hr
RI Grgurevic, Ivica/AEN 2615 2022; Plancak, Darije/HJB 2987 2022; Erjavec,
   Igor/AAU 8987 2020; Plančak, Darije/HJB 2987 2022; Brkljacic,
   Jelena/JQW 4422 2023; Vukicevic, Slobodan/AEG 2646 2022; Bozic,
   Darko/ADR 3813 2022
OI Plancak, Darije/0000 0003 4131 9264; Razdorov,
   Genadij/0000 0001 6370 8434; Erjavec, Igor/0000 0002 3038 9665; 
FU Ministry of Science and Technology of the Republic of Croatia
FX No conflict of interest for any authors. This study was supported by
   grants from the Ministry of Science and Technology of the Republic of
   Croatia.
CR Andl T, 2004, DEVELOPMENT, V131, P2257, DOI 10.1242/dev.01125
   Berry JE, 2006, J BONE MINER RES, V21, P246, DOI [10.1359/JBMR.051024, 10.1359/jbmr.051024]
   Bosshardt DD, 2005, J DENT RES, V84, P390, DOI 10.1177/154405910508400501
   Bozic D., 2011, COLLEGIUM A IN PRESS, V2, P12
   CELESTE AJ, 1990, P NATL ACAD SCI USA, V87, P9843, DOI 10.1073/pnas.87.24.9843
   Cox J, 2008, NAT BIOTECHNOL, V26, P1367, DOI 10.1038/nbt.1511
   Craig R, 2004, BIOINFORMATICS, V20, P1466, DOI 10.1093/bioinformatics/bth092
   Diekwisch TGH, 2001, INT J DEV BIOL, V45, P695
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Gatlin CL, 1998, ANAL BIOCHEM, V263, P93, DOI 10.1006/abio.1998.2809
   Gazzerro E, 2006, REV ENDOCR METAB DIS, V7, P51, DOI 10.1007/s11154 006 9000 6
   Ge Gaoxiang, 2006, Birth Defects Research, V78, P47, DOI 10.1002/bdrc.20060
   Giannobile WV, 1998, J PERIODONTOL, V69, P129, DOI 10.1902/jop.1998.69.2.129
   Grgurevic L, 2007, INT ORTHOP, V31, P743, DOI 10.1007/s00264 007 0404 z
   Grgurevic L, 2011, BIOCHEM BIOPH RES CO, V408, P26, DOI 10.1016/j.bbrc.2011.03.109
   Grzesik WJ, 2002, CRIT REV ORAL BIOL M, V13, P474, DOI 10.1177/154411130201300605
   Hakki SS, 2010, J PERIODONTOL, V81, P1663, DOI 10.1902/jop.2010.100074
   Helder MN, 1998, J DENT RES, V77, P545, DOI 10.1177/00220345980770040701
   Hirata A, 2009, J HISTOCHEM CYTOCHEM, V57, P397, DOI 10.1369/jhc.2008.952192
   Jikko A, 1999, J BONE MINER RES, V14, P1075, DOI 10.1359/jbmr.1999.14.7.1075
   Jin QM, 2004, CONNECT TISSUE RES, V45, P50, DOI 10.1080/03008200490278142
   Jin QM, 2003, J PERIODONTOL, V74, P202, DOI 10.1902/jop.2003.74.2.202
   Kaigler Darnell, 2006, Expert Opin Drug Deliv, V3, P647, DOI 10.1517/17425247.3.5.647
   Kémoun P, 2007, TISSUE CELL, V39, P257, DOI 10.1016/j.tice.2007.06.001
   Kessler E, 1996, SCIENCE, V271, P360, DOI 10.1126/science.271.5247.360
   Kim BG, 2009, J PROTEOME RES, V8, P4441, DOI 10.1021/pr900231a
   Kirsch T, 2000, J BIOL CHEM, V275, P35577, DOI 10.1074/jbc.M005648200
   Kwong FNK, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2436
   Lallier TE, 2007, CELL TISSUE RES, V327, P93, DOI 10.1007/s00441 006 0282 5
   Lavery K, 2009, BONE, V45, P27, DOI 10.1016/j.bone.2009.03.656
   Lechguer AN, 2011, J DENT RES, V90, P583, DOI 10.1177/0022034510391796
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lossdörfer S, 2008, J PERIODONTAL RES, V43, P563, DOI 10.1111/j.1600 0765.2008.01087.x
   Luan XH, 2006, DEV DYNAM, V235, P1167, DOI 10.1002/dvdy.20674
   Macri L, 2007, ADV DRUG DELIVER REV, V59, P1366, DOI 10.1016/j.addr.2007.08.015
   Martinovic S, 2006, ARCH HISTOL CYTOL, V69, P23, DOI 10.1679/aohc.69.23
   Mesilaty Gross S, 2009, CLIN CHIM ACTA, V403, P76, DOI 10.1016/j.cca.2009.01.024
   Moali C, 2005, J BIOL CHEM, V280, P24188, DOI 10.1074/jbc.M501486200
   Morsczeck C, 2009, ELECTROPHORESIS, V30, P1175, DOI 10.1002/elps.200800796
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Nakashima M, 2003, NAT BIOTECHNOL, V21, P1025, DOI 10.1038/nbt864
   Nemoto E, 2009, BONE, V44, P805, DOI 10.1016/j.bone.2008.12.029
   Petryk A, 2005, BONE, V36, P617, DOI 10.1016/j.bone.2005.01.018
   Plikus MV, 2005, EVOL DEV, V7, P440, DOI 10.1111/j.1525 142X.2005.05048.x
   Rappsilber J, 2007, NAT PROTOC, V2, P1896, DOI 10.1038/nprot.2007.261
   Ripamonti U, 1996, ARCH ORAL BIOL, V41, P121, DOI 10.1016/0003 9969(95)00110 7
   Ripamonti U, 2002, S AFR J SCI, V98, P361
   RIPAMONTI U, 1994, J PERIODONTAL RES, V29, P225, DOI 10.1111/j.1600 0765.1994.tb01216.x
   Schultz GS, 2009, WOUND REPAIR REGEN, V17, P153, DOI 10.1111/j.1524 475X.2009.00466.x
   Seo JH, 2009, BIOCHEM BIOPH RES CO, V384, P100, DOI 10.1016/j.bbrc.2009.04.082
   Shevchenko A, 2006, NAT PROTOC, V1, P2856, DOI 10.1038/nprot.2006.468
   Simic P, 2005, CYTOKINE GROWTH F R, V16, P299, DOI 10.1016/j.cytogfr.2005.02.010
   Sonoyama W, 2007, J DENT RES, V86, P594, DOI 10.1177/154405910708600703
   URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893
   Vukicevic S, 2009, CYTOKINE GROWTH F R, V20, P441, DOI 10.1016/j.cytogfr.2009.10.020
   WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241
   Wu L, 2009, J PERIODONTAL RES, V44, P645, DOI 10.1111/j.1600 0765.2008.01174.x
   Xiao Z, 2009, J PROTEOMICS, V72, P34, DOI 10.1016/j.jprot.2008.11.011
   Yamashiro T, 2003, J DENT RES, V82, P172, DOI 10.1177/154405910308200305
   Yeh LCC, 2000, J CELL PHYSIOL, V185, P87, DOI 10.1002/1097 4652(200010)185:1<87::AID JCP8>3.0.CO;2 8
   Zayzafoon M, 2006, J CELL BIOCHEM, V97, P56, DOI 10.1002/jcb.20675
   Zeichner David M, 2003, DEV DYNAM, V228, P651, DOI 10.1002/dvdy.10404
   Zhang AX, 2007, MOL CELL BIOCHEM, V304, P167, DOI 10.1007/s11010 007 9497 3
   Zhao M, 2003, J DENT RES, V82, P23, DOI 10.1177/154405910308200106
   Zouvelou V, 2009, J EXP ZOOL PART B, V312B, P361, DOI 10.1002/jez.b.21262
NR 65
TC 29
Z9 30
U1 0
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0303 6979
EI 1600 051X
J9 J CLIN PERIODONTOL
JI J. Clin. Periodontol.
PD JAN
PY 2012
VL 39
IS 1
BP 80
EP 90
DI 10.1111/j.1600 051X.2011.01794.x
PG 11
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA 861IP
UT WOS:000298012900010
PM 22093042
DA 2025 08 17
ER

PT J
AU Ye, N
   Jiang, DM
AF Ye, Nan
   Jiang, Dianming
TI Ghrelin accelerates the growth and osteogenic differentiation of rabbit
   mesenchymal stem cells through the ERK1/2 pathway
SO BMC BIOTECHNOLOGY
LA English
DT Article
DE rBMSC; MAPK; Ghrelin; Osteogenic differentiation
ID MARROW HEMATOPOIETIC STEM; BONE MARROW; P38 MAPK; TRANSPLANTATION;
   EXPRESSION; RECEPTOR; SECRETAGOGUE; ACTIVATION; INCREASES; THERAPY
AB Background: Mesenchymal stem cells (MSCs) can differentiate into chondroblasts, adipocytes, or osteoblasts under appropriate stimulation. Ghrelin, an endogenous ligand for the growth hormone secretagogue receptor (GHSR), stimulates growth hormone (GH) secretion, and has both orexigenic and adipogenic effects. This study sought to understand the potential involvement of members of MAPK serine/threonine kinases in the ghrelin induced growth of rabbit MSCs (rBMSC).
   Methods: We applied various concentrations of ghrelin to cultured rBMSC and observed the growth rate of the cells by MTT, changes in the phosphorylation state of ERK1/2, JNK and p38, and the expression levels of ALP, Runx2, and Osterix by wetern blot.
   Results: We found that the growth and osteogenic differentiation of ghrelin treated rBMSC are promoted primarily by phosphorylated ERK1/2, and that this phosphorylation, as well p38 phosphorylation, is mediated by GHSR.
   Conclusions: Our study suggests that ghrelin promotes the growth and osteogenic differentiation of rBMSC primarily through the ERK1/2 pathway.
C1 [Ye, Nan; Jiang, Dianming] Chongqing Med Univ, Affiliated Hosp 1, Dept Orthoped, Chongqing, Peoples R China.
   [Ye, Nan] Inner Mongolia Med Univ, Affiliated Hosp 2, Dpartment Cerv Surg, Hohhot, Peoples R China.
C3 Chongqing Medical University; Inner Mongolia Medical University
RP Jiang, DM (通讯作者)，Chongqing Med Univ, Affiliated Hosp 1, Dept Orthoped, Yuzhong Dist Yueyuan Rd 1, Chongqing, Peoples R China.
EM jiangdianming1122@126.com
RI YE, Nan/JEO 5628 2023
CR Bai R, 2012, CELL MOL BIOL NOISY, V58
   Delhanty PJD, 2006, J ENDOCRINOL, V188, P37, DOI 10.1677/joe.1.06404
   Fujitsuka Naoki, 2012, Critical Reviews in Oncogenesis, V17, P277
   Gao MJ, 2013, INT J CARDIOL, V167, P2724, DOI 10.1016/j.ijcard.2012.06.106
   Hosoda Hiroshi, 2004, Nihon Rinsho, V62 Suppl 9, P421
   Kamegai J, 1998, NEUROENDOCRINOLOGY, V68, P312, DOI 10.1159/000054379
   Kojima M, 2008, REGUL PEPTIDES, V145, P2, DOI 10.1016/j.regpep.2007.09.023
   Kojima M, 2010, ANN NY ACAD SCI, V1200, P140, DOI 10.1111/j.1749 6632.2010.05516.x
   Kojima M, 2010, RESULTS PROBL CELL D, V50, P185, DOI 10.1007/400_2009_28
   Kojima Masayasu, 2008, V46, P89, DOI 10.1007/400_2007_049
   Milewski L, 2012, GYNECOL ENDOCRINOL, V28, P310, DOI 10.3109/09513590.2011.631628
   Qian H, 2006, BLOOD, V107, P3503, DOI 10.1182/blood 2005 10 3932
   Rak A, 2009, GROWTH HORM IGF RES, V19, P68, DOI 10.1016/j.ghir.2008.08.006
   Ratajczak MZ, 2010, LEUKEMIA, V24, P976, DOI 10.1038/leu.2010.53
   Ricart E, 2012, DIGEST DIS, V30, P387, DOI 10.1159/000338134
   Rimmelé P, 2014, AM J HEMATOL, V89, pE235, DOI 10.1002/ajh.23837
   Ringdén O, 2012, J INTERN MED, V272, P472, DOI 10.1111/j.1365 2796.2012.02547.x
   Sadat K, 2014, J NUCL CARDIOL, V21, P351, DOI 10.1007/s12350 013 9846 4
   Sharma S, 2011, PEDIATR SURG INT, V27, P81, DOI 10.1007/s00383 010 2712 4
   Sreejit P, 2012, CELL TISSUE RES, V350, P55, DOI 10.1007/s00441 012 1458 9
   Suzuki S, 2010, CELLS TISSUES ORGANS, V191, P269, DOI 10.1159/000260061
   Wang ZL, 2015, J INFLAMM LOND, V12, DOI 10.1186/s12950 014 0046 z
   Wilson A, 2006, NAT REV IMMUNOL, V6, P93, DOI 10.1038/nri1779
   Wojtera E, 2014, INT J MOL SCI, V15, P19417, DOI 10.3390/ijms151119417
   Wollmer E, 2014, INTERNIST, V55, P547, DOI 10.1007/s00108 013 3432 3
   Wu YY, 2014, ONCOL LETT, V8, P1859, DOI 10.3892/ol.2014.2329
   Xu LJ, 2014, J TRANSL MED, V12, DOI 10.1186/s12967 014 0244 8
   Yang J, 2011, ACTA PHARMACOL SIN, V32, P1239, DOI 10.1038/aps.2011.79
   Zhang C, 2015, J CELL MOL MED, V19, P408, DOI 10.1111/jcmm.12461
   Zhang ZL, 2015, CELL BIOL INT, V39, P291, DOI 10.1002/cbin.10385
   Zhou SB, 2015, BRIT J DERMATOL, V172, P1278, DOI 10.1111/bjd.13251
NR 31
TC 14
Z9 17
U1 0
U2 24
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1472 6750
J9 BMC BIOTECHNOL
JI BMC Biotechnol.
PD JUN 9
PY 2015
VL 15
AR 51
DI 10.1186/s12896 015 0176 2
PG 10
WC Biotechnology & Applied Microbiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology
GA CK4SL
UT WOS:000356213400003
PM 26054524
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Franco Trepat, E
   Guillán Fresco, M
   Alonso Pérez, A
   López Fagúndez, M
   Pazos Pérez, A
   Crespo Golmar, A
   Gualillo, O
   Jorge Mora, A
   Bravo, SB
   Gómez, R
AF Franco Trepat, Eloi
   Guillan Fresco, Maria
   Alonso Perez, Ana
   Lopez Fagundez, Miriam
   Pazos Perez, Andres
   Crespo Golmar, Antia
   Gualillo, Oreste
   Jorge Mora, Alberto
   Bravo, Susana Belen
   Gomez, Rodolfo
TI Repurposing drugs to inhibit innate immune responses associated with
   TLR4, IL1, and NLRP3 signaling in joint cells
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE TLR4; IL1; NLRP3; Osteoarthritis; Chondrocytes; Synoviocytes
ID OSTEOARTHRITIS; CHONDROCYTES; INFLAMMATION; LIPOPOLYSACCHARIDE;
   EXPRESSION
AB Osteoarthritis (OA) affects more than 300 million people worldwide and it is about to become the first disabling disease. OA is characterized by the progressive degradation of the articular cartilage but is a disease of the whole joint. Articular innate immune responses (IIR) associated with tissue degradation contribute to its progression. However, no treatment is available to block these IIRs. Through data text mining and computational pharma cology, we identified two clinical available drugs, naloxone, and thalidomide, with potential inhibitory prop erties on toll like receptor 4 (TLR4), a major activator of these IIR. Proteome analysis confirmed that activation of this receptor or the IL1 receptor generated OA like and gout like proteomic changes in human primary chon drocytes. Both compounds were found to block TLR4 complex and inhibit TLR4 and IL1R mediated IIR in OA chondrocytes, osteoblasts, and synoviocytes. Furthermore, naloxone and thalidomide inhibitory effects involved the downregulation of the NLRP3 inflammasome pathway, which is downstream of TLR4/IL1R signaling. We demonstrated that these compounds, within a therapeutic range of concentrations, exhibited anti inflammatory and anti catabolic properties in joint primary OA cells without any toxic effect. This data underpins naloxone & thalidomide repurpose to treat OA associated inflammatory responses.
C1 [Franco Trepat, Eloi; Guillan Fresco, Maria; Alonso Perez, Ana; Lopez Fagundez, Miriam; Pazos Perez, Andres; Crespo Golmar, Antia; Jorge Mora, Alberto; Gomez, Rodolfo] Santiago Univ Clin Hosp, Inst IDIS, Musculoskeletal Pathol Grp, Santiago De Compostela 15706, Spain.
   [Gualillo, Oreste] Santiago Univ Clin Hosp, Inst Med Res, SERGAS, Res Lab NEIRID Lab 9, Santiago De Compostela 15706, Spain.
   [Bravo, Susana Belen] Santiago Univ Clin Hosp, Inst IDIS, Prote Unit, Santiago De Compostela 15706, Spain.
C3 Complexo Hospitalario Universitario de Santiago de Compostela; Complexo
   Hospitalario Universitario de Santiago de Compostela; Complexo
   Hospitalario Universitario de Santiago de Compostela
RP Gómez, R (通讯作者)，Santiago Univ Clin Hosp, Inst IDIS, Musculoskeletal Pathol Grp, Santiago De Compostela 15706, Spain.
EM Rodolfo.Gomez.Bahamonde@sergas.es
RI Gualillo, Oreste/B 8223 2008; Gomez, Rodolfo/B 4642 2012; Bravo Lopez,
   Susana Belen/F 8487 2016; Jorge Mora, Alberto/AAB 3156 2019;
   Guillán Fresco, María/IWM 5573 2023; Franco Trepat, Eloi/AAD 7837 2020;
   Lopez, Susana/F 8487 2016
OI Lopez Fagundez, Miriam/0000 0002 4577 737X; Bravo Lopez, Susana
   Belen/0000 0001 7615 3079; Franco Trepat, Eloi/0000 0001 7514 4672;
   Pazos Perez, Andres/0000 0001 8598 9476; Alonso Perez,
   Ana/0000 0001 5830 0960
FU Instituto de Salud Carlos III (ISCIII) & Fondo Europeo de Desarrollo
   Regional (FEDER) [PT20/00009, FI20/00210, CM20/00186, RD21/0002/0025,
   PI19/01446, PI16/01870, CPII20/00026, CP15/00007]; Spanish Ministry of
   Science via FECYT [PRECIPITA PR250]; Mutua Madrilena Foundation [MMA
   2018, MMA 2020]; Ministry of Science, Innovation, and Education
   [FPU17/01706]; UDC Margarita Salas [RS1. UDC.MS06];  [IDIS 2019]
FX This work was supported by the Instituto de Salud Carlos III (ISCIII) &
   Fondo Europeo de Desarrollo Regional (FEDER) via "Fondo de Investigacion
   Sanitaria" [grant numbers PT20/00009, FI20/00210, CM20/00186,
   RD21/0002/0025, PI19/01446, PI16/01870, CPII20/00026, CP15/00007]; the
   Spanish Ministry of Science via FECYT [grant number PRECIPITA PR250],
   Mutua Madrilena Foundation [grant numbers MMA 2018 & MMA 2020) and
   Ministry of Science, Innovation, and Education [grant numbers
   FPU17/01706 and UDC Margarita Salas RS1. UDC.MS06]. Support was also
   associated to personnel: E.F. T. [MMA 2018], M.G. F. [FPU17/01706],
   A.A. P. [IDIS 2019], M.L. F. [FI20/00210]. A.P. P. [MMA 2020], A.C. G.
   [Rio Hortega CM20/00186], A.J. M. [SERGAS no grant number], S.B.B. [IDIS
   no grant number], O.G. [SERGAS no grant number], R.G. [ISCIII & SERGAS
   via Miguel Servet II program CPII20/00026], V.L L. [PT20/00009] and M.
   P. R. [UDC Margarita Salas RS1. UDC.MS06]. All in vitro experiments (n =
   6) were independent biological replicas normalized by control and
   expressed as the mean +/  SEM. Human OA chondrocytes (hOC), human OA
   osteoblasts (hOB) and human SW982 synoviocytes (hSS) were treated with
   NLX [1.40 mu M, 14.0 mu M, 100 mu M], Th [3.00 mu M, 6.0 mu M, 500 mu
   M], CLI 095 [1 mu M], siTLR4 [15 nM] or siNLRP3 [15 nM] for 24 h and
   cotreated with LPS [100 ng/ml] or IL1 ss [0.1 ng/ml] for another 24 h.
   A D: Gene expression (mRNA) of TLR4 & NLRP3 inflammasome factors namely
   TLR4 (A) NLRP3 (B), CASP1 (C), and IL1 ss (D) determined by RT qPCR in
   LPS/IL1 ss stimulated hOC chondrocytes treated with NLX, Th, CLI 095,
   siTLR4, and siNLRP3. E: CASP1 enzymatic activity determined by
   Ac YVAD pNa reaction (optical density; O.D. 460 nm) in LPS/IL1
   ss stimulated hOC chondrocytes treated with NLX, Th, and CLI 095. F G:
   Cellular (F) and secreted (G) levels of IL1 ss determined by ELISA
   (pg/ml) in LPS/IL1 ss stimulated hOC chondrocytes treated with NLX, Th,
   and CLI 095. H K: Gene expression (mRNA) of TLR4 & NLRP3 inflammasome
   factors namely TLR4 (H), NLRP3 (I), CASP1 (J), and IL1 ss (K) determined
   by RT qPCR in LPS/IL1 ss stimulated hOB osteoblasts treated with NLX,
   Th, CLI 095, siTLR4, and siNLRP3. L: CASP1 enzymatic activity determined
   by AcYVAD pNa reaction (optical density; O.D. 460 nm) in LPS/IL1
   ss stimulated hOB osteoblasts treated with NLX, Th, and CLI 095. M N:
   Cellular (M) and secreted (N) levels of IL1 ss determined by ELISA
   (pg/ml) in LPS/IL1 ss stimulated hOB osteoblasts treated with NLX, Th,
   and CLI 095. OR: Gene expression (mRNA) of TLR4 & NLRP3 inflammasome
   factors namely TLR4 (O), NLRP3 (P), CASP1 (Q), and IL1 ss (R) determined
   by RT qPCR in LPS/IL1 ss stimulated hSS synoviocytes treated with NLX,
   Th, CLI 095, siTLR4, and siNLRP3. S: CASP1 enzymatic activity determined
   by Ac YVAD pNa reaction (optical density; O.D. 460 nm) in LPS/IL1
   ss stimulated hSS synoviocytes treated with NLX, Th, and CLI 095. T U:
   Cellular (T) and secreted (U) levels of IL1 ss determined by ELISA
   (pg/ml) in LPS/IL1 ss stimulated hSS synoviocytes treated with NLX, Th,
   and CLI 095. V: Diagram of TLR4, IL1R, and NLRP3 inflammasome signaling
   associated with naloxone (NLX) and thalidomide (Th) inhibitory effects.
CR Abdollahi Roodsaz S, 2007, ARTHRITIS RHEUM, V56, P2957, DOI 10.1002/art.22848
   Alonso Pérez A, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00504
   Aman ZS, 2022, ARTHROSCOPY, V38, P2543, DOI 10.1016/j.arthro.2022.02.009
   Andrés M, 2018, CURR RHEUMATOL REP, V20, DOI 10.1007/s11926 018 0739 z
   Blagojevic M, 2010, OSTEOARTHR CARTILAGE, V18, P24, DOI 10.1016/j.joca.2009.08.010
   Bustin SA, 2009, CLIN CHEM, V55, P611, DOI 10.1373/clinchem.2008.112797
   Çakir Özkan N, 2016, J CRANIOFAC SURG, V27, P615, DOI 10.1097/SCS.0000000000002527
   Chittepu VCSR, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11050238
   Conde J, 2011, ANN RHEUM DIS, V70, P551, DOI 10.1136/ard.2010.132399
   Couselo Seijas M, 2019, J CELL PHYSIOL, V234, P10512, DOI 10.1002/jcp.27723
   Chantada Vázquez MD, 2020, J PROTEOMICS, V212, DOI 10.1016/j.jprot.2019.103581
   Demidowich AP, 2016, MED HYPOTHESES, V92, P67, DOI 10.1016/j.mehy.2016.04.039
   Dolasia K, 2018, INT REV IMMUNOL, V37, P3, DOI 10.1080/08830185.2017.1397656
   Dumusc A, 2015, CURR OPIN RHEUMATOL, V27, P156, DOI 10.1097/BOR.0000000000000143
   Federal Drug Agency (FDA), THAL FDA PRESCR INF
   Federal Drug Agency (FDA), CLIN US NAL
   Franco Trepat E, 2022, BRIT J PHARMACOL, V179, P270, DOI 10.1111/bph.15707
   Franco Trepat E, 2019, J CLIN MED, V8, DOI 10.3390/jcm8081178
   Gómez R, 2015, NAT REV RHEUMATOL, V11, P159, DOI 10.1038/nrrheum.2014.209
   Gu HL, 2017, INT J MOL MED, V39, P734, DOI 10.3892/ijmm.2017.2885
   Hunter DJ, 2019, LANCET, V393, P1745, DOI 10.1016/S0140 6736(19)30417 9
   Hussey SE, 2013, BIOSCIENCE REP, V33, P37, DOI 10.1042/BSR20120098
   Jia T, 2019, INT IMMUNOPHARMACOL, V69, P382, DOI 10.1016/j.intimp.2019.01.049
   Katz J.N., 2020, OSTEOARTHR CARTIL OP, V2, DOI [10.1016/j.ocarto.2020.100059, DOI 10.1016/J.OCARTO.2020.100059]
   Kingsbury SR, 2014, RHEUMATOLOGY, V53, P937, DOI 10.1093/rheumatology/ket463
   Kovács B, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20184653
   Kraus VB, 2021, CALCIFIED TISSUE INT, V109, P329, DOI 10.1007/s00223 020 00701 7
   Li FF, 2018, J MOL MED, V96, P1189, DOI 10.1007/s00109 018 1691 0
   Loiarro M, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/674363
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140 6736(20)30628 0
   Munjal Akul, 2019, BioMolecular Concepts, V10, P111, DOI 10.1515/bmc 2019 0014
   Okura T, 2018, J ORTHOP RES, V36, P300, DOI 10.1002/jor.23608
   Oo WM, 2019, CLIN EXP RHEUMATOL, V37, P135
   Park BS, 2009, NATURE, V458, P1191, DOI 10.1038/nature07830
   Parvathaneni V, 2019, DRUG DISCOV TODAY, V24, P2076, DOI 10.1016/j.drudis.2019.06.014
   Pathan M, 2017, J EXTRACELL VESICLES, V6, DOI 10.1080/20013078.2017.1321455
   Qing YF, 2013, GENE, V524, P412, DOI 10.1016/j.gene.2013.04.039
   Rosenberg JH, 2017, MOL CELL BIOCHEM, V436, P59, DOI 10.1007/s11010 017 3078 x
   Saito T, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075 017 1296 y
   Sakellariou G, 2017, ANN RHEUM DIS, V76, P1484, DOI 10.1136/annrheumdis 2016 210815
   Scotece M, 2020, INFLAMM RES, V69, P415, DOI 10.1007/s00011 020 01326 0
   Sellam J, 2010, NAT REV RHEUMATOL, V6, P625, DOI 10.1038/nrrheum.2010.159
   Siddiq MA, 2022, CURR RHEUMATOL REV, V18, P20, DOI 10.2174/1573397117666211116111738
   Stausholm MB, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen 2019 031142
   Tardif G, 2022, ARTHRITIS RES THER, V24, DOI 10.1186/s13075 022 02801 1
   Teissier T, 2019, BIOGERONTOLOGY, V20, P279, DOI 10.1007/s10522 019 09808 3
   Thomas C, 2012, NAT STRUCT MOL BIOL, V19, P455, DOI 10.1038/nsmb.2260
   Thomas E, 2014, RHEUMATOLOGY, V53, P338, DOI 10.1093/rheumatology/ket346
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Van Spil WE, 2019, BIOCHEM PHARMACOL, V165, P41, DOI 10.1016/j.bcp.2019.02.037
   Villalvilla A, 2014, MOL NUTR FOOD RES, V58, P256, DOI 10.1002/mnfr.201200833
   Vincent Tonia L, 2019, F1000Res, V8, DOI 10.12688/f1000research.18831.1
   World Health Organization (WHO), 2004, GLOB BURD DIS 2004 U
   Yuan CH, 2020, BONE RES, V8, DOI 10.1038/s41413 020 00109 x
   Zhang GH, 2017, NAT COMMUN, V8, DOI 10.1038/s41467 017 00726 x
   Zhen GH, 2013, NAT MED, V19, P704, DOI 10.1038/nm.3143
NR 56
TC 3
Z9 3
U1 0
U2 8
PU ELSEVIER FRANCE EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY LES MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY LES MOULINEAUX, FRANCE
SN 0753 3322
EI 1950 6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD NOV
PY 2022
VL 155
AR 113671
DI 10.1016/j.biopha.2022.113671
EA SEP 2022
PG 14
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA 5A5NP
UT WOS:000862934600003
PM 36108390
OA gold
DA 2025 08 17
ER

PT J
AU Hagelauer, N
   Ziebart, T
   Pabst, A
   Walter, C
AF Hagelauer, Nadine
   Ziebart, Thomas
   Pabst, AndreasM.
   Walter, Christian
TI Bisphosphonates inhibit cell functions of HUVECs, fibroblasts and
   osteogenic cells via inhibition of protein geranylgeranylation
SO CLINICAL ORAL INVESTIGATIONS
LA English
DT Article
DE Bisphosphonate; Bisphosphonate associated osteonecrosis; Isoprenoid;
   Therapy
ID PROSTATE CANCER CELLS; MEVALONATE PATHWAY; IN VITRO; OSTEONECROSIS; RAS;
   ISOPRENYLATION; MONOTERPENES; PREVALENCE; EXPRESSION; LIMONENE
AB Objectives Bisphosphonate associated osteonecrosis of the jaw is a severe side effect in patients receiving nitrogen containing bisphosphonates (N BPs). One characteristic is its high recurrence rate; therefore, basic research for new therapeutic options is necessary. N BPs inhibit the farnesylpyrophosphate synthase in the mevalonate pathway causing a depletion of the cellular geranylgeranyl pool, resulting in a constriction of essential functions of different cell lines. Geranylgeraniol (GGOH) has been proven to antagonise the negative biological in vitro effects of bisphosphonates.
   Material and methods This study analyses the influence of the isoprenoids eugenol, farnesol, R limonene, menthol and squalene on different functions of zoledronate treated human umbilicord vein endothelial cells (HUVEC), fibroblasts and osteogenic cells. In addition to the 3 (4,5 dimethyl 2 thiazolyl) 2,5 diphenyl 2H tetrazolium bromide (MTT) vitality test, the migration capacity was analysed by scratch wound assay and the morphological architecture of the treated cells by phallacidin staining.
   Results In contrast to GGOH, none of the other tested isoprenoids were able to prevent cells from having negative zoledronate effects.
   Conclusions Despite structural analogy to GGOH, the investigated isoprenoids are not able to prevent the N BP effect. The negative impact of zoledronate on fibroblasts, HUVEC and osteogenic cells is due to inhibition of protein geranylgeranylation since the substitution of squalene and farnesyl did not have any effect on viability and wound healing capacity whereas GGOH did reduce the negative impact.
   Clinical relevance These data suggest the importance and exclusiveness of the mevalonate pathway intermediate GGOH as a potential therapeutic approach to bisphosphonate associated osteonecrosis of the jaws.
C1 [Hagelauer, Nadine; Ziebart, Thomas; Pabst, AndreasM.; Walter, Christian] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Oral & Maxillofacial Surg, D 55131 Mainz, Germany.
C3 Johannes Gutenberg University of Mainz
RP Walter, C (通讯作者)，Johannes Gutenberg Univ Mainz, Univ Med Ctr, Oral & Maxillofacial Surg, Augustuspl 2, D 55131 Mainz, Germany.
EM walter@mkg.klinik.uni mainz.de
RI Walter, Christian/GZG 8888 2022; Ziebart, Thomas/C 7048 2017
OI Ziebart, Thomas/0000 0001 8504 4958; Ziebart, Thomas/0000 0003 3296 7630
CR CASEY PJ, 1992, J LIPID RES, V33, P1731
   Crick DC, 1997, BIOCHEM BIOPH RES CO, V237, P483, DOI 10.1006/bbrc.1997.7145
   CROWELL PL, 1991, J BIOL CHEM, V266, P17679
   Dolder S, 2006, J BONE MINER RES, V21, P647, DOI 10.1359/JBMR.060111
   Guney E, 2008, NEUROENDOCRINOL LETT, V29, P252
   Hagelauer N, 2015, CLIN ORAL INVEST, V19, P139, DOI 10.1007/s00784 014 1219 0
   Hardcastle IR, 1999, BIOCHEM PHARMACOL, V57, P801, DOI 10.1016/S0006 2952(98)00349 9
   Holstein SA, 2002, BIOCHEMISTRY US, V41, P13698, DOI 10.1021/bi026251x
   Holstein SA, 2003, J LIPID RES, V44, P1209, DOI 10.1194/jlr.M300057 JLR200
   Kühl S, 2012, ORAL ONCOL, V48, P938, DOI 10.1016/j.oraloncology.2012.03.028
   Marcuzzi A, 2010, INT IMMUNOPHARMACOL, V10, P639, DOI 10.1016/j.intimp.2010.03.008
   Mashiba T, 2005, J BONE MINER METAB, V23, P36, DOI 10.1007/BF03026321
   Matura M, 2002, J AM ACAD DERMATOL, V47, P709, DOI 10.1067/mjd.2002.124817
   Mo HB, 2004, EXP BIOL MED, V229, P567, DOI 10.1177/153537020422900701
   Mühlbauer RC, 2003, BONE, V32, P372, DOI 10.1016/S8756 3282(03)00027 9
   Nogawa M, 2005, ONCOL RES, V15, P1
   Pabst AM, 2014, CLIN ORAL INVEST, V18, P1015, DOI 10.1007/s00784 013 1060 x
   Pabst AM, 2012, CLIN ORAL INVEST, V16, P87, DOI 10.1007/s00784 010 0507 6
   Patel T, 2007, J AM ACAD DERMATOL, V57, P873, DOI 10.1016/j.jaad.2007.04.008
   Peffley DM, 2003, J NUTR, V133, P38, DOI 10.1093/jn/133.1.38
   Pramod K, 2010, NAT PROD COMMUN, V5, P1999
   Reszka Alfred A, 2003, Curr Osteoporos Rep, V1, P45, DOI 10.1007/s11914 003 0008 5
   Shipman CM, 1998, CANCER RES, V58, P5294
   Thurnher M, 2012, CLIN CANCER RES, V18, P3524, DOI 10.1158/1078 0432.CCR 12 0489
   Van Beek ER, 2002, BONE, V30, P64, DOI 10.1016/S8756 3282(01)00655 X
   Virtanen SS, 2002, CANCER RES, V62, P2708
   Vogt A, 1996, ONCOGENE, V13, P1991
   Walker K, 2005, CURR OPIN GENET DEV, V15, P62, DOI 10.1016/j.gde.2004.11.001
   Walter C, 2011, ORAL DIS, V17, P194, DOI 10.1111/j.1601 0825.2010.01720.x
   Walter C, 2010, CLIN ORAL INVEST, V14, P35, DOI 10.1007/s00784 009 0266 4
   Walter C, 2008, EUR UROL, V54, P1066, DOI 10.1016/j.eururo.2008.06.070
   Walter C, 2007, SUPPORT CARE CANCER, V15, P197, DOI 10.1007/s00520 006 0120 z
   Walter C, 2014, CLIN ORAL INVEST, V18, P385, DOI 10.1007/s00784 013 0974 7
   Walter C, 2010, HEAD FACE MED, V6, DOI 10.1186/1746 160X 6 11
   Walter C, 2009, CANCER AM CANCER SOC, V115, P1631, DOI 10.1002/cncr.24119
   Wang IK, 2000, ONCOLOGY BASEL, V59, P245, DOI 10.1159/000012168
   Ziebart T, 2011, ORAL ONCOL, V47, P195, DOI 10.1016/j.oraloncology.2010.12.003
   Ziebart T, 2011, CLIN ORAL INVEST, V15, P105, DOI 10.1007/s00784 009 0365 2
NR 38
TC 18
Z9 19
U1 0
U2 14
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D 69121 HEIDELBERG, GERMANY
SN 1432 6981
EI 1436 3771
J9 CLIN ORAL INVEST
JI Clin. Oral Investig.
PD JUN
PY 2015
VL 19
IS 5
BP 1079
EP 1091
DI 10.1007/s00784 014 1320 4
PG 13
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA CI2ZG
UT WOS:000354616300015
PM 25261400
DA 2025 08 17
ER

PT J
AU Dragan, SL
   Kulej, M
   Mucha, L
   Morasiewicz, P
   Urbanski, W
   Dragan, B
   Wolanczyk, M
   Dragan, SF
AF Dragan, Szymon L.
   Kulej, Miroslaw
   Mucha, Lukasz
   Morasiewicz, Piotr
   Urbanski, Wiktor
   Dragan, Barbara
   Wolanczyk, Michal
   Dragan, Szymon F.
TI Graft of allogeneic knee extensor mechanism in treatment of giant cell
   tumor of the patella
SO POSTEPY HIGIENY I MEDYCYNY DOSWIADCZALNEJ
LA English
DT Article
DE Giant cell tumor; GCT; Patellar tumor; Knee extensor mechanism
   reconstruction; Knee extensor mechanism grafting; Allograft of patella
ID ALLOGRAFT RECONSTRUCTION; BONE; ARTHROPLASTY; RECURRENCE
AB Introduction: Cancer of the patella is a rare condition. Giant cell tumor of the patella is an extremely rare and a difficult to solve therapeutic problem. Depending on the degree of bone destruction, it may cause significant knee joint dysfunction. It is assumed that surgery is the treatment of choice.
   Material/Methods: This study presents an innovative treatment of a giant cell tumor of the patella in a 40 year old male with significant dysfunction of the knee extensor mechanism. Complex therapy included neoadjuvant treatment using a human monoclonal antibody IgG(2) that binds to RANKL (Denosumab) and follow up allogeneic grafting of knee extension mechanism.
   Results: Follow up CTs showed correct positioning and healing of grafted knee extensor mechanism. Early functional outcome was perfect. Seven weeks after the surgery, reduction of pain, improvement of the contour of the joint, full active extension and flexion of 110 degrees were noticed. Fifteen months after the surgery, the patient presented complete active extension and flexion of the knee joint, actively participated in professional life and CT tests did not reveal features of tumor recurrence.
   Conclusions: Treatment of isolated giant cell tumor of the patella with destruction of patella and joint dysfunction does not have a clear solution in the available literature. Such a condition may also exclude traditional procedures. In such cases, grafting of the whole extensor mechanism appears to be the appropriate treatment.
C1 [Dragan, Szymon L.; Kulej, Miroslaw; Morasiewicz, Piotr; Urbanski, Wiktor; Dragan, Szymon F.] Wroclaw Med Univ, Dept & Clin Orthopaed & Traumatol, Wroclaw, Poland.
   [Mucha, Lukasz] Wroclaw Univ Hosp, Clin Orthopaed & Traumatol, Wroclaw, Poland.
   [Wolanczyk, Michal] Wroclaw Med Univ, Dept Radiol, Wroclaw, Poland.
   [Dragan, Barbara] Wroclaw Med Univ, Dept & Clin Anaesthesiol & Intens Therapy, Wroclaw, Poland.
C3 Wroclaw Medical University; Wroclaw Medical University; Wroclaw Medical
   University; Wroclaw Medical University
RP Dragan, SL (通讯作者)，Zaklad Med Regeneracyjnej & Odtworczej Ortopedii, Katedra & Klin Ortopedii & Traumatol Narzadu Ruch, Borowska 213 Str, PL 50556 Wroclaw, Poland.
EM dragan.szymon@gmail.com
RI ; Dragan, Szymon Lukasz/ABH 6573 2022; Dragan, Szymon L./ABH 6573 2022;
   Morasiewicz, Piotr/AAW 1987 2021
OI Urbanski, Wiktor/0000 0003 3784 0233; Dragan, Szymon
   Feliks/0000 0001 5435 5198; Wolanczyk, Michal/0000 0002 4296 3353;
   Dragan, Barbara/0000 0003 3108 4211; Dragan, Szymon
   Lukasz/0000 0003 3565 3055; 
CR Barrack RL, 2003, CLIN ORTHOP RELAT R, P98, DOI 10.1097/01.blo.0000092993.90435.69
   Breitenseher M, 2001, RADIOLOGE, V41, P568, DOI 10.1007/s001170170147
   Burnett R Stephen J, 2005, J Bone Joint Surg Am, V87 Suppl 1, P175, DOI 10.2106/JBJS.E.00442
   Burnett RSJ, 2004, J BONE JOINT SURG AM, V86A, P2694, DOI 10.2106/00004623 200412000 00016
   Busfield BT, 2006, CLIN ORTHOP RELAT R, P145, DOI 10.1097/01.blo.000223980.44455.21
   CAMPANACCI M, 1987, J BONE JOINT SURG AM, V69A, P106, DOI 10.2106/00004623 198769010 00018
   Cavanna L, 2014, ONCOLOGIST, V19, P1207, DOI 10.1634/theoncologist.2014 0267
   Chen TH, 2005, INT ORTHOP, V29, P30, DOI 10.1007/s00264 004 0613 7
   EMERSON RH, 1994, CLIN ORTHOP RELAT R, P79
   Gouin F, 2013, ORTHOP TRAUMATOL SUR, V99, pS313, DOI 10.1016/j.otsr.2013.07.006
   Helito CP, 2013, ACTA ORTOP BRAS, V21, P315, DOI 10.1590/S1413 78522013000600003
   Klenke FM, 2011, CLIN ORTHOP RELAT R, V469, P1181, DOI 10.1007/s11999 010 1560 9
   Klenke FM, 2011, CLIN ORTHOP RELAT R, V469, P591, DOI 10.1007/s11999 010 1501 7
   Knochentumoren A, 2008, J BONE JOINT SURG AM, V90A, P1060, DOI 10.2106/JBJS.D.02771
   Lausten GS, 1996, INT ORTHOP, V20, P172, DOI 10.1007/s002640050057
   Leopold MSS, 1999, J BONE JOINT SURG AM, V81A, P1574, DOI 10.2106/00004623 199911000 00009
   Malhotra R, 2010, KNEE SURG SPORT TR A, V18, P167, DOI 10.1007/s00167 009 0908 8
   MARCOVE RC, 1978, CLIN ORTHOP RELAT R, P275
   MCDONALD DJ, 1986, J BONE JOINT SURG AM, V68A, P235, DOI 10.2106/00004623 198668020 00009
   Mercuri M, 2001, CLIN ORTHOP RELAT R, P35
   Nazarian DG, 1999, CLIN ORTHOP RELAT R, P123
   Nicholson NC, 1998, CLIN ORTHOP RELAT R, P250
   Puri Ajay, 2007, Indian J Orthop, V41, P101, DOI 10.4103/0019 5413.32039
   Purohit Shaligram, 2007, Indian J Orthop, V41, P91, DOI 10.4103/0019 5413.32037
   Salzer Kuntschik M, 1998, PROCEEDINGS OF THE GERMAN SOCIETY FOR PATHOLOGY 82ND MEETING   1998, P154
   Sobti A, 2016, ARCH BONE JT SURG AB, V4, P2
   Su YP, 2004, INT ORTHOP, V28, P239, DOI 10.1007/s00264 004 0564 z
   SUNG HW, 1982, J BONE JOINT SURG AM, V64, P755, DOI 10.2106/00004623 198264050 00015
   Trieb K, 2001, EUR J SURG ONCOL, V27, P200, DOI 10.1053/ejso.2000.1086
   Turcotte RE, 2006, ORTHOP CLIN N AM, V37, P35, DOI 10.1016/j.ocl.2005.08.005
   van der Heijden L, 2014, ONCOLOGIST, V19, P550, DOI 10.1634/theoncologist.2013 0432
   WILSON JS, 1976, AM J ROENTGENOL, V127, P856, DOI 10.2214/ajr.127.5.856
NR 32
TC 0
Z9 0
U1 0
U2 1
PU POLISH ACAD SCIENCES, INST IMMUNOL & EXP THERAPY
PI WROCLAW
PA RUDOLF WEIGL 12, WROCLAW, 53 114, POLAND
SN 0032 5449
EI 1732 2693
J9 POSTEP HIG MED DOSW
JI Postep. Hig. Med. Dosw.
PD NOV 12
PY 2019
VL 73
BP 581
EP 587
DI 10.5604/01.3001.0013.5602
PG 7
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA KA3DW
UT WOS:000505679600001
OA gold
DA 2025 08 17
ER

PT J
AU Di Vito, A
   Chiarella, E
   Sovereto, J
   Bria, J
   Perrotta, ID
   Salatino, A
   Baudi, F
   Sacco, A
   Antonelli, A
   Biamonte, F
   Barni, T
   Giudice, A
AF Di Vito, Anna
   Chiarella, Emanuela
   Sovereto, Jessica
   Bria, Jessica
   Perrotta, Ida Daniela
   Salatino, Alessandro
   Baudi, Francesco
   Sacco, Alessandro
   Antonelli, Alessandro
   Biamonte, Flavia
   Barni, Tullio
   Giudice, Amerigo
TI Novel insights into the pharmacological modulation of human periodontal
   ligament stem cells by the amino bisphosphonate Alendronate
SO EUROPEAN JOURNAL OF CELL BIOLOGY
LA English
DT Article
DE Alendronate; Human periodontal ligament mesenchymal; stem cells;
   Oxidative stress; Osteogenic differentiation
ID ZOLEDRONIC ACID; ANTIGENIC PROFILE; BONE; APOPTOSIS; DIFFERENTIATION;
   PROLIFERATION; OSTEONECROSIS; CYTOTOXICITY; INHIBIT; STRESS
AB Alendronate (ALN) is a second generation bisphosphonate widely used for osteoporosis and cancer induced bone lesions. Many studies have confirmed a strong relationship between osteonecrosis of the jaws (ONJ) development and oral bisphosphonates, especially ALN, although the molecular mechanisms underlying this pathology have not yet been elucidated. The reduction in bone turnover and vascularization usually observed in ONJ are the result of ALN action on different cell types harboured in oral microenvironment, such as osteoclasts, endothelial cells, and periodontal ligament stem cells (PDLSCs). In this perspective, the present study aims to investigate the effects of different ALN concentrations (2 mu M, 5 mu M, 10 mu M, 25 mu M, 50 mu M) on the phenotype and functional properties of human PDLSCs (hPDLSCs). hPDLSCs showed a decrease in cell viability (MTT assay) only when treated with ALN concentration of 10 mu M or larger for 48 h and 72 h. Cell cycle analysis revealed a moderate increase in proportion of S phase cells after exposure to low ALN concentration (2 5 mu M), an effect that was reverted after exposure to 10 50 mu M ALN. Conversely, cell death was evidenced via Annexin V/PI assay at very high concentration of ALN (50 mu M) after 4 days of treatment. In addition, we explored whether the effects of ALN on hPDLSCs growth and survival can be mediated by its ability to modulate oxidative stress. To this, we quantified the intracellular ROS amount and lipid peroxidation by using DCF probe and Bodipy staining, respectively. Flow cytometry analysis showed that ALN induced a dose dependent reduction of intracellular oxidative stress and lipid peroxidation upon treatment with low concentrations at both 48 h and 72 h. Increased levels of oxidative stress was reported at 50 mu M ALN and was also confirmed via TEM analysis. Despite the stability of the cellular immunophenotype, hPDLSCs showed impaired mobility after ALN exposure. Chronic exposure (7 14 days) to ALN in the range of 2 10 mu M significantly decreased the expression of the differentiation related factors ALP, RUNX2, COLI, and OPN as well as the osteogenic ability of hPDLSCs compared with untreated cells. Conversely, higher doses were found to be neutral. Our findings indicated that the effects of ALN on hPDLSCs behavior are dose dependent and suggest a role for oxidative stress in ALNinduced cell death that may lead to novel therapeutic approaches for ONJ.
C1 [Di Vito, Anna; Chiarella, Emanuela; Sovereto, Jessica; Bria, Jessica; Baudi, Francesco; Sacco, Alessandro; Biamonte, Flavia; Barni, Tullio] Magna Graecia Univ Catanzaro, Dept Clin & Expt Med, Catanzaro, Italy.
   [Perrotta, Ida Daniela] Univ Calabria, Ctr Microscopy & Microanal, Dept Biol Ecol & Earth Sci, Cosenza, Italy.
   [Salatino, Alessandro; Antonelli, Alessandro; Giudice, Amerigo] Magna Graecia Univ Catanzaro, Dept Hlth Sci, Catanzaro, Italy.
   [Di Vito, Anna] Magna Graecia Univ Catanzaro, Dept Clin & Expt Med, I 88100 Catanzaro, Italy.
C3 Magna Graecia University of Catanzaro; University of Calabria; Magna
   Graecia University of Catanzaro; Magna Graecia University of Catanzaro
RP Di Vito, A (通讯作者)，Magna Graecia Univ Catanzaro, Dept Clin & Expt Med, I 88100 Catanzaro, Italy.
EM divito@unicz.it
RI ; Baudi, Francesco/AAK 5748 2021; Biamonte, Flavia/AAC 4934 2019;
   Chiarella, Emanuela/H 4665 2018; Giudice, Amerigo/P 5520 2018
OI Salatino, Alessandro/0000 0001 9241 0768; Biamonte,
   Flavia/0000 0003 3248 3863; Di Vito, Anna/0000 0002 8294 8684
FU Department of Health Science, University Magna Graecia of Catanzaro;
   Master in Oral Surgery and Implantology; Universita degli Studi Magna
   Graecia di Catanzaro within the CRUI CARE Agreement
FX The author(s) disclosed receipt of the following financial support for
   the research, authorship, and/or publication of this article: The
   research referred to in this paper was funded by the Department of
   Health Science, University Magna Graecia of Catanzaro and by the Master
   in Oral Surgery and Implantology. Open access funding provided by
   Universita degli Studi Magna Graecia di Catanzaro within the CRUI CARE
   Agreement.
CR Arakaki N, 2013, BIOMED RES TOKYO, V34, P161, DOI 10.2220/biomedres.34.161
   Battaglia AM, 2022, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.868351
   Boonyapakorn T, 2008, ORAL ONCOL, V44, P857, DOI 10.1016/j.oraloncology.2007.11.012
   Caraglia M, 2006, ENDOCR RELAT CANCER, V13, P7, DOI 10.1677/erc.1.01094
   Chae JW, 2014, DRUG DEV IND PHARM, V40, P1325, DOI 10.3109/03639045.2013.819880
   Chang CH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105705
   Chen JL, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287 021 02661 7
   Chen TL, 2002, J CLIN PHARMACOL, V42, P1228, DOI 10.1177/009127002762491316
   Cheung E, 2020, J ONCOL PHARM PRACT, V26, P1180, DOI 10.1177/1078155220907965
   Chiarella E, 2022, BIOMEDICINES, V10, DOI 10.3390/biomedicines10051146
   Chiarella E, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21239214
   Chiarella E, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19124095
   Clezardin Philippe, 2013, Bonekey Rep, V2, P267, DOI 10.1038/bonekey.2013.1
   Di Sanzo M, 2018, GENE, V657, P92, DOI 10.1016/j.gene.2018.03.027
   Di Vito A, 2020, CELL TRANSPLANT, V29, DOI 10.1177/0963689720948497
   Di Vito A, 2019, CELL TRANSPLANT, V28, P129, DOI 10.1177/0963689718807680
   Ding N, 2018, J CELL PHYSIOL, V233, P7415, DOI 10.1002/jcp.26587
   Fromigue O, 2000, J BONE MINER RES, V15, P2211, DOI 10.1359/jbmr.2000.15.11.2211
   Huang J, 2021, INT J NANOMED, V16, P3161, DOI 10.2147/IJN.S305361
   Idris AI, 2008, CALCIFIED TISSUE INT, V82, P191, DOI 10.1007/s00223 008 9104 y
   Manzano Moreno FJ, 2019, INT J MED SCI, V16, P1534, DOI 10.7150/ijms.36994
   Manzano Moreno FJ, 2016, J ORAL MAXIL SURG, V74, P1765, DOI 10.1016/j.joms.2016.03.028
   Manzano Moreno FJ, 2015, CLIN ORAL INVEST, V19, P895, DOI 10.1007/s00784 014 1309 z
   Khan SA, 1997, J BONE MINER RES, V12, P1700, DOI 10.1359/jbmr.1997.12.10.1700
   Kim HK, 2009, CLIN ORTHOP RELAT R, V467, P3121, DOI 10.1007/s11999 008 0409 y
   Krüger TB, 2022, ACTA ODONTOL SCAND, V80, P619, DOI 10.1080/00016357.2022.2072522
   Krüger TB, 2016, ACTA ODONTOL SCAND, V74, P550, DOI 10.1080/00016357.2016.1217041
   Lan YC, 2013, ANTICANCER RES, V33, P3807
   Lee YJ, 2005, MOL BIOTECHNOL, V31, P1, DOI 10.1385/MB:31:1:001
   Li MY, 2020, STEM CELLS DEV, V29, P156, DOI 10.1089/scd.2019.0151
   LIN JH, 1992, DRUG METAB DISPOS, V20, P473
   Lockwood M, 2019, J BONE ONCOL, V18, DOI 10.1016/j.jbo.2019.100259
   Manzano Moreno FJ, 2015, J CRANIO MAXILL SURG, V43, P396, DOI 10.1016/j.jcms.2014.12.008
   Martini C, 2021, J PHYSIOL BIOCHEM, V77, P601, DOI 10.1007/s13105 021 00826 9
   Martins CA, 2015, J ENDODONT, V41, P45, DOI 10.1016/j.joen.2014.07.010
   McLeod NMH, 2014, J ORAL MAXIL SURG, V72, P503, DOI 10.1016/j.joms.2013.08.007
   Mesuraca M, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms232113214
   Moreau MF, 2007, BIOCHEM PHARMACOL, V73, P718, DOI 10.1016/j.bcp.2006.09.031
   Oryan A, 2021, LIFE SCI, V264, DOI 10.1016/j.lfs.2020.118681
   Correia VDP, 2006, DENT TRAUMATOL, V22, P312, DOI 10.1111/j.1600 9657.2005.00434.x
   Patntirapong Somying, 2022, J Oral Biol Craniofac Res, V12, P575, DOI 10.1016/j.jobcr.2022.07.011
   Patntirapong S, 2021, J ORAL PATHOL MED, V50, P191, DOI 10.1111/jop.13120
   Pourgonabadi S, 2018, IRAN J BASIC MED SCI, V21, P905, DOI 10.22038/IJBMS.2018.22877.5816
   Rogers Michael J., 2000, Cancer, V88, P2961, DOI 10.1002/1097 0142(20000615)88:12+<2961::AID CNCR12>3.0.CO;2 L
   Rosales HD, 2023, J CLIN MED, V12, DOI 10.3390/jcm12041416
   Ruggiero SL, 2014, J ORAL MAXIL SURG, V72, P1938, DOI 10.1016/j.joms.2014.04.031
   SATO M, 1991, J CLIN INVEST, V88, P2095, DOI 10.1172/JCI115539
   Scheper MA, 2009, SUPPORT CARE CANCER, V17, P1553, DOI 10.1007/s00520 009 0710 7
   Soares MQS, 2018, J ORAL MAXIL SURG, V76, P1893, DOI 10.1016/j.joms.2018.03.007
   Soydan SS, 2015, HUM EXP TOXICOL, V34, P1073, DOI 10.1177/0960327115569808
   Srivichit B, 2022, ARCH TOXICOL, V96, P1227, DOI 10.1007/s00204 021 03220 y
   Tao HQ, 2020, ACTA BIOCH BIOPH SIN, V52, P1055, DOI 10.1093/abbs/gmaa098
   Tsurukami Hiroshi, 2017, Clin Calcium, V27, P213, DOI CliCa1702213223
   Turek J, 2012, CALCIFIED TISSUE INT, V90, P202, DOI 10.1007/s00223 012 9570 0
   Valluru M, 2011, FRONT PHYSIOL, V2, DOI 10.3389/fphys.2011.00089
   Wehrhan F, 2015, CLIN ORAL INVEST, V19, P1289, DOI 10.1007/s00784 014 1354 7
   Yazici T, 2018, BIOL TRACE ELEM RES, V184, P358, DOI 10.1007/s12011 017 1187 8
   Zhang Xuechen, 2022, Biomater Transl, V3, P24, DOI 10.12336/biomatertransl.2022.01.004
NR 58
TC 6
Z9 6
U1 0
U2 7
PU ELSEVIER GMBH
PI MUNICH
PA HACKERBRUCKE 6, 80335 MUNICH, GERMANY
SN 0171 9335
EI 1618 1298
J9 EUR J CELL BIOL
JI Eur. J. Cell Biol.
PD DEC
PY 2023
VL 102
IS 4
AR 151354
DI 10.1016/j.ejcb.2023.151354
EA AUG 2023
PG 14
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA Y7AO3
UT WOS:001106752000001
PM 37604089
OA gold
DA 2025 08 17
ER

PT J
AU Bell, GI
   Meschino, MT
   Hughes Large, JM
   Broughton, HC
   Xenocostas, A
   Hess, DA
AF Bell, Gillian I.
   Meschino, Michael T.
   Hughes Large, Jennifer M.
   Broughton, Heather C.
   Xenocostas, Anargyros
   Hess, David A.
TI Combinatorial Human Progenitor Cell Transplantation Optimizes Islet
   Regeneration Through Secretion of Paracrine Factors
SO STEM CELLS AND DEVELOPMENT
LA English
DT Article
ID ALDEHYDE DEHYDROGENASE ACTIVITY; MESENCHYMAL STEM CELLS; PANCREATIC
   BETA CELLS; ADULT MOUSE PANCREAS; BONE MARROW CELLS; GROWTH FACTOR;
   HEPATOCYTE GROWTH; EGF RECEPTOR; DUCT CELLS; IN VIVO
AB Transplanted human bone marrow (BM) and umbilical cord blood (UCB) progenitor cells activate islet regenerative or revascularization programs depending on the progenitor subtypes administered. Using purification of multiple progenitor subtypes based on a conserved stem cell function, high aldehyde dehydrogenase (ALDH) activity (ALDH(hi)), we have recently shown that transplantation of BM derived ALDH(hi) progenitors improved systemic hyperglycemia and augmented insulin secretion by increasing islet associated proliferation and vascularization, without increasing islet number. Conversely, transplantation of culture expanded multipotentstromal cells (MSCs) derived from BM ALDH(hi) cells augmented total beta cell mass via formation of beta cell clusters associated with the ductal epithelium, without sustained islet vascularization. To identify paracrine effectors produced by islet regenerative MSCs, culture expanded BM ALDH(hi) MSCs were transplanted into streptozotocin treated nonobese diabetic/severe combine immune deficient (SCID) mice and segregated into islet regenerative versus nonregenerative cohorts based on hyperglycemia reduction, and subsequently compared for differential production of mRNA and secreted proteins. Regenerative MSCs showed increased expression of matrix metalloproteases, epidermal growth factor receptor (EGFR) activating ligands, and downstream effectors of Wnt signaling. Regenerative MSC supernatant also contained increased levels of pro angiogenic versus pro inflammatory cytokines, and augmented the expansion of ductal epithelial but not beta cells in vitro. Conversely, co culture with UCB ALDH(hi) cells induced beta cell but not ductal epithelial cell proliferation. Sequential transplantation of MSCs followed by UCB ALDH(hi) cells improved hyperglycemia and glucose tolerance by increasing beta cell mass associated with the ductal epithelium and by augmenting intra islet capillary densities. Thus, combinatorial human progenitor cell transplantation stimulated both islet regenerative and revascularization programs. Understanding the progenitor specific pathways that modulate islet regenerative and revascularization processes may provide new approaches for diabetes therapy.
C1 [Bell, Gillian I.; Meschino, Michael T.; Hughes Large, Jennifer M.; Broughton, Heather C.; Hess, David A.] Univ Western Ontario, Krembil Ctr Stem Cell Biol, Dept Physiol & Pharmacol, Program Regenerat Med,Vasc Biol Grp,Robarts Res I, London, ON N6A 5K8, Canada.
   [Xenocostas, Anargyros] London Hlth Sci Ctr, Dept Med, Div Hematol, London, ON, Canada.
C3 Western University (University of Western Ontario); London Health
   Sciences Centre
RP Hess, DA (通讯作者)，Univ Western Ontario, Krembil Ctr Stem Cell Biol, Dept Physiol & Pharmacol, Program Regenerat Med,Vasc Biol Grp,Robarts Res I, POB 5015,100 Perth Dr, London, ON N6A 5K8, Canada.
EM dhess@robarts.ca
RI Xenocostas, Anargyros/G 3358 2011; Hess, David/M 2828 2013
OI Hess, David/0000 0003 2186 3166
FU Canadian Institutes of Health Research (MOP) [86702]; Heart and Stroke
   Foundation of Canada
FX This work was supported the Canadian Institutes of Health Research
   (MOP#86702), and a New Investigator Award from the Heart and Stroke
   Foundation of Canada to D. A. Hess. We acknowledge Dr. Cheryle Seguin
   for critical review of the article, David Carter for analysis of
   microarray data, and Dr. Kristin Chadwick for cell sorting.
CR Alidibbiat A, 2008, J ENDOCRINOL, V196, P33, DOI 10.1677/JOE 07 0397
   Bell GI, 2011, STEM CELLS DEV, V18, P991
   Bonner Weir S, 2006, NAT CLIN PRACT ENDOC, V2, P240, DOI 10.1038/ncpendmet0186
   Bonner Weir S, 2004, PEDIATR DIABETES, V5, P16, DOI 10.1111/j.1399 543X.2004.00075.x
   Bonner Weir S, 2000, P NATL ACAD SCI USA, V97, P7999, DOI 10.1073/pnas.97.14.7999
   Bonner Weir S, 2005, NAT BIOTECHNOL, V23, P857, DOI 10.1038/nbt1115
   BONNERWEIR S, 1993, DIABETES, V42, P1715, DOI 10.2337/diabetes.42.12.1715
   Capoccia BJ, 2009, BLOOD, V113, P5340, DOI 10.1182/blood 2008 04 154567
   Ciceri F, 2010, CELL TRANSPLANT, V19, P1511, DOI 10.3727/096368910X514279
   Crisan M, 2008, CELL STEM CELL, V3, P301, DOI 10.1016/j.stem.2008.07.003
   D'Amour KA, 2005, NAT BIOTECHNOL, V23, P1534, DOI 10.1038/nbt1163
   D'Amour KA, 2006, NAT BIOTECHNOL, V24, P1392, DOI 10.1038/nbt1259
   Dor Y, 2004, NATURE, V429, P41, DOI 10.1038/nature02520
   Fiaschi Taesch NM, 2008, DIABETES, V57, P2745, DOI 10.2337/db08 1085
   García Ocaña A, 2003, J BIOL CHEM, V278, P343, DOI 10.1074/jbc.M207848200
   Guo TX, 2009, ENDOCR REV, V30, P214, DOI 10.1210/er.2009 0004
   Hakonen E, 2011, DIABETOLOGIA, V54, P1735, DOI 10.1007/s00125 011 2153 1
   Hess D, 2003, NAT BIOTECHNOL, V21, P763, DOI 10.1038/nbt841
   Hess DA, 2004, BLOOD, V104, P1648, DOI 10.1182/blood 2004 02 0448
   Hess DA, 2006, BLOOD, V107, P2162, DOI 10.1182/blood 2005 06 2284
   Hess DA, 2008, STEM CELLS, V26, P611, DOI 10.1634/stemcells.2007 0429
   Inada A, 2008, P NATL ACAD SCI USA, V105, P19915, DOI 10.1073/pnas.0805803105
   Katoh M, 2008, CURR DRUG TARGETS, V9, P565, DOI 10.2174/138945008784911750
   Keenan HA, 2010, DIABETES, V59, P2846, DOI 10.2337/db10 0676
   Klaus A, 2008, NAT REV CANCER, V8, P387, DOI 10.1038/nrc2389
   Kode JA, 2009, CYTOTHERAPY, V11, P377, DOI 10.1080/14653240903080367
   Kroon E, 2008, NAT BIOTECHNOL, V26, P443, DOI 10.1038/nbt1393
   Lechner A, 2003, NAT BIOTECHNOL, V21, P755, DOI 10.1038/nbt0703 755
   Lee J, 2009, STEM CELLS DEV, V18, P991, DOI 10.1089/scd.2008.0107
   Lee RH, 2006, P NATL ACAD SCI USA, V103, P17438, DOI 10.1073/pnas.0608249103
   Miettinen P, 2008, BIOCHEM SOC T, V36, P280, DOI 10.1042/BST0360280
   Miettinen PJ, 2006, DIABETES, V55, P3299, DOI 10.2337/db06 0413
   Minami K, 2005, P NATL ACAD SCI USA, V102, P15116, DOI 10.1073/pnas.0507567102
   Nostro MC, 2011, DEVELOPMENT, V138, P861, DOI 10.1242/dev.055236
   Otonkoski T, 1996, ENDOCRINOLOGY, V137, P3131, DOI 10.1210/en.137.7.3131
   Ryan EA, 2001, DIABETES, V50, P710, DOI 10.2337/diabetes.50.4.710
   Ryan EA, 2005, DIABETES, V54, P2060, DOI 10.2337/diabetes.54.7.2060
   Seaberg RM, 2004, NAT BIOTECHNOL, V22, P1115, DOI 10.1038/nbt1004
   Sengle G, 2008, J BIOL CHEM, V283, P13874, DOI 10.1074/jbc.M707820200
   Sengle G, 2011, J BIOL CHEM, V286, P5087, DOI 10.1074/jbc.M110.188615
   Shapiro AMJ, 2000, NEW ENGL J MED, V343, P230, DOI 10.1056/NEJM200007273430401
   Smukler SR, 2011, CELL STEM CELL, V8, P281, DOI 10.1016/j.stem.2011.01.015
   Sordi V, 2005, BLOOD, V106, P419, DOI 10.1182/blood 2004 09 3507
   Storms RW, 1999, P NATL ACAD SCI USA, V96, P9118, DOI 10.1073/pnas.96.16.9118
   Suarez Pinzon WL, 2005, J CLIN ENDOCR METAB, V90, P3401, DOI 10.1210/jc.2004 0761
   Urbán VS, 2008, STEM CELLS, V26, P244, DOI 10.1634/stemcells.2007 0267
   Xu XB, 2008, CELL, V132, P197, DOI 10.1016/j.cell.2007.12.015
   Yatoh S, 2007, DIABETES, V56, P1802, DOI 10.2337/db06 1670
   Zhang CY, 2007, P NATL ACAD SCI USA, V104, P2337, DOI 10.1073/pnas.0611101104
   Zhou Q, 2008, NATURE, V455, P627, DOI 10.1038/nature07314
NR 50
TC 35
Z9 41
U1 0
U2 11
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1547 3287
EI 1557 8534
J9 STEM CELLS DEV
JI Stem Cells Dev.
PD JUL
PY 2012
VL 21
IS 11
BP 1863
EP 1876
DI 10.1089/scd.2011.0634
PG 14
WC Cell & Tissue Engineering; Hematology; Medicine, Research &
   Experimental; Transplantation
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Hematology; Research & Experimental Medicine;
   Transplantation
GA 973NB
UT WOS:000306365700004
PM 22309189
DA 2025 08 17
ER

PT J
AU Ali, M
   Okamoto, M
   Komichi, S
   Watanabe, M
   Huang, HL
   Takahashi, Y
   Hayashi, M
AF Ali, Manahil
   Okamoto, Motoki
   Komichi, Shungo
   Watanabe, Masakatsu
   Huang, Hailing
   Takahashi, Yusuke
   Hayashi, Mikako
TI Lithium containing surface pre reacted glass fillers enhance hDPSC
   functions and induce reparative dentin formation in a rat pulp capping
   model through activation of Wnt/β catenin signaling
SO ACTA BIOMATERIALIA
LA English
DT Article
DE Direct pulp capping; Dentin regeneration; Lithium chloride; S PRG
   fillers; Wnt/beta catenin pathway
ID PATHWAY; CELLS; RESIN
AB Surface pre reacted glass (S PRG) fillers are new bioactive molecules used in dental clinic work to fill tooth defects. These fillers release various types of ions (Al +(3), BO 3, Na+, SiO3 2, Sr+2 and F ) and exhibit high biocompatibility, antibacterial capability, reduced plaque accumulation, and enhanced osteoblast differentiation. We previously showed that cement of S PRG fillers could induce tertiary dentin formation in rat models. Previous work also showed that lithium ions can activate the Wnt/beta catenin signaling pathway in vitro and induce dentin formation in pulpotomized teeth in vivo. In the current study, we sought to enhance the effect of S PRG cement by incorporating LiCl. We show that treatment of human dental pulp stem cells with eluates from S PRG/LiCl combination cements leads to an upregulation in cell migration, differentiation, and mineralization in vitro. In pulp capping animal trials, we found that S PRG/LiCl cements could induce tertiary dentin formation 28 days post capping. At 7 days post capping, we identified both beta catenin and Axin2 expression using immunofluorescence, indicative of Wnt/beta catenin signaling activity. In conclusion, S PRG/LiCl cement is highly effective in promoting human dental pulp stem cells profiles and in enhancing reparative dentin formation in rat teeth through activation of the Wnt/beta catenin canonical signaling pathway.
   Statement of Significance
   This is the first study to assess the behavior of S PRG fillers containing lithium ions on human dental pulp stem cells. We show that this new combination cement promotes positive cell responses by activating the endogenous Wnt/beta catenin signaling pathway in the pulp. The Wnt/beta catenin canonical signaling pathway is involved in many developmental and wound healing processes. The released lithium ions from the S PRG cement were systematically detected <0.01 mmol/L in our rat model. But it was efficient to induce tertiary dentin formation at the defect site. Since this novel bioactive cement is potentially a promising material for clinical pulp regenerative therapy, future human clinical trials will be needed. (C) 2019 Acta Materialia Inc. Published by Elsevier Ltd.
C1 [Ali, Manahil; Okamoto, Motoki; Komichi, Shungo; Watanabe, Masakatsu; Huang, Hailing; Takahashi, Yusuke; Hayashi, Mikako] Osaka Univ, Grad Sch Dent, Dept Restorat Dent & Endodontol, 1 8 Yamadaoka, Suita, Osaka 5650871, Japan.
C3 University of Osaka
RP Takahashi, Y (通讯作者)，Osaka Univ, Grad Sch Dent, Dept Restorat Dent & Endodontol, 1 8 Yamadaoka, Suita, Osaka 5650871, Japan.
EM manahilali@dent.osaka u.ac.jp; motoki@dent.osaka u.ac.jp;
   s.komichi@dent.osaka u.ac.jp; masa_watanabe@dent.osaka u.ac.jp;
   helenstory93@dent.osaka u.ac.jp; takahasi@dent.osaka u.ac.jp;
   mikarin@dent.osaka u.ac.jp
RI huang, hailing/MFK 1987 2025; Okamoto, Motoki/HMW 1510 2023; TAKAHASHI,
   YUSUKE/R 1782 2019
OI Takahashi, Yusuke/0000 0002 7974 1252; 
FU JSPS KAKENHI [16 K20453, 17 K11704, 17H06848]; Grants in Aid for
   Scientific Research [17H06848] Funding Source: KAKEN
FX This work was supported by JSPS KAKENHI [grant numbers #16 K20453, #17
   K11704, #17H06848.]
CR Accorinte MLR, 2008, OPER DENT, V33, P488, DOI 10.2341/07 143
   Asano K, 2014, OPER DENT, V39, P159, DOI 10.2341/13 034 L
   Awawdeh L, 2018, J ENDODONT, V44, P1603, DOI 10.1016/j.joen.2018.08.004
   Babb R, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 03145 6
   Bernkopf DB, 2015, J CELL SCI, V128, P33, DOI 10.1242/jcs.159145
   Boivin G, 1996, J BONE MINER RES, V11, P1302
   Clément Lacroix P, 2005, P NATL ACAD SCI USA, V102, P17406, DOI 10.1073/pnas.0505259102
   Fujimoto Y, 2010, DENT MATER J, V29, P392, DOI 10.4012/dmj.2010 015
   Hajira N. S. W. Najma, 2015, INT J DENT ORAL HLTH, V2, DOI [10.16966/2378 7090.166, DOI 10.16966/2378 7090.166]
   Han LL, 2011, DENT MATER J, V30, P898, DOI 10.4012/dmj.2011 101
   Han N., 2014, PLOS ONE, V9
   Han PP, 2015, J BONE MINER RES, V30, P1160, DOI 10.1002/jbmr.2445
   Han PP, 2012, BIOMATERIALS, V33, P6370, DOI 10.1016/j.biomaterials.2012.05.061
   Hanak AS, 2015, TOXICOL SCI, V143, P185, DOI 10.1093/toxsci/kfu224
   Hilton TJ, 2009, OPER DENT, V34, P615, DOI 10.2341/09 132 0
   Huang George T J, 2011, Front Biosci (Elite Ed), V3, P788, DOI 10.2741/e286
   Iijima M, 2017, DENT MATER J, V36, P461, DOI 10.4012/dmj.2016 307
   Ikemura K, 2008, DENT MATER J, V27, P315, DOI 10.4012/dmj.27.315
   Imazato S, 2009, DENT MATER J, V28, P11, DOI 10.4012/dmj.28.11
   Ishimoto K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121938
   Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172 1183.2002
   Jope RS, 2003, TRENDS PHARMACOL SCI, V24, P441, DOI 10.1016/S0165 6147(03)00206 2
   Jun SK, 2017, BIOMED RES INT UK, V2017, DOI 10.1155/2017/2495282
   Kawashima S, 2016, DENT MATER J, V35, P479, DOI 10.4012/dmj.2015 381
   Li X., 2017, SCI REP, V7, P45204, DOI [10.1038/srep45204, DOI 10.1038/SREP45204]
   Lin WZ, 2019, BMC ORAL HEALTH, V19, DOI 10.1186/s12903 018 0680 6
   Lipski M, 2018, CLIN ORAL INVEST, V22, P2021, DOI 10.1007/s00784 017 2296 7
   Liu F, 2010, J DENT RES, V89, P318, DOI 10.1177/0022034510363373
   Lucas Camila de Paula Telles Pires, 2017, Braz. Dent. J., V28, P51, DOI 10.1590/0103 6440201701135
   McNamara RP, 2010, J ENDODONT, V36, P1851, DOI 10.1016/j.joen.2010.08.021
   Miyauchi T., 2009, JPN J CONSERV DENT, V52, P469
   Njeh A., 2016, EVIDE BAS ENDODONT, V1, P3, DOI [DOI 10.1186/S41121 016 0003 9, 10.1186/s41121 016 0003 9]
   Okamoto M, 2018, CLIN ORAL INVEST, V22, P2879, DOI 10.1007/s00784 018 2374 5
   Okamoto Y, 2001, J ANAL ATOM SPECTROM, V16, P539, DOI 10.1039/b101969o
   Pan J, 2017, ORTHOD CRANIOFAC RES, V20, P146, DOI 10.1111/ocr.12190
   Peycheva K., 2015, Acta Medica Bulgarica, V42, P23
   Saku S, 2010, DENT MATER J, V29, P193, DOI 10.4012/dmj.2009 050
   Shorter E, 2009, BIPOLAR DISORD, V11, P4, DOI 10.1111/j.1399 5618.2009.00706.x
   SMITH DF, 1973, AM J PHYSIOL, V225, P159, DOI 10.1152/ajplegacy.1973.225.1.159
   Stringhini E, 2019, CLIN ORAL INVEST, V23, P1967, DOI 10.1007/s00784 018 2616 6
   Takahashi Y, 2019, CLIN ORAL INVEST, V23, P1723, DOI 10.1007/s00784 018 2596 6
   Tziafas D, 2000, J DENT, V28, P77, DOI 10.1016/S0300 5712(99)00047 0
   Vahabzadeh S, 2017, J BIOMED MATER RES B, V105, P391, DOI 10.1002/jbm.b.33485
   Yoneda M., 2015, Pharm. Anal. Acta, V6, P349, DOI [10.4172/2153 2435.1000349, DOI 10.4172/2153 2435.1000349]
   YOSHIMINE Y, 1995, ORAL SURG ORAL MED O, V79, P351, DOI 10.1016/S1079 2104(05)80229 X
   Zhong TY, 2019, AM J TRANSL RES, V11, P1819
NR 46
TC 33
Z9 35
U1 0
U2 36
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1742 7061
EI 1878 7568
J9 ACTA BIOMATER
JI Acta Biomater.
PD SEP 15
PY 2019
VL 96
BP 594
EP 604
DI 10.1016/j.actbio.2019.06.016
PG 11
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA IY1DX
UT WOS:000486132900047
PM 31212112
OA hybrid
DA 2025 08 17
ER

PT J
AU Chen, SY
   Shiau, AL
   Li, YT
   Lin, CC
   Jou, IM
   Liu, MF
   Wu, CL
   Wang, CR
AF Chen, Shih Yao
   Shiau, Ai Li
   Li, Yuan Tsung
   Lin, Chi Chen
   Jou, I Ming
   Liu, Ming Fei
   Wu, Chao Liang
   Wang, Chrong Reen
TI Transcription Factor Snail Regulates Tumor Necrosis Factor α Mediated
   Synovial Fibroblast Activation in the Rheumatoid Joint
SO ARTHRITIS & RHEUMATOLOGY
LA English
DT Article
ID EPITHELIAL MESENCHYMAL TRANSITION; COLLAGEN INDUCED ARTHRITIS; CADHERIN
   11; GROWTH FACTOR; TNF ALPHA; FIBROSIS; SYNOVIOCYTES; DISEASE;
   INFLAMMATION; EXPRESSION
AB Objective. The transcription factor Snail is involved in various biologic functions. We hypothesized that this molecule regulates tumor necrosis factor alpha (TNF alpha) mediated synovial fibroblast activation in the rheumatoid joint. The aim of this study was to examine the role of Snail in the expression of cadherin 11 (Cad 11) and myofibroblast markers, interleukin 6 (IL 6) production, and the invasive ability of cells.
   Methods. Synovium samples were obtained from patients with rheumatoid arthritis (RA) and from rats with collagen induced arthritis (CIA). Synovial fibroblasts were treated with TNF alpha or a Wnt signaling inducer, and the joints of rats with CIA were injected with a TNF alpha antagonist. Modulation of Snail expression in the synovial fibroblasts and joints was performed by lentiviral vector mediated transfer of complementary DNA or short hairpin RNA.
   Results. The expression of Snail and Cad 11 was higher in synovium and synovial fibroblasts from patients with RA compared with patients with osteoarthritis and was increased in rats with CIA. TNF alpha stimulation or activation of Wnt signaling up regulated the expression of Snail, Cad 11, and alpha smooth muscle actin (alpha SMA) in synovial fibroblasts, and anti TNF alpha therapy down regulated the expression of Snail, Cad 11, and alpha SMA in the joints of rats with CIA. Although synovial fibroblast transfectants in which Snail was overexpressed showed increased expression of Cad 11 and alpha SMA and enhanced TNF alpha mediated invasive capacity and IL 6 production, synovial fibroblast transfectants from rats with CIA in which Snail was silenced showed decreased expression and had the opposite effect on these functions. Normal joints in which Snail was overexpressed had hyperplastic synovium, with increased expression of Cad 11, alpha SMA, and IL 6. Silencing Snail expression ameliorated arthritis, with reduced Cad 11 expression and reduced levels of extracellular matrix deposition in the joints of rats with CIA, whereas overexpression of Snail exacerbated arthritis, with increased Cad 11 expression and increased levels of extracellular matrix deposition.
   Conclusion. Our results demonstrate that Snail regulates TNF alpha mediated activation of synovial fibroblasts in the rheumatoid joint. These findings may contribute to the pharmacologic development of therapeutics targeting synovial fibroblasts in patients with RA.
C1 [Chen, Shih Yao; Shiau, Ai Li; Li, Yuan Tsung; Jou, I Ming; Liu, Ming Fei; Wu, Chao Liang; Wang, Chrong Reen] Natl Cheng Kung Univ, Coll Med, Tainan 70101, Taiwan.
   [Lin, Chi Chen] Natl Chung Hsing Univ, Taichung 40227, Taiwan.
C3 National Cheng Kung University; National Chung Hsing University
RP Wu, CL (通讯作者)，Natl Cheng Kung Univ, Coll Med, Dept Biochem & Mol Biol, 1 Univ Rd, Tainan 70101, Taiwan.
EM wumolbio@mail.ncku.edu.tw; wangcr@mail.ncku.edu.tw
RI shiau, A Li/C 2885 2012; Chen, Shih Yao/GXM 5182 2022; Wu,
   Chao Liang/K 5272 2013; Liu, Mingfei/A 4081 2009
OI Chen, Shih Yao/0000 0003 4929 855X; Wu, Chao Liang/0000 0001 7821 9406;
   Lin, Tim. C.C/0000 0002 1464 0231
FU Ministry of Science and Technology, Taiwan [NSC 98 2628 B 006 014 MY3,
   NSC 100 2314 B 006 031 MY3, NSC 101 2320 B 006 033 MY3, MOST
   103 2314 B 006 058 MY3]
FX Supported by the Ministry of Science and Technology, Taiwan (grants NSC
   98 2628 B 006 014 MY3, NSC 100 2314 B 006 031 MY3, NSC
   101 2320 B 006 033 MY3, and MOST 103 2314 B 006 058 MY3).
CR Nieto MA, 2011, ANNU REV CELL DEV BI, V27, P347, DOI 10.1146/annurev cellbio 092910 154036
   Barberà MJ, 2004, ONCOGENE, V23, P7345, DOI 10.1038/sj.onc.1207990
   Bottini N, 2013, NAT REV RHEUMATOL, V9, P24, DOI 10.1038/nrrheum.2012.190
   Bourlier V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031274
   Cha HS, 2010, EXP MOL MED, V42, P428, DOI 10.3858/emm.2010.42.6.044
   Chang SK, 2011, P NATL ACAD SCI USA, V108, P8402, DOI 10.1073/pnas.1019437108
   Chang SK, 2010, IMMUNOL REV, V233, P256, DOI 10.1111/j.0105 2896.2009.00854.x
   Chen SY, 2009, ARTHRITIS RHEUM US, V60, P3290, DOI 10.1002/art.24940
   Chiang C, 2013, CYTOKINE GROWTH F R, V24, P123, DOI 10.1016/j.cytogfr.2012.09.002
   Choy EH, 2013, NAT REV RHEUMATOL, V9, P154, DOI 10.1038/nrrheum.2013.8
   Ekwall AKH, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3274
   Escrivà M, 2008, MOL CELL BIOL, V28, P1528, DOI 10.1128/MCB.02061 07
   Farré D, 2003, NUCLEIC ACIDS RES, V31, P3651, DOI 10.1093/nar/gkg605
   Feldmann M, 2002, NAT REV IMMUNOL, V2, P364, DOI 10.1038/nri802
   Francí C, 2006, ONCOGENE, V25, P5134, DOI 10.1038/sj.onc.1209519
   Gäbele E, 2009, BIOCHEM BIOPH RES CO, V378, P348, DOI 10.1016/j.bbrc.2008.10.155
   Hinz B, 2004, MOL BIOL CELL, V15, P4310, DOI 10.1091/mbc.E04 05 0386
   Hu BA, 2013, CURR OPIN RHEUMATOL, V25, P71, DOI 10.1097/BOR.0b013e32835b1352
   Kasperkovitz PV, 2005, ARTHRITIS RHEUM US, V52, P430, DOI 10.1002/art.20811
   Kiener HP, 2009, ARTHRITIS RHEUM US, V60, P1305, DOI 10.1002/art.24453
   Kim NH, 2011, J CELL BIOL, V195, P417, DOI 10.1083/jcb.201103097
   LAFYATIS R, 1989, J CLIN INVEST, V83, P1267, DOI 10.1172/JCI114011
   LeBleu VS, 2013, NAT MED, V19, P1047, DOI 10.1038/nm.3218
   Lee DM, 2007, SCIENCE, V315, P1006, DOI 10.1126/science.1137306
   Lee SH, 2010, ONCOGENE, V29, P4576, DOI 10.1038/onc.2010.208
   Li YT, 2012, ARTHRITIS RHEUM US, V64, P3240, DOI 10.1002/art.34550
   Lim SO, 2010, FEBS LETT, V584, P2231, DOI 10.1016/j.febslet.2010.04.006
   Lin Kimberly, 2010, Genes Cancer, V1, P409
   Lories RJ, 2013, NAT REV RHEUMATOL, V9, P328, DOI 10.1038/nrrheum.2013.25
   Mattey DL, 1997, ANN RHEUM DIS, V56, P426, DOI 10.1136/ard.56.7.426
   McInnes IB, 2011, NEW ENGL J MED, V365, P2205, DOI 10.1056/NEJMra1004965
   Meldrum KK, 2007, AM J PHYSIOL REG I, V292, pR1456, DOI 10.1152/ajpregu.00620.2005
   MullerLadner U, 1996, AM J PATHOL, V149, P1607
   Raghu G, 2008, AM J RESP CRIT CARE, V178, P948, DOI 10.1164/rccm.200709 1446OC
   Rowe RG, 2009, J CELL BIOL, V184, P399, DOI 10.1083/jcb.200810113
   Scarpa M, 2011, AM J PHYSIOL GASTR L, V300, pG316, DOI 10.1152/ajpgi.00141.2010
   Vandooren B, 2008, ARTHRITIS RHEUM, V58, P3051, DOI 10.1002/art.23886
   Verjee LS, 2013, P NATL ACAD SCI USA, V110, pE928, DOI 10.1073/pnas.1301100110
   Wang CR, 2008, ARTHRITIS RHEUM US, V58, P1650, DOI 10.1002/art.23517
   Wang CR, 2005, ARTHRITIS RHEUM US, V52, P1319, DOI 10.1002/art.20991
   Watson RS, 2010, LAB INVEST, V90, P1615, DOI 10.1038/labinvest.2010.145
   Woodrick RS, 2011, NAT REV RHEUMATOL, V7, P639, DOI 10.1038/nrrheum.2011.145
   Wu M, 2013, OSTEOARTHR CARTILAGE, V21, P1605, DOI 10.1016/j.joca.2013.07.015
   Wu MH, 2014, ARTHRITIS RHEUMATOL, V66, P1010, DOI 10.1002/art.38275
   Wynn TA, 2012, NAT MED, V18, P1028, DOI 10.1038/nm.2807
   Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173
NR 46
TC 26
Z9 27
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 2326 5191
EI 2326 5205
J9 ARTHRITIS RHEUMATOL
JI Arthritis Rheumatol.
PD JAN
PY 2015
VL 67
IS 1
BP 39
EP 50
DI 10.1002/art.38899
PG 12
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA AX4QY
UT WOS:000346917700006
PM 25303734
DA 2025 08 17
ER

PT J
AU Gloth, FM
AF Gloth, F. Michael, III
TI Pharmacological Management of Persistent Pain in Older Persons: Focus on
   Opioids and Nonopioids
SO JOURNAL OF PAIN
LA English
DT Article
DE Guidelines; persistent pain; recommendations; treatment; analgesics
ID AMERICAN ACADEMY; VALIDATION; SCREENER; RECOMMENDATIONS; OSTEOARTHRITIS;
   GUIDELINES; BEHAVIORS; ROTATION; SOCIETY; MISUSE
AB Managing persistent pain is challenging, particularly in older adults who often have comorbidities and physiological changes that affect dosing and adverse effect profiles. The latest guideline issued by the American Geriatrics Society in 2009 is an important clinical resource on prescribing analgesics for older adults. This guideline helps form an evidence based approach to treating persistent pain, along with other current endorsements, such as the relevant disease specific recommendations by the American College of Rheumatology, the European League Against Rheumatism, and Osteoarthritis Research Society International, as well as opioid specific guidelines issued by the American Pain Society, the American Academy of Pain Medicine, the Federation of State Medical Boards of the United States, and the American Society of Interventional Pain Physicians. Safety is of utmost concern, especially for older adults; these guidelines include key approaches for safe opioid prescribing. Combining analgesics that have multiple mechanisms of action with nonpharmaceutical approaches can be beneficial in providing pain relief. Nontraditional analgesics are also considered on a case by case basis, and a few of these options are weakly recommended. Therapies should be initiated at the lowest possible dose and slowly titrated to effect, while tailoring them to the therapeutic and side effect responses of the individual.
   Perspective: For treating persistent pain in older adults, acetaminophen and opioids are important therapies in the analgesic armamentarium. In contrast, oral nonselective and selective NSAIDs should rarely be used. All patients with neuropathic pain are candidates for treatment with adjuvant analgesics; those with localized neuropathic pain can benefit from topical lidocaine. (C) 2011 by the American Pain Society
C1 [Gloth, F. Michael, III] Johns Hopkins Univ, Sch Med, Div Geriatr Med & Gerontol, Baltimore, MD USA.
   [Gloth, F. Michael, III] Univ Maryland, Sch Epidemiol & Prevent Med, Baltimore, MD 21201 USA.
C3 Johns Hopkins University; University System of Maryland; University of
   Maryland Baltimore
RP Gloth, FM (通讯作者)，5505 Hopkins Bayview Circle, Baltimore, MD 21224 USA.
EM fgloth1@jhmi.edu
FU Merck; HCR Manor Care; CDC; American College of Rheumatology; Novartis;
   Endo Pharmaceuticals Inc.; American Geriatrics Society; Genentech;
   Amgen; Purdue; Pfizer
FX Grants/research support from Merck and HCR Manor Care; Consulting fees
   from CDC, American College of Rheumatology, Novartis, Endo
   Pharmaceuticals Inc., American Geriatrics Society, Merck, HCR Manor
   Care, Genentech, Amgen, Purdue, and Pfizer; Speaker's bureau from
   Novartis, Genentech, Purdue, Amgen, Endo Pharmaceuticals Inc., Merck,
   MER, American Geriatrics Society; Ownership interest/shareholder:Smart
   E Records, Allscripts; Royalty/patent holder: Humana Press (Springer);
   Royalties: DiaMedica Publishing; Royalty contract: Smart E Records.An
   educational grant was provided by Endo Pharmaceuticals Inc. for the
   symposium on which this paper was based and for subsequent manuscript
   development.
CR Barkin RL, 2010, DRUG AGING, V27, P775, DOI 10.2165/11539430 000000000 00000
   Butler SF, 2004, PAIN, V112, P65, DOI 10.1016/j.pain.2004.07.026
   Butler SF, 2008, J PAIN, V9, P360, DOI 10.1016/j.jpain.2007.11.014
   Butler SF, 2007, PAIN, V130, P144, DOI 10.1016/j.pain.2007.01.014
   Butler SF, 2009, J ADDICT MED, V3, P66, DOI 10.1097/ADM.0b013e31818e41da
   Chou R, 2009, J PAIN, V10, P147, DOI 10.1016/j.jpain.2008.10.007
   Chou R, 2009, J PAIN, V10, P131, DOI 10.1016/j.jpain.2008.10.009
   Chou R, 2009, J PAIN, V10, P113, DOI 10.1016/j.jpain.2008.10.008
   Desai SP, 2008, ARTHRIT RHEUM ARTHR, V59, P1058, DOI 10.1002/art.23929
   Federation State Med Boards US Inc, 2005, J PAIN PALLIAT CARE, V19, P73, DOI 10.1300/J354v19n02_14
   Ferrell B, 2002, J AM GERIATR SOC, V50, pS205, DOI 10.1046/j.1532 5415.50.6s.1.x
   Ferrell BA, 1998, J AM GERIATR SOC, V46, P635, DOI 10.1111/j.1532 5415.1998.tb01084.x
   Ferrell B, 2009, J AM GERIATR SOC, V57, P1331, DOI 10.1111/j.1532 5415.2009.02376.x
   Fick DM, 2003, ARCH INTERN MED, V163, P2716, DOI 10.1001/archinte.163.22.2716
   Fine PG, 2009, J PAIN SYMPTOM MANAG, V38, P418, DOI 10.1016/j.jpainsymman.2009.06.002
   Hanlon JT, 2009, J AM GERIATR SOC, V57, P335, DOI 10.1111/j.1532 5415.2008.02098.x
   Knotkova H, 2009, J PAIN SYMPTOM MANAG, V38, P426, DOI 10.1016/j.jpainsymman.2009.06.001
   Pergolizzi Joseph, 2008, Pain Pract, V8, P287, DOI 10.1111/j.1533 2500.2008.00204.x
   Trescot Andrea M, 2006, Pain Physician, V9, P1
   Webster LR, 2005, PAIN MED, V6, P432, DOI 10.1111/j.1526 4637.2005.00072.x
   Zhang W, 2008, OSTEOARTHR CARTILAGE, V16, P137, DOI 10.1016/j.joca.2007.12.013
   Zhang W, 2005, ANN RHEUM DIS, V64, P669, DOI 10.1136/ard.2004.028886
NR 22
TC 47
Z9 55
U1 0
U2 13
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1 3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 1526 5900
J9 J PAIN
JI J. Pain
PD MAR
PY 2011
VL 12
IS 3
SU 1
BP S14
EP S20
DI 10.1016/j.jpain.2010.11.006
PG 7
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Neurosciences & Neurology
GA 738HR
UT WOS:000288631400003
PM 21296028
OA Bronze
DA 2025 08 17
ER

PT J
AU Liu, S
   Yuan, XM
   Ma, C
   Zhao, J
   Xiong, ZL
AF Liu, Shuo
   Yuan, Xuemei
   Ma, Chang
   Zhao, Jing
   Xiong, Zhili
TI <SUP>1</SUP>H NMR based urinary metabolomic analysis for the preventive
   effects of gushudan on glucocorticoid induced osteoporosis rats
SO ANALYTICAL BIOCHEMISTRY
LA English
DT Article
DE Osteoporosis; GSD; H 1 NMR; Metabolomics
ID OXIDATIVE STRESS; OSTEOBLAST; TAURINE
AB Gushudan (GSD), a traditional Chinese medicine with a history of more than 15 years, has been shown to have anti osteoporosis effects, but the specific therapeutic mechanism behind it is still unclear. To further elucidate the pathogenesis of osteoporosis and the preventive mechanism of GSD on glucocorticoid induced osteoporosis (GIOP) rats, a rapid and comprehensive H 1 NMR metabolomics method was established to detect urinary metabolic profiles in the control group, model group and GSD treatment group in this study. The orthogonal partial least squares discriminant analysis (OPLS DA) was performed to investigate changes in the metabolites, and related metabolic pathways were discovered using MetaboAnalyst platform. As a result, a total of 27 differential metabolites were identified. Of these, 17 metabolites such as formate, allantoin and L threonate were newly discovered as GIOP potential biomarkers. Energy metabolism, intestinal flora metabolism, amino acid metabolism and oxidative stress response were significantly changed in the urinary profiles of GIOP rats, and GSD could play an anti osteoporosis role by regulating these metabolic pathways. This study compliments the earlier LC MS based urine metabolomics research, and helps further understand the pathogenesis of osteoporosis and the potential preventive effects of GSD on GIOP rats.
C1 [Liu, Shuo; Yuan, Xuemei; Ma, Chang; Zhao, Jing; Xiong, Zhili] Shenyang Pharmaceut Univ, Sch Pharm, 26 Huatuo Rd, Benxi 117004, Liaoning, Peoples R China.
C3 Shenyang Pharmaceutical University
RP Xiong, ZL (通讯作者)，Shenyang Pharmaceut Univ, Sch Pharm, 26 Huatuo Rd, Benxi 117004, Liaoning, Peoples R China.
EM bearry200@126.com
RI ZHAO, JING/HDN 0412 2022
FU National Natural Science Foundation of China [81773694]
FX This work was funded by the National Natural Science Foundation of China
   (grant no. 81773694).
CR Friedrich N, 2012, OMICS, V16, P612, DOI 10.1089/omi.2012.0066
   Gran Petra, 2011, BMC Physiology, V11, P10, DOI 10.1186/1472 6793 11 10
   Hansen SH, 2015, ADV EXP MED BIOL, V803, P397, DOI 10.1007/978 3 319 15126 7_30
   He Jian hua, 2005, Sichuan Da Xue Xue Bao Yi Xue Ban, V36, P225
   Hu J, 2008, BIOMATERIALS, V29, P3815, DOI 10.1016/j.biomaterials.2008.06.015
   [黄月 Huang Yue], 2016, [中国药学杂志, Chinese Pharmaceutical Journal], V51, P2045
   Huang Y, 2016, J CHROMATOGR B, V1027, P119, DOI 10.1016/j.jchromb.2016.05.019
   Jansson PJ, 2004, FREE RADICAL RES, V38, P855, DOI 10.1080/10715760410001700497
   Li X., 2016, LIFE SCI INSTRUM, V14, P3
   Li Yun Li Yun, 2017, Chinese Journal of Pharmacology and Toxicology, V31, P907
   Liang M.X, 2002, WORLD SCI TECHNOL MO, V4, P31
   Liu GM, 2016, FOOD FUNCT, V7, P964, DOI 10.1039/c5fo01486g
   Ma B, 2013, EUR J PHARMACOL, V718, P524, DOI 10.1016/j.ejphar.2013.06.030
   Markley JL, 2017, CURR OPIN BIOTECH, V43, P34, DOI 10.1016/j.copbio.2016.08.001
   Martin FPJ, 2008, MOL SYST BIOL, V4, DOI 10.1038/msb4100190
   Martinez Moral MP, 2019, ENVIRON SCI TECH LET, V6, P283, DOI 10.1021/acs.estlett.9b00142
   Ohlsson C, 2015, TRENDS ENDOCRIN MET, V26, P69, DOI 10.1016/j.tem.2014.11.004
   Pasiakos SM, 2011, NUTR REV, V69, P550, DOI 10.1111/j.1753 4887.2011.00420.x
   Pechlivanis A, 2010, J PROTEOME RES, V9, P6405, DOI 10.1021/pr100684t
   Qiu G.X., 2015, J BONE JOINT SURG, V8, P371
   Sadat Ali M, 2009, ANN SAUDI MED, V29, P215, DOI 10.5144/0256 4947.2009.215
   Shu YS, 2017, ANAL BIOANAL CHEM, V409, P4849, DOI 10.1007/s00216 017 0428 1
   Wang JH, 2017, PEERJ, V5, DOI 10.7717/peerj.3450
   Wang Q. P., 2001, Foreign Medicine, V21, P451
   Wen CY, 2019, MOL NUTR FOOD RES, V63, DOI 10.1002/mnfr.201800536
   Wu X, 2018, J CHROMATOGR B, V1072, P40, DOI 10.1016/j.jchromb.2017.10.005
   Xia JG, 2010, BIOINFORMATICS, V26, P2342, DOI 10.1093/bioinformatics/btq418
   Xia JG, 2010, NUCLEIC ACIDS RES, V38, pW71, DOI 10.1093/nar/gkq329
   Yadav VK, 2010, NAT MED, V16, P308, DOI 10.1038/nm.2098
   Yatsonsky D, 2019, WORLD J ORTHOP, V10, P123, DOI 10.5312/wjo.v10.i3.123
   Yuan XM, 2020, ANAL BIOCHEM, V591, DOI 10.1016/j.ab.2019.113559
   Zhang ZL, 2008, OSTEOPOROSIS INT, V19, P39, DOI 10.1007/s00198 007 0435 8
   Zhou CH, 2014, AMINO ACIDS, V46, P1673, DOI 10.1007/s00726 014 1729 8
NR 33
TC 18
Z9 20
U1 2
U2 32
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0003 2697
EI 1096 0309
J9 ANAL BIOCHEM
JI Anal. Biochem.
PD DEC 1
PY 2020
VL 610
AR 13992
DI 10.1016/j.ab.2020.113992
PG 8
WC Biochemical Research Methods; Biochemistry & Molecular Biology;
   Chemistry, Analytical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA OU6YT
UT WOS:000591673200008
PM 33075315
DA 2025 08 17
ER

PT J
AU Greenspan, SL
   Beck, TJ
   Resnick, NM
   Bhattacharya, R
   Parker, RA
AF Greenspan, SL
   Beck, TJ
   Resnick, NM
   Bhattacharya, R
   Parker, RA
TI Effect of hormone replacement, alendronate, or combination therapy on
   hip structural geometry: A 3 year, double blind, placebo controlled
   clinical trial
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE aging; estrogens; bone densitometry; osteoporosis; bisphosphonates
ID RANDOMIZED CONTROLLED TRIAL; CROSS SECTIONAL GEOMETRY; BONE MINERAL
   DENSITY; POSTMENOPAUSAL WOMEN; PROXIMAL FEMUR; FEMORAL NECK;
   ANTIRESORPTIVE AGENTS; VERTEBRAL FRACTURES; OSTEOPOROTIC WOMEN; RISK
AB Introduction: Fracture reduction is only partially explained by increased BMD. The aim of this study was to examine changes in structural geometry of the hip, derived from DXA in postmenopausal women after treatment with antiresorptive agents.
   Materials and Methods: This was a double blind, placebo controlled, randomized clinical trial of 373 women over the age of 65 years, who were randomized to hormone replacement therapy, alendronate, combination therapy, or placebo for 3 years. The outcomes included the DXA derived hip structure analysis program by Beck, which is an engineering interpretation of the DXA data. The indices included cross sectional area, section modulus (a measure of bending strength), outer diameter, cortical thickness, and buckling ratio (an index of cortical bone stability). Properties were measured in cross sectional regions traversing the femur at the narrowest point on the femoral neck, the intertrochanteric region, and the proximal shaft.
   Results: In the femoral neck, improvement in the hip structure analysis indices were generally significantly greater with combination therapy than either monotherapy; increases were also greater at the intertrochanter compared with hormone replacement therapy. For example, the section modulus at the intertrochanter and narrow neck increased 10.6% and 10.3%, respectively, with combination therapy, 9.1% and 7.3% with alendronate, 5.8% and 6.9% with hormone replacement therapy, and 3.4% and 3.2% with placebo (p < 0.01 across the four groups). Buckling ratio increased, suggesting decreased stability in the placebo group, whereas there was either no change or significant improvements (p < 0.05) in each active treatment group.
   Conclusions: We conclude that changes in the distribution of bone mass underlying the improvements in density with antiresorptive agents in combination or alone have positive effects on structural strength and stability at the proximal femur. This study provides additional information on the potential mechanisms for fracture reduction with antiresorptive agents.
C1 Univ Pittsburgh, Osteoporosis Prevent & Treatment Ctr, Dept Med, Pittsburgh, PA 15213 USA.
   Univ Pittsburgh, Div Geriatr Med, Pittsburgh, PA 15213 USA.
   Univ Pittsburgh, Inst Aging, Pittsburgh, PA 15213 USA.
   Johns Hopkins Sch Med, Dept Radiol, Baltimore, MD USA.
   Harvard Univ, Sch Publ Hlth, Ctr Biostat AIDS Res, Boston, MA 02115 USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of
   Higher Education (PCSHE); University of Pittsburgh; Johns Hopkins
   University; Johns Hopkins Medicine; Harvard University; Harvard T.H.
   Chan School of Public Health
RP Greenspan, SL (通讯作者)，Univ Pittsburgh, Osteoporosis Prevent & Treatment Ctr, Dept Med, Kaufmann Med Bldg,Suite 1110,3471 5th Ave, Pittsburgh, PA 15213 USA.
EM griffithsd@dom.pitt.edu
OI Resnick, Neil M./0009 0000 2023 809X
CR Anderson GL, 2004, JAMA J AM MED ASSOC, V291, P1701, DOI 10.1001/jama.291.14.1701
   BECK TJ, 1992, CALCIFIED TISSUE INT, V50, P24, DOI 10.1007/BF00297293
   Beck TJ, 2001, J BONE MINER RES, V16, P2103, DOI 10.1359/jbmr.2001.16.11.2103
   Beck TJ, 2000, J BONE MINER RES, V15, P2297, DOI 10.1359/jbmr.2000.15.12.2297
   Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140 6736(96)07088 2
   Boivin G, 2003, J CLIN ENDOCR METAB, V88, P4199, DOI 10.1210/jc.2002 022020
   Boivin GY, 2000, BONE, V27, P687, DOI 10.1016/S8756 3282(00)00376 8
   Cranney A, 2002, ENDOCR REV, V23, P508, DOI 10.1210/er.2001 2002
   Cummings SR, 2002, AM J MED, V112, P281, DOI 10.1016/S0002 9343(01)01124 X
   Delmas PD, 2004, BONE, V34, P599, DOI 10.1016/j.bone.2003.12.022
   Duan YB, 2003, J BONE MINER RES, V18, P1766, DOI 10.1359/jbmr.2003.18.10.1766
   Gere J.M., 2001, Mechanics of Material
   Greenspan SL, 2003, JAMA J AM MED ASSOC, V289, P2525, DOI 10.1001/jama.289.19.2525
   Greenspan SL, 1996, CALCIFIED TISSUE INT, V58, P409, DOI 10.1007/BF02509439
   GREENSPAN SL, 1994, J BONE MINER RES, V9, P1959, DOI 10.1002/jbmr.5650091216
   Hayes WC., 1985, BONE MINERAL RES, V3, P259
   Hillier TA, 2003, J BONE MINER RES, V18, pS21
   Hochberg MC, 2002, J CLIN ENDOCR METAB, V87, P1586, DOI 10.1210/jc.87.4.1586
   Lu Y, 1996, J BONE MINER RES, V11, P626
   Marcus R, 2002, ENDOCR REV, V23, P16, DOI 10.1210/er.23.1.16
   MARTIN RB, 1984, J BIOMECH, V17, P195, DOI 10.1016/0021 9290(84)90010 1
   Nelson DA, 2004, J BONE MINER RES, V19, P560, DOI 10.1359/JBMR.040104
   Nelson DA, 2000, J BONE MINER RES, V15, P1992, DOI 10.1359/jbmr.2000.15.10.1992
   Petit MA, 2005, BONE, V36, P568, DOI 10.1016/j.bone.2004.12.003
   Regan MM, 2001, J WOMEN HEALTH GEN B, V10, P343, DOI 10.1089/152460901750269661
   Roschger P, 2001, BONE, V29, P185, DOI 10.1016/S8756 3282(01)00485 9
   Rossouw JE, 2002, JAMA J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321
   Stepan J J, 2003, Endocr Regul, V37, P225
   Uusi Rasi K, 2005, BONE, V36, P948, DOI 10.1016/j.bone.2005.03.003
   Wasnich RD, 2000, J CLIN ENDOCR METAB, V85, P231, DOI 10.1210/jc.85.1.231
   Wells G, 2002, ENDOCR REV, V23, P529, DOI 10.1210/er.2001 5002
NR 31
TC 60
Z9 68
U1 0
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD SEP
PY 2005
VL 20
IS 9
BP 1525
EP 1532
DI 10.1359/JBMR.050508
PG 8
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 959AV
UT WOS:000231490200004
PM 16059624
OA Bronze
DA 2025 08 17
ER

PT J
AU Ochiai Shino, H
   Kato, H
   Sawada, T
   Onodera, S
   Saito, A
   Takato, T
   Shibahara, T
   Muramatsu, T
   Azuma, T
AF Ochiai Shino, Hiromi
   Kato, Hiroshi
   Sawada, Takashi
   Onodera, Shoko
   Saito, Akiko
   Takato, Tsuyoshi
   Shibahara, Takahiko
   Muramatsu, Takashi
   Azuma, Toshifumi
TI A Novel Strategy for Enrichment and Isolation of Osteoprogenitor Cells
   from Induced Pluripotent Stem Cells Based on Surface Marker Combination
SO PLOS ONE
LA English
DT Article
ID OSTEOBLAST DIFFERENTIATION; IN VITRO; OSTERIX; TRANSCRIPTION;
   PROGENITORS; GENERATION; INHIBITION; DERIVATION
AB In this study, we developed a new method to stimulate osteogenic differentiation in tissue nonspecific alkaline phosphatase (TNAP) positive cells liberated from human induced pluripotent stem cells (hiPSCs) derived embryoid bodies (EBs) with 14 days long TGF beta/IGF 1/FGF 2 treatment. TNAP is a marker protein of osteolineage cells. We analyzed and isolated TNAP positive and E cadherin negative nonepithelial cells by fluorescence activated cell sorting. Treating the cells with a combination of transforming growth factor (TGF) beta, insulin like growth factor (IGF) 1, and fibroblast growth factor (FGF) 2 for 14 days greatly enhanced TNAP expression and maximized expression frequency up to 77.3%. The isolated cells expressed high levels of osterix, which is an exclusive osteogenic marker. Culturing these TNAP positive cells in osteoblast differentiation medium (OBM) led to the expression of runt related transcription factor 2, type I collagen, bone sialoprotein, and osteocalcin (OCN). These cells responded to treatment with activated vitamin D3 by upregulating OCN. Furthermore, in OBM they were capable of generating many mineralized nodules with strong expression of receptor activator of NF kappaB ligand and sclerostin (SOST). Real time RT PCR showed a significant increase in the expression of osteocyte marker genes, including SOST, neuropeptide Y, and reelin. Scanning electron microscopy showed dendritic morphology. Examination of semi thin toluidine blue stained sections showed many interconnected dendrites. Thus, TNAP positive cells cultured in OBM may eventually become terminally differentiated osteocyte like cells. In conclusion, treating hiPSCs derived cells with a combination of TGF beta, IGF 1, and FGF 2 generated TNAP positive cells at high frequency. These TNAP positive cells had a high osteogenic potential and could terminally differentiate into osteocyte like cells. The method described here may reveal new pathways of osteogenesis and provide a novel tool for regenerative medicine and drug development.
C1 [Ochiai Shino, Hiromi; Onodera, Shoko; Saito, Akiko; Azuma, Toshifumi] Tokyo Dent Coll, Dept Biochem, Tokyo, Japan.
   [Kato, Hiroshi; Shibahara, Takahiko] Tokyo Dent Coll, Dept Oral & Maxillofacial Surg, Tokyo, Japan.
   [Sawada, Takashi] Tokyo Dent Coll, Dept Ultrastruct Sci, Tokyo, Japan.
   [Takato, Tsuyoshi] Univ Tokyo, Fac Med, Grad Sch Med, Dept Oral & Maxillofacial Surg,Div Tissue Engn, Tokyo 113, Japan.
   [Muramatsu, Takashi] Tokyo Dent Coll, Dept Endodont & Clin Cariol, Tokyo, Japan.
C3 Tokyo Dental College; Tokyo Dental College; Tokyo Dental College;
   University of Tokyo; Tokyo Dental College
RP Azuma, T (通讯作者)，Tokyo Dent Coll, Dept Biochem, Tokyo, Japan.
EM tazuma@tdc.ac.jp
RI AZUMA, TOSHIFUMI/HTQ 4727 2023; Muramatsu, Takashi/AAW 2646 2020
OI Onodera, Shoko/0000 0003 0673 3400
FU JSPS KAKENHI [25861761]; Grants in Aid for Scientific Research
   [25462878, 26861686, 25861761] Funding Source: KAKEN
FX This work was supported by JSPS KAKENHI Grant Number 25861761. The URL
   is "http://www.jsps.go.jp/j grantsinaid/". The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Arpornmaeklong P, 2009, STEM CELLS DEV, V18, P955, DOI 10.1089/scd.2008.0310
   Bilousova G, 2011, STEM CELLS, V29, P206, DOI 10.1002/stem.566
   Goudenege S, 2012, MOL THER, V20, P2153, DOI 10.1038/mt.2012.188
   Harkness L, 2011, BONE, V48, P231, DOI 10.1016/j.bone.2010.09.023
   Karp JM, 2006, STEM CELLS, V24, P835, DOI 10.1634/stemcells.2005 0383
   Li F, 2010, J CELL BIOCHEM, V109, P643, DOI 10.1002/jcb.22440
   Lian JB, 2006, REV ENDOCR METAB DIS, V7, P1, DOI 10.1007/s11154 006 9001 5
   Mahmood A, 2010, J BONE MINER RES, V25, P1216, DOI 10.1002/jbmr.34
   Mizuno Y, 2010, FASEB J, V24, P2245, DOI 10.1096/fj.09 137174
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Neve A, 2011, CELL TISSUE RES, V343, P289, DOI 10.1007/s00441 010 1086 1
   Ochiai H, 2012, J BIOL CHEM, V287, P22654, DOI 10.1074/jbc.M111.279091
   Sakurai H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047078
   Salani S, 2012, J CELL MOL MED, V16, P1353, DOI 10.1111/j.1582 4934.2011.01498.x
   Sinha KM, 2013, J CELL BIOCHEM, V114, P975, DOI 10.1002/jcb.24439
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Tanaka A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061540
   Tashiro K, 2009, STEM CELLS, V27, P1802, DOI 10.1002/stem.108
   Taura D, 2009, FEBS LETT, V583, P1029, DOI 10.1016/j.febslet.2009.02.031
   Tohmonda T, 2011, EMBO REP, V12, P451, DOI 10.1038/embor.2011.34
   Villa Diaz LG, 2012, STEM CELLS, V30, P1174, DOI 10.1002/stem.1084
   Woll Nicole L., 2006, V330, P149
   Woll NL, 2006, STEM CELLS DEV, V15, P865, DOI 10.1089/scd.2006.15.865
   Zhao S, 2002, J BONE MINER RES, V17, P2068, DOI 10.1359/jbmr.2002.17.11.2068
NR 24
TC 39
Z9 40
U1 1
U2 16
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD JUN 9
PY 2014
VL 9
IS 6
AR e99534
DI 10.1371/journal.pone.0099534
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA AI8LF
UT WOS:000337165600101
PM 24911063
OA Green Submitted, Green Published, gold
DA 2025 08 17
ER

PT J
AU Liu, YJ
   Chen, CY
   He, HX
   Wang, DS
   E, LL
   Liu, ZY
   Liu, HC
AF Liu, Yajing
   Chen, Caiyun
   He, Huixia
   Wang, Dongsheng
   E, LingLing
   Liu, Zhongyu
   Liu, Hongchen
TI Lentiviral mediated gene transfer into human adipose derived stem cells:
   role of NELL1 versus BMP2 in osteogenesis and adipogenesis in
   vitro
SO ACTA BIOCHIMICA ET BIOPHYSICA SINICA
LA English
DT Article
DE lentivirus; hADSCs; NELL1; osteogenesis; adipogenesis; BMP2
ID BONE MORPHOGENETIC PROTEIN 2; OSTEOBLAST DIFFERENTIATION; CALVARIAL
   DEFECTS; STROMAL CELLS; REGENERATION; EXPRESSION; THERAPY; VECTOR; MICE;
   VIVO
AB NEL like molecule 1 (NELL1) is a potent osteogenic factor associated with craniosynostosis. Adenoviruses, the most commonly used viral vectors for gene therapy, have several disadvantages that may restrict osteogenesis. Previous studies have shown that lentiviruses can serve as ideal vectors for gene therapy for bone regeneration. In this study, two lentiviral vectors (LvNELL1 and LvBMP2) that encode human NELL1 and bone morphogenetic protein 2 (BMP2), respectively, were constructed. The effect of LvNELL1 infection on the proliferation, osteogenesis, and adipogenesis of human adipose derived stem cells (hADSCs) in vitro was assessed and compared with that of LvBMP2. The results showed that hADSCs infected with LvNELL1 could efficiently and stably over express the target genes. 3 (4,5 dimethylthiazol 2 yl) 2,5 diphenyltetrazolium bromide assay results demonstrated that LvBMP2, but not LvNELL1, enhanced the proliferation of hADSCs. Assessment of alkaline phosphatase activity and cellular mineralization indicated that LvNELL1 infection promoted the osteogenic differentiation of hADSCs, and the effect was comparable with that of LvBMP2. Real time polymerase chain reaction (PCR) revealed that LvNELL1 infection upregulated OSX expression but not RUNX2 expression in hADSCs. In addition, adipogenic markers (lipid droplets, peroxisome proliferator activating receptor g, and lipoprotein lipase) analysis showed that LvNELL1 could dramatically inhibit the adipogenic differentiation of hADSCs, but LvBMP2 had no such effect. Taken together, these findings suggested that lentiviral mediated NELL1 gene transfer in hADSCs may be a novel and promising approach to achieve effective and precise bone regeneration.
C1 [Liu, Yajing; Chen, Caiyun; He, Huixia; Wang, Dongsheng; E, LingLing; Liu, Hongchen] Chinese Peoples Liberat Army Gen Hosp, Inst Stomatol, Beijing 100853, Peoples R China.
   [Liu, Zhongyu] Chinese Peoples Liberat Army Gen Hosp, Dept Gynecol, Beijing 100853, Peoples R China.
C3 Chinese People's Liberation Army General Hospital; Chinese People's
   Liberation Army General Hospital
RP Liu, HC (通讯作者)，Chinese Peoples Liberat Army Gen Hosp, Inst Stomatol, Beijing 100853, Peoples R China.
EM liuhongchen301@hotmail.com
RI chen, caiyun/HHY 7684 2022
FU National Natural Science Foundation of China [30973354]
FX This work was supported by a grant from the National Natural Science
   Foundation of China (30973354).
CR Aghaloo T, 2007, MOL THER, V15, P1872, DOI 10.1038/sj.mt.6300270
   Aghaloo T, 2006, AM J PATHOL, V169, P903, DOI 10.2353/ajpath.2006.051210
   Arrigoni E, 2009, CELL TISSUE RES, V338, P401, DOI 10.1007/s00441 009 0883 x
   Chen F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024638
   Cowan CM, 2007, J BONE MINER RES, V22, P918, DOI 10.1359/JBMR.070312
   Desai J, 2006, HUM MOL GENET, V15, P1329, DOI 10.1093/hmg/ddl053
   Deutsch H, 2010, SPINE J, V10, pE1, DOI 10.1016/j.spinee.2009.10.016
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Dull T, 1998, J VIROL, V72, P8463, DOI 10.1128/JVI.72.11.8463 8471.1998
   Egermann M, 2006, GENE THER, V13, P1290, DOI 10.1038/sj.gt.3302785
   Feeley BT, 2006, J ORTHOP RES, V24, P1709, DOI 10.1002/jor.20229
   Franceschi RT, 2005, J DENT RES, V84, P1093, DOI 10.1177/154405910508401204
   Gimble JM, 2006, J CELL BIOCHEM, V98, P251, DOI 10.1002/jcb.20777
   Hata K, 2003, MOL BIOL CELL, V14, P545, DOI 10.1091/mbc.E02 06 0356
   Huang HY, 2009, P NATL ACAD SCI USA, V106, P12670, DOI 10.1073/pnas.0906266106
   Ichida F, 2004, J BIOL CHEM, V279, P34015, DOI 10.1074/jbc.M403621200
   James AW, 2011, BIOCHEM BIOPH RES CO, V411, P126, DOI 10.1016/j.bbrc.2011.06.111
   Kusumoto K, 1997, BIOCHEM BIOPH RES CO, V239, P575, DOI 10.1006/bbrc.1997.7497
   Levi B, 2010, PLAST RECONSTR SURG, V126, P41, DOI 10.1097/PRS.0b013e3181da8858
   Li HW, 2007, BIOCHEM BIOPH RES CO, V356, P836, DOI 10.1016/j.bbrc.2007.02.165
   Lin L, 2009, CALCIFIED TISSUE INT, V85, P55, DOI 10.1007/s00223 009 9250 x
   Lu SS, 2007, SPINE J, V7, P50, DOI 10.1016/j.spinee.2006.04.020
   Matsubara T, 2008, J BIOL CHEM, V283, P29119, DOI 10.1074/jbc.M801774200
   Miyazaki M, 2008, SPINE, V33, P1410, DOI 10.1097/BRS.0b013e3181761003
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Naldini L, 1996, P NATL ACAD SCI USA, V93, P11382, DOI 10.1073/pnas.93.21.11382
   Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263
   Nishimura R, 2002, BONE, V31, P303, DOI 10.1016/S8756 3282(02)00826 8
   Pei LM, 2004, J CLIN INVEST, V113, P805, DOI 10.1172/JCI200421311
   Rosen ED, 2000, ANNU REV CELL DEV BI, V16, P145, DOI 10.1146/annurev.cellbio.16.1.145
   Spiegelman BM, 1998, DIABETES, V47, P507, DOI 10.2337/diabetes.47.4.507
   Takada I, 2009, EXPERT OPIN THER TAR, V13, P593, DOI [10.1517/14728220902915310 , 10.1517/14728220902915310]
   Takase M, 1998, BIOCHEM BIOPH RES CO, V244, P26, DOI 10.1006/bbrc.1998.8200
   Ting K, 1999, J BONE MINER RES, V14, P80, DOI 10.1359/jbmr.1999.14.1.80
   Truong T, 2007, J BONE MINER RES, V22, P7, DOI 10.1359/JBMR.061012
   Vigna E, 2002, MOL THER, V5, P252, DOI 10.1006/mthe.2002.0542
   Virk MS, 2008, BONE, V42, P921, DOI 10.1016/j.bone.2007.12.216
   Xu XL, 2005, ACTA ORTHOP, V76, P637, DOI 10.1080/17453670510041709
   Xue J, 2011, BONE, V48, P485, DOI 10.1016/j.bone.2010.10.166
   Zhang GH, 1996, BIOCHEM BIOPH RES CO, V227, P707, DOI 10.1006/bbrc.1996.1573
   Zhang HB, 1996, DEVELOPMENT, V122, P2977
   Zhang XC, 2010, INTRODUCTION TO THZ WAVE PHOTONICS, P1, DOI 10.1007/978 1 4419 0978 7_1
   Zhang XL, 2011, J BONE MINER RES, V26, P777, DOI 10.1002/jbmr.267
   Zhang XL, 2002, J CLIN INVEST, V110, P861, DOI 10.1172/JCI200215375
   Zhao M, 2005, J CELL BIOCHEM, V95, P1, DOI 10.1002/jcb.20411
   Zufferey R, 2002, CURR TOP MICROBIOL, V261, P107
   Zuk PA, 2002, MOL BIOL CELL, V13, P4279, DOI 10.1091/mbc.E02 02 0105
NR 47
TC 23
Z9 31
U1 1
U2 17
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1672 9145
J9 ACTA BIOCH BIOPH SIN
JI Acta Biochim. Biophys. Sin.
PD OCT
PY 2012
VL 44
IS 10
BP 856
EP 865
DI 10.1093/abbs/gms070
PG 10
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 027RI
UT WOS:000310370500007
PM 23017834
DA 2025 08 17
ER

PT J
AU Xu, L
   Zhou, JJ
   Liu, JY
   Liu, Y
   Wang, L
   Jiang, RW
   Diao, ZY
   Yan, GJ
   Pèault, B
   Sun, HX
   Ding, LJ
AF Xu, Lu
   Zhou, Jianjun
   Liu, Jingyu
   Liu, Yong
   Wang, Lei
   Jiang, Ruiwei
   Diao, Zhenyu
   Yan, Guijun
   Peault, Bruno
   Sun, Haixiang
   Ding, Lijun
TI Different Angiogenic Potentials of Mesenchymal Stem Cells Derived from
   Umbilical Artery, Umbilical Vein, and Wharton's Jelly
SO STEM CELLS INTERNATIONAL
LA English
DT Article
ID TUMOR ANGIOGENESIS; STROMAL CELLS; PHENOTYPIC CHARACTERIZATION;
   REGENERATIVE MEDICINE; CLINICAL APPLICATIONS; BONE MARROW; CORD; NOTCH;
   CD146; MECHANISMS
AB Human mesenchymal stem cells derived from the umbilical cord (UC) are a favorable source for allogeneic cell therapy. Here, we successfully isolated the stem cells derived from three different compartments of the human UC, including perivascular stem cells derived from umbilical arteries (UCA PSCs), perivascular stem cells derived from umbilical vein (UCV PSCs), and mesenchymal stem cells derived from Wharton's jelly (WJ MSCs). These cells had the similar phenotype and differentiation potential toward adipocytes, osteoblasts, and neuron like cells. However, UCA PSCs and UCV PSCs had more CD146(+) cells than WJ MSCs (P < 0.05). Tube formation assay in vitro showed the largest number of tube like structures and branch points in UCA PSCs among the three stem cells. Additionally, the total tube length in UCA PSCs and UCV PSCs was significantly longer than in WJ MSCs (P < 0.01). Microarray, qRT PCR, and Western blot analysis showed that UCA PSCs had the highest expression of the Notch ligand Jagged1 (JAG1), which is crucial for blood vessel maturation. Knockdown of Jagged1 significantly impaired the angiogenesis in UCA PSCs. In summary, UCA PSCs are promising cell populations for clinical use in ischemic diseases.
C1 [Xu, Lu; Zhou, Jianjun; Liu, Jingyu; Wang, Lei; Jiang, Ruiwei; Diao, Zhenyu; Yan, Guijun; Sun, Haixiang; Ding, Lijun] Nanjing Univ, Med Sch, Affiliated Drum Tower Hosp, Ctr Reprod Med,Dept Obstet & Gynecol, 321 Zhongshan Rd, Nanjing 210008, Jiangsu, Peoples R China.
   [Liu, Yong] Nanjing Univ, Med Sch, Affiliated Drum Tower Hosp, Cent Res Lab, 321 Zhongshan Rd, Nanjing 210008, Jiangsu, Peoples R China.
   [Peault, Bruno] Univ Edinburgh, MRC Ctr Regenerat Med, Edinburgh EH16 4UU, Midlothian, Scotland.
   [Peault, Bruno] Univ Calif Los Angeles, David Geffen Sch Med, Orthoped Hosp Res Ctr, Los Angeles, CA 90095 USA.
   [Peault, Bruno] Univ Calif Los Angeles, David Geffen Sch Med, Broad Stem Cell Ctr, Los Angeles, CA 90095 USA.
   [Ding, Lijun] Nanjing Univ, Med Sch, Affiliated Drum Tower Hosp, Clin Ctr Stem Cells, 321 Zhongshan Rd, Nanjing 210008, Jiangsu, Peoples R China.
C3 Nanjing University; Nanjing University; University of Edinburgh;
   University of California System; University of California Los Angeles;
   University of California Los Angeles Medical Center; David Geffen School
   of Medicine at UCLA; University of California System; University of
   California Los Angeles; University of California Los Angeles Medical
   Center; David Geffen School of Medicine at UCLA; Nanjing University
RP Sun, HX; Ding, LJ (通讯作者)，Nanjing Univ, Med Sch, Affiliated Drum Tower Hosp, Ctr Reprod Med,Dept Obstet & Gynecol, 321 Zhongshan Rd, Nanjing 210008, Jiangsu, Peoples R China.; Ding, LJ (通讯作者)，Nanjing Univ, Med Sch, Affiliated Drum Tower Hosp, Clin Ctr Stem Cells, 321 Zhongshan Rd, Nanjing 210008, Jiangsu, Peoples R China.
EM stevensunz@163.com; xmljding@163.com
RI JIANG, Ruiwei/ACI 9841 2022; Yan, Guijun/A 9809 2011; Liu,
   Yong/AGU 8971 2022; Liu, Jingyu/A 1503 2015; Ding, Lijun/JKI 9681 2023;
   duan, zhenyu/HNS 7793 2023
OI Jiang, Ruiwei/0000 0001 5857 8540; 
FU Nature Science Foundation of China [81571391, 30900847, 31571189];
   Nanjing Medical Science Development Project [JQ2014004, ZKX16042];
   Chinese Academy of Sciences [XDA01030501]; Medical Research Council
   [G1000816] Funding Source: researchfish; MRC [G1000816] Funding Source:
   UKRI
FX This work was supported through Lijun Ding by grants from the Nature
   Science Foundation of China (81571391, 30900847) and Nanjing Medical
   Science Development Project (JQ2014004, ZKX16042). Haixiang Sun is
   supported by the Nature Science Foundation of China (31571189) and
   Strategic Priority Research Program of the Chinese Academy of Sciences
   (XDA01030501).
CR Baksh D, 2007, STEM CELLS, V25, P1384, DOI 10.1634/stemcells.2006 0709
   Batsali AK, 2013, CURR STEM CELL RES T, V8, P144
   Benedito R, 2013, EXP CELL RES, V319, P1281, DOI 10.1016/j.yexcr.2013.01.010
   Benedito R, 2009, CELL, V137, P1124, DOI 10.1016/j.cell.2009.03.025
   Bhadada SV, 2011, FUND CLIN PHARMACOL, V25, P29, DOI 10.1111/j.1472 8206.2010.00814.x
   Boareto M, 2015, P NATL ACAD SCI USA, V112, pE3836, DOI 10.1073/pnas.1511814112
   Bronckaers A, 2014, PHARMACOL THERAPEUT, V143, P181, DOI 10.1016/j.pharmthera.2014.02.013
   Campagnolo P, 2010, CIRCULATION, V121, P1735, DOI 10.1161/CIRCULATIONAHA.109.899252
   Carmeliet P, 2011, NAT REV DRUG DISCOV, V10, P417, DOI 10.1038/nrd3455
   Carvalho MM, 2011, CURR STEM CELL RES T, V6, P221
   Chan B, 2005, DEV DYNAM, V232, P232, DOI 10.1002/dvdy.20220
   Chen HY, 2012, CELL IMMUNOL, V276, P83, DOI 10.1016/j.cellimm.2012.03.012
   Conconi M.T., 2011, The Open Tissue Engineering and Regenerative Medicine Journal, V4, P6, DOI [10.2174/1875043501104010006, DOI 10.2174/1875043501104010006]
   Corselli M, 2013, CYTOM PART A, V83A, P714, DOI [10.1002/cyto.22313, 10.1002/cyto.a.22313]
   Corselli M, 2013, BLOOD, V121, P2891, DOI 10.1182/blood 2012 08 451864
   Corselli M, 2010, ARTERIOSCL THROM VAS, V30, P1104, DOI 10.1161/ATVBAHA.109.191643
   Crisan M, 2008, CELL STEM CELL, V3, P301, DOI 10.1016/j.stem.2008.07.003
   Crisan M, 2012, J CELL MOL MED, V16, P2851, DOI 10.1111/j.1582 4934.2012.01617.x
   Dar A, 2012, CIRCULATION, V125, P87, DOI 10.1161/CIRCULATIONAHA.111.048264
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Geudens I, 2011, DEVELOPMENT, V138, P4569, DOI 10.1242/dev.062323
   Huang GTJ, 2010, TISSUE ENG PT A, V16, P605, DOI [10.1089/ten.tea.2009.0518, 10.1089/ten.TEA.2009.0518]
   Jiang TX, 2012, BLOOD, V120, P2330, DOI 10.1182/blood 2012 01 406108
   Kim DW, 2013, INT J MOL SCI, V14, P11692, DOI 10.3390/ijms140611692
   Kopan R, 2009, CELL, V137, P216, DOI 10.1016/j.cell.2009.03.045
   Krautler NJ, 2012, CELL, V150, P194, DOI 10.1016/j.cell.2012.05.032
   Li L, 1996, CIRC RES, V78, P188, DOI 10.1161/01.RES.78.2.188
   Mennan C, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/916136
   Nagamura Inoue Tokiko, 2014, World J Stem Cells, V6, P195, DOI 10.4252/wjsc.v6.i2.195
   Nemir M, 2014, EUR HEART J, V35, P2174, DOI 10.1093/eurheartj/ehs269
   Pedrosa AR, 2015, ONCOTARGET, V6, P24404, DOI 10.18632/oncotarget.4380
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Russell KC, 2010, STEM CELLS, V28, P788, DOI 10.1002/stem.312
   Sacchetti B, 2007, CELL, V131, P324, DOI 10.1016/j.cell.2007.08.025
   Shohara R, 2012, CYTOTHERAPY, V14, P1171, DOI 10.3109/14653249.2012.706705
   So JH, 2010, GENES CELLS, V15, P1099, DOI 10.1111/j.1365 2443.2010.01448.x
   Tang W, 2008, SCIENCE, V322, P583, DOI 10.1126/science.1156232
   Teixeira FG, 2013, CELL MOL LIFE SCI, V70, P3871, DOI 10.1007/s00018 013 1290 8
   Tsang WP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076153
   Wang ZQ, 2013, CANCER LETT, V330, P150, DOI 10.1016/j.canlet.2012.11.049
   Watson N, 2015, CYTOTHERAPY, V17, P18, DOI 10.1016/j.jcyt.2014.08.009
   Zhao H, 2014, CELL STEM CELL, V14, P160, DOI 10.1016/j.stem.2013.12.013
NR 42
TC 25
Z9 29
U1 0
U2 13
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1687 966X
EI 1687 9678
J9 STEM CELLS INT
JI Stem Cells Int.
PY 2017
VL 2017
AR 3175748
DI 10.1155/2017/3175748
PG 15
WC Cell & Tissue Engineering
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA FD1YF
UT WOS:000407331900001
PM 28874910
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Carvalho, EBS
   Veronesi, GF
   Manfredi, GGP
   Damante, CA
   Sant'Ana, ACP
   Greghi, SLA
   Zangrando, MSR
   Consolaro, A
   Rezende, MLR
AF Carvalho, Erika B. S.
   Veronesi, Giovana F.
   Manfredi, Gustavo G. P.
   Damante, Carla A.
   Sant'Ana, Adriana C. P.
   Greghi, Sebastiao L. A.
   Zangrando, Mariana S. R.
   Consolaro, Alberto
   Rezende, Maria L. R.
TI Bone demineralization improves onlay graft consolidation: A histological
   study in rat calvaria
SO JOURNAL OF PERIODONTOLOGY
LA English
DT Article
DE bone regeneration; bone transplantation; citric acid; tetracycline
ID PLATELET RICH PLASMA; LEVEL LASER THERAPY; AUTOGENOUS BONE; AUGMENTATION
   PROCEDURES; CORTICAL PERFORATIONS; CITRIC ACID; BOVINE BONE;
   TETRACYCLINE; DIFFERENTIATION; PROLIFERATION
AB Background Previous data suggest that bone demineralization may promote bone graft consolidation as well as proliferation and differentiation of pre osteoblasts, but the biological mechanisms involved in this process need to be clarified. This study investigated the effects of bone demineralization with citric acid (CA) and tetracycline (TCN) on the repair of onlay bone grafts. Methods Onlay bone grafts were performed on the calvaria of 126 Wistar rats. The contacting surfaces between bone graft and receptor bone bed were demineralized for 15, 30, and 60 seconds with TCN (50 mg/mL), or 10% CA, (pH 1), constituting the following test groups (n = 18): TCN15, TCN30, TCN60, CA15, CA30, and CA60. Control grafts (C) were performed without demineralization (n = 18). After 7, 30, and 60 days, biopsies were obtained for quantitative and qualitative histological analysis (a = 6). Results Demineralization accelerated the bone repair early from 7 days of healing. Higher percentage area of newly formed bone was observed in CA15 and TCN60 groups when compared to C in all evaluation periods (P = 0.02). At 30 days, C specimens had lower percentage of consolidated surfaces than TCN60, TCN30 and CA15 (P = 0.0015). At 60 days, CA15, CA60, and TCN60 presented bone surfaces almost completely filled by newly formed bone, against about 75% in C specimens (P = 0.0015). Conclusions Both CA and TCN were effective in accelerating osteogenesis at the interface between bone grafts and receptor bone beds, especially when applied for 15 seconds and 60 seconds, respectively.
C1 [Carvalho, Erika B. S.; Veronesi, Giovana F.; Manfredi, Gustavo G. P.; Damante, Carla A.; Sant'Ana, Adriana C. P.; Greghi, Sebastiao L. A.; Zangrando, Mariana S. R.; Rezende, Maria L. R.] Univ Sao Paulo, Bauru Sch Dent, Dept Prosthodont & Periodont, Bauru, SP, Brazil.
   [Consolaro, Alberto] Univ Sao Paulo, Bauru Sch Dent, Div Pathol, Dept Stomatol, Bauru, SP, Brazil.
C3 Universidade de Sao Paulo; Universidade de Sao Paulo
RP Rezende, MLR (通讯作者)，Bauru Sch Dent, Dept Prosthodont & Periodont, Alameda Octavio Pinheiro Brisolla 9 75, BR 17012901 Bauru, SP, Brazil.
EM malurezende@usp.br
RI Zangrando, Mariana/L 6139 2017; Sant'Ana, Adriana/D 2330 2012;
   Consolaro, Alberto/B 8565 2013; Fusetto Veronesi,
   Guilherme/LUY 1553 2024; Manfredi, Gustavo/F 7844 2014; Rezende,
   Maria/D 7729 2012; LA Greghi, Sebastião/D 6644 2012; Damante,
   Carla/B 9643 2012
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior [001];
   Fundacao de Amparoa Pesquisa do Estado de Sao Paulo [2014/15136 8]
FX Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior, Grant/Award
   Number: 001; Fundacao de Amparoa Pesquisa do Estado de Sao Paulo,
   Grant/Award Number: 2014/15136 8
CR Abed Ahmad Moghare, 2013, Dent Res J (Isfahan), V10, P232
   Almazin SM, 2009, J PERIODONTOL, V80, P999, DOI 10.1902/jop.2009.080574
   Anavi Y, 2011, J ORAL IMPLANTOL, V37, P379, DOI 10.1563/AAID JOI D 09 00128.1
   Chiapasco M, 2009, INT J ORAL MAX IMPL, V24, P237
   Clayton JA, 2014, NATURE, V509, P282, DOI 10.1038/509282a
   Dayangac E, 2016, CLIN IMPLANT DENT R, V18, P82, DOI 10.1111/cid.12238
   de Carvalho PSP, 2000, INT J ORAL MAX IMPL, V15, P565
   de Rezende MLR, 2015, J PERIODONTOL, V86, P146, DOI 10.1902/jop.2014.130657
   do Amaral NG, 2011, J APPL ORAL SCI, V19, P469, DOI 10.1590/S1678 77572011000500006
   Manfredi GGD, 2019, MICROSC RES TECHNIQ, V82, P1004, DOI 10.1002/jemt.23247
   DODDS RA, 1995, J BONE MINER RES, V10, P1666
   Domingues RS, 2013, EFFECT ACID DEMINERA, P170
   EKRYLANDER B, 1994, J BIOL CHEM, V269, P14853
   Faria PEP, 2008, CLIN ORAL IMPLAN RES, V19, P393, DOI 10.1111/j.1600 0501.2007.01485.x
   Gamal AY, 1998, J CLIN PERIODONTOL, V25, P404, DOI 10.1111/j.1600 051X.1998.tb02463.x
   Gordh M, 1997, OTOLARYNG HEAD NECK, V117, P664, DOI 10.1016/S0194 5998(97)70050 0
   Gordh M, 1999, PLAST RECONSTR SURG, V103, P1909, DOI 10.1097/00006534 199906000 00016
   HEATH JK, 1984, BIOCHIM BIOPHYS ACTA, V802, P151, DOI 10.1016/0304 4165(84)90046 1
   JONES S J, 1986, Scanning Electron Microscopy, P1555
   Jung GU, 2016, TISSUE ENG REGEN MED, V13, P70, DOI 10.1007/s13770 016 9021 0
   Kamal M, 2018, J CRANIOFAC SURG, V29, P1661, DOI 10.1097/SCS.0000000000004586
   Koerdt S, 2014, CLIN ORAL INVEST, V18, P179, DOI 10.1007/s00784 013 0938 y
   Krishnan L, 2015, CLIN ORTHOP RELAT R, V473, P2885, DOI 10.1007/s11999 015 4312 z
   LABAHN R, 1992, J PERIODONTOL, V63, P303, DOI 10.1902/jop.1992.63.4.303
   LORENZO JA, 1992, MATRIX, V12, P282, DOI 10.1016/S0934 8832(11)80080 6
   Melcher AH, 1976, BIOL PROCESSES RESOR
   Miranda SR, 2006, CLIN ORAL IMPLAN RES, V17, P694, DOI 10.1111/j.1600 0501.2006.01272.x
   Mittal M, TENN DENT ASS, V94, P21
   Muthukuru M, 2013, J PERIODONTOL, V84, P656, DOI 10.1902/jop.2012.120338
   Nagata MJH, 2005, J PERIODONTOL, V76, P908, DOI 10.1902/jop.2005.76.6.908
   Obradovic RR, 2009, LASER MED SCI, V24, P447, DOI 10.1007/s10103 008 0573 z
   ODonnell RJ, 1996, J ORTHOPAED RES, V14, P108, DOI 10.1002/jor.1100140118
   Rezende ML, 2014, J PERIODONTOL, V85, pE121, DOI 10.1902/jop.2013.130298
   Rojas Paulus JE, 2016, THESIS, P119
   Sakkas A, 2017, INT J IMPLANT DENT, V3, DOI 10.1186/s40729 017 0084 4
   Salmeron S, 2015, THESIS, P166
   Sandberg K, 2015, FASEB J, V29, P1646, DOI 10.1096/fj.14 269548
   Schwartz Z, 2000, J PERIODONTOL, V71, P586, DOI 10.1902/jop.2000.71.4.586
   Silva Aline Cristina, 2016, Braz. Dent. J., V27, P160, DOI 10.1590/0103 6440201600427
   Sugg KB, 2013, PLAST RECONSTR SURG, V131, P1014, DOI 10.1097/PRS.0b013e31828e217a
   Thor A, 2005, CLIN IMPLANT DENT R, V7, P209, DOI 10.1111/j.1708 8208.2005.tb00066.x
   URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893
   URIST MR, 1968, CLIN ORTHOP RELAT R, P59
   URIST MR, 1968, CLIN ORTHOP RELAT R, P61
   URIST MR, 1970, CLIN ORTHOP RELAT R, P279
   Valiati R, 2012, INT J MED SCI, V9, P853, DOI 10.7150/ijms.4440
   Zanetta Barbosa D, 2009, INT J ORAL MAX IMPL, V24, P463
NR 47
TC 1
Z9 1
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0022 3492
EI 1943 3670
J9 J PERIODONTOL
JI J. Periodont.
PD JUN
PY 2021
VL 92
IS 6
BP 1
EP 10
DI 10.1002/JPER.20 0390
EA OCT 2020
PG 10
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA SY3FG
UT WOS:000579561000001
PM 32997353
DA 2025 08 17
ER

PT J
AU Liang, S
   Zhang, H
   Du, Y
   Dou, CS
   Liu, SX
   Zhang, L
   Chen, YH
   Li, RZ
   Ma, JC
   Li, Z
   Lin, T
   Zhao, XC
   Zhang, QM
   Wang, WJ
   Ye, ZM
   Liang, XL
   Shi, W
   Zhang, B
AF Liang, Shun
   Zhang, Hong
   Du, Yue
   Dou, Caoshuai
   Liu, Shuangxin
   Zhang, Li
   Chen, Yuanhan
   Li, Ruizhao
   Ma, Jianchao
   Li, Zhuo
   Lin, Ting
   Zhao, Xinchen
   Zhang, Qianmei
   Wang, Wenjian
   Ye, Zhiming
   Liang, Xinling
   Shi, Wei
   Zhang, Bin
TI RANK Deficiency Ameliorates Podocyte Injury by Suppressing
   Calcium/Calcineurin/NFATc1 Signaling
SO KIDNEY & BLOOD PRESSURE RESEARCH
LA English
DT Article
DE Podocyte; Injury; Receptor activator of NF kappa B; Nuclear factor of
   activated T cells
ID FOCAL SEGMENTAL GLOMERULOSCLEROSIS; CYCLOSPORINE A; ACTIVATION; CALCIUM;
   DIFFERENTIATION; CALCINEURIN; OSTEOCLAST; THERAPY; STOP
AB Background/Aims: Podocyte injury and loss contribute to proteinuria, glomerulosclerosis and eventually kidney failure. Receptor activator of NF kappa B (RANK) belongs to the TNF receptor superfamily, which plays a key role in the pathogenesis of podocyte injury. However, the mechanism underlying the effect of RANK in podocyte injury remains unclear. Here, we sought to explore the possible molecular mechanisms involved in podocyte injury caused by RANK. Methods: Immortalized mouse podocytes were treated with si RNA targeting RANK for 48 h or ionomycin for 24 h before harvest. Western blot, quantitative RT PCR and immunofluorescence staining were used to evaluate the expression and function of RANK, nuclear factor of activated T cells c1 (NFATc1), transient receptor potential cation channel, subfamily C, member 6 (TRPC6) and calcineurin in podocytes. The Calcineurin Cellular Activity Assay kit was used to detect the phosphatase activity of calcineurin in cultured podocytes. A Ca2+ influx assay was performed to analyze alterations in Ca2+ entry under different conditions. Co immunoprecipitation assays were used to observe the relationship between RANK and TRPC6. Results: RANK m RNA and protein expression were markedly increased in injured podocytes (ionomycin stimulation). Further study found that translocation of NFATc1 to the nucleus was significantly reduced after knocking down RANK by siRNA. Meanwhile, we also demonstrated that loss of RANK suppressed the phosphatase activity of calcineurin and attenuated the ionomycin induced increase in Ca2+ influx. In addition, we showed that RANK knockdown in cultured podocytes decreased TRPC6 protein expression. Co immunoprecipitation experiments suggested that RANK binds to TRPC6 and that ionomycin enhanced the binding of RANK to TRPC6. Conclusion: Our findings demonstrated that RANK deficiency ameliorates podocyte injury by suppressing calcium/calcineurin/NFATc1 signaling, which may present a promising target for therapeutic intervention. (C) 2018 The Author(s) Published by S. Karger AG, Basel
C1 [Liang, Shun; Zhang, Hong; Du, Yue; Dou, Caoshuai; Liu, Shuangxin; Zhang, Li; Chen, Yuanhan; Li, Ruizhao; Ma, Jianchao; Li, Zhuo; Lin, Ting; Zhao, Xinchen; Zhang, Qianmei; Wang, Wenjian; Ye, Zhiming; Liang, Xinling; Shi, Wei; Zhang, Bin] Guangdong Acad Med Sci, Guangdong Gen Hosp, Guangdong Prov Inst Geriatr, Dept Nephrol, Guangzhou, Guangdong, Peoples R China.
   [Zhang, Hong; Zhang, Bin] Southern Med Univ, Sch Clin Med 2, Guangzhou, Guangdong, Peoples R China.
   [Du, Yue; Dou, Caoshuai; Zhang, Bin] South China Univ Technol, Sch Med, Guangzhou, Guangdong, Peoples R China.
   [Liang, Shun] Sun Yat Sen Univ, Affiliated Hosp 5, Dept Nephrol, Zhuhai, Peoples R China.
C3 Guangdong Academy of Medical Sciences & Guangdong General Hospital;
   Southern Medical University   China; Southern Medical University  
   China; South China University of Technology; Sun Yat Sen University
RP Zhang, B (通讯作者)，Guangdong Acad Med Sci, Guangdong Gen Hosp, Dept Nephrol, 106 Zhongshan 2 Rd, Guangzhou 510080, Guangdong, Peoples R China.
EM 13925056339@163.com
RI liu, shuangxin/AAS 7429 2020; 陈, 元翰/JXN 0032 2024
FU National Natural Science Foundation of China [81370808, 81570642,
   81670656]; National Construction Projects for Key Clinical Specialties
FX This work was supported by grants from National Natural Science
   Foundation of China (81370808; 81570642; 81670656) and in part by grants
   from the National Construction Projects for Key Clinical Specialties.
CR Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593
   Arif E, 2014, J BIOL CHEM, V289, P9502, DOI 10.1074/jbc.M113.505743
   Bose M, 2017, J INVEST MED, V65, P1093, DOI 10.1136/jim 2017 000456
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chen XW, 2016, J DIABETES COMPLICAT, V30, P760, DOI 10.1016/j.jdiacomp.2016.03.013
   Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092 8674(02)00699 2
   Cybulsky AV, 2011, CONTRIB NEPHROL, V169, P107, DOI 10.1159/000313948
   D'Agati VD, 2008, KIDNEY INT, V73, P399, DOI 10.1038/sj.ki.5002655
   Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412
   Greka A, 2012, SEMIN NEPHROL, V32, P319, DOI 10.1016/j.semnephrol.2012.06.003
   Gupta V, 2017, AM J PHYSIOL RENAL, V312, pF373, DOI 10.1152/ajprenal.00499.2016
   Hanada R, 2011, J MOL MED, V89, P647, DOI 10.1007/s00109 011 0749 z
   Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703
   Hsu CJ, 2010, J CELL BIOCHEM, V111, P138, DOI 10.1002/jcb.22677
   Kim J.S., 2016, BIOMED RES INT, V2016, DOI DOI 10.1155/2016/1630365
   Kim Jung Ha, 2016, Chonnam Med J, V52, P12, DOI 10.4068/cmj.2016.52.1.12
   Kim Jung Ha, 2014, J Bone Metab, V21, P233, DOI 10.11005/jbm.2014.21.4.233
   LEE HY, 1995, CLIN NEPHROL, V43, P375
   Liu SX, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041331
   LYTTON J, 1991, J BIOL CHEM, V266, P17067
   Meyrier AY, 2009, KIDNEY INT, V76, P487, DOI 10.1038/ki.2009.204
   Mundel P, 1997, EXP CELL RES, V236, P248, DOI 10.1006/excr.1997.3739
   Nijenhuis T, 2011, AM J PATHOL, V179, P1719, DOI 10.1016/j.ajpath.2011.06.033
   Okudera M, 2015, J ORAL SCI, V57, P305, DOI 10.2334/josnusd.57.305
   Pagtalunan ME, 1997, J CLIN INVEST, V99, P342, DOI 10.1172/JCI119163
   Perico L, 2017, AM J KIDNEY DIS, V70, P145, DOI 10.1053/j.ajkd.2016.12.013
   Reiser J., 2016, F1000Res, P5, DOI [DOI 10.12688/F1000RESEARCH.7255.1, 10.12688/f1000research.7255.1]
   ROSTOKER G, 1993, NEPHRON, V63, P335, DOI 10.1159/000187219
   Schlöndorff J, 2009, AM J PHYSIOL CELL PH, V296, pC558, DOI 10.1152/ajpcell.00077.2008
   Shankland SJ, 2006, KIDNEY INT, V69, P2131, DOI 10.1038/sj.ki.5000410
   Srivastava T, 2013, J CELL COMMUN SIGNAL, V7, P49, DOI 10.1007/s12079 012 0184 0
   Tahar G, 2010, INT J NEPHROL RENOV, V3, P117, DOI 10.2147/IJNRD.S10168
   Wang LM, 2011, MOL ENDOCRINOL, V25, P1376, DOI 10.1210/me.2011 0029
   Wang YQ, 2010, J AM SOC NEPHROL, V21, P1657, DOI 10.1681/ASN.2009121253
   Wei C, 2008, NAT MED, V14, P55, DOI 10.1038/nm1696
   Zhang B, 2012, INT J NEPHROL, V2012
   Zhang B, 2012, J MOL MED, V90, P1407, DOI 10.1007/s00109 012 0960 6
   Zhang L, 2013, BRIT J PHARMACOL, V170, P426, DOI 10.1111/bph.12292
NR 38
TC 11
Z9 13
U1 0
U2 11
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH 4009 BASEL, SWITZERLAND
SN 1420 4096
EI 1423 0143
J9 KIDNEY BLOOD PRESS R
JI Kidney Blood Pressure Res.
PY 2018
VL 43
IS 4
BP 1149
EP 1159
DI 10.1159/000492049
PG 11
WC Physiology; Urology & Nephrology; Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI EXPANDED)
SC Physiology; Urology & Nephrology; Cardiovascular System & Cardiology
GA GW8VJ
UT WOS:000447258800010
PM 30036881
OA gold
DA 2025 08 17
ER

PT J
AU Fitzgerald, RR
   Walters, JD
AF Fitzgerald, R. R.
   Walters, J. D.
TI Accumulation of topical naproxen by cultured oral epithelium
SO JOURNAL OF DENTAL RESEARCH
LA English
DT Article
DE analgesic; inflammatory periodontitis
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; CREVICULAR FLUID;
   PERIODONTAL DISEASES; GINGIVAL FIBROBLASTS; ADULT PERIODONTITIS;
   PROSTAGLANDIN E 2; BARRIER FUNCTION; BONE LOSS; KETOROLAC; SKIN
AB Topically administered non steroidal antiinflammatory drugs (NSAIDs) inhibit periodontal bone loss, but little is known about the mechanism by which they penetrate oral epithelium. Active transporters could potentially play a role in this process. In this study, we used a cell line derived from oral epithelium to investigate a role for transporters and to characterize conditions that enhance epithelial penetration. Using fluorescence to monitor uptake, we demonstrated that SCC 25 cell monolayers transport naproxen with a Michaelis constant (K m) and maximum velocity (V max) of 164 mu g/mL and 0.94 ng/min/mu g protein, respectively. At steady state, the intracellular/extracellular concentration ratio was 3.4. Naproxen accumulation was more efficient at acidic pH than under neutral or alkaline conditions. Small proportions of glycerol, Pluronic F 127, and glucosylceramide enhanced naproxen entry. The individual and combined effects of glycerol and Pluronic F 127 were of lesser magnitude than those obtained with glucosylceramide or at pH 6.3. Thus, SCC 25 cells possess transporters for naproxen.
C1 Ohio State Univ, Hlth Sci Ctr, Coll Dent, Sect Periodontol, Columbus, OH 43218 USA.
C3 University System of Ohio; Ohio State University
RP Walters, JD (通讯作者)，Ohio State Univ, Hlth Sci Ctr, Coll Dent, Sect Periodontol, 305 W 12th Ave,PO Box 182357, Columbus, OH 43218 USA.
EM walters.2@osu.edu
FU NIDCR NIH HHS [R01 DE012601] Funding Source: Medline
CR BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003 2697(76)90527 3
   Brayton JJ, 2002, J PERIODONTOL, V73, P1267, DOI 10.1902/jop.2002.73.11.1267
   Cavanaugh PF, 1998, J PERIODONTAL RES, V33, P75
   Choi MJ, 2005, AM J CLIN DERMATOL, V6, P215, DOI 10.2165/00128071 200506040 00002
   Coderch L, 2003, AM J CLIN DERMATOL, V4, P107, DOI 10.2165/00128071 200304020 00004
   Damiani P, 2002, J PHARMACEUT BIOMED, V29, P229, DOI 10.1016/S0731 7085(02)00063 8
   HOWELL TH, 1991, J PERIODONTAL RES, V26, P180, DOI 10.1111/j.1600 0765.1991.tb01643.x
   Howie NM, 2001, ORAL DIS, V7, P349, DOI 10.1034/j.1601 0825.2001.00731.x
   JEFFCOAT MK, 1995, J PERIODONTOL, V66, P329, DOI 10.1902/jop.1995.66.5.329
   JEFFCOAT MK, 1988, J PERIODONTAL RES, V23, P381, DOI 10.1111/j.1600 0765.1988.tb01617.x
   Kobayashi D, 2003, J PHARMACOL EXP THER, V306, P703, DOI 10.1124/jpet.103.051300
   MULLIN JM, 1988, J CELL PHYSIOL, V134, P357, DOI 10.1002/jcp.1041340306
   Oh TY, 2005, WORLD J GASTROENTERO, V11, P7450, DOI 10.3748/wjg.v11.i47.7450
   Oringer RJ, 2002, J PERIODONTOL, V73, P835, DOI 10.1902/jop.2002.73.8.835
   Paquette DW, 1997, J CLIN PERIODONTOL, V24, P521, DOI 10.1111/j.1600 051X.1997.tb00223.x
   Paquette DW, 2000, J CLIN PERIODONTOL, V27, P558, DOI 10.1034/j.1600 051x.2000.027008558.x
   Preshaw PM, 1998, J PERIODONTOL, V69, P777, DOI 10.1902/jop.1998.69.7.777
   RHEINWALD JG, 1981, CANCER RES, V41, P1657
   Sádecká J, 2001, J PHARMACEUT BIOMED, V25, P881, DOI 10.1016/S0731 7085(01)00374 0
   Salvi GE, 1997, CURR OPIN PERIODONT, V4, P51
   Salvi GE, 2005, J CLIN PERIODONTOL, V32, P108, DOI 10.1111/j.1600 051X.2005.00785.x
   Siskind LJ, 2002, J BIOL CHEM, V277, P26796, DOI 10.1074/jbc.M200754200
   Takagi Y, 2005, ARCH DERMATOL RES, V297, P18, DOI 10.1007/s00403 005 0567 7
   Takahashi A, 2002, INT J PHARM, V246, P179, DOI 10.1016/S0378 5173(02)00394 0
   Tipton DA, 2003, J PERIODONTOL, V74, P1754, DOI 10.1902/jop.2003.74.12.1754
   Vávrová K, 2003, BIOORGAN MED CHEM, V11, P5381, DOI 10.1016/j.bmc.2003.09.034
   Vesper H, 1999, J NUTR, V129, P1239, DOI 10.1093/jn/129.7.1239
   You GF, 2004, MED RES REV, V24, P762, DOI 10.1002/med.20014
   Zavarella MM, 2006, J DENT RES, V85, P452, DOI 10.1177/154405910608500511
NR 29
TC 4
Z9 4
U1 0
U2 3
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0022 0345
EI 1544 0591
J9 J DENT RES
JI J. Dent. Res.
PD AUG
PY 2007
VL 86
IS 8
BP 775
EP 779
DI 10.1177/154405910708600817
PG 5
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA 193OQ
UT WOS:000248284100017
PM 17652209
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Sun, LL
   Niu, HY
   Wu, YQ
   Dong, SY
   Li, XF
   Kim, BYS
   Liu, CS
   Ma, YF
   Jiang, W
   Yuan, Y
AF Sun, Lili
   Niu, Haoyi
   Wu, Yuqiong
   Dong, Shiyan
   Li, Xuefeng
   Kim, Betty Y. S.
   Liu, Changsheng
   Ma, Yifan
   Jiang, Wen
   Yuan, Yuan
TI Bio integrated scaffold facilitates large bone regeneration dominated by
   endochondral ossification
SO BIOACTIVE MATERIALS
LA English
DT Article
DE Endochondral ossification; Bio integrated scaffold; Hypoxia mimicking;
   Low dose bone morphogenetic protein 2; Large bone repair
ID MESENCHYMAL STEM CELLS; MORPHOGENETIC PROTEIN 2; OSTEOGENIC
   DIFFERENTIATION; CHONDROGENIC DIFFERENTIATION; OSTEOBLAST LINEAGE;
   SEGMENTAL DEFECT; STABILITY; HIF 1 ALPHA; FAK/MAPK; PATHWAYS
AB Repair of large bone defects caused by severe trauma, non union fractures, or tumor resection remains challenging because of limited regenerative ability. Typically, these defects heal through mixed routines, including intramembranous ossification (IMO) and endochondral ossification (ECO), with ECO considered more efficient. Current strategies to promote large bone healing via ECO are unstable and require high dose growth factors or complex cell therapy that cause side effects and raise expense while providing only limited benefit. Herein, we report a bio integrated scaffold capable of initiating an early hypoxia microenvironment with controllable release of low dose recombinant bone morphogenetic protein 2 (rhBMP 2), aiming to induce ECO dominated repair. Specifically, we apply a mesoporous structure to accelerate iron chelation, this promoting early chondrogenesis via deferoxamine (DFO) induced hypoxia inducible factor 1 alpha (HIF 1 alpha). Through the delicate segmentation of click crosslinked PEGylated Poly (glycerol sebacate) (PEGS) layers, we achieve programmed release of low dose rhBMP 2, which can facilitate cartilage to bone transformation while reducing side effect risks. We demonstrate this system can strengthen the ECO healing and convert mixed or mixed or IMO guided routes to ECO dominated approach in large size models with clinical relevance. Collectively, these findings demonstrate a biomaterial based strategy for driving ECO dominated healing, paving a promising pave towards its clinical use in addressing large bone defects.
C1 [Sun, Lili; Niu, Haoyi; Liu, Changsheng; Ma, Yifan; Yuan, Yuan] East China Univ Sci & Technol, Sch Mat Sci & Engn, Key Lab Ultrafine Mat, Minist Educ, Shanghai 200237, Peoples R China.
   [Sun, Lili; Niu, Haoyi; Liu, Changsheng; Yuan, Yuan] East China Univ Sci & Technol, Engn Res Ctr Biomed Mat, Minist Educ, Shanghai 200237, Peoples R China.
   [Dong, Shiyan; Li, Xuefeng; Ma, Yifan; Jiang, Wen] Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA.
   [Wu, Yuqiong] Shanghai Jiao Tong Univ Sch Med, Peoples Hosp 9, Dept Prosthodont, Shanghai 200011, Peoples R China.
   [Kim, Betty Y. S.] Univ Texas MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX USA.
C3 East China University of Science & Technology; East China University of
   Science & Technology; University of Texas System; UTMD Anderson Cancer
   Center; Shanghai Jiao Tong University; University of Texas System; UTMD
   Anderson Cancer Center
RP Ma, YF; Yuan, Y (通讯作者)，East China Univ Sci & Technol, Sch Mat Sci & Engn, Key Lab Ultrafine Mat, Minist Educ, Shanghai 200237, Peoples R China.; Ma, YF; Jiang, W (通讯作者)，Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA.
EM YMa10@mdanderson.org; wjiang4@mdanderson.org; yyuan@ecust.edu.cn
RI ; Jiang, Wen/HJB 4471 2022; Ma, Yifan/AAB 4406 2019; Dong,
   Shiyan/AAU 9849 2021
OI Ma, Yifan/0000 0002 9371 4365; Jiang, Wen/0000 0001 9154 633X; 
FU National Natural Science Foundation of China [31971264]; National
   Natural Science Foundation of China for Innovative Research Groups
   [51621002]; Frontiers Science Center for Materiobiology and Dynamic
   Chemistry [JKVD1211002]; China Postdoctoral Science Foundation
   [2020M681320]
FX The authors wish to express their gratitude to the financial supports
   from the National Natural Science Foundation of China (No.31971264) ,
   National Natural Science Foundation of China for Innovative Research
   Groups (No.51621002) , Frontiers Science Center for Materiobiology and
   Dynamic Chemistry (No. JKVD1211002) , and China Postdoctoral Sci  ence
   Foundation (2020M681320) .
CR Amarilio R, 2007, DEVELOPMENT, V134, P3917, DOI 10.1242/dev.008441
   Carragee EJ, 2011, SPINE J, V11, P471, DOI 10.1016/j.spinee.2011.04.023
   Chai YJ, 2017, J MATER CHEM B, V5, P4633, DOI 10.1039/c7tb00505a
   Chen W, 2021, SMALL, V17, DOI 10.1002/smll.202104012
   Claes L, 1997, J ORTHOP RES, V15, P577, DOI 10.1002/jor.1100150414
   Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016
   De La Vega RE, 2022, SCI ADV, V8, DOI 10.1126/sciadv.abl6242
   El Bialy I, 2017, PHARM RES DORDR, V34, P1152, DOI 10.1007/s11095 017 2147 x
   Faria MLE, 2007, VET SURG, V36, P122, DOI 10.1111/j.1532 950X.2007.00242.x
   Freeman FE, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abb5093
   Fu R, 2021, J TISSUE ENG, V12, DOI 10.1177/20417314211004211
   Gonçalves RC, 2021, BIOMATERIALS, V269, DOI 10.1016/j.biomaterials.2020.120628
   HALLAWAY PE, 1989, P NATL ACAD SCI USA, V86, P10108, DOI 10.1073/pnas.86.24.10108
   Hankemeier S, 2001, J ORTHOP RES, V19, P531, DOI 10.1016/S0736 0266(00)00044 9
   Hatt LP, 2022, CLIN TRANSL MED, V12, DOI 10.1002/ctm2.690
   Hoffman AM, 2016, STEM CELLS, V34, P1709, DOI 10.1002/stem.2377
   Huebsch N, 2010, NAT MATER, V9, P518, DOI [10.1038/nmat2732, 10.1038/NMAT2732]
   Itoh T, 1998, J VET MED SCI, V60, P451, DOI 10.1292/jvms.60.451
   Jin SW, 2016, J KOREAN NEUROSURG S, V59, P192, DOI 10.3340/jkns.2016.59.3.192
   Jones JR, 2006, BIOMATERIALS, V27, P964, DOI 10.1016/j.biomaterials.2005.07.017
   Jukes JM, 2008, P NATL ACAD SCI USA, V105, P6840, DOI 10.1073/pnas.0711662105
   Kalay E, 2022, INJURY, V53, P1854, DOI 10.1016/j.injury.2022.03.064
   Khan SN, 2005, J AM ACAD ORTHOP SUR, V13, P77, DOI 10.5435/00124635 200501000 00010
   Kisiel M, 2012, J CONTROL RELEASE, V162, P646, DOI 10.1016/j.jconrel.2012.08.004
   Kraus KH, 1999, J INVEST SURG, V12, P115
   Lin D, 2019, BIOMATERIALS, V196, P122, DOI 10.1016/j.biomaterials.2017.11.011
   Liu YT, 2021, ADV SCI, V8, DOI 10.1002/advs.202100143
   Liu YT, 2017, ACS APPL MATER INTER, V9, P30283, DOI 10.1021/acsami.7b02466
   Long FX, 2004, DEVELOPMENT, V131, P1309, DOI 10.1242/dev.01006
   Ma YF, 2023, ADV SCI, V10, DOI 10.1002/advs.202302622
   Ma YF, 2021, CHEM ENG J, V411, DOI 10.1016/j.cej.2021.128541
   Ma YF, 2016, ACTA BIOMATER, V44, P110, DOI 10.1016/j.actbio.2016.08.023
   Maes C, 2012, NAT REV RHEUMATOL, V8, P358, DOI 10.1038/nrrheum.2012.36
   McGovern JA, 2018, DIS MODEL MECH, V11, DOI 10.1242/dmm.033084
   Mckay WF, 2007, INT ORTHOP, V31, P729, DOI 10.1007/s00264 007 0418 6
   Moeinzadeh S, 2016, BIOMATERIALS, V92, P57, DOI 10.1016/j.biomaterials.2016.03.034
   Niu HY, 2019, BIOMATERIALS, V216, DOI 10.1016/j.biomaterials.2019.05.027
   Niu HY, 2017, ACS BIOMATER SCI ENG, V3, P3161, DOI 10.1021/acsbiomaterials.7b00315
   Park SY, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11080393
   Petersen A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 06504 7
   Quarto R, 2001, NEW ENGL J MED, V344, P385, DOI 10.1056/NEJM200102013440516
   Regard JB, 2011, P NATL ACAD SCI USA, V108, P20101, DOI 10.1073/pnas.1114656108
   Roddy Erika, 2018, Eur J Orthop Surg Traumatol, V28, P351, DOI 10.1007/s00590 017 2063 0
   Sarem M, 2018, P NATL ACAD SCI USA, V115, pE6135, DOI 10.1073/pnas.1805159115
   Scotti C, 2013, P NATL ACAD SCI USA, V110, P3997, DOI 10.1073/pnas.1220108110
   Scotti C, 2010, P NATL ACAD SCI USA, V107, P7251, DOI 10.1073/pnas.1000302107
   Sha DY, 2021, EUR POLYM J, V161, DOI 10.1016/j.eurpolymj.2021.110830
   Shen J, 2021, BIOACT MATER, V6, P503, DOI 10.1016/j.bioactmat.2020.08.025
   St Jacques B, 1999, GENE DEV, V13, P2072, DOI 10.1101/gad.13.16.2072
   Stefater JA, 2011, NATURE, V474, P511, DOI 10.1038/nature10085
   Stegen S, 2016, CELL METAB, V23, P265, DOI 10.1016/j.cmet.2016.01.002
   Stewart R, 2011, J ORTHOP TRAUMA, V25, P472, DOI 10.1097/BOT.0b013e31822588d8
   Sun LL, 2021, ADV FUNCT MATER, V31, DOI 10.1002/adfm.202008515
   Tang W, 2016, ACTA BIOMATER, V32, P309, DOI 10.1016/j.actbio.2015.12.006
   Tsuji K, 2006, NAT GENET, V38, P1424, DOI 10.1038/ng1916
   ul haq MI, 2013, ACS NANO, V7, P10704, DOI 10.1021/nn4035074
   Wang GJ, 2018, ACS BIOMATER SCI ENG, V4, P719, DOI 10.1021/acsbiomaterials.7b00916
   Wang YD, 2003, J BIOMED MATER RES A, V66A, P192, DOI 10.1002/jbm.a.10534
   Wang ZH, 2018, ACTA BIOMATER, V71, P279, DOI 10.1016/j.actbio.2018.03.011
   Wu ZH, 2022, CHEM ENG J, V434, DOI 10.1016/j.cej.2021.133860
   Wu ZH, 2020, ACS APPL MATER INTER, V12, P12109, DOI 10.1021/acsami.0c00068
   Xu RS, 2018, BONE RES, V6, DOI 10.1038/s41413 018 0034 7
   Yan B, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11151
   Yang Q, 2011, J BONE MINER RES, V26, P1188, DOI 10.1002/jbmr.337
   Yang YQ, 2012, INT J ORAL SCI, V4, P64, DOI 10.1038/ijos.2012.33
   Yao QQ, 2016, ACS APPL MATER INTER, V8, P32450, DOI 10.1021/acsami.6b10538
   Yoon BS, 2005, P NATL ACAD SCI USA, V102, P5062, DOI 10.1073/pnas.0500031102
   Zara JN, 2011, TISSUE ENG PT A, V17, P1389, DOI [10.1089/ten.TEA.2010.0555, 10.1089/ten.tea.2010.0555]
   Zhang Q, 2017, BIOMATERIALS, V149, P77, DOI 10.1016/j.biomaterials.2017.10.007
   Zhang WJ, 2016, ACTA BIOMATER, V33, P290, DOI 10.1016/j.actbio.2016.01.042
   Zheng X, 2021, BIOACT MATER, V6, P3485, DOI 10.1016/j.bioactmat.2021.03.011
   Zhou NA, 2015, CELL PHYSIOL BIOCHEM, V36, P44, DOI 10.1159/000374052
NR 73
TC 15
Z9 15
U1 12
U2 68
PU KEAI PUBLISHING LTD
PI BEIJING
PA 16 DONGHUANGCHENGGEN NORTH ST, Building 5, Room 411, BEIJING, DONGCHENG
   DISTRICT 100009, PEOPLES R CHINA
EI 2452 199X
J9 BIOACT MATER
JI Bioact. Mater.
PD MAY
PY 2024
VL 35
BP 208
EP 227
DI 10.1016/j.bioactmat.2024.01.019
PG 20
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA JE8V8
UT WOS:001171588700001
PM 38327823
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Wu, D
   Yin, HL
   Yang, C
   Zhang, ZM
   Fang, F
   Wang, JW
   Li, XL
   Xie, Y
   Hu, XH
   Zhuo, R
   Chen, YL
   Yu, JJ
   Li, TD
   Li, G
   Pan, J
AF Wu, Di
   Yin, Hongli
   Yang, Chun
   Zhang, Zimu
   Fang, Fang
   Wang, Jianwei
   Li, Xiaolu
   Xie, Yi
   Hu, Xiaohan
   Zhuo, Ran
   Chen, Yanling
   Yu, Juanjuan
   Li, Tiandan
   Li, Gen
   Pan, Jian
TI The BET PROTAC inhibitor GNE 987 displays anti tumor effects by
   targeting super enhancers regulated gene in osteosarcoma
SO BMC CANCER
LA English
DT Article
DE OS; BRD4; SEs; PROTAC; KRT80
ID HIGH GRADE OSTEOSARCOMA; NEOADJUVANT CHEMOTHERAPY; METHOTREXATE;
   EXTREMITIES; IFOSFAMIDE; ONCOGENES; CANCER; BRD4
AB BackgroundOsteosarcoma (OS) is one of the most common primary malignant tumors of bone in children, which develops from osteoblasts and typically occurs during the rapid growth phase of the bone. Recently, Super Enhancers(SEs)have been reported to play a crucial role in osteosarcoma growth and metastasis. Therefore, there is an urgent need to identify specific targeted inhibitors of SEs to assist clinical therapy. This study aimed to elucidate the role of BRD4 inhibitor GNE 987 targeting SEs in OS and preliminarily explore its mechanism.MethodsWe evaluated changes in osteosarcoma cells following treatment with a BRD4 inhibitor GNE 987. We assessed the anti tumor effect of GNE 987 in vitro and in vivo by Western blot, CCK8, flow cytometry detection, clone formation, xenograft tumor size measurements, and Ki67 immunohistochemical staining, and combined ChIP seq with RNA seq techniques to find its anti tumor mechanism.ResultsIn this study, we found that extremely low concentrations of GNE 987(2 10 nM) significantly reduced the proliferation and survival of OS cells by degrading BRD4. In addition, we found that GNE 987 markedly induced cell cycle arrest and apoptosis in OS cells. Further study indicated that VHL was critical for GNE 987 to exert its antitumor effect in OS cells. Consistent with in vitro results, GNE 987 administration significantly reduced tumor size in xenograft models with minimal toxicity, and partially degraded the BRD4 protein. KRT80 was identified through analysis of the RNA seq and ChIP seq data. U2OS HiC analysis suggested a higher frequency of chromatin interactions near the KRT80 binding site. The enrichment of H3K27ac modification at KRT80 was significantly reduced after GNE 987 treatment. KRT80 was identified as playing an important role in OS occurrence and development.ConclusionsThis research revealed that GNE 987 selectively degraded BRD4 and disrupted the transcriptional regulation of oncogenes in OS. GNE 987 has the potential to affect KRT80 against OS.
C1 [Wu, Di; Yin, Hongli; Yang, Chun; Zhang, Zimu; Fang, Fang; Wang, Jianwei; Li, Xiaolu; Xie, Yi; Hu, Xiaohan; Zhuo, Ran; Chen, Yanling; Yu, Juanjuan; Li, Tiandan; Li, Gen; Pan, Jian] Childrens Hosp Soochow Univ, Inst Pediat Res, Childrens Hosp, 92 Zhongnan St,SIP, Suzhou 215003, Peoples R China.
RP Li, G; Pan, J (通讯作者)，Childrens Hosp Soochow Univ, Inst Pediat Res, Childrens Hosp, 92 Zhongnan St,SIP, Suzhou 215003, Peoples R China.
EM ligen925@yeah.net; panjian2008@163.com
RI Hu, Xiaohan/AAT 4475 2021; Wang, Jianwei/AAV 2918 2021; chen,
   yanling/GRE 8287 2022
FU National Natural Science Foundation [82141110, 82072767, 81970163,
   81971867]; Natural Science Foundation of Jiangsu Province [BK20220047];
   Jiangsu Province's science and technology support program (Social
   Development) project [BE2021657, BE2021654, BE2022732]; National Key R&D
   Program of China [2022YFC2502702]; Suzhou Health Talent Training Project
   [GSWS2020047, GSWS2021028]; Science and Technology Development Project
   of Suzhou City [SKJY2021109, SKJY2021111, SKJY2021112, SKY202217 0,
   SKY2022175, SKY2022182]; National Outstanding Youth Cultivation Program
   Project [YYJQ004]; Jiangsu Provincial Health Commission Scientific
   Research Project [ZD2022056, Z2022031]
FX This work was supported by grants from the National Natural Science
   Foundation (82141110, 82072767, 81970163, 81971867); Natural Science
   Foundation of Jiangsu Province (BK20220047); Jiangsu Province's science
   and technology support program (Social Development) project (BE2021657,
   BE2021654, BE2022732); National Key R&D Program of China
   (2022YFC2502702); Suzhou Health Talent Training Project (GSWS2020047,
   GSWS2021028); the Science and Technology Development Project of Suzhou
   City (SKJY2021109, SKJY2021111, SKJY2021112, SKY202217 0, SKY2022175,
   SKY2022182); National Outstanding Youth Cultivation Program Project
   (YYJQ004) and Jiangsu Provincial Health Commission Scientific Research
   Project (ZD2022056, Z2022031).
CR Bacci G, 2008, J SURG ONCOL, V98, P415, DOI 10.1002/jso.21140
   Briccoli A, 2010, SURG ONCOL, V19, P193, DOI 10.1016/j.suronc.2009.05.002
   Chen DH, 2019, EUR J MED CHEM, V182, DOI 10.1016/j.ejmech.2019.111633
   Chen YL, 2022, CELL BIOSCI, V12, DOI 10.1186/s13578 022 00769 8
   Cheng ZJ, 2019, ACTA PHARMACOL SIN, V40, P814, DOI 10.1038/s41401 018 0187 3
   Choi JH, 2021, ADV ANAT PATHOL, V28, P119, DOI 10.1097/PAP.0000000000000293
   Coombes RC, 2023, NAT COMMUN, V14, DOI 10.1038/s41467 023 40061 y
   Daw NC, 2015, BRIT J CANCER, V112, P278, DOI 10.1038/bjc.2014.585
   Diehl CJ, 2022, CHEM SOC REV, V51, P8216, DOI 10.1039/d2cs00387b
   Donati B, 2018, MOL CANCER, V17, DOI 10.1186/s12943 018 0915 9
   Faivre EJ, 2020, NATURE, V578, P306, DOI 10.1038/s41586 020 1930 8
   Fang F, 2022, J EXP CLIN CANC RES, V41, DOI 10.1186/s13046 022 02428 9
   Feng M, 2023, J EXP CLIN CANC RES, V42, DOI 10.1186/s13046 023 02615 2
   Ferrari S, 2012, J CLIN ONCOL, V30, P2112, DOI 10.1200/JCO.2011.38.4420
   Gaspar N, 2021, LANCET ONCOL, V22, P1312, DOI 10.1016/S1470 2045(21)00387 9
   Gaspar N, 2018, EUR J CANCER, V88, P57, DOI 10.1016/j.ejca.2017.09.036
   Gill J, 2021, NAT REV CLIN ONCOL, V18, P609, DOI 10.1038/s41571 021 00519 8
   Hnisz D, 2013, CELL, V155, P934, DOI 10.1016/j.cell.2013.09.053
   Jang MK, 2005, MOL CELL, V19, P523, DOI 10.1016/j.molcel.2005.06.027
   Jiang YY, 2017, GUT, V66, P1358, DOI 10.1136/gutjnl 2016 311818
   Kawasaki K, 2020, GASTROENTEROLOGY, V158, P638, DOI 10.1053/j.gastro.2019.10.009
   Kim YI, 2023, CELL BIOSCI, V13, DOI 10.1186/s13578 023 01088 2
   Latif AL, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 020 20378 8
   Lee DH, 2015, INT J CANCER, V136, P2055, DOI 10.1002/ijc.29269
   Li CC, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 1030 y
   Li GH, 2021, J EXP CLIN CANC RES, V40, DOI 10.1186/s13046 021 01974 y
   Li SL, 2021, MOL CANCER, V20, DOI 10.1186/s12943 021 01453 0
   Li SL, 2021, J NANOBIOTECHNOL, V19, DOI 10.1186/s12951 021 01028 7
   Liao D, 2020, NAT CELL BIOL, V22, P868, DOI 10.1038/s41556 020 0522 z
   Linder M, 2018, EMBO MOL MED, V10, DOI 10.15252/emmm.201809408
   Liu HJ, 2023, ADV SCI, V10, DOI 10.1002/advs.202207439
   Lu B, 2020, MOL CANCER RES, V18, P57, DOI 10.1158/1541 7786.MCR 19 0470
   Ma LY, 2022, CANCER CHEMOTH PHARM, V90, P431, DOI 10.1007/s00280 022 04483 7
   Majumder P, 2020, J EXP MED, V217, DOI 10.1084/jem.20190668
   Marina NM, 2016, LANCET ONCOL, V17, P1396, DOI 10.1016/S1470 2045(16)30214 5
   Matsuoka K, 2020, CELL RES, V30, P885, DOI 10.1038/s41422 020 0370 1
   Meyers PA, 2008, J CLIN ONCOL, V26, P633, DOI 10.1200/JCO.2008.14.0095
   Mohammad HP, 2019, NAT MED, V25, P403, DOI 10.1038/s41591 019 0376 8
   Nilashi M, 2019, J INFECT PUBLIC HEAL, V12, P13, DOI 10.1016/j.jiph.2018.09.009
   Perone Y, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 09676 y
   Pillow TH, 2020, CHEMMEDCHEM, V15, P17, DOI 10.1002/cmdc.201900497
   Rahnamoun H, 2018, NAT STRUCT MOL BIOL, V25, P687, DOI 10.1038/s41594 018 0102 0
   Sanada H, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20184482
   Sang X, 2022, J IMMUNOL RES, V2022, DOI 10.1155/2022/7912484
   See YX, 2019, TRENDS GENET, V35, P145, DOI 10.1016/j.tig.2018.11.007
   Shi CC, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 2022 2
   Shi CZ, 2020, NEURO ONCOLOGY, V22, P1114, DOI 10.1093/neuonc/noaa084
   Shu SK, 2016, NATURE, V529, P413, DOI 10.1038/nature16508
   Song H, 2020, BIOMED PHARMACOTHER, V126, DOI 10.1016/j.biopha.2020.109941
   Stathis A, 2018, CANCER DISCOV, V8, P24, DOI 10.1158/2159 8290.CD 17 0605
   Sternicki LM, 2021, CHEMMEDCHEM, V16, P2206, DOI 10.1002/cmdc.202100113
   Suzuki HI, 2017, CELL, V168, P1000, DOI 10.1016/j.cell.2017.02.015
   Tasdemir N, 2016, CANCER DISCOV, V6, P612, DOI 10.1158/2159 8290.CD 16 0217
   Vähärautio A, 2014, SCIENCE, V346, P1291, DOI 10.1126/science.aaa3247
   Wada M, 2020, J HUM GENET, V65, P1019, DOI 10.1038/s10038 020 0795 x
   Wang C, 2020, GUT, V69, P727, DOI 10.1136/gutjnl 2019 318506
   Wang LM, 2017, BIOL RES, V50, DOI 10.1186/s40659 017 0124 9
   Wang X, 2019, NUCLEIC ACIDS RES, V47, P11481, DOI 10.1093/nar/gkz1038
   Wei XY, 2023, CANCER MED US, V12, P13991, DOI 10.1002/cam4.6040
   Zanella ER, 2022, NAT REV CLIN ONCOL, V19, P719, DOI 10.1038/s41571 022 00682 6
   Zhang JJ, 2020, CLIN CANCER RES, V26, P2681, DOI 10.1158/1078 0432.CCR 19 1418
   Zhao J, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046 019 1246 4
   Zheng CQ, 2020, ONCOL LETT, V20, P2557, DOI 10.3892/ol.2020.11855
   Zheng ZZ, 2022, NUCLEIC ACIDS RES, V50, P10230, DOI 10.1093/nar/gkac778
NR 64
TC 1
Z9 1
U1 2
U2 6
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471 2407
J9 BMC CANCER
JI BMC Cancer
PD AUG 1
PY 2024
VL 24
IS 1
AR 928
DI 10.1186/s12885 024 12691 y
PG 16
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA A5J4X
UT WOS:001282891000001
PM 39090568
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Ma, XH
   He, LQ
AF Ma, Xiaohong
   He, Liqun
TI The intervention effect of zuogui pill on chronic kidney disease mineral
   and bone disorder regulatory factor
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE Zuogui pill; Chronic kidney disease; Mineral and bone disorder; Bone
   metabolism; Nourish kidney
ID CHRONIC RENAL FAILURE; VASCULAR CALCIFICATION; VITAMIN D; PORIA COCOS;
   DIURETIC ACTIVITY; TRADITIONAL USES; GENE EXPRESSION; QUALITY CONTROL;
   METABOLOMICS; METABOLISM
AB Chronic kidney disease mineral and bone disorder (CKD MBD) play a critical role in the pathogenesis of cardiovascular complications in patients with chronic kidney disease (CKD). Zuogui pill as a traditional Chinese herbal drug has been used for nourish kidney essence improve bone malnutrition of renal bone disease by regulating the metabolism of calcium and phosphorus and participating in osteoblast metabolism. In the present study, 5/6 nephrectomy rat model was used to reveal the mechanism of zuogui pill in treatment of CKD MBD. Compared with sham rats, the levels of serum phosphorus, PTH, iPTH and creatinine were significantly decreased, while the serum calcium level was significantly increased, and the Cbfal protein level was significantly decreased and FGF23 protein level was significantly increased by Zuogui pill treatment. Compared with model rats, the BMD of rat was significantly increased by Zuogui pill treatment. Histological analysis revealed that the kidney injury of rats with CKD was significantly reduced by zuogui pill treatment. Compared with model rats, the CYP27B1 mRNA level was significantly increased, and the PTH mRNA level and NaPiIIa protein level were significantly decreased in the kidney by zuogui pill treatment. We inferred that zuogui pill exhibited potential therapeutic effects on CKD MBD in the rats by regulating bone metabolism and nourish kidney.
C1 [Ma, Xiaohong] Chenxinghai Hosp Zhongshan City, 18 Zhuyuan Rd, Zhongshan 528415, Guangdong, Peoples R China.
   [He, Liqun] Shanghai Univ Tradit Chinese Med & Pharmacol, Shuguang Hosp Affiliated, 185 Puan Rd, Shanghai 200021, Peoples R China.
C3 Shanghai University of Traditional Chinese Medicine
RP Ma, XH (通讯作者)，Chenxinghai Hosp Zhongshan City, 18 Zhuyuan Rd, Zhongshan 528415, Guangdong, Peoples R China.
EM 743457870@qq.com
RI He, Liqun/LKW 8210 2024
FU National Natural Science Foundation of China [81373615]; China
   Postdoctoral Science Foundation [2013M531200]
FX This study was supported by National Natural Science Foundation of China
   (81373615) and the class General Financial Grant from the China
   Postdoctoral Science Foundation (2013M531200).
CR Berndt TJ, 2005, AM J PHYSIOL RENAL, V289, pF1170, DOI 10.1152/ajprenal.00072.2005
   Chen DQ, 2017, NEPHROL DIAL TRANSPL, V32, P1154, DOI 10.1093/ndt/gfw415
   Chen DQ, 2017, REDOX BIOL, V12, P505, DOI 10.1016/j.redox.2017.03.017
   Chen H, 2016, REDOX BIOL, V10, P168, DOI 10.1016/j.redox.2016.09.014
   Chen H, 2014, ADV CLIN CHEM, V66, P101, DOI 10.1016/B978 0 12 801401 1.00004 9
   Chen L, 2018, ADV CLIN CHEM, V85, P91, DOI 10.1016/bs.acc.2018.02.005
   Chen L, 2018, BIOMED PHARMACOTHER, V101, P670, DOI 10.1016/j.biopha.2018.02.090
   [戴薇薇 DAI WeiWei], 2006, [中国老年学杂志, Chinese Journal of Gerontology], V26, P1066
   Davies MR, 2005, J AM SOC NEPHROL, V16, P917, DOI 10.1681/ASN.2004100835
   Edeling M, 2016, NAT REV NEPHROL, V12, P426, DOI 10.1038/nrneph.2016.54
   Feng YL, 2013, J ETHNOPHARMACOL, V150, P1114, DOI 10.1016/j.jep.2013.10.043
   HENRY HL, 1984, ANNU REV NUTR, V4, P493, DOI 10.1146/annurev.nu.04.070184.002425
   Komaba H, 2008, INTERNAL MED, V47, P989, DOI 10.2169/internalmedicine.47.1051
   Kou ShuAng Kou ShuAng, 2011, Journal of Liaoning University of Traditional Chinese Medicine, V13, P61
   Lee BC, 2009, J ETHNOPHARMACOL, V122, P131, DOI 10.1016/j.jep.2008.12.015
   [李瀚旻 Li HM], 2007, [中国组织工程研究与临床康复, Journal of Clinical Rehabilitative Tissue Engineering Research], V11, P5465
   Li Xiang, 2005, Zhonghua Yi Xue Za Zhi, V85, P2201
   Ling Z., 2008, CHIN ARCH TRADIT CHI
   Liu MJ, 2011, J TRADIT CHIN MED, V31, P98, DOI 10.1016/S0254 6272(11)60020 4
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Ma Xiaohong, 2013, Nan Fang Yi Ke Da Xue Xue Bao, V33, P1577
   Martin KJ, 2007, J AM SOC NEPHROL, V18, P875, DOI 10.1681/ASN.2006070771
   [孟玥 Meng Yue], 2016, [时珍国医国药, Lishizhen Medicine and Materia Medica Research], V27, P769
   Mizobuchi M, 2006, NEPHROL DIAL TRANSPL, V21, P911, DOI 10.1093/ndt/gfk008
   Moe S, 2006, KIDNEY INT, V69, P1945, DOI 10.1038/sj.ki.5000414
   Murer H, 2003, ANNU REV PHYSIOL, V65, P531, DOI 10.1146/annurev.physiol.65.042902.092424
   Nagpal S, 2005, ENDOCR REV, V26, P662, DOI 10.1210/er.2004 0002
   Rodriguez M, 2011, KIDNEY BLOOD PRESS R, V34, P261, DOI 10.1159/000326903
   Shimada T, 2004, J CLIN INVEST, V113, P561, DOI 10.1172/JCI200419081
   Shoben AB, 2008, J AM SOC NEPHROL, V19, P1613, DOI 10.1681/ASN.2007111164
   Stein GS, 2004, ONCOGENE, V23, P4315, DOI 10.1038/sj.onc.1207676
   Stubbs JR, 2007, J AM SOC NEPHROL, V18, P2116, DOI 10.1681/ASN.2006121385
   Tangkiatkumjai M., 2015, NEPHROLOGY CARLTON
   Tian T, 2014, J ETHNOPHARMACOL, V158, P373, DOI 10.1016/j.jep.2014.10.061
   Torremadé N, 2016, J BONE MINER RES, V31, P1865, DOI 10.1002/jbmr.2852
   Wang X., 2012, CHIN J INTEGR TRADIE, V13, P584
   Watanabe K, 2018, J ATHEROSCLER THROMB, V25, P170, DOI 10.5551/jat.40170
   Yang S. W., 2016, CHIN TRADIT PAT MED
   Zhang ZH, 2017, CLIN BIOCHEM, V50, P1078, DOI 10.1016/j.clinbiochem.2017.09.012
   Zhang ZH, 2016, SCI REP UK, V6, DOI 10.1038/srep22151
   Zhang ZH, 2015, SCI REP UK, V5, DOI 10.1038/srep14472
   [赵旭 Zhao Xu], 2015, [中医杂志, Journal of Traditional Chinese Medicine], V56, P1414
   Zhao YY, 2015, ADV CLIN CHEM, V68, P153, DOI 10.1016/bs.acc.2014.11.002
   Zhao YY, 2014, ADV CLIN CHEM, V65, P69, DOI 10.1016/B978 0 12 800141 7.00003 6
   Zhao YY, 2013, J ETHNOPHARMACOL, V149, P35, DOI 10.1016/j.jep.2013.06.031
   Zhao YY, 2013, J PHARMACEUT BIOMED, V81 82, P202, DOI 10.1016/j.jpba.2013.03.028
   Zhao YY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059617
   Zhao YY, 2012, J ETHNOPHARMACOL, V144, P775, DOI 10.1016/j.jep.2012.09.033
   Zhao YY, 2012, CLIN CHIM ACTA, V413, P1438, DOI 10.1016/j.cca.2012.06.005
   Zhao YY, 2012, CLIN CHIM ACTA, V413, P642, DOI 10.1016/j.cca.2011.12.014
   Zhong YF, 2013, KIDNEY INT, V84, P1108, DOI 10.1038/ki.2013.276
   [周焕 Zhou Huan], 2016, [华西药学杂志, West China Journal of Pharmaceutical Sciences], V31, P309
   Zhou LL, 2016, CURR OPIN NEPHROL HY, V25, P100, DOI 10.1097/MNH.0000000000000205
NR 53
TC 13
Z9 15
U1 3
U2 25
PU ELSEVIER FRANCE EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY LES MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY LES MOULINEAUX, FRANCE
SN 0753 3322
EI 1950 6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD OCT
PY 2018
VL 106
BP 54
EP 60
DI 10.1016/j.biopha.2018.06.092
PG 7
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA GR4QO
UT WOS:000442600300007
PM 29957466
DA 2025 08 17
ER

PT J
AU Jayanand
   Behari, J
AF Jayanand
   Behari, Jitendra
TI Changes in bone histology due to capacitive electric field stimulation
   of ovariectomized rat
SO INDIAN JOURNAL OF MEDICAL RESEARCH
LA English
DT Article
DE Alkaline phosphatase; capacitively coupled; collagen; electrical
   stimulation; ovariectomy; postmenopausal osteoporosis
ID PULSED ELECTROMAGNETIC FIELD; IN VITRO; ALKALINE PHOSPHATASE; MINERAL
   FORMATION; PROLIFERATION; OSTEOPOROSIS; FRACTURE; HYDROXYAPATITE;
   MECHANISM; SYSTEMS
AB Background & objectives: Postmenopausal osteoporosis leads to a significant decline in bone mass. That complicates the treatment outcome. The objective of the present stud), was to find out the effects of pulsed modulated low level electric field capacitively coupled on bone histology of induced osteoporotic rats, for screening the potential therapy for osteoporosis.
   Methods: Osteopororosis was induced by performed by bilateral ovariectomy of female Wistar rats. After one month of surgery electric field stimulation was delivered to one leg of experimatal rats while the other was sham exposed. After 60 days of exposure treated rats were sacrificed and femur and tibia bones were segregated into (i) control (CON), (ii) ovariectomized (OVX) and (iii) ovariectomized + electrical stimulation (OVX+ES).
   Results: Histopathological analyses showed that capacitively coupled pulsed electric field exposure treatment augmented and restored the bone marrow cell population. Immunohistological localization of alkaline phosphatase (ALP) showed the increased activity of this enzyme after electrostimulation, which showed an enhanced osteoblast differentiation. Collagen histochemistry showed high amount of collagen fiber in exposed rats bones than that of osteoporotic bones. Electron microscopic study revealed the enhancement of microstructural composition and compactness in cortical and trabecular part of treated bones.
   Interpretation & conclusions: Our results suggest that capacitively coupled pulsed electric field exposure treatment of specified parameters is efficacious in attenuating the effects of ovariectomy induced osteoporosis and restore the bone loss.
C1 [Jayanand; Behari, Jitendra] Jawaharlal Nehru Univ, Sch Environm Sci, Biophys Lab, New Delhi 110067, India.
C3 Jawaharlal Nehru University, New Delhi
RP Behari, J (通讯作者)，Jawaharlal Nehru Univ, Sch Environm Sci, Biophys Lab, New Delhi 110067, India.
EM jbehari2000@yahoo.co.in
CR ADEY WR, 1986, BIOELECTROCH BIOENER, V15, P447, DOI 10.1016/0302 4598(86)85033 4
   ALEXEEVA L, 1994, WHO TECH REP SER, V843, P1
   ANDERSON HC, 1989, LAB INVEST, V60, P320
   Andre Frei V, 2000, CALCIFIED TISSUE INT, V66, P204, DOI 10.1007/s002230010041
   BASSETT CAL, 1993, J CELL BIOCHEM, V51, P387, DOI 10.1002/jcb.2400510402
   BEHARI J, 1991, J BIOELECTRICITY, V10, P231, DOI 10.3109/15368379109031409
   BEHARI J, BIOPHYSICAL BONE BEH, P175
   BOSKEY AL, 1976, J PHYS CHEM US, V80, P40, DOI 10.1021/j100542a009
   Boskey AL, 1996, CONNECT TISSUE RES, V35, P357, DOI 10.3109/03008209609029212
   Chang K, 2006, CONNECT TISSUE RES, V47, P222, DOI 10.1080/03008200600858783
   Chang WHS, 2004, BIOELECTROMAGNETICS, V25, P457, DOI 10.1002/bem.20016
   GLIMCHER MJ, 1989, ANAT REC, V224, P139, DOI 10.1002/ar.1092240205
   Hartig M, 2000, EUR BIOPHYS J BIOPHY, V29, P499, DOI 10.1007/s002490000100
   HILL PA, 1997, ENDOCRINOLOGY, V138, P2311
   *INT OST FDN, 2003, FACTS OST ITS IMP RE, P1
   JEYANAND, 2003, INDIAN J EXP BIOL, V41, P58
   Kleerekoper M, 2006, OSTEOPOROSIS INT, V17, P1707, DOI 10.1007/s00198 006 0187 x
   KURAHASHI Y, 1969, Journal of Electron Microscopy, V18, P219
   Lau EMC, 2001, OSTEOPOROSIS INT, V12, P239, DOI 10.1007/s001980170135
   Li JKJ, 2006, ULTRASOUND MED BIOL, V32, P769, DOI 10.1016/j.ultrasmedbio.2006.01.017
   Lock CA, 2006, OSTEOPOROSIS INT, V17, P20, DOI 10.1007/s00198 005 1942 0
   LUBEN RA, 1991, HEALTH PHYS, V61, P15, DOI 10.1097/00004032 199107000 00002
   Martin RI, 1997, J BIOMED MATER RES, V35, P299, DOI 10.1002/(SICI)1097 4636(19970605)35:3<299::AID JBM4>3.0.CO;2 C
   MCLEOD KJ, 1993, J BONE MINER RES, V8, P977, DOI 10.1002/jbmr.5650080811
   Miao DS, 2002, J HISTOCHEM CYTOCHEM, V50, P333, DOI 10.1177/002215540205000305
   MORRIS DC, 1992, BONE MINER, V19, P287, DOI 10.1016/0169 6009(92)90877 G
   ROBERTSO.WG, 1973, CALC TISS RES, V11, P311, DOI 10.1007/BF02547230
   Selvarnurugan N, 2007, J ORTHOP RES, V25, P1213, DOI 10.1002/jor.20409
   Shupak N. M., 2003, Radio Science Bulletin, P9
   Spadaro JA, 2002, CALCIFIED TISSUE INT, V70, P496, DOI 10.1007/s00223 001 1001 6
   STEIN GS, 1993, ENDOCR REV, V14, P424, DOI 10.1210/er.14.4.424
   Wiesmann HP, 2001, BBA MOL CELL RES, V1538, P28, DOI 10.1016/S0167 4889(00)00135 X
NR 32
TC 9
Z9 10
U1 0
U2 1
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A 202, 2ND FLR, QUBE, C T S  NO 1498A 2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
SN 0971 5916
J9 INDIAN J MED RES
JI Indian J. Med. Res.
PD DEC
PY 2009
VL 130
IS 6
BP 720
EP 725
PG 6
WC Immunology; Medicine, General & Internal; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology; General & Internal Medicine; Research & Experimental
   Medicine
GA 547KF
UT WOS:000273885300010
PM 20090133
DA 2025 08 17
ER

PT J
AU Shimode, K
   Iwasaki, N
   Majima, T
   Funakoshi, T
   Sawaguchi, N
   Onodera, T
   Minami, A
AF Shimode, Kazumi
   Iwasaki, Norimasa
   Majima, Tokifumi
   Funakoshi, Tadanao
   Sawaguchi, Naohiro
   Onodera, Tomohiro
   Minami, Akio
TI Local Upregulation of Stromal Cell Derived Factor 1 After Ligament
   Injuries Enhances Homing Rate of Bone Marrow Stromal Cells in Rats
SO TISSUE ENGINEERING PART A
LA English
DT Article
ID MESENCHYMAL STEM CELLS; SDF 1; REGENERATION; MIGRATION; PROLIFERATION;
   FIBROBLASTS; OSTEOBLASTS; RECRUITMENT; CHEMOKINES; MECHANISM
AB In the present study the local expression of stromal cell derived factor 1 (SDF 1) after ligament injury and correlated change in the homing rate of systemically induced bone marrow stromal cells (BMSCs) to the injured site were clarified using a rat medial collateral ligament (MCL) injury model. SDF 1 was temporarily upregulated peaking at 2 weeks after injury. Correlated with the alteration in SDF 1 expression, the homing rate of systemically induced BMSCs was temporarily upregulated peaking at 2 4 weeks after injury. The SDF 1 expression in the MCL seems to play a crucial role in cell homing. In addition, SDF 1 did not influence the BMSCs behavior in vitro in terms of the proliferation, adhesivity, and expression of ligament fibroblast markers. The cell based therapy for ligament and tendon injury with reference to local expression of SDF 1 may be one of the available applications.
C1 [Shimode, Kazumi; Iwasaki, Norimasa; Majima, Tokifumi; Funakoshi, Tadanao; Sawaguchi, Naohiro; Onodera, Tomohiro; Minami, Akio] Hokkaido Univ, Grad Sch Med, Dept Orthopaed Surg, Sapporo, Hokkaido 0608638, Japan.
   [Iwasaki, Norimasa; Majima, Tokifumi; Minami, Akio] Hokkaido Univ, Frontier Res Ctr Postgenom Sci & Technol, Sapporo, Hokkaido 0608638, Japan.
C3 Hokkaido University; Hokkaido University
RP Iwasaki, N (通讯作者)，Hokkaido Univ, Grad Sch Med, Dept Orthopaed Surg, Kita 15,Nishi 7, Sapporo, Hokkaido 0608638, Japan.
EM niwasaki@med.hokudai.ac.jp
RI Onodera, Tomohiro/G 1686 2012; Iwasaki, Norimasa/D 6448 2012; Majima,
   Tokifumi/E 2412 2012
FU Ministry of Education, Culture, Sports, Science and Technology
   [B 1539044]; New Energy and Industrial Technology Development
   Organization [03A04002a]
FX Supported by a Grant in Aid for Science Research from the Ministry of
   Education, Culture, Sports, Science and Technology (B 1539044), and a
   Grant in Aid for New Energy and Industrial Technology Development
   Organization ( 03A04002a).
CR Abbott JD, 2004, CIRCULATION, V110, P3300, DOI 10.1161/01.CIR.0000147780.30124.CF
   Altman GH, 2001, FASEB J, V15, P270, DOI 10.1096/fj.01 0656fje
   Andriacchi T., 1988, Injury and Repair of the Musculoskeltal Soft Tissues, P103
   Ara T, 2003, IMMUNITY, V19, P257, DOI 10.1016/S1074 7613(03)00201 2
   Askari AT, 2003, LANCET, V362, P697, DOI 10.1016/S0140 6736(03)14232 8
   Beck LS, 1991, GROWTH FACTORS, V5, DOI 10.3109/08977199109000293
   BRUDER SP, 1994, J CELL BIOCHEM, V56, P283, DOI 10.1002/jcb.240560303
   Chen J, 2006, KNEE SURG SPORT TR A, V14, P750, DOI 10.1007/s00167 006 0043 8
   Cuevas P, 2004, NEUROL RES, V26, P230, DOI 10.1179/016164104225013897
   Fukada S, 2002, J CELL SCI, V115, P1285
   Gong XM, 2006, CELL BIOL INT, V30, P466, DOI 10.1016/j.cellbi.2006.01.007
   Hoehn M, 2002, P NATL ACAD SCI USA, V99, P16267, DOI 10.1073/pnas.242435499
   Ji JF, 2004, STEM CELLS, V22, P415, DOI 10.1634/stemcells.22 3 415
   Jung Y, 2006, BONE, V38, P497, DOI 10.1016/j.bone.2005.10.003
   Kannus P, 2003, SCAND J MED SCI SPOR, V13, P150, DOI 10.1034/j.1600 0838.2003.02225.x
   Kollet O, 2003, J CLIN INVEST, V112, P160, DOI 10.1172/JCI200317902
   Lagasse E, 2000, NAT MED, V6, P1229, DOI 10.1038/81326
   Lisignoli G, 2006, J CELL PHYSIOL, V206, P78, DOI 10.1002/jcp.20435
   MASON CPL, 2006, ULTRASOUND MED BIOL, V32, P449
   Medvinsky A, 2003, NATURE, V422, P823, DOI 10.1038/422823a
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   POSTLETHWAITE AE, 1987, J EXP MED, V165, P251, DOI 10.1084/jem.165.1.251
   Richards M, 1999, J ORTHOP RES, V17, P900, DOI 10.1002/jor.1100170615
   Riss T., 1992, Promega Notes Mag, V38, P18
   ROSS R, 1968, BIOL REV, V43, P51, DOI 10.1111/j.1469 185X.1968.tb01109.x
   Shen KC, 2006, BREAST CANCER RES TR, V98, P357, DOI 10.1007/s10549 006 9173 4
   Shen LH, 2006, NEUROSCIENCE, V137, P393, DOI 10.1016/j.neuroscience.2005.08.092
   Shen LH, 2007, J CEREBR BLOOD F MET, V27, P6, DOI 10.1038/sj.jcbfm.9600311
   Shimode K, 2007, TISSUE ENG, V13, P333, DOI 10.1089/ten.2006.0079
   Tögel F, 2005, KIDNEY INT, V67, P1772, DOI 10.1111/j.1523 1755.2005.00275.x
   WAKITANI S, 1994, J BONE JOINT SURG AM, V76A, P579, DOI 10.2106/00004623 199404000 00013
   Wang X, 2003, NATURE, V422, P897, DOI 10.1038/nature01531
   Watanabe N, 2002, MICROSC RES TECHNIQ, V58, P39, DOI 10.1002/jemt.10115
   Woo SLY, 1999, CLIN ORTHOP RELAT R, pS312
   Young RG, 1998, J ORTHOPAED RES, V16, P406, DOI 10.1002/jor.1100160403
NR 35
TC 20
Z9 21
U1 0
U2 14
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1937 3341
EI 1937 335X
J9 TISSUE ENG PT A
JI Tissue Eng. Part A
PD AUG
PY 2009
VL 15
IS 8
BP 2277
EP 2284
DI 10.1089/ten.tea.2008.0224
PG 8
WC Cell & Tissue Engineering; Cell Biology; Engineering, Biomedical;
   Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Engineering; Materials Science
GA 480AI
UT WOS:000268703400037
PM 19327017
DA 2025 08 17
ER

PT J
AU Zhang, BJ
   Li, HY
   He, L
   Han, ZW
   Zhou, T
   Zhi, W
   Lu, XB
   Lu, X
   Weng, J
AF Zhang, Bingjun
   Li, Hongyu
   He, Lei
   Han, Zhiwei
   Zhou, Teng
   Zhi, Wei
   Lu, Xiaobo
   Lu, Xiong
   Weng, Jie
TI Surface decorated hydroxyapatite scaffold with on demand delivery of
   dexamethasone and stromal cell derived factor 1 for enhanced
   osteogenesis
SO MATERIALS SCIENCE & ENGINEERING C MATERIALS FOR BIOLOGICAL APPLICATIONS
LA English
DT Article
DE Large sized bone regeneration; Porous hydroxyapatite scaffold; Surface
   functionalization; On demand release; Cell recruitment; Osteogenic
   differentiation
ID GLUCOCORTICOID INDUCED OSTEOPOROSIS; MESENCHYMAL STEM CELLS;
   BETA CYCLODEXTRIN; DRUG DELIVERY; CALCIUM PHOSPHATE; BONE REGENERATION;
   DIFFERENTIATION; OSTEOBLAST; RELEASE; CHITOSAN
AB In the process of bone regeneration, relatively early biological events including inflammatory response, angiogenesis, or stem cell homing, help the accompanying target actions of cell differentiation and calcification. Herein, we proposed a novel cell guided tissue engineering system based on a surface functionalized porous hydroxyapatite (HA) scaffolds with the ability to recruit cells and accelerate the differentiation of them along the osteoblastic lineage for optimizing large sized bone defect repair. Inspired by microstructural properties of natural bone, HA scaffolds similar to the trabecular bone structure were prepared via a sugar sphere leaching technique, in which the inter pore opening size was controllable. Dexamethasone (Dex) loaded hydroxypropyl beta cyclodextrin microspheres (Dex@CDMs) and stromal cell derived factor 1 (SDF 1) were uniformly immobilized onto HA surface by a cross linked alginate coating. The resulting scaffold (SDF 1/Dex@CDMs HA) enabled the on demand dual delivery of SDF 1 and Dex. In vitro cell culture assays showed that initially released SDF 1 markedly stimulated the migration of mesenchymal stem cells (MSCs) to the deep interior of the scaffold, providing abundant target cells for the function of Dex which was subsequently released. Osteogenic differentiation potential of these cells was also further facilitated via a synergistic action of SDF 1 and Dex. Additionally, in vivo studies demonstrated that the cell guided system effectively improved the early cell recruitment and vascularization within the deep interior of scaffold and significantly accelerated the extensive formation of osteoid and mineralized tissue compared with the controls. Accordingly, such a microsphere coating decorated multifunctional scaffold shows a promising potential for cell free bone tissue engineering applications.
C1 [Zhang, Bingjun; Li, Hongyu; He, Lei; Han, Zhiwei; Zhou, Teng; Zhi, Wei; Lu, Xiong; Weng, Jie] Southwest Jiaotong Univ, Sch Mat Sci & Engn, Minist Educ, Key Lab Adv Technol Mat, Chengdu 610031, Sichuan, Peoples R China.
   [Lu, Xiaobo] Southwest Med Univ, Affiliated Hosp, Dept Bone & Joint Surg, Luzhou 646000, Sichuan, Peoples R China.
C3 Southwest Jiaotong University; Southwest Medical University
RP Lu, X; Weng, J (通讯作者)，Southwest Jiaotong Univ, Sch Mat Sci & Engn, Minist Educ, Key Lab Adv Technol Mat, Chengdu 610031, Sichuan, Peoples R China.; Lu, XB (通讯作者)，Southwest Med Univ, Affiliated Hosp, Dept Bone & Joint Surg, Luzhou 646000, Sichuan, Peoples R China.
EM lux90366@126.com; luxiong2008@qq.com; jweng@swjtu.edu.cn
RI ; Weng, Jie/AAW 5626 2021; LU, xiong/B 3092 2010; Lu,
   Xiaobo/HKM 5201 2023; Zhang, Bingjun/LRT 5390 2024
OI Weng, Jie/0000 0002 7034 3215; Zhang, Bingjun/0000 0002 6149 7095; LU,
   xiong/0000 0001 6367 430X; 
FU National Key Research and Development Program of China [2016YFB0700803];
   National Natural Science Foundation of China [51572228]
FX This research was supported by grants from the National Key Research and
   Development Program of China (2016YFB0700803), and the National Natural
   Science Foundation of China (51572228).
CR Amini Ami R., 2012, Critical Reviews in Biomedical Engineering, V40, P363
   Bae SC, 2006, GENE, V366, P58, DOI 10.1016/j.gene.2005.10.017
   Bagherifard S, 2017, MAT SCI ENG C MATER, V71, P1241, DOI 10.1016/j.msec.2016.11.011
   Bonab MM, 2006, BMC CELL BIOL, V7, DOI 10.1186/1471 2121 7 14
   Browne S, 2014, J MATER CHEM B, V2, P6692, DOI 10.1039/c4tb00863d
   Castano Izquierdo H, 2007, J BIOMED MATER RES A, V82A, P129, DOI 10.1002/jbm.a.31082
   Centrella M, 2004, GENE, V342, P13, DOI 10.1016/j.gene.2004.06.036
   Ceradini DJ, 2004, NAT MED, V10, P858, DOI 10.1038/nm1075
   Cerchiara T, 2003, INT J PHARM, V258, P209, DOI 10.1016/S0378 5173(03)00202 3
   Chen FM, 2011, BIOMATERIALS, V32, P3189, DOI 10.1016/j.biomaterials.2010.12.032
   Crini G, 1998, CARBOHYD RES, V308, P37, DOI 10.1016/S0008 6215(98)00077 9
   Crisostomo PR, 2006, SHOCK, V26, P575, DOI 10.1097/01.shk.0000235087.45798.93
   Davis ME, 2004, NAT REV DRUG DISCOV, V3, P1023, DOI 10.1038/nrd1576
   Dimitriou R, 2011, BMC MED, V9, DOI 10.1186/1741 7015 9 66
   Ducy P, 2000, SCIENCE, V289, P1501, DOI 10.1126/science.289.5484.1501
   Fernandes CM, 2002, CHEM PHARM BULL, V50, P1597, DOI 10.1248/cpb.50.1597
   FilipovicGrcic J, 1996, INT J PHARM, V135, P183, DOI 10.1016/0378 5173(96)04470 5
   Fujio M, 2011, BONE, V49, P693, DOI 10.1016/j.bone.2011.06.024
   Gomes ME, 2006, TISSUE ENG, V12, P801, DOI 10.1089/ten.2006.12.801
   Guang LG, 2012, INT J BIOCHEM CELL B, V44, P1825, DOI 10.1016/j.biocel.2012.06.033
   Hamidouche Z, 2010, J CELL PHYSIOL, V224, P509, DOI 10.1002/jcp.22152
   Hosogane N, 2010, INT J BIOCHEM CELL B, V42, P1132, DOI 10.1016/j.biocel.2010.03.020
   Hoyos Nogués M, 2017, ACS APPL MATER INTER, V9, P21618, DOI 10.1021/acsami.7b03127
   Hwang H.D., 2015, TISSUE ENG PART A, V12, P2135
   Ishida Y, 1998, J BONE MINER RES, V13, P1822, DOI 10.1359/jbmr.1998.13.12.1822
   Ito S, 2007, BONE, V40, P84, DOI 10.1016/j.bone.2006.07.012
   Jaiswal N, 1997, J CELL BIOCHEM, V64, P295, DOI 10.1002/(SICI)1097 4644(199702)64:2<295::AID JCB12>3.3.CO;2 6
   Ji W, 2013, BIOMATERIALS, V34, P735, DOI 10.1016/j.biomaterials.2012.10.016
   Karageorgiou V, 2005, BIOMATERIALS, V26, P5474, DOI 10.1016/j.biomaterials.2005.02.002
   Kastellorizios M, 2015, J CONTROL RELEASE, V202, P101, DOI 10.1016/j.jconrel.2015.01.038
   Kim K, 2010, J DENT RES, V89, P842, DOI 10.1177/0022034510370803
   Kim K, 2009, BIOMACROMOLECULES, V10, P1810, DOI 10.1021/bm900240k
   Kortesidis A, 2005, BLOOD, V105, P3793, DOI 10.1182/blood 2004 11 4349
   Langer R, 2009, ADV MATER, V21, P3235, DOI 10.1002/adma.200902589
   Lee CH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120051
   Leprêtre S, 2009, BIOMATERIALS, V30, P6086, DOI 10.1016/j.biomaterials.2009.07.045
   Levengood SKL, 2010, BIOMATERIALS, V31, P3552, DOI 10.1016/j.biomaterials.2010.01.052
   Lim TC, 2010, J BIOMED MATER RES A, V94A, P1303, DOI 10.1002/jbm.a.32747
   Liu HR, 2015, MAT SCI ENG C MATER, V53, P83, DOI 10.1016/j.msec.2015.04.002
   Liu XM, 2008, BIOMATERIALS, V29, P1686, DOI 10.1016/j.biomaterials.2007.12.023
   Liu XM, 2007, J CONTROL RELEASE, V122, P54, DOI 10.1016/j.jconrel.2007.06.021
   Liu YS, 2014, BIOMATERIALS, V35, P4489, DOI 10.1016/j.biomaterials.2014.02.025
   Mao JJ, 2010, TISSUE ENG PART B RE, V16, P257, DOI 10.1089/ten.TEB.2009.0496
   Martins A, 2010, BIOMATERIALS, V31, P5875, DOI 10.1016/j.biomaterials.2010.04.010
   Mikami Y, 2007, BIOCHEM BIOPH RES CO, V362, P368, DOI 10.1016/j.bbrc.2007.07.192
   Molina ER, 2015, J CONTROL RELEASE, V219, P107, DOI 10.1016/j.jconrel.2015.08.038
   Nguyen LTH, 2012, J BIOMAT SCI POLYM E, V23, P1771, DOI 10.1163/092050611X597807
   Otsuru S, 2007, BIOCHEM BIOPH RES CO, V354, P453, DOI 10.1016/j.bbrc.2006.12.226
   Peled A, 2000, BLOOD, V95, P3289, DOI 10.1182/blood.V95.11.3289.011k33_3289_3296
   Peled A, 1999, SCIENCE, V283, P845, DOI 10.1126/science.283.5403.845
   Perez RA, 2016, MAT SCI ENG C MATER, V61, P922, DOI 10.1016/j.msec.2015.12.087
   Poldervaart MT, 2014, J CONTROL RELEASE, V184, P58, DOI 10.1016/j.jconrel.2014.04.007
   Qi X, 2017, SCI REP UK, V7, DOI 10.1038/srep42820
   Qu X, 2016, J MATER CHEM B, V4, P4901, DOI 10.1039/c6tb01262k
   Rajewski RA, 1996, J PHARM SCI, V85, P1142, DOI 10.1021/js960075u
   Raphel J, 2016, BIOMATERIALS, V83, P269, DOI 10.1016/j.biomaterials.2015.12.030
   Roseti L, 2017, MAT SCI ENG C MATER, V78, P1246, DOI 10.1016/j.msec.2017.05.017
   Scott MA, 2012, STEM CELLS DEV, V21, P655, DOI 10.1089/scd.2011.0517
   Seitz S, 2007, TISSUE ENG, V13, P1059, DOI 10.1089/ten.2006.0334
   Shen XF, 2016, BIOMATERIALS, V106, P205, DOI 10.1016/j.biomaterials.2016.08.023
   Son JS, 2011, J CONTROL RELEASE, V153, P133, DOI 10.1016/j.jconrel.2011.03.010
   Stella VJ, 1997, PHARMACEUT RES, V14, P556, DOI 10.1023/A:1012136608249
   Stocum DL, 2008, DEV DYNAM, V237, P3648, DOI 10.1002/dvdy.21774
   Sukegawa A, 2012, TISSUE ENG PT A, V18, P934, DOI [10.1089/ten.tea.2011.0380, 10.1089/ten.TEA.2011.0380]
   Sukul M, 2015, TISSUE ENG PT A, V21, P1822, DOI [10.1089/ten.tea.2014.0497, 10.1089/ten.TEA.2014.0497]
   Tang D, 2016, BIOMATERIALS, V83, P363, DOI 10.1016/j.biomaterials.2016.01.024
   Tang W, 2016, ACTA BIOMATER, V32, P309, DOI 10.1016/j.actbio.2015.12.006
   Thevenot PT, 2010, BIOMATERIALS, V31, P3997, DOI 10.1016/j.biomaterials.2010.01.144
   Thi THH, 2010, INT J PHARMACEUT, V400, P74, DOI 10.1016/j.ijpharm.2010.08.035
   Torres AL, 2013, MAT SCI ENG C MATER, V33, P4460, DOI 10.1016/j.msec.2013.07.003
   Uekama K, 1998, CHEM REV, V98, P2045, DOI 10.1021/cr970025p
   Wang Q, 2017, MATER LETT, V188, P387, DOI 10.1016/j.matlet.2016.11.098
   Wang Q, 2010, BIOMATERIALS, V31, P4980, DOI 10.1016/j.biomaterials.2010.02.052
   Weinstein RS, 2012, ENDOCRIN METAB CLIN, V41, P595, DOI 10.1016/j.ecl.2012.04.004
   Zhang BJ, 2017, J MATER CHEM B, V5, P8238, DOI 10.1039/c7tb01970j
   Zhao J, 2008, APPL SURF SCI, V255, P2942, DOI 10.1016/j.apsusc.2008.08.056
   Zhi W, 2014, J BIOMED MATER RES A, V102, P2491, DOI 10.1002/jbm.a.34919
NR 77
TC 43
Z9 43
U1 2
U2 104
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0928 4931
EI 1873 0191
J9 MAT SCI ENG C MATER
JI Mater. Sci. Eng. C Mater. Biol. Appl.
PD AUG 1
PY 2018
VL 89
BP 355
EP 370
DI 10.1016/j.msec.2018.04.008
PG 16
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA GI2YZ
UT WOS:000434239100038
PM 29752108
DA 2025 08 17
ER

PT J
AU Luo, KW
   Ko, CH
   Yue, GGL
   Lee, MYY
   Siu, WS
   Lee, JKM
   Shum, WT
   Fung, KP
   Leung, PC
   Li, G
   Evdokiou, A
   Lau, CBS
AF Luo, Ke Wang
   Ko, Chun Hay
   Yue, Grace G. L.
   Lee, Michelle Y. Y.
   Siu, Wing Sum
   Lee, Julia K. M.
   Shum, Wai Ting
   Fung, Kwok Pui
   Leung, Ping Chung
   Li, Gang
   Evdokiou, Andreas
   Lau, Clara B. S.
TI Anti tumor and anti osteolysis effects of the metronomic use of
   zoledronic acid in primary and metastatic breast cancer mouse models
SO CANCER LETTERS
LA English
DT Article
DE Zoledronic acid; Metronomic; Conventional; Anti osteolysis; Metastasis
ID PHASE II TRIAL; BONE METASTASES; BISPHOSPHONATES; CYCLOPHOSPHAMIDE;
   CELLS; CHEMOTHERAPY; COMBINATION; MECHANISMS; EFFICACY; THERAPY
AB This study aims to determine the effect of metronomic (0.0125 mg/kg twice a week for 4 weeks) zoledronic acid (ZOL) on cancer propagation and osteolysis against both metastatic and primary breast cancer in mice model. From our results, metronomic ZOL resulted in a significant reduction of tumor burden and did not promote lung or liver metastasis. The metronomic ZOL appeared to be more effective than the conventional regimen (0.1 mg/kg once in 4 weeks) in reducing breast cancer tumor burden, and regulating its movement to lung and liver. This dosing schedule of ZOL showed great potential against metastatic breast cancer. (C) 2013 Elsevier Ireland Ltd. All rights reserved.
C1 [Luo, Ke Wang; Ko, Chun Hay; Yue, Grace G. L.; Lee, Michelle Y. Y.; Siu, Wing Sum; Lee, Julia K. M.; Shum, Wai Ting; Fung, Kwok Pui; Leung, Ping Chung; Lau, Clara B. S.] Chinese Univ Hong Kong, Inst Chinese Med, Shatin, Hong Kong, Peoples R China.
   [Luo, Ke Wang; Ko, Chun Hay; Yue, Grace G. L.; Siu, Wing Sum; Lee, Julia K. M.; Shum, Wai Ting; Fung, Kwok Pui; Leung, Ping Chung; Lau, Clara B. S.] Chinese Univ Hong Kong, State Key Lab Phytochem & Plant Resources West Ch, Shatin, Hong Kong, Peoples R China.
   [Li, Gang] Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Sch Biomed Sci, Dept Orthopaed & Traumatol, Shatin, Hong Kong, Peoples R China.
   [Li, Gang] Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Sch Biomed Sci, Stem Cells & Regenerat Program, Shatin, Hong Kong, Peoples R China.
   [Fung, Kwok Pui] Chinese Univ Hong Kong, Sch Biomed Sci, Shatin, Hong Kong, Peoples R China.
   [Lee, Michelle Y. Y.; Evdokiou, Andreas] Univ Adelaide, Discipline Orthopaed & Trauma, Adelaide, SA, Australia.
C3 Chinese University of Hong Kong; Chinese University of Hong Kong;
   Chinese University of Hong Kong; Chinese University of Hong Kong;
   Chinese University of Hong Kong; University of Adelaide
RP Evdokiou, A (通讯作者)，Queen Elizabeth Hosp, Basil Hetzel Inst, 28 Woodville Rd, Woodville, SA 5011, Australia.
EM andreas.evdokiou@adelaide.edu.au; claralau@cuhk.edu.hk
RI Ko, Chun Hay/H 9652 2013; Fung, Kwok/R 9708 2018; Yue, Grace
   Gar Lee/AAY 3945 2020; Lau, Clara Bik San/AAF 3989 2020; Siu,
   Sammy/AAR 1168 2021; Li, Gang/J 7830 2018; Yue, Grace
   Gar Lee/JTU 8811 2023; Lau, Clara/AAF 3989 2020; Ko, Chun/H 9652 2013
OI Ko, Chun Hay/0000 0001 9180 2196; Li, Gang/0000 0002 3981 2239; Yue,
   Grace Gar Lee/0000 0002 1726 3566; Lau, Clara/0000 0002 7409 1270; Fung,
   Kwok Pui/0000 0001 6214 5123
CR [Anonymous], 2010, INT J CANCER, V127, P2893
   BREM S, 1976, CANCER RES, V36, P2807
   Brizzi MP, 2009, BMC CANCER, V9, DOI 10.1186/1471 2407 9 388
   Browder T, 2000, CANCER RES, V60, P1878
   Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220
   Coleman RE, 2001, CANCER TREAT REV, V27, P165, DOI 10.1053/ctrv.2000.0210
   Dass CR, 2007, MOL CANCER THER, V6, P3263, DOI 10.1158/1535 7163.MCT 07 0546
   Daubiné F, 2007, J NATL CANCER I, V99, P322, DOI 10.1093/jnci/djk054
   de Weerdt O, 2001, NETH J MED, V59, P50, DOI 10.1016/S0300 2977(01)00140 1
   Evdokiou A, 2003, BONE, V33, P216, DOI 10.1016/S8756 3282(03)00223 0
   Facchini G, 2010, CANCER BIOL THER, V10, P543, DOI 10.4161/cbt.10.6.12611
   Green J., 2010, BMJ BRIT MED J, V85, P674
   Kieran MW, 2005, J PEDIAT HEMATOL ONC, V27, P573, DOI 10.1097/01.mph.0000183863.10792.d4
   Kimmel DB, 2007, J DENT RES, V86, P1022, DOI 10.1177/154405910708601102
   Klement G, 2000, J CLIN INVEST, V105, pR15, DOI 10.1172/JCI8829
   Koto K, 2009, CANCER LETT, V274, P271, DOI 10.1016/j.canlet.2008.09.026
   Krzyzanowska MK, 2007, CANCER CHEMOTH PHARM, V60, P135, DOI 10.1007/s00280 006 0347 x
   Labrinidis A, 2010, INT J CANCER, V127, P345, DOI 10.1002/ijc.25051
   Labrinidis A, 2009, CLIN CANCER RES, V15, P3451, DOI 10.1158/1078 0432.CCR 08 1616
   Li YY, 2012, ANTI CANCER DRUG, V23, P970, DOI 10.1097/CAD.0b013e328355f0ec
   Li Zhao xu, 2012, Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, V28, P822
   Lipton A, 2007, EXPERT OPIN DRUG SAF, V6, P305, DOI 10.1517/14740338.6.3.305
   Miller KD, 2001, J CLIN ONCOL, V19, P1195, DOI 10.1200/JCO.2001.19.4.1195
   Orlando L, 2006, BMC CANCER, V6, DOI 10.1186/1471 2407 6 225
   Ottewell PD, 2009, MOL CANCER THER, V8, P2821, DOI 10.1158/1535 7163.MCT 09 0462
   Pasquier E, 2010, NAT REV CLIN ONCOL, V7, P455, DOI 10.1038/nrclinonc.2010.82
   Ryan P, 2009, POSTGRAD MED J, V85, P674, DOI 10.1136/pgmj.2008.076349
   Sato K, 2005, INT J CANCER, V116, P94, DOI 10.1002/ijc.20987
   Scharovsky OG, 2009, CURR ONCOL, V16, P91
   Sellmeyer DE, 2010, JAMA J AM MED ASSOC, V304, P1480, DOI 10.1001/jama.2010.1360
   Senaratne SG, 2002, BREAST CANCER RES, V4, P18, DOI 10.1186/bcr412
   Steeg PS, 2008, NAT CLIN PRACT ONCOL, V5, P206, DOI 10.1038/ncponc1066
   Suva LJ, 2009, ENDOCR RELAT CANCER, V16, P703, DOI 10.1677/ERC 09 0012
   Wolfe TD, 2011, CLIN EXP METASTAS, V28, P377, DOI 10.1007/s10585 011 9377 9
   Wood J, 2002, J PHARMACOL EXP THER, V302, P1055, DOI 10.1124/jpet.102.035295
   Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325
   Zhao XM, 2011, BMC CANCER, V11, DOI 10.1186/1471 2407 11 403
   Zhao XM, 2010, BREAST CANCER RES TR, V124, P733, DOI 10.1007/s10549 010 1183 6
   Zinonos I, 2009, MOL CANCER THER, V8, P2969, DOI 10.1158/1535 7163.MCT 09 0745
NR 39
TC 12
Z9 13
U1 0
U2 14
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304 3835
EI 1872 7980
J9 CANCER LETT
JI Cancer Lett.
PD OCT 1
PY 2013
VL 339
IS 1
BP 42
EP 48
DI 10.1016/j.canlet.2013.07.024
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 221NY
UT WOS:000324666800006
PM 23896464
DA 2025 08 17
ER

PT J
AU DuRaine, GD
   Athanasiou, KA
AF DuRaine, G. D.
   Athanasiou, K. A.
TI ERK activation is required for hydrostatic pressure induced tensile
   changes in engineered articular cartilage
SO JOURNAL OF TISSUE ENGINEERING AND REGENERATIVE MEDICINE
LA English
DT Article
DE self assembly; extracellular signal regulated kinase 1/2 (ERK 1/2);
   hydrostatic pressure; chondrocyte; tissue engineering; cartilage
ID DEPENDENT ENERGY UTILIZATION; OSTEOBLAST LIKE CELLS; MECHANICAL STRAIN;
   EXTRACELLULAR MATRIX; PROTEIN KINASES; GENE EXPRESSION; AMPK ACTIVATION;
   GROWTH FACTORS; ION CHANNELS; TISSUE
AB The objective of this study was to identify ERK 1/2 involvement in the changes in compressive and tensile mechanical properties associated with hydrostatic pressure treatment of self assembled cartilage constructs. In study 1, ERK 1/2 phosphorylation was detected by immunoblot, following application of hydrostatic pressure (1h of static 10MPa) applied at days 10 14 of self assembly culture. In study 2, ERK 1/2 activation was blocked during hydrostatic pressure application on days 10 14. With pharmacological inhibition of the ERK pathway by the MEK1/ERK inhibitor U0126 during hydrostatic pressure application on days 10 14, the increase in Young's modulus induced by hydrostatic pressure was blocked. Furthermore, this reduction in Young's modulus with U0126 treatment during hydrostatic pressure application corresponded to a decrease in total collagen expression. However, U0126 did not inhibit the increase in aggregate modulus or GAG induced by hydrostatic pressure. These findings demonstrate a link between hydrostatic pressure application, ERK signalling and changes in the biomechanical properties of a tissue engineered construct. Copyright (c) 2012 John Wiley & Sons, Ltd.
C1 [DuRaine, G. D.; Athanasiou, K. A.] Univ Calif Davis, Dept Biomed Engn, Davis, CA 95616 USA.
C3 University of California System; University of California Davis
RP Athanasiou, KA (通讯作者)，Univ Calif Davis, Dept Biomed Engn, One Shields Ave, Davis, CA 95616 USA.
EM athanasiou@ucdavis.edu
FU National Institutes of Health (NIH) [R01AR053286]; Postdoctoral
   Fellowship from the Arthritis Foundation
FX The authors would like to acknowledge support for this work from the
   National Institutes of Health (NIH; Grant No. R01AR053286) and a
   Postdoctoral Fellowship from the Arthritis Foundation (to G. DuRaine).
CR AFOKE NYP, 1987, J BONE JOINT SURG BR, V69, P536, DOI 10.1302/0301 620X.69B4.3611154
   Appleton CTG, 2010, LAB INVEST, V90, P20, DOI 10.1038/labinvest.2009.111
   ATHANASIOU KA, 1994, J ORTHOPAED RES, V12, P340, DOI 10.1002/jor.1100120306
   Aufderheide AC, 2007, TISSUE ENG, V13, P2195, DOI 10.1089/ten.2006.0291
   Bastow ER, 2005, J BIOL CHEM, V280, P11749, DOI 10.1074/jbc.M414495200
   Bobick BE, 2004, J BIOL CHEM, V279, P4588, DOI 10.1074/jbc.M309805200
   Browning JA, 1999, ACTA PHYSIOL SCAND, V166, P39
   BUCKWALTER JA, 1995, J RHEUMATOL, V22, P13
   Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264 6021:3510095
   Ding L, 2010, OSTEOARTHR CARTILAGE, V18, P1509, DOI 10.1016/j.joca.2010.08.014
   Elder BD, 2009, OSTEOARTHR CARTILAGE, V17, P114, DOI 10.1016/j.joca.2008.05.006
   Elder BD, 2009, TISSUE ENG PT A, V15, P1151, DOI 10.1089/ten.tea.2008.0200
   Elder BD, 2009, TISSUE ENG PART B RE, V15, P43, DOI 10.1089/ten.teb.2008.0435
   Elder BD, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002341
   Elluru RG, 2009, LARYNGOSCOPE, V119, P1153, DOI 10.1002/lary.20157
   Guilak F, 2000, PRINCIPLES AND PRACTICE OF ORTHOPAEDIC SPORTS MEDICINE, P53
   Hall AC, 1999, J CELL PHYSIOL, V178, P197, DOI 10.1002/(SICI)1097 4652(199902)178:2<197::AID JCP9>3.0.CO;2 3
   Hanson DA, 2002, MOL IMMUNOL, V38, P1329, DOI 10.1016/S0161 5890(02)00083 4
   Hatton JP, 2003, J BONE MINER RES, V18, P58, DOI 10.1359/jbmr.2003.18.1.58
   Hu JC, 2006, TISSUE ENG, V12, P969, DOI 10.1089/ten.2006.12.969
   Hung CT, 2000, J BIOMECH, V33, P73, DOI 10.1016/S0021 9290(99)00176 1
   Jessop HL, 2002, BONE, V31, P186, DOI 10.1016/S8756 3282(02)00797 4
   Kook SH, 2009, J CELL BIOCHEM, V106, P1060, DOI 10.1002/jcb.22085
   Kopakkala Tani M, 2004, CELL MOL BIOL, V50, P485
   Kraft JJ, 2011, CARTILAGE, V2, P254, DOI 10.1177/1947603510383686
   Krishna M, 2008, CELL MOL LIFE SCI, V65, P3525, DOI 10.1007/s00018 008 8170 7
   Laboureau J, 2004, EXP DERMATOL, V13, P70, DOI 10.1111/j.0906 6705.2004.00117.x
   Li J, 2010, CELL PROLIFERAT, V43, P333, DOI 10.1111/j.1365 2184.2010.00682.x
   Liu J, 2006, BIOCHEM BIOPH RES CO, V348, P1167, DOI 10.1016/j.bbrc.2006.07.175
   Martinac B, 2004, J CELL SCI, V117, P2449, DOI 10.1242/jcs.01232
   Mio K, 2007, J BIOSCI BIOENG, V104, P506, DOI 10.1263/jbb.104.506
   Mow VC, 1999, OSTEOARTHR CARTILAGE, V7, P41, DOI 10.1053/joca.1998.0161
   MOW VC, 1989, J BIOMECH, V22, P853, DOI 10.1016/0021 9290(89)90069 9
   Murakami S, 2000, P NATL ACAD SCI USA, V97, P1113, DOI 10.1073/pnas.97.3.1113
   Nakamura K, 1999, EXP CELL RES, V250, P351, DOI 10.1006/excr.1999.4535
   Natoli RM, 2010, ARTHRITIS RHEUM US, V62, P1097, DOI 10.1002/art.27313
   Olsen SM, 2011, ANN BIOMED ENG, V39, P688, DOI 10.1007/s10439 010 0203 3
   Prasadam I, 2010, ARTHRITIS RHEUM US, V62, P1349, DOI 10.1002/art.27397
   Rane SG, 1999, ADV SEC MESS PHOSPH, V33, P107
   Reusch HP, 1997, BIOCHEM BIOPH RES CO, V237, P239, DOI 10.1006/bbrc.1997.7121
   Ryan JA, 2009, J TISSUE ENG REGEN M, V3, P107, DOI 10.1002/term.146
   Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435
   Shin SY, 2009, J CELL SCI, V122, P425, DOI 10.1242/jcs.036319
   Soltoff SP, 2008, AM J PHYSIOL CELL PH, V295, pC590, DOI 10.1152/ajpcell.00140.2008
   Sweadner KJ, 2008, AM J PHYSIOL CELL PH, V295, pC588, DOI 10.1152/ajpcell.00388.2008
   WOESSNER JF, 1961, ARCH BIOCHEM BIOPHYS, V93, P440, DOI 10.1016/0003 9861(61)90291 0
   Yoon YM, 2002, J BIOL CHEM, V277, P8412, DOI 10.1074/jbc.M110608200
   Zákány R, 2005, EXP CELL RES, V305, P190, DOI 10.1016/j.yexcr.2004.12.016
NR 48
TC 6
Z9 6
U1 0
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1932 6254
EI 1932 7005
J9 J TISSUE ENG REGEN M
JI J. Tissue Eng. Regen. Med.
PD APR
PY 2015
VL 9
IS 4
BP 368
EP 374
DI 10.1002/term.1678
PG 7
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell
   Biology; Engineering, Biomedical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology; Engineering
GA CG1LM
UT WOS:000353034100005
PM 23255524
OA Green Accepted, gold
DA 2025 08 17
ER

PT J
AU Russell, T
   Watad, A
   Bridgewood, C
   Rowe, H
   Khan, A
   Rao, A
   Loughenbury, P
   Millner, P
   Dunsmuir, R
   Cuthbert, R
   Altaie, A
   Jones, E
   McGonagle, D
AF Russell, Tobias
   Watad, Abdulla
   Bridgewood, Charlie
   Rowe, Hannah
   Khan, Almas
   Rao, Abhay
   Loughenbury, Peter
   Millner, Peter
   Dunsmuir, Robert
   Cuthbert, Richard
   Altaie, Ala
   Jones, Elena
   McGonagle, Dennis
TI IL 17A and TNF Modulate Normal Human Spinal Entheseal Bone and Soft
   Tissue Mesenchymal Stem Cell Osteogenesis, Adipogenesis, and Stromal
   Function
SO CELLS
LA English
DT Article
DE mesenchymal stem cells; enthesis; TNF; IL 17; spondyloarthritis
ID OSTEOBLAST DIFFERENTIATION; ANKYLOSING SPONDYLITIS; MECHANICAL STRAIN;
   T CELLS; THERAPY; SPONDYLOARTHROPATHY; LOCALIZATION; HOMEOSTASIS;
   DICKKOPF 1; LESIONS
AB Objective: The spondylarthritides (SpA) are intimately linked to new bone formation and IL 17A and TNF pathways. We investigated spinal soft tissue and bone mesenchymal stem cell (MSC) responses to IL 17A and TNF, including their osteogenesis, adipogenesis, and stromal supportive function and ability to support lymphocyte recruitment. Methods: Normal spinal peri entheseal bone (PEB) and entheseal soft tissue (EST) were characterized for MSCs by immunophenotypic, osteogenic, chondrogenic, and adipogenic differentiation criteria. Functional and gene transcriptomic analysis was carried out on undifferentiated, adipo  differentiated, and osteo differentiated MSCs. The enthesis C C Motif Chemokine Ligand 20 C C Motif Chemokine Receptor 6 (CCL20 CCR6) axis was investigated at transcript and protein levels to ascertain whether entheseal MSCs influence local immune cell populations. Results: Cultured MSCs from both PEB and EST displayed a tri lineage differentiation ability. EST MSCs exhibited 4.9 fold greater adipogenesis (p < 0.001) and a 3 fold lower osteogenic capacity (p < 0.05). IL 17A induced greater osteogenesis in PEB MSCs compared to EST MSCs. IL 17A suppressed adipogenic differentiation, with a significant decrease in fatty acid binding protein 4 (FABP4), peroxisome proliferator activated receptor gamma (PPAR gamma), Cell Death Inducing DFFA Like Effector C (CIDEC), and Perilipin 1 (PLIN1). IL 17A significantly increased the CCL20 transcript (p < 0.01) and protein expression (p < 0.001) in MSCs supporting a role in type 17 lymphocyte recruitment. Conclusions: Normal spinal enthesis harbors resident MSCs with different in vitro functionalities in bone and soft tissue, especially in response to IL 17A, which enhanced osteogenesis and CCL20 production and reduced adipogenesis compared to unstimulated MSCs. This MSC stromal enthesis immune system may be a hitherto unappreciated mechanism of "fine tuning" tissue repair responses at the enthesis in health and could be relevant for SpA understanding.
C1 [Russell, Tobias; Watad, Abdulla; Bridgewood, Charlie; Rowe, Hannah; Cuthbert, Richard; Altaie, Ala; Jones, Elena; McGonagle, Dennis] Univ Leeds, Leeds Inst Rheumat & Musculoskeletal Med LIRMM, Leeds LS7 4SA, W Yorkshire, England.
   [Watad, Abdulla] Sheba Med Ctr, Dept Med B, Zabludowicz Ctr Autoimmune Dis, IL 52621 Ramat Gan, Israel.
   [Watad, Abdulla] Tel Aviv Univ, Sackler Fac Med, IL 69978 Ramat Aviv, Israel.
   [Khan, Almas; Rao, Abhay; Loughenbury, Peter; Millner, Peter; Dunsmuir, Robert] Leeds Teaching Hosp NHS Trust, Leeds LS1 3EX, W Yorkshire, England.
C3 University of Leeds; Chaim Sheba Medical Center; Tel Aviv University;
   Tel Aviv University; Sackler Faculty of Medicine; University of Leeds
RP McGonagle, D (通讯作者)，Univ Leeds, Leeds Inst Rheumat & Musculoskeletal Med LIRMM, Leeds LS7 4SA, W Yorkshire, England.
EM umtjwr@leeds.ac.uk; watad.abdulla@gmail.com; C.D.Bridgewood@leeds.ac.uk;
   umhmr@leeds.ac.uk; almas.khan@nhs.net; abhay.rao@nhs.net;
   p.loughenbury@nhs.net; Peter.millner@nhs.net; robert.dunsmuir@nhs.net;
   medrjc@googlemail.com; medaalt@leeds.ac.uk; E.Jones@leeds.ac.uk;
   D.G.McGonagle@leeds.ac.uk
RI Khan, Almas/AAJ 7410 2020; Bridgewood, Charlie/AAS 9592 2021; Jones,
   Elena/AAL 2818 2021
OI Jones, Elena/0000 0001 9365 2283; Rowe, Hannah/0000 0002 7135 3255;
   watad, abdulla/0000 0002 1404 8027; Russell, Tobias/0000 0001 7206 9312;
   Altaie, Ala/0000 0002 9203 1490; Khan, Almas/0000 0002 7916 6219;
   Loughenbury, Peter/0000 0002 0208 2623; 
FU Leeds NIHR Biomedical Research Centre; Novartis UK; Pfizer
   investigator initiated research grant; Celgene
FX D.M. is funded by the Leeds NIHR Biomedical Research Centre. Funding:
   Novartis UK Investigator Initiated non clinical research funding support
   (H.R., T.R., and C.B.), and research funded by a Pfizer
   investigator initiated research grant (R.C.). A.W. was funded by the
   Celgene supported PARTNER fellowship program.
CR Aldridge A, 2013, CYTOTHERAPY, V15, P89, DOI 10.1016/j.jcyt.2012.07.001
   Baraliakos X, 2019, ANN RHEUM DIS, V78, P1220, DOI 10.1136/annrheumdis 2018 214983
   Baraliakos X, 2014, ANN RHEUM DIS, V73, P710, DOI 10.1136/annrheumdis 2012 202698
   Benjamin M, 2001, J ANAT, V199, P503, DOI 10.1046/j.1469 7580.2001.19950503.x
   Benjamin M, 2009, ADV EXP MED BIOL, V649, P57
   Bennett AN, 2010, ANN RHEUM DIS, V69, P891, DOI 10.1136/ard.2009.112094
   Bridgewood C, 2021, RHEUMATOLOGY, V60, P2461, DOI 10.1093/rheumatology/keaa568
   Bridgewood C, 2019, ANN RHEUM DIS, V78, P929, DOI 10.1136/annrheumdis 2018 214944
   Callhoff J, 2015, ANN RHEUM DIS, V74, P1241, DOI 10.1136/annrheumdis 2014 205322
   Cambré I, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 06933 4
   Campbell TM, 2016, ARTHRITIS RHEUMATOL, V68, P1648, DOI 10.1002/art.39622
   Christodoulides C, 2006, J CELL SCI, V119, P2613, DOI 10.1242/jcs.02975
   Churchman SM, 2012, ARTHRITIS RHEUM US, V64, P2632, DOI 10.1002/art.34434
   Cox G, 2012, BONE, V50, P510, DOI 10.1016/j.bone.2011.07.016
   Croes M, 2016, BONE, V84, P262, DOI 10.1016/j.bone.2016.01.010
   Cuthbert RJ, 2017, ARTHRITIS RHEUMATOL, V69, P1816, DOI 10.1002/art.40150
   Cuthbert RJ, 2019, ANN RHEUM DIS, V78, P1559, DOI 10.1136/annrheumdis 2019 215210
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Fragkakis EM, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197969
   Ganguly P, 2019, STEM CELLS INT, V2019, DOI 10.1155/2019/5197983
   Gao GG, 2017, BBA MOL CELL BIOL L, V1862, P1197, DOI 10.1016/j.bbalip.2017.06.009
   Gracey E, 2020, NAT REV RHEUMATOL, V16, P193, DOI 10.1038/s41584 019 0364 x
   Han X, 2014, CELL DEATH DIFFER, V21, P1758, DOI 10.1038/cdd.2014.85
   Hansen JS, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 15059 4
   HILTON RC, 1984, ANN RHEUM DIS, V43, P302, DOI 10.1136/ard.43.2.302
   Hirota K, 2007, J EXP MED, V204, P2803, DOI 10.1084/jem.20071397
   Hyvärinen T, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 53414 9
   Jacques P, 2014, ANN RHEUM DIS, V73, P437, DOI 10.1136/annrheumdis 2013 203643
   Jo S, 2018, ARTHRITIS RES THER, V20, DOI 10.1186/s13075 018 1582 3
   Kim M, 2012, MECH AGEING DEV, V133, P215, DOI 10.1016/j.mad.2012.03.014
   Kim YG, 2014, ARCH ORAL BIOL, V59, P897, DOI 10.1016/j.archoralbio.2014.05.009
   Korkosz M, 2018, BMC MUSCULOSKEL DIS, V19, DOI 10.1186/s12891 018 2356 4
   Krajewska Wlodarczyk M, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19010080
   Kyurkchiev Dobroslav, 2014, World J Stem Cells, V6, P552, DOI 10.4252/wjsc.v6.i5.552
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lowe CE, 2011, J CELL SCI, V124, P2681, DOI 10.1242/jcs.079699
   Méndez Ferrer S, 2010, NATURE, V466, P829, DOI 10.1038/nature09262
   Mitchell JB, 2006, STEM CELLS, V24, P376, DOI 10.1634/stemcells.2005 0234
   Ogata Y, 2018, REGEN THER, V8, P20, DOI 10.1016/j.reth.2017.12.001
   Ono T, 2017, CURR OSTEOPOROS REP, V15, P367, DOI 10.1007/s11914 017 0381 0
   Ono T, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10928
   Osta B, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00425
   Pinzone JJ, 2009, BLOOD, V113, P517, DOI 10.1182/blood 2008 03 145169
   Pye SR, 2007, ANN RHEUM DIS, V66, P330, DOI 10.1136/ard.2006.052522
   Rauch A, 2019, NAT GENET, V51, P716, DOI 10.1038/s41588 019 0359 1
   RESNICK D, 1976, RADIOLOGY, V119, P559, DOI 10.1148/119.3.559
   Shah M, 2020, RMD OPEN, V6, DOI 10.1136/rmdopen 2020 001306
   Sherlock JP, 2012, NAT MED, V18, P1069, DOI 10.1038/nm.2817
   Shin JH, 2009, BIOCHEM PHARMACOL, V77, P1835, DOI 10.1016/j.bcp.2009.03.008
   Uluçkan Ö, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad8996
   van Tok MN, 2019, ARTHRITIS RHEUMATOL, V71, P612, DOI 10.1002/art.40770
   Wang XL, 2015, STEM CELL RES, V15, P14, DOI 10.1016/j.scr.2015.04.004
   Watad A, 2020, ANN RHEUM DIS, V79, P1044, DOI 10.1136/annrheumdis 2020 217309
   Watad A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02668
   Wendling D, 2019, EXPERT OPIN BIOL TH, V19, P55, DOI 10.1080/14712598.2019.1554053
   Wolock SL, 2019, CELL REP, V28, P302, DOI 10.1016/j.celrep.2019.06.031
   Yamazaki T, 2008, J IMMUNOL, V181, P8391, DOI 10.4049/jimmunol.181.12.8391
   Zúñiga LA, 2010, J IMMUNOL, V185, P6947, DOI 10.4049/jimmunol.1001269
NR 58
TC 26
Z9 28
U1 0
U2 6
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2073 4409
J9 CELLS BASEL
JI Cells
PD FEB
PY 2021
VL 10
IS 2
AR 341
DI 10.3390/cells10020341
PG 18
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA QN3OX
UT WOS:000622374400001
PM 33562025
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Hülskamp, MD
   Kronenberg, D
   Stange, R
AF Huelskamp, Michael David
   Kronenberg, Daniel
   Stange, Richard
TI The small molecule protein ligand interface stabiliser E7820 induces
   differential cell line specific responses of integrin α2 expression
SO BMC CANCER
LA English
DT Article
DE E7820; Integrin alpha 2; CAPER alpha; SPLINTS
ID GENE EXPRESSION; SELECTIVE DEGRADATION; INHIBITOR E7820; PHASE I;
   CANCER; GROWTH; CAPER; PROLIFERATION; MECHANISM; TOXICITY
AB BackgroundThe mechanism of small molecule stabilised protein protein interactions is of growing interest in the pharmacological discovery process. A plethora of different substances including the aromatic sulphonamide E7820 have been identified to act by such a mechanism. The process of E7820 induced CAPER alpha degradation and the resultant transcriptional down regulation of integrin alpha 2 expression has previously been described for a variety of different cell lines and been made responsible for E7820's antiangiogenic activity. Currently the application of E7820 in the treatment of various malignancies including pancreas carcinoma and breast cancer is being investigated in pre clinical and clinical trials. It has been shown, that integrin alpha 2 deficiency has beneficial effects on bone homeostasis in mice. To transfer E7820 treatment to bone related pathologies, as non healing fractures, osteoporosis and bone cancer might therefore be beneficial. However, at present no data is available on the effect of E7820 on osseous cells or skeletal malignancies.MethodsPre osteoblastic (MC3T3 and Saos 2) cells and endothelial (eEnd2 cells and HUVECs) cells, each of human and murine origin respectively, were investigated. Vitality assay with different concentrations of E7820 were performed. All consecutive experiments were done at a final concentration of 50ng/ml E7820. The expression and production of integrin alpha 2 and CAPER alpha were investigated by quantitative real time PCR and western blotting. Expression of CAPER alpha splice forms was differentiated by semi quantitiative reverse transcriptase PCR.ResultsHere we present the first data showing that E7820 can increase integrin alpha 2 expression in the pre osteoblast MC3T3 cell line whilst also reproducing canonical E7820 activity in HUVECs. We show that the aberrant activity of E7820 in MC3T3 cells is likely due to differential activity of CAPER alpha at the integrin alpha 2 promoter, rather than due to differential CAPER alpha degradation or differential expression of CAPER alpha spliceforms.ConclusionThe results presented here indicate that E7820 may not be suitable to treat certain malignancies of musculoskeletal origin, due to the increase in integrin alpha 2 expression it may induce. Further investigation of the differential functioning of CAPER alpha and the integrin alpha 2 promoter in cells of various origin would however be necessary to more clearly differentiate between cell lines that will positively respond to E7820 from those that will not.
C1 [Huelskamp, Michael David; Kronenberg, Daniel; Stange, Richard] Westfalische Wilhelms Univ Munster, Inst Musculoskeletal Med, Dept Regenerat Musculoskeletal Med, Albert Schweitzer Campus 1,Bldg W1, D 48149 Munster, Germany.
C3 University of Munster
RP Kronenberg, D (通讯作者)，Westfalische Wilhelms Univ Munster, Inst Musculoskeletal Med, Dept Regenerat Musculoskeletal Med, Albert Schweitzer Campus 1,Bldg W1, D 48149 Munster, Germany.
EM daniel.kronenberg@uni muenster.de
RI Kronenberg, Daniel/ABA 9255 2020
OI Hulskamp, Michael David/0000 0002 4840 0471
FU Deutsche Forgschungsgemeinschaft [EXC 1003  CiM, Sta 650/9 1];
   Medizinerkolleg (MedK) Munster; Projekt DEAL
FX The project was supported by the Deutsche Forgschungsgemeinschaft (EXC
   1003  CiM and Sta 650/9 1). MH was supported by a scholarship from the
   Medizinerkolleg (MedK) Munster. Open Access funding enabled and
   organized by Projekt DEAL.
CR ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304 419X(91)90011 9
   Bier D, 2015, PROG BIOPHYS MOL BIO, V119, P10, DOI 10.1016/j.pbiomolbio.2015.05.002
   Cheli Y, 2007, BBA GENE STRUCT EXPR, V1769, P546, DOI 10.1016/j.bbaexp.2007.06.004
   Chilewski SD, 2020, CELL CYCLE, V19, P432, DOI 10.1080/15384101.2020.1711579
   Chung CH, 2017, SCI REP UK, V7, DOI 10.1038/srep43612
   Desgrosellier JS, 2010, NAT REV CANCER, V10, P9, DOI 10.1038/nrc2748
   Engel BE, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.461
   Faust TB., 2019, NAT CHEM BIOL, V355, P1
   Filipovic N, 2016, COMPUT METHOD BIOMEC, V19, P581, DOI 10.1080/10255842.2015.1051973
   Fink EC, 2015, BLOOD, V126, P2366, DOI 10.1182/blood 2015 07 567958
   Fischer ES, 2016, CURR OPIN STRUC BIOL, V37, P115, DOI 10.1016/j.sbi.2016.01.004
   Funahashi Y, 2002, CANCER RES, V62, P6116
   Goel G, 2007, INT J TOXICOL, V26, P279, DOI 10.1080/10915810701464641
   Gullberg Donald E., 2002, Progress in Histochemistry and Cytochemistry, V37, P3, DOI 10.1016/S0079 6336(02)80008 0
   Han T, 2017, SCIENCE, V356, DOI 10.1126/science.aal3755
   Harper SJ, 2008, NAT REV CANCER, V8, P880, DOI 10.1038/nrc2505
   Huang GX, 2012, CANCER AM CANCER SOC, V118, P2106, DOI 10.1002/cncr.26488
   Ito K, 2014, CANCER SCI, V105, P1023, DOI 10.1111/cas.12450
   Jung DJ, 2002, J BIOL CHEM, V277, P1229, DOI 10.1074/jbc.M110417200
   Kerklaan BM, 2016, INVEST NEW DRUG, V34, P329, DOI 10.1007/s10637 016 0344 9
   Krönke J, 2014, SCIENCE, V343, P301, DOI 10.1126/science.1244851
   Kronenberg D, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21082835
   Läubli H, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02120
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lu N, 2006, MATRIX BIOL, V25, P118, DOI 10.1016/j.matbio.2005.10.002
   Lu N, 2010, MATRIX BIOL, V29, P166, DOI 10.1016/j.matbio.2009.11.003
   Mita M, 2011, CLIN CANCER RES, V17, P193, DOI 10.1158/1078 0432.CCR 10 0010
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022 1759(83)90303 4
   O'Leary NA, 2016, NUCLEIC ACIDS RES, V44, pD733, DOI 10.1093/nar/gkv1189
   Obata H, 1997, J BIOL CHEM, V272, P26643, DOI 10.1074/jbc.272.42.26643
   Petroski MD, 2005, NAT REV MOL CELL BIO, V6, P9, DOI 10.1038/nrm1547
   Ren D., 2019, J EXP CLIN CANC RES, V38, P1, DOI [10.1186/s13046 018 1018 6, DOI 10.1186/S13046 018 1018 6]
   RODAN SB, 1987, CANCER RES, V47, P4961
   Sang YZ, 2015, ONCOTARGET, V6, P42590, DOI 10.18632/oncotarget.6052
   Sawyer MB, 2010, J CLIN ONCOL, V28, DOI 10.1200/jco.2010.28.15_suppl.3537
   Semba T, 2004, CLIN CANCER RES, V10, P1430, DOI 10.1158/1078 0432.CCR 0109 03
   Stange R, 2013, BONE, V56, P48, DOI 10.1016/j.bone.2013.05.003
   Uehara T, 2017, NAT CHEM BIOL, V13, P675, DOI 10.1038/nchembio.2363
   Valeur E, 2019, MEDCHEMCOMM, V10, P1550, DOI 10.1039/c9md00263d
   Vigneault F, 2007, PROG RETIN EYE RES, V26, P99, DOI 10.1016/j.preteyeres.2006.10.004
   Wang D, 1999, J BONE MINER RES, V14, P893, DOI 10.1359/jbmr.1999.14.6.893
   WILLIAMS RL, 1989, CELL, V57, P1053, DOI 10.1016/0092 8674(89)90343 7
   Wu XB, 2019, BIOMED PHARMACOTHER, V114, DOI 10.1016/j.biopha.2019.108708
   Xu JH, 1998, J CELL BIOL, V140, P709, DOI 10.1083/jcb.140.3.709
   Yang CQ, 2003, CANCER RES, V63, P8312
   Yang Q, 2017, J PROTEOMICS, V168, P53, DOI 10.1016/j.jprot.2017.06.021
   ZUTTER MM, 1994, J BIOL CHEM, V269, P463
   ZUTTER MM, 1995, BLOOD, V86, P3006
NR 48
TC 6
Z9 6
U1 1
U2 7
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471 2407
J9 BMC CANCER
JI BMC Cancer
PD MAY 18
PY 2021
VL 21
IS 1
AR 571
DI 10.1186/s12885 021 08301 w
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA SN5TE
UT WOS:000658351000005
PM 34006252
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Hu, XL
   Wang, W
   Chen, XL
   Kong, C
   Zhao, X
   Wang, Z
   Zhang, HJ
   Lu, SB
AF Hu, Xinli
   Wang, Wei
   Chen, Xiaolong
   Kong, Chao
   Zhao, Xuan
   Wang, Zheng
   Zhang, Haojie
   Lu, Shibao
TI Trehalose Rescues Postmenopausal Osteoporosis Induced by Ovariectomy
   through Alleviating Osteoblast Pyroptosis via Promoting Autophagy
SO BIOMEDICINES
LA English
DT Article
DE autophagy; inflammation; osteoporosis; pyroptosis; trehalose
ID NLRP3 INFLAMMASOME; ACTIVATION; PROTEIN
AB Background: Osteoporosis, a prevalent bone metabolic disease, often requires long term drug treatments that may lead to serious side effects. Trehalose, a natural disaccharide found in various organisms, has been shown to have a promoting effect on autophagy. However, whether trehalose can improve bone mass recovery in ovariectomized rats and its underlying mechanisms remains unclear. In this study, trehalose was administered to ovariectomized rats to evaluate its therapeutic potential for osteoporosis following ovariectomy. Methods: Micro computed tomography (Micro CT), hematoxylin and eosin (HE) and immunohistochemical staining techniques were utilized to evaluate the impact of trehalose on osteoporosis induced by ovariectomy (OVX) in mice, both in imaging and histological dimensions. Furthermore, the influence of trehalose on osteoblastogenesis and functional activity was quantified through Alizarin Red S (ARS) staining and immunoblotting assays. Results: Trehalose effectively mitigated bone loss, elevated autophagy and suppressed pyroptosis in ovariectomized rats. Furthermore, 3 methyladenine diminished the protective effects of trehalose, particularly in promoting autophagy and inhibiting pyroptosis. Conclusions: Trehalose demonstrates significant potential in treating osteoporosis by suppressing NLRP3 inflammasome driven pyroptosis, primarily through autophagy promotion. This suggests that trehalose could be a promising, safer alternative treatment for osteoporosis.
C1 [Hu, Xinli; Wang, Wei; Chen, Xiaolong; Kong, Chao; Zhao, Xuan; Wang, Zheng; Zhang, Haojie; Lu, Shibao] Capital Med Univ, Xuanwu Hosp, Dept Orthoped, 45 Changchun St, Beijing 100053, Peoples R China.
   [Hu, Xinli; Wang, Wei; Chen, Xiaolong; Kong, Chao; Zhao, Xuan; Wang, Zheng; Zhang, Haojie; Lu, Shibao] Capital Med Univ, Xuanwu Hosp, Natl Clin Res Ctr Geriatr Dis, 45 Changchun St, Beijing 100053, Peoples R China.
C3 Capital Medical University; Capital Medical University
RP Hu, XL (通讯作者)，Capital Med Univ, Xuanwu Hosp, Dept Orthoped, 45 Changchun St, Beijing 100053, Peoples R China.; Hu, XL (通讯作者)，Capital Med Univ, Xuanwu Hosp, Natl Clin Res Ctr Geriatr Dis, 45 Changchun St, Beijing 100053, Peoples R China.
EM spinelu@163.com; wangwei37@buaa.edu.cn; chensmalldragon@163.com;
   kong98850@163.com; zxc911@126.com; spinewzccmu@163.com;
   haojiezhang@163.com; shibaolu@ccmu.edu.cn
RI ; 胡, 鑫立/HNQ 2730 2023; 张, 豪杰/GRX 0797 2022
OI Lu, Shibao/0000 0001 7052 7041; 
FU Post subsidy funds for National Clinical Research Center, Ministry of
   Science and Technology of China [303 01 001 0272 05]; Capital Medical
   University Xuanwu Hospital National Natural Science Foundation Youth
   Cultivation grant [QNPY202322]; R&D Program of Beijing Municipal
   Education Commission grant [22JG0059]; Key Science and Technology
   Project of Beijing Municipal Education Commission grant [KZ20231002537]
FX This research was funded by Post subsidy funds for National Clinical
   Research Center, Ministry of Science and Technology of China grant
   number [303 01 001 0272 05], Capital Medical University Xuanwu Hospital
   National Natural Science Foundation Youth Cultivation grant number
   [QNPY202322], R&D Program of Beijing Municipal Education Commission
   grant number [22JG0059] and the key Science and Technology Project of
   Beijing Municipal Education Commission grant number [KZ20231002537]. The
   APC was funded by [303 01 001 0272 05, QNPY202322].
CR Ballane G, 2017, OSTEOPOROSIS INT, V28, P1531, DOI 10.1007/s00198 017 3909 3
   Behera J, 2022, DIABETES, V71, P2777, DOI 10.2337/db21 0573
   Biasizzo M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.591803
   Chen QF, 2002, J BIOL CHEM, V277, P3274, DOI 10.1074/jbc.M109479200
   Chen X, 2016, SCI REP UK, V6, DOI 10.1038/srep28423
   Chou LF, 2019, NUTRIENTS, V11, DOI 10.3390/nu11010042
   Cong L, 2020, AGING US, V12, P6415, DOI 10.18632/aging.103038
   Das S, 2013, DRUG DES DEV THER, V7, P435, DOI 10.2147/DDDT.S31504
   Deretic V, 2013, NAT REV IMMUNOL, V13, P722, DOI 10.1038/nri3532
   Feghali Carol A., 1997, Frontiers in Bioscience (online), V2, pD12
   Fleshner M, 2017, NEUROPSYCHOPHARMACOL, V42, P36, DOI 10.1038/npp.2016.125
   Harris J, 2011, J BIOL CHEM, V286, P9587, DOI 10.1074/jbc.M110.202911
   Hu Q, 2018, BIOFACTORS, V44, P123, DOI 10.1002/biof.1395
   Hu XL, 2022, J NEUROINFLAMM, V19, DOI 10.1186/s12974 022 02602 y
   Hu XL, 2020, INT J BIOL SCI, V16, P2042, DOI 10.7150/ijbs.45467
   Huang RL, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.101
   Kany S, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20236008
   LeBoff MS, 2022, OSTEOPOROSIS INT, V33, P2049, DOI 10.1007/s00198 021 05900 y
   Li MB, 2022, DEV CELL, V57, P2365, DOI 10.1016/j.devcel.2022.09.013
   Li ZC, 2023, PHARMACOL RES, V187, DOI 10.1016/j.phrs.2022.106635
   Luo G, 2018, MOL MED REP, V17, P6605, DOI 10.3892/mmr.2018.8698
   Mao CY, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.204
   McAllister MJ, 2018, OSTEOARTHR CARTILAGE, V26, P612, DOI 10.1016/j.joca.2018.02.901
   Nakahira K, 2011, NAT IMMUNOL, V12, P222, DOI 10.1038/ni.1980
   Orsi A, 2012, MOL BIOL CELL, V23, P1860, DOI 10.1091/mbc.E11 09 0746
   Osta B, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00048
   Pasco JA, 2006, JAMA J AM MED ASSOC, V296, P1353, DOI 10.1001/jama.296.11.1353
   Pietschmann P, 2016, GERONTOLOGY, V62, P128, DOI 10.1159/000431091
   Rheinheimer J, 2017, METABOLISM, V74, P1, DOI 10.1016/j.metabol.2017.06.002
   Rovira Llopis S, 2018, ANTIOXID REDOX SIGN, V29, P749, DOI 10.1089/ars.2017.7313
   Ruscitti P, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/782382
   Saitoh T, 2008, NATURE, V456, P264, DOI 10.1038/nature07383
   Sarkar S, 2007, J BIOL CHEM, V282, P5641, DOI 10.1074/jbc.M609532200
   Song SS, 2022, PHARMACOL THERAPEUT, V237, DOI 10.1016/j.pharmthera.2022.108168
   Tanaka M, 2004, NAT MED, V10, P148, DOI 10.1038/nm985
   Tang Q, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.453
   Tao HQ, 2021, PHARMACOL RES, V174, DOI 10.1016/j.phrs.2021.105967
   Tao ZB, 2021, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.548812
   Tian HL, 2022, J CELL MOL MED, V26, P2163, DOI 10.1111/jcmm.17238
   Tsuchiya K, 2020, MICROBIOL IMMUNOL, V64, P252, DOI 10.1111/1348 0421.12771
   Wang SN, 2024, APPL BIOCHEM BIOTECH, V196, P1194, DOI 10.1007/s12010 023 04613 8
   Wang YL, 2023, EXP THER MED, V26, DOI 10.3892/etm.2023.12237
   Wu NX, 2020, MOL CELL BIOCHEM, V470, P175, DOI 10.1007/s11010 020 03760 4
   Xu XQ, 2020, FASEB J, V34, P8402, DOI 10.1096/fj.201902528RRR
   Yang XH, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 44766 3
   Yao ZQ, 2022, CELLS BASEL, V11, DOI 10.3390/cells11010132
   Yin X, 2019, BONE RES, V7, DOI 10.1038/s41413 019 0058 7
   Zendedel A, 2016, MOL NEUROBIOL, V53, P3063, DOI 10.1007/s12035 015 9203 5
   Zeng C, 2019, INT J BIOL SCI, V15, P1345, DOI 10.7150/ijbs.33568
   Zheng LW, 2017, J INVEST MED, V65, P1014, DOI 10.1136/jim 2017 000426
NR 50
TC 1
Z9 1
U1 5
U2 7
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2227 9059
J9 BIOMEDICINES
JI Biomedicines
PD OCT
PY 2024
VL 12
IS 10
AR 2224
DI 10.3390/biomedicines12102224
PG 19
WC Biochemistry & Molecular Biology; Medicine, Research & Experimental;
   Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Research & Experimental Medicine;
   Pharmacology & Pharmacy
GA K2T7U
UT WOS:001342460700001
PM 39457537
OA gold
DA 2025 08 17
ER

PT J
AU Meng, KL
   Jiao, MZ
   Shi, XG
   Xu, R
   Cheng, PX
   Lv, HT
   Zheng, XH
   Xiao, CN
AF Meng, Kai  Li
   Jiao, Mei Zhi
   Shi, Xian Gang
   Xu, Ru
   Cheng, Pei Xuan
   Lv, Hui Ting
   Zheng, Xiao Hui
   Xiao, Chao Ni
TI A rapid approach to capture the potential bioactive compounds from
   Rhizoma Drynariae, utilizing disease associated mutation in calcium
   sensing receptor to alter the binding affinity for agonists
SO JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
LA English
DT Article
DE Rhizoma Drynariae (RD); Osteoporosis; Calcium Sensing Receptor (CaSR);
   Extracellular domain (ECD); Halogenated alkane dehalogenase (Halo)
ID EXTRACELLULAR DOMAIN; CA2+ SENSING RECEPTOR; EXPRESSION; NARINGIN; SERUM
AB Rhizoma Drynariae (RD) was used clinically to treat osteoporosis in China due to stimulating bone formation and inhibiting bone resorption, however, the bioactive constituents with the dual effect on bone are still unknown exactly. Disease causing mutations in calcium sensing receptor (CaSR) can alter parathyroid hormone secretion and affect Ca2+ release from bone and Ca2+ reabsorption from kidney, which gives an indication that CaSR is a potential target for developing therapeutics to manage osteoporosis. Herein, a chromatographic approach was established, by immobilizing the mutant CaSR onto the surface of silica gels as stationary phase in a one step procedure and then adding the different amino acids into mobile phase as competitors, for exploring the bind ing features of the known agonists and further screening ligands from RD. The mutant CaSR coated column was prepared rapidly without the complicated purification and separation of the receptor, which had the large ca pacity of 13.1 mg CaSR /g silica gels and kept a good stability and specificity for at least 35 days. The CaSR mutation can weaken the binding affinities for three agonists, and the largest decreases occurred on the muta tional site Thr151Met for neomycin, on the two sites of Asn118Lys and Glu191Lys for gentamicin C, and on the site Phe612Ser for kanamycin, which gained new insights into their structure function relationship. The potential bioactive compounds from RD were screened using the mutant CaSR coated column and were recognized as coumaric acid 4 O beta D glucopyranoside, caffeic acid, and naringin using UPLC MS. Among them, naringin tar geting CaSR gives a possible explanation that RD could manage osteoporosis. These results indicated that, such a rapid and simple method, utilizing disease associated mutation in CaSR to alter the binding affinity for agonists, can be applied in capturing the potential bioactive compounds efficiently from complex matrices like herb medicines.
C1 [Xiao, Chao Ni] Northwest Univ, Key Lab Resource Biol & Biotechnol Western China, Minist Educ, Xian 710069, Peoples R China.
   Northwest Univ, Shaanxi Prov Key Lab Biotechnol, Xian 710069, Peoples R China.
   Northwest Univ, Coll Life Sci, Xian 710069, Peoples R China.
C3 Northwest University Xi'an; Northwest University Xi'an; Northwest
   University Xi'an
RP Xiao, CN (通讯作者)，Northwest Univ, Key Lab Resource Biol & Biotechnol Western China, Minist Educ, Xian 710069, Peoples R China.
EM xiaochaoni@nwu.edu.cn
RI Lv, Huiting/MTC 8903 2025
FU Shaanxi Key Research and Development Project [2018KWZ 05]
FX Funding This research was funded by Shaanxi Key Research and Development
   Project (2018KWZ 05) .
CR Bai M, 1996, J BIOL CHEM, V271, P19537, DOI 10.1074/jbc.271.32.19537
   Brown EM, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.135pe40
   BROWN EM, 1991, ENDOCRINOLOGY, V128, P3047, DOI 10.1210/endo 128 6 3047
   Chang WH, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.1159945
   Chen R, 2016, PHARM BIOL, V54, P3203, DOI 10.1080/13880209.2016.1216131
   Deng XN, 2020, CURR OPIN PHYSIOL, V17, P269, DOI 10.1016/j.cophys.2020.08.020
   Goldsmith PK, 1999, J BIOL CHEM, V274, P11303, DOI 10.1074/jbc.274.16.11303
   Gregson C L., Arch Osteoporos
   Hage DS, 2011, CURR DRUG METAB, V12, P313
   Hannan FM, 2012, HUM MOL GENET, V21, P2768, DOI 10.1093/hmg/dds105
   Heath H., J CLIN
   Hu JX, 2003, TRENDS ENDOCRIN MET, V14, P282, DOI 10.1016/S1043 2760(03)00104 8
   Huang Y, 2009, BIOCHEMISTRY US, V48, P388, DOI 10.1021/bi8014604
   KANIS JA, 1994, J BONE MINER RES, V9, P1137, DOI 10.1002/jbmr.5650090802
   Li XL, 2004, J PHARMACEUT BIOMED, V34, P159, DOI 10.1016/j.japna.2003.08.002
   Los GV, 2008, ACS CHEM BIOL, V3, P373, DOI 10.1021/cb800025k
   Magno AL, 2011, ENDOCR REV, V32, P3, DOI 10.1210/er.2009 0043
   Marie PJ, 2011, OSTEOPOROSIS INT, V22, P1659, DOI 10.1007/s00198 010 1369 0
   McLarnon SJ, 2002, BIOCHEM BIOPH RES CO, V297, P71, DOI 10.1016/S0006 291X(02)02133 2
   Mentaverri R, 2006, FASEB J, V20, P2562, DOI 10.1096/fj.06 6304fje
   Motejadded H, 2010, APPL BIOCHEM BIOTECH, V162, P2098, DOI 10.1007/s12010 010 8985 1
   Mou MW, 2015, ACTA POL PHARM, V72, P1073
   Pearce SHS, 1996, J CLIN INVEST, V98, P1860, DOI 10.1172/JCI118987
   Pearce SHS, 1996, NEW ENGL J MED, V335, P1115, DOI 10.1056/NEJM199610103351505
   Ryan ZC, 2006, BIOCHEM BIOPH RES CO, V349, P339, DOI 10.1016/j.bbrc.2006.08.047
   Song Shuang Hong, 2016, Bone Rep, V5, P262, DOI 10.1016/j.bonr.2016.09.001
   Song SH, 2017, MOLECULES, V22, DOI 10.3390/molecules22071033
   Thakker RV, 2004, CELL CALCIUM, V35, P275, DOI 10.1016/j.ceca.2003.10.010
   Trivedi R, 2010, EXPERT OPIN INV DRUG, V19, P995, DOI 10.1517/13543784.2010.501077
   Wang XL, 2008, CHEM PHARM BULL, V56, P46, DOI 10.1248/cpb.56.46
   Xu R, 2022, J CHROMATOGR B, V1208, DOI 10.1016/j.jchromb.2022.123409
   Xu T, 2016, EVID BASED COMPL ALT, V2016, DOI 10.1155/2016/8981650
   Yao HK, 2016, CHEM NAT COMPD+, V52, P669, DOI 10.1007/s10600 016 1735 z
   Zhang C, 2016, FRONT PHYSIOL, V7, DOI 10.3389/fphys.2016.00441
   Zhao XF, 2010, J CHROMATOGR B, V878, P2029, DOI 10.1016/j.jchromb.2010.05.040
NR 35
TC 3
Z9 4
U1 1
U2 17
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0731 7085
EI 1873 264X
J9 J PHARMACEUT BIOMED
JI J. Pharm. Biomed. Anal.
PD MAR 20
PY 2023
VL 226
AR 115253
DI 10.1016/j.jpba.2023.115253
EA JAN 2023
PG 10
WC Chemistry, Analytical; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Pharmacology & Pharmacy
GA G6CL2
UT WOS:000990013000001
PM 36657349
DA 2025 08 17
ER

PT J
AU Zhang, YL
   Yin, JH
   Ding, H
   Zhang, CQ
   Gao, YS
AF Zhang, Yuelei
   Yin, Junhui
   Ding, Hao
   Zhang, Changqing
   Gao, You Shui
TI Vitamin K2 Ameliorates Damage of Blood Vessels by
   Glucocorticoid: a Potential Mechanism for Its Protective Effects in
   Glucocorticoid induced Osteonecrosis of the Femoral Head in a Rat Model
SO INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES
LA English
DT Article
DE vitamin K 2; Eahy926; osteoblast; angiogenesis; osteonecrosis of femoral
   heads
ID ENDOTHELIAL GROWTH FACTOR; GAMMA CARBOXYLATION; GENE EXPRESSION;
   ANGIOGENESIS; OSTEOGENESIS; CELLS; VEGF; DEXAMETHASONE; TRANSITION;
   NECROSIS
AB Glucocorticoid has been reported to decrease blood vessel number and harm the blood supply in the femoral head, which is recognized to be an important mechanism of glucocorticoid induced osteonecrosis of the femoral head (ONFH). To prevent glucocorticoid induced ONFH, medication that promotes both bone formation and angiogenesis would be ideal. Vitamin K 2 has been revealed to play an important role in bone metabolism; however, few studies have focused on the effect of Vitamin K 2 on new vascular formation. Thus, this study aimed to investigate whether Vitamin K 2 promoted new blood vessel formation in the presence of glucocorticoids, both in vitro and in vivo. The effect of Vitamin K 2 on viability, migration, in vitro tube formation, and VEGF, vWF, CD31, KDR, Flt and PDGFB in EAhy926 incubated with or without dexamethasone were elucidated. VEGF, TGF beta and BMP 2, angiogenesis related proteins secreted by osteoblasts, were also detected in the osteoblast like cell line of MG63. In addition, blood vessels of the femoral head in rats administered with or without methylprednisolone and Vitamin K 2 were evaluated using angiography and CD31 staining. In vitro studies showed that Vitamin K 2 significantly protected endothelial cells from dexamethasone induced apoptosis, promoted endothelial cell migration and in vitro tube formation. Angiogenesis related proteins both in EAhy926 and MG63 were also upregulated by Vitamin K 2 when cotreated with dexamethasone. In vivo studies showed enhanced blood vessel volume and CD31 positive staining cells in rats cotreated with VK2 and methylprednisolone compared to rats treated with methylprednisolone only. Collectively, Vitamin K 2 has the ability to promote angiogenesis in vitro and to ameliorate vessels of the femoral head in glucocorticoid treated rats in vivo, indicating that Vitamin K 2 is a promising drug that may be used to prevent steroid induced ONFH.
C1 [Zhang, Yuelei; Yin, Junhui; Ding, Hao; Zhang, Changqing; Gao, You Shui] Shanghai Jiao Tong Univ, Dept Orthoped Surg, Affiliated Peoples Hosp 6, 600 Yishan Rd, Shanghai 200233, Peoples R China.
C3 Shanghai Jiao Tong University
RP Zhang, CQ; Gao, YS (通讯作者)，Shanghai Jiao Tong Univ, Dept Orthoped Surg, Affiliated Peoples Hosp 6, 600 Yishan Rd, Shanghai 200233, Peoples R China.
EM zhangcq@sjtu.edu.cn; acerzhang5233@sjtu.edu.cn
RI Ding, Hao/ISR 8790 2023; GAO, YOUSHUI/U 8349 2019
OI zhang, changqing/0000 0002 7408 4126
FU National Natural Science Foundation of China [81301572]; SMC Chen Xing
   Plan for Splendid Young Teachers of Shanghai Jiao Tong University
FX The current research was funded by the National Natural Science
   Foundation of China (No. 81301572) and the SMC Chen Xing Plan for
   Splendid Young Teachers of Shanghai Jiao Tong University. We would like
   to thank Shanghai Institute of Microsurgery for Extremities for
   providing experimental equipment and all staff for their instructions.
CR Atkins GJ, 2009, AM J PHYSIOL CELL PH, V297, pC1358, DOI 10.1152/ajpcell.00216.2009
   Azuma K, 2014, GERIATR GERONTOL INT, V14, P1, DOI 10.1111/ggi.12060
   Burstyn Cohen T, 2009, J CLIN INVEST, V119, P2942, DOI 10.1172/JCI39325
   Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0
   Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890
   COOLBAUGH CC, 1952, AM J PHYSIOL, V169, P26, DOI 10.1152/ajplegacy.1952.169.1.26
   Dai J, 2007, J DENT RES, V86, P937, DOI 10.1177/154405910708601006
   Deckers MML, 2002, ENDOCRINOLOGY, V143, P1545, DOI 10.1210/en.143.4.1545
   Eshkar Oren I, 2009, DEVELOPMENT, V136, P1263, DOI 10.1242/dev.034199
   Fang YF, 2012, J BONE MINER METAB, V30, P60, DOI 10.1007/s00774 011 0287 3
   Gerber HP, 1999, NAT MED, V5, P623, DOI 10.1038/9467
   Hamidi MS, 2013, J CLIN DENSITOM, V16, P409, DOI 10.1016/j.jocd.2013.08.017
   HANNINK M, 1989, BIOCHIM BIOPHYS ACTA, V989, P1, DOI 10.1016/0304 419X(89)90031 0
   Harada I, 1992, Nihon Seikeigeka Gakkai Zasshi, V66, P763
   HARADA S, 1995, CLIN ORTHOP RELAT R, P76
   Hasanbasic I, 2005, J THROMB HAEMOST, V3, P2790, DOI 10.1111/j.1538 7836.2005.01662.x
   Hegarty JM, 2013, DEVELOPMENT, V140, P1713, DOI 10.1242/dev.093112
   Herzog DPE, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/320123
   Iwamoto J, 2010, CALCIFIED TISSUE INT, V86, P234, DOI 10.1007/s00223 010 9333 8
   Jabalee J, 2015, DEV BIOL, V406, P52, DOI 10.1016/j.ydbio.2015.07.014
   Jang YH, 2013, LAB INVEST, V93, P194, DOI 10.1038/labinvest.2012.166
   Kerachian MA, 2006, ENDOTHELIUM J ENDOTH, V13, P237, DOI 10.1080/10623320600904211
   Kerachian MA, 2009, J STEROID BIOCHEM, V114, P121, DOI 10.1016/j.jsbmb.2009.02.007
   Kusumbe AP, 2014, NATURE, V507, P323, DOI 10.1038/nature13145
   Li HY, 2014, BIOMATERIALS, V35, P3803, DOI 10.1016/j.biomaterials.2014.01.039
   Li XD, 2005, OSTEOPOROSIS INT, V16, P101, DOI 10.1007/s00198 004 1649 7
   Maes C, 2010, EMBO J, V29, P424, DOI 10.1038/emboj.2009.361
   Mittermayr R, 2016, ACTA BIOMATER, V29, P11, DOI 10.1016/j.actbio.2015.10.028
   Muraoka N, 2005, BIRTH DEFECTS RES A, V73, P956, DOI 10.1002/bdra.20191
   Park SK, 2009, LARYNGOSCOPE, V119, P409, DOI 10.1002/lary.20085
   Abud APR, 2015, REGUL TOXICOL PHARM, V73, P992, DOI 10.1016/j.yrtph.2015.09.015
   Sasaki N, 2005, J BONE MINER METAB, V23, P41, DOI 10.1007/s00774 004 0539 6
   Shea MK, 2012, ADV NUTR, V3, P158, DOI 10.3945/an.111.001644
   Shikatani EA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046625
   Shiraki M, 2000, J BONE MINER RES, V15, P515, DOI 10.1359/jbmr.2000.15.3.515
   Stahl A, 2004, BIOCHEM BIOPH RES CO, V322, P684, DOI 10.1016/j.bbrc.2004.07.175
   Takeuchi Y, 2000, BONE, V27, P769, DOI 10.1016/S8756 3282(00)00396 3
   Tsai TL, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287 015 0065 6
   Uras N, 2012, J OBSTET GYNAECOL, V32, P533, DOI 10.3109/01443615.2012.677875
   Vogt CJ, 2001, MICROCIRCULATION, V8, P129, DOI 10.1080/713774024
   Vos M, 2012, SCIENCE, V336, P1306, DOI 10.1126/science.1218632
   Wan C, 2010, ANN NY ACAD SCI, V1192, P322, DOI 10.1111/j.1749 6632.2009.05238.x
   WEBSTER MK, 1993, MOL CELL BIOL, V13, P2031, DOI 10.1128/MCB.13.4.2031
   Weinstein RS, 2012, ENDOCRINE, V41, P183, DOI 10.1007/s12020 011 9580 0
   Weinstein RS, 2010, AGING CELL, V9, P147, DOI 10.1111/j.1474 9726.2009.00545.x
   Xia Q, 2005, CLIN EXP DERMATOL, V30, P165, DOI 10.1111/j.1365 2230.2005.01721.x
   Yang YQ, 2012, INT J ORAL SCI, V4, P64, DOI 10.1038/ijos.2012.33
   Yoshiji H, 2005, J HEPATOL, V42, P687, DOI 10.1016/j.jhep.2004.12.025
   Zarrinpashneh E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080268
NR 49
TC 62
Z9 71
U1 1
U2 23
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1449 2288
J9 INT J BIOL SCI
JI Int. J. Biol. Sci.
PY 2016
VL 12
IS 7
BP 776
EP 785
DI 10.7150/ijbs.15248
PG 10
WC Biochemistry & Molecular Biology; Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine   Other
   Topics
GA DM9AR
UT WOS:000376656400002
PM 27313492
OA gold, Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU Park, J
   Lin, YS
   Tsantrizos, YS
   Berghuis, AM
AF Park, Jaeok
   Lin, Yih Shyan
   Tsantrizos, Youla S.
   Berghuis, Albert M.
TI Structure of human farnesyl pyrophosphate synthase in complex with an
   aminopyridine bisphosphonate and two molecules of inorganic phosphate
SO ACTA CRYSTALLOGRAPHICA SECTION F STRUCTURAL BIOLOGY COMMUNICATIONS
LA English
DT Article
ID NITROGEN CONTAINING BISPHOSPHONATES; DIPHOSPHATE SYNTHASE; X RAY;
   INHIBITORS; DESIGN; MECHANISM; PROTEINS; DRUGS; CELLS; NMR
AB Human farnesyl pyrophosphate synthase (hFPPS) produces farnesyl pyrophosphate, an isoprenoid essential for a variety of cellular processes. The enzyme has been well established as the molecular target of the nitrogen containing bisphosphonates (N BPs), which are best known for their antiresorptive effects in bone but are also known for their anticancer properties. Crystal structures of hFPPS in ternary complexes with a novel bisphosphonate, YS0470, and the secondary ligands inorganic phosphate (P i), inorganic pyrophosphate (PPi) and isopentenyl pyrophosphate (IPP) have recently been reported. Only the co binding of the bisphosphonate with either PPi or IPP resulted in the full closure of the C terminal tail of the enzyme, a conformational change that is required for catalysis and that is also responsible for the potent in vivo efficacy of N BPs. In the present communication, a co crystal structure of hFPPS in complex with YS0470 and two molecules of P i is reported. The unusually close proximity between these ligands, which was confirmed by anomalous diffraction data, suggests that they interact with one another, with their anionic charges neutralized in their bound state. The structure also showed the tail of the enzyme to be fully disordered, indicating that simultaneous binding of two P i molecules with a bisphosphonate cannot induce the tail closing conformational change in hFPPS. Examination of homologous FPPSs suggested that this ligand dependent tail closure is only conserved in the mammalian proteins. The prevalence of P i bound hFPPS structures in the PDB raises a question regarding the in vivo relevance of P i binding to the function of the enzyme.
C1 [Park, Jaeok; Tsantrizos, Youla S.; Berghuis, Albert M.] McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada.
   [Lin, Yih Shyan; Tsantrizos, Youla S.] McGill Univ, Dept Chem, Montreal, PQ H3A 0B8, Canada.
   [Tsantrizos, Youla S.; Berghuis, Albert M.] McGill Univ, Grp Rech Axe Struct Prot, Montreal, PQ H3G 0B1, Canada.
   [Berghuis, Albert M.] McGill Univ, Dept Microbiol & Immunol, Montreal, PQ H3A 2B4, Canada.
C3 McGill University; McGill University; McGill University; McGill
   University
RP Berghuis, AM (通讯作者)，McGill Univ, Dept Biochem, 3655 Promenade Sir William Osler, Montreal, PQ H3G 1Y6, Canada.
EM albert.berghuis@mcgill.ca
RI Park, Jaeok/U 6904 2019; Berghuis, Albert/A 6495 2008
OI Berghuis, Albert/0000 0002 2663 025X; Park, Jaeok/0000 0002 8180 3950
FU Natural Sciences and Engineering Research Council of Canada; Canadian
   Institutes of Health Research [MOP 114889]; Fonds de Recherche Sante
   Quebec
FX We thank the members of the Berghuis laboratory for their help and
   support, especially Mr Dmitry Rodionov for advice on data processing.
   Assistance by the 08ID 1 beamline personnel at the Canadian Light Source
   is gratefully appreciated. Financial support for this research was
   provided by a grant from the Natural Sciences and Engineering Research
   Council of Canada awarded to YST and a grant (MOP 114889) from the
   Canadian Institutes of Health Research awarded to AMB. We also thank
   other funding agencies: JP is the recipient of a postdoctoral training
   award from the Fonds de Recherche Sante Quebec, and AMB holds a Canada
   Research Chair in Structural Biology.
CR Aripirala S, 2012, J MED CHEM, V55, P6445, DOI 10.1021/jm300425y
   BEVINGTON A, 1986, CLIN SCI, V71, P729, DOI 10.1042/cs0710729
   BRENNAN S, 1992, REV SCI INSTRUM, V63, P850, DOI 10.1063/1.1142625
   Cao R, 2008, PROTEINS, V73, P431, DOI 10.1002/prot.22066
   De Schutter JW, 2012, BIOORGAN MED CHEM, V20, P5583, DOI 10.1016/j.bmc.2012.07.019
   Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493
   Gabelli SB, 2006, PROTEINS, V62, P80, DOI 10.1002/prot.20754
   HOL WGJ, 1978, NATURE, V273, P443, DOI 10.1038/273443a0
   HOLLOWAY PW, 1967, BIOCHEM J, V104, P57, DOI 10.1042/bj1040057
   Huang CH, 2010, PROTEINS, V78, P888, DOI 10.1002/prot.22614
   Jahnke W, 2010, NAT CHEM BIOL, V6, P660, DOI [10.1038/NCHEMBIO.421, 10.1038/nchembio.421]
   Kavanagh KL, 2006, P NATL ACAD SCI USA, V103, P7829, DOI 10.1073/pnas.0601643103
   Koul HK, 2012, PROSTATE CANCER P D, V15, P111, DOI 10.1038/pcan.2011.41
   Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404
   Lin YS, 2012, J MED CHEM, V55, P3201, DOI 10.1021/jm201657x
   Mao JH, 2006, J AM CHEM SOC, V128, P14485, DOI 10.1021/ja061737c
   McTaggart SJ, 2006, CELL MOL LIFE SCI, V63, P255, DOI 10.1007/s00018 005 5298 6
   Mönkkönen H, 2008, ANTI CANCER DRUG, V19, P391, DOI 10.1097/CAD.0b013e3282f632bf
   Murshudov GN, 2011, ACTA CRYSTALLOGR D, V67, P355, DOI 10.1107/S0907444911001314
   Park J, 2012, BMC STRUCT BIOL, V12, DOI 10.1186/1472 6807 12 32
   Rondeau JM, 2006, CHEMMEDCHEM, V1, P267, DOI 10.1002/cmdc.200500059
   Sheldrick GM, 2010, ACTA CRYSTALLOGR D, V66, P479, DOI 10.1107/S0907444909038360
   Spina A, 2013, BIORESEARCH OPEN ACC, V2, P47, DOI 10.1089/biores.2012.0266
   Spina A, 2013, J CELL PHYSIOL, V228, P198, DOI 10.1002/jcp.24124
   TARSHIS LC, 1994, BIOCHEMISTRY US, V33, P10871, DOI 10.1021/bi00202a004
   Thorn A, 2011, J APPL CRYSTALLOGR, V44, P1285, DOI [10.1107/S0021889811041768, 10.1107/S00218898110417681285]
   Winter G, 2013, ACTA CRYSTALLOGR D, V69, P1260, DOI 10.1107/S0907444913015308
   Zhang YH, 2013, ACS MED CHEM LETT, V4, P423, DOI 10.1021/ml4000436
   Zhang YH, 2009, J AM CHEM SOC, V131, P5153, DOI 10.1021/ja808285e
NR 29
TC 9
Z9 10
U1 0
U2 11
PU INT UNION CRYSTALLOGRAPHY
PI CHESTER
PA 2 ABBEY SQ, CHESTER, CH1 2HU, ENGLAND
EI 2053 230X
J9 ACTA CRYSTALLOGR F
JI Acta Crystallogr. F Struct. Biol. Commun.
PD MAR
PY 2014
VL 70
BP 299
EP 304
DI 10.1107/S2053230X14002106
PN 3
PG 6
WC Biochemical Research Methods; Biochemistry & Molecular Biology;
   Biophysics; Crystallography
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics; Crystallography
GA AC3GU
UT WOS:000332405600005
PM 24598914
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Agin, HD
   Gunes, N
   Guler, R
AF Agin, Hatice Demircan
   Gunes, Nedim
   Guler, Ridvan
TI A comparative investigation of the effects of Resveratrol and dental
   pulp delivered mesenchimal stem cells on rat tibia bone defect healing
SO REVISTA CIENTIFICA FACULTAD DE CIENCIAS VETERINARIAS
LA English
DT Article
DE Bone defect; Resveratrol; mesenchymal stem cell; rat; experimental study
ID STEM/PROGENITOR CELLS; ALKALINE PHOSPHATASE; TRANS RESVERATROL;
   DIFFERENTIATION; PROLIFERATION; MECHANISMS; DENSITY; REPAIR
AB Resveratrol (3,4,5 trihydroxystilbene), an antioxidant compound, has a natural phytoalexin structure and also has many properties such as anti inflammatory, antineoplastic and antiplatelet. In addition, mesenchymal stem cells isolated from various tissues are considered as a potential cell source for bone regenerative therapies. The present study aims to examine the effects of Resveratrol and dental pulp  derived mesenchymal stem cells on new bone formation in rats, both isolated and combined, by immunohistochemical methods. Twenty eigth Spraque Dawley male rats were used in the study. The rats were divided into four groups with seven rats in each group; the control group (Group 1) (n=7), the Systemic Resveratrol group (Group 2) (n=7), the Stem cell group (Group 3) (n=7), the Stem cell + Systemic Resveratrol group (Group 4) (n=7). A defect was opened on the tibia bones of the rats in all groups with a trephane bur (diameter of 3 mm and a length of 4 mm). After the 4 week experiment, all rats were sacrificed following the experimental protocols specific to each group. The specimens of tibia were subjected to histomorphological examination in fixative solutions. Values of inflammation, connective tissue formation, osteoclastic activity, osteoblast values, new bone formation, BMP2 and BMP4 expression levels obtained for all groups were evaluated by statistical analysis. Compared to the control group, new bone formation and osteoblastic activity were found to be significantly higher in the Stem cell group and Stem cell + Systemic Resveratrol group. ( P =0.001) Additionally, new bone formation in the Systemic Resveratrol group was found to be significantly lower than in the Stem cell + Systemic Resveratrol group. ( P =0.006) No significant difference was observed between other groups. ( P >0.05) According to the results of the study, it was observed that Stem cell + Resveratrol treatment was more effective than isolated Resveratrol or isolated stem cell treatment applications, it induced the development of more bone trabeculae, decrease inflammation and increased the number of osteoblasts involved in bone formation. In the light of these data, it was concluded that the combined use of Resveratrol and Stem cells is more effective on the healing of bone defects than their isolated use.
C1 [Agin, Hatice Demircan] Minist Hlth, Oral & Dent Hlth Hosp, Dept Oral & Maxillofacial Surg, Diyarbakir, Turkiye.
   [Gunes, Nedim; Guler, Ridvan] Dicle Univ, Fac Dent, Dept Oral & Maxillofacial Surg, Diyarbakir, Turkiye.
C3 Diyarbakir Training & Research Hospital; Ministry of Health   Turkey;
   Dicle University
RP Guler, R (通讯作者)，Dicle Univ, Fac Dent, Dept Oral & Maxillofacial Surg, Diyarbakir, Turkiye.
EM ridvanguler06@gmail.com
RI Güler, Rıdvan/IXN 1173 2023
FU Dicle University Scientific Research Projects Coordination Office
   [DIdot;Scedil;.20.007]
FX This study is supported by Dicle University Scientific Research Projects
   Coordination Office with project number D & Idot;& Scedil;.20.007.
CR Almalki SG, 2016, DIFFERENTIATION, V92, P41, DOI 10.1016/j.diff.2016.02.005
   Ariano A, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24129897
   Bäckesjö CM, 2006, J BONE MINER RES, V21, P993, DOI 10.1359/JBMR.060415
   Bouxsein ML, 2001, J BONE JOINT SURG AM, V83A, P1219, DOI 10.2106/00004623 200108000 00012
   Casarin RC, 2014, INT J ORAL MAX SURG, V43, P900, DOI 10.1016/j.ijom.2014.01.009
   d'Aquino R, 2009, EUR CELLS MATER, V18, P75, DOI 10.22203/eCM.v018a07
   Erdal Y, 2017, FNG Bilim Tip Transplant. Derg. Internet, V2, P52, DOI mt7n
   Han GH, 2015, DRUG DISCOV THER, V9, P1, DOI 10.5582/ddt.2015.01007
   He X, 2010, BIOCHEM BIOPH RES CO, V401, P356, DOI 10.1016/j.bbrc.2010.09.053
   Huang GTJ, 2009, J DENT RES, V88, P792, DOI 10.1177/0022034509340867
   Isler SC, 2010, J APPL ORAL SCI, V18, P409
   Iwasa J, 2003, ARTIF ORGANS, V27, P249, DOI 10.1046/j.1525 1594.2003.07073.x
   Juan ME, 2002, J NUTR, V132, P257, DOI 10.1093/jn/132.2.257
   Kawaguchi H, 2004, J PERIODONTOL, V75, P1281, DOI 10.1902/jop.2004.75.9.1281
   Lee UL, 2011, REGEN MED, V6, P67, DOI 10.2217/RME.10.96
   Li JH, 2011, CHINESE MED J PEKING, V124, P4022, DOI 10.3760/cma.j.issn.0366 6999.2011.23.033
   Liao Han Tsung, 2014, World J Stem Cells, V6, P288, DOI 10.4252/wjsc.v6.i3.288
   Lin Qian, 2005, Int J Biomed Sci, V1, P76
   Liu ZP, 2005, J MED FOOD, V8, P14, DOI 10.1089/jmf.2005.8.14
   Miura M, 2003, P NATL ACAD SCI USA, V100, P5807, DOI 10.1073/pnas.0937635100
   Mizutani K, 1998, BIOCHEM BIOPH RES CO, V253, P859, DOI 10.1006/bbrc.1998.9870
   Mobasheri A, 2013, ANN NY ACAD SCI, V1290, P59, DOI 10.1111/nyas.12145
   Murakami Y, 2003, J PERIODONTOL, V74, P780, DOI 10.1902/jop.2003.74.6.780
   Murgia D, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9030094
   Ornstrup MJ, 2014, J CLIN ENDOCR METAB, V99, P4720, DOI 10.1210/jc.2014 2799
   Gomes JAP, 2010, INVEST OPHTH VIS SCI, V51, P1408, DOI 10.1167/iovs.09 4029
   Pisciotta A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050542
   Qin YH, 2014, POSTGRAD MED J, V90, P643, DOI 10.1136/postgradmedj 2013 132387
   Simon MJK, 2010, CLIN ORAL INVEST, V14, P51, DOI 10.1007/s00784 009 0312 2
   Song LH, 2006, TOXICOL IN VITRO, V20, P915, DOI 10.1016/j.tiv.2006.01.016
   Uysal T, 2011, ORTHOD CRANIOFAC RES, V14, P80, DOI 10.1111/j.1601 6343.2011.01511.x
   Yan X, 2010, STEM CELLS DEV, V19, P469, DOI 10.1089/scd.2009.0314
NR 32
TC 0
Z9 0
U1 0
U2 2
PU UNIV ZULIA, FACULTAD CIENCIAS VETERINARIAS
PI MARACAIBO
PA UNIVERSIDAD DEL ZULIA, MARACAIBO, VENEZUELA
SN 0798 2259
J9 REV CIENT FAC CIEN V
JI Rev. Cient. Fac. Cienc. Vet.
PY 2024
VL 34
IS 2
AR e34372
DI 10.52973/rcfcv e34372
PG 7
WC Veterinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Veterinary Sciences
GA ZW8U2
UT WOS:001278422800001
OA gold
DA 2025 08 17
ER

PT J
AU Nozawa, K
   Fujishiro, M
   Kawasaki, M
   Kaneko, H
   Iwabuchi, K
   Yanagida, M
   Suzuki, F
   Miyazawa, K
   Takasaki, Y
   Ogawa, H
   Takamori, K
   Sekigawa, I
AF Nozawa, Kazuhisa
   Fujishiro, Maki
   Kawasaki, Mikiko
   Kaneko, Hiroshi
   Iwabuchi, Kazuhisa
   Yanagida, Mitsuaki
   Suzuki, Fujihiko
   Miyazawa, Keiji
   Takasaki, Yoshinari
   Ogawa, Hideoki
   Takamori, Kenji
   Sekigawa, Iwao
TI Connective tissue growth factor promotes articular damage by increased
   osteoclastogenesis in patients with rheumatoid arthritis
SO ARTHRITIS RESEARCH & THERAPY
LA English
DT Article
ID TNF ALPHA; DIFFERENTIATION FACTOR; SYNOVIAL FIBROBLASTS; BREAST CANCER;
   CELLS; THERAPY; INFLIXIMAB; EXPRESSION; PATHWAY; CTGF
AB Introduction A protein analysis using a mass spectrometry indicated that there are serum proteins showing significant quantitative changes after the administration of infliximab. Among them, connective tissue growth factor (CTGF) seems to be related to the pathogenesis of rheumatoid arthritis (RA). Therefore, this study was conducted to investigate how CTGF is associated with the disease progression of RA.
   Methods Serum samples were collected from RA patients in active or inactive disease stages, and before or after treatments with infliximab. CTGF production was evaluated by ELISA, RTPCR, indirect immunofluorescence microscopy, and immunoblotting. Osteoclastogenesis was evaluated using tartrate resistant acid phosphatase (TRAP) staining, a bone resorption assay and osteoclasts specific catalytic enzymes productions.
   Results The serum concentrations of CTGF in RA were greater than in normal healthy controls and disease controls. Interestingly, those were significantly higher in active RA patients compared to inactive RA patients. Furthermore, the CTGF levels significantly were decreased by infliximab concomitant with the disease amelioration. In addition, tumour necrosis factor (TNF)alpha can induce the CTGF production from synovial fibroblasts even though TNF alpha can oppositely inhibit the production of CTGF from chondrocytes. CTGF promoted the induction of the quantitative and qualitative activities of osteoclasts in combination with M CSF and receptor activator of NF kappa B ligand (RANKL). In addition, we newly found integrin alpha V beta 3 on the osteoclasts as a CTGF receptor.
   Conclusions These results indicate that aberrant CTGF production induced by TNF alpha plays a central role for the abnormal osteoclastic activation in RA patients. Restoration of aberrant CTGF production may contribute to the inhibition of articular destruction in infliximab treatment.
C1 [Nozawa, Kazuhisa; Fujishiro, Maki; Kawasaki, Mikiko; Iwabuchi, Kazuhisa; Yanagida, Mitsuaki; Ogawa, Hideoki; Takamori, Kenji; Sekigawa, Iwao] Juntendo Univ, Grad Sch Med, Inst Environm & Gender Specif Med, Chiba 2790021, Japan.
   [Nozawa, Kazuhisa; Kaneko, Hiroshi; Sekigawa, Iwao] Juntendo Univ, Urayasu Hosp, Dept Rheumatol & Internal Med, Chiba 2790021, Japan.
   [Suzuki, Fujihiko] Juntendo Univ, Urayasu Hosp, Dept Pathol, Chiba 2790021, Japan.
   [Miyazawa, Keiji] Kissei Pharmaceut Co Ltd, Cent Res Labs, Nagano 3998304, Japan.
   [Takasaki, Yoshinari] Juntendo Univ, Sch Med, Dept Rheumatol, Tokyo 1138421, Japan.
C3 Juntendo University; Juntendo University; Juntendo University; Kissei
   Pharmaceutical Co Ltd; Juntendo University
RP Nozawa, K (通讯作者)，Juntendo Univ, Grad Sch Med, Inst Environm & Gender Specif Med, 2 1 1 Tomioka, Chiba 2790021, Japan.
EM kazunozawa@aol.com
OI Iwabuchi, Kazuhisa/0000 0002 4805 4206
FU Institute for Environment and Gender specific Medicine, Juntendo
   University Graduate School of Medicine
FX This work was supported by grants from The Institute for Environment and
   Gender specific Medicine, Juntendo University Graduate School of
   Medicine.
CR ARNETT FC, 1988, ARTHRITIS RHEUM US, V31, P315, DOI 10.1002/art.1780310302
   BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285
   Chen PS, 2007, J CELL SCI, V120, P2053, DOI 10.1242/jcs.03460
   Cooker LA, 2007, AM J PHYSIOL RENAL, V293, pF157, DOI 10.1152/ajprenal.00508.2006
   Davidson ENB, 2006, ARTHRITIS RHEUM US, V54, P1653, DOI 10.1002/art.21795
   FASSBENDER HG, 1992, SCAND J RHEUMATOL, V21, P10, DOI 10.3109/03009749209095055
   Feldmann M, 2001, ANNU REV IMMUNOL, V19, P163, DOI 10.1146/annurev.immunol.19.1.163
   Feldmann M, 1996, ANNU REV IMMUNOL, V14, P397, DOI 10.1146/annurev.immunol.14.1.397
   Gao BX, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar2081
   Gravallese EM, 2000, ARTHRITIS RHEUM, V43, P250, DOI 10.1002/1529 0131(200002)43:2<250::AID ANR3>3.0.CO;2 P
   Grotendorst Gary R., 1997, Cytokine and Growth Factor Reviews, V8, P171, DOI 10.1016/S1359 6101(97)00010 5
   Itoh Y, 2007, J IMMUNOL, V178, P3059, DOI 10.4049/jimmunol.178.5.3059
   Karger A, 2008, CELL SIGNAL, V20, P1865, DOI 10.1016/j.cellsig.2008.06.016
   Klimiuk PA, 2006, CLIN EXP RHEUMATOL, V24, P529
   Lam J, 2000, J CLIN INVEST, V106, P1481, DOI 10.1172/JCI11176
   Leung JCK, 2009, NEPHROL DIAL TRANSPL, V24, P458, DOI 10.1093/ndt/gfn524
   Lipsky PE, 2000, NEW ENGL J MED, V343, P1594, DOI 10.1056/NEJM200011303432202
   Maini R, 1999, LANCET, V354, P1932, DOI 10.1016/S0140 6736(99)05246 0
   MAINI RN, 1995, IMMUNOL REV, V144, P195, DOI 10.1111/j.1600 065X.1995.tb00070.x
   Manns JM, 2006, ARTHRITIS RHEUM, V54, P2415, DOI 10.1002/art.22021
   Mun SH, 2009, ARTHRITIS RHEUM US, V60, P678, DOI 10.1002/art.24299
   Murphy MG, 2005, J CLIN ENDOCR METAB, V90, P2022, DOI 10.1210/jc.2004 2126
   Nakamura I, 2007, J BONE MINER METAB, V25, P337, DOI 10.1007/s00774 007 0773 9
   Nakao K, 2005, BONE, V36, P884, DOI 10.1016/j.bone.2004.10.015
   Perbal B, 2004, LANCET, V363, P62, DOI 10.1016/S0140 6736(03)15172 0
   Polzer K, 2007, AUTOIMMUNITY, V40, P333, DOI 10.1080/08916930701356721
   Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071
   Redlich K, 2002, J CLIN INVEST, V110, P1419, DOI 10.1172/JCI200215582
   Sato K, 2006, J EXP MED, V203, P2673, DOI 10.1084/jem.20061775
   Schett G, 2006, WIEN MED WOCHENSCHR, V156, P34, DOI 10.1007/s10354 005 0244 7
   Sekigawa I, 2008, CLIN EXP RHEUMATOL, V26, P261
   Shigeyama Y, 2000, ARTHRITIS RHEUM, V43, P2523, DOI 10.1002/1529 0131(200011)43:11<2523::AID ANR20>3.0.CO;2 Z
   Shimo T, 2006, J BONE MINER RES, V21, P1045, DOI 10.1359/JBMR.060416
   Shinoda Y, 2008, J BIOL CHEM, V283, P24682, DOI 10.1074/jbc.M709857200
   Smolen JS, 2005, ARTHRITIS RHEUM, V52, P1020, DOI 10.1002/art.20982
   Takigawa M, 2003, J CELL PHYSIOL, V194, P256, DOI 10.1002/jcp.10206
   Tan TW, 2009, J CELL BIOCHEM, V107, P345, DOI 10.1002/jcb.22132
   Teitelbaum SL, 2007, AM J PATHOL, V170, P427, DOI 10.2353/ajpath.2007.060834
   Vitali C, 2002, ANN RHEUM DIS, V61, P554, DOI 10.1136/ard.61.6.554
   Wehling N, 2009, ARTHRITIS RHEUM US, V60, P801, DOI 10.1002/art.24352
   Wei S, 2005, J CLIN INVEST, V115, P282, DOI 10.1172/JCI200523394
   Yu F, 2009, CELL SIGNAL, V21, P867, DOI 10.1016/j.cellsig.2009.01.030
NR 42
TC 56
Z9 68
U1 0
U2 2
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1478 6354
J9 ARTHRITIS RES THER
JI Arthritis Res. Ther.
PY 2009
VL 11
IS 6
AR R174
DI 10.1186/ar2863
PG 13
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA 604MC
UT WOS:000278282100014
PM 19922639
OA Green Accepted, gold
DA 2025 08 17
ER

PT J
AU Chen, ZQ
   Cordero, J
   Alqarni, AM
   Slack, C
   Zeidler, MP
   Bellantuono, I
AF Chen, Zhengqi
   Cordero, Julia
   Alqarni, Adel M.
   Slack, Cathy
   Zeidler, Martin P.
   Bellantuono, Ilaria
TI Zoledronate Extends Health Span and Survival via the Mevalonate Pathway
   in a FOXO dependent Manner
SO JOURNALS OF GERONTOLOGY SERIES A BIOLOGICAL SCIENCES AND MEDICAL
   SCIENCES
LA English
DT Article
DE Aging; Bisphosphonates; DNA damage; Drosophila; Life span
ID LIFE SPAN; DNA DAMAGE; STEM CELLS; ACID; GENE; MORTALITY; RAPAMYCIN;
   CONSEQUENCES; PRENYLATION; MECHANISMS
AB Over recent decades, increased longevity has not been paralleled by extended health span, resulting in more years spent with multiple diseases in older age. As such, interventions to improve health span are urgently required. Zoledronate (Zol) is a nitrogen containing bisphosphonate, which inhibits the farnesyl pyrophosphate synthase enzyme, central to the mevalonate pathway. It is already used clinically to prevent fractures in osteoporotic patients, who have been reported to derive unexpected and unexplained survival benefits. Using Drosophila as a model we determined the effects of Zol on life span, parameters of health span (climbing ability and intestinal dysplasia), and the ability to confer resistance to oxidative stress using a combination of genetically manipulated Drosophila strains and Western blotting. Our study shows that Zol extended life span, improved climbing activity, and reduced intestinal epithelial dysplasia and permeability with age. Mechanistic studies showed that Zol conferred resistance to oxidative stress and reduced accumulation of X ray induced DNA damage via inhibition of farnesyl pyrophosphate synthase. Moreover, Zol was associated with inhibition of phosphorylated AKT in the mammalian traget of rapamycin pathway downstream of the mevalonate pathway and required dFOXO for its action, both molecules associated with increased longevity. Taken together, our work indicates that Zol, a drug already widely used to prevent osteoporosis and dosed only once a year, modulates important mechanisms of aging. Its repurposing holds great promise as a treatment to improve health span.
C1 [Chen, Zhengqi; Bellantuono, Ilaria] Univ Sheffield, Med Sch, Hlth Lifespan Inst, Dept Oncol & Metab, Sheffield, S Yorkshire, England.
   [Cordero, Julia] Univ Glasgow, Inst Canc Sci, Beatson Inst Canc, Glasgow, Lanark, Scotland.
   [Alqarni, Adel M.; Zeidler, Martin P.] Univ Sheffield, Dept Biomed Sci, Sheffield, S Yorkshire, England.
   [Slack, Cathy] Aston Univ, Sch Life & Hlth Sci, Birmingham, W Midlands, England.
C3 University of Sheffield; University of Glasgow; University of Sheffield;
   Aston University
RP Bellantuono, I (通讯作者)，Hlth Lifespan Inst, Dept Oncol & Metab, Med Sch, D Floor,Beech Hill Rd, Sheffield S10 2RX, S Yorkshire, England.
EM i.bellantuono@shef.ac.uk
RI Slack, Cathy/C 2016 2008; Bellantuono, Ilaria/ABF 2700 2021
OI Bellantuono, Ilaria/0000 0001 9994 6987; Slack,
   Cathy/0000 0002 7949 4079
FU University of Sheffield PhD studentship award; MRC [MC_PC_13076] Funding
   Source: UKRI
FX This work was supported by a University of Sheffield PhD studentship
   award.
CR [Anonymous], 2016, Discharging older patients from hospital
   Bellantuono I, 2018, NATURE, V554, P293, DOI 10.1038/d41586 018 01668 0
   Biteau B, 2008, CELL STEM CELL, V3, P442, DOI 10.1016/j.stem.2008.07.024
   Bjedov I, 2010, CELL METAB, V11, P35, DOI 10.1016/j.cmet.2009.11.010
   Camus MF, 2018, ECOL EVOL, V8, P5385, DOI 10.1002/ece3.4055
   Choi NH, 2008, AGING CELL, V7, P318, DOI 10.1111/j.1474 9726.2008.00380.x
   Colón Emeric CS, 2010, J BONE MINER RES, V25, P91, DOI 10.1359/jbmr.090704
   Das TP, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2015.403
   Dietzl G, 2007, NATURE, V448, P151, DOI 10.1038/nature05954
   Donlon TA, 2012, J GERONTOL A BIOL, V67, P1132, DOI 10.1093/gerona/gls067
   Durán RV, 2012, EMBO REP, V13, P121, DOI 10.1038/embor.2011.257
   Emran S, 2014, AGING US, V6, P390, DOI 10.18632/aging.100665
   Ferber EC, 2012, CELL DEATH DIFFER, V19, P968, DOI 10.1038/cdd.2011.179
   Fischer KE, 2016, AGING US, V8, P2370, DOI 10.18632/aging.101059
   Gargano JW, 2005, EXP GERONTOL, V40, P386, DOI 10.1016/j.exger.2005.02.005
   Grandison RC, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004067
   Gurkar AU, 2018, REDOX BIOL, V18, P191, DOI 10.1016/j.redox.2018.06.005
   Harrison DE, 2009, NATURE, V460, P392, DOI 10.1038/nature08221
   Jahn A, 2020, AGING DIS, V11, P60, DOI 10.14336/AD.2019.0416
   Kanazawa I, 2015, WORLD J DIABETES, V6, P1345, DOI 10.4239/wjd.v6.i18.1345
   Lambrinoudaki I, 2008, CLIN INTERV AGING, V3, P445, DOI 10.2147/CIA.S2046
   Lee JC, 2013, CELL, V155, P57, DOI 10.1016/j.cell.2013.08.034
   Lee P, 2016, J CLIN ENDOCR METAB, V101, P1945, DOI 10.1210/jc.2015 3467
   Liotta G, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0217829
   Liu H, 1996, MECH DEVELOP, V56, P73, DOI 10.1016/0925 4773(96)00512 6
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Lyles KW, 2007, NEW ENGL J MED, V357, P1799, DOI 10.1056/NEJMoa074941
   Maher RL, 2014, EXPERT OPIN DRUG SAF, V13, P57, DOI 10.1517/14740338.2013.827660
   Mahoney SJ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 03035 z
   Mannick JB, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009892
   Martins RR, 2018, BIO PROTOCOL, V8, DOI 10.21769/BioProtoc.2722
   Martins R, 2016, AGING CELL, V15, P196, DOI 10.1111/acel.12427
   McClung M, 2007, BONE, V41, P122, DOI 10.1016/j.bone.2007.03.011
   Mendoza MC, 2011, TRENDS BIOCHEM SCI, V36, P320, DOI 10.1016/j.tibs.2011.03.006
   Misra J, 2016, STEM CELLS, V34, P756, DOI 10.1002/stem.2255
   Mitchell SJ, 2018, CELL METAB, V27, P667, DOI 10.1016/j.cmet.2018.02.001
   Morsli S, 2021, MECH AGEING DEV, V193, DOI 10.1016/j.mad.2020.111391
   Moussian B, 2005, J MORPHOL, V264, P117, DOI 10.1002/jmor.10324
   Ren FF, 2010, P NATL ACAD SCI USA, V107, P21064, DOI 10.1073/pnas.1012759107
   Rera M, 2012, P NATL ACAD SCI USA, V109, P21528, DOI 10.1073/pnas.1215849110
   RILEY PA, 1994, INT J RADIAT BIOL, V65, P27, DOI 10.1080/09553009414550041
   Shell BC, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 29813 9
   Slack C, 2011, AGING CELL, V10, P735, DOI 10.1111/j.1474 9726.2011.00707.x
   Spradling AC, 1999, GENETICS, V153, P135
   Stefanatos R, 2018, FEBS LETT, V592, P743, DOI 10.1002/1873 3468.12902
   Tsai WB, 2008, NAT CELL BIOL, V10, P460, DOI 10.1038/ncb1709
   Varela I, 2008, NAT MED, V14, P767, DOI 10.1038/nm1786
   Vogeli C, 2007, J GEN INTERN MED, V22, P391, DOI 10.1007/s11606 007 0322 1
   Weiss HM, 2008, DRUG METAB DISPOS, V36, P2043, DOI 10.1124/dmd.108.021071
   World Health Organization, 2012, World Health Organ Tech Rep Ser, P1
   Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325
NR 51
TC 11
Z9 11
U1 0
U2 3
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1079 5006
EI 1758 535X
J9 J GERONTOL A BIOL
JI J. Gerontol. Ser. A Biol. Sci. Med. Sci.
PD AUG 12
PY 2022
VL 77
IS 8
BP 1494
EP 1502
DI 10.1093/gerona/glab172
EA AUG 2021
PG 9
WC Geriatrics & Gerontology; Gerontology
WE Science Citation Index Expanded (SCI EXPANDED); Social Science Citation Index (SSCI)
SC Geriatrics & Gerontology
GA 3T2UA
UT WOS:000755852900001
PM 34137822
OA Green Published, Green Accepted, hybrid, Green Submitted
DA 2025 08 17
ER

PT J
AU McElveen, JT
   Kutz, JW
AF McElveen, John T., Jr.
   Kutz, J. Walter, Jr.
TI Controversies in the Evaluation and Management of Otosclerosis
SO OTOLARYNGOLOGIC CLINICS OF NORTH AMERICA
LA English
DT Article
DE Otosclerosis; Stapedectomy; Stapedotomy; Bisphosphonates; Lasers;
   Implantable hearing devices; Middle ear actuators; Barotrauma
ID STAPEDOTOMY MINUS PROSTHESIS; STAPES SURGERY; ANTIBIOTIC PROPHYLAXIS;
   PISTON DIAMETER; SODIUM FLUORIDE; STAPEDECTOMY; HEARING; OUTCOMES; RISK;
   EAR
AB Controversies have been associated with the etiology, diagnosis, evaluation, and management of otosclerosis since Valsalva first described stapes fixation as a cause of hearing loss. Although the exact mechanism of the bone remodeling associated with otosclerosis remains uncertain, stapedotomy has been accepted as the surgical treatment of most patients with stapedial otosclerosis. There remains a disparity of opinion, however, regarding the role of preoperative imaging, surgical technique, implant selection, and medical therapy for cochlear otosclerosis. In addition, opinions vary regarding the optimal postoperative care of patients undergoing stapedotomy and a patient's ability to participate in activities that may result in barotrauma.
C1 [McElveen, John T., Jr.] Carolina Ear Res Inst, Carolina Ear & Hearing Clin, PC, 5900 Six Forks Rd,Suite 200, Raleigh, NC 27609 USA.
   [Kutz, J. Walter, Jr.] Univ Texas Southwestern Med Ctr Dallas, Dept Otolaryngol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.
C3 University of Texas System; University of Texas Southwestern Medical
   Center
RP McElveen, JT (通讯作者)，Carolina Ear Res Inst, Carolina Ear & Hearing Clin, PC, 5900 Six Forks Rd,Suite 200, Raleigh, NC 27609 USA.
EM mcelveencehc@aol.com
RI Kutz, Joe/ABF 4855 2020
CR Acar GO, 2014, OTOL NEUROTOL, V35, pE123, DOI 10.1097/MAO.0000000000000280
   Arnold W, 2007, EUR ARCH OTO RHINO L, V264, P741, DOI 10.1007/s00405 007 0253 9
   Asik B, 2016, LARYNGOSCOPE, V126, P191, DOI 10.1002/lary.25368
   Bittermann AJN, 2014, OTOLARYNG HEAD NECK, V150, P34, DOI 10.1177/0194599813509951
   BRETLAU P, 1989, AM J OTOL, V10, P20
   Calmels MN, 2007, ACTA OTO LARYNGOL, V127, P574, DOI 10.1080/00016480600987768
   CAUSSE JR, 1985, AM J OTOL, V6, P51
   FISCH U, 1982, AM J OTOL, V4, P112
   Fowler EP, 1960, ARCH OTOLARYNGOL, V83, P324
   Harrill WC, 1996, AM J OTOL, V17, P835
   HOUSE HP, 1961, ANN OTO RHINOL LARYN, V70, P1062, DOI 10.1177/000348946107000411
   House HP, 1956, AM LAR RHIN OT SOC M
   House JW, 2001, OTOLARYNG HEAD NECK, V125, P356, DOI 10.1067/mhn.2001.118183
   HOUSE JW, 1980, LARYNGOSCOPE, V90, P1804, DOI 10.1288/00005537 198011000 00007
   Hunter JB, 2016, OTOLARYNG CLIN N AM, V49, P1215, DOI 10.1016/j.otc.2016.05.012
   Hunter JB, 2016, OTOLARYNG HEAD NECK, V154, P1093, DOI 10.1177/0194599816633654
   ISSA TK, 1983, AM J OTOL, V4, P323
   Kabbara B, 2015, OTOL NEUROTOL, V36, pE73, DOI 10.1097/MAO.0000000000000692
   Kamalski DMA, 2014, OTOL NEUROTOL, V35, P1046, DOI 10.1097/MAO.0000000000000270
   Katzav J, 1996, AM J OTOL, V17, P847
   Kessel, 1878, Arch Ohrenheil, V13, P69
   Kludt E, 2016, HEARING RES, V340, P185, DOI 10.1016/j.heares.2016.01.016
   Krouchi L, 2013, ANN OTO RHINOL LARYN, V122, P374, DOI 10.1177/000348941312200605
   KWOK OT, 1989, AM J OTOLARYNG, V10, P1, DOI 10.1016/0196 0709(89)90086 0
   Lenarz T, 2013, OTOL NEUROTOL, V34, P1215, DOI 10.1097/MAO.0b013e318298aa76
   Lesinksi G, 2010, GLASSCOCK SHAMBAUGHS, P331
   Lippy WH, 1998, AM J OTOL, V19, P56
   Marx M, 2011, ACTA OTO LARYNGOL, V131, P351, DOI 10.3109/00016489.2010.549841
   Mathews JD, 2013, BMJ BRIT MED J, V346, DOI 10.1136/bmj.f2360
   Mazonakis M, 2007, EUR RADIOL, V17, P1352, DOI 10.1007/s00330 006 0417 9
   McCabe B F, 1966, Trans Pac Coast Otoophthalmol Soc Annu Meet, V47, P37
   MCKENNA MJ, 1989, OTOLARYNG HEAD NECK, V101, P415, DOI 10.1177/019459988910100401
   McKenna MJ, 1996, AM J OTOL, V17, P827
   MORRISON A W, 1967, Annals of the Royal College of Surgeons of England, V41, P202
   PARAHY C, 1983, LARYNGOSCOPE, V93, P717
   PAUW BKH, 1991, ANN OTO RHINOL LARYN, V100, P966, DOI 10.1177/000348949110001203
   Pearce MS, 2012, LANCET, V380, P499, DOI 10.1016/S0140 6736(12)60815 0
   Politzer A, 1913, GESCHICHTE OHRENHEIL, V2, P171
   Politzer A., 1893, Zeitschr Ohrenheil, V25, P309
   Quesnel AM, 2012, OTOL NEUROTOL, V33, P1308, DOI 10.1097/MAO.0b013e318268d1b3
   Riechelmann H, 2000, AM J OTOL, V21, P809
   ROSOWSKI JJ, 1995, AM J OTOL, V16, P486
   Sennaroglu L, 2001, OTOLARYNG HEAD NECK, V124, P279, DOI 10.1067/mhn.2001.112431
   SHAMBAUGH GE, 1964, ARCHIV OTOLARYNGOL, V80, P263, DOI 10.1001/archotol.80.3.263
   SHEA J J Jr, 1958, Ann Otol Rhinol Laryngol, V67, P932
   Shea PF, 1999, AM J OTOL, V20, P425
   Siebenmann F., 1900, C INT MED SEC OTOL, V13, P170
   Silverstein H, 1998, AM J OTOL, V19, P277
   Thiringer JK, 1998, OTOLARYNG HEAD NECK, V118, P9, DOI 10.1016/S0194 5998(98)70368 7
   Verschuur HP., 2004, COCHRANE DB SYST REV, V2004, pCD003996
   Vincent R, 2006, OTOL NEUROTOL, V27, pS25, DOI 10.1097/01.mao.0000235311.80066.df
   Vital V, 2008, AURIS NASUS LARYNX, V35, P475, DOI 10.1016/j.anl.2007.11.002
   Wegner I, 2016, OTOL NEUROTOL, V37, P1497, DOI 10.1097/MAO.0000000000001212
   Wegner I, 2013, OTOLARYNG HEAD NECK, V149, P360, DOI 10.1177/0194599813493393
   Wieczorek SS, 2013, AM J OTOLARYNG, V34, P619, DOI 10.1016/j.amjoto.2013.07.015
   Ottoline ACX, 2013, INT ARCH OTORHINOLAR, V17, P85, DOI 10.7162/S1809 97772013000100015
NR 56
TC 23
Z9 24
U1 0
U2 5
PU W B SAUNDERS CO ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103 2899 USA
SN 0030 6665
EI 1557 8259
J9 OTOLARYNG CLIN N AM
JI Otolaryngol. Clin. N. Am.
PD APR
PY 2018
VL 51
IS 2
BP 487
EP +
DI 10.1016/j.otc.2017.11.017
PG 14
WC Otorhinolaryngology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Otorhinolaryngology
GA GB6MI
UT WOS:000429182900019
PM 29502731
DA 2025 08 17
ER

PT J
AU Riggs, CM
   Thompson, SL
   So, YM
   Wong, JKY
   Wan, TSM
   Robinson, P
   Stewart, BD
   Ho, ENM
AF Riggs, Chris M.
   Thompson, Sarah L.
   So, Yat Ming
   Wong, Jenny K. Y.
   Wan, Terence S. M.
   Robinson, Paul
   Stewart, Brian D.
   Ho, Emmie N. M.
TI Tiludronic acid can be detected in blood and urine samples from
   Thoroughbred racehorses over 3 years after last administration
SO EQUINE VETERINARY JOURNAL
LA English
DT Article
DE bisphosphonates; doping control analysis; horse; liquid
   chromatography&#8208; mass spectrometry; tiludronic acid
ID BONE; BISPHOSPHONATES; GROWTH; HORSES
AB Background Administration of bisphosphonates, including tiludronic acid, to Thoroughbred racehorses below 3 and a half years of age is prohibited in most racing jurisdictions.
   Objectives To determine if evidence of administration of tiludronic acid could be obtained from analysis of blood and urine samples beyond 40 days after administration.
   Study design Retrospective cohort.
   Methods Horses maintained in a highly controlled environment and treated with Tildren((R) a) were selected from clinical records. Twenty four horses were identified, 21 of which were still in race training. Blood and urine samples were collected and analysed for the presence of tiludronic acid using ultra high performance liquid chromatography high resolution mass spectrometry.
   Results Tiludronic acid was detected in samples from every horse, including two that had been given a therapeutic dose of the drug 3 years prior to sample collection. The estimated concentrations of tiludronic acid in the blood collected at least 2 years post administration were consistently very low (less than 0.3 ng/mL). The estimated concentrations in urine were less consistent and were generally lower than those in blood, although higher levels were inconsistently detected in individual horses (up to about 16 ng/mL almost 1 year post administration in 1 horse and about 3.7 ng/mL at almost 3 years post administration in another).
   Main limitations The study was performed in horses that are older than the primary target group. A single sample was obtained from most horses and so we cannot comment on elimination profiles.
   Conclusions Evidence that a therapeutic dose of tiludronic acid has been administered to a horse can be obtained from detection of the drug in blood and urine samples over 3 years after it was administered.
C1 [Riggs, Chris M.; Thompson, Sarah L.; Robinson, Paul] Hong Kong Jockey Club, Sha Tin Racecourse, Vet Clin Serv, Sha Tin, Hong Kong, Peoples R China.
   [So, Yat Ming; Wong, Jenny K. Y.; Wan, Terence S. M.; Ho, Emmie N. M.] Hong Kong Jockey Club, Sha Tin Racecourse, Racing Lab, Hong Kong, Peoples R China.
   [Stewart, Brian D.] Hong Kong Jockey Club, Sha Tin Racecourse, Vet Regulat Welf & Biosecur Policy, Hong Kong, Peoples R China.
RP Riggs, CM (通讯作者)，Hong Kong Jockey Club, Sha Tin Racecourse, Vet Clin Serv, Sha Tin, Hong Kong, Peoples R China.
EM christopher.m.riggs@hkjc.org.hk
RI SO, Yat Ming/ABI 5288 2020
OI Ho, Emmie/0000 0001 8366 2066; So, Yat Ming/0000 0003 0015 781X; WAN,
   Terence See Ming/0000 0003 3779 2649
CR [Anonymous], 2017, BHA NOTICE BISPHOSPH
   Association of the Official Racing Chemists, GUID MIN CRIT ID CHR
   Bajaj D, 2014, BONE, V64, P57, DOI 10.1016/j.bone.2014.03.045
   Ballock RT, 2003, J BONE JOINT SURG AM, V85A, P715, DOI 10.2106/00004623 200304000 00021
   Delguste C, 2008, J VET PHARMACOL THER, V31, P108, DOI 10.1111/j.1365 2885.2007.00936.x
   Ehrlich PJ, 2002, OSTEOPOROSIS INT, V13, P688, DOI 10.1007/s001980200095
   García Aznar JM, 2005, BIOMECH MODEL MECHAN, V4, P147, DOI 10.1007/s10237 005 0067 x
   Holmes JM, 2014, VET J, V202, P443, DOI 10.1016/j.tvjl.2014.09.010
   International Federation of Horseracing Authorities, ART 6 INT AGR BREED
   Papapoulos SE, 2007, NEW ENGL J MED, V356, P1075, DOI 10.1056/NEJMc062792
   Popot MA, 2018, EQUINE VET J, V50, P488, DOI 10.1111/evj.12789
   Popot MA, 2014, J CHROMATOGR B, V958, P108, DOI 10.1016/j.jchromb.2014.03.018
   Thomsen V, 2003, SPECTROSCOPY, V18, P112
   Wong ASY, 2015, J CHROMATOGR B, V998, P1, DOI 10.1016/j.jchromb.2015.06.020
   Wong ASY, 2020, P 22 INT C RAC AN VE
NR 15
TC 7
Z9 9
U1 0
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0425 1644
EI 2042 3306
J9 EQUINE VET J
JI Equine Vet. J.
PD NOV
PY 2021
VL 53
IS 6
BP 1287
EP 1295
DI 10.1111/evj.13395
EA DEC 2020
PG 9
WC Veterinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Veterinary Sciences
GA WB9QM
UT WOS:000601086600001
PM 33247964
DA 2025 08 17
ER

PT J
AU Paloian, NJ
   Leaf, EM
   Giachelli, CM
AF Paloian, Neil J.
   Leaf, Elizabeth M.
   Giachelli, Cecilia M.
TI Osteopontin protects against high phosphate induced nephrocalcinosis and
   vascular calcification
SO KIDNEY INTERNATIONAL
LA English
DT Article
DE calcium; fibroblast growth factor 23; parathyroid hormone; phosphate;
   uremia; vascular calcification
ID CHRONIC KIDNEY DISEASE; DEFICIENT MICE; CARDIOVASCULAR DISEASE;
   ATHEROSCLEROTIC PLAQUES; AORTIC CALCIFICATION; ARTERY CALCIFICATION;
   PARATHYROID HORMONE; BINDING PROPERTIES; SERUM PHOSPHORUS;
   SODIUM PHOSPHATE
AB Pathologic calcification is a significant cause of increased morbidity and mortality in patients with chronic kidney disease. The precise mechanisms of ectopic calcification are not fully elucidated, but it is known to be caused by an imbalance of procalcific and anticalcific factors. In the chronic kidney disease population, an elevated phosphate burden is both highly prevalent and a known risk factor for ectopic calcification. Here we tested whether osteopontin, an inhibitor of calcification, protects against high phosphate load induced nephrocalcinosis and vascular calcification. Osteopontin knockout mice were placed on a high phosphate diet for 11 weeks. Osteopontin deficiency together with phosphate overload caused uremia, nephrocalcinosis characterized by substantial renal tubular and interstitial calcium deposition, and marked vascular calcification when compared with control mice. Although the osteopontin deficient mice did not exhibit hypercalcemia or hyperphosphatemia, they did show abnormalities in the mineral metabolism hormone fibroblast growth factor 23. Thus, endogenous osteopontin plays a critical role in the prevention of phosphate induced nephrocalcinosis and vascular calcification in response to high phosphate load. A better understanding of osteopontin's role in phosphate induced calcification will hopefully lead to better biomarkers and therapies for this disease, especially in patients with chronic kidney disease and other at risk populations. (C) Copyright 2016, International Society of Nephrology. Published by Elsevier Inc. All rights reserved.
C1 [Paloian, Neil J.] Univ Wisconsin, Dept Pediat, Sch Med & Publ Hlth, Madison, WI USA.
   [Leaf, Elizabeth M.; Giachelli, Cecilia M.] Univ Washington, Dept Bioengn, 3720 15th Ave NE,Foege N330L,Box 355061, Seattle, WA 98195 USA.
C3 University of Wisconsin System; University of Wisconsin Madison;
   University of Washington; University of Washington Seattle
RP Giachelli, CM (通讯作者)，Univ Washington, Dept Bioengn, 3720 15th Ave NE,Foege N330L,Box 355061, Seattle, WA 98195 USA.
EM ceci@uw.edu
RI Stefanadis, Christodoulos/ABH 2232 2020
OI Stefanadis, Christodoulos/0000 0001 5974 6454; Giachelli,
   Cecilia/0000 0002 6387 5993; Soberg, Elizabeth/0000 0002 5354 6010
FU National Institutes of Health [HL62329, HL081785, HL114611,
   5T32DK7662 22]; Department of Defense Peer Reviewed Orthopaedic Research
   Program [OR120074]
FX Funding for Dr. Giachelli's research is supported by National Institutes
   of Health grants HL62329, HL081785, and HL114611, and a grant from the
   Department of Defense Peer Reviewed Orthopaedic Research Program
   #OR120074. Dr. Paloian is supported by National Institutes of Health
   grant 5T32DK7662 22.
CR Abou Hassan N, 2012, CLIN J AM SOC NEPHRO, V7, P275, DOI 10.2215/CJN.06490711
   Addison WN, 2010, J BONE MINER RES, V25, P695, DOI 10.1359/jbmr.090832
   Adeney KL, 2009, J AM SOC NEPHROL, V20, P381, DOI 10.1681/ASN.2008040349
   Adragao T, 2004, NEPHROL DIAL TRANSPL, V19, P1480, DOI 10.1093/ndt/gfh217
   Barreto DV, 2011, NEPHRON CLIN PRACT, V117, pC363, DOI 10.1159/000321520
   Bushinsky DA, 2000, KIDNEY INT, V57, P550
   Calvo MS, 2014, ADV NUTR, V5, P104, DOI 10.3945/an.113.004861
   Chawla LS, 2014, NEW ENGL J MED, V371, P58, DOI 10.1056/NEJMra1214243
   CHEN Y, 1992, J BIOL CHEM, V267, P24871
   Cockell KA, 2002, J NUTR, V132, P252, DOI 10.1093/jn/132.2.252
   Darmon M, 2013, BRIT J HAEMATOL, V162, P489, DOI 10.1111/bjh.12415
   Dhingra R, 2007, ARCH INTERN MED, V167, P879, DOI 10.1001/archinte.167.9.879
   El Abbadi MM, 2009, KIDNEY INT, V75, P1297, DOI 10.1038/ki.2009.83
   Evenepoel P, 2015, NEPHROL DIAL TRANSPL, V30, P843, DOI 10.1093/ndt/gfu400
   Fliser D, 2007, J AM SOC NEPHROL, V18, P2600, DOI 10.1681/ASN.2006080936
   GIACHELLI CM, 1993, J CLIN INVEST, V92, P1686, DOI 10.1172/JCI116755
   HAASE P, 1975, J ANAT, V119, P19
   Hirose M, 2012, UROL RES, V40, P121, DOI 10.1007/s00240 011 0400 z
   Hudkins KL, 1999, J AM SOC NEPHROL, V10, P444
   Isakova T, 2011, KIDNEY INT, V79, P1370, DOI 10.1038/ki.2011.47
   Kaartinen MT, 2007, J HISTOCHEM CYTOCHEM, V55, P375, DOI 10.1369/jhc.6A7087.2006
   Kestenbaum B, 2005, J AM SOC NEPHROL, V16, P520, DOI 10.1681/ASN.2004070602
   Lehto S, 1996, ARTERIOSCL THROM VAS, V16, P978, DOI 10.1161/01.ATV.16.8.978
   Liaw L, 1998, J CLIN INVEST, V101, P1468
   Lochy S, 2013, INT J NEPHROL RENOV, V6, P61, DOI 10.2147/IJNRD.S41428
   London GM, 2005, CURR OPIN NEPHROL HY, V14, P525, DOI 10.1097/01.mnh.0000168336.67499.c0
   Lorenzen J, 2010, EUR J CLIN INVEST, V40, P294, DOI 10.1111/j.1365 2362.2010.02271.x
   MacKay EM, 1935, J EXP MED, V61, P319, DOI 10.1084/jem.61.3.319
   Markowitz GS, 2004, HUM PATHOL, V35, P675, DOI 10.1016/j.humpath.2003.12.005
   Martin A, 2011, FASEB J, V25, P2551, DOI 10.1096/fj.10 177816
   MASSRY SG, 1973, ANN INTERN MED, V78, P357, DOI 10.7326/0003 4819 78 3 357
   Matsui Y, 2003, ARTERIOSCL THROM VAS, V23, P1029, DOI 10.1161/01.ATV.0000074878.29805.D0
   Matsuzaki H, 2007, J CLIN BIOCHEM NUTR, V41, P179, DOI 10.3164/jcbn.2007025
   McEniery CM, 2009, HYPERTENSION, V53, P524, DOI 10.1161/HYPERTENSIONAHA.108.126615
   Mirams M, 2004, BONE, V35, P1192, DOI 10.1016/j.bone.2004.06.014
   Mo L, 2007, AM J PHYSIOL RENAL, V293, pF1935, DOI 10.1152/ajprenal.00383.2007
   Natali A, 2000, DIABETOLOGIA, V43, P632, DOI 10.1007/s001250051352
   New SEP, 2013, CIRC RES, V113, P72, DOI 10.1161/CIRCRESAHA.113.301036
   Ohri R, 2005, CALCIFIED TISSUE INT, V76, P307, DOI 10.1007/s00223 004 0071 7
   OLDBERG A, 1986, P NATL ACAD SCI USA, V83, P8819, DOI 10.1073/pnas.83.23.8819
   Roijers RB, 2011, AM J PATHOL, V178, P2879, DOI 10.1016/j.ajpath.2011.02.004
   Russo D, 2011, KIDNEY INT, V80, P112, DOI 10.1038/ki.2011.69
   Schlieper G, 2007, SEMIN DIALYSIS, V20, P113, DOI 10.1111/j.1525 139X.2007.00257.x
   Schulte K, 2014, J AM SOC NEPHROL, V25, P129, DOI 10.1681/ASN.2013040376
   Schwarz S, 2006, CLIN J AM SOC NEPHRO, V1, P825, DOI 10.2215/CJN.02101205
   Shao JS, 2011, ARTERIOSCL THROM VAS, V31, P1821, DOI 10.1161/ATVBAHA.111.230011
   Shavit L, 2015, KIDNEY INT, V88, P35, DOI 10.1038/ki.2015.76
   Shavit L, 2015, CLIN J AM SOC NEPHRO, V10, P278, DOI 10.2215/CJN.06030614
   Shimada T, 2004, J BONE MINER RES, V19, P429, DOI 10.1359/JBMR.0301264
   SINGH K, 1993, J BIOCHEM TOKYO, V114, P702, DOI 10.1093/oxfordjournals.jbchem.a124240
   Sodek J, 2000, CRIT REV ORAL BIOL M, V11, P279, DOI 10.1177/10454411000110030101
   Speer MY, 2005, CARDIOVASC RES, V66, P324, DOI 10.1016/j.cardiores.2005.01.023
   Speer MY, 2002, J EXP MED, V196, P1047, DOI 10.1084/jem.20020911
   Standal T, 2004, EXP ONCOL, V26, P179
   Vlachopoulos C, 2010, J AM COLL CARDIOL, V55, P1318, DOI 10.1016/j.jacc.2009.10.061
   Wada T, 1999, CIRC RES, V84, P166, DOI 10.1161/01.RES.84.2.166
   Weiss J, 2011, BMJ CASE REP, V2011
   Wesson JA, 2003, J AM SOC NEPHROL, V14, P139, DOI 10.1097/01.ASN.0000040593.93815.9D
   WITTEMAN JCM, 1986, LANCET, V2, P1120
   WITTEMAN JCM, 1990, AM J CARDIOL, V66, P1060, DOI 10.1016/0002 9149(90)90505 U
   Yamaguchi H, 2004, ENDOCR J, V51, P499, DOI 10.1507/endocrj.51.499
   Yan XM, 2005, GENES CELLS, V10, P489, DOI 10.1111/j.1365 2443.2005.00853.x
   Yuan Q, 2014, J BONE MINER RES, V29, P693, DOI 10.1002/jbmr.2079
NR 63
TC 71
Z9 81
U1 0
U2 15
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 0085 2538
EI 1523 1755
J9 KIDNEY INT
JI Kidney Int.
PD MAY
PY 2016
VL 89
IS 5
BP 1027
EP 1036
DI 10.1016/j.kint.2015.12.046
PG 10
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Urology & Nephrology
GA DK2DG
UT WOS:000374724200013
PM 27083280
OA Green Accepted, Bronze
DA 2025 08 17
ER

PT J
AU Zhou, XL
   Li, X
   Wei, TT
   Xu, Y
   Lei, C
AF Zhou, Xiaoling
   Li, Xin
   Wei, Tingting
   Xu, Ying
   Lei, Chen
TI 被撤回的出版物: Correlation Analysis of Adverse Reactions of Antiosteoporosis
   Drugs by Different Mechanisms with Bone Turnover and Vitamin D
   (Retracted Article)
SO EVIDENCE BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article; Retracted Publication
ID ACUTE PHASE RESPONSE; POSTMENOPAUSAL WOMEN; OSTEOPOROSIS; FRACTURES;
   ABALOPARATIDE
AB Objective. The risk factors for the most common adverse reactions of two types of antiosteoporosis drugs in the first treatment of postmenopausal osteoporosis were analyzed to investigate the relationship between the occurrence of adverse reactions and different bone transition states and vitamin D levels. Methods. A total of 381 postmenopausal women who were diagnosed with osteoporosis in the Osteoporosis Clinic of Ningxia Medical University General Hospital from January 2017 to June 2020 were enrolled. A telephone follow up survey was conducted on the mentioned subjects. According to the survey results, the mentioned subjects were selected according to their first use of antiosteoporosis drugs. They were divided into zoledronic acid and teriparatide acetate groups. The subjects in the two groups were divided into two groups according to the presence or absence of adverse reactions after medication and according to vitamin D level and P1NP level, and the correlation between the two factors and the occurrence of adverse reactions was analyzed. Results. Among the 307 patients treated with zoledronic acid for antiosteoporosis, 99 patients developed acute phase adverse reactions (APR+), accounting for 32.2% of the total subjects. 56.7 percent of the subjects had vitamin D deficiency. The 25(OH)D level of the APR+subjects was 16.75 +/  9.20ng/mL, significantly lower than that of the APR  patients (23.68 +/  10.67ng/mL). Serological P1NP level in APR+ patients was 73.95 +/  34.50ng/ml, significantly higher than that of APR  patients with 55.80 +/  36.91ng/ml. Musculoskeletal symptoms were observed in 14 of the 74 subjects treated with teriparatide acetate, accounting for 18.9% of the total subjects. The 25(OH)D level was deficient in 59.5% of the subjects. The 25(OH)D level of the subjects with musculoskeletal symptoms was 15.96 +/  8.17ng/ml, while that of the subjects without musculoskeletal symptoms was 20.86 +/  8.52ng/ml, which showed no statistical significance. The reason was considered to be related to the small sample size included in the study. The P1NP level of subjects with musculoskeletal symptoms was 96.85 +/  58.52ng/ml, significantly higher than the P1NP level of subjects without musculoskeletal symptoms (55.28 +/  27.87ng/ml). Conclusions. The 25(OH)D level in vivo was negatively correlated with the acute phase adverse reactions after the first infusion of zoledronic acid. When the rate of bone formation is increased and osteoblasts are active, the risk of acute phase adverse reactions is increased with the use of zoledronic acid as antiosteoporosis therapy. There was no significant correlation between 25(OH)D levels and musculoskeletal symptoms after teriparatide acetate treatment of osteoporosis. When the rate of bone formation is increased and osteoblasts are active, the risk of adverse reactions to musculoskeletal symptoms is increased with antiosteoporosis treatment with teriparatide acetate.
C1 [Zhou, Xiaoling] Ningxia Med Univ, Dept Nephrol, Gen Hosp, Yinchuan 750004, Ningxia, Peoples R China.
   [Li, Xin; Wei, Tingting; Xu, Ying; Lei, Chen] Ningxia Med Univ, Dept Endocrinol, Gen Hosp, Yinchuan 750004, Ningxia, Peoples R China.
C3 Ningxia Medical University; Ningxia Medical University
RP Lei, C (通讯作者)，Ningxia Med Univ, Dept Endocrinol, Gen Hosp, Yinchuan 750004, Ningxia, Peoples R China.
EM zxlingzzr@163.com; lixin001002@163.com; weitingting0216@163.com;
   xuying59468@163.com; nxleichen@163.com
RI 卫, 婷婷/IUQ 4456 2023
FU Key Science and Technology Project in Ningxia [2020BFG02011];
   First Class Discipline Construction Founded Project of Ningxia Medical
   University and the School of Clinical Medicine [NXYLXK2017A05]
FX This paper was supported by Key Science and Technology Project in
   Ningxia (2020BFG02011) and First Class Discipline Construction Founded
   Project of Ningxia Medical University and the School of Clinical
   Medicine (NXYLXK2017A05).
CR Alejandro P, 2018, RHEUM DIS CLIN N AM, V44, P437, DOI 10.1016/j.rdc.2018.03.004
   Bertoldo F, 2010, J BONE MINER RES, V25, P447, DOI 10.1359/jbmr.090819
   Cosman F, 2017, J BONE MINER RES, V32, P17, DOI 10.1002/jbmr.2991
   Dicuonzo G, 2003, J INTERF CYTOK RES, V23, P649, DOI 10.1089/107999003322558782
   Farr JN, 2013, J CLIN ENDOCR METAB, V98, pE249, DOI 10.1210/jc.2012 3406
   [李晓峰 Li Xiaofeng], 2017, [中国矫形外科杂志, Orthopedic Journal of China], V25, P1193
   Meier C, 2005, J BONE MINER RES, V20, P579, DOI 10.1359/JBMR.041207
   Miller PD, 2016, JAMA J AM MED ASSOC, V316, P722, DOI 10.1001/jama.2016.11136
   Olson Karin, 2007, J Oncol Pharm Pract, V13, P223, DOI 10.1177/1078155207080806
   Reid IR, 2010, J CLIN ENDOCR METAB, V95, P4380, DOI 10.1210/jc.2010 0597
   Si L, 2015, OSTEOPOROSIS INT, V26, P1929, DOI 10.1007/s00198 015 3093 2
   Siris E, 2014, OSTEOPOROSIS INT, V25, P1439, DOI 10.1007/s00198 014 2655 z
   Wang O, 2015, OSTEOPOROSIS INT, V26, P2631, DOI 10.1007/s00198 015 3162 6
NR 13
TC 2
Z9 2
U1 1
U2 5
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741 427X
EI 1741 4288
J9 EVID BASED COMPL ALT
JI Evid. based Complement Altern. Med.
PD OCT 12
PY 2021
VL 2021
AR 5402949
DI 10.1155/2021/5402949
PG 8
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Integrative & Complementary Medicine
GA YO5DI
UT WOS:000747959300007
PM 34675985
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU García, A
   Senis, YA
   Antrobus, R
   Hughes, CE
   Dwek, RA
   Watson, SP
   Zitzmann, N
AF Garcia, Angel
   Senis, Yotis A.
   Antrobus, Robin
   Hughes, Craig E.
   Dwek, Raymond A.
   Watson, Steve P.
   Zitzmann, Nicole
TI A global proteomics approach identifies novel phosphorylated signaling
   proteins in GPVI activated platelets:: Involvement of G6f, a novel
   platelet Grb2 binding membrane adapter
SO PROTEOMICS
LA English
DT Article
DE G6f; Gads; GPVI signaling; Grb2; platelet proteomics
ID COLLAGEN RECEPTOR GPVI; TYROSINE PHOSPHORYLATION; PHOSPHOLIPASE
   C GAMMA 2; MASS SPECTROMETRY; GLYCOPROTEIN VI; SPIN90; KINASE;
   ELECTROPHORESIS; TECHNOLOGY; ADHESION
AB Collagen related peptide (CRP) stimulates powerful activation of platelets through the glycoprotein VI (GPVI) FcR gamma chain complex. We have combined proteomics and traditional biochemistry approaches to study the proteome of CRP activated platelets, focusing in detail on tyrosine phosphorylation. In two separate approaches, phosphotyrosine immunoprecipitations followed by 1 D PAGE, and 2 DE, were used for protein separation. Proteins were identified by MS. By following these approaches, 96 proteins were found to undergo PTM in response to CRP in human platelets, including 11 novel platelet proteins such as Dok 1, SPIN90, osteoclast stimulating factor 1, and beta Pix. Interestingly, the type I transmembrane protein G6f was found to be specifically phosphorylated on Tyr 281 in response to platelet activation by CRP, providing a docking site for the adapter Grb2. G6f tyrosine phoshporylation was also found to take place in response to collagen, although not in response to the G protein coupled receptor agonists, thrombin and ADP. Further, we also demonstrate for the first time that Grb2 and its homolog Gads are tyrosine phosphorylated in CRP stimulated platelets. This study provides new insights into the mechanism of platelet activation through the GPVI collagen receptor, helping to build the basis for the development of new drug targets for thrombotic disease.
C1 Univ Santiago de Compostela, RIAIDT, Santiago De Compostela 15782, Spain.
   Univ Oxford, Dept Biochem, Glycobiol Inst, Oxford OX1 3QU, England.
   Univ Birmingham, Ctr Cardiovasc Sci, Inst Biomed Res, Div Med Sci, Birmingham, W Midlands, England.
C3 Universidade de Santiago de Compostela; University of Oxford; University
   of Birmingham
RP García, A (通讯作者)，Univ Santiago de Compostela, RIAIDT, Edificio CACTUS,Campus Univ Sur, Santiago De Compostela 15782, Spain.
EM agarcia@usc.es
RI ; Garcia, Angel/F 6736 2016; Watson, Stephen/Q 6292 2016; Garcia,
   Angel/ITU 6895 2023; Senis, Yotis/AAD 7183 2021; Watson,
   Steve/Q 6292 2016
OI Hughes, Craig/0000 0002 9790 5820; Garcia, Angel/0000 0003 1176 5917;
   Watson, Steve/0000 0002 7846 7423; Senis, Yotis/0000 0002 0947 9957;
   Zitzmann, Nicole/0000 0003 1969 4949
FU British Heart Foundation [CH/03/003/15571] Funding Source: Medline;
   Wellcome Trust [073107] Funding Source: Medline
CR Asazuma N, 2000, J BIOL CHEM, V275, P33427, DOI 10.1074/jbc.M001439200
   Asselin J, 1997, BLOOD, V89, P1235, DOI 10.1182/blood.V89.4.1235
   Best D, 2001, BRIT J HAEMATOL, V112, P609, DOI 10.1046/j.1365 2141.2001.02624.x
   Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310
   BorschHaubold AG, 1997, EUR J BIOCHEM, V245, P751, DOI 10.1111/j.1432 1033.1997.t01 1 00751.x
   de Vet ECJM, 2003, BIOCHEM J, V375, P207, DOI 10.1042/BJ20030293
   García A, 2005, MASS SPECTROM REV, V24, P918, DOI 10.1002/mas.20047
   García A, 2004, PROTEOMICS, V4, P656, DOI 10.1002/pmic.200300665
   García A, 2004, BLOOD, V103, P2088, DOI 10.1182/blood 2003 07 2392
   Görg A, 2004, PROTEOMICS, V4, P3665, DOI 10.1002/pmic.200401031
   Judd BA, 2002, J EXP MED, V195, P705, DOI 10.1084/jem.20011583
   Kamata T, 2005, BLOOD, V106, P833, DOI 10.1182/blood 2004 11 4458
   Kehrel B, 1998, BLOOD, V91, P491
   Kim DJ, 2006, J BIOL CHEM, V281, P617, DOI 10.1074/jbc.M504450200
   Lee J, 2005, EXP CELL RES, V307, P315, DOI 10.1016/j.yexcr.2005.03.028
   Lewandrowski U, 2006, MOL CELL PROTEOMICS, V5, P226, DOI 10.1074/mcp.M500324 MCP200
   Lim CS, 2003, J BIOL CHEM, V278, P52116, DOI 10.1074/jbc.M310974200
   Lim CS, 2001, J BIOL CHEM, V276, P12871, DOI 10.1074/jbc.M009411200
   MORTON LF, 1995, BIOCHEM J, V306, P337, DOI 10.1042/bj3060337
   Nieswandt B, 2003, BLOOD, V102, P449, DOI 10.1182/blood 2002 12 3882
   O'Neill EE, 2002, PROTEOMICS, V2, P288, DOI 10.1002/1615 9861(200203)2:3<288::AID PROT288>3.0.CO;2 0
   Oda A, 1998, BLOOD, V92, P1852, DOI 10.1182/blood.V92.6.1852.418k36_1852_1858
   Pasquet JM, 1999, MOL CELL BIOL, V19, P8326
   Reddy S, 1998, J CELL PHYSIOL, V177, P636, DOI 10.1002/(SICI)1097 4652(199812)177:4<636::AID JCP14>3.0.CO;2 H
   Robinson A, 1996, BLOOD, V88, P522, DOI 10.1182/blood.V88.2.522.bloodjournal882522
   Satoh S, 2001, J BIOL CHEM, V276, P39290, DOI 10.1074/jbc.M107026200
   Shevchenko A, 1996, P NATL ACAD SCI USA, V93, P14440, DOI 10.1073/pnas.93.25.14440
   Szymkiewicz I, 2004, FEBS LETT, V565, P33, DOI 10.1016/j.febslet.2004.03.100
   TYERS M, 1989, J CELL BIOCHEM, V40, P133, DOI 10.1002/jcb.240400202
   Watson SP, 2001, THROMB HAEMOSTASIS, V86, P276
   Wu WJ, 2003, CELL, V114, P715, DOI 10.1016/S0092 8674(03)00688 3
NR 31
TC 81
Z9 84
U1 0
U2 6
PU WILEY V C H VERLAG GMBH
PI WEINHEIM
PA PO BOX 10 11 61, D 69451 WEINHEIM, GERMANY
SN 1615 9853
J9 PROTEOMICS
JI Proteomics
PD OCT
PY 2006
VL 6
IS 19
BP 5332
EP 5343
DI 10.1002/pmic.200600299
PG 12
WC Biochemical Research Methods; Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA 094OW
UT WOS:000241249800023
PM 16941570
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Banerjee, H
   Roy, B
   Chaudhury, K
   Srinivasan, B
   Chakraborty, S
   Ren, HL
AF Banerjee, Hritwick
   Roy, Bibhas
   Chaudhury, Kaustav
   Srinivasan, Babji
   Chakraborty, Suman
   Ren, Hongliang
TI Frequency induced morphology alterations in microconfined biological
   cells
SO MEDICAL & BIOLOGICAL ENGINEERING & COMPUTING
LA English
DT Article
DE Cellular morphology; Microfluidic confinement; Ultrasound therapy; LIPUS
ID INTENSITY PULSED ULTRASOUND; THERAPEUTIC ULTRASOUND; ACTIN
   POLYMERIZATION; IN VITRO; CALIBRATION; CAVITATION; EXPRESSION; MECHANISM
AB Low intensity therapeutic ultrasound has demonstrated an impetus in bone signaling and tissue healing for decades now. Though this technology is clinically well proven, still there are breaches in studies to understand the fundamental principle of how osteoblast tissue regenerates physiologically at the cellular level with ultrasound interaction as a form of acoustic wave stimuli. Through this article, we illustrate an analysis for cytomechanical changes of cell membrane periphery as a basic first physical principle for facilitating late downstream biochemical pathways. With the help of in situ single cell direct analysis in a microfluidic confinement, we demonstrate that alteration of low intensity pulse ultrasound (LIPUS) frequency would physically perturb cell membrane and establish inherent cell oscillation. We experimentally demonstrate here that, at LIPUS resonance near 1.7 MHz (during 1 3 MHz alteration), cell membrane area would expand to 6.85 0.7% during ultrasound exposure while it contracts 44.68 0.8% in post actuation. Conversely, cell cross sectional area change (%) from its previous morphology during and after switching off LIPUS was reversibly different before and after resonance. For instance, at 1.5 MHz, LIPUS exposure produced 1.44 +/  0.5% expansion while in contrast 2 MHz instigates 1.6 +/  0.3% contraction. We conclude that alteration of LIPUS frequency from 1 3 MHz keeping other ultrasound parameters like exposure time, pulse repetition frequency (PRF), etc., constant, if applied to a microconfined biological single living cell, would perturb physical structure reversibly based on the system resonance during and post exposure ultrasound pulsing. We envision, in the near future, our results would constitute the foundation of mechanistic effects of low intensity therapeutic ultrasound and its allied potential in medical applications.
C1 [Banerjee, Hritwick; Srinivasan, Babji] Indian Inst Technol Gandhinagar, Dept Elect Engn, Gandhinagar 382355, Gujarat, India.
   [Banerjee, Hritwick; Chaudhury, Kaustav; Chakraborty, Suman] Indian Inst Technol Kharagpur, Dept Mech Engn, Kharagpur 721302, W Bengal, India.
   [Banerjee, Hritwick; Ren, Hongliang] Natl Univ Singapore, Dept Biomed Engn, Fac Engn, 9 Engn Dr 1, Singapore 117575, Singapore.
   [Banerjee, Hritwick; Ren, Hongliang] Natl Univ Singapore, Ctr Life Sci, Singapore Inst Neurotechnol SINAPSE, 28 Med Dr,05 COR, Singapore 117456, Singapore.
   [Roy, Bibhas] Indian Inst Technol Kharagpur, Dept Biotechnol, Kharagpur 721302, W Bengal, India.
   [Roy, Bibhas] Natl Univ Singapore, Mechanobiol Inst, T Lab, 10 01 5A Engn Dr 1, Singapore 117411, Singapore.
   [Chaudhury, Kaustav] Natl Inst Technol Rourkela, Rourkela 769008, Odisha, India.
   [Srinivasan, Babji] Indian Inst Technol Gandhinagar, Dept Chem Engn, Gandhinagar 382355, Gujarat, India.
   [Chakraborty, Suman] Indian Inst Technol Kharagpur, Sch Med Sci & Technol, Kharagpur 721302, W Bengal, India.
   [Ren, Hongliang] Natl Univ Singapore Suzhou, Res Inst NUSRI, Suzhou, Jiangsu, Peoples R China.
C3 Indian Institute of Technology System (IIT System); Indian Institute of
   Technology (IIT)   Gandhinagar; Indian Institute of Technology System
   (IIT System); Indian Institute of Technology (IIT)   Kharagpur; National
   University of Singapore; National University of Singapore; Center Life
   Science   NUS; Indian Institute of Technology System (IIT System);
   Indian Institute of Technology (IIT)   Kharagpur; National University of
   Singapore; National Institute of Technology (NIT System); National
   Institute of Technology Rourkela; Indian Institute of Technology System
   (IIT System); Indian Institute of Technology (IIT)   Gandhinagar; Indian
   Institute of Technology System (IIT System); Indian Institute of
   Technology (IIT)   Kharagpur
RP Banerjee, H (通讯作者)，Indian Inst Technol Gandhinagar, Dept Elect Engn, Gandhinagar 382355, Gujarat, India.; Banerjee, H (通讯作者)，Indian Inst Technol Kharagpur, Dept Mech Engn, Kharagpur 721302, W Bengal, India.; Banerjee, H; Ren, HL (通讯作者)，Natl Univ Singapore, Dept Biomed Engn, Fac Engn, 9 Engn Dr 1, Singapore 117575, Singapore.; Banerjee, H; Ren, HL (通讯作者)，Natl Univ Singapore, Ctr Life Sci, Singapore Inst Neurotechnol SINAPSE, 28 Med Dr,05 COR, Singapore 117456, Singapore.; Ren, HL (通讯作者)，Natl Univ Singapore Suzhou, Res Inst NUSRI, Suzhou, Jiangsu, Peoples R China.
EM biehb@nus.edu.sg; ren@nus.edu.sg
RI ; Chaudhury, Kaustav/I 7188 2018; Ren, Hongliang/N 9194 2017
OI Roy, Bibhas/0000 0003 1758 8675; Banerjee, Hritwick/0000 0003 2939 646X;
   Chaudhury, Kaustav/0000 0002 6595 4695; Ren,
   Hongliang/0000 0002 6488 1551
CR Alhadlaq A, 2004, STEM CELLS DEV, V13, P436, DOI 10.1089/scd.2004.13.436
   Artho PA, 2002, PHYS THER, V82, P257, DOI 10.1093/ptj/82.3.257
   Azuma Y, 2001, J BONE MINER RES, V16, P671, DOI 10.1359/jbmr.2001.16.4.671
   Baker KG, 2001, PHYS THER, V81, P1351, DOI 10.1093/ptj/81.7.1351
   Banerjee H, 2014, THESIS
   Banerjee H, 2013, MODELLING OPTIMIZATI
   Banerjee H, 2018, BIOMIMETICS BASEL, V3, DOI 10.3390/biomimetics3030015
   Bausch AR, 1998, BIOPHYS J, V75, P2038, DOI 10.1016/S0006 3495(98)77646 5
   Bose N, 2015, BIOMICROFLUIDICS, V9, DOI 10.1063/1.4928947
   Bruus H, 2012, LAB CHIP, V12, P1014, DOI 10.1039/c2lc21068a
   Cárdenas L, 2008, PLANT PHYSIOL, V146, P1611, DOI 10.1104/pp.107.113035
   Cermik D, 2001, J CLIN ENDOCR METAB, V86, P3387, DOI 10.1210/jc.86.7.3387
   Claes L, 2007, PROG BIOPHYS MOL BIO, V93, P384, DOI 10.1016/j.pbiomolbio.2006.07.021
   Daftary GS, 2006, ENDOCR REV, V27, P331, DOI 10.1210/er.2005 0018
   Das T, 2013, BIOMICROFLUIDICS, V7, DOI 10.1063/1.4789750
   Das T, 2011, INTEGR BIOL UK, V3, P684, DOI 10.1039/c1ib00001b
   Duck FA, 2007, PROG BIOPHYS MOL BIO, V93, P176, DOI 10.1016/j.pbiomolbio.2006.07.008
   El Ali J, 2006, NATURE, V442, P403, DOI 10.1038/nature05063
   Fávaro Pípi E, 2010, LASER MED SCI, V25, P727, DOI 10.1007/s10103 010 0772 2
   Feril LB, 2005, CANCER LETT, V221, P145, DOI 10.1016/j.canlet.2004.08.034
   Gebauer D, 2005, ULTRASOUND MED BIOL, V31, P1391, DOI 10.1016/j.ultrasmedbio.2005.06.002
   Hauser J, 2009, J ORTHOP RES, V27, P286, DOI 10.1002/jor.20741
   Hopkins PM, 2008, PRACTICAL ULTRASOUND
   Hu YX, 2014, ULTRASOUND MED BIOL, V40, P1587, DOI 10.1016/j.ultrasmedbio.2014.01.003
   Iwai T, 2007, J BONE MINER METAB, V25, P392, DOI 10.1007/s00774 007 0777 5
   Iwashina T, 2006, BIOMATERIALS, V27, P354, DOI 10.1016/j.biomaterials.2005.06.031
   Khan Y, 2008, J BONE JOINT SURG AM, V90A, P138, DOI 10.2106/JBJS.G.01218
   Kopechek JA, 2010, ULTRASOUND MED BIOL, V36, P1762, DOI 10.1016/j.ultrasmedbio.2010.05.020
   Krasovitski B, 2011, P NATL ACAD SCI USA, V108, P3258, DOI 10.1073/pnas.1015771108
   Leskinen JJ, 2012, ULTRASOUND MED BIOL, V38, P777, DOI 10.1016/j.ultrasmedbio.2012.01.019
   Li X, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.048102
   Lowry WE, 2010, J CELL SCI, V123, P643, DOI 10.1242/jcs.054304
   Maddala J, 2012, AICHE J, V58, P2120, DOI 10.1002/aic.12740
   Mahoney CM, 2009, J BIOL CHEM, V284, P8889, DOI 10.1074/jbc.M804281200
   de Albornoz PM, 2011, BRIT MED BULL, V100, P39, DOI 10.1093/bmb/ldr006
   Mettin R, 1997, PHYS REV E, V56, P2924, DOI 10.1103/PhysRevE.56.2924
   Miller DL, 2012, J ULTRAS MED, V31, P623, DOI 10.7863/jum.2012.31.4.623
   Mishra D., 2013, THESIS
   Mizrahi N, 2012, SOFT MATTER, V8, P2438, DOI 10.1039/c2sm07246g
   Mundi R, 2009, INDIAN J ORTHOP, V43, P132, DOI 10.4103/0019 5413.50847
   Noriega S, 2013, CELLS TISSUES ORGANS, V197, P14, DOI 10.1159/000339772
   Norvell SM, 2004, CALCIFIED TISSUE INT, V75, P396, DOI 10.1007/s00223 004 0213 y
   Pietak A, 2017, J R SOC INTERFACE, V14, DOI 10.1098/rsif.2017.0425
   Pounder NM, 2008, ULTRASONICS, V48, P330, DOI 10.1016/j.ultras.2008.02.005
   Roper J, 2012, JOVE J VIS EXP, DOI 10.3791/4024
   Saini V, 2011, ANN BIOMED ENG, V39, P378, DOI 10.1007/s10439 010 0156 6
   Santini MT, 2004, FEBS LETT, V557, P148, DOI 10.1016/S0014 5793(03)01466 2
   Schuster A, 2013, ANN ANAT, V195, P57, DOI 10.1016/j.aanat.2012.03.008
   Shaw A, 2008, ULTRASONICS, V48, P234, DOI 10.1016/j.ultras.2007.10.010
   Speed CA, 2001, RHEUMATOLOGY, V40, P1331, DOI 10.1093/rheumatology/40.12.1331
   Tabuchi Y, 2007, CANCER LETT, V246, P149, DOI 10.1016/j.canlet.2006.02.011
   Tan MK, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.024501
   ter Haar G, 2007, PROG BIOPHYS MOL BIO, V93, P111, DOI 10.1016/j.pbiomolbio.2006.07.005
   Van der Meer SM, 2004, ULTR S IEEE, V1, P2004
   Van Wamel A, 2004, ULTRASOUND MED BIOL, V30, P1255, DOI 10.1016/j.ultrasmedbio.2004.07.015
   Wang J, 2001, J BIOL CHEM, V276, P47763, DOI 10.1074/jbc.C100415200
   Ward T, 2008, BRIT J CANCER, V99, P841, DOI 10.1038/sj.bjc.6604519
   WELLS P N T, 1975, Ultrasound in Medicine and Biology, V1, P369, DOI 10.1016/0301 5629(75)90124 6
   Wood RW, 1927, PHILOS MAG, V4, P417
   Xing J, 2016, THESIS
   Yang L, 2008, BMC SYST BIOL, V2, DOI 10.1186/1752 0509 2 68
   YONEZAWA N, 1985, J BIOL CHEM, V260, P4410
   Yu HM, 2005, LAB CHIP, V5, P1089, DOI 10.1039/b504403k
   Zacherl M, 2009, ULTRASOUND MED BIOL, V35, P1290, DOI 10.1016/j.ultrasmedbio.2009.03.008
   Zhang S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038343
   Zhou SX, 2004, J BIOL CHEM, V279, P54463, DOI 10.1074/jbc.M404786200
   Zinin PV, 2009, PHYS REV E, V79, DOI 10.1103/PhysRevE.79.021910
   Zohar O, 1998, BIOPHYS J, V74, P82, DOI 10.1016/S0006 3495(98)77769 0
NR 68
TC 3
Z9 3
U1 0
U2 15
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D 69121 HEIDELBERG, GERMANY
SN 0140 0118
EI 1741 0444
J9 MED BIOL ENG COMPUT
JI Med. Biol. Eng. Comput.
PD APR
PY 2019
VL 57
IS 4
BP 819
EP 835
DI 10.1007/s11517 018 1908 y
PG 17
WC Computer Science, Interdisciplinary Applications; Engineering,
   Biomedical; Mathematical & Computational Biology; Medical Informatics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Computer Science; Engineering; Mathematical & Computational Biology;
   Medical Informatics
GA HS2UG
UT WOS:000463717500006
PM 30415434
DA 2025 08 17
ER

PT J
AU Sabandal, MMI
   Schäfer, E
   Aed, J
   Jung, S
   Kleinheinz, J
   Sielker, S
AF Sabandal, Martin Mariano Isabelo
   Schaefer, Edgar
   Aed, Jonathan
   Jung, Susanne
   Kleinheinz, Johannes
   Sielker, Sonja
TI Simvastatin induces adverse effects on proliferation and mineralization
   of human primary osteoblasts
SO HEAD & FACE MEDICINE
LA English
DT Article
DE Mineralization; Osteoblasts; Adverse effects; Simvastatin
ID MARROW STROMAL CELLS; DIFFERENTIATION; STATINS; MARKERS; FUTURE
AB Background Frequently statins were administered to reduce the LDL concentration in circulating blood. Especially simvastatin (SV) is an often prescribed statin. Pleiotropic effects of these drugs were reported. Thus, the aim of this study was to evaluate effects of SV on osteoblastic mineralization. Methods After informed consent primary osteoblasts were collected from tissue surplus after treatment of 14 individuals in the Department of Cranio Maxillofacial Surgery, University Hospital Munster. The cells were passaged according to established protocols. Viability, mineralization capability and osteoblastic marker (alkaline phosphatase) were determined at day 9, 13 and 16 after adding various SV concentrations (0.05 mu M, 0.1 mu M, 0.5 mu M, 1.0 mu M). Statistical analysis was performed using the Kruskal Wallis test. Results The cell cultures showed a time and dose dependent significantly decreased viability (p < 0.01) and a significantly increased mineralization (p < 0.01) in a late mineralization stage after adding SV. The typical alteration of the alkaline phosphatase (ALP) levels during osteogenic differentiation was not recognizable. Conclusions The pleiotropic effects found for different SV concentrations were possibly originated from other mineralization pathways beside the ALP induced one. Additionally, possible alterations of protein expression levels during mineralization and investigation of possible deviating application of SV in other treatment fields can be considered after gaining a deeper insight in the affected mechanisms.
C1 [Sabandal, Martin Mariano Isabelo; Schaefer, Edgar; Aed, Jonathan] Univ Munster, Sch Dent, Cent Interdisciplinary Ambulance, Albert Schweitzer Campus 1,Gebaude W30, D 48149 Munster, Germany.
   [Aed, Jonathan; Jung, Susanne; Kleinheinz, Johannes; Sielker, Sonja] Univ Hosp Munster, Dept Craniomaxillofacial Surg, Munster, Germany.
C3 University of Munster; University of Munster
RP Sabandal, MMI (通讯作者)，Univ Munster, Sch Dent, Cent Interdisciplinary Ambulance, Albert Schweitzer Campus 1,Gebaude W30, D 48149 Munster, Germany.
EM martin.sabandal@ukmuenster.de
RI ; Sielker, Sonja/ABG 2245 2022
OI Sabandal, Martin/0000 0001 6761 9535; 
CR Alghofaily M, 2018, J ENDODONT, V44, P1355, DOI 10.1016/j.joen.2018.06.013
   Allon I, 2014, J ORAL IMPLANTOL, V40, P251, DOI 10.1563/AAID JOI D 11 00222
   Annussek T, 2012, HEAD FACE MED, V8, DOI 10.1186/1746 160X 8 26
   Baek KH, 2005, J KOREAN MED SCI, V20, P438, DOI 10.3346/jkms.2005.20.3.438
   Chen PY, 2010, NUTR RES, V30, P191, DOI 10.1016/j.nutres.2010.03.004
   Chuang SC, 2013, EUR J PHARMACOL, V714, P74, DOI 10.1016/j.ejphar.2013.05.044
   Conte Neto N, 2011, HEAD FACE MED, V7, DOI 10.1186/1746 160X 7 7
   Dai LF, 2016, J BONE MINER METAB, V34, P23, DOI 10.1007/s00774 014 0638 y
   FAURANCLAVEL MJ, 1986, BONE, V7, P95, DOI 10.1016/8756 3282(86)90680 0
   Rosselli JEGC, 2014, ACTA CIR BRAS, V29, P87, DOI 10.1590/S0102 86502014000200003
   Goodman SB, 2007, J AM ACAD ORTHOP SUR, V15, P450, DOI 10.5435/00124635 200708000 00002
   Granéli C, 2014, STEM CELL RES, V12, P153, DOI 10.1016/j.scr.2013.09.009
   Gregory CA, 2004, ANAL BIOCHEM, V329, P77, DOI 10.1016/j.ab.2004.02.002
   Hadjidakis DJ, 2006, ANN NY ACAD SCI, V1092, P385, DOI 10.1196/annals.1365.035
   Hu Fei, 2009, Hua Xi Kou Qiang Yi Xue Za Zhi, V27, P313
   Illingworth DR, 2001, ADV PROTEIN CHEM, V56, P77
   Jitumori R, 2015, W INDIAN MED J, V64, P263, DOI 10.7727/wimj.2014.227
   Jung S, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0194467
   KARAYAN L, 1994, ARTERIOSCLER THROMB, V14, P1258, DOI 10.1161/01.ATV.14.8.1258
   Lee JB, 2016, MACROMOL BIOSCI, V16, P1027, DOI 10.1002/mabi.201500450
   Liu M, 2009, PHARMAZIE, V64, P43, DOI 10.1691/ph.2008.8671
   Liu ST, 2012, HUM CELL, V25, P29, DOI 10.1007/s13577 011 0028 x
   Liu XN, 2016, INT J NANOMED, V11, P6307, DOI 10.2147/IJN.S119520
   Maeda T, 2004, J CELL BIOCHEM, V92, P458, DOI 10.1002/jcb.20074
   Maeda T, 2001, BIOCHEM BIOPH RES CO, V280, P874, DOI 10.1006/bbrc.2000.4232
   Magan Fernandez A, 2018, J PERIODONTAL RES, V53, P91, DOI 10.1111/jre.12491
   Montazerolghaem M, 2016, J MATER SCI MATER M, V27, DOI 10.1007/s10856 015 5639 4
   Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946
   Najam O, 2015, CLIN LIPIDOL, V10, P481, DOI 10.2217/clp.15.40
   Oryan A, 2015, J CONTROL RELEASE, V215, P12, DOI 10.1016/j.jconrel.2015.07.022
   Pauly S, 2012, BMC MUSCULOSKEL DIS, V13, DOI 10.1186/1471 2474 13 208
   Rizzoli R, 2013, OSTEOPOROSIS INT, V24, P2929, DOI 10.1007/s00198 013 2530 3
   Seyhan N, 2016, J CRANIOFAC SURG, V27, P1367, DOI 10.1097/SCS.0000000000002728
   Siddiqui JA, 2016, PHYSIOLOGY, V31, P233, DOI 10.1152/physiol.00061.2014
   Sielker S, 2002, PREPRINT, DOI DOI 10.17504/PROTOCOLS.IO.MTEC6JE
   Sirtori CR, 2014, PHARMACOL RES, V88, P3, DOI 10.1016/j.phrs.2014.03.002
   Stone NJ, 2014, ANN INTERN MED, V160, P339, DOI 10.7326/M14 0126
   Tai IC, 2015, INT J NANOMED, V10, P5881, DOI 10.2147/IJN.S84273
   Titorencu I, 2007, CYTOTHERAPY, V9, P682, DOI 10.1080/14653240701561329
   Varela A, 2018, TOXICOL PATHOL, V46, P511, DOI 10.1177/0192623318779565
   Watts KL, 2005, AM J RESP CELL MOL, V32, P290, DOI 10.1165/rcmb.2004 0127OC
   Xie YH, 2018, DRUG DELIV TRANSL RE, V8, P1090, DOI 10.1007/s13346 018 0561 1
   Zhao BJ, 2014, FUND CLIN PHARMACOL, V28, P583, DOI 10.1111/fcp.12050
   Zhou YS, 2010, BIOMATERIALS, V31, P5325, DOI 10.1016/j.biomaterials.2010.03.037
NR 44
TC 10
Z9 10
U1 0
U2 12
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1746 160X
J9 HEAD FACE MED
JI Head Face Med.
PD AUG 20
PY 2020
VL 16
IS 1
AR 18
DI 10.1186/s13005 020 00232 4
PG 9
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA NK8PJ
UT WOS:000566992400001
PM 32819403
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Chang, JY
AF Chang, Jason Y.
TI Methylmercury induced IL 6 release requires phospholipase C activities
SO NEUROSCIENCE LETTERS
LA English
DT Article
DE Calcium; Cytokine; IL 6; Methylmercury; Phospholipase C
ID CEREBELLAR GRANULE NEURONS; OXIDATIVE STRESS; INTERLEUKIN 6 SYNTHESIS;
   14 PROSTAGLANDIN J(2); 15 DEOXY DELTA 12; HUMAN OSTEOBLASTS; NG108 15
   CELLS; METHYL MERCURY; ACTIVATION; A(2)
AB Methylmercury (MeHg) is a neurotoxin capable of causing severe damage to the CNS, especially in the developing fetus. Glia in the CNS release a number of cytokines that are important for proper CNS development and function. We reported earlier that MeHg could induce interleukin 6 (IL 6) release in primary mouse glia. This finding is significant considering previous reports indicating that sustained IL 6 exposure could be detrimental to cerebellar granule neurons, one of the major cellular targets of MeHg cytotoxicity. By using pharmacological antagonists against phophatidycholine  and phosphoinositol specific phospholipase C, the current study indicated that phospholipase C activity was necessary for MeHg induced IL 6 release. Results from pharmacological antagonists further suggested that the calcium signaling initiated by phospholipase C appeared essential for this event. In contrast, protein kinase C activity did not appear to be important. Even though mitogen activated protein kinases were important for IL 6 release in some experimental systems, these enzymes did not appear to be required for MeHg induced IL 6 release in glia. Based on these data and those reported by us and others, there is a possibility that MeHg induced phospholipase C activation initiates a calcium signaling that causes phospholipase A(2) activation. This, in turn, leads to arachidonic acid and lysophosphatidyl choline generation, both of which are potent inducers for IL 6 release. (C) 2011 Elsevier Ireland Ltd. All rights reserved.
C1 [Chang, Jason Y.] Univ Arkansas Med Sci, Coll Med, Dept Neurobiol & Dev Sci, Little Rock, AR 72205 USA.
   [Chang, Jason Y.] Univ Arkansas Med Sci, Coll Med, Dept Ophthalmol, Little Rock, AR 72205 USA.
C3 University of Arkansas System; University of Arkansas Medical Sciences;
   University of Arkansas System; University of Arkansas Medical Sciences
RP Chang, JY (通讯作者)，Univ Arkansas Med Sci, Coll Med, Dept Neurobiol & Dev Sci, Slot 510,4301 W Markham St, Little Rock, AR 72205 USA.
EM changjasony@uams.edu
RI Chang, Jason/P 7972 2019
FU Research to Prevent Blindness; NIH [NS047546]
FX This work was partially supported by funds from Research to Prevent
   Blindness. Technical support of Ms. Gail Wagner provided by a P30
   facility funded by the NIH (NS047546) was greatly appreciated.
CR Andrei C, 2004, P NATL ACAD SCI USA, V101, P9745, DOI 10.1073/pnas.0308558101
   Bootman MD, 2002, FASEB J, V16, DOI 10.1096/fj.02 0037rev
   Bordin L, 2003, BIOCHEMISTRY US, V42, P4485, DOI 10.1021/bi026842n
   Castoldi AF, 2000, J NEUROSCI RES, V59, P775, DOI 10.1002/(SICI)1097 4547(20000315)59:6<775::AID JNR10>3.0.CO;2 T
   Chang JY, 2007, NEUROSCI LETT, V416, P217, DOI 10.1016/j.neulet.2007.01.076
   Chang JY, 2009, NEUROSCI LETT, V461, P85, DOI 10.1016/j.neulet.2009.06.004
   Chang JY, 2008, NEUROTOXICOLOGY, V29, P1054, DOI 10.1016/j.neuro.2008.08.003
   Dong YS, 2001, GLIA, V36, P180, DOI 10.1002/glia.1107
   Edwards JR, 2005, TOXICOL APPL PHARM, V208, P222, DOI 10.1016/j.taap.2005.02.015
   Garg Tarun K., 2004, BMC Pharmacology, V4, P6, DOI 10.1186/1471 2210 4 6
   Garg TK, 2006, J NEUROIMMUNOL, V171, P17, DOI 10.1016/j.jneuroim.2005.09.007
   HARE MF, 1993, J PHARMACOL EXP THER, V266, P1626
   HARE MF, 1995, J PHARMACOL EXP THER, V272, P1016
   HOLLIDAY J, 1995, BRAIN RES, V673, P141, DOI 10.1016/0006 8993(94)01417 G
   Ihara H, 2005, BIOCHEM BIOPH RES CO, V326, P329, DOI 10.1016/j.bbrc.2004.11.037
   Kang MS, 2006, TOXICOL APPL PHARM, V216, P206, DOI 10.1016/j.taap.2006.04.016
   Kobayashi D, 2006, J PHARMACOL SCI, V102, P368, DOI 10.1254/jphs.FP0060669
   Kondo A, 2001, J INTERF CYTOK RES, V21, P943, DOI 10.1089/107999001753289550
   Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709
   Mazerik JN, 2007, INT J TOXICOL, V26, P553, DOI 10.1080/10915810701707759
   Monick MM, 1999, J IMMUNOL, V162, P3005
   Qiu ZH, 1998, J NEUROSCI, V18, P10445
   Rees DA, 2003, BRIT J PHARMACOL, V140, P764, DOI 10.1038/sj.bjp.0705488
   SARAFIAN TA, 1993, J NEUROCHEM, V61, P648
   Shanker G, 2002, MOL BRAIN RES, V106, P1, DOI 10.1016/S0169 328X(02)00403 5
   Snetkov VA, 2001, BRIT J PHARMACOL, V133, P243, DOI 10.1038/sj.bjp.0704076
   Spangelo BL, 1996, ENDOCRINOLOGY, V137, P4419, DOI 10.1210/en.137.10.4419
   Sun GY, 2005, MOL NEUROBIOL, V31, P27, DOI 10.1385/MN:31:1 3:027
   Tao FC, 2003, AM J PHYSIOL LUNG C, V284, pL90, DOI 10.1152/ajplung.00023.2002
   Venkatachalam K, 2002, NAT CELL BIOL, V4, pE263, DOI 10.1038/ncb1102 e263
   VERITY MA, 1994, J NEUROCHEM, V62, P705
NR 31
TC 9
Z9 9
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304 3940
EI 1872 7972
J9 NEUROSCI LETT
JI Neurosci. Lett.
PD JUN 8
PY 2011
VL 496
IS 3
BP 152
EP 156
DI 10.1016/j.neulet.2011.04.004
PG 5
WC Neurosciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Neurosciences & Neurology
GA 774TF
UT WOS:000291408800002
PM 21513770
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Bhuvanalakshmi, G
   Arfuso, F
   Kumar, AP
   Dharmarajan, A
   Warrier, S
AF Bhuvanalakshmi, G.
   Arfuso, Frank
   Kumar, Alan Prem
   Dharmarajan, Arun
   Warrier, Sudha
TI Epigenetic reprogramming converts human Wharton's jelly mesenchymal stem
   cells into functional cardiomyocytes by differential regulation of Wnt
   mediators
SO STEM CELL RESEARCH & THERAPY
LA English
DT Article
DE Mesenchymal stem cells; Epigenetic modification; Cardiomyocytes; DNA
   methyltransferase; Histone deacetylase; Wharton's jelly
ID OXIDE SIGNALING COMPONENTS; FRIZZLED RELATED PROTEIN 2; BONE MARROW;
   EXPRESSION; CARDIOMYOGENESIS; TRANSPLANTATION; MYOCARDIUM; APOPTOSIS;
   FIBROSIS; PATHWAY
AB Background: Lineage commitment of mesenchymal stem cells (MSCs) to cardiac differentiation is controlled by transcription factors that are regulated by epigenetic events, mainly histone deacetylation and promoter DNA methylation. Here, we studied the differentiation of human Wharton's jelly MSCs (WJMSCs) into the cardiomyocyte lineage via epigenetic manipulations.
   Methods: We introduced these changes using inhibitors of DNA methyl transferase and histone deacetylase, DC301, DC302, and DC303, in various combinations. We characterized for cardiogenic differentiation by assessing the expression of cardiac specific markers by immunolocalization, quantitative RT PCR, and flow cytometry. Cardiac functional studies were performed by FURA2AM staining and Greiss assay. The role of Wnt signaling during cardiac differentiation was analyzed by quantitative RT PCR. In vivo studies were performed in a doxorubicin induced cardiotoxic mouse model by injecting cardiac progenitor cells. Promoter methylation status of the cardiac transcription factor Nkx2.5 and the Wnt antagonist, secreted frizzled related protein 4 (sFRP4), after cardiac differentiation was studied by bisulfite sequencing.
   Results: By induction with DC301 and DC302, WJMSCs differentiated into cardiomyocyte like structures with an upregulation of Wnt antagonists, sFRP3 and sFRP4, and Dickkopf (Dkk) 1 and Dkk3. The cardiac function enhancer, vinculin, and DDX20, a DEAD box RNA helicase, were also upregulated in differentiated cardiomyocytes. Additionally, bisulfite sequencing revealed, for the first time in cardiogenesis, that sFRP4 is activated by promoter CpG island demethylation. In vivo, these MSC derived cardiac progenitors could not only successfully engraft to the site of cardiac injury in mice with doxorubicin induced cardiac injury, but also form functional cardiomyocytes and restore cardiac function.
   Conclusion: The present study unveils a link between Wnt inhibition and epigenetic modification to initiate cardiac differentiation, which could enhance the efficacy of stem cell therapy for ischemic heart disorders.
C1 [Bhuvanalakshmi, G.; Kumar, Alan Prem; Warrier, Sudha] Manipal Univ, Div Canc Stem Cells & Cardiovasc Regenerat, Manipal Inst Regenerat Med, Bangalore 560065, Karnataka, India.
   [Arfuso, Frank; Dharmarajan, Arun] Curtin Univ, Stem Cell & Canc Biol Lab, Sch Biomed Sci, Curtin Hlth Innovat Res Inst, Perth, WA 6845, Australia.
   [Arfuso, Frank] Univ Western Australia, Sch Anat Physiol & Human Biol, Fac Sci, 35 Stirling Highway, Crawley, WA 6009, Australia.
   [Kumar, Alan Prem] Natl Univ Singapore, Canc Sci Inst Singapore, Singapore 117599, Singapore.
   [Kumar, Alan Prem] Natl Univ Singapore, Dept Pharmacol, Yong Loo Lin Sch Med, Singapore 117597, Singapore.
   [Kumar, Alan Prem; Warrier, Sudha] Curtin Univ, Sch Biomed Sci, Curtin Hlth Innovat Res Inst, Perth, WA 6102, Australia.
   [Kumar, Alan Prem] Natl Univ Singapore, Canc Inst, Singapore 119074, Singapore.
   [Kumar, Alan Prem] Univ North Texas, Dept Biol Sci, Denton, TX 76203 USA.
   [Warrier, Sudha] Curtin Univ, Curtin Med Sch, Fac Hlth Sci, Perth, WA 6875, Australia.
C3 Manipal Academy of Higher Education (MAHE); Curtin University;
   University of Western Australia; National University of Singapore;
   National University of Singapore; Curtin University; National University
   of Singapore; University of North Texas System; University of North
   Texas Denton; Curtin University
RP Warrier, S (通讯作者)，Manipal Univ, Div Canc Stem Cells & Cardiovasc Regenerat, Manipal Inst Regenerat Med, Bangalore 560065, Karnataka, India.; Warrier, S (通讯作者)，Curtin Univ, Sch Biomed Sci, Curtin Hlth Innovat Res Inst, Perth, WA 6102, Australia.; Warrier, S (通讯作者)，Curtin Univ, Curtin Med Sch, Fac Hlth Sci, Perth, WA 6875, Australia.
EM sudha.warrier@manipal.edu
RI Arfuso, Frank/H 8761 2014; Kumar, Alan/ABE 7492 2020
OI Arfuso, Frank/0000 0001 7678 9472; Dharmarajan,
   Arun/0000 0002 6715 6005; 
FU Department of Biotechnology, India [BT/PR9235/MED/31/258/2014]
FX This work was supported partly by funding from the Department of
   Biotechnology, India (No. BT/PR9235/MED/31/258/2014) for SW.
CR Ahuja P, 2007, PHYSIOL REV, V87, P521, DOI 10.1152/physrev.00032.2006
   Andrée B, 1998, MECH DEVELOP, V70, P119, DOI 10.1016/S0925 4773(97)00186 X
   Bhuvanalakshmi G, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127517
   Bhuvanalakshmi G, 2014, STEM CELL REV REP, V10, P856, DOI 10.1007/s12015 014 9530 3
   Bloch W, 1999, CARDIOVASC RES, V43, P675, DOI 10.1016/S0008 6363(99)00160 1
   Brade T, 2006, CARDIOVASC RES, V72, P198, DOI 10.1016/j.cardiores.2006.06.025
   Bullock GR, 1982, TECHNIQUES IMMUNOCYT, pv
   Callis TE, 2005, CIRC RES, V97, P992, DOI 10.1161/01.RES.0000190670.92879.7d
   Castro Manrreza ME, 2014, STEM CELLS DEV, V23, P1217, DOI 10.1089/scd.2013.0363
   Cherry ABC, 2013, ANNU REV MED, V64, P277, DOI 10.1146/annurev med 050311 163324
   Clifford DM, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006536.pub3
   Dai WD, 2005, CIRCULATION, V112, P214, DOI 10.1161/CIRCULATIONAHA.104.527937
   Daskalopoulos EP, 2013, TRENDS CARDIOVAS MED, V23, P121, DOI 10.1016/j.tcm.2012.09.010
   David R, 2008, NAT CELL BIOL, V10, P338, DOI 10.1038/ncb1696
   Desai VG, 2013, TOXICOL APPL PHARM, V266, P109, DOI 10.1016/j.taap.2012.10.025
   Fu JD, 2006, ACTA PHARMACOL SIN, V27, P901, DOI 10.1111/j.1745 7254.2006.00380.x
   Gibb N, 2013, DEVELOPMENT, V140, P1537, DOI 10.1242/dev.088047
   Gorji SM, 2012, CELL J, V14, P142
   He W, 2010, P NATL ACAD SCI USA, V107, P21110, DOI 10.1073/pnas.1004708107
   Horrillo A, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.88
   Hsieh JY, 2010, STEM CELLS DEV, V19, P1895, DOI 10.1089/scd.2009.0485
   Jaspard B, 2000, MECH DEVELOP, V90, P263, DOI 10.1016/S0925 4773(99)00236 1
   Jost E, 2008, BRIT J HAEMATOL, V142, P745, DOI 10.1111/j.1365 2141.2008.07242.x
   Karamboulas C, 2006, J CELL SCI, V119, P4305, DOI 10.1242/jcs.03185
   Kaushik G, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa5843
   Kawamura T, 2005, J BIOL CHEM, V280, P19682, DOI 10.1074/jbc.M412428200
   Kitagawa H, 2011, ENDOCR J, V58, P77, DOI 10.1507/endocrj.K10E 393
   Klappacher GW, 2002, CELL, V109, P169, DOI 10.1016/S0092 8674(02)00714 6
   Kobayashi K, 2009, NAT CELL BIOL, V11, P46, DOI 10.1038/ncb1811
   Kogata N, 2006, CIRC RES, V98, P897, DOI 10.1161/01.RES.0000218193.51136.ad
   Laeremans H, 2011, CIRCULATION, V124, P1626, DOI 10.1161/CIRCULATIONAHA.110.976969
   Layman WS, 2010, CLIN GENET, V78, P11, DOI 10.1111/j.1399 0004.2010.01446.x
   Lian XJ, 2012, P NATL ACAD SCI USA, V109, pE1848, DOI 10.1073/pnas.1200250109
   LINTS TJ, 1993, DEVELOPMENT, V119, P969
   Liu ZQ, 2009, BBA MOL CELL RES, V1793, P300, DOI 10.1016/j.bbamcr.2008.08.013
   Mangi AA, 2003, NAT MED, V9, P1195, DOI 10.1038/nm912
   Matsushima K, TISSUE ENG A
   Mias C, 2009, STEM CELLS, V27, P2734, DOI 10.1002/stem.169
   Mouillet JF, 2008, ENDOCRINOLOGY, V149, P2168, DOI 10.1210/en.2007 1237
   Mozaffarian D, 2015, CIRCULATION, V131, pE29, DOI 10.1161/CIR.0000000000000152
   Mujoo K, 2006, STEM CELLS DEV, V15, P779, DOI 10.1089/scd.2006.15.779
   Mujoo K, 2008, P NATL ACAD SCI USA, V105, P18924, DOI 10.1073/pnas.0810230105
   Naito AT, 2006, P NATL ACAD SCI USA, V103, P19812, DOI 10.1073/pnas.0605768103
   Nimura K, 2009, NATURE, V460, P287, DOI 10.1038/nature08086
   Oh H, 2003, P NATL ACAD SCI USA, V100, P12313, DOI 10.1073/pnas.2132126100
   Ordovás JM, 2010, NAT REV CARDIOL, V7, P510, DOI 10.1038/nrcardio.2010.104
   Rice KL, 2007, ONCOGENE, V26, P6697, DOI 10.1038/sj.onc.1210755
   Schiefer L, 2014, CANCER GENE THER, V21, P297, DOI 10.1038/cgt.2014.30
   Senyo SE, 2013, NATURE, V493, P433, DOI 10.1038/nature11682
   Spallotta F, 2010, STEM CELLS, V28, P431, DOI 10.1002/stem.300
   Tomita S, 1999, CIRCULATION, V100, P247, DOI 10.1161/01.cir.100.suppl_2.ii 247
   Tzahor E, 2007, DEV CELL, V13, P10, DOI 10.1016/j.devcel.2007.06.006
   van Weerd JH, 2011, CARDIOVASC RES, V91, P203, DOI 10.1093/cvr/cvr138
   Vecellio M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051694
   Viola HM, 2007, CIRC RES, V100, P1036, DOI 10.1161/01.RES.0000263010.19273.48
   Wamstad JA, 2012, CELL, V151, P206, DOI 10.1016/j.cell.2012.07.035
   Wang HS, 2004, STEM CELLS, V22, P1330, DOI 10.1634/stemcells.2004 0013
   Warrier S, 2014, CANCER GENE THER, V21, P381, DOI 10.1038/cgt.2014.42
   Warrier S, 2012, PLACENTA, V33, P850, DOI 10.1016/j.placenta.2012.07.001
   Willems E, 2011, CIRC RES, V109, P360, DOI 10.1161/CIRCRESAHA.111.249540
   Zhang S, 2012, NAT MED, V18, P1639, DOI 10.1038/nm.2919
NR 61
TC 35
Z9 36
U1 1
U2 14
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1757 6512
J9 STEM CELL RES THER
JI Stem Cell Res. Ther.
PD AUG 14
PY 2017
VL 8
AR 185
DI 10.1186/s13287 017 0638 7
PG 15
WC Cell & Tissue Engineering; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA FD7QN
UT WOS:000407720700003
PM 28807014
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Cai, C
   Yuan, GJ
   Huang, Y
   Yang, N
   Chen, X
   Wen, L
   Wang, X
   Zhang, L
   Ding, Y
AF Cai, Chuan
   Yuan, Gong Jie
   Huang, Ye
   Yang, Nan
   Chen, Xin
   Wen, Li
   Wang, Xi
   Zhang, Liang
   Ding, Yin
TI Estrogen related receptor α is involved in the osteogenic
   differentiation of mesenchymal stem cells isolated from human
   periodontal ligaments
SO INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
LA English
DT Article
DE estrogen related receptor alpha; osteogenic differentiation; mesenchymal
   stem cells; periodontal ligament
ID ERR ALPHA; OSTEOBLAST DIFFERENTIATION; IN VITRO; BONE; CANCER; GENE;
   BETA
AB Recently, it has been reported that the orphan nuclear receptor estrogen related receptor a (ERRa) is involved in the osteogenic differentiation of mesenchymal stem cells (MSCs). Moreover, ERRa has been identified as a novel therapeutic target for treating osteoporosis and other bone diseases. Human periodontal ligament tissue derived mesenchymal stem cells (hPDLSCs) have recently been used in stem cell mediated therapies because of their multipotency, particularly toward osteogenic differentiation. However, it is still unclear whether ERRa can regulate the osteogenic differentiation of hPDLSCs. In the present study, we investigated the role of ERRa in the osteogenic differentiation of hPDLSCs in vitro. We isolated hPDLSCs and confirmed their capacity for multipotent differentiation. Furthermore, we examined ERRa expression in hPDLSCs by RT PCR and immunocytochemistry. We found that the expression of ERRa mRNA was significantly increased during the late stage of osteogenic differentiation of hPDLSCs. Moreover, transfection of recombinant lentiviral mediated miRNA targeting ERRa significantly suppressed ALP activity, mineralization capacity, and the mRNA expression of osteogenesis related genes (ALP, OCN, RUNX2 and OPN) in hPDLSCs. Our results indicate that ERRa may promote the osteogenic differentiation of hPDLSCs in vitro.
C1 [Cai, Chuan; Yuan, Gong Jie; Yang, Nan; Chen, Xin; Wen, Li; Wang, Xi; Zhang, Liang; Ding, Yin] Fourth Mil Med Univ, Sch Stomatol, Dept Orthodont, Xian 710032, Peoples R China.
   [Yuan, Gong Jie] Dalian Stomatol Hosp, Dept Orthodont, Dalian 116002, Peoples R China.
   [Huang, Ye] AF, Inst Aviat Med, Affiliated Hosp, Beijing 100089, Peoples R China.
   [Huang, Ye] AF, Dept Dermatol, Gen Hosp, Beijing 100142, Peoples R China.
   [Yang, Nan] PLA 309th Hosp, Dept Stomatol, Beijing 100091, Peoples R China.
   [Chen, Xin] Chinese PLA, Dept Gen Dent, Hosp 174, Xiamen 361003, Peoples R China.
C3 Air Force Medical University
RP Ding, Y (通讯作者)，Fourth Mil Med Univ, Sch Stomatol, Dept Orthodont, 145 West Changle Rd, Xian 710032, Peoples R China.
EM yin.ding@hotmail.com
RI Yang, Nan/ABD 1792 2020
FU Nature Science Foundation of China [30872913]
FX This study was supported by the Nature Science Foundation of China
   (grant 30872913). We thank Dr Jiaxing Zhou for generously providing the
   MCF 7 cell line. We also acknowledge Professor Hui Xu for critical
   reading of the manuscript.
CR Ariazi EA, 2006, CURR TOP MED CHEM, V6, P203, DOI 10.2174/1568026610606030203
   Auld KL, 2012, J MOL ENDOCRINOL, V48, P177, DOI 10.1530/JME 11 0140
   Bianco S, 2009, J BIOL CHEM, V284, P23286, DOI 10.1074/jbc.M109.028191
   Bonnelye E, 2008, RHEUMATOLOGY, V47, P1785, DOI 10.1093/rheumatology/ken368
   Bonnelye E, 2002, J BONE MINER RES, V17, P1392, DOI 10.1359/jbmr.2002.17.8.1392
   Bonnelye E, 2005, J CLIN ENDOCR METAB, V90, P3115, DOI 10.1210/jc.2004 2168
   Bonnelye E, 1997, MOL ENDOCRINOL, V11, P905, DOI 10.1210/me.11.7.905
   Bonnelye E, 2001, J CELL BIOL, V153, P971, DOI 10.1083/jcb.153.5.971
   Bonnelye E, 2010, J MOL ENDOCRINOL, V45, P365, DOI 10.1677/JME 10 0024
   Castet A, 2006, MOL ENDOCRINOL, V20, P1035, DOI 10.1210/me.2005 0227
   Chadipiralla K, 2010, CELL TISSUE RES, V340, P323, DOI 10.1007/s00441 010 0953 0
   Delhon I, 2009, ENDOCRINOLOGY, V150, P4463, DOI 10.1210/en.2009 0121
   Fujimoto J, 2009, J STEROID BIOCHEM, V116, P71, DOI 10.1016/j.jsbmb.2009.04.012
   Gallet M, 2010, TRENDS ENDOCRIN MET, V21, P637, DOI 10.1016/j.tem.2010.06.008
   Geurs NC, 2007, PERIODONTOL 2000, V44, P29, DOI 10.1111/j.1600 0757.2006.00194.x
   GIGUERE V, 1988, NATURE, V331, P91, DOI 10.1038/331091a0
   Hassell TM, 2005, COLOR ATLAS DENT MED
   Huss JM, 2004, MOL CELL BIOL, V24, P9079, DOI 10.1128/MCB.24.20.9079 9091.2004
   Komori T, 2010, CELL TISSUE RES, V339, P189, DOI 10.1007/s00441 009 0832 8
   Liang L, 2008, ARCH ORAL BIOL, V53, P553, DOI 10.1016/j.archoralbio.2007.12.011
   Liu GZ, 2009, J CELL BIOL, V185, P67, DOI 10.1083/jcb.200810137
   Liu YL, 2011, STEM CELLS, V29, P1804, DOI 10.1002/stem.728
   Liu Y, 2008, STEM CELLS, V26, P1065, DOI 10.1634/stemcells.2007 0734
   Lu DS, 2001, CANCER RES, V61, P6755
   Luo JM, 2003, MOL CELL BIOL, V23, P7947, DOI 10.1128/MCB.23.22.7947 7956.2003
   Pan F, 2011, BIOSCIENCE REP, V31, P117, DOI 10.1042/BSR20100029
   Rajalin AM, 2010, BIOCHEM BIOPH RES CO, V396, P477, DOI 10.1016/j.bbrc.2010.04.120
   Seo BM, 2004, LANCET, V364, P149, DOI 10.1016/S0140 6736(04)16627 0
   Sladek R, 1997, MOL CELL BIOL, V17, P5400, DOI 10.1128/MCB.17.9.5400
   Teyssier C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007942
   Trubiani O, 2008, J BIOMED MATER RES A, V87A, P986, DOI 10.1002/jbm.a.31837
   Vanacker JM, 1998, CELL GROWTH DIFFER, V9, P1007
   Vanacker JM, 1999, MOL ENDOCRINOL, V13, P764, DOI 10.1210/me.13.5.764
   Villena JA, 2007, P NATL ACAD SCI USA, V104, P1418, DOI 10.1073/pnas.0607696104
NR 34
TC 19
Z9 24
U1 0
U2 23
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1107 3756
J9 INT J MOL MED
JI Int. J. Mol. Med.
PD MAY
PY 2013
VL 31
IS 5
BP 1195
EP 1201
DI 10.3892/ijmm.2013.1305
PG 7
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA 131MF
UT WOS:000317997100025
PM 23525223
OA Bronze
DA 2025 08 17
ER

PT J
AU Yang, YR
   Chen, DY
   Li, YL
   Zou, JH
   Han, RQ
   Li, HK
   Zhang, J
AF Yang, Yanran
   Chen, Daiyun
   Li, Yilin
   Zou, Jinghua
   Han, Ruiqi
   Li, Hongkun
   Zhang, Jun
TI Effect of Puerarin on Osteogenic Differentiation in vitro and on New
   Bone Formation in vivo
SO DRUG DESIGN DEVELOPMENT AND THERAPY
LA English
DT Article
DE bone marrow derived mesenchymal stem cells; bone regeneration; micro CT;
   rapid maxillary expansion
ID RAPID MAXILLARY EXPANSION; MIDPALATAL SUTURE; PC12 CELLS; EXPRESSION;
   COLLAGEN; REGENERATION; INHIBITION; ACTIVATION; PATHWAYS; LASER
AB Purpose: Puerarin (C21H20O10) is a phytoestrogen that possesses various pharmacological effect, and several researches have revealed the relationship between puerarin and bone metabolism. This study was aimed to evaluate the potential influence of puerarin on the proliferation and osteogenic differentiation of rat bone marrow derived mesenchymal stem cells (BMSCs) as well as on new bone formation following rapid maxillary expansion (RME) model in rats. Methods: Rat BMSCs were adopted, and the cell proliferation was detected by cell counting kit 8 (CCK 8) assay in vitro experiments. Alkaline phosphatase (ALP) activity and alizarin red staining were analyzed quantitatively to show extracellular matrix mineralization. The mRNA and protein expression levels were used to detect osteogenic differentiation of BMSCs. In vivo bone regeneration was analyzed in a rat RME model. Eighteen 6 week old male Wistar rats were divided into 3 groups: group 1 without any treatment, group 2 received RME and saline solution (15mg/kg), group 3 received RME and puerarin solution (15mg/kg). After 2 weeks, micro computed tomography (Micro CT), hematoxylin and eosin (HE) staining, and Masson staining were used to detect the new bone formation and morphological changes. Besides, ALP and bone morphogenetic protein 2 (BMP2) expression levels in mid palatal suture were evaluated by immunohistochemical staining. Results: The results showed that puerarin upregulates cell proliferation dose dependently. ALP activity and mineralized matrix generation were clearly enhanced at certain specific concentrations (10 5 and 10 6 mol/L); the expression levels of the osteoblast related genes and proteins were increased. The measurement of micro CT imaging revealed that puerarin significantly promoted new bone formation. Concomitantly, the histological examinations showed that puerarin solution enhanced osteogenesis in mid palatal suture. Conclusion: Those works indicated that puerarin regulates osteogenesis in vitro and exerts a beneficial impact on bone regeneration in vivo, revealing that puerarin treatment may become one of the potential keys for improving the stability and preventing relapse of RME.
C1 [Yang, Yanran; Li, Yilin; Zou, Jinghua; Han, Ruiqi; Li, Hongkun; Zhang, Jun] Shandong Univ, Jinan, Peoples R China.
   [Yang, Yanran; Li, Yilin; Zou, Jinghua; Han, Ruiqi; Li, Hongkun; Zhang, Jun] Shandong Univ, Sch & Hosp Stomatol, Cheeloo Coll Med, Shandong Key Lab Oral Tissue Regenerat,Dept Orthod, Jinan, Peoples R China.
   [Yang, Yanran; Li, Yilin; Zou, Jinghua; Han, Ruiqi; Li, Hongkun; Zhang, Jun] Shandong Univ, Sch & Hosp Stomatol, Cheeloo Coll Med, Shandong Engn Lab Dent Mat & Oral Tissue Regenerat, Jinan, Peoples R China.
   [Chen, Daiyun] Shandong First Med Univ, Sch Stomatol, Dept Orthodont, Jinan, Peoples R China.
C3 Shandong University; Shandong University; Shandong University; Shandong
   First Medical University & Shandong Academy of Medical Sciences
RP Zhang, J (通讯作者)，Shandong Univ, Jinan, Peoples R China.; Zhang, J (通讯作者)，Shandong Univ, Sch & Hosp Stomatol, Cheeloo Coll Med, Shandong Key Lab Oral Tissue Regenerat,Dept Orthod, Jinan, Peoples R China.; Zhang, J (通讯作者)，Shandong Univ, Sch & Hosp Stomatol, Cheeloo Coll Med, Shandong Engn Lab Dent Mat & Oral Tissue Regenerat, Jinan, Peoples R China.
EM zhangj@sdu.edu.cn
FU Natural Science Foundation of Shandong Province, China [ZR2021QH340]
FX Acknowledgments This work was supported by the Natural Science
   Foundation of Shandong Province, China (No. ZR2021QH340) .
CR Akhir HM, 2020, BIOSCIENCE REP, V40, DOI 10.1042/BSR20201325
   Almalki SG, 2016, DIFFERENTIATION, V92, P41, DOI 10.1016/j.diff.2016.02.005
   Arai Y, 2021, ACTA BIOMATER, V125, P219, DOI 10.1016/j.actbio.2021.02.042
   ARONSON J, 1994, CLEFT PALATE CRAN J, V31, P473, DOI 10.1597/1545 1569(1994)031<0473:EACEWD>2.3.CO;2
   Arvystas MG, 1998, AM J ORTHOD DENTOFAC, V113, P15, DOI 10.1016/S0889 5406(98)70271 9
   Berebichez Fridman Roberto, 2018, Sultan Qaboos Univ Med J, V18, pe264, DOI 10.18295/squmj.2018.18.03.002
   Berendsen AD, 2015, BONE, V80, P14, DOI 10.1016/j.bone.2015.04.035
   Birlik M, 2016, J OROFAC ORTHOP, V77, P94, DOI 10.1007/s00056 016 0021 9
   Bo J, 2005, NEUROSCI RES, V53, P183, DOI 10.1016/j.neures.2005.06.014
   Brown C, 2019, J TISSUE ENG REGEN M, V13, P1738, DOI 10.1002/term.2914
   Canan S, 2017, AM J ORTHOD DENTOFAC, V151, P1125, DOI 10.1016/j.ajodo.2016.11.022
   Cesur MG, 2018, ORTHOD CRANIOFAC RES, V21, P160, DOI 10.1111/ocr.12232
   Chatterjee M, 2017, INT J ORAL SCI, V9, P87, DOI 10.1038/ijos.2017.11
   Chuang LSH, 2013, INT J CANCER, V132, P1260, DOI 10.1002/ijc.27964
   DASILVA OG, 1991, AM J ORTHOD DENTOFAC, V100, P171
   Dey D, 2017, TRANSL RES, V186, P95, DOI 10.1016/j.trsl.2017.06.004
   Diomede F, 2020, MATERIALS, V13, DOI 10.3390/ma13030706
   Duan PP, 2016, INT J BIOCHEM CELL B, V77, P23, DOI 10.1016/j.biocel.2016.05.015
   Evans KN, 2014, CLIN ORTHOP RELAT R, V472, P396, DOI 10.1007/s11999 013 3325 8
   Fu J, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287 021 02456 w
   Gugliandolo A, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22105236
   HARRIS H, 1990, CLIN CHIM ACTA, V186, P133, DOI 10.1016/0009 8981(90)90031 M
   HICKS EP, 1978, AM J ORTHOD DENTOFAC, V73, P121, DOI 10.1016/0002 9416(78)90183 5
   Ferreira FNH, 2016, LASER MED SCI, V31, P907, DOI 10.1007/s10103 016 1933 8
   Hu XL, 2021, CELL MOL BIOL LETT, V26, DOI 10.1186/s11658 021 00277 6
   ILIZAROV G A, 1969, Eksperimental'naya Khirurgiya i Anesteziologiya, V14, P27
   Kloen P, 2012, BONE, V51, P59, DOI 10.1016/j.bone.2012.03.032
   Lee OH, 2010, BIOFACTORS, V36, P459, DOI 10.1002/biof.119
   Li H, 2016, PHARM BIOL, V54, P111, DOI 10.3109/13880209.2015.1017885
   Li J, 2019, CHEM BIOL INTERACT, V297, P85, DOI 10.1016/j.cbi.2018.10.018
   Lima AL, 2005, ANGLE ORTHOD, V75, P416
   Lin SF, 2020, BIOSCI BIOTECH BIOCH, V84, P1455, DOI 10.1080/09168451.2020.1738912
   Linsley C, 2013, TISSUE ENG PT A, V19, P1416, DOI [10.1089/ten.TEA.2012.0523, 10.1089/ten.tea.2012.0523]
   Moser SC, 2019, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00794
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Percival CJ, 2013, DEV DYNAM, V242, P909, DOI 10.1002/dvdy.23992
   Rosa CB, 2017, LASER MED SCI, V32, P263, DOI 10.1007/s10103 016 2108 3
   Sailhan F, 2011, OSTEOPOROSIS INT, V22, P2011, DOI 10.1007/s00198 011 1613 2
   Sato M, 1998, J BONE MINER RES, V13, P1221, DOI 10.1359/jbmr.1998.13.8.1221
   SCHENDEL SA, 1976, AM J ORTHOD DENTOFAC, V70, P398, DOI 10.1016/0002 9416(76)90112 3
   Seibel Markus J, 2005, Clin Biochem Rev, V26, P97
   Sen B, 2020, J BONE MINER RES, V35, P1149, DOI 10.1002/jbmr.3975
   Shen GY, 2020, EBIOMEDICINE, V52, DOI 10.1016/j.ebiom.2020.102626
   Sheu SY, 2012, CHINESE MED J PEKING, V125, P3646, DOI 10.3760/cma.j.issn.0366 6999.2012.20.009
   STARNBACH H, 1966, ANGLE ORTHOD, V36, P152
   Sun XH, 2007, J PHARMACOL EXP THER, V323, P391, DOI 10.1124/jpet.107.125567
   Takigawa M, 2013, J CELL COMMUN SIGNAL, V7, P191, DOI 10.1007/s12079 013 0204 8
   Tatullo M, 2015, INT J MED SCI, V12, P72, DOI 10.7150/ijms.10706
   Tiyasatkulkovit W, 2014, PHYTOMEDICINE, V21, P1498, DOI 10.1016/j.phymed.2014.06.019
   Uysal T, 2011, J OROFAC ORTHOP, V72, P290, DOI 10.1007/s00056 011 0034 3
   Vasanthan J, 2021, CELLS BASEL, V10, DOI 10.3390/cells10010054
   Wang PP, 2012, J ASIAN NAT PROD RES, V14, P897, DOI 10.1080/10286020.2012.702757
   Wang YY, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 03899 z
   Wong R, 2007, OSTEOARTHR CARTILAGE, V15, P894, DOI 10.1016/j.joca.2007.02.009
   Xiao L, 2020, AGING US, V12, P21706, DOI 10.18632/aging.103976
   Yang Shuo, 2009, Zhongguo Zhong Xi Yi Jie He Za Zhi, V29, P707
   Yang X, 2017, CURR MOL MED, V17, P488, DOI 10.2174/1566524018666171219101142
   Zhang J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035736
   Zhang Q, 2012, CELL BIOL INT, V36, P419, DOI 10.1042/CBI20100900
   Zhang Y, 2019, BIOMED PHARMACOTHER, V109, P726, DOI 10.1016/j.biopha.2018.10.161
   Zhang Y, 2007, PLANTA MED, V73, P341, DOI 10.1055/s 2007 967168
   Zhang Y, 2016, BIOL PHARM BULL, V39, P2028, DOI 10.1248/bpb.b16 00522
   Zhao SY, 2015, DRUG DES DEV THER, V9, P2725, DOI 10.2147/DDDT.S82892
   Zhou YX, 2014, PHYTOTHER RES, V28, P961, DOI 10.1002/ptr.5083
   Zhou Y, 2020, INT J MOL MED, V46, P239, DOI 10.3892/ijmm.2020.4595
   ZIMRING J F, 1965, Angle Orthod, V35, P178
   Ziros PG, 2008, INT J BIOCHEM CELL B, V40, P1659, DOI 10.1016/j.biocel.2007.05.024
   Zou Y, 2013, FREE RADICAL RES, V47, P55, DOI 10.3109/10715762.2012.742518
NR 68
TC 15
Z9 17
U1 4
U2 23
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300 008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1177 8881
J9 DRUG DES DEV THER
JI Drug Des. Dev. Ther.
PY 2022
VL 16
BP 2885
EP 2900
DI 10.2147/DDDT.S379794
PG 16
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 5Y7EU
UT WOS:000879444700001
PM 36060929
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Coulibaly, MO
   Sietsema, DL
   Burgers, TA
   Mason, J
   Williams, BO
   Jones, CB
AF Coulibaly, Marlon O.
   Sietsema, Debra L.
   Burgers, Travis A.
   Mason, Jim
   Williams, Bart O.
   Jones, Clifford B.
TI Recent Advances in the Use of Serological Bone Formation Markers to
   Monitor Callus Development and Fracture Healing
SO CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION
LA English
DT Article
DE procollagen type I amino terminal propeptide (PINP); fracture healing;
   non union; collagen synthesis; bone metabolic marker; bone turnover
   marker
ID AMINO TERMINAL PROPEPTIDE; PROCOLLAGEN N PROTEINASE; MATRIX GLA PROTEIN;
   GAMMA CARBOXYGLUTAMIC ACID; TIBIAL SHAFT FRACTURES;
   EHLERS DANLOS SYNDROME; OSTEOBLAST LIKE CELLS; POSTMENOPAUSAL WOMEN;
   BIOCHEMICAL MARKERS; ALKALINE PHOSPHATASE
AB The failure of an osseous fracture to heal, or the development of a nonunion, is common; however, current diagnostic measures lack the capability of early and reliable detection of such events. Analyses of radiographic imaging and clinical examination, in combination, remain the gold standard for diagnosis; however, these methods are not reliable for early detection. Delayed diagnosis of a nonunion is costly from both the patient and treatment standpoints. In response, repeated efforts have been made to identify bone metabolic markers as diagnostic or prognostic tools for monitoring bone healing. Thus far, the evidence regarding a correlation between the kinetics of most bone metabolic markers and nonunion is very limited. With the aim of classifying the role of biological pathways of bone metabolism and of understanding bone conditions in the development of osteoporosis, advances have been made in our knowledge of the molecular basis of bone remodeling, fracture healing, and its failure. Procollagen type I amino terminal propeptide has been shown to be a reliable bone formation marker in osteoporosis therapy and its kinetics during fracture healing has been recently described. In this article, we suggest that procollagen type I amino terminal propeptide presents a good opportunity for early detection of nonunion. We also review the role and potential of serum PINP, as well as other markers, as indications of fracture healing.
C1 [Sietsema, Debra L.; Jones, Clifford B.] Orthopaed Associates Michigan, Grand Rapids, MI USA.
   [Sietsema, Debra L.; Jones, Clifford B.] Michigan State Univ, Grand Rapids, MI USA.
   [Sietsema, Debra L.; Burgers, Travis A.; Mason, Jim; Williams, Bart O.; Jones, Clifford B.] Van Andel Res Inst, Ctr Skeletal Dis Res, Grand Rapids, MI USA.
   [Coulibaly, Marlon O.] Grand Rapids Med Educ & Res Ctr, Grand Rapids, MI USA.
C3 Michigan State University; Van Andel Institute; Van Andel Research
   Institute; Michigan State University; Michigan State University Hospital
RP Jones, CB (通讯作者)，Orthopaed Associates Michigan, Grand Rapids, MI USA.
EM cbjones@oamichigan.com
RI ; Williams, Bart/A 3539 2013
OI Williams, Bart/0000 0002 5261 5301; Burgers, Travis/0000 0002 4912 6136
FU NIAMS/NIH [AR053292]; Grand Rapids Medical Education and Research
   Center; Van Andel Research Institute
FX We thank David Nadziejka for assistance with editing this manuscript.
   Bart O.Williams is supported by a grant from NIAMS/NIH (AR053292).
   Marlon O. Coulibaly is supported by the Grand Rapids Medical Education
   and Research Center. All authors thank the Van Andel Research Institute
   for support of the VARI Center for Skeletal Disease Research.
CR Adami S, 2008, CALCIFIED TISSUE INT, V83, P388, DOI 10.1007/s00223 008 9184 8
   Adams CI, 2001, INJURY, V32, P61, DOI 10.1016/S0020 1383(00)00121 2
   Alvarez L, 2001, BONE, V29, P447, DOI 10.1016/S8756 3282(01)00592 0
   Alvarez L, 2004, RHEUMATOLOGY, V43, P869, DOI 10.1093/rheumatology/keh185
   ANDERSON HC, 1990, AM J PATHOL, V136, P391
   Banks E, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000181
   Bauer DC, 2006, J BONE MINER RES, V21, P292, DOI 10.1359/JBMR.051018
   Body JJ, 2007, ANN ONCOL, V18, P1165, DOI 10.1093/annonc/mdm119
   BORNSTEIN P, 1972, SCIENCE, V175, P544, DOI 10.1126/science.175.4021.544
   Bornstein P, 2002, J BIOL CHEM, V277, P2605, DOI 10.1074/jbc.m106181200
   BORNSTEIN P, 1972, J BIOL CHEM, V247, P2808
   Brick KE, 2009, CLIN ORTHOP RELAT R, V467, P3096, DOI 10.1007/s11999 008 0599 3
   Buckwalter J.A., 2006, ROCKWOOD GREENS FRAC, VSixth, P297
   Burnett Bowie SAM, 2009, J CLIN ENDOCR METAB, V94, P1097, DOI 10.1210/jc.2008 1122
   Buttaro MA, 2003, ACTA ORTHOP SCAND, V74, P505, DOI 10.1080/00016470310017884
   Cabral WA, 2005, J BIOL CHEM, V280, P19259, DOI 10.1074/jbc.M414698200
   CELESTE AJ, 1986, EMBO J, V5, P1885, DOI 10.1002/j.1460 2075.1986.tb04440.x
   Chen PQ, 2005, J BONE MINER RES, V20, P962, DOI 10.1359/JBMR.050105
   Chevrel G, 2007, JOINT BONE SPINE, V74, P584, DOI 10.1016/j.jbspin.2007.01.039
   Chiba S, 2001, J VET MED SCI, V63, P603, DOI 10.1292/jvms.63.603
   Christensen B, 2008, J APPL PHYSIOL, V105, P420, DOI 10.1152/japplphysiol.00201.2008
   Claudon A, 2008, CLIN CHEM, V54, P1554, DOI 10.1373/clinchem.2008.105866
   Court Brown CM, 2008, J TRAUMA, V64, P1517, DOI 10.1097/TA.0b013e3181469840
   Court Brown CM, 2006, INJURY, V37, P691, DOI 10.1016/j.injury.2006.04.130
   Crameri RM, 2004, MATRIX BIOL, V23, P259, DOI 10.1016/j.matbio.2004.05.009
   Dahabreh Z, 2009, INT ORTHOP, V33, P1407, DOI 10.1007/s00264 008 0709 6
   Deal C, 2005, J BONE MINER RES, V20, P1905, DOI 10.1359/JBMR.050714
   Delmas PD, 2006, BONE, V39, P237, DOI 10.1016/j.bone.2006.02.003
   DELMAS PD, 1983, J CLIN ENDOCR METAB, V57, P1028, DOI 10.1210/jcem 57 5 1028
   DELMAS PD, 1983, J CLIN INVEST, V71, P1316, DOI 10.1172/JCI110882
   Delmas PD, 1999, J BONE MINER RES, V14, P66, DOI 10.1002/jbmr.5650140213
   Delmas PD, 2000, OSTEOPOROSIS INT, V11, P2, DOI 10.1007/s001980070002
   Denk E, 2007, J BONE MINER RES, V22, P1518, DOI 10.1359/JBMR.070617
   DENNEY JD, 1973, J LAB CLIN MED, V82, P226
   Dias IR, 2008, LAB ANIM UK, V42, P465, DOI 10.1258/la.2007.06037e
   DO, 2008, Calcif Tissue Int, V82, P155
   DONALDSON LJ, 1990, J EPIDEMIOL COMMUN H, V44, P241, DOI 10.1136/jech.44.3.241
   DUDA RJ, 1987, J CLIN INVEST, V79, P1249, DOI 10.1172/JCI112944
   EINHORN TA, 1988, CLIN ORTHOP RELAT R, P219
   Ekholm E, 2002, AM J PATHOL, V160, P1779, DOI 10.1016/S0002 9440(10)61124 8
   ERIKSEN EF, 1993, J BONE MINER RES, V8, P127
   FELIX R, 1978, BIOCHEM J, V170, P681, DOI 10.1042/bj1700681
   Ferguson CM, 1998, ANN NY ACAD SCI, V857, P33, DOI 10.1111/j.1749 6632.1998.tb10105.x
   FESSLER LI, 1975, P NATL ACAD SCI USA, V72, P4905, DOI 10.1073/pnas.72.12.4905
   FISHER LW, 1987, J BIOL CHEM, V262, P13457
   FLEISCHMAJER R, 1990, ANN NY ACAD SCI, V580, P161, DOI 10.1111/j.1749 6632.1990.tb17927.x
   FOULK DA, 1995, ORTHOPEDICS, V18, P333
   FRASER JD, 1990, CALCIFIED TISSUE INT, V46, P270, DOI 10.1007/BF02555007
   Gallagher JC, 2006, BONE, V39, P1268, DOI 10.1016/j.bone.2006.06.007
   Garnero P, 2008, CLIN CHEM, V54, P188, DOI 10.1373/clinchem.2007.094953
   Ge GX, 2004, J BIOL CHEM, V279, P41626, DOI 10.1074/jbc.M406630200
   Gerstenfeld LC, 2003, J CELL BIOCHEM, V88, P873, DOI 10.1002/jcb.10435
   Gerstenfeld LC, 2006, J HISTOCHEM CYTOCHEM, V54, P1215, DOI 10.1369/jhc.6A6959.2006
   Giannoudis PV, 2000, J BONE JOINT SURG BR, V82B, P655, DOI 10.1302/0301 620X.82B5.9899
   Gineyts E, 2000, BIOCHEM J, V345, P481, DOI 10.1042/0264 6021:3450481
   Goss PE, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1757
   GOTHLIN G, 1973, HISTOCHEMISTRY, V36, P225, DOI 10.1007/BF00306312
   GUNDBERG CM, 1985, J CLIN ENDOCR METAB, V60, P736, DOI 10.1210/jcem 60 4 736
   GUNJASMITH Z, 1981, BIOCHEM J, V197, P759, DOI 10.1042/bj1970759
   HAINING SA, 1986, BONE MINER, V1, P205
   Hale LV, 2007, BONE, V40, P1103, DOI 10.1016/j.bone.2006.11.027
   Hammett Stabler CA, 2004, CLIN LAB MED, V24, P175, DOI 10.1016/j.cll.2004.01.013
   Han B, 2007, J PROTEOME RES, V6, P4218, DOI 10.1021/pr070288s
   Harrison CA, 2006, BRIT J DERMATOL, V154, P401, DOI 10.1111/j.1365 2133.2005.07022.x
   HELSETH DL, 1981, J BIOL CHEM, V256, P7118
   Henle P, 2005, BONE, V37, P791, DOI 10.1016/j.bone.2005.06.015
   Herrmann M, 2002, CLIN CHEM, V48, P2263
   Herrmann M, 2007, CLIN CHEM LAB MED, V45, P1381, DOI 10.1515/CCLM.2007.282
   Hietaniemi K, 1998, ACTA ORTHOP SCAND, V69, P545, DOI 10.3109/17453679808997795
   HILL CS, 1990, CLIN CHIM ACTA, V186, P315, DOI 10.1016/0009 8981(90)90050 3
   HILTUNEN A, 1993, CLIN ORTHOP RELAT R, P23
   HODGE AJ, 1989, CONNECT TISSUE RES, V21, P467, DOI 10.3109/03008208909050004
   HOJIMA Y, 1994, J BIOL CHEM, V269, P11381
   Ingle BM, 1999, OSTEOPOROSIS INT, V10, P399, DOI 10.1007/s001980050246
   Ingle BM, 1999, OSTEOPOROSIS INT, V10, P408, DOI 10.1007/s001980050247
   Iu MF, 2005, J ENDOCRINOL, V185, P131, DOI 10.1677/joe.1.05962
   Ivaska KK, 2007, J BONE MINER RES, V22, P1155, DOI 10.1359/JBMR.070505
   Ivaska KK, 2004, J BIOL CHEM, V279, P18361, DOI 10.1074/jbc.M314324200
   JOERRING S, 1993, ARCH ORTHOP TRAUM SU, V112, P139, DOI 10.1007/BF00449991
   JOERRING S, 1994, ARCH ORTHOP TRAUM SU, V113, P334, DOI 10.1007/BF00426183
   JONES ED, 1951, AM J SURG, V81, P417, DOI 10.1016/0002 9610(51)90252 8
   Jung K, 2004, INT J CANCER, V111, P783, DOI 10.1002/ijc.20314
   Kaplan F., 1994, ORTHOPAEDIC BASIC SC, P127
   Komatsu DE, 2009, ENDOCRINOLOGY, V150, P1570, DOI 10.1210/en.2008 0814
   Komi J, 2006, J BONE MINER METAB, V24, P314, DOI 10.1007/s00774 006 0689 9
   Kon T, 2001, J BONE MINER RES, V16, P1004, DOI 10.1359/jbmr.2001.16.6.1004
   KUHLMAN JE, 1988, RADIOLOGY, V167, P483, DOI 10.1148/radiology.167.2.3357959
   Kurdy NMG, 1998, J ORTHOP TRAUMA, V12, P122, DOI 10.1097/00005131 199802000 00010
   Kurdy NMG, 2000, J ORTHOP TRAUMA, V14, P48, DOI 10.1097/00005131 200001000 00010
   KYRO A, 1993, ANN CHIR GYNAECOL FE, V82, P254
   LANE JM, 1986, J ORTHOP RES, V4, P318, DOI 10.1002/jor.1100040308
   Lawton DM, 1999, J CLIN PATHOL MOL PA, V52, P92, DOI 10.1136/mp.52.2.92
   Lawton DM, 1997, J CLIN PATHOL MOL PA, V50, P194, DOI 10.1136/mp.50.4.194
   Lein M, 2009, PROSTATE, V69, P624, DOI 10.1002/pros.20917
   LIAN J, 1989, P NATL ACAD SCI USA, V86, P1143, DOI 10.1073/pnas.86.4.1143
   Lindsey, 1996, J Am Acad Orthop Surg, V4, P35
   LINKHART SG, 1993, CLIN CHEM, V39, P2254
   LODER RT, 1988, CLIN ORTHOP RELAT R, P210
   Lotz J, 1999, ARCH ORTHOP TRAUM SU, V119, P212, DOI 10.1007/s004020050393
   Ly TV, 2008, J BONE JOINT SURG AM, V90A, P2254
   MANOLAGAS SC, 1981, J BIOL CHEM, V256, P7115
   MANOLAGAS SC, 1983, MOL CELL ENDOCRINOL, V33, P27, DOI 10.1016/0303 7207(83)90054 0
   MARSH D, Clin Orthop, P1998
   MAUVIEL A, 1993, J CELL BIOCHEM, V53, P288, DOI 10.1002/jcb.240530404
   McClung M, 2007, BONE, V41, P122, DOI 10.1016/j.bone.2007.03.011
   MCKIBBIN B, 1978, J BONE JOINT SURG BR, V60, P150, DOI 10.1302/0301 620X.60B2.350882
   MELKKO J, 1994, J EXP MED, V179, P405, DOI 10.1084/jem.179.2.405
   Melkko J, 1996, CLIN CHEM, V42, P947
   Meyer RA, 2006, J ORTHOP RES, V24, P1933, DOI 10.1002/jor.20124
   Miller PD, 2007, OSTEOPOROSIS INT, V18, P59, DOI 10.1007/s00198 006 0189 8
   MIYAHARA M, 1984, J BIOL CHEM, V259, P9891
   MOSS DW, 1982, CLIN CHEM, V28, P2007
   MULTIMAKI P, 1987, BIOCHEM BIOPH RES CO, V142, P536, DOI 10.1016/0006 291X(87)90307 X
   Nagel T, 2010, BIOMECH MODEL MECHAN, V9, P359, DOI 10.1007/s10237 009 0182 1
   Nakatsuka Kiyoshi, 2006, Clin Calcium, V16, P977
   Nawar EW, 2005, NATL HLTH STAT REP, V2007, P1
   Nork SE, 2006, ROCKWOOD GREENS FRAC, P1845
   NYMAN MT, 1991, ANN CHIR GYNAECOL, V80, P289
   OBRANT KJ, 1990, CLIN ORTHOP RELAT R, P300
   ONIMAHABIR JP, 1989, Injury, V20, P37
   Oremek G, 2007, ANTICANCER RES, V27, P1961
   OTSUBO K, 1992, BIOCHEMISTRY US, V31, P396, DOI 10.1021/bi00117a013
   PAGE M, 1986, HISTOCHEM J, V18, P251, DOI 10.1007/BF01676235
   PARALKAR VM, 1992, J CELL BIOL, V119, P1721, DOI 10.1083/jcb.119.6.1721
   Parker MJ, 2007, CLIN ORTHOP RELAT R, P175, DOI 10.1097/BLO.0b013e3180325a42
   Patil S, 2006, J BONE JOINT SURG BR, V88B, P928, DOI 10.1302/0301 620X.88B7.17639
   PEDERSEN BJ, 1995, BONE, V17, P91, DOI 10.1016/8756 3282(95)00149 8
   Pei DQ, 1999, J BIOL CHEM, V274, P8925, DOI 10.1074/jbc.274.13.8925
   Phieffer Laura S, 2006, Instr Course Lect, V55, P389
   Pope FM, 1997, J MED GENET, V34, P400, DOI 10.1136/jmg.34.5.400
   POSEN S, 1982, CLIN CHEM, V28, P153
   Powell JN, 2003, J BONE JOINT SURG AM, V85A, P2093
   PRICE PA, 1980, J CLIN INVEST, V66, P878, DOI 10.1172/JCI109954
   PRICE PA, 1980, P NATL ACAD SCI BIOL, V77, P2234, DOI 10.1073/pnas.77.4.2234
   PRICE PA, 1983, BIOCHEM BIOPH RES CO, V117, P765, DOI 10.1016/0006 291X(83)91663 7
   PRICE PA, 1981, J BIOL CHEM, V256, P2760
   Prockop DJ, 1998, MATRIX BIOL, V16, P399, DOI 10.1016/S0945 053X(98)90013 0
   PROCKOP DJ, 1979, NEW ENGL J MED, V301, P77, DOI 10.1056/NEJM197907123010204
   PROCKOP DJ, 1979, NEW ENGL J MED, V301, P13, DOI 10.1056/NEJM197907053010104
   RAMACHANDRAN GN, 1954, NATURE, V174, P269, DOI 10.1038/174269c0
   Rauch F, 2010, J BONE MINER RES, V25, P1367, DOI 10.1359/jbmr.091109
   REDDI AH, 1976, J CELL BIOL, V69, P557, DOI 10.1083/jcb.69.3.557
   REDDI AH, 1977, P NATL ACAD SCI USA, V74, P5589, DOI 10.1073/pnas.74.12.5589
   Reed AAC, 2003, J BONE JOINT SURG BR, V85B, P604, DOI 10.1302/0301 620X.85B4.12944
   RIIKONEN T, 1995, J BIOL CHEM, V270, P13548, DOI 10.1074/jbc.270.22.13548
   RIIKONEN T, 1995, J BIOL CHEM, V270, P376, DOI 10.1074/jbc.270.1.376
   ROBINS SP, 1983, BIOCHEM J, V215, P167, DOI 10.1042/bj2150167
   Rothem DE, 2009, J BONE MINER METAB, V27, P555, DOI 10.1007/s00774 009 0075 5
   SANDBERG M, 1989, J BONE JOINT SURG AM, V71A, P69, DOI 10.2106/00004623 198971010 00012
   Schwab AM, 2005, ENDOCRINOLOGY, V146, P4349, DOI 10.1210/en.2005 0601
   Seebeck P, 2005, BONE, V37, P669, DOI 10.1016/j.bone.2005.06.008
   Segmuller G, 1969, Z Orthop Ihre Grenzgeb, V106, P599
   Seibel Markus J, 2005, Clin Biochem Rev, V26, P97
   SIEBER E, 1953, Zentralbl Chir, V78, P1583
   Southwood LL, 2003, AM J VET RES, V64, P727, DOI 10.2460/ajvr.2003.64.727
   Taitsman LA, 2009, J TRAUMA, V67, P1389, DOI 10.1097/TA.0b013e318182afd0
   Thompson Z, 2002, J ORTHOPAED RES, V20, P1091, DOI 10.1016/S0736 0266(02)00017 7
   Traub W, 1971, Adv Protein Chem, V25, P243, DOI 10.1016/S0065 3233(08)60281 8
   Ueng SWN, 1997, J TRAUMA, V43, P640, DOI 10.1097/00005373 199710000 00013
   US Food and Drug Administration, 2000, OCT
   Uusitalo H, 2001, BONE, V28, P423, DOI 10.1016/S8756 3282(01)00406 9
   VEIS A, 1973, P NATL ACAD SCI USA, V70, P1464, DOI 10.1073/pnas.70.5.1464
   Veitch SW, 2006, OSTEOPOROSIS INT, V17, P364, DOI 10.1007/s00198 005 2025 y
   Waters RV, 2000, ACTA ORTHOP SCAND, V71, P316, DOI 10.1080/000164700317411951
   Watts NB, 2009, J BONE MINER RES, V24, P1125, DOI [10.1359/JBMR.081256, 10.1359/jbmr.081256]
   WEBB LX, 1986, Clin Orthop, V105, P133
   Weber BG, 1973, Verlag Hans Huber
   WEINER S, 1992, FASEB J, V6, P879, DOI 10.1096/fasebj.6.3.1740237
   Weiner S, 1999, J STRUCT BIOL, V126, P241, DOI 10.1006/jsbi.1999.4107
   Werb Z, 1998, ANN NY ACAD SCI, V857, P110, DOI 10.1111/j.1749 6632.1998.tb10111.x
   Weresh MJ, 2000, J ORTHOP TRAUMA, V14, P335, DOI 10.1097/00005131 200006000 00005
   Whelan DB, 2010, J TRAUMA, V68, P629, DOI 10.1097/TA.0b013e3181a7c16d
   Wu CC, 1997, J TRAUMA, V43, P263, DOI 10.1097/00005373 199708000 00010
   Yamagiwa H, 1999, BONE, V25, P197, DOI 10.1016/S8756 3282(99)00157 X
   Yokoyama K, 2008, INDIAN J ORTHOP, V42, P410, DOI 10.4103/0019 5413.43385
   Zanker CL, 2000, EUR J APPL PHYSIOL, V83, P434, DOI 10.1007/s004210000293
NR 176
TC 32
Z9 38
U1 0
U2 4
PU BEGELL HOUSE INC
PI DANBURY
PA 50 NORTH ST, DANBURY, CT 06810 USA
SN 1045 4403
EI 2162 6502
J9 CRIT REV EUKAR GENE
JI Crit. Rev. Eukaryot. Gene Expr.
PY 2010
VL 20
IS 2
BP 105
EP 127
DI 10.1615/CritRevEukarGeneExpr.v20.i2.20
PG 23
WC Biotechnology & Applied Microbiology; Genetics & Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA 697ZX
UT WOS:000285561400002
PM 21133841
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Zhou, YH
   Wu, CT
   Xiao, Y
AF Zhou, Yinghong
   Wu, Chengtie
   Xiao, Yin
TI Silicate based bioceramics for periodontal regeneration
SO JOURNAL OF MATERIALS CHEMISTRY B
LA English
DT Article
ID IN VITRO; LIGAMENT CELLS; OSTEOGENIC DIFFERENTIATION; IONIC PRODUCTS;
   PROLIFERATION; AKERMANITE; MEMBRANES; CHITOSAN; GELATIN
AB Periodontal disease is characterized by the destruction of the tissues that attach the tooth tothe alveolar bone. Various methods for regenerative periodontal therapy including the use of barrier membranes, bone replacement grafts, and growth factor delivery have been investigated; however, true regeneration of periodontal tissue is still a significant challenge to scientists and clinicians. The focus on periodontal tissue engineering has shifted from attempting to recreate tissue replacements/ constructs to the development of biomaterials that incorporate and release regulatory signals to achieve in situ periodontal regeneration. The release of ions and molecular cues from biomaterials may help to unlock latent regenerative potential in the body by regulating cell proliferation and differentiation towards different lineages (e. g. osteoblasts and cementoblasts). Silicate based bioactive materials, including bioactive silicate glasses and ceramics, have become the materials of choice for periodontal regeneration, due to their favourable osteoconductivity and bioactivity. This article will focus on the most recent advances in the in vitro and in vivo biological application of silicate based ceramics, specifically as it relates to periodontal tissue engineering.
C1 [Zhou, Yinghong; Xiao, Yin] Queensland Univ Technol, Inst Hlth & Biomed Innovat, Brisbane, Qld 4059, Australia.
   [Wu, Chengtie] Chinese Acad Sci, Shanghai Inst Ceram, State Key Lab High Performance Ceram & Superfine, Shanghai 200050, Peoples R China.
C3 Queensland University of Technology (QUT); Chinese Academy of Sciences;
   Shanghai Institute of Ceramics, CAS
RP Xiao, Y (通讯作者)，Queensland Univ Technol, Inst Hlth & Biomed Innovat, Brisbane, Qld 4059, Australia.
EM chengtiewu@mail.sic.ac.cn; yin.xiao@qut.edu.au
RI ; Xiao, Yin/AAM 4033 2020; Zhou, Yiyang/AAU 7705 2021
OI Zhou, Yinghong/0000 0001 9757 7735; Xiao, Yin/0000 0003 1785 3491; 
FU Recruitment Program of Global Young Talent, China; Shanghai Pujiang
   Talent Program [12PJ1409500]; Natural Science Foundation of China
   [31370963, 81201202, 81190132]; Innovative Project of SIC CAS, NHMRC
   [APP1032738]; ARC [DP120103697]
FX Funding for this study was provided by the Recruitment Program of Global
   Young Talent, China (Wu C.), the Shanghai Pujiang Talent Program
   (12PJ1409500), the Natural Science Foundation of China (Grant 31370963,
   81201202 and 81190132), and the Innovative Project of SIC CAS, NHMRC
   (APP1032738) and ARC (DP120103697).
CR Berezow AB, 2011, PERIODONTOL 2000, V55, P36, DOI 10.1111/j.1600 0757.2010.00350.x
   Cheung JWC, 2013, ACTA BIOMATER, V9, P6867, DOI 10.1016/j.actbio.2013.02.010
   Coelho PG, 2012, OR SURG OR MED OR PA, V114, P437, DOI 10.1016/j.oooo.2011.11.032
   Dan HX, 2014, BIOMATERIALS, V35, P113, DOI 10.1016/j.biomaterials.2013.09.074
   Di Alberti L, 2013, MINERVA STOMATOL
   Dietrich Thomas, 2013, J Clin Periodontol, V40 Suppl 14, pS70, DOI [10.1902/jop.2013.134008, 10.1111/jcpe.12062]
   Han PP, 2013, BIOMATER SCI UK, V1, P379, DOI 10.1039/c2bm00108j
   Hunter KT, 2013, J BIOMED MATER RES A, V101, P1016, DOI 10.1002/jbm.a.34396
   Kabashima H, 2013, J ORAL SCI, V55, P363, DOI 10.2334/josnusd.55.363
   Lee JS, 2012, J PERIODONTAL IMPLAN, V42, P50, DOI 10.5051/jpis.2012.42.2.50
   Liao W, 2013, MAT SCI ENG C MATER, V33, P3273, DOI 10.1016/j.msec.2013.04.008
   Owen GR, 2010, J BIOMED MATER RES A, V95A, P857, DOI 10.1002/jbm.a.32865
   Padilla S, 2006, ACTA BIOMATER, V2, P331, DOI 10.1016/j.actbio.2006.01.006
   Pandit N, 2010, J CONT DENT PRACT, V11, P025
   PITARU S, 1995, J PERIODONTAL RES, V30, P360, DOI 10.1111/j.1600 0765.1995.tb01288.x
   Shalumon KT, 2013, J BIOMED NANOTECHNOL, V9, P430, DOI 10.1166/jbn.2013.1559
   Sun HL, 2006, BIOMATERIALS, V27, P5651, DOI 10.1016/j.biomaterials.2006.07.027
   Wu CT, 2013, RSC ADV, V3, P17843, DOI 10.1039/c3ra43350a
   Wu CT, 2013, BIOMED MATER, V8, DOI 10.1088/1748 6041/8/3/032001
   Wu CT, 2011, ACTA BIOMATER, V7, P1797, DOI 10.1016/j.actbio.2010.12.018
   Xia LG, 2011, EUR CELLS MATER, V22, P68, DOI 10.22203/eCM.v022a06
   Xu C, 2012, J BIOMED MATER RES B, V100B, P1435, DOI 10.1002/jbm.b.32662
   Zhai WY, 2012, ACTA BIOMATER, V8, P341, DOI 10.1016/j.actbio.2011.09.008
   Zhang XF, 2014, J MATER CHEM B, V2, P1415, DOI 10.1039/c3tb21663b
   Zhang YF, 2014, J BIOMED MATER RES A, V102, P105, DOI 10.1002/jbm.a.34679
   Zhou YH, 2013, J MATER CHEM B, V1, P3380, DOI 10.1039/c3tb20445f
   Zhou YH, 2012, ACTA BIOMATER, V8, P2307, DOI 10.1016/j.actbio.2012.03.012
NR 27
TC 26
Z9 27
U1 0
U2 61
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2050 750X
EI 2050 7518
J9 J MATER CHEM B
JI J. Mat. Chem. B
PY 2014
VL 2
IS 25
BP 3907
EP 3910
DI 10.1039/c4tb00377b
PG 4
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA AI7WA
UT WOS:000337110700001
PM 32261640
DA 2025 08 17
ER

PT J
AU Pherwani, PU
   Sathaye, S
AF Pherwani, Pooja U.
   Sathaye, Sadhana
TI Esculetin affects the microarchitecture of long bones in vivo and
   the alkaline phosphatase activity and bone nodule formation in
   vitro
SO INDIAN JOURNAL OF EXPERIMENTAL BIOLOGY
LA English
DT Article
DE Bone imaging; Coumarin; Osteoporosis Ovariectomy; Trabecular
ID OVARIECTOMIZED RAT MODEL; CELL PROLIFERATION; DIFFERENTIATION;
   OSTEOPOROSIS; OSTHOLE; PATHWAY
AB Osteoporosis is a condition of deterioration of bone quality and quantity, making it susceptible to fractures. The current therapy, with its associated risks and also approval for only short period makes the search for better molecules on priority imperative for effective treatment. Esculetin, a phytoconstituent, known to inhibit osteoclast differentiation in vitro and increase bone density in vivo, could serve to cure osteoporosis. Here, we studied the effect of esculetin on the microarchitecture of long bones in the ovariectomized rat model. The cellular cause for in vivo effect was sought by studying its effect on the pre osteoblastic cell line. Osteopenia was induced by bilateral ovariectomy. Esculetin @1.0 or 10 mg/kg was administered for three months to osteopenic rats. Micro CT of tibias and femurs was performed. The effect of esculetin on pre osteoblastic MC3T3 E1 cells was studied. Cell viability in the presence of esculetin was determined by MTT assay. Alkaline phosphatase activity was determined using p nitrophenol as a substrate. Bone nodules were stained with Alizarin Red S. Esculetin treated groups showed a significant worsening of microarchitecture parameters in the trabecular and cortical regions of the femur and tibia. This deterioration was more evident in the trabecular region than the cortical region. Esculetin augmented bone loss in estrogen deficient rats without affecting the cell viability of MC3T3 E1 cells up to a concentration of 10 mu g/mL. However, it affected the alkaline phosphatase activity and mineralization effect in preosteoblastic cells in addition to its in vivo effect in ovariectomized rats.
C1 [Pherwani, Pooja U.; Sathaye, Sadhana] Inst Chem Technol ICT, Dept Pharmaceut Sci & Technol, Nathalal Parekh Marg, Mumbai 400019, Maharashtra, India.
   [Pherwani, Pooja U.] Bharati Vidyapeeths Coll Pharm, Sect 8, Navi Mumbai 400614, Maharashtra, India.
C3 Institute of Chemical Technology   Mumbai
RP Sathaye, S (通讯作者)，Inst Chem Technol ICT, Dept Pharmaceut Sci & Technol, Nathalal Parekh Marg, Mumbai 400019, Maharashtra, India.
EM sadhanasathaye@hotmail.com
RI pherwani, pooja/AAS 6827 2021
FU University of Mumbai
FX We are grateful to Dr. Naibedya Chattopadhyay, Central Drug Research
   Institute (CDRI), for providing technical know how and the facility for
   carrying out microcomputed tomography at his laboratory. We thank Mr.
   Suhas T. Mhaske, Ph.D. scholar at National Centre for Cell Science
   (NCCS), Pune, for providing assistance in cell line studies. The project
   was partially funded by the University of Mumbai.
CR ABE T, 1993, J BONE MINER RES, V8, P831
   Jiménez Orozco FA, 2011, EUR J PHARMACOL, V668, P35, DOI 10.1016/j.ejphar.2011.06.024
   Baek JM, 2015, BIOCHEM BIOPH RES CO, V461, P334, DOI 10.1016/j.bbrc.2015.04.034
   Bais Harsh Pal, 2001, Indian Journal of Experimental Biology, V39, P564
   Barhanpurkar Naik A, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287 017 0618 y
   Bhargavan B, 2012, J NUTR BIOCHEM, V23, P27, DOI 10.1016/j.jnutbio.2010.11.002
   Campbell Graeme M, 2014, Bonekey Rep, V3, P564, DOI 10.1038/bonekey.2014.59
   Chen LR, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20092213
   Christiansen Blaine A, 2016, Bone Rep, V5, P136, DOI 10.1016/j.bonr.2016.05.006
   Christiansen BA, 2011, OSTEOPOROSIS RESEARCH: ANIMAL MODELS, P45, DOI 10.1007/978 0 85729 293 3_5
   Gilani AH, 1998, PHARMACOL RES, V37, P31, DOI 10.1006/phrs.1997.0262
   KALU DN, 1991, BONE MINER, V15, P175, DOI 10.1016/0169 6009(91)90124 I
   Khaire CP, 2007, INDIAN MED PLANTS IL, P142
   Kim HS, 2018, J PERIODONTAL IMPLAN, V48, P34, DOI 10.5051/jpis.2018.48.1.34
   Kim Younghwa, 2017, Prev Nutr Food Sci, V22, P118, DOI 10.3746/pnf.2017.22.2.118
   Kormendi S, 2020, MICROCOMPUTED TOMOGR, DOI [10.1007/978 3 030 16641 0_7, DOI 10.1007/978 3 030 16641 0_7]
   Kuo PL, 2005, J PHARMACOL EXP THER, V314, P1290, DOI 10.1124/jpet.105.085092
   Lee EJ, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10071052
   Li XX, 2002, BIOL PHARM BULL, V25, P738, DOI 10.1248/bpb.25.738
   Liu MJ, 2018, J TRADIT CHIN MED, V38, P896
   Pherwani PU, 2020, INDIAN J PHARM EDUC, V54, P8, DOI 10.5530/ijper.54.1.2
   Pherwani PU, 2019, INDIAN DRUGS, V56, P74
   Ranka D, 2013, INDIAN J EXP BIOL, V51, P833
   Seo HJ, 2010, NUTR RES PRACT, V4, P356, DOI 10.4162/nrp.2010.4.5.356
   Shuai B, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132104
   Tang CH, 2008, EUR J PHARMACOL, V579, P40, DOI 10.1016/j.ejphar.2007.10.013
   Trivedi R, 2009, MOL CELL ENDOCRINOL, V302, P86, DOI 10.1016/j.mce.2009.01.011
   TUBARO A, 1988, Pharmacological Research Communications, V20, P83
   Yousefzadeh N, 2020, EXCLI J, V19, P89, DOI 10.17179/excli2019 1990
   Yun ES, 2012, BIOMED CHROMATOGR, V26, P1247, DOI 10.1002/bmc.2686
NR 30
TC 0
Z9 0
U1 0
U2 3
PU NATL INST SCIENCE COMMUNICATION NISCAIR
PI NEW DELHI
PA DR K S KRISHNAN MARG, PUSA CAMPUS, NEW DELHI 110 012, INDIA
SN 0019 5189
EI 0975 1009
J9 INDIAN J EXP BIOL
JI Indian J. Exp. Biol.
PD JUN
PY 2021
VL 59
IS 6
BP 391
EP 397
PG 7
WC Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Life Sciences & Biomedicine   Other Topics
GA TE6ZD
UT WOS:000670157700004
DA 2025 08 17
ER

PT J
AU Xu, WM
   Liu, XY
   He, XH
   Jiang, YP
   Zhang, JB
   Zhang, QY
   Wang, NN
   Qin, LP
   Xin, HL
AF Xu, Wumu
   Liu, Xiaoyan
   He, Xuhui
   Jiang, Yiping
   Zhang, Jiabao
   Zhang, Qiaoyan
   Wang, Nani
   Qin, Luping
   Xin, Hailiang
TI Bajitianwan attenuates D galactose induced memory impairment and bone
   loss through suppression of oxidative stress in aging rat model
SO JOURNAL OF ETHNOPHARMACOLOGY
LA English
DT Article
DE D galactose; Bajitianwan; Oxidative stress; Alzheimer's disease;
   Osteoporosis
ID INHIBITS OSTEOCLAST DIFFERENTIATION; MORINDA OFFICINALIS;
   POLYSACCHARIDES; ANTIOXIDANT; EXTRACTION; SCOPOLETIN; DISEASE; ROOTS;
   BRAIN; CELLS
AB Ethnopharmacological relevance: Osteoporosis and Alzheimer's disease (AD) are both senile diseases, which are closely related to oxidative stress. Bajitianwan (BJTW) is a classic Chinese formulation consisting of seven herbal drugs: the root of Morinda officinalis F.C.How., root and rhizome of Acorus tatarinowii Schott, the root bark of Lycium chinense Mill., the sclerotium of Poria cocos (Schw.) Wolf, the root of Polygala tenuifolia Willd., sclerotium with host wood of Poria cocos (Schw.) Wolf and root and rhizome of Panax ginseng C. A. Mey. BJTW has been used for the treatment of osteoporosis and AD for hundreds of years.
   Aim of the study: This study aimed to investigate the protective effects of BJTW in the amelioration of memory impairment and bone loss induced by D galactose and to explore the underlying mechanism.
   Materials and methods: The aging model was established in male Wistar rats by subcutaneous injection of D galactose (100 mg/kg), and the rats were treated with huperzine A, alendronate sodium, or the aqueous extract of BJTW for 4 months. Cognitive performance was evaluated with the Morris water maze. Rat femurs were scanned using microcomputed tomography to obtain three dimensional imagery of bone microstructure. The impact of D galactose on the expression of Forkhead box O1 and superoxide dismutase 2 in femur tissue was also evaluated.
   Results: For the model group, BJTW treatment significantly reduced the latency time for finding the target platform in the directional swimming test and increased time spent swimming in the target quadrant with the probe test. Additionally, BJTW treatment alleviated D galactose induced bone loss through regulation of levels of alkaline phosphatase, osteocalcin, osteoprotegerin, and receptor activator of nuclear factor kappa B ligand. Furthermore, BJTW treatment increased catalase and glutathione peroxidase levels in serum, reduced malondialdehyde content in hippocampus, and upregulated expression of Forkhead O1, which upregulated superoxide dismutase 2 in the femur.
   Conclusions: BJTW had positive effects on age related memory impairments and bone loss. It may be a promising antioxidant candidate for treatment of Alzheimer's disease and osteoporosis.
C1 [Xu, Wumu; Liu, Xiaoyan; He, Xuhui; Jiang, Yiping; Zhang, Jiabao; Zhang, Qiaoyan; Wang, Nani; Qin, Luping; Xin, Hailiang] Second Mil Med Univ, Sch Pharm, Shanghai 200433, Peoples R China.
   [Wang, Nani] Zhejiang Acad Tradit Chinese Med, Dept Med, Hangzhou 310007, Zhejiang, Peoples R China.
   [Qin, Luping] Zhejiang Chinese Med Univ, Sch Pharm, Hangzhou 310053, Peoples R China.
C3 Naval Medical University; Zhejiang Chinese Medical University
RP Xin, HL (通讯作者)，Second Mil Med Univ, Sch Pharm, Shanghai 200433, Peoples R China.; Wang, NN (通讯作者)，Zhejiang Acad Tradit Chinese Med, Dept Med, Hangzhou 310007, Zhejiang, Peoples R China.; Qin, LP (通讯作者)，Zhejiang Chinese Med Univ, Sch Pharm, Hangzhou 310053, Peoples R China.
EM specium@163.com; 15905518125@163.com; hexuhuismmu@163.com;
   yaoweixuan82@163.com; yzm5266@163.com; zqy1965@163.com; wnn8511@163.com;
   qinluping@126.com; hailiangxin@163.com
FU National Natural Science Foundation of China [U1603283, U1505226,
   81973447]
FX The work was supported by the National Natural Science Foundation of
   China (No. U1603283, U1505226, 81973447).
CR Ali T, 2015, J PINEAL RES, V58, P71, DOI 10.1111/jpi.12194
   Amouzougan A, 2017, JOINT BONE SPINE, V84, P611, DOI 10.1016/j.jbspin.2016.08.002
   Azman KF, 2019, BIOGERONTOLOGY, V20, P763, DOI 10.1007/s10522 019 09837 y
   Bartell SM, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4773
   Chen P, 2019, AGING US, V11, P7339, DOI 10.18632/aging.101733
   Cobley JN, 2018, REDOX BIOL, V15, P490, DOI 10.1016/j.redox.2018.01.008
   Cong F, 2017, BIOMED PHARMACOTHER, V92, P927, DOI 10.1016/j.biopha.2017.05.115
   Eijkelenboom A, 2013, NAT REV MOL CELL BIO, V14, P83, DOI 10.1038/nrm3507
   Gallo Oller G, 2018, J IMMUNOL METHODS, V457, P1, DOI 10.1016/j.jim.2018.03.004
   Hardas SS, 2013, REDOX BIOL, V1, P80, DOI 10.1016/j.redox.2013.01.002
   Hornick A, 2011, NEUROSCIENCE, V197, P280, DOI 10.1016/j.neuroscience.2011.09.006
   Hu YR, 2019, J INTEGR MED JIM, V17, P404, DOI 10.1016/j.joim.2019.09.002
   Kim HJ, 2018, J GINSENG RES, V42, P401, DOI 10.1016/j.jgr.2017.12.008
   Laurent MR, 2019, MATURITAS, V122, P51, DOI 10.1016/j.maturitas.2019.01.006
   Lee SH, 2013, J NAT PROD, V76, P615, DOI 10.1021/np300824h
   Lin H, 2019, WORLD J INTEGRATED T, V6, P802, DOI [10.13935/j.cnki.sjzx.190615, DOI 10.13935/J.CNKI.SJZX.190615]
   Lin HF., 2019, GUANGMING J CHIN MED, V34, P45, DOI [10.3969/j.issn.1003 8914.2019.01.019, DOI 10.3969/J.ISSN.1003 8914.2019.01.019]
   Manolagas SC, 2010, ENDOCR REV, V31, P266, DOI 10.1210/er.2009 0024
   Montine TJ, 2012, ACTA NEUROPATHOL, V123, P1, DOI [10.1007/s00401 011 0910 3, 10.1016/j.jalz.2011.10.007]
   Park E, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20112784
   Peng H.R., 1994, DICT TRADITIONAL CHI, V2, P1119
   Qu B, 2014, OSTEOPOROSIS INT, V25, P1853, DOI 10.1007/s00198 014 2699 0
   Salehpour F, 2017, NEUROBIOL AGING, V58, P140, DOI 10.1016/j.neurobiolaging.2017.06.025
   Shi Y, 2020, BIOMED PHARMACOTHER, V121, DOI 10.1016/j.biopha.2019.109566
   Wang CG, 2018, J CELL MOL MED, V22, P1583, DOI 10.1111/jcmm.13434
   Wang N, 2016, INT J BIOL MACROMOL, V83, P103, DOI 10.1016/j.ijbiomac.2015.11.032
   Wang NN, 2015, J CHROMATOGR B, V990, P64, DOI 10.1016/j.jchromb.2015.03.012
   Xia TS, 2019, J PHARMACEUT BIOMED, V166, P336, DOI 10.1016/j.jpba.2019.01.019
   Xu XH, 2016, INT IMMUNOPHARMACOL, V34, P212, DOI 10.1016/j.intimp.2016.03.001
   Zeng LL, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0088019, 10.1371/journal.pone.0087711]
   Zhang WX, 2015, CARBOHYD POLYM, V133, P154, DOI 10.1016/j.carbpol.2015.07.018
   Zhang ZG, 2016, FITOTERAPIA, V110, P166, DOI 10.1016/j.fitote.2016.03.013
   Zhao L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133289
NR 33
TC 29
Z9 30
U1 6
U2 71
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378 8741
EI 1872 7573
J9 J ETHNOPHARMACOL
JI J. Ethnopharmacol.
PD OCT 28
PY 2020
VL 261
AR 112992
DI 10.1016/j.jep.2020.112992
PG 9
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA NJ9BQ
UT WOS:000566339500010
PM 32590113
DA 2025 08 17
ER

PT J
AU Bae, Y
   Jung, MK
   Mun, JY
   Mallick, S
   Song, SJ
   Kim, DM
   Ko, KS
   Han, J
   Choi, JS
AF Bae, Yoonhee
   Jung, Min Kyo
   Mun, Ji Young
   Mallick, Sudipta
   Song, Su Jeong
   Kim, Dong Min
   Ko, Kyung Soo
   Han, Jin
   Choi, Joon Sig
TI DQAsomes Nanoparticles Promote Osteogenic Differentiation of Human
   Adipose derived Mesenchymal Stem Cells
SO BULLETIN OF THE KOREAN CHEMICAL SOCIETY
LA English
DT Article
DE Human adipose derived mesenchymal stem cells; DQAsomes; Osteoblast cells
ID GENE DELIVERY; PLASMID DNA; IN VITRO; MITOCHONDRIA; DEQUALINIUM; DEATH;
   CYTOTOXICITY; DENDRIMERS; RELEASE; PATHWAY
AB Mesenchymal stem cells (MSCs) can self renew and differentiate into multiple cell types. The delivery of drugs to MSCs is an important tool in the emerging fields of tissue regeneration and engineering. In this study, we determined the anticancer efficiency of DQAsomes, which displayed affinity toward human adipose derived mesenchymal stem cells (AD MSCs). Cytotoxicity assays were conducted to examine human AD MSCs. We also evaluated the cellular effects of human AD MSCs treated with DQAsomes by cell cycle distribution analysis, annexin V propidium iodide staining, and H2DCFDA and found that DQAsomes promoted the differentiation of AD MSCs into osteoblast cells. Furthermore, flow cytometry analysis revealed that human AD MSCs treated with DQAsomes maintained the phenotypic characteristics of human AD MSCs. We demonstrated that DQAsomes can be used in tissue engineering and have clinical relevance as effective drug and protein delivery systems.
C1 [Bae, Yoonhee; Han, Jin] Inje Univ, Coll Med, Cardiovasc & Metab Dis Ctr, Dept Physiol, Busan 614735, South Korea.
   [Jung, Min Kyo] Univ Ulsan, Coll Med, Dept Convergence Med, Seoul, South Korea.
   [Jung, Min Kyo] Asan Med Ctr, Asan Inst Life Sci, Seoul, South Korea.
   [Mun, Ji Young] Eulji Univ, Coll Hlth Sci, Dept Biomed Lab Sci, Seongnam 461713, South Korea.
   [Mallick, Sudipta; Song, Su Jeong; Kim, Dong Min; Choi, Joon Sig] Chungnam Natl Univ, Coll Nat Sci, Dept Biochem, Daejeon 305764, South Korea.
   [Ko, Kyung Soo] Inje Univ, Sanggye Paik Hosp, Cardiovasc & Metab Dis Ctr, Dept Internal Med, Seoul 139707, South Korea.
C3 Inje University; University of Ulsan; University of Ulsan; Asan Medical
   Center; Eulji University; Chungnam National University; Inje University
RP Han, J (通讯作者)，Inje Univ, Coll Med, Cardiovasc & Metab Dis Ctr, Dept Physiol, Busan 614735, South Korea.; Choi, JS (通讯作者)，Chungnam Natl Univ, Coll Nat Sci, Dept Biochem, Daejeon 305764, South Korea.
EM phyhanj@inje.ac.kr; joonsig@cnu.ac.kr
RI ; Mun, Jiyoung/IUN 3520 2023
OI Choi, Joon Sig/0000 0002 8463 841X; 
FU National Research Foundation of Korea (NRF)   Ministry of Education
   [NRF 2016R1D1A1A09917141]; National Research Foundation of Korea (NRF)  
   Ministry of Education, Science and Technology [2010 0020224]
FX This research was supported by the Basic Science Research Program
   through the National Research Foundation of Korea (NRF) funded by the
   Ministry of Education (NRF 2016R1D1A1A09917141), and by the Priority
   Research Centers Program through the National Research Foundation of
   Korea (NRF) funded by the Ministry of Education, Science and Technology
   (2010 0020224).
CR AshaRani PV, 2009, ACS NANO, V3, P279, DOI 10.1021/nn800596w
   Baksh D, 2004, J CELL MOL MED, V8, P301, DOI 10.1111/j.1582 4934.2004.tb00320.x
   Brammer KS, 2011, ACTA BIOMATER, V7, P683, DOI 10.1016/j.actbio.2010.09.022
   Chen Q, 2016, CELL DEATH DIFFER, V23, P1128, DOI 10.1038/cdd.2015.168
   D'Souza GGM, 2005, MITOCHONDRION, V5, P352, DOI 10.1016/j.mito.2005.07.001
   D'Souza GGM, 2003, J CONTROL RELEASE, V92, P189, DOI 10.1016/S0168 3659(03)00297 9
   Ferreira L, 2008, CELL STEM CELL, V3, P136, DOI 10.1016/j.stem.2008.07.020
   Galeano E, 2005, LEUKEMIA RES, V29, P1201, DOI 10.1016/j.leukres.2005.03.014
   García Pérez AI, 2011, LEUKEMIA RES, V35, P1395, DOI 10.1016/j.leukres.2011.03.012
   GOERGEN JL, 1993, CYTOTECHNOLOGY, V11, P189, DOI 10.1007/BF00749869
   Huang B, 2012, J CONTROL RELEASE, V162, P464, DOI 10.1016/j.jconrel.2012.07.034
   Klein E, 2010, BIOCONJUGATE CHEM, V21, P360, DOI 10.1021/bc900469z
   Kolhatkar RB, 2007, BIOCONJUGATE CHEM, V18, P2054, DOI 10.1021/bc0603889
   Malik N, 2000, J CONTROL RELEASE, V65, P133, DOI 10.1016/S0168 3659(99)00246 1
   McMahon JM, 2006, STEM CELLS DEV, V15, P87, DOI 10.1089/scd.2006.15.87
   Pajuelo L, 2011, INVEST NEW DRUG, V29, P1156, DOI 10.1007/s10637 010 9454 y
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Regelin AE, 2000, BBA BIOMEMBRANES, V1464, P151, DOI 10.1016/S0005 2736(00)00126 7
   Sancho P, 2007, LEUKEMIA RES, V31, P969, DOI 10.1016/j.leukres.2006.11.018
   Shah LS, 2007, NANO LETT, V7, P3071, DOI 10.1021/nl071547f
   Song XL, 2015, ONCOL REP, V34, P1953, DOI 10.3892/or.2015.4136
   Sudo K, 2007, STEM CELLS, V25, P1610, DOI 10.1634/stemcells.2006 0504
   Sun L, 2011, TOXICOL IN VITRO, V25, P1619, DOI 10.1016/j.tiv.2011.06.012
   Tanabe Shihori, 2014, World J Stem Cells, V6, P24, DOI 10.4252/wjsc.v6.i1.24
   Tatavarty R, 2014, CHEM COMMUN, V50, P8484, DOI 10.1039/c4cc02442g
   Tautzenberger A, 2010, BIOMATERIALS, V31, P2064, DOI 10.1016/j.biomaterials.2009.11.099
   Wang J, 2014, INT J NANOMED, V9, P3987, DOI 10.2147/IJN.S64103
   Wang LM, 2011, NANO LETT, V11, P772, DOI 10.1021/nl103992v
   WEISS MJ, 1987, P NATL ACAD SCI USA, V84, P5444, DOI 10.1073/pnas.84.15.5444
   Weissig V, 2000, DRUG DELIV, V7, P1, DOI 10.1080/107175400266722
   Yi CQ, 2010, ACS NANO, V4, P6439, DOI 10.1021/nn101373r
   Zhu JR, 2010, ACTA PHARMACOL SIN, V31, P273, DOI 10.1038/aps.2010.9
NR 32
TC 7
Z9 7
U1 1
U2 7
PU WILEY V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1229 5949
J9 B KOREAN CHEM SOC
JI Bull. Korean Chem. Soc.
PD JAN
PY 2018
VL 39
IS 1
BP 97
EP 104
DI 10.1002/bkcs.11355
PG 8
WC Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry
GA FS6CK
UT WOS:000419885300018
DA 2025 08 17
ER

PT J
AU Yoshino, M
   Watanabe, Y
   Tokunaga, Y
   Harada, E
   Fujii, C
   Numata, S
   Harada, M
   Tajima, A
   Ida, H
AF Yoshino, Makoto
   Watanabe, Yoriko
   Tokunaga, Yasuyuki
   Harada, Eimiei
   Fujii, Chieko
   Numata, Sanae
   Harada, Masaru
   Tajima, Asako
   Ida, Hiroyuki
TI Roles of specific cytokines in bone remodeling and hematopoiesis in
   Gaucher disease
SO PEDIATRICS INTERNATIONAL
LA English
DT Article
DE bone remodeling; cytokines; Gaucher disease; glucosylceramidase;
   hematologic disease
ID INHIBITS OSTEOCLAST FORMATION; COLONY STIMULATING FACTOR; M CSF;
   DIFFERENTIATION; INTERLEUKIN 18; METABOLISM; CHILDREN; GAMMA
AB Background: Gaucher disease type 1 and type 3 are characterized by bone disease and hematological symptoms. It is known that monocyte/macrophage lineage is activated in Gaucher disease, and accordingly certain cytokines are elevated in blood. The aim of the present study was to explore the possible relationships between cytokines and bone remodeling and hematological abnormalities in this disease.
   Methods: The concentrations of seven cytokines and two related proteins were measured in patients with Gaucher disease type 1 and type 3 (n = 8; age range, 2 50 years) who had received enzyme replacement therapy.
   Results: Concentrations of interleukin 18 and transforming growth factor beta 1 were elevated in patients of all clinical types. Elevation of these cytokines in Gaucher disease has not been previously reported. Analysis of correlation among cytokines and bone turnover markers showed that interleukin 18 concentration was correlated with each of two bone formation markers of bone specific alkaline phosphatase activity and osteocalcin concentration, whereas macrophage colony stimulating factor concentration correlated with the bone absorption marker of N telopeptide to helix in urine. Concentrations of macrophage colony stimulating factor and tumor necrosis factor alpha were inversely correlated with hemoglobin concentration.
   Conclusion: Interleukin 18 and monocyte macrophage colony stimulating factor are cytokines mainly involved in the mechanism of bone disease, while macrophage colony stimulating factor and tumor necrosis factor alpha may play a role in the development of hematological abnormalities in Gaucher disease.
C1 Kurume Univ, Sch Med, Dept Pediat & Child Hlth, Kurume, Fukuoka 8300011, Japan.
   Kurume Univ, Sch Med, Dept Internal Med 2, Kurume, Fukuoka, Japan.
   Jikei Univ, Sch Med, Dept Pediat, Tokyo, Japan.
C3 Kurume University; Kurume University; Jikei University
RP Yoshino, M (通讯作者)，Kurume Univ, Sch Med, Dept Pediat & Child Hlth, 67,Asahi machi, Kurume, Fukuoka 8300011, Japan.
EM yoshino@med.kurume u.ac.jp
OI Yoshino, Makoto/0000 0001 9048 1490; Watanabe,
   Yoriko/0000 0003 4685 8021
CR Allen MJ, 1997, QJM MON J ASSOC PHYS, V90, P19
   Barreda DR, 2004, DEV COMP IMMUNOL, V28, P509, DOI 10.1016/j.dci.2003.09.010
   Beutler E., 2001, METABOLIC MOL BASES, V3, P3635
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Cabera Salazar MA, 2004, CLIN CHIM ACTA, V344, P101, DOI 10.1016/j.cccn.2004.02.018
   Casal JA, 2002, CLIN CHEM LAB MED, V40, P52, DOI 10.1515/CCLM.2002.010
   Cornish J, 2003, ENDOCRINOLOGY, V144, P1194, DOI 10.1210/en.2002 220936
   FUJIMOTO S, 1995, J CLIN ENDOCR METAB, V80, P1922, DOI 10.1210/jc.80.6.1922
   GERY I, 1981, J CLIN INVEST, V68, P1182, DOI 10.1172/JCI110363
   Hollak CEM, 1997, BLOOD CELL MOL DIS, V23, P201, DOI 10.1006/bcmd.1997.0137
   Horwood NJ, 1998, J CLIN INVEST, V101, P595, DOI 10.1172/JCI1333
   Horwood NJ, 2001, J IMMUNOL, V166, P4915, DOI 10.4049/jimmunol.166.8.4915
   Hughes DE, 1996, NAT MED, V2, P1132, DOI 10.1038/nm1096 1132
   KANZAKI S, 1995, J CLIN ENDOCR METAB, V75, P1104
   Karst M, 2004, J CELL PHYSIOL, V200, P99, DOI 10.1002/jcp.20036
   Lichtenstein M, 1997, BLOOD CELL MOL DIS, V23, P395, DOI 10.1006/bcmd.1997.0156
   MANOLAGAS SC, 1995, NEW ENGL J MED, V332, P305, DOI 10.1056/NEJM199502023320506
   Michelakakis H, 1996, BBA MOL BASIS DIS, V1317, P219, DOI 10.1016/S0925 4439(96)00056 7
   Minehata K, 2002, BLOOD, V99, P2360, DOI 10.1182/blood.V99.7.2360
   Mora S, 1999, AM J GASTROENTEROL, V94, P398, DOI 10.1111/j.1572 0241.1999.867_r.x
   OGAWA M, 1993, BLOOD, V81, P2844
   OKAMURA H, 1995, NATURE, V378, P88, DOI 10.1038/378088a0
   Panis B, 2004, BONE, V35, P982, DOI 10.1016/j.bone.2004.06.004
   SHOENFELD Y, 1982, ARCH PATHOL LAB MED, V106, P388
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Tham DM, 2002, PHYSIOL GENOMICS, V11, P21, DOI 10.1152/physiolgenomics.00062.2002
   Tobiume H, 1997, J CLIN ENDOCR METAB, V82, P2056, DOI 10.1210/jc.82.7.2056
   Udagawa N, 1997, J EXP MED, V185, P1005, DOI 10.1084/jem.185.6.1005
   Yamada N, 2002, BONE, V30, P901, DOI 10.1016/S8756 3282(02)00722 6
   Yin T, 2006, J CLIN INVEST, V116, P1195, DOI 10.1172/JCI28568
   ZIMRAN A, 1992, MEDICINE, V71, P337, DOI 10.1097/00005792 199211000 00002
NR 31
TC 27
Z9 29
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1328 8067
EI 1442 200X
J9 PEDIATR INT
JI Pediatr. Int.
PD DEC
PY 2007
VL 49
IS 6
BP 959
EP 965
DI 10.1111/j.1442 200X.2007.02502.x
PG 7
WC Pediatrics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pediatrics
GA 235RX
UT WOS:000251253100031
PM 18045304
DA 2025 08 17
ER

PT J
AU Zhang, YM
   Lei, X
   He, R
   Mao, LT
   Jiang, P
   Ni, CL
   Zhong, XY
   Yin, ZY
   Wu, X
   Li, DP
   Zheng, QP
AF Zhang, Yiming
   Lei, Xuan
   He, Rong
   Mao, Liangtiao
   Jiang, Pan
   Ni, Chenlie
   Zhong, Xinyu
   Yin, Zhengyu
   Wu, Xuan
   Li, Dapeng
   Zheng, Qiping
TI Identification and preliminary validation of a four gene signature to
   predict metastasis and survival in osteosarcoma
SO AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH
LA English
DT Article
DE Osteosarcoma; prognosis; survival analysis; metastasis; bioinformatic
   analysis
ID IMMUNOTHERAPY; CHEMOTHERAPY; MECHANISM; MIGRATION; SARCOMA; TARGETS;
   GROWTH
AB Osteosarcoma is a primary malignant bone tumor that occurs frequently in children and adolescents and has a propensity for drug resistance, recurrence, and metastasis. The purpose of this study was to identify potential target genes to predict metastasis and survival in patients with osteosarcoma. We analyzed gene expression profiles and corresponding clinical data of patients with osteosarcoma in the Gene Expression Omnibus database and identified 202 genes that were differentially expressed between osteosarcoma cells and normal osteoblasts. Univariate and multivariable Cox regression analyses identified four risk genes that affected osteosarcoma prognosis: MCAM. ENPEP, LRRC1, and CPE. Independent prognostic analyses and clinical correlation studies showed that the four risk genes constituted an independent prognostic signature that correlated with survival and clinical parameters including age and distant metastasis. In a single sample Gene Set Enrichment Analysis, risk scores based on the prognostic signature correlated with tumor infiltration by immune cells and immune functions in osteosarcoma. A subsequent analysis showed that the expression levels of the four genes in the prognostic signature were predictive of overall survival and metastasis free survival of patients with osteosarcoma. Furthermore, Human Cancer Metastasis Database and qRT PCR analyses demonstrated that the four risk genes are overexpressed in osteosarcoma tissues and cell lines. In summary, we developed and validated a four gene prognostic signature that may be useful in osteosarcoma diagnosis and metastasis prediction.
C1 [Zhang, Yiming; Lei, Xuan; Mao, Liangtiao; Jiang, Pan; Ni, Chenlie; Zhong, Xinyu; Yin, Zhengyu; Li, Dapeng] Jiangsu Univ, Affiliated Hosp, 438 Jiefang Rd, Zhenjiang 212001, Jiangsu, Peoples R China.
   [He, Rong] Jiangsu Univ, Affiliated Peoples Hosp, Canc Inst, Zhenjiang 212000, Jiangsu, Peoples R China.
   [Jiang, Pan] Guizhou Orthoped Hosp, Guiyang 550002, Guizhou, Peoples R China.
   [Wu, Xuan; Zheng, Qiping] Jiangsu Univ, Sch Med, Jiangsu Key Lab Med Sci & Lab Med, Dept Hematol Lab Sci, Zhenjiang 212013, Jiangsu, Peoples R China.
   [Zheng, Qiping] Shenzhen Acad Peptide Targeting Technol Pingshan, Shenzhen 518118, Guangdong, Peoples R China.
   [Zheng, Qiping] Shenzhen Tyercan Biopharm Co Ltd, Shenzhen 518118, Guangdong, Peoples R China.
C3 Jiangsu University; Jiangsu University; Jiangsu University
RP Li, DP (通讯作者)，Jiangsu Univ, Affiliated Hosp, 438 Jiefang Rd, Zhenjiang 212001, Jiangsu, Peoples R China.; Zheng, QP (通讯作者)，Jiangsu Univ, Sch Med, Dept Lab Sci, 301 Xuefu Rd, Zhenjiang 212013, Jiangsu, Peoples R China.
EM lidapeng706@hotmail.com; qp_zheng@hotmail.com
OI Mao, Lianghao/0009 0007 0946 6420; Lei, Xuan/0000 0002 5240 0925
FU National Natural Science Foundation of China [81601931, 81672229];
   Natural Science Foundation of Jiangsu Province [BK20150475]; Youth
   Medical Key Talent Project of Jiangsu [QNRC2016844]; "Six One Projects"
   for highlevel health professionals in Jiangsu Province Top Talent
   Project [LGY2019089]; Jiangsu Provincial key research and development
   program [BE2020679]; Shenzhen Science and Technology Program
   [KQTD 20170810154011370]
FX This work was supported by the National Natural Science Foundation of
   China (No. 81601931; 81672229), the Natural Science Foundation of
   Jiangsu Province (BK20150475), the Youth Medical Key Talent Project of
   Jiangsu (QNRC2016844), "Six One Projects" for highlevel health
   professionals in Jiangsu Province Top Talent Project (LGY2019089),
   Jiangsu Provincial key research and development program (BE2020679), and
   the Shenzhen Science and Technology Program (No.
   KQTD 20170810154011370).
CR Almeida LL, 2018, STEM CELL REP, V11, P1040, DOI 10.1016/j.stemcr.2018.09.008
   Brown HK, 2017, CANCER LETT, V386, P189, DOI 10.1016/j.canlet.2016.11.019
   Bullinger L, 2017, J CLIN ONCOL, V35, P934, DOI 10.1200/JCO.2016.71.2208
   Chen CL, 2021, CANCER LETT, V500, P1, DOI 10.1016/j.canlet.2020.12.024
   Czarnecka AM, 2020, CANCERS, V12, DOI 10.3390/cancers12082130
   Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969
   Fan SL, 2016, ONCOTARGETS THER, V9, P2795, DOI 10.2147/OTT.S98991
   Feliciano A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076247
   Gianferante DM, 2017, NAT REV ENDOCRINOL, V13, P480, DOI 10.1038/nrendo.2017.16
   Harrison DJ, 2018, EXPERT REV ANTICANC, V18, P39, DOI 10.1080/14737140.2018.1413939
   Huang WT, 2019, AM J TRANSL RES, V11, P7538
   Isakoff MS, 2015, J CLIN ONCOL, V33, P3029, DOI 10.1200/JCO.2014.59.4895
   Ji XL, 2019, AGING US, V11, P5848, DOI 10.18632/aging.102193
   Lakshmikanthan S, 2011, BLOOD, V118, P2015, DOI 10.1182/blood 2011 04 349282
   Li JH, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00769
   Liu M, 2020, J DENT RES, V99, P959, DOI 10.1177/0022034520917058
   Luu HH, 2005, CLIN EXP METASTAS, V22, P319, DOI 10.1007/s10585 005 0365 9
   Meng Y, 2021, AM J TRANSL RES, V13, P532
   Meyers PA, 1998, J CLIN ONCOL, V16, P2452, DOI 10.1200/JCO.1998.16.7.2452
   Mintz MB, 2005, CANCER RES, V65, P1748, DOI 10.1158/0008 5472.CAN 04 2463
   Niu JF, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01628
   Ritter J, 2010, ANN ONCOL, V21, P320, DOI 10.1093/annonc/mdq276
   Schiano C, 2012, MED ONCOL, V29, P2998, DOI 10.1007/s12032 012 0158 3
   Sechler M, 2017, ONCOGENE, V36, P4150, DOI 10.1038/onc.2017.44
   Shah S, 2019, SEMIN CANCER BIOL, V54, P29, DOI 10.1016/j.semcancer.2018.03.005
   Shen SY, 2020, MOL CANCER, V19, DOI 10.1186/s12943 020 01269 4
   Tome Y, 2009, J CELL BIOCHEM, V108, P362, DOI 10.1002/jcb.22259
   Velletri T, 2021, CELL DEATH DIFFER, V28, P156, DOI 10.1038/s41418 020 0590 4
   Wang C, 2017, CANCER LETT, V403, P271, DOI 10.1016/j.canlet.2017.06.011
   Wang JS, 2019, MOL MED REP, V19, P2729, DOI 10.3892/mmr.2019.9912
   Wang X, 2021, BIOENGINEERED, V12, P1576, DOI 10.1080/21655979.2021.1920326
   Whelan JS, 2018, J CLIN ONCOL, V36, P188, DOI 10.1200/JCO.2017.75.1743
   Wu HB, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419 020 02962 4
   Wu Y, 2021, AM J TRANSL RES, V13, P5851
   Xu KT, 2021, BIOENGINEERED, V12, P3275, DOI 10.1080/21655979.2021.1947065
   Xu RD, 2018, CELL PROLIFERAT, V51, DOI 10.1111/cpr.12515
   Yang CF, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21196985
   Yin CD, 2021, BIOENGINEERED, V12, P172, DOI 10.1080/21655979.2020.1864096
   Yu YY, 2020, J CELL MOL MED, V24, P11230, DOI 10.1111/jcmm.15687
   Yuan YH, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00595
   Zhang C, 2020, AGING US, V12, P3486, DOI 10.18632/aging.102824
   Zhang YQ, 2018, CELL PHYSIOL BIOCHEM, V48, P1099, DOI 10.1159/000491976
   Zheng GT, 2018, NUCLEIC ACIDS RES, V46, pD950, DOI 10.1093/nar/gkx1008
   Zhu NQ, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935 020 01352 2
NR 44
TC 9
Z9 9
U1 0
U2 7
PU E CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1943 8141
J9 AM J TRANSL RES
JI Am. J. Transl. Res.
PY 2021
VL 13
IS 11
BP 12264
EP 12284
PG 21
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Research & Experimental Medicine
GA YD5QX
UT WOS:000740497800001
PM 34956452
DA 2025 08 17
ER

PT J
AU Streitbuerger, A
   Henrichs, M
   Ahrens, H
   Lanvers Kaminzky, C
   Gouin, F
   Gosheger, G
   Hardes, J
AF Streitbuerger, Arne
   Henrichs, Marcel
   Ahrens, Helmut
   Lanvers Kaminzky, Claudia
   Gouin, Francois
   Gosheger, Georg
   Hardes, Jendrik
TI Cytotoxic effect of clodronate and zoledronate on the chondrosarcoma
   cell lines HTB 94 and CAL 78
SO INTERNATIONAL ORTHOPAEDICS
LA English
DT Article
ID BREAST CANCER CELLS; BISPHOSPHONATES INHIBIT; POTENT INHIBITOR;
   MALIGNANT BONE; IN VITRO; PAMIDRONATE; METASTASES; PROSTATE; MECHANISMS;
   ADHESION
AB The wide surgical tumour resection is the only effective treatment in chondrosarcoma. However, a major problem remains the high rate of local recurrences and metastases due to the lack of adjuvant therapies. In this study the cytotoxic effect of the bisphosphonate clodronate (0.1 1000 mu M) and zoledronate (0.1 1000 mu M) in different concentrations on two chondrosarcoma cell lines (HTB 94 and CAL 78) has been investigated. After an incubation period of 48, 72 and 96 hours the chondrosarcoma cell viability was measured as the MTT proliferation rate. In concentrations of > 1 mu m zoledronate the cell activity was reduced by up to 95% for the CAL 78 cells. Further, zoledronate has been more effective in lower concentrations than clodronate in the reduction of cell viability for both cell lines. However, clodronate showed significant cytotoxic effects in high concentrations and after longer incubation periods. Further research is necessary, but in the light of these results bisphosphonates may also play a role in the treatment of chondrosarcomas.
C1 [Streitbuerger, Arne; Henrichs, Marcel; Ahrens, Helmut; Gosheger, Georg; Hardes, Jendrik] Univ Hosp Munster, Dept Orthoped, Munster, Germany.
   [Lanvers Kaminzky, Claudia] Univ Hosp Munster, Dept Pediat, Munster, Germany.
   [Gouin, Francois] CHU Nantes, Dept Orthoped, F 44035 Nantes 01, France.
C3 University of Munster; University of Munster; Nantes Universite; CHU de
   Nantes
RP Streitbuerger, A (通讯作者)，Univ Hosp Munster, Dept Orthoped, Munster, Germany.
EM streitb@ukmuenster.de
RI gouin, francois/L 1478 2015
OI Ahrens, Helmut/0009 0003 1730 9629
CR Berenson JR, 1999, ANNU REV MED, V50, P237
   Boissier S, 1997, CANCER RES, V57, P3890
   Brown JE, 2004, ENDOCR RELAT CANCER, V11, P207, DOI 10.1677/erc.0.0110207
   Choong PFM, 2003, CLIN ORTHOP RELAT R, pS19, DOI 10.1097/01.blo.0000093839.72468.da
   Coleman RE, 2002, AM J CLIN ONCOL CANC, V25, pS25, DOI 10.1097/00000421 200212001 00005
   Diel IJ, 1998, NEW ENGL J MED, V339, P357, DOI 10.1056/NEJM199808063390601
   Fiorenza F, 2002, J BONE JOINT SURG BR, V84B, P93, DOI 10.1302/0301 620X.84B1.11942
   Fournier P, 2002, CANCER RES, V62, P6538
   Gouin F, 2006, INT J CANCER, V119, P980, DOI 10.1002/ijc.21951
   Green JR, 2002, CURR OPIN ONCOL, V14, P609, DOI 10.1097/00001622 200211000 00004
   Guise TA, 1998, ENDOCR REV, V19, P18, DOI 10.1210/er.19.1.18
   Hiraga T, 2001, CANCER RES, V61, P4418
   Hortobagyi GN, 1996, NEW ENGL J MED, V335, P1785, DOI 10.1056/NEJM199612123352401
   Jagdev SP, 2001, BRIT J CANCER, V84, P1126, DOI 10.1054/bjoc.2001.1727
   Kanis JA, 1996, BONE, V19, P663, DOI 10.1016/S8756 3282(96)00285 2
   Mohammad KS, 2003, CLIN ORTHOP RELAT R, pS67, DOI 10.1097/01.blo.0000093047.96273.4e
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Rosen L, 2002, AM J CLIN ONCOL CANC, V25, pS19, DOI 10.1097/00000421 200212001 00004
   Rozeman LB, 2006, INT ORTHOP, V30, P437, DOI 10.1007/s00264 006 0212 x
   SATO M, 1991, J CLIN INVEST, V88, P2095, DOI 10.1172/JCI115539
   Senaratne SG, 2002, BREAST CANCER RES, V4, P18, DOI 10.1186/bcr412
   Shipman CM, 2000, ACTA ONCOL, V39, P829
   Sonnemann J, 2003, ANTI CANCER DRUG, V14, P767, DOI 10.1097/01.cad.0000094848.34612.41
   Sonnemann J, 2001, ANTI CANCER DRUG, V12, P459, DOI 10.1097/00001813 200106000 00007
   vanderPluijm G, 1996, J CLIN INVEST, V98, P698, DOI 10.1172/JCI118841
   VIRTANEN SS, 2000, CANCER RES, V62, P2708
   Vorotnjak M, 2004, ANTI CANCER DRUG, V15, P795, DOI 10.1097/00001813 200409000 00009
   Yano S, 2003, CLIN CANCER RES, V9, P5380
NR 28
TC 8
Z9 9
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0341 2695
EI 1432 5195
J9 INT ORTHOP
JI Int. Orthop.
PD SEP
PY 2011
VL 35
IS 9
BP 1369
EP 1373
DI 10.1007/s00264 010 1130 5
PG 5
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA 809OS
UT WOS:000294067200014
PM 20890703
OA Green Published
DA 2025 08 17
ER

PT J
AU Mckay, RR
   Kroeger, N
   Xie, W
   Lee, JL
   Knox, JJ
   Bjarnason, GA
   MacKenzie, MJ
   Wood, L
   Srinivas, S
   Vaishampayan, UN
   Rha, SY
   Pal, SK
   Donskov, F
   Tantravahi, SK
   Rini, BI
   Heng, DYC
   Choueiri, TK
AF Mckay, Rana R.
   Kroeger, Nils
   Xie, Wanling
   Lee, Jae Lyun
   Knox, Jennifer J.
   Bjarnason, Georg A.
   MacKenzie, Mary J.
   Wood, Lori
   Srinivas, Sandy
   Vaishampayan, Ulka N.
   Rha, Sun Young
   Pal, Sumanta K.
   Donskov, Frede
   Tantravahi, Srinivas K.
   Rini, Brian I.
   Heng, Daniel Y. C.
   Choueiri, Toni K.
TI Impact of Bone and Liver Metastases on Patients with Renal Cell
   Carcinoma Treated with Targeted Therapy
SO EUROPEAN UROLOGY
LA English
DT Article
DE Bone metastases; Liver metastases; mTOR inhibitors; Outcome; Renal cell
   carcinoma; VEGF therapy
ID PROGNOSTIC FACTORS; PROGRESSION FREE; SURVIVAL; SUNITINIB; CANCER;
   BISPHOSPHONATES; EVEROLIMUS; MODEL
AB Background: The skeleton and liver are frequently involved sites of metastasis in patients with metastatic renal cell carcinoma (RCC).
   Objective: To analyze outcomes based on the presence of bone metastases (BMs) and/or liver metastases (LMs) in patients with RCC treated with targeted therapy.
   Design, setting, and participants: We conducted a review from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) of 2027 patients with metastatic RCC.
   Outcome measurements and statistical analysis: We analyzed the impact of the site of metastasis on overall survival (OS) and time to treatment failure. Statistical analyses were performed using multivariable Cox regression.
   Results and limitations: The presence of BMs was 34% overall, and when stratified by IMDC risk groups was 27%, 33%, and 43% in the favorable , intermediate , and poor risk groups, respectively (p < 0.001). The presence of LMs was 19% overall and higher in the poor risk patients (23%) compared with the favorable  or intermediate risk groups (17%) (p = 0.003). When patients were classified into four groups based on the presence of BMs and/or LMs, the hazard ratio, adjusted for IMDC risk factors, was 1.4 (95% confidence interval [CI], 1.22 1.62) for BMs, 1.42 (95% CI, 1.17 1.73) for LMs, and 1.82 (95% CI, 1.47 2.26) for both BMs and LMs compared with other metastatic sites (p < 0.0001). The prediction model performance for OS was significantly improved when BMs and LMs were added to the IMDC prognostic model (likelihood ratio test p < 0.0001). Data in this analysis were collected retrospectively.
   Conclusions: The presence of BMs and LMs in patients treated with targeted agents has a negative impact on survival. Patients with BMs and/or LMs may benefit from earlier inclusion on clinical trials of novel agents or combination based therapies. (C) 2013 European Association of Urology. Published by Elsevier B.V. All rights reserved.
C1 [Mckay, Rana R.; Choueiri, Toni K.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
   [Kroeger, Nils; Heng, Daniel Y. C.] Univ Calgary, Tom Baker Canc Ctr, Dept Oncol, Calgary, AB, Canada.
   [Kroeger, Nils] Univ Med Greifswald, Dept Urol, Greifswald, Germany.
   [Xie, Wanling] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
   [Lee, Jae Lyun] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea.
   [Knox, Jennifer J.] Princess Margaret Hosp, Dept Hematol, Toronto, ON M4X 1K9, Canada.
   [Knox, Jennifer J.] Princess Margaret Hosp, Dept Med Oncol, Toronto, ON M4X 1K9, Canada.
   [Bjarnason, Georg A.] Univ Toronto, Sunnybrook Odette Canc Ctr, Div Med Oncol Hematol, Toronto, ON, Canada.
   [MacKenzie, Mary J.] London Reg Canc Program, Dept Med Oncol, London, ON, Canada.
   [Wood, Lori] Queen Elizabeth 2 Hlth Sci Ctr, Div Med Oncol, Halifax, NS, Canada.
   [Srinivas, Sandy] Stanford Med Ctr, Div Oncol, Stanford, CA USA.
   [Vaishampayan, Ulka N.] Wayne State Univ, Karmanos Canc Inst, Div Hematol Oncol, Detroit, MI USA.
   [Rha, Sun Young] Yonsei Univ, Coll Med, Yonsei Canc Ctr, Div Med Oncol, Seoul 120749, South Korea.
   [Pal, Sumanta K.] City Hope Comprehens Canc Ctr, Dept Med Oncol & Expt Therapeut, Duarte, CA USA.
   [Donskov, Frede] Aarhus Univ Hosp, Dept Oncol, DK 8000 Aarhus, Denmark.
   [Tantravahi, Srinivas K.] Univ Utah, Huntsman Canc Inst, Div Med Oncol Hematol, Salt Lake City, UT USA.
   [Rini, Brian I.] Cleveland Clin, Taussig Canc Inst, Dept Solid Tumor Oncol, Cleveland, OH 44106 USA.
C3 Harvard University; Harvard University Medical Affiliates; Dana Farber
   Cancer Institute; University of Calgary; Tom Baker Cancer Clinic;
   Universitat Greifswald; Greifswald Medical School; Harvard University;
   Harvard University Medical Affiliates; Dana Farber Cancer Institute;
   University of Ulsan; Asan Medical Center; University of Toronto;
   University Health Network Toronto; Princess Margaret Cancer Centre;
   University of Toronto; University Health Network Toronto; Princess
   Margaret Cancer Centre; University of Toronto; Sunnybrook Health Science
   Center; Sunnybrook Research Institute; Western University (University of
   Western Ontario); University Western Ontario Hospital; Queen Elizabeth
   II Health Sciences Centre; Stanford University; Stanford Medicine;
   Barbara Ann Karmanos Cancer Institute; Wayne State University; Yonsei
   University; Yonsei University Health System; City of Hope; Aarhus
   University; Utah System of Higher Education; University of Utah;
   Huntsman Cancer Institute; Cleveland Clinic Foundation
RP Choueiri, TK (通讯作者)，Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave, Boston, MA 02215 USA.
EM toni_choueiri@DFCI.harvard.edu
RI Lee, Jae Lyun/AGI 4843 2022; Bjarnason, Georg/L 6032 2019; Kroeger,
   Nils/AGG 4423 2022; Choueiri, Toni/K 5238 2019; Pal,
   Sumanta/ABY 3095 2022; Rini, Brian/MGV 8275 2025; Bjarnason, Georg
   Arnold/Q 5302 2016
OI Knox, Jennifer/0000 0003 3474 6647; Choueiri, Toni/0000 0002 9201 3217;
   Rha, Sun Young/0000 0002 2512 4531; Bjarnason, Georg
   Arnold/0000 0001 6903 5357; Donskov, Frede/0000 0002 8449 863X;
   Vaishampayan, Ulka/0000 0001 5800 4571
FU Bayer; Pfizer; Novartis; GlaxoSmithKline; Bayer Korea
FX Toni K. Choueiri certifies that all conflicts of interest, including
   specific financial interests and relationships and affiliations relevant
   to the subject matter or materials discussed in the manuscript (eg,
   employment/affiliation, grants or funding, consultancies, honoraria,
   stock ownership or options, expert testimony, royalties, or patents
   filed, received, or pending), are the following: Jae Lyun Lee has
   received honoraria from Novartis, Bayer, and Pfizer and research funding
   from Bayer. Jennifer J. Knox has been a consultant and played an
   advisory role at Aveo and has received research funding from Pfizer.
   Georg A. Bjarnason has been a consultant and played an advisory role at
   Pfizer and received honoraria and research funding from Pfizer. Mary J.
   MacKenzie has an advisory role at Novartis and Pfizer and has received
   research funding from both. Lori Wood has an advisory role at Pfizer and
   Novartis and has received research funding from Pfizer, Novartis, and
   GlaxoSmithKline. Ulka N. Vaishamayan has received honoraria and research
   funding from Pfizer, Novartis, and GlaxoSmithKline. Sun Young Rha has an
   advisory role at Novartis, Pfizer, and GlaxoSmithKline and has received
   research funding from Novartis and Bayer Korea. Frede Donskov has
   received research funding from Novartis. Brian I. Rini has an advisory
   role at Pfizer, GlaxoSmithKline, Aveo, Bayer, and Onyx and has received
   research funding from GlaxoSmithKline and Pfizer. Daniel Y.C. Heng has
   an advisory role at Aveo, Pfizer, Novartis, and Bayer. Toni K. Choueiri
   has received research funding from Pfizer and has an advisory role at
   Aveo, Pfizer, Novartis, GlaxoSmithKline, Genentech, Bayer, and Onyx. All
   remaining authors have nothing to disclose.
CR Beuselinck B, 2012, BRIT J CANCER, V107, P1665, DOI 10.1038/bjc.2012.385
   Beuselinck B, 2011, ANN ONCOL, V22, P794, DOI 10.1093/annonc/mdq554
   Bianchi M, 2012, ANN ONCOL, V23, P973, DOI 10.1093/annonc/mdr362
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Choueiri TK, 2007, CANCER AM CANCER SOC, V110, P543, DOI 10.1002/cncr.22827
   Donskov F, 2006, J CLIN ONCOL, V24, P1997, DOI 10.1200/JCO.2005.03.9594
   Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098
   Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205
   Heng DYC, 2009, J CLIN ONCOL, V27, P5794, DOI 10.1200/JCO.2008.21.4809
   Keizman D, 2012, EUR J CANCER, V48, P1031, DOI 10.1016/j.ejca.2012.02.050
   Mekhail TM, 2005, J CLIN ONCOL, V23, P832, DOI 10.1200/JCO.2005.05.179
   Moriceau G, 2010, CANCER RES, V70, P10329, DOI 10.1158/0008 5472.CAN 10 0578
   Motzer RJ, 2008, CANCER AM CANCER SOC, V113, P1552, DOI 10.1002/cncr.23776
   Motzer RJ, 2010, CANCER AM CANCER SOC, V116, P4256, DOI 10.1002/cncr.25219
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Négrier S, 2002, ANN ONCOL, V13, P1460, DOI 10.1093/annonc/mdf257
   Patil S, 2011, ANN ONCOL, V22, P295, DOI 10.1093/annonc/mdq342
   Pepe MS, 2013, STAT MED, V32, P1467, DOI 10.1002/sim.5727
   Riechelmann RP, 2008, AM J CLIN ONCOL CANC, V31, P182, DOI 10.1097/COC.0b013e3181574084
   Segal E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005233
   Woodward E, 2011, BONE, V48, P160, DOI 10.1016/j.bone.2010.09.008
NR 21
TC 201
Z9 210
U1 0
U2 22
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0302 2838
EI 1873 7560
J9 EUR UROL
JI Eur. Urol.
PD MAR
PY 2014
VL 65
IS 3
BP 577
EP 584
DI 10.1016/j.eururo.2013.08.012
PG 8
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Urology & Nephrology
GA 302AC
UT WOS:000330572600018
PM 23962746
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Savage, R
AF Savage, R
TI Cyclo oxygenase 2 inhibitors   When should they be used in the elderly?
SO DRUGS & AGING
LA English
DT Article
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; ACUTE MYOCARDIAL INFARCTION;
   SELECTIVE CYCLOOXYGENASE 2 INHIBITORS; THERAPEUTIC ARTHRITIS RESEARCH;
   EVENT TRIAL TARGET; RHEUMATOID ARTHRITIS; ULCER COMPLICATIONS;
   GASTROINTESTINAL TOXICITY; SYSTEMIC HYPERTENSION; BLOOD PRESSURE
AB Chronic pain in the elderly is frequently a result of arthritic disorders, particularly osteoarthritis. The cyclo oxygenase (COX) 2 inhibitors are as effective as standard NSAIDs for the relief of pain and for improving function in elderly patients with osteoarthritis and rheumatoid arthritis. COX 2 inhibitors increase the risk of serious gastroduodenal adverse reactions but there is evidence that they carry a lower risk for these adverse effects than standard NSAIDs, except when there is concurrent aspirin use. Since gastroduodenal disorders are the most frequently reported serious adverse effects of NSAIDs and these disorders occur more frequently in the elderly, COX 2 inhibitors offer an alternative to standard NSAIDs in this age group. However, they are not appropriate for many patients with cardiovascular and renal disease.
   The adverse reaction profile of the COX 2 inhibitors has confirmed the role of the COX 2 enzyme in renal function, salt and water homeostasis and the vascular endothelium. Thus, like standard NSAIDs, COX 2 inhibitors can cause renal failure, hypertension and exacerbation of cardiac failure. Of note is that these disorders are dose related. Thus, there are good reasons to avoid high doses of COX 2 inhibitors in the elderly. Clinical trials indicate that daily doses of rofecoxib 12.5 mg, celecoxib 100 200 mg, valdecoxib 10 mg and etoricoxib 60 mg are the minimum effective doses of these agents. Data from the New Zealand Intensive Medicines Monitoring Programme indicate that celecoxib 200 mg/day and rofecoxib 25 mg/day are/were the most commonly prescribed doses and that 6% of patients had taken rofecoxib 50 mg/day for longer than recommended. Recent research indicates that COX 2 inhibitors have a thrombotic potential, especially in high doses and when use is prolonged, and this further limits the extent to which they can be used in the elderly.
   Important interactions with COX 2 inhibitors in the elderly include those with warfarin, which can result in loss of control of anti coagulation, and those with ACE inhibitors, angiotensin II type 1 receptor antagonists and diuretics, which can result in loss of control of blood pressure and cardiac failure and, in hypovolaemic conditions, renal failure. The clinical significance of an interaction between celecoxib and aspirin to reduce the antiplatelet effect of the latter drug is unknown.
   Preliminary information from spontaneous reporting systems indicates that there may be differences in the risk of cardiac failure and hypertension between standard NSAIDs and COX 2 inhibitors and between rofecoxib and celecoxib. More formal studies using equivalent doses are needed to test this observation.
   Use of COX 2 inhibitors may be considered in the elderly to reduce the risk of gastroduodenal complications associated with standard NSAIDs but only when consideration has first been given to use of less toxic medicines as alternatives or supplements, the appropriate dose of the COX 2 inhibitor or standard NSAID, the presence and possible impact of co morbidities, and the implications of taking COX 2 inhibitors with any concomitant medications. Equally important is regular monitoring of the patient taking a COX 2 inhibitor for efficacy and adverse effects, and ensuring that the patient has a continuing need to keep taking the drug. Close attention also needs to be paid to intercurrent illnesses and new prescriptions that may reduce the safety of the COX 2 inhibitor.
   A standard NSAID plus a proton pump inhibitor may be equally effective as a COX 2 inhibitor in reducing the risk of gastroduodenal toxicity and if used the same prescribing advice applies. Current knowledge concerning the thrombotic potential of COX 2 inhibitors suggests that this combination, if tolerated, may be preferable to a COX 2 inhibitor, particularly where prolonged use is required. This knowledge also indicates that for patients with or at high risk of ischaemic heart disease or stroke, COX 2 inhibitors are contraindicated.
C1 Univ Otago, Dept Prevent & Social Med, New Zealand Pharmacovigilence Ctr, Dunedin, New Zealand.
C3 University of Otago
RP Univ Otago, Dept Prevent & Social Med, New Zealand Pharmacovigilence Ctr, POB 913, Dunedin, New Zealand.
EM ruth.savage@stonebow.otago.ac.nz
CR *ADRAC, 2003, ADVERSE DRUG REACT, V22, P15
   *ADRAC, 2002, ADVERSE DRUG REACT, V21, P3
   *ADRAC, 2001, ADVERSE DRUG REACT, V20, P2
   Ahmad SR, 2002, DRUG SAFETY, V25, P537, DOI 10.2165/00002018 200225070 00007
   Altman RD, 2000, ARTHRITIS RHEUM US, V43, P1905
   *ARC, 2004, NEW ZEAL DAT SHEET M
   Bate A, 2002, DRUG SAFETY, V25, P393, DOI 10.2165/00002018 200225060 00002
   Belton O, 2000, CIRCULATION, V102, P840
   *BEXTR, 2003, NEW ZEAL DAT SHEET
   Bombardier C, 2000, NEW ENGL J MED, V343, P1520, DOI 10.1056/NEJM200011233432103
   Bonner GF, 2001, AM J GASTROENTEROL, V96, P1306
   Boyd IW, 2000, MED J AUSTRALIA, V173, P274, DOI 10.5694/j.1326 5377.2000.tb125642.x
   Brater DC, 2001, AM J NEPHROL, V21, P1, DOI 10.1159/000046212
   BRESALIER RS, 2005, N ENGL J MED 0215
   Brinker A, 2004, DRUG AGING, V21, P479, DOI 10.2165/00002512 200421070 00005
   Brooks PM, 2002, CURR OPIN RHEUMATOL, V14, P573, DOI 10.1097/00002281 200209000 00017
   Catella Lawson F, 2001, NEW ENGL J MED, V345, P1809, DOI 10.1056/NEJMoa003199
   *CEL, NEW ZEAL DAT SHEET
   Chan FKL, 2002, NEW ENGL J MED, V347, P2104, DOI 10.1056/NEJMoa021907
   CLARK DWJ, 1992, DRUG SAFETY, V7, P460, DOI 10.2165/00002018 199207060 00006
   Clark DWJ, 2004, DRUG SAFETY, V27, P427, DOI 10.2165/00002018 200427070 00002
   Clemett D, 2000, DRUGS, V59, P957, DOI 10.2165/00003495 200059040 00017
   Collantes Estevez E, 2003, CURR MED RES OPIN, V19, P402, DOI 10.1185/030079903125001938
   *COMM SAF MED, 1986, BMJ BRIT MED J, V292, P1190
   COULTER D, 2003, P AUST SOC CLIN EXP, V10, P110
   COULTER D, 2002, PRESCRIBER UPDATE, V23, P21
   Coulter DM, 2003, BMJ BRIT MED J, V327, P1214, DOI 10.1136/bmj.327.7425.1214
   Curtis JP, 2003, BRIT MED J, V327, P1322, DOI 10.1136/bmj.327.7427.1322
   Ehrich EW, 1999, CLIN PHARMACOL THER, V65, P336, DOI 10.1016/S0009 9236(99)70113 X
   EID RY, 2001, AM J GASTROENTEROL S, V96, pS194
   Emery P, 1999, LANCET, V354, P2106, DOI 10.1016/S0140 6736(99)02332 6
   Farkouh ME, 2004, LANCET, V364, P675, DOI 10.1016/S0140 6736(04)16894 3
   *FDA, 2000, ROF STAT REV
   *FDA ADV COMM, 2000, CEL MED OFF REV
   Feenstra J, 2002, ARCH INTERN MED, V162, P265, DOI 10.1001/archinte.162.3.265
   Felson DT, 2001, ARTHRITIS RHEUM US, V44, P1477, DOI 10.1002/1529 0131(200107)44:7<1477::AID ART267>3.0.CO;2 O
   FitzGerald GA, 2001, NEW ENGL J MED, V345, P433, DOI 10.1056/NEJM200108093450607
   Furberg CD, 2005, CIRCULATION, V111, P249, DOI 10.1161/01.CIR.0000155081.76164.17
   Garnett WR, 2001, PHARMACOTHERAPY, V21, P1223, DOI 10.1592/phco.21.15.1223.33891
   Geba GP, 2002, JAMA J AM MED ASSOC, V287, P64, DOI 10.1001/jama.287.1.64
   GEBA GP, 2002, JAMA J AM MED ASSOC, V27, P287
   Graham DJ, 2005, LANCET, V365, P475, DOI 10.1016/S0140 6736(05)17864 7
   HARRISON A, 1999, PRESCRIBER UPDATE, V18, P4
   Henao J, 2002, AM J KIDNEY DIS, V39, P1313, DOI 10.1053/ajkd.2002.33412
   Jiang HK, 1999, CLIN RHEUMATOL, V18, P339, DOI 10.1007/s100670050114
   Kurth T, 2003, CIRCULATION, V108, P1191, DOI 10.1161/01.CIR.0000087593.07533.9B
   Langman MJ, 1999, JAMA J AM MED ASSOC, V282, P1929, DOI 10.1001/jama.282.20.1929
   Langman MJS, 2001, PHARMACOEPIDEM DR S, V10, P13, DOI 10.1002/pds.561
   Laporte JR, 2004, DRUG SAFETY, V27, P411, DOI 10.2165/00002018 200427060 00005
   Lewis SC, 2002, BRIT J CLIN PHARMACO, V54, P320, DOI 10.1046/j.1365 2125.2002.01636.x
   Mamdani M, 2003, ARCH INTERN MED, V163, P481, DOI 10.1001/archinte.163.4.481
   Mamdani M, 2004, LANCET, V363, P1751, DOI 10.1016/S0140 6736(04)16299 5
   Mamdani M, 2002, BRIT MED J, V325, P624, DOI 10.1136/bmj.325.7365.624
   McAdam BF, 1999, P NATL ACAD SCI USA, V96, P272, DOI 10.1073/pnas.96.1.272
   *MEDS ED TEAM, 2001, PRESCR UPDA, V22, P16
   *NAT I CLIN EXC, 2001, 27 GOV PUBL
   Ouellet M, 2001, P NATL ACAD SCI USA, V98, P14583, DOI 10.1073/pnas.251543298
   Page J, 2000, ARCH INTERN MED, V160, P777, DOI 10.1001/archinte.160.6.777
   Pilotto A, 2003, DRUG AGING, V20, P701, DOI 10.2165/00002512 200320090 00006
   Pincus T, 2001, ARTHRITIS RHEUM US, V44, P1587, DOI 10.1002/1529 0131(200107)44:7<1587::AID ART282>3.0.CO;2 X
   Rang H P., 1999, Pharmacology, V4, P229
   Ray WA, 2002, LANCET, V360, P1071, DOI 10.1016/S0140 6736(02)11131 7
   Riendeau D, 2001, J PHARMACOL EXP THER, V296, P558
   Rocha JL, 2001, LANCET, V357, P1946, DOI 10.1016/S0140 6736(00)05083 2
   Savage R., 2002, PRESCR UPDATE, V23, P20
   SAVAGE R, 2001, PRESCRIBER UPDATE, V21, P25
   SAVAGE RL, 1993, ARTHRITIS RHEUM, V36, P84, DOI 10.1002/art.1780360114
   SAVAGE RL, 2002, PRESCRIBER UPDATE, V23, P26
   Schnitzer TJ, 2004, LANCET, V364, P665, DOI 10.1016/S0140 6736(04)16893 1
   Schwartz JI, 2002, CLIN PHARMACOL THER, V72, P50, DOI 10.1067/mcp.2002.126182
   Scott LJ, 1999, DRUGS, V58, P499, DOI 10.2165/00003495 199958030 00016
   Silverstein FE, 2000, JAMA J AM MED ASSOC, V284, P1247, DOI 10.1001/jama.284.10.1247
   Slordal L, 2003, BRIT J CLIN PHARMACO, V55, P413, DOI 10.1046/j.1365 2125.2003.01777.x
   Solomon DH, 2004, CIRCULATION, V109, P2068, DOI 10.1161/01.CIR.0000127578.21885.3E
   SOLOMON SD, 2005, N ENGL J MED 0215
   Thomas MC, 2000, MED J AUSTRALIA, V172, P184, DOI 10.5694/j.1326 5377.2000.tb125548.x
   Van Hecken A, 2000, J CLIN PHARMACOL, V40, P1109
   Weaver A, 2003, AM J CARDIOL, V91, P1291, DOI 10.1016/S0002 9149(03)00369 2
   Weaver J, 2001, AM J GASTROENTEROL, V96, P3449
   Whelton A, 2000, ARCH INTERN MED, V160, P1465, DOI 10.1001/archinte.160.10.1465
   Whelton A, 2002, AM J CARDIOL, V90, P959, DOI 10.1016/S0002 9149(02)02661 9
   *WHO INT DRUG MON, 2003, SID EFF DRUGS ANN, V26, P548
   Zhao SZ, 2001, CLIN THER, V23, P1478, DOI 10.1016/S0149 2918(01)80121 1
NR 83
TC 33
Z9 38
U1 0
U2 13
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 1170 229X
EI 1179 1969
J9 DRUG AGING
JI Drugs Aging
PY 2005
VL 22
IS 3
BP 185
EP 200
DI 10.2165/00002512 200522030 00001
PG 16
WC Geriatrics & Gerontology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Geriatrics & Gerontology; Pharmacology & Pharmacy
GA 917XW
UT WOS:000228503600001
PM 15813652
DA 2025 08 17
ER

PT J
AU Choi, JW
   Shin, S
   Lee, CY
   Lee, J
   Seo, HH
   Lim, S
   Lee, S
   Kim, IK
   Lee, HB
   Kim, SW
   Hwang, KC
AF Choi, Jung Won
   Shin, Sunhye
   Lee, Chang Youn
   Lee, Jiyun
   Seo, Hyang Hee
   Lim, Soyeon
   Lee, Seahyoung
   Kim, Il Kwon
   Lee, Hoon Bum
   Kim, Sang Woo
   Hwang, Ki Chul
TI Rapid Induction of Osteogenic Markers in Mesenchymal Stem Cells by
   Adipose Derived Stromal Vascular Fraction Cells
SO CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
LA English
DT Article
DE Adipose derived stromal vascular fraction cells; Bone marrow derived
   mesenchymal stem cells; Osteogenesis; Transforming growth factor beta;
   Bone morphogenetic protein 2; Co culture system
ID BONE MORPHOGENETIC PROTEIN 2; OSTEOBLAST DIFFERENTIATION; REGENERATIVE
   MEDICINE; TGF BETA; TISSUE; BIOLOGY; LIPOSUCTION; MECHANISMS;
   EXPRESSION; DEFECTS
AB Background/Aims: Stromal vascular fraction (SVF) cells are a mixed cell population, and their regenerative capacity has been validated in various therapeutic models. The purpose of this study was to investigate the regenerative mechanisms utilized by implanted SVF cells. Using an in vitro co culture system, we sought to determine whether SVF implantation into impaired tissue affects endogenous mesenchymal stem cell (MSC) differentiation; MSCs can differentiate into a variety of cell types, and they have a strong regenerative capacity despite their low numbers in impaired tissue. Methods: Adipose derived SVF cells obtained from four donors were co cultured with bone marrow derived MSCs, and the differential expression of osteogenic markers and osteogenic differentiation inducers over time was analyzed in mono cultured MSCs and MSCs co cultured with SVF cells. Results: The co cultivation of MSCs with SVF cells significantly and mutually induced the expression of osteogenic specific markers via paracrine and/or autocrine regulation but did not induce adipocyte, chondrocyte or myoblast marker expression. More surprisingly, subsequent osteogenesis and/or comparable effects were rapidly induced within 48 h. Conclusion: To the best of our knowledge, this is the first study in which osteogenesis and/or comparable effects were rapidly induced in bone marrow derived MSCs and adipose derived SVF cells through co cultivation. Our findings suggest that the positive effects of SVF implantation into impaired bone may be attributed to the rapid induction of MSC osteogenesis, and the transplantation of co cultured and preconditioned SVF cells and/or MSCs may be more effective than the transplantation of untreated cells for the treatment of bone defects. (c) 2017 The Author(s) Published by S. Karger AG, Basel
C1 [Choi, Jung Won; Lim, Soyeon; Lee, Seahyoung; Kim, Il Kwon; Kim, Sang Woo; Hwang, Ki Chul] Catholic Kwandong Univ, Coll Med, Inst Biomed Convergence, Gangneung Si, Gangwon Do, South Korea.
   [Choi, Jung Won] Catholic Kwandong Univ, Coll Med, Dept Hlth & Environm, Gangneung Si, Gangwon Do, South Korea.
   [Shin, Sunhye; Lee, Chang Youn] Yonsei Univ, Grad Sch, Dept Integrated Omics Biomed Sci, Seoul, South Korea.
   [Lee, Jiyun; Seo, Hyang Hee] Yonsei Univ, Coll Med, Brain Korea PLUS Project Med Sci 21, Seoul, South Korea.
   [Lim, Soyeon; Lee, Seahyoung; Kim, Sang Woo; Hwang, Ki Chul] Catholic Kwandong Univ, Int St Marys Hosp, Incheon Metropolitan Cit, South Korea.
   [Kim, Il Kwon] Catholic Kwandong Univ, Int St Marys Hosp, Cell Therapy Ctr, Incheon Metropolitan Cit, South Korea.
   [Lee, Hoon Bum] Catholic Kwandong Univ, Int St Marys Hosp, Dept Plast & Reconstruct Surg, Incheon Metropolitan Cit, South Korea.
C3 Catholic Kwandong University; Catholic Kwandong University; Yonsei
   University; Yonsei University; Yonsei University Health System; Catholic
   Kwandong University; Catholic Kwandong University; Catholic Kwandong
   University
RP Kim, SW; Hwang, KC (通讯作者)，Catholic Kwandong Univ, Int St Marys Hosp, Incheon Metropolitan Cit, South Korea.
EM ksw74@cku.ac.kr; kchwang@cku.ac.kr
RI ; Kim, Soo/P 7880 2016; kim, sang soo/C 6573 2009; Lee, Chang
   Youn/JUF 8732 2023
OI Kim, Sang Woo/0000 0002 3144 4822; Lee, Changyoun/0000 0002 8379 3303; 
FU Korea Science and Engineering Foundation   Korean government (MEST)
   [NRF 2015M3A9E6029519]
FX This study was supported by a Korea Science and Engineering Foundation
   grant funded by the Korean government (MEST) (NRF 2015M3A9E6029519).
CR Alessandri G, 2004, LANCET, V364, P1872, DOI 10.1016/S0140 6736(04)17443 6
   Barry FP, 2004, INT J BIOCHEM CELL B, V36, P568, DOI 10.1016/j.biocel.2003.11.001
   Beederman M., 2013, J BIOMEDICAL SCI ENG, V6, P32, DOI DOI 10.4236/JBISE.2013.68A1004
   Bernardo ME, 2009, ANN NY ACAD SCI, V1176, P101, DOI 10.1111/j.1749 6632.2009.04607.x
   Blaber SP, 2012, J TRANSL MED, V10, DOI 10.1186/1479 5876 10 172
   Bora P, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287 017 0598 y
   Bourin P, 2013, CYTOTHERAPY, V15, P641, DOI 10.1016/j.jcyt.2013.02.006
   Calabrese G, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151181
   Centrella Michael, 1998, Frontiers in Bioscience, V3, pD113
   Charbord P, 2011, STEM CELL REV REP, V7, P32, DOI 10.1007/s12015 010 9125 6
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Choi JW, 2016, CELL PHYSIOL BIOCHEM, V39, P1595, DOI 10.1159/000447861
   Chung MT, 2013, STEM CELL TRANSL MED, V2, P808, DOI 10.5966/sctm.2012 0183
   De Bari C, 2001, ARTHRITIS RHEUM US, V44, P1928, DOI 10.1002/1529 0131(200108)44:8<1928::AID ART331>3.0.CO;2 P
   Derynck R, 2007, NAT CELL BIOL, V9, P1000, DOI 10.1038/ncb434
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Ducy P, 2000, DEV DYNAM, V219, P461, DOI 10.1002/1097 0177(2000)9999:9999<::AID DVDY1074>3.0.CO;2 C
   Fehrer C, 2007, AGING CELL, V6, P745, DOI 10.1111/j.1474 9726.2007.00336.x
   Guo J, 2016, J PLAST RECONSTR AES, V69, P180, DOI 10.1016/j.bjps.2015.10.014
   Han S, 2015, CRIT REV EUKAR GENE, V25, P145, DOI 10.1615/CritRevEukaryotGeneExpr.2015013057
   Harada H, 1999, J BIOL CHEM, V274, P6972, DOI 10.1074/jbc.274.11.6972
   Hoemann CD, 2009, PATHOL BIOL, V57, P318, DOI 10.1016/j.patbio.2008.06.004
   Hu HY, 2016, CELL PHYSIOL BIOCHEM, V38, P2375, DOI 10.1159/000445590
   Jurgens WJFM, 2013, BIORESEARCH OPEN ACC, V2, P315, DOI 10.1089/biores.2013.0024
   Karsenty G, 1999, GENE DEV, V13, P3037, DOI 10.1101/gad.13.23.3037
   Katagiri T, 2002, ORAL DIS, V8, P147, DOI 10.1034/j.1601 0825.2002.01829.x
   Kim KI, 2014, BIOMATERIALS, V35, P4792, DOI 10.1016/j.biomaterials.2014.02.048
   Lee YS, 2013, CELL PHYSIOL BIOCHEM, V31, P513, DOI 10.1159/000350072
   Lim S, 2017, INT J MED SCI, V14, P911, DOI 10.7150/ijms.19998
   Lin K, 2008, CYTOTHERAPY, V10, P417, DOI 10.1080/14653240801982979
   Liu TM, 2013, TISSUE ENG PART B RE, V19, P254, DOI [10.1089/ten.TEB.2012.0527, 10.1089/ten.teb.2012.0527]
   Mehrkens A, 2012, EUR CELLS MATER, V24, P308, DOI 10.22203/eCM.v024a22
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Nguyen A, 2016, J PLAST RECONSTR AES, V69, P170, DOI 10.1016/j.bjps.2015.10.015
   Prins HJ, 2016, STEM CELL TRANSL MED, V5, P1362, DOI 10.5966/sctm.2015 0369
   Raida M, 2006, INT J MOL MED, V18, P735
   Riordan NH, 2009, J TRANSL MED, V7, DOI 10.1186/1479 5876 7 29
   Sándor GK, 2013, J ORAL MAXIL SURG, V71, P938, DOI 10.1016/j.joms.2012.11.014
   Semon JA, 2013, STEM CELL TRANSL MED, V2, P789, DOI 10.5966/sctm.2013 0032
   Shui CX, 2003, J BONE MINER RES, V18, P213, DOI 10.1359/jbmr.2003.18.2.213
   Song SW, 2016, CELL PHYSIOL BIOCHEM, V40, P400, DOI 10.1159/000452555
   Sudhakar S, 2001, BIOCHEM BIOPH RES CO, V289, P616, DOI 10.1006/bbrc.2001.6033
   Thesleff T, 2011, NEUROSURGERY, V68, P1535, DOI 10.1227/NEU.0b013e31820ee24e
   van den Bos C, 1997, Hum Cell, V10, P45
   van Dijk A, 2011, STEM CELL RES, V7, P219, DOI 10.1016/j.scr.2011.06.003
   Varma MJO, 2007, STEM CELLS DEV, V16, P91, DOI 10.1089/scd.2006.0026
   Via Alessio Giai, 2012, Muscles Ligaments Tendons J, V2, P154
   Vogel C, 2012, NAT REV GENET, V13, P227, DOI 10.1038/nrg3185
   Warde Farley D, 2010, NUCLEIC ACIDS RES, V38, pW214, DOI 10.1093/nar/gkq537
   Wilson SM, 2012, J ORAL MAXIL SURG, V70, pE193, DOI 10.1016/j.joms.2011.10.029
   Xiao WL, 2015, CELL PHYSIOL BIOCHEM, V36, P1015, DOI 10.1159/000430275
   Yoshimura K, 2006, J CELL PHYSIOL, V208, P64, DOI 10.1002/jcp.20636
   Zuk PA, 2001, TISSUE ENG, V7, P211, DOI 10.1089/107632701300062859
NR 53
TC 26
Z9 26
U1 0
U2 7
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH 4009 BASEL, SWITZERLAND
SN 1015 8987
EI 1421 9778
J9 CELL PHYSIOL BIOCHEM
JI Cell. Physiol. Biochem.
PY 2017
VL 44
IS 1
BP 53
EP 65
DI 10.1159/000484582
PG 13
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA FT3YR
UT WOS:000423087200004
PM 29131029
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Esposito, P
   Rampino, T
   Gregorini, M
   Tinelli, C
   De Silvestri, A
   Malberti, F
   Coppo, R
   Dal Canton, A
AF Esposito, Pasquale
   Rampino, Teresa
   Gregorini, Marilena
   Tinelli, Carmine
   De Silvestri, Annalisa
   Malberti, Fabio
   Coppo, Rosanna
   Dal Canton, Antonio
CA IAMM Grp
TI Management of mineral metabolism in hemodialysis patients: discrepancy
   between interventions and perceived causes of failure
SO JOURNAL OF NEPHROLOGY
LA English
DT Article
DE Clinical audit; Compliance; Hemodialysis; Mineral disorders; Quality
   improvement
ID DISEASE; ADHERENCE; MORTALITY; PHOSPHATE; AUDIT; OUTCOMES; CALCIUM
AB Mineral and bone disorders (MBD) in patients undergoing hemodialysis (HD) are a major clinical complication. Current therapeutic strategies do not attain the expected results. The Italian audit on mineral metabolism was implemented to investigate MBD management through a "patient oriented" approach.
   Clinical and laboratory data pertinent to MBD from 509 prevalent adult patients on chronic HD were recorded and examined (audit), after which individual strategies were elaborated to improve MBD control. Their effectiveness was evaluated 6 months after the audit (Post 6).
   The audit disclosed poor MBD control in a high percentage of patients (56 %). Low compliance to treatment was the major determinant of failure (in 43.5 % of cases). Logistic regression showed a direct correlation between high degree of compliance and the achievement of therapeutic targets, e.g. parathyroid hormone: odds ratio (OR) 2.48, p = 0.015. In contrast, a minority of the proposed interventions (14.7 %) included strategies to improve patient compliance. At Post 6, despite a significant increase in drug prescription (p < 0.05 vs. audit), the rate of successful MBD control was unchanged.
   Low compliance with treatment is a major, but still neglected, cause of failure in the achievement of MBD control in HD patients.
C1 [Esposito, Pasquale; Rampino, Teresa; Gregorini, Marilena; Dal Canton, Antonio] Fdn IRCCS Policlin San Matteo, Dept Nephrol Dialysis & Transplantat, I 27100 Pavia, Italy.
   [Esposito, Pasquale; Rampino, Teresa; Gregorini, Marilena; Dal Canton, Antonio] Univ Pavia, I 27100 Pavia, Italy.
   [Tinelli, Carmine; De Silvestri, Annalisa] Fdn IRCCS Policlin San Matteo, Unit Biometry & Clin Epidemiol, I 27100 Pavia, Italy.
   [Malberti, Fabio] Ist Ospitalieri Cremona, Div Nefrol & Dialisi, Cremona, Italy.
   [Coppo, Rosanna] Regina Margherita Childrens Hosp, City Hlth & Sci Turin, Nephrol Dialysis & Transplantat Unit, Turin, Italy.
C3 IRCCS Fondazione San Matteo; University of Pavia; IRCCS Fondazione San
   Matteo; A.O.U. Citta della Salute e della Scienza di Torino
RP Esposito, P (通讯作者)，Fdn IRCCS Policlin San Matteo, Dept Nephrol Dialysis & Transplantat, Piazzale Golgi 19, I 27100 Pavia, Italy.
EM pasqualeesposito@hotmail.com
RI Esposito, Pasquale/NGR 5196 2025; GREGORINI, MARILENA/AFO 2242 2022;
   Gregorini, Marilena/AFO 2242 2022; Rampino, Teresa/AFI 8315 2022; De
   Silvestri, Annalisa/I 6024 2014; rampino, teresa/AFI 8315 2022; dal
   canton, antonio/G 4388 2013
OI Esposito, Pasquale/0000 0002 0834 5586; GREGORINI,
   MARILENA/0000 0003 1440 6872; Foramitti, Marina/0000 0001 7261 2311; De
   Silvestri, Annalisa/0000 0003 3128 8441; rampino,
   teresa/0000 0002 5311 9174; DAL CANTON, ANTONIO/0000 0002 2189 6315;
   Tinelli, Carmine/0000 0002 8749 1978
FU Accademia Nazionale di Medicina (ANM, Genova, Italy)
FX We thank Elisabetta Azzoni and Alberto Rossi, part of ANM staff, for the
   help provided during all the phases of the study. We also thank Societa
   Italiana di Nefrologia (SIN) for the scientific support. This study was
   supported by Accademia Nazionale di Medicina (ANM, Genova, Italy) that
   partially covered the travelling expenses for the auditors. The authors
   had no financial relationships with any organizations that might have an
   interest in the submitted work.
CR [Anonymous], CKD MINERAL BONE DIS
   Arenas MD, 2006, NEPHROL DIAL TRANSPL, V21, P1663, DOI 10.1093/ndt/gfl006
   Benjamin A, 2008, BMJ BRIT MED J, V336, P1241, DOI 10.1136/bmj.39527.628322.AD
   Block GA, 2004, J AM SOC NEPHROL, V15, P2208, DOI 10.1097/01.ASN.0000133041.27682.A2
   Collinson A, 2014, EUR J CLIN NUTR, V68, P392, DOI 10.1038/ejcn.2013.283
   Craver L, 2007, NEPHROL DIAL TRANSPL, V22, P1171, DOI 10.1093/ndt/gfl718
   de Lusignana S, 2013, KIDNEY INT, V84, P609, DOI 10.1038/ki.2013.96
   Arenas MD, 2010, J NEPHROL, V23, P525
   Eknoyan G, 2003, AM J KIDNEY DIS, V41, pS1, DOI 10.1016/S0272 6386(03)00111 2
   Esposito P, 2014, EUR J CLIN NUTR, V68, P859, DOI 10.1038/ejcn.2014.72
   Esposito P, 2013, INT J ARTIF ORGANS, V36, P305, DOI 10.5301/ijao.5000202
   Fouque D, 2013, NEPHROL DIAL TRANSPL, V28, P360, DOI 10.1093/ndt/gfs404
   Gallieni M, 2002, J NEPHROL, V15, P165
   Ganesh SK, 2001, J AM SOC NEPHROL, V12, P2131, DOI 10.1681/ASN.V12102131
   Hecking E, 2004, NEPHROL DIAL TRANSPL, V19, P100, DOI 10.1093/ndt/gfg418
   Iuga AO, 2014, RISK MANAG HEALTHC P, V7, P35, DOI 10.2147/RMHP.S19801
   Jamtvedt G, 2006, QUAL SAF HEALTH CARE, V15, P433, DOI 10.1136/qshc.2006.018549
   Jindal Kailash, 2006, J Am Soc Nephrol, V17, pS1
   Kalantar Zadeh K, 2013, PATIENT PREFER ADHER, V7, DOI 10.2147/PPA.S43486
   Kidney Disease: Improving Global Outcomes (KDIGO) CKD MBD Work Group, 2009, Kidney Int Suppl, pS1, DOI 10.1038/ki.2009.188
   Kugler C, 2011, J NEPHROL, V24, P366, DOI 10.5301/JN.2010.5823
   Kuhlmann MK, 2007, INT J ARTIF ORGANS, V30, P1008, DOI 10.1177/039139880703001110
   Martin KJ, 2012, AM J KIDNEY DIS, V60, P308, DOI 10.1053/j.ajkd.2012.01.027
   Mazzaferro S, 2011, J NEPHROL, V24, P225, DOI 10.5301/JN.2010.6193
   Meddings J, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472 6963 12 270
   Moe SM, 2007, ADV CHRONIC KIDNEY D, V14, P3, DOI 10.1053/j.ackd.2006.10.005
   Panichi V, 2010, J NEPHROL, V23, P556
   Polkinghorne KR, 2009, AM J KIDNEY DIS, V53, P99, DOI 10.1053/j.ajkd.2008.06.026
   Russell CL, 2011, NEPHROL NURS J, V38, P229
   Toussaint ND, 2011, NEPHROL DIAL TRANSPL, V26, P1319, DOI 10.1093/ndt/gfq602
   Uhlig K, 2010, AM J KIDNEY DIS, V55, P773, DOI 10.1053/j.ajkd.2010.02.340
   Young EW, 2004, AM J KIDNEY DIS, V44, pS34, DOI 10.1053/j.ajkd.2004.08.009
NR 32
TC 2
Z9 2
U1 0
U2 3
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D 69121 HEIDELBERG, GERMANY
SN 1121 8428
EI 1724 6059
J9 J NEPHROL
JI J. Nephrol.
PD DEC
PY 2014
VL 27
IS 6
BP 689
EP 697
DI 10.1007/s40620 014 0100 1
PG 9
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Urology & Nephrology
GA AU1RB
UT WOS:000345396800012
PM 24804853
DA 2025 08 17
ER

PT J
AU Krajisnik, T
   Bjorklund, P
   Marsel, R
   Ljunggren, O
   Akerstrom, G
   Jonsson, KB
   Westin, G
   Larsson, TE
AF Krajisnik, Tijana
   Bjorklund, Peyman
   Marsel, Richard
   Ljunggren, Osten
   Akerstrom, Goran
   Jonsson, Kenneth B.
   Westin, Gunnar
   Larsson, Tobias E.
TI Fibroblast growth factor 23 regulates parathyroid hormone and
   1α hydroxylase expression in cultured bovine parathyroid cells
SO JOURNAL OF ENDOCRINOLOGY
LA English
DT Article
ID DOMINANT HYPOPHOSPHATEMIC RICKETS; FAMILIAL TUMORAL CALCINOSIS;
   VITAMIN D METABOLISM; PHOSPHATE HOMEOSTASIS; DIALYSIS PATIENTS;
   SECONDARY HYPERPARATHYROIDISM; ONCOGENIC OSTEOMALACIA; CALCITRIOL
   THERAPY; LEVELS PREDICT; FGF 23
AB Fibroblast growth factor 23 (FGF23) is a circulating factor that decreases serum levels of inorganic phosphate (Pi) as well as 1,25 dihydroxyvitamin D 3. Recent studies also suggest a correlation between serum levels of FGF23 and parathyroid hormone (PTH) in patients with chronic kidney disease. It is, however, unknown whether FGF23 directly modulates PTH expression, or whether the correlation is secondary to abnormalities in Pi and vitamin D metabolism. The objective of the current study was therefore to elucidate possible direct effects of FGF23 on bovine parathyroid cells in vitro. Treatment of parathyroid cells with a stabilized form of recombinant FGF23 (FGF23(R176Q)) induced a rise in early response gene 1 mRNA transcripts, a marker of FGF23 signaling. FGF23(R176Q) potently and dose dependently decreased the PTH mRNA level within 12 h. In agreement, FGF23(R176Q) also decreased PTH secretion into conditioned media. In contrast, FGF23(R176Q) dose dependently increased 1 alpha hydroxylase expression within 3 h. FGF23 (R176Q) did not affect cell viability nor induce apoptosis, whereas a small but significant increase in cell proliferation was found. We conclude that FGF23 is a negative regulator of PTH mRNA expression and secretion in vitro. Our data suggest that FGF23 may be a physiologically relevant regulator of PTH. This defines a novel function of FGF23 in addition to the previously established roles in controlling vitamin D and Pi metabolism.
C1 Univ Uppsala Hosp, Dept Med Sci, S 75185 Uppsala, Sweden.
   Univ Uppsala Hosp, Dept Surg Sci, S 75185 Uppsala, Sweden.
C3 Uppsala University; Uppsala University Hospital; Uppsala University;
   Uppsala University Hospital
RP Larsson, TE (通讯作者)，Univ Uppsala Hosp, Dept Med Sci, S 75185 Uppsala, Sweden.
EM tobias.larsson@medsci.uu.se
RI , kenneth/GPF 8006 2022; Björklund, Peyman/A 1509 2014; Bjorklund,
   Peyman/A 1509 2014
OI Bjorklund, Peyman/0000 0002 9398 4496
CR Bai XY, 2004, ENDOCRINOLOGY, V145, P5269, DOI 10.1210/en.2004 0233
   Benet Pagès A, 2005, HUM MOL GENET, V14, P385, DOI 10.1093/hmg/ddi034
   Collins MT, 2005, J BONE MINER RES, V20, P1944, DOI 10.1359/JBMR.050718
   Feng JQ, 2006, NAT GENET, V38, P1310, DOI 10.1038/ng1905
   Fukagawa Masafumi, 2006, Clin Exp Nephrol, V10, P175, DOI 10.1007/s10157 006 0432 9
   Gupta S, 2000, ENTOMOL FENNICA, V11, P89, DOI 10.33338/ef.84049
   Hoffman WH, 2005, AM J MED GENET A, V134A, P233, DOI 10.1002/ajmg.a.30599
   Imanishi Y, 2004, KIDNEY INT, V65, P1943, DOI 10.1111/j.1523 1755.2004.00604.x
   Ito M, 2005, AM J PHYSIOL ENDOC M, V288, pE1101, DOI 10.1152/ajpendo.00502.2004
   Ito N, 2007, ENDOCR J, V54, P481, DOI 10.1507/endocrj.K06 217
   Jonsson KB, 2003, NEW ENGL J MED, V348, P1656, DOI 10.1056/NEJMoa020881
   Kazama JJ, 2005, KIDNEY INT, V67, P1120, DOI 10.1111/j.1523 1755.2005.00178.x
   Knutson A, 1998, DNA CELL BIOL, V17, P551, DOI 10.1089/dna.1998.17.551
   Kurosu H, 2006, J BIOL CHEM, V281, P6120, DOI 10.1074/jbc.C500457200
   Larsson T, 2005, J CLIN ENDOCR METAB, V90, P2424, DOI 10.1210/jc.2004 2238
   Larsson T, 2004, ENDOCRINOLOGY, V145, P3087, DOI 10.1210/en.2003 1768
   Larsson T, 2003, EUR J ENDOCRINOL, V148, P269, DOI 10.1530/eje.0.1480269
   Larsson T, 2003, KIDNEY INT, V64, P2272, DOI 10.1046/j.1523 1755.2003.00328.x
   Liu SG, 2003, J BIOL CHEM, V278, P37419, DOI 10.1074/jbc.M304544200
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lorenz Depiereux B, 2006, NAT GENET, V38, P1248, DOI 10.1038/ng1868
   Mirams M, 2004, BONE, V35, P1192, DOI 10.1016/j.bone.2004.06.014
   Nakanishi S, 2005, KIDNEY INT, V67, P1171, DOI 10.1111/j.1523 1755.2005.00184.x
   Nishi H, 2005, NEPHRON CLIN PRACT, V101, pC94, DOI 10.1159/000086347
   Riminucci M, 2003, J CLIN INVEST, V112, P683, DOI 10.1172/JC120031899
   Segersten U, 2002, J CLIN ENDOCR METAB, V87, P2967, DOI 10.1210/jc.87.6.2967
   Shigematsu T, 2004, AM J KIDNEY DIS, V44, P250, DOI 10.1053/j.ajkd.2004.04.029
   Shimada T, 2004, J CLIN INVEST, V113, P561, DOI 10.1172/JCI200419081
   Shimada T, 2004, BIOCHEM BIOPH RES CO, V314, P409, DOI 10.1016/j.bbrc.2003.12.102
   Shimada T, 2001, P NATL ACAD SCI USA, V98, P6500, DOI 10.1073/pnas.101545198
   Shimada T, 2002, ENDOCRINOLOGY, V143, P3179, DOI 10.1210/en.143.8.3179
   Shimada T, 2004, J BONE MINER RES, V19, P429, DOI 10.1359/JBMR.0301264
   Sitara D, 2004, MATRIX BIOL, V23, P421, DOI 10.1016/j.matbio.2004.09.007
   Urakawa I, 2006, NATURE, V444, P770, DOI 10.1038/nature05315
   WESTERBERG PA, 2007, IN PRESS NEPHROLOGY
   White KE, 2001, J CLIN ENDOCR METAB, V86, P497, DOI 10.1210/jc.86.2.497
   White KE, 2001, KIDNEY INT, V60, P2079, DOI 10.1046/j.1523 1755.2001.00064.x
   White KE, 2000, NAT GENET, V26, P345, DOI 10.1038/81664
   Yamazaki Y, 2002, J CLIN ENDOCR METAB, V87, P4957, DOI 10.1210/jc.2002 021105
NR 39
TC 375
Z9 409
U1 0
U2 8
PU SOC ENDOCRINOLOGY
PI BRISTOL
PA 22 APEX COURT, WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT, ENGLAND
SN 0022 0795
J9 J ENDOCRINOL
JI J. Endocrinol.
PD OCT
PY 2007
VL 195
IS 1
BP 125
EP 131
DI 10.1677/JOE 07 0267
PG 7
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 224HX
UT WOS:000250439200014
PM 17911404
OA Bronze
DA 2025 08 17
ER

PT J
AU Wu, L
   Gu, Y
   Liu, LL
   Tang, JC
   Mao, JN
   Xi, K
   Jiang, ZR
   Zhou, YD
   Xu, Y
   Deng, LF
   Chen, L
   Cui, WG
AF Wu, Liang
   Gu, Yong
   Liu, Lili
   Tang, Jincheng
   Mao, Jiannan
   Xi, Kun
   Jiang, Zhirong
   Zhou, Yidi
   Xu, Yun
   Deng, Lianfu
   Chen, Liang
   Cui, Wenguo
TI Hierarchical micro/nanofibrous membranes of sustained releasing VEGF for
   periosteal regeneration
SO BIOMATERIALS
LA English
DT Article
DE Electrospun fibers; Drug release; Periosteum; Angiogenesis; Osteogenesis
ID TISSUE ENGINEERED PERIOSTEUM; ENDOTHELIAL GROWTH FACTOR; GUIDED BONE
   REGENERATION; FIBERS; DIFFERENTIATION; SCAFFOLDS; ADHESION;
   PROLIFERATION; TOPOGRAPHY; STRENGTH
AB The periosteum plays a vital role in both development and injury healing process of bone. However, few researches have focused on artificial periosteum, which was also limited by the complexity on its construction and biological risks for clinical practice. In order to tackle this issue, inspired by the structural development of periosteum, we put forward a hierarchical micro/nanofibrous bionic periosteum with sustained releasing of VEGF as exogenous vascularized fibrous layer of periosteum to induce endogenous cambium layer in vivo for complete regeneration of periosteal and bone tissue, through collagen self assembly and micro sol electrospinning technologies. The VEGF encapsulated in hyaluronan PLLA core shell structure was demonstrated to be released in a durable way for angiogenesis in fibrous layer and bone defect area. Meanwhile, the self assembly of collagen together with electrospun fibers contributed to a hierarchical micro/nanostructure which greatly mimicked the microenvironment of extracellular matrix to provide structural and biochemical cues for cell adhesion, proliferation and differentiation, and lead to the formation of cambium layer which mimicked the in situ ossification manner as intramembranous ossification. As the motif of this study, the periosteal regeneration was characterized both by osteoblasts and periostin, which represented structural and molecular mechanisms respectively. Furthermore, the periosteal biomaterial proposed here possessed the superior abilities of scar inhibition, angiogenesis, osteogenesis to repair the bone defect in a uniform and rapid manner by inherent periosteal ossific mechanism involved in both intramembranous and endochondral ossification. Thus, the endogenous exogenous combined bionic periosteum proved to be efficient and versatile in triggering periosteal and bone regeneration and hopefully supply a promising strategy for solving clinical issue.
C1 [Wu, Liang; Gu, Yong; Liu, Lili; Tang, Jincheng; Mao, Jiannan; Xi, Kun; Jiang, Zhirong; Zhou, Yidi; Xu, Yun; Chen, Liang] Soochow Univ, Orthoped Inst, Affiliated Hosp 1, Dept Orthoped, 708 Renmin Rd, Suzhou 215006, Jiangsu, Peoples R China.
   [Deng, Lianfu; Cui, Wenguo] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp,Shanghai Inst Traumatol & Orthopaed, Shanghai Key Lab Prevent & Treatment Bone Joint D, 197 Malin Second Rd, Shanghai 200025, Peoples R China.
C3 Soochow University   China; Shanghai Jiao Tong University
RP Chen, L (通讯作者)，Soochow Univ, Orthoped Inst, Affiliated Hosp 1, Dept Orthoped, 708 Renmin Rd, Suzhou 215006, Jiangsu, Peoples R China.; Cui, WG (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp,Shanghai Inst Traumatol & Orthopaed, Shanghai Key Lab Prevent & Treatment Bone Joint D, 197 Malin Second Rd, Shanghai 200025, Peoples R China.
EM chenliang1972@sina.com; wgcui@sjtu.edu.cn
RI Liu, Lili/AGE 2808 2022; Gu, Yong/KDN 9278 2024; Xi, Kun/JMQ 1169 2023;
   Chen, Liang/JYQ 1606 2024
OI gu, yong/0000 0002 0482 1610; Wu, Liang/0000 0002 5208 7318; Chen,
   Liang/0000 0001 8016 7596; Xi, Kun/0000 0002 0458 9866; 
FU National Natural Science Foundation of China [81772312, 81601891,
   51873107]; National Key Research and Development Program of China
   [2018YFC1106204]; Standardized Diagnosis and Treatment Project of Key
   Diseases in Jiangsu Province [BE2015641]; Natural Science Foundation of
   Jiangsu Province [BK20170370]; Natural Science Foundation of the Jiangsu
   Higher Education Institutions of China [15KJB320012]; Jiangsu Provincial
   Special Program of Medical Science [BL2012004]; Jiangsu Provincial
   Clinical Orthopedic Center; Priority Academic Program Development of
   Jiangsu Higher Education Institutions (PAPD); Shanghai Municipal
   Education Commission Gaofeng Clinical Medicine Grant Support [20171906];
   Shanghai Jiao Tong University "Medical and Research" Program
   [ZH2018ZDA04]; Shanghai talent Development Fund [2018099]
FX Prof. L. C. acknowledges financial support from the National Natural
   Science Foundation of China (81772312 and 81601891), National Key
   Research and Development Program of China (2016YFC1101505), the
   Standardized Diagnosis and Treatment Project of Key Diseases in Jiangsu
   Province (BE2015641), the Natural Science Foundation of Jiangsu Province
   (BK20170370), the Natural Science Foundation of the Jiangsu Higher
   Education Institutions of China (15KJB320012), the Jiangsu Provincial
   Special Program of Medical Science (BL2012004), the Jiangsu Provincial
   Clinical Orthopedic Center, and the Priority Academic Program
   Development of Jiangsu Higher Education Institutions (PAPD). Prof. W. C.
   acknowledges financial support from the National Natural Science
   Foundation of China (51873107), National Key Research and Development
   Program of China (2018YFC1106204) the Shanghai Municipal Education
   Commission Gaofeng Clinical Medicine Grant Support (20171906), Shanghai
   Jiao Tong University "Medical and Research" Program (ZH2018ZDA04), the
   Shanghai talent Development Fund (2018099).
CR Abbah SA, 2015, ADV HEALTHC MATER, V4, P2488, DOI 10.1002/adhm.201500004
   Allen MR, 2004, BONE, V35, P1003, DOI 10.1016/j.bone.2004.07.014
   Bae SE, 2012, BIOMACROMOLECULES, V13, P2811, DOI 10.1021/bm300791h
   Barnes CP, 2007, TISSUE ENG, V13, P1593, DOI 10.1089/ten.2006.0292
   Berendsen AD, 2015, BONE, V80, P14, DOI 10.1016/j.bone.2015.04.035
   Cancedda R, 2007, BIOMATERIALS, V28, P4240, DOI 10.1016/j.biomaterials.2007.06.023
   Choi CKK, 2015, NANO LETT, V15, P6592, DOI 10.1021/acs.nanolett.5b02323
   Chua JS, 2014, BIOMATERIALS, V35, P7750, DOI 10.1016/j.biomaterials.2014.06.008
   Colnot C, 2012, J ORTHOP RES, V30, P1869, DOI 10.1002/jor.22181
   Dimitriou R, 2011, BMC MED, V9, DOI 10.1186/1741 7015 9 66
   Dwek JR, 2010, SKELETAL RADIOL, V39, P319, DOI 10.1007/s00256 009 0849 9
   Einhorn TA, 2015, NAT REV RHEUMATOL, V11, P45, DOI 10.1038/nrrheum.2014.164
   ELLENDER G, 1988, J ANAT, V158, P173
   Fan W, 2010, BIOMATERIALS, V31, P3580, DOI 10.1016/j.biomaterials.2010.01.083
   Feng XR, 2019, J CONTROL RELEASE, V302, P19, DOI 10.1016/j.jconrel.2019.03.020
   Frantz C, 2010, J CELL SCI, V123, P4195, DOI 10.1242/jcs.023820
   Fu XL, 2014, BIOMATERIALS, V35, P1496, DOI 10.1016/j.biomaterials.2013.11.013
   Gerstenfeld LC, 2003, J CELL BIOCHEM, V88, P873, DOI 10.1002/jcb.10435
   Goel A, 2006, COLLOIDAL CHEM
   Gómez Barrena E, 2015, BONE, V70, P93, DOI 10.1016/j.bone.2014.07.033
   Guda T, 2013, TISSUE ENG PT A, V19, P1879, DOI [10.1089/ten.tea.2012.0057, 10.1089/ten.TEA.2012.0057]
   Hennessy KM, 2009, BIOMATERIALS, V30, P1898, DOI 10.1016/j.biomaterials.2008.12.053
   Ho Shui Ling A, 2018, BIOMATERIALS, V180, P143, DOI 10.1016/j.biomaterials.2018.07.017
   Hoffman MD, 2013, BIOMATERIALS, V34, P8887, DOI 10.1016/j.biomaterials.2013.08.005
   Horiuchi K, 1999, J BONE MINER RES, V14, P1239, DOI 10.1359/jbmr.1999.14.7.1239
   Hu K, 2016, BONE, V91, P30, DOI 10.1016/j.bone.2016.06.013
   Huang DL, 2017, SCIENCE, V357, P703, DOI 10.1126/science.aan2556
   Humphries JD, 2006, J CELL SCI, V119, P3901, DOI 10.1242/jcs.03098
   Jackson DE, 2003, FEBS LETT, V540, P7, DOI 10.1016/S0014 5793(03)00224 2
   Kang YQ, 2014, ACS APPL MATER INTER, V6, P9622, DOI 10.1021/am502056q
   Kapustin AN, 2011, ARTERIOSCL THROM VAS, V31, P2169, DOI 10.1161/ATVBAHA.111.233601
   Kim TH, 2012, J BIOMED MATER RES A, V100A, P1512, DOI 10.1002/jbm.a.34086
   Kühn B, 2007, NAT MED, V13, P962, DOI 10.1038/nm1619
   Kuttappan S, 2018, ACTA BIOMATER, V78, P36, DOI 10.1016/j.actbio.2018.07.050
   Kwak S, 2016, NANOSCALE RES LETT, V11, P1, DOI 10.1186/s11671 016 1532 4
   Lee K, 2011, J R SOC INTERFACE, V8, P153, DOI 10.1098/rsif.2010.0223
   Li HC, 2017, ADV HEALTHC MATER, V6, DOI 10.1002/adhm.201601013
   Liu YQ, 2012, J CLIN INVEST, V122, P3101, DOI 10.1172/JCI61209
   Maes C, 2012, NAT REV RHEUMATOL, V8, P358, DOI 10.1038/nrrheum.2012.36
   Marcuzzo AV, 2017, APMIS, V125, P763, DOI 10.1111/apm.12728
   MARKS SC, 1988, AM J ANAT, V183, P1, DOI 10.1002/aja.1001830102
   Martins A, 2008, INT MATER REV, V53, P257, DOI 10.1179/174328008X353547
   Mendes RM, 2008, ARCH ORAL BIOL, V53, P1155, DOI 10.1016/j.archoralbio.2008.07.001
   Mi P, 2020, ADV MATER, V32, DOI 10.1002/adma.201902604
   Nam K, 2012, SOFT MATTER, V8, P472, DOI 10.1039/c1sm06543b
   Peach CJ, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19041264
   Schmidt Bleek K, 2014, J TISSUE ENG REGEN M, V8, P120, DOI 10.1002/term.1505
   Schönmeyr B, 2009, TISSUE ENG PT A, V15, P1833, DOI 10.1089/ten.tea.2008.0446
   Shi XT, 2014, ADV MATER, V26, P3290, DOI 10.1002/adma.201305804
   Shi XT, 2013, ADV HEALTHC MATER, V2, P1229, DOI 10.1002/adhm.201300012
   Syed Picard FN, 2014, J ORAL MAXIL SURG, V72, P1078, DOI 10.1016/j.joms.2014.02.005
   Tang D, 2016, BIOMATERIALS, V83, P363, DOI 10.1016/j.biomaterials.2016.01.024
   Willershausen I, 2014, J APPL ORAL SCI, V22, P29
   Xia GG, 2018, ADV HEALTHC MATER, V7, DOI 10.1002/adhm.201800593
   Xin TW, 2017, ACS APPL MATER INTER, V9, P41168, DOI 10.1021/acsami.7b13167
   Xu XL, 2008, EUR J PHARM BIOPHARM, V70, P165, DOI 10.1016/j.ejpb.2008.03.010
   Yang XC, 2009, TISSUE ENG PT A, V15, P945, DOI 10.1089/ten.tea.2007.0280
   Yang YQ, 2012, INT J ORAL SCI, V4, P64, DOI 10.1038/ijos.2012.33
   Yang Y, 2008, EUR J PHARM BIOPHARM, V69, P106, DOI 10.1016/j.ejpb.2007.10.016
   Yang Y, 2011, BIOMATERIALS, V32, P4243, DOI 10.1016/j.biomaterials.2011.02.042
   Zhang XH, 2009, ADV DRUG DELIVER REV, V61, P988, DOI 10.1016/j.addr.2009.07.005
   Zhao X, 2015, BIOMATERIALS, V61, P61, DOI 10.1016/j.biomaterials.2015.05.012
   Zhou YF, 2007, BIOMATERIALS, V28, P814, DOI 10.1016/j.biomaterials.2006.09.032
NR 63
TC 239
Z9 250
U1 15
U2 859
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142 9612
EI 1878 5905
J9 BIOMATERIALS
JI Biomaterials
PD JAN
PY 2020
VL 227
AR 119555
DI 10.1016/j.biomaterials.2019.119555
PG 16
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA JP5AF
UT WOS:000498276700002
PM 31655445
DA 2025 08 17
ER

PT J
AU Du, JJ
   Zheng, R
   Xiao, F
   Zhang, S
   He, KS
   Zhang, JJ
   Shao, YF
AF Du, Junjie
   Zheng, Rui
   Xiao, Feng
   Zhang, Shuai
   He, Keshuai
   Zhang, Junjie
   Shao, Yongfeng
TI Downregulated MicroRNA 195 in the Bicuspid Aortic Valve Promotes
   Calcification of Valve Interstitial Cells via Targeting SMAD7
SO CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
LA English
DT Article
DE Bicuspid aortic valve; Valvular calcification; Valve interstitial cell;
   MicroRNA 195; SMAD7
ID TGF BETA; ANTISENSE OLIGONUCLEOTIDE; BONE FORMATION; EXPRESSION;
   HOMEOSTASIS; OSTEOBLAST; THERAPY; PATHWAY; MIR 195
AB Background/Aims: Aortic stenosis caused by leaflet calcification in the bicuspid aortic valve (BAV) is more accelerative than that in the tricuspid aortic valve (TAV). MicroRNA 195 (miR 195) is downregulated more in stenotic than in insufficient BAVs, but its expression in BAVs compared with TAVs is unclear. We aimed to investigate the roles of miR 195 and its calcification related target SMAD7 in stenotic BAVs compared with those in TAVs. Methods: Twenty one stenotic BAV and 29 TAV samples were collected from surgical patients and examined for the expression of miR 195 and SMAD7 by RT PCR. The samples were also assessed by western blotting and immunohistochemistry for the functional protein alteration associated with calcification. Dual luciferase assay was performed to determine the putative target of miR 195 before the effects of miR 195 expression on osteogenic progression was demonstrated in cultured porcine valve interstitial cells (VICs). Results: Compared with TAV, the expression of miR 195 was remarkably lower in the BAV leaflet with higher expression of SMAD7, which was then validated as a direct target of miR 195. Their negative correlation was then confirmed in cultured VICs. Under an osteogenic environment, the cellular calcification was promoted in miR 195 repressed VICs expressing higher BMP 2 and Runx2 and higher activity of MMP 2 compared with the controls. Finally, higher MMP 2 and MMP 9 expression and more collagen distribution were observed in BAV than TAV samples. Conclusions: miR 195 is downregulated more in stenotic BAV than TAV in this study. The downregulation of miR 195 is associated with valvular calcification via targeting SMAD7, which promotes the remodeling of the extracellular matrix. (C) 2017 The Author(s) Published by S.Karger AG, Basel
C1 [Shao, Yongfeng] Nanjing Med Univ, Affiliated Hosp 1, Dept Cardiovasc Surg, Nanjing, Jiangsu, Peoples R China.
   [Xiao, Feng] Nanjing Med Univ, Wuxi Peoples Hosp, Dept Cardiol, Wuxi, Peoples R China.
C3 Nanjing Medical University; Nanjing Medical University; Jiangnan
   University
RP Shao, YF (通讯作者)，Nanjing Med Univ, Affiliated Hosp 1, Dept Cardiovasc Surg, Nanjing, Jiangsu, Peoples R China.
EM shaoyongfeng2010@aliyun.com
OI Zhang, Junjie/0000 0003 3690 1372; shao, yongfeng/0000 0002 8186 4147
FU Priority Academic Program of Jiangsu Higher Education Institutions
   [JX10231801]; Natural Science Foundation of Jiangsu Province
   [BK20151590]
FX This work was supported, in part, by the Priority Academic Program of
   Jiangsu Higher Education Institutions (Grants JX10231801) and the
   Natural Science Foundation of Jiangsu Province (BK20151590). The authors
   confirm that the funders had no influence over the study design, content
   of the article, or selection of this journal.
CR Ardizzone S, 2016, THER ADV GASTROENTER, V9, P527, DOI 10.1177/1756283X16636781
   Chen GD, 2015, BIOCHEM J, V471, P357, DOI 10.1042/BJ20150095
   Duan YJ, 2016, ONCOL REP, V36, P1837, DOI 10.3892/or.2016.5023
   Farrar EJ, 2016, BIOMATERIALS, V105, P25, DOI 10.1016/j.biomaterials.2016.07.034
   Garg V, 2006, CURR OPIN CARDIOL, V21, P180, DOI 10.1097/01.hco.0000221578.18254.70
   Girdauskas E, 2013, SEMIN THORAC CARDIOV, V25, P310, DOI 10.1053/j.semtcvs.2014.01.004
   Guo DG, 2016, ACTA BIOCH BIOPH SIN, V48, P290, DOI 10.1093/abbs/gmv136
   He JF, 2011, J BIOCHEM MOL TOXIC, V25, P404, DOI 10.1002/jbt.20396
   Holliday CJ, 2011, AM J PHYSIOL HEART C, V301, pH856, DOI 10.1152/ajpheart.00117.2011
   Kaden JJ, 2004, J HEART VALVE DIS, V13, P560
   Kim CR, 2017, INT J MOL MED, V39, P31, DOI 10.3892/ijmm.2016.2807
   Kurabayashi Masahiko, 2015, Clin Calcium, V25, P661, DOI CliCa1505661669
   Leopold Jane A, 2014, Cells, V3, P963, DOI 10.3390/cells3040963
   Li QL, 2015, BIOL REPROD, V92, DOI 10.1095/biolreprod.114.125203
   Liu GX, 2014, CLIN SCI, V127, P195, DOI 10.1042/CS20130706
   Miyazawa K, 2017, CSH PERSPECT BIOL, V9, DOI 10.1101/cshperspect.a022095
   MohanKumar K, 2016, PEDIATR RES, V79, P951, DOI 10.1038/pr.2016.18
   Mohler ER, 2001, CIRCULATION, V103, P1522, DOI 10.1161/01.cir.103.11.1522
   Nigam V, 2010, J HEART VALVE DIS, V19, P459
   Oury C, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17071120
   Pardali E, 2012, INT J BIOL SCI, V8, P195, DOI [10.7150/ijbs.8.195, 10.7150/ijbs.3805]
   Patel V, 2015, FASEB J, V29, P1859, DOI 10.1096/fj.14 257808
   Rathan S, 2016, SCI REP UK, V6, DOI 10.1038/srep25397
   Siu SC, 2010, J AM COLL CARDIOL, V55, P2789, DOI 10.1016/j.jacc.2009.12.068
   Wang Y, 2015, EUR HEART J, V36, P641
   Wang YJ, 2015, J CARDIOVASC PHARM, V66, P63, DOI 10.1097/FJC.0000000000000244
   Wirrig EE, 2014, ARTERIOSCL THROM VAS, V34, P737, DOI 10.1161/ATVBAHA.113.302071
   Wu MR, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.9
   Zampetaki A, 2014, CIRC RES, V115, P857, DOI 10.1161/CIRCRESAHA.115.304361
   Zorzi F, 2013, DIGEST LIVER DIS, V45, P552, DOI 10.1016/j.dld.2012.11.011
NR 30
TC 29
Z9 30
U1 1
U2 2
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH 4009 BASEL, SWITZERLAND
SN 1015 8987
EI 1421 9778
J9 CELL PHYSIOL BIOCHEM
JI Cell. Physiol. Biochem.
PY 2017
VL 44
IS 3
BP 884
EP 896
DI 10.1159/000485356
PG 13
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA FQ8KR
UT WOS:000418612200004
PM 29176317
OA gold
DA 2025 08 17
ER

PT J
AU Kumar, MR
   Freund, MS
AF Kumar, M. Ramesh
   Freund, Michael S.
TI Electrically conducting collagen and collagen mineral composites for
   current stimulation
SO RSC ADVANCES
LA English
DT Article
ID HYDROXYAPATITE; BRUSHITE; APATITE; GROWTH; PHOSPHATE; POLYMERS
AB Bifunctional films with higher electrochemical and bioactive properties have many promising applications including tissue engineering, drug delivery, nerve regeneration and bone healing. Since bone possesses natural bio potential and electromechanical properties, the idea of utilizing small electrical pulses to induce bone tissue growth has been explored in recent decades. Studies have revealed that electric stimulation (in the order of mV) has positive effects on the osteogenesis, and enhances the mineral formation in osteoblast like cells. However, the mechanisms behind these effects are not well understood. Electric stimulation is generally performed through the implantation of metal electrodes that need to be removed after the treatment. This sometimes requires surgery that can lead to complications including infection and damaging newly formed bone tissue. Therefore, in the search for new implant materials that are bioactive (allowing different cells to grow over it) and electrically conductive (to perform electrical stimulation), a composite material has been synthesized by integrating the electro active properties of the conducting polymer (poly 3,4 ethylenedioxythiophene, doped with polystyrene sulfonate, PEDOT:PSS) with the biological properties of collagen (protein, which is present in the cornea) and collagen calcium phosphate membranes (which mimics the composition of bone). It is shown that by varying the concentration of PEDOT: PSS, the composite (collagen PEDOT:PSS) or the hybrid (collagen hydroxyapatite PEDOT:PSS) membrane could be altered to be highly biocompatible and highly electrically conductive.
C1 [Kumar, M. Ramesh; Freund, Michael S.] Univ Manitoba, Winnipeg, MB R3T 2N2, Canada.
C3 University of Manitoba
RP Freund, MS (通讯作者)，Univ Manitoba, Winnipeg, MB R3T 2N2, Canada.
EM msfreund@fit.edu
RI Freund, Michael/C 1991 2016
OI Freund, Michael/0000 0003 1104 2292
FU Natural Sciences and Engineering Research Council (NSERC) of Canada;
   Canada Foundation for Innovation (CFI); Manitoba Research and Innovation
   Fund; University of Manitoba; Canada Research Chairs (CRC) Program
FX We thank our funding agencies: the Natural Sciences and Engineering
   Research Council (NSERC) of Canada, the Canada Foundation for Innovation
   (CFI), the Manitoba Research and Innovation Fund and the University of
   Manitoba. Additional financial support was provided in part from the
   Canada Research Chairs (CRC) Program. We thank Dr Michael McDonald and
   Dr Ravinder Sidhu for assistance with operating four point probe, SEM
   and EDX instruments.
CR Akkouch A, 2011, J BIOMED MATER RES A, V96A, P693, DOI 10.1002/jbm.a.33033
   Asplund M, 2009, BIOMED MATER, V4, DOI 10.1088/1748 6041/4/4/045009
   Baker HR, 2008, LANGMUIR, V24, P2970, DOI 10.1021/la703743m
   Collier JH, 2000, J BIOMED MATER RES, V50, P574, DOI 10.1002/(SICI)1097 4636(20000615)50:4<574::AID JBM13>3.0.CO;2 I
   Delvasto P, 2006, SOIL BIOL BIOCHEM, V38, P2645, DOI 10.1016/j.soilbio.2006.03.020
   Donavan KC, 2012, LANGMUIR, V28, P12581, DOI 10.1021/la302473j
   Fan YW, 2005, BIOMATERIALS, V26, P1623, DOI 10.1016/j.biomaterials.2004.06.019
   Fong R. N., 2013, MACROMOL BIOSCI, V13, P348
   Friedel B, 2009, MACROMOLECULES, V42, P6741, DOI 10.1021/ma901182u
   Gendron R, 2012, MACROMOL BIOSCI, V12, P360, DOI 10.1002/mabi.201100341
   Gonzalez Paz R. J., 2008, CARACTERIZACION MEDI
   Green RA, 2008, BIOMATERIALS, V29, P3393, DOI 10.1016/j.biomaterials.2008.04.047
   JOHNSSON MSA, 1992, CRIT REV ORAL BIOL M, V3, P61, DOI 10.1177/10454411920030010601
   Joschek S, 2000, BIOMATERIALS, V21, P1645, DOI 10.1016/S0142 9612(00)00036 3
   Juhasz JA, 2008, J MATER SCI MATER M, V19, P1823, DOI 10.1007/s10856 007 3344 7
   Kim DH, 2007, ADV FUNCT MATER, V17, P79, DOI 10.1002/adfm.200500594
   Kumar MR, 2010, CERAM TRANS, V218, P3
   Kumar MR, 2011, CRYST GROWTH DES, V11, P26, DOI 10.1021/cg101259h
   Kumar MR, 2009, BIOMACROMOLECULES, V10, P1970, DOI 10.1021/bm900379g
   LI HC, 1995, MACROMOL CHEM PHYSIC, V196, P1801, DOI 10.1002/macp.1995.021960601
   Li Y, 2008, THERMOCHIM ACTA, V469, P71, DOI 10.1016/j.tca.2008.01.006
   Lin YC, 2009, ACTA BIOMATER, V5, P2591, DOI 10.1016/j.actbio.2009.03.038
   Luna Zaragoza D., 2009, J. Minerals Materials Characterization Engineering, V8, P591, DOI DOI 10.4236/JMMCE.2009.88052
   Nagarajan S, 2008, MACROMOLECULES, V41, P3049, DOI 10.1021/ma0717845
   PEARCE EIF, 1988, J DENT RES, V67, P1056, DOI 10.1177/00220345880670070801
   Pelto JM, 2013, LANGMUIR, V29, P6099, DOI 10.1021/la4009366
   Piza MA, 2003, POLYMER, V44, P5663, DOI 10.1016/S0032 3861(03)00612 8
   Rehman I, 1997, J MATER SCI MATER M, V8, P1, DOI 10.1023/A:1018570213546
   Samouillan V, 2011, J FUNCT BIOMATER, V2, P230, DOI 10.3390/jfb2030230
   Schmidt CE, 1997, P NATL ACAD SCI USA, V94, P8948, DOI 10.1073/pnas.94.17.8948
   Supronowicz PR, 2002, J BIOMED MATER RES, V59, P499, DOI 10.1002/jbm.10015
   Teixeira Dias B, 2012, MACROMOL MATER ENG, V297, P359, DOI 10.1002/mame.201100180
   Trpkovska M, 1999, J MOL STRUCT, V481, P661, DOI 10.1016/S0022 2860(98)00923 5
   Vidal BD, 2011, MICRON, V42, P283, DOI 10.1016/j.micron.2010.09.010
   Wiesmann HP, 2001, BBA MOL CELL RES, V1538, P28, DOI 10.1016/S0167 4889(00)00135 X
   Xiao YH, 2010, J BIOMED MATER RES A, V92A, P766, DOI 10.1002/jbm.a.32412
   Youn JI, 2008, LASER MED SCI, V23, P229, DOI 10.1007/s10103 007 0464 8
NR 37
TC 15
Z9 18
U1 2
U2 65
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2046 2069
J9 RSC ADV
JI RSC Adv.
PY 2015
VL 5
IS 71
BP 57318
EP 57327
DI 10.1039/c5ra07500a
PG 10
WC Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry
GA CM6NM
UT WOS:000357805500009
DA 2025 08 17
ER

PT J
AU Huang, H
   Wang, Y
   Xie, WH
   Geng, Y
   Gao, D
   Zhang, ZL
AF Huang, Hong
   Wang, Yu
   Xie, Wenhui
   Geng, Yan
   Gao, Dai
   Zhang, Zhuoli
TI Impact of Treat to Target Therapy on Bone Mineral Density Loss in
   Patients With Rheumatoid Arthritis: A Prospective Cohort Study
SO FRONTIERS IN ENDOCRINOLOGY
LA English
DT Article
DE rheumatoid arthritis; treat to target strategy; disease activity; bone
   mineral density; osteoporosis
ID DISEASE ACTIVITY; CLINICAL PRACTICE; OSTEOPOROSIS; FREQUENCY; STRATEGY;
   WOMEN; MULTICENTER; PREVALENCE; VALIDATION; SEVERITY
AB BackgroundOsteoporosis is a common comorbidity of rheumatoid arthritis (RA). Although RA disease activity has been demonstrated to be associated with bone loss in previous studies, most of them were cross sectional studies and not in the context of treat to target (T2T) strategies. ObjectivesThis study aimed to evaluate the association of disease activity with bone mineral density (BMD) changes in the context of T2T strategies in a prospective RA cohort. MethodsRA patients were enrolled from a prospective CENTRA cohort of Peking University First Hospital. The follow ups have been scheduled every 3 to 6 months. BMD was repeated at baseline, 1 year, and then every other year. Demographics, baseline clinical features, laboratory data, and medications at each visit were recorded. Time adjusted mean disease activity scores were adopted to reflect the overall disease activity during follow up. The influence of univariable associations between predictors and BMD was investigated using linear regression. ResultsA total of 268 patients were included in our analysis. Their mean age was 50 (12.9) years, and 224 (83.6%) were women. The median (IQR) disease duration was 48.7 (107.6) months. Osteoporosis in the lumbar spine was observed in 23.1% of patients and 9.3% in the femoral neck at enrollment. Older age, higher SDAI score, and lower BMI were associated with osteoporosis at baseline. The proportion of patients who achieved DAS28 ESR, CDAI, and SDAI remission or LDA at the end of the first year was 71.5%, 68.8%, and 67.4%, respectively. Reevaluations of BMD at 1 year were applied to 144 patients. Mean decreases of BMDs were 1.75% at the lumbar spine and 1.40% at the femoral neck at 1 year from baseline, respectively. Patients who achieved remission had less yearly bone loss in the lumbar spine (p = 0.036). Female gender was identified as a risk factor in the multiple linear regression analyses, and lower disease activity and bisphosphonates were protective factors of continuous bone loss. ConclusionDisease activity is associated with bone loss in RA patients in the context of T2T strategies, and those who achieved remission had less yearly bone loss.
C1 [Huang, Hong; Wang, Yu; Xie, Wenhui; Geng, Yan; Gao, Dai; Zhang, Zhuoli] Peking Univ First Hosp, Dept Rheumatol & Clin Immunol, Beijing, Peoples R China.
RP Zhang, ZL (通讯作者)，Peking Univ First Hosp, Dept Rheumatol & Clin Immunol, Beijing, Peoples R China.
EM zhuoli.zhang@126.com
RI Xie, Wenhui/AAG 7962 2021
FU National Natural Science Foundation of China [81771740, 81901646];
   Innovation Fund for Outstanding Doctoral Candidates of Peking University
   Health Science Center [BMU2021BSS001]
FX Funding This work was supported by the National Natural Science
   Foundation of China (No. 81771740, 81901646) and Innovation Fund for
   Outstanding Doctoral Candidates of Peking University Health Science
   Center (No. BMU2021BSS001).
CR Adami G, 2019, CURR RHEUMATOL REP, V21, DOI 10.1007/s11926 019 0836 7
   Ahmad HA, 2018, ADV THER, V35, P232, DOI 10.1007/s12325 017 0657 x
   Alemao E, 2016, ARTHRIT CARE RES, V68, P308, DOI 10.1002/acr.22678
   Aletaha D, 2005, ARTHRITIS RES THER, V7, pR796, DOI 10.1186/ar1740
   Aletaha D, 2010, ARTHRITIS RHEUM US, V62, P2569, DOI 10.1002/art.27584
   Blavnsfeldt ABG, 2018, BONE, V114, P172, DOI 10.1016/j.bone.2018.06.008
   Book C, 2008, SCAND J RHEUMATOL, V37, P248, DOI 10.1080/03009740801998747
   Briot K, 2017, OSTEOPOROSIS INT, V28, P3301, DOI 10.1007/s00198 017 4189 7
   Chen JF, 2020, RHEUMATOLOGY, V59, P2471, DOI 10.1093/rheumatology/kez655
   Clarke B, 2008, CLIN J AM SOC NEPHRO, V3, pS131, DOI 10.2215/CJN.04151206
   Cohen S, 1999, ARTHRITIS RHEUM, V42, P2309, DOI 10.1002/1529 0131(199911)42:11<2309::AID ANR8>3.0.CO;2 K
   Dohn UM, 2009, ANN RHEUM DIS, V68, P1585, DOI 10.1136/ard.2008.097048
   Dougados M, 2016, CURR OPIN RHEUMATOL, V28, P282, DOI 10.1097/BOR.0000000000000267
   Finzel S, 2013, ANN RHEUM DIS, V72, P396, DOI 10.1136/annrheumdis 2011 201075
   GOUGH AKS, 1994, LANCET, V344, P23, DOI 10.1016/S0140 6736(94)91049 9
   Green MJ, 2001, BEST PRACT RES CL RH, V15, P105, DOI 10.1053/berh.2000.0129
   Dao HH, 2011, CLIN RHEUMATOL, V30, P1353, DOI 10.1007/s10067 011 1762 x
   Haugeberg G, 2000, ARTHRITIS RHEUM, V43, P522, DOI 10.1002/1529 0131(200003)43:3<522::AID ANR7>3.0.CO;2 Y
   Hauser B, 2014, RHEUMATOLOGY, V53, P1759, DOI 10.1093/rheumatology/keu162
   Huang H, 2022, RHEUMATOL THER, V9, P907, DOI 10.1007/s40744 022 00441 0
   Ibañez D, 2003, J RHEUMATOL, V30, P1977
   Kanis JA, 2010, OSTEOPOROSIS INT, V21, P407, DOI 10.1007/s00198 010 1253 y
   KANIS JA, 1994, J BONE MINER RES, V9, P1137, DOI 10.1002/jbmr.5650090802
   Kim D, 2016, RHEUMATOL INT, V36, P1205, DOI 10.1007/s00296 016 3453 z
   Kvien TK, 1997, SCAND J RHEUMATOL, V26, P412, DOI 10.3109/03009749709065712
   Kwon OC, 2019, CLIN EXP RHEUMATOL, V37, P813
   Lee EB, 2014, NEW ENGL J MED, V370, P2377, DOI 10.1056/NEJMoa1310476
   Lee SG, 2012, INT J RHEUM DIS, V15, P289, DOI 10.1111/j.1756 185X.2012.01729.x
   Lodder MC, 2004, ANN RHEUM DIS, V63, P1576, DOI 10.1136/ard.2003.016253
   McInnes IB, 2011, NEW ENGL J MED, V365, P2205, DOI 10.1056/NEJMra1004965
   PREVOO MLL, 1995, ARTHRITIS RHEUM, V38, P44, DOI 10.1002/art.1780380107
   Roux C, 2011, OSTEOPOROSIS INT, V22, P421, DOI 10.1007/s00198 010 1319 x
   Saag KG, 1998, NEW ENGL J MED, V339, P292, DOI 10.1056/NEJM199807303390502
   SAMBROOK PN, 1989, ANN RHEUM DIS, V48, P535, DOI 10.1136/ard.48.7.535
   Schipper LG, 2012, ANN RHEUM DIS, V71, P845, DOI 10.1136/annrheumdis 2011 200274
   Scott DL, 2010, LANCET, V376, P1094, DOI 10.1016/S0140 6736(10)60826 4
   Sinigaglia L, 2000, J RHEUMATOL, V27, P2582
   Smolen JS, 2003, RHEUMATOLOGY, V42, P244, DOI 10.1093/rheumatology/keg072
   Tong JJ, 2020, CLIN RHEUMATOL, V39, P357, DOI 10.1007/s10067 019 04787 9
   van der Goes MC, 2013, OSTEOPOROSIS INT, V24, P1429, DOI 10.1007/s00198 012 2073 z
   Xie W, 2018, CLIN EXP RHEUMATOL, V36, P820
   Xie WH, 2021, ANN RHEUM DIS, V80, P997, DOI 10.1136/annrheumdis 2021 220112
   Yoshii I, 2020, OSTEOPORO SARCOPENIA, V6, P75, DOI 10.1016/j.afos.2020.04.002
   Yue J, 2018, SEMIN ARTHRITIS RHEU, V48, P374, DOI 10.1016/j.semarthrit.2018.05.001
NR 44
TC 7
Z9 8
U1 0
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1664 2392
J9 FRONT ENDOCRINOL
JI Front. Endocrinol.
PD MAY 17
PY 2022
VL 13
AR 867610
DI 10.3389/fendo.2022.867610
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 1S3AV
UT WOS:000803927900001
PM 35655798
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Gregory, LS
   Forwood, MR
AF Gregory, L. S.
   Forwood, M. R.
TI Cyclooxygenase 2 inhibition delays the attainment of peak woven bone
   formation following four point bending in the rat
SO CALCIFIED TISSUE INTERNATIONAL
LA English
DT Article
DE woven bone; cyclooxygenase isoform; bone remodeling; periosteal callus;
   four point bending
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; LOADING IN VIVO; SPINAL FUSION;
   FRACTURE; INDOMETHACIN; COX 2; OSTEOBLASTS; ADAPTATION; RABBITS; INVIVO
AB Fracture healing is retarded in the presence of cyclooxygenase 2 (COX 2) inhibitors, demonstrating an important role of COX 2 in trauma induced woven bone adaptation. The aim of this experiment was to determine the influence of COX 2 inhibition on the remodeling and consolidation of nontraumatic woven bone produced by mechanical loading. A periosteal woven bone callus was initiated in the right tibia of female Wistar rats following a single bout of four point bending, applied as a haversine wave for 300 cycles at a frequency of 2 Hz and a magnitude of 65 N. Daily injections of vehicle (VEH, polyethylene glycol) or the COX 2 inhibitor 5,5 dimethyl 3 3(3 fluorophenyl) 4 (4 methylsulfonal)phenyl 2(5H) furanone (DFU, 2.0 mg center dot kg( 1) and 0.02 mg center dot kg( 1) i.p.), commenced 7 days postloading, and tibiae were examined 2, 3, 4, and 5 weeks postloading. Tibiae were dissected, embedded in polymethylmethacrylate, and sectioned for histomorphometric analysis of periosteal woven bone. No significant difference in peak woven bone area was observed between DFU treated and VEH rats. However, treatment with DFU resulted in a temporal defect in woven bone formation, where the achievement of peak woven bone area was delayed by 1 week. Woven bone remodeling was observed in DFU treated rats at 21 days postloading, demonstrating that remodeling of the periosteal callus is not prevented in the presence of a COX 2 inhibitor in the rat. We conclude that COX 2 inhibition does not significantly disrupt the mechanism of woven bone remodeling but alters its timing.
C1 Univ Queensland, Dept Anat & Dev Biol, Sch Biomed Sci, Brisbane, Qld 4072, Australia.
C3 University of Queensland
RP Gregory, LS (通讯作者)，Univ Queensland, Dept Anat & Dev Biol, Sch Biomed Sci, Brisbane, Qld 4072, Australia.
EM l.gregory@qut.edu.au
RI Forwood, Mark/ABA 9040 2021
OI Forwood, Mark/0000 0002 9963 1616
CR ALLEN HL, 1980, ACTA ORTHOP SCAND, V51, P595, DOI 10.3109/17453678008990848
   ALTMAN RD, 1995, J ORTHOP TRAUMA, V9, P392, DOI 10.1097/00005131 199505000 00006
   Bakker AD, 2003, BIOCHEM BIOPH RES CO, V305, P677, DOI 10.1016/S0006 291X(03)00831 3
   Boppart MD, 1998, BONE, V23, P409, DOI 10.1016/S8756 3282(98)00119 7
   Currey J., 1984, The Mechanical Adaptations of Bones
   Dahners LE, 2004, J AM ACAD ORTHOP SUR, V12, P139, DOI 10.5435/00124635 200405000 00001
   DEKEL S, 1981, J BONE JOINT SURG BR, V63, P185, DOI 10.1302/0301 620X.63B2.7217139
   Dimar JR, 1996, SPINE, V21, P1870, DOI 10.1097/00007632 199608150 00006
   Einhorn TA, 2002, J BONE MINER RES, V17, P977, DOI 10.1359/jbmr.2002.17.6.977
   Enlow D.H., 1963, PRINCIPLES BONE REMO
   Evans CE, 2004, J BONE JOINT SURG BR, V86B, P444, DOI 10.1302/0301 620X.86B3.14592
   Forwood MR, 1998, BONE, V23, P307, DOI 10.1016/S8756 3282(98)00090 8
   Forwood MR, 1996, J BONE MINER RES, V11, P1688
   Forwood MR, 1996, AM J PHYSIOL ENDOC M, V270, pE419, DOI 10.1152/ajpendo.1996.270.3.E419
   Gajraj NM, 2003, REGION ANESTH PAIN M, V28, P456, DOI 10.1016/j.rapm.2003.09.001
   Gerstenfeld LC, 2003, J ORTHOP RES, V21, P670, DOI 10.1016/S0736 0266(03)00003 2
   Goodman S, 2002, J ORTHOP RES, V20, P1164, DOI 10.1016/S0736 0266(02)00079 7
   Goodman SB, 2003, INT J IMMUNOPATH PH, V16, P201, DOI 10.1177/039463200301600303
   GOODSHIP AE, 1979, J BONE JOINT SURG AM, V61, P539, DOI 10.2106/00004623 197961040 00008
   IQBAL J, 2005, BIOCHEM BIOPH RES CO, V328, P572
   Joldersma M, 2000, J BIOMECH, V33, P53, DOI 10.1016/S0021 9290(99)00172 4
   KELLER J, 1993, ACTA ORTHOP SCAND, V64, P59, DOI 10.3109/17453679308994530
   Kusuzaki K, 2000, BONE, V27, P655, DOI 10.1016/S8756 3282(00)00383 5
   Li J, 2002, CALCIFIED TISSUE INT, V70, P320, DOI 10.1007/s00223 001 1025 y
   LI XJ, 1990, ANAT RECORD, V227, P12, DOI 10.1002/ar.1092270103
   Long J, 2002, J BONE JOINT SURG AM, V84A, P1763, DOI 10.2106/00004623 200210000 00004
   MACKIE EJ, 1990, BONE, V11, P295, DOI 10.1016/8756 3282(90)90083 B
   Okada Y, 2000, J CLIN INVEST, V105, P823, DOI 10.1172/JCI8195
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Pavalko FM, 1998, AM J PHYSIOL CELL PH, V275, pC1591
   REICH KM, 1991, AM J PHYSIOL, V261, pC428, DOI 10.1152/ajpcell.1991.261.3.C428
   Reuben SS, 2005, J BONE JOINT SURG AM, V87A, P536, DOI 10.2106/JBJS.D.02283
   RO J, 1976, ACTA ORTHOP SCAND, V47, P588, DOI 10.3109/17453677608988744
   RUBIN CT, 1995, J BONE MINER RES, V10, P488
   Simon AM, 2002, J BONE MINER RES, V17, P963, DOI 10.1359/jbmr.2002.17.6.963
   Su X, 2003, BONE, V32, P150, DOI 10.1016/S8756 3282(02)00945 6
   SUDMANN E, 1979, EUR J CLIN INVEST, V9, P333, DOI 10.1111/j.1365 2362.1979.tb00893.x
   Sudmann E, 1975, Acta Orthop Scand Suppl, V160, P91
   SUDMANN E, 1976, ARCH ORTHOP TRAUM SU, V85, P151, DOI 10.1007/BF00415452
   SUDMANN E, 1979, ACTA ORTHOP SCAND, V50, P621, DOI 10.3109/17453677908991283
   TURNER CH, 1994, J BONE MINER RES, V9, P87
   TURNER CH, 1991, BONE, V12, P73, DOI 10.1016/8756 3282(91)90003 2
   TURNER CH, 1992, BONE, V13, P417, DOI 10.1016/8756 3282(92)90084 A
   Zhang XP, 2002, J CLIN INVEST, V109, P1405, DOI 10.1172/JCI200215681
NR 44
TC 14
Z9 17
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0171 967X
EI 1432 0827
J9 CALCIFIED TISSUE INT
JI Calcif. Tissue Int.
PD MAR
PY 2007
VL 80
IS 3
BP 176
EP 183
DI 10.1007/s00223 006 0170 8
PG 8
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 145TN
UT WOS:000244888000005
PM 17334881
DA 2025 08 17
ER

PT J
AU Effenberger, KE
   Johnsen, SA
   Monroe, DG
   Spelsberg, TC
   Westendorf, JJ
AF Effenberger, KE
   Johnsen, SA
   Monroe, DG
   Spelsberg, TC
   Westendorf, JJ
TI Regulation of osteoblastic phenotype and gene expression by hop derived
   phytoestrogens
SO JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
LA English
DT Article
DE alkaline phosphatase; estrogen receptor; gene expression; hop plant;
   HRT; osteoblast like cells; phytoestrogens; osteoporosis; SERM;
   ligand binding affinity; proliferation
ID ESTROGEN RECEPTOR ALPHA; HORMONE REPLACEMENT THERAPY; BREAST CANCER
   CELLS; HUMULUS LUPULUS L.; DIETARY PHYTOESTROGENS; ER ALPHA;
   BONE RESORPTION; MESSENGER RNA; LINE MCF 7; IN VITRO
AB Certain plant derived compounds show selective estrogen receptor modulator (SERM) activity and may therefore be an alternative to the conventional hormone replacement therapy, which prevents osteoporosis but is also associated with an increased risk of breast and endometrial cancers. In the current study, we tested the effects of the hop derived compounds 8 prenylnaringenin, 6 prenylnaringenin, xanthohumol and isoxanthohumol (1) to modulate markers of differentiation and gene expression in osteoblasts and (2) to regulate proliferation in MCF 7 breast cancer cells. Additionally, we analyzed the ER binding affinities of these hop compounds as well as the ER mediation of their effects. Bone forming activity and ER subtype specificity were investigated by measuring alkaline phosphatase (AP) activity in hFOB/ER alpha cells and regulation of gene transcription for AP, interleukin 6, pS2 and von Willebrand factor (VWF) in U 2 OSIER(x and U 2 OS/ERP cells.
   Our results demonstrate that AP, pS2 and VWF mRNA levels are significantly increased by the Compounds in an estrogen like manner via both ER alpha and ER beta, while IL 6 is down regulated in U 2 OS/ER alpha cells. Consistently, AP enzymatic activity is up regulated by all compounds in hFOB/ER alpha 9 cells. Depending on their concentration, all compounds show proliferative effects in MCF 7 cells. Except for 8 PN the hop constituents display an ER beta preference. Reversal of estrogen specific AP induction in Ishikawa cells indicates an ER regulated mechanism. Finally, the flavonoids display cytotoxic effects only at high concentrations (> 10( 4) M).
   In summary, we have demonstrated for the first time that specific phytoestrogen compounds found in hop extracts exert estrogen like activities on bone metabolism. Regarding a potential for use in osteoporosis prevention therapy, the dosage of a phytoestrogen, which is taken, will play an important role concerning it desired in vivo profile. (c) 2005 Elsevier Ltd. All rights reserved.
C1 Univ Hamburg, Inst Expt & Clin Pharmacol & Toxicol, Univ Hosp Eppendorf, D 22527 Hamburg, Germany.
   Univ Hamburg, Ctr Mol Neurobiol, Univ Hosp Eppendorf, D 20251 Hamburg, Germany.
   Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA.
C3 University of Hamburg; University Medical Center Hamburg Eppendorf;
   University of Hamburg; University Medical Center Hamburg Eppendorf; Mayo
   Clinic
RP Effenberger, KE (通讯作者)，Univ Hamburg, Inst Expt & Clin Pharmacol & Toxicol, Univ Hosp Eppendorf, Vogt Koelln Str 30, D 22527 Hamburg, Germany.
EM keffenbe@uke.uni hamburg.de
RI Effenberger, Katharina/NNG 8162 2025; Johnsen, Steven/AAX 2322 2020
OI Johnsen, Steven/0000 0003 1198 5805
CR AKIYAMA T, 1987, J BIOL CHEM, V262, P5592
   Allred CD, 2001, CANCER RES, V61, P5045
   Anderson JJB, 1998, BAILLIERE CLIN ENDOC, V12, P543, DOI 10.1016/S0950 351X(98)80003 7
   Arts J, 1997, ENDOCRINOLOGY, V138, P5067, DOI 10.1210/en.138.11.5067
   Barkhem T, 2002, MOL PHARMACOL, V61, P1273, DOI 10.1124/mol.61.6.1273
   Bhat KPL, 2001, CANCER RES, V61, P6137
   Bilezikian JP, 1998, J BONE MINER RES, V13, P774, DOI 10.1359/jbmr.1998.13.5.774
   Bord S, 2001, J CLIN ENDOCR METAB, V86, P2309, DOI 10.1210/jc.86.5.2309
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003 2697(76)90527 3
   BROWN AMC, 1984, P NATL ACAD SCI BIOL, V81, P6344, DOI 10.1073/pnas.81.20.6344
   Budde U, 2001, Rev Clin Exp Hematol, V5, P335, DOI 10.1046/j.1468 0734.2001.00048.x
   Cummings SR., 2002, OSTEOPOROSIS, V5, P169
   Diel P, 2004, PLANTA MED, V70, P39, DOI 10.1055/s 2004 815453
   ERIKSEN EF, 1988, SCIENCE, V241, P84, DOI 10.1126/science.3388021
   Fanti P, 1998, OSTEOPOROSIS INT, V8, P274, DOI 10.1007/s001980050065
   Grodstein F, 1997, NEW ENGL J MED, V336, P1769, DOI 10.1056/NEJM199706193362501
   Gustafsson JÅ, 2000, J STEROID BIOCHEM, V74, P245, DOI 10.1016/S0960 0760(00)00130 8
   HARRIS SA, 1995, J BONE MINER RES, V10, P178
   HARRIS SA, 1995, J CELL BIOCHEM, V59, P193, DOI 10.1002/jcb.240590209
   HOLINKA CF, 1986, CANCER RES, V46, P2771
   Ju YH, 2000, J AGR FOOD CHEM, V48, P4628, DOI 10.1021/jf000164z
   Kayisli UA, 2002, J CLIN ENDOCR METAB, V87, P5539, DOI 10.1210/jc.2002 020716
   Kitaoka M, 1998, PLANTA MED, V64, P511, DOI 10.1055/s 2006 957504
   KOMM BS, 1988, SCIENCE, V241, P81, DOI 10.1126/science.3164526
   Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252
   Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863
   KUMAI A, 1984, TOXICOL LETT, V21, P203
   Kurzer MS, 1997, ANNU REV NUTR, V17, P353, DOI 10.1146/annurev.nutr.17.1.353
   Li BB, 2003, BIOL PHARM BULL, V26, P780, DOI 10.1248/bpb.26.780
   Liu JH, 2001, J AGR FOOD CHEM, V49, P2472, DOI 10.1021/jf0014157
   Milligan S, 2002, REPRODUCTION, V123, P235, DOI 10.1530/rep.0.1230235
   Milligan SR, 2000, J CLIN ENDOCR METAB, V85, P4912, DOI 10.1210/jc.85.12.4912
   Milligan SR, 1999, J CLIN ENDOCR METAB, V84, P2249, DOI 10.1210/jc.84.6.2249
   Miranda CL, 1999, FOOD CHEM TOXICOL, V37, P271, DOI 10.1016/S0278 6915(99)00019 8
   Miyamoto M, 1998, PLANTA MED, V64, P516, DOI 10.1055/s 2006 957505
   Monroe DG, 2003, J CELL BIOCHEM, V90, P315, DOI 10.1002/jcb.10633
   Morabito N, 2002, J BONE MINER RES, V17, P1904, DOI 10.1359/jbmr.2002.17.10.1904
   Morito K, 2001, BIOL PHARM BULL, V24, P351, DOI 10.1248/bpb.24.351
   NISHIDA M, 1985, Acta Obstetrica et Gynaecologica Japonica (Japanese Edition), V37, P1103
   NUNEZ AM, 1987, ENDOCRINOLOGY, V121, P1759, DOI 10.1210/endo 121 5 1759
   Pace P, 1997, J BIOL CHEM, V272, P25832, DOI 10.1074/jbc.272.41.25832
   Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508
   Power KA, 2003, BREAST CANCER RES TR, V81, P209, DOI 10.1023/A:1026114501364
   Qu Q, 1999, BONE, V25, P211, DOI 10.1016/S8756 3282(99)00153 2
   Reinholz GG, 2002, BREAST CANCER RES TR, V71, P257, DOI 10.1023/A:1014418017382
   Rickard DJ, 2003, J CELL BIOCHEM, V89, P633, DOI 10.1002/jcb.10539
   Rickard DJ, 1999, J CELL BIOCHEM, P123
   Riggs BL, 1995, ACTA ORTHOP SCAND, V66, P14, DOI 10.3109/17453679509157640
   Rizzoli R, 1997, LANCET, V349, pS20, DOI 10.1016/S0140 6736(97)90007 6
   Robinson JA, 1997, ENDOCRINOLOGY, V138, P2919, DOI 10.1210/en.138.7.2919
   Setchell KDR, 2003, AM J CLIN NUTR, V78, p593S, DOI 10.1093/ajcn/78.3.593S
   So FV, 1997, CANCER LETT, V112, P127, DOI 10.1016/S0304 3835(96)04557 0
   SOTO AM, 1985, J STEROID BIOCHEM, V23, P87, DOI 10.1016/0022 4731(85)90265 1
   Stevens JF, 1999, J AGR FOOD CHEM, V47, P2421, DOI 10.1021/jf990101k
   Subramaniam M, 1995, NUCLEIC ACIDS RES, V23, P4907, DOI 10.1093/nar/23.23.4907
   Tham DM, 1998, J CLIN ENDOCR METAB, V83, P2223, DOI 10.1210/jc.83.7.2223
   Tobe H, 1997, BIOSCI BIOTECH BIOCH, V61, P158, DOI 10.1271/bbb.61.158
   Waters KM, 2001, J CELL BIOCHEM, V83, P448, DOI 10.1002/jcb.1242
   Wuttke W, 2002, J STEROID BIOCHEM, V83, P133, DOI 10.1016/S0960 0760(02)00259 5
   Yamagishi T, 2001, ENDOCRINOLOGY, V142, P3632, DOI 10.1210/en.142.8.3632
   Zierau O, 2002, PLANTA MED, V68, P449, DOI 10.1055/s 2002 32089
   Zierau O, 2002, J STEROID BIOCHEM, V80, P125, DOI 10.1016/S0960 0760(01)00178 9
NR 62
TC 38
Z9 49
U1 0
U2 5
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960 0760
EI 1879 1220
J9 J STEROID BIOCHEM
JI J. Steroid Biochem. Mol. Biol.
PD SEP
PY 2005
VL 96
IS 5
BP 387
EP 399
DI 10.1016/j.jsbmb.2005.04.038
PG 13
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA 978BZ
UT WOS:000232848500006
PM 16019205
DA 2025 08 17
ER

PT J
AU Lee, YS
   Choi, EM
AF Lee, Young Soon
   Choi, Eun Mi
TI Effect of pollen from Typha angustata on hydrogen peroxide induced
   toxicity in osteoblastic MC3T3 E1 cells
SO JOURNAL OF ORAL PATHOLOGY & MEDICINE
LA English
DT Article
DE H2O2; MC3T3 E1 cells; osteoblast differentiation; oxidative stress;
   Typha angustata
ID ALKALINE PHOSPHATASE ACTIVITY; OXIDATIVE STRESS; ANTIOXIDANT SYSTEM;
   BETA; PROTEIN; DIFFERENTIATION; PATHWAYS; DAIDZEIN; KINASE
AB BACKGROUND: Typha angustata is a traditional Chinese medicine, commonly used for a variety of clinical disorders, including atherosclerosis and wound healing. In the present study, the protective effects of T. angustata pollen extract (TE) on the response of osteoblast to oxidative stress were evaluated.
   MATERIALS AND METHODS: Osteoblastic MC3T3 E1 cells were incubated with H2O2 and / or TE, and markers of osteoblast function and oxidative damage were examined.
   RESULTS: TE treatment significantly (P < 0.05) reversed the cytotoxic effect of H2O2 and this effect was blocked by ICI182780, suggesting that TE's effect might be partly involved in estrogen action. TE significantly (P < 0.05) increased collagen content, alkaline phosphatase activity, calcium deposition of osteoblasts in the presence of H2O2 and these effects were blocked by rottlerin and PD98059, suggesting that the induction of differentiation by TE is associated with increased activation of protein kinase C and ERK. Moreover, H2O2 induced reduction of osteocalcin was significantly recovered in the presence of TE. Pretreatment with TE also decreased the increase in receptor activator of nuclear factor kB ligand, malondialdehyde, and protein carbonyl induced by H2O2.
   CONCLUSION: These results suggest that the pollen of T. angustata may be useful for the protection of H(2)O(2)induced oxidative damage and dysfunction in osteoblasts. J Oral Pathol Med (2012) 41: 171 177
C1 [Lee, Young Soon; Choi, Eun Mi] Kyung Hee Univ, Dept Food & Nutr, Grad Sch Educ, Seoul 130701, South Korea.
C3 Kyung Hee University
RP Choi, EM (通讯作者)，Kyung Hee Univ, Dept Food & Nutr, Grad Sch Educ, 1 Hoegi Dong, Seoul 130701, South Korea.
EM cheunmi@hanmail.net
FU Kyung Hee University [KHU 20110050]
FX This work was supported by a grant from the Kyung Hee University in 2011
   (KHU 20110050).
CR Almeida M, 2007, J BIOL CHEM, V282, P27285, DOI 10.1074/jbc.M702810200
   Arai M, 2007, IUBMB LIFE, V59, P27, DOI 10.1080/15216540601156188
   Banfi G, 2008, CLIN CHEM LAB MED, V46, P1550, DOI 10.1515/CCLM.2008.302
   Basu S, 2001, BIOCHEM BIOPH RES CO, V288, P275, DOI 10.1006/bbrc.2001.5747
   Bi YM, 2006, BONE, V38, P778, DOI 10.1016/j.bone.2005.11.005
   BLAKEMAN DP, 1995, BIOCHEM PHARMACOL, V50, P929, DOI 10.1016/0006 2952(95)00214 K
   De Wilde A, 2004, J CELL PHYSIOL, V200, P253, DOI 10.1002/jcp.20008
   De Wilde A, 2006, J CELL PHYSIOL, V209, P786, DOI 10.1002/jcp.20767
   Dreher I, 1998, BIOCHEM BIOPH RES CO, V245, P101, DOI 10.1006/bbrc.1998.8393
   Esterbauer H, 1996, PATHOL BIOL, V44, P25
   Fatokun AA, 2006, BONE, V39, P542, DOI 10.1016/j.bone.2006.02.062
   Giorgio M, 2005, CELL, V122, P221, DOI 10.1016/j.cell.2005.05.011
   Hanai Y, 2006, MOL CELL ENDOCRINOL, V251, P42, DOI 10.1016/j.mce.2006.02.014
   Kim HJ, 2003, J BIOL CHEM, V278, P319, DOI 10.1074/jbc.M203750200
   Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252
   Lee SM, 2004, KOREAN J ORIENT PREV, V8, P33
   MIKSICEK RJ, 1995, P SOC EXP BIOL MED, V208, P44
   Muthusami S, 2005, CLIN CHIM ACTA, V360, P81, DOI 10.1016/j.cccn.2005.04.014
   QUARLES LD, 1992, J BONE MINER RES, V7, P683
   Shinohara Masahiro, 2007, Curr Osteoporos Rep, V5, P67
   Sowa H, 2002, J BIOL CHEM, V277, P36024, DOI 10.1074/jbc.M206030200
   Tullberg Reinert H, 1999, HISTOCHEM CELL BIOL, V112, P271, DOI 10.1007/s004180050447
   Tyner SD, 2002, NATURE, V415, P45, DOI 10.1038/415045a
   Uchida K, 1999, J BIOL CHEM, V274, P2234, DOI 10.1074/jbc.274.4.2234
   Xiao GZ, 2002, J BIOL CHEM, V277, P36181, DOI 10.1074/JBC.m206057200
   YAN SQ, 1994, CLIN ORTHOP RELAT R, P239
   Yang S, 2001, J BIOL CHEM, V276, P5452, DOI 10.1074/jbc.M001004200
NR 27
TC 5
Z9 6
U1 2
U2 10
PU WILEY BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0904 2512
J9 J ORAL PATHOL MED
JI J. Oral Pathol. Med.
PD FEB
PY 2012
VL 41
IS 2
BP 171
EP 177
DI 10.1111/j.1600 0714.2011.01077.x
PG 7
WC Dentistry, Oral Surgery & Medicine; Pathology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine; Pathology
GA 884TD
UT WOS:000299730800011
PM 21958211
DA 2025 08 17
ER

PT J
AU Fathilah, SN
   Mohamed, N
   Muhammad, N
   Mohamed, IN
   Soelaiman, IN
   Shuid, AN
AF Fathilah, Siti Noor
   Mohamed, Norazlina
   Muhammad, Norliza
   Mohamed, Isa Naina
   Soelaiman, Ima Nirwana
   Shuid, Ahmad Nazrun
TI Labisia pumila regulates bone related genes expressions in
   postmenopausal osteoporosis model
SO BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
DE Labisia pumila; Postmenopausal osteoporosis; Estrogen; OPG; BMP 2;
   RANKL; MCSF
ID ESTROGEN PLUS PROGESTIN; OVARIECTOMIZED RAT MODEL; OSTEOCLAST
   DIFFERENTIATION; AQUEOUS EXTRACT; STROMAL CELLS; OSTEOPROTEGERIN; WOMEN;
   17 BETA ESTRADIOL; INTERLEUKIN 6; DEFICIENCY
AB Background: Labisia Pumila var. alata (LPva) has shown potential as an alternative to estrogen replacement therapy (ERT) in prevention of estrogen deficient osteoporosis. In earlier studies using postmenopausal model, LPva was able to reverse the ovariectomy induced changes in biochemical markers, bone calcium, bone histomorphometric parameters and biomechanical strength. The mechanism behind these protective effects is unclear but LPva may have regulated factors that regulate bone remodeling. The aim of this study is to determine the bone protective mechanism of LPva by measuring the expressions of several factors involved in bone formative and resorptive activities namely Osteoprotegerin (OPG), Receptor Activator of Nuclear Factor kappa B Ligand (RANKL), Macrophage Colony Stimulating Factor (MCSF) and Bone Morphogenetic Protein 2 (BMP 2).
   Methods: Thirty two female Wistar rats were randomly divided into four groups: Sham operated (Sham), ovariectomized control (OVXC), ovariectomized with Labisia pumila var. alata (LPva) and ovariectomized with ERT (Premarin (R)) (ERT). The LPva and ERT were administered via daily oral gavages at doses of 17.5 mg/kg and 64.5 mu g/kg, respectively. Following two months of treatment, the rats were euthanized and the gene expressions of BMP 2, OPG, RANKL and MCSF in the femoral bones were measured using a branch   DNA technique.
   Results: The RANKL gene expression was increased while the OPG and BMP 2 gene expressions were reduced in the OVXC group compared to the SHAM group. There were no significant changes in the MCSF gene expressions among the groups. Treatment with either LPva or ERT was able to prevent these ovariectomy induced changes in the gene expressions in ovariectomized rats with similar efficacy.
   Conclusion: LPva may protect bone against estrogen deficiency induced changes by regulating the RANKL, OPG and BMP 2 gene expressions.
C1 [Fathilah, Siti Noor; Mohamed, Norazlina; Muhammad, Norliza; Mohamed, Isa Naina; Soelaiman, Ima Nirwana; Shuid, Ahmad Nazrun] Natl Univ Malaysia UKM, Fac Med, Dept Pharmacol, Kuala Lumpur 50300, Malaysia.
   [Fathilah, Siti Noor] Univ Putra Malaysia, Fac Med & Hlth Sci, Dept Human Anat, Div Pharmacol, Upm Serdang 43400, Selangor, Malaysia.
C3 Universiti Kebangsaan Malaysia; Universiti Putra Malaysia
RP Shuid, AN (通讯作者)，Natl Univ Malaysia UKM, Fac Med, Dept Pharmacol, Kuala Lumpur 50300, Malaysia.
EM anazrun@yahoo.com
RI Soelaiman, Ima/C 4289 2017; Mohamed, Norazlina/M 7306 2017; SHUID,
   AHMAD/AAS 7556 2020
OI shuid, ahmad nazrun/0000 0003 3526 990X; 
FU Faculty of Medicine Universiti Kebangsaan Malaysia; Ministry of Higher
   Education [UKM FF 03 FRGS0047 2009]
FX We are grateful to the staff of the Pharmacology Department, UKM Medical
   Centre for their technical support and Dr Thuan D. Bui for his
   contribution in helping with the data analysis of this study. We also
   thank the Faculty of Medicine Universiti Kebangsaan Malaysia and the
   Ministry of Higher Education for providing the grant FRGS,
   UKM FF 03 FRGS0047 2009 for this study.
CR Al Azzawi F, 2008, GYNECOL ENDOCRINOL, V24, P601, DOI 10.1080/09513590802296245
   Almeida M, 2007, J BIOL CHEM, V282, P27285, DOI 10.1074/jbc.M702810200
   Andras SC, 2001, MOL BIOTECHNOL, V19, P29, DOI 10.1385/MB:19:1:029
   Arcangelo V. P., 2005, PHARMACOTHERAPEUTICS
   Arron JR, 2000, NATURE, V408, P535, DOI 10.1038/35046196
   Ayida A. W., 2007, Journal of Medical and Biological Sciences, V1, P1
   Bord S, 2003, BONE, V32, P136, DOI 10.1016/S8756 3282(02)00953 5
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Burkill IH., 1935, DICT EC PRODUCTS MAL
   Cenci S, 2000, J CLIN INVEST, V106, P1229, DOI 10.1172/JCI11066
   Chen XW, 2002, BIOCHEM BIOPH RES CO, V295, P417, DOI 10.1016/S0006 291X(02)00667 8
   Chlebowski RT, 2003, JAMA J AM MED ASSOC, V289, P3243, DOI 10.1001/jama.289.24.3243
   Choi HK, 2010, J BIOSCI BIOENG, V109, P291, DOI 10.1016/j.jbiosc.2009.08.478
   CHOW JWM, 1992, ENDOCRINOLOGY, V130, P3025, DOI 10.1210/en.130.5.3025
   Devareddy L, 2008, J NUTR BIOCHEM, V19, P694, DOI 10.1016/j.jnutbio.2007.09.004
   Devareddy L, 2006, BONE, V38, P686, DOI 10.1016/j.bone.2005.10.024
   ERNST M, 1989, ENDOCRINOLOGY, V125, P825, DOI 10.1210/endo 125 2 825
   Ezumi MFW, 2007, INDIAN J PHARMACOL, V39, P30
   Fathilah SN, 2012, EVID BASED COMPL ALT, V2012, DOI 10.1155/2012/948080
   Fathilah SN, 2012, J ETHNOPHARMACOL, V142, P294, DOI 10.1016/j.jep.2012.04.029
   Fazliana M, 2009, MATURITAS, V62, P91, DOI 10.1016/j.maturitas.2008.10.004
   Ferguson N., 2004, Osteoporosis in focus
   Flagella M, 2006, ANAL BIOCHEM, V352, P50, DOI 10.1016/j.ab.2006.02.013
   Fuller K, 1998, J EXP MED, V188, P997, DOI 10.1084/jem.188.5.997
   He CC, 2010, J ETHNOPHARMACOL, V127, P229, DOI 10.1016/j.jep.2009.11.016
   Hofbauer LC, 1999, ENDOCRINOLOGY, V140, P4367, DOI 10.1210/en.140.9.4367
   Huang J, 2000, PHYTOCHEMISTRY, V54, P817, DOI 10.1016/S0031 9422(00)00173 4
   Husniza H, 2002, ESTROGENIC ANDROGENI, P8
   International Osteoporosis Foundation, 2009, J BONE MINER RES, V4, P113
   Ismal N M, 1997, Malays J Pathol, V19, P21
   Jamal J.A., 2003, Malays. J. Health Sci, V1, P53
   Jamia A.J., 1998, J PHARM PHARMACOL, V50, P79
   Jilka RL, 1998, BONE, V23, P75, DOI 10.1016/S8756 3282(98)00077 5
   KANZAKI H, 1995, HORM RES, V44, P30, DOI 10.1159/000184658
   KOMM BS, 1988, SCIENCE, V241, P81, DOI 10.1126/science.3164526
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lewiecki EM, 2006, EXPERT OPIN BIOL TH, V6, P1041, DOI 10.1517/14712598.6.10.1041
   Lloyd SAJ, 2008, CALCIFIED TISSUE INT, V82, P361, DOI 10.1007/s00223 008 9133 6
   Lorenzo J, 2000, J CLIN INVEST, V106, P749, DOI 10.1172/JCI11089
   Norhaiza M, 2009, J MED PLANTS RES, V3, P217
   Papanicolaou DA, 1998, ANN INTERN MED, V128, P127, DOI 10.7326/0003 4819 128 2 199801150 00009
   PECK WA, 1993, AM J MED, V94, P646
   Riley EH, 1996, CLIN ORTHOP RELAT R, P39, DOI 10.1097/00003086 199603000 00006
   Rossouw JE, 2002, JAMA J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321
   Runi S.P., 2001, BRIDGING SCI HERBAL, P112
   Shuid AN, 2011, J ETHNOPHARMACOL, V133, P538, DOI 10.1016/j.jep.2010.10.033
   Shuid AN, 2010, J BONE MINER METAB, V28, P149, DOI 10.1007/s00774 009 0122 2
   Shumaker SA, 2003, JAMA J AM MED ASSOC, V289, P2651, DOI 10.1001/jama.289.20.2651
   SIES H, 1995, AM J CLIN NUTR, V62, P1315
   Singh GD, 2009, FOOD CHEM TOXICOL, V47, P2661, DOI 10.1016/j.fct.2009.07.031
   Siti Noor Fathilah AA, 2013, RUMES, V1, P27
   STONE B C, 1988, Malayan Nature Journal, V42, P43
   TAKANOYAMAMOTO T, 1990, P NATL ACAD SCI USA, V87, P2172, DOI 10.1073/pnas.87.6.2172
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   THOMSEN K, 1986, CALCIFIED TISSUE INT, V39, P123, DOI 10.1007/BF02555106
   Viereck V, 2002, J CELL BIOCHEM, V84, P725, DOI 10.1002/jcb.10087
   Wauquier F, 2009, TRENDS MOL MED, V15, P468, DOI 10.1016/j.molmed.2009.08.004
   World Health Organization, 2007, SUMM M GEN 2007 5 7
   Yamagishi T, 2001, ENDOCRINOLOGY, V142, P3632, DOI 10.1210/en.142.8.3632
   Zakaria M., 1994, Tradisional Malay medicinal plants
   Zhou SH, 2003, MOL ENDOCRINOL, V17, P56, DOI 10.1210/me.2002 0210
NR 61
TC 17
Z9 19
U1 0
U2 9
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1472 6882
J9 BMC COMPLEM ALTERN M
JI BMC Complement. Altern. Med.
PD SEP 5
PY 2013
VL 13
AR 217
DI 10.1186/1472 6882 13 217
PG 7
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Integrative & Complementary Medicine
GA 216OU
UT WOS:000324294100001
PM 24007208
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Fahmy, UA
   Ahmed, OAA
   Alhakamy, NA
AF Fahmy, Usama Ahmed
   Ahmed, Osama Abdelhakim Aly
   Alhakamy, Nabil Abdulhafiz
TI Augmentation of Alendronate Cytotoxicity Against Breast Cancer Cells by
   Complexation with Trans activating Regulatory Protein
SO INTERNATIONAL JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE Alendronate sodium; breast cancer; ALS cytotoxicity; nanostructured
   lipid carriers; nanoparticles; bisphosphonates; cancer therapy;
   trans activating regulatory protein
ID LIPID CARRIERS NLCS; PENETRATING PEPTIDES; DRUG DELIVERY; CELLULAR
   UPTAKE; NANOPARTICLES; TAT; BISPHOSPHONATES; MICROSPHERES; LIPOSOMES;
   SYSTEM
AB Background and Objective: Alendronate sodium (ALS) is a member of the class bisphosphonates used to treat osteoporosis. Recent reports suggested that ALS may induce cell death and inhibit the proliferation of estrogen sensitive MCF 7 breast cancer cells. The aim of this work was the combination of ALS and trans activating regulatory protein (TAT) loaded nanostructured lipid carriers (NLCs) to potentiate ALS cytotoxicity against MCF 7 breast cancer cells. Materials and Methods: The ALS and TAT were prepared and loaded in NLCs. The formed NLCs were characterized for entrapment efficiency (%) (EE %), particle size and zeta potential. Cell viability was also carried out for the prepared NLCs. Results: The results revealed that the prepared NLCs were spherical, with particle sizes of 285.2 +/  14.1 nm and polydispersity index of 0.51. Zeta potential of ALS TAT NLCs was +21.1 +/  3.4 mV. The ALS EE percentage of the prepared NLCs was 12.2 +/  1.1%. At concentration of 10 mu g mL( 1), the investigated formulations showed cell survival percentage of 6.86, 20.34, 97.53 and 91.55% for ALS TAT NLCs, raw ALS, raw TAT and plain NLCs, respectively. The IC(50)( )values for the treatments were estimated as follows: ALS TAT NLCs, 1.98 +/  0.17 mu g mL( 1), raw ALS, 2.77 +/  0.36 mu g mL( 1), raw TAT, 1066.67 +/  21.22 mu g mL(')( 1) and plain NLCs, 10816.2 +/  112.32 mu g mL( 1). Conclusion: The combination of ALS with TAT protein loaded NLCs offered a dual mechanism of ALS activity potentiation and a promising candidate for breast cancer therapy.
C1 [Fahmy, Usama Ahmed; Ahmed, Osama Abdelhakim Aly; Alhakamy, Nabil Abdulhafiz] King Abdulaziz Univ, Fac Pharm, Dept Pharmaceut, POB 80200, Jeddah 21589, Saudi Arabia.
   [Ahmed, Osama Abdelhakim Aly] Menia Univ, Fac Pharm, Dept Pharmaceut & Ind Pharm, Al Minya, Egypt.
C3 King Abdulaziz University; Egyptian Knowledge Bank (EKB); Minia
   University
RP Fahmy, UA (通讯作者)，King Abdulaziz Univ, Fac Pharm, Dept Pharmaceut, POB 80200, Jeddah 21589, Saudi Arabia.
RI Alhakamy, Nabil/AAD 9804 2019; Fahmy, Usama/AAR 3249 2020; Ahmed,
   Osama/AAH 3042 2019; Ahmed Fahmy, Usama/I 7793 2013
OI Alhakamy, Nabil/0000 0002 3826 1519; Ahmed Fahmy,
   Usama/0000 0002 6094 5570
FU Deanship of Scientific Research (DSR) at King Abdulaziz University,
   Jeddah [G 207 166 1439]
FX This Project was funded by the Deanship of Scientific Research (DSR) at
   King Abdulaziz University, Jeddah, under grant no. (G 207 166 1439). The
   authors, therefore acknowledge with thanks DSR for technical and
   financial support.
CR Al Deeb SK, 2004, TALANTA, V64, P695, DOI 10.1016/j.talanta.2004.03.044
   Astriab Fisher A, 2002, PHARMACEUT RES, V19, P744, DOI 10.1023/A:1016136328329
   Battaglia L, 2012, EXPERT OPIN DRUG DEL, V9, P497, DOI 10.1517/17425247.2012.673278
   Beloqui A, 2016, NANOMED NANOTECHNOL, V12, P143, DOI 10.1016/j.nano.2015.09.004
   Bolhassani A, 2017, PEPTIDES, V87, P50, DOI 10.1016/j.peptides.2016.11.011
   Bonomini F, 2015, AGING DIS, V6, P109, DOI 10.14336/AD.2014.0305
   Chen GM, 2016, EXP THER MED, V12, P279, DOI 10.3892/etm.2016.3333
   Doktorovova S, 2014, EUR J PHARM BIOPHARM, V87, P1, DOI 10.1016/j.ejpb.2014.02.005
   Dupont E, 2011, METHODS MOL BIOL, V683, P21, DOI 10.1007/978 1 60761 919 2_2
   El Helw ARM, 2015, INT J NANOMED, V10, P5797, DOI 10.2147/IJN.S91556
   Fang CL, 2013, RECENT PAT NANOTECH, V7, P41, DOI 10.2174/187221013804484827
   Farkhani SM, 2014, PEPTIDES, V57, P78, DOI 10.1016/j.peptides.2014.04.015
   Ferreira DD, 2015, INT J NANOMED, V10, P2441, DOI 10.2147/IJN.S76168
   Futaki S, 2017, ACCOUNTS CHEM RES, V50, P2449, DOI 10.1021/acs.accounts.7b00221
   Herce HD, 2017, NAT CHEM, V9, P762, DOI [10.1038/nchem.2811, 10.1038/NCHEM.2811]
   Jobin ML, 2014, BIOCHIMIE, V107, P154, DOI 10.1016/j.biochi.2014.07.022
   Kim CW, 2010, J CONTROL RELEASE, V147, P45, DOI 10.1016/j.jconrel.2010.06.016
   Kim SE, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/320713
   Kristensen M, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17020185
   Lee JY, 2017, J IND ENG CHEM, V52, P277, DOI 10.1016/j.jiec.2017.03.057
   LI S, 2018, J NANOBIOTECHNOL, V16, DOI DOI 10.1186/S12951 018 0431 5
   Lönn P, 2016, SCI REP UK, V6, DOI 10.1038/srep32301
   Madane RG, 2016, DRUG DELIV, V23, P1326, DOI 10.3109/10717544.2014.975382
   Mudshinge SR, 2011, SAUDI PHARM J, V19, P129, DOI 10.1016/j.jsps.2011.04.001
   Park D, 2018, BIOMACROMOLECULES, V19, P2682, DOI 10.1021/acs.biomac.8b00292
   Poongothai S., 2010, Int. J. Pharm. Pharm. Sci, V2, P133
   Rennert G, 2017, CLIN CANCER RES, V23, P1684, DOI 10.1158/1078 0432.CCR 16 0547
   Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200
   SKEHAN P, 1990, JNCI J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107
   Song L, 2015, INT J ENDOCRINOL, V2015, DOI 10.1155/2015/280164
   Tamjidi F, 2013, INNOV FOOD SCI EMERG, V19, P29, DOI 10.1016/j.ifset.2013.03.002
   Tipton DA, 2011, J PERIODONTAL RES, V46, P39, DOI 10.1111/j.1600 0765.2010.01306.x
   Uprit S, 2013, SAUDI PHARM J, V21, P379, DOI 10.1016/j.jsps.2012.11.005
   Varkouhi AK, 2011, J CONTROL RELEASE, V151, P220, DOI 10.1016/j.jconrel.2010.11.004
   Vendeville A, 2004, MOL BIOL CELL, V15, P2347, DOI 10.1091/mbc.E03 12 0921
   Vichai V, 2006, NAT PROTOC, V1, P1112, DOI 10.1038/nprot.2006.179
   Wang Y, 2016, DRUG DELIV, V23, P3193, DOI 10.3109/10717544.2016.1160459
   Wang Y, 2013, INT J PHARMACEUT, V441, P748, DOI 10.1016/j.ijpharm.2012.10.019
   Weber S, 2014, EUR J PHARM BIOPHARM, V86, P7, DOI 10.1016/j.ejpb.2013.08.013
NR 39
TC 3
Z9 3
U1 0
U2 1
PU ASIAN NETWORK SCIENTIFIC INFORMATION ANSINET
PI FAISALABAD
PA 308 LASANI TOWN, SARGODHA RD, FAISALABAD, 38090, PAKISTAN
SN 1811 7775
EI 1812 5700
J9 INT J PHARMACOL
JI Int. J. Pharmacol.
PY 2019
VL 15
IS 6
BP 731
EP 737
DI 10.3923/ijp.2019.731.737
PG 7
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA IM6GN
UT WOS:000478091500009
DA 2025 08 17
ER

PT J
AU Peng, L
   Wang, HZ
   Song, KG
   Wang, H
   Liu, P
AF Peng, Li
   Wang, Hongzhi
   Song, Keguan
   Wang, Hai
   Liu, Ping
TI Lentivirus mediated TNF α gene silencing and overexpression of
   osteoprotegerin inhibit titanium particle induced inflammatory response
   and osteoclastogenesis in vitro
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE tumor necrosis factor alpha; osteoprotegerin; lentivirus; wear particle;
   osteoclastogenesis
ID BONE RESORPTION; WEAR DEBRIS; OSTEOBLAST DIFFERENTIATION; REGULATORY
   MECHANISM; RANKL; OSTEOLYSIS; THERAPY
AB Macrophages and osteoclasts release proinflammatory factors and promote osteoclastogenesis following the phagocytosis of wear particles. During this pathological process, receptor of nuclear factor kappa B ligand (RANKL) and tumor necrosis factor (TNF) alpha are critical factors contributing to resorption and the inflammatory response. The present study aimed to construct recombination lentivirus vectors carrying TNF alpha small interfering (si)RNA and osteoprotegerin (OPG) cDNA, and to examine the effects of Lenti siTNF alpha OPG on the wear particle induced inflammatory response and osteoclastogenesis in a titanium (Ti) particle induced inflammatory response cell model. Lenti siTNF alpha OPG vectors were constructed and transnfected into RAW264.7 and MC3T3 E1 cells, respectively, prior to particle stimulation. The protein levels of TNF alpha, OPG and RANKL were evaluated using western blot analysis and enzyme linked immunosorbent assays, and the mRNA expression levels of the inflammatory factors, TNF alpha, interleukin (IL) 1 beta and IL 6, as well as OPG and RANKL, were measured using reverse transcription quantitative polymerase chain reaction analysis. The activity of alkaline phosphatase (ALP) was examined using an ALP kit. In the presence of the Lenti siTNFa OPG vector, the mRNA expression levels of the inflammatory factors and RANKL were downregulated, as were the protein levels of TNF alpha. The mRNA expression and protein levels of OPG were upregulated, and ALP activity was increased. These findings suggested that Lenti siTNF alpha OPG transfection inhibited the wear particle induced inflammatory response and osteoclastogenesis, which warrants further investigation for the prevention and/or treatment of wear particle induced osteolysis.
C1 [Peng, Li; Wang, Hongzhi; Song, Keguan] Harbin Med Univ, Affiliated Hosp 1, Dept Orthopaed 3, Harbin 150001, Heilongjiang, Peoples R China.
   [Wang, Hai] Fujian Med Univ, Affiliated Hosp 1, Dept Orthopaed, Fuzhou 350004, Fujian, Peoples R China.
   [Liu, Ping] Harbin Med Univ, Dept Immunol, Harbin 150081, Heilongjiang, Peoples R China.
C3 Harbin Medical University; Fujian Medical University; Harbin Medical
   University
RP Song, KG (通讯作者)，Harbin Med Univ, Affiliated Hosp 1, Dept Orthopaed 3, 23 Youzheng St, Harbin 150001, Heilongjiang, Peoples R China.
EM songkeguan@sohhu.com
RI Wang, Hongzhi/IAP 6964 2023
FU National Natural Science Foundation of China [81170386]
FX The study was supported by funding from the National Natural Science
   Foundation of China (grant no. 81170386). All experiments were performed
   in the Laboratory of Cardiology of the First Affiliated Hospital of
   Harbin Medical University (Harbin, China). The authors would like to
   thank the managers and staff for their hospitability, time and opinions.
CR Abbas S, 2003, CYTOKINE, V22, P33, DOI 10.1016/S1043 4666(03)00106 6
   Abu Amer Y, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2170
   Adapala NS, 2010, J BIOL CHEM, V285, P36745, DOI 10.1074/jbc.M110.124628
   Agarwal S, 2004, CURR ORTHOPAED, V18, P220, DOI 10.1016/j.cuor.2004.03.002
   Akisue T, 2002, J BIOMED MATER RES, V59, P507, DOI 10.1002/jbm.1264
   Almeida M, 2011, J BIOL CHEM, V286, P44326, DOI 10.1074/jbc.M111.283481
   Bonnelye E, 2008, BONE, V42, P129, DOI 10.1016/j.bone.2007.08.043
   Boyce BF, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2165
   Dong L, 2008, J ORTHOP RES, V26, P1114, DOI 10.1002/jor.20607
   Froelich S, 2010, IMMUNOPHARM IMMUNOT, V32, P208, DOI 10.3109/08923970903420582
   Gallo Jiri, 2002, Biomedical Papers (Olomouc), V146, P21
   Goater JJ, 2002, J ORTHOPAED RES, V20, P169, DOI 10.1016/S0736 0266(01)00083 3
   Goodman SB, 2005, CLIN ORTHOP RELAT R, P39, DOI 10.1097/01.blo.0000149998.88218.05
   Greenfield EM, 2008, J AM ACAD ORTHOP SUR, V16, pS56, DOI 10.5435/00124635 200800001 00012
   Harris WH, 2001, CLIN ORTHOP RELAT R, P66
   He X, 2010, BIOCHEM BIOPH RES CO, V401, P356, DOI 10.1016/j.bbrc.2010.09.053
   Inose H, 2009, P NATL ACAD SCI USA, V106, P20794, DOI 10.1073/pnas.0909311106
   Kay MA, 2001, NAT MED, V7, P33, DOI 10.1038/83324
   Ollivere B, 2012, J BONE JOINT SURG BR, V94B, P10, DOI 10.1302/0301 620X.94B1.28047
   Philpott A, 2014, MATURITAS, V77, P185, DOI 10.1016/j.maturitas.2013.10.019
   Pivonka P, 2010, J THEOR BIOL, V262, P306, DOI 10.1016/j.jtbi.2009.09.021
   Purdue P Edward, 2006, HSS J, V2, P102, DOI 10.1007/s11420 006 9003 6
   Ritchlin CT, 2003, J CLIN INVEST, V111, P821, DOI 10.1172/JCI200316069
   Rucci N, 2007, J CELL BIOCHEM, V100, P464, DOI 10.1002/jcb.21059
   SCHMALZRIED TP, 1992, J BONE JOINT SURG AM, V74A, P849, DOI 10.2106/00004623 199274060 00006
   Takahashi N, 2011, FRONT BIOSCI LANDMRK, V16, P21, DOI 10.2741/3673
   Teitelbaum SL, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1857
   Theoleyre S, 2004, CYTOKINE GROWTH F R, V15, P457, DOI 10.1016/j.cytogfr.2004.06.004
   Wang CT, 2010, BIOMATERIALS, V31, P77, DOI 10.1016/j.biomaterials.2009.09.017
   Xu JK, 2009, CYTOKINE GROWTH F R, V20, P7, DOI 10.1016/j.cytogfr.2008.11.007
   Yoshino T, 2014, J HARD TISSUE BIOL, V23, P155, DOI 10.2485/jhtb.23.155
NR 31
TC 7
Z9 7
U1 0
U2 7
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791 2997
EI 1791 3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD JAN
PY 2016
VL 13
IS 1
BP 1010
EP 1018
DI 10.3892/mmr.2015.4620
PN B
PG 9
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Research & Experimental Medicine
GA DA5UI
UT WOS:000367867700054
PM 26648171
OA Bronze
DA 2025 08 17
ER

PT J
AU Ishikane, S
   Ikushima, E
   Igawa, K
   Tomooka, K
   Takahashi Yanaga, F
AF Ishikane, Shin
   Ikushima, Eigo
   Igawa, Kazunobu
   Tomooka, Katsuhiko
   Takahashi Yanaga, Fumi
TI Differentiation inducing factor 1 potentiates adipogenic differentiation
   and attenuates the osteogenic differentiation of bone marrow derived
   mesenchymal stem cells
SO BIOCHIMICA ET BIOPHYSICA ACTA MOLECULAR CELL RESEARCH
LA English
DT Article
DE Mesenchymal stem cells; Differentiation; Differentiation inducing
   factor 1; Glycogen synthase kinase 3
ID CYCLIN D1; PPAR GAMMA; MYOCARDIAL INFARCTION; EXPRESSION;
   PHOSPHORYLATION; ADIPOCYTES; INHIBITION; OSTEOBLAST; GSK 3 BETA; THERAPY
AB Mesenchymal stem cells (MSCs) are an attractive cell source for tissue regeneration and repair. However, their low differentiation efficacy currently impedes the development of MSC therapy. Therefore, in this study, we investigated the effects of differentiation inducing factor 1 (DIF 1) on the differentiation efficacy of bone marrow derived MSCs (BM MSCs) into adipogenic or osteogenic lineages. BM MSCs, which were obtained from Sprague Dawley rats, were positive for the MSC markers (CD29, CD73, and CD90). DIF 1 alone neither affected cell surface antigen expression nor induced adipogenic or osteogenic differentiation. However, DIF 1 significantly enhanced the effects of adipogenic differentiation stimuli, which were evaluated as the number of oil redO positive cells and the expression of adipocyte differentiation markers (peroxisome proliferator activated receptor gamma, adipocyte fatty acid binding protein, and adiponectin). In contrast, DIF 1 significantly attenuated the effects of osteogenic differentiation stimuli, which were evaluated as alizarin red S positive calcium deposition, and the expression of osteoblast differentiation markers alkaline phosphatase, runt related transcription factor 2, and osteopontin. We further investigated the mechanism by which DIF 1 affects MSC differentiation efficacy and found that glycogen synthase kinase 3 was the main factor mediating the action of DIF 1 on the adipogenic differentiation of BM MSCs, whereas it was only partially involved in osteogenic differentiation. These results suggest that DIF 1 supports MSC differentiation toward the desired cell fate by enhancing the differentiation efficacy.
C1 [Ishikane, Shin; Ikushima, Eigo; Takahashi Yanaga, Fumi] Univ Occupat & Environm Hlth, Sch Med, Dept Pharmacol, Yahatanishi Ku, 1 1 Iseigaoka, Kitakyushu, Fukuoka 8078555, Japan.
   [Igawa, Kazunobu; Tomooka, Katsuhiko] Kyushu Univ, Inst Mat Chem & Engn, Dept Mol & Mat Sci, Chikushi Campus 6 1 Kasuga Koen, Kasuga, Fukuoka 8168580, Japan.
C3 University of Occupational & Environmental Health   Japan; Kyushu
   University
RP Ishikane, S (通讯作者)，Univ Occupat & Environm Hlth, Sch Med, Dept Pharmacol, Yahatanishi Ku, 1 1 Iseigaoka, Kitakyushu, Fukuoka 8078555, Japan.
EM ishikane@med.uoeh u.ac.jp
RI Igawa, Kazunobu/AAI 3003 2020
FU UOEH Research Grant for the Promotion of Occupational Health; UOEH
   Research Grant for Young Scientists
FX This work was supported by a UOEH Research Grant for the Promotion of
   Occupational Health and a UOEH Research Grant for Young Scientists.
CR Almalki SG, 2016, DIFFERENTIATION, V92, P41, DOI 10.1016/j.diff.2016.02.005
   Arioka M, 2017, BIOCHEM PHARMACOL, V138, P31, DOI 10.1016/j.bcp.2017.05.004
   Biver E, 2014, MOL CELL ENDOCRINOL, V382, P120, DOI 10.1016/j.mce.2013.09.018
   Cho J, 2011, CIRC RES, V108, P478, DOI 10.1161/CIRCRESAHA.110.229658
   Cho J, 2009, J BIOL CHEM, V284, P36647, DOI 10.1074/jbc.M109.019109
   Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075
   Cristancho AG, 2011, NAT REV MOL CELL BIO, V12, P722, DOI 10.1038/nrm3198
   Meirelles LDS, 2006, J CELL SCI, V119, P2204, DOI 10.1242/jcs.02932
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Fan XL, 2020, CELL MOL LIFE SCI, V77, P2771, DOI 10.1007/s00018 020 03454 6
   Fu XR, 2019, CELLS BASEL, V8, DOI 10.3390/cells8080784
   Gambardella A, 2011, J BONE MINER RES, V26, P811, DOI 10.1002/jbmr.266
   Gwak J, 2012, CELL RES, V22, P237, DOI 10.1038/cr.2011.127
   Hu P, 2017, TOXICOL APPL PHARM, V329, P48, DOI 10.1016/j.taap.2017.05.019
   Ishikane S, 2008, STEM CELLS, V26, P2625, DOI 10.1634/stemcells.2008 0236
   Ishikane S, 2013, TRANSPLANTATION, V96, P697, DOI 10.1097/TP.0b013e31829f753d
   Ishikane S, 2010, J MOL CELL CARDIOL, V49, P753, DOI 10.1016/j.yjmcc.2010.07.019
   James AW, 2013, SCIENTIFICA, V2013, DOI 10.1155/2013/684736
   Jingushi K, 2012, BIOCHEM PHARMACOL, V83, P47, DOI 10.1016/j.bcp.2011.10.001
   Kaidanovich Beilin O, 2011, FRONT MOL NEUROSCI, V4, DOI 10.3389/fnmol.2011.00040
   Kerkela R, 2008, J CLIN INVEST, V118, P3609, DOI 10.1172/JCI36245
   Kim J, 2017, MOL CELL BIOCHEM, V430, P1, DOI 10.1007/s11010 017 2948 6
   Lee Hye Min, 2015, J Menopausal Med, V21, P93, DOI 10.6118/jmm.2015.21.2.93
   Li Y, 2018, CURR STEM CELL RES T, V13, P185, DOI 10.2174/1574888X12666171012141908
   Liang XT, 2014, CELL TRANSPLANT, V23, P1045, DOI 10.3727/096368913X667709
   Lozito TP, 2009, J CELL BIOCHEM, V107, P706, DOI 10.1002/jcb.22166
   MASENTO MS, 1988, BIOCHEM J, V256, P23, DOI 10.1042/bj2560023
   Matsuda T, 2010, J PHARMACOL SCI, V112, P320, DOI 10.1254/jphs.09348FP
   Matsuzaki E, 2006, J BONE MINER RES, V21, P1307, DOI 10.1359/JBMR.060512
   Meirelles LD, 2008, STEM CELLS, V26, P2287, DOI 10.1634/stemcells.2007 1122
   Morganstein DL, 2010, CELL RES, V20, P434, DOI 10.1038/cr.2010.11
   Mori J, 2005, EXP CELL RES, V310, P426, DOI 10.1016/j.yexcr.2005.07.024
   MORRIS HR, 1987, NATURE, V328, P811, DOI 10.1038/328811a0
   Moseti D, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17010124
   Patel P, 2017, CURR TOP DEV BIOL, V123, P277, DOI 10.1016/bs.ctdb.2016.11.011
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Planat Bénard V, 2004, CIRC RES, V94, P223, DOI 10.1161/01.RES.0000109792.43271.47
   Ibarra Ibarra BR, 2019, STEM CELLS INT, V2019, DOI 10.1155/2019/8940365
   Saidi N, 2017, BIOMED PHARMACOTHER, V89, P719, DOI 10.1016/j.biopha.2017.02.093
   Seya K, 2012, BRIT J PHARMACOL, V165, P870, DOI 10.1111/j.1476 5381.2011.01541.x
   Shimizu K, 2004, CANCER RES, V64, P2568, DOI 10.1158/0008 5472.CAN 03 3551
   Spiegelman BM, 1997, BIOCHIMIE, V79, P111, DOI 10.1016/S0300 9084(97)81500 3
   Takahashi Yanaga F, 2003, J BIOL CHEM, V278, P9663, DOI 10.1074/jbc.M205768200
   Takahashi Yanaga F, 2014, BIOCHEM PHARMACOL, V89, P340, DOI 10.1016/j.bcp.2014.03.006
   Takahashi Yanaga F, 2013, BIOCHEM PHARMACOL, V86, P191, DOI 10.1016/j.bcp.2013.04.022
   Tetsuo F, 2019, CANCER SCI, V110, P3761, DOI 10.1111/cas.14204
   Thompson CRL, 2000, MOL CELL, V6, P1509, DOI 10.1016/S1097 2765(00)00147 7
   Tompkins BA, 2018, CIRC RES, V122, P1006, DOI 10.1161/CIRCRESAHA.117.312486
   Wu MR, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.9
   Yasmin T, 2005, BIOCHEM BIOPH RES CO, V338, P903, DOI 10.1016/j.bbrc.2005.10.018
   Yuan ZY, 2016, CURR STEM CELL RES T, V11, P216, DOI 10.2174/1574888X10666150519093429
   Zwetsloot PP, 2016, CIRC RES, V118, P1223, DOI 10.1161/CIRCRESAHA.115.307676
NR 52
TC 10
Z9 10
U1 1
U2 21
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0167 4889
EI 1879 2596
J9 BBA MOL CELL RES
JI Biochim. Biophys. Acta Mol. Cell Res.
PD FEB
PY 2021
VL 1868
IS 2
AR 118909
DI 10.1016/j.bbamcr.2020.118909
PG 11
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA PN3VH
UT WOS:000604409500007
PM 33189784
DA 2025 08 17
ER

PT J
AU Takahashi, H
   Toyoda, M
   Birumachi, JI
   Horie, A
   Uyama, T
   Miyado, K
   Matsumoto, K
   Saito, H
   Umezawa, A
AF Takahashi, Hidekazu
   Toyoda, Masashi
   Birumachi, Jun ichi
   Horie, Akane
   Uyama, Taro
   Miyado, Kenji
   Matsumoto, Kenji
   Saito, Hirohisa
   Umezawa, Akihiro
TI Shortening of Human Cell Life Span by Induction of p16ink4a Through the
   Platelet Derived Growth Factor Receptor β
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
ID MARROW STROMAL CELLS; MESENCHYMAL STEM CELLS; EX VIVO EXPANSION; MATURE
   OSTEOBLASTS; SENESCENCE; BONE; DIFFERENTIATION; EXPRESSION; KINASE; P16
AB Mesenchymal stem cells (MSCs) are attracting a great deal of attention because they represent a valuable source of cells for use in regenerative medicine. In human cell culture it is important to obtain large numbers of cells for use in therapy. In this study, we attempted to prolong life span of a marrow derived mesenchymal stem cell using a combination of growth factors and hormones. Furthermore we tested whether chemically defined culture conditions are sufficient for maintenance of multipotent mesenchymal stem cells. Epidermal growth factor, platelet derived growth factor BB (PDGF BB), acidic fibroblast growth factor (FGF), basic FGF, and leukemia inhibitory factor were found to be key factors for the mesenchymal stem cell proliferation. The combination of these growth factors showed extremely strong mitogenic activity, and simultaneously induced the expression of cyclin dependent kinase inhibitor p16ink4a protein and premature senescence more rapidly than serum supported culture conditions. The induction of p16ink4a by growth factors was mediated through the mitogen activated protein kinase (MAPK) cascade. Excess growth stimulation by growth factors was thus one of the culture stress signals and a trigger of premature senescence at least in human cells. J. Cell. Physiol. 221: 335 342, 2009. (C) 2009 Wiley Liss, Inc.
C1 [Umezawa, Akihiro] Natl Inst Child Hlth & Dev, Dept Reprod Biol, Setagaya Ku, Tokyo 1578535, Japan.
   [Takahashi, Hidekazu] TOYOBO Co Ltd, Tsuruga Inst Biotechnol, Fukui, Japan.
   [Matsumoto, Kenji; Saito, Hirohisa] Natl Inst Child Hlth & Dev, Dept Allergy & Immunol, Tokyo 1578535, Japan.
C3 National Center for Child Health & Development   Japan; Toyobo Co., Ltd;
   National Center for Child Health & Development   Japan
RP Umezawa, A (通讯作者)，Natl Inst Child Hlth & Dev, Dept Reprod Biol, Setagaya Ku, 2 10 1 Okura, Tokyo 1578535, Japan.
EM umezawa@1985.jukuin.keio.ac.jp
RI MIYADO, KENJI/E 6568 2013
OI Miyado, Kenji/0000 0002 8339 6738; Saito, Hirohisa/0000 0002 6630 8337
CR Alberts B., 2002, Molecular Biology of the Cell
   Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742
   Beauséjour CM, 2003, EMBO J, V22, P4212, DOI 10.1093/emboj/cdg417
   Bébien M, 2003, ONCOGENE, V22, P1836, DOI 10.1038/sj.onc.1206334
   Campisi J, 2001, EXP GERONTOL, V36, P607, DOI 10.1016/S0531 5565(00)00230 8
   Chachques JC, 2004, INT J CARDIOL, V95, pS29, DOI 10.1016/S0167 5273(04)90009 5
   CHEN Q, 1995, P NATL ACAD SCI USA, V92, P4337, DOI 10.1073/pnas.92.10.4337
   Chen SL, 2004, AM J CARDIOL, V94, P92, DOI 10.1016/j.amjcard.2004.03.034
   Gojo S, 2003, EXP CELL RES, V288, P51, DOI 10.1016/S0014 4827(03)00132 0
   Hara E, 1996, MOL CELL BIOL, V16, P859
   HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014 4827(61)90192 6
   Horwitz EM, 1999, NAT MED, V5, P309, DOI 10.1038/6529
   Imabayashi H, 2003, EXP CELL RES, V288, P35, DOI 10.1016/S0014 4827(03)00130 7
   Itahana K, 2003, MOL CELL BIOL, V23, P389, DOI 10.1128/MCB.23.1.389 401.2003
   Iwasa H, 2003, GENES CELLS, V8, P131, DOI 10.1046/j.1365 2443.2003.00620.x
   Jaquet K, 2005, STEM CELLS DEV, V14, P299, DOI 10.1089/scd.2005.14.299
   Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962
   Koç ON, 2002, BONE MARROW TRANSPL, V30, P215, DOI 10.1038/sj.bmt.1703650
   Koç ON, 2000, J CLIN ONCOL, V18, P307, DOI 10.1200/JCO.2000.18.2.307
   Kohyama J, 2001, DIFFERENTIATION, V68, P235, DOI 10.1046/j.1432 0436.2001.680411.x
   Kopen GC, 1999, P NATL ACAD SCI USA, V96, P10711, DOI 10.1073/pnas.96.19.10711
   Lange C, 2005, KIDNEY INT, V68, P1613, DOI 10.1111/j.1523 1755.2005.00573.x
   Lange C, 2007, J CELL PHYSIOL, V213, P18, DOI 10.1002/jcp.21081
   Le Blanc K, 2004, LANCET, V363, P1439, DOI 10.1016/S0140 6736(04)16104 7
   LENNON DP, 1995, EXP CELL RES, V219, P211, DOI 10.1006/excr.1995.1221
   Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008
   Mahmood A, 2004, NEUROSURGERY, V55, P1185, DOI 10.1227/01.NEU.0000141042.14476.3C
   Makino S, 1999, J CLIN INVEST, V103, P697, DOI 10.1172/JCI5298
   Martin MJ, 2005, NAT MED, V11, P228, DOI 10.1038/nm1181
   Mori T, 2005, MOL CELL BIOL, V25, P5183, DOI 10.1128/MCB.25.12.5183 5195.2005
   Ng F, 2008, BLOOD, V112, P295, DOI 10.1182/blood 2007 07 103697
   Ochi K, 2003, J CELL PHYSIOL, V194, P45, DOI 10.1002/jcp.10185
   Parrinello S, 2003, NAT CELL BIOL, V5, P741, DOI 10.1038/ncb1024
   Petite H, 2000, NAT BIOTECHNOL, V18, P959, DOI 10.1038/79449
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Ramirez RD, 2001, GENE DEV, V15, P398, DOI 10.1101/gad.859201
   Raucci A, 2004, J BIOL CHEM, V279, P1747, DOI 10.1074/jbc.M310384200
   Rheinwald JG, 2002, MOL CELL BIOL, V22, P5157, DOI 10.1128/MCB.22.14.5157 5172.2002
   Sano M, 2001, EXP CELL RES, V266, P114, DOI 10.1006/excr.2001.5203
   Schichor C, 2006, EXP NEUROL, V199, P301, DOI 10.1016/j.expneurol.2005.11.027
   SEIFERT RA, 1993, J BIOL CHEM, V268, P4473
   Selvaggi TA, 1997, BLOOD, V89, P776, DOI 10.1182/blood.V89.3.776
   Serrano M, 1997, EXP CELL RES, V237, P7, DOI 10.1006/excr.1997.3824
   Sherr CJ, 2000, CELL, V102, P407, DOI 10.1016/S0092 8674(00)00046 5
   Shimo T, 2007, J CELL COMMUN SIGNAL, V1, P103, DOI 10.1007/s12079 007 0010 2
   Simonsen JL, 2002, NAT BIOTECHNOL, V20, P592, DOI 10.1038/nbt0602 592
   Takeda Y, 2004, J GENE MED, V6, P833, DOI 10.1002/jgm.583
   Tamama K, 2006, STEM CELLS, V24, P686, DOI 10.1634/stemcells.2005 0176
   Terai M, 2005, MOL BIOL CELL, V16, P1491, DOI 10.1091/mbc.E04 07 0652
   Tögel F, 2005, AM J PHYSIOL RENAL, V289, pF31, DOI 10.1152/ajprenal.00007.2005
   Toussaint O, 2000, EXP GERONTOL, V35, P927, DOI 10.1016/S0531 5565(00)00180 7
   Toyoda M, 2007, INT J HEMATOL, V86, P1, DOI 10.1532/IJH97.07055
   Tropepe V, 2001, NEURON, V30, P65, DOI 10.1016/S0896 6273(01)00263 X
   UMEZAWA A, 1991, MOL CELL BIOL, V11, P920, DOI 10.1128/MCB.11.2.920
   UMEZAWA A, 1992, J CELL PHYSIOL, V151, P197, DOI 10.1002/jcp.1041510125
   Wang WP, 2002, MOL CELL BIOL, V22, P3389, DOI 10.1128/MCB.22.10.3389 3403.2002
   Wei WY, 1999, EXP CELL RES, V253, P519, DOI 10.1006/excr.1999.4665
   Wiles MV, 1999, EXP CELL RES, V247, P241, DOI 10.1006/excr.1998.4353
   Williamson AJK, 2004, J BIOL CHEM, V279, P47912, DOI 10.1074/jbc.M409035200
   Yao CL, 2004, EXP HEMATOL, V32, P720, DOI 10.1016/j.exphem.2004.05.021
NR 60
TC 5
Z9 6
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0021 9541
EI 1097 4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD NOV
PY 2009
VL 221
IS 2
BP 335
EP 342
DI 10.1002/jcp.21860
PG 8
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA 502EP
UT WOS:000270438300009
PM 19582773
DA 2025 08 17
ER

PT J
AU Alfotawi, R
   Elsafadi, M
   Muthurangan, M
   Siyal, AA
   Alfayez, M
   Mahmmod, AA
AF Alfotawi, Randa
   Elsafadi, Mona
   Muthurangan, Manikandan
   Siyal, Abdul Aziz
   Alfayez, Musaad
   Mahmmod, Amer A.
TI A New Procedure in Bone Engineering Using Induced Adipose Tissue
SO JOURNAL OF INVESTIGATIVE SURGERY
LA English
DT Article
DE tissue engineering; tissue plasticity; stem cell; bone regeneration
ID STEM CELLS; ADIPOCYTE DIFFERENTIATION; MARROW; OVEREXPRESSION;
   PROLIFERATION
AB Background: Osteoporosis is associated with a metabolic imbalance between adipogenesis and osteogenesis. We hypothesized that implanting a carrier for differentiated stem cells and signaling molecules inside adipose tissues could be used to enable transdifferentiation between cells, upregulate osteogenesis, and support bone formation, which may regain the balance between osteogenesis and adipogenesis. Methodology: A CL1 human mesenchymal stem cell line was grown in an osteogenic medium to differentiate into osteoblasts, and the differentiated cells were then exposed to an adipogenic medium to stimulate differentiation into adipocytes. Osteogenic and adipogenic differentiation were confirmed by the following assays: alkaline phosphatase staining, Nile red Staining, and quantitative real time polymerase chain reaction (qPCR). The ratio of adipocytes to osteocytes for both cases was calculated. To evaluate bone induction in vivo, a calcium sulfate/hydroxyapatite cement was prepared in a syringe and then seeded with 10(6) cells/mL of rat bone marrow stromal cells (rMSCs) and covered with 1 mL of tissue culture media containing 0.1 mg of bone morphogenetic protein 7 (BMP 7). The construct was injected into the abdominal fat tissue of 10 male Sprague Dawley rats. Results: The conversion of osteocytes to adipocytes was 20 fold greater than the reverse conversion, and the area of bone regeneration was 15.7 +/  3.7%, the area of adipose tissue was 65.8 +/  13.1%, and the area of fibrous tissue was 18.3 +/  7.8%. Conclusion: Adipogenic interconversion and associated bone formation demonstrate the potential of a new therapy for balancing osteogenesis and adipogenesis.
C1 [Alfotawi, Randa] King Saud Univ, Oral & Maxillofacial Dept, Riyadh, Saudi Arabia.
   [Elsafadi, Mona; Muthurangan, Manikandan; Siyal, Abdul Aziz; Alfayez, Musaad; Mahmmod, Amer A.] King Saud Univ, Med Sch, Anat Dept, Stem Cell Unit, Riyadh, Saudi Arabia.
C3 King Saud University; King Saud University
RP Alfotawi, R (通讯作者)，King Saud Univ, Oral & Maxillofacial Dept, Riyadh, Saudi Arabia.
EM r.alfotawei@ksu.edu.sa
RI ; ALFOTAWI, RANDA/F 6014 2017; muthurangan, manikandan/GVU 5356 2022
OI Elsafadi, Mona/0000 0002 7096 998X; ALFOTAWI, RANDA/0000 0003 4556 4099;
   muthurangan, manikandan/0000 0003 3057 1851; 
FU Deanship of Scientific Research at King Saud University [RG 1439 062]
FX The authors would like to thank the Animal Experimental Unit of King
   Saud University for cooperation throughout the study, and BoneSupport AB
   (Lund, Sweden) for the provision of CERAMENT TM bone cement. The authors
   extend their appreciation to the Deanship of Scientific Research at King
   Saud University for funding this study through Research Group No.
   RG 1439 062.
CR Abdallah BM, 2015, BONE, V70, P28, DOI 10.1016/j.bone.2014.07.028
   Al Nbaheen M, 2013, STEM CELL REV REP, V9, P32, DOI 10.1007/s12015 012 9365 8
   Alfotawi R, 2017, J BIOMATER TISS ENG, V7, P1114, DOI 10.1166/jbt.2017.1679
   Alfotawi R, 2016, J BIOMATER TISS ENG, V6, P1, DOI 10.1166/jbt.2016.1412
   Alfotawi R, 2013, J TISSUE ENG, V4, DOI 10.1177/2041731413509645
   Ayoub A, 2015, FRONT ORAL BIOL, V17, P101, DOI 10.1159/000381700
   BERESFORD JN, 1992, J CELL SCI, V102, P341
   Choi JH, 2010, TISSUE ENG PART B RE, V16, P413, DOI 10.1089/ten.TEB.2009.0544
   Diekman BO, 2010, J BIOMED MATER RES A, V93A, P994, DOI 10.1002/jbm.a.32589
   Fan JB, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0072474, 10.1371/journal.pone.0076701]
   GIMBLE JM, 1995, J CELL BIOCHEM, V58, P393, DOI 10.1002/jcb.240580312
   Gomillion CT, 2006, BIOMATERIALS, V27, P6052, DOI 10.1016/j.biomaterials.2006.07.033
   Hao W, 2017, EXP THER MED, V14, P43, DOI 10.3892/etm.2017.4465
   Huang RL, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 017 0126 0
   Justesen J, 2001, BIOGERONTOLOGY, V2, P165, DOI 10.1023/A:1011513223894
   Kaplan FS, 2000, J BONE MINER RES, V15, P2084, DOI 10.1359/jbmr.2000.15.11.2084
   Koo KH, 1998, RADIOLOGY, V206, P745, DOI 10.1148/radiology.206.3.9494495
   Moerman EJ, 2004, AGING CELL, V3, P379, DOI 10.1111/j.1474 9728.2004.00127.x
   Peister A, 2004, BLOOD, V103, P1662, DOI 10.1182/blood 2003 09 3070
   Reikerås O, 2011, CLIN ORTHOP RELAT R, V469, P1479, DOI 10.1007/s11999 011 1796 z
   Sabatakos G, 2000, NAT MED, V6, P985, DOI 10.1038/79683
   Song L, 2004, FASEB J, V18, P980, DOI 10.1096/fj.03 1100fje
   Strem BM, 2005, TRENDS BIOTECHNOL, V23, P64, DOI 10.1016/j.tibtech.2004.12.003
   Taha MF, 2006, ANAT HISTOL EMBRYOL, V35, P271, DOI 10.1111/j.1439 0264.2006.00680.x
   Tseng Y H., 2007, Cell Sci. Rev, V3, P342
   Wan Derrick C, 2006, Dent Clin North Am, V50, P175, DOI 10.1016/j.cden.2005.11.003
   Wang HT, 2012, AGING CELL, V11, P704, DOI 10.1111/j.1474 9726.2012.00838.x
   Yoon E, 2007, TISSUE ENG, V13, P619, DOI 10.1089/ten.2006.0102
NR 28
TC 3
Z9 3
U1 0
U2 5
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0894 1939
EI 1521 0553
J9 J INVEST SURG
JI J. Invest. Surg.
PD JAN 2
PY 2021
VL 34
IS 1
BP 44
EP 54
DI 10.1080/08941939.2019.1604915
EA SEP 2019
PG 11
WC Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Surgery
GA PO7NL
UT WOS:000487870000001
PM 31558065
DA 2025 08 17
ER

PT J
AU Shimada, N
   Sakata, A
   Igarashi, T
   Takeuchi, M
   Nishimura, S
AF Shimada, Nobuhiro
   Sakata, Asuka
   Igarashi, Takashi
   Takeuchi, Mamoru
   Nishimura, Satoshi
TI M1 macrophage infiltration exacerbate muscle/bone atrophy after
   peripheral nerve injury
SO BMC MUSCULOSKELETAL DISORDERS
LA English
DT Article
DE M1 macrophage; Peripheral nerve injury; Muscle atrophy; Bone atrophy
ID NECROSIS FACTOR ALPHA; NEUROPATHIC PAIN; INFLAMMATORY MACROPHAGE;
   DISUSE; REHABILITATION; IMMOBILIZATION; CALCIUM; MICE
AB Background Peripheral nerve injury causes limb muscle/bone atrophy, leading to chronic pain. However, the mechanisms underlying muscle/bone atrophy after peripheral nerve injury remain unknown. It was recently reported that M1 macrophages are the main factors responsible for neurogenic inflammation after peripheral nerve injury. We hypothesized that M1 macrophages are important in muscle/bone atrophy after nerve injury. Therefore, we investigated the influence of M1 macrophages on muscle/bone atrophy after nerve injury in mice to prevent muscle/bone atrophy by suppressing M1 macrophages. Methods Hindlimb muscle weight and total bone density were measured in a chronic constriction injury (CCI) mouse model. Immunohistochemical analysis and intravital microscopy were performed to visualize hindlimb muscles/bones, and cells were quantified using flow cytometry. We compared M1 macrophage infiltration into muscles/bones and muscle/bone atrophy between macrophage depletion and untreated groups. We also investigated muscle/bone atrophy using administration models for anti inflammatory and neuropathic pain drugs. Results Peripheral nerve injury caused significant reduction in muscle weight and total bone density at 1 and 3 weeks after CCI, respectively, compared with that in controls. Osteoclast numbers were significantly higher at 1 week after CCI in the CCI group than in the control group. M1 macrophage infiltration into muscles was observed from 2 h after CCI via intravital microscopy and 1 week after CCI, and it was significantly higher 1 week after CCI than in the control group. In the macrophage depletion group, dexamethasone, pregabalin, and loxoprofen groups, M1 macrophage infiltration into muscles/bones was significantly lower and muscle weight and total bone density were significantly higher than in the untreated group. Conclusions M1 macrophage infiltration exacerbates muscle/bone atrophy after peripheral nerve injury. By suppressing M1 macrophages at the neural injury local site, muscle/bone atrophy could be avoided.
C1 [Shimada, Nobuhiro; Sakata, Asuka; Nishimura, Satoshi] Jichi Med Univ, Ctr Mol Med, 3311 1 Yakushiji, Shimotsuke, Tochigi 3290498, Japan.
   [Shimada, Nobuhiro; Igarashi, Takashi; Takeuchi, Mamoru] Jichi Med Univ, Dept Anesthesiol & Crit Care Med, 3311 1 Yakushiji, Shimotsuke, Tochigi 3290498, Japan.
   [Sakata, Asuka] Nara Med Univ, Dept Pediat, 840 Shijocho, Kashihara, Nara 6340813, Japan.
C3 Jichi Medical University; Jichi Medical University; Nara Medical
   University
RP Nishimura, S (通讯作者)，Jichi Med Univ, Ctr Mol Med, 3311 1 Yakushiji, Shimotsuke, Tochigi 3290498, Japan.
EM snishi tky@umin.ac.jp
FU JMU Graduate Student Start UP Award
FX This study was supported by the funding program of the JMU Graduate
   Student Start UP Award. We collected data on tools and drugs purchased
   with this fund.
CR Akyuz G, 2014, AM J PHYS MED REHAB, V93, P253, DOI 10.1097/PHM.0000000000000037
   Akyüz G, 2012, AGRI, V24, P97, DOI 10.5505/agri.2012.46320
   Austin PJ, 2010, J NEUROIMMUNOL, V229, P26, DOI 10.1016/j.jneuroim.2010.08.013
   BENNETT GJ, 1988, PAIN, V33, P87, DOI 10.1016/0304 3959(88)90209 6
   BERGMANN P, 1977, PARAPLEGIA, V15, P147, DOI 10.1038/sc.1977.20
   Byun MK, 2017, INT J CHRONIC OBSTR, V12, P669, DOI 10.2147/COPD.S130790
   Calvo M, 2012, LANCET NEUROL, V11, P629, DOI 10.1016/S1474 4422(12)70134 5
   Dayer JM, 2002, J RHEUMATOL, V29, P10
   Demulder A, 1998, CALCIFIED TISSUE INT, V63, P396, DOI 10.1007/s002239900547
   Dirks ML, 2014, ACTA PHYSIOL, V210, P628, DOI 10.1111/apha.12200
   HOTAMISLIGIL GS, 1994, P NATL ACAD SCI USA, V91, P4854, DOI 10.1073/pnas.91.11.4854
   Hulsman NM, 2009, EUR J PAIN, V13, P731, DOI 10.1016/j.ejpain.2008.09.006
   Kiguchi N, 2017, J PHARMACOL SCI, V133, P53, DOI 10.1016/j.jphs.2016.11.005
   Kiguchi N, 2015, PAIN, V156, P684, DOI 10.1097/j.pain.0000000000000097
   Kiguchi N, 2012, CURR OPIN PHARMACOL, V12, P55, DOI 10.1016/j.coph.2011.10.007
   Kiguchi N, 2010, PAIN, V149, P305, DOI 10.1016/j.pain.2010.02.025
   Kobayashi Y, 2015, J BIOL CHEM, V290, P12603, DOI 10.1074/jbc.M115.636506
   Komori T, 2011, NEUROREPORT, V22, P911, DOI 10.1097/WNR.0b013e32834cd76a
   Liu T, 2000, PAIN, V86, P25, DOI 10.1016/S0304 3959(99)00306 1
   Londhe P, 2015, BONE, V80, P131, DOI 10.1016/j.bone.2015.03.015
   Nishimura S, 2008, J CLIN INVEST, V118, P710, DOI 10.1172/JCI33328
   Park CH, 2013, LIFE SCI, V92, P740, DOI 10.1016/j.lfs.2013.02.008
   Rijsdijk M, 2014, ANESTH ANALG, V118, P1097, DOI 10.1213/ANE.0000000000000161
   Said G, 2013, HAND CLINIC, V115, P235, DOI 10.1016/B978 0 444 52902 2.00013 8
   Sekiguchi F, 2018, BIOL PHARM BULL, V41, P1127, DOI 10.1248/bpb.b18 00054
   van Wilgen CP, 2009, J REHABIL MED, V41, P122, DOI 10.2340/16501977 0292
   Verbunt JA, 2003, EUR J PAIN, V7, P9, DOI 10.1016/S1090 3801(02)00071 X
   Vlaeyen JWS, 2000, PAIN, V85, P317, DOI 10.1016/S0304 3959(99)00242 0
   Yanow J, 2008, THESCIENTIFICWORLDJO, V8, P229, DOI 10.1100/tsw.2008.33
NR 29
TC 16
Z9 19
U1 0
U2 19
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471 2474
J9 BMC MUSCULOSKEL DIS
JI BMC Musculoskelet. Disord.
PD JAN 20
PY 2020
VL 21
IS 1
AR 44
DI 10.1186/s12891 020 3069 z
PG 10
WC Orthopedics; Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics; Rheumatology
GA KM1GQ
UT WOS:000513866400004
PM 31959156
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Zhang, SM
   Wang, J
   Bilen, MA
   Lin, SH
   Stupp, SI
   Satcher, RL
AF Zhang, Shuming
   Wang, Jun
   Bilen, Mehmet A.
   Lin, Sue Hwa
   Stupp, Samuel I.
   Satcher, Robert L.
TI Modulation of prostate cancer cell gene expression by cell to cell
   contact with bone marrow stromal cells or osteoblasts
SO CLINICAL & EXPERIMENTAL METASTASIS
LA English
DT Article
DE Bone metastasis; Cell to cell contact; Co culture; Prostate cancer;
   Urokinase plasminogen activator
ID PLASMINOGEN ACTIVATOR SYSTEM; GROWTH FACTOR RECEPTOR; TUMOR CELLS;
   NUDE MICE; IN VITRO; EPITHELIAL CELLS; FLUID FLOW; METASTASIS; THERAPY;
   OPPORTUNITIES
AB After prostate cancer cells (PCa) arrive in bone, interactions with cells that include long bone osteoblasts (LBOB) and bone marrow stromal cells (BMSC) lead to metastasis formation. The effect of heterotypic cell cell contact between PCa cells and BMSC or LBOB on PCa cell gene expression is poorly understood. To establish the role of heterotypic contact in bone metastasis formation, we mixed and co cultured PC3 cells with rat BMSC, LBOB, or human prostate stromal cells (PS15). PC3 cells were then re isolated for gene array analysis, and imaged using in situ hybridization to confirm that heterotypic contact regulates gene expression. The gene expression was examined using focused gene arrays containing 96 each of tumor metastasis genes or osteogenesis genes. A total of 18 out of 192 genes in PC3 cells were found to be under or over expressed subsequent to heterotypic contact with BMSC when analyzed. A total of 15 genes out of 192 were regulated in co culture with LBOB, and 19 genes with PS15. Only two genes, uPA and Collagen III, were regulated by contact with BMSC or LBOB (both are bone derived cells), but not by contact with PS15. The relationship between cell cell contact and uPA expression was further explored by varying cell ratios in co culture. uPA over expression in PC3 was related to the BMSC:PC3 ratio, and was maximum at a 10:1 ratio, where most PC3 cells would be in contact with BMSC, as predicted by a theoretical model of heterotypic contact. In situ staining of micropatterned PC3 and BMSC cells showed that uPA over expression localizes to regions of heterotypic cell cell contact. Taken together, our results suggest that heterotypic cell to cell contact between PC3 and BMSC proportionally enhances gene expression for uPA, providing a mechanism for localized control of invasiveness.
C1 [Satcher, Robert L.] Univ Texas Houston, MD Anderson Canc Ctr, Dept Orthopaed Oncol, Houston, TX 77030 USA.
   [Zhang, Shuming; Stupp, Samuel I.] Northwestern Univ, Inst Bioengn & Nanosci Adv Med, Evanston, IL USA.
   [Wang, Jun; Satcher, Robert L.] Northwestern Univ, Dept Orthopaed Surg, Orthopaed Res Lab, Evanston, IL USA.
C3 University of Texas System; UTMD Anderson Cancer Center; University of
   Texas Health Science Center Houston; Northwestern University;
   Northwestern University
RP Satcher, RL (通讯作者)，Univ Texas Houston, MD Anderson Canc Ctr, Dept Orthopaed Oncol, Houston, TX 77030 USA.
EM rlsatcher@mdanderson.org
RI ; Satcher, Robert/K 7308 2018; Stupp, Samuel/B 6737 2009
OI Wang, Jun/0000 0002 2678 2456; 
FU Robert Wood Johnson Foundation
FX The authors would like to acknowledge Dr. Chung Lee for his generous
   support. The work in this manuscript was supported by a research grant
   from the Robert Wood Johnson Foundation.
CR Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097 0215(19970703)72:1<1::AID IJC1>3.0.CO;2 Z
   Angelucci A, 2006, ENDOCR RELAT CANCER, V13, P197, DOI 10.1677/erc.1.01100
   Benasciutti E, 2004, BLOOD, V104, P256, DOI 10.1182/blood 2003 08 2661
   Bhatia SN, 1999, FASEB J, V13, P1883, DOI 10.1096/fasebj.13.14.1883
   Chung LWK, 2005, J UROLOGY, V173, P10, DOI 10.1097/01.ju.0000141582.15218.10
   Festuccia C, 1998, INT J CANCER, V75, P418, DOI 10.1002/(SICI)1097 0215(19980130)75:3<418::AID IJC16>3.0.CO;2 4
   Festuccia C, 1998, CLIN EXP METASTAS, V16, P513, DOI 10.1023/A:1006590217724
   Festuccia C, 2000, INT J CANCER, V85, P407, DOI 10.1002/(SICI)1097 0215(20000201)85:3<407::AID IJC18>3.3.CO;2 #
   Harms JF, 2003, CLIN EXP METASTAS, V20, P327, DOI 10.1023/A:1024062911144
   Hart CA, 2005, BRIT J CANCER, V92, P503, DOI 10.1038/sj.bjc.6602325
   Hart CA, 2002, BRIT J CANCER, V86, P1136, DOI 10.1038/sj/bjc/6600207
   HUNG CT, 1995, CLIN ORTHOP RELAT R, P256
   Kassen A, 1996, PROSTATE, V28, P89, DOI 10.1002/(SICI)1097 0045(199602)28:2<89::AID PROS3>3.0.CO;2 I
   Kim SJ, 2004, CANCER RES, V64, P4201, DOI 10.1158/0008 5472.CAN 03 3763
   Kim SJ, 2003, CLIN CANCER RES, V9, P1200
   Lang SH, 1998, PROSTATE, V34, P203, DOI 10.1002/(SICI)1097 0045(19980215)34:3<203::AID PROS8>3.0.CO;2 I
   Margheri F, 2005, GENE THER, V12, P702, DOI 10.1038/sj.gt.3302456
   Millimaggi D, 2006, INT J ONCOL, V28, P909
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Nauman EA, 2001, J APPL PHYSIOL, V90, P1849, DOI 10.1152/jappl.2001.90.5.1849
   PAGET S, 1989, CANCER METAST REV, V8, P98
   Patel P, 2004, PROSTATE CANCER P D, V7, pS14, DOI 10.1038/sj.pcan.4500743
   Pulukuri SM, 2005, J BIOL CHEM, V280, P36529, DOI 10.1074/jbc.M503111200
   Rosol TJ, 2003, CANCER AM CANCER SOC, V97, P748, DOI 10.1002/cncr.11150
   Satcher RL, 2004, CLIN ORTHOP RELAT R, P54, DOI 10.1097/01.bio.0000141384.03118.b2
   Sensibar JA, 1999, PROSTATE, V38, P110, DOI 10.1002/(SICI)1097 0045(19990201)38:2<110::AID PROS4>3.0.CO;2 R
   Shah RB, 2004, CANCER RES, V64, P9209, DOI 10.1158/0008 5472.CAN 04 2442
   Siggelkow H, 1999, J CELL BIOCHEM, V75, P22, DOI 10.1002/(SICI)1097 4644(19991001)75:1<22::AID JCB3>3.3.CO;2 Y
   Sung SY, 2002, DIFFERENTIATION, V70, P506, DOI 10.1046/j.1432 0436.2002.700905.x
   Wang J, 2006, INT J MOL MED, V17, P849
   Zhang XP, 2004, CANCER RES, V64, P7086, DOI 10.1158/0008 5472.CAN 04 1498
NR 31
TC 16
Z9 18
U1 0
U2 6
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0262 0898
EI 1573 7276
J9 CLIN EXP METASTAS
JI Clin. Exp. Metastasis
PD DEC
PY 2009
VL 26
IS 8
BP 993
EP 1004
DI 10.1007/s10585 009 9289 0
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 518VF
UT WOS:000271722400006
PM 19787436
DA 2025 08 17
ER

PT J
AU Trinadh, M
   Kannan, G
   Rajasekhar, T
   Sainath, AVS
   Dhayal, M
AF Trinadh, Mummuluri
   Kannan, Govindaraj
   Rajasekhar, Tota
   Sainath, Annadanam V. Sesha
   Dhayal, Marshal
TI Synthesis of glycopolymers at various pendant spacer lengths of glucose
   moiety and their effects on adhesion, viability and proliferation of
   osteoblast cells
SO RSC ADVANCES
LA English
DT Article
ID WELL DEFINED GLYCOPOLYMERS; TIO2 THIN FILMS; MULTIVALENT LIGANDS; RAFT
   POLYMERIZATION; DRUG DELIVERY; CHEMOENZYMATIC SYNTHESIS;
   SIGNAL TRANSDUCTION; N ACETYLGLUCOSAMINE; BLOCK COPOLYMER;
   CONCANAVALIN A
AB Multivalent glycopolymers containing three different glucose pendant spacer lengths in the polymer backbone having various weight percentages of covalently bonded glucose moieties were obtained by the deacetylation of acetylated polymers synthesized via reversible addition fragmentation chain transfer (RAFT) process. This allowed us to control the packing density of the glucose moieties in one unit of the glycopolymer. The biological responses of these macromolecules in terms of cytotoxicity of glucose moieties at various spacer lengths and concentrations were investigated without perturbing the intrinsic chemical nature of functional moiety by employing in vitro osteoblast cells. Osteoblast cell adhesion, viability and proliferation response with synthesized glycopolymers revealed that the higher glycopolymer concentration tolerance limit was associated with an increase in pendant spacer length of glucose moiety in the glycopolymer.
C1 [Trinadh, Mummuluri; Rajasekhar, Tota; Sainath, Annadanam V. Sesha] CSIR Indian Inst Chem Technol, Polymers & Funct Mat Div, Hyderabad 500007, Andhra Pradesh, India.
   [Kannan, Govindaraj; Dhayal, Marshal] CSIR Ctr Cellular & Mol Biol, Clin Res Facil, Hyderabad 500007, Andhra Pradesh, India.
C3 Council of Scientific & Industrial Research (CSIR)   India; CSIR  
   Indian Institute of Chemical Technology (IICT); Council of Scientific &
   Industrial Research (CSIR)   India; CSIR   Centre for Cellular &
   Molecular Biology (CCMB)
RP Sainath, AVS (通讯作者)，CSIR Indian Inst Chem Technol, Polymers & Funct Mat Div, Hyderabad 500007, Andhra Pradesh, India.
EM avssainath@yahoo.com; marshal@ccmb.res.in
RI ; Govindaraj, Kannan/E 1375 2015; Sainath, Annadanam V
   Sesha/AGW 1045 2022
OI mummuluri, trinadh/0000 0001 9051 4870; Govindaraj,
   Kannan/0000 0001 9030 8735; 
FU Council for Scientific and Industrial Research, India [CSC 0134,
   BSC 0112]; CSIR; UGC; CSIR network project
FX AVSS and MD thank the Council for Scientific and Industrial Research,
   India, for financial support in network projects CSC 0134 and BSC 0112,
   respectively. We thank CSIR CCMB for the microscopy facility. MT, TR and
   GK thank CSIR, UGC and CSIR network project for providing fellowships,
   respectively. MD is thankful to Mr N R Chakravarthi, Microscopy Facility
   of CCMB, for his help in obtaining bright field images of cells.
CR Albertin L, 2004, MACROMOLECULES, V37, P7530, DOI 10.1021/ma049129+
   Ambrosi M, 2005, ORG BIOMOL CHEM, V3, P1593, DOI 10.1039/b414350g
   Ambrosi M, 2005, ORG BIOMOL CHEM, V3, P1476, DOI 10.1039/b411555b
   Anselme K, 2000, BIOMATERIALS, V21, P667, DOI 10.1016/S0142 9612(99)00242 2
   Babiuch K, 2011, MACROMOL BIOSCI, V11, P535, DOI 10.1002/mabi.201000374
   BAUER JS, 1993, J CELL BIOL, V122, P209, DOI 10.1083/jcb.122.1.209
   Cairo CW, 2002, J AM CHEM SOC, V124, P1615, DOI 10.1021/ja016727k
   Cameron NR, 2008, FARADAY DISCUSS, V139, P359, DOI 10.1039/b717177c
   Chen WH, 2010, CURR PHARM DESIGN, V16, P2388, DOI 10.2174/138161210791920478
   CHEN XM, 1995, MACROMOLECULES, V28, P6014, DOI 10.1021/ma00122a005
   Coullerez G, 2006, MACROMOL BIOSCI, V6, P634, DOI 10.1002/mabi.200600090
   Cunliffe D, 2004, EUR POLYM J, V40, P5, DOI 10.1016/j.eurpolymj.2003.10.020
   Dai XH, 2008, J PHYS CHEM B, V112, P3644, DOI 10.1021/jp710698c
   Dam TK, 2010, GLYCOBIOLOGY, V20, P1061, DOI 10.1093/glycob/cwq084
   Dard M, 2000, Clin Oral Investig, V4, P126, DOI 10.1007/s007840050128
   Dee KC, 1996, BIOTECHNOL BIOENG, V50, P438, DOI 10.1002/(SICI)1097 0290(19960520)50:4<438::AID BIT11>3.0.CO;2 F
   Dhayal M, 2014, MAT SCI ENG C MATER, V37, P99, DOI 10.1016/j.msec.2013.12.035
   Dhayal M, 2012, J BIOMED MATER RES A, V100A, P1168, DOI 10.1002/jbm.a.34061
   Dhayal M, 2009, LANGMUIR, V25, P2181, DOI 10.1021/la8031122
   Forster S, 1998, ADV MATER, V10, P195, DOI 10.1002/(SICI)1521 4095(199802)10:3<195::AID ADMA195>3.0.CO;2 V
   Gabius HJ, 2004, CHEMBIOCHEM, V5, P740, DOI 10.1002/cbic.200300753
   García Martín MG, 2000, POLYMER, V41, P821, DOI 10.1016/S0032 3861(99)00266 9
   Granville AM, 2007, MACROMOL SYMP, V255, P81, DOI 10.1002/masy.200750909
   GUTSCHE AT, 1994, BIOTECHNOL BIOENG, V43, P801, DOI 10.1002/bit.260430815
   Hawker CJ, 2005, SCIENCE, V309, P1200, DOI 10.1126/science.1109778
   Hidalgo Bastida LA, 2010, TISSUE ENG PART B RE, V16, P405, DOI [10.1089/ten.teb.2009.0714, 10.1089/ten.TEB.2009.0714]
   Hubbell JA, 1995, NAT BIOTECHNOL, V13, P565, DOI DOI 10.1038/NBT0695 565
   Kanai M, 1997, J AM CHEM SOC, V119, P9931, DOI 10.1021/ja972089n
   Kiessling LL, 2013, CHEM SOC REV, V42, P4476, DOI 10.1039/c3cs60097a
   Kiessling LL, 2006, ANGEW CHEM INT EDIT, V45, P2348, DOI 10.1002/anie.200502794
   Kiessling LL, 2000, CURR OPIN CHEM BIOL, V4, P696, DOI 10.1016/S1367 5931(00)00153 8
   Kim SH, 2003, J BIOMED MATER RES A, V67A, P1351, DOI 10.1002/jbm.a.10166
   KLEIN J, 1990, MAKROMOL CHEM, V191, P517
   KOBAYASHI A, 1993, P JPN ACAD B PHYS, V69, P89, DOI 10.2183/pjab.69.89
   Ladmiral V, 2004, EUR POLYM J, V40, P431, DOI 10.1016/j.eurpolymj.2003.10.019
   Lee JS, 2005, BIOMACROMOLECULES, V6, P1906, DOI 10.1021/bm049430y
   Li J, 1999, BIOORGAN MED CHEM, V7, P1549, DOI 10.1016/S0968 0896(99)00099 1
   Lowe AB, 2003, POLYMER, V44, P6761, DOI 10.1016/j.polymer.2003.08.039
   Lutolf MR, 2003, NAT BIOTECHNOL, V21, P513, DOI 10.1038/nbt818
   MIKI I, 1993, J IMMUNOL METHODS, V164, P255, DOI 10.1016/0022 1759(93)90318 2
   Miura Y, 2007, J POLYM SCI POL CHEM, V45, P5031, DOI 10.1002/pola.22369
   Miura Y, 2012, POLYM J, V44, P679, DOI 10.1038/pj.2012.4
   MORTELL KH, 1994, J AM CHEM SOC, V116, P12053, DOI 10.1021/ja00105a056
   Muthukrishnan S, 2006, MACROMOL BIOSCI, V6, P658, DOI 10.1002/mabi.200600064
   Nathaniel H., 2009, NATURE, V462, P426
   OKA JA, 1986, J CELL BIOL, V103, P1055, DOI 10.1083/jcb.103.3.1055
   PALOMINO E, 1994, ADV DRUG DELIVER REV, V13, P311, DOI 10.1016/0169 409X(94)90017 5
   Park KH, 1997, J BIOCHEM TOKYO, V121, P997
   Pasparakis G, 2008, ANGEW CHEM INT EDIT, V47, P4847, DOI 10.1002/anie.200801098
   Petrovic Z, 2004, INDIAN J CHEM B, V43, P132
   Pieters RJ, 2007, MED RES REV, V27, P796, DOI 10.1002/med.20089
   Roche AC, 2003, CELL MOL LIFE SCI, V60, P288, DOI 10.1007/s000180300024
   SCHNAAR RL, 1978, J BIOL CHEM, V253, P7940
   SCHNAAR RL, 1984, ANAL BIOCHEM, V143, P1, DOI 10.1016/0003 2697(84)90549 9
   Sharon N, 2006, BBA GEN SUBJECTS, V1760, P527, DOI 10.1016/j.bbagen.2005.12.008
   SHARON N, 1993, SCI AM, V268, P82, DOI 10.1038/scientificamerican0193 82
   SIM MM, 1993, J AM CHEM SOC, V115, P2260, DOI 10.1021/ja00059a023
   Spain SG, 2007, J POLYM SCI POL CHEM, V45, P2059, DOI 10.1002/pola.22106
   Spain SG, 2011, POLYM CHEM UK, V2, P60, DOI 10.1039/c0py00149j
   Vagaská B, 2010, PHYSIOL RES, V59, P309, DOI 10.33549/physiolres.931776
   VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97
   Varma AJ, 2004, CARBOHYD POLYM, V56, P429, DOI 10.1016/j.carbpol.2004.03.007
   Wang JY, 2010, CARBOHYD POLYM, V82, P578, DOI 10.1016/j.carbpol.2010.05.011
   Wilson CJ, 2005, TISSUE ENG, V11, P1, DOI 10.1089/ten.2005.11.1
   Woodcock JW, 2011, MACROMOLECULES, V44, P5764, DOI 10.1021/ma200991d
   Wulff G, 1997, MACROMOLECULES, V30, P4533, DOI 10.1021/ma961890z
   Wulff G, 1999, MACROMOL CHEM PHYSIC, V200, P774
   You ZW, 2010, BIOMATERIALS, V31, P3129, DOI 10.1016/j.biomaterials.2010.01.023
   Yun YH, 2004, BIOMATERIALS, V25, P147, DOI 10.1016/S0142 9612(03)00467 8
NR 69
TC 21
Z9 21
U1 0
U2 17
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2046 2069
J9 RSC ADV
JI RSC Adv.
PY 2014
VL 4
IS 70
BP 37400
EP 37410
DI 10.1039/c4ra05436a
PG 11
WC Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry
GA AO6IO
UT WOS:000341454000064
DA 2025 08 17
ER

PT J
AU Thompson, M
   Jones, G
   Venn, A
   Balogun, S
   Cicuttini, F
   Ragaini, B
   Aitken, D
AF Thompson, Michael
   Jones, Graeme
   Venn, Alison
   Balogun, Saliu
   Cicuttini, Flavia
   Ragaini, Bruna
   Aitken, Dawn
TI Prior Nonmelanoma Skin Cancer is Associated with Greater Bone Mineral
   Density, and Improved Bone Microarchitecture in Older Adults
SO AMERICAN JOURNAL OF MEDICINE
LA English
DT Article
DE BMD; Bone microarchitecture; Fracture; Nonmelanoma skin cancer; Vitamin
   D
ID RISK FACTORS; VITAMIN D; VERTEBRAL DEFORMITIES; PARATHYROID HORMONE; HIP
   FRACTURE; FALLS RISK; WOMEN; MEN; RADIATION; TASMANIA
AB BACKGROUND: Prior nonmelanoma skin cancer (NMSC), a biomarker of cumulative lifetime sun exposure, is associated with reduced fracture risk later in life. The mechanism is unknown. METHODS: Prospective cohort analysis of 1099 community dwelling adults aged 50 80 years with baseline and 10 year follow up assessments. Histopathologically confirmed NMSC diagnosis was established by linkage with the Tasmanian Cancer Registry. Bone mineral density (BMD) and vertebral deformity were quantified by DXA, 25 hydroxyvitamin D (25(OH)D) by radioimmunoassay, bone microarchitecture by high resolution peripheral quantitative CT, melanin density by spectrophotometry, and skin photosensitivity and clinical fracture by questionnaire. 25(OH)D <50 nmol/L was considered deficient. RESULTS: Participants with an NMSC reported prior to baseline were less likely to sustain an incident vertebral deformity over 10 years (RR = 0.74, P = .036). There were similar reductions for other fracture types but these did not reach significance. Prior NMSC was associated with baseline (RR = 1.23, P = .005) and 10 year longitudinal (RR = 5.9, P = .014) vitamin D sufficiency and greater total body BMD (beta = 0.021g/ cm(2), P = .034), but not falls risk or muscle strength. The relationship between prior NMSC and bone microarchitecture was age dependent (p(interaction) < 0.05). In the oldest age tertile, prior NMSC was associated with greater volumetric BMD (beta = 57.8 62.6, P = .002 0.01) and less porosity (beta = 4.6 to 5.2, P = .0020.009) at cortical, compact cortical and outer transitional zones. CONCLUSIONS: Prior NMSC was associated with fewer incident fractures in community dwelling older adults. This protective association is most likely mediated by modifiable fracture risk factors associated with an outdoor lifestyle, including 25(OH)D, BMD, and bone microarchitecture. (c) 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies. center dot The American Journal of Medicine (2024) 137:974 982
C1 [Thompson, Michael; Jones, Graeme; Venn, Alison; Balogun, Saliu; Ragaini, Bruna; Aitken, Dawn] Univ Tasmania, Menzies Inst Med Res, 17 Liverpool St, Hobart, Tas 7000, Australia.
   [Thompson, Michael] Royal Hobart Hosp, Dept Endocrinol, Hobart, Tas, Australia.
   [Cicuttini, Flavia] Monash Univ, Sch Publ Hlth & Prevent Med, Melbourne, Australia.
C3 University of Tasmania; Menzies Institute for Medical Research; Royal
   Hobart Hospital; Monash University
RP Thompson, M (通讯作者)，Univ Tasmania, Menzies Inst Med Res, 17 Liverpool St, Hobart, Tas 7000, Australia.
EM michael.thompson@ths.tas.gov.au
RI Jones, Graeme/J 7899 2014; Aitken, Dawn/L 6882 2013; Venn,
   Alison/J 2803 2013
OI Aitken, Dawn/0000 0001 5685 7634; jones, graeme/0000 0002 9814 0006; 
FU National Health and Medical Research Council of Australia (NHMRC)
   [302204]; Tasmanian Community Fund [D0015018]; Masonic Centenary Medical
   Research Foundation; Royal Hobart Hospital Research Foundation;
   Arthritis Foundation of Australia [MRI06161]
FX This study was conducted as part of the Tasmanian Older Adult Cohort
   Study which was supported by the National Health and Medical Research
   Council of Australia (NHMRC Grant ID 302204) ; Tasmanian Community Fund
   (Grant ID D0015018) ; Masonic Centenary Medical Research Foundation;
   Royal Hobart Hospital Research Foundation; and Arthritis Foundation of
   Australia (Grant ID MRI06161). No funding body played any role in the
   design of the study, the analysis of its data or the drafting of the
   current manuscript.
CR Bala Y, 2014, J BONE MINER RES, V29, P1356, DOI 10.1002/jbmr.2167
   Binstock M, 2014, BRIT J DERMATOL, V171, P713, DOI 10.1111/bjd.13283
   Cervo MM, 2020, CLIN NUTR, V39, P516, DOI 10.1016/j.clnu.2019.02.031
   Choque H, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.134783
   Czerny B, 2010, EUR J OBSTET GYN R B, V149, P82, DOI 10.1016/j.ejogrb.2009.12.010
   Dusingize JC, 2017, J INVEST DERMATOL, V137, P1700, DOI 10.1016/j.jid.2017.03.027
   Dwyer T, 1998, CANCER EPIDEM BIOMAR, V7, P203
   Hart PH, 2011, NAT REV IMMUNOL, V11, P584, DOI 10.1038/nri3045
   Ismail AA, 2000, J BONE MINER RES, V15, P278, DOI 10.1359/jbmr.2000.15.2.278
   JOHNELL O, 1995, J BONE MINER RES, V10, P1802, DOI 10.1002/jbmr.5650101125
   Kanis J, 1999, OSTEOPOROSIS INT, V9, P45, DOI 10.1007/s001980050115
   Kennel KA, 2003, OSTEOPOROSIS INT, V14, P631, DOI 10.1007/s00198 003 1417 0
   Laslett LL, 2012, OSTEOPOROSIS INT, V23, P67, DOI 10.1007/s00198 011 1741 8
   Lord SR, 2003, PHYS THER, V83, P237, DOI 10.1093/ptj/83.3.237
   Ma CC, 2020, ARCH OSTEOPOROS, V15, DOI 10.1007/s11657 020 0696 9
   MARTIN TJ, 1988, BAILLIERE CLIN ENDOC, V2, P1
   Nagarajan P, 2019, CLIN CANCER RES, V25, P2379, DOI 10.1158/1078 0432.CCR 18 1122
   Ragaini BS, 2021, DISCOV ONCOL, V12, DOI 10.1007/s12672 021 00426 5
   Ross AC, 2011, J CLIN ENDOCR METAB, V96, P53, DOI 10.1210/jc.2010 2704
   Samelson EJ, 2019, LANCET DIABETES ENDO, V7, P34, DOI [10.1016/s2213 8587(18)30308 5, 10.1016/S2213 8587(18)30308 5]
   Scott D, 2011, SCAND J MED SCI SPOR, V21, pE168, DOI 10.1111/j.1600 0838.2010.01229.x
   Sigurdsson G, 2000, OSTEOPOROSIS INT, V11, P1031, DOI 10.1007/s001980070024
   Slawinska M, 2019, ARCH DERMATOL RES, V311, P697, DOI 10.1007/s00403 019 01952 7
   Srikanth V, 2007, OSTEOPOROSIS INT, V18, P687, DOI 10.1007/s00198 006 0303 y
   Stokes B, 2020, Int J Popul Data Sci, V4, P1137, DOI 10.23889/ijpds.v4i2.1137
   Thompson M., 2021, J Clin Endocrinol Metab, V106, pe2995, DOI 10.1210/clinem/dgab197
   Thompson MJW, 2020, CALCIFIED TISSUE INT, V107, P335, DOI 10.1007/s00223 020 00728 w
   Thompson MJW, 2020, OSTEOPOROSIS INT, V31, P1517, DOI 10.1007/s00198 020 05304 4
   Thompson MJW, 2018, OSTEOPOROSIS INT, V29, P1887, DOI 10.1007/s00198 018 4568 8
   Thompson MJW, 2017, OSTEOPOROSIS INT, V28, P2061, DOI 10.1007/s00198 017 4001 8
   Thompson MJW, 2017, SKIN RES TECHNOL, V23, P235, DOI 10.1111/srt.12328
   Tuckey RC, 2018, J STEROID BIOCHEM, V181, P1, DOI 10.1016/j.jsbmb.2018.02.008
   van der Mei IAF, 2007, J NEUROL, V254, P581, DOI 10.1007/s00415 006 0315 8
   van der Mei IAF, 2012, INTERN MED J, V42, P1137, DOI 10.1111/j.1445 5994.2012.02788.x
NR 34
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002 9343
EI 1555 7162
J9 AM J MED
JI Am. J. Med.
PD OCT
PY 2024
VL 137
IS 10
DI 10.1016/j.amjmed.2024.05.036
EA SEP 2024
PG 10
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA H6P2P
UT WOS:001324634600001
PM 38866304
DA 2025 08 17
ER

PT J
AU Puidokas, T
   Kubilius, M
   Stumbras, A
   Juodzbalys, G
AF Puidokas, Tomas
   Kubilius, Mantas
   Stumbras, Arturas
   Juodzbalys, Gintaras
TI Effect of leukocytes included in platelet concentrates on cell behaviour
SO PLATELETS
LA English
DT Article
DE Cytokine; growth factor; leukocyte; platelet concentrate; review
ID RICH PLASMA FORMULATIONS; GROWTH FACTORS; REGENERATIVE MEDICINE; BASIC
   SCIENCE; PRP; CLASSIFICATION; OSTEOARTHRITIS; PRESERVATION; ADVANTAGES;
   INJURY
AB This literature review's aim is to evaluate the function of white blood cells (WBCs) and to conclude whether leukocyte's inclusion in platelet concentrates promotes or inhibits tissue regeneration. An electronic literature search was performed on MEDLINE through its online site (PubMed) and on the EMBASE database for articles published between 1986 and 2019. Consecutive screenings at the title/abstract and full text levels were performed. All in vitro studies that reported the comparison of leukocyte rich and leukocyte poor platelet concentrates were included. The search included 14 articles that matched the inclusion criteria. A systematic review shows that leukocytes are responsible for less promoted migration and osteogenic differentiation of human bone marrow stem cells (HBMSCs), lesser cartilage cell, gingival fibroblast and osteoblast proliferation. Decreased tendon cell metabolism and a cytotoxic effect of leukocytes on synoviocytes have also been identified. Additionally, leukocytes were accountable for a cytokine (IL 1 beta, IL 8, TNF alpha, MMP 1 and MMP 9) increase and NF kappa B signaling pathway initiation. WBCs were also linked to growth factors (VEGF, PDGF AA/BB). Leukocyte and platelet functions are alike when considering growth factor release. Nevertheless, in the presence of WBCs, platelet concentrates promote cell migration, proliferation, and differentiation less effectively and are responsible for a potentially prolonged inflammation phase due to cytokine release.
C1 [Puidokas, Tomas; Kubilius, Mantas; Stumbras, Arturas; Juodzbalys, Gintaras] Lithuanian Univ Hlth Sci, Dept Maxillofacial Surg, Kaunas, Lithuania.
C3 Lithuanian University of Health Sciences
RP Puidokas, T (通讯作者)，Lithuanian Univ Hlth Sci, Dept Maxillofacial Surg, Kaunas, Lithuania.
EM tomaspuidokas@yahoo.com
RI Puidokas, Tomas/C 8590 2019; Juodzbalys, Gintaras/AAQ 5511 2020
OI Puidokas, Tomas/0000 0002 5274 5341; Juodzbalys,
   Gintaras/0000 0002 5126 2217
CR Allegrini Sergio Jr., 2008, Roczniki Pomorskiej Akademii Medycznej w Szczecinie, V54, P70
   Anitua E, 1999, INT J ORAL MAX IMPL, V14, P529
   Anitua E, 2007, BIOMATERIALS, V28, P4551, DOI 10.1016/j.biomaterials.2007.06.037
   Anitua E, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121713
   Anitua E, 2013, ANN ANAT, V195, P461, DOI 10.1016/j.aanat.2013.04.004
   Anitua E, 2012, J CONTROL RELEASE, V157, P29, DOI 10.1016/j.jconrel.2011.07.004
   Arnoczky SP, 2013, SPORTS MED ARTHROSC, V21, P180, DOI 10.1097/JSA.0b013e3182999712
   Assirelli E, 2015, KNEE SURG SPORT TR A, V23, P2690, DOI 10.1007/s00167 014 3113 3
   Beck TM, 2010, J PERIODONTOL, V81, P1765, DOI 10.1902/jop.2010.100286
   Bielecki T, 2012, CURR PHARM BIOTECHNO, V13, P1153, DOI 10.2174/138920112800624373
   Bielecki T, 2012, CURR PHARM BIOTECHNO, V13, P1121, DOI 10.2174/138920112800624292
   Bijlsma JWJ, 2011, LANCET, V377, P2115, DOI 10.1016/S0140 6736(11)60243 2
   Braun HJ, 2014, AM J SPORT MED, V42, P1204, DOI 10.1177/0363546514525593
   Cabaro S, 2018, PLATELETS, V29, P463, DOI 10.1080/09537104.2017.1319046
   Cavallo C, 2014, J BONE JOINT SURG AM, V96A, P423, DOI 10.2106/JBJS.M.00726
   Chen X, 2018, AM J SPORT MED, V46, P2020, DOI 10.1177/0363546517743746
   Cieslik Bielecka A, 2007, ORAL SURG ORAL MED O, V103, P303, DOI 10.1016/j.tripleo.2006.08.034
   Clokie C M, 2001, J Can Dent Assoc, V67, P92
   Coleman JW, 2001, INT IMMUNOPHARMACOL, V1, P1397, DOI 10.1016/S1567 5769(01)00086 8
   Corbella S, 2017, INT J ORAL MAX IMPL, V32, P1001, DOI 10.11607/jomi.5263
   Davis VL, 2014, J ORAL IMPLANTOL, V40, P511, DOI 10.1563/AAID JOI D 12 00106
   Del Corso M., 2010, J IMPLANT ADV CLIN D, V1, P27
   Dohan Ehrenfest David M, 2014, Muscles Ligaments Tendons J, V4, P3
   Ehrenfest DMD, 2018, PLATELETS, V29, P171, DOI 10.1080/09537104.2017.1293812
   Felson DT, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2531
   Ferrer F, 2000, VOX SANG, V78, P235, DOI 10.1159/000031187
   Giusti I, 2018, EXP THER MED, V15, P4029, DOI 10.3892/etm.2018.5887
   Ho JOY, 2014, J TISSUE ENG, V5, DOI 10.1177/2041731414549678
   Kennedy MI, 2018, CURR REV MUSCULOSKE, V11, P573, DOI 10.1007/s12178 018 9516 x
   Kia C, 2018, CURR REV MUSCULOSKE, V11, P566, DOI 10.1007/s12178 018 9515 y
   KNIGHTON DR, 1986, ANN SURG, V204, P322, DOI 10.1097/00000658 198609000 00011
   Kobayashi Y, 2016, J ORTHOP SCI, V21, P683, DOI 10.1016/j.jos.2016.07.009
   Krismer AM, 2017, J ORTHOP RES, V35, P2733, DOI 10.1002/jor.23599
   Kubilius Marius, 2012, Stomatologija, V14, P3
   Lacci Kathleen M., 2010, Yale Journal of Biology and Medicine, V83, P1
   Lo Giudice G, 2015, INT J DENT, V2015, DOI 10.1155/2015/261652
   Mariani E, 2015, BMC MICROBIOL, V15, DOI 10.1186/s12866 015 0482 9
   Michael Toffler NT, 2009, J IMPLANT ADV CLIN D, V1, P21
   Misch C M, 2000, J Oral Implantol, V26, P42
   Moojen DJF, 2008, J ORTHOP RES, V26, P404, DOI 10.1002/jor.20519
   OSTLER MS, 1994, J PROSTHET DENT, V71, P144, DOI 10.1016/0022 3913(94)90022 1
   Pavlovic V, 2016, OPEN MED WARSAW, V11, P242, DOI 10.1515/med 2016 0048
   Precheur Harry V, 2007, Dent Clin North Am, V51, P729
   Regan MC, 2011, CELLULAR BIOL WOUND
   Roberts TT, 2012, ORGANOGENESIS, V8, P114, DOI 10.4161/org.23306
   Rooney AA, 2016, ENVIRON INT, V92 93, P617, DOI 10.1016/j.envint.2016.01.005
   Rose LF, 2004, PERIODONTICS MED SUR, P48
   Rubio Azpeitia E, 2016, AM J SPORT MED, V44, P1952, DOI 10.1177/0363546516643814
   Sandor GKB, 2003, BONE REGENERATION CR
   Lana JFSD, 2017, REGEN MED, V12, P565, DOI 10.2217/rme 2017 0042
   Schaffer CJ, 1996, INT REV CYTOL, V169, P151, DOI 10.1016/S0074 7696(08)61986 5
   Sisti A, 2012, CLIN ORAL IMPLAN RES, V23, P526, DOI 10.1111/j.1600 0501.2011.02386.x
   Southworth TM, 2019, J KNEE SURG, V32, P37, DOI 10.1055/s 0038 1675170
   Sundman EA, 2011, AM J SPORT MED, V39, P2135, DOI 10.1177/0363546511417792
   Taniguchi Y, 2018, NAGOYA J MED SCI, V80, P39, DOI 10.18999/nagjms.80.1.39
   Tashjian RZ, 2012, CLIN SPORT MED, V31, P589, DOI 10.1016/j.csm.2012.07.001
   Thomopoulos S, 2015, J ORTHOP RES, V33, P832, DOI 10.1002/jor.22806
   Tomford William W., 2000, Cell and Tissue Banking, V1, P105, DOI 10.1023/A:1010158731885
   Venet F, 2008, J LEUKOCYTE BIOL, V83, P523, DOI 10.1189/jlb.0607371
   Wu PK, 2018, J CHIN MED ASSOC, V81, P643, DOI 10.1016/j.jcma.2017.08.024
   Yang ZM, 2016, ONCOL LETT, V12, P1445, DOI 10.3892/ol.2016.4777
   Yin WJ, 2016, MED SCI MONITOR, V22, P1280, DOI 10.12659/MSM.898218
   Yin WJ, 2017, MOL MED REP, V15, P2940, DOI 10.3892/mmr.2017.6365
   Yin WJ, 2016, J TRANSL MED, V14, DOI 10.1186/s12967 016 0825 9
NR 64
TC 8
Z9 9
U1 0
U2 7
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0953 7104
EI 1369 1635
J9 PLATELETS
JI Platelets
PD NOV 17
PY 2019
VL 30
IS 8
BP 937
EP 945
DI 10.1080/09537104.2019.1646900
EA JUL 2019
PG 9
WC Cell Biology; Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Hematology
GA JB3TC
UT WOS:000479442300001
PM 31340699
DA 2025 08 17
ER

PT J
AU Ning, BH
   Londono, I
   Laporte, C
   Villemure, I
AF Ning, Bohao
   Londono, Irene
   Laporte, Catherine
   Villemure, Isabelle
TI Zoledronate reduces loading induced microdamage in cortical ulna of
   ovariectomized rats
SO JOURNAL OF THE MECHANICAL BEHAVIOR OF BIOMEDICAL MATERIALS
LA English
DT Article
DE Microdamage; Remodeling; Osteoporosis; Osteopenia; Zoledronate; Micro CT
ID IN VIVO MICRODAMAGE; MECHANICAL PROPERTIES; STRESS FRACTURE; TRABECULAR
   BONE; BISPHOSPHONATE TREATMENT; FATIGUE MICRODAMAGE; BIOMECHANICAL
   PROPERTIES; DAMAGE MORPHOLOGY; DIFFUSE DAMAGE; LONG BONES
AB As a daily physiological mechanism in bone, microdamage accumulation dissipates energy and helps to prevent fractures. However, excessive damage accumulation might bring adverse effects to bone mechanical properties, which is especially problematic among the osteoporotic and osteopenic patients treated by bisphosphonates. Some pre clinical studies in the literature applied forelimb loading models to produce well controlled microdamage in cortical bone. Ovariectomized animals were also extensively studied to assimilate human conditions of estrogen related bone loss. In the present study, we combined both experimental models to investigate microdamage accumulation in the context of osteopenia and zoledronate treatment. Three month old normal and ovariectomized rats treated by saline or zoledronate underwent controlled compressive loading on their right forelimb to create in vivo microdamage, which was then quantified by barium sulfate contrast enhanced microCT imaging. Weekly in vivo micro CT scans were taken to evaluate bone (re)modeling and to capture microstructural changes over time. After sacrifice, three point bending tests were performed to assess bone mechanical properties. Results show that the zoledronate treatment can reduce cortical microdamage accumulation in ovariectomized rats, which might be explained by the enhancement of several bone structural properties such as ultimate force, yield force, cortical bone area and volume. The rats showed increased bone formation volume and surface after the generation of microdamage, especially for the normal and the ovariectomized groups. Woven bone formation was also observed in loaded ulnae, which was most significant in ovariectomized rats. Although all the rats showed strong correlations between periosteal bone formation and microdamage accumulation, the correlation levels were lower for the zoledronate treated groups, potentially because of their lower levels of microdamage. The present study provides insights to further investigations of pharmaceutical treatments for osteoporosis and osteopenia. The same experimental concept can be applied in future studies on microdamage and drug testing.
C1 [Ning, Bohao; Villemure, Isabelle] Polytech Montreal, Dept Mech Engn, POB 6079,Stn Ctr Ville, Montreal, PQ H3C 3A7, Canada.
   [Ning, Bohao; Londono, Irene; Laporte, Catherine; Villemure, Isabelle] CHU St Justine, Res Ctr, 3175 Cote St Catherine Rd, Montreal, PQ H3T 1C5, Canada.
   [Laporte, Catherine] Ecole Technol Super, Dept Elect Engn, 1100 Notre Dame St West, Montreal, PQ H3C 1K3, Canada.
C3 Universite de Montreal; Polytechnique Montreal; Universite de Montreal;
   Centre Hospitalier Universitaire Sainte Justine; University of Quebec;
   Ecole de Technologie Superieure   Canada
RP Villemure, I (通讯作者)，Polytech Montreal, Dept Mech Engn, POB 6079,Stn Ctr Ville, Montreal, PQ H3C 3A7, Canada.
EM isabelle.villemure@polymtl.ca
RI ; Ning, Bohao/GPS 4685 2022
OI Londono, Irene/0000 0001 8058 2685; 
FU Natural Sciences and Engineering Research Council of Canada
   (NSERC/Discovery NSERC/CREATE)
FX <B>Funding</B> was provided by the Natural Sciences and Engineering
   Research Council of Canada (NSERC/Discovery & NSERC/CREATE) .
CR Allen M, 2018, CURR OSTEOPOROS REP, V16, P198, DOI 10.1007/s11914 018 0430 3
   Allen MR, 2017, TOXICOL PATHOL, V45, P851, DOI 10.1177/0192623317733925
   Allen MR, 2011, BONE, V49, P56, DOI 10.1016/j.bone.2010.10.159
   Allen MR., 2007, IBMS BoneKEy, V4, P49, DOI [10.1138/20060248, DOI 10.1138/20060248]
   Altman D G., 1990, Practical Statistics for Medical Research, DOI DOI 10.1201/9780429258589
   [Anonymous], 1994, World Health Organ Tech Rep Ser, V843, P1
   [Anonymous], 2015, STAT TUTORIALS SOFTW
   Aref MW, 2016, OSTEOPOROSIS INT, V27, P3637, DOI 10.1007/s00198 016 3701 9
   Åstrand J, 2006, BMC MUSCULOSKEL DIS, V7, DOI 10.1186/1471 2474 7 63
   BARON R, 1984, ANAT RECORD, V208, P137, DOI 10.1002/ar.1092080114
   Baumann AP, 2015, BONE, V75, P55, DOI 10.1016/j.bone.2015.01.022
   Bentolila V, 1998, BONE, V23, P275, DOI 10.1016/S8756 3282(98)00104 5
   Bigosinski K, 2010, SPORTS HEALTH, V2, P116, DOI 10.1177/1941738109357300
   Bilston LE, 2002, CLIN BIOMECH, V17, P716, DOI 10.1016/S0268 0033(02)00108 0
   Birkhold AI, 2016, SCI REP UK, V6, DOI 10.1038/srep23480
   Birkhold AI, 2014, BONE, V66, P15, DOI 10.1016/j.bone.2014.05.013
   Black DM, 2022, BONE, V156, DOI 10.1016/j.bone.2021.116297
   Black DM, 2019, ENDOCR REV, V40, P333, DOI 10.1210/er.2018 00001
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Brennan O, 2011, J ORTHOP RES, V29, P419, DOI 10.1002/jor.21229
   Buccino F, 2023, J MECH BEHAV BIOMED, V137, DOI 10.1016/j.jmbbm.2022.105576
   Buettmann EG, 2016, J BIOMECH, V49, P3564, DOI 10.1016/j.jbiomech.2016.08.020
   Burch MA, 2021, EUR CELLS MATER, V41, P739, DOI 10.22203/eCM.v041a47
   Burr DB, 2020, BONE, V138, DOI 10.1016/j.bone.2020.115518
   Burr DB, 2016, CLIN REV BONE MINER, V14, P197, DOI 10.1007/s12018 016 9217 1
   Burr DB, 2015, BONE, V71, P58, DOI 10.1016/j.bone.2014.10.010
   Burr DB, 2014, J BONE MINER RES, V29, P2534, DOI 10.1002/jbmr.2366
   Burr DB, 1998, J BIOMECH, V31, P337, DOI 10.1016/S0021 9290(98)00016 5
   Burr DB, 2002, BONE, V30, P2, DOI 10.1016/S8756 3282(01)00619 6
   BURR DB, 1985, J BIOMECH, V18, P189, DOI 10.1016/0021 9290(85)90204 0
   Caron R, 2023, J MECH BEHAV BIOMED, V137, DOI 10.1016/j.jmbbm.2022.105540
   CARTER DR, 1981, ACTA ORTHOP SCAND, V52, P481, DOI 10.3109/17453678108992136
   Chang JK, 2005, CONNECT TISSUE RES, V46, P200, DOI 10.1080/03008200500344025
   Chapurlat RD, 2009, OSTEOPOROSIS INT, V20, P1299, DOI 10.1007/s00198 009 0899 9
   Choudhari C, 2016, J BIOMECH, V49, P1103, DOI 10.1016/j.jbiomech.2016.02.034
   Coates BA, 2020, J BIOMECH, V108, DOI 10.1016/j.jbiomech.2020.109866
   Cole W.W., 2020, Stress Fractures in Athletes: Diagnosis and Management, P181, DOI [10.1007/978 3 030 46919 1_13, DOI 10.1007/978 3 030 46919 1_13]
   Coluzzi F, 2015, THER CLIN RISK MANAG, V11, P515, DOI 10.2147/TCRM.S79409
   Cooper D, 2007, CALCIFIED TISSUE INT, V80, P211, DOI 10.1007/s00223 005 0274 6
   Cottrell J, 2010, PHARMACEUTICALS, V3, P1668, DOI 10.3390/ph3051668
   Da Wang Y, 2020, WATER RESOUR RES, V56, DOI 10.1029/2019WR026052
   Diab T, 2006, BONE, V38, P427, DOI 10.1016/j.bone.2005.09.002
   Diab T, 2005, BONE, V37, P96, DOI 10.1016/j.bone.2005.03.014
   Diab T, 2007, BONE, V40, P612, DOI 10.1016/j.bone.2006.09.027
   Dimai HP, 2017, BONE, V104, P39, DOI 10.1016/j.bone.2016.12.016
   Domander Richard, 2021, Wellcome Open Res, V6, P37, DOI 10.12688/wellcomeopenres.16619.1
   Fazzalari NL, 1998, BONE, V23, P373, DOI 10.1016/S8756 3282(98)00111 2
   Feher A, 2010, BONE, V46, P203, DOI 10.1016/j.bone.2009.10.023
   Frost H., 1960, HENRY FORD HOSP MEDI, V8, P25
   Gargac JA, 2014, J MECH BEHAV BIOMED, V30, P234, DOI 10.1016/j.jmbbm.2013.11.009
   Gasser JA, 2008, J BONE MINER RES, V23, P544, DOI 10.1359/JBMR.071207
   Gedmintas L, 2013, J BONE MINER RES, V28, P1729, DOI 10.1002/jbmr.1893
   Guarnieri M, 2012, LAB ANIMAL, V41, P337, DOI 10.1038/laban.152
   Hao Y, 2015, BONE, V81, P702, DOI 10.1016/j.bone.2015.09.018
   Herman BC, 2010, BONE, V47, P766, DOI 10.1016/j.bone.2010.07.006
   Hod N, 2006, ISRAEL MED ASSOC J, V8, P882
   Hohlbaum K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179588
   Hornby SB, 2003, CALCIFIED TISSUE INT, V72, P519, DOI 10.1007/s00223 002 2015 4
   Hotchkiss CE, 1998, BONE, V23, P479, DOI 10.1016/S8756 3282(98)00124 0
   Iwaniec U T., 2013, Osteoporosis, P939
   Iwata K, 2006, BONE, V39, P1053, DOI 10.1016/j.bone.2006.05.006
   Jaccard James., 1998, INTERACTION EFFECTS
   Jee W. S. S., 2001, Journal of Musculoskeletal & Neuronal Interactions, V1, P193
   Jilka RL, 2013, J GERONTOL A BIOL, V68, P1209, DOI 10.1093/gerona/glt046
   Johnson H.J., 2015, ITK SOFTWARE GUIDE B, V2
   Kádár B, 2007, IN VIVO, V21, P861
   KALU DN, 1991, BONE MINER, V15, P175, DOI 10.1016/0169 6009(91)90124 I
   Keppel G., 2004, Design and analysis: A researcher's handbook, fourth edition, Vfourth
   Kettenberger U, 2014, BIOMATERIALS, V35, P9995, DOI 10.1016/j.biomaterials.2014.09.005
   Khosla S, 2007, J BONE MINER RES, V22, P1479, DOI 10.1359/JBMR.0707ONJ
   Kidd LJ, 2011, J ORTHOP RES, V29, P1827, DOI 10.1002/jor.21464
   Kim H, 2006, TOXICOLOGY, V220, P169, DOI 10.1016/j.tox.2005.12.010
   Kimmel DB, 1998, ANIMAL MODELS IN ORTHOPAEDIC RESEARCH, P279
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   Lambers FM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083662
   Landrigan MD, 2011, BONE, V48, P443, DOI 10.1016/j.bone.2010.10.160
   Lelovas PP, 2008, COMPARATIVE MED, V58, P424
   Leng HJ, 2008, J MECH BEHAV BIOMED, V1, P68, DOI 10.1016/j.jmbbm.2007.06.002
   Li J, 2001, CALCIFIED TISSUE INT, V69, P281, DOI 10.1007/s002230010036
   Li Y., 2020, P 2020 10 INT C BIOM, P253, DOI [10.1145/3397391.3397450, DOI 10.1145/3397391.3397450]
   Liu XQ, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00355
   Ma S, 2017, SCI REP UK, V7, DOI 10.1038/srep43399
   Marx RE, 2003, J ORAL MAXIL SURG, V61, P1115, DOI 10.1016/S0278 2391(03)00720 1
   Mashiba T, 2000, J BONE MINER RES, V15, P613, DOI 10.1359/jbmr.2000.15.4.613
   Meixner CN, 2017, CALCIFIED TISSUE INT, V101, P75, DOI 10.1007/s00223 017 0257 4
   Moon J, 2013, ARCH ORTHOP TRAUM SU, V133, P889, DOI 10.1007/s00402 013 1760 3
   MORI S, 1993, BONE, V14, P103, DOI 10.1016/8756 3282(93)90235 3
   Mulcahy LE, 2015, EUR CELLS MATER, V30, P271, DOI 10.22203/eCM.v030a19
   Mustafy T, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0207323
   Nagaraja S, 2005, J BIOMECH, V38, P707, DOI 10.1016/j.jbiomech.2004.05.013
   O'Brien FJ, 2005, J ORTHOP RES, V23, P475, DOI 10.1016/j.orthres.2004.08.005
   Oh BH, 2018, CLIN ORTHOP SURG, V10, P389, DOI 10.4055/cios.2018.10.3.389
   Ohta S, 2022, J HAND SURG AM, V47, DOI 10.1016/j.jhsa.2021.02.012
   Oliviero S, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0225127
   Patterson Buckendahl P, 2001, AM J PHYSIOL REG I, V280, pR79, DOI 10.1152/ajpregu.2001.280.1.R79
   Pattin CA, 1996, J BIOMECH, V29, P69, DOI 10.1016/0021 9290(94)00156 1
   Pountos I, 2012, SCI WORLD J, DOI 10.1100/2012/606404
   Robling AG, 2002, J BONE MINER RES, V17, P1545, DOI 10.1359/jbmr.2002.17.8.1545
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]
   Schriefer JL, 2005, J BIOMECH, V38, P467, DOI 10.1016/j.jbiomech.2004.04.020
   Seref Ferlengez Z, 2015, BONEKEY REP, V4, DOI 10.1038/bonekey.2015.11
   Seref Ferlengez Z, 2014, J BONE MINER RES, V29, P2537, DOI 10.1002/jbmr.2309
   Shane E., 2013, OSTEOPOROSIS, P1873
   Shane E, 2014, J BONE MINER RES, V29, P1, DOI 10.1002/jbmr.1998
   Sneddon LU, 2017, J EXP BIOL, V220, P3007, DOI 10.1242/jeb.147058
   Stadelmann VA, 2011, CLIN BIOMECH, V26, P101, DOI 10.1016/j.clinbiomech.2010.08.014
   STEVENS WC, 1975, ANESTHESIOLOGY, V42, P408, DOI 10.1097/00000542 197504000 00008
   Stollings LM, 2016, ANESTHESIOLOGY, V125, P399, DOI 10.1097/ALN.0000000000001195
   Tan SHS, 2015, OSTEOPOROSIS INT, V26, P421, DOI 10.1007/s00198 014 2885 0
   Thurner PJ, 2006, BONE, V39, P289, DOI 10.1016/j.bone.2006.01.147
   Tolgyesi A., 2022, Orthopaedic Proceedings, V104 B, P11, DOI [10.1302/1358 992x.2022.12.011, DOI 10.1302/1358 992X.2022.12.011]
   Turnbull TL, 2011, J BIOMECH, V44, P2395, DOI 10.1016/j.jbiomech.2011.06.032
   Turner A. Simon, 2001, European Cells & Materials, V1, P66
   Uthgenannt BA, 2007, J BONE MINER RES, V22, P1548, DOI 10.1359/JBMR.0070614
   Uthgenannt BA, 2007, J BIOMECH, V40, P317, DOI 10.1016/j.jbiomech.2006.01.005
   VAN PT, 1982, ANAT RECORD, V202, P445, DOI 10.1002/ar.1092020403
   Vashishth D, 2000, BONE, V26, P147, DOI 10.1016/S8756 3282(99)00253 7
   Vashishth D, 2003, J BIOMECH, V36, P121, DOI 10.1016/S0021 9290(02)00319 6
   Verborgt O, 2000, J BONE MINER RES, V15, P60, DOI 10.1359/jbmr.2000.15.1.60
   Wallace J.M., 2019, Basic and Applied Bone Biology, P125, DOI DOI 10.1016/B978 0 12 813259 3.00007 5
   Wang JY, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/5138175
   Wang XA, 2006, J BIOMECH, V39, P781, DOI 10.1016/j.jbiomech.2005.02.007
   Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799
   Wenzel TE, 1996, BONE, V19, P89, DOI 10.1016/8756 3282(96)88871 5
   Wohl GR, 2009, BONE, V44, P320, DOI 10.1016/j.bone.2008.09.010
   WRIGHT TM, 1976, J BIOMED MATER RES, V10, P637, DOI 10.1002/jbm.820100420
   Wu ZH, 2013, BONE, V55, P208, DOI 10.1016/j.bone.2013.02.019
   Zhang XH, 2018, BONE, V108, P156, DOI 10.1016/j.bone.2018.01.011
   Zioupos P, 2001, J MICROSC OXFORD, V201, P270, DOI 10.1046/j.1365 2818.2001.00783.x
NR 129
TC 1
Z9 1
U1 1
U2 9
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1751 6161
EI 1878 0180
J9 J MECH BEHAV BIOMED
JI J. Mech. Behav. Biomed. Mater.
PD FEB
PY 2024
VL 150
AR 106350
DI 10.1016/j.jmbbm.2023.106350
EA JAN 2024
PG 12
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA GP5J4
UT WOS:001153881700001
PM 38171139
OA Green Submitted
DA 2025 08 17
ER

PT J
AU Parvathi, K
   Krishnan, AG
   Jayakumar, AAR
   Nair, MB
AF Parvathi, K.
   Krishnan, Amit G.
   Jayakumar, Anitha A. R.
   Nair, Manitha B.
TI Poly(L lactic acid) nanofibers containing Cissus quadrangularis
   induced osteogenic differentiation in vitro
SO INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
LA English
DT Article
DE Cissus quadrangularis; Electrospinning; Osteoinduction
ID PETROLEUM ETHER EXTRACT; ELECTROSPUN NANOFIBER; GENE EXPRESSION; LINN.;
   SURFACES; SCAFFOLD; MATRIX; CELLS; RAT
AB Cissus quadrangularis (CQ) is known as "bone setter" in Ayurvedic Medicine because of its ability to promote fracture healing. Polymers incorporated with CQ at lower concentration have shown to enhance osteogenic differentiation of mesenchymal stem cells (MSCs) in vitro. However, for the healing of clinically relevant critical sized bone defects, large amount of CQ would be required. Based on this perception, a herbal fibrous sheet containing high weight percentage of CQ [20,40 and 60 wt/wt% in poly (L lactic acid) (PLLA)] was fabricated through electrospinning. The solution concentration, flow rate, voltage and tip target distance was optimized to obtain nanofibers. The hydrophobicity of PLLA fibers was reduced through CQ incorporation. There was considerable increase in the adhesion, proliferation and osteogenic differentiation of MSCs on herbal fibers than normal fibers, mainly on P Q20 and P CQ40. MSCs were differentiated into osteoblasts without providing any osteogenic supplements in the medium, indicating its osteoinductive capability. The herbal sheet also could promote mineralization when immersed in simulated body fluid for 14 days. These studies specify that PLLA nanofibers loaded with 20 and 40 wt% of CQ could serve as a potential candidate for bone tissue engineering applications. (C) 2017 Elsevier B.V. All rights reserved.
C1 [Parvathi, K.; Krishnan, Amit G.; Jayakumar, Anitha A. R.; Nair, Manitha B.] Amrita Vishwa Vidyapeetham, Ctr Nanosci & Mol Med, Kochi 682041, Kerala, India.
C3 Amrita Vishwa Vidyapeetham; Amrita Vishwa Vidyapeetham Kochi
RP Jayakumar, AAR; Nair, MB (通讯作者)，Amrita Vishwa Vidyapeetham, Ctr Nanosci & Mol Med, Kochi 682041, Kerala, India.
EM rjayakumar@aims.amrita.edu; manithanair@aims.amrita.edu
RI ; Nair, Manitha/B 6725 2013; Rangasamy, Jayakumar/J 4117 2013
OI Rangasamy, Jayakumar/0000 0002 0066 4208; 
FU Department of Science and Technology, Government of India [SRNM:
   PG 01:2015]
FX Financial support for this work came from the Department of Science and
   Technology, Government of India (M. Tech grant Number: SRNM:
   PG 01:2015). The authors thank Mr. Sajin P and Mr. Dennis Ravi for SEM
   analysis
CR Anitha A, 2017, TISSUE ENG PT A, V23, P345, DOI [10.1089/ten.tea.2016.0337, 10.1089/ten.TEA.2016.0337]
   Belin S, 2010, CURR GENOMICS, V11, P52, DOI 10.2174/138920210790217936
   Brahmkshatriya Hemal R, 2015, Ayu, V36, P169, DOI 10.4103/0974 8520.175542
   Buchko CJ, 1999, POLYMER, V40, P7397, DOI 10.1016/S0032 3861(98)00866 0
   Ducy P, 1999, GENE DEV, V13, P1025, DOI 10.1101/gad.13.8.1025
   GRINNELL F, 1982, J BIOL CHEM, V257, P4888
   Gulfam M, 2011, LANGMUIR, V27, P10993, DOI 10.1021/la201253z
   Gupta A. K., 2016, CLIN RES
   Jain S, 2016, BIOMED MATER, V11, DOI 10.1088/1748 6041/11/5/055007
   Jin GR, 2013, BIOMATERIALS, V34, P724, DOI 10.1016/j.biomaterials.2012.10.026
   Khan W. S., 2012, STEM CELLS INT, V2012
   KOKUBO T, 1990, J BIOMED MATER RES, V24, P721, DOI 10.1002/jbm.820240607
   Lee JH, 1998, J COLLOID INTERF SCI, V205, P323, DOI 10.1006/jcis.1998.5688
   Liang D, 2007, ADV DRUG DELIVER REV, V59, P1392, DOI 10.1016/j.addr.2007.04.021
   Lissenberg Thunnissen SN, 2011, INT ORTHOP, V35, P1271, DOI 10.1007/s00264 011 1301 z
   Megelski S, 2002, MACROMOLECULES, V35, P8456, DOI 10.1021/ma020444a
   Mehta M, 2001, PHYTOCHEM ANALYSIS, V12, P91, DOI 10.1002/pca.569
   Muthusami S, 2011, J CELL BIOCHEM, V112, P1035, DOI 10.1002/jcb.23016
   Nagani K., 2013, J PHARMACOGN PHYTOCH, V2, P149
   Najafi Taher R, 2015, RSC ADV, V5, P50462, DOI 10.1039/c5ra03813h
   Ngadiman NHA, 2017, P I MECH ENG H, V231, P597, DOI 10.1177/0954411917699021
   Padmakumar S, 2016, ACS APPL MATER INTER, V8, P6925, DOI 10.1021/acsami.6b00874
   Pajoumshariati S, 2016, ANN BIOMED ENG, V44, P1808, DOI 10.1007/s10439 015 1478 1
   Potu BK, 2009, UPSALA J MED SCI, V114, P140, DOI 10.1080/03009730902891784
   Potu BK, 2009, CLINICS, V64, P993, DOI 10.1590/S1807 59322009001000010
   Raghavan RN, 2013, P I MECH ENG H, V227, P859, DOI 10.1177/0954411913489804
   Shamaz BH, 2015, NANOTECHNOLOGY, V26, DOI 10.1088/0957 4484/26/40/405101
   Shirwaikar A, 2003, J ETHNOPHARMACOL, V89, P245, DOI 10.1016/j.jep.2003.08.004
   Siddiqui S, 2015, CELL PROLIFERAT, V48, P443, DOI 10.1111/cpr.12195
   Singh Nimisha, 2013, Natl J Maxillofac Surg, V4, P52, DOI 10.4103/0975 5950.117884
   Sivan U, 2016, J TISSUE ENG REGEN M, V10, pE546, DOI 10.1002/term.1865
   Soumya S, 2012, CARBOHYD POLYM, V87, P1787, DOI 10.1016/j.carbpol.2011.09.094
   Stohs SJ, 2013, PHYTOTHER RES, V27, P1107, DOI 10.1002/ptr.4846
   Suganya S, 2014, J APPL POLYM SCI, V131, DOI 10.1002/app.39835
   Sun B, 2014, PROG POLYM SCI, V39, P862, DOI 10.1016/j.progpolymsci.2013.06.002
   UDUPA KN, 1964, INDIAN J MED RES, V52, P26
   Wang C, 2015, NANOSCALE RES LETT, V10, DOI 10.1186/s11671 015 1146 2
   Wei JH, 2009, BIOMED MATER, V4, DOI 10.1088/1748 6041/4/4/045002
NR 38
TC 32
Z9 32
U1 0
U2 25
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0141 8130
EI 1879 0003
J9 INT J BIOL MACROMOL
JI Int. J. Biol. Macromol.
PD APR
PY 2018
VL 110
SI SI
BP 514
EP 521
DI 10.1016/j.ijbiomac.2017.11.094
PG 8
WC Biochemistry & Molecular Biology; Chemistry, Applied; Polymer Science
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry; Polymer Science
GA GB9ND
UT WOS:000429399600055
PM 29155154
DA 2025 08 17
ER

PT J
AU Vojinovic, J
   Damjanov, N
AF Vojinovic, Jelena
   Damjanov, Nemanja
TI HDAC Inhibition in Rheumatoid Arthritis and Juvenile Idiopathic
   Arthritis
SO MOLECULAR MEDICINE
LA English
DT Article
ID HISTONE DEACETYLASE INHIBITORS; SUBEROYLANILIDE HYDROXAMIC ACID;
   RECEPTOR ANTAGONIST ANAKINRA; JOINT INFLAMMATION; BONE DESTRUCTION;
   DOUBLE BLIND; IN VIVO; DISEASE; EXPRESSION; METHOTREXATE
AB Rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA) are heterogeneous autoimmune diseases characterized by chronic joint inflammation. Methotrexate is used as the gold standard to treat rheumatoid arthritis, yet there are many patients in whom the disease cannot be controlled or who experience unacceptable intolerance. Most of the biologics currently used are effective, but mostly if combined with methotrexate, Long term possible side effects, such as impaired host defense mechanisms against infection and lymphoma, are distinct disadvantages and a major concern of anticytokine therapies. Parenteral administration is a problem, particularly in children, Thus, there is a need to explore new treatment options. Here we review the properties of histone deacetylase inhibitors (HDACi) as they apply to rheumatoid arthritis by looking at effects on cytokine production, T cell differentiation and the function of macrophages, dendritic cells, osteoblasts, osteoclasts and synovial fibroblasts. We also review the safety and efficacy of givinostat (ITF 2357) in the treatment of systemic onset juvenile idiopathic arthritis (SOJIA) and its influence on the cytokine networks in SOJIA. Givinostat is an orally active HDACi which was given to children with SOJIA. After 12 wk of treatment, there were significant benefits, particularly in reducing the pain and arthritic component of the disease and decreasing the neutrophilia. CD4OL IL 1 alpha and IFN gamma in whole blood lysates decreased at wks 2 and 4 compared with baseline leve s. The clinical data are consistent with those from animal models of rheumatoid arthritis and suggest that trials with HDACi are promising as a safe oral alternative to anticytokines and methotrexate. (C) 2011 The Feinstein Institute for Medical Research, www.feinsteininstitute.org Online address: http://www.molmed.org doi: 10.2119/molmed.2011.00030
C1 [Vojinovic, Jelena] Univ Clin Ctr, Dept Pediat Rheumatol, Pediat Clin, Nish, Serbia.
   [Damjanov, Nemanja] Inst Rheumatol, Belgrade, Serbia.
RP Vojinovic, J (通讯作者)，Univ Clin Ctr Nis, Dept Pediat Rheumatol, Bul Dr Zoran Djindjic 48, Nish 18000, Serbia.
EM vojinovic.jelena@gmail.com
RI ; Vojinovic, Jelena/V 6726 2019
OI Vojinovic, Jelena/0000 0002 6701 3370; 
CR BACKDAHL L, 2010, J BIOCH CELL BIOL, V41, P176
   Blanchard F, 2005, DRUG DISCOV TODAY, V10, P197, DOI 10.1016/S1359 6446(04)03309 4
   Brennan FM, 2008, J CLIN INVEST, V118, P3537, DOI 10.1172/JCI36389
   Brogdon JL, 2007, BLOOD, V109, P1123, DOI 10.1182/blood 2006 04 019711
   Carta S, 2006, BLOOD, V108, P1618, DOI 10.1182/blood 2006 03 014126
   Cawston TE, 2010, CELL TISSUE RES, V339, P221, DOI 10.1007/s00441 009 0887 6
   Choo QY, 2010, RHEUMATOLOGY, V49, P1447, DOI 10.1093/rheumatology/keq108
   Choy EHS, 2001, NEW ENGL J MED, V344, P907, DOI 10.1056/NEJM200103223441207
   Chung YL, 2003, MOL THER, V8, P707, DOI 10.1016/S1525 0016(03)00235 1
   Criswell LA, 2010, IMMUNOL REV, V233, P55, DOI 10.1111/j.0105 2896.2009.00862.x
   Edens RE, 2006, INT IMMUNOPHARMACOL, V6, P1673, DOI 10.1016/j.intimp.2006.07.001
   Elaut G, 2007, CURR PHARM DESIGN, V13, P2584, DOI 10.2174/138161207781663064
   Ermann J, 2001, NAT IMMUNOL, V2, P759, DOI 10.1038/ni0901 759
   Foell D, 2010, JAMA J AM MED ASSOC, V303, P1266, DOI 10.1001/jama.2010.375
   Furlan A, 2011, MOL MED, V17, P353, DOI 10.2119/molmed.2011.00020
   Gattorno M, 2008, ARTHRITIS RHEUM, V58, P1505, DOI 10.1002/art.23437
   Giannini EH, 1997, ARTHRITIS RHEUM, V40, P1202
   GIANNINI EH, 1992, NEW ENGL J MED, V326, P1043, DOI 10.1056/NEJM199204163261602
   Goldbach Mansky R, 2006, NEW ENGL J MED, V355, P581, DOI 10.1056/NEJMoa055137
   Grabiec AM, 2010, J IMMUNOL, V184, P2718, DOI 10.4049/jimmunol.0901467
   Halili MA, 2009, CURR TOP MED CHEM, V9, P309, DOI 10.2174/156802609788085250
   Horiuchi M, 2009, J RHEUMATOL, V36, P1580, DOI 10.3899/jrheum.081115
   Horneff G, 2004, ANN RHEUM DIS, V63, P1638, DOI 10.1136/ard.2003.014886
   Huber LC, 2007, ARTHRITIS RHEUM US, V56, P3523, DOI 10.1002/art.22948
   Ilowite N, 2009, CLIN RHEUMATOL, V28, P129, DOI 10.1007/s10067 008 0995 9
   Imboden JB, 2009, ANNU REV PATHOL MECH, V4, P417, DOI 10.1146/annurev.pathol.4.110807.092254
   Joosten LAB, 2011, MOL MED, V17, P391, DOI 10.2119/molmed.2011.00058
   Jüengel A, 2010, CURR OPIN RHEUMATOL, V22, P284, DOI 10.1097/BOR.0b013e3283389641
   Kawabata Tomoko, 2010, Arthritis Res Ther, V12, pR133, DOI 10.1186/ar3071
   Leoni F, 2005, MOL MED, V11, P1, DOI 10.2119/2006 00005.Dinarello
   Leoni F, 2002, P NATL ACAD SCI USA, V99, P2995, DOI 10.1073/pnas.052702999
   Lequerré T, 2008, ANN RHEUM DIS, V67, P302, DOI 10.1136/ard.2007.076034
   Lewis EC, 2011, MOL MED, V17, P369, DOI 10.2119/molmed.2010.00152
   Li X, 2010, BIOCHEM BIOPH RES CO, V397, P131, DOI 10.1016/j.bbrc.2010.05.111
   Lin HS, 2007, BRIT J PHARMACOL, V150, P862, DOI 10.1038/sj.bjp.0707165
   Manabe H, 2008, INFLAMM RES, V57, P4, DOI 10.1007/s00011 007 7036 z
   Mangge H, 2002, IMMUNOBIOLOGY, V206, P459, DOI 10.1078/0171 2985 00194
   Nakamura T, 2005, J IMMUNOL, V175, P5809, DOI 10.4049/jimmunol.175.9.5809
   Nasu Y, 2008, OSTEOARTHR CARTILAGE, V16, P723, DOI 10.1016/j.joca.2007.10.014
   Nencioni A, 2007, CLIN CANCER RES, V13, P3933, DOI 10.1158/1078 0432.CCR 06 2903
   Nishida K, 2004, ARTHRITIS RHEUM US, V50, P3365, DOI 10.1002/art.20709
   Papagoras C, 2010, AUTOIMMUN REV, V9, P574, DOI 10.1016/j.autrev.2010.04.002
   Pascual V, 2005, J EXP MED, V201, P1479, DOI 10.1084/jem.20050473
   Peart MJ, 2005, P NATL ACAD SCI USA, V102, P3697, DOI 10.1073/pnas.0500369102
   Perlman H, 2003, J IMMUNOL, V170, P838, DOI 10.4049/jimmunol.170.2.838
   Petty RE, 2004, J RHEUMATOL, V31, P390
   Reddy P, 2008, J CLIN INVEST, V118, P2562, DOI 10.1172/JCI34712
   Rodrigues HM, 2009, MOL IMMUNOL, V47, P12, DOI 10.1016/j.molimm.2009.01.010
   Ruperto N, 2004, ARTHRITIS RHEUM US, V50, P2191, DOI 10.1002/art.20288
   Schroeder TM, 2005, J BONE MINER RES, V20, P2254, DOI 10.1359/JBMR.050813
   Smolen JS, 2010, ANN RHEUM DIS, V69, P964, DOI 10.1136/ard.2009.126532
   Suzuki T, 2006, J MED CHEM, V49, P4809, DOI 10.1021/jm060554y
   Tao R, 2007, NAT MED, V13, P1299, DOI 10.1038/nm1652
   Tran CN, 2007, AM J PATHOL, V171, P1588, DOI 10.2353/ajpath.2007.070004
   Vastert SJ, 2009, BEST PRACT RES CL RH, V23, P655, DOI 10.1016/j.berh.2009.08.003
   Verbsky JW, 2004, J RHEUMATOL, V31, P2071
   Vojinovic J, 2011, ARTHRITIS RHEUM US, V63, P1452, DOI 10.1002/art.30238
   Wang Z, 2009, EUR RESPIR J, V34, P145, DOI 10.1183/09031936.00084808
   Yokota S, 2008, LANCET, V371, P998, DOI 10.1016/S0140 6736(08)60454 7
   Young DA, 2005, ARTHRITIS RES THER, V7, pR503, DOI 10.1186/ar1702
NR 60
TC 100
Z9 120
U1 0
U2 17
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1076 1551
EI 1528 3658
J9 MOL MED
JI Mol. Med.
PD MAY JUN
PY 2011
VL 17
IS 5 6
BP 397
EP 403
DI 10.2119/molmed.2011.00030
PG 7
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA 776HS
UT WOS:000291525700007
PM 21308151
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Cen, CD
   Wu, J
   Zhang, Y
   Luo, C
   Xie, LN
   Zhang, X
   Yang, XL
   Li, M
   Bi, Y
   Li, TY
   He, TC
AF Cen, Chaode
   Wu, Jun
   Zhang, Yong
   Luo, Cong
   Xie, Lina
   Zhang, Xin
   Yang, Xiaolan
   Li, Ming
   Bi, Yang
   Li, Tingyu
   He, Tongchuan
TI Improving Magnetofection of Magnetic Polyethylenimine Nanoparticles into
   MG 63 Osteoblasts Using a Novel Uniform Magnetic Field
SO NANOSCALE RESEARCH LETTERS
LA English
DT Article
DE Magnetofection; Magnetic nanoparticles; Uniform magnetic field;
   Polyethylenimine; Non viral gene delivery
ID IRON OXIDE NANOPARTICLES; GENE DELIVERY; FOLIC ACID; DNA; TRANSFECTION;
   OSTEOSARCOMA; CYTOTOXICITY; THERAPY; MECHANISM; AUTOPHAGY
AB This study aimed to improve the magnetofection of MG 63 osteoblasts by integrating the use of a novel uniform magnetic field with low molecular weight polyethylenimine modified superparamagnetic iron oxide nanoparticles (PEI SPIO NPs). The excellent characteristics of PEI SPIO NPs such as size, zeta potential, the pDNA binding and protective ability were determined to be suitable for gene delivery. The novel uniform magnetic field enabled polyethylenimine modified superparamagnetic iron oxide nanoparticles/pDNA complexes (PEI SPIO NPs/pDNAcomplexes) to rapidly and uniformly distribute on the surface of MG 63 cells, averting local transfection and decreasing disruption of the membrane caused by the centralization of positively charged PEI SPIO NPs, thereby increasing the effective coverage of magnetic gene carriers during transfection, and improving magnetofection efficiency. This innovative uniform magnetic field can be used to determine the optimal amount between PEI SPIO NPs and pDNA, as well as screen for the optimal formulation design of magnetic gene carrier under the homogenous conditions. Most importantly, the novel uniform magnetic field facilitates the transfection of PEI SPIO NPs/pDNA into osteoblasts, thereby providing a novel approach for the targeted delivery of therapeutic genes to osteosarcoma tissues as well as a reference for the treatment of other tumors.
C1 [Cen, Chaode] Guizhou Prov Orthoped Hosp, Dept Orthoped, Guiyang 550000, Guizhou, Peoples R China.
   [Zhang, Yong] First Peoples Hosp Guiyang, Dept Gynaecol, Guiyang 550000, Guizhou, Peoples R China.
   [Wu, Jun; Luo, Cong; Xie, Lina; Zhang, Xin; Li, Ming] Chongqing Med Univ, Childrens Hosp, Lab Orthoped Biomat, Dept Orthoped, Chongqing 400014, Peoples R China.
   [Wu, Jun; Luo, Cong; Xie, Lina; Zhang, Xin; Li, Ming; Bi, Yang; Li, Tingyu] China Int Sci & Technol Cooperat Base Child Dev &, Chongqing Engn Res Ctr Stem Cell Therapy, Key Lab Child Dev & Disorders, Minist Educ, Chongqing 400014, Peoples R China.
   [Yang, Xiaolan] Chongqing Med Univ, Dept Chem, Key Lab Clin Diagnost, Minist Educ, Chongqing 40016, Peoples R China.
   [He, Tongchuan] Univ Chicago, Med Ctr, Dept Surg, Orthoped Ctr,Lab Mol Oncol, Chicago, IL 60637 USA.
C3 Chongqing Medical University; Chongqing Medical University; University
   of Chicago; University of Chicago Medical Center
RP Luo, C (通讯作者)，Chongqing Med Univ, Childrens Hosp, Lab Orthoped Biomat, Dept Orthoped, Chongqing 400014, Peoples R China.; Luo, C (通讯作者)，China Int Sci & Technol Cooperat Base Child Dev &, Chongqing Engn Res Ctr Stem Cell Therapy, Key Lab Child Dev & Disorders, Minist Educ, Chongqing 400014, Peoples R China.
EM luocong919@sohu.com
RI 杨, 晓兰/Y 9481 2019; Luo, Cong/ABA 7933 2020
FU National Natural Science Foundation of China [30973062]; Chongqing
   Science and Technology Research Projects [CSTC2011ggB1004]; National
   Clinical Key Specialty Construction Projects [[2013] 544]
FX The National Natural Science Foundation of China (No. 30973062),
   Chongqing Science and Technology Research Projects (No.
   CSTC2011ggB1004), and National Clinical Key Specialty Construction
   Projects (No. The Medical Letter of The National Health Office [2013]
   544) supported the study.
CR Akinc A, 2005, J GENE MED, V7, P657, DOI 10.1002/jgm.696
   Alsaggar M, 2015, ADV GENET, V89, P1, DOI 10.1016/bs.adgen.2014.10.001
   Ang D, 2011, ACTA BIOMATER, V7, P1319, DOI 10.1016/j.actbio.2010.09.037
   Bieber T, 2002, J CONTROL RELEASE, V82, P441, DOI 10.1016/S0168 3659(02)00129 3
   Bortner CD, 1999, J BIOL CHEM, V274, P21953, DOI 10.1074/jbc.274.31.21953
   Brissault B, 2006, BIOCONJUGATE CHEM, V17, P759, DOI 10.1021/bc050287v
   Cheng L, 2016, INT J NANOMED, V11, P5277, DOI 10.2147/IJN.S115364
   Dai ZJ, 2011, BIOMATERIALS, V32, P8626, DOI 10.1016/j.biomaterials.2011.07.044
   Doi Knayo, 2015, Virus (Nagoya), V65, P27, DOI 10.2222/jsv.65.27
   Du JJ, 2016, REGEN BIOMATER, V3, P223, DOI 10.1093/rb/rbw023
   Fouriki A, 2014, J TISSUE ENG REGEN M, V8, P169, DOI 10.1002/term.1508
   Friebele Jill C, 2015, Am J Orthop (Belle Mead NJ), V44, P547
   Hall A, 2013, BBA BIOENERGETICS, V1827, P1213, DOI 10.1016/j.bbabio.2013.07.001
   Harrison DJ, 2018, EXPERT REV ANTICANC, V18, P39, DOI 10.1080/14737140.2018.1413939
   [何为 He Wei], 2013, [重庆大学学报, Journal of Chongqing University], V36, P86
   Hellmund M, 2015, BIOMATER SCI UK, V3, P1459, DOI 10.1039/c5bm00187k
   Huth S, 2004, J GENE MED, V6, P923, DOI 10.1002/jgm.577
   Itaka K, 2004, J GENE MED, V6, P76, DOI 10.1002/jgm.470
   Kim DY, 2015, J BIOMED NANOTECHNOL, V11, P522, DOI 10.1166/jbn.2015.2060
   Lo YL, 2015, NANOSCALE, V7, P8554, DOI 10.1039/c5nr01404b
   Lungu CN, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17040555
   Luo D, 2000, NAT BIOTECHNOL, V18, P893, DOI 10.1038/78523
   Luo X, 2017, INT J NANOMED, V12, P5331, DOI 10.2147/IJN.S137245
   Ma YJ, 2011, INT J PHARMACEUT, V419, P247, DOI 10.1016/j.ijpharm.2011.07.017
   Mah C, 2002, MOL THER, V6, P106, DOI 10.1006/mthe.2001.0636
   Merdan T, 2002, PHARMACEUT RES, V19, P140, DOI 10.1023/A:1014212630566
   Misaghi A, 2018, SICOT J, V4, DOI 10.1051/sicotj/2017028
   Mislick KA, 1996, P NATL ACAD SCI USA, V93, P12349, DOI 10.1073/pnas.93.22.12349
   Moghimi SM, 2005, MOL THER, V11, P990, DOI 10.1016/j.ymthe.2005.02.010
   Namgung R, 2010, BIOMATERIALS, V31, P4204, DOI 10.1016/j.biomaterials.2010.01.123
   Omata D, 2015, ADV GENET, V89, P25, DOI 10.1016/bs.adgen.2014.11.001
   Oral O, 2015, ANN BIOMED ENG, V43, P2816, DOI 10.1007/s10439 015 1331 6
   Park W, 2014, BIOMATERIALS, V35, P7239, DOI 10.1016/j.biomaterials.2014.05.010
   Peking P, 2016, MOL THER NUCL ACIDS, V5, DOI 10.1038/mtna.2016.3
   Plank C, 2003, BIOL CHEM, V384, P737, DOI 10.1515/BC.2003.082
   Remaut K, 2014, J CONTROL RELEASE, V195, P29, DOI 10.1016/j.jconrel.2014.08.002
   Scherer F, 2002, GENE THER, V9, P102, DOI 10.1038/sj.gt.3301624
   Sonawane ND, 2003, J BIOL CHEM, V278, P44826, DOI 10.1074/jbc.M308643200
   Ustinova TM, 2018, B EXP BIOL MED+, V164, P473, DOI 10.1007/s10517 018 4015 z
   Vainauska D, 2012, MEDICINA LITHUANIA, V48, P324, DOI 10.3390/medicina48060048
   Wang F, 2018, INT J NANOMED, V13, P857, DOI 10.2147/IJN.S147747
   Wang HY, 2015, ADV DRUG DELIVER REV, V81, P142, DOI 10.1016/j.addr.2014.10.031
   Wang Y, 2015, ACTA BIOMATER, V17, P115, DOI 10.1016/j.actbio.2015.01.007
   Wedekind MF, 2018, PEDIAT BLOOD CANC, V19, DOI 10.1002/pbc.27227.
   Wen M, 2008, MOL VIS, V14, P114
   Wilhelm C, 2003, BIOMATERIALS, V24, P1001, DOI 10.1016/S0142 9612(02)00440 4
   Xie L, 2015, BIOMATER SCI UK, V3, P446, DOI 10.1039/c4bm00317a
   Xu Z, 2015, INT J APPL ELECTROM, V47, P777, DOI 10.3233/JAE 140123
   Yang HJ, 2015, MOL CELL BIOCHEM, V402, P203, DOI 10.1007/s11010 015 2328 z
   Young JL, 2015, ADV GENET, V89, P49, DOI 10.1016/bs.adgen.2014.10.003
   Zhang GL, 2015, ACS APPL MATER INTER, V7, P14192, DOI 10.1021/acsami.5b04294
   Zhao X, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098919
   Zhou YB, 2012, J MATER SCI MATER M, V23, P2697, DOI 10.1007/s10856 012 4720 5
NR 53
TC 17
Z9 17
U1 2
U2 23
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1931 7573
EI 1556 276X
J9 NANOSCALE RES LETT
JI Nanoscale Res. Lett.
PD MAR 12
PY 2019
VL 14
AR 90
DI 10.1186/s11671 019 2882 5
PG 14
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary;
   Physics, Applied
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Materials Science; Physics
GA HP0JU
UT WOS:000461353000001
PM 30874913
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Uskokovic, V
   Wu, VM
AF Uskokovic, Vuk
   Wu, Victoria M.
TI When Nothing Turns Itself Inside out and Becomes Something: Coating
   Poly(Lactic Co Glycolic Acid) Spheres with Hydroxyapatite
   Nanoparticles vs. the Other Way Around
SO JOURNAL OF FUNCTIONAL BIOMATERIALS
LA English
DT Article
DE bone; calcium phosphate; core/shell particles; drug delivery;
   nanocomposite; zeta potential
ID CALCIUM PHOSPHATE NANOPARTICLES; PHASE COMPOSITION CONTROL;
   DRUG DELIVERY PLATFORMS; IN VITRO; PLGA MICROSPHERES; SUSTAINED RELEASE;
   BONE; SCAFFOLDS; GROWTH; PH
AB To stabilize drugs physisorbed on the surface of hydroxyapatite (HAp) nanoparticles and prevent burst release, these nanoparticles are commonly coated with polymers. Bioactive HAp, however, becomes shielded from the surface of such core/shell entities, which partially defeats the purpose of using it. The goal of this study was to assess the biological and pharmacokinetic effects of inverting this classical core/shell structure by coating poly(lactic co glycolic acid) (PLGA) spheres with HAp nanoparticles. The HAp shell did not hinder the release of vancomycin; rather, it increased the release rate to a minor degree, compared to that from undecorated PLGA spheres. The decoration of PLGA spheres with HAp induced lesser mineral deposition and lesser upregulation of osteogenic markers compared to those induced by the composite particles where HAp nanoparticles were embedded inside the PLGA spheres. This was explained by homeostatic mechanisms governing the cell metabolism, which ensure than the sensation of a product of this metabolism in the cell interior or exterior is met with the reduction in the metabolic activity. The antagonistic relationship between proliferation and bone production was demonstrated by the higher proliferation rate of cells challenged with HAp coated PLGA spheres than of those treated with PLGA coated HAp. It is concluded that the overwhelmingly positive response of tissues to HAp coated biomaterials for bone replacement is unlikely to be due to the direct induction of new bone growth in osteoblasts adhering to the HAp coating. Rather, these positive effects are consequential to more elementary aspects of cell attachment, mechanotransduction, and growth at the site of contact between the HAp coated material and the tissue.
C1 [Uskokovic, Vuk; Wu, Victoria M.] TardigradeNano LLC, 7 Pk Vista, Irvine, CA 92604 USA.
   [Uskokovic, Vuk] San Diego State Univ, Dept Mech Engn, 5500 Campanile Dr, San Diego, CA 92182 USA.
C3 California State University System; San Diego State University
RP Uskokovic, V (通讯作者)，TardigradeNano LLC, 7 Pk Vista, Irvine, CA 92604 USA.; Uskokovic, V (通讯作者)，San Diego State Univ, Dept Mech Engn, 5500 Campanile Dr, San Diego, CA 92182 USA.
EM vuk.uskokovic@tardigradenano.com; victoria.wu@tardigradenano.com
RI Uskokovic, Vuk/S 7986 2018
OI Uskokovic, Vuk/0000 0003 3256 1606
FU (National Institute of Dental and Craniofacial Research) [R00 DE021416]
FX This research was partially funded by R00 DE021416 (National Institute
   of Dental and Craniofacial Research).
CR Abay Akar N, 2019, TURK J BIOL, V43, P235, DOI 10.3906/biy 1904 63
   Ahmed MK, 2020, INT J PHARMACEUT, V577, DOI 10.1016/j.ijpharm.2019.118950
   Ahmed MK, 2019, J MATER SCI, V54, P14524, DOI 10.1007/s10853 019 03947 1
   BATESON G, 1972, STEPS ECOLOGY MIND C
   BERNARDI G, 1969, BIOCHIM BIOPHYS ACTA, V174, P423, DOI 10.1016/0005 2787(69)90273 1
   Bian CH, 2015, IET NANOBIOTECHNOL, V9, P1, DOI 10.1049/iet nbt.2013.0066
   Buzzi V, 2013, J Encapsulation Adsorpt Sci, V03, P99, DOI [10.4236/jeas.2013.34012, DOI 10.4236/JEAS.2013.34012]
   Chanchareonsook N, 2013, J BIOMED MATER RES A, V101, P2258, DOI 10.1002/jbm.a.34542
   Di Natale C, 2020, MATERIALS, V13, DOI 10.3390/ma13081807
   Duan PG, 2019, J ORTHOP TRANSL, V19, P68, DOI 10.1016/j.jot.2019.04.006
   Fujii S, 2009, LANGMUIR, V25, P9759, DOI 10.1021/la901100z
   Gavini E, 2004, EUR J PHARM BIOPHARM, V57, P207, DOI 10.1016/j.ejpb.2003.10.018
   Ghiasi B, 2020, DRUG DEV IND PHARM, V46, P1035, DOI 10.1080/03639045.2020.1776321
   Ghorbani F, 2018, E POLYMERS, V18, P247, DOI 10.1515/epoly 2017 0196
   GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042 6822(73)90341 3
   Hogsbro M, 2017, OTOL NEUROTOL, V38, pE152, DOI 10.1097/MAO.0000000000001442
   Huang D, 2014, J R SOC INTERFACE, V11, DOI 10.1098/rsif.2014.0101
   Ignjatovic NL, 2019, TOXICOL RES UK, V8, P287, DOI 10.1039/c9tx00007k
   Ignjatovic NL, 2016, COLLOID SURFACE B, V148, P629, DOI 10.1016/j.colsurfb.2016.09.041
   Itokazu M, 1998, BIOMATERIALS, V19, P817, DOI 10.1016/S0142 9612(97)00237 8
   Johansson P, 2016, INT J NANOMED, V11, P1435, DOI 10.2147/IJN.S100424
   Jongpaiboonkit L, 2009, ACS APPL MATER INTER, V1, P1504, DOI 10.1021/am9001716
   Kang SW, 2008, J BIOMED MATER RES A, V85A, P747, DOI 10.1002/jbm.a.31572
   Kazemzadeh Narbat M, 2012, J BIOMED MATER RES B, V100B, P1344, DOI 10.1002/jbm.b.32701
   Khan MA, 2016, J COLLOID INTERF SCI, V471, P48, DOI 10.1016/j.jcis.2016.03.007
   Kim SS, 2006, BIOMATERIALS, V27, P1399, DOI 10.1016/j.biomaterials.2005.08.016
   Lee JH, 2017, J BIOMED MATER RES B, V105, P647, DOI 10.1002/jbm.b.33589
   Lemaire S, 2011, CLIN INFECT DIS, V52, pS493, DOI 10.1093/cid/cir165
   MEURMAN JH, 1977, J DENT RES, V56, pA62
   Mirakabad FST, 2014, ASIAN PAC J CANCER P, V15, P517, DOI 10.7314/APJCP.2014.15.2.517
   Nie W, 2019, INT J NANOMED, V14, P3929, DOI 10.2147/IJN.S205194
   Okajima LS, 2020, J PERIODONTAL RES, V55, P660, DOI 10.1111/jre.12752
   PARK KC, 1980, J DENT RES, V59, P946
   QUARLES LD, 1992, J BONE MINER RES, V7, P683
   Reible DD., 2014, Processes, Assessment and Remediation of Contaminated Sediments, P325
   Riau AK, 2020, ACTA BIOMATER, V107, P299, DOI 10.1016/j.actbio.2020.01.023
   Son J, 2020, NANOMED NANOTECHNOL, V24, DOI 10.1016/j.nano.2020.102151
   Tamai H, 1999, J COLLOID INTERF SCI, V212, P585, DOI 10.1006/jcis.1998.6023
   Tseng YY, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12020091
   TSUJI A, 1982, MICROBIOL IMMUNOL, V26, P15, DOI 10.1111/j.1348 0421.1982.tb00149.x
   Uskokovic V., 2009, RES COG J PHIL, V6, P286
   Uskokovic V, 2007, TECHNOL SOC, V29, P43, DOI 10.1016/j.techsoc.2006.10.005
   Uskokovic V, 2020, INT J PHARMACEUT, V583, DOI 10.1016/j.ijpharm.2020.119316
   Uskokovic V, 2020, CERAM INT, V46, P11443, DOI 10.1016/j.ceramint.2020.02.001
   Uskokovic V, 2019, ACS BIOMATER SCI ENG, V5, P3483, DOI 10.1021/acsbiomaterials.9b00255
   Uskokovic V, 2019, BIOINTERPHASES, V14, DOI 10.1116/1.5090396
   Uskokovic V, 2015, MAT SCI ENG C MATER, V57, P434, DOI 10.1016/j.msec.2015.07.050
   Uskokovic Vuk, 2013, Rev J Chem, V3, P271
   Uskokovic V, 2014, EXPERT OPIN DRUG DEL, V11, P1899, DOI 10.1517/17425247.2014.944860
   Uskokovic V, 2014, ACS APPL MATER INTER, V6, P13209, DOI 10.1021/am503043t
   Uskokovic V, 2014, J PHARM SCI US, V103, P567, DOI 10.1002/jps.23824
   Uskokovic V, 2013, MAT SCI ENG C MATER, V33, P3362, DOI 10.1016/j.msec.2013.04.023
   Uskokovic V, 2013, J BIOMED MATER RES A, V101, P1416, DOI 10.1002/jbm.a.34426
   Uskokovic V, 2013, J BIOMED MATER RES A, V101, P1427, DOI 10.1002/jbm.a.34437
   Uskokovic V, 2011, ARCH ORAL BIOL, V56, P521, DOI 10.1016/j.archoralbio.2010.11.011
   Uskokovic V, 2011, J BIOMED MATER RES B, V96B, P152, DOI 10.1002/jbm.b.31746
   von Foerster Heinz., 1981, OBSERVING SYSTEMS
   Vukomanovic M, 2011, COLLOID SURFACE B, V87, P226, DOI 10.1016/j.colsurfb.2011.05.023
   Vukomanovic M, 2011, COLLOID SURFACE B, V82, P404, DOI 10.1016/j.colsurfb.2010.09.011
   Wang DX, 2013, INT J NANOMED, V8, P1855, DOI 10.2147/IJN.S43706
   Wang LQ, 2011, INVEST OPHTH VIS SCI, V52, P7392, DOI 10.1167/iovs.11 7601
   Wang MM, 2019, LANGMUIR, V35, P16111, DOI 10.1021/acs.langmuir.9b02373
   Witek L, 2020, J BIOMED MATER RES B, V108, P1304, DOI 10.1002/jbm.b.34478
   Wójcik Pastuszka D, 2019, MATERIALS, V12, DOI 10.3390/ma12081202
   Wu V, 2019, FOUND SCI, V24, P617, DOI 10.1007/s10699 019 09602 x
   Wu VM, 2018, ACS APPL MATER INTER, V10, P34013, DOI 10.1021/acsami.8b12784
   Xu QG, 2008, J CONTROL RELEASE, V127, P146, DOI 10.1016/j.jconrel.2008.01.017
   Yu XL, 2018, RSC ADV, V8, P37424, DOI 10.1039/c8ra06659k
   Zhe Z, 2011, NANOSCI NANOTECH LET, V3, P472, DOI 10.1166/nnl.2011.1204
NR 69
TC 5
Z9 5
U1 0
U2 19
PU MDPI
PI BASEL
PA MDPI AG, Grosspeteranlage 5, CH 4052 BASEL, SWITZERLAND
EI 2079 4983
J9 J FUNCT BIOMATER
JI J. Func. Biomater.
PD SEP
PY 2022
VL 13
IS 3
AR 102
DI 10.3390/jfb13030102
PG 18
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA 4V4HE
UT WOS:000859438600001
PM 35893470
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Fizazi, K
   Albiges, L
   Massard, C
   Escudier, B
   Loriot, Y
AF Fizazi, K.
   Albiges, L.
   Massard, C.
   Escudier, B.
   Loriot, Y.
TI Novel and bone targeted agents for CRPC
SO ANNALS OF ONCOLOGY
LA English
DT Article
DE bone targeted agents; chemotherapy; endocrine therapy; immunotherapy;
   prostate cancer
ID RANDOMIZED PHASE II; PROSTATE CANCER; SURVIVAL; METASTASES; DOCETAXEL;
   TRIAL; IMMUNOTHERAPY; PREDNISONE; RADIUM 223; EFFICACY
AB Clearly, no neoplasm other than prostate cancer has benefited from so many breakthroughs since the beginning of this decade: the past two years can be considered exceptional due to the number of emerging agents against castration resistant prostate cancer (CRPC), which have demonstrated positive outcomes in phase Ill trials. Until 2010, docetaxel (Taxotere) was the only agent capable of improving survival in patients with metastatic CRPC. Since then, positive results from phase Ill trials have been reported for sipuleucel T, cabazitaxel, denosumab, abiraterone, radium 223, and enzalutamide, while other promising agents including notably orteronel, ipilimumab and cabozantinib are currently under study. Taken together, the incorporation of these agents in the routine management of patients with CRPC is likely to expand their median life expectancy, which was only similar to 1 year until the early 2000, to >30 months in the near future. The availability of these agents will lead to new challenges and questions, such as: Can our societies afford the costs? Should we use these agents sequentially or in combination with an incremental benefit? Can we personalise treatment based on the biology of the individual's disease? How will we develop new active compounds in the context where a half dozen approved agents may confound their potential overall survival effect?
C1 [Fizazi, K.; Albiges, L.; Massard, C.; Escudier, B.; Loriot, Y.] Univ Paris Sud, Inst Gustave Roussy, Dept Canc Med, F 94800 Villejuif, France.
C3 UNICANCER; Gustave Roussy; Universite Paris Saclay
RP Fizazi, K (通讯作者)，Univ Paris Sud, Inst Gustave Roussy, Dept Canc Med, F 94800 Villejuif, France.
EM karim.fizazi@igr.fr
RI ; massard, christophe/HTQ 3843 2023; Escudier, Bernard/AES 5186 2022;
   Albiges, Laurence/JOZ 9308 2023; Loriot, Yohann/W 5572 2019
OI ALBIGES, Laurence/0000 0002 5734 3480; 
FU Amgen; Sanoli; Astellas
FX KF has participated in advisory boards for Amgen, Algeta/Bayer
   AstraZeneca, Exelixis and Novartis. YL has received research funding
   from Amgen, Sanoli and Astellas.
CR [Anonymous], J CLIN ONCOL S5
   Chi KN, 2010, J CLIN ONCOL, V28, P4247, DOI 10.1200/JCO.2009.26.8771
   De Bono JS, 2011, NEW ENGL J MED, V364, P1995, DOI 10.1056/NEJMoa1014618
   de Bono JS, 2010, LANCET, V376, P1147, DOI 10.1016/S0140 6736(10)61389 X
   Fizazi K, 2003, CLIN CANCER RES, V9, P2587
   Fizazi K, ABIRATERONE AC UNPUB
   Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140 6736(10)62344 6
   Fizazi K, 2009, J CLIN ONCOL, V27, P1564, DOI 10.1200/JCO.2008.19.2146
   Kantoff PW, 2010, NEW ENGL J MED, V363, P411, DOI 10.1056/NEJMoa1001294
   Kantoff PW, 2010, J CLIN ONCOL, V28, P1099, DOI 10.1200/JCO.2009.25.0597
   Loriot Y, 2012, ANN ONCOL, V23, P1085, DOI 10.1093/annonc/mdr573
   Loriot Y, 2010, EUR J CANCER, V46, P1770, DOI 10.1016/j.ejca.2010.04.010
   Nilsson S, 2007, LANCET ONCOL, V8, P587, DOI 10.1016/S1470 2045(07)70147 X
   Parker C, 2011, EUR J CANCER, V47, P3, DOI 10.1016/S0959 8049(11)70100 9
   Pili R, 2011, J CLIN ONCOL, V29, P4022, DOI 10.1200/JCO.2011.35.6295
   Rajpar S, 2010, ANN ONCOL, V21, P1864, DOI 10.1093/annonc/mdq037
   Slovin SF, 2009, J CLIN ONCOL, V27, p15s
   Smith DH, 2012, J CLIN ONCOL, V30, DOI 10.1200/jco.2012.30.30_suppl.66
   Wirth M., 2012, J CLIN ONCOL S5, V30
   Yu EY, 2011, UROLOGY, V77, P1166, DOI 10.1016/j.urology.2011.01.006
NR 20
TC 8
Z9 10
U1 1
U2 4
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0923 7534
EI 1569 8041
J9 ANN ONCOL
JI Ann. Oncol.
PD SEP
PY 2012
VL 23
SU 10
BP 264
EP 267
DI 10.1093/annonc/mds353
PG 4
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 014YA
UT WOS:000309410600037
PM 22987974
OA Bronze
DA 2025 08 17
ER

PT J
AU Meinen, R
   Galli Lysak, I
   Villiger, PM
   Aeberli, D
AF Meinen, Rahel
   Galli Lysak, Inna
   Villiger, Peter M.
   Aeberli, Daniel
TI Influence of bisphosphonate therapy on bone geometry, volumetric bone
   density and bone strength of femoral shaft in postmenopausal women with
   rheumatoid arthritis
SO BMC MUSCULOSKELETAL DISORDERS
LA English
DT Article
DE Femoral bone; pQCT; Bisphosphonates; RA; Bone strength; AFF
ID GLUCOCORTICOID INDUCED OSTEOPOROSIS; QUANTITATIVE COMPUTED TOMOGRAPHY;
   JUVENILE IDIOPATHIC ARTHRITIS; MINERAL DENSITY; MUSCULOSKELETAL
   ABNORMALITIES; ATYPICAL FRACTURES; AMERICAN COLLEGE; DISEASE ACTIVITY;
   HIP GEOMETRY; RADIUS
AB Background: There is evidence that postmenopausal women with rheumatoid arthritis (RA) on glucocorticoid (GC) therapy and bisphosphonate (BP) have an increased risk for atypical subtrochanteric and atypical diaphyseal femoral fracture (AFF). The underlying mechanism has not been elucidated so far. Using peripheral quantitative computed tomography (pQCT), the aim of the present study was to compare bone geometry, volumetric bone mineral density (vBMD) and bone strength of femoral shaft in BP treated and BP naive postmenopausal women with RA.
   Methods: Prospective cross sectional pQCT scans were taken at 33 % of total femur of BP treated and BP naive RA patients. Bone parameters of the two groups were compared and correlated to disease characteristics and muscle cross sectional area (CSA).
   Results: A total of 60 consecutive postmenopausal RA patients, 20 with BP therapy and 40 BP naive, were included in the study. The median age of the subjects was 63.5 years (range 48 85 years), and median disease duration (RA) was 12.0 years (range 2 47 years). Height and weight of the patients of the two groups were comparable. Women in the BP group were on average 4.3 years older (p = 0.044), and duration since menopause was on average 5.76 years longer (p = 0.045). In the BP group, there was a 13.31 % reduced muscle cross sectional area around the proximal thigh (p = 0.013); cortical CSA was smaller by 5.3 % (p = 0.043); however, total and medullary CSA, as well as cortical vBMD and the polar bone stress strain index of the femoral shaft were similar in the two groups. In regression analysis, age, time since menopause and muscular CSA were significant factors determining cortical CSA, cortical thickness and femoral index (p < 0.05). Regression model showed no significant effect of BP therapy on bone geometry and density of the femoral diaphysis at 33 %.
   Conclusion: Differences in cortical CSA between BP treated and BP naive postmenopausal RA patients were found to be associated only with differences in age, time since menopause and muscle cross sectional area around the proximal thigh. In interpreting our results, it should be kept in mind that BP was given only to patients with increased fracture risk. This fact might have a confounding effect on our findings of differences between the two groups.
C1 [Meinen, Rahel; Galli Lysak, Inna; Villiger, Peter M.; Aeberli, Daniel] Univ Hosp Bern, Inselspital Bern, Dept Rheumatol Immunol & Allergol, Bern, Switzerland.
C3 University of Bern; University Hospital of Bern
RP Aeberli, D (通讯作者)，Univ Hosp Bern, Inselspital Bern, Dept Rheumatol Immunol & Allergol, Bern, Switzerland.
EM daniel.aeberli@insel.ch
RI Aeberli, Daniel/HKF 1343 2023; Villiger, Peter/AAV 8132 2021
FU Alfred and Anneliese Sutter Stottner Stiftung; Osteoporose Plattform;
   Novartis foundation for medical biological research
FX The study was financially supported by a research grants from the Alfred
   and Anneliese Sutter Stottner Stiftung, from the Osteoporose Plattform
   and from the Novartis foundation for medical biological research to DA.
CR Aeberli D, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4180
   Aeberli D, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3056
   Aletaha D, 2010, ANN RHEUM DIS, V69, P1580, DOI [10.1136/ard.2010.138461, 10.1002/art.27584]
   Allen MR, 2011, BONE, V49, P56, DOI 10.1016/j.bone.2010.10.159
   Bechtold S, 2005, OSTEOPOROSIS INT, V16, P757, DOI 10.1007/s00198 004 1747 6
   Zanchetta MB, 2014, J BONE MINER RES, V29, P999, DOI 10.1002/jbmr.2107
   Böttcher J, 2005, RHEUMATOL INT, V25, P457, DOI 10.1007/s00296 004 0560 z
   Bottcher Joachim, 2006, Int J Biomed Sci, V2, P241
   Chen F, 2014, BONE, V62, P64, DOI 10.1016/j.bone.2014.01.011
   Chen L, 2013, BMC GERIATR, V13, DOI 10.1186/1471 2318 13 74
   Eckstein F, 2004, ANN BIOMED ENG, V32, P487, DOI 10.1023/B:ABME.0000017543.20342.07
   Eser P, 2004, BONE, V34, P869, DOI 10.1016/j.bone.2004.01.001
   Eser P, 2011, ARTHRIT CARE RES, V63, P383, DOI 10.1002/acr.20394
   Eser P, 2010, RHEUMATOLOGY, V49, P977, DOI 10.1093/rheumatology/keq014
   Eser P, 2009, J BONE MINER RES, V24, P1981, DOI [10.1359/jbmr.090521, 10.1359/JBMR.090521]
   Felin EMO, 2007, ARTHRITIS RHEUM, V56, P984, DOI 10.1002/art.22420
   Frost H, 2004, UTHA PARADIGM SKELET, V1
   Grossman JM, 2010, ARTHRIT CARE RES, V62, P1515, DOI 10.1002/acr.20295
   Hagen JE, 2014, J BONE JOINT SURG AM, V96A, P1905, DOI 10.2106/JBJS.N.00075
   Hansen KE, 2011, J BONE MINER RES, V26, P1989, DOI 10.1002/jbmr.362
   Haugeberg G, 2003, CURR OPIN RHEUMATOL, V15, P469, DOI 10.1097/00002281 200307000 00016
   HORBER FF, 1986, KIDNEY INT, V30, P411, DOI 10.1038/ki.1986.199
   Kocijan R, 2014, J BONE MINER RES, V29, P1005, DOI 10.1002/jbmr.2109
   Lekamwasam S, 2012, OSTEOPOROSIS INT, V23, P2257, DOI 10.1007/s00198 012 1958 1
   Lochmüller EM, 2002, J BONE MINER RES, V17, P1629, DOI 10.1359/jbmr.2002.17.9.1629
   MacIntyre NJ, 2012, PHYSIOTHER CAN, V64, P284, DOI 10.3138/ptc.2011 22BH
   Martelli S, 2014, CLIN BIOMECH, V29, P869, DOI 10.1016/j.clinbiomech.2014.08.001
   PREVOO MLL, 1995, ARTHRITIS RHEUM, V38, P44, DOI 10.1002/art.1780380107
   Roth J, 2007, RHEUMATOLOGY, V46, P1180, DOI 10.1093/rheumatology/kem100
   Roth J, 2004, ARTHRITIS RHEUM US, V50, P1277, DOI 10.1002/art.20128
   Ruff C. B., 2005, Journal of Musculoskeletal & Neuronal Interactions, V5, P202
   Sasaki S, 2012, J BONE MINER METAB, V30, P561, DOI 10.1007/s00774 012 0358 0
   Schiessl H, 1996, INT CONGR SER, V1105, P141
   Schilcher J, 2011, NEW ENGL J MED, V364, P1728, DOI 10.1056/NEJMoa1010650
   Schoenau E, 2001, J CLIN ENDOCR METAB, V86, P613, DOI 10.1210/jcem.86.2.7186
   Seibel MJ, 2004, J BONE MINER RES, V19, P323, DOI 10.1359/JBMR.0301231
   Shane E, 2010, J BONE MINER RES, V25, P2267, DOI 10.1002/jbmr.253
   Shiomi K, 2014, J PHARM PHARMACOL, V66, P418, DOI 10.1111/jphp.12171
   Szulc P, 2006, J BONE MINER RES, V21, P1856, DOI 10.1359/JBMR.060904
   Taormina DP, 2014, BONE, V63, P1, DOI 10.1016/j.bone.2014.02.006
   Tournis S, 2012, J RHEUMATOL, V39, P1215, DOI 10.3899/jrheum.110579
   Uchiyama S, 2015, BONE, V75, P84, DOI 10.1016/j.bone.2015.02.018
   Zebaze R, 2015, J BONE MINER RES, V30, P24, DOI 10.1002/jbmr.2419
NR 43
TC 4
Z9 4
U1 0
U2 1
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471 2474
J9 BMC MUSCULOSKEL DIS
JI BMC Musculoskelet. Disord.
PD AUG 5
PY 2016
VL 17
AR 324
DI 10.1186/s12891 016 1167 8
PG 6
WC Orthopedics; Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics; Rheumatology
GA EM0NU
UT WOS:000395015800001
PM 27491286
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Sun, XC
   Wang, H
   Zhang, D
   Li, JH
   Yin, LQ
   Yan, YF
   Ma, X
   Xia, HF
AF Sun, Xue Cheng
   Wang, Hu
   Zhang, Dan
   Li, Jian Hui
   Yin, Li Qiang
   Yan, Yu Fang
   Ma, Xu
   Xia, Hong Fei
TI Combining Bone Collagen Matrix with hUC MSCs for Application to Alveolar
   Process Cleft in a Rabbit Model
SO STEM CELL REVIEWS AND REPORTS
LA English
DT Article
DE Alveolar process cleft; Bone collagen matrix; Young rabbit; hUC MSCs;
   Micro CT
ID MESENCHYMAL STEM CELLS; HUMAN UMBILICAL CORD; STROMAL CELLS; CRANIAL
   BONE; DEFECTS; REPAIR; DIFFERENTIATION; REGENERATION; APOPTOSIS; THERAPY
AB Background Most materials used clinically for filling severe bone defects either cannot induce bone re generation or exhibit low bone conversion, therefore, their therapeutic effects are limited. Human umbilical cord mesenchymal stem cells (hUC MSCs) exhibit good osteoinduction. However, the mechanism by which combining a heterogeneous bone collagen matrix with hUC MSCs to repair the bone defects of alveolar process clefts remains unclear.
   Methods A rabbit alveolar process cleft model was established by removing the bone tissue from the left maxillary bone. Forty eight young Japanese white rabbits (JWRs) were divided into normal, control, material and MSCs groups. An equal volume of a bone collagen matrix alone or combined with hUC MSCs was implanted in the defect. X ray, micro focus computerized tomography (micro CT), blood analysis, histochemical staining and TUNEL were used to detect the newly formed bone in the defect area at 3 and 6 months after the surgery.
   Results The bone formation rate obtained from the skull tissue in MSCs group was significantly higher than that in control group at 3 months (P < 0.01) and 6 months (P < 0.05) after the surgery. The apoptosis rate in the MSCs group was significantly higher at 3 months after the surgery (P < 0.05) and lower at 6 months after the surgery (P < 0.01) than those in the normal group.
   Conclusions Combining bone collagen matrix with hUC MSCs promoted the new bone regeneration in the rabbit alveolar process cleft model through promoting osteoblasts formations and chondrocyte growth, and inducing type I collagen formation and BMP 2 generation.
C1 [Sun, Xue Cheng; Wang, Hu; Zhang, Dan; Li, Jian Hui; Ma, Xu; Xia, Hong Fei] Natl Res Inst Family Planning, Reprod & Genet Ctr, Beijing 100081, Peoples R China.
   [Wang, Hu; Zhang, Dan; Li, Jian Hui; Ma, Xu; Xia, Hong Fei] Peking Union Med Coll, Grad Sch, Beijing 100730, Peoples R China.
   [Sun, Xue Cheng] Zibo Maternal & Child Hlth Hosp, Med Genet, Zibo 255000, Peoples R China.
   [Yin, Li Qiang; Yan, Yu Fang] Yantai Zhenghai Biotech Co Ltd, Yantai 264006, Shandong, Peoples R China.
   [Ma, Xu; Xia, Hong Fei] Natl Res Inst Family Planning, Genet Ctr, Beijing 100081, Peoples R China.
C3 National Research Institute for Family Planning   China; Chinese Academy
   of Medical Sciences   Peking Union Medical College; Peking Union Medical
   College; National Research Institute for Family Planning   China
RP Ma, X; Xia, HF (通讯作者)，Natl Res Inst Family Planning, Reprod & Genet Ctr, Beijing 100081, Peoples R China.; Ma, X; Xia, HF (通讯作者)，Peking Union Med Coll, Grad Sch, Beijing 100730, Peoples R China.; Ma, X; Xia, HF (通讯作者)，Natl Res Inst Family Planning, Genet Ctr, Beijing 100081, Peoples R China.
EM hongfeixia@126.com; gentic@263.net.cn
FU National Key Research and Development Program of China [2016YFC1000803]
FX This work was funded by grants from the National Key Research and
   Development Program of China (Grant No. 2016YFC1000803).
CR Al Asfour A, 2014, DENT TRAUMATOL, V30, P198, DOI 10.1111/edt.12066
   An JH, 2013, TISSUE ENG PT A, V19, P685, DOI [10.1089/ten.tea.2012.0047, 10.1089/ten.TEA.2012.0047]
   Baksh D, 2007, STEM CELLS, V25, P1384, DOI 10.1634/stemcells.2006 0709
   Barry FP, 2004, INT J BIOCHEM CELL B, V36, P568, DOI 10.1016/j.biocel.2003.11.001
   Clyne B, 1999, J EMERG MED, V17, P1019, DOI 10.1016/S0736 4679(99)00135 3
   COHEN M, 1991, PLAST RECONSTR SURG, V87, P423, DOI 10.1097/00006534 199103000 00004
   De Miguel MP, 2012, CURR MOL MED, V12, P574
   Ding DC, 2015, CELL TRANSPLANT, V24, P339, DOI 10.3727/096368915X686841
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   ESTEBAN JM, 1994, AM J CLIN PATHOL, V102, P158, DOI 10.1093/ajcp/102.2.158
   Fu Jiang C, 2009, CHINESE MED J PEKING, V122, P225, DOI 10.3760/cma.j.issn.0366 6999.2009.02.021
   Gallego L, 2010, TISSUE ENG PT A, V16, P1179, DOI [10.1089/ten.tea.2009.0517, 10.1089/ten.TEA.2009.0517]
   Gimbel M, 2007, J CRANIOFAC SURG, V18, P895, DOI 10.1097/scs.0b013e3180a771af
   Gurtner GC, 2008, NATURE, V453, P314, DOI 10.1038/nature07039
   Hammerle CHF, 1998, CLIN ORAL IMPLAN RES, V9, P151, DOI 10.1034/j.1600 0501.1998.090302.x
   Hollinger JO, 1998, J BIOMED MATER RES, V43, P356, DOI 10.1002/(SICI)1097 4636(199824)43:4<356::AID JBM3>3.0.CO;2 7
   Jahanbin A, 2016, J ORAL MAXIL SURG, V74, DOI 10.1016/j.joms.2015.11.033
   Jin YZ, 2018, CLIN ORTHOP SURG, V10, P271, DOI 10.4055/cios.2018.10.3.271
   Kandalam U, 2021, TISSUE ENG PT A, V27, P424, DOI [10.1089/ten.tea.2020.0052, 10.1089/ten.TEA.2020.0052]
   Kinnaird T, 2004, CIRCULATION, V109, P1543, DOI 10.1161/01.CIR.0000124062.31102.57
   Korn P, 2017, CLIN ORAL INVEST, V21, P2521, DOI 10.1007/s00784 017 2050 1
   Kotobuki N, 2008, CELL TRANSPLANT, V17, P705, DOI 10.3727/096368908786092793
   Kugimiya F, 2005, J BIOL CHEM, V280, P35704, DOI 10.1074/jbc.M505166200
   LAROSSA D, 1995, PLAST RECONSTR SURG, V96, P789, DOI 10.1097/00006534 199509001 00004
   Lee JS, 2010, J CLIN PERIODONTOL, V37, P382, DOI 10.1111/j.1600 051X.2010.01544.x
   Li YC, 2020, TOXICOL LETT, V321, P12, DOI 10.1016/j.toxlet.2019.12.011
   Linero I, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107001
   Liu SY, 2014, J BIOSCI BIOENG, V117, P229, DOI 10.1016/j.jbiosc.2013.07.001
   Liu Y, 2008, STEM CELLS, V26, P1065, DOI 10.1634/stemcells.2007 0734
   Pellicciari C, 1996, EXP CELL RES, V229, P370, DOI 10.1006/excr.1996.0382
   Rosenthal RK, 1999, CLIN ORTHOP RELAT R, P61
   Schlagheck ML, 2020, EUR J HAEMATOL, V105, P75, DOI 10.1111/ejh.13412
   SCHMITZ JP, 1986, CLIN ORTHOP RELAT R, P299, DOI 10.1097/00003086 198604000 00036
   Smith BT, 2017, ACTA BIOMATER, V50, P68, DOI 10.1016/j.actbio.2016.12.024
   Stepan J, 1974, Cas Lek Cesk, V113, P952
   Su RC, 2020, CHEMOSPHERE, V257, DOI 10.1016/j.chemosphere.2020.127111
   Sun XC, 2019, INT J PEDIATR OTORHI, V124, P164, DOI 10.1016/j.ijporl.2019.05.002
   Tai CCE, 2000, J ORAL MAXIL SURG, V58, P1241, DOI 10.1053/joms.2000.16623
   Takamoto N, 1998, CONNECT TISSUE RES, V37, P163, DOI 10.3109/03008209809002436
   Takushima A, 1998, J SURG RES, V78, P68, DOI 10.1006/jsre.1998.5378
   Tassi SA, 2017, J PERIODONTAL RES, V52, P793, DOI 10.1111/jre.12455
   Tilly JL, 1997, CELL DEATH DIFFER, V4, P180, DOI 10.1038/sj.cdd.4400238
   Toyota A, 2021, CELL TRANSPLANT, V30, DOI 10.1177/0963689720975391
   Wang LM, 2009, TISSUE ENG PT A, V15, P2259, DOI 10.1089/ten.tea.2008.0393
   Wang N, 2018, J TISSUE ENG REGEN M, V12, pE1154, DOI 10.1002/term.2450
   Wang Q, 2011, BONE, V48, P524, DOI 10.1016/j.bone.2010.10.178
   Xavier LL, 2005, BRAIN RES PROTOC, V16, P58, DOI 10.1016/j.brainresprot.2005.10.002
   Xu Y, 2010, STEM CELLS DEV, V19, P1511, DOI 10.1089/scd.2009.0321
   Zhang L, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 0777 5
NR 49
TC 2
Z9 2
U1 0
U2 14
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 2629 3269
EI 2629 3277
J9 STEM CELL REV REP
JI Stem Cell Rev. Rep.
PD JAN
PY 2023
VL 19
IS 1
BP 133
EP 154
DI 10.1007/s12015 021 10221 y
EA AUG 2021
PG 22
WC Cell & Tissue Engineering; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA 7R6SM
UT WOS:000687111700002
PM 34420159
OA Green Submitted
DA 2025 08 17
ER

PT J
AU Grotheer, V
   Skrynecki, N
   Oezel, L
   Grassmann, J
   Windolf, J
   Suschek, C
AF Grotheer, Vera
   Skrynecki, Nadine
   Oezel, Lisa
   Grassmann, Jan
   Windolf, Joachim
   Suschek, Christoph, V
TI Osteogenic differentiation of human mesenchymal stromal cells and
   fibroblasts differs depending on tissue origin and replicative
   senescence
SO SCIENTIFIC REPORTS
LA English
DT Article
ID PULP STEM CELLS; BONE MORPHOGENETIC PROTEIN 2; HUMAN ADIPOSE TISSUE;
   HUMAN DENTAL PULP; TGF BETA; TRANSCRIPTION FACTOR; OSTEOBLAST
   DIFFERENTIATION; MARROW; REGENERATION; INHIBITION
AB The need for an autologous cell source for bone tissue engineering and medical applications has led researchers to explore multipotent mesenchymal stromal cells (MSC), which show stem cell plasticity, in various human tissues. However, MSC with different tissue origins vary in their biological properties and their capability for osteogenic differentiation. Furthermore, MSC based therapies require large scale ex vivo expansion, accompanied by cell type specific replicative senescence, which affects osteogenic differentiation. To elucidate cell type specific differences in the osteogenic differentiation potential and replicative senescence, we analysed the impact of BMP and TGF beta signaling in adipose derived stromal cells (ASC), fibroblasts (FB), and dental pulp stromal cells (DSC). We used inhibitors of BMP and TGF beta signaling, such as SB431542, dorsomorphin and/or a supplemental addition of BMP 2. The expression of high affinity binding receptors for BMP 2 and calcium deposition with alizarin red S were evaluated to assess osteogenic differentiation potential. Our study demonstrated that TGF beta signaling inhibits osteogenic differentiation of ASC, DSC and FB in the early cell culture passages. Moreover, DSC had the best osteogenic differentiation potential and an activation of BMP signaling with BMP 2 could further enhance this capacity. This phenomenon is likely due to an increased expression of activin receptor like kinase 3 and  6. However, in DSC with replicative senescence (in cell culture passage 10), osteogenic differentiation sharply decreased, and the simultaneous use of BMP 2 and SB431542 did not result in further improvement of this process. In comparison, ASC retain a similar osteogenic differentiation potential regardless of whether they were in the early (cell culture passage 3) or later (cell culture passage 10) stages. Our study elucidated that ASC, DSC, and FB vary functionally in their osteogenic differentiation, depending on their tissue origin and replicative senescence. Therefore, our study provides important insights for cell based therapies to optimize prospective bone tissue engineering strategies.
C1 [Grotheer, Vera; Skrynecki, Nadine; Oezel, Lisa; Grassmann, Jan; Windolf, Joachim; Suschek, Christoph, V] Heinrich Heine Univ, Med Fac, Clin Orthoped & Trauma Surg, Moorenstr 5, D 40225 Dusseldorf, Germany.
C3 Heinrich Heine University Dusseldorf
RP Grotheer, V (通讯作者)，Heinrich Heine Univ, Med Fac, Clin Orthoped & Trauma Surg, Moorenstr 5, D 40225 Dusseldorf, Germany.
EM vera.grotheer@med.uni duesseldorf.de
RI Windolf, Joachim/JCD 9752 2023; Grotheer, Vera/NDT 5315 2025
FU Umea University
FX Open access funding provided by Umea University.
CR Abbo O, 2017, CYTOTHERAPY, V19, P395, DOI 10.1016/j.jcyt.2016.11.012
   Abdal Wahab M, 2020, J PERIODONTAL RES, V55, P441, DOI 10.1111/jre.12728
   Acosta JC, 2013, NAT CELL BIOL, V15, P978, DOI 10.1038/ncb2784
   Alonso N, 2010, TISSUE ENG PART C ME, V16, P1183, DOI 10.1089/ten.TEC.2009.0824
   Ananian CE, 2018, WOUND REPAIR REGEN, V26, P274, DOI 10.1111/wrr.12645
   Ashraf S, 2016, OSTEOARTHR CARTILAGE, V24, P196, DOI 10.1016/j.joca.2015.07.008
   Bainbridge P, 2013, J WOUND CARE, V22, P407
   Bartsch G Jr, 2005, STEM CELLS DEV, V14, P337, DOI 10.1089/scd.2005.14.337
   Bayraktar S., 2016, J TISSUE ENG REGEN M, V12, P144
   Beane OS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115963
   Cancedda R, 2007, BIOMATERIALS, V28, P4240, DOI 10.1016/j.biomaterials.2007.06.023
   Caruana G, 2015, ANN ITAL CHIR, V86, P1
   Chalisserry EP, 2017, J TISSUE ENG, V8, DOI 10.1177/2041731417702531
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Cheng NC, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.558354
   Cui XL, 2019, MOL MED REP, V19, P5053, DOI 10.3892/mmr.2019.10209
   D'Alimonte I, 2017, STEM CELLS DEV, V26, P843, DOI 10.1089/scd.2016.0190
   DAHL LK, 1952, P SOC EXP BIOL MED, V80, P474, DOI 10.3181/00379727 80 19661
   Dickinson BP, 2008, PLAST RECONSTR SURG, V121, P209, DOI 10.1097/01.prs.0000293870.64781.12
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Elahi KC, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/5646384
   Elshabrawy HA, 2015, ANGIOGENESIS, V18, P433, DOI 10.1007/s10456 015 9477 2
   Fillingham Y, 2016, BONE JOINT J, V98B, P6, DOI [10.1302/0301 620X.98B1.36350, 10.1302/0301 620X.98B.36350]
   Franceschi RT, 2003, J CELL BIOCHEM, V88, P446, DOI 10.1002/jcb.10369
   Fraser JK, 2006, TRENDS BIOTECHNOL, V24, P150, DOI 10.1016/j.tibtech.2006.01.010
   Freitag J, 2019, REGEN MED, V14, P213, DOI 10.2217/rme 2018 0161
   FRIEDENSTEIN AJ, 1968, TRANSPLANTATION, V6, P230, DOI 10.1097/00007890 196803000 00009
   Gerstenfeld LC, 2003, J CELL BIOCHEM, V88, P873, DOI 10.1002/jcb.10435
   Gilda JE, 2013, ANAL BIOCHEM, V440, P186, DOI 10.1016/j.ab.2013.05.027
   Götherström C, 2014, STEM CELL TRANSL MED, V3, P255, DOI 10.5966/sctm.2013 0090
   Gregory CA, 2004, ANAL BIOCHEM, V329, P77, DOI 10.1016/j.ab.2004.02.002
   Gronthos S, 2000, P NATL ACAD SCI USA, V97, P13625, DOI 10.1073/pnas.240309797
   Hinz B, 2007, J INVEST DERMATOL, V127, P526, DOI 10.1038/sj.jid.5700613
   Hrubi E, 2018, HUM CELL, V31, P139, DOI 10.1007/s13577 018 0202 5
   Huang AH, 2010, J BIOMECH, V43, P128, DOI 10.1016/j.jbiomech.2009.09.018
   Huang HI, 2010, TISSUE ENG PT A, V16, P1491, DOI 10.1089/ten.TEA.2009.0431
   Ikeda H, 2011, ANN BIOMED ENG, V39, P26, DOI 10.1007/s10439 010 0115 2
   Jacobs FA, 2016, FRONT ENDOCRINOL, V7, DOI 10.3389/fendo.2016.00108
   Jaiswal N, 1997, J CELL BIOCHEM, V64, P295, DOI 10.1002/(SICI)1097 4644(199702)64:2<295::AID JCB12>3.3.CO;2 6
   Javed A, 2009, CELLS TISSUES ORGANS, V189, P133, DOI 10.1159/000151719
   Junker JPE, 2010, CELLS TISSUES ORGANS, V191, P105, DOI 10.1159/000232157
   Kawamura H, 2018, STEM CELL REP, V10, P920, DOI 10.1016/j.stemcr.2018.01.030
   Kugimiya F, 2005, J BIOL CHEM, V280, P35704, DOI 10.1074/jbc.M505166200
   Lee KS, 2000, MOL CELL BIOL, V20, P8783, DOI 10.1128/MCB.20.23.8783 8792.2000
   Lee UL, 2011, REGEN MED, V6, P67, DOI 10.2217/RME.10.96
   Lin SX, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.5
   Liu RJ, 2009, BMC MUSCULOSKEL DIS, V10, DOI 10.1186/1471 2474 10 51
   Luong LN, 2012, BIOMATERIALS, V33, P283, DOI 10.1016/j.biomaterials.2011.09.052
   Maeda K, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20225525
   Maeda S, 2004, EMBO J, V23, P552, DOI 10.1038/sj.emboj.7600067
   Marcellini S, 2012, BIOESSAYS, V34, P953, DOI 10.1002/bies.201200061
   Mattioli Belmonte M, 2015, FRONT PHYSIOL, V6, DOI 10.3389/fphys.2015.00266
   Mbalaviele G, 2005, J CELL BIOCHEM, V94, P403, DOI 10.1002/jcb.20253
   Mehrazarin S, 2011, J ENDODONT, V37, P662, DOI 10.1016/j.joen.2011.02.009
   Nakashima M, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287 017 0506 5
   Nakayama H, 2017, ORAL DIS, V23, P620, DOI 10.1111/odi.12619
   Oh J, 2014, NAT MED, V20, P870, DOI 10.1038/nm.3651
   Oner A, 2018, CELL REPROGRAM, V20, P329, DOI 10.1089/cell.2018.0045
   Panés J, 2016, LANCET, V388, P1281, DOI 10.1016/S0140 6736(16)31203 X
   Patel M, 2009, ARCH ORAL BIOL, V54, P898, DOI 10.1016/j.archoralbio.2009.06.008
   Peranteau WH, 2006, BLOOD, V108, P4268, DOI 10.1182/blood 2006 04 018986
   Phinney DG, 1999, J CELL BIOCHEM, V75, P424, DOI 10.1002/(SICI)1097 4644(19991201)75:3<424::AID JCB8>3.0.CO;2 8
   Piva E, 2017, J ENDODONT, V43, P568, DOI 10.1016/j.joen.2016.11.018
   Quarto N, 2012, STEM CELLS, V30, P2709, DOI 10.1002/stem.1250
   Rawadi G, 2003, J BONE MINER RES, V18, P1842, DOI 10.1359/jbmr.2003.18.10.1842
   Requicha JF, 2012, STEM CELL REV REP, V8, P1211, DOI 10.1007/s12015 012 9397 0
   Ringdén O, 2006, TRANSPLANTATION, V81, P1390, DOI 10.1097/01.tp.0000214462.63943.14
   Rohart F, 2016, PEERJ, V4, DOI 10.7717/peerj.1845
   Sakaguchi Y, 2005, ARTHRITIS RHEUM US, V52, P2521, DOI 10.1002/art.21212
   Sinha KM, 2013, J CELL BIOCHEM, V114, P975, DOI 10.1002/jcb.24439
   Sommar P, 2010, J PLAST RECONSTR AES, V63, P1036, DOI 10.1016/j.bjps.2009.02.072
   Strioga M, 2012, STEM CELLS DEV, V21, P2724, DOI 10.1089/scd.2011.0722
   Thakkar UG, 2015, CYTOTHERAPY, V17, P940, DOI 10.1016/j.jcyt.2015.03.608
   Tigges J, 2014, MECH AGEING DEV, V138, P26, DOI 10.1016/j.mad.2014.03.004
   Tofiño Vian M, 2018, CELL PHYSIOL BIOCHEM, V47, P11, DOI 10.1159/000489739
   Van Linthout S, 2014, CARDIOVASC RES, V102, P258, DOI 10.1093/cvr/cvu062
   Wagner W, 2008, CELLS TISSUES ORGANS, V188, P160, DOI 10.1159/000112821
   Walenda G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077656
   Whittard JD, 2001, EXP CELL RES, V263, P65, DOI 10.1006/excr.2000.5099
   Wu MR, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.9
   Yue B, 2005, CALCIFIED TISSUE INT, V77, P395, DOI 10.1007/s00223 005 0180 y
   Yui PB, 2008, NAT CHEM BIOL, V4, P33, DOI 10.1038/nchembio.2007.54
   Zhang C, 2008, P NATL ACAD SCI USA, V105, P6936, DOI 10.1073/pnas.0710831105
   Zhang C, 2010, J ORTHOP SURG RES, V5, DOI 10.1186/1749 799X 5 37
   Zuk PA, 2002, MOL BIOL CELL, V13, P4279, DOI 10.1091/mbc.E02 02 0105
   Zuk P, 2011, CONNECT TISSUE RES, V52, P119, DOI 10.3109/03008207.2010.484515
NR 86
TC 30
Z9 30
U1 0
U2 9
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD JUN 7
PY 2021
VL 11
IS 1
AR 11968
DI 10.1038/s41598 021 91501 y
PG 17
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA SU1BR
UT WOS:000662876200005
PM 34099837
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Schmid, VB
   Seewald, W
   Lees, P
   King, JN
AF Schmid, V. B.
   Seewald, W.
   Lees, P.
   King, J. N.
TI In vitro and ex vivo inhibition of COX isoforms by
   robenacoxib in the cat: a comparative study
SO JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS
LA English
DT Article
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; CYCLOOXYGENASE INHIBITORS;
   DIFFERENTIAL INHIBITION; PAIN MANAGEMENT; OSTEOARTHRITIS;
   PHARMACOKINETICS; BLOOD; DOGS; PHARMACODYNAMICS; TOLERABILITY
AB Robenacoxib is a novel nonsteroidal anti inflammatory drug (NSAID) developed for use in companion animals. Whole blood assays were used to characterize in the cat the pharmacodynamics of robenacoxib for inhibition of the cyclooxygenase (COX) isoforms, COX 1 and COX 2, in comparison with other NSAIDs. Based on in vitro IC(50)COX 1:IC(50)COX 2 ratios, robenacoxib was COX 2 selective (ratio = 32.2), diclofenac (ratio = 3.9) and meloxicam (ratio = 2.7) were only weakly COX 2 preferential, and ketoprofen (ratio = 0.049) was COX 1 selective. In an in vivo pharmacokinetic ex vivo pharmacodynamic study, after both p.o. (1 2 mg/kg) and subcutaneous (2 mg/kg) dosing, robenacoxib achieved peak blood concentrations rapidly (T(max) = 1 h for both administration routes) and was cleared from blood relatively rapidly (mean residence time was 1.70 h after p.o. and 1.79 h after subcutaneous dosing). In ex vivo COX isoform inhibition assays, orally (1 2 mg/kg) or subcutaneously (2 mg/kg) administered robenacoxib significantly inhibited COX 2, with a relatively short duration of action in the central compartment, and had no effect on COX 1. Therefore robenacoxib was COX 2 selective and spared COX 1 in vivo. In contrast, meloxicam (0.3 mg/kg via subcutaneous injection) inhibited both COX 1 and COX 2 isoforms significantly for at least 24 h, indicating nonselectivity in vivo.
C1 [Schmid, V. B.] Novartis Ctr Rech Sante Anim SA, CH 1566 St Aubin, Switzerland.
   [Seewald, W.; King, J. N.] Novartis Anim Hlth Inc, Basel, Switzerland.
   [Lees, P.] Royal Vet Coll, Hatfield, Herts, England.
C3 Novartis; Novartis; University of London; University of London Royal
   Veterinary College
RP Schmid, VB (通讯作者)，Novartis Ctr Rech Sante Anim SA, CH 1566 St Aubin, Switzerland.
EM vincent.schmid@novartis.com
OI lees, peter/0000 0002 8966 3737
CR Brune K, 2007, RHEUMATOLOGY, V46, P911, DOI 10.1093/rheumatology/kem070
   Duncan B, 2007, VET ANAESTH ANALG, V34, P228, DOI 10.1111/j.1467 2995.2006.00322.x
   Gierse James K, 2002, Vet Ther, V3, P270
   Giraudel JM, 2009, J VET PHARMACOL THER, V32, P31, DOI 10.1111/j.1365 2885.2008.01031.x
   Giraudel JM, 2005, AM J VET RES, V66, P700, DOI 10.2460/ajvr.2005.66.700
   Hanson PD, 2006, VET THER, V7, P127
   Jung M, 2009, J VET PHARMACOL THER, V32, P41, DOI 10.1111/j.1365 2885.2008.01035.x
   King JN, 2009, J VET PHARMACOL THER, V32, P1, DOI 10.1111/j.1365 2885.2008.00962.x
   KING JN, 2010, RES VET SCI IN PRESS
   Lees P, 2004, J VET PHARMACOL THER, V27, P479, DOI 10.1111/j.1365 2885.2004.00617.x
   Lees P, 2003, VET J, V165, P21, DOI 10.1016/S1090 0233(02)00168 5
   Lees Peter, 2003, Inflammopharmacology, V11, P385, DOI 10.1163/156856003322699564
   MASFERRER JL, 1994, P NATL ACAD SCI USA, V91, P3228, DOI 10.1073/pnas.91.8.3228
   McCann ME, 2004, AM J VET RES, V65, P503, DOI 10.2460/ajvr.2004.65.503
   Millis Darryl L, 2002, Vet Ther, V3, P453
   Pairet M, 1998, INFLAMM RES, V47, pS93
   Pairet M, 1996, FUND CLIN PHARMACOL, V10, P1, DOI 10.1111/j.1472 8206.1996.tb00144.x
   PATRIGNANI P, 1994, J PHARMACOL EXP THER, V271, P1705
   Pollmeier M, 2006, VET REC, V159, P547, DOI 10.1136/vr.159.17.547
   Robertson SA, 2005, VET CLIN N AM SMALL, V35, P129, DOI 10.1016/j.cvsm.2004.08.001
   Robertson SA, 2004, J FELINE MED SURG, V6, P321, DOI 10.1016/j.jfms.2003.10.002
   Schnitzer TJ, 2004, LANCET, V364, P665, DOI 10.1016/S0140 6736(04)16893 1
   Sessions JK, 2005, AM J VET RES, V66, P812, DOI 10.2460/ajvr.2005.66.812
   Taylor PM, 2004, J FELINE MED SURG, V6, P313, DOI 10.1016/j.jfms.2003.10.003
   Warner TD, 1999, P NATL ACAD SCI USA, V96, P7563, DOI 10.1073/pnas.96.13.7563
   Watson DJ, 2000, ARCH INTERN MED, V160, P2998, DOI 10.1001/archinte.160.19.2998
   Young JM, 1996, INFLAMM RES, V45, P246, DOI 10.1007/BF02259611
NR 27
TC 28
Z9 28
U1 1
U2 10
PU WILEY BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0140 7783
J9 J VET PHARMACOL THER
JI J. Vet. Pharmacol. Ther.
PD OCT
PY 2010
VL 33
IS 5
BP 444
EP 452
DI 10.1111/j.1365 2885.2010.01166.x
PG 9
WC Pharmacology & Pharmacy; Veterinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy; Veterinary Sciences
GA 650ED
UT WOS:000281831100007
PM 20840388
OA Green Published
DA 2025 08 17
ER

PT J
AU Kato, Y
   Hiasa, M
   Ichikawa, R
   Hasuzawa, N
   Kadowaki, A
   Iwatsuki, K
   Shima, K
   Endo, Y
   Kitahara, Y
   Inoue, T
   Nomura, M
   Omote, H
   Moriyama, Y
   Miyaji, T
AF Kato, Yuri
   Hiasa, Miki
   Ichikawa, Reiko
   Hasuzawa, Nao
   Kadowaki, Atsushi
   Iwatsuki, Ken
   Shima, Kazuhiro
   Endo, Yasuo
   Kitahara, Yoshiro
   Inoue, Tsuyoshi
   Nomura, Masatoshi
   Omote, Hiroshi
   Moriyama, Yoshinori
   Miyaji, Takaaki
TI Identification of a vesicular ATP release inhibitor for the treatment of
   neuropathic and inflammatory pain
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE vesicular nucleotide transporter; purinergic chemical transmission;
   analgesic effect; antiinflammatory effect; clodronate
ID NUCLEOTIDE TRANSPORTER; BISPHOSPHONATES; MECHANISMS; MICROGLIA;
   CLODRONATE; IMMUNE; BONE; EXOCYTOSIS; MANAGEMENT; DISORDERS
AB Despite the high incidence of neuropathic and inflammatory pain worldwide, effective drugs with few side effects are currently unavailable for the treatment of chronic pain. Recently, researchers have proposed that inhibitors of purinergic chemical transmission, which plays a key role in the pathological pain response, may allow for targeted treatment of pathological neuropathic and inflammatory pain. However, such therapeutic analgesic agents have yet to be developed. In the present study, we demonstrated that clodronate, a first generation bisphosphonate with comparatively fewer side effects than traditional treatments, significantly attenuates neuropathic and inflammatory pain unrelated to bone abnormalities via inhibition of vesicular nucleotide transporter (VNUT), a key molecule for the initiation of purinergic chemical transmission. In vitro analyses indicated that clodronate inhibits VNUT at a half maximal inhibitory concentration of 15.6 nM without affecting other vesicular neurotransmitter transporters, acting as an allosteric modulator through competition with Cl . A low concentration of clodronate impaired vesicular ATP release from neurons, microglia, and immune cells. In vivo analyses revealed that clodronate is more effective than other therapeutic agents in attenuating neuropathic and inflammatory pain, as well as the accompanying inflammation, in wild type but not VNUT /  mice, without affecting basal nociception. These findings indicate that clodronate may represent a unique treatment strategy for chronic neuropathic and inflammatory pain via inhibition of vesicular ATP release.
C1 [Kato, Yuri; Moriyama, Yoshinori; Miyaji, Takaaki] Okayama Univ, Adv Sci Res Ctr, Okayama 7008530, Japan.
   [Kato, Yuri; Hiasa, Miki; Omote, Hiroshi; Moriyama, Yoshinori] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Membrane Biochem, Okayama 7008530, Japan.
   [Ichikawa, Reiko; Iwatsuki, Ken; Kitahara, Yoshiro] Ajinomoto Co Inc, Inst Innovat, Kawasaki, Kanagawa 2105893, Japan.
   [Hasuzawa, Nao] Kyushu Univ, Grad Sch Med Sci, Dept Med & Bioregulatory Sci, Fukuoka 8128582, Japan.
   [Kadowaki, Atsushi; Inoue, Tsuyoshi] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Biophys Chem, Okayama 7008530, Japan.
   [Iwatsuki, Ken] Tokyo Univ Agr, Dept Nutr Sci & Food Safety, Tokyo 1568502, Japan.
   [Shima, Kazuhiro; Endo, Yasuo] Tohoku Univ, Grad Sch Dent, Div Oral Mol Regulat, Sendai, Miyagi 9808575, Japan.
   [Moriyama, Yoshinori] Matsumoto Dent Univ, Dept Biochem, Siojiri 3990781, Japan.
C3 Okayama University; Okayama University; Ajinomoto Co Inc; Kyushu
   University; Okayama University; Tokyo University of Agriculture; Tohoku
   University; Matsumoto Dental University
RP Moriyama, Y; Miyaji, T (通讯作者)，Okayama Univ, Adv Sci Res Ctr, Okayama 7008530, Japan.; Moriyama, Y (通讯作者)，Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Membrane Biochem, Okayama 7008530, Japan.; Moriyama, Y (通讯作者)，Matsumoto Dent Univ, Dept Biochem, Siojiri 3990781, Japan.
EM pineal13@yahoo.co.jp; miyaji t@okayama u.ac.jp
RI ; INOUE, Tsuyoshi/B 1604 2011; OMOTE, Hiroshi/B 1635 2011; Moriyama,
   Yoshinori/ABG 5483 2021
OI Miyaji, Takaaki/0000 0002 7257 7621; Omote, Hiroshi/0000 0002 9385 4667
FU Advanced Research and Development Programs for Medical Innovation of the
   Japan Agency for Medical Research and Development; Astellas Foundation
   for Research on Metabolic Disorders; Salt Science Foundation [1554];
   Smoking Research Foundation; Takeda Science Foundation;  [26893154]; 
   [25253008];  [26460067]; Grants in Aid for Scientific Research
   [17K17306, 16K11672, 16K08230] Funding Source: KAKEN
FX We thank Prof. M. Tominaga, Dr. H. Furue, and Dr. Y. Takayama (National
   Institute for Physiological Sciences, Okazaki, Japan); Prof. N. Nelson
   (Tel Aviv University, Tel Aviv, Israel); Dr. S. Sakamoto (Kyushu
   University, Japan); Dr. N. Juge, Dr. K. Sawada, Mr. S. Itano, and Mr. T.
   Sekiya (Okayama University, Japan); and the Central Research Laboratory
   at the Medical School and Advanced Science Research Center, Okayama
   University, Japan, for their help in this study. This work was
   supported, in part, by a Grant in Aid for Research Activity Start up
   (Grant 26893154 to Y. K.); a Grant in Aid for Scientific Research (A)
   (Grant 25253008 to Y. M.); and the Advanced Research and Development
   Programs for Medical Innovation of the Japan Agency for Medical Research
   and Development (T. M.), a Grant in Aid for Scientific Research (C)
   (Grant 26460067 to T. M.), the Astellas Foundation for Research on
   Metabolic Disorders (T. M.), the Salt Science Foundation (Grant 1554 to
   T. M.), the Smoking Research Foundation (T.M.), and the Takeda Science
   Foundation (T.M.).
CR BANKER GA, 1977, BRAIN RES, V126, P397, DOI 10.1016/0006 8993(77)90594 7
   Brunner F, 2009, EUR J PAIN, V13, P17, DOI 10.1016/j.ejpain.2008.03.005
   Burnstock G, 2008, NAT REV DRUG DISCOV, V7, P575, DOI 10.1038/nrd2605
   Cao Q, 2014, J BIOL CHEM, V289, P23189, DOI 10.1074/jbc.M114.567107
   Cekic C, 2016, NAT REV IMMUNOL, V16, P177, DOI 10.1038/nri.2016.4
   Costa L, 2009, NAT CLIN PRACT ONCOL, V6, P163, DOI 10.1038/ncponc1323
   DIXON WJ, 1980, ANNU REV PHARMACOL, V20, P441, DOI 10.1146/annurev.pa.20.040180.002301
   Dominguez LJ, 2011, BIOGERONTOLOGY, V12, P397, DOI 10.1007/s10522 011 9344 5
   Dworkin RH, 2003, ARCH NEUROL CHICAGO, V60, P1524, DOI 10.1001/archneur.60.11.1524
   Forster IC, 2013, MOL ASPECTS MED, V34, P386, DOI 10.1016/j.mam.2012.07.007
   Gerstein HC, 2008, NEW ENGL J MED, V358, P2545, DOI 10.1056/NEJMoa0802743
   Gold MS, 2010, NAT MED, V16, P1248, DOI 10.1038/nm.2235
   Harirforoosh S, 2013, J PHARM PHARM SCI, V16, P821, DOI 10.18433/J3VW2F
   Hiasa M, 2014, PHYSIOL REP, V2, DOI 10.14814/phy2.12034
   Imura Y, 2013, GLIA, V61, P1320, DOI 10.1002/glia.22517
   Jensen TS, 2009, CURR OPIN NEUROL, V22, P467, DOI 10.1097/WCO.0b013e3283311e13
   Juge N, 2010, NEURON, V68, P99, DOI 10.1016/j.neuron.2010.09.002
   Jung J, 2013, BIOCHEM BIOPH RES CO, V430, P488, DOI 10.1016/j.bbrc.2012.12.009
   Kato Y, 2013, BIOL PHARM BULL, V36, P1688
   Kim S, 2013, EUR J PHARMACOL, V699, P14, DOI 10.1016/j.ejphar.2012.11.031
   Kumamaru H, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742 2094 9 116
   Larsson M, 2012, CEREB CORTEX, V22, P1203, DOI 10.1093/cercor/bhr203
   Leviatan S, 2010, J BIOL CHEM, V285, P23548, DOI 10.1074/jbc.M110.125492
   Marchand F, 2005, NAT REV NEUROSCI, V6, P521, DOI 10.1038/nrn1700
   Masuda T, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12529
   Miyaji T, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms6928
   Miyaji T, 2011, J BIOL CHEM, V286, P42881, DOI 10.1074/jbc.M111.277269
   Muratore M, 2011, DRUG DES DEV THER, V5, P445, DOI 10.2147/DDDT.S12139
   Nishida K, 2014, NEUROSCI LETT, V579, P75, DOI 10.1016/j.neulet.2014.07.017
   Oya M, 2013, BIOCHEM BIOPH RES CO, V438, P145, DOI 10.1016/j.bbrc.2013.07.043
   Pazianas M, 2011, BONE, V49, P103, DOI 10.1016/j.bone.2011.01.003
   Porreca F, 2009, PAIN MED, V10, P654, DOI 10.1111/j.1526 4637.2009.00583.x
   Ren K, 2010, NAT MED, V16, P1267, DOI 10.1038/nm.2234
   Rogers MJ, 2011, BONE, V49, P34, DOI 10.1016/j.bone.2010.11.008
   Rogers MJ, 1996, J BONE MINER RES, V11, P1482
   SAHNI M, 1993, J CLIN INVEST, V91, P2004, DOI 10.1172/JCI116422
   Sakaki H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059778
   Sakamoto S, 2014, SCI REP UK, V4, DOI 10.1038/srep06689
   Sawada K, 2008, P NATL ACAD SCI USA, V105, P5683, DOI 10.1073/pnas.0800141105
   Schäcke H, 2002, PHARMACOL THERAPEUT, V96, P23, DOI 10.1016/S0163 7258(02)00297 8
   SELTZER Z, 1990, PAIN, V43, P205, DOI 10.1016/0304 3959(90)91074 S
   Shimada Shimizu N, 2013, FEBS J, V280, P1430, DOI 10.1111/febs.12138
   Shinozaki Y, 2014, SCI REP UK, V4, DOI 10.1038/srep04329
   Tokunaga A, 2010, J BIOL CHEM, V285, P17406, DOI 10.1074/jbc.M110.112417
   Tsuda M, 2005, TRENDS NEUROSCI, V28, P101, DOI 10.1016/j.tins.2004.12.002
   Woolf CJ, 2009, CELL, V137, P987, DOI 10.1016/j.cell.2009.05.033
   Xu ZZ, 2010, NAT MED, V16, P592, DOI 10.1038/nm.2123
NR 47
TC 90
Z9 93
U1 0
U2 6
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027 8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD AUG 1
PY 2017
VL 114
IS 31
BP E6297
EP E6305
DI 10.1073/pnas.1704847114
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA FC2FR
UT WOS:000406653300007
PM 28720702
OA Green Published
DA 2025 08 17
ER

PT J
AU Nabeshima, A
   Pajarinen, J
   Lin, TH
   Jiang, XY
   Gibon, E
   Córdova, LA
   Loi, F
   Lu, L
   Jämsen, E
   Egashira, K
   Yang, F
   Yao, ZY
   Goodman, SB
AF Nabeshima, Akira
   Pajarinen, Jukka
   Lin, Tzu hua
   Jiang, Xinyi
   Gibon, Emmanuel
   Cordova, Luis A.
   Loi, Florence
   Lu, Laura
   Jamsen, Eemeli
   Egashira, Kensuke
   Yang, Fan
   Yao, Zhenyu
   Goodman, Stuart B.
TI Mutant CCL2 protein coating mitigates wear particle induced bone loss in
   a murine continuous polyethylene infusion model
SO BIOMATERIALS
LA English
DT Article
DE Osteolysis; Mutant CCL2 protein; Implant coating; Macrophage; Total
   joint replacement
ID MONOCYTE CHEMOATTRACTANT PROTEIN 1; PERIPROSTHETIC OSTEOLYSIS; TITANIUM
   PARTICLES; IMPLANT WEAR; MCP 1; MACROPHAGES; MODULATE; ATHEROSCLEROSIS;
   EXPRESSION; DELIVERY
AB Wear particle induced osteolysis limits the long term survivorship of total joint replacement (TJR). Monocyte/macrophages are the key cells of this adverse reaction. Monocyte Chemoattractant Protein 1 (MCP 1/CCL2) is the most important chemokine regulating trafficking of monocyte/macrophages in particle induced inflammation. 7ND recombinant protein is a mutant of CCL2 that inhibits CCL2 signaling. We have recently developed a layer by layer (LBL) coating platform on implant surfaces that can release biologically active 7ND. In this study, we investigated the effect of 7ND on wear particle induced bone loss using the murine continuous polyethylene (PE) particle infusion model with 7ND coating of a titanium rod as a local drug delivery device. PE particles were infused into hollow titanium rods with or without 7ND coating implanted In the distal femur for 4 weeks. Specific groups were also injected with RAW 264.7 as the reporter macrophages. Wear particle induced bone loss and the effects of 7ND were evaluated by microCT, immunohistochemical staining, and bioluminescence imaging. Local delivery of 7ND using the LBL coating decreased systemic macrophage recruitment, the number of osteoclasts and wear particle induced bone loss. The development of a novel orthopaedic implant coating with anti CCL2 protein may be a promising strategy to mitigate peri prosthetic osteolysis. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [Nabeshima, Akira; Pajarinen, Jukka; Lin, Tzu hua; Jiang, Xinyi; Gibon, Emmanuel; Cordova, Luis A.; Loi, Florence; Lu, Laura; Jamsen, Eemeli; Yang, Fan; Yao, Zhenyu; Goodman, Stuart B.] Stanford Univ, Dept Orthopaed Surg, Stanford, CA 94305 USA.
   [Goodman, Stuart B.] Stanford Univ, Dept Bioengn, Stanford, CA 94305 USA.
   [Cordova, Luis A.] Univ Chile, Dept Oral & Maxillofacial Surg, Fac Dent, Santiago, Chile.
   [Egashira, Kensuke] Kyushu Univ, Dept Cardiovasc Res Dev & Translat Med, Fukuoka, Japan.
C3 Stanford University; Stanford University; Universidad de Chile; Kyushu
   University
RP Goodman, SB (通讯作者)，Stanford Univ, Dept Orthopaed Surg, Sch Med, 450 Broadway St, Redwood City, CA 94063 USA.
EM goodbone@stanford.edu
RI Córdova, Luis/I 5767 2016; Nabeshima, Akira/JOH 3173 2023; Goodman,
   Stuart/AAZ 7499 2020; Yang, Fan/GYU 4249 2022
OI Cordova, Luis/0000 0002 9036 2835; Jamsen, Eemeli/0000 0002 0267 0070;
   Goodman, Stuart/0000 0002 1919 3717; 
FU NIH [2R01AR055650, 1R01AR063717]; Ellenburg Chair in Surgery at Stanford
   University
FX This work was supported by NIH grants 2R01AR055650, 1R01AR063717, and
   the Ellenburg Chair in Surgery at Stanford University.
CR Baay M, 2011, CLIN DEV IMMUNOL, DOI 10.1155/2011/565187
   Berman JP, 2013, EXPERT OPIN EMERG DR, V18, P193, DOI 10.1517/14728214.2013.801453
   Bose S, 2013, ARCH PHARM RES, V36, P1039, DOI 10.1007/s12272 013 0161 z
   Boudou T, 2010, ADV MATER, V22, P441, DOI 10.1002/adma.200901327
   CAMPBELL P, 1995, J BIOMED MATER RES, V29, P127, DOI 10.1002/jbm.820290118
   De A, 2003, MOL THER, V7, P681, DOI 10.1016/S1525 0016(03)00070 4
   Deshmane SL, 2009, J INTERF CYTOK RES, V29, P313, DOI 10.1089/jir.2008.0027
   Egashira K, 2007, ARTERIOSCL THROM VAS, V27, P2563, DOI 10.1161/ATVBAHA.107.154609
   Gallo J, 2013, INNATE IMMUN LONDON, V19, P213, DOI 10.1177/1753425912451779
   Gibon E, 2012, J ORTHOP RES, V30, P547, DOI 10.1002/jor.21548
   Goodman SB, 2007, BIOMATERIALS, V28, P5044, DOI 10.1016/j.biomaterials.2007.06.035
   Goodman SB, 2013, BIOMATERIALS, V34, P3174, DOI 10.1016/j.biomaterials.2013.01.074
   Goodman Stuart B, 2013, Instr Course Lect, V62, P201
   Gschwandtner M, 2016, NEUROSCI LETT, V626, P164, DOI 10.1016/j.neulet.2016.05.037
   Huang ZN, 2010, J BIOMED MATER RES A, V94A, P1264, DOI 10.1002/jbm.a.32803
   Ingham E, 2005, BIOMATERIALS, V26, P1271, DOI 10.1016/j.biomaterials.2004.04.035
   Ishikawa M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104954
   Jämsen E, 2014, J ORTHOP RES, V32, P1241, DOI 10.1002/jor.22658
   Jiang X., 2015, J ORTHOP RES, V34, P58
   Keeney M, 2013, BIOMATERIALS, V34, P10287, DOI 10.1016/j.biomaterials.2013.09.028
   Lee HW, 2013, BBA REV CANCER, V1835, P170, DOI 10.1016/j.bbcan.2012.12.007
   Ma T, 2008, BIOMATERIALS, V29, P3738, DOI 10.1016/j.biomaterials.2008.05.031
   Marshall A, 2008, J AM ACAD ORTHOP SUR, V16, pS1, DOI 10.5435/00124635 200800001 00003
   Min JH, 2016, ACS NANO, V10, P4441, DOI 10.1021/acsnano.6b00087
   Morrison NA, 2014, J CELL BIOCHEM, V115, P303, DOI 10.1002/jcb.24663
   Nakashima Y, 1999, J BONE JOINT SURG BR, V81B, P155, DOI 10.1302/0301 620X.81B1.8884
   Ni WH, 2001, CIRCULATION, V103, P2096
   Nich C, 2013, J BIOMED MATER RES A, V101, P3033, DOI 10.1002/jbm.a.34599
   Ohtani K, 2004, GENE THER, V11, P1273, DOI 10.1038/sj.gt.3302288
   Okamoto M, 2012, BIOL PHARM BULL, V35, P2069, DOI 10.1248/bpb.b12 00528
   Pajarinen J, 2014, J MATER CHEM B, V2, P7094, DOI [10.1039/c4tb01005a, 10.1039/C4TB01005A]
   Pajarinen J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142736
   Pajarinen J, 2013, ACTA BIOMATER, V9, P9229, DOI 10.1016/j.actbio.2013.06.027
   Pajarinen J, 2010, J BIOMED MATER RES A, V94A, P84, DOI 10.1002/jbm.a.32674
   Panee J, 2012, CYTOKINE, V60, P1, DOI 10.1016/j.cyto.2012.06.018
   Pérez Anes A, 2015, ACS APPL MATER INTER, V7, P12882, DOI 10.1021/acsami.5b02402
   Purdue P Edward, 2006, HSS J, V2, P102, DOI 10.1007/s11420 006 9003 6
   Rodriguez A, 2009, J BIOMED MATER RES A, V90A, P106, DOI 10.1002/jbm.a.32050
   Semple BD, 2010, J CEREBR BLOOD F MET, V30, P459, DOI 10.1038/jcbfm.2009.240
   Taki N, 2005, J ORTHOP RES, V23, P376, DOI 10.1016/j.orthres.2004.08.023
   Tuan RS, 2008, J AM ACAD ORTHOP SUR, V16, pS42, DOI 10.5435/00124635 200800001 00010
   Xing ZQ, 2010, DIS MODEL MECH, V3, P451, DOI 10.1242/dmm.003186
   Yadav A, 2010, CLIN CHIM ACTA, V411, P1570, DOI 10.1016/j.cca.2010.07.006
   Yao ZY, 2014, J BIOMED MATER RES A, V102, P3291, DOI 10.1002/jbm.a.34981
   Yumimoto K, 2015, J CLIN INVEST, V125, P621, DOI 10.1172/JCI78782
   Zelikin AN, 2010, ACS NANO, V4, P2494, DOI 10.1021/nn100634r
   Zhang J, 2010, PROG MOL BIOL TRANSL, V95, P31, DOI 10.1016/B978 0 12 385071 3.00003 4
   ZHANG YJ, 1995, MOL CELL BIOL, V15, P4851
   ZHANG YJ, 1994, J BIOL CHEM, V269, P15918
NR 49
TC 37
Z9 38
U1 0
U2 28
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142 9612
EI 1878 5905
J9 BIOMATERIALS
JI Biomaterials
PD FEB
PY 2017
VL 117
BP 1
EP 9
DI 10.1016/j.biomaterials.2016.11.039
PG 9
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA EI8SL
UT WOS:000392777900001
PM 27918885
OA Green Accepted
DA 2025 08 17
ER

PT J
AU He, X
   Li, YL
   Wang, XR
   Guo, X
   Niu, Y
AF He, X
   Li, YL
   Wang, XR
   Guo, X
   Niu, Y
TI Mesenchymal stem cells transduced by PLEGFP N1 retroviral vector
   maintain their biological features and differentiation
SO CHINESE MEDICAL JOURNAL
LA English
DT Article
DE mesenchymal stem cells; bone marrow; enhanced green fluorescent protein;
   retroviral vector; gene therapy
ID GREEN FLUORESCENT PROTEIN; BONE MARROW; IN VIVO; GENE; EXPRESSION;
   FUSION; STROMA; MODEL
AB Background Enhanced green fluorescent protein (EGFP) has been an important reporter gene for gene therapy. Human mesenchymal stem cells (hMSCs) are ideal target cells in cell transplantation and tissue engineering. We investigated their biological characteristics and differentiation mediated by PLEGFP N1 retroviral transduction.
   Methods hMSCs were isolated from human bone marrow by density gradient fractionation and adherence to plastic flasks. Individual colonies were selected and cultured in tissue dishes. Packaging cells PT67 were transfected by PLEGFP N1 retroviral vector, and hMSCs were transduced by viral supernatant infection. Meanwhile, hMSCs EGFP were identified by Immune phenotypes and whether it could differentiate into osteoblasts or adipocytes under conditioned media was investigated.
   Results The rate of stably transduced hMSCs EGFP was up to 96% after being screened by G418. hMSCs EGFP exhibited fibroblast like morphological features. Flow cytometric analyses showed that hMSCs EGFP were positive for CD73, CD105, CD166, CD90, and CD44, but negative for CD34, and CD45. In addition, it could functionally be induced into osteocytes or adipocytes under conditioned media. These biological features of hMSCs EGFP were consistent with those of hMSCs.
   Conclusions hMSCs transduced by PLEGFP N1 retroviral vector can be used in vivo securely because they can maintain their biological characteristics and differentiation. It is a simple and reliable way to trace the changes of hMSCs in vivo by EGFP during cell transplantation and gene therapy.
C1 Jilin Univ, Minist Educ, Key Lab Pathobiol, Changchun 130021, Peoples R China.
   Hong Kong Univ Sci & Technol, Peking Univ, Med Ctr, Shenzhen 518000, Peoples R China.
C3 Jilin University; Hong Kong University of Science & Technology; Peking
   University
RP Li, YL (通讯作者)，Jilin Univ, Minist Educ, Key Lab Pathobiol, Changchun 130021, Peoples R China.
EM ylli@mail.jlu.edu.cn
RI he, Xu/IQV 2081 2023
CR Al Khaldi A, 2003, ANN THORAC SURG, V75, P204, DOI 10.1016/S0003 4975(02)04291 1
   Barry F, 2001, BIOCHEM BIOPH RES CO, V289, P519, DOI 10.1006/bbrc.2001.6013
   Barry FP, 1999, BIOCHEM BIOPH RES CO, V265, P134, DOI 10.1006/bbrc.1999.1620
   Bentzon JF, 2005, BIOCHEM BIOPH RES CO, V330, P633, DOI 10.1016/j.bbrc.2005.03.072
   Bianco P, 2001, STEM CELLS, V19, P180, DOI 10.1634/stemcells.19 3 180
   Bos C, 2004, RADIOLOGY, V233, P781, DOI 10.1148/radiol.2333031714
   CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295
   Conget PA, 1999, J CELL PHYSIOL, V181, P67, DOI 10.1002/(SICI)1097 4652(199910)181:1<67::AID JCP7>3.0.CO;2 C
   Dennis JE, 2002, STEM CELLS, V20, P205, DOI 10.1634/stemcells.20 3 205
   Devine SM, 2001, EXP HEMATOL, V29, P244, DOI 10.1016/S0301 472X(00)00635 4
   Han CX, 2005, INT J MOL MED, V16, P205
   Hayakawa J, 2003, INT J HEMATOL, V77, P456, DOI 10.1007/BF02986613
   Kobune M, 2003, EXP HEMATOL, V31, P715, DOI 10.1016/S0301 472X(03)00177 2
   Kwon YJ, 2003, J VIROL, V77, P5712, DOI 10.1128/JVI.77.10.5712 5720.2003
   Lange C, 2005, STEM CELLS DEV, V14, P70, DOI 10.1089/scd.2005.14.70
   Lange C, 2005, WORLD J GASTROENTERO, V11, P4497, DOI 10.3748/wjg.v11.i29.4497
   Lee K, 2001, MOL THER, V3, P857, DOI 10.1006/mthe.2001.0327
   Li JZ, 2003, J GENE MED, V5, P748, DOI 10.1002/jgm.412
   Li Zhi yong, 2005, Zhonghua Kou Qiang Yi Xue Za Zhi, V40, P150
   Min JY, 2002, ANN THORAC SURG, V74, P1568, DOI 10.1016/S0003 4975(02)03952 8
   Minguell JJ, 2001, EXP BIOL MED, V226, P507, DOI 10.1177/153537020122600603
   PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Qu TY, 2004, RESTOR NEUROL NEUROS, V22, P459
   RAMA KJ, 2000, J BIOL CHEM, V275, P9645
   Saito T, 2002, ANN THORAC SURG, V74, P19, DOI 10.1016/S0003 4975(02)03591 9
   Seshi B, 2000, BLOOD CELL MOL DIS, V26, P234, DOI 10.1006/bcmd.2000.0301
   Spees JL, 2003, P NATL ACAD SCI USA, V100, P2397, DOI 10.1073/pnas.0437997100
   Tai GP, 2005, BIOCHEM BIOPH RES CO, V333, P1116, DOI 10.1016/j.bbrc.2005.05.195
   Xia ZD, 2005, BIOMATERIALS, V26, P5790, DOI 10.1016/j.biomaterials.2005.02.018
   Xie Zheng Jun, 2005, Di Yi Jun Yi Da Xue Xue Bao, V25, P281
   Zhang Y, 2004, CHINESE MED J PEKING, V117, P882
NR 32
TC 7
Z9 19
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0366 6999
EI 2542 5641
J9 CHINESE MED J PEKING
JI Chin. Med. J.
PD OCT
PY 2005
VL 118
IS 20
BP 1728
EP 1734
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA 978KG
UT WOS:000232871400009
PM 16313759
DA 2025 08 17
ER

PT J
AU Kim, GH
   Park, YD
   Lee, SY
   El Fiqi, A
   Kim, JJ
   Lee, EJ
   Kim, HW
   Kim, EC
AF Kim, Ga Hyun
   Park, Yong Duk
   Lee, So Youn
   El Fiqi, Ahmed
   Kim, Jung Ju
   Lee, Eun Jung
   Kim, Hae Won
   Kim, Eun Cheol
TI Odontogenic stimulation of human dental pulp cells with bioactive
   nanocomposite fiber
SO JOURNAL OF BIOMATERIALS APPLICATIONS
LA English
DT Article
DE Nanofiber matrix; mesoporous bioactive glass nanoparticles; human dental
   pulp cells; odontogenesis; integrin; BMP
ID OSTEOBLAST DIFFERENTIATION; OSTEOGENIC DIFFERENTIATION; NANOFIBROUS
   MATRIX; DRUG DELIVERY; EXPRESSION; INTEGRIN; KINASE; PROLIFERATION;
   BIOMATERIALS; REGENERATION
AB The aim of the present study was to investigate the effects of a composite nanofibrous matrix made of biopolymer blend polycaprolactone gelatin (BP) and mesoporous bioactive glass nanoparticles (BGNs) on the odontogenic differentiation of human dental pulp cells (HDPCs). BGN BP nanomatrices, with BGN content of up to 20wt%, were produced via electrospinning. The differentiation of the HDPCs was evaluated by using an ALP activity assay, calcified nodule formation, and mRNA expression for markers. Integrin and its underlying signal pathways were assessed via reverse transcriptase polymerase chain reaction and Western blot analysis. Although cell growth and attachment on the BGN BP nanomatrix was similar to that on BP, ALP activity, mineralized nodule formation, and mRNA, expressions involving ALP, osteocalcin, osteopontin, dentin sialophosphoprotein, and dentin matrix protein 1 were greater on BGN BP. BGN BP upregulated the key adhesion receptors (integrin components 1, 2, 5, and 1) and activated integrin downstream pathways, such as phosphorylated focal adhesion kinase (p FAK), and p paxillin. In addition, BGN BP activated BMP receptors, BMP 2 mRNA, and p Smad 1/5/8, and such activation was blocked by the BMP antagonist, noggin. Furthermore, BGN BP induced phosphorylation of extracellular signal regulated kinase, protein kinase 38, and c Jun N terminal kinase mitogen activated protein kinases and activated expression of the transcription factors Runx2 and Osterix in HDPCs. Collectively, the results indicated for the first time that a BGN BP composite nanomatrix promoted odontogenic differentiation of HDPCs through the integrin, BMP, and mitogen activated protein kinases signaling pathway. Moreover, the nanomatrix is considered to be promising scaffolds for the culture of HDPCs and dental tissue engineering.
C1 [Kim, Ga Hyun; Lee, So Youn; Kim, Eun Cheol] Kyung Hee Univ, Sch Dent, Dept Oral & Maxillofacial Pathol, Res Ctr Tooth & Periodontal Regenerat MRC, Seoul 130701, South Korea.
   [Park, Yong Duk] Kyung Hee Univ, Sch Dent, Dept Prevent & Soc Dent, Seoul 130701, South Korea.
   [El Fiqi, Ahmed; Kim, Jung Ju; Lee, Eun Jung; Kim, Hae Won] Dankook Univ, Dept Nanobiomed Sci, Cheonan, South Korea.
   [El Fiqi, Ahmed; Kim, Jung Ju; Lee, Eun Jung; Kim, Hae Won] Dankook Univ, PLUS NBM Global Res Ctr BK21, Cheonan, South Korea.
   [El Fiqi, Ahmed; Kim, Jung Ju; Lee, Eun Jung; Kim, Hae Won] Dankook Univ, Coll Dent, Cheonan, South Korea.
   [El Fiqi, Ahmed; Kim, Jung Ju; Lee, Eun Jung; Kim, Hae Won] Dankook Univ, Inst Tissue Regenerat Engn ITREN, Cheonan, South Korea.
C3 Kyung Hee University; Kyung Hee University; Dankook University; Dankook
   University; Dankook University; Dankook University
RP Kim, EC (通讯作者)，Kyung Hee Univ, Sch Dent, Dept Oral & Maxillofacial Pathol, 1 Heogi Dong, Seoul 130701, South Korea.
EM eckim@khu.ac.kr
RI El Fiqi (Ph.D.), Associate Professor of Nano Biomaterials,
   Ahmed/N 1814 2018; Kim, Cheorl Ho/T 6753 2019
OI El Fiqi, Ahmed/0000 0002 2344 1728
FU National Research Foundation of Korea (NRF)   Korean government (MSIP)
   [2012R1A5A2051384, 2009 0093829]; Ministry for Health, Welfare & Family
   Affairs, Republic of Korea [A111412]
FX This work was supported by a National Research Foundation of Korea (NRF)
   grant funded by the Korean government (MSIP) (No. 2012R1A5A2051384 & No.
   2009 0093829) and by a grant of the Korean Healthcare Technology R&D
   Project of the Ministry for Health, Welfare & Family Affairs, Republic
   of Korea (A111412).
CR Abou Neel EA, 2010, J TISSUE ENG, V1, DOI 10.4061/2010/390127
   Allo BA, 2010, LANGMUIR, V26, P18340, DOI 10.1021/la102845k
   Bae WJ, 2012, DENT MATER, V28, P1271, DOI 10.1016/j.dental.2012.09.011
   El Fiqi A, 2013, ACTA BIOMATER, V9, P9508, DOI 10.1016/j.actbio.2013.07.036
   El Fiqi A, 2012, NANOSCALE, V4, P7475, DOI 10.1039/c2nr31775c
   Gong WY, 2012, CHIN J DENT RES, V15, P145
   Guicheux J, 2003, J BONE MINER RES, V18, P2060, DOI 10.1359/jbmr.2003.18.11.2060
   Hanks CT, 1998, EUR J ORAL SCI, V106, P260, DOI 10.1111/j.1600 0722.1998.tb02185.x
   HARRIS H, 1990, CLIN CHIM ACTA, V186, P133, DOI 10.1016/0009 8981(90)90031 M
   Hoppe A, 2011, BIOMATERIALS, V32, P2757, DOI 10.1016/j.biomaterials.2011.01.004
   Keselowsky BG, 2007, J BIOMED MATER RES A, V80A, P700, DOI 10.1002/jbm.a.30898
   Khanna Jain R, 2012, J TISSUE ENG, V3, DOI 10.1177/2041731412467998
   Kim JJ, 2014, J BIOMATER APPL, V28, P1069, DOI 10.1177/0885328213495903
   Kim NR, 2009, ORAL SURG ORAL MED O, V108, pE94, DOI 10.1016/j.tripleo.2009.07.031
   Kim YS, 2010, J ENDODONT, V36, P1824, DOI 10.1016/j.joen.2010.08.020
   Kitagawa M, 2007, ARCH ORAL BIOL, V52, P727, DOI 10.1016/j.archoralbio.2007.02.006
   Lee SY, 2012, J DENT RES, V91, P407, DOI 10.1177/0022034511436113
   Lee SI, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061960
   Lin HM, 2012, J MATER SCI MATER M, V23, P2619, DOI 10.1007/s10856 012 4734 z
   Lu ZL, 2010, TISSUE ENG PT A, V16, P3075, DOI 10.1089/ten.tea.2010.0204
   Mi Shan shan, 2012, Beijing Da Xue Xue Bao Yi Xue Ban, V44, P39
   Miyazono K, 2005, CYTOKINE GROWTH F R, V16, P251, DOI 10.1016/j.cytogfr.2005.01.009
   Mizuno M, 2000, J CELL PHYSIOL, V184, P207, DOI 10.1002/1097 4652(200008)184:2<207::AID JCP8>3.3.CO;2 L
   Morinobu M, 2003, J BONE MINER RES, V18, P1706, DOI 10.1359/jbmr.2003.18.9.1706
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Nakashima M, 2005, J ENDODONT, V31, P711, DOI 10.1097/01.don.0000164138.49923.e5
   Patel KD, 2012, J MATER CHEM, V22, P24945, DOI 10.1039/c2jm33830k
   Qu TJ, 2013, J MATER CHEM B, V1, P4764, DOI 10.1039/c3tb21002b
   Shih YRV, 2011, J BONE MINER RES, V26, P730, DOI 10.1002/jbmr.278
   Singh RK, 2014, ACS APPL MATER INTER, V6, P2201, DOI 10.1021/am4056936
   Sprio AE, 2012, STEM CELLS DEV, V21, P3278, DOI 10.1089/scd.2012.0141
   Vatankhah E, 2014, ACTA BIOMATER, V10, P709, DOI 10.1016/j.actbio.2013.09.015
   Wang SN, 2014, ACTA BIOMATER, V10, P2792, DOI 10.1016/j.actbio.2014.02.013
   Woo KM, 2007, BIOMATERIALS, V28, P335, DOI 10.1016/j.biomaterials.2006.06.013
   Xia H, 2004, J BIOL CHEM, V279, P33024, DOI 10.1074/jbc.M313265200
   Xia W, 2006, J CONTROL RELEASE, V110, P522, DOI 10.1016/j.jconrel.2005.11.002
   Yan XX, 2004, ANGEW CHEM INT EDIT, V43, P5980, DOI 10.1002/anie.200460598
   Yasuda Y, 2008, J ENDODONT, V34, P1057, DOI 10.1016/j.joen.2008.06.007
   Yu HS, 2009, J BIOMED MATER RES A, V88A, P747, DOI 10.1002/jbm.a.31709
   Yun HS, 2011, ACTA BIOMATER, V7, P2651, DOI 10.1016/j.actbio.2011.02.014
NR 40
TC 45
Z9 46
U1 0
U2 40
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0885 3282
EI 1530 8022
J9 J BIOMATER APPL
JI J. Biomater. Appl.
PD JAN
PY 2015
VL 29
IS 6
BP 854
EP 866
DI 10.1177/0885328214546884
PG 13
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA AX2II
UT WOS:000346766400006
PM 25098335
DA 2025 08 17
ER

PT J
AU Sethi, V
   Qin, L
   Cox, E
   Trocóniz, IF
   Della Pasqua, O
AF Sethi, Vidhu
   Qin, Li
   Cox, Eugene
   Troconiz, Inaki F.
   Della Pasqua, Oscar
TI Model Based Meta Analysis Supporting the Combination of Acetaminophen
   and Topical Diclofenac in Acute Pain: A Therapy for Mild to Moderate
   Osteoarthritis Pain?
SO PAIN AND THERAPY
LA English
DT Article
DE Acetaminophen; Diclofenac; Combination therapy; Model based
   meta analysis; Osteoarthritis; Acute pain
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; RANDOMIZED CONTROLLED TRIAL;
   POSTOPERATIVE PAIN; ANALGESIC EFFICACY; PARACETAMOL ACETAMINOPHEN;
   MANAGEMENT; SAFETY; NSAIDS; RELIEF; PROPACETAMOL
AB IntroductionAcetaminophen and topical diclofenac (AtopD) have complementary mechanisms of action and are therefore candidates for combination use in osteoarthritis (OA) pain. However, an evidence gap exists on their combination use in OA pain. This study aimed to assess the effects of this combination and compare its performance relative to monotherapies on pain score reduction and opioid sparing effect by leveraging evidence from acute pain setting using a model based meta analysis (MBMA).MethodsA literature search was conducted using the MEDLINE database to identify randomized controlled trials (RCTs) studying the combination for acute pain. Subsequently, an MBMA of RCTs was implemented in conjunction with extrapolation principles to infer efficacy in the population of interest. Pain score reduction and opioid sparing effect (OSE) were selected as the measures of efficacy.ResultsA total of 11 RCTs encompassing 1396 patients were included. Exploratory evaluation revealed AtopD combination to show greater pain score reduction versus acetaminophen monotherapy. However, pain score reduction was more susceptible to confounding by opioid patient controlled analgesia (PCA) than OSE. Therefore, a parsimonious MBMA evaluating OSE was developed from 5 of the 11 RCTs (n = 353 patients). The analysis revealed a statistically significant interaction coefficient, suggesting a reduction of 32% in opioid use with the combination versus acetaminophen monotherapy. Differences in the effect size of the combination were less conclusive versus diclofenac monotherapy.ConclusionOur results indicate greater pain reduction and opioid sparing efficacy for the AtopD combination versus acetaminophen monotherapy. Given the similar pain pathways and mechanisms of action of the two drugs in acute and mild to moderate OA pain, comparable beneficial effects from the combination therapy may be anticipated following extrapolation to chronic OA pain. Prospective RCTs and real world studies in OA pain are needed to confirm the differences in the efficacy of the combination treatment observed in our study.
C1 [Sethi, Vidhu] Haleon, Med Affairs, GSK Asia House,Rochester Pk, Singapore 139234, Singapore.
   [Qin, Li; Cox, Eugene] Certara, Quantitat Sci, Princeton, NJ USA.
   [Troconiz, Inaki F.] Univ Navarra, Sch Pharm & Nutr, Dept Pharmaceut Technol & Chem, Pamplona, Spain.
   [Della Pasqua, Oscar] GlaxoSmithKline, Clin Pharmacol Modelling & Simulat, Brentford, England.
   [Della Pasqua, Oscar] UCL, Clin Pharmacol & Therapeut Grp, BMA House,Tavistock Sq, London WC1H 9JP, England.
C3 University of Navarra; GlaxoSmithKline; Glaxosmithkline United Kingdom;
   University of London; University College London
RP Della Pasqua, O (通讯作者)，GlaxoSmithKline, Clin Pharmacol Modelling & Simulat, Brentford, England.
EM o.dellapaqua@ucl.ac.uk
RI Qin, Li/A 3244 2016; Troconiz, Inaki/I 1740 2017
OI Qin, Li/0000 0001 5002 3372; Della Pasqua, Oscar/0000 0002 6211 1430;
   Sood, Vidhu/0000 0001 7767 2452
FU Haleon (formerly GlaxoSmithKline Consumer Healthcare), Singapore
FX We would like to express our gratitude for Aneta Gomulka Pilat, Joanna
   Jarosz, Paulina Pierzchala from Certara evidence & access at Krakow for
   literature data support. We thank the participants of the original
   studies upon which this analysis is based.
CR Alchin J, 2022, CURR MED RES OPIN, V38, P811, DOI 10.1080/03007995.2022.2049551
   Altman RD, 2004, CLIN EXP RHEUMATOL, V22, P110
   Altman RD, 2004, J RHEUMATOL, V31, P5
   Anderson BJ, 2008, PEDIATR ANESTH, V18, P915, DOI 10.1111/j.1460 9592.2008.02764.x
   Bannuru RR, 2010, OSTEOARTHR CARTILAGE, V18, pS250, DOI 10.1016/S1063 4584(10)60585 7
   Beck DH, 2000, ANESTH ANALG, V90, P431, DOI 10.1097/00000539 200002000 00035
   Bell J, 2019, AB0808 COMBINATION O
   Bodden J, 2021, ARTHRITIS RES THER, V23, DOI 10.1186/s13075 021 02524 9
   Breivik EK, 1999, CLIN PHARMACOL THER, V66, P625, DOI 10.1016/S0009 9236(99)90073 5
   Brewer AR, 2010, PHYSICIAN SPORTSMED, V38, P62, DOI 10.3810/psm.2010.06.1784
   Bruyère O, 2019, SEMIN ARTHRITIS RHEU, V49, P337, DOI 10.1016/j.semarthrit.2019.04.008
   Bruyère O, 2014, SEMIN ARTHRITIS RHEU, V44, P253, DOI 10.1016/j.semarthrit.2014.05.014
   Cazzola M, 2014, REUMATISMO, V66, P4, DOI 10.4081/reumatismo.2014.758
   Chan P, 2022, PHARM RES DORDR, V39, P1761, DOI 10.1007/s11095 022 03201 5
   Cohen SP, 2021, LANCET, V397, P2082, DOI 10.1016/S0140 6736(21)00393 7
   Conaghan PG, 2019, DRUG AGING, V36, P7, DOI 10.1007/s40266 019 00658 9
   Cooper C, 2019, DRUG AGING, V36, P15, DOI 10.1007/s40266 019 00660 1
   Courtney P, 2002, ANN RHEUM DIS, V61, P767, DOI 10.1136/ard.61.9.767
   D'Agate S, 2021, BRIT J CLIN PHARMACO, V87, P2777, DOI 10.1111/bcp.14682
   D'Agate S, 2020, BRIT J CLIN PHARMACO, V86, P1585, DOI 10.1111/bcp.14268
   D'Arcy Y, 2021, POSTGRAD MED, V133, P879, DOI 10.1080/00325481.2021.1949199
   Deveza LA, 2018, OSTEOARTHR CARTILAGE, V26, P293, DOI 10.1016/j.joca.2017.12.003
   Doherty M, 2011, ANN RHEUM DIS, V70, P1534, DOI 10.1136/ard.2011.154047
   Elzaki WM, 2016, J ENDODONT, V42, P835, DOI 10.1016/j.joen.2016.02.014
   European Medicines Agency, 2017, GUIDELINE CLIN DEV M
   Geenen R, 2018, ANN RHEUM DIS, V77, P797, DOI 10.1136/annrheumdis 2017 212662
   Gewandter JS, 2021, PAIN, V162, P2669, DOI 10.1097/j.pain.0000000000002283
   Hannam JA, 2014, PEDIATR ANESTH, V24, P953, DOI 10.1111/pan.12422
   Hiller A, 2004, ACTA ANAESTH SCAND, V48, P1185, DOI 10.1111/j.1399 6576.2004.00473.x
   Honvo G, 2019, DRUG AGING, V36, P45, DOI 10.1007/s40266 019 00661 0
   Jackson H, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen 2017 019694
   Leopoldino AO, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD013273
   Long HB, 2022, ARTHRITIS RHEUMATOL, V74, P1172, DOI 10.1002/art.42089
   Madabushi R, 2022, PHARM RES DORDR, V39, P1669, DOI 10.1007/s11095 022 03288 w
   Majeed MH, 2018, CURR RHEUMATOL REP, V20, DOI 10.1007/s11926 018 0794 5
   Mandema JW, 2011, CLIN PHARMACOL THER, V90, P766, DOI 10.1038/clpt.2011.242
   Mandema JW, 2005, CEPHALALGIA, V25, P715, DOI 10.1111/j.1468 2982.2004.00939.x
   Maringwa J, 2021, CLIN PHARMACOL THER, V109, P1583, DOI 10.1002/cpt.2130
   Marshall S, 2019, CPT PHARMACOMET SYST, V8, P87, DOI 10.1002/psp4.12372
   Matsutani N, 2014, SURG TODAY, V44, P712, DOI 10.1007/s00595 013 0743 x
   MATTHEWS RW, 1984, BRIT DENT J, V157, P357, DOI 10.1038/sj.bdj.4805486
   McCarberg B, 2013, CURR MED RES OPIN, V29, P539, DOI 10.1185/03007995.2013.785391
   McCormick T, 2019, ANAEST INTENS CARE M, V20, P405, DOI 10.1016/j.mpaic.2019.05.010
   Montgomery JE, 1996, BRIT J ANAESTH, V77, P445, DOI 10.1093/bja/77.4.445
   Munishankar B, 2008, INT J OBSTET ANESTH, V17, P9, DOI 10.1016/j.ijoa.2007.06.006
   MURPHY JE, 1978, J INT MED RES, V6, P375, DOI 10.1177/030006057800600504
   National Institute for Health and Care Excellence (NICE), 2022, GUIDELINE NO NG226
   Ong CKS, 2010, ANESTH ANALG, V110, P1170, DOI 10.1213/ANE.0b013e3181cf9281
   Osani MC, 2021, ARTHRIT CARE RES, V73, P1413, DOI 10.1002/acr.24363
   Paladini A., 2020, PAIN MANAGEMENT PRAC
   Perrot S, 2015, BEST PRACT RES CL RH, V29, P90, DOI 10.1016/j.berh.2015.04.017
   Qin L, 2022, J HUM HYPERTENS, V36, P989, DOI 10.1038/s41371 021 00600 w
   Raffa RB, 2003, EXPERT OPIN PHARMACO, V4, P1697, DOI 10.1517/14656566.4.10.1697
   Rannou F, 2016, SEMIN ARTHRITIS RHEU, V45, pS18, DOI 10.1016/j.semarthrit.2015.11.007
   Riad W, 2007, ANAESTHESIA, V62, P1241, DOI 10.1111/j.1365 2044.2007.05248.x
   Salaffi F, 2014, REUMATISMO, V66, P57, DOI 10.4081/reumatismo.2014.766
   SEIDEMAN P, 1993, ACTA ORTHOP SCAND, V64, P285, DOI 10.3109/17453679308993626
   Shah S, 2012, POSTGRAD MED J, V88, P73, DOI 10.1136/postgradmedj 2011 130291
   Siddik SM, 2001, REGION ANESTH PAIN M, V26, P310, DOI 10.1053/rapm.2001.21828
   Stewart M, 2018, RHEUMATOL INT, V38, P1985, DOI 10.1007/s00296 018 4132 z
   Taneja A, 2016, J CLIN PHARMACOL, V56, P609, DOI 10.1002/jcph.629
   Thakur M, 2014, NAT REV RHEUMATOL, V10, P374, DOI 10.1038/nrrheum.2014.47
   Thorlund JB, 2019, OSTEOARTHR CARTILAGE, V27, P871, DOI 10.1016/j.joca.2019.01.005
   U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER), 2018, Meta analyses of randomized controlled clinical trials to evaluate the safety of human drugs or biological products guidance for industry
   van Laar Mart, 2012, Open Rheumatol J, V6, P320, DOI 10.2174/1874312901206010320
   Welsch P, 2020, EUR J PAIN, V24, P685, DOI 10.1002/ejp.1522
   Witjes H, 2020, CLIN PHARMACOL THER, V107, P435, DOI 10.1002/cpt.1624
   Woo WW, 2005, ANN EMERG MED, V46, P352, DOI 10.1016/j.annemergmed.2005.01.023
   Wu XX, 2023, CLIN J PAIN, V39, P484, DOI 10.1097/AJP.0000000000001135
   Yoo BCS., 1996, J KOREAN RHEUM ASS, V3, P70
NR 70
TC 3
Z9 4
U1 0
U2 1
PU SPRINGER INT PUBL AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH 6330, SWITZERLAND
SN 2193 8237
EI 2193 651X
J9 PAIN THER
JI PAIN THER.
PD FEB
PY 2024
VL 13
IS 1
BP 145
EP 159
DI 10.1007/s40122 023 00569 z
EA JAN 2024
PG 15
WC Clinical Neurology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Neurosciences & Neurology
GA FE3O5
UT WOS:001137208300002
PM 38183573
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Lu, K
   Wu, YM
   Shi, Q
   Gong, YQ
   Zhang, T
   Li, C
AF Lu, K.
   Wu, Y.  m.
   Shi, Q.
   Gong, Y.  q.
   Zhang, T.
   Li, C.
TI The impact of acute phase reaction on mortality and re fracture after
   zoledronic acid in hospitalized elderly osteoporotic fracture patients
SO OSTEOPOROSIS INTERNATIONAL
LA English
DT Article
DE Acute phase reaction; Elderly people; Mortality; Osteoporosis;
   Osteoporotic fracture; Re fracture
ID LYMPHOCYTE SUBSETS; HIP FRACTURE; DOUBLE BLIND; TNF ALPHA; RISK;
   BISPHOSPHONATES; FRAILTY; INFLAMMATION; MECHANISMS; INFUSION
AB This study involving 674 elderly osteoporotic fracture (OPF) patients undergoing orthopedic surgery investigated the long term outcomes of acute phase reaction (APR) after initial zoledronic acid (ZOL). Those who had an APR had a 97% higher risk of mortality and a 73% lower rate of re fracture than patients who did not.IntroductionAnnual infusion of ZOL efficiently decreases the risk of fracture. A temporary APR, consisting of flu like symptoms, myalgia, and fever, is frequently observed within 3 days after the first dose. This work aimed to identify whether the occurrence of APR after initial ZOL infusion is a reliable indicator of drug efficacy for mortality and re fracture in elderly OPF patients undergoing orthopedic surgery.MethodsThis retrospectively observed work was constructed on a database prospectively collected from the Osteoporotic Fracture Registry System of a tertiary level A hospital in China. Six hundred seventy four patients 50 years old or older with newly identified hip/morphological vertebral OPF who received ZOL for the first time after orthopedic surgery were included in the final analysis. APR was identified as a maximum axillary body temperature greater than 37.3 degrees C for the first 3 days after ZOL infusion. We utilized models of multivariate Cox proportional hazards to compare the risk of all cause mortality in OPF patients with APR (APR+) and without APR (APR ). Competing risks regression analysis was used to examine the association between the occurrence of APR and re fracture when mortality was taken into account.ResultsIn a fully adjusted Cox proportional hazards model, APR+ patients had a significantly higher risk of death than APR  patients with a hazard ratio [HR] 1.97 (95% CI, 1.09 3.56; P value = 0.02). Furthermore, in an adjusted competing risk regression analysis, APR+ patients had a significantly reduced risk of re fracture compared with APR  patients with a sub distribution HR, 0.27 (95% CI, 0.11 0.70; P value = 0.007).ConclusionsOur findings suggested a potential association between the occurrence of APR and increased mortality risk. An initial dose of ZOL following orthopedic surgery was found to be protective against re fracture in older patients with OPFs.
C1 [Lu, K.; Wu, Y.  m.; Li, C.] Jiangsu Univ, Dept Orthoped, Affiliated Kunshan Hosp, 566 East Qianjin Rd, Suzhou 215300, Jiangsu, Peoples R China.
   [Shi, Q.] Soochow Univ, Orthoped Inst Soochow Univ, Dept Orthoped, Affiliated Hosp 1, Suzhou, Jiangsu, Peoples R China.
   [Gong, Y.  q.] Jiangsu Univ, Informat Dept, Affiliated Kunshan Hosp, Suzhou, Jiangsu, Peoples R China.
   [Zhang, T.] Kunshan Ctr Dis Control & Prevent, Chron Dis Dept, Suzhou, Jiangsu, Peoples R China.
C3 Jiangsu University; Soochow University   China; Jiangsu University
RP Li, C (通讯作者)，Jiangsu Univ, Dept Orthoped, Affiliated Kunshan Hosp, 566 East Qianjin Rd, Suzhou 215300, Jiangsu, Peoples R China.
EM sgu8434@sina.com; 10391478@qq.com; shiqin@suda.edu.cn;
   zhexuan0127@sina.com; 869611860@qq.com; lichong1705@163.com
RI ; Lu, Ke/KBC 3813 2024
OI Li, Chong/0000 0002 1526 221X; Lu, Ke/0000 0002 0029 7874; Shi,
   Qin/0000 0002 9403 752X
FU China Postdoctoral Science Foundation (CN) [2022M711439]; Elderly Health
   Research Project of Jiangsu Province (CN) [LKZ2022020]; Suzhou
   Collaborative Innovation Research Project of Medical and Industrial
   Integration (CN) [SLJ2022023]; Open Project of Jiangsu Provincial Key
   Laboratory of Geriatric Disease Prevention and Transformation (CN)
   [KJS2222]; Suzhou Key Clinical Diagnosis and Treatment Technology
   Project (CN) [LCZX202024]
FX The study was supported by China Postdoctoral Science Foundation (CN)
   (2022M711439), Elderly Health Research Project of Jiangsu Province (CN)
   (LKZ2022020), Suzhou Collaborative Innovation Research Project of
   Medical and Industrial Integration (CN) (SLJ2022023), Open Project of
   Jiangsu Provincial Key Laboratory of Geriatric Disease Prevention and
   Transformation (CN) (KJS2222), and Suzhou Key Clinical Diagnosis and
   Treatment Technology Project (CN) (LCZX202024).
CR Adami G, 2022, J BONE MINER RES, V37, P1622, DOI 10.1002/jbmr.4534
   Axelsson KF, 2016, OSTEOPOROSIS INT, V27, P3165, DOI 10.1007/s00198 016 3643 2
   Bachour F, 2017, ARCH OSTEOPOROS, V12, DOI 10.1007/s11657 017 0372 x
   Barbour KE, 2014, J BONE MINER RES, V29, P2057, DOI 10.1002/jbmr.2245
   Bertoldo F, 2010, J BONE MINER RES, V25, P447, DOI 10.1359/jbmr.090819
   Bhandari M, 2005, J BONE JOINT SURG AM, V87A, P293, DOI 10.2106/JBJS.D.01772
   Bjarnason I, 2018, GASTROENTEROLOGY, V154, P500, DOI 10.1053/j.gastro.2017.10.049
   Black DM, 2022, J BONE MINER RES, V37, P21, DOI 10.1002/jbmr.4434
   BLACK DM, 2007, NEW ENGL J MED, V356, P1809, DOI DOI 10.1056/NEJMOA067312
   Boonen S, 2012, NEW ENGL J MED, V367, P1714, DOI 10.1056/NEJMoa1204061
   Bruunsgaard H, 2000, CLIN EXP IMMUNOL, V121, P255, DOI 10.1046/j.1365 2249.2000.01281.x
   Bruunsgaard H, 1999, J GERONTOL A BIOL, V54, pM357, DOI 10.1093/gerona/54.7.M357
   Capuron L, 2011, BIOL PSYCHIAT, V70, P175, DOI 10.1016/j.biopsych.2010.12.006
   Center JR, 1999, LANCET, V353, P878, DOI 10.1016/S0140 6736(98)09075 8
   CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021 9681(87)90171 8
   Chen F, 2016, OSTEOPOROSIS INT, V27, P1469, DOI 10.1007/s00198 015 3398 1
   Chen J, 2017, EXP THER MED, V14, P1802, DOI 10.3892/etm.2017.4646
   García Dabrio MC, 2012, ACTA HAEMATOL BASEL, V127, P244, DOI 10.1159/000337051
   de Araújo AL, 2013, IMMUNOTHERAPY UK, V5, P879, DOI [10.2217/IMT.13.77, 10.2217/imt.13.77]
   De Martinis M, 2006, EXP MOL PATHOL, V80, P219, DOI 10.1016/j.yexmp.2005.11.004
   Desborough JP, 2000, BRIT J ANAESTH, V85, P109, DOI 10.1093/bja/85.1.109
   Devogelaer JP, 2007, OSTEOPOROSIS INT, V18, P1211, DOI 10.1007/s00198 007 0367 3
   Ding Y, 2017, ORTHOP SURG, V9, P284, DOI 10.1111/os.12338
   Eriksen EF, 2009, J BONE MINER RES, V24, P1308, DOI [10.1359/JBMR.090209, 10.1359/jbmr.090209]
   Ferrucci L, 2005, BLOOD, V105, P2294, DOI 10.1182/blood 2004 07 2599
   Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170
   Franceschi C, 2014, J GERONTOL A BIOL, V69, pS4, DOI 10.1093/gerona/glu057
   Fried LP, 2001, J GERONTOL A BIOL, V56, pM146, DOI 10.1093/gerona/56.3.M146
   Friedl G, 2009, J BONE JOINT SURG AM, V91A, P274, DOI 10.2106/JBJS.G.01193
   Fülöp T, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00271
   Gabay C, 1999, NEW ENGL J MED, V340, P448, DOI 10.1056/NEJM199902113400607
   Galluzzo S, 2007, EXPERT OPIN THER TAR, V11, P941, DOI 10.1517/14728222.11.7.941
   Hasegawa Y, 2000, GERONTOLOGY, V46, P185, DOI 10.1159/000022157
   Kernan WN, 2000, NEW ENGL J MED, V343, P1826, DOI 10.1056/NEJM200012213432501
   Koutalos AA, 2022, EUR J ORTHOP SURG TR, V32, P1145, DOI 10.1007/s00590 021 03092 z
   Li YT, 2015, OSTEOPOROSIS INT, V26, P431, DOI 10.1007/s00198 014 2903 2
   Lu K, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.991913
   Lu K, 2022, OSTEOPOROSIS INT, V33, P2381, DOI 10.1007/s00198 022 06493 w
   Lyles KW, 2007, NEW ENGL J MED, V357, P1799, DOI 10.1056/NEJMoa074941
   Maricic M, 2010, CLIN RHEUMATOL, V29, P1079, DOI 10.1007/s10067 010 1486 3
   Montecino Rodriguez E, 2013, J CLIN INVEST, V123, P958, DOI 10.1172/JCI64096
   Morley JE, 2013, J AM MED DIR ASSOC, V14, P392, DOI 10.1016/j.jamda.2013.03.022
   Okimoto N, 2020, J BONE MINER METAB, V38, P230, DOI 10.1007/s00774 019 01050 8
   Olson Karin, 2007, J Oncol Pharm Pract, V13, P223, DOI 10.1177/1078155207080806
   Palui R, 2022, THER ADV ENDOCRINOL, V13, DOI 10.1177/20420188221112904
   Prieto Alhambra D, 2011, BRIT MED J, V343, DOI 10.1136/bmj.d7222
   Quan HD, 2005, MED CARE, V43, P1130, DOI 10.1097/01.mlr.0000182534.19832.83
   Quan HD, 2011, AM J EPIDEMIOL, V173, P676, DOI 10.1093/aje/kwq433
   Reid DM, 2009, LANCET, V373, P1253, DOI 10.1016/S0140 6736(09)60250 6
   Reid IR, 2010, J CLIN ENDOCR METAB, V95, P4380, DOI 10.1210/jc.2010 0597
   Roelofs AJ, 2006, CLIN CANCER RES, V12, p6222S, DOI 10.1158/1078 0432.CCR 06 0843
   Russell RGG, 2006, ANN NY ACAD SCI, V1068, P367, DOI 10.1196/annals.1346.041
   Shiraki M, 2021, CALCIFIED TISSUE INT, V109, P666, DOI 10.1007/s00223 021 00884 7
   Soysal P, 2016, AGEING RES REV, V31, P1, DOI 10.1016/j.arr.2016.08.006
   Tran T, 2018, J CLIN ENDOCR METAB, V103, P3205, DOI 10.1210/jc.2017 02656
   Ungprasert P, 2015, EUR J INTERN MED, V26, P285, DOI 10.1016/j.ejim.2015.03.008
   Valdiglesias V, 2015, J TOXICOL ENV HEAL A, V78, P790, DOI 10.1080/15287394.2015.1051170
   van Geel TACM, 2009, ANN RHEUM DIS, V68, P99, DOI 10.1136/ard.2008.092775
   van Geel Tineke A C M, 2010, Curr Osteoporos Rep, V8, P118, DOI 10.1007/s11914 010 0023 2
   Varady NH, 2021, CLIN ORTHOP RELAT R, V479, P1970, DOI 10.1097/CORR.0000000000001772
   Wark JD, 2012, OSTEOPOROSIS INT, V23, P503, DOI 10.1007/s00198 011 1563 8
   Xue DT, 2014, J ORTHOP SURG RES, V9, DOI 10.1186/1749 799X 9 45
NR 62
TC 5
Z9 5
U1 0
U2 5
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0937 941X
EI 1433 2965
J9 OSTEOPOROSIS INT
JI Osteoporosis Int.
PD SEP
PY 2023
VL 34
IS 9
BP 1613
EP 1623
DI 10.1007/s00198 023 06803 w
EA MAY 2023
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA O9LK9
UT WOS:000996239000001
PM 37247006
DA 2025 08 17
ER

PT J
AU Mori, T
   Sato, Y
   Miyamoto, K
   Kobayashi, T
   Shimizu, T
   Kanagawa, H
   Katsuyama, E
   Fujie, A
   Hao, W
   Tando, T
   Iwasaki, R
   Kawana, H
   Morioka, H
   Matsumoto, M
   Saya, H
   Toyama, Y
   Miyamoto, T
AF Mori, T.
   Sato, Y.
   Miyamoto, K.
   Kobayashi, T.
   Shimizu, T.
   Kanagawa, H.
   Katsuyama, E.
   Fujie, A.
   Hao, W.
   Tando, T.
   Iwasaki, R.
   Kawana, H.
   Morioka, H.
   Matsumoto, M.
   Saya, H.
   Toyama, Y.
   Miyamoto, T.
TI TNFα promotes osteosarcoma progression by maintaining tumor cells in an
   undifferentiated state
SO ONCOGENE
LA English
DT Article
DE osteosarcoma; tumorigenesis; osteoblast differentiation; gene mutation;
   TNF alpha
ID INFLAMMATION; PATHWAY; CANCER; EPIDEMIOLOGY
AB Chronic inflammation is frequently associated with tumorigenesis in elderly people. By contrast, young people without chronic inflammation often develop tumors considered independent of chronic inflammation but driven instead by mutations. Thus, whether inflammation has a significant role in tumor progression in tumors driven by mutations remains largely unknown. Here we show that TNF alpha is required for the tumorigenesis of osteosarcoma, the most common tumor in children and adolescents. We show that transplantation of AX osteosarcoma cells, which harbor mutations driving c Myc overexpression and Ink4a deficiency, in wild type mice promotes lethal tumorigenesis accompanied by ectopic bone formation and multiple metastases, phenotypes seen in osteosarcoma patients. Such tumorigenesis was completely abrogated in TNF alpha deficient mice. AX cells have the capacity to undergo osteoblastic differentiation; however, that activity was significantly inhibited by TNF alpha treatment, suggesting that TNF alpha maintains AX cells in an undifferentiated state. TNF alpha inhibition of AX cell osteoblastic differentiation occurred through ERK activation, and a pharmacological TNF alpha inhibitor effectively inhibited both AX cell tumorigenesis and increased osteoblastic gene expression and increased survival of tumor bearing mice. Lethal tumorigenesis of AX cells was also abrogated in IL 1 alpha/IL 1 beta doubly deficient mice. We found that both TNF alpha and IL 1 maintained AX cells in an undifferentiated state via ERK activation. Thus, inflammatory cytokines are required to promote tumorigenesis even in mutation induced tumors, and TNF alpha/IL 1 and ERK may represent therapeutic targets for osteosarcoma.
C1 [Mori, T.; Sato, Y.; Miyamoto, K.; Kobayashi, T.; Kanagawa, H.; Katsuyama, E.; Fujie, A.; Hao, W.; Tando, T.; Morioka, H.; Matsumoto, M.; Toyama, Y.; Miyamoto, T.] Keio Univ, Sch Med, Dept Orthoped Surg, Tokyo 1608582, Japan.
   [Sato, Y.] Keio Univ, Sch Med, Dept Musculoskeletal Reconstruct & Regenerat Surg, Tokyo 1608582, Japan.
   [Kobayashi, T.; Miyamoto, T.] Keio Univ, Sch Med, Dept Integrated Bone Metab & Immunol, Tokyo 1608582, Japan.
   [Shimizu, T.; Saya, H.] Keio Univ, Sch Med, Inst Adv Med Res, Div Gene Regulat, Tokyo 1608582, Japan.
   [Shimizu, T.] Hoshi Univ, Sch Pharm & Pharmaceut Sci, Dept Pathophysiol, Tokyo 142, Japan.
   [Iwasaki, R.; Kawana, H.] Keio Univ, Sch Med, Dept Dent & Oral Surg, Tokyo 1608582, Japan.
C3 Keio University; Keio University; Keio University; Keio University;
   Hoshi University; Keio University
RP Miyamoto, T (通讯作者)，Keio Univ, Sch Med, Dept Orthoped Surg, 35 Shinano Machi, Tokyo 1608582, Japan.
EM miyamoto@z5.keio.jp
RI Toyama, Yoshiaki/K 5743 2013; Saya, Hideyuki/J 4325 2013
OI Saya, Hideyuki/0000 0001 6610 1902; 
FU Takeda Science Foundation, Japan; Grants in Aid for Scientific Research
   [22130001, 25861341, 24501320, 24390359] Funding Source: KAKEN
FX T Miyamoto was supported by a Grant in aid for Scientific Research,
   Takeda Science Foundation, Japan.
CR BENSTED JPM, 1961, BRIT J RADIOL, V34, P160, DOI 10.1259/0007 1285 34 399 160
   DAHLIN DC, 1975, CLIN ORTHOP RELAT R, P23
   Feldmann M, 2003, NAT MED, V9, P1245, DOI 10.1038/nm939
   Hagemann C, 2001, CELL SIGNAL, V13, P863, DOI 10.1016/S0898 6568(01)00220 0
   Hoejberg L, 2012, MELANOMA RES, V22, P327, DOI 10.1097/CMR.0b013e3283543d72
   Ishikawa T, 2013, CANCER SCI, V104, P880, DOI 10.1111/cas.12163
   KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092 8674(91)90112 C
   Kan ZY, 2010, NATURE, V466, P869, DOI 10.1038/nature09208
   Kim SJ, 2004, CLIN IMAG, V28, P291, DOI 10.1016/S0899 7071(03)00206 7
   Kubota Y, 2009, J EXP MED, V206, P1089, DOI 10.1084/jem.20081605
   MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092 8674(95)90401 8
   Mavaddat N, 2013, JNCI J NATL CANCER I, V105, P812, DOI 10.1093/jnci/djt095
   Mirabello L, 2009, CANCER AM CANCER SOC, V115, P1531, DOI 10.1002/cncr.24121
   Morrison WB, 2012, J VET INTERN MED, V26, P18, DOI 10.1111/j.1939 1676.2011.00836.x
   Nakamura T, 2011, ONCOL LETT, V2, P315, DOI 10.3892/ol.2011.238
   Ottaviani G, 2009, CANCER TREAT RES, V152, P3, DOI 10.1007/978 1 4419 0284 9_1
   Paroni G, 2001, J BIOL CHEM, V276, P21907, DOI 10.1074/jbc.M011565200
   Peyssonnaux C, 2001, BIOL CELL, V93, P53, DOI 10.1016/S0248 4900(01)01125 X
   Picci P, 2007, ORPHANET J RARE DIS, V2, DOI 10.1186/1750 1172 2 6
   Rutkowski P, 2003, J SURG ONCOL, V84, P151, DOI 10.1002/jso.10305
   Sansone P, 2012, J CLIN ONCOL, V30, P1005, DOI 10.1200/JCO.2010.31.8907
   Sheppard DG, 2001, CLIN RADIOL, V56, P22, DOI 10.1053/crad.2000.0599
   Shimizu T, 2010, ONCOGENE, V29, P5687, DOI 10.1038/onc.2010.312
   Shimizu T, 2012, MOL CANCER RES, V10, P454, DOI 10.1158/1541 7786.MCR 11 0347
   Ueki A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050621
   Vasto S, 2009, MECH AGEING DEV, V130, P40, DOI 10.1016/j.mad.2008.06.003
   Vendramini Costa DB, 2012, CURR PHARM DESIGN, V18, P3831
   Waldner MJ, 2012, INT J BIOL SCI, V8, P1248, DOI 10.7150/ijbs.4614
   WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002
   World Health Organization, 2007, WORLD HLTH STAT
   YOSHIKAWA H, 1985, CANCER AM CANCER SOC, V56, P1682, DOI 10.1002/1097 0142(19851001)56:7<1682::AID CNCR2820560735>3.0.CO;2 8
NR 31
TC 56
Z9 58
U1 1
U2 6
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950 9232
EI 1476 5594
J9 ONCOGENE
JI Oncogene
PD AUG 14
PY 2014
VL 33
IS 33
BP 4236
EP 4241
DI 10.1038/onc.2013.545
PG 6
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA AO2MB
UT WOS:000341155800005
PM 24336323
OA hybrid
DA 2025 08 17
ER

PT J
AU Saraiva, AS
   Ribeiro, IAC
   Fernandes, MH
   Cerdeira, AC
   Vieira, BJC
   Waerenborgh, JC
   Pereira, LCJ
   Cláudio, R
   Carmezim, MJ
   Gomes, P
   Gonçalves, LM
   Santos, CF
   Bettencourt, AF
AF Saraiva, Ana S.
   Ribeiro, Isabel A. C.
   Fernandes, Maria H.
   Cerdeira, Ana Claudia
   Vieira, Bruno J. C.
   Waerenborgh, Joao Carlos
   Pereira, Laura C. J.
   Claudio, Ricardo
   Carmezim, Maria Joao
   Gomes, Pedro
   Goncalves, Lidia M.
   Santos, Catarina F.
   Bettencourt, Ana F.
TI 3D printed platform multi loaded with bioactive, magnetic nanoparticles
   and an antibiotic for re growing bone tissue
SO INTERNATIONAL JOURNAL OF PHARMACEUTICS
LA English
DT Article
DE Polylactic acid 3D platform; Iron oxide nanoparticles;
   Superparamagnetic; Nanohydroxyapatite; Antibacterial; Bone regeneration
ID IRON OXIDE NANOPARTICLES; POROUS SCAFFOLDS; DRUG DELIVERY; STEM CELL;
   IN VITRO; HYDROXYAPATITE; COLLAGEN; CEMENT; DIFFERENTIATION;
   NANOTOPOGRAPHY
AB Polymeric platforms obtained by three dimensional (3D) printing are becoming increasingly important as multifunctional therapeutic systems for bone treatment applications. In particularly, researchers aim to control bacterial biofilm on these 3D platforms and enhance re growing bone tissue, at the same time. This study aimed to fabricate a 3D printed polylactic acid platform loaded with hydroxyapatite (HA), iron oxide nanoparticles (IONPs) and an antibiotic (minocycline) with tuneable properties and multistimuli response. IONPs were produced by a facile chemical co precipitation method showing an average diameter between 11 and 15 nm and a superparamagnetic behaviour which was preserved when loaded into the 3D platforms. The presence of two types of nanoparticles (IONPs and HA) modify the nanomorphological/nanotopographical feature of the 3D platforms justifying their adequate bioactivity profile and in vitro cellular effects on immortalized and primary osteoblasts, including cytocompatibility and increased osteogenesis related gene expression (RUNX2, BGLAP and SPP1). Disk diffusion assays and SEM analysis confirmed the effect of the 3D platforms loaded with minocycline against Staphylococcus aureus. Altogether results showed that fabricated 3D platforms combined the exact therapeutic antibiofilm dose of the antibiotic against S. aureus, with the enhanced osteogenic stimulation of the HA and IONPs nanoparticles which is a disruptive approach for bone targeting applications.
C1 [Saraiva, Ana S.; Ribeiro, Isabel A. C.; Goncalves, Lidia M.; Bettencourt, Ana F.] Univ Lisbon, Fac Pharm, Res Inst Med iMed ULisboa, Ave Prof Gama Pinto, P 1649003 Lisbon, Portugal.
   [Fernandes, Maria H.; Gomes, Pedro] Univ Porto, Lab Bone Metab & Regenerat, Fac Dent Med, Porto, Portugal.
   [Fernandes, Maria H.; Gomes, Pedro] Univ Porto, REQUIMTE LAQV, Porto, Portugal.
   [Cerdeira, Ana Claudia; Vieira, Bruno J. C.; Waerenborgh, Joao Carlos; Pereira, Laura C. J.] Univ Lisbon, Inst Super Tecn, C2TN, DECN, EN10,Km 139 7, P 2695066 Bobadela Lrs, Portugal.
   [Claudio, Ricardo; Carmezim, Maria Joao; Santos, Catarina F.] Inst Politecn Setubal, CDP2T, ESTSetubal, Campus IPS, P 2910 Setubal, Portugal.
   [Claudio, Ricardo] Univ Lisbon, Inst Super Tecn, IDMEC, Av Rovisco Pais, P 1049001 Lisbon, Portugal.
   [Carmezim, Maria Joao; Santos, Catarina F.] Univ Lisbon, CQE Inst Super Tecn, Av Rovisco Pais, P 1049001 Lisbon, Portugal.
C3 Universidade de Lisboa; Universidade do Porto; Universidade do Porto;
   Universidade de Lisboa; Instituto Politecnico de Setubal; Universidade
   de Lisboa; Universidade de Lisboa
RP Bettencourt, AF (通讯作者)，Univ Lisbon, Fac Pharm, Res Inst Med iMed ULisboa, Ave Prof Gama Pinto, P 1649003 Lisbon, Portugal.; Santos, CF (通讯作者)，Inst Politecn Setubal, CDP2T, ESTSetubal, Campus IPS, P 2910 Setubal, Portugal.; Santos, CF (通讯作者)，Univ Lisbon, CQE Inst Super Tecn, Av Rovisco Pais, P 1049001 Lisbon, Portugal.
EM catarina.santos@estsetubal.ips.pt; asimao@ff.ulisboa.pt
RI Cerdeira, Ana/U 5486 2018; Claudio, Ricardo/I 5287 2015; Fernandes,
   Maria Helena/K 6917 2014; Goncalves, Lidia/H 6410 2011; Pereira,
   Laura/G 3579 2013; Fernandes, Maria/K 6917 2014; Gomes,
   Pedro/K 2433 2014; Ribeiro, Isabel/JBJ 5802 2023; Cardoso Vieira, Bruno
   Jose/F 8061 2012; Ribeiro, Isabel/A 6098 2014; Waerenborgh,
   João/C 3701 2011; Santos, Catarina/G 6817 2011; de campos simao
   bettencourt, ana/ABG 2839 2021; Gonçalves, Lídia/H 6410 2011; Vieira,
   Bruno/F 8061 2012; Carmezim, Maria/AAA 3534 2021; Cláudio,
   Ricardo/I 5287 2015
OI Cerdeira, Ana/0000 0002 1486 8770; Claudio, Ricardo/0000 0002 4773 1957;
   Fernandes, Maria Helena/0000 0001 9391 9574; Goncalves,
   Lidia/0000 0002 6799 2740; Pereira, Laura/0000 0002 8818 0039; Cardoso
   Vieira, Bruno Jose/0000 0002 6536 9875; Carmezim,
   Maria/0000 0002 0110 187X; Ribeiro, Isabel/0000 0002 7110 6393; Santos,
   Catarina/0000 0002 8567 0032; Waerenborgh, Joao
   Carlos/0000 0001 6171 4099; 
FU FCT Fundacao para a Ciencia e Tecnologia, I.P [UIDB/04138/2020,
   UIDP/04138/2020, PTDC/BTM SAL/29335/2017, UIDB/50022/2020,
   CQE UIDB/00100/2020, UIDB/50006/2020, UID/Multi/04349/2013,
   PDTC/QUI QIN/32240/2017]; GCT grant [BL156/2019_IST ID]; Fundação para a
   Ciência e a Tecnologia [PTDC/BTM SAL/29335/2017, UID/Multi/04349/2013]
   Funding Source: FCT
FX Support for this work was provided by National Funds through FCT
   Fundacao para a Ciencia e Tecnologia, I.P, under the projects with
   references UIDB/04138/2020 and UIDP/04138/2020, PTDC/BTM SAL/29335/2017,
   UIDB/50022/2020, CQE UIDB/00100/2020, UIDB/50006/2020,
   UID/Multi/04349/2013, PDTC/QUI QIN/32240/2017 and GCT grant to A.C.C.
   (BL156/2019_IST ID).
CR Barrow M, 2017, BIOMATER SCI UK, V6, P101, DOI 10.1039/c7bm00515f
   Boyer C, 2010, NPG ASIA MATER, V2, P23, DOI 10.1038/asiamat.2010.6
   Chen HM, 2018, ACS APPL MATER INTER, V10, P44279, DOI 10.1021/acsami.8b17427
   Chocholata P, 2019, MATERIALS, V12, DOI 10.3390/ma12040568
   Dalby MJ, 2014, NAT MATER, V13, P558, DOI [10.1038/NMAT3980, 10.1038/nmat3980]
   De Santis R, 2011, J APPL POLYM SCI, V122, P3599, DOI 10.1002/app.34771
   Dinali R, 2017, CRIT REV MICROBIOL, V43, P493, DOI 10.1080/1040841X.2016.1267708
   Dulinska Litewka J, 2019, MATERIALS, V12, DOI 10.3390/ma12040617
   Fang CH, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879 017 2621 4
   Ferreira M, 2017, INT J PHARMACEUT, V532, P241, DOI 10.1016/j.ijpharm.2017.08.089
   Frutos G, 2010, ACTA BIOMATER, V6, P804, DOI 10.1016/j.actbio.2009.08.028
   Gomes PS, 2008, ACTA BIOMATER, V4, P630, DOI 10.1016/j.actbio.2007.12.006
   Gomes PS, 2007, ARCH ORAL BIOL, V52, P251, DOI 10.1016/j.archoralbio.2006.10.005
   Goya GF, 2003, J APPL PHYS, V94, P3520, DOI 10.1063/1.1599959
   Guo ZQ, 2017, RSC ADV, V7, P34063, DOI 10.1039/c7ra03574h
   Hao LL, 2019, NANOSCALE, V11, P23423, DOI 10.1039/c9nr07170a
   Hayrapetyan A, 2015, TISSUE ENG PART B RE, V21, P75, DOI [10.1089/ten.teb.2014.0119, 10.1089/ten.TEB.2014.0119]
   HUSER D, 1986, J PHYS C SOLID STATE, V19, P3697, DOI 10.1088/0022 3719/19/19/023
   Jackson RJ, 2018, ACS OMEGA, V3, P4342, DOI 10.1021/acsomega.8b00219
   Kato Y, 2015, J ASIAN CERAM SOC, V3, P44, DOI 10.1016/j.jascer.2014.10.007
   Kharisov BI, 2014, RSC ADV, V4, P45354, DOI 10.1039/c4ra06902a
   Kim DH, 2012, J CELL BIOL, V197, P351, DOI 10.1083/jcb.201108062
   Kim HM, 2005, BIOMATERIALS, V26, P4366, DOI 10.1016/j.biomaterials.2004.11.022
   Kokubo T, 2006, BIOMATERIALS, V27, P2907, DOI 10.1016/j.biomaterials.2006.01.017
   Kostiv U, 2017, RSC ADV, V7, P8786, DOI 10.1039/c7ra00224f
   Kotani H, 2002, J BONE MINER RES, V17, P1814, DOI 10.1359/jbmr.2002.17.10.1814
   Li J, 2019, NANOSCALE, V11, P6905, DOI 10.1039/c8nr09802f
   Li K, 2017, DRUG DISCOV TODAY, V22, P1421, DOI 10.1016/j.drudis.2017.04.008
   Liu Y, 2016, ADV MATER, V28, P8740, DOI 10.1002/adma.201602628
   Lu JW, 2018, NANOMED NANOTECHNOL, V14, P811, DOI 10.1016/j.nano.2017.12.025
   Mahdavi M, 2013, MOLECULES, V18, P7533, DOI 10.3390/molecules18077533
   Martin V, 2019, MAT SCI ENG C MATER, V101, P15, DOI 10.1016/j.msec.2019.03.056
   Martínez Mera I, 2007, MATER LETT, V61, P4447, DOI 10.1016/j.matlet.2007.02.018
   Matos AC, 2014, MAT SCI ENG C MATER, V38, P218, DOI 10.1016/j.msec.2014.02.002
   Matos JC, 2019, NANOMATERIALS BASEL, V9, DOI 10.3390/nano9070943
   Mydosh JA., 1993, SPIN GLASSES
   Ortolani Alessandro, 2016, Joints, V4, P228, DOI 10.11138/jts/2016.4.4.228
   Park EJ, 2014, ARCH TOXICOL, V88, P1607, DOI 10.1007/s00204 014 1210 1
   Pontes C, 2016, INT J PHARMACEUT, V513, P697, DOI 10.1016/j.ijpharm.2016.09.074
   Roca AG, 2007, J PHYS CHEM C, V111, P18577, DOI 10.1021/jp075133m
   Santos C, 2012, J R SOC INTERFACE, V9, P3397, DOI 10.1098/rsif.2012.0487
   Santos C, 2015, CRYST GROWTH DES, V15, P4417, DOI 10.1021/acs.cgd.5b00737
   Sathyanarayanan Madhu Bala, 2013, ISRN Microbiol, V2013, P272086, DOI 10.1155/2013/272086
   Singh AV, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0025029, 10.1371/journal.pone.0026803]
   Sneha Murugesan, 2015, Int J Nanomedicine, V10 Suppl 1, P99, DOI 10.2147/IJN.S79985
   Subhi HT, 2018, ICPAS, V2018, P7, DOI [10.14500/icpas2018.mim104, DOI 10.14500/ICPAS2018.MIM104]
   Sun JF, 2014, SCI REP UK, V4, DOI 10.1038/srep05125
   Valenti MT, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010041
   van Vugt TAG, 2018, J BONE JOINT SURG AM, V100, P2153, DOI 10.2106/JBJS.17.01140
   Vandenberghe RE, 2000, HYPERFINE INTERACT, V126, P247, DOI 10.1023/A:1012603603203
   Vohra S, 2008, J MATER SCI MATER M, V19, P3567, DOI 10.1007/s10856 008 3525 z
   Waerenborgh JC, 2005, MATER LETT, V59, P1644, DOI 10.1016/j.matlet.2005.01.033
   Wan TY, 2015, INJURY, V46, pS39, DOI 10.1016/S0020 1383(15)30053 X
   Wang K, 2016, ACS APPL MATER INTER, V8, P5082, DOI 10.1021/acsami.5b10531
   Wang QW, 2016, BIOMATERIALS, V86, P11, DOI 10.1016/j.biomaterials.2016.02.004
   Wu W, 2015, SCI TECHNOL ADV MAT, V16, DOI 10.1088/1468 6996/16/2/023501
   Xia Y, 2019, MAT SCI ENG C MATER, V104, DOI 10.1016/j.msec.2019.109955
   Xia Y, 2019, NANOMED NANOTECHNOL, V21, DOI 10.1016/j.nano.2019.102069
   Zhang JH, 2014, J MATER CHEM B, V2, P7583, DOI 10.1039/c4tb01063a
   Zhao Y, 2019, COLLOID SURFACE B, V174, P70, DOI 10.1016/j.colsurfb.2018.11.003
NR 60
TC 25
Z9 29
U1 2
U2 57
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0378 5173
EI 1873 3476
J9 INT J PHARMACEUT
JI Int. J. Pharm.
PD JAN 25
PY 2021
VL 593
AR 120097
DI 10.1016/j.ijpharm.2020.120097
PG 13
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA PN8UC
UT WOS:000604746700003
PM 33217547
DA 2025 08 17
ER

PT J
AU Punzalan, LL
   Jiang, LL
   Mao, D
   Das Mahapatra, A
   Sato, S
   Takemoto, Y
   Tsujimura, M
   Kusamori, K
   Nishikawa, M
   Zhou, L
   Uesugi, M
AF Punzalan, Louvy Lynn
   Jiang, Lulu
   Mao, Di
   Das Mahapatra, Amarjyoti
   Sato, Shinichi
   Takemoto, Yasushi
   Tsujimura, Mari
   Kusamori, Kosuke
   Nishikawa, Makiya
   Zhou, Lu
   Uesugi, Motonari
TI Chemoproteomic Profiling of a Pharmacophore Focused Chemical Library
SO CELL CHEMICAL BIOLOGY
LA English
DT Article
ID HUMAN GLYOXALASE I; ALLOSTERIC SITES; BINDING; INHIBITOR; DISCOVERY;
   TARGET; MOLECULES; DESIGN; LIGAND
AB Pharmacophore focused chemical libraries are continuously being created in drug discovery programs, yet screening assays to maximize the usage of such libraries are not fully explored. Here, we report a chemical proteomics approach to reutilizing a focused chemical library of 1,800 indole containing molecules for discovering uncharacterized ligand protein pairs. Gel based protein profiling of the library using a photo affinity indole probe 1 enabled us to find new ligands for glyoxalase 1 (Glo1), an enzyme involved in the detoxification of methylglyoxal. Structure optimization of the ligands yielded an inhibitor for Glo1 (9). Molecule 9 increased the cellular methylglyoxal levels in human cells and suppressed the osteoclast formation of mouse bone marrow derived macrophages. X ray structure analyses revealed that the molecule lies at a site abutting the substrate binding site, which is consistent with the enzyme kinetic profile of 9. Overall, this study exemplifies how chemical proteomics can be used to exploit existing focused chemical libraries.
C1 [Punzalan, Louvy Lynn; Mao, Di; Das Mahapatra, Amarjyoti; Sato, Shinichi; Takemoto, Yasushi; Uesugi, Motonari] Kyoto Univ, Inst Chem Res, Uji, Kyoto 6110011, Japan.
   [Jiang, Lulu; Zhou, Lu; Uesugi, Motonari] Fudan Univ, Sch Pharm, Shanghai 201203, Peoples R China.
   [Tsujimura, Mari; Kusamori, Kosuke; Nishikawa, Makiya] Tokyo Univ Sci, Fac Pharmaceut Sci, 2641 Yamazaki, Noda, Chiba 2788510, Japan.
   [Uesugi, Motonari] Kyoto Univ, Inst Integrated Cell Mat Sci WPI iCeMS, Uji, Kyoto 6110011, Japan.
C3 Kyoto University; Fudan University; Tokyo University of Science; Kyoto
   University
RP Uesugi, M (通讯作者)，Kyoto Univ, Inst Chem Res, Uji, Kyoto 6110011, Japan.; Zhou, L; Uesugi, M (通讯作者)，Fudan Univ, Sch Pharm, Shanghai 201203, Peoples R China.; Uesugi, M (通讯作者)，Kyoto Univ, Inst Integrated Cell Mat Sci WPI iCeMS, Uji, Kyoto 6110011, Japan.
EM zhoulu@fudan.edu.cn; uesugi@scl.kyoto u.ac.jp
RI DasMahapatra, Amarjyoti/NPJ 0259 2025; jiang, lulu/GWC 5395 2022; SATO,
   SHINICHI/KHC 6212 2024; Uesugi, Motonari/AAM 9777 2020
OI Das Mahapatra, Amarjyoti/0000 0002 4411 6844; Mao,
   Di/0000 0002 7950 7669; Kusamori, Kosuke/0000 0003 2065 6122; SATO,
   SHINICHI/0000 0003 3085 419X; 
FU JSPS [17H06408, 19H00922]; International Collaborative Research Program
   of Institute for Chemical Research, Kyoto University [2019 61];
   Grants in Aid for Scientific Research [17H06408, 19H00922] Funding
   Source: KAKEN
FX The authors thank Dr. M. Kawatani for the protocol of osteoclast
   formation; Dr. T. Morii and Dr. S. Futaki for providing access to their
   ITC machine and fluorescence gel imager; Mr. H. Hakariya for helping in
   the DNA sequencing; Dr. R. Nakagawa and Dr. S. Kuraku for the LC MS/MS
   analysis; Dr. F. Quiocho for editing the manuscript. This work was
   supported by JSPS (17H06408 and 19H00922 to M.U.) and the International
   Collaborative Research Program of Institute for Chemical Research, Kyoto
   University (grant no. 2019 61). This work was inspired by the
   international and interdisciplinary environments of WPI iCeMS, JSPS A3
   Foresight Program "Asian Chemical Probe Research Hub,'' and JSPS
   CORE to CORE Program "Asian Chemical Biology Initiative.''
CR Adams PD, 2002, ACTA CRYSTALLOGR D, V58, P1948, DOI 10.1107/S0907444902016657
   Al Balas QA, 2016, DRUG DES DEV THER, V10, P2623, DOI 10.2147/DDDT.S110997
   Asada S, 2003, J AM CHEM SOC, V125, P4992, DOI 10.1021/ja0292703
   Bachovchin DA, 2010, P NATL ACAD SCI USA, V107, P20941, DOI 10.1073/pnas.1011663107
   Baggelaar MP, 2019, ACS CHEM BIOL, V14, P2295, DOI 10.1021/acschembio.9b00640
   Cameron AD, 1997, EMBO J, V16, P3386, DOI 10.1093/emboj/16.12.3386
   Cameron AD, 1999, BIOCHEMISTRY US, V38, P13480, DOI 10.1021/bi990696c
   Chiba T, 2012, BIOORG MED CHEM LETT, V22, P7486, DOI 10.1016/j.bmcl.2012.10.045
   Cognetta AB, 2015, CHEM BIOL, V22, P928, DOI 10.1016/j.chembiol.2015.05.018
   CORNISHB.A, 1974, BIOCHEM J, V137, P143, DOI 10.1042/bj1370143
   Alves FRD, 2009, MINI REV MED CHEM, V9, P782, DOI 10.2174/138955709788452649
   Dhar A, 2009, J CHROMATOGR B, V877, P1093, DOI 10.1016/j.jchromb.2009.02.055
   Distler MG, 2012, J CLIN INVEST, V122, P2306, DOI 10.1172/JCI61319
   Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158
   Frisco Cabanos HL, 2014, ANGEW CHEM INT EDIT, V53, P11208, DOI 10.1002/anie.201405829
   Galligan JJ, 2018, P NATL ACAD SCI USA, V115, P9228, DOI 10.1073/pnas.1802901115
   Hardy JA, 2004, CURR OPIN STRUC BIOL, V14, P706, DOI 10.1016/j.sbi.2004.10.009
   Harris CJ, 2011, COMB CHEM HIGH T SCR, V14, P521
   Janssen APA, 2018, ACS CHEM BIOL, V13, P2406, DOI 10.1021/acschembio.8b00534
   Jin T, 2017, CHEM PHARM BULL, V65, P455, DOI 10.1248/cpb.c16 00800
   Kaushik NK, 2013, MOLECULES, V18, P6620, DOI 10.3390/molecules18066620
   Kawatani M, 2008, P NATL ACAD SCI USA, V105, P11691, DOI 10.1073/pnas.0712239105
   Li WW, 2007, J AM CHEM SOC, V129, P9594, DOI 10.1021/ja073650c
   Liu M, 2010, BIOPHYS CHEM, V147, P28, DOI 10.1016/j.bpc.2009.12.007
   More SS, 2006, BIOORG MED CHEM LETT, V16, P6039, DOI 10.1016/j.bmcl.2006.08.121
   More SS, 2009, J MED CHEM, V52, P4650, DOI 10.1021/jm900382u
   Nokin MJ, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 12119 7
   Ota E, 2018, ACS CHEM BIOL, V13, P876, DOI 10.1021/acschembio.7b00988
   Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076 6879(97)76066 X
   Parker CG, 2017, CELL, V168, P527, DOI 10.1016/j.cell.2016.12.029
   Perez C, 2019, J MED CHEM, V62, P1609, DOI 10.1021/acs.jmedchem.8b01868
   Perron A, 2018, J BIOL CHEM, V293, P8285, DOI 10.1074/jbc.RA118.002316
   Ramsay RR, 2017, MOLECULES, V22, DOI 10.3390/molecules22071192
   Sakamoto H, 2001, CLIN CANCER RES, V7, P2513
   Sato S, 2007, J AM CHEM SOC, V129, P873, DOI 10.1021/ja0655643
   Stratmann B, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18030480
   Suplatov D, 2015, ACTA NATURAE, V7, P34, DOI 10.32607/20758251 2015 7 4 34 54
   Takasawa R, 2008, BIOORGAN MED CHEM, V16, P3969, DOI 10.1016/j.bmc.2008.01.031
   Takasawa R, 2011, BIOORG MED CHEM LETT, V21, P4337, DOI 10.1016/j.bmcl.2011.05.046
   THORNALLEY PJ, 1993, MOL ASPECTS MED, V14, P287, DOI 10.1016/0098 2997(93)90002 U
   Thornalley PJ, 1996, GEN PHARMACOL VASC S, V27, P565, DOI 10.1016/0306 3623(95)02054 3
   Welsch ME, 2010, CURR OPIN CHEM BIOL, V14, P347, DOI 10.1016/j.cbpa.2010.02.018
   Winn MD, 2011, ACTA CRYSTALLOGR D, V67, P235, DOI 10.1107/S0907444910045749
   Xu D, 2016, MOL BIOSYST, V12, P3067, DOI 10.1039/c6mb00231e
   Yuan MG, 2011, BIOORGAN MED CHEM, V19, P1189, DOI 10.1016/j.bmc.2010.12.039
   Zerbe BS, 2012, J CHEM INF MODEL, V52, P2236, DOI [10.1021/ci300175u, 10.1021/cI300175u]
   Zhai J, 2013, CHEMMEDCHEM, V8, P1462, DOI 10.1002/cmdc.201300243
   Zhang H, 2015, ACTA PHARMACOL SIN, V36, P1145, DOI 10.1038/aps.2015.59
   Zhang MZ, 2015, EUR J MED CHEM, V89, P421, DOI 10.1016/j.ejmech.2014.10.065
   Zhang XY, 2019, NAT CHEM BIOL, V15, P737, DOI 10.1038/s41589 019 0279 5
   Zhou J, 2019, ACS CHEM BIOL, V14, P164, DOI 10.1021/acschembio.8b00969
   Zuhl AM, 2012, J AM CHEM SOC, V134, P5068, DOI 10.1021/ja300799t
NR 52
TC 4
Z9 4
U1 0
U2 24
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 2451 9448
J9 CELL CHEM BIOL
JI Cell Chem. Biol.
PD JUN 18
PY 2020
VL 27
IS 6
BP 708
EP +
DI 10.1016/j.chembiol.2020.04.007
PG 21
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA MB7PR
UT WOS:000542791900011
PM 32402240
OA Bronze, Green Submitted
DA 2025 08 17
ER

PT J
AU Wan, JL
   He, ZY
   Zhao, YC
   Hao, XX
   Cui, JR
   Chen, AM
   Zhou, J
   Zhang, JM
AF Wan, Junlai
   He, Zhiyi
   Zhao, Yingchao
   Hao, Xiaoxia
   Cui, Jiarui
   Chen, Anmin
   Zhou, Jun
   Zhang, Jiaming
TI Novel strategy of senescence elimination via toxicity exempted kinome
   perturbations by nanoliposome based thermosensitive hydrogel for
   osteoarthritis therapy
SO ADVANCED COMPOSITES AND HYBRID MATERIALS
LA English
DT Article
DE Osteoarthritis; Cellular senescence; Protein kinase; Nanoliposome;
   Hydrogel
ID DRUG DISCOVERY; IDENTIFICATION; METABOLISM
AB Cellular senescence and the senescence associated secretory phenotype (SASP) have been implicated in osteoarthritis (OA). This study aims to determine whether multi kinase inhibitor YKL 05 099 (Y099) has potential in senescence elimination and OA therapy and whether delivering Y099 by nanoliposmal hydrogel improves the performance of the kinase inhibitor. Y099 inhibited IL 1 beta induced inflammation and catabolism and promoted anabolism of chondrocytes. To attenuate the inhibition of cell viability, nanoliposomal Y099 loaded thermosensitive hydrogel (Y099 Lip Gel) was developed for sustained release and toxicity exemption. Notably, Y099 Lip Gel exhibited a pronounced effect on promoting anabolism and suppressing catabolism and inflammation without causing the inhibition of chondrocyte viability. Moreover, Y099 Lip Gel remarkably increased the master regulator of chondrocyte phenotype Sox9 expression. After four intra articular injections of Y099 Lip Gel in the OA murine model, the histological lesions of cartilage were attenuated by Y099 Lip Gel with subchondral bone loss and osteoclast formation inhibited. Transcriptomic analysis and experimental validations revealed that Y099 Lip Gel suppressed cellular senescence by inhibiting the expression of senescence inducers and SASP factors. Furthermore, the phosphoproteomic analysis showed that Y099 Lip Gel exerted a significant influence on kinome phosphorylation, inhibiting the MAPK and NF kappa B signaling activations. The protective effects of Y099 Lip Gel were also validated in cultured human OA cartilage explants. In conclusion, nanoliposomal Y099 loaded thermosensitive hydrogel has considerable potential in OA therapy. Nanoliposome based hydrogel system has strength in reducing kinase inhibition induced cytotoxicity, enhancing cellular tolerance to kinome perturbation, and improving the performance of protein kinase inhibitors. Senescence elimination via toxicity exempted kinome perturbations achieved by advanced nanotechnology is a promising strategy for OA.
C1 [Wan, Junlai; He, Zhiyi; Chen, Anmin; Zhang, Jiaming] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Orthoped, Wuhan 430030, Peoples R China.
   [Zhao, Yingchao] Huazhong Univ Sci & Technol, Union Hosp, Inst Radiat Oncol, Tongji Med Coll, Wuhan 430022, Peoples R China.
   [Zhao, Yingchao] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Canc Ctr, Wuhan 430022, Peoples R China.
   [Hao, Xiaoxia] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Rehabil, Wuhan 430030, Peoples R China.
   [Cui, Jiarui] Shanghai Univ Tradit Chinese Med, Longhua Hosp, Shanghai 200032, Peoples R China.
   [Zhou, Jun] Showa Univ, Dept Conservat Dent, Div Biomat & Engn, Sch Dent, Tokyo 1428555, Japan.
   [Zhou, Jun] Tokyo Med & Dent Univ TMDU, Inst Biomat & Bioengn, Dept Biofunct Res, Tokyo 1010062, Japan.
C3 Huazhong University of Science & Technology; Huazhong University of
   Science & Technology; Huazhong University of Science & Technology;
   Huazhong University of Science & Technology; Shanghai University of
   Traditional Chinese Medicine; Showa University; Institute of Science
   Tokyo; Tokyo Medical & Dental University (TMDU)
RP Chen, AM; Zhang, JM (通讯作者)，Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Orthoped, Wuhan 430030, Peoples R China.; Zhou, J (通讯作者)，Showa Univ, Dept Conservat Dent, Div Biomat & Engn, Sch Dent, Tokyo 1428555, Japan.; Zhou, J (通讯作者)，Tokyo Med & Dent Univ TMDU, Inst Biomat & Bioengn, Dept Biofunct Res, Tokyo 1010062, Japan.
EM anminchen@hust.edu.cn; zhoujun@dent.showa u.ac.jp;
   jiaming_zhangtjmc@icloud.com
RI He, Zhiyi/AAQ 5150 2020; Zhang, Jiaming/JDC 3656 2023
OI Zhang, Jiaming/0000 0001 8520 566X
FU Japan Society for the Promotion of Science [19K24154]; National Natural
   Science Foundation of China [81902262]; Grants in Aid for Scientific
   Research [23K16036] Funding Source: KAKEN
FX This study was supported by Grants in Aid for Research Activity Start up
   (Grant No. 19K24154) from Japan Society for the Promotion of Science
   (Jun Zhou) and the National Natural Science Foundation of China (Grant
   No. 81902262) (Anmin Chen).
CR Al Lawati H, 2019, EUR J PHARM BIOPHARM, V142, P179, DOI 10.1016/j.ejpb.2019.06.025
   Amirthalingam M, 2021, AGEING RES REV, V71, DOI 10.1016/j.arr.2021.101443
   Ao Y, 2023, CELLS BASEL, V12, DOI 10.3390/cells12040639
   Avelar RA, 2020, GENOME BIOL, V21, DOI 10.1186/s13059 020 01990 9
   Ayala Aguilera CC, 2022, J MED CHEM, V65, P1047, DOI 10.1021/acs.jmedchem.1c00963
   Blanco MNF, 2021, OSTEOARTHR CARTILAGE, V29, P1389, DOI 10.1016/j.joca.2021.07.003
   Cao H, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392 021 00830 x
   Cohen P, 2021, NAT REV DRUG DISCOV, V20, P551, DOI 10.1038/s41573 021 00195 4
   Coryell PR, 2021, NAT REV RHEUMATOL, V17, P47, DOI 10.1038/s41584 020 00533 7
   Cui JR, 2022, FRONT PHYSIOL, V13, DOI 10.3389/fphys.2022.974266
   Cui JR, 2022, AGEING RES REV, V77, DOI 10.1016/j.arr.2022.101608
   Dang CC, 2022, ADV COMPOS HYBRID MA, V5, P606, DOI 10.1007/s42114 022 00500 8
   Dhillon S, 2017, DRUGS, V77, P1987, DOI 10.1007/s40265 017 0835 9
   Fukui T, 2021, OSTEOARTHR CARTILAGE, V29, P68, DOI 10.1016/j.joca.2020.07.012
   Glasson SS, 2010, OSTEOARTHR CARTILAGE, V18, pS17, DOI 10.1016/j.joca.2010.05.025
   Guo Q, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419 020 03341 9
   Hao X, 2022, BONE JOINT RES, V11, P214, DOI 10.1302/2046 3758.114.BJR 2021 0192.R1
   Hernandez Segura A, 2018, TRENDS CELL BIOL, V28, P436, DOI 10.1016/j.tcb.2018.02.001
   Hou C., 2020, Eng. Sci, V11, P19, DOI DOI 10.30919/ES8D1128
   Hou CX, 2023, J MATER SCI TECHNOL, V142, P185, DOI 10.1016/j.jmst.2022.10.007
   Hu WH, 2021, ANN RHEUM DIS, V80, P413, DOI 10.1136/annrheumdis 2020 218089
   Huang WJ, 2022, NAT REV NEPHROL, V18, P611, DOI 10.1038/s41581 022 00601 z
   Hunter DJ, 2019, LANCET, V393, P1745, DOI 10.1016/S0140 6736(19)30417 9
   Jin GZ, 2020, NANOMATERIALS BASEL, V10, DOI 10.3390/nano10122368
   Kim BYS, 2010, NEW ENGL J MED, V363, P2434, DOI 10.1056/NEJMra0912273
   Kim GW, 2015, OSTEOARTHR CARTILAGE, V23, P966, DOI 10.1016/j.joca.2015.01.016
   Kolde R, 2012, BIOINFORMATICS, V28, P573, DOI 10.1093/bioinformatics/btr709
   Li FS, 2023, J MATER SCI TECHNOL, V148, P250, DOI 10.1016/j.jmst.2022.12.003
   Li J, 2015, ASIAN J PHARM SCI, V10, P81, DOI 10.1016/j.ajps.2014.09.004
   Liang S, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01378
   Liu FM, 2022, P NATL ACAD SCI USA, V119, DOI 10.1073/pnas.2202157119
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lotinun S, 2019, J CLIN INVEST, V129, P3058, DOI 10.1172/JCI122936
   Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059 014 0550 8
   Lu WJ, 2021, BIOMED PHARMACOTHER, V134, DOI 10.1016/j.biopha.2020.111103
   Ma YP, 2021, ADV COMPOS HYBRID MA, V4, P906, DOI 10.1007/s42114 021 00358 2
   MANKIN HJ, 1981, J BONE JOINT SURG AM, V63, P131, DOI 10.2106/00004623 198163010 00017
   Manteca A, 2010, MOL CELL PROTEOMICS, V9, P1423, DOI 10.1074/mcp.M900449 MCP200
   McNulty MA, 2011, CARTILAGE, V2, P354, DOI 10.1177/1947603511402665
   Metz KS, 2018, CELL SYST, V7, P347, DOI 10.1016/j.cels.2018.07.001
   Moran G, 2021, Protein Kinases
   Mu Q, 2023, ADV COMPOS HYBRID MA, V6, DOI 10.1007/s42114 022 00607 y
   Novikov FN, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 02568 6
   Park H, 2022, BIOMATER SCI UK, V10, P3223, DOI 10.1039/d1bm01941d
   Ren XS, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24055056
   Roskoski R Jr, 2023, PHARMACOL RES, V187, DOI 10.1016/j.phrs.2022.106552
   Rubbert Roth A, 2020, NEW ENGL J MED, V383, P1511, DOI 10.1056/NEJMoa2008250
   Seo BB, 2022, BIOACT MATER, V7, P14, DOI 10.1016/j.bioactmat.2021.05.028
   Singh AP, 2019, SIGNAL TRANSDUCT TAR, V4, DOI 10.1038/s41392 019 0068 3
   Tang CC, 2021, ELIFE, V10, DOI 10.7554/eLife.67772
   Tarumoto Y, 2020, BLOOD, V135, P56, DOI 10.1182/blood.2019001576
   Valentino A, 2022, ANTIOXIDANTS BASEL, V11, DOI 10.3390/antiox11061210
   Velpurisiva Praveena, 2018, Bioengineering Basel, V5, P83, DOI 10.3390/bioengineering5040083
   Wei YL, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abb3946
   Wein MN, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13176
   Weng PW, 2022, INT J MOL SCI, V23
   Xiao JJ, 2022, CELL DEATH DIS, V13, DOI 10.1038/s41419 022 05260 3
   Yang WY, 2022, ADV COMPOS HYBRID MA, V5, P3146, DOI 10.1007/s42114 022 00556 6
   Yin MN, 2021, FERTIL STERIL, V116, P478, DOI 10.1016/j.fertnstert.2021.01.027
   Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118
   Zarrin AA, 2021, NAT REV DRUG DISCOV, V20, P39, DOI 10.1038/s41573 020 0082 8
   Zhang H., 2021, Elife, V10
   Zhang JM, 2022, FRONT GENET, V13, DOI 10.3389/fgene.2022.821508
   Zhang JM, 2021, J CELL PHYSIOL, V236, P7504, DOI 10.1002/jcp.30386
   Zhou J, 2022, BONE JOINT RES, V11, P362, DOI 10.1302/2046 3758.116.BJR 2021 0436.R1
   Zhu J, 2022, SCI ADV, pabk0011
NR 66
TC 19
Z9 20
U1 9
U2 72
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 2522 0128
EI 2522 0136
J9 ADV COMPOS HYBRID MA
JI Adv. Compos. Hybrid Mater.
PD JUN
PY 2023
VL 6
IS 3
AR 104
DI 10.1007/s42114 023 00673 w
PG 23
WC Nanoscience & Nanotechnology; Materials Science, Composites
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Materials Science
GA G9VX0
UT WOS:000992557600002
OA hybrid
DA 2025 08 17
ER

PT J
AU Hasegawa, Y
   Tanino, H
   Horiguchi, J
   Miura, D
   Ishikawa, T
   Hayashi, M
   Takao, S
   Kim, SJ
   Yamagami, K
   Miyashita, M
   Konishi, M
   Shigeoka, Y
   Suzuki, M
   Taguchi, T
   Kubota, T
   Akazawa, K
   Kohno, N
AF Hasegawa, Yoshie
   Tanino, Hirokazu
   Horiguchi, Jun
   Miura, Daishu
   Ishikawa, Takashi
   Hayashi, Mitsuhiro
   Takao, Shintaro
   Kim, Seung Jin
   Yamagami, Kazuhiko
   Miyashita, Masaru
   Konishi, Muneharu
   Shigeoka, Yasushi
   Suzuki, Masato
   Taguchi, Tetsuya
   Kubota, Tomoyuki
   Akazawa, Kouhei
   Kohno, Norio
CA JONIE Study Grp
TI Randomized Controlled Trial of Zoledronic Acid plus Chemotherapy versus
   Chemotherapy Alone as Neoadjuvant Treatment of HER2 Negative Primary
   Breast Cancer (JONIE Study)
SO PLOS ONE
LA English
DT Article
ID ANTITUMOR ACTIVITY; TUMOR RESPONSE; WOMEN; THERAPY; BISPHOSPHONATE;
   LETROZOLE
AB Purpose
   Zoledronic acid (ZOL) is a nitrogen containing bisphosphonate that induces osteoclast apoptosis and inhibits bone resorption by inhibiting the mevalonate pathway. Its benefit for the prevention of skeletal complications due to bone metastases has been established. However, the antitumor efficacy of ZOL, although suggested by multiple preclinical and clinical studies, has not yet been clinically proven. We performed the present randomized Phase 2 trial to investigate the antitumor effect of ZOL with chemotherapy (CT).
   Methods
   Asian patients with HER2 negative invasive breast cancer were randomly assigned to either the CT or CT+ZOL (CTZ) group. One hundred and eighty eight patients were randomized to either the CT group (n = 95) or the CTZ group (n = 93) from March 2010 to April 2012, and 180 patients were assessed. All patients received four cycles of FEC100 (fluorouracil 500 mg/m(2), epirubicin 100 mg/m(2), and cyclophosphamide 500 mg/m(2)), followed by 12 cycles of paclitaxel at 80 mg/m(2) weekly. ZOL (4 mg) was administered three to four times weekly for 7 weeks to the patients in the CTZ group. The primary endpoint was the pathological complete response (pCR) rate, which was defined as no invasive cancer in the breast tissue specimen. Safety was assessed in all patients who received at least one dose of the study drug.
   Results
   This randomized controlled trial indicated that the rates of pCR in CTZ group (14.8%) was doubled to CT group (7.7%), respectively (one sided chi square test, p = 0.068), though the additional efficacy of zoledronic acid was not demonstrated statistically. The pCR rate in postmenopausal patients was 18.4% and 5.1% in the CTZ and CT groups, respectively (one sided Fisher's exact test, p = 0.071), and that in patients with triple negative breast cancer was 35.3% and 11.8% in the CTZ and CT groups, respectively (one sided Fisher's exact test, p = 0.112). Thus the addition of ZOL to neoadjuvant CT has potential anticancer benefits in postmenopausal patients and patients with triple negative breast cancer. Further investigation is warranted.
C1 [Hasegawa, Yoshie] Hirosaki Municipal Hosp, Dept Breast Surg, Aomori, Japan.
   [Tanino, Hirokazu] Kitasato Univ Hosp, Dept Breast & Thyroid Surg, Sagamihara, Kanagawa, Japan.
   [Horiguchi, Jun] Gunma Univ Hosp, Dept Breast & Endocrine Surg, Gunma, Japan.
   [Miura, Daishu] Toranomon Gen Hosp, Dept Breast & Endocrine Surg, Tokyo, Japan.
   [Ishikawa, Takashi] Yokohama City Univ, Med Ctr, Dept Breast & Thyroid Surg, Yokohama, Kanagawa, Japan.
   [Hayashi, Mitsuhiro] Tokyo Med Univ, Hachioji Med Ctr, Dept Breast Oncol, Tokyo 1608402, Japan.
   [Takao, Shintaro] Hyogo Canc Ctr, Dept Breast Surg, Akashi, Hyogo, Japan.
   [Kim, Seung Jin] Osaka Univ, Grad Sch Med, Dept Breast & Endocrine Surg, Osaka, Japan.
   [Yamagami, Kazuhiko] Shinko Hosp, Dept Breast Oncol, Kobe, Hyogo, Japan.
   [Miyashita, Masaru] Konan Hosp, Dept Surg, Kobe, Hyogo, Japan.
   [Konishi, Muneharu] Hyogo Prefectural Nishinomiya Hosp, Dept Surg, Kobe, Hyogo, Japan.
   [Shigeoka, Yasushi] Yodogawa Christians Hosp, Dept Med Oncol, Osaka, Japan.
   [Suzuki, Masato] Teikyo Univ, Chiba Med Ctr, Dept Surg, Chiba, Japan.
   [Taguchi, Tetsuya] Kyoto Prefectural Univ Med, Dept Endocrine & Breast Surg, Kyoto, Japan.
   [Kubota, Tomoyuki] Kamiiida Daiichi Gen Hosp, Dept Breast Surg, Nagoya, Aichi, Japan.
   [Akazawa, Kouhei] Niigata Univ, Med & Dent Hosp, Dept Med Informat, Niigata, Japan.
   [Kohno, Norio] Kobe Kaisei Hosp, Dept Breast Oncol, Kobe, Hyogo, Japan.
C3 Kitasato University; Gunma University; Toranomon Hospital; Yokohama City
   University; Tokyo Medical University; Hyogo Cancer Center; University of
   Osaka; Teikyo University; Kyoto Prefectural University of Medicine;
   Niigata University
RP Hasegawa, Y (通讯作者)，Hirosaki Municipal Hosp, Dept Breast Surg, Aomori, Japan.
EM vo irene.yoshie@nifty.com
RI Kohno, Norio/Q 5594 2019; Tanino, Hirokazu/AAN 4455 2021
FU Novaltis Pharma; Grants in Aid for Scientific Research [26461939]
   Funding Source: KAKEN
FX This study was supported by Novaltis Pharma. The funder had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Aft R, 2010, LANCET ONCOL, V11, P421, DOI 10.1016/S1470 2045(10)70054 1
   Almubarak Hussain, 2011, J Carcinog, V10, P2, DOI 10.4103/1477 3163.75723
   Charehbili A, 2014, ANN ONCOL, V25, P998, DOI 10.1093/annonc/mdu102
   Coleman R, 2013, CANCER RES, V73, DOI 10.1158/0008 5472.SABCS13 S4 07
   Coleman R, 2013, ANN ONCOL, V24, P398, DOI 10.1093/annonc/mds277
   Coleman R, 2011, BREAST CANCER RES TR, V127, P429, DOI 10.1007/s10549 011 1429 y
   Coleman RE, 2010, BRIT J CANCER, V102, P1099, DOI 10.1038/sj.bjc.6605604
   Coleman RE, 2011, NEW ENGL J MED, V365, P1396, DOI 10.1056/NEJMoa1105195
   Fehm T, 2012, BMC CANCER, V12, DOI 10.1186/1471 2407 12 308
   Fleisch H, 2002, BREAST CANCER RES, V4, P30, DOI 10.1186/bcr414
   Gnant M, 2011, LANCET ONCOL, V12, P631, DOI 10.1016/S1470 2045(11)70122 X
   Gnant M, 2009, NEW ENGL J MED, V360, P679, DOI 10.1056/NEJMoa0806285
   Green JR, 2011, CRIT REV ONCOL HEMAT, V77, pS3, DOI 10.1016/S1040 8428(11)70003 8
   Kohno N, 2005, J CLIN ONCOL, V23, P3314, DOI 10.1200/JCO.2005.05.116
   Neville Webbe HL, 2010, BRIT J CANCER, V102, P1010, DOI 10.1038/sj.bjc.6605579
   Ottewell PD, 2010, INT J CANCER, V126, P522, DOI 10.1002/ijc.24756
NR 16
TC 20
Z9 20
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD DEC 3
PY 2015
VL 10
IS 12
AR e0143643
DI 10.1371/journal.pone.0143643
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA CX9QI
UT WOS:000366040000019
PM 26633806
OA gold, Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU Elron Gross, I
   Glucksam, Y
   Biton, IE
   Margalit, R
AF Elron Gross, Inbar
   Glucksam, Yifat
   Biton, Inbal E.
   Margalit, Rimona
TI A novel Diclofenac carrier for local treatment of osteoarthritis
   applying live animal MRI
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article
DE Drug carrier; NSAIDs; Osteoarthritis; MRI; Local administration
ID DRUG DELIVERY; IN VITRO; MODEL; BIOADHESIVE; SODIUM; KNEE;
   CYCLOOXYGENASES; FORMULATION; LIPOSOMES; EFFICACY
AB The prevailing chronic treatment for osteoarthritis   oral administration of NSAIDs   is accompanied by severe adverse effects and risks of gastrointestinal (GI) toxicity. The working hypothesis of this study was that increased NSAID efficacy and alleviation of adverse effects can be achieved by local administration of a new slow release NSAID carrier formulation. Diclofenac was the test NSAID and collagomers   novel vesicular shaped microparticles based on collagen lipid conjugates   were the carriers. Collagomers were stable in simulated synovial fluid and showed: high efficiency drug encapsulation (85%): slow drug release (T 1/2=11 days); high affinity to target cells (Kd=2.6 nM collagen). In vitro activity of Diclofenac released from the carriers was similar to fresh drug solutions. Diclofenac collagomer therapeutic effects were studied in osteoarthritis induced rats, using live animal MRI. A single intra articular injection of the Diclofenac collagomer formulation reduced inflammation over 3 weeks significantly vs. untreated animals (p<0.001), and vs. the conventional treatment which is free drug PerOs (p<0.03). Bypassing the GI, the novel treatment circumvents adverse effects of the conventional approach. In conclusion, the collagomers performed as functional Diclofenac depots for local treatment of osteoarthritis, avoiding GI adverse effects. The in vivo results merit further investigations of this novel NSAID formulation as a valid option to the conventional treatment. (C) 2009 Elsevier B.V. All rights reserved.
C1 [Elron Gross, Inbar; Glucksam, Yifat; Margalit, Rimona] Tel Aviv Univ, Dept Biochem, IL 69978 Tel Aviv, Israel.
   [Biton, Inbal E.] Tel Aviv Univ, Alfredo Federico Strauss Ctr Computat Neuroimagin, IL 69978 Tel Aviv, Israel.
C3 Tel Aviv University; Tel Aviv University
RP Margalit, R (通讯作者)，Tel Aviv Univ, Dept Biochem, IL 69978 Tel Aviv, Israel.
EM rimona@post.tau.ac.il
CR Bove SE, 2003, OSTEOARTHR CARTILAGE, V11, P821, DOI 10.1016/S1063 4584(03)00163 8
   Braunwald E., 2001, Harrisons Principles of Internal Medicine
   Cestelli A, 2001, J CONTROL RELEASE, V76, P139, DOI 10.1016/S0168 3659(01)00431 X
   Cevc G, 2001, BBA BIOMEMBRANES, V1514, P191, DOI 10.1016/S0005 2736(01)00369 8
   Cevc G, 2008, INT J PHARMACEUT, V360, P29, DOI 10.1016/j.ijpharm.2008.01.051
   CHAMOUARD JM, 1985, BIOCHEM PHARMACOL, V34, P1695, DOI 10.1016/0006 2952(85)90636 7
   *CLINICALTRIALS GO, 2007, NCT00426621 CLINICAL
   Elron Gross I, 2008, BBA BIOMEMBRANES, V1778, P931, DOI 10.1016/j.bbamem.2008.01.002
   Fischer S, 2005, ARCH BIOCHEM BIOPHYS, V434, P108, DOI 10.1016/j.abb.2004.10.029
   Ge ZG, 2006, ARTHRIT RHEUM ARTHR, V55, P493, DOI 10.1002/art.21994
   Gerwin N, 2006, ADV DRUG DELIVER REV, V58, P226, DOI 10.1016/j.addr.2006.01.018
   Guingamp C, 1997, ARTHRITIS RHEUM, V40, P1670, DOI 10.1002/art.1780400917
   Guzman RE, 2003, TOXICOL PATHOL, V31, P619, DOI 10.1080/01926230390241800
   Hardman J.G., 2001, GOODMAN GILMANS PHAR, V10th
   Jiang Y., 2000, Journal of Musculoskeletal & Neuronal Interactions, V1, P45
   Khazaeinia Tahereh, 2003, J Pharm Pharm Sci, V6, P352
   Khazaeinia Tahereh, 2004, Inflammopharmacology, V12, P69, DOI 10.1163/156856004773121383
   Larsen C, 2008, J PHARM SCI US, V97, P4622, DOI 10.1002/jps.21346
   Levin G, 2000, CHEMOTHERAPY, V46, P429, DOI 10.1159/000007323
   Loeuille D, 1997, J RHEUMATOL, V24, P133
   MARGALIT R, 1991, J CONTROL RELEASE, V17, P285, DOI 10.1016/0168 3659(91)90147 6
   PEER DAM, 2005, Patent No. 20050243532005
   Pomonis JD, 2005, PAIN, V114, P339, DOI 10.1016/j.pain.2004.11.008
   Rother M, 2007, ANN RHEUM DIS, V66, P1178, DOI 10.1136/ard.2006.065128
   Saravanan M, 2004, INT J PHARM, V283, P71, DOI 10.1016/j.ijpharm.2004.06.023
   Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145
   Thakkar Hetal, 2005, AAPS PharmSciTech, V6, pE65, DOI 10.1208/pt060112
   Towheed TE, 2006, J RHEUMATOL, V33, P567
   Tsai MF, 2005, J BIOMAT SCI POLYM E, V16, P1319, DOI 10.1163/156856205774269520
   Tunçay M, 2000, J MICROENCAPSUL, V17, P145
   Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97
   YERUSHALMI N, 1994, BBA BIOMEMBRANES, V1189, P13, DOI 10.1016/0005 2736(94)90274 7
   Yerushalmi N, 1998, ARCH BIOCHEM BIOPHYS, V349, P21, DOI 10.1006/abbi.1997.0356
NR 33
TC 34
Z9 37
U1 0
U2 22
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0168 3659
EI 1873 4995
J9 J CONTROL RELEASE
JI J. Control. Release
PD APR 2
PY 2009
VL 135
IS 1
BP 65
EP 70
DI 10.1016/j.jconrel.2008.12.005
PG 6
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Pharmacology & Pharmacy
GA 430BJ
UT WOS:000264963500010
PM 19146892
DA 2025 08 17
ER

PT J
AU Song, PY
   Chen, TY
   Rui, SL
   Duan, XD
   Deng, B
   Armstrong, DG
   Ma, Y
   Deng, WQ
AF Song, Peiyang
   Chen, Tianyi
   Rui, Shunli
   Duan, Xiaodong
   Deng, Bo
   Armstrong, David G.
   Ma, Yu
   Deng, Wuquan
TI Canagliflozin promotes osteoblastic MC3T3 E1 differentiation via
   AMPK/RUNX2 and improves bone microarchitecture in type 2 diabetic mice
SO FRONTIERS IN ENDOCRINOLOGY
LA English
DT Article
DE SGLT2 inhibitors; canagliflozin; bone metabolism; AMPK; RUNX2; type 2
   diabetes mellitus
ID 2 INHIBITORS; GLUCOSE; EMPAGLIFLOZIN; MELLITUS; INCREASE; RECEPTOR;
   INSULIN; AMPK
AB Individuals with type 2 diabetes mellitus (T2DM) have an increased risk of bone metabolic disorders and bone fracture due to disease progression and clinical treatment. The effect of sodium glucose cotransporter 2 (SGLT2) inhibitors, now greatly prescribed for the treatment of T2DM, on bone metabolism is not clear. This study aimed to explore the possible influence of bone metabolic disorder and the underlying mechanism through a comparison of three different SGLT2 inhibitors (canagliflozin, dapagliflozin, and empagliflozin) in the treatment of type 2 diabetic mice. For the in vivo experiments, four groups (DM, DM+Cana, DM+Dapa, and DM+Empa) were established using micro CT to detect the bone microarchitecture and bone related parameters. The study results indicated that canagliflozin, but not dapagliflozin or empagliflozin, increased bone mineral density (p<0.05) and improved bone microarchitecture in type 2 diabetic mice. Furthermore, canagliflozin promoted osteoblast differentiation at a concentration of 5 mu M under high glucose concentration (HG). Phosphorylated adenosine 5' monophosphate (AMP) activated protein kinase (AMPK) alpha (Thr172) has been confirmed to activate run related transcription factor 2 (RUNX2) to perform this function. This effect can be partially reversed by the AMPK inhibitor dorsomorphin (compound C) and strengthened by the AMPK activator acadesine (AICAR) in vitro. The level trend of RUNX2 and p AMPK in vivo were consistent with those in vitro. This study suggested that canagliflozin played a beneficial role in bone metabolism in type 2 diabetic mice compared with dapagliflozin and empagliflozin. It provides some theoretical support for the chosen drugs, especially for patients with osteoporosis or a high risk of fracture.
C1 [Song, Peiyang; Chen, Tianyi; Rui, Shunli; Deng, Bo; Ma, Yu; Deng, Wuquan] Chongqing Univ, Chongqing Univ Cent Hosp, Chongqing Emergency Med Ctr, Sch Med,Dept Endocrinol, Chongqing, Peoples R China.
   [Duan, Xiaodong] Southwest Med Univ, Affiliated Hosp, Dept Rehabil, Luzhou, Sichuan, Peoples R China.
   [Armstrong, David G.] Univ Southern Calif, Keck Sch Med, Dept Surg, Los Angeles, CA USA.
C3 Chongqing University; Southwest Medical University; University of
   Southern California
RP Ma, Y; Deng, WQ (通讯作者)，Chongqing Univ, Chongqing Univ Cent Hosp, Chongqing Emergency Med Ctr, Sch Med,Dept Endocrinol, Chongqing, Peoples R China.
EM 81846846@qq.com; wuquandeng@cqu.edu.cn
FU Chongqing Youth High end Talent Studio [ZQNYXGDRCGZS2021008];
   Fundamental Research Funds for the Central Universities
   [2021CDJYGRH 012]; National Institutes of Health, National Institute of
   Diabetes and Digestive and Kidney Diseases [1R01124789 01A1]; National
   Science Foundation (NSF) Center to Stream Healthcare in Place (#C2SHiP)
   CNS [2052578]; Direct For Computer & Info Scie & Enginr; Division Of
   Computer and Network Systems [2052578] Funding Source: National Science
   Foundation
FX This work was supported by the Chongqing Youth High end Talent Studio
   (ZQNYXGDRCGZS2021008) and the Fundamental Research Funds for the Central
   Universities (2021CDJYGRH 012) awarded to WD. This study is also
   partially supported by National Institutes of Health, National Institute
   of Diabetes and Digestive and Kidney Diseases (1R01124789 01A1) and
   National Science Foundation (NSF) Center to Stream Healthcare in Place
   (#C2SHiP) CNS (2052578) awarded to AD.
CR Abdul Ghani MA, 2011, ENDOCR REV, V32, P515, DOI 10.1210/er.2010 0029
   Akune T, 2002, J CELL BIOL, V159, P147, DOI 10.1083/jcb.200204046
   Ara A, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23010037
   Bilezikian JP, 2016, J CLIN ENDOCR METAB, V101, P43, DOI 10.1210/jc.2015 1860
   Blau JE, 2018, NAT REV NEPHROL, V14, P473, DOI 10.1038/s41581 018 0028 0
   Blau JE, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.99123
   Chao EC, 2010, NAT REV DRUG DISCOV, V9, P551, DOI 10.1038/nrd3180
   Chava S, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 0791 7
   Chung YJ, 2021, CARDIOVASC RES, V117, P2794, DOI 10.1093/cvr/cvaa323
   Cianciolo G, 2020, MOLECULES, V25, DOI 10.3390/molecules25122757
   De Pascalis A, 2021, J NEPHROL, V34, P673, DOI 10.1007/s40620 020 00845 7
   Dyck JRB, 2022, J MOL CELL CARDIOL, V167, P17, DOI 10.1016/j.yjmcc.2022.03.005
   Eller Vainicher C, 2020, J DIABETES RES, V2020, DOI 10.1155/2020/7608964
   Eom YS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0168569
   Fralick M, 2019, ANN INTERN MED, V170, P155, DOI 10.7326/M18 0567
   Guo HH, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0261127
   Guo XT, 2022, EXP CELL RES, V415, DOI 10.1016/j.yexcr.2022.113120
   Ha KH, 2022, J DIABETES INVEST, V13, P986, DOI 10.1111/jdi.13768
   Hardie DG, 2007, NAT REV MOL CELL BIO, V8, P774, DOI 10.1038/nrm2249
   Hardie DG, 2012, NAT REV MOL CELL BIO, V13, P251, DOI 10.1038/nrm3311
   Hidayat K, 2019, OSTEOPOROSIS INT, V30, P1923, DOI 10.1007/s00198 019 04968 x
   Kanazawa I, 2018, INTERNAL MED, V57, P2773, DOI 10.2169/internalmedicine.0905 18
   Karim L, 2018, BONE, V114, P32, DOI 10.1016/j.bone.2018.05.030
   Kohler S, 2018, DIABETES CARE, V41, P1809, DOI 10.2337/dc17 1525
   Leng WL, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/6305735
   Lin F, 2020, MENOPAUSE, V27, P326, DOI 10.1097/GME.0000000000001473
   Ljunggren Ö, 2012, DIABETES OBES METAB, V14, P990, DOI 10.1111/j.1463 1326.2012.01630.x
   McCarty MF, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23094776
   Mu W, 2018, PHARMACOL RES, V129, P462, DOI 10.1016/j.phrs.2017.11.020
   Napoli N, 2017, NAT REV ENDOCRINOL, V13, P208, DOI 10.1038/nrendo.2016.153
   Ock M, 2022, J CLIN PHARM THER, V47, P1028, DOI 10.1111/jcpt.13640
   Oelze M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112394
   Ogawa N, 2007, HORM METAB RES, V39, P871, DOI 10.1055/s 2007 991157
   Parreiras e Silva LT, 2018, ANN NY ACAD SCI, V1415, P47, DOI 10.1111/nyas.13657
   Perkovic V, 2019, NEW ENGL J MED, V380, P2295, DOI 10.1056/NEJMoa1811744
   Ren CX, 2021, ADV HEALTHC MATER, V10, DOI 10.1002/adhm.202100196
   Rieg T, 2014, AM J PHYSIOL RENAL, V306, pF188, DOI 10.1152/ajprenal.00518.2013
   Sassi F, 2018, BMC ENDOCR DISORD, V18, DOI 10.1186/s12902 018 0283 x
   Scheen AJ, 2014, DIABETES METAB, V40, pS4, DOI 10.1016/S1262 3636(14)72689 8
   Schimmack G, 2006, DIABETES OBES METAB, V8, P591, DOI 10.1111/j.1463 1326.2005.00561.x
   Stein GS, 2004, ONCOGENE, V23, P4315, DOI 10.1038/sj.onc.1207676
   Sun RX, 2022, ORAL DIS, V28, P1170, DOI 10.1111/odi.13808
   Thrailkill KM, 2020, BONE, V141, DOI 10.1016/j.bone.2020.115625
   Thrailkill KM, 2020, BONE, V133, DOI 10.1016/j.bone.2020.115254
   Thrailkill KM, 2017, BONE, V94, P141, DOI 10.1016/j.bone.2016.10.026
   Tong XS, 2020, CELL PROLIFERAT, V53, DOI 10.1111/cpr.12714
   Uthman L, 2021, CARDIOVASC DRUG THER, V35, P1083, DOI 10.1007/s10557 020 07083 w
   Watts NB, 2016, J CLIN ENDOCR METAB, V101, P156, DOI 10.1210/jc.2015 3167
   Yabe D, 2015, EXPERT OPIN DRUG SAF, V14, P795, DOI 10.1517/14740338.2015.1034105
   Yang L, 2019, J ENDOCRINOL INVEST, V42, P1125, DOI 10.1007/s40618 019 01034 5
   Zhang YS, 2021, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.735824
   Zhang ZQ, 2021, DIABET METAB SYND OB, V14, P227, DOI 10.2147/DMSO.S289712
   Zhao B, 2021, J DIABETES INVEST, V12, P1400, DOI 10.1111/jdi.13481
   Zhou H, 2018, REDOX BIOL, V15, P335, DOI 10.1016/j.redox.2017.12.019
   Zhou H, 2022, CELL PROLIFERAT, V55, DOI 10.1111/cpr.13162
   Zhou Z, 2019, DIABETOLOGIA, V62, P1854, DOI 10.1007/s00125 019 4955 5
   Zhuo M, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.30762
NR 57
TC 11
Z9 13
U1 0
U2 19
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1664 2392
J9 FRONT ENDOCRINOL
JI Front. Endocrinol.
PD DEC 16
PY 2022
VL 13
AR 1081039
DI 10.3389/fendo.2022.1081039
PG 14
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 7L2BE
UT WOS:000905776700001
PM 36589840
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Yang, X
   Zhang, H
   Wang, J
   Zhang, Z
   Li, C
AF Yang, X.
   Zhang, H.
   Wang, J.
   Zhang, Z.
   Li, C.
TI Puerarin decreases bone loss and collagen destruction in rats with
   ligature induced periodontitis
SO JOURNAL OF PERIODONTAL RESEARCH
LA English
DT Article
DE extracellular matrix metalloproteinase inducer; nuclear factor kappa B;
   periodontitis; puerarin; receptor activator of nuclear factor kappa B
   ligand
ID MATRIX METALLOPROTEINASE INDUCER; CCL4 INDUCED HEPATIC FIBROSIS;
   TUMOR NECROSIS FACTOR; KAPPA B ACTIVATION; RECEPTOR ACTIVATOR;
   INFLAMMATORY RESPONSE; TEMPORAL EXPRESSION; PI3K/AKT PATHWAY; TNF ALPHA;
   IN VIVO
AB Background and ObjectivePuerarin, the most abundant isoflavonoid in kudzu root, shows various bioactivities, including bone sparing, anti inflammatory and antiproteinase properties. This study aimed to evaluate the effects of puerarin in a rat model of ligature induced periodontitis.
   Material and MethodsRat models of periodontitis were developed by bilaterally placing ligatures around the first mandibular molars. Puerarin was administrated daily by gavage at doses of 100, 200 and 400mg/kg, starting a day before the placement of ligatures. Rats were humanely killed 7d after the induction of periodontitis. Micro computed tomography and sirius red staining were used to evaluate alveolar bone loss and collagen destruction, respectively. Histomorphometrical analysis was used to assess the inflammatory cell infiltration. Immunohistochemistry and tartrate resistant acid phosphatase were used to detect receptor activator of nuclear factor kappa B ligand and osteoprotegerin expressions, and osteoclast activity in the gingiva and alveolar bone. The activation of nuclear factor kappa B, production of tumor necrosis factor (TNF)  and interleukin (IL) 1, glycosylation of extracellular matrix metalloproteinase inducer, and production of matrix metalloproteinase (MMP) 2 and MMP 9 in the gingiva were assessed by Western blot.
   ResultsPuerarin at doses of 200 and 400mg/kg significantly reduced the alveolar bone loss compared with the vehicle group. Collagen destruction and inflammatory cell infiltration were significantly less in the puerarin treated group (200mg/kg) compared with that of the vehicle group. Puerarin (200mg/kg) also reduced the ratio of receptor activator of nuclear factor kappa B ligand/osteoprotegerin and osteoclast activity. Western blot analysis showed that puerarin (200mg/kg) inhibited the activation of nuclear factor kappa B p65, which is associated with lower IL 1 and TNF  production, and reduced the glycosylation of extracellular matrix metalloproteinase inducer, which is associated with lower levels of MMP 2 and MMP 9.
   ConclusionsPuerarin reduced the alveolar bone loss and collagen destruction in rats with ligature induced periodontitis by inhibiting the production of RANKL, IL 1, TNF , MMP 2 and MMP 9. Thus, puerarin can be considered a promising agent for adjunctive therapy of periodontitis.
C1 [Yang, X.; Zhang, H.; Zhang, Z.] Wuhan Univ, State Key Lab Breeding Base Basic Sci Stomatol Hu, Minist Educ, Sch & Hosp Stomatol, Wuhan 430079, Hubei, Peoples R China.
   [Yang, X.; Zhang, H.; Zhang, Z.] Wuhan Univ, Key Lab Oral Biomed, Minist Educ, Sch & Hosp Stomatol, Wuhan 430079, Hubei, Peoples R China.
   [Zhang, H.; Li, C.] Wuhan Univ, Dept Periodontol, Sch & Hosp Stomatol, Wuhan 430079, Hubei, Peoples R China.
   [Wang, J.] Guangxi Med Univ, Dept Periodont & Oral Med, Coll Stomatol, Nanning, Guangxi, Peoples R China.
C3 Wuhan University; Wuhan University; Wuhan University; Guangxi Medical
   University
RP Li, C (通讯作者)，Wuhan Univ, Dept Periodontol, Sch & Hosp Stomatol, 237 Luoyu Rd, Wuhan 430079, Hubei, Peoples R China.
EM lcz56@163.com
RI Li, Chengzhang/R 1988 2019; ZHANG, ZHEN/X 6370 2018
OI Li, Chengzhang/0000 0002 0494 4258; Zhang, Zhen/0000 0001 8226 9182
FU National Natural Science Foundation Emphases Item of China [81371146]
FX The study was supported by grants from the National Natural Science
   Foundation Emphases Item of China (no. 81371146).
CR Araujo AA, 2013, J CLIN PERIODONTOL, V40, P1104, DOI 10.1111/jcpe.12160
   Beklen A, 2007, J DENT RES, V86, P347, DOI 10.1177/154405910708600409
   Belibasakis GN, 2012, J CLIN PERIODONTOL, V39, P239, DOI 10.1111/j.1600 051X.2011.01810.x
   Bostanci N, 2007, J PERIODONTAL RES, V42, P287, DOI 10.1111/j.1600 0765.2006.00946.x
   Bostanci N, 2007, J CLIN PERIODONTOL, V34, P370, DOI 10.1111/j.1600 051X.2007.01061.x
   Boyce Brendan F., 2005, Keio Journal of Medicine, V54, P127, DOI 10.2302/kjm.54.127
   Branco de Almeida LS, 2012, J PERIODONTOL, V83, P664, DOI 10.1902/jop.2011.110370
   Cai X, 2008, J PERIODONTAL RES, V43, P14, DOI 10.1111/j.1600 0765.2007.00989.x
   desAraujo JR, 2013, PLOS ONE, V8
   Dong F, 2014, EVID BASED COMPL ALT, V2014
   Dong W, 2009, J PERIODONTAL RES, V44, P125, DOI 10.1111/j.1600 0765.2008.01105.x
   Fu MMJ, 2015, J PERIODONTOL, V86, P82, DOI 10.1902/jop.2014.140366
   Gibson MP, 2013, J PERIODONTAL RES, V48, P221, DOI 10.1111/j.1600 0765.2012.01523.x
   Górska R, 2003, J CLIN PERIODONTOL, V30, P1046, DOI 10.1046/j.0303 6979.2003.00425.x
   Graves DT, 2003, J PERIODONTOL, V74, P391, DOI 10.1902/jop.2003.74.3.391
   Guimaraes MR, 2011, J PERIODONTAL RES, V46, P269, DOI 10.1111/j.1600 0765.2010.01342.x
   Guo C, 2013, FOOD CHEM TOXICOL, V56, P436, DOI 10.1016/j.fct.2013.02.051
   Hu WZ, 2011, PHARMACOL REP, V63, P781, DOI 10.1016/S1734 1140(11)70590 4
   Huang F, 2012, BIOCHIMIE, V94, P1143, DOI 10.1016/j.biochi.2012.01.018
   Kawakami T, 2011, BMC CANCER, V11, DOI 10.1186/1471 2407 11 300
   Kim KM, 2010, TOXICOL APPL PHARM, V244, P106, DOI 10.1016/j.taap.2009.12.023
   Kinane DF, 2011, J CLIN PERIODONTOL, V38, P44, DOI 10.1111/j.1600 051X.2010.01682.x
   Kirkwood KL, 2007, PERIODONTOL 2000, V43, P294, DOI 10.1111/j.1600 0757.2006.00166.x
   Li R, 2013, FOOD CHEM TOXICOL, V52, P69, DOI 10.1016/j.fct.2012.10.059
   Liang JB, 2012, MOL MED REP, V5, P1419, DOI 10.3892/mmr.2012.854
   Liu L, 2013, J PERIODONTAL RES, V48, P615, DOI 10.1111/jre.12047
   Liu L, 2010, J PERIODONTAL RES, V45, P541, DOI 10.1111/j.1600 0765.2010.01269.x
   Liu LH, 2010, BIOCHEM BIOPH RES CO, V391, P1000, DOI 10.1016/j.bbrc.2009.12.005
   Liu LS, 2012, J ENDODONT, V38, P943, DOI 10.1016/j.joen.2012.03.010
   Mahdy HM, 2014, CAN J PHYSIOL PHARM, V92, P252, DOI 10.1139/cjpp 2013 0398
   MAKELA M, 1994, J DENT RES, V73, P1397, DOI 10.1177/00220345940730080201
   Michihara S, 2012, J NUTR SCI VITAMINOL, V58, P202, DOI 10.3177/jnsv.58.202
   Napimoga MH, 2013, J NAT PROD, V76, P2316, DOI 10.1021/np400691n
   Napimoga MH, 2009, INT IMMUNOPHARMACOL, V9, P216, DOI 10.1016/j.intimp.2008.11.010
   Papadimitropoulou A, 2013, MOL CELL BIOCHEM, V379, P107, DOI 10.1007/s11010 013 1632 8
   Pihlstrom BL, 2005, LANCET, V366, P1809, DOI 10.1016/S0140 6736(05)67728 8
   Prasain JK, 2003, J AGR FOOD CHEM, V51, P4213, DOI 10.1021/jf030174a
   STASHENKO P, 1987, J IMMUNOL, V138, P1464
   Wang D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025011
   Wang XX, 2005, METABOLISM, V54, P1536, DOI 10.1016/j.metabol.2005.05.022
   Wang XX, 2003, J BONE MINER METAB, V21, P268, DOI 10.1007/s00774 003 0420 z
   Wang Y, 2014, PHYTOMEDICINE, V21, P1032, DOI 10.1016/j.phymed.2014.04.012
   Wong KH, 2011, J ETHNOPHARMACOL, V134, P584, DOI 10.1016/j.jep.2011.02.001
   Wong R, 2007, OSTEOARTHR CARTILAGE, V15, P894, DOI 10.1016/j.joca.2007.02.009
   Xiao C, 2011, EUR J PHARMACOL, V666, P242, DOI 10.1016/j.ejphar.2011.05.061
   Xu LY, 2013, PHYTOMEDICINE, V20, P1172, DOI 10.1016/j.phymed.2013.06.008
   Yang D, 2013, J PERIODONTAL RES, V48, P411, DOI 10.1111/jre.12019
   Yang XJ, 2010, BASIC CLIN PHARMACOL, V107, P637, DOI 10.1111/j.1742 7843.2010.00548.x
   Yao XJ, 2012, J ETHNOPHARMACOL, V141, P322, DOI 10.1016/j.jep.2012.02.038
   Zhang L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097824
   Zhang Y, 2007, PLANTA MED, V73, P341, DOI 10.1055/s 2007 967168
   Zhou T, 2013, ACTA ODONTOL SCAND, V71, P349, DOI 10.3109/00016357.2012.682092
   Zhou YX, 2014, PHYTOTHER RES, V28, P961, DOI 10.1002/ptr.5083
   Zhu LX, 2012, INT J BIOCHEM CELL B, V44, P1139, DOI 10.1016/j.biocel.2012.04.003
   Zhu X, 2014, CURR MED CHEM, V21, P2138, DOI 10.2174/0929867321666131227163352
NR 55
TC 33
Z9 37
U1 1
U2 31
PU WILEY BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0022 3484
EI 1600 0765
J9 J PERIODONTAL RES
JI J. Periodont. Res.
PD DEC
PY 2015
VL 50
IS 6
BP 748
EP 757
DI 10.1111/jre.12261
PG 10
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA CU6QT
UT WOS:000363658300007
PM 25645818
DA 2025 08 17
ER

PT J
AU Lamego, I
   Marques, MPM
   Duarte, IF
   Martins, AS
   Oliveira, H
   Gil, AM
AF Lamego, Ines
   Marques, M. Paula M.
   Duarte, Iola F.
   Martins, Ana S.
   Oliveira, Helena
   Gil, Ana M.
TI Impact of the Pd2Spermine Chelate on Osteosarcoma Metabolism:
   An NMR Metabolomics Study
SO JOURNAL OF PROTEOME RESEARCH
LA English
DT Article
DE palladium anticancer drugs; osteosarcoma; osteoblasts; metabolomics; NMR
ID COLORIMETRIC ASSAY; PLATINUM COMPLEXES; DNA INTERACTIONS; ANTICANCER;
   CISPLATIN; PALLADIUM(II); CYTOTOXICITY; SPERMINE; CELLS; SPECTROSCOPY
AB A metabolomics study of Pd(2)Sperrnine(Spm) on osteosarcoma MG 63 and oSteoblastic HOb cells is presented to assess the impact of the potential palladium drug on cell metabolism compared with cisplatin (cDDP). Despite its higher cytotoxicity, Pd(2)Spm indticed lower (and reversible) metabolic impact on MG 63 cells and the absence of apoptosis; conversely, it induced significant deviations in osteoblastic:amino acid metabolism. However, when in combination with doxorubicin and methotrexate, Pd(2)Spm induced strong metabolic deviations on lipids, choline compounds, amino acids, nucleotides, and compounds related to antioxidative.mechanisms (e.g., glutathione,,inositol, hypoxanthine), similarly to the cDDP cocktail. Synergetic effects included triggering of lipid biosynthesis by Pd(2)Spm in the presence of doxorubicin (and reinforced by methotrexate) and changes in the glycosylation substrate uridine diphosphate acetylgalactosamine and methionine and serine metabolisms. This work provides promising results related to the impact of Pd(2)Spm on osteosarcoma cellular metabolism, particularly in drug combination protocols. Lipid metabolism, glycosylation, and amino acid metabolisms emerge as relevant features for targeted studies to further understand a potential anticancer mechanism of combined Pd(2)Spm.
C1 [Lamego, Ines; Duarte, Iola F.; Martins, Ana S.; Gil, Ana M.] Univ Aveiro, Dept Chem, P 3810 Aveiro, Portugal.
   [Lamego, Ines; Duarte, Iola F.; Martins, Ana S.; Gil, Ana M.] Univ Aveiro, CICECO Aveiro Inst Mat CICECO UA, P 3810 Aveiro, Portugal.
   [Lamego, Ines; Marques, M. Paula M.] Univ Coimbra, R&D Unit Mol Phys Chem, P 3000213 Coimbra, Portugal.
   [Marques, M. Paula M.] Univ Coimbra, Fac Sci & Technol, Dept Life Sci, P 3000213 Coimbra, Portugal.
   [Oliveira, Helena] Univ Aveiro, Dept Biol, P 3810 Aveiro, Portugal.
   [Oliveira, Helena] Univ Aveiro, CESAM, P 3810 Aveiro, Portugal.
C3 Universidade de Aveiro; Universidade de Aveiro; Universidade de Coimbra;
   Universidade de Coimbra; Universidade de Aveiro; Universidade de Aveiro
RP Gil, AM (通讯作者)，Univ Aveiro, Dept Chem, P 3810 Aveiro, Portugal.; Gil, AM (通讯作者)，Univ Aveiro, CICECO Aveiro Inst Mat CICECO UA, P 3810 Aveiro, Portugal.
EM agil@ua.pt
RI Gil, Ana/B 5440 2013; Duarte, Iola/H 5505 2013; Marques, Maria
   Paula/M 4130 2013; Marques, Maria/M 4130 2013; Oliveira,
   Helena/M 5068 2013; Gil, Ana/O 3871 2019
OI Gil, Ana/0000 0003 3766 4364; Duarte, Iola/0000 0003 4289 9256; Lamego,
   Ines/0000 0002 6079 1698; Marques, Maria Paula/0000 0002 8391 0055;
   Martins, Ana Sofia/0000 0001 6865 5853; Oliveira,
   Helena/0000 0002 4673 0696; 
FU FCT/MEC [FCT/UID/CTM/ 50011/2013]; Portuguese Foundation for Science and
   Technology [PTDC/QEQMED/1890/2014, 3599]; European Community Fund FEDER
   [3599 PPCDT]; FCT funds [UID/MULTI/00070/2013, PTDC/SAL BEB/66896/2006,
   SFRH/BD/63916/2009, SFRH/BD/111576/2015, SFRH/BPD/111736/2015];
   Portuguese National NMR Network (RNRMN); FEDER; Fundação para a Ciência
   e a Tecnologia [SFRH/BD/63916/2009, UID/Multi/00070/2013,
   SFRH/BD/111576/2015, SFRH/BPD/111736/2015] Funding Source: FCT
FX This work was developed within the scope of the project CICECO Aveiro
   Institute of Materials (ref. FCT/UID/CTM/ 50011/2013), financed by
   national funds through the FCT/MEC and cofinanced by FEDER under the
   PT2020 Partnership Agreement. We acknowledge financial support from the
   Portuguese Foundation for Science and Technology: PTDC/QEQMED/1890/2014,
   within Project 3599, to Promote Scientific Production and Technological
   Development, as well as the formation of thematic networks (3599 PPCDT),
   jointly financed by the European Community Fund FEDER. FCT funds are
   also acknowledged from UID/MULTI/00070/2013 (R&D Group "Molecular
   Physical Chemistry", University of Coimbra), PTDC/SAL BEB/66896/2006,
   SFRH/BD/63916/2009, SFRH/BD/111576/2015, and SFRH/BPD/111736/2015 grants
   and from the Portuguese National NMR Network (RNRMN). We thank the
   Associate Laboratory IBMC INEB for kindly providing the MG 63 cell line,
   and I.F.D. acknowledges FCT/MCTES for a research contract under the
   "Investigador FCT" 2014 Program.
CR [Anonymous], 2009, ANAL CHEM, V81, P56
   de Carvalho ALMB, 2016, FARADAY DISCUSS, V187, P273, DOI 10.1039/c5fd00148j
   Berben L, 2012, INT J NURS STUD, V49, P1039, DOI 10.1016/j.ijnurstu.2012.01.015
   Brabec V, 2005, DRUG RESIST UPDATE, V8, P131, DOI 10.1016/j.drup.2005.04.006
   Bradshaw Pierce EL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058089
   Braga SS, 2014, BIOMETALS, V27, P507, DOI 10.1007/s10534 014 9725 8
   Butkinaree C, 2010, BBA GEN SUBJECTS, V1800, P96, DOI 10.1016/j.bbagen.2009.07.018
   Cloarec O, 2005, ANAL CHEM, V77, P1282, DOI 10.1021/ac048630x
   Codina G, 1999, HELV CHIM ACTA, V82, P1025, DOI 10.1002/(SICI)1522 2675(19990707)82:7<1025::AID HLCA1025>3.3.CO;2 T
   Corduneanu O, 2010, BIOELECTROCHEMISTRY, V78, P97, DOI 10.1016/j.bioelechem.2009.08.003
   Cuperlovic Culf M, 2014, METABOLITES, V4, P807, DOI 10.3390/metabo4030807
   Dieterle F, 2006, ANAL CHEM, V78, P4281, DOI 10.1021/ac051632c
   Duarte IF, 2013, MOL PHARMACEUT, V10, P4242, DOI 10.1021/mp400335k
   Duarte IF, 2010, J PROTEOME RES, V9, P5877, DOI 10.1021/pr100635n
   Duarte IF, 2009, ANAL CHEM, V81, P5023, DOI 10.1021/ac900545q
   Fiuza SM, 2011, CHEM BIOL DRUG DES, V77, P477, DOI 10.1111/j.1747 0285.2011.01081.x
   Giovagnini L, 2005, J MED CHEM, V48, P1588, DOI 10.1021/jm049191x
   Kapdi AR, 2014, CHEM SOC REV, V43, P4751, DOI 10.1039/c4cs00063c
   Komeda S, 2011, METALLOMICS, V3, P650, DOI 10.1039/c1mt00012h
   Kostova I, 2006, CURR MED CHEM, V13, P1085, DOI 10.2174/092986706776360941
   Kostova I, 2009, ANTI CANCER AGENT ME, V9, P827, DOI 10.2174/187152009789124646
   Lamego I, 2014, J PROTEOME RES, V13, P6033, DOI 10.1021/pr500907d
   Lefort N, 2014, J PHARMACEUT BIOMED, V93, P77, DOI 10.1016/j.jpba.2013.08.017
   Lovejoy KS, 2009, DALTON T, P10651, DOI 10.1039/b913896j
   Malina J, 2014, INORG CHEM, V53, P1662, DOI 10.1021/ic402796k
   Marques M. P. M., 2013, ISRN Spectroscopy, DOI 10.1155/2013/287353
   Messori L, 2013, CHEM COMMUN, V49, P10100, DOI 10.1039/c3cc46400h
   Mirbahai L, 2011, INT J BIOCHEM CELL B, V43, P990, DOI 10.1016/j.biocel.2010.07.002
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022 1759(83)90303 4
   NAVARRORANNINGER C, 1993, J INORG BIOCHEM, V52, P37, DOI 10.1016/0162 0134(93)85621 E
   Nowotarski SL, 2013, EXPERT REV MOL MED, V15, DOI 10.1017/erm.2013.3
   Pan XY, 2011, J PROTEOME RES, V10, P3493, DOI 10.1021/pr200114v
   Qu Y, 2015, DALTON T, V44, P3563, DOI 10.1039/c4dt03237c
   Ray S, 2007, J AM CHEM SOC, V129, P15042, DOI 10.1021/ja075889z
   ROSENBERG B, 1969, NATURE, V222, P385, DOI 10.1038/222385a0
   Silva TM, 2014, AMINO ACIDS, V46, P339, DOI 10.1007/s00726 013 1621 y
   Silva TM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055651
   SKEHAN P, 1990, JNCI J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107
   Soares AS, 2007, LETT DRUG DES DISCOV, V4, P460, DOI 10.2174/157018007781788516
   Tummala R, 2010, ONCOL REP, V24, P15, DOI 10.3892/or_00000823
   Vermathen M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128478
   Veselkov KA, 2009, ANAL CHEM, V81, P56, DOI 10.1021/ac8011544
   Vichai V, 2006, NAT PROTOC, V1, P1112, DOI 10.1038/nprot.2006.179
   Voigt W, 2005, METH MOLEC MED, V110, P39
   Wheate NJ, 2010, DALTON T, V39, P8113, DOI 10.1039/c0dt00292e
   Whelan JS, 2015, ANN ONCOL, V26, P407, DOI 10.1093/annonc/mdu526
   Wiltshaw W., 1979, Platinum Metals Review, V23, P90, DOI DOI 10.1595/003214079X2339098
   Wishart DS, 2007, NUCLEIC ACIDS RES, V35, pD521, DOI 10.1093/nar/gkl923
   Zheng JF, 2015, MED SCI MONITOR, V21, P1781, DOI 10.12659/MSM.894669
NR 49
TC 26
Z9 28
U1 0
U2 31
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1535 3893
EI 1535 3907
J9 J PROTEOME RES
JI J. Proteome Res.
PD APR
PY 2017
VL 16
IS 4
BP 1773
EP 1783
DI 10.1021/acs.jproteome.7b00035
PG 11
WC Biochemical Research Methods
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA ER7IO
UT WOS:000398985700035
PM 28244322
OA Green Published
DA 2025 08 17
ER

PT J
AU Pengjam, Y
   Panichayupakaranant, P
   Tanrattanakul, V
AF Pengjam, Yutthana
   Panichayupakaranant, Pharkphoom
   Tanrattanakul, Varaporn
TI Curcuminoid (CRE Ter)/Liposome as delivery platform for
   anti osteoclastogenesis via NF κB/ERK pathways in RANKL induced RAW
   264.7 cells through PLA foams
SO HELIYON
LA English
DT Article
DE Curcuminoid (CRE Ter); Liposome encapsulates; NF kappa B/ERK pathways;
   Osteoclastogenesis; PLA foams
ID CATHEPSIN K; DIFFERENTIATION; LIPOSOMES; CANCER; BIOAVAILABILITY;
   ACTIVATION; CHEMISTRY; SCAFFOLD
AB Aims: Curcuminoid (CRE Ter) is the active component of turmeric, and is widely understood to offer anticancer, antioxidant, and anti inflammatory properties. The drawbacks, however, include rapid metabolism and systemic elimination as well as minimal bioavailability. In an attempt to address the issue of bioavailability, this study seeks to encapsulate CRE Ter in a liposome before its incorporation on PLA foams in order to inhibit the process of osteoclastogenesis which takes place in RANKL induced RAW 264.7 cells.
   Main methods: Having encapsulated the CRE Ter into the liposomes, the influence of the release of liposomal CRETer from PLA foams in order to inhibit the process of osteoclastogenesis in the case of RANKL induced RAW 264.7 cells was investigated. By measuring the decline in tartrate resistant acid phosphatase (TRAP) content it was possible to evaluate the influence of CRE Ter/Liposome upon osteoclastogenesis in vitro. Immunocytochemistry was employed to assess the marker for the monocyte/macrophage cells F4/80 content, while Western blots were used to evaluate the underlying mechanisms involved.
   Key findings: The findings demonstrate a novel method which employs tissue engineering scaffolds, which are produced to work alongside advanced additive manufacturing techniques with their basis in concepts from the field of alternative medicine. Initially, it was confirmed that CRE Ter/Liposome at 20 mu g/ml is able to inhibit the creation of multinucleated osteoclasts which are induced by the receptor activator of the nuclear factor kappa B ligand (RANKL) in RAW 264.7 cells. It was shown that the CRE Ter/liposome was able to increase the F4/80 content (F4/80 immunohistochemistry) in the RANKL treated RAW 264.7 cells. The TRAP content was lowered by the CRE Ter/liposome along with the osteoclast specific gene content such as cathepsin K, via the use of liposomeencapsulated PLA foams. When treated with CRE Ter/liposome, RANKL induced NF kappa B and ERK components such as NF kappa B p65, ERK, phospho NF kappa B p65, and phospho ERK pathways were all suppressed.
   Significance: The successful encapsulation of CRE Ter into the liposomes offered a new opportunity to provide a new inhibitor of osteoclastogenesis and offers the possibility of developing treatments capable of addressing diseases which concern abnormal bone lysis.
C1 [Pengjam, Yutthana] Prince Songkla Univ, Fac Med Technol, Hat Yai 90110, Thailand.
   [Panichayupakaranant, Pharkphoom] Prince Songkla Univ, Fac Pharmaceut Sci, Dept Pharmacognosy & Pharmaceut Bot, Hat Yai 90112, Thailand.
   [Panichayupakaranant, Pharkphoom] Prince Songkla Univ, Fac Pharmaceut Sci, Phytomed & Pharmaceut Biotechnol Excellence Ctr, Hat Yai 90112, Thailand.
   [Tanrattanakul, Varaporn] Prince Songkla Univ, Dept Mat Sci & Technol, Fac Sci, Hat Yai 90110, Thailand.
C3 Prince of Songkla University; Prince of Songkla University; Prince of
   Songkla University; Prince of Songkla University
RP Pengjam, Y (通讯作者)，Prince Songkla Univ, Fac Med Technol, Hat Yai 90110, Thailand.
EM yutthana.p@psu.ac.th
RI ; PANICHAYUPAKARANANT, PHARKPHOOM/X 5227 2018
OI Pengjam, Yutthana/0000 0001 9329 4084; Panichayupakaranant,
   Pharkphoom/0000 0003 1097 8822; 
FU Prince of Songkla University [MET6202025S]; Thailand Science Research
   and Innovation [MET6405004S]
FX This work was supported by the Prince of Songkla University (Grant
   number MET6202025S) and the Thailand Science Research and Innovation
   (Grant number MET6405004S).
CR Abu Amer Y, 2013, OSTEOPOROSIS INT, V24, P2377, DOI 10.1007/s00198 013 2313 x
   Akbarzadeh A, 2013, NANOSCALE RES LETT, V8, DOI 10.1186/1556 276X 8 102
   Anand P, 2008, CANCER LETT, V267, P133, DOI 10.1016/j.canlet.2008.03.025
   Anand P, 2007, MOL PHARMACEUT, V4, P807, DOI 10.1021/mp700113r
   Bansal SS, 2011, CANCER PREV RES, V4, P1158, DOI 10.1158/1940 6207.CAPR 10 0006
   Basnet P, 2012, J PHARM SCI US, V101, P598, DOI 10.1002/jps.22785
   Basu P, 2019, POLYMERS BASEL, V11, DOI 10.3390/polym11111821
   Bharti AC, 2004, J IMMUNOL, V172, P5940, DOI 10.4049/jimmunol.172.10.5940
   Bose S, 2013, MATER TODAY, V16, P496, DOI 10.1016/j.mattod.2013.11.017
   Boyce BF, 2015, ENDOCRINOL METAB, V30, P35, DOI 10.3803/EnM.2015.30.1.35
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chang R, 2014, INT J NANOMED, V9, P461, DOI 10.2147/IJN.S55505
   Chen BY, 2015, POLYM ENG SCI, V55, P1339, DOI 10.1002/pen.24073
   Cheng C, 2017, RSC ADV, V7, P25978, DOI 10.1039/c7ra02861j
   Daily JW, 2016, J MED FOOD, V19, P717, DOI 10.1089/jmf.2016.3705
   Dei Cas M, 2019, NUTRIENTS, V11, DOI 10.3390/nu11092147
   Dhandayuthapani B, 2011, INT J POLYM SCI, V2011, DOI 10.1155/2011/290602
   du Souich P, 2014, PHARMACOL THERAPEUT, V142, P362, DOI 10.1016/j.pharmthera.2014.01.002
   Feng T, 2017, INT J NANOMED, V12, P6027, DOI 10.2147/IJN.S132434
   Fernández Romero AM, 2018, PHARMACEUTICS, V10, DOI 10.3390/pharmaceutics10040256
   Giordano A, 2019, NUTRIENTS, V11, DOI 10.3390/nu11102376
   Ikeda K, 2016, J BIOCHEM, V159, P1, DOI 10.1093/jb/mvv112
   Kim BH, 2017, MOL CELLS, V40, P752, DOI 10.14348/molcells.2017.0098
   Kim JH, 2016, INT J MOL MED, V37, P649, DOI 10.3892/ijmm.2016.2477
   Lateh L., 2018, Petty Patent, Patent No. 14639
   Lateh L, 2019, PHARMACOGN MAG, V15, P730, DOI 10.4103/pm.pm_162_19
   Lee K, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19103004
   Mammana S, 2019, J TISSUE ENG REGEN M, V13, P1109, DOI 10.1002/term.2857
   Mansouri K, 2020, BMC CANCER, V20, DOI 10.1186/s12885 020 07256 8
   Morko J, 2009, BONE, V44, P717, DOI 10.1016/j.bone.2008.11.019
   Nakamura M, 2021, BIOMED RES TOKYO, V42, P13, DOI 10.2220/biomedres.42.13
   Nelson KM, 2017, J MED CHEM, V60, P1620, DOI 10.1021/acs.jmedchem.6b00975
   Pengjam Y, 2016, PHYTOMEDICINE, V23, P417, DOI 10.1016/j.phymed.2016.01.006
   Pochampally R., 2017, NANOMED CANC PAN STA, P291
   Priyadarsini KI, 2014, MOLECULES, V19, P20091, DOI 10.3390/molecules191220091
   Sandur SK, 2007, CARCINOGENESIS, V28, P1765, DOI 10.1093/carcin/bgm123
   Sarkar N, 2019, ACS APPL MATER INTER, V11, P17184, DOI 10.1021/acsami.9b01218
   Lopes MS, 2012, PROCEDIA ENGINEER, V42, P1402, DOI 10.1016/j.proeng.2012.07.534
   Sercombe L, 2015, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00286
   Sinjari B, 2019, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.00633
   Sungsee P, 2019, J APPL POLYM SCI, V136, DOI 10.1002/app.48259
   Vallet Regí M, 2011, ADV MATER, V23, P5177, DOI 10.1002/adma.201101586
   Viale M, 2016, CHEM RES TOXICOL, V29, P1393, DOI 10.1021/acs.chemrestox.6b00207
   Weisberg SP, 2008, ENDOCRINOLOGY, V149, P3549, DOI 10.1210/en.2008 0262
   Xie L, 2011, INT IMMUNOPHARMACOL, V11, P323, DOI 10.1016/j.intimp.2010.08.013
   Yang C, 2020, J CELL MOL MED, V24, P1553, DOI 10.1111/jcmm.14842
   Yeh CC, 2015, DRUG DES DEV THER, V9, P2285, DOI 10.2147/DDDT.S78277
   Zuo DY, 2012, ADV POLYM TECH, V31, P310, DOI 10.1002/adv.20254
NR 48
TC 6
Z9 6
U1 0
U2 7
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
EI 2405 8440
J9 HELIYON
JI Heliyon
PD SEP
PY 2021
VL 7
IS 9
AR e07823
DI 10.1016/j.heliyon.2021.e07823
EA SEP 2021
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA WC7NY
UT WOS:000704442300018
PM 34611555
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Thadhani, RI
   Rosen, S
   Ofsthun, NJ
   Usvyat, LA
   Dalrymple, LS
   Maddux, FW
   Hymes, JL
AF Thadhani, Ravi, I
   Rosen, Sophia
   Ofsthun, Norma J.
   Usvyat, Len A.
   Dalrymple, Lorien S.
   Maddux, Franklin W.
   Hymes, Jeffrey L.
TI Conversion from Intravenous Vitamin D Analogs to Oral Calcitriol in
   Patients Receiving Maintenance Hemodialysis
SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
LA English
DT Article
DE Mineral Bone Disorder; calcium; phosphate; parathyroid hormone; adult;
   humans; United States; paricalcitol; 1 alpha hydroxyergocalciferol;
   calcitriol; cinacalcet; phosphates; length of stay; survival rate;
   retrospective studies; follow up studies; intention to treat analysis;
   ergocalciferols; dihydroxy vitamin D3; Vitamin D; secondary
   hyperparathyroidism; renal dialysis; minerals; calcium phosphates
ID SECONDARY HYPERPARATHYROIDISM; DIALYSIS PATIENTS; MORTALITY;
   PARICALCITOL
AB Background and objectivesIn the United States, intravenous vitamin D analogs are the first line therapy for management of secondary hyperparathyroidism in hemodialysis patients. Outside the United States, oral calcitriol (1,25 dihydroxyvitamin D 3) is routinely used. We examined standard laboratory parameters of patients on in center hemodialysis receiving intravenous vitamin D who switched to oral calcitriol.Design, setting, participants, & measurementsWe conducted a retrospective cohort study of adult patients treated within Fresenius Kidney Care clinics. During a 6 month period (December 2013 to May 2014), we identified patients on an intravenous vitamin D analog (doxercalciferol or paricalcitol) who switched to oral calcitriol and matched them to patients receiving an intravenous vitamin D analog. Mean serum calcium, phosphate, and intact parathyroid hormone (iPTH) concentrations were examined for up to 12 months of follow up. We used Poisson and Cox proportional hazards regression models to examine hospitalization and survival rates. The primary analysis was conducted as intention to treat; secondary analyses included an as treated evaluation.ResultsA total of 2280 patients who switched to oral calcitriol were matched to 2280 patients receiving intravenous vitamin D. Compared with patients on intravenous vitamin D, mean calcium and phosphate levels in the oral calcitriol group were lower after the change to oral calcitriol. In contrast, iPTH levels were higher in the oral calcitriol group. At 12 months, the percentage of patients with composite laboratories in target range (calcium <10 mg/dl, phosphate 3.0?5.5 mg/dl, and iPTH 150?600 pg/ml) were comparable between groups (45% versus 45%; P=0.96). Hospital admissions, length of hospital stay, and survival were comparable between groups. An as treated analysis and excluding those receiving cinacalcet did not reveal significant between group differences.ConclusionsAmong patients receiving in center hemodialysis who were switched to oral calcitriol versus those on an intravenous vitamin D analog, the aggregate of all mineral and bone laboratory parameters in range was largely similar between groups.
C1 [Thadhani, Ravi, I] Cedars Sinai Med Ctr, Dept Biomed Sci, Los Angeles, CA 90048 USA.
   [Rosen, Sophia; Ofsthun, Norma J.; Usvyat, Len A.; Dalrymple, Lorien S.; Hymes, Jeffrey L.] Fresenius Med Care North Amer, 920 Winter St, Waltham, MA 02451 USA.
   [Maddux, Franklin W.] Fresenius Med Care AG & Co KGaA, Bad Homburg, Germany.
C3 Cedars Sinai Medical Center
RP Usvyat, LA (通讯作者)，Fresenius Med Care North Amer, 920 Winter St, Waltham, MA 02451 USA.
EM Len.Usvyat@fmc na.com
RI Larkin, John/G 1880 2018
OI Larkin, John/0000 0001 8873 8971
FU Fresenius Medical Care North America; National Institutes of Health,
   Kaneka Corp.; Thermo Fisher Scientific
FX Fresenius Medical Care North America funded this study. Dr. Thadhani is
   supported by research funding from the National Institutes of Health,
   Kaneka Corp., and Thermo Fisher Scientific.
CR ANDRESS DL, 1989, NEW ENGL J MED, V321, P274, DOI 10.1056/NEJM198908033210502
   Andress DL, 2001, AM J KIDNEY DIS, V38, pS41, DOI 10.1053/ajkd.2001.28108
   Bond TC, 2015, PERITON DIALYSIS INT, V35, P62, DOI 10.3747/pdi.2012.00324
   FISCHER ER, 1993, CLIN NEPHROL, V40, P216
   Kidney Disease: Improving Global Outcomes (KDIGO) CKD MBD Work Group, 2009, Kidney Int Suppl, pS1, DOI 10.1038/ki.2009.188
   Kumar J, 2016, J RENAL NUTR, V26, P265, DOI 10.1053/j.jrn.2016.02.006
   QUARLES LD, 1994, KIDNEY INT, V45, P1710, DOI 10.1038/ki.1994.223
   Roggeri DP, 2015, INT J NEPHROL RENOV, V8, P1, DOI 10.2147/IJNRD.S72011
   Tanaka S, 2016, NEPHROL DIAL TRANSPL, V31, P1152, DOI 10.1093/ndt/gfw205
   Tentori F, 2006, KIDNEY INT, V70, P1858, DOI 10.1038/sj.ki.5001868
   United States Renal Data System, 2018, Annual Report
   Wolf M, 2008, J AM SOC NEPHROL, V19, P1379, DOI 10.1681/ASN.2007091002
   Zhou HY, 2009, CLIN NEPHROL, V71, P276
   Zisman AL, 2005, AM J NEPHROL, V25, P591, DOI 10.1159/000089707
NR 14
TC 6
Z9 7
U1 0
U2 5
PU AMER SOC NEPHROLOGY
PI WASHINGTON
PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA
SN 1555 9041
EI 1555 905X
J9 CLIN J AM SOC NEPHRO
JI Clin. J. Am. Soc. Nephrol.
PD MAR 6
PY 2020
VL 15
IS 3
BP 384
EP 391
DI 10.2215/CJN.07960719
PG 8
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Urology & Nephrology
GA LC8KE
UT WOS:000525580900014
PM 32111702
OA Green Published
DA 2025 08 17
ER

PT J
AU Mukherjee, D
   Srinivasan, B
   Anbu, J
   Azamthulla, M
   Banala, VT
   Ramachandra, SG
AF Mukherjee, Dhrubojyoti
   Srinivasan, Bharath
   Anbu, J.
   Azamthulla, Mohammad
   Banala, Venkatesh Teja
   Ramachandra, S. G.
TI Improvement of bone microarchitecture in methylprednisolone induced rat
   model of osteoporosis by using thiolated chitosan based risedronate
   mucoadhesive film
SO DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY
LA English
DT Article
DE Thiolation; mucoadhesive films; osteoporosis; risedronate sodium;
   methylprednisolone; trabecular microarchitecture
ID NANOPARTICLE BASED FORMULATION; IN VITRO CHARACTERIZATION;
   POSTMENOPAUSAL OSTEOPOROSIS; MOLECULAR MECHANISMS; ZOLEDRONIC ACID;
   DRUG DELIVERY; BUCCAL FILMS; SYSTEM; BISPHOSPHONATES; HYDROXYAPATITE
AB Objective: In this study, we investigated the potential of thiolated chitosan based mucoadhesive film, loaded with risedronate sodium in the treatment of osteoporosis.
   Significance: Risedronate sodium is a bisphosphonate derivative having very low bioavailability when administered through the oral route. Moreover, the adverse effects associated with the drug when administered through GIT necessitate an alternative and feasible route which can improve its bioavailability and therapeutic efficacy.
   Methods: Thiolation of chitosan was interpreted by different analytical techniques. The mucoadhesive films were prepared by the solvent evaporation method and evaluated for drug content analysis, swelling degree, mucoadhesive parameters, and permeation characterization. For the screening of preclinical efficacy and pharmacodynamic parameters, a methylprednisolone induced osteoporotic rat model was used. The trabecular microarchitecture and biochemical markers were evaluated for determination of bone resorption.
   Results: The different analytical characterization of synthesized thiolated chitosan revealed that chitosan was successfully incorporated with thiol groups. The formulation containing 2:1 ratio of thiolated chitosan and HPMC 4KM was found to have the maximum swelling degree, mucoadhesive strength with a good force of adhesion and better in vitro permeability compared to the marketed formulation. With respect to trabecular microarchitecture, the drug loaded film formulation showed superior and promising results. Furthermore, the film formulation also improved the serum level of biomarkers better than the marketed formulation.
   Conclusions: The results significantly suggest that risedronate loaded novel mucoadhesive film formulation could be a logical approach in the therapeutic intervention of osteoporosis.
C1 [Mukherjee, Dhrubojyoti; Srinivasan, Bharath] MS Ramaiah Univ Appl Sci, Dept Pharmaceut, Bengaluru, India.
   [Anbu, J.; Azamthulla, Mohammad] MS Ramaiah Univ Appl Sci, Dept Pharmacol, Bengaluru, India.
   [Banala, Venkatesh Teja] Cent Drug Res Inst, Pharmaceut Dept, Lucknow, Uttar Pradesh, India.
   [Ramachandra, S. G.] Indian Inst Sci, Cent Anim Facil, Bengaluru, India.
C3 M. S. Ramaiah University of Applied Sciences; M. S. Ramaiah University
   of Applied Sciences; Council of Scientific & Industrial Research (CSIR)
     India; CSIR   Central Drug Research Institute (CDRI); Indian Institute
   of Science (IISC)   Bangalore
RP Mukherjee, D (通讯作者)，MS Ramaiah Univ Appl Sci, Fac Pharm, Dept Pharmaceut, New BEL Rd, Msr Nagar 560054, Bengaluru, India.
EM djmk83@yahoo.com
RI ; Anbu, Jayaraman/AAF 5513 2019; MUKHERJEE, DHRUBOJYOTI/I 6444 2016; G,
   Ramachandra/C 2776 2012; Srinivasan, Bharath/AAF 7723 2019
OI Subbaraya Gudde, Ramachandra/0000 0002 0744 3627; MUKHERJEE,
   DHRUBOJYOTI/0000 0003 3011 5733; Srinivasan, Dr
   Bharath/0000 0001 9248 3094
FU M. S. Ramaiah University of Applied Sciences; Gokula Education
   Foundation (GEF)
FX The authors would sincerely thank M. S. Ramaiah University of Applied
   Sciences and Gokula Education Foundation (GEF) for supporting the
   project. Authors gratefully acknowledge Fleming Laboratories, Hyderabad
   for providing gift sample of risedronate sodium. Authors are thankful to
   Dr. Alakkawar and Dr. Krishnaveni, Government Veterinary College,
   Hebbal, Bangalore in carrying out the Histopathological study and Indian
   Institute of Science for carrying out SEM studies. The authors wish to
   thank Dr. Janice Joseph, Faculty of Dental Sciences, M. S. Ramaiah
   University of Applied Sciences for assisting in English language editing
   process of the manuscript.
CR Bae J, 2015, INT J PHARMACEUT, V480, P37, DOI 10.1016/j.ijpharm.2015.01.020
   Bassi P, 2017, SAUDI PHARM J, V25, P32, DOI 10.1016/j.jsps.2015.06.003
   Bayrak Z, 2011, EUR J PHARM BIOPHARM, V78, P499, DOI 10.1016/j.ejpb.2011.02.014
   Belgamwar Veena, 2009, Current Drug Delivery, V6, P113
   Bertram U, 2006, EUR J PHARM SCI, V27, P62, DOI 10.1016/j.ejps.2005.08.005
   Bigucci F, 2015, CARBOHYD POLYM, V130, P32, DOI 10.1016/j.carbpol.2015.04.067
   Bitto A, 2008, BRIT J PHARMACOL, V155, P896, DOI 10.1038/bjp.2008.305
   Britto Douglas de, 2005, Polímeros, V15, P142
   Coxon FP, 2000, J BONE MINER RES, V15, P1467, DOI 10.1359/jbmr.2000.15.8.1467
   Donmez BO, 2012, PHARMACOL REP, V64, P878, DOI 10.1016/S1734 1140(12)70882 4
   Duranova H, 2014, ACTA VET SCAND, V56, DOI 10.1186/s13028 014 0064 0
   Eastell R, 2015, J BONE MINER RES, V30, P483, DOI 10.1002/jbmr.2361
   El Gendy N. A., 2009, Current Drug Delivery, V6, P50
   Enrione J, 2010, ELECTRON J BIOTECHN, V13, DOI 10.2225/vol13 issue5 fulltext 15
   Huang W, 2009, MAT SCI ENG C MATER, V29, P2221, DOI 10.1016/j.msec.2009.05.015
   Ikeuchi Takahashi Y, 2013, INT J PHARMACEUT, V453, P454, DOI 10.1016/j.ijpharm.2013.06.007
   Jeon OC, 2016, EUR J PHARM SCI, V82, P1, DOI 10.1016/j.ejps.2015.11.004
   Kalleny NK, 2011, EGYPT J HISTOL, V34, P117
   Kashani IR, 2011, ARCH MED SCI, V7, P45, DOI 10.5114/aoms.2011.20603
   Kast CE, 2003, INT J PHARM, V256, P183, DOI 10.1016/S0378 5173(03)00076 0
   Khajuria DK, 2015, EUR J PHARM SCI, V66, P173, DOI 10.1016/j.ejps.2014.10.015
   Khajuria DK, 2014, SCI PHARM, V82, P357, DOI 10.3797/scipharm.1310 06
   Khajuria DK, 2011, REV BRAS REUMATOL, V51, P365
   King CS, 1996, CALCIFIED TISSUE INT, V59, P184, DOI 10.1007/s002239900107
   Liao SK, 2004, MACROMOL RES, V12, P466, DOI 10.1007/BF03218428
   Martiniakova M, 2009, SLOVAK J ANIM SCI, V42, P4
   Millard PS, 1997, AM FAM PHYSICIAN, V55, P1315
   Mitchell DY, 2000, J CLIN PHARMACOL, V40, P258, DOI 10.1177/00912700022008928
   Morales JO, 2011, EUR J PHARM BIOPHARM, V77, P187, DOI 10.1016/j.ejpb.2010.11.023
   Mukherjee D., 2013, ISRN Pharmacology, V2013, P1
   Munasur AP, 2006, INT J PHARMACEUT, V323, P43, DOI 10.1016/j.ijpharm.2006.05.051
   Nafee Noha Adel, 2003, Acta Pharmaceutica (Zagreb), V53, P199
   Paggiosi MA, 2014, OSTEOPOROSIS INT, V25, P2729, DOI 10.1007/s00198 014 2817 z
   Reginster JY, 2004, J INTERN MED, V255, P615, DOI 10.1111/j.1365 2796.2004.01292.x
   Roelofs AJ, 2006, CLIN CANCER RES, V12, p6222S, DOI 10.1158/1078 0432.CCR 06 0843
   Rogers MJ, 2011, BONE, V49, P34, DOI 10.1016/j.bone.2010.11.008
   Rotta J, 2011, CIENCIA TECNOL ALIME, V31, P450, DOI 10.1590/S0101 20612011000200026
   Sahana H, 2013, J BIOMED NANOTECHNOL, V9, P193, DOI 10.1166/jbn.2013.1482
   Salamat Miller N, 2005, ADV DRUG DELIVER REV, V57, P1666, DOI 10.1016/j.addr.2005.07.003
   Salman S, 2012, IRAN J REPROD MED, V10, P363
   Sanz R, 2018, INT J PHARMACEUT, V535, P393, DOI 10.1016/j.ijpharm.2017.11.027
   Senel S, 2000, INT J PHARM, V193, P197, DOI 10.1016/S0378 5173(99)00334 8
   Shidhaye SS, 2008, AAPS PHARMSCITECH, V9, P909, DOI 10.1208/s12249 008 9125 x
   Shivanand K, 2011, DARU, V19, P224
   SQUIER CA, 1993, ADV DRUG DELIVER REV, V12, P13, DOI 10.1016/0169 409X(93)90038 6
   Taha EA, 2003, CHEM PHARM BULL, V51, P1444, DOI 10.1248/cpb.51.1444
   Tanodekaew S, 2004, BIOMATERIALS, V25, P1453, DOI 10.1016/j.biomaterials.2003.08.020
   Trastullo R, 2016, EUR J PHARM BIOPHARM, V105, P115, DOI 10.1016/j.ejpb.2016.05.026
   TURNER RT, 1995, CALCIFIED TISSUE INT, V56, P311, DOI 10.1007/BF00318052
   Weinstein RS, 2000, AM J MED, V108, P153, DOI 10.1016/S0002 9343(99)00420 9
   Yehia Soad A., 2009, Current Drug Delivery, V6, P17
NR 51
TC 34
Z9 35
U1 0
U2 19
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0363 9045
EI 1520 5762
J9 DRUG DEV IND PHARM
JI Drug Dev. Ind. Pharm.
PY 2018
VL 44
IS 11
BP 1845
EP 1856
DI 10.1080/03639045.2018.1503297
PG 12
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA GU4IS
UT WOS:000445247500013
PM 30028215
DA 2025 08 17
ER

PT J
AU Schech, AJ
   Nemieboka, BE
   Brodie, AH
AF Schech, Amanda J.
   Nemieboka, Brandon E.
   Brodie, Angela H.
TI Zoledronic acid inhibits aromatase activity and phosphorylation:
   Potential mechanism for additive zoledronic acid and letrozole drug
   interaction
SO JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
LA English
DT Article
DE Zoledronic acid; Letrozole; Aromatase enzyme
ID BREAST CANCER CELLS; BISPHOSPHONATES INDUCE APOPTOSIS; ENDOTHELIAL
   GROWTH FACTOR; MEMBRANE LOCALIZATION; MEVALONATE PATHWAY;
   PROSTATE CANCER; RAT UTERUS; IN VITRO; EXPRESSION; THERAPY
AB Zoledronic acid (ZA), a bisphosphonate originally indicated for use in osteoporosis, has been reported to exert a direct effect on breast cancer cells, although the mechanism of this effect is currently unknown. Data from the ABCSG 12 and ZO FAST clinical trials suggest that treatment with the combination of ZA and aromatase inhibitors (AI) result in increased disease free survival in breast cancer patients over AI alone. To determine whether the mechanism of this combination involved inhibition of aromatase, AC 1 cells (MCF 7 human breast cancer cells transfected with an aromatase construct) were treated simultaneously with combinations of ZA and AI letrozole. This combination significantly increased inhibition of aromatase activity of AC 1 cells when compared to letrozole alone. Treatment of 1 nM letrozole in combination with 1 mu M or 10 mu M ZA resulted in an additive drug interaction on inhibition of cell viability, as measured by MTT assay. Treatment with ZA was found to inhibit phosphorylation of aromatase on serine residues. Zoledronic acid was also shown to be more effective in inhibiting cell viability in aromatase transfected AC 1 cells when compared to inhibition of cell viability observed in non transfected MCF 7. Estradiol was able to partially rescue the effect of 1 mu M and 10 mu M ZA on cell viability following treatment for 72 h, as shown by a shift to the right in the estradiol dose response curve. In conclusion, these results indicate that the combination of ZA and letrozole results in an additive inhibition of cell viability. Furthermore, ZA alone can inhibit aromatase activity through inhibition of serine phosphorylation events important for aromatase enzymatic activity and contributes to inhibition of cell viability. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Brodie, Angela H.] Univ Maryland, Sch Med, Dept Pharmacol & Expt Therapeut, Hlth Sci Facil 1, Baltimore, MD 21201 USA.
   [Nemieboka, Brandon E.] Univ Maryland Baltimore Cty, Dept Chem & Biochem, Baltimore, MD 21250 USA.
   [Brodie, Angela H.] Univ Maryland, Marlene & Stewart Greenebaum Canc Ctr, Baltimore, MD 21201 USA.
C3 University System of Maryland; University of Maryland Baltimore;
   University System of Maryland; University of Maryland Baltimore County;
   University System of Maryland; University of Maryland Baltimore
RP Brodie, AH (通讯作者)，Univ Maryland, Sch Med, Dept Pharmacol & Expt Therapeut, Hlth Sci Facil 1, Room 580G,685 W Baltimore St, Baltimore, MD 21201 USA.
EM amandaschech@gmail.com; bnemie2@gmail.com; abrodie@umaryland.edu
FU Angela H. Brodie's NIH [R01, CA62483]
FX All work was funded by Angela H. Brodie's NIH R01, CA62483.
CR Almubarak Hussain, 2011, J Carcinog, V10, P2, DOI 10.4103/1477 3163.75723
   BRODIE AMH, 1977, ENDOCRINOLOGY, V100, P1684, DOI 10.1210/endo 100 6 1684
   Brufsky AM, 2012, CANCER AM CANCER SOC, V118, P1192, DOI 10.1002/cncr.26313
   Catalano S, 2009, MOL ENDOCRINOL, V23, P1634, DOI 10.1210/me.2009 0039
   Coleman RE, 2010, ADJUVANT TREATMENT Z
   Eidtmann H, 2010, ANN ONCOL, V21, P2188, DOI 10.1093/annonc/mdq217
   Fromigue O, 2000, J BONE MINER RES, V15, P2211, DOI 10.1359/jbmr.2000.15.11.2211
   Gnant M, 2011, LANCET ONCOL, V12, P631, DOI 10.1016/S1470 2045(11)70122 X
   Gnant M, 2009, NEW ENGL J MED, V360, P679, DOI 10.1056/NEJMoa0806285
   Iguchi T, 2003, CELL SIGNAL, V15, P719, DOI 10.1016/S0898 6568(03)00007 X
   Jagdev SP, 2001, BRIT J CANCER, V84, P1126, DOI 10.1054/bjoc.2001.1727
   Kazi AA, 2005, MOL ENDOCRINOL, V19, P2006, DOI 10.1210/me.2004 0388
   Kazi AA, 2009, BIOL REPROD, V81, P378, DOI 10.1095/biolreprod.109.076117
   Long BJ, 1998, J STEROID BIOCHEM, V67, P293, DOI 10.1016/S0960 0760(98)00122 8
   Miller TW, 2008, J STEROID BIOCHEM, V112, P95, DOI 10.1016/j.jsbmb.2008.09.001
   Neville Webbe HL, 2010, BRIT J CANCER, V102, P1010, DOI 10.1038/sj.bjc.6605579
   Oades GM, 2003, J UROLOGY, V170, P246, DOI 10.1097/01.ju.0000070685.34760.5f
   Senaratne SG, 2002, BRIT J CANCER, V86, P1479, DOI 10.1038/sj.bjc.6600297
   Senaratne SG, 2000, BRIT J CANCER, V82, P1459, DOI 10.1054/bjoc.1999.1131
   Thiantanawat A, 2003, CANCER RES, V63, P8037
   Verdijk R, 2007, CANCER LETT, V246, P308, DOI 10.1016/j.canlet.2006.03.011
   Vogel CL, 2004, ONCOLOGIST, V9, P687, DOI 10.1634/theoncologist.9 6 687
   Wardley A, 2005, BRIT J CANCER, V92, P1869, DOI 10.1038/sj.bjc.6602551
   Yue W, 2003, J STEROID BIOCHEM, V86, P265, DOI 10.1016/S0960 0760(03)00366 2
   ZHOU D, 1990, CANCER RES, V50, P6949
NR 25
TC 12
Z9 14
U1 0
U2 9
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960 0760
J9 J STEROID BIOCHEM
JI J. Steroid Biochem. Mol. Biol.
PD NOV
PY 2012
VL 132
IS 3 5
BP 195
EP 202
DI 10.1016/j.jsbmb.2012.05.008
PG 8
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA 028HL
UT WOS:000310413300001
PM 22659283
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Brown, EM
AF Brown, Edward M.
TI Clinical utility of calcimimetics targeting the extracellular
   calcium sensing receptor (CaSR)
SO BIOCHEMICAL PHARMACOLOGY
LA English
DT Article
DE Calcimimetic; Calcium sensing receptor; Parathyroid; Primary
   hyperparathyroidism; Secondary hyperparathyroidism; Parathyroid cancer;
   Stage 5 kidney disease; Renal transplantation; Lithium induced
   hypercalcemia; Familial hypocalciuric hypercalcemia
ID BONE MINERAL DENSITY; SECONDARY HYPERPARATHYROIDISM; PARATHYROID
   HYPERPLASIA; SERUM CALCIUM; CA2+ SENSING RECEPTOR; TRANSPLANT PATIENTS;
   CINACALCET HCL; HYPERCALCEMIA; R 568; INCREASES
AB Calcimimetics, which activate the extracellular calcium (Ca o(2+)) sensing receptor in the parathyroid and other tissues participating in Ca o(2+) homeostasis, were the first described allosteric activators of a G protein coupled receptor. Cinacalcet, the only calcimimetic currently approved for human use, is used clinically for treating secondary hyperparathyroidism (e.g., overactivity of parathyroid glands) in patients being dialyzed for chronic kidney disease. By sensitizing the parathyroids to Ca o(2+), cinacalcet lowers the circulating parathyroid hormone (PTH) level. It also reduces serum calcium and phosphate, changes increasing the percentage of patients achieving the guidelines recommended by the National Kidney Foundation (NKF) for these minerals. Studies are underway addressing whether better adherence to these guidelines in patients receiving cinacalcet reduces cardiovascular disease and related mortality, which are both common is the dialysis population. The second approved use of cinacalcet is for treating hypercalcemia in patients with inoperable parathyroid carcinoma. In this setting, it provides the first medical therapy chronically lowering serum calcium concentration in this condition, albeit not to normal in most patients. Its effect on the long term prognosis of these patients, if any, is presently unclear. "Off label" administration of cinacalcet [i.e., not yet approved by the US Food and Drug Administration (FDA)] effectively lowers serum calcium and/or PTH in various other forms of hyperparathyroidism and increases serum phosphate in renal phosphate wasting syndromes by reducing PTH induced phosphaturia. In the future, the drug could conceivably be utilized to modulate the activity of the CaSR in other tissues (i.e., kidney, colon) in therapeutically desirable ways. (C) 2010 Elsevier Inc. All rights reserved.
C1 [Brown, Edward M.] Brigham & Womens Hosp, Div Endocrinol Diabet & Hypertens, Dept Med, Boston, MA 02115 USA.
   [Brown, Edward M.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
C3 Harvard University; Harvard University Medical Affiliates; Brigham &
   Women's Hospital; Harvard University; Harvard Medical School
RP Brown, EM (通讯作者)，Brigham & Womens Hosp, Div Endocrinol Diabet & Hypertens, Dept Med, EBRC 223A,221 Longwood Ave, Boston, MA 02115 USA.
EM embrown@partners.org
FU US National Institutes of Health [DK078331]
FX Edward M. Brown, M.D. receives grant support from the US National
   Institutes of Health (DK078331).
CR Adams GB, 2006, NATURE, V439, P599, DOI 10.1038/nature04247
   Alon US, 2008, CLIN J AM SOC NEPHRO, V3, P658, DOI 10.2215/CJN.04981107
   Aucella F, 2005, J NEPHROL, V18, P537
   Bergua C, 2008, TRANSPLANTATION, V86, P413, DOI 10.1097/TP.0b013e31817c13e1
   Bilezikian JP, 2009, J CLIN ENDOCR METAB, V94, P335, DOI 10.1210/jc.2008 1763
   Block GA, 2004, NEW ENGL J MED, V350, P1516, DOI 10.1056/NEJMoa031633
   Borchhardt KA, 2008, TRANSPLANTATION, V86, P919, DOI 10.1097/TP.0b013e318186b7fb
   Bräuner Osborne H, 2007, CURR DRUG TARGETS, V8, P169, DOI 10.2174/138945007779315614
   Breitwieser GE, 2004, CELL CALCIUM, V35, P209, DOI 10.1016/j.ceca.2003.10.013
   Bringhurst FR., 1998, Williams Textbook of Endocrinology, V9th, P1155
   Brown AJ, 2007, NAT CLIN PRACT ENDOC, V3, P134, DOI 10.1038/ncpendmet0394
   Brown EM, 2007, NAT CLIN PRACT ENDOC, V3, P122, DOI 10.1038/ncpendmet0388
   BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0
   Canaff L, 2002, J BIOL CHEM, V277, P30337, DOI 10.1074/jbc.M201804200
   Chang W, 2007, J BONE MINER RES, V22, pS79
   Chertow GM, 2007, CLIN J AM SOC NEPHRO, V2, P898, DOI 10.2215/CJN.04381206
   Chin J, 2000, J AM SOC NEPHROL, V11, P903, DOI 10.1681/ASN.V115903
   Chonchol M, 2009, AM J KIDNEY DIS, V53, P197, DOI 10.1053/j.ajkd.2008.09.021
   Cunningham J, 2005, KIDNEY INT, V68, P1793, DOI 10.1111/j.1523 1755.2005.00596.x
   Drüeke TB, 2009, CLIN J AM SOC NEPHRO, V4, P234, DOI 10.2215/CJN.04520908
   Drueke T, 2007, NEPHROL DIAL TRANSPL, V22, P1828, DOI 10.1093/ndt/gfm177
   Dvorak MM, 2004, P NATL ACAD SCI USA, V101, P5140, DOI 10.1073/pnas.0306141101
   Egbuna OI, 2007, CLIN TRANSPLANT, V21, P558, DOI 10.1111/j.1399 0012.2007.00690.x
   GARRETT JE, 1995, J BIOL CHEM, V270, P12919, DOI 10.1074/jbc.270.21.12919
   Gattone VH, 2009, J AM SOC NEPHROL, V20, P1527, DOI 10.1681/ASN.2008090927
   Geibel J, 2006, P NATL ACAD SCI USA, V103, P9390, DOI 10.1073/pnas.0602996103
   Geller JL, 2007, J BONE MINER RES, V22, P931, DOI 10.1359/JBMR.070304
   Marqués GG, 2009, TRANSPL P, V41, P2139, DOI 10.1016/j.transproceed.2009.06.090
   Gregoor PS, 2007, KIDNEY INT, V71, P470, DOI 10.1038/sj.ki.5002065
   Hauache OM, 2001, BRAZ J MED BIOL RES, V34, P577, DOI 10.1590/S0100 879X2001000500004
   Hoenderop JGJ, 2005, PHYSIOL REV, V85, P373, DOI 10.1152/physrev.00003.2004
   Hu JX, 2007, J CELL MOL MED, V11, P908, DOI 10.1111/j.1582 4934.2007.00096.x
   Hu JX, 2002, J BIOL CHEM, V277, P46622, DOI 10.1074/jbc.M207100200
   Huang C, 2010, CURR OPIN NEPHROL HY, V19, P106, DOI 10.1097/MNH.0b013e328332e7b2
   HUANG Y, 2007, J BIOL CHEM
   Ivanovski O, 2009, ATHEROSCLEROSIS, V205, P55, DOI 10.1016/j.atherosclerosis.2008.10.043
   JADOUL M, NDT PLUS, V3, P37
   Jüppner H, 2007, THER APHER DIAL, V11, pS3, DOI 10.1111/j.1744 9987.2007.00513.x
   Kessler A, 2004, BIOORG MED CHEM LETT, V14, P3345, DOI 10.1016/j.bmcl.2004.03.056
   Koleganova N, 2009, KIDNEY INT, V75, P60, DOI 10.1038/ki.2008.490
   Kruse AE, 2007, NEPHROL DIAL TRANSPL, V22, P2362, DOI 10.1093/ndt/gfm270
   Lomonte C, 2007, NEPHROL DIAL TRANSPL, V22, P2056, DOI 10.1093/ndt/gfm156
   Lopez I, 2006, J AM SOC NEPHROL, V17, P795, DOI 10.1681/ASN.2005040342
   Lopez I, 2009, AM J PHYSIOL RENAL, V296, pF1376, DOI 10.1152/ajprenal.90737.2008
   López V, 2009, TRANSPL P, V41, P2394, DOI 10.1016/j.transproceed.2009.06.055
   MAILLARD MP, 2009, J HYPERTENS
   Malluche HH, 2008, CLIN NEPHROL, V69, P269
   Marcocci C, 2009, J CLIN ENDOCR METAB, V94, P2766, DOI 10.1210/jc.2008 2640
   MARX SJ, 1982, NEW ENGL J MED, V306, P257, DOI 10.1056/NEJM198202043060502
   Matsuo K, 2008, ARCH BIOCHEM BIOPHYS, V473, P201, DOI 10.1016/j.abb.2008.03.027
   Meir T, 2009, AM J PHYSIOL RENAL, V297, pF1192, DOI 10.1152/ajprenal.00360.2009
   Mentaverri R, 2006, FASEB J, V20, P2562, DOI 10.1096/fj.06 6304fje
   Meola M, 2009, NEPHROL DIAL TRANSPL, V24, P982, DOI 10.1093/ndt/gfn654
   Miedlich SU, 2004, J BIOL CHEM, V279, P7254, DOI 10.1074/jbc.M307191200
   Mizobuchi M, 2007, BIOCHEM BIOPH RES CO, V362, P11, DOI 10.1016/j.bbrc.2007.07.177
   Moe SM, 2005, KIDNEY INT, V67, P760, DOI 10.1111/j.1523 1755.2005.67139.x
   Nechama M, 2009, AM J PHYSIOL RENAL, V296, pF795, DOI 10.1152/ajprenal.90625.2008
   Nemeth EF, 2004, J PHARMACOL EXP THER, V308, P627, DOI 10.1124/jpet.103.057273
   Nemeth EF, 1998, P NATL ACAD SCI USA, V95, P4040, DOI 10.1073/pnas.95.7.4040
   Ogata H, 2003, J AM SOC NEPHROL, V14, P959, DOI 10.1097/01.ASN.0000056188.23717.E5
   Pallure V, 2008, ACTA DERM VENEREOL, V88, P62, DOI 10.2340/00015555 0325
   Peacock M, 2005, J CLIN ENDOCR METAB, V90, P135, DOI 10.1210/jc.2004 0842
   Peacock M, 2009, J CLIN ENDOCR METAB, V94, P4860, DOI 10.1210/jc.2009 1472
   Petrel C, 2004, J BIOL CHEM, V279, P18990, DOI 10.1074/jbc.M400724200
   Pitt SC, 2009, SURG CLIN N AM, V89, P1227, DOI 10.1016/j.suc.2009.06.011
   PLATT C, 2009, PEDIAT NEPHROL
   Rodriguez ME, 2007, AM J PHYSIOL RENAL, V292, pF1390, DOI 10.1152/ajprenal.00262.2006
   Rodríguez M, 2008, KIDNEY INT, V74, pS50, DOI 10.1038/ki.2008.546
   Rogers NM, 2007, SEMIN DIALYSIS, V20, P150, DOI 10.1111/j.1525 139X.2007.00263.x
   Rubin MR, 2008, J CLIN ENDOCR METAB, V93, P3462, DOI 10.1210/jc.2007 1215
   Saunders BD, 2009, WORLD J SURG, V33, P2314, DOI 10.1007/s00268 009 9942 4
   Shiraishia K, 2001, AM J NEPHROL, V21, P507, DOI 10.1159/000046658
   Silverberg SJ, 2007, J CLIN ENDOCR METAB, V92, P3803, DOI 10.1210/jc.2007 0585
   Sloand JA, 2006, AM J KIDNEY DIS, V48, P832, DOI 10.1053/j.ajkd.2006.07.019
   Teng M, 2003, NEW ENGL J MED, V349, P446, DOI 10.1056/NEJMoa022536
   Theman TA, 2009, CURR PHARM BIOTECHNO, V10, P289, DOI 10.2174/138920109787847538
   Timmers HJLM, 2006, J INTERN MED, V260, P177, DOI 10.1111/j.1365 2796.2006.01684.x
   Prieto FJT, 2009, TRANSPL P, V41, P2144, DOI 10.1016/j.transproceed.2009.06.088
   Wada M, 2000, KIDNEY INT, V57, P50, DOI 10.1046/j.1523 1755.2000.00837.x
   Wada M, 1998, KIDNEY INT, V53, P448, DOI 10.1046/j.1523 1755.1998.00782.x
   Zhang ZX, 2002, J BIOL CHEM, V277, P33736, DOI 10.1074/jbc.M200978200
NR 81
TC 56
Z9 65
U1 0
U2 22
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0006 2952
EI 1873 2968
J9 BIOCHEM PHARMACOL
JI Biochem. Pharmacol.
PD AUG 1
PY 2010
VL 80
IS 3
BP 297
EP 307
DI 10.1016/j.bcp.2010.04.002
PG 11
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 610DV
UT WOS:000278712100002
PM 20382129
DA 2025 08 17
ER

PT J
AU Liu, YL
   Liu, WJ
   Hu, CH
   Xue, ZF
   Wang, G
   Ding, BF
   Luo, HL
   Tang, L
   Kong, XW
   Chen, XY
   Liu, N
   Ding, Y
   Jin, Y
AF Liu, Yali
   Liu, Wenjia
   Hu, Chenghu
   Xue, Zengfu
   Wang, Guang
   Ding, Bofu
   Luo, Hailang
   Tang, Liang
   Kong, Xiangwei
   Chen, Xiaoyan
   Liu, Na
   Ding, Yin
   Jin, Yan
TI MiR 17 Modulates Osteogenic Differentiation Through a Coherent
   Feed Forward Loop in Mesenchymal Stem Cells Isolated from Periodontal
   Ligaments of Patients with Periodontitis
SO STEM CELLS
LA English
DT Article
DE Mesenchymal stem cells; microRNA; Osteogenic differentiation;
   Inflammatory microenvironment
ID TUMOR NECROSIS FACTOR; HUMAN ADIPOSE TISSUE; BONE MARROW; IN VITRO; LUNG
   CANCERS; MICRORNAS; SMURF1; PROLIFERATION; EXPRESSION; CLUSTER
AB Chronic inflammatory diseases, such as rheumatoid arthritis and periodontitis, are the most common causes of bone tissue destruction. Recently, human periodontal ligament tissue derived mesenchymal stem cells (PDLSCs), a population of multipotent stem cells, have been used to reconstruct tissues destroyed by chronic inflammation. However, the impact of the local inflammatory microenvironment on tissue specific stem cells and the mechanisms controlling the effects of the local inflammatory environment remain poorly understood. In this study, we found that the multidifferentiation potential of mesenchymal stem cells (MSCs) isolated from periodontitis affected periodontal ligament tissue (P PDLSCs) was significantly lower than that of MSCs isolated from healthy human periodontal ligament tissue (H PDLSCs). Inflammation in the microenvironment resulted in an inhibition of miR 17 levels, and a perturbation in the expression of miR 17 partly reversed the differentiation potential of PDLSCs in this microenvironment. Furthermore, inflammation in the microenvironment promoted the expression of Smad ubiquitin regulatory factor one (Smurf1), an important negative regulator of MSC osteogenic differentiation. Western blotting and 3' untranslated regions (3' UTR) reporter assays confirmed that Smurf1 is a direct target of miR 17 in PDLSCs. Our data demonstrate that excessive inflammatory cytokine levels, miR 17, and Smurf1 were all involved in a coherent feed forward loop. In this circuit, inflammatory cytokines led to direct activation of Smurf1 and downregulation of miR 17, thereby increasing degradation of Smurf1 mediated osteoblast specific factors. The elucidation of the molecular mechanisms governing MSC osteogenic differentiation in a chronic inflammatory microenvironment could provide us with a better knowledge of chronic inflammatory disorder and improve stem cell mediated inflammatory bone disease therapy. STEM CELLS 2011;29:1804 1816
C1 [Liu, Yali; Liu, Wenjia; Wang, Guang; Kong, Xiangwei; Chen, Xiaoyan; Ding, Yin] Fourth Mil Med Univ, Sch Stomatol, Dept Orthodont, Xian 710032, Shaanxi, Peoples R China.
   [Liu, Yali; Liu, Wenjia; Hu, Chenghu; Wang, Guang; Ding, Bofu; Luo, Hailang; Tang, Liang; Kong, Xiangwei; Chen, Xiaoyan; Liu, Na; Jin, Yan] Fourth Mil Med Univ, Res & Dev Ctr Tissue Engn, Xian 710032, Shaanxi, Peoples R China.
   [Hu, Chenghu; Luo, Hailang; Tang, Liang; Jin, Yan] Fourth Mil Med Univ, Dept Oral Histol & Pathol, Sch Stomatol, Xian 710032, Shaanxi, Peoples R China.
   [Xue, Zengfu] Fourth Mil Med Univ, Xijing Hosp Digest Dis, Xian 710032, Shaanxi, Peoples R China.
   [Liu, Yali] KunMing Med Coll, Dept Orthodont, Sch Stomatol, Kunming, Peoples R China.
C3 Air Force Medical University; Air Force Medical University; Air Force
   Medical University; Air Force Medical University; Kunming Medical
   University
RP Ding, Y (通讯作者)，Fourth Mil Med Univ, Sch Stomatol, Dept Orthodont, 145 W Changle Rd, Xian 710032, Shaanxi, Peoples R China.
EM dingyin@fmmu.edu.cn; yanjin@fmmu.edu.cn
RI Hu, Cheng Hu/I 4210 2013; Kong, Xiangwei/IWL 9350 2023; Jin,
   Yan/I 4204 2013
OI Hu, Cheng Hu/0000 0003 2443 6485; 
FU Nature Science Foundation of China [30725042, 81020108019, 31030033];
   National Basic Research Program (973 Program) [2010CB944800,
   2011CB964700]
FX This work was supported by grants from the Nature Science Foundation of
   China (30725042, 81020108019, and 31030033) and the National Basic
   Research Program (973 Program) (2010CB944800 and 2011CB964700).
CR Armitage GC, 2004, PERIODONTOL 2000, V34, P22, DOI 10.1046/j.0906 6713.2002.003422.x
   Asselin Labat ML, 2010, NATURE, V465, P798, DOI 10.1038/nature09027
   Bretz WA, 2005, J AM GERIATR SOC, V53, P1532, DOI 10.1111/j.1532 5415.2005.53468.x
   Chen SC, 2006, J PERIODONTAL RES, V41, P547, DOI 10.1111/j.1600 0765.2006.00904.x
   Cloonan N, 2008, GENOME BIOL, V9, DOI 10.1186/gb 2008 9 8 r127
   Queiroz Adriana Corrêa de, 2008, Braz. Dent. J., V19, P3
   Ding J, 2009, LIFE SCI, V84, P499, DOI 10.1016/j.lfs.2009.01.013
   El Awady AR, 2010, J PERIODONTOL, V81, P1324, DOI 10.1902/jop.2010.100054
   Fontana L, 2007, NAT CELL BIOL, V9, P775, DOI 10.1038/ncb1613
   Fontana L, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002236
   Gangaraju VK, 2009, NAT REV MOL CELL BIO, V10, P116, DOI 10.1038/nrm2621
   Garzon R, 2008, CURR OPIN HEMATOL, V15, P352, DOI 10.1097/MOH.0b013e328303e15d
   Górska R, 2003, J CLIN PERIODONTOL, V30, P1046, DOI 10.1046/j.0303 6979.2003.00425.x
   Graves DT, 2003, J PERIODONTOL, V74, P391, DOI 10.1902/jop.2003.74.3.391
   Gronthos S, 2000, P NATL ACAD SCI USA, V97, P13625, DOI 10.1073/pnas.240309797
   Guo R, 2008, J BIOL CHEM, V283, P23084, DOI 10.1074/jbc.M709848200
   Hayashita Y, 2005, CANCER RES, V65, P9628, DOI 10.1158/0008 5472.CAN 05 2352
   Hobert O, 2004, TRENDS BIOCHEM SCI, V29, P462, DOI 10.1016/j.tibs.2004.07.001
   Hossain A, 2006, MOL CELL BIOL, V26, P8191, DOI 10.1128/MCB.00242 06
   Huang J, 2010, STEM CELLS, V28, P357, DOI 10.1002/stem.288
   Inose H, 2009, P NATL ACAD SCI USA, V106, P20794, DOI 10.1073/pnas.0909311106
   JANDINSKI JJ, 1991, J PERIODONTOL, V62, P36, DOI 10.1902/jop.1991.62.1.36
   Kaneki H, 2006, J BIOL CHEM, V281, P4326, DOI 10.1074/jbc.M509430200
   Kapinas K, 2010, J BIOL CHEM, V285, P25221, DOI 10.1074/jbc.M110.116137
   Kastrinaki MC, 2008, ANN RHEUM DIS, V67, P741, DOI 10.1136/ard.2007.076174
   Kim YJ, 2009, J BONE MINER RES, V24, P816, DOI 10.1359/JBMR.081230
   Lawrie CH, 2007, BRIT J HAEMATOL, V137, P503, DOI 10.1111/j.1365 2141.2007.06611.x
   Li H, 2009, J CLIN INVEST, V119, P3666, DOI 10.1172/JCI39832
   Li LH, 2005, ANNU REV CELL DEV BI, V21, P605, DOI 10.1146/annurev.cellbio.21.012704.131525
   Li ZY, 2009, J BIOL CHEM, V284, P15676, DOI 10.1074/jbc.M809787200
   Liu Y, 2008, STEM CELLS, V26, P1065, DOI 10.1634/stemcells.2007 0734
   Luzi E, 2008, J BONE MINER RES, V23, P287, DOI 10.1359/JBMR.071011
   Matsubara H, 2007, ONCOGENE, V26, P6099, DOI 10.1038/sj.onc.1210425
   Mendell JT, 2008, CELL, V133, P217, DOI 10.1016/j.cell.2008.04.001
   Mizuno Y, 2008, BIOCHEM BIOPH RES CO, V368, P267, DOI 10.1016/j.bbrc.2008.01.073
   Mizuno Y, 2009, FEBS LETT, V583, P2263, DOI 10.1016/j.febslet.2009.06.006
   Mraz M, 2009, LEUKEMIA LYMPHOMA, V50, P506, DOI 10.1080/10428190902763517
   Pihlstrom BL, 2005, LANCET, V366, P1809, DOI 10.1016/S0140 6736(05)67728 8
   PIHLSTROM BL, 1992, J PERIODONTOL, V63, P1072, DOI 10.1902/jop.1992.63.12s.1072
   Ripa RS, 2006, CIRCULATION, V113, P1983, DOI 10.1161/CIRCULATIONAHA.105.610469
   Roberts FA, 1997, J DENT RES, V76, P1833, DOI 10.1177/00220345970760120501
   Scherr M, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkm971
   SCHNEIDER EL, 1976, P NATL ACAD SCI USA, V73, P3584, DOI 10.1073/pnas.73.10.3584
   Seo BM, 2004, LANCET, V364, P149, DOI 10.1016/S0140 6736(04)16627 0
   Shi S, 2005, Orthod Craniofac Res, V8, P191, DOI 10.1111/j.1601 6343.2005.00331.x
   Shi ST, 2002, NAT BIOTECHNOL, V20, P587, DOI 10.1038/nbt0602 587
   Stenderup K, 2003, BONE, V33, P919, DOI 10.1016/j.bone.2003.07.005
   Stolzing A, 2008, MECH AGEING DEV, V129, P163, DOI 10.1016/j.mad.2007.12.002
   Sun LY, 2007, LUPUS, V16, P121, DOI 10.1177/0961203306075793
   Sun LY, 2009, STEM CELLS, V27, P1421, DOI 10.1002/stem.68
   Takakura S, 2008, CANCER SCI, V99, P1147, DOI 10.1111/j.1349 7006.2008.00800.x
   Wang Z, 2006, TISSUE ENG, V12, P1753, DOI 10.1089/ten.2006.12.1753
   Yamashita M, 2005, CELL, V121, P101, DOI 10.1016/j.cell.2005.01.035
   Yang ZH, 2009, TISSUE ENG PART C ME, V15, P571, DOI 10.1089/ten.tec.2008.0561
   Yeh JK, 1999, AM J PHYSIOL ENDOC M, V276, pE34, DOI 10.1152/ajpendo.1999.276.1.E34
   Zhao L, 2010, J BONE MINER RES, V25, P1246, DOI 10.1002/jbmr.28
   Zhao M, 2004, J BIOL CHEM, V279, P12854, DOI 10.1074/jbc.M313294200
   Zuk PA, 2002, MOL BIOL CELL, V13, P4279, DOI 10.1091/mbc.E02 02 0105
NR 58
TC 158
Z9 179
U1 0
U2 59
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1066 5099
EI 1549 4918
J9 STEM CELLS
JI Stem Cells
PD NOV
PY 2011
VL 29
IS 11
BP 1804
EP 1816
DI 10.1002/stem.728
PG 13
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology;
   Oncology; Cell Biology; Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology
GA 842CN
UT WOS:000296565500017
PM 21898695
DA 2025 08 17
ER

PT J
AU Cupp, ME
   Song, B
   Kibler, P
   Raghavender, US
   Nayak, SK
   Thomsen, W
   Galande, AK
AF Cupp, M. E.
   Song, B.
   Kibler, P.
   Raghavender, U. S.
   Nayak, S. K.
   Thomsen, W.
   Galande, A. K.
TI Investigating hydrophobic ligand receptor interactions in parathyroid
   hormone receptor using peptide probes
SO JOURNAL OF PEPTIDE SCIENCE
LA English
DT Article
DE parathyroid hormone; structureactivity relationship; peptidomimetics;
   hydrophobicity
ID AMINO ACIDS; ANALOGS; MINIMIZATION; PTH(1 11)
AB With an increasing number of new chemical entities entering clinical studies, and an increasing share of the market, peptides and peptidomimetics constitute one of the most promising classes of therapeutics. The success of synthetic peptides as therapeutics relies on the lead optimization step in which the lead candidates are modified to improve drug like properties of peptides related to potency, pharmacokinetics, solubility, and stability, among others. Peptidomimetics based on the N terminal stretch of the first 11 amino acids of the PTH have been investigated as potential lead compounds for the treatment of osteoporosis. On the basis of a peptide reported in the literature, referred to here as the Parent Peptide (H Aib Val Aib Glu Ile Gln Leu Nle His Gln Har NH2), we conducted systematic SAR analyses to investigate the effects of altering peptide hydrophobicity on PTH receptor functional potency as measured by the cAMP (cyclic adenosine monophosphate) accumulation and  arrestin recruitment assays. Among hydrophobic residues, we found that the Val2 position shows the least flexibility in terms of the SAR studies, whereas the Leu7 position appeared to be most flexible. Through circular dichroism and nuclear magnetic resonance spectroscopy studies, we were able to establish that changes in hydrophobic residues significantly change the extent of peptide helicity and that the helical character correlates well with receptor agonist activity. Here, we report several novel PTH 111 peptidomimetics that show comparable or enhanced potency to stimulate Gs signaling over  arrestin recruitment as compared with such properties of PTH 134 and the Parent Peptide. Copyright (c) 2013 European Peptide Society and John Wiley & Sons, Ltd.
C1 [Cupp, M. E.; Song, B.; Kibler, P.; Raghavender, U. S.; Nayak, S. K.; Thomsen, W.; Galande, A. K.] SRI Int, Biosci Div, Harrisonburg, VA 22801 USA.
C3 SRI International
RP Galande, AK (通讯作者)，SRI Int, Biosci Div, Harrisonburg, VA 22801 USA.
EM amit.galande@sri.com
CR Barazza A, 2005, J PEPT RES, V65, P23, DOI 10.1111/j.1399 3011.2005.00207.x
   Bartholow M., 2012, Pharmacy Times
   Caporale A, 2012, AMINO ACIDS, V43, P207, DOI 10.1007/s00726 011 1065 1
   Caporale A, 2010, J MED CHEM, V53, P8072, DOI 10.1021/jm1008264
   Caporale A, 2010, AMINO ACIDS, V39, P1369, DOI 10.1007/s00726 010 0591 6
   Caporale A, 2009, EUR J PHARMACOL, V611, P1, DOI 10.1016/j.ejphar.2009.03.040
   Castro M, 2005, P NATL ACAD SCI USA, V102, P16084, DOI 10.1073/pnas.0503942102
   Cheng Marilyn Lee, 2012, Indian J Endocrinol Metab, V16, P343, DOI 10.4103/2230 8210.95661
   Datta NS, 2009, CELL SIGNAL, V21, P1245, DOI 10.1016/j.cellsig.2009.02.012
   Galande AK, 2005, CHEMBIOCHEM, V6, P1991, DOI 10.1002/cbic.200500083
   Gardella T.J., 2009, IBMS BoneKEy, V6, P71
   Gensure RC, 2005, BIOCHEM BIOPH RES CO, V328, P666, DOI 10.1016/j.bbrc.2004.11.069
   Gesty Palmer D, 2009, SCI TRANSL MED, V1, DOI 10.1126/scitranslmed.3000071
   Jin L, 2000, J BIOL CHEM, V275, P27238
   Olson KR, 2007, ASSAY DRUG DEV TECHN, V5, P137, DOI 10.1089/adt.2006.052
   Pioszak AA, 2008, P NATL ACAD SCI USA, V105, P5034, DOI 10.1073/pnas.0801027105
   Schiller PW, 1999, BIOPOLYMERS, V51, P411, DOI 10.1002/(SICI)1097 0282(1999)51:6<411::AID BIP4>3.0.CO;2 Z
   Shimizu M, 2000, J BIOL CHEM, V275, P21836, DOI 10.1074/jbc.M909861199
   Shimizu M, 2001, ENDOCRINOLOGY, V142, P3068, DOI 10.1210/en.142.7.3068
   Shimizu N, 2004, J BONE MINER RES, V19, P2078, DOI 10.1359/JBMR.040914
   Tsomaia N, 2004, BIOCHEMISTRY US, V43, P690, DOI 10.1021/bi035703i
   Vilardaga JP, 2011, CELL MOL LIFE SCI, V68, P1, DOI 10.1007/s00018 010 0465 9
   Violin JD, 2007, TRENDS PHARMACOL SCI, V28, P416, DOI 10.1016/j.tips.2007.06.006
   WISHART DS, 1992, BIOCHEMISTRY US, V31, P1647, DOI 10.1021/bi00121a010
NR 24
TC 3
Z9 3
U1 0
U2 13
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1075 2617
EI 1099 1387
J9 J PEPT SCI
JI J. Pept. Sci.
PD JUN
PY 2013
VL 19
IS 6
BP 337
EP 344
DI 10.1002/psc.2502
PG 8
WC Biochemistry & Molecular Biology; Chemistry, Analytical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA 142KX
UT WOS:000318797200002
PM 23564659
DA 2025 08 17
ER

PT J
AU Duan, ZF
   Choy, E
   Harmon, D
   Yang, C
   Ryu, K
   Schwab, J
   Mankin, H
   Hornicek, FJ
AF Duan, Zhenfeng
   Choy, Edwin
   Harmon, David
   Yang, Cao
   Ryu, Keinosuke
   Schwab, Joseph
   Mankin, Henry
   Hornicek, Francis J.
TI Insulin like growth factor I receptor tyrosine kinase inhibitor
   cyclolignan picropodophyllin inhibits proliferation and induces
   apoptosis in multidrug resistant osteosarcoma cell lines
SO MOLECULAR CANCER THERAPEUTICS
LA English
DT Article
ID UVEAL MELANOMA; EWINGS SARCOMA; BREAST CANCER; TUMOR GROWTH; MOUSE
   MODEL; EXPRESSION; PATHWAY; IGF 1R; PPP; ACTIVATION
AB Insulin like growth factor I receptor (IGF IR) is an important mediator of tumor cell survival and shows prognostic significance in sarcoma. To explore potential therapeutic strategies for interrupting signaling through this pathway, we assessed the ability of cyclolignan picropodophyllin (PPP), a member of the cyclolignan family, to selectively inhibit the receptor tyrosine kinase activity of IGF IR in several sarcoma cell line model systems. Of the diverse sarcoma subtypes studied, osteosarcoma cell lines were found to be particularly sensitive to IGF IR inhibition, including several multidrug resistant osteosarcoma cell lines with documented resistance to various conventional anticancer drugs. PPP shows relatively little toxicity in human osteoblast cell lines when compared with osteosarcoma cell lines. These studies show that PPP significantly inhibits IGF IR expression and activation in both chemotherapy sensitive and chemotherapy resistant osteosarcoma cell lines. This inhibition of the IGF IR pathway correlates with suppression of proliferation of osteosarcoma cell lines and with apoptosis induction as measured by monitoring of poly(ADP ribose) polymerase and its cleavage product and by quantitative measurement of apoptosis associated CK18Asp396. Importantly, PPP increases the cytotoxic effects of doxorubicin in doxorubicin resistant osteosarcoma cell lines U 2OS(MR) and KHOS(MR). Furthermore, small interfering RNA down regulation of IGF IR expression in drug resistant cell lines also caused resensitization to doxorubicin. Our data suggest that inhibition of IGF IR with PPP offers a novel and selective therapeutic strategy for ostosarcoma, and at the same time, PPP is effective at reversing the drug resistant phenotype in osteosarcoma cell lines. [Mol Cancer Ther 2009;8(8):2122 30]
C1 [Duan, Zhenfeng; Yang, Cao; Ryu, Keinosuke; Schwab, Joseph; Mankin, Henry; Hornicek, Francis J.] Massachusetts Gen Hosp, Ctr Sarcoma & Connect Tissue Oncol, Boston, MA 02114 USA.
   [Choy, Edwin; Harmon, David] Massachusetts Gen Hosp, MGH Canc Ctr, Boston, MA 02114 USA.
   [Choy, Edwin; Harmon, David] Massachusetts Gen Hosp, Dept Hematol Oncol, Boston, MA 02114 USA.
C3 Harvard University; Harvard University Medical Affiliates; Massachusetts
   General Hospital; Harvard University; Harvard University Medical
   Affiliates; Massachusetts General Hospital; Harvard University; Harvard
   University Medical Affiliates; Massachusetts General Hospital
RP Duan, ZF (通讯作者)，Massachusetts Gen Hosp, Ctr Sarcoma & Connect Tissue Oncol, Jackson Bldg,Room 1115,55 Fruit St, Boston, MA 02114 USA.
EM zduan@partners.org
OI Choy, Edwin/0000 0001 9896 8084; HUITRON, EFREN/0009 0008 2046 3359;
   Yang, Cao/0000 0002 0058 614X; Hornicek, Francis/0000 0002 6916 8042
FU Gattegno and Wechsler funds; Ovarian Cancer Research Foundation (OCRF);
   National Cancer Institute; NIH [R01 CA119617]; Jennifer Hunter Yates
   Foundation
FX The Gattegno and Wechsler funds; the Ovarian Cancer Research Foundation
   (OCRF) and National Cancer Institute, NIH (Nanotechnology Platform
   Partnership) grant R01 CA119617 (Z. Duan); and the Jennifer Hunter Yates
   Foundation (E. Choy).
CR BASERGA R, 1995, CANCER RES, V55, P249
   Casa AJ, 2008, FRONT BIOSCI LANDMRK, V13, P3273, DOI 10.2741/2925
   Chitnis MM, 2008, CLIN CANCER RES, V14, P6364, DOI 10.1158/1078 0432.CCR 07 4879
   Chou AJ, 2006, EXPERT REV ANTICANC, V6, P1075, DOI 10.1586/14737140.6.7.1075
   Chou Alexander J, 2008, Paediatr Drugs, V10, P315, DOI 10.2165/00148581 200810050 00005
   Cohen P, 2001, GROWTH HORM IGF RES, V11, P336, DOI 10.1054/ghir.2001.0255
   Duan ZF, 2006, CLIN CANCER RES, V12, P5055, DOI 10.1158/1078 0432.CCR 06 0861
   Economou MA, 2008, INVEST OPHTH VIS SCI, V49, P2620, DOI 10.1167/iovs.07 0742
   Economou MA, 2008, INVEST OPHTH VIS SCI, V49, P2337, DOI 10.1167/iovs.07 0819
   Girnita A, 2004, CANCER RES, V64, P236, DOI 10.1158/0008 5472.CAN 03 2522
   Girnita A, 2006, CLIN CANCER RES, V12, P1383, DOI 10.1158/1078 0432.CCR 05 1106
   HENDERSON BE, 1982, CANCER RES, V42, P3232
   Jemal A, 2008, CA CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010
   Jones HE, 2006, BRIT J CANCER, V95, P172, DOI 10.1038/sj.bjc.6603237
   KAPPEL CC, 1994, CANCER RES, V54, P2803
   Kim SY, 2009, ONCOLOGIST, V14, P83, DOI 10.1634/theoncologist.2008 0189
   Klinakis A, 2009, P NATL ACAD SCI USA, V106, P2359, DOI 10.1073/pnas.0810221106
   Kurmasheva RT, 2006, BBA REV CANCER, V1766, P1, DOI 10.1016/j.bbcan.2006.05.003
   Lann D, 2008, J MAMMARY GLAND BIOL, V13, P371, DOI 10.1007/s10911 008 9100 x
   LeRoith D, 2003, CANCER LETT, V195, P127, DOI 10.1016/S0304 3835(03)00159 9
   Lourda M, 2007, INT J CANCER, V120, P611, DOI 10.1002/ijc.22327
   Manara MC, 2007, CLIN CANCER RES, V13, P1322, DOI 10.1158/1078 0432.CCR 06 1518
   Manara MC, 2005, INT J ONCOL, V27, P1605
   Menu E, 2007, INT J CANCER, V121, P1857, DOI 10.1002/ijc.22845
   Oh SH, 2008, CLIN CANCER RES, V14, P1581, DOI 10.1158/1078 0432.CCR 07 0952
   Pasello M, 2008, CANCER RES, V68, P6661, DOI 10.1158/0008 5472.CAN 07 5840
   Peretz S, 2002, RADIAT RES, V158, P174, DOI 10.1667/0033 7587(2002)158[0174:IREPAM]2.0.CO;2
   Pollak M, 2008, NAT REV CANCER, V8, P915, DOI 10.1038/nrc2536
   Renehan AG, 2004, LANCET, V363, P1346, DOI 10.1016/S0140 6736(04)16044 3
   Rowlands MA, 2009, INT J CANCER, V124, P2416, DOI 10.1002/ijc.24202
   Sachdev D, 2007, MOL CANCER THER, V6, P1, DOI 10.1158/1535 7163.MCT 06 0080
   Siegel HJ, 2008, EXPERT REV ANTICANC, V8, P1257, DOI 10.1586/14737140.8.8.1257
   Surmacz E, 2003, ONCOGENE, V22, P6589, DOI 10.1038/sj.onc.1206772
   Trent JC, 2008, CURR OPIN ONCOL, V20, P393, DOI 10.1097/CCO.0b013e328303ba31
   ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460 2075.1986.tb04528.x
   Vasilcanu D, 2004, ONCOGENE, V23, P7854, DOI 10.1038/sj.onc.1208065
   Vasilcanu R, 2008, ONCOGENE, V27, P1629, DOI 10.1038/sj.onc.1210797
   Viereck V, 2007, J CELL BIOCHEM, V102, P28, DOI 10.1002/jcb.21274
   Xie YT, 1999, CANCER RES, V59, P3588
   Yang C, 2009, CANCER CHEMOTH PHARM, V64, P607, DOI 10.1007/s00280 008 0912 6
   Yang C, 2009, APOPTOSIS, V14, P124, DOI 10.1007/s10495 008 0282 x
NR 41
TC 75
Z9 81
U1 0
U2 6
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106 4404 USA
SN 1535 7163
J9 MOL CANCER THER
JI Mol. Cancer Ther.
PD AUG
PY 2009
VL 8
IS 8
BP 2122
EP 2130
DI 10.1158/1535 7163.MCT 09 0115
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 484FM
UT WOS:000269029300007
PM 19638450
OA Green Accepted, Green Submitted
DA 2025 08 17
ER

PT J
AU Gordon, CM
   Cleveland, RH
   Baltrusaitis, K
   Massaro, J
   D'Agostino, RB
   Liang, MG
   Snyder, B
   Walters, M
   Li, X
   Braddock, DT
   Kleinman, ME
   Kieran, MW
   Gordon, LB
AF Gordon, C. M.
   Cleveland, R. H.
   Baltrusaitis, K.
   Massaro, J.
   D'Agostino, R. B., Sr.
   Liang, M. G.
   Snyder, B.
   Walters, M.
   Li, X.
   Braddock, D. T.
   Kleinman, M. E.
   Kieran, M. W.
   Gordon, L. B.
TI Extraskeletal Calcifications in Hutchinson Gilford Progeria Syndrome
SO BONE
LA English
DT Article
DE Progeria; Extraskeletal calcifications; Magnesium; Parathyroid hormone;
   HGPS; Lamin; Aging; Laminopathy
ID MOUSE MODEL; PSEUDOXANTHOMA ELASTICUM; FARNESYLATION INHIBITORS;
   CLINICAL TRIAL; CHILDREN; CALCINOSIS
AB Purpose: Children with Hutchinson Gilford progeria syndrome (HGPS), a rare premature aging disease, exhibit extraskeletal calcifications detected by radiographic analysis and on physical examination. The aim of this study was to describe the natural history and pathophysiology of these abnormal calcifications in HGPS, and to determine whether medications and/or supplements tested in clinical trials alter their development.
   Methods: Children from two successive clinical trials administering 1) lonafarnib (n = 26) and 2) lonafarnib + pravastatin + zoledronic acid (n = 37) were studied at baseline (pre therapy), one year on therapy, and at end of therapy (3.3 4.3 years after the baseline visit). Calcium supplementation (oral calcium carbonate) was administered during the first year of the second trial and was subsequently discontinued. Information on calcifications was obtained from physical examinations, radiographs, and serum and urinary biochemical measures. The mineral content of two skin derived calcifications was determined by x ray diffraction.
   Results: Extraskeletal calcifications were detected radiographically in 12/39 (31%) patients at baseline. The odds of exhibiting calcifications increased with age (p = 0.045). The odds were unaffected by receipt of lonafarnib, pravastatin, and zoledronate therapies. However, administration of calcium carbonate supplementation, in conjunction with all three therapeutic agents, significantly increased the odds of developing calcifications (p = 0.009), with the odds plateauing after the supplement's discontinuation. Composition analysis of calcinosis cutis showed hydroxyapatite similar to bone. Although serum calcium, phosphorus, and parathyroid hormone (PTH) were within normal limits at baseline and on therapy, PTH increased significantly after lonafarnib initiation (p < 0.001). Both the urinary calcium/creatinine ratio and tubular reabsorption of phosphate (TRP) were elevated at baseline in 22/39 (56%) and 31/37 (84%) evaluable patients, respectively, with no significant changes while on therapy. The mean calcium x phosphorus product (Ca x Pi) was within normal limits, but plasma magnesium decreased over both clinical trials. Fibroblast growth factor 23 (FGF23) was lower compared to age matched controls (p = 0.03).
   Conclusions: Extraskeletal calcifications increased with age in children with HGPS and were composed of hydroxyapatite. The urinary calcium/creatinine ratio and TRP were elevated for age while FGF23 was decreased. Magnesium decreased and PTH increased after lonafarnib therapy which may alter the ability to mobilize calcium. These findings demonstrate that children with HGPS with normal renal function and an unremarkable Ca x Pi develop extraskeletal calcifications by an unidentified mechanism that may involve decreased plasma magnesium and FGF23. Calcium carbonate accelerated their development and is, therefore, not recommended for routine supplementation in these children.
C1 [Gordon, C. M.] Boston Childrens Hosp, Div Adolescent Young Adult Med, 333 Longwood Ave,5th Floor, Boston, MA 02115 USA.
   [Cleveland, R. H.; Walters, M.] Boston Childrens Hosp, Dept Radiol, Boston, MA USA.
   [Baltrusaitis, K.; Massaro, J.; D'Agostino, R. B., Sr.] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA.
   [Liang, M. G.] Boston Childrens Hosp, Dept Dermatol, Boston, MA USA.
   [Snyder, B.] Boston Childrens Hosp, Dept Orthopaed, Boston, MA USA.
   [Li, X.; Braddock, D. T.] Yale Univ, Dept Pathol, New Haven, CT USA.
   [Kleinman, M. E.; Gordon, L. B.] Boston Childrens Hosp, Dept Anesthesiol Preoperat & Pain Med, Boston, MA USA.
   [Kieran, M. W.] Boston Childrens Hosp, Div Hematol Oncol, Boston, MA USA.
   [Gordon, L. B.] Brown Univ, Hasbro Childrens Hosp, Dept Pediat, Providence, RI 02912 USA.
   [Gordon, L. B.] Brown Univ, Warren Alpert Med Sch, Providence, RI 02912 USA.
C3 Harvard University; Harvard University Medical Affiliates; Boston
   Children's Hospital; Harvard University; Harvard University Medical
   Affiliates; Boston Children's Hospital; Boston University; Harvard
   University; Harvard University Medical Affiliates; Boston Children's
   Hospital; Harvard University; Harvard University Medical Affiliates;
   Boston Children's Hospital; Yale University; Harvard University; Harvard
   University Medical Affiliates; Boston Children's Hospital; Harvard
   University; Harvard University Medical Affiliates; Boston Children's
   Hospital; Brown University; Hasbro Children's Hospital; Brown University
RP Gordon, CM (通讯作者)，Boston Childrens Hosp, Div Adolescent Young Adult Med, 333 Longwood Ave,5th Floor, Boston, MA 02115 USA.
EM Catherine.Gordon@childrens.harvard.edu
RI Gordon, Catherine/GOH 1814 2022; Kleinman, Monica/AAO 5641 2020; Gordon,
   Leslie/AAJ 5793 2021; Li, Xiaofeng/F 3735 2011
OI Li, Xiaofeng/0009 0005 3765 0124; 
FU Progeria Research Foundation [PRF2002 CB, PRFCLIN2007 02,
   PRFCLIN2009 03]; National Heart, Lung, and Blood Institute
   [1RC2HL101631 0]; Harvard Clinical and Translational Science Center
   (National Center for Research Resources, National Institutes of Health)
   [UL1 TR001102]; Harvard Clinical and Translational Science Center
   (National Center for Advancing Translational Sciences, National
   Institutes of Health) [UL1 TR001102]
FX We gratefully acknowledge the children with progeria and their families
   for participation in this study, Dr. Adele Boskey and Dr. Nancy Pleshko
   for their expert assistance with the X ray diffraction analyses, and
   funding from the Progeria Research Foundation (PRF2002 CB,
   PRFCLIN2007 02 and PRFCLIN2009 03), National Heart, Lung, and Blood
   Institute grant 1RC2HL101631 0, and the Harvard Clinical and
   Translational Science Center (National Center for Research Resources and
   the National Center for Advancing Translational Sciences, National
   Institutes of Health Award UL1 TR001102).
CR Bolland MJ, 2008, BMJ BRIT MED J, V336, P262, DOI 10.1136/bmj.39440.525752.BE
   Bolland Mark J, 2011, BMJ, V342, pd2040, DOI 10.1136/bmj.d2040
   Bolland MJ, 2010, BMJ BRIT MED J, V341, DOI 10.1136/bmj.c3691
   Bouvard B., 2016, Morphologie, V100, P250, DOI 10.1016/j.morpho.2016.01.004
   Cañas CA, 2015, JCR J CLIN RHEUMATOL, V21, P267, DOI 10.1097/RHU.0000000000000264
   Clarke B, 2008, CLIN J AM SOC NEPHRO, V3, pS131, DOI 10.2215/CJN.04151206
   Cleveland RH, 2012, PEDIATR RADIOL, V42, P1089, DOI 10.1007/s00247 012 2423 1
   De Sandre Giovannoli A, 2003, SCIENCE, V300, P2055, DOI 10.1126/science.1084125
   Eriksson M, 2003, NATURE, V423, P293, DOI 10.1038/nature01629
   Folsom LJ, 2015, CURR OSTEOPOROS REP, V13, P78, DOI 10.1007/s11914 015 0254 3
   Gerhard Herman M, 2012, HYPERTENSION, V59, P92, DOI 10.1161/HYPERTENSIONAHA.111.180919
   Gordon CM, 2011, J BONE MINER RES, V26, P1670, DOI 10.1002/jbmr.392
   Gordon LB, 2018, PEDIATR RES, V83, P982, DOI 10.1038/pr.2018.9
   Gordon LB, 2016, CIRCULATION, V134, P114, DOI 10.1161/CIRCULATIONAHA.116.022188
   Gordon LB, 2014, CIRCULATION, V130, P27, DOI 10.1161/CIRCULATIONAHA.113.008285
   Gordon LB, 2012, P NATL ACAD SCI USA, V109, P16666, DOI 10.1073/pnas.1202529109
   Harvey NC, 2018, J BONE MINER RES, V33, P803, DOI 10.1002/jbmr.3375
   Honjo S, 2008, REJUV RES, V11, P809, DOI 10.1089/rej.2007.0649
   Hsu VM, 2017, SCAND J RHEUMATOL, V46, P118, DOI 10.1080/03009742.2016.1219766
   Ibarra M, 2010, J RHEUMATOL, V37, P876, DOI 10.3899/jrheum.090833
   Jiang QJ, 2012, EXP DERMATOL, V21, P694, DOI 10.1111/j.1600 0625.2012.01553.x
   Kupetsky Rincon EA, 2012, CTS CLIN TRANSL SCI, V5, P259, DOI 10.1111/j.1752 8062.2011.00390.x
   Luo Y, 2016, CURR MOL MED, V16, P4, DOI 10.2174/1566524016666151222142446
   Merideth MA, 2008, NEW ENGL J MED, V358, P592, DOI 10.1056/NEJMoa0706898
   Murali SK, 2016, PLOS BIOL, V14, DOI 10.1371/journal.pbio.1002427
   Nitschke Y, 2017, CURR OSTEOPOROS REP, V15, P255, DOI 10.1007/s11914 017 0370 3
   Pachman LM, 2006, ARTHRITIS RHEUM US, V54, P3345, DOI 10.1002/art.22158
   PLESHKO N, 1991, BIOPHYS J, V60, P786, DOI 10.1016/S0006 3495(91)82113 0
   Prakash A, 2018, JAMA CARDIOL, V3, P326, DOI 10.1001/jamacardio.2017.5235
   Querido W, 2018, APPL SPECTROSC, V72, P1581, DOI 10.1177/0003702818789165
   Ramnitz MS, 2016, J BONE MINER RES, V31, P1845, DOI 10.1002/jbmr.2870
   Savinov AY, 2015, J AM HEART ASSOC, V4, DOI 10.1161/JAHA.115.002499
   Villa Bellosta R, 2013, CIRCULATION, V127, P2442, DOI 10.1161/CIRCULATIONAHA.112.000571
   Villa Bellosta R, 2011, CIRC J, V75, P2705, DOI 10.1253/circj.CJ 11 0477
   Wu LL, 2015, ACTA BIOMATER, V27, P294, DOI 10.1016/j.actbio.2015.08.042
   Xu C, 2005, GENE, V357, P1, DOI 10.1016/j.gene.2005.06.017
NR 36
TC 3
Z9 4
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD AUG
PY 2019
VL 125
BP 103
EP 111
DI 10.1016/j.bone.2019.05.008
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA IG1MI
UT WOS:000473555300013
PM 31077852
OA Bronze, Green Accepted
DA 2025 08 17
ER

PT J
AU Danielyan, L
   Schäfer, R
   Schulz, A
   Ladewig, T
   Lourhmati, A
   Buadze, M
   Schmitt, AL
   Verleysdonk, S
   Kabisch, D
   Koeppen, K
   Siegel, G
   Proksch, B
   Kluba, T
   Eckert, A
   Köhle, C
   Schöneberg, T
   Northoff, H
   Schwab, M
   Gleiter, CH
AF Danielyan, L.
   Schaefer, R.
   Schulz, A.
   Ladewig, T.
   Lourhmati, A.
   Buadze, M.
   Schmitt, A. L.
   Verleysdonk, S.
   Kabisch, D.
   Koeppen, K.
   Siegel, G.
   Proksch, B.
   Kluba, T.
   Eckert, A.
   Koehle, C.
   Schoeneberg, T.
   Northoff, H.
   Schwab, M.
   Gleiter, C. H.
TI Survival, neuron like differentiation and functionality of mesenchymal
   stem cells in neurotoxic environment: the critical role of
   erythropoietin
SO CELL DEATH AND DIFFERENTIATION
LA English
DT Article
DE erythropoietin; hypoxia; MSCs; Abeta; cholinergic differentiation;
   glutamate
ID BETA AMYLOID TOXICITY; WNT SIGNALING PATHWAY; UMBILICAL CORD BLOOD;
   NF KAPPA B; ALZHEIMERS DISEASE; PARKINSONS DISEASE; MULTIPLE SCLEROSIS;
   CEREBRAL ISCHEMIA; BONE MARROW; RAT BRAIN
AB Mesenchymal stem cells (MSCs) can ameliorate symptoms in several neurodegenerative diseases. However, the toxic environment of a degenerating central nervous system (CNS) characterized by hypoxia, glutamate (Glu) excess and amyloid beta (Abeta) pathology may hamper the survival and regenerative/replacing capacities of engrafted stem cells. Indeed, human MSC (hMSC) exposed to hypoxia were disabled in (i) the capacity of their muscarinic receptors (mAChRs) to respond to acetylcholine (ACh) with a transient increase in intracellular [Ca2+], (ii) their capacity to metabolize Glu, reflected by a strong decrease in glutamine synthetase activity, and (iii) their survival on exposure to Glu. Cocultivation of MSC with PC12 cells expressing the amyloid precursor protein gene (APPsw PC12) increased the release of IL 6 from MSC. HMSC exposed to erythropoietin (EPO) showed a cholinergic neuron like phenotype reflected by increased cellular levels of choline acetyltransferase, ACh and mAChR. All their functional deficits observed under hypoxia, Glu exposure and APPsw PC12 cocultivation were reversed by the application of EPO, which increased the expression of Wnt3a. EPO also enhanced the metabolism of Abeta in MSC by increasing their neprilysin content. Our data show that cholinergic neuron like differentiation of MSC, their functionality and resistance to a neurotoxic environment is regulated and can be improved by EPO, highlighting its potential for optimizing cellular therapies of the CNS. Cell Death and Differentiation (2009) 16, 1599 1614; doi: 10.1038/cdd.2009.95; published online 17 July 2009
C1 [Danielyan, L.; Lourhmati, A.; Buadze, M.; Schmitt, A. L.; Kabisch, D.; Proksch, B.; Schwab, M.; Gleiter, C. H.] Univ Tubingen Hosp, Dept Clin Pharmacol, D 72076 Tubingen, Germany.
   [Schaefer, R.; Siegel, G.; Northoff, H.] Univ Tubingen Hosp, Inst Clin & Expt Transfus Med, D 72076 Tubingen, Germany.
   [Schulz, A.; Schoeneberg, T.] Univ Leipzig, Fac Med, Inst Biochem, Leipzig, Germany.
   [Ladewig, T.; Koeppen, K.] Univ Tubingen Hosp, Ctr Ophthalmol, D 72076 Tubingen, Germany.
   [Verleysdonk, S.] Univ Tubingen, Interfac Inst Biochem, Tubingen, Germany.
   [Kluba, T.] Univ Tubingen Hosp, Dept Orthopaed, D 72076 Tubingen, Germany.
   [Eckert, A.] Psychiat Univ Clin, Neurobiol Res Lab, Basel, Switzerland.
   [Koehle, C.] Univ Tubingen, Dept Toxicol, Inst Pharmacol & Toxicol, Tubingen, Germany.
   [Schwab, M.] Univ Tubingen, Dr Margarete Fischer Bosch Inst Clin Pharmacol, Stuttgart, Germany.
C3 Eberhard Karls University of Tubingen; Eberhard Karls University
   Hospital; Eberhard Karls University of Tubingen; Eberhard Karls
   University Hospital; Leipzig University; Eberhard Karls University of
   Tubingen; Eberhard Karls University Hospital; Eberhard Karls University
   of Tubingen; Eberhard Karls University of Tubingen; Eberhard Karls
   University Hospital; Eberhard Karls University of Tubingen; Eberhard
   Karls University Hospital; Eberhard Karls University of Tubingen;
   Eberhard Karls University Hospital
RP Danielyan, L (通讯作者)，Univ Tubingen Hosp, Dept Clin Pharmacol, Otfried Mueller Str 45, D 72076 Tubingen, Germany.
EM lusine.danielyan@med.uni tuebingen.de;
   richard.schaefer@med.uni tuebingen.de
RI ; Schwab, Matthias/ABH 7449 2020; Danielyan, Lusine/AEB 6634 2022
OI Buadze, Marine/0000 0002 4175 0065; Eckert, Anne/0000 0002 9341 3669;
   Danielyan, Lusine/0000 0003 4130 8477; Schwab,
   Matthias/0000 0002 9984 075X; 
CR Arien Zakay H, 2007, J MOL NEUROSCI, V32, P179, DOI 10.1007/s12031 007 0027 2
   Bisaglia M, 2002, NEUROCHEM INT, V41, P43, DOI 10.1016/S0197 0186(01)00136 X
   Caccamo A, 2006, NEURON, V49, P671, DOI 10.1016/j.neuron.2006.01.020
   Chong ZZ, 2005, CURR NEUROVASC RES, V2, P387, DOI 10.2174/156720205774962683
   Colter DC, 2001, P NATL ACAD SCI USA, V98, P7841, DOI 10.1073/pnas.141221698
   Danielyan L, 2005, EUR J CELL BIOL, V84, P907, DOI 10.1016/j.ejcb.2005.07.001
   Danielyan L, 2007, NEUROCHEM RES, V32, P1489, DOI 10.1007/s11064 007 9337 6
   de Boer J, 2004, BONE, V34, P818, DOI 10.1016/j.bone.2004.01.016
   de Hemptinne I, 2004, J NEUROCHEM, V91, P155, DOI 10.1111/j.1471 4159.2004.02709.x
   Decker MJ, 2005, SLEEP, V28, P169, DOI 10.1093/sleep/28.2.169
   Dings J, 1998, NEUROSURGERY, V43, P1082, DOI 10.1097/00006123 199811000 00045
   Ehrenreich H, 2007, BRAIN, V130, P2577, DOI 10.1093/brain/awm203
   Esneault E, 2008, J CEREBR BLOOD F MET, V28, P1552, DOI 10.1038/jcbfm.2008.40
   Farías GG, 2004, NEUROBIOL DIS, V17, P337, DOI 10.1016/j.nbd.2004.07.016
   Gonzalez FF, 2007, DEV NEUROSCI BASEL, V29, P321, DOI 10.1159/000105473
   Habler OP, 1997, TRANSFUS SCI, V18, P425, DOI 10.1016/S0955 3886(97)00041 6
   Harrison JS, 2002, BLOOD, V99, P394, DOI 10.1182/blood.V99.1.394
   Henry Feugeas MC, 2008, MED HYPOTHESES, V70, P866, DOI 10.1016/j.mehy.2007.07.027
   Honma T, 2006, EXP NEUROL, V199, P56, DOI 10.1016/j.expneurol.2005.05.004
   Hoogduijn MJ, 2009, STEM CELLS DEV, V18, P103, DOI 10.1089/scd.2008.0032
   Iwata N, 2001, SCIENCE, V292, P1550, DOI 10.1126/science.1059946
   Katoh M, 2008, CURR DRUG TARGETS, V9, P565, DOI 10.2174/138945008784911750
   Kemp CR, 2007, DEV DYNAM, V236, P2011, DOI 10.1002/dvdy.21198
   Kern S, 2006, STEM CELLS, V24, P1294, DOI 10.1634/stemcells.2005 0342
   Kim SS, 2008, STEM CELLS, V26, P2217, DOI 10.1634/stemcells.2008 0108
   Kumral A, 2007, NEONATOLOGY, V92, P269, DOI 10.1159/000105493
   Lassmann H, 2003, BRAIN, V126, P1347, DOI 10.1093/brain/awg127
   Lim JH, 2008, CANCER RES, V68, P5177, DOI 10.1158/0008 5472.CAN 07 6234
   Pacary E, 2006, J CELL SCI, V119, P2667, DOI 10.1242/jcs.03004
   Park HJ, 2008, J NEUROCHEM, V107, P141, DOI 10.1111/j.1471 4159.2008.05589.x
   PATEL NS, 2005, J NEUROINFLAMM, V11, P1
   Robinson SR, 2000, NEUROCHEM INT, V36, P471, DOI 10.1016/S0197 0186(99)00150 3
   Schäfer R, 2007, CYTOTHERAPY, V9, P397, DOI 10.1080/14653240701392949
   Slevin M, 2008, EUR J NEUROL, V15, P25, DOI 10.1111/j.1468 1331.2007.01995.x
   Strunk T, 2008, ACTA PAEDIATR, V97, P16, DOI 10.1111/j.1651 2227.2007.00560.x
   Theus MH, 2008, EXP NEUROL, V210, P656, DOI 10.1016/j.expneurol.2007.12.020
   Tilleux S, 2007, J NEUROSCI RES, V85, P2059, DOI 10.1002/jnr.21325
   Tsang SWY, 2007, NEUROBIOL AGING, V28, P1381, DOI 10.1016/j.neurobiolaging.2006.06.001
   Volmar CH, 2008, CYTOKINE, V42, P336, DOI 10.1016/j.cyto.2008.03.007
   Walton RM, 2008, J NEUROSCI METH, V169, P158, DOI 10.1016/j.jneumeth.2007.12.011
   Webster NJ, 2006, NEUROBIOL AGING, V27, P439, DOI 10.1016/j.neurobiolaging.2005.02.002
   Xue YQ, 2007, NEUROSCIENCE, V146, P1245, DOI 10.1016/j.neuroscience.2007.02.004
   Zhang J, 2005, BRAIN RES, V1034, P34, DOI 10.1016/j.brainres.2004.11.036
   Zhu X, 1996, P NATL ACAD SCI USA, V93, P2827, DOI 10.1073/pnas.93.7.2827
   Zwezdaryk KJ, 2007, EXP HEMATOL, V35, P640, DOI 10.1016/j.exphem.2007.01.044
NR 45
TC 51
Z9 54
U1 0
U2 20
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1350 9047
EI 1476 5403
J9 CELL DEATH DIFFER
JI Cell Death Differ.
PD DEC
PY 2009
VL 16
IS 12
BP 1599
EP 1614
DI 10.1038/cdd.2009.95
PG 16
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 519QY
UT WOS:000271783600005
PM 19609278
OA Bronze
DA 2025 08 17
ER

PT J
AU Adriaansen, J
   Kuhlman, RR
   Van Holten, J
   Kaynor, C
   Vervoordeldonk, MJBM
   Tak, PP
AF Adriaansen, J.
   Kuhlman, R. R.
   Van Holten, J.
   Kaynor, C.
   Vervoordeldonk, M. J. B. M.
   Tak, P. P.
TI Intraarticular interferon β gene therapy ameliorates adjuvant arthritis
   in rats
SO HUMAN GENE THERAPY
LA English
DT Article
ID COLLAGEN INDUCED ARTHRITIS; RECEPTOR ANTAGONIST PRODUCTION;
   NECROSIS FACTOR ALPHA; ADENOASSOCIATED VIRUS; PROINFLAMMATORY CYTOKINES;
   REDUCES INFLAMMATION; IMMUNE RESPONSES; TISSUE INHIBITOR; SYNOVIAL
   TISSUE; SRC KINASE
AB Interferon (IFN) beta has significant immunomodulatory properties and has received much interest as a potentially therapeutic agent for rheumatoid arthritis (RA). Systemic IFN beta treatment of patients with RA was not effective, probably because of pharmacokinetic issues. Therefore, we studied the effect of local IFN beta production by adenovirus mediated gene transfer to the ankle joints of arthritic rats. Adjuvant arthritis (AA) in rats was used as a model to study intraarticular gene therapy with an adenoviral vector encoding the rat IFN beta gene (Ad. IFN beta). The effect on paw swelling was measured by water displacement plethysmometry. Synovial tissue of the hind paws was examined by immunohistochemistry. Bone destruction was analyzed on the basis of radiographs. In addition, quantitative real time polymerase chain reaction was used to assess IFN beta expression. Levels of IFN beta mRNA and protein peaked 2 days after intraarticular injection and declined thereafter. Local delivery of Ad. IFN beta after the onset of disease reduced paw swelling significantly. This was accompanied by a reduction in synovial inflammation. The clinical effects in rat AA lasted up to 9 days. Strikingly, Ad. IFN beta treatment protected bone from erosion, reduced levels of c Cbl and Cbl b (both signaling molecules essential for osteoclast activity), and reduced the matrix metalloproteinase 3:tissue inhibitor of metalloproteinase 1 ratio in the joint. Immunohistochemical analysis of the synovial tissue revealed a clear shift toward a more antiinflammatory cytokine profile. Local overexpression of IFN beta inhibits arthritis progression and protects against bone destruction in rat AA. These findings validate IFN beta as a therapeutic molecule for intraarticular gene therapy of arthritis.
C1 Univ Amsterdam, Acad Med Ctr, Div Clin Immunol & Rheumatol, NL 1105 AZ Amsterdam, Netherlands.
   Arthrogen BV, NL 1105 BA Amsterdam, Netherlands.
   Biogen Idec Inc, Cambridge, MA 02142 USA.
C3 University of Amsterdam; Academic Medical Center Amsterdam; Biogen
RP Tak, PP (通讯作者)，Univ Amsterdam, Acad Med Ctr, Div Clin Immunol & Rheumatol, Meibergdreef 9,Room F4 218, NL 1105 AZ Amsterdam, Netherlands.
EM P.P.Tak@amc.uva.nl
CR Adriaansen J, 2005, ANN RHEUM DIS, V64, P1677, DOI 10.1136/ard.2004.035063
   Akbar AN, 2000, IMMUNOL TODAY, V21, P337, DOI 10.1016/S0167 5699(00)01652 2
   Alliston T, 2002, NATURE, V416, P686, DOI 10.1038/416686a
   Apparailly F, 2005, HUM GENE THER, V16, P426, DOI 10.1089/hum.2005.16.426
   Bakker AC, 2002, ARTHRITIS RHEUM, V46, P1661, DOI 10.1002/art.10481
   Bessis N, 2004, GENE THER, V11, pS10, DOI 10.1038/sj.gt.3302364
   Boyle DL, 2002, ARTHRITIS RHEUM US, V46, P3076, DOI 10.1002/art.10595
   Bresnihan B, 1999, BEST PRACT RES CL RH, V13, P645, DOI 10.1053/berh.1999.0051
   Brooks AR, 2004, J GENE MED, V6, P395, DOI 10.1002/jgm.516
   Cha HS, 2003, CLIN EXP RHEUMATOL, V21, P593
   Chirmule N, 1999, GENE THER, V6, P1574, DOI 10.1038/sj.gt.3300994
   Chiusaroli R, 2003, DEV BIOL, V261, P537, DOI 10.1016/S0012 1606(03)00299 9
   CLARK IM, 1993, ARTHRITIS RHEUM, V36, P372, DOI 10.1002/art.1780360313
   Coclet Ninin J, 1997, EUR CYTOKINE NETW, V8, P345
   Crotti TN, 2002, ANN RHEUM DIS, V61, P1047, DOI 10.1136/ard.61.12.1047
   DEMAEYER E, 1988, INT REV IMMUNOL, V17, P53
   Distler JHW, 2005, P NATL ACAD SCI USA, V102, P2892, DOI 10.1073/pnas.0409781102
   Ersoy E, 2005, EUR J NEUROL, V12, P208, DOI 10.1111/j.1468 1331.2004.00986.x
   Haynes DR, 2001, RHEUMATOLOGY, V40, P623, DOI 10.1093/rheumatology/40.6.623
   Horne WC, 2005, IMMUNOL REV, V208, P106, DOI 10.1111/j.0105 2896.2005.00335.x
   Ijima K, 2001, HUM GENE THER, V12, P1063, DOI 10.1089/104303401750214285
   Jooss K, 2003, GENE THER, V10, P955, DOI 10.1038/sj.gt.3302037
   Joosten LAB, 1999, J IMMUNOL, V163, P5049
   Lai CM, 2002, DNA CELL BIOL, V21, P895, DOI 10.1089/104454902762053855
   Lubberts E, 2000, CLIN EXP IMMUNOL, V120, P375, DOI 10.1046/j.1365 2249.2000.01217.x
   Lubberts E, 2000, J CLIN INVEST, V105, P1697, DOI 10.1172/JCI7739
   Miyazaki T, 2004, J BIOL CHEM, V279, P17660, DOI 10.1074/jbc.M311032200
   Nguyen KHY, 1998, J RHEUMATOL, V25, P1118
   Palmer G, 2004, ANN RHEUM DIS, V63, P43, DOI 10.1136/ard.2002.005546
   Rannou FO, 2006, JOINT BONE SPINE, V73, P29, DOI 10.1016/j.jbspin.2004.12.013
   Rep MHG, 1996, J NEUROIMMUNOL, V67, P111
   Rep MHG, 1999, J NEUROIMMUNOL, V96, P92, DOI 10.1016/S0165 5728(98)00271 9
   Smeets RL, 2003, GENE THER, V10, P1004, DOI 10.1038/sj.gt.3301986
   Smeets TJM, 2003, ANN RHEUM DIS, V62, P635, DOI 10.1136/ard.62.7.635
   Smeets TJM, 2000, ARTHRITIS RHEUM US, V43, P270, DOI 10.1002/1529 0131(200002)43:2<270::AID ANR5>3.0.CO;2 H
   Strand V, 2004, RHEUMATOLOGY, V43, P10, DOI 10.1093/rheumatology/keh202
   Tak PP, 2004, FRONT BIOSCI LANDMRK, V9, P3242, DOI 10.2741/1475
   Tak PP, 1999, RHEUMATOLOGY, V38, P362, DOI 10.1093/rheumatology/38.4.362
   Tak PP, 2001, ARTHRITIS RHEUM, V44, P1897, DOI 10.1002/1529 0131(200108)44:8<1897::AID ART328>3.0.CO;2 4
   Takayanagi H, 2002, NATURE, V416, P744, DOI 10.1038/416744a
   Triantaphyllopoulos KA, 1999, ARTHRITIS RHEUM, V42, P90, DOI 10.1002/1529 0131(199901)42:1<90::AID ANR12>3.0.CO;2 A
   van de Loo FAJ, 2004, GENE THER, V11, P581, DOI 10.1038/sj.gt.3302182
   van Holten J, 2005, ANN RHEUM DIS, V64, P64, DOI 10.1136/ard.2003.020347
   van Holten J, 2004, ARTHRITIS RES THER, V6, pR239, DOI 10.1186/ar1165
   van Holten J, 2002, ARTHRITIS RES, V4, P346, DOI 10.1186/ar598
   van Lent PLEM, 2002, OSTEOARTHR CARTILAGE, V10, P234, DOI 10.1053/joca.2001.0501
   Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb 2002 3 7 research0034
   Woods JM, 2001, J IMMUNOL, V166, P1214, DOI 10.4049/jimmunol.166.2.1214
   Zhong L, 1999, EUR J IMMUNOL, V29, P964, DOI 10.1002/(SICI)1521 4141(199903)29:03<964::AID IMMU964>3.0.CO;2 P
NR 49
TC 31
Z9 40
U1 0
U2 2
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1043 0342
EI 1557 7422
J9 HUM GENE THER
JI Hum. Gene Ther.
PD OCT
PY 2006
VL 17
IS 10
BP 985
EP 996
DI 10.1089/hum.2006.17.985
PG 12
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
   Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
   Experimental Medicine
GA 095JG
UT WOS:000241303400004
PM 16984225
DA 2025 08 17
ER

PT J
AU Unger, S
   Paul, DA
   Nino, MC
   McKay, CP
   Miller, S
   Sochett, E
   Braverman, N
   Clarke, JTR
   Cole, DEC
   Superti Furga, A
AF Unger, S
   Paul, DA
   Nino, MC
   McKay, CP
   Miller, S
   Sochett, E
   Braverman, N
   Clarke, JTR
   Cole, DEC
   Superti Furga, A
TI Mucolipidosis II presenting as severe neonatal hyperparathyroidism
SO EUROPEAN JOURNAL OF PEDIATRICS
LA English
DT Article; Proceedings Paper
CT 6th International Skeletal Dysplasia Conference
CY AUG 22, 2003
CL Warrenton, VA
DE hyperparathyroidism; I cell disease; mucolipidosis II; neonatal
ID FAMILIAL HYPOCALCIURIC HYPERCALCEMIA; PLACENTAL CALCIUM TRANSPORT;
   LETHAL SKELETAL DYSPLASIA; CELL DISEASE; RECEPTOR GENE; SECONDARY
   HYPERPARATHYROIDISM; SENSING RECEPTOR; PACMAN DYSPLASIA; VITAMIN D;
   FEATURES
AB Mucolipidosis II (ML II or I cell disease) (OMIM 252500) is an autosomal recessive lysosomal enzyme targeting disorder that usually presents between 6 and 12 months of age with a clinical phenotype resembling Hurler syndrome and a radiological picture of dysostosis multiplex. When ML II is severe enough to be detected in the newborn period, the radiological changes have been described as similar to hyperparathyroidism or rickets. The biological basis of these findings has not been explored and few biochemical measurements have been recorded. We describe three unrelated infants with ML II who had radiological features of intrauterine hyperparathyroidism and biochemical findings consistent with severe secondary neonatal hyperparathyroidism (marked elevation of serum parathyroid hormone and alkaline phosphatase levels). The vitamin D metabolites were not substantially different from normal and repeatedly normal calcium concentrations excluded vitamin D deficiency rickets and neonatal severe hyperparathyroidism secondary to calcium sensing receptor gene mutations (OMIM 239200). The pathogenesis of severe hyperparathyroidism in the fetus and newborn with ML II is unexplained. We hypothesize that the enzyme targeting, defect of ML II interferes with transplacental calcium transport leading to a calcium starved fetus and activation of the parathyroid response to maintain extracellular calcium concentrations within the normal range. Conclusion: Newborns with mucolipidosis II can present with radiological and biochemical signs of hyperparathyroidism. Awareness of this phenomenon may help in avoiding diagnostic pitfalls and establishing a proper diagnosis and therapy.
C1 Hosp Sick Children, Div Clin & Metab Dis, Toronto, ON M5G 1X8, Canada.
   Christiana Care Hlth Syst, Sect Neonatol, Dept Pediat, Newark, NJ USA.
   Thomas Jefferson Univ, Dept Pediat, Philadelphia, PA 19107 USA.
   Johns Hopkins Univ, Sch Med, McKusick Nathans Inst Genet Med, Baltimore, MD USA.
   DuPont Hosp Children, Nephrol Sect, Dept Pediat, Wilmington, DE USA.
   Hosp Sick Children, Dept Diagnost Imaging, Toronto, ON M5G 1X8, Canada.
   Hosp Sick Children, Dept Endocrinol, Toronto, ON M5G 1X8, Canada.
   Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada.
   Univ Toronto, Dept Med, Toronto, ON, Canada.
   Sunnybrook & Womens Coll, Ctr Hlth Sci, Dept Clin Pathol, Toronto, ON, Canada.
   Univ Lausanne, Dept Pediat, Div Mol Pediat, Lausanne, Switzerland.
   CHU Vaudois, CH 1011 Lausanne, Switzerland.
C3 University of Toronto; Hospital for Sick Children (SickKids); Christiana
   Care Health System; Thomas Jefferson University; Johns Hopkins
   University; Nemours Alfred I. duPont Hospital for Children; University
   of Toronto; Hospital for Sick Children (SickKids); University of
   Toronto; Hospital for Sick Children (SickKids); University of Toronto;
   University of Toronto; University of Toronto; Sunnybrook Health Science
   Center; Sunnybrook Research Institute; University of Lausanne;
   University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)
RP Hosp Sick Children, Div Clin & Metab Dis, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.
EM Sheila.Unger@hospvd.ch
RI Paul, David/H 6775 2019; unger, sheila/E 9177 2015; superti furga,
   andrea/E 9162 2015
OI Braverman, Nancy/0000 0003 1621 5164; Unger, Sheila/0000 0002 9539 8941
CR BABCOCK DS, 1986, PEDIATR RADIOL, V16, P32, DOI 10.1007/BF02387502
   Bai M, 1997, J CLIN INVEST, V99, P88, DOI 10.1172/JCI119137
   Becker Y, 1995, VIRUS GENES, V11, P191, DOI 10.1007/BF01728658
   Bocca G, 2000, NEUROPEDIATRICS, V31, P49, DOI 10.1055/s 2000 15300
   CIPOLLONI C, 1980, HELV PAEDIATR ACTA, V35, P85
   Cole DEC, 1997, AM J MED GENET, V71, P202, DOI 10.1002/(SICI)1096 8628(19970808)71:2<202::AID AJMG16>3.0.CO;2 I
   Herman T E, 1996, J Perinatol, V16, P400
   HO C, 1995, NAT GENET, V11, P389, DOI 10.1038/ng1295 389
   Hochberg Rick, 2001, Zootaxa, V11, P1
   KARAPLIS AC, 1994, GENE DEV, V8, P277, DOI 10.1101/gad.8.3.277
   Kovacs CS, 1998, J CLIN INVEST, V101, P2812, DOI 10.1172/JCI2940
   Kovacs CS, 1996, P NATL ACAD SCI USA, V93, P15233, DOI 10.1073/pnas.93.26.15233
   Kovacs CS, 2001, ENDOCRINOLOGY, V142, P4983, DOI 10.1210/en.142.11.4983
   Kovacs CS, 2001, J CLIN INVEST, V107, P1007, DOI 10.1172/JCI11321
   LEMAITRE L, 1978, PEDIATR RADIOL, V7, P97, DOI 10.1007/BF00975678
   LEROY JG, 1967, SCIENCE, V157, P804, DOI 10.1126/science.157.3790.804
   LEROY JG, 1971, J PEDIATR US, V79, P360, DOI 10.1016/S0022 3476(71)80142 7
   LOUGHEAD JL, 1990, AM J PERINAT, V7, P350, DOI 10.1055/s 2007 999521
   Miller SF, 2003, PEDIATR RADIOL, V33, P256, DOI 10.1007/s00247 002 0859 4
   OKADA S, 1985, CLIN GENET, V28, P207
   PATRIQUIN HB, 1977, AM J ROENTGENOL, V129, P37, DOI 10.2214/ajr.129.1.37
   PAZZAGLIA UE, 1989, PEDIATR RADIOL, V20, P80, DOI 10.1007/BF02010640
   PAZZAGLIA UE, 1989, PEDIATR RADIOL, V19, P406, DOI 10.1007/BF02387638
   PAZZAGLIA UE, 1992, CLIN ORTHOP RELAT R, P283
   POLLAK MR, 1993, CELL, V75, P1297, DOI 10.1016/0092 8674(93)90617 Y
   RAPOLA J, 1977, CLIN GENET, V11, P107
   REITMAN ML, 1981, J BIOL CHEM, V256, P1977
   Salle BL, 2000, AM J CLIN NUTR, V71, p1317S, DOI 10.1093/ajcn/71.5.1317s
   SAUL R, 2004, AM J HUM GENET S, V75, P652
   SHOHAT M, 1993, AM J MED GENET, V45, P558, DOI 10.1002/ajmg.1320450506
   SPRITZ RA, 1978, J PEDIATR US, V93, P954, DOI 10.1016/S0022 3476(78)81218 9
   WHELAN DT, 1983, CLIN GENET, V24, P90
   Wilcox WR, 1998, AM J MED GENET, V77, P272
   Yashiro N, 1985, Radiat Med, V3, P95
NR 34
TC 32
Z9 34
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0340 6199
EI 1432 1076
J9 EUR J PEDIATR
JI Eur. J. Pediatr.
PD APR
PY 2005
VL 164
IS 4
BP 236
EP 243
DI 10.1007/s00431 004 1591 x
PG 8
WC Pediatrics
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC Pediatrics
GA 918EN
UT WOS:000228525200009
PM 15580357
DA 2025 08 17
ER

PT J
AU Yoshimoto, S
   Morita, H
   Okamura, K
   Hiraki, A
   Hashimoto, S
AF Yoshimoto, Shohei
   Morita, Hiromitsu
   Okamura, Kazuhiko
   Hiraki, Akimitsu
   Hashimoto, Shuichi
TI IL 6 Plays a Critical Role in Stromal Fibroblast RANKL Induction and
   Consequent Osteoclastogenesis in Ameloblastoma Progression
SO LABORATORY INVESTIGATION
LA English
DT Article
DE ameloblastoma; odontogenic tumor; fibroblast; osteoclastogenesis; Age;
   Pathologic diagnosis
ID KAPPA B LIGAND; RECEPTOR ACTIVATOR; INHIBITORY FACTOR; CELLS;
   OSTEOPROTEGERIN; DIFFERENTIATION; EXPRESSION; RESORPTION
AB Ameloblastoma (AB) is the most common benign, epithelial odontogenic tumor that occurs in the jawbone. AB is a slow growing, benign epithelial tumor but shows locally invasive growth, with bone resorption or recurrence if not adequately resected. From these points of view, understanding the mechanism of AB induced bone resorption is necessary for better clinical therapy and improving patients' quality of life. In bone resorption, osteoclasts play critical roles, and RANKL is a pivotal regulator of osteoclastogenesis. However, the source of RANKL expressing cells in the AB tumor microenvironment is controversial, and the mechanism of osteoclastogenesis in AB pro gression is not fully understood. In this study, we investigated the distribution of the RNA expression of RANKL in AB specimens. We found that PDGFRa  and S100A4 positive stromal fi  broblasts expressed RANKL in the AB tumor microenvironment. Moreover, we analyzed the mechanisms of osteoclastogenesis in the AB tumor microenvironment using the human AB cell line AM 1 and a human primary periodontal ligament fibroblast cells. The results of histopatho logic and in vitro studies clarified that the interaction between AB cells and stromal fibroblasts upregulated IL 6 expression and that AB cells induced RANKL expression in stromal fibroblasts and consequent osteoclastogenesis in AB progression. (c) 2022 THE AUTHORS. Published by Elsevier Inc. on behalf of the United States & Canadian Academy of Pathology. This is an open access article under the CC BY license (http:// creativecommons.org/licenses/by/4.0/).
C1 [Yoshimoto, Shohei; Okamura, Kazuhiko; Hashimoto, Shuichi] Fukuoka Dent Coll, Dept Morphol Biol, Div Biomed Sci, Sect Pathol, Fukuoka, Japan.
   [Yoshimoto, Shohei] Fukuoka Dent Coll, Oral Med Res Ctr, Fukuoka, Japan.
   [Morita, Hiromitsu] Fukuoka Dent Coll, Ctr Visiting Dent Serv, Dept Gen Dent, Fukuoka, Japan.
   [Hiraki, Akimitsu] Fukuoka Dent Coll, Dept Oral & Maxillofacial Surg, Div Oral & Med Management, Sect Oral Oncol, Fukuoka, Japan.
C3 Fukuoka Dental College (FDC); Fukuoka Dental College (FDC); Fukuoka
   Dental College (FDC); Fukuoka Dental College (FDC)
RP Yoshimoto, S (通讯作者)，Fukuoka Dent Coll, Dept Morphol Biol, Div Biomed Sci, Sect Pathol, Fukuoka, Japan.; Yoshimoto, S (通讯作者)，Fukuoka Dent Coll, Oral Med Res Ctr, Fukuoka, Japan.
EM yoshimoto@fdcnet.ac.jp
OI Okamura, Kazuhiko/0000 0002 1603 8412; YOSHIMOTO,
   SHOHEI/0000 0002 3195 2448
FU Japan Society for the Promotion of Science (JSPS) /KAKENHI [20K18490,
   21K10058, 18K07033]; Fukuoka Public Health Promotion Organization Cancer
   Research Fund; Kai  bara Morikazu Medical Science Promotion Foundation
FX This work was supported in part by the Grant in Aid for Young Scientists
   (20K18490 to S.Y.) and Grants in Aid for Scientific Research (C)
   (21K10058 to H.M. and 18K07033 to S.H.) from the Japan Society for the
   Promotion of Science (JSPS) /KAKENHI, Kai  bara Morikazu Medical Science
   Promotion Foundation, and Fukuoka Public Health Promotion Organization
   Cancer Research Fund.
CR Biffi G, 2021, PHYSIOL REV, V101, P147, DOI 10.1152/physrev.00048.2019
   Chairani E, 2022, BIOCHEM BIOPHYS REP, V30, DOI 10.1016/j.bbrep.2022.101233
   El Naggar AK, 2017, WHO CLASSIFICATION H
   Fuchigami T, 2014, BIOCHEM BIOPH RES CO, V451, P491, DOI 10.1016/j.bbrc.2014.07.137
   Fujii S, 2022, J PATHOL, V256, P119, DOI 10.1002/path.5814
   Gao Y, 1998, BONE, V22, P487, DOI 10.1016/S8756 3282(98)00040 4
   Harada H, 1998, J ORAL PATHOL MED, V27, P207
   Higashino N, 2019, LAB INVEST, V99, P777, DOI 10.1038/s41374 018 0185 6
   Hong J, 2007, INT J ORAL MAX SURG, V36, P283, DOI 10.1016/j.ijom.2006.11.003
   ISHIMI Y, 1990, J IMMUNOL, V145, P3297
   Karsdal MA, 2012, SEMIN ARTHRITIS RHEU, V42, P131, DOI 10.1016/j.semarthrit.2012.01.004
   Kikuta J, 2015, J DENT RES, V94, P140, DOI 10.1177/0022034514555364
   Komatsu N, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI143060
   Komohara Y, 2017, J PATHOL, V241, P313, DOI 10.1002/path.4824
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lin DP, 2015, IMMUNOLOGY, V144, P472, DOI 10.1111/imm.12395
   Nakashima T, 2011, NAT MED, V17, P1231, DOI 10.1038/nm.2452
   O'Brien CA, 1999, J BIOL CHEM, V274, P19301, DOI 10.1074/jbc.274.27.19301
   Öhlund D, 2017, J EXP MED, V214, P579, DOI 10.1084/jem.20162024
   Okamoto K, 2017, PHYSIOL REV, V97, P1295, DOI 10.1152/physrev.00036.2016
   Palmqvist P, 2002, J IMMUNOL, V169, P3353, DOI 10.4049/jimmunol.169.6.3353
   REICHART PA, 1995, ORAL ONCOL, V31B, P86
   Sandra F, 2005, ORAL ONCOL, V41, P637, DOI 10.1016/j.oraloncology.2005.02.008
   Sathi GSA, 2008, HISTOPATHOLOGY, V53, P458, DOI 10.1111/j.1365 2559.2008.03127.x
   Sato R, 2021, CANCER RES, V81, P4751, DOI 10.1158/0008 5472.CAN 20 3941
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Sims NA, 2021, CYTOKINE, V146, DOI 10.1016/j.cyto.2021.155655
   Takayanagi H, 2021, J BONE MINER METAB, V39, P13, DOI 10.1007/s00774 020 01191 1
   Tay JYY, 2004, J DENT RES, V83, P349, DOI 10.1177/154405910408300415
   Tsukasaki M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 03147 6
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Yoshimoto S, 2022, LAB INVEST, V102, P80, DOI 10.1038/s41374 021 00671 w
   Yoshimoto S, 2019, CANCER MED US, V8, P7822, DOI 10.1002/cam4.2667
NR 33
TC 7
Z9 7
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0023 6837
EI 1530 0307
J9 LAB INVEST
JI Lab. Invest.
PD JAN
PY 2023
VL 103
IS 1
AR 100023
DI 10.1016/j.labinv.2022.100023
EA JAN 2023
PG 12
WC Medicine, Research & Experimental; Pathology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pathology
GA J3VM7
UT WOS:001008924500001
PM 36748192
OA hybrid
DA 2025 08 17
ER

PT J
AU Lin, SS
   Qiu, MG
   Chen, JT
AF Lin, Shishui
   Qiu, Meiguang
   Chen, Jianting
TI IL 4 Modulates Macrophage Polarization in Ankylosing Spondylitis
SO CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
LA English
DT Article
DE Osteoclast (OC); Interleukin 4 (IL 4); Receptor activator of NF kB
   ligand (RANKL); Macrophage polarization; Histone deacetylation
ID COLLAGEN INDUCED ARTHRITIS; GENE THERAPY; OSTEOCLAST DIFFERENTIATION;
   OSTEOPROTEGERIN LIGAND; M2 MACROPHAGES; RANKL; MICE; ACTIVATION;
   EXPRESSION; CYTOKINE
AB Background/Aims: Osteoclasts (OC) originate from monocytes/macrophages and play a critical role in the development of ankylosing spondylitis (AS). Receptor activator of NF kB ligand (RANKL) is critical for the differentiation and maturation of OC from monocytes/macrophages, the underlying mechanisms of which processes have not been completely elucidated. Interleukin 4 (IL 4) attenuates the pathogenesis of AS via ill defined mechanisms. Methods: We used a proteoglycan induced arthritis (PGIA) model in Balb/c mice to study AS in humans. We injected IL 4 into the articular cavity and evaluated its effects on PGIA by incidence of arthritis, clinical and pathological arthritis severity and PET tracer uptake. We isolated and analyzed the number and polarization of macrophages in the articular cavity before and after IL 4 treatment. We analyzed RANKL levels in macrophage subtypes. We then isolated bone marrow derived macrophages and treated them with IL 4 in vitro, with or without histone deacetylase inhibitors trichostatin A (TSA), and then analyzed the polarization of cultured macrophages before and after IL 4 treatment and RANKL levels in macrophage subtypes. Results: IL 4 treatment decreased the incidence and severity of arthritis in a mouse AS model, and polarized macrophages from a classical M1 subtype to an M2 subtype in vivo and in vitro. RANKL was predominantly produced by M1, but not by M2 macrophages. IL 4 mediated inhibition of RANKL in macrophages was abolished by TSA. Conclusion: Our data suggest that the therapeutic effects of IL 4 on AS may result from a M1 to M2 macrophage polarization and its inhibition of RANKL expression on macrophages, possibly through enhanced histone deacetylation. Copyright (C) 2015 S. Karger AG, Basel
C1 [Lin, Shishui; Chen, Jianting] Southern Med Univ, Nanfang Hosp, Dept Spinal Surg, Guangzhou 510515, Guangdong, Peoples R China.
   [Lin, Shishui; Qiu, Meiguang] Fujian Med Univ, Fujian Prov Hosp, Dept Trauma Surg, Fuzhou, Peoples R China.
C3 Southern Medical University   China; Fujian Provincial Hospital; Fujian
   Medical University
RP Chen, JT (通讯作者)，Southern Med Univ, Nanfang Hosp, Dept Spinal Surg, 1838 North Guangzhou Ave, Guangzhou 510515, Guangdong, Peoples R China.
EM jianting_chen@163.com
CR Anandarajah AP, 2009, ADV EXP MED BIOL, V649, P85
   Boyle DL, 1999, GENE THER, V6, P1911, DOI 10.1038/sj.gt.3301049
   Braem K, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3772
   Colbert RA, 2014, MOL IMMUNOL, V57, P44, DOI 10.1016/j.molimm.2013.07.013
   Cottard V, 2000, GENE THER, V7, P1930, DOI 10.1038/sj.gt.3301324
   Davey Ranasinghe N, 2013, CURR OPIN RHEUMATOL, V25, P509, DOI 10.1097/BOR.0b013e3283620777
   Fan X, 2004, J CELL BIOCHEM, V93, P807, DOI 10.1002/jcb.20217
   Fields PE, 2002, J IMMUNOL, V169, P647, DOI 10.4049/jimmunol.169.2.647
   Fuller K, 1998, J EXP MED, V188, P997, DOI 10.1084/jem.188.5.997
   Geissmann F, 2010, SCIENCE, V327, P656, DOI 10.1126/science.1178331
   Golder V, 2013, AUST FAM PHYSICIAN, V42
   Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978
   Honma M, 2014, CURR OSTEOPOROS REP, V12, P115, DOI 10.1007/s11914 014 0189 0
   Kaim AH, 2002, RADIOLOGY, V223, P446, DOI 10.1148/radiol.2232010914
   Kuroda E, 2009, J IMMUNOL, V183, P3652, DOI 10.4049/jimmunol.0900864
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   López Bravo M, 2013, J ALLERGY CLIN IMMUN, V132, P1409, DOI 10.1016/j.jaci.2013.08.039
   Lories RJU, 2005, J CLIN INVEST, V115, P1571, DOI 10.1172/JCI23738
   Lubberts E, 2000, J CLIN INVEST, V105, P1697, DOI 10.1172/JCI7739
   Martinez FO, 2013, BLOOD, V121, pE57, DOI 10.1182/blood 2012 06 436212
   Morita Y, 2001, J CLIN INVEST, V107, P1275, DOI 10.1172/JCI11490
   Myers LK, 2002, CLIN IMMUNOL, V102, P185, DOI 10.1006/clim.2001.5162
   Robinson PC, 2014, MOL IMMUNOL, V57, P2, DOI 10.1016/j.molimm.2013.06.013
   Serrat N, 2012, EUR J IMMUNOL, V42, P3028, DOI 10.1002/eji.201242413
   Svensson L, 2002, EUR J IMMUNOL, V32, P2944, DOI 10.1002/1521 4141(2002010)32:10<2944::AID IMMU2944>3.0.CO;2 4
   Takayanagi H, 2002, ARTHRITIS RES THER, V4, pS227, DOI 10.1186/ar581
   Tanaka S, 2007, AM J NEPHROL, V27, P466, DOI 10.1159/000106484
   Tarner IH, 2002, CLIN IMMUNOL, V105, P304, DOI 10.1006/clim.2002.5299
   van Meegeren MER, 2013, BRIT J HAEMATOL, V160, P515, DOI 10.1111/bjh.12148
   Veremeyko T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081774
   Weischenfeldt Joachim, 2008, CSH Protoc, V2008, DOI 10.1101/pdb.prot5080
   Xiao XW, 2014, P NATL ACAD SCI USA, V111, pE1211, DOI 10.1073/pnas.1321347111
   Xing LP, 2005, IMMUNOL REV, V208, P19, DOI 10.1111/j.0105 2896.2005.00336.x
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Yoshino S, 1998, J IMMUNOL, V160, P3067
NR 35
TC 38
Z9 41
U1 0
U2 12
PU Cell Physiol Biochem Press GmbH & Co
PI Dsseldorf
PA Herzogstr. 85, Dsseldorf, GERMANY
SN 1015 8987
EI 1421 9778
J9 CELL PHYSIOL BIOCHEM
JI Cell. Physiol. Biochem.
PY 2015
VL 35
IS 6
BP 2213
EP 2222
DI 10.1159/000374026
PG 10
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA CL3FA
UT WOS:000356834600012
PM 25896783
OA gold
DA 2025 08 17
ER

PT J
AU Mukhtar, N
   Alghamdi, B
   Alswailem, M
   Alsagheir, A
   Alzahrani, AS
AF Mukhtar, Noha
   Alghamdi, Balgees
   Alswailem, Meshael
   Alsagheir, Afaf
   Alzahrani, Ali S.
TI Case report: Familial hypoparathyroidism with elevated parathyroid
   hormone due to an inactivating PTH mutation
SO FRONTIERS IN ENDOCRINOLOGY
LA English
DT Article
DE hypoparathyroidism; familial hypoparathyroidism; hypocalcemia;
   parathyroid hormone; PTH; mutation
ID STEM CELL TRANSPLANTATION; SIGNAL SEQUENCE MUTATION; STIFF MAN SYNDROME;
   GENE PTH; CALCIUM; AUTOANTIBODIES; BIOSYNTHESIS; PEPTIDE; BLOOD; FORM
AB Introduction: So far, only 11 PTH mutations have been described as causes of familial isolated hypoparathyroidism (FIH). In this report, we describe a family with FIH but with significant elevation of functionally inactive PTH due to a PTH mutation. We also show a positive therapeutic outcome of recombinant human PTH (teriparatide) therapy in one of the siblings who was not well controlled on large doses of calcitriol and calcium replacement therapy. Case description: The proband is a 34 year old woman who has a history of chronic severe hypocalcemia (HypoCa) since birth. She and her three brothers (33 year old male twins, and a 21 year old male) were diagnosed with pseudohypoparathyroidism type 1b (PHPT 1b) based on the presence of chronic HypoCa (serum Ca 1.6 1.85 mmol/l) since birth associated with significantly elevated plasma PTH levels in the range of 310 564 pg/dl (normal range 10 65) and absence of signs of Albright hereditary osteodystrophy. Molecular studies: WES showed no pathogenic, likely pathogenic or variants of unknown significance in any known calcium associated genetic disorder but a bi allelic variant in the PTH itself ((NM_000315.4:c.128G>A, p.Gly43Glu). This was confirmed by Sanger sequencing in the patient and her affected brothers. Management: Because the patient's HypoCa was not controlled on large doses of calcitriol and calcium carbonate, a trial of teriparatide 20 mcg SC daily was started and resulted in normalization of calcium, decline in PTH levels and significant improvement in her general wellbeing. Conclusion: High PTH in the presence of congenital hypocalcemia is not always due to receptor or post receptor defect and can be due to a biologically inactive mutated PTH. In such cases, treatment with teriparatide may result in stabilization of biochemical profile and improvement in quality of life.
C1 [Mukhtar, Noha; Alzahrani, Ali S.] King Faisal Specialist Hosp & Res Ctr, Dept Med, Riyadh, Saudi Arabia.
   [Alghamdi, Balgees; Alswailem, Meshael; Alzahrani, Ali S.] King Faisal Specialist Hosp & Res Ctr, Dept Mol Oncol, Riyadh, Saudi Arabia.
   [Alsagheir, Afaf] King Faisal Specialist Hosp & Res Ctr, Dept Paediat, Riyadh, Saudi Arabia.
C3 King Faisal Specialist Hospital & Research Center; King Faisal
   Specialist Hospital & Research Center; King Faisal Specialist Hospital &
   Research Center
RP Alzahrani, AS (通讯作者)，King Faisal Specialist Hosp & Res Ctr, Dept Med, Riyadh, Saudi Arabia.; Alzahrani, AS (通讯作者)，King Faisal Specialist Hosp & Res Ctr, Dept Mol Oncol, Riyadh, Saudi Arabia.
EM aliz@kfshrc.edu.sa
RI Alzahrani, Ali/L 3664 2017
FX The author(s) declare that no financial support was received for the
   research, authorship, and/or publication of this article.
CR Alfares A, 2017, MOL GENET METAB, V121, P91, DOI 10.1016/j.ymgme.2017.04.002
   Alghamdi B, 2023, J ENDOCR SOC, V7, DOI 10.1210/jendso/bvad035
   ARNOLD A, 1990, J CLIN INVEST, V86, P1084, DOI 10.1172/JCI114811
   Ashraf S, 2013, J CLIN INVEST, V123, P5179, DOI 10.1172/JCI69000
   Cinque L, 2017, J CLIN ENDOCR METAB, V102, P3961, DOI 10.1210/jc.2017 00250
   Cooper MS, 2008, BRIT MED J, V336, P1298, DOI 10.1136/bmj.39582.589433.BE
   Datta R, 2007, P NATL ACAD SCI USA, V104, P19989, DOI 10.1073/pnas.0708725104
   Ding CL, 2001, J CLIN INVEST, V108, P1215, DOI 10.1172/JCI13180
   Dixon Joanne, 2018, BMJ Case Rep, V2018, DOI 10.1136/bcr 2017 223811
   Ertl DA, 2012, BONE, V51, P629, DOI 10.1016/j.bone.2012.06.009
   Gardella T J., 2016, Endocrinology: Adult and Pediatric, VSeventh, P969, DOI DOI 10.1016/B978 0 323 18907 1.00056 1
   Georges G, 2018, NEUROLOGY, V90
   Georges GE, 2018, BIOL BLOOD MARROW TR, V24, pS120, DOI 10.1016/j.bbmt.2017.12.060
   Gild ML, 2020, J CLIN ENDOCR METAB, V105, P2408, DOI 10.1210/clinem/dgaa279
   GORIN F, 1990, ANN NEUROL, V28, P711
   HABENER JF, 1979, J CELL BIOL, V80, P715, DOI 10.1083/jcb.80.3.715
   HABENER JF, 1978, P NATL ACAD SCI USA, V75, P2616, DOI 10.1073/pnas.75.6.2616
   Hánna P, 2023, P NATL ACAD SCI USA, V120, DOI 10.1073/pnas.2208047120
   Hannan FM, 2018, NAT REV ENDOCRINOL, V15, P33, DOI 10.1038/s41574 018 0115 0
   Hawkes CP, 2022, J CLIN ENDOCR METAB, V107, pE2449, DOI 10.1210/clinem/dgac086
   KARAPLIS AC, 1995, J BIOL CHEM, V270, P1629, DOI 10.1074/jbc.270.4.1629
   Lee JH, 2020, ENDOCRINOL METAB, V35, P64, DOI 10.3803/EnM.2020.35.1.64
   Lee S, 2015, J BONE MINER RES, V30, P1803, DOI 10.1002/jbmr.2532
   MALLETTE LE, 1989, ENDOCRIN METAB CLIN, V18, P601, DOI 10.1016/S0889 8529(18)30355 4
   Mannstadt M, 2013, NEW ENGL J MED, V368, P2532, DOI 10.1056/NEJMc1300278
   Nesbit MA, 2013, NEW ENGL J MED, V368, P2476, DOI 10.1056/NEJMoa1300253
   Newey PJ, 2022, CLIN ENDOCRINOL, V97, P483, DOI 10.1111/cen.14644
   PARKINSON DB, 1992, NAT GENET, V1, P149, DOI 10.1038/ng0592 149
   Sanders S, 2014, JAMA NEUROL, V71, P1296, DOI 10.1001/jamaneurol.2014.1297
   Shaw N, 2009, ENDOCR DEV, V16, P73, DOI 10.1159/000223690
   SOLIMENA M, 1988, NEW ENGL J MED, V318, P1012, DOI 10.1056/NEJM198804213181602
   Song XX, 2020, MOL GENET GENOM MED, V8, DOI 10.1002/mgg3.1360
   Sunthornthepvarakul T, 1999, J CLIN ENDOCR METAB, V84, P3792, DOI 10.1210/jc.84.10.3792
   Thakker RV, 2004, CELL CALCIUM, V35, P275, DOI 10.1016/j.ceca.2003.10.010
   Tomar N, 2013, J CLIN ENDOCR METAB, V98, P3884, DOI 10.1210/jc.2013 2158
   TONOKI H, 1991, CYTOGENET CELL GENET, V56, P103, DOI 10.1159/000133059
   Vlad B, 2023, BIOMEDICINES, V11, DOI 10.3390/biomedicines11092500
   Yi HS, 2012, CLIN ENDOCRINOL, V76, P625, DOI 10.1111/j.1365 2265.2011.04256.x
NR 38
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1664 2392
J9 FRONT ENDOCRINOL
JI Front. Endocrinol.
PD OCT 7
PY 2024
VL 15
AR 1415639
DI 10.3389/fendo.2024.1415639
PG 8
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA J8R1A
UT WOS:001339668200001
PM 39435356
OA gold
DA 2025 08 17
ER

PT J
AU Kawagishi Hotta, M
   Hasegawa, S
   Igarashi, T
   Date, Y
   Ishii, Y
   Inoue, Y
   Hasebe, Y
   Yamada, T
   Arima, M
   Iwata, Y
   Kobayashi, T
   Nakata, S
   Sugiura, K
   Akamatsu, H
AF Kawagishi Hotta, Mika
   Hasegawa, Seiji
   Igarashi, Toshio
   Date, Yasushi
   Ishii, Yoshie
   Inoue, Yu
   Hasebe, Yuichi
   Yamada, Takaaki
   Arima, Masaru
   Iwata, Yohei
   Kobayashi, Tsukane
   Nakata, Satoru
   Sugiura, Kazumitsu
   Akamatsu, Hirohiko
TI Increase of gremlin 2 with age in human adipose derived stromal/stem
   cells and its inhibitory effect on adipogenesis
SO REGENERATIVE THERAPY
LA English
DT Article
DE Adipose derived stromal/stem stem cells; Adipogenic differentiation;
   GREM2; Individual differences; Aging; GREM2 knockdown
ID MESENCHYMAL STEM CELLS; BONE MARROW; DAN FAMILY; DIFFERENTIATION; BMP;
   CERBERUS; GENE; PRDC; PROLIFERATION; OSTEOGENESIS
AB Introduction: Adipose derived stromal/stem cells (ASCs) have attracted attention as a promising material for regenerative medicine. Previously, we reported an age related decrease in the adipogenic potential of ASCs from human subjects and found that the individual difference in this potential increased with age, although the mechanisms remain unclear. Recently, other groups demonstrated that a secreted antagonist of bone morphogenetic protein (BMP) signaling, Gremlin 2 (GREM2), inhibits the differentiation of bone marrow derived mesenchymal stem cells (BMSCs) into osteoblasts and the adipogenesis of 3T3 L1 cell. Here, we examined the effects of GREM2 on the differentiation of ASCs into adipocytes.
   Methods: To examine changes in GREM2 expression levels with age, immunohistochemistry was performed on subcutaneous adipose tissues from subjects 12 97 years of age. Next, GREM2 gene expression levels in ASCs collected from subjects 5 90 years of age were examined by RT PCR, and the change with age and correlation between the expression level and the adipogenic potential of ASCs were analyzed. In addition, to assess whether GREM2 affects adipogenesis, ASCs (purchased from a vendor) were cultured to induce adipogenesis with recombinant GREM2 protein, and siRNA induced GREM2 knockdown experiment was also performed using aged ASCs.
   Results: In adipose tissues, GREM2 expression was observed in cells, including ASCs, but not in mature adipocytes, and the expression level per cell increased with age. GREM2 expression levels in ASCs cultured in vitro also increased with age, and the individual differences in the level increased with age. Of note, partial correlation analysis controlled for age revealed that the adipogenic potential of ASCs and the GREM2 gene expression level were negatively correlated. Furthermore, based on a GREM2 addition experiment, GREM2 has inhibitory effects on the adipogenesis of ASCs through activation of Wnt/beta catenin signaling. On the other hand, GREM2 knockdown in aged ASCs promoted adipogenesis.
   Conclusions: The GREM2 expression level was confirmed to play a role in the age related decrease in adipogenic potential observed in ASCs isolated from adipose tissues as well as in the enhancement of the individual difference, which increased with age. GREM2 in adipose tissues increased with age, which suggested that GREM2 functions as an inhibitory factor of adipogenesis in ASCs. (C) 2019, The Japanese Society for Regenerative Medicine. Production and hosting by Elsevier B.V.
C1 [Kawagishi Hotta, Mika; Hasegawa, Seiji; Igarashi, Toshio; Date, Yasushi; Ishii, Yoshie; Inoue, Yu; Hasebe, Yuichi; Yamada, Takaaki; Nakata, Satoru] Nippon Menard Cosmet Co Ltd, Res Labs, Nagoya, Aichi, Japan.
   [Kawagishi Hotta, Mika; Hasegawa, Seiji; Date, Yasushi; Inoue, Yu; Hasebe, Yuichi] Nagoya Univ, MENARD Collaborat Res Chair, Grad Sch Med, Nagoya, Aichi, Japan.
   [Kawagishi Hotta, Mika; Ishii, Yoshie; Yamada, Takaaki; Akamatsu, Hirohiko] Fujita Hlth Univ, Dept Appl Cell & Regenerat Med, Sch Med, Toyoake, Aichi, Japan.
   [Hasegawa, Seiji; Yamada, Takaaki; Arima, Masaru; Iwata, Yohei; Kobayashi, Tsukane; Sugiura, Kazumitsu] Fujita Hlth Univ, Dept Dermatol, Sch Med, Toyoake, Aichi, Japan.
C3 Nagoya University; Fujita Health University; Fujita Health University
RP Kawagishi Hotta, M (通讯作者)，Nippon Menard Cosmet Co Ltd, Nishi Ku, 2 7 Torimi Cho, Nagoya, Aichi 4510071, Japan.
EM hotta.mika@menard.co.jp
RI Date, Yasushi/C 5349 2016; Hasegawa, Seiji/A 3514 2016
OI Inoue, Yu/0000 0002 7540 6940; HASEGAWA, Seiji/0000 0002 7052 5991;
   Hotta, Mika/0000 0001 7815 5801
CR Avsian Kretchmer O, 2004, MOL ENDOCRINOL, V18, P1, DOI 10.1210/me.2003 0227
   Beane OS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115963
   Bodle JC, 2014, TISSUE ENG PART C ME, V20, P972, DOI [10.1089/ten.tec.2013.0683, 10.1089/ten.TEC.2013.0683]
   Bowers RR, 2008, CELL CYCLE, V7, P1191, DOI 10.4161/cc.7.9.5815
   Bylund JB, 2017, STEM CELLS DEV, V26, P678, DOI 10.1089/scd.2016.0226
   Bylund JB, 2016, JOVE J VIS EXP, DOI 10.3791/53919
   Christodoulides C, 2009, TRENDS ENDOCRIN MET, V20, P16, DOI 10.1016/j.tem.2008.09.002
   Fraser JK, 2006, TRENDS BIOTECHNOL, V24, P150, DOI 10.1016/j.tibtech.2006.01.010
   Guo W, 2008, J BIOL CHEM, V283, P9136, DOI 10.1074/jbc.M708968200
   Hsu DR, 1998, MOL CELL, V1, P673, DOI 10.1016/S1097 2765(00)80067 2
   Ideno H, 2009, EXP CELL RES, V315, P474, DOI 10.1016/j.yexcr.2008.11.019
   Ikeda Y, 2016, EUR J OBSTET GYN R B, V203, P72, DOI 10.1016/j.ejogrb.2016.05.026
   Izadpanah R, 2006, J CELL BIOCHEM, V99, P1285, DOI 10.1002/jcb.20904
   Kattamuri C, 2012, J MOL BIOL, V424, P313, DOI 10.1016/j.jmb.2012.10.003
   Kawagishi Hotta M, 2017, REGEN THER, V6, P29, DOI 10.1016/j.reth.2016.12.004
   Kern S, 2006, STEM CELLS, V24, P1294, DOI 10.1634/stemcells.2005 0342
   Li QF, 2013, FEBS LETT, V587, P1742, DOI 10.1016/j.febslet.2013.04.002
   Li W, 2018, CELL PHYSIOL BIOCHEM, V47, P579, DOI 10.1159/000490012
   Minabe Saegusa C, 1998, DEV GROWTH DIFFER, V40, P343
   Mitterberger MC, 2014, J GERONTOL A BIOL, V69, P13, DOI 10.1093/gerona/glt043
   Müller II, 2013, DIS MODEL MECH, V6, P332, DOI 10.1242/dmm.010488
   Müller II, 2006, DEV DYNAM, V235, P2881, DOI 10.1002/dvdy.20925
   Nolan K, 2016, CELL REP, V16, P2077, DOI 10.1016/j.celrep.2016.07.046
   Oedayrajsingh Varma MJ, 2006, CYTOTHERAPY, V8, P166, DOI 10.1080/14653240600621125
   Pearce JJH, 1999, DEV BIOL, V209, P98, DOI 10.1006/dbio.1999.9240
   Sudo S, 2004, J BIOL CHEM, V279, P23134, DOI 10.1074/jbc.M402376200
   Tanwar V, 2014, STEM CELLS, V32, P1774, DOI 10.1002/stem.1703
   Wang CL, 2017, J CELL BIOCHEM, V118, P286, DOI 10.1002/jcb.25635
   Wei J, 2012, ARTHRITIS RHEUM US, V64, P2734, DOI 10.1002/art.34424
   Wu Q, 2015, MOL MED REP, V12, P5891, DOI 10.3892/mmr.2015.4117
   Yang HJ, 2014, CELLS TISSUES ORGANS, V199, P373, DOI 10.1159/000369969
   Yoo KH, 2009, CELL IMMUNOL, V259, P150, DOI 10.1016/j.cellimm.2009.06.010
   Zuniga E, 2011, DEVELOPMENT, V138, P5147, DOI 10.1242/dev.067785
NR 33
TC 11
Z9 11
U1 0
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2352 3204
J9 REGEN THER
JI Regen. Ther.
PD DEC 1
PY 2019
VL 11
BP 324
EP 330
DI 10.1016/j.reth.2019.09.002
PG 7
WC Cell & Tissue Engineering; Engineering, Biomedical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Engineering
GA JQ6OW
UT WOS:000499063400043
PM 31709279
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Cipriano, AF
   Miller, C
   Liu, HN
AF Cipriano, Aaron F.
   Miller, Christopher
   Liu, Huinan
TI Anodic Growth and Biomedical Applications of TiO2 Nanotubes
SO JOURNAL OF BIOMEDICAL NANOTECHNOLOGY
LA English
DT Article
DE Metal Oxide Nanotubes; Titania (TiO2) Nanotubes; Electrochemical
   Anodization; Nanotubes for Biomedical Applications
ID BONE MORPHOGENETIC PROTEIN; TITANIA NANOTUBES; THIN FILMS; FORMATION
   MECHANISM; OSTEOBLAST DIFFERENTIATION; STAPHYLOCOCCUS EPIDERMIDIS;
   ELECTROCHEMICAL FORMATION; CELL DIFFERENTIATION; BIOCHEMICAL MARKERS;
   OSTEOGENIC ACTIVITY
AB Over the past decades, self assembled, vertically aligned nanotubes have been generated on metallic substrates via anodization, which attracted significant scientific interest for a broad range of applications. These nano tubular structures integrate highly controllable geometry at the nano scale with fascinating chemical and biological properties. In this review, we first discussed mechanistic aspects of nanotube growth primarily on titanium (Ti) substrates by controlled anodization, a relatively inexpensive and scalable electrochemical process. We thoroughly reviewed electrochemical conditions that led to formation of self assembled, vertically aligned nano tubular layers as they apply primarily to Ti substrates; we also reviewed anodization conditions that have led to formation of nanotubes on zirconium and various Ti alloys. We discussed how to adjust a set of anodization parameters to fine tune the geometry of vertically oriented titania (TiO2) nanotubes, such as nanotube diameter, wall thickness, and length. We critically analyzed the key anodization parameters in the literature, including applied voltage, anodization duration, voltage ramp, electrolyte composition and concentration, electrolyte pH, electrolyte temperature, and electrolyte fluoride and water concentrations. Lastly, we discussed the promising properties of anodically grown TiO2 nano tubular arrays for a wide range of biomedical applications, including directing cell bioactivity, anti bacterial efficacy, modulating deposition of hydroxyapatite, drug delivery, biosensors, and orthopedic implants (in vivo). We highlighted ongoing in vitro and in vivo studies on the effects of nanotube geometry and aspect ratio on their hydrophilicity and interactions with biological entities at the protein, cellular and tissue level.
C1 [Cipriano, Aaron F.; Miller, Christopher; Liu, Huinan] Univ Calif Riverside, Dept Bioengn, Riverside, CA 92521 USA.
   [Cipriano, Aaron F.; Liu, Huinan] Univ Calif Riverside, Mat Sci & Engn Program, Riverside, CA 92521 USA.
   [Liu, Huinan] Univ Calif Riverside, Stem Cell Ctr, Riverside, CA 92521 USA.
C3 University of California System; University of California Riverside;
   University of California System; University of California Riverside;
   University of California System; University of California Riverside
RP Liu, HN (通讯作者)，Univ Calif Riverside, Dept Bioengn, Riverside, CA 92521 USA.
EM huinan.liu@ucr.edu
CR Allam NK, 2008, SOL ENERG MAT SOL C, V92, P1468, DOI 10.1016/j.solmat.2008.06.007
   Andrew W., 2001, IND ELECT ENG CHEM T, P11
   [Anonymous], ANGEW CHEM
   Arnold M, 2004, CHEMPHYSCHEM, V5, P383, DOI 10.1002/cphc.200301014
   Aw MS, 2013, INT J PHARMACEUT, V443, P154, DOI 10.1016/j.ijpharm.2013.01.004
   Bai J, 2008, J MATER SCI, V43, P1880, DOI 10.1007/s10853 007 2418 8
   Balaur E, 2005, J MATER CHEM, V15, P4488, DOI 10.1039/b509672c
   Bauer S, 2006, ELECTROCHEM COMMUN, V8, P1321, DOI 10.1016/j.elecom.2006.05.030
   Beranek R, 2003, ELECTROCHEM SOLID ST, V6, pB12, DOI 10.1149/1.1545192
   Berger S, 2008, PHYS STATUS SOLIDI R, V2, P102, DOI 10.1002/pssr.200802019
   Bhatnagar RS, 1999, TISSUE ENG, V5, P53, DOI 10.1089/ten.1999.5.53
   Bjursten LM, 2010, J BIOMED MATER RES A, V92A, P1218, DOI 10.1002/jbm.a.32463
   Branemark P I., 1977, Osseointegrated implants in the treatment of the edentulous jaw. Experience from a 10 year period.pdf
   Cai QY, 2005, J MATER RES, V20, P230, DOI 10.1557/JMR.2005.0020
   Cao Y, 2005, CANCER RES, V65, P1124, DOI 10.1158/0008 5472.CAN 04 2128
   CARLSSON L, 1986, ACTA ORTHOP SCAND, V57, P285, DOI 10.3109/17453678608994393
   Casaletto MP, 2001, APPL SURF SCI, V172, P167, DOI 10.1016/S0169 4332(00)00844 8
   Chen XY, 2013, COLLOID SURFACE B, V103, P149, DOI 10.1016/j.colsurfb.2012.10.022
   Choi Angela O., 2007, Journal of Nanobiotechnology, V5, P1, DOI 10.1186/1477 3155 5 1
   Choi JS, 2004, ELECTROCHIM ACTA, V49, P2645, DOI 10.1016/j.electacta.2004.02.015
   Christenson RH, 1997, CLIN BIOCHEM, V30, P573, DOI 10.1016/S0009 9120(97)00113 6
   Cipriano AF, 2014, J BIOMED NANOTECHNOL, V10, P660, DOI 10.1166/jbn.2014.1760
   Cipriano AF, 2013, J MATER SCI MATER M, V24, P989, DOI 10.1007/s10856 013 4853 1
   Costerton JW, 1999, SCIENCE, V284, P1318, DOI 10.1126/science.284.5418.1318
   Craighead HG, 2001, CURR OPIN SOLID ST M, V5, P177, DOI 10.1016/S1359 0286(01)00005 5
   CURTIS ASG, 1964, JNCI J NATL CANCER I, V33, P15
   Dalby MJ, 2007, NAT MATER, V6, P997, DOI 10.1038/nmat2013
   Dodig M, 1999, DEV BIOL, V209, P298, DOI 10.1006/dbio.1999.9258
   Donlan RM, 2001, EMERG INFECT DIS, V7, P277, DOI 10.3201/eid0702.010226
   Eftekhari A, 2003, SENSOR ACTUAT B CHEM, V88, P234, DOI 10.1016/S0925 4005(02)00321 0
   Ercan B, 2011, NANOTECHNOLOGY, V22, DOI 10.1088/0957 4484/22/29/295102
   Escada ALA, 2013, NANOSCI NANOTECH LET, V5, P510, DOI 10.1166/nnl.2013.1557
   Esfandiari N, 2014, J BIOMED MATER RES A, V102, P2625, DOI 10.1002/jbm.a.34934
   Farokhzad OC, 2004, CANCER RES, V64, P7668, DOI 10.1158/0008 5472.CAN 04 2550
   Favier F, 2001, SCIENCE, V293, P2227, DOI 10.1126/science.1063189
   Feng CX, 2014, J SOLID STATE ELECTR, V18, P163, DOI 10.1007/s10008 013 2257 2
   Feng XJ, 2008, ACTA BIOMATER, V4, P318, DOI 10.1016/j.actbio.2007.08.005
   FOG A, 1984, SENSOR ACTUATOR, V5, P137, DOI 10.1016/0250 6874(84)80004 9
   Fux CA, 2005, TRENDS MICROBIOL, V13, P34, DOI 10.1016/j.tim.2004.11.010
   Ghicov A, 2005, ELECTROCHEM COMMUN, V7, P505, DOI 10.1016/j.elecom.2005.03.007
   Gottlieb T, 2002, MED J AUSTRALIA, V176, P609, DOI 10.5694/j.1326 5377.2002.tb04595.x
   Guan DS, 2011, J NANOSCI NANOTECHNO, V11, P3641, DOI 10.1166/jnn.2011.3765
   Guan RG, 2013, MAT SCI ENG C MATER, V33, P3661, DOI 10.1016/j.msec.2013.04.054
   Gulati K, 2012, ACTA BIOMATER, V8, P449, DOI 10.1016/j.actbio.2011.09.004
   Hahn R, 2007, ELECTROCHEM COMMUN, V9, P947, DOI 10.1016/j.elecom.2006.11.037
   Hanaor DAH, 2011, J MATER SCI, V46, P855, DOI 10.1007/s10853 010 5113 0
   HAZAN R, 1993, BIOMATERIALS, V14, P570, DOI 10.1016/0142 9612(93)90172 X
   Hoyer P, 1996, LANGMUIR, V12, P1411, DOI 10.1021/la9507803
   Huang N, 2003, BIOMATERIALS, V24, P2177, DOI 10.1016/S0142 9612(03)00046 2
   Huo KF, 2013, BIOMATERIALS, V34, P3467, DOI 10.1016/j.biomaterials.2013.01.071
   Ivanova EP, 2010, LANGMUIR, V26, P1973, DOI 10.1021/la902623c
   Izano EA, 2008, APPL ENVIRON MICROB, V74, P470, DOI 10.1128/AEM.02073 07
   Jang SH, 2009, THIN SOLID FILMS, V517, P5038, DOI 10.1016/j.tsf.2009.03.166
   Jaroenworaluck A, 2007, J MATER SCI, V42, P6729, DOI 10.1007/s10853 006 1474 9
   Jeong YH, 2009, THIN SOLID FILMS, V517, P5365, DOI 10.1016/j.tsf.2009.03.167
   Jonásová L, 2004, BIOMATERIALS, V25, P1187, DOI 10.1016/j.biomaterials.2003.08.009
   Jung DR, 2001, CRIT REV BIOTECHNOL, V21, P111, DOI 10.1080/20013891081700
   Jung JH, 2002, CHEM MATER, V14, P1445, DOI [10.1021/cm011625e, 10.1021/cmOI1625]
   Kafi AKM, 2009, TALANTA, V79, P97, DOI 10.1016/j.talanta.2009.03.015
   Kar A, 2006, SURF COAT TECH, V201, P3723, DOI 10.1016/j.surfcoat.2006.09.008
   Kasuga T, 1998, LANGMUIR, V14, P3160, DOI 10.1021/la9713816
   Kim EJ, 2013, J NANOSCI NANOTECHNO, V13, P1679, DOI 10.1166/jnn.2013.6963
   Kim H, 2013, J NANOSCI NANOTECHNO, V13, P4342, DOI 10.1166/jnn.2013.7015
   Kim WG, 2009, THIN SOLID FILMS, V517, P5033, DOI 10.1016/j.tsf.2009.03.165
   Kobayashi S, 2002, J AM CHEM SOC, V124, P6550, DOI 10.1021/ja0260622
   Kunze J, 2008, ELECTROCHIM ACTA, V53, P6995, DOI 10.1016/j.electacta.2008.01.027
   Lansdown A B G, 2002, J Wound Care, V11, P125
   Lee BG, 2009, T NONFERR METAL SOC, V19, P842, DOI 10.1016/S1003 6326(08)60361 1
   Lee HC, 2013, SENSORS BASEL, V13, P14161, DOI 10.3390/s131014161
   Li HR, 2013, APPL SURF SCI, V284, P179, DOI 10.1016/j.apsusc.2013.07.076
   LI PJ, 1994, J BIOMED MATER RES, V28, P7, DOI 10.1002/jbm.820280103
   LI PJ, 1994, J AM CERAM SOC, V77, P1307, DOI 10.1111/j.1151 2916.1994.tb05407.x
   Li QH, 2004, APPL PHYS LETT, V85, P6389, DOI 10.1063/1.1840116
   Liang FX, 2012, MATER RES BULL, V47, P54, DOI 10.1016/j.materresbull.2011.10.006
   Liang K, 2013, NANOSCI NANOTECH LET, V5, P162, DOI 10.1166/nnl.2013.1492
   Liang YQ, 2011, THIN SOLID FILMS, V519, P5150, DOI 10.1016/j.tsf.2011.01.075
   Liao YH, 2009, MATER CHEM PHYS, V114, P542, DOI 10.1016/j.matchemphys.2008.10.014
   Lin SW, 2011, SENSOR ACTUAT B CHEM, V156, P505, DOI 10.1016/j.snb.2011.02.046
   Long M, 1998, BIOMATERIALS, V19, P1621, DOI 10.1016/S0142 9612(97)00146 4
   Lu H.F., 2008, NANOTECHNOLOGY, V19
   Luo BM, 2008, MATER LETT, V62, P4512, DOI 10.1016/j.matlet.2008.08.015
   Ma J, 2013, J NANOSCI NANOTECHNO, V13, P3801, DOI 10.1166/jnn.2013.7020
   Macak JM, 2007, CURR OPIN SOLID ST M, V11, P3, DOI 10.1016/j.cossms.2007.08.004
   Macak JM, 2006, CHEM PHYS LETT, V428, P421, DOI 10.1016/j.cplett.2006.07.062
   Macak JM, 2006, ELECTROCHIM ACTA, V52, P1258, DOI 10.1016/j.electacta.2006.07.021
   Macak JM, 2005, ELECTROCHIM ACTA, V50, P3679, DOI 10.1016/j.electacta.2005.01.014
   Macák JM, 2005, ANGEW CHEM INT EDIT, V44, P2100, DOI 10.1002/anie.200462459
   MACDONALD DD, 1993, J ELECTROCHEM SOC, V140, pL27, DOI 10.1149/1.2056179
   Mahajan V., 2005, MRS P, V876, pR12
   Mahdavi A, 2008, P NATL ACAD SCI USA, V105, P2307, DOI 10.1073/pnas.0712117105
   Michailowski A, 2001, CHEM PHYS LETT, V349, P1, DOI 10.1016/S0009 2614(01)01159 9
   Minagar S, 2012, ACTA BIOMATER, V8, P2875, DOI 10.1016/j.actbio.2012.04.005
   MINKIN C, 1982, CALCIFIED TISSUE INT, V34, P285, DOI 10.1007/BF02411252
   Mohamadnia A., 2007, COMP CLIN PATHOL, V16, P265, DOI DOI 10.1007/S00580 007 0692 0
   Mohamed AE, 2010, J NANOSCI NANOTECHNO, V10, P1998, DOI 10.1166/jnn.2010.2102
   Mor G. K., 2004, MRS P, P836
   Mor GK, 2005, NANO LETT, V5, P191, DOI 10.1021/nl048301k
   Mor GK, 2006, THIN SOLID FILMS, V496, P42, DOI 10.1016/j.tsf.2005.08.190
   Mor GK, 2005, ADV FUNCT MATER, V15, P1291, DOI 10.1002/adfm.200500096
   Mor GK, 2003, J MATER RES, V18, P2588, DOI 10.1557/JMR.2003.0362
   Mor GK, 2006, SOL ENERG MAT SOL C, V90, P2011, DOI 10.1016/j.solmat.2006.04.007
   Muti MN, 2008, J ENG SCI TECHNOL, V3, P163
   Nalwa H.S., 2000, Synthesis and processing, V1
   Nalwa H. S., 2004, ENCY NANOSCIENCE NAN, V1 25
   Neupane MP, 2011, J MATER CHEM, V21, P12078, DOI 10.1039/c1jm10297d
   Nguyen QA, 2008, ELECTROCHEM COMMUN, V10, P471, DOI 10.1016/j.elecom.2008.01.010
   Oh S, 2009, P NATL ACAD SCI USA, V106, P2130, DOI 10.1073/pnas.0813200106
   Oh SH, 2005, BIOMATERIALS, V26, P4938, DOI 10.1016/j.biomaterials.2005.01.048
   Olivares Navarrete R, 2010, BIOMATERIALS, V31, P2728, DOI 10.1016/j.biomaterials.2009.12.029
   Park J, 2007, NANO LETT, V7, P1686, DOI 10.1021/nl070678d
   Parkhutik V. P., 1992, J PHYS D, P25
   Paulose M, 2006, J PHOTOCH PHOTOBIO A, V178, P8, DOI 10.1016/j.jphotochem.2005.06.013
   Paulose M, 2007, J PHYS CHEM C, V111, P14992, DOI 10.1021/jp075258r
   Paulose M, 2006, J PHYS CHEM B, V110, P16179, DOI 10.1021/jp064020k
   Peng LL, 2009, NANO LETT, V9, P1932, DOI 10.1021/nl9001052
   Perathoner S, 2007, CATAL TODAY, V122, P3, DOI 10.1016/j.cattod.2007.01.039
   Pierucci S., 2009, AIDIC C SERIES
   Popat KC, 2007, SMALL, V3, P1878, DOI 10.1002/smll.200700412
   Popat KC, 2007, BIOMATERIALS, V28, P4880, DOI 10.1016/j.biomaterials.2007.07.037
   Popat KC, 2007, BIOMATERIALS, V28, P3188, DOI 10.1016/j.biomaterials.2007.03.020
   Popat KC, 2007, J BIOMED MATER RES A, V80A, P955, DOI 10.1002/jbm.a.31028
   Portney NG, 2006, ANAL BIOANAL CHEM, V384, P620, DOI 10.1007/s00216 005 0247 7
   Puckett SD, 2010, BIOMATERIALS, V31, P706, DOI 10.1016/j.biomaterials.2009.09.081
   Rai M, 2009, BIOTECHNOL ADV, V27, P76, DOI 10.1016/j.biotechadv.2008.09.002
   Raja KS, 2007, ELECTROCHEM COMMUN, V9, P1069, DOI 10.1016/j.elecom.2006.12.024
   Raja KS, 2005, ELECTROCHIM ACTA, V51, P154, DOI 10.1016/j.electacta.2005.04.011
   Reddy ST, 2006, TRENDS IMMUNOL, V27, P573, DOI 10.1016/j.it.2006.10.005
   Richter C, 2007, ADV MATER, V19, P946, DOI 10.1002/adma.200602389
   Rivera Chacon DM, 2013, J BIOMED NANOTECHNOL, V9, P1092, DOI 10.1166/jbn.2013.1601
   Rohde H, 2007, BIOMATERIALS, V28, P1711, DOI 10.1016/j.biomaterials.2006.11.046
   Ruan CM, 2006, SOL ENERG MAT SOL C, V90, P1283, DOI 10.1016/j.solmat.2005.08.005
   Ryoo HM, 1997, MOL ENDOCRINOL, V11, P1681, DOI 10.1210/me.11.11.1681
   Sennik E, 2010, INT J HYDROGEN ENERG, V35, P4420, DOI 10.1016/j.ijhydene.2010.01.100
   Shin J, 2013, J NANOSCI NANOTECHNO, V13, P5807, DOI [10.1166/jnn.2013.7064, 10.1166/jnn.2013.7033]
   Shirkhanzadeh M, 1998, J MATER SCI MATER M, V9, P67, DOI 10.1023/A:1008838813120
   Sieber I, 2005, ELECTROCHEM COMMUN, V7, P97, DOI 10.1016/j.elecom.2004.11.012
   Sieber I, 2005, ELECTROCHEM SOLID ST, V8, pJ10, DOI 10.1149/1.1859676
   Singh R. S., 2001, J MATER RES, V16, P3
   Sreekantan S, 2009, J ALLOY COMPD, V485, P478, DOI 10.1016/j.jallcom.2009.05.152
   Sreetankan S., 2009, J PHYSIOL SCI, V20, P10
   Stancheva M, 2012, ELECTROCHIM ACTA, V78, P65, DOI 10.1016/j.electacta.2012.05.093
   Su ZX, 2008, ADV MATER, V20, P3663, DOI 10.1002/adma.200800845
   Swaminathan R, 2001, CLIN CHIM ACTA, V313, P95, DOI 10.1016/S0009 8981(01)00656 8
   Tan W. T., 2012, INT J PHOTOENERGY, V2012, P9
   Taveira LV, 2005, J ELECTROCHEM SOC, V152, pB405, DOI 10.1149/1.2008980
   Tian T, 2008, MATER SCI POLAND, V26, P487
   Tian T, 2007, J MATER SCI, V42, P5539, DOI 10.1007/s10853 006 1104 6
   Tian ZRR, 2003, J AM CHEM SOC, V125, P12384, DOI 10.1021/ja0369461
   Tsuchiya H, 2005, CORROS SCI, V47, P3324, DOI 10.1016/j.corsci.2005.05.041
   Tsuchiya H, 2005, CHEM PHYS LETT, V410, P188, DOI 10.1016/j.cplett.2005.05.065
   Tsuchiya H, 2005, ELECTROCHEM COMMUN, V7, P49, DOI 10.1016/j.elecom.2004.11.004
   Tsuchiya H, 2009, CORROS SCI, V51, P1528, DOI 10.1016/j.corsci.2008.11.011
   Uchida M, 2003, J BIOMED MATER RES A, V64A, P164, DOI 10.1002/jbm.a.10414
   Valota A, 2009, ELECTROCHIM ACTA, V54, P4321, DOI 10.1016/j.electacta.2009.02.098
   Varghese OK, 2004, J NANOSCI NANOTECHNO, V4, P733, DOI 10.1166/jnn.2004.092
   Varghese OK, 2003, SENSOR ACTUAT B CHEM, V93, P338, DOI 10.1016/S0925 4005(03)00222 3
   Varghese OK, 2003, ADV MATER, V15, P624, DOI 10.1002/adma.200304586
   Vitiello RP, 2006, ELECTROCHEM COMMUN, V8, P544, DOI 10.1016/j.elecom.2006.01.023
   von Wilmowsky C, 2012, CLIN ORAL IMPLAN RES, V23, P359, DOI 10.1111/j.1600 0501.2010.02139.x
   von Wilmowsky C, 2009, J BIOMED MATER RES B, V89B, P165, DOI 10.1002/jbm.b.31201
   Wagner V, 2006, NAT BIOTECHNOL, V24, P1211, DOI 10.1038/nbt1006 1211
   Wang C, 2012, SCI CHINA CHEM, V55, P2373, DOI 10.1007/s11426 012 4680 0
   WANG EA, 1990, P NATL ACAD SCI USA, V87, P2220, DOI 10.1073/pnas.87.6.2220
   Wang J, 2009, J PHYS CHEM C, V113, P4026, DOI 10.1021/jp811201x
   Wang LN, 2013, J NANOSCI NANOTECHNO, V13, P5316, DOI 10.1166/jnn.2013.7458
   Wang N, 2011, BIOMATERIALS, V32, P6900, DOI 10.1016/j.biomaterials.2011.06.023
   Wang ZL, 2006, SCIENCE, V312, P242, DOI 10.1126/science.1124005
   Webster TJ, 2000, BIOMATERIALS, V21, P1803, DOI 10.1016/S0142 9612(00)00075 2
   Wrobel G, 2012, CRYST GROWTH DES, V12, P5051, DOI 10.1021/cg301002s
   Wu WJ, 1998, J COLLOID INTERF SCI, V199, P206, DOI 10.1006/jcis.1997.5329
   Xiao XF, 2007, MATER CHEM PHYS, V106, P27, DOI 10.1016/j.matchemphys.2007.05.014
   Yang DJ, 2008, IEEE T NANOTECHNOL, V7, P131, DOI 10.1109/TNANO.2007.909439
   Yang DJ, 2008, MATER LETT, V62, P775, DOI 10.1016/j.matlet.2007.06.058
   Yao BD, 2003, APPL PHYS LETT, V82, P281, DOI 10.1063/1.1537518
   Yim EKF, 2007, EXP CELL RES, V313, P1820, DOI 10.1016/j.yexcr.2007.02.031
   Yunl KD, 2013, J NANOSCI NANOTECHNO, V13, P3864, DOI 10.1166/jnn.2013.7023
   Zainovia L., 2010, NANOTECHNOLOGY, V21
   Zhang ZM, 2012, ANAL CHIM ACTA, V727, P13, DOI 10.1016/j.aca.2012.03.033
   Zhao J, 2005, ELECTRON LETT, V41, P771, DOI 10.1049/el:20051328
   Zhao JL, 2008, MATER LETT, V62, P4428, DOI 10.1016/j.matlet.2008.07.054
   Zhao LZ, 2013, BIOMATERIALS, V34, P19, DOI 10.1016/j.biomaterials.2012.09.041
   Zhao RR, 2010, ELECTROCHIM ACTA, V55, P5647, DOI 10.1016/j.electacta.2010.04.102
NR 182
TC 59
Z9 62
U1 5
U2 168
PU AMER SCIENTIFIC PUBLISHERS
PI VALENCIA
PA 26650 THE OLD RD, STE 208, VALENCIA, CA 91381 0751 USA
SN 1550 7033
EI 1550 7041
J9 J BIOMED NANOTECHNOL
JI J. Biomed. Nanotechnol.
PD OCT
PY 2014
VL 10
IS 10
SI SI
BP 2977
EP 3003
DI 10.1166/jbn.2014.1927
PG 27
WC Nanoscience & Nanotechnology; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Materials Science
GA AL9QR
UT WOS:000339476300023
PM 25992426
DA 2025 08 17
ER

PT J
AU Yu, XQ
   Zeng, Y
   Bao, MY
   Wen, JR
   Zhu, GG
   Cao, CJ
   He, XL
   Li, L
AF Yu, Xiaoqin
   Zeng, Ye
   Bao, Mingyue
   Wen, Jirui
   Zhu, Guangguang
   Cao, Chengjian
   He, Xueling
   Li, Liang
TI Low magnitude vibration induces osteogenic differentiation of bone
   marrow mesenchymal stem cells via miR 378a 3p/Grb2 pathway to promote
   bone formation in a rat model of age related bone loss
SO FASEB JOURNAL
LA English
DT Article
DE age related bone loss; bone marrow mesenchymal stem cells; growth factor
   receptor bound protein 2; low magnitude vibration; miR 378a 3p;
   osteogenic differentiation
ID WHOLE BODY VIBRATION; MINERAL DENSITY; FRACTURE RISK; OSTEOPOROSIS;
   OSTEOBLAST; MICRORNA; THERAPY; MORPHOLOGY
AB The dysfunction of bone marrow mesenchymal stem cells (BMSCs) in osteogenic differentiation is one of the main causes of age related bone loss. Our previous studies have shown that low magnitude vibration (LMV) induces the osteogenic differentiation of BMSCs derived from ovariectomized osteoporotic rats. To investigate whether LMV promotes osteogenic differentiation of BMSCs and its underlying mechanisms in aged rats, 20 month old female Sprague Dawley rats (n = 20) were randomly divided into LMV group (rats were vibrated at 0.3 g and 90 Hz for 30 minutes, once daily, 5 days a week until 12 weeks for subsequent analysis, n = 10), static group (rats were placed in the box on the vibration platform without vibration, n = 10); 6 month old female Sprague Dawley rats were used as control (young group, n = 10). The bone mineral density and bone strength of aged rats were significantly decreased compared with the young rats. Furthermore, the primary BMSCs isolated and cultured from the aged rats with the whole bone marrow differential pasting method showed a decreased ability in osteogenic differentiation compared with that from the young rats. Then the differentially expressed miRNAs between the aged and young rat derived BMSCs were screened by high throughput sequencing and verified by qRT PCR, and we found that miR 378a 3p was significantly downregulated in the aged rat derived BMSCs compared with the young rat derived BMSCs. By transfecting miRNA mimics and inhibitors, miR 378a 3p was confirmed to promote the expression levels of osteogenic genes (Runx2, ALP, Col I, and OCN) and ALP activity of the aged rat derived BMSCs. Meanwhile, the expression levels of osteogenic genes and miR 378a 3p of aged rat derived BMSCs were significantly upregulated by LMV (cells were vibrated at 0.3 g and 90 Hz for 30 minutes a day, until 5 days for subsequent analysis), while the LMV induced osteogenic gene expression levels of aged rat derived BMSCs were suppressed by miR 378a 3p inhibitors. Furthermore, the inhibition of growth factor receptor bound protein 2 (Grb2) by miR 378a 3p and Grb2 siRNA promoted the LMV induced osteogenic differentiation of aged rat derived BMSCs. Additionally, LMV was found to promote bone mineral density and bone strength of aged rats in vivo, as well as upregulating the expression level of miR 378a 3p and downregulating the expression level of Grb2 of BMSCs from aged rats. These results suggest that LMV induces osteogenic differentiation of BMSCs through miR 378a 3p/Grb2 pathway to improve bone mineral density and mechanical properties in a rat model of age related bone loss.
C1 [Yu, Xiaoqin; Zeng, Ye; Bao, Mingyue; Wen, Jirui; Zhu, Guangguang; Cao, Chengjian; He, Xueling; Li, Liang] Sichuan Univ, Inst Biomed Engn, West China Sch Basic Med Sci & Forens Med, Chengdu 610041, Peoples R China.
   [He, Xueling] Sichuan Univ, Lab Anim Ctr, Chengdu, Peoples R China.
C3 Sichuan University; Sichuan University
RP Li, L (通讯作者)，Sichuan Univ, Inst Biomed Engn, West China Sch Basic Med Sci & Forens Med, Chengdu 610041, Peoples R China.
EM lilianghx@163.com
RI Zeng, Ye/E 3010 2010; Li, Liang/T 4075 2019; HE, Xueling/NNH 1431 2025;
   Wen, Jirui/GRX 8236 2022
FU National Natural Science Foundation of China (NSFC) [11572209, 11872260,
   11272225]
FX National Natural Science Foundation of China (NSFC), Grant/Award Number:
   11572209, 11872260 and 11272225
CR Arfat Y, 2018, MOL THER NUCL ACIDS, V11, P323, DOI 10.1016/j.omtn.2017.11.009
   BALDWIN AL, 1984, J HISTOCHEM CYTOCHEM, V32, P259, DOI 10.1177/32.3.6198357
   Bartel DP, 2018, CELL, V173, P20, DOI 10.1016/j.cell.2018.03.006
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Canalis E, 2007, NEW ENGL J MED, V357, P905, DOI 10.1056/NEJMra067395
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   Coughlan T, 2014, CLIN MED, V14, P187, DOI 10.7861/clinmedicine.14 2 187
   Eskildsen T, 2011, P NATL ACAD SCI USA, V108, P6139, DOI 10.1073/pnas.1016758108
   Guo Q, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.22
   He XL, 2019, PROG BIOPHYS MOL BIO, V148, P47, DOI 10.1016/j.pbiomolbio.2017.09.023
   Issler O, 2015, NAT REV NEUROSCI, V16, P201, DOI 10.1038/nrn3879
   Karinkanta S, 2010, NAT REV ENDOCRINOL, V6, P396, DOI 10.1038/nrendo.2010.70
   Kusuyama J, 2018, J CELL PHYSIOL, V233, P2549, DOI 10.1002/jcp.26130
   Lau E, 2011, J ORTHOP RES, V29, P1075, DOI 10.1002/jor.21334
   Lau E, 2010, BONE, V46, P1508, DOI 10.1016/j.bone.2010.02.031
   Lee So Min, 2017, J Phys Ther Sci, V29, P1125, DOI 10.1589/jpts.29.1125
   Leslie William D, 2011, Curr Osteoporos Rep, V9, P129, DOI 10.1007/s11914 011 0060 5
   Li CJ, 2015, J CLIN INVEST, V125, P1509, DOI 10.1172/JCI77716
   Li HM, 2019, BIOSCIENCE REP, V39, DOI 10.1042/BSR20191011
   Ma RS, 2012, HIP INT, V22, P218, DOI 10.5301/HIP.2012.9033
   Marx Robert E, 2014, Int J Oral Maxillofac Implants, V29, pe247, DOI 10.11607/jomi.te61
   Muir J, 2013, J SCI MED SPORT, V16, P526, DOI 10.1016/j.jsams.2013.01.004
   Nagalingam RS, 2013, J BIOL CHEM, V288, P11216, DOI 10.1074/jbc.M112.442384
   Okubo R, 2017, OSTEOPOROSIS INT, V28, P1461, DOI 10.1007/s00198 017 3905 7
   Pagnotti GM, 2019, NAT REV ENDOCRINOL, V15, P339, DOI 10.1038/s41574 019 0170 1
   Paspaliaris V, 2019, STEM CELLS INT, V2019, DOI 10.1155/2019/1730978
   Prè D, 2013, BONE MARROW RES, DOI 10.1155/2013/803450
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Ramanadham S, 2008, AM J PATHOL, V172, P868, DOI 10.2353/ajpath.2008.070756
   Rosen CJ, 2016, NEW ENGL J MED, V375, P1583, DOI 10.1056/NEJMe1611863
   Rupaimoole R, 2017, NAT REV DRUG DISCOV, V16, P203, DOI 10.1038/nrd.2016.246
   Shanb AA, 2017, J BACK MUSCULOSKELET, V30, P903, DOI 10.3233/BMR 160607
   Sun F, 2019, J MOL CELL CARDIOL, V133, P188, DOI 10.1016/j.yjmcc.2019.06.011
   Suttamanatwong S, 2017, CONNECT TISSUE RES, V58, P90, DOI 10.3109/03008207.2016.1139580
   Wang X, 2013, MATER RES LETT, V1, P19, DOI 10.1080/21663831.2012.686586
   Wysocki A, 2011, ANN INTERN MED, V155, P680, DOI 10.7326/0003 4819 155 10 201111150 00006
   Yuan Y, 2017, J CELL PHYSIOL, V232, P1239, DOI 10.1002/jcp.25688
   Zeng YE, 2017, PROG BIOPHYS MOL BIO, V148, P54
   Zhao XY, 2020, J MOL CELL BIOL, V12, P55, DOI 10.1093/jmcb/mjz028
   Zuo B, 2015, J BONE MINER RES, V30, P330, DOI 10.1002/jbmr.2352
NR 40
TC 21
Z9 22
U1 0
U2 31
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0892 6638
EI 1530 6860
J9 FASEB J
JI Faseb J.
PD SEP
PY 2020
VL 34
IS 9
BP 11754
EP 11771
DI 10.1096/fj.201902830RRR
EA JUL 2020
PG 18
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine   Other
   Topics; Cell Biology
GA NK8TC
UT WOS:000548007900001
PM 32652777
DA 2025 08 17
ER

PT J
AU Muñoz Ortego, J
   Vestergaard, P
   Rubio, JB
   Wordsworth, P
   Judge, A
   Javaid, MK
   Arden, NK
   Cooper, C
   Díez Pérez, A
   Prieto Alhambra, D
AF Munoz Ortego, Juan
   Vestergaard, Peter
   Blanch Rubio, Josep
   Wordsworth, Paul
   Judge, Andrew
   Javaid, M. Kassim
   Arden, Nigel K.
   Cooper, Cyrus
   Diez Perez, Adolfo
   Prieto Alhambra, Daniel
TI Ankylosing Spondylitis Is Associated With an Increased Risk of Vertebral
   and Nonvertebral Clinical Fractures: A Population Based Cohort Study
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE SPONDYLITIS; SPONDYLOARTHROPATHY; EPIDEMIOLOGY; ELECTRONIC HEALTH
   RECORDS; FRACTURE; BONE
ID BONE MINERAL DENSITY; RADIOGRAPHIC PROGRESSION; HIGH PREVALENCE;
   OSTEOPOROSIS; DISORDERS
AB The objective of this work was to study the associations between ankylosing spondylitis (AS) and clinical vertebral and nonvertebral fractures. Data from a large population based public health database in Spain, Sistema d'Informacio per al Desenvolupament de l'Investigacio en Atencio Primaria (SIDIAP), were used in this parallel cohort study. All participants registered in SIDIAP on January 1, 2006, were screened to identify those with a diagnosis of AS. Five age matched, gender matched, and general practice surgery matched controls were selected for each patient with AS. All participants were followed until December 31, 2011, transfer out date, or death date. Fractures during this time were classified as vertebral or nonvertebral. Adjustment was made for potential confounders (tobacco smoking, alcohol consumption, body mass index, and use of oral steroids). Of 4,920,353 eligible patients in SIDIAP, 6474 AS patients with matched controls (n = 32,346) were available. A higher proportion of patients with AS versus controls had clinical vertebral (0.86% versus 0.41%) and nonvertebral (3.4% versus 2.7%) fractures. Adjusted Cox regression models showed an increased risk of clinical vertebral (hazard ratio [HR] 1.93; 95% confidence interval [CI], 1.39 to 2.68; p<0.001) and nonvertebral (HR 1.19; 95% CI, 1.02 to 1.39; p = 0.03) fractures among patients with AS. However, the observed increased risks were apparent only in those not on regular nonsteroidal anti inflammatory drugs (NSAIDs). There were no interactions with inflammatory bowel disease, psoriasis, or previous back pain. Patients with AS are at increased risk of vertebral and nonvertebral clinical fractures, independently of various risk factors. Regular use of NSAIDs appears to eliminate the excess fracture risk related to AS, but the mechanisms involved are unknown. (C) 2014 American Society for Bone and Mineral Research
C1 [Munoz Ortego, Juan] Hosp Univ Sagrat Cor, Dept Rheumatol, Barcelona, Spain.
   [Vestergaard, Peter] Aalborg Univ, Aalborg Univ Hosp, Aalborg, Denmark.
   [Blanch Rubio, Josep] Dept Rheumatol, Barcelona, Spain.
   [Wordsworth, Paul; Judge, Andrew; Javaid, M. Kassim; Arden, Nigel K.; Cooper, Cyrus; Prieto Alhambra, Daniel] Univ Oxford, Oxford Natl Inst Hlth Res Musculoskeletal Biomed, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Oxford, England.
   [Judge, Andrew; Cooper, Cyrus; Prieto Alhambra, Daniel] Univ Southampton, Med Res Council Lifecourse Epidemiol Unit, Southampton, Hants, England.
   [Diez Perez, Adolfo; Prieto Alhambra, Daniel] Parc Salut Mar, Musculoskeletal Res Unit, Barcelona, Spain.
   [Diez Perez, Adolfo; Prieto Alhambra, Daniel] Parc Salut Mar, Red Temat Invest Cooperat Envejecimiento & Fragil, Barcelona, Spain.
   [Diez Perez, Adolfo; Prieto Alhambra, Daniel] Inst Salud Carlos III, Barcelona, Spain.
   [Prieto Alhambra, Daniel] Univ Autonoma Barcelona, Grp Recerca Malalties Prevalents, Aparell Locomotor Res Grp, Inst Invest Atencio Primaria Jordi Gol Primary Ca, E 08193 Barcelona, Spain.
C3 Aalborg University; Aalborg University Hospital; University of Oxford;
   UK Research & Innovation (UKRI); Medical Research Council UK (MRC);
   University of Southampton; Hospital del Mar Research Institute; Hospital
   del Mar; Hospital del Mar Research Institute; Hospital del Mar;
   Instituto de Salud Carlos III; Autonomous University of Barcelona
RP Prieto Alhambra, D (通讯作者)，Nuffield Orthopaed Ctr, Botnar Res Ctr, Windmill Rd, Oxford OX3 7LD, England.
EM Daniel.prietoalhambra@ndorms.ox.ac.uk
RI ; Cooper, Cyrus/ADV 7232 2022
OI Cooper, Cyrus/0000 0003 3510 0709; Judge, Andrew/0000 0003 3015 0432;
   Diez Perez, Adolfo/0000 0001 8162 0209; Javaid,
   Muhammad/0000 0001 7985 0048; Vestergaard, Peter/0000 0002 9046 2967;
   Prieto Alhambra, Daniel/0000 0002 3950 6346; , JUAN
   MUNOZ ORTEGO/0000 0001 8760 5720
FU Spanish Foundation of Rheumatology (Sociedad Espanola de Reumatologia  
   Becas FER); Oxford NIHR Musculoskeletal Biomedical Research Unit;
   RETICEF URFOA; Medical Research Council [U1475000001, MC_UU_12011/1,
   MC_UP_A620_1014] Funding Source: researchfish; National Institute for
   Health Research [NF SI 0508 10082, NF SI 0513 10085] Funding Source:
   researchfish
FX Financial support for this study was provided by the Spanish Foundation
   of Rheumatology (Sociedad Espanola de Reumatologia   Becas FER 2011).
   Jenny Lloyd, PhD, provided editorial assistance on the final version of
   the manuscript and was funded by the authors. DPA, AJ, MKJ, and NKA
   receive partial support from the Oxford NIHR Musculoskeletal Biomedical
   Research Unit. DPA receives partial funding from the RETICEF URFOA
   (IMIM, Parc de Salut Mar and Instituto de Salud Carlos III, Barcelona,
   Spain).
CR Allali F, 2003, ANN RHEUM DIS, V62, P347, DOI 10.1136/ard.62.4.347
   [Anonymous], 2012, INFORM PRIM CARE
   [Anonymous], COCHRANE DATABASE SY
   Arends S, 2011, OSTEOPOROSIS INT, V22, P1431, DOI 10.1007/s00198 010 1338 7
   Blackwell KA, 2010, TRENDS ENDOCRIN MET, V21, P294, DOI 10.1016/j.tem.2009.12.004
   Braun J, 1998, ARTHRITIS RHEUM US, V41, P58, DOI 10.1002/1529 0131(199801)41:1<58::AID ART8>3.0.CO;2 G
   Bultink IEM, 2012, CURR RHEUMATOL REP, V14, P224, DOI 10.1007/s11926 012 0252 8
   COOPER C, 1994, J RHEUMATOL, V21, P1877
   Costantino F, 2015, ANN RHEUM DIS, V74, P689, DOI 10.1136/annrheumdis 2013 204436
   DONNELLY S, 1994, ANN RHEUM DIS, V53, P117, DOI 10.1136/ard.53.2.117
   FOX MW, 1993, J NEUROSURG, V78, P871, DOI 10.3171/jns.1993.78.6.0871
   Franck H, 2004, J RHEUMATOL, V31, P2236
   Geusens P, 2001, J RHEUMATOL, V28, P1856
   Ghozani I, 2009, BONE, V44, P772, DOI 10.1016/j.bone.2008.12.028
   GRAHAM B, 1989, SPINE, V14, P803, DOI 10.1097/00007632 198908000 00005
   Kroon F, 2012, ANN RHEUM DIS, V71, P1623, DOI 10.1136/annrheumdis 2012 201370
   Montala N, 2011, J RHEUMATOL, V38, P893, DOI 10.3899/jrheum.100851
   Pages Castellà A, 2012, BMC MUSCULOSKEL DIS, V13, DOI 10.1186/1471 2474 13 79
   RALSTON SH, 1990, BMJ BRIT MED J, V300, P563, DOI 10.1136/bmj.300.6724.563
   Royston P, 2009, STATA J, V9, P252, DOI 10.1177/1536867X0900900205
   Sieper J, 2008, ARTHRITIS RHEUM US, V58, P649, DOI 10.1002/art.23260
   Sterne Jonathan A C, 2009, BMJ, V338, pb2393, DOI 10.1136/bmj.b2393
   van der Heijde D, 2011, ANN RHEUM DIS, V70, P905, DOI 10.1136/ard.2011.151563
   van der Weijden MAC, 2012, CLIN RHEUMATOL, V31, P1529, DOI 10.1007/s10067 012 2018 0
   van der Weijden MAC, 2012, OSTEOPOROSIS INT, V23, P1683, DOI 10.1007/s00198 011 1766 z
   Vosse D, 2009, ANN RHEUM DIS, V68, P1839, DOI 10.1136/ard.2008.100503
   Wanders A, 2005, ARTHRITIS RHEUM US, V52, P1756, DOI 10.1002/art.21054
   Westerveld LA, 2009, EUR SPINE J, V18, P145, DOI 10.1007/s00586 008 0764 0
   WILL R, 1989, LANCET, V2, P1483
NR 29
TC 64
Z9 66
U1 0
U2 12
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD AUG
PY 2014
VL 29
IS 8
BP 1770
EP 1776
DI 10.1002/jbmr.2217
PG 7
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA AN0AQ
UT WOS:000340243900009
PM 24619796
OA Bronze
DA 2025 08 17
ER

PT J
AU Tao, L
   Gao, Y
   Li, YS
   Yang, LQ
   Yao, JJ
   Huang, HD
   Yu, JL
   Han, B
   Wang, BW
   Liu, ZH
AF Tao, Lu
   Gao, Ying
   Li, Yushen
   Yang, Liuqing
   Yao, Jingjing
   Huang, Handan
   Yu, Jinling
   Han, Bing
   Wang, Bowei
   Liu, Zhihui
TI The preventive effect of photocrosslinked Hep/GelMA hydrogel loaded with
   PRF on MRONJ
SO BMC ORAL HEALTH
LA English
DT Article
DE Hydrogel; Medication related osteonecrosis of the jaw; Bisphosphonates;
   Platelet rich fibrin
ID MEDICATION RELATED OSTEONECROSIS; PLATELET RICH FIBRIN;
   BISPHOSPHONATE RELATED OSTEONECROSIS; SURGEONS POSITION PAPER; AMERICAN
   ASSOCIATION; JAW; OSTEOPOROSIS; THERAPY; TRENDS; RATS
AB Background Medication related osteonecrosis of the Jaw (MRONJ) is a rare but severe side effect in patients treated with medications such as Bisphosphonates (BPs). Its pathophysiological mechanism needs to be more precise. Establishing preventive measures and treatment standards is necessary. This study aimed to develop a composite hydrogel scaffold constituted by methacrylated gelatin (GelMA), methacrylated heparin (HepMA) and PRF, and investigate its potential application value in the prevention of MRONJ. Methods GelMA, HepMA, and PRF were prepared using specific ratios for hydrogel scaffolds. Through mechanical properties and biocompatibility analysis, the release rate of growth factors and the ability to promote bone differentiation in vitro were evaluated. To explore the healing enhancing effects of hydrogels in vivo, the composite hydrogel scaffold was implanted to the MRONJ rat model. Micro computed tomography (Micro CT) and histological examination were conducted to evaluate the bone morphology and tissue regeneration. Results The Hep/GelMA PRF hydrogel improved the degradation rate and swelling rate. It was also used to control the release rate of growth factors effectively. In vitro, the Hep/GelMA PRF hydrogel was biocompatible and capable of reversing the inhibitory effect of zoledronic acid (ZOL) on the osteogenic differentiation of MC3T3 E1s. In vivo, the micro CT analysis and histological evaluation demonstrated that the Hep/GelMA PRF group exhibited the best tissue reconstruction. Moreover, compared to the ZOL group, the expression of osteogenesis proteins, including osteocalcin (OCN), type collagen I (Col I), and bone morphogenetic protein 2 (BMP 2) in the Hep/GelMA PRF group were all significantly upregulated (P < 0.05). Conclusions The Hep/GelMA PRF hydrogel scaffold could effectively control the release rate of growth factors, induce osteogenic differentiation, reduce inflammation, and keep a stable microenvironment for tissue repair. It has potential application value in the prevention of MRONJ.
C1 [Tao, Lu; Gao, Ying; Li, Yushen; Yang, Liuqing; Yao, Jingjing; Huang, Handan; Yu, Jinling; Liu, Zhihui] Jilin Univ, Hosp Stomatol, Changchun 130021, Peoples R China.
   [Tao, Lu; Gao, Ying; Li, Yushen; Yang, Liuqing; Yao, Jingjing; Huang, Handan; Yu, Jinling; Liu, Zhihui] Jilin Prov Key Lab Tooth Dev & Bone Remodeling, Changchun 130021, Peoples R China.
   [Wang, Bowei] Second Hosp Jilin Univ, Changchun 130041, Peoples R China.
   [Han, Bing] Jilin Univ, Sch Pharmaceut Sci, Dept Biopharm, Changchun 130021, Peoples R China.
C3 Jilin University; Jilin University; Jilin University
RP Liu, ZH (通讯作者)，Jilin Univ, Hosp Stomatol, Changchun 130021, Peoples R China.; Liu, ZH (通讯作者)，Jilin Prov Key Lab Tooth Dev & Bone Remodeling, Changchun 130021, Peoples R China.; Wang, BW (通讯作者)，Second Hosp Jilin Univ, Changchun 130041, Peoples R China.; Han, B (通讯作者)，Jilin Univ, Sch Pharmaceut Sci, Dept Biopharm, Changchun 130021, Peoples R China.
EM hanb@jlu.edu.cn; wangbw@jlu.edu.cn; liu_zh@jlu.edu.cn
RI Yang, Liuqing/HQY 8902 2023; 志辉, 刘/HRC 8063 2023; yao,
   jingjing/ABB 8042 2020; Liu, Weiwei/L 9732 2019; Li,
   Yushen/HNS 7568 2023
FU General Program of National Natural Science Foundation of China
   [82370934]; Science and Technology Department of Jilin Province
   [20220401102YY]; Science and Technology Department of Jilin Province
   [20230204076YY]; Graduate Innovation Fund of Jilin University [2022241]
FX This research was funded by the General Program of National Natural
   Science Foundation of China (Grant No. 82370934). This research was
   funded by the Science and Technology Department of Jilin Province (Grant
   No. 20220401102YY ). This research was funded by the Science and
   Technology Department of Jilin Province (Grant No. 20230204076YY ). This
   research was funded by the Graduate Innovation Fund of Jilin University
   (Grant No.2022241)
CR Anwandter A, 2016, J DENT, V52, P23, DOI 10.1016/j.jdent.2016.06.005
   Barbosa JS, 2021, J MED CHEM, V64, P1260, DOI 10.1021/acs.jmedchem.0c01292
   Baron R, 2011, BONE, V48, P677, DOI 10.1016/j.bone.2010.11.020
   Bennardo F, 2023, J. BMC Oral Health, V23
   Benoit DSW, 2005, ACTA BIOMATER, V1, P461, DOI 10.1016/j.actbio.2005.03.002
   Choukroun J, 2006, ORAL SURG ORAL MED O, V101, P299, DOI 10.1016/j.tripleo.2005.07.012
   Diab DL, 2013, THER ADV MUSCULOSKEL, V5, P107, DOI 10.1177/1759720X13477714
   Du W, 2022, INT J ORAL SCI, V14, DOI 10.1038/s41368 022 00166 4
   Gönen ZB, 2017, CRANIO, V35, P332, DOI 10.1080/08869634.2016.1203093
   Hadad H, 2022, SCI REP UK, V12, DOI 10.1038/s41598 022 20128 4
   Huang J, 2021, INT J NANOMED, V16, P3161, DOI 10.2147/IJN.S305361
   Jamalpour MR, 2022, BMC ORAL HEALTH, V22, DOI 10.1186/s12903 022 02275 2
   Kim T, 2018, AM J PATHOL, V188, P2318, DOI 10.1016/j.ajpath.2018.06.019
   Kuznik A, 2020, J. Eur J Pharmacol, P866
   Lewiecki EM, 2011, DRUGS, V71, P791, DOI 10.2165/11585470 000000000 00000
   Liu YX, 2010, BIOMATERIALS, V31, P1158, DOI 10.1016/j.biomaterials.2009.10.040
   LIU YX, 1995, CIRC RES, V77, P638, DOI 10.1161/01.RES.77.3.638
   Maluf G, 2018, J ORAL MAXIL SURG, V76, P88, DOI 10.1016/j.joms.2017.06.004
   Marx RE, 2003, J ORAL MAXIL SURG, V61, P1115, DOI 10.1016/S0278 2391(03)00720 1
   Messer JG, 2018, BONE, V108, P79, DOI 10.1016/j.bone.2017.12.025
   Özalp Ö, 2021, BMC ORAL HEALTH, V21, DOI 10.1186/s12903 021 01965 7
   Papapoulos SE, 2007, NEW ENGL J MED, V356, P1075, DOI 10.1056/NEJMc062792
   Reid IR, 2022, LANCET, V399, P1080, DOI 10.1016/S0140 6736(21)02646 5
   Reid IR, 2020, Zoledronate J Bone, P137
   Ruggiero SL, 2022, J ORAL MAXIL SURG, V80, P920, DOI 10.1016/j.joms.2022.02.008
   Ruggiero SL, 2014, J ORAL MAXIL SURG, V72, P1938, DOI 10.1016/j.joms.2014.04.031
   SCOTT JE, 1965, HISTOCHEMISTRY, V5, P221, DOI 10.1007/BF00306130
   Szentpeteri Szofia, 2020, J Oral Maxillofac Surg, V78, P738, DOI 10.1016/j.joms.2019.12.008
   Taysi AE, 2019, J. Brazilian Oral Res,, P33
   Tenore G, 2020, J CLIN MED, V9, DOI 10.3390/jcm9113505
   Van den Bulcke AI, 2000, BIOMACROMOLECULES, V1, P31, DOI 10.1021/bm990017d
   Williams DW, 2014, AM J PATHOL, V184, P3084, DOI 10.1016/j.ajpath.2014.07.010
   Wysowski DK, 2013, BONE, V57, P423, DOI 10.1016/j.bone.2013.09.008
   Yan R, 2022, INT J ORAL SCI, V14, DOI 10.1038/s41368 022 00182 4
   Yarom N, 2019, J CLIN ONCOL, V37, P2270, DOI 10.1200/JCO.19.01186
   Yu WL, 2020, ORAL DIS, V26, P609, DOI 10.1111/odi.13275
   Zhang J, 2021, BIOMATER SCI UK, V9, P745, DOI 10.1039/c9bm01446b
NR 37
TC 6
Z9 6
U1 6
U2 29
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1472 6831
J9 BMC ORAL HEALTH
JI BMC Oral Health
PD AUG 29
PY 2024
VL 24
IS 1
AR 1010
DI 10.1186/s12903 024 04792 8
PG 13
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA E5V2D
UT WOS:001303670900007
PM 39210345
OA gold
DA 2025 08 17
ER

PT J
AU Chen, KT
   Aenlle, KK
   Curtis, KM
   Roos, BA
   Howard, GA
AF Chen, Ketian
   Aenlle, Kristina K.
   Curtis, Kevin M.
   Roos, Bernard A.
   Howard, Guy A.
TI Hepatocyte growth factor (HGF) and 1,25 dihydroxyvitamin D together
   stimulate human bone marrow derived stem cells toward the osteogenic
   phenotype by HGF induced up regulation of VDR
SO BONE
LA English
DT Article
DE Hepatocyte growth factor; Stem cell; Mesenchymal stem cell;
   1,25 dihydroxyvitamin D; Osteoprogenitors; p63
ID VITAMIN D RECEPTOR; P53 FAMILY; PROLIFERATION; BINDING; DIFFERENTIATION;
   EXPRESSION; INDUCTION; TARGET; GENE; MET
AB Bone formation and remodeling require generation of osteoprogenitors from bone marrow stem cells (MSC), which are regulated by growth factors and hormones, with putative roles in mesenchymal cell differentiation. Hepatocyte growth factor (HGF) is a pleiotropic growth factor, and together with its high affinity receptor cMet are widely expressed in normal tissues. 1,25 dihydroxyvitamin D (1,25OHD) is the most active metabolite of vitamin D; produced mainly in the kidney, but also by osteoblasts. We previously reported that HGF and 1,25OHD act together to increase osteogenic differentiation of human MSC (hMSC) potentially through increasing p53. Although p53 does not induce the vitamin D receptor (VDR), p63, a member of the p53 family of transcription factors has been reported to up regulate VDR expression in some tumor cell fines, and thus might play a part in HGF regulated VDR expression. Our hypothesis is that the combination of HGF and 1,25OHD can induce hMSC differentiation by up regulation of 1,25OHD and/or VDR expression to increase cell response(s) to 1,25OHD. Using real time RT qPCR, Western blots, luciferase reporter assays, and siRNAs, as well as antibodies to specific signaling molecules we showed that HGF induced VDR gene expression, as well as up regulated p63 gene expression. p63 gene knockdown by siRNA eliminated the effects of HGF on VDR gene expression as measured by RT qPCR, Western blots and luciferase reporter assay, and downstream on osteogenic differentiation markers, including alkaline phosphatase staining. Differentiation is a coordinated process of cell cycle exit and tissue specific gene expression. These results suggest HGF might be a good candidate to coordinate the regulation of these two processes during hMSC osteogenic differentiation. p63 could be a key connecting molecule on the pathway of HGF induced VDR expression. Understanding the role of these factors and their actions could have important clinical implications for the use of hMSC in the development of novel stem cell therapies. Published by Elsevier Inc.
C1 [Chen, Ketian; Aenlle, Kristina K.; Curtis, Kevin M.; Roos, Bernard A.; Howard, Guy A.] Vet Affairs Med Ctr, GRECC, Miami, FL 33125 USA.
   [Chen, Ketian; Aenlle, Kristina K.; Curtis, Kevin M.; Roos, Bernard A.; Howard, Guy A.] Vet Affairs Med Ctr, Res Serv, Miami, FL 33125 USA.
   [Chen, Ketian; Aenlle, Kristina K.; Curtis, Kevin M.; Roos, Bernard A.; Howard, Guy A.] Univ Miami, Miller Sch Med, Geriatr Inst, Miami, FL 33101 USA.
   [Roos, Bernard A.; Howard, Guy A.] Univ Miami, Miller Sch Med, Dept Med, Miami, FL 33101 USA.
   [Roos, Bernard A.] Univ Miami, Miller Sch Med, Dept Neurol, Miami, FL 33101 USA.
   [Chen, Ketian; Howard, Guy A.] Univ Miami, Miller Sch Med, Dept Biochem & Mol Biol, Miami, FL 33101 USA.
C3 Geriatric Research Education & Clinical Center; US Department of
   Veterans Affairs; Veterans Health Administration (VHA); US Department of
   Veterans Affairs; Veterans Health Administration (VHA); University of
   Miami; University of Miami; University of Miami; University of Miami
RP Howard, GA (通讯作者)，VA Med Ctr, Res Serv 151, 1201 NW 16th St, Miami, FL 33125 USA.
EM Ketian_Chen@hotmail.com; Kristinaaenlle@gmail.com;
   Kevinmcurtis@gmail.com; BRoos@med.miami.edu; GHoward1@med.miami.edu
RI ; Curtis, Kevin/B 8020 2011; Howard, Guy/KEI 5998 2024
OI Curtis, Kevin/0000 0002 7480 1818; 
FU Merit Review awards from the Department of Veterans Affairs
FX This work was supported by Merit Review awards from the Department of
   Veterans Affairs to BAR and GAH. We thank Dr. Carlos Perez Stable for
   suggestions and critical discussions regarding this work. We thank David
   Vazquez and B. Nubia Rodriguez for excellent technical assistance. Dr.
   Howard is the recipient of a Senior Research Career Scientist award from
   the Department of Veterans Affairs.
CR Abdallah BM, 2008, GENE THER, V15, P109, DOI 10.1038/sj.gt.3303067
   Blanquaert F, 1999, ENDOCRINOLOGY, V140, P1069, DOI 10.1210/en.140.3.1069
   Bourdon JC, 2007, CURR PHARM BIOTECHNO, V8, P332, DOI 10.2174/138920107783018444
   Carlberg C, 2007, J STEROID BIOCHEM, V103, P338, DOI 10.1016/j.jsbmb.2006.12.044
   Chen KT, 2011, BONE, V49, P1194, DOI 10.1016/j.bone.2011.08.023
   D'Ippolito G, 1999, J BONE MINER RES, V14, P1115, DOI 10.1359/jbmr.1999.14.7.1115
   D'Ippolito G, 2002, BONE, V31, P269, DOI 10.1016/S8756 3282(02)00820 7
   Forte G, 2006, STEM CELLS, V24, P23, DOI 10.1634/stemcells.2004 0176
   Grano M, 1996, P NATL ACAD SCI USA, V93, P7644, DOI 10.1073/pnas.93.15.7644
   Hammond DE, 2004, CURR TOP MICROBIOL, V286, P21
   HOWARD GA, 1981, J BIOL CHEM, V256, P7738
   HUGHES MR, 1991, J RECEPTOR RES, V11, P699, DOI 10.3109/10799899109066437
   INABA M, 1993, BLOOD, V82, P53, DOI 10.1182/blood.V82.1.53.bloodjournal82153
   Kommagani R, 2006, ONCOGENE, V25, P3745, DOI 10.1038/sj.onc.1209412
   Kommagani R, 2010, CELL DEATH DIFFER, V17, P398, DOI 10.1038/cdd.2009.135
   Kommagani R, 2007, J BIOL CHEM, V282, P29847, DOI 10.1074/jbc.M703641200
   Kommagani R, 2009, J CELL SCI, V122, P2828, DOI 10.1242/jcs.049619
   Korecki CL, 2009, CALCIFIED TISSUE INT, V85, P405, DOI 10.1007/s00223 009 9281 3
   Krampera M, 2007, BONE, V40, P382, DOI 10.1016/j.bone.2006.09.006
   Kratchmarova I, 2005, SCIENCE, V308, P1472, DOI 10.1126/science.1107627
   Levrero M, 2000, J CELL SCI, V113, P1661
   Li JJ, 1998, EUR J ORAL SCI, V106, P408, DOI 10.1111/j.1600 0722.1998.tb02207.x
   LIU C, 1987, HISTOCHEMISTRY, V86, P559, DOI 10.1007/BF00489547
   Marin MC, 2000, BBA REV CANCER, V1470, pM93, DOI 10.1016/S0304 419X(00)00010 X
   Matilainen JM, 2010, J BIOL CHEM, V285, P24174, DOI 10.1074/jbc.M110.124073
   Neuss S, 2004, STEM CELLS, V22, P405, DOI 10.1634/stemcells.22 3 405
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Raff M, 2003, ANNU REV CELL DEV BI, V19, P1, DOI 10.1146/annurev.cellbio.19.111301.143037
   Sensebé L, 2009, TRANSPLANTATION, V87, pS49, DOI 10.1097/TP.0b013e3181a28635
   Shen Q, 2005, J BIOL CHEM, V280, P40589, DOI 10.1074/jbc.M504166200
   Siddappa Ramakrishnaiah, 2007, Curr Stem Cell Res Ther, V2, P209, DOI 10.2174/157488807781696267
   Stuart KA, 2000, INT J EXP PATHOL, V81, P17, DOI 10.1046/j.1365 2613.2000.00138.x
   Takai K, 1997, BLOOD, V89, P1560, DOI 10.1182/blood.V89.5.1560.1560_1560_1565
   Zhu L, 2001, CURR OPIN GENET DEV, V11, P91, DOI 10.1016/S0959 437X(00)00162 3
NR 34
TC 15
Z9 17
U1 0
U2 14
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD JUL
PY 2012
VL 51
IS 1
BP 69
EP 77
DI 10.1016/j.bone.2012.04.002
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 960HS
UT WOS:000305379200009
PM 22521434
DA 2025 08 17
ER

PT J
AU Schnabel, C
   Jett, K
   Friedman, JM
   Frieling, I
   Kruse, HP
   Mautner, V
AF Schnabel, Claudia
   Jett, Kimberly
   Friedman, Jan M.
   Frieling, Isolde
   Kruse, Hans Peter
   Mautner, Victor
TI Effect of vitamin D3 treatment on bone density in
   neurofibromatosis 1 patients: A retrospective clinical study
SO JOINT BONE SPINE
LA English
DT Article
DE Neurofibromatosis 1; Cholecalciferol; Bone mineral density; Dual energy
   X ray absorptiometry (DXA); 25 hydroxy vitamin D 3 deficiency
ID MINERAL DENSITY; D SUPPLEMENTATION; CANCER MORTALITY; D DEFICIENCY;
   CALCIUM; PREVALENCE; EXPOSURE; TYPE 1; RISK
AB Objectives: We have previously demonstrated reduced bone density and an increased incidence of 25 hydroxy vitamin D3 (25 OH D 3) deficiency in adults with neurofibromatosis 1 (NF1) compared to healthy controls. Vitamin D 3 is a cheap, safe, and effective supplement in the general population, but its value in NF1 patients has not been demonstrated. This study investigates the therapeutic potential of oral vitamin D 3 on bone mineral density (BMD) in NF1 patients with vitamin D 3 deficiency.
   Methods: We measured serum 25 OH D 3, parathyroid hormone, calcium, and bone alkaline phosphatase concentrations, urinary deoxypyridinoline concentrations, and BMD in 35 adults with NF1. Nineteen patients received vitamin D 3 supplementation for 2 years, six patients received supplementation for 1 year and 10 patients received no supplementation. Supplementation was administered in a dose that maintained the serum 25 OH D 3 level above 30 mu g/l. BMD was measured again at 1 and 2 years, and biochemical assessments of bone metabolism were measured at least every half year during therapy.
   Results: Treated subjects had significantly reduced loss of BMD, as measured by T score at the hip (p = 0.011) and lumbar spine (p = 0.022). The effect on hip BMD was apparent at 1 year in comparison to baseline (p = 0.02) and was greater at 2 years in comparison to measurements at 1 year (p = 0.02).
   Conclusions: Vitamin D 3 supplementation improves BMD in adult NF1 patients. Further studies are needed to elucidate the mechanisms responsible for reduced BMD in NF1 patients. (C) 2012 Societe francaise de rhumatologie. Published by Elsevier Masson SAS. All rights reserved.
C1 [Schnabel, Claudia] Univ Hosp Hamburg Eppendorf, Inst Clin Chem, Hamburg, Germany.
   [Jett, Kimberly; Friedman, Jan M.] Univ British Columbia, Child & Family Res Inst, Dept Med Genet, Vancouver, BC V5Z 2H6, Canada.
   [Frieling, Isolde; Kruse, Hans Peter] Ctr Osteoporosis Hamburg Neuer Wall, Hamburg, Germany.
   [Mautner, Victor] Univ Hosp Hamburg Eppendorf, Dept Neurol, Hamburg, Germany.
C3 University of Hamburg; University Medical Center Hamburg Eppendorf;
   Child & Family Research Institute; University of British Columbia;
   University of Hamburg; University Medical Center Hamburg Eppendorf
RP Jett, K (通讯作者)，Univ British Columbia, Child & Family Res Inst, Dept Med Genet, 950,28th Ave,Rm 2070, Vancouver, BC V5Z 2H6, Canada.
EM cschnabel@uke.uni hamburg.de; kjett@interchange.ubc.ca;
   jan.friedman@ubc.ca; frieling@osteoporosezentrum hamburg.de;
   h.kruse@uke.uni hamburg.de; v.mautner@uke.uni hamburg.de
RI ; Schnabel, Claudia/HHR 9279 2022
OI Jett, Kimberly/0000 0002 3841 4562; Friedman, Jan/0000 0002 7482 9570
FU Orion Pharma; Wealth Cup; Stiftung Hilfe aus Dank; German Lay
   Organisation Bundesverb and Neurofibromatose
FX This work was supported in part by Orion Pharma, Wealth Cup, Stiftung
   Hilfe aus Dank and German Lay Organisation Bundesverb and
   Neurofibromatose. Study design: SC and VM. Study conduct: SC, IF, HPK
   and VM. Data collection: CS and KJ. Data analysis: KJ and JMF. Data
   interpretation: KJ and JMF. Drafting manuscript: SC and KJ. Revising
   manuscript content: SC, KJ, JMF, and VM. Approving final version of
   manuscript: JMF and VM. KJ and JMF take responsibility for the integrity
   of the data analysis.
CR Alwan S, 2007, AM J MED GENET A, V143A, P1326, DOI 10.1002/ajmg.a.31754
   [Anonymous], 1988, ARCH NEUROL CHICAGO, V45, P575, DOI 10.1097/00005537 199606000 00007
   Bischoff Ferrari HA, 2006, AM J CLIN NUTR, V84, P18, DOI 10.1093/ajcn/84.1.18
   Bæksgaard L, 1998, OSTEOPOROSIS INT, V8, P255, DOI 10.1007/s001980050062
   Bodiwala D, 2003, CANCER LETT, V192, P145, DOI 10.1016/S0304 3835(02)00710 3
   Bours SPG, 2011, J CLIN ENDOCR METAB, V96, P1360, DOI 10.1210/jc.2010 2135
   Brunetti Pierri N, 2008, MOL GENET METAB, V94, P105, DOI 10.1016/j.ymgme.2007.12.004
   Chapuy MC, 1997, OSTEOPOROSIS INT, V7, P439, DOI 10.1007/s001980050030
   Chen TC, 2003, TRENDS ENDOCRIN MET, V14, P423, DOI 10.1016/j.tem.2003.09.004
   *DACHV DEUTSCHSPR, 2006, DVO LEITL PROPH DIAG
   DawsonHughes B, 1997, NEW ENGL J MED, V337, P670, DOI 10.1056/NEJM199709043371003
   DELMAS PD, 1993, AM J MED, V95, pS11, DOI 10.1016/0002 9343(93)90375 Y
   Di Daniele N, 2004, PHARMACOL RES, V50, P637, DOI [10.1016/S1043 6618(04)00145 8, 10.1016/j.phrs.2004.05.010]
   Friedman JM, 2002, J CHILD NEUROL, V17, P548, DOI 10.1177/088307380201700802
   Friedman JM, 1997, AM J MED GENET, V70, P138, DOI 10.1002/(SICI)1096 8628(19970516)70:2<138::AID AJMG7>3.0.CO;2 U
   GARLAND C, 1985, LANCET, V1, P307, DOI 10.1016/S0140 6736(85)91082 7
   GARLAND CF, 1989, LANCET, V2, P1176, DOI 10.1016/s0140 6736(89)91789 3
   GARLAND FC, 1990, PREV MED, V19, P614, DOI 10.1016/0091 7435(90)90058 R
   HANCHETTE CL, 1992, CANCER, V70, P2861, DOI 10.1002/1097 0142(19921215)70:12<2861::AID CNCR2820701224>3.0.CO;2 G
   Heaney RP, 2003, J AM COLL NUTR, V22, P142, DOI 10.1080/07315724.2003.10719287
   Holick MF, 2004, AM J CLIN NUTR, V80, p1678S, DOI 10.1093/ajcn/80.6.1678S
   Holick MF, 2007, NEW ENGL J MED, V357, P266, DOI 10.1056/NEJMra070553
   Holick MF, 2006, J CLIN INVEST, V116, P2062, DOI 10.1172/JCI29449
   HUSON SM, 1989, J MED GENET, V26, P704, DOI 10.1136/jmg.26.11.704
   Illés T, 2001, OSTEOPOROSIS INT, V12, P823, DOI 10.1007/s001980170032
   Kuorilehto T, 2005, OSTEOPOROSIS INT, V16, P928, DOI 10.1007/s00198 004 1801 4
   Lammert M, 2006, J MED GENET, V43, P810, DOI 10.1136/jmg.2006.041095
   Lammert M, 2005, OSTEOPOROSIS INT, V16, P1161, DOI 10.1007/s00198 005 1940 2
   MARKESTAD T, 2004, ACTA PAEDIATR SCAND, V73, P225
   Marshall D, 1996, BRIT MED J, V312, P1254, DOI 10.1136/bmj.312.7041.1254
   Seitz S, 2010, OSTEOPOROSIS INT, V21, P119, DOI 10.1007/s00198 009 0933 y
   Tucker T, 2009, J MED GENET, V46, P259, DOI 10.1136/jmg.2008.061895
   Viljakainen HT, 2006, J BONE MINER RES, V21, P836, DOI [10.1359/jbmr.060302, 10.1359/JBMR.060302]
   Yang FC, 2006, J CLIN INVEST, V116, P2880, DOI 10.1172/JCI29092
   Yu X, 2005, BONE, V36, P793, DOI 10.1016/j.bone.2005.01.022
NR 35
TC 14
Z9 15
U1 0
U2 13
PU ELSEVIER FRANCE EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY LES MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY LES MOULINEAUX, FRANCE
SN 1297 319X
EI 1778 7254
J9 JOINT BONE SPINE
JI Joint Bone Spine
PD MAY
PY 2013
VL 80
IS 3
BP 315
EP 319
DI 10.1016/j.jbspin.2012.07.010
PG 5
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA 167AM
UT WOS:000320602500017
PM 23021159
DA 2025 08 17
ER

PT J
AU Zeng, YW
   Huang, C
   Duan, DM
   Lou, AJ
   Guo, Y
   Xiao, TH
   Wei, JG
   Liu, S
   Wang, Z
   Yang, QH
   Zhou, L
   Wu, ZH
   Wang, L
AF Zeng, Yuwei
   Huang, Chuang
   Duan, Dongming
   Lou, Aiju
   Guo, Yuan
   Xiao, Tianhua
   Wei, Jianguo
   Liu, Song
   Wang, Zhao
   Yang, Qihao
   Zhou, Lei
   Wu, Zenghui
   Wang, Le
TI Injectable temperature sensitive hydrogel system incorporating
   deferoxamine loaded microspheres promotes H type blood vessel related
   bone repair of a critical size femoral defect
SO ACTA BIOMATERIALIA
LA English
DT Article
DE Deferoxamine; Gelatin microspheres; Thermoresponsive hydrogel; H  type
   blood vessel; Critical femoral defect
ID ANGIOGENESIS; CELL; OSTEOGENESIS; DELIVERY; SCAFFOLD; OSTERIX; GROWTH
AB Insufficient vascularization is a major challenge in the repair of critical sized bone defects. Deferoxamine (DFO) has been reported to play a potential role in promoting the formation of H type blood vessels, a specialized vascular subtype with coupled angiogenesis and osteogenesis. However, whether DFO pro motes the expression of H type vessels in critical femoral defects with complete periosteal damage re mains unknown. Moreover, stable drug loading systems need to be designed owing to the short half life and high dose toxic effects of DFO. In this study, we developed an injectable DFO gelatin microspheres (GMs) hydrogel complex as a stable drug loading system for the treatment of critical femoral defects in rats. Our results showed that sustained release of DFO in critical femoral defects stimulated the gen eration of functional H type vessels. The DFO GMs hydrogel complex effectively promoted proliferation, formation, and migration of human umbilical vein endothelial cells in vitro. In vivo , the application of the DFO GMs hydrogel complex expanded the distribution range and prolonged the expression time of H type vessels in the defect area and was positively correlated with the number of osterix + cells and new bone tissue. Topical application of the HIF 1 alpha inhibitor PX 478 partially blocked the stimulation of H type vessels by DFO, whereas the osteogenic potential of the latter was also weakened. Our results ex tended the local application of DFO and provided a theoretical basis for targeting H type vessels to treat large femoral defects.Statement of significanceAbundant functional blood vessels are essential for bone repair. The H type blood vessel is a functional subtype with angiogenesis and osteogenesis coupling potential. A drug loading system with long term controlled release was first used to investigate the formation of H type blood vessels in critical femoral defects and promotion of bone repair. Our results showed that the application of DFO GMs hydrogel com plex expanded the distribution range and expression time of H type vessels, and was positively correlated with the number of osteoblasts and volume of new bone tissue. These results expanded the local appli cation approach of DFO and provide a theoretical basis for targeting H type vessels to treat large femoral defects.(c) 2022 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
C1 [Zeng, Yuwei; Huang, Chuang; Duan, Dongming; Xiao, Tianhua; Wei, Jianguo; Wang, Zhao; Yang, Qihao; Zhou, Lei; Wu, Zenghui; Wang, Le] Guangzhou Med Univ, Affiliated Hosp 3, Guangzhou Key Lab Spine Dis Prevent & Treatment, 63 Duobao Rd, Guangzhou 510150, Peoples R China.
   [Zeng, Yuwei; Huang, Chuang; Duan, Dongming; Xiao, Tianhua; Wei, Jianguo; Liu, Song; Wang, Zhao; Yang, Qihao; Zhou, Lei; Wu, Zenghui; Wang, Le] Guangzhou Med Univ, Affiliated Hosp 3, Dept Orthopaed Surg, 63 Duobao Rd, Guangzhou 510150, Peoples R China.
   [Lou, Aiju] Liwan Cent Hosp Guangzhou, Dept Rheumatol, 35 Liwan Rd, Guangzhou 510030, Peoples R China.
   [Guo, Yuan] Guangzhou Med Univ, Affiliated Hosp 3, Dept Stomatol, 63 Duobao Rd, Guangzhou 510150, Peoples R China.
C3 Guangzhou Medical University; Guangzhou Medical University; Guangzhou
   Medical University
RP Zhou, L; Wu, ZH; Wang, L (通讯作者)，Guangzhou Med Univ, Affiliated Hosp 3, Guangzhou Key Lab Spine Dis Prevent & Treatment, 63 Duobao Rd, Guangzhou 510150, Peoples R China.; Zhou, L; Wu, ZH; Wang, L (通讯作者)，Guangzhou Med Univ, Affiliated Hosp 3, Dept Orthopaed Surg, 63 Duobao Rd, Guangzhou 510150, Peoples R China.
EM zhoul@gzhmu.edu.cn; 3094206329@qq.com; wangle8273@163.com
RI ; Jiang, Wei/AAD 4758 2020; YANG, qihao/HCH 4787 2022; Zhou,
   Lei/AAK 1192 2021
OI Zhou, Lei/0000 0001 8056 9464; Yang, Qihao/0000 0001 6407 9297; 
FU National Natural Sci  ence Foundation of China; Natural Science
   Foundation of Guangdong Province; Science and Technology Plan Project of
   Guangzhou City;  [82072409];  [51903087];  [2019A1515012020]; 
   [202102010 0 08]
FX This work received funding from the National Natural Sci  ence
   Foundation of China (Grant Nos. 82072409 , 51903087) , the Natural
   Science Foundation of Guangdong Province (Grant No. 2019A1515012020) ,
   and the Science and Technology Plan Project of Guangzhou City (Grant No.
   202102010 0 08) .
CR Amini Ami R., 2012, Critical Reviews in Biomedical Engineering, V40, P363
   An B, 2016, ADV DRUG DELIVER REV, V97, P69, DOI 10.1016/j.addr.2015.11.013
   Bax DV, 2021, ACTA BIOMATER, V135, P150, DOI 10.1016/j.actbio.2021.08.027
   Bayanzay K, 2016, J BLOOD MED, V7, P159, DOI 10.2147/JBM.S61540
   Berendsen AD, 2015, BONE, V80, P14, DOI 10.1016/j.bone.2015.04.035
   Brittenham GM, 2011, NEW ENGL J MED, V364, P146, DOI 10.1056/NEJMct1004810
   Burger MG, 2022, ACTA BIOMATER, V149, P111, DOI 10.1016/j.actbio.2022.07.014
   Cipitria A, 2017, ACTA BIOMATER, V60, P50, DOI 10.1016/j.actbio.2017.07.032
   Coutu DL, 2017, NAT BIOTECHNOL, V35, P1202, DOI 10.1038/nbt.4006
   Ding ZZ, 2019, ACS BIOMATER SCI ENG, V5, P4077, DOI 10.1021/acsbiomaterials.9b00621
   Diomede F, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21093242
   Dong ZX, 2021, MAT SCI ENG C MATER, V122, DOI 10.1016/j.msec.2021.111949
   Donneys A, 2019, NPJ REGEN MED, V4, DOI 10.1038/s41536 019 0072 9
   dos Santos BP, 2019, ACTA BIOMATER, V99, P154, DOI 10.1016/j.actbio.2019.08.028
   Eid R, 2017, BBA MOL CELL RES, V1864, P399, DOI 10.1016/j.bbamcr.2016.12.002
   Farr AC, 2021, MOL PHARMACEUT, V18, P593, DOI 10.1021/acs.molpharmaceut.0c00474
   Foox M, 2015, EXPERT OPIN DRUG DEL, V12, P1547, DOI 10.1517/17425247.2015.1037272
   Galea GL, 2021, DEV DYNAM, V250, P414, DOI 10.1002/dvdy.278
   Gromolak S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21249726
   Grosso A, 2017, FRONT BIOENG BIOTECH, V5, DOI 10.3389/fbioe.2017.00068
   Hettiaratchi MH, 2017, ACTA BIOMATER, V59, P21, DOI 10.1016/j.actbio.2017.06.028
   Holden P, 2019, TISSUE ENG PART B RE, V25, P461, DOI [10.1089/ten.TEB.2019.0111, 10.1089/ten.teb.2019.0111]
   Huang CL, 2015, J BONE MINER RES, V30, P1217, DOI 10.1002/jbmr.2460
   Jing XZ, 2020, J CELL PHYSIOL, V235, P9864, DOI 10.1002/jcp.29799
   Kossover O, 2020, ACS BIOMATER SCI ENG, V6, P100, DOI 10.1021/acsbiomaterials.9b00672
   Kusumbe AP, 2014, NATURE, V507, P323, DOI 10.1038/nature13145
   Li H, 2021, J DENT RES, V100, P983, DOI 10.1177/00220345211002120
   Li HW, 2020, ACS APPL MATER INTER, V12, P36823, DOI 10.1021/acsami.0c06906
   Li L, 2020, COLLOID SURFACE B, V186, DOI 10.1016/j.colsurfb.2019.110720
   Lienau J, 2009, J ORTHOP RES, V27, P1133, DOI 10.1002/jor.20870
   Liu Q, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.601224
   Maes C, 2013, CALCIFIED TISSUE INT, V92, P307, DOI 10.1007/s00223 012 9689 z
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Nguyen BNB, 2017, J BIOMED MATER RES A, V105, P1123, DOI 10.1002/jbm.a.36008
   Nouri Felekori M, 2019, INT J PHARMACEUT, V557, P208, DOI 10.1016/j.ijpharm.2018.12.054
   Oest ME, 2007, J ORTHOP RES, V25, P941, DOI 10.1002/jor.20372
   Peng Y, 2020, THERANOSTICS, V10, P426, DOI 10.7150/thno.34126
   Percival CJ, 2013, DEV DYNAM, V242, P909, DOI 10.1002/dvdy.23992
   Rindone AN, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 26455 w
   Roddy Erika, 2018, Eur J Orthop Surg Traumatol, V28, P351, DOI 10.1007/s00590 017 2063 0
   Romeo SG, 2019, NAT CELL BIOL, V21, P430, DOI 10.1038/s41556 019 0304 7
   Sanchez Casanova S, 2020, BIOMATERIALS, V241, DOI 10.1016/j.biomaterials.2020.119909
   Saran U, 2014, ARCH BIOCHEM BIOPHYS, V561, P109, DOI 10.1016/j.abb.2014.07.006
   Semenza GL, 1997, KIDNEY INT, V51, P553, DOI 10.1038/ki.1997.77
   Semenza GL, 2016, J INVEST MED, V64, P361, DOI 10.1097/JIM.0000000000000206
   Sen C, 2007, ARCH ORTHOP TRAUM SU, V127, P153, DOI 10.1007/s00402 006 0274 7
   Sgarioto M, 2012, CR BIOL, V335, P520, DOI 10.1016/j.crvi.2012.07.003
   Shen X, 2009, J ORTHOP RES, V27, P1298, DOI 10.1002/jor.20886
   Sheng HF, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/3120458
   Simunovic F, 2021, CELLS BASEL, V10, DOI 10.3390/cells10071749
   Stewart R, 2011, J ORTHOP TRAUMA, V25, P472, DOI 10.1097/BOT.0b013e31822588d8
   Vasilyev A V, 2019, Stomatologiia (Mosk), V98, P5, DOI 10.17116/stomat2019980625
   Wang JM, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 04150 5
   Wang L, 2018, BIOMATERIALS, V175, P44, DOI 10.1016/j.biomaterials.2018.05.017
   Wang L, 2017, MOL MED REP, V16, P6642, DOI 10.3892/mmr.2017.7451
   Wang L, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.36
   Wiener CM, 1996, BIOCHEM BIOPH RES CO, V225, P485, DOI 10.1006/bbrc.1996.1199
   Xie H, 2014, NAT MED, V20, P1270, DOI 10.1038/nm.3668
   Xu R, 2018, NAT MED, V24, P823, DOI 10.1038/s41591 018 0020 z
   Yuan ZY, 2021, SMALL, V17, DOI 10.1002/smll.202006596
   Zhang JK, 2020, CELL PROLIFERAT, V53, DOI 10.1111/cpr.12874
   Zhao YF, 2020, ANN NY ACAD SCI, V1474, P5, DOI 10.1111/nyas.14348
   Zhou XM, 2008, GENE DEV, V22, P1231, DOI 10.1101/gad.1643308
   Zhou X, 2010, P NATL ACAD SCI USA, V107, P12919, DOI 10.1073/pnas.0912855107
NR 64
TC 41
Z9 44
U1 8
U2 109
PU ELSEVIER SCI LTD
PI London
PA 125 London Wall, London, ENGLAND
SN 1742 7061
EI 1878 7568
J9 ACTA BIOMATER
JI Acta Biomater.
PD NOV
PY 2022
VL 153
BP 108
EP 123
DI 10.1016/j.actbio.2022.09.018
EA NOV 2022
PG 16
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA 6K1CN
UT WOS:000887249600007
PM 36115651
DA 2025 08 17
ER

PT J
AU Bispo, DSC
   Jesus, CSH
   Correia, M
   Ferreira, F
   Bonifazio, G
   Goodfellow, BJ
   Oliveira, MB
   Mano, JF
   Gil, AM
AF Bispo, Daniela S. C.
   Jesus, Catarina S. H.
   Correia, Marlene
   Ferreira, Filipa
   Bonifazio, Giulia
   Goodfellow, Brian J.
   Oliveira, Mariana B.
   Mano, Joao F.
   Gil, Ana M.
TI NMR Metabolomics Assessment of Osteogenic Differentiation of
   Adipose Tissue Derived Mesenchymal Stem Cells
SO JOURNAL OF PROTEOME RESEARCH
LA English
DT Article
DE stem cells; differentiation; osteogenic differentiation; osteogenesis;
   metabolic switch; NMR; metabolomics; metabonomics
ID BONE MARROW; OSTEOBLAST; MINERALIZATION; PROLIFERATION; ADIPOGENESIS;
   SPECTROSCOPY; OSTEOPONTIN; METABOLISM; MECHANISMS; RESORPTION
AB This Article presents, for the first time to our knowledge, an untargeted nuclear magnetic resonance (NMR) metabolomic characterization of the polar intracellular metabolic adaptations of human adipose derived mesenchymal stem cells during osteogenic differentiation. The use of mesenchymal stem cells (MSCs) for bone regeneration is a promising alternative to conventional bone grafts, and untargeted metabolomics may unveil novel metabolic information on the osteogenic differentiation of MSCs, allowing their behavior to be understood and monitored/guided toward effective therapies. Our results unveiled statistically relevant changes in the levels of just over 30 identified metabolites, illustrating a highly dynamic process with significant variations throughout the whole 21 day period of osteogenic differentiation, mainly involving amino acid metabolism and protein synthesis; energy metabolism and the roles of glycolysis, the tricarboxylic acid cycle, and oxidative phosphorylation; cell membrane metabolism; nucleotide metabolism (including the specific involvement of O glycosylation intermediates and NAD(+)); and metabolic players in protective antioxidative mechanisms (such as glutathione and specific amino acids). Different metabolic stages are proposed and are supported by putative biochemical explanations for the metabolite changes observed. This work lays the groundwork for the use of untargeted NMR metabolomics to find potential metabolic markers of osteogenic differentiation efficacy.
C1 [Bispo, Daniela S. C.; Jesus, Catarina S. H.; Correia, Marlene; Ferreira, Filipa; Bonifazio, Giulia; Goodfellow, Brian J.; Oliveira, Mariana B.; Mano, Joao F.; Gil, Ana M.] Univ Aveiro, CICECO Aveiro Inst Mat CICECO UA, Dept Chem, P 3810193 Aveiro, Portugal.
   [Bonifazio, Giulia] Univ Pavia, Dept Biotechnol Lazzaro Spallanzani, I 27100 Pavia, PV, Italy.
C3 Universidade de Aveiro; University of Pavia
RP Gil, AM (通讯作者)，Univ Aveiro, CICECO Aveiro Inst Mat CICECO UA, Dept Chem, P 3810193 Aveiro, Portugal.
EM agil@ua.pt
RI Correia, Marlene/AAE 9158 2022; Gil, Ana/B 5440 2013; Oliveira,
   Mariana/A 1440 2014; Gil, Ana/O 3871 2019; Mano, João/A 4418 2009;
   Jesus, Catarina/K 6557 2019; Mano, Joao/A 4418 2009; Bispo,
   Daniela/IRZ 9053 2023; Goodfellow, Brian/F 4638 2016
OI Jesus, Catarina/0000 0003 1812 1663; Cardoso Correia,
   Marlene/0000 0002 2026 9088; Gil, Ana/0000 0003 3766 4364; Goodfellow,
   Brian/0000 0003 3191 7121; Cabedal Bispo, Daniela
   Sofia/0000 0002 5813 5421; Mano, Joao/0000 0002 2342 3765; Oliveira,
   Mariana/0000 0002 6104 6075; 
FU Portuguese Foundation for Science and Technology (FCT) through the
   COMPETE2020 program [PTDC/BTM ORG/28835/2017]; European Union fund FEDER
   [POCI 01 0145 FEDER 028835]; University of Aveiro; Sociedade Portuguesa
   de Quimica; FCT [SFRH/BD/150655/2020]; CICECO Aveiro Institute of
   Materials project   national funds through the FCT/MEC [UIDB/50011/2020,
   UIDP/50011/2020]; FEDER under the PT2020 Partnership Agreement; FEDER
   through COMPETE 2020 [022161]; FEDER through POCI [022161]; FEDER
   through PORL [022161]; FCT through PIDDAC [022161]; Fundação para a
   Ciência e a Tecnologia [PTDC/BTM ORG/28835/2017, SFRH/BD/150655/2020]
   Funding Source: FCT
FX We acknowledge the Portuguese Foundation for Science and Technology
   (FCT) for cofunding the BIOIMPLANT project (PTDC/BTM ORG/28835/2017)
   through the COMPETE2020 program and European Union fund FEDER
   (POCI 01 0145 FEDER 028835). C.S.H.J. is grateful to the same project
   for funding their contracts with the University of Aveiro. D.S.C.B.
   acknowledges the Sociedade Portuguesa de Quimica and FCT for her Ph.D.
   grant SFRH/BD/150655/2020. All authors are grateful to the CICECO Aveiro
   Institute of Materials project, with references UIDB/50011/2020 and
   UIDP/50011/2020, financed by national funds through the FCT/MEC and when
   appropriate cofinanced by FEDER under the PT2020 Partnership Agreement.
   The NMR spectrometer used in this work is part of the National NMR
   Network (PTNMR) and is partially supported by infrastructure project no.
   022161 (cofinanced by FEDER through COMPETE 2020, POCI and PORL and FCT
   through PIDDAC).
CR Addison WN, 2007, J BIOL CHEM, V282, P15872, DOI 10.1074/jbc.M701116200
   Alakpa EV, 2016, CHEM US, V1, DOI 10.1016/j.chempr.2016.07.001
   Amer MH, 2021, BIOMATERIALS, V266, DOI 10.1016/j.biomaterials.2020.120450
   Ansari S, 2021, PHARMACEUTICALS BASE, V14, DOI 10.3390/ph14040289
   Asou Y, 2001, ENDOCRINOLOGY, V142, P1325, DOI 10.1210/en.142.3.1325
   Atashi F, 2015, STEM CELLS DEV, V24, P1150, DOI 10.1089/scd.2014.0484
   Baht GS, 2018, CURR OSTEOPOROS REP, V16, P138, DOI 10.1007/s11914 018 0423 2
   Beck GR, 2001, CELL GROWTH DIFFER, V12, P61
   Berben L, 2012, INT J NURS STUD, V49, P1039, DOI 10.1016/j.ijnurstu.2012.01.015
   Bhinderwala F, 2018, J PROTEOME RES, V17, P4017, DOI 10.1021/acs.jproteome.8b00567
   Bispo DSC, 2021, STEM CELL REV REP, V17, P2003, DOI 10.1007/s12015 021 10193 z
   Bow A, 2020, BIORESEARCH OPEN ACC, V9, P37, DOI 10.1089/biores.2020.0005
   Bridge PD, 1999, J CLIN EPIDEMIOL, V52, P229, DOI 10.1016/S0895 4356(98)00168 1
   BUTLER WT, 1989, CONNECT TISSUE RES, V23, P123, DOI 10.3109/03008208909002412
   Castiglione F, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 16043 8
   Chen CT, 2008, STEM CELLS, V26, P960, DOI 10.1634/stemcells.2007 0509
   Ciancaglini P, 2010, J BONE MINER RES, V25, P716, DOI 10.1359/jbmr.091023
   Ciciarello M, 2013, STEM CELLS DEV, V22, P1097, DOI 10.1089/scd.2012.0432
   Cloarec O, 2005, ANAL CHEM, V77, P1282, DOI 10.1021/ac048630x
   da Silva CG, 2020, CHEM PHYS LIPIDS, V232, DOI 10.1016/j.chemphyslip.2020.104964
   Duarte IF, 2009, ANAL CHEM, V81, P5023, DOI 10.1021/ac900545q
   Fu XK, 2018, ADV SCI, V5, DOI 10.1002/advs.201700755
   Gibon E, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287 016 0300 9
   Golub EE, 2009, BBA GEN SUBJECTS, V1790, P1592, DOI 10.1016/j.bbagen.2009.09.006
   Granchi D, 2019, NUTRIENTS, V11, DOI 10.3390/nu11112576
   Hodgkinson T, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abb7921
   Hu YY, 2010, P NATL ACAD SCI USA, V107, P22425, DOI 10.1073/pnas.1009219107
   Iaquinta MR, 2019, FRONT CELL DEV BIOL, V7, DOI 10.3389/fcell.2019.00268
   Jia B, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.648627
   Jun JH, 2008, J CELL BIOCHEM, V103, P1246, DOI 10.1002/jcb.21508
   Karner CM, 2015, J CLIN INVEST, V125, P551, DOI 10.1172/JCI78470
   Kim DH, 2009, SPINE J, V9, P886, DOI 10.1016/j.spinee.2009.05.006
   Kim HJ, 2020, MOL CELLS, V43, P160, DOI 10.14348/molcells.2019.0247
   Klemenz AC, 2019, CELLS BASEL, V8, DOI 10.3390/cells8070697
   Klontzas ME, 2019, ACTA BIOMATER, V88, P224, DOI 10.1016/j.actbio.2019.02.017
   Klontzas ME, 2017, STEM CELLS DEV, V26, P723, DOI 10.1089/scd.2016.0315
   Komori T, 2020, J ORAL BIOSCI, V62, P223, DOI 10.1016/j.job.2020.05.004
   Komori T, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20071694
   Koyama T, 2015, EXP CELL RES, V338, P194, DOI 10.1016/j.yexcr.2015.08.009
   Kurutas EB, 2016, NUTR J, V15, DOI 10.1186/s12937 016 0186 5
   Lee SJ, 2018, ANAL CHIM ACTA, V1024, P112, DOI 10.1016/j.aca.2018.04.018
   Lefevre C, 2019, STEM CELLS INT, V2019, DOI 10.1155/2019/9323864
   Levental KR, 2017, SCI ADV, V3, DOI 10.1126/sciadv.aao1193
   Li JZ, 2018, INT J MOL MED, V41, P184, DOI 10.3892/ijmm.2017.3198
   Li JJ, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287 020 02123 6
   Li P, 2018, AMINO ACIDS, V50, P29, DOI 10.1007/s00726 017 2490 6
   Li Y, 2011, J BONE MINER RES, V26, P2656, DOI 10.1002/jbmr.480
   Lin CH, 2018, J CELL MOL MED, V22, P786, DOI 10.1111/jcmm.13356
   Liu XJ, 2018, CELL, V175, P502, DOI 10.1016/j.cell.2018.08.040
   Loeffler J, 2018, TRENDS ENDOCRIN MET, V29, P99, DOI 10.1016/j.tem.2017.11.008
   Lorthongpanich C, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1494 4
   Lou J, 2018, BIOMOL THER, V26, P584, DOI 10.4062/biomolther.2018.049
   Mastrangelo A, 2016, BIOCHEM J, V473, P2187, DOI 10.1042/BCJ20160241
   Mattar P, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00560
   McMurray RJ, 2011, NAT MATER, V10, P637, DOI [10.1038/NMAT3058, 10.1038/nmat3058]
   McNamara LE, 2011, BIOMATERIALS, V32, P7403, DOI 10.1016/j.biomaterials.2011.06.063
   Mitchell A, 2015, CYTOM PART A, V87A, P1012, DOI 10.1002/cyto.a.22777
   Mohamed Ahmed S, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 0914 1
   Moriishi T, 2020, PLOS GENET, V16, DOI 10.1371/journal.pgen.1008586
   Nagel AK, 2014, MOL CELL PROTEOMICS, V13, P3381, DOI 10.1074/mcp.M114.040691
   Orapiriyakul W, 2020, ACS NANO, V14, P10027, DOI 10.1021/acsnano.0c03130
   Orriss IR, 2009, J CELL PHYSIOL, V220, P155, DOI 10.1002/jcp.21745
   Otto F, 2003, J CELL BIOCHEM, V89, P9, DOI 10.1002/jcb.10491
   Paiva KBS, 2017, PROG MOL BIOL TRANSL, V148, P203, DOI 10.1016/bs.pmbts.2017.05.001
   Pattappa G, 2011, J CELL PHYSIOL, V226, P2562, DOI 10.1002/jcp.22605
   Peng LY, 2008, STEM CELLS DEV, V17, P761, DOI 10.1089/scd.2007.0217
   Rampler E, 2019, MOLECULES, V24, DOI 10.3390/molecules24193615
   Ranstam J, 2016, OSTEOARTHR CARTILAGE, V24, P763, DOI 10.1016/j.joca.2016.01.008
   Roberti A, 2021, MOL METAB, V45, DOI 10.1016/j.molmet.2021.101165
   Roberts JN, 2016, ACS NANO, V10, P6667, DOI 10.1021/acsnano.6b01765
   Roberts SJ, 2004, BIOCHEM J, V382, P59, DOI 10.1042/BJ20040511
   Roci I, 2020, METABOLOMICS, V16, DOI 10.1007/s11306 020 01749 0
   Romagnoli C, 2013, FEBS J, V280, P867, DOI 10.1111/febs.12075
   Roszek K, 2019, J CELL PHYSIOL, V234, P320, DOI 10.1002/jcp.26904
   Saccenti E, 2014, METABOLOMICS, V10, P361, DOI 10.1007/s11306 013 0598 6
   Santoyo Ramos P, 2012, GLYCOSYLATION, P287, DOI 10.5772/47874
   Segers K, 2019, BIOANALYSIS, V11, P2297, DOI 10.4155/bio 2019 0014
   Sekrecka Belniak A, 2010, BIOCHEM BIOPH RES CO, V391, P1432, DOI 10.1016/j.bbrc.2009.12.083
   Seras Franzoso J, 2014, NANOMEDICINE UK, V9, P207, DOI 10.2217/nnm.13.43
   Shares BH, 2018, J BIOL CHEM, V293, P16019, DOI 10.1074/jbc.RA118.004102
   Shi CM, 2008, J TISSUE ENG REGEN M, V2, P482, DOI 10.1002/term.120
   Shum LC, 2016, STEM CELLS DEV, V25, P114, DOI 10.1089/scd.2015.0193
   STEIN GS, 1993, ENDOCR REV, V14, P424, DOI 10.1210/er.14.4.424
   Surrati A, 2021, CELL PHYSIOL BIOCHEM, V55, P311, DOI 10.33594/000000377
   Surrati A, 2016, ANALYST, V141, P3776, DOI 10.1039/c6an00170j
   Szpalski C, 2012, TISSUE ENG PART B RE, V18, P258, DOI [10.1089/ten.TEB.2011.0440, 10.1089/ten.teb.2011.0440]
   Trygg J, 2007, J PROTEOME RES, V6, P469, DOI 10.1021/pr060594q
   Tsimbouri PM, 2012, ACS NANO, V6, P10239, DOI 10.1021/nn304046m
   Tsimbouri PM, 2017, NAT BIOMED ENG, V1, P758, DOI 10.1038/s41551 017 0127 4
   Valle Prieto A, 2010, STEM CELLS DEV, V19, P1885, DOI 10.1089/scd.2010.0093
   Veselkov KA, 2009, ANAL CHEM, V81, P56, DOI 10.1021/ac8011544
   Vidal L, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.00061
   Villa I, 2017, J TRANSL MED, V15, DOI 10.1186/s12967 017 1233 5
   Wishart DS, 2007, NUCLEIC ACIDS RES, V35, pD521, DOI 10.1093/nar/gkl923
   Wu HF, 2008, ANAL BIOCHEM, V372, P204, DOI 10.1016/j.ab.2007.10.002
   Yadav MC, 2011, J BONE MINER RES, V26, P286, DOI 10.1002/jbmr.195
   Yang JL, 2014, ACS NANO, V8, P9941, DOI 10.1021/nn504767g
   Younger E M, 1989, J Orthop Trauma, V3, P192, DOI 10.1097/00005131 198909000 00002
   Yu YL, 2019, CELL METAB, V29, P966, DOI 10.1016/j.cmet.2019.01.016
   Yuan XG, 2020, COMMUN BIOL, V3, DOI 10.1038/s42003 020 01514 y
   Zhao GF, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/3427430
   Zhou CH, 2014, AMINO ACIDS, V46, P1673, DOI 10.1007/s00726 014 1729 8
NR 102
TC 18
Z9 20
U1 1
U2 33
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1535 3893
EI 1535 3907
J9 J PROTEOME RES
JI J. Proteome Res.
PD MAR 4
PY 2022
VL 21
IS 3
BP 654
EP 670
DI 10.1021/acs.jproteome.1c00832
EA JAN 2022
PG 17
WC Biochemical Research Methods
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA 0A1FG
UT WOS:000746896500001
PM 35061379
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Santos, SC
   Spaniol, KG
   Chaves Silva, NE
   Fernandes, RPM
   Tavares, DS
   Acchar, W
   dos Santos, EA
AF Santos, Silmara C.
   Spaniol, Katharina G.
   Chaves Silva, Nikolas E.
   Fernandes, Roberta P. M.
   Tavares, Debora S.
   Acchar, Wilson
   dos Santos, Euler A.
TI Copper containing bioactive glass/PVA membranes for guided bone
   regeneration
SO JOURNAL OF NON CRYSTALLINE SOLIDS
LA English
DT Article
DE PVA; Bioactive glass; Copper; Osteoblast behavior; Antibacterial
   activity
ID SOL GEL; OSTEOGENIC DIFFERENTIATION; DRUG DELIVERY; GLASSES; PHOSPHATE;
   IONS; MAGNESIUM; CELLS; FABRICATION; MECHANISMS
AB The purpose of this paper was to produce CuO containing bioactive glass/PVA membranes with osteogenic and antibacterial properties to use as a membrane barrier for guided bone regeneration (GBR). The composite membranes were obtained by aqueous tape casting using PVA and a sol gel derived bioactive glass composed of 60% SiO2 center dot(36 x)% CaO center dot 4% P2O5 center dot x% CuO (mol %), where x = 0, 1 and 3%. The tape casting process could not show changes either in the composition of the glass or in its structure. When immersed in SFB, all composite membranes showed ability to form an apatite layer. The presence of CuO in the membranes improved the osteoblastic proliferation along with a higher damage to the bacteria membrane. Considering their low swelling rate, important surface bioactivity and low level degradation over time, these membranes meet the basic requirements to act as a GBR barrier, while demonstrating a high ability to control the bacteria growth.
C1 [Santos, Silmara C.; dos Santos, Euler A.] Univ Fed Sergipe, Grad Program Mat Sci & Engn, BR 49100000 Sao Cristovao, SE, Brazil.
   [Spaniol, Katharina G.; Acchar, Wilson] Univ Fed Rio Grande do Norte, Grad Program Mat Sci & Engn, BR 59078900 Natal, RN, Brazil.
   [Chaves Silva, Nikolas E.; Fernandes, Roberta P. M.] Univ Fed Sergipe, Dept Physiol, BR 49100000 Sao Cristovao, SE, Brazil.
   [Tavares, Debora S.] Univ Fed Sergipe, Dept Hlth Educ, BR 49400000 Lagarto, SE, Brazil.
C3 Universidade Federal de Sergipe; Universidade Federal do Rio Grande do
   Norte; Universidade Federal de Sergipe; Universidade Federal de Sergipe
RP Santos, SC (通讯作者)，Univ Fed Sergipe, Grad Program Mat Sci & Engn, BR 49100000 Sao Cristovao, SE, Brazil.
EM silmaracaldas@academico.ufs.br
RI ; Chaves Silva, Nikolas/X 8196 2018; ARAUJO DOS SANTOS,
   EULER/J 2635 2015; Fernandes, Roberta/J 4301 2014
OI Chaves Silva, Nikolas Emanuel/0000 0003 0668 7782; Gabriela Spaniol,
   Katharina/0000 0002 1183 5922; ARAUJO DOS SANTOS,
   EULER/0000 0001 5704 4010; Santos, Silmara/0000 0002 1177 914X; 
FU CNPq; FAPITEC/SE; CAPES [88881.157913/2017 01]
FX The authors acknowledge financial support from the Brazilian research
   agencies CNPq, FAPITEC/SE and CAPES in the form of the PROMOB
   CAPES/FAPITEC SE (N. 88881.157913/2017 01 grant).
CR [Anonymous], 2016, Crc handbook of chemistry and physics: A ready reference book of chemical and physical data, 2016 2017
   Arif Z, 2019, INDIAN J CHEM TECHN, V26, P44
   Bai W, 2007, COLLOID SURFACE B, V58, P105, DOI 10.1016/j.colsurfb.2007.02.015
   BANSAL NP, 1990, J AM CERAM SOC, V73, P2647, DOI 10.1111/j.1151 2916.1990.tb06741.x
   Bejarano J, 2015, BIOMED MATER, V10, DOI 10.1088/1748 6041/10/2/025001
   Ben Halima N, 2016, RSC ADV, V6, P39823, DOI 10.1039/c6ra05742j
   Birck C, 2014, EXPRESS POLYM LETT, V8, P941, DOI 10.3144/expresspolymlett.2014.95
   Birmingham E, 2012, EUR CELLS MATER, V23, P13, DOI 10.22203/eCM.v023a02
   Boateng JS, 2008, J PHARM SCI US, V97, P2892, DOI 10.1002/jps.21210
   Bottino MC, 2012, DENT MATER, V28, P703, DOI 10.1016/j.dental.2012.04.022
   BRINKER CJ, 1985, J NON CRYST SOLIDS, V70, P301, DOI 10.1016/0022 3093(85)90103 6
   Cacciotti I, 2017, J MATER SCI, V52, P8812, DOI 10.1007/s10853 017 1010 0
   Cao WP, 1996, CERAM INT, V22, P493, DOI 10.1016/0272 8842(95)00126 3
   Cattalini JP, 2015, J R SOC INTERFACE, V12, DOI 10.1098/rsif.2015.0509
   Cerruti M G., 2004, Effect of the immersion in solutions that simulate body fluids
   Chang HI, 2011, REGENERATIVE MEDICINE AND TISSUE ENGINEERING   CELLS AND BIOMATERIALS, P569
   Ciraldo FE, 2018, ACTA BIOMATER, V75, P3, DOI 10.1016/j.actbio.2018.05.019
   Costa ACS, 2019, MATER CHEM PHYS, V232, P1, DOI 10.1016/j.matchemphys.2019.04.027
   Czekanska EM, 2012, EUR CELLS MATER, V24, P1
   Ding HC, 2014, CRYST GROWTH DES, V14, P763, DOI 10.1021/cg401619s
   Dollimore D., 1976, Surface Technology, V4, P121, DOI DOI 10.1016/0376 4583(76)90024 8
   Drago L, 2018, MATERIALS, V11, DOI 10.3390/ma11020326
   Dziadek M, 2018, MATER LETT, V215, P87, DOI 10.1016/j.matlet.2017.12.075
   Elgali I, 2017, EUR J ORAL SCI, V125, P315, DOI 10.1111/eos.12364
   Elliott JC., 2013, Structure and Chemistry of the Apatites and Other Calcium Orthophosphates
   FERRIS FG, 1986, CAN J MICROBIOL, V32, P52, DOI 10.1139/m86 010
   GAILIT J, 1988, J BIOL CHEM, V263, P12927
   Gelb LD, 1999, LANGMUIR, V15, P305, DOI 10.1021/la9808418
   Götz W, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11030117
   Grass G, 2011, APPL ENVIRON MICROB, V77, P1541, DOI 10.1128/AEM.02766 10
   Gritsch L, 2020, MACROMOL BIOSCI, V20, DOI 10.1002/mabi.201900355
   Gritsch L, 2019, J MATER CHEM B, V7, P6109, DOI 10.1039/c9tb00897g
   Gritsch L, 2018, CARBOHYD POLYM, V179, P370, DOI 10.1016/j.carbpol.2017.09.095
   Han PP, 2013, BIOMATER SCI UK, V1, P379, DOI 10.1039/c2bm00108j
   Hazan R, 2012, BMC MICROBIOL, V12, DOI 10.1186/1471 2180 12 259
   Hench LL, 2014, J MOL STRUCT, V1073, P24, DOI 10.1016/j.molstruc.2014.03.066
   Hench LL, 1998, J BIOMED MATER RES, V41, P511, DOI 10.1002/(SICI)1097 4636(19980915)41:4<511::AID JBM1>3.0.CO;2 F
   Hoppe A., 2014, BIOACTIVE GLASS DERI
   Hoppe A, 2011, BIOMATERIALS, V32, P2757, DOI 10.1016/j.biomaterials.2011.01.004
   HOTZA D, 1995, MAT SCI ENG A STRUCT, V202, P206, DOI 10.1016/0921 5093(95)09785 6
   Ingle AP, 2014, APPL MICROBIOL BIOT, V98, P1001, DOI 10.1007/s00253 013 5422 8
   Itoh S, 2008, J BIOL CHEM, V283, P9157, DOI 10.1074/jbc.M709463200
   Kadri NA, 2011, CLINICS, V66, P1489, DOI 10.1590/S1807 59322011000800031
   Kamoun EA, 2015, ARAB J CHEM, V8, P1, DOI 10.1016/j.arabjc.2014.07.005
   Kargozar S, 2019, MAT SCI ENG C MATER, V97, P1009, DOI 10.1016/j.msec.2019.01.028
   Kaur G, 2016, J BIOMED MATER RES B, V104, P1248, DOI 10.1002/jbm.b.33443
   Kokubo T, 2006, BIOMATERIALS, V27, P2907, DOI 10.1016/j.biomaterials.2006.01.017
   Lázaro GS, 2014, J NON CRYST SOLIDS, V386, P19, DOI 10.1016/j.jnoncrysol.2013.11.038
   Leal AI, 2013, DENT MATER, V29, P427, DOI 10.1016/j.dental.2013.01.009
   Li JY, 2016, ACTA BIOMATER, V36, P254, DOI 10.1016/j.actbio.2016.03.011
   Li W, 2015, ACS APPL MATER INTER, V7, P20845, DOI 10.1021/acsami.5b06128
   Lin S, 2009, J MATER CHEM, V19, P1276, DOI 10.1039/b814292k
   Liu Jie, 2014, Open Dent J, V8, P56, DOI 10.2174/1874210601408010056
   Loty C, 2001, J BONE MINER RES, V16, P231, DOI 10.1359/jbmr.2001.16.2.231
   McBirney SE, 2016, BIOMED OPT EXPRESS, V7, P4034, DOI 10.1364/BOE.7.004034
   Miola M, 2016, MATERIALS, V9, DOI 10.3390/ma9060405
   Naung Noel Ye, 2019, Dent Clin North Am, V63, P419, DOI 10.1016/j.cden.2019.02.008
   NBR ISO, 2002, ESPECIFICACOES GEOME
   Nielsen FH, 2004, J TRACE ELEM EXP MED, V17, P137, DOI 10.1002/jtra.20004
   OGISO B, 1991, J CELL PHYSIOL, V146, P442, DOI 10.1002/jcp.1041460315
   Perez MG, 2017, ANAL BIOCHEM, V535, P43, DOI 10.1016/j.ab.2017.07.027
   Ravarian R, 2010, CERAM INT, V36, P291, DOI 10.1016/j.ceramint.2009.09.016
   Rogers WJ, 2012, WOODH PUBL SER BIOM, V46, P20
   Santos SC, 2018, J NON CRYST SOLIDS, V494, P50, DOI 10.1016/j.jnoncrysol.2018.04.054
   Santos SC, 2016, J NON CRYST SOLIDS, V439, P30, DOI 10.1016/j.jnoncrysol.2016.02.013
   Schuhladen K., 2019, Bioactive Glasses as Angiogenic Agents for Tissue Engineering, P33, DOI [10.1016/B978 0 12 801238 3.11115 8, DOI 10.1016/B978 0 12 801238 3.11115 8]
   Shim JH, 2013, TISSUE ENG PT A, V19, P317, DOI [10.1089/ten.TEA.2011.0730, 10.1089/ten.tea.2011.0730]
   Silva Lazaro Gilderman, 2012, Key Engineering Materials, V493 494, P102, DOI 10.4028/www.scientific.net/KEM.493 494.102
   Spaniol KG, 2019, CERAM INT, V45, P12417, DOI 10.1016/j.ceramint.2019.03.173
   Stavropoulos Franci, 2002, Oral Maxillofac Surg Clin North Am, V14, P15, DOI 10.1016/S1042 3699(02)00013 4
   Sulowska J, 2014, J THERM ANAL CALORIM, V116, P51, DOI 10.1007/s10973 014 3705 7
   Sulowska J, 2012, J THERM ANAL CALORIM, V109, P705, DOI 10.1007/s10973 012 2328 0
   Tilocca A, 2009, P ROY SOC A MATH PHY, V465, P1003, DOI 10.1098/rspa.2008.0462
   Todan L, 2013, J THERM ANAL CALORIM, V114, P91, DOI 10.1007/s10973 012 2875 4
   Urso E, 2015, J VASC RES, V52, P172, DOI 10.1159/000438485
   URUSHIZAKI F, 1990, INT J PHARMACEUT, V58, P135
   Wang JL, 2016, POLYMERS BASEL, V8, DOI 10.3390/polym8040115
   Wu CT, 2013, BIOMATERIALS, V34, P422, DOI 10.1016/j.biomaterials.2012.09.066
   Yang F, 2009, ACTA BIOMATER, V5, P3295, DOI 10.1016/j.actbio.2009.05.023
   Yu BB, 2012, LANGMUIR, V28, P17465, DOI 10.1021/la303768b
   Yu WL, 2017, J MATER CHEM B, V5, P1039, DOI 10.1039/c6tb02747d
   Zgurskaya HI, 2015, ACS INFECT DIS, V1, P512, DOI 10.1021/acsinfecdis.5b00097
   Zhang KR, 2019, MATTER US, V1, P770, DOI 10.1016/j.matt.2019.05.021
   Zhang YY, 2015, J NANOMATER, V2015, DOI 10.1155/2015/784574
   Zheng K, 2017, ADV COLLOID INTERFAC, V249, P363, DOI 10.1016/j.cis.2017.03.008
   Zheng K, 2017, COLLOID SURFACE B, V150, P159, DOI 10.1016/j.colsurfb.2016.11.016
   Zreiqat H, 2002, J BIOMED MATER RES, V62, P175, DOI 10.1002/jbm.10270
NR 87
TC 14
Z9 14
U1 1
U2 32
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0022 3093
EI 1873 4812
J9 J NON CRYST SOLIDS
JI J. Non Cryst. Solids
PD APR 1
PY 2021
VL 557
AR 120628
DI 10.1016/j.jnoncrysol.2020.120628
EA FEB 2021
PG 12
WC Materials Science, Ceramics; Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA QL7UP
UT WOS:000621288400002
OA Bronze
DA 2025 08 17
ER

PT J
AU Etemadi, N
   Mehdikhani, M
   Poorazizi, E
   Rafienia, M
AF Etemadi, Niloofar
   Mehdikhani, Mehdi
   Poorazizi, Elahe
   Rafienia, Mohammad
TI Novel bilayer electrospun poly(caprolactone)/silk fibroin/strontium
   carbonate fibrous nanocomposite membrane for guided bone regeneration
SO JOURNAL OF APPLIED POLYMER SCIENCE
LA English
DT Article
DE biomaterials; biomedical applications; membranes
ID SILK FIBROIN; STRONTIUM; SCAFFOLDS; COMPOSITE; NANOPARTICLES;
   MECHANISMS; STRENGTH; BEHAVIOR; DRUG
AB In this study, a thin layer with a thickness of about 120 mu m of poly(caprolactone) (PCL) was fabricated by electrospinning method. Then, a fibrous nanocomposite composed of PCL/silk fibroin/strontium carbonate (PCL/SF/SrCO3) was electrospun on the prepared layer. Then, they were characterized. The mechanical properties, water uptake, degradation rate, wettability, porosity, and bioactivity of the electrospun membrane were scrutinized in vitro. Cytotoxicity of the samples was assessed by using osteoblast like cells (SAOS 2) and L929 fibroblasts. Moreover, the cell adhesion, alkaline phosphatase (ALP) activity, and calcium deposition through alizarin red staining were conducted. Results revealed that the bilayer structure doubled the optimum mechanical properties and the addition of SrCO3 up to 15% 20% increased ALP activity, calcium deposition, and bioactivity. According to the results, the nanofibrous bilayer membrane containing 20 wt% SrCO3, 20 wt% SF, and 60 wt% PCL was chosen as the optimum sample. Therefore, this membrane could be applied in guided bone regeneration (GBR).
C1 [Etemadi, Niloofar] Islamic Azad Univ, Najafabad Branch, Dept Mat Engn, Najafabad, Iran.
   [Mehdikhani, Mehdi] Univ Isfahan, Dept Biomed Engn, Fac Engn, Esfahan, Iran.
   [Poorazizi, Elahe] Islamic Azad Univ, Najafabad Branch, Dept Biochem, Najafabad, Iran.
   [Rafienia, Mohammad] Isfahan Univ Med Sci IUMS, Biosensor Res Ctr BRC, Esfahan, Iran.
C3 Islamic Azad University; University of Isfahan; Islamic Azad University;
   Isfahan University of Medical Sciences
RP Mehdikhani, M (通讯作者)，Univ Isfahan, Dept Biomed Engn, Fac Engn, Esfahan, Iran.; Rafienia, M (通讯作者)，Biosensor Res Ctr BRC, Esfahan, Iran.
EM m.mehdikhani@eng.ui.ac.ir; m_rafienia@med.mui.ac.ir
RI Poorazizi, Elahe/AAN 2555 2021; rafienia, mohamamd/V 3848 2017
OI Poorazizi, Elahe/0000 0003 4509 1885; 
FU Isfahan University of Medical Science (IUMS)
FX Isfahan University of Medical Science (IUMS)
CR Alehosseini M, 2018, MATER TODAY PROC, V5, P15783, DOI 10.1016/j.matpr.2018.04.192
   Atla SB, 2017, CRYSTALS, V7, DOI 10.3390/cryst7120371
   Cai YR, 2017, MAT SCI ENG C MATER, V70, P148, DOI 10.1016/j.msec.2016.08.070
   Capuccini C, 2009, J BIOMED MATER RES A, V89A, P594, DOI 10.1002/jbm.a.31975
   Castro AGB, 2018, MAT SCI ENG C MATER, V85, P154, DOI 10.1016/j.msec.2017.12.023
   Causa F, 2006, J BIOMED MATER RES A, V76A, P151, DOI 10.1002/jbm.a.30528
   Coïc M, 2010, REV STOMATOL CHIR, V111, P286, DOI 10.1016/j.stomax.2010.10.006
   Salles THC, 2017, MAT SCI ENG C MATER, V77, P912, DOI 10.1016/j.msec.2017.03.190
   de Andrade DC, 2018, BRAZ J CHEM ENG, V35, P395, DOI 10.1590/0104 6632.20180352s20160355
   Dehnavi SS, 2018, MAT SCI ENG C MATER, V90, P236, DOI 10.1016/j.msec.2018.04.065
   Dwivedi Ruby, 2020, J Oral Biol Craniofac Res, V10, P381, DOI 10.1016/j.jobcr.2019.10.003
   Elgali I, 2017, EUR J ORAL SCI, V125, P315, DOI 10.1111/eos.12364
   Estellé P, 2018, RENEW SUST ENERG REV, V94, P931, DOI 10.1016/j.rser.2018.07.006
   Freitas R. A., 1999, BASIC CAPABILITIES
   Haghighat A, 2019, J ORAL MAXIL SURG, V77, P2027, DOI 10.1016/j.joms.2019.05.012
   Hasnain M. S., 2018, APPL NANOCOMPOSITE M, P127
   Hwang JW, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/6715295
   Iron R, 2019, MATER TECHNOL, V34, P540, DOI 10.1080/10667857.2019.1591728
   Lee JH, 2017, ACTA BIOMATER, V60, P93, DOI 10.1016/j.actbio.2017.07.021
   Li YY, 2020, ACTA BIOMATER, V113, P196, DOI 10.1016/j.actbio.2020.06.017
   Liu DH, 2019, CHEM ENG J, V362, P269, DOI 10.1016/j.cej.2019.01.015
   Lu P, 2018, RSC ADV, V8, P6315, DOI 10.1039/c7ra11565b
   Luo JJ, 2018, COLLOID SURFACE B, V163, P369, DOI 10.1016/j.colsurfb.2017.12.043
   Ma FB, 2019, CARBOHYD POLYM, V213, P266, DOI 10.1016/j.carbpol.2019.02.068
   Mandal BB, 2012, P NATL ACAD SCI USA, V109, P7699, DOI 10.1073/pnas.1119474109
   Meka SRK, 2016, COLLOID SURFACE B, V146, P649, DOI 10.1016/j.colsurfb.2016.07.012
   Melek L.N., 2015, Tanta Dental Journal, V12, P211, DOI DOI 10.1016/J.TDJ.2015.05.003
   Melke J, 2016, ACTA BIOMATER, V31, P1, DOI 10.1016/j.actbio.2015.09.005
   Mobika J, 2020, J MOL STRUCT, V1206, DOI 10.1016/j.molstruc.2020.127739
   Mobini S., 2016, REGEN RECONSTR RESTO, V1, P8, DOI [10.7508/rrr.2016.01.002, DOI 10.7508/RRR.2016.01.002]
   Nazeer MA, 2019, POLYMER, V168, P86, DOI 10.1016/j.polymer.2019.02.023
   Prabha RD, 2019, MAT SCI ENG C MATER, V94, P509, DOI 10.1016/j.msec.2018.09.054
   Prasadh S, 2018, ORAL SCI INT, V15, P48, DOI 10.1016/S1348 8643(18)30005 3
   Rad MM, 2017, MAT SCI ENG C MATER, V80, P75, DOI 10.1016/j.msec.2017.05.125
   Raquel Maia F., 2019, Principles of regenerative medicine, V3rd, P535, DOI [10.1016/B978 0, DOI 10.1016/B978 0, 10.1016/B978 0 12 809880 6.00032 1, DOI 10.1016/B978 0 12 809880 6.00032 1]
   Raz P, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/5163603
   Rekha S, 2019, MATER LETT, V236, P637, DOI 10.1016/j.matlet.2018.11.009
   Ren K, 2017, MAT SCI ENG C MATER, V78, P324, DOI 10.1016/j.msec.2017.04.084
   Roohaniesfahani I, 2019, MAT SCI ENG C MATER, V94, P976, DOI 10.1016/j.msec.2018.10.053
   Roseti L, 2017, MAT SCI ENG C MATER, V78, P1246, DOI 10.1016/j.msec.2017.05.017
   Saidak Z, 2012, PHARMACOL THERAPEUT, V136, P216, DOI 10.1016/j.pharmthera.2012.07.009
   Salehi AOM, 2020, INT J BIOL MACROMOL, V161, P377, DOI 10.1016/j.ijbiomac.2020.06.045
   Shaltooki M, 2019, MAT SCI ENG C MATER, V105, DOI 10.1016/j.msec.2019.110138
   Shi R, 2014, POLYM DEGRAD STABIL, V109, P293, DOI 10.1016/j.polymdegradstab.2014.07.017
   Tariverdian T, 2019, CERAM INT, V45, P14029, DOI 10.1016/j.ceramint.2019.04.102
   Türkkan S, 2017, MAT SCI ENG C MATER, V80, P484, DOI 10.1016/j.msec.2017.06.016
   Wang LP, 2020, INT J BIOL MACROMOL, V142, P366, DOI 10.1016/j.ijbiomac.2019.09.107
   Wang T, 2018, BIOMATERIALS, V182, P279, DOI 10.1016/j.biomaterials.2018.08.028
   Wang WW, 2019, MATERIALS, V12, DOI 10.3390/ma12010100
   Weng L, 2017, J BIOMED MATER RES B, V105, P753, DOI 10.1002/jbm.b.33598
   Woodruff MA, 2012, MATER TODAY, V15, P430, DOI 10.1016/S1369 7021(12)70194 3
   Xue JJ, 2015, COLLOID SURFACE B, V135, P846, DOI 10.1016/j.colsurfb.2015.03.031
   Xue JJ, 2014, INT J PHARMACEUT, V475, P566, DOI 10.1016/j.ijpharm.2014.09.026
   Yang SY, 2015, BIOMED MATER, V10, DOI 10.1088/1748 6041/10/3/035011
   Zafar B, 2020, MATERIALIA, V9, DOI 10.1016/j.mtla.2019.100518
   Zhang ES, 2016, MAT SCI ENG C MATER, V58, P278, DOI 10.1016/j.msec.2015.08.032
NR 56
TC 20
Z9 23
U1 4
U2 54
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0021 8995
EI 1097 4628
J9 J APPL POLYM SCI
JI J. Appl. Polym. Sci.
PD APR 20
PY 2021
VL 138
IS 16
AR e50264
DI 10.1002/app.50264
EA NOV 2020
PG 18
WC Polymer Science
WE Science Citation Index Expanded (SCI EXPANDED)
SC Polymer Science
GA PW4YK
UT WOS:000588543500001
DA 2025 08 17
ER

PT J
AU Holan, V
   Cechova, K
   Zajicova, A
   Kossl, J
   Hermankova, B
   Bohacova, P
   Hajkova, M
   Krulova, M
   Svoboda, P
   Javorkova, E
AF Holan, Vladimir
   Cechova, Kristina
   Zajicova, Alena
   Kossl, Jan
   Hermankova, Barbora
   Bohacova, Pavla
   Hajkova, Michaela
   Krulova, Magdalena
   Svoboda, Petr
   Javorkova, Eliska
TI The Impact of Morphine on the Characteristics and Function Properties of
   Human Mesenchymal Stem Cells
SO STEM CELL REVIEWS AND REPORTS
LA English
DT Article
DE Mesenchymal stem cells; Morphine; Opioid receptors; Gene expression;
   Growth factors; Cytokines
ID STROMAL CELLS; RECEPTOR EXPRESSION; WOUND CLOSURE; GROWTH FACTOR;
   ANGIOGENESIS; DIFFERENTIATION; MECHANISMS; REPAIR; MICE; MU
AB Morphine is an analgesic drug therapeutically administered to relieve pain. However, this drug has numerous side effects, which include impaired healing and regeneration after injuries or tissue damages. It suggests negative effects of morphine on stem cells which are responsible for tissue regeneration. Therefore, we studied the impact of morphine on the properties and functional characteristics of human bone marrow derived mesenchymal stem cells (MSCs). The presence of  ,   and  opioid receptors (OR) in untreated MSCs, and the enhanced expression of OR in MSCs pretreated with proinflammatory cytokines, was demonstrated using immunoblotting and by flow cytometry. Morphine modified in a dose dependent manner the MSC phenotype, inhibited MSC proliferation and altered the ability of MSCs to differentiate into adipocytes or osteoblasts. Furthermore, morphine rather enhanced the expression of genes for various immunoregulatory molecules in activated MSCs, but significantly inhibited the production of the vascular endothelial growth factor, hepatocyte growth factor or leukemia inhibitory factor. All of these observations are underlying the selective impact of morphine on stem cells, and offer an explanation for the mechanisms of the negative effects of opioid drugs on stem cells and regenerative processes after morphine administration or in opioid addicts.
C1 [Holan, Vladimir; Zajicova, Alena; Kossl, Jan; Hermankova, Barbora; Bohacova, Pavla; Hajkova, Michaela; Krulova, Magdalena; Javorkova, Eliska] Czech Acad Sci, Inst Expt Med, Dept Transplantat Immunol, Prague 14220, Czech Republic.
   [Holan, Vladimir; Kossl, Jan; Hermankova, Barbora; Bohacova, Pavla; Hajkova, Michaela; Krulova, Magdalena; Javorkova, Eliska] Charles Univ Prague, Dept Cell Biol, Fac Sci, Prague 12843 2, Czech Republic.
   [Cechova, Kristina; Svoboda, Petr] Czech Acad Sci, Inst Physiol, Dept Biomath, Prague 14220, Czech Republic.
   [Cechova, Kristina] Charles Univ Prague, Dept Biochem, Fac Sci, Prague 12843 2, Czech Republic.
C3 Czech Academy of Sciences; Institute of Experimental Medicine of the
   Czech Academy of Sciences; Charles University Prague; Czech Academy of
   Sciences; Institute of Physiology of the Czech Academy of Sciences;
   Charles University Prague
RP Holan, V (通讯作者)，Czech Acad Sci, Inst Expt Med, Dept Transplantat Immunol, Prague 14220, Czech Republic.; Holan, V (通讯作者)，Charles Univ Prague, Dept Cell Biol, Fac Sci, Prague 12843 2, Czech Republic.
EM holan@biomed.cas.cz
RI Kössl, Jan/N 7871 2019; Hajkova, Michaela/U 8924 2017; Javorkova,
   Eliska/HPD 9705 2023; Cechova, Kristina/M 1498 2017; Krulova,
   Magdalena/A 6255 2012; Svoboda, Petr/C 2619 2012; Hermankova,
   Barbora/JEF 6015 2023; Bohacova, Pavla/U 9076 2017
OI Hajkova, Michaela/0000 0003 1922 4891; Krulova,
   Magdalena/0000 0003 3622 376X; Svoboda, Petr/0000 0002 3076 4672; Kossl,
   Jan/0000 0001 7503 4131; Bohacova, Pavla/0000 0001 5398 3598
FU Grant Agency of the Czech Republic [17 07070S, 17 05903S]; Ministry of
   Education, Youth and Sports of the Czech Republic [LO1309, LO1508];
   Institute of Physiology [RVO: 6798523]; Charles University, Prague [SVV
   244 260435]
FX This work was supported by grants from the Grant Agency of the Czech
   Republic no. 17 07070S and 17 05903S, the projects LO1309 and LO1508
   from the Ministry of Education, Youth and Sports of the Czech Republic,
   institutional support of the Institute of Physiology (RVO: 6798523) and
   by the project SVV 244 260435 from Charles University, Prague.
CR Abdyazdani N, 2017, NEUROSCI LETT, V636, P205, DOI 10.1016/j.neulet.2016.11.025
   Abumaree M, 2012, STEM CELL REV REP, V8, P375, DOI 10.1007/s12015 011 9312 0
   Barlass U, 2018, GUT, V67, P719, DOI 10.1136/gutjnl 2017 313717
   Bayer R, 2015, DRUG ALCOHOL DEPEN, V156, P139, DOI 10.1016/j.drugalcdep.2015.09.005
   Bortolotto V, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00254
   Cechova K, 2018, J NEUROIMMUNOL, V321, P12, DOI 10.1016/j.jneuroim.2018.05.008
   Chiossone L, 2016, STEM CELLS, V34, P1909, DOI 10.1002/stem.2369
   Chrastil J, 2013, CLIN ORTHOP RELAT R, V471, P4076, DOI 10.1007/s11999 013 3232 z
   Conway K, 2006, WOUND REPAIR REGEN, V14, P2, DOI 10.1111/j.1743 6109.2005.00081.x
   Dholakiya SL, 2016, TOXICOL LETT, V247, P45, DOI 10.1016/j.toxlet.2016.01.010
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   English K, 2013, IMMUNOL CELL BIOL, V91, P19, DOI 10.1038/icb.2012.56
   Feizy N, 2016, NEUROCHEM RES, V41, P1410, DOI 10.1007/s11064 016 1847 7
   Ferrara N, 2001, ACTA HAEMATOL BASEL, V106, P148, DOI 10.1159/000046610
   Hahn JW, 2010, J NEUROCHEM, V112, P1431, DOI 10.1111/j.1471 4159.2009.06479.x
   Higuchi S, 2012, CIRC J, V76, P204, DOI 10.1253/circj.CJ 11 0309
   Hofer HR, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287 016 0394 0
   Holán V, 2003, CLIN EXP IMMUNOL, V132, P40, DOI 10.1046/j.1365 2249.2003.02103.x
   Holan V, 2016, STEM CELL REV REP, V12, P654, DOI 10.1007/s12015 016 9688 y
   Holan V, 2015, STEM CELL TRANSL MED, V4, P1052, DOI 10.5966/sctm.2015 0039
   Lam CF, 2008, ANESTH ANALG, V107, P686, DOI 10.1213/ane.0b013e31817e6719
   Le Blanc K, 2006, CYTOTHERAPY, V8, P559, DOI 10.1080/14653240601045399
   Nicola NA, 2015, CYTOKINE GROWTH F R, V26, P533, DOI 10.1016/j.cytogfr.2015.07.001
   Plein LM, 2018, BRIT J PHARMACOL, V175, P2717, DOI 10.1111/bph.13750
   Rook JM, 2007, BIOCHEM PHARMACOL, V74, P752, DOI 10.1016/j.bcp.2007.06.005
   Rook JM, 2009, BIOCHEM PHARMACOL, V77, P1747, DOI 10.1016/j.bcp.2009.03.003
   Sasaki M, 2008, J IMMUNOL, V180, P2581, DOI 10.4049/jimmunol.180.4.2581
   Squillaro T, 2016, CELL TRANSPLANT, V25, P829, DOI 10.3727/096368915X689622
   Tu T, 2015, CELL RES, V25, P275, DOI 10.1038/cr.2015.15
   Ujcikova H, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186797
   Willner D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103043
   Yan HW, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 06637 7
   Yue X., 2015, CANC CELL MICROENVIR, V2, pe877, DOI [10.14800/ccm.877, DOI 10.14800/CCM.877]
NR 33
TC 22
Z9 22
U1 0
U2 10
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 2629 3269
EI 2629 3277
J9 STEM CELL REV REP
JI Stem Cell Rev. Rep.
PD DEC
PY 2018
VL 14
IS 6
BP 801
EP 811
DI 10.1007/s12015 018 9843 8
PG 11
WC Cell & Tissue Engineering; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA GZ5NX
UT WOS:000449471900005
PM 30136142
DA 2025 08 17
ER

PT J
AU Parisi, E
   Almadén, Y
   Ibarz, M
   Panizo, S
   Cardús, A
   Rodriguez, M
   Fernandez, E
   Valdivielso, JM
AF Parisi, Eva
   Almaden, Yolanda
   Ibarz, Merce
   Panizo, Sara
   Cardus, Anna
   Rodriguez, Mariano
   Fernandez, Elvira
   Valdivielso, Jose M.
TI N methyl D aspartate receptors are expressed in rat parathyroid
   gland and regulate PTH secretion
SO AMERICAN JOURNAL OF PHYSIOLOGY RENAL PHYSIOLOGY
LA English
DT Article
DE secondary hyperparathyroidism; ERK MAPK
ID ACTIVATED PROTEIN KINASE; GLUTAMATE RECEPTORS; INTRACELLULAR CALCIUM;
   METABOLISM; KIDNEY; CELLS; A(2)
AB Parisi E, Almaden Y, Ibarz M, Panizo S, Cardus A, Rodriguez M, Fernandez E, Valdivielso JM. N methyl D aspartate receptors are expressed in rat parathyroid gland and regulate PTH secretion. Am J Physiol Renal Physiol 296: F1291 F1296, 2009. First published April 8, 2009; doi: 10.1152/ajprenal.90557.2008. N methyl D aspartate receptors (NMDAR) are tetrameric amino acid receptors which act as membrane calcium channels. The presence of the receptor has been detected in the principal organs responsible for calcium homeostasis (kidney and bone), pointing to a possible role in mineral metabolism. In the present work, the presence of the receptor was determined in normal parathyroid glands (PTG) by real time PCR, immunoprecipitation, and immunohistrochemistry. Healthy animals showed a decrease in blood parathyroid hormone (PTH) levels 15 min after the treatment with NMDA. This effect was also observed in animals with high levels of PTH induced EDTA injection, but not in uremic animals with secondary hyperparathyroidism (2HPT). Normal rat PTG incubated in media with low calcium concentration (0.8 mM CaCl2) showed a decrease in PTH release when NMDA was added to the media. This effect of NMDA was abolished when glands were coincubated with MK801 (a pharmacological blocker of the NMDA channel) or PD98059 (an inhibitor of the ERK MAPK pathway). Glands obtained from animals with 2HPT showed no effect of NMDA in the in vitro release of PTH, together with a decrease in the expression of NMDAR1. In conclusion, NMDA receptor is present in PTG and is involved in the regulation of the PTH release. The mechanism by which NMDAR exerts its function is through the activation of the MAPK cascade. In uremic 2HPT animals the receptor expression is downregulated and the treatment with NMDA does not affect PTH secretion.
C1 [Parisi, Eva; Panizo, Sara; Cardus, Anna; Valdivielso, Jose M.] Hosp Arnau Vilanova, IRBLLEIDA, Res Lab, Lleida 25198, Spain.
   [Fernandez, Elvira] Hosp Arnau Vilanova, IRBLLEIDA, Dept Nephrol, Lleida 25198, Spain.
   [Ibarz, Merce] Hosp Arnau Vilanova, IRBLLEIDA, Dept Biochem, Lleida 25198, Spain.
   [Almaden, Yolanda; Rodriguez, Mariano] Hosp Univ Reina Sofia, Unidad Invest, Cordoba, Spain.
   [Almaden, Yolanda; Rodriguez, Mariano] Hosp Univ Reina Sofia, Dept Nephrol, Cordoba, Spain.
C3 University Hospital Arnau de Vilanova; University Hospital Arnau de
   Vilanova; University Hospital Arnau de Vilanova; Hospital Universitario
   Reina Sofia   Cordoba; Hospital Universitario Reina Sofia   Cordoba
RP Valdivielso, JM (通讯作者)，Hosp Arnau Vilanova, Lab Invest HUAV UDL, Rovira Roure 80, Lleida 25198, Spain.
EM valdivielso@medicina.udl.es
RI Giráldez, Elvira/D 3358 2009; Cardus, Anna/P 6265 2019; PANIZO,
   SARA/H 4130 2017; PANIZO GARCIA, SARA/H 4130 2017; Parisi,
   Eva/B 5691 2009; Valdivielso, Jose/B 5673 2009; Valdivielso, Jose
   Manuel/B 5673 2009; Parisi, Eva/AAB 3169 2020
OI PANIZO GARCIA, SARA/0000 0001 7591 9001; Cardus,
   Anna/0000 0003 4699 6205; Rodriguez, Mariano/0000 0002 9380 6614;
   Parisi, Eva/0000 0001 5891 7530; Ibarz, Mercedes/0000 0003 0590 946X;
   Valdivielso, Jose Manuel/0000 0003 1343 0184; 
FU Fundacio Dr. Pifarre [PI07/0427]; REDINREN [16/06]; Miguel Servet
   program
FX This work was supported by Fundacio Dr. Pifarre grants, FIS PI07/0427
   and REDINREN (16/06). J. M. Valdivielso holds a contract from the Miguel
   Servet program.
CR Almadén Y, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V133693
   BOURDEAU A, 1994, ENDOCRINOLOGY, V135, P1109, DOI 10.1210/en.135.3.1109
   Chenu C, 1998, BONE, V22, P295, DOI 10.1016/S8756 3282(97)00295 0
   Corbetta S, 2002, J CLIN ENDOCR METAB, V87, P2201, DOI 10.1210/jc.87.5.2201
   Cunningham J, 2004, NEPHROL DIAL TRANSPL, V19, P9, DOI 10.1093/ndt/gfh1050
   Deng AH, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000013293.11876.4E
   FITZPATRICK LA, 1986, BIOCHEM BIOPH RES CO, V138, P960, DOI 10.1016/S0006 291X(86)80589 7
   FITZPATRICK LA, 1989, ENDOCRINOLOGY, V124, P97, DOI 10.1210/endo 124 1 97
   FUKUDA N, 1993, J CLIN INVEST, V92, P1436, DOI 10.1172/JCI116720
   Hazan I, 1997, BIOCHEM J, V326, P867, DOI 10.1042/bj3260867
   INAGAKI N, 1995, FASEB J, V9, P686, DOI 10.1096/fasebj.9.8.7768362
   Kifor O, 1997, J BONE MINER RES, V12, P715, DOI 10.1359/jbmr.1997.12.5.715
   Kifor O, 2001, AM J PHYSIOL RENAL, V280, pF291, DOI 10.1152/ajprenal.2001.280.2.F291
   Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709
   Leung JC, 2002, AM J PHYSIOL REG I, V283, pR964, DOI 10.1152/ajpregu.00629.2001
   MORI H, 1995, NEUROPHARMACOLOGY, V34, P1219, DOI 10.1016/0028 3908(95)00109 J
   NEMETH EF, 1989, AM J PHYSIOL, V257, pE505, DOI 10.1152/ajpendo.1989.257.4.E505
   Patton AJ, 1998, BONE, V22, P645, DOI 10.1016/S8756 3282(98)00061 1
   Perez Ruiz L, 2006, NEPHRON EXP NEPHROL, V103, pE126, DOI 10.1159/000092198
   Said SI, 1996, P NATL ACAD SCI USA, V93, P4688, DOI 10.1073/pnas.93.10.4688
   SHANNON HE, 1989, J PHARMACOL EXP THER, V251, P518
   SHOBACK D, 1995, J BONE MINER RES, V10, P743, DOI 10.1002/jbmr.5650100511
   Silver J, 2002, AM J PHYSIOL RENAL, V283, pF367, DOI 10.1152/ajprenal.00061.2002
   THOMAS S, 1990, BONE MINER, V8, P1, DOI 10.1016/0169 6009(91)90135 M
   YONEDA Y, 1986, BRAIN RES, V383, P387, DOI 10.1016/0006 8993(86)90046 6
NR 25
TC 22
Z9 23
U1 0
U2 4
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 1931 857X
EI 1522 1466
J9 AM J PHYSIOL RENAL
JI Am. J. Physiol. Renal Physiol.
PD JUN
PY 2009
VL 296
IS 6
BP F1291
EP F1296
DI 10.1152/ajprenal.90557.2008
PG 6
WC Physiology; Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Physiology; Urology & Nephrology
GA 449PO
UT WOS:000266342700008
PM 19357180
DA 2025 08 17
ER

PT J
AU Gencer, EB
   Lor, YK
   Abomaray, F
   El Andaloussi, S
   Pernemalm, M
   Sharma, N
   Hagey, DW
   Görgens, A
   Gustafsson, MO
   Le Blanc, K
   Toonsi, MA
   Walther Jallow, L
   Goetherström, C
AF Gencer, Emine Beguem
   Lor, Yuk Kit
   Abomaray, Fawaz
   El Andaloussi, Samir
   Pernemalm, Maria
   Sharma, Nidhi
   Hagey, Daniel W.
   Gorgens, Andre
   Gustafsson, Manuela O.
   Le Blanc, Katarina
   Toonsi, Mawaddah Asad
   Walther Jallow, Lilian
   Goetherstrom, Cecilia
TI Transcriptomic and proteomic profiles of fetal versus adult mesenchymal
   stromal cells and mesenchymal stromal cell derived extracellular
   vesicles
SO STEM CELL RESEARCH & THERAPY
LA English
DT Article
DE Mesenchymal stromal cells; Fetal mesenchymal stem cells; Biosignature;
   Transcriptomic; Proteomic; Extracellular vesicles
ID GROWTH FACTOR BETA; STEM CELLS; EXPRESSION; DIFFERENTIATION; LIVER;
   SIGNATURES; THERAPY; MSC
AB Background Mesenchymal stem/stromal cells (MSCs) can regenerate tissues through engraftment and differentiation but also via paracrine signalling via extracellular vesicles (EVs). Fetal derived MSCs (fMSCs) have been shown, both in vitro and in animal studies, to be more efficient than adult MSC (aMSCs) in generating bone and muscle but the underlying reason for this difference has not yet been clearly elucidated. In this study, we aimed to systematically investigate the differences between fetal and adult MSCs and MSC derived EVs at the phenotypic, RNA, and protein levels. Methods We carried out a detailed and comparative characterization of culture expanded fetal liver derived MSCs (fMSCs) and adult bone marrow derived MSCs (aMSCs) phenotypically, and the MSCs and MSC derived EVs were analysed using transcriptomics and proteomics approaches with RNA Sequencing and Mass Spectrometry. Results Fetal MSCs were smaller, exhibited increased proliferation and colony forming capacity, delayed onset of senescence, and demonstrated superior osteoblast differentiation capability compared to their adult counterparts. Gene Ontology analysis revealed that fMSCs displayed upregulated gene sets such as "Positive regulation of stem cell populations", "Maintenance of stemness" and "Muscle cell development/contraction/Myogenesis" in comparison to aMSCs. Conversely, aMSCs displayed upregulated gene sets such as "Complement cascade", "Adipogenesis", "Extracellular matrix glycoproteins" and "Cellular metabolism", and on the protein level, "Epithelial cell differentiation" pathways. Signalling entropy analysis suggested that fMSCs exhibit higher signalling promiscuity and hence, higher potency than aMSCs. Gene ontology comparisons revealed that fetal MSC derived EVs (fEVs) were enriched for "Collagen fibril organization", "Protein folding", and "Response to transforming growth factor beta" compared to adult MSC derived EVs (aEVs), whereas no significant difference in protein expression in aEVs compared to fEVs could be detected. Conclusions This study provides detailed and systematic insight into the differences between fMSCs and aMSCs, and MSC derived EVs. The key finding across phenotypic, transcriptomic and proteomic levels is that fMSCs exhibit higher potency than aMSCs, meaning they are in a more undifferentiated state. Additionally, fMSCs and fMSC derived EVs may possess greater bone forming capacity compared to aMSCs. Therefore, using fMSCs may lead to better treatment efficacy, especially in musculoskeletal diseases.
C1 [Gencer, Emine Beguem; Lor, Yuk Kit; Abomaray, Fawaz; Toonsi, Mawaddah Asad; Walther Jallow, Lilian; Goetherstrom, Cecilia] Karolinska Inst, Dept Clin Sci Intervent & Technol, Div Obstet & Gynecol, Stockholm, Sweden.
   [El Andaloussi, Samir; Hagey, Daniel W.; Gorgens, Andre; Gustafsson, Manuela O.] Karolinska Inst, Clin Res Ctr, Dept Lab Med, Biomol Med, Stockholm, Sweden.
   [El Andaloussi, Samir; Hagey, Daniel W.; Gorgens, Andre; Gustafsson, Manuela O.; Le Blanc, Katarina] Karolinska Univ Hosp Huddinge, Karolinska Comprehens Canc Ctr, Stockholm, Sweden.
   [El Andaloussi, Samir; Hagey, Daniel W.; Gorgens, Andre; Gustafsson, Manuela O.; Le Blanc, Katarina] Karolinska Comprehens Canc Ctr, Stockholm, Sweden.
   [Pernemalm, Maria; Sharma, Nidhi] Karolinska Inst, Dept Oncol Pathol, Sci Life Lab, Canc Prote Mass Spectrometry, Stockholm, Sweden.
   [Gorgens, Andre] Univ Duisburg Essen, Univ Hosp Essen, Inst Transfus Med, Essen, Germany.
   [Le Blanc, Katarina] Karolinska Inst, Div Clin Immunol & Transfus Med, Stockholm, Sweden.
   Umm Al Qura Univ, Dept Pediat, Coll Med, Mecca, Saudi Arabia.
C3 Karolinska Institutet; Karolinska Institutet; Karolinska Institutet;
   Karolinska University Hospital; Karolinska Institutet; University of
   Duisburg Essen; Karolinska Institutet; Umm Al Qura University
RP Goetherström, C (通讯作者)，Karolinska Inst, Dept Clin Sci Intervent & Technol, Div Obstet & Gynecol, Stockholm, Sweden.
RI Gorgens, Andre/C 3835 2016; Görgens, André/C 3835 2016; pernemalm,
   maria/HMV 1086 2023; Hagey, Daniel/ABN 2849 2022
OI Gorgens, Andre/0000 0001 9198 0857; 
FU European Union [681045]; Sweden's Innovation Agency [2017   00243];
   Swedish Research Council [2020   01666]; Region Stockholm; Centre for
   Innovative Medicine (CIMED); TUBITAK [2219]; Swedish Research Council
   [2020 01666, 2017 00243] Funding Source: Swedish Research Council;
   Vinnova [2017 00243] Funding Source: Vinnova
FX This project has received funding from the European Union's Horizon 2020
   research and innovation programme under agreement No 681045, Sweden's
   Innovation Agency (2017   00243), Swedish Research Council (2020  
   01666), Region Stockholm, The Centre for Innovative Medicine (CIMED),
   and TUBITAK 2219. AG is an International Society for Advancement of
   Cytometry (ISAC) Marylou Ingram Scholar 2019 2024.
CR Alcaraz MJ, 2019, Cells, V9
   Alvites R., 2022, PHARMACEUTICS, V14
   Amable PR, 2014, BMC CELL BIOL, V15, DOI 10.1186/s12860 014 0046 0
   Arthur A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21249759
   Banerji CRS, 2013, SCI REP UK, V3, DOI 10.1038/srep03039
   Barilani M, 2022, J CELL PHYSIOL, V237, P1753, DOI 10.1002/jcp.30638
   Boekel J, 2015, NAT BIOTECHNOL, V33, P137, DOI 10.1038/nbt.3134
   Branca RMM, 2014, NAT METHODS, V11, P59, DOI [10.1038/NMETH.2732, 10.1038/nmeth.2732]
   Campagnoli C, 2001, BLOOD, V98, P2396, DOI 10.1182/blood.V98.8.2396
   Chan J, 2006, STEM CELLS, V24, P1879, DOI 10.1634/stemcells.2005 0564
   Corso G, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 10646 x
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Galderisi U, 2022, STEM CELL REV REP, V18, P23, DOI 10.1007/s12015 021 10231 w
   Gebken J, 2000, PATHOBIOLOGY, V68, P106, DOI 10.1159/000055910
   Görgens A, 2022, J EXTRACELL VESICLES, V11, DOI 10.1002/jev2.12238
   Götherström C, 2003, BONE MARROW TRANSPL, V32, P265, DOI 10.1038/sj.bmt.1704111
   Götherström C, 2021, CLIN OBSTET GYNECOL, V64, P898, DOI 10.1097/GRF.0000000000000656
   Götherström C, 2005, HAEMATOLOGICA, V90, P1017
   Grafel I, 2014, NAT MED, V20, P670, DOI 10.1038/nm.3544
   Guillot PV, 2008, DIFFERENTIATION, V76, P946, DOI 10.1111/j.1432 0436.2008.00279.x
   Guillot PV, 2007, STEM CELLS, V25, P646, DOI 10.1634/stemcells.20060208
   HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014 4827(65)90211 9
   Heldring N, 2015, HUM GENE THER, V26, P506, DOI 10.1089/hum.2015.072
   Hill M, 2019, EUR J HUM GENET, V27, P1244, DOI 10.1038/s41431 019 0387 4
   Jovic D, 2022, STEM CELL REV REP, V18, P1525, DOI 10.1007/s12015 022 10369 1
   Kennea NL, 2009, CELL CYCLE, V8, P1069, DOI 10.4161/cc.8.7.8121
   Kim BS, 2008, STEM CELLS DEV, V17, P185, DOI 10.1089/scd.2007.0076
   Kodama J, 2022, BONE REP, V17, DOI 10.1016/j.bonr.2022.101636
   Le Blanc K, 2003, SCAND J IMMUNOL, V57, P11, DOI 10.1046/j.1365 3083.2003.01176.x
   Liberzon A, 2011, BIOINFORMATICS, V27, P1739, DOI 10.1093/bioinformatics/btr260
   Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059 014 0550 8
   Moggridge S, 2018, J PROTEOME RES, V17, P1730, DOI 10.1021/acs.jproteome.7b00913
   Oliveros JC, 2007, VENNY INTERACTIVE TO
   Otsuru S, 2018, CYTOTHERAPY, V20, P62, DOI 10.1016/j.jcyt.2017.09.012
   Phinney DG, 2017, STEM CELLS, V35, P851, DOI 10.1002/stem.2575
   Picelli S, 2014, NAT PROTOC, V9, P171, DOI 10.1038/nprot.2014.006
   Qiu GG, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1484 6
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Tauer JT, 2019, J BONE MINER RES, V34, P207, DOI 10.1002/jbmr.3617
   Teschendorff AE, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15599
   Timmers L, 2008, STEM CELL RES, V1, P129, DOI 10.1016/j.scr.2008.02.002
   Waddington C. H., 1957, The strategy of the genes. A discussion of some aspects of theoretical biology. With an appendix by H. Kacser.
   Wiklander OPB, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aav8521
   Wiklander OPB, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01326
   Xu T, 2020, J NANOBIOTECHNOL, V18, DOI 10.1186/s12951 020 00601 w
   Zhang BC, 2020, CELL TRANSPLANT, V29, DOI 10.1177/0963689720908500
   Zhang ZY, 2010, BIOMATERIALS, V31, P608, DOI 10.1016/j.biomaterials.2009.09.078
   Zhang ZY, 2009, STEM CELLS, V27, P126, DOI 10.1634/stemcells.2008 0456
   Zhu YF, 2020, MOL CELL PROTEOMICS, V19, P1047, DOI 10.1074/mcp.TIR119.001646
NR 50
TC 12
Z9 13
U1 3
U2 12
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1757 6512
J9 STEM CELL RES THER
JI Stem Cell Res. Ther.
PD MAR 13
PY 2024
VL 15
IS 1
AR 77
DI 10.1186/s13287 024 03683 7
PG 18
WC Cell & Tissue Engineering; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA LA6C2
UT WOS:001184084200007
PM 38475970
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Sun, JH
   Wang, HY
   Xiao, JH
   Yang, QD
   Liu, HY
   Yang, ZK
   Liu, YQ
   Huang, X
   Yang, L
   Ma, L
   Cao, ZG
AF Sun, Jiahui
   Wang, Huiyi
   Xiao, Junhong
   Yang, Qiudong
   Liu, Heyu
   Yang, Zhengkun
   Liu, Yuqi
   Huang, Xin
   Yang, Liu
   Ma, Li
   Cao, Zhengguo
TI Chamomile Tincture and Lidocaine Hydrochloride Gel Ameliorates
   Periodontitis: A Preclinical Study
SO BIOMEDICINES
LA English
DT Article
DE periodontitis; chamomile; inflammation; Type II interferon (IFN gamma)
ID LIGATURE INDUCED PERIODONTITIS; MATRIX METALLOPROTEINASES;
   PLANT EXTRACTS; DISEASE; INHIBITION; EFFICACY; MODELS
AB Background/Objectives: Periodontitis is a common oral disease marked by gingival inflammation and alveolar bone loss. This study evaluated the efficacy of chamomile tincture and lidocaine hydrochloride (CLH) gel in mitigating periodontal inflammation and bone loss and uncovered the molecular mechanisms involved, both in vitro and in vivo. Methods: A periodontitis model was induced in Sprague Dawley rats by ligating the mandibular first molars. Sixty rats were divided into four groups: control (C), periodontitis (PD), periodontitis + CLH gel once daily (G1), and periodontitis + CLH gel thrice daily (G3). Clinical, micro computed tomography (micro CT), biological, and histological evaluations were performed, focusing on osteoclastogenesis, osteogenesis, and inflammatory cytokine production. The effect of CLH gel on inflammatory responses in RAW264.7 cells was also assessed through co culture assays under Porphyromonas gingivalis (P. gingivalis) infection, with RNA sequencing, qPCR, and Western blot analyses to explore underlying mechanisms. Results: CLH gel significantly reduced gingival and systemic inflammation and mitigated bone loss by enhancing the bone volume to tissue volume ratio and trabecular thickness via the RANKL/OPG axis in rats. The G3 group showed marked reductions in osteoclasts and increases in osterix positive cells compared to other groups. In vitro, CLH gel reduced the inflammatory phenotype of macrophages in the periodontitis microenvironment by modulating Type II interferon (IFN gamma) networks. Conclusions: CLH gel reduced inflammation and bone loss in rat periodontitis, promoting osteogenesis and inhibiting osteoclastogenesis. It also suppressed macrophage inflammation via Type II interferon networks under P. gingivalis stimulation. These findings suggest that CLH gel has potential as an adjunctive therapy for periodontitis.
C1 [Sun, Jiahui; Wang, Huiyi; Xiao, Junhong; Yang, Qiudong; Liu, Heyu; Yang, Zhengkun; Liu, Yuqi; Huang, Xin; Yang, Liu; Ma, Li; Cao, Zhengguo] Wuhan Univ, Sch & Hosp Stomatol, Minist Educ, Hubei Key Lab Stomatol,State Key Lab Oral & Maxill, Wuhan 430079, Peoples R China.
   [Huang, Xin; Yang, Liu; Ma, Li; Cao, Zhengguo] Wuhan Univ, Sch & Hosp Stomatol, Dept Periodontol, Wuhan 430079, Peoples R China.
C3 Wuhan University; Wuhan University
RP Ma, L; Cao, ZG (通讯作者)，Wuhan Univ, Sch & Hosp Stomatol, Minist Educ, Hubei Key Lab Stomatol,State Key Lab Oral & Maxill, Wuhan 430079, Peoples R China.; Ma, L; Cao, ZG (通讯作者)，Wuhan Univ, Sch & Hosp Stomatol, Dept Periodontol, Wuhan 430079, Peoples R China.
EM sunjiahui@whu.edu.cn; 2014301040148@whu.edu.cn; junhongxiao@whu.edu.cn;
   2022103040006@whu.edu.cn; liuheyu21@whu.edu.cn;
   2017302220097@whu.edu.cn; liuyuqi@whu.edu.cn; huangxin1994@whu.edu.cn;
   leah_yangl@whu.edu.cn; mali2017@whu.edu.cn; caozhengguo@whu.edu.cn
RI ; Huang, Xin/JOK 2239 2023
OI Cao, Zhengguo/0000 0002 4261 9034; Huang, Xin/0000 0002 4063 5292; 
FU National Natural Science Foundation of China;  [82370967];  [82170963]; 
   [82301092]
FX This research was supported by the National Natural Science Foundation
   of China (82370967 and 82170963 to Zhengguo Cao and 82301092 to Li Ma).
CR Alpagot T, 2001, J CLIN PERIODONTOL, V28, P353, DOI 10.1034/j.1600 051x.2001.028004353.x
   Batista ALA, 2014, COMPLEMENT THER CLIN, V20, P93, DOI 10.1016/j.ctcp.2013.08.002
   Ashby MT, 2008, J DENT RES, V87, P900, DOI 10.1177/154405910808701003
   Barbato L, 2015, CLIN CASES MINER BON, V12, P174, DOI 10.11138/ccmbm/2015.12.2.174
   Cai X, 2008, J PERIODONTAL RES, V43, P14, DOI 10.1111/j.1600 0765.2007.00989.x
   Chandran Anu, 2021, J Indian Soc Periodontol, V25, P106, DOI 10.4103/jisp.jisp_152_20
   Chapple ILC, 2018, J PERIODONTOL, V89, pS74, DOI 10.1002/JPER.17 0719
   Chen Y, 2023, J ENDOCRINOL INVEST, V46, P2031, DOI 10.1007/s40618 023 02052 0
   Cheng J, 2012, J INTERF CYTOK RES, V32, P34, DOI 10.1089/jir.2011.0019
   Dantas JBD, 2022, PHYTOTHER RES, V36, P1115, DOI 10.1002/ptr.7378
   de Molon RS, 2018, MICROSC RES TECHNIQ, V81, P1412, DOI 10.1002/jemt.23101
   de Molon RS, 2014, J PERIODONTOL, V85, P465, DOI 10.1902/jop.2013.130225
   de Molon RS, 2013, J INVESTIG CLIN DENT, V4, P211, DOI 10.1111/jicd.12018
   Donos N, 2020, J CLIN PERIODONTOL, V47, P199, DOI 10.1111/jcpe.13232
   Bueno CRE, 2021, SAUDI DENT J, V33, P987, DOI 10.1016/j.sdentj.2021.07.004
   França LFC, 2017, J CLIN PERIODONTOL, V44, P568, DOI 10.1111/jcpe.12729
   Gosciniak A, 2021, PHARMACEUTICS, V13, DOI 10.3390/pharmaceutics13122185
   Guimaraes MV, 2016, J PERIODONTOL, V87, P706, DOI 10.1902/jop.2016.150411
   Hannas AR, 2007, ACTA ODONTOL SCAND, V65, P1, DOI 10.1080/00016350600963640
   Hans VM, 2016, J CLIN DIAGN RES, V10, pZC16, DOI 10.7860/JCDR/2016/18956.8435
   [何晓宇 He Xiaoyu], 2021, [实用口腔医学杂志, Journal of Practical Stomatology], V37, P212
   Holzhausen M, 2002, J PERIODONTOL, V73, P1030, DOI 10.1902/jop.2002.73.9.1030
   Ilgenli T, 2006, ORAL DIS, V12, P573, DOI 10.1111/j.1601 0825.2006.01244.x
   Kassi E, 2004, J AGR FOOD CHEM, V52, P6956, DOI 10.1021/jf0400765
   Khan Amjad A, 2018, Med Sci (Basel), V6, DOI 10.3390/medsci6020033
   Khuda F, 2024, J VET DENT, V41, P49, DOI 10.1177/08987564231178459
   Kulkarni R, 2023, BIOCHEM BIOPH RES CO, V667, P64, DOI 10.1016/j.bbrc.2023.05.008
   Lappin DF, 2000, J PERIODONTAL RES, V35, P369, DOI 10.1034/j.1600 0765.2000.035006369.x
   Lee HE, 2018, BIOCHEM BIOPH RES CO, V503, P2117, DOI 10.1016/j.bbrc.2018.07.168
   Lee J, 2022, J CLIN PERIODONTOL, V49, P799, DOI 10.1111/jcpe.13671
   [李宁 Li Ning], 2021, [口腔医学研究, Journal of Oral Science Research], V37, P914
   Li SY, 2024, FRONT IMMUNOL, V15, DOI 10.3389/fimmu.2024.1396122
   Miao L, 2017, BIOSCIENCE REP, V37, DOI 10.1042/BSR20170973
   Mizutani H, 2013, J PERIODONTAL RES, V48, P748, DOI 10.1111/jre.12065
   Naghsh Narges, 2023, Dent Res J (Isfahan), V20, P70
   Nakatsu S, 2014, J PERIODONTAL RES, V49, P314, DOI 10.1111/jre.12109
   Nazarian S., 2023, StatPearls
   Nizam N, 2014, INFLAMMATION, V37, P1771, DOI 10.1007/s10753 014 9907 0
   OFFENBACHER S, 1993, J PERIODONTOL, V64, P432, DOI 10.1902/jop.1993.64.5s.432
   Ono T, 2020, INFLAMM REGEN, V40, DOI 10.1186/s41232 019 0111 3
   Ozdemir H, 2012, J PERIODONTAL RES, V47, P74, DOI 10.1111/j.1600 0765.2011.01406.x
   Pourabbas R., 2005, Iranian Journal of Pharmaceutical Research, V4, P105
   Raja A, 2022, ANTIOXIDANTS BASEL, V11, DOI 10.3390/antiox11071316
   Sanz M, 2020, J CLIN PERIODONTOL, V47, P4, DOI 10.1111/jcpe.13290
   Soeroso Y, 2017, THER CLIN RISK MANAG, V13, P307, DOI 10.2147/TCRM.S130257
   Srivastava JK, 2010, MOL MED REP, V3, P895, DOI 10.3892/mmr.2010.377
   Sun XY, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.763334
   Tan JY, 2021, J IMMUNOL RES, V2021, DOI 10.1155/2021/9919024
   Tang MM, 2024, J ETHNOPHARMACOL, V319, DOI 10.1016/j.jep.2023.117324
   Teles RP, 2006, PERIODONTOL 2000, V42, P180, DOI 10.1111/j.1600 0757.2006.00192.x
   Wang H J, 2023, Zhonghua Yi Xue Za Zhi, V103, P2420, DOI 10.3760/cma.j.cn112137 20230504 00720
   Wong RL, 2017, J ORAL IMPLANTOL, V43, P437, DOI 10.1563/aaid joi D 17 00157
   Xiao JH, 2023, INFLAMMATION, V46, P1997, DOI 10.1007/s10753 023 01856 9
   Yin LY, 2022, JPN DENT SCI REV, V58, P336, DOI 10.1016/j.jdsr.2022.10.002
   Yu J, 2016, BIOCHEM BIOPH RES CO, V472, P182, DOI 10.1016/j.bbrc.2016.02.091
   Zhou SH, 2022, FRONT CELL INFECT MI, V12, DOI 10.3389/fcimb.2022.813953
NR 56
TC 0
Z9 0
U1 6
U2 7
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2227 9059
J9 BIOMEDICINES
JI Biomedicines
PD NOV
PY 2024
VL 12
IS 11
AR 2629
DI 10.3390/biomedicines12112629
PG 18
WC Biochemistry & Molecular Biology; Medicine, Research & Experimental;
   Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Research & Experimental Medicine;
   Pharmacology & Pharmacy
GA N8K8A
UT WOS:001366764800001
PM 39595193
OA gold
DA 2025 08 17
ER

PT J
AU Sun, FL
   Zhang, YH
   Li, Q
AF Sun, Fenglong
   Zhang, Yaohua
   Li, Qiang
TI Therapeutic mechanisms of ibuprofen, prednisone and betamethasone in
   osteoarthritis
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE osteoarthritis; ibuprofen; prednisone; betamethasone; interleukin 6;
   interleukin 8
ID HUMAN ARTICULAR CHONDROCYTES; COLLAGEN GENE EXPRESSION;
   NECROSIS FACTOR ALPHA; IL 10 OVEREXPRESSION; SYNOVIAL FLUID;
   GROWTH FACTORS; TNF ALPHA; CYTOKINES; CARTILAGE; INFLAMMATION
AB The present study aimed to investigate the therapeutic mechanisms of nonsteroidal anti inflammatory drugs (NSAIDs) and steroids in osteoarthritis (OA). The CHON 002 human chondrocyte cell line was used in the study. The levels of the cytokines, interleukin (IL) 1 beta, IL 6, IL 8 and IL 10, released by cells treated with tumor necrosis factor alpha (TNF alpha) were determined by ELISA. Levels of collagen I, aggrecan, matrix metalloproteinase (MMP) 1, MMP 13, signal transducer and activator of transcription (STAT) 3, nuclear factor kappa B (NF kappa B) subunit p65 and inhibitory subunit of NF kappa B (I kappa B) following treatment with IL 1 beta, IL 6, IL 8 or IL 10 were assessed by western blot. Levels of IL 6 and IL 8 were measured by ELISA following administration of TNF alpha combined with certain drugs. In addition, these parameters were evaluated by western blot following incubation with drugs in combination with IL 6 or IL 8 and after knockdown of STAT3, by addition of small interfering RNA (siRNA) STAT3 (siSTAT3), an inhibitor of the proteasome (MG132) or both. IL 1 beta, IL 6, IL 8 and IL 10 were upregulated by TNF alpha. Addition of IL 6 or IL 8 led to increased collagen I, MMP 1 and MMP 13 protein levels, and also promoted STAT3 phosphorylation and increased the expression of NF kappa B subunit p65, but had no effect on aggrecan protein levels. When siSTAT3 and MG132 treatment was combined, levels of collagen I, MMP 1 and MMP 13 were reduced. Additionally, levels of IL 6 and IL 8 were significantly decreased by prednisone, ibuprofen and betamethasone. However, no significant differences were observed following treatment with piroxicam or indomethacin. In combination with IL 6 or IL 8, prednisone, ibuprofen and betamethasone significantly reduced the levels of collagen I, MMP 1 and MMP 13, and inactivated NF kappa B and STAT3 pathways. In conclusion, prednisone, ibuprofen and betamethasone may prevent OA by suppressing the expression of IL 6 and IL 8, subsequently inactivating NF kappa B and STAT3 pathways, and ultimately, leading to decreased levels of collagen I, MMP 1, and MMP 13.
C1 [Sun, Fenglong; Zhang, Yaohua; Li, Qiang] Capital Med Univ, Beijing Rehabil Hosp, Dept Orthoped, 32 Badachu, Beijing 100144, Peoples R China.
C3 Capital Medical University
RP Sun, FL (通讯作者)，Capital Med Univ, Beijing Rehabil Hosp, Dept Orthoped, 32 Badachu, Beijing 100144, Peoples R China.
EM sunfenglong3369@126.com
RI zhang, yaohua/NVL 7830 2025
CR Abramson SB, 2004, J RHEUMATOL, V31, P70, DOI 10.1097/BOR.0b013e328349c2b1
   Borzì RM, 2004, CLIN ORTHOP RELAT R, pS53, DOI 10.1097/01.blo.0000143805.64755.4f
   Borzi RM, 2002, ARTHRITIS RHEUM, V46, P3201, DOI 10.1002/art.10650
   Cho H, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/595273
   Cho H, 2013, CONNECT TISSUE RES, V54, P181, DOI 10.3109/03008207.2013.775258
   Cross M, 2014, ANN RHEUM DIS, V73, P1323, DOI 10.1136/annrheumdis 2013 204763
   Cruz R., 2014, REC PAT BIOMARK, V4, P1
   Felson DT, 2006, NEW ENGL J MED, V354, P841, DOI 10.1056/NEJMcp051726
   Fernandes JC, 2002, BIORHEOLOGY, V39, P237
   Goldring MB, 1999, CONNECT TISSUE RES, V40, P1, DOI 10.3109/03008209909005273
   GOLDRING MB, 1994, J CELL BIOCHEM, V54, P85, DOI 10.1002/jcb.240540110
   GUERNE PA, 1990, J IMMUNOL, V144, P499
   Hayashi S, 2013, OSTEOARTHR CARTILAGE, V21, pS46, DOI 10.1016/j.joca.2013.02.114
   Hunter DJ, 2014, NAT REV RHEUMATOL, V10, P437, DOI 10.1038/nrrheum.2014.44
   Jansen NWD, 2008, BRIT J HAEMATOL, V142, P953, DOI 10.1111/j.1365 2141.2008.07278.x
   Kaneko S, 2000, CYTOKINES CELL MOL T, V6, P71, DOI 10.1080/13684730050515796
   Kapoor M, 2011, NAT REV RHEUMATOL, V7, P33, DOI 10.1038/nrrheum.2010.196
   Latourte A, 2015, ECTS IBMS
   LOTZ M, 1992, J IMMUNOL, V148, P466
   Malemud CJ, 2010, DRUG AGING, V27, P95, DOI 10.2165/11319950 000000000 00000
   Martel Pelletier Johanne, 2004, Osteoarthritis Cartilage, V12 Suppl A, pS31
   MATSUKAWA A, 1995, J IMMUNOL, V154, P5418
   Mrosewski I, 2014, CELL TISSUE RES, V357, P207, DOI 10.1007/s00441 014 1868 y
   Müller RD, 2008, CYTOKINE, V44, P377, DOI 10.1016/j.cyto.2008.10.012
   Olivotto E, 2015, RMD OPEN, V1, DOI 10.1136/rmdopen 2015 000061
   Olson TS, 2002, AM J PHYSIOL REG I, V283, pR7, DOI 10.1152/ajpregu.00738.2001
   Porée B, 2008, J BIOL CHEM, V283, P4850, DOI 10.1074/jbc.M706387200
   Richardson DW, 2000, AM J VET RES, V61, P624, DOI 10.2460/ajvr.2000.61.624
   Rowan AD, 2001, ARTHRITIS RHEUM US, V44, P1620, DOI 10.1002/1529 0131(200107)44:7<1620::AID ART285>3.0.CO;2 B
   SAKLATVALA J, 1986, NATURE, V322, P547, DOI 10.1038/322547a0
   Sokolove J, 2013, THER ADV MUSCULOSKEL, V5, P77, DOI 10.1177/1759720X12467868
   Sultana F, 2015, CHEM BIOL INTERACT, V230, P58, DOI 10.1016/j.cbi.2015.02.007
   Valcamonica E, 2014, CLIN EXP RHEUMATOL, V32, P243
   Wang YQ, 2001, CHINESE MED J PEKING, V114, P723
NR 34
TC 24
Z9 28
U1 1
U2 15
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791 2997
EI 1791 3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD FEB
PY 2017
VL 15
IS 2
BP 981
EP 987
DI 10.3892/mmr.2016.6068
PG 7
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Research & Experimental Medicine
GA EL9GE
UT WOS:000394927600063
PM 28035387
OA Bronze
DA 2025 08 17
ER

PT J
AU Pangrazio, A
   Caldana, M
   Iacono, N
   Mantero, S
   Vezzoni, P
   Villa, A
   Sobacchi, C
AF Pangrazio, A.
   Caldana, M. E.
   Iacono, N. L.
   Mantero, S.
   Vezzoni, P.
   Villa, A.
   Sobacchi, C.
TI Autosomal recessive osteopetrosis: report of 41 novel mutations in the
   TCIRG1 gene and diagnostic implications
SO OSTEOPOROSIS INTERNATIONAL
LA English
DT Article
DE ARO; Diagnosis; Genomic deletion; Osteopetrosis; TCIRG1
ID INFANTILE MALIGNANT OSTEOPETROSIS; VACUOLAR PROTON PUMP; A3 SUBUNIT;
   ATPASE; OSTEOPOROSIS; PHYSIOLOGY; DEFECTS
AB Here we report 41 novel mutations in the TCIRG1 gene that is responsible for the disease in more than 50% of ARO patients. The characterisation of mutations in this gene might be useful in the process of drug design for osteoporosis treatment.
   Autosomal recessive osteopetrosis (ARO) is a genetically heterogeneous disorder due to reduced bone resorption by osteoclasts. In this process, a crucial role is played by the proton pump V ATPase. Biallelic mutations in the TCIRG1 gene, encoding for the a3 subunit of this pump, are responsible for more than one half of ARO patients.
   Patients with a clinical diagnosis of ARO have been collected for 7 years and mutation analysis of the TCIRG1 gene was performed using direct DNA sequencing of PCR amplified exons according to both a standard protocol and a modified one.
   We report here 41 novel mutations identified in 67 unpublished patients, all with biallelic mutations. In particular, we describe two novel large genomic deletions and two splice site mutations in the 5' UTR of the TCIRG1 gene, in patients previously classified as mono allelic.
   Our data highlights the importance of two large genomic deletions and mutations in the 5' UTR with respect to patient management and, more critically, to prenatal diagnosis. With the present work, we strongly contribute to the molecular dissection of TCIRG1 deficient ARO and identify several protein residues which are fundamental for proton pump function and could thus be the target of future drugs designed to inhibit osteoclast resorptive activity.
C1 [Pangrazio, A.; Caldana, M. E.; Iacono, N. L.; Mantero, S.; Vezzoni, P.; Villa, A.; Sobacchi, C.] Ist Clin Humanitas IRCCS, I 20089 Rozzano, MI, Italy.
   [Pangrazio, A.; Caldana, M. E.; Iacono, N. L.; Mantero, S.; Vezzoni, P.; Villa, A.; Sobacchi, C.] CNR, Inst Genet & Biomed Res IRGB, Milan Unit, I 20138 Milan, Italy.
C3 IRCCS Humanitas Research Hospital; Consiglio Nazionale delle Ricerche
   (CNR); Istituto di Ricerca Genetica e Biomedica (IRGB CNR)
RP Villa, A (通讯作者)，Ist Clin Humanitas IRCCS, Via Manzoni 113, I 20089 Rozzano, MI, Italy.
EM anna.villa@humanitasresearch.it
RI SOBACCHI, CRISTINA/J 9345 2018; Vezzoni, Paolo/R 3416 2019; Mantero,
   Stefano/AAE 5515 2021; Sobacchi, Cristina/J 9345 2018
OI Villa, Anna/0000 0003 4428 9013; Vezzoni, Paolo/0000 0002 6382 3923;
   Mantero, Stefano/0000 0003 0608 2724; Sobacchi,
   Cristina/0000 0002 2684 7184
FU Fondazione Cariplo; Telethon Foundation [GGP10116]; Ministero della
   Salute [47]; E rare project JTC; PRIN [200999KRFW 002]; Giovani
   Ricercatori grant [GR 2008 1134625]
FX This work was supported by Fondazione Cariplo grant to CS, Telethon
   Foundation (grant GGP10116) to CS, by Ministero della Salute,
   convenzione 47 (role of new inflammatory molecules in pregnancy
   pathologies and in maternal neonatal health) to PV, by E rare project
   JTC 2007 OSTEOPETR to AV, by PRIN Project 200999KRFW 002 to PV and by
   Giovani Ricercatori grant (GR 2008 1134625) to CS. The technical
   assistance of Dario Strina is acknowledged.
CR Bliznetz EA, 2009, EUR J HUM GENET, V17, P664, DOI 10.1038/ejhg.2008.234
   Forgac M, 2007, NAT REV MOL CELL BIO, V8, P917, DOI 10.1038/nrm2272
   Frattini A, 2000, NAT GENET, V25, P343, DOI 10.1038/77131
   Heinemann T, 1999, GENOMICS, V57, P398, DOI 10.1006/geno.1999.5751
   Henriksen K, 2011, ENDOCR REV, V32, P31, DOI 10.1210/er.2010 0006
   Kornak U, 2000, HUM MOL GENET, V9, P2059, DOI 10.1093/hmg/9.13.2059
   Mazzolari E, 2009, AM J HEMATOL, V84, P473, DOI 10.1002/ajh.21447
   Michigami T, 2002, BONE, V30, P436, DOI 10.1016/S8756 3282(01)00684 6
   Nyman JKE, 2010, CALCIFIED TISSUE INT, V87, P273, DOI 10.1007/s00223 010 9395 7
   Pangrazio A, 2010, HUM MUTAT, V31, pE1071, DOI 10.1002/humu.21167
   Pangrazio A, 2009, J BONE MINER RES, V24, P162, DOI 10.1359/JBMR.080818
   Partridge AW, 2004, PROTEINS, V54, P648, DOI 10.1002/prot.10611
   Phadke SR, 2010, INDIAN J MED RES, V131, P508
   Scimeca JC, 2003, HUM MUTAT, V21, P151, DOI 10.1002/humu.10165
   Sobacchi C, 2001, HUM MOL GENET, V10, P1767, DOI 10.1093/hmg/10.17.1767
   Susani L, 2004, HUM MUTAT, V24, P225, DOI 10.1002/humu.20076
   Taranta A, 2003, AM J PATHOL, V162, P57, DOI 10.1016/S0002 9440(10)63798 4
   Toei M, 2010, BIOCHEMISTRY US, V49, P4715, DOI 10.1021/bi100397s
   Villa A, 2009, CALCIFIED TISSUE INT, V84, P1, DOI 10.1007/s00223 008 9196 4
   Wang Y, 2008, J BIOL CHEM, V283, P20696, DOI 10.1074/jbc.M803258200
   Yuan FL, 2010, MOL BIOL REP, V37, P3561, DOI 10.1007/s11033 010 0004 7
   Yuan P, 2011, J BONE MINER METAB, V29, P251, DOI 10.1007/s00774 010 0228 6
NR 22
TC 36
Z9 37
U1 0
U2 5
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0937 941X
J9 OSTEOPOROSIS INT
JI Osteoporosis Int.
PD NOV
PY 2012
VL 23
IS 11
BP 2713
EP 2718
DI 10.1007/s00198 011 1878 5
PG 6
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 028MA
UT WOS:000310425200015
PM 22231430
DA 2025 08 17
ER

PT J
AU Zhou, L
   Chen, X
   Liu, T
   Zhu, CH
   Si, M
   Jargstorf, J
   Li, M
   Pan, GQ
   Gong, YH
   Luo, ZP
   Yang, HL
   Pei, M
   He, F
AF Zhou, Long
   Chen, Xi
   Liu, Tao
   Zhu, Caihong
   Si, Michelle
   Jargstorf, Joseph
   Li, Mao
   Pan, Guoqing
   Gong, Yihong
   Luo, Zong Ping
   Yang, Huilin
   Pei, Ming
   He, Fan
TI SIRT1 dependent anti senescence effects of cell deposited matrix on
   human umbilical cord mesenchymal stem cells
SO JOURNAL OF TISSUE ENGINEERING AND REGENERATIVE MEDICINE
LA English
DT Article
DE mesenchymal stem cells; extracellular matrix; decellularization;
   oxidative stress; premature senescence; osteogenesis; collagen type I;
   SIRT1
ID EXTRACELLULAR MATRIX; BONE MARROW; OXIDATIVE STRESS; SENESCENCE;
   DIFFERENTIATION; PROLIFERATION; EXPRESSION; CARTILAGE; CHONDROGENESIS;
   OSTEOBLASTS
AB Human umbilical cord derived mesenchymal stem cells (UC MSCs) are considered an attractive cell source for tissue regeneration. However, environmental oxidative stress can trigger premature senescence in MSCs and thus compromises their regenerative potential. Extracellular matrix (ECM) derived from MSCs has been shown to facilitate cell proliferation and multi lineage differentiation. This investigation evaluated the effect of cell deposited decellularized ECM (DECM) on oxidative stress induced premature senescence in UC MSCs. Sublethal dosages of H2O2, ranging from 50m to 200m, were used to induce senescence in MSCs. We found that DECM protected UC MSCs from oxidative stress induced premature senescence. When treated with H2O2 at the same concentration, cell proliferation of DECM cultured UC MSCs was twofold higher than those on standard tissue culture polystyrene (TCPS). After exposure to 100m H2O2, fewer senescence associated  galactosidase positive cells were observed on DECM than those on TCPS (17.6 +/  4.0% vs. 60.4 +/  6.2%). UC MSCs cultured on DECM also showed significantly lower levels of senescence related regulators, such as p16(INK4) and p21. Most importantly, DECM preserved the osteogenic differentiation potential of UC MSCs with premature senescence. The underlying molecular mechanisms involved the silent information regulator type 1 (SIRT1) dependent signalling pathway, confirmed by the fact that the SIRT1 inhibitor nicotinamide counteracted the DECM mediated anti senescent effect. Collagen type I, rather than fibronectin, partially contributed to the protective effect of decellularized matrix. These findings provide a new strategy of using stem cell deposited matrix to overcome the challenge of cellular senescence and to facilitate the clinical application of MSCs in regenerative medicine. Copyright (c) 2017 John Wiley & Sons, Ltd.
C1 [Zhou, Long; Chen, Xi; Zhu, Caihong; Si, Michelle; Jargstorf, Joseph; Li, Mao; Pan, Guoqing; Luo, Zong Ping; Yang, Huilin; He, Fan] Soochow Univ, Orthopaed Inst, Med Coll, Suzhou, Jiangsu, Peoples R China.
   [Zhou, Long; Liu, Tao; Li, Mao; Luo, Zong Ping; Yang, Huilin; He, Fan] Soochow Univ, Dept Orthopaed, Affiliated Hosp 1, Suzhou, Jiangsu, Peoples R China.
   [Chen, Xi] Soochow Univ, Sch Biol & Basic Med Sci, Med Coll, Suzhou, Jiangsu, Peoples R China.
   [Si, Michelle] Univ Waterloo, Dept Biol & Chem, Fac Sci, Waterloo, ON, Canada.
   [Jargstorf, Joseph] Univ Waterloo, Dept Biol, Fac Sci, Waterloo, ON, Canada.
   [Gong, Yihong] Sun Yat Sen Univ, Sch Engn, Guangzhou, Guangdong, Peoples R China.
   [Pei, Ming] West Virginia Univ, Dept Orthopaed, Stem Cell & Tissue Engn Lab, Morgantown, WV USA.
   [Pei, Ming] West Virginia Univ, Div Exercise Physiol, Morgantown, WV USA.
C3 Soochow University   China; Soochow University   China; Soochow
   University   China; University of Waterloo; University of Waterloo; Sun
   Yat Sen University; West Virginia University; West Virginia University
RP He, F (通讯作者)，Soochow Univ, Orthopaed Inst, 708 Renmin Rd, Suzhou 215007, Jiangsu, Peoples R China.
EM fanhe@suda.edu.cn
RI Pan, Guoqing/E 1445 2014; Pei, Ming/N 8175 2017; Liu, Tao/AIA 7232 2022
OI Pan, Guoqing/0000 0001 5187 796X; 
FU National Natural Science Foundation of China [31570978, 51203194,
   21574091, 51303120]; Natural Science Foundation of Jiangsu Province
   [BK20140323, BK20130335]; National Institutes of Health (NIH)
   [AR062763 01A1, AR067747 01A1]; Musculoskeletal Transplant Foundation
   (MTF); Priority Academic Program Development of Jiangsu Higher Education
   Institutions (PAPD)
FX The authors are grateful to Suzanne Danley (West Virginia University,
   USA) and Paula Sahyoun (University of Waterloo, Canada) for carefully
   reviewing and editing the manuscript. This work was supported by the
   National Natural Science Foundation of China (No. 31570978, No.
   51203194, No. 21574091, No. 51303120); the Natural Science Foundation of
   Jiangsu Province (No. BK20140323, No. BK20130335); the National
   Institutes of Health (NIH) (AR062763 01A1 and AR067747 01A1) and
   Established Investigator Grant from Musculoskeletal Transplant
   Foundation (MTF) to M.P.; and the Priority Academic Program Development
   of Jiangsu Higher Education Institutions (PAPD).
CR Borodkina A, 2014, AGING US, V6, P481, DOI 10.18632/aging.100673
   Brinckmann J, 2010, LAB INVEST, V90, P739, DOI 10.1038/labinvest.2010.49
   Cheng HC, 2011, MOL BIOL REP, V38, P5161, DOI 10.1007/s11033 010 0665 2
   Choi HR, 2011, AGING CELL, V10, P148, DOI 10.1111/j.1474 9726.2010.00654.x
   Drullion C, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.111
   Han LM, 2010, NUCLEIC ACIDS RES, V38, P7458, DOI 10.1093/nar/gkq609
   Hasegawa K, 2008, BIOCHEM BIOPH RES CO, V372, P51, DOI 10.1016/j.bbrc.2008.04.176
   He F, 2014, J ENDOCRINOL, V223, P167, DOI 10.1530/JOE 14 0430
   He F, 2013, J TISSUE ENG REGEN M, V7, P73, DOI 10.1002/term.505
   He H, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/578290
   Henrotin YE, 2003, OSTEOARTHR CARTILAGE, V11, P747, DOI 10.1016/S1063 4584(03)00150 X
   Hsieh JY, 2010, STEM CELLS DEV, V19, P1895, DOI 10.1089/scd.2009.0485
   Kefaloyianni E, 2006, CELL SIGNAL, V18, P2238, DOI 10.1016/j.cellsig.2006.05.004
   Kim JH, 2016, J TISSUE ENG REGEN M, V10, pE1, DOI 10.1002/term.1754
   Krishnamurthty J, 2004, J CLIN INVEST, V114, P1299, DOI 10.1172/JCI200422475
   Ksiazek K, 2009, REJUV RES, V12, P105, DOI 10.1089/rej.2009.0830
   Lai YL, 2010, STEM CELLS DEV, V19, P1095, DOI 10.1089/scd.2009.0217
   Li GR, 2010, J BIOL CHEM, V285, P5461, DOI 10.1074/jbc.M109.037127
   Li JT, 2014, BIOMATERIALS, V35, P642, DOI 10.1016/j.biomaterials.2013.09.099
   Li JT, 2012, TISSUE ENG PART B RE, V18, P270, DOI [10.1089/ten.TEB.2011.0583, 10.1089/ten.teb.2011.0583]
   Li M, 2009, ANAT REC, V292, P1107, DOI 10.1002/ar.20925
   Lin H, 2012, BIOMATERIALS, V33, P4480, DOI 10.1016/j.biomaterials.2012.03.012
   Linsley C, 2013, TISSUE ENG PT A, V19, P1416, DOI [10.1089/ten.TEA.2012.0523, 10.1089/ten.tea.2012.0523]
   Lou PJ, 2010, BIOMATERIALS, V31, P1568, DOI 10.1016/j.biomaterials.2009.11.048
   Mitchell KE, 2003, STEM CELLS, V21, P50, DOI 10.1634/stemcells.21 1 50
   Pei M, 2011, Eur Cell Mater, V22, P333
   Pei M, 2013, STEM CELLS DEV, V22, P889, DOI 10.1089/scd.2012.0495
   Shay JW, 2000, NAT REV MOL CELL BIO, V1, P72, DOI 10.1038/35036093
   Tavana O, 2010, CELL CYCLE, V9, P3328, DOI 10.4161/cc.9.16.12688
   Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092 8674(01)00527 X
   Vidal MA, 2012, STEM CELLS DEV, V21, P273, DOI 10.1089/scd.2010.0589
   Watt FM, 2013, NAT REV MOL CELL BIO, V14, P467, DOI 10.1038/nrm3620
   Ye K, 2015, NANO LETT, V15, P4720, DOI 10.1021/acs.nanolett.5b01619
   Yew TL, 2011, AGING CELL, V10, P349, DOI 10.1111/j.1474 9726.2011.00676.x
   Zhang Y, 2015, BIOMATERIALS, V64, P88, DOI 10.1016/j.biomaterials.2015.06.038
   Zhang Y, 2014, TISSUE ENG PART B RE, V20, P655, DOI [10.1089/ten.teb.2014.0014, 10.1089/ten.TEB.2014.0014]
   Zhou L, 2015, J PINEAL RES, V59, P190, DOI 10.1111/jpi.12250
NR 37
TC 31
Z9 36
U1 0
U2 44
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1932 6254
EI 1932 7005
J9 J TISSUE ENG REGEN M
JI J. Tissue Eng. Regen. Med.
PD FEB
PY 2018
VL 12
IS 2
BP E1008
EP E1021
DI 10.1002/term.2422
PG 14
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell
   Biology; Engineering, Biomedical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology; Engineering
GA FW3CY
UT WOS:000425184900031
PM 28107614
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Al Zube, L
   Breitbart, EA
   O'Connor, JP
   Parsons, JR
   Bradica, G
   Hart, CE
   Lin, SS
AF Al Zube, Loay
   Breitbart, Eric A.
   O'Connor, J. Patrick
   Parsons, J. Russell
   Bradica, Gino
   Hart, Charles E.
   Lin, Sheldon S.
TI Recombinant Human Platelet Derived Growth Factor BB (rhPDGF BB) and
   Beta Tricalcium Phosphate/Collagen Matrix Enhance Fracture Healing in a
   Diabetic Rat Model
SO JOURNAL OF ORTHOPAEDIC RESEARCH
LA English
DT Article
DE diabetes mellitus; fracture; BB Wistar rat; rhPDGF BB; drug delivery
ID OSTEOBLAST ENRICHED CULTURES; BONE FORMATION; PERIODONTAL REGENERATION;
   DEOXYRIBONUCLEIC ACID; COLLAGEN SYNTHESIS; FACTOR EXPRESSION; PARIETAL
   BONE; WISTAR RAT; PDGF BB; CELLS
AB Diabetes mellitus is a common systemic disease that has been associated with poor fracture healing outcomes. The mechanism through which diabetes impairs bone regeneration is unknown. One possible mechanism maybe related to either decreased or uncoordinated release of local growth factors at the fracture site. Indeed, previous studies have found reduced platelet derived growth factor (PDGF) levels in the fracture callus of diabetic rats, suggesting that local application of PDGF may overcome the negative effects of diabetes and promote fracture healing. To test this hypothesis, low (22 mu g) and high (75 nu g) doses of recombinant human PDGF BB (rhPDGF BB) were applied directly to femur fracture sites in BB Wistar diabetic rats that were then compared to untreated or vehicle treated animals. rhPDGF BB treatment significantly increased early callus cell proliferation compared to that in control specimens. Low dose rhPDGF BB treatment significantly increased callus peak torque values (p < 0.05) at 8 weeks after fracture as compared to controls. High dose rhPDGF BB treatment increased callus bone area at 12 weeks postfracture. These data indicate that rhPDGF BB treatment ameliorates the effects of diabetes on fracture healing by promoting early cellular proliferation that ultimately leads to more bone formation. Local application of rhPDGF BB may be a new therapeutic approach to treat diabetes impaired fracture healing. (C) 2009 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 27:1074 1081, 2009
C1 [Al Zube, Loay; Breitbart, Eric A.; O'Connor, J. Patrick; Parsons, J. Russell; Lin, Sheldon S.] Univ Med & Dent New Jersey, New Jersey Med Sch, Newark, NJ 07103 USA.
   [Al Zube, Loay; Breitbart, Eric A.; O'Connor, J. Patrick; Parsons, J. Russell; Lin, Sheldon S.] Univ Med & Dent New Jersey, Grad Sch Biomed Sci, Newark, NJ 07103 USA.
   [Al Zube, Loay] New Jersey Inst Technol, Dept Biomed Engn, Newark, NJ 07102 USA.
   [Hart, Charles E.] BioMimet Therapeut Inc, Franklin, TN USA.
   [Bradica, Gino] Kensey Nash Corp, Exton, PA USA.
C3 Rutgers University System; Rutgers University New Brunswick; Rutgers
   University Biomedical & Health Sciences; Rutgers University System;
   Rutgers University New Brunswick; Rutgers University Biomedical & Health
   Sciences; New Jersey Institute of Technology
RP Lin, SS (通讯作者)，Univ Med & Dent New Jersey, New Jersey Med Sch, 185 S Orange Ave, Newark, NJ 07103 USA.
EM linss@umdnj.edu
RI ; Al Zube, Loay/LIC 1934 2024
OI Bradica, Gino/0009 0008 6336 1379; 
FU BioMimetic Therapeutics, Inc., Franklin, TN
FX This study was supported by BioMimetic Therapeutics, Inc., Franklin, TN.
   We thank Sharonda Meade, Vikrant Azad, Ann Marie Simon, and Markus
   Meyenhofer for their help throughout the study.
CR *AM DIAB ASS, DIAB STAT 2005
   Beam HA, 2002, J ORTHOPAED RES, V20, P1210, DOI 10.1016/S0736 0266(02)00066 9
   BEAM HA, 2002, ORTHOP RES SOC, V27
   Camelo M, 2003, INT J PERIODONT REST, V23, P213
   CANALIS E, 1989, J CELL PHYSIOL, V140, P530, DOI 10.1002/jcp.1041400319
   Carlevaro MF, 2000, J CELL SCI, V113, P59
   CENTRELLA M, 1989, ENDOCRINOLOGY, V125, P13, DOI 10.1210/endo 125 1 13
   CENTRELLA M, 1992, J CLIN INVEST, V89, P1076, DOI 10.1172/JCI115687
   Chaudhary LR, 2004, BONE, V34, P402, DOI 10.1016/j.bone.2003.11.014
   Chaudhary LR, 2000, J CELL BIOCHEM, V76, P354, DOI 10.1002/(SICI)1097 4644(20000301)76:3<354::AID JCB2>3.3.CO;2 L
   DOXEY DL, 1995, LIFE SCI, V57, P1111, DOI 10.1016/0024 3205(95)02056 O
   EINHORN TA, 1988, J ORTHOP RES, V6, P317, DOI 10.1002/jor.1100060303
   Fredriksson L, 2004, CYTOKINE GROWTH F R, V15, P197, DOI 10.1016/j.cytogfr.2004.03.007
   Funk JR, 2000, J ORTHOP RES, V18, P126, DOI 10.1002/jor.1100180118
   Gandhi A, 2006, BONE, V38, P540, DOI 10.1016/j.bone.2005.10.019
   Gandhi A, 2005, BONE, V37, P482, DOI 10.1016/j.bone.2005.04.039
   GANDHI A, 2002, ORTHOP RES SOC, V27
   Gilbertson DG, 2001, J BIOL CHEM, V276, P27406, DOI 10.1074/jbc.M101056200
   GROTENDORST GR, 1985, J CLIN INVEST, V76, P2323, DOI 10.1172/JCI112243
   Guo P, 2003, AM J PATHOL, V162, P1083, DOI 10.1016/S0002 9440(10)63905 3
   Hirschi KK, 1999, CIRC RES, V84, P298, DOI 10.1161/01.RES.84.3.298
   Hollinger JO, 2008, J ORTHOP RES, V26, P83, DOI 10.1002/jor.20453
   JOYCE ME, 1991, PROG CLIN BIOL RES, V365, P391
   KAWAGUCHI H, 1994, ENDOCRINOLOGY, V135, P774, DOI 10.1210/en.135.2.774
   KOENIG RJ, 1976, NEW ENGL J MED, V295, P417, DOI 10.1056/NEJM197608192950804
   Kortesidis A, 2005, BLOOD, V105, P3793, DOI 10.1182/blood 2004 11 4349
   Lu HF, 2003, ENDOCRINOLOGY, V144, P346, DOI 10.1210/en.2002 220072
   MACEY LR, 1989, J BONE JOINT SURG AM, V71A, P722, DOI 10.2106/00004623 198971050 00014
   MCCARTHY TL, 1989, ENDOCRINOLOGY, V125, P2118, DOI 10.1210/endo 125 4 2118
   NAKHOODA AF, 1977, DIABETES, V26, P100, DOI 10.2337/diabetes.26.2.100
   Nevins M, 2005, J PERIODONTOL, V76, P2205, DOI 10.1902/jop.2005.76.12.2205
   Nevins M, 2003, J PERIODONTOL, V74, P1282, DOI 10.1902/jop.2003.74.9.1282
   Perlman MH, 1999, FOOT ANKLE INT, V20, P491, DOI 10.1177/107110079902000805
   Reddy G, 2001, DIABETES RES CLIN PR, V54, P1, DOI 10.1016/S0168 8227(01)00273 X
   ROSS R, 1979, HORMONES CELL CULTUR, P3
   RYDZIEL S, 1994, ENDOCRINOLOGY, V134, P2541, DOI 10.1210/en.134.6.2541
   Simon AM, 2002, J BONE MINER RES, V17, P963, DOI 10.1359/jbmr.2002.17.6.963
   SLATER M, 1995, J ORTHOP RES, V13, P655, DOI 10.1002/jor.1100130504
   Tanaka H, 2002, J ENDOCRINOL, V174, DOI 10.1677/joe.0.1740063
   TISDEL CL, 1995, FOOT ANKLE INT, V16, P332, DOI 10.1177/107110079501600604
   TOPPING RE, 1994, CLIN ORTHOP RELAT R, P220
   Tyndall WA, 2003, CLIN ORTHOP RELAT R, P319, DOI 10.1097/01.blo.0000048138.30533.e2
   WRAY JB, 1965, J SURG RES, V5, P479, DOI 10.1016/S0022 4804(65)80046 4
NR 43
TC 87
Z9 93
U1 0
U2 20
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0736 0266
EI 1554 527X
J9 J ORTHOP RES
JI J. Orthop. Res.
PD AUG
PY 2009
VL 27
IS 8
BP 1074
EP 1081
DI 10.1002/jor.20842
PG 8
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA 468UK
UT WOS:000267848200015
PM 19170096
OA Bronze
DA 2025 08 17
ER

PT J
AU Krauser, JA
   Jin, Y
   Walles, M
   Pfaar, U
   Sutton, J
   Wiesmann, M
   Graf, D
   Pflimlin Fritschy, V
   Wolf, T
   Camenisch, G
   Swart, P
AF Krauser, Joel A.
   Jin, Yi
   Walles, Markus
   Pfaar, Ulrike
   Sutton, James
   Wiesmann, Marion
   Graf, Daniel
   Pflimlin Fritschy, Veronique
   Wolf, Thierry
   Camenisch, Gian
   Swart, Piet
TI Phenotypic and metabolic investigation of a CSF 1R kinase receptor
   inhibitor (BLZ945) and its pharmacologically active metabolite
SO XENOBIOTICA
LA English
DT Article
DE Contribution ratio; enzyme phenotyping; in vitro clearance; in vitro
   metabolism; metabolic isomerization
ID IN VITRO METABOLISM; HUMAN LIVER; CARBONYL REDUCTASES;
   4 METHYLNITROSAMINO 1 (3 PYRIDYL) 1 BUTANONE NNK; ENZYMES; MICROSOMES;
   CARCINOGENS; ACTIVATION; REDUCTION; RELEVANCE
AB 1. 4 [2((1R 2R) 2 Hydroxycyclohexylamino) benzothiazol 6 yloxyl] pyridine 2 carboxylic acid methylamide (BLZ945) is a small molecule inhibitor of CSF 1R kinase activity within osteoclasts designed to prevent skeletal related events in metastatic disease. Key metabolites were enzymatically and structurally characterized to understand the metabolic fate of BLZ945 and pharmacological implications. The relative intrinsic clearances for metabolites were derived from in vitro studies using human hepatocytes microsomes and phenotyped with recombinant P450 enzymes.
   2. Formation of a pharmacologically active metabolite (M9) was observed in human hepatocytes. The M9 metabolite is a structural isomer (diastereomer) of BLZ945 and is about 4 fold less potent. This isomer was enzymatically formed via P450 oxidation of the BLZ945 hydroxyl group followed by aldo keto reduction to the alcohol (M9).
   3. Two reaction phenotyping approaches based on fractional clearances were applied to BLZ945 using hepatocytes and liver microsomes. The fraction metabolized (fm) or contribution ratio was determined for each metabolic reaction type (oxidation glucuronidation or isomerization) as well as for each metabolite. The results quantitatively illustrate contribution ratios of the involved enzymes and pathways e. g. the isomerization to metabolite M9 accounted for 24% intrinsic clearance in human hepatocytes. In summary contribution ratios for the Phase I and Phase II pathways can be determined in hepatocytes.
C1 [Krauser, Joel A.; Jin, Yi; Walles, Markus; Graf, Daniel; Pflimlin Fritschy, Veronique; Wolf, Thierry; Camenisch, Gian; Swart, Piet] Novartis Inst BioMed Res, Dept Drug Metab & Pharmacokinet, Basel, Switzerland.
   [Pfaar, Ulrike] Novartis Oncol, Dept Clin Pharmacol, Basel, Switzerland.
   [Sutton, James] Novartis Inst BioMed Res, Dept Global Discovery Chem, Emeryville, CA USA.
   [Wiesmann, Marion] Novartis Inst BioMed Res, Dept Oncol Res, Basel, Switzerland.
C3 Novartis; Novartis; Novartis; Novartis USA; Novartis
RP Krauser, JA (通讯作者)，Novartis Pharma AG, NIBR DMPK Isotope Labs, WSJ 507 9 53, CH 4056 Basel, Switzerland.
EM Joel.krauser@novartis.com
CR [Anonymous], 2008, Guidance for industry safety testing of drug metabolites
   [Anonymous], 2009, Guidance Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals M3(R2)
   Atalla A, 2001, CHEM BIOL INTERACT, V130, P737, DOI 10.1016/S0009 2797(00)00304 5
   Atalla A, 2000, XENOBIOTICA, V30, P755, DOI 10.1080/00498250050119826
   Bauman DR, 2005, MOL PHARMACOL, V67, P60, DOI 10.1124/mol.104.006569
   Bjornsson TD, 2003, DRUG METAB DISPOS, V31, P815, DOI 10.1124/dmd.31.7.815
   Botta L., 1985, DRUG FATE METABOLISM, V5, P99
   Bousquet Melou A, 2002, XENOBIOTICA, V32, P895, DOI 10.1080/00498250210163261
   European Medicine Agency, 2012, GUID INV DRUG INT
   FDA, 2012, DRUG INT STUD DES DA
   GEBEL T, 1992, BIOCHEM PHARMACOL, V44, P2005, DOI 10.1016/0006 2952(92)90103 P
   Guengerich FP, 1996, J PHARMACOKINET BIOP, V24, P521, DOI 10.1007/BF02353478
   Jamieson SMF, 2014, BIOCHEM PHARMACOL, V88, P36, DOI 10.1016/j.bcp.2013.12.019
   Malátková P, 2010, CURR DRUG METAB, V11, P639, DOI 10.2174/138920010794233530
   NEWTON DJ, 1995, DRUG METAB DISPOS, V23, P154
   Obach RS, 1999, DRUG METAB DISPOS, V27, P1350
   Ogilvie BW., 2008, Drug Drug Interactions, P231
   Oppermann U, 2007, ANNU REV PHARMACOL, V47, P293, DOI 10.1146/annurev.pharmtox.47.120505.105316
   Palackal NT, 2002, J BIOL CHEM, V277, P24799, DOI 10.1074/jbc.M112424200
   Pyonteck SM, 2013, NAT MED, V19, P1264, DOI 10.1038/nm.3337
   Rowbotham SE, 2010, DRUG METAB DISPOS, V38, P1261, DOI 10.1124/dmd.109.030866
   SHIMADA T, 1994, J PHARMACOL EXP THER, V270, P414
   Stanley ER, 1997, MOL REPROD DEV, V46, P4, DOI 10.1002/(SICI)1098 2795(199701)46:1<4::AID MRD2>3.0.CO;2 V
   Stresser DM, 2004, DRUG METAB DISPOS, V32, P105, DOI 10.1124/dmd.32.1.105
   Sutton J, 2010, 239 ACS NAT M 2010 M
   Tong Z, 2010, DRUG METAB DISPOS, V38, P801, DOI 10.1124/dmd.110.032169
   Totah RA, 2005, CLIN PHARMACOL THER, V77, P341, DOI 10.1016/j.clpt.2004.12.267
   Tucker GT, 2001, BRIT J CLIN PHARMACO, V52, P107, DOI 10.1046/j.0306 5251.2001.temp.1441.x
   Varatharajan S, 2012, EUR J CLIN PHARMACOL, V68, P1577, DOI 10.1007/s00228 012 1291 9
   Wang T, 2011, INT J TOXICOL, V30, P300, DOI 10.1177/1091581811401920
   Wiesmann M, 2010, P 101 ANN M AM ASS C
   Yeo KR, 2004, BRIT J CLIN PHARMACO, V57, P687
   Zhang YY, 2009, XENOBIOTICA, V39, P283, DOI 10.1080/00498250802714907
   Zhu DM, 2010, PURE APPL CHEM, V82, P117, DOI 10.1351/PAC CON 09 01 03
NR 34
TC 32
Z9 36
U1 2
U2 33
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69 77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 0049 8254
EI 1366 5928
J9 XENOBIOTICA
JI Xenobiotica
PD FEB
PY 2015
VL 45
IS 2
BP 107
EP 123
DI 10.3109/00498254.2014.945988
PG 17
WC Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy; Toxicology
GA AX0NK
UT WOS:000346648700002
PM 25180976
DA 2025 08 17
ER

PT J
AU Mattheolabakis, G
   Mackenzie, GG
   Huang, LQ
   Ouyang, N
   Cheng, KW
   Rigas, B
AF Mattheolabakis, George
   Mackenzie, Gerardo G.
   Huang, Liqun
   Ouyang, Nengtai
   Cheng, Ka Wing
   Rigas, Basil
TI Topically Applied Phospho Sulindac Hydrogel is Efficacious and Safe in
   the Treatment of Experimental Arthritis in Rats
SO PHARMACEUTICAL RESEARCH
LA English
DT Article
DE arthritis; hydrogel; NSAIDs; phospho sulindac; transdermal
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; RHEUMATOID ARTHRITIS;
   AQUEOUS SOLUTIONS; SKIN PERMEATION; IBUPROFEN; OXT 328; DELIVERY;
   CANCER; RISK; GEL
AB Formulate phospho sulindac (P S, OXT 328) in a Pluronic hydrogel to be used as a topical anti inflammatory agent and study its efficacy, safety and pharmacokinetics in an arthritis model.
   LEW/crlBR rats with Freund's adjuvant induced arthritis were treated with P S formulated in Pluronic hydrogel (PSH). We determined the clinical manifestations of arthritis including the locomotor activity of the rats; evaluated joints for inflammation, bone resorption, cartilage damage, COX 2 expression and NF kappa B activation; assayed plasma IL 6 and IL 10 levels; and studied the pharmacokinetics of P S in rats after topical or oral administration.
   PSH applied at the onset of arthritis or when arthritis was fully developed, suppressed it by 56 82%, improved the locomotor activity of the rats 2.1 4.4 fold, suppressed synovial inflammation, bone resorption, cartilage damage, NF kappa B activation and COX 2 expression but not plasma IL 6 and IL 10 levels. There were no side effects. PSH produced rapidly high local levels of P S with < 14% of P S reaching the circulation, while orally administered P S was rapidly metabolized generating much lower joint levels of P S.
   Topical application of PSH is efficacious and safe in the treatment of Freund's adjuvant induced arthritis; has a favorable pharmacokinetic profile; and likely acts by suppressing key pro inflammatory signaling pathways.
C1 [Mattheolabakis, George; Mackenzie, Gerardo G.; Huang, Liqun; Ouyang, Nengtai; Cheng, Ka Wing; Rigas, Basil] SUNY Stony Brook, Dept Med, Canc Prevent Div, HSC, Stony Brook, NY 11794 USA.
C3 State University of New York (SUNY) System; Stony Brook University
RP Rigas, B (通讯作者)，SUNY Stony Brook, Dept Med, Canc Prevent Div, HSC, T17 080, Stony Brook, NY 11794 USA.
EM basil.rigas@stonybrookmedicine.edu
RI ; Mackenzie, Gerardo/AAW 5114 2020; Cheng, Ka/V 9433 2019
OI Mackenzie, Gerardo/0000 0002 6460 7165; 
FU Department of Defense [W81XWH1110799]; National Institute of Health
   [R01CA139454]; NIH [R01CA139454]; DOD [W81XWH 11 1 0799]; U.S.
   Department of Defense (DOD) [W81XWH1110799] Funding Source: U.S.
   Department of Defense (DOD)
FX This work was supported by the Department of Defense grant W81XWH1110799
   and National Institute of Health grant R01CA139454. The authors have
   nothing to disclose except for BR, who has an equity position in Medicon
   Pharmaceuticals, Inc., and NO who is affiliated with the same.This work
   received financial support from NIH grant R01CA139454 and DOD grant
   W81XWH 11 1 0799. We also thank William and Jane Knapp for their
   support.
CR Ahnand KS, 2005, ANN NY ACAD SCI, V1056, P218
   Alamanos Y, 2005, AUTOIMMUN REV, V4, P130, DOI 10.1016/j.autrev.2004.09.002
   Alexandridis P, 1997, CURR OPIN COLLOID IN, V2, P478, DOI 10.1016/S1359 0294(97)80095 7
   Anderson BC, 2001, J CONTROL RELEASE, V70, P157, DOI 10.1016/S0168 3659(00)00341 2
   Anderson GD, 1996, J CLIN INVEST, V97, P2672, DOI 10.1172/JCI118717
   [Anonymous], AM J MED
   Bendele A, 1999, TOXICOL PATHOL, V27, P134, DOI 10.1177/019262339902700125
   Bendele A. M., 2001, Journal of Musculoskeletal & Neuronal Interactions, V1, P377
   Cabana A, 1997, J COLLOID INTERF SCI, V190, P307, DOI 10.1006/jcis.1997.4880
   Cheng KW, 2012, INT J ONCOL, V41, P1199, DOI 10.3892/ijo.2012.1577
   Eurenius E, 2005, ARTHRIT RHEUM ARTHR, V53, P48, DOI 10.1002/art.20924
   Farkouh ME, 2009, AM J CARDIOL, V103, P1227, DOI 10.1016/j.amjcard.2009.01.014
   Farrington K, 2009, TALANTA, V78, P653, DOI 10.1016/j.talanta.2008.12.013
   Foster B, 2009, LANGMUIR, V25, P6760, DOI 10.1021/la900298m
   Huang L, 2011, BRIT J PHARMACOL, V162, P1521, DOI 10.1111/j.1476 5381.2010.01162.x
   Huang LQ, 2010, CARCINOGENESIS, V31, P1982, DOI 10.1093/carcin/bgq149
   Huang ZJ, 2011, J PAIN, V12, P141, DOI 10.1016/j.jpain.2010.06.008
   Kalia YN, 2004, ADV DRUG DELIVER REV, V56, P619, DOI 10.1016/j.addr.2003.10.026
   LIONE A, 1995, REPROD TOXICOL, V9, P7, DOI 10.1016/0890 6238(94)00051 W
   Mackenzie GG, 2010, GASTROENTEROLOGY, V139, P1320, DOI 10.1053/j.gastro.2010.06.044
   Mattheolabakis G, 2010, INT J PHARMACEUT, V385, P187, DOI 10.1016/j.ijpharm.2009.10.033
   McGettigan P, 2006, JAMA J AM MED ASSOC, V296, P1633, DOI 10.1001/jama.296.13.jrv60011
   Naik, 2000, Pharm Sci Technol Today, V3, P318, DOI 10.1016/S1461 5347(00)00295 9
   Okur NÜ, 2011, INT J PHARMACEUT, V416, P136, DOI 10.1016/j.ijpharm.2011.06.026
   Pillai O, 2003, J CONTROL RELEASE, V89, P127, DOI 10.1016/S0168 3659(03)00094 4
   Prausnitz MR, 2004, NAT REV DRUG DISCOV, V3, P115, DOI 10.1038/nrd1304
   Rahme E, 2010, LANCET, V376, P146, DOI 10.1016/S0140 6736(10)60839 2
   Rainsford K. D., 1999, American Journal of Medicine, V107, p27S
   Ray WA, 2002, LANCET, V360, P1071, DOI 10.1016/S0140 6736(02)11131 7
   Rhee YS, 2008, INT J PHARMACEUT, V364, P14, DOI 10.1016/j.ijpharm.2008.07.029
   Roman Blas JA, 2006, OSTEOARTHR CARTILAGE, V14, P839, DOI 10.1016/j.joca.2006.04.008
   SCHMOLKA IR, 1972, J BIOMED MATER RES, V6, P571, DOI 10.1002/jbm.820060609
   Sostres C, 2010, BEST PRACT RES CL GA, V24, P121, DOI 10.1016/j.bpg.2009.11.005
   Taboada M, 2011, J CLIN ENDOCR METAB, V96, P3502, DOI 10.1210/jc.2011 1449
   Wan DH, 2010, ACTA PHYS CHIM SIN, V26, P3243, DOI 10.3866/PKU.WHXB20101207
   WANKA G, 1994, MACROMOLECULES, V27, P4145, DOI 10.1021/ma00093a016
   Whiteley P E, 2001, Curr Protoc Pharmacol, VChapter 5, DOI 10.1002/0471141755.ph0505s13
   Wong CC, 2012, J PHARMACOL EXP THER, V340, P422, DOI 10.1124/jpet.111.188508
   Xie G, 2012, BRIT J PHARMACOL, V165, P2152, DOI 10.1111/j.1476 5381.2011.01705.x
   Yerramsetty KM, 2010, INT J PHARMACEUT, V398, P83, DOI 10.1016/j.ijpharm.2010.07.029
NR 40
TC 11
Z9 13
U1 0
U2 19
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0724 8741
J9 PHARM RES DORDR
JI Pharm. Res.
PD JUN
PY 2013
VL 30
IS 6
BP 1471
EP 1482
DI 10.1007/s11095 012 0953 8
PG 12
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Pharmacology & Pharmacy
GA 142KF
UT WOS:000318795400003
PM 23483440
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Liu, Y
   Liu, HJ
   Li, M
   Zhou, PR
   Xing, XP
   Xia, WB
   Zhang, ZL
   Liao, E
   Chen, DC
   Liu, J
   Tao, T
   Wu, W
   Xu, L
AF Liu Yi
   Liu Haijuan
   Li Mei
   Zhou Peiran
   Xing Xiaoping
   Xia Weibo
   Zhang Zhenlin
   Liao Eryuan
   Chen Decai
   Liu Jian
   Tao Tianzun
   Wu Wen
   Xu Ling
TI Association of farnesyl diphosphate synthase polymorphisms and response
   to alendronate treatment in Chinese postmenopausal women with
   osteoporosis
SO CHINESE MEDICAL JOURNAL
LA English
DT Article
DE farnesyl diphosphate synthase polymorphism; alendronate; osteoporosis;
   pharmacogenomics
ID BONE MINERAL DENSITY; THERAPY; PHARMACOGENOMICS; FRACTURE; RISK; BSMI
AB Background Genetic factors are important in the pathogenesis of osteoporosis, but less is known about the genetic determinants of osteoporosis treatment. We aimed to explore the association between the gene polymorphisms of key enzyme farnesyl diphosphate synthase (FDPS) in mevalonate signaling pathway of osteoclast and response to alendronate therapy in osteoporotic postmenopausal women in China.
   Methods The study group comprised 639 postmenopausal women aged (62.2 +/  7.0) years with osteoporosis or osteopenia who had been randomly assigned to low dose group (70 mg/2w) or standard dose group (70 mg/w) of alendronate in this 1 year study. We identified allelic variant of the FDPS gene using the polymerase chain reaction and restriction enzyme Faul. Before and after treatment, serum levels of calcium, phosphate, alkaline phosphatase (ALP), cross linked C telopeptide of type I collagen (beta CTX) were detected. Bone mineral density (BMD) at lumbar spine and proximal femur was measured. The association was analyzed between the polymorphisms of FDPS gene and the changes of BMD, bone turnover biomarkers after the treatment.
   Results The FDPS rs2297480 polymorphisms were associated with baseline BMD at femoral neck, and patients with CC genotype had significantly higher baseline femoral neck BMD ((733.6 +/  84.1) mg/crn(2)) than those with AC genotypes ((703.0 +/  86.9) mg/cm(2)) and AA genotypes ((649.8 +/  62.4) mg/cm(2)) (P < 0.01). No significant difference in BMD at lumbar spine was observed among different genotypes of FDPS. The percentage change of serum ALP level was significantly lower in patients with CC genotype ( 22.9%) than that in those with AC genotype ( 24.1%) and AA genotype ( 29.8%) of FDPS after 12 months of alendronate treatment (P < 0.05). Neither percentage change of BMD nor beta CTX level after alendronate treatment had association with FDPS genotype.
   Conclusions FDPS gene was probably a candidate gene to predict femoral neck BMD at baseline. FDPS gene alleles could predict change percentage of ALP after treatment of alendronate, but possibly had no significant relationship with the responsiveness of BMD to alendronate therapy.
C1 [Liu Yi; Li Mei; Zhou Peiran; Xing Xiaoping; Xia Weibo] Chinese Acad Med Sci, Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Endocrinol,Key Lab Endocrinol,Minist Hlth, Beijing 100730, Peoples R China.
   [Xu Ling] Chinese Acad Med Sci, Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Obstet & Gynecol, Beijing 100730, Peoples R China.
   [Liu Haijuan] Peoples Hosp Liaocheng, Dept Endocrinol, Liaocheng 252002, Shandong, Peoples R China.
   [Zhang Zhenlin] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 6, Dept Osteoporosis & Bone Dis, Metab Bone Dis & Genet Res Unit, Shanghai 200233, Peoples R China.
   [Liao Eryuan] Cent S Univ, Xiangya Hosp 2, Inst Endocrinol & Metab, Changsha 410011, Hunan, Peoples R China.
   [Chen Decai] Sichuan Univ, West China Hosp, Osteoporosis Educ Ctr, Dept Endocrinol, Chengdu 610041, Sichuan, Peoples R China.
   [Liu Jian] Fourth Liberat Army Univ, Xijing Hosp, Dept Orthoped, Xian 710032, Shannxi, Peoples R China.
   [Tao Tianzun] Harbin Med Univ, Affiliated Hosp 2, Dept Orthoped, Harbin 150081, Heilongjiang, Peoples R China.
   [Wu Wen] Guangdong Gen Hosp, Dept Endocrinol, Guangzhou 510080, Guangdong, Peoples R China.
C3 Chinese Academy of Medical Sciences   Peking Union Medical College;
   Peking Union Medical College; Peking Union Medical College Hospital;
   Chinese Academy of Medical Sciences   Peking Union Medical College;
   Peking Union Medical College; Peking Union Medical College Hospital;
   Shanghai Jiao Tong University; Central South University; Sichuan
   University; Air Force Medical University; Harbin Medical University;
   Guangdong Academy of Medical Sciences & Guangdong General Hospital
RP Li, M (通讯作者)，Chinese Acad Med Sci, Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Endocrinol,Key Lab Endocrinol,Minist Hlth, Beijing 100730, Peoples R China.
EM limeilzh@sina.com
FU National Natural Science Foundation of China [81100623]; National Key
   Program of Clinical Science [WBYZ 2011 873]
FX This work was supported by grants from the National Natural Science
   Foundation of China (No. 81100623) and National Key Program of Clinical
   Science (No. WBYZ 2011 873).
CR Arko B, 2002, J STEROID BIOCHEM, V81, P147, DOI 10.1016/S0960 0760(02)00061 4
   Bergstrom JD, 2000, ARCH BIOCHEM BIOPHYS, V373, P231, DOI 10.1006/abbi.1999.1502
   Beukelman T, 2010, OSTEOPOROSIS INT, V21, P1573, DOI 10.1007/s00198 009 1114 8
   Choi HJ, 2010, YONSEI MED J, V51, P231, DOI 10.3349/ymj.2010.51.2.231
   Cummings SR, 2002, JAMA J AM MED ASSOC, V288, P1889, DOI 10.1001/jama.288.15.1889
   Evans WE, 2003, NEW ENGL J MED, V348, P538, DOI 10.1056/NEJMra020526
   Fang Y, 2006, BONE, V39, P938, DOI 10.1016/j.bone.2006.04.016
   Favus MJ, 2010, NEW ENGL J MED, V363, P2027, DOI 10.1056/NEJMct1004903
   Giroux S, 2007, BONE, V40, P1299, DOI 10.1016/j.bone.2007.01.004
   KANIS JA, 1994, J BONE MINER RES, V9, P1137, DOI 10.1002/jbmr.5650090802
   Levy ME, 2007, MATURITAS, V57, P247, DOI 10.1016/j.maturitas.2007.01.005
   MacDonald HM, 2001, J BONE MINER RES, V16, P1634, DOI 10.1359/jbmr.2001.16.9.1634
   Marini F, 2008, CURR MED RES OPIN, V24, P2609, DOI [10.1185/03007990802352894, 10.1185/03007990802352894 ]
   Meunier PJ, 2004, NEW ENGL J MED, V350, P459, DOI 10.1056/NEJMoa022436
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Olmos JM, 2012, PHARMACOGENOMICS J, V12, P227, DOI 10.1038/tpj.2010.88
   Palacios S, 2012, MATURITAS, V71, P194, DOI 10.1016/j.maturitas.2011.11.010
   Palomba S, 2003, CLIN ENDOCRINOL, V58, P365, DOI 10.1046/j.1365 2265.2003.01724.x
   Qureshi AM, 2002, CALCIFIED TISSUE INT, V70, P158, DOI 10.1007/s00223 001 1035 9
   Ralston SH, 2002, J CLIN ENDOCR METAB, V87, P2460, DOI 10.1210/jc.87.6.2460
   Rees Margaret, 2011, Menopause Int, V17, P50, DOI 10.1258/mi.2011.011013
   Riancho JA, 2012, PHARMACOGENOMICS, V13, P815, DOI [10.2217/PGS.12.50, 10.2217/pgs.12.50]
   Romanelli MG, 2009, GENOMICS, V93, P227, DOI 10.1016/j.ygeno.2008.11.002
   Saltman LH, 2005, J CELL PHYSIOL, V204, P871, DOI 10.1002/jcp.20329
   Silvestri S, 2006, MENOPAUSE, V13, P451, DOI 10.1097/01.gme.0000182804.14385.a2
   Weivoda MM, 2011, J CELL BIOCHEM, V112, P1506, DOI 10.1002/jcb.23087
NR 26
TC 9
Z9 13
U1 0
U2 7
PU MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI MUMBAI
PA B 9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR E, MUMBAI, 400075,
   INDIA
SN 0366 6999
J9 CHINESE MED J PEKING
JI Chin. Med. J.
PD FEB 20
PY 2014
VL 127
IS 4
BP 662
EP 668
DI 10.3760/cma.j.issn.0366 6999.20132382
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA AD8EE
UT WOS:000333498500013
PM 24534219
OA gold
DA 2025 08 17
ER

PT J
AU Shen, WR
   Kitaura, H
   Qi, JW
   Ogawa, S
   Ohori, F
   Noguchi, T
   Marahleh, A
   Nara, Y
   Adya, P
   Mizoguchi, I
AF Shen, Wei Ren
   Kitaura, Hideki
   Qi, Jiawei
   Ogawa, Saika
   Ohori, Fumitoshi
   Noguchi, Takahiro
   Marahleh, Aseel
   Nara, Yasuhiko
   Adya, Pramusita
   Mizoguchi, Itaru
TI Local administration of high dose diabetes medicine exendin 4 inhibits
   orthodontic tooth movement in mice
SO ANGLE ORTHODONTIST
LA English
DT Article
DE Diabetes; GLP 1; Exendin 4; Osteoclast; Orthodontic tooth movement
ID GLUCAGON LIKE PEPTIDE 1; RECEPTOR AGONIST; BETA CELL; GLP 1; EXPRESSION;
   APOPTOSIS
AB Objectives: To investigate the effects of exendin 4 on orthodontic tooth movement distance, root resorption, and expression levels of osteoclast related cytokines in a mouse model.
   Materials and Methods: A 10 g NiTi coil spring was placed between the anterior alveolar bone and upper left first molar of 8 week old male C57BL/6 mice. Twenty microliters of exendin 4 solution (containing 0.2 mu g, 4 mu g, or 20 mu g exendin 4) or phosphate buffered saline (PBS) were injected on the buccal side of the upper left first molar at 2 day intervals (4 mice per group). Mice were sacrificed on day 12; silicone impressions were taken to record tooth movement distance. The left maxillae of the PBS and 20 mu g exendin 4 groups were also excised for histological analysis and quantitative reverse transcription polymerase chain reaction analysis.
   Results: Orthodontic tooth movement distance was smaller in the 20 mu g exendin 4 group than in the PBS group (P < .01). Compared with the PBS grouP < the 20 mu g exendin 4 group showed lower osteoclast number (P < .05), odontoclast number (P < .05), and root resorption surface percentage (P < .05). Relative to maxillae with PBS injections, maxillae with 20 mu g exendin 4 injections had lower receptor activator of nuclear factor kappa B ligand (RANKL) mRNA expression (P < .05), TNF alpha mRNA expression (P < .05), and RANKL/osteoprotegerin (OPG) ratio (P < .01). There were no differences in the expression of OPG mRNA.
   Conclusions: Exendin 4 inhibits orthodontic tooth movement. Therefore, additional attention is needed for orthodontic patients who receive exendin 4 for diabetes treatment. GLP 1 receptor may be a treatment target for patients with severe root resorption.
C1 [Shen, Wei Ren; Kitaura, Hideki; Qi, Jiawei; Ogawa, Saika; Ohori, Fumitoshi; Noguchi, Takahiro; Marahleh, Aseel; Nara, Yasuhiko; Adya, Pramusita; Mizoguchi, Itaru] Tohoku Univ, Grad Sch Dent, Div Orthodont & Dentofacial Orthoped, Sendai, Miyagi, Japan.
C3 Tohoku University
RP Kitaura, H (通讯作者)，Tohoku Univ, Grad Sch Dent, Div Orthodont & Dentofacial Orthoped, Dept Translat Med,Aoba Ku, 4 1 Seiryo Machi, Sendai, Miyagi 9808575, Japan.
EM hideki.kitaura.b4@tohoku.ac.jp
RI Kitaura, Hideki/AAS 8064 2020; Marahleh, Aseel/AHA 5443 2022; 齐,
   地质环境承载力/HRB 5861 2023
OI Marahleh, Aseel/0000 0002 4324 3155; 
FU JSPS KAKENHI grants from the Japan Society for the Promotion of Science
   [16K11776, 19K10397, 18K09862]; Grants in Aid for Scientific Research
   [20J14571, 19K10397, 18K09862, 16K11776] Funding Source: KAKEN
FX This work was supported in part by JSPS KAKENHI grants from the Japan
   Society for the Promotion of Science (Nos. 16K11776 and 19K10397 to HK
   and No. 18K09862 to IM).
CR Arakawa M, 2010, DIABETES, V59, P1030, DOI 10.2337/db09 1694
   Arakawa M, 2009, BIOCHEM BIOPH RES CO, V390, P809, DOI 10.1016/j.bbrc.2009.10.054
   Cao YY, 2015, CHINESE MED J PEKING, V128, P3211, DOI 10.4103/0366 6999.170259
   Dorecka M, 2013, PHARMACOL REP, V65, P884, DOI 10.1016/S1734 1140(13)71069 7
   Drucker DJ, 2003, ENDOCRINOLOGY, V144, P5145, DOI 10.1210/en.2003 1147
   Fujimura Y, 2009, EUR J ORTHODONT, V31, P572, DOI 10.1093/ejo/cjp068
   Garber AJ, 2011, DIABETES CARE, V34, pS279, DOI 10.2337/dc11 s231
   Garczorz W, 2018, CARDIOVASC THER, V36, DOI 10.1111/1755 5922.12317
   Hakami Z, 2015, EUR J ORTHODONT, V37, P87, DOI 10.1093/ejo/cju016
   Kanzaki H, 2004, J DENT RES, V83, P920, DOI 10.1177/154405910408301206
   Kitaura H, 2008, J DENT RES, V87, P396, DOI 10.1177/154405910808700405
   Körner M, 2007, J NUCL MED, V48, P736, DOI 10.2967/jnumed.106.038679
   Lee YS, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/3094642
   Liu HH, 2019, INT IMMUNOPHARMACOL, V75, DOI 10.1016/j.intimp.2019.105801
   Lopatiene Kristina, 2008, Stomatologija, V10, P89
   Ma X, 2013, J BONE MINER RES, V28, P1641, DOI 10.1002/jbmr.1898
   Mansur SA, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00051
   Meng JR, 2016, STEM CELL REP, V6, P579, DOI 10.1016/j.stemcr.2016.02.002
   Mieczkowska A, 2013, BONE, V56, P337, DOI 10.1016/j.bone.2013.07.003
   Nuche Berenguer B, 2011, J ENDOCRINOL, V209, P203, DOI 10.1530/JOE 11 0015
   Nuche Berenguer B, 2009, CALCIFIED TISSUE INT, V84, P453, DOI 10.1007/s00223 009 9220 3
   Ogawa S, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0223989
   Pereira M, 2015, BONE, V81, P459, DOI 10.1016/j.bone.2015.08.006
   Pereira M, 2017, FRONT ENDOCRINOL, V8, DOI 10.3389/fendo.2017.00327
   Shen WR, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/5783639
   Standl E, 2019, EUR J PREV CARDIOL, V26, P7, DOI 10.1177/2047487319881021
   Tyrovola Joanna B, 2008, J Oral Sci, V50, P367
   Verna C, 2000, EUR J ORTHODONT, V22, P343, DOI 10.1093/ejo/22.4.343
   Wang N, 2017, CELL PHYSIOL BIOCHEM, V44, P1696, DOI 10.1159/000485776
   Wei Q, 2012, PEPTIDES, V37, P18, DOI 10.1016/j.peptides.2012.06.018
   Yamada C, 2008, ENDOCRINOLOGY, V149, P574, DOI 10.1210/en.2007 1292
   Yang CY, 2018, INT J ORAL SCI, V10, DOI 10.1038/s41368 017 0004 8
   Zhang YS, 2018, OSTEOPOROSIS INT, V29, P2639, DOI 10.1007/s00198 018 4649 8
NR 33
TC 7
Z9 8
U1 0
U2 9
PU E H ANGLE EDUCATION RESEARCH FOUNDATION, INC
PI NEWTON N
PA 1615 BEACON ST, NEWTON N, MA 02468 1507 USA
SN 0003 3219
EI 1945 7103
J9 ANGLE ORTHOD
JI Angle Orthod.
PD JAN
PY 2021
VL 91
IS 1
BP 111
EP 118
DI 10.2319/021320 103.1
PG 8
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA PH4AE
UT WOS:000600356900015
PM 33289799
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Lee, WY
   Li, N
   Lin, S
   Wang, B
   Lan, HY
   Li, G
AF Lee, Wayne Y.
   Li, Nan
   Lin, Sien
   Wang, Bin
   Lan, Hui Y.
   Li, Gang
TI miRNA 29b improves bone healing in mouse fracture model
SO MOLECULAR AND CELLULAR ENDOCRINOLOGY
LA English
DT Article
DE miR 29b 3p; Bone healing; Mouse fracture; Microbubble ultrasound system
ID MESENCHYMAL STEM CELLS; OSTEOGENIC DIFFERENTIATION; MORPHOGENETIC
   PROTEIN 2; GENE THERAPY; SAFETY; MINERALIZATION; ANGIOGENESIS;
   OSTEOBLASTS; INHIBITION; MICRORNAS
AB A number of miRNAs regulates bone remodeling and their levels in circulation were associated with bone fracture, however no miRNAs have yet been shown to improve fracture healing directly. This study aimed to investigate the effect of miR 29b 3p on mice femoral fracture healing through site specific delivery with microbubble ultrasound system. miR 29b 3p promoted osteogenesis of mouse bone marrow derived mesenchymal stem cells as indicated with quantitative real time polymerase chain reaction (qPCR) and Alizarin red S staining. Animal study showed that single injection of miR 29b 3p at week 2 post fracture improved healing outcome as indicated by significant decrease of callus width and area with radiographic analysis without causing significant weight loss. Static bone histomorphometry analysis showed that miR 29b 3p increased bone volume fraction (BV/TV), and micro computed tomography (micro CT) measurement showed increased BV/TV of high density bone and bone mineral density (BMD) of the callus. 3 point bending mechanical test showed improved relative stiffness. However, repeated injection of miR 29b 3p at weeks 2 and 3 did not result in additive therapeutic outcome, and caused increased total tissue volume and reduced BMD of the callus. This is the first report showing significant therapeutic effect of miR 29b 3p on femoral fracture healing through site specific delivery with microbubble ultrasound system. Further studies are warranted to investigate the underlying mechanisms and to refine the treatment protocol. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
C1 [Lee, Wayne Y.; Lin, Sien; Wang, Bin; Li, Gang] Chinese Univ Hong Kong, Fac Med, Dept Orthopaed & Traumatol, Hong Kong, Hong Kong, Peoples R China.
   [Lee, Wayne Y.; Lin, Sien; Wang, Bin; Li, Gang] Chinese Univ Hong Kong, Prince Wales Hosp, Li Ka Shing Inst Hlth Sci, Stem Cells & Regenerat Med Lab, Hong Kong, Hong Kong, Peoples R China.
   [Lee, Wayne Y.; Lin, Sien; Wang, Bin; Li, Gang] Chinese Univ Hong Kong, Fac Med, Lui Che Woo Inst Innovat Med, SMART Program, Hong Kong, Hong Kong, Peoples R China.
   [Li, Nan] Chinese Univ Hong Kong, Fac Med, Sch Biomed Sci, Hong Kong, Hong Kong, Peoples R China.
   [Lan, Hui Y.] Chinese Univ Hong Kong, Prince Wales Hosp, Li Ka Shing Inst Hlth Sci, Dept Med & Therapeut,Fac Med, Hong Kong, Hong Kong, Peoples R China.
C3 Chinese University of Hong Kong; Chinese University of Hong Kong; Prince
   of Wales Hospital; Chinese University of Hong Kong; Chinese University
   of Hong Kong; Chinese University of Hong Kong; Prince of Wales Hospital
RP Lee, WY (通讯作者)，Prince Wales Hosp, Li Ka Shing Inst Hlth Sci, Room 501, Shatin, Hong Kong, Peoples R China.
EM waynelee@ort.cuhk.edu.hk
RI Lee, Wayne YW/H 8298 2013; WANG, BIN/O 2346 2019; Lin, Sien/J 7773 2018;
   Lan, Hui yao/C 9734 2015; Lee, Wayne/H 8298 2013; Li, Gang/J 7830 2018;
   Lan, Hui/C 9734 2015
OI Lee, Wayne YW/0000 0002 0486 360X; WANG, BIN/0000 0002 1348 1494; Lin,
   Sien/0000 0002 7292 7062; Lan, Hui yao/0000 0003 4283 9755; Li,
   Gang/0000 0002 3981 2239; 
FU SMART program; Lui Che Woo Institute of Innovative Medicine; Faculty of
   Medicine; Chinese University of Hong Kong
FX This study was supported in part by SMART program, Lui Che Woo Institute
   of Innovative Medicine, Faculty of Medicine, The Chinese University of
   Hong Kong. This research project was made possible by resources donated
   by Lui Che Woo Foundation Limited.
CR Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002
   Bonauer A, 2009, SCIENCE, V324, P1710, DOI 10.1126/science.1174381
   Cao X, 2011, NAT MED, V17, P1344, DOI 10.1038/nm.2499
   Carragee EJ, 2011, SPINE J, V11, P471, DOI 10.1016/j.spinee.2011.04.023
   Chang PC, 2009, HUM GENE THER, V20, P486, DOI 10.1089/hum.2008.114
   Chen S, 2010, GENE THER, V17, P1411, DOI 10.1038/gt.2010.85
   Deiuliis JA, 2016, INT J OBESITY, V40, P88, DOI 10.1038/ijo.2015.170
   Delloye C, 2007, J BONE JOINT SURG BR, V89B, P574, DOI 10.1302/0301 620X.89B5.19039
   Deng Y, 2013, BIOMATERIALS, V34, P6717, DOI 10.1016/j.biomaterials.2013.05.042
   Dimitriou R, 2005, INJURY, V36, P1392, DOI 10.1016/j.injury.2005.07.019
   Dimitriou R, 2011, INJURY, V42, pS3, DOI 10.1016/j.injury.2011.06.015
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Eskildsen T, 2011, P NATL ACAD SCI USA, V108, P6139, DOI 10.1073/pnas.1016758108
   Evans CH, 2010, EXPERT REV MOL MED, V12, DOI 10.1017/S1462399410001493
   Gebeshuber CA, 2009, EMBO REP, V10, P400, DOI 10.1038/embor.2009.9
   Govender S, 2002, J BONE JOINT SURG AM, V84A, P2123, DOI 10.2106/00004623 200212000 00001
   Gregory CA, 2004, ANAL BIOCHEM, V329, P77, DOI 10.1016/j.ab.2004.02.002
   Hayes J, 2014, TRENDS MOL MED, V20, P460, DOI 10.1016/j.molmed.2014.06.005
   He YX, 2012, OSTEOPOROSIS INT, V23, P377, DOI 10.1007/s00198 011 1812 x
   Hwang HW, 2007, SCIENCE, V315, P97, DOI 10.1126/science.1136235
   Kapinas K, 2010, J BIOL CHEM, V285, P25221, DOI 10.1074/jbc.M110.116137
   Kapinas K, 2009, J CELL BIOCHEM, V108, P216, DOI 10.1002/jcb.22243
   Kusenda Branislav, 2006, Biomedical Papers (Olomouc), V150, P205
   Kwong FNK, 2008, J AM ACAD ORTHOP SUR, V16, P619, DOI 10.5435/00124635 200811000 00001
   Lan HY, 2012, SEMIN NEPHROL, V32, P236, DOI 10.1016/j.semnephrol.2012.04.002
   Lee WYW, 2012, TISSUE ENG PT A, V18, P484, DOI [10.1089/ten.tea.2011.0130, 10.1089/ten.TEA.2011.0130]
   Li H, 2009, J CLIN INVEST, V119, P3666, DOI 10.1172/JCI39832
   Li ZY, 2009, J BIOL CHEM, V284, P15676, DOI 10.1074/jbc.M809787200
   Lian JB, 2012, NAT REV ENDOCRINOL, V8, P212, DOI 10.1038/nrendo.2011.234
   Liao YH, 2014, BIOMATERIALS, V35, P4901, DOI 10.1016/j.biomaterials.2014.02.055
   Lieberman JR, 1999, J BONE JOINT SURG AM, V81A, P905, DOI 10.2106/00004623 199907000 00002
   Liu Y, 2010, HYPERTENSION, V55, P974, DOI 10.1161/HYPERTENSIONAHA.109.144428
   Maegdefessel L, 2012, J CLIN INVEST, V122, P497, DOI 10.1172/JCI61598
   McKenzie JA, 2011, BONE, V48, P250, DOI 10.1016/j.bone.2010.09.005
   Morel DR, 2000, INVEST RADIOL, V35, P80, DOI 10.1097/00004424 200001000 00009
   Mott JL, 2007, ONCOGENE, V26, P6133, DOI 10.1038/sj.onc.1210436
   Murata K, 2014, J BONE MINER RES, V29, P316, DOI 10.1002/jbmr.2040
   Qin W, 2011, J AM SOC NEPHROL, V22, P1462, DOI 10.1681/ASN.2010121308
   Rossi M, 2013, J CELL PHYSIOL, V228, P1506, DOI 10.1002/jcp.24306
   Seeliger C, 2014, J BONE MINER RES, V29, P1718, DOI 10.1002/jbmr.2175
   Thomas CE, 2003, NAT REV GENET, V4, P346, DOI 10.1038/nrg1066
   Unger EC, 2004, ADV DRUG DELIVER REV, V56, P1291, DOI 10.1016/j.addr.2003.12.006
   Valentin Opran A, 2002, CLIN ORTHOP RELAT R, P110
   van Rooij E, 2012, NAT REV DRUG DISCOV, V11, P860, DOI 10.1038/nrd3864
   Viggeswarapu M, 2001, J BONE JOINT SURG AM, V83A, P364, DOI 10.2106/00004623 200103000 00008
   Waki TL S.Y., 2014, ORS ANN M NEW ORL LO
   Wang XG, 2013, NAT MED, V19, P93, DOI 10.1038/nm.3026
   Xie A, 2012, JACC CARDIOVASC IMAG, V5, P1253, DOI 10.1016/j.jcmg.2012.05.017
   Yin H, 2014, NAT REV GENET, V15, P541, DOI 10.1038/nrg3763
   Zhang JF, 2011, RNA BIOL, V8, P829, DOI 10.4161/rna.8.5.16043
NR 50
TC 47
Z9 50
U1 0
U2 22
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0303 7207
J9 MOL CELL ENDOCRINOL
JI Mol. Cell. Endocrinol.
PD JUL 15
PY 2016
VL 430
IS C
BP 97
EP 107
DI 10.1016/j.mce.2016.04.014
PG 11
WC Cell Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Endocrinology & Metabolism
GA DP4HO
UT WOS:000378457200010
PM 27113026
DA 2025 08 17
ER

PT J
AU Smith, BD
   Kaufman, MD
   Wise, SC
   Ahn, YM
   Caldwell, TM
   Leary, CB
   Lu, WP
   Tan, GG
   Vogeti, L
   Vogeti, S
   Wilky, BA
   Davis, LE
   Sharma, M
   Ruiz Soto, R
   Flynn, DL
AF Smith, Bryan D.
   Kaufman, Michael D.
   Wise, Scott C.
   Ahn, Yu Mi
   Caldwell, Timothy M.
   Leary, Cynthia B.
   Lu, Wei Ping
   Tan, Gege
   Vogeti, Lakshminarayana
   Vogeti, Subha
   Wilky, Breelyn A.
   Davis, Lara E.
   Sharma, Maitreyi
   Ruiz Soto, Rodrigo
   Flynn, Daniel L.
TI Vimseltinib: A Precision CSF1R Therapy for Tenosynovial Giant Cell
   Tumors and Diseases Promoted by Macrophages
SO MOLECULAR CANCER THERAPEUTICS
LA English
DT Article
ID KINASE INHIBITOR; CSF 1R INHIBITOR; TYROSINE KINASE; JNJ 40346527;
   EMACTUZUMAB; RESISTANCE; ANTIBODY; REVEALS; SAFETY; SERUM
AB Macrophages can be co opted to contribute to neoplastic, neurologic, and inflammatory diseases. Colony stimulating factor 1 receptor (CSF1R) dependent macrophages and other inflammatory cells can suppress the adaptive immune system in cancer and contribute to angiogenesis, tumor growth, and metastasis. CSF1R expressing osteoclasts mediate bone degradation in osteolytic cancers and cancers that metastasize to bone. In the rare disease tenosynovial giant cell tumor (TGCT), aberrant CSF1 expression and production driven by a gene translocation leads to the recruitment and growth of tumors formed by CSF1R dependent inflammatory cells. Small molecules and antibodies targeting the CSF1/CSF1R axis have shown promise in the treatment of TGCT and cancer, with pexidartinib recently receiving FDA approval for treatment of TGCT. Many small molecule kinase inhibitors of CSF1R also inhibit the closely related kinases KIT, PDGFRA, PDGFRB, and FLT3, thus CSF1R suppression may be limited by off target activity and associated adverse events. Vimseltinib (DCC 3014) is an oral, switch control tyrosine kinase inhibitor specifically designed to selectively and potently inhibit CSF1R by exploiting unique features of the switch control region that regulates kinase conformational activation. In preclinical studies, vimseltinib durably suppressed CSF1R activity in vitro and in vivo, depleted macrophages and other CSF1R dependent cells, and resulted in inhibition of tumor growth and bone degradation in mouse cancer models. Translationally, in a phase I clinical study, vimseltinib treatment led to modulation of biomarkers of CSF1R inhibition and reduction in tumor burden in TGCT patients.
C1 [Smith, Bryan D.; Kaufman, Michael D.; Wise, Scott C.; Ahn, Yu Mi; Caldwell, Timothy M.; Leary, Cynthia B.; Lu, Wei Ping; Tan, Gege; Vogeti, Lakshminarayana; Vogeti, Subha; Sharma, Maitreyi; Ruiz Soto, Rodrigo; Flynn, Daniel L.] Deciphera Pharmaceut LLC, Waltham, MA 02451 USA.
   [Wilky, Breelyn A.] Univ Colorado, Canc Ctr, Aurora, CO USA.
   [Davis, Lara E.] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA.
C3 University of Colorado System; University of Colorado Anschutz Medical
   Campus; Oregon Health & Science University
RP Flynn, DL (通讯作者)，Deciphera Pharmaceut LLC, Res & Dev, 200 Smith Rd, Waltham, MA 02451 USA.
EM dflynn@deciphera.com
FU Deciphera Pharmaceuticals, LLC
FX Wethank Benjamin Turner and Molly Hood for their contributions to enzyme
   and cell assay data. We thank Keisuke Kuida for his contributions to the
   phase 1 clinical trial. We thank Matthew Sherman for guidance and
   critical feedback. We thank Stacie Bulfer for assistance with the X ray
   co crystal structure. This work was funded by Deciphera Pharmaceuticals,
   LLC.
CR Ahn YM, 2010, BIOORG MED CHEM LETT, V20, P5793, DOI 10.1016/j.bmcl.2010.07.134
   Anastassiadis T, 2011, NAT BIOTECHNOL, V29, P1039, DOI 10.1038/nbt.2017
   Autio KA, 2020, CLIN CANCER RES, V26, P5609, DOI 10.1158/1078 0432.CCR 20 0855
   Bendell JC, 2013, MOL CANCER THER, V12, DOI 10.1158/1535 7163.TARG 13 A252
   Cannarile MA, 2017, J IMMUNOTHER CANCER, V5, DOI 10.1186/s40425 017 0257 y
   Cassier PA, 2020, EUR J CANCER, V141, P162, DOI 10.1016/j.ejca.2020.09.038
   Cassier PA, 2015, LANCET ONCOL, V16, P949, DOI 10.1016/S1470 2045(15)00132 1
   Chan WW, 2011, CANCER CELL, V19, P556, DOI 10.1016/j.ccr.2011.03.003
   Chen HJ, 2010, SPINE, V35, pE1339, DOI 10.1097/BRS.0b013e3181e574f5
   Czako B, 2020, J MED CHEM, V63, P9888, DOI 10.1021/acs.jmedchem.0c00936
   DeNardo DG, 2011, CANCER DISCOV, V1, P54, DOI 10.1158/2159 8274.CD 10 0028
   European Medicines Agency, 2020, COMM MED PROD HUM US, P144
   Fabian MA, 2005, NAT BIOTECHNOL, V23, P329, DOI 10.1038/nbt1068
   Gelderblom H, 2021, CANCER AM CANCER SOC, V127, P884, DOI 10.1002/cncr.33312
   Genovese MC, 2015, J RHEUMATOL, V42, P1752, DOI 10.3899/jrheum.141580
   Ho J, 2020, GENE CHROMOSOME CANC, V59, P96, DOI 10.1002/gcc.22807
   Kaufman MD, 2015, United States Patent and Trademark Office, Patent No. [9,181,223 B2, 9181223]
   Lamb YN, 2019, DRUGS, V79, P1805, DOI 10.1007/s40265 019 01210 0
   Machiels JP, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc 2020 001153
   Manthey CL, 2009, MOL CANCER THER, V8, P3151, DOI 10.1158/1535 7163.MCT 09 0255
   Mitchem JB, 2013, CANCER RES, V73, P1128, DOI 10.1158/0008 5472.CAN 12 2731
   Mun SH, 2020, EXP MOL MED, V52, P1239
   Papadopoulos KP, 2017, CLIN CANCER RES, V23, P5703, DOI 10.1158/1078 0432.CCR 16 3261
   Radi ZA, 2011, AM J PATHOL, V179, P240, DOI 10.1016/j.ajpath.2011.03.029
   Razak A, 2020, CONN TISS ONC SOC AN
   Razak ARA, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc 2020 001006
   Ries CH, 2014, CANCER CELL, V25, P846, DOI 10.1016/j.ccr.2014.05.016
   Ruffell B, 2015, CANCER CELL, V27, P462, DOI 10.1016/j.ccell.2015.02.015
   Sankhala KK, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.11078
   Sato T, 2011, BLOOD, V117, P3286, DOI 10.1182/blood 2010 01 266742
   Smith BD, 2019, CANCER CELL, V35, P738, DOI 10.1016/j.ccell.2019.04.006
   Smith BD, 2015, MOL CANCER THER, V14, P2023, DOI 10.1158/1535 7163.MCT 14 1105
   Spangenberg E, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 11674 z
   Tap WD, 2015, NEW ENGL J MED, V373, P428, DOI 10.1056/NEJMoa1411366
   Tap WD, 2019, LANCET, V394, P478, DOI 10.1016/S0140 6736(19)30764 0
   Taylor MH, 2019, MOL CANCER THER, V18, DOI 10.1158/1535 7163.TARG 19 C087
   von Tresckow B, 2015, CLIN CANCER RES, V21, P1843, DOI 10.1158/1078 0432.CCR 14 1845
   Wang T, 2011, INT J TOXICOL, V30, P300, DOI 10.1177/1091581811401920
   West RB, 2006, P NATL ACAD SCI USA, V103, P690, DOI 10.1073/pnas.0507321103
   Wyckoff JB, 2007, CANCER RES, V67, P2649, DOI 10.1158/0008 5472.CAN 06 1823
   Wynn TA, 2013, NATURE, V496, P445, DOI 10.1038/nature12034
   Zhang C, 2013, P NATL ACAD SCI USA, V110, P5689, DOI 10.1073/pnas.1219457110
NR 42
TC 40
Z9 42
U1 0
U2 14
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106 4404 USA
SN 1535 7163
EI 1538 8514
J9 MOL CANCER THER
JI Mol. Cancer Ther.
PD NOV
PY 2021
VL 20
IS 11
BP 2098
EP 2109
DI 10.1158/1535 7163.MCT 21 0361
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA WS6ID
UT WOS:000715281700002
PM 34433663
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Hannan, FM
   Walls, GV
   Babinsky, VN
   Nesbit, MA
   Kallay, E
   Hough, TA
   Fraser, WD
   Cox, RD
   Hu, JX
   Spiegel, AM
   Thakker, RV
AF Hannan, Fadil M.
   Walls, Gerard V.
   Babinsky, Valerie N.
   Nesbit, M. Andrew
   Kallay, Enikoe
   Hough, Tertius A.
   Fraser, William D.
   Cox, Roger D.
   Hu, Jianxin
   Spiegel, Allen M.
   Thakker, Rajesh V.
TI The Calcilytic Agent NPS 2143 Rectifies Hypocalcemia in a Mouse Model
   With an Activating Calcium Sensing Receptor (CaSR) Mutation: Relevance
   to Autosomal Dominant Hypocalcemia Type 1 (ADH1)
SO ENDOCRINOLOGY
LA English
DT Article
ID FUNCTIONAL CHARACTERIZATION; 7 TRANSMEMBRANE DOMAIN; ALLOSTERIC
   MODULATORS; PARATHYROID HORMONE; HUMAN CA2+; BONE; HYPERCALCIURIA;
   IDENTIFICATION; PHENOTYPES; SECRETION
AB Autosomal dominant hypocalcemia type 1 (ADH1) is caused by germline gain of function mutations of the calcium sensing receptor (CaSR) and may lead to symptomatic hypocalcemia, inappropriately low serum PTH concentrations and hypercalciuria. Negative allosteric CaSR modulators, known as calcilytics, have been shown to normalize the gain of function associated with ADH causing CaSR mutations in vitro and represent a potential targeted therapy for ADH1. However, the effectiveness of calcilytic drugs for the treatment of ADH1 associated hypocalcemia remains to be established. We have investigated NPS 2143, a calcilytic compound, for the treatment of ADH1 by in vitro and in vivo studies involving a mouse model, known as Nuf, which harbors a gain of function CaSR mutation, Leu723Gln. Wild type (Leu723) and Nuf mutant (Gln723) CaSRs were expressed in HEK293 cells, and the effect of NPS 2143 on their intracellular calcium responses was determined by flow cytometry. NPS 2143 was also administered as a single ip bolus to wild type and Nuf mice and plasma concentrations of calcium and PTH, and urinary calcium excretion measured. In vitro administration of NPS 2143 decreased the intracellular calcium responses of HEK293 cells expressing the mutant Gln723 CaSR in a dose dependent manner, thereby rectifying the gain of function associated with the Nuf mouse CaSR mutation. Intraperitoneal injection of NPS 2143 in Nuf mice led to significant increases in plasma calcium and PTH without elevating urinary calcium excretion. These studies of a mouse model with an activating CaSR mutation demonstrate NPS 2143 to normalize the gain of function causing ADH1 and improve the hypocalcemia associated with this disorder.
C1 [Hannan, Fadil M.; Walls, Gerard V.; Babinsky, Valerie N.; Nesbit, M. Andrew; Kallay, Enikoe; Thakker, Rajesh V.] Univ Oxford, Oxford Ctr Diabet Endocrinol & Metab, Radcliffe Dept Med, Acad Endocrine Unit, Oxford OX3 7LJ, England.
   [Hough, Tertius A.; Cox, Roger D.] MRC, Mammalian Genet Unit, Didcot OX11 0RD, Oxon, England.
   [Hough, Tertius A.; Cox, Roger D.] MRC Harwell, Mary Lyon Ctr, Didcot OX11 0RD, Oxon, England.
   [Fraser, William D.] Univ E Anglia, Dept Med, Norwich Med Sch, Norwich NR4 7TJ, Norfolk, England.
   [Hu, Jianxin] NIDDK, Bioorgan Chem Lab, Bethesda, MD 20892 USA.
   [Spiegel, Allen M.] Albert Einstein Coll Med, Bronx, NY 10461 USA.
C3 University of Oxford; MRC Harwell; MRC Harwell; University of East
   Anglia; National Institutes of Health (NIH)   USA; NIH National
   Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Yeshiva
   University; Montefiore Medical Center; Albert Einstein College of
   Medicine
RP Thakker, RV (通讯作者)，Churchill Hosp, Oxford Ctr Diabet Endocrinol & Metab, Radcliffe Dept Med, Acad Endocrine Unit, Oxford OX3 7LJ, England.
EM rajesh.thakker@ndm.ox.ac.uk
RI ; Hu, Jianxin/N 3498 2013; Walls, Gerard/I 5652 2019
OI Kallay, Eniko/0000 0002 4996 0104; Cox, Roger/0000 0001 7170 5014;
   Hannan, Fadil/0000 0002 2975 5170; Thakker, Rajesh/0000 0002 1438 3220
FU United Kingdom Medical Research Council [G9825289, G1000467]; National
   Institute for Health Research Oxford Biomedical Research Centre
   Programme; MRC [G9825289, MC_U142661184, G0501780, G1000467,
   MC_UP_1502/1, MR/K006312/1] Funding Source: UKRI; Medical Research
   Council [G9825289, MR/K006312/1, MC_U142661184, G1000467, MC_UP_1502/1,
   G0501780] Funding Source: researchfish; National Institute for Health
   Research [CL 2009 13 001] Funding Source: researchfish
FX This work was supported by the United Kingdom Medical Research Council
   Program Grants G9825289 and G1000467 (to M.A.N., F.M.H., and R.V.T.) and
   by the National Institute for Health Research Oxford Biomedical Research
   Centre Programme (M.A.N. and R.V.T.).
CR Breitwieser GE, 2014, PHARMACOL RES, V83, P30, DOI 10.1016/j.phrs.2013.11.006
   Dong BZ, 2015, J BONE MINER RES, V30, P1980, DOI 10.1002/jbmr.2551
   Drude S, 2011, LAB ANIMAL, V40, P119, DOI 10.1038/laban0411 119
   Gowen M, 2000, J CLIN INVEST, V105, P1595, DOI 10.1172/JCI9038
   Hannan FM, 2013, BEST PRACT RES CL EN, V27, P359, DOI 10.1016/j.beem.2013.04.007
   Hannan FM, 2012, HUM MOL GENET, V21, P2768, DOI 10.1093/hmg/dds105
   Harding B, 2009, ENDOCR RELAT CANCER, V16, P1313, DOI 10.1677/ERC 09 0082
   Hofer AM, 2003, NAT REV MOL CELL BIO, V4, P530, DOI 10.1038/nrm1154
   Hough TA, 2004, P NATL ACAD SCI USA, V101, P13566, DOI 10.1073/pnas.0405516101
   Hu JX, 2006, J BIOL CHEM, V281, P21558, DOI 10.1074/jbc.M603682200
   Hu JX, 2005, J BIOL CHEM, V280, P5113, DOI 10.1074/jbc.M413403200
   Huang Y, 2007, J BIOL CHEM, V282, P9517, DOI 10.1074/jbc.M609045200
   John MR, 2011, BONE, V49, P233, DOI 10.1016/j.bone.2011.04.007
   Kinoshita Y, 2014, J CLIN ENDOCR METAB, V99, pE363, DOI 10.1210/jc.2013 3430
   Kumar S, 2010, BONE, V46, P534, DOI 10.1016/j.bone.2009.09.028
   Leach K, 2013, ENDOCRINOLOGY, V154, P1105, DOI 10.1210/en.2012 1887
   Leach K, 2012, ENDOCRINOLOGY, V153, P4304, DOI 10.1210/en.2012 1449
   Letz S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115178
   Letz S, 2010, J CLIN ENDOCR METAB, V95, pE229, DOI 10.1210/jc.2010 0651
   Lia Baldini AS, 2013, EUR J ENDOCRINOL, V168, pK27, DOI 10.1530/EJE 12 0714
   Loupy A, 2012, J CLIN INVEST, V122, P3355, DOI 10.1172/JCI57407
   Miedlich SU, 2004, J BIOL CHEM, V279, P7254, DOI 10.1074/jbc.M307191200
   Nemeth EF, 2013, BEST PRACT RES CL EN, V27, P373, DOI 10.1016/j.beem.2013.02.008
   Nemeth EF, 2001, J PHARMACOL EXP THER, V299, P323
   Nesbit MA, 2013, NEW ENGL J MED, V368, P2476, DOI 10.1056/NEJMoa1300253
   Pearce SHS, 1996, J CLIN INVEST, V98, P1860, DOI 10.1172/JCI118987
   Pearce SHS, 1996, NEW ENGL J MED, V335, P1115, DOI 10.1056/NEJM199610103351505
   Petrel C, 2004, J BIOL CHEM, V279, P18990, DOI 10.1074/jbc.M400724200
   Raue F, 2011, CLIN ENDOCRINOL, V75, P760, DOI 10.1111/j.1365 2265.2011.04142.x
   Stechman MJ, 2010, LAB ANIM UK, V44, P218, DOI 10.1258/la.2010.009128
   Thim SB, 2014, ACTA PAEDIATR, V103, P1117, DOI 10.1111/apa.12743
   Vargas Poussou R, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000025781.16723.68
   Watanabe S, 2002, LANCET, V360, P692, DOI 10.1016/S0140 6736(02)09842 2
   Yamamoto M, 2000, J CLIN ENDOCR METAB, V85, P4583, DOI 10.1210/jc.85.12.4583
NR 34
TC 54
Z9 58
U1 0
U2 14
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0013 7227
EI 1945 7170
J9 ENDOCRINOLOGY
JI Endocrinology
PD SEP
PY 2015
VL 156
IS 9
BP 3114
EP 3121
DI 10.1210/en.2015 1269
PG 8
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA CS6ZV
UT WOS:000362234100009
PM 26052899
OA Green Published, Green Accepted, Green Submitted, hybrid
DA 2025 08 17
ER

PT B
AU Zwerina, J
   Redlich, K
   Schett, G
   Smolen, JS
AF Zwerina, J
   Redlich, K
   Schett, G
   Smolen, JS
BE Shoenfeld, Y
   Gershwin, ME
TI Pathogenesis of rheumatoid arthritis: Targeting cytokines
SO AUTOIMMUNE DISEASES AND TREATMENT: ORGAN SPECIFIC AND SYSTEMIC DISORDERS
SE Annals of the New York Academy of Sciences Series
LA English
DT Article; Proceedings Paper
CT 4th International Congress of Autoimmunity
CY NOV 03 08, 2004
CL Budapest, HUNGARY
DE rheumatoid arthritis; cytokines; TNF; IL 1; IL 6; IL 15; disease
   activity; joint damage; osteoclasts; therapy; anti TNF; IL 1ra;
   anti IL 6R (MRA)
ID TUMOR NECROSIS FACTOR; INTERLEUKIN 1 RECEPTOR ANTAGONIST;
   COLLAGEN INDUCED ARTHRITIS; PLACEBO CONTROLLED TRIAL; CARTILAGE PANNUS
   JUNCTION; CELL GROWTH FACTOR; LEUKEMIA INHIBITORY FACTOR; ALPHA
   MONOCLONAL ANTIBODY; ANTIGEN INDUCED ARTHRITIS; DOUBLE BLIND
AB Although considerable progress has been made by adequate treatment with traditional disease modifying antirheumatic drugs (DMARDs), therapy of rheumatoid arthritis (RA) still remains difficult. The discovery of the importance of cytokines such as tumor necrosis factor (TNF), interleukin 1 (IL 1), interleukin 6 (IL 6), and interleukin 15 (IL 15), which are also stimulated by consequences of autoimmune responses, has led to the development of anticytokine therapies ("biologicals"). Blocking TNF or also, to some extent, IL 1 has proved beneficial in DMARD resistant RA patients in multiple clinical trials. Along with clinical improvement, TNF blockade has been shown to halt radiographic disease progression, a major risk factor for disability. Recently, clinical trials have shown a significant therapeutic benefit of biological inhibitors of IL 6, and also of IL 15, with an efficacy comparable to that of TNF blockers. All these agents are particularly efficacious when combined with methotrexate. Although clinical remission is difficult to achieve even with anticytokine treatment, these drugs offer the potential to decrease disease activity and improve quality of life in a majority of RA patients, and it is conceivable that combinations of biological therapies may pave the path to even better success, which ultimately is remission or even cure.
C1 Med Univ Vienna, Div Rheumatol, A 1090 Vienna, Austria.
C3 Medical University of Vienna
RP Smolen, JS (通讯作者)，Med Univ Vienna, Div Rheumatol, Waehringer Guertel 18 20, A 1090 Vienna, Austria.
EM josef.smolen@wienkav.at
RI Smolen, Josef/ADI 7087 2022
CR Alleva DG, 1997, J IMMUNOL, V159, P2941
   Alonzi T, 1998, J EXP MED, V187, P461, DOI 10.1084/jem.187.4.461
   AREND WP, 1990, J CLIN INVEST, V85, P1694, DOI 10.1172/JCI114622
   BELLIDO T, 1995, J CLIN INVEST, V95, P2886, DOI 10.1172/JCI117995
   Bresnihan B, 1998, ARTHRITIS RHEUM, V41, P2196, DOI 10.1002/1529 0131(199812)41:12<2196::AID ART15>3.0.CO;2 2
   Campion GV, 1996, ARTHRITIS RHEUM, V39, P1092, DOI 10.1002/art.1780390704
   CARSON WE, 1994, J EXP MED, V180, P1395, DOI 10.1084/jem.180.4.1395
   Choy EHS, 2002, ARTHRITIS RHEUM US, V46, P3143, DOI 10.1002/art.10623
   CHU CQ, 1991, ARTHRITIS RHEUM, V34, P1125, DOI 10.1002/art.1780340908
   CHU CQ, 1992, BRIT J RHEUMATOL, V31, P653
   Clair EWS, 2004, ARTHRITIS RHEUM US, V50, P3432, DOI 10.1002/art.20568
   Cohen S, 2002, ARTHRITIS RHEUM, V46, P614, DOI 10.1002/art.10141
   Cohen SB, 2004, ANN RHEUM DIS, V63, P1062, DOI 10.1136/ard.2003.016014
   COOKE TD, 1975, ARTHRITIS RHEUM, V18, P541, DOI 10.1002/art.1780180603
   Coxon A, 2002, ARTHRITIS RHEUM, V46, P2604, DOI 10.1002/art.10546
   DEBETS JMH, 1988, J IMMUNOL, V141, P1197
   DELEURAN BW, 1992, BRIT J RHEUMATOL, V31, P801
   Dinarello CA, 2002, CLIN EXP RHEUMATOL, V20, pS1
   DINARELLO CA, 1991, BLOOD, V77, P1627
   DINARELLO CA, 1986, J EXP MED, V163, P1433, DOI 10.1084/jem.163.6.1433
   Doherty TM, 1996, J IMMUNOL, V156, P735
   FATTORI E, 1994, BLOOD, V83, P2570
   Ferrari Lacraz S, 2004, J IMMUNOL, V173, P5818, DOI 10.4049/jimmunol.173.9.5818
   FIRESTEIN GS, 1992, AM J PATHOL, V140, P1309
   FONTANA A, 1982, RHEUMATOL INT, V2, P49, DOI 10.1007/BF00541245
   Fox SW, 2000, J CELL PHYSIOL, V184, P334, DOI 10.1002/1097 4652(200009)184:3<334::AID JCP7>3.0.CO;2 U
   Genovese MC, 2002, ARTHRITIS RHEUM, V46, P1443, DOI 10.1002/art.10308
   GORONZY JJ, 1995, RHEUM DIS CLIN N AM, V21, P655
   Goya S, 2003, J PATHOL, V200, P82, DOI 10.1002/path.1321
   GRABSTEIN KH, 1994, SCIENCE, V264, P965, DOI 10.1126/science.8178155
   Gracie JA, 1999, J CLIN INVEST, V104, P1393, DOI 10.1172/JCI7317
   Gravallese EM, 2002, ANN RHEUM DIS, V61, P84, DOI 10.1136/ard.61.suppl_2.ii84
   GUERNE PA, 1989, J CLIN INVEST, V83, P585, DOI 10.1172/JCI113921
   Guler HP, 2001, ARTHRITIS RHEUM, V44, pS370
   HARAOUI B, 1991, ARTHRITIS RHEUM, V34, P153, DOI 10.1002/art.1780340205
   Hibi M, 1996, J MOL MED JMM, V74, P1, DOI 10.1007/BF00202068
   HILL RJ, 1991, BLOOD, V77, P42
   Horai R, 2000, J EXP MED, V191, P313, DOI 10.1084/jem.191.2.313
   HOUSSIAU FA, 1988, ARTHRITIS RHEUM US, V31, P784, DOI 10.1002/art.1780310614
   Hyrich KL, 2001, CURR OPIN RHEUMATOL, V13, P300, DOI 10.1097/00002281 200107000 00010
   IKEBUCHI K, 1987, P NATL ACAD SCI USA, V84, P9035, DOI 10.1073/pnas.84.24.9035
   ISHIBASHI T, 1989, P NATL ACAD SCI USA, V86, P5953, DOI 10.1073/pnas.86.15.5953
   Joosten LAB, 1999, J IMMUNOL, V163, P5049
   Jorgensen C, 1996, CLIN EXP IMMUNOL, V106, P20
   Kanegane H, 1996, BLOOD, V88, P230
   Katsume A, 2002, CYTOKINE, V20, P304, DOI 10.1006/cyto.2002.2012
   KEFFER J, 1991, EMBO J, V10, P4025, DOI 10.1002/j.1460 2075.1991.tb04978.x
   Kim JM, 2003, GENE THER, V10, P1543, DOI 10.1038/sj.gt.3302042
   Kobayashi M, 2005, ARTHRITIS RHEUM US, V52, P128, DOI 10.1002/art.20776
   Kudo O, 2003, BONE, V32, P1, DOI 10.1016/S8756 3282(02)00915 8
   KURIHARA N, 1990, J IMMUNOL, V144, P4226
   Lam J, 2000, J CLIN INVEST, V106, P1481, DOI 10.1172/JCI11176
   LEWTHWAITE J, 1995, ANN RHEUM DIS, V54, P366, DOI 10.1136/ard.54.5.366
   Lipsky PE, 2000, NEW ENGL J MED, V343, P1594, DOI 10.1056/NEJM200011303432202
   Lorenzo JA, 1998, ENDOCRINOLOGY, V139, P3022, DOI 10.1210/en.139.6.3022
   Maini R, 1999, LANCET, V354, P1932, DOI 10.1016/S0140 6736(99)05246 0
   Maini RN, 1998, ARTHRITIS RHEUM, V41, P1552, DOI 10.1002/1529 0131(199809)41:9<1552::AID ART5>3.0.CO;2 W
   MCINNES I, 2004, ANN M AM COLL RHEUM
   McInnes IB, 2004, CURR OPIN PHARMACOL, V4, P392, DOI 10.1016/j.coph.2004.04.003
   McInnes IB, 1997, NAT MED, V3, P189, DOI 10.1038/nm0297 189
   McInnes IB, 1996, NAT MED, V2, P175, DOI 10.1038/nm0296 175
   Mihara M, 2001, CLIN IMMUNOL, V98, P319, DOI 10.1006/clim.2000.4989
   Miranda Carús ME, 2004, J IMMUNOL, V173, P1463, DOI 10.4049/jimmunol.173.2.1463
   Moreland LW, 1999, ANN INTERN MED, V130, P478, DOI 10.7326/0003 4819 130 6 199903160 00004
   MullerLadner U, 1997, J IMMUNOL, V158, P3492
   Nishimoto N, 2004, ARTHRITIS RHEUM US, V50, P1761, DOI 10.1002/art.20303
   NISHIMOTO N, 1994, J EXP MED, V179, P1343, DOI 10.1084/jem.179.4.1343
   Nishimoto N, 2000, BLOOD, V95, P56, DOI 10.1182/blood.V95.1.56
   Ogata Y, 1999, J IMMUNOL, V162, P2754
   OKADA M, 1983, J EXP MED, V157, P583, DOI 10.1084/jem.157.2.583
   Okamoto H, 1997, ARTHRITIS RHEUM, V40, P1096, DOI 10.1002/art.1780400614
   Palmer G, 2003, EUR J IMMUNOL, V33, P434, DOI 10.1002/immu.200310018
   Partsch G, 1997, J RHEUMATOL, V24, P518
   PAVELKA K, 2002, ARTHRITIS RHEUM, V48, P281
   PERLMUTTER DH, 1986, J CLIN INVEST, V78, P1349, DOI 10.1172/JCI112721
   PETTIPHER ER, 1986, P NATL ACAD SCI USA, V83, P8749, DOI 10.1073/pnas.83.22.8749
   POLI V, 1994, EMBO J, V13, P1189, DOI 10.1002/j.1460 2075.1994.tb06368.x
   Quinn MA, 2005, ARTHRITIS RHEUM US, V52, P27, DOI 10.1002/art.20712
   RATHANASWAMI P, 1993, ARTHRITIS RHEUM, V36, P1295, DOI 10.1002/art.1780360914
   Redlich K, 2004, AM J PATHOL, V164, P543, DOI 10.1016/S0002 9440(10)63144 6
   Ruchatz H, 1998, J IMMUNOL, V160, P5654
   Sasai M, 1999, ARTHRITIS RHEUM, V42, P1635, DOI 10.1002/1529 0131(199908)42:8<1635::AID ANR11>3.0.CO;2 Q
   Schett G, 2003, ARTHRITIS RHEUM, V48, P2042, DOI 10.1002/art.11150
   SHERGY W, 2003, ANN RHEUM DIS S1, V62, P273
   Smolen JS, 2005, ARTHRITIS RHEUM, V52, P1020, DOI 10.1002/art.20982
   Smolen JS, 2003, NAT REV DRUG DISCOV, V2, P473, DOI 10.1038/nrd1109
   Steiner G, 1999, RHEUMATOLOGY, V38, P202, DOI 10.1093/rheumatology/38.3.202
   Steiner Gunter, 2002, Arthritis Res, V4 Suppl 2, pS1, DOI 10.1186/ar551
   SUEMATSU S, 1989, P NATL ACAD SCI USA, V86, P7547, DOI 10.1073/pnas.86.19.7547
   Sweeney SE, 2004, INT J BIOCHEM CELL B, V36, P372, DOI 10.1016/S1357 2725(03)00259 0
   Takagi N, 1998, ARTHRITIS RHEUM, V41, P2117, DOI 10.1002/1529 0131(199812)41:12<2117::AID ART6>3.3.CO;2 G
   TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167 5699(92)90116 O
   THORBECKE GJ, 1992, P NATL ACAD SCI USA, V89, P7375, DOI 10.1073/pnas.89.16.7375
   Thurkow EW, 1997, J PATHOL, V181, P444
   TOSATO G, 1988, SCIENCE, V239, P502, DOI 10.1126/science.2829354
   van de Putte BA, 2004, ANN RHEUM DIS, V63, P508, DOI 10.1136/ard.2003.013052
   van Vollenhoven R, 2003, ANN RHEUM DIS, V62, P1195, DOI 10.1136/ard.2003.009589
   VANDENBERG WB, 1994, CLIN EXP IMMUNOL, V95, P237
   WEICHSELBAUM A, 1878, ARCH PATHOL ANAT PHY, P461
   Weinblatt ME, 2003, ARTHRITIS RHEUM US, V48, P35, DOI 10.1002/art.10697
   WENDLING D, 1993, J RHEUMATOL, V20, P259
   WINCHESTER RJ, 1981, SPRINGER SEMIN IMMUN, V4, P89, DOI 10.1007/BF01857089
   WOOLEY PH, 1993, ARTHRITIS RHEUM, V36, P1305, DOI 10.1002/art.1780360915
   YOSHIZAKI K, 1989, BLOOD, V74, P1360
   YOSHIZAKI K, 1982, J IMMUNOL, V128, P1296
   Zwerina J, 2004, ARTHRITIS RHEUM, V50, P277, DOI 10.1002/art.11487
NR 106
TC 124
Z9 140
U1 0
U2 9
PU NEW YORK ACAD SCIENCES
PI NEW YORK
PA 2 EAST 63RD ST, NEW YORK, NY 10021 USA
BN 1 57331 612 1
J9 ANN NY ACAD SCI
JI Ann.NY Acad.Sci.
PY 2005
VL 1051
BP 716
EP 729
DI 10.1196/annals.1361.116
PG 14
WC Immunology; Multidisciplinary Sciences
WE Conference Proceedings Citation Index   Science (CPCI S); Science Citation Index Expanded (SCI EXPANDED)
SC Immunology; Science & Technology   Other Topics
GA BDG54
UT WOS:000233393100074
PM 16127012
DA 2025 08 17
ER

PT J
AU Pangrazio, A
   Fasth, A
   Sbardellati, A
   Orchard, PJ
   Kasow, KA
   Raza, J
   Albayrak, C
   Albayrak, D
   Vanakker, OM
   De Moerloose, B
   Vellodi, A
   Notarangelo, LD
   Schlack, C
   Strauss, G
   Kühl, JS
   Caldana, E
   Lo Iacono, N
   Susani, L
   Kornak, U
   Schulz, A
   Vezzoni, P
   Villa, A
   Sobacchi, C
AF Pangrazio, Alessandra
   Fasth, Anders
   Sbardellati, Andrea
   Orchard, Paul J.
   Kasow, Kimberly A.
   Raza, Jamal
   Albayrak, Canan
   Albayrak, Davut
   Vanakker, Olivier M.
   De Moerloose, Barbara
   Vellodi, Ashok
   Notarangelo, Luigi D.
   Schlack, Claire
   Strauss, Gabriele
   Kuehl, Joern Sven
   Caldana, Elena
   Lo Iacono, Nadia
   Susani, Lucia
   Kornak, Uwe
   Schulz, Ansgar
   Vezzoni, Paolo
   Villa, Anna
   Sobacchi, Cristina
TI SNX10 Mutations Define a Subgroup of Human Autosomal Recessive
   Osteopetrosis With Variable Clinical Severity
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE OSTEOPETROSIS; SNX10; VASTERBOTTEN; HSCT; DIAGNOSIS
ID MALIGNANT OSTEOPETROSIS; POOR; INVOLVEMENT; DISEASE; DOMAIN
AB Human Autosomal Recessive Osteopetrosis (ARO) is a genetically heterogeneous disorder caused by reduced bone resorption by osteoclasts. In 2000, we found that mutations in the TCIRG1 gene encoding for a subunit of the proton pump (V ATPase) are responsible for more than one half of ARO cases. Since then, five additional genes have been demonstrated to be involved in the pathogenesis of the disease, leaving approximately 25% of cases that could not be associated with a genotype. Very recently, a mutation in the sorting nexin 10 (SNX10) gene, whose product is suggested to interact with the proton pump, has been found in 3 consanguineous families of Palestinian origin, thus adding a new candidate gene in patients not previously classified. Here we report the identification of 9 novel mutations in this gene in 14 ARO patients from 12 unrelated families of different geographic origin. Interestingly, we define the molecular defect in three cases of Vasterbottenian osteopetrosis, named for the Swedish Province where a higher incidence of the disease has been reported. In our cohort of more than 310 patients from all over the world, SNX10 dependent ARO constitutes 4% of the cases, with a frequency comparable to the receptor activator of NF B ligand (RANKL), receptor activator of NF B (RANK) and osteopetrosis associated transmembrane protein 1 (OSTM1) dependent subsets. Although the clinical presentation is relatively variable in severity, bone seems to be the only affected tissue and the defect can be almost completely rescued by hematopoietic stem cell transplantation (HSCT). These results confirm the involvement of the SNX10 gene in human ARO and identify a new subset with a relatively favorable prognosis as compared to TCIRG1 dependent cases. Further analyses will help to better understand the role of SNX10 in osteoclast physiology and verify whether this protein might be considered a new target for selective antiresorptive therapies. (c) 2013 American Society for Bone and Mineral Research.
C1 [Pangrazio, Alessandra; Caldana, Elena; Lo Iacono, Nadia; Susani, Lucia; Vezzoni, Paolo; Villa, Anna; Sobacchi, Cristina] CNR, Unita Org Supporto, Ist Ric Genet & Biomed, Milan Unit, I 20133 Milan, Italy.
   [Pangrazio, Alessandra; Caldana, Elena; Lo Iacono, Nadia; Susani, Lucia; Vezzoni, Paolo; Villa, Anna; Sobacchi, Cristina] Humanitas Clin & Res Ctr, I 20089 Rozzano, MI, Italy.
   [Fasth, Anders] Univ Gothenburg, Dept Pediat, Div Immunol, Gothenburg, Sweden.
   [Sbardellati, Andrea] Ctr Ric Sviluppo & Studi Super Sardegna, Bioinformat Lab, Pula, Italy.
   [Orchard, Paul J.] Univ Minnesota, Dept Pediat, Div Pediat Bone Marrow Transplantat, Minneapolis, MN 55455 USA.
   [Kasow, Kimberly A.] Univ N Carolina, Div Pediat Hematol Oncol, Dept Pediat, Chapel Hill, NC USA.
   [Raza, Jamal] Natl Inst Child Hlth, Karachi, Pakistan.
   [Albayrak, Canan; Albayrak, Davut] Ondokuz Mayis Univ, Dept Pediat Hematol & Oncol, Samsun, Turkey.
   [Vanakker, Olivier M.] Ghent Univ Hosp, Ctr Med Genet, Ghent, Belgium.
   [De Moerloose, Barbara] Ghent Univ Hosp, Dept Pediat Hematol & Oncol, Ghent, Belgium.
   [Vellodi, Ashok] Great Ormond St Childrens Hosp, London, England.
   [Notarangelo, Luigi D.] Harvard Univ, Sch Med, Div Immunol, Childrens Hosp Boston, Boston, MA USA.
   [Schlack, Claire; Kornak, Uwe] Charite, Inst Med Genet & Human Genet, D 13353 Berlin, Germany.
   [Strauss, Gabriele; Kuehl, Joern Sven] Charite, Dept Pediat, D 13353 Berlin, Germany.
   [Schulz, Ansgar] Univ Med Ctr, Dept Pediat & Adolescent Med, Ulm, Germany.
C3 Consiglio Nazionale delle Ricerche (CNR); Istituto di Ricerca Genetica e
   Biomedica (IRGB CNR); IRCCS Humanitas Research Hospital; University of
   Gothenburg; University of Minnesota System; University of Minnesota Twin
   Cities; University of North Carolina; University of North Carolina
   Chapel Hill; Ondokuz Mayis University; Ghent University; Ghent
   University Hospital; Ghent University; Ghent University Hospital;
   University of London; University College London; Great Ormond Street
   Hospital for Children NHS Foundation Trust; Harvard University; Harvard
   Medical School; Harvard University Medical Affiliates; Boston Children's
   Hospital; Free University of Berlin; Humboldt University of Berlin;
   Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt
   University of Berlin; Charite Universitatsmedizin Berlin; Ulm University
RP Sobacchi, C (通讯作者)，Humanitas Clin & Res Ctr, Via Manzoni 113, I 20089 Rozzano, MI, Italy.
EM cristina.sobacchi@humanitasresearch.it
RI Susani, Lucia/HHM 4185 2022; De+Moerloose, Barbara/AAN 3298 2020;
   Sobacchi, Cristina/J 9345 2018; SOBACCHI, CRISTINA/J 9345 2018; Vezzoni,
   Paolo/R 3416 2019; Vanakker, Olivier/AAN 2900 2021; Notarangelo,
   Luigi/F 9718 2016; Fasth, Anders/I 1109 2019
OI Vezzoni, Paolo/0000 0002 6382 3923; Sobacchi,
   Cristina/0000 0002 2684 7184; Albayrak, Davut/0000 0002 7947 3817;
   Susani, Lucia/0000 0003 3368 2135; Fasth, Anders/0000 0002 0033 740X; De
   Moerloose, Barbara/0000 0002 2449 539X; Villa, Anna/0000 0003 4428 9013;
   
FU Telethon Foundation [GGP12178]; PRIN Project [200999KRFW 002]; Giovani
   Ricercatori from Ministero della Salute [GR 2008 1134625]; PNR CNR Aging
   Program
FX This work was partially supported by the Telethon Foundation (grant
   GGP12178 to CS); by the PRIN Project (200999KRFW 002 to PV); by Giovani
   Ricercatori from Ministero della Salute (grant GR 2008 1134625 to CS);
   and by PNR CNR Aging Program 2012 2014. This work was partially
   performed on behalf of the ESID and the Inborn Error Working Party of
   the EBMT. We are grateful to the affected individuals and their families
   for their cooperation. In particular, we thank the parents of patient 1
   for giving the consent to publish the pictures of their son. Richard
   Lovins (clinical research nurse) is acknowledged for his assistance with
   data collection. Dr Victoria Bordon (HSCT coordinator, Ghent University
   Hospital) and Dr David Creytens (Department of Pathology, Ghent
   University Hospital) are acknowledged for contributing clinical data and
   histological images on patient 9.
CR Aker M, 2012, J MED GENET, V49, P221, DOI 10.1136/jmedgenet 2011 100520
   Bliznetz EA, 2009, EUR J HUM GENET, V17, P664, DOI 10.1038/ejhg.2008.234
   Chen YQ, 2012, CELL RES, V22, P333, DOI 10.1038/cr.2011.134
   Fasth A, 2009, AM J HEMATOL, V84, P469, DOI 10.1002/ajh.21454
   Frattini A, 2003, J BONE MINER RES, V18, P1740, DOI 10.1359/jbmr.2003.18.10.1740
   Guerrini MM, 2008, AM J HUM GENET, V83, P64, DOI 10.1016/j.ajhg.2008.06.015
   Hecht J, 2007, GENE EXPR PATTERNS, V7, P102, DOI 10.1016/j.modgep.2006.05.014
   Humphreys K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022547
   Kornak U, 2001, CELL, V104, P205, DOI 10.1016/S0092 8674(01)00206 9
   Mazzolari E, 2009, AM J HEMATOL, V84, P473, DOI 10.1002/ajh.21447
   Pangrazio A, 2006, J BONE MINER RES, V21, P1098, DOI 10.1359/JBMR.060403
   Qin BM, 2006, J BIOL CHEM, V281, P36891, DOI 10.1074/jbc.M608884200
   Sobacchi C, 2001, HUM MOL GENET, V10, P1767, DOI 10.1093/hmg/10.17.1767
   Sobacchi C, 2007, NAT GENET, V39, P960, DOI 10.1038/ng2076
   Teasdale RD, 2012, BIOCHEM J, V441, P39, DOI 10.1042/BJ20111226
   Van Wesenbeeck L, 2007, J CLIN INVEST, V117, P919, DOI 10.1172/JCI30328
   Villa A, 2009, CALCIFIED TISSUE INT, V84, P1, DOI 10.1007/s00223 008 9196 4
   Worby CA, 2002, NAT REV MOL CELL BIO, V3, P919, DOI 10.1038/nrm974
   Zhou CZ, 2003, J BIOL CHEM, V278, P50371, DOI 10.1074/jbc.M304392200
   Zhu C, 2012, J CELL BIOCHEM, V113, P1608, DOI 10.1002/jcb.24029
NR 20
TC 48
Z9 56
U1 0
U2 10
PU WILEY BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD MAY
PY 2013
VL 28
IS 5
BP 1041
EP 1049
DI 10.1002/jbmr.1849
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 131VF
UT WOS:000318024300010
PM 23280965
DA 2025 08 17
ER

PT J
AU Kalantar Zadeh, K
   Kovesdy, CP
AF Kalantar Zadeh, Kamyar
   Kovesdy, Csaba P.
TI Clinical Outcomes with Active versus Nutritional Vitamin D
   Compounds in Chronic Kidney Disease
SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
LA English
DT Article
ID SERUM PARATHYROID HORMONE; SECONDARY HYPERPARATHYROIDISM;
   ALKALINE PHOSPHATASE; HEMODIALYSIS PATIENTS; BONE DISEASE; D DEFICIENCY;
   VASCULAR CALCIFICATION; MINERAL METABOLISM; IMPROVED SURVIVAL; DIALYSIS
   PATIENTS
AB Increasing confusion exists as to which vitamin D compounds are more appropriate for persons with chronic kidney disease (CKD). Some opinion based guidelines recommend administration of such nutritional vitamin D agents as ergocalciferol or cholecalciferol as the first therapy in hyperparathyroidism associated with low circulating levels of 25 hydroxy vitamin D (<30 ng/ml) in nondialysis dependent CKD patients. Insufficient to deficient levels of 25 hydroxy vitamin D have been reported in the majority of individuals with CKD, including both nondialysis dependent and maintenance dialysis patients. Epidemiologic studies have almost consistently indicated the survival benefit of active vitamin D agents across all stages of CKD, including among dialysis patients with 25 hydroxy vitamin D deficiency. To date, no large observational or interventional studies have shown any survival advantage of nutritional vitamin D in CKD patients. Several recent (postguideline) small studies have yielded mixed results regarding the potential benefits of ergocalciferol in CKD, including satisfactory to inadequate lowering of PTH level to target ranges, improving response to erythropoietin stimulating agents, and salutary effects on glycemic controls. Compared with nutritional vitamin D agents, active vitamin D compounds appear to more effectively lower the circulating levels of alkaline phosphatase, a conveniently available biomarker associated with increased mortality and coronary artery calcification in CKD patients. The ideal vitamin D therapy for CKD patients should be the one that improves survival irrespective of suggested or imposed target ranges for arbitrary or opinion based surrogate end points. Randomized controlled trials are needed to verify which agents offer superior survival advantages. Clin J Am Soc Nephrol 4: 1529 1539, 2009. doi: 10.2215/CJN.02140309
C1 [Kalantar Zadeh, Kamyar] Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, Harold Simmons Ctr Chron Dis Res & Epidemiol, Torrance, CA 90509 USA.
   [Kalantar Zadeh, Kamyar] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
   [Kalantar Zadeh, Kamyar] Univ Calif Los Angeles, Sch Publ Hlth, Dept Epidemiol, Los Angeles, CA 90095 USA.
   [Kovesdy, Csaba P.] Salem Vet Affairs Med Ctr, Div Nephrol, Salem, VA USA.
   [Kovesdy, Csaba P.] Univ Virginia, Dept Med, Charlottesville, VA USA.
C3 University of California System; University of California Los Angeles;
   University of California Los Angeles Medical Center; Lundquist
   Institute; University of California System; University of California Los
   Angeles; University of California Los Angeles Medical Center; David
   Geffen School of Medicine at UCLA; University of California System;
   University of California Los Angeles; US Department of Veterans Affairs;
   Veterans Health Administration (VHA); Salem Veterans Affairs Medical
   Center; University of Virginia
RP Kalantar Zadeh, K (通讯作者)，Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, Harold Simmons Ctr Chron Dis Res & Epidemiol, 1124 W Carson St,C1 Annex, Torrance, CA 90509 USA.
EM kamkal@ucla.edu
RI ; Kalantar Zadeh, Kamyar/Q 4734 2018
OI Kalantar Zadeh, Kamyar/0000 0002 8666 0725; 
FU NIDDK NIH HHS [R01 DK078106, R21 DK078012] Funding Source: Medline
CR Al Aly Z, 2007, AM J KIDNEY DIS, V50, P59, DOI 10.1053/j.ajkd.2007.04.010
   Andress Dennis L, 2008, Endocr Pract, V14, P18
   ANDRESS DL, 1989, NEW ENGL J MED, V321, P274, DOI 10.1056/NEJM198908033210502
   BAKER LRI, 1989, KIDNEY INT, V35, P661, DOI 10.1038/ki.1989.36
   BAKER LRI, 1986, CLIN NEPHROL, V26, P185
   Belozeroff V, 2009, CLIN J AM SOC NEPHRO, V4, P673, DOI 10.2215/CJN.03790808
   BERL T, 1978, ANN INTERN MED, V88, P774, DOI 10.7326/0003 4819 88 6 774
   Blair D, 2008, J RENAL NUTR, V18, P375, DOI 10.1053/j.jrn.2008.04.008
   Brown AJ, 1998, AM J KIDNEY DIS, V32, pS25, DOI 10.1053/ajkd.1998.v32.pm9808141
   Brown AJ, 2007, NAT CLIN PRACT ENDOC, V3, P134, DOI 10.1038/ncpendmet0394
   Chandra Prakash, 2008, Endocr Pract, V14, P10
   Coburn JW, 2004, AM J KIDNEY DIS, V43, P877, DOI 10.1053/j.ajkd.2004.01.012
   Coyne D, 2006, AM J KIDNEY DIS, V47, P263, DOI 10.1053/j.ajkd.2005.10.007
   DeVille J, 2006, NEPHROLOGY, V11, P555, DOI 10.1111/j.1440 1797.2006.00698.x
   Donadio C, 2007, CLIN NEPHROL, V67, P131
   Drüeke TB, 2007, CLIN J AM SOC NEPHRO, V2, P1106, DOI 10.2215/CJN.03140707
   DUKKIPATI R, 2009, J REN NUTR IN PRESS
   DUSSO AS, 1991, J CLIN ENDOCR METAB, V72, P157, DOI 10.1210/jcem 72 1 157
   Dusso AS, 2005, AM J PHYSIOL RENAL, V289, pF8, DOI 10.1152/ajprenal.00336.2004
   Eknoyan G, 2003, AM J KIDNEY DIS, V41, pS1, DOI 10.1016/S0272 6386(03)00111 2
   Fellström BC, 2009, NEW ENGL J MED, V360, P1395, DOI 10.1056/NEJMoa0810177
   Greenland S, 2000, INT J EPIDEMIOL, V29, P722, DOI 10.1093/ije/29.4.722
   Greenland S, 2008, AM J EPIDEMIOL, V167, P523, DOI 10.1093/aje/kwm355
   Gutiérrez OM, 2008, NEW ENGL J MED, V359, P584, DOI 10.1056/NEJMoa0706130
   Holick MF, 2007, NEW ENGL J MED, V357, P266, DOI 10.1056/NEJMra070553
   Holick MF, 2006, NEW ENGL J MED, V354, P2287
   Jean G, 2008, NEPHRON CLIN PRACT, V110, pC58, DOI 10.1159/000151534
   Jean G, 2008, NEPHROL DIAL TRANSPL, V23, P3670, DOI 10.1093/ndt/gfn339
   Jorge C, 2005, NEPHRON CLIN PRACT, V101, P122, DOI 10.1159/000086682
   Kalantar Zadeh K, 2007, KIDNEY INT, V71, P827, DOI 10.1038/sj.ki.5002208
   Kalantar Zadeh K, 2006, KIDNEY INT, V70, P771, DOI 10.1038/sj.ki.5001514
   Kalantar Zadeh K, 2007, NAT CLIN PRACT NEPHR, V3, P493, DOI 10.1038/ncpneph0570
   KALANTARZADEH K, 2009, AM J KIDNEY IN PRESS
   KALANTARZADEH K, 2009, KIDNEY IN S IN PRESS
   Kovesdy CP, 2008, KIDNEY INT, V73, P1355, DOI 10.1038/ki.2008.35
   Kovesdy CP, 2008, KIDNEY INT, V73, P1296, DOI 10.1038/ki.2008.64
   Kovesdy CP, 2008, CLIN J AM SOC NEPHRO, V3, P168, DOI 10.2215/CJN.03850907
   Kovesdy CP, 2008, INT UROL NEPHROL, V40, P427, DOI 10.1007/s11255 008 9346 7
   Kovesdy CP, 2008, ARCH INTERN MED, V168, P397, DOI 10.1001/archinternmed.2007.110
   Langub MC, 2003, ENDOCRINOLOGY, V144, P1135, DOI 10.1210/en.2002 221026
   Lee GH, 2007, J RENAL NUTR, V17, P38, DOI 10.1053/j.jrn.2006.07.006
   Levin A, 2007, KIDNEY INT, V71, P31, DOI 10.1038/sj.ki.5002009
   Lips P, 2001, J CLIN ENDOCR METAB, V86, P1212, DOI 10.1210/jc.86.3.1212
   Lomashvili KA, 2008, KIDNEY INT, V73, P1024, DOI 10.1038/ki.2008.26
   Lomashvili KA, 2004, J AM SOC NEPHROL, V15, P1392, DOI 10.1097/01.ASN.0000128955.83129.9C
   Lomashvili KA, 2005, J AM SOC NEPHROL, V16, P2495, DOI 10.1681/ASN.2004080694
   London GM, 2007, J AM SOC NEPHROL, V18, P613, DOI 10.1681/ASN.2006060573
   MALLUCHE HH, 1978, CLIN NEPHROL, V10, P219
   Martin KJ, 2005, KIDNEY INT, V68, P1236, DOI 10.1111/j.1523 1755.2005.00517.x
   Martin KJ, 1998, J AM SOC NEPHROL, V9, P1427
   Maung HM, 2001, AM J KIDNEY DIS, V37, P532
   MAXWELL DR, 1978, CLIN PHARMACOL THER, V23, P515
   Melamed ML, 2006, KIDNEY INT, V70, P351, DOI 10.1038/sj.ki.5001542
   Moe SM, 2001, AM J KIDNEY DIS, V38, P792, DOI 10.1053/ajkd.2001.27697
   Monier Faugere MC, 2007, CLIN J AM SOC NEPHRO, V2, P1255, DOI 10.2215/CJN.03461006
   MORINIERE P, 1985, NEPHRON, V39, P309, DOI 10.1159/000183396
   Nakai S, 2008, THER APHER DIAL, V12, P49, DOI 10.1111/j.1744 9987.2007.00540.x
   Naves Díaz M, 2008, KIDNEY INT, V74, P1070, DOI 10.1038/ki.2008.343
   O'Neill WC, 2006, CIRC RES, V99, pE2, DOI 10.1161/01.RES.0000234909.24367.a9
   Palmer SC, 2007, ANN INTERN MED, V147, P840, DOI 10.7326/0003 4819 147 12 200712180 00004
   PRZEDLACKI J, 1995, NEPHRON, V69, P433, DOI 10.1159/000188515
   Regidor DL, 2008, J AM SOC NEPHROL, V19, P2193, DOI 10.1681/ASN.2008010014
   Rubin MR, 2007, CLIN CHEM, V53, P1470, DOI 10.1373/clinchem.2007.085506
   SAAB G, 2008, NEPHRON DIAL TRANSPL, V105, pC132
   Sahota O, 1999, CLIN ENDOCRINOL, V51, P217, DOI 10.1046/j.1365 2265.1999.00764.x
   Salusky IB, 2004, PEDIATR NEPHROL, V19, P709, DOI 10.1007/s00467 004 1433 0
   SCHIBLER D, 1968, CLIN SCI, V35, P363
   Schoppet M, 2008, KIDNEY INT, V73, P989, DOI 10.1038/ki.2008.104
   Schumock GT, 2008, CURR MED RES OPIN, V24, P3037, DOI [10.1185/03007990802437943, 10.1185/03007990802437943 ]
   Shah N, 2005, PERITON DIALYSIS INT, V25, P362
   SHANTOUF R, 2009, CLIN J AM S IN PRESS
   Shimada T, 2004, BIOCHEM BIOPH RES CO, V314, P409, DOI 10.1016/j.bbrc.2003.12.102
   Shinaberger CS, 2008, CLIN J AM SOC NEPHRO, V3, P1769, DOI 10.2215/CJN.01760408
   Shoben AB, 2008, J AM SOC NEPHROL, V19, P1613, DOI 10.1681/ASN.2007111164
   Shoji T, 2004, NEPHROL DIAL TRANSPL, V19, P179, DOI 10.1093/ndt/gfg513
   Slatopolsky E, 2003, KIDNEY INT, V63, P2020, DOI 10.1046/j.1523 1755.2003.00029.x
   Teng M, 2005, J AM SOC NEPHROL, V16, P1115, DOI 10.1681/ASN.2004070573
   Teng M, 2003, NEW ENGL J MED, V349, P446, DOI 10.1056/NEJMoa022536
   Tentori F, 2006, KIDNEY INT, V70, P1858, DOI 10.1038/sj.ki.5001868
   Tentori F, 2009, NEPHROL DIAL TRANSPL, V24, P963, DOI 10.1093/ndt/gfn592
   Thomas MK, 1998, NEW ENGL J MED, V338, P777, DOI 10.1056/NEJM199803193381201
   Torres PU, 2002, KIDNEY INT, V61, P1178, DOI 10.1046/j.1523 1755.2002.00241 1.x
   Wanner C, 2005, NEW ENGL J MED, V353, P238, DOI 10.1056/NEJMoa043545
   Wolf M, 2007, KIDNEY INT, V72, P1004, DOI 10.1038/sj.ki.5002451
   Wolf M, 2008, J AM SOC NEPHROL, V19, P1379, DOI 10.1681/ASN.2007091002
   Zisman AL, 2007, AM J NEPHROL, V27, P36, DOI 10.1159/000098561
NR 86
TC 86
Z9 101
U1 0
U2 3
PU AMER SOC NEPHROLOGY
PI WASHINGTON
PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA
SN 1555 9041
EI 1555 905X
J9 CLIN J AM SOC NEPHRO
JI Clin. J. Am. Soc. Nephrol.
PD SEP
PY 2009
VL 4
IS 9
BP 1529
EP 1539
DI 10.2215/CJN.02140309
PG 11
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Urology & Nephrology
GA 492EI
UT WOS:000269637100020
PM 19661219
OA Bronze, Green Published
DA 2025 08 17
ER

PT J
AU Marcos, RL
   Leal, ECP
   Arnold, G
   Magnenet, V
   Rahouadj, R
   Wang, X
   Demeurie, F
   Magdalou, J
   de Carvalho, MHC
   Lopes Martins, RAB
AF Marcos, Rodrigo Labat
   Pinto Leal Junior, Ernesto Cesar
   Arnold, Gilles
   Magnenet, Vincent
   Rahouadj, Rachid
   Wang, Xiong
   Demeurie, Frank
   Magdalou, Jacques
   Catelli de Carvalho, Maria Helena
   Brandao Lopes Martins, Rodrigo Alvaro
TI Low level laser therapy in collagenase induced Achilles tendinitis in
   rats: Analyses of biochemical and biomechanical aspects
SO JOURNAL OF ORTHOPAEDIC RESEARCH
LA English
DT Article
DE anti inflammatory drugs; LLLT; phototherapy; tendon; biomechanics
ID GENE EXPRESSION; MATRIX METALLOPROTEINASES; SKELETAL MUSCLE;
   TENDON RUPTURE; NM; CELLS; PROSTAGLANDIN E 2; TENDINOPATHY; MMP 1; COX 2
AB NSAIDs are widely prescribed and used over the years to treat tendon injuries despite its well known long term side effects. In the last years several animal and human trials have shown that low level laser therapy (LLLT) presents modulatory effects on inflammatory markers, however the mechanisms involved are not fully understood. The aim of this study was to evaluate the short term effects of LLLT or sodium diclofenac treatments on biochemical markers and biomechanical properties of inflamed Achilles tendons. Wistar rats Achilles tendons (n?=?6/group) were injected with saline (control) or collagenase at peritendinous area of Achilles tendons. After 1?h animals were treated with two different doses of LLLT (810?nm, 1 and 3?J) at the sites of the injections, or with intramuscular sodium diclofenac. Regarding biochemical analyses, LLLT significantly decreased (p?<?0.05) COX 2, TNF a, MMP 3, MMP 9, and MMP 13 gene expression, as well as prostaglandin E2 (PGE2) production when compared to collagenase group. Interestingly, diclofenac treatment only decreased PGE2 levels. Biomechanical properties were preserved in the laser treated groups when compared to collagenase and diclofenac groups. We conclude that LLLT was able to reduce tendon inflammation and to preserve tendon resistance and elasticity. (c) 2012 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 30:19451951, 2012
C1 [Marcos, Rodrigo Labat; Brandao Lopes Martins, Rodrigo Alvaro] Univ Sao Paulo, Inst Biomed Sci, Dept Pharmacol, Lab Pharmacol & Expt Therapeut, BR 05508900 Sao Paulo, Brazil.
   [Marcos, Rodrigo Labat; Wang, Xiong; Magdalou, Jacques] Nancy Univ, CNRS, LPPIA, UMR 7561, Nancy, France.
   [Pinto Leal Junior, Ernesto Cesar; Brandao Lopes Martins, Rodrigo Alvaro] Nove de Julho Univ UNINOVE, Post Grad Program Biophoton Appl Hlth Sci, Sao Paulo, Brazil.
   [Pinto Leal Junior, Ernesto Cesar; Brandao Lopes Martins, Rodrigo Alvaro] Nove de Julho Univ UNINOVE, Post Grad Program Rehabil Sci, Sao Paulo, Brazil.
   [Arnold, Gilles] UHA, LPMT, EA 4365, F 68093 Mulhouse, France.
   [Magnenet, Vincent] Nancy Univ, CNRS, LEMTA, UMR 7563, F 54500 Vandoeuvre Les Nancy, France.
   [Rahouadj, Rachid; Demeurie, Frank] Nancy Univ, LAEGO ENSG, F 54500 Vandoeuvre Les Nancy, France.
   [Catelli de Carvalho, Maria Helena] Univ Sao Paulo, Inst Biomed Sci, Dept Pharmacol, Lab Hypertens, BR 05508900 Sao Paulo, Brazil.
C3 Universidade de Sao Paulo; Universite de Lorraine; Centre National de la
   Recherche Scientifique (CNRS); Universidade Nove de Julho; Universidade
   Nove de Julho; Universites de Strasbourg Etablissements Associes;
   Universite de Haute Alsace (UHA); Universite de Lorraine; Centre
   National de la Recherche Scientifique (CNRS); CNRS   Institute for
   Engineering & Systems Sciences (INSIS); Universite de Lorraine;
   Universidade de Sao Paulo; Institute Biomed Science, University Sao
   Paulo
RP Lopes Martins, RAB (通讯作者)，Univ Sao Paulo, Inst Biomed Sci, Dept Pharmacol, Lab Pharmacol & Expt Therapeut, Av Prof Lineu Prestes 1524, BR 05508900 Sao Paulo, Brazil.
EM rmartins@icb.usp.br
RI Lopes Martins, Rodrigo/E 2013 2013; Leal Junior, Ernesto
   Cesar/H 8920 2016; Arnold, Gilles/JXM 4315 2024; Lopes Martins, Rodrigo
   Alvaro/G 6972 2012; Marcos, Rodrigo/F 3524 2015
OI Lopes Martins, Rodrigo/0000 0002 4533 1335; Arnold,
   Gilles/0000 0002 8648 5058; Leal Junior, Ernesto
   Cesar/0000 0001 6393 7616; Lopes Martins, Rodrigo
   Alvaro/0000 0003 4942 988X; Pinto, Arnold/0000 0002 4583 2850
FU FAPESP [2009/02117 5]; Forte [2009 02117] Funding Source: Forte; Formas
   [2009 02117] Funding Source: Formas
FX Grant sponsor: This study was funded by a grant from FAPESP
   2009/02117 5.
CR Aimbire F, 2007, PHOTOMED LASER SURG, V25, P112, DOI 10.1089/pho.2006.1041
   Aimbire F, 2006, PHOTOMED LASER SURG, V24, P33, DOI 10.1089/pho.2006.24.33
   Albertini R, 2007, J PHOTOCH PHOTOBIO B, V89, P50, DOI 10.1016/j.jphotobiol.2007.08.005
   Albertini R, 2004, J PHOTOCH PHOTOBIO B, V74, P101, DOI 10.1016/j.jphotobiol.2004.03.002
   Almekinders LC, 1998, MED SCI SPORT EXER, V30, P1183, DOI 10.1097/00005768 199808000 00001
   Archambault J, 2002, J ORTHOPAED RES, V20, P36, DOI 10.1016/S0736 0266(01)00075 4
   Asundi KR, 2008, EUR J APPL PHYSIOL, V102, P265, DOI 10.1007/s00421 007 0582 9
   Bjordal JM, 2006, BRIT J SPORT MED, V40, P76, DOI 10.1136/bjsm.2005.020842
   Cilli F, 2004, CLIN J SPORT MED, V14, P232, DOI 10.1097/00042752 200407000 00006
   Correa F, 2007, PHOTOMED LASER SURG, V25, P245, DOI 10.1089/pho.2007.2079
   de Almeida P, 2011, PHOTOCHEM PHOTOBIOL, V87, P1159, DOI 10.1111/j.1751 1097.2011.00968.x
   Gan XD, 2001, J INTERF CYTOK RES, V21, P93, DOI 10.1089/107999001750069953
   Hemvani N, 2005, PHOTOMED LASER SURG, V23, P476, DOI 10.1089/pho.2005.23.476
   Hosaka YZ, 2010, BIOMED RES TOKYO, V31, P35, DOI 10.2220/biomedres.31.35
   HUSTON KA, 1994, NEW ENGL J MED, V331, P748, DOI 10.1056/NEJM199409153311116
   Karousou E, 2008, CLIN ORTHOP RELAT R, V466, P1577, DOI 10.1007/s11999 008 0255 y
   Kim CH, 2005, INT J BIOCHEM CELL B, V37, P375, DOI 10.1016/j.biocel.2004.07.013
   Kjær M, 2004, PHYSIOL REV, V84, P649, DOI 10.1152/physrev.00031.2003
   Lakemeier S, 2010, BMC MUSCULOSKEL DIS, V11, DOI 10.1186/1471 2474 11 271
   Marcos RL, 2011, PHOTOCHEM PHOTOBIOL, V87, P1447, DOI 10.1111/j.1751 1097.2011.00999.x
   Riley G, 2008, NAT CLIN PRACT RHEUM, V4, P82, DOI 10.1038/ncprheum0700
   Schnabel LV, 2009, J ORTHOP RES, V27, P1392, DOI 10.1002/jor.20887
   Sendzik J, 2010, INT J ANTIMICROB AG, V35, P366, DOI 10.1016/j.ijantimicag.2009.10.009
   Sendzik J, 2009, INT J ANTIMICROB AG, V33, P194, DOI 10.1016/j.ijantimicag.2008.08.004
   Smith AG, 1999, BRIT J SPORT MED, V33, P423, DOI 10.1136/bjsm.33.6.423
   Smith MM, 2008, ARTHRITIS RHEUM US, V58, P1055, DOI 10.1002/art.23388
   Thampatty BP, 2007, GENE, V386, P154, DOI 10.1016/j.gene.2006.08.027
   Thampatty BP, 2006, GENE, V372, P103, DOI 10.1016/j.gene.2005.12.013
   Tsai WC, 2010, J ORTHOP RES, V28, P487, DOI 10.1002/jor.21009
   Wang JHC, 2006, CLIN ORTHOP RELAT R, P320, DOI 10.1097/01.blo.0000195927.81845.46
   Yang GG, 2005, GENE, V363, P166, DOI 10.1016/j.gene.2005.08.006
NR 31
TC 63
Z9 68
U1 0
U2 14
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0736 0266
EI 1554 527X
J9 J ORTHOP RES
JI J. Orthop. Res.
PD DEC
PY 2012
VL 30
IS 12
BP 1945
EP 1951
DI 10.1002/jor.22156
PG 7
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA 027XO
UT WOS:000310387600011
PM 22674405
OA Bronze
DA 2025 08 17
ER

PT J
AU Lagadec, P
   Balaguer, T
   Boukhechba, F
   Michel, G
   Bouvet Gerbettaz, S
   Bouler, JM
   Scimeca, JC
   Rochet, N
AF Lagadec, Patricia
   Balaguer, Thierry
   Boukhechba, Florian
   Michel, Gregory
   Bouvet Gerbettaz, Sebastien
   Bouler, Jean Michel
   Scimeca, Jean Claude
   Rochet, Nathalie
TI Calcium supplementation decreases BCP induced inflammatory processes in
   blood cells through the NLRP3 inflammasome down regulation
SO ACTA BIOMATERIALIA
LA English
DT Article
DE Biphasic calcium phosphate; Blood; Coagulation; Calcium; Inflammation
ID IN VITRO; PHOSPHATE MICROPARTICLES; HUMAN OSTEOBLASTS; HUMAN MONOCYTES;
   ACTIVATION; DIFFERENTIATION; RESPONSES; P2X7; HYDROXYAPATITE;
   MACROPHAGES
AB Interaction of host blood with biomaterials is the first event occurring after implantation in a bone defect. This study aimed at investigating the cellular and molecular consequences arising at the interface between whole blood and biphasic calcium phosphate (BCP) particles. We observed that, due to calcium capture, BCP inhibited blood coagulation, and that this inhibition was reversed by calcium supplementation. Therefore, we studied the impact of calcium supplementation on BCP effects on blood cells. Comparative analysis of BCP and calcium supplemented BCP (BCP/Ca) effects on blood cells showed that BCP as well as BCP/Ca induced monocyte proliferation, as well as a weak but significant hemolysis. Our data showed for the first time that calcium supplementation of BCP microparticles had anti inflammatory properties compared to BCP alone that induced an inflammatory response in blood cells. Our results strongly suggest that the anti inflammatory property of calcium supplemented BCP results from its down modulating effect on P2X7R gene expression and its capacity to inhibit ATP/P2X7R interactions, decreasing the NLRP3 inflammasome activation. Considering that monocytes have a vast regenerative potential, and since the excessive inflammation often observed after bone substitutes implantation limits their performance, our results might have great implications in terms of understanding the mechanisms leading to an efficient bone reconstruction.
   Statement of significance
   Although scaffolds and biomaterials unavoidably come into direct contact with blood during bone defect filling, whole blood biomaterials interactions have been poorly explored. By studying in 3D the interactions between biphasic calcium phosphate (BCP) in microparticulate form and blood, we showed for the first time that calcium supplementation of BCP microparticles (BCP/Ca) has anti inflammatory properties compared to BCP induced inflammation in whole blood cells and provided information related to the molecular mechanisms involved. The present study also showed that BCP, as well as BCP/Ca particles stimulate monocyte proliferation. As monocytes represent a powerful target for regenerative therapies and as an excessive inflammation limits the performance of biomaterials in bone tissue engineering, our results might have great implications to improve bone reconstruction. (C) 2017 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
C1 [Lagadec, Patricia; Balaguer, Thierry; Boukhechba, Florian; Bouvet Gerbettaz, Sebastien; Scimeca, Jean Claude; Rochet, Nathalie] Univ Cote dAzur, CNRS, INSERM, iBV, Nice, France.
   [Balaguer, Thierry] Ctr Hosp Univ, Pole Chirurg Reparatrice & Osteo Articulaire, Nice, France.
   [Boukhechba, Florian] Graftys, Aix En Provence, France.
   [Michel, Gregory] Univ Cote dAzur, INSERM, C3M, Nice, France.
   [Bouler, Jean Michel] Univ Nantes, CNRS, UMR6230, CEISAM, Nantes, France.
C3 Centre National de la Recherche Scientifique (CNRS); Universite Cote
   d'Azur; Institut National de la Sante et de la Recherche Medicale
   (Inserm); CHU Nice; CHU de Toulouse; Institut National de la Sante et de
   la Recherche Medicale (Inserm); Universite Cote d'Azur; Centre National
   de la Recherche Scientifique (CNRS); CNRS   Institute of Chemistry
   (INC); Nantes Universite
RP Lagadec, P (通讯作者)，Univ Cote dAzur, iBV, Inst Biol Valrose, UFR Med,Tour Pasteur, 28 Ave Valombrose, F 06107 Nice 2, France.
EM lagadec@unice.fr
RI ROCHET, Nathalie/N 1819 2018; Scimeca, Jean Claude/P 3830 2016; ROCHET,
   Nathalie/S 3027 2019; Michel, Grégory/M 4124 2018; BOULER,
   Jean Michel/C 2099 2011; LAGADEC, Patricia/P 4538 2016; Michel,
   Gregory/M 4124 2018
OI ROCHET, Nathalie/0000 0002 9995 6699; Scimeca,
   Jean Claude/0000 0003 3773 6110; Michel, Gregory/0000 0002 6902 7514;
   BOULER, Jean Michel/0000 0001 9784 5584
FU l'Agence Nationale de la Recherche, France [ANR 2010 EMMA 032];
   "Fondation des gueules cassees", France [22 2015]; Foundation for Baltic
   and East European Studies [22/2015] Funding Source: Foundation for
   Baltic and East European Studies
FX This work was supported by funding from l'Agence Nationale de la
   Recherche, France (grant No. ANR 2010 EMMA 032] and from the "Fondation
   des gueules cassees", France (grant No. 22 2015).
CR Anderson JM, 2008, SEMIN IMMUNOL, V20, P86, DOI 10.1016/j.smim.2007.11.004
   Balaguer T, 2010, TISSUE ENG PT A, V16, P3495, DOI [10.1089/ten.tea.2010.0227, 10.1089/ten.TEA.2010.0227]
   Barbeck M, 2015, BIOMED MATER, V10, DOI 10.1088/1748 6041/10/5/055007
   Bauernfeind FG, 2009, J IMMUNOL, V183, P787, DOI 10.4049/jimmunol.0901363
   Benahmed M, 1996, BIOMATERIALS, V17, P2173, DOI 10.1016/0142 9612(96)00046 4
   Bouler J.M., 2017, ACTA BIOMATER
   Bouler JM, 2000, KEY ENG MAT, V192 1, P119, DOI 10.4028/www.scientific.net/KEM.192 195.119
   Browne S, 2015, FRONT BIOENG BIOTECH, V3, DOI 10.3389/fbioe.2015.00067
   Burke JR, 2003, CURR OPIN DRUG DI DE, V6, P720
   Cavagna R, 1999, J LONG TERM EFF MED, V9, P403
   Chen QX, 2014, INNATE IMMUN LONDON, V20, P290, DOI 10.1177/1753425913490575
   Cheng JD, 2005, J HEPATOL, V43, P465, DOI 10.1016/j.jhep.2005.02.033
   Cheng SW, 2013, HUM CELL, V26, P114, DOI 10.1007/s13577 012 0041 8
   Chevrier A, 2007, OSTEOARTHR CARTILAGE, V15, P316, DOI 10.1016/j.joca.2006.08.007
   Di Virgilio F, 2007, TRENDS PHARMACOL SCI, V28, P465, DOI 10.1016/j.tips.2007.07.002
   Engberg AE, 2015, BIOMATERIALS, V36, P55, DOI 10.1016/j.biomaterials.2014.09.011
   Fellah BH, 2010, J BIOMED MATER RES A, V93A, P1588, DOI 10.1002/jbm.a.32663
   Franceschini A, 2015, FASEB J, V29, P2450, DOI 10.1096/fj.14 268714
   Grandjean Laquerriere A, 2007, BIOMATERIALS, V28, P400, DOI 10.1016/j.biomaterials.2006.09.015
   Harada Y, 1996, J BIOMED MATER RES, V31, P19, DOI 10.1002/(SICI)1097 4636(199605)31:1<19::AID JBM3>3.3.CO;2 L
   Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704
   Huang S, 2016, BIOMATERIALS, V77, P111, DOI 10.1016/j.biomaterials.2015.10.067
   Jensen T, 2007, THROMB HAEMOSTASIS, V97, P822, DOI 10.1160/TH07 01 0039
   Kopf BS, 2015, ACTA BIOMATER, V19, P180, DOI 10.1016/j.actbio.2015.03.022
   Latz E, 2013, NAT REV IMMUNOL, V13, P397, DOI 10.1038/nri3452
   Lee GS, 2012, NATURE, V492, P123, DOI 10.1038/nature11588
   Levi M, 2010, CRIT CARE MED, V38, pS26, DOI 10.1097/CCM.0b013e3181c98d21
   Malard O, 1999, J BIOMED MATER RES, V46, P103, DOI 10.1002/(SICI)1097 4636(199907)46:1<103::AID JBM12>3.0.CO;2 Z
   Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097 2765(02)00599 3
   Mendonça R, 2016, INFLAMM RES, V65, P665, DOI 10.1007/s00011 016 0955 9
   Mouline CC, 2010, EUR CELLS MATER, V20, P379
   Mountziaris PM, 2008, TISSUE ENG PART B RE, V14, P179, DOI 10.1089/ten.teb.2008.0038
   Ogle ME, 2016, EXP BIOL MED, V241, P1084, DOI 10.1177/1535370216650293
   Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239
   Paul AJ, 2015, J BIOMED MATER RES A, V103, P2830, DOI 10.1002/jbm.a.35424
   Pazár B, 2011, J IMMUNOL, V186, P2495, DOI 10.4049/jimmunol.1001284
   Posner LJ, 1997, BONE, V21, P321, DOI 10.1016/S8756 3282(97)00154 3
   Ransford AO, 1998, J BONE JOINT SURG BR, V80B, P13, DOI 10.1302/0301 620X.80B1.7276
   Rice JM, 2003, CALCIFIED TISSUE INT, V72, P726, DOI 10.1007/s00223 002 2045 y
   Ross PE, 1997, J CELL BIOL, V138, P987, DOI 10.1083/jcb.138.5.987
   Samstad EO, 2014, J IMMUNOL, V192, P2837, DOI 10.4049/jimmunol.1302484
   Shiu HT, 2014, TISSUE ENG PART B RE, V20, P697, DOI [10.1089/ten.teb.2013.0709, 10.1089/ten.TEB.2013.0709]
   Sikora J, 2014, BLOOD, V124, P2150, DOI 10.1182/blood 2014 05 572024
   Soltan M, 2012, IMPLANT DENT, V21, P13, DOI 10.1097/ID.0b013e31823fcf85
   Stojanovic I, 2007, CLIN IMMUNOL, V123, P311, DOI 10.1016/j.clim.2007.03.004
   TAKEICHI M, 1977, J CELL BIOL, V75, P464, DOI 10.1083/jcb.75.2.464
   Vanaja SK, 2015, TRENDS CELL BIOL, V25, P308, DOI 10.1016/j.tcb.2014.12.009
   Wang X., 2016, J TISSUE ENG REGEN M
   Xia Z, 2006, BIOMED MATER, V1, pR1, DOI 10.1088/1748 6041/1/1/R01
   Yan ZH, 2011, J GEN PHYSIOL, V138, P437, DOI 10.1085/jgp.201110647
   Yang H, 2010, BBA GENE REGUL MECH, V1799, P149, DOI 10.1016/j.bbagrm.2009.11.019
   Yang J., 2015, CLIN ORAL IMPLANTS R
NR 52
TC 8
Z9 9
U1 0
U2 12
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1742 7061
EI 1878 7568
J9 ACTA BIOMATER
JI Acta Biomater.
PD JUL 15
PY 2017
VL 57
BP 462
EP 471
DI 10.1016/j.actbio.2017.05.039
PG 10
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA EZ9HY
UT WOS:000405041900040
PM 28528118
DA 2025 08 17
ER

PT J
AU Medici, D
   Shore, EM
   Lounev, VY
   Kaplan, FS
   Kalluri, R
   Olsen, BR
AF Medici, Damian
   Shore, Eileen M.
   Lounev, Vitali Y.
   Kaplan, Frederick S.
   Kalluri, Raghu
   Olsen, Bjorn R.
TI Conversion of vascular endothelial cells into multipotent stem like
   cells
SO NATURE MEDICINE
LA English
DT Article
ID TO MESENCHYMAL TRANSITION; FIBRODYSPLASIA OSSIFICANS PROGRESSIVA;
   GROWTH FACTOR BETA; ATRIOVENTRICULAR CUSHION TRANSFORMATION; CARDIAC
   FIBROSIS; PROGENITOR CELLS; EMBRYONIC HEART; BMP RECEPTOR;
   SKELETOGENESIS; MOUSE
AB Mesenchymal stem cells can give rise to several cell types, but varying results depending on isolation methods and tissue source have led to controversies about their usefulness in clinical medicine. Here we show that vascular endothelial cells can transform into multipotent stem like cells by an activin like kinase 2 (ALK2) receptor dependent mechanism. In lesions from individuals with fibrodysplasia ossificans progressiva (FOP), a disease in which heterotopic ossification occurs as a result of activating ALK2 mutations, or from transgenic mice expressing constitutively active ALK2, chondrocytes and osteoblasts expressed endothelial markers. Lineage tracing of heterotopic ossification in mice using a Tie2 Cre construct also suggested an endothelial origin of these cell types. Expression of constitutively active ALK2 in endothelial cells caused endothelial to mesenchymal transition and acquisition of a stem cell like phenotype. Similar results were obtained by treatment of untransfected endothelial cells with the ligands transforming growth factor beta 2 (TGF beta 2) or bone morphogenetic protein 4 (BMP4) in an ALK2 dependent manner. These stem like cells could be triggered to differentiate into osteoblasts, chondrocytes or adipocytes. We suggest that conversion of endothelial cells to stem like cells may provide a new approach to tissue engineering. (C) 2010 Nature America, Inc. All rights reserved.
C1 [Medici, Damian; Kalluri, Raghu] Harvard Univ, Beth Israel Deaconess Med Ctr, Div Matrix Biol, Sch Med,Dept Med, Boston, MA 02215 USA.
   [Shore, Eileen M.; Lounev, Vitali Y.; Kaplan, Frederick S.] Univ Penn, Sch Med, Dept Orthopaed Surg, Philadelphia, PA 19104 USA.
   [Shore, Eileen M.; Lounev, Vitali Y.] Univ Penn, Sch Med, Dept Genet, Philadelphia, PA 19104 USA.
   [Shore, Eileen M.; Lounev, Vitali Y.; Kaplan, Frederick S.] Univ Penn, Sch Med, Ctr Res Fibrodysplasia Ossificans Progressiva & R, Philadelphia, PA 19104 USA.
   [Kaplan, Frederick S.] Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA.
   [Kalluri, Raghu] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02215 USA.
   [Kalluri, Raghu] Harvard Mit Div Hlth Sci & Technol, Boston, MA USA.
   [Olsen, Bjorn R.] Harvard Univ, Sch Dent, Dept Dev Biol, Boston, MA 02215 USA.
C3 Harvard University; Harvard University Medical Affiliates; Beth Israel
   Deaconess Medical Center; Harvard Medical School; University of
   Pennsylvania; University of Pennsylvania; University of Pennsylvania;
   University of Pennsylvania; Harvard University; Harvard Medical School;
   Harvard University; Harvard University
RP Medici, D (通讯作者)，Harvard Univ, Beth Israel Deaconess Med Ctr, Div Matrix Biol, Sch Med,Dept Med, Boston, MA 02215 USA.
EM dmedici@bidmc.harvard.edu; bjorn_olsen@hms.harvard.edu
RI Shore, Eileen/D 2593 2009; Kalluri, Raghu/E 2677 2015
OI Kalluri, Raghu/0000 0002 2190 547X
FU US National Institutes of Health
FX We thank M. Xu for technical assistance, J. Bischoff (Children's
   Hospital Boston) for providing primary cultures of human endothelial
   cells, A. Maidment for X rays and Y. Mishina (University of Michigan)
   for providing caALK2 transgenic mice. We also thank E. Hay (Harvard
   Medical School) for human corneal fibroblasts. This work was supported
   by grants from the US National Institutes of Health to B.R.O., R. K., F.
   S. K. and E. M. S. and to the University of Pennsylvania Vector Core.
   Additional support was from the International Fibrodysplasia Ossificans
   Progressiva Association, the Ian Cali and the Weldon Family Endowments,
   the Penn Center for Musculoskeletal Disorders, the Isaac and Rose Nassau
   Professorship of Orthopaedic Molecular Medicine and the Rita Allen
   Foundation.
CR Akhurst RJ, 2001, TRENDS CELL BIOL, V11, pS44, DOI 10.1016/S0962 8924(01)82259 5
   Amarilio R, 2007, DEVELOPMENT, V134, P3917, DOI 10.1242/dev.008441
   Arciniegas E, 2007, AM J PHYSIOL LUNG C, V293, pL1, DOI 10.1152/ajplung.00378.2006
   Azhar M, 2009, DEV DYNAM, V238, P431, DOI 10.1002/dvdy.21854
   Boye E, 2001, J CLIN INVEST, V107, P745, DOI 10.1172/JCI11432
   Boyer AS, 1999, DEV BIOL, V208, P530, DOI 10.1006/dbio.1999.9211
   Camenisch TD, 2002, DEV BIOL, V248, P170, DOI 10.1006/dbio.2002.0731
   Chamberlain G, 2007, STEM CELLS, V25, P2739, DOI 10.1634/stemcells.2007 0197
   Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890
   Dai J, 2007, J DENT RES, V86, P937, DOI 10.1177/154405910708601006
   Fukuda T, 2006, GENESIS, V44, P159, DOI 10.1002/dvg.20201
   Goumans MJ, 2008, TRENDS CARDIOVAS MED, V18, P293, DOI 10.1016/j.tcm.2009.01.001
   Hay ED, 2005, DEV DYNAM, V233, P706, DOI 10.1002/dvdy.20345
   ILIZAROV GA, 1988, B HOSP JOINT DIS ORT, V48, P1
   Jinnin M, 2008, NAT MED, V14, P1236, DOI 10.1038/nm.1877
   Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104
   Kaplan FS, 2008, J BONE MINER METAB, V26, P521, DOI 10.1007/s00774 008 0879 8
   Kaplan FS, 2007, J BONE JOINT SURG AM, V89A, P347, DOI 10.2106/JBJS.F.00472
   Karhausen J, 2005, CELL CYCLE, V4, P256
   Kizu A, 2009, AM J PATHOL, V175, P1371, DOI 10.2353/ajpath.2009.090698
   Lai YT, 2000, DEV BIOL, V222, P1, DOI 10.1006/dbio.2000.9698
   Lee JG, 2006, EXP EYE RES, V83, P1309, DOI 10.1016/j.exer.2006.04.007
   Lewinson D, 2001, HISTOCHEM CELL BIOL, V116, P381, DOI 10.1007/s004180100331
   Li JH, 2009, AM J PATHOL, V175, P1380, DOI 10.2353/ajpath.2009.090096
   Lounev VY, 2009, J BONE JOINT SURG AM, V91A, P652, DOI 10.2106/JBJS.H.01177
   Mercado Pimentel ME, 2007, CELLS TISSUES ORGANS, V185, P146, DOI 10.1159/000101315
   Mironov V., 1995, ANN BIOMED ENG, V23
   Okagawa H, 2007, DEV BIOL, V306, P179, DOI 10.1016/j.ydbio.2007.03.015
   Paruchuri S, 2006, CIRC RES, V99, P861, DOI 10.1161/01.RES.0000245188.41002.2c
   Potenta S, 2008, BRIT J CANCER, V99, P1375, DOI 10.1038/sj.bjc.6604662
   Shore EM, 2008, BONE, V43, P427, DOI 10.1016/j.bone.2008.05.013
   Shore EM, 2006, NAT GENET, V38, P525, DOI 10.1038/ng1783
   Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006
   Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822
   Wang JK, 2005, DEV BIOL, V286, P299, DOI 10.1016/j.ydbio.2005.07.035
   Zeisberg EM, 2007, CANCER RES, V67, P10123, DOI 10.1158/0008 5472.CAN 07 3127
   Zeisberg EM, 2007, NAT MED, V13, P952, DOI 10.1038/nm1613
   Zeisberg EM, 2008, J AM SOC NEPHROL, V19, P2282, DOI 10.1681/ASN.2008050513
NR 38
TC 598
Z9 673
U1 0
U2 78
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013 1917 USA
SN 1078 8956
J9 NAT MED
JI Nat. Med.
PD DEC
PY 2010
VL 16
IS 12
BP 1400
EP U80
DI 10.1038/nm.2252
PG 9
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA 690ZH
UT WOS:000285048900033
PM 21102460
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Nowwarote, N
   Sukarawan, W
   Kanjana, K
   Pavasant, P
   Fournier, BPJ
   Osathanon, T
AF Nowwarote, Nunthawan
   Sukarawan, Waleerat
   Kanjana, Kiattipan
   Pavasant, Prasit
   Fournier, Benjamin P. J.
   Osathanon, Thanaphum
TI Interleukin 6 promotes an in vitro mineral deposition by stem
   cells isolated from human exfoliated deciduous teeth
SO ROYAL SOCIETY OPEN SCIENCE
LA English
DT Article
DE interleukin 6; stem cells; deciduous teeth; osteogenic differentiation
ID FIBROBLAST GROWTH FACTOR; INDUCED REX 1 EXPRESSION; NF KAPPA B;
   BONE MARROW; RECEPTOR ACTIVATOR; SIGNALING PATHWAY; IL 6;
   DIFFERENTIATION; PROLIFERATION
AB Interleukin 6 (IL 6) plays various roles including stem cell regulation. The present study investigated the effect of IL 6 on cell proliferation, colony forming unit ability, stem cell marker expression and differentiation ability in stem cells isolated from human exfoliated deciduous teeth (SHEDs). We reported that the isolated cells from dental pulp tissues for deciduous teeth expressed CD44, CD90 and CD105 but not CD45. These cells were able to differentiate into osteoblasts, adipocytes and neuronal like cells. IL 6 treatment resulted in the significant increase of NANOG, SOX2 and REX1 mRNA expression. However, IL 6 had no effect on cell proliferation and colony forming unit ability. IL 6 did not alter adipogenic and neurogenic differentiation potency. IL 6 supplementation in osteogenic medium led to a significant increase of mineralization. Furthermore, IL 6 upregulated ALP, ANKH and PIT1 mRNA levels. In conclusion, IL 6 participates in the regulation of pluripotent marker expression and is also involved in mineralization process of SHEDs. Hence, IL 6 could be employed as a supplementary substance in culture medium to maintain sternness and to induce osteogenic induction in SHEDs for future regenerative cell therapy.
C1 [Nowwarote, Nunthawan; Sukarawan, Waleerat; Kanjana, Kiattipan; Pavasant, Prasit; Osathanon, Thanaphum] Chulalongkorn Univ, Excellence Ctr Regenerat Dent, Bangkok 10330, Thailand.
   [Sukarawan, Waleerat] Chulalongkorn Univ, Dept Pediat Dent, Fac Dent, Bangkok 10330, Thailand.
   [Pavasant, Prasit; Osathanon, Thanaphum] Chulalongkorn Univ, Dept Anat, Fac Dent, Bangkok 10330, Thailand.
   [Osathanon, Thanaphum] Chulalongkorn Univ, Genom & Precis Dent Res Grp, Fac Dent, Bangkok 10330, Thailand.
   [Fournier, Benjamin P. J.] Cordeliers Res Ctr, INSERM, UMRS 1138, Lab Mol Oral Pathophysiol, F 75006 Paris, France.
   [Fournier, Benjamin P. J.] Paris Descartes, F 75006 Paris, France.
   [Fournier, Benjamin P. J.] Pierre & Marie Curie, F 75006 Paris, France.
   [Fournier, Benjamin P. J.] Paris Diderot Univ, Fac Dent, Sorbonne Paris Cite, Paris, France.
C3 Chulalongkorn University; Chulalongkorn University; Chulalongkorn
   University; Chulalongkorn University; Institut National de la Sante et
   de la Recherche Medicale (Inserm); Universite Paris Cite; Sorbonne
   Universite; Sorbonne Universite; Universite Paris Cite
RP Osathanon, T (通讯作者)，Chulalongkorn Univ, Excellence Ctr Regenerat Dent, Bangkok 10330, Thailand.; Osathanon, T (通讯作者)，Chulalongkorn Univ, Dept Anat, Fac Dent, Bangkok 10330, Thailand.; Osathanon, T (通讯作者)，Chulalongkorn Univ, Genom & Precis Dent Res Grp, Fac Dent, Bangkok 10330, Thailand.
EM thanaphum.o@chula.ac.th
RI Nowwarote, Nunthawan/ABI 3005 2020; Fournier, Benjamin/E 1791 2011
OI Fournier, Benjamin/0000 0003 4383 7524; Osathanon,
   Thanaphum/0000 0003 1649 6357; Nowwarote, Nunthawan/0000 0001 5315 5565
FU Chulalongkorn Academic Advancement Into Its 2nd Century Project; Faculty
   Research Grant, Faculty of Dentistry, Chulalongkorn University;
   Ratchadapisek Sompote Fund for Postdoctoral Fellowship, Chulalongkorn
   University; Thailand Research Fund [TRF RSA6180019]
FX This study was supported by the Chulalongkorn Academic Advancement Into
   Its 2nd Century Project and in part by the Faculty Research Grant,
   Faculty of Dentistry, Chulalongkorn University. N.N. is supported by the
   Ratchadapisek Sompote Fund for Postdoctoral Fellowship, Chulalongkorn
   University. T.O. was supported by Thailand Research Fund
   (TRF RSA6180019).
CR Foster Brian L., 2008, Birth Defects Research, V84, P281, DOI 10.1002/bdrc.20136
   Gallagher D, 2013, CELL STEM CELL, V13, P564, DOI 10.1016/j.stem.2013.10.002
   Govituattana N, 2015, ARCH ORAL BIOL, V60, P160, DOI 10.1016/j.archoralbio.2014.09.008
   Govitvattana N, 2013, ORAL DIS, V19, P673, DOI 10.1111/odi.12052
   Hernández Quintero M, 2006, CELL TISSUE RES, V325, P77, DOI 10.1007/s00441 006 0173 9
   Huang RL, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 017 0126 0
   Islam O, 2009, MOL BIOL CELL, V20, P188, DOI 10.1091/mbc.E08 05 0463
   Isobe Y, 2016, INT J ORAL MAX SURG, V45, P124, DOI 10.1016/j.ijom.2015.06.022
   Kamimura D, 2004, REV PHYSIOL BIOCH P, V149, P1, DOI 10.1007/s10254 003 0012 2
   Kondo M, 2015, ARTHRITIS RHEUMATOL, V67, P1250, DOI 10.1002/art.39036
   Li D, 2007, CELLS TISSUES ORGANS, V186, P169, DOI 10.1159/000105674
   Lieder R, 2014, BIORESEARCH OPEN ACC, V3, P29, DOI 10.1089/biores.2013.0035
   Miura M, 2003, P NATL ACAD SCI USA, V100, P5807, DOI 10.1073/pnas.0937635100
   Mrácek T, 2004, CYTOKINE, V26, P9, DOI 10.1016/j.cyto.2003.12.001
   Nasi S, 2016, ANN RHEUM DIS, V75, P1372, DOI 10.1136/annrheumdis 2015 207487
   Nowwarote N, 2017, J CELL BIOCHEM, V118, P1480, DOI 10.1002/jcb.25807
   Nowwarote N, 2015, ARCH ORAL BIOL, V60, P408, DOI 10.1016/j.archoralbio.2014.11.017
   Osathanon T, 2013, J CELL BIOCHEM, V114, P2551, DOI 10.1002/jcb.24602
   Palmqvist P, 2002, J IMMUNOL, V169, P3353, DOI 10.4049/jimmunol.169.6.3353
   Pricola KL, 2009, J CELL BIOCHEM, V108, P577, DOI 10.1002/jcb.22289
   Song HY, 2005, INT J BIOCHEM CELL B, V37, P2357, DOI 10.1016/j.biocel.2005.05.007
   Su H, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00405
   Sukarawan W, 2014, ODONTOLOGY, V102, P160, DOI 10.1007/s10266 013 0124 3
   Sulistio YA, 2018, MOL NEUROBIOL, V55, P3513, DOI 10.1007/s12035 017 0594 3
   Wei HX, 2013, CELL TISSUE BANK, V14, P699, DOI 10.1007/s10561 012 9354 9
   Xie ZY, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 017 0766 0
   Xu YY, 2017, ONCOTARGET, V8, P45848, DOI 10.18632/oncotarget.17435
   Yoshitake F, 2008, J BIOL CHEM, V283, P11535, DOI 10.1074/jbc.M607999200
   Yu DD, 2015, ONCOTARGET, V6, P42687, DOI 10.18632/oncotarget.5883
NR 29
TC 9
Z9 10
U1 0
U2 3
PU ROYAL SOC
PI LONDON
PA 6 9 CARLTON HOUSE TERRACE, LONDON SW1Y 5AG, ENGLAND
SN 2054 5703
J9 ROY SOC OPEN SCI
JI R. Soc. Open Sci.
PD OCT
PY 2018
VL 5
IS 10
AR 180864
DI 10.1098/rsos.180864
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA HB5BU
UT WOS:000451073300041
PM 30473835
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Kim, D
   Cho, SW
   Her, SJ
   Yang, JY
   Kim, SW
   Kim, SY
   Shin, CS
AF Kim, Dohee
   Cho, Sun Wook
   Her, Sun Ju
   Yang, Jae Yun
   Kim, Sang Wan
   Kim, Seong Yeon
   Shin, Chan Soo
TI Retrovirus mediated gene transfer of receptor activator of nuclear
   factor κB Fc prevents bone loss in ovariectomized mice
SO STEM CELLS
LA English
DT Article
DE receptor activator of nuclear factor kappa B; receptor activator of
   nuclear factor kappa B Fc; mesenchymal stem cell gene therapy;
   osteoporosis; ovariectomy
ID MARROW STROMAL CELLS; HEMATOPOIETIC STEM CELLS; OSTEOCLAST
   DIFFERENTIATION; NONHEMATOPOIETIC TISSUES; OSTEOPROTEGERIN LIGAND;
   MULTIPLE MYELOMA; PROGENITOR CELLS; SPINAL CORD; IN VIVO; ENGRAFTMENT
AB Postmenopausal osteoporosis is characterized by increased bone resorption due to estrogen deficiency. Receptor activator of nuclear factor kappa B Fc (RANK Fc), a fusion protein that specifically blocks receptor activator of nuclear factor ligand binding to RANK, has been known to be efficient and well tolerated in animal models of osteoporosis. Here we show that cell based gene therapy with RANK Fc effectively prevented bone loss in ovariectomized (OVX) mice. Thirty one young adult female C57BI/6 mice were used, and repeated intraperitoneal injection of mesenchymal stem cells (MSCs) transduced with retrovirus was performed as follows: 1) Sham operated mice (n = 8); 2) OVX mice treated with phosphate buffered saline (OVX PBS; n = 8); 3) OVX mice injected with MSCs transduced with control retrovirus (OVX green fluorescent protein [GFP]; n = 7); and 4) OVX mice injected with MSCs transduced with RANK Fc (OVX RANK Fc; n = 8). Cellular expression of RANK Fc was confirmed by Western blot analysis of cell lysates and conditioned medium and also by enzyme linked immunosorbent assay for the mice serum. Measurement of bone mineral density (BMD) by dual energy x ray absorptiometry (PIXI mus) revealed that the OVX RANK Fc group gained significantly higher BMD than either the OVX PBS group or OVX GFP group after 8 weeks. The expression of GFP, which is coexpressed with RANK Fc, was detected by polymerase chain reaction analysis of DNA isolated from femur and intra abdominal fat, whereas no GFP signal was identified in liver, brain, heart, lung, or bone marrow aspirates. These suggest that expression of RANK Fc by genetically modified MSCs may be a feasible option for the prevention of bone loss induced by ovariectomy.
C1 Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul 110744, South Korea.
C3 Seoul National University (SNU)
RP Shin, CS (通讯作者)，Seoul Natl Univ, Coll Med, Dept Internal Med, 28 Yungun Dong, Seoul 110744, South Korea.
EM csshin@snu.ac.kr
RI Cho, Sun/HPB 9019 2023; Kim, Sang Wan/J 5399 2012; Shin,
   Chan/I 7320 2012; Kim, Seong/J 5408 2012; Kim, Sang/J 5399 2012
OI Kim, Sang Wan/0000 0001 9561 9110; 
CR Azizi SA, 1998, P NATL ACAD SCI USA, V95, P3908, DOI 10.1073/pnas.95.7.3908
   Bailey EC, 2002, J BIOL CHEM, V277, P33632, DOI 10.1074/jbc.M202203200
   Balsam LB, 2004, NATURE, V428, P668, DOI 10.1038/nature02460
   Bartholomew A, 2001, HUM GENE THER, V12, P1527, DOI 10.1089/10430340152480258
   Bekker PJ, 2001, J BONE MINER RES, V16, P348, DOI 10.1359/jbmr.2001.16.2.348
   Bellino FL, 2000, MENOPAUSE, V7, P14, DOI 10.1097/00042192 200007010 00004
   Bianco P, 2001, STEM CELLS, V19, P180, DOI 10.1634/stemcells.19 3 180
   BIENZLE D, 1994, P NATL ACAD SCI USA, V91, P350, DOI 10.1073/pnas.91.1.350
   Body JJ, 2003, CANCER AM CANCER SOC, V97, P887, DOI 10.1002/cncr.11138
   Bolon B, 2001, MOL THER, V3, P197, DOI 10.1006/mthe.2001.0245
   Bucay N, 1998, GENE DEV, V12, P1260, DOI 10.1101/gad.12.9.1260
   Chuah MKL, 2000, HUM GENE THER, V11, P729, DOI 10.1089/10430340050015626
   Dickson GR, 2004, FOLIA BIOL KRAKOW, V52, P125
   DING LM, 1997, BLOOD, V89, P446
   Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412
   Hofbauer LC, 2001, J MOL MED, V79, P243, DOI 10.1007/s001090100226
   Hofstetter CP, 2002, P NATL ACAD SCI USA, V99, P2199, DOI 10.1073/pnas.042678299
   Holdsworth DW, 2000, J BONE MINER RES, V15, P2451, DOI 10.1359/jbmr.2000.15.12.2451
   Honore P, 2000, NAT MED, V6, P521, DOI 10.1038/74999
   Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540
   Jeon MJ, 2003, J BIOL CHEM, V278, P23270, DOI 10.1074/jbc.M211610200
   Jin HK, 2002, J CLIN INVEST, V109, P1183, DOI 10.1072/JCI200214862
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Krebsbach PH, 2003, J GENE MED, V5, P11, DOI 10.1002/jgm.292
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   LAZARUS HM, 1995, BONE MARROW TRANSPL, V16, P557
   Li Y, 2002, NEUROLOGY, V59, P514, DOI 10.1212/WNL.59.4.514
   Murry CE, 2004, NATURE, V428, P664, DOI 10.1038/nature02446
   Nakashima T, 2003, CURR OPIN RHEUMATOL, V15, P280, DOI 10.1097/00002281 200305000 00016
   Ortiz LA, 2003, P NATL ACAD SCI USA, V100, P8407, DOI 10.1073/pnas.1432929100
   Pearse RN, 2001, P NATL ACAD SCI USA, V98, P11581, DOI 10.1073/pnas.201394498
   Pereira RF, 1998, P NATL ACAD SCI USA, V95, P1142, DOI 10.1073/pnas.95.3.1142
   Prockop DJ, 2003, P NATL ACAD SCI USA, V100, P11917, DOI 10.1073/pnas.1834138100
   Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71
   Schwarz EJ, 1999, HUM GENE THER, V10, P2539, DOI 10.1089/10430349950016870
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Sordillo EM, 2003, CANCER AM CANCER SOC, V97, P802, DOI 10.1002/cncr.11134
   STEWART FM, 1993, BLOOD, V81, P2566
   Toma C, 2002, CIRCULATION, V105, P93, DOI 10.1161/hc0102.101442
NR 40
TC 32
Z9 35
U1 0
U2 3
PU ALPHAMED PRESS
PI DURHAM
PA 318 BLACKWELL ST, STE 260, DURHAM, NC 27701 2884 USA
SN 1066 5099
J9 STEM CELLS
JI Stem Cells
PD JUL
PY 2006
VL 24
IS 7
BP 1798
EP 1805
DI 10.1634/stemcells.2005 0480
PG 8
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology;
   Oncology; Cell Biology; Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology
GA 085YE
UT WOS:000240639500018
PM 16556708
OA Bronze
DA 2025 08 17
ER

PT J
AU McArdle, A
   Chung, MT
   Paik, KJ
   Duldulao, C
   Chan, C
   Rennert, R
   Walmsley, GG
   Senarath Yapa, K
   Hu, M
   Seo, E
   Lee, M
   Wan, DC
   Longaker, MT
AF McArdle, Adrian
   Chung, Michael T.
   Paik, Kevin J.
   Duldulao, Chris
   Chan, Charles
   Rennert, Robert
   Walmsley, Graham G.
   Senarath Yapa, Kshemendra
   Hu, Michael
   Seo, Elly
   Lee, Min
   Wan, Derrick C.
   Longaker, Michael T.
TI Positive Selection for Bone Morphogenetic Protein Receptor Type IB
   Promotes Differentiation and Specification of Human Adipose Derived
   Stromal Cells Toward an Osteogenic Lineage
SO TISSUE ENGINEERING PART A
LA English
DT Article
ID STEM CELLS; REGENERATIVE MEDICINE; GENE EXPRESSION; IN VIVO;
   THY 1 POSITIVE CELLS; BIOMIMETIC APATITE; CALVARIAL DEFECTS;
   GROWTH FACTOR; OSTEOBLAST; MARROW
AB Background: Adipose tissue represents an abundant and easily accessible source of multipotent cells that may serve as an excellent building block for tissue engineering. However, adipose derived stromal cells (ASCs) are a heterogeneous group and subpopulations may be identified with enhanced osteogenic potential.
   Methods: Human ASC subpopulations were prospectively isolated based on expression of bone morphogenetic protein receptor type IB (BMPR IB). Unsorted, BMPR IB(+), and BMPR IB( ) cells were analyzed for their osteogenic capacity through histological staining and gene expression. To evaluate their in vivo osteogenic potential, critical sized calvarial defects were created in immunocompromised mice and treated with unsorted, BMPR IB(+), or BMPR IB( ) cells. Healing was assessed using microcomputed tomography and pentachrome staining of specimens at 8 weeks.
   Results: Increased osteogenic differentiation was noted in the BMPR IB(+) subpopulation, as demonstrated by alkaline phosphatase staining at day 7 and extracellular matrix mineralization with Alizarin red staining at day 14. This was also associated with increased expression for osteocalcin, a late marker of osteogenesis. Radiographic analysis demonstrated significantly enhanced healing of critical sized calvarial defects treated with BMPR IB(+) ASCs compared with unsorted or BMPR IB( ) cells. This was confirmed through pentachrome staining, which revealed more robust bone regeneration in the BMPR IB(+) group.
   Conclusion: BMPR IB(+) human ASCs have an enhanced ability to form bone both in vitro and in vivo. These data suggest that positive selection for BMPR IB(+) and manipulation of the BMP pathway in these cells may yield a highly osteogenic subpopulation of cells for bone tissue engineering.
C1 [McArdle, Adrian; Chung, Michael T.; Paik, Kevin J.; Duldulao, Chris; Chan, Charles; Rennert, Robert; Walmsley, Graham G.; Senarath Yapa, Kshemendra; Hu, Michael; Wan, Derrick C.; Longaker, Michael T.] Stanford Univ, Sch Med, Hagey Lab Pediat Regenerat Med, Div Plast & Reconstruct Surg,Dept Surg, Stanford, CA 94305 USA.
   [McArdle, Adrian; Chan, Charles; Walmsley, Graham G.; Seo, Elly; Longaker, Michael T.] Stanford Univ, Inst Stem Cell Biol & Regenerat Med, Stanford, CA 94305 USA.
   [Lee, Min] Univ Calif Los Angeles, Weintraub Ctr Reconstruct Biotechnol, Dept Bioengn, Lab Biomat & Bioengn,Div Adv Prosthodont, Los Angeles, CA USA.
C3 Stanford University; Stanford University; University of California
   System; University of California Los Angeles
RP Longaker, MT (通讯作者)，Stanford Univ, Sch Med, Hagey Lab Pediat Regenerat Med, Div Plast & Reconstruct Surg,Dept Surg, 257 Campus Dr, Stanford, CA 94305 USA.
EM dwan@stanford.edu; longaker@stanford.edu
OI Seo, Eun Young/0000 0002 9044 3969; Wan, Derrick/0000 0003 4666 1683
FU National Institutes of Health [RO1 DE021683, RO1 DE019434, UO1 HL09977];
   Tissue Engineering Fellowship from Lucile Packard Children's Hospital at
   Stanford; Hagey Laboratory for Pediatric Regenerative Medicine; Oak
   Foundation; ACS Franklin H. Martin Faculty Research Fellowship; Stanford
   University Child Health Research Institute Faculty Scholar Award
FX The authors gratefully acknowledge the following funding sources that
   supported this study: the National Institutes of Health research grants
   RO1 DE021683, RO1 DE019434, and UO1 HL09977 to M. T. L; the Tissue
   Engineering Fellowship from Lucile Packard Children's Hospital at
   Stanford to A. M.; The Hagey Laboratory for Pediatric Regenerative
   Medicine; and the Oak Foundation. D. C. W. was supported by the ACS
   Franklin H. Martin Faculty Research Fellowship, the Hagey Laboratory for
   Pediatric Regenerative Medicine, and the Stanford University Child
   Health Research Institute Faculty Scholar Award.
CR Aoki H, 2001, J CELL SCI, V114, P1483
   Aslan H, 2006, STEM CELLS, V24, P1728, DOI 10.1634/stemcells.2005 0546
   CANCELA L, 1990, J BIOL CHEM, V265, P15040
   Chapekar MS, 2000, J BIOMED MATER RES, V53, P617, DOI 10.1002/1097 4636(2000)53:6<617::AID JBM1>3.3.CO;2 3
   Chen D, 1998, J CELL BIOL, V142, P295, DOI 10.1083/jcb.142.1.295
   Chen D, 1997, CALCIFIED TISSUE INT, V60, P283, DOI 10.1007/s002239900230
   Chen XD, 1999, J BONE MINER RES, V14, P362, DOI 10.1359/jbmr.1999.14.3.362
   Chou YF, 2004, BIOMATERIALS, V25, P5323, DOI 10.1016/j.biomaterials.2003.12.037
   Chou YF, 2005, BIOMATERIALS, V26, P285, DOI 10.1016/j.biomaterials.2004.02.030
   Chou YF, 2005, J BIOMED MATER RES B, V75B, P81, DOI 10.1002/jbm.b.30261
   Chu HH, 2012, THER DELIV, V3, P693, DOI 10.4155/TDE.12.50
   Chung MT, 2013, TISSUE ENG PT A, V19, P989, DOI [10.1089/ten.tea.2012.0370, 10.1089/ten.TEA.2012.0370]
   Cowan CM, 2004, NAT BIOTECHNOL, V22, P560, DOI 10.1038/nbt958
   David R, 2005, STEM CELLS, V23, P477, DOI 10.1634/stemcells.2004 0177
   Eyckmans J, 2013, BIOMATERIALS, V34, P4612, DOI 10.1016/j.biomaterials.2013.03.011
   Gimble JM, 2007, CIRC RES, V100, P1249, DOI 10.1161/01.RES.0000265074.83288.09
   Gimble JM, 2003, CURR TOP DEV BIOL, V58, P137, DOI 10.1016/S0070 2153(03)58005 X
   Glotzbach JP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021211
   Gupta DM, 2008, J CRANIOFAC SURG, V19, P192, DOI 10.1097/scs.0b013e31815c93b7
   HAYNESWORTH SE, 1992, BONE, V13, P81, DOI 10.1016/8756 3282(92)90364 3
   Hosoya A, 2012, HISTOCHEM CELL BIOL, V137, P733, DOI 10.1007/s00418 012 0928 1
   Hyun J, 2013, STEM CELL TRANSL MED, V2, P690, DOI 10.5966/sctm.2013 0035
   Jiang T, 2010, BIOMATERIALS, V31, P3564, DOI 10.1016/j.biomaterials.2010.01.050
   Kwan MD, 2008, HUM MOL GENET, V17, pR93, DOI 10.1093/hmg/ddn071
   Lee NK, 2007, CELL, V130, P456, DOI 10.1016/j.cell.2007.05.047
   Levi B, 2011, STEM CELLS, V29, P2018, DOI 10.1002/stem.757
   Levi B, 2011, J BIOL CHEM, V286, P39497, DOI 10.1074/jbc.M111.256529
   Levi B, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011177
   Massagué J, 2000, GENE DEV, V14, P627
   McArdle A, 2013, PLAST RECONSTR SURG, V131, P400, DOI 10.1097/PRS.0b013e318278d88c
   Mitchell JB, 2006, STEM CELLS, V24, P376, DOI 10.1634/stemcells.2005 0234
   Moustakas A, 2002, GENE DEV, V16, P1867, DOI 10.1101/gad.1016802
   Nakamura H, 2010, J HISTOCHEM CYTOCHEM, V58, P455, DOI 10.1369/jhc.2010.955393
   Panetta NJ, 2010, PLAST RECONSTR SURG, V125, P483, DOI 10.1097/PRS.0b013e3181c82d75
   Park TG, 2002, J BIOMED MATER RES, V59, P127, DOI 10.1002/jbm.1224
   Quarto N, 2008, BONE, V42, P1040, DOI 10.1016/j.bone.2008.01.026
   Quarto R, 2001, NEW ENGL J MED, V344, P385, DOI 10.1056/NEJM200102013440516
   Rada T, 2011, STEM CELL REV REP, V7, P64, DOI 10.1007/s12015 010 9147 0
   Singhatanadgit W, 2006, J CELL PHYSIOL, V209, P912, DOI 10.1002/jcp.20799
   Singhatanadgit W, 2011, IN VITRO CELL DEV AN, V47, P251, DOI 10.1007/s11626 010 9378 z
   Suto M, 2013, ARCH ORAL BIOL, V58, P1021, DOI 10.1016/j.archoralbio.2013.02.014
   Wan DC, 2007, J BIOL CHEM, V282, P26450, DOI 10.1074/jbc.M703282200
   Wan DC, 2006, P NATL ACAD SCI USA, V103, P12335, DOI 10.1073/pnas.0604849103
   Wang XW, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng154
   Wissink MJB, 2000, J CONTROL RELEASE, V64, P103, DOI 10.1016/S0168 3659(99)00145 5
   WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241
   Yoon BS, 2005, P NATL ACAD SCI USA, V102, P5062, DOI 10.1073/pnas.0500031102
   Zuk PA, 2002, MOL BIOL CELL, V13, P4279, DOI 10.1091/mbc.E02 02 0105
NR 48
TC 22
Z9 26
U1 0
U2 6
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1937 3341
EI 1937 335X
J9 TISSUE ENG PT A
JI Tissue Eng. Part A
PD NOV 1
PY 2014
VL 20
IS 21 22
BP 3031
EP 3040
DI 10.1089/ten.tea.2014.0101
PG 10
WC Cell & Tissue Engineering; Cell Biology; Engineering, Biomedical;
   Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Engineering; Materials Science
GA AS9XU
UT WOS:000344592600021
PM 24854876
OA Green Published
DA 2025 08 17
ER

PT J
AU Bretti, C
   De Stefano, C
   Cardiano, P
   Cataldo, S
   Pettignano, A
   Arena, G
   Sgarlata, C
   Grasso, GI
   Lando, G
   Sammartano, S
AF Bretti, Clemente
   De Stefano, Concetta
   Cardiano, Paola
   Cataldo, Salvatore
   Pettignano, Alberto
   Arena, Giuseppe
   Sgarlata, Carmelo
   Grasso, Giuseppa Ida
   Lando, Gabriele
   Sammartano, Silvio
TI Risedronate complexes with Mg<SUP>2+</SUP>, Zn<SUP>2+</SUP>,
   Pb<SUP>2+</SUP>, and Cu<SUP>2+</SUP>: Species thermodynamics and
   sequestering ability in NaCl(aq) at different ionic strengths
   and at T=298.15 K
SO JOURNAL OF MOLECULAR LIQUIDS
LA English
DT Article
DE Risedronic acid; Potentiometry; Calorimetry; Solution thermodynamics;
   Sequestering ability
ID DIFFERENT METAL CATIONS; BIOLOGICAL FLUIDS; DIFFERENT MEDIA; BONE;
   BISPHOSPHONATES; SEQUESTRATION; EQUILIBRIUM; BINDING; BIOAVAILABILITY;
   PROTONATION
AB In this paper, potentiometry and calorimetry were used to determine the thermodynamics of interaction between risedronate and four bivalent metal cations, namely: Mg2+, Zn2+, Pb2+, and Cu2+ in aqueous NaCl solutions at different ionic strengths and at T = 298.15 K. The data analysis allowed us to ascertain that the main species formed were the MLH2, MLH, ML and M2L; however scarcely soluble species precipitated at acidic pH values, between 4 and 7 depending on the metal cation involved, probably due to the formation of the neutral M2L(s) species. Comparison of the stability constants with other similar ligands suggests that metal complexation occurs through the phosphonate with an additional stabilizing contribution due to the pyridine moiety. The dissection of the free energy term revealed that the entropic change is the main contribution to the stability of the complexes for all equilibria, except those regarding the formation of the M2L species, and the main forces involved in these processes are entropic in nature, such as the desolvation of both the ligand and the metal cations. The sequestering ability was evaluated computing the pL(0.5) parameter at different pH and ionic strength values; the highest ones were found for Cu2+ in acidic solutions and at low ionic strength, whereas pL(0.5) values for both Pb2+ and Zn2+ were slightly lower. Results reported in this work may be helpful in the assessment of the use of risedronate as effective chelating agent and for understanding the mechanism of action of this molecule as a drug. (C) 2021 Elsevier B.V. All rights reserved.
C1 [Bretti, Clemente; De Stefano, Concetta; Cardiano, Paola; Lando, Gabriele; Sammartano, Silvio] Farmaceut Ambientali Univ Messina, Dipartimento Sci Chim Biol Fartnaceut Ambientali, Viale Ferdinando Stagno dAlcontres Messina 31, I 98166 Messina, Vill S Agata, Italy.
   [Cataldo, Salvatore; Pettignano, Alberto] Univ Palermo, Dipartimento Fis & Chim Emilio Segre, Viale Sci, I 90128 Palermo, Italy.
   [Arena, Giuseppe; Sgarlata, Carmelo; Grasso, Giuseppa Ida] Univ Catania, Dipartimento Sci Chim, Viale A Doria 6, I 95125 Catania, Italy.
C3 University of Palermo; University of Catania
RP Lando, G (通讯作者)，Farmaceut Ambientali Univ Messina, Dipartimento Sci Chim Biol Fartnaceut Ambientali, Viale Ferdinando Stagno dAlcontres Messina 31, I 98166 Messina, Vill S Agata, Italy.
EM glando@unime.it
RI Lando, Gabriele/AAE 1222 2022; SGARLATA, Carmelo/ABC 4868 2021; cataldo,
   salvatore/K 9993 2018; CARDIANO, Paola/Q 3484 2016
OI Grasso, Giuseppa Ida/0000 0002 1330 3233; cataldo,
   salvatore/0000 0002 9773 4021; CARDIANO, Paola/0000 0002 1380 5380;
   SGARLATA, Carmelo/0000 0002 9284 1303
FU MIUR (Ministero dell'Istruzione, dell'Universita e della Ricerca); PRIN
   project [2015MP34H3]
FX We thank MIUR (Ministero dell'Istruzione, dell'Universita e della
   Ricerca) for financial support (cofounded PRIN project with Prot.
   2015MP34H3), UniME (Research & Mobility2017, Prot. 009041), and ``UniCT
   (Piano della ricerca 2016 18 and Piaceri 2020 22, linea 2)".
CR Alderighi L, 1999, COORDIN CHEM REV, V184, P311, DOI 10.1016/S0010 8545(98)00260 4
   [Anonymous], 2004, NIST STANDARD REFERE
   Arena G, 2016, ANAL BIOANAL CHEM, V408, P6413, DOI 10.1007/s00216 016 9759 6
   Bigi A, 2018, J FUNCT BIOMATER, V9, DOI 10.3390/jfb9010006
   Bretti C., 2017, SM J BIOEQUIV AVAILA, V1, P1001
   Bretti C, 2006, J SOLUTION CHEM, V35, P1401, DOI 10.1007/s10953 006 9068 3
   Bretti C, 2017, J SOLUTION CHEM, V46, P1903, DOI 10.1007/s10953 017 0660 5
   Bretti C, 2017, CHEMOSPHERE, V183, P107, DOI 10.1016/j.chemosphere.2017.05.099
   Bretti C, 2016, CHEMOSPHERE, V150, P341, DOI 10.1016/j.chemosphere.2016.02.023
   Bretti C, 2014, J CHEM ENG DATA, V59, P3728, DOI 10.1021/je500621v
   Bronsted JN, 1922, J AM CHEM SOC, V44, P877, DOI 10.1021/ja01426a001
   Brüning J, 2011, J PHARM SCI US, V100, P863, DOI 10.1002/jps.22327
   Carbone EJ, 2017, NANOMED NANOTECHNOL, V13, P37, DOI 10.1016/j.nano.2016.08.015
   Cataldo S, 2018, NEW J CHEM, V42, P7640, DOI 10.1039/c7nj04456a
   Chindamo G, 2020, NANOMATERIALS BASEL, V10, DOI 10.3390/nano10050875
   Chou ACC, 2015, BONE, V79, P170, DOI 10.1016/j.bone.2015.06.003
   CIAVATTA L, 1980, ANN CHIM ROME, V70, P551
   Cigala RM, 2010, J CHEM ENG DATA, V55, P4757, DOI 10.1021/je100384f
   Cole LE, 2016, ADV DRUG DELIVER REV, V99, P12, DOI 10.1016/j.addr.2015.10.005
   Crea F, 2014, CURR MED CHEM, V21, P3819, DOI 10.2174/0929867321666140601160740
   De Stefano C, 1997, WATER SCI TECHNOL LI, V25, P71
   Deacon GB, 2015, CRYST GROWTH DES, V15, P4646, DOI 10.1021/acs.cgd.5b00917
   DESTEFANO C, 1987, ANN CHIM ROME, V77, P643
   DESTEFANO C, 1994, ANN CHIM ROME, V84, P159
   Errassifi F, 2014, J COLLOID INTERF SCI, V420, P101, DOI 10.1016/j.jcis.2014.01.017
   Fang XJ, 2020, J HAZARD MATER, V392, DOI 10.1016/j.jhazmat.2020.122291
   Fleisch HA, 1997, ANN MED, V29, P55, DOI 10.3109/07853899708998743
   Foti C, 2013, J CHEM THERMODYN, V66, P151, DOI 10.1016/j.jct.2013.07.005
   GRENTHE I, 1997, MODELLING AQUATIC CH
   GUGGENHEIM EA, 1955, T FARADAY SOC, V51, P747, DOI 10.1039/tf9555100747
   Hofstetter B, 2012, J BONE MINER RES, V27, P995, DOI 10.1002/jbmr.1572
   Hounslow AM, 2008, J MED CHEM, V51, P4170, DOI 10.1021/jm7015792
   Ironside MS, 2010, EUR J PHARM BIOPHARM, V76, P120, DOI 10.1016/j.ejpb.2010.05.013
   Itoh A, 2016, BIOL PHARM BULL, V39, P323, DOI 10.1248/bpb.b15 00630
   Lin TJ, 2019, CHEM PHYS LETT, V716, P83, DOI 10.1016/j.cplett.2018.12.008
   Lloyd SA, 2015, BONE, V81, P562, DOI 10.1016/j.bone.2015.08.021
   Love C, 2003, RADIOGRAPHICS, V23, P341, DOI 10.1148/rg.232025103
   Malavasi M, 2016, ARCH ORAL BIOL, V68, P43, DOI 10.1016/j.archoralbio.2016.03.021
   Matczak Jon E, 2005, COORDIN CHEM REV, V249, P2458, DOI 10.1016/j.ccr.2005.06.001
   Matczak Jon E, 2002, POLYHEDRON, V21, P321, DOI 10.1016/S0277 5387(01)00996 2
   Mukherjee S, 2009, J AM CHEM SOC, V131, P8374, DOI 10.1021/ja902895p
   Nancollas GH, 2006, BONE, V38, P617, DOI 10.1016/j.bone.2005.05.003
   Prasad C, 2016, BONE, V90, P123, DOI 10.1016/j.bone.2016.03.010
   Scatchard G, 1936, CHEM REV, V19, P309, DOI 10.1021/cr60064a008
   Sgarlata C, 2013, ANAL BIOANAL CHEM, V405, P1085, DOI 10.1007/s00216 012 6565 7
   Tassone P, 2003, BRIT J CANCER, V88, P1971, DOI 10.1038/sj.bjc.6600986
NR 46
TC 8
Z9 9
U1 0
U2 7
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0167 7322
EI 1873 3166
J9 J MOL LIQ
JI J. Mol. Liq.
PD DEC 1
PY 2021
VL 343
AR 117699
DI 10.1016/j.molliq.2021.117699
EA OCT 2021
PG 9
WC Chemistry, Physical; Physics, Atomic, Molecular & Chemical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Physics
GA WI9WM
UT WOS:000708703200066
DA 2025 08 17
ER

PT J
AU Obermüller, N
   Rosenkranz, AR
   Müller, HW
   Hidde, D
   Veres, A
   Decker Burgard, S
   Weisz, I
   Geiger, H
AF Obermueller, Nicholas
   Rosenkranz, Alexander R.
   Mueller, Hans Walter
   Hidde, Dennis
   Veres, Andras
   Decker Burgard, Sabine
   Weisz, Isolde
   Geiger, Helmut
TI Long Term Therapy Outcomes When Treating Chronic Kidney Disease Patients
   with Paricalcitol in German and Austrian Clinical Practice (TOP Study)
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE parathormone (PTH); paricalcitol; secondary hyperparathyroidism (sHPT);
   chronic kidney disease (CKD); dialysis; predialysis
ID VITAMIN D; SECONDARY HYPERPARATHYROIDISM; HEMODIALYSIS PATIENTS;
   PARATHYROID HORMONE; DIALYSIS PATIENTS; INTESTINAL CALCIUM; PTH;
   MULTICENTER; PHOSPHORUS; CALCITRIOL
AB Paricalcitol is approved for prevention and therapy of secondary hyperparathyroidism (sHPT) in patients with chronic kidney disease (CKD), with only short term data in clinical routine settings. A 12 month observational study was conducted in Germany and Austria (90 centers, 761 patients) from 2008 to 2013. Laboratory values, demographical, and clinical data were documented in 629 dialysis patients and 119 predialysis patients. In predialysis patients, median intact parathormone (iPTH) was 180.0 pg/mL (n = 105) at the start of the study, 115.7 pg/mL (n = 105) at last documentation, and 151.8 pg/mL (n = 50) at month 12, with 32.4% of the last documented iPTH values in the KDOQI (Kidney Disease Outcomes Quality Initiative) target range. In dialysis patients, median iPTH was 425.5 pg/mL (n = 569) at study start, 262.3 pg/mL (n = 569) at last documentation, and 266.1 pg/mL (n = 318) at month 12, with 36.5% of dialysis patients in the KDOQI target range. Intravenous paricalcitol showed more homogenous iPTH control than oral treatment. Combined analysis of all dialysis patients indicated comparable and stable mean serum calcium and phosphate levels throughout the study. Clinical symptoms, such as itching, bone pain, and fatigue, were improved compared with study entry. The spectrum and frequency of adverse events mirrored the known pattern for patients on dialysis. Paricalcitol is efficacious and has a consistent safety profile in sHPT over 12 months.
C1 [Obermueller, Nicholas; Geiger, Helmut] Goethe Univ, Div Nephrol 3, Med Clin, Univ Hosp Frankfurt, Theodor Stern Kai 7, D 60590 Frankfurt, Germany.
   [Rosenkranz, Alexander R.] Med Univ Graz, Dept Internal Med, Clin Div Nephrol, Auenbruggerpl 27, A 8036 Graz, Austria.
   [Mueller, Hans Walter; Hidde, Dennis; Veres, Andras; Decker Burgard, Sabine] AbbVie Deutschland GmbH & Co KG, Mainzer Str 81, D 65189 Wiesbaden, Germany.
   [Weisz, Isolde] AbbVie GmbH, Lembockgasse 61, A 1230 Vienna, Austria.
C3 Goethe University Frankfurt; Goethe University Frankfurt Hospital;
   Medical University of Graz; AbbVie; AbbVie
RP Geiger, H (通讯作者)，Goethe Univ, Div Nephrol 3, Med Clin, Univ Hosp Frankfurt, Theodor Stern Kai 7, D 60590 Frankfurt, Germany.
EM obermueller@em.uni frankfurt.de; alexander.rosenkranz@medunigraz.at;
   hans walter.mueller@web.de; dennis.hidde@abbvie.com;
   andras.veres@abbvie.com; sabine.decker burgard@abbvie.com;
   isolde.weisz@abbvie.com; h.geiger@em.uni frankfurt.de
FU AbbVie Deutschland GmbH & Co KG, Wiesbaden, Germany
FX The design and financial support for this study was provided by AbbVie
   Deutschland GmbH & Co KG, Wiesbaden, Germany. AbbVie is a manufacturer
   of the drug Zemplar (R) (paricalcitol). AbbVie participated in the data
   analysis, interpretation of data, and review and approval of the
   manuscript. Sabine Decker Burgard, Dennis Hidde, Hans Walter Muller,
   Andras Veres, and Isolde Weisz are employees of AbbVie and may own
   AbbVie stock or stock options. Alexander R. Rosenkranz did not receive
   honoraria from AbbVie Deutschland GmbH & Co. KG. Helmut Geiger and
   Nicholas Obermuller have received speaker and/or advisory honoraria from
   AbbVie Deutschland GmbH & Co. KG.
CR Alvarez JA, 2012, AM J CLIN NUTR, V96, P672, DOI 10.3945/ajcn.112.040642
   Andress D, 2007, DRUGS, V67, P1999, DOI 10.2165/00003495 200767140 00003
   Biggar P, 2014, NEPHRON CLIN PRACT, V126, P39, DOI 10.1159/000357677
   Brancaccio D, 2007, DRUGS, V67, P1981, DOI 10.2165/00003495 200767140 00002
   Brown AJ, 2002, J LAB CLIN MED, V139, P279, DOI 10.1067/mlc.2002.122819
   Brown EG, 1999, DRUG SAFETY, V20, P109, DOI 10.2165/00002018 199920020 00002
   Christakos S, 2016, PHYSIOL REV, V96, P365, DOI 10.1152/physrev.00014.2015
   Coyne D, 2006, AM J KIDNEY DIS, V47, P263, DOI 10.1053/j.ajkd.2005.10.007
   Coyne DW, 2014, CLIN J AM SOC NEPHRO, V9, P1620, DOI 10.2215/CJN.10661013
   Cozzolino M, 2012, NEPHROL DIAL TRANSPL, V27, P3588, DOI 10.1093/ndt/gfs108
   de Francisco ALM, 2011, NEPHRON CLIN PRACT, V118, pC143, DOI 10.1159/000319936
   Dusso A. S., 2004, NEPHROL, V24, P10, DOI [10.1053/j.semnephrol.2003.08.01814730505, DOI 10.1053/J.SEMNEPHROL.2003.08.01814730505]
   Eknoyan G, 2003, AM J KIDNEY DIS, V41, pS1, DOI 10.1016/S0272 6386(03)00111 2
   Frei U., 2006, NIERENERSATZTHERAPIE
   Goodkin DA, 2004, AM J KIDNEY DIS, V44, pS16, DOI 10.1053/j.akjd.2004.08.006
   Han TZ, 2013, BIOMED RES INT UK, V2013, DOI 10.1155/2013/320560
   Jager KJ, 2007, KIDNEY INT, V72, P671, DOI 10.1038/sj.ki.5002397
   Ketteler M., 2012, DIALYSIS TRANSPLANT, V27, P3270, DOI [10.1093/ndt/gfs01822387567, DOI 10.1093/NDT/GFS01822387567]
   Kidney Disease: Improving Global Outcomes (KDIGO) CKD MBD Work Group, 2009, Kidney Int Suppl, pS1, DOI 10.1038/ki.2009.188
   Levey AS, 2009, ANN INTERN MED, V150, P604, DOI 10.7326/0003 4819 150 9 200905050 00006
   Levin A, 2007, KIDNEY INT, V71, P31, DOI 10.1038/sj.ki.5002009
   Lindberg J, 2001, CLIN NEPHROL, V56, P315
   Llach F, 1998, AM J KIDNEY DIS, V32, pS48, DOI 10.1053/ajkd.1998.v32.pm9808143
   Lund RJ, 2010, AM J NEPHROL, V31, P165, DOI 10.1159/000266204
   Lundwall K, 2015, AM J NEPHROL, V42, P265, DOI 10.1159/000441364
   Martin KJ, 1998, J AM SOC NEPHROL, V9, P1427
   Quori A, 2011, NEFROLOGIA, V31, P457, DOI 10.3265/Nefrologia.pre2011.Apr.10605
   Rayner H. C., 2004, DIALYSIS TRANSPLANT, V19, P108, DOI [10.1093/ndt/gfg48314671046, DOI 10.1093/NDT/GFG48314671046]
   Robinson BM, 2006, J AM SOC NEPHROL, V17, P2910, DOI 10.1681/ASN.2005101078
   Ross EA, 2008, AM J NEPHROL, V28, P97, DOI 10.1159/000109398
   Ryan Jackson W, 2015, Clin Biochem Rev, V36, P53
   Spigel David R, 2010, Biotechnol Healthc, V7, P18
   Tentori F, 2008, AM J KIDNEY DIS, V52, P519, DOI 10.1053/j.ajkd.2008.03.020
   Wu Wong JR, 2015, J STEROID BIOCHEM, V148, P202, DOI 10.1016/j.jsbmb.2014.12.002
   Wu Wong JR, 2006, ATHEROSCLEROSIS, V186, P20, DOI 10.1016/j.atherosclerosis.2005.06.046
NR 35
TC 0
Z9 0
U1 0
U2 2
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD OCT
PY 2017
VL 18
IS 10
AR 2057
DI 10.3390/ijms18102057
PG 20
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA FM0QL
UT WOS:000414671800041
PM 28956807
OA gold, Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU Li, F
   Whyte, N
   Niyibizi, C
AF Li, Feng
   Whyte, Noelle
   Niyibizi, Christopher
TI Differentiating multipotent mesenchymal stromal cells generate factors
   that exert paracrine activities on exogenous MSCs: Implications for
   paracrine activities in bone regeneration
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Mesenchymal stem cells and paracrine activities; Mesenchymal stem cells;
   Bone morphogenetic protein 2; Bone regeneration
ID EPITHELIUM DERIVED FACTOR; OSTEOGENESIS IMPERFECTA; STEM CELLS; SYSTEMIC
   TRANSPLANTATION; MOUSE MODEL; THERAPY; MICE; GROWTH; ANGIOGENESIS;
   SERPINF1
AB The mechanisms by which multipotent mesenchymal stromal cells (MSCs) contribute to tissue repair following transplantation into host tissues remains poorly understood. Current concepts suggest that, in addition to differentiation into cells of the host tissues, MSCs also generate trophic factors that modulate host tissue microenvironment to aid in the repair process. In this communication, we assessed whether factors secreted by MSCs undergoing osteogenic differentiation induce expression of osteoblast markers in exogenous MSCs as well as their migration. Murine MSCs were cultured in osteogenic medium, and at different time points, medium conditioned by the cells was collected and assessed for its effects on differentiation and migration of exogenous MSCs. In addition, we determined whether MSCs infused into mice femurs expressed genes encoding for factors predicted to play a role in paracrine activities. The results showed that MSCs maintained in osteogenic medium, secreted factors at specific time points that induced alkaline phosphatase activity (ALP) in exogenous MSCs as well as their migration. MSCs infused into mice femurs and retrieved at different days expressed genes that encoded predicted factors that play a role in cell differentiation and migration. Neutralizing antibodies to bone morphogenetic protein 2 (BMP 2) led to the decrease in ALP activity by exogenous MSCs. These data demonstrated that, as MSCs differentiate toward osteogenic lineage, they secrete factors that induce recruitment and differentiation of endogenous progenitors. These data reveal mechanisms by which donor MSCs may contribute to the bone reparative process and provide a platform for designing approaches for stem cell therapies of musculoskeletal disorders. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Li, Feng; Whyte, Noelle; Niyibizi, Christopher] Penn State Coll Med, Dept Orthopaed & Rehabil, Div Musculoskeletal Sci, Hershey, PA 17033 USA.
   [Niyibizi, Christopher] Penn State Coll Med, Dept Biochem & Mol Biol, Hershey, PA 17033 USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE);
   Pennsylvania State University; Penn State Health; Pennsylvania
   Commonwealth System of Higher Education (PCSHE); Pennsylvania State
   University; Penn State Health
RP Niyibizi, C (通讯作者)，Penn State Coll Med, Dept Orthopaed & Rehabil, Div Musculoskeletal Sci, H089,500 Univ Dr, Hershey, PA 17033 USA.
EM Cniyibizi@psu.edu
OI Li, Feng/0000 0003 3346 2175
FU Tobacco Cure Grant; Brittle Bone Foundation Fellowship
FX The work was supported by in part by Tobacco Cure Grant to CN and
   Brittle Bone Foundation Fellowship to FL.
CR Ek ETH, 2007, CLIN EXP METASTAS, V24, P93, DOI 10.1007/s10585 007 9062 1
   Evans CH, 2009, EUR CELLS MATER, V18, P96, DOI 10.22203/eCM.v018a09
   Gambotto A, 2000, GENE THER, V7, P2036, DOI 10.1038/sj.gt.3301335
   Gnecchi M, 2008, CIRC RES, V103, P1204, DOI 10.1161/CIRCRESAHA.108.176826
   Guillot PV, 2008, BLOOD, V111, P1717, DOI 10.1182/blood 2007 08 105809
   Hoeben A, 2004, PHARMACOL REV, V56, P549, DOI 10.1124/pr.56.4.3
   Homan EP, 2011, J BONE MINER RES, V26, P2798, DOI 10.1002/jbmr.487
   Horwitz EM, 1999, NAT MED, V5, P309, DOI 10.1038/6529
   Horwitz EM, 2002, P NATL ACAD SCI USA, V99, P8932, DOI 10.1073/pnas.132252399
   Jethva R, 2009, CYTOTHERAPY, V11, P3, DOI 10.1080/14653240902753477
   Lapidot T, 2005, BLOOD, V106, P1901, DOI 10.1182/blood 2005 04 1417
   Li F, 2007, STEM CELLS, V25, P3183, DOI 10.1634/stemcells.2007 0466
   Li F, 2010, BONE, V47, P546, DOI 10.1016/j.bone.2010.05.040
   Lien CY, 2009, J BONE MINER RES, V24, P837, DOI [10.1359/JBMR.081257, 10.1359/jbmr.081257]
   Niyibizi C, 2004, MOL THER, V9, P955, DOI 10.1016/j.ymthe.2004.02.022
   Niyibizi Christopher, 2009, Int J Clin Rheumtol, V4, P57, DOI 10.2217/17584272.4.1.57
   Panaroni C, 2009, BLOOD, V114, P459, DOI 10.1182/blood 2008 12 195859
   Tombran Tink J, 2004, BIOCHEM BIOPH RES CO, V316, P573, DOI 10.1016/j.bbrc.2004.02.076
   Venturi G, 2012, J BONE MINER RES, V27, P723, DOI 10.1002/jbmr.1480
NR 19
TC 26
Z9 29
U1 0
U2 11
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0006 291X
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD OCT 5
PY 2012
VL 426
IS 4
BP 475
EP 479
DI 10.1016/j.bbrc.2012.08.095
PG 5
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 024HT
UT WOS:000310101000006
PM 22960177
DA 2025 08 17
ER

PT J
AU Hatakeyama, Y
   Miyakoshi, N
   Kasukawa, Y
   Watanabe, A
   Hirayama, M
   Senma, S
   Ono, I
   Shimada, Y
AF Hatakeyama, Yuji
   Miyakoshi, Naohisa
   Kasukawa, Yuji
   Watanabe, Arata
   Hirayama, Masashi
   Senma, Seietsu
   Ono, Iwao
   Shimada, Yoichi
TI Vertebral Histomorphometry in a Child with Glucocorticoid Induced
   Osteoporosis
SO TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE
LA English
DT Article
DE bisphosphonate; bone histomorphometry; glucocorticoid induced
   osteoporosis; growth; osteoblast
ID BONE HISTOMORPHOMETRY; ALENDRONATE; MECHANISMS; ARTHRITIS; THERAPY
AB Vertebral fractures are an under recognized problem in children with glucocorticoid induced osteoporosis (GIO). They cause severe back pain and spinal column deformity with a decrease of quality of life. For evaluating the bone mass, bone mineral density measurements have been widely carried out using dual energy X ray absorptiometry. However, bone histomorphometric analyses of GIO in children are scarce. Bone histomorphometric analyses of vertebral bodies have not been reported. Our aim is to report the first bone histomorphometric data for vertebrae from an autopsied child with GIO. A 15 year old girl with systemic lupus erythematosus was started on a daily oral dose of 10 mg of prednisolone at 6 years of age. She presented with back pain from 12 years of age. Magnetic resonance imaging at 14 years of age showed a compression fracture of the first lumbar (L1) vertebral body. At 15 years of age, she died of heart failure owing to pulmonary hypertension. Collapsed (L1) and non collapsed (seventh thoracic vertebrae; 17) vertebral bodies were autopsied for bone histomorphometry and compared. T7 showed severe osteoporosis (bone volume, 4.99%; trabecular thickness, 59 mu m; trabecular separation, 1,134 mu m). Compared with T7, L1 showed increased bone volume (33.9%) and trabecular thickness (77 mu m), and decreased trabecular separation (156 mu m) owing to the impact of the vertebral fracture. The bone formation and bone resorption parameters were comparable between the two vertebrae. These histological findings suggest that severe osteoporosis developed after long term glucocorticoid administration, and that the remodeling activities were similar in the fractured and non fractured vertebrae.
C1 [Hatakeyama, Yuji; Senma, Seietsu] Nakadori Gen Hosp, Dept Orthoped Surg, Akita 0100012, Japan.
   [Miyakoshi, Naohisa; Kasukawa, Yuji; Shimada, Yoichi] Akita Univ, Sch Med, Dept Orthoped Surg, Akita 010, Japan.
   [Watanabe, Arata; Hirayama, Masashi] Nakadori Gen Hosp, Dept Pediat, Akita, Japan.
   [Ono, Iwao] Nakadori Gen Hosp, Div Clin Pathol, Akita, Japan.
C3 Akita University
RP Hatakeyama, Y (通讯作者)，Nakadori Gen Hosp, Dept Orthoped Surg, Minamidori Misonocho 3 15, Akita 0100012, Japan.
EM yjhatake@y5.dion.ne.jp
RI Hirayama, Masashi/MGW 4759 2025
CR Bianchi ML, 2000, ARTHRITIS RHEUM US, V43, P1960, DOI 10.1002/1529 0131(200009)43:9<1960::AID ANR6>3.0.CO;2 J
   Brumsen C, 1997, MEDICINE, V76, P266, DOI 10.1097/00005792 199707000 00005
   Canalis E, 2004, BONE, V34, P593, DOI 10.1016/j.bone.2003.11.026
   Canalis E, 2002, ANN NY ACAD SCI, V966, P73, DOI 10.1111/j.1749 6632.2002.tb04204.x
   Chappard D, 1996, J BONE MINER RES, V11, P676
   Glorieux FH, 2000, BONE, V26, P103, DOI 10.1016/S8756 3282(99)00257 4
   Huber AM, 2010, ARTHRIT CARE RES, V62, P516, DOI 10.1002/acr.20171
   MELLISH RWE, 1991, J BONE MINER RES, V6, P689
   Meunier P, 1973, Clin Endocrinol Metab, V2, P239, DOI 10.1016/S0300 595X(73)80042 8
   Nishiyama S, 2001, CLIN PEDIAT ENDOCRIN, V10, P113
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Rudge S, 2005, RHEUMATOLOGY, V44, P813, DOI 10.1093/rheumatology/keh538
   Valta H, 2007, J RHEUMATOL, V34, P831
   VARONOS S, 1987, CALCIFIED TISSUE INT, V41, P75, DOI 10.1007/BF02555248
   Ward LM, 2004, J BONE MINER RES, V19
   Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799
NR 16
TC 3
Z9 3
U1 0
U2 2
PU TOHOKU UNIV MEDICAL PRESS
PI SENDAI
PA 2 1, SEIRYO MACHI, AOBA KU, SENDAI, MIYAGI 980 8575, JAPAN
SN 0040 8727
EI 1349 3329
J9 TOHOKU J EXP MED
JI Tohoku J. Exp. Med.
PD AUG
PY 2012
VL 227
IS 4
BP 263
EP 267
DI 10.1620/tjem.227.263
PG 5
WC Medicine, General & Internal; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine; Research & Experimental Medicine
GA 988XD
UT WOS:000307523900004
PM 22820697
OA Bronze
DA 2025 08 17
ER

PT J
AU Más, BA
   Cattani, SMD
   Rangel, RDC
   Ribeiro, GD
   Cruz, NC
   Leite, FD
   Nascente, PAD
   Duek, EAD
AF Mas, Bruna Antunes
   de Mello Cattani, Silvia Mara
   Cipriano Rangel, Rita de Cassia
   Ribeiro, Gabrielle de Almeida
   Cruz, Nilson Cristino
   Leite, Fabio de Lima
   de Paula Nascente, Pedro Augusto
   de Rezende Duek, Eliana Aparecida
TI Surface Characterization and Osteoblast like Cells Culture on Collagen
   Modified PLDLA Scaffolds
SO MATERIALS RESEARCH IBERO AMERICAN JOURNAL OF MATERIALS
LA English
DT Article
DE bioabsorbable polymers; collagen immobilization; PLDLA scaffolds;
   surface modification; tissue engineering
ID BIOMATERIALS; ADHESION; POLYMERS; FILMS; IMMOBILIZATION; ADSORPTION;
   PEPTIDES; PROPERTY; IMPLANTS; GROWTH
AB Surface modification techniques based on the grafting of chemical functional groups and immobilization of bioactive molecules have been used to improve biocompatibility and clinical performance of bioabsorbable scaffolds in tissue engineering and medicine regenerative applications. This study aimed at developing and characterizing a biomimetic surface to stimulate bone regeneration by a simple and low cost method of surface biofunctionalization of the poly (L co D, L lactic acid) PLDLA scaffolds. The method was obtained by grafting reaction of carboxyl groups ( COOH) on their surface via acrylic acid (AAc) polymerization process, followed by immobilization of collagen type I (Col). Such approach resulted in a surface morphology markedly modified after treatment, with increase of pores and roughness on PLDLA AAc surfaces and a network of fibrillar collagen deposition in nonspecific areas of PLDLA Col surfaces. The cytocompatibility of collagen immobilized scaffolds was significantly improved in terms of cellular adhesion, proliferation, collagen synthesis and maintenance of osteoblast like phenotype, indicating, therefore, the fundamental role of collagen protein over the biological interactions that occur by bio recognition mimetic mechanisms at biomaterials interface. These results indicate that the surface modification method used here may be useful as a strategy to develop biofunctional scaffolds, which provide a more successful clinical application of biomaterials in the tissue engineering field.
C1 [Mas, Bruna Antunes; de Rezende Duek, Eliana Aparecida] Univ Estadual Campinas UNICAMP, Fac Mech Engn, Dept Mat Engn, BR 13083970 Campinas, SP, Brazil.
   [Mas, Bruna Antunes; de Mello Cattani, Silvia Mara; de Rezende Duek, Eliana Aparecida] Pontificia Univ Catolica Sao Paulo PUC SP, Lab Biomat, BR 18030070 Sorocaba, SP, Brazil.
   [Cipriano Rangel, Rita de Cassia; Cruz, Nilson Cristino] Univ Estadual Paulista UNESP, Lab Technol Plasmas, BR 18085180 Sorocaba, SP, Brazil.
   [Ribeiro, Gabrielle de Almeida; Leite, Fabio de Lima] Univ Fed Sao Carlos UFSCar, Dept Mat Engn, BR 18052780 Sorocaba, SP, Brazil.
   [de Paula Nascente, Pedro Augusto] Univ Fed Sao Carlos UFSCar, Dept Mat Engn, BR 13565905 Sao Carlos, SP, Brazil.
C3 Universidade Estadual de Campinas; Pontificia Universidade Catolica de
   Sao Paulo; Universidade Estadual Paulista; Universidade Federal de Sao
   Carlos; Universidade Federal de Sao Carlos
RP Más, BA (通讯作者)，Univ Estadual Campinas UNICAMP, Fac Mech Engn, Dept Mat Engn, Rua Mendeleyev 200, BR 13083970 Campinas, SP, Brazil.
EM masbruna@fem.unicamp.br
RI Duek, Eliana/J 2499 2012; de Lima Leite, Fabio/B 8466 2008; C Cruz,
   Nilson/C 8519 2012; Cruz, Nilson/AAG 8366 2020; Rangel, Rita de Cassia
   Teixeira/JYP 6026 2024; RANGEL, RITA/JYP 6026 2024
OI Duek, Eliana/0000 0001 6327 7363; C Cruz, Nilson/0000 0002 0354 3890;
   Rangel, Rita de Cassia Teixeira/0000 0001 9713 0220; Leite,
   Fabio/0000 0001 9620 9789
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [2012/12081 2, 2007/05089 9]; National Institute of Science and
   Technology in Biofabrication (INCT Biofabris); Fundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP) [12/12081 2] Funding Source:
   FAPESP
FX This work was supported by Fundacao de Amparo a Pesquisa do Estado de
   Sao Paulo (FAPESP, grant no. 2012/12081 2), (FAPESP, grant no.
   2007/05089 9) and the National Institute of Science and Technology in
   Biofabrication (INCT Biofabris).
CR Adamczak M, 2011, ACTA BIOENG BIOMECH, V13, P63
   Anselme K, 2000, BIOMATERIALS, V21, P667, DOI 10.1016/S0142 9612(99)00242 2
   Arima Y, 2007, BIOMATERIALS, V28, P3074, DOI 10.1016/j.biomaterials.2007.03.013
   BEAMSON G, 1992, MOL PHYS, V76, P919, DOI 10.1080/00268979200101761
   Blumenstein R, 2002, INT J ONCOL, V21, P447
   Cai KY, 2002, BIOMATERIALS, V23, P1603, DOI 10.1016/S0142 9612(01)00287 3
   Campos MLAM, 2001, QUIM NOVA, V24, P257, DOI 10.1590/S0100 40422001000200018
   Cheng ZY, 2004, BIOMATERIALS, V25, P1991, DOI 10.1016/j.biomaterials.2003.08.038
   Chollet C, 2007, BIOMOL ENG, V24, P477, DOI 10.1016/j.bioeng.2007.07.012
   Ciambelli GS, 2013, MATER RES IBERO AM J, V16, P28, DOI 10.1590/S1516 14392012005000146
   De Bartolo L, 2007, BIOMOL ENG, V24, P23, DOI 10.1016/j.bioeng.2006.07.001
   Dhyani V, 2014, ACS APPL MATER INTER, V6, P5005, DOI 10.1021/am4060595
   Ellis SJ, 2010, CELL TISSUE RES, V339, P121, DOI 10.1007/s00441 009 0828 4
   García García JM, 2012, J BIOMED MATER RES A, V100A, P7, DOI 10.1002/jbm.a.33215
   González Paz RJ, 2013, REACT FUNCT POLYM, V73, P690, DOI 10.1016/j.reactfunctpolym.2013.02.005
   He FP, 2013, COLLOID SURFACE B, V103, P209, DOI 10.1016/j.colsurfb.2012.10.018
   Hegazy D., 2012, Journal of Chemical Engineering, V1, P42
   Hersel U, 2003, BIOMATERIALS, V24, P4385, DOI 10.1016/S0142 9612(03)00343 0
   Jiao YP, 2007, BIOMED MATER, V2, pR24, DOI 10.1088/1748 6041/2/4/R02
   Ke Y, 2010, ACTA BIOMATER, V6, P1329, DOI 10.1016/j.actbio.2009.10.026
   Kyle S, 2009, TRENDS BIOTECHNOL, V27, P423, DOI 10.1016/j.tibtech.2009.04.002
   Lee Duron A., 2008, P163, DOI 10.1201/9781420051834.ch6
   Li YX, 2012, J BIOMED MATER RES A, V100A, P3496, DOI 10.1002/jbm.a.34276
   Linsley C, 2013, TISSUE ENG PT A, V19, P1416, DOI [10.1089/ten.TEA.2012.0523, 10.1089/ten.tea.2012.0523]
   Liu YC, 2013, BIOTECHNOL ADV, V31, P688, DOI 10.1016/j.biotechadv.2012.10.003
   Ma ZW, 2007, COLLOID SURFACE B, V60, P137, DOI 10.1016/j.colsurfb.2007.06.019
   Ma ZW, 2005, BIOMATERIALS, V26, P1253, DOI 10.1016/j.biomaterials.2004.04.031
   Motta AC, 2007, POLIMEROS, V17, P123, DOI 10.1590/S0104 14282007000200011
   Nascente PAP, 2005, J MOL CATAL A CHEM, V228, P145, DOI 10.1016/j.molcata.2004.09.075
   Ng KW, 2005, TISSUE ENG, V11, P182, DOI 10.1089/ten.2005.11.182
   Parenteau Bareil R, 2010, MATERIALS, V3, P1863, DOI 10.3390/ma3031863
   Rahmany MB, 2013, ACTA BIOMATER, V9, P5431, DOI 10.1016/j.actbio.2012.11.019
   Ratner BD, 2007, POLYM INT, V56, P1183, DOI 10.1002/pi.2319
   Roach P, 2007, J MATER SCI MATER M, V18, P1263, DOI 10.1007/s10856 006 0064 3
   Shen J, 2009, J BIOMED MATER RES B, V91B, P897, DOI 10.1002/jbm.b.31472
   Shin H, 2007, BIOMATERIALS, V28, P126, DOI 10.1016/j.biomaterials.2006.08.007
   Steffens GCM, 2002, BIOMATERIALS, V23, P3523, DOI 10.1016/S0142 9612(02)00091 1
   Sultana N, 2012, BIOFABRICATION, V4, DOI 10.1088/1758 5082/4/1/015003
   Paragkumar NT, 2006, APPL SURF SCI, V253, P2758, DOI 10.1016/j.apsusc.2006.05.047
   Vladkova TG, 2010, INT J POLYM SCI, V2010, DOI 10.1155/2010/296094
   von der Mark K, 2010, CELL TISSUE RES, V339, P131, DOI 10.1007/s00441 009 0896 5
   von Wilmowsky C, 2014, ORAL MAXILLOFAC SURG, V18, P243, DOI 10.1007/s10006 013 0398 1
   Wang LY, 2009, J MACROMOL SCI A, V46, P765, DOI 10.1080/10601320903004517
   Williams DF, 2009, BIOMATERIALS, V30, P5897, DOI 10.1016/j.biomaterials.2009.07.027
   Yokoyama Y, 2006, NUCL INSTRUM METH B, V242, P37, DOI 10.1016/j.nimb.2005.08.020
NR 45
TC 19
Z9 19
U1 0
U2 19
PU UNIV FED SAO CARLOS, DEPT ENGENHARIA MATERIALS
PI SAO CARLOS
PA LABORATORIA DE MATERIAIS VITREOS, CAIXA POSTAL 676, SAO CARLOS,
   13565 905SP, BRAZIL
SN 1516 1439
EI 1980 5373
J9 MATER RES IBERO AM J
JI Mater. Res. Ibero am. J. Mater.
PD NOV DEC
PY 2014
VL 17
IS 6
BP 1523
EP 1534
DI 10.1590/1516 1439.269414
PG 12
WC Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA CB6WG
UT WOS:000349766900021
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Goodman, SB
   Trindade, M
   Ma, T
   Genovese, M
   Smith, RL
AF Goodman, SB
   Trindade, M
   Ma, T
   Genovese, M
   Smith, RL
TI Pharmacologic modulation of periprosthetic osteolysis
SO CLINICAL ORTHOPAEDICS AND RELATED RESEARCH
LA English
DT Article
ID NECROSIS FACTOR ALPHA; DEBRIS INDUCED OSTEOLYSIS; BONE INGROWTH;
   TITANIUM ALLOY; RECEPTOR ACTIVATOR; HUMAN MACROPHAGES; LOCAL INFUSION;
   GENE THERAPY; INTERLEUKIN 10; POLYETHYLENE
AB Wear and periprosthetic osteolysis of total joint replacements continue to be the most important problems in arthroplasty surgery. Despite the introduction of improved technologies including alternative bearing surfaces for TJRs, wear is inevitable because of relative movement at different interfaces and processes such as electrolysis and material degradation. Worn, clinically failing implants need to be followed closely and revised when appropriate. However, early wear and minor osteolysis do not result necessarily in progressive failure of the prosthesis. Indeed such cases may be followed up clinically and radiographically to establish the functional and biologic sequelae of wear and the timeline of these events. This scenario provides an opportunity to modulate the adverse biologic reaction associated with wear particles that includes chronic inflammation, the foreign body response, and periprosthetic bone destruction. Currently, immunological events associated with wear particles are becoming understood more clearly. Strategies to mitigate adverse processes associated with wear debris include local or systemic administration of immune modulators, signaling molecules, anti inflammatory agents and growth factors, and altering osteoclast function. Ultimately, prevention of accelerated wear and periprosthetic osteolysis will be achieved with improved bearing surfaces and prosthetic designs.
C1 Stanford Univ, Med Ctr, Div Orthopaed Surg, Stanford, CA 94305 USA.
   Stanford Univ, Med Ctr, Div Rheumatol & Immunol, Stanford, CA 94305 USA.
C3 Stanford University; Stanford University
RP Stanford Univ, Med Ctr, Div Orthopaed Surg, 300 Pasteur Dr, Stanford, CA 94305 USA.
EM goodbone@stanford.edu
RI ; Goodman, Stuart/AAZ 7499 2020
OI Goodman, Stuart/0000 0002 1919 3717; 
CR Anderson GI, 2001, J BIOMED MATER RES, V58, P406, DOI 10.1002/jbm.1035
   [Anonymous], 2006, ACTA BIOMATER, DOI DOI 10.1016/j.actbio.2005.09.004
   Åstrand J, 1999, ACTA ORTHOP SCAND, V70, P67, DOI 10.3109/17453679909000961
   Blaine TA, 1997, J BONE JOINT SURG AM, V79A, P1519, DOI 10.2106/00004623 199710000 00009
   Carmody EE, 2002, ARTHRITIS RHEUM US, V46, P1298, DOI 10.1002/art.10227
   CHIBA J, 1994, CLIN ORTHOP RELAT R, V300, P304
   Childs LM, 2002, J BONE MINER RES, V17, P192, DOI 10.1359/jbmr.2002.17.2.192
   Childs LM, 2001, J BONE MINER RES, V16, P338, DOI 10.1359/jbmr.2001.16.2.338
   Childs LM, 2001, J BONE JOINT SURG AM, V83A, P1789, DOI 10.2106/00004623 200112000 00004
   Clohisy JC, 2003, J ORTHOPAED RES, V21, P202, DOI 10.1016/S0736 0266(02)00133 X
   DIGIOVINE FS, 1996, THERAPEUTIC MODULATI, P37
   Fritz EA, 2002, J ORTHOPAED RES, V20, P490, DOI 10.1016/S0736 0266(01)00154 1
   Goater JJ, 2002, J ORTHOPAED RES, V20, P169, DOI 10.1016/S0736 0266(01)00083 3
   Goodman S, 2003, J BIOMED MATER RES A, V65A, P43, DOI 10.1002/jbm.a.10279
   Goodman S, 2002, J ORTHOP RES, V20, P1164, DOI 10.1016/S0736 0266(02)00079 7
   Goodman SB, 2003, J BIOMED MATER RES A, V65A, P454, DOI 10.1002/jbm.a.3000
   GOODMAN SB, 1991, BIOMATERIALS, V12, P194, DOI 10.1016/0142 9612(91)90199 K
   Goodman SB, 1999, J BONE JOINT SURG BR, V81B, P1069, DOI 10.1302/0301 620X.81B6.9638
   GOODMAN SB, 1991, CLIN ORTHOP RELAT R, V271, P300
   Haynes DR, 2001, J BONE JOINT SURG BR, V83B, P902, DOI 10.1302/0301 620X.83B6.10905
   HERMAN JH, 1994, J RHEUMATOL, V21, P338
   Horowitz SM, 1996, J BIOMED MATER RES, V31, P91, DOI 10.1002/(SICI)1097 4636(199605)31:1<91::AID JBM11>3.0.CO;2 P
   Huk OL, 2003, J ORTHOP RES, V21, P81, DOI 10.1016/S0736 0266(02)00099 2
   Im GI, 2001, J BIOMED MATER RES, V58, P531
   Kim KJ, 2001, J BIOMED MATER RES, V58, P393, DOI 10.1002/jbm.1033
   MacQuarrie RA, 2004, J BIOMED MATER RES B, V69B, P104, DOI 10.1002/jbm.b.20031
   Mandell GL, 1995, J CARDIOVASC PHARM, V25, pS20, DOI 10.1097/00005344 199500252 00005
   Millett PJ, 2002, J BONE JOINT SURG AM, V84A, P236, DOI 10.2106/00004623 200202000 00011
   Nakashima Y, 1998, J BONE JOINT SURG BR, V80B, P694, DOI 10.1302/0301 620X.80B4.8374
   Nakashima Y, 1999, J BONE JOINT SURG AM, V81A, P603, DOI 10.2106/00004623 199905000 00002
   Nakashima Y, 1999, J BONE JOINT SURG BR, V81B, P155, DOI 10.1302/0301 620X.81B1.8884
   Pandey R, 1996, ACTA ORTHOP SCAND, V67, P221, DOI 10.3109/17453679608994677
   Papatheofanis Frank J., 1996, Am J Ther, V3, P21, DOI 10.1097/00045391 199601000 00005
   Pollice PE, 2001, J BONE JOINT SURG AM, V83A, P1057, DOI 10.2106/00004623 200107000 00012
   Pollice PF, 1998, J ORTHOP RES, V16, P697, DOI 10.1002/jor.1100160611
   Ren WP, 2004, J ORTHOP RES, V22, P21, DOI 10.1016/S0736 0266(03)00130 X
   Ren WP, 2003, BIOMATERIALS, V24, P4819, DOI 10.1016/S0142 9612(03)00384 3
   Sabokbar A, 1996, ACTA ORTHOP SCAND, V67, P593, DOI 10.3109/17453679608997763
   SCHMALZRIED TP, 1992, CLIN ORTHOP RELAT R, P60
   Schwarz EM, 2000, ARTHRITIS RES, V2, P165, DOI 10.1186/ar81
   Shanbhag AS, 1997, CLIN ORTHOP RELAT R, P33
   Sun JS, 2000, J BIOMED MATER RES, V52, P509, DOI 10.1002/1097 4636(20001205)52:3<509::AID JBM9>3.0.CO;2 P
   Thadani PJ, 2002, ORTHOPEDICS, V25, P59
   Trindade MCD, 2001, BIOMATERIALS, V22, P2067, DOI 10.1016/S0142 9612(00)00376 8
   Trindade MCD, 1999, J ORTHOP RES, V17, P797, DOI 10.1002/jor.1100170602
   Zhang XP, 2001, J BONE MINER RES, V16, P660, DOI 10.1359/jbmr.2001.16.4.660
NR 46
TC 29
Z9 35
U1 0
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0009 921X
EI 1528 1132
J9 CLIN ORTHOP RELAT R
JI Clin. Orthop. Rel. Res.
PD JAN
PY 2005
IS 430
BP 39
EP 45
DI 10.1097/01.blo.0000149998.88218.05
PG 7
WC Orthopedics; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics; Surgery
GA 885GQ
UT WOS:000226145500005
PM 15662302
DA 2025 08 17
ER

PT J
AU Zhai, Y
   Wang, YY
   Rao, NQ
   Li, JZ
   Li, XX
   Fang, TJZ
   Zhao, YM
   Ge, LH
AF Zhai, Yue
   Wang, Yuanyuan
   Rao, Nanquan
   Li, Jingzhi
   Li, Xiaoxia
   Fang, Tengjiaozi
   Zhao, Yuming
   Ge, Lihong
TI Activation and Biological Properties of Human β Defensin 4 in Stem Cells
   Derived From Human Exfoliated Deciduous Teeth
SO FRONTIERS IN PHYSIOLOGY
LA English
DT Article
DE human beta defensin 4; SHED; anti inflammatory; stem cell
   differentiation; pulp regeneration
ID MINERAL TRIOXIDE AGGREGATE; OSTEOGENIC DIFFERENTIATION; GENE EXPRESSION;
   PORPHYROMONAS GINGIVALIS; INFLAMMATORY RESPONSE; IN VITRO;
   PROLIFERATION; BETA DEFENSIN 2; INHIBITION; HEALTHY
AB Pulpitis in primary teeth, a condition caused by presence of bacteria, is highly prevalent worldwide. The use of biocompatibility materials with anti inflammatory, anti bacterial, and regenerative properties is critical for prognosis of this endodontic disease. This study aimed to identify expression of human beta defensin 4 (HBD4) in stem cells derived from human exfoliated deciduous teeth (SHED) and characterize the effects of HBD4 on SHED. Quantitative polymerase chain reaction (qPCR) was used to detect HBD4 expression in SHED and the effect of HBD4 on inflammatory factors in lipopolysaccharide (LPS) stimulated SHED. Affinity measurement was made by the Fortebio Octet System to explore the potential interaction between LPS and HBD4. Western blot analysis was used to explore the effect of HBD4 on mitogen activated protein kinase (MAPK) pathway. Colony forming unit methods and scanning electron microscopy were applied to study antimicrobial effect of HBD4 on Fusobacterium nucleatum and Porphyromonas gingivalis. Alkaline phosphatase staining, alizarin red staining, qPCR and western blot were taken to detect effects of HBD4 on osteoblast/odontoblast differentiation of SHED. RT2 Profiler PCR Array was used to explore the potential signaling pathways involved in the osteogenic/odontogenic differentiation. HBD4 was highly expressed in SHED stimulated by TNF alpha and IL 1 alpha. HBD4 could bind to LPS directly and down regulate IL 1 alpha, IL 1 beta, IL 6, TNF alpha in LPS stimulated SHED, thus the activation of MAPK pathway decreased. HBD4 was sensitive to P. gingivalis and enhanced osteoblast/odontoblast differentiation potential of SHED by modulating Notch pathway. HBD4 was highly expressed in SHED stimulated by proinflammatory cytokines, and possessed anti inflammatory, anti bacterial activity. HBD4 promoted osteogenic/odontogenic differentiation of SHED. HBD4 may thus represent a suitable agent for vital pulp therapy in future clinic application.
C1 [Zhai, Yue; Wang, Yuanyuan; Rao, Nanquan; Li, Jingzhi; Li, Xiaoxia; Fang, Tengjiaozi; Zhao, Yuming; Ge, Lihong] Peking Univ, Dept Pediat Dent, Sch & Hosp Stomatol, Beijing, Peoples R China.
C3 Peking University
RP Ge, LH (通讯作者)，Peking Univ, Dept Pediat Dent, Sch & Hosp Stomatol, Beijing, Peoples R China.
EM gelh0919@126.com
RI Ge, Li/T 3955 2018; Wang, Wu/G 2683 2018; Zhang, Zhen/GXH 3666 2022
FU National Natural Science Foundation of China [303076129]; Peking
   University Taisheng Stomatology Development Fund [94000 6672 H78]
FX This study has been supported by the National Natural Science Foundation
   of China (303076129) and the Peking University Taisheng Stomatology
   Development Fund (No. 94000 6672 H78).
CR Bagheri L, 2018, J TISSUE ENG REGEN M, V12, P304, DOI 10.1002/term.2455
   Balto HA, 2004, J ENDODONT, V30, P25, DOI 10.1097/00004770 200401000 00005
   Bogen G, 2008, J AM DENT ASSOC, V139, P305, DOI 10.14219/jada.archive.2008.0160
   Cao JJ, 2017, INT J MOL MED, V40, P378, DOI 10.3892/ijmm.2017.3037
   da Rosa WLO, 2018, J BIOMED MATER RES B, V106, P1358, DOI 10.1002/jbm.b.33934
   DAHLEN G, 1977, SCAND J DENT RES, V85, P272
   da Rosa WLD, 2017, J BIOMED MATER RES A, V105, P941, DOI 10.1002/jbm.a.35968
   Dommisch H, 2005, ORAL MICROBIOL IMMUN, V20, P163, DOI 10.1111/j.1399 302X.2005.00206.x
   Gomes BRFA, 2007, J ENDODONT, V33, P1049, DOI 10.1016/j.joen.2007.05.017
   Joly S, 2004, J CLIN MICROBIOL, V42, P1024, DOI 10.1128/JCM.42.3.1024 1029.2004
   Kim YS, 2010, J ENDODONT, V36, P64, DOI 10.1016/j.joen.2009.09.022
   Kraus D, 2012, J CELL PHYSIOL, V227, P994, DOI 10.1002/jcp.22808
   Lee SI, 2015, CLIN ORAL INVEST, V19, P1419, DOI 10.1007/s00784 014 1361 8
   Lee SI, 2011, J ENDODONT, V37, P1525, DOI 10.1016/j.joen.2011.07.006
   Lee SH, 2012, J ENDODONT, V38, P351, DOI 10.1016/j.joen.2011.12.026
   Liu HY, 2013, APPL MICROBIOL BIOT, V97, P3395, DOI 10.1007/s00253 012 4588 9
   Liu LY, 2013, J TRAUMA ACUTE CARE, V75, P789, DOI 10.1097/TA.0b013e3182a6862b
   Lyu JL, 2017, CYTOKINE, V92, P48, DOI 10.1016/j.cyto.2016.12.015
   Matsuzaki K, 1999, BBA BIOMEMBRANES, V1462, P1, DOI 10.1016/S0005 2736(99)00197 2
   Miura M, 2003, P NATL ACAD SCI USA, V100, P5807, DOI 10.1073/pnas.0937635100
   Motzkus D, 2006, FASEB J, V20, P1701, DOI 10.1096/fj.05 4970fje
   Mutluay M, 2018, PEDIATR DENT, V40, P37
   Nair PNR, 2008, INT ENDOD J, V41, P128
   Nakajo K, 2006, ORAL MICROBIOL IMMUN, V21, P283, DOI 10.1111/j.1399 302X.2006.00289.x
   Ozdemir Y, 2015, J ORAL SCI, V57, P145, DOI 10.2334/josnusd.57.145
   Paris S, 2009, J ENDODONT, V35, P520, DOI 10.1016/j.joen.2008.12.015
   Pazgier M, 2006, CELL MOL LIFE SCI, V63, P1294, DOI 10.1007/s00018 005 5540 2
   Schneider JJ, 2005, J MOL MED, V83, P587, DOI 10.1007/s00109 005 0657 1
   Schwendicke F, 2016, CLIN ORAL INVEST, V20, P1121, DOI 10.1007/s00784 016 1802 7
   Semple F, 2010, EUR J IMMUNOL, V40, P1073, DOI 10.1002/eji.200940041
   Sharma H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119525
   Shiba H, 2003, BIOCHEM BIOPH RES CO, V306, P867, DOI 10.1016/S0006 291X(03)01075 1
   Sukarawan W, 2016, ARCH ORAL BIOL, V65, P1, DOI 10.1016/j.archoralbio.2016.01.010
   Tsai AI, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/2851906
   Uraki S, 2014, INT J ONCOL, V45, P1059, DOI 10.3892/ijo.2014.2507
   Wang D, 2019, ARCH ORAL BIOL, V98, P156, DOI 10.1016/j.archoralbio.2018.11.022
   Wilson SS, 2013, J MOL BIOL, V425, P4965, DOI 10.1016/j.jmb.2013.09.038
   Xie C, 2005, PEPTIDES, V26, P2377, DOI 10.1016/j.peptides.2005.06.002
   Xie J, 2019, DIABETOL METAB SYNDR, V11, DOI 10.1186/s13098 019 0433 y
   Yu HG, 2013, J BIOL CHEM, V288, P12270, DOI 10.1074/jbc.M112.411884
   Zhang C, 2008, J DENT RES, V87, P250, DOI 10.1177/154405910808700312
   Zhou J, 2018, INT J NANOMED, V13, P555, DOI 10.2147/IJN.S150897
   Zhou M, 2018, NANOMED NANOTECHNOL, V14, P1227, DOI 10.1016/j.nano.2018.02.004
   Zhu C, 2016, EXP THER MED, V12, P2150, DOI 10.3892/etm.2016.3579
NR 44
TC 26
Z9 27
U1 0
U2 15
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1664 042X
J9 FRONT PHYSIOL
JI Front. Physiol.
PD OCT 22
PY 2019
VL 10
AR 1304
DI 10.3389/fphys.2019.01304
PG 11
WC Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Physiology
GA JL2UR
UT WOS:000495387800001
PM 31695620
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Chen, JF
   Wen, JR
   Fu, YK
   Li, X
   Huang, J
   Guan, XX
   Zhou, Y
AF Chen, Jiafei
   Wen, Junru
   Fu, Yike
   Li, Xiang
   Huang, Jie
   Guan, Xiaoxu
   Zhou, Yi
TI A bifunctional bortezomib loaded porous nano hydroxyapatite/alginate
   scaffold for simultaneous tumor inhibition and bone regeneration
SO JOURNAL OF NANOBIOTECHNOLOGY
LA English
DT Article
DE BTZ; nHA@SA scaffold; nHA; Anti tumor; Bone regeneration
ID CAVEOLIN 1 EXPRESSION; GOLD NANORODS; RECEPTOR; CELLS; DIFFERENTIATION;
   PROLIFERATION; METASTASIS; THERAPY
AB Treatments of osteolytic lesions due to malignant metastasis remain one of the major clinical challenges. The residual tumor cells after surgical resections and an acidic tumor microenvironment are unfavorable for osteogenic induction. Bortezomib (BTZ), a proteasome inhibitor used in chemotherapy, also has an osteogenic potential in concentration  and Ca2+ dependent manners. In this study, controlled delivery of BTZ in a novel bifunctional scaffold based on nano hydroxyapatite (nHA) and sodium alginate (SA) nanocomposite, namely BTZ/nHA@SA, has been explored. By smartly adjusting microenvironments, a sustainable release of Ca2+ from nHA could be achieved, which was not only able to cross link SA but also to regulate the switch between the dual functions of tumor inhibition and bone regeneration of BTZ to promote the osteogenic pathway. The freeze dried BTZ/nHA@SA scaffold has excellent interconnectivity, is capable to promote the attachment and proliferation of mouse embryonic osteoblast precursor cells, as well as effectively induces breast cancer cell death in vitro. Furthermore, in vivo, studies using a mouse tumor model and a rabbit femoral defect model showed that the BTZ/nHA@SA scaffold could promote tumor ablation, and also enhance bone repair. Therefore, the BTZ/nHA@SA scaffold has unique dual functions of inhibiting tumor recurrence and promoting bone tissue regeneration simultaneously. This smart bi functional scaffold offers a promising novel approach for oncological treatments by synchronously orchestrating tumor inhibition and tissue regeneration for the repair of neoplastic bone defects.
C1 [Chen, Jiafei; Wen, Junru; Guan, Xiaoxu; Zhou, Yi] Zhejiang Univ Med, Affiliated Hosp Stomatol, Sch Stomatol, Hangzhou 310006, Zhejiang, Peoples R China.
   [Chen, Jiafei; Wen, Junru; Guan, Xiaoxu; Zhou, Yi] Key Lab Oral Biomed Res Zhejiang Prov, Hangzhou 310006, Zhejiang, Peoples R China.
   [Fu, Yike; Li, Xiang] Zhejiang Univ, Sch Mat Sci & Engn, State Key Lab Silicon Mat, Hangzhou 310027, Peoples R China.
   [Fu, Yike; Li, Xiang] Zhejiang Univ, ZJU Hangzhou Global Sci & Technol Innovat Ctr, Hangzhou 311200, Peoples R China.
   [Huang, Jie] UCL, Dept Mech Engn, London WC1E 7JE, England.
C3 Zhejiang University; Zhejiang University; University of London;
   University College London
RP Guan, XX; Zhou, Y (通讯作者)，Zhejiang Univ Med, Affiliated Hosp Stomatol, Sch Stomatol, Hangzhou 310006, Zhejiang, Peoples R China.; Guan, XX; Zhou, Y (通讯作者)，Key Lab Oral Biomed Res Zhejiang Prov, Hangzhou 310006, Zhejiang, Peoples R China.; Li, X (通讯作者)，Zhejiang Univ, Sch Mat Sci & Engn, State Key Lab Silicon Mat, Hangzhou 310027, Peoples R China.; Li, X (通讯作者)，Zhejiang Univ, ZJU Hangzhou Global Sci & Technol Innovat Ctr, Hangzhou 311200, Peoples R China.
EM xiang.li@zju.edu.cn; 7312020@zju.edu.cn; zyuthscsa@zju.edu.cn
OI Guan, Xiaoxu/0000 0002 3286 9769; Huang, Jie/0000 0001 7951 2217; Fu,
   Yike/0009 0005 8946 3072
FU Zhejiang Provincial Natural Science Foundation of China [LY23H140001];
   National Natural Science Foundation of China [52172289, 51902288];
   Provincial Key research program of Zhejiang Province [2020C04005];
   Fundamental Research Funds for the Central Universities
FX Jiafei Chen and Junru Wen contributed equally to this work. We thank Q.
   Chu, Z. Hu, F. Li and C. Zhou guidance on some experiments. This
   research was supported by Zhejiang Provincial Natural Science Foundation
   of China under Grant No.LY23H140001, National Natural Science Foundation
   of China (52172289, 51902288), Provincial Key research program of
   Zhejiang Province (2020C04005) and Fundamental Research Funds for the
   Central Universities.
CR Arellano DL, 2022, J BONE MINER RES, V37, P1446, DOI 10.1002/jbmr.4615
   Awasthi S, 2021, J MATER CHEM B, V9, P228, DOI 10.1039/d0tb02407d
   Baker N, 2012, J CELL BIOCHEM, V113, P3773, DOI 10.1002/jcb.24252
   Dang WT, 2019, APPL MATER TODAY, V16, P42, DOI 10.1016/j.apmt.2019.04.015
   Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590
   Dodero A, 2021, ADV MATER INTERFACES, V8, DOI 10.1002/admi.202100809
   Dong F, 2005, BRIT J PHARMACOL, V145, P323, DOI 10.1038/sj.bjp.0706193
   Dvir T, 2011, NAT NANOTECHNOL, V6, P13, DOI [10.1038/nnano.2010.246, 10.1038/NNANO.2010.246]
   Edwards CM, 2007, BLOOD, V110, p82A
   Fang YP, 2021, OXID MED CELL LONGEV, V2021, DOI 10.1155/2021/9661200
   Futakuchi M, 2016, ADV DRUG DELIVER REV, V99, P206, DOI 10.1016/j.addr.2015.11.017
   Gangadharan V, 2015, AM J PHYSIOL CELL PH, V308, pC41, DOI 10.1152/ajpcell.00037.2014
   Gao YJ, 2019, MAR DRUGS, V17, DOI 10.3390/md17100557
   Han WJ, 2021, BIOMATERIALS, V269, DOI 10.1016/j.biomaterials.2020.120624
   Han Y, 2013, ACTA BIOMATER, V9, P9107, DOI 10.1016/j.actbio.2013.06.022
   Hassani A, 2022, CARBOHYD POLYM, V277, DOI 10.1016/j.carbpol.2021.118807
   He C, 2021, ADV FUNCT MATER, V31, DOI 10.1002/adfm.202006214
   Heider U, 2006, EUR J HAEMATOL, V77, P233, DOI 10.1111/j.1600 0609.2006.00692.x
   Janeway KA, 2010, LANCET ONCOL, V11, P670, DOI 10.1016/S1470 2045(10)70062 0
   Jeon O, 2022, BIOACT MATER, V15, P185, DOI 10.1016/j.bioactmat.2021.11.025
   Jha AK, 2019, J GLOB ONCOL, V5, DOI 10.1200/JGO.19.00015
   Jiang PL, 2019, THERANOSTICS, V9, P2950, DOI 10.7150/thno.29617
   Jiao HX, 2016, VASC PHARMACOL, V84, P55, DOI 10.1016/j.vph.2016.06.004
   Jung HJ, 2012, BLOOD, V119, P2568, DOI 10.1182/blood 2011 09 377598
   Larraza I, 2020, MATERIALS, V13, DOI 10.3390/ma13051081
   Liao JF, 2021, BIOACT MATER, V6, P2221, DOI 10.1016/j.bioactmat.2021.01.006
   Liu JH, 2022, BIOMOLECULES, V12, DOI 10.3390/biom12010051
   Liu Y, 2022, MATER TODAY BIO, V14, DOI 10.1016/j.mtbio.2022.100227
   Lyu Y, 2019, SMALL METHODS, V3, DOI 10.1002/smtd.201900553
   Miao H, 2021, ADV FUNCT MATER, V31, DOI 10.1002/adfm.202007188
   Mori M, 2020, MAR DRUGS, V18, DOI 10.3390/md18100520
   Pan Y, 2022, MATER TODAY CHEM, V24, DOI 10.1016/j.mtchem.2022.100829
   Pang LB, 2022, BIOACT MATER, V12, P1, DOI 10.1016/j.bioactmat.2021.10.030
   Podar K, 2004, BLOOD, V104, p673A
   Qian KY, 2020, BIOMATERIALS, V259, DOI 10.1016/j.biomaterials.2020.120299
   Rammal H, 2017, ACS APPL MATER INTER, V9, P12791, DOI 10.1021/acsami.7b01665
   Rubin J, 2007, J BONE MINER RES, V22, P1408, DOI 10.1359/jbmr.070601
   Sanchez E, 2016, BLOOD, V128, DOI 10.1182/blood.V128.22.3297.3297
   Shebi A, 2018, CARBOHYD POLYM, V201, P39, DOI 10.1016/j.carbpol.2018.08.012
   Soares IPM, 2022, DENT MATER, V38, P960, DOI 10.1016/j.dental.2022.03.006
   Song XL, 2022, FRONT BIOENG BIOTECH, V10, DOI 10.3389/fbioe.2022.832727
   Spraker Perlman HL, 2019, PEDIATR BLOOD CANCER, V66, DOI 10.1002/pbc.27444
   Sun JC, 2013, MATERIALS, V6, P1285, DOI 10.3390/ma6041285
   Tao JG, 2022, J BONE MINER RES, V37, P629, DOI 10.1002/jbmr.4496
   Terpos E, 2013, BLOOD, V122, DOI 10.1182/blood.V122.21.3090.3090
   Ulrich GD, 2022, J POLYM ENVIRON, V30, P3688, DOI 10.1007/s10924 022 02459 5
   Vankayala R, 2018, ADV MATER, V30, DOI 10.1002/adma.201706320
   Varaprasad K, 2020, CARBOHYD POLYM, V236, DOI 10.1016/j.carbpol.2020.116025
   Volsi AL, 2017, ACS APPL MATER INTER, V9, P14453, DOI 10.1021/acsami.7b03711
   Wang C, 2021, BIOMED RES INT, V2021, DOI 10.1155/2021/5551504
   Wang XC, 2017, NPG ASIA MATER, V9, DOI 10.1038/am.2017.47
   Wang YH, 2016, COLLOID SURFACE B, V140, P297, DOI 10.1016/j.colsurfb.2015.12.056
   Waxman I., 2008, BLOOD, V112, P4983, DOI [10.1182/blood.V112.11.4983.4983, DOI 10.1182/BLOOD.V112.11.4983.4983]
   Xu LQ, 2016, MOL CANCER THER, V15, P854, DOI 10.1158/1535 7163.MCT 15 0669
   Yang XY, 2012, BIOCHEM BIOPH RES CO, V426, P334, DOI 10.1016/j.bbrc.2012.08.079
   Yang Y, 2020, NANOSCALE, V12, P13548, DOI 10.1039/d0nr02800b
   Yuan JP, 2022, MATER TODAY BIO, V15, DOI 10.1016/j.mtbio.2022.100318
   Zhang J, 2016, AM J PHYSIOL CELL PH, V311, pC482, DOI 10.1152/ajpcell.00324.2015
   Zhang K, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aax6946
   Zhao CC, 2020, CHEM ENG J, V401, DOI 10.1016/j.cej.2020.125989
   Zheng J, 2019, LWT FOOD SCI TECHNOL, V103, P131, DOI 10.1016/j.lwt.2018.12.081
NR 61
TC 9
Z9 9
U1 3
U2 48
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1477 3155
J9 J NANOBIOTECHNOL
JI J. Nanobiotechnol.
PD JUN 1
PY 2023
VL 21
IS 1
AR 174
DI 10.1186/s12951 023 01940 0
PG 15
WC Biotechnology & Applied Microbiology; Nanoscience & Nanotechnology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Science & Technology   Other
   Topics
GA I0FO2
UT WOS:000999621000001
PM 37264410
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Liu, Q
   Zhao, J
   Tan, R
   Zhou, H
   Lin, Z
   Zheng, M
   Romas, E
   Xu, J
   Sims, NA
AF Liu, Q.
   Zhao, J.
   Tan, R.
   Zhou, H.
   Lin, Z.
   Zheng, M.
   Romas, E.
   Xu, J.
   Sims, N. A.
TI Parthenolide inhibits pro inflammatory cytokine production and exhibits
   protective effects on progression of collagen induced arthritis in a rat
   model
SO SCANDINAVIAN JOURNAL OF RHEUMATOLOGY
LA English
DT Article
ID NF KAPPA B; TUMOR NECROSIS FACTOR; FIBROBLAST LIKE SYNOVIOCYTES;
   RHEUMATOID ARTHRITIS; SESQUITERPENE LACTONE; OSTEOCLAST FORMATION; BONE
   DESTRUCTION; GENE EXPRESSION; INTERSTITIAL COLLAGENASE; SIGNALING
   PATHWAYS
AB Objectives: Progressive destruction of synovial joint cartilage and bone occurs in pathological conditions such as rheumatoid arthritis (RA) because of the overproduction of pro inflammatory cytokines and activation of nuclear factor kappa B (NF kappa B). Through the screening of NF kappa B inhibitors by a luciferase reporter gene assay, we identified parthenolide (PAR) as the most potent NF kappa B inhibitor, among several PAR analogue compounds. This study was undertaken to determine whether PAR inhibits pro inflammatory cytokine production, cartilage degradation, and inflammatory arthritis.
   Method: The mRNA levels of pro inflammatory cytokines were examined by real time polymerase chain reaction (PCR). Proteoglycan content and release were determined by measuring glycosaminoglycan (GAG) levels using the dimethylmethylene blue (DMMB) dye binding assay. The potential role of PAR in treatment of arthritis was studied using a collagen induced arthritis (CIA) model.
   Results: We established that PAR, as a prototype compound, suppressed lipopolysaccharide (LPS) and tumour necrosis factor (TNF) alpha induced increases in matrix metalloproteinase (MMP) 1, MMP 3, inducible nitric oxide synthase (iNOS), and interleukin (IL) 1 beta mRNA in chondrocytes. In addition, PAR prevented proteoglycan degradation triggered by pro inflammatory cytokines. PAR treatment at the onset of CIA symptoms significantly reduced synovitis, inflammation, and pannus formation scores. Reduced synovial inflammation after PAR treatment was also reflected in significantly less bone erosion and cartilage damage.
   Conclusions: These data indicate a protective effect of PAR on the catabolic insults of pro inflammatory cytokines on chondrocyte metabolism and GAG release in vitro and in CIA. PAR had anti inflammatory and structure modifying effects on experimental arthritis, suggesting that PAR may be useful as a potential alternative or adjunct therapy for inflammatory arthritis.
C1 [Liu, Q.] Guangxi Med Univ, Affiliated Hosp 1, Res Ctr Regenerat Med, Nanning, Peoples R China.
   [Liu, Q.; Zhao, J.] Guangxi Med Univ, Affiliated Hosp 1, Dept Orthopaed Surg, Nanning, Peoples R China.
   [Liu, Q.; Xu, J.] Univ Western Australia, Sch Pathol & Lab Med, Perth, WA 6009, Australia.
   [Tan, R.] Nanjing Univ, Sch Med, Inst Funct Biomol, Nanjing, Jiangsu, Peoples R China.
   [Zhou, H.] China Japan Friendship Hosp, Dept Rheumatol & Immunol, Beijing, Peoples R China.
   [Lin, Z.; Zheng, M.] Univ Western Australia, Sch Surg, Ctr Orthopaed Res, Perth, WA 6009, Australia.
   [Romas, E.; Sims, N. A.] St Vincents Inst Med Res, Melbourne, Vic 3065, Australia.
   [Romas, E.; Sims, N. A.] Univ Melbourne, Melbourne, Vic 3010, Australia.
   [Romas, E.] St Vincents Hosp, Dept Med, Melbourne, Vic, Australia.
C3 Guangxi Medical University; Guangxi Medical University; University of
   Western Australia; Nanjing University; China Japan Friendship Hospital;
   University of Western Australia; St. Vincent's Institute of Medical
   Research; University of Melbourne; NSW Health; St Vincents Hospital
   Sydney; St Vincent's Health; St Vincent's Hospital Melbourne
RP Sims, NA (通讯作者)，St Vincents Inst Med Res, 41 Victoria Parade, Melbourne, Vic 3065, Australia.
EM nsims@svi.edu.au
RI zhao, jin/LBH 0351 2024; Sims, Natalie/A 7192 2012
OI Sims, Natalie/0000 0003 1421 8468; Zheng, Minghao/0000 0003 1185 4768;
   Zhao, Jinmin/0000 0002 1047 8820; Xu, Jiake/0000 0003 2021 8309
FU National Health and Medical Research Council (NHMRC) [247909]; NHMRC of
   Australia; Western Australia Medical and Health Research Infrastructure
   Fund; University of Western Australia Research Collaboration Awards;
   National Natural Science Foundation of China (NSFC) [81228013]; Guangxi
   Medical University
FX We acknowledge the excellent animal care and assistance by J Dickens and
   N McGregor, expert histology by I Poulton and pQCT analysis by E Walker.
   This work was supported by National Health and Medical Research Council
   (NHMRC) Project Grant 247909 to NAS and ER. This work was funded in part
   by NHMRC of Australia, Western Australia Medical and Health Research
   Infrastructure Fund, University of Western Australia Research
   Collaboration Awards, and a grant from the National Natural Science
   Foundation of China (NSFC, no. 81228013). Dr Q. Liu is a visiting
   scholar to The University of Western Australia sponsored by Guangxi
   Medical University.
CR Borden P, 1996, J BIOL CHEM, V271, P23577, DOI 10.1074/jbc.271.38.23577
   Bork PM, 1997, FEBS LETT, V402, P85, DOI 10.1016/S0014 5793(96)01502 5
   Burger D, 1998, ARTHRITIS RHEUM, V41, P1748, DOI 10.1002/1529 0131(199810)41:10<1748::AID ART7>3.0.CO;2 3
   COOPER WO, 1992, CLIN EXP IMMUNOL, V89, P244
   El Mabrouk M, 2007, BBA MOL CELL RES, V1773, P309, DOI 10.1016/j.bbamcr.2006.11.018
   ENGSTROMLAURENT A, 1985, ANN RHEUM DIS, V44, P83, DOI 10.1136/ard.44.2.83
   FARNDALE RW, 1986, BIOCHIM BIOPHYS ACTA, V883, P173, DOI 10.1016/0304 4165(86)90306 5
   Gooi JH, 2010, BONE, V46, P1486, DOI 10.1016/j.bone.2010.02.018
   Gough A, 1998, J RHEUMATOL, V25, P1282
   Gravallese EM, 1998, AM J PATHOL, V152, P943
   HALL IH, 1979, J PHARM SCI US, V68, P537, DOI 10.1002/jps.2600680505
   Hehner SP, 1999, J IMMUNOL, V163, P5617
   Hehner SP, 1998, J BIOL CHEM, V273, P1288, DOI 10.1074/jbc.273.3.1288
   HENDERSON B, 1989, CLIN EXP IMMUNOL, V75, P306
   Hirsch E, 2005, AM J OBSTET GYNECOL, V192, P1836, DOI 10.1016/j.ajog.2004.12.070
   Horwood NJ, 1999, BIOCHEM BIOPH RES CO, V265, P144, DOI 10.1006/bbrc.1999.1623
   Idris AI, 2010, FASEB J, V24, P4545, DOI 10.1096/fj.10 164095
   Imagawa K, 2011, BIOCHEM BIOPH RES CO, V405, P362, DOI 10.1016/j.bbrc.2011.01.007
   Jimi E, 2004, NAT MED, V10, P617, DOI 10.1038/nm1054
   Juliana C, 2010, J BIOL CHEM, V285, P9792, DOI 10.1074/jbc.M109.082305
   Kim KS, 2009, EUR J PHARMACOL, V613, P167, DOI 10.1016/j.ejphar.2009.04.026
   King TJ, 2012, AM J PATHOL, V181, P121, DOI 10.1016/j.ajpath.2012.03.037
   Lam J, 2000, J CLIN INVEST, V106, P1481, DOI 10.1172/JCI11176
   LARSEN A, 1995, J RHEUMATOL, V22, P1974
   Le Goff B, 2014, CYTOKINE, V68, P101, DOI 10.1016/j.cyto.2014.04.001
   Lin Z, 2008, OSTEOARTHR CARTILAGE, V16, P450, DOI 10.1016/j.joca.2007.08.003
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Luqman S, 2010, PHYTOTHER RES, V24, P949, DOI 10.1002/ptr.3171
   Macfarlane GJ, 2011, RHEUMATOLOGY, V50, P1672, DOI 10.1093/rheumatology/ker119
   Mathema VB, 2012, INFLAMMATION, V35, P560, DOI 10.1007/s10753 011 9346 0
   Okazaki Y, 2005, J RHEUMATOL, V32, P1440
   Parada Turska J, 2008, INFLAMMATION, V31, P281, DOI 10.1007/s10753 008 9076 0
   Rao JK, 2003, ARTHRIT RHEUM ARTHR, V49, P619, DOI 10.1002/art.11377
   Redlich K, 2002, J CLIN INVEST, V110, P1419, DOI 10.1172/JCI200215582
   Romas E, 2000, ARTHRITIS RHEUM, V43, P821, DOI 10.1002/1529 0131(200004)43:4<821::AID ANR12>3.0.CO;2 T
   Romas E, 2002, AM J PATHOL, V161, P1419, DOI 10.1016/S0002 9440(10)64417 3
   Romas E, 2002, BONE, V30, P340, DOI 10.1016/S8756 3282(01)00682 2
   SAKURAI H, 1995, J CLIN INVEST, V96, P2357, DOI 10.1172/JCI118292
   Sasaki K, 1998, J BIOCHEM TOKYO, V123, P431, DOI 10.1093/oxfordjournals.jbchem.a021955
   Shah DM, 2005, AM J OBSTET GYNECOL, V192, P1842
   Sims NA, 2004, ARTHRITIS RHEUM US, V50, P2338, DOI 10.1002/art.20382
   Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074 7613(00)80042 4
   Vincenti MP, 2002, ARTHRITIS RES, V4, P157, DOI 10.1186/ar401
   WESSELINGH SL, 1993, ANN NEUROL, V33, P576, DOI 10.1002/ana.410330604
   White CA, 2007, J REPROD IMMUNOL, V73, P28, DOI 10.1016/j.jri.2006.05.003
   Yip KHM, 2004, J BONE MINER RES, V19, P1905, DOI 10.1359/JBMR.040919
NR 46
TC 32
Z9 33
U1 1
U2 22
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0300 9742
EI 1502 7732
J9 SCAND J RHEUMATOL
JI Scand. J. Rheumatol.
PD MAY
PY 2015
VL 44
IS 3
BP 182
EP 191
DI 10.3109/03009742.2014.938113
PG 10
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA CH9YO
UT WOS:000354392800002
PM 25439190
DA 2025 08 17
ER

PT J
AU Seo, BK
   Ryu, HK
   Park, YC
   Huh, JE
   Baek, YH
AF Seo, Byung Kwan
   Ryu, Hee Kyoung
   Park, Yeon Cheol
   Huh, Jeong Eun
   Baek, Yong Hyeon
TI Dual effect of WIN 34B on osteogenesis and osteoclastogenesis in
   cytokine induced mesenchymal stem cells and bone marrow cells
SO JOURNAL OF ETHNOPHARMACOLOGY
LA English
DT Article
DE WIN 34B; Osteogenesis; Osteoclastogenesis; Mesenchymal stem cells; Bone
   marrow cells; Osteoporosis
ID IN VITRO; OSTEOPOROSIS; DIFFERENTIATION; PHOSPHORYLATION;
   OSTEOARTHRITIS; MINERALIZATION; ACTIVATION; PATHWAYS; THERAPY; RUNX2
AB Ethnopharmacological relevance: As an n butanol fractionated extracted mixture of Lonicera japonica Thunb, dried flowers and Anemarrhena asphodeloides Bunge, root, WIN 34B has been reported the analgesic, anti inflammatory, cartilage repairing and protective effects in previous studies.
   Aim of the study: To investigate the effect of WIN 34B on osteogenesis and osteoclastogenesis in cytokine induced mesenchymal stem cells and bone marrow cells.
   Materials and methods: To examine the effect of WIN 34B on osteogenic differentiation, human mesenchymal stem cells (hMSCs) were treated with WIN 34B (1 mu g/mL and 10 mu g/mL). Alkaline phosphatase (ALP) activity was evaluated and Von Kossa staining was conducted. Mice bone marrow macrophages (BMMs) were obtained and treated with receptor activator of nuclear factor kappa B ligand (RANKL) and macrophage colony stimulating factor (m CSF) to induce osteoclastogenesis. To investigate osteoclast differentiation, tartrate resistant acid phosphatase (TRAP) staining was conducted after treatment with WIN 34B. Osteoclastogenic conditions were induced by stimulating the cells with interleukin (IL) 1 alpha, IL 17, and tumor necrosis factor (TNF alpha) in hMSCs and BMMs co culture systems. The expression levels of osteoprotegerin (OPG), RANKL, runt related transcription factor 2 (RUNX2), IL 17, c Fos, TNF alpha, and glyceraldehyde 3 phosphate dehydrogenase (GAPDH) were measured by reverse transcription polymerase chain reaction (RT PCR). The expression levels of nuclear factor kappaB (NF KB), inhibitory kappa B alpha (I kappa B alpha), phospho NF kappa B, phospho I kappa B alpha, beta actin, p38 MAPK, phospho c Jun N terminal kinase UNK), phospho extracellular signal regulated kinase (ERK), phospho p38 mitogen activated protein kinase (MAPK), phospho JNK, and phospho ERK were measured by western blot analysis.
   Results: WIN 34B promoted ALP activity and mineralization of hMSCs. In TRAP stained BMMs, the number of multinucleated cells decreased after WIN 34B treatment. WIN 34B increased the OPG/RAN KL ratio and the expression of RUNX2, and suppressed the expression of IL 17, c Fos, and TNF alpha. It also suppressed the activation of NF kappa B, I kappa B alpha, p38 MAPK, and JNK in a dose dependent manner.
   Conclusions: These results demonstrated that WIN 34B increased osteogenesis and decreased osteoclastogenesis in cytokine induced mesenchymal stem cells and bone marrow cells via inhibition of the NF kappa B, JNK, and p38 MAPK pathways. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
C1 [Seo, Byung Kwan; Ryu, Hee Kyoung; Park, Yeon Cheol; Baek, Yong Hyeon] Kyung Hee Univ, Grad Sch, Dept Clin Korean Med, 26 Kyungheedae Ro, Seoul 02447, South Korea.
   [Huh, Jeong Eun] Kyung Hee Univ, East West Bone & Joint Res Inst, Oriental Med Res Ctr Bone & Joint Dis, 892 Dongnam Ro, Seoul 05278, South Korea.
C3 Kyung Hee University; Korea Institute of Oriental Medicine (KIOM); Kyung
   Hee University
RP Baek, YH (通讯作者)，Kyung Hee Univ, Dept Acupuncture & Moxibust, Coll Korean Med, 26 Kyungheedae Ro, Seoul 02447, South Korea.
EM byhacu@khu.ac.kr
FU National Research Foundation of Korea (NRF)   Ministry of Education,
   Science and Technology [NRF 2013R1A1A2010049]; Traditional Korean
   Medicine R&D program   Ministry of Health & Welfare through the Korea
   Health Industry Development Institute (KHIDI) [HI15C0117]
FX This research was supported by the Basic Science Research Program,
   through the National Research Foundation of Korea (NRF) funded by the
   Ministry of Education, Science and Technology (NRF 2013R1A1A2010049) and
   the Traditional Korean Medicine R&D program funded by the Ministry of
   Health & Welfare through the Korea Health Industry Development Institute
   (KHIDI) (HI15C0117).
CR Bandeira F, 2014, ARQ BRAS ENDOCRINOL, V58, P504, DOI 10.1590/0004 2730000003384
   Baron R, 2012, J CLIN ENDOCR METAB, V97, P311, DOI 10.1210/jc.2011 2332
   Bobis S, 2006, FOLIA HISTOCHEM CYTO, V44, P215
   Bonewald LF, 2003, CALCIFIED TISSUE INT, V72, P537, DOI 10.1007/s00223 002 1057 y
   Burge R, 2007, J BONE MINER RES, V22, P465, DOI [10.1359/jbmr.061113, 10.1359/JBMR.061113]
   Cosman F, 2014, OSTEOPOROSIS INT, V25, P2359, DOI 10.1007/s00198 014 2794 2
   Costa Rodrigues J, 2011, CELL PROLIFERAT, V44, P264, DOI 10.1111/j.1365 2184.2011.00751.x
   Enomoto H, 2003, J BIOL CHEM, V278, P23971, DOI 10.1074/jbc.M302457200
   Fu WM, 2014, EXP CELL RES, V322, P202, DOI 10.1016/j.yexcr.2013.12.008
   Huh JE, 2013, EVID BASED COMPL ALT, V2013, DOI 10.1155/2013/527561
   Huh JE, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472 6882 12 256
   Huh JE, 2012, J ETHNOPHARMACOL, V143, P779, DOI 10.1016/j.jep.2012.06.041
   Huh JE, 2011, J ETHNOPHARMACOL, V137, P1011, DOI 10.1016/j.jep.2011.07.025
   Jones EA, 2002, ARTHRITIS RHEUM US, V46, P3349, DOI 10.1002/art.10696
   Kang M, 2010, J ETHNOPHARMACOL, V131, P485, DOI 10.1016/j.jep.2010.07.025
   Kassem M, 2008, CELL TISSUE RES, V331, P157, DOI 10.1007/s00441 007 0509 0
   Khosla S, 2001, ENDOCRINOLOGY, V142, P5050, DOI 10.1210/en.142.12.5050
   Lane NE, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2656
   MINKIN C, 1982, CALCIFIED TISSUE INT, V34, P285, DOI 10.1007/BF02411252
   Miyazaki T, 2000, J CELL BIOL, V148, P333, DOI 10.1083/jcb.148.2.333
   O'Brien CA, 2013, BONE, V54, P258, DOI 10.1016/j.bone.2012.08.121
   Oshita K, 2011, ARTHRITIS RHEUM US, V63, P1658, DOI 10.1002/art.30309
   Pérez Sayáns M, 2010, ORAL SURG ORAL MED O, V109, P679, DOI 10.1016/j.tripleo.2009.10.042
   Siffert R. S., 1951, Journal of Experimental Medicine, V93, P415, DOI 10.1084/jem.93.5.415
   Sun YG, 2013, J PHARMACEUT BIOMED, V81 82, P34, DOI 10.1016/j.jpba.2013.03.022
   SW K., 2013, KOREAN J MED, V85, P364
   Theoleyre S, 2004, CYTOKINE GROWTH F R, V15, P457, DOI 10.1016/j.cytogfr.2004.06.004
   Wright NC, 2014, J BONE MINER RES, V29, P2520, DOI 10.1002/jbmr.2269
   Yang F, 2003, J IMMUNOL, V170, P5630, DOI 10.4049/jimmunol.170.11.5630
   Yoo HJ, 2008, J PHARM PHARMACOL, V60, P779, DOI 10.1211/jpp.60.6.0014
   Zhang X, 2006, CALCIFIED TISSUE INT, V79, P169, DOI 10.1007/s00223 006 0083 6
NR 31
TC 12
Z9 12
U1 0
U2 35
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378 8741
J9 J ETHNOPHARMACOL
JI J. Ethnopharmacol.
PD DEC 4
PY 2016
VL 193
BP 227
EP 236
DI 10.1016/j.jep.2016.07.022
PG 10
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA ED7ZF
UT WOS:000389090600024
PM 27401292
DA 2025 08 17
ER

PT J
AU Tevlek, A
   Odabas, S
   Çelik, E
   Aydin, HM
AF Tevlek, Atakan
   Odabas, Sedat
   Celik, Ekin
   Aydin, Halil Murat
TI Preparation of MC3T3 E1 cell sheets through short term osteogenic medium
   application
SO ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY
LA English
DT Article
DE Cell sheet; MC3T3 E1 pre osteoblast cells; osteogenic medium; osteogenic
   differentiation
ID IN VITRO; DIFFERENTIATION; OSTEOPONTIN; EXPRESSION; CULTURE;
   PROLIFERATION; DETACHMENT; SURFACES; RECOVERY; MODEL
AB Cell sheet engineering is an emerging field based on the acquisition of cells together with their extracellular matrix (ECM) and is used not only in vitro but also in regeneration studies of various tissues in the clinic. Within this scope, wide variety of cell types have been investigated in terms of sheet formation and underlying mechanism. MC3T3 E1 is a mouse pre osteoblast cell line that has greatly attracted researchers' attention for bone tissue engineering (BTE) applications thanks to its high proliferation and differentiation properties. The potential of MC3T3 E1 cells on sheet formation and the effects of culture conditions have not been investigated in detail. This study aims to examine the effects of growth and osteogenic medium on cell sheet formation of MC3T3 E1. As a result of this study; intact, ECM rich, transferable cell sheets at the beginning of the mineralization phase of the differentiation process were obtained by using osteogenic medium. Hereafter, 3D tissue model can be constructed by stacking MC3T3 cell sheets in vitro. This 3D model can conveniently be used for the development of novel biomaterials and in vitro drug screening applications to reduce the need for animal experiments.
C1 [Tevlek, Atakan] Hacettepe Univ, Inst Sci, Bioengn Div, Ankara, Turkey.
   [Odabas, Sedat] Ankara Univ, Dept Chem, Fac Sci, Ankara, Turkey.
   [Celik, Ekin] Hacettepe Univ, Inst Sci, Bioengn Div, Ankara, Turkey.
   [Celik, Ekin] Hacettepe Univ, Inst Sci, Adv Technol Applicat & Res Ctr, Ankara, Turkey.
   [Aydin, Halil Murat] Hacettepe Univ, Environm Engn Dept, TR 06800 Ankara, Turkey.
   [Aydin, Halil Murat] Hacettepe Univ, Bioengn Div, TR 06800 Ankara, Turkey.
   [Aydin, Halil Murat] Hacettepe Univ, Ctr Bioengn, TR 06800 Ankara, Turkey.
C3 Hacettepe University; Ankara University; Hacettepe University; Hacettepe
   University; Hacettepe University; Hacettepe University; Hacettepe
   University
RP Aydin, HM (通讯作者)，Hacettepe Univ, Environm Engn Dept, TR 06800 Ankara, Turkey.; Aydin, HM (通讯作者)，Hacettepe Univ, Bioengn Div, TR 06800 Ankara, Turkey.; Aydin, HM (通讯作者)，Hacettepe Univ, Ctr Bioengn, TR 06800 Ankara, Turkey.
EM hmaydin@hacettepe.edu.tr
RI ; Tevlek, Atakan/AAH 7746 2019; Odabas, Sedat/AAG 7813 2020; çelik,
   ekin/JXM 5937 2024
OI Tevlek, Atakan/0000 0003 0601 8642; CELIK, EKIN/0000 0003 1966 3907; 
FU Scientific and Technological Research Council of Turkey (TUBITAK);
   TUBITAK
FX This study was supported by The Scientific and Technological Research
   Council of Turkey (TUBITAK) within the scope of 2211 C Priority Areas
   Related to Doctoral Scholarship Programme. The scholarship was granted
   to A. Tevlek by TUBITAK.
CR Akahane M, 2016, BONE JOINT RES, V5, P569, DOI 10.1302/2046 3758.511.BJR 2016 0013.R1
   Akiyama Y, 2004, LANGMUIR, V20, P5506, DOI 10.1021/la036139f
   Alaribe FN, 2016, BIOLOGIA, V71, P353, DOI 10.1515/biolog 2016 0056
   [Anonymous], JOINTS
   Asakawa N, 2010, BIOMATERIALS, V31, P3903, DOI 10.1016/j.biomaterials.2010.01.105
   Bramfeldt H, 2010, CURR MED CHEM, V17, P3944, DOI 10.2174/092986710793205327
   Chen GN, 2015, BIOMED REP, V3, P749, DOI 10.3892/br.2015.522
   Choi JY, 1996, J CELL BIOCHEM, V61, P609, DOI 10.1002/(SICI)1097 4644(19960616)61:4<609::AID JCB15>3.0.CO;2 A
   Czekanska EM, 2012, EUR CELLS MATER, V24, P1
   Denhardt DT, 1998, J CELL BIOCHEM, P92, DOI 10.1002/(SICI)1097 4644(1998)72:30/31+<92::AID JCB13>3.0.CO;2 A
   Elbert DL, 2011, CURR OPIN BIOTECH, V22, P674, DOI 10.1016/j.copbio.2011.04.001
   FRANCESCHI RT, 1992, J BONE MINER RES, V7, P235
   GIPSON IK, 1982, INVEST OPHTH VIS SCI, V23, P269
   Guillaume Gentil O, 2008, ADV MATER, V20, P560, DOI 10.1002/adma.200700758
   Guillaume Gentil O, 2011, BIOMATERIALS, V32, P4376, DOI 10.1016/j.biomaterials.2011.02.058
   HATA RI, 1989, J CELL PHYSIOL, V138, P8, DOI 10.1002/jcp.1041380103
   Henkel J., 2013, BioNanoMaterials, V14, P171, DOI [DOI 10.1515/BNM 2013 0021, 10.1515/bnm 2013 0021]
   Hong Y, 2013, BIOMATERIALS, V34, P11, DOI 10.1016/j.biomaterials.2012.09.043
   Huang WB, 2004, BONE, V34, P799, DOI 10.1016/j.bone.2003.11.027
   Kanai N, 2014, ANN TRANSL MED, V2, DOI 10.3978/j.issn.2305 5839.2014.03.06
   KAO J, 1990, EXP MOL PATHOL, V53, P1, DOI 10.1016/0014 4800(90)90020 E
   Kirkham G., 2007, Topics in tissue engineering, V3, P1, DOI 10.1016/j.cryobiol.2014.07.005
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Komori T, 2010, CELL TISSUE RES, V339, P189, DOI 10.1007/s00441 009 0832 8
   Kuo ZK, 2016, SCI REP UK, V6, DOI 10.1038/srep32884
   Long T, 2014, BIOMATERIALS, V35, P2752, DOI 10.1016/j.biomaterials.2013.12.039
   Mao AS, 2015, P NATL ACAD SCI USA, V112, P14452, DOI 10.1073/pnas.1508520112
   Maruyama Z, 2007, DEV DYNAM, V236, P1876, DOI 10.1002/dvdy.21187
   Matsuda N, 2007, ADV MATER, V19, P3089, DOI 10.1002/adma.200701978
   Nishida K, 2004, TRANSPLANTATION, V77, P379, DOI 10.1097/01.TP.0000110320.45678.30
   OKANO T, 1993, J BIOMED MATER RES, V27, P1243, DOI 10.1002/jbm.820271005
   Pirraco RP, 2011, TISSUE ENG PT A, V17, P1507, DOI 10.1089/ten.tea.2010.0470
   Prince M, 2001, J CELL BIOCHEM, V80, P424, DOI 10.1002/1097 4644(20010301)80:3<424::AID JCB160>3.0.CO;2 6
   QUARLES LD, 1992, J BONE MINER RES, V7, P683
   Rutkovskiy A, 2016, MED SCI MONIT BASIC, V22, P95, DOI 10.12659/MSMBR.901142
   Sawa Y, 2013, BIOMED RES INT, V2013, P1
   Shimizu K, 2007, BIOTECHNOL BIOENG, V96, P803, DOI 10.1002/bit.21094
   Siffert R. S., 1951, Journal of Experimental Medicine, V93, P415, DOI 10.1084/jem.93.5.415
   Standal T, 2004, EXP ONCOL, V26, P179
   Tevlek A, 2017, MAT SCI ENG C MATER, V72, P316, DOI 10.1016/j.msec.2016.11.082
   Wang ZS, 2016, COLLOID SURFACE B, V141, P102, DOI 10.1016/j.colsurfb.2016.01.036
   Wei FL, 2012, J CELL PHYSIOL, V227, P3216, DOI 10.1002/jcp.24012
   Wong In S, 2013, J APPL POLYM SCI, V129, P3061, DOI 10.1002/app.39032
   Yazid MD, 2010, CANCER CELL INT, V10, DOI 10.1186/1475 2867 10 42
   Yuan Q, 2014, J BONE MINER RES, V29, P693, DOI 10.1002/jbmr.2079
   Zahn R, 2012, BIOMATERIALS, V33, P3421, DOI 10.1016/j.biomaterials.2012.01.019
   Zoch ML, 2016, BONE, V82, P42, DOI 10.1016/j.bone.2015.05.046
NR 47
TC 15
Z9 15
U1 1
U2 17
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 2169 1401
EI 2169 141X
J9 ARTIF CELL NANOMED B
JI Artif. Cell. Nanomed. Biotechnol.
PY 2018
VL 46
SU 2
BP 1145
EP 1153
DI 10.1080/21691401.2018.1481081
PG 9
WC Biotechnology & Applied Microbiology; Engineering, Biomedical; Materials
   Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Engineering; Materials Science
GA HM1BA
UT WOS:000459181400110
PM 29886755
DA 2025 08 17
ER

PT J
AU Zhang, LW
   Lv, B
   Shi, XY
   Gao, GY
AF Zhang, Liwen
   Lv, Bin
   Shi, Xinya
   Gao, Guangyu
TI High Expression of N Acetylgalactosaminyl transferase 1 (GALNT1)
   Associated with Invasion, Metastasis, and Proliferation in Osteosarcoma
SO MEDICAL SCIENCE MONITOR
LA English
DT Article
DE Genes, vif; Medical Oncology; Osteosarcoma
ID HEPATOCELLULAR CARCINOMA; COLORECTAL CANCER; POLYPEPTIDE; GLYCOSYLATION;
   SUPPRESSES; THERAPY
AB Background: Osteosarcoma (OS) is very common worldwide, and the mechanisms underlying its development remain un clear. This study aims to identify key genes promoting the reproduction, invasion, and transfer of osteosarcoma cells.
   Material/Methods: Gene expression profile data (GSE42352 and GSE42572) were downloaded from the Gene Expression Omnibus database. Differentially expressed genes were calculated using R software. Gene ontology and enriched pathway analysis of mRNAs were analyzed by using FunRich. Verification of the genes was conducted by using quantitative real time polymerase chain reaction and western blot analyses to measure gene expression. Transwell and wound healing assays were performed on osteosarcoma cells after knockdown to detect whether the genes enhanced the aggressiveness of osteosarcoma.
   Results: In total, 34 genes were selected after filtering. Kyoto Encyclopedia of Genes and Genomes enrichment analysis demonstrated that the genes were enriched in multiple tumor pathways. N acetylgalactosaminyl transferase 1 (GALNT1) was identified for further study, and its expression was higher in osteosarcoma cells than in human osteoblasts. The invasion ability of cells was significantly decreased after gene knockdown.
   Conclusions: Through the use of microarray and bioinformatics analysis, differentially expressed genes were selected and a complete gene network was constructed. Our findings provide new biomarkers for the treatment and prognosis of osteosarcoma. These biomarkers may contribute to the discovery of new therapeutic targets for clinical application.
C1 [Zhang, Liwen] Suzhou Univ, Dept Oncol, Affiliated Hosp 3, Changzhou, Jiangsu, Peoples R China.
   [Lv, Bin] Nanchang Univ, Jiangxi Key Lab Canc Metastasis & Precis Treatmen, Affiliated Hosp 3, Nanchang, Jiangxi, Peoples R China.
   [Shi, Xinya] Changshu Second Peoples Hosp, Dept Oncol, Suzhou, Jiangsu, Peoples R China.
   [Gao, Guangyu] Soochow Univ, Dept Oncol, Affiliated Hosp 2, Suzhou, Jiangsu, Peoples R China.
C3 Soochow University   China; Nanchang University; Soochow University  
   China
RP Zhang, LW (通讯作者)，Suzhou Univ, Dept Oncol, Affiliated Hosp 3, Changzhou, Jiangsu, Peoples R China.; Gao, GY (通讯作者)，Soochow Univ, Dept Oncol, Affiliated Hosp 2, Suzhou, Jiangsu, Peoples R China.
EM crystalzlw7788@163.com; 1149546912@qq.com
RI lv, bin/MBH 2664 2025
CR Bennett EP, 2012, GLYCOBIOLOGY, V22, P736, DOI 10.1093/glycob/cwr182
   Djamgoz MBA, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0092
   Gerken TA, 2006, J BIOL CHEM, V281, P32403, DOI 10.1074/jbc.M605149200
   Hakomori S, 2001, ADV EXP MED BIOL, V491, P369
   Harrison DJ, 2018, EXPERT REV ANTICANC, V18, P39, DOI 10.1080/14737140.2018.1413939
   Hua D, 2012, INT J MOL MED, V30, P1267, DOI 10.3892/ijmm.2012.1130
   Huang MJ, 2015, ONCOTARGET, V6, P5650, DOI 10.18632/oncotarget.3117
   Isakoff MS, 2015, J CLIN ONCOL, V33, P3029, DOI 10.1200/JCO.2014.59.4895
   Kempf Bielack B, 2005, J CLIN ONCOL, V23, P559, DOI 10.1200/JCO.2005.04.063
   Kitada S, 2013, BRIT J CANCER, V109, P472, DOI 10.1038/bjc.2013.331
   Li C, 2016, CANCER RES, V76, P1273, DOI 10.1158/0008 5472.CAN 15 2309
   Liao D, 2015, CLIN CANCER RES, V21, P5349, DOI 10.1158/1078 0432.CCR 15 0198
   Luetke A, 2014, CANCER TREAT REV, V40, P523, DOI 10.1016/j.ctrv.2013.11.006
   Milde Langosch K, 2015, BREAST CANCER RES TR, V151, P515, DOI 10.1007/s10549 015 3425 0
   Perez R, 2003, J GASTROINTEST SURG, V7, P884, DOI 10.1016/j.gassur.2003.08.001
   Premkumar LS, 2013, LIFE SCI, V92, P415, DOI 10.1016/j.lfs.2012.08.010
   Shan Y, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 0425 0
   Sun W, 2016, INT J MOL MED, V38, P466, DOI 10.3892/ijmm.2016.2657
   Tominaga O, 1997, JPN J CANCER RES, V88, P855, DOI 10.1111/j.1349 7006.1997.tb00461.x
   Wang ZW, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/4628962
   Wu YM, 2011, CANCER RES, V71, P7270, DOI 10.1158/0008 5472.CAN 11 1161
   Yue TT, 2009, MOL CELL PROTEOMICS, V8, P1697, DOI 10.1074/mcp.M900135 MCP200
NR 22
TC 6
Z9 7
U1 0
U2 9
PU INT SCIENTIFIC INFORMATION, INC
PI MELVILLE
PA 150 BROADHOLLOW RD, STE 114, MELVILLE, NY 11747 USA
SN 1643 3750
J9 MED SCI MONITOR
JI Med. Sci. Monitor
PD DEC 7
PY 2020
VL 26
AR e927837
DI 10.12659/MSM.927837
PG 9
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA PB1NT
UT WOS:000596096900001
PM 33284788
OA Green Published
DA 2025 08 17
ER

PT J
AU Bisdas, S
   Pinho, NC
   Smolarz, A
   Sader, R
   Vogl, TJ
   Mack, MG
AF Bisdas, S.
   Pinho, N. Chambron
   Smolarz, A.
   Sader, R.
   Vogl, T. J.
   Mack, M. G.
TI Biphosphonate induced osteonecrosis of the jaws: CT and MRI spectrum of
   findings in 32 patients
SO CLINICAL RADIOLOGY
LA English
DT Article
ID BISPHOSPHONATES; OSTEOMYELITIS
AB AIM: To evaluate the computed tomography (CT) and magnetic resonance imaging (MRI) findings of biphosphonate therapy associated changes of the mandible and maxilla.
   MATERIALS AND METHODS: Thirty two patients with a clinical history of pain, purulent discharge, and swelling in the mandible or maxilla as well as non heating dental extraction were examined. All patients had received biphosphonate medication for approximately 33 months. Non contrast enhanced CT and contrast enhanced MRI were performed and, subsequently, all patients underwent a surgical removal of the affected bone, the histological diagnosis of which confirmed osteonecrosis. The images were read by two head and neck radiologists in consensus.
   RESULTS: Osteonecrosis with Actinomyces infection was identified in the mandible of 18 patients, in the maxilla of eight patients, and in both jaws in six patients. The CT images showed predominantly osteolytic lesions and sclerotic regions in the jaws with or without periostal bone proliferation. There was a reduction of the marrow space in the jaws. The T1 weighted MRI signal was hypointense in nearly all cases. The gadolinium enhanced MRI images revealed intensity changes of the cortical and subcortical bone structures in at[ patients. The T2 weighted MRI signal was hypointense on the affected side in the majority of the cases (28/32). Pathological gadolinium enhancement was observed in the neighbouring soft tissues, including the masticator space in all patients. Reactive lymphadenopathy was found in all patients in submental and jugulodigastric areas.
   CONCLUSION: Biphosphonate induced osteonecrosis of the jaws presents a wide variety of CT and MRI features that are readily recognized and help to determine the extent of the disease; however, they are not specific for the disease. (c) 2007 Published by Elsevier Ltd on behalf of The Royal College of Radiologists.
C1 [Bisdas, S.; Vogl, T. J.; Mack, M. G.] Johann Wolfgang Goethe Univ Hosp, Dept Diagnost & Intervent Radiol, D 60590 Frankfurt, Germany.
   [Pinho, N. Chambron; Smolarz, A.; Sader, R.] Johann Wolfgang Goethe Univ Hosp, Dept Dentomaxillofacial & Plast Surg, D 60590 Frankfurt, Germany.
C3 Goethe University Frankfurt; Goethe University Frankfurt Hospital;
   Goethe University Frankfurt; Goethe University Frankfurt Hospital
RP Bisdas, S (通讯作者)，Johann Wolfgang Goethe Univ Hosp, Dept Diagnost & Intervent Radiol, Theodor Stern Kai 7, D 60590 Frankfurt, Germany.
EM sbisdas@yahoo.com
RI Bisdas, Sotirios/P 2549 2016
OI Bisdas, Sotirios/0000 0001 9930 5549
CR Badros A, 2006, J CLIN ONCOL, V24, P945, DOI 10.1200/JCO.2005.04.2465
   BOUQUOT JE, 1992, ORAL SURG ORAL MED O, V73, P307, DOI 10.1016/0030 4220(92)90127 C
   Carneiro E, 2006, AM J NEURORADIOL, V27, P1096
   Chiandussi S, 2006, DENTOMAXILLOFAC RAD, V35, P236, DOI 10.1259/dmfr/27458726
   Chong J, 2000, AM J NEURORADIOL, V21, P175
   Conte P, 2004, ONCOLOGIST, V9, P28, DOI 10.1634/theoncologist.9 90004 28
   Farrugia MC, 2006, LARYNGOSCOPE, V116, P115, DOI 10.1097/01.mlg.0000187398.51857.3c
   Greenberg MS, 2004, ORAL SURG ORAL MED O, V98, P259, DOI 10.1016/j.tripleo.2004.08.001
   Hansen T, 2006, J ORAL PATHOL MED, V35, P155, DOI 10.1111/j.1600 0714.2006.00391.x
   Hellstein JW, 2005, J ORAL MAXIL SURG, V63, P682, DOI 10.1016/j.joms.2005.01.010
   Hishberg A, 1994, J ORAL PATHOL MED, V23, P337
   Rodan Gideon A., 2002, Current Molecular Medicine (Hilversum), V2, P571, DOI 10.2174/1566524023362104
   Rogers Michael J., 2003, Current Pharmaceutical Design, V9, P2643, DOI 10.2174/1381612033453640
   Ross JR, 2004, HEALTH TECHNOL ASSES, V8, pIII
   Ruggiero SL, 2004, J ORAL MAXIL SURG, V62, P527, DOI 10.1016/j.joms.2004.02.004
   UNGER E, 1988, AM J ROENTGENOL, V150, P605, DOI 10.2214/ajr.150.3.605
   Wang J, 2003, J ORAL MAXIL SURG, V61, P1104, DOI 10.1016/S0278 2391(03)00328 8
   Weber A., 2003, Head and neck imaging, V4th, P930
NR 18
TC 97
Z9 106
U1 0
U2 8
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0009 9260
EI 1365 229X
J9 CLIN RADIOL
JI Clin. Radiol.
PD JAN
PY 2008
VL 63
IS 1
BP 71
EP 77
DI 10.1016/j.crad.2007.04.023
PG 7
WC Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI EXPANDED)
SC Radiology, Nuclear Medicine & Medical Imaging
GA 255QY
UT WOS:000252673700009
PM 18068792
DA 2025 08 17
ER

PT J
AU Stiffel, VM
   Rundle, CH
   Sheng, MHC
   Das, S
   Lau, KHW
AF Stiffel, Virginia M.
   Rundle, Charles H.
   Sheng, Matilda H C
   Das, Subhashri
   Lau, Kin Hing William
TI A Novel EphA4 Signaling Based Therapeutic Strategy for Osteoarthritis in
   Mice
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE OSTEOARTHRITIS; POSTTRAUMATIC OSTEOARTHRITIS; ARTICULAR CARTILAGE;
   THERAPEUTICS ANABOLIC AND ANTIRESORPTIVE
ID SUBCHONDRAL BONE; ARTICULAR CARTILAGE; FC RECEPTORS; OSTEOCLASTOGENESIS;
   LIGANDS; EPHB4; PART
AB This study took advantage of the recent discovery that the EphA4 signaling has anti catabolic effects on osteoclasts/macrophages/synoviocytes but pro anabolic effects on articular chondrocytes and sought to develop an EphA4 signaling based therapeutic strategy for osteoarthritis (OA) using a mouse model of OA/posttraumatic OA (PTOA). The injured joint of C57BL/6J mice received biweekly intraarticular injections of a soluble EphA4 binding ligand (EfnA4 fc) at 1 day after the tibial plateau injury or at 5 weeks post injury. The animals were euthanized 5 weeks later. The injured right and contralateral uninjured left joints were analyzed for hallmarks of OA by histology. Relative severity was determined by a modified Mankin OA scoring system and serum COMP and CTX II levels. Tibial plateau injury caused more severe OA in Epha4 null mice than in wild type (WT) littermates, suggesting a protective role of EphA4 signaling in OA. A prototype strategy of an EphA4 signaling based strategy involving biweekly injections of EfnA4 fc into injured joints was developed and was shown to be highly effective in preventing OA/PTOA when it was administered at 1 day post injury and in treating OA/PTOA when it was applied after OA has been established. The efficacy of this prototype was dose  and time dependent. The effects were not caused by the Fc moiety of EfnA4 fc. Other soluble EfnA ligands of EphA4, ie, EfnA1 fc and EfnA2 fc, were also effective. A prototype of a novel EphA4 signaling based therapy was developed for OA/PTOA that not only reduces the progressive destruction of articular cartilage but may also promote regeneration of the damaged cartilage. (c) 2022 American Society for Bone and Mineral Research (ASBMR). This article has been contributed to by US Government employees and their work is in the public domain in the USA.
C1 [Stiffel, Virginia M.; Rundle, Charles H.; Sheng, Matilda H C; Das, Subhashri; Lau, Kin Hing William] Jerry L Pettis Mem VA Med Ctr, Musculoskeletal Dis Ctr 151, 11201 Benton St, Loma Linda, CA 92357 USA.
   [Rundle, Charles H.; Sheng, Matilda H C; Lau, Kin Hing William] Loma Linda Univ, Sch Med, Dept Med, Loma Linda, CA 92354 USA.
C3 Loma Linda University
RP Lau, KHW (通讯作者)，Jerry L Pettis Mem VA Med Ctr, Musculoskeletal Dis Ctr 151, 11201 Benton St, Loma Linda, CA 92357 USA.
EM william.lau@va.gov
FU Department of Defense; US Army Medical Research and Materiel Command
   (USAMRMC) [W81XWH 14 1 0207]; Biomedical Laboratory Research and
   Development Service, Department of Veterans Affairs, Veterans Health
   Administration, Office of Research and Development [IO1 BX002964];
   Department of Veterans Affairs, Veterans Health Administration, Office
   of Research and Development [1K6 BX002782]
FX The work is supported in part by a grant from the Department of Defense,
   the US Army Medical Research and Materiel Command (USAMRMC) under grant
   no. W81XWH 14 1 0207, and a Merit Review grant (IO1 BX002964) from the
   Biomedical Laboratory Research and Development Service, Department of
   Veterans Affairs, Veterans Health Administration, Office of Research and
   Development. The views, opinions, and/or findings contained in this
   report are those of the authors and should not be construed as an
   official position, policy, or decision of the Department of the Army,
   the Department of Veterans Affairs, or the United States government,
   unless so designated by other documentation. K HWL is also the recipient
   of a Research Career Scientist award (1K6 BX002782) from the Department
   of Veterans Affairs, Veterans Health Administration, Office of Research
   and Development. In conducting research using animals, the investigators
   adhered to the Animal Welfare Act Regulations and other federal statutes
   relating to animals and experiments involving animals and the principles
   set forth in the current version of the National Institutes of Health
   (NIH) Guidelines for Research Involving Recombinant DNA Molecules. The
   authors thank Ms Nancy Lowen for her excellent technical assistance in
   carrying out the histology processing of the samples. Authors' roles:
   VMS, CHR, MH CS, and SD performed the experiments. K HWL, VMS, CHR, and
   MH CS interpreted the data. K HWL, VMS, and MH CS conceived the study.
   K HWL directed and supervised the study. VMS, CHR, and K HWL wrote and
   edited the manuscript. All authors reviewed and approved the manuscript.
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Anderson DD, 2011, J ORTHOP RES, V29, P802, DOI 10.1002/jor.21359
   Arthur A, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.598612
   Bowden TA, 2009, STRUCTURE, V17, P1386, DOI 10.1016/j.str.2009.07.018
   Chen L, 2011, OSTEOARTHR CARTILAGE, V19, P711, DOI 10.1016/j.joca.2011.01.018
   D'Lima D, 2006, ARTHRITIS RHEUM US, V54, P1814, DOI 10.1002/art.21874
   Darling TK, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01473
   Gale NW, 1996, NEURON, V17, P9, DOI 10.1016/S0896 6273(00)80276 7
   Goldshmit Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024636
   Himanen JP, 2004, NAT NEUROSCI, V7, P501, DOI 10.1038/nn1237
   Hwang HS, 2015, INT J MOL SCI, V16, P26035, DOI 10.3390/ijms161125943
   Irie N, 2009, J BIOL CHEM, V284, P14637, DOI 10.1074/jbc.M807598200
   Kadri A, 2010, ANN RHEUM DIS, V69, P1533, DOI 10.1136/ard.2009.124586
   Kullander K, 2002, NAT REV MOL CELL BIO, V3, P475, DOI 10.1038/nrm856
   Lau KHW, 2015, J CELL BIOCHEM, V116, P1785, DOI 10.1002/jcb.25137
   Lorda Diez CI, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024546
   Lotz MK, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3046
   Lubis Andri Mt, 2012, Acta Med Indones, V44, P62
   MANKIN HJ, 1971, J BONE JOINT SURG AM, VA 53, P523, DOI 10.2106/00004623 197153030 00009
   Matthews GL, 2011, EXPERT OPIN EMERG DR, V16, P479, DOI 10.1517/14728214.2011.576670
   Ng KW, 2011, ANN BIOMED ENG, V39, P2491, DOI 10.1007/s10439 011 0356 8
   Pritzker KPH, 2006, OSTEOARTHR CARTILAGE, V14, P13, DOI 10.1016/j.joca.2005.07.014
   Punzi L, 2016, RMD OPEN, V2, DOI 10.1136/rmdopen 2016 000279
   Raghavan M, 1996, ANNU REV CELL DEV BI, V12, P181, DOI 10.1146/annurev.cellbio.12.1.181
   Reginster JY, 2013, ANN RHEUM DIS, V72, P179, DOI 10.1136/annrheumdis 2012 202231
   Scanzello CR, 2017, J ORTHOP RES, V35, P735, DOI 10.1002/jor.23471
   Schindler OS, 2011, ACTA ORTHOP BELG, V77, P709
   Shimizu S, 2007, ARTHRITIS RHEUM US, V56, P3358, DOI 10.1002/art.22941
   Spanevello MD, 2013, J NEUROTRAUM, V30, P1023, DOI 10.1089/neu.2012.2729
   Steinert AF, 2008, INJURY, V39, pS97, DOI 10.1016/j.injury.2008.01.034
   Stiffel V, 2020, CALCIFIED TISSUE INT, V106, P158, DOI 10.1007/s00223 019 00614 0
   Stiffel V, 2014, J BONE MINER RES, V29, P804, DOI 10.1002/jbmr.2084
   Stiffel VM, 2020, CALCIFIED TISSUE INT, V107, P576, DOI 10.1007/s00223 020 00747 7
   Ströbel S, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar2942
   Sulica A, 1995, NAT IMMUN, V14, P123
   Tat SK, 2010, BEST PRACT RES CL RH, V24, P51, DOI 10.1016/j.berh.2009.08.004
   Tat SK, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2782
   Tat SK, 2008, ARTHRITIS RHEUM US, V58, P3820, DOI 10.1002/art.24029
   Valverde Franco G, 2016, ARTHRITIS RES THER, V18, DOI 10.1186/s13075 016 0965 6
   Valverde Franco G, 2012, ARTHRITIS RHEUM US, V64, P3614, DOI 10.1002/art.34638
   Wang M, 2013, GENET MOL RES, V12, P738, DOI 10.4238/2013.March.13.2
   Yano F, 2013, ANN RHEUM DIS, V72, P748, DOI 10.1136/annrheumdis 2012 201745
   Zhang W, 2010, OSTEOARTHR CARTILAGE, V18, P476, DOI 10.1016/j.joca.2010.01.013
   Zhang XL, 2004, J ORTHOP RES, V22, P742, DOI 10.1016/j.orthres.2003.12.007
   Zhou RP, 1998, PHARMACOL THERAPEUT, V77, P151, DOI 10.1016/S0163 7258(97)00112 5
NR 44
TC 5
Z9 5
U1 1
U2 8
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD APR
PY 2022
VL 37
IS 4
BP 660
EP 674
DI 10.1002/jbmr.4500
EA JAN 2022
PG 15
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 0O0JV
UT WOS:000748240400001
PM 34989027
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Maugeri, D
   Mamazza, C
   Lo Gludice, F
   Puglisi, N
   Muscoso, EG
   Rizzotto, M
   Testaì, M
   Bennati, E
   Lentini, A
   Panebianco, P
AF Maugeri, D
   Mamazza, C
   Lo Gludice, F
   Puglisi, N
   Muscoso, EG
   Rizzotto, M
   Testaì, M
   Bennati, E
   Lentini, A
   Panebianco, P
TI Interleukin 18 (IL 18) and matrix metalloproteinase 9 (MMP 9) in
   post menopausal osteoporosis
SO ARCHIVES OF GERONTOLOGY AND GERIATRICS
LA English
DT Article
DE alendronate; risedronate; raloxifene; BMD; IL 18; MMP 9
ID BONE RESORPTION; FRACTURE RISK; EXPRESSION; REDUCTION; CELLS; WOMEN;
   OSTEOBLASTS; METABOLISM; RALOXIFENE; CYTOKINES
AB This survey covered 60 post menopausal women with osteoporosis. The patients were divided into three equal groups, and each group was treated with one of the three so called anti resorptive drugs, namely alendronate (10 mg/day) risedronate (5 mg/day) and raloxifene (60 mg/day) for 12 months. The Elisa technique was used to measure circulating IL 18 and MMP 9. Lumbar bone mineral density (BMD) levels were determined by using dexa mineralometry (Lunar DPX) at baseline and after 12 months of treatment. The results showed comparable responses of the patients treated with alendronate or risedronate, being a significant increase in BMD, an increase in circulating IL 18, and only slight modifications in circulating MMP 9 levels. After 12 months of treatment with raloxifene, there were minimal, non significant increases in BMD, slight modifications in IL 18 levels, and a siganificant reduction in circulating MMP 9 levels. The conclusions can be drawn that all three drugs, albeit through different mechanisms, can be considered valid treatments for post menopausal osteoporosis. Although measurements of circulating IL 8 and MMP 9 levels allowed us to differentiate the effects of the three drugs used, as of today, they have no real role in the diagnosis and/or follow up of osteoporosis. (c) 2004 Elsevier Ireland Ltd. All rights reserved.
C1 Catania Univ, Dept Senescent Urol & Neurol Sci, Cannizzaro Hosp, I 95126 Catania, Italy.
C3 University of Catania
RP Catania Univ, Dept Senescent Urol & Neurol Sci, Cannizzaro Hosp, Via Messina 829, I 95126 Catania, Italy.
EM dmaugeri@tin.it
CR Atkins GJ, 2000, BONE, V26, P653, DOI 10.1016/S8756 3282(00)00280 5
   Bendre MS, 2003, BONE, V33, P28, DOI 10.1016/S8756 3282(03)00086 3
   Black DM, 2000, J CLIN ENDOCR METAB, V85, P4118, DOI 10.1210/jc.85.11.4118
   Ettinger B, 1999, JAMA J AM MED ASSOC, V282, P637, DOI 10.1001/jama.282.7.637
   Harris ST, 1999, JAMA J AM MED ASSOC, V282, P1344, DOI 10.1001/jama.282.14.1344
   Heikkilä P, 2003, J SURG RES, V111, P45, DOI 10.1016/S0022 4804(03)00000 0
   Hosohara K, 2002, CLIN DIAGN LAB IMMUN, V9, P777, DOI 10.1128/CDLI.9.4.777 783.2002
   Joronen K, 2000, HISTOCHEM CELL BIOL, V114, P157
   Liu Li, 2004, Hua Xi Kou Qiang Yi Xue Za Zhi, V22, P325
   Makiishi Shimobayashi C, 2001, BIOCHEM BIOPH RES CO, V281, P361, DOI 10.1006/bbrc.2001.4380
   Martin TJ, 1998, CRIT REV EUKAR GENE, V8, P107, DOI 10.1615/CritRevEukarGeneExpr.v8.i2.10
   Mori N, 2002, BLOOD, V99, P1341, DOI 10.1182/blood.V99.4.1341
   Nold M, 2003, N S ARCH PHARMACOL, V367, P68, DOI 10.1007/s00210 002 0648 5
   Onodera S, 2002, J BIOL CHEM, V277, P7865, DOI 10.1074/jbc.M106020200
   Ortega N, 2003, ANN NY ACAD SCI, V995, P109, DOI 10.1111/j.1749 6632.2003.tb03214.x
   PAIKKA V, 2001, ENDOCRINOLOGY, V142, P5371
   Rousselle AV, 2001, HISTOL HISTOPATHOL, V16, P727, DOI 10.14670/HH 16.727
   Sasaki H, 2004, CLIN DIAGN LAB IMMUN, V11, P106, DOI 10.1128/CDLI.11.1.106 110.2004
   Simsek G, 2003, CHINESE J PHYSIOL, V46, P181
   Stamenkovic I, 2003, J PATHOL, V200, P448, DOI 10.1002/path.1400
   Suzuki Yasuo, 2004, Nihon Rinsho, V62 Suppl 2, P107
   Udagawa N, 1997, J EXP MED, V185, P1005, DOI 10.1084/jem.185.6.1005
   Valleala H, 2003, LIFE SCI, V73, P2413, DOI 10.1016/S0024 3205(03)00657 X
   Wang JE, 2004, SHOCK, V22, P376, DOI 10.1097/01.shk.0000140299.48063.89
   Wittrant Y, 2002, BIOCHEM BIOPH RES CO, V293, P38, DOI 10.1016/S0006 291X(02)00179 1
   Wolczynski S, 2001, GYNECOL ENDOCRINOL, V15, P225, DOI 10.1080/713602831
   Yamada N, 2002, BONE, V30, P901, DOI 10.1016/S8756 3282(02)00722 6
   Zhao HB, 1998, CHINESE MED J PEKING, V111, P551
NR 28
TC 13
Z9 14
U1 0
U2 3
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0167 4943
EI 1872 6976
J9 ARCH GERONTOL GERIAT
JI Arch. Gerontol. Geriatr.
PD MAY JUN
PY 2005
VL 40
IS 3
BP 299
EP 305
DI 10.1016/j.archger.2004.10.001
PG 7
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Geriatrics & Gerontology
GA 920FQ
UT WOS:000228675200008
PM 15814163
DA 2025 08 17
ER

PT J
AU Shi, XT
   Ren, L
   Tian, M
   Yu, JK
   Huang, W
   Du, C
   Wang, DA
   Wang, YJ
AF Shi, Xuetao
   Ren, Li
   Tian, Ming
   Yu, Jiakuo
   Huang, Wei
   Du, Chang
   Wang, Dong An
   Wang, Yingjun
TI In vivo and in vitro osteogenesis of stem
   cells induced by controlled release of drugs from microspherical
   scaffolds
SO JOURNAL OF MATERIALS CHEMISTRY
LA English
DT Article
ID BONE; HYDROXYAPATITE; DEXAMETHASONE; ALENDRONATE; BISPHOSPHONATES;
   DIFFERENTIATION; PROLIFERATION; NANOCRYSTALS; MECHANISMS; MATURATION
AB In this study, the in vivo and in vitro osteogenesis was successfully induced in situ by the controlled release of alendronate (AL) and dexamethasone (Dex) from the poly(lactic co glycolic acid) (PLGA)/hydroxyapatite (HA) sintering microsphere scaffold (SMS). This microspherically based controlled release system is constructed with two levels of structure: AL attached HA particles and a Dex PLGA matrix. Bone marrow mesenchymal stem cells (BMSCs) cultured on AL loaded PLGA/HA sintering microsphere scaffold (PLGA/HA AL SMS) and AL Dex loaded PLGA/HA sintering microsphere scaffold (PLGA/HA Com SMS) displayed a strong osteogenic commitment locally in vitro. The osteogenic commitment of BMSCs on the scaffolds were verified by an alkaline phosphatase (ALP) activity assay, real time PCR and immunohistochemistry analysis. The results demonstrated that BMSCs cultured on PLGA/HA AL SMS and PLGA/HA Com SMS exhibited superior osteogenic differentiation owing to significantly high gene expression of typical osteogenic genes osteocalcin (OC), type I collagen, BMP 2, and also protein secretion of type I collagen. In addition, BMSCs laden with PLGA/HA AL SMS and PLGA/HA Com SMS were also implanted into the back subcutis of mice and bone defects surgically created on rabbit femurs. The histology and immunohistochemistry results indicated that the scaffolds promoted BMSCs osteogenic commitment and also the new bone formation in vivo. In conclusion, this controlled release system is promising for implanted biomedical devices to improve bone reparation and regeneration.
C1 [Shi, Xuetao; Ren, Li; Huang, Wei; Du, Chang; Wang, Yingjun] S China Univ Technol, Sch Mat Sci & Engn, Guangzhou 510641, Guangdong, Peoples R China.
   [Tian, Ming; Yu, Jiakuo] Peking Univ, Hosp 3, Inst Sports Med, Beijing 100871, Peoples R China.
   [Wang, Dong An] Nanyang Technol Univ, Div Bioengn, Sch Chem & Biomed Engn, Singapore 637457, Singapore.
   [Shi, Xuetao; Ren, Li; Huang, Wei; Du, Chang; Wang, Dong An] S China Univ Technol, Key Lab Specially Funct Mat & Adv Mfg Technol, Minist Educ, Guangzhou 510641, Peoples R China.
C3 South China University of Technology; Peking University; Nanyang
   Technological University; South China University of Technology
RP Ren, L (通讯作者)，S China Univ Technol, Sch Mat Sci & Engn, Guangzhou 510641, Guangdong, Peoples R China.
EM mrshixuetao@hotmail.com
RI Wang, Dong an/G 6195 2010; Yu, Jia Kuo/ISS 2254 2023; Du,
   Chang/H 4200 2012; Shi, Xuetao/D 5180 2012; ren, li/L 2454 2017
OI Wang, Dong An/0000 0002 7927 1422; Ren, Li/0000 0003 0604 9166; Shi,
   Xuetao/0000 0001 9919 8931; Du, Chang/0000 0002 6460 0764
FU China Scholarship Council (CSC) [2007U33046]; National Natural Science
   Foundation of China [50572029]; Ministry of Education [305012]; National
   Natural Science of China [50732003]
FX Shi Xuetao is a China Scholarship Council (CSC) scholarship recipient
   (2007U33046). This research was supported by National Natural Science
   Foundation of China (Grant 50572029), the Key Programs of the Ministry
   of Education (Grant 305012), the State Key Program of National Natural
   Science of China (Grant 50732003). The research was also AcRF Tier 1 RG
   64/08, Ministry of Education, Singapore.
CR Boanini E, 2007, ADV MATER, V19, P2499, DOI 10.1002/adma.200602497
   Borden M, 2002, BIOMATERIALS, V23, P551, DOI 10.1016/S0142 9612(01)00137 5
   Boyan BD, 1999, CLIN PLAST SURG, V26, P629
   Cartmell S, 2009, J PHARM SCI US, V98, P430, DOI 10.1002/jps.21431
   Chang MW, 2010, LANGMUIR, V26, P5115, DOI 10.1021/la903592s
   Fisher JE, 1999, P NATL ACAD SCI USA, V96, P133, DOI 10.1073/pnas.96.1.133
   Fleisch H, 1998, ENDOCR REV, V19, P80, DOI 10.1210/er.19.1.80
   Fleming JE Jr, 2000, ORTHOP CLIN N AM, V31, P357, DOI 10.1016/S0030 5898(05)70156 5
   Hutmacher DW, 2000, BIOMATERIALS, V21, P2529, DOI 10.1016/S0142 9612(00)00121 6
   Im GI, 2004, BIOMATERIALS, V25, P4105, DOI 10.1016/j.biomaterials.2003.11.024
   Iqbal MS, 2006, CHROMATOGRAPHIA, V64, P219, DOI 10.1365/s10337 006 0019 3
   Jabbarzadeh E, 2007, BIOTECHNOL BIOENG, V98, P1094, DOI 10.1002/bit.21495
   Jadlowiec JA, 2003, EXPERT OPIN BIOL TH, V3, P409, DOI 10.1517/eobt.3.3.409.21183
   Jo I, 2007, BIOTECHNOL BIOPROC E, V12, P48, DOI 10.1007/BF02931803
   Kavanagh KL, 2006, P NATL ACAD SCI USA, V103, P7829, DOI 10.1073/pnas.0601643103
   Kim H, 2005, BIOCHEM BIOPH RES CO, V332, P1053, DOI 10.1016/j.bbrc.2005.05.051
   Kim H, 2003, BIOMATERIALS, V24, P4671, DOI 10.1016/S0142 9612(03)00358 2
   Kneser U, 2006, J CELL MOL MED, V10, P7, DOI 10.1111/j.1582 4934.2006.tb00287.x
   Kuljanin J, 2002, J PHARMACEUT BIOMED, V28, P1215, DOI 10.1016/S0731 7085(02)00021 3
   LIU W, 2004, CURR OPIN ORTHOP, V15, P364
   Ma PX, 2001, TISSUE ENG, V7, P23, DOI 10.1089/107632701300003269
   Meyer U., 2006, Bone and Cartilage. Bone and Cartilage Engineering, P7, DOI [10.1007/3 540 33606 02, DOI 10.1007/3 540 33606 02]
   Na K, 2007, BIOMATERIALS, V28, P2631, DOI 10.1016/j.biomaterials.2007.02.008
   OHGUSHI H, 1990, J BIOMED MATER RES, V24, P1563, DOI 10.1002/jbm.820241202
   Palazzo B, 2007, ADV FUNCT MATER, V17, P2180, DOI 10.1002/adfm.200600361
   Park K, 2008, BIOMATERIALS, V29, P2490, DOI 10.1016/j.biomaterials.2008.02.017
   Phillips JE, 2006, J CELL SCI, V119, P581, DOI 10.1242/jcs.02758
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Sakaguchi Y, 2005, ARTHRITIS RHEUM US, V52, P2521, DOI 10.1002/art.21212
   Shi XT, 2010, EUR J PHARM SCI, V39, P59, DOI 10.1016/j.ejps.2009.10.012
   Shi XT, 2010, J BIOMED MATER RES A, V92A, P963, DOI 10.1002/jbm.a.32423
   Shi XT, 2009, BIOMATERIALS, V30, P3996, DOI 10.1016/j.biomaterials.2009.04.021
   Shi XT, 2009, ACTA BIOMATER, V5, P1697, DOI 10.1016/j.actbio.2009.01.010
   Shi XT, 2009, INT J PHARMACEUT, V373, P85, DOI 10.1016/j.ijpharm.2009.02.013
   Shi XT, 2009, PHARM RES DORDR, V26, P422, DOI 10.1007/s11095 008 9759 0
   Uccelli A, 2008, NAT REV IMMUNOL, V8, P726, DOI 10.1038/nri2395
   VACANTI CA, 1994, OTOLARYNG CLIN N AM, V27, P263
   von Knoch F, 2005, BIOMATERIALS, V26, P6941, DOI 10.1016/j.biomaterials.2005.04.059
   Walsh S, 2001, RHEUMATOLOGY, V40, P74, DOI 10.1093/rheumatology/40.1.74
   Wang DA, 2005, TISSUE ENG, V11, P201, DOI 10.1089/ten.2005.11.201
NR 40
TC 26
Z9 31
U1 1
U2 101
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 0959 9428
EI 1364 5501
J9 J MATER CHEM
JI J. Mater. Chem.
PY 2010
VL 20
IS 41
BP 9140
EP 9148
DI 10.1039/c0jm00976h
PG 9
WC Chemistry, Physical; Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Materials Science
GA 663GP
UT WOS:000282871600024
DA 2025 08 17
ER

PT J
AU Chow, T
   Wutami, I
   Lucarelli, E
   Choong, PF
   Duchi, S
   Di Bella, C
AF Chow, Thomas
   Wutami, Ilycia
   Lucarelli, Enrico
   Choong, Peter F.
   Duchi, Serena
   Di Bella, Claudia
TI Creating In Vitro Three Dimensional Tumor Models: A Guide for the
   Biofabrication of a Primary Osteosarcoma Model
SO TISSUE ENGINEERING PART B REVIEWS
LA English
DT Article
DE osteosarcoma; tumor microenvironment; three dimensional tumor models;
   preclinical in vitro models
ID PLASMINOGEN ACTIVATOR RECEPTOR; MESENCHYMAL STEM CELLS;
   FUNCTIONAL CHARACTERIZATION; OSTEOCLAST DIFFERENTIATION; CANCER
   PROGRESSION; DRUG SENSITIVITY; BONE REPAIR; SCAFFOLDS; HYDROGELS; GROWTH
AB Osteosarcoma (OS) is a highly aggressive primary bone tumor. The mainstay for its treatment is multiagent chemotherapy and surgical resection, with a 50 70% 5 year survival rate. Despite the huge effort made by clinicians and researchers in the past 30 years, limited progress has been made to improve patient outcomes. As novel therapeutic approaches for OS become available, such as monoclonal antibodies, small molecules, and immunotherapies, the need for OS preclinical model development becomes equally pressing. Three dimensional (3D) OS models represent an alternative system to study this tumor: In contrast to two dimensional monolayers, 3D matrices can recapitulate key elements of the tumor microenvironment (TME), such as the cellular interaction with the bone mineralized matrix. The advancement of tissue engineering and biofabrication techniques enables the incorporation of specific TME aspects into 3D models, to investigate the contribution of individual components to tumor progression and enhance understanding of basic OS biology. The use of biomaterials that mimic the extracellular matrix could also facilitate the testing of drugs targeting the TME itself, allowing a larger range of therapeutics to be tested, while averting the ethical implications and high cost associated with in vivo preclinical models. This review aims at serving as a practical guide by delineating the OS TME ("what it is like") and, in turn, propose various biofabrication strategies to create a 3D model ("how to recreate it"), to improve the in vitro representation of the OS tumor and ultimately generate more accurate drug response profiles.
   Impact statement
   Osteosarcoma (OS) is a rare and highly aggressive bone cancer, with poor prognosis. Unfortunately, current in vitro preclinical models, such as monolayer cell culture, fail to recapitulate the tumor microenvironment (TME) and thus accurate neoplastic behavior, ultimately hindering therapeutic discovery. The employment of three dimensional (3D) OS models has the potential to better recreate the spatial, mechanical, and biological complexity of the TME, key elements that are crucial for understanding tumor prognosis and treatment effectiveness. The accuracy and fidelity of such models can be improved by systematic incorporation of each TME aspect. Therefore, by first asking "what it is like" followed by "how to recreate it," this review presents practical biofabrication strategies to build an appropriate 3D OS model to better represent in vitro tumor pathogenesis and response to novel therapies.
C1 [Chow, Thomas; Wutami, Ilycia] Univ Melbourne, Fac Med Dent & Hlth Sci, Melbourne Med Sch, Parkville, Vic, Australia.
   [Chow, Thomas; Wutami, Ilycia; Choong, Peter F.; Duchi, Serena; Di Bella, Claudia] St Vincents Hosp Melbourne, BioFab3D ACMD, Fitzroy, Vic, Australia.
   [Lucarelli, Enrico] IRCCS Ist Ortoped Rizzoli, Unit Orthopaed Pathol & Osteoarticular Tissue Reg, Bologna, Italy.
   [Choong, Peter F.; Duchi, Serena; Di Bella, Claudia] Univ Melbourne, Dept Surg, St Vincents Hosp Melbourne, Fitzroy, Vic, Australia.
   [Choong, Peter F.; Di Bella, Claudia] St Vincents Hosp Melbourne, Dept Orthopaed, Fitzroy, Vic, Australia.
C3 University of Melbourne; St Vincent's Health; St Vincent's Hospital
   Melbourne; St Vincent's Health; St Vincent's Hospital Melbourne;
   University of Melbourne; St Vincent's Health; St Vincent's Hospital
   Melbourne
RP Duchi, S (通讯作者)，Univ Melbourne, Dept Surg, Level 2,Clin Sci Bldg,29 Regent St, Fitzroy, Vic 3065, Australia.
EM sduchi@unimelb.edu.au
RI Lucarelli, Enrico/G 3588 2015; Chow, Thomas/AAD 8915 2021; Choong,
   Peter/F 1109 2014
OI Duchi, Serena/0000 0002 6418 3323; Chow, Thomas/0000 0003 1895 2539
FU St Vincent's Hospital ( Melbourne) Research Endowment Fund
   2019_2020_Duchi; NHMRC Early Leadership Investigator Grant for
   musculoskeletal bioengineering; NHMRC [1154203]; National Health and
   Medical Research Council of Australia [1154203] Funding Source: NHMRC
FX This work was supported by St Vincent's Hospital ( Melbourne) Research
   Endowment Fund 2019_2020_Duchi. C.D.B. holds an NHMRC Early Leadership
   Investigator Grant for musculoskeletal bioengineering. P.F.C. holds an
   NHMRC Practitioner Fellowship (1154203).
CR Abarrategi A, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/3631764
   Adamopoulos C, 2016, EXP BIOL MED, V241, P1296, DOI 10.1177/1535370216648806
   Ahmed EM, 2015, J ADV RES, V6, P105, DOI 10.1016/j.jare.2013.07.006
   Akiyama T, 2008, MOL CANCER THER, V7, P3461, DOI 10.1158/1535 7163.MCT 08 0530
   Alessandri K, 2013, P NATL ACAD SCI USA, V110, P14843, DOI 10.1073/pnas.1309482110
   Amanda J.S., 2018, FRONT ONCOL, V8, P7
   [Anonymous], 2020, CELLS BASEL, DOI DOI 10.3390/CELLS9040976
   Arantzazu A., 2015, CELL MOL LIFE SCI, V72, P16
   Asti A, 2014, INT J ARTIF ORGANS, V37, P187, DOI [10.5301/ijao.5000307, 10.530/ijao.5000307]
   Avnet S, 2008, INT J ONCOL, V33, P1231, DOI 10.3892/ijo_00000113
   Baranski Zuzanna, 2015, Genes Cancer, V6, P503
   Benton JA, 2009, TISSUE ENG PT A, V15, P3221, DOI [10.1089/ten.tea.2008.0545, 10.1089/ten.TEA.2008.0545]
   Bertassoni LE, 2014, LAB CHIP, V14, P2202, DOI 10.1039/c4lc00030g
   Bonuccelli G, 2014, ONCOTARGET, V5, P7575, DOI 10.18632/oncotarget.2243
   Bose S, 2013, MATER TODAY, V16, P496, DOI 10.1016/j.mattod.2013.11.017
   Brahimi Horn MC, 2009, J CELL SCI, V122, P1055, DOI 10.1242/jcs.035022
   Bremnes RM, 2011, J THORAC ONCOL, V6, P209, DOI 10.1097/JTO.0b013e3181f8a1bd
   Byrne MB, 2014, TRENDS BIOTECHNOL, V32, P556, DOI 10.1016/j.tibtech.2014.09.006
   Caliari SR, 2016, NAT METHODS, V13, P405, DOI 10.1038/nmeth.3839
   Camci Unal G, 2013, BIOMACROMOLECULES, V14, P1085, DOI 10.1021/bm3019856
   Chaddad H, 2017, EXP CELL RES, V360, P138, DOI 10.1016/j.yexcr.2017.08.035
   Chen XD, 2007, J BONE MINER RES, V22, P1943, DOI 10.1359/JBMR.070725
   Chen YT, 2011, TISSUE ENG PART C ME, V17, P1211, DOI 10.1089/ten.tec.2011.0092
   Chocholata P, 2019, MATERIALS, V12, DOI 10.3390/ma12040568
   Choudhury D, 2018, TRENDS BIOTECHNOL, V36, P787, DOI 10.1016/j.tibtech.2018.03.003
   Christensen J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132725
   Clarke B, 2008, CLIN J AM SOC NEPHRO, V3, pS131, DOI 10.2215/CJN.04151206
   Cortini M, 2019, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.00814
   Cortini M, 2017, CANCER LETT, V405, P90, DOI 10.1016/j.canlet.2017.07.024
   Cortini M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166500
   Dai J, 2019, J MECH BEHAV BIOMED, V90, P226, DOI 10.1016/j.jmbbm.2018.10.012
   Dailiana Z.H., 2008, 55 ANN M ORTH RES SO, V1601
   De Luca A, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046 017 0663 5
   Del Monte U, 2009, CELL CYCLE, V8, P505, DOI 10.4161/cc.8.3.7608
   Desmaison A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080447
   DEVITA VT, 1975, CANCER, V35, P98, DOI 10.1002/1097 0142(197501)35:1<98::AID CNCR2820350115>3.0.CO;2 B
   Dwivedi Ruby, 2020, J Oral Biol Craniofac Res, V10, P381, DOI 10.1016/j.jobcr.2019.10.003
   Elenjord R, 2009, FEBS J, V276, P5275, DOI 10.1111/j.1742 4658.2009.07223.x
   Engelholm LH, 2001, LAB INVEST, V81, P1403, DOI 10.1038/labinvest.3780354
   Fallica B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048024
   Francisco L, 2017, PROCEDIA MANUF, V12, P291, DOI 10.1016/j.promfg.2017.08.032
   Fu DH, 2011, BMC MUSCULOSKEL DIS, V12, DOI 10.1186/1471 2474 12 146
   Furlan F, 2007, J BONE MINER RES, V22, P1387, DOI 10.1359/JBMR.070516
   Gaebler M, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00203
   Gao CD, 2014, INT J MOL SCI, V15, P4714, DOI 10.3390/ijms15034714
   Gao ST, 2017, BIOFABRICATION, V9, DOI 10.1088/1758 5090/aa7fdb
   Gkretsi V, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00145
   Gorgieva S, 2011, BIOMATERIALS APPLICATIONS FOR NANOMEDICINE, P17
   Gorska M, 2016, ANTICANCER RES, V36, P221
   Grandori C, 2018, TRENDS CANCER, V4, P634, DOI 10.1016/j.trecan.2018.07.005
   Grist SM, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 54001 8
   Gunatillake Pathiraja A., 2003, European Cells & Materials, V5, P1
   Gungor Ozkerim PS, 2018, BIOMATER SCI UK, V6, P915, DOI 10.1039/c7bm00765e
   Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022
   Hao SJ, 2018, ADV DRUG DELIVER REV, V125, P3, DOI 10.1016/j.addr.2018.01.002
   Heo DN, 2014, J MATER CHEM B, V2, P1584, DOI 10.1039/c3tb21246g
   Heymann M.F., 2017, OSTEOSARCOMA BIOL BE, P105
   Holy CE, 2000, J BIOMED MATER RES, V51, P376, DOI 10.1002/1097 4636(20000905)51:3<376::AID JBM11>3.0.CO;2 G
   Hoshiba T, 2010, EXPERT OPIN BIOL TH, V10, P1717, DOI 10.1517/14712598.2010.534079
   Hospodiuk M, 2017, BIOTECHNOL ADV, V35, P217, DOI 10.1016/j.biotechadv.2016.12.006
   Huang BW, 2018, J CONTROL RELEASE, V270, P246, DOI 10.1016/j.jconrel.2017.12.005
   Huang Q, 2018, AM J CANCER RES, V8, P763
   Huebsch N, 2010, NAT MATER, V9, P518, DOI [10.1038/nmat2732, 10.1038/NMAT2732]
   Hughes CS, 2010, PROTEOMICS, V10, P1886, DOI 10.1002/pmic.200900758
   Isakoff MS, 2015, J CLIN ONCOL, V33, P3029, DOI 10.1200/JCO.2014.59.4895
   Jabbari E, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132377
   Jansen LE, 2015, J MECH BEHAV BIOMED, V50, P299, DOI 10.1016/j.jmbbm.2015.06.023
   Kalli M, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00055
   Kawao N, 2014, AM J PHYSIOL ENDOC M, V307, pE278, DOI 10.1152/ajpendo.00129.2014
   Khetan S, 2013, NAT MATER, V12, P458, DOI [10.1038/NMAT3586, 10.1038/nmat3586]
   Koirala P, 2016, SCI REP UK, V6, DOI 10.1038/srep30093
   Kolesky DB, 2014, ADV MATER, V26, P3124, DOI 10.1002/adma.201305506
   Koshy ST, 2014, BIOMATERIALS, V35, P2477, DOI 10.1016/j.biomaterials.2013.11.044
   Lamora A, 2016, J CLIN MED, V5, DOI 10.3390/jcm5110096
   Lamoureux F, 2007, CANCER RES, V67, P7308, DOI 10.1158/0008 5472.CAN 06 4130
   Lauvrak SU, 2013, BRIT J CANCER, V109, P2228, DOI 10.1038/bjc.2013.549
   Lee JH, 2018, J TISSUE ENG, V9, DOI 10.1177/2041731418768285
   Lee VK, 2014, CELL MOL BIOENG, V7, P460, DOI 10.1007/s12195 014 0340 0
   Lenna S, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046 020 01548 4
   Liliana E. M., 2012, BIOCHIM BIOPHYS ACTA, V1826, P8
   Lin PP, 2009, CARCINOGENESIS, V30, P1789, DOI 10.1093/carcin/bgp180
   Lindsey BA, 2017, RHEUMATOL THER, V4, P25, DOI 10.1007/s40744 016 0050 2
   Liu TY, 2019, FRONT CELL DEV BIOL, V7, DOI 10.3389/fcell.2019.00060
   Liu YX, 2010, BIOMATERIALS, V31, P1158, DOI 10.1016/j.biomaterials.2009.10.040
   Mahmood N, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00024
   Mandrycky C, 2016, BIOTECHNOL ADV, V34, P422, DOI 10.1016/j.biotechadv.2015.12.011
   Marturano Kruik A, 2018, BIOMATERIALS, V150, P150, DOI 10.1016/j.biomaterials.2017.10.020
   Maurizi A, 2018, CANCERS, V10, DOI 10.3390/cancers10070218
   MEYSKENS FL, 1984, CANCER RES, V44, P271
   Miller JS, 2012, NAT MATER, V11, P768, DOI [10.1038/NMAT3357, 10.1038/nmat3357]
   Misaghi A, 2018, SICOT J, V4, DOI 10.1051/sicotj/2017028
   Mitsui N, 2006, LIFE SCI, V79, P575, DOI 10.1016/j.lfs.2006.01.040
   Mohseny AB, 2011, LAB INVEST, V91, P1195, DOI 10.1038/labinvest.2011.72
   Molina ER, 2020, TISSUE ENG PART B RE, V26, P249, DOI 10.1089/ten.teb.2019.0302
   Murphy SV, 2014, NAT BIOTECHNOL, V32, P773, DOI 10.1038/nbt.2958
   Mutsaers AJ, 2014, BONE, V62, P56, DOI 10.1016/j.bone.2014.02.003
   Mutsaers AJ, 2013, BONE, V55, P166, DOI 10.1016/j.bone.2013.02.016
   Muz B, 2015, HYPOXIA, V3, P83, DOI 10.2147/HP.S93413
   Neufurth M, 2014, BIOMATERIALS, V35, P8810, DOI 10.1016/j.biomaterials.2014.07.002
   Ottaviano L, 2010, GENE CHROMOSOME CANC, V49, P40, DOI 10.1002/gcc.20717
   Oztan Y. Cagri, 2020, Bioprinting, V18, pe00079, DOI 10.1016/j.bprint.2020.e00079
   Park KM, 2017, ANNU REV BIOMED ENG, V19, P109, DOI 10.1146/annurev bioeng 071516 044619
   Pavlou M, 2019, ACTA BIOMATER, V96, P247, DOI 10.1016/j.actbio.2019.07.011
   Picci P, 2007, ORPHANET J RARE DIS, V2, DOI 10.1186/1750 1172 2 6
   Punzo Francesca, 2020, Oncotarget, V11, P687, DOI 10.18632/oncotarget.27479
   Quinn JMW, 2001, J BONE MINER RES, V16, P1787, DOI 10.1359/jbmr.2001.16.10.1787
   Rosenberg A.E., WHO CLASSIF TUMOURS
   Roseti L, 2017, MAT SCI ENG C MATER, V78, P1246, DOI 10.1016/j.msec.2017.05.017
   Rubio R, 2013, ONCOGENE, V32, P4970, DOI 10.1038/onc.2012.507
   Santoro M, 2015, P NATL ACAD SCI USA, V112, P10304, DOI 10.1073/pnas.1506684112
   Sawkins MJ, 2013, ACTA BIOMATER, V9, P7865, DOI 10.1016/j.actbio.2013.04.029
   Sawyer S.W., 2016, J. Tissue Sci. Eng, V7, DOI DOI 10.4172/2157 7552.1000173
   Schugens C, 1996, J BIOMED MATER RES, V30, P449, DOI 10.1002/(SICI)1097 4636(199604)30:4<449::AID JBM3>3.0.CO;2 P
   Schuurman W, 2013, MACROMOL BIOSCI, V13, P551, DOI 10.1002/mabi.201200471
   Sitarski AM, 2018, ACS BIOMATER SCI ENG, V4, P324, DOI 10.1021/acsbiomaterials.7b00097
   Skylar Scott MA, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aaw2459
   Sofia S., 2016, J BONE ONCOL, V5, P3
   Song HHG, 2014, ADV DRUG DELIVER REV, V79 80, P19, DOI 10.1016/j.addr.2014.06.002
   Tan PHS, 2014, TISSUE ENG PT A, V20, P1758, DOI [10.1089/ten.tea.2013.0245, 10.1089/ten.TEA.2013.0245]
   Tan PHS, 2011, BIOMATERIALS, V32, P6131, DOI 10.1016/j.biomaterials.2011.04.084
   Tappa K, 2018, J FUNCT BIOMATER, V9, DOI 10.3390/jfb9010017
   Tomasina C, 2019, MATERIALS, V12, DOI 10.3390/ma12172701
   Trachtenberg JE, 2018, ACS BIOMATER SCI ENG, V4, P347, DOI 10.1021/acsbiomaterials.6b00641
   Turnbull G, 2018, BIOACT MATER, V3, P278, DOI 10.1016/j.bioactmat.2017.10.001
   Vääräniemi J, 2004, J BONE MINER RES, V19, P1432, DOI 10.1359/JBMR.040603
   Visvader JE, 2011, NATURE, V469, P314, DOI 10.1038/nature09781
   Wang XH, 2019, MICROMACHINES BASEL, V10, DOI 10.3390/mi10120814
   Xavier JR, 2015, ACS NANO, V9, P3109, DOI 10.1021/nn507488s
   Xu T, 2015, ADV HEALTHC MATER, V4, P2238, DOI 10.1002/adhm.201500345
   Yang Yi, 2017, Genes Cancer, V8, P484, DOI 10.18632/genesandcancer.133
   Yu D, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000016827
   Yue K, 2015, BIOMATERIALS, V73, P254, DOI 10.1016/j.biomaterials.2015.08.045
   Zeng W, 2011, CANCER LETT, V313, P129, DOI 10.1016/j.canlet.2011.09.023
   Zhang LZ, 2010, PATHOL ONCOL RES, V16, P111, DOI 10.1007/s12253 009 9198 1
   Zhang RY, 1999, J BIOMED MATER RES, V44, P446
   Zhang Y., 2017, Osteosarcoma   Biology, Behavior and Mechanisms
   Zhang Y, 2019, JOVE J VIS EXP, DOI 10.3791/59271
   Zheng Y, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 0780 x
NR 138
TC 26
Z9 26
U1 1
U2 37
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1937 3368
EI 1937 3376
J9 TISSUE ENG PART B RE
JI Tissue Eng. Part B Rev.
PD OCT 1
PY 2021
VL 27
IS 5
BP 514
EP 529
DI 10.1089/ten.teb.2020.0254
EA DEC 2020
PG 16
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell
   Biology; Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology; Engineering;
   Materials Science
GA WL2JV
UT WOS:000595790100001
PM 33138724
DA 2025 08 17
ER

PT J
AU Simoni, D
   Gebbia, N
   Invidiata, FP
   Eleopra, M
   Marchetti, P
   Rondanin, R
   Baruchello, R
   Provera, S
   Marchicro, C
   Tolomeo, M
   Marinelli, L
   Limongelli, V
   Novellino, E
   Kwaasi, A
   Dunford, J
   Buccheri, S
   Caccamo, N
   Dieli, F
AF Simoni, Danicle
   Gebbia, Nicola
   Invidiata, Francesco Paolo
   Eleopra, Marco
   Marchetti, Paolo
   Rondanin, Riccardo
   Baruchello, Riccardo
   Provera, Stefano
   Marchicro, Carla
   Tolomeo, Manho
   Marinelli, Luciana
   Limongelli, Vittorio
   Novellino, Ettore
   Kwaasi, Aaron
   Dunford, James
   Buccheri, Siniona
   Caccamo, Nadia
   Dieli, Francesco
TI Design, Synthesis, and Biological Evaluation of Novel
   Aminobisphosphonates Possessing an in Vivo Antitumor Activity Through a
   γδ T Lymphocytes Mediated Activation Mechanism
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID TRYPANOSOMA CRUZI; STRUCTURAL BASIS; ZOLEDRONIC ACID; BONE RESORPTION;
   ATOMIC CHARGES; BISPHOSPHONATES; CELLS; PYROPHOSPHATE; INHIBITION;
   IMMUNOTHERAPY
AB A small series of aminobisphosphonates (N BPs) structurally related to zoledronic acid was synthesized with the aim of improving activity toward activation of human gamma delta T cells and in turn their in vivo antitumor activity. The absence of the 1 OH moiety, together with the position and the different basicity of the nitrogen, appears crucial for antitumor activity. In comparison to zoledronic acid, compound 6a shows a greater ability to activate gamma delta T cells expression (100 times more) and a proapoptotic effect that is better than zoledronic acid. The potent activation of gamma delta T cells, in addition to evidence of the in vivo antitumor activity of 6a, suggests it may be a new potential drug candidate for cancer treatment.
C1 [Gebbia, Nicola] CoRiBiA, Palermo, Italy.
   [Invidiata, Francesco Paolo] Univ Palermo, Dipartimento Farmacochim Tossicol & Biol, I 90133 Palermo, Italy.
   [Provera, Stefano; Marchicro, Carla] GlaxoSmithKline, Med Res Ctr, Verona, Italy.
   [Tolomeo, Manho] Univ Palermo, Div Ematol Serv AIDS Policlin, Palermo, Italy.
   [Marinelli, Luciana; Limongelli, Vittorio; Novellino, Ettore] Univ Naples Federico II, Dipartimento Chim Farmaceut & Tossicol, I 80131 Naples, Italy.
   [Kwaasi, Aaron; Dunford, James] Univ Oxford, Nuffield Dept Orthopaed Surg, Nuffield Orthopaed Ctr, Botnar Res Ctr,Inst Musculoskeletal Sci, Oxford OX3 7LD, England.
   [Buccheri, Siniona; Caccamo, Nadia; Dieli, Francesco] Univ Palermo, Dipartimento Biopatol & Metodol Biomed, Palermo, Italy.
   [Simoni, Danicle; Eleopra, Marco; Marchetti, Paolo; Rondanin, Riccardo; Baruchello, Riccardo] Univ Ferrara, Dipartimento Sci Farmaceut, I 44100 Ferrara, Italy.
C3 University of Palermo; GlaxoSmithKline; GlaxoSmithKline Italy;
   Glaxosmithkline United Kingdom; University of Palermo; University of
   Naples Federico II; Nuffield Orthopaedic Centre; University of Oxford;
   University of Palermo; University of Ferrara
RP Simoni, D (通讯作者)，Univ Ferrara, Dipartimento Sci Farmaceut, Via Fossato Mortara 17 19, I 44100 Ferrara, Italy.
EM smd@unife.it
RI ; Dieli, Francesco/J 5018 2018; Marchetti, Paolo/K 1469 2016; Caccamo,
   Nadia/J 6808 2018; Marinelli, Luciana/AHE 5969 2022; tolomeo,
   manlio/HSB 9635 2023
OI Marinelli, Luciana/0000 0002 4084 8044; Tolomeo,
   Manlio/0000 0002 7974 2319; Dieli, Francesco/0000 0002 6685 352X;
   CACCAMO, Nadia Rosalia/0000 0002 1018 5710; Limongelli,
   Vittorio/0000 0002 4861 1199; Dunford, James/0000 0002 9932 4042;
   Novellino, Ettore/0000 0002 2181 2142
FU Ministero dell' Universita e della Ricerca Scientifica e Tecnologica
   [PRIN 2006]
FX This work was financially supported in part by Ministero dell'
   Universita e della Ricerca Scientifica e Tecnologica (PRIN 2006).
CR ANDERSON KC, 2000, HEMATOLOGY, P166
   BAYLY CI, 1993, J PHYS CHEM US, V97, P10269, DOI 10.1021/j100142a004
   BESLER BH, 1990, J COMPUT CHEM, V11, P431, DOI 10.1002/jcc.540110404
   Cheng F, 2004, J MED CHEM, V47, P5149, DOI 10.1021/jm040036s
   Clézardin P, 2005, CANCER RES, V65, P4971, DOI 10.1158/0008 5472.CAN 05 0264
   CORNELL WD, 1993, J AM CHEM SOC, V115, P9620, DOI 10.1021/ja00074a030
   CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002
   Dieli F, 2003, BLOOD, V102, P2310, DOI 10.1182/blood 2003 05 1655
   Dieli F, 2007, CANCER RES, V67, P7450, DOI 10.1158/0008 5472.CAN 07 0199
   Espinosa E, 2001, J BIOL CHEM, V276, P18337, DOI 10.1074/jbc.M100495200
   Feldman EJ, 2005, J CLIN ONCOL, V23, P4110, DOI 10.1200/JCO.2005.09.133
   Fleisch H, 1998, ENDOCR REV, V19, P80, DOI 10.1210/er.19.1.80
   FLEISCH H, 1969, SCIENCE, V165, P1262, DOI 10.1126/science.165.3899.1262
   FRISCH MJ, 2003, GAUSSIAN 03
   Green JR, 2003, CANCER, V97, P840, DOI 10.1002/cncr.11128
   Groh V, 1998, SCIENCE, V279, P1737, DOI 10.1126/science.279.5357.1737
   Hosfield DJ, 2004, J BIOL CHEM, V279, P8526, DOI 10.1074/jbc.C300511200
   Hudock MP, 2006, J MED CHEM, V49, P215, DOI 10.1021/jm0582625
   Huey R, 2007, J COMPUT CHEM, V28, P1145, DOI 10.1002/jcc.20634
   Kabelitz D, 2004, J IMMUNOL, V173, P6767, DOI 10.4049/jimmunol.173.11.6767
   Kavanagh KL, 2006, P NATL ACAD SCI USA, V103, P7829, DOI 10.1073/pnas.0601643103
   Kuroda J, 2003, BLOOD, V102, P2229, DOI 10.1182/blood 2003 01 0305
   Linck D, 2005, LEUKEMIA LYMPHOMA, V46, P285, DOI 10.1080/10428190400015535
   Martin MB, 2001, J MED CHEM, V44, P909, DOI 10.1021/jm0002578
   Morita CT, 2007, IMMUNOL REV, V215, P59, DOI 10.1111/j.1600 065X.2006.00479.x
   Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096 987X(19981115)19:14<1639::AID JCC10>3.0.CO;2 B
   Rogers MJ, 1999, BONE, V24, p73S, DOI 10.1016/S8756 3282(99)00070 8
   Rondeau JM, 2006, CHEMMEDCHEM, V1, P267, DOI 10.1002/cmdc.200500059
   Russell RGG, 1999, BONE, V25, P97, DOI 10.1016/S8756 3282(99)00116 7
   Schultze JL, 1999, J MOL MED, V77, P322, DOI 10.1007/s001090050358
   SHEARES BT, 1989, BIOCHEMISTRY US, V28, P8129, DOI 10.1021/bi00446a025
   SINGH UC, 1984, J COMPUT CHEM, V5, P129, DOI 10.1002/jcc.540050204
   Smyth MJ, 2001, NAT IMMUNOL, V2, P293, DOI 10.1038/86297
   SUBHASH G, 2004, J MED CHEM, V47, P175, DOI DOI 10.1021/JM030084X
   Takeuchi M, 1998, CHEM PHARM BULL, V46, P1703
   TARSHIS LC, 1994, BIOCHEMISTRY US, V33, P10871, DOI 10.1021/bi00202a004
   *TRIP INC, SYBYL 7 3 MOL MOD SY
   WEBB JL, 1966, ENZYMES METABOLIC IN, P66
   Widler L, 2002, J MED CHEM, V45, P3721, DOI 10.1021/jm020819i
   Wilhelm M, 2003, BLOOD, V102, P200, DOI 10.1182/blood 2002 12 3665
   Zhang YH, 2007, J MED CHEM, V50, P6067, DOI 10.1021/jm700991k
NR 41
TC 72
Z9 82
U1 0
U2 13
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022 2623
EI 1520 4804
J9 J MED CHEM
JI J. Med. Chem.
PD NOV 13
PY 2008
VL 51
IS 21
BP 6800
EP 6807
DI 10.1021/jm801003y
PG 8
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI EXPANDED); Index Chemicus (IC)
SC Pharmacology & Pharmacy
GA 369YX
UT WOS:000260730900022
PM 18937434
DA 2025 08 17
ER

PT J
AU Cappon, GD
   Fleernan, TL
   Cook, JC
   Hurtt, ME
AF Cappon, GD
   Fleernan, TL
   Cook, JC
   Hurtt, ME
TI Combined treatment potentiates the developmental toxicity of ibuprofen
   and acetazolamide in rats
SO DRUG AND CHEMICAL TOXICOLOGY
LA English
DT Article
DE acetazolamide; ibuprofen teratology; rat
ID CARBONIC ANHYDRASE; MATERNAL TOXICITY; FETAL DEVELOPMENT; WISTAR RATS;
   UTERINE; TERATOGENESIS; INHIBITION; RELAXATION; MECHANISMS; PREGNANCY
AB Aspirin (ASA), an irreversible cyclooxygenase (COX) inhibitor, induces ventricular septal defect (VSD) and diaphragmatic hernia (DH) in rat fetuses when administered on gestation days (GDs) 9 10, a critical period for cardiovascular (CV) and midline development. Evaluation of a spectrum of nonsteroidal antiinflammatory drugs (NSAIDs; reversible COX inhibitors) showed that while some NSAIDs induced VSD in rats, none of the NSAIDs evaluated produced DH. In addition to inhibiting COX, ASA also inhibits carbonic anhydrase. The purpose of this study was to determine whether concurrent inhibition of COX and carbonic anhydrase would produce a teratogenic profile that includes both VSD and DH. To inhibit both COX and carbonic anhydrase, ibuprofen (COX inhibitor) and acetazolamide (carbonic anhydrase inhibitor) were coadministered on GDs 9 10. Groups of 20 female Crl:CD(SD)IGS BR rats were given either 300 mg kg( 1) day( 1) ibuprofen, 1000 mg kg( 1) day( 1) acetazolamide, or both (combination of ibuprofen and acetazolamide). Fetuses were evalaated on GD 21 for external and visceral development. Ibuprofen induced VSD in 3.7% of fetuses per litter; no defects in appendicular skeletal development were noted. Acetazolamide induced VSD in 5.9% of the fetuses per litter and appendicular defects in 41% of the fetuses per litter. Coadministration of ibuprofen and acetazolamide produced VSD in 18.7% of the fetuses per litter and appendicular defects in 77% of the fetuses per litter; however, there were no DH. Therefore, while concurrent inhibition of COX and carbonic anhydrase did not produce DH, potentiation was noted for the induct ion of VSD and appendicular anomalies.
C1 Pfizer Global Res & Dev, Groton, CT 06340 USA.
C3 Pfizer; Pfizer USA
RP Cappon, GD (通讯作者)，Pfizer Global Res & Dev, Bldg 274,Eastern Point Rd,MS 8274 60, Groton, CT 06340 USA.
EM Gregg_D_Cappon@Groton.Pfizer.com
CR ARIYUKI F, 1987, J NUTR, V117, P342, DOI 10.1093/jn/117.2.342
   Bird IM, 2003, AM J PHYSIOL REG I, V284, pR245, DOI 10.1152/ajpregu.00108.2002
   BOURA ALA, 1994, CLIN EXP PHARMACOL P, V21, P737, DOI 10.1111/j.1440 1681.1994.tb02441.x
   Cappon GD, 2003, BIRTH DEFECTS RES B, V68, P47, DOI 10.1002/bdrb.10008
   Chahoud I, 1999, REPROD TOXICOL, V13, P375, DOI 10.1016/S0890 6238(99)00035 0
   Cook JC, 2003, BIRTH DEFECTS RES B, V68, P5, DOI 10.1002/bdrb.10005
   DECARVALHO RR, 1994, BRAZ J MED BIOL RES, V27, P2915
   DeSesso JM., 1997, HDB DEV TOXICOLOGY, P111
   GANT NF, 1987, AM J KIDNEY DIS, V9, P303, DOI 10.1016/S0272 6386(87)80126 9
   Gupta U, 2003, BIRTH DEFECTS RES B, V68, P27, DOI 10.1002/bdrb.10007
   Habermehl DA, 2000, BIOL REPROD, V62, P781, DOI 10.1095/biolreprod62.3.781
   HANNAH RS, 1971, TERATOLOGY, V4, P135, DOI 10.1002/tera.1420040204
   KAVLOCK RJ, 1993, TERATOLOGY, V48, P247, DOI 10.1002/tera.1420480308
   KHERA KS, 1985, TERATOLOGY, V31, P129, DOI 10.1002/tera.1420310115
   KIMMEL CA, 1971, TERATOLOGY, V4, P15, DOI 10.1002/tera.1420040104
   KIMURA T, 1992, AM J OBSTET GYNECOL, V167, P1409, DOI 10.1016/S0002 9378(11)91726 8
   KIVILAAKSO E, 1982, AM J SURG, V144, P554, DOI 10.1016/0002 9610(82)90579 7
   KUHN DC, 1987, AM J OBSTET GYNECOL, V157, P194, DOI 10.1016/S0002 9378(87)80379 4
   MAREN TH, 1993, MOL PHARMACOL, V44, P901
   MAREN TH, 1965, SCIENCE, V150, P79, DOI 10.1126/science.150.3692.79
   MATSUMOTO T, 1992, J REPROD MED, V37, P529
   RITTER EJ, 1982, TERATOLOGY, V25, P95, DOI 10.1002/tera.1420250113
   SCHARDEIN JL, 1987, TERATOGEN CARCIN MUT, V7, P255, DOI 10.1002/tcm.1770070307
   SCOTT WJ, 1970, TERATOLOGY, V3, P261, DOI 10.1002/tera.1420030308
   SCOTT WJ, 1981, TERATOLOGY, V24, P37, DOI 10.1002/tera.1420240105
   Solomon HM, 1997, TERATOLOGY, V55, P185, DOI 10.1002/(SICI)1096 9926(199703)55:3<185::AID TERA3>3.3.CO;2 G
   Streck RD, 2003, BIRTH DEFECTS RES B, V68, P57, DOI 10.1002/bdrb.10006
   STUCKHARDT JL, 1984, TERATOGEN CARCIN MUT, V4, P181, DOI 10.1002/tcm.1770040203
   UGEN KE, 1987, TERATOLOGY, V36, P133, DOI 10.1002/tera.1420360117
   UGEN KE, 1985, TERATOLOGY, V31, P273, DOI 10.1002/tera.1420310213
   UGEN KE, 1986, TERATOLOGY, V34, P195, DOI 10.1002/tera.1420340208
   VANE JR, 1971, NATURE NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0
   Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97
   WILSON JG, 1968, TERATOLOGY, V1, P51, DOI 10.1002/tera.1420010107
   Wise LD, 1997, TERATOLOGY, V55, P249, DOI 10.1002/(SICI)1096 9926(199704)55:4<249::AID TERA5>3.0.CO;2 W
NR 35
TC 13
Z9 13
U1 0
U2 1
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0148 0545
EI 1525 6014
J9 DRUG CHEM TOXICOL
JI Drug Chem. Toxicol.
PY 2005
VL 28
IS 4
BP 409
EP 421
DI 10.1080/01480540500262805
PG 13
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Pharmacology & Pharmacy; Toxicology
GA 982XG
UT WOS:000233194600004
PM 16298872
DA 2025 08 17
ER

PT J
AU Hernigou, P
   Sitbon, J
   Dubory, A
   Auregan, JC
AF Hernigou, Philippe
   Sitbon, Jordan
   Dubory, Arnaud
   Auregan, Jean Charles
TI y Vitamin D history part III: the "modern times"new questions for
   orthopaedic practice: deficiency, cell therapy, osteomalacia, fractures,
   supplementation, infections
SO INTERNATIONAL ORTHOPAEDICS
LA English
DT Article
DE Vitamin D and orthopaedic surgery; Cell therapy and vitamin D; Fracture
   healing and vitamin D; Osteomalacia; Osteoporosis; Arthroplasty
   infection and vitamin D; Supplementation
ID HYPOVITAMINOSIS D; D ASSAYS; ADULTS; HEALTH; SKIN; ASSOCIATION; CALCIUM;
   SMOKING; LENGTH; RISK
AB PurposeThe nutritional basis for rickets was described between 1880 and 1915, at the same period of discovery of other vital substances or vitamins. In contrast, rickets could also be prevented or cured by sunshine. But as the capacity to produce vitamin D depends on exposure to ultraviolet B rays (UVB) from sunlight or artificial sources, vitamin D became one of the most frequently used drugs in the twentieth century to compensate for insufficient exposure to UVB of humans. Furthermore, as the understanding of vitamin D metabolism grew during the twentieth century, other concerns than rickets occurred for the orthopaedic surgeon: In recent history, deficiency is explored as being an associated factor of different bone pathologies as fracture or prosthetic infection. The aim of this review is to analyze these new data on vitamin D.Materials and methodsDuring the twentieth century, there were many concerns for the orthopaedic surgeon: sources and synthesis of vitamin D, regulation of the calcium deposition process for both children and adults, when vitamin D deficiency is observed, and what the best method of vitamin D supplementation is. As target genes regulated by vitamin D are not limited to those involved in mineral homeostasis, orthopedists recently discovered that vitamin D might prevent periprosthetic infection.ResultsThe primary source (80%) of vitamin D is dermal synthesis related to the sun. Dietary sources (20%) of vitamin D are fat fishe, beef, liver, and eggs. Vitamin D is produced industrially to be used in fortified foods and supplements. Maintenance of skeletal calcium balance is mediated through vitamin D receptors. Progenitor cells, chondrocytes, osteoblasts, and osteoclasts contain these receptors which explains the role of vitamin D in cell therapy, in the prevention of rickets and osteomalacia. Despite fortified foods, the prevalence of deficiency remains endemic in north latitudes. However, the definition of vitamin D insufficiency or deficiency remains controversial. Vitamin D has been evaluated in patients undergoing fractures and elective orthopaedic procedures Although supplementation may not be able to prevent or cure all the orthopaedic pathologies, oral supplementation is able to improve the vitamin D levels of deficient patients. These vitamin D level improvements might be associated with better functional and clinical outcomes after some surgical procedures and improvement of immunity to decrease the risk of infection in arthroplasties.ConclusionVitamin D deficiency is frequent and concerns millions of people in the world. It is therefore normal to find hypovitaminosis in various orthopaedic populations including trauma and arthroplasties. However, we do not know exactly if this phenomenon only reflects the general prevalence of vitamin D deficiency or has an influence on the outcome of some pathologies on specific populations at risk. After the success of treatment of rickets, it is disappointing that we are still wondering in the twenty first century whether supplementation of a substance synthetized millions of years ago by plankton and necessary for growth of all the animals may improve (or not) clinical and functional outcomes of a simple fracture in humans.
C1 [Hernigou, Philippe; Sitbon, Jordan; Dubory, Arnaud] Hop Henri Mondor, F 94010 Creteil, France.
   [Auregan, Jean Charles] Hop Antoine Beclere, F 92140 Clamart, France.
C3 Assistance Publique Hopitaux Paris (APHP); Universite
   Paris Est Creteil Val de Marne (UPEC); Hopital Universitaire
   Henri Mondor   APHP; Assistance Publique Hopitaux Paris (APHP); Hopital
   Universitaire Antoine Beclere   APHP
RP Hernigou, P (通讯作者)，Hop Henri Mondor, F 94010 Creteil, France.
EM philippe.hernigou@wanadoo.fr
OI Auregan, Jean Charles/0000 0001 6545 153X
CR Adams JS, 2010, J CLIN ENDOCR METAB, V95, P471, DOI 10.1210/jc.2009 1773
   Anderson PH, 2017, CURR OSTEOPOROS REP, V15, P443, DOI 10.1007/s11914 017 0394 8
   Antonucci R, 2018, J PEDIATR ENDOCR MET, V31, P247, DOI 10.1515/jpem 2017 0391
   BAKER AR, 1988, P NATL ACAD SCI USA, V85, P3294, DOI 10.1073/pnas.85.10.3294
   Bee CR, 2013, J ORTHOP TRAUMA, V27, pE103, DOI 10.1097/BOT.0b013e31825cf8fb
   Bikle D, 2009, J CLIN ENDOCR METAB, V94, P26, DOI 10.1210/jc.2008 1454
   Bischoff Ferrari HA, 2006, AM J CLIN NUTR, V84, P18, DOI 10.1093/ajcn/84.1.18
   Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140 6736(96)07088 2
   Borel P, 2015, CRIT REV FOOD SCI, V55, P1193, DOI 10.1080/10408398.2012.688897
   Bouillon R, 2003, J CELL BIOCHEM, V88, P332, DOI 10.1002/jcb.10360
   Breer S, 2012, INT ORTHOP, V36, P2581, DOI 10.1007/s00264 012 1708 1
   Calvo MS, 2004, AM J CLIN NUTR, V80, p1710S, DOI 10.1093/ajcn/80.6.1710S
   Carter GD, 2009, ANN CLIN BIOCHEM, V46, P79, DOI 10.1258/acb.2008.008135
   Chapuy MC, 1997, OSTEOPOROSIS INT, V7, P439, DOI 10.1007/s001980050030
   Cheng JB, 2004, P NATL ACAD SCI USA, V101, P7711, DOI 10.1073/pnas.0402490101
   Cheng JB, 2003, J BIOL CHEM, V278, P38084, DOI 10.1074/jbc.M307028200
   CLEMENS TL, 1982, LANCET, V1, P74
   DeLuca HF, 2004, AM J CLIN NUTR, V80, p1689S, DOI 10.1093/ajcn/80.6.1689S
   DELUCA HF, 1988, FASEB J, V2, P224, DOI 10.1096/fasebj.2.3.3280376
   Dusso AS, 2005, AM J PHYSIOL RENAL, V289, pF8, DOI 10.1152/ajprenal.00336.2004
   EGUCHI M, 1980, INT ORTHOP, V3, P257
   EGUCHI M, 1987, INT ORTHOP, V11, P77, DOI 10.1007/BF00266062
   Ettehad H, 2014, TRAUMA MON, V19, DOI 10.5812/traumamon.10946
   Farrell CJL, 2012, CLIN CHEM, V58, P531, DOI 10.1373/clinchem.2011.172155
   Fraser WD, 2009, ANN CLIN BIOCHEM, V46, P3, DOI 10.1258/acb.2008.008225
   Hegde V, 2017, J BONE JOINT SURG AM, V99, P1737, DOI 10.2106/JBJS.16.01598
   Heidari B, 2011, INT ORTHOP, V35, P1627, DOI 10.1007/s00264 010 1186 2
   Hernigou P, 2019, INT ORTHOP, V43, P735, DOI 10.1007/s00264 019 04288 z
   Hernigou P, 2018, INT ORTHOP, V42, P2273, DOI 10.1007/s00264 018 3857 3
   Hernigou P, 2018, INT ORTHOP, V42, P1639, DOI 10.1007/s00264 018 3941 8
   Hernigou P, 2018, INT ORTHOP, V42, P2563, DOI 10.1007/s00264 018 3916 9
   HERRERA G, 1949, Int J Lepr, V17, P35
   Hewison M, 2012, RHEUM DIS CLIN N AM, V38, P125, DOI 10.1016/j.rdc.2012.03.012
   Hintzpeter B, 2008, EUR J CLIN NUTR, V62, P1079, DOI 10.1038/sj.ejcn.1602825
   HOLICK MF, 1980, SCIENCE, V210, P203, DOI 10.1126/science.6251551
   HOLICK MF, 1989, LANCET, V2, P1104
   Holick MF, 2007, NEW ENGL J MED, V357, P266, DOI 10.1056/NEJMra070553
   Hyppönen E, 2007, AM J CLIN NUTR, V85, P860, DOI 10.1093/ajcn/85.3.860
   Inkrott BP, 2016, ORTHOPEDICS, V39, pE651, DOI 10.3928/01477447 20160606 04
   Kennedy C, 2003, J INVEST DERMATOL, V120, P548, DOI 10.1046/j.1523 1747.2003.12092.x
   Kim EW, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006608
   Koenig J, 2000, INT J VITAM NUTR RES, V70, P214, DOI 10.1024/0300 9831.70.5.214
   Koh JS, 2002, INT J DERMATOL, V41, P21, DOI 10.1046/j.1365 4362.2002.01352.x
   Lamberg Allardt CJE, 2001, J BONE MINER RES, V16, P2066, DOI 10.1359/jbmr.2001.16.11.2066
   Lips P, 1996, ANN INTERN MED, V124, P400, DOI 10.7326/0003 4819 124 4 199602150 00003
   Liu PT, 2007, J IMMUNOL, V179, P2060, DOI 10.4049/jimmunol.179.4.2060
   Looker AC, 2008, AM J CLIN NUTR, V88, P1519, DOI 10.3945/ajcn.2008.26182
   Maier GS, 2016, J ORTHOP TRAUMATOL, V17, P297, DOI 10.1007/s10195 016 0414 y
   Maier GS, 2014, INT ORTHOP, V38, P1499, DOI 10.1007/s00264 014 2338 6
   Malabanan A, 1998, LANCET, V351, P805, DOI 10.1016/S0140 6736(05)78933 9
   MATSUOKA LY, 1987, J CLIN ENDOCR METAB, V64, P1165, DOI 10.1210/jcem 64 6 1165
   MCKENNA MJ, 1992, AM J MED, V93, P69, DOI 10.1016/0002 9343(92)90682 2
   Meyer HE, 2002, J BONE MINER RES, V17, P709, DOI 10.1359/jbmr.2002.17.4.709
   Michelson JD, 2016, FOOT ANKLE INT, V37, P186, DOI 10.1177/1071100715609054
   Moan J, 2008, P NATL ACAD SCI USA, V105, P668, DOI 10.1073/pnas.0710615105
   Nagpal S, 2005, ENDOCR REV, V26, P662, DOI 10.1210/er.2004 0002
   Olivares Navarrete R, 2012, STEM CELLS DEV, V21, P1726, DOI 10.1089/scd.2011.0411
   Phinney KW, 2012, ANAL CHEM, V84, P956, DOI 10.1021/ac202047n
   Pike JW, 2016, VITAM HORM, V100, P21, DOI 10.1016/bs.vh.2015.10.011
   Rockell JEP, 2006, OSTEOPOROSIS INT, V17, P1382, DOI 10.1007/s00198 006 0118 x
   Ross A.C., 2011, I MED US COMMITTEE R
   Ross AC, 2011, J CLIN ENDOCR METAB, V96, P53, DOI 10.1210/jc.2010 2704
   Rovner AJ, 2008, ARCH PEDIAT ADOL MED, V162, P513, DOI 10.1001/archpedi.162.6.513
   Shin KY, 2017, KNEE SURG SPORT TR A, V25, P3424, DOI 10.1007/s00167 016 4209 8
   Sorbi R, 2012, INT ORTHOP, V36, P1275, DOI 10.1007/s00264 012 1482 0
   Sprague S, 2016, J ORTHOP TRAUMA, V30, pE64, DOI 10.1097/BOT.0000000000000451
   Uday S, 2018, ARCH DIS CHILD, V103, P901, DOI 10.1136/archdischild 2018 314826
   Van de Peppel J, 2013, FRONT PHYSIOL, V5, P137
   WEBB AR, 1988, J CLIN ENDOCR METAB, V67, P373, DOI 10.1210/jcem 67 2 373
   White JH, 2010, J STEROID BIOCHEM, V121, P234, DOI 10.1016/j.jsbmb.2010.03.034
   Woeckel VJ, 2013, GENE, V512, P438, DOI 10.1016/j.gene.2012.07.051
   Zhao JG, 2017, JAMA J AM MED ASSOC, V318, P2466, DOI 10.1001/jama.2017.19344
   Zhou SH, 2012, J BONE MINER RES, V27, P1992, DOI 10.1002/jbmr.1655
NR 73
TC 24
Z9 26
U1 0
U2 9
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0341 2695
EI 1432 5195
J9 INT ORTHOP
JI Int. Orthop.
PD JUL
PY 2019
VL 43
IS 7
BP 1755
EP 1771
DI 10.1007/s00264 019 04334 w
PG 17
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA IC5UO
UT WOS:000471034400026
PM 31037319
DA 2025 08 17
ER

PT J
AU Lu, L
   Liu, Y
   Zhang, X
   Lin, J
AF Lu, Lei
   Liu, Yang
   Zhang, Xu
   Lin, Jiang
TI The therapeutic role of bone marrow stem cell local injection in rat
   experimental periodontitis
SO JOURNAL OF ORAL REHABILITATION
LA English
DT Article
DE bone marrow stem cell; IL 1 beta; periodontitis; regeneration; TNF alpha
ID GINGIVAL CREVICULAR FLUID; MESENCHYMAL STROMAL CELLS; TNF ALPHA;
   RHEUMATOID ARTHRITIS; CONSENSUS REPORT; REGENERATION; DEFECTS; BMSCS;
   IL 1; MODULATION
AB Mesenchymal stem cell therapy brings hope for regenerating damaged periodontal tissues. The present study aimed to investigate the therapeutic role of local bone marrow stem cell (BMSC) injection in ligation induced periodontitis and the underlying mechanisms. Alveolar bone lesion was induced by placing ligatures subgingivally around the bilateral maxillary second molars for 28 days. The alveolar bone lesion was confirmed by micro CT analysis and bone histomorphometry. Allogeneic BMSC transplantation was carried out at 28 day after ligation. The survival state of the transplanted BMSC was observed by bioluminescent imaging. The implantation of the BMSC into the gingival tissues and periodontal ligament was confirmed by green fluorescent protein (GFP) immunohistochemical staining. The expression level of pro inflammatory, tumour necrosis factor alpha (TNF alpha) and interleukin 1 beta (IL 1 beta), and receptor activator of nuclear factor kappa B ligand (RANKL) and osteoprotegerin (OPG) in periodontal tissues were evaluated by immunohistochemical staining and real time PCR. Significant reverse of alveolar bone lesion was observed after BMSC transplantation. The expression of TNF alpha and IL 1 beta was down regulated by BMSC transplantation. The number of tartrate resistant acid phosphatase (TRAP) positive osteoclasts in the periodontal ligament was reduced, and the increased RANKL expression and decreased OPG expression were also reversed after BMSC transplantation. It is concluded that allogeneic BMSC local injection could inhibit the inflammation of the periodontitis tissue and promote periodontal tissue regeneration.
C1 [Lu, Lei; Zhang, Xu] Fourth Mil Med Univ, Dept Oral Anat & Physiol, State Key Lab Mil Stomatol, Xian, Shaanxi, Peoples R China.
   [Lu, Lei; Zhang, Xu] Fourth Mil Med Univ, Natl Clin Res Ctr Oral Dis, Xian, Shaanxi, Peoples R China.
   [Lu, Lei; Zhang, Xu] Fourth Mil Med Univ, Shaanxi Key Lab Stomatol, Sch Stomatol, Xian, Shaanxi, Peoples R China.
   [Liu, Yang; Zhang, Xu] Harbin Med Univ, Hosp 4, Dept Stomatol, Technol Innovat Pk, Harbin, Heilongjiang, Peoples R China.
   [Lin, Jiang] Harbin Med Univ, Dept Periodontol, Hosp 4, Harbin, Heilongjiang, Peoples R China.
   [Lin, Jiang] Capital Med Univ, Beijing Tongren Hosp, Dept Stomatol, Beijing, Peoples R China.
C3 Air Force Medical University; Air Force Medical University; Air Force
   Medical University; Harbin Medical University; Harbin Medical
   University; Capital Medical University
RP Zhang, X (通讯作者)，Harbin Med Univ, Hosp 4, Dept Stomatol, Technol Innovat Pk, Harbin, Heilongjiang, Peoples R China.; Lin, J (通讯作者)，Harbin Med Univ, Dept Periodontol, Hosp 4, Harbin, Heilongjiang, Peoples R China.
EM zhangxu2227@126.com; Kelvinperio@163.com
RI lin, jiang/AAC 4001 2020
FU National Natural Science Foundation of China [81570984, 81500875]; Hei
   Longjiang Natural Science Foundation [QC2016115]
FX The National Natural Science Foundation of China, Grant/Award Number:
   81570984 and 81500875; Hei Longjiang Natural Science Foundation,
   Grant/Award Number: QC2016115
CR Aichelmann Reidy ME, 2008, J PERIODONTOL, V79, P387, DOI [10.1902/jop.2008.060521, 10.1902/jop.2008.060521 ]
   Al Jumah MA, 2012, INT J MOL SCI, V13, P9298, DOI 10.3390/ijms13079298
   Ansboro S, 2017, CURR OPIN RHEUMATOL, V29, P201, DOI 10.1097/BOR.0000000000000370
   Araujo AA, 2013, J CLIN PERIODONTOL, V40, P1104, DOI 10.1111/jcpe.12160
   Basegmez C, 2011, J CLIN PHARMACOL, V51, P915, DOI 10.1177/0091270010373929
   Bassir SH, 2016, J CELL PHYSIOL, V231, P50, DOI 10.1002/jcp.25067
   Beyth S, 2005, BLOOD, V105, P2214, DOI 10.1182/blood 2004 07 2921
   Bosshardt DD, 2009, PERIODONTOL 2000, V51, P208, DOI 10.1111/j.1600 0757.2009.00317.x
   Cao F, 2006, CIRCULATION, V113, P1005, DOI 10.1161/CIRCULATIONAHA.105.588954
   Cetinkaya B, 2013, J PERIODONTOL, V84, P84, DOI 10.1902/jop.2012.110467
   Chen FM, 2010, BIOMATERIALS, V31, P7892, DOI 10.1016/j.biomaterials.2010.07.019
   Chen FH, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2514
   Conklin LS, 2017, CYTOTHERAPY, V19, P655, DOI 10.1016/j.jcyt.2017.03.006
   Cui D, 2017, MOL IMMUNOL, V91, P65, DOI 10.1016/j.molimm.2017.08.012
   Ebelt H, 2007, STEM CELLS, V25, P236, DOI 10.1634/stemcells.2006 0374
   Graves DT, 2011, J DENT RES, V90, P143, DOI 10.1177/0022034510385236
   Guo J, 2007, INFLAMMATION, V30, P97, DOI 10.1007/s10753 007 9025 3
   Horton JA, 2013, STEM CELLS, V31, P2231, DOI 10.1002/stem.1483
   Hughes FJ, 2010, P I MECH ENG H, V224, P1345, DOI 10.1243/09544119JEIM820
   Huo SF, 2017, J EXP NANOSCI, V12, P208, DOI 10.1080/17458080.2017.1301684
   Ivanovski S, 2014, J DENT RES, V93, P1212, DOI 10.1177/0022034514544301
   Jiang ZL, 2013, DIS MARKERS, V34, P295, DOI [10.1155/2013/156798, 10.3233/DMA 130974]
   Kiernan CH, 2016, CYTOTHERAPY, V18, P957, DOI 10.1016/j.jcyt.2016.05.002
   KINANE DF, 1992, ARCH ORAL BIOL, V37, P153, DOI 10.1016/0003 9969(92)90011 V
   Li LL, 2019, J ORAL REHABIL, V46, P756, DOI 10.1111/joor.12800
   Lin NH, 2009, PERIODONTOL 2000, V51, P239, DOI 10.1111/j.1600 0757.2009.00303.x
   Liu TL, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/1416047
   Liu XX, 2014, J MOL HISTOL, V45, P181, DOI 10.1007/s10735 013 9541 4
   Long RM, 2017, INT J ARTIF ORGANS, V40, P169, DOI 10.5301/ijao.5000555
   Ma X, 2015, INT J CLIN EXP MED, V8, P6053
   Mahla RS, 2016, INT J CELL BIOL, V2016
   Mandl S, 2002, J CELL BIOCHEM, P239, DOI 10.1002/jcb.10454
   Nakashima T, 2000, BIOCHEM BIOPH RES CO, V275, P768, DOI 10.1006/bbrc.2000.3379
   Nan Z, 2018, BIOCHEM BIOPH RES CO, V499, P727, DOI 10.1016/j.bbrc.2018.03.043
   Needleman IG, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001724.pub2
   Ni C, 2019, BIOMATERIALS, V206, P115, DOI 10.1016/j.biomaterials.2019.03.039
   Patel SA, 2010, J IMMUNOL, V184, P5885, DOI 10.4049/jimmunol.0903143
   Pihlstrom BL, 2005, LANCET, V366, P1809, DOI 10.1016/S0140 6736(05)67728 8
   Polymeri A, 2016, HORM METAB RES, V48, P700, DOI 10.1055/s 0042 118458
   Reddy MS, 2015, J PERIODONTOL, V86, pS131, DOI 10.1902/jop.2015.140379
   Reynolds MA, 2015, J PERIODONTOL, V86, pS105, DOI 10.1902/jop.2015.140378
   Salvi GE, 1997, J CLIN PERIODONTOL, V24, P8, DOI 10.1111/j.1600 051X.1997.tb01178.x
   Sharma J, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00526
   Shi Y, 2010, CIRCULATION, V121, P2624, DOI 10.1161/CIRCULATIONAHA.109.893248
   Smith PC, 2015, PERIODONTOL 2000, V67, P234, DOI 10.1111/prd.12068
   Tani Ishii N, 1999, J DENT RES, V78, P1617, DOI 10.1177/00220345990780100601
   Teles R, 2010, J PERIODONTOL, V81, P89, DOI 10.1902/jop.2009.090397
   Tuan RS, 2003, ARTHRITIS RES THER, V5, P32, DOI 10.1186/ar614
   Villar Cristina C, 2010, Dent Clin North Am, V54, P73, DOI 10.1016/j.cden.2009.08.011
   Wang BA, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 1060 5
   Wang XL, 2003, BLOOD, V102, P3478, DOI 10.1182/blood 2003 05 1432
   Wei S, 2005, J CLIN INVEST, V115, P282, DOI 10.1172/JCI200523394
   Yin F, 2014, STEM CELLS, V32, P1278, DOI 10.1002/stem.1638
   Zhang YH, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt455
NR 54
TC 22
Z9 23
U1 1
U2 24
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0305 182X
EI 1365 2842
J9 J ORAL REHABIL
JI J. Oral Rehabil.
PD NOV
PY 2020
VL 47
SU 1
SI SI
BP 73
EP 82
DI 10.1111/joor.12843
EA JUL 2019
PG 10
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA OS5DA
UT WOS:000478297200001
PM 31220354
DA 2025 08 17
ER

PT J
AU Chien, CC
   Yen, BL
   Lee, FK
   Lai, TH
   Chen, YC
   Chan, SH
   Huang, HI
AF Chien, Chih Cheng
   Yen, Betty Linju
   Lee, Fa Kung
   Lai, Tsung Hsuan
   Chen, Yao Chang
   Chan, Shu Hui
   Huang, Hsing I
TI In vitro differentiation of human placenta derived multipotent cells
   into hepatocyte like cells
SO STEM CELLS
LA English
DT Article
DE placenta; differentiation; hepatocyte; regenerative medicine
ID MESENCHYMAL STEM CELLS; HUMAN UMBILICAL CORD; LIVER EPITHELIAL CELLS;
   MARROW STROMAL CELLS; HEPATIC OVAL CELLS; BONE MARROW; PROGENITOR CELLS;
   ALPHA FETOPROTEIN; MATURE HEPATOCYTES; GENE EXPRESSION
AB Multipotent cells isolated from human term placenta (placenta derived multipotent cells [PDMCs]) have been known to be able to differentiate into mesodermal lineage cells, including adipocytes and osteoclasts. The low infection rate and young age of placenta compared with other tissue origins of adult stem cells make theses cells attractive target for cell based therapy. However, the differentiation potential of PDMCs toward hepatic cells has not been evaluated yet. In this study, we cultivated PDMCs with hepatic differentiation medium to evaluate the ability of these cells in differentiating toward hepatic cells. After treatment, the morphologies of differentiated PDMCs changed to polygonal epithelial cell like. The differentiated cells not only show the hepatocyte like morphologies but also express hepatocyte specific markers, including albumin and cytokeratin 18. The bioactivity assays revealed that these hepatocyte like cells could uptake lipoprotein and store glycogen. Furthermore, the addition of rifampicin increased the gene expression of CYP3A4, which is similar with the activities of human liver cells. According to our previous results, PDMCs were capable of differentiating into mesodermal and ectodermal lineage cells. Our results indicate that PDMCs can differentiate into three germ layer cells, which is similar to embryonic stem cells. In conclusion, placenta might be an easily accessible source for progenitor cells that are capable of differentiating toward hepatocyte like cells in vitro.
C1 Cathay Gen Hosp, Cathay Med Res Inst, Taipei 22141, Taiwan.
   Cathay Gen Hosp, Dept Obstet & Gynecol, Taipei, Taiwan.
   Fu Jen Catholic Univ, Dept Med, Taipei, Taiwan.
   Natl Hlth Res Inst, Stem Cell Res Ctr, Taipei, Taiwan.
   Natl Taiwan Univ, Dept Forens Med, Taipei 10764, Taiwan.
C3 Cathay General Hospital; Cathay General Hospital; Fu Jen Catholic
   University; National Health Research Institutes   Taiwan; National
   Taiwan University
RP Huang, HI (通讯作者)，Cathay Gen Hosp, Cathay Med Res Inst, 32,Ln 160,Jian Cheng Rd, Taipei 22141, Taiwan.
EM hihuang@cgh.org.tw
RI ; Yen, B./B 1088 2010; Chen, Hsieh Chih/L 6941 2019
OI Yen, B. Linju/0000 0002 6905 3018; Chien,
   Chih Cheng/0000 0002 8368 2005; 
CR Avital L, 2001, BIOCHEM BIOPH RES CO, V288, P156
   Chen HM, 1997, CRIT REV EUKAR GENE, V7, P11, DOI 10.1615/CritRevEukarGeneExpr.v7.i1 2.20
   Cheng MY, 2003, J BIOMAT SCI POLYM E, V14, P1155, DOI 10.1163/156856203769231628
   D'Ippolito G, 1999, J BONE MINER RES, V14, P1115, DOI 10.1359/jbmr.1999.14.7.1115
   Di Campli C, 2004, DIGEST LIVER DIS, V36, P603, DOI 10.1016/j.dld.2004.03.017
   EVARTS RP, 1987, CARCINOGENESIS, V8, P1737, DOI 10.1093/carcin/8.11.1737
   Ferrari G, 1998, SCIENCE, V279, P1528, DOI 10.1126/science.279.5356.1528
   Fischbach GD, 2004, J CLIN INVEST, V114, P1364, DOI 10.1172/JCI200423549
   Gordon GJ, 2000, AM J PATHOL, V156, P607, DOI 10.1016/S0002 9440(10)64765 7
   Hamazaki T, 2001, FEBS LETT, V497, P15, DOI 10.1016/S0014 5793(01)02423 1
   HAMMER RE, 1987, SCIENCE, V235, P53, DOI 10.1126/science.2432657
   Herzog EL, 2003, BLOOD, V102, P3483, DOI 10.1182/blood 2003 05 1664
   Hong SH, 2005, BIOCHEM BIOPH RES CO, V330, P1153, DOI 10.1016/j.bbrc.2005.03.086
   in't Anker PS, 2004, STEM CELLS, V22, P1338, DOI 10.1634/stemcells.2004 0058
   Ishii T, 2005, EXP CELL RES, V309, P68, DOI 10.1016/j.yexcr.2005.05.028
   Iwahori T, 2003, HEPATOLOGY, V37, P665, DOI 10.1053/jhep.2003.50094
   Jain KK, 2005, EXPERT OPIN BIOL TH, V5, P153, DOI 10.1517/14712598.5.2.153
   Kakinuma S, 2003, STEM CELLS, V21, P217, DOI 10.1634/stemcells.21 2 217
   Kamiya A, 2002, HEPATOLOGY, V35, P1351, DOI 10.1053/jhep.2002.33331
   Kang XQ, 2005, WORLD J GASTROENTERO, V11, P3479, DOI 10.3748/wjg.v11.i22.3479
   Kawasaki T, 2005, J GASTROEN HEPATOL, V20, P857, DOI 10.1111/j.1400 1746.2005.03812.x
   Kawashima I, 1996, BLOOD, V87, P4136, DOI 10.1182/blood.V87.10.4136.bloodjournal87104136
   Kim JW, 2004, ANN HEMATOL, V83, P733, DOI 10.1007/s00277 004 0918 z
   Kitten O, 1998, LIVER, V18, P398
   Kubota H, 2002, J BIOL CHEM, V277, P27629, DOI 10.1074/jbc.M202117200
   Lagasse E, 2000, NAT MED, V6, P1229, DOI 10.1038/81326
   Lange C, 2005, TRANSPL P, V37, P276, DOI 10.1016/j.transproceed.2004.11.087
   Lee KD, 2004, HEPATOLOGY, V40, P1275, DOI 10.1002/hep.20469
   Mahley RW, 1999, J LIPID RES, V40, P1
   Malhi H, 2002, J CELL SCI, V115, P2679
   Nosanchuk JD, 1996, BONE MARROW TRANSPL, V18, P355
   Omori M, 1997, HEPATOLOGY, V25, P1115, DOI 10.1002/hep.510250512
   Pederson C, 1999, CANCER NURS, V22, P397, DOI 10.1097/00002820 199912000 00001
   Pereira RF, 1998, P NATL ACAD SCI USA, V95, P1142, DOI 10.1073/pnas.95.3.1142
   PEREIRA RF, 1995, P NATL ACAD SCI USA, V92, P4857, DOI 10.1073/pnas.92.11.4857
   Petersen BE, 1999, SCIENCE, V284, P1168, DOI 10.1126/science.284.5417.1168
   Petersen BE, 1998, HEPATOLOGY, V27, P433, DOI 10.1002/hep.510270218
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Rader DJ, 2000, SEMIN THROMB HEMOST, V26, P521, DOI 10.1055/s 2000 13208
   Rambhatla L, 2003, CELL TRANSPLANT, V12, P1, DOI 10.3727/000000003783985179
   RAWLINGS DJ, 1995, P NATL ACAD SCI USA, V92, P1570, DOI 10.1073/pnas.92.5.1570
   Reyes M, 2001, BLOOD, V98, P2615, DOI 10.1182/blood.V98.9.2615
   Sandhu JS, 1996, BLOOD, V88, P1973, DOI 10.1182/blood.V88.6.1973.bloodjournal8861973
   SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0
   Schwartz RE, 2002, J CLIN INVEST, V109, P1291, DOI 10.1172/JCI200215182
   Seo MJ, 2005, BIOCHEM BIOPH RES CO, V328, P258, DOI 10.1016/j.bbrc.2004.12.158
   Shamsul B S, 2004, Med J Malaysia, V59 Suppl B, P196
   Sharma AD, 2005, AM J PATHOL, V167, P555, DOI 10.1016/S0002 9440(10)62997 5
   Siddiqui MT, 2002, CANCER CYTOPATHOL, V96, P49, DOI 10.1002/cncr.10311
   Sumida A, 2000, BIOCHEM BIOPH RES CO, V267, P756, DOI 10.1006/bbrc.1999.2029
   Suzuki A, 2004, HEPATO GASTROENTEROL, V51, P423
   Tilghman S M, 1985, Oxf Surv Eukaryot Genes, V2, P160
   Wang PP, 2004, BIOCHEM BIOPH RES CO, V320, P712, DOI 10.1016/j.bbrc.2004.05.213
   Wang YF, 2005, LIVER TRANSPLANT, V11, P635, DOI 10.1002/lt.20419
   Wells JM, 2000, DEVELOPMENT, V127, P1563
   Wulf GG, 2004, TISSUE ENG, V10, P1136, DOI 10.1089/1076327041887600
   Yen BL, 2005, STEM CELLS, V23, P3, DOI 10.1634/stemcells.2004 0098
   Zhao DC, 2005, WORLD J GASTROENTERO, V11, P3431, DOI 10.3748/wjg.v11.i22.3431
   Zhao LR, 2002, EXP NEUROL, V174, P11, DOI 10.1006/exnr.2001.7853
   Zhao Y, 2003, P NATL ACAD SCI USA, V100, P2426, DOI 10.1073/pnas.0536882100
   Zuk PA, 2002, MOL BIOL CELL, V13, P4279, DOI 10.1091/mbc.E02 02 0105
   Zvaifler NJ, 2000, ARTHRITIS RES, V2, P477, DOI 10.1186/ar130
NR 62
TC 134
Z9 146
U1 0
U2 17
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1066 5099
EI 1549 4918
J9 STEM CELLS
JI Stem Cells
PD JUL
PY 2006
VL 24
IS 7
BP 1759
EP 1768
DI 10.1634/stemcells.2005 0521
PG 10
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology;
   Oncology; Cell Biology; Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology
GA 085YE
UT WOS:000240639500014
PM 16822884
OA Bronze
DA 2025 08 17
ER

PT J
AU Katayama, N
   Kato, H
   Taguchi, Y
   Tanaka, A
   Umeda, M
AF Katayama, Nobuhito
   Kato, Hirohito
   Taguchi, Yoichiro
   Tanaka, Akio
   Umeda, Makoto
TI The Effects of Synthetic Oligopeptide Derived from Enamel Matrix
   Derivative on Cell Proliferation and Osteoblastic Differentiation of
   Human Mesenchymal Stem Cells
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE human mesenchymal stem cells; oligopeptides; cell differentiation;
   enamel matrix derivative
ID PERIODONTAL LIGAMENT CELLS; FULL LENGTH AMELOGENIN; BONE MARROW CELLS;
   IN VITRO; INSITU HYBRIDIZATION; REGENERATION; PROTEINS; GROWTH; MODEL;
   EMDOGAIN(R)
AB Enamel matrix derivative (EMD) is widely used in periodontal tissue regeneration therapy. However, because the bioactivity of EMD varies from batch to batch, and the use of a synthetic peptide could avoid use from an animal source, a completely synthetic peptide (SP) containing the active component of EMD would be useful. In this study an oligopeptide synthesized derived from EMD was evaluated for whether it contributes to periodontal tissue regeneration. We investigated the effects of the SP on cell proliferation and osteoblast differentiation of human mesenchymal stem cells (MSCs), which are involved in tissue regeneration. MSCs were treated with SP (0 to 1000 ng/mL), to determine the optimal concentration. We examined the effects of SP on cell proliferation and osteoblastic differentiation indicators such as alkaline phosphatase activity, the production of procollagen type 1 C peptide and osteocalcin, and on mineralization. Additionally, we investigated the role of extracellular signal related kinases (ERK) in cell proliferation and osteoblastic differentiation induced by SP. Our results suggest that SP promotes these processes in human MSCs, and that ERK inhibitors suppress these effects. In conclusion, SP promotes cell proliferation and osteoblastic differentiation of human MSCs, probably through the ERK pathway.
C1 [Katayama, Nobuhito; Taguchi, Yoichiro; Umeda, Makoto] Osaka Dent Univ, Dept Periodontol, Osaka 5731121, Japan.
   [Kato, Hirohito; Tanaka, Akio] Osaka Dent Univ, Dept Oral Pathol, Osaka 5731121, Japan.
RP Katayama, N (通讯作者)，Osaka Dent Univ, Dept Periodontol, Osaka 5731121, Japan.
EM katayama@cc.osaka dent.ac.jp; kato h@cc.osaka dent.ac.jp;
   taguchi@cc.osaka dent.ac.jp; tanaka@cc.osaka dent.ac.jp;
   umeda m@cc.osaka dent.ac.jp
FU Japan Society for the Promotion of Science [24593138]; Grants in Aid for
   Scientific Research [24593138] Funding Source: KAKEN
FX This study was supported in part by a Grant in Aid for Scientific
   Research from the Japan Society for the Promotion of Science (C) (No.
   24593138 to A.T.).
CR AUBIN JE, 1995, BONE, V17, pS77, DOI 10.1016/8756 3282(95)00183 E
   Blair HC, 2002, BIOCHEM J, V364, P329, DOI 10.1042/BJ20020165
   Bosshardt DD, 2008, J CLIN PERIODONTOL, V35, P87, DOI 10.1111/j.1600 051X.2008.01264.x
   Cheng L, 2012, CELL PROLIFERAT, V45, P456, DOI 10.1111/j.1365 2184.2012.00834.x
   Dean DD, 2002, CELLS TISSUES ORGANS, V171, P117, DOI 10.1159/000063705
   Gestrelius S, 1997, J CLIN PERIODONTOL, V24, P685, DOI 10.1111/j.1600 051X.1997.tb00250.x
   Grandin HM, 2012, TISSUE ENG PART B RE, V18, P181, DOI [10.1089/ten.TEB.2011.0365, 10.1089/ten.teb.2011.0365]
   Guida L, 2007, J PERIODONTOL, V78, P2190, DOI 10.1902/jop.2007.070185
   Hägewald S, 2004, ORAL SURG ORAL MED O, V98, P243, DOI 10.1016/j.tripleo.2004.02.063
   Hammarstrom L, 1997, J CLIN PERIODONTOL, V24, P669, DOI 10.1111/j.1600 051X.1997.tb00248.x
   Hammarstrom L, 1997, J CLIN PERIODONTOL, V24, P658, DOI 10.1111/j.1600 051X.1997.tb00247.x
   Hasegawa N, 2006, J PERIODONTOL, V77, P1003, DOI 10.1902/jop.2006.050341
   Heijl L, 1997, J CLIN PERIODONTOL, V24, P693, DOI 10.1111/j.1600 051X.1997.tb00251.x
   Hida T, 2010, ORAL SCI INT, V7, P26, DOI 10.1016/S1348 8643(10)80010 2
   Huang YC, 2010, CELL TISSUE RES, V342, P205, DOI 10.1007/s00441 010 1064 7
   IKEDA T, 1992, J HISTOCHEM CYTOCHEM, V40, P1079, DOI 10.1177/40.8.1619274
   Iwata T, 2002, J DENT RES, V81, P387, DOI 10.1177/154405910208100606
   Jue SS, 2010, CLIN ORAL IMPLAN RES, V21, P741, DOI 10.1111/j.1600 0501.2009.01901.x
   Jung RE, 2003, CLIN ORAL IMPLAN RES, V14, P556, DOI 10.1034/j.1600 0501.2003.00921.x
   Junttila MR, 2008, FASEB J, V22, P954, DOI 10.1096/fj.06 7859rev
   Kato H, 2013, J PERIODONTOL, V84, P1476, DOI 10.1902/jop.2012.120469
   Kawanaka A, 2009, J OSAKA DENT U, V43, P111
   Keila S, 2004, J DENT RES, V83, P134, DOI 10.1177/154405910408300210
   Kim NH, 2005, J PERIODONTOL, V76, P1934, DOI 10.1902/jop.2005.76.11.1934
   Lai CF, 2001, J BIOL CHEM, V276, P14443, DOI 10.1074/jbc.M010021200
   LERNER RA, 1982, NATURE, V299, P592, DOI 10.1038/299592a0
   Matsuda N, 2002, EUR J ORAL SCI, V110, P439, DOI 10.1034/j.1600 0722.2002.21340.x
   Maycock J, 2002, CONNECT TISSUE RES, V43, P472, DOI 10.1080/03008200290000880
   Miron RJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071008
   Miron RJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023375
   Nanci A, 2006, PERIODONTOL 2000, V40, P11, DOI 10.1111/j.1600 0757.2005.00141.x
   Nevins M, 2003, J PERIODONTOL, V74, P1282, DOI 10.1902/jop.2003.74.9.1282
   Noguchi M., 2012, ORAL MED PATHOL, V16, P75, DOI DOI 10.3353/omp.16.75
   Nokhbehsaim M, 2011, J PERIODONTOL, V82, P1725, DOI 10.1902/jop.2011.100678
   Ohyama M, 2002, J PERIODONTOL, V73, P543, DOI 10.1902/jop.2002.73.5.543
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   SHINNICK TM, 1983, ANNU REV MICROBIOL, V37, P425, DOI 10.1146/annurev.mi.37.100183.002233
   Taguchi Y, 2012, J HARD TISSUE BIOL, V21, P375, DOI 10.2485/jhtb.21.375
   Tsumanuma Y, 2011, BIOMATERIALS, V32, P5819, DOI 10.1016/j.biomaterials.2011.04.071
   van den Dolder J, 2006, J PERIODONTAL RES, V41, P471, DOI 10.1111/j.1600 0765.2006.00894.x
   WEINREB M, 1990, J BONE MINER RES, V5, P831
   Yang Y, 2010, BIOMATERIALS, V31, P8574, DOI 10.1016/j.biomaterials.2010.06.026
   Yasui N., 2012, J ORAL TISSUE ENG, V9, P126
   Yuan K, 2006, J PERIODONTOL, V77, P1355, DOI 10.1902/jop.2006.050321
   Zeldich E, 2007, J DENT RES, V86, P41, DOI 10.1177/154405910708600106
NR 45
TC 13
Z9 15
U1 0
U2 9
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
SN 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD AUG
PY 2014
VL 15
IS 8
BP 14026
EP 14043
DI 10.3390/ijms150814026
PG 18
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA AO7GD
UT WOS:000341519600054
PM 25123134
OA Green Published, gold, Green Submitted
DA 2025 08 17
ER

PT J
AU Yi, J
   Byun, Y
   Kang, SS
   Shim, KM
   Jang, K
   Lee, JY
AF Yi, Jongdarm
   Byun, Yujin
   Kang, Seong Soo
   Shim, Kyung Mi
   Jang, Kwangsik
   Lee, Jae Young
TI Enhanced Chondrogenic Differentiation of Electrically Primed Human
   Mesenchymal Stem Cells for the Regeneration of Osteochondral Defects
SO BIOMATERIALS RESEARCH
LA English
DT Article
ID EXTRACELLULAR MATRIX; CHONDROCYTES; STIMULATION; PROLIFERATION;
   SPECIFICATION; HYDROGELS; MOBILITY; FIELDS; GROWTH; REPAIR
AB Background: Mesenchymal stem cells (MSCs) offer a promising avenue for cartilage regeneration; however, their therapeutic efficacy requires substantial improvement. Cell priming using electrical stimulation (ES) is a promising approach to augmenting the therapeutic potential of MSCs and has shown potential for various regenerative applications. This study aimed to promote the ES mediated chondrogenic differentiation of human MSCs and facilitate the repair of injured articular cartilage. Methods: MSCs were subjected to ES under various conditions (e.g., voltage, frequency, and number of repetitions) to enhance their capability of chondrogenesis and cartilage regeneration. Chondrogenic differentiation of electrically primed MSCs (epMSCs) was assessed based on gene expression and sulfated glycosaminoglycan production, and epMSCs with hyaluronic acid were transplanted into a rat osteochondral defect model. Transcriptomic analysis was performed to determine changes in gene expression by ES. Results: epMSCs exhibited significantly increased chondrogenic gene expression and sulfated glycosaminoglycan production compared with those in unstimulated controls. Macroscopic and histological results showed that in vivo epMSC transplantation considerably enhanced cartilage regeneration. Furthermore, ES markedly altered the expression of numerous genes of MSCs, including those associated with the extracellular matrix, the Wnt signaling pathway, and cartilage development. Conclusion: ES can effectively prime MSCs to improve articular cartilage repair, offering a promising strategy for enhancing the efficacy of various MSC based therapies.
C1 [Yi, Jongdarm; Lee, Jae Young] Gwangju Inst Sci & Technol, Sch Mat Sci & Engn, Gwangju 61005, South Korea.
   [Byun, Yujin; Kang, Seong Soo; Shim, Kyung Mi; Jang, Kwangsik] Chonnam Natl Univ, Coll Vet Med, Dept Vet Surg, BK21 FOUR Program, Gwangju 61186, South Korea.
   [Byun, Yujin; Kang, Seong Soo; Shim, Kyung Mi; Jang, Kwangsik] Chonnam Natl Univ, FOUR Program BK21, Gwangju, South Korea.
   [Byun, Yujin; Kang, Seong Soo; Shim, Kyung Mi; Jang, Kwangsik] Chonnam Natl Univ, Biomat R&BD Ctr, Gwangju, South Korea.
C3 Gwangju Institute of Science & Technology (GIST); Chonnam National
   University; Chonnam National University; Chonnam National University
RP Lee, JY (通讯作者)，Gwangju Inst Sci & Technol, Sch Mat Sci & Engn, Gwangju 61005, South Korea.; Jang, K (通讯作者)，Chonnam Natl Univ, Coll Vet Med, Dept Vet Surg, BK21 FOUR Program, Gwangju 61186, South Korea.; Jang, K (通讯作者)，Chonnam Natl Univ, FOUR Program BK21, Gwangju, South Korea.; Jang, K (通讯作者)，Chonnam Natl Univ, Biomat R&BD Ctr, Gwangju, South Korea.
EM rhkdtlr0327@nate.com; jaeyounglee@gist.ac.kr
RI ; Lee, Jae Yeong/AEP 9607 2022
OI Lee, Jae Young/0000 0003 4493 2494; 
FU Challengeable Future Defense Technology Research and Development Program
   through the Agency for Defense Development (ADD)   Defense Acquisition
   Program Administration (DAPA) in 2024 [915060201]
FX This research was supported by the Challengeable Future Defense
   Technology Research and Development Program through the Agency for
   Defense Development (ADD) funded by the Defense Acquisition Program
   Administration (DAPA) in 2024 (No. 915060201).
CR Bae Hyun Cheol, 2018, Biomater Res, V22, P28, DOI 10.1186/s40824 018 0134 x
   Balikov DA, 2016, NANOSCALE, V8, P13730, DOI 10.1039/c6nr04400j
   Bobis S, 2006, FOLIA HISTOCHEM CYTO, V44, P215
   Boeuf S, 2010, STEM CELL RES THER, V1, DOI 10.1186/scrt31
   Cooley MA, 2008, DEV BIOL, V319, P336, DOI 10.1016/j.ydbio.2008.04.029
   Denhardt DT, 2001, J CLIN INVEST, V107, P1055, DOI 10.1172/JCI12980
   Eischen Loges M, 2018, PEERJ, V6, DOI 10.7717/peerj.4959
   Fox AJS, 2009, SPORTS HEALTH, V1, P461, DOI 10.1177/1941738109350438
   Fujita H, 2007, EXP CELL RES, V313, P1853, DOI 10.1016/j.yexcr.2007.03.002
   Fukai T, 2011, ANTIOXID REDOX SIGN, V15, P1583, DOI 10.1089/ars.2011.3999
   Gao ZQ, 2023, J ORTHOP SURG RES, V18, DOI 10.1186/s13018 023 03923 1
   Garcia Carvajal Z.Y., 2013, REGENERATIVE MED TIS
   Geng YB, 2020, J CANCER, V11, P6234, DOI 10.7150/jca.46901
   Ghaneialvar H, 2018, INDIAN J CLIN BIOCHE, V33, P46, DOI 10.1007/s12291 017 0641 x
   Ghosh AK, 2012, J CELL PHYSIOL, V227, P493, DOI 10.1002/jcp.22783
   Gille J, 2016, CARTILAGE, V7, P309, DOI 10.1177/1947603516638901
   Goessling W, 2009, CELL, V136, P1136, DOI 10.1016/j.cell.2009.01.015
   Guttmann Raviv N, 2007, J BIOL CHEM, V282, P26294, DOI 10.1074/jbc.M609711200
   Hwang SJ, 2018, J BIOMED MATER RES A, V106, P311, DOI 10.1002/jbm.a.36224
   Vaca González JJ, 2020, BIOELECTROCHEMISTRY, V134, DOI 10.1016/j.bioelechem.2020.107536
   Jia ZF, 2019, MAT SCI ENG C MATER, V99, P541, DOI 10.1016/j.msec.2019.01.115
   Jiang LJ, 2021, FRONT MOL BIOSCI, V8, DOI 10.3389/fmolb.2021.703110
   Jo H, 2017, ACTA BIOMATER, V48, P100, DOI 10.1016/j.actbio.2016.10.035
   Jun JI, 2011, NAT REV DRUG DISCOV, V10, P945, DOI 10.1038/nrd3599
   Kim S, 2018, ACS APPL MATER INTER, V10, P33032, DOI 10.1021/acsami.8b11546
   Lam ATL, 2020, STEM CELL RES, V44, DOI 10.1016/j.scr.2020.101738
   Lee GS, 2019, BIOCHEM BIOPH RES CO, V513, P990, DOI 10.1016/j.bbrc.2019.04.027
   Li XY, 2023, FRONT CELL DEV BIOL, V11, DOI 10.3389/fcell.2023.1181619
   Li YC, 2023, BIOACT MATER, V22, P312, DOI 10.1016/j.bioactmat.2022.10.010
   Lin S, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287 017 0672 5
   Lin ZQ, 2023, MACROMOL RES, V31, P1179, DOI 10.1007/s13233 023 00196 9
   Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126
   Melnik S, 2018, CELL DISCOV, V4, DOI 10.1038/s41421 018 0033 2
   Merregaert J, 2010, J BIOL CHEM, V285, P37823, DOI 10.1074/jbc.M110.136408
   Noronha NCND, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1224 y
   Ning T, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1133 0
   Oh H, 2012, ARTHRITIS RHEUM US, V64, P2568, DOI 10.1002/art.34481
   Park YB, 2015, J ORTHOP RES, V33, P1580, DOI 10.1002/jor.22950
   Richter A, 2011, EUR CELLS MATER, V21, P355, DOI 10.22203/eCM.v021a26
   Roughley Peter J, 2014, J Exp Orthop, V1, P8, DOI 10.1186/s40634 014 0008 7
   Ryu C, 2023, BIOMATER RES, V27, DOI 10.1186/s40824 023 00448 w
   Suthon S, 2021, FRONT CELL DEV BIOL, V09, DOI 10.3389/fcell.2021.667581
   Thrivikraman G, 2018, BIOMATERIALS, V150, P60, DOI 10.1016/j.biomaterials.2017.10.003
   Trougakos IP, 2002, INT J BIOCHEM CELL B, V34, P1430, DOI 10.1016/S1357 2725(02)00041 9
   Tvaroska I, 2024, MOLECULES, V29, DOI 10.3390/molecules29071417
   Usami Y, 2016, LAB INVEST, V96, P186, DOI 10.1038/labinvest.2015.142
   Vaiciuleviciute R, 2023, BIOENGINEERING BASEL, V10, DOI 10.3390/bioengineering10040454
   van der Kraan PM, 2002, OSTEOARTHR CARTILAGE, V10, P631, DOI 10.1053/joca.2002.0806
   Wan XY, 2021, ADV FUNCT MATER, V31, DOI 10.1002/adfm.202010626
   Wang YH, 2021, BIOCHEM BIOPH RES CO, V534, P429, DOI 10.1016/j.bbrc.2020.11.064
   Wu J, 2023, BIOMATER RES, V27, DOI 10.1186/s40824 023 00349 y
   Yoon IS, 2011, J BIOSCI BIOENG, V112, P402, DOI 10.1016/j.jbiosc.2011.06.018
   Zhang K, 2014, SCI REP UK, V4, DOI 10.1038/srep05836
   Zuscik MJ, 2008, J CLIN INVEST, V118, P429, DOI 10.1172/JCI34174
NR 54
TC 2
Z9 2
U1 1
U2 3
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1226 4601
EI 2055 7124
J9 BIOMATER RES
JI Biomater. Res.
PD DEC 18
PY 2024
VL 28
AR 0109
DI 10.34133/bmr.0109
PG 15
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA P7Q3E
UT WOS:001379803000001
PM 39697183
OA gold, Green Accepted
DA 2025 08 17
ER

PT J
AU Franks, LN
   Ford, BM
   Fujiwara, T
   Zhao, HB
   Prather, PL
AF Franks, Lirit N.
   Ford, Benjamin M.
   Fujiwara, Toshifumi
   Zhao, Haibo
   Prather, Paul L.
TI The tamoxifen derivative ridaifen B is a high affinity selective
   CB2 receptor inverse agonist exhibiting anti inflammatory and
   anti osteoclastogenic effects
SO TOXICOLOGY AND APPLIED PHARMACOLOGY
LA English
DT Article
DE Cannabinoid receptors; G protein coupled receptors; Inverse agonist;
   Antagonist; Drug action
ID CANNABINOID RECEPTORS; FUNCTIONAL SELECTIVITY; BONE MASS; IN VITRO;
   APOPTOSIS; CELLS; MODEL; RALOXIFENE; BRAIN; INVOLVEMENT
AB Selective estrogen receptor modulators (SERMs) target estrogen receptors (ERs) to treat breast cancer and osteoporosis. Several SERMs exhibit anti cancer activity not related to ERs. To discover novel anti cancer drugs acting via ER independent mechanisms, derivatives of the SERM tamoxifen, known as the "ridaifen" compounds, have been developed that exhibit reduced or no ER affinity, while maintaining cytotoxicity. Tamoxifen and other SERMs bind to cannabinoid receptors with moderate affinity. Therefore, ER independent effects of SERMs might be mediated via cannabinoid receptors. This study determined whether RID B, a first generation ridaifen compound, exhibits affinity and/or activity at CB1 and/or CB2 cannabinoid receptors. RID B binds with high affinity (K i = 43.7 nM) and 17 fold selectivity to CB2 over CB1 receptors. RID B acts as an inverse agonist at CB2 receptors, modulating G protein and adenylyl cyclase activity with potency values predicted by CB2 affinity. Characteristic of an antagonist, RID B co incubation produces a parallel rightward shift in the concentration effect curve of CB2 agonist WIN 55,212 2 to inhibit adenylyl cyclase activity. CB2 inverse agonists are reported to exhibit anti inflammatory and anti ostoeclastogenic effects. In LPS activated macrophages, RID B exhibits anti inflammatory effects by reducing levels of nitric oxide (NO), IL 6 and IL 1 alpha, but not TNF alpha. Only reduction of NO concentration by RID B is mediated by cannabinoid receptors. RID B also exhibits pronounced anti osteoclastogenic effects, reducing the number of osteoclasts differentiating from primary bone marrow macrophages in a cannabinoid receptor dependent manner. In summary, the tamoxifen derivative RID B, developed with reduced affinity for ERs, is a high affinity selective CB2 inverse agonist with anti inflammatory and anti osteoclastogenic properties.
C1 [Franks, Lirit N.; Ford, Benjamin M.; Prather, Paul L.] Univ Arkansas Med Sci, Coll Med, Dept Pharmacol & Toxicol, Slot 611,4301 West Markham St, Little Rock, AR 72205 USA.
   [Fujiwara, Toshifumi; Zhao, Haibo] Univ Arkansas Med Sci, Coll Med, Endocrinol Div, Dept Internal Med, Little Rock, AR 72205 USA.
C3 University of Arkansas System; University of Arkansas Medical Sciences;
   University of Arkansas System; University of Arkansas Medical Sciences
RP Prather, PL (通讯作者)，Univ Arkansas Med Sci, Coll Med, Dept Pharmacol & Toxicol, Slot 611,4301 West Markham St, Little Rock, AR 72205 USA.
EM hzhao@uams.edu; pratherpaull@uams.edu
RI ; Prather, Paul/KUD 3581 2024; Zhao, Haibo/ABG 9729 2021
OI ZHAO, HAIBO/0000 0003 0836 7555; 
FU UAMS Department of Pharmacology and Toxicology; NIH/NIDA [DA039143];
   NIH/NIAMS [AR062012, AR068509]
FX These studies were supported by bridging funds provided by the UAMS
   Department of Pharmacology and Toxicology and NIH/NIDA award no.
   DA039143 (PLP). The osteoclast studies were made possible by Dr. Haibo
   Zhao's laboratory supported by NIH/NIAMS grants: AR062012 and AR068509.
CR Alexander A, 2009, CANCER LETT, V285, P6, DOI 10.1016/j.canlet.2009.04.005
   Bhutani Garima, 2013, J Midlife Health, V4, P147, DOI 10.4103/0976 7800.118991
   Bosier B, 2010, BIOCHEM PHARMACOL, V80, P1, DOI 10.1016/j.bcp.2010.02.013
   Bouaboula M, 1997, J BIOL CHEM, V272, P22330, DOI 10.1074/jbc.272.35.22330
   Brailoiu GC, 2014, BIOCHEMISTRY US, V53, P4990, DOI 10.1021/bi500632a
   Cabral GA, 2015, J NEUROIMMUNE PHARM, V10, P193, DOI 10.1007/s11481 015 9615 z
   Cabral GA, 2009, EXPERT REV MOL MED, V11, DOI 10.1017/S1462399409000957
   CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099
   Clark A J, 2005, Pain Res Manag, V10 Suppl A, p44A
   Coleman JW, 2001, INT IMMUNOPHARMACOL, V1, P1397, DOI 10.1016/S1567 5769(01)00086 8
   Cosenza M, 2000, SYNAPSE, V38, P477, DOI 10.1002/1098 2396(20001215)38:4<477::AID SYN13>3.0.CO;2 Y
   Dhopeshwarkar A, 2016, J PHARMACOL EXP THER, V358, P342, DOI 10.1124/jpet.116.232561
   Feng RT, 2015, MOL CARCINOGEN, V54, P1796, DOI 10.1002/mc.22251
   Ford BM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167240
   García C, 2011, BRIT J PHARMACOL, V163, P1495, DOI 10.1111/j.1476 5381.2011.01278.x
   Goupil E, 2012, MINI REV MED CHEM, V12, P817, DOI 10.2174/138955712800959143
   Grotenhermen F, 2012, DTSCH ARZTEBL INT, V109, P495, DOI 10.3238/arztebl.2012.0495
   Guo WZ, 2013, BIOCHEM PHARMACOL, V86, P1272, DOI 10.1016/j.bcp.2013.08.020
   Guo WZ, 2013, BIOL PHARM BULL, V36, P1008, DOI 10.1248/bpb.b13 00129
   Hilborn E, 2016, BRIT J CANCER, V114, P248, DOI 10.1038/bjc.2015.464
   Hojnik M, 2015, BIOMED REP, V3, P554, DOI 10.3892/br.2015.469
   Holdsworth SR, 2015, CLIN J AM SOC NEPHRO, V10, P2243, DOI 10.2215/CJN.07590714
   Idris AI, 2005, NAT MED, V11, P774, DOI 10.1038/nm1255
   Idris AI, 2008, ENDOCRINOLOGY, V149, P5619, DOI 10.1210/en.2008 0150
   Kenakin T, 2010, PHARMACOL REV, V62, P265, DOI 10.1124/pr.108.000992
   Kumar P, 2013, BIOCHEM BIOPH RES CO, V435, P76, DOI 10.1016/j.bbrc.2013.04.040
   Lombard C, 2005, LEUKEMIA RES, V29, P915, DOI 10.1016/j.leukres.2005.01.014
   Lunn CA, 2008, BRIT J PHARMACOL, V153, P226, DOI 10.1038/sj.bjp.0707480
   Maekawa T, 2006, EUR J PHARMACOL, V542, P179, DOI 10.1016/j.ejphar.2006.05.040
   Manna Subrata, 2016, Sign Transduct Insights, V5, P1
   Manna S, 2016, CLIN CANCER RES, V22, P1421, DOI 10.1158/1078 0432.CCR 15 0857
   Martinkovich S, 2014, CLIN INTERV AGING, V9, P1437, DOI 10.2147/CIA.S66690
   Maximov PY, 2013, CURR CLIN PHARMACOL, V8, P135, DOI 10.2174/1574884711308020006
   McKallip RJ, 2002, BLOOD, V100, P627, DOI 10.1182/blood 2002 01 0098
   McKallip RJ, 2006, MOL PHARMACOL, V70, P897, DOI 10.1124/mol.106.023937
   Murataeva N, 2012, PHARMACOL RES, V66, P437, DOI 10.1016/j.phrs.2012.08.002
   Nagahara Y, 2008, CANCER SCI, V99, P608, DOI 10.1111/j.1349 7006.2007.00709.x
   Nagahara Y, 2013, BIOCHEM BIOPH RES CO, V435, P657, DOI 10.1016/j.bbrc.2013.05.040
   Ouyang Q, 2013, ACS MED CHEM LETT, V4, P387, DOI 10.1021/ml3004236
   Payandeh Mehrdad, 2015, Asian Pac J Cancer Prev, V16, P4863
   Pertwee RG, 2010, CURR MED CHEM, V17, P1360, DOI 10.2174/092986710790980050
   Pertwee RG, 2006, INT J OBESITY, V30, pS13, DOI 10.1038/sj.ijo.0803272
   Poirier AA, 2016, NEUROBIOL AGING, V48, P61, DOI 10.1016/j.neurobiolaging.2016.08.004
   Prather PL, 2013, BIOCHEM BIOPH RES CO, V441, P339, DOI 10.1016/j.bbrc.2013.10.057
   Presley C, 2015, PHARMACOL RES PERSPE, V3, DOI 10.1002/prp2.159
   Presley CS, 2015, BIOORGAN MED CHEM, V23, P5390, DOI 10.1016/j.bmc.2015.07.057
   Rathinam VAK, 2016, CELL, V165, P792, DOI 10.1016/j.cell.2016.03.046
   Reiner A, 2015, INT J MOL SCI, V16, P758, DOI 10.3390/ijms16010758
   Rhee Man Hee, 2002, J Vet Sci, V3, P179
   Ross RA, 1999, BRIT J PHARMACOL, V126, P665, DOI 10.1038/sj.bjp.0702351
   Schuehly W, 2011, CHEM BIOL, V18, P1053, DOI 10.1016/j.chembiol.2011.05.012
   Shiina I, 2008, BIOCHEM PHARMACOL, V75, P1014, DOI 10.1016/j.bcp.2007.11.005
   Shoemaker JL, 2005, J PHARMACOL EXP THER, V315, P828, DOI 10.1124/jpet.105.089474
   Shoemaker JL, 2005, J PHARMACOL EXP THER, V314, P868, DOI 10.1124/jpet.105.085282
   Teixeira D, 2016, ENVIRON TOXICOL, V31, P1496, DOI 10.1002/tox.22154
   Tsukuda S, 2013, BIOORGAN MED CHEM, V21, P311, DOI 10.1016/j.bmc.2012.10.037
   Turcotte C, 2016, CELL MOL LIFE SCI, V73, P4449, DOI 10.1007/s00018 016 2300 4
   Ueda Y, 2005, EUR J PHARMACOL, V520, P164, DOI 10.1016/j.ejphar.2005.08.013
   Ueda Y, 2007, LIFE SCI, V80, P414, DOI 10.1016/j.lfs.2006.09.026
   Valdeolivas S, 2012, ACS CHEM NEUROSCI, V3, P400, DOI 10.1021/cn200114w
   Vidinsky B, 2012, FOLIA BIOL PRAGUE, V58, P75
   Wasik AM, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.106
   Wilkerson JL, 2012, PAIN, V153, P1091, DOI 10.1016/j.pain.2012.02.015
   Yang P, 2013, J MED CHEM, V56, P2045, DOI 10.1021/jm3017464
   Yao B. B., 2006, BRIT J PHARMACOL, V153, P390
   Yazgan B, 2016, J MOL NEUROSCI, V60, P214, DOI 10.1007/s12031 016 0785 9
   Zhou J, 2015, CALCIFIED TISSUE INT, V96, P465, DOI 10.1007/s00223 015 9967 7
NR 67
TC 10
Z9 11
U1 0
U2 9
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0041 008X
EI 1096 0333
J9 TOXICOL APPL PHARM
JI Toxicol. Appl. Pharmacol.
PD AUG 15
PY 2018
VL 353
BP 31
EP 42
DI 10.1016/j.taap.2018.06.009
PG 12
WC Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy; Toxicology
GA GO6DX
UT WOS:000440125400004
PM 29906493
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Douglas, JT
   Rivera, AA
   Lyons, GR
   Lott, PF
   Wang, DZ
   Zayzafoon, M
   Siegal, GP
   Cao, X
   Theiss, SM
AF Douglas, Joanne T.
   Rivera, Angel A.
   Lyons, Gray R.
   Lott, Patricia F.
   Wang, Dezhi
   Zayzafoon, Majd
   Siegal, Gene P.
   Cao, Xu
   Theiss, Steven M.
TI Ex Vivo Transfer of the Hoxc 8 interacting Domain of Smad1 by a
   Tropism modified Adenoviral Vector Results in Efficient Bone Formation
   in a Rabbit Model of Spinal Fusion
SO JOURNAL OF SPINAL DISORDERS & TECHNIQUES
LA English
DT Article
DE adenoviral vector; bone marrow stromal cell; gene transfer; rabbit;
   spinal fusion
ID MESENCHYMAL STEM CELLS; GENE THERAPY; OSTEOBLAST DIFFERENTIATION;
   MORPHOGENETIC PROTEIN 7; MODIFIED FIBERS; BMP2 GENE; RECEPTOR;
   SPONDYLOLISTHESIS; OSTEOINDUCTION; EXPRESSION
AB Study Design: Ex vivo gene transfer for spinal fusion.
   Objective: This study aimed to evaluate ex vivo transfer of the nuclear localized Hoxc 8 interacting domain of Smad1 (termed Smad1C) to rabbit bone marrow stromal cells (BMSCs) by a tropism modified human adenovirus serotype 5 (Ad5) vector as a novel therapeutic approach for spinal fusion.
   Summary of Background Data: Novel approaches are needed to improve the success of bone union after spinal fusion. One such approach is the ex vivo transfer of a gene encoding an osteoinductive factor to BMSCs which are subsequently reimplanted into the host. We have previously shown that heterologous expression of the Hoxc 8 interacting domain of Smad1 in the nuclei of osteoblast precursor cells is able to stimulate the expression of genes related to osteoblast differentiation and induce osteogenesis in vivo. Gene delivery vehicles based on human Ad5 are well suited for gene transfer for spinal fusion because they can mediate high level, short term gene expression. However, Ad5 based vectors with native tropism poorly transduce BMSCs, necessitating the use of vectors with modified tropism to achieve efficient gene transfer.
   Methods: The gene encoding Smad1C was transferred to rabbit BMSCs by an Ad5 vector with native tropism or a vector retargeted to alpha(v) integrins, which are abundantly expressed on rabbit BMSCs. Transduced BMSCs were maintained in osteoblastic differentiation medium for 30 days. Alkaline phosphatase activity was determined and cells stained for calcium deposition. As positive controls for osteogenesis, we used Ad5 vectors expressing bone morphogenetic protein 2. As negative controls, BMSCs were mock transduced or transduced with an Ad5 vector expressing beta galactosidase. In an immunocompetent rabbit model of spinal fusion, transduced BMSCs were coated onto absorbable gelatin sponge and implanted between decorticated transverse processes L6 and L7 of 8 week old female New Zealand white rabbits. Animals were killed 4 weeks after implantation of the sponges, the fusion masses harvested and the area of new bone quantified using image analysis software.
   Results: The Smad1C expressing tropism modified Ad5 vector mediated a significantly higher level of alkaline phosphatase activity and calcium deposition in transduced rabbit BMSCs than all other vectors. The rabbit BMSCs transduced ex vivo with the Smad1C expressing tropism modified Ad5 vector mediated a greater amount of new bone formation than BMSCs transduced with any other vector.
   Conclusions: Delivery of the Smad1C gene construct to BMSCs by an alpha(v) integrin targeted Ad5 vector shows promise for spinal fusion and other applications requiring the formation of new bone in vivo.
C1 [Lott, Patricia F.; Wang, Dezhi; Theiss, Steven M.] Univ Alabama, Div Orthoped Surg, Dept Surg, Birmingham, AL 35294 USA.
   [Douglas, Joanne T.; Rivera, Angel A.] Univ Alabama, Dept Med, Div Human Gene Therapy, Birmingham, AL 35294 USA.
   [Douglas, Joanne T.; Rivera, Angel A.] Univ Alabama, Dept Obstet & Gynecol, Birmingham, AL 35294 USA.
   [Douglas, Joanne T.; Rivera, Angel A.; Lyons, Gray R.; Zayzafoon, Majd; Siegal, Gene P.; Cao, Xu] Univ Alabama, Dept Pathol, Birmingham, AL 35294 USA.
   [Douglas, Joanne T.; Siegal, Gene P.] Univ Alabama, Gene Therapy Ctr, Birmingham, AL 35294 USA.
   [Douglas, Joanne T.; Zayzafoon, Majd; Siegal, Gene P.; Cao, Xu; Theiss, Steven M.] Univ Alabama, Ctr Metab Bone Dis, Birmingham, AL 35294 USA.
C3 University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham
RP Theiss, SM (通讯作者)，Univ Alabama, Div Orthoped Surg, Dept Surg, 510 20th St S,FOT 940, Birmingham, AL 35294 USA.
EM smtheiss@uab.edu
RI Rivera, Ángel/GRJ 2093 2022; Siegal, Gene/A 8653 2009
FU NIH [P30AR046031, P30AR48311, R01CA108585, R01CA093796, CA098543];
   Haley's Hope Memorial Support Fund for Osteosarcoma Research at the
   University of Alabama at Birmingham
FX Supported by NIH grants P30AR046031, P30AR48311, R01CA108585,
   R01CA093796, and CA098543 and Haley's Hope Memorial Support Fund for
   Osteosarcoma Research at the University of Alabama at Birmingham.
CR Alden TD, 1999, J NEUROSURG, V90, P109, DOI 10.3171/spi.1999.90.1.0109
   Barnett BG, 2002, BBA GENE STRUCT EXPR, V1575, P1, DOI 10.1016/S0167 4781(02)00249 X
   Bergelson JM, 1997, SCIENCE, V275, P1320, DOI 10.1126/science.275.5304.1320
   Boden SD, 2000, SPINE, V25, P376, DOI 10.1097/00007632 200002010 00020
   BRIDWELL KH, 1993, J SPINAL DISORD, V6, P461, DOI 10.1097/00002517 199306060 00001
   Clark G., 1981, Staining Procedures, P187
   Conget PA, 1999, J CELL PHYSIOL, V181, P67, DOI 10.1002/(SICI)1097 4652(199910)181:1<67::AID JCP7>3.0.CO;2 C
   Dmitriev I, 1998, J VIROL, V72, P9706, DOI 10.1128/JVI.72.12.9706 9713.1998
   Douglas JT, 2007, MOL BIOTECHNOL, V36, P71, DOI 10.1007/s12033 007 0021 5
   Friedlaender GE, 2001, J BONE JOINT SURG AM, V83A, pS151
   GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022 1317 36 1 59
   HAVRILESKY LJ, 1995, CANCER RES, V55, P944
   He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509
   HENRY LJ, 1994, J VIROL, V68, P5239, DOI 10.1128/JVI.68.8.5239 5246.1994
   Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092 8674(00)81250 7
   Kim M, 2002, EUR J CANCER, V38, P1917, DOI 10.1016/S0959 8049(02)00131 4
   Krasnykh VN, 1996, J VIROL, V70, P6839, DOI 10.1128/JVI.70.10.6839 6846.1996
   Kretzschmar M, 1997, GENE DEV, V11, P984, DOI 10.1101/gad.11.8.984
   Li RH, 2001, TRENDS BIOTECHNOL, V19, P255, DOI 10.1016/S0167 7799(01)01665 1
   Lieberman JR, 2002, MOL THER, V6, P141, DOI 10.1006/mthe.2000.0663
   Liu ZY, 2004, J BIOL CHEM, V279, P11313, DOI 10.1074/jbc.M312731200
   Ludwig SC, 2000, EUR SPINE J, V9, pS119, DOI 10.1007/PL00008317
   MCGUIRE RA, 1993, SPINE, V18, P1662, DOI 10.1097/00007632 199309000 00015
   McKay B, 2002, SPINE, V27, pS66, DOI 10.1097/00007632 200208151 00014
   Mittereder N, 1996, J VIROL, V70, P7498, DOI 10.1128/JVI.70.11.7498 7509.1996
   Olmsted Davis EA, 2002, HUM GENE THER, V13, P1337, DOI 10.1089/104303402760128568
   Riew KD, 1998, CALCIFIED TISSUE INT, V63, P357, DOI 10.1007/s002239900540
   Riew KD, 2003, J BONE JOINT SURG AM, V85A, P866, DOI 10.2106/00004623 200305000 00014
   Sandhu HS, 2003, SPINE, V28, pS85, DOI 10.1097/00007632 200308011 00014
   Shi XM, 1999, J BIOL CHEM, V274, P13711, DOI 10.1074/jbc.274.19.13711
   STEIDEL CC, 1992, APJS, V80, P90
   Theiss SM, 2000, SPINE, V25, P2588, DOI 10.1097/00007632 200010150 00008
   Tomko RP, 1997, P NATL ACAD SCI USA, V94, P3352, DOI 10.1073/pnas.94.7.3352
   Tsuda H, 2005, J GENE MED, V7, P1322, DOI 10.1002/jgm.777
   Tsuda H, 2003, MOL THER, V7, P354, DOI 10.1016/S1525 0016(02)00062 X
   URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893
   Vaccaro AR, 2002, SPINE, V27, pS59, DOI 10.1097/00007632 200208151 00013
   WEST JL, 1991, J BONE JOINT SURG AM, V73A, P1179, DOI 10.2106/00004623 199173080 00006
   WICKHAM TJ, 1993, CELL, V73, P309, DOI 10.1016/0092 8674(93)90231 E
   Wong NC, 1998, CLIN EXP METASTAS, V16, P50
   Yang XL, 2000, J BIOL CHEM, V275, P1065, DOI 10.1074/jbc.275.2.1065
   Yoon ST, 2004, GENE THER, V11, P360, DOI 10.1038/sj.gt.3302203
   Zayzafoon M, 2005, J BIOL CHEM, V280, P7049, DOI 10.1074/jbc.M412680200
   ZDEBLICK TA, 1993, SPINE, V18, P983, DOI 10.1097/00007632 199306150 00006
NR 44
TC 7
Z9 7
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1536 0652
EI 1539 2465
J9 J SPINAL DISORD TECH
JI J. Spinal Disord. Tech.
PD FEB
PY 2010
VL 23
IS 1
BP 63
EP 73
DI 10.1097/BSD.0b013e318193b693
PG 11
WC Clinical Neurology; Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Neurosciences & Neurology; Orthopedics
GA 622LP
UT WOS:000279665600013
PM 20084034
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Su, JS
   Gu, JM
   Dong, Z
   Mei, B
AF Su, Jiansheng
   Gu, Jiamei
   Dong, Zhuo
   Mei, Bing
TI Ibuprofen Rescues Abnormalities in Periodontal Tissues in Conditional
   Presenilin 1 and Presenilin 2 Double Knockout Mice
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE ibuprofen; presenilins; inflammatory response; periodontal tissues
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; ALZHEIMERS DISEASE; COGNITIVE
   FUNCTION; NEURODEGENERATIVE PHENOTYPES; TRANSGENIC MICE; TOOTH LOSS; OUT
   MICE; INFLAMMATION; CYCLOOXYGENASE; INHIBITORS
AB We used forebrain specific conditional presenilin 1 (PS1) and presenilin 2 (PS2) double knockout mice (dKO mice) that exhibit symptoms of neurodegenerative diseases, especially Alzheimer's disease, to investigate whether ibuprofen can rescue brain and periodontal tissue abnormalities by attenuating the inflammatory response. Mandibles were dissected for alveolar bone height analysis. Maxillae were fixed and decalcified for histological observation and osteoclast detection. ELISA measurements from the hippocampus, cortex, and gingiva of the mandibular incisor teeth were used to assay inflammatory mediators. We confirmed periodontal tissue abnormalities and inflammatory responses in brain and periodontal tissues in naive nine  and 12 month old dKO mice. The other two groups of age matched dKO mice that received 375 ppm ibuprofen treatment for six consecutive months exhibited significantly attenuated damage in periodontal tissues and reduction in several inflammation related factors in brain and periodontal tissues. Our findings showed that the anti inflammatory drug ibuprofen significantly decreased inflammation through the cyclooxygenase (COX) pathway in brain and periodontal tissues in dKO mice, and then attenuated abnormalities in periodontal tissues. This suggests that ibuprofen could be an ideal drug for preventing both nervous system and periodontal tissue damage caused by inflammatory responses.
C1 [Su, Jiansheng; Gu, Jiamei] Tongji Univ, Lab Oral Biomed Sci & Translat Med, Sch Stomatol, Shanghai 200072, Peoples R China.
   [Dong, Zhuo; Mei, Bing] E China Normal Univ, Shanghai Key Lab Brain Funct Genom, Key Lab Brain Funct Genom, Minist Educ, Shanghai 200062, Peoples R China.
C3 Tongji University; East China Normal University
RP Su, JS (通讯作者)，Tongji Univ, Lab Oral Biomed Sci & Translat Med, Sch Stomatol, Middle Yanchang Rd 399, Shanghai 200072, Peoples R China.
EM sjs@tongji.edu.cn; jiamei.gu@live.cn; dz820612@163.com;
   bmei@brain.ecnu.edu.cn
FU National Natural Science Foundation of China [30840031, 30970726,
   81070876]; Nanometre Science and Technology Project of Shanghai
   [11nm0504300]; Shanghai Municipal Education Commission [11ZZ38];
   Specialized Research Fund for the Doctoral Program of Higher Education
   [20110072110041]; 973 Project [2009CB918402]
FX We deeply appreciate the generosity of Joe Tsien (Medical College of
   Georgia, USA) for providing PS1/PS2 double knockout mice. This work was
   supported by grants from the National Natural Science Foundation of
   China (30840031, 30970726 and 81070876), the Nanometre Science and
   Technology Project of Shanghai (11nm0504300) and the Shanghai Municipal
   Education Commission (11ZZ38), and Specialized Research Fund for the
   Doctoral Program of Higher Education (20110072110041) and was supported,
   in part, by the 973 Project (2009CB918402).
CR Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197 4580(00)00124 X
   Armitage GC, 2004, PERIODONTOL 2000, V34, P9, DOI 10.1046/j.0906 6713.2002.003421.x
   Avlund Kirsten, 2004, Gerodontology, V21, P17, DOI 10.1046/j.1741 2358.2003.00003.x
   Beglopoulos V, 2004, J BIOL CHEM, V279, P46907, DOI 10.1074/jbc.M409544200
   Cochran DL, 2008, J PERIODONTOL, V79, P1569, DOI 10.1902/jop.2008.080233
   Dong SZ, 2007, EUR J NEUROSCI, V26, P101, DOI 10.1111/j.1460 9568.2007.05641.x
   Donoviel DB, 1999, GENE DEV, V13, P2801, DOI 10.1101/gad.13.21.2801
   Ebersole Jeffrey L, 2002, Ann Periodontol, V7, P102, DOI 10.1902/annals.2002.7.1.102
   Ellefsen B, 2008, J AM GERIATR SOC, V56, P59, DOI 10.1111/j.1532 5415.2007.01495.x
   Ellefsen B, 2009, J AM DENT ASSOC, V140, P1392, DOI 10.14219/jada.archive.2009.0076
   Feng RB, 2004, P NATL ACAD SCI USA, V101, P8162, DOI 10.1073/pnas.0402733101
   Feng RB, 2001, NEURON, V32, P911, DOI 10.1016/S0896 6273(01)00523 2
   Grabe HJ, 2009, J CLIN PERIODONTOL, V36, P550, DOI 10.1111/j.1600 051X.2009.01426.x
   Han WF, 2011, MOL CELL BIOCHEM, V347, P13, DOI 10.1007/s11010 010 0607 2
   Heneka MT, 2005, BRAIN, V128, P1442, DOI 10.1093/brain/awh452
   Hoozemans JJM, 2003, CURR DRUG TARGETS, V4, P461, DOI 10.2174/1389450033490902
   HOWELL TH, 1993, CRIT REV ORAL BIOL M, V4, P177, DOI 10.1177/10454411930040020301
   Hutton M, 1997, HUM MOL GENET, V6, P1639, DOI 10.1093/hmg/6.10.1639
   in 't Veld BA, 2001, NEW ENGL J MED, V345, P1515, DOI 10.1056/NEJMoa010178
   Jiang X, 2009, J ALZHEIMERS DIS, V18, P515, DOI 10.3233/JAD 2009 1164
   Kamer AR, 2012, J ALZHEIMERS DIS, V28, P613, DOI 10.3233/JAD 2011 102004
   Kaye EK, 2010, J AM GERIATR SOC, V58, P713, DOI 10.1111/j.1532 5415.2010.02788.x
   Li YK, 2003, J NEUROSCI, V23, P1605
   Lim GP, 2001, NEUROBIOL AGING, V22, P983, DOI 10.1016/S0197 4580(01)00299 8
   Lim GP, 2000, J NEUROSCI, V20, P5709, DOI 10.1523/JNEUROSCI.20 15 05709.2000
   McGeer PL, 2000, DRUG AGING, V17, P1, DOI 10.2165/00002512 200017010 00001
   McGeer PL, 1996, NEUROLOGY, V47, P425, DOI 10.1212/WNL.47.2.425
   Saura CA, 2004, NEURON, V42, P23, DOI 10.1016/S0896 6273(04)00182 5
   Shen J, 2007, P NATL ACAD SCI USA, V104, P403, DOI 10.1073/pnas.0608332104
   Simmons DL, 2004, PHARMACOL REV, V56, P387, DOI 10.1124/pr.56.3.3
   Stalder AK, 1998, AM J PATHOL, V153, P767, DOI 10.1016/S0002 9440(10)65620 9
   Stewart R, 2008, PSYCHOSOM MED, V70, P936, DOI 10.1097/PSY.0b013e3181870aec
   Stewart WF, 1997, NEUROLOGY, V48, P626, DOI 10.1212/WNL.48.3.626
   Vlad SC, 2008, NEUROLOGY, V70, P1672, DOI 10.1212/01.wnl.0000311269.57716.63
   Wang D, 2011, BIOCHEM BIOPH RES CO, V410, P229, DOI 10.1016/j.bbrc.2011.05.120
   Yamamoto T, 1998, ANN ANAT, V180, P519, DOI 10.1016/S0940 9602(98)80058 7
   Yang YX, 1998, MOL BRAIN RES, V60, P40, DOI 10.1016/S0169 328X(98)00164 8
NR 38
TC 9
Z9 10
U1 1
U2 24
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD SEP
PY 2013
VL 14
IS 9
BP 18457
EP 18469
DI 10.3390/ijms140918457
PG 13
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA 274RN
UT WOS:000328623900064
PM 24018889
OA Green Published, gold, Green Submitted
DA 2025 08 17
ER

PT J
AU Demirci, G
   Guven, MN
   Altuncu, S
   Konca, YU
   Avci, D
   Acar, HY
AF Demirci, Gozde
   Guven, Melek Naz
   Altuncu, Seckin
   Konca, Yeliz Utku
   Avci, Duygu
   Acar, Havva Yagci
TI (Bis)phosphonic Acid Functionalized Poly(ethyleneimine)  Poly(amido
   amine)s for Selective In Vitro Transfection of Osteosarcoma Cells
SO ACS APPLIED POLYMER MATERIALS
LA English
DT Article
DE poly(amido amine)s; poly(ethyleneimine)s; alendronate; (bis)phosphonic
   acid; cytotoxicity; transfection; gene delivery; osteosarcoma
ID LOW MOLECULAR WEIGHT; BRANCHED POLYETHYLENIMINE; PAMAM DENDRIMERS;
   NONVIRAL VECTOR; GENE; DELIVERY; CYTOTOXICITY; DNA; POLYAMIDOAMINE;
   BISPHOSPHONATES
AB Osteosarcoma is aggressive bone cancer, whose treatment has not changed significantly for the past few decades. Although gene therapy methods have emerged as potential treatment routes, the need for efficient and nontoxic gene delivery systems targeting osteosarcoma cells remains a challenge. High molecular weight poly(ethyleneimine)s (PEIs) are used as universal transfection agents; however, they cause significant cytotoxicity. On the other hand, poly(amido amine)s (PAAs) are biocompatible, biodegradable polymers with promising transfection efficiency, which should be improved further. In this paper, we combined low molecular weight branched PEI (1800 Da) and PAA macromers functionalized with various amounts of (bis)phosphonic acid groups and pentanol (via 5 amino 1 pentanol (AP)). The (bis)phosphonic acid groups on these polymers (PAEIs) are intended to facilitate bone targeting. The molecular weights of the PAEI polymers were between 2600 and 8600 g/mol. Their cytotoxicities and green fluorescence protein (GFP) transfection efficiencies were tested on an osteosarcoma cell line (U 2 OS cells), which is challenging to transfect, and healthy muscle cells (C2C12). Both the cytotoxicity and transfection efficiency of PAEIs were affected by the phosphonic acid (via APA, 2 aminoethyl phosphonic acid) or bisphosphonic acid (via ALE, sodium alendronate) content of the polymers. PAEIs are more cytocompatible than both linear and branched 25 kDa PEI. ALE containing PAEIs provided better transfection than APA containing ones. The most efficient PAEI polymer, containing a 0.7:0.3 AP/ALE ratio, displayed a transfection efficiency that was five times higher than that of 25 kDa PEI with dramatically better cytocompatibility. This is comparable to FuGENE, but PAEI is more advantageous in selective transfection of the U 2 OS. This set of polymers may be promising candidates for targeted gene therapy of osteosarcoma.
C1 [Demirci, Gozde; Acar, Havva Yagci] Koc Univ, Grad Sch Mat Sci & Engn, TR 34450 Istanbul, Turkey.
   [Guven, Melek Naz; Altuncu, Seckin; Konca, Yeliz Utku; Avci, Duygu] Bogazici Univ, Dept Chem, TR 34342 Istanbul, Turkey.
C3 Koc University; Bogazici University
RP Acar, HY (通讯作者)，Koc Univ, Grad Sch Mat Sci & Engn, TR 34450 Istanbul, Turkey.; Konca, YU; Avci, D (通讯作者)，Bogazici Univ, Dept Chem, TR 34342 Istanbul, Turkey.; Acar, HY (通讯作者)，Koc Univ, Dept Chem, TR 34450 Istanbul, Turkey.
EM ykonca@ku.edu.tr; avcid@boun.edu.tr; fyagci@ku.edu.tr
RI Konca, Yeliz/Y 9571 2018; guven, melek naz/JRX 2180 2023; Avci,
   Duygu/AAN 3288 2020
OI Avci, Duygu/0000 0002 9927 0291; Yagci Acar, Havva/0000 0001 5601 8814;
   Demirci, Gozde/0000 0003 4952 7981; 
FU Scientific and Technological Research Council of Turkey (TUBITAK)
   [117Z330]
FX This work was financed by the Scientific and Technological Research
   Council of Turkey (TUBITAK, grant number 117Z330).
CR Abedi Gaballu F, 2018, APPL MATER TODAY, V12, P177, DOI 10.1016/j.apmt.2018.05.002
   Almulathanon AAY, 2018, PHARM RES DORDR, V35, DOI 10.1007/s11095 017 2328 7
   Altuncu S, 2020, J BIOMED MATER RES A, V108, P2100, DOI 10.1002/jbm.a.36969
   Ben Hamouda S, 2010, CR CHIM, V13, P372, DOI 10.1016/j.crci.2009.10.009
   Bingol HB, 2018, EUR POLYM J, V108, P57, DOI 10.1016/j.eurpolymj.2018.08.029
   Cavuslar O, 2018, NEW J CHEM, V42, P10078, DOI 10.1039/c8nj00628h
   Choi YJ, 2010, DRUG CHEM TOXICOL, V33, P357, DOI 10.3109/01480540903493507
   Christensen LV, 2006, BIOCONJUGATE CHEM, V17, P1233, DOI 10.1021/bc0602026
   Coué G, 2013, J BIOMAT SCI POLYM E, V24, P957, DOI 10.1080/09205063.2012.727378
   Deng JZ, 2011, ACTA BIOMATER, V7, P2200, DOI 10.1016/j.actbio.2011.02.003
   Digiacomo L, 2018, BIOCHEM BIOPH RES CO, V503, P508, DOI 10.1016/j.bbrc.2018.05.016
   Emilitri E, 2007, MACROMOLECULES, V40, P4785, DOI 10.1021/ma062115e
   Feng LD, 2015, AUST J CHEM, V68, P806, DOI 10.1071/CH14350
   Ferruti P, 2002, MACROMOL RAPID COMM, V23, P332, DOI 10.1002/1521 3927(20020401)23:5/6<332::AID MARC332>3.0.CO;2 I
   Ferruti P, 2007, BIOMACROMOLECULES, V8, P1498, DOI 10.1021/bm061126c
   Fischer D, 1999, PHARMACEUT RES, V16, P1273, DOI 10.1023/A:1014861900478
   Forrest ML, 2004, PHARM RES DORDR, V21, P365, DOI 10.1023/B:PHAM.0000016251.42392.1e
   Gibney KA, 2012, MACROMOL BIOSCI, V12, P1279, DOI 10.1002/mabi.201200052
   Godbey WT, 1999, P NATL ACAD SCI USA, V96, P5177, DOI 10.1073/pnas.96.9.5177
   Green JJ, 2007, ADV MATER, V19, P2836, DOI 10.1002/adma.200700371
   Gu WY, 2013, INT J NANOMED, V8, DOI 10.2147/IJN.S44393
   Guven MN, 2020, POLYMER, V190, DOI 10.1016/j.polymer.2020.122248
   Huang JY, 2015, CHEM COMMUN, V51, P8473, DOI 10.1039/c5cc02193f
   Huang RQ, 2008, BIOMATERIALS, V29, P238, DOI 10.1016/j.biomaterials.2007.09.024
   Jiang Y, 2012, PHYS CHEM CHEM PHYS, V14, P914, DOI 10.1039/c1cp21862j
   Jones NA, 2000, BBA GENE STRUCT EXPR, V1517, P1, DOI 10.1016/S0167 4781(00)00220 7
   Kalyanaraman B, 2017, REDOX BIOL, V12, P833, DOI 10.1016/j.redox.2017.04.018
   Kean T, 2005, J CONTROL RELEASE, V103, P643, DOI 10.1016/j.jconrel.2005.01.001
   Kennel KA, 2009, MAYO CLIN PROC, V84, P632, DOI 10.1016/S0025 6196(11)60752 0
   Kim T, 2004, BIOMACROMOLECULES, V5, P2487, DOI 10.1021/bm049563j
   Kumar A, 2010, INT J PHARMACEUT, V392, P294, DOI 10.1016/j.ijpharm.2010.03.054
   La Beck NM, 2021, SEMIN CANCER BIOL, V68, P175, DOI 10.1016/j.semcancer.2019.12.001
   Lavignac N, 2004, MACROMOL BIOSCI, V4, P922, DOI 10.1002/mabi.200400093
   Lee JH, 2003, BIOCONJUGATE CHEM, V14, P1214, DOI 10.1021/bc034095g
   Lin C, 2007, BIOCONJUGATE CHEM, V18, P138, DOI 10.1021/bc060200l
   Lin C, 2008, J CONTROL RELEASE, V132, P267, DOI 10.1016/j.jconrel.2008.06.022
   Lipton A, 2008, CANCER TREAT REV, V34, pS25, DOI 10.1016/j.ctrv.2008.03.008
   Liu S, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 11190 0
   Lynn DM, 2000, J AM CHEM SOC, V122, P10761, DOI 10.1021/ja0015388
   Mahato M, 2012, J POLYM SCI POL CHEM, V50, P2344, DOI 10.1002/pola.26017
   Martínez Negro M, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11120632
   Moghimi SM, 2005, MOL THER, V11, P990, DOI 10.1016/j.ymthe.2005.02.010
   Nouri F, 2017, INT J NANOMED, V12, P5557, DOI 10.2147/IJN.S140734
   Ohashi S, 2001, J Orthop Sci, V6, P75, DOI 10.1007/s007760170028
   Oskuee RK, 2010, J GENE MED, V12, P729, DOI 10.1002/jgm.1490
   Pack DW, 2005, NAT REV DRUG DISCOV, V4, P581, DOI 10.1038/nrd1775
   Peng L, 2010, BIOMATERIALS, V31, P4467, DOI 10.1016/j.biomaterials.2010.02.031
   Piest M, 2010, J CONTROL RELEASE, V148, P83, DOI 10.1016/j.jconrel.2010.07.109
   Pignatello R, 2009, NANOMEDICINE UK, V4, P161, DOI 10.2217/17435889.4.2.161
   Richardson SCW, 2001, BIOMACROMOLECULES, V2, P1023, DOI 10.1021/bm010079f
   Rosen H.N., 2019, Pharmacology of bisphosphonates
   Sayles LC, 2019, CANCER DISCOV, V9, P46, DOI 10.1158/2159 8290.CD 17 1152
   Subbiah V, 2015, ONCOTARGET, V6, P40642, DOI 10.18632/oncotarget.5841
   Sun M, 2010, ANN NY ACAD SCI, V1211, P107, DOI 10.1111/j.1749 6632.2010.05812.x
   Sun YP, 2017, MACROMOL BIOSCI, V17, DOI 10.1002/mabi.201600297
   Sunshine JC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037543
   Tan ML, 2009, CANCER BIOL THER, V8, P106, DOI 10.4161/cbt.8.2.7385
   Tripathi SK, 2013, RSC ADV, V3, P15687, DOI 10.1039/c3ra42013b
   Ullah I, 2017, J MATER CHEM B, V5, P3253, DOI 10.1039/c7tb00275k
   Vader P, 2012, PHARM RES DORDR, V29, P352, DOI 10.1007/s11095 011 0545 z
   Wan CF, 2015, MOL MED REP, V12, P2835, DOI 10.3892/mmr.2015.3703
   Yang HN, 2015, CARBOHYD POLYM, V122, P265, DOI 10.1016/j.carbpol.2014.12.073
   Zeng M, 2019, NANO LETT, V19, P381, DOI 10.1021/acs.nanolett.8b04098
   Zeng M, 2017, POLYMERS BASEL, V9, DOI 10.3390/polym9050161
   Zhang HW, 2010, J CONTROL RELEASE, V143, P359, DOI 10.1016/j.jconrel.2010.01.020
   Zhou DZ, 2016, J CONTROL RELEASE, V244, P336, DOI 10.1016/j.jconrel.2016.06.014
   Zhou DZ, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1600102
   Zinselmeyer BH, 2002, PHARM RES DORDR, V19, P960, DOI 10.1023/A:1016458104359
NR 68
TC 6
Z9 6
U1 1
U2 33
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 2637 6105
J9 ACS APPL POLYM MATER
JI ACS Appl. Polym. Mater.
PD AUG 13
PY 2021
VL 3
IS 8
BP 3776
EP 3787
DI 10.1021/acsapm.1c00297
EA JUL 2021
PG 12
WC Materials Science, Multidisciplinary; Polymer Science
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science; Polymer Science
GA UB5QG
UT WOS:000685899900010
DA 2025 08 17
ER

PT J
AU Shaikh, G
   Zhang, J
   Perez Aso, M
   Mediero, A
   Cronstein, B
AF Shaikh, Gibran
   Zhang, Jin
   Perez Aso, Miguel
   Mediero, Aranzazu
   Cronstein, Bruce
TI Adenosine A2A receptor promotes collagen type III synthesis
   via  catenin activation in human dermal fibroblasts
SO BRITISH JOURNAL OF PHARMACOLOGY
LA English
DT Article
ID GROWTH FACTOR BETA; CONCISE GUIDE; PHARMACOLOGICAL BLOCKADE; OSTEOCLAST
   FORMATION; SKIN FIBROSIS; CYCLIC AMP; PROTEIN; INHIBITION; EXPRESSION;
   MODEL
AB Background and PurposeAdenosine A(2A) receptor stimulation promotes the synthesis of collagen type I and type III (Col1 and Col3), mediators of fibrosis and scarring. The A(2A) receptor modulates collagen balance via cAMP/PKA/p38 MAPK/Akt pathways. Wnt signalling is important in fibrosis and the cAMP and Wnt pathways converge. Because the A(2A) receptor is Gs linked and increases cAMP, we determined whether A(2A) receptors and Wnt signalling interact.
   Experimental ApproachTotal  catenin, de phosphorylated  catenin (canonical activation, de phospho  catenin) and phosphorylated  catenin at Ser(552) (non canonical activation, p Ser(552)  catenin) levels were determined in primary human dermal fibroblasts, cytosol and nucleus, by western blot analysis and fluorescence microscopy, before and after stimulation by A(2A) receptor selective agonist CGS21680, with/without A(2A) receptor selective antagonist (SCH56261) pretreatment.  Catenin was knocked down by transfection with scrambled siRNA or specific siRNA, and Col1 and Col3 levels determined by western blots.
   Key ResultsCGS21680 stimulation rapidly (15min) increased cellular  catenin levels. Both de phospho  catenin and p Ser(552)  catenin levels were also increased. CGS21680 stimulated the translocation of total de phospho and p Ser(552)  catenin to the nucleus. A(2A) receptor stimulation increased Col1 synthesis similarly in  catenin knockeddown and scrambled cells. However,  catenin knockdown abolished the increase in Col3 synthesis induced in A(2A) receptor stimulated fibroblasts.
   Conclusions and ImplicationsA(2A) receptor stimulation promotes Col3 synthesis via the activation of canonical and non canonical  catenin, consistent with a role for A(2A) receptors in dermal fibrosis and scarring.
C1 [Shaikh, Gibran; Zhang, Jin; Perez Aso, Miguel; Mediero, Aranzazu; Cronstein, Bruce] NYU, Sch Med, Dept Med, New York, NY 10016 USA.
   [Zhang, Jin] Ningbo Univ, Sch Med, LiHuili Hosp, Dept Immunol & Rheumatol, Ningbo, Zhejiang, Peoples R China.
   [Mediero, Aranzazu] IIS Fdn Jimenez Diaz UAM, Bone & Joint Res Unit, Madrid 28040, Spain.
C3 New York University; Ningbo University; Fundacion Jimenez Diaz
RP Cronstein, B (通讯作者)，NYU, Sch Med, Med, 227 East 30th St, New York, NY 10016 USA.; Cronstein, B (通讯作者)，NYU, Sch Med, Clin Translat Sci Inst, 227 East 30th St, New York, NY 10016 USA.; Cronstein, B (通讯作者)，NYU, Sch Med, Dept Med, Div Translat Med, 227 East 30th St, New York, NY 10016 USA.
EM bruce.cronstein@med.nyu.edu
RI Cronstein, Bruce/JTD 2507 2023; Mediero, Aranzazu/AAA 8362 2020
OI Mediero, Aranzazu/0000 0002 5368 574X; Cronstein,
   Bruce/0000 0002 4295 7383; Pintor, Jesus/0000 0002 9191 7679
FU National Institutes of Health [2R56AR056672 06]
FX This work was funded by a National Institutes of Health Grant (Award
   #2R56AR056672 06).
CR Alexander SPH, 2015, BRIT J PHARMACOL, V172, P5744, DOI 10.1111/bph.13348
   Alexander SPH, 2015, BRIT J PHARMACOL, V172, P6024, DOI 10.1111/bph.13354
   Alexander SPH, 2015, BRIT J PHARMACOL, V172, P5729, DOI 10.1111/bph.13347
   Andrews JP, 2016, MATRIX BIOL, V51, P37, DOI 10.1016/j.matbio.2016.01.013
   Baarsma HA, 2011, AM J PHYSIOL LUNG C, V301, pL956, DOI 10.1152/ajplung.00123.2011
   Balbir Gurman A, 2012, BEST PRACT RES CL RH, V26, P13, DOI 10.1016/j.berh.2012.01.011
   Bikkavilli RK, 2008, J CELL SCI, V121, P3598, DOI 10.1242/jcs.032854
   Borea PA, 2016, TRENDS PHARMACOL SCI, V37, P419, DOI 10.1016/j.tips.2016.02.006
   Chan ESL, 2006, ARTHRITIS RHEUM US, V54, P2632, DOI 10.1002/art.21974
   Chan ESL, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4229
   Chen JQ, 2013, J BONE MINER RES, V28, P1160, DOI 10.1002/jbmr.1834
   Cheon SS, 2006, FASEB J, V20, P692, DOI 10.1096/fj.05 4759com
   Cheon SS, 2002, P NATL ACAD SCI USA, V99, P6973, DOI 10.1073/pnas.102657399
   Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018
   Curtis MJ, 2015, BRIT J PHARMACOL, V172, P3461, DOI 10.1111/bph.12856
   Eltzschig HK, 2011, NAT MED, V17, P1391, DOI 10.1038/nm.2507
   Fang DX, 2007, J BIOL CHEM, V282, P11221, DOI 10.1074/jbc.M611871200
   Fernández P, 2008, AM J PATHOL, V172, P1675, DOI 10.2353/ajpath.2008.070952
   Fernández P, 2013, AM J PATHOL, V183, P1740, DOI 10.1016/j.ajpath.2013.08.024
   Fredholm BB, 2011, PHARMACOL REV, V63, P1, DOI 10.1124/pr.110.003285
   Haskó G, 2004, TRENDS IMMUNOL, V25, P33, DOI 10.1016/j.it.2003.11.003
   Haskó G, 2008, NAT REV DRUG DISCOV, V7, P759, DOI 10.1038/nrd2638
   Henderson WR, 2010, P NATL ACAD SCI USA, V107, P14309, DOI 10.1073/pnas.1001520107
   Hino S, 2005, MOL CELL BIOL, V25, P9063, DOI 10.1128/MCB.25.20.9063 9072.2005
   Jang J, 2014, INT J MOL MED, V34, P632, DOI 10.3892/ijmm.2014.1807
   Karmouty Quintana H, 2012, FASEB J, V26, P2546, DOI 10.1096/fj.11 200907
   Komiya Yuko, 2008, Organogenesis, V4, P68
   Kong TQ, 2006, FASEB J, V20, P2242, DOI 10.1096/fj.06 6419com
   Liang MH, 2008, MOL CELL NEUROSCI, V37, P440, DOI 10.1016/j.mcn.2007.10.017
   Mediero A, 2014, FASEB J, V28, P4901, DOI 10.1096/fj.14 255703
   Mediero A, 2013, BRIT J PHARMACOL, V169, P1372, DOI 10.1111/bph.12227
   Montesinos MC, 2002, AM J PATHOL, V160, P2009, DOI 10.1016/S0002 9440(10)61151 0
   Navarro D, 2010, CARCINOGENESIS, V31, P394, DOI 10.1093/carcin/bgp317
   Perez Aso M, 2014, FASEB J, V28, P802, DOI 10.1096/fj.13 241646
   Perez Aso M, 2013, PURINERG SIGNAL, V9, P573, DOI 10.1007/s11302 013 9368 1
   Perez Aso M, 2012, FASEB J, V26, P4254, DOI 10.1096/fj.12 209627
   Poon R, 2009, BMC CELL BIOL, V10, DOI 10.1186/1471 2121 10 38
   Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593
   Rooney B, 2011, FEBS LETT, V585, P531, DOI 10.1016/j.febslet.2011.01.004
   Saidak Z, 2015, J BIOL CHEM, V290, P6903, DOI 10.1074/jbc.M114.621219
   Shaikh G, 2016, PURINERG SIGNAL, V12, P191, DOI 10.1007/s11302 016 9498 3
   Sorokin A, 2003, AM J PHYSIOL RENAL, V285, pF579, DOI 10.1152/ajprenal.00019.2003
   Southan C, 2016, NUCLEIC ACIDS RES, V44, pD1054, DOI 10.1093/nar/gkv1037
   Takahashi N, 2002, EUR J BIOCHEM, V269, P4559, DOI 10.1046/j.1432 1033.2002.03157.x
   Takemaru KI, 2000, J CELL BIOL, V149, P249, DOI 10.1083/jcb.149.2.249
   Tapia Rojas C, 2015, BIOCHEM J, V466, P415, DOI 10.1042/BJ20140207
   van Es JH, 2005, NAT CELL BIOL, V7, P381, DOI 10.1038/ncb1240
   Wei J, 2011, ARTHRITIS RHEUM US, V63, P1707, DOI 10.1002/art.30312
   Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59
   Xie HR, 2008, DEVELOPMENT, V135, P717, DOI 10.1242/dev.015339
   Zhang N, 2011, CANCER CELL, V20, P427, DOI 10.1016/j.ccr.2011.08.016
   Zhou BY, 2012, J BIOL CHEM, V287, P7026, DOI 10.1074/jbc.M111.276311
NR 52
TC 31
Z9 34
U1 0
U2 19
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0007 1188
EI 1476 5381
J9 BRIT J PHARMACOL
JI Br. J. Pharmacol.
PD DEC
PY 2016
VL 173
IS 23
BP 3279
EP 3291
DI 10.1111/bph.13615
PG 13
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA EB4NP
UT WOS:000387348900001
PM 27595240
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Liu, S
   Ye, PY
   Sang, ZQ
   Gong, W
   Sun, P
   Tao, S
   Zhang, QY
   Qin, LP
   Zhao, QM
AF Liu, Sha
   Ye, Pingyu
   Sang, Zhenqi
   Gong, Wan
   Sun, Peng
   Tao, Shan
   Zhang, Qiaoyan
   Qin, Lupin
   Zhao, Qiming
TI Magnetic hydrothermal carbonaceous nanospheres bonded cell membranes as
   a stable and reusable platform for discovering natural bioactive
   components
SO CHEMICAL ENGINEERING JOURNAL
LA English
DT Article
DE Magnetic hydrothermal carbonaceous; nanomaterials; Cell membrane;
   Covalent biofunctionalization; Biomimetic recognition; Drug screening;
   Improved stability and reusability
ID CAMOUFLAGED NANOPARTICLES; TRADITIONAL MEDICINE; BIOMASS; CARBONIZATION;
   MECHANISMS; STRATEGY; SYSTEM; GREEN
AB The covalent bionic modifications of hydrothermal carbonaceous nanomaterials (HCNs) are of great potential in extraction and separation engineering because they can avoid present disadvantages of chemical functionali zation and achieve selective recognition capacity with stability and sustainability. This article developed novel dual functionalized HCNs with sealed magnetic nanospheres (MNs) and cell membranes (CMs) of osteoblast, via the hydrothermal carbonization of glucose on MN surface and the aqueous amidation between terminal amino groups on CMs and surface carboxyl groups on HCNs. Owing to the specific combinations between drugs and membrane receptors, CMs bonded magnetic HCNs (CM MHCNs) were applied as a drug discovery platform to screen potential anti osteoporosis components from traditional herb medicine. The introduction of hydrothermal carbonaceous layer on MNs was proved to sharply improve their water dispersibility, resistance to oxidation and acids and CM grafting capacity with good magnetic property. These combined with the covalent bonding be tween prepared MHCNs and CMs provided the enhanced stability, where the loss amount (7.0 mg g 1) was dramatically reduced in comparison with that of CMs adsorbed MHCNs (17.9 mg g 1) and MNs (18.7 mg g 1). The resultant CM MHCNs showed high adsorption ability, rapid binding kinetics, good selectivity and reus ability. Consequently, two novel potential anti osteoporosis compounds: isopimpinellin and xanthotoxol were successfully discovered from Common Cnidium Fruit, which were confirmed by pharmacodynamic experiments. Their possible membrane receptors were further investigated by molecular docking and western blot analysis. These researches on CM MHCNs offer a deep insight into green design of stable biomaterials and show their promising prospect in the discovery of drug leads, thus promoting the development of traditional herb medicines.
C1 [Liu, Sha; Ye, Pingyu; Sang, Zhenqi; Gong, Wan; Sun, Peng; Zhang, Qiaoyan; Qin, Lupin; Zhao, Qiming] Zhejiang Chinese Med Univ, Coll Pharmaceut Sci, Fuchun Campus, Hangzhou 311403, Peoples R China.
   [Tao, Shan] Zhejiang Univ, Coll Pharmaceut Sci, Zijingang Campus, Hangzhou 310058, Peoples R China.
C3 Zhejiang Chinese Medical University; Zhejiang University
RP Zhang, QY; Qin, LP; Zhao, QM (通讯作者)，Zhejiang Chinese Med Univ, Coll Pharmaceut Sci, Fuchun Campus, Hangzhou 311403, Peoples R China.
EM zqy1965@163.com; lpqin@zcmu.edu.cn; a_ming8156@163.com
RI Liu, Shafei/NBX 5894 2025
FU National Natural Science Foundation of China [82004208]; Postdoctoral
   Science Foundation of China [2020M681948]; Zhejiang Provincial
   Postdoctoral Science Foundation [ZJ2020104]; Research Project of
   Zhejiang Chinese Medical University [BZXCG 2020 11, 2020ZZ07,
   2021JKZKTS030B]
FX Acknowledgements Financial support from National Natural Science
   Foundation of China (82004208) , Postdoctoral Science Foundation of
   China (2020M681948) , Zhejiang Provincial Postdoctoral Science
   Foundation (ZJ2020104) , and Research Project of Zhejiang Chinese
   Medical Uni versity (BZXCG 2020 11, 2020ZZ07, 2021JKZKTS030B) . We also
   appreciate the technical support from the Public Platform of Medical
   Research Center, Academy of Chinese Medical Science, Zhejiang Chi nese
   Medical University, and the aided characterization analysis from
   Shiyanjia Lab ( www.shiyanjia.com ) .
CR Bu LL, 2019, ADV FUNCT MATER, V29, DOI 10.1002/adfm.201807733
   Bu YS, 2022, TRAC TREND ANAL CHEM, V151, DOI 10.1016/j.trac.2022.116601
   Bu YS, 2018, CHEM COMMUN, V54, P13427, DOI 10.1039/c8cc08530g
   Chen HW, 2017, ACS APPL MATER INTER, V9, P39953, DOI 10.1021/acsami.7b09931
   Dhas N, 2022, J CONTROL RELEASE, V346, P71, DOI 10.1016/j.jconrel.2022.04.019
   Ding CP, 2020, ADV FUNCT MATER, V30, DOI 10.1002/adfm.201909781
   Engelke M, 1996, TOXICOL IN VITRO, V10, P111, DOI 10.1016/0887 2333(95)00103 4
   Fabricant DS, 2001, ENVIRON HEALTH PERSP, V109, P69, DOI 10.2307/3434847
   Fang RH, 2018, ADV MATER, V30, DOI 10.1002/adma.201706759
   Frtús A, 2020, J CONTROL RELEASE, V328, P59, DOI 10.1016/j.jconrel.2020.08.036
   Gajewski A, 2021, BIOMED PHARMACOTHER, V143, DOI 10.1016/j.biopha.2021.112150
   Guo Bao feng, 2011, Zhong Xi Yi Jie He Xue Bao, V9, P1110, DOI 10.3736/jcim20111012
   Hu Q, 2019, CHEM ENG J, V364, P269, DOI 10.1016/j.cej.2019.01.171
   Huang RY, 2021, J MATER CHEM B, V9, P4267, DOI 10.1039/d0tb02713h
   Huang WG, 2022, CHEM ENG J, V431, DOI 10.1016/j.cej.2021.133849
   Jin ZX, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287 021 02228 6
   Karahan HE, 2020, J MATER CHEM B, V8, P9668, DOI 10.1039/d0tb01027h
   Li W, 2013, ANGEW CHEM INT EDIT, V52, P8151, DOI 10.1002/anie.201303927
   Liu J, 2015, NAT MATER, V14, P763, DOI [10.1038/NMAT4317, 10.1038/nmat4317]
   Liu JR, 2019, CHEM MATER, V31, P7186, DOI 10.1021/acs.chemmater.9b01449
   Lu AH, 2007, ANGEW CHEM INT EDIT, V46, P1222, DOI 10.1002/anie.200602866
   Ma JF, 2017, CARBOHYD POLYM, V164, P127, DOI 10.1016/j.carbpol.2017.01.087
   Malhotra N, 2020, MOLECULES, V25, DOI 10.3390/molecules25092256
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   Mohammadi V, 2020, MICROCHIM ACTA, V187, DOI 10.1007/s00604 020 4215 x
   Niu WH, 2015, J AM CHEM SOC, V137, P5555, DOI 10.1021/jacs.5b02027
   Paul SM, 2010, NAT REV DRUG DISCOV, V9, P203, DOI 10.1038/nrd3078
   Rawadi G, 2003, J BONE MINER RES, V18, P1842, DOI 10.1359/jbmr.2003.18.10.1842
   Sevilla M, 2009, CHEM EUR J, V15, P4195, DOI 10.1002/chem.200802097
   Siddiqui MTH, 2018, ENVIRON CHEM LETT, V16, P821, DOI 10.1007/s10311 018 0724 9
   Tang J, 2017, J CLEAN PROD, V145, P25, DOI 10.1016/j.jclepro.2017.01.038
   Tian H, 2019, ADV MATER, V31, DOI 10.1002/adma.201903886
   Tu YY, 2016, ANGEW CHEM INT EDIT, V55, P10210, DOI 10.1002/anie.201601967
   Ukon Y, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20102557
   Wang ZG, 2016, NANO RES, V9, P214, DOI 10.1007/s12274 016 0992 2
   White RJ, 2011, GREEN CHEM, V13, P2428, DOI 10.1039/c1gc15349h
   Wu T, 2016, ACS APPL MATER INTER, V8, P7370, DOI 10.1021/acsami.6b00264
   Xia Q, 2019, ACTA PHARM SIN B, V9, P675, DOI 10.1016/j.apsb.2019.01.011
   Xiao Ya Ping, 2018, Zhongguo Zhong Yao Za Zhi, V43, P21, DOI 10.19540/j.cnki.cjcmm.20171106.002
   Xuan MJ, 2018, ANGEW CHEM INT EDIT, V57, P6049, DOI 10.1002/anie.201712996
   Xue SW, 2021, COLLOID SURFACE A, V616, DOI 10.1016/j.colsurfa.2021.126333
   Yan DY, 2020, J CELL MOL MED, V24, P2330, DOI 10.1111/jcmm.14915
   Yu XR, 2022, MICROCHIM ACTA, V189, DOI 10.1007/s00604 022 05324 3
   Yu Y, 2021, J CELL MOL MED, V25, P4835, DOI 10.1111/jcmm.16459
   Zhang B, 2021, J MATER CHEM A, V9, P24759, DOI 10.1039/d1ta06874a
   Zhao QM, 2022, APPL SURF SCI, V571, DOI 10.1016/j.apsusc.2021.151249
   Zhao QM, 2019, CHEM ENG J, V372, P1164, DOI 10.1016/j.cej.2019.05.014
   Zhao X, 2021, J ENVIRON MANAGE, V298, DOI 10.1016/j.jenvman.2021.113487
   Zhao X, 2015, SCIENCE, V347, pS38
   Zhou HH, 2013, NATURE, V494, P121, DOI 10.1038/nature11774
NR 50
TC 8
Z9 8
U1 2
U2 42
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 1385 8947
EI 1873 3212
J9 CHEM ENG J
JI Chem. Eng. J.
PD FEB 15
PY 2023
VL 454
AR 140238
DI 10.1016/j.cej.2022.140238
EA NOV 2022
PN 2
PG 13
WC Engineering, Environmental; Engineering, Chemical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering
GA 6Z7ZN
UT WOS:000897990200002
DA 2025 08 17
ER

PT J
AU Pasqualone, M
   Oberti, TG
   Andreetta, HA
   Cortizo, MS
AF Pasqualone, Magali
   Oberti, Tamara G.
   Andreetta, Hector A.
   Susana Cortizo, M.
TI Fumarate copolymers based membranes overlooking future transdermal
   delivery devices: synthesis and properties
SO JOURNAL OF MATERIALS SCIENCE MATERIALS IN MEDICINE
LA English
DT Article
ID MECHANICAL PROPERTIES; DRUG DELIVERY; DIISOPROPYL FUMARATE; MATRIX
   PATCHES; CHAIN TRANSFER; BONE; BISPHOSPHONATES; POLYMERIZATION; GEL;
   ALENDRONATE
AB Novel copolymers of vinyl acetate and dialkylfumarates, poly(VA co DRF) with R = isopropyl (DIPF) or octan 2 yl (DOF), were synthesized by radical copolymerization under microwave conditions. The products were characterized by H 1 NMR and FTIR spectroscopies, size exclusion chromatography and differential scanning calorimetry. Based on these copolymers three membranes supported on polyvinyl alcohol were prepared and their morphology, swelling and mechanical properties were studied. The swelling kinetic was analyzed and interpreted in light of the Fick transport model, showing that the water transport occurs through a non Fickian diffusion mechanism. The results show that the membrane prepared of poly(VA co DOF) exhibited excellent properties as potential platform for transdermal delivery system: they exhibited good tensile strength, moderated swelling and form thin and transparent films.
C1 [Pasqualone, Magali; Oberti, Tamara G.; Susana Cortizo, M.] Consejo Nacl Invest Cient & Tecn, CCT, Inst Invest Fisicoquim Teor & Aplicadas, La Plata, Buenos Aires, Argentina.
   [Andreetta, Hector A.] Univ Nacl La Plata, Fac Ciencias Exactas, Lab Farmacotecnia, Dept Ciencias Biol, RA 1900 La Plata, Buenos Aires, Argentina.
C3 Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET);
   National University of La Plata; INIFTA; National University of La Plata
RP Cortizo, MS (通讯作者)，Consejo Nacl Invest Cient & Tecn, CCT, Inst Invest Fisicoquim Teor & Aplicadas, La Plata, Buenos Aires, Argentina.
EM gcortizo@inifta.unlp.edu.ar
OI Oberti, Tamara/0000 0001 8641 747X
FU Universidad Nacional de La Plata [11/X515]
FX This work was supported by Universidad Nacional de La Plata (Project
   11/X515). The authors are grateful to Fernando Amarilla for measuring
   the mechanical properties.
CR Al Arbash AH, 1999, J POLYM SCI POL CHEM, V37, P1839, DOI 10.1002/(SICI)1099 0518(19990615)37:12<1839::AID POLA13>3.0.CO;2 E
   Aparicio M, 2004, J SOL GEL SCI TECHN, V31, P103, DOI 10.1023/B:JSST.0000047969.56298.d7
   AULTON ME, 1981, DRUG DEV IND PHARM, V7, P649, DOI 10.3109/03639048109055689
   Britton D, 1998, MACROMOLECULES, V31, P2828, DOI 10.1021/ma971284j
   Chase JL, 1998, AM J HEALTH SYST PH, V55, P892, DOI 10.1093/ajhp/55.9.892
   Choi A, 2008, INT J PHARMACEUT, V357, P126, DOI 10.1016/j.ijpharm.2008.01.050
   Cortizo MS, 2008, J TISSUE ENG REGEN M, V2, P33, DOI 10.1002/term.62
   Cortizo MS, 2001, J BIOMAT SCI POLYM E, V12, P945, DOI 10.1163/156856201753252499
   FLORY PJ, 1945, J AM CHEM SOC, V67, P2048, DOI 10.1021/ja01227a506
   Funke AP, 2003, DRUG DEV IND PHARM, V29, P785, DOI 10.1081/DDC 120021778
   Ganji F, 2010, IRAN POLYM J, V19, P375
   George SC, 2001, PROG POLYM SCI, V26, P985, DOI 10.1016/S0079 6700(00)00036 8
   González I, 2007, POLYMER, V48, P2542, DOI 10.1016/j.polymer.2007.03.015
   Guo RW, 2011, EUR J PHARM BIOPHARM, V79, P574, DOI 10.1016/j.ejpb.2011.06.006
   Heatley F, 2001, MACROMOLECULES, V34, P7636, DOI 10.1021/ma0101299
   Josse S, 2005, BIOMATERIALS, V26, P2073, DOI 10.1016/j.biomaterials.2004.05.019
   Khan Y, 2008, J BONE JOINT SURG AM, V90A, P36, DOI 10.2106/JBJS.G.01260
   Kim HW, 2004, BIOMATERIALS, V25, P1279, DOI 10.1016/j.biomaterials.2003.07.003
   Koinuma Y, 1997, KOBUNSHI RONBUNSHU, V54, P301, DOI 10.1295/koron.54.301
   Kusamori K, 2010, J BONE MINER RES, V25, P2306, DOI 10.1002/jbmr.147
   Lin JH, 1996, BONE, V18, P75, DOI 10.1016/8756 3282(95)00445 9
   Fernandez JM, 2011, J TISSUE ENG REGEN M, V5, pE126, DOI 10.1002/term.394
   Fernandez JM, 2010, J BIOMAT SCI POLYM E, V21, P1297, DOI 10.1163/092050609X12517190417632
   Mukherjee B, 2005, EUR J PHARM BIOPHARM, V59, P475, DOI 10.1016/j.ejpb.2004.09.009
   Nam SH, 2011, INT J PHARMACEUT, V419, P114, DOI 10.1016/j.ijpharm.2011.07.027
   Oberti TG, 2012, J THERM ANAL CALORIM, V109, P1525, DOI 10.1007/s10973 011 1917 7
   Oliveira AL, 2010, J BIOMED MATER RES B, V92B, P55, DOI 10.1002/jbm.b.31489
   OTSU T, 1985, MAKROMOL CHEM, P133
   OTSU T, 1992, J POLYM SCI POL CHEM, V30, P1559, DOI 10.1002/pola.1992.080300807
   Ramachandran C, 2000, ADV DRUG DELIVER REV, V42, P197, DOI 10.1016/S0169 409X(00)00062 4
   RITGER P L, 1987, Journal of Controlled Release, V5, P23, DOI 10.1016/0168 3659(87)90034 4
   SCHENK R, 1986, CALCIFIED TISSUE INT, V38, P342, DOI 10.1007/BF02555748
   Shu XZ, 2002, EUR J PHARM BIOPHARM, V54, P235, DOI 10.1016/S0939 6411(02)00052 8
   Snorradóttir BS, 2011, EUR J PHARM SCI, V42, P559, DOI 10.1016/j.ejps.2011.02.011
   Stamatialis DF, 2008, J MEMBRANE SCI, V308, P1, DOI 10.1016/j.memsci.2007.09.059
   Cortizo MS, 2007, J APPL POLYM SCI, V103, P3785, DOI 10.1002/app.24653
   Taghizadeh SM, 2009, DRUG DEV IND PHARM, V35, P487, DOI [10.1080/03639040802448638, 10.1080/03639040802448638 ]
   Tan HS, 1999, PHARM SCI TECHNOL TO, V2, P60, DOI 10.1016/S1461 5347(99)00119 4
   Gangoiti MV, 2008, EUR J PHARMACOL, V600, P140, DOI 10.1016/j.ejphar.2008.10.031
   YAMADA K, 1986, POLYMER, V27, P1054, DOI 10.1016/0032 3861(86)90071 6
NR 40
TC 14
Z9 14
U1 0
U2 11
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0957 4530
EI 1573 4838
J9 J MATER SCI MATER M
JI J. Mater. Sci. Mater. Med.
PD JUL
PY 2013
VL 24
IS 7
BP 1683
EP 1692
DI 10.1007/s10856 013 4925 2
PG 10
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA 171WZ
UT WOS:000320962100007
PM 23588672
OA Green Submitted
DA 2025 08 17
ER

PT J
AU Shimohira, T
   Niimi, H
   Ohsugi, Y
   Tsuchiya, Y
   Morita, K
   Yoshida, S
   Hatasa, M
   Shiba, T
   Kadokura, H
   Yokose, S
   Katagiri, S
   Iwata, T
   Aoki, A
AF Shimohira, Tsuyoshi
   Niimi, Hiromi
   Ohsugi, Yujin
   Tsuchiya, Yosuke
   Morita, Kazuki
   Yoshida, Sumiko
   Hatasa, Masahiro
   Shiba, Takahiko
   Kadokura, Hiroshi
   Yokose, Satoshi
   Katagiri, Sayaka
   Iwata, Takanori
   Aoki, Akira
TI Low Level Erbium Doped Yttrium Aluminum Garnet Laser Irradiation Induced
   Alteration of Gene Expression in Osteogenic Cells from Rat Calvariae
SO PHOTOBIOMODULATION PHOTOMEDICINE AND LASER SURGERY
LA English
DT Article
DE Er; YAG laser; photobiomodulation; microarray; osteogenic cell;
   mechanotransduction; gene expression
ID CHROMATIN STRUCTURE; OSTEOCYTE; PROLIFERATION; PROTEIN; DIFFERENTIATION;
   OSTEONECROSIS; FIBROBLASTS; HOMEOSTASIS; PATHWAYS; THERAPY
AB Objective: The aim of this study was to investigate the effect of low level erbium doped yttrium aluminum garnet (Er:YAG) laser irradiation on gene expression in osteogenic cells from rat calvariae. Background: Previous studies showed beneficial effects of laser irradiation on bone related cells. However, few studies have examined the gene expression alteration by laser irradiation on osteogenic cells in a calcified condition. Materials and methods: Osteogenic cells were prepared by culturing rat calvarial osteoblast like cells in osteoinductive medium for 21 days. The cells at the bottom of the culture dish were irradiated with Er:YAG laser (wavelength: 2.94 mu m, energy density: 3.1 and 8.2 J/cm(2)) positioned at distance of 25 cm. Lactate dehydrogenase (LDH) assay of the irradiated cells was performed. After screening for genes related to bone formation, mechanotransduction, and thermal effect by quantitative polymerase chain reaction (qPCR), gene expression at 3 h after 3.1 J/cm(2) irradiation was comprehensively analyzed using microarray. Results: No dramatical increase in surface temperature and LDH activities after laser irradiation were observed. Sost expression was significantly reduced at 3 h after 3.1 J/cm(2) irradiation. Bcar1 and Hspa1a expression was significantly increased following 8.2 J/cm(2) irradiation. Microarray analysis identified 116 differentially expressed genes. Gene set enrichment analysis showed enrichment of histone H3 K9 methylation and modification gene sets. Conclusions: Er:YAG laser irradiation, especially at 3.1 J/cm(2), showed positive effect on the expression of genes related to bone formation in osteogenic cells, without inducing significant cell damage. These findings may represent critical mechanisms of early bone formation after Er:YAG laser irradiation.
C1 [Shimohira, Tsuyoshi; Niimi, Hiromi; Ohsugi, Yujin; Tsuchiya, Yosuke; Morita, Kazuki; Yoshida, Sumiko; Hatasa, Masahiro; Shiba, Takahiko; Katagiri, Sayaka; Iwata, Takanori; Aoki, Akira] Tokyo Med & Dent Univ TMDU, Grad Sch Med & Dent Sci, Dept Periodontol, Tokyo, Japan.
   [Kadokura, Hiroshi; Yokose, Satoshi] Meikai Univ, Sch Dent, Dept Restorat & Biomat Sci, Div Endodont & Operat Dent, Saitama, Japan.
C3 Institute of Science Tokyo; Tokyo Medical & Dental University (TMDU);
   Meikai University
RP Ohsugi, Y; Katagiri, S (通讯作者)，Tokyo Med & Dent Univ TMDU, Dept Periodontol, Bunkyo Ku, 1 5 45 Yushima, Tokyo 1138549, Japan.
EM ohsugi.peri@tmd.ac.jp; katagiri.peri@tmd.ac.jp
RI Shiba, Takahiko/JFK 8657 2023
FU Japan Society for the Promotion of Science [16K11825, 20K09971,
   20K18501]; Academy of Laser Dentistry; Nanken Kyoten, TMDU;
   Grants in Aid for Scientific Research [20K23020, 20K09971, 20K18501,
   16K11825, 22KJ1198, 21J22613, 21K19590, 21K16984, 20H03863] Funding
   Source: KAKEN
FX This work was supported by the Japan Society for the Promotion of
   Science (16K11825 and 20K09971 to A.A. and 20K18501 to Y.O.) and Dr.
   Eugene Seidner Research Grants from the Academy of Laser Dentistry to
   S.K. and Y.O. This study was also supported by Nanken Kyoten, TMDU.
CR Aleksic V, 2010, LASER MED SCI, V25, P559, DOI 10.1007/s10103 010 0761 5
   Aoki A, 2015, PERIODONTOL 2000, V68, P217, DOI 10.1111/prd.12080
   Arany PR, 2016, J DENT RES, V95, P977, DOI 10.1177/0022034516648939
   Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556
   Ballini A, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/6927401
   Ballini A, 2017, STEM CELLS INT, V2017, DOI 10.1155/2017/3292810
   BLAND JM, 1995, BRIT MED J, V310, P170, DOI 10.1136/bmj.310.6973.170
   Weber JBB, 2016, LASER MED SCI, V31, P1261, DOI 10.1007/s10103 016 1929 4
   Chang MK, 2014, J BONE MINER RES, V29, P29, DOI 10.1002/jbmr.2059
   Chen X, 2017, ONCOTARGET, V8, P112152, DOI 10.18632/oncotarget.22899
   Dallas SL, 2013, ENDOCR REV, V34, P658, DOI 10.1210/er.2012 1026
   Delgado Calle J, 2012, J BONE MINER RES, V27, P926, DOI 10.1002/jbmr.1491
   Fyodorov DV, 2018, NAT REV MOL CELL BIO, V19, P192, DOI 10.1038/nrm.2017.94
   Gu GL, 2006, CELL TISSUE RES, V323, P263, DOI 10.1007/s00441 005 0066 3
   Hayashi M, 2012, NATURE, V485, P69, DOI 10.1038/nature11000
   IKEDA T, 1992, J HISTOCHEM CYTOCHEM, V40, P1079, DOI 10.1177/40.8.1619274
   Iwasaki A, 2018, J BIOPHOTONICS, P11
   Leal MDC, 2015, GENE, V562, P1, DOI 10.1016/j.gene.2015.02.027
   Li FL, 2020, BRIT J ORAL MAX SURG, V58, P256, DOI [10.1016/j.bjoms.2019.12.00, 10.1016/j.bjoms.2019.12.001]
   Lin TC, 2021, J FORMOS MED ASSOC, V120, P388, DOI 10.1016/j.jfma.2020.06.005
   Litzenberger JB, 2010, CALCIFIED TISSUE INT, V86, P325, DOI 10.1007/s00223 010 9343 6
   Marrazzo P, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/7230987
   Martins MD, 2021, J BIOPHOTONICS, V14, DOI 10.1002/jbio.202000274
   McDonald MM, 2017, BLOOD, V129, P3452, DOI 10.1182/blood 2017 03 773341
   Merigo E, 2016, J PHOTOCH PHOTOBIO B, V155, P130, DOI 10.1016/j.jphotobiol.2015.12.005
   Mizutani K, 2016, PERIODONTOL 2000, V71, P185, DOI 10.1111/prd.12123
   Nakashima T, 2011, NAT MED, V17, P1231, DOI 10.1038/nm.2452
   Nguyen AM, 2013, BONE, V54, P196, DOI 10.1016/j.bone.2012.11.016
   Niimi H, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00459
   Ogita M, 2015, LASER MED SCI, V30, P1855, DOI 10.1007/s10103 014 1691 4
   Ohsugi Y, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21239002
   Ohsugi Y, 2020, FASEB J, V34, P12877, DOI 10.1096/fj.202001032R
   Ohsugi Y, 2019, J BIOPHOTONICS, V12, DOI 10.1002/jbio.201800245
   Ozcivici E, 2010, NAT REV RHEUMATOL, V6, P50, DOI 10.1038/nrrheum.2009.239
   Paic F, 2009, BONE, V45, P682, DOI 10.1016/j.bone.2009.06.010
   Parker S, 2007, BRIT DENT J, V202, P523, DOI 10.1038/bdj.2007.370
   Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506
   Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007
   Robling AG, 2008, J BIOL CHEM, V283, P5866, DOI 10.1074/jbc.M705092200
   Rubin J, 2006, GENE, V367, P1, DOI 10.1016/j.gene.2005.10.028
   Sasaki F, 2020, BIOCHEM BIOPH RES CO, V521, P806, DOI 10.1016/j.bbrc.2019.10.174
   Sawada Y, 2006, CELL, V127, P1015, DOI 10.1016/j.cell.2006.09.044
   Schwartz HO, 2011, LASER MED SCI, V26, P539, DOI 10.1007/s10103 011 0902 5
   Sebastian A, 2017, BONE, V96, P76, DOI 10.1016/j.bone.2016.10.009
   Shashikant T, 2019, METHOD CELL BIOL, V151, P219, DOI 10.1016/bs.mcb.2018.11.002
   Shimohira T, 2021, PHOTOBIOMOD PHOTOMED, V39, P100, DOI 10.1089/photob.2020.4833
   Shippy R, 2006, NAT BIOTECHNOL, V24, P1123, DOI 10.1038/nbt1241
   Sommer AP, 2001, J CLIN LASER MED SUR, V19, P29, DOI 10.1089/104454701750066910
   Spagnuolo Gianrico, 2018, Dent J (Basel), V6, DOI 10.3390/dj6040072
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Tsukasaki M, 2020, CELL REP, V32, DOI 10.1016/j.celrep.2020.108124
   Turner CH, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.268pt3
   Uda Y, 2017, CURR OSTEOPOROS REP, V15, P318, DOI 10.1007/s11914 017 0373 0
   Wang K, 2019, J BONE MINER RES, V34, P979, DOI 10.1002/jbmr.3720
   Wein Marc N, 2015, J Bone Miner Res, V30, P400, DOI 10.1002/jbmr.2381
   Yokose S, 1996, ENDOCRINOLOGY, V137, P469, DOI 10.1210/en.137.2.469
   Yokose S, 2013, J Bio Integ, V3, P53, DOI DOI 10.32176/BIOINTEG.3.1_53
   Yoshino T, 2009, J PERIODONTOL, V80, P82, DOI [10.1902/jop.2009.080097, 10.1902/jop.2009.080097 ]
   Zhang W, 2016, SCI REP UK, V6, DOI 10.1038/srep27622
NR 59
TC 4
Z9 4
U1 0
U2 9
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
EI 2578 5478
J9 PHOTOBIOMOD PHOTOMED
JI Photobiomodulation Photomed. Laser Surg.
PD AUG 1
PY 2021
VL 39
IS 8
BP 566
EP 577
DI 10.1089/photob.2020.4958
EA JUL 2021
PG 12
WC Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Surgery
GA UD6WS
UT WOS:000680089500001
PM 34339325
DA 2025 08 17
ER

PT J
AU Scimeca, M
   Anemona, L
   Granaglia, A
   Bonfiglio, R
   Urbano, N
   Toschi, N
   Santeusanio, G
   Schiaroli, S
   Mauriello, S
   Tancredi, V
   Schillaci, O
   Bonanno, E
   Mauriello, A
AF Scimeca, Manuel
   Anemona, Lucia
   Granaglia, Annarita
   Bonfiglio, Rita
   Urbano, Nicoletta
   Toschi, Nicola
   Santeusanio, Giuseppe
   Schiaroli, Stefania
   Mauriello, Silvestro
   Tancredi, Virginia
   Schillaci, Orazio
   Bonanno, Elena
   Mauriello, Alessandro
TI Plaque calcification is driven by different mechanisms of mineralization
   associated with specific cardiovascular risk factors
SO NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
LA English
DT Article
DE Plaque calcification; Atherosclerosis; Mineralization; BMP 2; Risk
   factors
ID ARTERY CALCIFICATION; CORONARY; MICROCALCIFICATIONS; IMPACT
AB Background and aims: The aim of this study was to investigate possible associations among markers of mineralization, plaque instability and the main risk factors of atherosclerosis.
   Methods and results: A Tissue MicroArray containing 52 samples of calcified carotid plaques from 52 symptomatic and asymptomatic patients were built. TMA serial sections were used to study the expression of inflammatory and mineralization markers (BMP 2, BMP 4, VDR, RANKL, Osteopontin, Sclerostin, beta catenin and calmodulin) by immunohistochemistry. Our data clearly demonstrated the expression of mineralization markers in atheromatic plaques. Indeed, with the exception of RANKL, all investigated markers were expressed in at least 60% of cases. Specifically, multivariate analysis displayed significant associations between both the expression of BMP 2 and the presence of unstable plaques as well as between the expression of beta catenin and the presence of stable plaques. We also found a significant inverse association between both a) the presence of hypertension and VDR and b) smoking habits and calmodulin expression. Finally, we noted a higher density of RANKL positive cells in plaques from diabetic patients as compared to non diabetic ones and a significant positive association between hypertriglyceridemia and BMP 4 expression.
   Conclusion: Our results support the hypothesis that the process of atherosclerotic plaque calcification presents a number of similarities with the physiological processes that occur in bone, involving both osteoblasts  and osteoclasts like arterial cells. Finally, the present study suggests that risk factors, such as hypertension, cigarette smoke and diabetes, can cause the destabilization of the atheromatic plaque acting on calcification process as well as inflammation. (C) 2019 The Italian Society of Diabetology, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition, and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights reserved.
C1 [Scimeca, Manuel; Toschi, Nicola; Mauriello, Silvestro; Schillaci, Orazio] Univ Roma Tor Vergata, Dept Biomed & Prevent, Via Montpellier 1, I 00133 Rome, Italy.
   [Scimeca, Manuel; Tancredi, Virginia] San Raffaele Univ, Via Val Cannuta 247, I 00166 Rome, Italy.
   [Scimeca, Manuel] Fdn Umberto Veronesi FUV, Piazza Velasca 5, I 20122 Milan, Italy.
   [Scimeca, Manuel; Bonanno, Elena; Mauriello, Alessandro] St Camillus Int Univ Hlth Sci, Via St Alessandro 8, I 00131 Rome, Italy.
   [Anemona, Lucia; Granaglia, Annarita; Bonfiglio, Rita; Santeusanio, Giuseppe; Schiaroli, Stefania] Univ Roma Tor Vergata, Dept Expt Med, Rome, Italy.
   [Urbano, Nicoletta] Policlin Tor Vergata, Nucl Med, Rome, Italy.
   [Toschi, Nicola] Athinoula A Martinos Ctr Biomed Imaging, Dept Radiol, Boston, MA USA.
   [Toschi, Nicola] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA 02115 USA.
   [Tancredi, Virginia] Univ Roma Tor Vergata, Sch Sport & Exercise Sci, Dept Syst Med, Rome, Italy.
   [Tancredi, Virginia] Univ Roma Tor Vergata, Ctr Space Biomed, Rome, Italy.
   [Schillaci, Orazio] IRCCS Neuromed, Pozzilli, Italy.
   [Bonanno, Elena] IRCCS Neuromed Lab Diagnost Med & Villa Platani, Avellino, Italy.
   [Mauriello, Alessandro] Univ Roma Tor Vergata, TOR, Rome, Italy.
C3 University of Rome Tor Vergata; Vita Salute San Raffaele University;
   University of Rome Tor Vergata; University of Rome Tor Vergata; Policlin
   Tor Vergata; Harvard University; Harvard Medical School; Harvard
   University Medical Affiliates; Massachusetts General Hospital;
   University of Rome Tor Vergata; University of Rome Tor Vergata; IRCCS
   Neuromed; University of Rome Tor Vergata
RP Mauriello, A (通讯作者)，Univ Roma Tor Vergata, Dept Expt Med & Surg, Via Montpellier 1, I 00133 Rome, Italy.
EM manuel.scimeca@uniroma2.it; anemona@uniroma2.it; a.granaglia@gmail.com;
   bonfiglio.rita@gmail.com; n.urbano@virgilio.it; toschi@med.uniroma2.it;
   santeusa@uniroma2.it; schiaroli@yahoo.com;
   mauriello.silvestro@gmail.com; tancredi@uniroma2.it;
   orazio.schillaci@uniroma2.it; elena.bonanno@uniroma2.it;
   alessandro.mauriello@uniroma2.it
RI Bonanno, Elena/J 7609 2018; Granaglia, Annarita/AAH 5209 2021; Anemona,
   lucia/AAB 3491 2022; SCHILLACI, ORAZIO/AAA 3481 2021; Tancredi,
   Virginia/AAA 9364 2019; Toschi, Nicola/J 2555 2012
OI TANCREDI, VIRGINIA/0000 0003 4779 2212; /0000 0001 7852 1517; Toschi,
   Nicola/0000 0003 1929 5833
FU Fondazione Umberto Veronesi
FX Authors wish to thank Dr. Manuela Montanaro for technical support.
   Manuel Scimeca is recipient of a fellowship from the Fondazione Umberto
   Veronesi.
CR Aikawa E, 2007, CIRCULATION, V116, P2841, DOI 10.1161/CIRCULATIONAHA.107.732867
   Alexopoulos N, 2009, NAT REV CARDIOL, V6, P681, DOI 10.1038/nrcardio.2009.165
   Bailey G, 2016, CURR ATHEROSCLER REP, V18, DOI 10.1007/s11883 016 0601 6
   Bischetti S, 2017, NUTR METAB CARDIOVAS, V27, P768, DOI 10.1016/j.numecd.2017.05.006
   Bonfiglio R, 2018, J MAMMARY GLAND BIOL, V23, P89, DOI 10.1007/s10911 018 9396 0
   Cardellini M, 2019, AGING DIS, V10, P71, DOI 10.14336/AD.2018.0117
   Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890
   Durham AL, 2018, CARDIOVASC RES, V114, P590, DOI 10.1093/cvr/cvy010
   Franczyk Agata, 2014, Cardiovascular & Hematological Disorders   Drug Targets, V14, P34
   Gilbert MP, 2015, ENDOCR REV, V36, P194, DOI 10.1210/er.2012 1042
   Hunt JL, 2002, STROKE, V33, P1214, DOI 10.1161/01.STR.0000013741.41309.67
   Hunter GK, 2013, CALCIFIED TISSUE INT, V93, P348, DOI 10.1007/s00223 013 9698 6
   Hutcheson JD, 2014, CURR OPIN LIPIDOL, V25, P327, DOI 10.1097/MOL.0000000000000105
   Kobayashi Y, 2015, BONEKEY REP, V4, DOI 10.1038/bonekey.2015.82
   Kwee RM, 2010, J VASC SURG, V51, P1015, DOI 10.1016/j.jvs.2009.08.072
   Ling Y, 2018, J BONE MINER METAB, V36, P352, DOI 10.1007/s00774 017 0841 8
   Maldonado N, 2012, AM J PHYSIOL HEART C, V303, pH619, DOI 10.1152/ajpheart.00036.2012
   Mauriello A, 2013, ATHEROSCLEROSIS, V229, P124, DOI 10.1016/j.atherosclerosis.2013.03.010
   Mehta V, 2017, CUREUS J MED SCIENCE, V9, DOI 10.7759/cureus.1038
   Moe SM, 2004, CIRC RES, V95, P560, DOI 10.1161/01.RES.0000141775.67189.98
   Nandalur KR, 2006, AM J ROENTGENOL, V186, P547, DOI 10.2214/AJR.04.1216
   Odink AE, 2010, J HUM HYPERTENS, V24, P86, DOI 10.1038/jhh.2009.42
   Patil Santosh R, 2015, J Nat Sci Biol Med, V6, pS1, DOI 10.4103/0976 9668.166048
   RICHARDSON PD, 1989, LANCET, V2, P941
   Sakamoto A, 2018, CURR OPIN CARDIOL, V33, P645, DOI 10.1097/HCO.0000000000000558
   Sangiorgi G, 1998, J AM COLL CARDIOL, V31, P126, DOI 10.1016/S0735 1097(97)00443 9
   Scimeca M, 2018, MICROSC RES TECHNIQ, V81, P745, DOI 10.1002/jemt.23031
   Scimeca M, 2018, FUTURE ONCOL, V14, P9, DOI 10.2217/fon 2017 0472
   Scimeca M, 2014, BMC CANCER, V14, DOI 10.1186/1471 2407 14 286
   Tarkin JM, 2016, CIRC RES, V118, P750, DOI 10.1161/CIRCRESAHA.115.306247
   Tesauro M, 2017, J INTERN MED, V281, P471, DOI 10.1111/joim.12605
   Virmani R, 2000, ARTERIOSCL THROM VAS, V20, P1262, DOI 10.1161/01.ATV.20.5.1262
   Whelton PK, 2018, J AM COLL CARDIOL, V71, P2199, DOI 10.1016/j.jacc.2017.11.005
   Zhang Y, 2018, J STROKE CEREBROVASC, V27, P1796, DOI 10.1016/j.jstrokecerebrovasdis.2018.02.011
NR 34
TC 26
Z9 27
U1 1
U2 13
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0939 4753
EI 1590 3729
J9 NUTR METAB CARDIOVAS
JI Nutr. Metab. Carbiovasc. Dis.
PD DEC
PY 2019
VL 29
IS 12
BP 1330
EP 1336
DI 10.1016/j.numecd.2019.08.009
PG 7
WC Cardiac & Cardiovascular Systems; Endocrinology & Metabolism; Nutrition
   & Dietetics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cardiovascular System & Cardiology; Endocrinology & Metabolism;
   Nutrition & Dietetics
GA JM5KW
UT WOS:000496253900008
PM 31653516
DA 2025 08 17
ER

PT J
AU Zhong, CH
   Xu, HZ
   Chen, JW
   Cai, WX
   Zhou, JL
   Peng, H
AF Zhong, Changheng
   Xu, Hanzhe
   Chen, Junwen
   Cai, Wenxiang
   Zhou, Jianlin
   Peng, Hao
TI Human Umbilical Cord Mesenchymal Stem Cells Prevent Steroid Induced
   Avascular Necrosis of the Femoral Head by Modulating Cellular Autophagy
SO BIOMEDICINES
LA English
DT Article
DE glucocorticoid induced osteonecrosis of femoral head; human umbilical
   cord mesenchymal stem cell; autophagy; core decompression; osteoblasts
ID OSTEONECROSIS; OSTEOGENESIS; PATHWAY
AB Background: Glucocorticoids (GCs) are critical regulatory molecules in the body, commonly utilized in clinical practice for their potent anti inflammatory and immunosuppressive properties. However, prolonged, high dose GC therapy is frequently associated with femoral head necrosis, a condition known as glucocorticoid induced osteonecrosis of the femoral head (GC ONFH). Emerging evidence suggests that enhanced autophagy may mitigate apoptosis, thereby protecting osteoblasts from GC induced damage and delaying the progression of ONFH. This study aims to evaluate whether human umbilical cord mesenchymal stem cells (hUCMSCs) can alleviate GC induced osteoblast injury through autophagy modulation. Methods: In vitro, osteoblasts were exposed to GCs for 48 h, followed by co culture with hUCMSCs for an additional 12 h before further analysis. The osteoblasts were categorized into four experimental groups: (A) control group, (B) Dex group, (C) Dex + hUCMSC group, and (D) Dex + hUCMSC + 3 MA group. In vivo, rabbits were assigned to one of four groups: Con, MPS, core decompression (CD), and CD + hUCMSC (n = 12 per group), and subsequently subjected to CT imaging and HE staining. Results: In vitro results demonstrate that hUCMSC treatment mitigated GC induced osteoblast apoptosis and preserved osteogenic activity through autophagy modulation. In vivo, infusion of hUCMSCs enhanced trabecular thickness in the femoral head and improved the femoral head microenvironment. Conclusions: These findings suggest that hUCMSCs protect osteoblasts from GC induced damage by regulating autophagy, offering new insights into the potential therapeutic use of hUCMSCs for treating ONFH via autophagy enhancement.
C1 [Zhong, Changheng; Xu, Hanzhe; Chen, Junwen; Cai, Wenxiang; Zhou, Jianlin; Peng, Hao] Wuhan Univ, Dept Orthoped Surg, Renmin Hosp, Wuhan 430060, Peoples R China.
C3 Wuhan University
RP Zhou, JL; Peng, H (通讯作者)，Wuhan Univ, Dept Orthoped Surg, Renmin Hosp, Wuhan 430060, Peoples R China.
EM 18706827939@163.com; 2024283020153@whu.edu.cn; 2018283020157@whu.edu.cn;
   2020283020214@whu.edu.cn; zjl2022@whu.edu.cn; penghao8599@163.com
RI 蔡, 文祥/JWP 6959 2024; Zhou, Jianlin/HGC 6414 2022
FU Hubei Provincial key research and development program; National Natural
   Science Foundation of China [82272251]; Wuhan University Education and
   Development Foundation [2002330];  [2021BCA147]
FX This work was supported by grants from the Hubei Provincial key research
   and development program (2021BCA147), the National Natural Science
   Foundation of China (No. 81672154), the Wuhan University Education and
   Development Foundation (No. 2002330), and the National Natural Science
   Foundation of China (No. 82272251).
CR Bai SC, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/9192413
   Benignus C, 2020, OPER ORTHOP TRAUMATO, V32, P89, DOI 10.1007/s00064 019 00640 z
   Bougioukli S, 2018, HUM GENE THER, V29, P507, DOI 10.1089/hum.2017.097
   Cen SZ, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1380 0
   Chang C, 2020, J AUTOIMMUN, V110, DOI 10.1016/j.jaut.2020.102460
   Chen CY, 2022, SCI ADV, V8, DOI 10.1126/sciadv.abg8335
   Chen Junwen, 2024, Aging US, V16, P7928, DOI 10.18632/aging.205794
   Chen K, 2020, INT J BIOL SCI, V16, P1888, DOI 10.7150/ijbs.40917
   Fan T, 2020, J CELL PHYSIOL, V235, P7982, DOI 10.1002/jcp.29453
   García Bonilla M, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 020 01626 6
   Haimovici A, 2022, CELL DEATH DIS, V13, DOI 10.1038/s41419 022 04768 y
   Han D, 2010, BIOCHEM J, V425, P541, DOI 10.1042/BJ20090429
   Han H, 2022, DRUG DES DEV THER, V16, P2627, DOI 10.2147/DDDT.S365279
   Harr MW, 2010, AUTOPHAGY, V6, P912, DOI 10.4161/auto.6.7.13290
   Houdek MT, 2014, STEM CELLS CLONING, V7, P65, DOI 10.2147/SCCAA.S36584
   Jia XH, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046 020 01749 x
   Jiao FJ, 2025, NEURAL REGEN RES, V20, P139, DOI 10.4103/NRR.NRR D 23 01195
   Jin LL, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 24412 1
   Jing XM, 2019, MOL CANCER, V18, DOI 10.1186/s12943 019 1089 9
   Jipa A, 2021, AUTOPHAGY, V17, P2565, DOI 10.1080/15548627.2020.1856494
   Konarski W, 2023, HEALTHCARE BASEL, V11, DOI 10.3390/healthcare11131846
   Kong N, 2022, BONE RES, V10, DOI 10.1038/s41413 022 00196 y
   Li GC, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419 020 2284 8
   Li J, 2022, REGEN BIOMATER, V9, DOI 10.1093/rb/rbac071
   Li KL, 2022, J NANOBIOTECHNOL, V20, DOI 10.1186/s12951 021 01236 1
   Li W, 2021, PLOS PATHOG, V17, DOI 10.1371/journal.ppat.1009462
   Liang XZ, 2022, J ORTHOP SURG RES, V17, DOI 10.1186/s13018 022 02977 x
   Lin T, 2019, TISSUE ENG PT A, V25, P1096, DOI [10.1089/ten.tea.2018.0292, 10.1089/ten.TEA.2018.0292]
   Liu BY, 2019, CELL TISSUE BANK, V20, P173, DOI 10.1007/s10561 019 09751 0
   Liu YJ, 2021, INT J BIOL SCI, V17, P1353, DOI 10.7150/ijbs.57962
   Luo P, 2018, INT ORTHOP, V42, P1747, DOI 10.1007/s00264 018 3994 8
   Mandhair HK, 2020, WORLD J STEM CELLS, V12, P303, DOI 10.4252/wjsc.v12.i5.303
   Menasché P, 2018, NAT REV CARDIOL, V15, P659, DOI 10.1038/s41569 018 0013 0
   Nie N, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24044092
   Nishikawa G, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 1508 2
   Park HJ, 2014, NEUROBIOL AGING, V35, P1920, DOI 10.1016/j.neurobiolaging.2014.01.028
   Peng PJ, 2023, FOOD CHEM TOXICOL, V180, DOI 10.1016/j.fct.2023.114004
   Prasher P, 2022, CANCER CELL INT, V22, DOI 10.1186/s12935 022 02808 3
   Qu YY, 2022, FRONT CELL NEUROSCI, V16, DOI 10.3389/fncel.2022.888836
   Sena P, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23095211
   Song J, 2023, J CACHEXIA SARCOPENI, V14, P915, DOI 10.1002/jcsm.13177
   Sun DZ, 2019, NAT REV UROL, V16, P363, DOI 10.1038/s41585 019 0169 3
   Sun HY, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419 021 04313 3
   Tan YW, 2022, CELL DEATH DIS, V13, DOI 10.1038/s41419 022 04764 2
   Tang YH, 2018, MOL MED REP, V17, P158, DOI 10.3892/mmr.2017.7840
   Taucher E, 2022, CANCERS, V14, DOI 10.3390/cancers14071637
   Teramoto K, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 75761 8
   Thirusangu P, 2021, CANCERS, V13, DOI 10.3390/cancers13092004
   Wang WD, 2024, J ORTHOP SURG RES, V19, DOI 10.1186/s13018 024 04775 z
   Wang ZH, 2015, AUTOPHAGY, V11, P2358, DOI 10.1080/15548627.2015.1106779
   Wu YH, 2022, SCI ADV, V8, DOI 10.1126/sciadv.abn9912
   Yang GH, 2021, BIOMED RES INT, V2021, DOI 10.1155/2021/6380141
   Yang Y, 2020, CELL DEATH DIFFER, V27, P858, DOI 10.1038/s41418 019 0480 9
   Yao GH, 2019, THERANOSTICS, V9, P8253, DOI 10.7150/thno.37351
   Yao XD, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 020 01658 y
   Yoon PW, 2021, CLIN ORTHOP SURG, V13, P37, DOI 10.4055/cios20128
   Zhang J, 2024, BIOMOLECULES, V14, DOI 10.3390/biom14060667
   Zhang SQ, 2021, DRUG DES DEV THER, V15, P983, DOI 10.2147/DDDT.S298691
   Zhang WW, 2019, THERANOSTICS, V9, P2198, DOI 10.7150/thno.30798
   Zhou H, 2023, BIOACT MATER, V23, P409, DOI 10.1016/j.bioactmat.2022.11.007
NR 60
TC 1
Z9 1
U1 0
U2 0
PU MDPI
PI BASEL
PA MDPI AG, Grosspeteranlage 5, CH 4052 BASEL, SWITZERLAND
EI 2227 9059
J9 BIOMEDICINES
JI Biomedicines
PD DEC
PY 2024
VL 12
IS 12
AR 2817
DI 10.3390/biomedicines12122817
PG 23
WC Biochemistry & Molecular Biology; Medicine, Research & Experimental;
   Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Research & Experimental Medicine;
   Pharmacology & Pharmacy
GA Q7Y7O
UT WOS:001386791200001
PM 39767723
OA gold
DA 2025 08 17
ER

PT J
AU Chang, R
   Sun, LL
   Webster, TJ
AF Chang, Run
   Sun, Linlin
   Webster, Thomas J.
TI Selective inhibition of MG 63 osteosarcoma cell proliferation induced by
   curcumin loaded self assembled arginine rich RGD nanospheres
SO INTERNATIONAL JOURNAL OF NANOMEDICINE
LA English
DT Article
DE osteosarcoma; selective inhibition; curcumin; arginine rich;
   arginine glycine aspartic acid; self assembly
ID FACTOR KAPPA B; DRUG DELIVERY; APOPTOSIS; PEPTIDES; ALPHA(V)BETA(3);
   EXPRESSION; STABILITY; MICELLES; ROLES; CYCLE
AB Osteosarcoma is the most frequent primary malignant form of bone cancer, comprising 30% of all bone cancer cases. The objective of this in vitro study was to develop a treatment against osteosarcoma with higher selectivity toward osteosarcoma cells and lower cytotoxicity toward normal healthy osteoblast cells. Curcumin (or diferuloylmethane) has been found to have antioxidant and anticancer effects by multiple cellular pathways. However, it has lower water solubility and a higher degradation rate in alkaline conditions. In this study, the amphiphilic peptide C18GR7RGDS was used as a curcumin carrier in aqueous solution. This peptide contains a hydrophobic aliphatic tail group leading to their self assembly by hydrophobic interactions, as well as a hydrophilic head group composed of an arginine rich and an arginine glycine aspartic acid structure. Through characterization by transmission electron microscopy, self assembled structures of spherical amphiphilic nanoparticles (APNPs) with diameters of 10 20 nm in water and phosphate buffered saline were observed, but this structure dissociated when the pH value was reduced to 4. Using a method of codissolution with acetic acid and dialysis tubing, the solubility of curcumin was enhanced and a homogeneous solution was formed in the presence of APNPs. Successful encapsulation of curcumin in APNPs was then confirmed by Fourier transform infrared and X ray diffraction analyses. The cytotoxicity and cellular uptake of the APNP/curcumin complexes on both osteosarcoma and normal osteoblast cell lines were also evaluated by methyl thiazolyl tetrazolium assays and confocal fluorescence microscopy. The results showed that the curcumin loaded APNPs had significant selective cytotoxicity against MG 63 osteosarcoma cells when compared with normal osteoblasts. We have demonstrated for the first time that APNPs can encapsulate hydrophobic curcumin in their hydrophobic cores, and curcumin loaded APNPs could be an innovative treatment for the selective inhibition of osteosarcoma cells.
C1 [Chang, Run; Sun, Linlin; Webster, Thomas J.] Northeastern Univ, Dept Chem Engn, Boston, MA 02115 USA.
   [Webster, Thomas J.] King Abdulaziz Univ, Ctr Excellence Adv Mat Res, Jeddah 21413, Saudi Arabia.
C3 Northeastern University; King Abdulaziz University
RP Webster, TJ (通讯作者)，Northeastern Univ, Dept Chem Engn, 360 Huntington Ave, Boston, MA 02115 USA.
EM th.webster@neu.edu
RI webster, thomas/D 1523 2013; Sun, Linlin/H 3297 2017
FU Northeastern University
FX The authors would like to thank Northeastern University for funding,
   William Fowle for TEM training, and Wenwen (Vivian) Liu for her
   assistance with confocal microscopy.
CR Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506
   Bellamy LJNY., 2013, INFRA RED SPECTRA CO
   Brennan P, 1998, BIOCHEM PHARMACOL, V55, P965, DOI 10.1016/S0006 2952(97)00535 2
   Broadhead Matthew L., 2011, Sarcoma, V2011, P959248, DOI 10.1155/2011/959248
   Chandler D, 2005, NATURE, V437, P640, DOI 10.1038/nature04162
   Chang R, 2014, INT J NANOMED, V9, P461, DOI 10.2147/IJN.S55505
   Chen JX, 2010, ORG BIOMOL CHEM, V8, P3142, DOI 10.1039/c003538f
   Choudhuri T, 2005, J BIOL CHEM, V280, P20059, DOI 10.1074/jbc.M410670200
   Collins HM, 2013, BMC CANCER, V13, DOI 10.1186/1471 2407 13 37
   Cotterill SJ, 2004, PEDIATR BLOOD CANCER, V42, P59, DOI 10.1002/pbc.10437
   DAVID NA, 1972, ANNU REV PHARMACOLOG, V12, P353, DOI 10.1146/annurev.pa.12.040172.002033
   DUTRA FR, 1950, AM J PATHOL, V26, P197
   Fahr A, 2007, EXPERT OPIN DRUG DEL, V4, P403, DOI 10.1517/17425247.4.4.403
   Futaki S, 2013, CURR PHARM DESIGN, V19, P2863
   Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028
   Hanslick JL, 2009, NEUROBIOL DIS, V34, P1, DOI 10.1016/j.nbd.2008.11.006
   Hassenpflug WA, 2007, THROMB RES, V120, pS172, DOI 10.1016/S0049 3848(07)70239 6
   He JP, 2014, ASIAN PAC J CANCER P, V15, P5967, DOI 10.7314/APJCP.2014.15.15.5967
   Javali NM, 2012, PHARM RES DORDR, V29, P3347, DOI 10.1007/s11095 012 0830 5
   Jin H, 2004, BRIT J CANCER, V90, P561, DOI 10.1038/sj.bjc.6601576
   Jin Song, 2009, Orthop Surg, V1, P144, DOI 10.1111/j.1757 7861.2009.00019.x
   Jobin C, 1999, J IMMUNOL, V163, P3474
   Khaw AK, 2013, J CELL BIOCHEM, V114, P1257, DOI 10.1002/jcb.24466
   Kumar A, 2010, CRIT REV THER DRUG, V27, P279, DOI 10.1615/CritRevTherDrugCarrierSyst.v27.i4.10
   Liu EY, 2007, J NEURO ONCOL, V85, P263, DOI 10.1007/s11060 007 9421 4
   Liu S, 2006, MOL PHARMACEUT, V3, P472, DOI 10.1021/mp060049x
   Mohanty C, 2010, BIOMATERIALS, V31, P6597, DOI 10.1016/j.biomaterials.2010.04.062
   NAGARAJAN R, 1991, LANGMUIR, V7, P2934, DOI 10.1021/la00060a012
   Nakase I, 2004, MOL THER, V10, P1011, DOI 10.1016/j.ymthe.2004.08.010
   Nakase I, 2007, BIOCHEMISTRY US, V46, P492, DOI 10.1021/bi0612824
   Notman R, 2006, J AM CHEM SOC, V128, P13982, DOI 10.1021/ja063363t
   Ottaviani G, 2009, CANCER TREAT RES, V152, P421, DOI 10.1007/978 1 4419 0284 9_23
   Pollard T.D., 2008, CELL BIOL, V2nd
   Raj A, 2014, J DRUG TARGET, V22, P518, DOI 10.3109/1061186X.2014.897709
   Ramanathan M, 2013, PHYS CHEM CHEM PHYS, V15, P10580, DOI 10.1039/c3cp50620g
   Rothbard JB, 2002, J MED CHEM, V45, P3612, DOI 10.1021/jm0105676
   Southall NT, 2002, J PHYS CHEM B, V106, P521, DOI 10.1021/jp015514e
   Staudt LM, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000109
   Strimpakos AS, 2008, ANTIOXID REDOX SIGN, V10, P511, DOI 10.1089/ars.2007.1769
   Tonnesen HH, 2002, PHARMAZIE, V57, P820
   Tu RS, 2004, ADV DRUG DELIVER REV, V56, P1537, DOI 10.1016/j.addr.2003.10.047
   WANG ZQ, 1995, CANCER RES, V55, P6244
   Wilken R, 2011, MOL CANCER, V10, DOI 10.1186/1476 4598 10 12
   Williams AC, 2004, ADV DRUG DELIVER REV, V56, P603, DOI 10.1016/j.addr.2003.10.025
   Xu XD, 2012, POLYM CHEM UK, V3, P2479, DOI 10.1039/c2py20299a
   Zhao XB, 2010, CHEM SOC REV, V39, P3480, DOI 10.1039/b915923c
NR 46
TC 35
Z9 40
U1 0
U2 43
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300 008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178 2013
J9 INT J NANOMED
JI Int. J. Nanomed.
PY 2015
VL 10
BP 3351
EP 3365
DI 10.2147/IJN.S78756
PG 15
WC Nanoscience & Nanotechnology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Pharmacology & Pharmacy
GA CH2XQ
UT WOS:000353889000004
PM 26005346
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Akoury, E
   Ahangar, P
   Nour, A
   Lapointe, J
   Guérard, KP
   Haglund, L
   Rosenzweig, DH
   Weber, MH
AF Akoury, Elie
   Ahangar, Pouyan
   Nour, Antone
   Lapointe, Jacques
   Guerard, Karl Philippe
   Haglund, Lisbet
   Rosenzweig, Derek H.
   Weber, Michael H.
TI Low dose zoledronate for the treatment of bone metastasis secondary to
   prostate cancer
SO CANCER CELL INTERNATIONAL
LA English
DT Article
DE Bone metastases secondary to prostate; Zoledronate; Direct in vitro
   treatment; Low doses; Cellular assays
ID BREAST CANCER; LUNG CANCER; PROGNOSTIC FACTORS; ACID; BISPHOSPHONATES;
   CELLS; APOPTOSIS; DELIVERY; DISEASE; OSSEOINTEGRATION
AB BackgroundBisphosphonates (BPs) including zoledronate (zol) have become standard care for bone metastases as they effectively inhibit tumor induced osteolysis and associated pain. Several studies have also suggested that zol has direct anti tumor activity. Systemic administration at high doses is the current approach to deliver zol, yet it has been associated with debilitating side effects. Local therapeutic delivery offers the ability to administer much lower total dosage, while at the same time maintaining sustained high local drug concentration directly at the target treatment site. Here, we aimed to assess effects of lower doses of zol on bone metastases over a longer time.MethodsProstate cancer cell line LAPC4 and prostate induced bone metastasis cells were treated with zol at 1, 3 and 10 mu M for 7days. Following treatment, cell proliferation was assessed using Almarblue((R)), Vybrant MTT (R), and Live/Dead((R)) viability/cytotoxicity assays. Additionally, cell migration and invasion were carried out using Falcon cell culture inserts and Cultrex((R)) 3D spheroid cell invasion assays respectively.ResultsWe show that treatment with 3 10 mu M zol over 7 days significantly decreased cell proliferation in both the prostate cancer cell line LAPC4 and cells from spine metastases secondary to prostate cancer. Using the same low dose and longer time course for treatment, we demonstrate that 10 mu M zol also significantly inhibits tumor cell migration and 3D cell growth/invasion.ConclusionsThis project harnesses the potential of using zol at low doses for longer treatment periods, which may be a viable treatment modality when coupled with biomaterials or biodevices for local delivery.
C1 [Akoury, Elie; Ahangar, Pouyan; Nour, Antone; Haglund, Lisbet; Rosenzweig, Derek H.; Weber, Michael H.] McGill Univ, Dept Surg, Div Orthopaed, Montreal, PQ, Canada.
   [Akoury, Elie; Ahangar, Pouyan; Nour, Antone; Haglund, Lisbet; Rosenzweig, Derek H.; Weber, Michael H.] McGill Univ, Hlth Ctr, Res Inst, Injury Repair Recovery Program, Montreal, PQ, Canada.
   [Lapointe, Jacques; Guerard, Karl Philippe] McGill Univ, Dept Surg, Div Urol, Montreal, PQ, Canada.
   [Lapointe, Jacques; Guerard, Karl Philippe] McGill Univ, Hlth Ctr, Res Inst, Canc Res Program, Montreal, PQ, Canada.
C3 McGill University; McGill University; McGill University; McGill
   University
RP Rosenzweig, DH; Weber, MH (通讯作者)，McGill Univ, Dept Surg, Div Orthopaed, Montreal, PQ, Canada.; Rosenzweig, DH; Weber, MH (通讯作者)，McGill Univ, Hlth Ctr, Res Inst, Injury Repair Recovery Program, Montreal, PQ, Canada.
EM derek.rosenzweig@mcgill.ca; michael.weber@hotmail.com
RI ; Haglund, Lisbet/N 3095 2013
OI Guerard, Karl Philippe/0000 0002 7229 3952; rosenzweig,
   derek/0000 0002 6593 8177; 
FU AO Start Up Grant [S 16 138W]; Research Institute of the McGill
   University Health Centre (RI MUHC); MITACs Accelerate program; RI MUHC
FX This research was funded by AO Start Up Grant Number S 16 138W to MHW,
   and by internal start up funding from the Research Institute of the
   McGill University Health Centre (RI MUHC) to DHR. E.A was supported by
   MITACs Accelerate program and by a postdoctoral fellowship from the
   RI MUHC.
CR Batista N, 2016, J CLIN NEUROSCI, V34, P15, DOI 10.1016/j.jocn.2016.05.023
   Benyettou F, 2017, ACS APPL MATER INTER, V9, P40006, DOI 10.1021/acsami.7b11423
   Berger Walter, 2005, Proceedings of the American Association for Cancer Research Annual Meeting, V46, P1176
   Bobyn JD, 2009, J BONE JOINT SURG AM, V91A, P23, DOI 10.2106/JBJS.I.00518
   Body JJ, 1996, CANCER TREAT REV, V22, P265, DOI 10.1016/S0305 7372(96)90020 1
   Bowden SA, 2017, TRANSL PEDIATR, V6, P256, DOI 10.21037/tp.2017.09.10
   Carteni G, 2006, ONCOLOGIST, V11, P841, DOI 10.1634/theoncologist.11 7 841
   Chaudhari KR, 2012, J CONTROL RELEASE, V158, P470, DOI 10.1016/j.jconrel.2011.11.020
   Clarke MJ, 2017, GLOB SPINE J, V7, P460, DOI 10.1177/2192568217710911
   Coleman RE, 2001, CANCER TREAT REV, V27, P165, DOI 10.1053/ctrv.2000.0210
   Conry RM, 2016, CLIN SARCOMA RES, V6, DOI 10.1186/s13569 016 0046 2
   Di Salvatore M, 2011, CELL PROLIFERAT, V44, P139, DOI 10.1111/j.1365 2184.2011.00745.x
   Drake MT, 2008, MAYO CLIN PROC, V83, P1032, DOI 10.4065/83.9.1032
   Edmondson R, 2014, ASSAY DRUG DEV TECHN, V12, P207, DOI 10.1089/adt.2014.573
   Ferretti G, 2005, ONCOLOGY BASEL, V69, P35, DOI 10.1159/000087286
   Fromigue O, 2000, J BONE MINER RES, V15, P2211, DOI 10.1359/jbmr.2000.15.11.2211
   Härmä V, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010431
   Ibrahim A, 2003, CLIN CANCER RES, V9, P2394
   Insalaco L, 2012, J CELL MOL MED, V16, P2186, DOI 10.1111/j.1582 4934.2012.01527.x
   Ishiguro T, 2017, CANCER SCI, V108, P283, DOI 10.1111/cas.13155
   Jagdev SP, 2001, BRIT J CANCER, V84, P1126, DOI 10.1054/bjoc.2001.1727
   Kellesarian SV, 2017, ACTA ODONTOL SCAND, V75, P530, DOI 10.1080/00016357.2017.1350994
   Kim EH, 2016, ONCOTARGET, V7, P70869, DOI 10.18632/oncotarget.12281
   Kiper HD, 2013, BIOMED PHARMACOTHER, V67, P527, DOI 10.1016/j.biopha.2013.04.006
   Klein KA, 1997, NAT MED, V3, P402, DOI 10.1038/nm0497 402
   Koto K, 2017, ONCOL LETT, V14, P1648, DOI 10.3892/ol.2017.6355
   Lacerna L, 2003, SEMIN ONCOL, V30, P150, DOI 10.1053/j.seminoncol.2003.08.017
   Lin CF, 2016, CYTOTECHNOLOGY, V68, P1233, DOI 10.1007/s10616 015 9884 7
   Lin JH, 1996, BONE, V18, P75, DOI 10.1016/8756 3282(95)00445 9
   Lu Y, 2018, MAT SCI ENG C MATER, V82, P225, DOI 10.1016/j.msec.2017.08.043
   Macedo F, 2017, ONCOL REV, V11, P43, DOI 10.4081/oncol.2017.321
   Maisano R, 2001, CRIT REV ONCOL HEMAT, V40, P239, DOI 10.1016/S1040 8428(01)00092 0
   Matsumoto S, 2005, LUNG CANCER, V47, P31, DOI 10.1016/j.lungcan.2004.06.003
   Miettinen SSA, 2009, J ORTHOP SCI, V14, P431, DOI 10.1007/s00776 009 1352 9
   Muschitz C, 2017, WIEN MED WOCHENSCHR, V167, P18, DOI 10.1007/s10354 016 0502 x
   Nogués X, 2018, MED CLIN BARCELONA, V150, P479, DOI 10.1016/j.medcli.2017.10.019
   Nooh A, 2017, J BONE ONCOL, V6, P8, DOI 10.1016/j.jbo.2017.01.001
   Cattalini J, 2012, TISSUE ENG PART B RE, V18, P323, DOI 10.1089/ten.teb.2011.0737
   Reuben JS, 2011, ORAL SURG ORAL MED O, V111, P196, DOI 10.1016/j.tripleo.2010.09.068
   Rosen LS, 2003, J CLIN ONCOL, V21, P3150, DOI 10.1200/JCO.2003.04.105
   Rosenzweig DH, 2012, OSTEOARTHR CARTILAGE, V20, P1591, DOI 10.1016/j.joca.2012.08.012
   Rosenzweig DH, 2015, INT J MOL SCI, V16, P15118, DOI 10.3390/ijms160715118
   Saad F, 2002, JNCI J NATL CANCER I, V94, P1458, DOI 10.1093/jnci/94.19.1458
   Sciubba DM, 2016, GLOB SPINE J, V6, P482, DOI 10.1055/s 0035 1564807
   Selvaggi G, 2005, CRIT REV ONCOL HEMAT, V56, P365, DOI 10.1016/j.critrevonc.2005.03.011
   Senaratne SG, 2000, BRIT J CANCER, V82, P1459, DOI 10.1054/bjoc.1999.1131
   Sörensen TC, 2013, J PHARM PHARMACOL, V65, P201, DOI 10.1111/j.2042 7158.2012.01588.x
   Tassone P, 2003, BRIT J CANCER, V88, P1971, DOI 10.1038/sj.bjc.6600986
   Trautner BW, 2004, ARCH INTERN MED, V164, P842, DOI 10.1001/archinte.164.8.842
   Verron E, 2014, ACTA BIOMATER, V10, P4887, DOI 10.1016/j.actbio.2014.07.012
   Wood J, 2002, J PHARMACOL EXP THER, V302, P1055, DOI 10.1124/jpet.102.035295
   Wu CC, 2012, BIOMED MATER, V7, DOI 10.1088/1748 6041/7/3/035009
   Yamazaki D, 2005, CANCER SCI, V96, P379, DOI 10.1111/j.1349 7006.2005.00062.x
   Zhang W, 2010, CLIN CANCER RES, V16, P3420, DOI 10.1158/1078 0432.CCR 09 2904
NR 54
TC 14
Z9 16
U1 0
U2 15
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1475 2867
J9 CANCER CELL INT
JI Cancer Cell Int.
PD FEB 8
PY 2019
VL 19
AR 28
DI 10.1186/s12935 019 0745 x
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA HK8CJ
UT WOS:000458216700001
PM 30787671
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Huo, YQ
   Pan, XH
   Wang, XQ
   Jiao, XJ
   Li, ZQ
   Li, QB
AF Huo, Yan Qing
   Pan, Xiao Han
   Wang, Xi Qian
   Jiao, Xie Jia
   Li, Zhi Qiang
   Li, Qing Bo
TI Effect of PI3K mediated autophagy in human osteosarcoma MG63 cells on
   sensitivity to chemotherapy with Gefitinib
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE
LA English
DT Article
DE Osteosarcoma; autophagy; PI3K; Bcl 2; Beclin 1; LC 3
ID PI3K/AKT SIGNALING PATHWAY; CANCER CELLS; APOPTOSIS; PROLIFERATION;
   MODEL; ACTIVATION
AB Background: Osteosarcoma is one of the most common malignant bone tumor in adolescent. With high malignant degree and poorer prognosis, osteosarcoma seriously influences the prognostic survival of patients. Autophagy which is relatively conservative, is the main means of degrading autologous organelles or proteins in the evolutionary of eukaryocyte, regulating and controlling the cell proliferation and function. Objective: To explore the effect of PI3K mediated autophagy in human osteosarcoma MG63 cells on sensitivity to chemotherapy with Gefitinib. Methods: MTT and flow cytometry were employed to measure cell proliferation and cell apoptosis of human osteosarcoma MG63 cells treated with Gefitinib combined with autophagy inhibitor 3 methyladenine (3 MA), autophagy promoter rapamycin, PI3K inhibitor LY294002. The expression of intracellular protein and its total mRNA was detected by Western blot and RT PCR after different drugs treated on MG63 cells. Results and conclusion: Western blot showed that basic autophagy level of MG63 cells was significantly lower than that of osteoblast hFOB cells. MTT, western blot and RT PCR analysis revealed that the cell proliferation inhibition rate of MG63 cells treated with Gefitinib combined with 3 MA, RAPA, LY294002 were significantly inhibited. Besides, the expressions of autophagy associated proteins and total mRNA in human osteosarcoma cells were enhanced. In addition, the result of flow cytometry demonstrated that Gefitinib alone or combined with other drugs could increase the cell numbers in G1 phase and reduce the cell numbers in S phase. Taken together, our data showed that upregulating the autophagy significantly reduced the sensitivity of MG63 cells to chemotherapy with DDP and DDP induced autophagy of MG63 cells by blocking the cell cycle at G1 phase.
C1 [Huo, Yan Qing; Pan, Xiao Han; Wang, Xi Qian; Jiao, Xie Jia; Li, Zhi Qiang; Li, Qing Bo] Shandong Univ, Dept Orthoped, Hosp 2, Jinan 250033, Shandong, Peoples R China.
C3 Shandong University
RP Li, QB (通讯作者)，Shandong Univ, Hosp 2, 247 Beiyuan St, Jinan 250033, Shandong, Peoples R China.
EM liqingbo8889@sina.com
RI Pan, Xiaohan/KQU 9542 2024; Li, Zhiqiang/O 6657 2018
CR Akin D, 2014, AUTOPHAGY, V10, P2021, DOI 10.4161/auto.32229
   Cai H, 2015, CELL PHYSIOL BIOCHEM, V35, P1689, DOI 10.1159/000373982
   Cao JP, 2015, J ZHEJIANG U MED SCI, V3, P204
   Chen J, 2014, J CANCER RES CLIN, V140, P1205, DOI 10.1007/s00432 014 1644 0
   [程尼涛 Cheng Nitao], 2015, [基础医学与临床, Basic & Clinical Medicine], V35, P401
   Deng SJ, 2015, FOOD CHEM TOXICOL, V75, P173, DOI 10.1016/j.fct.2014.11.019
   [杜海磊 DU Hai lei], 2010, [中国病理生理杂志, Chinese Journal of Pathophysiology], V26, P401
   Grignani G, 2015, LANCET ONCOL, V16, P98, DOI 10.1016/S1470 2045(14)71136 2
   Guglielmotto M, 2014, AUTOPHAGY, V10, P1827, DOI 10.4161/auto.30001
   Hu D, 2014, VACCINE, V32, P2308, DOI 10.1016/j.vaccine.2014.02.069
   Huang AC, 2013, INT J ONCOL, V43, P485, DOI 10.3892/ijo.2013.1952
   Jiang LL, 2015, ONCOTARGET, V6, P8286, DOI 10.18632/oncotarget.3221
   Jin H, 2015, ONCOL REP, V34, P2782, DOI 10.3892/or.2015.4258
   Kong GB, 2015, TUMOR BIOL, V36, P7735, DOI 10.1007/s13277 015 3512 1
   Li D, 2015, SHANDONG MED J, V55, P106
   Li GD, 2009, CANCER, V28, P445
   Li HY, 2015, ANIMAL HUSBANDRY VET, V47, P143
   Li J, 2014, INT J GYNECOL CANCER, V24, P437, DOI 10.1097/IGC.0000000000000065
   Martinez J, 2015, NAT CELL BIOL, V17, P893, DOI 10.1038/ncb3192
   Mu YL, 2015, J MED RES, V44, P16
   Nataraj V, 2015, J SURG ONCOL, V112, P662, DOI 10.1002/jso.24045
   [祁伟祥 Qi Weixiang], 2011, [肿瘤, Tumor], V31, P846
   Ruan RQ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125746
   Shen C., 2015, INT J CLIN EXP MED, V1852, P310
   Shen C, 2015, APOPTOSIS, V20, P1176, DOI 10.1007/s10495 015 1146 9
   Shimose S, 2014, J ORTHOP SCI, V19, P997, DOI 10.1007/s00776 014 0617 0
   Shrivastava S, 2015, EXP MOL PATHOL, V98, P313, DOI 10.1016/j.yexmp.2015.03.031
   Song HJ, 2015, TUMOR BIOL, V36, P6773, DOI 10.1007/s13277 015 3405 3
   Tang Jin long, 2012, Chinese Journal of Pathology, V41, P573, DOI 10.3760/cma.j.issn.0529 5807.2012.08.018
   Tang XL, 2015, EUR J CELL BIOL, V94, P223, DOI 10.1016/j.ejcb.2015.03.003
   Tian PG, 2015, BIOCHEM BIOPH RES CO, V463, P518, DOI 10.1016/j.bbrc.2015.05.061
   [王彬彬 Wang Binbin], 2015, [中国肿瘤临床, Chinese Journal of Clinical Oncology], V42, P446
   Wilkinson DS, 2015, AUTOPHAGY, V11, P856, DOI 10.1080/15548627.2015.1017197
   Ye LX, 2014, ATHEROSCLEROSIS, V237, P146, DOI 10.1016/j.atherosclerosis.2014.08.052
   Zhang LH, 2013, CHINESE J LAB DIAGNO, V17, P100
   Zhou Y, 2015, INT J GYNECOL CANCER, V25, P380
   Zhou Y, 2013, CHINESE J BIOCH PHAR, V1, P57
NR 37
TC 1
Z9 1
U1 0
U2 13
PU E CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1940 5901
J9 INT J CLIN EXP MED
JI Int. J. Clin. Exp. Med.
PY 2017
VL 10
IS 1
BP 944
EP 950
PG 7
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA EO2CE
UT WOS:000396503400104
DA 2025 08 17
ER

PT J
AU Cipriani, C
   Pepe, J
   Clementelli, C
   Manai, R
   Colangelo, L
   Fassino, V
   Nieddu, L
   Minisola, S
AF Cipriani, Cristiana
   Pepe, Jessica
   Clementelli, Carolina
   Manai, Rizieri
   Colangelo, Luciano
   Fassino, Valeria
   Nieddu, Luciano
   Minisola, Salvatore
TI Effect of a single intravenous zoledronic acid administration on
   biomarkers of acute kidney injury (AKI) in patients with osteoporosis: a
   pilot study
SO BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
LA English
DT Article
DE acute kidney injury; osteoporosis; renal failure; zoledronic acid
ID GELATINASE ASSOCIATED LIPOCALIN; CONCISE GUIDE; MOLECULE 1 KIM 1;
   PHARMACOLOGY; WOMEN; TERM; BISPHOSPHONATES; IBANDRONATE; DIAGNOSIS;
   EFFICACY
AB AIMS
   The pilot study was designed to evaluate the early effect of intravenous (i.v.) zoledronic acid (ZA) on renal function.
   METHODS
   Five mg i.v. ZA was administered to 23 patients with osteoporosis (17 women and 6 men, mean age 73 7 SD years). Urinary NGAL, KIM 1, and MCP 1, plasma (p) MCP 1 and serum (s) IL 18, serum calcium (sCa), Creatinine clearance (CrCl), parathyroid hormone (PTH), plasma C terminal FGF23 (pFGF23), serum (s) Klotho, calcium excretion (CaEx) and renal threshold phosphate concentration/GFR (TmPO4/GFR) were assessed at baseline, 24h and Day 30 after administration.
   RESULTS
   There was a significant decrease in sCa and CaEx at 24h ( 4.1 +/  2.8%, P<0.01 and  28 +/  59%, P<0.05, respectively) and Day 30 ( 3.9 +/  4%, P<0.001 and  26 +/  43%, P<0.01) and a significant increase in PTH (79.8 +/  95.8%) at Day 30 (P<0.001) compared to baseline. TmPO4/GFR decreased significantly at 24h and Day 30 ( 8.6 +/  15.9%, P<0.05 and  11.3 +/  13.5%, P<0.001) compared to baseline. We observed no difference in the concentration of pFGF23, sKlotho and urinary AKI biomarkers at any time points. Mean levels of sIL 18 and pMCP 1 increased significantly at 24h (44 +/  88%; P<0.01 and 198 +/  237%; P<0.001) and returned to baseline at Day 30.
   CONCLUSIONS
   Our pilot study suggests that there is no direct acute effect of ZA on kidney function. The increase in plasma MCP 1 and serum IL 18 concentration could be associated with the stimulation of immunity mechanisms occurring soon after the administration of the drug. Secondary hyperparathyroidism develops shortly after the infusion of ZA and is maintained even after 1 month.
C1 [Cipriani, Cristiana; Pepe, Jessica; Clementelli, Carolina; Manai, Rizieri; Colangelo, Luciano; Fassino, Valeria; Minisola, Salvatore] Sapienza Univ Rome, Dept Internal Med & Med Disciplines, Viale Policlin 155, I 00161 Rome, Italy.
   [Nieddu, Luciano] UNINT Univ, Fac Econ, Via Cristoforo Colombo 200, I 00147 Rome, Italy.
C3 Sapienza University Rome
RP Cipriani, C (通讯作者)，Sapienza Univ Rome, Dept Internal Med & Med Disciplines, Viale Policlin 155, I 00161 Rome, Italy.
EM cristiana.cipriani@gmail.com
RI ; Cipriani, Cristiana/K 9497 2016; Nieddu, Luciano/AAX 5455 2020;
   COLANGELO, LUCIANO/ABA 9338 2022
OI COLANGELO, LUCIANO/0000 0002 5835 9310; Cipriani,
   Cristiana/0000 0002 0141 1202; Nieddu, Luciano/0000 0001 5174 3347; 
FU 'Sapienza' University of Rome
FX The project was funded by the 'Sapienza' University of Rome 2013
   Research Grant.
CR Alexander SPH, 2015, BRIT J PHARMACOL, V172, P5744, DOI 10.1111/bph.13348
   Alexander SPH, 2015, BRIT J PHARMACOL, V172, P5979, DOI 10.1111/bph.13353
   Alexander SPH, 2015, BRIT J PHARMACOL, V172, P5729, DOI 10.1111/bph.13347
   Alge JL, 2015, CLIN J AM SOC NEPHRO, V10, P147, DOI 10.2215/CJN.12191213
   Alzawawy A, 2009, INT J RHEUM DIS, V12, P311, DOI 10.1111/j.1756 185X.2009.01429.x
   [Anonymous], KIDNEY INT S
   Bellomo R, 2012, LANCET, V380, P756, DOI 10.1016/S0140 6736(11)61454 2
   Black DM, 2015, J BONE MINER RES, V30, P934, DOI 10.1002/jbmr.2442
   Black DM, 2010, NEW ENGL J MED, V362, P1761, DOI 10.1056/NEJMoa1001086
   BLACK DM, 2007, NEW ENGL J MED, V356, P1809, DOI DOI 10.1056/NEJMOA067312
   Boonen S, 2008, KIDNEY INT, V74, P641, DOI 10.1038/ki.2008.193
   Chalikias G, 2016, CARDIOVASC DRUG THER, V30, P515, DOI 10.1007/s10557 016 6683 0
   Christov M, 2014, CURR OPIN NEPHROL HY, V23, P340, DOI 10.1097/01.mnh.0000447021.51722.2f
   Cipriani C, 2015, INTERN EMERG MED, V10, P151, DOI 10.1007/s11739 014 1125 0
   Cipriani C, 2013, J CLIN ENDOCR METAB, V98, P2709, DOI 10.1210/jc.2013 1586
   Deshmane SL, 2009, J INTERF CYTOK RES, V29, P313, DOI 10.1089/jir.2008.0027
   Doi K, 2016, J INTENSIVE CARE, V4, DOI 10.1186/s40560 016 0146 3
   Edelstein CL, 2008, ADV CHRONIC KIDNEY D, V15, P222, DOI 10.1053/j.ackd.2008.04.003
   Ensrud KE, 2004, J BONE MINER RES, V19, P1259, DOI 10.1359/JBMR.040326
   Gonnelli S, 2014, BONE, V61, P27, DOI 10.1016/j.bone.2013.12.017
   Gracie JA, 2003, J LEUKOCYTE BIOL, V73, P213, DOI 10.1189/jlb.0602313
   Granata F, 2006, EUR J IMMUNOL, V36, P1938, DOI 10.1002/eji.200535567
   Greenspan SL, 2015, JAMA INTERN MED, V175, P913, DOI 10.1001/jamainternmed.2015.0747
   Haase Fielitz A, 2014, ANN CLIN BIOCHEM, V51, P335, DOI 10.1177/0004563214521795
   Han WK, 2002, KIDNEY INT, V62, P237, DOI 10.1046/j.1523 1755.2002.00433.x
   Hu MC, 2010, J NEPHROL, V23, pS136
   Hu MC, 2010, KIDNEY INT, V78, P1240, DOI 10.1038/ki.2010.328
   Huang Yun, 2011, Inflammation & Allergy Drug Targets, V10, P260
   Kassi G, 2014, IMMUNOL INVEST, V43, P544, DOI 10.3109/08820139.2014.892510
   Khosla S, 2012, J CLIN ENDOCR METAB, V97, P2272, DOI 10.1210/jc.2012 1027
   Lichosik M, 2015, CENT EUR J IMMUNOL, V40, P447, DOI 10.5114/ceji.2015.56967
   Luedders DW, 2015, ANTICANCER RES, V35, P1797
   Metzger J, 2010, KIDNEY INT, V78, P1252, DOI 10.1038/ki.2010.322
   Mishra J, 2003, J AM SOC NEPHROL, V14, P2534, DOI 10.1097/01.ASN.0000088027.54400.C6
   Mori K, 2005, J CLIN INVEST, V115, P610, DOI 10.1172/JCI200523056
   Munshi R, 2011, J AM SOC NEPHROL, V22, P165, DOI 10.1681/ASN.2010060641
   Nozaki Y, 2014, LUPUS, V23, P769, DOI 10.1177/0961203314526292
   Pierson Marchandise M, 2017, BRIT J CLIN PHARMACO, V83, P1341, DOI 10.1111/bcp.13216
   Reid IR, 2015, J INTERN MED, V277, P690, DOI 10.1111/joim.12339
   Reid IR, 2015, NAT REV ENDOCRINOL, V11, P418, DOI 10.1038/nrendo.2015.71
   Roelofs AJ, 2009, BRIT J HAEMATOL, V144, P245, DOI 10.1111/j.1365 2141.2008.07435.x
   Southan C, 2016, NUCLEIC ACIDS RES, V44, pD1054, DOI 10.1093/nar/gkv1037
   Srisawat N, 2011, CLIN J AM SOC NEPHRO, V6, P1815, DOI 10.2215/CJN.11261210
   Waikar SS, 2008, CLIN J AM SOC NEPHRO, V3, P844, DOI 10.2215/CJN.05191107
   WALTON RJ, 1975, LANCET, V2, P309, DOI 10.1016/S0140 6736(75)92736 1
   Yi B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099633
NR 46
TC 12
Z9 13
U1 0
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0306 5251
EI 1365 2125
J9 BRIT J CLIN PHARMACO
JI Br. J. Clin. Pharmacol.
PD OCT
PY 2017
VL 83
IS 10
BP 2266
EP 2273
DI 10.1111/bcp.13332
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA FG8ZD
UT WOS:000410726700015
PM 28543687
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Afzal, M
   Kazmi, I
   Al Abbasi, FA
   Alshehri, S
   Ghoneim, MM
   Imam, SS
   Nadeem, MS
   Al Zahrani, MH
   Alzarea, SI
   Alquraini, A
AF Afzal, Muhammad
   Kazmi, Imran
   Al Abbasi, Fahad A.
   Alshehri, Sultan
   Ghoneim, Mohammed M.
   Imam, Syed Sarim
   Nadeem, Muhammad Shahid
   Al Zahrani, Maryam Hassan
   Alzarea, Sami I.
   Alquraini, Ali
TI Current Overview on Therapeutic Potential of Vitamin D in Inflammatory
   Lung Diseases
SO BIOMEDICINES
LA English
DT Article
DE inflammatory lung disorders; cholecalciferol; mechanism; metabolic
   pathways; treatment
ID OBSTRUCTIVE PULMONARY DISEASE; D DEFICIENCY; CYSTIC FIBROSIS; D
   SUPPLEMENTATION; PARATHYROID HORMONE; FUNCTION DECLINE; FOLLOW UP;
   ADULTS; ASTHMA; IMPACT
AB Inflammatory lung disorders (ILDs) are one of the world's major reasons for fatalities and sickness, impacting millions of individuals of all ages and constituting a severe and pervasive health hazard. Asthma, lung cancer, bronchiectasis, pulmonary fibrosis acute respiratory distress syndrome, and COPD all include inflammation as a significant component. Microbe invasions, as well as the damage and even death of host cells, can cause and sustain inflammation. To counteract the negative consequences of irritants, the airways are equipped with cellular and host defense immunological systems that block the cellular entrance of these irritants or eliminate them from airway regions by triggering the immune system. Failure to activate the host defense system will trigger chronic inflammatory cataracts, leading to permanent lung damage. This damage makes the lungs more susceptible to various respiratory diseases. There are certain restrictions of the available therapy for lung illnesses. Vitamins are nutritional molecules that are required for optimal health but are not produced by the human body. Cholecalciferol (Vitamin D) is classified as a vitamin, although it is a hormone. Vitamin D is thought to perform a function in bone and calcium homeostasis. Recent research has found that vitamin D can perform a variety of cellular processes, including cellular proliferation; differentiation; wound repair; healing; and regulatory systems, such as the immune response, immunological, and inflammation. The actions of vitamin D on inflammatory cells are dissected in this review, as well as their clinical significance in respiratory illnesses.
C1 [Afzal, Muhammad; Alzarea, Sami I.] Jouf Univ, Coll Pharm, Dept Pharmacol, Sakaka 72341, Saudi Arabia.
   [Kazmi, Imran; Al Abbasi, Fahad A.; Nadeem, Muhammad Shahid; Al Zahrani, Maryam Hassan] King Abdulaziz Univ, Fac Sci, Dept Biochem, Jeddah 21589, Saudi Arabia.
   [Alshehri, Sultan; Imam, Syed Sarim] King Saud Univ, Coll Pharm, Dept Pharmaceut, Riyadh 11451, Saudi Arabia.
   [Ghoneim, Mohammed M.] AlMaarefa Univ, Coll Pharm, Dept Pharm Practice, Ad Diriyah 13713, Saudi Arabia.
   [Alquraini, Ali] Al Baha Univ, Fac Clin Pharm, Dept Pharmaceut Chem, Al Baha 65779, Saudi Arabia.
C3 Al Jouf University; King Abdulaziz University; King Saud University;
   Almaarefa University; Al Baha University
RP Kazmi, I (通讯作者)，King Abdulaziz Univ, Fac Sci, Dept Biochem, Jeddah 21589, Saudi Arabia.
EM afzalgufran@ju.edu.sa; ikazmi@kau.edu.sa; fabbasi@kau.edu.sa;
   salshehri1@ksu.edu.sa; mghoneim@mcst.edu.sa; simam@ksu.edu.sa;
   mhalim@kau.edu.sa; mhsalzahrani@kau.sdu.sa; samisz@ju.edu.sa;
   aalquraini@bu.edu.sa
RI Nadeem, Muhammad/H 2372 2017; Imam, Syed/Z 3769 2019; Alquraini,
   Ali/GRF 3311 2022; Afzal, Muhammad/I 6313 2019; Al Abbasi,
   Fahad/GQP 6183 2022; Alanazi, Saleh/HKN 9388 2023; Nadeem, Muhammad
   Shahid/H 2372 2017; Ghoneim, Mohammed/ABE 7965 2021; Kazmi,
   Imran/GRJ 9647 2022; Alzarea, Sami/GQH 7031 2022
OI , Sultan/0000 0002 0922 9819; Kazmi, Imran/0000 0003 1881 5219;
   Alquraini, Ali/0000 0003 4216 572X; Afzal, Muhammad/0000 0003 2570 3223;
   Nadeem, Muhammad Shahid/0000 0003 4112 0925; Ghoneim,
   Mohammed/0000 0002 9179 4373; Imam, Syed Sarim/0000 0002 8913 0826; 
FU Deanship of Scientific Research at Jouf University, Saudi Arabia
   [DSR 2021 01 0314]
FX FundingThis work was funded by the Deanship of Scientific Research at
   Jouf University, Saudi Arabia, under grant No (DSR 2021 01 0314).
CR Abrishami A, 2021, EUR J NUTR, V60, P2249, DOI 10.1007/s00394 020 02411 0
   Ahmad S, 2021, J NUTR BIOCHEM, V90, DOI 10.1016/j.jnutbio.2020.108571
   Akiba T, 2018, CLIN CANCER RES, V24, P4089, DOI 10.1158/1078 0432.CCR 18 0483
   Al Beltagi M, 2020, PEDIATR PULM, V55, P108, DOI 10.1002/ppul.24552
   Alexander J, 2020, NUTRIENTS, V12, DOI 10.3390/nu12082358
   Alvarez JA, 2017, METABOLISM, V70, P31, DOI 10.1016/j.metabol.2017.02.006
   [Anonymous]
   Bae M, 2020, MOLECULES, V25, DOI 10.3390/molecules25225346
   Bergman P, 2021, J INTERN MED, V289, P131, DOI 10.1111/joim.13158
   Bilezikian JP, 2020, EUR J ENDOCRINOL, V183, pR133, DOI 10.1530/EJE 20 0665
   Brehm JM, 2014, CURR ALLERGY ASTHM R, V14, DOI 10.1007/s11882 014 0461 5
   Brumpton BM, 2016, AM J EPIDEMIOL, V183, P739, DOI 10.1093/aje/kwv243
   Cannell JJ, 2006, EPIDEMIOL INFECT, V134, P1129, DOI 10.1017/S0950268806007175
   Cantorna MT, 2016, INFECT IMMUN, V84, P3094, DOI 10.1128/IAI.00679 16
   Cazzola M, 2012, PHARMACOL REV, V64, P450, DOI 10.1124/pr.111.004580
   Cepeda J, 2019, REV CHIL PEDIATR CHI, V90, DOI 10.32641/rchped.v90i1.747
   Chen FY, 2019, EUR REV MED PHARMACO, V23, P8637, DOI 10.26355/eurrev_201910_19181
   Chen L, 2016, RESP RES, V17, DOI 10.1186/s12931 016 0362 3
   Chesdachai S, 2016, J STEROID BIOCHEM, V164, P36, DOI 10.1016/j.jsbmb.2015.09.013
   Chishimba L, 2010, THORAX, V65, P456, DOI 10.1136/thx.2009.128793
   Dancer RCA, 2015, THORAX, V70, P617, DOI 10.1136/thoraxjnl 2014 206680
   Dinour D, 2015, PEDIATR NEPHROL, V30, P145, DOI 10.1007/s00467 014 2889 1
   Dixit Deepali, 2016, P T, V41, P703
   Drent M, 2018, CURR OPIN PULM MED, V24, P287, DOI [10.1097/MCP.0000000000000467, 10.1097/mcp.0000000000000467]
   Balcells ME, 2019, MICROB PATHOGENESIS, V131, P158, DOI 10.1016/j.micpath.2019.03.041
   Castillo ME, 2020, J STEROID BIOCHEM, V203, DOI 10.1016/j.jsbmb.2020.105751
   Evans JR, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000253.pub4
   Foong RE, 2013, NUTRIENTS, V5, P2880, DOI 10.3390/nu5082880
   Ford ES, 2004, DIABETES CARE, V27, P2966, DOI 10.2337/diacare.27.12.2966
   Forno E, 2020, JAMA J AM MED ASSOC, V324, P752, DOI 10.1001/jama.2020.12384
   Foumani AA, 2019, INT J CHRONIC OBSTR, V14, P1495, DOI 10.2147/COPD.S207400
   Gabaj NN, 2020, BIOCHEM MEDICA, V30, DOI 10.11613/BM.2020.020501
   Gallelli L, 2020, J CLIN PHARMACOL, V60, P815, DOI 10.1002/jcph.1644
   Ganji V, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 67967 7
   Gao YJ, 2020, AGING US, V12, P4371, DOI 10.18632/aging.102890
   Gnagnarella P, 2020, ADV EXP MED BIOL, V1268, P53, DOI 10.1007/978 3 030 46227 7_4
   Jiménez DG, 2015, NUTR HOSP, V32, P1629, DOI 10.3305/nh.2015.32.4.9503
   Grant WB, 2020, NUTRIENTS, V12, DOI 10.3390/nu12040988
   Greenwald P, 2007, AM J CLIN NUTR, V85, p314S, DOI 10.1093/ajcn/85.1.314S
   Grossmann RE, 2012, EUR J CLIN NUTR, V66, P1072, DOI 10.1038/ejcn.2012.82
   Guijarro T, 2018, MOL MED, V24, DOI 10.1186/s10020 018 0064 z
   Hall SC, 2017, CLIN THER, V39, P917, DOI 10.1016/j.clinthera.2017.04.002
   Han H, 2021, AM J RESP CELL MOL, V64, P357, DOI 10.1165/rcmb.2020 0086OC
   Hansdottir S, 2011, VITAM HORM, V86, P217, DOI 10.1016/B978 0 12 386960 9.00009 5
   Herr C, 2011, RESP RES, V12, DOI 10.1186/1465 9921 12 31
   Hoffer LJ, 2016, NUTR J, V15, DOI 10.1186/s12937 016 0203 8
   Hoong CWS, 2020, HORM METAB RES, V52, P775, DOI 10.1055/a 1243 5462
   Hoyt M, 2019, AM J CLIN NUTR, V109, P392, DOI 10.1093/ajcn/nqy251
   Iqbal SF, 2011, J INVEST MED, V59, P1200, DOI 10.2130/JIM.0b013e31823279f0
   JACOBUS CH, 1992, NEW ENGL J MED, V326, P1173, DOI 10.1056/NEJM199204303261801
   Jain SK, 2020, J AM COLL NUTR, V39, P694, DOI 10.1080/07315724.2020.1789518
   Jakovac H, 2020, AM J PHYSIOL ENDOC M, V318, pE589, DOI 10.1152/ajpendo.00138.2020
   Jolliffe DA, 2019, THORAX, V74, P337, DOI 10.1136/thoraxjnl 2018 212092
   Jovic TH, 2020, NUTRIENTS, V12, DOI 10.3390/nu12092550
   Kho AT, 2013, BMC MED GENOMICS, V6, DOI 10.1186/1755 8794 6 47
   Kloc M, 2021, CELL IMMUNOL, V360, DOI 10.1016/j.cellimm.2020.104259
   Konstantinopoulou S, 2017, PAEDIATR RESPIR REV, V24, P39, DOI 10.1016/j.prrv.2016.10.009
   Kose M, 2017, PEDIATR PULM, V52, P69, DOI 10.1002/ppul.23500
   Kumar R, 2021, VIRUS RES, V292, DOI [10.1016/j.viruses.2020.198235, 10.1016/j.virusres.2020.198235]
   Lee J, 2021, EUR J CLIN NUTR, V75, P501, DOI 10.1038/s41430 020 00748 7
   Li XY, 2020, ANN PALLIAT MED, V9, P286, DOI 10.21037/apm.2020.02.26
   Litonjua AA, 2020, NEW ENGL J MED, V382, P525, DOI 10.1056/NEJMoa1906137
   Litonjua AA, 2016, JAMA J AM MED ASSOC, V315, P362, DOI 10.1001/jama.2015.18589
   Loukou I, 2020, PEDIATR PULM, V55, P1375, DOI 10.1002/ppul.24460
   Loukou I, 2015, MINI REV MED CHEM, V15, P974, DOI 10.2174/138955751512150731111529
   Lykkedegn S, 2015, AM J PHYSIOL LUNG C, V308, pL587, DOI 10.1152/ajplung.00117.2014
   Mak G, 2011, CURR OPIN PULM MED, V17, P1, DOI 10.1097/MCP.0b013e3283411440
   Manavi KR, 2020, INT J VITAM NUTR RES, V90, P389, DOI 10.1024/0300 9831/a000640
   Mandell EW, 2020, AM J RESP CELL MOL, V63, P79, DOI 10.1165/rcmb.2019 0295OC
   Maretzke F, 2020, NUTRIENTS, V12, DOI 10.3390/nu12040969
   Giménez VMM, 2020, LIFE SCI, V254, DOI 10.1016/j.lfs.2020.117808
   Martineau AR, 2019, HEALTH TECHNOL ASSES, V23, P1, DOI 10.3310/hta23020
   Marzetti E, 2013, INT J BIOCHEM CELL B, V45, P2288, DOI 10.1016/j.biocel.2013.06.024
   McGlade JP, 2007, CLIN EXP ALLERGY, V37, P1267, DOI 10.1111/j.1365 2222.2007.02750.x
   Mercola J, 2020, NUTRIENTS, V12, DOI 10.3390/nu12113361
   Mirzakhani H, 2016, J CLIN INVEST, V126, P4702, DOI 10.1172/JCI89031
   Mitchell F, 2020, LANCET DIABETES ENDO, V8, P570, DOI 10.1016/S2213 8587(20)30183 2
   Mohan M, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008874
   MUDDE AH, 1987, CANCER AM CANCER SOC, V59, P1543, DOI 10.1002/1097 0142(19870501)59:9<1543::AID CNCR2820590902>3.0.CO;2 L
   Norton R, 2012, ANTICANCER RES, V32, P211
   Oliveira MS, 2019, PEDIATR PULM, V54, P563, DOI 10.1002/ppul.24260
   Ong JS, 2018, HUM MOL GENET, V27, P4315, DOI 10.1093/hmg/ddy307
   Panahi Y, 2016, CURR PHARM DESIGN, V22, P164, DOI 10.2174/1381612822666151112145226
   Pelaia G, 2004, J CELL BIOCHEM, V93, P142, DOI 10.1002/jcb.20124
   Pelaia G, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/879783
   Pfeffer PE, 2012, THORAX, V67, P1018, DOI 10.1136/thoraxjnl 2012 202139
   Pincikova T, 2017, CLIN EXP IMMUNOL, V189, P359, DOI 10.1111/cei.12984
   Rafiq R, 2017, INT J CHRONIC OBSTR, V12, P2583, DOI 10.2147/COPD.S132117
   Ramnath N, 2011, EXPERT REV RESP MED, V5, P305, DOI [10.1586/ERS.11.31, 10.1586/ers.11.31]
   Richart T, 2011, AM J HYPERTENS, V24, P102, DOI 10.1038/ajh.2010.124
   Royce SG, 2014, PHARMACOL THERAPEUT, V141, P250, DOI 10.1016/j.pharmthera.2013.10.008
   Rozmus D, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21217822
   RUDNICKI M, 1993, J INTERN MED, V234, P195, DOI 10.1111/j.1365 2796.1993.tb00730.x
   Samefors M, 2014, EUR J ENDOCRINOL, V170, P667, DOI 10.1530/EJE 13 0855
   Schapochnik A, 2018, TOXICOL APPL PHARM, V355, P60, DOI 10.1016/j.taap.2018.06.020
   Schrumpf JA, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01433
   Schwalfenberg GK, 2011, MOL NUTR FOOD RES, V55, P96, DOI 10.1002/mnfr.201000174
   Shojaeefar E, 2021, CELL BIOL INT, V45, P54, DOI 10.1002/cbin.11469
   Soe HHK, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010858.pub2
   Solidoro Paolo, 2016, Minerva Med, V107, P12
   Sulli A, 2021, NUTRIENTS, V13, DOI 10.3390/nu13030717
   Sundararaman A, 2020, APPL MICROBIOL BIOT, V104, P8089, DOI 10.1007/s00253 020 10832 4
   Sutherland ER, 2010, AM J RESP CRIT CARE, V181, P699, DOI 10.1164/rccm.200911 1710OC
   Todd JJ, 2015, SPORTS MED, V45, P213, DOI 10.1007/s40279 014 0266 7
   Tzilas V, 2019, PULM PHARMACOL THER, V55, P17, DOI 10.1016/j.pupt.2019.01.003
   Verleden SE, 2012, TRANSPLANTATION, V93, P224, DOI 10.1097/TP.0b013e31823d98bc
   Wang P, 2020, REPROD TOXICOL, V94, P40, DOI 10.1016/j.reprotox.2020.03.008
   Wei H, 2018, MEDICINE, V97, DOI [10.1097/MD.0000000000012282, 10.1097/md.0000000000012282]
   Win SS, 2019, J STEROID BIOCHEM, V188, P1, DOI 10.1016/j.jsbmb.2018.11.016
   Worm M, 2018, Allergol Select, V2, P62, DOI 10.5414/ALX1430E
   Xu J, 2017, MOL MED REP, V16, P7432, DOI 10.3892/mmr.2017.7546
   Yao L, 2017, INT J MOL MED, V39, P1403, DOI 10.3892/ijmm.2017.2961
   Zdrenghea MT, 2017, REV MED VIROL, V27, DOI 10.1002/rmv.1909
   Zhang LQ, 2015, CELL PHYSIOL BIOCHEM, V36, P299, DOI 10.1159/000374072
   Zheng SX, 2020, BIOCHEM PHARMACOL, V177, DOI 10.1016/j.bcp.2020.113955
   Zhu M, 2016, INT J CHRONIC OBSTR, V11, DOI 10.2147/COPD.S101382
NR 116
TC 8
Z9 10
U1 1
U2 12
PU MDPI
PI BASEL
PA MDPI AG, Grosspeteranlage 5, CH 4052 BASEL, SWITZERLAND
EI 2227 9059
J9 BIOMEDICINES
JI Biomedicines
PD DEC
PY 2021
VL 9
IS 12
AR 1843
DI 10.3390/biomedicines9121843
PG 20
WC Biochemistry & Molecular Biology; Medicine, Research & Experimental;
   Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Research & Experimental Medicine;
   Pharmacology & Pharmacy
GA XX2OQ
UT WOS:000736142300001
PM 34944659
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Yasin, N
   Veenman, L
   Singh, S
   Azrad, M
   Bode, J
   Vainshtein, A
   Caballero, B
   Marek, I
   Gavish, M
AF Yasin, Nasra
   Veenman, Leo
   Singh, Sukhdev
   Azrad, Maya
   Bode, Julia
   Vainshtein, Alex
   Caballero, Beatriz
   Marek, Ilan
   Gavish, Moshe
TI Classical and Novel TSPO Ligands for the Mitochondrial TSPO Can Modulate
   Nuclear Gene Expression: Implications for Mitochondrial Retrograde
   Signaling
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE modulation of nuclear gene expression; mitochondrial 18 kDa translocator
   protein (TSPO); TSPO ligand; PK 11195; 2 Cl MGV 1; retrograde
   mitochondrial nuclear signaling pathway; microscopy; mitochondria; cell
   nucleus
ID TRANSLOCATOR PROTEIN TSPO; PERIPHERAL BENZODIAZEPINE RECEPTOR; 18 KDA
   TSPO; CA2+ INDUCED PERMEABILITY TRANSITION; HUMAN GLIOBLASTOMA CELLS;
   RAT BRAIN MITOCHONDRIA; OSTEOBLAST LIKE CELLS; NEURODEGENERATIVE
   DISEASES; DRUG DEVELOPMENT; APOPTOSIS
AB It is known that knockdown of the mitochondrial 18 kDa translocator protein (TSPO) as well as TSPO ligands modulate various functions, including functions related to cancer. To study the ability of TSPO to regulate gene expression regarding such functions, we applied microarray analysis of gene expression to U118MG glioblastoma cells. Within 15 min, the classical TSPO ligand PK 11195 induced changes in expression of immediate early genes and transcription factors. These changes also included gene products that are part of the canonical pathway serving to modulate general gene expression. These changes are in accord with real time, reverse transcriptase (RT) PCR. At the time points of 15, 30, 45, and 60 min, as well as 3 and 24 h of PK 11195 exposure, the functions associated with the changes in gene expression in these glioblastoma cells covered well known TSPO functions. These functions included cell viability, proliferation, differentiation, adhesion, migration, tumorigenesis, and angiogenesis. This was corroborated microscopically for cell migration, cell accumulation, adhesion, and neuronal differentiation. Changes in gene expression at 24 h of PK 11195 exposure were related to downregulation of tumorigenesis and upregulation of programmed cell death. In the vehicle treated as well as PK 11195 exposed cell cultures, our triple labeling showed intense TSPO labeling in the mitochondria but no TSPO signal in the cell nuclei. Thus, mitochondrial TSPO appears to be part of the mitochondria to nucleus signaling pathway for modulation of nuclear gene expression. The novel TSPO ligand 2 Cl MGV 1 appeared to be very specific regarding modulation of gene expression of immediate early genes and transcription factors.
C1 [Yasin, Nasra; Veenman, Leo; Azrad, Maya; Vainshtein, Alex; Caballero, Beatriz; Gavish, Moshe] Technion Israel Inst Technol, Dept Neurosci, Ruth & Bruce Rappaport Fac Med, IL 32525433 Haifa, Israel.
   [Singh, Sukhdev; Marek, Ilan] Technion Israel Inst Technol, Dept Organ Chem, Fac Chem, IL 3200003 Haifa, Israel.
   [Bode, Julia] Heidelberg Univ, Schaller Res Grp, Neuenheimer Feld 581, D 69120 Heidelberg, Germany.
   [Bode, Julia] German Canc Res Ctr, Neuenheimer Feld 581, D 69120 Heidelberg, Germany.
   [Caballero, Beatriz] Univ Oviedo, Fac Med, Dept Morphol & Cell Biol, Oviedo 33008, Asturias, Spain.
C3 Technion Israel Institute of Technology; Rappaport Faculty of Medicine;
   Technion Israel Institute of Technology; Ruprecht Karls University
   Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ);
   University of Oviedo
RP Veenman, L; Gavish, M (通讯作者)，Technion Israel Inst Technol, Dept Neurosci, Ruth & Bruce Rappaport Fac Med, IL 32525433 Haifa, Israel.
EM nasra19@campus.technion.ac.il; veenmanl@tx.technion.ac.il;
   sukhdev.giri@gmail.com; mayabz@gmail.com; j.bode@dkfz heidelberg.de;
   alexanderv21184@gmail.com; bea1979c@hotmail.com;
   chilanm@tx.technion.ac.il; mgavish@tx.technion.ac.il
RI ; Singh, Sukhdev/F 8183 2013; Marek, Ilan/AFN 7450 2022; Caballero
   García, Beatriz/AAC 2636 2020
OI Caballero Garcia, Beatriz/0000 0003 0242 9620; Bode,
   Julia/0000 0002 8081 2425; SINGH, Dr Sukhdev/0000 0001 5648 7936
FU Center for Absorption in Science of the Ministry of Immigrant
   Absorption; Committee for Planning and Budgeting of the Council for
   Higher Education; Israel Science Foundation
FX We thank Liat Linde and Nili Avidan of the Genomics Core Facility of the
   Rappaport Family Medical Research Institute, and Edith Suss Toby and
   Ortal Schwartz, of the Bioimaging Center of the Biomedical Core Facility
   of the Bruce Rappaport Faculty of Medicine, all of the Technion, Israel
   Institute of Technology for their expert assistance and advice, in
   particular regarding the assays for gene expression. This work is
   supported in part by a joint grant from the Center for Absorption in
   Science of the Ministry of Immigrant Absorption and the Committee for
   Planning and Budgeting of the Council for Higher Education under the
   framework of the KAMEA program (Leo Veenman). The Israel Science
   Foundation is thankfully acknowledged for their support for this
   research (Leo Veenman and Moshe Gavish). Furthermore, we wish to
   acknowledge the anonymous reviewers and editors for their invaluable
   suggestions of improvements, and their unwavering encouragement to
   continue with this project.
CR Arnould T, 2002, EMBO J, V21, P53, DOI 10.1093/emboj/21.1.53
   Azarashvili T, 2015, ARCH BIOCHEM BIOPHYS, V587, P70, DOI 10.1016/j.abb.2015.10.012
   Azarashvili T, 2007, CELL CALCIUM, V42, P27, DOI 10.1016/j.ceca.2006.11.004
   Balsemao Pires E, 2011, BMC PLANT BIOL, V11, DOI 10.1186/1471 2229 11 108
   Batoko H, 2015, TRENDS BIOCHEM SCI, V40, P497, DOI 10.1016/j.tibs.2015.07.001
   BENJAMINI Y, 1995, J ROY STAT SOC B, V57, P289, DOI 10.1111/j.2517 6161.1995.tb02031.x
   Biswas G, 2008, P NATL ACAD SCI USA, V105, P186, DOI 10.1073/pnas.0706183104
   Bode J, 2014, AUSTIN J PHARM THER, V2, P1053
   Bode J, 2012, PHARMACOGENET GENOM, V22, P538, DOI 10.1097/FPC.0b013e3283539cdc
   Bonsack F, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974 016 0619 2
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003 2697(76)90527 3
   Butow RA, 2004, MOL CELL, V14, P1, DOI 10.1016/S1097 2765(04)00179 0
   Caballero B, 2014, CNS NEUROL DISORD DR, V13, P574, DOI 10.2174/18715273113126660194
   Caballero B, 2013, RECENT PATENTS ENDOC, V7, P86, DOI 10.2174/1872214811307020002
   Cagin U, 2015, INT J BIOCHEM CELL B, V63, P10, DOI 10.1016/j.biocel.2015.01.026
   Chen C, 2015, PROTEIN CELL, V6, P862, DOI 10.1007/s13238 015 0175 z
   Choi J, 2011, GLIA, V59, P219, DOI 10.1002/glia.21091
   Costa B, 2015, APOPTOSIS, V20, P383, DOI 10.1007/s10495 014 1063 3
   Da Pozzo E, 2015, BIOCHEM SOC T, V43, P559, DOI 10.1042/BST20150028
   Feala JD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029374
   Gatliff J, 2016, BIOCHEM J, V473, P107, DOI 10.1042/BJ20150899
   Gavish M, 1999, PHARMACOL REV, V51, P629
   Gomes AP, 2013, CELL, V155, P1624, DOI 10.1016/j.cell.2013.11.037
   Guilarte T.R., 2016, TRENDS PHARM SCI
   Gut P, 2015, TRENDS ENDOCRIN MET, V26, P349, DOI 10.1016/j.tem.2015.04.001
   Hong SH, 2006, J NEUROSCI RES, V83, P1293, DOI 10.1002/jnr.20829
   Issop L, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152919
   Jayakumar AR, 2002, J NEUROCHEM, V83, P1226, DOI 10.1046/j.1471 4159.2002.01261.x
   Karlstetter M, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742 2094 11 3
   Kim T, 2016, EXPERT OPIN THER PAT, V26, P1353, DOI 10.1080/13543776.2016.1230605
   Kim T, 2016, EXPERT OPIN THER PAT, V26, P1325, DOI 10.1080/13543776.2016.1230606
   Krämer A, 2014, BIOINFORMATICS, V30, P523, DOI 10.1093/bioinformatics/btt703
   Kugler W, 2008, CELL ONCOL, V30, P435, DOI 10.3233/CLO 2008 0431
   Lagutina I. S., 2002, Ontogenez, V33, P100
   Lehtonen MT, 2012, MOL PLANT MICROBE IN, V25, P363, DOI 10.1094/MPMI 10 11 0265
   Levin E, 2005, BIOCHEMISTRY US, V44, P9924, DOI 10.1021/bi050150s
   Li F, 2016, BIOCHEMISTRY US, V55, P2821, DOI 10.1021/acs.biochem.6b00142
   Lin MY, 2015, EXP CELL RES, V334, P35, DOI 10.1016/j.yexcr.2015.01.004
   Liu G. J., 2017, CELL CYCLE, V19
   Maaser K, 2004, BIOCHEM BIOPH RES CO, V324, P878, DOI 10.1016/j.bbrc.2004.09.127
   Macia J, 2009, J R SOC INTERFACE, V6, P393, DOI 10.1098/rsif.2008.0236
   MCENERY MW, 1992, P NATL ACAD SCI USA, V89, P3170, DOI 10.1073/pnas.89.8.3170
   Middleton RJ, 2015, BIOCHEM SOC T, V43, P553, DOI 10.1042/BST20150039
   Midzak A, 2015, BIOCHEM SOC T, V43, P572, DOI 10.1042/BST20150061
   Mukherjee S, 2012, CURR MOL MED, V12, P443
   Papadopoulos V, 2006, TRENDS PHARMACOL SCI, V27, P402, DOI 10.1016/j.tips.2006.06.005
   PARIKH VS, 1987, SCIENCE, V235, P576, DOI 10.1126/science.3027892
   Randles M, 2011, J COMPUT SYST SCI, V77, P293, DOI 10.1016/j.jcss.2010.01.008
   Rosenberg N, 2014, J BIOENERG BIOMEMBR, V46, P197, DOI 10.1007/s10863 014 9542 3
   Rosenberg N, 2011, J BIOENERG BIOMEMBR, V43, P739, DOI 10.1007/s10863 011 9388 x
   Ruksha T, 2012, ARCH DERMATOL RES, V304, P839, DOI 10.1007/s00403 012 1294 5
   Selvaraj V, 2016, J ENDOCRINOL, V231, pR1, DOI 10.1530/JOE 16 0241
   Shargorodsky L, 2012, APOPTOSIS, V17, P647, DOI 10.1007/s10495 012 0725 2
   STAROSTARUBINSTEIN S, 1987, P NATL ACAD SCI USA, V84, P891, DOI 10.1073/pnas.84.3.891
   Tullai JW, 2007, J BIOL CHEM, V282, P23981, DOI 10.1074/jbc.M702044200
   Vainshtein A, 2015, CELL DEATH DISCOV, V1, DOI 10.1038/cddiscovery.2015.27
   Vanhee C, 2011, PLANT CELL, V23, P785, DOI 10.1105/tpc.110.081570
   Veenman L, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.294
   Veenman L, 2012, CURR MOL MED, V12, P398
   Veenman L, 2008, J BIOENERG BIOMEMBR, V40, P199, DOI 10.1007/s10863 008 9142 1
   Veenman L, 2007, CURR PHARM DESIGN, V13, P2385
   Veenman L, 2006, PHARMACOL THERAPEUT, V110, P503, DOI 10.1016/j.pharmthera.2005.09.007
   Veenman L, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17060880
   Veenman L, 2014, ANTI CANCER AGENT ME, V14, P559, DOI 10.2174/1871520614666140309230338
   Veenman L, 2012, PHARMACOGENET GENOM, V22, P606, DOI 10.1097/FPC.0b013e3283544531
   Veenman L, 2010, APOPTOSIS, V15, P753, DOI 10.1007/s10495 010 0460 5
   Wang HS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167307
   Wu M, 2013, INT J NANOMED, V8, P4033, DOI 10.2147/IJN.S52132
   Wu YQ, 2015, J NEURAL TRANSM, V122, P1399, DOI 10.1007/s00702 015 1398 0
   Xiao JJ, 2010, EXP BIOL MED, V235, P478, DOI 10.1258/ebm.2009.009291
   YELISEEV AA, 1995, J BIOL CHEM, V270, P21167, DOI 10.1074/jbc.270.36.21167
   Yeliseev AA, 2000, J BIOL CHEM, V275, P5657, DOI 10.1074/jbc.275.8.5657
   Yi MQ, 2004, J CELL BIOL, V167, P661, DOI 10.1083/jcb.200406038
   Zdralevic Masa, 2015, Methods Mol Biol, V1265, P321, DOI 10.1007/978 1 4939 2288 8_22
   Zeno S, 2012, CURR MOL MED, V12, P494
   Zeno S, 2009, BIOCHEMISTRY US, V48, P4652, DOI 10.1021/bi900064t
   Zhang ZW, 2015, PLANTA, V242, P1263, DOI 10.1007/s00425 015 2384 3
NR 77
TC 48
Z9 49
U1 1
U2 11
PU MDPI AG
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
SN 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD APR
PY 2017
VL 18
IS 4
DI 10.3390/ijms18040786
PG 35
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA EW6SA
UT WOS:000402639400110
PM 28387723
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Rozanc, J
   Zizek, M
   Milojevic, M
   Maver, U
   Finsgar, M
AF Rozanc, Jan
   Zizek, Marko
   Milojevic, Marko
   Maver, Uros
   Finsgar, Matjaz
TI Dexamethasone Loaded Bioactive Coatings on Medical Grade Stainless Steel
   Promote Osteointegration
SO PHARMACEUTICS
LA English
DT Article
DE dexamethasone; carboxymethyl cellulose; medical grade stainless steel;
   controlled drug release; electrochemistry
ID COPPER CORROSION INHIBITOR; OSTEOGENIC DIFFERENTIATION; DRUG DELIVERY;
   LONG TERM; RELEASE; CELLS; ACID; SOLUBILITY; FILMS; XPS
AB In this study, a multilayer bioactive coating based on carboxymethyl cellulose (CMC) and dexamethasone (DEX) was prepared on medical grade stainless steel (AISI 316LVM). Its aim was the controlled drug delivery of the incorporated anti inflammatory drug, which at the same time promotes osteogenic differentiation of mesenchymal stem cells. Due to DEX's limited solubility in physiological fluids, which limits the loading capacity of coatings, it was further combined with beta cyclodextrin to increase its concentration in the bioactive coating. Controlled release of DEX from the multilayer coating was achieved in four steps: a "burst", i.e., very fast, release step (in an immersion interval of 0 10 min), a fast release step (10 30 min), a slow release step (60 360 min), and a plateau step (360 4320 min), following a zero order release or Higuchi model release mechanism. Successful layer by layer coating formation was confirmed using attenuated total reflectance Fourier transform infrared spectroscopy (ATR FTIR). It was shown that the application of the coating significantly increases the hydrophilic character of AISI 316LVM, and also significantly increases the surface roughness, which is known to promote cell growth. In addition, electrochemical measurements demonstrated that the coating application does not increase the susceptibility of medical grade stainless steel to corrosion. In vitro cell testing using all cell types with which such coatings come into contact in the body (osteoblasts, chondrocytes, and mesenchymal stem cells (MSCs)) showed very good biocompatibility towards all of the mentioned cells. It further confirmed that the coatings promoted MSCs osteogenic differentiation, which is the desired mode of action for orthopedic implants.
C1 [Rozanc, Jan; Milojevic, Marko; Maver, Uros] Univ Maribor, Inst Biomed Sci, Fac Med, Maribor 2000, Slovenia.
   [Rozanc, Jan; Milojevic, Marko; Maver, Uros] Univ Maribor, Fac Med, Maribor 2000, Slovenia.
   [Zizek, Marko; Finsgar, Matjaz] Univ Maribor, Fac Chem & Chem Engn, Maribor 2000, Slovenia.
C3 University of Maribor; University of Maribor; University of Maribor
RP Maver, U (通讯作者)，Univ Maribor, Inst Biomed Sci, Fac Med, Maribor 2000, Slovenia.; Maver, U (通讯作者)，Univ Maribor, Fac Med, Maribor 2000, Slovenia.; Finsgar, M (通讯作者)，Univ Maribor, Fac Chem & Chem Engn, Maribor 2000, Slovenia.
EM jan.rozanc@um.si; marko.zizek@student.um.si; marko.milojevic@um.si;
   uros.maver@um.si; matjaz.finsgar@um.si
RI ; Finsgar, Matjaz/ISU 9511 2023; Maver, Uros/D 8796 2012; Maver,
   Uroš/D 8796 2012
OI Zizek, Marko/0000 0002 2800 2089; Finsgar, Matjaz/0000 0002 8302 9284;
   Maver, Uros/0000 0002 2237 3786; Rozanc, Jan/0000 0003 4283 6087; 
FU Slovene Ministry of Science, Education, and Sport [C3330 19 952029];
   Slovenian Research Agency [P2 0032, P3 0036, L4 1843, J3 2538, J1 2470,
   J2 1725, J1 9169]
FX Financial support for this project was provided by the Slovene Ministry
   of Science, Education, and Sport through grant C3330 19 952029. This
   research was also funded by the Slovenian Research Agency grant numbers
   P2 0032, P3 0036, L4 1843, J3 2538, J1 2470, J2 1725, and J1 9169.
CR Andreasen CM, 2018, J TISSUE ENG REGEN M, V12, pE1122, DOI 10.1002/term.2447
   Atran P, 2019, INT J NANOMED, V14, P4613, DOI 10.2147/IJN.S197737
   Barsoukov E, 2005, IMPEDANCE SPECTROSCOPY: THEORY, EXPERIMENT, AND APPLICATIONS, 2ND EDITION, P1, DOI 10.1002/0471716243
   Borcherding K, 2021, INJURY, V52, pS106, DOI 10.1016/j.injury.2020.11.050
   Bukovec M, 2018, J MATER ENG PERFORM, V27, P1122, DOI 10.1007/s11665 018 3186 0
   Daghrery A, 2020, COLLOID SURFACE B, V191, DOI 10.1016/j.colsurfb.2020.111011
   Daud NM, 2018, ANN ANAT, V220, P29, DOI 10.1016/j.aanat.2018.06.009
   Eliaz N, 2019, MATERIALS, V12, DOI 10.3390/ma12030407
   Erbil HY, 2021, COLLOID INTERFAC, V5, DOI 10.3390/colloids5010008
   Fayed O, 2021, MOL PHARMACEUT, V18, P1121, DOI 10.1021/acs.molpharmaceut.0c01042
   Finsgar M, 2016, SCI REP UK, V6, DOI 10.1038/srep26653
   Finsgar M, 2014, CORROS SCI, V83, P164, DOI 10.1016/j.corsci.2014.02.016
   Finsgar M, 2014, CORROS SCI, V80, P82, DOI 10.1016/j.corsci.2013.11.022
   Fiorica C, 2017, CARBOHYD POLYM, V166, P281, DOI 10.1016/j.carbpol.2017.02.071
   Gittens RA, 2011, BIOMATERIALS, V32, P3395, DOI 10.1016/j.biomaterials.2011.01.029
   Gonzalez JS, 2019, POLYMERS BASEL, V11, DOI 10.3390/polym11040702
   Haasters F, 2009, J ANAT, V214, P759, DOI 10.1111/j.1469 7580.2009.01065.x
   Ibrahim A, 2017, THER ADV GASTROENTER, V10, P829, DOI 10.1177/1756283X17730748
   Jiang KY, 2017, BIOMATERIALS, V114, P71, DOI 10.1016/j.biomaterials.2016.11.004
   Kang CW, 2018, ADV MANUF, V6, P20, DOI 10.1007/s40436 017 0207 4
   Kazemzadeh Narbat M, 2021, CRIT REV BIOTECHNOL, V41, P94, DOI 10.1080/07388551.2020.1828810
   Kong JZ, 2020, SURF COAT TECH, V381, DOI 10.1016/j.surfcoat.2019.125108
   Langenbach F, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt328
   Lepicka M, 2017, WEAR, V382, P62, DOI 10.1016/j.wear.2017.04.017
   Lewallen EA, 2015, TISSUE ENG PART B RE, V21, P218, DOI [10.1089/ten.TEB.2014.0333, 10.1089/ten.teb.2014.0333]
   Li MH, 2017, MAT SCI ENG C MATER, V73, P198, DOI 10.1016/j.msec.2016.12.070
   Loftsson Thorsteinn, 2005, Expert Opin Drug Deliv, V2, P335, DOI 10.1517/17425247.2.1.335
   Massart D.L., 1997, HDB CHEMOMETRICS Q A
   Maver T, 2019, FRONT CHEM, V7, DOI 10.3389/fchem.2019.00217
   Maver U, 2020, CARBOHYD POLYM, V230, DOI 10.1016/j.carbpol.2019.115612
   Maver U, 2018, EUR J PHARM BIOPHARM, V128, P230, DOI 10.1016/j.ejpb.2018.05.002
   Mohan T, 2019, ACS BIOMATER SCI ENG, V5, P5825, DOI 10.1021/acsbiomaterials.9b01288
   Najafi F, 2020, J BIOMED MATER RES A, V108, P485, DOI 10.1002/jbm.a.36830
   Naranda J, 2017, PEERJ, V5, DOI 10.7717/peerj.3079
   ORMEROD EJ, 1985, IN VITRO CELL DEV B, V21, P143, DOI 10.1007/BF02621351
   Osathanon Thanaphum, 2011, J Oral Sci, V53, P23
   Park CY, 2019, NUTRIENTS, V11, DOI 10.3390/nu11020243
   Park S, 2018, ACS APPL MATER INTER, V10, P17714, DOI 10.1021/acsami.8b04433
   Patra JK, 2018, J NANOBIOTECHNOL, V16, DOI 10.1186/s12951 018 0392 8
   Schneider N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120538
   Sid D, 2021, J ENZYM INHIB MED CH, V36, P605, DOI 10.1080/14756366.2020.1869225
   Singh P, 2020, INT J PHARMACEUT, V586, DOI 10.1016/j.ijpharm.2020.119542
   Song R, 2018, DRUG DES DEV THER, V12, P3117, DOI 10.2147/DDDT.S165440
   Sordi MB, 2021, J MATER SCI MATER M, V32, DOI 10.1007/s10856 020 06475 6
   Ständert V, 2021, BIOACT MATER, V6, P2331, DOI 10.1016/j.bioactmat.2021.01.012
   Su N, 2019, INT J BIOL SCI, V15, P776, DOI 10.7150/ijbs.27063
   Surmenev RA, 2019, CURR OPIN BIOMED ENG, V10, P35, DOI 10.1016/j.cobme.2019.02.003
   Talha M, 2014, RSC ADV, V4, P13340, DOI 10.1039/c3ra47881e
   TANAKA S, 1985, CHEM PHARM BULL, V33, P3929
   van Beek JHGM, 2016, INTERFACE FOCUS, V6, DOI 10.1098/rsfs.2015.0079
   Vuolo M., 2021, INT J DRUG POLICY, DOI 10.1016/j.drugpo.2021.103182
   Yang ZJ, 2021, BIOMATERIALS, V269, DOI 10.1016/j.biomaterials.2020.120534
   Yazdani J, 2018, BIOMED PHARMACOTHER, V105, P553, DOI 10.1016/j.biopha.2018.06.013
   Zhang YN, 2021, ACS APPL MATER INTER, V13, P7051, DOI 10.1021/acsami.0c17664
   Zykova Y, 2019, EUR POLYM J, V114, P72, DOI 10.1016/j.eurpolymj.2019.02.029
NR 55
TC 13
Z9 13
U1 0
U2 24
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1999 4923
J9 PHARMACEUTICS
JI Pharmaceutics
PD APR
PY 2021
VL 13
IS 4
AR 568
DI 10.3390/pharmaceutics13040568
PG 20
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA RS1GO
UT WOS:000643532900001
PM 33923814
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Alaee, F
   Hong, SH
   Dukas, AG
   Pensak, MJ
   Rowe, DW
   Lieberman, JR
AF Alaee, Farhang
   Hong, Seung Hyun
   Dukas, Alex G.
   Pensak, Michael J.
   Rowe, David W.
   Lieberman, Jay R.
TI Evaluation of Osteogenic Cell Differentiation in Response to Bone
   Morphogenetic Protein or Demineralized Bone Matrix in a Critical Sized
   Defect Model Using GFP Reporter Mice
SO JOURNAL OF ORTHOPAEDIC RESEARCH
LA English
DT Article
DE femoral defect; rhBMP 2; demineralized bone matrix; bone
   histomorphometry; GFP reporters
ID SEGMENTAL FEMORAL DEFECTS; PROSTATE CANCER; SPINAL FUSION; GENE THERAPY;
   REPAIR; GRAFT; EXPRESSION; FRACTURES; PROMOTER; IDENTIFY
AB We evaluated the osteoprogenitor response to rhBMP 2 and DBM in a transgenic mouse critical sized defect. The mice expressed Col3.6GFPtopaz (a pre osteoblastic marker), Col2.3GFPemerald (an osteoblastic marker) and a smooth muscle actin (alpha SMA Cherry, a pericyte/myofibroblast marker). We assessed defect healing at various time points using radiographs, frozen, and conventional histologic analyses. GFP signal in regions of interest corresponding to the areas of new bone formation was quantified using a novel computer assisted algorithm. All defects treated with rhBMP 2 healed. In contrast, the majority of the defects in the DBM (27/30) and control (28/30) groups did not heal. Quantitation of pre osteoblasts demonstrated a maximal response (% GFP + cells/ TV) in the Col3.6GFPtopaz mice at day 7 (7.2% +/  6.0, p < 0.05 compared to days 14, 21, 28, and 56). The maximal response of the Col2.3GFP cells was seen at days 14 (8.04% +/  5.0) and 21 (8.31% +/  4.32), p < 0.05. In contrast, DBM and control groups showed a limited osteogenic response at all time points. In conclusion, we demonstrated that the BMP and DBM induce vastly different osteogenic responses which should influence their clinical application as bone graft substitutes. (C) 2014 Orthopaedic Research Society. Published by Wiley Periodicals, Inc.
C1 [Alaee, Farhang; Dukas, Alex G.; Pensak, Michael J.] Univ Connecticut, Ctr Hlth, New England Musculoskeletal Inst, Dept Orthopaed Surg, Farmington, CT 06030 USA.
   [Hong, Seung Hyun] Univ Connecticut, Dept Comp Sci & Engn, Storrs, CT 06269 USA.
   [Rowe, David W.] Univ Connecticut, Ctr Hlth, Sch Dent Med, Dept Reconstruct Sci, Farmington, CT 06030 USA.
   [Lieberman, Jay R.] Univ So Calif, Keck Sch Med, Dept Orthopaed Surg, Los Angeles, CA 90033 USA.
C3 University of Connecticut; University of Connecticut; University of
   Connecticut; University of Southern California
RP Lieberman, JR (通讯作者)，Univ So Calif, Keck Sch Med, Dept Orthopaed Surg, Los Angeles, CA 90033 USA.
EM jay.lieberman@med.usc.edu
OI Dukas, Alex/0000 0003 1300 4038
FU Musculoskeletal Transplant Foundation
FX Grant sponsor: Musculoskeletal Transplant Foundation.
CR Alaee F, 2014, GENE THER, V21, P139, DOI 10.1038/gt.2013.66
   [Anonymous], [No title captured]
   Arrington ED, 1996, CLIN ORTHOP RELAT R, P300, DOI 10.1097/00003086 199608000 00037
   Barradas AM, EUR CELL MAT, V21, P407
   Barradas AM, EUR CELL MAT, V21, P429
   Bilic Curcic I, 2005, GENESIS, V43, P87, DOI 10.1002/gene.20156
   Bilic Curcic I, 2005, BONE, V37, P678, DOI 10.1016/j.bone.2005.06.009
   Boyce AS, 2009, J ORTHOP TRAUMA, V23, P685, DOI 10.1097/BOT.0b013e3181a10378
   Doi Y, BONE, V49, P777
   Feeley BT, 2005, J BONE MINER RES, V20, P2189, DOI 10.1359/JBMR.050802
   Filgueira L, 2004, J HISTOCHEM CYTOCHEM, V52, P411, DOI 10.1177/002215540405200312
   Fu RW, 2013, ANN INTERN MED, V158, P890, DOI 10.7326/0003 4819 158 12 201306180 00006
   GERHART TN, 1993, CLIN ORTHOP RELAT R, P317
   Govender S, 2002, J BONE JOINT SURG AM, V84A, P2123, DOI 10.2106/00004623 200212000 00001
   Granholm S, BONE, V52, P83
   Gruskin E, ADV DRUG DELIV REV, V64, P1063
   Hong Seung Hyun, 2012, J Tissue Sci Eng, VSuppl 1, P004
   Hsu WK, 2008, J NUCL MED, V49, P414, DOI 10.2967/jnumed.107.045666
   Huang YZ, 2012, INT J ARTIF ORGANS, V35, P1061, DOI 10.5301/ijao.5000122
   Jiang X, 2005, J HISTOCHEM CYTOCHEM, V53, P593, DOI 10.1369/jhc.4A6401.2005
   Kalajzic I, 2002, J BONE MINER RES, V17, P15, DOI 10.1359/jbmr.2002.17.1.15
   Kalajzic I., 2007, Journal of Musculoskeletal & Neuronal Interactions, V7, P320
   Kalajzic Z, 2008, BONE, V43, P501, DOI 10.1016/j.bone.2008.04.023
   Lieberman JR, 1999, J BONE JOINT SURG AM, V81A, P905, DOI 10.2106/00004623 199907000 00002
   Marijanovic I, 2003, CROAT MED J, V44, P412
   Martin GJ, 1999, SPINE, V24, P637, DOI 10.1097/00007632 199904010 00005
   Morone MA, 1998, SPINE, V23, P159, DOI 10.1097/00007632 199801150 00003
   Murakami N, 2002, J BIOMED MATER RES, V62, P169, DOI 10.1002/jbm.10236
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Peterson B, 2005, TISSUE ENG, V11, P120, DOI 10.1089/ten.2005.11.120
   Schindeler A, J BONE JOINT SURG BR, V93, P1134
   Seeherman HJ, 2012, J BONE JOINT SURG AM, V94A, P1765, DOI 10.2106/JBJS.K.00523
   Starman JS, 2012, J TRAUMA ACUTE CARE, V72, P676, DOI 10.1097/TA.0b013e318232cf5a
   Ushiku C, J ORTHOP RES, V28, P1338
   Vandermeer JS, J BONE JOINT SURG AM, V93, P905
   Vögelin E, 2005, J BONE JOINT SURG AM, V87A, P1323, DOI 10.2106/JBJS.C.00913
   Wang JC, 2007, EUR SPINE J, V16, P1233, DOI 10.1007/s00586 006 0282 x
NR 37
TC 27
Z9 28
U1 1
U2 13
PU WILEY BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0736 0266
EI 1554 527X
J9 J ORTHOP RES
JI J. Orthop. Res.
PD SEP
PY 2014
VL 32
IS 9
BP 1120
EP 1128
DI 10.1002/jor.22657
PG 9
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA AN4VR
UT WOS:000340587200006
PM 24888702
OA Bronze
DA 2025 08 17
ER

PT J
AU Adibi, R
   Moein, S
   Gheisari, Y
AF Adibi, Rezvan
   Moein, Shiva
   Gheisari, Yousof
TI Zoledronic acid targets chemo resistant polyploid giant cancer cells
SO SCIENTIFIC REPORTS
LA English
DT Article
ID LUNG CANCER; TUMOR CELLS; INHIBITOR; CARCINOMA; CISPLATIN;
   ENDOREDUPLICATION; METASTASES; DOCETAXEL
AB Although polyploid giant cancer cells (PGCCs) are known as a key source of failure of current therapies, sufficient drugs to target these cells are not yet introduced. Considering the similarities of polyploid cells in regeneration and cancer, we hypothesized that zoledronic acid (ZA), an osteoclast targeting agent, might be used to eliminate PGCCs. The 5637 bladder cancer cell line was treated with various doses of cisplatin to enrich polyploid cells and the efficacy of different concentrations of ZA in reducing this population was assessed. The metabolic profile of PGCCs was investigated with gas chromatography mass spectrometry. Lipid profiles, mitochondrial density, and ROS content were also measured to assess the response of the cells to ZA. Cancer cells surviving after three days of exposure with 6 mu M cisplatin were mainly polyploid. These cells demonstrated special morphological features such as fusion with diploid or other polyploid cells and originated in daughter cells through budding. ZA could substantially eradicate PGCCs with the maximal effect observed with 50 mu M which resulted in the drop of PGCC fraction from 60 +/  7.5 to 19 +/  1.7%. Enriched PGCCs after cisplatin treatment demonstrated a drastic metabolic shift compared to untreated cancer cells with an augmentation of lipids. Further assays confirmed the high content of lipid droplets and cholesterol in these cells which were reduced after ZA administration. Additionally, the mitochondrial density and ROS increased in PGCCs both of which declined in response to ZA. Taken together, we propose that ZA is a potent inhibitor of PGCCs which alters the metabolism of PGCCs. Although this drug has been successfully exploited as adjuvant therapy for some malignancies, the current evidence on its effects on PGCCs justifies further trials to assess its potency for improving the success of current therapies for tackling tumor resistance and relapse.
C1 [Adibi, Rezvan; Gheisari, Yousof] Isfahan Univ Med Sci, Dept Genet & Mol Biol, Esfahan, Iran.
   [Moein, Shiva; Gheisari, Yousof] Isfahan Univ Med Sci, Regenerat Med Res Ctr, Esfahan 8174673461, Iran.
C3 Isfahan University of Medical Sciences; Isfahan University of Medical
   Sciences
RP Gheisari, Y (通讯作者)，Isfahan Univ Med Sci, Dept Genet & Mol Biol, Esfahan, Iran.; Gheisari, Y (通讯作者)，Isfahan Univ Med Sci, Regenerat Med Res Ctr, Esfahan 8174673461, Iran.
EM ygheisari@med.mui.ac.ir
RI Gheisari, Yousof/N 4459 2017; Moein, Shiva/ABD 3110 2021
OI Gheisari, Yousof/0000 0001 9665 1091; 
FU Isfahan University of Medical Sciences [398933, 1400479]
FX This study was supported by Isfahan University of Medical Sciences
   (Grant Numbers: 398933, 1400479).
CR Adibi R., 2021, RES SQUARE, DOI [10.21203/rs.3.rs 440506/v1, DOI 10.21203/RS.3.RS 440506/V1]
   Ahmadbeigi N, 2011, STEM CELLS DEV, V20, P1337, DOI 10.1089/scd.2010.0266
   Amend SR, 2019, PROSTATE, V79, P1489, DOI 10.1002/pros.23877
   Chen Jason J, 2010, N Am J Med Sci (Boston), V3, P43
   Dewhurst SM, 2014, CANCER DISCOV, V4, P175, DOI 10.1158/2159 8290.CD 13 0285
   Di Salvatore M, 2011, CELL PROLIFERAT, V44, P139, DOI 10.1111/j.1365 2184.2011.00745.x
   Díaz Carballo D, 2018, CANCER RES, V78, P2318, DOI 10.1158/0008 5472.CAN 17 1861
   Donovan P, 2014, MOL BIOSYST, V10, P741, DOI 10.1039/c3mb70484j
   Elsayed M, 2016, BIOL PHARM BULL, V39, P1238, DOI 10.1248/bpb.b15 00746
   Erenpreisa J, 2013, CANCER CELL INT, V13, DOI 10.1186/1475 2867 13 92
   FOLCH J, 1957, J BIOL CHEM, V226, P497
   Henics T, 1999, BIOL CELL, V91, P485, DOI 10.1016/S0248 4900(00)88205 2
   Ibrahim T, 2013, INT J ONCOL, V42, P1263, DOI 10.3892/ijo.2013.1809
   Ikeda T, 2003, PATHOL INT, V53, P450, DOI 10.1046/j.1440 1827.2003.01503.x
   Kostecka LG, 2021, MED ONCOL, V38, DOI 10.1007/s12032 021 01584 w
   Koto K, 2010, ONCOL REP, V24, P233, DOI 10.3892/or_00000851
   Li XY, 2012, MED ONCOL, V29, P714, DOI 10.1007/s12032 011 9904 1
   Lin XP, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00317
   Lipton A, 2007, EXPERT OPIN DRUG SAF, V6, P305, DOI 10.1517/14740338.6.3.305
   Liu HT, 2021, LARYNGOSCOPE INVEST, V6, P1228, DOI 10.1002/lio2.667
   Liu LL, 2013, MOL CANCER RES, V11, P1326, DOI 10.1158/1541 7786.MCR 13 0172
   Liu TY, 2019, GASTROENTEROLOGY, V157, P1475, DOI 10.1053/j.gastro.2019.09.044
   Lopez Sánchez LM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099143
   Mardani A, 2019, J MED ETHICS HIST ME, V12
   Matsukuma S, 2014, THORAC CANCER, V5, P354, DOI 10.1111/1759 7714.12090
   Mattiolo P, 2021, VIRCHOWS ARCH, V478, P319, DOI 10.1007/s00428 020 02889 3
   Mirzayans R, 2018, CANCERS, V10, DOI 10.3390/cancers10040118
   Moein S, 2020, BBA REV CANCER, V1874, DOI 10.1016/j.bbcan.2020.188408
   Motwani M, 2000, CLIN CANCER RES, V6, P924
   Munir R, 2019, BRIT J CANCER, V120, P1090, DOI 10.1038/s41416 019 0451 4
   Nguyen PL, 2022, ANTIOXIDANTS BASEL, V11, DOI 10.3390/antiox11010117
   Niu N, 2017, ONCOGENE, V36, P4887, DOI 10.1038/onc.2017.72
   Ogden A, 2015, CANCER LETT, V367, P89, DOI 10.1016/j.canlet.2015.06.025
   Perry CM, 2004, DRUGS, V64, P1197, DOI 10.2165/00003495 200464110 00004
   Porporato PE, 2018, CELL RES, V28, P265, DOI 10.1038/cr.2017.155
   Puig PE, 2008, CELL BIOL INT, V32, P1031, DOI 10.1016/j.cellbi.2008.04.021
   RAND CW, 1947, J NEUROPATH EXP NEUR, V6, P1
   Raskin KA, 2013, J AM ACAD ORTHOP SUR, V21, P118, DOI 10.5435/JAAOS 21 02 118
   RATHER LJ, 1951, AMA ARCH PATHOL, V52, P98
   Saad F, 2010, SEMIN ONCOL, V37, pS38, DOI 10.1053/j.seminoncol.2010.06.001
   Saimura, 1999, Breast Cancer, V6, P121, DOI 10.1007/BF02966918
   Salmina K, 2010, EXP CELL RES, V316, P2099, DOI 10.1016/j.yexcr.2010.04.030
   Sharma S, 2014, MOL ONCOL, V8, P469, DOI 10.1016/j.molonc.2013.12.014
   Sirois I, 2019, MOL CANCER RES, V17, P2492, DOI 10.1158/1541 7786.MCR 19 0264
   Takegahara N, 2016, J BIOL CHEM, V291, P3439, DOI 10.1074/jbc.M115.677427
   Turgeman I, 2018, ANTI CANCER DRUG, V29, P466, DOI 10.1097/CAD.0000000000000612
   Wang LW, 2020, BMC CANCER, V20, DOI 10.1186/s12885 020 07568 9
   Weaver BAA, 2007, CANCER RES, V67, P10103, DOI 10.1158/0008 5472.CAN 07 2266
   Yeung YT, 2018, EBIOMEDICINE, V28, P51, DOI 10.1016/j.ebiom.2018.01.017
   Yoh K, 2012, ANTICANCER RES, V32, P4131
   Zack TI, 2013, NAT GENET, V45, P1134, DOI 10.1038/ng.2760
   Zhang J, 2022, SEMIN CANCER BIOL, V81, P54, DOI 10.1016/j.semcancer.2021.04.005
   Zhang S, 2014, ONCOGENE, V33, P116, DOI 10.1038/onc.2013.96
   Zhang SW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080120
   Zhang WH, 2011, CANCER AM CANCER SOC, V117, P4092, DOI 10.1002/cncr.26021
   Zhou WH, 2015, ONCOTARGET, V6, P21557, DOI 10.18632/oncotarget.5317
NR 56
TC 15
Z9 17
U1 0
U2 5
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD JAN 9
PY 2023
VL 13
IS 1
AR 419
DI 10.1038/s41598 022 27090 1
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 7Z3IW
UT WOS:000915457700022
PM 36624105
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Yu, KE
   Kwon, HK
   Dussik, CM
   Cahill, S
   Back, J
   Alder, KD
   Lee, FY
AF Yu, Kristin E.
   Kwon, Hyuk Kwon
   Dussik, Christopher M.
   Cahill, Sean, V
   Back, Jungho
   Alder, Kareme D.
   Lee, Francis Y.
TI Enhancement of Impaired MRSA Infected Fracture Healing by Combinatorial
   Antibiotics and Modulation of Sustained Inflammation
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE CYTOKINES; ENDOCRINE PATHWAYS; INJURY; FRACTURE HEALING; INFECTION;
   PRECLINICAL STUDIES
ID INTRACELLULAR STAPHYLOCOCCUS AUREUS; NECROSIS FACTOR ALPHA; BONE; CELLS;
   MODEL; OSTEOMYELITIS; PROPHYLAXIS; PENETRATION; OSTEOBLASTS; INVOLVEMENT
AB Fracture healing is impaired in the setting of infection, which begets protracted inflammation. The most problematic causative agent of musculoskeletal infection is methicillin resistant Staphylococcus aureus (MRSA). We hypothesized that modulation of excessive inflammation combined with cell penetrating antibiotic treatments facilitates fracture healing in a murine MRSA infected femoral fracture model. Sterile and MRSA contaminated open transverse femoral osteotomies were induced in 10 week old male C57BL/6 mice and fixed via intramedullary nailing. In the initial therapeutic cohort, empty, vancomycin (V), rifampin (R), vancomycin rifampin (VR), or vancomycin rifampin trametinib (VRT) hydrogels were applied to the fracture site intraoperatively. Rifampin was included because of its ability to penetrate eukaryotic cells to target intracellular bacteria. Unbiased screening demonstrated ERK activation was upregulated in the setting of MRSA infection. As such, the FDA approved mitogen activated protein kinase kinase (MEK)1 pERK1/2 inhibitor trametinib was evaluated as an adjunctive therapeutic agent to selectively mitigate excessive inflammation after infected fracture. Two additional cohorts were created mimicking immediate and delayed postoperative antibiotic administration. Systemic vancomycin or VR was administered for 2 weeks, followed by 2 weeks of VRT hydrogel or oral trametinib therapy. Hematologic, histological, and cytokine analyses were performed using serum and tissue isolates obtained at distinct postoperative intervals. Radiography and micro computed tomography (mu CT) were employed to assess fracture healing. Pro inflammatory cytokine levels remained elevated in MRSA infected mice with antibiotic treatment alone, but increasingly normalized with trametinib therapy. Impaired callus formation and malunion were consistently observed in the MRSA infected groups and was partially salvaged with systemic antibiotic treatment alone. Mice that received VR alongside adjuvant MEK1 pERK1/2 inhibition displayed the greatest restoration of bone and osseous union. A combinatorial approach involving adjuvant cell penetrating antibiotic treatments alongside mitigation of excessive inflammation enhanced healing of infected fractures. (c) 2022 American Society for Bone and Mineral Research (ASBMR).
C1 [Yu, Kristin E.; Kwon, Hyuk Kwon; Dussik, Christopher M.; Back, Jungho; Alder, Kareme D.; Lee, Francis Y.] Yale Univ, Sch Med, Dept Orthopaed & Rehabil, 330 Cedar St,TMP 523,POB 208071, New Haven, CT 06520 USA.
   [Cahill, Sean, V] Washington Univ, Sch Med, Dept Orthoped Surg, St Louis, MO USA.
   [Alder, Kareme D.] Mayo Clin, Dept Orthoped Surg, Rochester, MN USA.
C3 Yale University; Washington University (WUSTL); Mayo Clinic
RP Yu, KE (通讯作者)，Yale Univ, Sch Med, Dept Orthopaed & Rehabil, 330 Cedar St,TMP 523,POB 208071, New Haven, CT 06520 USA.
EM kristin.yu@yale.edu
RI ; kwon, hyuk kwon/AAS 4154 2021
OI Alder, Kareme/0000 0002 7796 4188; Back, Jungho/0000 0002 8085 975X; 
FU NIH; National Institute of Arthritis and Musculoskeletal and Skin
   Diseases [R01AR056246, 1R01AR068353]
FX This research was supported by NIH and National Institute of Arthritis
   and Musculoskeletal and Skin Diseases grants R01AR056246 and
   1R01AR068353. Authors' roles: KEY, HK K, and JB designed the study. HK K
   and JB prepared study reagents. KEY, HK K, CMD, SVC, and KDA performed
   experiments. KEY, HK K, and JB analyzed data and generated figures. All
   authors prepared the manuscript. FYL oversaw study design, experiments,
   data analysis, and manuscript preparation.
CR Abu Amer Y, 2008, AUTOIMMUNITY, V41, P204, DOI 10.1080/08916930701694543
   Alder KD, 2020, BONE, V141, DOI 10.1016/j.bone.2020.115568
   Back J, 2021, BONE RES, V9, DOI 10.1038/s41413 021 00158 w
   Cahill SV, 2021, J ORTHOP RES, V39, P402, DOI 10.1002/jor.24965
   Chen QB, 2014, CELL PHYSIOL BIOCHEM, V34, P1890, DOI 10.1159/000366387
   DAROUICHE RO, 1994, ANTIMICROB AGENTS CH, V38, P1059, DOI 10.1128/AAC.38.5.1059
   Diep BA, 2006, LANCET, V367, P731, DOI 10.1016/S0140 6736(06)68231 7
   DINARELLO CA, 1994, FASEB J, V8, P1314, DOI 10.1096/fasebj.8.15.8001745
   Dinarello CA, 2009, ANNU REV IMMUNOL, V27, P519, DOI 10.1146/annurev.immunol.021908.132612
   Doggrell SA, 2005, EXPERT OPIN THER TAR, V9, P191, DOI 10.1517/14728222.9.1.191
   Ellington JK, 2006, J ORTHOP RES, V24, P87, DOI 10.1002/jor.20003
   Ellington JK, 2001, INFECT IMMUN, V69, P5235, DOI 10.1128/IAI.69.9.5235 5242.2001
   Fiset S, 2018, J BONE JOINT SURG AM, V100, DOI 10.2106/JBJS.18.00035
   Gao T, 2020, BONE JOINT RES, V9, P71, DOI 10.1302/2046 3758.92.BJR 2019 0201.R1
   Giavaresi G, 2012, J ORTHOP RES, V30, P348, DOI 10.1002/jor.21531
   Hake ME, 2015, INJURY, V46, P1447, DOI 10.1016/j.injury.2015.05.008
   Inzana JA, 2016, BIOMATERIALS, V81, P58, DOI 10.1016/j.biomaterials.2015.12.012
   Jimi E, 2004, NAT MED, V10, P617, DOI 10.1038/nm1054
   Karnes JM, 2015, BONE, V78, P87, DOI 10.1016/j.bone.2015.05.001
   Klosterhalfen B, 1996, J TRAUMA, V40, P372, DOI 10.1097/00005373 199603000 00008
   Kwon HK, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abf2665
   Li X, 2021, ACS APPL BIO MATER, V4, P6219, DOI 10.1021/acsabm.1c00540
   LittlewoodEvans AJ, 1997, INFECT IMMUN, V65, P3438, DOI 10.1128/IAI.65.8.3438 3443.1997
   Lüthje FL, 2020, APMIS, V128, P275, DOI 10.1111/apm.13027
   Marriott I, 2005, BONE, V37, P504, DOI 10.1016/j.bone.2005.05.011
   Marriott I, 2004, IMMUNOL RES, V30, P291, DOI 10.1385/IR:30:3:291
   Mårtensson K, 2004, J BONE MINER RES, V19, P1805, DOI 10.1359/JBMR.040805
   Morgenstern M, 2018, BONE JOINT RES, V7, P447, DOI 10.1302/2046 3758.77.BJR 2018 0043.R1
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Seo SW, 2010, BONE, V46, P695, DOI 10.1016/j.bone.2009.10.032
   Shi SF, 2013, SCAND J INFECT DIS, V45, P334, DOI 10.3109/00365548.2012.726740
   ter Boo GJA, 2015, BIOMATERIALS, V52, P113, DOI 10.1016/j.biomaterials.2015.02.020
   Tucker KA, 2000, FEMS MICROBIOL LETT, V186, P151, DOI 10.1016/S0378 1097(00)00125 7
   Vallejo JG, 1996, INFECT IMMUN, V64, P5042, DOI 10.1128/IAI.64.12.5042 5046.1996
   Yu K, 2020, BONE JOINT RES, V9, P49, DOI 10.1302/2046 3758.92.BJR 2019 0131.R1
NR 35
TC 7
Z9 9
U1 2
U2 28
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD JUL
PY 2022
VL 37
IS 7
BP 1352
EP 1365
DI 10.1002/jbmr.4570
EA JUN 2022
PG 14
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 2V2YU
UT WOS:000812704400001
PM 35616626
OA Bronze
DA 2025 08 17
ER

PT J
AU Jin, ZX
   Da, WW
   Zhao, YJ
   Wang, TT
   Xu, H
   Shu, B
   Gao, X
   Shi, Q
   Ma, Y
   Zhang, Y
   Wang, YJ
   Tang, DZ
AF Jin, Zhenxiong
   Da, Weiwei
   Zhao, Yongjian
   Wang, Tengteng
   Xu, Hao
   Shu, Bing
   Gao, Xiang
   Shi, Qi
   Ma, Yong
   Zhang, Yan
   Wang, Yongjun
   Tang, Dezhi
TI Role of skeletal muscle satellite cells in the repair of osteoporotic
   fractures mediated by β catenin
SO JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE
LA English
DT Article
DE Skeletal muscle stem cells; Osteoporotic fracture; Osteoblast;
   beta Catenin
ID DIFFERENTIATION; PREVENTION; EXPANSION; FATES
AB Background Osteoporosis is a metabolic disease, and osteoporotic fracture (OPF) is one of its most serious complications. It is often ignored that the influence of the muscles surrounding the fracture on the healing of OPF. We aimed to clarify the role of skeletal muscle satellite cells (SMSCs) in promoting OPF healing by beta catenin, to improve our understanding of SMSCs, and let us explore its potential as a therapeutic target.
   Methods Skeletal muscles were obtained from control non OPF or OPF patients for primary SMSCs culture (n = 3, 33% females, mean age 60 +/  15.52). Expression of SMSCs was measured. In vivo, 3 month old female C57BL/6 mice underwent OVX surgery. Three months later, the left tibia fracture model was again performed. The control and the treatment group (n = 24, per group, female). The treatment group was treated with an agonist (osthole). Detection of SMSCs in muscles and fracture healing at 7, 14, and 28 three time points (n = 8, 8, 8, female). To further clarify the scientific hypothesis, we innovatively used Pax7 Cre(ERT2/+);beta catenin(fx/fx) transgenic mice (n = 12, per group, male). Knock out beta catenin in SMSC to observe the proliferation and osteogenic differentiation of SMSCs, and OPF healing. In vitro primary cells of SMSCs from 3 month old litter negative beta catenin(fx/fx) transgenic mice. After adenovirus CRE transfection, the myogenic and osteogenic differentiation of SMSC was observed.
   Results We find that human SMSCs reduced proliferation and osteogenic differentiation in patients with OPF ( 38.63%, P < 0.05). And through animal experiments, it was found that activation of beta catenin promoted the proliferation and osteogenic differentiation of SMSC at the fracture site, thereby accelerating the healing of the fracture site (189.47%, P < 0.05). To prove this point of view, in the in vivo Pax7 Cre(ERT2/+);beta catenin(fx/fx) transgenic mouse experiment, we innovatively found that knocking out beta catenin in SMSC will cause a decrease in bone mass and bone microstructure, and accompanied by delayed fracture healing ( 35.04%, P < 0.001). At the same time, through in vitro SMSC culture experiments, it was found that their myogenic ( 66.89%, P < 0.01) and osteogenic differentiation ( 16.5%, P < 0.05) ability decreased.
   Conclusions These results provide the first practical evidence for a direct contribution of SMSCs to promote the healing of OPF with important clinical implications as it may help in the treatment of delayed healing and non union of OPFs, and mobilization of autologous stem cell therapy in orthopaedic applications.
C1 [Jin, Zhenxiong; Da, Weiwei; Zhao, Yongjian; Wang, Tengteng; Xu, Hao; Shi, Qi; Zhang, Yan; Tang, Dezhi] Shanghai Univ Tradit Chinese Med, Longhua Hosp, Shanghai, Peoples R China.
   [Jin, Zhenxiong; Da, Weiwei; Zhao, Yongjian; Xu, Hao; Shu, Bing; Shi, Qi; Zhang, Yan; Wang, Yongjun; Tang, Dezhi] Shanghai Univ Tradit Chinese Med, Inst Spine, Shanghai, Peoples R China.
   [Jin, Zhenxiong; Shu, Bing; Wang, Yongjun] Shanghai Univ Tradit Chinese Med, 1200 Cailun Rd, Shanghai 201203, Peoples R China.
   [Gao, Xiang] Fudan Univ, Dept Orthoped, Huadong Hosp, Shanghai, Peoples R China.
   [Ma, Yong] Nanjing Univ Tradit Chinese Med, Dept Orthoped, Nanjing, Jiangsu, Peoples R China.
C3 Shanghai University of Traditional Chinese Medicine; Shanghai University
   of Traditional Chinese Medicine; Shanghai University of Traditional
   Chinese Medicine; Fudan University; Nanjing University of Chinese
   Medicine
RP Wang, YJ (通讯作者)，Shanghai Univ Tradit Chinese Med, 1200 Cailun Rd, Shanghai 201203, Peoples R China.; Zhang, Y; Tang, DZ (通讯作者)，Shanghai Univ Tradit Chinese Med, Longhua Hosp, Inst Spine, 725 Wan Ping South Rd, Shanghai 200032, Peoples R China.
EM medicineyan@aliyun.com; yjwang8888@126.com; dztang702@126.com
RI Wang, Lan/JGM 3426 2023; Da, Weiwei/AFV 5795 2022
FU National Key R&D Program of China [2018YFC1704300]; National Natural
   Science Foundation of China [81973883]; Shanghai Scientific Research
   Project [19ZR1458000]; Shanghai Traditional Chinese Medicine Medical
   Center of Chronic Disease [2017ZZ01010]; first round of a three year
   Action Plan to Promote Clinical Skills and Clinical Innovation in
   Municipal Hospitals [16CR1017A]; 'Innovation Team' development projects
   [IRT1270]; Three Year Action to Accelerate the Development of
   Traditional Chinese Medicine Plan [ZY(2018 2020) CCCX 3003]
FX This study was sponsored by research grants from the National Key R&D
   Program of China (2018YFC1704300), the National Natural Science
   Foundation of China (81973883), the Shanghai Scientific Research Project
   (19ZR1458000), the first round of a three year Action Plan to Promote
   Clinical Skills and Clinical Innovation in Municipal Hospitals
   (16CR1017A), the Shanghai Traditional Chinese Medicine Medical Center of
   Chronic Disease (2017ZZ01010), the 'Innovation Team' development
   projects (IRT1270), and the Three Year Action to Accelerate the
   Development of Traditional Chinese Medicine Plan
   [ZY(2018 2020) CCCX 3003]. The authors certify that they comply with the
   ethical guidelines for authorship and publishing of the Journal of
   Cachexia, Sarcopenia and Muscle.
CR Aloysius A, 2018, SCI SIGNAL, V11, DOI 10.1126/scisignal.aan3000
   Anderson JE, 2017, BIOL REV, V92, P1389, DOI 10.1111/brv.12286
   [Anonymous], 2016, N Engl J Med, V374, P1797, DOI 10.1056/NEJMx160008
   Banks E, 2004, JAMA J AM MED ASSOC, V291, P2212, DOI 10.1001/jama.291.18.2212
   Bhandari M, 2019, NEW ENGL J MED, V381, P2199, DOI 10.1056/NEJMoa1906190
   Brauer Carmen A, 2009, JAMA, V302, P1573, DOI 10.1001/jama.2009.1462
   Braun T, 2011, NAT REV MOL CELL BIO, V12, P349, DOI 10.1038/nrm3118
   Cai Y, 2018, ACTA PHARMACOL SIN, V39, P74, DOI 10.1038/aps.2017.129
   Center JR, 2007, JAMA J AM MED ASSOC, V297, P387, DOI 10.1001/jama.297.4.387
   Chen D, 2017, ARTERIOSCL THROM VAS, V37, P856, DOI 10.1161/ATVBAHA.116.308587
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   Ding K, 2017, EXP CELL RES, V352, P84, DOI 10.1016/j.yexcr.2017.01.016
   Fink B, 2001, CLIN ORTHOP RELAT R, P207
   Goldring K, 2002, J PATHOL, V197, P457, DOI 10.1002/path.1157
   Günther S, 2013, CELL STEM CELL, V13, P590, DOI 10.1016/j.stem.2013.07.016
   Jin ZX, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287 021 02228 6
   Judson RN, 2018, CELL STEM CELL, V22, P177, DOI 10.1016/j.stem.2017.12.010
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   Leder BZ, 2019, J BONE MINER RES, V34, P1549, DOI 10.1002/jbmr.3823
   Li S, 2019, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.01010
   Liu H, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad8949
   Liu N, 2017, NAT CELL BIOL, V19, P202, DOI 10.1038/ncb3477
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Marg A, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 13650 z
   Meng YC, 2020, MOL THER NUCL ACIDS, V20, P345, DOI 10.1016/j.omtn.2019.11.038
   Mullard A, 2016, NAT REV DRUG DISCOV, V15, P669, DOI 10.1038/nrd.2016.207
   Neugebauer J, 2018, HUM MOL GENET, V27, P4249, DOI 10.1093/hmg/ddy318
   Ono Y, 2011, CELL DEATH DIFFER, V18, P222, DOI 10.1038/cdd.2010.95
   Rudolf A, 2016, CELL REP, V15, P1277, DOI 10.1016/j.celrep.2016.04.022
   Sambasivan R, 2011, DEVELOPMENT, V138, P3647, DOI 10.1242/dev.067587
   Scott RW, 2019, CELL STEM CELL, V25, P797, DOI 10.1016/j.stem.2019.11.004
   Singer A, 2015, MAYO CLIN PROC, V90, P53, DOI 10.1016/j.mayocp.2014.09.011
   Slimani L, 2015, J CACHEXIA SARCOPENI, V6, P73, DOI 10.1002/jcsm.12011
   Suzuki A, 2018, DEVELOPMENT, V145, DOI 10.1242/dev.168351
   Tang DZ, 2010, J BONE MINER RES, V25, P1234, DOI 10.1002/jbmr.21
   Wada MR, 2002, DEVELOPMENT, V129, P2987
   Xie Y, 2019, BONE RES, V7, DOI 10.1038/s41413 019 0066 7
   Yao L, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 23775 8
   Zhou YL, 2019, J INFECTION, V78, P364, DOI 10.1016/j.jinf.2019.03.004
NR 39
TC 18
Z9 20
U1 1
U2 34
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 2190 5991
EI 2190 6009
J9 J CACHEXIA SARCOPENI
JI J. Cachexia Sarcopenia Muscle
PD APR
PY 2022
VL 13
IS 2
BP 1403
EP 1417
DI 10.1002/jcsm.12938
EA FEB 2022
PG 15
WC Geriatrics & Gerontology; Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC Geriatrics & Gerontology; General & Internal Medicine
GA 0K6NM
UT WOS:000757115300001
PM 35178895
OA Green Published
DA 2025 08 17
ER

PT J
AU Taheri, S
   Fashami, FM
   Peiravian, F
   Yousefi, N
AF Taheri, Saeed
   Fashami, Fatemeh Mirzayeh
   Peiravian, Farzad
   Yousefi, Nazila
TI Teriparatide in the Treatment of Severe Postmenopausal Osteoporosis: A
   Cost Utility Analysis
SO IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCH
LA English
DT Article
DE Teriparatide; Cost effectiveness; Osteoporosis; Economic evaluation;
   Cost utility
ID PARATHYROID HORMONE 1 34; BONE MINERAL DENSITY; VITAMIN D DEFICIENCY;
   HIP FRACTURE; ECONOMIC EVALUATION; VERTEBRAL FRACTURES; IRANIAN
   POPULATION; WOMEN; ALENDRONATE; PREVENTION
AB Teriparatide is a new agent serves as a treatment of choice for severe post menopausal osteoporotic patients who are at high risk of fracture or have failed or been intolerant of previous osteoporosis therapy. The objective of this study is to estimate the cost utility of teriparatide compared with no treatment from health system perspective in Iran. A micro simulation model was developed for a cohort of hypothetical Iranian patient population (women aged 70 years, T score  2.5 with previous fracture or T score  3.0 without prior fracture) over a lifetime horizon. The model consisted of the seven health states. During each cycle, patients could have a fracture, remain healthy, remain in a post fracture state or die. Background fracture risks, mortality rates, persistence rates, utilities, medical and drug costs were derived using published sources. Total accumulated life time costs and quality adjusted life years (QALYs) were estimated. Teriparatide was associated with 4.786 QALYs and total direct costs of IRR 143,168,259 over a lifetime horizon. Compared to no treatment, teriparatide provided an additional 0.145 QALY at an incremental cost of IRR 33,511,013. The resulting incremental cost effectiveness ratio was IRR 230,333,030/QALYs gained. The probabilistic analysis showed that accepting a willingness to pay 2 and 3 GDP/capita in Iran, the probability of teriparatide being cost effective were 51% and 83%, respectively. Compared to no treatment, teriparatide was indicated to be more costly and associated with fewer fractures, more life years, and more QALYs. The result showed that teriparatide may be considered a cost effective intervention when targeted to the appropriate patients.
C1 [Taheri, Saeed; Fashami, Fatemeh Mirzayeh; Peiravian, Farzad; Yousefi, Nazila] Shahid Beheshti Univ Med Sci, Dept Pharmacoecon & Pharma Management, Sch Pharm, Tehran, Iran.
C3 Shahid Beheshti University Medical Sciences
RP Yousefi, N (通讯作者)，Shahid Beheshti Univ Med Sci, Dept Pharmacoecon & Pharma Management, Sch Pharm, Tehran, Iran.
EM n.yousefi@sbmu.ac.ir
RI ; Yousefi, Nazila/AAP 6666 2021; Mirzayeh Fashami, Fatemeh/IZS 7393 2023
OI Mirzayeh Fashami, Fatemeh/0000 0003 0189 9065; Taheri,
   Saeed/0000 0003 0614 8762
FU CinnaGen Corporation
FX This paper is the outcome of a study approved by students' research
   committee of Shahid Beheshti University of Medical Sciences. This study
   was funded by CinnaGen Corporation. Saeed Taheri was paid consultants
   for the purposes of this project. Nazila Yousefi, Farzad Peiravian, and
   Fatemeh Mirzayeh Fashami have disclosed that they have no relevant
   financial relationships. The authors have no conflicts of interest to
   declare.
CR Abdi F, 2017, IRAN J PHARM RES, V16, P380
   Abdoli G., 2009, EC RES REV, V10, P135
   Abolhassani F, 2006, BONE, V39, P408, DOI 10.1016/j.bone.2006.01.144
   [Anonymous], 2017, UPTODATE CLIN GUID
   [Anonymous], 2016, TAR HEALTHC SERV PUB
   [Anonymous], CHOOS INT AR COST EF
   [Anonymous], MIDDL E AFR AUD
   Azar AAEF, 2017, MED J ISLAM REPUB IR, P31
   Azizsoltani A, 2018, IRAN J PHARM RES, V17, P1057
   Borgstrom Fredrik, 2010, J Med Econ, V13, P381, DOI 10.3111/13696998.2010.499072
   Camacho PM, 2016, ENDOCR PRACT, V22, P1111, DOI 10.4158/EP161435.ESGL
   Harvey N, 2010, NAT REV RHEUMATOL, V6, P99, DOI 10.1038/nrrheum.2009.260
   Johnell O, 2006, OSTEOPOROSIS INT, V17, P1726, DOI 10.1007/s00198 006 0172 4
   Johnell O, 2004, OSTEOPOROSIS INT, V15, P38, DOI 10.1007/s00198 003 1490 4
   Johnell O, 2003, PHARMACOECONOMICS, V21, P305, DOI 10.2165/00019053 200321050 00002
   Jönsson B, 2011, OSTEOPOROSIS INT, V22, P967, DOI 10.1007/s00198 010 1424 x
   Kanis JA, 2012, OSTEOPOROSIS INT, V23, P2239, DOI 10.1007/s00198 012 1964 3
   Kanis JA, 2004, OSTEOPOROSIS INT, V15, P108, DOI 10.1007/s00198 003 1516 y
   Kanis JA, 2004, OSTEOPOROSIS INT, V15, P20, DOI 10.1007/s00198 003 1463 7
   Kiani S, 2010, ARCH IRAN MED, V13, P333, DOI 010134/AIM.0014
   Landfeldt E, 2012, OSTEOPOROSIS INT, V23, P433, DOI 10.1007/s00198 011 1549 6
   Lindsay R, 2001, J BONE MINER RES, V16, pS162
   Liu H, 2006, ARCH INTERN MED, V166, P1209, DOI 10.1001/archinte.166.11.1209
   Lundberg L, 1999, EUR J PUBLIC HEALTH, V9, P211, DOI 10.1093/eurpub/9.3.211
   Lundkvist J, 2006, OSTEOPOROSIS INT, V17, P201, DOI 10.1007/s00198 005 1959 4
   Maghbooli Z, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen 2016 014898
   Maharlouei N, 2014, ARCH OSTEOPOROS, V9, DOI 10.1007/s11657 013 0165 9
   Marques A, 2016, CALCIFIED TISSUE INT, V99, P131, DOI 10.1007/s00223 016 0132 8
   Melton LJ, 2005, J BONE MINER RES, V20, P886, DOI 10.1359/jbmr.2005.20.5.886
   Moayyeri A, 2006, OSTEOPOROSIS INT, V17, P1252, DOI 10.1007/s00198 006 0105 2
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Parthan A, 2014, BONE, V59, P105, DOI 10.1016/j.bone.2013.11.002
   Randell A, 1995, OSTEOPOROSIS INT, V5, P427, DOI 10.1007/BF01626603
   Rezaei S, 2017, EPIDEMIOL HEALTH, V39, DOI 10.4178/epih.e2017038
   Saeb M., 2014, IRAN J INJURY VIOLEN, V6, P16
   Soveid M, 2005, OSTEOPOROSIS INT, V16, P1412, DOI 10.1007/s00198 005 1854 z
   Stevenson M, 2005, HEALTH TECHNOL ASSES, V9, P1
   Ström O, 2007, OSTEOPOROSIS INT, V18, P1047, DOI 10.1007/s00198 007 0349 5
   Tabrizi R, 2018, IRAN J MED SCI, V43, P125
   Tosteson ANA, 2008, AM J MANAG CARE, V14, P605
   van Schoor NM, 2008, BONE, V42, P260, DOI 10.1016/j.bone.2007.11.002
   Zethraeus N, 2002, SSE EFI WORK PAP SER
NR 42
TC 9
Z9 9
U1 0
U2 3
PU SHAHEED BEHESHTI UNIV, SCH PHARMACY
PI TEHRAN
PA NO 10 SHAMS ALLEY, VALI E ASR ST, TEHRAN, 00000, IRAN
SN 1735 0328
EI 1726 6890
J9 IRAN J PHARM RES
JI Iran. J. Pharm. Res.
PD SPR
PY 2019
VL 18
IS 2
BP 1073
EP 1085
DI 10.22037/ijpr.2019.1100679
PG 13
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA HZ6JW
UT WOS:000468959200049
PM 31531089
DA 2025 08 17
ER

PT J
AU Yamamoto, S
   Karaboyas, A
   Komaba, H
   Taniguchi, M
   Nomura, T
   Bieber, BA
   De Sequera, P
   Christensson, A
   Pisoni, RL
   Robinson, BM
   Fukagawa, M
AF Yamamoto, Suguru
   Karaboyas, Angelo
   Komaba, Hirotaka
   Taniguchi, Masatomo
   Nomura, Takanobu
   Bieber, Brian A.
   De Sequera, Patricia
   Christensson, Anders
   Pisoni, Ronald L.
   Robinson, Bruce M.
   Fukagawa, Masafumi
TI Mineral and bone disorder management in hemodialysis patients: comparing
   PTH control practices in Japan with Europe and North America: the
   Dialysis Outcomes and Practice Patterns Study (DOPPS)
SO BMC NEPHROLOGY
LA English
DT Article
DE Parathyroid hormone; Hemodialysis; Dialysis outcomes and practice
   patterns study; PTH slope; Japanese society for Dialysis therapy
ID CLINICAL PRACTICE GUIDELINE; KIDNEY DISEASE; SECONDARY
   HYPERPARATHYROIDISM; CKD MBD; MORTALITY; RISK; ASSOCIATION; CALCIUM;
   CINACALCET; PHOSPHATE
AB Background: High circulating level of parathyroid hormone (PTH) is associated with elevated mortality in dialysis patients. The Japanese Society for Dialysis Therapy guideline suggests a lower PTH target than other international guidelines; thus, PTH control may differ in Japan compared with other regions, and be associated with mortality.
   Methods: We analyzed data from hemodialysis patients with >= 3 measurements of PTH during the first 9 months after enrollment in the Dialysis Outcomes and Practice Patterns Study (DOPPS) phases 4 5 (2009 2015). PTH control was assessed by the mean, slope, and mean squared error (MSE) of all PTH measurements over the 9 month run in period. Distribution of each PTH control was assessed by regions (Europe/Australia/New Zealand [Eur/ANZ], Japan and North America) and dialysis vintage. Mortality rates were compared across PTH control categories using Cox regression models.
   Results: Mean PTH was lower in Japan than in other regions across dialysis vintage categories. In patients with dialysis vintage < 90 days, PTH level was more likely to decline > 5% per month in Japan (48% of patients) versus Eur/ANZ (35%) and North America (35%). In patients with dialysis vintage > 1 year, Japanese patients maintained steady PTH, while patients in Eur/ANZ and North America were more likely to experience a PTH increase. Mean PTH was associated with mortality in the overall samples (highest mortality rate for PTH > 600 pg/mL, hazard ratio, 1.35; 95% confidence interval, 1.20 to 1.52 vs PTH 200 399 pg/mL), and the association was obvious in the prevalent patients (hazard ratio, 1.44; 95% confidence interval, 1.26 to 1.65). PTH slope and MSE did not show significant association with mortality in the overall sample as well as in subjects stratified both by region and dialysis vintage.
   Conclusion: PTH control in hemodialysis patients, as measured by keeping a stable PTH level over 9 months, was observed in Japan contrasted with other regions. High PTH mean, but not increased PTH slope and MSE, was associated with mortality especially in prevalent patients.
C1 [Yamamoto, Suguru] Niigata Univ, Div Clin Nephrol & Rheumatol, Grad Sch Med & Dent Sci, 1 757 Asahimachi Dori, Niigata 9518510, Japan.
   [Karaboyas, Angelo; Bieber, Brian A.; Pisoni, Ronald L.; Robinson, Bruce M.] Arbor Res Collaborat Hlth, Ann Arbor, MI USA.
   [Komaba, Hirotaka; Fukagawa, Masafumi] Tokai Univ, Div Nephrol Endocrinol & Metab, Sch Med, Isehara, Kanagawa, Japan.
   [Taniguchi, Masatomo] Fukuoka Renal Clin, Fukuoka, Fukuoka, Japan.
   [Nomura, Takanobu] Kyowa Hakko Kirin Co Ltd, Med Affairs Dept, Tokyo, Japan.
   [De Sequera, Patricia] Univ Hosp Infanta Leonor, Madrid, Spain.
   [Christensson, Anders] Skane Univ Hosp, Dept Nephrol, Lund, Sweden.
C3 Niigata University; Arbor Research Collaborative for Health; Tokai
   University; Kyowa Kirin Ltd; Hospital Universitario Infanta Leonor; Lund
   University; Skane University Hospital
RP Yamamoto, S (通讯作者)，Niigata Univ, Div Clin Nephrol & Rheumatol, Grad Sch Med & Dent Sci, 1 757 Asahimachi Dori, Niigata 9518510, Japan.
EM yamamots@med.niigata u.ac.jp
RI ; Yamamoto, Suguru/F 8066 2014; Komaba, Hirotaka/C 9199 2011;
   de Sequera, Patricia/HZH 5681 2023
OI Christensson, Anders/0000 0002 7328 8418; Bieber,
   Brian/0000 0001 8505 0979; Robinson, Bruce/0000 0003 0749 1714;
   Yamamoto, Suguru/0000 0002 8279 2966; Komaba,
   Hirotaka/0000 0002 1704 4507; 
FU Amgen; Kyowa Hakko Kirin; Baxter Healthcare; Fresenius Medical Care
   Asia Pacific Ltd.; Fresenius Medical Care Canada Inc.; Kidney Care UK;
   MEDICE Arzneimittel Putter GmbH Co KG; Otsuka America Pharmaceutical,
   Inc.; Association of German Nephrology Centres (Verband Deutsche
   Nierenzentren e.V.); AstraZeneca; European Renal Association European
   Dialysis & Transplant Association (ERA EDTA); German Society of
   Nephrology (DGfN); Janssen; Japanese Society for Peritoneal Dialysis
   (JSPD); Keryx; Proteon; Societa Italiana di Nefrologia (SIN); Vifor
   Fresenius Medical Care Renal Pharma; Belgian Federal Public Service of
   Public Health in Belgium; French National Institute of Health and
   Medical Research (INSERM) in France; Cancer Care Ontario (CCO) through
   the Ontario Renal Network (ORN) in Canada; National Health & Medical
   Research Council (NHMRC) in Australia; National Institute for Health
   Research (NIHR) via the Comprehensive Clinical Research Network (CCRN)
   in the United Kingdom; Thailand Research Foundation (TRF); Chulalongkorn
   University Matching Fund; King Chulalongkorn Memorial Hospital Matching
   Fund; National Research Council of Thailand (NRCT) in Thailand
FX The DOPPS Program is supported by Amgen, Kyowa Hakko Kirin, and Baxter
   Healthcare, Fresenius Medical Care Asia Pacific Ltd., Fresenius Medical
   Care Canada Inc., Kidney Care UK, MEDICE Arzneimittel Putter GmbH & Co
   KG, Otsuka America Pharmaceutical, Inc., and The Association of German
   Nephrology Centres (Verband Deutsche Nierenzentren e.V.). Additional
   support for specific projects and countries is provided by Amgen,
   AstraZeneca, European Renal Association European Dialysis & Transplant
   Association (ERA EDTA), German Society of Nephrology (DGfN), Janssen,
   Japanese Society for Peritoneal Dialysis (JSPD), Keryx, Proteon, Societa
   Italiana di Nefrologia (SIN), and Vifor Fresenius Medical Care Renal
   Pharma. Public funding and support is provided for specific DOPPS
   projects, ancillary studies, or affiliated research projects by the
   Belgian Federal Public Service of Public Health in Belgium; the French
   National Institute of Health and Medical Research (INSERM) in France;
   Cancer Care Ontario (CCO) through the Ontario Renal Network (ORN) in
   Canada; the National Health & Medical Research Council (NHMRC) in
   Australia; the National Institute for Health Research (NIHR) via the
   Comprehensive Clinical Research Network (CCRN) in the United Kingdom;
   and the Thailand Research Foundation (TRF), Chulalongkorn University
   Matching Fund, King Chulalongkorn Memorial Hospital Matching Fund, and
   National Research Council of Thailand (NRCT) in Thailand. All support is
   provided without restrictions on publications.
CR Bellasi A, 2016, CLIN NEPHROL, V86, P113, DOI 10.5414/CN108827
   Bover J, 2017, J NEPHROL, V30, P677, DOI 10.1007/s40620 017 0404 z
   Drechsler C, 2009, NEPHROL DIAL TRANSPL, V24, P3151, DOI 10.1093/ndt/gfp260
   Eknoyan G, 2003, AM J KIDNEY DIS, V41, pS1, DOI 10.1016/S0272 6386(03)00111 2
   Floege J, 2011, NEPHROL DIAL TRANSPL, V26, P1948, DOI 10.1093/ndt/gfq219
   Fukagawa M, 2013, THER APHER DIAL, V17, P247, DOI 10.1111/1744 9987.12058
   Fukagawa M, 2011, AM J NEPHROL, V33, P427, DOI 10.1159/000327654
   Fukagawa M, 2008, THER APHER DIAL, V12, P514, DOI 10.1111/j.1744 9987.2008.00648.x
   Gallieni M, 2016, J NEPHROL, V29, P71, DOI 10.1007/s40620 015 0202 4
   Goodkin DA, 2003, J AM SOC NEPHROL, V14, P3270, DOI 10.1097/01.ASN.0000100127.54107.57
   Gutiérrez OM, 2008, NEW ENGL J MED, V359, P584, DOI 10.1056/NEJMoa0706130
   Isakova T, 2017, AM J KIDNEY DIS, V70, P737, DOI 10.1053/j.ajkd.2017.07.019
   Jadoul M, 2006, KIDNEY INT, V70, P1358, DOI 10.1038/sj.ki.5001754
   Fernandez Martín JL, 2015, NEPHROL DIAL TRANSPL, V30, P1542, DOI 10.1093/ndt/gfv099
   Moe S, 2006, KIDNEY INT, V69, P1945, DOI 10.1038/sj.ki.5000414
   Moe SM, 2015, CIRCULATION, V132, P27, DOI 10.1161/CIRCULATIONAHA.114.013876
   Robinson BM, 2016, LANCET, V388, P294, DOI 10.1016/S0140 6736(16)30448 2
   Saran R, 2018, AM J KIDNEY DIS, V71, pS1, DOI 10.1053/j.ajkd.2018.01.002
   Taniguchi M, 2013, THER APHER DIAL, V17, P221, DOI 10.1111/1744 9987.12030
   Taylor JMG, 2002, AM J EPIDEMIOL, V156, P774, DOI 10.1093/aje/kwf110
   Tentori F, 2008, AM J KIDNEY DIS, V52, P519, DOI 10.1053/j.ajkd.2008.03.020
   Tentori F, 2015, CLIN J AM SOC NEPHRO, V10, P98, DOI 10.2215/CJN.12941213
   Torres PAU, 2017, J NEPHROL, V30, P653, DOI 10.1007/s40620 017 0398 6
   Uhlig K, 2010, AM J KIDNEY DIS, V55, P773, DOI 10.1053/j.ajkd.2010.02.340
   Villa Bellosta R, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173831
   Yamamoto S, 2017, J NEPHROL, V30, P623, DOI 10.1007/s40620 017 0406 x
   Yamamoto Suguru, 2013, Biochem J, V456, pe1, DOI 10.1042/BJ20131282
NR 27
TC 21
Z9 25
U1 0
U2 3
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471 2369
J9 BMC NEPHROL
JI BMC Nephrol.
PD OCT 5
PY 2018
VL 19
AR 253
DI 10.1186/s12882 018 1056 5
PG 10
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Urology & Nephrology
GA GV8YB
UT WOS:000446435700002
PM 30290781
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Edem, PE
   Sinnes, JP
   Pektor, S
   Bausbacher, N
   Rossin, R
   Yazdani, A
   Miederer, M
   Kjær, A
   Valliant, JF
   Robillard, MS
   Rösch, F
   Herth, MM
AF Edem, Patricia E.
   Sinnes, Jean Philippe
   Pektor, Stefanie
   Bausbacher, Nicole
   Rossin, Raffaella
   Yazdani, Abdolreza
   Miederer, Matthias
   Kjaer, Andreas
   Valliant, John F.
   Robillard, Marc S.
   Roesch, Frank
   Herth, Matthias M.
TI Evaluation of the inverse electron demand Diels Alder reaction in rats
   using a scandium 44 labelled tetrazine for pretargeted PET imaging
SO EJNMMI RESEARCH
LA English
DT Article
DE Scandium 44 (Sc 44); Positron emission tomography (PET); Tetrazine;
   Trans cyclooctene (TCO); Pretargeted imaging; Inverse electron demand
   Diels Alder (IEDDA); Bisphosphonates; Alendronic acid
ID IN VIVO CHEMISTRY; BIOORTHOGONAL CHEMISTRY; SCANDIUM(III) COMPLEXES;
   TRANS CYCLOOCTENE; BONE SEEKING; SC 44; RADIONUCLIDE;
   RADIOIMMUNOTHERAPY; CANCER; PARAMETERS
AB BackgroundPretargeted imaging allows the use of short lived radionuclides when imaging the accumulation of slow clearing targeting agents such as antibodies. The biotin (strept)avidin and the bispecific antibody hapten interactions have been applied in clinical pretargeting studies; unfortunately, these systems led to immunogenic responses in patients. The inverse electron demand Diels Alder (IEDDA) reaction between a radiolabelled tetrazine (Tz) and a trans cyclooctene (TCO) functionalized targeting vector is a promising alternative for clinical pretargeted imaging due to its fast reaction kinetics. This strategy was first applied in nuclear medicine using an In 111 labelled Tz to image TCO functionalized antibodies in tumour bearing mice. Since then, the IEDDA has been used extensively in pretargeted nuclear imaging and radiotherapy; however, these studies have only been performed in mice. Herein, we report the Sc 44 labelling of a Tz and evaluate it in pretargeted imaging in Wistar rats.Results(44)Sc was obtained from an in house Ti 44/Sc 44 generator. A 1,4,7,10 tetraazacyclododecane 1,4,7,10 tetraacetic acid (DOTA) functionalized tetrazine was radiolabelled with Sc 44 resulting in radiochemical yields of 85 95%, a radiochemical purity >99% at an apparent molar activity of 1GBq/mmol. The Sc 44 labelled Tz maintained stability in solution for up to 24h. A TCO functionalized bisphosphonate, which accumulates in skeletal tissue, was used as a targeting vector to evaluate the Sc 44 labelled Tz. Biodistribution data of the Sc 44 labelled Tz showed specific uptake (0.90.3% ID/g) in the bones (humerus and femur) of rats pre treated with the TCO functionalized bisphosphonate. This uptake was not present in rats not receiving pre treatment (<0.03% ID/g).Conclusions p id=Par3 We have prepared a Sc 44 labelled Tz and used it in pretargeted PET imaging with rats treated with TCO functionalized bisphosponates. This allowed for the evaluation of the IEDDA reaction in animals larger than a typical mouse. Non target accumulation was low, and there was a 30 fold higher bone uptake in the pre treated rats compared to the non treated controls. Given its convenient half life and the ability to perform positron emission tomography with a previously studied DOTA functionalized Tz, scandium 44 (t(1/2)=3.97h) proved to be a suitable radioisotope for this study.
C1 [Edem, Patricia E.; Kjaer, Andreas; Herth, Matthias M.] Rigshosp, Dept Clin Physiol Nucl Med & PET, Blegdamsvej 9, DK 2100 Copenhagen, Denmark.
   [Edem, Patricia E.; Kjaer, Andreas] Univ Copenhagen, Dept Biomed Sci, Cluster Mol Imaging, Blegdamsvej 3, DK 2200 Copenhagen, Denmark.
   [Edem, Patricia E.; Herth, Matthias M.] Univ Copenhagen, Dept Drug Design & Pharmacol, Jagtvej 162, DK 2100 Copenhagen, Denmark.
   [Sinnes, Jean Philippe; Roesch, Frank] Johannes Gutenberg Univ Mainz, Saarstr 21, D 55122 Mainz, Germany.
   [Pektor, Stefanie; Bausbacher, Nicole; Miederer, Matthias] Univ Med Ctr Mainz, Langenbeckstr 1, D 55131 Mainz, Germany.
   [Yazdani, Abdolreza; Valliant, John F.] McMaster Univ, 1280 Main St W, Hamilton, ON L8S 4L8, Canada.
   [Rossin, Raffaella; Robillard, Marc S.] Tagworks Pharmaceut, Geert Grootepl Zuid 10, NL 6525 GA Nijmegen, Netherlands.
   [Yazdani, Abdolreza] Shahid Beheshti Univ Med Sci, Sch Pharm, Pharmaceut Chem & Radiopharm Dept, POB 14155 6153, Tehran, Iran.
C3 Rigshospitalet; University of Copenhagen; University of Copenhagen;
   Johannes Gutenberg University of Mainz; Johannes Gutenberg University of
   Mainz; McMaster University; Shahid Beheshti University Medical Sciences
RP Herth, MM (通讯作者)，Rigshosp, Dept Clin Physiol Nucl Med & PET, Blegdamsvej 9, DK 2100 Copenhagen, Denmark.; Herth, MM (通讯作者)，Univ Copenhagen, Dept Drug Design & Pharmacol, Jagtvej 162, DK 2100 Copenhagen, Denmark.
EM Patricia.edem@sund.ku.dk; matthias.herth@sund.ku.dk
RI Roesch, Frank/AAU 9403 2020; Kjaer, Andreas/E 8932 2015; Miederer,
   Matthias/C 4405 2014
OI Kjaer, Andreas/0000 0002 2706 5547; 
FU European Union's Horizon 2020 research and innovation programme
   [668532]; Iran's National Elites Foundation; H2020 Societal Challenges
   Programme [668532] Funding Source: H2020 Societal Challenges Programme
FX This project has received funding from the European Union's Horizon 2020
   research and innovation programme under grant agreement no 668532:
   Click it and from the Iran's National Elites Foundation.
CR Altai M, 2016, J NUCL MED, V57, P431, DOI 10.2967/jnumed.115.162248
   Baum RichardP., 2014, THERAPEUTIC NUCL MED
   Bergmann R, 2016, EJNMMI RES, V6, DOI 10.1186/s13550 016 0161 3
   Boswell CA, 2014, MOL PHARMACEUT, V11, P1591, DOI 10.1021/mp400748t
   Bunka M, 2016, APPL RADIAT ISOTOPES, V110, P129, DOI 10.1016/j.apradiso.2016.01.006
   Denk C, 2014, ANGEW CHEM INT EDIT, V53, P9655, DOI 10.1002/anie.201404277
   Devaraj NK, 2009, ANGEW CHEM INT EDIT, V48, P7013, DOI 10.1002/anie.200903233
   Eppard E, 2017, THERANOSTICS, V7, P4359, DOI 10.7150/thno.20586
   Herth MM, 2013, CHEM COMMUN, V49, P3805, DOI 10.1039/c3cc41027g
   Holub J, 2015, CONTRAST MEDIA MOL I, V10, P122, DOI 10.1002/cmmi.1606
   Houghton JL, 2017, MOL CANCER THER, V16, P124, DOI 10.1158/1535 7163.MCT 16 0503
   Kerdjoudj R, 2016, DALTON T, V45, P1398, DOI 10.1039/c5dt04084a
   Knight JC, 2014, AM J NUCL MED MOLEC, V4, P96
   Koumarianou E, 2012, APPL RADIAT ISOTOPES, V70, P2669, DOI 10.1016/j.apradiso.2012.08.004
   Kratochwil C, 2016, J NUCL MED, V57, P1170, DOI 10.2967/jnumed.115.171397
   Larson SM, 2015, NAT REV CANCER, V15, P347, DOI 10.1038/nrc3925
   Meckel M, 2016, EJNMMI RADIOPHARM CH, V1, DOI 10.1186/s41181 016 0017 1
   Meyer JP, 2017, J MED CHEM, V60, P8201, DOI 10.1021/acs.jmedchem.7b01108
   Müller C, 2013, J NUCL MED, V54, P2168, DOI 10.2967/jnumed.113.123810
   Nichols B, 2014, CHEM COMMUN, V50, P5215, DOI 10.1039/c3cc49530b
   Passah A, 2017, EUR J NUCL MED MOL I, V44, P41, DOI 10.1007/s00259 016 3469 3
   Pfister T, 2005, BASIC CLIN PHARMACOL, V97, P374, DOI 10.1111/j.1742 7843.2005.pto_160.x
   Pniok M, 2014, CHEM EUR J, V20, P7944, DOI 10.1002/chem.201402041
   Roesch F, 2012, CURR RADIOPHARM, V5, P187, DOI 10.2174/1874471011205030187
   Rossin R, 2013, J NUCL MED, V54, P1989, DOI 10.2967/jnumed.113.123745
   Rossin R, 2010, ANGEW CHEM INT EDIT, V49, P3375, DOI 10.1002/anie.200906294
   SATO M, 1991, J CLIN INVEST, V88, P2095, DOI 10.1172/JCI115539
   Saxon E, 2000, SCIENCE, V287, P2007, DOI 10.1126/science.287.5460.2007
   Schillaci O, 2017, EUR J NUCL MED MOL I, V44, P563, DOI 10.1007/s00259 017 3616 5
   Shah MA, 2017, BIOCONJUGATE CHEM, V28, P3007, DOI 10.1021/acs.bioconjchem.7b00612
   Stéen EJL, 2018, BIOMATERIALS, V179, P209, DOI 10.1016/j.biomaterials.2018.06.021
   van den Bosch SM, 2013, NUCL MED BIOL, V40, P415, DOI 10.1016/j.nucmedbio.2012.12.006
   Van Heertum RL, 2015, DRUG DES DEV THER, V9, P5215, DOI 10.2147/DDDT.S87561
   Vito A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167425
   Vugts DJ, 2011, BIOCONJUGATE CHEM, V22, P2072, DOI 10.1021/bc200298v
   Yazdani A, 2017, DALTON T, V46, P14691, DOI 10.1039/c7dt01497j
   Yazdani A, 2016, J MED CHEM, V59, P9381, DOI 10.1021/acs.jmedchem.6b00938
NR 37
TC 27
Z9 30
U1 1
U2 32
PU SPRINGEROPEN
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 2191 219X
J9 EJNMMI RES
JI EJNMMI Res.
PD MAY 28
PY 2019
VL 9
AR 49
DI 10.1186/s13550 019 0520 y
PG 8
WC Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI EXPANDED)
SC Radiology, Nuclear Medicine & Medical Imaging
GA IA3WC
UT WOS:000469492700001
PM 31140047
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Lu, QQ
   Liu, H
   Cao, T
AF Lu, Qiqi
   Liu, Hua
   Cao, Tong
TI Efficient Isolation of Bone Marrow Adipocyte Progenitors by Silica
   Microbeads Incubation
SO STEM CELLS AND DEVELOPMENT
LA English
DT Article
ID INDUCED OSTEOCLAST DIFFERENTIATION; MESENCHYMAL STEM CELLS; ACID BINDING
   PROTEINS; IN VITRO; ADIPOGENESIS; FAT; OSTEOBLASTOGENESIS;
   SUBPOPULATION; OBESITY; MODEL
AB Excessive bone marrow adipocytes (BMAs) formation is tightly associated with development of osteoporosis. Considering the high heterogeneity of bone marrow stromal cells (BMSCs), identification of bone marrow adipocyte progenitors (BMAPs) within heterogeneous BMSCs may provide better cellular models for research regarding osteoporosis development and therapy. However, currently there is no efficient method or specific surface makers that are available for BMAPs isolation. In the current study, we developed a novel BMAPs isolation method based on silica microbeads incubation and subsequent centrifugation in ficoll paque. The Sca 1(+)CD73( )CD90( )CD105(+) subpopulation selected by this method exhibited significantly stronger adipogenic potential than nonselected BMSCs in vitro and could homogeneously differentiate into mature adipocytes within 4 days. Moreover, these cells also highly expressed a series of adipogenesis related genes even before differentiation. After long term culture, however, BMAPs would gradually lose high adipogenic ability, but sorting CD105(+) cells from BMAPs in later passages was able to retrieve the highly adipogenic subpopulation. In conclusion, this study demonstrated that BMAPs subpopulation could be effectively isolated from heterogeneous BMSCs by a special silica microbeads incubation method and re enriched by sorting CD105(+) cells. These findings offer convenient and repeatable approaches to obtain pure BMAPs for research regarding pathogenic mechanisms and therapeutics development of osteoporosis.
C1 [Lu, Qiqi; Cao, Tong] Natl Univ Singapore, Fac Dent, Singapore 119083, Singapore.
   [Lu, Qiqi; Cao, Tong] Natl Univ Singapore, NUS Grad Sch Integrat Sci & Engn, Singapore 119083, Singapore.
   [Liu, Hua] Zhejiang Univ, Ctr Stem Cell & Tissue Engn, Hangzhou 310003, Zhejiang, Peoples R China.
   [Liu, Hua] Zhejiang Univ, Zhejiang Prov Key Lab Tissue Engn & Regenerat Med, Hangzhou 310003, Zhejiang, Peoples R China.
C3 National University of Singapore; National University of Singapore;
   Zhejiang University; Zhejiang University
RP Cao, T (通讯作者)，Natl Univ Singapore, Fac Dent, Singapore 119083, Singapore.
EM dencaot@nus.edu.sg
RI Tong CAO, iHuman/B 1008 2008
OI Liu, Hua/0000 0001 7729 1246; CAO, Tong/0000 0002 7994 9627
FU Academic Research Fund, Singapore Ministry of Education [R221000023112];
   National University Health System [R221000053515]
FX This work was partially supported by grants from Academic Research Fund,
   Singapore Ministry of Education: R221000023112 and research grant,
   National University Health System: R221000053515.
CR Abdallah BM, 2012, BONE, V50, P540, DOI 10.1016/j.bone.2011.06.030
   Bakondi B, 2009, MOL THER, V17, P1938, DOI 10.1038/mt.2009.185
   BERESFORD JN, 1992, J CELL SCI, V102, P341
   Chan GK, 2002, GERONTOLOGY, V48, P62, DOI 10.1159/000048929
   Clabaut A, 2010, DIFFERENTIATION, V80, P40, DOI 10.1016/j.diff.2010.04.004
   Duque G, 2008, CURR OPIN RHEUMATOL, V20, P429, DOI 10.1097/BOR.0b013e3283025e9c
   Goto H, 2011, CYTOKINE, V56, P662, DOI 10.1016/j.cyto.2011.09.005
   Grey A, 2007, J CLIN ENDOCR METAB, V92, P1305, DOI 10.1210/jc.2006 2646
   Halade GV, 2010, J NUTR BIOCHEM, V21, P1162, DOI 10.1016/j.jnutbio.2009.10.002
   Hozumi A, 2009, BIOCHEM BIOPH RES CO, V382, P780, DOI 10.1016/j.bbrc.2009.03.111
   Kawai M, 2009, NAT REV RHEUMATOL, V5, P365, DOI 10.1038/nrrheum.2009.102
   Liu H, 2009, J CELL MOL MED, V13, P2436, DOI 10.1111/j.1582 4934.2009.00793.x
   Maeda K, 2005, CELL METAB, V1, P107, DOI 10.1016/j.cmet.2004.12.008
   Maurin AC, 2000, BONE, V26, P485, DOI 10.1016/S8756 3282(00)00252 0
   Muraglia A, 2000, J CELL SCI, V113, P1161
   Obinata M, 2007, CANCER SCI, V98, P275, DOI 10.1111/j.1349 7006.2007.00399.x
   Pevsner Fischer M, 2011, STEM CELL REV REP, V7, P560, DOI 10.1007/s12015 011 9229 7
   Post S, 2008, BONE, V43, P32, DOI 10.1016/j.bone.2008.03.011
   Poulos SP, 2010, EXP BIOL MED, V235, P1185, DOI 10.1258/ebm.2010.010063
   Rosen CJ, 2009, CRIT REV EUKAR GENE, V19, P109, DOI 10.1615/CritRevEukarGeneExpr.v19.i2.20
   Rosen ED, 2000, ANNU REV CELL DEV BI, V16, P145, DOI 10.1146/annurev.cellbio.16.1.145
   Rosen ED, 2006, NAT REV MOL CELL BIO, V7, P885, DOI 10.1038/nrm2066
   Russell KC, 2010, STEM CELLS, V28, P788, DOI 10.1002/stem.312
   Takada I, 2009, NAT REV RHEUMATOL, V5, P442, DOI 10.1038/nrrheum.2009.137
   Tan NS, 2002, MOL CELL BIOL, V22, P5114, DOI 10.1128/MCB.22.14.5114 5127.2002
   Yang JY, 2009, J NUTR BIOCHEM, V20, P537, DOI 10.1016/j.jnutbio.2008.05.013
   Zebisch K, 2012, ANAL BIOCHEM, V425, P88, DOI 10.1016/j.ab.2012.03.005
NR 27
TC 5
Z9 5
U1 0
U2 10
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1547 3287
EI 1557 8534
J9 STEM CELLS DEV
JI Stem Cells Dev.
PD SEP 15
PY 2013
VL 22
IS 18
BP 2520
EP 2531
DI 10.1089/scd.2013.0199
PG 12
WC Cell & Tissue Engineering; Hematology; Medicine, Research &
   Experimental; Transplantation
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Hematology; Research & Experimental Medicine;
   Transplantation
GA 246AF
UT WOS:000326506900007
PM 23806125
OA Green Published
DA 2025 08 17
ER

PT J
AU Kumar, S
   Majhi, RK
   Sanyasi, S
   Goswami, C
   Goswami, L
AF Kumar, Satish
   Majhi, Rakesh Kumar
   Sanyasi, Sridhar
   Goswami, Chandan
   Goswami, Luna
TI Acrylic acid grafted tamarind kernel polysaccharide based hydrogel for
   bone tissue engineering in absence of any osteo inducing factors
SO CONNECTIVE TISSUE RESEARCH
LA English
DT Article
DE Biocompatibility; bone; hydrogel; osteoblasts; polysaccharide; tissue
   engineering
ID IN VITRO; STEM CELLS; DIFFERENTIATION; SCAFFOLDS; ADHESION; MEDICINE;
   DESIGN
AB Purpose: With increased life expectancy, disorders in lifestyle and other clinical conditions, and the changes in the connective tissues such as in bone, impose diverse biomedical problems. Cells belong to osteogenic lineages are extremely specific for their surface requirements. Therefore, suitable surfaces are the critical bottle neck for successful bone tissue engineering. This study involves assessment of polysaccharide based hydrogel which effectively allows growth, differentiation and mineralisation of osteogenic cells even in the absence of osteogenic inducing factors. Materials and methods: Tamarind Kernel Polysaccharide was grafted with acrylic acid at different mole ratio. The critical parameter, surface morphology for bio application was assessed by SEM. MTT assay has been performed with hydrogels on Saos 2 cells. The biocompatibility and adhesion of different cell lines (F 11, Saos 2, Raw 264.7 and MSCs) on hydrogel surface was performed by Phalloidin and DAPI staining. Further the differentiation, mineralization and expression of different osteogenic markers, ALP assay, Alizarin Red staining and q PCR was performed. Results: The hydrogels show highly porous and interconnected pores. MTT assay demonstrates the hydrogel have no cytotoxicity towards Saos 2 cells and are suitable for proliferation of different lineage of cell lines. ALP, Alizarin red staining and q PCR assay shows that the hydrogel surface enhances the differentiation, mineralization and expression of different osteogenic genes in Saos 2 cells in the absence of any osteogenic inducing factors. Conclusion Synthesized hydrogel surface triggers signalling events towards osteogenesis even in the absence of added growth factors. We proposed that this material can be used for effective bone tissue engineering in vitro at low cost.
C1 [Kumar, Satish; Sanyasi, Sridhar; Goswami, Luna] KIIT Univ, Sch Biotechnol, Bhubaneswar, Odisha, India.
   [Majhi, Rakesh Kumar; Goswami, Chandan] Natl Inst Sci Educ & Res, Sch Biol Sci, Bhubaneswar, Orissa, India.
   [Majhi, Rakesh Kumar; Goswami, Chandan] Homi Bhabha Natl Inst, Training Sch Complex, Bombay, Maharashtra, India.
C3 Kalinga Institute of Industrial Technology (KIIT); National Institute of
   Science Education & Research (NISER); Homi Bhabha National Institute
RP Goswami, L (通讯作者)，KIIT Univ, Sch Biotechnol, Bhubaneswar, Odisha, India.
EM lbh_1975@yahoo.co.in
RI ; Majhi, Rakesh/AAB 4342 2020; kumar, satish/AAY 1891 2020
OI Majhi, Rakesh Kumar/0000 0001 6999 1349; 
FU ICMR [5/20/1(Bio)/2014/NCD I]
FX Funding from ICMR (5/20/1(Bio)/2014/NCD I) and intramural support from
   NISER is appreciated.
CR Ahmad Aftab, 2013, Asian Pacific Journal of Tropical Biomedicine, V3, P337, DOI 10.1016/S2221 1691(13)60075 1
   Aravamudhan A, 2013, J BIOMED NANOTECHNOL, V9, P719, DOI 10.1166/jbn.2013.1574
   Bennett SL, 2003, J CARDIAC SURG, V18, P494, DOI 10.1046/j.0886 0440.2003.00303.x
   Benoit DSW, 2006, TISSUE ENG, V12, P1663, DOI 10.1089/ten.2006.12.1663
   Birmingham E, 2012, EUR CELLS MATER, V23, P13, DOI 10.22203/eCM.v023a02
   Chen GP, 2002, MACROMOL BIOSCI, V2, P67, DOI 10.1002/1616 5195(20020201)2:2<67::AID MABI67>3.0.CO;2 F
   Goswami C, 2007, J NEUROCHEM, V103, P1319, DOI 10.1111/j.1471 4159.2007.04846.x
   Hoare TR, 2008, POLYMER, V49, P1993, DOI 10.1016/j.polymer.2008.01.027
   Ishida N, 2002, J BIOL CHEM, V277, P41147, DOI 10.1074/jbc.M205063200
   Jalota S, 2006, J BIOMED MATER RES A, V78A, P481, DOI 10.1002/jbm.a.30851
   Jen AC, 1996, BIOTECHNOL BIOENG, V50, P357, DOI 10.1002/(SICI)1097 0290(19960520)50:4<357::AID BIT2>3.3.CO;2 F
   LANGER R, 1993, SCIENCE, V260, P920, DOI 10.1126/science.8493529
   Lee KY, 2001, CHEM REV, V101, P1869, DOI 10.1021/cr000108x
   MUZZARELLI RAA, 1994, BIOMATERIALS, V15, P1075, DOI 10.1016/0142 9612(94)90093 0
   Nguyen LH, 2012, TISSUE ENG PART B RE, V18, P363, DOI 10.1089/ten.teb.2012.0012
   Oryan A, 2014, J ORTHOP SURG RES, V9, DOI 10.1186/1749 799X 9 18
   Peppas NA, 2000, ANNU REV BIOMED ENG, V2, P9, DOI 10.1146/annurev.bioeng.2.1.9
   Planell JA, 2009, WOODHEAD PUBL MATER, P3, DOI 10.1533/9781845696610.1.3
   Rutkovskiy A, 2016, MED SCI MONIT BASIC, V22, P95, DOI 10.12659/MSMBR.901142
   Sanyasi S, 2017, MACROMOL BIOSCI, V17, DOI 10.1002/mabi.201600268
   Sanyasi S, 2014, CARBOHYD POLYM, V101, P1033, DOI 10.1016/j.carbpol.2013.10.047
   Simao R, 2011, J STRENGTH COND RES, V25, P1333, DOI 10.1519/JSC.0b013e3181da85bf
   Slaughter BV, 2009, ADV MATER, V21, P3307, DOI 10.1002/adma.200802106
   Sun GM, 2011, P NATL ACAD SCI USA, V108, P20976, DOI 10.1073/pnas.1115973108
   Wang YS, 2008, J BIOMED MATER RES A, V84A, P769, DOI 10.1002/jbm.a.31289
   Zhang X, 2006, CALCIFIED TISSUE INT, V79, P169, DOI 10.1007/s00223 006 0083 6
NR 26
TC 12
Z9 12
U1 2
U2 41
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0300 8207
EI 1607 8438
J9 CONNECT TISSUE RES
JI Connect. Tissue Res.
PY 2018
VL 59
SU 1
BP 111
EP 121
DI 10.1080/03008207.2018.1442444
PG 11
WC Cell Biology; Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Orthopedics
GA GF7MO
UT WOS:000432152500018
PM 29458266
DA 2025 08 17
ER

PT J
AU Naidu, VGM
   Babu, KRD
   Thwin, MM
   Satish, RL
   Kumar, PV
   Gopalakrishnakone, P
AF Naidu, V. G. M.
   Babu, Kuppan Rajendran Dinesh
   Thwin, Maung Maung
   Satish, R. L.
   Kumar, Prem V.
   Gopalakrishnakone, P.
TI RANKL targeted peptides inhibit osteoclastogenesis and attenuate
   adjuvant induced arthritis by inhibiting NF κB activation and down
   regulating inflammatory cytokines
SO CHEMICO BIOLOGICAL INTERACTIONS
LA English
DT Article
DE RANK; RANKL; Arthritis; NF kappa B; Osteoprotegrin; Peptidomimetics
ID RECEPTOR ACTIVATOR; NUCLEAR FACTOR; BONE RESORPTION; OSTEOPROTEGERIN;
   CELLS; DIFFERENTIATION; EXPRESSION; LIGAND
AB Peptides designed from osteoprotegerin (OPG) have previously been shown to inhibit receptor activator of NF kappa B ligand (RANKL) and prevent bone loss without significantly inhibiting inflammation. The objective of this study was to develop a novel peptide with dual inhibitory activity against bone loss and inflammation using site directed mutagenesis. Out of the three putative sites (i.e., Tyr70 Asp78, Tyr82 Glu96, and Leu113 Arg122) available on OPG for RANKL binding, Leu113 Arg122 was used as a template for peptide synthesis. Peptide mutants of the template sequence (112YLEIEFCLKHR122) were synthesized and initially screened for their inhibitory effect on RANK RANKL binding by competitive ELISA. The most active peptide was further evaluated in vitro for RANKL induced osteoclastogenesis in mouse macrophage cells, and in vivo for Freund's complete adjuvant induced arthritis (ALA) in Lewis rats. The efficacy of the candidate peptide was compared with that of the standard drug celecoxib. The peptide YR 11 (YLEIEFSLKHR), obtained by direct substitution of cysteine with a serine residue in the template sequence, significantly (p < 0.05) inhibited RANK RANKL binding, and RANKL induced TRAP activity and formation of multinucleated osteoclasts without any cytotoxicity. Administration of YR 11 peptide at the dose of 30 mg/kg (i.p.) ameliorated both bone loss and inflammation in AIA rats. To elucidate the mechanism for inhibition of inflammation in arthritic rats, serum and tissue cytokines (TNF alpha, IL 1 beta, and IL 6) were analyzed by ELISA and RT PCR methods. Results confirmed that YR 11 peptide inhibited pro inflammatory cytokines in the sera and hind paw tissues of AIA rats through its suppressive effect on RANKL induced nuclear translocation of NF kappa B. The results obtained in this study substantiate the therapeutic benefit of this novel peptide in the prevention of bone loss and inflammation in rheumatoid arthritis with reduced side effects. (C) 2013 Elsevier Ireland Ltd. All rights reserved.
C1 [Naidu, V. G. M.; Babu, Kuppan Rajendran Dinesh; Thwin, Maung Maung; Satish, R. L.; Gopalakrishnakone, P.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Anat, Venom & Toxin Res Programme, Singapore 117597, Singapore.
   [Kumar, Prem V.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Orthopaed Surg, Singapore 117597, Singapore.
C3 National University of Singapore; National University of Singapore
RP Gopalakrishnakone, P (通讯作者)，Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Anat, Venom & Toxin Res Programme, Lower Kent Ridge Rd, Singapore 117597, Singapore.
EM antgopal@nus.edu.sg
OI Naidu, VGM/0000 0003 1520 2177; HYDERABAD, NIPER/0000 0001 7521 1150;
   Lakshminarasappa, Satish/0000 0002 1454 3503
FU National University of Health Systems (NUHS), Singapore; NUHS NUS cross
   departmental collaborative grant, National University of Singapore,
   Singapore
FX V.G.M. Naidu, Maung Maung Thwin, Kuppan Rajendran Dinesh Babu, R.L.
   Satish, Prem V. Kumar, P. Gopalakrishnakone are all employees of the
   National University of Health Systems (NUHS), Singapore, which supports
   the research project. All authors declared that they have no further
   financial and non financial competing interests. This study was funded
   by the NUHS NUS cross departmental collaborative grant, National
   University of Singapore, Singapore.
CR Bezerra MC, 2005, BRAZ J MED BIOL RES, V38, P161, DOI 10.1590/S0100 879X2005000200004
   Bolon B, 2002, CELL MOL LIFE SCI, V59, P1569, DOI 10.1007/s00018 002 8530 7
   Chen WS, 1999, J EXP MED, V189, P1757, DOI 10.1084/jem.189.11.1757
   Cheng X, 2004, J BIOL CHEM, V279, P8269, DOI 10.1074/jbc.M309690200
   Choi HJ, 2010, EUR J PHARMACOL, V636, P28, DOI 10.1016/j.ejphar.2010.03.023
   Eden W.V., 2001, CURR PROTOC IMMUNOL, V15
   Heath DJ, 2007, CANCER RES, V67, P202, DOI 10.1158/0008 5472.CAN 06 1287
   Hermeling S, 2004, PHARM RES DORDR, V21, P897, DOI 10.1023/B:PHAM.0000029275.41323.a6
   Ichikawa H, 2006, MOL CANCER RES, V4, P275, DOI 10.1158/1541 7786.MCR 05 0227
   Igarashi K, 2002, BIOCHEM PHARMACOL, V63, P523, DOI 10.1016/S0006 2952(01)00861 9
   Jimi E, 2004, NAT MED, V10, P617, DOI 10.1038/nm1054
   Kim HS, 2011, J ETHNOPHARMACOL, V136, P392, DOI 10.1016/j.jep.2011.01.016
   Kotake S, 2010, PHARMACEUTICALS, V3, P1394, DOI 10.3390/ph3051394
   Lee JH, 2009, J BIOL CHEM, V284, P13725, DOI 10.1074/jbc.M806941200
   Lee YR, 2008, LIFE SCI, V82, P1203, DOI 10.1016/j.lfs.2008.04.006
   Mason JM, 2010, FUTURE MED CHEM, V2, P1813, DOI 10.4155/FMC.10.259
   Moldogazieva NT, 2007, BIOCHEMISTRY MOSCOW+, V72, P529, DOI 10.1134/S0006297907050094
   Rehman Q, 2001, ARTHRITIS RES, V3, P221, DOI 10.1186/ar305
   Reuter S, 2010, MOL CANCER RES, V8, P1425, DOI 10.1158/1541 7786.MCR 10 0141
   Schellekens H, 2002, CLIN THER, V24, P1720, DOI 10.1016/S0149 2918(02)80075 3
   Tunyogi Csapo M, 2008, ARTHRITIS RHEUM US, V58, P2397, DOI 10.1002/art.23653
   Urushibara M, 2004, ARTHRITIS RHEUM US, V50, P794, DOI 10.1002/art.20206
   Verdrengh M, 2010, BONE, V46, P752, DOI 10.1016/j.bone.2009.10.028
   Vitovski S, 2007, J BIOL CHEM, V282, P31601, DOI 10.1074/jbc.M706078200
   Wakamatsu K, 2005, ARTHRITIS RES THER, V7, pR1348, DOI 10.1186/ar1834
NR 25
TC 25
Z9 29
U1 1
U2 14
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0009 2797
EI 1872 7786
J9 CHEM BIOL INTERACT
JI Chem. Biol. Interact.
PD APR 25
PY 2013
VL 203
IS 2
BP 467
EP 479
DI 10.1016/j.cbi.2012.12.016
PG 13
WC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology
GA 148HK
UT WOS:000319235100011
PM 23333834
DA 2025 08 17
ER

PT J
AU Qiu, HH
   Wang, W
   Hu, KJ
   Liu, WW
   Pan, SM
   Lv, Q
   Xu, GL
   Yu, QF
AF Qiu, Huanhuan
   Wang, Wei
   Hu, Kejun
   Liu, Wangwang
   Pan, Shumin
   Lv, Qi
   Xu, Guanglin
   Yu, Qingfeng
TI EuHD1 protects against inflammatory injury driven by NLRP3 inflammasome
SO INTERNATIONAL IMMUNOPHARMACOLOGY
LA English
DT Article
DE NSAIDs; NLRP3 inflammasome; Acute lung injury; Acute liver injury
ID ACUTE LUNG INJURY; HYDROGEN SULFIDE; IN VITRO
AB Non steroidal anti inflammatory drugs (NSAIDs) possessing anti inflammatory, analgesic and antipyretic activities, are widely used in the treatment of osteoarthritis, rheumatism and rheumatoid arthritis. However, its longterm or large use will cause serious gastrointestinal injury or cardiovascular adverse reactions, which limits its clinical application. We have synthesized a new class of NSAIDs, EuHD1, which can release hydrogen sulfide and have better gastrointestinal safety. However, the anti inflammatory molecular mechanism of the drug is still unclear. In this paper, we explored the mechanism of EuHD1 on NLRP3 inflammasome and its effects on acute lung injury and acute liver injury in mice. In vitro results demonstrated that EuHD1 inhibited macrophage pyroptosis and LDH release induced by LPS combined with ATP. In addition, EuHD1 blocked NLRP3 inflammasome activation and suppressed following Caspase 1 activation and secretion of mature IL 1 beta. EuHD1 restrained intracellular ROS production and the formation of ASC oligomers, which inhibited the assembly and activation of NLRP3 inflammasome. In vivo results further showed that EuHD1 alleviated LPS induced acute lung injury in mice, and inhibited the production of mature IL 1 beta and Caspase 1 (p20). Besides, EuHD1 improved D GalN/LPS induced acute liver injury, and inhibited SOD/MDA levels and oxidative stress injury, and blocked the activation of NLRP3 inflammasome. In summary, we found that EuHD1 inhibits the assembly and activation of NLRP3 inflammasome through restraining the production of ROS and the formation of ASC oligomers, and has therapeutic effects on acute lung injury and liver injury in mice, indicating that EuHD1 has the potential to treat NLRP3 inflammasome related diseases.
C1 [Hu, Kejun; Liu, Wangwang; Pan, Shumin; Lv, Qi; Xu, Guanglin; Yu, Qingfeng] Nanjing Normal Univ, Coll Life Sci, Nanjing, Peoples R China.
   [Qiu, Huanhuan; Wang, Wei] Nanjing Normal Univ, Sch Food Sci & Pharmaceut Engn, Nanjing, Peoples R China.
   [Yu, Qingfeng] China Pharmaceut Univ, Sch Sci, Nanjing, Peoples R China.
   [Xu, Guanglin] Nanjing Normal Univ, Coll Life Sci, Jiangsu Key Lab Mol & Med Biotechnol, Nanjing, Peoples R China.
C3 Nanjing Normal University; Nanjing Normal University; China
   Pharmaceutical University; Nanjing Normal University
RP Xu, GL; Yu, QF (通讯作者)，Nanjing Normal Univ, Coll Life Sci, Nanjing, Peoples R China.
EM xuguanglin@njnu.edu.cn; yuqingfeng@cpu.edu.cn
FU National Natural Science Foundation of China [81,773,948]; Priority
   Academic Program Development of Jiangsu Higher Education Institutions
   (PAPD); NSFC for Talents Training in Basic Science [J1103507, J1210025]
FX This work was supported by Project 81,773,948 supported by Na  tional
   Natural Science Foundation of China, the Priority Academic Program
   Development of Jiangsu Higher Education Institutions (PAPD) , NSFC for
   Talents Training in Basic Science (Grant Nos. J1103507, J1210025) .
CR Ali H, 2020, BMC PHARMACOL TOXICO, V21, DOI 10.1186/s40360 020 00458 7
   Blackler R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035196
   Cayla G, 2012, INT J CARDIOL, V156, P69, DOI 10.1016/j.ijcard.2010.10.027
   Chai FN, 2018, BIOMED PHARMACOTHER, V98, P180, DOI 10.1016/j.biopha.2017.11.133
   Chen ZM, 2019, ARTHRITIS RES THER, V21, DOI 10.1186/s13075 019 2085 6
   Costa SKPF, 2020, ANTIOXID REDOX SIGN, V33, P1003, DOI 10.1089/ars.2019.7884
   Faustin B, 2007, MOL CELL, V25, P713, DOI 10.1016/j.molcel.2007.01.032
   Filipovic MR, 2018, CHEM REV, V118, P377, DOI 10.1021/acs.chemrev.7b00205
   Franchi L, 2014, J IMMUNOL, V193, P4214, DOI 10.4049/jimmunol.1400582
   García Rayado G, 2018, EXPERT REV CLIN PHAR, V11, P1031, DOI 10.1080/17512433.2018.1516143
   Gugliandolo E, 2018, PHARMACOL RES, V132, P220, DOI 10.1016/j.phrs.2017.12.022
   Guo L, 2021, RESP PHYSIOL NEUROBI, V283, DOI 10.1016/j.resp.2020.103532
   Ising C, 2019, NATURE, V575, P669, DOI 10.1038/s41586 019 1769 z
   Lawlor KE, 2014, BBA GEN SUBJECTS, V1840, P1433, DOI 10.1016/j.bbagen.2013.08.014
   Predmore BL, 2012, ANTIOXID REDOX SIGN, V17, P119, DOI 10.1089/ars.2012.4612
   Li L, 2007, FREE RADICAL BIO MED, V42, P706, DOI 10.1016/j.freeradbiomed.2006.12.011
   Lin WC, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18020347
   Lin YQ, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.580593
   Lohmander LS, 2005, ANN RHEUM DIS, V64, P449, DOI 10.1136/ard.2004.023572
   Luan JY, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02201
   Mason DR, 2012, J INNATE IMMUN, V4, P16, DOI 10.1159/000334247
   Matthay MA, 2019, NAT REV DIS PRIMERS, V5, DOI 10.1038/s41572 019 0069 0
   Meshram MA, 2021, EUR J MED CHEM, V225, DOI 10.1016/j.ejmech.2021.113804
   Mokra D, 2020, PHYSIOL RES, V69, pS353, DOI 10.33549/physiolres.934602
   Niu XF, 2017, INFLAMMATION, V40, P1111, DOI 10.1007/s10753 017 0553 1
   Ozaki E, 2015, J INFLAMM RES, V8, P15, DOI 10.2147/JIR.S51250
   Park JH, 2015, IMMUNOL LETT, V165, P10, DOI 10.1016/j.imlet.2015.03.003
   Pinkerton JW, 2017, MOL IMMUNOL, V86, P44, DOI 10.1016/j.molimm.2017.01.014
   Pircher J, 2012, ARTERIOSCL THROM VAS, V32, P2884, DOI 10.1161/ATVBAHA.112.300627
   Qi CX, 2021, J POLYM ENVIRON, V29, P4088, DOI 10.1007/s10924 021 02179 2
   Sparatore A, 2009, FREE RADICAL BIO MED, V46, P586, DOI 10.1016/j.freeradbiomed.2008.11.013
   Tai FWD, 2021, CLIN MED, V21, P131, DOI 10.7861/clinmed.2021 0039
   Thibault MP, 2019, J PEDIATR GASTR NUTR, V68, P623, DOI 10.1097/MPG.0000000000002308
   Toldo S, 2018, NAT REV CARDIOL, V15, P203, DOI 10.1038/nrcardio.2017.161
   Wallace JL, 2015, NAT REV DRUG DISCOV, V14, P329, DOI 10.1038/nrd4433
   Wang HG, 2020, INT J BIOL SCI, V16, P2752, DOI 10.7150/ijbs.47595
   Yuan S, 2017, ANTIOXID REDOX SIGN, V27, P634, DOI 10.1089/ars.2017.7096
   Zhang P, 2020, FREE RADICAL BIO MED, V147, P23, DOI 10.1016/j.freeradbiomed.2019.11.033
   Zheng YQ, 2018, MED RES REV, V38, P57, DOI 10.1002/med.21433
   Zhong Y, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00333
NR 40
TC 5
Z9 6
U1 2
U2 11
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1567 5769
EI 1878 1705
J9 INT IMMUNOPHARMACOL
JI Int. Immunopharmacol.
PD FEB
PY 2023
VL 115
AR 109712
DI 10.1016/j.intimp.2023.109712
EA JAN 2023
PG 11
WC Immunology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology; Pharmacology & Pharmacy
GA 8N7TY
UT WOS:000925351100001
PM 37724954
DA 2025 08 17
ER

PT J
AU Mota, RF
   de Araujo, PHC
   Cezine, MER
   Matsuo, FS
   Metzner, RJM
   Junior, CAOD
   Peronni, KC
   Hayashi, H
   Shimamura, M
   Nakagami, H
   Osako, MK
AF Mota, Ryerson Fonseca
   de Araujo, Paulo Henrique Cavalcanti
   Cezine, Maria Eduarda Ramos
   Matsuo, Flavia Sayuri
   Metzner, Rodrigo Jair Morandi
   de Biagi Junior, Carlos Alberto Oliveira
   Peronni, Kamila Chagas
   Hayashi, Hiroki
   Shimamura, Munehisa
   Nakagami, Hironori
   Osako, Mariana Kiomy
TI RANKL Impairs the TLR4 Pathway by Increasing TRAF6 and RANK Interaction
   in Macrophages
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Article
ID NF KAPPA B; ADIPOSE TISSUE MACROPHAGES; FREE FATTY ACIDS; OSTEOCLAST
   DIFFERENTIATION; INSULIN RESISTANCE; RECEPTOR ACTIVATOR; UBIQUITIN
   LIGASE; TNF RECEPTOR; EARLY ONSET; OSTEOPROTEGERIN
AB High serum levels of osteoprotegerin (OPG) are found in patients with obesity, type 2 diabetes, sepsis, or septic shock and are associated with a high mortality rate in stroke. The primary known function of OPG is to bind to the receptor activator of NF kappa B ligand (RANKL), and by doing so, it inhibits the binding between RANKL and its receptor (RANK). TLR4 signaling in macrophages involves TRAF6 recruitment and contributes to low grade chronic inflammation in adipose tissue. LPS is a classical activator of the TLR4 pathway and induces the expression of inflammatory cytokines in macrophages. We have previously observed that in the presence of RANKL, there is no LPS induced activation of TLR4 in macrophages. In this study, we investigated the crosstalk between RANK and TLR4 pathways in macrophages stimulated with both RANKL and LPS to unveil the role of OPG in inflammatory processes. We found that RANKL inhibits TLR4 activation by binding to RANK, promoting the binding between TRAF6 and RANK, lowering TLR4 activation and the expression of proinflammatory mediators. Furthermore, high OPG levels aggravate inflammation by inhibiting RANKL. Our findings elect RANKL as a candidate for drug development as a way to mitigate the impact of obesity induced inflammation in patients.
C1 [Mota, Ryerson Fonseca; de Araujo, Paulo Henrique Cavalcanti; Cezine, Maria Eduarda Ramos; Matsuo, Flavia Sayuri; Metzner, Rodrigo Jair Morandi; Osako, Mariana Kiomy] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Cell & Mol Biol, Ribeirao Preto, SP, Brazil.
   [de Biagi Junior, Carlos Alberto Oliveira; Peronni, Kamila Chagas] Inst Canc Res, Guarapuava, PR, Brazil.
   [Hayashi, Hiroki; Shimamura, Munehisa; Nakagami, Hironori] Osaka Univ, Grad Sch Med, Dept Hlth Dev & Med, Suita, Osaka, Japan.
C3 Universidade de Sao Paulo; University of Osaka
RP Osako, MK (通讯作者)，Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Cell & Mol Biol, Ribeirao Preto, SP, Brazil.
EM ryersonmota@gmail.com; phcaraujo@usp.br; mariaecezine@usp.br;
   flaviamatsuo@gmail.com; rjmmetzner@gmail.com; biagi@usp.br;
   kcperoni@gmail.com; hayashih@cgt.med.osaka u.ac.jp;
   shimamuu@cgt.med.osaka u.ac.jp; nakagami@gts.med.osaka u.ac.jp;
   mko@fmrp.usp.br
RI Osako, Mariana/H 3337 2019; ARAUJO, PAULO/B 4602 2016; Matsuo,
   Flávia/AAI 4718 2021; de Biagi, Carlos/W 7117 2018; Nakagami,
   Hironori/GLU 0570 2022
OI Hayashi, Hiroki/0000 0001 5722 3764; Cavalcanti de Araujo, Paulo
   Henrique/0000 0002 3132 381X; Peronni, Kamila/0000 0002 8747 9282;
   Osako, Mariana Kiomy/0000 0002 5021 8433; Nakagami,
   Hironori/0000 0003 4494 3601; Oliveira de Biagi Junior, Carlos
   Alberto/0000 0003 0700 3135; Shimamura, Munehisa/0000 0003 0374 0787
FU Sao Paulo Research Foundation (FAPESP) [2014/11092 6, 2016/00508 2,
   2016/00651 0, 2016/22009 8, 2016/21579 5, 2015/26088 7]; National
   Council for Scientific and Technological Development Research (CNPq);
   Foundation for Support to Teaching, Research and Assistance of Clinical
   Hospital of Ribeirao Preto Medical School of University of Sao Paulo
   (FAEPA HCFMRP USP); Formas [2016 00508] Funding Source: Formas; Vinnova
   [2016 00508] Funding Source: Vinnova
FX We are grateful to Marcia Triunfol at Publicase for reviewing this
   manuscript, Silvia Regina Andrade Nascimento for her technical
   assistance, and the Institute for Cancer Research (IPEC) for providing
   the infrastructure for bioinformatics analysis. This work was supported
   by the Sao Paulo Research Foundation (FAPESP) (grant numbers
   2014/11092 6, 2016/00508 2, 2016/00651 0, 2016/22009 8, 2016/21579 5,
   and 2015/26088 7), National Council for Scientific and Technological
   Development Research (CNPq), and Foundation for Support to Teaching,
   Research and Assistance of Clinical Hospital of Ribeirao Preto Medical
   School of University of Sao Paulo (FAEPA HCFMRP USP).
CR Altintas MM, 2011, J LIPID RES, V52, P480, DOI 10.1194/jlr.M011338
   Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593
   Armstrong AP, 2002, J BIOL CHEM, V277, P44347, DOI 10.1074/jbc.M202009200
   Blanco Melo D, 2020, CELL, V181, P1036, DOI 10.1016/j.cell.2020.04.026
   Bradley JR, 2008, J PATHOL, V214, P149, DOI 10.1002/path.2287
   Brunner PM, 2015, EXP DERMATOL, V24, P522, DOI 10.1111/exd.12709
   Bucay N, 1998, GENE DEV, V12, P1260, DOI 10.1101/gad.12.9.1260
   Buccafusca R, 2008, MOL GENET METAB, V95, P81, DOI 10.1016/j.ymgme.2008.05.008
   Burgess TL, 1999, J CELL BIOL, V145, P527, DOI 10.1083/jcb.145.3.527
   Cullberg KB, 2014, NUTR DIABETES, V4, DOI 10.1038/nutd.2014.10
   Darnay BG, 1999, J BIOL CHEM, V274, P7724, DOI 10.1074/jbc.274.12.7724
   Darnay BG, 2007, ADV EXP MED BIOL, V597, P152
   Goyal P, 2020, ANN INTERN MED, V173, P855, DOI 10.7326/M20 2730
   Grgurevic L, 2011, BIOCHEM BIOPH RES CO, V408, P26, DOI 10.1016/j.bbrc.2011.03.109
   Holecki M, 2007, OBESITY, V15, P1925, DOI 10.1038/oby.2007.229
   Holtmann H, 1999, MOL CELL BIOL, V19, P6742
   Holtmann H, 2001, J BIOL CHEM, V276, P3508, DOI 10.1074/jbc.M004376200
   Hoshino K, 1999, J IMMUNOL, V162, P3749
   Huang Q, 2014, J MOL NEUROSCI, V53, P41, DOI 10.1007/s12031 013 0192 4
   Jiang YP, 1999, SCIENCE, V283, P543, DOI 10.1126/science.283.5401.543
   Kanda H, 2006, J CLIN INVEST, V116, P1494, DOI 10.1172/JCI26498
   Kemperman H, 2019, J APPL LAB MED, V3, P559, DOI 10.1373/jalm.2018.026559
   Kiechl S, 2013, NAT MED, V19, P358, DOI 10.1038/nm.3084
   LaFleur AM, 2004, MEDIAT INFLAMM, V13, P349, DOI 10.1080/09629350400014172
   Lamothe B, 2007, BIOCHEM BIOPH RES CO, V359, P1044, DOI 10.1016/j.bbrc.2007.06.017
   Lamothe B, 2008, J BIOL CHEM, V283, P24871, DOI 10.1074/jbc.M802749200
   Loser K, 2006, NAT MED, V12, P1372, DOI 10.1038/nm1518
   Lu YC, 2008, CYTOKINE, V42, P145, DOI 10.1016/j.cyto.2008.01.006
   Lumeng CN, 2007, DIABETES, V56, P16, DOI 10.2337/db06 1076
   Lumeng CN, 2007, J CLIN INVEST, V117, P175, DOI 10.1172/JCI29881
   Lumeng CN, 2008, DIABETES, V57, P3239, DOI 10.2337/db08 0872
   Maruyama K, 2006, J IMMUNOL, V177, P3799, DOI 10.4049/jimmunol.177.6.3799
   Matsuo FS, 2020, AM J PHYSIOL ENDOC M, V318, pE866, DOI 10.1152/ajpendo.00397.2019
   Murano I, 2008, J LIPID RES, V49, P1562, DOI 10.1194/jlr.M800019 JLR200
   Murray PJ, 2014, IMMUNITY, V41, P14, DOI 10.1016/j.immuni.2014.06.008
   NATHAN CF, 1983, J EXP MED, V158, P670, DOI 10.1084/jem.158.3.670
   Nguyen MTA, 2007, J BIOL CHEM, V282, P35279, DOI 10.1074/jbc.M706762200
   Richardson S, 2020, JAMA J AM MED ASSOC, V323, P2052, DOI 10.1001/jama.2020.6775
   Rocha DM, 2016, ATHEROSCLEROSIS, V244, P211, DOI 10.1016/j.atherosclerosis.2015.11.015
   Rydén M, 2004, BIOCHEM BIOPH RES CO, V318, P168, DOI 10.1016/j.bbrc.2004.04.010
   Saccani S, 2002, NAT IMMUNOL, V3, P69, DOI 10.1038/ni748
   Sattar N, 2020, DIABETES METAB SYND, V14, P1149, DOI 10.1016/j.dsx.2020.06.060
   Schaalan M, 2017, EUR CYTOKINE NETW, V28, P52, DOI 10.1684/ecn.2017.0393
   Secchiero P, 2006, AM J PATHOL, V169, P2236, DOI 10.2353/ajpath.2006.060398
   Shi H, 2006, J CLIN INVEST, V116, P3015, DOI 10.1172/JCI28898
   Shimamura M, 2014, P NATL ACAD SCI USA, V111, P8191, DOI 10.1073/pnas.1400544111
   Skaug B, 2009, ANNU REV BIOCHEM, V78, P769, DOI 10.1146/annurev.biochem.78.070907.102750
   Song TJ, 2012, BIOMARKERS, V17, P738, DOI 10.3109/1354750X.2012.727027
   Souza SC, 1998, J BIOL CHEM, V273, P24665, DOI 10.1074/jbc.273.38.24665
   Sun LJ, 2004, MOL CELL, V14, P289, DOI 10.1016/S1097 2765(04)00236 9
   Takahashi N, 1999, BIOCHEM BIOPH RES CO, V256, P449, DOI 10.1006/bbrc.1999.0252
   Thalmann Sebastien, 2008, V456, P195, DOI 10.1007/978 1 59745 245 8_14
   Toshchakov V, 2002, NAT IMMUNOL, V3, P392, DOI 10.1038/ni774
   Verstak B, 2009, J BIOL CHEM, V284, P24192, DOI 10.1074/jbc.M109.023044
   Wajda J, 2019, J STROKE CEREBROVASC, V28, P1160, DOI 10.1016/j.jstrokecerebrovasdis.2019.01.006
   Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246
   Willenborg S, 2012, BLOOD, V120, P613, DOI 10.1182/blood 2012 01 403386
   Wu RW, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20205141
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Ye H, 2002, NATURE, V418, P443, DOI 10.1038/nature00888
   Yu M, 2006, SHOCK, V26, P174, DOI 10.1097/01.shk.0000225404.51320.82
   Zhang Bicheng, 2020, PLOS ONE, V15, DOI DOI 10.1371/JOURNAL.PONE.0235458
   Zinchuk V, 2007, ACTA HISTOCHEM CYTOC, V40, P101, DOI 10.1267/ahc.07002
NR 63
TC 12
Z9 13
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 2314 6133
EI 2314 6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PD APR 12
PY 2022
VL 2022
AR 7740079
DI 10.1155/2022/7740079
PG 13
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA 1A5NZ
UT WOS:000791804500002
PM 35463988
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Yuan, ZY
   Memarzadeh, K
   Stephen, AS
   Allaker, RP
   Brown, RA
   Huang, J
AF Yuan, Zhiyu
   Memarzadeh, Kaveh
   Stephen, Abish S.
   Allaker, Robert P.
   Brown, Robert A.
   Huang, Jie
TI Development of a 3D Collagen Model for the In Vitro Evaluation of
   Magnetic assisted Osteogenesis
SO SCIENTIFIC REPORTS
LA English
DT Article
ID MESENCHYMAL STEM CELLS; COMPRESSED COLLAGEN; STROMAL CELLS;
   DIFFERENTIATION; EXPRESSION; FIELDS; LINES; MINERALIZATION; SCAFFOLDS;
   MG 63
AB Magnetic stimulation has been applied to bone regeneration, however, the cellular and molecular mechanisms of repair still require a better understanding. A three dimensional (3D) collagen model was developed using plastic compression, which produces dense, cellular, mechanically strong native collagen structures. Osteoblast cells (MG 63) and magnetic iron oxide nanoparticles (IONPs) were incorporated into collagen gels to produce a range of cell laden models. A magnetic bio reactor to support cell growth under static magnetic fields (SMFs) was designed and fabricated by 3D printing. The influences of SMFs on cell proliferation, differentiation, extracellular matrix production, mineralisation and gene expression were evaluated. Polymerase chain reaction (PCR) further determined the effects of SMFs on the expression of runt related trans cription factor 2 (Runx2), osteonectin (ON), and bone morphogenic proteins 2 and 4 (BMP 2 and BMP 4). Results demonstrate that SMFs, IONPs and the collagen matrix can stimulate the proliferation, alkaline phosphatase production and mineralisation of MG 63 cells, by influencing matrix/cell interactions and encouraging the expression of Runx2, ON, BMP 2 and BMP 4. Therefore, the collagen model developed here not only offers a novel 3D bone model to better understand the effect of magnetic stimulation on osteogenesis, but also paves the way for further applications in tissue engineering and regenerative medicine.
C1 [Yuan, Zhiyu; Huang, Jie] UCL, Dept Mech Engn, Torrington Pl, London WC1E 7JE, England.
   [Memarzadeh, Kaveh] Orthopaed Res UK, Furlong House,10A Chandos St, London W1G 9DQ, England.
   [Stephen, Abish S.; Allaker, Robert P.] Queen Mary Univ London, Barts & London Sch Med & Dent, Inst Dent, London E1 2AT, England.
   [Brown, Robert A.] UCL, Tissue Repair & Engn Ctr, Stanmore Campus, London HA7 4LP, England.
C3 University of London; University College London; University of London;
   Queen Mary University London; University of London; University College
   London
RP Huang, J (通讯作者)，UCL, Dept Mech Engn, Torrington Pl, London WC1E 7JE, England.
EM jie.huang@ucl.ac.uk
RI ; Huang, Jie/GWQ 5005 2022; Stephen, Abish/JFA 0236 2023
OI Huang, Jie/0000 0001 7951 2217; Stephen, Abish/0000 0002 7912 7084; 
CR Aaron RK, 2004, CLIN ORTHOP RELAT R, P21, DOI 10.1097/01.blo.0000118699.26862.41
   ANDRIANARIVO AG, 1992, J CELL PHYSIOL, V153, P256, DOI 10.1002/jcp.1041530205
   Bell SE, 2001, J CELL SCI, V114, P2755
   BOSTROM MPG, 1995, J ORTHOPAED RES, V13, P357, DOI 10.1002/jor.1100130309
   Brown RA, 2005, ADV FUNCT MATER, V15, P1762, DOI 10.1002/adfm.200500042
   Brown RA, 2002, EXP CELL RES, V274, P310, DOI 10.1006/excr.2002.5471
   Brown RA, 2013, EXP CELL RES, V319, P2460, DOI 10.1016/j.yexcr.2013.07.001
   Buxton PG, 2008, BONE, V43, P377, DOI 10.1016/j.bone.2008.03.028
   Cai Q., 2015, MAT SCI ENG C
   Chekina N, 2011, J MATER CHEM, V21, P7630, DOI 10.1039/c1jm10621j
   Chen L, 2012, BIOMATERIALS, V33, P1437, DOI 10.1016/j.biomaterials.2011.10.056
   Chicatun F, 2011, BIOMACROMOLECULES, V12, P2946, DOI 10.1021/bm200528z
   Chiu KH, 2007, ANN BIOMED ENG, V35, P1932, DOI 10.1007/s10439 007 9370 2
   COWIN SC, 1986, J BIOMECH ENG T ASME, V108, P83, DOI 10.1115/1.3138584
   Czekanska EM, 2014, J BIOMED MATER RES A, V102, P2636, DOI 10.1002/jbm.a.34937
   Darendeliler M A, 1997, Int J Adult Orthodon Orthognath Surg, V12, P43
   Dini L, 2005, MICRON, V36, P195, DOI 10.1016/j.micron.2004.12.009
   Dobson J, 2008, NAT NANOTECHNOL, V3, P139, DOI 10.1038/nnano.2008.39
   Dutta RC, 2009, BIOTECHNOL ADV, V27, P334, DOI 10.1016/j.biotechadv.2009.02.002
   Even Ram S, 2005, CURR OPIN CELL BIOL, V17, P524, DOI 10.1016/j.ceb.2005.08.015
   Gersbach CA, 2004, EXP CELL RES, V300, P406, DOI 10.1016/j.yexcr.2004.07.031
   Ghezzi CE, 2011, BIOMATERIALS, V32, P4761, DOI 10.1016/j.biomaterials.2011.03.043
   Griffith LG, 2006, NAT REV MOL CELL BIO, V7, P211, DOI 10.1038/nrm1858
   Hsu SH, 2010, CYTOTECHNOLOGY, V62, P143, DOI 10.1007/s10616 010 9271 3
   Huang HM, 2006, CLIN ORTHOP RELAT R, P201, DOI 10.1097/01.blo.0000203464.35561.be
   Jones JR, 2006, BIOMATERIALS, V27, P964, DOI 10.1016/j.biomaterials.2005.07.017
   Kale S, 2000, NAT BIOTECHNOL, V18, P954, DOI 10.1038/79439
   Kartsogiannis V, 2004, MOL CELL ENDOCRINOL, V228, P79, DOI 10.1016/j.mce.2003.06.002
   Komori T, 2010, CELL TISSUE RES, V339, P189, DOI 10.1007/s00441 009 0832 8
   Kotani H, 2002, J BONE MINER RES, V17, P1814, DOI 10.1359/jbmr.2002.17.10.1814
   Leisten I, 2012, BIOMATERIALS, V33, P1736, DOI 10.1016/j.biomaterials.2011.11.034
   Levis HJ, 2010, BIOMATERIALS, V31, P7726, DOI 10.1016/j.biomaterials.2010.07.012
   Lind M, 1998, ACTA ORTHOP SCAND, V69, P2
   Marelli B, 2011, SOFT MATTER, V7, P9898, DOI 10.1039/c1sm06027a
   Marelli B, 2010, BIOMACROMOLECULES, V11, P1470, DOI 10.1021/bm1001087
   Meng J, 2010, NANOSCALE, V2, P2565, DOI 10.1039/c0nr00178c
   Mi SL, 2010, TISSUE ENG PT A, V16, P2091, DOI 10.1089/ten.TEA.2009.0748
   Micol LA, 2011, BIOMATERIALS, V32, P1543, DOI 10.1016/j.biomaterials.2010.10.028
   Mills LA, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen 2012 002276
   Mollon B, 2008, J BONE JOINT SURG AM, V90A, P2322, DOI 10.2106/JBJS.H.00111
   Mudera V, 2007, J TISSUE ENG REGEN M, V1, P192, DOI 10.1002/term.25
   Nisbet D., 2008, J BIOMATERIALS APPL
   Nyga A, 2011, J CELL COMMUN SIGNAL, V5, P239, DOI 10.1007/s12079 011 0132 4
   Pacini S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009861
   Pautke C, 2004, ANTICANCER RES, V24, P3743
   Phillips JB, 2005, TISSUE ENG, V11, P1611, DOI 10.1089/ten.2005.11.1611
   Rhee S, 2007, ADV DRUG DELIVER REV, V59, P1299, DOI 10.1016/j.addr.2007.08.006
   Rosen AD, 2003, CELL BIOCHEM BIOPHYS, V39, P163, DOI 10.1385/CBB:39:2:163
   RUBIN CT, 1985, CALCIFIED TISSUE INT, V37, P411, DOI 10.1007/BF02553711
   Saunders WB, 2005, J CELL SCI, V118, P2325, DOI 10.1242/jcs.02360
   TERMINE JD, 1981, CELL, V26, P99, DOI 10.1016/0092 8674(81)90037 4
   Tomasek JJ, 2002, NAT REV MOL CELL BIO, V3, P349, DOI 10.1038/nrm809
   Tsai MT, 2009, J ORTHOP RES, V27, P1169, DOI 10.1002/jor.20862
   TURNER CH, 1994, J BONE MINER RES, V9, P87
   Valenti MT, 2014, ANTICANCER RES, V34, P1617
   Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb 2002 3 7 research0034
   Wei Y, 2011, BIOMED MATER, V6, DOI 10.1088/1748 6041/6/5/055008
   YAMAGISHI A, 1992, PHYSICA B, V177, P523, DOI 10.1016/0921 4526(92)90162 L
   Yamaguchi A, 1996, BIOCHEM BIOPH RES CO, V220, P366, DOI 10.1006/bbrc.1996.0411
   Ye J, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471 2105 13 134
   Yip D, 2013, BIOCHEM BIOPH RES CO, V433, P327, DOI 10.1016/j.bbrc.2013.03.008
   Zhao ZR, 2005, MOL THER, V12, P247, DOI 10.1016/j.ymthe.2005.03.009
NR 62
TC 34
Z9 38
U1 4
U2 29
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD NOV 2
PY 2018
VL 8
AR 16270
DI 10.1038/s41598 018 33455 2
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA GZ0SK
UT WOS:000449075100039
PM 30389949
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Cai, ZX
   Guo, ZY
   Yang, CH
   Wang, F
   Zhang, PB
   Wang, Y
   Guo, M
   Wang, ZL
   Huang, J
   Zhang, L
AF Cai, Zhongxing
   Guo, Ziyi
   Yang, Chaohui
   Wang, Fei
   Zhang, Peibiao
   Wang, Yu
   Guo, Min
   Wang, Zongliang
   Huang, Jing
   Zhang, Long
TI Surface Biofunctionalization of Gadolinium Phosphate Nanobunches for
   Boosting Osteogenesis/Chondrogenesis Differentiation
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE surface modification; rare earth; biological evaluation; osteoblast
   differentiation; bone tissue engineering; MRI
ID TISSUE ENGINEERING SCAFFOLDS; OSTEOGENIC DIFFERENTIATION; DRUG DELIVERY;
   BONE; HYDROXYAPATITE; NANOPARTICLES; POLYMERIZATION; REGENERATION;
   PROMOTE; SILICON
AB In order to achieve smart biomedical micro/nanomaterials, promote interaction with biomolecules, improve osteogenic/chondrogenic differentiation, exhibit better dispersion in bone implants and ultimately maximize functionality, we innovatively and successfully designed and synthesized polymer PBLG modified GdPO4 center dot H2O nanobunches by hydroxylation, silylation and glutamylation processes. The effects of different feeding ratios on the surface coating of GdPO4 center dot H2O with Si OH, the grafting gamma aminopropyltriethoxysilane (APS) and the in situ ring opening polymerization reaction of poly(g benzyl L glutamate) (PBLG) were investigated, and the physical and chemical properties were characterized in detail. When GdPO4 center dot H2O@SiO2 APS:NCA = 4:1, the PBLG g GdPO4 center dot H2O grafting rate was 5.93%, with good stability and dispersion in degradable polymeric materials. However, the MRI imaging signal was sequentially weakened as the modification process proceeded. Despite this, the biological effects had surprising findings. All the modifiers at appropriate concentrations were biocompatible and biologically active and the biomacromolecules of COL I and COL II in particular were expressed at least 3 times higher in GdPO4 center dot H2O@SiO2 compared to the PLGA. This indicates that the appropriate surface modification and functionalization of gadolinium containing micro/nanomaterials can promote interaction with cells and encourage bone regeneration by regulating biomacromolecules and can be used in the field of biomedical materials.
C1 [Cai, Zhongxing; Guo, Ziyi; Yang, Chaohui; Wang, Fei; Huang, Jing; Zhang, Long] Changchun Univ Technol, Sch Chem Engn, Changchun 130012, Peoples R China.
   [Cai, Zhongxing; Guo, Ziyi; Yang, Chaohui; Wang, Fei; Huang, Jing] Changchun Univ Technol, Sch Adv Inst Mat Sci, Changchun 130012, Peoples R China.
   [Zhang, Peibiao; Wang, Yu; Guo, Min; Wang, Zongliang] Chinese Acad Sci, Changchun Inst Appl Chem, Key Lab Polymer Ecomat, Changchun 130022, Peoples R China.
C3 Changchun University of Technology; Changchun University of Technology;
   Chinese Academy of Sciences; Changchun Institute of Applied Chemistry,
   CAS
RP Huang, J; Zhang, L (通讯作者)，Changchun Univ Technol, Sch Chem Engn, Changchun 130012, Peoples R China.; Huang, J (通讯作者)，Changchun Univ Technol, Sch Adv Inst Mat Sci, Changchun 130012, Peoples R China.
EM huangjing@ccut.edu.cn; zhanglongzhl@163.com
RI ; Guo, Ziyi/LEL 9142 2024; Wang, Zongliang/L 8740 2019
OI Huang, Jing/0000 0001 6588 3113; Wang, Zongliang/0000 0001 6101 8317; 
CR Agathokleous E, 2018, ENVIRON POLLUT, V238, P1044, DOI 10.1016/j.envpol.2018.02.068
   Arroyo Crespo JJ, 2018, ADV FUNCT MATER, V28, DOI 10.1002/adfm.201800931
   Baipaywad P, 2022, NANO CONVERG, V9, DOI 10.1186/s40580 022 00303 z
   Bozorgi A, 2021, BIOMATER SCI UK, V9, P4541, DOI 10.1039/d1bm00504a
   Bunpetch V, 2019, BIOMATERIALS, V192, P323, DOI 10.1016/j.biomaterials.2018.11.025
   CARLISLE EM, 1970, SCIENCE, V167, P279, DOI 10.1126/science.167.3916.279
   Chang YC, 1996, LANGMUIR, V12, P5824, DOI 10.1021/la950686m
   Cheng W, 2019, ACS NANO, V13, P8537, DOI 10.1021/acsnano.9b04436
   Chiu LH, 2014, BIOMATERIALS, V35, P2680, DOI 10.1016/j.biomaterials.2013.12.005
   Choi JS, 2010, J AM CHEM SOC, V132, P11015, DOI 10.1021/ja104503g
   Corey ZJ, 2022, ADV SCI, V9, DOI 10.1002/advs.202202671
   Dadej A, 2021, PHARMACEUTICS, V13, DOI 10.3390/pharmaceutics13101693
   Datta P, 2013, J BIOMED NANOTECHNOL, V9, P870, DOI 10.1166/jbn.2013.1592
   Dhavale RP, 2018, J COLLOID INTERF SCI, V529, P415, DOI 10.1016/j.jcis.2018.06.006
   Fiume E, 2021, CERAMICS BASEL, V4, P542, DOI 10.3390/ceramics4040039
   Gao JJ, 2022, COMPOS PART B ENG, V235, DOI 10.1016/j.compositesb.2022.109758
   Götz W, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11030117
   Hu C, 2019, BIOMATERIALS, V219, DOI 10.1016/j.biomaterials.2019.119366
   Huang J, 2016, ADV HEALTHC MATER, V5, P2182, DOI 10.1002/adhm.201600249
   Li JM, 2019, FASEB J, V33, P6378, DOI 10.1096/fj.201802187R
   Li LL, 2018, J MATER CHEM B, V6, P3315, DOI 10.1039/c8tb00232k
   Liao F, 2019, MAT SCI ENG C MATER, V104, DOI 10.1016/j.msec.2019.109999
   Liu C, 2021, J ENVIRON CHEM ENG, V9, DOI 10.1016/j.jece.2021.105980
   Luo M, 2022, APPL MATER TODAY, V26, DOI 10.1016/j.apmt.2021.101304
   Mastrogiacomo S, 2018, ADV HEALTHC MATER, V7, DOI 10.1002/adhm.201800202
   Natarajan D, 2022, BIOENG TRANSL MED, V7, DOI 10.1002/btm2.10262
   Nethi SK, 2015, NANOSCALE, V7, P9760, DOI 10.1039/c5nr01327e
   Patra CR, 2008, ADV MATER, V20, P753, DOI 10.1002/adma.200701611
   Pichaandi J, 2013, CHEM MATER, V25, P2035, DOI 10.1021/cm304091r
   Pozdniakova NV, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23063297
   Pu R, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 022 33726 7
   Qiu LH, 2022, FRONT BIOENG BIOTECH, V10, DOI 10.3389/fbioe.2022.1053944
   Quan BD, 2021, BIOMACROMOLECULES, V22, P2996, DOI 10.1021/acs.biomac.1c00402
   Ravichandran R, 2012, BIOMATERIALS, V33, P846, DOI 10.1016/j.biomaterials.2011.10.030
   Samadian S, 2022, INT J POLYM MATER PO, V71, P395, DOI 10.1080/00914037.2020.1848828
   Shapoval O, 2021, NANOSCALE, V13, P19023, DOI 10.1039/d1nr06127e
   Shen XC, 2004, CHEM LETT, V33, P1468, DOI 10.1246/cl.2004.1468
   Sun L., 2022, WORLD J PEDIATR, V7, P2235, DOI 10.1021/acssensors.2c00683
   Sun MQ, 2020, MATER LETT, V277, DOI 10.1016/j.matlet.2020.128320
   Sun Y, 2013, ACS NANO, V7, P11290, DOI 10.1021/nn405082y
   Wang Q, 2018, J BIOMED NANOTECHNOL, V14, P628, DOI 10.1166/jbn.2018.2516
   Wei JC, 2009, MACROMOL BIOSCI, V9, P631, DOI 10.1002/mabi.200800324
   Wu CY, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22158050
   Wu YL, 2020, J RARE EARTH, V38, P1086, DOI 10.1016/j.jre.2020.01.008
   Yu CC, 2022, NANO RES, V15, P9160, DOI 10.1007/s12274 022 4573 2
   Yu M, 2006, NANOTECHNOLOGY, V17, P3245, DOI 10.1088/0957 4484/17/13/028
   Yu XJ, 2019, ANGEW CHEM INT EDIT, V58, P2017, DOI 10.1002/anie.201812272
   Zhang DD, 2020, ACS APPL MATER INTER, V12, P27889, DOI 10.1021/acsami.0c00553
   Zhang YC, 2022, COLLOID SURFACE B, V218, DOI 10.1016/j.colsurfb.2022.112771
   Zhang ZF, 2010, APPL SURF SCI, V256, P3856, DOI 10.1016/j.apsusc.2010.01.040
   Zhao PP, 2019, CHEM ENG J, V359, P1120, DOI 10.1016/j.cej.2018.11.071
   Zheng S, 2019, NEW J CHEM, V43, P9989, DOI 10.1039/c9nj01675a
   Zhou PY, 2021, BIOACT MATER, V6, P810, DOI 10.1016/j.bioactmat.2020.09.018
   Zhu DY, 2019, INT J NANOMED, V14, P1085, DOI 10.2147/IJN.S193576
NR 54
TC 4
Z9 4
U1 2
U2 28
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
SN 1661 6596
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD FEB
PY 2023
VL 24
IS 3
AR 2032
DI 10.3390/ijms24032032
PG 21
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA 8U5UT
UT WOS:000930017700001
PM 36768355
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Tseng, HW
   Pitt, ME
   Glant, TT
   McRae, AF
   Kenna, TJ
   Brown, MA
   Pettit, AR
   Thomas, GP
AF Tseng, Hsu Wen
   Pitt, Miranda E.
   Glant, Tibor T.
   McRae, Allan F.
   Kenna, Tony J.
   Brown, Matthew A.
   Pettit, Allison R.
   Thomas, Gethin P.
TI Inflammation driven bone formation in a mouse model of ankylosing
   spondylitis: sequential not parallel processes
SO ARTHRITIS RESEARCH & THERAPY
LA English
DT Article
DE Ankylosing spondylitis; Proteoglycan induced spondylitis mouse model;
   Enthesis; Intervertebral disc destruction; Chondroidal bone formation;
   Spondyloarthropathy; Arthritis; Osteoproliferation
ID RADIOGRAPHIC PROGRESSION; OSTEOBLAST FUNCTION; ENTHESITIS; DISEASE;
   CELLS; SPINE; OSSIFICATION; INFLIXIMAB; ARTHRITIS; EFFICACY
AB Background: Ankylosing spondylitis (AS) is an immune mediated arthritis particularly targeting the spine and pelvis and is characterised by inflammation, osteoproliferation and frequently ankylosis. Current treatments that predominately target inflammatory pathways have disappointing efficacy in slowing disease progression. Thus, a better understanding of the causal association and pathological progression from inflammation to bone formation, particularly whether inflammation directly initiates osteoproliferation, is required.
   Methods: The proteoglycan induced spondylitis (PGISp) mouse model of AS was used to histopathologically map the progressive axial disease events, assess molecular changes during disease progression and define disease progression using unbiased clustering of semi quantitative histology. PGISp mice were followed over a 24 week time course. Spinal disease was assessed using a novel semi quantitative histological scoring system that independently evaluated the breadth of pathological features associated with PGISp axial disease, including inflammation, joint destruction and excessive tissue formation (osteoproliferation). Matrix components were identified using immunohistochemistry.
   Results: Disease initiated with inflammation at the periphery of the intervertebral disc (IVD) adjacent to the longitudinal ligament, reminiscent of enthesitis, and was associated with upregulated tumor necrosis factor and metalloproteinases. After a lag phase, established inflammation was temporospatially associated with destruction of IVDs, cartilage and bone. At later time points, advanced disease was characterised by substantially reduced inflammation, excessive tissue formation and ectopic chondrocyte expansion. These distinct features differentiated affected mice into early, intermediate and advanced disease stages. Excessive tissue formation was observed in vertebral joints only if the IVD was destroyed as a consequence of the early inflammation. Ectopic excessive tissue was predominantly chondroidal with chondrocyte like cells embedded within collagen type II  and X rich matrix. This corresponded with upregulation of mRNA for cartilage markers Col2a1, sox9 and Comp. Osteophytes, though infrequent, were more prevalent in later disease.
   Conclusions: The inflammation driven IVD destruction was shown to be a prerequisite for axial disease progression to osteoproliferation in the PGISp mouse. Osteoproliferation led to vertebral body deformity and fusion but was never seen concurrent with persistent inflammation, suggesting a sequential process. The findings support that early intervention with anti inflammatory therapies will be needed to limit destructive processes and consequently prevent progression of AS.
C1 [Pettit, Allison R.] Univ Queensland, Mater Res Inst, Translat Res Inst, 37 Kent St, Woolloongabba, Qld 4102, Australia.
   [Tseng, Hsu Wen; Pitt, Miranda E.; McRae, Allan F.; Kenna, Tony J.; Brown, Matthew A.; Thomas, Gethin P.] Univ Queensland, Diamantina Inst, Translat Res Inst, 37 Kent St, Woolloongabba, Qld 4102, Australia.
   [Glant, Tibor T.] Rush Univ, Med Ctr, Dept Orthoped Surg, Sect Mol Med, 1735 W Harrison St,Cohn Res Bldg, Chicago, IL 60612 USA.
   [McRae, Allan F.] Univ Queensland, Queensland Brain Inst, QBI Bldg, St Lucia, Qld 4072, Australia.
C3 Mater Research; University of Queensland; University of Queensland; Rush
   University; University of Queensland
RP Pettit, AR (通讯作者)，Univ Queensland, Mater Res Inst, Translat Res Inst, 37 Kent St, Woolloongabba, Qld 4102, Australia.; Thomas, GP (通讯作者)，Univ Queensland, Diamantina Inst, Translat Res Inst, 37 Kent St, Woolloongabba, Qld 4102, Australia.
EM allison.pettit@mater.uq.edu.au; gethin.thomas@uq.edu.au
RI Brown, Matthew/E 5749 2010; Pitt, Miranda/C 7997 2017; Kenna,
   Tony/A 6035 2011; Pettit, Allison/O 4462 2019; McRae, Allan/J 2644 2014;
   Thomas, Gethin/A 3624 2011; Brown, Matthew A/E 5749 2010
OI Pitt, Miranda/0000 0002 8255 4036; Kenna, Tony/0000 0001 6844 3463;
   Pettit, Allison/0000 0003 4707 7892; McRae, Allan/0000 0001 5286 5485;
   Thomas, Gethin/0000 0001 9081 3686; Brown, Matthew A/0000 0003 0538 8211
FU National Health and Medical Research Council (NHMRC) [APP1006450];
   University of Queensland PhD Scholarship; NHMRC Career Development
   Fellowship [519744]; Mater Foundation; NHMRC [APP1024879]; National
   Institutes of Health/National Institute of Arthritis and Musculoskeletal
   and Skin Diseases [R01 AR062991]
FX This study was supported by National Health and Medical Research Council
   (NHMRC) project grant APP1006450. The cartilage extract was kindly
   provided by TTG. H WT was supported by a University of Queensland PhD
   Scholarship. ARP is supported by NHMRC Career Development Fellowship
   519744 and the Mater Foundation. MAB is supported by NHMRC Senior
   Principal Research Fellowship APP1024879, and TTG by the National
   Institutes of Health/National Institute of Arthritis and Musculoskeletal
   and Skin Diseases (R01 AR062991).
CR Appel H, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar2035
   Appel H, 2006, ARTHRITIS RHEUM US, V54, P2845, DOI 10.1002/art.22060
   Appel H, 2006, ARTHRITIS RHEUM US, V54, P1805, DOI 10.1002/art.21907
   Appel H, 2013, ARTHRITIS RHEUM US, V65, P1522, DOI 10.1002/art.37937
   Appel H, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3370
   Arends S, 2011, J RHEUMATOL, V38, P1644, DOI 10.3899/jrheum.101128
   Bárdos T, 2005, ANN RHEUM DIS, V64, P981, DOI 10.1136/ard.2004.029710
   Barkham N, 2009, ARTHRITIS RHEUM US, V60, P946, DOI 10.1002/art.24408
   Benjamin M, 2009, ANN RHEUM DIS, V68, P1003, DOI 10.1136/ard.2008.091074
   Bleil J, 2014, ARTHRITIS RHEUMATOL, V66, P1745, DOI 10.1002/art.38404
   Braem K, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3772
   Cai HX, 2012, SPINE, V37, pE639, DOI 10.1097/BRS.0b013e318242a132
   CALIN A, 1988, BRIT J RHEUMATOL, V27, P393
   Corthay A, 2000, ARTHRITIS RHEUM US, V43, P844, DOI 10.1002/1529 0131(200004)43:4<844::AID ANR15>3.0.CO;2 B
   Finnegan A, 2002, J IMMUNOL, V169, P3345, DOI 10.4049/jimmunol.169.6.3345
   François RJ, 2000, ARTHRITIS RHEUM US, V43, P2011, DOI 10.1002/1529 0131(200009)43:9<2011::AID ANR12>3.0.CO;2 Y
   HAMMER RE, 1990, CELL, V63, P1099, DOI 10.1016/0092 8674(90)90512 D
   Haroon N, 2013, ARTHRITIS RHEUM US, V65, P2645, DOI 10.1002/art.38070
   Haynes KR, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar4096
   Ito Y, 2001, OSTEOARTHR CARTILAGE, V9, P215, DOI 10.1053/joca.2000.0378
   Lories RJU, 2007, ARTHRITIS RHEUM, V56, P489, DOI 10.1002/art.22372
   Lories RJU, 2004, ANN RHEUM DIS, V63, P595, DOI 10.1136/ard.2003.013599
   Loughenbury PR, 2006, CLIN ANAT, V19, P487, DOI 10.1002/ca.20200
   Maksymowych WP, 2009, ARTHRITIS RHEUM US, V60, P93, DOI 10.1002/art.24132
   Matzelle MM, 2012, ARTHRITIS RHEUM US, V64, P1540, DOI 10.1002/art.33504
   Milia AF, 2011, J CELL MOL MED, V15, P270, DOI 10.1111/j.1582 4934.2009.00984.x
   Nosikova Y, 2013, SPINE J, V13, P443, DOI 10.1016/j.spinee.2012.11.050
   Poddubnyy D, 2012, ARTHRITIS RHEUM US, V64, P1388, DOI 10.1002/art.33465
   Ruutu M, 2012, ARTHRITIS RHEUM US, V64, P2211, DOI 10.1002/art.34423
   Soliman E, 2012, RHEUMATOL INT, V32, P1711, DOI 10.1007/s00296 011 1852 8
   van der Heijde D, 2005, ARTHRITIS RHEUM US, V52, P582, DOI 10.1002/art.20852
   van der Heijde D, 2012, ANN RHEUM DIS, V71, P369, DOI 10.1136/annrheumdis 2011 200208
   van Duivenvoorde LM, 2012, ARTHRITIS RHEUM US, V64, P3210, DOI 10.1002/art.34600
   van Tubergen A, 2012, NAT REV RHEUMATOL, V8, P253, DOI 10.1038/nrrheum.2012.33
   Walsh NC, 2009, J BONE MINER RES, V24, P1572, DOI [10.1359/JBMR.090320, 10.1359/jbmr.090320]
   Wanders A, 2005, ARTHRITIS RHEUM US, V52, P1756, DOI 10.1002/art.21054
   Yang CH, 2004, ARTHRIT RHEUM ARTHR, V51, P691, DOI 10.1002/art.20696
   Yang L, 2014, P NATL ACAD SCI USA, V111, P12097, DOI 10.1073/pnas.1302703111
NR 38
TC 39
Z9 47
U1 0
U2 9
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1478 6354
EI 1478 6362
J9 ARTHRITIS RES THER
JI Arthritis Res. Ther.
PD JAN 29
PY 2016
VL 18
AR 35
DI 10.1186/s13075 015 0805 0
PG 12
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA DC3OC
UT WOS:000369127600001
PM 26831337
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Muinelo Romay, L
   Garcia, D
   Alonso Alconada, L
   Vieito, M
   Carmona, M
   Martínez, N
   Aguín, S
   Abal, M
   López López, R
AF Muinelo Romay, Laura
   Garcia, Daniel
   Alonso Alconada, Lorena
   Vieito, Maria
   Carmona, Marta
   Martinez, Nieves
   Aguin, Santiago
   Abal, Miguel
   Lopez Lopez, Rafael
TI Zoledronic Acid as an Antimetastatic Agent for Different Human Tumor
   Cell Lines
SO ANTICANCER RESEARCH
LA English
DT Article
DE Zoledronic acid; metastasis; invasion; 3D culture assays
ID DIRECT ANTITUMOR ACTIVITY; BREAST CANCER CELLS; BONE METASTASES;
   BISPHOSPHONATES; CARCINOMA; INHIBITION; APOPTOSIS; INVASION; INSIGHTS;
   GROWTH
AB Background: Zoledronic acid effectively reduces skeletal events in patients with metastatic disease. The results of pre clinical and emerging clinical data suggest an additional activity of zoledronic acid as an antitumor agent, interfering with the growth and dissemination of malignant cells. However, the mechanisms by which zoledronic acid impairs tumor progression are practically unknown. In the present study, we aimed to investigate the impact of zoledronic acid on invasion and colony formation ability of different human tumour cell lines. Materials and Methods: Human ovarian (SKOV3), colonic (HCT116), endometrial (HEC1A and Ishikawa) and breast cancer (MCF 7, MDA MB 231, HCC1937, SKBR3 and T47D) cell lines were treated with different concentrations (10 100 mu M) of zoledronic acid and analyzed using 3D assays to test their invasiveness and their ability to grow anchorage independently, both hallmarks of aggressive tumor cell behavior. Results: The most intense effect of the drug on tumor invasion was observed on MDA MB 231 cells, but at high concentrations HEC1A, SKOV3 and SKBR3 cells also exhibited reduced invasion capacity. We also found a significant reduction of colony formation under zoledronic acid treatment in MCF 7, T47 D, HCT116, Ishikawa, HEC1A and SKOV3 cells. Conclusion: Zoledronic acid presents an interesting potential for use as anti metastatic agent for different solid tumor types, affecting relevant steps of tumor dissemination.
C1 [Muinelo Romay, Laura; Garcia, Daniel; Alonso Alconada, Lorena; Vieito, Maria; Carmona, Marta; Martinez, Nieves; Aguin, Santiago; Abal, Miguel; Lopez Lopez, Rafael] Clin Univ Hosp, Hlth Res Inst Santiago IDIS, Med Oncol Deparment, Santiago De Compostela, Spain.
C3 Complexo Hospitalario Universitario de Santiago de Compostela
RP López López, R (通讯作者)，SERGAS, Hlth Res Inst Santiago IDIS, Santiago De Compostela, Spain.
EM rafael.lopez.lopez@sergas.es
RI ; Garcia Souto, Daniel/H 2213 2015; García Souto, Daniel/H 2213 2015
OI Lopez Lopez, Rafael/0000 0003 1315 655X; Garcia Souto,
   Daniel/0000 0002 0997 8799; Abal Posada, Miguel/0000 0003 3533 7781;
   Alonso Alconada, Lorena/0000 0002 7368 5798; Vieito,
   Maria/0000 0001 7531 343X; Martinez Lago, Nieves/0000 0002 0408 6871
FU Spanish Association Against Cancer (Spain); Basque Government (Spain)
FX The Authors thank the kind collaboration of the group of Dr. Perez
   Fernandez (Faculty of Phisiology, University of Santiago de Compostela,
   Spain) for supplying most of the cell lines used in this study. DG and
   LAA are recipients of fellowships from Spanish Association Against
   Cancer (Spain) and the Basque Government (Spain), respectively.
CR Aft R, 2010, LANCET ONCOL, V11, P421, DOI 10.1016/S1470 2045(10)70054 1
   Almubarak Hussain, 2011, J Carcinog, V10, P2, DOI 10.4103/1477 3163.75723
   Boissier S, 2000, CANCER RES, V60, P2949
   Bosch Barrera J, 2011, CLIN TRANSL ONCOL, V13, P148, DOI 10.1007/s12094 011 0634 9
   Buhaescu I, 2007, CLIN BIOCHEM, V40, P575, DOI 10.1016/j.clinbiochem.2007.03.016
   Coleman RE, 2010, BRIT J CANCER, V102, P1099, DOI 10.1038/sj.bjc.6605604
   Denoyelle C, 2003, BRIT J CANCER, V88, P1631, DOI 10.1038/sj.bjc.6600925
   Diel IJ, 1998, NEW ENGL J MED, V339, P357, DOI 10.1056/NEJM199808063390601
   Dumon JC, 2004, EUR UROL, V45, P521, DOI 10.1016/j.eururo.2003.12.012
   Fromigue O, 2000, J BONE MINER RES, V15, P2211, DOI 10.1359/jbmr.2000.15.11.2211
   Gnant M, 2009, NEW ENGL J MED, V360, P679, DOI 10.1056/NEJMoa0806285
   Kuroda J, 2004, CANCER SCI, V95, P186, DOI 10.1111/j.1349 7006.2004.tb03202.x
   Li XY, 2012, MED ONCOL, V29, P714, DOI 10.1007/s12032 011 9904 1
   Lipton A, 2000, CANCER, V88, P1082, DOI 10.1002/(SICI)1097 0142(20000301)88:5<1082::AID CNCR20>3.0.CO;2 Z
   Merrell M, 2003, BREAST CANCER RES TR, V81, P231, DOI 10.1023/A:1026126430905
   Mönkkönen H, 2006, BRIT J PHARMACOL, V147, P437, DOI 10.1038/sj.bjp.0706628
   Montague R, 2004, EUR UROL, V46, P389, DOI 10.1016/j.eururo.2004.04.022
   Muinelo Romay L, 2011, MOL CANCER THER, V10, P1357, DOI 10.1158/1535 7163.MCT 10 1019
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Mystakidou K, 2005, CANCER TREAT REV, V31, P303, DOI 10.1016/j.ctrv.2005.03.005
   Nishida S, 2003, LIFE SCI, V73, P2655, DOI 10.1016/S0024 3205(03)00664 7
   Oxford G, 2003, CANCER LETT, V189, P117, DOI 10.1016/S0304 3835(02)00510 4
   Russell RGG, 1999, BONE, V25, P97, DOI 10.1016/S8756 3282(99)00116 7
   Senaratne SG, 2002, BREAST CANCER RES, V4, P18, DOI 10.1186/bcr412
   Sewing L, 2008, APOPTOSIS, V13, P782, DOI 10.1007/s10495 008 0211 z
   Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024
   Wood J, 2002, J PHARMACOL EXP THER, V302, P1055, DOI 10.1124/jpet.102.035295
   Yuasa T, 2007, CURR MED CHEM, V14, P2126
NR 28
TC 14
Z9 15
U1 0
U2 9
PU INT INST ANTICANCER RESEARCH
PI ATHENS
PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU KALAMOU RD KAPANDRITI, PO BOX 22,
   ATHENS 19014, GREECE
SN 0250 7005
EI 1791 7530
J9 ANTICANCER RES
JI Anticancer Res.
PD DEC
PY 2013
VL 33
IS 12
BP 5295
EP 5300
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 277EN
UT WOS:000328801900010
PM 24324062
DA 2025 08 17
ER

PT J
AU Chen, WQ
   Foo, SS
   Taylor, A
   Lulla, A
   Merits, A
   Hueston, L
   Forwood, MR
   Walsh, NC
   Sims, NA
   Herrero, LJ
   Mahalingam, S
AF Chen, Weiqiang
   Foo, Suan Sin
   Taylor, Adam
   Lulla, Aleksei
   Merits, Andres
   Hueston, Linda
   Forwood, Mark R.
   Walsh, Nicole C.
   Sims, Natalie A.
   Herrero, Lara J.
   Mahalingam, Suresh
TI Bindarit, an Inhibitor of Monocyte Chemotactic Protein Synthesis,
   Protects against Bone Loss Induced by Chikungunya Virus Infection
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID KAPPA B LIGAND; RHEUMATOID ARTHRITIS; MOUSE MODEL; ADJUVANT ARTHRITIS;
   RECEPTOR ACTIVATOR; RANKL EXPRESSION; SYNOVIAL TISSUE; MCP 1 SYNTHESIS;
   MESSENGER RNA; DISEASE
AB The recent global resurgence of arthritogenic alphaviruses, in particular chikungunya virus (CHIKV), highlights an urgent need for the development of therapeutic intervention strategies. While there has been significant progress in defining the pathophysiology of alphaviral disease, relatively little is known about the mechanisms involved in CHIKV induced arthritis or potential therapeutic options to treat the severe arthritic symptoms associated with infection. Here, we used microcomputed tomographic (mu CT) and histomorphometric analyses to provide previously undescribed evidence of reduced bone volume in the proximal tibial epiphysis of CHIKV infected mice compared to the results for mock controls. This was associated with a significant increase in the receptor activator of nuclear factor kappa B ligand/osteoprotegerin (RANKL/OPG) ratio in infected murine joints and in the serum of CHIKV patients. The expression levels of the monocyte chemoattractant proteins (MCPs), including MCP 1/CCL2, MCP 2/CCL8, and MCP 3/CCL7, were also highly elevated in joints of CHIKV infected mice, accompanied by increased cellularity within the bone marrow in tibial epiphysis and ankle joints. Both this effect and CHIKV induced bone loss were significantly reduced by treatment with the MCP inhibitor bindarit. Collectively, these findings demonstrate a unique role for MCPs in promoting CHIKV induced osteoclastogenesis and bone loss during disease and suggest that inhibition of MCPs with bindarit may be an effective therapy for patients affected with alphavirus induced bone loss.
   IMPORTANCE
   Arthritogenic alphaviruses, including chikungunya virus (CHIKV) and Ross River virus (RRV), cause worldwide outbreaks of polyarthritis, which can persist in patients for months following infection. Previous studies have shown that host proinflammatory soluble factors are associated with CHIKV disease severity. Furthermore, it is established that chemokine (C C motif) ligand 2 (CCL2/MCP 1) is important in cellular recruitment and inducing bone resorbing osteoclast (OC) formation. Here, we show that CHIKV replicates in bone and triggers bone loss by increasing the RANKL/OPG ratio. CHIKV infection results in MCP induced cellular infiltration in the inflamed joints, and bone loss can be ameliorated by treatment with an MCP inhibiting drug, bindarit. Taken together, our data reveal a previously undescribed role for MCPs in CHIKV induced bone loss: one of recruiting monocytes/OC precursors to joint sites and thereby favoring a pro osteoclastic microenvironment. This suggests that bindarit may be an effective treatment for alphavirus induced bone loss and arthritis in humans.
C1 [Chen, Weiqiang; Foo, Suan Sin; Taylor, Adam; Herrero, Lara J.; Mahalingam, Suresh] Griffith Univ, Inst Glyc, Gold Coast, Qld, Australia.
   [Lulla, Aleksei; Merits, Andres] Univ Tartu, Inst Technol, EE 50090 Tartu, Estonia.
   [Hueston, Linda] Westmead Hosp, Arbovirus Emerging Dis Unit, Ctr Infect Dis & Microbiol Lab Serv, Westmead, NSW 2145, Australia.
   [Forwood, Mark R.] Griffith Univ, Sch Med Sci, Gold Coast, Qld, Australia.
   [Forwood, Mark R.] Griffith Univ, Griffith Hlth Inst, Gold Coast, Qld, Australia.
   [Walsh, Nicole C.; Sims, Natalie A.] Univ Melbourne, St Vincents Inst Med Res, Melbourne, Vic, Australia.
   [Walsh, Nicole C.; Sims, Natalie A.] Univ Melbourne, Dept Med, St Vincents Hosp, Melbourne, Vic, Australia.
C3 Griffith University; Griffith University   Gold Coast Campus; University
   of Tartu; NSW Health; Westmead Hospital; University of Sydney; Griffith
   University; Griffith University   Gold Coast Campus; Griffith
   University; Griffith University   Gold Coast Campus; Menzies Health
   Institute Queensland; St. Vincent's Institute of Medical Research;
   University of Melbourne; NSW Health; St Vincents Hospital Sydney;
   University of Melbourne; St Vincent's Health; St Vincent's Hospital
   Melbourne
RP Mahalingam, S (通讯作者)，Griffith Univ, Inst Glyc, Gold Coast, Qld, Australia.
EM s.mahalingam@griffith.edu.au
RI Merits, Andres/H 3125 2015; Walsh, Nicole/KYQ 7959 2024; Forwood,
   Mark/ABA 9040 2021; Chen, Weiqiang/AAZ 6116 2021; Sims,
   Natalie/A 7192 2012; Herrero, Lara/A 4628 2015; Taylor, Adam/C 2981 2017
OI Merits, Andres/0000 0001 8193 0071; Chen, Weiqiang/0000 0002 8840 1823;
   Forwood, Mark/0000 0002 9963 1616; Mahalingam,
   Suresh/0000 0003 3141 8410; Sims, Natalie/0000 0003 1421 8468; Taylor,
   Adam/0000 0002 7159 3961; Herrero, Lara/0000 0002 5661 9828; 
FU Australian National Health and Medical Research Council (NHMRC) [628011,
   1033068]; NHMRC; Australian Research Council
FX This work was supported by Australian National Health and Medical
   Research Council (NHMRC) grants (628011 and 1033068) to S.M. A.T. is the
   recipient of a NHMRC Peter Doherty Early Career Fellowship, L.J. is the
   recipient of an Australian Research Council Discovery Early Career
   Researcher Award, and S.M. is the recipient of an NHMRC Senior Research
   Fellowship.
CR Abe M, 2009, J BONE MINER METAB, V27, P16, DOI 10.1007/s00774 008 0012 z
   Ainola M, 2008, CLIN EXP RHEUMATOL, V26, P240
   [Anonymous], 2013, Australian code for the care and use of animals for scientific purposes, V8th, DOI DOI 10.1017/S0962728600005674
   Berchiche YA, 2011, MOL PHARMACOL, V79, P488, DOI 10.1124/mol.110.068486
   Bhatia M, 2005, AM J PHYSIOL GASTR L, V288, pG1259, DOI 10.1152/ajpgi.00435.2004
   Ble A, 2011, AM J NEPHROL, V34, P367, DOI 10.1159/000330685
   Borgherini G, 2007, CLIN INFECT DIS, V44, P1401, DOI 10.1086/517537
   Bouquillard E, 2009, ANN RHEUM DIS, V68, P1505, DOI 10.1136/ard.2008.097626
   Bouquillard É, 2009, JOINT BONE SPINE, V76, P654, DOI 10.1016/j.jbspin.2009.08.005
   Boyce BF, 2008, ARCH BIOCHEM BIOPHYS, V473, P139, DOI 10.1016/j.abb.2008.03.018
   Chen WQ, 2014, P NATL ACAD SCI USA, V111, P6040, DOI 10.1073/pnas.1318859111
   Choi SJ, 2000, BLOOD, V96, P671
   Chow A, 2011, J INFECT DIS, V203, P149, DOI 10.1093/infdis/jiq042
   CIOLI V, 1992, J RHEUMATOL, V19, P1735
   Crotti TN, 2002, ANN RHEUM DIS, V61, P1047, DOI 10.1136/ard.61.12.1047
   de Jager W, 2007, ANN RHEUM DIS, V66, P589, DOI 10.1136/ard.2006.061853
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412
   Foo SS, 2011, FUTURE VIROL, V6, P1407, DOI 10.2217/FVL.11.123
   Fumoto T, 2014, J BONE MINER RES, V29, P830, DOI 10.1002/jbmr.2096
   Gardner J, 2010, J VIROL, V84, P8021, DOI 10.1128/JVI.02603 09
   Ge SJ, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742 2094 9 171
   Goldbergova MP, 2012, MOL IMMUNOL, V52, P273, DOI 10.1016/j.molimm.2012.06.006
   Guglielmotti A, 2002, INFLAMM RES, V51, P252, DOI 10.1007/PL00000301
   Haringman JJ, 2006, ANN RHEUM DIS, V65, P294, DOI 10.1136/ard.2005.037176
   Her ZS, 2010, J IMMUNOL, V184, P5903, DOI 10.4049/jimmunol.0904181
   Herrero LJ, 2013, ARTHRITIS RHEUM US, V65, P2724, DOI 10.1002/art.38090
   Hoarau JJ, 2010, J IMMUNOL, V184, P5914, DOI 10.4049/jimmunol.0900255
   Horwood NJ, 1999, BIOCHEM BIOPH RES CO, V265, P144, DOI 10.1006/bbrc.1999.1623
   Hueber W, 2007, ANN RHEUM DIS, V66, P712, DOI 10.1136/ard.2006.054924
   Ikic M, 2014, INT ORTHOP, V38, P183, DOI 10.1007/s00264 013 2121 0
   Josseran L, 2006, EMERG INFECT DIS, V12, P1994
   Kelvin AA, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001279
   Kim HR, 2014, ARTHRITIS RHEUMATOL, V66, P538, DOI 10.1002/art.38286
   Kim MS, 2005, J BIOL CHEM, V280, P16163, DOI 10.1074/jbc.M412713200
   Kong YY, 1999, NATURE, V402, P304, DOI 10.1038/35005552
   Kraenzlin M, 1989, PHARM DIAGNOSTICS CL, P289
   Labadie K, 2010, J CLIN INVEST, V120, P894, DOI 10.1172/JCI40104
   Larrieu S, 2010, J CLIN VIROL, V47, P85, DOI 10.1016/j.jcv.2009.11.014
   Li J, 2000, P NATL ACAD SCI USA, V97, P1566, DOI 10.1073/pnas.97.4.1566
   Lidbury BA, 2008, J INFECT DIS, V197, P1585, DOI 10.1086/587841
   Lokireddy S, 2008, VIROL J, V5, DOI 10.1186/1743 422X 5 31
   Malvy D, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471 2334 9 200
   Manimunda SP, 2010, T ROY SOC TROP MED H, V104, P392, DOI 10.1016/j.trstmh.2010.01.011
   Miyamoto K, 2009, BIOCHEM BIOPH RES CO, V383, P373, DOI 10.1016/j.bbrc.2009.04.020
   Mora E, 2012, CELL CYCLE, V11, P159, DOI 10.4161/cc.11.1.18559
   Morrison TE, 2011, AM J PATHOL, V178, P32, DOI 10.1016/j.ajpath.2010.11.018
   Noret M, 2012, J INFECT DIS, V206, P455, DOI 10.1093/infdis/jis368
   Onan D, 2009, ENDOCRINOLOGY, V150, P2244, DOI 10.1210/en.2008 1597
   Pettit AR, 2006, RHEUMATOLOGY, V45, P1068, DOI 10.1093/rheumatology/kel045
   Phuklia W, 2013, VIRUS RES, V177, P179, DOI 10.1016/j.virusres.2013.08.011
   Pilichou A, 2008, CLIN BIOCHEM, V41, P746, DOI 10.1016/j.clinbiochem.2008.02.011
   Poo YS, 2014, J VIROL, V88, P6862, DOI 10.1128/JVI.03364 13
   Redlich K, 2012, NAT REV DRUG DISCOV, V11, P234, DOI 10.1038/nrd3669
   Rulli NE, 2011, J INFECT DIS, V204, P1026, DOI 10.1093/infdis/jir470
   Rulli NE, 2009, ARTHRITIS RHEUM US, V60, P2513, DOI 10.1002/art.24682
   Saidenberg Kermanac'h N, 2004, BONE, V35, P1200, DOI 10.1016/j.bone.2004.07.004
   SASO L, 1992, J RHEUMATOL, V19, P1859
   Söderström K, 2010, P NATL ACAD SCI USA, V107, P13028, DOI 10.1073/pnas.1000546107
   Sourisseau M, 2007, PLOS PATHOG, V3, P804, DOI 10.1371/journal.ppat.0030089
   Steiner JL, 2014, CYTOKINE, V66, P60, DOI 10.1016/j.cyto.2013.12.011
   Tanaka K, 2014, CLIN EXP IMMUNOL, V175, P172, DOI 10.1111/cei.12201
   Theoleyre S, 2004, CYTOKINE GROWTH F R, V15, P457, DOI 10.1016/j.cytogfr.2004.06.004
   Tsetsarkin K, 2006, VECTOR BORNE ZOONOT, V6, P325, DOI 10.1089/vbz.2006.6.325
   Tsou CL, 2007, J CLIN INVEST, V117, P902, DOI 10.1172/JCI29919
   van Tuyl LHD, 2010, ANN RHEUM DIS, V69, P1623, DOI 10.1136/ard.2009.121764
   VANDAMME J, 1992, J EXP MED, V176, P59, DOI 10.1084/jem.176.1.59
   Walsh NC, 2013, GENES IMMUN, V14, P336, DOI 10.1038/gene.2013.29
   Walsh NC, 2010, IMMUNOL REV, V233, P301, DOI 10.1111/j.0105 2896.2009.00857.x
   Wasilewska A, 2010, PEDIATR NEPHROL, V25, P2067, DOI 10.1007/s00467 010 1583 1
   Wintges K, 2013, J BONE MINER RES, V28, P2070, DOI 10.1002/jbmr.1937
   Xu XJ, 2013, INT J ENDOCRINOL, V2013, DOI 10.1155/2013/534352
   Zhou GX, 2010, HEPATOB PANCREAT DIS, V9, P201
   Zoja C, 1998, KIDNEY INT, V53, P726, DOI 10.1046/j.1523 1755.1998.00804.x
NR 74
TC 93
Z9 103
U1 1
U2 11
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036 2904 USA
SN 0022 538X
EI 1098 5514
J9 J VIROL
JI J. Virol.
PD JAN
PY 2015
VL 89
IS 1
BP 581
EP 593
DI 10.1128/JVI.02034 14
PG 13
WC Virology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Virology
GA AX8RL
UT WOS:000347176100049
PM 25339772
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Beaupere, C
   Garcia, M
   Larghero, J
   Fève, B
   Capeau, J
   Lagathu, C
AF Beaupere, Carine
   Garcia, Marie
   Larghero, Jerome
   Feve, Bruno
   Capeau, Jacqueline
   Lagathu, Claire
TI The HIV proteins Tat and Nef promote human bone marrow mesenchymal stem
   cell senescence and alter osteoblastic differentiation
SO AGING CELL
LA English
DT Article
DE HIV proteins; senescence; oxidative stress; inflammation; autophagy;
   osteoblastic differentiation
ID NF KAPPA B; ANTIRETROVIRAL THERAPY; AUTOPHAGY; DISEASE; OSTEOPOROSIS;
   INFECTION; RAPAMYCIN; MARKERS
AB To maintain bone mass turnover and bone mineral density (BMD), bone marrow (BM) mesenchymal stem cells (MSCs) are constantly recruited and subsequently differentiated into osteoblasts. HIV infected patients present lower BMD than non HIV infected individuals and a higher prevalence of osteopenia/osteoporosis. In antiretroviral treatment (ART) naive patients, encoded HIV proteins represent pathogenic candidates. They are released by infected cells within BM and can impact on neighbouring cells. In this study, we tested whether HIV proteins Tat and/or Nef could induce senescence of human BM MSCs and reduce their capacity to differentiate into osteoblasts. When compared to nontreated cells, MSCs chronically treated with Tat and/or Nef up to 30 days reduced their proliferative activity and underwent early senescence, associated with increased oxidative stress and mitochondrial dysfunction. The antioxidant molecule N acetyl  cysteine had no or minimal effects on Tat  or Nef induced senescence. Tat but not Nef induced an early increase in NF kappa B activity and cytokine/chemokine secretion. Tat induced effects were prevented by the NF kappa B inhibitor parthenolide, indicating that Tat triggered senescence via NF kappa B activation leading to oxidative stress. Otherwise, Nef  but not Tat treated cells displayed early inhibition of autophagy. Rapamycin, an autophagy inducer, reversed Nef  induced senescence and oxidative stress. Moreover, Tat+Nef had cumulative effects. Finally, Tat and/or Nef decreased the MSC potential of osteoblastic differentiation. In conclusion, our in vitro data show that Tat and Nef could reduce the number of available precursors by inducing MSC senescence, through either enhanced inflammation or reduced autophagy. These results offer new insights into the pathophysiological mechanisms of decreased BMD in HIV infected patients.
C1 [Beaupere, Carine; Garcia, Marie; Feve, Bruno; Capeau, Jacqueline; Lagathu, Claire] Sorbonne Univ, UPMC Univ Paris 06, UMR S 938, CDR St Antoine, F 75012 Paris, France.
   [Beaupere, Carine; Garcia, Marie; Feve, Bruno; Capeau, Jacqueline; Lagathu, Claire] INSERM, UMR S 938, CDR St Antoine, F 75012 Paris, France.
   [Beaupere, Carine; Garcia, Marie; Feve, Bruno; Capeau, Jacqueline; Lagathu, Claire] Inst Cardiometab & Nutr, Paris, France.
   [Larghero, Jerome] Inst Univ Hematol, INSERM, UMR1160, Hop St Louis, F 75010 Paris, France.
   [Larghero, Jerome] Hop St Louis, AP HP, Unit Therapie Cellulaire & CIC Biotherapies, Paris, France.
   [Larghero, Jerome] Univ Paris Diderot, Sorbonne Paris Cite, F 75475 Paris, France.
   [Feve, Bruno] Hop St Antoine, APHP, F 75012 Paris, France.
   [Capeau, Jacqueline] Hop Tenon, APHP, F 75020 Paris, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   Sorbonne Universite; Sorbonne Universite; Institut National de la Sante
   et de la Recherche Medicale (Inserm); Sorbonne Universite; Universite
   Paris Cite; Institut National de la Sante et de la Recherche Medicale
   (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital
   Universitaire Saint Louis   APHP; Assistance Publique Hopitaux Paris
   (APHP); Universite Paris Cite; Hopital Universitaire Saint Louis   APHP;
   Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP);
   Universite Paris Cite; Hopital Universitaire Hotel Dieu   APHP; Sorbonne
   Universite; Hopital Universitaire Saint Antoine   APHP; Hopital
   Universitaire Ambroise Pare   APHP; Assistance Publique Hopitaux Paris
   (APHP); Hopital Universitaire Ambroise Pare   APHP; Universite Paris
   Cite; Hopital Universitaire Hotel Dieu   APHP; Sorbonne Universite;
   Hopital Universitaire Tenon   APHP
RP Lagathu, C (通讯作者)，INSERM, UMRS 938, CdR St Antoine, Fac Med Pierre & Marie Curie, 27 Rue Chaligny, F 75012 Paris, France.
EM claire.lagathu@inserm.fr
OI Feve, Bruno/0000 0001 6577 9009; Lagathu, Claire/0000 0003 0700 8286;
   Beaupere, Carine/0000 0002 7220 4892
FU UPMC; INSERM; ANRS
FX Research was funded by UPMC, INSERM and ANRS. Personal support is
   acknowledged as follows: DIM BIOTHERAPIES doctoral fellowship (CB).
CR Aukrust P, 1999, J CLIN ENDOCR METAB, V84, P145, DOI 10.1210/jc.84.1.145
   Barkhordarian A, 2011, PATHOLOG RES INT, V2011
   Boya P, 2004, BBA BIOENERGETICS, V1659, P178, DOI 10.1016/j.bbabio.2004.08.007
   Brandl A, 2011, EXP CELL RES, V317, P1541, DOI 10.1016/j.yexcr.2011.02.015
   Brown TT, 2006, AIDS, V20, P2165, DOI 10.1097/QAD.0b013e32801022eb
   Capeau J, 2011, CLIN INFECT DIS, V53, P1127, DOI 10.1093/cid/cir628
   Castronuovo D, 2013, EUR REV MED PHARMACO, V17, P2413
   Coppé JP, 2008, PLOS BIOL, V6, P2853, DOI 10.1371/journal.pbio.0060301
   Cotter EJ, 2007, AIDS RES HUM RETROV, V23, P1521, DOI 10.1089/aid.2007.0112
   Cotter EJ, 2011, AIDS RES HUM RETROV, V27, P187, DOI 10.1089/aid.2010.0114
   Debaisieux S, 2012, TRAFFIC, V13, P355, DOI 10.1111/j.1600 0854.2011.01286.x
   Dinkins C, 2010, SEMIN CELL DEV BIOL, V21, P712, DOI 10.1016/j.semcdb.2010.04.004
   Dolan SE, 2006, J CLIN ENDOCR METAB, V91, P2938, DOI 10.1210/jc.2006 0127
   Fehrer C, 2005, EXP GERONTOL, V40, P926, DOI 10.1016/j.exger.2005.07.006
   Fiume G, 2012, NUCLEIC ACIDS RES, V40, P3548, DOI 10.1093/nar/gkr1224
   Freida D, 2013, CELL REP, V5, P601, DOI 10.1016/j.celrep.2013.09.019
   Gibellini D, 2010, BIOCHEM BIOPH RES CO, V401, P429, DOI 10.1016/j.bbrc.2010.09.071
   Gougeon ML, 2003, NAT REV IMMUNOL, V3, P392, DOI 10.1038/nri1087
   Haskelberg H, 2011, AIDS REV, V13, P240
   Hernandez Vallejo SJ, 2013, AGING CELL, V12, P955, DOI 10.1111/acel.12119
   Ju SM, 2012, MOL CELLS, V33, P335, DOI 10.1007/s10059 012 2287 0
   Kasper G, 2009, STEM CELLS, V27, P1288, DOI 10.1002/stem.49
   Killian MS, 2012, AIDS RES THER, V9, DOI 10.1186/1742 6405 9 16
   Kim M, 2012, MECH AGEING DEV, V133, P215, DOI 10.1016/j.mad.2012.03.014
   Kyei GB, 2009, J CELL BIOL, V186, P255, DOI 10.1083/jcb.200903070
   Larghero J, 2008, ANN RHEUM DIS, V67, P443, DOI 10.1136/ard.2007.071233
   Mahieux R, 2001, J VIROL, V75, P1736, DOI 10.1128/JVI.75.4.1736 1743.2001
   Markaki M, 2013, GERONTOLOGY, V59, P340, DOI 10.1159/000348599
   Mazziotti G, 2010, AM J MED, V123, P877, DOI 10.1016/j.amjmed.2010.02.028
   McNamara LA, 2013, J INFECT DIS, V207, P1807, DOI 10.1093/infdis/jit118
   Nair S, 2012, CELL CYCLE, V11, P2092, DOI 10.4161/cc.20317
   Nazari Shafti TZ, 2011, RETROVIROLOGY, V8, DOI 10.1186/1742 4690 8 3
   Powderly WG, 2002, J ACQ IMMUN DEF SYND, V29, pS28, DOI 10.1097/00126334 200202011 00005
   Raymond AD, 2011, AIDS RES HUM RETROV, V27, P167, DOI 10.1089/aid.2009.0170
   Rubinsztein DC, 2011, CELL, V146, P682, DOI 10.1016/j.cell.2011.07.030
   Saadane A, 2007, AM J RESP CELL MOL, V36, P728, DOI 10.1165/rcmb.2006 0323OC
   Stolzing A, 2008, MECH AGEING DEV, V129, P163, DOI 10.1016/j.mad.2007.12.002
   Stone B, 2010, ARCH BIOCHEM BIOPHYS, V503, P66, DOI 10.1016/j.abb.2010.07.029
   Tchkonia T, 2013, J CLIN INVEST, V123, P966, DOI 10.1172/JCI64098
   Tilstra JS, 2011, AGING DIS, V2, P449
   Verma S, 2002, J CLIN PATHOL, V55, P693, DOI 10.1136/jcp.55.9.693
   Zhang HS, 2011, ARCH BIOCHEM BIOPHYS, V505, P266, DOI 10.1016/j.abb.2010.10.018
   Zhou S, 2008, AGING CELL, V7, P335, DOI 10.1111/j.1474 9726.2008.00377.x
NR 43
TC 74
Z9 84
U1 0
U2 15
PU WILEY BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1474 9718
EI 1474 9726
J9 AGING CELL
JI Aging Cell
PD AUG
PY 2015
VL 14
IS 4
BP 534
EP 546
DI 10.1111/acel.12308
PG 13
WC Cell Biology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Geriatrics & Gerontology
GA CM8IC
UT WOS:000357941900004
PM 25847297
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Ogasawara, T
   Ohba, S
   Yano, F
   Kawaguchi, H
   Chung, U
   Saito, T
   Yonehara, Y
   Nakatsuka, T
   Mori, Y
   Takato, T
   Hoshi, K
AF Ogasawara, Toru
   Ohba, Shinsuke
   Yano, Fumiko
   Kawaguchi, Hiroshi
   Chung, Ung il
   Saito, Tadahito
   Yonehara, Yoshiyuki
   Nakatsuka, Takashi
   Mori, Yoshiyuki
   Takato, Tsuyoshi
   Hoshi, Kazuto
TI Nanog promotes osteogenic differentiation of the mouse mesenchymal cell
   line C3H10T1/2 by modulating bone morphogenetic protein (BMP) signaling
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
ID EMBRYONIC STEM CELLS; MEDIATED DOWN REGULATION; OSTEOBLAST
   DIFFERENTIATION; STROMAL CELLS; LIFE SPAN; EXPRESSION; CDK6;
   PLURIPOTENCY; MAINTAINS; MASS
AB How the pluripotency of stem cells is maintained and the role of transcription factors in this maintenance remain major questions. In the present study, in order to clarify the mechanism underlying the pluripotency of stem cells for the advancement of regenerative medicine, we examined the effect of forced Nanog expression in mesenchymal cells, with a particular focus on osteogenic differentiation. The human mesenchymal stromal cells (hMSCs) or mouse mesenchymal cell line C3H10T1/2 cells were transduced with the Nanog gene or control green fluorescent protein (GFP) gene by using retrovirus vectors. Short term, forced Nanog gene expression had few effects on the terminal osteogenic differentiation of either hMSCs or C3H10T1/2 cells. To determine its long term effects, we established C3H10T1/2 cells expressing Nanog constitutively. Constitutive Nanog expression strongly induced osteogenic differentiation of C3H10T1/2 cells. In regard to cell proliferation, constitutive Nanog expression only repressed the proliferation of the cells treated with rhBMP 2. Moreover, Nanog also had the potential to promote the proliferation of C3H10T1/2 cells in the absence of rhBMP 2. Constitutive Nanog expression enhanced phosphorylation of Smad1/5/8 and suppressed Cdk4 and cyclinD1. The promoter activities of both the osteocalcin and Id 1 genes were activated in cells expressing Nanog constitutively. To identify downstream molecules of Nanog involved in the promotion of osteogenic differentiation, we performed a DNA microarray analysis and discovered that NFATc1 was one of the downstream effectors of Nanog. These results indicate that Nanog functions as a modulator of BMP signaling in C3H10T1/2 cells probably through a genome reprogramming process. J. Cell. Physiol. 228: 163171, 2013. (c) 2012 Wiley Periodicals, Inc.
C1 [Ogasawara, Toru] Univ Tokyo, Dept Oral & Maxillofacial Surg, Grad Sch Med, Fac Med & Fac Med,Bunkyo Ku, Tokyo 1138655, Japan.
   [Ohba, Shinsuke; Yano, Fumiko; Chung, Ung il] Univ Tokyo, Ctr Dis Biol & Integrat Med, Fac Med, Bunkyo Ku, Tokyo 1138655, Japan.
   [Chung, Ung il] Univ Tokyo, Dept Bioengn, Grad Sch Technol, Bunkyo Ku, Tokyo 1138655, Japan.
   [Kawaguchi, Hiroshi] Univ Tokyo, Dept Orthopaed Surg, Grad Sch Med, Bunkyo Ku, Tokyo 1138655, Japan.
   [Kawaguchi, Hiroshi] Univ Tokyo, Fac Med, Tokyo 1138655, Japan.
   [Saito, Tadahito; Yonehara, Yoshiyuki] Nihon Univ, Dept Oral & Maxillofacial Surg, Sch Dent, Div 2,Chiyoda Ku, Tokyo, Japan.
   [Nakatsuka, Takashi] Saitama Med Univ, Dept Plast & Reconstruct Surg, Iruma, Saitama, Japan.
   [Hoshi, Kazuto] Univ Tokyo, Dept Cartilage & Bone Regenerat Fujisoft, Grad Sch Med, Bunkyo Ku, Tokyo 1138655, Japan.
C3 University of Tokyo; University of Tokyo; University of Tokyo;
   University of Tokyo; University of Tokyo; Nihon University; Saitama
   Medical University; University of Tokyo
RP Ogasawara, T (通讯作者)，Univ Tokyo, Dept Oral & Maxillofacial Surg, Grad Sch Med, Fac Med & Fac Med,Bunkyo Ku, Hongo 7 3 1, Tokyo 1138655, Japan.
EM togasawara tky@umin.ac.jp
RI Ogasawara, Toru/I 1629 2014
OI Ohba, Shinsuke/0000 0002 6874 8539; Ogasawara, Toru/0000 0002 2996 081X
FU Japan Society for the Promotion of Science (JSPS) [15791158, 17791438,
   22659365]; Daiwa Securities Health Foundation; Nihon University School
   of Dentistry; Grants in Aid for Scientific Research [24593050, 17791438,
   24390451, 15791158, 23659938, 23390459, 23592913, 25670847, 22689052,
   22659365] Funding Source: KAKEN
FX We thank Dr. S. Yamanaka (University of Kyoto) and Astellas Pharma Inc.
   for kindly providing materials. We also thank Dr. T. Akagawa for helpful
   discussion and support. This work was supported in part by Grants in Aid
   for Scientific Research (15791158, 17791438, 22659365) from Japan
   Society for the Promotion of Science (JSPS), and grants from Daiwa
   Securities Health Foundation and Uemura Fund, Nihon University School of
   Dentistry.
CR Adachi N, 2005, J RHEUMATOL, V32, P1615
   Chambers I, 2003, CELL, V113, P643, DOI 10.1016/S0092 8674(03)00392 1
   Franz Odendaal TA, 2006, DEV DYNAM, V235, P176, DOI 10.1002/dvdy.20603
   Fromigué O, 2010, J BIOL CHEM, V285, P25251, DOI 10.1074/jbc.M110.110502
   Go MJ, 2008, EXP CELL RES, V314, P1147, DOI 10.1016/j.yexcr.2007.11.021
   Hare JM, 2009, J AM COLL CARDIOL, V54, P2277, DOI 10.1016/j.jacc.2009.06.055
   Hyslop L, 2005, STEM CELLS, V23, P1035, DOI 10.1634/stemcells.2005 0080
   Itoh S, 2006, BONE, V39, P505, DOI 10.1016/j.bone.2006.02.074
   Kobune M, 2005, EXP HEMATOL, V33, P1544, DOI 10.1016/j.exphem.2005.09.004
   Kochupurakkal BS, 2008, BIOCHEM BIOPH RES CO, V365, P846, DOI 10.1016/j.bbrc.2007.11.073
   Koga T, 2005, NAT MED, V11, P880, DOI 10.1038/nm1270
   Meijer GJ, 2008, BIOMATERIALS, V29, P3053, DOI 10.1016/j.biomaterials.2008.03.012
   Mitsui K, 2003, CELL, V113, P631, DOI 10.1016/S0092 8674(03)00393 3
   Ogasawara T, 2004, MOL CELL BIOL, V24, P6560, DOI 10.1128/mcb.24.15.6560 6568.2004
   Ogasawara T, 2004, J BONE MINER RES, V19, P1128, DOI 10.1359/jbmr.2004.19.7.1128
   Ogasawara T, 2009, ASIAN J ORAL MAXILLO, V21, P18, DOI [10.1016/S0915 6992(09)80016 2, DOI 10.1016/S0915 6992(09)80016 2]
   Ohba S, 2008, DEV CELL, V14, P689, DOI 10.1016/j.devcel.2008.03.007
   Piestun D, 2006, BIOCHEM BIOPH RES CO, V343, P279, DOI 10.1016/j.bbrc.2006.02.152
   Riekstina U, 2009, STEM CELL REV REP, V5, P378, DOI 10.1007/s12015 009 9094 9
   Simonsen JL, 2002, NAT BIOTECHNOL, V20, P592, DOI 10.1038/nbt0602 592
   Suzuki A, 2006, P NATL ACAD SCI USA, V103, P10294, DOI 10.1073/pnas.0506945103
   Terai M, 2005, MOL BIOL CELL, V16, P1491, DOI 10.1091/mbc.E04 07 0652
   Winslow MM, 2006, DEV CELL, V10, P771, DOI 10.1016/j.devcel.2006.04.006
   Zanotti S, 2011, J BIOL CHEM, V286, P4576, DOI 10.1074/jbc.M110.161893
   Zhang JY, 2005, BIOCHEM BIOPH RES CO, V338, P1098, DOI 10.1016/j.bbrc.2005.10.071
   Zhang X, 2009, J CELL BIOL, V184, P67, DOI 10.1083/jcb.200801009
NR 26
TC 12
Z9 14
U1 0
U2 22
PU WILEY BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0021 9541
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD JAN
PY 2013
VL 228
IS 1
BP 163
EP 171
DI 10.1002/jcp.24116
PG 9
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA 018QW
UT WOS:000309678000020
PM 22585661
DA 2025 08 17
ER

PT J
AU Suh, KS
   Chon, S
   Choi, EM
AF Suh, Kwang Sik
   Chon, Suk
   Choi, Eun Mi
TI Protective effects of honokiol against methylglyoxal induced osteoblast
   damage
SO CHEMICO BIOLOGICAL INTERACTIONS
LA English
DT Article
DE Honokiol; Methylglyoxal; Osteoblasts; Cytotoxicity; Mitochondrial
   function
ID GLYCATION END PRODUCTS; MITOCHONDRIAL SUPEROXIDE PRODUCTION;
   SMOOTH MUSCLE CELLS; OXIDATIVE STRESS; IN VITRO; MAGNOLIA OFFICINALIS;
   ENDOTHELIAL CELLS; MAILLARD REACTION; SOLUBLE RECEPTOR; VASCULAR INJURY
AB Honokiol is an active compound isolated from Magnolia officinalis that has been used without notable side effects in traditional medicine. We investigated the effects of honokiol against methylglyoxal (MG)induced cytotoxicity in MC3T3 E1 osteoblast cells and the possible molecular mechanism(s) involved. The results showed that honokiol alleviated MG induced cell death and the production of intracellular ROS, mitochondrial superoxide, cardiolipin peroxidation, and inflammatory cytokines. MG induction of the soluble receptor for advanced glycation end product (AGE) was reduced by pretreatment with honokiol. Furthermore, honokiol increased the levels of Nrf2 and increased the levels of glutathione and the activity of glyoxalase I. Pretreatment with honokiol prior to MG exposure reduced MG induced mitochondrial dysfunction and alleviated MG induced reduction of nitric oxide and PGC1 alpha levels, suggesting that honokiol may induce mitochondrial biogenesis. It was concluded that honokiol could be useful in the attenuation of MG induced cell damage. (C) 2015 Elsevier Ireland Ltd. All rights reserved.
C1 [Suh, Kwang Sik] Kyung Hee Univ Hosp, Res Inst Endocrinol, 1 Hoegi Dong, Seoul 130702, South Korea.
   [Chon, Suk; Choi, Eun Mi] Kyung Hee Univ, Sch Med, Dept Endocrinol & Metab, 1 Hoegi Dong, Seoul 130701, South Korea.
C3 Kyung Hee University; Kyung Hee University Hospital; Kyung Hee
   University
RP Choi, EM (通讯作者)，Kyung Hee Univ, Sch Med, Dept Endocrinol & Metab, 1 Hoegi Dong, Seoul 130701, South Korea.
EM cheunmi@hanmail.net
FU Basic Science Research Program through the National Research Foundation
   of Korea (NRF)   Ministry of Education [NRF 2013R1A1A2A10004361]; Korea
   Health Technology R&D Project through the Korea Health Industry
   Development Institute (KHIDI)   Ministry of Health & Welfare, Republic
   of Korea [HI14C 2700 020014]
FX This research was supported by the Basic Science Research Program
   through the National Research Foundation of Korea (NRF) funded by the
   Ministry of Education (NRF 2013R1A1A2A10004361) and by a grant of the
   Korea Health Technology R&D Project through the Korea Health Industry
   Development Institute (KHIDI), funded by the Ministry of Health &
   Welfare, Republic of Korea. (Grant Number: HI14C 2700 020014).
CR Abordo EA, 1999, BIOCHEM PHARMACOL, V58, P641, DOI 10.1016/S0006 2952(99)00132 X
   Addabbo F, 2009, AM J PATHOL, V174, P34, DOI 10.2353/ajpath.2009.080650
   Ahmed MU, 1997, BIOCHEM J, V324, P565, DOI 10.1042/bj3240565
   Breuer ME, 2012, J INHERIT METAB DIS, V35, P193, DOI 10.1007/s10545 011 9375 8
   Brouwers O, 2011, J BIOL CHEM, V286, P1374, DOI 10.1074/jbc.M110.144097
   Calkins MJ, 2009, ANTIOXID REDOX SIGN, V11, P497, DOI 10.1089/ARS.2008.2242
   Chan WH, 2007, J CELL BIOCHEM, V100, P1056, DOI 10.1002/jcb.21114
   Chiang J, 2009, EUR J PHARMACOL, V610, P119, DOI 10.1016/j.ejphar.2009.03.035
   Choi EM, 2011, INFLAMM RES, V60, P1005, DOI 10.1007/s00011 011 0360 3
   Choi EM, 2011, INT IMMUNOPHARMACOL, V11, P1541, DOI 10.1016/j.intimp.2011.05.011
   Colhoun HM, 2011, DIABETES, V60, P2379, DOI 10.2337/db11 0291
   Dikalov S, 2008, BIOCHEM PHARMACOL, V76, P589, DOI 10.1016/j.bcp.2008.06.012
   Du J, 2003, J CELL BIOCHEM, V88, P1235, DOI 10.1002/jcb.10478
   Edeas M, 2010, PATHOL BIOL, V58, P220, DOI 10.1016/j.patbio.2009.09.011
   Finkel T, 2006, NATURE, V444, P151, DOI 10.1038/444151a
   Goldin A, 2006, CIRCULATION, V114, P597, DOI 10.1161/CIRCULATIONAHA.106.621854
   Hock MB, 2009, ANNU REV PHYSIOL, V71, P177, DOI 10.1146/annurev.physiol.010908.163119
   Humpert PM, 2007, HORM METAB RES, V39, P899, DOI 10.1055/s 2007 993155
   Jakubowski W, 2000, CELL BIOL INT, V24, P757, DOI 10.1006/cbir.2000.0556
   Karbowski M, 2012, ACTA NEUROPATHOL, V123, P157, DOI 10.1007/s00401 011 0921 0
   Kimura S, 2009, BIOCHEM BIOPH RES CO, V387, P109, DOI 10.1016/j.bbrc.2009.06.136
   Lee IC, 2014, FOOD CHEM TOXICOL, V63, P174, DOI 10.1016/j.fct.2013.11.006
   Liou KT, 2003, EUR J PHARMACOL, V475, P19, DOI 10.1016/S0014 2999(03)02121 6
   Liu XW, 2012, CRIT CARE, V16, DOI 10.1186/cc11354
   Liu YW, 2012, PHARMACOL BIOCHEM BE, V101, P93, DOI 10.1016/j.pbb.2011.12.003
   Lv LS, 2011, CHEM RES TOXICOL, V24, P579, DOI 10.1021/tx100457h
   Matafome P, 2013, ENDOCRINE, V43, P472, DOI 10.1007/s12020 012 9795 8
   Miniati M, 2011, RESP RES, V12, DOI 10.1186/1465 9921 12 37
   Miyazawa N, 2010, FREE RADICAL RES, V44, P101, DOI 10.3109/10715760903321788
   Mukhopadhyay P, 2007, BIOCHEM BIOPH RES CO, V358, P203, DOI 10.1016/j.bbrc.2007.04.106
   Nguyen T, 2009, J BIOL CHEM, V284, P13291, DOI 10.1074/jbc.R900010200
   Nicodemus KK, 2001, DIABETES CARE, V24, P1192, DOI 10.2337/diacare.24.7.1192
   Nin JW, 2011, DIABETES CARE, V34, P442, DOI 10.2337/dc10 1087
   Nishikawa T, 2000, NATURE, V404, P787, DOI 10.1038/35008121
   Nisoli E, 2005, SCIENCE, V310, P314, DOI 10.1126/science.1117728
   Nomura K, 2000, BIOCHEM J, V351, P183, DOI 10.1042/0264 6021:3510183
   Ojuka EO, 2003, FASEB J, V17, P675, DOI 10.1096/fj.02 0951com
   Ott C, 2014, REDOX BIOL, V2, P411, DOI 10.1016/j.redox.2013.12.016
   Park J, 2004, EUR J PHARMACOL, V496, P189, DOI 10.1016/j.ejphar.2004.05.047
   Pedchenko VK, 2005, DIABETES, V54, P2952, DOI 10.2337/diabetes.54.10.2952
   PETIT JM, 1992, EUR J BIOCHEM, V209, P267, DOI 10.1111/j.1432 1033.1992.tb17285.x
   PHILLIPS SA, 1993, EUR J BIOCHEM, V212, P101, DOI 10.1111/j.1432 1033.1993.tb17638.x
   Raposeiras Roubín S, 2010, EUR J HEART FAIL, V12, P1092, DOI 10.1093/eurjhf/hfq117
   Reddy VP, 2006, DRUG DISCOV TODAY, V11, P646, DOI 10.1016/j.drudis.2006.05.016
   Rosca MG, 2002, AM J PHYSIOL RENAL, V283, pF52, DOI 10.1152/ajprenal.00302.2001
   Schroeder P, 2007, FREE RADICAL BIO MED, V43, P128, DOI 10.1016/j.freeradbiomed.2007.04.002
   Schulz E, 2008, CIRCULATION, V118, P1347, DOI 10.1161/CIRCULATIONAHA.108.784298
   Sejersen H, 2009, BIOGERONTOLOGY, V10, P203, DOI 10.1007/s10522 008 9172 4
   Semchyshyn H. M., 2012, INTERPLAY OXIDATIVE
   Sena CM, 2012, PHARMACOL RES, V65, P497, DOI 10.1016/j.phrs.2012.03.004
   Shinohara M, 1998, J CLIN INVEST, V101, P1142, DOI 10.1172/JCI119885
   Squires RF, 1999, NEUROCHEM RES, V24, P1593, DOI 10.1023/A:1021116502548
   Taguchi K, 2012, P NATL ACAD SCI USA, V109, P13561, DOI 10.1073/pnas.1121572109
   THORNALLEY PJ, 1988, LEUKEMIA RES, V12, P897, DOI 10.1016/0145 2126(88)90016 1
   THORNALLEY PJ, 1990, BIOCHEM J, V269, P1
   Ungvari Z, 2008, AM J PHYSIOL HEART C, V294, pH2121, DOI 10.1152/ajpheart.00012.2008
   Vesce S, 2005, J BIOL CHEM, V280, P38720, DOI 10.1074/jbc.M506575200
   Wang AL, 2007, EXP EYE RES, V84, P905, DOI 10.1016/j.exer.2007.01.011
   Wang H, 2006, LIFE SCI, V79, P2448, DOI 10.1016/j.lfs.2006.08.009
   WATANABE K, 1983, PLANTA MED, V49, P103, DOI 10.1055/s 2007 969825
   Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092 8674(00)80611 X
   Yamagishi Sho ichi, 2010, Front Biosci (Elite Ed), V2, P1184
   Zhou Z, 2006, J EXP MED, V203, P1067, DOI 10.1084/jem.20051947
NR 63
TC 9
Z9 10
U1 0
U2 12
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0009 2797
EI 1872 7786
J9 CHEM BIOL INTERACT
JI Chem. Biol. Interact.
PD JAN 25
PY 2016
VL 244
BP 169
EP 177
DI 10.1016/j.cbi.2015.12.015
PG 9
WC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology
GA DC3XF
UT WOS:000369152000018
PM 26723916
DA 2025 08 17
ER

PT J
AU Nitzsche, A
   Hennig, CL
   von Brandenstein, K
   Döding, A
   Schulze Späte, U
   Symmank, J
   Jacobs, C
AF Nitzsche, Ann
   Hennig, Christoph Ludwig
   von Brandenstein, Katrin
   Doeding, Annika
   Schulze Spaete, Ulrike
   Symmank, Judit
   Jacobs, Collin
TI GDF15 Modulates the Zoledronic Acid Induced Hyperinflammatory
   Mechanoresponse of Periodontal Ligament Fibroblasts
SO CELLS
LA English
DT Article
DE zoledronic acid; orthodontic tooth movement; periodontal ligament
   fibroblasts; GDF15; senescence; DNA damage response; inflammatory
   mechanoresponse
ID ORTHODONTIC TOOTH MOVEMENT; DIFFERENTIATION FACTOR 15; S PHASE ARREST;
   DNA DAMAGE; IN VITRO; OSTEOCLAST DIFFERENTIATION; ROOT RESORPTION;
   BISPHOSPHONATE; CELLS; BONE
AB Orthodontic tooth movement (OTM) is thought to be impeded by bisphosphonate (BP) therapy, mainly due to increased osteoclast apoptosis and changes in the periodontal ligament (PdL), a connecting tissue between the alveolar bone and teeth. PdL cells, mainly fibroblasts (PdLFs), are crucial regulators in OTM by modulating force induced local inflammatory processes. Recently, we identified the TGF beta/BMP superfamily member GDF15 as an important modulator in OTM, promoting the pro inflammatory mechanoresponses of PdLFs. The precise impact of the highly potent BP zoledronate (ZOL) on the mechanofunctionality of PdLFs is still under investigated. Therefore, the aim of this study was to further characterize the ZOL induced changes in the initial inflammatory mechanoresponse of human PdLFs (hPdLFs) and to further clarify a potential interrelationship with GDF15 signaling. Thus, two day in vitro treatment with 0.5 mu M, 5 mu M and 50 mu M of ZOL altered the cellular properties of hPdLFs partially in a concentration dependent manner. In particular, exposure to ZOL decreased their metabolic activity, the proliferation rate, detected using Ki 67 immunofluorescent staining, and survival, analyzed using trypan blue. An increasing occurrence of DNA strand breaks was observed using TUNEL and an activated DNA damage response was demonstrated using H2A.X (phosphoS139) staining. While the osteogenic differentiation of hPdLFs was unaffected by ZOL, increased cellular senescence was observed using enhanced p21(Waf1/Cip1/Sdi1) and beta galactosidase staining. In addition, cytokine encoding genes such as IL6, IL8, COX2 and GDF15, which are associated with a senescence associated secretory phenotype, were up regulated by ZOL. Subsequently, this change in the hPdLF phenotype promoted a hyperinflammatory response to applied compressive forces with an increased expression of the pro inflammatory markers IL1 beta, IL6 and GDF15, as well as the activation of monocytic THP1 cells. GDF15 appeared to be particularly relevant to these changes, as siRNA mediated down regulation balanced these hyperinflammatory responses by reducing IL 1 beta and IL 6 expression (IL1B p value < 0.0001; IL6 p value < 0.001) and secretion (IL 1 beta p value < 0.05; IL 6 p value < 0.001), as well as immune cell activation (p value < 0.0001). In addition, ZOL related reduced RANKL/OPG values and inhibited osteoclast activation were enhanced in GDF15 deficient hPdLFs (both p values < 0.0001; all statistical tests: one way ANOVA, Tukey ' s post hoc test). Thus, GDF15 may become a promising new target in the personalized orthodontic treatment of bisphosphonatepatients.
C1 [Nitzsche, Ann; Hennig, Christoph Ludwig; von Brandenstein, Katrin; Symmank, Judit; Jacobs, Collin] Univ Hosp Jena, Dept Orthodont, Leutragraben 3, D 07743 Jena, Germany.
   [Doeding, Annika; Schulze Spaete, Ulrike] Univ Hosp Jena, Dept Conservat Dent & Periodont, Sect Geriodont, Leutragraben 3, D 07743 Jena, Germany.
C3 Friedrich Schiller University of Jena; Friedrich Schiller University of
   Jena
RP Symmank, J (通讯作者)，Univ Hosp Jena, Dept Orthodont, Leutragraben 3, D 07743 Jena, Germany.
EM ann.nitzsche@med.uni jena.de; christoph ludwig.hennig@med.uni jena.de;
   katrin.brandenstein@med.uni jena.de; annika.doeding@med.uni jena.de;
   ulrike.schulze spaete@med.uni jena.de; judit.symmank@med.uni jena.de;
   collin.jacobs@med.uni jena.de
RI ; Schulze Späte, Ulrike/K 6345 2018; Jacobs, Collin/KMY 3514 2024;
   Symmank, Judit/AAQ 7082 2021
OI Schulze Spate, Ulrike/0000 0002 8046 0394; Symmank,
   Judit/0000 0001 9347 0172
FU Deutsche Gesellschaft fr Kieferorthopdie e.V. (DGKFO)
FX No Statement Available
CR Agis H, 2010, J DENT RES, V89, P40, DOI 10.1177/0022034509354298
   Ajwa N, 2019, J FAM MED PRIM CARE, V8, P3783, DOI 10.4103/jfmpc.jfmpc_825_19
   Andrade I., 2012, Seminars in Orthodontics, V18, P257, DOI DOI 10.1053/J.SODO.2012.06.004
   Aquino Martinez R, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21207441
   Aquino Martinez R, 2020, BONE, V132, DOI 10.1016/j.bone.2019.115220
   ARCEO N, 1991, J PERIODONTOL, V62, P499, DOI 10.1902/jop.1991.62.8.499
   Basdra EK, 1997, EUR J ORTHODONT, V19, P615, DOI 10.1093/ejo/19.6.615
   Bauskin AR, 2006, CANCER RES, V66, P4983, DOI 10.1158/0008 5472.CAN 05 4067
   Bayram M, 2006, EUR J OBSTET GYN R B, V127, P227, DOI 10.1016/j.ejogrb.2006.01.027
   Bootcov MR, 1997, P NATL ACAD SCI USA, V94, P11514, DOI 10.1073/pnas.94.21.11514
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Breit SN, 2011, GROWTH FACTORS, V29, P187, DOI 10.3109/08977194.2011.607137
   Brockhaus J, 2021, BIOMOLECULES, V11, DOI 10.3390/biom11070932
   Brooks PJ, 2009, ANGLE ORTHOD, V79, P1108, DOI 10.2319/121508 638R.1
   Silva PGD, 2017, J ORAL PATHOL MED, V46, P1046, DOI 10.1111/jop.12640
   Di Vito A, 2020, CELL TRANSPLANT, V29, DOI 10.1177/0963689720948497
   Di W, 2023, COLLOID SURFACE B, V222, DOI 10.1016/j.colsurfb.2022.113064
   Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140 6736(10)62344 6
   FLANAGAN AM, 1991, CALCIFIED TISSUE INT, V49, P407, DOI 10.1007/BF02555852
   Ghasemi M, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms222312827
   Goldvaser H, 2019, CURR TREAT OPTION ON, V20, DOI 10.1007/s11864 019 0623 8
   Grimm S, 2021, CLIN ORAL INVEST, V25, P3453, DOI 10.1007/s00784 020 03667 w
   Hattinger CM, 2019, EXPERT OPIN DRUG MET, V15, P299, DOI 10.1080/17425255.2019.1588885
   Hinoi E, 2012, J BONE MINER RES, V27, P938, DOI 10.1002/jbmr.1538
   Huang KC, 2019, INT J MED SCI, V16, P751, DOI 10.7150/ijms.32612
   Huang KC, 2015, BMC MUSCULOSKEL DIS, V16, DOI 10.1186/s12891 015 0818 5
   Igarashi K, 1996, J DENT RES, V75, P1644, DOI 10.1177/00220345960750090501
   Iguchi T, 2007, INT J ONCOL, V31, P285
   Jacobs C, 2015, CLIN ORAL INVEST, V19, P699, DOI 10.1007/s00784 014 1284 4
   Jung J, 2018, CLIN ORAL INVEST, V22, P2527, DOI 10.1007/s00784 018 2349 6
   Kaipatur NR, 2013, AM J ORTHOD DENTOFAC, V144, P557, DOI 10.1016/j.ajodo.2013.06.015
   Kaneko J, 2018, INFLAMM REGEN, V38, DOI 10.1186/s41232 018 0074 9
   Kara M, 2022, J BIOCHEM MOL TOXIC, V36, DOI 10.1002/jbt.23083
   Karras JC, 2009, AM J ORTHOD DENTOFAC, V136, P843, DOI 10.1016/j.ajodo.2007.11.035
   Kim EH, 2016, ONCOTARGET, V7, P70869, DOI 10.18632/oncotarget.12281
   Kim HJ, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20061467
   Kim TW, 1999, AM J ORTHOD DENTOFAC, V115, P645, DOI 10.1016/S0889 5406(99)70290 8
   Kirkland JL, 2020, J INTERN MED, V288, P518, DOI 10.1111/joim.13141
   Komatsu Y, 2016, INT J MOL MED, V38, P139, DOI 10.3892/ijmm.2016.2582
   Konstantonis D, 2013, BIOGERONTOLOGY, V14, P741, DOI 10.1007/s10522 013 9449 0
   Li S, 2020, EXP CELL RES, V387, DOI 10.1016/j.yexcr.2019.111745
   Li YN, 2018, KAOHSIUNG J MED SCI, V34, P207, DOI 10.1016/j.kjms.2018.01.007
   Li ZH, 2017, MOL MED REP, V16, P8380, DOI 10.3892/mmr.2017.7625
   Liu L, 2006, J DENT RES, V85, P757, DOI 10.1177/154405910608500813
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lösch L, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms241210011
   Mattia L, 2023, BONE REP, V18, DOI 10.1016/j.bonr.2023.101676
   Min KW, 2016, ONCOGENE, V35, P377, DOI 10.1038/onc.2015.95
   Misra J, 2016, STEM CELLS, V34, P756, DOI 10.1002/stem.2255
   Mücke T, 2016, SEMIN MUSCULOSKEL R, V20, P305, DOI 10.1055/s 0036 1592367
   Nanci A, 2006, PERIODONTOL 2000, V40, P11, DOI 10.1111/j.1600 0757.2005.00141.x
   de Sousa FRN, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 87375 9
   Ohnuki H, 2012, ARCH ORAL BIOL, V57, P906, DOI 10.1016/j.archoralbio.2011.11.015
   Park H, 2016, ONCOTARGET, V7, P9634, DOI 10.18632/oncotarget.7457
   Patel CG, 2014, CLIN CANCER RES, V20, P3955, DOI 10.1158/1078 0432.CCR 14 0434
   Rody WJ, 2001, AM J ORTHOD DENTOFAC, V120, P477, DOI 10.1067/mod.2001.118623
   Samakkarnthai P, 2023, AGING US, V15, P3331, DOI 10.18632/aging.204701
   Schiegnitz E, 2016, J ORAL PATHOL MED, V45, P63, DOI 10.1111/jop.12323
   Schuldt L, 2022, EPIGENETICS US, V17, P1892, DOI 10.1080/15592294.2022.2090654
   Schuldt L, 2022, CELLS BASEL, V11, DOI 10.3390/cells11060955
   Seifi Massoud, 2017, J Dent Res Dent Clin Dent Prospects, V11, P257, DOI 10.15171/joddd.2017.045
   Sharma Arishya, 2012, Methods Mol Biol, V920, P613, DOI 10.1007/978 1 61779 998 3_40
   Siddiqui MS, 2015, MUTAT RES REV MUTAT, V766, P1, DOI 10.1016/j.mrrev.2015.07.001
   Sirisoontorn I, 2012, AM J ORTHOD DENTOFAC, V141, P563, DOI 10.1016/j.ajodo.2011.11.016
   Sokos D, 2015, J PERIODONTAL RES, V50, P152, DOI 10.1111/jre.12197
   SOMERMAN MJ, 1990, ARCH ORAL BIOL, V35, P241, DOI 10.1016/0003 9969(90)90062 F
   Stemmler A, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms222413608
   Stockert JC, 2018, ACTA HISTOCHEM, V120, P159, DOI 10.1016/j.acthis.2018.02.005
   Stopeck AT, 2010, J CLIN ONCOL, V28, P5132, DOI 10.1200/JCO.2010.29.7101
   Symmank J, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22116069
   Symmank J, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 72736 7
   Symmank J, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 47639 x
   Tanaka Y, 2013, ARCH ORAL BIOL, V58, P628, DOI 10.1016/j.archoralbio.2012.11.010
   Taniguchi N, 2020, J PERIODONTOL, V91, P947, DOI 10.1002/JPER.19 0385
   Tsai SH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041065
   Ullrich N, 2019, INT J ORAL SCI, V11, DOI 10.1038/s41368 019 0066 x
   Valieva Y, 2022, DIAGNOSTICS, V12, DOI 10.3390/diagnostics12102309
   Vanhara P, 2009, DIFFERENTIATION, V78, P213, DOI 10.1016/j.diff.2009.07.008
   Vansant L, 2018, ARCH ORAL BIOL, V95, P170, DOI 10.1016/j.archoralbio.2018.08.003
   Wang ZP, 2000, CANCER, V88, P2787, DOI 10.1002/1097 0142(20000615)88:12<2787::AID CNCR18>3.0.CO;2 2
   Watanabe J, 2020, J DENT RES, V99, P552, DOI 10.1177/0022034520906793
   Wedel S, 2023, AGING CELL, V22, DOI 10.1111/acel.13752
   Westhrin M, 2015, HAEMATOLOGICA, V100, pE511, DOI 10.3324/haematol.2015.124511
   Wise GE, 2008, J DENT RES, V87, P414, DOI 10.1177/154405910808700509
   Wong L, 2018, AM J ORTHOD DENTOFAC, V153, P362, DOI 10.1016/j.ajodo.2017.07.017
   Wrana JL, 2000, CYTOKINE GROWTH F R, V11, P5, DOI 10.1016/S1359 6101(99)00024 6
   Yamashita J, 2021, BONE, V143, DOI 10.1016/j.bone.2020.115611
   Yang XJ, 2020, CELL DEATH DISCOV, V6, DOI 10.1038/s41420 020 0273 4
   Yasin ZNM, 2022, DIFFERENTIATION, V128, P67, DOI 10.1016/j.diff.2022.10.001
NR 89
TC 5
Z9 5
U1 2
U2 6
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2073 4409
J9 CELLS BASEL
JI Cells
PD JAN
PY 2024
VL 13
IS 2
AR 147
DI 10.3390/cells13020147
PG 19
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA GG8Q3
UT WOS:001151609400001
PM 38247838
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Park, H
   Bergeron, E
   Senta, H
   Guillemette, K
   Beauvais, S
   Blouin, R
   Sirois, J
   Faucheux, N
AF Park, Hyunjin
   Bergeron, Eric
   Senta, Helena
   Guillemette, Kim
   Beauvais, Sabrina
   Blouin, Richard
   Sirois, Joel
   Faucheux, Nathalie
TI Sanguinarine induces apoptosis of human osteosarcoma cells through the
   extrinsic and intrinsic pathways
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Alkaloid; Apoptosis; Cancer; Caspase; Viability
ID BCL 2 FAMILY PROTEINS; COMBINATION CHEMOTHERAPY; DOWN REGULATION;
   CANCER CELLS; DEATH; LINES; OSTEOBLASTS; ACTIVATION; ALKALOIDS;
   CASPASE 3
AB The quaternary benzo[c]phenanthridine alkaloid sanguinarine inhibits the proliferation of cancerous cells from different origins, including lung, breast, pancreatic and colon, but nothing is known of its effects on osteosarcoma, a primary malignant bone tumour. We have found that sanguinarine alters the morphology and reduces the viability of MG 63 and SaOS 2 human osteosarcoma cell lines in concentration  and time dependent manner. Incubation with 1 sanguinarine for 4 and 24 h killed more efficiently MG 63 cells than SaOS 2 cells, while incubation with 5 mu mol/L sanguinarine killed almost 100% of both cell populations within 24 h. This treatment also changed the mitochondrial membrane potential in both MG 63 and SaOS 2 cells within 1 h, caused chromatin condensation and the formation of apoptotic bodies. It activated multicaspases, and increased the activities of caspase 8 and caspase 9 in both MG 63 and SaOS 2 cells. These data highlight sanguinarine as a novel potential agent for bone cancer therapy. (C) 2010 Elsevier Inc. All rights reserved.
C1 [Park, Hyunjin; Bergeron, Eric; Senta, Helena; Guillemette, Kim; Beauvais, Sabrina; Faucheux, Nathalie] Univ Sherbrooke, Canada Res Chair Cell Biomat Biohybrid Syst, Dept Chem Engn & Biotechnol Engn, Sherbrooke, PQ J1K 2R1, Canada.
   [Blouin, Richard] Univ Sherbrooke, Dept Biol, Sherbrooke, PQ J1K 2R1, Canada.
C3 University of Sherbrooke; University of Sherbrooke
RP Faucheux, N (通讯作者)，Univ Sherbrooke, Canada Res Chair Cell Biomat Biohybrid Syst, Dept Chem Engn & Biotechnol Engn, 2500 Univ Blvd, Sherbrooke, PQ J1K 2R1, Canada.
EM Nathalie.Faucheux@Usherbrooke.ca
RI Bergeron, Eric/G 6544 2011
FU Canada Research Chair in Cell Biomaterial Biohybrid Systems; Natural
   Sciences and Engineering Research Council of Canada; Universite de
   Sherbrooke through "Equipe de recherche en production et immobilisation
   de principes actifs" research group; Fonds de la recherche en sante du
   Quebec
FX We thank Dr. Owen Parkes for editing the English text. This research was
   supported through a Canada Research Chair in Cell Biomaterial Biohybrid
   Systems, a Natural Sciences and Engineering Research Council of Canada
   program, and Universite de Sherbrooke through "Equipe de recherche en
   production et immobilisation de principes actifs" research group. Eric
   Bergeron was supported by a Fonds de la recherche en sante du Quebec
   fellowship.
CR Adhami VM, 2003, CLIN CANCER RES, V9, P3176
   Ahmad N, 2000, CLIN CANCER RES, V6, P1524
   Ahsan H, 2007, CANCER LETT, V249, P198, DOI 10.1016/j.canlet.2006.08.018
   Chang MC, 2007, TOXICOL APPL PHARM, V218, P143, DOI 10.1016/j.taap.2006.10.025
   Chipuk JE, 2010, MOL CELL, V37, P299, DOI 10.1016/j.molcel.2010.01.025
   Choi WY, 2009, ANTICANCER RES, V29, P4457
   Davies JH, 2002, BONE, V31, P319, DOI 10.1016/S8756 3282(02)00822 0
   De Stefano I, 2009, BIOCHEM PHARMACOL, V78, P1374, DOI 10.1016/j.bcp.2009.07.011
   Debiton E, 2003, CANCER CHEMOTH PHARM, V51, P474, DOI 10.1007/s00280 003 0609 9
   Eyre R, 2009, PEDIATR BLOOD CANCER, V53, P941, DOI 10.1002/pbc.22194
   Ferrari S, 2007, CURR OPIN ONCOL, V19, P341, DOI 10.1097/CCO.0b013e328122d73f
   FRANCESCHI RT, 1985, J CELL PHYSIOL, V123, P401, DOI 10.1002/jcp.1041230316
   GODOWSKI K C, 1989, Journal of Clinical Dentistry, V1, P96
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092 8674(00)81683 9
   Jang BC, 2009, TOXICOL IN VITRO, V23, P281, DOI 10.1016/j.tiv.2008.12.013
   Jang HS, 2005, BBA GEN SUBJECTS, V1726, P309, DOI 10.1016/j.bbagen.2005.08.010
   Kim S, 2008, J CELL BIOCHEM, V104, P895, DOI 10.1002/jcb.21672
   Kroemer G, 2009, CELL DEATH DIFFER, V16, P3, DOI 10.1038/cdd.2008.150
   Kroemer G, 2007, PHYSIOL REV, V87, P99, DOI 10.1152/physrev.00013.2006
   Kurokawa M, 2009, CELL, V138, P838, DOI 10.1016/j.cell.2009.08.021
   LENFELD J, 1981, PLANTA MED, V43, P161, DOI 10.1055/s 2007 971493
   Longhi A, 2006, CANCER TREAT REV, V32, P423, DOI 10.1016/j.ctrv.2006.05.005
   MAHADY GB, 1994, PLANTA MED, V60, P553, DOI 10.1055/s 2006 959570
   Malikova Jana, 2006, Biomedical Papers (Olomouc), V150, P5
   Matkar SS, 2008, CHEM BIOL INTERACT, V172, P63, DOI 10.1016/j.cbi.2007.12.006
   Pautke C, 2004, ANTICANCER RES, V24, P3743
   Picci P, 2007, ORPHANET J RARE DIS, V2, DOI 10.1186/1750 1172 2 6
   Pradelli LA, 2010, CELL MOL LIFE SCI, V67, P1589, DOI 10.1007/s00018 010 0285 y
   RODAN SB, 1987, CANCER RES, V47, P4961
   Serafim TL, 2008, BIOCHEM PHARMACOL, V76, P1459, DOI 10.1016/j.bcp.2008.07.013
   Shapira L, 2009, CLIN ORAL IMPLAN RES, V20, P50, DOI 10.1111/j.1600 0501.2008.01594.x
   Slaninová I, 2001, CELL BIOL TOXICOL, V17, P51, DOI 10.1023/A:1010907231602
   SMILEY ST, 1991, P NATL ACAD SCI USA, V88, P3671, DOI 10.1073/pnas.88.9.3671
   Vrba J, 2009, TOXICOL IN VITRO, V23, P580, DOI 10.1016/j.tiv.2009.01.016
   Wang ZX, 2010, BONE, V47, P445, DOI 10.1016/j.bone.2010.05.027
   Weerasinghe P, 2001, CELL BIOL TOXICOL, V17, P371, DOI 10.1023/A:1013796432521
   Zhao Y, 2009, BIOCHEM BIOPH RES CO, V390, P642, DOI 10.1016/j.bbrc.2009.10.020
NR 37
TC 51
Z9 61
U1 1
U2 10
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0006 291X
EI 1090 2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD AUG 27
PY 2010
VL 399
IS 3
BP 446
EP 451
DI 10.1016/j.bbrc.2010.07.114
PG 6
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 647AK
UT WOS:000281587400025
PM 20678472
DA 2025 08 17
ER

PT J
AU Simsek, G
   Uzun, H
   Aydin, S
   Karter, Y
   Benian, A
   Dariyerli, N
   Kaya, S
   Yigit, G
AF Simsek, G
   Uzun, H
   Aydin, S
   Karter, Y
   Benian, A
   Dariyerli, N
   Kaya, S
   Yigit, G
TI The role of nitric oxide on bone metabolism in ovariectomized rats
   following chronic ethanol intake
SO LIFE SCIENCES
LA English
DT Article
DE ethanol; ovariectomy; estrogen deficiency; nitric oxide; L NAME;
   cytokine; bone
ID MODERATE ALCOHOL CONSUMPTION; OSTEOBLASTIC CELL PROLIFERATION; ESTROGEN
   REPLACEMENT THERAPY; NONCIRRHOTIC MALE ALCOHOLICS; ADULT FEMALE RATS;
   POSTMENOPAUSAL WOMEN; INDUCED HYPERTHYROIDISM; MINERAL DENSITY;
   OSTEOPOROTIC CYTOKINES; SYNTHASE EXPRESSION
AB This experimental study was designed to examine the effect of nitric oxide (NO) on bone metabolism in ovariectomized rats following chronic ethanol treatment. Chronic ethanol intake was produced by gradual substitution (within 3 weeks) of tap water in diet with 5,10,15 and finally 20% of ethanol. Thereafter, the rats were maintained under these conditions for a duration of 4 months. The rats were divided into two groups. The first group received sham operation (SHAM) and the rats in Group II were ovariectomized (OVX). Five weeks after the SHAM and ovariectomy, the rats were treated with ethanol for 4 months. After this period of ethanol administration the NOS inhibitor N W nitro L arginine methyl ester (L NAME) was given for three weeks along with ethanol to the same rats. Serum interleukin (IL) 1beta, IL 6, tumor necrosis factor (TNF) alpha, NO, calcium (Ca), phosphorous (P), parathyroid hormone (PTH), 25 HydroxyvitaminD(3) [25(OH)D 3], alkaline phosphatase (ALP), bone alkaline phosphatase (b ALP), alanine amino transferase (ALT), aspartate amino transferase (AST), gamma glutamyltransferase (GGT) levels were measured in different stages of the experiment. IL 1beta, IL 6, TNFalpha and NO levels increased after ethanol administration in SHAM and OVX rats. The decrease in serum Ca was significant while the changes in P, PTH and 25 (OH)D3 levels were not. ALP and b ALP levels were significantly decreased; ALT, AST and GGT levels were significantly increased. In ovariectomized and SHAM rats, administration of L NAME together with ethanol, produced a significant increase in IL 1beta, IL 6 and TNFalpha levels. In this group, Ca and P levels were significantly increased, PTH and 25 (OH)D 3 levels were significantly decreased. Also, there was a signicant decrease in ALT, AST, ALP, b ALP, and GGT levels. NO increase due to alcohol intake may function as a protective mechanism preventing bone resorption in cases of estrogen insufficiency. (C) 2005 Elsevier Inc. All rights reserved.
C1 Univ Istanbul, Cerrahpasa Med Fac, Dept Physiol, Istanbul, Turkey.
   Univ Istanbul, Cerrahpasa Med Fac, Dept Biochem, Istanbul, Turkey.
   Univ Istanbul, Cerrahpasa Med Fac, Dept Internal Med, Istanbul, Turkey.
   Univ Istanbul, Cerrahpasa Med Fac, Dept Gynocol & Obstet, Istanbul, Turkey.
C3 Istanbul University; Istanbul University   Cerrahpasa; Istanbul
   University   Cerrahpasa; Istanbul University; Istanbul University;
   Istanbul University   Cerrahpasa; Istanbul University   Cerrahpasa;
   Istanbul University
RP Simsek, G (通讯作者)，Sayhan Sitesi, 16,CB 10, Istanbul, Turkey.
EM gdincsimsek@yahoo.com
RI aydın, seval/AAD 3579 2021; DARIYERLI, Nuran/AGQ 3880 2022; Benian,
   Ali/A 4932 2018; şimşek, gönül/AAC 9310 2021; Uzun, Hafize/D 4811 2019;
   Simsek, Gonul/D 4992 2019
OI Benian, Ali/0000 0001 8135 3788; Uzun, Hafize/0000 0002 1347 8498;
   Simsek, Gonul/0000 0001 9403 4102
CR BARRAGRY JM, 1979, GUT, V20, P559, DOI 10.1136/gut.20.7.559
   BIKLE DD, 1985, ANN INTERN MED, V103, P42, DOI 10.7326/0003 4819 103 1 42
   BIKLE DD, 1993, ALCOHOL CLIN EXP RES, V17, P690, DOI 10.1111/j.1530 0277.1993.tb00821.x
   Cavolina JM, 1997, ENDOCRINOLOGY, V138, P1567, DOI 10.1210/en.138.4.1567
   Chae HJ, 1997, J PHARM PHARMACOL, V49, P897, DOI 10.1111/j.2042 7158.1997.tb06132.x
   Cheleuitte D, 1998, J CLIN ENDOCR METAB, V83, P2043, DOI 10.1210/jc.83.6.2043
   Cicinelli E, 1999, AM J OBSTET GYNECOL, V180, P334, DOI 10.1016/S0002 9378(99)70209 7
   Cicinelli E, 1996, FERTIL STERIL, V66, P1036, DOI 10.1016/S0015 0282(16)58706 8
   Damoulis PD, 1997, J BONE MINER RES, V12, P412, DOI 10.1359/jbmr.1997.12.3.412
   DAMOULIS PD, 1994, BIOCHEM BIOPH RES CO, V201, P924, DOI 10.1006/bbrc.1994.1790
   Dyer SA, 1998, ALCOHOL, V16, P337, DOI 10.1016/S0741 8329(98)00025 1
   Elmas I, 2001, FORENSIC SCI INT, V119, P212, DOI 10.1016/S0379 0738(00)00429 1
   Fanti P, 1997, ALCOHOL CLIN EXP RES, V21, P1150, DOI 10.1111/j.1530 0277.1997.tb04266.x
   FEITELBERG S, 1987, METABOLISM, V36, P322, DOI 10.1016/0026 0495(87)90201 0
   FELSON DT, 1993, NEW ENGL J MED, V329, P1141, DOI 10.1056/NEJM199310143291601
   Feskanich D, 1999, J WOMENS HEALTH, V8, P65, DOI 10.1089/jwh.1999.8.65
   GAMERO P, 1994, J CLIN ENDOCR METAB, V78, P955
   GASCONBARRE M, 1982, METABOLISM, V31, P67, DOI 10.1016/0026 0495(82)90028 2
   GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003 2697(82)90118 X
   HISHIKAWA K, 1995, FEBS LETT, V360, P291, DOI 10.1016/0014 5793(95)00124 R
   Kassem M, 1996, J CLIN ENDOCR METAB, V81, P513, DOI 10.1210/jc.81.2.513
   KELLER ET, 1979, A BIOL SCI MED SCI B, V52, P311
   Kidder LS, 1998, ALCOHOL CLIN EXP RES, V22, P2159, DOI 10.1111/j.1530 0277.1998.tb05929.x
   Kimble RB, 1997, ALCOHOL CLIN EXP RES, V21, P385
   Klein RF, 1996, ALCOHOL CLIN EXP RES, V20, P572, DOI 10.1111/j.1530 0277.1996.tb01095.x
   Kubes P, 2000, AM J MED, V109, P150, DOI 10.1016/S0002 9343(00)00480 0
   LAITINEN K, 1990, ALCOHOL CLIN EXP RES, V14, P551, DOI 10.1111/j.1530 0277.1990.tb01198.x
   LAITINEN K, 1994, BONE MINER, V24, P171, DOI 10.1016/S0169 6009(08)80134 1
   LAITINEN K, 1992, AM J MED, V93, P642, DOI 10.1016/0002 9343(92)90197 J
   LAITINEN K, 1993, METABOLISM, V42, P875, DOI 10.1016/0026 0495(93)90063 T
   LANCASTER FE, 1995, METAB BRAIN DIS, V10, P125, DOI 10.1007/BF01991860
   MAKINO Y, 1990, J NEUROCHEM, V55, P963, DOI 10.1111/j.1471 4159.1990.tb04585.x
   MANFREDINI R, 1992, EUR REV MED PHARMACO, V14, P293
   MANOLAGAS SC, 1995, NEW ENGL J MED, V332, P305, DOI 10.1056/NEJM199502023320506
   MONCADA S, 1993, NEW ENGL J MED, V329, P2002
   PACIFICI R, 1991, P NATL ACAD SCI USA, V88, P5134, DOI 10.1073/pnas.88.12.5134
   RALSTON SH, 1995, J BONE MINER RES, V10, P1040
   Riggs BL, 1998, J BONE MINER RES, V13, P763, DOI 10.1359/jbmr.1998.13.5.763
   ROSSELLI M, 1994, BIOCHEM BIOPH RES CO, V202, P1543, DOI 10.1006/bbrc.1994.2107
   Sampson HW, 1997, ALCOHOL CLIN EXP RES, V21, P1165, DOI 10.1097/00000374 199710000 00002
   Schneider DL, 1997, ARCH INTERN MED, V157, P1241, DOI 10.1001/archinte.157.11.1241
   SHAFER RB, 1972, GASTROENTEROLOGY, V63, P235
   Siddiqi A, 1999, J CLIN ENDOCR METAB, V84, P435, DOI 10.1210/jc.84.2.435
   Simsek G, 2003, CHINESE J PHYSIOL, V46, P181
   Simsek G, 1997, MED SCI RES, V25, P421
   Simsek G, 2003, TOHOKU J EXP MED, V201, P81, DOI 10.1620/tjem.201.81
   TURNER RT, 1994, ENDOCR REV, V15, P275, DOI 10.1210/er.15.3.275
   Turner RT, 2000, ALCOHOL CLIN EXP RES, V24, P1693, DOI 10.1111/j.1530 0277.2000.tb01971.x
   Turner RT, 1998, ALCOHOL CLIN EXP RES, V22, P1591, DOI 10.1111/j.1530 0277.1998.tb03953.x
   Turner RT, 2001, J BONE MINER RES, V16, P589, DOI 10.1359/jbmr.2001.16.3.589
   van't Hof RJ, 2001, IMMUNOLOGY, V103, P255, DOI 10.1046/j.1365 2567.2001.01261.x
   VantHof RJ, 1997, J BONE MINER RES, V12, P1797, DOI 10.1359/jbmr.1997.12.11.1797
   Venkov CD, 1999, THROMB HAEMOSTASIS, V81, P638
   Wimalawansa SJ, 2000, J BONE MINER RES, V15, P2240, DOI 10.1359/jbmr.2000.15.11.2240
   WRONSKI TJ, 1986, BONE, V7, P119, DOI 10.1016/8756 3282(86)90683 6
   You HJ, 2003, BIOCHEM BIOPH RES CO, V303, P1129, DOI 10.1016/S0006 291X(03)00477 7
NR 56
TC 5
Z9 8
U1 0
U2 6
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0024 3205
J9 LIFE SCI
JI Life Sci.
PD MAR 11
PY 2005
VL 76
IS 17
BP 1965
EP 1974
DI 10.1016/j.lfs.2004.09.034
PG 10
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA 900CV
UT WOS:000227193900006
PM 15707879
DA 2025 08 17
ER

PT J
AU Ramos, CA
   Asgari, Z
   Liu, EL
   Yvon, E
   Heslop, HE
   Rooney, CM
   Brenner, MK
   Dotti, G
AF Ramos, Carlos Almeida
   Asgari, Zahra
   Liu, Enli
   Yvon, Eric
   Heslop, Helen E.
   Rooney, Clio M.
   Brenner, Malcolm K.
   Dotti, Gianpietro
TI An Inducible Caspase 9 Suicide Gene to Improve the Safety of Mesenchymal
   Stromal Cell Therapies
SO STEM CELLS
LA English
DT Article
DE Mesenchymal stromal cells; Suicide gene; Caspase 9
ID CYTOTOXIC T LYMPHOCYTES; VERSUS HOST DISEASE; STEM CELLS; OSTEOGENESIS
   IMPERFECTA; MYOCARDIAL INFARCTION; CYTOSINE DEAMINASE; DELIVERY
   VEHICLES; DONOR LYMPHOCYTES; TUMOR STROMA; BONE
AB Mesenchymal stromal cells (MSCs) have been infused in hundreds of patients to date, with minimal reported side effects. However, follow up is limited and long term side effects are unknown. Because several animal models have raised safety concerns, we sought to develop a system allowing control over the growth and survival of MSCs used therapeutically. We have previously described a suicide system based on an inducible caspase 9 (iCasp9) protein that is activated using a specific chemical inducer of dimerization (CID), analogs of which have been safely tested in a phase I study. Here, we show that MSCs can be easily transduced with this system and selected to high purity (greater than 97%) with clinical grade immuno magnetic procedures. The transduced cells maintain their basic physiology, including expression of surface antigens (such as positivity for CD73, CD90, and CD105, and negativity for hematopoietic markers) and their potential to differentiate into diverse connective tissue lineages (adipocytes, osteoblasts, and chondroblasts). Those cells and their differentiated progeny can be selectively eliminated in vitro or in vivo within 24 hours after exposure to pharmacological levels of CID, with evidence of apoptosis in more than 95% of iCasp9 positive cells. In conclusion, we have developed directed MSC killing to provide a necessary safety mechanism for therapies using progenitor cells. We believe that this approach will become of increasing value as clinical applications for MSCs develop further. STEM CELLS 2010;28:1107 1115
C1 [Ramos, Carlos Almeida] Baylor Coll Med, Dept Med, Ctr Cell & Gene Therapy, Methodist Hosp, Houston, TX 77030 USA.
   [Ramos, Carlos Almeida; Asgari, Zahra; Liu, Enli; Yvon, Eric; Heslop, Helen E.; Rooney, Clio M.; Brenner, Malcolm K.; Dotti, Gianpietro] Texas Childrens Hosp, Houston, TX 77030 USA.
   [Heslop, Helen E.; Rooney, Clio M.; Brenner, Malcolm K.] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA.
   [Rooney, Clio M.] Baylor Coll Med, Dept Pathol & Immunol, Houston, TX 77030 USA.
   [Rooney, Clio M.] Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA.
C3 Baylor College of Medicine; Baylor College Medical Hospital; Houston
   Methodist; Baylor College of Medicine; Baylor College Medical Hospital;
   Baylor College of Medicine; Baylor College of Medicine; Baylor College
   of Medicine
RP Ramos, CA (通讯作者)，Baylor Coll Med, Dept Med, Ctr Cell & Gene Therapy, Methodist Hosp, 1 Baylor Plaza BCM 505, Houston, TX 77030 USA.
EM caramos@bcm.edu
RI Brenner, Malcolm/Y 2509 2019; Heslop, Helen/AAC 9500 2020; Rooney,
   Cliona/ABD 5475 2021; Nascimento Ramos, Carlos Alberto do/JGL 9480 2023
OI Rooney, Cliona/0000 0003 3210 2864; Ramos, Carlos/0000 0002 4004 7837; 
FU Specialized Centers for Cell Based Therapy [NIH NHLBI 1 U54 HL081007]
FX This work was supported by a Specialized Centers for Cell Based Therapy
   Grant NIH NHLBI 1 U54 HL081007. We thank Dr. David Spencer (Baylor
   College of Medicine) for kindly providing AP20187.
CR Bonini C, 2003, NAT MED, V9, P367, DOI 10.1038/nm0403 367
   Bonini C, 1997, SCIENCE, V276, P1719, DOI 10.1126/science.276.5319.1719
   Breitbach M, 2007, BLOOD, V110, P1362, DOI 10.1182/blood 2006 12 063412
   Chamberlain G, 2007, STEM CELLS, V25, P2739, DOI 10.1634/stemcells.2007 0197
   Chang MG, 2006, CIRCULATION, V113, P1832, DOI 10.1161/CIRCULATIONAHA.105.593038
   CHESTER JD, 2005, INTRO CELLULAR MOL B, P458
   Ciceri F, 2009, LANCET ONCOL, V10, P489, DOI 10.1016/S1470 2045(09)70074 9
   Denny WA, 2002, CURR PHARM DESIGN, V8, P1349, DOI 10.2174/1381612023394584
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Hall B, 2007, INT J HEMATOL, V86, P8, DOI 10.1532/IJH97.06230
   Horwitz EM, 2007, BIOL BLOOD MARROW TR, V13, P53, DOI 10.1016/j.bbmt.2006.10.016
   Horwitz EM, 1999, NAT MED, V5, P309, DOI 10.1038/6529
   Horwitz EM, 2002, P NATL ACAD SCI USA, V99, P8932, DOI 10.1073/pnas.132252399
   Iuliucci JD, 2001, J CLIN PHARMACOL, V41, P870, DOI 10.1177/00912700122010771
   Karnoub AE, 2007, NATURE, V449, P557, DOI 10.1038/nature06188
   Kievit E, 1999, CANCER RES, V59, P1417
   Lange C, 1997, GENE THER, V4, P303, DOI 10.1038/sj.gt.3300395
   LeBlanc K, 2008, LANCET, V371, P1579, DOI 10.1016/S0140 6736(08)60690 X
   Lee RH, 2006, P NATL ACAD SCI USA, V103, P17438, DOI 10.1073/pnas.0608249103
   Lee RH, 2009, CELL STEM CELL, V5, P54, DOI 10.1016/j.stem.2009.05.003
   Li ZX, 2002, SCIENCE, V296, P497, DOI 10.1126/science.1068893
   MacCorkle RA, 1998, P NATL ACAD SCI USA, V95, P3655, DOI 10.1073/pnas.95.7.3655
   Montini E, 2006, NAT BIOTECHNOL, V24, P687, DOI 10.1038/nbt1216
   MOOLTEN FL, 1986, CANCER RES, V46, P5276
   MULLEN CA, 1992, P NATL ACAD SCI USA, V89, P33, DOI 10.1073/pnas.89.1.33
   Nauta AJ, 2007, BLOOD, V110, P3499, DOI 10.1182/blood 2007 02 069716
   Phinney DG, 2007, STEM CELLS, V25, P2896, DOI 10.1634/stemcells.2007 0637
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71
   Quintarelli C, 2007, BLOOD, V110, P2793, DOI 10.1182/blood 2007 02 072843
   Riddell SR, 1996, NAT MED, V2, P216, DOI 10.1038/nm0296 216
   SALE GE, 1983, EXP HEMATOL, V11, P961
   Sauce D, 2002, BLOOD, V99, P1165, DOI 10.1182/blood.V99.4.1165
   Spencer DM, 1996, CURR BIOL, V6, P839, DOI 10.1016/S0960 9822(02)00607 3
   Straathof KC, 2005, BLOOD, V105, P4247, DOI 10.1182/blood 2004 11 4564
   Studeny M, 2004, JNCI J NATL CANCER I, V96, P1593, DOI 10.1093/jnci/djh299
   Studeny M, 2002, CANCER RES, V62, P3603
   Tey SK, 2007, BIOL BLOOD MARROW TR, V13, P913, DOI 10.1016/j.bbmt.2007.04.005
   Thomis DC, 2001, BLOOD, V97, P1249, DOI 10.1182/blood.V97.5.1249
   Tolar J, 2007, STEM CELLS, V25, P371, DOI 10.1634/stemcells.2005 0620
   Tyndall A, 2009, BONE MARROW TRANSPL, V43, P821, DOI 10.1038/bmt.2009.63
   WEI MX, 1994, HUM GENE THER, V5, P969, DOI 10.1089/hum.1994.5.8 969
   Yoon YS, 2004, CIRCULATION, V109, P3154, DOI 10.1161/01.CIR.0000134696.08436.65
NR 43
TC 74
Z9 95
U1 0
U2 6
PU WILEY BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1066 5099
J9 STEM CELLS
JI Stem Cells
PD JUN
PY 2010
VL 28
IS 6
BP 1107
EP 1115
DI 10.1002/stem.433
PG 9
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology;
   Oncology; Cell Biology; Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology
GA 615AQ
UT WOS:000279103500012
PM 20506146
OA Bronze, Green Accepted
DA 2025 08 17
ER

PT J
AU Hu, X
   Li, L
   Yu, XY
   Zhang, RY
   Yan, SJ
   Zeng, ZY
   Shu, Y
   Zhao, C
   Wu, XY
   Lei, JY
   Li, YS
   Zhang, WW
   Yang, C
   Wu, K
   Wu, Y
   An, LP
   Huang, SF
   Ji, XJ
   Gong, C
   Yuan, CF
   Zhang, LH
   Liu, W
   Huang, B
   Feng, YX
   Zhang, B
   Haydon, RC
   Luu, HH
   Reid, RR
   Lee, MJ
   Wolf, JM
   Yu, ZB
   He, TC
AF Hu, Xue
   Li, Li
   Yu, Xinyi
   Zhang, Ruyi
   Yan, Shujuan
   Zeng, Zongyue
   Shu, Yi
   Zhao, Chen
   Wu, Xingye
   Lei, Jiayan
   Li, Yasha
   Zhang, Wenwen
   Yang, Chao
   Wu, Ke
   Wu, Ying
   An, Liping
   Huang, Shifeng
   Ji, Xiaojuan
   Gong, Cheng
   Yuan, Chengfu
   Zhang, Linghuan
   Liu, Wei
   Huang, Bo
   Feng, Yixiao
   Zhang, Bo
   Haydon, Rex C.
   Luu, Hue H.
   Reid, Russell R.
   Lee, Michael J.
   Wolf, Jennifer Moriatis
   Yu, Zebo
   He, Tong Chuan
TI CRISPR/Cas9 mediated reversibly immortalized mouse bone marrow stromal
   stem cells (BMSCs) retain multipotent features of mesenchymal stem cells
   (MSCs)
SO ONCOTARGET
LA English
DT Article
DE mesenchymal stem cells (MSCs); bone marrow stromal stem cells (BMSCs);
   CRISPR/Cas9 genome editing; BMP9; osteogenic differentiation
ID BMP 9 INDUCED OSTEOGENIC DIFFERENTIATION; PROTEIN 9 BMP9; MORPHOGENETIC
   PROTEINS; OSTEO/ODONTOBLASTIC DIFFERENTIATION; OSTEOBLAST
   DIFFERENTIATION; GROWTH; NOTCH; WNT; PROGENITORS; EXPRESSION
AB Mesenchymal stem cells (MSCs) are multipotent non hematopoietic progenitor cells that can undergo self renewal and differentiate into multi lineages. Bone marrow stromal stem cells (BMSCs) represent one of the most commonly used MSCs. In order to overcome the technical challenge of maintaining primary BMSCs in long term culture, here we seek to establish reversibly immortalized mouse BMSCs (imBMSCs). By exploiting CRISPR/Cas9 based homology directed repair (HDR) mechanism, we target SV40T to mouse Rosa26 locus and efficiently immortalize mouse BMSCs (i.e., imBMSCs). We also immortalize BMSCs with retroviral vector SSR #41 and establish imBMSC41 as a control line. Both imBMSCs and imBMSC41 exhibit long term proliferative capability although imBMSC41 cells have a higher proliferation rate. SV40T mRNA expression is 130% higher in imBMSC41 than that in imBMSCs. However, FLP expression leads to 86% reduction of SV40T expression in imBMSCs, compared with 63% in imBMSC41 cells. Quantitative genomic PCR analysis indicates that the average copy number of SV40T and hygromycin is 1.05 for imBMSCs and 2.07 for imBMSC41, respectively. Moreover, FLP expression removes 92% of SV40T in imBMSCs at the genome DNA level, compared with 58% of that in imBMSC41 cells, indicating CRISPR/ Cas9 HDR mediated immortalization of BMSCs can be more effectively reversed than that of retrovirus mediated random integrations. Nonetheless, both imBMSCs and imBMSC41 lines express MSC markers and are highly responsive to BMP9 induced osteogenic, chondrogenic and adipogenic differentiation in vitro and in vivo. Thus, the engineered imBMSCs can be used as a promising alternative source of primary MSCs for basic and translational research in the fields of MSC biology and regenerative medicine.
C1 [Hu, Xue; Yu, Xinyi; Zhao, Chen; Wu, Xingye; Lei, Jiayan; Huang, Shifeng; Liu, Wei; Feng, Yixiao; Yu, Zebo] Chongqing Med Univ, Affiliated Hosp 1, Dept Blood Transfus, Chongqing 400016, Peoples R China.
   [Hu, Xue; Yu, Xinyi; Zhao, Chen; Wu, Xingye; Lei, Jiayan; Huang, Shifeng; Liu, Wei; Feng, Yixiao; Yu, Zebo] Chongqing Med Univ, Affiliated Hosp 1, Dept Nephrol, Chongqing 400016, Peoples R China.
   [Hu, Xue; Yu, Xinyi; Zhao, Chen; Wu, Xingye; Lei, Jiayan; Huang, Shifeng; Liu, Wei; Feng, Yixiao; Yu, Zebo] Chongqing Med Univ, Affiliated Hosp 1, Dept Orthopaed Surg, Chongqing 400016, Peoples R China.
   [Hu, Xue; Yu, Xinyi; Zhao, Chen; Wu, Xingye; Lei, Jiayan; Huang, Shifeng; Liu, Wei; Feng, Yixiao; Yu, Zebo] Chongqing Med Univ, Affiliated Hosp 1, Dept Gen Surg, Chongqing 400016, Peoples R China.
   [Hu, Xue; Li, Li; Yu, Xinyi; Zhang, Ruyi; Yan, Shujuan; Zeng, Zongyue; Shu, Yi; Zhao, Chen; Wu, Xingye; Lei, Jiayan; Li, Yasha; Zhang, Wenwen; Yang, Chao; Wu, Ke; Wu, Ying; An, Liping; Huang, Shifeng; Ji, Xiaojuan; Gong, Cheng; Yuan, Chengfu; Zhang, Linghuan; Liu, Wei; Huang, Bo; Feng, Yixiao; Zhang, Bo; Haydon, Rex C.; Luu, Hue H.; Reid, Russell R.; Lee, Michael J.; Wolf, Jennifer Moriatis; He, Tong Chuan] Univ Chicago, Med Ctr, Dept Orthopaed Surg & Rehabil Med, Mol Oncol Lab, Chicago, IL 60637 USA.
   [Hu, Xue; Zhang, Ruyi; Yan, Shujuan; Zeng, Zongyue; Shu, Yi; Wu, Ke; Huang, Shifeng; Huang, Bo; He, Tong Chuan] Chongqing Med Univ, Key Lab Diagnost Med, Minist Educ, Chongqing 400016, Peoples R China.
   [Hu, Xue; Zhang, Ruyi; Yan, Shujuan; Zeng, Zongyue; Shu, Yi; Wu, Ke; Huang, Shifeng; Huang, Bo; He, Tong Chuan] Chongqing Med Univ, Sch Lab Med, Chongqing 400016, Peoples R China.
   [Li, Li] Chongqing Univ, Sch Biomed Engn, Dept Biomed Engn, Chongqing 400044, Peoples R China.
   [Shu, Yi; Li, Yasha; Yang, Chao; Ji, Xiaojuan; Zhang, Linghuan] Chongqing Med Univ, Childrens Hosp, Chongqing 400014, Peoples R China.
   [Zhang, Wenwen] Binzhou Med Univ, Affiliated Yantai Hosp, Dept Lab Med & Clin Diagnost, Yantai 264100, Peoples R China.
   [Wu, Ying] Beijing Univ Chinese Med, Dept Immunol & Microbiol, Beijing 100029, Peoples R China.
   [An, Liping; Zhang, Bo] Lanzhou Univ, Key Lab Orthopaed Surg Gansu Prov, Lanzhou 730030, Gansu, Peoples R China.
   [An, Liping; Zhang, Bo] Lanzhou Univ, Dept Orthopaed Surg, Hosp 2, Lanzhou 730030, Gansu, Peoples R China.
   [Gong, Cheng] Wuhan Univ, Affiliated Zhongnan Hosp, Dept Surg, Wuhan 430071, Hubei, Peoples R China.
   [Yuan, Chengfu] China Three Gorges Univ, Dept Biochem & Mol Biol, Sch Med, Yichang 443002, Peoples R China.
   [Reid, Russell R.] Univ Chicago, Med Ctr, Dept Surg, Sect Plast Surg, Chicago, IL 60637 USA.
C3 Chongqing Medical University; Chongqing Medical University; Chongqing
   Medical University; Chongqing Medical University; University of Chicago;
   University of Chicago Medical Center; Chongqing Medical University;
   Chongqing Medical University; Chongqing University; Chongqing Medical
   University; Binzhou Medical University; Beijing University of Chinese
   Medicine; Lanzhou University; Lanzhou University; Wuhan University;
   China Three Gorges University; University of Chicago; University of
   Chicago Medical Center
RP Yu, ZB (通讯作者)，Chongqing Med Univ, Affiliated Hosp 1, Dept Blood Transfus, Chongqing 400016, Peoples R China.; Yu, ZB (通讯作者)，Chongqing Med Univ, Affiliated Hosp 1, Dept Nephrol, Chongqing 400016, Peoples R China.; Yu, ZB (通讯作者)，Chongqing Med Univ, Affiliated Hosp 1, Dept Orthopaed Surg, Chongqing 400016, Peoples R China.; Yu, ZB (通讯作者)，Chongqing Med Univ, Affiliated Hosp 1, Dept Gen Surg, Chongqing 400016, Peoples R China.; He, TC (通讯作者)，Univ Chicago, Med Ctr, Dept Orthopaed Surg & Rehabil Med, Mol Oncol Lab, Chicago, IL 60637 USA.; He, TC (通讯作者)，Chongqing Med Univ, Key Lab Diagnost Med, Minist Educ, Chongqing 400016, Peoples R China.; He, TC (通讯作者)，Chongqing Med Univ, Sch Lab Med, Chongqing 400016, Peoples R China.
EM yuzebo2001@163.com; tche@uchicago.edu
RI Yang, Chao/IWE 1103 2023; Reid, Russell/LIF 6227 2024; YU,
   XINYI/NKP 6249 2025; Liu, Wei/L 2099 2019
OI Zeng, Zongyue/0000 0002 4333 5412; 
FU National Institutes of Health [AT004418, DE020140]; US Department of
   Defense [OR130096]; Scoliosis Research Society; National Key Research
   and Development Program of China [2016YFC1000803, 2011CB707906];
   National Natural Science Foundation of China [81401536]; Foundation for
   Outstanding Young Scientist of Shandong Province [BS2014YY035];
   University of Chicago Cancer Center Support Grant [P30CA014599];
   National Center for Advancing Translational Sciences of the National
   Institutes of Health [UL1 TR000430]
FX The authors thank Dr. Linda Degenstein of the Transgenic Mouse and
   Embryonic Stem Cell Facility at The University of Chicago for providing
   the animal samples. The reported work was supported in part by research
   grants from the National Institutes of Health (AT004418, DE020140 to TCH
   and RRR), the US Department of Defense (OR130096 to JMW), the Scoliosis
   Research Society (TCH and MJL), the National Key Research and
   Development Program of China (2016YFC1000803 and 2011CB707906 to TCH),
   the National Natural Science Foundation of China (#81401536 to WWZ), and
   the Foundation for Outstanding Young Scientist of Shandong Province
   (#BS2014YY035 to WWZ). This project was also supported in part by The
   University of Chicago Cancer Center Support Grant (P30CA014599) and the
   National Center for Advancing Translational Sciences of the National
   Institutes of Health through Grant Number UL1 TR000430. Funding sources
   were not involved in the study design; in the collection, analysis and
   interpretation of data; in the writing of the report; and in the
   decision to submit the paper for publication.
CR Bi Y, 2014, CELL PHYSIOL BIOCHEM, V34, P1318, DOI 10.1159/000366340
   Bi Y, 2009, J CELL BIOCHEM, V108, P295, DOI 10.1002/jcb.22254
   Caplan AI, 2001, TRENDS MOL MED, V7, P259, DOI 10.1016/S1471 4914(01)02016 0
   Chen LA, 2010, J BONE MINER RES, V25, P2447, DOI 10.1002/jbmr.133
   Chen X, 2015, GENES DIS, V2, P96, DOI 10.1016/j.gendis.2014.12.001
   Cheng HW, 2003, J BONE JOINT SURG AM, V85A, P1544, DOI 10.2106/00004623 200308000 00017
   Denduluri SK, 2016, TISSUE ENG PART C ME, V22, P280, DOI 10.1089/ten.tec.2015.0244
   Denduluri SK, 2015, GENES DIS, V2, P13, DOI 10.1016/j.gendis.2014.10.004
   Deng F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113064
   Deng YL, 2016, CELL PHYSIOL BIOCHEM, V39, P871, DOI 10.1159/000447797
   Deng ZL, 2008, FRONT BIOSCI LANDMRK, V13, P2001, DOI 10.2741/2819
   Doudna JA, 2014, SCIENCE, V346, P1077, DOI 10.1126/science.1258096
   Fan JM, 2017, ONCOTARGET, V8, P27105, DOI 10.18632/oncotarget.15637
   FANNING E, 1992, J VIROL, V66, P1289, DOI 10.1128/JVI.66.3.1289 1293.1992
   FANNING E, 1992, ANNU REV BIOCHEM, V61, P55
   FRIEDENSTEIN AJ, 1966, J EMBRYOL EXP MORPH, V16, P381
   FRIEDENSTEIN AJ, 1968, TRANSPLANTATION, V6, P230, DOI 10.1097/00007890 196803000 00009
   Guruharsha KG, 2012, NAT REV GENET, V13, P654, DOI 10.1038/nrg3272
   He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509
   Hu N, 2013, J CELL SCI, V126, P532, DOI 10.1242/jcs.114231
   Huang EY, 2012, J BONE MINER RES, V27, P1566, DOI 10.1002/jbmr.1622
   Huang EY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032428
   Huang JY, 2009, LIVER INT, V29, P1569, DOI 10.1111/j.1478 3231.2009.02111.x
   Jo A, 2014, GENES DIS, V1, P149, DOI 10.1016/j.gendis.2014.09.004
   Kang Q, 2004, GENE THER, V11, P1312, DOI 10.1038/sj.gt.3302298
   Kang Q, 2009, STEM CELLS DEV, V18, P545, DOI 10.1089/scd.2008.0130
   Kim JH, 2013, THER ADV MUSCULOSKEL, V5, P13, DOI 10.1177/1759720X12466608
   Lamplot JD, 2013, AM J STEM CELLS, V2, P1
   Lampot JD, 2015, CELL TRANSPLANT, V24, P1053, DOI 10.3727/096368914X681054
   Li M, 2013, INT J MED SCI, V10, P1035, DOI 10.7150/ijms.6639
   Li RD, 2014, CURR CANCER DRUG TAR, V14, P274, DOI 10.2174/1568009614666140305105805
   Liao J, 2017, GENE THER, V24, P333, DOI 10.1038/gt.2017.24
   Liao J, 2017, ONCOTARGET, V8, P53851
   Liao JY, 2017, CELL PHYSIOL BIOCHEM, V41, P1905, DOI 10.1159/000471945
   Liu X, 2013, J CELL MOL MED, V17, P1160, DOI 10.1111/jcmm.12097
   Louvi A, 2012, SEMIN CELL DEV BIOL, V23, P473, DOI 10.1016/j.semcdb.2012.02.005
   Lu S, 2016, AM J TRANSL RES, V8, P3710
   Luo J, 2005, CURR GENE THER, V5, P167, DOI 10.2174/1566523053544218
   Luo J, 2007, NAT PROTOC, V2, P1236, DOI 10.1038/nprot.2007.135
   Luo JY, 2010, J BIOL CHEM, V285, P29588, DOI 10.1074/jbc.M110.130518
   Luo Q, 2004, J BIOL CHEM, V279, P55958, DOI 10.1074/jbc.M407810200
   Luther G, 2011, CURR GENE THER, V11, P229
   Luu HH, 2007, J ORTHOP RES, V25, P665, DOI 10.1002/jor.20359
   MACDONALD C, 1990, CRIT REV BIOTECHNOL, V10, P155, DOI 10.3109/07388559009068265
   Mali P, 2013, NAT METHODS, V10, P957, DOI [10.1038/NMETH.2649, 10.1038/nmeth.2649]
   Mali P, 2013, NAT BIOTECHNOL, V31, P833, DOI 10.1038/nbt.2675
   MCLEAN JS, 1993, TRENDS BIOTECHNOL, V11, P232, DOI 10.1016/0167 7799(93)90134 U
   Olsen BR, 2000, ANNU REV CELL DEV BI, V16, P191, DOI 10.1146/annurev.cellbio.16.1.191
   Peng Y, 2004, J BIOL CHEM, V279, P32941, DOI 10.1074/jbc.M403344200
   Peng Y, 2003, J CELL BIOCHEM, V90, P1149, DOI 10.1002/jcb.10744
   Phinney DG, 2013, CYTOTHERAPY, V15, P140, DOI 10.1016/j.jcyt.2012.11.005
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Ramboer E, 2014, J HEPATOL, V61, P925, DOI 10.1016/j.jhep.2014.05.046
   Rastegar Farbod, 2010, World J Stem Cells, V2, P67, DOI 10.4252/wjsc.v2.i4.67
   Raucci A, 2008, J CELL PHYSIOL, V215, P442, DOI 10.1002/jcp.21323
   Reddel RR, 2000, CARCINOGENESIS, V21, P477, DOI 10.1093/carcin/21.3.477
   Sánchez Rivera FJ, 2015, NAT REV CANCER, V15, P387, DOI 10.1038/nrc3950
   Sato T, 2015, STEM CELL REP, V5, P75, DOI 10.1016/j.stemcr.2015.05.011
   Sharff KA, 2009, J BIOL CHEM, V284, P649, DOI 10.1074/jbc.M806389200
   SHAY JW, 1991, BIOCHIM BIOPHYS ACTA, V1072, P1, DOI 10.1016/0304 419X(91)90003 4
   Shenaq DS, 2010, STEM CELLS INT, V2010, DOI 10.4061/2010/519028
   Soleimani M, 2009, NAT PROTOC, V4, P102, DOI 10.1038/nprot.2008.221
   Song DZ, 2017, J CELL MOL MED, V21, P2782, DOI 10.1111/jcmm.13193
   Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007
   Tang N, 2009, J CELL MOL MED, V13, P2448, DOI 10.1111/j.1582 4934.2008.00569.x
   Teven CM, 2014, GENES DIS, V1, P199, DOI 10.1016/j.gendis.2014.09.005
   Varga AC, 2005, ONCOGENE, V24, P5713, DOI 10.1038/sj.onc.1208919
   Wang HF, 2016, ANNU REV BIOCHEM, V85, P227, DOI 10.1146/annurev biochem 060815 014607
   Wang J, 2017, CELL PHYSIOL BIOCHEM, V41, P484, DOI 10.1159/000456885
   Wang JH, 2014, STEM CELLS DEV, V23, P1405, DOI 10.1089/scd.2013.0580
   Wang N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097316
   Wang RN, 2014, GENES DIS, V1, P87, DOI 10.1016/j.gendis.2014.07.005
   Wang Y, 2013, J ORTHOP RES, V31, P1796, DOI 10.1002/jor.22427
   Wei Q, 2017, CELL PHYSIOL BIOCHEM, V41, P2383, DOI 10.1159/000475909
   Westerman KA, 1996, P NATL ACAD SCI USA, V93, P8971, DOI 10.1073/pnas.93.17.8971
   Wu N, 2014, GENE THER, V21, P629, DOI 10.1038/gt.2014.40
   Yang K, 2016, LAB INVEST, V96, P116, DOI 10.1038/labinvest.2015.144
   Yang K, 2012, J INVEST DERMATOL, V132, P2479, DOI 10.1038/jid.2012.145
   Ye JX, 2016, BIOMED MATER, V11, DOI 10.1088/1748 6041/11/2/025021
   Zambrowicz BP, 1997, P NATL ACAD SCI USA, V94, P3789, DOI 10.1073/pnas.94.8.3789
   Zanotti S, 2010, MOL CELL BIOL, V30, P886, DOI 10.1128/MCB.01285 09
   Zhang FG, 2017, ONCOTARGET, V8, P12968, DOI 10.18632/oncotarget.14673
   Zhang HM, 2014, GENES DIS, V1, P6, DOI 10.1016/j.gendis.2014.08.004
   Zhang HM, 2015, BIOMATERIALS, V39, P145, DOI 10.1016/j.biomaterials.2014.11.007
   Zhang Q, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132666
   Zhang WL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011917
   Zhao C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092908
   Zhu GH, 2009, DIFFERENTIATION, V78, P195, DOI 10.1016/j.diff.2009.06.001
NR 88
TC 37
Z9 47
U1 2
U2 22
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949 2553
J9 ONCOTARGET
JI Oncotarget
PD DEC 19
PY 2017
VL 8
IS 67
BP 111847
EP 111865
DI 10.18632/oncotarget.22915
PG 19
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Cell Biology
GA FS1VO
UT WOS:000419567000089
PM 29340096
OA gold, Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU Gusman, DJR
   Ervolino, E
   Theodoro, LH
   Garcia, VG
   Nagata, MJH
   Alves, BES
   de Araujo, NJ
   Matheus, HR
   de Almeida, JM
AF Rodrigues Gusman, David Jonathan
   Ervolino, Edilson
   Theodoro, Leticia Helena
   Garcia, Valdir Gouveia
   Hitomi Nagata, Maria Jose
   Sendao Alves, Breno Edson
   de Araujo, Nathalia Januario
   Matheus, Henrique Rinaldi
   de Almeida, Juliano Milanezi
TI Antineoplastic agents exacerbate periodontal inflammation and aggravate
   experimental periodontitis
SO JOURNAL OF CLINICAL PERIODONTOLOGY
LA English
DT Article
DE alveolar bone loss; antineoplastic agents; cisplatin; fluorouracil;
   periodontal disease; periodontium
ID LOW LEVEL LASER; OSTEOCLAST DIFFERENTIATION; PHOTODYNAMIC THERAPY; BONE
   LOSS; 5 FLUOROURACIL; RATS; CISPLATIN; CHEMOTHERAPY; MECHANISMS; DISEASE
AB Aim This study evaluated the effects of 5 fluorouracil (5 FU) and cisplatin (CIS) in healthy periodontal tissues and in the early stages of experimental periodontitis (EP) in rats. Methods One hundred and eighty male rats were divided into three groups, which were submitted to the following systemic treatments: physiological saline solution (PSS); CIS and 5FU. Each group was subdivided into two subgroups: without (NEP) and with (EP) induction of EP. Animals were euthanized at 3, 5 and 7 days post treatment. Histological, histometric (percentage of bone in the furcation [PBF]) and immunohistochemical (for tumour necrosis factor alpha, interleukin 1 beta and receptor activator of nuclear factor kappa B ligand) analyses were performed. Data were statistically analysed. Results CIS NEP and 5FU NEP showed more inflammation than PSS NEP at 3, 5 and 7 days. CIS EP and 5FU EP showed more inflammation and lower PBF than PSS EP at all periods of evaluation. 5FU EP showed lower PBF than CIS EP at 5 and 7 days. Conclusion 5 FU and CIS exacerbated periodontal inflammation and aggravated the progression of EP in its early stages.
C1 [Rodrigues Gusman, David Jonathan; Theodoro, Leticia Helena; Garcia, Valdir Gouveia; Hitomi Nagata, Maria Jose; Sendao Alves, Breno Edson; de Araujo, Nathalia Januario; Matheus, Henrique Rinaldi; de Almeida, Juliano Milanezi] Sao Paulo State Univ, UNESP, Dept Surg & Integrated Clin, Div Periodont,Sch Dent, Aracatuba, SP, Brazil.
   [Rodrigues Gusman, David Jonathan] Univ Western Sao Paulo, UNOESTE, Dept Periodont, Presidente Prudente, SP, Brazil.
   [Ervolino, Edilson] Sao Paulo State Univ, UNESP, Sch Dent, Dept Basic Sci, Aracatuba, SP, Brazil.
   [Sendao Alves, Breno Edson] Maringa Univ Ctr, UNINGA, Dept Periodont, Maringa, Parana, Brazil.
C3 Universidade Estadual Paulista; Universidade do Oeste Paulista;
   Universidade Estadual Paulista; Centro Universitario Inga (UNINGA)
RP de Almeida, JM (通讯作者)，UNESP, Disciplina Periodontia, Fac Odontol Aracatuba, Dept Cirurgia & Clin Integrada, Aracatuba, SP, Brazil.
EM jumilanezi@hotmail.com
RI Nagata, Maria/C 3737 2013; Garcia, Valdir/C 8765 2012; Matheus,
   Henrique/AAI 2286 2020; Almeida, Juliano/F 7995 2012; Nagata, Maria
   Jose/C 3737 2013; Gusman, David/AAZ 6220 2020; ERVOLINO,
   EDILSON/HJZ 4522 2023; Theodoro, Leticia/KXR 0044 2024
OI Garcia, Valdir/0000 0002 6715 8334; Rinaldi Matheus,
   Henrique/0000 0003 3318 5980; Almeida, Juliano/0000 0002 5995 5747;
   Ervolino, Edilson/0000 0003 4859 0583; Theodoro, Leticia
   Helena/0000 0003 3026 8369; Nagata, Maria Jose/0000 0001 5903 5652;
   Gusman, David Jonathan Rodrigues/0000 0003 0071 1630
FU Sao Paulo State Foundation for Research (FAPESP Sao Paulo, SP, Brazil)
   [2014/11427 8]
FX It was conducted at the Department of Surgery and Integrated
   Clinic Division of Periodontics, Sao Paulo State University (UNESP),
   School of Dentistry, Aracatuba, Sao Paulo, Brazil. The authors thank the
   Sao Paulo State Foundation for Research (FAPESP Sao Paulo, SP, Brazil)
   for supporting this study (2014/11427 8).
CR Andrade EF, 2017, J CLIN PERIODONTOL, V44, P1153, DOI 10.1111/jcpe.12794
   Cho JM, 2008, CANCER LETT, V260, P96, DOI 10.1016/j.canlet.2007.10.022
   Ciancio SG, 2005, J PERIODONTOL, V76, P2061, DOI 10.1902/jop.2005.76.11 S.2061
   Cochran DL, 2008, J PERIODONTOL, V79, P1569, DOI 10.1902/jop.2008.080233
   Dasari S, 2014, EUR J PHARMACOL, V740, P364, DOI 10.1016/j.ejphar.2014.07.025
   de Almeida JM, 2007, J PERIODONTOL, V78, P566, DOI 10.1902/jop.2007.060214
   de Molon RS, 2014, J PERIODONTOL, V85, P465, DOI 10.1902/jop.2013.130225
   Du Bois D, 1989, Nutrition, V5, P303
   Food and Drug Administration, 2016, DOS CALC CONV CHEM H
   Garcia VG, 2014, J PERIODONTAL RES, V49, P584, DOI 10.1111/jre.12138
   Garcia VG, 2015, SUPPORT CARE CANCER, V23, P2007, DOI 10.1007/s00520 014 2563 y
   Graves DT, 2008, J CLIN PERIODONTOL, V35, P89, DOI 10.1111/j.1600 051X.2007.01172.x
   Groeger SE, 2015, PERIODONTOL 2000, V69, P46, DOI 10.1111/prd.12094
   JOHNSON IH, 1975, J PERIODONTAL RES, V10, P332, DOI 10.1111/j.1600 0765.1975.tb00042.x
   Kilkenny C, 2010, J GENE MED, V12, P561, DOI [10.1002/jgm.1473, 10.1113/jphysiol.2010.192278, 10.1111/j.1476 5381.2010.00872.x]
   Kim JH, 2009, J IMMUNOL, V183, P1862, DOI 10.4049/jimmunol.0803007
   KLAUSEN B, 1991, J PERIODONTOL, V62, P59, DOI 10.1902/jop.1991.62.1.59
   Kobayashi K, 2000, J EXP MED, V191, P275, DOI 10.1084/jem.191.2.275
   Kudo O, 2003, BONE, V32, P1, DOI 10.1016/S8756 3282(02)00915 8
   Lalla RV, 2014, CANCER AM CANCER SOC, V120, P1453, DOI 10.1002/cncr.28592
   Liauw SL, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005148
   LISTGARTEN MA, 1975, J PERIODONTOL, V46, P677, DOI 10.1902/jop.1975.46.11.677
   Logan RM, 2007, CANCER TREAT REV, V33, P448, DOI 10.1016/j.ctrv.2007.03.001
   Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074
   Lorch JH, 2011, LANCET ONCOL, V12, P153, DOI 10.1016/S1470 2045(10)70279 5
   Matheus HR, 2018, J CLIN PERIODONTOL, V45, P241, DOI 10.1111/jcpe.12824
   Mazzeo MA, 2009, MED ORAL PATOL ORAL, V14, pE108
   Miller RP, 2010, TOXINS, V2, P2490, DOI 10.3390/toxins2112490
   Mizutani S, 2015, J PERIODONTAL RES, V50, P74, DOI 10.1111/jre.12183
   Nagata MJH, 2014, J PERIODONTOL, V85, P1702, DOI 10.1902/jop.2014.140083
   Schroeder HE, 1997, PERIODONTOL 2000, V13, P91, DOI 10.1111/j.1600 0757.1997.tb00097.x
   Sonis ST, 2004, CANCER AM CANCER SOC, V100, P1995, DOI 10.1002/cncr.20162
   Theodoro LH, 2016, J PERIODONTAL RES, V51, P669, DOI 10.1111/jre.12347
   Theodoro LH, 2017, SUPPORT CARE CANCER, V25, P3261, DOI 10.1007/s00520 017 3738 0
   Theoleyre S, 2004, CYTOKINE GROWTH F R, V15, P457, DOI 10.1016/j.cytogfr.2004.06.004
   Tsukamoto Y, 2012, J PERIODONTAL RES, V47, P750, DOI 10.1111/j.1600 0765.2012.01490.x
   van Kuilenburg ABP, 2003, CLIN CANCER RES, V9, P4363
   Vermorken JB, 2014, ANN ONCOL, V25, P682, DOI 10.1093/annonc/mdu003
   Wang D, 2005, NAT REV DRUG DISCOV, V4, P307, DOI 10.1038/nrd1691
   WHO, 2014, WORLD CANC REPORT 20
   Zuza EP, 2018, CLIN ORAL INVEST, V22, P1197, DOI 10.1007/s00784 017 2207 y
NR 41
TC 13
Z9 13
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0303 6979
EI 1600 051X
J9 J CLIN PERIODONTOL
JI J. Clin. Periodontol.
PD APR
PY 2019
VL 46
IS 4
BP 457
EP 469
DI 10.1111/jcpe.13101
PG 13
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA HU5TY
UT WOS:000465343400007
PM 30854670
DA 2025 08 17
ER

PT J
AU Yang, MY
   Chiu, CD
   Ke, YC
   Yang, YC
   Chang, KB
   Chen, CM
   Lee, HT
   Tang, CL
   Liu, BS
   Hung, HS
AF Yang, Meng Yin
   Chiu, Cheng Di
   Ke, Yi Chun
   Yang, Yi Chin
   Chang, Kai Bo
   Chen, Chien Min
   Lee, Hsu Tung
   Tang, Chien Lun
   Liu, Bai Shuan
   Hung, Huey Shan
TI Differentiation Induction of Mesenchymal Stem Cells by a Au Delivery
   Platform
SO CELLS
LA English
DT Article
DE Au; stromal cell derived factor 1 alpha; mesenchymal stem cell;
   differentiation; drug delivery
ID CYCLE PROGRESSION; BONE MARROW; MIGRATION; MACROPINOCYTOSIS; MECHANISMS;
   INHIBITORS; COLLAGEN; CXCR4; AXIS
AB Au decorated with type I collagen (Col) was used as a core material to cross link with stromal cell derived factor 1 alpha (SDF1 alpha) in order to investigate biological performance. The Au based nanoparticles were subjected to physicochemical determination using scanning electron microscopy (SEM), dynamic light scattering (DLS) and ultraviolet visible (UV Vis) and Fourier transform infrared spectroscopy (FTIR). Mesenchymal stem cells (MSCs) were used to evaluate the biocompatibility of this nanoparticle using the MTT assay and measuring reactive oxygen species (ROS) production. Also, the biological effects of the SDF 1 alpha conjugated nanoparticles (Au Col SDF1 alpha) were assessed and the mechanisms were explored. Furthermore, we investigated the cell differentiation inducing potential of these conjugated nanoparticles on MSCs toward endothelial cells, neurons, osteoblasts and adipocytes. We then ultimately explored the process of cell entry and transportation of the nanoparticles. Using a mouse animal model and retro orbital sinus injection, we traced in vivo biodistribution to determine the biosafety of the Au Col SDF1 alpha nanoparticles. In summary, our results indicate that Au Col is a promising drug delivery system; it can be used to carry SDF1 alpha to improve MSC therapeutic efficiency.
C1 [Yang, Meng Yin; Yang, Yi Chin; Lee, Hsu Tung; Tang, Chien Lun] Taichung Vet Gen Hosp, Neurol Inst, Dept Neurosurg, Taichung, Taiwan.
   [Yang, Meng Yin] Grad Inst Med Sci, Natl Def Med Ctr, Taipei 11490, Taiwan.
   [Yang, Meng Yin] Cent Taiwan Univ Sci & Technol, Coll Nursing, Taichung, Taiwan.
   [Yang, Meng Yin; Lee, Hsu Tung] Natl Chung Hsing Univ, Coll Med, Dept Postbaccalaureate Med, Taichung, Taiwan.
   [Chiu, Cheng Di] China Med Univ Hosp, Dept Neurosurg, Taichung, Taiwan.
   [Chiu, Cheng Di] China Med Univ Hosp, Spine Ctr, Taichung, Taiwan.
   [Ke, Yi Chun; Chang, Kai Bo; Hung, Huey Shan] China Med Univ, Grad Inst Biomed Sci, Taichung, Taiwan.
   [Chen, Chien Min] Changhua Christian Hosp, Dept Surg, Div Neurosurg, Changhua 50006, Taiwan.
   [Chen, Chien Min] Natl Chin Yi Univ Technol, Dept Leisure Ind Management, Taichung, Taiwan.
   [Liu, Bai Shuan] Cent Taiwan Univ Sci & Technol, Dept Med Imaging & Radiol Sci, Taichung, Taiwan.
   [Hung, Huey Shan] China Med Univ Hosp, Translat Med Res, Taichung, Taiwan.
C3 Taichung Veterans General Hospital; National Defense Medical University;
   Central Taiwan University Science & Technology; National Chung Hsing
   University; China Medical University Taiwan; China Medical University
   Hospital   Taiwan; China Medical University Taiwan; China Medical
   University Hospital   Taiwan; China Medical University Taiwan; Changhua
   Christian Hospital; National Chin Yi University of Technology; Central
   Taiwan University Science & Technology; China Medical University Taiwan;
   China Medical University Hospital   Taiwan
RP Hung, HS (通讯作者)，China Med Univ, Grad Inst Biomed Sci, Taichung, Taiwan.; Hung, HS (通讯作者)，China Med Univ Hosp, Translat Med Res, Taichung, Taiwan.
EM yangmy04@gmail.com; cdchiu4046@gmail.com; fish951753go@yahoo.com.tw;
   jean1007@gmail.com; kbwork2021@gmail.com; 96015@cch.org.tw;
   leesd2001@gmail.com; chienluntang@gmail.com; bsliu@ctust.edu.tw;
   hunghs@mail.cmu.edu.tw
RI ; Chu, Chin Chen/HPG 9246 2023; yang, yi chin/HWH 3234 2023; YANG,
   CHIN/HWH 3234 2023
OI Chiu, Cheng Di/0000 0003 0369 0935; yang, yi chin/0000 0002 9651 3761;
   Lee, Hsu Tung/0000 0002 0992 2568; Yang, Meng Yin/0000 0002 2544 8181
FU Taichung Veterans General Hospital, Taichung [TCVGH CTUST1117702,
   TCVGH CTUST1127702, TCVGH 1114901B, TCVGH 1124901B]; Ministry of Science
   and Technology, Taiwan [MOST 111 2314 B 039 045]
FX This work was supported by grants from Taichung Veterans General
   Hospital, Taichung (TCVGH CTUST1117702, TCVGH CTUST1127702,
   TCVGH 1114901B, TCVGH 1124901B) and the Ministry of Science and
   Technology, Taiwan (MOST 111 2314 B 039 045).
CR Adamiak M, 2015, ONCOTARGET, V6, P18819, DOI 10.18632/oncotarget.4710
   Al Saqr A, 2021, NANOMATERIALS BASEL, V11, DOI 10.3390/nano11030808
   Asadi N, 2020, MATER CHEM PHYS, V242, DOI 10.1016/j.matchemphys.2019.122528
   BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812
   Belbachir K, 2009, ANAL BIOANAL CHEM, V395, P829, DOI 10.1007/s00216 009 3019 y
   Bernal A, 2018, CELL MOL LIFE SCI, V75, P2177, DOI 10.1007/s00018 018 2794 z
   Bharathala S, 2019, NANOTECHNOLOGY IN MODERN ANIMAL BIOTECHNOLOGY: CONCEPTS AND APPLICATIONS, P113, DOI 10.1016/B978 0 12 818823 1.00008 9
   Bolívar Monsalve EJ, 2021, MATER ADV, V2, P4447, DOI 10.1039/d1ma00092f
   Chen HC, 2021, COLLOID SURFACE A, V628, DOI 10.1016/j.colsurfa.2021.127298
   Chen YW, 2018, NANOMED NANOTECHNOL, V14, P699, DOI 10.1016/j.nano.2017.12.023
   Chiu CF, 2021, CANCERS, V13, DOI 10.3390/cancers13215317
   D'Aguanno S, 2020, CELLS BASEL, V9, DOI 10.3390/cells9051287
   Daniel JA, 2015, TRAFFIC, V16, P635, DOI 10.1111/tra.12272
   Dar A, 2006, EXP HEMATOL, V34, P967, DOI 10.1016/j.exphem.2006.04.002
   Doherty GJ, 2009, ANNU REV BIOCHEM, V78, P857, DOI 10.1146/annurev.biochem.78.081307.110540
   Downing KH, 1998, CURR OPIN CELL BIOL, V10, P16, DOI 10.1016/S0955 0674(98)80082 3
   Falcone S, 2006, J CELL SCI, V119, P4758, DOI 10.1242/jcs.03238
   Gartel AL, 1996, P SOC EXP BIOL MED, V213, P138
   Gomes FCA, 1999, BRAZ J MED BIOL RES, V32, P619, DOI 10.1590/S0100 879X1999000500016
   Gu LS, 2019, TRENDS BIOTECHNOL, V37, P464, DOI 10.1016/j.tibtech.2018.10.007
   Guo K, 2020, EXP MOL PATHOL, V114, DOI 10.1016/j.yexmp.2020.104416
   Gupta VK, 2022, TRENDS CELL BIOL, V32, P773, DOI 10.1016/j.tcb.2022.03.010
   Hsieh SC, 2016, ACS APPL MATER INTER, V8, P28982, DOI 10.1021/acsami.6b09330
   Huang CY, 2013, J MED BIOL ENG, V33, P139, DOI 10.5405/jmbe.1109
   Hung HS, 2021, POLYMERS BASEL, V13, DOI 10.3390/polym13234265
   Hung HS, 2021, CELLS BASEL, V10, DOI 10.3390/cells10112854
   Hung HS, 2021, NANOMATERIALS BASEL, V11, DOI 10.3390/nano11082046
   Kanlaya R, 2013, CELL BIOCHEM BIOPHYS, V67, P1171, DOI 10.1007/s12013 013 9630 8
   Kupcho K, 2019, APOPTOSIS, V24, P184, DOI 10.1007/s10495 018 1502 7
   Li HR, 2020, J BIOL ENG, V14, DOI 10.1186/s13036 020 00236 3
   Li Q, 2013, BIOCHEM BIOPH RES CO, V441, P675, DOI 10.1016/j.bbrc.2013.10.071
   Liu JY, 2017, ACTA BIOMATER, V55, P13, DOI 10.1016/j.actbio.2017.03.055
   Llanos P, 2015, AM J PHYSIOL ENDOC M, V308, pE294, DOI 10.1152/ajpendo.00189.2014
   Loizidou M, 2010, BRIT J SURG, V97, P463, DOI 10.1002/bjs.7074
   Ma Q, 1998, P NATL ACAD SCI USA, V95, P9448, DOI 10.1073/pnas.95.16.9448
   Madkour L.H., 2019, Nanoelectronic Materials: Fundamentals and Applications, V116
   Malgieri A, 2010, INT J CLIN EXP MED, V3, P248
   MANABE T, 1993, J CELL PHYSIOL, V157, P445, DOI 10.1002/jcp.1041570303
   Meirelles LD, 2009, CYTOKINE GROWTH F R, V20, P419, DOI 10.1016/j.cytogfr.2009.10.002
   Nejati K, 2022, J CLUST SCI, V33, P1, DOI 10.1007/s10876 020 01955 9
   Patra JK, 2018, J NANOBIOTECHNOL, V16, DOI 10.1186/s12951 018 0392 8
   Pisani C, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 64062 9
   Qian K, 2014, J AM CHEM SOC, V136, P9842, DOI 10.1021/ja504097v
   Saji Viswanathan S., 2010, International Journal of Nano and Biomaterials, V3, P119, DOI 10.1504/IJNBM.2010.037801
   Salem SS, 2021, BIOL TRACE ELEM RES, V199, P344, DOI 10.1007/s12011 020 02138 3
   Samsonraj RM, 2017, STEM CELL TRANSL MED, V6, P2173, DOI 10.1002/sctm.17 0129
   Sarfraz N, 2021, CHEM ASIAN J, V16, P720, DOI 10.1002/asia.202001202
   Shen CC, 2021, BIOMEDICINES, V9, DOI 10.3390/biomedicines9111632
   Wu XM, 2017, INT J BIOL MACROMOL, V98, P292, DOI 10.1016/j.ijbiomac.2017.01.127
   Xiao HL, 2007, SPECTROSC INT J, V21, P91, DOI 10.1155/2007/496174
   Xu JY, 2014, BBA MOL BASIS DIS, V1842, P2106, DOI 10.1016/j.bbadis.2014.07.008
   Yazdanian M, 2022, BIOINORG CHEM APPL, V2022, DOI 10.1155/2022/2311910
   Yi CQ, 2010, ACS NANO, V4, P6439, DOI 10.1021/nn101373r
   Yu AYH, 2021, MATER TODAY ADV, V12, DOI 10.1016/j.mtadv.2021.100191
   Zeng Jialiu, 2020, J Life Sci (Westlake Village), V2, P25, DOI 10.36069/jols/20201204
   Zhou Y, 2018, CHIN J NAT MEDICINES, V16, P801, DOI 10.1016/S1875 5364(18)30122 5
NR 56
TC 0
Z9 0
U1 0
U2 8
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2073 4409
J9 CELLS BASEL
JI Cells
PD JUL
PY 2023
VL 12
IS 14
AR 1893
DI 10.3390/cells12141893
PG 26
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA N8DH6
UT WOS:001039251400001
PM 37508556
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Tao, ZS
   Li, TL
   Wei, S
AF Tao, Zhou Shan
   Li, Tian Lin
   Wei, Shan
TI Probucol promotes osteoblasts differentiation and prevents osteoporosis
   development through reducing oxidative stress
SO MOLECULAR MEDICINE
LA English
DT Article
DE Osteoporosis; Osteogenesis; Oxidative stress; Bone metabolism; Probucol
ID BONE; ASSOCIATION; INHIBITOR
AB Probucol (PBC) is a potent cholesterol lowering drug and has been studied extensively for its powerful antioxidative stress. The purpose of this study is to investigate the role of PBC in ovariectomized rat model and to explore the mechanism of osteogenic differentiation of MC3TE E1 Cells. RT qPCR and Immunofluorescence were used to measure the expression level of SOD2, SIRT1, intracellular oxidative stress levels and osteogenic markers proteins. Moreover, CCK 8 assay was conducted to detect cell viability. Alizarin red staining and alkaline phosphatase staining were applied to examine osteogenic function and calcium deposits. The ovariectomized rat model was set up successfully and HE staining were employed to examine femoral trabeculae tissue. Our results showed that PBC suppressed MC3TE E1 resist oxidative stress to promote osteogenic differentiation. Additionally, it was confirmed that PBC promoted osteogenic differentiation of MC3TE E1 through inhibiting oxidative stress. Further study indicated that PBC exerted its beneficial function by suppressing oxidative stress mediated alter bone metabolism to alleviate osteoporosis in vivo. Our research suggested that the PBC modulated oxidative stress inhibition is responsible for activation of the process of osteogenic differentiation, providing a novel insight into the treatment of osteoporosis.
C1 [Tao, Zhou Shan; Li, Tian Lin] Yijishan Hosp, Wannan Med Coll, Dept Orthoped, Affiliated Hosp 1, 2 Zhe Shan Xi Rd, Wuhu 241001, Anhui, Peoples R China.
   [Wei, Shan] Anhui Polytech Univ, Sch Mech Engn, Wuhu 241000, Peoples R China.
   [Wei, Shan] Anhui Polytech Univ, Addit Mfg Inst, Wuhu 241000, Peoples R China.
C3 Wannan Medical College; Anhui Polytechnic University; Anhui Polytechnic
   University
RP Tao, ZS (通讯作者)，Yijishan Hosp, Wannan Med Coll, Dept Orthoped, Affiliated Hosp 1, 2 Zhe Shan Xi Rd, Wuhu 241001, Anhui, Peoples R China.
EM tzs19900327@126.com
OI tao, zhoushan/0000 0001 6300 9289
FU National Natural Science Foundation of China [82002322]; Yijishan
   Hospital, Wannan Medical College [GF2019G04, PF2019005, GF2019T02,
   PF2019007]; Young and Middle aged Key Project of Wannan Medical College
   [WK2020ZF16]
FX This study was supported by a Grant from National Natural Science
   Foundation of China (82002322), Funding of "Peak" Training Program and
   "Panfeng" Innovation Team Project for Scientific Research of Yijishan
   Hospital, Wannan Medical College (Grant no. GF2019G04, PF2019005,
   GF2019T02 and PF2019007) and Young and Middle aged Key Project of Wannan
   Medical College (WK2020ZF16).
CR Baek KH, 2010, CALCIFIED TISSUE INT, V87, P226, DOI 10.1007/s00223 010 9393 9
   Brommage R, 2019, BONE RES, V7, DOI 10.1038/s41413 018 0038 3
   Chan PM, 2013, EVID BASED COMPL ALT, V2013, DOI 10.1155/2013/304713
   Chen WK, 2022, OXID MED CELL LONGEV, V2022, DOI 10.1155/2022/7420726
   Cheng Y, 2019, INT J MOL MED, V44, P652, DOI 10.3892/ijmm.2019.4216
   Colle D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067658
   Diem SJ, 2014, J CLIN ENDOCR METAB, V99, pE1732, DOI 10.1210/jc.2014 2288
   Durgun M, 2020, J ENZYM INHIB MED CH, V35, P950, DOI 10.1080/14756366.2020.1746784
   Farlay D, 2016, J BONE MINER RES, V31, P190, DOI 10.1002/jbmr.2607
   Farrokhi Effat, 2015, Iranian Biomedical Journal, V19, P160, DOI 10.7508/ibj.2015.03.005
   Feng X, 2011, ANNU REV PATHOL MECH, V6, P121, DOI 10.1146/annurev pathol 011110 130203
   Iqbal M, 2004, REDOX REP, V9, P167, DOI 10.1179/135100004225005174
   Jacobs MB, 2012, FERTIL STERIL, V97, P118, DOI 10.1016/j.fertnstert.2011.10.028
   Jiang JL, 2002, BRIT J PHARMACOL, V135, P1175, DOI 10.1038/sj.bjp.0704563
   Kim SW, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 45591 4
   Li TL, 2021, J BONE MINER METAB, V39, P934, DOI 10.1007/s00774 021 01240 3
   Li YX, 2021, ACTA BIOCH BIOPH SIN, V53, P212, DOI 10.1093/abbs/gmaa163
   Liu X, 2021, ACTA BIOCH BIOPH SIN, V53, P1495, DOI 10.1093/abbs/gmab135
   Liu Z, 2016, SCI REP UK, V6, DOI 10.1038/srep27447
   Lu SY, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 03187 w
   Ma L, 2019, BONE RES, V7, DOI 10.1038/s41413 019 0050 2
   Mohamad S, 2012, EVID BASED COMPL ALT, V2012, DOI 10.1155/2012/372878
   Munmun F, 2021, J PINEAL RES, V71, DOI 10.1111/jpi.12749
   Nakamura A, 2009, TISSUE ENG PART C ME, V15, P169, DOI 10.1089/ten.tec.2007.0334
   Song CY, 2022, CALCIFIED TISSUE INT, V110, P117, DOI 10.1007/s00223 021 00892 7
   Su XS, 2014, CLIN EXP PHARMACOL P, V41, P73, DOI 10.1111/1440 1681.12182
   Tao ZS, 2022, J MATER SCI MATER M, V33, DOI 10.1007/s10856 021 06627 2
   Tao ZS, 2020, BIOMED PHARMACOTHER, V132, DOI 10.1016/j.biopha.2020.110911
   Tao ZS, 2019, J BONE MINER METAB, V37, P1026, DOI 10.1007/s00774 019 01008 w
   Tao ZS, 2016, J BIOMATER APPL, V30, P952, DOI 10.1177/0885328215610898
   Tao ZS, 2022, CALCIFIED TISSUE INT, V110, P723, DOI 10.1007/s00223 021 00936 y
   Wang HR, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 020 01788 3
   Wang ZQ, 2013, EVID BASED COMPL ALT, V2013, DOI 10.1155/2013/356260
   Yamashita S, 2009, ATHEROSCLEROSIS, V207, P16, DOI 10.1016/j.atherosclerosis.2009.04.002
   Yu Y, 2018, CELL CYCLE, V17, P2374, DOI 10.1080/15384101.2018.1534510
   Zhan YF, 2020, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01587
   Zhang HX, 2019, PULM PHARMACOL THER, V57, DOI 10.1016/j.pupt.2019.101803
   Zhou W, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/4019619
NR 38
TC 35
Z9 37
U1 2
U2 22
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1076 1551
EI 1528 3658
J9 MOL MED
JI Mol. Med.
PD DEC
PY 2022
VL 28
IS 1
AR 75
DI 10.1186/s10020 022 00503 7
PG 14
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA 2M8SC
UT WOS:000817961700003
PM 35764958
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Yogui, FC
   Momesso, GAC
   Faverani, LP
   Polo, TOB
   Ramalho Ferreira, G
   Hassumi, JS
   Rossi, AC
   Freire, AR
   Prado, FB
   Okamoto, R
AF Yogui, Fernanda Costa
   Correa Momesso, Gustavo Antonio
   Faverani, Leonardo Perez
   Braga Polo, Tarik Ocon
   Ramalho Ferreira, Gabriel
   Hassumi, Jaqueline Suemi
   Rossi, Ana Claudia
   Freire, Alexandre Rodrigues
   Prado, Felippe Bevilacqua
   Okamoto, Roberta
TI A SERM increasing the expression of the osteoblastogenesis and
   mineralization related proteins and improving quality of bone tissue in
   an experimental model of osteoporosis
SO JOURNAL OF APPLIED ORAL SCIENCE
LA English
DT Article
DE Raloxifene; Immunohistochemistry; Osteoporosis; Dental implants; WNT
   signaling
ID POSTMENOPAUSAL WOMEN; RALOXIFENE; SCLEROSTIN; FRACTURE; RISK;
   PROLIFERATION; DEFICIENT; LRP5
AB Raloxifene is an antiresorptive drug, selective estrogen receptor modulator (SERM) used in the treatment of osteoporosis. Objective: To evaluate proteins related to bone repair at the peri implant bone in a rat model of osteoporosis treated with raloxifene. Material and Methods: 72 rats were divided into three groups: SHAM (healthy animals), OVX (ovariectomized animals), and RLX (ovariectomized animals treated with raloxifene). Raloxifene was administered by gavage (1 mg/kg/day). Tibial implantation was performed 30 days after ovariectomy, and animals were euthanized at 14, 42, and 60 days postoperatively. Samples were collected and analyzed by immunohistochemical reactions, molecular analysis, and microtomographic parameters. Results: RLX showed intense staining of all investigated proteins at both time points except for RUNX2. These results were similar to SHAM and opposite to OVX, showing mild staining. The PCR gene expression of OC and ALP values for RLX (P<0.05) followed by SHAM and OVX groups. For BSP data, the highest expression was observed in the RLX groups and the lowest expression was observed in the OVX groups (P<0.05). For RUNX2 data, RLX and SHAM groups showed greater values compared to OVX (P<0.05). At 60 days postoperatively, microtomography parameters, related to closed porosity, showed higher values for (Po.N), (Po.V), and (Po) in RLX and SHAM groups, whereas OVX groups showed lower results (P<0.05); (BV) values (P=0.009); regarding total porosity (Po.tot), RLX group had statistically significant lower values than OVX and SHAM groups (P=0.009). Regarding the open porosity (Po.V and Po), the SHAM group presented the highest values, followed by OVX and RLX groups (P<0.05). The Structural Model Index (SMI), RLX group showed a value closer to zero than SHAM group (P<0.05). Conclusions: Raloxifene had a positive effect on the expression of osteoblastogenesis/mineralization related proteins and on micro CT parameters related to peri implant bone healing.
C1 [Yogui, Fernanda Costa; Okamoto, Roberta] Univ Estadual Paulista UNESP, Fac Odontol Aracatuba, Dept Ciencias Basicas, Aracatuba, SP, Brazil.
   [Correa Momesso, Gustavo Antonio; Faverani, Leonardo Perez; Braga Polo, Tarik Ocon; Ramalho Ferreira, Gabriel; Hassumi, Jaqueline Suemi] Univ Estadual Paulista UNESP, Fac Odontol Aracatuba, Dept Cirurgia & Clin Integrada, Rua Jose Bonifacio 1193, BR 16015050 Aracatuba, SP, Brazil.
   [Rossi, Ana Claudia; Freire, Alexandre Rodrigues; Prado, Felippe Bevilacqua] Univ Estadual Campinas, Fac Odontol Piracicaba, Dept Anat, Piracicaba, SP, Brazil.
C3 Universidade Estadual Paulista; Universidade Estadual Paulista;
   Universidade Estadual de Campinas
RP Faverani, LP (通讯作者)，Univ Estadual Paulista UNESP, Fac Odontol Aracatuba, Dept Cirurgia & Clin Integrada, Rua Jose Bonifacio 1193, BR 16015050 Aracatuba, SP, Brazil.
EM leofaverani@foa.unesp.br
RI Faverani, Leonardo/E 5876 2012; Okamoto, Roberta/C 4562 2012; Prado,
   Felippe/C 4331 2012; Polo, Tárik/O 1882 2018; Rodrigues Freire,
   Alexandre/F 2697 2012; Rossi, Ana/J 8692 2015; Momesso,
   Gustavo/D 6721 2017; Freire, Alexandre/F 2697 2012; Okamoto,
   Roberta/X 6438 2019
OI Faverani, Leonardo/0000 0003 2249 3048; Okamoto,
   Roberta/0000 0002 6773 6966; Costa Yogui, Fernanda/0000 0002 0760 7337;
   Rodrigues Freire, Alexandre/0000 0002 0175 0896; 
FU FAPESP [2013/11277 3, 2012/15912 2]
FX The authors would like to express their gratitude to FAPESP
   (#2013/11277 3 and 2012/15912 2) for the financial support.
CR Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Chung YE, 2012, OSTEOPOROSIS INT, V23, P1235, DOI 10.1007/s00198 011 1675 1
   Cummings SR, 1999, JAMA J AM MED ASSOC, V281, P2189, DOI 10.1001/jama.281.23.2189
   de Oliveira D, 2017, J APPL ORAL SCI, V25, P42
   Delmas PD, 2003, BONE, V33, P522, DOI 10.1016/S8756 3282(03)00241 2
   Ellies DL, 2006, J BONE MINER RES, V21, P1738, DOI 10.1359/JBMR.060810
   Ettinger B, 1999, JAMA J AM MED ASSOC, V282, P637, DOI 10.1001/jama.282.7.637
   Evans HM, 1922, P NATL ACAD SCI USA, V8, P38, DOI 10.1073/pnas.8.3.38
   Gurban CV, 2011, ROM J MORPHOL EMBRYO, V52, P1113
   Kassem M, 2008, ARCH BIOCHEM BIOPHYS, V473, P183, DOI 10.1016/j.abb.2008.03.028
   Kato M, 2002, J CELL BIOL, V157, P303, DOI 10.1083/jcb.200201089
   Lin Z, 2011, J PERIODONTOL, V82, P1007, DOI 10.1902/jop.2010.100577
   Luvizuto ER, 2011, ARCH ORAL BIOL, V56, P984, DOI 10.1016/j.archoralbio.2011.03.015
   Luvizuto ER, 2010, BONE, V46, P1021, DOI 10.1016/j.bone.2009.12.016
   Luvizuto ER, 2010, ARCH ORAL BIOL, V55, P52, DOI 10.1016/j.archoralbio.2009.11.001
   Ramalho Ferreira G, 2017, CLIN ORAL INVEST, V21, P1485, DOI 10.1007/s00784 016 1909 x
   Ramalho Ferreira G, 2015, J BIOMED OPT, V20, DOI 10.1117/1.JBO.20.3.038003
   Riggs BL, 2002, ENDOCR REV, V23, P279, DOI 10.1210/er.23.3.279
   Roschger P, 2001, BONE, V29, P185, DOI 10.1016/S8756 3282(01)00485 9
   Ruggiero SL, 2014, J ORAL MAXIL SURG, V72, P1938, DOI 10.1016/j.joms.2014.04.031
   Sroga GE, 2012, CURR OSTEOPOROS REP, V10, P141, DOI 10.1007/s11914 012 0103 6
   Stringhetta Garcia CT, 2016, BONE, V85, P45, DOI 10.1016/j.bone.2015.11.023
   Stuermer EK, 2014, BONE, V64, P187, DOI 10.1016/j.bone.2014.04.008
   Tanaka S, 2011, OSTEOPOROSIS INT, V22, P587, DOI 10.1007/s00198 010 1328 9
   Teófilo JM, 2004, ARCH ORAL BIOL, V49, P755, DOI 10.1016/j.archoralbio.2004.02.013
   Thurner PJ, 2007, ENG FRACT MECH, V74, P1928, DOI 10.1016/j.engfracmech.2006.05.024
   van Bezooijen RL, 2004, J EXP MED, V199, P805, DOI 10.1084/jem.20031454
   Wells GA, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001155.pub2
   Winkler DG, 2003, EMBO J, V22, P6267, DOI 10.1093/emboj/cdg599
NR 29
TC 24
Z9 24
U1 3
U2 13
PU UNIV SAO PAULO FAC ODONTOLOGIA BAURU
PI BAURU SP
PA AL DR OCTAVIO PINHEIRO BRISOLLA, 9 75, BAURU SP, 17012 901, BRAZIL
SN 1678 7757
EI 1678 7765
J9 J APPL ORAL SCI
JI J. Appl. Oral Sci.
PY 2018
VL 26
AR e20170329
DI 10.1590/1678 7757 2017 0329
PG 13
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA GF2IJ
UT WOS:000431761500001
PM 29742257
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Kovacevic, B
   Ignjatovic, M
   Zivaljevic, V
   Cuk, V
   Scepanovic, M
   Petrovic, Z
   Paunovic, I
AF Kovacevic, Bojan
   Ignjatovic, Mile
   Zivaljevic, Vladan
   Cuk, Vladimir
   Scepanovic, Milena
   Petrovic, Zaklina
   Paunovic, Ivan
TI Parathyroidectomy for the attainment of NKF K/DOQI™ and KDIGO
   recommended values for bone and mineral metabolism in dialysis patients
   with uncontrollable secondary hyperparathyroidism
SO LANGENBECKS ARCHIVES OF SURGERY
LA English
DT Article
DE Secondary hyperparathyroidism; NKF K/DOQI; KDIGO; Parathyroidectomy;
   Calcimimetics
ID MORTALITY RISK; MEDICAL THERAPY; BLOOD PRESSURE; TARGET VALUES;
   SERUM CALCIUM; HEMODIALYSIS; CINACALCET; ASSOCIATION; OUTCOMES; HORMONE
AB The National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF K/DOQI (TM)) 2003 and Kidney Disease: Improving Global Outcomes (KDIGO) 2009 have established guidelines for the treatement of secondary hyperparathyroidism. This study evaluated the impact of parathyroidectomy to achieve recommended values for parathyroid hormone, calcium, phosphorus and CaxPO(4) product in dialysis patients with severe secondary hyperparathyroidism that is resistant to medical treatment.
   This study included 43 consecutive patients who underwent parathyroidectomy for a severe form of secondary hyperparathyroidism (SHPT) that is unresponsive to medical treatment. The serum iPTH, calcium and phosphorus levels were measured prior to surgery, every morning after surgery for 5 days and on the first, sixth and eighth postoperative months.
   Following parathyroidectomy, a significant decline in iPTH values was observed in all patients; however, after the 8 month study period, only one of these patients achieved a serum iPTH concentration within the K/DOQI recommended target range. Unlike iPTH, targeting for calcium, phosphorus and CaxPO(4) at the last follow up were 55.8%, 60.5% and 93%, respectively. These values indicated a significant improvement in comparison to preoperative percentages. In regards to the KDIGO recommended guidelines, the iPTH levels did not significantly change at the end of our study compared to preoperative values; however, calcium levels significantly declined and phosphorus levels significantly improved compared to preoperative values.
   Although the majority of patients fail to reach recommended iPTH values, parathyroidectomy remains a valuable tool to attain these NKF K/DOQI recommendations for serum calcium, phosphorus and CaxPO(4) in dialysis patients with secondary hyperparathyroidism resistant to medical therapy. Parathyroidectomy was shown to be an inadequate intervention for achieving KDIGO recommendations.
C1 [Kovacevic, Bojan; Ignjatovic, Mile; Cuk, Vladimir; Scepanovic, Milena; Petrovic, Zaklina] KBC Zvezdara Univ, Ctr Clin, Clin Surg Nikola Spasic, Belgrade 11000, Serbia.
   [Zivaljevic, Vladan; Paunovic, Ivan] Clin Ctr Serbia, Ctr Endocrine Surg, Inst Endocrinol Diabet & Dis Metab, Belgrade 11000, Serbia.
C3 Clinical Centre of Serbia
RP Kovacevic, B (通讯作者)，KBC Zvezdara Univ, Ctr Clin, Clin Surg Nikola Spasic, D Tucovica 161, Belgrade 11000, Serbia.
EM bkzvez@gmail.com
RI ; Kovacevic, Bojan/HSE 4872 2023
OI Zivaljevic, Vladan/0000 0002 6661 6751; Kovacevic,
   Bojan/0000 0001 6595 337X
CR Al Aly Z, 2004, AM J NEPHROL, V24, P422, DOI 10.1159/000080087
   Arenas MD, 2006, NEPHROL DIAL TRANSPL, V21, P1663, DOI 10.1093/ndt/gfl006
   Barreto FC, 2008, KIDNEY INT, V73, P771, DOI 10.1038/sj.ki.5002769
   Block GA, 2004, NEW ENGL J MED, V350, P1516, DOI 10.1056/NEJMoa031633
   Block GA, 1998, AM J KIDNEY DIS, V31, P607, DOI 10.1053/ajkd.1998.v31.pm9531176
   Coen G, 2001, NEPHRON, V88, P149, DOI 10.1159/000045976
   Costa Hong V, 2007, SURGERY, V142, P699, DOI 10.1016/j.surg.2007.06.015
   Danese MD, 2008, CLIN J AM SOC NEPHRO, V3, P1423, DOI 10.2215/CJN.01060308
   Dukkipati R, 2010, J RENAL NUTR, V20, P243, DOI 10.1053/j.jrn.2009.10.006
   Eknoyan G, 2003, AM J KIDNEY DIS, V41, pS1, DOI 10.1016/S0272 6386(03)00111 2
   Gal Moscovici A, 2005, CLIN NEPHROL, V63, P284
   Ganesh SK, 2001, J AM SOC NEPHROL, V12, P2131, DOI 10.1681/ASN.V12102131
   Goldsmith DJA, 1997, AM J KIDNEY DIS, V29, P593, DOI 10.1016/S0272 6386(97)90343 7
   Kestenbaum B, 2004, KIDNEY INT, V66, P2010, DOI 10.1111/j.1523 1755.2004.00972.x
   Kidney Disease: Improving Global Outcomes (KDIGO) CKD MBD Work Group, 2009, Kidney Int Suppl, pS1, DOI 10.1038/ki.2009.188
   Kimata Naoki, 2007, Hemodial Int, V11, P340, DOI 10.1111/j.1542 4758.2007.00190.x
   Lindberg JS, 2005, J AM SOC NEPHROL, V16, P800, DOI 10.1681/ASN.2004060512
   Mazzaferro S, 2008, NEPHROL DIAL TRANSPL, V23, P2319, DOI 10.1093/ndt/gfm931
   Moe SM, 2005, KIDNEY INT, V67, P760, DOI 10.1111/j.1523 1755.2005.67139.x
   Narayan R, 2007, AM J KIDNEY DIS, V49, P801, DOI 10.1053/j.ajkd.2007.03.009
   Noordzij M, 2005, AM J KIDNEY DIS, V46, P925, DOI 10.1053/j.ajkd.2005.08.013
   Schneider R, 2010, SURGERY, V148, P1091, DOI 10.1016/j.surg.2010.09.009
   Tentori F, 2008, AM J KIDNEY DIS, V52, P519, DOI 10.1053/j.ajkd.2008.03.020
   Tominaga Y, 2008, THER APHER DIAL, V12, pS21, DOI 10.1111/j.1744 9987.2008.00627.x
   Ureña P, 2009, NEPHROL DIAL TRANSPL, V24, P2852, DOI 10.1093/ndt/gfp144
   Young EW, 2005, KIDNEY INT, V67, P1179, DOI 10.1111/j.1523 1755.2005.00185.x
NR 26
TC 24
Z9 26
U1 0
U2 8
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1435 2443
EI 1435 2451
J9 LANGENBECK ARCH SURG
JI Langenbecks Arch. Surg.
PD MAR
PY 2012
VL 397
IS 3
BP 413
EP 420
DI 10.1007/s00423 011 0901 9
PG 8
WC Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Surgery
GA 895JR
UT WOS:000300492900009
PM 22240976
DA 2025 08 17
ER

PT J
AU Mao, L
   Wang, ML
   Li, YY
   Liu, YX
   Wang, JF
   Xue, CH
AF Mao, Lei
   Wang, Meiling
   Li, Yuanyuan
   Liu, Yaxuan
   Wang, Jingfeng
   Xue, Changhu
TI Docosahexaenoic acid containing phosphatidylcholine induced osteoblastic
   differentiation by modulating key transcription factors
SO JOURNAL OF FOOD BIOCHEMISTRY
LA English
DT Article
DE DHA PC; osteogenesis; PPAR gamma; RUNX2
ID BONE FORMATION; OSTEOPOROSIS; PHOSPHORYLATION; INHIBITION; CBFA1; GAMMA;
   RUNX2; MECHANISMS; CELLS; DHA
AB In this study, the pro osteogenic effects of docosahexaenoic acid containing phosphatidylcholine (DHA PC) were investigated both in vitro and in vivo. In vitro experiments showed that DHA PC promoted mesenchymal stem cells (MSCs) proliferation and differentiation into osteoblasts. Luciferase reporter gene assay and western blotting indicated that DHA PC significantly increased RUNX2 transcriptional activity and translation level. Although DHA PC did not affect total peroxisome proliferator activated receptor gamma (PPAR gamma) protein level, it promoted ERK mediated phosphorylation of PPAR. at serine 112 locus, which was positively associated with osteogenesis. The effect of DHA PC on osteogenic differentiation was further verified in MC3T3 E1 cells. In vivo experiments indicated that DHA PC increased bone formation rate of adolescent mice. In summary, our study showed that DHA PC promoted osteogenesis by up regulating RUNX2 expression and ERK mediated PPAR. serine 112 phosphorylation, which might provide an adjunctive therapy for the treatment of osteoporosis as a novel functional food.
C1 [Mao, Lei; Wang, Meiling; Li, Yuanyuan; Liu, Yaxuan; Wang, Jingfeng; Xue, Changhu] Ocean Univ China, Coll Food Sci & Engn, Qingdao, Peoples R China.
C3 Ocean University of China
RP Wang, JF (通讯作者)，Ocean Univ China, Coll Food Sci & Engn, Qingdao, Peoples R China.
EM jfwang@ouc.edu.cn
RI Wang, Meiling/GSI 6167 2022
FU Key Research & Development Plan of Shandong Province [2016YYSP017];
   National Natural Science Foundation of China [2016YYSP017, 313];
   Shandong Province
FX Key Research & Development Plan of Shandong Province, Grant/Award
   Number: No. 2016YYSP017; National Natural Science Foundation of China,
   Grant/Award Number: 313 and 2016YYSP017; Shandong Province
CR Adams M, 1997, J BIOL CHEM, V272, P5128, DOI 10.1074/jbc.272.8.5128
   Ai Aql ZS, 2008, J DENT RES, V87, P107, DOI 10.1177/154405910808700215
   Burge R, 2007, J BONE MINER RES, V22, P465, DOI [10.1359/jbmr.061113, 10.1359/JBMR.061113]
   Candelario J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052583
   Chapurlat RD, 2006, NAT CLIN PRACT ENDOC, V2, P211, DOI 10.1038/ncpendmet0121
   Che HX, 2018, FOOD FUNCT, V9, P643, DOI 10.1039/c7fo01342f
   Crockett JC, 2011, J CELL SCI, V124, P991, DOI 10.1242/jcs.063032
   de Paula FJA, 2010, EXPERT OPIN PHARMACO, V11, P867, DOI 10.1517/14656560903575662
   Ducy P, 2000, SCIENCE, V289, P1501, DOI 10.1126/science.289.5484.1501
   Enomoto H, 2004, J CELL SCI, V117, P417, DOI 10.1242/jcs.00866
   Florencio Silva R, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/421746
   Ge CX, 2018, BONE, V107, P1, DOI 10.1016/j.bone.2017.10.023
   Ge CX, 2016, J CELL PHYSIOL, V231, P587, DOI 10.1002/jcp.25102
   Han YJ, 2018, BONE RES, V6, DOI 10.1038/s41413 018 0019 6
   Hossain Z, 2006, MOL CELL BIOCHEM, V285, P155, DOI 10.1007/s11010 005 9074 6
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Komori T, 2010, ADV EXP MED BIOL, V658, P43, DOI 10.1007/978 1 4419 1050 9_5
   Levental KR, 2017, SCI ADV, V3, DOI 10.1126/sciadv.aao1193
   Liu Z, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11149
   Long FX, 2012, NAT REV MOL CELL BIO, V13, P27, DOI 10.1038/nrm3254
   Lü LX, 2018, COLLOID SURFACE B, V167, P550, DOI 10.1016/j.colsurfb.2018.04.060
   Mao L., 2017, J FOOD BIOCHEM, V42
   Meirelles LD, 2003, BRIT J HAEMATOL, V123, P702, DOI 10.1046/j.1365 2141.2003.04669.x
   Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092 8674(00)80260 3
   Nakanishi A, 2015, J NUTR BIOCHEM, V26, P1317, DOI 10.1016/j.jnutbio.2015.06.007
   Nian H, 2009, PHYTOMEDICINE, V16, P320, DOI 10.1016/j.phymed.2008.12.006
   Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092 8674(00)80259 7
   Querido W, 2013, CELL TISSUE RES, V354, P573, DOI 10.1007/s00441 013 1669 8
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Rayaprolu SJ, 2017, J FOOD BIOCHEM, V41, DOI 10.1111/jfbc.12374
   Sambrook P, 2006, LANCET, V367, P2010, DOI 10.1016/S0140 6736(06)68891 0
   Shi HH, 2018, J AGR FOOD CHEM, V66, P475, DOI 10.1021/acs.jafc.7b04565
   Shirouchi B, 2007, J AGR FOOD CHEM, V55, P7170, DOI 10.1021/jf071225x
   Siris E, 2014, OSTEOPOROSIS INT, V25, P1439, DOI 10.1007/s00198 014 2655 z
   Stechschulte LA, 2016, EBIOMEDICINE, V10, P174, DOI 10.1016/j.ebiom.2016.06.040
   Veronesi F, 2011, CRIT REV EUKAR GENE, V21, P363, DOI 10.1615/CritRevEukarGeneExpr.v21.i4.60
NR 36
TC 5
Z9 5
U1 2
U2 21
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0145 8884
EI 1745 4514
J9 J FOOD BIOCHEM
JI J. Food Biochem.
PD DEC
PY 2018
VL 42
IS 6
AR e12661
DI 10.1111/jfbc.12661
PG 8
WC Biochemistry & Molecular Biology; Food Science & Technology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Food Science & Technology
GA HJ1RP
UT WOS:000456942100035
OA gold
DA 2025 08 17
ER

PT J
AU Yin, JC
   Zhuang, GH
   Zhu, Y
   Hu, XL
   Zhao, HM
   Zhang, RQ
   Guo, H
   Fan, XC
   Cao, Y
AF Yin, Jichao
   Zhuang, Guihua
   Zhu, Yi
   Hu, Xinglv
   Zhao, Hongmou
   Zhang, Rongqiang
   Guo, Hao
   Fan, Xiaochen
   Cao, Yi
TI MiR 615 3p inhibits the osteogenic differentiation of human lumbar
   ligamentum flavum cells via suppression of osteogenic regulators GDF5
   and FOXO1
SO CELL BIOLOGY INTERNATIONAL
LA English
DT Article
DE FOXO1; GDF5; ligamentum flavum; miR 615 3p; osteogenesis
ID BONE MARROW; OSSIFICATION; PROMOTES; RUNX2
AB Ossification of the ligamentum flavum (OLF) is a disease of heterotopic ossification in spinal ligaments. The key of the OLF pathogenesis is the differentiation of fibroblasts into osteoblasts. In this study, we explored the role of miR 615 3p in the osteogenic differentiation of human LF cells. The expression of miR 615 3p was detected during the osteogenic differentiation of hFOB1.19 human osteoblasts, human BMSCs, and human LF cells. The qPCR results showed that miR 615 3p was being decreased during the osteogenic differentiation of these cell lineages. Then, both gain and loss function experiments, respectively performed by single strand miR 615 3p mimic and antagomir, revealed that miR 615 3p negatively regulated the osteogenesis of hLF cells, manifested by a lighter staining degree with Alizarin Red and a decreased level of osteogenic marker genes, including alkaline phosphatase (ALP), RUNX2, osterix (ostx), osteocalcin (OCN), and osteopontin (OPN). Subsequently, our data on bioinformatic analysis, 30' UTR luciferase activity assay, and protein level detection indicated that miR 615 3p directly targeted and suppressed the expression of FOXO1 and GDF5. Furthermore, knockdown of either FOXO1 or GDF5 could inhibit the osteogenic differentiation of hLF cells, which displayed a similar effect with the miR 615 3p mimic. In conclusion, miR 615 3p negatively regulates the osteogenic differentiation of hLF cells through post transcriptionally suppressing osteogenic regulators GDF5 and FOXO1. It can be regarded as a potential target for human OLF therapy.
C1 [Yin, Jichao; Zhuang, Guihua] Xi An Jiao Tong Univ, Sch Publ Hlth, Hlth Sci Ctr, Dept Epidemiol & Biostat, 76 West Yanta Rd, Xian 710061, Shaanxi, Peoples R China.
   [Yin, Jichao; Hu, Xinglv] Xian Hosp Tradit Chinese Med, Dept Orthoped & Traumatol, Xian, Peoples R China.
   [Zhu, Yi; Zhao, Hongmou; Guo, Hao; Fan, Xiaochen; Cao, Yi] Xian Honghui Hosp, Dept Tradit Chinese Med, Orthoped Diag & Treatment Ctr, Xian, Peoples R China.
   [Zhang, Rongqiang] Shaanxi Univ Chinese Med, Dept Publ Hlth, Xian, Peoples R China.
C3 Xi'an Jiaotong University; Shaanxi University of Chinese Medicine
RP Zhuang, GH (通讯作者)，Xi An Jiao Tong Univ, Sch Publ Hlth, Hlth Sci Ctr, Dept Epidemiol & Biostat, 76 West Yanta Rd, Xian 710061, Shaanxi, Peoples R China.
EM zhuoruxl1@sina.com
RI Fan, Xiaochen/JAC 3319 2023
CR Ahn DK, 2014, ASIAN SPINE J, V8, P89, DOI 10.4184/asj.2014.8.1.89
   Baur ST, 2000, DEVELOPMENT, V127, P605
   Cai HX, 2012, SPINE, V37, pE639, DOI 10.1097/BRS.0b013e318242a132
   Carthew RW, 2009, CELL, V136, P642, DOI 10.1016/j.cell.2009.01.035
   Fan DW, 2007, J BIOL CHEM, V282, P29958, DOI 10.1074/jbc.M611779200
   Hou XF, 2016, CLIN SPINE SURG, V29, P86, DOI 10.1097/BSD.0000000000000081
   Hupkes M, 2014, BMC MOL BIOL, V15, DOI 10.1186/1471 2199 15 1
   Jia J, 2013, FEBS LETT, V587, P3027, DOI 10.1016/j.febslet.2013.07.030
   Jiang A, 2011, EXP BIOL MED, V236, P672, DOI 10.1258/ebm.2011.010349
   Lang N, 2013, EUR SPINE J, V22, P857, DOI 10.1007/s00586 012 2492 8
   Li EQ, 2014, MOL CELL BIOCHEM, V390, P69, DOI 10.1007/s11010 013 1957 3
   Li H, 2007, EUR SPINE J, V16, P1075, DOI 10.1007/s00586 007 0356 4
   Li HQ, 2015, MOL MED REP, V12, P1561, DOI 10.3892/mmr.2015.3497
   Liu H, 2014, J CELL PHYSIOL, V229, P1494, DOI 10.1002/jcp.24591
   Liu L, 2017, CELL BIOL INT, V41, P112, DOI 10.1002/cbin.10704
   Liu Y, 2010, CLIN ORTHOP RELAT R, V468, P3333, DOI 10.1007/s11999 010 1511 5
   Miyamoto Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109637
   Mukai R, 2015, MOL CLIN ONCOL, V3, P487, DOI 10.3892/mco.2015.514
   Nickel J, 2005, J MOL BIOL, V349, P933, DOI 10.1016/j.jmb.2005.04.015
   Pan T, 2016, ACS APPL MATER INTER, V8, P19217, DOI 10.1021/acsami.6b02969
   Qu S, 2006, ENDOCRINOLOGY, V147, P5641, DOI 10.1210/en.2006 0541
   Qu XC, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17081370
   Quah S, 2015, EVODEVO, V6, DOI 10.1186/s13227 015 0027 1
   Sohn S, 2014, J CLIN DENSITOM, V17, P195, DOI 10.1016/j.jocd.2013.04.005
   Song Li Jie, 2015, Asian Pac J Cancer Prev, V16, P3667
   Sun Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119783
   Wang FS, 2013, ARTHRITIS RHEUM US, V65, P1530, DOI 10.1002/art.37948
   Yeh CH, 2016, SPINE J, V16, P896, DOI 10.1016/j.spinee.2016.03.026
   Zhang WG, 2015, MATH PROBL ENG, V2015, DOI 10.1155/2015/765362
NR 29
TC 33
Z9 40
U1 0
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1065 6995
EI 1095 8355
J9 CELL BIOL INT
JI Cell Biol. Int.
PD JUL
PY 2017
VL 41
IS 7
BP 779
EP 786
DI 10.1002/cbin.10780
PG 8
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA EX4NI
UT WOS:000403211100008
PM 28460412
DA 2025 08 17
ER

PT J
AU Qian, H
   Yang, H
   Xui, WR
   Yan, YM
   Chen, QL
   Zhu, W
   Cao, HL
   Yin, Q
   Zhou, HX
   Mao, F
   Chen, YC
AF Qian, Hui
   Yang, Huan
   Xui, Wenrong
   Yan, Yongmin
   Chen, Qiaolin
   Zhu, Wei
   Cao, Huiling
   Yin, Qin
   Zhou, Hongxing
   Mao, Fei
   Chen, Yongchang
TI Bone marrow mesenchymal stem cells ameliorate rat acute renal failure by
   differentiation into renal tubular epithelial like cells
SO INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
LA English
DT Article
DE mesenchymal stem cells; acute renal failure; differentiation; kidney
ID MYELOMONOCYTIC CELLS; HEME OXYGENASE; KIDNEY INJURY; REPAIR; CONTRIBUTE;
   RECOVERY; FUSION
AB In the present study, we investigated the therapeutic potential of mesenchymal stem cells (MSCs) in a rat acute renal failure (ARF) model and explored the possible in vivo and in vitro mechanisms of action. Rat and human MSCs were isolated from bone marrow. After being co cultured with injured kidney tissues in trans well dishes in vitro, the rat MSCs became rounded renal tubular epithelial like cells, and highly expressed renal markers such as cytokeratin 18 (CK18) and aquaporin 1 (AQP1). Human MSCs were infused into rats with ARF, and techniques of microscopy, histology, PCR, RT PCR and fluorescence in situ hybridization were used to characterize the MSCs after transplantation. We found that there were more exogenous human MSCs localized to injured kidney tissues. The kidney recovery rate in the transplanted MSC group was higher than in the control group. Genes associated with human renal tubular epithelial cells such as AQP1 and parathyroid hormone receptor 1 were detected. These findings suggest that the injured kidney tissue induced rat and human MSCs to differentiate into renal tubular epithelial like cells in vitro and in vivo, and exogenous human MSCs can home specifically to injured regions and efficiently cure rat ARF. These results demonstrate that cell therapy has potential as a novel intervention in ARF.
C1 [Xui, Wenrong] Jiangsu Univ, Sch Med Technol, Zhenjiang Key Inst, Clin Lab Med, Zhenjiang 212013, Jiangsu, Peoples R China.
   [Xui, Wenrong; Yin, Qin] Jiangsu Univ, Affiliated Hosp, Dept Clin Lab Med, Zhenjiang 212001, Peoples R China.
C3 Jiangsu University; Jiangsu University
RP Xui, WR (通讯作者)，Jiangsu Univ, Sch Med Technol, Zhenjiang Key Inst, Clin Lab Med, 301 Xuefu Rd, Zhenjiang 212013, Jiangsu, Peoples R China.
EM icls@ujs.edu.cn
RI ; Mao, Fei/HDN 1058 2022
OI Qian, Hui/0000 0002 0098 3196; 
FU National Natural Science Foundation [30471983, BK2007092, BK2007705];
   Ministry of Public Health of China [WKJ2005 2 024]; Foundation of
   Zhenjiang Key Institute of Clinical Laboratory Medicine [SH2006066,
   SH2006070]; Jiangsu Province's Outstanding Medical Academic Leader
   Program [LJ200614]; Scientific Research Foundation; Jiangsu University
   [07JDG056]; Innovation Center for Medical Graduate Student Studies
FX This work was supported by the National Natural Science Foundation of
   China, grant no. 30471983, the Natural Science Foundation of the Jiangsu
   Province, grant nos. BK2007092 and BK2007705, the Natural Science
   Foundation of the Ministry of Public Health of China, grant no.
   WKJ2005 2 024, the Foundation of Zhenjiang Key Institute of Clinical
   Laboratory Medicine, grant nos. SH2006066 and SH2006070, the Jiangsu
   Province's Outstanding Medical Academic Leader Program, grant no.
   LJ200614 and the Scientific Research Foundation of Jiangsu University,
   grant no. 07JDG056. We thank the Innovation Center for Medical Graduate
   Student Studies of Jiangsu Province for helpful and critical reading of
   the manuscript.
CR Bellomo R, 2005, CURR OPIN CRIT CARE, V11, P542, DOI 10.1097/01.ccx.0000184165.02498.14
   Brodie JC, 2005, PHARMACOL REV, V57, P299, DOI 10.1124/pr.57.3.3
   Camargo FD, 2004, J CLIN INVEST, V113, P1266, DOI 10.1172/JCI200421301
   Haller H, 2007, INTERNIST, V48, P813, DOI 10.1007/s00108 007 1910 1
   Herrera MB, 2007, KIDNEY INT, V72, P430, DOI 10.1038/sj.ki.5002334
   Herrera MB, 2004, INT J MOL MED, V14, P1035
   Hung SC, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000416
   Kale S, 2003, J CLIN INVEST, V112, P42, DOI 10.1172/JCI200317856
   Lange C, 2005, KIDNEY INT, V68, P1613, DOI 10.1111/j.1523 1755.2005.00573.x
   Morigi M, 2004, J AM SOC NEPHROL, V15, P1794, DOI 10.1097/01.ASN.0000128974.07460.34
   NATH KA, 1992, J CLIN INVEST, V90, P267, DOI 10.1172/JCI115847
   Natsu K, 2004, TISSUE ENG, V10, P1093, DOI 10.1089/1076327041887754
   Nöth U, 2007, J BIOMED MATER RES A, V83A, P626, DOI 10.1002/jbm.a.31254
   OLLE L, 2004, NEURODEGENERATION, V7, P42
   Pittenger MF, 2004, CIRC RES, V95, P9, DOI 10.1161/01.RES.0000135902.99383.6f
   [钱晖 Qian Hui], 2004, [解剖学报, Acta Anatomica Sinica], V35, P440
   Qiao C, 2008, CELL BIOL INT, V32, P8, DOI 10.1016/j.cellbi.2007.08.002
   Ricardo SD, 2005, NEPHROLOGY, V10, P276, DOI 10.1111/j.1440 1797.2005.00373.x
   [孙晓春 Sun Xiaochun], 2004, [中国生物医学工程学报, Chinese Journal of Biomedical Engineering], V23, P40
   Tögel F, 2005, AM J PHYSIOL RENAL, V289, pF31, DOI 10.1152/ajprenal.00007.2005
   Tögel F, 2005, KIDNEY INT, V67, P1772, DOI 10.1111/j.1523 1755.2005.00275.x
   Tögel F, 2007, AM J PHYSIOL RENAL, V292, pF1626, DOI 10.1152/ajprenal.00339.2006
   Tsai RYL, 2002, DEV CELL, V2, P707, DOI 10.1016/S1534 5807(02)00195 8
   Vigneau C, 2006, CURR OPIN NEPHROL HY, V15, P238, DOI 10.1097/01.mnh.0000222689.76841.db
   Willenbring H, 2004, NAT MED, V10, P744, DOI 10.1038/nm1062
   Wong CY, 2008, PATHOLOGY, V40, P52, DOI 10.1080/00313020701716367
   Wynn RF, 2004, BLOOD, V104, P2643, DOI 10.1182/blood 2004 02 0526
   Xiang Y, 2007, CELL BIOL INT, V31, P444, DOI 10.1016/j.cellbi.2006.11.012
   Xu WR, 2004, ONCOL REP, V12, P501
   Xu WR, 2004, EXP BIOL MED, V229, P623, DOI 10.1177/153537020422900706
   ZAGER RA, 1995, KIDNEY INT, V48, P1624, DOI 10.1038/ki.1995.457
   ZHU W, 2003, J BIOL ENG RES, V22, P41
NR 32
TC 121
Z9 145
U1 0
U2 25
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1107 3756
EI 1791 244X
J9 INT J MOL MED
JI Int. J. Mol. Med.
PD SEP
PY 2008
VL 22
IS 3
BP 325
EP 332
DI 10.3892/ijmm_00000026
PG 8
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA 352TD
UT WOS:000259519400008
PM 18698491
OA Bronze
DA 2025 08 17
ER

PT J
AU Ghorbaninejad, M
   Khademi Shirvan, M
   Hosseini, S
   Meyfour, A
   Shahhoseini, M
   Eslaminejad, MB
AF Ghorbaninejad, Mahsa
   Khademi Shirvan, Maliheh
   Hosseini, Samaneh
   Meyfour, Anna
   Shahhoseini, Maryam
   Eslaminejad, Mohamadreza Baghaban
TI Effective role of Curcumin on expression regulation of EZH2 histone
   methyltransferase as a dynamic epigenetic factor in osteogenic
   differentiation of human mesenchymal stem cells
SO BIOCHIMICA ET BIOPHYSICA ACTA GENE REGULATORY MECHANISMS
LA English
DT Article
DE Curcumin; EZH2; Osteogenesis; Epigenetic modification
ID TRANSCRIPTION FACTOR; OSTEOBLAST; INHIBITOR; METHYLATION; SWITCH; SERUM
AB Background: Efficient differentiation of mesenchymal stem cells (MSCs) into a desired cell lineage remains challenging in cell based therapy and regenerative medicine. Numerous efforts have been made to efficiently promote differentiation of MSCs into osteoblast lineage. Accordingly, epigenetic signatures emerge as a key conductor of cell differentiation. Among them, Enhancer of Zeste Homolog 2 (EZH2), a histone methyltransferase appears to suppress osteogenesis. Curcumin is an osteoinductive natural polyphenol compound which suppos edly modulates epigenetic mechanisms. Hence, the current study aims to address the role of the EZH2 epigenetic factor in osteogenic activity of MSCs after Curcumin treatment.Methods: The effect of Curcumin on viability and osteogenic differentiation was evaluated at different time points in vitro. The expression level of EZH2 was assessed using quantitative real time polymerase chain reaction (qRT PCR) after 14 and 21 days.Results: MTT results showed no cytotoxic effects at concentrations of 10 and 15 mu M of Curcumin and cells sur vived up to 70 % at all time points. qRT PCR results demonstrated that Curcumin significantly enhanced the expression levels of osteogenic markers that included Runx2, Osterix, Collagen type I, Osteopontin and Osteocalcin at day 21.Conclusions: Interestingly, we observed that the expression level of the EZH2 gene was downregulated in the presence of Curcumin compared to the control group during osteogenesis. This study confirmed that Curcumin acts as an epigenetic switch to regulate osteoblast differentiation specifically through the EZH2 suppression.
C1 [Ghorbaninejad, Mahsa; Meyfour, Anna] Shahid Beheshti Univ Med Sci, Res Inst Gastroenterol & Liver Dis, Basic & Mol Epidemiol Gastrointestinal Disorders R, Tehran, Iran.
   [Ghorbaninejad, Mahsa; Khademi Shirvan, Maliheh; Hosseini, Samaneh; Meyfour, Anna; Eslaminejad, Mohamadreza Baghaban] ACECR, Royan Inst Stem Cell Biol & Technol, Cell Sci Res Ctr, Dept Stem Cells & Dev Biol, Tehran, Iran.
   [Ghorbaninejad, Mahsa; Khademi Shirvan, Maliheh; Shahhoseini, Maryam] ACECR, Royan Inst Reprod Biomed, Reprod Biomed Res Ctr, Dept Genet, Tehran, Iran.
   [Hosseini, Samaneh] ACECR, Royan Inst Stem Cell Biol & Technol, Cell Sci Res Ctr, Dept Cell Engn, Tehran, Iran.
   [Shahhoseini, Maryam] ACECR, Royan Inst Reprod Biomed, Reprod Epidemiol Res Ctr, Tehran, Iran.
   [Shahhoseini, Maryam] Univ Tehran, Coll Sci, Sch Biol, Dept Cell & Mol Biol, Tehran, Iran.
C3 Shahid Beheshti University Medical Sciences; Academic Center for
   Education, Culture & Research (ACECR); Academic Center for Education,
   Culture & Research (ACECR); Academic Center for Education, Culture &
   Research (ACECR); Academic Center for Education, Culture & Research
   (ACECR); University of Tehran
RP Eslaminejad, MB (通讯作者)，ACECR, Royan Inst Stem Cell Biol & Technol, Cell Sci Res Ctr, Dept Stem Cells & Dev Biol, Tehran, Iran.; Shahhoseini, M (通讯作者)，ACECR, Royan Inst Reprod Biomed, Reprod Biomed Res Ctr, Dept Genet, Tehran, Iran.
EM m.shahhoseini@royaninstitute.org; eslami@royaninstitute.org
RI Baghaban Eslaminejad, Mohamadreza/S 3645 2017; Hosseini,
   Samaneh/I 1232 2019
OI Baghaban Eslaminejad, Mohamadreza/0000 0002 1036 0072; 
CR AUBIN JE, 1995, BONE, V17, pS77, DOI 10.1016/8756 3282(95)00183 E
   Caplan AI, 2007, J CELL PHYSIOL, V213, P341, DOI 10.1002/jcp.21200
   Chou RH, 2011, AM J TRANSL RES, V3, P243
   Deng P, 2015, INT J ORAL SCI, V7, P197, DOI 10.1038/ijos.2015.41
   Duan R, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045 020 00937 8
   Fani N, 2016, EXP CELL RES, V344, P176, DOI 10.1016/j.yexcr.2015.10.009
   Franceschi RT, 2003, CONNECT TISSUE RES, V44, P109, DOI 10.1080/03008200390152188
   Fu SQ, 2010, CANCER AM CANCER SOC, V116, P4670, DOI 10.1002/cncr.25414
   Ghorbaninejad M, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 020 01966 3
   Han SM, 2014, EXP MOL MED, V46, DOI 10.1038/emm.2014.28
   Hemming S, 2014, STEM CELLS, V32, P802, DOI 10.1002/stem.1573
   Hibino S, 2014, ONCOGENESIS, V3, DOI 10.1038/oncsis.2014.17
   Hosseini E, 2016, J ASSIST REPROD GEN, V33, P1105, DOI 10.1007/s10815 016 0727 z
   Hua WF, 2010, EUR J PHARMACOL, V637, P16, DOI 10.1016/j.ejphar.2010.03.051
   Huang Z, 2017, STEM CELL REV REP, V13, P50, DOI 10.1007/s12015 016 9699 8
   Hyun K, 2017, EXP MOL MED, V49, DOI 10.1038/emm.2017.11
   Javidi MA, 2015, EXP CLIN ENDOCR DIAB, V123, P632, DOI 10.1055/s 0035 1555775
   Jiang Q, 2021, KAOHSIUNG J MED SCI, V37, P513, DOI 10.1002/kjm2.12346
   Jing H, 2016, MOL THER, V24, P217, DOI 10.1038/mt.2015.152
   Ke DS, 2020, MOL CELL ENDOCRINOL, V500, DOI 10.1016/j.mce.2019.110637
   Kim KH, 2016, NAT MED, V22, P128, DOI 10.1038/nm.4036
   Komori T, 2010, CELL TISSUE RES, V339, P189, DOI 10.1007/s00441 009 0832 8
   Lee Zang Hee, 2015, J Bone Metab, V22, P51, DOI 10.11005/jbm.2015.22.2.51
   LIAN JB, 1992, CRIT REV ORAL BIOL M, V3, P269, DOI 10.1177/10454411920030030501
   McCubrey JA, 2017, AGING US, V9, P1477, DOI 10.18632/aging.101250
   Miranda TB, 2009, MOL CANCER THER, V8, P1579, DOI 10.1158/1535 7163.MCT 09 0013
   Moran JM, 2012, INT J MOL SCI, V13, P16104, DOI 10.3390/ijms131216104
   Neckers L, 2018, CELL STRESS CHAPERON, V23, P467, DOI 10.1007/s12192 018 0877 2
   Nishikawa K, 2010, J CLIN INVEST, V120, P3455, DOI 10.1172/JCI42528
   Otsuka E, 1998, EUR J PHARMACOL, V349, P345, DOI 10.1016/S0014 2999(98)00190 3
   Parekkadan B, 2010, ANNU REV BIOMED ENG, V12, P87, DOI 10.1146/annurev bioeng 070909 105309
   Pierantozzi E, 2011, STEM CELLS DEV, V20, P915, DOI 10.1089/scd.2010.0353
   Poundarik AA, 2012, P NATL ACAD SCI USA, V109, P19178, DOI 10.1073/pnas.1201513109
   PUCHTLER H, 1969, J HISTOCHEM CYTOCHEM, V17, P110, DOI 10.1177/17.2.110
   Qiu WX, 2020, J CELL MOL MED, V24, P317, DOI 10.1111/jcmm.14729
   Shrestha A, 2021, J MED CHEM, V64, P14913, DOI 10.1021/acs.jmedchem.1c01116
   Siffert R. S., 1951, Journal of Experimental Medicine, V93, P415, DOI 10.1084/jem.93.5.415
   Sinha KM, 2013, J CELL BIOCHEM, V114, P975, DOI 10.1002/jcb.24439
   Tai PWL, 2014, GENE, V550, P1, DOI 10.1016/j.gene.2014.05.044
   Thirunavukkarasu K, 2000, J BIOL CHEM, V275, P25163, DOI 10.1074/jbc.M000322200
   Thomas D, 2006, J CELL BIOCHEM, V98, P757, DOI 10.1002/jcb.20850
   Wang XJ, 2020, FREE RADICAL BIO MED, V159, P164, DOI 10.1016/j.freeradbiomed.2020.07.023
   Wei QS, 2016, SCAND J CLIN LAB INV, V76, P33, DOI 10.3109/00365513.2015.1087045
   Wei YK, 2011, NAT CELL BIOL, V13, P87, DOI 10.1038/ncb2139
   Wu GQ, 2016, ONCOTARGET, V7, P26535, DOI 10.18632/oncotarget.8532
   Zhang C, 2010, J ORTHOP SURG RES, V5, DOI 10.1186/1749 799X 5 37
   Zhao JY, 2010, J ASIAN NAT PROD RES, V12, P335, DOI 10.1080/10286021003730348
NR 47
TC 6
Z9 8
U1 1
U2 4
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1874 9399
EI 1876 4320
J9 BBA GENE REGUL MECH
JI Biochim. Biophys. Acta Gene Regul. Mech.
PD MAR
PY 2023
VL 1866
IS 1
AR 194903
DI 10.1016/j.bbagrm.2022.194903
EA DEC 2022
PG 13
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA G6HV4
UT WOS:000990153800001
PM 36538966
DA 2025 08 17
ER

PT J
AU Guaraná, WL
   Lima, CAD
   Barbosa, AD
   Crovella, S
   Sandrin Garcia, P
AF Guarana, Werbson Lima
   Lima, Camilla Albertina Dantas
   Barbosa, Alexandre Domingues
   Crovella, Sergio
   Sandrin Garcia, Paula
TI Farnesyl Diphosphate Synthase Gene Associated with Loss of Bone Mass
   Density and Alendronate Treatment Failure in Patients with Primary
   Osteoporosis
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE FDPS; genetic variant; postmenopausal osteoporosis; pharmacogenetic;
   alendronate sodium; aminobisphosphonates
ID BISPHOSPHONATE TREATMENT; POSTMENOPAUSAL WOMEN; POLYMORPHISMS;
   PREVENTION; THERAPY; TARGET
AB Aminobisphosphonates (NBPs) are the first choice medication for osteoporosis (OP); NBP treatment aims at increasing bone mineral density (BMD) by inhibiting the activity of farnesyl diphosphate synthase (FDPS) enzyme in osteoclasts. Despite its efficacy, inadequate response to the drug and side effects have been reported. The A allele of the rs2297480 (A > C) SNP, found in the regulatory region of the FDPS gene, is associated with reduced gene transcription. This study evaluates the FDPS variant rs2297480 (A > C) association with OP patients' response to alendronate sodium treatment. A total of 304 OP patients and 112 controls were enrolled; patients treated with alendronate sodium for two years were classified, according to BMD variations at specific regions (lumbar spine (L1 L4), femoral neck (FN) and total hip (TH), as responders (OP R) (n = 20) and non responders (OP NR) (n = 40). We observed an association of CC genotype with treatment failure (p = 0.045), followed by a BMD decrease in the regions L1 L4 (CC =  2.21% +/  2.56; p = 0.026) and TH (CC =  2.06% +/  1.84; p = 0.015) after two years of alendronate sodium treatment. Relative expression of the FDPS gene was also evaluated in OP R and OP NR patients. Higher expression of the FDPS gene was also observed in OP NR group (FC = 1.84 +/  0.77; p = 0.006) when compared to OP R. In conclusion, the influence observed of FDPS expression and the rs2897480 variant on alendronate treatment highlights the importance of a genetic approach to improve the efficacy of treatment for primary osteoporosis.
C1 [Guarana, Werbson Lima; Lima, Camilla Albertina Dantas; Sandrin Garcia, Paula] Univ Fed Pernambuco, Keizo Asami Inst, Biosci Ctr, Recife Campus, BR 50670901 Recife, Brazil.
   [Lima, Camilla Albertina Dantas] Univ Fed Pernambuco, Technol & Geosci Ctr, Dept Oceanog, Recife Campus, BR 50740550 Recife, Brazil.
   [Barbosa, Alexandre Domingues] Univ Fed Pernambuco, Clin Hosp, Rheumatol Div, Recife Campus, BR 50740900 Recife, Brazil.
   [Crovella, Sergio] Qatar Univ, Lab Anim Res Ctr LARC, POB 2713, Doha, Qatar.
   [Sandrin Garcia, Paula] Univ Fed Pernambuco, Biosci Ctr, Dept Genet, Recife Campus, BR 50730120 Recife, Brazil.
C3 Universidade Federal de Pernambuco; Universidade Federal de Pernambuco;
   Universidade Federal de Pernambuco; Qatar University; Universidade
   Federal de Pernambuco
RP Guaraná, WL; Sandrin Garcia, P (通讯作者)，Univ Fed Pernambuco, Keizo Asami Inst, Biosci Ctr, Recife Campus, BR 50670901 Recife, Brazil.; Sandrin Garcia, P (通讯作者)，Univ Fed Pernambuco, Biosci Ctr, Dept Genet, Recife Campus, BR 50730120 Recife, Brazil.
EM werbson.guarana@ufpe.br; camilla.lima@ufpe.br;
   domingues.reumato@gmail.com; paula.sandrin@ufpe.br
RI ; Sandrin Garcia, Paula/GLR 7506 2022; Crovella, Sergio/LUZ 5866 2024
OI Guarana, Werbson Lima/0000 0003 1806 5219; Sandrin Garcia,
   Paula/0000 0003 4641 7429; DOMINGUES BARBOSA,
   ALEXANDRE/0000 0002 8055 0509; Lima, Camilla/0000 0003 0320 3674; 
FU Conselho Nacional de Pesquisa (CNPq)
FX No Statement Available
CR Ahsan T, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0228000
   Bignon J.D., 1995, 12th IHWC HLA Class II Reference Protocol
   Cairoli E, 2014, OSTEOPOROSIS INT, V25, P1401, DOI 10.1007/s00198 014 2619 3
   da Silva AG, 2011, ARQ BRAS ENDOCRINOL, V55, P272, DOI 10.1590/S0004 27302011000400006
   de Lima CAD, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 52612 9
   Diez Perez A, 2012, OSTEOPOROSIS INT, V23, P2769, DOI 10.1007/s00198 012 2093 8
   Drake MT, 2015, CLIN THER, V37, P1837, DOI 10.1016/j.clinthera.2015.06.006
   Francis Roger M, 2004, J Br Menopause Soc, V10, P76, DOI 10.1258/136218004774202409
   Gong L, 2011, PHARMACOGENET GENOM, V21, P50, DOI 10.1097/FPC.0b013e328335729c
   Grove JE, 2000, J BONE MINER RES, V15, P971, DOI 10.1359/jbmr.2000.15.5.971
   Kang H, 2021, J EDUC EVAL HEALTH P, V18
   Kanis J.A., 2007, ASSESSMENT OSTEOPORO
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   Lakens D, 2022, COLLABRA PSYCHOL, V8, DOI 10.1525/collabra.33267
   Lakens D, 2018, NAT HUM BEHAV, V2, P168, DOI 10.1038/s41562 018 0311 x
   Lee SH, 2016, J CLIN ENDOCR METAB, V101, P1215, DOI 10.1210/jc.2015 3972
   Levy ME, 2007, MATURITAS, V57, P247, DOI 10.1016/j.maturitas.2007.01.005
   Lewiecki EM, 2018, OSTEOPOROSIS INT, V29, P717, DOI 10.1007/s00198 017 4345 0
   López Delgado L, 2016, EXPERT OPIN DRUG MET, V12, P389, DOI 10.1517/17425255.2016.1154533
   Marini F, 2008, CURR MED RES OPIN, V24, P2609, DOI [10.1185/03007990802352894, 10.1185/03007990802352894 ]
   Marozik P, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0221511
   Olmos JM, 2012, PHARMACOGENOMICS J, V12, P227, DOI 10.1038/tpj.2010.88
   Pérez Castrillón JL, 2014, RHEUMATOL INT, V34, P1073, DOI 10.1007/s00296 013 2914 x
   Radominski SC, 2017, REV BRAS REUMATOL, V57, pS452
   Ralston SH, 2010, ENDOCR REV, V31, P629, DOI 10.1210/er.2009 0044
   Rivadeneira F, 2016, TRENDS ENDOCRIN MET, V27, P262, DOI 10.1016/j.tem.2016.03.006
   Roudsari JM, 2012, CASP J INTERN MED, V3, P478
   Roush K, 2011, AM J NURS, V111, P26, DOI 10.1097/01.NAJ.0000403358.44058.f7
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73
   Silva BC, 2015, CURR OPIN PHARMACOL, V22, P41, DOI 10.1016/j.coph.2015.03.005
   Sugden CJ, 2005, BIOCHEM BIOPH RES CO, V334, P555, DOI 10.1016/j.bbrc.2005.06.117
   Wang C, 2015, PHARMACOGENOMICS J, V15, P158, DOI 10.1038/tpj.2014.52
   Wasnich Richard D, 2004, Menopause, V11, P622
NR 34
TC 2
Z9 2
U1 1
U2 1
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
SN 1661 6596
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD JUN
PY 2024
VL 25
IS 11
AR 5623
DI 10.3390/ijms25115623
PG 12
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA UG3K9
UT WOS:001246864800001
PM 38891810
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Tarasewicz, A
   Komorniczak, M
   Zakrzewska, A
   Biedunkiewicz, B
   Malgorzewicz, S
   Jankowska, M
   Jasiulewicz, K
   Plonka, N
   Dabrowska, M
   Debska Slizien, A
   Tylicki, L
AF Tarasewicz, Agnieszka
   Komorniczak, Michal
   Zakrzewska, Agnieszka
   Biedunkiewicz, Bogdan
   Malgorzewicz, Sylwia
   Jankowska, Magdalena
   Jasiulewicz, Katarzyna
   Plonka, Natalia
   Dabrowska, Malgorzata
   Debska Slizien, Alicja
   Tylicki, Leszek
TI The Efficacy and Safety of High Dose Cholecalciferol Therapy in
   Hemodialysis Patients
SO BIOMEDICINES
LA English
DT Article
DE vitamin D; cholecalciferol; 25 hydroxycholecalciferol; calcidiol;
   calcitriol; hemodialysis; parathyroid hormone; chronic kidney disease;
   chronic kidney disease mineral and bone disorder
ID CHRONIC KIDNEY DISEASE; VITAMIN D DEFICIENCY; SUPPLEMENTATION
AB Vitamin D deficiency and insufficiency are highly prevalent in CKD, affecting over 80% of hemodialysis (HD) patients and requiring therapeutic intervention. Nephrological societies suggest the administration of cholecalciferol according to the guidelines for the general population. The aim of the observational study was to evaluate the efficacy and safety of the therapy with a high dose of cholecalciferol in HD patients with 25(OH)D deficiency and insufficiency to reach the target serum 25(OH)D level > 30 ng/mL. A total of 22 patients (16 M), with an average age of 72.5 +/  13.03 years and 25(OH)D concentration of 13.05 (9.00 17.90) ng/mL, were administered cholecalciferol at a therapeutic dose of 70,000 IU/week (20,000 IU + 20,000 IU + 30,000 IU, immediately after each dialysis session). All patients achieved the target value > 30 ng/mL, with a mean time of 2.86 +/  1.87 weeks. In the first week, the target level of 25(OH)D (100%) was reached by 2 patients (9.09%), in the second week by 15 patients (68.18%), in the fourth week by 18 patients (81.18%), and in the ninth week by all 22 patients (100%). A significant increase in 1,25(OH)(2)D levels was observed during the study. However, only 2 patients (9.09%) achieved a concentration of 1,25(OH)(2)D above 25 ng/mL the lower limit of the reference range. The intact PTH concentrations remained unchanged during the observation period. No episodes of hypercalcemia were detected, and one new episode of hyperphosphatemia was observed. In conclusion, our study showed that the administration of a high therapeutic dose of cholecalciferol allowed for a quick, effective, and safe leveling of 25(OH)D concentration in HD patients.
C1 [Tarasewicz, Agnieszka; Komorniczak, Michal; Zakrzewska, Agnieszka; Biedunkiewicz, Bogdan; Jankowska, Magdalena; Jasiulewicz, Katarzyna; Plonka, Natalia; Debska Slizien, Alicja; Tylicki, Leszek] Med Univ Gdansk, Dept Nephrol Transplantol & Internal Dis, Smoluchowskiego 17, PL 80214 Gdansk, Poland.
   [Malgorzewicz, Sylwia] Med Univ Gdansk, Dept Clin Nutr, Debinki 7, PL 80211 Gdansk, Poland.
   [Dabrowska, Malgorzata] Univ Clin Ctr, Cent Clin Lab, Smoluchowskiego 17, PL 80214 Gdansk, Poland.
C3 Fahrenheit Universities; Medical University Gdansk; Fahrenheit
   Universities; Medical University Gdansk
RP Tarasewicz, A; Tylicki, L (通讯作者)，Med Univ Gdansk, Dept Nephrol Transplantol & Internal Dis, Smoluchowskiego 17, PL 80214 Gdansk, Poland.
EM ataras@gumed.edu.pl; michal.komorniczak@gumed.edu.pl;
   agnieszka.zakrzewska@gumed.edu.pl; bogdan.biedunkiewicz@gumed.edu.pl;
   sylwia.malgorzewicz@gumed.edu.pl; magdalena.jankowska@gumed.edu.pl;
   katarzyna.jasiulewicz@gumed.edu.pl; natalia.plonka@gumed.edu.pl;
   mdabrowska@uck.gda.pl; adeb@gumed.edu.pl; leszek.tylicki@gumed.edu.pl
RI Debska Slizien, Maria Alicja/KPY 6960 2024; Małgorzewicz,
   Sylwia/AAA 5945 2022; Magdalena, Jankowska/AAT 8185 2021;
   Dębska Ślizień, Alicja/KPY 6960 2024; Biedunkiewicz, Bogdan/R 1168 2018;
   Tylicki, Leszek/T 8466 2018
OI Debska Slizien, Maria Alicja/0000 0001 8210 8063; Jankowska,
   Magdalena/0000 0002 2432 6350; Komorniczak, Michal/0000 0002 5766 1913;
   Tarasewicz, Agnieszka/0000 0002 6722 1540; Malgorzewicz,
   Sylwia/0000 0001 8773 9649; Tylicki, Leszek/0000 0002 5515 5072
CR Armas LAG, 2012, CLIN J AM SOC NEPHRO, V7, P1428, DOI 10.2215/CJN.12761211
   Brandenburg V, 2022, NUTRIENTS, V14, DOI 10.3390/nu14153009
   Cao MY, 2023, FRONT NUTR, V10, DOI 10.3389/fnut.2023.1132528
   Chowdhury R, 2014, BMJ BRIT MED J, V348, DOI 10.1136/bmj.g1903
   Cicarma E, 2009, ANTICANCER RES, V29, P3495
   Descombes E, 2014, INT J NEPHROL, V2014, DOI 10.1155/2014/597429
   Friedl C, 2017, INT J NEPHROL RENOV, V10, P109, DOI 10.2147/IJNRD.S97637
   Guella A, 2023, PHARM PRACT GRANADA, V21, DOI 10.18549/PharmPract.2023.1.2773
   Huish SA, 2021, ENDOCR CONNECT, V10, P1291, DOI 10.1530/EC 21 0372
   Jankowska M, 2016, TRANSPL P, V48, P1427, DOI 10.1016/j.transproceed.2015.11.039
   Jankowska M, 2017, NUTRIENTS, V9, DOI 10.3390/nu9030282
   Jean G, 2008, NEPHRON CLIN PRACT, V110, pC58, DOI 10.1159/000151534
   Jean G, 2017, NUTRIENTS, V9, DOI 10.3390/nu9040328
   Jean G, 2009, NEPHROL DIAL TRANSPL, V24, P3799, DOI 10.1093/ndt/gfp370
   Kidney Dis Improving Global, 2017, KIDNEY INT SUPPL, V7, P1, DOI 10.1016/j.kisu.2017.04.001
   Kim SM, 2014, J RENAL NUTR, V24, P20, DOI 10.1053/j.jrn.2013.07.003
   Marcinowska Suchowierska E, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00550
   Marckmann P, 2012, NEPHROL DIAL TRANSPL, V27, P3523, DOI 10.1093/ndt/gfs138
   Massart A, 2014, AM J KIDNEY DIS, V64, P696, DOI 10.1053/j.ajkd.2014.04.020
   Matias PJ, 2023, SEMIN DIALYSIS, V36, P29, DOI 10.1111/sdi.13066
   Matuszkiewicz Rowinska J, 2022, FRONT MED LAUSANNE, V8, DOI 10.3389/fmed.2021.781191
   Mieczkowski M, 2014, MED SCI MONITOR, V20, P2228, DOI 10.12659/MSM.892315
   Pilz S, 2011, AM J KIDNEY DIS, V58, P374, DOI 10.1053/j.ajkd.2011.03.020
   Pludowski P, 2023, NUTRIENTS, V15, DOI 10.3390/nu15030695
   Pludowski P, 2022, NUTRIENTS, V14, DOI 10.3390/nu14071483
   Tangpricha V, 2014, AM J KIDNEY DIS, V64, P667, DOI 10.1053/j.ajkd.2014.08.004
   Tokmak F, 2008, NEPHROL DIAL TRANSPL, V23, P4016, DOI 10.1093/ndt/gfn367
   Tylicki P, 2022, VIRUSES BASEL, V14, DOI 10.3390/v14030451
   Vieth R, 2020, EUR J CLIN NUTR, V74, P1493, DOI 10.1038/s41430 020 0697 1
   Wasse H, 2012, AM J CLIN NUTR, V95, P522, DOI 10.3945/ajcn.111.025502
   Zitt E, 2015, BMC NEPHROL, V16, DOI 10.1186/s12882 015 0116 3
NR 31
TC 1
Z9 1
U1 0
U2 1
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2227 9059
J9 BIOMEDICINES
JI Biomedicines
PD FEB
PY 2024
VL 12
IS 2
AR 377
DI 10.3390/biomedicines12020377
PG 11
WC Biochemistry & Molecular Biology; Medicine, Research & Experimental;
   Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Research & Experimental Medicine;
   Pharmacology & Pharmacy
GA JS6O5
UT WOS:001175194300001
PM 38397979
OA gold, Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU De Bonis, A
   Uskokovic, V
   Barbaro, K
   Fadeeva, I
   Curcio, M
   Imperatori, L
   Teghil, R
   Rau, JV
AF De Bonis, Angela
   Uskokovic, Vuk
   Barbaro, Katia
   Fadeeva, Inna
   Curcio, Mariangela
   Imperatori, Luca
   Teghil, Roberto
   Rau, Julietta, V
TI Pulsed laser deposition temperature effects on strontium substituted
   hydroxyapatite thin films for biomedical implants
SO CELL BIOLOGY AND TOXICOLOGY
LA English
DT Article
DE Strontium substituted hydroxyapatite; Thin films; Pulsed laser
   deposition; Biomedical implants; Biocompatibility; Bioactivity; Dental
   pulp stem cells
ID AMORPHOUS CALCIUM PHOSPHATE; DOPED HYDROXYAPATITE; IN VITRO;
   MECHANICAL PROPERTIES; TITANIUM SURFACES; BONE; COATINGS; OSTEOBLAST;
   RANELATE; SR
AB Substituting small molecule drugs with abundant and easily affordable ions may have positive effects on the way countless disease treatments are approached. The interest in strontium cation in bone therapies soared in the wake of the success of strontium ranelate in the treatment of osteoporosis. A new method for producing thin strontium containing hydroxyapatite (Sr HA, Ca9Sr(PO4)(6)(OH)(2)) films as coatings that render bioinert titanium implant bioactive is reported here. The method is based on the combination of a mechanochemical synthesis of Sr HA targets and their deposition in form of thin films on top of titanium with the use of laser ablation at low pressure. The films were 1 2 mu m in thickness and their formation was studied at different temperatures, including 25, 300, and 500 degrees C. Highly crystalline Sr HA target transformed during pulsed laser deposition to a fully amorphous film, whose degree of long range order recovered with temperature. Particle edges became somewhat sharper and surface roughness moderately increased with temperature, but the (Ca+Sr)/P atomic ratio, which increased 1.5 times during the film formation, remained approximately constant at different temperatures. Despite the mostly amorphous structure of the coatings, their affinity for capturing atmospheric carbon dioxide and accommodating it as carbonate ions that replace both phosphates and hydroxyls of HA was confirmed in an X ray photoelectron spectroscopic analysis. As the film deposition temperature increased, the lattice voids got reduced in concentration and the structure gradually "closed," becoming more compact and entailing a linear increase in microhardness with temperature, by 0.03 GPa/degrees C for the entire 25 500 degrees C range. Biocompatibility and bioactivity of Sr HA thin films deposited on titanium were confirmed in an interaction with dental pulp stem cells, suggesting that these coatings, regardless of the processing temperature, may be viable candidates for the surface components of metallic bone implants.
C1 [De Bonis, Angela; Curcio, Mariangela; Teghil, Roberto] Univ Basilicata, Dipartimento Sci, Via Ateneo Lucano 10, Potenza 85100, Italy.
   [Uskokovic, Vuk] Univ Calif Irvine, Dept Mech & Aerosp Engn, Engn Gateway 4200, Irvine, CA 92697 USA.
   [Barbaro, Katia] Ist Zooprofilatt Sperimentale Lazio & Toscana M A, Via Appia Nuova 1411, Rome 00178, Italy.
   [Fadeeva, Inna] Russian Acad Sci, AA Baikov Inst Met & Mat Sci, Leninsky Prospect 49, Moscow 119991, Russia.
   [Imperatori, Luca; Rau, Julietta, V] Consiglio Nazl Ric ISM CNR, Ist Struttura Mat, Via Fosso Cavaliere 100, Rome 00133, Italy.
C3 University of Basilicata; University of California System; University of
   California Irvine; IZS Lazio e Toscana; Russian Academy of Sciences;
   Baikov Institute of Metallurgy & Materials Science (IMET RAS); Consiglio
   Nazionale delle Ricerche (CNR); Istituto di Struttura della Materia
   (ISM CNR)
RP Rau, JV (通讯作者)，Consiglio Nazl Ric ISM CNR, Ist Struttura Mat, Via Fosso Cavaliere 100, Rome 00133, Italy.
EM giulietta.rau@ism.cnr.it
RI ; Teghil, Roberto/I 2966 2019; Curcio, Mariangela/ABA 5999 2020; De
   Bonis, Angela/AAC 1738 2021; Rau, Julietta/E 6598 2017; Uskokovic,
   Vuk/S 7986 2018
OI De Bonis, Angela/0000 0002 1177 2896; Uskokovic, Vuk/0000 0003 3256 1606
FU Italian Ministry of Health [IZS LT 02/15, IZS LT 01/17 RC]
FX The present research was partially supported by the Italian Ministry of
   Health, grant codes IZS LT 02/15 RC and IZS LT 01/17 RC.
CR Aina V, 2013, MAT SCI ENG C MATER, V33, P1132, DOI 10.1016/j.msec.2012.12.005
   Amiri A, 2017, ANAL CHIM ACTA, V950, P64, DOI 10.1016/j.aca.2016.11.027
   Avci M, 2017, CERAM INT, V43, P9431, DOI 10.1016/j.ceramint.2017.04.117
   Azari A, 2017, J MATER SCI MATER M, V28, DOI 10.1007/s10856 017 5921 8
   Bastan FE, 2020, INT J APPL CERAM TEC, V17, P1155, DOI 10.1111/ijac.13422
   Behera RR, 2018, J MECH BEHAV BIOMED, V86, P143, DOI 10.1016/j.jmbbm.2018.06.020
   Bohner M, 2009, BIOMATERIALS, V30, P6403, DOI 10.1016/j.biomaterials.2009.08.007
   Boivin G, 1996, J BONE MINER RES, V11, P1302
   Bonnelye E, 2008, BONE, V42, P129, DOI 10.1016/j.bone.2007.08.043
   Boyd AR, 2015, MAT SCI ENG C MATER, V46, P290, DOI 10.1016/j.msec.2014.10.046
   Boyd AR, 2015, J MATER SCI MATER M, V26, DOI 10.1007/s10856 014 5377 z
   Brodie J, 2008, BAKERY PROCESSES CHE
   Bulina NV, 2018, INORG MATER+, V54, P820, DOI 10.1134/S0020168518080034
   Capuccini C, 2008, ACTA BIOMATER, V4, P1885, DOI 10.1016/j.actbio.2008.05.005
   Caverzasio J, 2008, BONE, V42, P1131, DOI 10.1016/j.bone.2008.02.010
   Chadha RK, 2020, CERAM INT, V46, P1091, DOI 10.1016/j.ceramint.2019.09.076
   Chen FF, 2017, ACS APPL MATER INTER, V9, P39534, DOI 10.1021/acsami.7b09484
   Chen JY, 2006, KEY ENG MATER, V309 311, P271, DOI 10.4028/www.scientific.net/KEM.309 311.271
   Coelho PG, 2011, INT J ORAL MAX IMPL, V26, P63
   Combes C, 2010, ACTA BIOMATER, V6, P3362, DOI 10.1016/j.actbio.2010.02.017
   COOK SD, 1988, CLIN ORTHOP RELAT R, P225
   Curcio M, 2017, J MATER SCI, V52, P9140, DOI 10.1007/s10853 017 0771 9
   DEBRUIJN JD, 1994, BIOMATERIALS, V15, P543, DOI 10.1016/0142 9612(94)90021 3
   Ding XX, 2019, ACS BIOMATER SCI ENG, V5, P4574, DOI 10.1021/acsbiomaterials.9b00584
   dos Santos EA, 2012, MAT SCI ENG C MATER, V32, P2086, DOI 10.1016/j.msec.2012.05.041
   Duer M, 2013, NAT MATER, V12, P1081, DOI 10.1038/nmat3822
   Eftekharzadeh S, 2017, INT UROL NEPHROL, V49, P183, DOI 10.1007/s11255 016 1464 z
   Essamlali Y, 2017, ENERG CONVERS MANAGE, V149, P355, DOI 10.1016/j.enconman.2017.07.028
   Ferro D, 2006, SURF COAT TECH, V200, P4701, DOI 10.1016/j.surfcoat.2005.02.150
   Frasnelli M, 2017, MAT SCI ENG C MATER, V71, P653, DOI 10.1016/j.msec.2016.10.047
   Fu DL, 2017, J ZHEJIANG UNIV SC B, V18, P778, DOI 10.1631/jzus.B1600517
   Ge M, 2018, INT J NANOMED, V13, P1707, DOI 10.2147/IJN.S154605
   Geng Z, 2018, BIOMATER SCI UK, V6, P2694, DOI 10.1039/c8bm00716k
   Geng Z, 2017, MAT SCI ENG C MATER, V71, P852, DOI 10.1016/j.msec.2016.10.079
   Horiuchi N, 2018, SOLID STATE IONICS, V315, P19, DOI 10.1016/j.ssi.2017.11.029
   Ignjatovic N, 2013, J MATER SCI MATER M, V24, P343, DOI 10.1007/s10856 012 4793 1
   JOHNSON AR, 1973, CALC TISS RES, V11, P215, DOI 10.1007/BF02547220
   JOHNSON AR, 1968, CALC TISS RES, V2, P242, DOI 10.1007/BF02279212
   Kallistová A, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 23826 0
   Kim HM, 2005, BIOMATERIALS, V26, P4366, DOI 10.1016/j.biomaterials.2004.11.022
   Kokubo T, 2006, BIOMATERIALS, V27, P2907, DOI 10.1016/j.biomaterials.2006.01.017
   Kottegoda N, 2017, ACS NANO, V11, P1214, DOI 10.1021/acsnano.6b07781
   Kung KC, 2010, J ALLOY COMPD, V508, P384, DOI 10.1016/j.jallcom.2010.08.057
   Lee JH, 2017, J BIOMED MATER RES B, V105, P647, DOI 10.1002/jbm.b.33589
   Lee K, 2018, J NANOSCI NANOTECHNO, V18, P1449, DOI 10.1166/jnn.2018.14887
   Li H, 2017, ADV MATER, V29, DOI 10.1002/adma.201703548
   Li JF, 2019, J BIOMED MATER RES A, V107, P631, DOI 10.1002/jbm.a.36579
   Li Z, 2016, MAT SCI ENG C MATER, V69, P956, DOI 10.1016/j.msec.2016.08.002
   Lincks J, 1998, BIOMATERIALS, V19, P2219, DOI 10.1016/S0142 9612(98)00144 6
   Ling SJ, 2017, SCI ADV, V3, DOI 10.1126/sciadv.1601939
   Mao LX, 2017, ACTA BIOMATER, V61, P217, DOI 10.1016/j.actbio.2017.08.015
   MARIE PJ, 1986, METABOLISM, V35, P547, DOI 10.1016/0026 0495(86)90013 2
   McManamon C, 2014, LANGMUIR, V30, P11412, DOI 10.1021/la502802f
   Meininger M, 2016, MAT SCI ENG C MATER, V67, P65, DOI 10.1016/j.msec.2016.04.102
   Mishra VK, 2014, CERAM INT, V40, P11319, DOI 10.1016/j.ceramint.2014.03.128
   Mondal S, 2017, INT J NANOMED, V12, P8389, DOI 10.2147/IJN.S147355
   Montesi M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172100
   Nagano M, 1996, BIOMATERIALS, V17, P1771, DOI 10.1016/0142 9612(95)00357 6
   NELSON BK, 1986, GEOCHIM COSMOCHIM AC, V50, P1941, DOI 10.1016/0016 7037(86)90250 4
   Ni GX, 2006, BIOMATERIALS, V27, P4348, DOI 10.1016/j.biomaterials.2006.03.048
   Nieh TG, 2001, J MATER RES, V16, P3238, DOI 10.1557/JMR.2001.0446
   OMDAHL JL, 1972, J BIOL CHEM, V247, P5520
   Pal'chik NA, 1997, RUSS J APPL CHEM+, V70, P1513
   Petrakova NV, 2018, DOKL CHEM, V483, P283, DOI 10.1134/S0012500818110095
   Quade M, 2018, MAT SCI ENG C MATER, V84, P159, DOI 10.1016/j.msec.2017.11.038
   Querido W, 2016, MICRON, V80, P122, DOI 10.1016/j.micron.2015.10.006
   Querido W, 2013, CELL TISSUE RES, V354, P573, DOI 10.1007/s00441 013 1669 8
   Rau JV, 2008, MATER CHEM PHYS, V112, P504, DOI 10.1016/j.matchemphys.2008.06.004
   Rau JV, 2010, MATER RES BULL, V45, P1304, DOI 10.1016/j.materresbull.2010.04.028
   Rau JV, 2009, ACS APPL MATER INTER, V1, P1813, DOI 10.1021/am900356e
   Rau JV, 2004, J BIOMED MATER RES B, V71B, P441, DOI 10.1002/jbm.b.30111
   Reginster JY, 2015, OSTEOPOROSIS INT, V26, P1667, DOI 10.1007/s00198 015 3109 y
   Robinson L, 2017, J MATER SCI MATER M, V28, DOI 10.1007/s10856 017 5846 2
   Saidak Z, 2012, PHARMACOL THERAPEUT, V136, P216, DOI 10.1016/j.pharmthera.2012.07.009
   Shen J, 2017, J BIOMED MATER RES B, V105, P124, DOI 10.1002/jbm.b.33539
   SHORR E, 1952, Bull Hosp Joint Dis, V13, P59
   Stepan JJ, 2013, J BONE MINER METAB, V31, P606, DOI 10.1007/s00774 013 0494 1
   Teng HP, 2018, SURF COAT TECH, V350, P1112, DOI 10.1016/j.surfcoat.2018.02.017
   Terra J, 2009, PHYS CHEM CHEM PHYS, V11, P568, DOI 10.1039/b802841a
   Tite T, 2018, MATERIALS, V11, DOI 10.3390/ma11112081
   Tlotleng M, 2014, MAT SCI ENG C MATER, V43, P189, DOI 10.1016/j.msec.2014.06.032
   Tsui YC, 1998, BIOMATERIALS, V19, P2015, DOI 10.1016/S0142 9612(98)00103 3
   Tuukkanen J, 2017, CURR PHARM DESIGN, V23, P3786, DOI [10.2174/1381612823666170615105454, 10.2174/1381612823666170609084016]
   Uskokovic V, 2019, CRYST GROWTH DES, V19, P4340, DOI 10.1021/acs.cgd.9b00061
   Uskokovic V, 2019, ACS BIOMATER SCI ENG, V5, P3483, DOI 10.1021/acsbiomaterials.9b00255
   Uskokovic V, 2017, J MATER CHEM B, V5, P1430, DOI [10.1039/c6tb03387c, 10.1039/C6TB03387C]
   Uskokovic V, 2016, MATERIALS, V9, DOI 10.3390/ma9060434
   Uskokovic V, 2013, J BIOMED MATER RES A, V101, P1427, DOI 10.1002/jbm.a.34437
   Uskokovic V, 2011, J BIOMED MATER RES B, V96B, P152, DOI 10.1002/jbm.b.31746
   Wang TL, 2019, J ALLOY COMPD, V799, P71, DOI 10.1016/j.jallcom.2019.05.338
   Wang Y, 2013, NAT MATER, V12, P1144, DOI [10.1038/NMAT3787, 10.1038/nmat3787]
   Wopenka B, 2005, MAT SCI ENG C BIO S, V25, P131, DOI 10.1016/j.msec.2005.01.008
   Yang F, 2011, STEM CELLS, V29, P981, DOI 10.1002/stem.646
   Yang XR, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 1094 8
   Yu DG, 2013, ACTA PHARMACOL SIN, V34, P393, DOI 10.1038/aps.2012.167
NR 95
TC 28
Z9 28
U1 1
U2 21
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0742 2091
EI 1573 6822
J9 CELL BIOL TOXICOL
JI Cell Biol. Toxicol.
PD DEC
PY 2020
VL 36
IS 6
BP 537
EP 551
DI 10.1007/s10565 020 09527 3
EA MAY 2020
PG 15
WC Cell Biology; Toxicology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Toxicology
GA OQ9IO
UT WOS:000530772300001
PM 32377851
DA 2025 08 17
ER

PT J
AU Park, JS
   Jeong, JH
   Byun, JK
   Lim, MA
   Kim, EK
   Kim, SM
   Choi, SY
   Park, SH
   Min, JK
   Cho, ML
AF Park, Jin Sil
   Jeong, Jeong Hee
   Byun, Jae Kyeong
   Lim, Mi Ae
   Kim, Eun Kyung
   Kim, Sung Min
   Choi, Si Young
   Park, Sung Hwan
   Min, Jun Ki
   Cho, Mi La
TI Regulator of Calcineurin 3 Ameliorates Autoimmune Arthritis by
   Suppressing Th17 Cell Differentiation
SO AMERICAN JOURNAL OF PATHOLOGY
LA English
DT Article
ID RHEUMATOID ARTHRITIS; TUMOR SUPPRESSOR; NUCLEAR FACTOR; NFAT; GROWTH;
   SYNOVIOCYTES; INHIBITOR; PEPTIDE; PROTEIN; IL 17
AB Regulator of calcineurin 3 (RCAN3), an endogenous regulator of the calcineurin nuclear factor of activated T cells (NFAT) signaling pathway, inhibits the phosphatase activity of calcineurin, the nuclear translocation of NFAT, and the NEAT downstream pathway. To investigate the effects of RCAN3 on T cell regulatory function and the development and progression of inflammatory arthritis, we studied the effects of RCAN3 transfection on regulation of Th17 cell differentiation in a murine T lymphoma cell line and primary splenic CD4+ T cells. Overexpression of RCAN3 suppressed Th17 cell differentiation through the down regulation of RAR receptor orphan receptor gamma T mRNA and up regulation of forkhead box P3 mRNA. In mice with collagen induced arthritis, injection of an RCAN3 overexpression vector controlled arthritis development in vivo. Injection of RCAN3 reduced the formation of osteoclasts and expression of inflammatory cytokines in vivo. Antioxidants stimulated the expression of RCAN3 in vitro, and combination therapy with pcDNA RCAN3 had a synergistic suppressive effect on the development of arthritis. These data suggest that RCAN3 may be an effective treatment for rheumatoid arthritis.
C1 [Park, Jin Sil; Jeong, Jeong Hee; Byun, Jae Kyeong; Lim, Mi Ae; Kim, Eun Kyung; Kim, Sung Min; Choi, Si Young; Park, Sung Hwan; Min, Jun Ki; Cho, Mi La] Catholic Univ Korea, Catholic Res Inst Med Sci, Rheumatism Res Ctr, Seoul, South Korea.
   [Park, Sung Hwan] Catholic Univ Korea, Div Rheumatol, Dept Internal Med, Seoul, South Korea.
   [Min, Jun Ki] Catholic Univ Korea, Clin Med Res Inst, Bucheon St Marys Hosp, Seoul, South Korea.
C3 Catholic University of Korea; Catholic University of Korea; Catholic
   University of Korea
RP Min, JK (通讯作者)，Catholic Univ Korea, Coll Med, Bucheon St Marys Hosp, Div Rheumatol, 327 Sosa Ro, Bucheon Si 14647, Gyeonggi Do, South Korea.; Cho, ML (通讯作者)，Catholic Univ Korea, Coll Med, Catholic Inst Med Sci, Rheumatism Res Ctr, 222 Banpo Daero, Seoul 06591, South Korea.
EM min6403@catholic.ac.kr; iammila@catholic.ac.kr
RI Choi, Si Young/HEL 0560 2022
FU Basic Science Research Program through the National Research Foundation
   of Korea   Ministry of Education, Science and Technology
   [NRF 2013R1A1A2008849]; Korean Health Technology R&D Project, Ministry
   for Health & Welfare, Republic of Korea [HI14C1894, BI14C1851]
FX Supported by the Basic Science Research Program through the National
   Research Foundation of Korea funded by Ministry of Education, Science
   and Technology grant NRF 2013R1A1A2008849 (J. S.P.) and Korean Health
   Technology R&D Project, Ministry for Health & Welfare, Republic of Korea
   grants HI14C1894 (J. S.P.) and BI14C1851 (J. K.M.).
CR [Anonymous], 2011, Guide for the Care and Use of Laboratory Animals
   [Anonymous], 2001, CURR PROTOC IMMUNOL
   Aubareda A, 2006, CELL SIGNAL, V18, P1430, DOI 10.1016/j.cellsig.2005.11.006
   Baek KH, 2009, NATURE, V459, P1126, DOI 10.1038/nature08062
   Barnett ML, 1998, ARTHRITIS RHEUM, V41, P290, DOI 10.1002/1529 0131(199802)41:2<290::AID ART13>3.3.CO;2 I
   BROMLEY M, 1984, ARTHRITIS RHEUM US, V27, P968, DOI 10.1002/art.1780270902
   Cao X, 2002, BIOCHEM J, V367, P459, DOI 10.1042/BJ20011797
   Mulero M, 2007, BBA MOL CELL RES, V1773, P330, DOI 10.1016/j.bbamcr.2006.12.007
   Chen Z, 2006, P NATL ACAD SCI USA, V103, P8137, DOI 10.1073/pnas.0600666103
   Davies KJA, 2007, FASEB J, V21, P3023, DOI 10.1096/fj.06 7246com
   Durant L, 2010, IMMUNITY, V32, P605, DOI 10.1016/j.immuni.2010.05.003
   Ermak G, 2011, FASEB J, V25, P3306, DOI 10.1096/fj.11 185728
   Feldmann M, 1996, CELL, V85, P307, DOI 10.1016/S0092 8674(00)81109 5
   Firestein GS, 1996, ARTHRITIS RHEUM, V39, P1781, DOI 10.1002/art.1780391103
   Fossiez F, 1996, J EXP MED, V183, P2593, DOI 10.1084/jem.183.6.2593
   Fujikawa Y, 1996, BRIT J RHEUMATOL, V35, P213
   Görlach J, 2000, EMBO J, V19, P3618, DOI 10.1093/emboj/19.14.3618
   Gravallese EM, 2002, ANN RHEUM DIS, V61, P84, DOI 10.1136/ard.61.suppl_2.ii84
   Harris TJ, 2007, J IMMUNOL, V179, P4313, DOI 10.4049/jimmunol.179.7.4313
   Hill JA, 2002, J BIOL CHEM, V277, P10251, DOI 10.1074/jbc.M110722200
   Hu YP, 2013, CLIN RHEUMATOL, V32, P161, DOI 10.1007/s10067 012 2041 1
   Kitahara K, 2007, CURR OPIN RHEUMATOL, V19, P238, DOI 10.1097/BOR.0b013e328099af80
   Korn T, 2009, ANNU REV IMMUNOL, V27, P485, DOI 10.1146/annurev.immunol.021908.132710
   Laurence A, 2007, IMMUNITY, V26, P371, DOI 10.1016/j.immuni.2007.02.009
   Leech M, 2008, CLIN EXP IMMUNOL, V152, P345, DOI 10.1111/j.1365 2249.2008.03629.x
   LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0
   Martínez Hoyer S, 2015, CARCINOGENESIS, V36, P792, DOI 10.1093/carcin/bgv056
   Martínez Hoyer S, 2013, BBA MOL CELL RES, V1833, P2311, DOI 10.1016/j.bbamcr.2013.05.021
   Martínez Martínez S, 2004, CURR MED CHEM, V11, P997, DOI 10.2174/0929867043455576
   Mulero MC, 2009, J BIOL CHEM, V284, P9394, DOI 10.1074/jbc.M805889200
   Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9
   Park JS, 2013, ARTHRITIS RHEUM US, V65, P949, DOI 10.1002/art.37841
   Park JI, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0051377, 10.1371/journal.pone.0037010]
   Perry I, 2005, CLIN EXP IMMUNOL, V139, P2, DOI 10.1111/j.1365 2249.2005.02662.x
   Reppert S, 2015, EUR J IMMUNOL, V45, P1426, DOI 10.1002/eji.201445150
   Sakaguchi N, 2003, NATURE, V426, P454, DOI 10.1038/nature02119
   Shin SY, 2006, FEBS LETT, V580, P5965, DOI 10.1016/j.febslet.2006.09.064
   Takayanagi H, 2000, ARTHRITIS RHEUM US, V43, P259, DOI 10.1002/1529 0131(200002)43:2<259::AID ANR4>3.0.CO;2 W
   Takayanagi H, 2007, ANN NY ACAD SCI, V1116, P227, DOI 10.1196/annals.1402.071
   Vega RB, 2003, J BIOL CHEM, V278, P36981, DOI 10.1074/jbc.R300023200
   Wei L, 2007, J BIOL CHEM, V282, P34605, DOI 10.1074/jbc.M705100200
   Yamanishi Y, 2002, P NATL ACAD SCI USA, V99, P10025, DOI 10.1073/pnas.152333199
   Yang XXO, 2007, J BIOL CHEM, V282, P9358, DOI 10.1074/jbc.C600321200
   Zhu JF, 2010, ANNU REV IMMUNOL, V28, P445, DOI 10.1146/annurev immunol 030409 101212
NR 44
TC 15
Z9 15
U1 1
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002 9440
EI 1525 2191
J9 AM J PATHOL
JI Am. J. Pathol.
PD SEP
PY 2017
VL 187
IS 9
BP 2034
EP 2045
DI 10.1016/j.ajpath.2017.05.008
PG 12
WC Pathology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pathology
GA FF6WY
UT WOS:000409158900012
PM 28704638
OA Bronze
DA 2025 08 17
ER

PT J
AU Underwood, KF
   D'Souza, DR
   Mochin Peters, M
   Pierce, AD
   Kommineni, S
   Choe, M
   Bennett, J
   Gnatt, A
   Habtemariam, B
   MacKerell, AD
   Passaniti, A
AF Underwood, Karen F.
   D'Souza, David R.
   Mochin Peters, Maria
   Pierce, Adam D.
   Kommineni, Sravya
   Choe, Moran
   Bennett, Jessica
   Gnatt, Averell
   Habtemariam, Bahru
   MacKerell, Alexander D., Jr.
   Passaniti, Antonino
TI Regulation of RUNX2 Transcription Factor DNA Interactions and Cell
   Proliferation by Vitamin D3 (Cholecalciferol) Prohormone Activity
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE VITAMIN D3; RUNX2 TRANSCRIPTION FACTOR; DNA BINDING; COMPUTATIONAL
   METHODS; CELL PROLIFERATION
ID 25 HYDROXYVITAMIN D 3; ENDOTHELIAL CELLS; BREAST CANCER;
   PHOSPHORYLATION; EXPRESSION; OSTEOBLAST; GROWTH; UBIQUITINATION;
   ORGANIZATION; ACTIVATION
AB The fat soluble prohormone cholecalciferol (Vitamin D3) is a precursor of the circulating 25 OH Vitamin D3, which is converted by 1 alpha hydroxylase to the biologically active 1,25 OH Vitamin D3. Active Vitamin D3 interacts with the Vitamin D receptor (VDR), a transcription factor that plays an important role in calcium mobilization and bone formation. RUNX2 is a DNA binding transcription factor that regulates target genes important in bone formation, angiogenesis, and cancer metastasis. Using computer assisted drug design (CADD) and a microtiter plate based DNA binding enzyme linked immunosorbent assay (D ELISA) to measure nuclear RUNX2 DNA binding, we have found that Vitamin D3 prohormones can modulate RUNX2 DNA binding, which was dose dependent and sensitive to trypsin, salt, and phosphatase treatment. Unlabeled oligonucleotide or truncated, dominant negative RUNX2 proteins were competitive inhibitors of RUNX2 DNA binding. The RUNX2 heterodimeric partner, Cbf beta, was detected in the binding complexes with specific antibodies. Evaluation of several RUNX2:DNA targeted small molecules predicted by CADD screening revealed a previously unknown biological activity of the inactive Vitamin D3 precursor, cholecalciferol. Cholecalciferol modulated RUNX2:DNA binding at nanomolar concentrations even in cells with low VDR. Cholecalciferol and 25 OH Vitamin D3 prohormones were selective inhibitors of RUNX2 positive endothelial, bone, and breast cancer cell proliferation, but not of cells lacking RUNX2 expression. These compounds may have application in modulating RUNX2 activity in an angiogenic setting, in metastatic cells, and to promote bone formation in disease mediated osteoporosis. The combination CADD discovery and D ELISA screening approaches allows the testing of other novel derivatives of Vitamin D and/or transcriptional inhibitors with the potential to regulate DNA binding and biological function. (c) 2012 American Society for Bone and Mineral Research.
C1 [Passaniti, Antonino] Univ Maryland, Sch Med, Dept Pathol, Greenebaum Canc Ctr BRB 9 045, Baltimore, MD 21201 USA.
   [Underwood, Karen F.; D'Souza, David R.; Mochin Peters, Maria; Pierce, Adam D.; Kommineni, Sravya; Bennett, Jessica] Univ Maryland, Sch Med, Marlene & Stewart Greenebaum Canc Ctr, Baltimore, MD 21201 USA.
   [Habtemariam, Bahru; MacKerell, Alexander D., Jr.] Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, Baltimore, MD 21201 USA.
C3 University System of Maryland; University of Maryland Baltimore;
   University System of Maryland; University of Maryland Baltimore;
   University System of Maryland; University of Maryland Baltimore
RP Passaniti, A (通讯作者)，Univ Maryland, Sch Med, Dept Pathol, Greenebaum Canc Ctr BRB 9 045, 655W Baltimore St, Baltimore, MD 21201 USA.
EM apass001@umaryland.edu
RI ; MacKerell, Alex/AAA 2560 2020
OI MacKerell, Alex/0000 0001 8287 6804; 
FU NIH [RO1 CA108846]; AHA [GRNT2130014]; VA Merit Award; University of
   Maryland
FX The authors thank other members of the laboratory for providing samples
   and advice, including Brandon Cooper and Keli Renoud and Dr. Joseph P.
   Stains (Department of Orthopedics) for providing osteocalcin PCR
   primers, SaOs2, and MG63 human osteosarcoma cells. We thank Drs. Rena
   Lapidus and Mariola Sadowska for assistance with the kinetic
   spectrophotometric measurements and Drs. Sara Chumsri, Kate Kaczuk, and
   Simeon Goldblum for critical reading of the manuscript. The
   computational support of the University of Maryland Computer Aided Drug
   Design Center is also greatly appreciated. This study was funded in part
   by NIH RO1 CA108846, AHA Grant in Aid GRNT2130014, a VA Merit Award to
   AP, and by the University of Maryland Cancer Restitution Funds (CRF)
   provided to the Marlene & Stewart Greenebaum Cancer Center. This paper
   is subject to the NIH Public Access Policy.
CR Adams JS, 2008, NAT CLIN PRACT ENDOC, V4, P80, DOI 10.1038/ncpendmet0716
   Akamatsu Y, 1997, J BIOL CHEM, V272, P14497, DOI 10.1074/jbc.272.23.14497
   Anglin Ian, 2004, Cancer Treat Res, V119, P189
   Bae SC, 2006, GENE, V366, P58, DOI 10.1016/j.gene.2005.10.017
   BARAN DT, 1992, J CELL BIOCHEM, V50, P124, DOI 10.1002/jcb.240500203
   Barnes GL, 2004, CANCER RES, V64, P4506, DOI 10.1158/0008 5472.CAN 03 3851
   BARSONY J, 1992, J BIOL CHEM, V267, P24457
   Bhattacharya N, 2010, INT J CANCER, V127, P404, DOI 10.1002/ijc.25054
   Bravo J, 2001, NAT STRUCT BIOL, V8, P371, DOI 10.1038/86264
   Campbell FC, 2010, BIOCHEM PHARMACOL, V79, P1, DOI 10.1016/j.bcp.2009.09.005
   Chen TC, 2000, J NUTR BIOCHEM, V11, P267, DOI 10.1016/S0955 2863(00)00077 2
   Chi YY, 2009, BIOCHEM BIOPH RES CO, V386, P493, DOI 10.1016/j.bbrc.2009.06.061
   Christakos S, 2010, ENDOCRIN METAB CLIN, V39, P243, DOI 10.1016/j.ecl.2010.02.002
   CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170
   Costa JL, 2009, BMC GENOMICS, V10, DOI 10.1186/1471 2164 10 499
   D'Souza DR, 2009, J BIOL CHEM, V284, P17947, DOI 10.1074/jbc.M109.002378
   Deeb KK, 2007, NAT REV CANCER, V7, P684, DOI 10.1038/nrc2196
   DUCY P, 1995, MOL CELL BIOL, V15, P1858
   FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263 7855(88)80054 7
   Fujita T, 2004, J CELL BIOL, V166, P85, DOI 10.1083/jcb.200401138
   Hancock CN, 2005, J MED CHEM, V48, P4586, DOI 10.1021/jm0501174
   Hartzell DD, 2009, BMC GENOMICS, V10, DOI 10.1186/1471 2164 10 497
   Hellman LM, 2007, NAT PROTOC, V2, P1849, DOI 10.1038/nprot.2007.249
   Hiatt RA, 1998, J NATL CANCER I, V90, P461, DOI 10.1093/jnci/90.6.461
   Hicks S, 1998, Curr Opin Drug Discov Devel, V1, P223
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263 7855(96)00018 5
   Jacobs ET, 2011, CANCER EPIDEM BIOMAR, V20, P585, DOI 10.1158/1055 9965.EPI 10 1257
   Kemmis CM, 2006, J NUTR, V136, P887, DOI 10.1093/jn/136.4.887
   Knight JA, 2007, CANCER EPIDEM BIOMAR, V16, P422, DOI 10.1158/1055 9965.EPI 06 0865
   Kundu M, 2002, NAT GENET, V32, P639, DOI 10.1038/ng1050
   Laflamme C, 2010, ARCH ORAL BIOL, V55, P689, DOI 10.1016/j.archoralbio.2010.06.010
   Lou YR, 2004, FASEB J, V18, DOI 10.1096/fj.03 0140fje
   Namba K, 2000, ONCOGENE, V19, P106, DOI 10.1038/sj.onc.1203257
   Narvaez CJ, 2001, STEROIDS, V66, P301, DOI 10.1016/S0039 128X(00)00202 6
   Nicklaus MC, 1997, J MED CHEM, V40, P920, DOI 10.1021/jm960596u
   Pierce AD, 2011, J CELL BIOCH
   Pommier Y, 2005, TRENDS PHARMACOL SCI, V26, P138, DOI 10.1016/j.tips.2005.01.008
   Pommier Y, 2009, CHEM REV, V109, P2894, DOI 10.1021/cr900097c
   Pratap J, 2006, CANCER METAST REV, V25, P589, DOI 10.1007/s10555 006 9032 0
   Qiao M, 2006, J BIOL CHEM, V281, P7118, DOI 10.1074/jbc.M508162200
   Qiao M, 2004, J BIOL CHEM, V279, P42709, DOI 10.1074/jbc.M404480200
   Rajgopal A, 2007, J CELL BIOCHEM, V100, P1509, DOI 10.1002/jcb.21137
   Read Jason T., 2009, V505, P97, DOI 10.1007/978 1 60327 575 0_6
   Renard P, 2001, Nucleic Acids Res, V29, pE21, DOI 10.1093/nar/29.4.e21
   Shen R, 2006, J BIOL CHEM, V281, P16347, DOI 10.1074/jbc.M603439200
   Stein GS, 2004, J CELL BIOCHEM, V91, P287, DOI 10.1002/jcb.10777
   Stein GS, 2004, ONCOGENE, V23, P4315, DOI 10.1038/sj.onc.1207676
   Sun LX, 2004, ONCOGENE, V23, P4722, DOI 10.1038/sj.onc.1207589
   Sun LX, 2001, CANCER RES, V61, P4994
   Tahirov TH, 2001, CELL, V104, P755, DOI 10.1016/S0092 8674(02)02053 6
   Tang YY, 2000, J BIOL CHEM, V275, P39579, DOI 10.1074/jbc.M007350200
   Tokar E, 2005, CLIN EXP METASTAS, V22, P275, DOI 10.1007/s10585 005 8393 z
   Vitolol MI, 2007, CANCER BIOL THER, V6, P856, DOI 10.4161/cbt.6.6.4241
   Vuori KA, 2009, FEBS J, V276, P7366, DOI 10.1111/j.1742 4658.2009.07446.x
   Warren AJ, 2000, EMBO J, V19, P3004, DOI 10.1093/emboj/19.12.3004
   Zelzer E, 2001, MECH DEVELOP, V106, P97, DOI 10.1016/S0925 4773(01)00428 2
NR 56
TC 15
Z9 19
U1 0
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD APR
PY 2012
VL 27
IS 4
BP 913
EP 925
DI 10.1002/jbmr.1504
PG 13
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 911HO
UT WOS:000301708100020
PM 22189971
OA Bronze
DA 2025 08 17
ER

PT J
AU Fisher, A
   Fisher, L
   Srikusalanukul, W
   Smith, PN
AF Fisher, Alexander
   Fisher, Leon
   Srikusalanukul, Wichat
   Smith, Paul N.
TI Bone Turnover Status: Classification Model and Clinical Implications
SO INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
LA English
DT Article
DE bone turnover markers; classification; nonvertebral fracture; prediction
ID CHRONIC KIDNEY DISEASE; INDEPENDENT RISK FACTORS; MINERAL DENSITY;
   REFERENCE INTERVALS; FRACTURE RISK; HIP FRACTURE; BIOCHEMICAL MARKERS;
   PARATHYROID HORMONE; POSTMENOPAUSAL WOMEN; SERUM CONCENTRATIONS
AB Aim: To develop a practical model for classification bone turnover status and evaluate its clinical usefulness.
   Methods: Our classification of bone turnover status is based on internationally recommended biomarkers of both bone formation (N terminal propeptide of type1 procollagen, P1NP) and bone resorption (beta C terminal cross linked telopeptide of type I collagen, bCTX), using the cutoffs proposed as therapeutic targets. The relationships between turnover subtypes and clinical characteristic were assessed in 1223 hospitalised orthogeriatric patients (846 women, 377 men; mean age 78.1 +/  9.50 years): 451(36.9%) subjects with hip fracture (HF), 396(32.4%) with other non vertebral (non HF) fractures (HF) and 376 (30.7%) patients without fractures.
   Resalts: Six subtypes of bone turnover status were identified: 1   normal turnover (P1NP>32 mu g/L, bCTX <= 0.250 mu g/L and P1NP/bCTX>100.0[(median value]); 2 low bone formation (P1NP <= 32 mu g/L), normal bone resorption (bCTX <= 0.250 mu g/L) and P1NP/bCTX>100.0 (subtype2A) or P1NP/bCTX<100.0 (subtype 2B); 3 low bone formation, high bone resorption (bCTX>0.250 mu g/L) and P1NP/bCTX<100.0; 4 high bone turnover (both markers elevated) and P1NP/bCTX>100.0 (subtype 4A) or P1NP/bCTX<100.0 (subtype 4B). Compared to subtypes 1 and 2A, subtype 2B was strongly associated with nonvertebral fractures (odds ratio [OR] 2.0), especially HF (OR 3.2), age>75 years and hyperparathyroidism. Hypoalbuminaemia and not using osteoporotic therapy were two independent indicators common for subtypes 3, 4A and 4B; these three subtypes were associated with in hospital mortality. Subtype 3 was associated with fractures (OR 1.7, for HF OR 2.4), age>75 years, chronic heart failure (CHF), anaemia, and history of malignancy, and predicted post operative myocardial injury, high inflammatory response and length of hospital stay (LOS) a bove 10 days. Subtype 4A was associated with chronic kidney disease (CKD), anaemia, history of malignancy and walking aids use and predicted LOS>20 days, but was not discriminative for fractures. Subtype 4B was associated with fractures (OR 2.1, for HF OR 2.5), age>75 years, CKD and indicated risks of myocardial injury, high inflammatory response and LOS>10 days.
   Conclusions: We proposed a classification model of bone turnover status and demonstrated that in orthogeriatric patients altered subtypes are closely related to presence of nonvertebral fractures, comorbidities and poorer in hospital outcomes. However, further research is needed to establish optimal cut points of various biomarkers and improve the classification model.
C1 [Fisher, Alexander; Srikusalanukul, Wichat] Canberra Hosp, ACT Hlth, Dept Geriatr Med, Canberra, ACT, Australia.
   [Fisher, Alexander; Smith, Paul N.] Canberra Hosp, ACT Hlth, Dept Orthopaed Surg, Canberra, ACT, Australia.
   [Fisher, Leon] Frankston Hosp, Peninsula Hlth, Melbourne, Vic, Australia.
   [Fisher, Alexander; Smith, Paul N.] Australian Natl Univ, Med Sch, Canberra, ACT, Australia.
C3 ACT Health Australia; Australian National University; Canberra Hospital;
   ACT Health Australia; Australian National University; Canberra Hospital;
   Peninsula Health; Frankston Hospital; Australian National University
RP Fisher, A (通讯作者)，Canberra Hosp, Dept Geriatr Med, POB 11, Woden, ACT 2606, Australia.
EM alex.fisher@act.gov.au
OI Fisher, Leon/0000 0002 3860 4606
CR Adami S, 2008, CALCIFIED TISSUE INT, V82, P341, DOI 10.1007/s00223 008 9126 5
   Afshinnia F, 2016, J CLIN ENDOCR METAB, V101, P2468, DOI 10.1210/jc.2016 1099
   Alonso S, 2012, J ENDOCRINOL INVEST, V35, P640, DOI 10.3275/7923
   Alvarez Ríos AI, 2015, EXP GERONTOL, V69, P79, DOI 10.1016/j.exger.2015.05.011
   [Anonymous], J BONE MINER RES
   Ardawi MSM, 2010, BONE, V47, P804, DOI 10.1016/j.bone.2010.07.017
   Baron Roland, 2007, Curr Osteoporos Rep, V5, P73
   Bauer DC, 2009, J BONE MINER RES, V24, P2032, DOI [10.1359/jbmr.090526, 10.1359/JBMR.090526]
   Bieglmayer C, 2009, EUR J CLIN INVEST, V39, P230, DOI 10.1111/j.1365 2362.2009.02087.x
   Biver E, 2012, CURR OPIN ENDOCRINOL, V19, P468, DOI 10.1097/MED.0b013e3283591492
   Blumsohn A, 2011, OSTEOPOROSIS INT, V22, P1935, DOI 10.1007/s00198 010 1379 y
   Burch J, 2014, HEALTH TECHNOL ASSES, V18, P1, DOI 10.3310/hta18110
   Carbone LD, 2017, CALCIFIED TISSUE INT, V100, P599, DOI 10.1007/s00223 017 0245 8
   Cavalier E, 2016, OSTEOPOROSIS INT, V27, P2181, DOI 10.1007/s00198 016 3561 3
   Cesari M, 2005, OSTEOPOROSIS INT, V16, P691, DOI 10.1007/s00198 004 1739 6
   Chen JS, 2008, J AM GERIATR SOC, V56, P2020, DOI 10.1111/j.1532 5415.2008.01954.x
   Chen Z, 2010, J AM GERIATR SOC, V58, P2337, DOI 10.1111/j.1532 5415.2010.03183.x
   Cheung AM, 2016, INT J WOMENS HEALTH, V8, P537, DOI 10.2147/IJWH.S112621
   Chubb SAP, 2017, CLIN BIOCHEM, V50, P162, DOI 10.1016/j.clinbiochem.2016.09.010
   Chubb SAP, 2016, CLIN BIOCHEM, V49, P529, DOI 10.1016/j.clinbiochem.2015.12.002
   Chubb SAP, 2015, J CLIN ENDOCR METAB, V100, P90, DOI 10.1210/jc.2014 2646
   Coen G, 1998, NEPHROL DIAL TRANSPL, V13, P2294, DOI 10.1093/ndt/13.9.2294
   Curtis JR, 2012, J CLIN ENDOCR METAB, V97, P1937, DOI 10.1210/jc.2011 2431
   Dai ZL, 2016, BONE, V83, P171, DOI 10.1016/j.bone.2015.11.005
   de Papp AE, 2007, BONE, V40, P1222, DOI 10.1016/j.bone.2007.01.008
   Delgado Calle J, 2017, BONE, V96, P29, DOI 10.1016/j.bone.2016.10.007
   Delmas PD, 2000, OSTEOPOROSIS INT, V11, pS2, DOI 10.1007/s001980070002
   Diez Perez A, 2017, OSTEOPOROSIS INT, V28, P767, DOI 10.1007/s00198 017 3906 6
   Domiciano DS, 2016, J BONE MINER RES, V31, P1146, DOI 10.1002/jbmr.2795
   Drake MT, 2017, BONE, V96, P8, DOI 10.1016/j.bone.2016.12.004
   Drevet S, 2014, ORTHOP TRAUMATOL SUR, V100, P669, DOI 10.1016/j.otsr.2014.05.003
   Eastell R, 2017, LANCET DIABETES ENDO, V5, P908, DOI 10.1016/S2213 8587(17)30184 5
   Eastell R, 2011, J BONE MINER RES, V26, P1662, DOI 10.1002/jbmr.342
   Eastell R, 2012, BONE, V50, P1141, DOI 10.1016/j.bone.2012.02.003
   Eastell R, 2011, BONE, V49, P82, DOI 10.1016/j.bone.2011.02.011
   Eastell R, 2011, J BONE MINER RES, V26, P530, DOI 10.1002/jbmr.251
   Ebeling PR, 1996, J CLIN ENDOCR METAB, V81, P3366, DOI 10.1210/jc.81.9.3366
   Finnes TE, 2014, BONE, V64, P1, DOI 10.1016/j.bone.2014.03.010
   Fisher A, 2017, CLIN INTERV AGING, V12, P1131, DOI 10.2147/CIA.S141097
   Fisher L, 2015, INT J MED SCI, V12, P100, DOI 10.7150/ijms.10696
   Fohtung RB, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.116.004344
   Garnero P, 2013, OSTEOPOROSIS INT, V24, P489, DOI 10.1007/s00198 012 1978 x
   Garnero P, 2017, MOL DIAGN THER, V21, P401, DOI 10.1007/s40291 017 0272 1
   Garnero P, 2014, BONE, V66, P46, DOI 10.1016/j.bone.2014.05.016
   Gavala A, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/1951707
   Gielen E, 2017, CALCIFIED TISSUE INT, V101, P111, DOI 10.1007/s00223 017 0266 3
   Glover SJ, 2008, BONE, V42, P623, DOI 10.1016/j.bone.2007.12.218
   Glover SJ, 2009, J BONE MINER RES, V24, P389, DOI 10.1359/JBMR.080703
   Goisser S, 2015, J AM MED DIR ASSOC, V16, P661, DOI 10.1016/j.jamda.2015.03.002
   Gossiel Fatma, 2014, Bonekey Rep, V3, P573, DOI 10.1038/bonekey.2014.68
   Greenblatt MB, 2017, CLIN CHEM, V63, P464, DOI 10.1373/clinchem.2016.259085
   Guañabens N, 2016, CLIN CHEM LAB MED, V54, P293, DOI 10.1515/cclm 2015 0162
   Gulin T, 2016, CALCIFIED TISSUE INT, V98, P67, DOI 10.1007/s00223 015 0070 x
   Hannemann A, 2016, BONE, V93, P216, DOI 10.1016/j.bone.2015.06.020
   Hu MC, 2013, ANNU REV PHYSIOL, V75, P503, DOI 10.1146/annurev physiol 030212 183727
   Hu WW, 2013, INT J ENDOCRINOL, V2013, DOI 10.1155/2013/513925
   Idolazzi L, 2016, OSTEOPOROSIS INT, V27, P3301, DOI 10.1007/s00198 016 3647 y
   Iwasaki Y, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/3485785
   Jenkins N, 2013, BONE, V55, P271, DOI 10.1016/j.bone.2013.04.003
   Jin ES, 2017, MEDICINE, V96, DOI [10.1097/MD.0000000000006164, 10.1097/md.0000000000006164]
   Kado DM, 2000, J BONE MINER RES, V15, P1974, DOI 10.1359/jbmr.2000.15.10.1974
   Kanis JA, 2017, OSTEOPOROSIS INT, V28, P2023, DOI 10.1007/s00198 017 4009 0
   Kanis JA, 2014, OSTEOPOROSIS INT, V25, P2533, DOI 10.1007/s00198 014 2787 1
   Kazama JJ, 2017, CLIN EXP NEPHROL, V21, P46, DOI 10.1007/s10157 016 1368 3
   Kenny AM, 2006, OSTEOPOROSIS INT, V17, P1420, DOI 10.1007/s00198 006 0148 4
   Kim SW, 2017, J BONE MINER RES, V32, P892, DOI 10.1002/jbmr.3038
   Koivula MK, 2012, CLIN BIOCHEM, V45, P920, DOI 10.1016/j.clinbiochem.2012.03.023
   Korkmaz U, 2012, EUR J INTERN MED, V23, P154, DOI 10.1016/j.ejim.2011.11.009
   Krege JH, 2014, OSTEOPOROSIS INT, V25, P2159, DOI 10.1007/s00198 014 2646 0
   Kuo TR, 2017, BIOMARK RES, V5, DOI 10.1186/s40364 017 0097 4
   Laudisio A, 2009, CLIN RHEUMATOL, V28, P145, DOI 10.1007/s10067 008 0998 6
   Leavy B, 2017, CALCIFIED TISSUE INT, V100, P1, DOI 10.1007/s00223 016 0194 7
   Lerchbaum E, 2014, OSTEOPOROSIS INT, V25, P455, DOI 10.1007/s00198 013 2411 9
   Lerchbaum E, 2013, OSTEOPOROSIS INT, V24, P1321, DOI 10.1007/s00198 012 2076 9
   Li J, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0096185, 10.1371/journal.pone.0090225]
   Lind L, 2000, CRIT CARE MED, V28, P93, DOI 10.1097/00003246 200001000 00015
   Looker AC, 2014, OSTEOPOROSIS INT, V25, P2389, DOI 10.1007/s00198 014 2769 3
   Lyles KW, 2014, JACC HEART FAIL, V2, P390, DOI 10.1016/j.jchf.2014.04.002
   Manolagas SC, 2010, TRENDS ENDOCRIN MET, V21, P369, DOI 10.1016/j.tem.2010.01.010
   Marques EA, 2017, J BONE MINER RES, V32, P1237, DOI 10.1002/jbmr.3104
   Martin A, 2012, PHYSIOL REV, V92, P131, DOI 10.1152/physrev.00002.2011
   Martínez J, 2009, CLIN CHIM ACTA, V409, P70, DOI 10.1016/j.cca.2009.08.020
   McClung M, 2017, BONE, V98, P37, DOI 10.1016/j.bone.2017.02.013
   Michelsen J, 2013, BONE, V57, P399, DOI 10.1016/j.bone.2013.09.010
   Miller PD, 2014, BONE RES, V2, DOI 10.1038/boneres.2014.44
   Miyauchi A, 2010, BONE, V47, P493, DOI 10.1016/j.bone.2010.05.022
   Moe SM, 2017, CURR OSTEOPOROS REP, V15, P194, DOI 10.1007/s11914 017 0364 1
   Morris HA, 2017, CLIN CHIM ACTA, V467, P34, DOI 10.1016/j.cca.2016.06.036
   Myint PK, 2014, STROKE, V45, P373, DOI 10.1161/STROKEAHA.113.002999
   Nakatoh S, J BONE MINER METAB
   Nakatoh S, 2016, J BONE MINER METAB, V34, P216, DOI 10.1007/s00774 015 0665 3
   Naylor KE, 2016, OSTEOPOROSIS INT, V27, P2585, DOI 10.1007/s00198 016 3573 z
   Naylor KE, 2016, OSTEOPOROSIS INT, V27, P21, DOI 10.1007/s00198 015 3145 7
   Nomura Y, 2013, J BONE MINER METAB, V31, P644, DOI 10.1007/s00774 013 0460 y
   Olmos JM, 2010, CLIN CHIM ACTA, V411, P1511, DOI 10.1016/j.cca.2010.06.010
   Orford NR, 2016, AM J RESP CRIT CARE, V193, P736, DOI 10.1164/rccm.201508 1514OC
   Ott SM, 2017, ANN INTERN MED, V167, pJC19, DOI 10.7326/ACPJC 2017 167 4 019
   Pan ML, 2017, NUTRIENTS, V9, DOI 10.3390/nu9060616
   Pfister R, 2014, JACC HEART FAIL, V2, P380, DOI 10.1016/j.jchf.2014.03.010
   Qu XH, 2013, INT J CARDIOL, V166, P385, DOI 10.1016/j.ijcard.2011.10.114
   Portillo MR, 2017, REV ENDOCR METAB DIS, V18, P79, DOI 10.1007/s11154 017 9421 4
   Rogers A, 2000, J BONE MINER RES, V15, P1398, DOI 10.1359/jbmr.2000.15.7.1398
   Ryder KM, 2010, J BONE MINER METAB, V28, P233, DOI 10.1007/s00774 009 0123 1
   Sambrook PN, 2007, OSTEOPOROSIS INT, V18, P603, DOI 10.1007/s00198 006 0290 z
   Sambrook PN, 2006, J BONE MINER RES, V21, P549, DOI 10.1359/JBMR.060104
   Sapir Koren R, 2014, BIOFACTORS, V40, P555, DOI 10.1002/biof.1186
   Seeman E, 2016, OSTEOPOROSIS INT, V27, P33, DOI 10.1007/s00198 015 3374 9
   Seguro LPC, 2015, OSTEOPOROSIS INT, V26, P459, DOI 10.1007/s00198 014 2860 9
   Seibel Markus J, 2006, Clin Biochem Rev, V27, P123
   Seibel Markus J, 2005, Clin Biochem Rev, V26, P97
   Shieh A, 2016, J CLIN ENDOCR METAB, V101, P2802, DOI 10.1210/jc.2015 4262
   Shigdel R, 2016, J BONE MINER RES, V31, P758, DOI 10.1002/jbmr.2751
   Shou ZX, 2017, GERIATR GERONTOL INT, V17, P773, DOI 10.1111/ggi.12785
   Sinnott B, 2006, OSTEOPOROSIS INT, V17, P684, DOI 10.1007/s00198 005 0034 5
   Smith LM, 2002, CRIT CARE MED, V30, P837, DOI 10.1097/00003246 200204000 00020
   Szulc P, 2008, OSTEOPOROSIS INT, V19, P1683, DOI 10.1007/s00198 008 0660 9
   Szulc P, 2017, OSTEOPOROS INT
   Szulc Pawel, 2012, Bonekey Rep, V1, P144, DOI 10.1038/bonekey.2012.144
   Torres PAU, 2017, J NEPHROL, V30, P653, DOI 10.1007/s40620 017 0398 6
   Tsai JN, 2017, BONE, V95, P20, DOI 10.1016/j.bone.2016.11.009
   Tsujimoto M, 2011, BONE, V48, P798, DOI 10.1016/j.bone.2010.12.006
   Valderrábano RJ, 2017, J CLIN ENDOCR METAB, V102, P2199, DOI 10.1210/jc.2017 00266
   Van den Berghe G, 2003, J CLIN ENDOCR METAB, V88, P4623, DOI 10.1210/jc.2003 030358
   van Diepen S, 2008, CIRCULATION, V118, P1946, DOI 10.1161/CIRCULATIONAHA.108.784009
   Vasikaran S, 2011, OSTEOPOROSIS INT, V22, P391, DOI 10.1007/s00198 010 1501 1
   Vasikaran SD, 2016, ENDOCRINE, V52, P222, DOI 10.1007/s12020 016 0900 2
   Verheyen N, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173799
   Veronese N, 2017, J BONE MINER RES, V32, P1126, DOI 10.1002/jbmr.3089
   Vescini F, 2016, J ENDOCRINOL INVEST, V39, P807, DOI 10.1007/s40618 016 0434 8
   Watts NB, 1999, BRIT MED J, V319, P1371
   Wiklund P, 2012, OSTEOPOROSIS INT, V23, P963, DOI 10.1007/s00198 011 1631 0
   Wiklund R, 2016, OSTEOPOROSIS INT, V27, P923, DOI 10.1007/s00198 015 3390 9
   Wilson LM, 2017, ANN INTERN MED, V166, P649, DOI 10.7326/M16 2752
   Wu XY, 2014, BMC ENDOCR DISORD, V14, DOI 10.1186/1472 6823 14 8
   Yeap BB, 2015, J CLIN ENDOCR METAB, V100, P3934, DOI 10.1210/jc.2015 1899
NR 135
TC 25
Z9 31
U1 0
U2 4
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1449 1907
J9 INT J MED SCI
JI Int. J. Med. Sci.
PY 2018
VL 15
IS 4
BP 323
EP 338
DI 10.7150/ijms.22747
PG 16
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA FX2UZ
UT WOS:000425920300005
PM 29511368
OA Green Published, gold, Green Submitted
DA 2025 08 17
ER

PT J
AU Bugatti, S
   Bogliolo, L
   Manzo, A
   De Stefano, L
   Delvino, P
   Motta, F
   Montecucco, C
AF Bugatti, Serena
   Bogliolo, Laura
   Manzo, Antonio
   De Stefano, Ludovico
   Delvino, Paolo
   Motta, Francesca
   Montecucco, Carlomaurizio
TI Impact of Anti Citrullinated Protein Antibodies on Progressive Systemic
   Bone Mineral Density Loss in Patients With Early Rheumatoid Arthritis
   After Two Years of Treat to Target
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE rheumatoid arthritis; anti citrullinated protein autoantibodies; bone
   mineral density; osteoporosis 3; rheumatoid factor
ID AUTOANTIBODIES; CRITERIA; CLASSIFICATION; OSTEOPOROSIS; MANAGEMENT;
   DIAGNOSIS; ONSET; RATES
AB Objectives To investigate the association of anti citrullinated protein antibodies (ACPA) with changes in systemic bone mineral density (BMD) in patients with early rheumatoid arthritis (RA) after two years of treat to target. Methods BMD was measured at the lumbar spine (LS) and femoral neck (FN) in 100 patients with recent onset RA at baseline and after 24 months of treatment aimed at low disease activity (LDA) according to the 28 joints disease activity score (DAS28 <3.2). Multivariable regression analyses were performed to determine independent associations between autoantibodies and other disease and treatment related parameters with BMD loss. Results After 24 months, the majority of the patients were at least in LDA (78%), with slightly more ACPA positive subjects achieving the target. The BMD had significantly decreased at both the LS (mean [SD] percent loss  1.8 [6.2], p=0.03) and the FN ( 2.4 [7.3], p=0.03) in ACPA positive but not in ACPA negative patients. Consequently, the proportion of patients with reduced BMD (Z score <= 1) after 24 months was significantly higher among ACPA positive patients at both the spine (39.5% vs 19.3%, p=0.05) and the hip (37.2% vs 12.2%, p=0.007). The association between ACPA and BMD loss was independent of other variables including age, gender, disease activity, cumulative dose of glucocorticoids and duration of therapy with bisphosphonates at the LS but not the FN. Conclusions ACPA are associated with ongoing BMD loss at the spine despite suppression of inflammation and adoption of prophylactic measures. ACPA positive RA patients should be therefore strictly monitored for the development of osteoporosis.
C1 [Bugatti, Serena; Bogliolo, Laura; Manzo, Antonio; De Stefano, Ludovico; Delvino, Paolo; Motta, Francesca; Montecucco, Carlomaurizio] IRCCS Policlin San Matteo Fdn, Div Rheumatol, Pavia, Italy.
   [Bugatti, Serena; Manzo, Antonio; De Stefano, Ludovico; Delvino, Paolo; Motta, Francesca; Montecucco, Carlomaurizio] Univ Pavia, Dept Internal Med & Therapeut, Pavia, Italy.
C3 IRCCS Fondazione San Matteo; University of Pavia
RP Bugatti, S (通讯作者)，IRCCS Policlin San Matteo Fdn, Div Rheumatol, Pavia, Italy.; Bugatti, S (通讯作者)，Univ Pavia, Dept Internal Med & Therapeut, Pavia, Italy.
EM serena.bugatti@unipv.it
RI Bugatti, Serena/K 4970 2018; Delvino, Paolo/ADV 9586 2022; De Stefano,
   Ludovico/IRZ 3185 2023; Motta, Francesca/GLT 0756 2022
OI Delvino, Paolo/0000 0002 6383 8236; Bogliolo, Laura/0000 0002 1661 0482;
   De Stefano, Ludovico/0000 0002 2312 2161; Motta,
   Francesca/0000 0002 8093 2734
FU IRCCS Policlinico San Matteo Foundation, Pavia, Italy
FX This study was supported in part by funding from the IRCCS Policlinico
   San Matteo Foundation, Pavia, Italy.
CR Aletaha D, 2010, ANN RHEUM DIS, V69, P1580, DOI [10.1136/ard.2010.138461, 10.1002/art.27584]
   Amkreutz JAMP, 2021, ARTHRITIS RHEUMATOL, V73, P921, DOI 10.1002/art.41623
   ARNETT FC, 1988, ARTHRITIS RHEUM US, V31, P315, DOI 10.1002/art.1780310302
   Balduzzi S, 2017, CLIN EXP RHEUMATOL, V35, P401
   Blake GM, 2007, J CLIN DENSITOM, V10, P102, DOI 10.1016/j.jocd.2006.11.001
   Bugatti S, 2016, REUMATISMO, V68, P117, DOI 10.4081/reumatismo.2016.914
   Bugatti S, 2018, FRONT MED LAUSANNE, V5, DOI 10.3389/fmed.2018.00339
   Bugatti S, 2016, ARTHRITIS RES THER, V18, DOI 10.1186/s13075 016 1116 9
   Güler Yüksel M, 2008, ANN RHEUM DIS, V67, P823, DOI 10.1136/ard.2007.073817
   Güler Yüksel M, 2018, CALCIFIED TISSUE INT, V102, P592, DOI 10.1007/s00223 017 0335 7
   Harre U, 2017, SEMIN IMMUNOPATHOL, V39, P355, DOI 10.1007/s00281 017 0634 0
   Harre U, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7651
   Harre U, 2012, J CLIN INVEST, V122, P1791, DOI 10.1172/JCI60975
   Haugeberg G, 2014, BMC MUSCULOSKEL DIS, V15, DOI 10.1186/1471 2474 15 289
   Hecht C, 2015, ANN RHEUM DIS, V74, P2151, DOI 10.1136/annrheumdis 2014 205428
   Hsu CY, 2020, THER ADV CHRONIC DIS, V11, DOI 10.1177/2040622320981517
   Jensen TW, 2014, ANN RHEUM DIS, V73, P1123, DOI 10.1136/annrheumdis 2012 203171
   Keller KK, 2020, JOINT BONE SPINE, V87, P181, DOI 10.1016/j.jbspin.2019.09.006
   Kleyer A, 2014, ANN RHEUM DIS, V73, P854, DOI 10.1136/annrheumdis 2012 202958
   Koga T, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175281
   Krishnamurthy A, 2016, ANN RHEUM DIS, V75, P721, DOI 10.1136/annrheumdis 2015 208093
   Llorente I, 2020, FRONT MED LAUSANNE, V7, DOI 10.3389/fmed.2020.601618
   Lucassen MJJ, 2021, OSTEOPOROSIS INT, V32, P1441, DOI 10.1007/s00198 020 05781 7
   Mazzucchelli R, 2018, RMD OPEN, V4, DOI 10.1136/rmdopen 2018 000671
   Montecucco C, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3838
   Nuti R, 2019, INTERN EMERG MED, V14, P85, DOI 10.1007/s11739 018 1874 2
   Orsolini G, 2019, PHARMACOL RES, V147, DOI 10.1016/j.phrs.2019.104354
   Orsolini G, 2017, CALCIFIED TISSUE INT, V101, P17, DOI 10.1007/s00223 017 0253 8
   Rossini M, 2016, REUMATISMO, V68, P1, DOI 10.4081/reumatismo.2016.870
   Rotta D, 2020, FRONT MED LAUSANNE, V7, DOI 10.3389/fmed.2020.613720
   Simon D, 2018, BONE, V116, P87, DOI 10.1016/j.bone.2018.07.017
   Smolen JS, 2020, ANN RHEUM DIS, V79, P685, DOI 10.1136/annrheumdis 2019 216655
   Steffen U, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01483
   Stemmler F, 2018, ANN RHEUM DIS, V77, P973, DOI 10.1136/annrheumdis 2017 212404
   Tomizawa T, 2019, ARTHRITIS RES THER, V21, DOI 10.1186/s13075 019 1956 1
   van der Goes MC, 2013, OSTEOPOROSIS INT, V24, P1429, DOI 10.1007/s00198 012 2073 z
   van der Heijde D, 2000, J RHEUMATOL, V27, P261
   Wright NC, 2012, J CLIN DENSITOM, V15, P39, DOI 10.1016/j.jocd.2011.06.003
   Wysham KD, 2018, ARTHRIT CARE RES, V70, P961, DOI 10.1002/acr.23440
   Yoshii I, 2020, OSTEOPORO SARCOPENIA, V6, P75, DOI 10.1016/j.afos.2020.04.002
   Zerbini CAF, 2017, OSTEOPOROSIS INT, V28, P429, DOI 10.1007/s00198 016 3769 2
NR 41
TC 12
Z9 12
U1 0
U2 2
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1664 3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD JUN 14
PY 2021
VL 12
AR 701922
DI 10.3389/fimmu.2021.701922
PG 8
WC Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology
GA TA4AX
UT WOS:000667192700001
PM 34194443
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Huang, Y
   Jia, XL
   Bai, K
   Gong, XH
   Fan, YB
AF Huang, Yan
   Jia, Xiaoling
   Bai, Ke
   Gong, Xianghui
   Fan, Yubo
TI Effect of Fluid Shear Stress on Cardiomyogenic Differentiation of Rat
   Bone Marrow Mesenchymal Stem Cells
SO ARCHIVES OF MEDICAL RESEARCH
LA English
DT Article
DE Mesenchymal stem cells; Differentiation; Cardiomyocytes; Shear stress;
   5 Azacytidine
ID ACTIVATED PROTEIN KINASE; STROMAL CELLS; ENDOTHELIAL CELLS; CARDIAC
   MYOCYTES; IN VITRO; FLOW; MECHANOBIOLOGY; CARDIOMYOCYTES; THERAPY
AB Background and Aims. Bone marrow mesenchymal stem cells (BMSCs) are a potential source of material for the construction of tissue engineered cardiac grafts because of their potential to transdifferentiate into cardiomyocytes after chemical treatment or co culture with cardiomyocytes. Recent evidence has shown that mechanical loads could regulate the BMSC differentiation into osteoblasts and endothelial cells through various signaling pathways. We investigated whether fluid shear stress (FSS), which is a mechanical load generated by fluid flow, can regulate rat BMSC (rBMSC) differentiation into cardiomyocytes.
   Methods. rBMSCs were isolated from marrow of rat femur and tibia using density gradient centrifugation combined with adhesion method and identified with surface marker, proliferation character and differentiation potential in vitro. Cultured rBMSCs with or without 5 azacytidine (5 aza) treatment were exposed to laminar shear stress with a parallel plate type device and analyzed by RT PCR, immunocytochemistry, FACS and Western blotting for the cardiomyogenic differentiation.
   Results. Appropriate FSS treatment alone induced cardiomyogenic differentiation of rBMSCs, as confirmed by the expression of cardiomyocyte related markers at both mRNA and protein levels. Furthermore, when rBMSC cultures were exposed to both FSS and 5 aza, expression levels of cardiomyocyte related markers significantly increased to a degree suggestive of a synergistic interaction.
   Conclusions. The results demonstrate that FSS is an important factor affecting cardiomyogenic differentiation of rBMSCs. This provides a new avenue for mechanistic studies of stem cell differentiation and a new approach to obtain more committed differentiated cells. (C) 2010 IMSS. Published by Elsevier Inc.
C1 [Huang, Yan; Jia, Xiaoling; Bai, Ke; Gong, Xianghui; Fan, Yubo] Beihang Univ, Sch Biol Sci & Med Engn, Minist Educ, Key Lab Biomech & Mechanobiol, Beijing 100191, Peoples R China.
C3 Beihang University
RP Fan, YB (通讯作者)，Beihang Univ, Sch Biol Sci & Med Engn, Minist Educ, Key Lab Biomech & Mechanobiol, XueYuan Rd 37, Beijing 100191, Peoples R China.
EM yubofan@buaa.edu.cn
RI Gong, Xianghui/AAW 1133 2020; jia, xiaolong/HII 6615 2022
FU National Natural Science Foundation of China [10925208]; Research Fund
   for the Doctoral Program of Higher Education of China [20091102110031]
FX This project was supported by the National Natural Science Foundation of
   China (Grant No. 10925208) and by Research Fund for the Doctoral Program
   of Higher Education of China (Grant No. 20091102110031). We thank
   International Science Editing for the language editing.
CR Ando J, 2009, CIRC J, V73, P1983, DOI 10.1253/circj.CJ 09 0583
   Antonitsis Polychronis, 2007, Interact Cardiovasc Thorac Surg, V6, P593, DOI 10.1510/icvts.2007.157875
   Bai K, 2010, J BIOMECH, V43, P1176, DOI 10.1016/j.jbiomech.2009.11.030
   Berry MF, 2006, AM J PHYSIOL HEART C, V290, pH2196, DOI 10.1152/ajpheart.01017.2005
   Burlacu A, 2008, EUR J CELL BIOL, V87, P173, DOI 10.1016/j.ejcb.2007.09.003
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044
   Feng C, 2009, EXP CELL RES, V315, P3044, DOI 10.1016/j.yexcr.2009.05.005
   FRANGOS JA, 1985, SCIENCE, V227, P1477, DOI 10.1126/science.3883488
   Gomes ME, 2006, TISSUE ENG, V12, P177, DOI 10.1089/ten.2006.12.177
   Hove JR, 2003, NATURE, V421, P172, DOI 10.1038/nature01282
   Inuernicia G, 2008, EXP CELL RES, V314, P366, DOI 10.1016/j.yexcr.2007.08.006
   Kablar B, 2003, DEV BIOL, V258, P307, DOI 10.1016/S0012 1606(03)00139 8
   Kong CR, 2005, J APPL PHYSIOL, V98, P2328, DOI 10.1152/japplphysiol.01084.2004
   Kreke MR, 2008, TISSUE ENG PT A, V14, P529, DOI 10.1089/tea.2007.0068
   Lattanzi L, 1998, J CLIN INVEST, V101, P2119, DOI 10.1172/JCI1505
   Lee Michael S, 2004, Rev Cardiovasc Med, V5, P82
   Li XH, 2007, J MOL CELL CARDIOL, V42, P295, DOI 10.1016/j.yjmcc.2006.07.002
   Li Y, 2009, ARCH BIOCHEM BIOPHYS, V490, P171, DOI 10.1016/j.abb.2009.08.016
   Martin Rendon E, 2008, VOX SANG, V95, P137, DOI 10.1111/j.1423 0410.2008.01076.x
   Murry CE, 2004, NATURE, V428, P664, DOI 10.1038/nature02446
   Park JS, 2007, FRONT BIOSCI LANDMRK, V12, P5098, DOI 10.2741/2551
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Rebelatto CK, 2009, BIOCHEM BIOPH RES CO, V378, P456, DOI 10.1016/j.bbrc.2008.11.061
   Shepler SA, 2007, CRIT CARE NURS Q, V30, P74, DOI 10.1097/00002727 200701000 00009
   Shim WSN, 2004, BIOCHEM BIOPH RES CO, V324, P481, DOI 10.1016/j.bbrc.2004.09.087
   Tzima E, 2006, CIRC RES, V98, P176, DOI 10.1161/01.RES.0000200162.94463.d7
   Wang TZ, 2006, INT J CARDIOL, V109, P74, DOI 10.1016/j.ijcard.2005.05.072
   Xie XJ, 2006, ACTA PHARMACOL SIN, V27, P1153, DOI 10.1111/j.1745 7254.2006.00436.x
   Yi FF, 2009, ARCH MED RES, V40, P339, DOI 10.1016/j.arcmed.2009.06.005
   You J, 2001, J BIOL CHEM, V276, P13365, DOI 10.1074/jbc.M009846200
   Zeng LF, 2006, J CELL BIOL, V174, P1059, DOI 10.1083/jcb.200605113
   Zetser A, 1999, J BIOL CHEM, V274, P5193, DOI 10.1074/jbc.274.8.5193
   Zhou R, 2006, J AM COLL CARDIOL, V48, P2094, DOI 10.1016/j.jacc.2006.08.026
NR 34
TC 106
Z9 122
U1 2
U2 50
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 0188 4409
EI 1873 5487
J9 ARCH MED RES
JI Arch. Med. Res.
PD OCT
PY 2010
VL 41
IS 7
BP 497
EP 505
DI 10.1016/j.arcmed.2010.10.002
PG 9
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA 703BG
UT WOS:000285948200002
PM 21167388
DA 2025 08 17
ER

PT J
AU Jandl, K
   Heinemann, A
AF Jandl, Katharina
   Heinemann, Akos
TI The therapeutic potential of CRTH2/DP2 beyond allergy and asthma
SO PROSTAGLANDINS & OTHER LIPID MEDIATORS
LA English
DT Article; Proceedings Paper
CT 6th European Workshop on Lipid Mediators (EWLM)
CY SEP 27 30, 2016
CL Goethe Univ, Frankfurt, GERMANY
HO Goethe Univ
DE CRTH2 DP2 DP1 PGD(2); Inflammation pharmacological target
ID PROSTAGLANDIN D 2 RECEPTOR; INNATE LYMPHOID CELLS; HOMOLOGOUS MOLECULE;
   ANTAGONIST OC000459; DIFFERENTIAL EXPRESSION; EOSINOPHIL MIGRATION;
   PROSTANOID RECEPTORS; INDUCED INFLAMMATION; HUMAN OSTEOBLASTS;
   PROTEIN KINASE
AB Prostaglandin (PG) D 2 has been in the focus of research for quite a long time, but its biological effects and its roles in human disease are still not fully characterized. When in 2001 a second major PGD(2) receptor termed chemoattractant receptor homologue expressed on Th 2 cells (CRTH2; alternative name DP2) was discovered, diverse investigations started to shed more light on the complex and often controversial actions of the prostaglandin. With various immunomodulating effects, such as induction of migration, activation, and cytokine release of leukocytes observed both in vivo and in vitro, CRTH2 has emerged as a promising target for the treatment of allergic diseases. However, with more and more research being performed on CRTH2, it has also become clear that its biological actions are far more diverse than expected at the beginning. In this review, we aim to summarize the roles that PGD(2)   and CRTH2 in particular   might play in diseases of the central nervous system, kidney, intestine, lung, hair and skin, bone and cartilage, and in cancer. Based on current data we propose that blocking CRTH2 might be a potential therapeutic approach to numerous conditions beyond classical allergic diseases and asthma.
C1 [Jandl, Katharina; Heinemann, Akos] Med Univ Graz, Inst Expt & Clin Pharmacol, Graz, Austria.
   [Jandl, Katharina] Ludwig Boltzmann Inst Lung Vasc Res, Graz, Austria.
   [Heinemann, Akos] BioTechMed Graz, Graz, Austria.
C3 Medical University of Graz; Ludwig Boltzmann Institute; Ludwig Boltzmann
   Institute for Lung Vascular Research
RP Heinemann, A (通讯作者)，Med Univ Graz, Inst Expt & Clin Pharmacol, Graz, Austria.
EM akos.heinemann@medunigraz.at
OI Jandl, Katharina/0000 0002 7892 6618; Heinemann,
   Akos/0000 0002 8554 2372
FU Austrian Science Fund FWF [P22521 B18]; Austrian National Bank [14263];
   Ph.D Program DK MOLIN [FWF W1241]; Austrian Science Fund (FWF) [W1241]
   Funding Source: Austrian Science Fund (FWF)
FX Supported by the Austrian Science Fund FWF (grant P22521 B18 to A.H.)
   and the Austrian National Bank (grant 14263 to A.H.). K.J. was funded by
   the Ph.D Program DK MOLIN (FWF W1241).
CR Abe H, 1999, GENE, V227, P71, DOI 10.1016/S0378 1119(98)00599 X
   Asano K., 2011, AM THOR SOC INT C, pA5579
   Ayabe S, 2013, J PHARMACOL SCI, V121, P312, DOI 10.1254/jphs.12275FP
   Barnes N, 2012, CLIN EXP ALLERGY, V42, P38, DOI 10.1111/j.1365 2222.2011.03813.x
   Bie QL, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/923135
   Black AT, 2008, TOXICOL APPL PHARM, V232, P14, DOI 10.1016/j.taap.2008.05.017
   Boehme SA, 2009, INT IMMUNOL, V21, P621, DOI 10.1093/intimm/dxp031
   Boehme SA, 2009, INT IMMUNOL, V21, P81, DOI 10.1093/intimm/dxn127
   Boehme SA, 2009, INT IMMUNOL, V21, P1, DOI 10.1093/intimm/dxn118
   Boin F, 2008, ARTHRITIS RHEUM US, V58, P1165, DOI 10.1002/art.23406
   Colombe L, 2008, EXP DERMATOL, V17, P63, DOI 10.1111/j.1600 0625.2007.00639.x
   Cosmi L, 2000, EUR J IMMUNOL, V30, P2972, DOI 10.1002/1521 4141(200010)30:10<2972::AID IMMU2972>3.0.CO;2 #
   Di Giorgio FP, 2008, CELL STEM CELL, V3, P637, DOI 10.1016/j.stem.2008.09.017
   Durand M, 2008, J BONE MINER RES, V23, P1097, DOI 10.1359/JBMR.080228
   Elinav E, 2013, NAT REV CANCER, V13, P759, DOI 10.1038/nrc3611
   Erpenbeck VJ, 2016, PULM PHARMACOL THER, V39, P54, DOI 10.1016/j.pupt.2016.06.005
   Fukuoka T, 2014, ANTICANCER RES, V34, P2771
   Gallant MA, 2005, J BONE MINER RES, V20, P672, DOI 10.1359/JBMR.041211
   Gervais FG, 2001, J ALLERGY CLIN IMMUN, V108, P982, DOI 10.1067/mai.2001.119919
   Gosset P, 2003, J IMMUNOL, V170, P4943, DOI 10.4049/jimmunol.170.10.4943
   Haba R, 2014, J NEUROSCI, V34, P2514, DOI 10.1523/JNEUROSCI.1407 13.2014
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hatanaka M, 2010, J PHARMACOL SCI, V113, P89, DOI 10.1254/jphs.10001SC
   He R, 2010, J ALLERGY CLIN IMMUN, V126, P784, DOI 10.1016/j.jaci.2010.07.006
   Hijnen D, 2005, J INVEST DERMATOL, V125, P1149, DOI 10.1111/j.0022 202X.2005.23932.x
   Hirai H, 2001, J EXP MED, V193, P255, DOI 10.1084/jem.193.2.255
   Hirawa N, 2001, NEPHRON, V87, P321, DOI 10.1159/000045937
   Horak F, 2012, ALLERGY, V67, P1572, DOI 10.1111/all.12042
   Ito H, 2012, J AM SOC NEPHROL, V23, P1797, DOI 10.1681/ASN.2012020126
   Jandl K, 2016, J ALLERGY CLIN IMMUN, V137, P833, DOI 10.1016/j.jaci.2015.11.012
   Johnsson M, 2011, J INNATE IMMUN, V3, P594, DOI 10.1159/000331326
   Joo HW, 2016, N S ARCH PHARMACOL, V389, P809, DOI 10.1007/s00210 016 1257 z
   Jung KM, 2003, MOL PHARMACOL, V63, P607, DOI 10.1124/mol.63.3.607
   Kanda N, 2010, BIOCHEM PHARMACOL, V79, P982, DOI 10.1016/j.bcp.2009.11.012
   Karagöz B, 2010, CENT EUR J MED, V5, P431, DOI 10.2478/s11536 009 0047 0
   Kataoka N, 2013, IMMUNOLOGY, V140, P78, DOI 10.1111/imm.12112
   Khidhir KG, 2013, FASEB J, V27, P557, DOI 10.1096/fj.12 218156
   Kida T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167729
   Koyani CN, 2016, BIOCHEM PHARMACOL, V104, P29, DOI 10.1016/j.bcp.2016.01.011
   Koyani CN, 2014, INT J CARDIOL, V173, P472, DOI 10.1016/j.ijcard.2014.03.086
   Krug N, 2014, J ALLERGY CLIN IMMUN, V133, P414, DOI 10.1016/j.jaci.2013.10.013
   Kuna P, 2016, DRUG DES DEV THER, V10, P2759, DOI 10.2147/DDDT.S105142
   Lingblom C, 2017, ALLERGY, V72, P1406, DOI 10.1111/all.13140
   Liu L.A.Y. Garza, 2012, SCI TRANSL MED, V4
   Maicas N, 2012, ARTHRITIS RHEUM US, V64, P130, DOI 10.1002/art.30656
   MALL G, 1991, VIRCHOWS ARCH A, V419, P339, DOI 10.1007/BF01606525
   Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205
   Matsushima Y, 2011, MOL IMMUNOL, V49, P304, DOI 10.1016/j.molimm.2011.08.023
   Matsuzaki K, 2003, J GASTROEN HEPATOL, V18, P1081, DOI 10.1046/j.1440 1746.2003.03088.x
   Mizoguchi A, 2001, P NATL ACAD SCI USA, V98, P11674, DOI 10.1073/pnas.201398898
   Mjösberg JM, 2011, NAT IMMUNOL, V12, P1055, DOI 10.1038/ni.2104
   Mohri I, 2006, J NEUROSCI, V26, P4383, DOI 10.1523/JNEUROSCI.4531 05.2006
   Monneret G, 2001, BLOOD, V98, P1942, DOI 10.1182/blood.V98.6.1942
   Moon TC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108595
   Murata T, 2013, P NATL ACAD SCI USA, V110, P5205, DOI 10.1073/pnas.1218091110
   Murata T, 2008, P NATL ACAD SCI USA, V105, P20009, DOI 10.1073/pnas.0805171105
   Nagata K, 1999, FEBS LETT, V459, P195, DOI 10.1016/S0014 5793(99)01251 X
   Nagata K, 1999, J IMMUNOL, V162, P1278
   Nelson AM, 2013, J INVEST DERMATOL, V133, P881, DOI 10.1038/jid.2012.398
   Nicolaou A, 2013, PROSTAG LEUKOTR ESS, V88, P131, DOI 10.1016/j.plefa.2012.03.009
   Ohinata K, 2008, FEBS LETT, V582, P679, DOI 10.1016/j.febslet.2008.01.050
   Oiwa M, 2008, CLIN EXP ALLERGY, V38, P1357, DOI 10.1111/j.1365 2222.2008.03007.x
   Onaka Y, 2016, BEHAV BRAIN RES, V314, P77, DOI 10.1016/j.bbr.2016.07.050
   Pettipher R, 2014, ALLERGY, V69, P1223, DOI 10.1111/all.12451
   Pirooznia SK, 2014, NEURON, V81, P961, DOI 10.1016/j.neuron.2014.02.024
   Qu WM, 2006, P NATL ACAD SCI USA, V103, P17949, DOI 10.1073/pnas.0608581103
   Radnai B, 2016, J CROHNS COLITIS, V10, P1087, DOI 10.1093/ecco jcc/jjw061
   Santus P, 2016, EXPERT OPIN INV DRUG, V25, P1083, DOI 10.1080/13543784.2016.1212838
   Sarashina H, 2014, J IMMUNOL, V192, P459, DOI 10.4049/jimmunol.1302080
   Sargent C., 2009, EFFECT SELECTIVE CRT
   Satoh T, 1999, BIOCHEM BIOPH RES CO, V258, P50, DOI 10.1006/bbrc.1999.0587
   Satoh T, 2006, J IMMUNOL, V177, P2621, DOI 10.4049/jimmunol.177.4.2621
   Satoh T, 2010, ACTA DERM VENEREOL, V90, P18, DOI 10.2340/00015555 0759
   Sawyer N, 2002, BRIT J PHARMACOL, V137, P1163, DOI 10.1038/sj.bjp.0704973
   Schmidt JA, 2013, BRIT J PHARMACOL, V168, P1626, DOI 10.1111/bph.12053
   Shirasaki H, 2009, ANN ALLERG ASTHMA IM, V102, P110, DOI 10.1016/S1081 1206(10)60239 6
   Snell N, 2013, RESP MED, V107, P1722, DOI 10.1016/j.rmed.2013.06.006
   Spik I, 2005, J IMMUNOL, V174, P3703, DOI 10.4049/jimmunol.174.6.3703
   Stebbins KJ, 2010, J PHARMACOL EXP THER, V332, P764, DOI 10.1124/jpet.109.161919
   Stinson SE, 2015, J ALLERGY CLIN IMMUN, V135, P395, DOI 10.1016/j.jaci.2014.08.027
   Straumann A, 2013, ALLERGY, V68, P375, DOI 10.1111/all.12096
   Sturm EM, 2014, J IMMUNOL, V193, P827, DOI 10.4049/jimmunol.1303484
   Sugimoto H, 2003, J PHARMACOL EXP THER, V305, P347, DOI 10.1124/jpet.102.046748
   Tajima T, 2008, J PHARMACOL EXP THER, V326, P493, DOI 10.1124/jpet.108.137992
   Takeshita K, 2004, INT IMMUNOL, V16, P947, DOI 10.1093/intimm/dxh096
   Tanaka K, 2004, BIOCHEM BIOPH RES CO, V316, P1009, DOI 10.1016/j.bbrc.2004.02.151
   TASAKI Y, 1991, PROSTAGLANDINS, V41, P303, DOI 10.1016/0090 6980(91)90001 V
   THRALL RS, 1979, AM J PATHOL, V95, P117
   Tokuda H, 1999, PROSTAG LEUKOTR ESS, V61, P189, DOI 10.1054/plef.1999.0089
   Trimarco A, 2014, NAT NEUROSCI, V17, P1682, DOI 10.1038/nn.3857
   Tsubosaka Y, 2014, J IMMUNOL, V193, P5835, DOI 10.4049/jimmunol.1303478
   Tsuchida T, 2004, Nephron Physiol, V96, P42, DOI [DOI 10.1159/000076407, 10.1159/000076407]
   Ueda S., 2009, AM THOR SOC INT C, pA5662
   van den Brule S, 2010, J PHARMACOL EXP THER, V335, P472, DOI 10.1124/jpet.110.169250
   Wojno EDT, 2015, MUCOSAL IMMUNOL, V8, P1313, DOI 10.1038/mi.2015.21
   Yahara H, 2010, J EUR ACAD DERMATOL, V24, P75, DOI 10.1111/j.1468 3083.2009.03267.x
   Yoon Y. S., 2016, SCI REP, V6
   Yue L, 2014, BONE, V60, P112, DOI 10.1016/j.bone.2013.12.011
   Yue L, 2012, BONE, V51, P338, DOI 10.1016/j.bone.2012.06.003
   Zhou Y, 2015, J CLIN INVEST, V125, P3178, DOI 10.1172/JCI79792
NR 100
TC 35
Z9 36
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1098 8823
EI 2212 196X
J9 PROSTAG OTH LIPID M
JI Prostaglandins Other Lipid Mediat.
PD NOV
PY 2017
VL 133
SI SI
BP 42
EP 48
DI 10.1016/j.prostaglandins.2017.08.006
PG 7
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC Biochemistry & Molecular Biology; Cell Biology
GA FR0CQ
UT WOS:000418729100007
PM 28818625
OA Green Accepted, hybrid
DA 2025 08 17
ER

PT J
AU Ahern, E
   Harjunpää, H
   O'Donnell, JS
   Allen, S
   Dougall, WC
   Teng, MWL
   Smyth, MJ
AF Ahern, Elizabeth
   Harjunpaa, Heidi
   O'Donnell, Jake S.
   Allen, Stacey
   Dougall, William C.
   Teng, Michele W. L.
   Smyth, Mark J.
TI RANKL blockade improves efficacy of PD1 PD L1 blockade or dual PD1 PD L1
   and CTLA4 blockade in mouse models of cancer
SO ONCOIMMUNOLOGY
LA English
DT Article
DE CD8+T cells; metastasis; RANK; RANKL; tumors
ID REGULATORY T CELLS; PROSTATE CANCER; BONE METASTASES; ADVANCED MELANOMA;
   PD 1 BLOCKADE; BREAST CANCER; TUMOR MICROENVIRONMENT; ANTI CTLA 4
   ANTIBODIES; UNTREATED MELANOMA; ANTITUMOR ACTIVITY
AB Receptor activator of NF kappa B ligand (RANKL) and its receptor RANK, are members of the tumor necrosis factor and receptor superfamilies, respectively. Antibodies targeting RANKL have recently been evaluated in combination with anti CTLA4 in case reports of human melanoma and mouse models of cancer. However, the efficacy of anti RANKL in combination with antibodies targeting other immune checkpoint receptors such as PD1 has not been reported. In this study, we demonstrated that blockade of RANKL improves anti metastatic activity of antibodies targeting PD1/PD L1 and improves subcutaneous growth suppression in mouse models of melanoma, prostate and colon cancer. Suppression of experimental lung metastasis following combination anti RANKL with anti PD1 requires NK cells and IFN gamma, whereas subcutaneous tumor growth suppression with this combination therapy is attenuated in the absence of T cells and IFN gamma Furthermore, addition of anti RANKL to anti PD1 and anti CTLA4 resulted in superior anti tumor responses, irrespective of the ability of anti CTLA4 isotype to engage activating FcR, and concurrent or delayed RANKL blockade was most effective. Early during treatment assessment reveals this triple combination therapy compared to dual anti PD1 and anti CTLA4 combination therapy further increased the proportion of tumor infiltrating CD4(+) and CD8(+) T cells that can produce both IFN gamma and TNF. Finally, RANKL expression appears to identify tumor specific CD8(+) T cells expressing higher levels of PD1 which can be modulated by anti PD1. These data set the scene for clinical evaluation of denosumab use in patients receiving contemporary immune checkpoint blockade.
C1 [Ahern, Elizabeth; O'Donnell, Jake S.; Dougall, William C.; Smyth, Mark J.] QIMR Berghofer Med Res Inst, Immunol Canc & Infect Lab, Dept Immunol, Herston, Qld, Australia.
   [Harjunpaa, Heidi; O'Donnell, Jake S.; Allen, Stacey; Teng, Michele W. L.] QIMR Berghofer Med Res Inst, Dept Immunol, Canc Immunoregulat & Immunotherapy Lab, Herston, Qld, Australia.
   [Harjunpaa, Heidi; O'Donnell, Jake S.; Teng, Michele W. L.; Smyth, Mark J.] Univ Queensland, Fac Med, Herston, Qld, Australia.
   [Ahern, Elizabeth] Royal Brisbane & Womens Hosp, Div Canc Care Serv, Med Oncol, Herston, Qld, Australia.
   [Dougall, William C.] QIMR Berghofer Med Res Inst, Immunooncol Discovery Lab, Dept Immunol, Herston, Qld, Australia.
C3 QIMR Berghofer Medical Research Institute; QIMR Berghofer Medical
   Research Institute; University of Queensland; Royal Brisbane & Women's
   Hospital; QIMR Berghofer Medical Research Institute
RP Teng, MWL (通讯作者)，QIMR Berghofer Med Res Inst, Canc Immunoregulat & Immunotherapy Lab, 300 Herston Rd, Herston, Qld 4006, Australia.; Smyth, MJ (通讯作者)，QIMR Berghofer Med Res Inst, Immunol Canc & Infect Lab, 300 Herston Rd, Herston, Qld 4006, Australia.
EM Michele.Teng@qimrberghofer.edu.au; Mark.Smyth@qimrberghofer.edu.au
RI Smyth, Mark/H 8709 2014; Teng, Michele/S 5055 2016
OI Dougall, William/0000 0001 9487 251X; Harjunpaa,
   Heidi/0000 0002 1380 9939; O'Donnell, Jake/0000 0003 2960 7992; Ahern,
   Elizabeth Stephanie/0000 0002 2062 5695
FU National Health and Medical Research Council (NH&MRC) Senior Principal
   Research Fellowship [1078671]; Cancer Council of Queensland [1102242];
   University of Queensland (UQ) Australian Postgraduate Award (APA); UQ
   International Postgraduate Research Scholarship; UQ APA; QIMR Berghofer
   Top Up award
FX M.J.S. was supported by a National Health and Medical Research Council
   (NH&MRC) Senior Principal Research Fellowship (1078671) and The Cancer
   Council of Queensland (1102242). E.A. and was supported by a University
   of Queensland (UQ) Australian Postgraduate Award (APA). H.H. was
   supported by a UQ International Postgraduate Research Scholarship, a UQ
   APA, and a QIMR Berghofer Top Up award. J.S.O'D was supported by a UQ
   APA and a QIMR Berghofer Top Up award.
CR Ahern E, 2017, CLIN CANCER RES, V23, P5789, DOI 10.1158/1078 0432.CCR 17 0606
   An G, 2016, BLOOD, V128, P1590, DOI 10.1182/blood 2016 03 707547
   Ansell SM, 2015, NEW ENGL J MED, V372, P311, DOI 10.1056/NEJMoa1411087
   BALEY PA, 1995, J STEROID BIOCHEM, V52, P403, DOI 10.1016/0960 0760(95)00001 G
   Blackburn SD, 2009, NAT IMMUNOL, V10, P29, DOI 10.1038/ni.1679
   Blake SJ, 2016, CANCER DISCOV, V6, P446, DOI 10.1158/2159 8290.CD 15 0944
   Bostwick A Doran, 2015, J Immunother Cancer, V3, P19, DOI 10.1186/s40425 015 0064 2
   Chang JE, 2015, TRENDS IMMUNOL, V36, P30, DOI 10.1016/j.it.2014.11.003
   Chen PL, 2016, CANCER DISCOV, V6, P827, DOI 10.1158/2159 8290.CD 15 1545
   Dougall William C, 2014, Bonekey Rep, V3, P519, DOI 10.1038/bonekey.2014.14
   Fizazi K, 2009, J CLIN ONCOL, V27, P1564, DOI 10.1200/JCO.2008.19.2146
   Foster BA, 1997, CANCER RES, V57, P3325
   Furness AJS, 2014, TRENDS IMMUNOL, V35, P290, DOI 10.1016/j.it.2014.05.002
   GREENBERG NM, 1995, P NATL ACAD SCI USA, V92, P3439, DOI 10.1073/pnas.92.8.3439
   Henry DH, 2011, J CLIN ONCOL, V29, P1125, DOI 10.1200/JCO.2010.31.3304
   Hochweller K, 2005, EUR J IMMUNOL, V35, P1086, DOI 10.1002/eji.200425891
   Hu H, 2014, BREAST CANCER RES TR, V146, P515, DOI 10.1007/s10549 014 3049 9
   Hurwitz Arthur A, 2001, Curr Protoc Immunol, VChapter 20, DOI 10.1002/0471142735.im2005s45
   Johnston RJ, 2014, CANCER CELL, V26, P923, DOI 10.1016/j.ccell.2014.10.018
   Jones DH, 2002, ANN RHEUM DIS, V61, P32, DOI 10.1136/ard.61.suppl_2.ii32
   Kakavand H, 2017, MODERN PATHOL, V30, P1666, DOI 10.1038/modpathol.2017.89
   Kamijo S, 2006, BIOCHEM BIOPH RES CO, V347, P124, DOI 10.1016/j.bbrc.2006.06.098
   Lacey DL, 2012, NAT REV DRUG DISCOV, V11, P401, DOI 10.1038/nrd3705
   Larkin J, 2015, NEW ENGL J MED, V373, P23, DOI [10.1056/NEJMoa1504030, 10.1056/NEJMc1509660]
   Lipton A, 2007, J CLIN ONCOL, V25, P4431, DOI 10.1200/JCO.2007.11.8604
   Messenheimer DJ, 2017, CLIN CANCER RES, V23, P6165, DOI 10.1158/1078 0432.CCR 16 2677
   Mittal D, 2017, CANCER IMMUNOL RES, V5, P1098, DOI 10.1158/2326 6066.CIR 17 0341
   Motzer RJ, 2015, NEW ENGL J MED, V373, P1803, DOI 10.1056/NEJMoa1510665
   Ngiow SF, 2015, CANCER RES, V75, P3800, DOI 10.1158/0008 5472.CAN 15 1082
   O'Donnell JS, 2017, CANCER TREAT REV, V52, P71, DOI 10.1016/j.ctrv.2016.11.007
   Peggs KS, 2009, J EXP MED, V206, P1717, DOI 10.1084/jem.20082492
   Reck M, 2016, NEW ENGL J MED, V375, P1823, DOI 10.1056/NEJMoa1606774
   Robert C, 2015, NEW ENGL J MED, V372, P2521, DOI 10.1056/NEJMoa1503093
   Robert C, 2015, NEW ENGL J MED, V372, P320, DOI 10.1056/NEJMoa1412082
   Scagliotti GV, 2012, J THORAC ONCOL, V7, P1823, DOI 10.1097/JTO.0b013e31826aec2b
   Seiwert TY, 2016, LANCET ONCOL, V17, P956, DOI 10.1016/S1470 2045(16)30066 3
   Selby MJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161779
   Selby MJ, 2013, CANCER IMMUNOL RES, V1, P32, DOI 10.1158/2326 6066.CIR 13 0013
   Sharma P, 1999, ONCOGENE, V18, P5349, DOI 10.1038/sj.onc.1203037
   Simpson TR, 2013, J EXP MED, V210, P1695, DOI 10.1084/jem.20130579
   Smith MR, 2012, LANCET, V379, P39, DOI 10.1016/S0140 6736(11)61226 9
   Smyth MJ, 2016, NAT REV CLIN ONCOL, V13, P143, DOI 10.1038/nrclinonc.2015.209
   Stopeck AT, 2010, J CLIN ONCOL, V28, P5132, DOI 10.1200/JCO.2010.29.7101
   Vilain RE, 2017, CLIN CANCER RES, V23, P5024, DOI 10.1158/1078 0432.CCR 16 0698
   Wang RX, 2002, EUR J IMMUNOL, V32, P1090, DOI 10.1002/1521 4141(200204)32:4<1090::AID IMMU1090>3.3.CO;2 G
   Weber JS, 2015, LANCET ONCOL, V16, P375, DOI 10.1016/S1470 2045(15)70076 8
   Wherry EJ, 2011, NAT IMMUNOL, V12, P492, DOI 10.1038/ni.2035
   Wolchok JD, 2017, NEW ENGL J MED, V377, P1345, DOI 10.1056/NEJMoa1709684
   Wong BR, 1997, J BIOL CHEM, V272, P25190, DOI 10.1074/jbc.272.40.25190
   Young A, 2016, CANCER CELL, V30, P391, DOI 10.1016/j.ccell.2016.06.025
NR 50
TC 76
Z9 84
U1 0
U2 12
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 2162 402X
J9 ONCOIMMUNOLOGY
JI OncoImmunology
PY 2018
VL 7
IS 6
AR e1431088
DI 10.1080/2162402X.2018.1431088
PG 13
WC Oncology; Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Immunology
GA GF8IU
UT WOS:000432214900009
PM 29872559
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Schröder, A
   Alefeld, A
   Forneck, A
   Spanier, G
   Deschner, J
   Proff, P
   Kirschneck, C
AF Schroeder, Agnes
   Alefeld, Annika
   Forneck, Anne
   Spanier, Gerrit
   Deschner, James
   Proff, Peter
   Kirschneck, Christian
TI Impact of melatonin on periodontal ligament fibroblasts during
   mechanical strain
SO EUROPEAN JOURNAL OF ORTHODONTICS
LA English
DT Article
ID PROMOTES OSTEOBLAST DIFFERENTIATION; ORTHODONTIC TOOTH MOVEMENT; HUMAN
   GINGIVAL FIBROBLASTS; MESENCHYMAL STEM CELLS; SIGNAL TRANSDUCTION;
   SALIVARY MELATONIN; COLLAGEN SYNTHESIS; GENE EXPRESSION; HPDL CELLS;
   BONE
AB Background The endogenous hormone melatonin regulates the circadian rhythm and impacts on bone metabolism. As patient compliance to wear removable orthodontic appliances is generally higher at night, when melatonin release is increased, a boosting effect on tooth movement would be favourable for therapy, whereas an inhibiting effect would indicate daytime wear to be more therapy effective. We hypothesize that melatonin has either a stimulating or impeding effect on the expression profile of periodontal ligament fibroblasts (PDLF) during simulated orthodontic compressive and tensile strain, which would suggest either an accelerating or inhibiting impact on orthodontic tooth movement in vivo. Methods PDLF were preincubated with melatonin for 24 h and then subjected to tensile or compressive strain to mimic tension and pressure sides in PDL. In addition, the selective melatonin MTNR1B receptor antagonist 4P PDOT was used. We investigated melatonin effects on collagen synthesis, expression of inflammatory and bone remodelling genes/proteins by quantitative real time polymerase chain reaction, enzyme linked immunosorbent assays, and total collagen assays. PDLF induced osteoclastogenesis was analysed in a coculture model by tartrate resistant acid phosphatise (TRAP) staining. Results Expression of melatonin receptors in PDLF was not affected by compressive strain. Melatonin increased expression of inflammatory factors and elevated collagen synthesis during mechanical strain. Melatonin showed no effects on OPG or RANKL expression without mechanical strain, but increased RANKL gene expression during compression. Conclusions Expression of melatonin receptors by PDLF enable them to detect fluctuating melatonin concentrations in the periodontal ligament. Melatonin increased collagen synthesis and expression of inflammatory mediators, but had no effect on genes involved in bone remodelling. Therefore, we suggest that melatonin has no accelerating effect on PDLF induced osteoclastogenesis.
C1 [Schroeder, Agnes; Alefeld, Annika; Forneck, Anne; Proff, Peter; Kirschneck, Christian] Univ Med Ctr Regensburg, Dept Orthodont, Franz Josef Strauss Allee 11, D 93503 Regensburg, Germany.
   [Spanier, Gerrit] Univ Med Ctr Regensburg, Dept Maxillo Facial Surg, Regensburg, Germany.
   [Deschner, James] Johannes Gutenberg Univ Mainz, Dept Periodontol & Operat Dent, Univ Med Ctr, Mainz, Germany.
C3 University of Regensburg; University of Regensburg; Johannes Gutenberg
   University of Mainz
RP Schröder, A (通讯作者)，Univ Med Ctr Regensburg, Dept Orthodont, Franz Josef Strauss Allee 11, D 93503 Regensburg, Germany.
EM agnes.schroeder@ukr.de
RI Schröder, Agnes/AHC 9286 2022; Kirschneck, Christian/MSZ 9098 2025
OI Kirschneck, Christian/0000 0001 9473 8724
FU Society for the Promotion of Scientific Dentistry in Bavaria VFwZ Bayern
   e.V.
FX This study was supported by a grant from the Society for the Promotion
   of Scientific Dentistry in Bavaria VFwZ Bayern e.V. (Kirschneck
   06 23 2020).
CR Alhashimi N, 2001, AM J ORTHOD DENTOFAC, V119, P307, DOI 10.1067/mod.2001.110809
   Almughrabi OM, 2013, J PERIODONTAL RES, V48, P315, DOI 10.1111/jre.12010
   Bumann A, 1997, EUR J ORTHODONT, V19, P29, DOI 10.1093/ejo/19.1.29
   Chang YC, 2002, J PERIODONTAL RES, V37, P196, DOI 10.1034/j.1600 0765.2002.00663.x
   Coste B, 2012, NATURE, V483, P176, DOI 10.1038/nature10812
   Coste B, 2010, SCIENCE, V330, P55, DOI 10.1126/science.1193270
   Cutando A, 2006, J PERIODONTOL, V77, P1533, DOI 10.1902/jop.2006.050287
   Drobnik J, 2013, PHARMACOL REP, V65, P642, DOI 10.1016/S1734 1140(13)71041 7
   Dubocovich ML, 1997, N S ARCH PHARMACOL, V355, P365, DOI 10.1007/PL00004956
   Feldens CA, 2015, ANGLE ORTHOD, V85, P1027, DOI 10.2319/100914 722.1
   Gaikwad Shashank S, 2014, J Int Oral Health, V6, P27
   Garcia RI, 2001, PERIODONTOL 2000, V25, P21, DOI 10.1034/j.1600 0757.2001.22250103.x
   Gilad E, 1998, FASEB J, V12, P685, DOI 10.1096/fasebj.12.9.685
   Gómez Florit M, 2013, BIOCHEM PHARMACOL, V86, P1784, DOI 10.1016/j.bcp.2013.10.009
   Gomez Moreno G, 2007, J PERIODONTAL RES, V42, P536, DOI 10.1111/j.1600 0765.2007.00978.x
   HAMM HE, 1980, P NATL ACAD SCI BIOL, V77, P4998, DOI 10.1073/pnas.77.8.4998
   He YL, 2004, CONNECT TISSUE RES, V45, P28, DOI 10.1080/03008200490278124
   Hormdee D, 2005, CLIN EXP IMMUNOL, V142, P490, DOI 10.1111/j.1365 2249.2005.02937.x
   Itoh MT, 2007, J PINEAL RES, V42, P92, DOI 10.1111/j.1600 079X.2006.00389.x
   Itoh MT, 1999, MOL HUM REPROD, V5, P402, DOI 10.1093/molehr/5.5.402
   Kanzaki H, 2002, J BONE MINER RES, V17, P210, DOI 10.1359/jbmr.2002.17.2.210
   Kara A, 2013, FREE RADICAL BIO MED, V55, P21, DOI 10.1016/j.freeradbiomed.2012.11.002
   Kirschneck C, 2019, MEDIAT INFLAMM, V2019, DOI 10.1155/2019/2514956
   Kirschneck C, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 15281 0
   KLEIN DC, 1970, ENDOCRINOLOGY, V86, P1436, DOI 10.1210/endo 86 6 1436
   Konecná B, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22052390
   Koyama H, 2002, J BONE MINER RES, V17, P1219, DOI 10.1359/jbmr.2002.17.7.1219
   Krishnan V., 2015, Biological mechanisms of tooth movement
   KURIHARA N, 1990, J IMMUNOL, V144, P4226
   Lekic P, 1996, ANAT REC, V245, P327
   LERNER AB, 1958, J AM CHEM SOC, V80, P2587, DOI 10.1021/ja01543a060
   Liu J, 2013, INT J MOL SCI, V14, P10063, DOI 10.3390/ijms140510063
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lombardo G, 2020, EUR J PAEDIATR DENT, V21, P115, DOI 10.23804/ejpd.2020.21.02.05
   López Martínez F, 2012, INT J DENT, V2012, DOI 10.1155/2012/628406
   MacKenzie RS, 2002, BIOCHEM PHARMACOL, V63, P587, DOI 10.1016/S0006 2952(01)00881 4
   Massova I, 1998, FASEB J, V12, P1075, DOI 10.1096/fasebj.12.12.1075
   McArthur AJ, 1997, ENDOCRINOLOGY, V138, P627, DOI 10.1210/en.138.2.627
   MCNULTY S, 1994, J NEUROENDOCRINOL, V6, P523, DOI 10.1111/j.1365 2826.1994.tb00615.x
   Meikle MC, 2006, EUR J ORTHODONT, V28, P221, DOI 10.1093/ejo/cj1001
   MILES A, 1985, CLIN CHEM, V31, P2041
   Mirhashemi Amir Hossein, 2016, J Dent (Tehran), V13, P388
   Nakade O, 1999, J PINEAL RES, V27, P106, DOI 10.1111/j.1600 079X.1999.tb00603.x
   Nazet U, 2020, EUR J ORTHODONT, V42, P359, DOI 10.1093/ejo/cjz052
   Nikmanesh M, 2019, BIOTECHNOL BIOENG, V116, P2730, DOI 10.1002/bit.27104
   Nonaka S, 2013, CELL MOL NEUROBIOL, V33, P885, DOI 10.1007/s10571 013 9953 4
   Okada N, 1997, J PERIODONTAL RES, V32, P559, DOI 10.1111/j.1600 0765.1997.tb00932.x
   Ostrowska Z, 2003, Endocr Regul, V37, P211
   Petit L, 1999, BIOCHEM PHARMACOL, V58, P633, DOI 10.1016/S0006 2952(99)00134 3
   Pihlstrom BL, 2005, LANCET, V366, P1809, DOI 10.1016/S0140 6736(05)67728 8
   Radio NM, 2006, J PINEAL RES, V40, P332, DOI 10.1111/j.1600 079X.2006.00318.x
   REDMAN J, 1983, SCIENCE, V219, P1089, DOI 10.1126/science.6823571
   REPPERT SM, 1995, NEURON, V15, P1003, DOI 10.1016/0896 6273(95)90090 X
   REPPERT SM, 1995, P NATL ACAD SCI USA, V92, P8734, DOI 10.1073/pnas.92.19.8734
   REPPERT SM, 1994, NEURON, V13, P1177, DOI 10.1016/0896 6273(94)90055 8
   Roth JA, 1999, J BIOL CHEM, V274, P22041, DOI 10.1074/jbc.274.31.22041
   Satomura K, 2007, J PINEAL RES, V42, P231, DOI 10.1111/j.1600 079X.2006.00410.x
   Schröder A, 2020, J OROFAC ORTHOP, V81, P360, DOI 10.1007/s00056 020 00232 8
   Schröder A, 2018, J OROFAC ORTHOP, V79, P337, DOI 10.1007/s00056 018 0145 1
   Sethi S, 2010, J PINEAL RES, V49, P222, DOI 10.1111/j.1600 079X.2010.00784.x
   Shimizu N, 1998, J PERIODONTOL, V69, P670, DOI 10.1902/jop.1998.69.6.670
   Shimozuma M, 2011, HISTOCHEM CELL BIOL, V135, P389, DOI 10.1007/s00418 011 0800 8
   SOMJEN D, 1980, BIOCHIM BIOPHYS ACTA, V627, P91, DOI 10.1016/0304 4165(80)90126 9
   Son JH, 2014, J PINEAL RES, V57, P385, DOI 10.1111/jpi.12177
   Srinath R, 2010, J PERIODONTOL, V81, P277, DOI 10.1902/jop.2009.090327
   Staufer Kirsten, 2004, J Orofac Orthop, V65, P13, DOI 10.1007/s00056 004 0207 4
   Stefulj J, 2001, J PINEAL RES, V30, P243, DOI 10.1034/j.1600 079X.2001.300408.x
   Tachibana R, 2014, INT J MOL SCI, V15, P17304, DOI 10.3390/ijms151017304
   Takahashi I, 2003, J DENT RES, V82, P646, DOI 10.1177/154405910308200815
   Tsubota M, 2002, J DENT RES, V81, P673, DOI 10.1177/154405910208101004
   VAKKURI O, 1985, ACTA PHYSIOL SCAND, V124, P409, DOI 10.1111/j.1748 1716.1985.tb07676.x
   Wolf M, 2016, INNATE IMMUN LONDON, V22, P674, DOI 10.1177/1753425916669417
   Wolf M, 2016, CLIN ORAL INVEST, V20, P923, DOI 10.1007/s00784 015 1580 7
   Yi WJ, 2017, INT IMMUNOPHARMACOL, V48, P146, DOI 10.1016/j.intimp.2017.05.006
NR 74
TC 7
Z9 7
U1 1
U2 18
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0141 5387
EI 1460 2210
J9 EUR J ORTHODONT
JI Eur. J. Orthodont.
PD DEC 1
PY 2022
VL 44
IS 6
BP 659
EP 668
DI 10.1093/ejo/cjac013
EA APR 2022
PG 10
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA 6S5ML
UT WOS:000784524800001
PM 35396993
DA 2025 08 17
ER

PT J
AU Panayi, GS
   Corrigall, VM
AF Panayi, Gabriel S.
   Corrigall, Valerie M.
TI Immunoglobulin heavy chain binding protein (BiP): a stress protein that
   has the potential to be a novel therapy for rheumatoid arthritis
SO BIOCHEMICAL SOCIETY TRANSACTIONS
LA English
DT Article
DE animal model; immunoglobulin heavy chain binding protein (BiP);
   inflammation; moonlighting protein; rheumatoid arthritis; stress
   protein; therapy
ID T CELLS; CHAPERONE; RECEPTOR; PATHOGENESIS; GRP78/BIP; SYNOVITIS;
   MEMBRANE; CYTOKINE; EFFICACY; ANTIBODY
AB Immunoglobulin heavy chain binding protein (BiP) or glucose regulated protein 78 (Grp78) is a vital ubiquitous resident of the endoplasmic reticulum (ER). As an intracellular chaperone, BiP correctly folds nascent polypeptides within the ER and regulates the unfolded protein response ensuring protection of the cell from denatured protein and reinforcing its anti apoptotic role, when the cell is under stress. Additionally, BiP is a member of the heat shock protein (HSP) 70 family and, as a stress protein, is up regulated by conditions of reduced oxygen and glucose. Cell stress induces surface expression and secretion of BiP. Consequently, BiP is detectable in several bodily fluids including serum, synovial fluid (SF) and oviductal fluid. However, as an extracellular protein, BiP has additional properties that are quite distinct from the intracellular functions. Extracellular BiP is immunoregulatory and anti inflammatory causing development of tolerogenic dendritic cells (DCs), induction of regulatory T cells, abrogation of osteoclast development and function, induction of anti inflammatory cytokine production, including interleukin (IL) 10, IL 1 receptor antagonist and soluble tumour necrosis factor (TNF) receptor type II, and attenuation of TNF alpha and IL 6. Together, these functions help drive the resolution of inflammation. Disease models of inflammatory arthritis have helped to demonstrate the novel mode of action of BiP in which the pharmacokinetics and pharmacodynamics are dissociated. The three murine models to be discussed each show BiP induced long term therapeutic protection and therefore has potential for long lasting drug free therapy in rheumatoid arthritis (RA).
C1 [Panayi, Gabriel S.; Corrigall, Valerie M.] Kings Coll London, Sch Med, Acad Dept Rheumatol, London SE1 1UL, England.
C3 University of London; King's College London
RP Corrigall, VM (通讯作者)，Kings Coll London, Sch Med, Acad Dept Rheumatol, London SE1 1UL, England.
EM valerie.corrigall@kcl.ac.uk
CR Asea A, 2002, J BIOL CHEM, V277, P15028, DOI 10.1074/jbc.M200497200
   Asea A, 2000, NAT MED, V6, P435, DOI 10.1038/74697
   Askling J, 2009, ARTHRITIS RHEUM US, V60, P3180, DOI 10.1002/art.24941
   Bodman Smith MD, 2004, RHEUMATOLOGY, V43, P1283, DOI 10.1093/rheumatology/keh312
   Brownlie RJ, 2006, ARTHRITIS RHEUM US, V54, P854, DOI 10.1002/art.21654
   Cope AP, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2412
   Copley SD, 2012, BIOESSAYS, V34, P578, DOI 10.1002/bies.201100191
   Corrigall VM, 2004, ARTHRITIS RHEUM US, V50, P1164, DOI 10.1002/art.20134
   Corrigall VM, 2001, J IMMUNOL, V166, P1492, DOI 10.4049/jimmunol.166.3.1492
   Corrigall VM, 2002, CRIT REV IMMUNOL, V22, P281
   Delpino A, 2002, BIOSCIENCE REP, V22, P407, DOI 10.1023/A:1020966008615
   Gething MJ, 1999, SEMIN CELL DEV BIOL, V10, P465, DOI 10.1006/scdb.1999.0318
   Habich C, 2002, J IMMUNOL, V168, P569, DOI 10.4049/jimmunol.168.2.569
   Lorenzetti R., 2014, ANN MED, V8, P1, DOI DOI 10.3109/07853890.2014.941919
   Marín Briggiler CI, 2010, FERTIL STERIL, V93, P1574, DOI 10.1016/j.fertnstert.2008.12.132
   Matsuno H, 2002, RHEUMATOLOGY, V41, P329, DOI 10.1093/rheumatology/41.3.329
   Matsuno H, 1998, ARTHRITIS RHEUM, V41, P2014, DOI 10.1002/1529 0131(199811)41:11<2014::AID ART17>3.0.CO;2 T
   Nam JL, 2014, ANN RHEUM DIS, V73, P516, DOI 10.1136/annrheumdis 2013 204577
   Panayi GS, 2001, RHEUM DIS CLIN N AM, V27, P317, DOI 10.1016/S0889 857X(05)70204 0
   RICHMAN AI, 1981, ARTHRITIS RHEUM US, V24, P701, DOI 10.1002/art.1780240512
   Shields AM, 2011, CLIN EXP IMMUNOL, V165, P292, DOI 10.1111/j.1365 2249.2011.04433.x
   Shields AM, 2012, RHEUMATOLOGY, V51, P780, DOI 10.1093/rheumatology/ker412
   Timlin H, 2014, EXPERT OPIN BIOL TH, V14, P893, DOI 10.1517/14712598.2014.900536
   Yoo SA, 2012, J EXP MED, V209, P871, DOI 10.1084/jem.20111783
   Yoshida K, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3463
   Zaiss M, 2010, ANN RHEUM DIS, V69, DOI 10.1136/ard.2010.129593o
NR 26
TC 34
Z9 45
U1 0
U2 13
PU PORTLAND PRESS LTD
PI LONDON
PA 5TH FLR, 90 HIGH HOLBORN, LONDON WC1V 6LJ, ENGLAND
SN 0300 5127
EI 1470 8752
J9 BIOCHEM SOC T
JI Biochem. Soc. Trans.
PD DEC
PY 2014
VL 42
BP 1752
EP 1755
DI 10.1042/BST20140230
PN 6
PG 4
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA AU2DT
UT WOS:000345427100045
PM 25399601
DA 2025 08 17
ER

PT J
AU Chang, YC
   Li, JL
   Mirhaidari, G
   Zbinden, J
   Barker, J
   Blum, K
   Reinhardt, J
   Best, C
   Kelly, J
   Shoji, T
   Yi, T
   Breuer, C
AF Chang, Yu Chun
   Li, Junlang
   Mirhaidari, Gabriel
   Zbinden, Jacob
   Barker, Jenny
   Blum, Kevin
   Reinhardt, James
   Best, Cameron
   Kelly, John
   Shoji, Toshihiro
   Yi, Tai
   Breuer, Christopher
TI Zoledronate alters natural progression of tissue engineered vascular
   grafts
SO FASEB JOURNAL
LA English
DT Article
DE bisphosphonates; inflammation; macrophages; neovessel; stenosis
ID BLOOD VESSELS; IN VITRO; BISPHOSPHONATES; MACROPHAGES; COLLAGEN; ACID;
   COMPLICATIONS; ACCUMULATION; APOPTOSIS; DISEASE
AB Macrophages are a critical driver of neovessel formation in tissue engineered vascular grafts (TEVGs), but also contribute to graft stenosis, a leading clinical trial complication. Macrophage depletion via liposomal delivery of clodronate, a first generation bisphosphonate, mitigates stenosis, but simultaneously leads to a complete lack of tissue development in TEVGs. This result and the associated difficulty of utilizing liposomal delivery means that clodronate may not be an ideal means of preventing graft stenosis. Newer generation bisphosphonates, such as zoledronate, may have differential effects on graft development with more facile drug delivery. We sought to examine the effect of zoledronate on TEVG neotissue formation and its potential application for mitigating TEVG stenosis. Thus, mice implanted with TEVGs received zoledronate or no treatment and were monitored by serial ultrasound for graft dilation and stenosis. After two weeks, TEVGs were explanted for histological examination. The overall graft area and remaining graft material (polyglycolic acid) were higher in the zoledronate treatment group. These effects were associated with a corresponding decrease in macrophage infiltration. In addition, zoledronate affected the deposition of collagen in TEVGs, specifically, total and mature collagen. These differences may be, in part, explained by a depletion of leukocytes within the bone marrow that subsequently led to a decrease in the number of tissue infiltrating macrophages. TEVGs from zoledronate treated mice demonstrated a significantly greater degree of smooth muscle cell presence. There was no statistical difference in graft patency between treatment and control groups. While zoledronate led to a decrease in the number of macrophages in the TEVGs, the severity of stenosis appears to have increased significantly. Zoledronate treatment demonstrates that the process of smooth muscle cell mediated neointimal hyperplasia may occur separately from a macrophage mediated mechanism.
C1 [Chang, Yu Chun; Li, Junlang; Mirhaidari, Gabriel; Zbinden, Jacob; Barker, Jenny; Blum, Kevin; Reinhardt, James; Best, Cameron; Kelly, John; Shoji, Toshihiro; Yi, Tai; Breuer, Christopher] Nationwide Childrens Hosp, Ctr Regenerat Med, Abigail Wexner Res Inst, Columbus, OH 43205 USA.
   [Chang, Yu Chun; Mirhaidari, Gabriel; Best, Cameron] Ohio State Univ, Coll Med, Biomed Sci Grad Program, Columbus, OH 43210 USA.
   [Zbinden, Jacob; Blum, Kevin] Ohio State Univ, Dept Biomed Engn, Coll Engn, Columbus, OH 43210 USA.
   [Barker, Jenny] Ohio State Univ, Dept Plast & Reconstruct Surg, Med Ctr, Columbus, OH 43210 USA.
C3 University System of Ohio; Ohio State University; Nationwide Childrens
   Hospital; University System of Ohio; Ohio State University; University
   System of Ohio; Ohio State University; University System of Ohio; Ohio
   State University
RP Chang, YC (通讯作者)，Nationwide Childrens Hosp, Ctr Regenerat Med, Res Inst, 700 Childrens Dr, Columbus, OH 43205 USA.
EM yu chun.chang@nationwidechildrens.org
RI Breuer, Christoph/F 4482 2011; Li, Junlang/GSO 0056 2022; Barker,
   Jenny/KYR 0129 2024; Reinhardt, James/JXY 0154 2024
OI Best, Cameron/0000 0001 7426 0137; Reinhardt, James/0000 0001 8406 8421
FU HHS \ National Institutes of Health (NIH) [R01HL098228, 5T32AI106704 04,
   T32HL098039 06A1, F31HL1145962, T32HL098039]; American Heart Association
   (AHA) [18POST33990231]; Pharmaceutical Research and Manufacturers of
   America Foundation (PhRMA Foundation); National Institute of Allergy and
   Infectious Diseases [T32AI106704] Funding Source: NIH RePORTER
FX HHS vertical bar National Institutes of Health (NIH), Grant/Award
   Number: R01HL098228, 5T32AI106704 04, T32HL098039 06A1, F31HL1145962 and
   T32HL098039; American Heart Association (AHA), Grant/Award Number:
   18POST33990231; Pharmaceutical Research and Manufacturers of America
   Foundation (PhRMA Foundation)
CR Allen MR, 2008, OSTEOPOROSIS INT, V19, P329, DOI 10.1007/s00198 007 0533 7
   Benavidez OJ, 2007, ANN THORAC SURG, V84, P147, DOI 10.1016/j.athoracsur.2007.02.048
   Best C, 2017, ACS BIOMATER SCI ENG, V3, P1972, DOI 10.1021/acsbiomaterials.6b00123
   Best CA, 2019, ACTA BIOMATER, V94, P183, DOI 10.1016/j.actbio.2019.05.063
   Camilleri JP., 2008, CLIN EXP IMMUNOL, V99, p269, DOI [10.1111/j.1365 2249.1995.tb05544.x, DOI 10.1111/J.1365]
   Cheung YF, 2005, INT J CARDIOL, V102, P509, DOI 10.1016/j.ijcard.2004.05.051
   Ferretti G, 2005, ONCOLOGY BASEL, V69, P35, DOI 10.1159/000087286
   Fournier P, 2002, CANCER RES, V62, P6538
   Fowler DW, 2017, CANCER IMMUNOL IMMUN, V66, P1205, DOI 10.1007/s00262 017 2011 1
   Garnero P, 2001, BONE, V28, P461, DOI 10.1016/S8756 3282(01)00431 8
   Gilboa SM, 2010, CIRCULATION, V122, P2254, DOI 10.1161/CIRCULATIONAHA.110.947002
   Hibino N, 2015, FASEB J, V29, P2431, DOI 10.1096/fj.14 268334
   Hibino N, 2011, FASEB J, V25, P4253, DOI 10.1096/fj.11 186585
   Iguchi T, 2007, INT J ONCOL, V31, P285
   Lawson MA, 2010, J BIOMED MATER RES B, V92B, P149, DOI 10.1002/jbm.b.31500
   Lee YU, 2014, JOVE J VIS EXP, DOI 10.3791/51632
   Liu RH, 2018, TISSUE ENG PART B RE, V24, P133, DOI [10.1089/ten.TEB.2017.0350, 10.1089/ten.teb.2017.0350]
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Morais JM, 2010, AAPS J, V12, P188, DOI 10.1208/s12248 010 9175 3
   Moreau MF, 2007, BIOCHEM PHARMACOL, V73, P718, DOI 10.1016/j.bcp.2006.09.031
   Moschetta M, 2010, EUR J CANCER, V46, P420, DOI 10.1016/j.ejca.2009.10.019
   Naito Y, 2014, ANAT REC, V297, P83, DOI 10.1002/ar.22838
   Opperman KS, 2019, NEOPLASIA, V21, P777, DOI 10.1016/j.neo.2019.05.006
   Puljula E, 2015, ACS MED CHEM LETT, V6, P397, DOI 10.1021/ml5004603
   Rogers TL, 2013, CELL ONCOL, V36, P505, DOI 10.1007/s13402 013 0156 2
   Roh JD, 2008, BIOMATERIALS, V29, P1454, DOI 10.1016/j.biomaterials.2007.11.041
   Roh JD, 2010, P NATL ACAD SCI USA, V107, P4669, DOI 10.1073/pnas.0911465107
   Russell RGG, 2011, BONE, V49, P2, DOI 10.1016/j.bone.2011.04.022
   Sabatino R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101260
   Sercombe L, 2015, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00286
   Shinoka Toshiharu, 2008, Yale Journal of Biology and Medicine, V81, P161
   Sugiura T, 2018, SEMIN THORAC CARDIOV, V30, P175, DOI 10.1053/j.semtcvs.2018.02.002
   Thompson RW, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000023
   Triedman JK, 2016, CIRCULATION, V133, P2716, DOI 10.1161/CIRCULATIONAHA.116.023544
   Wehrhan F, 2017, J CRANIO MAXILL SURG, V45, P944, DOI 10.1016/j.jcms.2017.02.023
   WHITTAKER P, 1994, BASIC RES CARDIOL, V89, P397, DOI 10.1007/BF00788278
   Wood J, 2002, J PHARMACOL EXP THER, V302, P1055, DOI 10.1124/jpet.102.035295
   Wu L, 2011, EUR J VASC ENDOVASC, V41, P288, DOI 10.1016/j.ejvs.2010.07.028
   Wu L, 2009, EUR J PHARMACOL, V602, P124, DOI 10.1016/j.ejphar.2008.10.043
   Wynn TA, 2016, IMMUNITY, V44, P450, DOI 10.1016/j.immuni.2016.02.015
   Ylitalo R, 1996, J LAB CLIN MED, V127, P200, DOI 10.1016/S0022 2143(96)90079 7
   Ylitalo R, 1998, PHARMACOL TOXICOL, V83, P125, DOI 10.1111/j.1600 0773.1998.tb01455.x
NR 42
TC 4
Z9 4
U1 0
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0892 6638
EI 1530 6860
J9 FASEB J
JI Faseb J.
PD OCT
PY 2021
VL 35
IS 10
AR e21849
DI 10.1096/fj.202001606RR
PG 11
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine   Other
   Topics; Cell Biology
GA UZ5IH
UT WOS:000702238200003
PM 34473380
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Ma, C
   Gao, J
   Liang, J
   Dai, WX
   Wang, ZF
   Xia, MJ
   Chen, T
   Huang, S
   Na, J
   Xu, L
   Feng, SM
   Dai, KR
   Liu, GW
AF Ma, Chao
   Gao, Juan
   Liang, Jun
   Dai, Weixiang
   Wang, Zhenfei
   Xia, Mengjiao
   Chen, Tao
   Huang, Sen
   Na, Jian
   Xu, Long
   Feng, Shiming
   Dai, Kerong
   Liu, Guangwang
TI HDAC6 inactivates Runx2 promoter to block osteogenesis of bone marrow
   stromal cells in age related bone loss of mice
SO STEM CELL RESEARCH & THERAPY
LA English
DT Article
DE Aging; Osteoporosis; Bone marrow stromal cells; Runx2; Histone
   deacetylases 6; Androgen receptor
ID OSTEOBLAST DIFFERENTIATION; HISTONE DEACETYLASES; STEM CELLS;
   ACETYLATION; DOMAIN; CBFA1; GENE
AB Background Senile osteoporosis can cause bone fragility and increased risk for fractures and has been one of the most prevalent and severe diseases affecting the elderly population worldwidely. The underlying mechanisms are currently intensive areas of investigation. In age related bone loss, decreased bone formation overweighs increased bone resorption. The molecular mechanisms underlying defective bone formation in age related bone loss are not completely understood. In particular, the specific role of histone acetylation in age related bone loss has not been examined thoroughly. Methods We employed 6  and 18 month old mice to investigate the mechanisms of defective bone formation in age related bone loss. Bone marrow stromal cells (BMSCs) were induced to undergo in vitro osteogenic differentiation. Chromatin immunoprecipitation (ChIP) was used to investigate the binding of histone deacetylases (HDACs) on Runx2 promoter in BMSCs. Luciferase reporter and transient transfection assay were employed to study Runx2 gene expression modulation by HDAC and androgen receptor (AR). siRNA and HDAC6 inhibitor, Tubastatin A, were used to inhibit HDAC6 in vitro. And systemic administration of Tubastatin A was used to block HDAC6 in vivo. Results Age related trabecular bone loss was observed in 18 month old mice compared with 6 month old mice. In vitro osteogenic differentiation potential of BMSCs from 18 month old mice was weaker than 6 month old mice, in which there was Runx2 expression inactivation in BMSCs of 18 month old mice compared with 6 month old mice, which was attributable to HDAC6 mediated histone hypoacetylation in Runx2 promoter. There was competitive binding of HDAC6 and AR on Runx2 promoter to modulate Runx2 expression in BMSCs. More importantly, through siRNA  or specific inhibitor mediated HDAC6 inhibition, we could activate Runx2 expression, rescue in vitro osteogenesis potential of BMSCs, and alleviate in vivo age related bone loss of mice. Conclusion HDAC6 accumulation and histone hypoacetylation on Runx2 promoter contributed to the attenuation of in vitro osteogenic differentiation potential of BMSCs from aged mice. Through HDAC6 inhibition, we could activate Runx2 expression and osteogenic differentiation potential of BMSCs from aged mice and alleviate the age related bone loss of aged mice. Our study will benefit not only for understanding the age related bone loss, but also for finding new therapies to treat senile osteoporosis.
C1 [Ma, Chao; Dai, Weixiang; Wang, Zhenfei; Xia, Mengjiao; Chen, Tao; Huang, Sen; Na, Jian; Xu, Long; Feng, Shiming; Liu, Guangwang] Xuzhou Med Univ, Dept Orthoped Surg, Xuzhou Cent Hosp,Xuzhou Clin Med Coll,Nanjing Uni, Affiliated XuZhou Hosp,Med Coll,Southeast Univ,Xu, Xuzhou 221009, Jiangsu, Peoples R China.
   [Gao, Juan] Xuzhou Med Univ, Dept Gynaecol & Obstet, Xuzhou Cent Hosp,Xuzhou Clin Med Coll,Nanjing Uni, Affiliated XuZhou Hosp,Med Coll,Southeast Univ,Xu, Xuzhou 221009, Jiangsu, Peoples R China.
   [Liang, Jun] Xuzhou Med Univ, Dept Endocrinol, Xuzhou Cent Hosp,Xuzhou Clin Med Coll,Nanjing Uni, Affiliated XuZhou Hosp,Med Coll,Southeast Univ,Xu, Xuzhou 221009, Jiangsu, Peoples R China.
   [Dai, Kerong] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Dept Orthopaed Surg, Shanghai Key Lab Orthopaed Implants,Sch Med, Shanghai 200011, Peoples R China.
C3 Southeast University   China; Xuzhou Medical University; Southeast
   University   China; Xuzhou Medical University; Xuzhou Medical
   University; Southeast University   China; Shanghai Jiao Tong University
RP Liu, GW (通讯作者)，Xuzhou Med Univ, Dept Orthoped Surg, Xuzhou Cent Hosp,Xuzhou Clin Med Coll,Nanjing Uni, Affiliated XuZhou Hosp,Med Coll,Southeast Univ,Xu, Xuzhou 221009, Jiangsu, Peoples R China.
EM guangwangliu@163.com
RI gao, juan/GXV 1381 2022
FU Project of Health Innovation Teams of Xuzhou [XWCX201601, 2019TD002];
   Xuzhou Medical Foundation for Youth Reserved Experts Fund [2014006];
   Jiangsu Provincial Medical Youth Talent [QNRC2016392]; Jiangsu Health
   Commission of Health [H201673, ZDRCC2016022]; Six one Project for
   High level Health Talents in Jiangsu Province [LGY2018047]; Six Talent
   Peaks Project in Jiangsu Province [2019 WSW 173]
FX This study was supported by the Project of Health Innovation Teams of
   Xuzhou (XWCX201601), Xuzhou Plan of introducing a team of clinical
   medical experts (2019TD002), Xuzhou Medical Foundation for Youth
   Reserved Experts Fund (2014006), Jiangsu Provincial Medical Youth Talent
   (QNRC2016392), Jiangsu Health Commission of Health (H201673 and
   ZDRCC2016022), Six one Project for High level Health Talents in Jiangsu
   Province (LGY2018047) and Six Talent Peaks Project in Jiangsu Province
   (2019 WSW 173).
CR Bellantuono I, 2009, BBA MOL BASIS DIS, V1792, P364, DOI 10.1016/j.bbadis.2009.01.008
   Bertos NR, 2001, BIOCHEM CELL BIOL, V79, P243, DOI 10.1139/bcb 79 3 243
   Boeger H, 2003, MOL CELL, V11, P1587, DOI 10.1016/S1097 2765(03)00231 4
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321
   Destaing O, 2005, J CELL SCI, V118, P2901, DOI 10.1242/jcs.02425
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Ehnert S, 2012, BMC MED, V10, DOI 10.1186/1741 7015 10 101
   Ferguson VL, 2003, BONE, V33, P387, DOI 10.1016/S8756 3282(03)00199 6
   FRIEDENSTEIN AJ, 1978, EXP HEMATOL, V6, P440
   Frith J, 2008, TRANSFUS MED HEMOTH, V35, P216, DOI [10.1159/000127448, 000127448]
   Frost H. M., 2001, Journal of Musculoskeletal & Neuronal Interactions, V2, P121
   Hubbert C, 2002, NATURE, V417, P455, DOI 10.1038/417455a
   Jacobs SA, 2001, EMBO J, V20, P5232, DOI 10.1093/emboj/20.18.5232
   Kimura A, 2005, J BIOCHEM, V138, P647, DOI 10.1093/jb/mvi184
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Kurdistani SK, 2003, NAT REV MOL CELL BIO, V4, P276, DOI 10.1038/nrm1075
   Lee HW, 2006, MOL ENDOCRINOL, V20, P2432, DOI 10.1210/me.2006 0061
   Liu T, 2015, INT J MOL MED, V35, P238, DOI 10.3892/ijmm.2014.2004
   Maroni P, 2012, BIOCHEM BIOPH RES CO, V428, P271, DOI 10.1016/j.bbrc.2012.10.044
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092 8674(00)80259 7
   Santo L, 2012, BLOOD, V119, P2579, DOI 10.1182/blood 2011 10 387365
   Schroeder TM, 2005, J BONE MINER RES, V20, P2254, DOI 10.1359/JBMR.050813
   Schroeder TM, 2004, J BIOL CHEM, V279, P41998, DOI 10.1074/jbc.M403702200
   Shogren Knaak M, 2006, SCIENCE, V311, P844, DOI 10.1126/science.1124000
   Wang Y, 2018, BMC ORAL HEALTH, V18, DOI 10.1186/s12903 018 0624 1
   Watanabe Ken, 2005, Molecular Aspects of Medicine, V26, P221, DOI 10.1016/j.mam.2005.01.006
   Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799
   Wysocka J, 2005, CELL, V121, P859, DOI 10.1016/j.cell.2005.03.036
   Xu F, 2005, CELL, V121, P375, DOI 10.1016/j.cell.2005.03.011
   Zhang W, 2008, J BONE MINER RES, V23, P1118, DOI [10.1359/jbmr.080304, 10.1359/JBMR.080304]
NR 32
TC 31
Z9 38
U1 0
U2 19
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1757 6512
J9 STEM CELL RES THER
JI Stem Cell Res. Ther.
PD AUG 28
PY 2021
VL 12
IS 1
AR 484
DI 10.1186/s13287 021 02545 w
PG 14
WC Cell & Tissue Engineering; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA UI9RF
UT WOS:000690933800002
PM 34454588
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Liu, S
   Kiyoi, T
   Takemasa, E
   Maeyama, K
AF Liu, Shuang
   Kiyoi, Takeshi
   Takemasa, Erika
   Maeyama, Kazutaka
TI Systemic Lentivirus Mediated Delivery of Short Hairpin RNA Targeting
   Calcium Release Activated Calcium Channel 3 as Gene Therapy for
   Collagen Induced Arthritis
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID OPERATED CA2+ ENTRY; ORAI1; OSTEOCLAST; CRAC; DIFFERENTIATION;
   INHIBITION; AUTOIMMUNE; INFLUX; CELLS
AB Immune cells, including T cells, B cells, and osteoclasts, in conjunction with their associated cytokines, have been studied as primary molecular therapeutic targets for the management of rheumatoid arthritis (RA) patients. The increase in cytosolic Ca2+ levels through the activation of store operated Ca2+ release activated channels (CRACs) is involved in mediating a disparate array of cellular responses by these immune cells. This study was undertaken to investigate the feasibility and efficiency of the regulation of Ca2+ entry in the treatment of RA. To moderately suppress Ca2+ entry via CRACs, we gene silenced CRACM3,which was induced by systemic application of specific short hairpin RNAs (shRNAs) using a lentiviral delivery system, in a murine model of collagen induced arthritis (CIA). The inflammatory responses were determined by measuring the levels of a panel of cytokines and chemokines in the joints and serum. Ag specific responses were evaluated by determining the cytokine profile of T cells stimulated with autoantigen. We also analyzed the ability of specific CRACM3 shRNA to regulate mature osteoclast function in CIA mice. The therapeutic effect of lentiviral delivered CRACM3 shRNA was associated with gene silencing of CRACM3, along with the successful biodistribution of the virus. Extracellular Ca2+ influx in the splenocytes, thymocytes, and knee joint synovial cells was moderately suppressed. Inflammatory responses and autoimmune responses were reduced by CRACM3 gene silencing. A decrease in mature osteoclast activity also was observed in CRACM3 shRNA treated CIA mice. These results indicate that regulation of Ca2+ entry through lentivirus mediated CRACM3 gene silencing is beneficial in the treatment of RA.
C1 [Liu, Shuang; Kiyoi, Takeshi; Takemasa, Erika; Maeyama, Kazutaka] Ehime Univ, Dept Pharmacol, Grad Sch Med, Toon, Ehime 7910295, Japan.
   [Kiyoi, Takeshi] Ehime Univ, Dept Biosci, Integrated Ctr Sci, Toon, Ehime 7910295, Japan.
C3 Ehime University; Ehime University
RP Liu, S (通讯作者)，Ehime Univ, Dept Pharmacol, Grad Sch Med, Toon, Ehime 7910295, Japan.
EM liussmzk@m.ehime u.ac.jp
RI Shuang, Liu/AAW 2695 2020
FU Ehime University [054102020]; Grants in Aid for Scientific Research
   [15K19575] Funding Source: KAKEN
FX This work was supported by Grant in Aid for Research Promotion 054102020
   from Ehime University.
CR Baba Y, 2011, TRENDS IMMUNOL, V32, P589, DOI 10.1016/j.it.2011.09.004
   Baryshnikov SG, 2009, AM J PHYSIOL CELL PH, V297, pC1103, DOI 10.1152/ajpcell.00283.2009
   Bisaillon JM, 2010, AM J PHYSIOL CELL PH, V298, pC993, DOI 10.1152/ajpcell.00325.2009
   Bogado CE, 2011, DRUG TODAY, V47, P605, DOI 10.1358/dot.2011.47.8.1603507
   Bradley Elizabeth W., 2008, V455, P19, DOI 10.1007/978 1 59745 104 8_2
   DeHaven WI, 2007, J BIOL CHEM, V282, P17548, DOI 10.1074/jbc.M611374200
   Delgado M, 2001, NAT MED, V7, P563, DOI 10.1038/87887
   El Azreq MA, 2013, J IMMUNOL, V191, P5941, DOI 10.4049/jimmunol.1301940
   Gross SA, 2007, J BIOL CHEM, V282, P19375, DOI 10.1074/jbc.M701962200
   Gwack Y, 2007, J BIOL CHEM, V282, P16232, DOI 10.1074/jbc.M609630200
   Hoth M, 2013, CURR TOP MEMBR, V71, P237, DOI 10.1016/B978 0 12 407870 3.00010 X
   Hwang SY, 2012, FASEB J, V26, P1484, DOI 10.1096/fj.11 194399
   Lin FF, 2013, J PHARMACOL EXP THER, V345, P225, DOI 10.1124/jpet.112.202788
   Lis A, 2007, CURR BIOL, V17, P794, DOI 10.1016/j.cub.2007.03.065
   Liu S, 2014, IMMUNOL CELL BIOL, V92, P752, DOI 10.1038/icb.2014.45
   McCarl CA, 2009, J ALLERGY CLIN IMMUN, V124, P1311, DOI 10.1016/j.jaci.2009.10.007
   Mercer JC, 2006, J BIOL CHEM, V281, P24979, DOI 10.1074/jbc.M604589200
   Moreno JL, 2003, BLOOD, V102, P1078, DOI 10.1182/blood 2002 11 3437
   Parekh AB, 2010, NAT REV DRUG DISCOV, V9, P399, DOI 10.1038/nrd3136
   Potier M, 2009, FASEB J, V23, P2425, DOI 10.1096/fj.09 131128
   Qui B, 2011, CELL CALCIUM, V50, P261, DOI 10.1016/j.ceca.2011.05.015
   Robinson LJ, 2012, LAB INVEST, V92, P1071, DOI 10.1038/labinvest.2012.72
   Smolen JS, 2014, ANN RHEUM DIS, V73, P492, DOI 10.1136/annrheumdis 2013 204573
   Zhou YD, 2011, J CELL PHYSIOL, V226, P1082, DOI 10.1002/jcp.22423
NR 24
TC 28
Z9 30
U1 0
U2 7
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022 1767
EI 1550 6606
J9 J IMMUNOL
JI J. Immunol.
PD JAN 1
PY 2015
VL 194
IS 1
BP 76
EP 83
DI 10.4049/jimmunol.1401976
PG 8
WC Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology
GA AX1IH
UT WOS:000346700500010
PM 25422506
DA 2025 08 17
ER

PT J
AU Wang, H
   Ji, T
   Qu, H
   Yan, T
   Li, D
   Yang, R
   Tang, X
AF Wang, H.
   Ji, T.
   Qu, H.
   Yan, T.
   Li, D.
   Yang, R.
   Tang, X.
TI Indocyanine green fluorescence imaging may detect tumour residuals
   during surgery for bone and soft  tissue tumours
SO BONE & JOINT JOURNAL
LA English
DT Article
ID CANCER; MARGIN
AB AimsThe aim of this study was to determine the rate of indocyanine green (ICG) staining of bone and soft tissue tumours, as well as the stability and accuracy of ICG fluorescence imaging in detecting tumour residuals during surgery for bone and soft tissue tumours.MethodsICG fluorescence imaging was performed during surgery in 34 patients with bone and soft  tissue tumours. ICG was administered intravenously at a dose of 2 mg/kg over a period of 60 minutes on the day prior to surgery. The tumour stain rate and signal   to background ratio of each tumour were post hoc analyzed. After tumour resection, the tumour bed was scanned to locate sites with fluorescence residuals, which were subsequently inspected and biopsied.ResultsThe overall tumour stain rate was 88% (30/34 patients), and specific stain rates included 90% for osteosarcomas and 92% for giant cell tumours. For malignant tumours, the overall stain rate was 94%, while it was 82% for benign tumours. The ICG tumour stain was not influenced by different pathologies, such as malignant versus benign pathology, the re  ception (or lack thereof) of neoadjuvant chemotherapies, the length of time between drug administration and surgery, the number of doses of denosumab for patients with giant cell tumours, or the tumour response to neoadjuvant chemotherapy. The overall accuracy rate of successfully predicting tumour residuals using fluorescence was 49% (23/47 pieces of tissue). The accuracy rate after en bloc resection was significantly lower than that after piecemeal resection (16% vs 71%; p < 0.001).ConclusionA high percentage of bone and soft tissue tumours can be stained by ICG and the tumour staining with ICG was stable. This approach can be used in both benign and malignant tumours, regardless of whether neoadjuvant chemotherapy is adopted. The technique is also useful to detect tumour residuals in the wound, especially in patients undergoing piecemeal resection.
C1 [Wang, H.; Ji, T.; Qu, H.; Yan, T.; Li, D.; Yang, R.; Tang, X.] Peking Univ Peoples Hosp, Beijing, Peoples R China.
C3 Peking University
RP Tang, X (通讯作者)，Peking Univ Peoples Hosp, Beijing, Peoples R China.
EM tang15877@126.com
RI Qu, Hui Qi/B 4719 2009
OI Guo, Wei/0000 0003 2471 5767
FU National Natural Science Foundation of China [81872180]
FX Acknowledgements Funding statement: The authors disclose receipt of the
   following financial or material support for the research, authorship,
   and/or publication of this article: this work was supported by the
   National Natural Science Foundation of China (81872180) .
CR [Anonymous], 2001, B WORLD HEALTH ORGAN, V79, P373, DOI 10.1001/jama.2013.281053
   Cates MM, 2019, MODERN PATHOL, V32, P1421, DOI 10.1038/s41379 019 0278 9
   Cendán JC, 2005, J AM COLL SURGEONS, V201, P194, DOI 10.1016/j.jamcollsurg.2005.03.014
   Chen QY, 2020, JAMA SURG, V155, P300, DOI 10.1001/jamasurg.2019.6033
   Gillani SFUS, 2020, CUREUS J MED SCIENCE, V12, DOI 10.7759/cureus.11953
   Gundle KR, 2018, J CLIN ONCOL, V36, P704, DOI 10.1200/JCO.2017.74.6941
   Kawaguchi N, 2004, CLIN ORTHOP RELAT R, P165, DOI 10.1097/01.blo.0000116308.86761.f5
   Kumar ACS, 2021, CANCER INVEST, V39, P153, DOI 10.1080/07357907.2020.1865395
   Lau CT, 2019, PEDIATR SURG INT, V35, P1035, DOI 10.1007/s00383 019 04502 4
   Lauwerends LJ, 2021, LANCET ONCOL, V22, pE186, DOI 10.1016/S1470 2045(20)30600 8
   Lieto E, 2018, SURG INNOV, V25, P62, DOI 10.1177/1553350617751451
   Nicoli F, 2021, ANN SURG, V273, pE63, DOI 10.1097/SLA.0000000000003857
   Predina JD, 2019, J THORAC CARDIOV SUR, V157, P2061, DOI 10.1016/j.jtcvs.2018.10.169
   Predina JD, 2019, CANCER AM CANCER SOC, V125, P807, DOI 10.1002/cncr.31851
   Predina JD, 2018, MOL CLIN ONCOL, V8, P86, DOI 10.3892/mco.2017.1491
   Reinhart MB, 2016, SURG INNOV, V23, P166, DOI 10.1177/1553350615604053
   Vahrmeijer AL, 2013, NAT REV CLIN ONCOL, V10, P507, DOI 10.1038/nrclinonc.2013.123
   Veys I, 2018, J SURG ONCOL, V117, P228, DOI 10.1002/jso.24807
NR 18
TC 6
Z9 6
U1 2
U2 9
PU BRITISH EDITORIAL SOC BONE & JOINT SURGERY
PI LONDON
PA 22 BUCKINGHAM STREET, LONDON WC2N 6ET, ENGLAND
SN 2049 4394
J9 BONE JOINT J
JI Bone Joint J.
PD MAY
PY 2023
VL 105B
IS 5
BP 551
EP 558
DI 10.1302/0301 620X.105B5
PG 8
WC Orthopedics; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics; Surgery
GA I3QL8
UT WOS:001001957500001
PM 37121591
DA 2025 08 17
ER

PT J
AU Phull, S
   Marx, D
   Akens, MK
   Ghert, M
   Towler, MR
AF Phull, Sunjeev
   Marx, Daniella
   Akens, Margarete K.
   Ghert, Michelle
   Towler, Mark R.
TI In vitro assessment of a gallium doped glass polyalkenoate
   cement: chemotherapeutic potential, cytotoxicity and osteogenic effects
SO BIOMEDICAL MATERIALS
LA English
DT Article
DE cancer; bone metastasis; glass polyalkenoate cement; drug delivery
ID BONE METASTASIS; LUNG CANCER; CELL LINES; RIBONUCLEOTIDE REDUCTASE;
   LOCAL CHEMOTHERAPY; ACRYLIC CEMENT; DOUBLE BLIND; NITRATE; MECHANISMS;
   RESORPTION
AB Metastatic bone lesions are often osteolytic, which causes advanced stage cancer sufferers to experience severe pain and an increased risk of developing a pathological fracture. Gallium (Ga) ion possesses antineoplastic and anti bone resorption properties, suggesting the potential for its local administration to impede the growth of metastatic bone lesions. This study investigated the chemotherapeutic potential, cytotoxicity, and osteogenic effects of a Ga doped glass polyalkenoate cement (GPC) (C TA2) compared to its non gallium (C TA0) counterpart. Ion release profiles revealed a biphasic pattern characterized by an initial burst followed by a gradually declining release of ions. C TA2 continued to release Ga steadily throughout the experimentation period (7 d) and exhibited prolonged zinc (Zn) release compared to C TA0. Interestingly, the Zn release from both GPCs appeared to cause a chemotherapeutic effect against H1092 lung cancer cells in vitro, with the prolonged Zn release from C TA2 extending this effect. Unfortunately, both GPCs enhanced the viability of HCC2218 breast cancer cells, suggesting that the chemotherapeutic effects of Zn could be tied to cellular differences in preferred Zn concentrations. The utilization of SAOS 2 and MC3T3 cell lines as bone cell models yielded conflicting results, with the substantial decline in MC3T3 viability closely associated with silicon (Si) release, indicating cellular variations in Si toxicity. Despite this ambiguity, both GPCs exhibited harmful effects on the osteogenesis of primary rat osteoblasts, raising concerns about excessive burst Zn release. While Ga/Zn doped GPCs hold promise for treating metastatic bone lesions caused by lung cancers, further optimization is required to mitigate cytotoxicity on healthy bone.
C1 [Phull, Sunjeev; Marx, Daniella] Toronto Metropolitan Univ, Dept Mech Engn, Toronto, ON, Canada.
   [Phull, Sunjeev; Marx, Daniella] St Michaels Hosp, Li Ka Shing Knowledge Inst, Toronto, ON, Canada.
   [Akens, Margarete K.] Univ Hlth Network, Toronto, ON, Canada.
   [Akens, Margarete K.] Univ Toronto, Dept Med Biophys, Toronto, ON, Canada.
   [Akens, Margarete K.] Univ Toronto, Dept Surg, Toronto, ON, Canada.
   [Ghert, Michelle] McMaster Univ, Dept Surg, Hamilton, ON L8V 5C2, Canada.
   [Towler, Mark R.] Missouri S&T, Dept Chem & Biochem Engn, Rolla, MO 65409 USA.
C3 Toronto Metropolitan University; University of Toronto; Saint Michaels
   Hospital Toronto; Li Ka Shing Knowledge Institute; University of
   Toronto; University Health Network Toronto; University of Toronto;
   University of Toronto; McMaster University; University of Missouri
   System; Missouri University of Science & Technology
RP Towler, MR (通讯作者)，Missouri S&T, Dept Chem & Biochem Engn, Rolla, MO 65409 USA.
EM mtowler@mst.edu
RI Akens, Margarete/K 5502 2013; Marx, Daniella/AHA 7664 2022; Ghert,
   Michelle/JZE 1212 2024
OI Akens, Margarete/0000 0003 3523 2381; 
FU Natural Sciences and Engineering Research Council (NSERC)
   [RGPIN 2019 04634]
FX This work was supported by the Natural Sciences and Engineering Research
   Council (NSERC) (Discovery Grant # RGPIN 2019 04634) awarded to Dr
   Towler.
CR Akens MK, 2010, BREAST CANCER RES TR, V119, P325, DOI 10.1007/s10549 009 0356 7
   Alhalawani AMF, 2016, J POLYM ENG, V36, P221, DOI 10.1515/polyeng 2015 0079
   Anselmetti Giovanni Carlo, 2010, Semin Intervent Radiol, V27, P199, DOI 10.1055/s 0030 1253518
   Bhowmik D, 2019, CURR MED RES OPIN, V35, P513, DOI 10.1080/03007995.2018.1532884
   Bielby RC, 2004, TISSUE ENG, V10, P1018, DOI 10.1089/ten.2004.10.1018
   Bockman R, 2003, SEMIN ONCOL, V30, P5, DOI 10.1016/S0093 7754(03)00170 2
   Boyd D, 2006, J MATER SCI MATER M, V17, P397, DOI 10.1007/s10856 006 8465 x
   Brauer DS, 2011, BIOMED MATER, V6, DOI 10.1088/1748 6041/6/4/045007
   Broaddus VC, 2021, Murray & Nadel's Textbook of Respiratory Medicine, V1
   Brown RB, 2023, NUTRIENTS, V15, DOI 10.3390/nu15173735
   Chattopadhyay S, 2007, MOL CANCER THER, V6, P404, DOI 10.1158/1535 7163.MCT 06 0343
   CHITAMBAR CR, 1987, CANCER RES, V47, P3929
   CHITAMBAR CR, 1994, CANCER RES, V54, P3224
   CHITAMBAR CR, 1988, BLOOD, V72, P1930
   CHITAMBAR CR, 1992, BLOOD, V80, P505
   Christudoss P, 2010, BIOMED RES INDIA, V21, P445
   Cvitkovic FR, 2006, CANCER J, V12, P47, DOI 10.1097/00130404 200601000 00009
   Czekanska EM, 2014, J BIOMED MATER RES A, V102, P2636, DOI 10.1002/jbm.a.34937
   De Berardis B, 2010, TOXICOL APPL PHARM, V246, P116, DOI 10.1016/j.taap.2010.04.012
   Dean JR, 2000, CLIN RADIOL, V55, P471, DOI 10.1053/crad.2000.0478
   Decker S, 1999, J BONE JOINT SURG BR, V81B, P545, DOI 10.1302/0301 620X.81B3.9167
   Doweidar H, 2009, J MATER SCI, V44, P2899, DOI 10.1007/s10853 009 3383 1
   Draenert FG, 2008, CHEMOTHERAPY, V54, P412, DOI 10.1159/000153315
   Drake MT, 2008, MAYO CLIN PROC, V83, P1032, DOI 10.4065/83.9.1032
   Foroutan T, 2014, NANOMED J, V1, P308, DOI 10.7508/NMJ.2015.05.004
   Garg U, 2016, CLINICAL CHALLENGES IN THERAPEUTIC DRUG MONITORING: SPECIAL POPULATIONS, PHYSIOLOGICAL CONDITIONS AND PHARMACOGENOMICS, P165, DOI 10.1016/B978 0 12 802025 8.00007 6
   Genta Incorporated, 2012, LABEL: GANITEgallium nitrate injection, solution, concentrate
   GOLDMAN ID, 1985, PHARMACOL THERAPEUT, V28, P77, DOI 10.1016/0163 7258(85)90083 X
   GRECO F, 1992, ORTHOPEDICS, V15, P189
   Gumulec J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099790
   Gupta SK, 2005, J SURG ONCOL, V91, P204, DOI 10.1002/jso.20306
   HALL TJ, 1990, BONE MINER, V8, P211, DOI 10.1016/0169 6009(90)90106 P
   Hao GY, 2018, RSC ADV, V8, P22182, DOI 10.1039/c8ra02095g
   HART MM, 1971, P NATL ACAD SCI USA, V68, P1623, DOI 10.1073/pnas.68.7.1623
   HATA Y, 1994, ONCOL RES, V6, P19
   Healey JH, 2003, CLIN ORTHOP RELAT R, pS263, DOI 10.1097/01.blo.0000093053.96273.ee
   HERNIGOU P, 1989, J BONE JOINT SURG BR, V71, P804, DOI 10.1302/0301 620X.71B5.2584251
   Hill R, 1996, J MATER SCI LETT, V15, P1122, DOI 10.1007/BF00539955
   Hoppe A, 2011, BIOMATERIALS, V32, P2757, DOI 10.1016/j.biomaterials.2011.01.004
   Jansen G, 1999, CANC DRUG DISC DEV, P293
   Jin XX, 2012, ANAL CHEM, V84, P4520, DOI 10.1021/ac3004677
   Kaur G, 2014, J BIOMED MATER RES A, V102, P254, DOI 10.1002/jbm.a.34690
   Keenan TJ, 2016, J MATER SCI, V51, P1107, DOI 10.1007/s10853 015 9442 x
   Kim EJ, 2013, BIOL TRACE ELEM RES, V152, P105, DOI 10.1007/s12011 012 9593 4
   LARSON SM, 1980, JNCI J NATL CANCER I, V64, P41
   Lee S, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22189910
   LIEWEHR FR, 1995, ENDOD DENT TRAUMATOL, V11, P20
   Luttropp CA, 1998, J NUCL MED, V39, P1405
   Marx D, 2021, J BIOMED MATER RES A, V109, P1366, DOI 10.1002/jbm.a.37127
   Matherly LH, 2007, CANCER METAST REV, V26, P111, DOI 10.1007/s10555 007 9046 2
   Matherly LH, 2018, CANCER CHEMOTH PHARM, V81, P1, DOI 10.1007/s00280 017 3473 8
   Myette MS, 1998, CANCER LETT, V129, P199, DOI 10.1016/S0304 3835(98)00104 9
   NELSON JB, 1995, NAT MED, V1, P944, DOI 10.1038/nm0995 944
   Nicholson JW, 2021, J MATER SCI MATER M, V32, DOI 10.1007/s10856 021 06501 1
   Nicholson JW, 2009, J BIOMATER APPL, V24, P293, DOI 10.1177/0885328209344441
   Ninsontia C, 2017, AM J PHYSIOL CELL PH, V312, pC487, DOI 10.1152/ajpcell.00173.2016
   O'Donnell MD, 2010, ACTA BIOMATER, V6, P2382, DOI 10.1016/j.actbio.2010.01.006
   Pautke C, 2004, ANTICANCER RES, V24, P3743
   Phull S, 2021, MATER RES EXPRESS, V8, DOI 10.1088/2053 1591/ac07e5
   Phull SS, 2021, J BONE ONCOL, V26, DOI 10.1016/j.jbo.2020.100345
   Prochazka E, 2010, INT ORTHOP, V34, P137, DOI 10.1007/s00264 008 0717 6
   Qu Z, 2023, NUTRIENTS, V15, DOI 10.3390/nu15071703
   Reffitt DM, 2003, BONE, V32, P127, DOI 10.1016/S8756 3282(02)00950 X
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Rosa MA, 2003, J BONE JOINT SURG BR, V85B, P712, DOI 10.1302/0301 620X.85B5.13588
   Rusch P, 2021, ARCH GYNECOL OBSTET, V303, P195, DOI 10.1007/s00404 020 05789 8
   Russo Abrahao T, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191270
   Ryan C, 2022, BONE, V158, DOI 10.1016/j.bone.2020.115783
   Saad F, 2007, CANCER AM CANCER SOC, V110, P1860, DOI 10.1002/cncr.22991
   Saldaña L, 2011, ACTA BIOMATER, V7, P4210, DOI 10.1016/j.actbio.2011.07.019
   Sheppard AJ, 2022, FRONT BIOENG BIOTECH, V10, DOI 10.3389/fbioe.2022.836764
   Skrajnowska D, 2019, NUTRIENTS, V11, DOI 10.3390/nu11102273
   Sung H, 2021, CA CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Suva LJ, 2011, NAT REV ENDOCRINOL, V7, P208, DOI 10.1038/nrendo.2010.227
   Suva LJ, 2009, ENDOCR RELAT CANCER, V16, P703, DOI 10.1677/ERC 09 0012
   Tanino R, 2020, MOL CANCER THER, V19, P502, DOI 10.1158/1535 7163.MCT 19 0018
   Taylor Sarah E B, 2014, Bonekey Rep, V3, P585, DOI 10.1038/bonekey.2014.80
   Verron E, 2010, BRIT J PHARMACOL, V159, P1681, DOI 10.1111/j.1476 5381.2010.00665.x
   Visentin M, 2012, HEMATOL ONCOL CLIN N, V26, P629, DOI 10.1016/j.hoc.2012.02.002
   Waller DG, 2018, Medical pharmacology and therapeutics, Vfifth, P631
   Wang Y, 2019, WORLD J SURG ONCOL, V17, DOI 10.1186/s12957 019 1617 5
   WARRELL RP, 1983, CANCER AM CANCER SOC, V51, P1982, DOI 10.1002/1097 0142(19830601)51:11<1982::AID CNCR2820511104>3.0.CO;2 L
   WARRELL RP, 1984, J CLIN INVEST, V73, P1487, DOI 10.1172/JCI111353
   WARRELL RP, 1987, J CLIN ONCOL, V5, P292, DOI 10.1200/JCO.1987.5.2.292
   WARRELL RP, 1991, J CLIN ONCOL, V9, P1467, DOI 10.1200/JCO.1991.9.8.1467
   Wasson EA., 1991, CLIN MATER, V7, P289, DOI [DOI 10.1016/0267 6605(91)90072 N, 10.1016/0267 6605(91)90072 N]
   Wren AW, 2012, J MATER SCI MATER M, V23, P1823, DOI 10.1007/s10856 012 4624 4
   Wu SY, 2021, TRANSL LUNG CANCER R, V10, P439, DOI 10.21037/tlcr 20 835
   Xiang Y, 2011, CHEM MATER, V23, P2703, DOI 10.1021/cm102889q
   Zhang Z, 2017, SCI REP UK, V7, DOI [10.1038/s41598 017 02144 x, 10.1038/srep46161]
NR 90
TC 0
Z9 0
U1 0
U2 2
PU IOP Publishing Ltd
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 1748 6041
EI 1748 605X
J9 BIOMED MATER
JI Biomed. Mater.
PD SEP 1
PY 2024
VL 19
IS 5
AR 055006
DI 10.1088/1748 605X/ad5ba5
PG 13
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA XP7N3
UT WOS:001262951400001
PM 38917820
OA hybrid
DA 2025 08 17
ER

PT J
AU Qiu, ZX
   Dan, ZS
   Che, XM
AF Qiu, Zhixue
   Dan, Zhongshu
   Che, Xiaoming
TI FoxC1 promotes osteosarcoma cell proliferation and metastasis through
   the activation of EZH2
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE
LA English
DT Article
DE FoxC1; osteosarcoma; proliferation; metastasis; EZH2
ID EPITHELIAL MESENCHYMAL TRANSITION; BREAST CANCER;
   HEPATOCELLULAR CARCINOMA; TARGETED THERAPY; DOWN REGULATION;
   POOR PROGNOSIS; EXPRESSION; INVASION; GROWTH
AB The underlying mechanism of osteosarcoma proliferation, migration and invasion remains to be elucidated. Here, we set out to investigate the role of FoxC1 in the regulation of osteosarcoma cell proliferation and metastasis and to assess its role as potential therapeutic target. The evidence was as follows: we found that FoxC1 was markedly up regulated in both osteosarcoma samples and osteosarcoma cell lines, compared to adjacent non tumor tissues and osteoblast cell line hFOB1.19, respectively. In addition, we found that in the osteosarcoma cell lines Saos 2 and U2OS, siRNAs targeting FoxC1 remarkably reduced the endogenous expression of FoxC1 and, concomitantly, inhibited cancer cell proliferation and invasion. Using qChIP and a luciferase assay, we found that FoxC1 directly targets EZH2. Consistently with this notion, we found that the mRNA and protein expression of EZH2 were down regulated upon FoxC1 knockdown in Saos 2 and U2OS cells. Finally, the silencing of EZH2 by siRNA could markedly reversed the inhibitory effect of FoxC1 knockdown on osteosarcoma cell growth and invasion.
C1 [Qiu, Zhixue; Dan, Zhongshu; Che, Xiaoming] Orthopaed Qinghai Prov Peoples Hosp, 2th Gonghe Rd, Qinghai 810700, Peoples R China.
RP Qiu, ZX (通讯作者)，Orthopaed Qinghai Prov Peoples Hosp, 2th Gonghe Rd, Qinghai 810700, Peoples R China.
EM anming19640@sina.com
CR Chung TKH, 2012, INT J CANCER, V130, P1036, DOI 10.1002/ijc.26060
   Fluge O, 2009, BRIT J CANCER, V101, P1282, DOI 10.1038/sj.bjc.6605333
   Huang WJ, 2015, GASTROENTEROLOGY, V149, P1053, DOI 10.1053/j.gastro.2015.05.058
   Hussein YR, 2012, HUM PATHOL, V43, P1638, DOI 10.1016/j.humpath.2011.12.004
   Jaffe N, 2009, CANCER TREAT RES, V152, P239, DOI 10.1007/978 1 4419 0284 9_12
   Lin ZY, 2014, CANCER SCI, V105, P1288, DOI 10.1111/cas.12499
   Mirabello L, 2009, CANCER AM CANCER SOC, V115, P1531, DOI 10.1002/cncr.24121
   Muggerud AA, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2466
   Osborne TS, 2012, J COMP PATHOL, V146, P132, DOI 10.1016/j.jcpa.2011.12.007
   Sasaki H, 2010, ONCOL REP, V23, P677, DOI 10.3892/or_00000684
   Shaikh AB, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17040506
   Sizemore ST, 2012, J BIOL CHEM, V287, P24631, DOI 10.1074/jbc.M112.375865
   Song QC, 2014, ONCOL REP, V31, P1263, DOI 10.3892/or.2014.2989
   Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075
   Xu Y, 2014, HISTOPATHOLOGY, V64, P963, DOI 10.1111/his.12347
   Xu ZY, 2012, INT J BIOL SCI, V8, P1130, DOI 10.7150/ijbs.4769
   Yang JL, 2013, CURR OPIN ONCOL, V25, P398, DOI 10.1097/CCO.0b013e3283622c1b
   Zhang KL, 2014, ONCOL REP, V32, P2143, DOI 10.3892/or.2014.3459
NR 18
TC 3
Z9 3
U1 0
U2 0
PU E CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1940 5901
J9 INT J CLIN EXP MED
JI Int. J. Clin. Exp. Med.
PY 2017
VL 10
IS 1
BP 376
EP 384
PG 9
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA EO2CE
UT WOS:000396503400036
DA 2025 08 17
ER

PT J
AU Zhra, M
   Magableh, AM
   Samhan, LM
   Fatani, LM
   Qasem, RJ
   Aljada, A
AF Zhra, Mahmoud
   Magableh, Ahmad M.
   Samhan, Lara M.
   Fatani, Lein M.
   Qasem, Rani J.
   Aljada, Ahmad
TI The Expression of a Subset of Aging and Antiaging Markers Following the
   Chondrogenic and Osteogenic Differentiation of Mesenchymal Stem Cells of
   Placental Origin
SO CELLS
LA English
DT Article
DE LMNA/C; SIRT7; SM22 alpha; mesenchymal stem cells; phenotypic drift;
   osteocytes; chondrocytes; adipocytes
ID PLASMINOGEN ACTIVATOR INHIBITOR 1; HUMAN BONE MARROW; LAMIN A/C; P53;
   SENESCENCE; GENE
AB Mesenchymal stem cells (MSCs) of placental origin hold great promise in tissue engineering and regenerative medicine for diseases affecting cartilage and bone. However, their utility has been limited by their tendency to undergo premature senescence and phenotypic drift into adipocytes. This study aimed to explore the potential involvement of a specific subset of aging and antiaging genes by measuring their expression prior to and following in vitro induced differentiation of placental MSCs into chondrocytes and osteoblasts as opposed to adipocytes. The targeted genes of interest included the various LMNA/C transcript variants (lamin A, lamin C, and lamin A triangle 10), sirtuin 7 (SIRT7), and SM22 alpha, along with the classic aging markers plasminogen activator inhibitor 1 (PAI 1), p53, and p16(INK4a). MSCs were isolated from the decidua basalis of human term placentas, expanded, and then analyzed for phenotypic properties by flow cytometry and evaluated for colony forming efficiency. The cells were then induced to differentiate in vitro into chondrocytes, osteocytes, and adipocytes following established protocols. The mRNA expression of the targeted genes was measured by RT qPCR in the undifferentiated cells and those fully differentiated into the three cellular lineages. Compared to undifferentiated cells, the differentiated chondrocytes demonstrated decreased expression of SIRT7, along with decreased PAI 1, lamin A, and SM22 alpha expression, but the expression of p16(INK4a) and p53 increased, suggesting their tendency to undergo premature senescence. Interestingly, the cells maintained the expression of lamin C, which indicates that it is the primary lamin variant influencing the mechanoelastic properties of the differentiated cells. Notably, the expression of all targeted genes did not differ from the undifferentiated cells following osteogenic differentiation. On the other hand, the differentiation of the cells into adipocytes was associated with decreased expression of lamin A and PAI 1. The distinct patterns of expression of aging and antiaging genes following in vitro induced differentiation of MSCs into chondrocytes, osteocytes, and adipocytes potentially reflect specific roles for these genes during and following differentiation in the fully functional cells. Understanding these roles and the network of signaling molecules involved can open opportunities to improve the handling and utility of MSCs as cellular precursors for the treatment of cartilage and bone diseases.
C1 [Zhra, Mahmoud; Aljada, Ahmad] Alfaisal Univ, Coll Med, Dept Biochem & Mol Med, Riyadh 11533, Saudi Arabia.
   [Magableh, Ahmad M.; Samhan, Lara M.; Fatani, Lein M.] Alfaisal Univ, Coll Med, Riyadh 11533, Saudi Arabia.
   [Qasem, Rani J.] Middle East Univ, Coll Pharm, Dept Pharmacol & Pharm Practice, Amman 11831, Jordan.
C3 Alfaisal University; Middle East University
RP Aljada, A (通讯作者)，Alfaisal Univ, Coll Med, Dept Biochem & Mol Med, Riyadh 11533, Saudi Arabia.; Qasem, RJ (通讯作者)，Middle East Univ, Coll Pharm, Dept Pharmacol & Pharm Practice, Amman 11831, Jordan.
EM rqasem@meu.edu.jo; aaljada@alfaisal.edu
RI Aljada, Ahmad/KYQ 4122 2024; Zhra, Mahmoud/KSM 1667 2024
OI Aljada, Ahmad/0000 0001 8337 5454; Zhra, Mahmoud/0000 0001 5067 4984;
   Magableh, Ahmad/0009 0004 3296 4020; Samhan, Lara
   M./0000 0002 6595 859X; Qasem, Rani/0000 0001 9624 8470
FU King Abdullah International Medical Research Center (KAIMRC) [RC12/105];
   Alfaisal University
FX The investigation disclosed herein was supported by various funds
   available through the King Abdullah International Medical Research
   Center (KAIMRC), grant number RC12/105, and Alfaisal University
CR Abomaray FM, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/5184601
   Akter R, 2009, J BONE MINER RES, V24, P283, DOI 10.1359/JBMR.081010
   Al Saaidi R, 2015, CHROMOSOMA, V124, P1, DOI 10.1007/s00412 014 0484 7
   Barlow S, 2008, STEM CELLS DEV, V17, P1095, DOI 10.1089/scd.2007.0154
   Bermeo S, 2015, J CELL BIOCHEM, V116, P2344, DOI 10.1002/jcb.25185
   Brooke G, 2008, STEM CELLS DEV, V17, P929, DOI 10.1089/scd.2007.0156
   Buhrmann C, 2014, J BIOL CHEM, V289, P22048, DOI 10.1074/jbc.M114.568790
   Cenni V, 2020, AGEING RES REV, V62, DOI 10.1016/j.arr.2020.101073
   Cesari M, 2010, CARDIOVASC THER, V28, pe72, DOI 10.1111/j.1755 5922.2010.00171.x
   Chen EEM, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.429
   Chen Q, 2016, CELL DEATH DIFFER, V23, P1128, DOI 10.1038/cdd.2015.168
   Chen R, 2014, J MOL CELL CARDIOL, V72, P263, DOI 10.1016/j.yjmcc.2014.04.003
   Constantinescu D, 2006, STEM CELLS, V24, P177, DOI 10.1634/stemcells.2004 0159
   Copland IB, 2009, STEM CELLS, V27, P467, DOI 10.1634/stemcells.2008 0520
   Denu RA, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/5841716
   Diekman BO, 2018, AGING CELL, V17, DOI 10.1111/acel.12771
   Ferreira MSV, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 017 0757 1
   González Cruz RD, 2018, FRONT CELL DEV BIOL, V6, DOI 10.3389/fcell.2018.00151
   González Cruz RD, 2018, CELL MOL BIOENG, V11, P131, DOI 10.1007/s12195 018 0518 y
   Hadadeh O, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049065
   Han Y, 2019, CELLS BASEL, V8, DOI 10.3390/cells8080886
   Hashimoto S, 2009, ARTHRITIS RHEUM US, V60, P2340, DOI 10.1002/art.24706
   He YL, 2015, STEM CELLS, V33, P1304, DOI 10.1002/stem.1925
   Infante A, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 0995 x
   Khan H, 2018, CURR STEM CELL RES T, V13, P378, DOI 10.2174/1574888X11666160429122527
   Kim H, 2021, NPJ AGING MECH DIS, V7, DOI 10.1038/s41514 021 00058 7
   Kim M, 2012, MECH AGEING DEV, V133, P215, DOI 10.1016/j.mad.2012.03.014
   Kim TR, 2010, BIOCHEM BIOPH RES CO, V400, P100, DOI 10.1016/j.bbrc.2010.08.018
   Kimmel JC, 2021, CELL REP, V35, DOI 10.1016/j.celrep.2021.109046
   Lagunas Rangel FA, 2022, CELL MOL LIFE SCI, V79, DOI 10.1007/s00018 022 04342 x
   Lin CH, 2018, J CELL MOL MED, V22, P786, DOI 10.1111/jcmm.13356
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Ma WT, 2024, MOL BIOTECHNOL, V66, P1, DOI 10.1007/s12033 023 00736 9
   Malashicheva A, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.761469
   Malashicheva A, 2015, MOL GENET METAB, V115, P118, DOI 10.1016/j.ymgme.2015.04.006
   Mariotti E, 2008, STEM CELLS DEV, V17, P1039, DOI 10.1089/scd.2008.0212
   Miao SB, 2017, ARTERIOSCL THROM VAS, V37, P1849, DOI 10.1161/ATVBAHA.117.309378
   Moerman EJ, 2004, AGING CELL, V3, P379, DOI 10.1111/j.1474 9728.2004.00127.x
   Naito M, 2012, HISTOCHEM CELL BIOL, V137, P235, DOI 10.1007/s00418 011 0890 3
   Peng X, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097283
   Pignolo RJ, 2021, JBMR PLUS, V5, DOI 10.1002/jbm4.10488
   Raza U, 2024, PHYSIOL REV, V104, P253, DOI 10.1152/physrev.00044.2022
   Remark LH, 2023, BONE RES, V11, DOI 10.1038/s41413 023 00283 8
   Sehgal P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057891
   Shen JB, 2011, CARDIOVASC RES, V90, P28, DOI 10.1093/cvr/cvq378
   Somoza RA, 2014, TISSUE ENG PART B RE, V20, P596, DOI [10.1089/ten.teb.2013.0771, 10.1089/ten.TEB.2013.0771]
   Takafuji Y, 2019, J CELL PHYSIOL, V234, P9687, DOI 10.1002/jcp.27655
   Vaughan DE, 2017, ARTERIOSCL THROM VAS, V37, P1446, DOI 10.1161/ATVBAHA.117.309451
   Wang XY, 2006, J CELL BIOL, V172, P115, DOI 10.1083/jcb.200507106
   Wong XR, 2022, CSH PERSPECT BIOL, V14, DOI 10.1101/cshperspect.a040113
   Yamamoto K, 2002, P NATL ACAD SCI USA, V99, P890, DOI 10.1073/pnas.022608799
   Yoon MH, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 1378 7
   Zhang B, 2019, J PHYSIOL BIOCHEM, V75, P11, DOI 10.1007/s13105 019 00661 z
NR 53
TC 1
Z9 1
U1 1
U2 4
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2073 4409
J9 CELLS BASEL
JI Cells
PD JUN
PY 2024
VL 13
IS 12
AR 1022
DI 10.3390/cells13121022
PG 14
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA WL2X8
UT WOS:001254970000001
PM 38920652
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Kuang, CM
   Zhu, YH
   Guan, YJ
   Xia, JL
   Ouyang, J
   Liu, GZ
   Hao, M
   Liu, JB
   Guo, JJ
   Zhang, WX
   Feng, XL
   Li, X
   Zhang, JY
   Wu, X
   Xu, H
   Li, GC
   Xie, L
   Fan, SQ
   Qiu, LG
   Zhou, W
AF Kuang, Chunmei
   Zhu, Yinghong
   Guan, Yongjun
   Xia, Jiliang
   Ouyang, Jian
   Liu, Guizhu
   Hao, Mu
   Liu, Jiabin
   Guo, Jiaojiao
   Zhang, Wenxia
   Feng, Xiangling
   Li, Xin
   Zhang, Jingyu
   Wu, Xuan
   Xu, Hang
   Li, Guancheng
   Xie, Lu
   Fan, Songqing
   Qiu, Lugui
   Zhou, Wen
TI COX2 confers bone marrow stromal cells to promoting TNFα/TNFR1β mediated
   myeloma cell growth and adhesion
SO CELLULAR ONCOLOGY
LA English
DT Article
DE Multiple myeloma; BMSCs; Cyclooxygenase 2; TNF&#945
ID MULTIPLE MYELOMA; DRUG RESISTANCE; EXPRESSION; CYCLOOXYGENASE 2;
   MICROENVIRONMENT; INHIBITION; OSTEOCLAST; SURVIVAL; DIFFERENTIATION;
   OVEREXPRESSION
AB Purpose Bone marrow stromal cells (BMSCs) have been implicated in multiple myeloma (MM) progression. However, the underlying mechanisms remain largely elusive. Therefore, we aimed to explore key factors in BMSCs that contribute to MM development. Methods RNA sequencing was used to perform gene expression profiling in BMSCs. Enzyme linked immunosorbent assays (ELISAs) were performed to determine the concentrations of PGE2 and TNF alpha in sera and conditioned media (CM). Western blotting, qRT PCR and IHC were used to examine the expression of cyclooxygenase 2 (COX2) in BMSCs and to analyze the regulation of TNF alpha by COX2. Cell growth and adhesion assays were employed to explore the function of COX2 in vitro. A 5T33MMvt KaLwRij mouse model was used to study the effects of COX2 inhibition in vivo. Results COX2 was found to be upregulated in MM patient derived BMSCs and to play a critical role in BMSC induced MM cell proliferation and adhesion. Administration of PGE2 to CM derived from BMSCs promoted MM cell proliferation and adhesion. Conversely, inhibition of COX2 in BMSCs greatly compromised BMSC induced MM cell proliferation and adhesion. PCR array based analysis of inflammatory cytokines indicated that COX2 upregulates the expression of TNF alpha. Subsequent rescue assays showed that an anti TNF alpha monoclonal antibody could antagonize COX2 mediated MM cell proliferation and adhesion. Administration of NS398, a specific COX2 inhibitor, inhibited in vivo tumor growth and improved the survival of 5TMM mice. Conclusions Our results indicate that COX2 contributes to BMSC induced MM proliferation and adhesion by increasing the secretion of PGE2 and TNF alpha. Targeting COX2 in BMSCs may serve as a potential therapeutic approach of treating MM.
C1 [Kuang, Chunmei; Zhu, Yinghong; Guan, Yongjun; Xia, Jiliang; Liu, Jiabin; Guo, Jiaojiao; Zhang, Jingyu; Wu, Xuan; Xu, Hang; Li, Guancheng; Zhou, Wen] Cent South Univ, Key Lab Carcinogenesis & Canc Invas,Sch Basic Med, Xiangya Hosp,Canc Res Inst,Chinese Minist Educ, Key Lab Carcinogenesis,Chinese Minist Hlth,Dept H, Changsha 410078, Peoples R China.
   [Xia, Jiliang; Ouyang, Jian; Xie, Lu] Shanghai Acad Sci & Technol, Shanghai Ctr Bioinformat Technol, Shanghai 201203, Peoples R China.
   [Liu, Guizhu] Chinese Acad Sci, Inst Nutr Sci, Key Lab Nutr & Metab, Shanghai 200030, Peoples R China.
   [Hao, Mu; Zhang, Wenxia; Qiu, Lugui] Chinese Acad Med Sci & Peking Union Med Coll, Inst Hematol & Blood Dis Hosp, State Key Lab Expt Hematol, Tianjin 300020, Peoples R China.
   [Feng, Xiangling] Cent South Univ, Xiang Ya Sch Publ Hlth, Changsha 410078, Peoples R China.
   [Li, Xin] Cent South Univ, Xiangya Hosp 3, Dept Hematol, Changsha 410013, Peoples R China.
   [Fan, Songqing] Cent South Univ, Xiangya Hosp 2, Dept Pathol, Changsha 410008, Hunan, Peoples R China.
C3 Central South University; Shanghai Academy of Science & Technology;
   Chinese Academy of Sciences; Chinese Academy of Sciences; Chinese
   Academy of Medical Sciences   Peking Union Medical College; Institute of
   Hematology & Blood Diseases Hospital   CAMS; Peking Union Medical
   College; Central South University; Central South University; Central
   South University
RP Zhou, W (通讯作者)，Cent South Univ, Key Lab Carcinogenesis & Canc Invas,Sch Basic Med, Xiangya Hosp,Canc Res Inst,Chinese Minist Educ, Key Lab Carcinogenesis,Chinese Minist Hlth,Dept H, Changsha 410078, Peoples R China.
EM wenzhou@csu.edu.cn
RI Yang, Yong/GLQ 5561 2022; zhao, wei/IQS 1144 2023; Yuanlei,
   Zhang/AGW 9772 2022; Zhang, Jingyu/B 8500 2012; Lu, Xie/IWM 7931 2023;
   Zhao, Wensi/JDW 1266 2023
OI Xie, Lu/0000 0001 7541 2243; Zhou, Wen/0000 0003 0834 9306; Zhu,
   Yinghong/0009 0009 7984 9560; 
FU Ministry of Science and Technology of China [2018 YFAO107800]; National
   Natural Science Foundation of China [81974010, 81800209, 81630007]; Key
   Technology Research and Development program of the Ministry of Science
   and Technology of Hunan Province, China [2020WK2006]; Strategic Priority
   Research Program of Central South University [ZLXD2017004]; SKLEH Pilot
   Research Grant [ZK16 04]; Fundamental Research Funds for Graduate of
   Central South University [2018zzts235, 2018zzts079, 2019zzts087]
FX This work was supported by grants from the Ministry of Science and
   Technology of China (2018 YFAO107800), the National Natural Science
   Foundation of China (81974010, 81800209 and 81630007), the Key
   Technology Research and Development program of the Ministry of Science
   and Technology of Hunan Province, China (2020WK2006), the Strategic
   Priority Research Program of Central South University (ZLXD2017004), a
   SKLEH Pilot Research Grant (ZK16 04) and Fundamental Research Funds for
   Graduate of Central South University (2018zzts235, 2018zzts079,
   2019zzts087). We thank Liang Zeng for providing the multiple myeloma
   bone marrow sections. We thank Lisha Wu and Shanshan Liu of the first
   affiliated Xiangya hospital for their technical support with flow
   cytometry and imaging.
CR Ara T, 2009, CANCER RES, V69, P329, DOI 10.1158/0008 5472.CAN 08 0613
   Azab AK, 2012, BLOOD, V119, P5782, DOI 10.1182/blood 2011 09 380410
   Bianchi G, 2015, BLOOD, V125, P3049, DOI 10.1182/blood 2014 11 568881
   Brenner D, 2015, NAT REV IMMUNOL, V15, P362, DOI 10.1038/nri3834
   Cetin M, 2005, AM J HEMATOL, V80, P169, DOI 10.1002/ajh.20460
   Chang MA, 2014, J CELL BIOCHEM, V115, P2188, DOI 10.1002/jcb.24897
   Cottini F, 2015, CLIN ADV HEMATOL ONC, V13, P236
   Di Nicola M, 2002, BLOOD, V99, P3838, DOI 10.1182/blood.V99.10.3838
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016 5085(94)90246 1
   Fabre C, 2012, CLIN CANCER RES, V18, P4669, DOI 10.1158/1078 0432.CCR 12 0779
   Frassanito MA, 2014, LEUKEMIA, V28, P904, DOI 10.1038/leu.2013.254
   Gooding S, 2016, CURR OPIN PHARMACOL, V28, P43, DOI 10.1016/j.coph.2016.02.013
   Hoang B, 2006, BLOOD, V107, P4484, DOI 10.1182/blood 2005 09 3926
   Hu JP, 2018, CANCER LETT, V414, P214, DOI 10.1016/j.canlet.2017.11.020
   Hua M, 2009, P NATL ACAD SCI USA, V106, P3372, DOI 10.1073/pnas.0813306106
   Jing YY, 2018, CANCER LETT, V434, P22, DOI 10.1016/j.canlet.2018.07.001
   Kast R. E., 2006, Inflammopharmacology, V14, P256, DOI 10.1007/s10787 006 1532 6
   Kellinsalmi M, 2007, EUR J PHARMACOL, V572, P102, DOI 10.1016/j.ejphar.2007.06.030
   Kim HS, 2012, BREAST CANCER RES TR, V132, P51, DOI 10.1007/s10549 011 1521 3
   La Rocca F, 2017, CELL ONCOL, V40, P483, DOI 10.1007/s13402 017 0338 4
   Landowski TH, 2003, ONCOGENE, V22, P2417, DOI 10.1038/sj.onc.1206315
   Li QB, 2007, ACTA PHARMACOL SIN, V28, P1031, DOI 10.1111/j.1745 7254.2007.00550.x
   Liu L, 2011, LEUKEMIA, V25, P23, DOI 10.1038/leu.2010.225
   Manier S, 2017, NAT REV CLIN ONCOL, V14, P100, DOI 10.1038/nrclinonc.2016.122
   Markovina S, 2010, MOL CANCER, V9, DOI 10.1186/1476 4598 9 176
   Meads MB, 2016, ONCOGENE, V35, P2723, DOI 10.1038/onc.2015.334
   Mitsiades CS, 2007, HEMATOL ONCOL CLIN N, V21, P1007, DOI 10.1016/j.hoc.2007.08.007
   Mitsiades CS, 2004, CANCER CELL, V5, P221, DOI 10.1016/S1535 6108(04)00050 9
   Morgan GJ, 2012, NAT REV CANCER, V12, P335, DOI 10.1038/nrc3257
   Nefedova Y, 2004, BLOOD, V103, P3503, DOI 10.1182/blood 2003 07 2340
   Ono K, 2002, J BONE MINER RES, V17, P774, DOI 10.1359/jbmr.2002.17.5.774
   Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394
   Roy P, 2017, ONCOGENE, V36, P1417, DOI 10.1038/onc.2016.309
   Shi C, 2018, INT J ONCOL, V53, P1138, DOI 10.3892/ijo.2018.4462
   Silbermann Rebecca, 2011, Curr Opin Support Palliat Care, V5, P251, DOI 10.1097/SPC.0b013e328349c524
   Tan X, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.111
   Ulivi V, 2008, J CELL BIOCHEM, V104, P1393, DOI 10.1002/jcb.21717
   Valcárcel M, 2011, J TRANSL MED, V9, DOI 10.1186/1479 5876 9 142
   Waldschmidt JM, 2017, BRIT J HAEMATOL, V179, P36, DOI 10.1111/bjh.14807
   Wang JH, 2014, BLOOD, V124, P555, DOI 10.1182/blood 2014 03 562439
   Wu X, 2020, BRIT J HAEMATOL, V190, P52, DOI 10.1111/bjh.16503
   Xia JL, 2020, MOL ONCOL, V14, P763, DOI 10.1002/1878 0261.12641
   Xie JY, 2010, CL LYMPH MYELOM LEUK, V10, P385, DOI 10.3816/CLML.2010.n.072
   Xu GS, 2012, BLOOD, V119, P4205, DOI 10.1182/blood 2011 05 353300
   Zheng Z, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.211
   Zhou W, 2013, CANCER CELL, V23, P48, DOI 10.1016/j.ccr.2012.12.001
   Zhu YH, 2020, MOL CARCINOGEN, V59, P265, DOI 10.1002/mc.23150
NR 48
TC 7
Z9 8
U1 0
U2 27
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 2211 3428
EI 2211 3436
J9 CELL ONCOL
JI Cell. Oncol.
PD JUN
PY 2021
VL 44
IS 3
BP 643
EP 659
DI 10.1007/s13402 021 00590 4
EA MAR 2021
PG 17
WC Oncology; Cell Biology; Pathology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Cell Biology; Pathology
GA SU8BA
UT WOS:000623818900001
PM 33646559
DA 2025 08 17
ER

PT J
AU Maggio, M
   Lauretani, F
   Ceda, GP
   De Vita, F
   Bondi, G
   Corsonello, A
   Cattabiani, C
   Lattanzio, F
   Ruggiero, C
   Nouvenne, A
   Meschi, T
   Bandinelli, S
   Ferrucci, L
AF Maggio, Marcello
   Lauretani, Fulvio
   Ceda, Gian Paolo
   De Vita, Francesca
   Bondi, Giuliana
   Corsonello, Andrea
   Cattabiani, Chiara
   Lattanzio, Fabrizia
   Ruggiero, Carmelinda
   Nouvenne, Antonio
   Meschi, Tiziana
   Bandinelli, Stefania
   Ferrucci, Luigi
TI Use of proton pump inhibitors is associated with lower trabecular bone
   density in older individuals
SO BONE
LA English
DT Article
DE Bone mineral density; Trabecular bone mineral density; Proton pump
   inhibitors; InCHIANTI Study; Elderly
ID COMMUNITY ACQUIRED PNEUMONIA; CLOSTRIDIUM DIFFICILE INFECTION;
   ACID SUPPRESSIVE DRUGS; MINERAL DENSITY; HIP FRACTURE; POSTMENOPAUSAL
   WOMEN; RISK; OSTEOPOROSIS; METAANALYSIS; OMEPRAZOLE
AB Proton pump inhibitors (PPIs) are highly effective in the treatment of upper gastrointestinal acid related conditions and are fast becoming one of the most frequently prescribed treatments in adult or older persons. Recent data show that long term use of PPIs in older subjects is associated with important undesirable effects, including a higher risk of osteoporotic fractures. The mechanisms of this association are unclear and the relationship between the use of PPIs and parameters of bone mass and geometry has never been fully explored.
   This study investigates the relationship between the chronic use of PPIs and the parameters of bone mass (cortical and trabecular bone mineral density   vBMDc and vBMDt) and bone geometry (cortical and trabecular cross sectional area   tCSA and cCSA) in older individuals.
   The study population consisted of 1038 subjects (452 men and 586 women) 65 years or older, selected from the InCHIANTI study, with complete information on computerized tomography performed at tibial level (pQCT) and on medications. Participants were classified as PPI users and nonusers based on self report of PPI use over the last 15 days, with PPI users (36 subjects, 14 men and 22 women) making up 3.4% of the study population (mean age 75.7 +/  7.4 years). The relationship between use of PPIs and pQCT bone parameters was tested by multivariate linear regression analysis adjusted for age, sex and several clinical factors and/or statistically confounding variables identified by partial correlation coefficient and Spearman partial rank order correlation coefficients, as appropriate (age, sex, EMI, caloric intake, IGF 1, IL 6, calcium, estradiol, bioavailable testosterone, vitamin D, parathyroid hormone, cross sectional muscle area, and level of physical activity). PPI users showed age  and sex adjusted lower vBMDt than nonusers (180.5 +/  54.8 vs. 207.9 +/  59.4, p = 0.001). The inverse association between PPI use and vBMDt remained almost unchanged after adjustment for multiple confounders. There was no statistically significant difference in vBMDc, tCSA and cCSA between PPI users and nonusers. In community dwelling older persons, the use of PPIs is inversely associated with vBMDt, an early marker of the osteoporotic process. These findings suggest that PPI use might increase the risk of fractures in older subjects through its detrimental effects on trabecular bone. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Maggio, Marcello; Ceda, Gian Paolo; Bondi, Giuliana; Meschi, Tiziana] Univ Parma, Sect Geriatr, Dept Clin & Expt Med, I 43126 Parma, PR, Italy.
   [Maggio, Marcello; Lauretani, Fulvio; Ceda, Gian Paolo; De Vita, Francesca; Nouvenne, Antonio; Meschi, Tiziana] Univ Hosp Parma, Geriatr Rehabil Dept, I 43126 Parma, PR, Italy.
   [Corsonello, Andrea] INRCA, Unit Geriatr Pharmacoepidemiol, Contrada Muoio Piccolo Snc, I 87100 Cosenza, CS, Italy.
   [Lattanzio, Fabrizia] INRCA Ancona, Sci Direct, I 60124 Ancona, AN, Italy.
   [Ruggiero, Carmelinda] Univ Perugia, Sch Med, Inst Gerontol & Geriatr, Dept Clin & Expt Med, I 06100 Perugia, PG, Italy.
   [Bandinelli, Stefania] Local Hlth Agcy, Geriatr Unit, I 50122 Florence, FI, Italy.
   [Ferrucci, Luigi] NIA, NIH, Baltimore, MD 21224 USA.
C3 University of Parma; University Hospital of Parma; University of Parma;
   University Hospital of Parma; IRCCS INRCA; IRCCS INRCA; University of
   Perugia; National Institutes of Health (NIH)   USA; NIH National
   Institute on Aging (NIA)
RP Maggio, M (通讯作者)，Univ Parma, Sect Geriatr, Dept Clin & Expt Med, Via Gramsci 14, I 43126 Parma, PR, Italy.
EM marcellomaggio2001@yahoo.it
RI Andrea, Corsonello/AAC 1845 2022; bandinelli, stefania/AAL 4570 2020;
   Fanelli, Francesca/O 1734 2015; Ferrucci, Luigi/AED 9724 2022;
   Lattanzio, Fabrizia/D 2896 2018; Meschi, Tiziana/K 5032 2016; Ceda,
   Gian/B 5841 2011; RUGGIERO, CARMELINDA/K 6169 2016; Lauretani,
   Fulvio/K 5115 2016; meschi, tiziana/K 5032 2016
OI Corsonello, Andrea/0000 0002 7276 3256; Ruggiero,
   Carmelinda/0000 0002 1245 1963; Ferrucci, Luigi/0000 0002 6273 1613;
   Bandinelli, Stefania/0000 0002 6491 0850; Ceda, Gian
   Paolo/0000 0002 9648 8295; Lattanzio, Fabrizia/0000 0003 4051 1289;
   Nouvenne, Antonio/0000 0002 2680 2242; Lauretani,
   Fulvio/0000 0002 5287 9972; meschi, tiziana/0000 0002 7538 6863
FU Italian Ministry of Health [ICS 110.1/RS97.71]; US National Institute on
   Aging [N01 AG 916413, N01 AG 821336]; Intramural Research Program of the
   US National Institute on Aging [263 MD 9164 13, 263 MD 821336]; Italian
   Ministry of Health and Emilia Romagna Region [RF 2010 2312659]
FX The InCHIANTI Study was supported as a "targeted project" (ICS
   110.1/RS97.71) by the Italian Ministry of Health and in part by the US
   National Institute on Aging (Contracts N01 AG 916413 and N01 AG 821336),
   and by the Intramural Research Program of the US National Institute on
   Aging (Contracts 263 MD 9164 13 and 263 MD 821336) and by grant
   RF 2010 2312659 from the Italian Ministry of Health and Emilia Romagna
   Region. None of the sponsoring institutions interfered with the
   collection, analysis, presentation, or interpretation of the data
   reported here.
CR Abraham NS, 2012, CURR OPIN GASTROEN, V28, P615, DOI 10.1097/MOG.0b013e328358d5b9
   Abrahamsen B, 2011, ARCH INTERN MED, V171, P998, DOI 10.1001/archinternmed.2011.20
   Bartali B, 2004, ARCH GERONTOL GERIAT, V38, P51, DOI 10.1016/S0167 4943(03)00084 0
   Bashford JNR, 1998, BMJ BRIT MED J, V317, P452, DOI 10.1136/bmj.317.7156.452
   Bavishi C, 2011, ALIMENT PHARM THER, V34, P1269, DOI 10.1111/j.1365 2036.2011.04874.x
   Bhatt DL, 2010, CIRCULATION, V122, pE438, DOI 10.1161/CIR.0b013e3181efaab5
   Charlot M, 2011, BRIT MED J, V342, DOI 10.1136/bmj.d2690
   Chen H, 2013, INT J ENDOCRINOL, V2013, P213
   Cundy T, 2008, CLIN ENDOCRINOL, V69, P338, DOI 10.1111/j.1365 2265.2008.03194.x
   Ferrucci L, 2000, J AM GERIATR SOC, V48, P1618, DOI 10.1111/j.1532 5415.2000.tb03873.x
   Forgacs I, 2008, BMJ BRIT MED J, V336, P2, DOI 10.1136/bmj.39406.449456.BE
   Rodríguez LAG, 2009, EPIDEMIOLOGY, V20, P800, DOI 10.1097/EDE.0b013e3181b5f27d
   Grant K, 2006, PHARM WORLD SCI, V28, P189, DOI 10.1007/s11096 006 9028 4
   Gray SL, 2010, ARCH INTERN MED, V170, P765, DOI 10.1001/archinternmed.2010.94
   Hoorn EJ, 2010, AM J KIDNEY DIS, V56, P112, DOI 10.1053/j.ajkd.2009.11.019
   Howell MD, 2010, ARCH INTERN MED, V170, P784, DOI 10.1001/archinternmed.2010.89
   Johnstone J, 2010, ALIMENT PHARM THER, V31, P1165, DOI 10.1111/j.1365 2036.2010.04284.x
   Kwok CS, 2011, BONE, V48, P768, DOI 10.1016/j.bone.2010.12.015
   Laheij RJF, 2004, JAMA J AM MED ASSOC, V292, P1955, DOI 10.1001/jama.292.16.1955
   Lau YT, 2012, PHARMACOTHERAPY, V32, P67, DOI 10.1002/PHAR.1007
   Lauretani F, 2006, BONE, V39, P915, DOI 10.1016/j.bone.2006.03.014
   Lauretani F, 2008, J BONE MINER RES, V23, P400, DOI 10.1359/JBMR.071103
   Linsky A, 2010, ARCH INTERN MED, V170, P772, DOI 10.1001/archinternmed.2010.73
   Maggio M, 2013, JAMA INTERN MED, V173, P518, DOI 10.1001/jamainternmed.2013.2851
   MARCUARD SP, 1994, ANN INTERN MED, V120, P211, DOI 10.7326/0003 4819 120 3 199402010 00006
   McCarthy DM, 2010, CURR OPIN GASTROEN, V26, P624, DOI 10.1097/MOG.0b013e32833ea9d9
   McLean RR, 2004, NEW ENGL J MED, V350, P2042, DOI 10.1056/NEJMoa032739
   Faulhaber GAM, 2010, ARCH INTERN MED, V170, P1776, DOI 10.1001/archinternmed.2010.374
   Naunton M, 2000, J CLIN PHARM THER, V25, P333, DOI 10.1046/j.1365 2710.2000.00312.x
   Ozdil K, 2013, RHEUMATOL INT, V33, P2255, DOI 10.1007/s00296 013 2709 0
   PAHOR M, 1994, EUR J EPIDEMIOL, V10, P405, DOI 10.1007/BF01719664
   Pasina L, 2011, EUR J INTERN MED, V22, P205, DOI 10.1016/j.ejim.2010.11.009
   Pilotto A, 2006, J AM GERIATR SOC, V54, P1537, DOI 10.1111/j.1532 5415.2006.00899.x
   Pisani P, 1997, INT J EPIDEMIOL, V26, pS152, DOI 10.1093/ije/26.suppl_1.S152
   RECKER RR, 1985, NEW ENGL J MED, V313, P70, DOI 10.1056/NEJM198507113130202
   Regolisti G, 2010, AM J KIDNEY DIS, V56, P168, DOI 10.1053/j.ajkd.2010.03.013
   Rittweger J, 2000, BONE, V27, P319, DOI 10.1016/S8756 3282(00)00327 6
   Russo CR, 2003, OSTEOPOROSIS INT, V14, P531, DOI 10.1007/s00198 002 1322 y
   Saad AZM, 2005, INT J CLIN PRACT, V59, P31, DOI 10.1111/j.1368 5031.2004.00298.x
   Saito M, 2006, CALCIFIED TISSUE INT, V79, P160, DOI 10.1007/s00223 006 0035 1
   Siris ES, 2001, JAMA J AM MED ASSOC, V286, P2815, DOI 10.1001/jama.286.22.2815
   Sultan N, 2008, CAN J GASTROENTEROL, V22, P761, DOI 10.1155/2008/821385
   Targownik LE, 2012, AM J GASTROENTEROL, V107, P1361, DOI 10.1038/ajg.2012.200
   Targownik LE, 2010, GASTROENTEROLOGY, V138, P896, DOI 10.1053/j.gastro.2009.11.014
   U.S. Food and drug Administration, POSS FRACT RISK HIGH
   Valuck RJ, 2004, J CLIN EPIDEMIOL, V57, P422, DOI 10.1016/j.jclinepi.2003.08.015
   VERDU EF, 1994, SCAND J GASTROENTERO, V29, P1065, DOI 10.3109/00365529409094889
   Vermeulen A, 1999, J CLIN ENDOCR METAB, V84, P3666, DOI 10.1210/jc.84.10.3666
   Walker NM, 2001, PHARM WORLD SCI, V23, P116, DOI 10.1023/A:1011278030001
   Yang Yu Xiao, 2012, Curr Gastroenterol Rep, V14, P473, DOI 10.1007/s11894 012 0290 4
   Yu EW, 2008, CALCIFIED TISSUE INT, V83, P251, DOI 10.1007/s00223 008 9170 1
   Yu EW, 2011, AM J MED, V124, P519, DOI 10.1016/j.amjmed.2011.01.007
NR 52
TC 43
Z9 47
U1 0
U2 22
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD DEC
PY 2013
VL 57
IS 2
BP 437
EP 442
DI 10.1016/j.bone.2013.09.014
PG 6
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 250JB
UT WOS:000326848000016
PM 24076021
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Labusca, LS
   Herea, DD
   Radu, E
   Danceanu, C
   Chiriac, H
   Lupu, N
AF Labusca, Luminita Simion
   Herea, Dumitru Daniel
   Radu, Ecaterina
   Danceanu, Camelia
   Chiriac, Horia
   Lupu, Nicoleta
TI Human Adipose Derived Stem Cells and Osteoblasts Interaction with
   Fe Cr Nb B Magnetic Nanoparticles
SO JOURNAL OF NANOSCIENCE AND NANOTECHNOLOGY
LA English
DT Article
DE Magnetic Nanoparticles; Magnetic Hyperthermia; Human Adipose Derived
   Stem Cells; Human Osteoblasts; Cytotoxicity; Particle Upload
ID IN VIVO TRACKING; ENDOTHELIAL CELLS; HYPERTHERMIA; TISSUE;
   DIFFERENTIATION; PROLIFERATION; DELIVERY; THERAPY; MARKER
AB The use of materials at nanoscale is currently of increasing interest for life sciences and medicine. Magnetic nanoparticles (MNPs) are under scrutiny for a large array of applications in nanomedicine as diagnostic and therapeutic tools. Proprietary Fe Cr Nb B MNPs display heating properties that recommends them as potent agents for delivery of local hyperthermia for the treatment of solid tumours. Stem cell mediated delivery represents a safe and accurate modality to target remote or metastatic tumour sites. In this study we investigated the interaction of Fe Cr Nb B nanoparticles with human adipose derived mesenchymal stem cells and human primary osteoblasts. We found that: (a) bare and chitosan coated Fe Cr Nb B are internalized by both cell types, (b) they can be detected up to 28 days inside the cells without signs of membrane disruption and (c) they do not display in vitro toxicity. MNPs are uploaded by cells in a time dependent manner with maximum uptake after 7 8 days cell particle incubation. Particle internalization do not interfere with proliferative and differentiation potential (osteogenesis and adipogenesis) demonstrating an unaltered cellular phenotype. Further investigation of the potential effect of MNPs internalization on cytoskeleton dynamics and in inducing oxidative stress will be required as it is of interest for predicting cell migration and survival after transplantation. Present results are encouraging for designing a stem cell mediated delivery of Fe Cr Nb B magnetic nanoparticles to solid tumour sites for hyperthermia applications.
C1 [Labusca, Luminita Simion; Herea, Dumitru Daniel; Radu, Ecaterina; Danceanu, Camelia; Chiriac, Horia; Lupu, Nicoleta] Natl Inst Res & Dev Tech Phys, 47 Mangeron Blvd, Iasi 700050, Romania.
   [Labusca, Luminita Simion] SBIM, KG, 39 Basaltstr, D 60487 Frankfurt, Germany.
C3 National Institute of Research & Development for Technical Physics  
   Romania
RP Labusca, LS (通讯作者)，Natl Inst Res & Dev Tech Phys, 47 Mangeron Blvd, Iasi 700050, Romania.; Labusca, LS (通讯作者)，SBIM, KG, 39 Basaltstr, D 60487 Frankfurt, Germany.
RI Labusca, Luminita/AAF 8572 2020; Lupu, Nicoleta/B 7291 2011; Herea,
   Dumitru/A 4917 2019; Chiriac, Horia/C 4821 2011; Herea,
   Dumitru Daniel/A 4917 2019
OI Herea, Dumitru Daniel/0000 0002 8455 8380
FU ANCSI NUCLEU Programme [PN 16 37 01 03]
FX This work was supported by ANCSI NUCLEU Programme, under Grant PN 16 37
   01 03.
CR Adams C, 2016, ADV HEALTHC MATER, V5, P841, DOI 10.1002/adhm.201500885
   Agotegaray M, 2016, J BIOMAT SCI POLYM E, V27, P1069, DOI 10.1080/09205063.2016.1170417
   Arbab AS, 2005, NMR BIOMED, V18, P553, DOI 10.1002/nbm.991
   Attaluri A, 2015, INT J HYPERTHER, V31, P359, DOI 10.3109/02656736.2015.1005178
   Azhar S. L., 2016, PHARMAZIE, V67, P817
   Berman SMC, 2011, WIRES NANOMED NANOBI, V3, P343, DOI 10.1002/wnan.140
   Bertolo A, 2015, STEM CELL TRANSL MED, V4, P84, DOI 10.5966/sctm.2014 0156
   Bull E, 2014, INT J NANOMED, V9, P1641, DOI 10.2147/IJN.S48979
   Chiriac H., 2013, MAGN MAGN MAT, V380, P13
   Chiriac H., 2014, J APPL PHYS, V1154
   Cho H, 2013, BIOTECHNOL APPL BIOC, V60, P596, DOI 10.1002/bab.1109
   Cores J, 2015, J FUNCT BIOMATER, V6, P526, DOI 10.3390/jfb6030526
   da Silva AC, 2010, EINSTEIN SAO PAULO, V8, P361, DOI [10.1590/s1679 45082010rw1757, 10.1590/S1679 45082010RW1757]
   Danková J, 2015, INT J NANOMED, V10, P7307, DOI 10.2147/IJN.S93670
   Du YM, 2013, INT J MOL SCI, V14, P18682, DOI 10.3390/ijms140918682
   Fu PP, 2014, J FOOD DRUG ANAL, V22, P64, DOI 10.1016/j.jfda.2014.01.005
   Hashimoto M, 2017, J BIOMATER TISS ENG, V7, P139, DOI 10.1166/jbt.2017.1555
   Huang CY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096550
   Kalber TL, 2016, INT J NANOMED, V11, P1973, DOI 10.2147/IJN.S94255
   Kanda J, 2011, EXPERT REV HEMATOL, V4, P71, DOI [10.1586/ehm.10.81, 10.1586/EHM.10.81]
   Kasten A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108055
   Kedziorek DA, 2010, METHODS MOL BIOL, V660, P171, DOI 10.1007/978 1 60761 705 1_11
   Kettler K, 2014, ENVIRON TOXICOL CHEM, V33, P481, DOI 10.1002/etc.2470
   Kim DH, 2007, CELL TRANSPLANT, V16, P1007, DOI 10.3727/000000007783472381
   Kim YC, 2011, WATER SCI TECHNOL, V64, P469, DOI 10.2166/wst.2011.566
   Labusca L, 2012, CURR STEM CELL RES T, V7, P319, DOI 10.2174/157488812802481490
   Landázuri N, 2013, SMALL, V9, P4017, DOI 10.1002/smll.201300570
   Lartigue L, 2013, ACS NANO, V7, P3939, DOI 10.1021/nn305719y
   Lima J, 2015, J MAGN MAGN MATER, V393, P526, DOI 10.1016/j.jmmm.2015.05.087
   Markides H, 2012, J NANOMATER, V2012, DOI 10.1155/2012/614094
   Matsubara T., 2013, INT J CLIN MED, V4, P35763
   O'Brien T, 2009, MAYO CLIN PROC, V84, P859, DOI 10.4065/84.10.859
   Orynbayeva Z, 2015, NANOMEDICINE UK, V10, P1555, DOI [10.2217/NNM.15.14, 10.2217/nnm.15.14]
   Schäfer R, 2010, BMC CELL BIOL, V11, DOI 10.1186/1471 2121 11 22
   Stocke NA, 2017, BIOMATERIALS, V120, P115, DOI 10.1016/j.biomaterials.2016.12.019
   Wang QX, 2017, J BIOMATER TISS ENG, V7, P590, DOI 10.1166/jbt.2017.1601
   Wang YXJ, 2015, WORLD J GASTROENTERO, V21, P13400, DOI 10.3748/wjg.v21.i47.13400
   Wimpenny I, 2012, STEM CELL RES THER, V3, DOI 10.1186/scrt104
   Zarjou A, 2010, J BONE MINER RES, V25, P164, DOI 10.1359/jbmr.091002
   Zhang L, 2016, J NANOSCI NANOTECHNO, V16, P9008, DOI 10.1166/jnn.2016.12741
   Zhang Z, 2009, CYTOTHERAPY, V11, P43, DOI 10.1080/14653240802420243
   Zhao Q, 2012, THERANOSTICS, V2, P113, DOI 10.7150/thno.3854
   Zhu Y, 2017, ACS NANO, V11, P3690, DOI 10.1021/acsnano.6b08193
   Zuk PA, 2002, MOL BIOL CELL, V13, P4279, DOI 10.1091/mbc.E02 02 0105
NR 44
TC 8
Z9 9
U1 2
U2 63
PU AMER SCIENTIFIC PUBLISHERS
PI VALENCIA
PA 26650 THE OLD RD, STE 208, VALENCIA, CA 91381 0751 USA
SN 1533 4880
EI 1533 4899
J9 J NANOSCI NANOTECHNO
JI J. Nanosci. Nanotechnol.
PD JUL
PY 2018
VL 18
IS 7
BP 5143
EP 5153
DI 10.1166/jnn.2018.15330
PG 11
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary; Physics, Applied; Physics, Condensed Matter
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science;
   Physics
GA FX4ON
UT WOS:000426057800089
PM 29442706
DA 2025 08 17
ER

PT J
AU Zhou, CH
   Cai, ZH
   Guo, JL
   Li, CF
   Qin, CH
   Yan, JW
   Yang, DH
AF Zhou, Chunhao
   Cai, Zhihai
   Guo, Jialiang
   Li, Chengfu
   Qin, Chenghe
   Yan, Juanwen
   Yang, Dehong
TI Injective hydrogel loaded with liposomes encapsulated MY 1 promotes
   wound healing and increases tensile strength by accelerating fibroblast
   migration via the PI3K/AKT Rac1 signaling pathway
SO JOURNAL OF NANOBIOTECHNOLOGY
LA English
DT Article
DE Wound healing; Liposome; GelMA; PI3K/AKT; Rac1; Cell migration;
   hPTH(3 34)(29 34)
ID BONE REGENERATION; DEHISCENCE; DYNAMICS; RAC1; RISK
AB Failed skin wound healing, through delayed wound healing or wound dehiscence, is a global public health issue that imposes significant burdens on individuals and society. Although the application of growth factor is an effective method to improve the pace and quality of wound healing, the clinically approved factors are limited. Parathyroid hormone (PTH) demonstrates promising results in wound healing by promoting collagen deposition and cell migration, but its application is limited by potentially inhibitory effects when administered continuously and locally. Through partially replacing and repeating the amino acid domains of PTH(1 34), we previously designed a novel PTH analog, PTH(3 34)(29 34) or MY 1, and found that it avoided the inhibitory effects of PTH while retaining its positive functions. To evaluate its role in wound healing, MY 1 was encapsulated in liposomes and incorporated into the methacryloyl gelatin (GelMA) hydrogel, through which an injectable nanocomposite hydrogel (GelMA MY@Lipo, or GML) was developed. In vitro studies revealed that the GML had similar properties in terms of the appearance, microstructure, functional groups, swelling, and degradation capacities as the GelMA hydrogel. In vitro drug release testing showed a relatively more sustainable release of MY 1, which was still detectable in vivo 9 days post application. When the GML was topically applied to the wound areas of rat models, wound closure as well as tensile strength were improved. Further studies showed that the effects of GML on wound repair and tensile strength were closely related to the promotion of fibroblast migration to the wound area through the controlled release of MY 1. Mechanically, MY 1 enhanced fibroblast migration by activating PI3K/AKT signaling and its downstream molecule, Rac1, by which it increased fibroblast aggregation in the early stage and resulting in denser collagen deposition at a later time. Overall, these findings demonstrated that the nanocomposite hydrogel system promoted skin wound healing and increased tensile strength, thus offering new potential in the treatment of wound healing.
C1 [Zhou, Chunhao; Cai, Zhihai; Guo, Jialiang; Li, Chengfu; Yang, Dehong] Southern Med Univ, Nanfang Hosp, Dept Orthoped Spinal Surg, 1838 Guangzhou North Ave, Guangzhou 510515, Peoples R China.
   [Qin, Chenghe] Southern Med Univ, Nanfang Hosp, Dept Orthoped Traumatol, Guangzhou 510515, Peoples R China.
   [Yan, Juanwen] Southern Med Univ, Nanfang Hosp, Dept Stomatol, Guangzhou 510515, Peoples R China.
C3 Southern Medical University   China; Southern Medical University  
   China; Southern Medical University   China
RP Yang, DH (通讯作者)，Southern Med Univ, Nanfang Hosp, Dept Orthoped Spinal Surg, 1838 Guangzhou North Ave, Guangzhou 510515, Peoples R China.; Yan, JW (通讯作者)，Southern Med Univ, Nanfang Hosp, Dept Stomatol, Guangzhou 510515, Peoples R China.
EM 645613053@qq.com; drmyang@yahoo.com
FU National Natural Science Foundation of China [82271616, 82171573];
   Guangzhou Municipal Science and Technology Program key projects
   [202103000052]
FX This work was supported by the National Natural Science Foundation of
   China (Grant No. 82271616 and 82171573) and the Guangzhou Municipal
   Science and Technology Program key projects (202103000052).
CR Ashraf A, 2009, PLAST RECONSTR SURG, V124, P1118, DOI 10.1097/PRS.0b013e3181b5a349
   Barreiro G, 2019, BMC SURG, V19, DOI 10.1186/s12893 019 0523 7
   Barrientos S, 2014, WOUND REPAIR REGEN, V22, P569, DOI 10.1111/wrr.12205
   Byrne KM, 2016, CELL SYST, V2, P38, DOI 10.1016/j.cels.2016.01.003
   Castilho RM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010503
   Cheng RY, 2020, BIOMATERIALS, V232, DOI 10.1016/j.biomaterials.2019.119706
   Chiavistelli S, 2015, BONE RES, V3, DOI 10.1038/boneres.2014.49
   Eleftheriadou I, 2019, EXPERT OPIN PHARMACO, V20, P1153, DOI 10.1080/14656566.2019.1598378
   Evrova O, 2020, BIOMATERIALS, V232, DOI 10.1016/j.biomaterials.2019.119722
   Feng LB, 2023, ADV HEALTHC MATER, V12, DOI 10.1002/adhm.202203201
   Fort L, 2018, NAT CELL BIOL, V20, P1159, DOI 10.1038/s41556 018 0198 9
   Gao C, 2022, NANO LETT, V22, P8801, DOI 10.1021/acs.nanolett.2c01994
   Ha P, 2018, Clin Surg (Las Vegas), P1
   He YH, 2020, BONE, V135, DOI 10.1016/j.bone.2020.115326
   Hecker TM, 2004, DRUGS, V64, P133, DOI 10.2165/00003495 200464020 00002
   Jahanmard F, 2023, J CONTROL RELEASE, V358, P667, DOI 10.1016/j.jconrel.2023.05.022
   Jiang WL, 2018, J CELL MOL MED, V22, P2510, DOI 10.1111/jcmm.13516
   Johnson ON, 2021, PRS GLOB OPEN, V9, DOI 10.1097/GOX.0000000000003496
   Kanazawa S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012228
   Kraynov VS, 2000, SCIENCE, V290, P333, DOI 10.1126/science.290.5490.333
   Li GQ, 2023, NAT COMMUN, V14, DOI 10.1038/s41467 023 38597 0
   Li MN, 2021, J MATER CHEM B, V9, P4700, DOI 10.1039/d1tb00449b
   Li SY, 2023, BIOMATER RES, V27, DOI 10.1186/s40824 023 00352 3
   Lindner HB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127876
   Lintel H, 2022, WOUND REPAIR REGEN, DOI 10.1111/wrr.13062
   Liu H, 2024, INT J BIOL MACROMOL, V257, DOI 10.1016/j.ijbiomac.2023.128481
   Menger MM, 2023, J TRANSL MED, V21, DOI 10.1186/s12967 023 04661 y
   Moretti L, 2022, J BIOL CHEM, V298, DOI 10.1016/j.jbc.2021.101530
   Navarro Lérida I, 2015, DEV CELL, V32, P318, DOI 10.1016/j.devcel.2014.12.019
   Nonsuwan P, 2023, CARBOHYD POLYM, V321, DOI 10.1016/j.carbpol.2023.121294
   Porfidia Raffaele, 2020, Wounds, V32, pE114
   Ren F, 2020, THERIOGENOLOGY, V155, P205, DOI 10.1016/j.theriogenology.2020.06.012
   Rosen RD MB, 2023, StatPearls Internet
   Sandy Hodgetts K, 2023, J WOUND CARE, V32, pS4, DOI 10.12968/jowc.2023.32.Sup8a.S4
   Sandy Hodgetts K, 2015, INT WOUND J, V12, P265, DOI 10.1111/iwj.12088
   Sarojini H, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.594586
   Saxena A, 2023, J PHARM BIOALLIED SC, V15, pS1145, DOI 10.4103/jpbs.jpbs_187_23
   Shen YF, 2020, CELL COMMUN SIGNAL, V18, DOI 10.1186/s12964 020 00541 w
   Shi HX, 2015, INT J BIOL SCI, V11, P845, DOI 10.7150/ijbs.11921
   Sim IW, 2020, J CLIN ONCOL, V38, P2971, DOI 10.1200/JCO.19.02192
   Smith LG, 2004, CURR BIOL, V14, pR109, DOI 10.1016/j.cub.2004.01.016
   Tang H, 2020, Cell Death Dis, P11
   Theocharidis G, 2022, NAT BIOMED ENG, V6, P1118, DOI 10.1038/s41551 022 00905 2
   Wang ZG, 2016, MOL NEUROBIOL, V53, P7298, DOI 10.1007/s12035 015 9583 6
   Wang ZX, 2023, ASIAN J PHARM SCI, V18, DOI 10.1016/j.ajps.2023.100800
   Xu WL, 2023, ACTA BIOMATER, V160, P225, DOI 10.1016/j.actbio.2023.02.004
   Xue ML, 2015, ADV WOUND CARE, V4, P119, DOI 10.1089/wound.2013.0485
   Yanli Z, 2023, ADV HEALTHC MATER, V12, DOI 10.1002/adhm.202300332
   Yao ZX, 2021, MAT SCI ENG C MATER, V119, DOI 10.1016/j.msec.2020.111446
   Yu JR, 2020, ACTA BIOMATER, V108, P67, DOI 10.1016/j.actbio.2020.03.015
   Yuk H, 2019, NATURE, V575, P169, DOI 10.1038/s41586 019 1710 5
   Zhang T, 2020, BIOMED PHARMACOTHER, V129, DOI 10.1016/j.biopha.2020.110287
   Zhou C., 2023, Cell Commun Signal, V21, P1
NR 53
TC 2
Z9 2
U1 8
U2 27
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1477 3155
J9 J NANOBIOTECHNOL
JI J. Nanobiotechnol.
PD JUL 5
PY 2024
VL 22
IS 1
AR 396
DI 10.1186/s12951 024 02666 3
PG 22
WC Biotechnology & Applied Microbiology; Nanoscience & Nanotechnology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Science & Technology   Other
   Topics
GA XN3Q8
UT WOS:001262330000001
PM 38965546
OA gold
DA 2025 08 17
ER

PT J
AU Basu, S
   Pacelli, S
   Feng, Y
   Lu, QH
   Wang, JX
   Paul, A
AF Basu, Sayantani
   Pacelli, Settimio
   Feng, Yi
   Lu, Qinghua
   Wang, Jinxi
   Paul, Arghya
TI Harnessing the Noncovalent Interactions of DNA Backbone with 2D Silicate
   Nanodisks To Fabricate Injectable Therapeutic Hydrogels
SO ACS NANO
LA English
DT Article
DE nanocomposites; DNA; two dimensional nanosilicates; physical
   cross linking; injectable hydrogels; controlled release
ID MESENCHYMAL STEM CELLS; BONE SIALOPROTEIN; PHOTOELECTRON SPECTROSCOPY;
   OSTEOBLAST DIFFERENTIATION; NANOCOMPOSITE HYDROGELS; ALLOGRAFT
   INCORPORATION; CONTROLLED DELIVERY; LOCAL DELIVERY; METAL IONS;
   REGENERATION
AB Injectable hydrogels present several advantages over prefabricated scaffolds including ease of delivery, shear thinning property, and broad applicability in the fields of drug delivery and tissue engineering. Here, we report an approach to develop injectable hydrogels with sustained drug release properties, exploiting the chemical nature of the DNA backbone and silicate nanodisks. A two step gelation method is implemented for generating a combination of noncovalent network points, leading to a physically cross linked hydrogel. The first step initiates the development of an interconnected structure by utilizing DNA denaturation and rehybridization mechanism to form hydrogen bonds between complementary base pairs of neighboring DNA strands. The anisotropic charge distribution of two dimensional silicate nanodisks (nSi) makes them an active center in the second step of the gelation process. Silicate nanodisks create additional network points via attractive electrostatic interactions with the DNA backbone, thereby enhancing the mechanical resilience of the formulated hydrogel. The thermally stable hydrogels displayed an increase in elasticity and yield stress as a function of nSi concentration. They were able to form self supporting structures post injection due to their rapid recovery after removal of cyclic stress. Moreover, the presence of nanosilicate was shown to modulate the release of a model osteogenic drug dexamethasone (Dex). The bioactivity of released Dex was confirmed from in vitro osteogenic differentiation of human adipose stem cells and in vivo bone formation in a rat cranial bone defect model. Overall, our DNA based nanocomposite hydrogel obtained from a combination of noncovalent network points can serve as an injectable material for bone regeneration and carrier for sustained release of therapeutics.
C1 [Basu, Sayantani; Pacelli, Settimio; Paul, Arghya] Univ Kansas, Sch Engn, Dept Chem & Petr Engn, BioIntel Res Lab, Lawrence, KS 66045 USA.
   [Feng, Yi; Lu, Qinghua; Wang, Jinxi] Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, Harrington Lab Mol Orthoped,Dept Orthoped Surg, Kansas City, KS 66160 USA.
C3 University of Kansas; University of Kansas; University of Kansas Medical
   Center
RP Paul, A (通讯作者)，Univ Kansas, Sch Engn, Dept Chem & Petr Engn, BioIntel Res Lab, Lawrence, KS 66045 USA.
EM arghyapaul@ku.edu
RI Lu, Qinghua/AAG 3378 2021; Paul, Arghya/AAT 4155 2020
OI Paul, Arghya/0000 0003 4788 0378; Pacelli, Settimio/0000 0002 4879 3615
FU University of Kansas; Institutional Development Award (IDeA) from the
   National Institute of General Medical Sciences (NIGMS) of the NIH
   [P20GM103638]; University of Kansas New Faculty General Research Fund;
   U.S. National Institutes of Health (NIH) [R01 DE018713]
FX The authors acknowledge the University of Kansas for funding and
   assistance which made possible the realization of this research project.
   A.P. acknowledges an investigator grant provided by the Institutional
   Development Award (IDeA) from the National Institute of General Medical
   Sciences (NIGMS) of the NIH Award Number P20GM103638, University of
   Kansas New Faculty General Research Fund. J.W. would like to acknowledge
   Mary A. and Paul R. Harrington Distinguished Professorship Endowment and
   the funding support provided by the U.S. National Institutes of Health
   (NIH) under Award Number R01 DE018713. The authors acknowledge Prof.
   Stevin Gehrke for providing assistance and access to all his laboratory
   instruments. Finally, the authors are thankful to Dr. Prem Thapa from
   the University of Kansas Microscopy and Analytical Imaging Laboratory
   for his assistance with SEM, TEM imaging, XPS and EDX analysis.
CR Ahmad R, 2003, BIOPHYS J, V84, P2460, DOI 10.1016/S0006 3495(03)75050 4
   Ahmadi F, 2015, RES PHARM SCI, V10, P1
   Aronin CEP, 2010, BIOMATERIALS, V31, P6417, DOI 10.1016/j.biomaterials.2010.04.061
   Aubin JE, 1998, J CELL BIOCHEM, P73, DOI 10.1002/(SICI)1097 4644(1998)72:30/31+<73::AID JCB11>3.0.CO;2 L
   Caramella C, 2016, J DRUG DELIV SCI TEC, V32, P206, DOI 10.1016/j.jddst.2015.05.015
   Carrow JK, 2018, P NATL ACAD SCI USA, V115, pE3905, DOI 10.1073/pnas.1716164115
   Cerofolini GF, 2003, SURF INTERFACE ANAL, V35, P968, DOI 10.1002/sia.1632
   Ekenseair AK, 2013, ADV DRUG DELIVER REV, V65, P89, DOI 10.1016/j.addr.2012.08.017
   Gaharwar AK, 2014, ACS NANO, V8, P9833, DOI 10.1021/nn503719n
   Gaharwar AK, 2013, ADV MATER, V25, P3329, DOI 10.1002/adma.201300584
   Gaihre B, 2017, J FUNCT BIOMATER, V8, DOI 10.3390/jfb8040049
   Ganss B, 1999, CRIT REV ORAL BIOL M, V10, P79, DOI 10.1177/10454411990100010401
   Gao Y., 2015, J NANOTECHNOL ENG ME, V6
   Glassman MJ, 2013, ADV FUNCT MATER, V23, P1182, DOI 10.1002/adfm.201202034
   Glynn ERA, 2013, J ANIM SCI BIOTECHNO, V4, DOI 10.1186/2049 1891 4 40
   Guo WW, 2014, CHEM COMMUN, V50, P4065, DOI 10.1039/c3cc49140d
   Guvendiren M, 2012, SOFT MATTER, V8, P260, DOI 10.1039/c1sm06513k
   Han DS, 2014, J CRANIOFAC SURG, V25, P196, DOI 10.1097/SCS.0000000000000378
   Hoffman MD, 2013, BIOMATERIALS, V34, P8887, DOI 10.1016/j.biomaterials.2013.08.005
   Huang C, 2012, CELL TISSUE RES, V347, P553, DOI 10.1007/s00441 011 1217 3
   Jatav S, 2014, APPL CLAY SCI, V97 98, P72, DOI 10.1016/j.clay.2014.06.004
   Jikko A, 1999, J BONE MINER RES, V14, P1075, DOI 10.1359/jbmr.1999.14.7.1075
   Jin YF, 2017, ACS APPL MATER INTER, V9, P17457, DOI 10.1021/acsami.7b03613
   Joshi YM, 2008, P ROY SOC A MATH PHY, V464, P469, DOI 10.1098/rspa.2007.0250
   Kahn JS, 2017, ACCOUNTS CHEM RES, V50, P680, DOI 10.1021/acs.accounts.6b00542
   Khunmanee S, 2017, J TISSUE ENG, V8, DOI 10.1177/2041731417726464
   Korin E, 2017, ACS BIOMATER SCI ENG, V3, P882, DOI 10.1021/acsbiomaterials.7b00040
   Kretlow JD, 2009, ADV MATER, V21, P3368, DOI 10.1002/adma.200802009
   Kulkarni SK, 2005, BIOSENS BIOELECTRON, V21, P95, DOI 10.1016/j.bios.2004.09.004
   Kulterer B, 2007, BMC GENOMICS, V8, DOI 10.1186/1471 2164 8 70
   Lee CK, 2008, ANGEW CHEM INT EDIT, V47, P2470, DOI 10.1002/anie.200704600
   Lee KY, 2012, PROG POLYM SCI, V37, P106, DOI 10.1016/j.progpolymsci.2011.06.003
   Li C, 2015, ADV MATER, V27, P3298, DOI 10.1002/adma.201501102
   Mello MLS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043169
   Moretti RD, 2017, FUTUR SCI OA, V3, DOI 10.4155/fsoa 2016 0083
   Nishikawa M, 2014, J CONTROL RELEASE, V180, P25, DOI 10.1016/j.jconrel.2014.02.001
   Pacelli S, 2018, CELL MOL BIOENG, V11, P211, DOI 10.1007/s12195 018 0521 3
   Pacelli S, 2017, ACTA BIOMATER, V58, P479, DOI 10.1016/j.actbio.2017.05.026
   Pacelli S, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 06028 y
   Pandey PK, 2017, PHYS CHEM CHEM PHYS, V19, P804, DOI 10.1039/c6cp06229f
   Park H, 2014, J CONTROL RELEASE, V196, P146, DOI 10.1016/j.jconrel.2014.10.008
   Patel A, 2014, THER DELIV, V5, P337, DOI [10.4155/tde.14.5, 10.4155/TDE.14.5]
   Paul A, 2016, J MATER CHEM B, V4, P3544, DOI 10.1039/c5tb02745d
   Paul A, 2014, ACS NANO, V8, P8050, DOI 10.1021/nn5020787
   Peak CW, 2018, LANGMUIR, V34, P917, DOI 10.1021/acs.langmuir.7b02540
   Schexnailder P, 2009, PHYS CHEM CHEM PHYS, V11, P2760, DOI 10.1039/b820452g
   Schmid F., 2001, ENCY LIFE SCI, DOI [DOI 10.1038/NPG.ELS.0003142, 10.1038/npg.els.0003142]
   Seib FP, 2013, ADV HEALTHC MATER, V2, P1606, DOI 10.1002/adhm.201300034
   Serec K, 2016, NUCLEIC ACIDS RES, V44, P8456, DOI 10.1093/nar/gkw696
   Shamsi M, 2013, J INORG ORGANOMET P, V23, P4, DOI 10.1007/s10904 012 9694 8
   Shao Y, 2017, ACCOUNTS CHEM RES, V50, P659, DOI 10.1021/acs.accounts.6b00524
   Shigekawa H, 1996, APPL PHYS LETT, V68, P1433, DOI 10.1063/1.116104
   Shin M, 2015, ADV FUNCT MATER, V25, P1270, DOI 10.1002/adfm.201403992
   Son, 2014, ENV HLTH TOXICOL, V29
   Strandman S, 2016, GELS BASEL, V2, DOI 10.3390/gels2020016
   Tan HP, 2012, CHEM COMMUN, V48, P10289, DOI 10.1039/c2cc35449g
   Thakur A, 2016, NANOSCALE, V8, P12362, DOI 10.1039/c6nr02299e
   Topuz F, 2009, BIOMACROMOLECULES, V10, P2652, DOI 10.1021/bm900585v
   Turel I, 2011, CURR TOP MED CHEM, V11, P2661, DOI 10.2174/156802611798040787
   Um SH, 2006, NAT MATER, V5, P797, DOI 10.1038/nmat1741
   Vo TN, 2012, ADV DRUG DELIVER REV, V64, P1292, DOI 10.1016/j.addr.2012.01.016
   Volkov IL, 2017, J PHYS CHEM B, V121, P2400, DOI 10.1021/acs.jpcb.6b11218
   Wang D, 2017, ACCOUNTS CHEM RES, V50, P733, DOI 10.1021/acs.accounts.6b00581
   Wang FF, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145677
   Wang J, 2000, CALCIFIED TISSUE INT, V67, P314, DOI 10.1007/s002230001130
   Wang JX, 2006, CALCIFIED TISSUE INT, V79, P179, DOI 10.1007/s00223 006 0018 2
   Waters R, 2016, NANOSCALE, V8, P7371, DOI 10.1039/c5nr07806g
   Wilson SA, 2017, ACS APPL MATER INTER, V9, P43449, DOI 10.1021/acsami.7b13602
   Wu CJ, 2011, MACROMOLECULES, V44, P8215, DOI 10.1021/ma200562k
   Xiong XL, 2013, MACROMOL RAPID COMM, V34, P1271, DOI 10.1002/marc.201300411
   Xu L, 2007, BIOMATERIALS, V28, P750, DOI 10.1016/j.biomaterials.2006.09.022
   Xu YX, 2010, ACS NANO, V4, P7358, DOI 10.1021/nn1027104
   Yuasa M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116462
   Zhao L, 2014, VACCINE, V32, P327, DOI 10.1016/j.vaccine.2013.11.069
NR 74
TC 105
Z9 114
U1 5
U2 185
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1936 0851
EI 1936 086X
J9 ACS NANO
JI ACS Nano
PD OCT
PY 2018
VL 12
IS 10
BP 9866
EP 9880
DI 10.1021/acsnano.8b02434
PG 15
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science
GA GY6ZZ
UT WOS:000448751800023
PM 30189128
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Jeffries, KM
   Brander, SM
   Britton, MT
   Fangue, NA
   Connon, RE
AF Jeffries, Ken M.
   Brander, Susanne M.
   Britton, Monica T.
   Fangue, Nann A.
   Connon, Richard E.
TI Chronic exposures to low and high concentrations of ibuprofen elicit
   different gene response patterns in a euryhaline fish
SO ENVIRONMENTAL SCIENCE AND POLLUTION RESEARCH
LA English
DT Article
DE Inland silverside; NSAIDs; Transcriptomics; Microarray; Gene expression;
   qPCR; Ecotoxicology
ID ANTIINFLAMMATORY DRUGS; ORGANIC CONTAMINANTS; PHARMACEUTICALS;
   TRANSCRIPTOME; EXPRESSION; CHEMICALS; HORMONES; BLOOD; REPRODUCTION;
   GENERATION
AB Ibuprofen is one of the most commonly detected pharmaceuticals in wastewater effluent; however, the effects of ibuprofen on aquatic organisms are poorly understood. This study presents the transcriptome wide response of the inland silverside, Menidia beryllina, to chronic exposure to ibuprofen. At the lowest exposure concentration (0.0115 mg/L), we detected a downregulation of many genes involved in skeletal development, aerobic respiration, and immune function. At the highest exposure concentration (1.15 mg/L), we detected increased expression of regulatory genes in the arachidonic acid metabolism pathway and several immune genes involved in an inflammatory response. Additionally, there was differential expression of genes involved in oxidative stress responses and a downregulation of genes involved in osmoregulation. This study provides useful information for monitoring the effects of this common wastewater effluent contaminant in the environment and for the generation of biomarkers of exposure to ibuprofen that may be transferable to other fish species.
C1 [Jeffries, Ken M.; Connon, Richard E.] Univ Calif Davis, Sch Vet Med, Anat Physiol & Cell Biol, Davis, CA 95616 USA.
   [Jeffries, Ken M.; Fangue, Nann A.] Univ Calif Davis, Wildlife Fish & Conservat Biol, Davis, CA 95616 USA.
   [Brander, Susanne M.] Univ N Carolina, Biol & Marine Biol, Wilmington, NC 28403 USA.
   [Britton, Monica T.] Univ Calif Davis, Bioinformat Core Facil, Genome Ctr, Davis, CA 95616 USA.
C3 University of California System; University of California Davis;
   University of California System; University of California Davis;
   University of North Carolina; University of North Carolina Wilmington;
   University of California System; University of California Davis
RP Jeffries, KM (通讯作者)，Univ Calif Davis, Sch Vet Med, Anat Physiol & Cell Biol, One Shields Ave, Davis, CA 95616 USA.
EM kenmjeffries@gmail.com
FU California Department of Fish and Wildlife [E1183010]; State and Federal
   Contractors Water Agency [201301957]; Delta Stewardship Council
FX The authors thank Linda Deanovic and Marie Stillway of the University of
   California Davis Aquatic Toxicology Laboratory for maintaining the fish
   and conducting the exposures, Jennifer Truong and Bethany DeCourten for
   assisting with the processing of the samples, and Will White and Simone
   Hasenbein for statistical support. This research was funded by the
   California Department of Fish and Wildlife (contract #E1183010, to REC
   and SMB), and the State and Federal Contractors Water Agency (contract
   #201301957, to REC). A Delta Science Postdoctoral Fellowship from the
   Delta Stewardship Council provided funding for KMJ.
CR Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389
   Ankley GT, 2006, ENVIRON SCI TECHNOL, V40, P4055, DOI 10.1021/es0630184
   [Anonymous], 2021, GLMM FAQ
   Ashton D, 2004, SCI TOTAL ENVIRON, V333, P167, DOI 10.1016/j.scitotenv.2004.04.062
   Bhandari K, 2011, COMP BIOCHEM PHYS C, V153, P251, DOI 10.1016/j.cbpc.2010.11.004
   BRAIN P, 1989, WEED RES, V29, P93, DOI 10.1111/j.1365 3180.1989.tb00845.x
   Brander SM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074251
   Brander SM, 2013, MONITORING WATER QUALITY: POLLUTION ASSESSMENT, ANALYSIS, AND REMEDIATION, P103, DOI 10.1016/B978 0 444 59395 5.00005 4
   Brander SM, 2012, ENVIRON TOXICOL CHEM, V31, P2848, DOI 10.1002/etc.2019
   Brander SM, 2009, ENVIRON TOXICOL CHEM, V28, P1493, DOI 10.1897/08 374.1
   Brozinski JM, 2013, ENVIRON SCI TECHNOL, V47, P342, DOI 10.1021/es303013j
   Buser HR, 1999, ENVIRON SCI TECHNOL, V33, P2529, DOI 10.1021/es981014w
   Chadzinska M, 2008, IMMUNOLOGY, V125, P601, DOI 10.1111/j.1365 2567.2008.02874.x
   Conesa A, 2005, BIOINFORMATICS, V21, P3674, DOI 10.1093/bioinformatics/bti610
   Connon RE, 2012, SENSORS BASEL, V12, P12741, DOI 10.3390/s120912741
   Connon RE, 2011, ENVIRON TOXICOL CHEM, V30, P290, DOI 10.1002/etc.400
   Connon RE, 2009, BMC GENOMICS, V10, DOI 10.1186/1471 2164 10 608
   Core Development Team R., 2010, R LANG ENV STAT COMP
   David A, 2009, ENVIRON TOXICOL PHAR, V27, P390, DOI 10.1016/j.etap.2009.01.002
   Doyle MA, 2011, J ENVIRON MONITOR, V13, P3168, DOI 10.1039/c1em10629e
   Fent K, 2006, AQUAT TOXICOL, V76, P122, DOI 10.1016/j.aquatox.2005.09.009
   Fernandez MP, 2007, SCI TOTAL ENVIRON, V373, P250, DOI 10.1016/j.scitotenv.2006.11.018
   Flippin JL, 2007, AQUAT TOXICOL, V81, P73, DOI 10.1016/j.aquatox.2006.11.002
   GITLIN JD, 1988, J BIOL CHEM, V263, P6281
   Gonzalez Rey M, 2011, AQUAT TOXICOL, V105, P264, DOI 10.1016/j.aquatox.2011.06.015
   Grabherr MG, 2011, NAT BIOTECHNOL, V29, P644, DOI 10.1038/nbt.1883
   Gravel A, 2009, COMP BIOCHEM PHYS C, V149, P481, DOI 10.1016/j.cbpc.2008.11.002
   Haas BJ, 2013, NAT PROTOC, V8, P1494, DOI 10.1038/nprot.2013.084
   Han S, 2010, AQUAT TOXICOL, V98, P256, DOI 10.1016/j.aquatox.2010.02.013
   Heckmann LH, 2008, GENOME BIOL, V9, DOI 10.1186/gb 2008 9 2 r40
   Islas Flores H, 2014, ENVIRON SCI POLLUT R, V21, P5157, DOI 10.1007/s11356 013 2477 0
   Jackson VC, 2011, J CELL BIOCHEM, V112, P1857, DOI 10.1002/jcb.23104
   Jeffries KM, 2014, EVOL APPL, V7, P286, DOI 10.1111/eva.12119
   Jeffries KM, 2012, ECOL EVOL, V2, P1747, DOI 10.1002/ece3.274
   Jeffries KM, 2010, ENVIRON TOXICOL CHEM, V29, P2379, DOI 10.1002/etc.265
   Ji K, 2013, J HAZARD MATER, V254, P242, DOI 10.1016/j.jhazmat.2013.03.036
   Kolpin DW, 2002, ENVIRON SCI TECHNOL, V36, P1202, DOI 10.1021/es011055j
   Liao BK, 2009, AM J PHYSIOL REG I, V296, pR1897, DOI 10.1152/ajpregu.00029.2009
   Liu H, 2011, FISH SHELLFISH IMMUN, V30, P992, DOI 10.1016/j.fsi.2010.12.033
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lutz CS, 2013, WIRES RNA, V4, P593, DOI 10.1002/wrna.1183
   Maruya KA, 2014, INTEGR ENVIRON ASSES, V10, P69, DOI 10.1002/ieam.1483
   Metcalfe CD, 2003, ENVIRON TOXICOL CHEM, V22, P2872, DOI 10.1897/02 469
   Milan M, 2013, AQUAT TOXICOL, V126, P17, DOI 10.1016/j.aquatox.2012.10.007
   Morthorst JE, 2013, COMP BIOCHEM PHYS C, V157, P251, DOI 10.1016/j.cbpc.2012.12.001
   Moyle P.B., 1976, Inland fishes of California
   Munakata A, 2010, GEN COMP ENDOCR, V165, P456, DOI 10.1016/j.ygcen.2009.04.011
   Nallani GC, 2011, CHEMOSPHERE, V84, P1371, DOI 10.1016/j.chemosphere.2011.05.008
   Nelson ER, 2013, BONE, V53, P42, DOI 10.1016/j.bone.2012.11.011
   Pounds N, 2008, ECOTOX ENVIRON SAFE, V70, P47, DOI 10.1016/j.ecoenv.2007.07.003
   Robb EL, 2014, CAN J ZOOL, V92, P603, DOI 10.1139/cjz 2013 0131
   Saravanan M, 2012, ENVIRON TOXICOL PHAR, V34, P14, DOI 10.1016/j.etap.2012.02.005
   Satone H, 2011, AQUAT TOXICOL, V103, P79, DOI 10.1016/j.aquatox.2011.02.009
   Sifakis EG, 2012, COMPUT BIOL MED, V42, P19, DOI 10.1016/j.compbiomed.2011.10.003
   Staples JF, 2009, COMP BIOCHEM PHYS A, V153, P95, DOI 10.1016/j.cbpa.2009.02.010
   Supek F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021800
   Vandenberg LN, 2012, ENDOCR REV, V33, P378, DOI 10.1210/er.2011 1050
   Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb 2002 3 7 research0034
   Vieira FA, 2013, GEN COMP ENDOCR, V191, P45, DOI 10.1016/j.ygcen.2013.05.025
   Villeneuve DL, 2012, ENVIRON SCI TECHNOL, V46, P51, DOI 10.1021/es201150a
   Yu Y, 2013, SCI TOTAL ENVIRON, V442, P310, DOI 10.1016/j.scitotenv.2012.10.001
NR 61
TC 40
Z9 43
U1 0
U2 49
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D 69121 HEIDELBERG, GERMANY
SN 0944 1344
EI 1614 7499
J9 ENVIRON SCI POLLUT R
JI Environ. Sci. Pollut. Res.
PD NOV
PY 2015
VL 22
IS 22
BP 17397
EP 17413
DI 10.1007/s11356 015 4227 y
PG 17
WC Environmental Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Environmental Sciences & Ecology
GA CX0YJ
UT WOS:000365423100013
PM 25731088
DA 2025 08 17
ER

PT J
AU Peter, B
   Eisenwort, G
   Sadovnik, I
   Bauer, K
   Willmann, M
   Rülicke, T
   Berger, D
   Stefanzl, G
   Greiner, G
   Hoermann, G
   Keller, A
   Wolf, D
   Culen, M
   Winter, GE
   Hoffmann, T
   Schiefer, AI
   Sperr, WR
   Zuber, J
   Mayer, J
   Valent, P
AF Peter, Barbara
   Eisenwort, Gregor
   Sadovnik, Irina
   Bauer, Karin
   Willmann, Michael
   Ruelicke, Thomas
   Berger, Daniela
   Stefanzl, Gabriele
   Greiner, Georg
   Hoermann, Gregor
   Keller, Alexandra
   Wolf, Dominik
   Culen, Martin
   Winter, Georg E.
   Hoffmann, Thomas
   Schiefer, Ana Iris
   Sperr, Wolfgang R.
   Zuber, Johannes
   Mayer, Jiri
   Valent, Peter
TI BRD4 degradation blocks expression of MYC and multiple forms of stem
   cell resistance in Ph<SUP>+</SUP> chronic myeloid leukemia
SO AMERICAN JOURNAL OF HEMATOLOGY
LA English
DT Article
ID BONE MARROW MICROENVIRONMENT; BCR ABL1 COMPOUND MUTATIONS; TYROSINE
   KINASE INHIBITORS; BCR ABL; IMATINIB MESYLATE; CLINICAL RESISTANCE;
   PROGENITOR CELLS; CHRONIC PHASE; TARGET; BIOLOGY
AB In most patients with chronic myeloid leukemia (CML) clonal cells can be kept under control by BCR::ABL1 tyrosine kinase inhibitors (TKI). However, overt resistance or intolerance against these TKI may occur. We identified the epigenetic reader BRD4 and its downstream effector MYC as growth regulators and therapeutic targets in CML cells. BRD4 and MYC were found to be expressed in primary CML cells, CD34(+)/CD38( ) leukemic stem cells (LSC), and in the CML cell lines KU812, K562, KCL22, and KCL22(T315I). The BRD4 targeting drug JQ1 was found to suppress proliferation in KU812 cells and primary leukemic cells in the majority of patients with chronic phase CML. In the blast phase of CML, JQ1 was less effective. However, the BRD4 degrader dBET6 was found to block proliferation and/or survival of primary CML cells in all patients tested, including blast phase CML and CML cells exhibiting the T315I variant of BCR::ABL1. Moreover, dBET6 was found to block MYC expression and to synergize with BCR::ABL1 TKI in inhibiting the proliferation in the JQ1 resistant cell line K562. Furthermore, BRD4 degradation was found to overcome osteoblast induced TKI resistance of CML LSC in a co culture system and to block interferon gamma induced upregulation of the checkpoint antigen PD L1 in LSC. Finally, dBET6 was found to suppress the in vitro survival of CML LSC and their engraftment in NSG mice. Together, targeting of BRD4 and MYC through BET degradation sensitizes CML cells against BCR::ABL1 TKI and is a potent approach to overcome multiple forms of drug resistance in CML LSC.
C1 [Peter, Barbara; Eisenwort, Gregor; Sadovnik, Irina; Bauer, Karin; Willmann, Michael; Ruelicke, Thomas; Greiner, Georg; Hoermann, Gregor; Keller, Alexandra; Sperr, Wolfgang R.; Valent, Peter] Med Univ Vienna, Ludwig Boltzmann Inst Hematol & Oncol, Waehringer Guertel 18 20, A 1090 Vienna, Austria.
   [Peter, Barbara; Eisenwort, Gregor; Sadovnik, Irina; Bauer, Karin; Berger, Daniela; Stefanzl, Gabriele; Keller, Alexandra; Sperr, Wolfgang R.; Valent, Peter] Med Univ Vienna, Dept Internal Med 1, Div Hematol & Hemostaseol, Waehringer Guertel 18 20, A 1090 Vienna, Austria.
   [Willmann, Michael] Univ Vet Med Vienna, Univ Clin Small Anim Internal Med Small Anim, Dept Compan Anim & Horses, Vienna, Austria.
   [Ruelicke, Thomas] Univ Vet Med Vienna, Inst Lab Anim Sci, Vienna, Austria.
   [Greiner, Georg; Hoermann, Gregor] Med Univ Vienna, Dept Lab Med, Vienna, Austria.
   [Hoermann, Gregor] MLL Munich Leukemia Lab, Munich, Germany.
   [Wolf, Dominik] Innsbruck Med Univ, Dept Hematol & Oncol, Innsbruck, Austria.
   [Wolf, Dominik] Univ Hosp Bonn, Ctr Integrated Oncol Cologne Bonn, Dept Hematol Oncol & Rheumatol, Bonn, Germany.
   [Culen, Martin; Mayer, Jiri] Masaryk Univ, Fac Med, Dept Internal Med Hematol & Oncol, Brno, Czech Republic.
   [Culen, Martin; Mayer, Jiri] Univ Hosp Brno, Dept Internal Med Hematol & Oncol, Brno, Czech Republic.
   [Winter, Georg E.] Austrian Acad Sci, CeMM Res Ctr Mol Med, Vienna, Austria.
   [Hoffmann, Thomas; Zuber, Johannes] Vienna BioCtr VBC, Res Inst Mol Pathol IMP, Vienna, Austria.
   [Schiefer, Ana Iris] Med Univ Vienna, Dept Pathol, Vienna, Austria.
   [Zuber, Johannes] Med Univ Vienna, Vienna BioCtr VBC, Vienna, Austria.
C3 Ludwig Boltzmann Institute; Medical University of Vienna; Medical
   University of Vienna; University of Veterinary Medicine Vienna;
   University of Veterinary Medicine Vienna; Medical University of Vienna;
   MLL Munich Leukemia Laboratory; Medical University of Innsbruck;
   University of Bonn; Masaryk University Brno; University Hospital Brno;
   Austrian Academy of Sciences; CeMM Research Center for Molecular
   Medicine of the Austrian Academy of Sciences; Vienna Biocenter (VBC);
   Research Institute of Molecular Pathology (IMP); Medical University of
   Vienna; Medical University of Vienna; Vienna Biocenter (VBC)
RP Valent, P (通讯作者)，Med Univ Vienna, Ludwig Boltzmann Inst Hematol & Oncol, Waehringer Guertel 18 20, A 1090 Vienna, Austria.; Valent, P (通讯作者)，Med Univ Vienna, Dept Internal Med 1, Div Hematol & Hemostaseol, Waehringer Guertel 18 20, A 1090 Vienna, Austria.
EM peter.valent@meduniwien.ac.at
RI ; Peter, Barbara/O 8110 2018; Schiefer, Ana Iris/AAX 8123 2020;
   Hoermann, Gregor/B 8832 2016; Zuber, Johannes/E 7517 2011; Valent,
   Peter/B 8533 2016; Eisenwort, Gregor/E 7761 2018; berger,
   daniela/O 7476 2018
OI Wolf, Dominik/0000 0002 4761 075X; Valent, Peter/0000 0003 0456 5095;
   Sperr, Wolfgang/0000 0003 3288 8027; Hoermann,
   Gregor/0000 0002 7374 4380; Rulicke, Thomas/0000 0002 2121 9496; Zuber,
   Johannes/0000 0001 8810 6835; Bauer, Karin/0000 0001 9927 042X; Greiner,
   Georg/0000 0002 0917 4117; Eisenwort, Gregor/0000 0003 2735 4645;
   Sadovnik, Irina/0000 0001 5418 5942
FU Austrian Science Fund [F4701 B20, F4704 B20, F4710 B20, P30625 B28];
   Celgene; Austrian Science Fund (FWF) [P30625] Funding Source: Austrian
   Science Fund (FWF)
FX Austrian Science Fund, Grant/Award Numbers: F4701 B20, F4704 B20,
   F4710 B20, P30625 B28; Celgene, Grant/Award Number: Research Grant
CR Aceves Luquero CI, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006124
   Agarwal P, 2015, ADV CANCER RES, V127, P227, DOI 10.1016/bs.acr.2015.04.007
   Arlinghaus Ralph, 2004, Cancer Treat Res, V119, P239
   Arrigoni E, 2018, STEM CELL TRANSL MED, V7, P305, DOI 10.1002/sctm.17 0175
   Barnes DJ, 2006, CELL CYCLE, V5, P2862, DOI 10.4161/cc.5.24.3573
   Byrgazov K, 2018, HAEMATOLOGICA, V103, DOI 10.3324/haematol.2017.176347
   Corbin AS, 2011, J CLIN INVEST, V121, P396, DOI 10.1172/JCI35721
   Cortes JE, 2013, NEW ENGL J MED, V369, P1783, DOI 10.1056/NEJMoa1306494
   Dawson MA, 2012, NEW ENGL J MED, V367, P647, DOI 10.1056/NEJMra1112635
   Deininger Michael, 2008, J Natl Compr Canc Netw, V6 Suppl 2, pS11
   Deininger MWN, 2000, BLOOD, V96, P3343, DOI 10.1182/blood.V96.10.3343
   Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401
   Druker BJ, 2006, NEW ENGL J MED, V355, P2408, DOI 10.1056/NEJMoa062867
   Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504
   Fong CY, 2015, NATURE, V525, P538, DOI 10.1038/nature14888
   Godley LA, 2012, NEW ENGL J MED, V366, P960, DOI 10.1056/NEJMcibr1113401
   Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538
   Herrmann H, 2012, ONCOTARGET, V3, P1588, DOI 10.18632/oncotarget.733
   Hogg SJ, 2017, CELL REP, V18, P2162, DOI 10.1016/j.celrep.2017.02.011
   Hughes TP, 2019, NEW ENGL J MED, V381, P2315, DOI 10.1056/NEJMoa1902328
   Jabbour E, 2008, BLOOD, V112, P53, DOI 10.1182/blood 2007 11 123950
   Jiang X, 2007, LEUKEMIA, V21, P926, DOI 10.1038/sj.leu.2404609
   Kantarjian H, 2002, NEW ENGL J MED, V346, P645, DOI 10.1056/NEJMoa011573
   Kantarjian H, 2006, NEW ENGL J MED, V354, P2542, DOI 10.1056/NEJMoa055104
   Kantarjian Hagop, 2008, J Natl Compr Canc Netw, V6 Suppl 2, pS37
   Kavalerchik E, 2008, J CLIN ONCOL, V26, P2911, DOI 10.1200/JCO.2008.17.5745
   Khorashad JS, 2013, BLOOD, V121, P489, DOI 10.1182/blood 2012 05 431379
   Krause DS, 2007, TRENDS MOL MED, V13, P470, DOI 10.1016/j.molmed.2007.09.003
   Martinelli G, 2005, HAEMATOLOGICA, V90, P534
   Melo JV, 2004, HEMATOL ONCOL CLIN N, V18, P545, DOI 10.1016/j.hoc.2004.03.008
   Nair RR, 2010, BIOCHEM PHARMACOL, V80, P602, DOI 10.1016/j.bcp.2010.04.003
   Nicolini FE, 2007, HAEMATOLOGICA, V92, P1238, DOI 10.3324/haematol.11369
   O'Brien SG, 2003, NEW ENGL J MED, V348, P994, DOI 10.1056/NEJMoa022457
   O'Hare T, 2009, CANCER CELL, V16, P401, DOI 10.1016/j.ccr.2009.09.028
   Peter B, 2018, LEUKEMIA, V32, P1016, DOI 10.1038/leu.2017.338
   Quintás Cardama A, 2008, CLIN CANCER RES, V14, P4392, DOI 10.1158/1078 0432.CCR 08 0117
   Rathert P, 2015, NATURE, V525, P543, DOI 10.1038/nature14898
   Sattler M, 2002, CANCER CELL, V1, P479, DOI 10.1016/S1535 6108(02)00074 0
   Shah NP, 2002, CANCER CELL, V2, P117, DOI 10.1016/S1535 6108(02)00096 X
   Shah NP, 2004, SCIENCE, V305, P399, DOI 10.1126/science.1099480
   SKORSKI T, 1995, BLOOD, V86, P726, DOI 10.1182/blood.V86.2.726.bloodjournal862726
   Talpaz M, 2006, NEW ENGL J MED, V354, P2531, DOI 10.1056/NEJMoa055229
   Valent P, 2008, BRIT J HAEMATOL, V142, P361, DOI 10.1111/j.1365 2141.2008.07197.x
   Valent P, 2012, NAT REV CANCER, V12, P767, DOI 10.1038/nrc3368
   Wang L, 2008, CLIN PHARMACOL THER, V83, P258, DOI 10.1038/sj.clpt.6100268
   Wedeh G, 2015, LEUKEMIA, V29, P2230, DOI 10.1038/leu.2015.138
   Weisberg E, 2005, CANCER CELL, V7, P129, DOI 10.1016/j.ccr.2005.01.007
   Weisberg E, 2007, NAT REV CANCER, V7, P345, DOI 10.1038/nrc2126
   Winter GE, 2017, MOL CELL, V67, P5, DOI 10.1016/j.molcel.2017.06.004
   Winter GE, 2015, SCIENCE, V348, P1376, DOI 10.1126/science.aab1433
   Winter GE, 2012, NAT CHEM BIOL, V8, P905, DOI [10.1038/nchembio.1085, 10.1038/NCHEMBIO.1085]
   Zabriskie MS, 2014, CANCER CELL, V26, P428, DOI 10.1016/j.ccr.2014.07.006
   Zhang B, 2013, BLOOD, V121, P1824, DOI 10.1182/blood 2012 02 412890
   Zuber J, 2011, NATURE, V478, P524, DOI 10.1038/nature10334
NR 54
TC 22
Z9 23
U1 0
U2 13
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0361 8609
EI 1096 8652
J9 AM J HEMATOL
JI Am. J. Hematol.
PD SEP
PY 2022
VL 97
IS 9
BP 1215
EP 1225
DI 10.1002/ajh.26650
EA JUL 2022
PG 11
WC Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Hematology
GA 4C9FZ
UT WOS:000826289800001
PM 35794848
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Chester, AH
   Sarathchandra, P
   McCormack, A
   Yacoub, MH
AF Chester, Adrian H.
   Sarathchandra, Padmini
   McCormack, Ann
   Yacoub, Magdi H.
TI Organ Culture Model of Aortic Valve Calcification
SO FRONTIERS IN CARDIOVASCULAR MEDICINE
LA English
DT Article
DE aortic valve; calcification; porcine; adenosine; lipopolysaccharide;
   osteoblasts; valve interstitial cells; valve calcification model
ID INTERSTITIAL CELLS; INFLAMMATION; EXPRESSION; STENOSIS
AB A significant amount of knowledge has been gained with the use of cell based assays to elucidate the mechanisms that mediate heart valve calcification. However, cells used in these studies lack their association with the extra cellular matrix or the influence of other cellular components of valve leaflets. We have developed a model of calcification using intact porcine valve leaflets, that relies upon a biological stimulus to drive the formation of calcified nodules within the valve leaflets. Alizarin Red positive regions were formed in response to lipopolysaccharide and inorganic phosphate, which could be quantified when viewed under polarized light. Point analysis and elemental mapping analysis of electron microscope images confirmed the presence of nodules containing calcium and phosphorus. Immunohistochemical staining showed that the development of these calcified regions corresponded with the expression of RUNX2, osteocalcin, NF kB and the apoptosis marker caspase 3. The formation of calcified nodules and the expression of bone markers were both inhibited by adenosine in a concentration dependent manner, illustrating that the model is amenable to pharmacological manipulation. This organ culture model offers an increased level of tissue complexity in which to study the mechanisms that are involved in heart valve calcification.
C1 [Chester, Adrian H.; Yacoub, Magdi H.] Magdi Yacoub Inst, Heart Sci Ctr, Harefield, Middx, England.
   [Chester, Adrian H.; Sarathchandra, Padmini; McCormack, Ann; Yacoub, Magdi H.] Imperial Coll London, Imperial Coll, Natl Heart & Lung Inst, London, England.
C3 Imperial College London
RP Chester, AH (通讯作者)，Magdi Yacoub Inst, Heart Sci Ctr, Harefield, Middx, England.; Chester, AH (通讯作者)，Imperial Coll London, Imperial Coll, Natl Heart & Lung Inst, London, England.
EM a.chester@imperial.ac.uk
FU Magdi Yacoub Institute
FX This study was funded by The Magdi Yacoub Institute.
CR Akiyoshi T, 2016, ATHEROSCLEROSIS, V244, P51, DOI 10.1016/j.atherosclerosis.2015.11.005
   Babu AN, 2008, ANN THORAC SURG, V86, P71, DOI 10.1016/j.athoracsur.2008.03.008
   Balachandran K, 2010, AM J PATHOL, V177, P49, DOI 10.2353/ajpath.2010.090631
   Benton JA, 2009, ARTERIOSCL THROM VAS, V29, P1950, DOI 10.1161/ATVBAHA.109.195271
   Blaser MC, 2021, CIRC RES, V128, P1371, DOI 10.1161/CIRCRESAHA.120.317979
   Cloyd KL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048154
   Cowell SJ, 2005, NEW ENGL J MED, V352, P2389, DOI 10.1056/NEJMoa043876
   Fisher CI, 2013, BIOMECH MODEL MECHAN, V12, P5, DOI 10.1007/s10237 012 0377 8
   Goto S, 2019, FRONT CARDIOVASC MED, V6, DOI 10.3389/fcvm.2019.00049
   Honda S, 2014, ARTERIOSCL THROM VAS, V34, P270, DOI 10.1161/ATVBAHA.113.302610
   Jian B, 2003, ANN THORAC SURG, V75, P457, DOI 10.1016/S0003 4975(02)04312 6
   Kruithof BPT, 2021, J MOL CELL CARDIOL, V156, P95, DOI 10.1016/j.yjmcc.2021.03.003
   Kutryb Zajac B, 2020, CLIN RES CARDIOL, V109, P137, DOI 10.1007/s00392 019 01495 x
   Liu YY, 2020, MOL CELL BIOCHEM, V471, P91, DOI 10.1007/s11010 020 03769 9
   Meng XZ, 2008, AM J PHYSIOL CELL PH, V294, pC29, DOI 10.1152/ajpcell.00137.2007
   OBRIEN KD, 1995, CIRCULATION, V92, P2163, DOI 10.1161/01.CIR.92.8.2163
   Osman L, 2006, CIRCULATION, V114, pI566, DOI 10.1161/CIRCULATIONAHA.105.001214
   Osman L, 2006, CIRCULATION, V114, pI547, DOI 10.1161/CIRCULATIONAHA.105.001115
   Parra Izquierdo I, 2019, BBA MOL BASIS DIS, V1865, P2168, DOI 10.1016/j.bbadis.2019.04.014
   Rajamannan NM, 2005, CIRCULATION, V112, pI229, DOI 10.1161/01.CIRCULATIONAHA.104.524306
   Rajamannan NM, 2003, CIRCULATION, V107, P2181, DOI 10.1161/01.CIR.0000070591.21548.69
   Rathan S, 2014, J HEART VALVE DIS, V23, P387
   Richards J, 2013, AM J PATHOL, V182, P1922, DOI 10.1016/j.ajpath.2013.01.037
   Rossebo AB, 2008, NEW ENGL J MED, V359, P1343, DOI 10.1056/NEJMoa0804602
   Rutkovskiy A, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.117.006339
   Sider KL, 2011, INT J INFLAMM, V2011, DOI 10.4061/2011/364310
   Venardos N, 2014, J SURG RES, V190, P1, DOI 10.1016/j.jss.2014.03.051
   Wirrig EE, 2011, J MOL CELL CARDIOL, V50, P561, DOI 10.1016/j.yjmcc.2010.12.005
   Yacoub N, 2005, NAT CLIN PRACT CARD, V2, P60, DOI 10.1038/ncpcardio0112
   Yip CYY, 2009, ARTERIOSCL THROM VAS, V29, P936, DOI 10.1161/ATVBAHA.108.182394
   Zabirnyk A, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.568764
   Zheng DD, 2019, CLIN RES CARDIOL, V108, P691, DOI 10.1007/s00392 018 1398 9
   Zheng KH, 2020, CARDIOL CLIN, V38, P1, DOI 10.1016/j.ccl.2019.09.010
NR 33
TC 6
Z9 7
U1 0
U2 9
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 2297 055X
J9 FRONT CARDIOVASC MED
JI Front. Cardiovasc. Med.
PD OCT 1
PY 2021
VL 8
AR 734692
DI 10.3389/fcvm.2021.734692
PG 15
WC Cardiac & Cardiovascular Systems
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cardiovascular System & Cardiology
GA WL8SI
UT WOS:000710668400001
PM 34660737
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Jia, CR
   Liu, HX
   Li, M
   Wu, ZK
   Feng, XH
AF Jia, Chunrong
   Liu, Hongxiao
   Li, Min
   Wu, Zhikui
   Feng, Xinghua
TI Effects of icariin on cytokine induced ankylosing spondylitis with
   fibroblastic osteogenesis and its molecular mechanism
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY
LA English
DT Article
DE Ankylosing spondylitis; icariin; cytokine; ossification; fibroblast
ID BONE MORPHOGENETIC PROTEIN 2; EXPRESSION; TRANSCRIPTION; OSTEOCALCIN;
   OSTEOBLAST; DISEASE; DRUGS; CELLS; BETA
AB The aim of this study is to explore the effects of icariin on cytokine induced ankylosing spondylitis fibroblast osteogenesis type expression and its molecular mechanism. The normal fibroblasts were collected as normal control group, and the fibroblasts of hip joint capsule of AS patients were collected, which were respectively added in fetal bovine serum (group AS), fetal bovine serum and cytokines (BMP 2+TGF beta 1) (group AS), and cell factor solution (icariin group), and observed of the osteogenic expression of fibroblast, to evaluate the impact of Icariin on it. The ALP activity, the content of collagen, osteocalcin content and cbfa1mRNA and OCmRNA of fibroblast of AS group increased compared to the normal control group and AS control group (P < 0.01), indicating that icariin can significantly inhibit the above changes (P < 0.01). Icariin can inhibit fibroblast further osteogenic differentiation through inhibiting the effect of cytokines on the fibroblast osteogenesis type markers and osteogenic gene expression and osteogenic differentiation.
C1 [Jia, Chunrong] Capital Med Univ, Beijing Tiantan Hosp, Dept Tradit Chinese Med, Beijing 100050, Peoples R China.
   [Liu, Hongxiao; Feng, Xinghua] Chinese Acad Tradit Chinese Med, Dept Rheumatol, Guanganmen Hosp, Beijing 100053, Peoples R China.
   [Li, Min; Wu, Zhikui] China Acad Tradit Chinese Med, Dept Mol Biol, Guanganmen Hosp, Beijing 100053, Peoples R China.
C3 Capital Medical University; China Academy of Chinese Medical Sciences;
   Guang'anmen Hospital, CACMS; China Academy of Chinese Medical Sciences;
   Guang'anmen Hospital, CACMS
RP Feng, XH (通讯作者)，Chinese Acad Tradit Chinese Med, Dept Rheumatol, Guanganmen Hosp, 5 Guanganmen Beixiange Xicheng Dist, Beijing 100053, Peoples R China.
EM xinghuafengcn@126.com
CR Backhaus M, 2011, ORTHOPADE, V40, P917, DOI 10.1007/s00132 011 1792 8
   Bond Deborah, 2013, Nurs Stand, V28, P52, DOI 10.7748/ns2013.12.28.16.52.e7807
   BORTELL R, 1990, J CELL BIOCHEM, V44, P81, DOI 10.1002/jcb.240440203
   Boumah CE, 2005, PROG NUCLEIC ACID RE, V80, P287, DOI 10.1016/S0079 6603(05)80007 8
   Busquets Perez N, 2013, EXPERT OPIN EMERG DR, V18, P71, DOI 10.1517/14728214.2013.752815
   Chen YP, 2013, CELL PHYSIOL BIOCHEM, V32, P755, DOI 10.1159/000354477
   Dean LE, 2014, RHEUMATOLOGY, V53, P650, DOI 10.1093/rheumatology/ket387
   Di Guglielmo GM, 2003, NAT CELL BIOL, V5, P410, DOI 10.1038/ncb975
   Zambrano Zaragoza JF, 2013, INT J INFLAMM, V2013, DOI 10.1155/2013/501653
   HARRIS SE, 1994, J BONE MINER RES, V9, P855
   Inohaya K, 2000, DEV GENES EVOL, V210, P570, DOI 10.1007/s004270000094
   Jang H, 2014, BONE, V61, P10, DOI 10.1016/j.bone.2013.12.028
   Lee JW, 2013, DEV BIOL, V382, P98, DOI 10.1016/j.ydbio.2013.07.020
   Loeys BL, 2013, PEDIATR ENDOCR REV P, V10, P417
   Mehlhorn AT, 2007, CELL PROLIFERAT, V40, P809, DOI 10.1111/j.1365 2184.2007.00473.x
   Murdy GR, 1996, CLIN ORTHOP RELAT R, V323, P24
   Papagoras C, 2013, CLIN EXP RHEUMATOL, V31, P612
   Slobodin G, 2012, ISR MED ASSOC J, V14, P763
   Steiman AJ, 2013, RHEUMATOL INT, V33, P1105, DOI 10.1007/s00296 012 2619 6
   Wallis D, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4350
   Xu HH, 2013, BRAZ J MED BIOL RES, V46, P809, DOI 10.1590/1414 431X20132929
NR 21
TC 9
Z9 11
U1 0
U2 7
PU E CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1936 2625
J9 INT J CLIN EXP PATHO
JI Int. J. Clin. Exp. Pathol.
PY 2014
VL 7
IS 12
BP 9104
EP 9109
PG 6
WC Oncology; Pathology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Pathology
GA AZ6RG
UT WOS:000348345900100
PM 25674296
DA 2025 08 17
ER

PT J
AU Tadier, S
   Bareille, R
   Siadous, R
   Marsan, O
   Charvillat, C
   Cazalbou, S
   Amédée, J
   Rey, C
   Combes, C
AF Tadier, Solene
   Bareille, Reine
   Siadous, Robin
   Marsan, Olivier
   Charvillat, Cedric
   Cazalbou, Sophie
   Amedee, Joelle
   Rey, Christian
   Combes, Christele
TI Strontium loaded mineral bone cements as sustained release systems:
   Compositions, release properties, and effects on human osteoprogenitor
   cells
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART B APPLIED BIOMATERIALS
LA English
DT Article
DE bone cement; strontium; apatite; drug release; cell culture
ID CALCIUM PHOSPHATE CEMENT; IN VITRO BIOACTIVITY; HYDROXYAPATITE; SR;
   DIFFERENTIATION; OSTEOCLAST; TOXICITY; RANELATE; APATITES; BEHAVIOR
AB This study aims to evaluate in vitro the release properties and biological behavior of original compositions of strontium (Sr) loaded bone mineral cements. Strontium was introduced into vaterite CaCO3 dicalcium phosphate dihydrate cement via two routes: as SrCO3 in the solid phase (SrS cements), and as SrCl2 dissolved in the liquid phase (SrL cements), leading to different cement compositions after setting. Complementary analytical techniques implemented to thoroughly investigate the release/dissolution mechanism of Sr loaded cements at pH 7.4 and 37 degrees C during 3 weeks revealed a sustained release of Sr and a centripetal dissolution of the more soluble phase (vaterite) limited by a diffusion process. In all cases, the initial burst of the Ca and Sr release (highest for the SrL cements) that occurred over 48 h did not have a significant effect on the expression of bone markers (alkaline phosphatase, osteocalcin), the levels of which remained overexpressed after 15 days of culture with human osteoprogenitor (HOP) cells. At the same time, proliferation of HOP cells was significantly higher on SrS cements. Interestingly, this study shows that we can optimize the sustained release of Sr2+, the cement biodegradation and biological activity by controlling the route of introduction of strontium in the cement paste. (C) 2011 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater 100B: 378390, 2012.
C1 [Tadier, Solene; Marsan, Olivier; Charvillat, Cedric; Rey, Christian; Combes, Christele] Univ Toulouse, CIRIMAT, UPS INPT CNRS, ENSIACET, F 31030 Toulouse 4, France.
   [Bareille, Reine; Siadous, Robin; Amedee, Joelle] Univ Bordeaux, U1026, F 33076 Bordeaux, France.
   [Bareille, Reine; Siadous, Robin; Amedee, Joelle] INSERM, U1026, F 33076 Bordeaux, France.
   [Cazalbou, Sophie] Univ Toulouse, CIRIMAT, UPS INPT CNRS, Fac Pharm, F 31062 Toulouse 4, France.
C3 Universite de Toulouse; Universite Federale Toulouse Midi Pyrenees
   (ComUE); Universite Toulouse III   Paul Sabatier; Institut National
   Polytechnique de Toulouse; Centre National de la Recherche Scientifique
   (CNRS); Universite de Bordeaux; Institut National de la Sante et de la
   Recherche Medicale (Inserm); Universite de Toulouse; Universite Federale
   Toulouse Midi Pyrenees (ComUE); Universite Toulouse III   Paul Sabatier;
   Institut National Polytechnique de Toulouse; Centre National de la
   Recherche Scientifique (CNRS)
RP Combes, C (通讯作者)，Univ Toulouse, CIRIMAT, UPS INPT CNRS, ENSIACET, 4 Allee Emile Monso,BP 44362, F 31030 Toulouse 4, France.
EM christele.combes@ensiacet.fr
RI ; CAZALBOU, sophie/G 5683 2012; Rey, Christian/HOI 0501 2023; AMEDEE,
   Joelle/F 3369 2013; MARSAN, Olivier/HMW 0895 2023
OI COMBES, Christele/0000 0001 5009 1973; CAZALBOU,
   sophie/0000 0002 0408 004X; Tadier, Solene/0000 0002 7660 1705
CR Alkhraisat MH, 2008, BIOMATERIALS, V29, P4691, DOI 10.1016/j.biomaterials.2008.08.026
   Alkhralsat MH, 2008, ACTA BIOMATER, V4, P664, DOI 10.1016/j.actbio.2007.12.001
   Banerjee SS, 2010, ACTA BIOMATER, V6, P4167, DOI 10.1016/j.actbio.2010.05.012
   Bohner M, 2010, EUR CELLS MATER, V20, P1
   Bonnelye E, 2008, BONE, V42, P129, DOI 10.1016/j.bone.2007.08.043
   Bracci B, 2009, J INORG BIOCHEM, V103, P1666, DOI 10.1016/j.jinorgbio.2009.09.009
   Braux J, 2011, ACTA BIOMATER, V7, P2593, DOI 10.1016/j.actbio.2011.02.013
   Capuccini C, 2009, J BIOMED MATER RES A, V89A, P594, DOI 10.1002/jbm.a.31975
   Cazalbou S, 2005, J MATER SCI MATER M, V16, P405, DOI 10.1007/s10856 005 6979 2
   Christoffersen J, 1997, BONE, V20, P47, DOI 10.1016/S8756 3282(96)00316 X
   Cohen Solal M, 2002, NEPHROL DIAL TRANSPL, V17, P30, DOI 10.1093/ndt/17.suppl_2.30
   Combes C, 2006, J BIOMED MATER RES A, V79A, P318, DOI 10.1002/jbm.a.30795
   Dahl SG, 2001, BONE, V28, P446, DOI 10.1016/S8756 3282(01)00419 7
   Fernández M, 2002, J MATER SCI MATER M, V13, P1251, DOI 10.1023/A:1021135314619
   Guo DG, 2010, J MATER SCI MATER M, V21, P1927, DOI 10.1007/s10856 010 4044 2
   Guo DG, 2005, BIOMATERIALS, V26, P4073, DOI 10.1016/j.biomaterials.2004.10.032
   Alkhraisat MH, 2010, ACTA BIOMATER, V6, P1522, DOI 10.1016/j.actbio.2009.10.043
   HIGUCHI T, 1963, J PHARM SCI, V52, P1145, DOI 10.1002/jps.2600521210
   KAMHI SR, 1963, ACTA CRYSTALLOGR, V16, P770, DOI 10.1107/S0365110X63002000
   Landi E, 2008, ACTA BIOMATER, V4, P656, DOI 10.1016/j.actbio.2007.10.010
   Leroux L, 2000, KEY ENG MAT, V192 1, P235, DOI 10.4028/www.scientific.net/KEM.192 195.235
   Li CH, 2010, J BONE MINER RES, V25, P968, DOI 10.1359/jbmr.091038
   Li RH, 2003, J ORTHOP RES, V21, P997, DOI 10.1016/S0736 0266(03)00082 2
   Li YF, 2010, BIOMATERIALS, V31, P9006, DOI 10.1016/j.biomaterials.2010.07.112
   Lutterotti L, 2010, NUCL INSTRUM METH B, V268, P334, DOI 10.1016/j.nimb.2009.09.053
   Marie PJ, 2001, CALCIFIED TISSUE INT, V69, P121, DOI 10.1007/s002230010055
   Marie PJ, 2006, BONE, V38, P10, DOI 10.1016/j.bone.2005.07.029
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022 1759(83)90303 4
   Ni GX, 2010, J MATER SCI MATER M, V21, P377, DOI 10.1007/s10856 009 3866 2
   Nielsen SP, 2004, BONE, V35, P583, DOI 10.1016/j.bone.2004.04.026
   O'Donnell MD, 2008, ACTA BIOMATER, V4, P1455, DOI 10.1016/j.actbio.2008.04.018
   O'Sullivan C, 2010, J BIOMED MATER RES B, V95B, P141, DOI 10.1002/jbm.b.31694
   Pan HB, 2009, ACTA BIOMATER, V5, P1678, DOI 10.1016/j.actbio.2008.11.032
   Panzavolta S, 2008, J BIOMED MATER RES A, V84A, P965, DOI 10.1002/jbm.a.31412
   Pina S, 2010, EUR CELLS MATER, V20, P162
   Ratier A, 2004, INT J PHARMACEUT, V274, P261, DOI 10.1016/j.ijpharm.2004.01.021
   Romieu G, 2010, ACTA BIOMATER, V6, P3208, DOI 10.1016/j.actbio.2010.02.008
   Saint Jean SJ, 2005, J MATER SCI MATER M, V16, P993, DOI 10.1007/s10856 005 4754 z
   Schnitzler V, 2011, ACTA BIOMATER, V7, P759, DOI 10.1016/j.actbio.2010.09.017
   SUDARSANAN K, 1969, ACTA CRYSTALL B STRU, VB 25, P1534, DOI 10.1107/S0567740869004298
   Tadier S, 2011, J BIOMED B IN PRESS
   VILAMITJANAAMEDEE J, 1993, IN VITRO CELL DEV AN, V29, P699
   Villars F, 2002, AM J PHYSIOL CELL PH, V282, pC775, DOI 10.1152/ajpcell.00310.2001
   Wang XP, 2008, J MATER SCI MATER M, V19, P1183, DOI 10.1007/s10856 007 3209 0
   Wang XP, 2007, ACTA BIOMATER, V3, P757, DOI 10.1016/j.actbio.2007.01.004
   Wu CT, 2007, BIOMATERIALS, V28, P3171, DOI 10.1016/j.biomaterials.2007.04.002
   Xue WC, 2007, SURF COAT TECH, V201, P4685, DOI 10.1016/j.surfcoat.2006.10.012
   Yang L, 2010, BIOMATERIALS, V31, P2976, DOI 10.1016/j.biomaterials.2010.01.002
   Yang XY, 2010, J BIOMED MATER RES A, V95A, P1170, DOI 10.1002/jbm.a.32936
NR 49
TC 37
Z9 39
U1 0
U2 50
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1552 4973
EI 1552 4981
J9 J BIOMED MATER RES B
JI J. Biomed. Mater. Res. Part B
PD FEB
PY 2012
VL 100B
IS 2
BP 378
EP 390
DI 10.1002/jbm.b.31959
PG 13
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA 872EV
UT WOS:000298792500009
PM 22102621
OA Green Submitted, Bronze
DA 2025 08 17
ER

PT J
AU Klotz, DM
   Link, T
   Goeckenjan, M
   Wimberger, P
   Poetsch, AR
   Jaschke, N
   Hofbauer, LC
   Göbel, A
   Rachner, TD
   Kuhlmann, JD
AF Klotz, Daniel Martin
   Link, Theresa
   Goeckenjan, Maren
   Wimberger, Pauline
   Poetsch, Anna R.
   Jaschke, Nikolai
   Hofbauer, Lorenz C.
   Gobel, Andy
   Rachner, Tilman D.
   Kuhlmann, Jan Dominik
TI Evaluation of circulating Dickkopf 1 as a prognostic biomarker in
   ovarian cancer patients
SO CLINICAL CHEMISTRY AND LABORATORY MEDICINE
LA English
DT Article
DE blood based biomarker; ovarian cancer; prognosis; soluble Dickkopf 1
ID CONSENSUS CONFERENCE; BONE DISEASE; EXPRESSION; DKK1; PROSTATE;
   BEVACIZUMAB; PREVALENCE; MUTATIONS; MEDIATOR; BREAST
AB Objectives: Dickkopf 1 (DKK1) is a secreted protein, known for suppressing the differentiation and activity of bone building osteoblasts by acting as an inhibitor of Wnt signalling. Soluble DKK1 (sDKK1) has been proposed as prognostic biomarker for a wide range of malignancies, however, clinical relevance of sDKK1 as potential blood based marker for ovarian cancer is unknown. Methods: sDKK1 levels were quantified in a cohort of 150 clinically documented ovarian cancer patients by a commercially available DKK1 ELISA (Biomedica, Vienna, Austria). Results: Median sDKK1 level was significantly elevated at primary diagnosis of ovarian cancer compared to healthy controls (estimated difference (ED) of 7.75 ng/mL (95% CI: 3.01 12.30 ng/mL, p=0.001)). Higher levels of sDKK1 at diagnosis indicated an increased volume of intraoperative malignant ascites (ED 7.08 pmol/L, 95% CI: 1.46 13.05, p=0.02) and predicted suboptimal debulking surgery (ED 6.88 pmol/L, 95% CI: 1.73 11.87, p=0.01). sDKK1 did not correlate with CA125 and higher sDKK1 levels predicted a higher risk of recurrence and poor survival (PFS: HR=0.507, 95% CI: 0.317 0.809; p=0.004; OS: HR=0.561, 95% CI: 0.320 0.986; p=0.044). Prognostic relevance of sDKK1 was partly sustained in wtBRCA patients (PFS: HR=0.507, 95% CI: 0.317 0.809; p=0.004). Conclusions: This is the first study demonstrating the prognostic relevance of sDKK1 in ovarian cancer patients, including those with wtBRCA1/2 status. Our data encourage further evaluation of sDKK1 in ovarian cancer patients, possibly in terms of a therapy monitoring marker or a response predictor for sDKK1 directed targeted therapies.
C1 [Klotz, Daniel Martin; Link, Theresa; Goeckenjan, Maren; Wimberger, Pauline; Kuhlmann, Jan Dominik] Tech Univ Dresden, Med Fac, Dept Gynecol & Obstet, Dresden, Germany.
   [Klotz, Daniel Martin; Link, Theresa; Goeckenjan, Maren; Wimberger, Pauline; Poetsch, Anna R.; Jaschke, Nikolai; Hofbauer, Lorenz C.; Gobel, Andy; Rachner, Tilman D.; Kuhlmann, Jan Dominik] Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Dresden, Germany.
   [Klotz, Daniel Martin; Link, Theresa; Goeckenjan, Maren; Wimberger, Pauline; Poetsch, Anna R.; Jaschke, Nikolai; Hofbauer, Lorenz C.; Gobel, Andy; Rachner, Tilman D.; Kuhlmann, Jan Dominik] German Canc Consortium DKTK, Partner Site Dresden, Heidelberg, Germany.
   [Klotz, Daniel Martin; Link, Theresa; Goeckenjan, Maren; Wimberger, Pauline; Poetsch, Anna R.; Jaschke, Nikolai; Hofbauer, Lorenz C.; Gobel, Andy; Rachner, Tilman D.; Kuhlmann, Jan Dominik] German Canc Res Ctr, Heidelberg, Germany.
   [Klotz, Daniel Martin; Link, Theresa; Goeckenjan, Maren; Wimberger, Pauline; Poetsch, Anna R.; Jaschke, Nikolai; Hofbauer, Lorenz C.; Gobel, Andy; Rachner, Tilman D.; Kuhlmann, Jan Dominik] Natl Ctr Tumor Dis NCT, Dresden, Germany.
   [Klotz, Daniel Martin; Link, Theresa; Goeckenjan, Maren; Wimberger, Pauline; Poetsch, Anna R.; Jaschke, Nikolai; Hofbauer, Lorenz C.; Gobel, Andy; Rachner, Tilman D.; Kuhlmann, Jan Dominik] Tech Univ Dresden, Fac Med, Dresden, Germany.
   [Klotz, Daniel Martin; Link, Theresa; Goeckenjan, Maren; Wimberger, Pauline; Poetsch, Anna R.; Jaschke, Nikolai; Hofbauer, Lorenz C.; Gobel, Andy; Rachner, Tilman D.; Kuhlmann, Jan Dominik] Helmholtz Zentrum Dresden Rossendorf HZDR, Dresden, Germany.
   [Poetsch, Anna R.] Tech Univ Dresden, Biotechnol Ctr, Dresden, Germany.
   [Jaschke, Nikolai; Hofbauer, Lorenz C.; Gobel, Andy; Rachner, Tilman D.] Tech Univ Dresden, Dept Med 3, Div Endocrinol Diabet & Bone Dis, Dresden, Germany.
C3 Technische Universitat Dresden; Technische Universitat Dresden; Carl
   Gustav Carus University Hospital; Helmholtz Association; German Cancer
   Research Center (DKFZ); Helmholtz Association; German Cancer Research
   Center (DKFZ); Helmholtz Association; German Cancer Research Center
   (DKFZ); Ruprecht Karls University Heidelberg; National Center for Tumor
   Diseases; Technische Universitat Dresden; Helmholtz Association;
   Helmholtz Zentrum Dresden Rossendorf (HZDR); Technische Universitat
   Dresden; Technische Universitat Dresden
RP Kuhlmann, JD (通讯作者)，Tech Univ Dresden, Med Fac, Dept Gynecol & Obstet, Dresden, Germany.; Kuhlmann, JD (通讯作者)，Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Dresden, Germany.; Kuhlmann, JD (通讯作者)，German Canc Consortium DKTK, Partner Site Dresden, Heidelberg, Germany.; Kuhlmann, JD (通讯作者)，German Canc Res Ctr, Heidelberg, Germany.; Kuhlmann, JD (通讯作者)，Natl Ctr Tumor Dis NCT, Dresden, Germany.; Kuhlmann, JD (通讯作者)，Tech Univ Dresden, Fac Med, Dresden, Germany.; Kuhlmann, JD (通讯作者)，Helmholtz Zentrum Dresden Rossendorf HZDR, Dresden, Germany.
EM jan.kuhlmann@uniklinikum dresden.de
RI Poetsch, Anna/AEM 6582 2022; Klotz, Daniel/JLM 7578 2023; Hofbauer,
   Lorenz/G 2490 2010; Hofbauer, Lorenz C./G 2490 2010
OI Hofbauer, Lorenz C./0000 0002 8691 8423; Poetsch,
   Anna/0000 0003 3056 4360
FU Deutsche Forschungsgemeinschaft [GO 3055/1 1, HO 1875/24 1, HO
   1875/25 1, HO 1875/26 1, HO 1875/27 1, RA 2151/4 1, RA 2151/5 1];
   Deutsche Krebshilfe (Mildred Scheel Nachwuchszentrum) [70113573]
FX The work was funded by the Deutsche Forschungsgemeinschaft to AG (GO
   3055/1 1) , LCH (HO 1875/24 1, 26 1, and 27 1) and to TDR (RA 2151/4 1
   and 5 1) as part of the DFG Schwerpunktprogramm 2084 mu Bone as well as
   by the Deutsche Krebshilfe to AG and TDR (#70113573 and as part of the
   Mildred Scheel Nachwuchszentrum) . Author contributions: TDR, AG, DMK,
   JDK, PW and LCH made substantial contributions to the conception and
   design of the study. DMK, AG, JDK, TL, MG, NJ contributed to the
   experimental work or to the acquisition of clinical samples/data or to
   the analysis/interpretation of the results. JDK, AG and DMK, TL were
   involved in draf ting the manuscript, creating figures or revising the
   manuscript. All authors have accepted responsibility for the entire
   content of this manuscript and approved its submission. Competing
   interests: Authors state no conflict of interest. Informed consent:
   Written informed consent was obtained from all study participants and
   the study was approved by the Local Research Ethics Committee in Dresden
   (EK74032013) . Ethical approval: The study was approved by the Local
   Research Ethics Committee in Dresden (EK74032013) . All study
   methodologies conformed to the standards set by the Declaration of
   Helsinki.
CR [Anonymous], 2009, INT J GYNECOL OBSTET, V105, P3
   Baert T, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01273
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Burger RA, 2011, NEW ENGL J MED, V365, P2473, DOI 10.1056/NEJMoa1104390
   Buys SS, 2005, AM J OBSTET GYNECOL, V193, P1630, DOI 10.1016/j.ajog.2005.05.005
   Choi SH, 2017, ONCOTARGET, V8, P58974, DOI 10.18632/oncotarget.19769
   D'Amico L, 2016, J EXP MED, V213, P827, DOI 10.1084/jem.20150950
   du Bois A, 2005, ANN ONCOL, V16, P7, DOI 10.1093/annonc/mdi961
   Fulciniti M, 2009, BLOOD, V114, P371, DOI 10.1182/blood 2008 11 191577
   Glinka A, 1998, NATURE, V391, P357, DOI 10.1038/34848
   Goldstein SD, 2016, ONCOTARGET, V7, P21114, DOI 10.18632/oncotarget.8522
   González Martín A, 2019, NEW ENGL J MED, V381, P2391, DOI 10.1056/NEJMoa1910962
   Haas MS, 2021, MOL CANCER RES, V19, P717, DOI 10.1158/1541 7786.MCR 20 0799
   Hall CL, 2008, PROSTATE, V68, P1396, DOI 10.1002/pros.20805
   Hall CL, 2010, CANCER RES, V70, P9916, DOI 10.1158/0008 5472.CAN 10 0440
   Harter P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186043
   Heath DJ, 2009, J BONE MINER RES, V24, P425, DOI 10.1359/JBMR.081104
   Huang JF, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000020388
   Jaschke N, 2020, CANCER LETT, V482, P1, DOI 10.1016/j.canlet.2020.03.031
   Kaiser M, 2008, EUR J HAEMATOL, V80, P490, DOI 10.1111/j.1600 0609.2008.01065.x
   Karam A, 2017, ANN ONCOL, V28, P711, DOI 10.1093/annonc/mdx011
   Kast K, 2016, J MED GENET, V53, P465, DOI 10.1136/jmedgenet 2015 103672
   Klotz DM, 2020, ARCH GYNECOL OBSTET, V302, P1087, DOI 10.1007/s00404 020 05677 1
   Krause U, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.67
   de Oliveira LRLB, 2021, BRIT J RADIOL, V94, DOI 10.1259/bjr.20210091
   Link T, 2020, INT J CANCER, V146, P2608, DOI 10.1002/ijc.32676
   Link T, 2019, MOL ONCOL, V13, P1268, DOI 10.1002/1878 0261.12484
   Moore K, 2018, NEW ENGL J MED, V379, P2495, DOI 10.1056/NEJMoa1810858
   Prat J, 2014, INT J GYNECOL OBSTET, V124, P1, DOI 10.1016/j.ijgo.2013.10.001
   Rachner TD, 2014, BMC CANCER, V14, DOI 10.1186/1471 2407 14 649
   Rachner TD, 2014, CANCER LETT, V346, P172, DOI 10.1016/j.canlet.2014.01.010
   Ray Coquard I, 2019, NEW ENGL J MED, V381, P2416, DOI 10.1056/NEJMoa1911361
   Salim H, 2015, BMC CANCER, V15, DOI 10.1186/s12885 015 1635 9
   Smadja DM, 2010, ARTERIOSCL THROM VAS, V30, P2544, DOI 10.1161/ATVBAHA.110.213751
   Stuart GCE, 2011, INT J GYNECOL CANCER, V21, P750, DOI 10.1097/IGC.0b013e31821b2568
   Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847
   Torre LA, 2018, CA CANCER J CLIN, V68, P284, DOI 10.3322/caac.21456
   Voorzanger Rousselot N, 2007, BRIT J CANCER, V97, P964, DOI 10.1038/sj.bjc.6603959
   Voorzanger Rousselot N, 2009, CALCIFIED TISSUE INT, V84, P348, DOI 10.1007/s00223 009 9225 y
   Wang SZ, 2011, CLIN EXP METASTAS, V28, P581, DOI 10.1007/s10585 011 9393 9
   Wang SZ, 2009, INT J BIOL MARKER, V24, P165, DOI 10.1177/172460080902400306
   Wimberger P, 2010, ANN SURG ONCOL, V17, P1642, DOI 10.1245/s10434 010 0964 9
   Xu WH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037624
   Zhang C, 2019, J CANCER, V10, P3133, DOI 10.7150/jca.30335
   Zhang R, 2019, SOL ST LIGHT TECHNOL, V4, P1, DOI 10.1007/978 3 319 99211 2_1
   Zhou SJ, 2014, DIAGN PATHOL, V9, DOI 10.1186/s13000 014 0161 4
   Zhu G, CANCER MANAG RES, V13, P659
NR 47
TC 5
Z9 6
U1 0
U2 3
PU WALTER DE GRUYTER GMBH
PI BERLIN
PA GENTHINER STRASSE 13, D 10785 BERLIN, GERMANY
SN 1434 6621
EI 1437 4331
J9 CLIN CHEM LAB MED
JI Clin. Chem. Lab. Med.
PD JAN
PY 2022
VL 60
IS 1
BP 109
EP 117
DI 10.1515/cclm 2021 0504
PG 9
WC Medical Laboratory Technology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Medical Laboratory Technology
GA XK8TI
UT WOS:000727730300022
PM 34687595
DA 2025 08 17
ER

PT J
AU Tu, J
   Huo, ZJ
   Yu, Y
   Zhu, DD
   Xu, A
   Huang, MF
   Hu, RF
   Wang, RY
   Gingold, JA
   Chen, YH
   Tsai, KL
   Forcioli Conti, NR
   Huang, SXL
   Webb, TR
   Su, J
   Bazer, DA
   Jia, PL
   Yustein, JT
   Wang, LL
   Hung, MC
   Zhao, ZM
   Huff, CD
   Shen, JN
   Zhao, RY
   Lee, DF
AF Tu, Jian
   Huo, Zijun
   Yu, Yao
   Zhu, Dandan
   Xu, An
   Huang, Mo Fan
   Hu, Ruifeng
   Wang, Ruoyu
   Gingold, Julian A.
   Chen, Yi Hung
   Tsai, Kuang Lei
   Forcioli Conti, Nicolas R.
   Huang, Sarah X. L.
   Webb, Thomas R.
   Su, Jie
   Bazer, Danielle A.
   Jia, Peilin
   Yustein, Jason T.
   Wang, Lisa L.
   Hung, Mien Chie
   Zhao, Zhongming
   Huff, Chad D.
   Shen, Jingnan
   Zhao, Ruiying
   Lee, Dung Fang
TI Hereditary retinoblastoma iPSC model reveals aberrant spliceosome
   function driving bone malignancies
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE hereditary retinoblastoma; iPSCs; pRB; spliceosomal genes; osteosarcoma
ID TUMOR SUPPRESSOR; CANCER; FAMILY; PRB; RB; TRANSCRIPTION; PROTEINS
AB The RB1 gene is frequently mutated in human cancers but its role in tumorigenesis remains incompletely defined. Using an induced pluripotent stem cell (iPSC) model of hereditary retinoblastoma (RB), we report that the spliceosome is an up regulated target responding to oncogenic stress in RB1 mutant cells. By investigating transcriptomes and genome occupancies in RB iPSC derived osteoblasts (OBs), we discover that both E2F3a, which mediates spliceosomal gene expression, and pRB, which antagonizes E2F3a, coregulate more than one third of spliceosomal genes by cobinding to their promoters or enhancers. Pharmacological inhibition of the spliceosome in RB1 mutant cells leads to global intron retention, decreased cell proliferation, and impaired tumorigenesis. Tumor specimen studies and genome wide TCGA (The Cancer Genome Atlas) expression profile analyses support the clinical relevance of pRB and E2F3a in modulating spliceosomal gene expression in multiple cancer types including osteosarcoma (OS). High levels of pRB/E2F3a regulated spliceosomal genes are associated with poor OS patient survival. Collectively, these findings reveal an undiscovered connection between pRB, E2F3a, the spliceosome, and tumorigenesis, pointing to the spliceosomal machinery as a potentially widespread therapeutic vulnerability of pRB deficient cancers.
C1 [Tu, Jian; Huo, Zijun; Zhu, Dandan; Xu, An; Chen, Yi Hung; Zhao, Ruiying; Lee, Dung Fang] Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Dept Integrat Biol & Pharmacol, Houston, TX 77030 USA.
   [Tu, Jian] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Musculoskeletal Oncol, Guangzhou 510080, Peoples R China.
   [Tu, Jian] Sun Yat Sen Univ, Affiliated Hosp 1, Guangdong Prov Key Lab Orthoped & Traumatol, Guangzhou 510080, Peoples R China.
   [Huo, Zijun] Sun Yat sen Univ, Dept Endocrinol, Affiliated Hosp, Guangzhou 510080, Peoples R China.
   [Yu, Yao] Univ Texas MD Anderson Canc Ctr, Dept Epidemiol, Houston, TX 77030 USA.
   [Huang, Mo Fan; Wang, Ruoyu; Tsai, Kuang Lei; Zhao, Zhongming; Huff, Chad D.; Lee, Dung Fang] Univ Texas MD Anderson Canc Ctr, UTHlth Grad Sch Biomed Sci, Houston, TX 77030 USA.
   [Hu, Ruifeng; Lee, Dung Fang] Univ Texas Hlth Sci Ctr Houston, Sch Biomed Informat, Ctr Precis Hlth, Houston, TX 77030 USA.
   [Wang, Ruoyu] Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Dept Biochem & Mol Biol, Houston, TX 77030 USA.
   [Gingold, Julian A.] Einstein Montefiore Med Ctr, Dept Obstet Gynecol & Womens Hlth, Bronx, NY 10461 USA.
   [Forcioli Conti, Nicolas R.; Huang, Sarah X. L.; Lee, Dung Fang] Univ Texas Hlth Sci Ctr Houston, Brown Fdn Inst Mol Med Prevent Human Dis, Ctr Stem Cell & Regenerat Med, Houston, TX 77030 USA.
   [Webb, Thomas R.] Wildflower Biopharma Inc, Encinitas, CA 92024 USA.
   [Su, Jie] Accutar Biotechnol Inc, Brooklyn, NY 11226 USA.
   [Bazer, Danielle A.] SUNY Stony Brook, Renaissance Sch Med, Dept Neurol, Stony Brook, NY 11794 USA.
   [Yustein, Jason T.] Baylor Coll Med, Texas Childrens Canc & Hematol Ctr, Houston, TX 77030 USA.
   [Yustein, Jason T.] Baylor Coll Med, Faris Virani Ewing Sarcoma Ctr, Houston, TX 77030 USA.
   [Wang, Lisa L.] Texas Childrens Hosp, Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA.
   [Hung, Mien Chie] China Med Univ, Grad Inst Biomed Sci, Taichung 404, Taiwan.
   [Hung, Mien Chie] China Med Univ, Ctr Mol Med, Taichung 404, Taiwan.
   [Zhao, Zhongming] Asia Univ, Dept Biotechnol, Taichung 413, Taiwan.
C3 University of Texas System; University of Texas Health Science Center
   Houston; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen
   University; University of Texas System; UTMD Anderson Cancer Center;
   University of Texas System; UTMD Anderson Cancer Center; University of
   Texas System; University of Texas Health Science Center Houston;
   University of Texas System; University of Texas Health Science Center
   Houston; Montefiore Medical Center; University of Texas System;
   University of Texas Health Science Center Houston; State University of
   New York (SUNY) System; Stony Brook University; Stony Brook University
   Hospital; Baylor College of Medicine; Texas Children's Cancer Center;
   Baylor College of Medicine; Baylor College of Medicine; Baylor College
   Medical Hospital; China Medical University Taiwan; China Medical
   University Taiwan; Asia University Taiwan
RP Zhao, RY; Lee, DF (通讯作者)，Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Dept Integrat Biol & Pharmacol, Houston, TX 77030 USA.; Lee, DF (通讯作者)，Univ Texas MD Anderson Canc Ctr, UTHlth Grad Sch Biomed Sci, Houston, TX 77030 USA.; Lee, DF (通讯作者)，Univ Texas Hlth Sci Ctr Houston, Sch Biomed Informat, Ctr Precis Hlth, Houston, TX 77030 USA.; Lee, DF (通讯作者)，Univ Texas Hlth Sci Ctr Houston, Brown Fdn Inst Mol Med Prevent Human Dis, Ctr Stem Cell & Regenerat Med, Houston, TX 77030 USA.
EM ruiying.zhao@uth.tmc.edu; dung fang.lee@uth.tmc.edu
RI Hung, Mien Chie/ABD 5911 2021; Gingold, Julian/AAD 7321 2020; Webb,
   Thomas/J 4511 2013; Wang, Ruoyu/HCI 3739 2022; Hu,
   Ruifeng/AAF 8619 2019; Wang, Bo/KEH 0105 2024; Huang,
   Mo Fan/MEP 7322 2025
OI Tsai, Kuang Lei/0000 0002 5428 4219; Wang, Ruoyu/0000 0002 3644 1284;
   XU, AN/0000 0003 1776 7972; Lee, Dung Fang/0000 0003 2387 597X; Chen,
   Yi Hung/0000 0001 8029 7323; Gingold, Julian/0000 0002 0354 5933; Hu,
   Ruifeng/0000 0001 5549 3082; Hung, Mien Chie/0000 0003 4317 4740
FU UTHealth start up funds [37516 11998, 37516 11999]; Cancer Prevention
   and Research Institute of Texas (CPRIT) [RR16009]; NIH/NCI (National
   Cancer Institute) [R01CA246130]; UTHealth Cancer Genomics Core Pilot
   Grant [RP180734]; CPRIT [RP180734, RP210045, RR160019]; Ke Lin Program
   Fellowship; National Natural Science Foundation of China [82103078,
   82002510]; CPRIT Postdoctoral Fellow in the Biomedical Informatics,
   Genomics and Translational Cancer Research Training Program (CPRIT
   Grant) [RP210045]; Department of Defense Horizon Award
   [W81XWH 20 1 0389]; NIH/National Library of Medicine [R01LM012806];
   Andrew Sabin Family Foundation Fellowship; Scientific Research
   Cultivating Project of Sun Yat sen University [80000 18827202,
   80000 18823701]; Fundamental Research Funds for the Central Universities
   [19ykzd10]; Scientific Research 3x 3 Project of Sun Yat sen University
   [Y70215]; NIH/NCI [R01CA246130]; Rolanette and Berdon Lawrence Bone
   Disease Program of Texas; Pablove Foundation Childhood Cancer Research
   Grant [690785]; National Library of Medicine [R01LM012806] Funding
   Source: NIH RePORTER
FX We thank Wenyi Wei for plasmids; Ying Liu, Yen Ting Chiang, and D. F.L.
   laboratory members for technical assistance and/or discussion; John F.
   Hancock and Kartik Venkatachalam for reagents and suggestions; and The
   University of Texas Health Science Center at Houston (UTHealth) Cancer
   Genomics Core for technical support and the next generation sequencing
   service. We also acknowledge St. Jude Children's Research Hospital as
   the source of SD6. This work was mainly supported by UTHealth start up
   funds (to D. F.L., 37516 11998; to R.Z., 37516 11999), Cancer Prevention
   and Research Institute of Texas (CPRIT) RR16009 (to D. F.L.), and
   NIH/NCI (National Cancer Institute) R01CA246130 (to D. F.L., C.D.H., and
   R.Z.). This work was partially supported by a UTHealth Cancer Genomics
   Core Pilot Grant (to D. F.L. and R.Z., CPRIT Grant RP180734). The
   UTHealth Cancer Genomics Core was supported by CPRIT RP180734. J.T. and
   Z.H. were supported by the Ke Lin Program Fellowship. J.T. was supported
   by the National Natural Science Foundation of China (Grant 82103078),
   and Z.H. was supported by the National Natural Science Foundation of
   China (Grant 82002510). A.X. was a CPRIT Postdoctoral Fellow in the
   Biomedical Informatics, Genomics and Translational Cancer Research
   Training Program (CPRIT Grant RP210045). D.Z. was supported by a
   Department of Defense Horizon Award (W81XWH 20 1 0389). Z.Z. was
   partially supported by the NIH/National Library of Medicine
   (R01LM012806) and CPRIT (RP180734 and RP210045). C.D.H. and Y.Y. were
   supported by the Andrew Sabin Family Foundation Fellowship. J. Shen was
   supported by the Scientific Research Cultivating Project of Sun Yat sen
   University (Nos. 80000 18827202 and 80000 18823701), Fundamental
   Research Funds for the Central Universities (No. 19ykzd10), and
   Scientific Research 3x 3 Project of Sun Yat sen University (No. Y70215).
   D. F.L. was supported by the CPRIT (RR160019), NIH/NCI R01CA246130,
   Rolanette and Berdon Lawrence Bone Disease Program of Texas, and a
   Pablove Foundation Childhood Cancer Research Grant (690785). D. F.L. is
   a CPRIT Scholar in Cancer Research.
CR Adler AS, 2014, GENE DEV, V28, P1068, DOI 10.1101/gad.237206.113
   Ahlander J, 2009, BIOCHEM BIOPH RES CO, V384, P280, DOI 10.1016/j.bbrc.2009.04.107
   Anufrieva KS, 2018, GENOME MED, V10, DOI 10.1186/s13073 018 0557 y
   Batanian JR, 2002, J CLIN PATHOL MOL PA, V55, P389, DOI 10.1136/mp.55.6.389
   Bonnal S, 2012, NAT REV DRUG DISCOV, V11, P847, DOI 10.1038/nrd3823
   Brough R, 2018, ONCOGENE, V37, P5701, DOI 10.1038/s41388 018 0368 z
   Ceron J, 2007, BMC DEV BIOL, V7, DOI 10.1186/1471 213X 7 30
   Chen X, 2014, CELL REP, V7, P104, DOI 10.1016/j.celrep.2014.03.003
   Chicas A, 2010, CANCER CELL, V17, P376, DOI 10.1016/j.ccr.2010.01.023
   Cohen Eliav M, 2013, J PATHOL, V229, P630, DOI 10.1002/path.4129
   Cook R, 2015, CELL REP, V10, P2006, DOI 10.1016/j.celrep.2015.02.059
   Coschi CH, 2014, CANCER DISCOV, V4, P840, DOI 10.1158/2159 8290.CD 14 0215
   El Marabti E, 2018, FRONT MOL BIOSCI, V5, DOI 10.3389/fmolb.2018.00080
   García Cao M, 2002, NAT GENET, V32, P415, DOI 10.1038/ng1011
   Gilbert LA, 2013, CELL, V154, P442, DOI 10.1016/j.cell.2013.06.044
   Graña X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575
   Hilgendorf KI, 2013, GENE DEV, V27, P1003, DOI 10.1101/gad.211326.112
   Hsu TYT, 2015, NATURE, V525, P384, DOI 10.1038/nature14985
   Ishak CA, 2016, MOL CELL, V64, P1074, DOI 10.1016/j.molcel.2016.10.021
   Jia PL, 2019, CELL REP, V26, P496, DOI 10.1016/j.celrep.2018.12.066
   Karni R, 2007, NAT STRUCT MOL BIOL, V14, P185, DOI 10.1038/nsmb1209
   Kearns NA, 2014, DEVELOPMENT, V141, P219, DOI 10.1242/dev.103341
   Kim H, 2018, P NATL ACAD SCI USA, V115, pE11128, DOI 10.1073/pnas.1814044115
   Knudsen ES, 2008, NAT REV CANCER, V8, P714, DOI 10.1038/nrc2401
   Lagisetti C, 2013, J MED CHEM, V56, P10033, DOI 10.1021/jm401370h
   Lee DF, 2015, CELL, V161, P240, DOI 10.1016/j.cell.2015.02.045
   Lee SCW, 2016, NAT MED, V22, P976, DOI 10.1038/nm.4165
   Lin YH, 2017, TRENDS MOL MED, V23, P737, DOI 10.1016/j.molmed.2017.06.004
   Manning AL, 2014, MOL CELL, V53, P993, DOI 10.1016/j.molcel.2014.01.032
   Manning AL, 2010, GENE DEV, V24, P1364, DOI 10.1101/gad.1917310
   Okoro Danielle R, 2012, Genes Cancer, V3, P311, DOI 10.1177/1947601912455323
   Oser MG, 2019, CANCER DISCOV, V9, P230, DOI 10.1158/2159 8290.CD 18 0389
   Rasheva VI, 2006, MOL CELL BIOL, V26, P3468, DOI 10.1128/MCB.26.9.3468 3477.2006
   Shi YG, 2017, NAT REV MOL CELL BIO, V18, P655, DOI 10.1038/nrm.2017.86
   Steensma DP, 2021, LEUKEMIA, V35, P3542, DOI 10.1038/s41375 021 01328 9
   Sveen A, 2016, ONCOGENE, V35, P2413, DOI 10.1038/onc.2015.318
   Temming P, 2017, PEDIATR BLOOD CANCER, V64, P71, DOI 10.1002/pbc.26193
   Thomas DM, 2001, MOL CELL, V8, P303, DOI 10.1016/S1097 2765(01)00327 6
   Velez Cruz R, 2016, GENE DEV, V30, P2500, DOI 10.1101/gad.288282.116
   Wong FL, 1997, JAMA J AM MED ASSOC, V278, P1262, DOI 10.1001/jama.278.15.1262
   Zhang XH, 2015, MOL THER NUCL ACIDS, V4, DOI 10.1038/mtna.2015.37
   Zhou R., 2018, J VIS EXP, P57664
NR 42
TC 22
Z9 24
U1 1
U2 6
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027 8424
EI 1091 6490
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD APR 19
PY 2022
VL 119
IS 16
AR e2117857119
DI 10.1073/pnas.2117857119
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 2P4YZ
UT WOS:000819749900013
PM 35412907
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Van Raemdonck, K
   Umar, S
   Palasiewicz, K
   Volkov, S
   Volin, MV
   Arami, S
   Chang, HJ
   Zanotti, B
   Sweiss, N
   Shahrara, S
AF Van Raemdonck, Katrien
   Umar, Sadiq
   Palasiewicz, Karol
   Volkov, Suncica
   Volin, Michael V.
   Arami, Shiva
   Chang, Huan J.
   Zanotti, Brian
   Sweiss, Nadera
   Shahrara, Shiva
TI CCL21/CCR7 signaling in macrophages promotes joint inflammation and
   Th17 mediated osteoclast formation in rheumatoid arthritis
SO CELLULAR AND MOLECULAR LIFE SCIENCES
LA English
DT Article
DE Rheumatoid arthritis; M1 macrophages; Th17 cells; Osteoclastogenesis;
   CCL21; CCR7
ID CCR7; EXPRESSION; CHEMOKINE; CCL19; DIFFERENTIATION; SUSCEPTIBILITY;
   LIGANDS; DISEASE; DRIVE; TLR5
AB In rheumatoid arthritis (RA), synovial tissue abundantly expresses CCL21, a chemokine strongly associated with RA susceptibility. In this study, we aimed to characterize the functional significance of CCL21/CCR7 signaling in different phases of RA pathogenesis. We determined that CCR7 is a hallmark of RA M1 synovial fluid (SF) macrophages, and its expression in RA monocytes and in vitro differentiated macrophages is closely associated with disease activity score (DAS28). In early stages of RA, monocytes infiltrate the synovial tissue. However, blockade of SF CCL21 or CCR7 prevents RA SF mediated monocyte migration. CCR7 expression in the newly migrated macrophages can be accentuated by LPS and IFN gamma and suppressed by IL 4 treatment. We also uncovered that CCL21 stimulation increases the number of M1 polarized macrophages (CD14+CD86+), resulting in elevated transcription of IL 6 and IL 23. These CCL21 induced M1 cytokines differentiate naive T cells to Th17 cells, without affecting Th1 cell polarization. In the erosive stages of disease, CCL21 potentiates RA osteoclastogenesis through M1 driven Th17 polarization. Disruption of this intricate crosstalk, by blocking IL 6, IL 23, or IL 17 function, impairs the osteoclastogenic capacity of CCL21. Consistent with our in vitro findings, we establish that arthritis mediated by CCL21 expands the joint inflammation to bone erosion by connecting the differentiation of M1 macrophages with Th17 cells. Disease progression is further exacerbated by CCL21 induced neovascularization. We conclude that CCL21 is an attractive novel target for RA therapy, as blockade of its function may abrogate erosive arthritis modulated by M1 macrophages and Th17 cell crosstalk.
C1 [Van Raemdonck, Katrien; Umar, Sadiq; Palasiewicz, Karol; Arami, Shiva; Chang, Huan J.; Shahrara, Shiva] Jesse Brown VA Med Ctr, Chicago, IL USA.
   [Van Raemdonck, Katrien; Umar, Sadiq; Palasiewicz, Karol; Volkov, Suncica; Arami, Shiva; Chang, Huan J.; Sweiss, Nadera; Shahrara, Shiva] Univ Illinois, Div Rheumatol, Dept Med, 840 S Wood St,CSB Suite 1114, Chicago, IL 60612 USA.
   [Volin, Michael V.; Zanotti, Brian] Midwestern Univ, Dept Microbiol & Immunol, Downers Grove, IL 60515 USA.
C3 US Department of Veterans Affairs; Veterans Health Administration (VHA);
   Jesse Brown VA Medical Center; University of Illinois System; University
   of Illinois Chicago; University of Illinois Chicago Hospital; Midwestern
   University; Midwestern University   Downers Grove
RP Shahrara, S (通讯作者)，Jesse Brown VA Med Ctr, Chicago, IL USA.; Shahrara, S (通讯作者)，Univ Illinois, Div Rheumatol, Dept Med, 840 S Wood St,CSB Suite 1114, Chicago, IL 60612 USA.
EM shahrara@uic.edu
RI ; Umar, Sadiq/H 3769 2019
OI Shahrara, Shiva/0000 0002 6698 8491; Sweiss, Nadera/0000 0003 2215 0221;
   Palasiewicz, Karol/0000 0002 2894 6047; Umar, Sadiq/0000 0002 4733 5751
FU NIAID NIH HHS [R41 AI147697, R01 AI167155] Funding Source: Medline;
   NIAMS NIH HHS [R03 AR065778, R03 AR056099] Funding Source: Medline; U.S.
   Department of Veterans Affairs [1I01BX002286] Funding Source: Medline;
   BLRD VA [I01 BX002286] Funding Source: Medline; Foundation for the
   National Institutes of Health [AR065778, AR056099] Funding Source:
   Medline
CR ARNETT FC, 1988, ARTHRITIS RHEUM US, V31, P315, DOI 10.1002/art.1780310302
   Ato M, 2006, J IMMUNOL, V176, P5486, DOI 10.4049/jimmunol.176.9.5486
   Bowes J, 2012, ANN RHEUM DIS, V71, P1350, DOI 10.1136/annrheumdis 2011 200802
   Chamberlain ND, 2012, J IMMUNOL, V189, P475, DOI 10.4049/jimmunol.1102977
   Cosway EJ, 2018, J IMMUNOL, V201, P516, DOI 10.4049/jimmunol.1800348
   Ellingsen T, 2014, SCAND J RHEUMATOL, V43, P91, DOI 10.3109/03009742.2013.803149
   Flanagan K, 2004, CELL IMMUNOL, V231, P75, DOI 10.1016/j.cellimm.2004.12.006
   Förster R, 1999, CELL, V99, P23, DOI 10.1016/S0092 8674(00)80059 8
   Gunn MD, 1999, J EXP MED, V189, P451, DOI 10.1084/jem.189.3.451
   Huang QQ, 2018, J IMMUNOL, V200, P130, DOI 10.4049/jimmunol.1700229
   Jiang Y, 2015, CELL PHYSIOL BIOCHEM, V37, P979, DOI 10.1159/000430224
   Kim KW, 2015, AM J PATHOL, V185, P3011, DOI 10.1016/j.ajpath.2015.07.017
   Kim SJ, 2014, J IMMUNOL, V193, P3902, DOI 10.4049/jimmunol.1302998
   Kuwabara T, 2009, J IMMUNOL, V183, P2513, DOI 10.4049/jimmunol.0800729
   Li GM, 2017, RHEUMATOL INT, V37, P1673, DOI 10.1007/s00296 017 3784 4
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   McGeachy MJ, 2007, NAT IMMUNOL, V8, P1390, DOI 10.1038/ni1539
   Misslitz A, 2004, J EXP MED, V200, P481, DOI 10.1084/jem.20040383
   Moschovakis GL, 2019, CELL MOL IMMUNOL, V16, P791, DOI 10.1038/s41423 018 0056 5
   Nickel T, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/320953
   Otero C, 2006, J IMMUNOL, V177, P2314, DOI 10.4049/jimmunol.177.4.2314
   Pickens SR, 2012, ARTHRITIS RHEUM US, V64, P2471, DOI 10.1002/art.34452
   Pickens SR, 2011, ARTHRITIS RHEUM US, V63, P914, DOI 10.1002/art.30232
   Pickens SR, 2011, ARTHRITIS RHEUM US, V63, P2289, DOI 10.1002/art.30324
   Raychaudhuri S, 2008, NAT GENET, V40, P1216, DOI 10.1038/ng.233
   Revu S, 2018, CELL REP, V22, P2642, DOI 10.1016/j.celrep.2018.02.044
   Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb 2002 3 7 research0034
   Weninger W, 2003, J IMMUNOL, V170, P4638, DOI 10.4049/jimmunol.170.9.4638
   Xuan WJ, 2015, J LEUKOCYTE BIOL, V97, P61, DOI 10.1189/jlb.1A0314 170R
   Zhou SA, 2010, ANAT REC, V293, P48, DOI 10.1002/ar.21015
NR 30
TC 76
Z9 76
U1 1
U2 37
PU SPRINGER BASEL AG
PI BASEL
PA PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND
SN 1420 682X
EI 1420 9071
J9 CELL MOL LIFE SCI
JI Cell. Mol. Life Sci.
PD APR
PY 2020
VL 77
IS 7
BP 1387
EP 1399
DI 10.1007/s00018 019 03235 w
PG 13
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA KY8RQ
UT WOS:000522844100006
PM 31342120
OA Green Published
DA 2025 08 17
ER

PT J
AU Matsubara, Y
   Saito, E
   Suzuki, H
   Watanabe, N
   Murata, M
   Ikeda, Y
AF Matsubara, Yumiko
   Saito, Emi
   Suzuki, Hidenori
   Watanabe, Naohide
   Murata, Mitsuru
   Ikeda, Yasuo
TI Generation of megakaryocytes and platelets from human subcutaneous
   adipose tissues
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Adipocyte precursor cells; Megakaryocytes; Platelets
ID UNILOCULAR FAT CELLS; EMBRYONIC STEM CELLS; FUNCTIONAL PLATELETS;
   IN VITRO; DEDIFFERENTIATION; DIFFERENTIATION; PROLIFERATION; ADIPOCYTES;
   MECHANISMS; ADHESION
AB Recent advances in regenerative medicine have created a broad spectrum of stem cell research. Among them, tissue stem cell regulations are important issues to clarify the molecular mechanism of differentiation. Adipose tissues have been shown to contain abundant preadipocytes, which are multipotent to differentiate into cells including adipocytes, chondrocytes, and osteoblasts. In this study, we have first shown that megakaryocytes and platelets can be generated from adipocyte precursor cells. Human adipocyte precursor cells were cultured in conditioned media for 12 days to differentiate adipocytes. followed by 12 days of culture in media containing thrombopoietin. The ultrastructures of adipocyte precursor cell  and bone marrow CD34 positive cell derived megakaryocytes and platelets were similar. In addition, adipocyte precursor cell derived platelets exhibited surface expression of P selectin and bound fibrinogen upon stimulation with platelet agonists, suggesting that these platelets were functional. This is the first demonstration that human subcutaneous adipocyte precursor cells can generate megakaryocyte and functional platelets in an in vitro culture system. (C) 2008 Elsevier Inc. All rights reserved.
C1 [Matsubara, Yumiko; Watanabe, Naohide; Ikeda, Yasuo] Keio Univ, Sch Med, Dept Internal Med, Shinjuku Ku, Tokyo 1608582, Japan.
   [Saito, Emi] Japan Womens Univ, Dept Food & Nutr, Tokyo, Japan.
   [Suzuki, Hidenori] Tokyo Metropolitan Inst Med Sci, Ctr Electron Microscopy, Tokyo 113, Japan.
   [Murata, Mitsuru] Keio Univ, Sch Med, Dept Lab Med, Tokyo, Japan.
C3 Keio University; Japan Womens University; Tokyo Metropolitan Institute
   of Medical Science; Keio University
RP Matsubara, Y (通讯作者)，Keio Univ, Sch Med, Dept Internal Med, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.
EM yumikoma@sc.itc.keio.ac.jp
RI Murata, Mitsuru/A 7845 2015
FU Ministry of Education, Culture, Sports, Science, and Technology of Japan
   [18209021]; Grants in Aid for Scientific Research [18209021] Funding
   Source: KAKEN
FX This work was supported by Grants in Aid from the Ministry of Education,
   Culture, Sports, Science, and Technology of Japan (#18209021).
CR Casteilla L, 2006, DIABETES METAB, V32, P393, DOI 10.1016/S1262 3636(07)70297 5
   Chen SB, 2004, J AM CHEM SOC, V126, P410, DOI 10.1021/ja037390k
   Davì G, 2007, NEW ENGL J MED, V357, P2482, DOI 10.1056/NEJMra071014
   Fujimoto TT, 2003, BLOOD, V102, P4044, DOI 10.1182/blood 2003 06 1773
   Gaur M, 2006, J THROMB HAEMOST, V4, P436, DOI 10.1111/j.1538 7836.2006.01744.x
   Gimble JM, 2007, CIRC RES, V100, P1249, DOI 10.1161/01.RES.0000265074.83288.09
   Gomillion CT, 2006, BIOMATERIALS, V27, P6052, DOI 10.1016/j.biomaterials.2006.07.033
   Justesen J, 2004, TISSUE ENG, V10, P381, DOI 10.1089/107632704323061744
   Kaushansky K, 2008, BLOOD, V111, P981, DOI 10.1182/blood 2007 05 088500
   KAZAMA T, 2008, BIOCHEM BIOPH RES CO, V317, P769
   Kerrigan SW, 2004, BLOOD, V104, P1327, DOI 10.1182/blood 2003 10 3633
   Matsubara Y, 2005, BLOOD, V106, p1009A
   Matsumoto T, 2008, J CELL PHYSIOL, V215, P210, DOI 10.1002/jcp.21304
   McGann CJ, 2001, P NATL ACAD SCI USA, V98, P13699, DOI 10.1073/pnas.221297398
   Nobusue H, 2008, CELL TISSUE RES, V332, P435, DOI 10.1007/s00441 008 0593 9
   Sengenès C, 2005, J CELL PHYSIOL, V205, P114, DOI 10.1002/jcp.20381
   Shigematsu M, 1999, CELL STRUCT FUNCT, V24, P89, DOI 10.1247/csf.24.89
   Stroncek DF, 2007, LANCET, V370, P427, DOI 10.1016/S0140 6736(07)61198 2
   SUGIHARA H, 1987, J LIPID RES, V28, P1038
   SUGIHARA H, 1986, DIFFERENTIATION, V31, P42, DOI 10.1111/j.1432 0436.1986.tb00381.x
   SUZUKI H, 1994, J ELECTRON MICROSC, V43, P282
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Takayama N, 2008, BLOOD, V111, P5298, DOI 10.1182/blood 2007 10 117622
   Varga Szabo D, 2008, ARTERIOSCL THROM VAS, V28, P403, DOI 10.1161/ATVBAHA.107.150474
   Yagi K, 2004, BIOCHEM BIOPH RES CO, V321, P967, DOI 10.1016/j.bbrc.2004.07.055
   Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526
   Zauli G, 1997, BLOOD, V89, P883, DOI 10.1182/blood.V89.3.883
NR 27
TC 25
Z9 31
U1 0
U2 3
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0006 291X
EI 1090 2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD JAN 23
PY 2009
VL 378
IS 4
BP 716
EP 720
DI 10.1016/j.bbrc.2008.11.117
PG 5
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 394LE
UT WOS:000262447400007
PM 19059379
DA 2025 08 17
ER

PT J
AU Yu, JM
   Zhu, F
   Yang, AQ
   Wang, Z
   Yuan, C
   Xia, GH
   Wang, W
   Song, XW
   Chen, ZZ
   Wu, YJ
   Sun, YH
   Pan, LX
   Ke, YS
   Wang, HG
AF Yu, Jiaming
   Zhu, Feng
   Yang, Aqiang
   Wang, Zhi
   Yuan, Chi
   Xia, Guohua
   Wang, Wei
   Song, Xuanwei
   Chen, Zhengzheng
   Wu, Yinji
   Sun, Yihang
   Pan, Lingxiao
   Ke, Yongsheng
   Wang, Hegui
TI Effects of Drug Coated Balloons on Inflammatory Cytokines After
   Interventional Therapy for Coronary Artery Calcification
SO JOURNAL OF INTERVENTIONAL CARDIOLOGY
LA English
DT Article
DE coronary artery calcification (CAC); DCB; interleukin 6 (IL 6);
   intercellular adhesion molecule 1 (ICAM 1); tumor necrosis factor alpha
   (TNF alpha)
ID PACLITAXEL ELUTING BALLOON; IN STENT RESTENOSIS; HEART DISEASE;
   FOLLOW UP; ATHEROSCLEROSIS; ANGIOPLASTY; SAFETY; OSTEOBLASTS; MORTALITY;
   EFFICACY
AB Objective: To investigate the effects of a drug coated balloon (DCB) on inflammatory cytokines in patients with coronary artery calcification (CAC) after interventional therapy. Methods: This study included 58 patients with coronary heart disease who underwent coronary angiography (CAG) from October 2020 to September 2021. Patients were divided into CAC and non CAC groups, and a DCB was used to intervene in the target lesions. Ten milliliter preoperative and postoperative blood samples were drawn from the coronary lesions in both groups to detect the expression of serum interleukin 6 (IL 6), tumor necrosis factor alpha (TNF alpha), and intercellular adhesion molecule 1 (ICAM 1). All patients were subjected to a 6 month follow up to observe the incidence of major adverse cardiac events (MACEs). Results: No significant differences in baseline clinical data were found between the groups. Serum IL 6, TNF alpha, and ICAM 1 expressions in coronary blood samples immediately before DCB were not significantly different from those after DCB in all patients. After DCB, serum TNF alpha expression in the CAC group was significantly lower than that in the non CAC group (p<0.05). In contrast, no significant difference in serum IL 6 and ICAM 1 expression was found between the groups. During the 6 month follow up, no significant difference in the incidence of MACE was found between both groups. Conclusions: DCB reduced the expression of inflammatory cytokine TNF alpha in CAC, which may be one of the key mechanisms underlying the treatment of CAC by DCB.
C1 [Yu, Jiaming; Zhu, Feng; Yang, Aqiang; Wang, Zhi; Yuan, Chi; Xia, Guohua; Wang, Wei; Song, Xuanwei; Chen, Zhengzheng; Wu, Yinji; Sun, Yihang; Pan, Lingxiao; Ke, Yongsheng; Wang, Hegui] Yijishan Hosp, Wannan Med Coll, Dept Cardiol, Wuhu, Peoples R China.
C3 Wannan Medical College
RP Wang, HG (通讯作者)，Yijishan Hosp, Wannan Med Coll, Dept Cardiol, Wuhu, Peoples R China.
EM 2431944341@qq.com; 15755366795@163.com; 2696256933@qq.com;
   wangzhi_1711@163.com; yuanchi0921@163.com; 12461531@qq.com;
   984780593@qq.com; songxuanwei1991@163.com; chenzhenzhen0325@163.com;
   wuyinji 597623570@163.com; 729716500@qq.com; panlingxiao22@163.com;
   keyongsheng@163.com; wanghegui@wnmc.edu.cn
RI yu, jiaming/GYV 0416 2022; Xia, Guohua/HNR 8540 2023
FU University Natural Science Research Project of Anhui Province
   [KJ2015ZD42]; Anhui Province University Natural Science Research
   Projects [YR201615]; Introduction of Talent Projects of Yijishan
   Hospital of Wannan Medical College; Funding of "Climbing Peak" Training
   Program for Innovative Technology Team of Yijishan Hospital, Wannan
   Medical College
FX This work was supported by the Anhui Province University Natural Science
   Research Projects (KJ2015ZD42), Introduction of Talent Projects of
   Yijishan Hospital of Wannan Medical College (YR201615), and Funding of
   "Climbing Peak" Training Program for Innovative Technology Team of
   Yijishan Hospital, Wannan Medical College. We would like to express our
   gratitude to LetPub for their assistance in revising the language and
   grammar, punctuation, spelling, and clarity of this paper.
CR Aikawa E, 2007, CIRCULATION, V116, P2841, DOI 10.1161/CIRCULATIONAHA.107.732867
   Basavarajaiah S, 2013, J INTERV CARDIOL, V26, P259, DOI 10.1111/j.1540 8183.2013.12010.x
   Buccheri D, 2019, FUTUR CARDIOL, V15, P437, DOI 10.2217/fca 2019 0009
   Byrne RA, 2013, LANCET, V381, P461, DOI 10.1016/S0140 6736(12)61964 3
   Chowdhury MM, 2020, JACC BASIC TRANSL SC, V5, P685, DOI 10.1016/j.jacbts.2020.04.007
   Cortese B, 2020, JACC CARDIOVASC INTE, V13, P2840, DOI 10.1016/j.jcin.2020.08.035
   Costopoulos C, 2013, JACC CARDIOVASC INTE, V6, P1153, DOI 10.1016/j.jcin.2013.07.005
   Cremers B, 2012, CLIN RES CARDIOL, V101, P469, DOI 10.1007/s00392 012 0415 7
   Danesh J, 2005, JAMA J AM MED ASSOC, V294, P1799, DOI 10.1001/jama.294.14.1799
   Hill TP, 2005, DEV CELL, V8, P727, DOI 10.1016/j.devcel.2005.02.013
   Ito R, 2018, J INTERV CARDIOL, V31, P436, DOI 10.1111/joic.12484
   Jeger RV, 2020, LANCET, V396, P1504, DOI 10.1016/S0140 6736(20)32173 5
   Kaptoge S, 2010, LANCET, V375, P132, DOI 10.1016/S0140 6736(09)61717 7
   Kastrati A, 1997, J AM COLL CARDIOL, V30, P1428, DOI 10.1016/S0735 1097(97)00334 3
   Kleber FX, 2016, CLIN RES CARDIOL, V105, P613, DOI 10.1007/s00392 015 0957 6
   Kleber FX, 2013, CLIN RES CARDIOL, V102, P785, DOI 10.1007/s00392 013 0609 7
   Libby P, 2019, J AM COLL CARDIOL, V74, P1594, DOI 10.1016/j.jacc.2019.07.061
   Libby P, 2009, J AM COLL CARDIOL, V54, P2129, DOI 10.1016/j.jacc.2009.09.009
   Ng VG, 2015, EUR J CLIN INVEST, V45, P333, DOI 10.1111/eci.12407
   Pathak A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00943
   Popa C, 2007, J LIPID RES, V48, P751, DOI 10.1194/jlr.R600021 JLR200
   Scheller B, 2008, CLIN RES CARDIOL, V97, P773, DOI 10.1007/s00392 008 0682 5
   Scheller B, 2006, NEW ENGL J MED, V355, P2113, DOI 10.1056/NEJMoa061254
   Shao JS, 2005, J CLIN INVEST, V115, P1210, DOI 10.1172/JCI200524140
   Swerdlow DI, 2012, LANCET, V379, P1214, DOI 10.1016/S0140 6736(12)60110 X
   Unverdorben M, 2013, EUROINTERVENTION, V9, P620, DOI 10.4244/EIJV9I5A99
   Vos NS, 2014, EUROINTERVENTION, V10, P584, DOI 10.4244/EIJV10I5A101
   Wang HW, 2005, FASEB J, V19, P1018, DOI 10.1096/fj.04 3094fje
   Wang X, 2017, JACC CARDIOVASC IMAG, V10, P869, DOI 10.1016/j.jcmg.2017.05.014
   Westendorf JJ, 2004, GENE, V341, P19, DOI 10.1016/j.gene.2004.06.044
   Williams M, 2008, JACC CARDIOVASC IMAG, V1, P61, DOI 10.1016/j.jcmg.2007.09.001
   Yu X, 2019, CLIN RES CARDIOL, V108, P234, DOI 10.1007/s00392 018 1346 8
   Zhang HB, 2018, JAMA INTERN MED, V178, P239, DOI 10.1001/jamainternmed.2017.7821
   Zheng X, 2016, JAMA INTERN MED, V176, P512, DOI 10.1001/jamainternmed.2016.0166
NR 34
TC 0
Z9 0
U1 1
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0896 4327
EI 1540 8183
J9 J INTERV CARDIOL
JI J. Interv. Cardiol.
PD SEP 25
PY 2024
VL 2024
AR 1082261
DI 10.1155/2024/1082261
PG 7
WC Cardiac & Cardiovascular Systems
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cardiovascular System & Cardiology
GA I3N8P
UT WOS:001329366800001
OA gold
DA 2025 08 17
ER

PT J
AU Weisbord, SD
AF Weisbord, Steven D.
TI Patient Centered Dialysis Care: Depression, Pain, and Quality of Life
SO SEMINARS IN DIALYSIS
LA English
DT Article
ID STAGE RENAL DISEASE; CHRONIC HEMODIALYSIS; PSYCHOSOCIAL FACTORS;
   SYMPTOMS; MORTALITY; ADHERENCE; PREVALENCE; HOSPITALIZATION;
   ASSOCIATIONS; FLUOXETINE
AB Remarkable advancements have been made in the provision of chronic dialysis therapy since its inception decades ago. A series of studies inform current dialysis dosing recommendations, while advancements in strategies to treat mineral and bone disease, acid base and electrolyte disturbances, and anemia have facilitated the management of these well recognized complications of ESRD. The collective result has been a model of chronic dialysis care focused principally on the achievement of metabolic and dialysis related targets. In fact, guidelines such as the Kidney Disease Outcomes Quality Initiative put forth by the National Kidney Foundation recommend metrics that characterize successful dialysis care, including the attainment of specific solute clearance targets; maintenance of hemoglobin, calcium, phosphorous, and parathyroid hormone levels within target ranges; and the preferred use of primary arteriovenous fistulae for vascular access. This focus on serologic and dialysis specific outcomes has helped renal providers manage the biochemical effects related to the loss of kidney function and has reduced ESRD related morbidity and mortality. Yet, absent from this model of care is an emphasis on the treatment of bothersome symptoms and the impact of such treatment on quality of life (QOL). Among the many symptoms that affect patients on chronic dialysis, depression and pain are particularly common, strongly associated with decrements in QOL, and potentially treatable. This review discusses key research findings and unanswered questions pertaining to the prevalence, significance, and treatment of depression and pain and the effect of such treatment on QOL in patients dependent on chronic dialysis, with the broad goal of incorporating symptom management strategies into a paradigm of patient centered dialysis care.
C1 [Weisbord, Steven D.] VA Pittsburgh Healthcare Syst, Med Serv Line, Renal Sect, Pittsburgh, PA USA.
   [Weisbord, Steven D.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, Pittsburgh, PA USA.
   [Weisbord, Steven D.] Univ Pittsburgh, Sch Med, Dept Med, Renal Electrolyte Div, Pittsburgh, PA 15213 USA.
C3 US Department of Veterans Affairs; Veterans Health Administration (VHA);
   VA Pittsburgh Healthcare System; US Department of Veterans Affairs;
   Veterans Health Administration (VHA); VA Pittsburgh Healthcare System;
   Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh
RP Weisbord, SD (通讯作者)，VA Pittsburgh Healthcare Syst, 7E Room 120,111F U, Pittsburgh, PA 15240 USA.
EM weisbordsd@upmc.edu
CR Atalay H, 2010, INT UROL NEPHROL, V42, P527, DOI 10.1007/s11255 009 9686 y
   Barakzoy AS, 2006, J AM SOC NEPHROL, V17, P3198, DOI 10.1681/ASN.2006050477
   Barrantes F, 2013, KIDNEY INT, V84, P390, DOI 10.1038/ki.2013.136
   BARRETT BJ, 1990, NEPHRON, V55, P10, DOI 10.1159/000185911
   Belayev LY, 2015, HEMODIAL INT, V19, P216, DOI 10.1111/hdi.12247
   BINIK YM, 1982, KIDNEY INT, V21, P840, DOI 10.1038/ki.1982.108
   Blumenfield M, 1997, INT J PSYCHIAT MED, V27, P71, DOI 10.2190/WQ33 M54T XN7L V8MX
   Boulware LE, 2006, CLIN J AM SOC NEPHRO, V1, P496, DOI 10.2215/CJN.00030505
   Cukor D, 2014, J AM SOC NEPHROL, V25, P196, DOI 10.1681/ASN.2012111134
   Cukor D, 2009, KIDNEY INT, V75, P1223, DOI 10.1038/ki.2009.51
   Davison SN, 2010, J PAIN SYMPTOM MANAG, V39, P477, DOI 10.1016/j.jpainsymman.2009.08.008
   Davison SN, 2005, J PAIN SYMPTOM MANAG, V30, P465, DOI 10.1016/j.jpainsymman.2005.05.013
   Davison SN, 2003, AM J KIDNEY DIS, V42, P1239, DOI 10.1053/j.ajkd.2003.08.025
   Drayer RA, 2006, GEN HOSP PSYCHIAT, V28, P306, DOI 10.1016/j.genhosppsych.2006.03.008
   Duarte PS, 2009, KIDNEY INT, V76, P414, DOI 10.1038/ki.2009.156
   Elsurer R, 2013, RENAL FAILURE, V35, P667, DOI 10.3109/0886022X.2013.780617
   EVANS RW, 1990, JAMA J AM MED ASSOC, V263, P825
   EVANS RW, 1985, NEW ENGL J MED, V312, P553, DOI 10.1056/NEJM198502283120905
   Farrokhi F, 2014, AM J KIDNEY DIS, V63, P623, DOI 10.1053/j.ajkd.2013.08.024
   Harris TJ, 2012, NEPHROL DIAL TRANSPL, V27, P758, DOI 10.1093/ndt/gfr355
   Hedayati SS, 2008, KIDNEY INT, V74, P930, DOI 10.1038/ki.2008.311
   Hedayati SS, 2006, KIDNEY INT, V69, P1662, DOI 10.1038/sj.ki.5000308
   Hedayati SS, 2005, AM J KIDNEY DIS, V46, P642, DOI 10.1053/j.ajkd.2005.07.002
   Huffman Jeff C, 2013, Cardiovasc Psychiatry Neurol, V2013, P695925, DOI 10.1155/2013/695925
   JOHNSON JP, 1982, KIDNEY INT, V22, P286, DOI 10.1038/ki.1982.167
   Kessler RC, 2003, JAMA J AM MED ASSOC, V289, P3095, DOI 10.1001/jama.289.23.3095
   Khalil AA, 2011, J REN CARE, V37, P30, DOI 10.1111/j.1755 6686.2011.00202.x
   Kimmel PL, 2008, J NEPHROL, V21, pS54
   Kimmel PL, 2000, KIDNEY INT, V57, P2093, DOI 10.1046/j.1523 1755.2000.00059.x
   Kimmel PL, 2006, SEMIN NEPHROL, V26, P68, DOI 10.1016/j.semnephrol.2005.06.015
   Kimmel PL, 2000, AM J KIDNEY DIS, V35, pS132, DOI 10.1016/S0272 6386(00)70240 X
   Kimmel PL, 2003, AM J KIDNEY DIS, V42, P713, DOI 10.1016/S0272 6386(03)00907 7
   Klassen Andre, 2013, Clin Nephrol, V79 Suppl 1, pS28
   Koo JR, 2005, AM J MED SCI, V329, P1, DOI 10.1097/00000441 200501000 00001
   Kutner NG, 2002, SEMIN DIALYSIS, V15, P107, DOI 10.1046/j.1525 139X.2002.00034.x
   Levy NB, 1996, GEN HOSP PSYCHIAT, V18, P8, DOI 10.1016/0163 8343(95)00073 9
   Lopes AA, 2002, KIDNEY INT, V62, P199, DOI 10.1046/j.1523 1755.2002.00411.x
   Lopes GB, 2010, NEPHRON CLIN PRACT, V115, pE35, DOI 10.1159/000286348
   Merkus MP, 1999, NEPHROL DIAL TRANSPL, V14, P1163, DOI 10.1093/ndt/14.5.1163
   Park HC, 2010, CLIN NEPHROL, V73, P374
   SACKS CR, 1990, AM J KIDNEY DIS, V15, P31, DOI 10.1016/S0272 6386(12)80589 0
   Watnick S, 2005, AM J KIDNEY DIS, V46, P919, DOI 10.1053/j.ajkd.2005.08.006
   Watnick S, 2003, AM J KIDNEY DIS, V41, P105, DOI 10.1053/ajkd.2003.50029
   Weisbord SD, 2005, J AM SOC NEPHROL, V16, P2487, DOI 10.1681/ASN.2005020157
   Weisbord SD, 2007, CLIN J AM SOC NEPHRO, V2, P960, DOI 10.2215/CJN.00990207
   Weisbord SD, 2014, CLIN J AM SOC NEPHRO, V9, P1594, DOI 10.2215/CJN.00220114
   Weisbord SD, 2013, CLIN J AM SOC NEPHRO, V8, P90, DOI 10.2215/CJN.04450512
NR 47
TC 53
Z9 56
U1 0
U2 15
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0894 0959
EI 1525 139X
J9 SEMIN DIALYSIS
JI Semin. Dial.
PD MAR
PY 2016
VL 29
IS 2
BP 158
EP 164
DI 10.1111/sdi.12464
PG 7
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Urology & Nephrology
GA DG7SC
UT WOS:000372283000010
PM 26748494
DA 2025 08 17
ER

PT J
AU Ehnert, S
   Fentz, AK
   Schreiner, A
   Birk, J
   Wilbrand, B
   Ziegler, P
   Reumann, MK
   Wang, HB
   Falldorf, K
   Nussler, AK
AF Ehnert, Sabrina
   Fentz, Anne Kristin
   Schreiner, Anna
   Birk, Johannes
   Wilbrand, Benjamin
   Ziegler, Patrick
   Reumann, Marie K.
   Wang, Hongbo
   Falldorf, Karsten
   Nussler, Andreas K.
TI Extremely low frequency pulsed electromagnetic fields cause
   antioxidative defense mechanisms in human osteoblasts via induction of
   •O2<SUP> </SUP> and H2O2
SO SCIENTIFIC REPORTS
LA English
DT Article
ID LOTUS SEEDPOD PROCYANIDINS; OXIDATIVE STRESS; REACTIVE OXYGEN; HIP
   FRACTURE; DIFFERENTIATION; MINERALIZATION; PROLIFERATION; ACTIVATION;
   EXPOSURE; ENZYMES
AB Recently, we identified a specific extremely low frequency pulsed electromagnetic field (ELF PEMF) that supports human osteoblast (hOBs) function in an ERK1/2 dependent manner, suggesting reactive oxygen species (ROS) being key regulators in this process. Thus, this study aimed at investigating how ELF PEMF exposure can modulate hOBs function via ROS. Our results show that single exposure to ELF PEMF induced ROS production in hOBs, without reducing intracellular glutathione. Repetitive exposure (>3) to ELF PEMF however reduced ROS levels, suggesting alterations in the cells antioxidative stress response. The main ROS induced by ELF PEMF were center dot O 2( ) and H2O2, therefore expression/activity of antioxidative enzymes related to these ROS were further investigated. ELF PEMF exposure induced expression of GPX3, SOD2, CAT and GSR on mRNA, protein and enzyme activity level. Scavenging center dot O 2( ) and H2O2 diminished the ELF PEMF effect on hOBs function (AP activity and mineralization). Challenging the hOBs with low amounts of H2O2 on the other hand improved hOBs function. In summary, our data show that ELF PEMF treatment favors differentiation of hOBs by producing nontoxic amounts of ROS, which induces antioxidative defense mechanisms in these cells. Thus, ELF PEMF treatment might represent an interesting adjunct to conventional therapy supporting bone formation under oxidative stress conditions, e.g. during fracture healing.
C1 [Ehnert, Sabrina; Schreiner, Anna; Birk, Johannes; Wilbrand, Benjamin; Ziegler, Patrick; Reumann, Marie K.; Nussler, Andreas K.] Eberhard Karls Univ Tubingen, Siegfried Weller Inst Trauma Res, Schnarrenbergstr 95, D 72076 Tubingen, Germany.
   [Fentz, Anne Kristin; Falldorf, Karsten] Sachtleben GmbH, Spectrum UKE, Martinistr 64, D 20251 Hamburg, Germany.
   [Wang, Hongbo] Huazhong Univ Sci & Technol, Wuhan Union Hosp, Tongji Med Coll, Jiefang Dadao 1277, Wuhan 430022, Hubei, Peoples R China.
C3 Eberhard Karls University of Tubingen; Huazhong University of Science &
   Technology
RP Ehnert, S (通讯作者)，Eberhard Karls Univ Tubingen, Siegfried Weller Inst Trauma Res, Schnarrenbergstr 95, D 72076 Tubingen, Germany.
EM sabrina.ehnert@med.uni tuebingen.de
RI Nussler, Andreas/H 3557 2019; Falldorf, Karsten/AAJ 1118 2020; Ehnert,
   Sabrina/AAE 8163 2019
FU Elsbeth Bonhoff Foundation [EBS124]; Sachtleben GmbH (Hamburg)
FX The authors thank Hannah Scheffler for her excellent technical
   assistance. This work was partially supported by the Elsbeth Bonhoff
   Foundation (EBS124) and the Sachtleben GmbH (Hamburg).
CR Aaron RK, 2004, CLIN ORTHOP RELAT R, P21, DOI 10.1097/01.blo.0000118699.26862.41
   Blank Martin, 2009, Pathophysiology, V16, P71, DOI 10.1016/j.pathophys.2009.01.006
   Brauer Carmen A, 2009, JAMA, V302, P1573, DOI 10.1001/jama.2009.1462
   Buldak RJ, 2012, BIOELECTROMAGNETICS, V33, P641, DOI 10.1002/bem.21732
   Calcabrini C., 2016, BIOTECHNOL APPL BIOC
   Chen CT, 2008, STEM CELLS, V26, P960, DOI 10.1634/stemcells.2007 0509
   Cifra M, 2011, PROG BIOPHYS MOL BIO, V105, P223, DOI 10.1016/j.pbiomolbio.2010.07.003
   Ciombor Deborah McK, 2005, Foot Ankle Clin, V10, P579, DOI 10.1016/j.fcl.2005.06.006
   Cohen P, 2009, CURR OPIN CELL BIOL, V21, P317, DOI 10.1016/j.ceb.2009.01.015
   Di Carlo AL, 2001, BIOELECTROCHEMISTRY, V53, P87, DOI 10.1016/S0302 4598(00)00116 1
   Diamantopoulos AP, 2012, AGE AGEING, V41, P86, DOI 10.1093/ageing/afr114
   Duan YQ, 2013, FOOD FUNCT, V4, P1252, DOI 10.1039/c3fo60116a
   Ehnert Sabrina, 2015, Bone Rep, V3, P48, DOI 10.1016/j.bonr.2015.08.002
   Emre M, 2011, CELL BIOCHEM BIOPHYS, V59, P71, DOI 10.1007/s12013 010 9113 0
   Falone S, 2016, INT J RADIAT BIOL, V92, P281, DOI 10.3109/09553002.2016.1150619
   Fathi E, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173877
   Franco R, 2007, J BIOL CHEM, V282, P30452, DOI 10.1074/jbc.M703091200
   Friedman J, 2007, BIOCHEM J, V405, P559, DOI 10.1042/BJ20061653
   Funk RHW, 2009, PROG HISTOCHEM CYTO, V43, P177, DOI 10.1016/j.proghi.2008.07.001
   Gehart H, 2010, EMBO REP, V11, P834, DOI 10.1038/embor.2010.160
   Goodman R, 2009, INT J RADIAT BIOL, V85, P851, DOI [10.3109/09553000903072488, 10.1080/09553000903072488]
   Griffin XL, 2008, INJURY, V39, P419, DOI 10.1016/j.injury.2007.12.014
   Hannouche D, 2001, J BONE JOINT SURG BR, V83B, P157, DOI 10.1302/0301 620X.83B2.12106
   Hiemer B, 2016, INT J MOL MED, V38, P57, DOI 10.3892/ijmm.2016.2590
   Icks A, 2012, WIEN KLIN WOCHENSCHR, V124, P391, DOI 10.1007/s00508 012 0188 z
   Jiang DP, 2016, BRAIN RES, V1642, P10, DOI 10.1016/j.brainres.2016.02.053
   Johnell O, 2006, OSTEOPOROSIS INT, V17, P1726, DOI 10.1007/s00198 006 0172 4
   Kalyanaraman B, 2012, FREE RADICAL BIO MED, V52, P1, DOI 10.1016/j.freeradbiomed.2011.09.030
   Lee DH, 2006, CELL BIOL TOXICOL, V22, P39, DOI 10.1007/s10565 006 0018 z
   Lei T, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 00668 w
   Lin H, 2001, J CELL BIOCHEM, V81, P143, DOI 10.1002/1097 4644(20010401)81:1<143::AID JCB1030>3.0.CO;2 4
   Luo XP, 2016, BIOMED PHARMACOTHER, V82, P640, DOI 10.1016/j.biopha.2016.06.005
   Manolagas SC, 2010, ENDOCR REV, V31, P266, DOI 10.1210/er.2009 0024
   Matés JM, 1999, CLIN BIOCHEM, V32, P595, DOI 10.1016/S0009 9120(99)00075 2
   Peng C, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/831841
   Prasad Ganesh, 2003, Acta Orthop Belg, V69, P546
   Raggi F, 2008, ELECTROMAGN BIOL MED, V27, P325, DOI 10.1080/15368370802493271
   SKEHAN P, 1990, JNCI J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107
   Storch K, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167931
   Wauquier F, 2009, TRENDS MOL MED, V15, P468, DOI 10.1016/j.molmed.2009.08.004
   Yumoto H, 2015, CELL PHYSIOL BIOCHEM, V35, P601, DOI 10.1159/000369722
   Zhang X, 2010, BIOCHEM BIOPH RES CO, V396, P662, DOI 10.1016/j.bbrc.2010.04.154
   Zhou J, 2014, BIOELECTROMAGNETICS, V35, P30, DOI 10.1002/bem.21794
NR 43
TC 68
Z9 70
U1 0
U2 18
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD NOV 6
PY 2017
VL 7
AR 14544
DI 10.1038/s41598 017 14983 9
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA FL7GN
UT WOS:000414415000044
PM 29109418
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Nel, I
   Herzog, H
   Aktas, B
AF Nel, Ivonne
   Herzog, Henrike
   Aktas, Bahriye
TI Combined Analysis of Disseminated Tumor Cells (DTCs) and Circulating
   Tumor DNA (ctDNA) in a Patient Suffering from Triple Negative Breast
   Cancer Revealed Elevated Risk
SO FRONTIERS IN BIOSCIENCE LANDMARK
LA English
DT Article
DE breast cancer; TNBC; disseminated tumor cells; bisphosphonates; liquid
   biopsy; circulating cell free tumor DNA
ID BONE MARROW; STRATEGIES; SURVIVAL; TARGET; REPAIR; PI3K
AB Background: Disseminated tumor cells (DTCs) in bone marrow aspirates of patients with primary breast cancer may serve as independent prognostic markers associated with impaired survival. Due to limited therapy options and high risk of recurrence particularly, women diagnosed with the aggressive triple negative breast cancer (TNBC) require personalized treatment choices. Genetic profiling of circulating cell free tumor DNA (ctDNA) might help to find individual treatment options and to monitor disease course.
   Methods: Here we report the case of a 66 year old patient with TNBC. She received neoadjuvant chemotherapy (NACT) that had to be interrupted due to intolerance. Surgical resection of the residual tumor resulted in pathologic complete response (pCR), though.
   Results: Bone marrow aspiration during surgery revealed an unusual high number of DTCs and thus elevated risk for recurrence. Analysis of pre surgical blood and urine samples revealed the presence of plasma derived and urinary ctDNA after NACT and indicated poor prognosis. Subsequent targeted sequencing showed that pathogenic variants occurred in urinary and plasma derived ctDNA emphasizing the potential of liquid biopsy usage for early detection of relapse. Despite the detection of residual molecular disease after NACT, the presented patient reached pCR and could benefit from standard treatment until present.
   Conclusions: In this case, liquid biopsy based biomarkers did not necessarily correlate to clinical outcome. Further, ctDNA analysis did not reveal approved therapeutic options to target the identified pathogenic variants. Adjuvant bisphosphonate treatment was applied based on the positive DTC status and may improve the patients' prognosis. Further investigations are required to identify TNBC patients at risk for recurrence.
C1 [Nel, Ivonne; Herzog, Henrike; Aktas, Bahriye] Univ Leipzig, Med Ctr, Dept Gynecol, D 04103 Leipzig, Germany.
C3 Leipzig University
RP Nel, I (通讯作者)，Univ Leipzig, Med Ctr, Dept Gynecol, D 04103 Leipzig, Germany.
EM ivonne.nel@medizin.uni leipzig.de
RI Nel, Ivonne/ABF 7456 2022; Aktas, Bahriye/AAW 1201 2021
OI Nel, Ivonne/0000 0001 5188 203X; 
FU Leipzig University   German Research Foundation
FX This research received no external funding and was financed by interal
   means. The publication was funded by the Open Access Publishing Fund of
   Leipzig University supported by the German Research Foundation within
   the program Open Access Publication Funding.
CR Britten CD, 2013, CANCER CHEMOTH PHARM, V71, P1395, DOI 10.1007/s00280 013 2121 1
   Cao L, 2020, CANCER BIOL MED, V17, P293, DOI 10.20892/j.issn.2095 3941.2019.0465
   Cavallone L, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 71236 y
   Chung JH, 2017, ANN ONCOL, V28, P2866, DOI 10.1093/annonc/mdx490
   Cortesi L, 2021, TARGET ONCOL, V16, P255, DOI 10.1007/s11523 021 00796 4
   Courtney KD, 2010, J CLIN ONCOL, V28, P1075, DOI 10.1200/JCO.2009.25.3641
   Denkert C, 2017, LANCET, V389, P2430, DOI 10.1016/S0140 6736(16)32454 0
   Diel IJ, 2008, ANN ONCOL, V19, P2007, DOI 10.1093/annonc/mdn429
   Diel IJ, 1998, NEW ENGL J MED, V339, P357, DOI 10.1056/NEJM199808063390601
   Duffy MJ, 2021, CLIN CHEM LAB MED, V59, P1353, DOI 10.1515/cclm 2021 0171
   Flaherty KT, 2012, NEW ENGL J MED, V367, P107, DOI 10.1056/NEJMoa1203421
   Garcia Murillas I, 2019, JAMA ONCOL, V5, P1473, DOI 10.1001/jamaoncol.2019.1838
   Gass P, 2018, BMC CANCER, V18, DOI 10.1186/s12885 018 4925 1
   Gupta GK, 2020, CANCERS, V12, DOI 10.3390/cancers12092392
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hartkopf AD, 2021, EUR J CANCER, V154, P128, DOI 10.1016/j.ejca.2021.06.028
   Hudes G, 2007, NEW ENGL J MED, V356, P2271, DOI 10.1056/NEJMoa066838
   Jänne PA, 2013, LANCET ONCOL, V14, P38, DOI 10.1016/S1470 2045(12)70489 8
   Keenan TE, 2020, J NATL COMPR CANC NE, V18, P479, DOI 10.6004/jnccn.2020.7554
   Larkin J, 2014, NEW ENGL J MED, V371, P1867, DOI 10.1056/NEJMoa1408868
   Li Y, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.731535
   Lodish MB, 2010, BEST PRACT RES CL EN, V24, P439, DOI 10.1016/j.beem.2010.02.002
   Magbanua MJM, 2021, ANN ONCOL, V32, P229, DOI 10.1016/j.annonc.2020.11.007
   Marotti JD, 2017, AM J PATHOL, V187, P2133, DOI 10.1016/j.ajpath.2017.05.018
   McCabe N, 2006, CANCER RES, V66, P8109, DOI 10.1158/0008 5472.CAN 06 0140
   Motzer RJ, 2010, CANCER AM CANCER SOC, V116, P4256, DOI 10.1002/cncr.25219
   Pelizzari G, 2019, CANCER TREAT REV, V72, P7, DOI 10.1016/j.ctrv.2018.10.014
   Powles T, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1384
   Radovich M, 2020, JAMA ONCOL, V6, P1410, DOI 10.1001/jamaoncol.2020.2295
   Siddappa CM, 2019, BREAST CANCER RES TR, V178, P317, DOI 10.1007/s10549 019 05405 7
   Tomlinson IPM, 2012, MUTAGENESIS, V27, P219, DOI 10.1093/mutage/ger070
   Wimberger P, 2020, J CLIN ONCOL, V38, P580
   Wu R, 2011, CLIN CANCER RES, V17, P7359, DOI 10.1158/1078 0432.CCR 11 1388
NR 33
TC 7
Z9 7
U1 1
U2 5
PU IMR PRESS
PI ROBINSON
PA 112 ROBINSON RD, ROBINSON, SINGAPORE
SN 2768 6701
EI 2768 6698
J9 FRONT BIOSCI LANDMRK
JI Front. Biosci.
PD JUN 24
PY 2022
VL 27
IS 7
DI 10.31083/j.fbl2707208
PG 6
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 3G4SS
UT WOS:000831346400024
PM 35866394
OA gold
DA 2025 08 17
ER

PT J
AU Saito, H
   Noda, H
   Gatault, P
   Bockenhauer, D
   Loke, KY
   Hiort, O
   Silve, C
   Sharwood, E
   Martin, RM
   Dillon, MJ
   Gillis, D
   Harris, M
   Rao, SD
   Pauli, RM
   Gardella, TJ
   Jüppner, H
AF Saito, Hiroshi
   Noda, Hiroshi
   Gatault, Philippe
   Bockenhauer, Detlef
   Loke, Kah Yin
   Hiort, Olaf
   Silve, Caroline
   Sharwood, Erin
   Martin, Regina Matsunaga
   Dillon, Michael J.
   Gillis, David
   Harris, Mark
   Rao, Sudhaker D.
   Pauli, Richard M.
   Gardella, Thomas J.
   Juppner, Harald
TI Progression of Mineral Ion Abnormalities in Patients With Jansen
   Metaphyseal Chondrodysplasia
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
ID PEPTIDE RECEPTOR MUTATION; HORMONE RELATED PEPTIDE; GROWTH FACTOR 23;
   PARATHYROID HORMONE; PTH; HYPERCALCEMIA; DYSPLASIA; AGONIST; CALCIUM
AB Context: Five different activating PTH/PTH related peptide (PTHrP) receptor (PTHR1) mutations have been reported as causes of Jansen metaphyseal chondrodysplasia (JMC), a rare disorder characterized by severe growth plate abnormalities and PTH independent hypercalcemia.
   Objectives: Assess the natural history of clinical and laboratory findings in 24 patients with JMC and characterize the disease causing mutant receptors in vitro.
   Patients and Methods: The H223R mutation occurred in 18 patients. T410P, I458R and I458K each occurred in single cases; T410R was present in a father and his two sons. Laboratory records were analyzed individually and in aggregate.
   Results: Postnatal calcium levels were normal in most patients, but elevated between 0.15 and 10 years (11.8 +/  1.37 mg/dL) and tended to normalize in adults (10.0 +/  1.03 mg/dL). Mean phosphate levels were at the lower end of the age specific normal ranges. Urinary calcium/creatinine (mg/mg) were consistently elevated (children, 0.80 +/  0.40; adults, 0.28 +/  0.19). Adult heights were well below the 3rd percentile for all patients, except for those with the T410R mutation. Most patients with JMC had undergone orthopedic surgical procedures, most had nephrocalcinosis, and two had advanced chronic kidney disease. The five PTHR1 mutants showed varying degrees of constitutive and PTH stimulated cAMP signaling activity when expressed in HEK293 reporter cells. The inverse agonist [L 11,dW(12),W 23,Y 36] PTHrP(7 36) reduced basal cAMP signaling for each PTHR1 mutant.
   Conclusions: Except for T410R, the other PTHR1 mutations were associated with indistinguishable mineral ion abnormalities and cause similarly severe growth impairment. Hypercalciuria persisted into adulthood. An inverse agonist ligand effectively reduced in vitro PTH independent cAMP formation at all five PTHR1 mutants, suggesting a potential path toward therapy.
C1 [Saito, Hiroshi; Noda, Hiroshi; Gardella, Thomas J.; Juppner, Harald] Massachusetts Gen Hosp, Endocrine Unit, 50 Blossom St, Boston, MA 02114 USA.
   [Saito, Hiroshi; Noda, Hiroshi; Gardella, Thomas J.; Juppner, Harald] Harvard Med Sch, Boston, MA 02114 USA.
   [Gatault, Philippe] Univ Hosp, Serv Nephrol Hypertensiol, Transplantat Dialyses, F 37044 Tours, France.
   [Bockenhauer, Detlef; Dillon, Michael J.] UCL, Royal Free Hosp, Ctr Nephrol, London WC1E 6BT, England.
   [Bockenhauer, Detlef; Dillon, Michael J.] Great Ormond St Hosp Sick Children, Dept Paediat Nephrol, London WC1N 3JH, England.
   [Loke, Kah Yin] Natl Univ Singapore Hosp, Dept Pediat, Singapore 119074, Singapore.
   [Hiort, Olaf] Univ Lubeck, Dept Pediat, Div Pediat Endocrinol & Diabet, D 23538 Lubeck, Germany.
   [Silve, Caroline] Hop Cochin, AP HP, Serv Biochim & Genet Mol, F 75014 Paris, France.
   [Silve, Caroline] Ctr Reference Malad Rares Calcium Phosphore & Fil, AP HP, F 75014 Paris, France.
   [Sharwood, Erin; Harris, Mark] Lady Cilento Childrens Hosp, Endocrinol Dept, Brisbane, Qld 4010, Australia.
   [Martin, Regina Matsunaga] Univ Sao Paulo, Hosp Clin, Div Endocrinol, Osteometab Disorders Unit,Sch Med, BR 05403900 Sao Paulo, Brazil.
   [Martin, Regina Matsunaga] Univ Sao Paulo, Hosp Clin, Div Endocrinol, Lab Hormones & Mol Genet LIM42,Sch Med, BR 05403900 Sao Paulo, Brazil.
   [Gillis, David] Hadassah Hebrew Univ Hosp, Dept Pediat, IL 91120 Jerusalem, Israel.
   [Harris, Mark] Univ Queensland, Translat Res Inst, Mater Res Inst, Woolloongabba, Qld 4102, Australia.
   [Rao, Sudhaker D.] Henry Ford Hosp, Dept Med, Bone & Mineral Res Lab, Detroit, MI 48202 USA.
   [Rao, Sudhaker D.] Henry Ford Hosp, Dept Med, Div Endocrinol Diabet & Bone & Mineral Disorders, Detroit, MI 48202 USA.
   [Pauli, Richard M.] Univ Wisconsin, Dept Pediat, Div Genet & Metab, Sch Med & Publ Hlth, Madison, WI 53792 USA.
   [Juppner, Harald] Massachusetts Gen Hosp, Pediat Nephrol Unit, Boston, MA 02114 USA.
   [Silve, Caroline] Hop Bicetre, INSERM Unite 1169, F 94270 Paris, France.
C3 Harvard University; Harvard University Medical Affiliates; Massachusetts
   General Hospital; Harvard University; Harvard Medical School; CHU Tours;
   University of London; University College London; Royal Free London NHS
   Foundation Trust; UCL Medical School; University of London; University
   College London; Great Ormond Street Hospital for Children NHS Foundation
   Trust; National University of Singapore; University of Lubeck;
   Assistance Publique Hopitaux Paris (APHP); Universite Paris Cite;
   Hopital Universitaire Cochin   APHP; Assistance Publique Hopitaux Paris
   (APHP); Childrens Health Queensland Hospital & Health Service;
   Queensland Childrens Hospital; Universidade de Sao Paulo; Universidade
   de Sao Paulo; Hebrew University of Jerusalem; Hadassah University
   Medical Center; Hadassah University Hospital; University of Queensland;
   Mater Research; Henry Ford Health System; Henry Ford Hospital; Henry
   Ford Health System; Henry Ford Hospital; University of Wisconsin System;
   University of Wisconsin Madison; Harvard University; Harvard University
   Medical Affiliates; Massachusetts General Hospital; Assistance Publique
   Hopitaux Paris (APHP); Hopital Universitaire Bicetre   APHP; Institut
   National de la Sante et de la Recherche Medicale (Inserm); Universite
   Paris Saclay
RP Jüppner, H (通讯作者)，Massachusetts Gen Hosp, Endocrine Unit, 50 Blossom St, Boston, MA 02114 USA.; Jüppner, H (通讯作者)，Harvard Med Sch, Boston, MA 02114 USA.
EM jueppner@helix.mgh.harvard.edu
RI Bockenhauer, Detlef/AAF 6495 2020; Loke, Kah/E 6586 2015; Martin,
   Regina/U 2315 2019; SAITO, HIROSHI/KOC 9910 2024; Rao,
   Sudhaker/ABG 8204 2021
OI Noda, Hiroshi/0000 0002 1488 1596; Sharwood, Erin/0000 0002 7251 5164; 
FU National Institutes of Health/National Institute of Diabetes and
   Digestive and Kidney Diseases [DK11794, DK46718, R01DK113039]
FX This work was supported by National Institutes of Health/National
   Institute of Diabetes and Digestive and Kidney Diseases Grants DK11794
   (to H.J. and T.J.G.) DK46718 (to H.J.), and R01DK113039 (to H.J. and
   T.J.G.).
CR Bastepe M, 2004, J CLIN ENDOCR METAB, V89, P3595, DOI 10.1210/jc.2004 0036
   Brown EM, 2015, PARATHYROIDS: BASIC AND CLINICAL CONCEPTS, 3RD EDITION, P101, DOI 10.1016/B978 0 12 397166 1.00006 0
   Brown WW, 2009, J CLIN ENDOCR METAB, V94, P17, DOI 10.1210/jc.2008 0220
   Carter PH, 2015, MOL ENDOCRINOL, V29, P307, DOI 10.1210/me.2014 1129
   Carter PH, 2001, ENDOCRINOLOGY, V142, P1534, DOI 10.1210/en.142.4.1534
   Cheloha RW, 2016, ACS CHEM BIOL, V11, P2752, DOI 10.1021/acschembio.6b00404
   Fadrowski JJ, 2011, CLIN J AM SOC NEPHRO, V6, P1427, DOI 10.2215/CJN.06460710
   Frame B., 1980, Pediatric Diseases Related to Calcium, P269
   Gardella T J., 2016, Endocrinology: Adult and Pediatric, VSeventh, P969, DOI DOI 10.1016/B978 0 323 18907 1.00056 1
   Gardella TJ, 1996, ENDOCRINOLOGY, V137, P3936, DOI 10.1210/en.137.9.3936
   Guo J, 2017, J BONE MINER RES, V32, pS34
   Jansen M., 1934, Z. Orthrop., V61, P253
   KRUSE K, 1993, EUR J PEDIATR, V152, P912, DOI 10.1007/BF01957529
   LEE KC, 1995, ENDOCRINOLOGY, V136, P453, DOI 10.1210/en.136.2.453
   Maes C., 2016, ENDOCRINOLOGY ADULT, DOI DOI 10.1016/B978 0 323 18907 1.00060 3
   Minagawa M, 1997, ENDOCR J, V44, P493, DOI 10.1507/endocrj.44.493
   Nampoothiri S, 2016, J CLIN ENDOCR METAB, V101, P4283, DOI 10.1210/jc.2016 2054
   Onuchic L, 2012, J CLIN ENDOCR METAB, V97, P1098, DOI 10.1210/jc.2011 3082
   Parfitt AM, 1996, J CLIN ENDOCR METAB, V81, P3584, DOI 10.1210/jc.81.10.3584
   Rao DS., 1979, Vitamin D, Basic Research and its Clinical Application, P1173
   Rosen HN, 1997, CALCIFIED TISSUE INT, V61, P455, DOI 10.1007/s002239900367
   Savoldi G, 2013, AM J MED GENET A, V161, P2614, DOI 10.1002/ajmg.a.36115
   Schipani E, 1999, J CLIN ENDOCR METAB, V84, P3052, DOI 10.1210/jc.84.9.3052
   SCHIPANI E, 1995, SCIENCE, V268, P98, DOI 10.1126/science.7701349
   Schipani E, 1996, NEW ENGL J MED, V335, P708, DOI 10.1056/NEJM199609053351004
   SCHWARTZ GJ, 1976, PEDIATRICS, V58, P259
   Silve C, 2015, PARATHYROIDS: BASIC AND CLINICAL CONCEPTS, 3RD EDITION, P587, DOI 10.1016/B978 0 12 397166 1.00040 0
   SILVERTHORN KG, 1987, PEDIATR RADIOL, V17, P119, DOI 10.1007/BF02388087
NR 28
TC 18
Z9 18
U1 0
U2 4
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0021 972X
EI 1945 7197
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD JUL
PY 2018
VL 103
IS 7
BP 2660
EP 2669
DI 10.1210/jc.2018 00332
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA GM5GT
UT WOS:000438162300026
PM 29788189
OA Bronze, Green Submitted, Green Published
DA 2025 08 17
ER

PT J
AU Benyettou, F
   Lalatonne, Y
   Chebbi, I
   Di Benedetto, M
   Serfaty, JM
   Lecouvey, M
   Motte, L
AF Benyettou, Farah
   Lalatonne, Yoann
   Chebbi, Imene
   Di Benedetto, Melanie
   Serfaty, Jean Michel
   Lecouvey, Marc
   Motte, Laurence
TI A multimodal magnetic resonance imaging nanoplatform for cancer
   theranostics
SO PHYSICAL CHEMISTRY CHEMICAL PHYSICS
LA English
DT Article
ID IN VITRO; BONE; NANOPARTICLES; BREAST; BISPHOSPHONATES; NANOTECHNOLOGY;
   ANGIOGENESIS; ALENDRONATE; CELLS
AB We describe an innovative multimodal system, which combines magnetic targeting of therapeutic agents with both magnetic resonance and fluorescence imaging into one system. This new magnetic nanoplatform consists of superparamagnetic gamma Fe2O3 nanoparticles, used clinically as an MRI contrast agent, conjugated to therapeutic molecules of the hydroxylmethylene bisphosphonate family (HMBPs): alendronate with an amine function as the terminal group. In vitro tests with breast cancer cells show that the gamma Fe2O3@alendronate hybrid nanomaterial reduces cell viability and acts as a drug delivery system. We also investigated the anti tumoural properties in vivo in nude mice xenografted with MDA MB 231 tumours. We show that the presence of both gamma Fe2O3@alendronate and a magnetic field significantly reduced the development of tumours. The amine functionalities can be used as precursor groups for the covalent coupling of peptides or monoclonal antibodies for specific biological targeting. The feasibility of this process was demonstrated by coupling rhodamine B, a fluorescence marker, to the gamma Fe2O3@alendronate nanohybrid. The system showed fluorescent properties and high affinity for cells. Flow cytometry and fluorescence microscopy were used to study the kinetics of gamma Fe2O3@alendronate uptake by cells. The magnetic and fluorescent nanoparticles are potential candidates for smart drug delivery systems. Also, the superparamagnetic behaviour of such nanoparticles may be exploited as MRI contrast agents to improve therapeutic diagnostics.
C1 [Benyettou, Farah; Lalatonne, Yoann; Chebbi, Imene; Di Benedetto, Melanie; Lecouvey, Marc; Motte, Laurence] Univ Paris 13, CNRS, UMR 7244, Lab CSPBAT, F 93017 Bobigny, France.
   [Lalatonne, Yoann] Hop Avicenne, Dept Nucl Med, F 93009 Bobigny, France.
   [Serfaty, Jean Michel] Univ Paris 07, INSERM, U698, Dept Radiol,Bichat Hosp, F 75018 Paris, France.
C3 Centre National de la Recherche Scientifique (CNRS); CNRS   Institute of
   Chemistry (INC); Universite Paris 13; Assistance Publique Hopitaux Paris
   (APHP); Hopital Universitaire Avicenne   APHP; Universite Paris 13;
   Institut National de la Sante et de la Recherche Medicale (Inserm);
   Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP);
   Hopital Universitaire Bichat Claude Bernard   APHP
RP Motte, L (通讯作者)，Univ Paris 13, CNRS, UMR 7244, Lab CSPBAT, F 93017 Bobigny, France.
EM laurence.motte torcheux@univ paris13.fr
RI Di BENENDETTO, Melanie/C 1512 2018; Lalatonne, Yoann/AAQ 3764 2020;
   Lecouvey, Marc/ADO 6272 2022; serfaty, jean michel/D 5243 2015; Di
   Benedetto, Melanie/JAC 8455 2023; motte, laurence/AAD 8647 2022
OI Di BENENDETTO, Melanie/0000 0003 1119 3752; motte,
   laurence/0000 0001 6129 539X; Lalatonne, Yoann/0000 0003 2235 6561
CR Benyettou F, 2009, INT J PHARMACEUT, V379, P324, DOI 10.1016/j.ijpharm.2009.04.010
   Boissier S, 2000, CANCER RES, V60, P2949
   Cenni E, 2008, BIOMATERIALS, V29, P1400, DOI 10.1016/j.biomaterials.2007.12.022
   Chebbi I, 2010, INT J PHARMACEUT, V383, P116, DOI 10.1016/j.ijpharm.2009.09.011
   Das M, 2009, SMALL, V5, P2883, DOI 10.1002/smll.200901219
   Douziech Eyrolles L, 2007, INT J NANOMED, V2, P541
   FERNANDEZPACHEC.R, 2007, ACTA BIOMATER, V3, P838
   Hashimoto K, 2007, BIOCHEM BIOPH RES CO, V354, P478, DOI 10.1016/j.bbrc.2007.01.014
   Hiraga T, 2001, CANCER RES, V61, P4418
   Jain KK, 2005, TECHNOL CANCER RES T, V4, P645, DOI 10.1177/153303460500400608
   Kunzmann V, 2000, BLOOD, V96, P384
   Lalatonne Y, 2008, CHEM COMMUN, P2553, DOI 10.1039/b801911h
   Lalatonne Y, 2009, J MAGN MAGN MATER, V321, P1653, DOI 10.1016/j.jmmm.2009.02.107
   Lenglet L, 2009, J MAGN MAGN MATER, V321, P1639, DOI 10.1016/j.jmmm.2009.02.104
   Martin TJ., 2000, Aust Prescriber, V23, P130
   MERELL MA, 2007, EUR J PHARMACOL, V27, P570
   Mutin PH, 2005, J MATER CHEM, V15, P3761, DOI 10.1039/b505422b
   Nancollas GH, 2006, BONE, V38, P617, DOI 10.1016/j.bone.2005.05.003
   Ribatti D, 2007, CLIN RHEUMATOL, V26, P1094, DOI 10.1007/s10067 006 0455 3
   Russell RGG, 2007, BONE, V40, pS21, DOI 10.1016/j.bone.2007.03.002
   SASAKI A, 1995, CANCER RES, V55, P3551
   Scherer F, 2002, GENE THER, V9, P102, DOI 10.1038/sj.gt.3301624
   Sengupta S, 2007, BRIT J CANCER, V96, P1315, DOI 10.1038/sj.bjc.6603707
   Stearns ME, 1996, INVAS METAST, V16, P116
   STRESING V, 2007, CANC LETT SHANNON, V16, P257
   Sun C, 2008, ADV DRUG DELIVER REV, V60, P1252, DOI 10.1016/j.addr.2008.03.018
   Wang MD, 2007, EXPERT REV ANTICANC, V7, P833, DOI 10.1586/14737140.7.6.833
   Wang XL, 2009, NANO RES, V2, P365, DOI 10.1007/s12274 009 9035 6
   Yiu HHP, 2010, ADV FUNCT MATER, V20, P1599, DOI 10.1002/adfm.200902117
   Zeisberger SM, 2006, BRIT J CANCER, V95, P272, DOI 10.1038/sj.bjc.6603240
NR 30
TC 54
Z9 59
U1 0
U2 31
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1463 9076
EI 1463 9084
J9 PHYS CHEM CHEM PHYS
JI Phys. Chem. Chem. Phys.
PY 2011
VL 13
IS 21
BP 10020
EP 10027
DI 10.1039/c0cp02034f
PG 8
WC Chemistry, Physical; Physics, Atomic, Molecular & Chemical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Physics
GA 765TR
UT WOS:000290732000013
PM 21409252
DA 2025 08 17
ER

PT J
AU Jiang, HT
   Deng, R
   Deng, Y
   Nie, M
   Deng, YX
   Luo, HH
   Yang, YY
   Ni, N
   Ran, CC
   Deng, ZL
AF Jiang, Hai Tao
   Deng, Rui
   Deng, Yan
   Nie, Mao
   Deng, Yi Xuan
   Luo, Hong Hong
   Yang, Yuan Yuan
   Ni, Na
   Ran, Cheng Cheng
   Deng, Zhong Liang
TI The role of Serpina3n in the reversal effect of ATRA on
   dexamethasone inhibited osteogenic differentiation in mesenchymal stem
   cells
SO STEM CELL RESEARCH & THERAPY
LA English
DT Article
DE Glucocorticoid induced osteoporosis (GIOP); Dexamethasone; ATRA;
   Serpina3n; BMP9; Osteogenic differentiation
ID TRANS RETINOIC ACID; MOUSE EMBRYONIC FIBROBLASTS; SUPPRESS
   BONE FORMATION; OSTEOBLAST DIFFERENTIATION; WNT/BETA CATENIN;
   GLUCOCORTICOIDS; COX 2; BMP9; ADIPOGENESIS; MECHANISMS
AB Background Glucocorticoid induced osteoporosis (GIOP) is the most common secondary osteoporosis. Patients with GIOP are susceptible to fractures and the subsequent delayed bone union or nonunion. Thus, effective drugs and targets need to be explored. In this regard, the present study aims to reveal the possible mechanism of the anti GIOP effect of all trans retinoic acid (ATRA). Methods Bone morphogenetic protein 9 (BMP9) transfected mesenchymal stem cells (MSCs) were used as an in vitro osteogenic model to deduce the relationship between ATRA and dexamethasone (DEX). The osteogenic markers runt related transcription factor 2 (RUNX2), alkaline phosphatase (ALP), and osteopontin were detected using real time quantitative polymerase chain reaction, Western blot, and immunofluorescent staining assay. ALP activities and matrix mineralization were evaluated using ALP staining and Alizarin Red S staining assay, respectively. The novel genes associated with ATRA and DEX were detected using RNA sequencing (RNA seq). The binding of the protein DNA complex was validated using chromatin immunoprecipitation (ChIP) assay. Rat GIOP models were constructed using intraperitoneal injection of dexamethasone at a dose of 1 mg/kg, while ATRA intragastric administration was applied to prevent and treat GIOP. These effects were evaluated based on the serum detection of the osteogenic markers osteocalcin and tartrate resistant acid phosphatase 5b, histological staining, and micro computed tomography analysis. Results ATRA enhanced BMP9 induced ALP, RUNX2 expressions, ALP activities, and matrix mineralization in mouse embryonic fibroblasts as well as C3H10T1/2 and C2C12 cells, while a high concentration of DEX attenuated these markers. When DEX was combined with ATRA, the latter reversed DEX inhibited ALP activities and osteogenic markers. In vivo analysis showed that ATRA reversed DEX inhibited bone volume, bone trabecular number, and thickness. During the reversal process of ATRA, the expression of retinoic acid receptor beta (RAR beta) was elevated. RAR beta inhibitor Le135 partly blocked the reversal effect of ATRA. Meanwhile, RNA seq demonstrated that serine protease inhibitor, clade A, member 3N (Serpina3n) was remarkably upregulated by DEX but downregulated when combined with ATRA. Overexpression of Serpina3n attenuated ATRA promoted osteogenic differentiation, whereas knockdown of Serpina3n blocked DEX inhibited osteogenic differentiation. Furthermore, ChIP assay revealed that RAR beta can regulate the expression of Serpina3n. Conclusion ATRA can reverse DEX inhibited osteogenic differentiation both in vitro and in vivo, which may be closely related to the downregulation of DEX promoted Serpina3n. Hence, ATRA may be viewed as a novel therapeutic agent, and Serpina3n may act as a new target for GIOP.
C1 [Jiang, Hai Tao; Deng, Rui; Nie, Mao; Ran, Cheng Cheng; Deng, Zhong Liang] Chongqing Med Univ, Affiliated Hosp 2, Dept Orthopaed, 76 Linjiang Rd, Chongqing 400010, Peoples R China.
   [Jiang, Hai Tao; Deng, Yan; Deng, Yi Xuan; Luo, Hong Hong; Yang, Yuan Yuan; Ni, Na; Ran, Cheng Cheng] Chongqing Med Univ, Chongqing Key Lab Biochem & Mol Pharmacol, 1 Yixueyuan Rd, Chongqing 400010, Peoples R China.
   [Deng, Yan; Deng, Yi Xuan; Luo, Hong Hong; Yang, Yuan Yuan] Chongqing Med Univ, Sch Pharm, Dept Pharmacol, 1 Yixueyuan Rd, Chongqing 400010, Peoples R China.
   [Ni, Na] Chongqing Med Univ, Sch Lab Med, Minist Educ, Key Lab Diagnost Med, 1 Yixueyuan Rd, Chongqing 400010, Peoples R China.
C3 Chongqing Medical University; Chongqing Medical University; Chongqing
   Medical University; Chongqing Medical University
RP Deng, ZL (通讯作者)，Chongqing Med Univ, Affiliated Hosp 2, Dept Orthopaed, 76 Linjiang Rd, Chongqing 400010, Peoples R China.
EM dengzl@cqmu.edu.cn
RI Yang, Yuan/HGA 5556 2022; deng, yan/JDW 8815 2023; Nie,
   Mao/GZM 0399 2022; luo, honghong/JVO 2523 2024
OI Nie, Mao/0000 0003 3295 3482; Jiang, Haitao/0000 0003 4720 3262
FU National Natural Science Foundation of China (NSFC) [81672230]; Natural
   Science Foundation of Chongqing [cstc2019jscx gksbX0027,
   cstc2019jcyj msxmX0249]
FX This work was supported by research grant from the National Natural
   Science Foundation of China (NSFC), grant number 81672230 to ZhongLiang
   Deng; research grant from the Natural Science Foundation of Chongqing,
   grant number cstc2019jscx gksbX0027 to Zhong Liang Deng and
   cstc2019jcyj msxmX0249 to Mao Nie.
CR Balkan W, 2011, J BONE MINER METAB, V29, P652, DOI 10.1007/s00774 011 0261 0
   Bi WJ, 2013, DEV GROWTH DIFFER, V55, P744, DOI 10.1111/dgd.12090
   Briot K, 2015, RMD OPEN, V1, DOI 10.1136/rmdopen 2014 000014
   Buckley L, 2018, NEW ENGL J MED, V379, P2547, DOI 10.1056/NEJMcp1800214
   Bushue N, 2010, ADV DRUG DELIVER REV, V62, P1285, DOI 10.1016/j.addr.2010.07.003
   Cash DE, 1997, J CELL BIOL, V136, P445, DOI 10.1083/jcb.136.2.445
   Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890
   Chen L, 2016, BMB REP, V49, P122, DOI 10.5483/BMBRep.2016.49.2.228
   Chen LA, 2010, J BONE MINER RES, V25, P2447, DOI 10.1002/jbmr.133
   Chotiyarnwong P, 2020, NAT REV ENDOCRINOL, V16, P437, DOI 10.1038/s41574 020 0341 0
   Compston J, 2018, ENDOCRINE, V61, P7, DOI 10.1007/s12020 018 1588 2
   Cosman F, 2014, OSTEOPOROSIS INT, V25, P2359, DOI 10.1007/s00198 014 2794 2
   Costantini L, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020360
   di Masi A, 2015, MOL ASPECTS MED, V41, P1, DOI 10.1016/j.mam.2014.12.003
   Gong GC, 2020, BIOCHEM BIOPH RES CO, V532, P598, DOI 10.1016/j.bbrc.2020.08.094
   Green AC, 2017, EXP CELL RES, V350, P284, DOI 10.1016/j.yexcr.2016.12.007
   Green AC, 2018, J BONE MINER RES, V33, P2202, DOI 10.1002/jbmr.3558
   Gueugneau M, 2018, J CACHEXIA SARCOPENI, V9, P929, DOI 10.1002/jcsm.12315
   He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509
   Heit C, 2013, HUM GENOMICS, V7, DOI 10.1186/1479 7364 7 22
   HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092 8674(92)90479 V
   Hofbauer LC, 2009, MOL ENDOCRINOL, V23, P1525, DOI 10.1210/me.2009 0069
   Horvath AJ, 2004, J MOL EVOL, V59, P488, DOI 10.1007/s00239 004 2640 9
   Hsu I, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.423
   Huang J, 2014, BIOMATERIALS, V35, P9649, DOI 10.1016/j.biomaterials.2014.08.016
   Hummel R, 2020, BRIT J PHARMACOL, V177, P5208, DOI 10.1111/bph.15259
   Ishida M, 2018, ENDOCRINOLOGY, V159, P3775, DOI 10.1210/en.2018 00639
   Jia D, 2006, ENDOCRINOLOGY, V147, P5592, DOI 10.1210/en.2006 0459
   Jiang HT, 2019, J STEROID BIOCHEM, V191, DOI 10.1016/j.jsbmb.2019.04.012
   Kim HJ, 2006, J CLIN INVEST, V116, P2152, DOI 10.1172/JCI28084
   Larange A, 2016, ANNU REV IMMUNOL, V34, P369, DOI 10.1146/annurev immunol 041015 055427
   Lengner CJ, 2004, J CELL PHYSIOL, V200, P327, DOI 10.1002/jcp.20118
   Li S, 2018, ONCOL REP, V40, P1743, DOI 10.3892/or.2018.6572
   Liao YP, 2019, J CELL BIOCHEM, V120, P9572, DOI 10.1002/jcb.28234
   Lin LB, 2016, BMB REP, V49, P179, DOI 10.5483/BMBRep.2016.49.3.206
   Liu Y, 2014, INT J BIOCHEM CELL B, V47, P47, DOI 10.1016/j.biocel.2013.11.018
   Liu Y, 2018, DRUG DES DEV THER, V12, P3419, DOI 10.2147/DDDT.S178190
   Luo J, 2007, NAT PROTOC, V2, P1236, DOI 10.1038/nprot.2007.135
   Luu HH, 2007, J ORTHOP RES, V25, P665, DOI 10.1002/jor.20359
   Porcù E, 2018, CELL DEATH DIFFER, V25, P1808, DOI 10.1038/s41418 018 0149 9
   Rauch A, 2010, CELL METAB, V11, P517, DOI 10.1016/j.cmet.2010.05.005
   Seibel MJ, 2013, LANCET DIABETES ENDO, V1, P59, DOI 10.1016/S2213 8587(13)70045 7
   Shao Y, 2016, INT J MOL MED, V38, P1693, DOI 10.3892/ijmm.2016.2782
   Sharff KA, 2009, J BIOL CHEM, V284, P649, DOI 10.1074/jbc.M806389200
   Smit McBride Z, 2011, INVEST OPHTH VIS SCI, V52, P8965, DOI 10.1167/iovs.10 7084
   Song B, 2019, INT IMMUNOPHARMACOL, V74, DOI 10.1016/j.intimp.2019.105685
   Teitelbaum SL, 2015, CLIN EXP RHEUMATOL, V33, pS37
   Wang H, 2019, BIOMED PHARMACOTHER, V118, DOI 10.1016/j.biopha.2019.109279
   Wang JH, 2013, BONE, V57, P311, DOI 10.1016/j.bone.2013.08.015
   Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799
   Wu ZD, 1996, MOL CELL BIOL, V16, P4128
   Yang YJ, 2018, ACTA PHARMACOL SIN, V39, P633, DOI 10.1038/aps.2017.134
   Zhang HM, 2015, BIOMATERIALS, V39, P145, DOI 10.1016/j.biomaterials.2014.11.007
   Zhang S, 2016, MOL CELL ENDOCRINOL, V422, P243, DOI 10.1016/j.mce.2015.12.018
NR 54
TC 9
Z9 11
U1 4
U2 17
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1757 6512
J9 STEM CELL RES THER
JI Stem Cell Res. Ther.
PD MAY 17
PY 2021
VL 12
IS 1
AR 291
DI 10.1186/s13287 021 02347 0
PG 19
WC Cell & Tissue Engineering; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA SM7ZW
UT WOS:000657819500003
PM 34001245
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Hansen, C
   Pedersen, BD
   Konradsen, H
   Abrahamsen, B
AF Hansen, C.
   Pedersen, B. D.
   Konradsen, H.
   Abrahamsen, B.
TI Anti osteoporotic therapy in Denmark predictors and demographics of poor
   refill compliance and poor persistence
SO OSTEOPOROSIS INTERNATIONAL
LA English
DT Article
DE Osteoporosis; Persistence; Refill compliance; Register based; Risk
   groups; Socioeconomic
ID MEDICAL TREATMENT; DRUG THERAPY; ADHERENCE; PATIENT; FRACTURES; WOMEN;
   ALENDRONATE; RATES
AB In this study of 100,949 new users of oral bisphosphonates age a parts per thousand yen35 years, "early quitters" were found to differ from others with poor refill compliance in terms of socioeconomic, demographic, and treatment related characteristics. New risk factors for poor compliance and persistence were identified.
   Poor compliance with anti osteoporotic therapy is an on going worldwide challenge. In this study, we hypothesized that "early quitters" differ in socioeconomics, demographics, co medications, and comorbid conditions from other patients with low compliance.
   The study was a register based nationwide cohort study of anti osteoporotic therapy comprising 100,949 men and women. Statistical analysis including backward stepwise logistic regression analysis was used to explain causes of treatment failure and Kaplan Meier survival analysis to estimate persistence of treatment.
   It was noted that 56.6 % of the patients were persistent and compliant, 4.7 % of the patients were persistent but "low compliant" while 38.7 % of the patients were "early quitters". "Early quitters" were found to differ in socioeconomics from "low compliant" patients. Differences concerning increased risk of "early quitters" were associated with high household income, subjects' age 71.9 79 years, living in the countryside or village, prior treatment with analgesics and anti parkinson drugs, and dementia. Differences concerning decreased risk of "early quitters" were associated with male, living in an apartment, children living at home, living close to a university hospital, anti osteoporotic therapy other than alendronate, number of drugs especially above three, pulmonary disease, collagen disease.
   The results suggest a need for improved support for patients to facilitate the interpretation of the disease and the perception of the benefits and risks of treatment to reduce the risk of "early quitters". We were able to identify new risk groups that may be candidates for targeted actions.
C1 [Hansen, C.; Pedersen, B. D.] Univ Southern Denmark, Fac Hlth Sci, Inst Clin Res, Res Unit Nursing, DK 5230 Odense M, Denmark.
   [Hansen, C.] Gentofte Univ Hosp, Dept Med C, Res Unit, DK 2900 Hellerup, Denmark.
   [Konradsen, H.] Gentofte Univ Hosp, Res Unit, DK 2900 Hellerup, Denmark.
   [Abrahamsen, B.] Gentofte Univ Hosp, Dept Med F, DK 2900 Hellerup, Denmark.
   [Abrahamsen, B.] Univ Southern Denmark, Fac Hlth Sci, Inst Clin Res, DK 5230 Odense M, Denmark.
C3 University of Southern Denmark; University of Copenhagen; Herlev &
   Gentofte Hospital; University of Copenhagen; Herlev & Gentofte Hospital;
   University of Copenhagen; Herlev & Gentofte Hospital; University of
   Southern Denmark
RP Hansen, C (通讯作者)，Univ Southern Denmark, Fac Hlth Sci, Inst Clin Res, Res Unit Nursing, Campusvej 55, DK 5230 Odense M, Denmark.
EM chansen@health.sdu.dk
RI Abrahamsen, Bo/B 8920 2008; Hansen, Carrinna/J 4359 2019
OI Abrahamsen, Bo/0000 0002 2730 6080; Hansen,
   Carrinna/0000 0003 2164 6997; Konradsen, Hanne/0000 0002 7477 125X
FU University of Southern Denmark; Gentofte University Hospital; Capital
   Region; Research Foundation for Health Research; Aase and Ejnar
   Danielsens Foundation; Osteoporosis Society Denmark; Cabinetmaker Sophus
   Jacobsen and wife Astrid Jacobsens Fond
FX Allocated funds from University of Southern Denmark, Gentofte University
   Hospital, Capital Region, Research Foundation for Health Research, Aase
   and Ejnar Danielsens Foundation, The Osteoporosis Society Denmark,
   Cabinetmaker Sophus Jacobsen and wife Astrid Jacobsens Fond
CR Abrahamsen B, 2009, OSTEOPOROSIS INT, V20, P1633, DOI 10.1007/s00198 009 0920 3
   [Anonymous], 2008, Adherence to Long Term Therapies   Evidence for action
   Balkrishnan R, 1998, CLIN THER, V20, P764, DOI 10.1016/S0149 2918(98)80139 2
   Barat I, 2001, BRIT J CLIN PHARMACO, V51, P615, DOI 10.1046/j.0306 5251.2001.01401.x
   Barker C, 2009, AM STAT, V63, P78, DOI 10.1198/tast.2009.0015
   Block AE, 2008, J GEN INTERN MED, V23, P1447, DOI 10.1007/s11606 008 0697 7
   Cadarette SM, 2010, CURR OPIN RHEUMATOL, V22, P397, DOI 10.1097/BOR.0b013e32833ac7fe
   Christensen PM, 2005, BASIC CLIN PHARMACOL, V96, P387, DOI 10.1111/j.1742 7843.2005.pto_08.x
   Ciechanowski PS, 2001, AM J PSYCHIAT, V158, P29, DOI 10.1176/appi.ajp.158.1.29
   Cooper C, 2012, BRIT MED J, V344, DOI 10.1136/bmj.e4191
   Cortet Bernard, 2006, Joint Bone Spine, V73, pe1, DOI 10.1016/j.jbspin.2006.02.006
   Danmarks Statistik, 2008, DANM STAT
   Devold HM, 2012, PHARMACOEPIDEM DR S, V21, P297, DOI 10.1002/pds.2344
   DiMatteo MR, 2004, HEALTH PSYCHOL, V23, P207, DOI 10.1037/0278 6133.23.2.207
   Fraenkel L, 2006, ARTHRIT RHEUM ARTHR, V55, P729, DOI 10.1002/art.22229
   Genant HK, 1999, OSTEOPOROSIS INT, V10, P259, DOI 10.1007/s001980050224
   GRIFFITH S, 1990, BRIT J GEN PRACT, V40, P114
   Haynes RB, 2008, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD000011.pub4, 10.1002/14651858.CD000011.pub3]
   Imaz I, 2010, OSTEOPOROSIS INT, V21, P1943, DOI 10.1007/s00198 009 1134 4
   Kothawala P, 2007, MAYO CLIN PROC, V82, P1493, DOI 10.4065/82.12.1493
   Landfeldt E, 2012, OSTEOPOROSIS INT, V23, P433, DOI 10.1007/s00198 011 1549 6
   Lassen L C, 1989, Scand J Prim Health Care, V7, P179, DOI 10.3109/02813438909087237
   Lindberg Mats Jacob Hermansson, 2008, Ugeskr Laeger, V170, P1912
   McLeod K, 2011, J OSTEOPOROS, V2011, DOI 10.4061/2011/197454
   Meadows ES, 2012, BMC WOMENS HEALTH, V12, DOI 10.1186/1472 6874 12 1
   Nielsen DS, 2010, SCAND J PUBLIC HEALT, V38, P502, DOI 10.1177/1403494810371243
   Reginster JY, 2006, BONE, V38, P4, DOI 10.1016/j.bone.2005.11.024
   Roerholt C, 2009, OSTEOPOROSIS INT, V20, P299, DOI 10.1007/s00198 008 0651 x
   Sale JEM, 2010, J EVAL CLIN PRACT, V16, P590, DOI 10.1111/j.1365 2753.2009.01176.x
   Silverman S, 2010, REV ENDOCR METAB DIS, V11, P275, DOI 10.1007/s11154 010 9138 0
   Siris ES, 2006, MAYO CLIN PROC, V81, P1013, DOI 10.4065/81.8.1013
   Sundhedsstyrelsen, 2008, SUND HEL LIV NAT MAL
   Wastesson JW, 2013, OSTEOPOROSIS INT, V24, P433, DOI 10.1007/s00198 012 1945 6
   World Health Organization, 2008, WORLD HLTH REP
NR 34
TC 31
Z9 33
U1 0
U2 8
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0937 941X
EI 1433 2965
J9 OSTEOPOROSIS INT
JI Osteoporosis Int.
PD JUL
PY 2013
VL 24
IS 7
BP 2079
EP 2097
DI 10.1007/s00198 012 2221 5
PG 19
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 162RQ
UT WOS:000320283300016
PM 23179576
DA 2025 08 17
ER

PT J
AU Moraes, PD
   Silva, CAB
   Soares, AB
   Passador Santos, F
   Corrêa, MEP
   de Araújo, NS
   de Araújo, VC
AF Moraes, Paulo de Camargo
   Barcellos Silva, Carolina Amalia
   Soares, Andresa Borges
   Passador Santos, Fabricio
   Pizzigatti Correa, Maria Elvira
   de Araujo, Ney Soares
   de Araujo, Vera Cavalcanti
TI Tooth alterations in areas of bisphosphonate induced osteonecrosis
SO CLINICAL ORAL INVESTIGATIONS
LA English
DT Article
DE Bisphosphonates; Osteonecrosis; Tooth alterations; Pulp calcification
ID 1 HYDROXYETHYLIDENE 1,1 BISPHOSPHONATE HEBP; MULTIPLE MYELOMA; JAWS;
   MECHANISMS; ASSOCIATION; MANAGEMENT; THERAPY; UPDATE; SINGLE; CELLS
AB Osteonecrosis of the jaw is a potential side effect when using bisphosphonates. Most studies on the effects of bisphosphonates on teeth have been conducted in vitro or in animal models of tooth development. Therefore, the aim of this study was to describe alterations found in human teeth extracted from areas of bisphosphonate induced osteonecrosis.
   Using a retrospective study design, 16 teeth from 13 patients were extracted from areas of bisphosphonate induced osteonecrosis during surgical debridement. The specimens were decalcified and embedded in paraffin. A series of 5 mu m sections were prepared, stained with hematoxylin and eosin (H&E) and observed under a light microscope.
   The majority of the patients were female (53.85 %), with a mean age of 60.23 +/  13.18 years. Zoledronate (IV) was the most common bisphosphonate used (92.3 %), over a mean period of 2 years. The commonest alteration observed was hypercementosis (87.5 %), followed by pulpar necrosis (81.25 %), pulp stones attached to the dentine and loose pulp stones in the pulp chamber and root canals in addition to linear calcifications (68.75 %), dentinoid/osteoid material formation (18.75 %), and dental ankylosis (6.25 %).
   Patients undergoing bisphosphonate therapy present diverse tooth alterations, which should be closely monitored by clinicians to prevent complications.
   It is paramount that the teeth involved in oral lesions are always examined. Attention should be drawn to the need to establish preventive measures, in terms of dental treatment, for patients prior to starting bisphosphonate therapy.
C1 [Moraes, Paulo de Camargo; Barcellos Silva, Carolina Amalia; Soares, Andresa Borges; Passador Santos, Fabricio; de Araujo, Ney Soares; de Araujo, Vera Cavalcanti] Sao Leopoldo Mand Inst & Res Ctr, Dept Oral Pathol, BR 13045610 Campinas, SP, Brazil.
   [Pizzigatti Correa, Maria Elvira] Univ Estadual Campinas, Hematol & Blood Transfus Ctr, Campinas, SP, Brazil.
C3 Faculdade Sao Leopoldo Mandic; Universidade Estadual de Campinas
RP Silva, CAB (通讯作者)，Sao Leopoldo Mand Inst & Res Ctr, Dept Oral Pathol, Rua Jose Rocha Junqueira 13, BR 13045610 Campinas, SP, Brazil.
EM cabs.barcellos@hotmail.com
RI Araujo, Vera/G 3586 2014; Passador Santos, Fabricio/AAR 5899 2020;
   Pizzigatti Correa, Maria Elvira/J 4389 2012; Silva,
   Carolina/JQV 4022 2023
OI Araujo, Vera/0000 0002 5860 3715
FU FAPESP/Brazil [2011/21157 0]; Fundacao de Amparo a Pesquisa do Estado de
   Sao Paulo (FAPESP) [11/21157 0] Funding Source: FAPESP
FX The authors wish to thank Nadir Severina de Freitas for her excellent
   technical expertise and assistance. Carolina Amalia Barcellos Silva was
   funded by a scholarship program from FAPESP/Brazil (2011/21157 0).
CR ALATLIKUT I, 1994, SCAND J DENT RES, V102, P260
   Allen MR, 2009, J ORAL MAXIL SURG, V67, P61, DOI 10.1016/j.joms.2009.01.007
   Antonini F, 2010, J CRANIOFAC SURG, V21, P1962, DOI 10.1097/SCS.0b013e3181f4ee4e
   Assael LA, 2011, ORAL MAXIL SURG CLIN, V23, P443, DOI 10.1016/j.coms.2011.04.002
   Boonyapakorn T, 2008, ORAL ONCOL, V44, P857, DOI 10.1016/j.oraloncology.2007.11.012
   Borromeo GL, 2011, AUST DENT J, V56, P2, DOI 10.1111/j.1834 7819.2010.01283.x
   Brandsten C, 1995, CONNECT TISSUE RES, V32, P275, DOI 10.3109/03008209509013734
   Coxon FP, 2008, BONE, V42, P848, DOI 10.1016/j.bone.2007.12.225
   Cvikl B, 2011, INT ENDOD J, V44, P33, DOI 10.1111/j.1365 2591.2010.01792.x
   Dominguez LJ, 2011, BIOGERONTOLOGY, V12, P397, DOI 10.1007/s10522 011 9344 5
   Drake MT, 2008, MAYO CLIN PROC, V83, P1032, DOI 10.4065/83.9.1032
   Edwards BJ, 2008, J AM DENT ASSOC, V139, P1674, DOI 10.14219/jada.archive.2008.0110
   Fleisch H, 1998, ENDOCR REV, V19, P80, DOI 10.1210/er.19.1.80
   Grbic JT, 2008, J AM DENT ASSOC, V139, P32, DOI 10.14219/jada.archive.2008.0017
   Kim JH, 2011, ORAL DIS, V17, P705, DOI 10.1111/j.1601 0825.2011.01829.x
   Kühl S, 2012, ORAL ONCOL, V48, P938, DOI 10.1016/j.oraloncology.2012.03.028
   Mavrokokki T, 2007, J ORAL MAXIL SURG, V65, P415, DOI 10.1016/j.joms.2006.10.061
   McLeod NMH, 2011, BRIT J ORAL MAX SURG, V49, P335, DOI 10.1016/j.bjoms.2010.08.005
   MORSE DR, 1991, ORAL SURG ORAL MED O, V72, P721, DOI 10.1016/0030 4220(91)90019 9
   Pichardo SEC, 2013, OR SURG OR MED OR PA, V116, P287, DOI 10.1016/j.oooo.2013.05.005
   Pozzi S, 2011, ONCOLOGIST, V16, P651, DOI 10.1634/theoncologist.2010 0225
   Ravosa MJ, 2011, ARCH ORAL BIOL, V56, P491, DOI 10.1016/j.archoralbio.2010.11.003
   Roelofs AJ, 2006, CLIN CANCER RES, V12, p6222S, DOI 10.1158/1078 0432.CCR 06 0843
   Ruggiero SL, 2006, ORAL SURG ORAL MED O, V102, P433, DOI 10.1016/j.tripleo.2006.06.004
   Ruggiero SL, 2009, J ORAL MAXIL SURG, V67, P2, DOI 10.1016/j.joms.2009.01.009
   Santamaria Júnior Milton, 2010, Braz. oral res., V24, P309
   Sener S, 2009, CLIN ORAL INVEST, V13, P209, DOI 10.1007/s00784 008 0212 x
   Silverman SL, 2009, AM J MED, V122, P33, DOI 10.1016/j.amjmed.2008.12.005
   Urade M, 2011, J ORAL MAXIL SURG, V69, pE364, DOI 10.1016/j.joms.2011.03.051
   Vermeer JAF, 2013, BONE, V57, P242, DOI 10.1016/j.bone.2013.08.007
   Wehrhan F, 2011, ORAL SURG ORAL MED O, V112, P216, DOI 10.1016/j.tripleo.2011.02.028
   WESSELINK PR, 1989, CALCIFIED TISSUE INT, V45, P104, DOI 10.1007/BF02561409
NR 32
TC 11
Z9 11
U1 0
U2 8
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D 69121 HEIDELBERG, GERMANY
SN 1432 6981
EI 1436 3771
J9 CLIN ORAL INVEST
JI Clin. Oral Investig.
PD MAR
PY 2015
VL 19
IS 2
BP 489
EP 495
DI 10.1007/s00784 014 1270 x
PG 7
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA CC4VT
UT WOS:000350353300038
PM 24948337
DA 2025 08 17
ER

PT J
AU Jia, YH
   Wang, K
   Wang, HF
   Zhang, BT
   Yang, K
   Zhang, ZL
   Dong, HJ
   Wang, JX
AF Jia, Yihe
   Wang, Ke
   Wang, Huifang
   Zhang, Botao
   Yang, Kan
   Zhang, Zhilan
   Dong, Haijuan
   Wang, Jinxin
TI Discovery of selective covalent cathepsin K inhibitors containing novel
   4 cyanopyrimidine warhead based on quantum chemical calculations and
   binding mode analysis
SO BIOORGANIC & MEDICINAL CHEMISTRY
LA English
DT Article
DE Covalent Cat K inhibitor; Osteoporosis; Nitrile warheads; Quantum
   chemical calculations; Binding mode analysis
ID BONE TURNOVER; HIGHLY POTENT; OSTEOPOROSIS; CYSTEINE; REACTIVITY;
   NITRILE; ODANACATIB; TARGET
AB Cathepsin K (Cat K), mainly expressed by osteoclasts, plays an important role in bone resorption. Covalent Cat K inhibitors will show great potential in the future treatment of osteoporosis. It has been reported that the selectivity of covalent cathepsin K inhibitors was related to the drug's safety. The type of warhead has a crucial influence on the enzyme bioactivity and selectivity of covalent inhibitors. In order to develop novel covalent inhibitors with the selective new warhead, quantum chemical calculations were performed to estimate the reactivity of the nitrile warheads. Moreover, binding mode analysis between ligands and high homology Cat K, S and B revealed differences in non covalent interactions. Novel covalent Cat K inhibitors containing 4 cyanopyr imidine warhead (11) were determined for the first time. Among them, compound 34 significantly inhibited Cat K (IC50 = 61.9 nM) with excellent selectivity compared to Cat S (>810 fold) and Cat B (>1620 fold), respec tively. Binding mode analysis of Cat K 34 complex provided the basis for further optimization. Compound 34 could be a valuable lead compound for further research on safe and effective Cat K inhibitors.
C1 [Jia, Yihe; Wang, Ke; Wang, Huifang; Zhang, Botao; Zhang, Zhilan; Wang, Jinxin] China Pharmaceut Univ, Dept Med Chem, Nanjing 211198, Peoples R China.
   [Yang, Kan] Hebei Univ, Coll Pharmaceut Sci, Key Lab Pharmaceut Qual Control Hebei Prov, Baoding 071002, Peoples R China.
   [Dong, Haijuan] China Pharmaceut Univ, Publ Lab Platform, Nanjing 210009, Peoples R China.
C3 China Pharmaceutical University; Hebei University; China Pharmaceutical
   University
RP Wang, JX (通讯作者)，China Pharmaceut Univ, Dept Med Chem, Nanjing 211198, Peoples R China.
EM jinxinwangcpu@126.com
RI wang, jinxin/CAA 0620 2022; WANG, Danni/KOC 8899 2024; Zhang,
   Botao/H 7712 2016
FU National Natural Science Foundation of China; Natural Science Foundation
   of Jiangsu Province;  [82073710];  [82003597];  [BK20191318]
FX This work was supported by the National Natural Science Foundation of
   China (No 82073710, 82003597) , the Natural Science Foundation of
   Jiangsu Province (BK20191318) .
CR [Anonymous], 2016, GAUSSVIEW 5
   Berteotti A, 2014, ACS MED CHEM LETT, V5, P501, DOI 10.1021/ml400489b
   Boyd MJ, 2009, BIOORG MED CHEM LETT, V19, P675, DOI 10.1016/j.bmcl.2008.12.053
   Brömme D, 2009, EXPERT OPIN INV DRUG, V18, P585, DOI [10.1517/13543780902832661, 10.1517/13543780902832661 ]
   Cee VJ, 2015, J MED CHEM, V58, P9171, DOI 10.1021/acs.jmedchem.5b01018
   Chappard D, 2010, MICROSC RES TECHNIQ, V73, P726, DOI 10.1002/jemt.20813
   Chapurlat RD, 2015, THER ADV MUSCULOSKEL, V7, P103, DOI 10.1177/1759720X15580903
   Costa AG, 2011, NAT REV RHEUMATOL, V7, P447, DOI 10.1038/nrrheum.2011.77
   Drake MT, 2017, ENDOCR REV, V38, P325, DOI 10.1210/er.2015 1114
   Du HY, 2021, NUCLEIC ACIDS RES, V49, pD1122, DOI 10.1093/nar/gkaa876
   Duong Le T, 2012, Bonekey Rep, V1, P67, DOI 10.1038/bonekey.2012.67
   Eastell R, 2014, J BONE MINER RES, V29, P458, DOI 10.1002/jbmr.2047
   Ehmke V, 2012, ORG BIOMOL CHEM, V10, P5764, DOI 10.1039/c2ob00034b
   Flanagan ME, 2014, J MED CHEM, V57, P10072, DOI 10.1021/jm501412a
   Frisch M.J., 2016, Gaussian 16, Revision A.03
   Frizler M, 2011, J MED CHEM, V54, P396, DOI 10.1021/jm101272p
   Gao MJ, 2022, NUCLEIC ACIDS RES, V50, pD445, DOI 10.1093/nar/gkab868
   Gauthier JY, 2008, BIOORG MED CHEM LETT, V18, P923, DOI 10.1016/j.bmcl.2007.12.047
   Kafienah W, 1998, BIOCHEM J, V331, P727, DOI 10.1042/bj3310727
   Kumar S, 2007, BONE, V40, P122, DOI 10.1016/j.bone.2006.07.015
   Lecaille F, 2008, BIOCHIMIE, V90, P208, DOI 10.1016/j.biochi.2007.08.011
   Legault C.Y, 2009, CYLVIEW20
   Li BJ, 2011, J CELL BIOCHEM, V112, P1229, DOI 10.1002/jcb.23049
   Löser R, 2008, ANGEW CHEM INT EDIT, V47, P4331, DOI 10.1002/anie.200705858
   Lu J, 2018, J ENZYM INHIB MED CH, V33, P890, DOI 10.1080/14756366.2018.1465417
   Luo YL, 2021, J CHEM INF MODEL, V61, P5307, DOI 10.1021/acs.jcim.1c01278
   Marenich AV, 2009, J PHYS CHEM B, V113, P6378, DOI 10.1021/jp810292n
   Melton LJ, 1997, J BONE MINER RES, V12, P16, DOI 10.1359/jbmr.1997.12.1.16
   Oballa RM, 2007, BIOORG MED CHEM LETT, V17, P998, DOI 10.1016/j.bmcl.2006.11.044
   Odvina CV, 2005, J CLIN ENDOCR METAB, V90, P1294, DOI 10.1210/jc.2004 0952
   Reid IR, 2015, NAT REV ENDOCRINOL, V11, P418, DOI 10.1038/nrendo.2015.71
   Rizzoli R, 2016, OSTEOPOROSIS INT, V27, P2099, DOI 10.1007/s00198 016 3503 0
   Teno N, 2010, CURR TOP MED CHEM, V10, P752, DOI 10.2174/156802610791113423
   Turk V, 2001, EMBO J, V20, P4629, DOI 10.1093/emboj/20.17.4629
   Wijkmans J, 2011, EXPERT OPIN THER PAT, V21, P1611, DOI 10.1517/13543776.2011.616283
NR 35
TC 1
Z9 1
U1 5
U2 13
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0968 0896
EI 1464 3391
J9 BIOORGAN MED CHEM
JI Bioorg. Med. Chem.
PD NOV 15
PY 2022
VL 74
AR 117053
DI 10.1016/j.bmc.2022.117053
EA OCT 2022
PG 15
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Chemistry,
   Organic
WE Science Citation Index Expanded (SCI EXPANDED); Index Chemicus (IC)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Chemistry
GA 6L3HO
UT WOS:000888077500003
PM 36270112
DA 2025 08 17
ER

PT J
AU Lee, SS
   Kim, SM
   Kim, YS
   Lee, SK
AF Lee, Sang Shin
   Kim, Soung Min
   Kim, Yeon Sook
   Lee, Suk Keun
TI Extensive protein expression changes induced by pamidronate in RAW 264.7
   cells as determined by IP HPLC
SO PEERJ
LA English
DT Article
DE Pamidronate; Bisphosphonate; RAW 264.7 cells; Global protein
   expressions; Molecular signaling; IP HPLC
ID BISPHOSPHONATE RELATED OSTEONECROSIS; PAGETS DISEASE; SUPPURATIVE
   OSTEOMYELITIS; OSTEOCLASTIC RESORPTION; BONE RESORPTION; BREAST CANCER;
   JAWS; ALENDRONATE; EFFICACY; SURVIVAL
AB Background: Bisphosphonate therapy has become a popular treatment for osteoporosis, Paget's disease, multiple myeloma, osteogenesis imperfecta, myocardial infarction, and cancer despite its serious side effects. Bisphosphonate induced molecular signaling changes in cells are still not clearly elucidated.
   Methods: As bisphosphonates are primarily engulfed by macrophages, we treated RAW 264.7 cells (a murine macrophage cell line) with pamidronate and investigated global protein expressional changes in cells by immunoprecipitation high performance liquid chromatography (IP HPLC) using 218 antisera.
   Results: Pamidronate upregulated proliferation activating proteins associated with p53/Rb/E2F and Wnt/beta catenin pathways, but downregulated the downstream of RAS signaling, pAKT1/2/3, ERK 1, and p ERK 1, and subsequently suppressed cMyc/MAX/MAD network. However, in situ proliferation index of pamidronate treated RAW264.7 cells was slightly increased by 3.2% vs. non treated controls. Pamidronate treated cells showed increase in the expressions of histoneand DNA methylation related proteins but decrease of protein translation related proteins. NFkB signaling was also suppressed as indicated by the down regulations of p38 and p p38 and the up regulation of mTOR, while the protein expressions related to cellular protection, HSP 70, NRF2, INK 1, and LC3 were upregulated. Consequently, pamidronate downregulated the protein expressions related to immediate inflammation,cellular differentiation, survival, angiogenesis, and osteoclastogenesis, but upregulated PARP 1 and FAS mediated apoptosis proteins. These observations suggest pamidronate affects global protein expressions in RAW 264.7 cells by stimulating cellular proliferation, protection, and apoptosis but suppressing immediate inflammation, differentiation, osteoclastogenesis, and angiogenesis. Accordingly, pamidronate appears to affect macrophages in several ways eliciting not only its therapeutic effects but also atypical epigenetic modification, protein translation, RAS and NFkB signalings. Therefore, our observations suggest pamidronate induced protein expressions are dynamic, and the affected proteins should be monitored by IP HPLC to achieve the therapeutic goals during treatment.
C1 [Lee, Sang Shin; Lee, Suk Keun] Gangneung Wonju Natl Univ, Coll Dent, Dept Oral Pathol, Kangnung, Gangwondo, South Korea.
   [Kim, Soung Min] Seoul Natl Univ, Coll Dent, Dept Oral & Maxillofacial Surg, Seoul, South Korea.
   [Kim, Yeon Sook] Cheongju Univ, Coll Hlth & Med Sci, Dept Dent Hyg, Cheongju, South Korea.
C3 Gangneung Wonju National University; Seoul National University (SNU);
   Cheongju University
RP Lee, SK (通讯作者)，Gangneung Wonju Natl Univ, Coll Dent, Dept Oral Pathol, Kangnung, Gangwondo, South Korea.
EM sklee@gwnu.ac.kr
OI Kim, Yeon Sook/0000 0002 5787 7052
CR Abelson A, 2008, CURR MED RES OPIN, V24, P695, DOI 10.1185/030079908X260899
   Acevedo C, 2015, BONE, V81, P352, DOI 10.1016/j.bone.2015.08.002
   Akram Z, 2017, BRIT J CLIN PHARMACO, V83, P444, DOI 10.1111/bcp.13147
   Alqhtani N R, 2017, Bone Rep, V6, P64, DOI 10.1016/j.bonr.2017.02.002
   Jiménez ABA, 2018, REUMATOL CLIN, V14, P334, DOI 10.1016/j.reuma.2017.04.002
   Ata Ali J, 2016, CLIN ORAL IMPLAN RES, V27, pE38, DOI 10.1111/clr.12526
   Bhavsar NV, 2016, OSTEOPOROSIS INT, V27, P2611, DOI 10.1007/s00198 016 3577 8
   Burr DB, 2009, ORTHOD CRANIOFAC RES, V12, P221, DOI 10.1111/j.1601 6343.2009.01456.x
   Carmagnola D, 2013, ACTA ODONTOL SCAND, V71, P1410, DOI 10.3109/00016357.2013.765592
   CECCHINI MG, 1987, J BONE MINER RES, V2, P135
   Chen CY, 2012, J MOL MODEL, V18, P4007, DOI 10.1007/s00894 012 1398 z
   Chen Z, 2018, EUR REV MED PHARMACO, V22, P1380, DOI 10.26355/eurrev_201803_14482
   Chevreau M, 2017, JOINT BONE SPINE, V84, P393, DOI 10.1016/j.jbspin.2017.03.009
   Chirappapha P, 2017, GLAND SURG, V6, P93, DOI 10.21037/gs.2016.07.04
   Choi WS, 2017, MAX PLAST RECONSTR S, V39, DOI 10.1186/s40902 016 0099 4
   Clarke NJ, 1998, FEBS LETT, V430, P419, DOI 10.1016/S0014 5793(98)00706 6
   Escudero ND, 2012, BONE MARROW RES, DOI 10.1155/2012/526236
   Ebetino FH, 2011, BONE, V49, P20, DOI 10.1016/j.bone.2011.03.774
   ENDO Y, 1993, CALCIFIED TISSUE INT, V52, P248, DOI 10.1007/BF00298728
   Favia G, 2009, BONE, V45, P406, DOI 10.1016/j.bone.2009.05.008
   Fernández D, 2002, ACTA CRYSTALLOGR C, V58, pM494, DOI 10.1107/S010827010201497X
   Guimaraes EP, 2013, CASE REP DENT, V2013, DOI 10.1155/2013/402096
   Hammer F, 2005, J BONE MINER RES, V20, P350, DOI 10.1359/JBMR.041113
   Hansen PJ, 2013, CLIN ORAL INVEST, V17, P1829, DOI 10.1007/s00784 012 0873 3
   Henneman L, 2011, BBA MOL CELL BIOL L, V1811, P227, DOI 10.1016/j.bbalip.2011.01.002
   Hoefert S, 2016, CLIN ORAL INVEST, V20, P1043, DOI 10.1007/s00784 015 1584 3
   Hoefert S, 2016, OR SURG OR MED OR PA, V121, P222, DOI 10.1016/j.oooo.2015.10.008
   Hoefert S, 2015, CLIN ORAL INVEST, V19, P1307, DOI 10.1007/s00784 014 1358 3
   Iguchi K, 2010, EUR J PHARMACOL, V641, P35, DOI 10.1016/j.ejphar.2010.05.010
   Ito M, 2001, BONE, V28, P609, DOI 10.1016/S8756 3282(01)00429 X
   Jayasena A, 2015, INT J RHEUM DIS, V18, P287, DOI 10.1111/1756 185X.12560
   Jeong HG, 2017, IMAGNG SCI DENT, V47, P41, DOI 10.5624/isd.2017.47.1.45
   Kaiser T, 2013, BREAST CANCER RES TR, V140, P35, DOI 10.1007/s10549 013 2613 z
   Kameka AM, 2014, CAN J VET RES, V78, P274
   Kamel AA, 2012, EUR J MED CHEM, V51, P239, DOI 10.1016/j.ejmech.2012.02.047
   Kawata T, 2004, EXP ANIM TOKYO, V53, P47, DOI 10.1538/expanim.53.47
   Khojasteh A, 2019, CLIN ORAL INVEST, V23, P1803, DOI 10.1007/s00784 018 2579 7
   Kim MK, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 38946 4
   Kim MK, 2015, J ORAL MAXIL SURG, V73, P2352, DOI 10.1016/j.joms.2015.06.154
   Kim SM, 2018, J CRANIO MAXILL SURG, V46, P119, DOI 10.1016/j.jcms.2017.10.017
   Kim SM, 2017, EUR ARCH OTO RHINO L, V274, P3485, DOI 10.1007/s00405 017 4657 x
   Kim SM, 2017, OR SURG OR MED OR PA, V123, P220, DOI 10.1016/j.oooo.2016.09.225
   Kim SM, 2017, EUR ARCH OTO RHINO L, V274, P215, DOI 10.1007/s00405 016 4167 2
   Kim Yeon Sook, 2015, [The Korean Journal of Oral and Maxillofacial Pathology, 대한구강악안면병리학회지], V39, P615
   Kravets I, 2018, AM J MED, V131, P1298, DOI 10.1016/j.amjmed.2018.04.028
   Kün Darbois JD, 2018, CLIN ORAL INVEST, V22, P2997, DOI 10.1007/s00784 018 2385 2
   박정민, 2009, [The Korean Journal of Oral and Maxillofacial Pathology, 대한구강악안면병리학회지], V33, P181
   Lee Suk Keun, 2013, [The Korean Journal of Oral and Maxillofacial Pathology, 대한구강악안면병리학회지], V37, P183
   Luo LP, 2013, FOOD CHEM, V138, P315, DOI 10.1016/j.foodchem.2012.10.043
   Majoor BCJ, 2017, J BONE MINER RES, V32, P264, DOI 10.1002/jbmr.2999
   Marx RE, 2012, INT J ORAL MAX SURG, V41, P283, DOI 10.1016/j.ijom.2011.12.016
   Marx RE, 2005, J ORAL MAXIL SURG, V63, P1567, DOI 10.1016/j.joms.2005.07.010
   Mayahara M, 2003, ANAT REC PART A, V274A, P817, DOI 10.1002/ar.a.10092
   MIAN M, 1994, PHARMACOLOGY, V49, P336, DOI 10.1159/000139251
   Miyazaki T, 2011, ANAL BIOCHEM, V410, P7, DOI 10.1016/j.ab.2010.11.014
   Nishida S, 2003, LIFE SCI, V73, P2655, DOI 10.1016/S0024 3205(03)00664 7
   Ohlrich EJ, 2016, ARCH ORAL BIOL, V63, P7, DOI 10.1016/j.archoralbio.2015.11.013
   Park MH, 2018, J BIOL CHEM, V293, P18710, DOI 10.1074/jbc.TM118.003341
   Polyzos SA, 2011, EXP CLIN ENDOCR DIAB, V119, P519, DOI 10.1055/s 0031 1284365
   Ribatti D, 2008, ONCOL REP, V19, P1109
   Ruggiero SL, 2004, J ORAL MAXIL SURG, V62, P527, DOI 10.1016/j.joms.2004.02.004
   SANSOM LN, 1995, BONE, V17, pS479, DOI 10.1016/8756 3282(95)00259 6
   Saraff V, 2018, ARCH DIS CHILD, V103, P92, DOI 10.1136/archdischild 2017 313234
   Sarasquete ME, 2009, ORAL DIS, V15, P382, DOI 10.1111/j.1601 0825.2009.01568.x
   SATO M, 1991, J CLIN INVEST, V88, P2095, DOI 10.1172/JCI115539
   Seo MH, 2019, MAX PLAST RECONSTR S, V41
   Sharma D, 2016, SCI REP UK, V6, DOI 10.1038/srep20580
   Singer FR, 2014, J CLIN ENDOCR METAB, V99, P4408, DOI 10.1210/jc.2014 2910
   Stefanucci A, 2015, MED CHEM, V11, P417, DOI 10.2174/1573406410666141226132630
   Tatsuda Y, 2010, EUR J PHARMACOL, V627, P348, DOI 10.1016/j.ejphar.2009.10.067
   Wat WZM, 2014, THER CLIN RISK MANAG, V10, P977, DOI 10.2147/TCRM.S58367
   Yoon CS, 2018, MAX PLAST RECONSTR S, V40
   Yoon CS, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 32014 z
   Zhang QZ, 2013, CLIN CANCER RES, V19, P3176, DOI 10.1158/1078 0432.CCR 13 0042
   Zhang X, 2016, J HEPATOL, V64, P160, DOI 10.1016/j.jhep.2015.09.005
   Ziebart T, 2011, CLIN ORAL INVEST, V15, P105, DOI 10.1007/s00784 009 0365 2
NR 76
TC 8
Z9 8
U1 0
U2 10
PU PEERJ INC
PI LONDON
PA 341 345 OLD ST, THIRD FLR, LONDON, EC1V 9LL, ENGLAND
SN 2167 8359
J9 PEERJ
JI PeerJ
PD MAY 21
PY 2020
VL 8
AR e9202
DI 10.7717/peerj.9202
PG 34
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA LP6KF
UT WOS:000534427100007
PM 32509464
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Rangel, LBA
   de Siqueira, D
   Soares, OD
   Santana, HS
   Miguel, ED
   da Cunha, M
   Oliveira, ALD
   Pedrosa, DF
   Resgala, LCR
   Neto, HAR
   Gomes Rochette, NF
   Eis, SR
   Graceli, JB
   Silva, IV
AF Azevedo Rangel, Leticia Batista
   de Siqueira, Daniel
   Soares, Olivia do Rosario
   Santana, Higor Scardini
   Miguel, Emilio de Castro
   da Cunha, Maura
   de Abreu Oliveira, Andre Lacerda
   Pedrosa, Diego Franca
   Rangel Resgala, Ludmilla Carvalho
   Rangel Neto, Helder Azevedo
   Gomes Rochette, Neuza Felix
   Eis, Sergio Ragi
   Graceli, Jones Bernardes
   Silva, Ian Victor
TI Vitamin K Supplementation Modulates Bone Metabolism and Ultra Structure
   of Ovariectomized Mice
SO CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
LA English
DT Article
DE Ovariectomized; Vitamin K; Bone Mineral Density; Bone Microarchitecture;
   Mineral Metabolism
ID POSTMENOPAUSAL WOMEN; ESTROGEN RECEPTOR; MINERAL DENSITY; SEX STEROIDS;
   MENATETRENONE; FRACTURES; OSTEOPOROSIS; METAANALYSIS; MECHANISMS;
   THERAPY
AB Background/Aims: Osteoporosis is a bone metabolic disease that affects mostly post menopausal women. There has been shown that vitamin K (VK) supplementation during menopause may decrease bone loss as well as risk of bone breaking. Aiming to clarify the beneficial role of VK in bone metabolism during menopause, we investigated mineral metabolism and bone ultrastructure of ovariectomized (OVX) mice. Methods: To determine the effects chronic use of VK in bone structure and mineral metabolism in OVX mice, we used several methods, such as DXA, mu CTScan, and SEM as well as biomolecular techniques, such as ELISA and qRT PCR. In addition, complete analysis of serum hormonal and other molecules associated to bone and lipid metabolism were evaluated overview the effects of VK in menopause murine model. Results: VK treatment significantly affects Pi metabolism independently of OVX, changing Pi plasma, urinary output, balance, and Pi bone mass. Interestingly, VK also increased VLDL in mice independently of castration. In addition, VK increased compact bone mass in OVX mice when we evaluated it by DXA, histomorphometry, mu CTScanning. VK increased bone formation markers, osteocalcin, HYP  osteocalcin, and AP whereas it decreased bone resorption markers, such as urinary DPD/creatinine ratio and plasmatic TRAP. Surprisingly, SEM images revealed that VK treatment led to amelioration of microfractures observed in OVX untreated controls. In addition, SHAM operated VK treated mice exhibited higher number of migrating osteoblasts and in situ secretion of AP. OVX led to decreased to in situ secretion of AP that was restored by VK treatment. Moreover, VK treatment increased mRNA expression of bone Calbindin 28KDa independently of OVX. Conclusion: VK treatment in OVX mice exhibited beneficial effects on bone ultrastructure, mostly by altering osteoblastic function and secretion of organic bone matrix. Therefore, VK could be useful to treat osteopenic/osteoporotic patients.
C1 [Azevedo Rangel, Leticia Batista; de Siqueira, Daniel; Soares, Olivia do Rosario; Santana, Higor Scardini; Miguel, Emilio de Castro; Pedrosa, Diego Franca; Rangel Resgala, Ludmilla Carvalho; Rangel Neto, Helder Azevedo; Gomes Rochette, Neuza Felix; Graceli, Jones Bernardes; Silva, Ian Victor] Univ Fed Espirito Santo, Dept Morphol, Aging Cell Biol Lab, 1468 Marechal Campos Av Basic I,Room 5, BR 29043090 Vitoria, ES, Brazil.
   [Azevedo Rangel, Leticia Batista; de Siqueira, Daniel; Soares, Olivia do Rosario; Pedrosa, Diego Franca; Rangel Resgala, Ludmilla Carvalho; Graceli, Jones Bernardes; Silva, Ian Victor] Univ Fed Espirito Santo, RENORBIO, Hlth Sci Ctr, Programa Pos Grad Biotecnol, Vitoria, Brazil.
   [Azevedo Rangel, Leticia Batista; Silva, Ian Victor] Univ Fed Espirito Santo, Dept Physiol Sci, Hlth Sci Ctr, Programa Pos Grad Bioquim & Farmacol, Vitoria, Brazil.
   [Azevedo Rangel, Leticia Batista] Univ Fed Espirito Santo, Hlth Sci Ctr, Dept Pharmaceut Sci, Lab Cellular & Mol Biol Human Canc, Vitoria, Brazil.
   [da Cunha, Maura; de Abreu Oliveira, Andre Lacerda] Univ Estadual N Fluminen, Lab Cell Biol, Biotechnol Ctr, Campos dos Goytacazes, Brazil.
   [Rangel Resgala, Ludmilla Carvalho] Ctr Univ Redentor, UniREDENTOR, Itaperuna, Brazil.
   [Graceli, Jones Bernardes] Ctr Diagnost & Pesquisa Osteoporose Espirito Sant, Vitoria, Brazil.
   [Eis, Sergio Ragi; Graceli, Jones Bernardes] Univ Fed Espirito Santo, Lab Endocrinol & Cellular Toxicol, Programa Pos Grad Ciencias Fisiol, Dept Morphol,Dept Physiol Sci,Hlth Sci Ctr, Vitoria, Brazil.
C3 Universidade Federal do Espirito Santo; Universidade Federal do Espirito
   Santo; Universidade Federal do Espirito Santo; Universidade Federal do
   Espirito Santo; Universidade Federal do Espirito Santo
RP Silva, IV (通讯作者)，Univ Fed Espirito Santo, Dept Morphol, Aging Cell Biol Lab, 1468 Marechal Campos Av Basic I,Room 5, BR 29043090 Vitoria, ES, Brazil.
EM lbce18@yahoo.com
RI Bernardes Graceli, Jones/ABC 7439 2021; de Castro Miguel,
   Emilio/B 5855 2018; Da Cunha, Maura/L 1412 2014; Da Cunha,
   Maura/AFR 4892 2022; Oliveira, André/D 8826 2013; Rangel,
   Leticia/E 6241 2018; de Castro Miguel, Emílio/B 5855 2018; Silva,
   Ian/K 7011 2012
OI de Castro Miguel, Emilio/0000 0003 4130 672X; Da Cunha,
   Maura/0000 0003 1078 3742; 
FU FACITEC [017/2006, 036/2006]; FAPES [172.1/2005, 012/2014]; DECIT SUS
   [31614990/2005]; CNPq [480807/2006]
FX The authors thank FACITEC [no. 017/2006 and no. 036/2006], FAPES [no.
   172.1/2005 and no. 012/2014], DECIT SUS [no. 31614990/2005] and CNPq
   [no. 480807/2006] for financial support. The authors would also
   gratefully acknowledge the Centro de Diagnostico e Pesquisa da
   Osteoporose do Espirito Santo CEDOES (Vitoria/ES, Brazil) and Instituto
   Tommasi de Pesquisa e Desenvolvimento (Vila Velha, Brazil). We are also
   greatfull to Servico de Psiquiatria Aplicadas (SPA), Specialy to
   Nathaniel Carioca, MD, and Maria Thereza Murad, Physi D, and other staff
   personal who kindly let me concluded this work during my treatment
   (IVS).
CR Anderson PH, 2017, CURR OSTEOPOROS REP, V15, P443, DOI 10.1007/s11914 017 0394 8
   [Anonymous], BONE
   Asawa Y, 2004, BONE, V35, P870, DOI 10.1016/j.bone.2004.06.007
   Binkley N, 2009, J BONE MINER RES, V24, P983, DOI [10.1359/JBMR.081254, 10.1359/jbmr.081254]
   Blagosklonny MV, 2012, AM J PATHOL, V181, P1142, DOI 10.1016/j.ajpath.2012.06.024
   Cockayne S, 2006, ARCH INTERN MED, V166, P1256, DOI 10.1001/archinte.166.12.1256
   Compston JE, 2001, PHYSIOL REV, V81, P419, DOI 10.1152/physrev.2001.81.1.419
   Dalghi MG, 2013, J BIOL CHEM, V288, P23380, DOI 10.1074/jbc.M113.470542
   Davey RA, 2004, J BONE MINER RES, V19, P882, DOI 10.1359/JBMR.040206
   Dick CF, 2012, BBA GEN SUBJECTS, V1820, P1001, DOI 10.1016/j.bbagen.2012.02.019
   El Khassawna T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071665
   Emaus N, 2010, OSTEOPOROSIS INT, V21, P1731, DOI 10.1007/s00198 009 1126 4
   Eshraghian A, 2017, MINERVA ENDOCRINOL, V42, P164, DOI 10.23736/S0391 1977.16.02587 6
   Fu XY, 2012, NUTR METAB, V9, DOI 10.1186/1743 7075 9 12
   Gomes Rochette NF, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169266
   Guralp O, 2014, MATURITAS, V77, P294, DOI 10.1016/j.maturitas.2013.11.002
   Hao LY, 2016, CELL PHYSIOL BIOCHEM, V38, P1267, DOI 10.1159/000443074
   He SS, 2017, MATURITAS, V104, P29, DOI 10.1016/j.maturitas.2017.07.014
   Ishida Y, 2004, AM J MED, V117, P549, DOI 10.1016/j.amjmed.2004.05.019
   Iwamoto J, 2006, NUTR REV, V64, P509, DOI [10.1301/nr.2006.dec.509 517, 10.1111/j.1753 4887.2006.tb00184.x]
   Iwamoto J, 2014, NUTRIENTS, V6, P1971, DOI 10.3390/nu6051971
   Iwamoto J, 2009, NUTR RES, V29, P221, DOI 10.1016/j.nutres.2009.03.012
   Khalil R, 2018, MOL CELL ENDOCRINOL, V465, P61, DOI 10.1016/j.mce.2017.11.011
   Merlo E, 2016, ENDOCRINOLOGY, V157, P2978, DOI 10.1210/en.2015 1896
   MORRIS DP, 1993, J BIOL CHEM, V268, P8735
   Newman P, 2014, J BONE MINE RES, V17, P426
   Otsuka M, 2005, LIFE SCI, V76, P2473, DOI 10.1016/j.lfs.2004.12.020
   Otsuki T, 2004, INT J MOL MED, V14, P669
   Pavone V, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00803
   Pike JW, 2017, ENDOCRIN METAB CLIN, V46, P815, DOI 10.1016/j.ecl.2017.07.001
   Pisani P, 2016, WORLD J ORTHOP, V7, P171, DOI 10.5312/wjo.v7.i3.171
   RECKER RR, 1992, JAMA J AM MED ASSOC, V268, P2403, DOI 10.1001/jama.268.17.2403
   Rooney AM, 2017, ANN NY ACAD SCI, V1410, P85, DOI 10.1111/nyas.13523
   Shiraki M, 2000, J BONE MINER RES, V15, P515, DOI 10.1359/jbmr.2000.15.3.515
   Silva IV, 2000, AM J PHYSIOL RENAL, V278, pF238, DOI 10.1152/ajprenal.2000.278.2.F238
   Silva IV, 2003, J BONE MINER RES, V18, P615, DOI 10.1359/jbmr.2003.18.4.615
   Silva IV, 2002, ARCH BIOCHEM BIOPHYS, V406, P183, DOI 10.1016/S0003 9861(02)00405 8
   Souza LS, 2018, J CLIN DENSITOM, V21, P227, DOI 10.1016/j.jocd.2017.03.005
   Stevenson FC, 1992, J ENDOCRINOL S, V135, P9
   Sturgeon CM, 2017, CLIN CHIM ACTA, V467, P42, DOI 10.1016/j.cca.2016.10.016
   Tabb MM, 2003, J BIOL CHEM, V278, P43919, DOI 10.1074/jbc.M303136200
   Torbergsen AC, 2015, CLIN NUTR, V34, P101, DOI 10.1016/j.clnu.2014.01.016
   Yang XC, 2016, CELL PHYSIOL BIOCHEM, V40, P781, DOI 10.1159/000453138
   You L, 2016, CELL PHYSIOL BIOCHEM, V39, P253, DOI 10.1159/000445621
   Zhang Y, 2016, CELL PHYSIOL BIOCHEM, V38, P283, DOI 10.1159/000438629
NR 45
TC 13
Z9 15
U1 0
U2 14
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH 4009 BASEL, SWITZERLAND
SN 1015 8987
EI 1421 9778
J9 CELL PHYSIOL BIOCHEM
JI Cell. Physiol. Biochem.
PY 2018
VL 51
IS 1
BP 356
EP 374
DI 10.1159/000495234
PG 19
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA HB4SV
UT WOS:000451047200024
PM 30453296
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Liu, JW
   Chang, XY
   Dong, DM
AF Liu, Jingwei
   Chang, Xueying
   Dong, Daming
TI MicroRNA 181a 5p Curbs Osteogenic Differentiation and Bone Formation
   Partially Through Impairing Runx1 Dependent Inhibition of AIF 1
   Transcription
SO ENDOCRINOLOGY AND METABOLISM
LA English
DT Article
DE MicroRNAs; Transcription factors; Ovariectomy; Osteoporosis;
   Osteogenesis
ID INFLAMMATORY FACTOR I; OSTEOBLAST DIFFERENTIATION; CELLS; OSTEOPOROSIS;
   PATHOGENESIS; MICRORNAS
AB Background: Evidence has revealed the involvement of microRNAs (miRNAs) in modulating osteogenic differentiation, implying the promise of miRNA based therapies for treating osteoporosis. This study investigated whether miR 181a 5p influences osteogen ic differentiation and bone formation and aimed to establish the mechanisms in depth. Methods: Clinical serum samples were obtained from osteoporosis patients, and MC3T3 E1 cells were treated with osteogenic duction medium (OIM) to induce osteogenic differentiation. miR 181a 5p , Runt related transcription factor 1 (Runx1) , and/or lograft inflammatory factor 1 (AIF 1) associated oligonucleotides or vectors were transfected into MC3T3 E1 cells to explore their function in relation to the number of calcified nodules, alkaline phosphatase (ALP) staining and activity, expression levels of osteo genesis related proteins, and apoptosis. Luciferase activity, RNA immunoprecipitation, and chromatin immunoprecipitation assays were employed to validate the binding relationship between miR 181a 5p and Runx1, and the transcriptional regulatory relationship between Runx1 and AIF 1. Ovariectomy (OVX) induced mice were injected with a miR 181a 5p antagonist for in vivo verification. Results: miR 181a 5p was highly expressed in the serum of osteoporosis patients. OIM treatment decreased miR 181a 5p and AIF 1 expression, but promoted Runx1 expression in MC3T E1 cells. Meanwhile, upregulated miR 181a 5p suppressed OIM induced increases in calcified nodules, ALP content, and osteogenesis related protein expression. Mechanically, miR 181a 5p targeted Runx1, which acted as a transcription factor to negatively modulate AIF 1 expression. Downregulated Runx1 suppressed the miR 181a 5p inhibitor mediated promotion of osteogenic differentiation, and downregulated AIF 1 reversed the miR 181a 5p mimic duced inhibition of osteogenic differentiation. Tail vein injection of a miR 181a 5p antagonist induced bone formation in OVX in duced osteoporotic mice. Conclusion: In conclusion, miR 181a 5p affects osteogenic differentiation and bone formation partially via the modulation of Runx1/AIF 1 axis.
C1 [Liu, Jingwei; Dong, Daming] Harbin Med Univ, Dept Orthoped, Affiliated Hosp 1, Harbin, Peoples R China.
   [Chang, Xueying] Harbin Med Univ, Dept Nephrol, Affiliated Hosp 1, Harbin, Peoples R China.
   [Dong, Daming] Harbin Med Univ, Dept Orthoped, Affiliated Hosp 1, 23 Youzheng Rd, Harbin 150001, Heilongjiang, Peoples R China.
C3 Harbin Medical University; Harbin Medical University; Harbin Medical
   University
RP Dong, DM (通讯作者)，Harbin Med Univ, Dept Orthoped, Affiliated Hosp 1, 23 Youzheng Rd, Harbin 150001, Heilongjiang, Peoples R China.
EM dongdaming1965@hotmail.com
RI ; Liu, Jingwei/HZJ 7668 2023
OI Liu, Jingwei/0000 0003 4670 4655; 
FU Sunshine Health Foundation of Heilongjiang Province [2021HX001]
FX Acknowledgments This research was funded by the Sunshine Health
   Foundation of Heilongjiang Province (No. 2021HX001) .
CR Bellavia D, 2019, CELL MOL LIFE SCI, V76, P3723, DOI 10.1007/s00018 019 03162 w
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   da Silva RL, 2021, SCI REP UK, V11, DOI 10.1038/s41598 020 79068 6
   Dirckx N, 2019, NAT REV ENDOCRINOL, V15, P651, DOI 10.1038/s41574 019 0246 y
   Eastell R, 2016, NAT REV DIS PRIMERS, V2, DOI [10.1038/nrdp.2016.69, 10.1038/nrdp.2016.70]
   Elizondo DM, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00173
   Fuggle NR, 2019, NAT REV ENDOCRINOL, V15, P535, DOI 10.1038/s41574 019 0220 8
   Hendrickx G, 2015, NAT REV RHEUMATOL, V11, P462, DOI 10.1038/nrrheum.2015.48
   Khosla S, 2017, LANCET DIABETES ENDO, V5, P898, DOI 10.1016/S2213 8587(17)30188 2
   Khraiwesh B, 2010, CELL, V140, P111, DOI 10.1016/j.cell.2009.12.023
   Lee WC, 2017, ENDOCR REV, V38, P255, DOI 10.1210/er.2017 00064
   Lewiecki EM, 2011, NAT REV RHEUMATOL, V7, P631, DOI 10.1038/nrrheum.2011.130
   Lian JB, 2012, NAT REV ENDOCRINOL, V8, P212, DOI 10.1038/nrendo.2011.234
   Liu QL, 2018, MOL MED REP, V17, P4797, DOI 10.3892/mmr.2018.8416
   Lu TX, 2018, J ALLERGY CLIN IMMUN, V141, P1202, DOI 10.1016/j.jaci.2017.08.034
   Luo Y, 2019, ARCH ORAL BIOL, V97, P176, DOI 10.1016/j.archoralbio.2018.10.028
   Okamoto H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043800
   Papaioannou G, 2014, CELL MOL LIFE SCI, V71, P4747, DOI 10.1007/s00018 014 1700 6
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Shao BY, 2015, FASEB J, V29, P3935, DOI 10.1096/fj.15 272823
   Sikora M, 2020, IMMUNOL LETT, V218, P1, DOI 10.1016/j.imlet.2019.12.002
   Soung DY, 2014, MOL ENDOCRINOL, V28, P546, DOI 10.1210/me.2013 1305
   Tang CY, 2021, PLOS GENET, V17, DOI 10.1371/journal.pgen.1009233
   Tang CY, 2020, BIOCHEM J, V477, P2421, DOI 10.1042/BCJ20200036
   Tang J, 2020, J BIOL CHEM, V295, P11669, DOI 10.1074/jbc.RA119.007896
   Tang PF, 2014, RNA BIOL, V11, P1355, DOI 10.1080/15476286.2014.996462
   Waki T, 2016, BMC MUSCULOSKEL DIS, V17, DOI 10.1186/s12891 016 0931 0
   Wang YX, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 1153 1
   Xu YX, 2021, J CELL MOL MED, V25, P5025, DOI 10.1111/jcmm.16451
   Yang YL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142863
   Zhao WH, 2018, J CELL PHYSIOL, V233, P9191, DOI 10.1002/jcp.26939
   Zhu HT, 2021, BIOENGINEERED, V12, P1426, DOI 10.1080/21655979.2021.1915672
NR 32
TC 7
Z9 8
U1 0
U2 2
PU KOREAN ENDOCRINE SOC
PI SEOUL
PA 101 2503, 109 MAPO DAERO, MAPO GU, SEOUL, 04146, SOUTH KOREA
SN 2093 596X
EI 2093 5978
J9 ENDOCRINOL METAB
JI Endocrinol. Metab.
PD FEB
PY 2023
VL 38
IS 1
BP 156
EP 173
DI 10.3803/EnM.2022.1516
PG 18
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA H4PB6
UT WOS:000995789200018
PM 36604945
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Hytönen, MK
   Arumilli, M
   Lappalainen, AK
   Kallio, H
   Snellman, M
   Sainio, K
   Lohi, H
AF Hytonen, Marjo K.
   Arumilli, Meharji
   Lappalainen, Anu K.
   Kallio, Heli
   Snellman, Marjatta
   Sainio, Kirsi
   Lohi, Hannes
TI A Novel GUSB Mutation in Brazilian Terriers with Severe Skeletal
   Abnormalities Defines the Disease as Mucopolysaccharidosis VII
SO PLOS ONE
LA English
DT Article
ID BETA GLUCURONIDASE DEFICIENCY; ENZYME REPLACEMENT THERAPY; L IDURONIDASE
   LARONIDASE; MPS VII; OSTEOBLAST DIFFERENTIATION; OSTEOGENESIS
   IMPERFECTA; IDENTIFICATION; MODEL; MOUSE; CDNA
AB Hundreds of different human skeletal disorders have been characterized at molecular level and a growing number of resembling dysplasias with orthologous genetic defects are being reported in dogs. This study describes a novel genetic defect in the Brazilian Terrier breed causing a congenital skeletal dysplasia. Affected puppies presented severe skeletal deformities observable within the first month of life. Clinical characterization using radiographic and histological methods identified delayed ossification and spondyloepiphyseal dysplasia. Pedigree analysis suggested an autosomal recessive disorder, and we performed a genome wide association study to map the disease locus using Illumina's 22K SNP chip arrays in seven cases and eleven controls. A single association was observed near the centromeric end of chromosome 6 with a genome wide significance after permutation (p(genome) = 0.033). The affected dogs shared a 13 Mb homozygous region including over 200 genes. A targeted next generation sequencing of the entire locus revealed a fully segregating missense mutation (c.866C > T) causing a pathogenic p.P289L change in a conserved functional domain of beta glucuronidase (GUSB). The mutation was confirmed in a population of 202 Brazilian terriers (p = 7,71 x 10( 29)). GUSB defects cause mucopolysaccharidosis VII (MPS VII) in several species and define the skeletal syndrome in Brazilian Terriers. Our results provide new information about the correlation of the GUSB genotype to phenotype and establish a novel canine model for MPS VII. Currently, MPS VII lacks an efficient treatment and this model could be utilized for the development and validation of therapeutic methods for better treatment of MPS VII patients. Finally, since almost one third of the Brazilian terrier population carries the mutation, breeders will benefit from a genetic test to eradicate the detrimental disease from the breed.
C1 [Hytonen, Marjo K.; Arumilli, Meharji; Kallio, Heli; Lohi, Hannes] Univ Helsinki, Dept Vet Biosci, Res Programs Unit, Helsinki, Finland.
   [Hytonen, Marjo K.; Arumilli, Meharji; Lohi, Hannes] Folkhalsan Inst Genet, Helsinki, Finland.
   [Hytonen, Marjo K.; Sainio, Kirsi] Univ Helsinki, Inst Biomed, Helsinki, Finland.
   [Lappalainen, Anu K.; Snellman, Marjatta] Univ Helsinki, Fac Vet Med, Helsinki, Finland.
C3 University of Helsinki; University of Helsinki; University of Helsinki
RP Hytönen, MK (通讯作者)，Univ Helsinki, Dept Vet Biosci, Res Programs Unit, Helsinki, Finland.
EM hannes.lohi@helsinki.fi
RI ; Lohi, Hannes/F 4596 2011
OI Hytonen, Marjo/0000 0003 1976 5874; Lohi, Hannes/0000 0003 1087 5532;
   Arumilli, Meharji/0000 0003 4072 0996
FU Academy of Finland; Sigrid Juselius Foundation; Jane and Aatos Erkko
   Foundation; University of Helsinki Research Funds; Biocentrum Helsinki;
   European Comission [GA 201370]
FX This work was supported by the Academy of Finland (www.aka.fi), the
   Sigrid Juselius Foundation (www.sigridjuselius.fi), the Jane and Aatos
   Erkko Foundation (www.jaes.fi), The University of Helsinki Research
   Funds (/www.helsinki.fi/funds), Biocentrum Helsinki
   (www.helsinki.fi/biocentrum), and the European Comission (FP7 LUPA,
   GA 201370)(www.eurolupa.org). The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR ADAR R, 1986, COLLAGEN REL RES, V6, P267
   Adzhubei IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/nmeth0410 248
   Aldenboven M, 2008, BIOL BLOOD MARROW TR, V14, P485, DOI 10.1016/j.bbmt.2008.01.009
   Bannasch D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009632
   BIRKENMEIER EH, 1989, J CLIN INVEST, V83, P1258, DOI 10.1172/JCI114010
   Campbell BG, 2000, ARCH BIOCHEM BIOPHYS, V384, P37, DOI 10.1006/abbi.2000.2099
   Campbell BG, 2001, J BONE MINER RES, V16, P1147, DOI 10.1359/jbmr.2001.16.6.1147
   Cheng D, 2003, J BIOL CHEM, V278, P13611, DOI 10.1074/jbc.C300042200
   Clarke LA, 2009, PEDIATRICS, V123, P229, DOI 10.1542/peds.2007 3847
   DEJONG JGN, 1992, CLIN CHEM, V38, P803
   Dombrowski DCS, 2004, JAVMA J AM VET MED A, V224, P553, DOI 10.2460/javma.2004.224.553
   Drögemüller C, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000579
   Fyfe JC, 1999, GENOMICS, V58, P121, DOI 10.1006/geno.1999.5825
   GITZELMANN R, 1994, VET PATHOL, V31, P435, DOI 10.1177/030098589403100405
   Gwynn B, 1998, MOL CELL BIOL, V18, P6474, DOI 10.1128/MCB.18.11.6474
   HASKINS ME, 1984, PEDIATR RES, V18, P980, DOI 10.1203/00006450 198418100 00014
   Jain S, 1996, NAT STRUCT BIOL, V3, P375, DOI 10.1038/nsb0496 375
   LOMBARDO A, 1980, CLIN CHIM ACTA, V108, P337, DOI 10.1016/0009 8981(80)90339 3
   Muenzer J, 2004, J PEDIATR US, V144, pS27, DOI 10.1016/j.jpeds.2004.01.052
   OSHIMA A, 1987, P NATL ACAD SCI USA, V84, P685, DOI 10.1073/pnas.84.3.685
   Parker HG, 2009, SCIENCE, V325, P995, DOI 10.1126/science.1173275
   Ponder KP, 2002, P NATL ACAD SCI USA, V99, P13102, DOI 10.1073/pnas.192353499
   Prasad VK, 2010, SEMIN HEMATOL, V47, P59, DOI 10.1053/j.seminhematol.2009.10.008
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Ray J, 1998, GENOMICS, V48, P248, DOI 10.1006/geno.1997.5189
   Schultheiss PC, 2000, VET PATHOL, V37, P502, DOI 10.1354/vp.37 5 502
   SLY WS, 1973, J PEDIATR US, V82, P249, DOI 10.1016/S0022 3476(73)80162 3
   Sly WS, 2001, P NATL ACAD SCI USA, V98, P2205, DOI 10.1073/pnas.051623698
   Sulonen AM, 2011, GENOME BIOL, V12, DOI 10.1186/gb 2011 12 9 r94
   Tomatsu S, 2003, HUM MOL GENET, V12, P961, DOI 10.1093/hmg/ddg119
   Tomatsu S, 2002, P NATL ACAD SCI USA, V99, P14982, DOI 10.1073/pnas.232570999
   Tomatsu S, 2009, HUM MUTAT, V30, P511, DOI 10.1002/humu.20828
   Valayannopoulos V, 2011, RHEUMATOLOGY, V50, pV49, DOI 10.1093/rheumatology/ker396
   Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603
   Warman ML, 2011, AM J MED GENET A, V155A, P943, DOI 10.1002/ajmg.a.33909
   Wraith JE, 2007, PEDIATRICS, V120, pE37, DOI 10.1542/peds.2006 2156
   Wraith JE, 2004, J PEDIATR US, V144, P581, DOI 10.1016/j.jpeds.2004.01.046
   Zhao M, 2004, J BIOL CHEM, V279, P12854, DOI 10.1074/jbc.M313294200
   Zhao M, 2003, J BIOL CHEM, V278, P27939, DOI 10.1074/jbc.M304132200
NR 39
TC 17
Z9 17
U1 0
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD JUL 5
PY 2012
VL 7
IS 7
AR e40281
DI 10.1371/journal.pone.0040281
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 974LI
UT WOS:000306436300044
PM 22815736
OA Green Submitted, gold, Green Published
DA 2025 08 17
ER

PT J
AU Ingrasciotta, Y
   Jin, YZ
   Foti, SS
   Landon, JE
   Tari, M
   Mattace Raso, F
   Kim, SC
   Trifiro, G
AF Ingrasciotta, Ylenia
   Jin, Yinzhu
   Foti, Saveria S. S.
   Landon, Joan E. E.
   Tari, Michele
   Mattace Raso, Francesco
   Kim, Seoyoung C. C.
   Trifiro, Gianluca
TI Real world patient characteristics and use of disease modifying
   anti rheumatic drugs in patients with rheumatoid arthritis: a
   cross national study
SO CLINICAL RHEUMATOLOGY
LA English
DT Article
DE Biologics; Claims database; Disease modifying anti rheumatic drugs;
   Real world data; Rheumatoid arthritis
ID BONE MINERAL DENSITY; SYSTEMIC SCLEROSIS; VITAMIN D; FRACTURE RISK;
   MUSCULOSKELETAL INVOLVEMENT; PREDICTIVE FACTORS; OSTEOPOROSIS;
   PREVALENCE; ASSOCIATION; SCLERODERMA
AB Introduction Rheumatoid arthritis (RA) is associated with significant morbidity and economic burden. This study aimed to compare baseline characteristics and patterns of anti inflammatory drug use and disease modifying anti rheumatic drug (DMARD) use among patients with RA in Southern Italy versus the United States. Method Using Caserta Local Health Unit (Italy) and Optum's de identified Clinformatics (R) Data Mart (United States) claims databases, patients with >= 2 diagnosis codes for RA during the study period (Caserta: 2010 2018; Optum: 2010 2019) were identified. Baseline patient characteristics, as well as proportion of RA patients untreated/treated with NSAIDs/glucocorticoids/conventional DMARDs (csDMARDs)/biological/targeted synthetic DMARDs (b/tsDMARDs) during the first year of follow up, and the proportion of RA patients with >= 1 switch/add on between the first and the second year of follow up, were calculated. These analyses were then stratified by age group (< 65; >= 65). Results A total of 9227 RA patients from Caserta and 195,951 from Optum databases were identified (two thirds were females). During the first year of follow up, 45.9% RA patients from Optum versus 79.9% from Caserta were exclusively treated with NSAIDs/glucocorticoids; 17.2% versus 11.3% from Optum and Caserta, respectively, were treated with csDMARDs, mostly methotrexate or hydroxychloroquine in both cohorts. Compared to 0.6% of RA patients from Caserta, 3.2% of the Optum cohort received >= 1 b/tsDMARD dispensing. Moreover, 61,655 (33.7%) patients from Optum cohort remained untreated compared to 748 (8.3%) patients from the Caserta cohort. The subgroup analyses stratified by age showed that 42,989 (39.8%) of elderly RA patients were untreated compared to 18,666 (24.9%) young adult RA patients in Optum during the first year of follow up. Moreover, a higher proportion of young adult RA patients was treated with b/tsDMARDs, with and without csDMARDs, compared to elderly RA patients (Optum(< 65:) 6.4%; Optum(>= 65): 1.0%; P value < 0.001; Caserta(< 65): 0.8%; Caserta(>= 65): 0.1%; P value < 0.001). Among RA patients untreated during the first year after ID, 41.2% and 48.4% RA patients from Caserta and Optum, respectively, received NSAIDs, glucocorticoids, and cs/b/tsDMARDs within the second year of follow up. Stratifying the analysis by age groups, 50.6% of untreated young RA patients received study drug dispensing within the second year of follow up, compared to only 36.7% of elderly RA patients in Optum. Interestingly, more young adult RA patients treated with csDMARDs during the first year after ID received a therapy escalation to b/tsDMARD within the second year after ID in both cohorts, compared to elderly RA patients (Optum(< 65): 7.8%; Optum(>= 65): 1.8%; Caserta(< 65): 3.2%; Casert(a > 65): 0.6%). Conclusions Most of RA patients, with heterogeneous baseline characteristics in Optum and Caserta cohorts, were treated with anti inflammatory/csDMARDs rather than bDMARDs/tsDMARDs during the first year post diagnosis, especially in elderly RA patients, suggesting a need for better understanding and dealing with barriers in the use of these agents for RA patients.
C1 [Ingrasciotta, Ylenia; Trifiro, Gianluca] Univ Verona, Dept Diagnost & Publ Hlth, Verona, Italy.
   [Ingrasciotta, Ylenia; Foti, Saveria S. S.; Trifiro, Gianluca] Azienda Osped Univ G Martino, Acad Spin Off INSPIRE Innovat Solut Med Predict &, Messina, Italy.
   [Ingrasciotta, Ylenia; Mattace Raso, Francesco] Erasmus MC Univ Med Ctr, Dept Internal Med, Rotterdam, Netherlands.
   [Jin, Yinzhu; Kim, Seoyoung C. C.] Brigham & Womens Hosp, Div Pharmacoepidemiol & Pharmacoecon, Boston, MA USA.
   [Jin, Yinzhu; Landon, Joan E. E.; Kim, Seoyoung C. C.] Harvard Med Sch, Boston, MA USA.
   [Tari, Michele] Caserta Local Hlth Unit, Caserta, Italy.
   [Kim, Seoyoung C. C.] Brigham & Womens Hosp, Div Rheumatol Inflammat & Immun, Boston, MA USA.
C3 University of Verona; AOU Policlinico Gaetano Martino; Erasmus
   University Rotterdam; Erasmus MC; Harvard University; Harvard University
   Medical Affiliates; Brigham & Women's Hospital; Harvard University;
   Harvard Medical School; Harvard University; Harvard University Medical
   Affiliates; Brigham & Women's Hospital
RP Ingrasciotta, Y (通讯作者)，Univ Verona, Dept Diagnost & Publ Hlth, Verona, Italy.; Ingrasciotta, Y (通讯作者)，Azienda Osped Univ G Martino, Acad Spin Off INSPIRE Innovat Solut Med Predict &, Messina, Italy.; Ingrasciotta, Y (通讯作者)，Erasmus MC Univ Med Ctr, Dept Internal Med, Rotterdam, Netherlands.
EM ylenia.ingrasciotta@univr.it
RI Jin, Yinzhu/AAA 9359 2021; Raso, Francesco/L 2541 2015
OI Mattace Raso, Francesco/0000 0002 1688 6497
FU Division of Pharmacoepidemiology and Pharmacoeconomics at the Brigham
   and Women's Hospital
FX This study was in part supported by the internal resources of the
   Division of Pharmacoepidemiology and Pharmacoeconomics at the Brigham
   and Women's Hospital.
CR Angelini J, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10071002
   Association of the British Pharmaceutical Industry, 2011, DEM VAL REAL WORLD D
   Austin PC, 2009, STAT MED, V28, P3083, DOI 10.1002/sim.3697
   Bonafede M, 2018, AM J MANAG CARE, V24, pSP279
   Desai RJ, 2022, RHEUMATOLOGY, V61, P121, DOI 10.1093/rheumatology/keab294
   Desai RJ, 2017, J MANAG CARE SPEC PH, V23, P809, DOI 10.18553/jmcp.2017.23.8.809
   Drosos AA, 2020, CLIN RHEUMATOL, V39, P1363, DOI 10.1007/s10067 020 05001 x
   Erol K, 2018, ACTA REUMATOL PORT, V43, P32
   Fakhouri W, 2018, OPEN ACCESS RHEUMATO, V10, P103, DOI 10.2147/OARRR.S164738
   Garrison LP, 2007, VALUE HEALTH, V10, P326, DOI 10.1111/j.1524 4733.2007.00186.x
   Genazzani AA, 2007, BIODRUGS, V21, P351, DOI 10.2165/00063030 200721060 00003
   Gherghescu I, 2021, PHARMACEUTICS, V13, DOI 10.3390/pharmaceutics13010048
   Giacomelli R, 2017, AUTOIMMUN REV, V16, P911, DOI 10.1016/j.autrev.2017.07.012
   Harrold LR, 2020, CLIN RHEUMATOL, V39, P391, DOI 10.1007/s10067 019 04727 7
   Helmick CG, 2008, ARTHRITIS RHEUM US, V58, P15, DOI 10.1002/art.23177
   Hunter TM, 2017, RHEUMATOL INT, V37, P1551, DOI 10.1007/s00296 017 3726 1
   Villa Blanco JI, 2009, DRUG AGING, V26, P739, DOI 10.2165/11316740 000000000 00000
   Ingrasciotta Y, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0222836
   Ingrasciotta Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122899
   Ingrasciotta Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089072
   Innala L, 2016, ARTHRITIS RES THER, V18, DOI 10.1186/s13075 016 0928 y
   Jin YZ, 2020, ARTHRIT CARE RES, V72, P1248, DOI 10.1002/acr.24343
   Jin YZ, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075 017 1366 1
   Kato E, 2017, INT J RHEUM DIS, V20, P839, DOI 10.1111/1756 185X.12998
   Khosrow Khavar F, 2022, ANN RHEUM DIS, V81, P798, DOI 10.1136/annrheumdis 2021 221915
   Kim SY, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3260
   Kobak S, 2018, THER ADV MUSCULOSKEL, V10, P3, DOI 10.1177/1759720X17740075
   Köhler BM, 2019, J CLIN MED, V8, DOI 10.3390/jcm8070938
   Leon L, 2018, CLIN EXP RHEUMATOL, V36, P29
   Mertens M, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005121.pub3
   Michaud K, 2003, ARTHRITIS RHEUM US, V48, P2750, DOI 10.1002/art.11439
   Myasoedova E, 2010, ARTHRITIS RHEUM US, V62, P1576, DOI 10.1002/art.27425
   Nallamothu BK, 2008, CIRCULATION, V118, P1294, DOI 10.1161/CIRCULATIONAHA.107.703579
   Olofsson T, 2017, ANN RHEUM DIS, V76, P1245, DOI 10.1136/annrheumdis 2016 210239
   Oppelt KA, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.630456
   Parisi S, 2019, REUMATISMO, V71, P22, DOI 10.4081/reumatismo.2019.1202
   Perrone V, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18115679
   Putrik P, 2014, ANN RHEUM DIS, V73, P198, DOI 10.1136/annrheumdis 2012 202603
   Rossini M, 2014, RHEUMATOL INT, V34, P659, DOI 10.1007/s00296 014 2974 6
   Ruban TN, 2016, CLIN RHEUMATOL, V35, P759, DOI 10.1007/s10067 015 3031 x
   Saturni S, 2014, PULM PHARMACOL THER, V27, P129, DOI 10.1016/j.pupt.2014.01.005
   Scheinberg MA, 2012, NAT REV RHEUMATOL, V8, P430, DOI 10.1038/nrrheum.2012.84
   Skolnick P, 2018, ANNU REV PHARMACOL, V58, P143, DOI 10.1146/annurev pharmtox 010617 052534
   Smolen JS, 2020, ANN RHEUM DIS, V79, P685, DOI 10.1136/annrheumdis 2019 216655
   Smolen JS, 2017, ANN RHEUM DIS, V76, P960, DOI 10.1136/annrheumdis 2016 210715
   Taylor PC, 2016, RHEUMATOL INT, V36, P685, DOI 10.1007/s00296 015 3415 x
   Theis KA, 2019, JCR J CLIN RHEUMATOL, V25, P341, DOI 10.1097/RHU.0000000000000896
   Tutuncu Z, 2007, RHEUM DIS CLIN N AM, V33, P57, DOI 10.1016/j.rdc.2006.12.006
   Van De Laar CJ, 2020, CLINICOECONOMIC OUTC, V12, P213, DOI 10.2147/CEOR.S231558
   VANDERHEIJDE DMFM, 1990, LANCET, V335, P539, DOI 10.1016/0140 6736(90)90771 V
   Viola E, 2016, EXPERT OPIN DRUG SAF, V15, P61, DOI 10.1080/14740338.2016.1221401
   Winthrop Kevin L, 2016, Clin Exp Rheumatol, V34, P69
   World Health Organization, 2021, CHRON RHEUM COND
   Xu X, 2016, ALTERN THER HEALTH M, V22, P32
   Yi EH, 2020, RHEUMATOL THER, V7, P65, DOI 10.1007/s40744 020 00194 8
   Zamora Legoff JA, 2016, CLIN RHEUMATOL, V35, P1137, DOI 10.1007/s10067 016 3239 4
NR 56
TC 10
Z9 10
U1 0
U2 5
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0770 3198
EI 1434 9949
J9 CLIN RHEUMATOL
JI Clin. Rheumatol.
PD APR
PY 2023
VL 42
IS 4
BP 1047
EP 1059
DI 10.1007/s10067 022 06478 4
EA DEC 2022
PG 13
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA A1UX3
UT WOS:000900791200005
PM 36534353
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Erdemci, F
   Gunaydin, Y
   Sencimen, M
   Bassorgun, I
   Ozler, M
   Oter, S
   Gulses, A
   Gunal, A
   Sezgin, S
   Bayar, GR
   Dogan, N
   Gider, IK
AF Erdemci, F.
   Gunaydin, Y.
   Sencimen, M.
   Bassorgun, I.
   Ozler, M.
   Oter, S.
   Gulses, A.
   Gunal, A.
   Sezgin, S.
   Bayar, G. R.
   Dogan, N.
   Gider, I. K.
TI Histomorphometric evaluation of the effect of systemic and topical ozone
   on alveolar bone healing following tooth extraction in rats
SO INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY
LA English
DT Article
DE ozone; alveolar bone; histomorphometry; alveolar surgery
ID HYPERBARIC OXYGEN THERAPY; IN VITRO; SURGERY; DENTISTRY; MECHANISM
AB The aim of this study was to investigate the effects of systemic and topical ozone applications on alveolar bone healing following tooth extraction. One hundred and twelve male Wistar rats were divided into eight groups of 14 rats each; seven groups were experimental (A G) and one formed the control group (K). The experimental groups were further divided into two sub groups, with seven rats in each  sacrificed on days 14 and 28 (subgroups 1 and 2). The maxillary right central incisors were extracted under general anaesthesia following the administration of local anaesthesia. After sacrifice, semi serial histological sections were prepared, and mineralized and trabecular bone and osteoid and osteoblast surfaces were measured. Measurements of the trabecular bone showed statistically higher values in the groups treated with systemic ozone (D 2: 50.01 +/  2.12; E 2: 49.03 +/  3.03; F 2: 48.76 +/  2.61; G(2): 50.24 +/  3.37) than in the groups that underwent topical ozone administration (A(2): 46.01 +/  3.07; B 2: 46.79 +/  3.09; C 2: 47.07 +/  2.12; P = 0.030 (G(2) A(2), G(2) B 2, G(2) C 2)). Within the limitations of the current study, it may be concluded that postoperative long term systemic ozone application can accelerate alveolar bone healing following extraction. However, additional studies are required to clarify the effects of the different ozone applications on new bone formation.
C1 [Erdemci, F.] Sivas Mil Hosp, Sivas, Turkey.
   [Gunaydin, Y.; Sencimen, M.; Bayar, G. R.; Dogan, N.] Gulhane Mil Med Acad, Dept Oral & Maxillofacial Surg, Ankara, Turkey.
   [Bassorgun, I.] Akdeniz Univ, Dept Pathol, TR 07058 Antalya, Turkey.
   [Ozler, M.; Oter, S.] Gulhane Mil Med Acad, Dept Physiol, Ankara, Turkey.
   [Gulses, A.] Ankara Mevki Mil Hosp, Ankara, Turkey.
   [Gunal, A.] Gulhane Mil Med Acad, Dept Pathol, Ankara, Turkey.
   [Sezgin, S.] Aksaz Mil Hosp, Marmaris, Mugla, Turkey.
   [Gider, I. K.] Edremit Mil Hosp, Balikesir, Turkey.
C3 Gulhane Military Medical Academy; Akdeniz University; Gulhane Military
   Medical Academy; Mevki Military Hospital; Gulhane Military Medical
   Academy; Aksaz Military Hospital
RP Gulses, A (通讯作者)，Mevki Mil Hosp, TR 06130 Ankara, Turkey.
EM aydingulses@gmail.com
RI Gülses, Aydin/LLM 3215 2024; Bayar, Gurkan Rasit/I 7677 2014; Bassorgun,
   Cumhur/I 6615 2017; Bayar, Gurkan/I 7677 2014; Oter, Sukru/K 2129 2012
OI Bayar, Gurkan Rasit/0000 0003 4119 9629; Oter, Sukru/0000 0002 3361 1313
FU Scientific Research Council of Gulhane Military Medical Academy
FX This project was sponsored by the Scientific Research Council of Gulhane
   Military Medical Academy.
CR Agrillo A, 2007, J CRANIOFAC SURG, V18, P1068, DOI 10.1097/SCS.0b013e3181572609
   Aslan MK, 2012, J PEDIATR SURG, V47, P1730, DOI 10.1016/j.jpedsurg.2012.03.082
   Azarpazhooh A, 2008, J DENT, V36, P104, DOI 10.1016/j.jdent.2007.11.008
   Bocci V, 1998, J BIOL REG HOMEOS AG, V12, P67
   Bocci V, 2012, J PHARM PHARMACOL, V64, P482, DOI 10.1111/j.2042 7158.2011.01427.x
   Bocci V, 2009, MED RES REV, V29, P646, DOI 10.1002/med.20150
   Borrelli E, 2011, ACTA NEUROCHIR SUPPL, V108, P123, DOI 10.1007/978 3 211 99370 5_19
   Ciborowski M, 2012, J PROTEOME RES, V11, P6231, DOI 10.1021/pr3008946
   Daniluk M, 2000, Ortop Traumatol Rehabil, V2, P61
   Filippi A, 1997, OZONE SCI ENG, V19, P387, DOI 10.1080/01919512.1997.10382866
   Górnicki A, 2000, ACTA BIOCHIM POL, V47, P963
   Gultekin FA, 2013, J RADIAT RES, V54, P36, DOI 10.1093/jrr/rrs073
   Harding SA, 2008, INT J ORAL MAX SURG, V37, P617, DOI 10.1016/j.ijom.2008.04.004
   Mutlu I, 2012, CLIN ORAL INVEST, V16, P1363, DOI 10.1007/s00784 011 0644 6
   Nabil S, 2011, INT J ORAL MAX SURG, V40, P229, DOI 10.1016/j.ijom.2010.10.005
   Nogales Carlos Goes, 2008, J Contemp Dent Pract, V9, P75
   Schulz S, 2012, BIOCHEM PHARMACOL, V83, P506, DOI 10.1016/j.bcp.2011.11.025
   Steinhart H, 1999, EUR ARCH OTO RHINO L, V256, P153, DOI 10.1007/s004050050130
   Stübinger S, 2006, QUINTESSENCE INT, V37, P353
   TUKEL SS, 1994, BIOCHEM MOL BIOL INT, V33, P1033
   YAMAYOSHI T, 1993, DRUG EXP CLIN RES, V19, P59
   Zimmermann D, 2012, OZONE SCI ENG, V34, P484, DOI 10.1080/01919512.2012.718223
NR 22
TC 26
Z9 27
U1 0
U2 9
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1 3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0901 5027
EI 1399 0020
J9 INT J ORAL MAX SURG
JI Int. J. Oral Maxillofac. Surg.
PD JUN
PY 2014
VL 43
IS 6
BP 777
EP 783
DI 10.1016/j.ijom.2013.12.007
PG 7
WC Dentistry, Oral Surgery & Medicine; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine; Surgery
GA AI2NK
UT WOS:000336694900018
PM 24491848
DA 2025 08 17
ER

PT J
AU Zheng, WB
   Li, LJ
   Zhao, DC
   Wang, O
   Jiang, Y
   Xia, WB
   Li, M
AF Zheng, Wen Bin
   Li, Lu Jiao
   Zhao, Di Chen
   Wang, Ou
   Jiang, Yan
   Xia, Wei Bo
   Li, Mei
TI A novel variant in AIRE causing a rare, non classical autoimmune
   polyendocrine syndrome type 1
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE autoimmune polyendocrine syndrome type 1; heterozygous novel variant;
   autoimmune regulator; non classical
ID CANDIDIASIS ECTODERMAL DYSTROPHY; REGULATOR GENE; MUTATIONS;
   AUTOANTIBODIES; MECHANISMS
AB Autoimmune polyendocrine syndrome type 1 (APS 1) is a rare inherited autoimmune disease, characterized by a classic triad, including chronic mucocutaneous candidiasis, primary adrenocortical insufficiency and hypoparathyroidism. The present study investigated phenotypes and pathogenic variants in a Chinese woman with non classical APS 1. Disease associated variants in a patient with APS 1 were identified via targeted next generation sequencing and the variant was confirmed via Sanger sequencing. Serum levels of calcium, phosphorus, parathyroid hormone (PTH), follicle stimulating hormone (FSH), luteinizing hormone (LH), estradiol and urinary levels of calcium were measured. Blood count assays and bone marrow morphology were investigated. The patient was a 32 year old woman who had suffered from typical carpopedal spasms since she was 7 years old. She developed syncope, primary amenorrhea, intermittent diarrhea and general fatigue in subsequent years. Hypocalcemia, hyperphosphatemia, low levels of PTH and estradiol, elevated levels of FSH and LH, and absence of erythroblasts were observed, which indicated hypoparathyroidism, primary ovarian insufficiency and pure red cell aplasia. A novel heterozygous missense variant (NM_000383.2: c.623G>T, NP_000374.1: p.Gly208Val) in exon 5 of autoimmune regulator and a reported variant (NM_000383.2: c.371C>T, NP_000374.1: p.Pro124Leu) in exon 3 were detected, of which the c.623G>T variant may be a pathogenic variation that induces APS 1. Under a regular follow up and therapeutic adjustment of calcium, calcitriol, hormone replacement therapy and methylprednisolone, the endocrine function and clinical symptoms of the patient were notably improved. The results of the present study expand the known genetic and phenotypical spectra of APS 1.
C1 [Zheng, Wen Bin; Li, Lu Jiao; Zhao, Di Chen; Wang, Ou; Jiang, Yan; Xia, Wei Bo; Li, Mei] Chinese Acad Med Sci & Peking Union Med Coll, Dept Endocrinol, Peking Union Med Coll Hosp, Natl Hlth Commiss Key Lab Endocrinol, 1 Shuaifuyuan, Beijing 100730, Peoples R China.
C3 Chinese Academy of Medical Sciences   Peking Union Medical College;
   Peking Union Medical College; Peking Union Medical College Hospital
RP Li, M (通讯作者)，Chinese Acad Med Sci & Peking Union Med Coll, Dept Endocrinol, Peking Union Med Coll Hosp, Natl Hlth Commiss Key Lab Endocrinol, 1 Shuaifuyuan, Beijing 100730, Peoples R China.
EM limeilzh@sina.com
RI Wang, Ou/CAJ 3739 2022
FU National Natural Science Foundation of China [81570802, 81873668];
   Chinese Academy of Medical Sciences Innovative Fund for Medical Sciences
   [2016 I2M 3 003]; National Key Research and Development Program of China
   [2016YFC0901501]
FX The present study was supported by the National Natural Science
   Foundation of China (grant nos. 81570802 and 81873668, respectively),
   Chinese Academy of Medical Sciences Innovative Fund for Medical Sciences
   (grant no. 2016 I2M 3 003) and the National Key Research and Development
   Program of China (grant no. 2016YFC0901501).
CR AHONEN P, 1990, NEW ENGL J MED, V322, P1829, DOI 10.1056/NEJM199006283222601
   Alimohammadi M, 2008, NEW ENGL J MED, V358, P1018, DOI 10.1056/NEJMoa0706487
   Anderson MS, 2002, SCIENCE, V298, P1395, DOI 10.1126/science.1075958
   Björses P, 2000, AM J HUM GENET, V66, P378, DOI 10.1086/302765
   Brandi ML, 2016, J CLIN ENDOCR METAB, V101, P2273, DOI 10.1210/jc.2015 3907
   Bruserud O, 2016, CURR OPIN IMMUNOL, V43, P8, DOI 10.1016/j.coi.2016.07.003
   Bruserud O, 2016, J CLIN ENDOCR METAB, V101, P2975, DOI 10.1210/jc.2016 1821
   Cetani F, 2001, J CLIN ENDOCR METAB, V86, P4747, DOI 10.1210/jc.86.10.4747
   Cihakova D, 2001, HUM MUTAT, V18, P225, DOI 10.1002/humu.1178
   Gutierrez MJ, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00377
   Habibullah M, 2018, J IMMUNOL, V201, P3175, DOI 10.4049/jimmunol.1701527
   Husebye ES, 2018, NEW ENGL J MED, V378, P1132, DOI 10.1056/NEJMra1713301
   Ilmarinen T, 2006, FEBS J, V273, P315, DOI 10.1111/j.1742 4658.2005.05065.x
   Ilmarinen T, 2005, HUM MUTAT, V26, P322, DOI 10.1002/humu.20224
   Jin P, 2014, J ENDOCRINOL INVEST, V37, P941, DOI 10.1007/s40618 014 0120 7
   Johnnidis JB, 2005, P NATL ACAD SCI USA, V102, P7233, DOI 10.1073/pnas.0502670102
   Kisand K, 2011, ANN NY ACAD SCI, V1246, P77, DOI 10.1111/j.1749 6632.2011.06308.x
   Liu Cai hong, 2010, Zhonghua Yixue Yichuanxue Zazhi, V27, P18, DOI 10.3760/cma.j.issn.1003 9406.2010.01.004
   Liu Y, 2017, OSTEOPOROSIS INT, V28, P2985, DOI 10.1007/s00198 017 4143 8
   Means RT, 2016, BLOOD, V128, P2504, DOI 10.1182/blood 2016 05 717140
   Meloni A, 2002, J CLIN ENDOCR METAB, V87, P841, DOI 10.1210/jc.87.2.841
   Meloni A, 2012, J CLIN ENDOCR METAB, V97, P1114, DOI 10.1210/jc.2011 2461
   Nagamine K, 1997, NAT GENET, V17, P393, DOI 10.1038/ng1297 393
   Oftedal BE, 2015, IMMUNITY, V42, P1185, DOI 10.1016/j.immuni.2015.04.021
   Orlova EM, 2017, J CLIN ENDOCR METAB, V102, P3546, DOI 10.1210/jc.2017 00139
   Perheentupa J, 2006, J CLIN ENDOCR METAB, V91, P2843, DOI 10.1210/jc.2005 2611
   Peterson P, 2008, NAT REV IMMUNOL, V8, P948, DOI 10.1038/nri2450
   Pitkänen J, 2000, J BIOL CHEM, V275, P16802, DOI 10.1074/jbc.M908944199
   Ramsey C, 2002, HUM MOL GENET, V11, P3299, DOI 10.1093/hmg/11.26.3299
   Rosatelli MC, 1998, HUM GENET, V103, P428, DOI 10.1007/s004390050846
   Sepe V, 2018, NEW ENGL J MED, V378, P2543, DOI 10.1056/NEJMc1805308
   Su MA, 2008, J CLIN INVEST, V118, P1712, DOI 10.1172/JCI34523
   Sun Yong Xiang, 2016, Zhongguo Dang Dai Er Ke Za Zhi, V18, P147
   Wolff ASB, 2008, GENES IMMUN, V9, P130, DOI 10.1038/sj.gene.6364457
   Wolff ASB, 2007, J CLIN ENDOCR METAB, V92, P595, DOI 10.1210/jc.2006 1873
   Zhang JY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053981
   Zhao BJ, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/3930750
   Zhu WF, 2017, IMMUNOGENETICS, V69, P643, DOI 10.1007/s00251 017 0995 5
   ZLOTOGORA J, 1992, J MED GENET, V29, P824, DOI 10.1136/jmg.29.11.824
NR 39
TC 2
Z9 2
U1 0
U2 7
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791 2997
EI 1791 3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD AUG
PY 2020
VL 22
IS 2
BP 1285
EP 1294
DI 10.3892/mmr.2020.11227
PG 10
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Research & Experimental Medicine
GA NL1MP
UT WOS:000567188300072
PM 32627016
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Obayashi, M
   Shibasaki, Y
   Koakutsu, T
   Hayashi, Y
   Shoji, T
   Hirayama, K
   Yamazaki, M
   Takayanagi, Y
   Shibata, H
   Nakamura, M
   Maruo, H
AF Obayashi, Miku
   Shibasaki, Yasushi
   Koakutsu, Toru
   Hayashi, Yoshiro
   Shoji, Tsuyoshi
   Hirayama, Kazuhisa
   Yamazaki, Masanori
   Takayanagi, Yasuhiro
   Shibata, Hiroshi
   Nakamura, Masato
   Maruo, Hirotoshi
TI Pancreatic undifferentiated carcinoma with osteoclast like giant cells
   curatively resected after pembrolizumab therapy for lung metastases: a
   case report
SO BMC GASTROENTEROLOGY
LA English
DT Article
DE Undifferentiated carcinoma with osteoclast like giant cells; UCOGC;
   Pancreatic ductal adenocarcinoma; Lung metastasis; Pembrolizumab; PD 1;
   PD L1; Mismatch repair; Microsatellite instability; Case report
ID TUMOR; ANTIBODY
AB Background Therapy targeting programmed death 1 or programmed death 1 ligand 1 (PD 1/PD L1) has been developed for various solid malignant tumors, such as melanoma and non small cell lung cancer (NSCLC), but this approach has little effect in the treatment of pancreatic cancer. Pancreatic undifferentiated carcinoma with osteoclast like giant cells (UCOGC) is a rare pancreatic malignancy having unique morphology and is considered a variant of pancreatic ductal adenocarcinoma (PDAC). Although UCOGC has been reported to have better prognosis than conventional PDAC, the optimal treatment for UCOGC with distant metastases has not been determined. Case presentation A 66 year old man was initially diagnosed with NSCLC with multiple intrapulmonary metastases and abdominal lymph node metastasis in the tail of the pancreas, and bronchial biopsy and diagnostic imaging were performed. Pathologic examination of the lung showed poorly differentiated adenocarcinoma cells expressing epithelial marker and PD L1. Therefore, pembrolizumab monotherapy for NSCLC was given. The pulmonary lesions shrank markedly and were in complete remission after 8 months of anti PD 1 therapy, though no therapeutic effect was observed in the pancreatic site. Distal pancreatectomy was then performed, and histopathological examination showed that the tumor was UCOGC originating from the pancreas. The histologic findings of the resected specimen mimicked those of the lung biopsy specimen, leading to the final assessment that the lung tumors were metastatic foci that migrated from the UCOGC, and only the metastatic lesions benefited from pembrolizumab therapy. Conclusion Immune checkpoint inhibitors have limited therapeutic effects on primary lesions of pancreatic cancer, but they may exert antitumor effects on pulmonary metastases of UCOGC.
C1 [Obayashi, Miku; Shibasaki, Yasushi; Koakutsu, Toru; Hayashi, Yoshiro; Shoji, Tsuyoshi; Hirayama, Kazuhisa; Yamazaki, Masanori; Maruo, Hirotoshi] Shizuoka City Shimizu Hosp, Dept Surg, Shimizu Ku, 1231 Miyakami, Shizuoka 4248636, Japan.
   [Takayanagi, Yasuhiro] Shizuoka City Shimizu Hosp, Dept Gastroenterol, Shimizu Ku, 1231 Miyakami, Shizuoka 4248636, Japan.
   [Shibata, Hiroshi] Shizuoka City Shimizu Hosp, Dept Resp Med, Shimizu Ku, 1231 Miyakami, Shizuoka 4248636, Japan.
   [Nakamura, Masato] Shizuoka City Shimizu Hosp, Dept Pathol, Shimizu Ku, 1231 Miyakami, Shizuoka 4248636, Japan.
RP Maruo, H (通讯作者)，Shizuoka City Shimizu Hosp, Dept Surg, Shimizu Ku, 1231 Miyakami, Shizuoka 4248636, Japan.
EM maruo@shimizuhospital.com
OI Shibasaki, Yasushi/0000 0002 9286 2534
CR Blando J, 2019, P NATL ACAD SCI USA, V116, P1692, DOI 10.1073/pnas.1811067116
   Chalmers ZR, 2017, GENOME MED, V9, DOI 10.1186/s13073 017 0424 2
   Feng MY, 2017, CANCER LETT, V407, P57, DOI 10.1016/j.canlet.2017.08.006
   Ganesh K, 2019, NAT REV GASTRO HEPAT, V16, P361, DOI 10.1038/s41575 019 0126 x
   Goel A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009393
   Herbst RS, 2019, ANN ONCOL, V30, P281, DOI 10.1093/annonc/mdy545
   Herbst RS, 2014, NATURE, V515, P563, DOI 10.1038/nature14011
   Hissong E, 2018, AM J SURG PATHOL, V42, P453, DOI 10.1097/PAS.0000000000001018
   Koorstra JBM, 2008, AM J SURG PATHOL, V32, P1905, DOI 10.1097/PAS.0b013e31818371cd
   Le DT, 2017, SCIENCE, V357, P409, DOI 10.1126/science.aan6733
   Luchini C, 2019, ANN ONCOL, V30, P1232, DOI 10.1093/annonc/mdz116
   Luchini C, 2018, HUM PATHOL, V81, P157, DOI 10.1016/j.humpath.2018.07.006
   Luchini C, 2017, J PATHOL, V243, P148, DOI 10.1002/path.4941
   Luchini Claudio, 2016, Surg Pathol Clin, V9, P547, DOI 10.1016/j.path.2016.05.003
   Lukás Z, 2006, PANCREAS, V32, P325
   Moore JC, 2010, WORLD J GASTRO ENDOS, V2, P15, DOI 10.4253/wjge.v2.i1.15
   Munari E, 2019, HUM PATHOL, V90, P54, DOI 10.1016/j.humpath.2019.05.003
   Muraki T, 2016, AM J SURG PATHOL, V40, P1203, DOI 10.1097/PAS.0000000000000689
   Nai GA, 2005, PANCREATOLOGY, V5, P279, DOI 10.1159/000085283
   Patnaik A, 2015, CLIN CANCER RES, V21, P4286, DOI 10.1158/1078 0432.CCR 14 2607
   Reck M, 2016, NEW ENGL J MED, V375, P1823, DOI 10.1056/NEJMoa1606774
   Rimm DL, 2017, JAMA ONCOL, V3, P1051, DOI 10.1001/jamaoncol.2017.0013
   Rooney MS, 2015, CELL, V160, P48, DOI 10.1016/j.cell.2014.12.033
   Salem ME, 2018, MOL CANCER RES, V16, P805, DOI 10.1158/1541 7786.MCR 17 0735
   Siegel RL, 2019, CA CANCER J CLIN, V69, P7, DOI 10.3322/caac.21551
   Smyth MJ, 2016, NAT REV CLIN ONCOL, V13, P143, DOI 10.1038/nrclinonc.2015.209
   Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690
   Velcheti V, 2019, IMMUNOTHERAPY UK, V11, P889, DOI 10.2217/imt 2019 0061
   Zischek C, 2009, ANN SURG, V250, P747, DOI 10.1097/SLA.0b013e3181bd62d0
NR 29
TC 26
Z9 28
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471 230X
J9 BMC GASTROENTEROL
JI BMC Gastroenterol.
PD JUL 11
PY 2020
VL 20
IS 1
AR 220
DI 10.1186/s12876 020 01362 4
PG 7
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Gastroenterology & Hepatology
GA MP2NQ
UT WOS:000552046300002
PM 32652936
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Bollerslev, J
   Rejnmark, L
   Marcocci, C
   Shoback, DM
   Sitges Serra, A
   van Biesen, W
   Dekkers, OM
AF Bollerslev, Jens
   Rejnmark, Lars
   Marcocci, Claudio
   Shoback, Dolores M.
   Sitges Serra, Antonio
   van Biesen, Wim
   Dekkers, Olaf M.
TI European Society of Endocrinology Clinical Guideline: Treatment of
   chronic hypoparathyroidism in adults
SO EUROPEAN JOURNAL OF ENDOCRINOLOGY
LA English
DT Article
ID CALCIUM SENSING RECEPTOR; QUALITY OF LIFE; CONGENITAL
   HYPERPARATHYROIDISM SECONDARY; PARATHYROID HORMONE SECRETION; VITAMIN D
   DEFICIENCY; SERUM CALCIUM; MATERNAL HYPOPARATHYROIDISM; TOTAL
   THYROIDECTOMY; BONE METABOLISM; URINARY CALCIUM
AB Hypoparathyroidism (HypoPT) is a rare (orphan) endocrine disease with low calcium and inappropriately low (insufficient) circulating parathyroid hormone levels, most often in adults secondary to thyroid surgery. Standard treatment is activated vitamin D analogues and calcium supplementation and not replacement of the lacking hormone, as in other hormonal deficiency states. The purpose of this guideline is to provide clinicians with guidance on the treatment and monitoring of chronic HypoPT in adults who do not have end stage renal disease. We intend to draft a practical guideline, focusing on operationalized recommendations deemed to be useful in the daily management of patients. This guideline was developed and solely sponsored by The European Society of Endocrinology, supported by CBO (Dutch Institute for Health Care Improvement) and based on the Grading of Recommendations Assessment, Development and Evaluation (GRADE) principles as a methodological base. The clinical question on which the systematic literature search was based and for which available evidence was synthesized was: what is the best treatment for adult patients with chronic HypoPT? This systematic search found 1100 articles, which was reduced to 312 based on title and abstract. The working group assessed these for eligibility in more detail, and 32 full text articles were assessed. For the final recommendations, other literature was also taken into account. Little evidence is available on how best to treat HypoPT. Data on quality of life and the risk of complications have just started to emerge, and clinical trials on how to optimize therapy are essentially non existent. Most studies are of limited sample size, hampering firm conclusions. No studies are available relating target calcium levels with clinically relevant endpoints. Hence it is not possible to formulate recommendations based on strict evidence. This guideline is therefore mainly based on how patients are managed in clinical practice, as reported in small case series and based on the experiences of the authors.
C1 [Bollerslev, Jens] Oslo Univ Hosp, Med Clin, Sect Specialized Endocrinol, Oslo, Norway.
   [Bollerslev, Jens] Univ Oslo, Fac Med, Oslo, Norway.
   [Rejnmark, Lars] Aarhus Univ Hosp, Dept Endocrinol & Internal Med, DK 8000 Aarhus, Denmark.
   [Marcocci, Claudio] Univ Pisa, Dept Clin & Expt Med, Pisa, Italy.
   [Shoback, Dolores M.] Univ Calif San Francisco, San Francisco VA Med Ctr, Dept Vet Affairs, Endocrine Res Unit, San Francisco, CA 94143 USA.
   [Sitges Serra, Antonio] Hosp Univ Mar, Endocrine Surg Unit, Barcelona, Spain.
   [van Biesen, Wim] Ghent Univ Hosp, Div Renal, Ghent, Belgium.
   [Dekkers, Olaf M.] Leiden Univ Med Ctr, Dept Med, Div Endocrinol, Leiden, Netherlands.
   [Dekkers, Olaf M.] Leiden Univ Med Ctr, Dept Clin Epidemiol, Leiden, Netherlands.
   [Dekkers, Olaf M.] Aarhus Univ Hosp, Dept Clin Epidemiol, DK 8000 Aarhus, Denmark.
C3 University of Oslo; University of Oslo; Aarhus University; University of
   Pisa; US Department of Veterans Affairs; Veterans Health Administration
   (VHA); San Francisco VA Medical Center; University of California System;
   University of California San Francisco; Ghent University; Ghent
   University Hospital; Leiden University; Leiden University Medical Center
   (LUMC); Leiden University; Leiden University Medical Center (LUMC);
   Aarhus University
RP Bollerslev, J (通讯作者)，Oslo Univ Hosp, Med Clin, Sect Specialized Endocrinol, Oslo, Norway.
EM Jens.bollerslev@medisin.uio.no
OI Dekkers, Olaf/0000 0002 1333 7580
FU European Society of Endocrinology
FX This guideline was sponsored by the European Society of Endocrinology.
CR Alikasifoglu A, 2005, CLIN PEDIATR, V44, P267, DOI 10.1177/000992280504400312
   Aloia JF, 2011, J CLIN ENDOCR METAB, V96, P2987, DOI 10.1210/jc.2011 0090
   Andrews J, 2013, J CLIN EPIDEMIOL, V66, P719, DOI 10.1016/j.jclinepi.2012.03.013
   ARATA RO, 1974, MEDICINA BUENOS AIRE, V34, P463
   Arlt W, 2002, EUR J ENDOCRINOL, V146, P215, DOI 10.1530/eje.0.1460215
   Atkinson Stephanie A, 2011, Perspect Infirm, V8, P5
   Autier P, 2014, LANCET DIABETES ENDO, V2, P76, DOI 10.1016/S2213 8587(13)70165 7
   Balshem H, 2011, J CLIN EPIDEMIOL, V64, P401, DOI 10.1016/j.jclinepi.2010.07.015
   Barczynski M, 2007, LANGENBECK ARCH SURG, V392, P693, DOI 10.1007/s00423 007 0165 6
   Betterle C, 2014, AUTOIMMUN REV, V13, P417, DOI 10.1016/j.autrev.2014.01.044
   Bilezikian JP, 2011, J BONE MINER RES, V26, P2317, DOI 10.1002/jbmr.483
   Callies F, 1998, EUR J ENDOCRINOL, V139, P284, DOI 10.1530/eje.0.1390284
   Cannata Andía JB, 2002, NEPHROL DIAL TRANSPL, V17, P16, DOI 10.1093/ndt/17.suppl_11.16
   CAPLAN RH, 1990, OBSTET GYNECOL, V76, P485
   Caudarella R, 2007, J Endocrinol Invest, V30, P29
   Coe FL, 2011, CLIN J AM SOC NEPHRO, V6, P2083, DOI 10.2215/CJN.11321210
   Cooper MS, 2008, BRIT MED J, V336, P1298, DOI 10.1136/bmj.39582.589433.BE
   Cooper MS, 2011, BEST PRACT RES CL EN, V25, P975, DOI 10.1016/j.beem.2011.07.001
   CUNDY T, 1987, CLIN ENDOCRINOL, V26, P667, DOI 10.1111/j.1365 2265.1987.tb00824.x
   Cusano NE, 2015, BEST PRACT RES CL EN, V29, P47, DOI 10.1016/j.beem.2014.09.001
   Cusano NE, 2014, J CLIN ENDOCR METAB, V99, P3694, DOI 10.1210/jc.2014 2267
   Cusano NE, 2013, J CLIN ENDOCR METAB, V98, P2356, DOI 10.1210/jc.2013 1239
   Cusano NE, 2013, J CLIN ENDOCR METAB, V98, P137, DOI 10.1210/jc.2012 2984
   DAVIES M, 1977, LANCET, V1, P55
   Demirel N, 2009, ANN TROP PAEDIATR, V29, P149, DOI 10.1179/146532809X440770
   EASTELL R, 1985, BRIT MED J, V291, P955, DOI 10.1136/bmj.291.6500.955
   Edafe O, 2014, BRIT J SURG, V101, P307, DOI 10.1002/bjs.9384
   El Hajj Fuleihan G, 1998, J CLIN ENDOCR METAB, V83, P2366, DOI 10.1210/jc.83.7.2366
   Epstein M, 2006, NEW ENGL J MED, V355, P1834, DOI 10.1056/NEJMc066308
   FATEMI S, 1991, J CLIN ENDOCR METAB, V73, P1067, DOI 10.1210/jcem 73 5 1067
   Francis RM, 2015, MATURITAS, V80, P119, DOI 10.1016/j.maturitas.2014.11.018
   GRAHAM WP, 1964, J CLIN ENDOCR METAB, V24, P512, DOI 10.1210/jcem 24 6 512
   Grodski S, 2008, WORLD J SURG, V32, P1367, DOI 10.1007/s00268 008 9545 5
   Guyatt GH, 2015, J CLIN EPIDEMIOL, V68, P597, DOI 10.1016/j.jclinepi.2014.12.011
   Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1294, DOI 10.1016/j.jclinepi.2011.03.017
   Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P395, DOI 10.1016/j.jclinepi.2010.09.012
   HARVEY JA, 1988, J BONE MINER RES, V3, P253
   Heath H, 1996, J CLIN ENDOCR METAB, V81, P1312, DOI 10.1210/jcem.81.4.8636323
   HILL LF, 1976, CLIN ENDOCRINOL, V5, pS167, DOI 10.1111/j.1365 2265.1976.tb03824.x
   Höbaus J, 2013, ANTI CANCER AGENT ME, V13, P20, DOI 10.2174/187152013804487434
   Horwitz MJ, 2008, J CLIN ENDOCR METAB, V93, P3307, DOI 10.1210/jc.2008 1216
   KANIS JA, 1977, BRIT MED J, V1, P78, DOI 10.1136/bmj.1.6053.78
   KANIS JA, 1977, CLIN ENDOCRINOL, V7, pS191, DOI 10.1111/j.1365 2265.1977.tb03381.x
   Kannan Subramanian, 2014, Indian J Endocrinol Metab, V18, P821, DOI 10.4103/2230 8210.141365
   Karp HJ, 2009, BRIT J NUTR, V102, P1341, DOI 10.1017/S0007114509990195
   Ketteler M, 2015, KIDNEY INT, V87, P502, DOI 10.1038/ki.2014.425
   Khan MI, 2011, ENDOCR PRACT, V17, P18, DOI 10.4158/EP10302.RA
   Kovacs CS, 2014, PHYSIOL REV, V94, P1143, DOI 10.1152/physrev.00014.2014
   Kovacs CS, 2006, ENDOCRIN METAB CLIN, V35, P21, DOI 10.1016/j.ecl.2005.09.004
   Kovacs CS, 1997, ENDOCR REV, V18, P832, DOI 10.1210/er.18.6.832
   Krysiak R, 2011, GYNECOL ENDOCRINOL, V27, P529, DOI 10.3109/09513590.2010.507284
   KURZEL RB, 1990, AM J PERINAT, V7, P333, DOI 10.1055/s 2007 999516
   LANDING BH, 1970, J PEDIATR US, V77, P842, DOI 10.1016/S0022 3476(70)80245 1
   Lienhardt A, 2001, J CLIN ENDOCR METAB, V86, P5313, DOI 10.1210/jc.86.11.5313
   Lima K, 2011, EUR J ENDOCRINOL, V165, P345, DOI 10.1530/EJE 10 1206
   Lorente Poch L, 2015, BRIT J SURG, V102, P359, DOI 10.1002/bjs.9676
   Lorente Poch L, 2015, GLAND SURG, V4, P82, DOI 10.3978/j.issn.2227 684X.2014.12.04
   LOUGHEAD JL, 1990, AM J PERINAT, V7, P350, DOI 10.1055/s 2007 999521
   Lubi M, 2012, J CLIN ENDOCR METAB, V97, pE2090, DOI 10.1210/jc.2012 2301
   Malberti F, 2013, DRUGS, V73, P673, DOI 10.1007/s40265 013 0054 y
   Mannstadt M, 2013, LANCET DIABETES ENDO, V1, P275, DOI 10.1016/S2213 8587(13)70106 2
   MARKESTAD T, 1983, BRIT J OBSTET GYNAEC, V90, P971, DOI 10.1111/j.1471 0528.1983.tb06774.x
   MASCHIO G, 1981, AM J MED, V71, P623, DOI 10.1016/0002 9343(81)90215 1
   Mather KJ, 1999, J CLIN ENDOCR METAB, V84, P424, DOI 10.1210/jc.84.2.424
   Mestman JH, 1998, SEMIN PERINATOL, V22, P485, DOI 10.1016/S0146 0005(98)80028 1
   Mitchell DM, 2012, J CLIN ENDOCR METAB, V97, P4507, DOI 10.1210/jc.2012 1808
   MURDOCH DL, 1993, BRIT J CLIN PHARMACO, V35, P373, DOI 10.1111/j.1365 2125.1993.tb04153.x
   NEWMAN GH, 1984, EUR J CLIN PHARMACOL, V27, P41
   O'Seaghdha CM, 2010, HUM MOL GENET, V19, P4296, DOI 10.1093/hmg/ddq342
   OKANO K, 1982, J CLIN ENDOCR METAB, V55, P238, DOI 10.1210/jcem 55 2 238
   Ong GSY, 2012, J CLIN ENDOCR METAB, V97, P3138, DOI 10.1210/jc.2012 1429
   PARFITT AM, 1972, ANN INTERN MED, V77, P557, DOI 10.7326/0003 4819 77 4 557
   Pearce S, 1999, LANCET, V353, P83, DOI 10.1016/S0140 6736(05)76148 1
   Pearle MS, 2014, J UROLOGY, V192, P316, DOI 10.1016/j.juro.2014.05.006
   PORTER RH, 1978, NEW ENGL J MED, V298, P577, DOI 10.1056/NEJM197803162981101
   Powers J, 2013, J BONE MINER RES, V28, P2570, DOI 10.1002/jbmr.2004
   Puzziello A, 2014, ENDOCRINE, V47, P537, DOI 10.1007/s12020 014 0209 y
   Qaseem A, 2014, ANN INTERN MED, V161, P659, DOI 10.7326/M13 2908
   Rathod A, 2015, CLIN J AM SOC NEPHRO, V10, P452, DOI 10.2215/CJN.12511213
   RECKER RR, 1985, AM J CLIN NUTR, V41, P254, DOI 10.1093/ajcn/41.2.254
   Rejnmark L, 2003, EUR J CLIN INVEST, V33, P41, DOI 10.1046/j.1365 2362.2003.01103.x
   Rejnmark L, 2014, SCIENTIFICA, V2014, DOI 10.1155/2014/765629
   Rodríguez Ortiz ME, 2014, NEPHROL DIAL TRANSPL, V29, P282, DOI 10.1093/ndt/gft400
   Ross AC, 2011, J CLIN ENDOCR METAB, V96, P53, DOI 10.1210/jc.2010 2704
   Rubin MR, 2008, J BONE MINER RES, V23, P2018, DOI 10.1359/JBMR.080803
   RUDE RK, 1984, ENDOCRINOL JAPON, V31, P227
   SADEGHINEJAD A, 1980, JAMA J AM MED ASSOC, V243, P254
   SALLE BL, 1981, J CLIN ENDOCR METAB, V52, P810, DOI 10.1210/jcem 52 4 810
   SANTOS F, 1986, AM J DIS CHILD, V140, P139, DOI 10.1001/archpedi.1986.02140160057032
   Sato K, 2002, J CLIN ENDOCR METAB, V87, P3068, DOI 10.1210/jc.87.7.3068
   SEINO Y, 1987, BONE MINER, V2, P479
   Shoback D, 2008, NEW ENGL J MED, V359, P391, DOI 10.1056/NEJMcp0803050
   Shomali M E, 1999, Endocr Pract, V5, P198
   Sikjaer T, 2014, OSTEOPOROSIS INT, V25, P1717, DOI 10.1007/s00198 014 2677 6
   Sikjaer T, 2011, J BONE MINER RES, V26, P2358, DOI 10.1002/jbmr.470
   Sitges Serra A, 2010, BRIT J SURG, V97, P1687, DOI 10.1002/bjs.7219
   Straub DA, 2007, NUTR CLIN PRACT, V22, P286, DOI 10.1177/0115426507022003286
   Thakker RV, 2001, LANCET, V357, P974, DOI 10.1016/S0140 6736(00)04254 9
   TOULIATOS JS, 1995, AM J MED SCI, V310, P56, DOI 10.1097/00000441 199508000 00003
   Underbjerg L, 2015, J BONE MINER RES, V30, P1738, DOI 10.1002/jbmr.2501
   Underbjerg L, 2014, J BONE MINER RES, V29, P2504, DOI 10.1002/jbmr.2273
   Underbjerg L, 2013, J BONE MINER RES, V28, P2277, DOI 10.1002/jbmr.1979
   Winer KK, 2008, J CLIN ENDOCR METAB, V93, P3389, DOI 10.1210/jc.2007 2552
   Winer KK, 2012, J CLIN ENDOCR METAB, V97, P391, DOI 10.1210/jc.2011 1908
   Winer KK, 2003, J CLIN ENDOCR METAB, V88, P4214, DOI 10.1210/jc.2002 021736
   WRIGHT AD, 1969, BRIT MED J, V1, P23, DOI 10.1136/bmj.1.5635.23
   Zamfirescu I, 2011, THYROID, V21, P483, DOI 10.1089/thy.2010.0296
NR 107
TC 315
Z9 344
U1 0
U2 24
PU BIOSCIENTIFICA LTD
PI BRISTOL
PA EURO HOUSE, 22 APEX COURT WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT,
   ENGLAND
SN 0804 4643
EI 1479 683X
J9 EUR J ENDOCRINOL
JI Eur. J. Endocrinol.
PD AUG
PY 2015
VL 173
IS 2
BP EG1
EP EG20
DI 10.1530/EJE 15 0628
PG 20
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA CO1XH
UT WOS:000358949000003
PM 26160136
DA 2025 08 17
ER

PT J
AU Coulter, JA
   Page, NL
   Worthington, J
   Robson, T
   Hirst, DG
   McCarthy, HO
AF Coulter, Jonathan A.
   Page, Natalie L.
   Worthington, Jenny
   Robson, Tracy
   Hirst, David G.
   McCarthy, Helen O.
TI Transcriptional regulation of inducible nitric oxide synthase gene
   therapy: targeting early stage and advanced prostate cancer
SO JOURNAL OF GENE MEDICINE
LA English
DT Article
DE gene therapy; hOC; iNOS; PSMA; prostate cancer
ID OSTEOCALCIN DEFICIENT MICE; MEMBRANE ANTIGEN PSMA; INDUCED APOPTOSIS;
   OSTEOBLAST DIFFERENTIATION; BIOCHEMICAL MARKERS; MULTIPLE MYELOMA; BONE
   METABOLISM; TUMOR CELLS; PC12 CELLS; PROMOTER
AB Background Using the tumour type specific human osteocalcin (hOC) promoter, we have previously reported strong promoter activation in hormone independent prostate cancer cells in vitro. In the present study, we present a comparative study of the tissue specific promoter prostate specific membrane antigen (PSMA), and the tumour type specific hOC promoter driving the inducible nitric oxide synthase (iNOS) transgene using both in vitro and in vivo models.
   Methods In vitro cytotoxicity was assessed by clonogenic assay. Quantification of nitric oxide expression was determined by the Griess test. In vivo anti tumour efficacy was determined by tumour growth delay following direct intra tumoural injection of the constructs into PC3 xenografts. In addition, tumours were dissected post mortem and examined for morphological differences as well as changes in apoptotic protein expression.
   Results PSMA/iNOS produced cytotoxicity in both androgen dependant and independent cell lines. Nitric oxide quantification confirmed that increased cytotoxicity was directly associated with nitric oxide production. Tumour growth delays were observed in all groups treated with the iNOS expressing constructs ranging from 10.7 days for the hOC/iNOS single dose treatment group to a maximum of 52.2 days for the hOC/iNOS multiple dose group. Intra tumoural assessment of iNOS and cleaved poly (ADP ribose) polymerase protein expression demonstrated a significant up regulation of both proteins, indicating cytotoxicity mediated through the intrinsic apoptotic pathway.
   Conclusions Highly significant tumour growth delay coupled with no detrimental side effects were observed following treatment with the PSMA/iNOS and hOC/iNOS constructs. We consider that these findings provide a basis for the development of systemically delivered PSMA/iNOS or hOC/iNOS targeting early stage and advanced prostate cancer. Copyright. (C) 2010 John Wiley & Sons, Ltd.
C1 [Coulter, Jonathan A.; Page, Natalie L.; Robson, Tracy; Hirst, David G.; McCarthy, Helen O.] Queens Univ Belfast, McClay Res Ctr, Sch Pharm, Belfast BT9 7BL, Antrim, North Ireland.
   [Worthington, Jenny] Univ Ulster, Ctr Mol Biosci, Coleraine BT52 1SA, Londonderry, North Ireland.
C3 Queens University Belfast; Ulster University
RP McCarthy, HO (通讯作者)，Queens Univ Belfast, Ctr Med Biol, Sch Pharm, 97 Lisburn Rd, Belfast BT9 7BL, Antrim, North Ireland.
EM h.mccarthy@qub.ac.uk
OI Coulter, Jonathan/0000 0003 4112 2357; Robson,
   Tracy/0000 0003 4262 6872; McCarthy, Helen/0000 0002 1254 3745
CR Bal Price A, 2000, J NEUROCHEM, V75, P1455, DOI 10.1046/j.1471 4159.2000.0751455.x
   Barnes GL, 2003, CANCER RES, V63, P2631
   Boskey AL, 1998, BONE, V23, P187, DOI 10.1016/S8756 3282(98)00092 1
   Brubaker KD, 2003, PROSTATE, V56, P13, DOI 10.1002/pros.10233
   Chung P, 2003, NITRIC OXIDE BIOL CH, V8, P119, DOI 10.1016/S1089 8603(02)00147 7
   Colombatti M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004608
   Cook T, 2004, CANCER RES, V64, P8015, DOI 10.1158/0008 5472.CAN 04 2212
   Coulter JA, 2008, GENE THER, V15, P495, DOI 10.1038/gt.2008.7
   De Ridder M, 2008, NITRIC OXIDE BIOL CH, V19, P164, DOI 10.1016/j.niox.2008.04.015
   Ducy P, 1996, NATURE, V382, P448, DOI 10.1038/382448a0
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Fitzpatrick B, 2008, NITRIC OXIDE BIOL CH, V19, P217, DOI 10.1016/j.niox.2008.05.001
   Ghosh A, 2004, J CELL BIOCHEM, V91, P528, DOI 10.1002/jcb.10661
   Grasso YZ, 1998, CANCER RES, V58, P1456
   HAUSCHKA PV, 1989, ANAT REC, V224, P180, DOI 10.1002/ar.1092240208
   Hinata N, 2006, INT J UROL, V13, P834, DOI 10.1111/j.1442 2042.2006.01418.x
   ISRAELI RS, 1993, CANCER RES, V53, P227
   Jung CY, 2001, GENE, V271, P143, DOI 10.1016/S0378 1119(01)00513 3
   Kawakami S, 1997, EUR UROL, V32, P58
   Kayed H, 2007, MOL CANCER, V6, DOI 10.1186/1476 4598 6 83
   Kim PKM, 2001, INT IMMUNOPHARMACOL, V1, P1421, DOI 10.1016/S1567 5769(01)00088 1
   Koeneman KS, 2000, WORLD J UROL, V18, P102, DOI 10.1007/s003450050181
   Koeneman KS, 1999, PROSTATE, V39, P246
   Kularatne SA, 2009, MOL PHARMACEUT, V6, P790, DOI 10.1021/mp9000712
   Lee SJ, 2003, J MOL BIOL, V330, P749, DOI 10.1016/S0022 2836(03)00640 5
   Lipton A, 2007, CLIN LYMPHOMA MYELOM, V7, P346, DOI 10.3816/CLM.2007.n.011
   McCarthy HO, 2007, J GENE MED, V9, P511, DOI 10.1002/jgm.1045
   Messmer UK, 1996, ARCH BIOCHEM BIOPHYS, V327, P1, DOI 10.1006/abbi.1996.0085
   Natal C, 2008, APOPTOSIS, V13, P1356, DOI 10.1007/s10495 008 0263 0
   NISHIMOTO SK, 1980, J BIOL CHEM, V255, P6579
   Noss KR, 2002, ANTICANCER RES, V22, P1505
   O McCarthy H, 2007, GENE THER, V14, P246, DOI 10.1038/sj.gt.3302871
   O'Keefe DS, 2000, PROSTATE, V45, P149
   O'Keefe DS, 1998, BBA GENE STRUCT EXPR, V1443, P113
   Oettgen P, 1999, J BIOL CHEM, V274, P29439, DOI 10.1074/jbc.274.41.29439
   Porasuphatana S, 2003, COMP BIOCHEM PHYS C, V134, P281, DOI 10.1016/S1532 0456(02)00271 5
   Robson T, 2003, J BIOMED BIOTECHNOL, P110, DOI 10.1155/S1110724303209074
   Shacka JJ, 2006, CELL DEATH DIFFER, V13, P1506, DOI 10.1038/sj.cdd.4401831
   Shao C, 2003, CANCER RES, V63, P8437
   Shao CL, 2004, J RADIAT RES, V45, P97, DOI 10.1269/jrr.45.97
   Shirakawa T, 1998, CANCER GENE THER, V5, P274
   SMITH MR, 1995, CANCER RES, V55, P2640
   Soler MN, 2000, J GENE MED, V2, P344
   Szabó C, 2003, TOXICOL LETT, V140, P105, DOI 10.1016/S0378 4274(02)00507 6
   Terao S, 2009, ANTICANCER RES, V29, P1533
   Terpos E, 2006, CANCER TREAT REV, V32, P15, DOI 10.1016/S0305 7372(06)80004 6
   Vaday GG, 2006, PROSTATE, V66, P124, DOI 10.1002/pros.20306
   Wai PY, 2006, J BIOL CHEM, V281, P18973, DOI 10.1074/jbc.M511962200
   Wardman P, 2007, RADIAT RES, V167, P475, DOI 10.1667/RR0827.1
   Wissenbach U, 2001, J BIOL CHEM, V276, P19461, DOI 10.1074/jbc.M009895200
   Worthington J, 2000, GENE THER, V7, P1126, DOI 10.1038/sj.gt.3301224
   Worthington J, 2005, GENE THER, V12, P1417, DOI 10.1038/sj.gt.3302552
   Xu WM, 2002, CELL RES, V12, P311, DOI 10.1038/sj.cr.7290133
   Yeung F, 2002, J BIOL CHEM, V277, P2468, DOI 10.1074/jbc.M105947200
   Zhao FJ, 2009, PROSTATE CANCER P D, V12, P166, DOI 10.1038/pcan.2008.39
   Zhao WM, 2009, UROL ONCOL SEMIN ORI, V27, P539, DOI 10.1016/j.urolonc.2008.05.003
   Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549
NR 57
TC 22
Z9 23
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1099 498X
EI 1521 2254
J9 J GENE MED
JI J. Gene. Med.
PD SEP
PY 2010
VL 12
IS 9
BP 755
EP 765
DI 10.1002/jgm.1495
PG 11
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
   Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
   Experimental Medicine
GA 655XU
UT WOS:000282290300005
PM 20821746
OA Bronze
DA 2025 08 17
ER

PT J
AU Karunakaran, G
   Cho, EB
   Kumar, GS
   Kolesnikov, E
   Karpenkov, DY
   Gopinathan, J
   Pillai, MM
   Selvakumar, R
   Boobalan, S
   Gorshenkov, MV
AF Karunakaran, Gopalu
   Cho, Eun Bum
   Kumar, Govindan Suresh
   Kolesnikov, Evgeny
   Karpenkov, Dmitriy Yu
   Gopinathan, Janarthanan
   Pillai, Mamatha Muraleedharan
   Selvakumar, Rajendran
   Boobalan, Selvakumar
   Gorshenkov, Mikhail V.
TI Sodium dodecyl sulfate mediated microwave synthesis of biocompatible
   superparamagnetic mesoporous hydroxyapatite nanoparticles using black
   Chlamys varia seashell as a calcium source for biomedical
   applications
SO CERAMICS INTERNATIONAL
LA English
DT Article
DE Microwave synthesis; Electron microscopy; Apatite; Biomedical
   applications
ID ASSISTED HYDROTHERMAL SYNTHESIS; DOPED HYDROXYAPATITE; MAGNETIC
   NANOPARTICLES; ANTIBACTERIAL ACTIVITY; MECHANICAL PROPERTIES; GREEN
   SYNTHESIS; RAPID FORMATION; NANORODS; BONE; SIZE
AB Designing biocompatible superparamagnetic mesoporous nanoparticles for advanced healthcare applications has received much attention. In this research, we have synthesized intrinsic mesoporous superparamagnetic hydroxyapatite (HAp) nanoparticles using bio waste of black Chlamys varia seashell as a calcium source by sodium dodecyl sulfate (SDS) enabled microwave assisted synthesis approach. The synthesized Fe doped HAp nano particles were characterized using various characterization techniques to know the phase purity and morphological features. The incorporation of Fe greatly affected the morphology of HAp nanoparticles without affecting their crystalline phase. Superparamagnetic behavior was observed with the incorporation of Fe in the HAp nanoparticles. Further, saturation magnetization was enhanced with higher incorporation of Fe ions. The cytotoxicity studies of the synthesized pure and Fe doped HAp samples conducted using a human osteoblasts cell line (MG63), which indicated that Fe doped HAp nanoparticles are biocompatible. Further, antibacterial activity analysis also confirmed their excellent antibacterial performance against different pathogens. Hence, SDS enabled microwave assisted synthesis approach using seashell as a calcium source would be a better approach for the production of intrinsic mesoporous superparamagnetic HAp nanoparticles for various biomedical applications, such as drug targeting, hyperthermia cancer therapy, and magnetic resonance imaging.
C1 [Karunakaran, Gopalu; Cho, Eun Bum] Seoul Natl Univ Sci & Technol Seoul Tech, Biosensor Res Inst, Dept Fine Chem, Gongneung Ro 232, Seoul 01811, South Korea.
   [Kumar, Govindan Suresh] KS Rangasamy Coll Arts & Sci Autonomous, Dept Phys, Tiruchengode 637215, Tamil Nadu, India.
   [Kolesnikov, Evgeny] Natl Univ Sci & Technol MISiS, Dept Funct Nanosyst & High Temp Mat, Leninskiy Pr 4, Moscow 119049, Russia.
   [Kolesnikov, Evgeny; Karpenkov, Dmitriy Yu] Moscow MV Lomonosov State Univ, Dept Magnetism, Fac Phys, GSP 1, Moscow 119991, Russia.
   [Gopinathan, Janarthanan; Pillai, Mamatha Muraleedharan; Selvakumar, Rajendran] PSG Inst Adv Studies, Tissue Engn Lab, Coimbatore 641004, Tamil Nadu, India.
   [Gopinathan, Janarthanan] Seoul Natl Univ Sci & Technol Seoul Tech, Dept Chem & Biomol Engn, Gongneung Ro 232, Seoul Z01811, South Korea.
   [Boobalan, Selvakumar] KS Rangasamy Coll Arts & Sci Autonomous, Dept Biotechnol, Tiruchengode 637215, Tamil Nadu, India.
   [Gorshenkov, Mikhail V.] Natl Univ Sci & Technol MISiS, Dept Phys Mat Sci, Leninskiy Pr 4, Moscow 119049, Russia.
C3 National University of Science & Technology (MISIS); Lomonosov Moscow
   State University; National University of Science & Technology (MISIS)
RP Karunakaran, G; Cho, EB (通讯作者)，Seoul Natl Univ Sci & Technol Seoul Tech, Biosensor Res Inst, Dept Fine Chem, Gongneung Ro 232, Seoul 01811, South Korea.
EM karunakarang5@seoultech.ac.kr; echo@seoultech.ac.kr
RI KARUNAKARAN, GOPALU/H 9378 2014; R, Selvakumar/AAY 5154 2021;
   Karunakaran, Gopalu/AAC 4518 2019; Cho, Eun Bum/A 3688 2015; M Pillai,
   Mamatha/B 9900 2017; Gorshenkov, Mikhail/N 5186 2019; JANARTHANAN,
   GOPINATHAN/U 6554 2018; Kolesnikov, Evgeny/H 8515 2015; Pillai,
   Mamatha/B 9900 2017; Karpenkov, Dmitriy/ABC 1428 2020; ,
   Boobalan/AAJ 1993 2021; Kumar, G. Suresh/H 7246 2013
OI KARUNAKARAN, GOPALU/0000 0003 0863 9442; M Pillai,
   Mamatha/0000 0002 4081 0353; , Dr S.Boobalan/0000 0002 0478 2826; Cho,
   Eun Bum/0000 0002 4169 0189; Janarthanan,
   Gopinathan/0000 0002 0851 2874; Kumar, G. Suresh/0000 0003 4441 6107
FU Ministry of Science and ICT through the National Research Foundation of
   Korea (KRF) [2018H1D3A1A01037054]; Ministry of Education and Science of
   the Russian Federation [211]; National Research Foundation of Korea
   [2018H1D3A1A01037054] Funding Source: Korea Institute of Science &
   Technology Information (KISTI), National Science & Technology
   Information Service (NTIS)
FX This research was supported by the Korean Research Fellowship program
   funded by the Ministry of Science and ICT through the National Research
   Foundation of Korea (KRF grant no. 2018H1D3A1A01037054). The work was
   carried out with the financial support from the Ministry of Education
   and Science of the Russian Federation in the framework of increase
   Competitiveness Program of NUST "MISIS," implemented by a governmental
   decree dated 16th of March 2013, number 211.
CR AL Wafi R, 2016, J ALLOY COMPD, V689, P169, DOI 10.1016/j.jallcom.2016.07.285
   BARON J, 1989, AQUACULTURE, V77, P103, DOI 10.1016/0044 8486(89)90194 4
   Basu D, 2014, INDIAN J ANAESTH, V58, P529, DOI 10.4103/0019 5049.144647
   Basu S, 2018, ACS BIOMATER SCI ENG, V4, P857, DOI 10.1021/acsbiomaterials.7b00813
   BAUER AW, 1966, AM J CLIN PATHOL, V45, P493
   Begam H, 2017, CERAM INT, V43, P3752, DOI 10.1016/j.ceramint.2016.12.010
   Berry CC, 2004, INT J PHARMACEUT, V269, P211, DOI 10.1016/j.ijpharm.2003.09.042
   Boukha Z, 2018, APPL CATAL A GEN, V566, P1, DOI 10.1016/j.apcata.2018.08.017
   Cao JM, 2005, J MATER SCI, V40, P6311, DOI 10.1007/s10853 005 4221 8
   Chandra VS, 2015, CERAM INT, V41, P13153, DOI 10.1016/j.ceramint.2015.07.088
   Chlala D, 2018, CATAL TODAY, V307, P41, DOI 10.1016/j.cattod.2017.04.018
   del Campo R, 2017, MAT SCI ENG C MATER, V78, P667, DOI 10.1016/j.msec.2017.04.143
   Deng JP, 2005, LANGMUIR, V21, P8947, DOI 10.1021/la051252m
   Derkus B, 2016, TALANTA, V158, P100, DOI 10.1016/j.talanta.2016.05.045
   Eziefula UG, 2018, CONSTR BUILD MATER, V192, P287, DOI 10.1016/j.conbuildmat.2018.10.096
   Mercado DF, 2014, ACS APPL MATER INTER, V6, P3937, DOI 10.1021/am405217j
   Grosvenor AP, 2004, SURF INTERFACE ANAL, V36, P1564, DOI 10.1002/sia.1984
   Guerra López J, 2001, J RAMAN SPECTROSC, V32, P255, DOI 10.1002/jrs.689
   Han S., 2017, Biosurf. Biotribol., V3, P75, DOI [DOI 10.1016/J.BSBT.2017.07.001, 10.1016/j.bsbt.2017.07.001]
   Hu K, 1997, LANGMUIR, V13, P5418, DOI 10.1021/la970483t
   Iafisco M, 2013, CHEM MATER, V25, P2610, DOI 10.1021/cm4007298
   Iannotti V, 2017, INORG CHEM, V56, P4446, DOI 10.1021/acs.inorgchem.6b03143
   Jenkins L, 1996, ALCATEL TELECOMMUN R, P138
   Jiang M, 2002, PHYS REV B, V66, DOI 10.1103/PhysRevB.66.224107
   Joe A, 2018, J SOLID STATE CHEM, V267, P124, DOI 10.1016/j.jssc.2018.08.003
   Karunakaran G, 2019, CERAM INT, V45, P970, DOI 10.1016/j.ceramint.2018.09.273
   Karunakaran G, 2017, JOM US, V69, P1325, DOI 10.1007/s11837 017 2349 z
   Karunakaran G, 2017, POWDER TECHNOL, V305, P488, DOI 10.1016/j.powtec.2016.10.034
   Kaygili O, 2014, CERAM INT, V40, P9395, DOI 10.1016/j.ceramint.2014.02.009
   Kim H, 2018, CERAM INT, V44, P20490, DOI 10.1016/j.ceramint.2018.08.045
   Kumar GS, 2018, CERAM INT, V44, P11257, DOI 10.1016/j.ceramint.2018.03.170
   Kumar GS, 2017, MRS COMMUN, V7, P183, DOI 10.1557/mrc.2017.18
   Kumar GS, 2017, CERAM INT, V43, P3457, DOI 10.1016/j.ceramint.2016.11.163
   Kumar VA, 2018, CERAM INT, V44, P10345, DOI 10.1016/j.ceramint.2018.03.045
   Lak A, 2008, J AM CERAM SOC, V91, P3580, DOI 10.1111/j.1551 2916.2008.02690.x
   Laranjeira MS, 2016, COLLOID SURFACE B, V146, P363, DOI 10.1016/j.colsurfb.2016.06.042
   Liu JB, 2004, CHEM PHYS LETT, V396, P429, DOI 10.1016/j.cplett.2004.08.094
   Mene RU, 2014, J ALLOY COMPD, V584, P487, DOI 10.1016/j.jallcom.2013.09.111
   Nagyné Kovács T, 2018, CERAM INT, V44, P22976, DOI 10.1016/j.ceramint.2018.09.096
   Nandi SK, 2015, MAT SCI ENG C MATER, V49, P816, DOI 10.1016/j.msec.2015.01.078
   Núñez D, 2018, MATER LETT, V230, P64, DOI 10.1016/j.matlet.2018.07.077
   Pal A, 2019, J MECH BEHAV BIOMED, V90, P328, DOI 10.1016/j.jmbbm.2018.10.027
   Patil RM, 2018, BIOCHEM BIOPHYS REP, V13, P63, DOI 10.1016/j.bbrep.2017.12.002
   Periyasamy S, 2018, J ENVIRON CHEM ENG, V6, P1443, DOI 10.1016/j.jece.2018.01.007
   Pon On W, 2008, MATER CHEM PHYS, V112, P453, DOI 10.1016/j.matchemphys.2008.05.082
   Priyadarshini B, 2018, ADV POWDER TECHNOL, V29, P2792, DOI 10.1016/j.apt.2018.07.028
   Ramesh S, 2018, CERAM INT, V44, P10525, DOI 10.1016/j.ceramint.2018.03.072
   Robles Aguila MJ, 2017, CERAM INT, V43, P12705, DOI 10.1016/j.ceramint.2017.06.154
   Samaele N, 2010, POWDER TECHNOL, V203, P243, DOI 10.1016/j.powtec.2010.05.014
   Shah V, 2019, J MOL LIQ, V273, P222, DOI 10.1016/j.molliq.2018.10.042
   Shi PJ, 2018, MAT SCI ENG C MATER, V90, P706, DOI 10.1016/j.msec.2018.04.026
   Shkir M, 2019, CERAM INT, V45, P50, DOI 10.1016/j.ceramint.2018.09.132
   Singh B, 2018, J MATER SCI, V53, P8807, DOI 10.1007/s10853 018 2225 4
   Sobczak Kupiec A, 2018, CERAM INT, V44, P13630, DOI 10.1016/j.ceramint.2018.04.199
   Supova M, 2015, CERAM INT, V41, P9203, DOI 10.1016/j.ceramint.2015.03.316
   Tampieri A, 2012, ACTA BIOMATER, V8, P843, DOI 10.1016/j.actbio.2011.09.032
   Ullah I, 2018, CERAM INT, V44, P21338, DOI 10.1016/j.ceramint.2018.08.187
   Uskokovic V, 2019, MAT SCI ENG C MATER, V94, P798, DOI 10.1016/j.msec.2018.10.028
   Vani R, 2011, NANOTECHNOLOGY, V22, DOI 10.1088/0957 4484/22/28/285701
   Veerla SC, 2019, MAT SCI ENG C MATER, V98, P311, DOI 10.1016/j.msec.2018.12.148
   Wu HC, 2007, NANOTECHNOLOGY, V18, DOI 10.1088/0957 4484/18/16/165601
   Xiao X, 2018, COLLOID SURFACE A, V555, P548, DOI 10.1016/j.colsurfa.2018.07.036
   Zhao SK, 2019, SENSOR ACTUAT B CHEM, V286, P501, DOI 10.1016/j.snb.2019.01.127
   Zheng XW, 2003, J COLLOID INTERF SCI, V268, P357, DOI 10.1016/j.jcis.2003.09.021
   Zilm ME, 2014, J MATER CHEM B, V2, P7176, DOI 10.1039/c4tb00925h
NR 65
TC 21
Z9 21
U1 2
U2 42
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0272 8842
EI 1873 3956
J9 CERAM INT
JI Ceram. Int.
PD AUG 15
PY 2019
VL 45
IS 12
BP 15143
EP 15155
DI 10.1016/j.ceramint.2019.04.256
PG 13
WC Materials Science, Ceramics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA IH2JV
UT WOS:000474322000081
DA 2025 08 17
ER

PT J
AU Wang, BY
   Wang, Y
   Chen, HN
   Yao, SY
   Lai, XF
   Qiu, Y
   Cai, JY
   Huang, YN
   Wei, XY
   Guan, YJ
   Wang, T
   Wang, JC
   Xiang, AP
AF Wang, Boyan
   Wang, Yi
   Chen, Hainan
   Yao, Senyu
   Lai, Xiaofan
   Qiu, Yuan
   Cai, Jianye
   Huang, Yinong
   Wei, Xiaoyue
   Guan, Yuanjun
   Wang, Tao
   Wang, Jiancheng
   Xiang, Andy Peng
TI Inhibition of TGFβ improves hematopoietic stem cell niche and
   ameliorates cancer related anemia
SO STEM CELL RESEARCH & THERAPY
LA English
DT Article
DE Cancer related anemia; Cachexia; Erythropoiesis; Hematopoietic stem
   cells niche; Mesenchymal stromal cells; TGF beta; SB505124
AB Background: Cancer cachexia is a wasting syndrome that is quite common in terminal stage cancer patients. Cancer related anemia is one of the main features of cancer cachexia and mostly results in a poor prognosis. The disadvantages of the current therapies are obvious, but few new treatments have been developed because the pathological mechanism remains unclear.
   Methods: C57BL/6 mice were subcutaneously injected with Lewis lung carcinoma cells to generate a cancer related anemia model. The treated group received daily intraperitoneal injections of SB505124. Blood parameters were determined with a routine blood counting analyzer. Erythroid cells and hematopoietic stem/progenitor cells were analyzed by flow cytometry. The microarchitecture changes of the femurs were determined by micro computed tomography scans. Smad2/3 phosphorylation was analyzed by immunofluorescence and Western blotting. The changes in the hematopoietic stem cell niche were revealed by qPCR analysis of both fibrosis related genes and hematopoietic genes, fibroblastic colony forming unit assays, and lineage differentiation of mesenchymal stromal cells.
   Results: The mouse model exhibited hematopoietic suppression, marked by a decrease of erythrocytes in the peripheral blood, as well as an increase of immature erythroblasts and reduced differentiation of multipotent progenitors in the bone marrow. The ratio of bone volume/total volume, trabecular number, and cortical wall thickness all appeared to decrease, and the increased osteoclast number has led to the release of latent TGF beta and TGF beta signaling over activation. Excessive TGF beta deteriorated the hematopoietic stem cell niche, inducing fibrosis of the bone marrow as well as the transition of mesenchymal stromal cells. Treatment with SB505124, a small molecule inhibitor of TGF beta signaling, significantly attenuated the symptoms of cancer related anemia in this model, as evidenced by the increase of erythrocytes in the peripheral blood and the normalized proportion of erythroblast cell clusters. Meanwhile, hindered hematopoiesis and deteriorated hematopoietic stem cell niche were also shown to be restored with SB505124 treatment.
   Conclusion: This study investigated the role of TGF beta released by bone remodeling in the progression of cancer related anemia and revealed a potential therapeutic approach for relieving defects in hematopoiesis.
C1 [Wang, Boyan; Wang, Yi; Chen, Hainan; Yao, Senyu; Qiu, Yuan; Wei, Xiaoyue; Wang, Tao; Wang, Jiancheng; Xiang, Andy Peng] Sun Yat Sen Univ, Affiliated Hosp 7, Sci Res Ctr, 628 Zhenyuan Rd, Shenzhen, Guangdong, Peoples R China.
   [Wang, Boyan; Wang, Yi; Chen, Hainan; Yao, Senyu; Lai, Xiaofan; Qiu, Yuan; Cai, Jianye; Huang, Yinong; Wei, Xiaoyue; Wang, Tao; Wang, Jiancheng; Xiang, Andy Peng] Sun Yat Sen Univ, Ctr Stem Cell Biol & Tissue Engn, Key Lab Stem Cells & Tissue Engn, Minist Educ, 74 Zhongshan 2nd Rd, Guangzhou, Guangdong, Peoples R China.
   [Lai, Xiaofan] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Anesthesiol, Guangzhou, Peoples R China.
   [Cai, Jianye] Sun Yat Sen Univ, Dept Hepat Surg, Affiliated Hosp 3, Organ Transplantat Inst, Guangzhou, Peoples R China.
   [Cai, Jianye] Sun Yat Sen Univ, Liver Transplantat Ctr, Affiliated Hosp 3, Organ Transplantat Inst, Guangzhou, Peoples R China.
   [Huang, Yinong] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Neurol, Guangzhou, Peoples R China.
   [Guan, Yuanjun] Sun Yat Sen Univ, Zhongshan Sch Med, Core Facil Ctr, Guangzhou, Peoples R China.
   [Xiang, Andy Peng] Sun Yat Sen Univ, Zhongshan Sch Med, Dept Biochem, Guangzhou, Peoples R China.
C3 Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University;
   Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University;
   Sun Yat Sen University; Sun Yat Sen University
RP Wang, JC; Xiang, AP (通讯作者)，Sun Yat Sen Univ, Affiliated Hosp 7, Sci Res Ctr, 628 Zhenyuan Rd, Shenzhen, Guangdong, Peoples R China.
EM wangjch38@mail.sysu.edu.cn; xiangp@mail.sysu.edu.cn
RI Cai, Jianye/GOK 2676 2022; Wang, Yi/MTB 8098 2025
OI Xiang, Peng/0000 0003 3409 5012; 
FU National Key Research and Development Program of China, Stem Cell and
   Translational Research [2018YFA0107200, 2017YFA0103403, 2017YFA0103802];
   Strategic Priority Research Program of the Chinese Academy of Sciences
   [XDA16010103, XDA16020701]; National Natural Science Foundation of China
   [81730005, 31771616, 81802402, 81971372]; Key Research and Development
   Program of Guangdong Province [2016B030229002, 2017B020231001,
   2019B020234001, 2019B020236002, 2019B020235002]; Key Scientific and
   Technological Program of Guangzhou City [201803040011, 201704020223];
   Fundamental Research Funds for the Central Universities [19ykpy158];
   Research Start up Fund of the Seventh Affiliated Hospital, Sun YatSen
   University [393011]
FX This study was supported by grants from the National Key Research and
   Development Program of China, Stem Cell and Translational Research
   (2018YFA0107200, 2017YFA0103403, 2017YFA0103802), the Strategic Priority
   Research Program of the Chinese Academy of Sciences (XDA16010103,
   XDA16020701), the National Natural Science Foundation of China
   (81730005, 31771616, 81802402, 81971372), the Key Research and
   Development Program of Guangdong Province (2016B030229002,
   2017B020231001, 2019B020234001, 2019B020236002, 2019B020235002), the Key
   Scientific and Technological Program of Guangzhou City (201803040011,
   201704020223), the Fundamental Research Funds for the Central
   Universities (19ykpy158), and the Research Start up Fund of the Seventh
   Affiliated Hospital, Sun YatSen University (393011). The funders had no
   role in the design of the study, data collection, data analysis,
   interpretation, or the writing of this report.
CR Abou Ezzi G, 2019, STEM CELL REP, V13, P48, DOI 10.1016/j.stemcr.2019.05.017
   Adams GB, 2006, NATURE, V439, P599, DOI 10.1038/nature04247
   Anthony BA, 2014, TRENDS IMMUNOL, V35, P32, DOI 10.1016/j.it.2013.10.002
   Bataller A, 2019, LEUKEMIA, V33, P1076, DOI 10.1038/s41375 019 0420 1
   Bhagat TD, 2013, BLOOD, V121, P2875, DOI 10.1182/blood 2011 12 397067
   Birgegård G, 2005, ONCOLOGY BASEL, V68, P3, DOI 10.1159/000083128
   Blank U, 2015, BLOOD, V125, P3542, DOI 10.1182/blood 2014 12 618090
   Byfield SD, 2004, MOL PHARMACOL, V65, P744, DOI 10.1124/mol.65.3.744
   Caro JJ, 2001, CANCER AM CANCER SOC, V91, P2214, DOI 10.1002/1097 0142(20010615)91:12<2214::AID CNCR1251>3.0.CO;2 P
   Ceglia I, 2016, EXP HEMATOL, V44, P1138, DOI 10.1016/j.exphem.2016.08.007
   Chen K, 2009, P NATL ACAD SCI USA, V106, P17413, DOI 10.1073/pnas.0909296106
   Chen L, 2018, BIOMED PHARMACOTHER, V101, P670, DOI 10.1016/j.biopha.2018.02.090
   Comazzetto S, 2019, CELL STEM CELL, V24, P477, DOI 10.1016/j.stem.2018.11.022
   Crane GM, 2017, NAT REV IMMUNOL, V17, P573, DOI 10.1038/nri.2017.53
   Dallas SL, 2002, J BIOL CHEM, V277, P21352, DOI 10.1074/jbc.M111663200
   Decker M, 2017, NAT CELL BIOL, V19, P677, DOI 10.1038/ncb3530
   Doleschel D, 2015, THERANOSTICS, V5, P905, DOI 10.7150/thno.11304
   Duan XH, 2016, THERANOSTICS, V6, P2183, DOI 10.7150/thno.17140
   Gad SC, 2006, INT J TOXICOL, V25, P499, DOI 10.1080/10915810600961531
   Gomes AC, 2016, EXP HEMATOL, V44, P85, DOI 10.1016/j.exphem.2015.11.007
   Gore AJ, 2016, J CLIN INVEST, V126, P2774, DOI 10.1172/JCI88840
   Himburg HA, 2018, CELL STEM CELL, V23, P370, DOI 10.1016/j.stem.2018.07.003
   Iwayama T, 2015, GENE DEV, V29, P1106, DOI 10.1101/gad.260554.115
   Janssens K, 2000, NAT GENET, V26, P273, DOI 10.1038/81563
   Joyce CE, 2019, J CLIN INVEST, V129, P3821, DOI 10.1172/JCI125375
   Jung SY, 2020, INVEST NEW DRUG, V38, P812, DOI 10.1007/s10637 019 00835 y
   Katz LH, 2016, CANCER LETT, V379, P166, DOI 10.1016/j.canlet.2016.03.033
   Kelley RK, 2019, CLIN TRANSL GASTROEN, V10, DOI 10.14309/ctg.0000000000000056
   Kilgour RD, 2010, J CACHEXIA SARCOPENI, V1, P177, DOI 10.1007/s13539 010 0016 0
   King TE, 2014, NEW ENGL J MED, V370, P2083, DOI 10.1056/NEJMoa1402582
   Kollet O, 2007, ANNU REV IMMUNOL, V25, P51, DOI 10.1146/annurev.immunol.25.022106.141631
   Korpal M, 2009, NAT MED, V15, P960, DOI 10.1038/nm.1943
   Kramann R, 2015, CELL STEM CELL, V16, P51, DOI 10.1016/j.stem.2014.11.004
   Lazar Karsten P, 2011, VOX SANG, V101, P65, DOI 10.1111/j.1423 0410.2010.01453.x
   Ludwig H, 2004, EUR J CANCER, V40, P2293, DOI 10.1016/j.ejca.2004.06.019
   Lymperi S, 2011, BLOOD, V117, P1540, DOI 10.1182/blood 2010 05 282855
   Madeddu C, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.01294
   Manso BA, 2019, LEUKEMIA, V33, P638, DOI 10.1038/s41375 018 0280 0
   Mansour A, 2012, J EXP MED, V209, P537, DOI 10.1084/jem.20110994
   Méndez Ferrer S, 2010, NATURE, V466, P829, DOI 10.1038/nature09262
   Morrison SJ, 2014, NATURE, V505, P327, DOI 10.1038/nature12984
   Paulson RF, 2011, CURR OPIN HEMATOL, V18, P139, DOI 10.1097/MOH.0b013e32834521c8
   Pinzur L, 2018, J CACHEXIA SARCOPENI, V9, P1079, DOI 10.1002/jcsm.12342
   Pohlers D, 2009, BBA MOL BASIS DIS, V1792, P746, DOI 10.1016/j.bbadis.2009.06.004
   Quatromoni JG, 2011, J HEMATOL ONCOL, V4, DOI 10.1186/1756 8722 4 48
   Ratajczak MZ, 2013, THERANOSTICS, V3, P3, DOI 10.7150/thno.4621
   Rizzo JD, 2010, J CLIN ONCOL, V28, P4996, DOI 10.1200/JCO.2010.29.2201
   Rodgers GM, 2019, ACTA HAEMATOL BASEL, V142, P13, DOI 10.1159/000496967
   Rodgers GM, 2012, J NATL COMPR CANC NE, V10, P628, DOI 10.6004/jnccn.2012.0064
   Severe N, 2019, CELL STEM CELL, V25, P570, DOI 10.1016/j.stem.2019.06.003
   Shi LL, 2019, THERANOSTICS, V9, P4115, DOI 10.7150/thno.35131
   Soleimani M, 2009, NAT PROTOC, V4, P102, DOI 10.1038/nprot.2008.221
   Spivak JL, 2005, NAT REV CANCER, V5, P543, DOI 10.1038/nrc1648
   Suragani RNVS, 2014, NAT MED, V20, P408, DOI 10.1038/nm.3512
   Taichman RS, 2005, BLOOD, V105, P2631, DOI 10.1182/blood 2004 06 2480
   Tang Y, 2009, NAT MED, V15, P757, DOI 10.1038/nm.1979
   Visnjic D, 2004, BLOOD, V103, P3258, DOI 10.1182/blood 2003 11 4011
   Wagner M, 2014, JOVE J VIS EXP, DOI 10.3791/52347
   Wang JC, 2018, STEM CELLS, V36, P589, DOI 10.1002/stem.2769
   Waning DL, 2015, NAT MED, V21, P1262, DOI 10.1038/nm.3961
   Wei QZ, 2018, IMMUNITY, V48, P632, DOI 10.1016/j.immuni.2018.03.024
   WORTHLEY EG, 1969, TOXICOL APPL PHARM, V15, P275, DOI 10.1016/0041 008X(69)90027 1
   Xian LL, 2012, NAT MED, V18, P1095, DOI 10.1038/nm.2793
   Xie L, 2015, STEM CELLS INT, V2015, DOI 10.1155/2015/762098
   Xie YL, 2015, J CELL BIOCHEM, V116, P2735, DOI 10.1002/jcb.25233
   Yamaguchi M, 2000, NEUROREPORT, V11, P1991, DOI 10.1097/00001756 200006260 00037
   Ye F, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045 017 0401 7
   Zhang HJ, 2016, CELL STEM CELL, V18, P668, DOI 10.1016/j.stem.2016.03.002
   Zhen GH, 2013, NAT MED, V19, P704, DOI 10.1038/nm.3143
   Zhou BO, 2014, CELL STEM CELL, V15, P154, DOI 10.1016/j.stem.2014.06.008
   Zhou L, 2008, BLOOD, V112, P3434, DOI 10.1182/blood 2008 02 139824
   Zingariello M, 2013, BLOOD, V121, P3345, DOI 10.1182/blood 2012 06 439661
NR 72
TC 12
Z9 12
U1 1
U2 17
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1757 6512
J9 STEM CELL RES THER
JI Stem Cell Res. Ther.
PD JAN 18
PY 2021
VL 12
IS 1
AR 65
DI 10.1186/s13287 020 02120 9
PG 17
WC Cell & Tissue Engineering; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA PX9PF
UT WOS:000611683200001
PM 33461597
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Xu, XY
   Li, RX
   Zhou, Y
   Zou, Q
   Ding, QL
   Wang, JF
   Jin, WF
   Hua, GQ
   Gao, JJ
AF Xu, Xiaoya
   Li, Ruixia
   Zhou, Yi
   Zou, Qiong
   Ding, Qiaoling
   Wang, Jinfeng
   Jin, Weifang
   Hua, Guoqiang
   Gao, Jianjun
TI Dysregulated systemic lymphocytes affect the balance of
   osteogenic/adipogenic differentiation of bone mesenchymal stem cells
   after local irradiation
SO STEM CELL RESEARCH & THERAPY
LA English
DT Article
DE Irradiation; Lymphocytes; Bone mesenchymal stem cells (BMSCs); RUNX2;
   PPAR gamma
ID KAPPA B LIGAND; RECEPTOR ACTIVATOR; ESTROGEN DEFICIENCY;
   RADIATION THERAPY; T CELLS; BODY IRRADIATION; KEY MECHANISM; EXPRESSION;
   MARROW; MICE
AB Background: While it is known that irradiation can induce local and systemic bone loss over time, how focal irradiation induces systemic bone complications remains unclear. Immune cells are thought to be crucial to bone homeostasis, and abnormal immune cells lead to serious disruption of bone homeostasis, such as in acute lymphoblastic leukaemia. This disruption primarily occurs due to inhibition of the osteogenic differentiation of bone mesenchymal stem cells (BMSCs).
   Methods: In this study, we detected local and systemic bone loss in trabecular bone by micro computed tomography (micro CT) and measurement of peroxisome proliferator activated receptor gamma (PPAR.) and runt related transcription factor 2 (RUNX2) expression in BMSCs using real time polymerase chain reaction and western blotting. Additionally, changes in lymphocytes (B cells and CD4(+) and CD8(+) T cells) in the peripheral blood and bone marrow were analysed by flow cytometry. BMSC derived osteoblasts and adipocytes, cultured in osteogenic or adipogenic media or co cultured with lymphocytes, were detected by BCIP/NBT, Alizarin Red S and Oil Red O staining.
   Results: Focal irradiation induced local and systemic bone loss in trabecular bone. Increased PPAR. expression and decreased RUNX2 expression were observed, accompanied by upregulated adipogenesis and downregulated osteogenesis of BMSCs. B cells and CD8(+) T lymphocytes were increased in the blood and bone marrow after irradiation, while CD4(+) T lymphocytes were decreased in the blood. Inhibition of RUNX2 expression and reduction of alkaline phosphatase activity and mineralization deposits were observed in lymphocyte co cultured BMSCs, accompanied by an increase in PPAR. expression and in the number of lipid droplets.
   Conclusions: Focal irradiation induced local and systemic bone loss in trabecular bone. Increased B cells and CD8(+) T lymphocytes led to systemic bone loss by decreasing BMSC osteogenesis.
C1 [Xu, Xiaoya; Zhou, Yi; Zou, Qiong; Ding, Qiaoling; Wang, Jinfeng; Jin, Weifang; Hua, Guoqiang; Gao, Jianjun] Fudan Univ, Inst Radiat Med, Dept Radiat Biol, 2094 Xie Tu Rd, Shanghai 200032, Peoples R China.
   [Li, Ruixia] Fudan Univ, Obstet & Gynecol Hosp, 419 Fangxie Rd, Shanghai 200011, Peoples R China.
   [Gao, Jianjun] Fudan Univ, Inst Radiat Med, Dept Bone Metab, 2094 Xie Tu Rd, Shanghai 200032, Peoples R China.
C3 Fudan University; Fudan University; Fudan University
RP Gao, JJ (通讯作者)，Fudan Univ, Inst Radiat Med, Dept Radiat Biol, 2094 Xie Tu Rd, Shanghai 200032, Peoples R China.; Gao, JJ (通讯作者)，Fudan Univ, Inst Radiat Med, Dept Bone Metab, 2094 Xie Tu Rd, Shanghai 200032, Peoples R China.
EM mulei80@sina.com
RI ding, qiaoling/JDM 9742 2023; Xu, Xiaoya/AAF 1426 2020
FU National Natural Science Foundation of China [81102071]
FX This work was supported by funds from the National Natural Science
   Foundation of China (No. 81102071, to XX).
CR Baxter NN, 2005, JAMA J AM MED ASSOC, V294, P2587, DOI 10.1001/jama.294.20.2587
   Bernier J, 2004, NAT REV CANCER, V4, P737, DOI 10.1038/nrc1451
   Cao X, 2011, P NATL ACAD SCI USA, V108, P1609, DOI 10.1073/pnas.1015350108
   Carbonneau CL, 2012, BLOOD, V119, P717, DOI 10.1182/blood 2011 06 361626
   Cenci S, 2000, J CLIN INVEST, V106, P1229, DOI 10.1172/JCI11066
   Chen Z, 2009, OSTEOPOROSIS INT, V20, P527, DOI 10.1007/s00198 008 0721 0
   D'Amelio P, 2008, BONE, V43, P92, DOI 10.1016/j.bone.2008.02.017
   Despars G, 2013, PLOS ONE, V8, P1
   Georgiou KR, 2012, AM J STEM CELLS, V1, P205
   Giuliani N, 2002, BLOOD, V100, P4615, DOI 10.1182/blood 2002 04 1121
   Grahnemo L, 2015, J ENDOCRINOL, V224, P97, DOI 10.1530/JOE 14 0508
   Han X, 2009, ORAL MICROBIOL IMMUN, V24, P190, DOI 10.1111/j.1399 302X.2008.00494.x
   Han XZ, 2013, INFECT IMMUN, V81, P1502, DOI 10.1128/IAI.00043 13
   Hopewell JW, 2003, MED PEDIATR ONCOL, V41, P208, DOI 10.1002/mpo.10338
   Hui SK, 2010, AM J OBSTET GYNECOL, V203, DOI 10.1016/j.ajog.2010.06.001
   Igdem S, 2010, INT J RADIAT ONCOL, V77, P818, DOI 10.1016/j.ijrobp.2009.05.059
   Ignatowska Jankowska B, 2009, J PHYSIOL PHARMACOL, V60, P99
   Ikushima H, 2006, GYNECOL ONCOL, V103, P1100, DOI 10.1016/j.ygyno.2006.06.038
   Islander U, 2011, MOL CELL ENDOCRINOL, V335, P14, DOI 10.1016/j.mce.2010.05.018
   Jia D, 2011, RADIAT RES, V176, P624, DOI 10.1667/RR2505.1
   Jones JR, 2005, P NATL ACAD SCI USA, V102, P6207, DOI 10.1073/pnas.0306743102
   Kanematsu M, 2000, J BONE MINER RES, V15, P1321, DOI 10.1359/jbmr.2000.15.7.1321
   Komori T, 2002, J CELL BIOCHEM, V87, P1, DOI 10.1002/jcb.10276
   Komori T, 2008, FRONT BIOSCI LANDMRK, V13, P898, DOI 10.2741/2730
   Kondo H, 2009, RADIAT RES, V171, P283, DOI 10.1667/RR1463.1
   Kristensen B, 1996, BREAST CANCER RES TR, V39, P321, DOI 10.1007/BF01806160
   Kwon JW, 2008, AM J ROENTGENOL, V191, P987, DOI 10.2214/AJR.07.3634
   Li Y, 2007, BLOOD, V109, P3839, DOI 10.1182/blood 2006 07 037994
   Mitchell MJ, 1998, RADIOGRAPHICS, V18, P1125, DOI 10.1148/radiographics.18.5.9747611
   Mori G, 2013, CLIN DEV IMMUNOL, V2013, DOI [10.1155/2013/720504, DOI 10.1155/2013/720504.]
   Nishiyama K., 1992, EUR RADIOL, V2, P322
   Onal M, 2012, J BIOL CHEM, V287, P29851, DOI 10.1074/jbc.M112.377945
   Pacifici R, 2008, CELL IMMUNOL, V252, P68, DOI 10.1016/j.cellimm.2007.06.008
   PIERCE SM, 1992, INT J RADIAT ONCOL, V23, P915, DOI 10.1016/0360 3016(92)90895 O
   Qin L, 2006, BONE, V39, P863, DOI 10.1016/j.bone.2006.04.018
   Qiu J, 2012, ENVIRON TOXICOL PHAR, V33, P149, DOI 10.1016/j.etap.2011.12.009
   Roggia C, 2001, P NATL ACAD SCI USA, V98, P13960, DOI 10.1073/pnas.251534698
   Ryan MR, 2005, P NATL ACAD SCI USA, V102, P16735, DOI 10.1073/pnas.0505168102
   Su WX, 2012, INT J RADIAT BIOL, V88, P635, DOI 10.3109/09553002.2012.703362
   Tang WJ, 2010, CALCIFIED TISSUE INT, V86, P404, DOI 10.1007/s00223 010 9355 2
   Tyagi AM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044552
   Wheater G, 2011, OSTEOPOROSIS INT, V22, P3067, DOI 10.1007/s00198 011 1607 0
   Willey JS, 2008, RADIAT RES, V170, P388, DOI 10.1667/RR1388.1
   Williams HJ, 2006, EUR RADIOL, V16, P619, DOI 10.1007/s00330 005 0010 7
   Wright LE, 2015, J BONE MINER RES, V30, P1268, DOI 10.1002/jbmr.2458
   Yang GC, 2015, STEM CELLS INT, V2015, DOI 10.1155/2015/162410
   Yeo L, 2011, ANN RHEUM DIS, V70, P2022, DOI 10.1136/ard.2011.153312
NR 47
TC 22
Z9 25
U1 1
U2 14
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1757 6512
J9 STEM CELL RES THER
JI Stem Cell Res. Ther.
PD MAR 20
PY 2017
VL 8
AR 71
DI 10.1186/s13287 017 0527 0
PG 11
WC Cell & Tissue Engineering; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA EO8ZG
UT WOS:000396978400004
PM 28320453
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Goulet, JL
   Buta, E
   Brennan, M
   Heapy, A
   Fraenkel, L
AF Goulet, Joseph L.
   Buta, Eugenia
   Brennan, Matthew
   Heapy, Alicia
   Fraenkel, Liana
TI Discontinuing a non steroidal anti inflammatory drug (NSAID) in patients
   with knee osteoarthritis: Design and protocol of a placebo controlled,
   noninferiority, randomized withdrawal trial
SO CONTEMPORARY CLINICAL TRIALS
LA English
DT Article
DE Knee osteoarthritis; Randomized clinical trial; Withdrawal trial;
   Noninferiority trial; NSAID
ID QUALITY OF LIFE; VETERANS AFFAIRS; PAIN; MANAGEMENT; EFFICACY; SAFETY;
   INTERVENTIONS; METAANALYSIS; REDUCTION; MELOXICAM
AB Background: Knee osteoarthritis (OA) is the most common cause of knee pain in older adults. Despite the limited data supporting their use, non steroidal anti inflammatory drugs (NSAID) are among the most commonly prescribed medications for knee OA. The use of NSAIDs for knee pain warrants careful examination because of toxicity associated with this class of medications.
   Methods: We describe the design of a placebo controlled, noninferiority, randomized withdrawal trial to examine discontinuation of an NSAID in patients with painful knee OA. Participants will be veterans enrolled in the VA Healthcare System with knee OA pain despite NSAID use and/or relatively higher risk of NSAID toxicity. After a two week run in period where eligible subjects will replace their current NSAID with the study NSAID (meloxicam), those remaining eligible (target N = 544) will be randomized to receive four weeks of either placebo or continued meloxicam. The primary outcome is knee pain (Western Ontario and McMaster Universities Osteoarthritis Index pain subscale, range 0 20) at four weeks post randomization. The primary hypothesis is that placebo will be noninferior to (that is, not much worse than) meloxicam within a non inferiority margin of 1. Secondary outcomes include lower extremity disability, global impression of change, adherence to study medication and use of co therapies.
   Discussion: This study is the first clinical trial to date examining the effects of withdrawing an NSAID for OA knee pain. If successful, this trial will provide evidence against the continued use of NSAIDs in patients with OA knee pain.
C1 [Goulet, Joseph L.; Buta, Eugenia; Brennan, Matthew; Heapy, Alicia; Fraenkel, Liana] VA Connecticut Healthcare Syst Pain Res Informat, Hlth Serv Res & Dev Ctr Innovat, West Haven, CT USA.
   [Goulet, Joseph L.] Yale Sch Med, Dept Emergency Med, New Haven, CT USA.
   [Buta, Eugenia] Yale Sch Publ Hlth, Dept Biostat, New Haven, CT USA.
   [Heapy, Alicia] Yale Sch Med, Dept Psychiat, New Haven, CT USA.
   [Fraenkel, Liana] Yale Sch Med, Dept Internal Med, New Haven, CT USA.
C3 US Department of Veterans Affairs; Veterans Health Administration (VHA);
   VA Connecticut Healthcare System; Yale University; Yale University; Yale
   University; Yale University
RP Goulet, JL (通讯作者)，VA Connecticut Healthcare Syst, 950 Campbell Ave 35a,B35a, West Haven, CT 06516 USA.
EM Joseph.Goulet@VA.gov
OI Buta, Eugenia/0000 0001 8478 4233; Goulet, Joseph
   Lucien/0000 0002 0842 804X
FU Veterans Health Administration Health Services Research and Development
   Service [IIR 11 113, CRE 12 012]
FX This study was supported by awards from the Veterans Health
   Administration Health Services Research and Development Service IIR
   11 113 (Fraenkel, PI; Brennan), and CRE 12 012 (Goulet, PI; Buta, and
   Heapy).
CR Abraham NS, 2010, CIRCULATION, V122, P2619, DOI 10.1161/CIR.0b013e318202f701
   Alderson P, 2003, BRIT MED J, V326, P475, DOI 10.1136/bmj.326.7387.475
   Allen KD, 2008, J RHEUMATOL, V35, P1102
   Allen KD, 2007, J RHEUMATOL, V34, P2132
   Allen KD, 2010, ANN INTERN MED, V153, P570, DOI 10.7326/0003 4819 153 9 201011020 00006
   AMERY W, 1975, J CLIN PHARMACOL, V15, P674, DOI 10.1002/j.1552 4604.1975.tb05919.x
   Angst F, 2001, ANN RHEUM DIS, V60, P834
   Asch SM, 2004, ANN INTERN MED, V141, P938, DOI 10.7326/0003 4819 141 12 200412210 00010
   Barkin Robert L, 2004, Am J Ther, V11, P124, DOI 10.1097/00045391 200403000 00007
   Bennell KL, J SCI MED SPORT, V14, P4
   Bjordal JM, 2007, EUR J PAIN, V11, P125, DOI 10.1016/j.ejpain.2006.02.013
   Bjordal JM, 2004, BMJ BRIT MED J, V329, P1317, DOI 10.1136/bmj.38273.626655.63
   Briggs A, 1999, ANN PHARMACOTHER, V33, P1154, DOI 10.1345/aph.18411
   Christensen R, 2007, ANN RHEUM DIS, V66, P433, DOI 10.1136/ard.2006.065904
   D'Agostino RB, 2003, STAT MED, V22, P169, DOI 10.1002/sim.1425
   Davies Neal M, 2006, Expert Rev Neurother, V6, P1643, DOI 10.1586/14737175.6.11.1643
   Dieppe P, 2004, BMJ BRIT MED J, V329, P31, DOI 10.1136/bmj.329.7456.31
   Distel M, 1996, BRIT J RHEUMATOL, V35, P68
   Dominick KL, 2006, J RHEUMATOL, V33, P348
   Fabsitz RR, 1997, J SLEEP RES, V6, P50, DOI 10.1046/j.1365 2869.1997.00026.x
   Felson DT, 2000, ANN INTERN MED, V133, P726, DOI 10.7326/0003 4819 133 9 200011070 00015
   Hawker GA, 2011, OSTEOARTHR CARTILAGE, V19, P366, DOI 10.1016/j.joca.2011.01.021
   Hawker GA, 2009, CURR OPIN RHEUMATOL, V21, P507, DOI 10.1097/BOR.0b013e32832e99d7
   Hernandez Diaz S., 2001, AM J MED S3A, V110, p7S
   Jordan KP, 2009, CURR OPIN RHEUMATOL, V21, P525, DOI 10.1097/BOR.0b013e32832e45fc
   JUNIPER EF, 1994, J CLIN EPIDEMIOL, V47, P81, DOI 10.1016/0895 4356(94)90036 1
   Katz N, 2009, CLIN J PAIN, V25, P797, DOI 10.1097/AJP.0b013e3181b12dec
   Kazis LE, 1998, ARCH INTERN MED, V158, P626, DOI 10.1001/archinte.158.6.626
   KEEFE FJ, 1990, BEHAV THER, V21, P49, DOI 10.1016/S0005 7894(05)80188 1
   KEEFE FJ, 1990, BEHAV THER, V21, P435, DOI 10.1016/S0005 7894(05)80357 0
   Kerns RD, 2014, HEALTH PSYCHOL, V33, P938, DOI 10.1037/a0034406
   Kidd BL, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2147
   KOPEC JA, 1993, J CLIN EPIDEMIOL, V46, P959, DOI 10.1016/0895 4356(93)90163 U
   Lee C, 2004, ARTHRIT RHEUM ARTHR, V51, P746, DOI 10.1002/art.20698
   LITTLE RJA, 1995, J AM STAT ASSOC, V90, P1112, DOI 10.2307/2291350
   Maisiak R, 1996, ARTHRITIS RHEUM US, V39, P1391, DOI 10.1002/art.1780390818
   Mazzuca SA, 2004, ARTHRIT RHEUM ARTHR, V51, P933, DOI 10.1002/art.20831
   McConnell S, 2001, ARTHRIT RHEUM ARTHR, V45, P453, DOI 10.1002/1529 0131(200110)45:5<453::AID ART365>3.0.CO;2 W
   Meek IL, 2010, PHARMACEUTICALS, V3, P2146, DOI 10.3390/ph3072146
   Messier SP, 2010, CLIN GERIATR MED, V26, P461, DOI 10.1016/j.cger.2010.05.001
   Otis J.D., 2007, Managing chronic pain: A cognitive behavioral therapy approach
   Porcheret M, 2007, RHEUMATOLOGY, V46, P1694, DOI 10.1093/rheumatology/kem232
   Pruessner JC, 2003, PSYCHONEUROENDOCRINO, V28, P916, DOI 10.1016/S0306 4530(02)00108 7
   RENE J, 1992, ARTHRITIS RHEUM, V35, P511, DOI 10.1002/art.1780350504
   Rogers J.C., 2003, ARTHRITIS RHEUM, V49, pS80
   Rubin DB, 1996, J AM STAT ASSOC, V91, P473, DOI 10.1080/01621459.1996.10476908
   Schafer J. L., 1997, ANAL INCOMPLETE MULT
   Scott Long J., 1997, ADV QUANTITATIVE TEC
   SHERBOURNE CD, 1991, SOC SCI MED, V32, P705, DOI 10.1016/0277 9536(91)90150 B
   Strand Vibeke, 2004, Curr Rheumatol Rep, V6, P20, DOI 10.1007/s11926 004 0080 6
   Vitiello MV, 2009, J CLIN SLEEP MED, V5, P355
   Vonkeman HE, 2010, SEMIN ARTHRITIS RHEU, V39, P294, DOI 10.1016/j.semarthrit.2008.08.001
   Yocum D, 2000, ARCH INTERN MED, V160, P2947, DOI 10.1001/archinte.160.19.2947
   Zhao SZ, 1999, PHARMACOTHERAPY, V19, P1269, DOI 10.1592/phco.19.16.1269.30879
NR 54
TC 6
Z9 6
U1 0
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1551 7144
EI 1559 2030
J9 CONTEMP CLIN TRIALS
JI Contemp. Clin. Trials
PD FEB
PY 2018
VL 65
BP 1
EP 7
DI 10.1016/j.cct.2017.11.020
PG 7
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED); Social Science Citation Index (SSCI)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA FW3IX
UT WOS:000425201200001
PM 29198731
DA 2025 08 17
ER

PT J
AU Susa, M
   Choy, E
   Liu, XZ
   Schwab, J
   Hornicek, FJ
   Mankin, H
   Duan, ZF
AF Susa, Michiro
   Choy, Edwin
   Liu, Xianzhe
   Schwab, Joseph
   Hornicek, Francis J.
   Mankin, Henry
   Duan, Zhenfeng
TI Cyclin G Associated Kinase Is Necessary for Osteosarcoma Cell
   Proliferation and Receptor Trafficking
SO MOLECULAR CANCER THERAPEUTICS
LA English
DT Article
ID GROWTH FACTOR RECEPTOR; POTENTIAL THERAPEUTIC TARGET; CLATHRIN COATED
   VESICLES; FACTOR I; PHASE I; MULTIDRUG RESISTANCE; MULTIPLE MYELOMA;
   DRUG RESISTANCE; AUXILIN; EXPRESSION
AB Osteosarcoma is the most frequent primary malignant bone tumor among the children. The advent of neoadjuvant chemotherapy significantly improved the prognosis of patients with osteosarcoma in the 1980s, but it has since plateaued in the past decades. Recently, one of the most researched areas in sarcoma treatment is tyrosine kinases. Here, we describe research on a serine/threonine kinase, cyclin G associated kinase (GAK), which has not been reported in osteosarcoma previously. In this study, a lentiviral based human shRNA library was utilized to screen for kinases in KHOS and U 2OS osteosarcoma cells. The expression of GAK was examined in osteosarcoma and the effect on cell proliferation was analyzed by GAK siRNA knockdown. The level ofGAKexpression and its correlation to prognosis was analyzed in osteosarcoma tissue microarray. The effect of GAK depletion on insulin like growth factor and epidermal growth factor receptor mediated signal transduction was analyzed by Western blot. We observed that GAK was overexpressed in both osteosarcoma cell lines and tissue samples when compared with human osteoblasts. GAK knockdown by siRNA decreased cell proliferation in both drug sensitive and multidrug resistant osteosarcoma cell lines. Immunohistochemistry of osteosarcoma tissue microarray revealed that overexpression of GAK was associated with poor prognosis. Finally, knockdown of GAK resulted in alterations of receptor trafficking and several downstream proteins. In conclusion, our results suggest that osteosarcoma cell proliferation and survival are dependent on GAK. These findings may lead to the development of new therapeutic options for osteosarcoma. Mol Cancer Ther; 9(12); 3342  50. (C) 2010 AACR.
C1 [Susa, Michiro; Choy, Edwin; Liu, Xianzhe; Schwab, Joseph; Hornicek, Francis J.; Mankin, Henry; Duan, Zhenfeng] Massachusetts Gen Hosp, Ctr Sarcoma & Connect Tissue Oncol, Sarcoma Biol Lab, Boston, MA 02114 USA.
   [Susa, Michiro; Liu, Xianzhe; Schwab, Joseph; Hornicek, Francis J.; Duan, Zhenfeng] Massachusetts Gen Hosp, Dept Orthopaed Surg, Boston, MA 02114 USA.
C3 Harvard University; Harvard University Medical Affiliates; Massachusetts
   General Hospital; Harvard University; Harvard University Medical
   Affiliates; Massachusetts General Hospital
RP Duan, ZF (通讯作者)，Massachusetts Gen Hosp, Ctr Sarcoma & Connect Tissue Oncol, Sarcoma Biol Lab, 55 Fruit St Jackson 1115, Boston, MA 02114 USA.
EM zduan@partners.org
RI ; Susa, Michiro/L 2291 2013
OI HUITRON, EFREN/0009 0008 2046 3359; Choy, Edwin/0000 0001 9896 8084;
   Hornicek, Francis/0000 0002 6916 8042
FU Gaetagno and Wechsler funds; Kenneth Stanton Fund; National Cancer
   Institute [R01 CA119617]; Sarcoma Foundation of America; Jennifer Hunter
   Yates Sarcoma Foundation
FX This project was supported by a grant from the Gaetagno and Wechsler
   funds. Support has also been provided by the Kenneth Stanton Fund. Z.
   Duan is supported, in part, by a grant from the National Cancer
   Institute (Nanotechnology Platform Partnership), R01 CA119617, and
   Sarcoma Foundation of America. E. Choy is supported by the Jennifer
   Hunter Yates Sarcoma Foundation.
CR AHLE S, 1990, J CELL BIOL, V111, P19, DOI 10.1083/jcb.111.1.19
   Bai T, 2010, BMC DEV BIOL, V10, DOI 10.1186/1471 213X 10 7
   Burrow S, 1998, J SURG ONCOL, V69, P21, DOI 10.1002/(SICI)1096 9098(199809)69:1<21::AID JSO5>3.0.CO;2 M
   Demetri GD, 2002, NEW ENGL J MED, V347, P472, DOI 10.1056/NEJMoa020461
   Duan ZF, 2010, CANCER LETT, V293, P220, DOI 10.1016/j.canlet.2010.01.014
   Duan ZF, 2009, MOL CANCER THER, V8, P2122, DOI 10.1158/1535 7163.MCT 09 0115
   Freeman SS, 2008, CANCER AM CANCER SOC, V113, P1453, DOI 10.1002/cncr.23782
   Gall WE, 2000, CURR BIOL, V10, P1349, DOI 10.1016/S0960 9822(00)00771 5
   Garland LL, 2006, CLIN CANCER RES, V12, P5182, DOI 10.1158/1078 0432.CCR 06 0214
   Greener T, 2000, J BIOL CHEM, V275, P1365, DOI 10.1074/jbc.275.2.1365
   Greener T, 2001, NAT CELL BIOL, V3, P215, DOI 10.1038/35055137
   Hughes DPM, 2004, CANCER RES, V64, P2047, DOI 10.1158/0008 5472.CAN 03 3096
   Jiang RF, 2000, J BIOL CHEM, V275, P8439, DOI 10.1074/jbc.275.12.8439
   Jimeno A, 2008, J CLIN ONCOL, V26, P5504, DOI 10.1200/JCO.2008.17.9788
   Kanaoka Y, 1997, FEBS LETT, V402, P73, DOI 10.1016/S0014 5793(96)01484 6
   KAPPEL CC, 1994, CANCER RES, V54, P2803
   Kaye SB, 2008, J CLIN ONCOL, V26, P2616, DOI 10.1200/JCO.2008.16.2123
   Kimura SH, 1997, GENOMICS, V44, P179, DOI 10.1006/geno.1997.4873
   Korolchuk VI, 2002, TRAFFIC, V3, P428, DOI 10.1034/j.1600 0854.2002.30606.x
   Krishna R, 2000, EUR J PHARM SCI, V11, P265, DOI 10.1016/S0928 0987(00)00114 7
   MacEwen EG, 2004, J CELL BIOCHEM, V92, P77, DOI 10.1002/jcb.20046
   Mross K, 2008, J CLIN ONCOL, V26, P5511, DOI 10.1200/JCO.2008.16.1547
   Newmyer SL, 2003, DEV CELL, V4, P929, DOI 10.1016/S1534 5807(03)00157 6
   Oda Yoshinao, 1995, General and Diagnostic Pathology, V141, P97
   Ottaviani G, 2009, CANCER TREAT RES, V152, P3, DOI 10.1007/978 1 4419 0284 9_1
   Pishvaee B, 2000, NAT CELL BIOL, V2, P958, DOI 10.1038/35046619
   POLLAK MN, 1990, JNCI J NATL CANCER I, V82, P301, DOI 10.1093/jnci/82.4.301
   Ray MR, 2006, INT J CANCER, V118, P1108, DOI 10.1002/ijc.21469
   Schöffski P, 2009, ONCOLOGIST, V14, P559, DOI 10.1634/theoncologist.2009 0010
   Sonneveld P, 2001, BRIT J HAEMATOL, V115, P895, DOI 10.1046/j.1365 2141.2001.03171.x
   Susa M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010764
   Susa M, 2009, BMC CANCER, V9, DOI 10.1186/1471 2407 9 399
   Szakács G, 2006, NAT REV DRUG DISCOV, V5, P219, DOI 10.1038/nrd1984
   Tiedemann RE, 2010, BLOOD, V115, P1594, DOI 10.1182/blood 2009 09 243980
   Umeda A, 2000, EUR J CELL BIOL, V79, P336, DOI 10.1078/S0171 9335(04)70037 0
   Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086
   Wen YH, 2007, HUM PATHOL, V38, P1184, DOI 10.1016/j.humpath.2007.01.002
   Yagüe E, 2007, CANCER RES, V67, P1130, DOI 10.1158/0008 5472.CAN 06 2574
   Yang C, 2010, CARCINOGENESIS, V31, P552, DOI 10.1093/carcin/bgp330
   Yim YI, 2005, J CELL SCI, V118, P2405, DOI 10.1242/jcs.02356
   Zhang CX, 2005, TRAFFIC, V6, P1103, DOI 10.1111/j.1600 0854.2005.00346.x
   Zhang L, 2004, P NATL ACAD SCI USA, V101, P10296, DOI 10.1073/pnas.0403175101
NR 42
TC 26
Z9 28
U1 0
U2 5
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106 4404 USA
SN 1535 7163
EI 1538 8514
J9 MOL CANCER THER
JI Mol. Cancer Ther.
PD DEC
PY 2010
VL 9
IS 12
BP 3342
EP 3350
DI 10.1158/1535 7163.MCT 10 0637
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 694KL
UT WOS:000285296300023
PM 20881269
OA Green Submitted, Bronze
DA 2025 08 17
ER

PT J
AU Cao, LH
   Liu, W
   Zhong, YC
   Zhang, YR
   Gao, D
   He, TT
   Liu, Y
   Zou, Z
   Mo, YQ
   Peng, SP
   Shuai, CJ
AF Cao, Lihua
   Liu, Wei
   Zhong, Yancheng
   Zhang, Yanru
   Gao, Dan
   He, Tiantian
   Liu, Ying
   Zou, Zi
   Mo, Yuqing
   Peng, Shuping
   Shuai, Cijun
TI Linc02349 promotes osteogenesis of human umbilical cord derived stem
   cells by acting as a competing endogenous RNA for miR 25 3p and
   miR 33b 5p
SO CELL PROLIFERATION
LA English
DT Article
DE Linc02349; miR 25 3p and miR 33b 5p; osteogenic differentiation
ID LONG NONCODING RNAS; HUMAN BONE MARROW; MOUSE MODEL; DIFFERENTIATION;
   TRANSPLANTATION; ROLES; OSTEOBLASTOGENESIS; PLURIPOTENCY; BIOGENESIS;
   EXPRESSION
AB Objectives Increasing evidences suggest that inducing mesenchymal stem cells to differentiate into osteoblasts has been as an especially important component in the prevention and therapy for degenerative bone disease. Here, we identify a novel lncRNA, linc02349, which increases significantly during osteogenic differentiation.
   Materials and methods Human umbilical cord derived stem cells (hUC MSCs) and dental pulp mesenchymal stem cells were used. Overexpression and knockdown of linc02349 in cell lines were generated using lentiviral mediated gene delivery method. Bioinformatics prediction, Ago2 RIP assay and dual luciferase reporter system were employed to examine miRNA which interacts with linc02349. The RNA FISH assay was performed to identify the subcelluar location of linc02349. Alizarin Red S staining, ALP staining and qPCR were applied to identify the osteogenic differentiation. The potential linc02349 regulated genes, miR 25 3p and miR 33b 5p, were explored by ChIP, RIP and Western blotting assays. Micro CT was used to measure the osteogenic content in bone formation assay in vivo.
   Results Linc02349 overexpression improves osteogenic differentiation by in vitro and in vivo analysis. Mechanistically, linc02349 acts as a molecular sponge for miR 25 3p and miR 33b 5p to control expression abundance of SMAD5 and Wnt10b, respectively, which eventually activated Dlx5/OSX pathway and hence promoted osteogenic differentiation. In addition, we revealed that STAT3 interacts with linc02349 promoter region and positively regulates the linc02349 transcriptional activity.
   Conclusion These findings identify that linc02349 modulates the osteogenic differentiation through acting as a sponge RNA of miR 25 3p and miR 33b 5p and regulating SMAD5 and Wnt10b, and proposed a new interaction between STAT3 and linc02349, which could be a potential target in the process the osteogenesis of hUC MSCs for future clinical application.
C1 [Cao, Lihua; Zhong, Yancheng; Zhang, Yanru; Gao, Dan; He, Tiantian; Liu, Ying; Zou, Zi; Mo, Yuqing; Peng, Shuping] Cent South Univ, Hunan Canc Hosp, NHC Key Lab Carcinogenesis, Changsha, Hunan, Peoples R China.
   [Cao, Lihua; Zhong, Yancheng; Zhang, Yanru; Gao, Dan; He, Tiantian; Liu, Ying; Zou, Zi; Mo, Yuqing; Peng, Shuping] Cent South Univ, Affiliated Canc Hosp, Xiangya Sch Med, Changsha, Peoples R China.
   [Cao, Lihua; Zhong, Yancheng; Zhang, Yanru; Gao, Dan; He, Tiantian; Liu, Ying; Zou, Zi; Mo, Yuqing; Peng, Shuping] Cent South Univ, Sch Basic Med Sci, Changsha, Peoples R China.
   [Cao, Lihua; Peng, Shuping] Cent South Univ, Canc Res Inst, Key Lab Carcinogenesis & Canc Invas, Chinese Minist Educ, Changsha, Peoples R China.
   [Liu, Wei] Cent South Univ, XiangYa Hosp 2, Nation Clin Res Ctr Metab Dis, Inst Metab & Endocrinol, Changsha, Peoples R China.
   [Shuai, Cijun] Jiangxi Univ Sci & Technol, Inst Bioaddit Mfg, Nanchang, Jiangxi, Peoples R China.
   [Shuai, Cijun] Cent South Univ, State Key Lab High Performance Complex Mfg, Changsha, Peoples R China.
C3 Central South University; Central South University; Central South
   University; Central South University; Central South University; Jiangxi
   University of Science & Technology; Central South University
RP Peng, SP (通讯作者)，Cent South Univ, Hunan Canc Hosp, NHC Key Lab Carcinogenesis, Changsha, Hunan, Peoples R China.; Peng, SP (通讯作者)，Cent South Univ, Affiliated Canc Hosp, Xiangya Sch Med, Sch Basic Med Sci, Changsha, Hunan, Peoples R China.; Shuai, CJ (通讯作者)，Jiangxi Univ Sci & Technol, Ganzhou 341000, Peoples R China.
EM shuping@csu.edu.cn; shuai@csu.edu.cn
RI Liu, Wei/HTL 7329 2023; Shuai, Cijun/AAC 9740 2019
OI Peng, shuping/0000 0001 9567 9295; 
FU Program of Introducing Talents of Discipline to Universities [111 2 12];
   Hunan Provincial Innovation Foundation for Postgraduate [CX20190232];
   National Natural Science Foundation of China [81572577, 81871494,
   81871498]; Hunan Province Natural Science Foundation of China
   [2016JJ1027]
FX Program of Introducing Talents of Discipline to Universities,
   Grant/Award Number: No.111 2 12; Hunan Provincial Innovation Foundation
   for Postgraduate, Grant/Award Number: No.CX20190232; National Natural
   Science Foundation of China, Grant/Award Number: No.81871494; National
   Natural Science Foundation of China, Grant/Award Number: No. 81871498;
   the National Natural Science Foundation of China, Grant/Award Number:
   No.81572577; Hunan Province Natural Science Foundation of China,
   Grant/Award Number: No.2016JJ1027
CR Aghebati Maleki L, 2019, J CELL PHYSIOL, V234, P8570, DOI 10.1002/jcp.27833
   Baksh D, 2007, STEM CELLS, V25, P1384, DOI 10.1634/stemcells.2006 0709
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092 8674(04)00045 5
   Bennett CN, 2005, P NATL ACAD SCI USA, V102, P3324, DOI 10.1073/pnas.0408742102
   Cawthorn WP, 2012, BONE, V50, P477, DOI 10.1016/j.bone.2011.08.010
   Chang YJ, 2006, STEM CELLS, V24, P679, DOI 10.1634/stemcells.2004 0308
   Confalonieri D, 2018, TISSUE ENG PART B RE, V24, P155, DOI [10.1089/ten.teb.2017.0305, 10.1089/ten.TEB.2017.0305]
   Do DV, 2013, GENE DEV, V27, P1378, DOI 10.1101/gad.221176.113
   Ding DC, 2015, CELL TRANSPLANT, V24, P339, DOI 10.3727/096368915X686841
   El Omar R, 2014, TISSUE ENG PART B RE, V20, P523, DOI [10.1089/ten.teb.2013.0664, 10.1089/ten.TEB.2013.0664]
   Fatica A, 2014, NAT REV GENET, V15, P7, DOI 10.1038/nrg3606
   Feng P, 2020, VIRTUAL PHYS PROTOTY, V15, P211, DOI 10.1080/17452759.2020.1719457
   Feng P, 2019, APPL MATER TODAY, V17, P216, DOI 10.1016/j.apmt.2019.08.005
   Flynn RA, 2014, CELL STEM CELL, V14, P752, DOI 10.1016/j.stem.2014.05.014
   He SW, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 2148 2
   Jia B, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1161 9
   Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870
   Kariminekoo S, 2016, ARTIF CELL NANOMED B, V44, P749, DOI 10.3109/21691401.2015.1129620
   Khan A, 2018, NUCLEIC ACIDS RES, V46, pD260, DOI [10.1093/nar/gkx1126, 10.1093/nar/gkx1188]
   Kiernan J, 2016, STEM CELL TRANSL MED, V5, P683, DOI 10.5966/sctm.2015 0231
   Kim HS, 2017, STEM CELLS, V35, P248, DOI 10.1002/stem.2401
   Komori T, 2017, ADV EXP MED BIOL, V962, P83, DOI 10.1007/978 981 10 3233 2_6
   Krampera M, 2006, BONE, V39, P678, DOI 10.1016/j.bone.2006.04.020
   Langlais D, 2012, MOL CELL, V47, P38, DOI 10.1016/j.molcel.2012.04.021
   Lee JM, 2012, INT IMMUNOPHARMACOL, V13, P219, DOI 10.1016/j.intimp.2012.03.024
   Lee MH, 2003, BIOCHEM BIOPH RES CO, V309, P689, DOI 10.1016/j.bbrc.2003.08.058
   Liang WJ, 2020, CELL BIOL INT, V44, P317, DOI 10.1002/cbin.11235
   Liao YP, 2019, J CELL BIOCHEM, V120, P9572, DOI 10.1002/jcb.28234
   Liu B, 2004, INT J BIOCHEM CELL B, V36, P766, DOI 10.1016/S1357 2725(03)00250 4
   Marino L, 2019, INT J STEM CELLS, V12, P218, DOI 10.15283/ijsc18034
   Peng SP, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/8273648
   Quinn JJ, 2016, NAT REV GENET, V17, P47, DOI 10.1038/nrg.2015.10
   Rajasingh J, 2007, CIRC RES, V101, P910, DOI 10.1161/CIRCRESAHA.107.156786
   Salmena L, 2011, CELL, V146, P353, DOI 10.1016/j.cell.2011.07.014
   Shuai CJ, 2020, MATER DESIGN, V190, DOI 10.1016/j.matdes.2020.108564
   Shuai CJ, 2020, MATER RES EXPRESS, V7, DOI 10.1088/2053 1591/ab62f5
   Shuai CJ, 2020, POLYMERS BASEL, V12, DOI 10.3390/polym12010199
   Shuai CJ, 2020, MAT SCI ENG C MATER, V108, DOI 10.1016/j.msec.2019.110486
   Sun H, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045 018 0648 7
   Thein Han W, 2011, TISSUE ENG PT A, V17, P2943, DOI 10.1089/ten.tea.2010.0674
   Vescini F, 2016, J ENDOCRINOL INVEST, V39, P807, DOI 10.1007/s40618 016 0434 8
   Wang CG, 2019, EXP MOL PATHOL, V107, P77, DOI 10.1016/j.yexmp.2019.01.012
   Weng JQ, 2017, IMPLANT DENT, V26, P178, DOI 10.1097/ID.0000000000000569
   Wu H, 2017, BMC CELL BIOL, V18, DOI 10.1186/s12860 017 0145 9
   Xiao N, 2013, CYTOTHERAPY, V15, P1374, DOI 10.1016/j.jcyt.2013.06.013
   Yan PX, 2017, CURR OPIN GENET DEV, V46, P170, DOI 10.1016/j.gde.2017.07.009
   Yang YP, 2009, CYTOKINE, V46, P137, DOI 10.1016/j.cyto.2008.12.015
   Yang YW, 2020, MATER CHEM FRONT, V4, P973, DOI 10.1039/c9qm00772e
   Yu S, 2013, CELLS TISSUES ORGANS, V197, P209, DOI 10.1159/000343740
   Zhang ZX, 1997, J BIOL CHEM, V272, P30607, DOI 10.1074/jbc.272.49.30607
   Zhong YC, 2019, ONCOGENE, V38, P1381, DOI 10.1038/s41388 018 0512 9
NR 51
TC 54
Z9 55
U1 1
U2 27
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0960 7722
EI 1365 2184
J9 CELL PROLIFERAT
JI Cell Prolif.
PD MAY
PY 2020
VL 53
IS 5
AR e12814
DI 10.1111/cpr.12814
EA APR 2020
PG 14
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA LU9UR
UT WOS:000529150000001
PM 32346990
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Nguyen, KN
   Graner, AN
   Fringuello, AR
   Zizzo, Z
   Valenzuela, L
   Anyanwu, K
   Lillehei, KO
   Youssef, AS
   Guzman, S
   Coughlan, C
   Graner, MW
AF Nguyen, Khoa N.
   Graner, Arin N.
   Fringuello, Anthony R.
   Zizzo, Zoe
   Valenzuela, Lorena
   Anyanwu, Kamara
   Lillehei, Kevin O.
   Youssef, A. Samy
   Guzman, Samuel
   Coughlan, Christina
   Graner, Michael W.
TI Extracellular Vesicles from a Novel Chordoma Cell Line, ARF 8, Promote
   Tumorigenic Microenvironmental Changes When Incubated with the Parental
   Cells and with Human Osteoblasts
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE chordoma; cell line; extracellular vesicles (EVs); proteomics;
   integrins; epithelial to mesenchymal transition (EMT); extracellular
   matrix; secretome; collagen; migration
ID SKULL BASE; EXPRESSION; CHONDROSARCOMA; MATRIX; CANCER; TUMORS; SPINE;
   BONE
AB Chordomas are rare, generally slow growing spinal tumors that nonetheless exhibit progressive characteristics over time, leading to malignant phenotypes and high recurrence rates, despite maximal therapeutic interventions. The tumors are notoriously resistant to therapies and are often located in regions that complicate achieving gross total resections. Cell lines from these tumors are rare as well. We cultured a new chordoma cell line (ARF 8) derived from an extensive clival chordoma that extended back to the cervical spine. We characterized the ARF 8 cellular and extracellular vesicle (EV) proteomes, as well as the impacts of ARF 8 EVs on the proteomes and secretomes of recipient cells (both ARF 8 and human osteoblasts) in autocrine and paracrine settings. Our proteomic analyses suggested roles for transforming growth factor beta (TGFB/TGF beta), cell matrix interactions involving the epithelial to mesenchymal transition (EMT), and cell extracellular matrix interactions in cell migration, consistent with a migratory/metastatic tumor phenotype. We demonstrated that ARF 8 tumor cell migration was dependent on general (arginine glycine aspartic acid [RGD] based) integrin activity and that ARF 8 EVs could promote such migration. ARF 8 EVs also prompted proteomic/secretomic changes in human osteoblast cells, again with indications that cell cell and cell extracellular matrix interactions would be activated. All the characteristics typically associated with chordomas as cancers migration and invasion, therapeutic resistance, metastatic potential can be driven by tumor EVs. Overall, ARF 8 EVs promoted predicted tumorigenic phenotypes in recipient cells and suggested novel therapeutic targets for chordomas.
C1 [Nguyen, Khoa N.; Graner, Arin N.; Fringuello, Anthony R.; Lillehei, Kevin O.; Youssef, A. Samy; Graner, Michael W.] Univ Colorado, Anschutz Med Campus, Dept Neurosurg, Aurora, CO 80045 USA.
   [Nguyen, Khoa N.] Univ Colorado, Sch Med, 13001 E 17th Pl, Aurora, CO 80045 USA.
   [Zizzo, Zoe] Colorado Coll, Dept Biochem, 14 E Cache La Poudre St, Colorado Springs, CO 80903 USA.
   [Valenzuela, Lorena] Regis Univ, Dept Biomed Sci, 3333 Regis Blvd, Denver, CO 80221 USA.
   [Anyanwu, Kamara] Claremont McKenna Coll, Dept Biomed Sci, 888 N Columbia Ave, Claremont, CA 91711 USA.
   [Guzman, Samuel] Univ Colorado, Dept Pathol, Anschutz Med Campus, Aurora, CO 80045 USA.
   [Coughlan, Christina] Univ Colorado, Anschutz Med Campus, Dept Neurol, Aurora, CO 80045 USA.
   [Fringuello, Anthony R.] State Univ New York Downstate Hlth Sci Univ, Dept Neurosci, 450 Clarkson Ave Suite J, Brooklyn, NY 11203 USA.
C3 University of Colorado System; University of Colorado Anschutz Medical
   Campus; University of Colorado System; University of Colorado Anschutz
   Medical Campus; Colorado College; Regis University; Claremont Colleges;
   Claremont McKenna College; Claremont Graduate University; University of
   Colorado System; University of Colorado Anschutz Medical Campus;
   University of Colorado System; University of Colorado Anschutz Medical
   Campus; State University of New York (SUNY) System; SUNY Downstate
   Health Sciences University
RP Graner, MW (通讯作者)，Univ Colorado, Anschutz Med Campus, Dept Neurosurg, Aurora, CO 80045 USA.
EM khoa.n.nguyen@cuanschutz.edu; arin.graner@cuanschutz.edu;
   anthony.fringuello@gmail.com; z_zizzo@coloradocollege.edu;
   lvalenzuela004@regis.edu; canyanwu22@students.claremontmckenna.edu;
   kevin.lillehei@cuanschutz.edu; samy.youssef@cuanschutz.edu;
   samuel.j.guzman@cuanschutz.edu; christina.coughlan@cuanschutz.edu;
   michael.graner@cuanschutz.edu
RI Coughlan, Christina/HZL 8805 2023
OI Coughlan, Christina/0000 0002 7229 7056; Zizzo, Zoe/0000 0003 4492 075X;
   Graner, Michael/0000 0002 3097 0257; Nguyen, Khoa/0000 0002 5236 3159
FU NIH; University of Colorado Department of Neurosurgery Research Funds
   [SCR_021988, RRID: SCR_021984]; Cancer Center Support Grant
   [P30CA046934]; University of Colorado School of Medicine's Research
   Track program; University of Colorado Cancer Center's Cancer Research
   Experience for Undergraduates (CREU) program [R25CA240122]; University
   of Colorado Cancer Center;  [NIMH1R21MH118174 01];  [4R33MH118174]
FX The study was funded by NIH grants NIMH1R21MH118174 01 and 4R33MH118174,
   the University of Colorado Department of Neurosurgery Research Funds,
   and Tissue Bank. We thank Dr. Monika Dzieciatkowska of the Mass
   Spectrometry Proteomics Shared Resource Facility (RRID: SCR_021988) and
   the Genomics Shared Resource (RRID: SCR_021984), acknowledging the
   Cancer Center Support Grant (P30CA046934). Khoa N. Nguyen is a member of
   the University of Colorado School of Medicine's Research Track program.
   Khoa N. Nguyen and Zoe Zizzo were fellows of the University of Colorado
   Cancer Center's Cancer Research Experience for Undergraduates (CREU)
   program. CREU is supported by R25CA240122 and the University of Colorado
   Cancer Center.
CR Arab T, 2021, J EXTRACELL VESICLES, V10, DOI 10.1002/jev2.12079
   Asao T, 2023, EXTRACELL VESICLES C, V4, P461, DOI 10.20517/evcna.2023.37
   Aydemir E, 2024, J NEUROL SURG PART B, V85, P161, DOI 10.1055/a 2018 4627
   Bachurski D, 2019, J EXTRACELL VESICLES, V8, DOI 10.1080/20013078.2019.1596016
   Bai JW, 2022, NEUROSURG REV, V45, P1451, DOI 10.1007/s10143 021 01576 4
   Barber SM, 2021, J CLIN MED, V10, DOI 10.3390/jcm10051054
   Brown NJ, 2023, J NEURO ONCOL, DOI 10.1007/s11060 023 04477 2
   Carminati L, 2020, AM J PHYSIOL CELL PH, V319, pC980, DOI 10.1152/ajpcell.00383.2020
   Carvalho AS, 2020, FRONT BIOSCI LANDMRK, V25, P398, DOI 10.2741/4811
   Chen M, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00961
   Choi JH, 2021, ADV ANAT PATHOL, V28, P119, DOI 10.1097/PAP.0000000000000293
   Cichon MA, 2014, CELL ADHES MIGR, V8, P588, DOI 10.4161/19336918.2014.972788
   Dridi M, 2021, ANN DIAGN PATHOL, V53, DOI 10.1016/j.anndiagpath.2021.151760
   FALCONER MA, 1968, J NEUROSURG, V29, P261, DOI 10.3171/jns.1968.29.3.0261
   FIROOZNIA H, 1976, AM J ROENTGENOL, V127, P797, DOI 10.2214/ajr.127.5.797
   Frezza AM, 2019, CURR OPIN ONCOL, V31, P114, DOI 10.1097/CCO.0000000000000502
   Gao XZ, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.1002742
   Graner MW, 2019, ANNU REV GENOM HUM G, V20, P331, DOI 10.1146/annurev genom 083118 015324
   Graner MW, 2018, DIAGNOSTIC AND THERAPEUTIC APPLICATIONS OF EXOSOMES IN CANCER, P325, DOI 10.1016/B978 0 12 812774 2.00018 3
   Harryman WL, 2017, NEOPLASIA, V19, P919, DOI 10.1016/j.neo.2017.08.005
   Heery CR, 2016, ONCOL THER, V4, P35, DOI 10.1007/s40487 016 0016 0
   Hellwinkel JE, 2016, NEURO ONCOLOGY, V18, P497, DOI 10.1093/neuonc/nov170
   Huang B, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13885
   International Agency for Research on Cancer, 2020, WHO classification of tumours editorial board, soft tissue and bone tumours, V3
   Jeppesen DK, 2023, TRENDS CELL BIOL, V33, P667, DOI 10.1016/j.tcb.2023.01.002
   Jia YW, 2022, THERANOSTICS, V12, P6548, DOI 10.7150/thno.74305
   Jin MC, 2024, NEUROSURG FOCUS, V56, DOI 10.3171/2024.2.FOCUS2417
   Kaplan Z, 2021, LIFE BASEL, V11, DOI 10.3390/life11101099
   Kapp TG, 2017, SCI REP UK, V7, DOI 10.1038/srep39805
   Kawaai K, 2024, CELL ONCOL, V47, P1663, DOI 10.1007/s13402 024 00946 6
   Khan Z, 2016, CELL TISSUE RES, V365, P657, DOI 10.1007/s00441 016 2474 y
   Kremenevski N, 2020, NEUROENDOCRINOLOGY, V110, P836, DOI 10.1159/000509386
   Liang CC, 2007, NAT PROTOC, V2, P329, DOI 10.1038/nprot.2007.30
   Lin CY, 2014, BIOCHEM PHARMACOL, V91, P522, DOI 10.1016/j.bcp.2014.08.008
   Lin CY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067990
   Lin CY, 2013, INT J MOL SCI, V14, P15459, DOI 10.3390/ijms140815459
   Liu YY, 2018, PEERJ, V6, DOI 10.7717/peerj.4928
   López Cuevas P, 2021, DIS MODEL MECH, V14, DOI 10.1242/dmm.047001
   Ludwig BS, 2021, CANCERS, V13, DOI 10.3390/cancers13071711
   McMaster ML, 2001, CANCER CAUSE CONTROL, V12, P1, DOI 10.1023/A:1008947301735
   Meng T, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00030
   Miettinen M, 2015, AM J SURG PATHOL, V39, P1305, DOI 10.1097/PAS.0000000000000462
   Miladinovic V, 2025, SKELETAL RADIOL, V54, P287, DOI 10.1007/s00256 024 04742 z
   Naka T, 2008, HUM PATHOL, V39, P217, DOI 10.1016/j.humpath.2007.06.005
   Narita D, 2016, NEOPLASMA, V63, P141, DOI 10.4149/neo_2016_017
   Nieberler M, 2017, CANCERS, V9, DOI 10.3390/cancers9090116
   Noya C, 2023, CANCERS, V15, DOI 10.3390/cancers15184493
   Oushy S, 2018, PHILOS T R SOC B, V372, DOI 10.1098/rstb.2016.0477
   Pang XC, 2019, PHARMACOL RES, V144, P235, DOI 10.1016/j.phrs.2019.04.030
   Pathan M, 2015, PROTEOMICS, V15, P2597, DOI 10.1002/pmic.201400515
   PINTO RS, 1975, NEURORADIOLOGY, V9, P231, DOI 10.1007/BF00333738
   Redzic JS, 2014, PHARMACOGEN PERS MED, V7, P65, DOI 10.2147/PGPM.S39768
   Rinner B, 2012, INT J ONCOL, V40, P443, DOI 10.3892/ijo.2011.1235
   Scheil Bertram S, 2014, INT J ONCOL, V44, P1041, DOI 10.3892/ijo.2014.2268
   Seguin L, 2015, TRENDS CELL BIOL, V25, P234, DOI 10.1016/j.tcb.2014.12.006
   Shen J, 2013, SPINE, V38, P2165, DOI 10.1097/BRS.0000000000000010
   Stacchiotti S, 2015, LANCET ONCOL, V16, pE71, DOI 10.1016/S1470 2045(14)71190 8
   Takacs GP, 2023, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.993444
   Ulici V, 2022, ARCH PATHOL LAB MED, V146, P386, DOI 10.5858/arpa.2020 0258 RA
   Varsavsky M, 2013, OSTEOPOROSIS INT, V24, P713, DOI 10.1007/s00198 012 2012 z
   Vasaikar SV, 2021, BRIT J CANCER, V124, P259, DOI 10.1038/s41416 020 01178 9
   Vuong HG, 2022, WORLD NEUROSURG, V162, pE635, DOI 10.1016/j.wneu.2022.03.088
   Walcott BP, 2012, LANCET ONCOL, V13, pE69, DOI 10.1016/S1470 2045(11)70337 0
   Wang B, 2017, BIOSCIENCE REP, V37, DOI 10.1042/BSR20171092
   Wang Y, 2012, J NEUROSURG SPINE, V17, P292, DOI 10.3171/2012.7.SPINE12175
   Xavier CPR, 2020, CELLS BASEL, V9, DOI 10.3390/cells9051141
   Yáñez Mó M, 2015, J EXTRACELL VESICLES, V4, DOI 10.3402/jev.v4.27066
NR 67
TC 0
Z9 0
U1 0
U2 1
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
SN 1661 6596
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD DEC
PY 2024
VL 25
IS 23
AR 12731
DI 10.3390/ijms252312731
PG 25
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA P2R7Q
UT WOS:001376453100001
PM 39684443
OA gold, Green Submitted
DA 2025 08 17
ER

PT J
AU Simon, D
   Minopoulou, I
   Kemenes, S
   Bayat, S
   Tascilar, K
   Mutlu, MY
   Valor Méndez, L
   Krönke, G
   Hueber, AJ
   Schett, G
   Kleyer, A
AF Simon, David
   Minopoulou, Ioanna
   Kemenes, Stephan
   Bayat, Sara
   Tascilar, Koray
   Mutlu, Melek Yalcin
   Valor Mendez, Larissa
   Kroenke, Gerhard
   Hueber, Axel J.
   Schett, Georg
   Kleyer, Arnd
TI Baricitinib Improves Bone Properties and Biomechanics in Patients With
   Rheumatoid Arthritis: Results of the Prospective Interventional BARE
   BONE Trial
SO ARTHRITIS & RHEUMATOLOGY
LA English
DT Article
ID NECROSIS FACTOR INHIBITORS; COMPUTED TOMOGRAPHY; MINERAL DENSITY; DISTAL
   RADIUS; ADALIMUMAB; DISEASE; DAMAGE; OSTEOBLASTS; PROGRESSION; STRENGTH
AB Objective. Rheumatoid arthritis (RA) is characterized by erosive joint damage, deterioration of bone mass, and biomechanics. Preclinical evidence suggests a beneficial effect of Janus kinase inhibition (JAKi) on bone properties, but clinical data are scarce to date. In this study, we evaluated the effect of JAKi through baricitinib (BARI) on 1) volumetric bone mineral density (vBMD), bone microstructure, biomechanics, and erosion repair and 2) synovial inflammation in RA patients.
   Methods. Prospective, single arm, interventional, open label, single center phase 4 study in RA patients with pathological bone status and clinical indication of JAKi (BARE BONE trial). Participants received BARI (4 mg/day) over 52 weeks. To assess bone properties and synovial inflammation, high resolution computed tomography scans and magnetic resonance imaging were performed at baseline (BL), week 24, and week 52. Clinical response and safety were monitored.
   Results. Thirty RA patients were included. BARI significantly improved disease activity (Disease Activity Score in 28 joints using the erythrocyte sedimentation rate: 4.82 +/  0.90 to 2.71 +/  0.83) and synovial inflammation (RAMRIS synovitis score: 5.3 [4.2] to 2.7 [3.5]). We observed a significant improvement in trabecular vBMD with a mean change of 6.11 mgHA/mm3 (95% confidence interval [95% CI] 0.01 12.26). Biomechanical properties also improved with mean change from baseline in estimated stiffness of 2.28 kN/mm (95% CI 0.30 4.25) and estimated failure load of 98.8 N (95% CI 15.9 181.7). The number and size of erosions in the metacarpal joints remained stable. No new safety signals with BARI treatment were observed.
   Conclusion. Bones of RA patients improve with BARI therapy, as shown by an increase in trabecular bone mass and an improvement of biomechanical properties.
C1 [Simon, David; Minopoulou, Ioanna; Kemenes, Stephan; Bayat, Sara; Tascilar, Koray; Mutlu, Melek Yalcin; Valor Mendez, Larissa; Kroenke, Gerhard; Schett, Georg; Kleyer, Arnd] Friedrich Alexander Univ Erlangen Nurnberg FAU, Dept Internal Med Rheumatol & Immunol 3, Erlangen, Germany.
   [Simon, David; Minopoulou, Ioanna; Kemenes, Stephan; Bayat, Sara; Tascilar, Koray; Mutlu, Melek Yalcin; Valor Mendez, Larissa; Kroenke, Gerhard; Schett, Georg; Kleyer, Arnd] Univ Klinikum Erlangen, Erlangen, Germany.
   [Simon, David; Minopoulou, Ioanna; Kemenes, Stephan; Bayat, Sara; Tascilar, Koray; Mutlu, Melek Yalcin; Valor Mendez, Larissa; Kroenke, Gerhard; Schett, Georg; Kleyer, Arnd] FAU Erlangen Nurnberg, Deutsch Zentrum Immuntherapie, Erlangen, Germany.
   [Hueber, Axel J.] Paracelsus Med Univ, Div Rheumatol, Klinikum Nurnberg, Nurnberg, Germany.
C3 University of Erlangen Nuremberg; University of Erlangen Nuremberg;
   University of Erlangen Nuremberg; Klinikum Nurnberg Nord
RP Kleyer, A (通讯作者)，Friedrich Alexander Univ Erlangen Nurnberg FAU, Dept Internal Med Rheumatol & Immunol 3, Erlangen, Germany.; Kleyer, A (通讯作者)，Univ Klinikum Erlangen, Erlangen, Germany.; Kleyer, A (通讯作者)，FAU Erlangen Nurnberg, Deutsch Zentrum Immuntherapie, Erlangen, Germany.
EM arnd.kleyer@uk erlangen.de
RI Simon, David/MCJ 7757 2025; Krönke, Gerhard/C 6615 2014; Kemenes,
   Stephan/LLK 8905 2024; TASCILAR, Koray/F 9070 2015; Tascilar,
   Koray/F 9070 2015; Kronke, Gerhard/C 6615 2014; Kleyer,
   Arnd/AAB 2292 2022
OI Simon, David/0000 0001 8310 7820; Kleyer, Arnd/0000 0002 2026 7728;
   TASCILAR, Koray/0000 0002 8109 826X; Valor Mendez,
   Larissa/0000 0002 4872 3502; Schett, Georg/0000 0001 8740 9615; Kronke,
   Gerhard/0000 0002 7566 4325; 
FU We would like to thank Dr. Dagmar Werner, Louis Schuster, and Fabian
   Hartmann for administrative study support and Dr. Klaus Engel (Siemens
   Healthineers) for technical support to create cinematic rendering images
   and videos. We thank Louis Schuster (LS) fo
FX We would like to thank Dr. Dagmar Werner, Louis Schuster, and Fabian
   Hartmann for administrative study support and Dr. Klaus Engel (Siemens
   Healthineers) for technical support to create cinematic rendering images
   and videos. We thank Louis Schuster (LS) for assisting in the HR pQCT
   analysis. Dr. Hueber was involved in the conception of the study and the
   first draft of the study protocol. Open Access funding enabled and
   organized by Projekt DEAL.
CR Adam S, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aay4447
   Batteux B, 2021, BONE, V153, DOI 10.1016/j.bone.2021.116137
   Boutroy S, 2005, J CLIN ENDOCR METAB, V90, P6508, DOI 10.1210/jc.2005 1258
   Boutroy S, 2008, J BONE MINER RES, V23, P392, DOI 10.1359/JBMR.071108
   BOYCE BF, 1989, ENDOCRINOLOGY, V125, P1142, DOI 10.1210/endo 125 3 1142
   Boyle DL, 2015, ANN RHEUM DIS, V74, P1311, DOI 10.1136/annrheumdis 2014 206028
   Ciobanu DA, 2020, EXP THER MED, V20, P3498, DOI 10.3892/etm.2020.8982
   Damerau A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21239004
   Dohn UM, 2009, ANN RHEUM DIS, V68, P1585, DOI 10.1136/ard.2008.097048
   Dougados M, 2017, ANN RHEUM DIS, V76, P88, DOI 10.1136/annrheumdis 2016 210094
   Favalli EG, 2012, THER ADV MUSCULOSKEL, V4, P213, DOI 10.1177/1759720X12449082
   Finzel S, 2019, ANN RHEUM DIS, V78, P1186, DOI 10.1136/annrheumdis 2018 214894
   Finzel S, 2013, ANN RHEUM DIS, V72, P396, DOI 10.1136/annrheumdis 2011 201075
   Finzel S, 2011, ANN RHEUM DIS, V70, P1587, DOI 10.1136/ard.2010.148395
   GENANT HK, 1985, ORTHOP CLIN N AM, V16, P557
   GOUGH AKS, 1994, LANCET, V344, P23, DOI 10.1016/S0140 6736(94)91049 9
   Ideguchi H, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1943
   ISHIMI Y, 1990, J IMMUNOL, V145, P3297
   Ito M, 1999, OSTEOPOROSIS INT, V10, P377, DOI 10.1007/s001980050243
   Janckila AJ, 2001, CLIN CHEM, V47, P74
   Kim S, 2003, GENE DEV, V17, P1979, DOI 10.1101/gad.1119303
   Kleyer A, 2014, ANN RHEUM DIS, V73, P854, DOI 10.1136/annrheumdis 2012 202958
   Krieckaert CLM, 2013, RHEUMATOLOGY, V52, P547, DOI 10.1093/rheumatology/kes320
   LaBranche TP, 2012, ARTHRITIS RHEUM US, V64, P3531, DOI 10.1002/art.34649
   Lam J, 2000, J CLIN INVEST, V106, P1481, DOI 10.1172/JCI11176
   MacNeil JA, 2008, BONE, V42, P1203, DOI 10.1016/j.bone.2008.01.017
   McInnes IB, 2007, NAT REV IMMUNOL, V7, P429, DOI 10.1038/nri2094
   Murakami K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181126
   Odegård S, 2006, ARTHRITIS RHEUM, V54, P68, DOI 10.1002/art.21548
   Ostergaard M, 2003, J RHEUMATOL, V30, P1385
   Pawar A, 2021, ACR OPEN RHEUMATOL, V3, P531, DOI 10.1002/acr2.11292
   Rau R, 1996, ARTHRITIS RHEUM, V39, P162, DOI 10.1002/art.1780390123
   Seeman E, 2008, J BONE MINER METAB, V26, P1, DOI 10.1007/s00774 007 0793 5
   Shimizu T, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075 017 1430 x
   Simon D, 2019, ARTHRITIS RES THER, V21, DOI 10.1186/s13075 019 1938 3
   Simon D, 2017, J BONE MINER RES, V32, P722, DOI 10.1002/jbmr.3025
   Siu S, 2015, ARTHRIT CARE RES, V67, P754, DOI 10.1002/acr.22519
   Stemmler F, 2018, ANN RHEUM DIS, V77, P973, DOI 10.1136/annrheumdis 2017 212404
   Takayanagi H, 2009, NAT REV RHEUMATOL, V5, P667, DOI 10.1038/nrrheum.2009.217
   Taylor PC, 2017, NEW ENGL J MED, V376, P652, DOI 10.1056/NEJMoa1608345
   Udagawa N, 2000, ENDOCRINOLOGY, V141, P3478, DOI 10.1210/en.141.9.3478
   van Staa TP, 2006, ARTHRITIS RHEUM US, V54, P3104, DOI 10.1002/art.22117
   Vilayphiou N, 2010, BONE, V46, P1030, DOI 10.1016/j.bone.2009.12.015
   Welsing PMJ, 2001, ARTHRITIS RHEUM, V44, P2009, DOI 10.1002/1529 0131(200109)44:9<2009::AID ART349>3.0.CO;2 L
   Wijbrandts CA, 2009, ANN RHEUM DIS, V68, P373, DOI 10.1136/ard.2008.091611
   Yue J, 2017, ARTHRIT CARE RES, V69, P1156, DOI 10.1002/acr.23133
NR 46
TC 19
Z9 19
U1 1
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 2326 5191
EI 2326 5205
J9 ARTHRITIS RHEUMATOL
JI Arthritis Rheumatol.
PD NOV
PY 2023
VL 75
IS 11
BP 1923
EP 1934
DI 10.1002/art.42617
EA SEP 2023
PG 12
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA X7YU8
UT WOS:001069557600001
PM 37229650
OA hybrid
DA 2025 08 17
ER

PT J
AU Shimizu, S
   Okuda, N
   Kato, N
   Rittling, SR
   Okawa, A
   Shinomiya, K
   Muneta, T
   Denhardt, DT
   Noda, M
   Tsuji, K
   Asou, Y
AF Shimizu, Sadanori
   Okuda, Naoki
   Kato, Norihiko
   Rittling, Susan R.
   Okawa, Atsushi
   Shinomiya, Kenichi
   Muneta, Takeshi
   Denhardt, David T.
   Noda, Masaki
   Tsuji, Kunikazu
   Asou, Yoshinori
TI Osteopontin Deficiency Impairs Wear Debris Induced Osteolysis via
   Regulation of Cytokine Secretion From Murine Macrophages
SO ARTHRITIS AND RHEUMATISM
LA English
DT Article
ID NF KAPPA B; TITANIUM PARTICLES; INTRACELLULAR OSTEOPONTIN;
   BONE RESORPTION; GENE THERAPY; POLYETHYLENE; PHAGOCYTOSIS; ALPHA;
   ACCUMULATION; INDUCTION
AB Objective. To investigate the molecular mechanisms underlying particle induced osteolysis, we focused on osteopontin (OPN), a cytokine and cell attachment protein that is associated with macrophage chemoattractant and osteoclast activation.
   Methods. We compared OPN protein levels in human periprosthetic osteolysis tissues with those in osteoarthritis (OA) synovial tissues. To investigate the functions of OPN during particle induced osteolysis in vivo, titanium particles were implanted onto the calvaria of OPN deficient mice and their wild type (WT) littermates. Mice were killed on day 10 and evaluated immunohistologically. The effects of OPN deficiency on the secretion of inflammatory cytokines were examined using cultured bone marrow derived macrophages (BMMs). BMMs from OPN deficient and WT mice were cultured with titanium particles for 12 hours, and the concentrations of inflammatory cytokines in the conditioned media were measured by enzyme linked immunosorbent assay.
   Results. Expression of OPN protein was enhanced in human periprosthetic osteolysis tissues as compared with OA synovial tissues. In the particle induced model of osteolysis of the calvaria, bone resorption was significantly suppressed by OPN deficiency via inhibition of osteoclastogenesis, whereas an inflammatory reaction was observed regardless of the genotype. Results of immunostaining indicated that OPN protein was highly expressed in the membrane and bone surface at the area of bone resorption in WT mice. When BMMs were exposed to titanium particles, the concentration of proinflammatory cytokines, such as tumor necrosis factor alpha, interleukin 1 alpha (IL 1 alpha), IL 1 alpha, and IL 6, as well as chemotactic factors, such as monocyte chemoattractant protein 1 and macrophage inflammatory protein 1 alpha, in the conditioned medium were significantly reduced by OPN deficiency. Whereas phagocytic activity of BMMs was not attenuated by OPN deficiency, phagocytosis mediated NF kappa B activation was impaired in OPN deficient BMMs. These data indicated that OPN was implicated in the development of particle induced osteolysis via the orchestration of pro /antiinflammatory cytokines secreted from macrophages.
   Conclusion. OPN plays critical roles in wear debris induced osteolysis, suggesting that OPN is a candidate therapeutic target for periprosthetic osteolysis.
C1 [Asou, Yoshinori] Tokyo Med & Dent Univ, Dept Orthoped Surg, Bunkyo Ku, Tokyo 1138519, Japan.
   [Shimizu, Sadanori; Okuda, Naoki; Shinomiya, Kenichi; Muneta, Takeshi; Noda, Masaki; Tsuji, Kunikazu] Int Res Ctr Mol Sci Tooth & Bone Dis, Tokyo, Japan.
   [Denhardt, David T.] Rutgers State Univ, Piscataway, NJ USA.
C3 Institute of Science Tokyo; Tokyo Medical & Dental University (TMDU);
   Rutgers University System; Rutgers University New Brunswick
RP Asou, Y (通讯作者)，Tokyo Med & Dent Univ, Dept Orthoped Surg, Bunkyo Ku, 1 5 45 Yushima, Tokyo 1138519, Japan.
EM aso.orth@tmd.ac.jp
RI ; Tsuji, Kunikazu/HDM 9242 2022
OI Muneta, Takeshi/0000 0003 1018 2939; 
FU 21st Century Global Center of Excellence
FX Supported by a 21st Century Global Center of Excellence program grant.
CR Asou Y, 2001, ENDOCRINOLOGY, V142, P1325, DOI 10.1210/en.142.3.1325
   Blanchoin L, 2000, NATURE, V404, P1007, DOI 10.1038/35010008
   Caron E, 1998, SCIENCE, V282, P1717, DOI 10.1126/science.282.5394.1717
   Chellaiah MA, 2005, J BIOL CHEM, V280, P32930, DOI 10.1074/jbc.M500154200
   Chellaiah MA, 2000, J BIOL CHEM, V275, P11993, DOI 10.1074/jbc.275.16.11993
   Childs LM, 2002, J BONE MINER RES, V17, P192, DOI 10.1359/jbmr.2002.17.2.192
   Childs LM, 2001, J BONE JOINT SURG AM, V83A, P1789, DOI 10.2106/00004623 200112000 00004
   Cox D, 1997, J EXP MED, V186, P1487, DOI 10.1084/jem.186.9.1487
   Denhardt DT, 1998, J CELL BIOCHEM, P92, DOI 10.1002/(SICI)1097 4644(1998)72:30/31+<92::AID JCB13>3.0.CO;2 A
   DENHARDT DT, 1993, FASEB J, V7, P1475, DOI 10.1096/fasebj.7.15.8262332
   Denhardt DT, 2001, J CLIN INVEST, V107, P1055, DOI 10.1172/JCI12980
   Goodman SB, 2005, CLIN ORTHOP RELAT R, P39, DOI 10.1097/01.blo.0000149998.88218.05
   Goodman SB, 1998, J BONE JOINT SURG BR, V80B, P531, DOI 10.1302/0301 620X.80B3.8158
   Granchi D, 2005, BIOMATERIALS, V26, P2371, DOI 10.1016/j.biomaterials.2004.07.045
   Granchi D, 1998, J BONE JOINT SURG BR, V80B, P912, DOI 10.1302/0301 620X.80B5.8513
   Green TR, 1998, BIOMATERIALS, V19, P2297, DOI 10.1016/S0142 9612(98)00140 9
   GROVE M, 1993, MOL CELL BIOL, V13, P5276, DOI 10.1128/MCB.13.9.5276
   Harris WH, 2001, CLIN ORTHOP RELAT R, P66
   Jacobs JJ, 2001, CLIN ORTHOP RELAT R, P71
   KANEHISA J, 1988, BONE, V9, P73, DOI 10.1016/8756 3282(88)90106 8
   Kurtz SM, 1999, BIOMATERIALS, V20, P1659, DOI 10.1016/S0142 9612(99)00053 8
   Merkel KD, 1999, AM J PATHOL, V154, P203, DOI 10.1016/S0002 9440(10)65266 2
   Nakashima Y, 1999, J BONE JOINT SURG BR, V81B, P155, DOI 10.1302/0301 620X.81B1.8884
   O'Regan A, 2000, INT J EXP PATHOL, V81, P373, DOI 10.1046/j.1365 2613.2000.00163.x
   PATARCA R, 1993, CRIT REV IMMUNOL, V13, P225
   Ragab AA, 1999, J ORTHOPAED RES, V17, P803, DOI 10.1002/jor.1100170603
   Rittling SR, 1999, EXP NEPHROL, V7, P103
   Rittling SR, 1998, J BONE MINER RES, V13, P1101, DOI 10.1359/jbmr.1998.13.7.1101
   Saeki Y, 2003, BRIT J HAEMATOL, V123, P263, DOI 10.1046/j.1365 2141.2003.04589.x
   Schwarz EM, 2000, J ORTHOPAED RES, V18, P849, DOI 10.1002/jor.1100180602
   Shanbhag AS, 1997, CLIN ORTHOP RELAT R, P33
   Soloviev A, 2005, J ORTHOP RES, V23, P1258, DOI 10.1016/j.orthres.2005.03.019
   Standal T, 2004, HAEMATOLOGICA, V89, P174
   Suzuki K, 2002, J BONE MINER RES, V17, P1486, DOI 10.1359/jbmr.2002.17.8.1486
   Taki N, 2005, J ORTHOP RES, V23, P376, DOI 10.1016/j.orthres.2004.08.023
   Taki N, 2007, BONE, V40, P1276, DOI 10.1016/j.bone.2006.12.053
   Tatro JM, 2007, J ORTHOP RES, V25, P361, DOI 10.1002/jor.20289
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   UEDA A, 1994, J IMMUNOL, V153, P2052
   Ulrich Vinther M, 2002, J BONE JOINT SURG AM, V84A, P1405, DOI 10.2106/00004623 200208000 00017
   von Knoch M, 2004, J ORTHOP RES, V22, P237, DOI 10.1016/j.orthres.2003.08.013
   WILLERT HG, 1977, J BIOMED MATER RES, V11, P157, DOI 10.1002/jbm.820110202
   Xu GW, 2005, J CLIN INVEST, V115, P1060
   Yoshitake H, 1999, P NATL ACAD SCI USA, V96, P8156, DOI 10.1073/pnas.96.14.8156
   Yumoto K, 2002, P NATL ACAD SCI USA, V99, P4556, DOI 10.1073/pnas.052523599
   Zohar R, 2000, J CELL PHYSIOL, V184, P118, DOI 10.1002/(SICI)1097 4652(200007)184:1<118::AID JCP13>3.0.CO;2 Y
   Zreiqat H, 2003, J BIOMED MATER RES A, V65A, P109, DOI 10.1002/jbm.a.10441
NR 47
TC 29
Z9 32
U1 1
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0004 3591
EI 1529 0131
J9 ARTHRITIS RHEUM US
JI Arthritis Rheum.
PD MAY
PY 2010
VL 62
IS 5
BP 1329
EP 1337
DI 10.1002/art.27400
PG 9
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA 619LT
UT WOS:000279432400016
PM 20155835
DA 2025 08 17
ER

PT J
AU De Leo, S
   Trevisan, M
   Moneta, C
   Colombo, C
AF De Leo, Simone
   Trevisan, Matteo
   Moneta, Claudia
   Colombo, Carla
TI Endocrine related adverse conditions induced by tyrosine kinase
   inhibitors
SO ANNALES D ENDOCRINOLOGIE
LA English
DT Article
DE Tyrosine kinase inhibitors; Adverse events; Endocrine; Endocrinopathy
ID RENAL CELL CARCINOMA; SUNITINIB INDUCED HYPOTHYROIDISM;
   MEDULLARY THYROID CANCER; REGORAFENIB INDUCED HYPOTHYROIDISM;
   GASTROINTESTINAL STROMAL TUMOR; PHASE II TRIAL; JAPANESE PATIENTS;
   HEPATOCELLULAR CARCINOMA; SURVIVAL ANALYSIS; OPEN LABEL
AB Tyrosine kinase inhibitors (TKIs) have improved outcome for many tumors. Although better tolerated than cytotoxic chemotherapy, they may cause several adverse events (AEs) and various endocrine related toxicities have been reported under TKI treatment. The toxicity profile varies between the different TKI compounds. This review focuses on the main endocrinopathies caused by TKIs. Thyroid dysfunction and, in particular, hypothyroidism are the most frequent and best described. Several potential mecha nisms have been hypothesized, including thyroid gland dysfunction, hormone metabolism impairment and hypothalamus pituitary thyroid axis imbalance. TKIs have been reported to influence almost all glands. In particular, they are associated with adrenal insufficiency, growth retardation due to growth hormone (GH) and/or insulin like growth factor 1 (IGF1) deficiency, hypogonadism, and male and female fertility impairment. TKIs may affect bone metabolism, in particular decreasing osteoclastogenesis and bone turnover and, in turn, they may cause secondary hyperparathyroidism. Hypocalcemia has been reported under lenvatinib and vandetanib treatment and parathyroid hormone (PTH) dependent and PTH independent mechanisms have been hypothesized. Metabolic alterations during TKI treatment range from hypoglycemia with imatinib and dasatinib to hyperglycemia with nilotinib; dyslipidemia improved with imatinib and worsened with nilotinib, sunitinib, pazopanib, sorafenib, and famitinib. Endocrine related AEs should be managed by dedicated endocrinologists. Hormone deficiencies are eas ily managed by replacement therapy, while endocrine hyperfunction may be improved by symptomatic treatment. Severe situations should be managed in coordination with the oncologist, trying to limit the need for TKI dose reduction or interruption.(c) 2023 Elsevier Masson SAS. All rights reserved.
C1 [De Leo, Simone; Colombo, Carla] IRCCS Ist Auxol Italiano, Dept Endocrine & Metab Dis, Endocrine Oncol Unit, Milan, Italy.
   [Trevisan, Matteo; Moneta, Claudia; Colombo, Carla] Univ Milan, Dept Pathophysiol & Transplantat, Milan, Italy.
C3 IRCCS Istituto Auxologico Italiano; University of Milan
RP De Leo, S (通讯作者)，IRCCS Ist Auxol Italiano, Dept Endocrine & Metab Dis, Endocrine Oncol Unit, Milan, Italy.
EM s.deleo@auxologico.it
RI de leo, simone/D 5947 2015; Colombo, Carla/J 9777 2018; Trevisan,
   Matteo/AAV 4599 2021
OI de leo, simone/0000 0002 1534 8216; Colombo, Carla/0000 0003 0716 481X;
   Moneta, Claudia/0000 0001 8728 7144; 
FU Italian Ministry of Health [THY CANC 2022.03.08.03]
FX This study was partially funded by the Italian Ministry of Health
   (THY CANC 2022.03.08.03).
CR Abdel Rahman O, 2014, EXPERT REV ANTICANC, V14, P1063, DOI 10.1586/14737140.2014.929501
   Abdulrahman RM, 2010, J CLIN ENDOCR METAB, V95, P3758, DOI 10.1210/jc.2009 2507
   Afshar M, 2019, EXPERT REV ANTICANC, V19, P529, DOI 10.1080/14737140.2019.1609355
   Akaza H, 2015, JPN J CLIN ONCOL, V45, P576, DOI 10.1093/jjco/hyv045
   Alemán JO, 2014, ENDOCR RELAT CANCER, V21, pR247, DOI 10.1530/ERC 12 0400
   Alshamsan Bader, 2021, Cancer Manag Res, V13, P6755, DOI 10.2147/CMAR.S323499
   Badran A, 2020, JCO GLOB ONCOL, V6, P19, DOI 10.1200/JGO.19.00111
   Baldazzi V, 2012, CANCER AM CANCER SOC, V118, P3165, DOI 10.1002/cncr.26435
   Barnabei A, 2022, CANCERS, V14, DOI 10.3390/cancers14030593
   Basolo A, 2022, SEMIN CANCER BIOL, V79, P197, DOI 10.1016/j.semcancer.2020.12.008
   Bastin J, 2019, ACTA CLIN BELG, V74, P169, DOI 10.1080/17843286.2018.1476115
   Berman E, 2006, NEW ENGL J MED, V354, P2006, DOI 10.1056/NEJMoa051140
   Beukhof CM, 2017, J CLIN ENDOCR METAB, V102, P2922, DOI 10.1210/jc.2016 4025
   Bilgir O, 2010, INT J CLIN PRACT, V64, P45, DOI 10.1111/j.1742 1241.2008.01856.x
   Bozkurt O, 2016, J CHEMOTHERAPY, V28, P230, DOI 10.1179/1973947815Y.0000000039
   Brassard M, 2011, J CLIN ENDOCR METAB, V96, P2741, DOI 10.1210/jc.2010 2771
   Braun D, 2012, J CLIN ENDOCR METAB, V97, pE100, DOI 10.1210/jc.2011 1837
   Broekman F, 2011, WORLD J CLIN ONCOL, V2, P80, DOI 10.5306/wjco.v2.i2.80
   Brose MS, 2018, CANCER TREAT REV, V66, P64, DOI 10.1016/j.ctrv.2018.04.007
   Bruix J, 2013, EUR J CANCER, V49, P3412, DOI 10.1016/j.ejca.2013.05.028
   Buda Nowak A, 2017, MED ONCOL, V34, DOI 10.1007/s12032 017 0928 z
   Buffier P, 2018, ANN ENDOCRINOL PARIS, V79, P574, DOI 10.1016/j.ando.2018.07.011
   Cabanillas ME, 2019, SEMIN ONCOL, V46, P57, DOI 10.1053/j.seminoncol.2018.11.004
   Caldemeyer L, 2016, CURR HEMATOL MALIG R, V11, P71, DOI 10.1007/s11899 016 0309 2
   Castinetti F, 2018, ANN ENDOCRINOL PARIS, V79, P591, DOI 10.1016/j.ando.2018.07.005
   Choueiri TK, 2015, NEW ENGL J MED, V373, P1814, DOI 10.1056/NEJMoa1510016
   Colombo C, 2019, J CLIN ENDOCR METAB, V104, P779, DOI 10.1210/jc.2018 01836
   Dahlhoff M, 2011, J BIOL CHEM, V286, P39297, DOI 10.1074/jbc.M111.243493
   Daimon M, 2012, JPN J CLIN ONCOL, V42, P742, DOI 10.1093/jjco/hys076
   de Groot JWB, 2005, CLIN PHARMACOL THER, V78, P433, DOI 10.1016/j.clpt.2005.06.010
   De Leo S, 2023, THYROID, V33, P74, DOI 10.1089/thy.2022.0439
   DeAngelo DJ, 2012, BLOOD CANCER J, V2, DOI 10.1038/bcj.2012.30
   Desai J, 2006, ANN INTERN MED, V145, P660, DOI 10.7326/0003 4819 145 9 200611070 00008
   Dora JM, 2008, EUR J ENDOCRINOL, V158, P771, DOI 10.1530/EJE 08 0006
   Drui D, 2018, ANN ENDOCRINOL PARIS, V79, P569, DOI 10.1016/j.ando.2018.07.003
   Dy GK, 2013, CA CANCER J CLIN, V63, P249, DOI 10.3322/caac.21184
   Elshimy G, 2020, J INVEST MED HIGH IM, V8, DOI 10.1177/2324709620936808
   Eroukhmanoff J, 2016, BMC CANCER, V16, DOI 10.1186/s12885 016 2705 3
   Fallahi Poupak, 2021, Eur J Endocrinol, V184, pR29, DOI 10.1530/EJE 20 0683
   Fallahi P, 2014, EXPERT OPIN DRUG SAF, V13, P723, DOI 10.1517/14740338.2014.913021
   Fisher MJ, 2021, NAT MED, V27, P165, DOI 10.1038/s41591 020 01193 6
   Fukuoka H, 2011, J CLIN INVEST, V121, P4712, DOI 10.1172/JCI60417
   Funakoshi T, 2013, ACTA ONCOL, V52, P691, DOI 10.3109/0284186X.2012.752579
   Garcia Gomez A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034914
   Giampieri R, 2017, SCI REP UK, V7, DOI 10.1038/srep45703
   Gore ME, 2009, LANCET ONCOL, V10, P757, DOI 10.1016/S1470 2045(09)70162 7
   Gottardi M, 2005, NEW ENGL J MED, V353, P2722, DOI 10.1056/NEJMc052500
   Grouthier V, 2020, ONCOLOGIST, V25, P696, DOI 10.1634/theoncologist.2019 0555
   Gupta Abramson V, 2008, J CLIN ONCOL, V26, P4714, DOI 10.1200/JCO.2008.16.3279
   Huang LL, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045 020 00977 0
   Hutson TE, 2013, LANCET ONCOL, V14, P1287, DOI 10.1016/S1470 2045(13)70465 0
   Illouz F, 2014, EUR J ENDOCRINOL, V171, pR91, DOI 10.1530/EJE 14 0198
   Illouz F, 2009, EUR J ENDOCRINOL, V160, P331, DOI 10.1530/EJE 08 0648
   Jannin A, 2019, CRIT REV ONCOL HEMAT, V141, P23, DOI 10.1016/j.critrevonc.2019.05.015
   Jazvic M, 2015, ANTICANCER RES, V35, P481
   Kappers MHW, 2011, J CLIN ENDOCR METAB, V96, P3087, DOI 10.1210/jc.2011 1172
   Karaagaç M, 2020, J ONCOL PHARM PRACT, V26, P1657, DOI 10.1177/1078155220904138
   Kim JH, 2019, TARGET ONCOL, V14, P689, DOI 10.1007/s11523 019 00672 2
   Kim TD, 2010, THYROID, V20, P1209, DOI 10.1089/thy.2010.0251
   Kitajima K, 2012, EUR J RADIOL, V81, P2060, DOI 10.1016/j.ejrad.2011.06.035
   Koehler VF, 2022, CANCERS, V14, DOI 10.3390/cancers14143405
   Koizumi Y, 2019, ENDOCR J, V66, P787, DOI 10.1507/endocrj.EJ19 0140
   Kudo M, 2018, LANCET, V391, P1163, DOI 10.1016/S0140 6736(18)30207 1
   Lechner MG, 2018, THYROID, V28, P437, DOI 10.1089/thy.2017.0579
   Lechner MG, 2018, THYROID, V28, P445, DOI 10.1089/thy.2017.0587
   Lee N, 2023, TARGET ONCOL, V18, P247, DOI 10.1007/s11523 023 00951 z
   Liapis K, 2008, ANN PHARMACOTHER, V42, P1882, DOI 10.1345/aph.1L410
   Makita N, 2013, THYROID, V23, P151, DOI 10.1089/thy.2012.0456
   Makita N, 2010, THYROID, V20, P323, DOI 10.1089/thy.2009.0414
   Mannavola D, 2007, J CLIN ENDOCR METAB, V92, P3531, DOI 10.1210/jc.2007 0586
   Mathew A, 2021, HORM METAB RES, V53, P794, DOI 10.1055/a 1658 3077
   Matrana MR, 2013, EUR J CANCER, V49, P3169, DOI 10.1016/j.ejca.2013.06.003
   Maynard MA, 2014, NEW ENGL J MED, V371, P86, DOI [10.1056/NEJMc1405198, 10.1056/NEJMoa1308893]
   Miyake H, 2010, UROL ONCOL SEMIN ORI, V28, P515, DOI 10.1016/j.urolonc.2009.08.011
   Monti S, 2022, THYROID, V32, P46, DOI 10.1089/thy.2021.0040
   Motzer RJ, 2013, NEW ENGL J MED, V369, P722, DOI 10.1056/NEJMoa1303989
   Motzer RJ, 2013, LANCET ONCOL, V14, P552, DOI 10.1016/S1470 2045(13)70093 7
   Mukohara T, 2010, CANCER SCI, V101, P963, DOI 10.1111/j.1349 7006.2009.01465.x
   National Cancer Institute, 2017, Common Terminology Criteria for Adverse Events (CTCAE) v5.0, DOI DOI 10.1080/00140139.2010.489653
   Ohba K, 2013, THYROID, V23, P443, DOI 10.1089/thy.2012.0378
   Pani F, 2017, EUR J ENDOCRINOL, V177, P85, DOI 10.1530/EJE 17 0231
   Pani F, 2015, THYROID, V25, P1255, DOI 10.1089/thy.2015.0170
   Patyna S, 2008, TOXICOL PATHOL, V36, P905, DOI 10.1177/0192623308326151
   Prisciandaro M, 2019, AM J CLIN ONCOL CANC, V42, P42, DOI 10.1097/COC.0000000000000478
   Procopio G, 2022, JAMA ONCOL, V8, P910, DOI 10.1001/jamaoncol.2022.0238
   Quinn DI, 2021, ESMO OPEN, V6, DOI 10.1016/j.esmoop.2021.100105
   Rambhatla A, 2021, J ASSIST REPROD GEN, V38, P1897, DOI 10.1007/s10815 021 02181 6
   Rea D, 2014, HAEMATOLOGICA, V99, P1197, DOI 10.3324/haematol.2014.104075
   Riesenbeck LM, 2011, WORLD J UROL, V29, P807, DOI 10.1007/s00345 010 0627 2
   Rimassa L, 2019, CANCER TREAT REV, V77, P20, DOI 10.1016/j.ctrv.2019.05.004
   Robinson BG, 2010, J CLIN ENDOCR METAB, V95, P2664, DOI 10.1210/jc.2009 2461
   Rock EP, 2007, ONCOLOGIST, V12, P107, DOI 10.1634/theoncologist.12 1 107
   Rogiers A, 2010, THYROID, V20, P317, DOI 10.1089/thy.2009.0125
   Schlumberger M, 2017, ANN ONCOL, V28, P2813, DOI 10.1093/annonc/mdx479
   Schlumberger M, 2016, CLIN CANCER RES, V22, P44, DOI 10.1158/1078 0432.CCR 15 1127
   Schlumberger M, 2015, NEW ENGL J MED, V372, P621, DOI 10.1056/NEJMoa1406470
   Schmidinger M, 2011, CANCER AM CANCER SOC, V117, P534, DOI 10.1002/cncr.25422
   Schöffski P, 2020, EUR J CANCER, V134, P62, DOI 10.1016/j.ejca.2020.04.021
   Sequist LV, 2015, NEW ENGL J MED, V372, P1700, DOI 10.1056/NEJMoa1413654
   Shah RR, 2017, DRUG SAFETY, V40, P211, DOI 10.1007/s40264 016 0485 y
   Shao YY, 2021, ONCOLOGIST, V26, P422, DOI 10.1002/onco.13755
   Sherman SI, 2008, NEW ENGL J MED, V359, P31, DOI 10.1056/NEJMoa075853
   Shinohara N, 2011, BRIT J CANCER, V104, P241, DOI 10.1038/sj.bjc.6606029
   Shomura M, 2020, CANCERS, V12, DOI 10.3390/cancers12113078
   Song Y, 2016, ASIA PAC J CLIN ONCO, V12, P174, DOI 10.1111/ajco.12473
   Staehler M, 2021, INT J CANCER, V148, P950, DOI 10.1002/ijc.33238
   Sugita K, 2015, ANTICANCER RES, V35, P4059
   Tada T, 2020, HEPATOL RES, V50, P75, DOI 10.1111/hepr.13427
   Takada S, 2019, UROL INT, V102, P435, DOI 10.1159/000499089
   Tomita Y, 2011, EUR J CANCER, V47, P2592, DOI 10.1016/j.ejca.2011.07.014
   Ueda T, 2013, JPN J CLIN ONCOL, V43, P616, DOI 10.1093/jjco/hyt054
   Valerio L, 2023, J ENDOCRINOL INVEST, V46, P1663, DOI 10.1007/s40618 023 02025 3
   Valerio L, 2020, ENDOCR RELAT CANCER, V27, P97, DOI 10.1530/ERC 19 0259
   Vasileiadis T, 2019, BMC CANCER, V19, DOI 10.1186/s12885 019 5610 8
   Verloop H, 2013, EUR J ENDOCRINOL, V168, P163, DOI 10.1530/EJE 12 0828
   Weickhardt AJ, 2013, CANCER AM CANCER SOC, V119, P2383, DOI 10.1002/cncr.28089
   Wells SA, 2012, J CLIN ONCOL, V30, P134, DOI 10.1200/JCO.2011.35.5040
   Wolter P, 2008, BRIT J CANCER, V99, P448, DOI 10.1038/sj.bjc.6604497
   Wong E, 2007, THYROID, V17, P351, DOI 10.1089/thy.2006.0308
   Worden F, 2015, ENDOCR RELAT CANCER, V22, P877, DOI 10.1530/ERC 15 0252
   Xie L, 2020, CANCER MANAG RES, V12, P91, DOI 10.2147/CMAR.S232823
   Yavuz S, 2014, THYROID, V24, P1223, DOI 10.1089/thy.2013.0621
   Zatelli M, 2014, J ENDOCRINOL INVEST, V37, P917, DOI 10.1007/s40618 014 0133 2
   Zhang JM, 2009, NAT REV CANCER, V9, P28, DOI 10.1038/nrc2559
NR 124
TC 16
Z9 16
U1 4
U2 8
PU MASSON EDITEUR
PI MOULINEAUX CEDEX 9
PA 21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE
SN 0003 4266
EI 2213 3941
J9 ANN ENDOCRINOL PARIS
JI Ann Endocrinol.
PD MAY
PY 2023
VL 84
IS 3
BP 374
EP 381
DI 10.1016/j.ando.2023.03.009
EA APR 2023
PG 8
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA G6NQ4
UT WOS:000990306700001
PM 36963756
DA 2025 08 17
ER

PT J
AU Yang, N
   Ma, TF
   Wang, WZ
   Sun, JX
   Zhang, XZ
   Hu, JM
   Zhu, C
AF Yang, Ning
   Ma, Tengfei
   Wang, Wenzhi
   Sun, Jiaxuan
   Zhang, Xianzuo
   Hu, Jinming
   Zhu, Chen
TI Carbon monoxide (CO) releasing micelles enable efficient treatment of
   MRSA induced septic arthritis and rheumatoid arthritis
SO NANO TODAY
LA English
DT Article
DE Carbon monoxide; Antibacterial; Anti inflammation; Septic arthritis;
   Rheumatoid arthritis
ID VISIBLE LIGHT; INFLAMMATION; MACROPHAGES
AB Septic arthritis (SA) and rheumatoid arthritis (RA) are prevalent and challenging joint diseases that often lead to severe consequences, including sepsis, disability, and life threatening conditions. However, their distinct etiologies and pathological mechanisms require different treatment strategies. We herein report a single formulation of carbon monoxide (CO) releasing micelles capable of efficient treatment of both SA and RA diseases. Our findings demonstrate that the local release of CO under red light stimulus effectively eradicates methicillinresistant Staphylococcus aureus (MRSA) pathogens while safeguarding MRSA infected chondrocytes and osteogenic cells. Furthermore, CO delivery orchestrates macrophage polarization homeostasis via the nuclear factor erythroid 2 related factor (Nrf2)/heme oxygenase 1 (HO 1) pathway, manifesting unique anti inflammatory and anti osteoclastic effects. These remarkable properties empower CO releasing micelles to emerge as a singular treatment approach, addressing both SA and RA in murine models without the need for conventional medications such as antibiotics and nonsteroidal anti inflammatory drugs (NSAIDs).
C1 [Yang, Ning; Wang, Wenzhi; Sun, Jiaxuan; Zhang, Xianzuo; Zhu, Chen] Univ Sci & Technol China, Affiliated Hosp USTC 1, Dept Orthopaed, Div Life Sci & Med, Hefei 230001, Anhui, Peoples R China.
   [Ma, Tengfei; Hu, Jinming] Univ Sci & Technol China, Affiliated Hosp USTC 1, Sch Chem & Mat Sci, Dept Pharm,Div Life Sci & Med, Hefei 230026, Anhui, Peoples R China.
   [Ma, Tengfei; Hu, Jinming] Univ Sci & Technol China, Sch Chem & Mat Sci, Dept Polymer Sci & Engn, Hefei 230026, Anhui, Peoples R China.
C3 Chinese Academy of Sciences; University of Science & Technology of
   China, CAS; Chinese Academy of Sciences; University of Science &
   Technology of China, CAS; Chinese Academy of Sciences; University of
   Science & Technology of China, CAS
RP Zhu, C (通讯作者)，Univ Sci & Technol China, Affiliated Hosp USTC 1, Dept Orthopaed, Div Life Sci & Med, Hefei 230001, Anhui, Peoples R China.; Hu, JM (通讯作者)，Univ Sci & Technol China, Affiliated Hosp USTC 1, Sch Chem & Mat Sci, Dept Pharm,Div Life Sci & Med, Hefei 230026, Anhui, Peoples R China.; Hu, JM (通讯作者)，Univ Sci & Technol China, Sch Chem & Mat Sci, Dept Polymer Sci & Engn, Hefei 230026, Anhui, Peoples R China.
EM jmhu@ustc.edu.cn; zhuchena@ustc.edu.cn
RI Ma, Tengfei/KVX 9874 2024; Zhang, Xianzuo/ACI 0276 2022; Hu,
   Jinming/F 2137 2011; Wang, Wenzhi/KFS 5776 2024
FU National Key R&D Program of China [2020YFA0710700]; National Natural
   Scientific Foundation of China (NNSFC) [82272512, 82072425, 52273155,
   52073270, 82072466]; Natural Science Foundation of Anhui Province,
   Distinguishing Youth Project [2108085J40]; Anhui Provincial Department
   of Education Higher Education Research [2022AH010076]
FX We gratefully acknowledge the financial support of the National Key R&D
   Program of China (2020YFA0710700) , the National Natural Scientific
   Foundation of China (NNSFC) Projects (82272512, 82072425, 52273155,
   52073270, and 82072466) , the Natural Science Foundation of Anhui
   Province, Distinguishing Youth Project (2108085J40) , Anhui Provincial
   Department of Education Higher Education Research Program (2022AH010076)
   .
CR Aljefri DM, 2019, CLIN INFECT DIS, V69, P1881, DOI 10.1093/cid/ciz051
   Anderson SN, 2015, CHEMISTRYOPEN, V4, P590, DOI 10.1002/open.201500167
   Antoci V, 2007, CLIN ORTHOP RELAT R, P200, DOI 10.1097/BLO.0b013e31811ff866
   Barichello T, 2022, CRIT CARE, V26, DOI 10.1186/s13054 021 03862 5
   Bykerk VP, 2015, ANN RHEUM DIS, V74, P96, DOI 10.1136/annrheumdis 2013 203660
   Byrne JD, 2022, SCI TRANSL MED, V14, DOI 10.1126/scitranslmed.abl4135
   Cao L., 2023, Nano Lett., P23, DOI [10.1021/acs.nanolett.1023c02434, DOI 10.1021/ACS.NANOLETT.1023C02434]
   Chakraborty I, 2014, ACCOUNTS CHEM RES, V47, P2603, DOI 10.1021/ar500172f
   Chakraborty P, 2022, CANCER RES, V82, P1969, DOI 10.1158/0008 5472.CAN 21 3155
   Chen S, 2023, BIOACT MATER, V25, P176, DOI 10.1016/j.bioactmat.2023.01.022
   Cheng J, 2021, ANGEW CHEM INT EDIT, V60, P13513, DOI 10.1002/anie.202104024
   Cheng J, 2020, CHEM SCI, V11, P4499, DOI 10.1039/d0sc00135j
   Choi S, 2017, EXP MOL MED, V49, DOI 10.1038/emm.2017.193
   Delgado Noguera MF, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012125.pub2
   Deng CF, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 22454 z
   Nguyen D, 2015, BIOMACROMOLECULES, V16, P2776, DOI 10.1021/acs.biomac.5b00716
   Fong DH, 2002, EMBO J, V21, P2323, DOI 10.1093/emboj/21.10.2323
   Frazee BW, 2009, ANN EMERG MED, V54, P695, DOI 10.1016/j.annemergmed.2009.06.511
   Gao L, 2022, ANGEW CHEM INT EDIT, V61, DOI 10.1002/anie.202112782
   García García A, 2023, BIOACT MATER, V24, P174, DOI 10.1016/j.bioactmat.2022.12.017
   GARDNER GC, 1990, AM J MED, V88, P503, DOI 10.1016/0002 9343(90)90430 L
   Ge GR, 2022, SCI CHINA LIFE SCI, V65, P588, DOI 10.1007/s11427 020 1939 1
   Ge J, 2023, J NANOBIOTECHNOL, V21, DOI 10.1186/s12951 023 01802 9
   Ghali O, 2010, J BONE MINER RES, V25, P1616, DOI 10.1002/jbmr.52
   Kaandorp CJE, 1997, ANN RHEUM DIS, V56, P470, DOI 10.1136/ard.56.8.470
   Katsnelson A, 2019, ACS CENTRAL SCI, V5, P1632, DOI 10.1021/acscentsci.9b01015
   Kim B, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 04390 7
   Kwon DH, 2019, ANTIOXIDANTS BASEL, V8, DOI 10.3390/antiox8090413
   Lee GY, 2020, ACTA PHARMACOL SIN B, V10, P2362, DOI 10.1016/j.apsb.2020.05.010
   Liang HY, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 06603 5
   Liao S, 2020, REDOX BIOL, V36, DOI 10.1016/j.redox.2020.101644
   Liu W, 2021, J PINEAL RES, V71, DOI 10.1111/jpi.12769
   Locati M, 2020, ANNU REV PATHOL MECH, V15, P123, DOI 10.1146/annurev pathmechdis 012418 012718
   Mathews CJ, 2010, LANCET, V375, P846, DOI 10.1016/S0140 6736(09)61595 6
   Motterlini R, 2010, NAT REV DRUG DISCOV, V9, P728, DOI 10.1038/nrd3228
   Onyiah JC, 2013, GASTROENTEROLOGY, V144, P789, DOI 10.1053/j.gastro.2012.12.025
   Qin Y, 2022, ANN RHEUM DIS, V81, P1504, DOI 10.1136/ard 2022 222605
   Sanchez Lopez E, 2019, CELL METAB, V29, P1350, DOI 10.1016/j.cmet.2019.03.011
   Singh S, 2021, CELL REP MED, V2, DOI 10.1016/j.xcrm.2021.100277
   Southam HM, 2018, REDOX BIOL, V18, P114, DOI 10.1016/j.redox.2018.06.008
   Tao SY, 2020, ANGEW CHEM INT EDIT, V59, P21864, DOI 10.1002/anie.202010009
   Tardito S, 2019, AUTOIMMUN REV, V18, DOI 10.1016/j.autrev.2019.102397
   Tong JY, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abd4742
   Wang LP, 2023, ACS APPL MATER INTER, V15, P41772, DOI 10.1021/acsami.3c02898
   Wang T, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 021 27816 1
   Wang TT, 2018, CYTOKINE GROWTH F R, V44, P38, DOI 10.1016/j.cytogfr.2018.10.002
   Wegiel B, 2014, J CLIN INVEST, V124, P4926, DOI 10.1172/JCI72853
   Wegiel B, 2013, CANCER RES, V73, P7009, DOI 10.1158/0008 5472.CAN 13 1075
   Xiu WJ, 2020, RESEARCH CHINA, V2020, DOI 10.34133/2020/9426453
   Yang N, 2021, CLIN TRANSL MED, V11, DOI 10.1002/ctm2.447
   Yang XX, 2021, ACTA PHARM SIN B, V11, P1434, DOI 10.1016/j.apsb.2020.10.010
   Yokota K, 2021, ARTHRITIS RHEUMATOL, V73, P1145, DOI 10.1002/art.41666
   Zhang HM, 2018, CELL MOL IMMUNOL, V15, P506, DOI 10.1038/cmi.2017.11
   Zhou F, 2019, ACTA PHARM SIN B, V9, P973, DOI 10.1016/j.apsb.2019.01.015
NR 54
TC 6
Z9 6
U1 6
U2 33
PU ELSEVIER SCI LTD
PI London
PA 125 London Wall, London, ENGLAND
SN 1748 0132
EI 1878 044X
J9 NANO TODAY
JI Nano Today
PD AUG
PY 2024
VL 57
AR 102389
DI 10.1016/j.nantod.2024.102389
EA JUL 2024
PG 15
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science
GA YB9Q0
UT WOS:001266147400001
DA 2025 08 17
ER

PT J
AU McMillin, DW
   Ooi, M
   Delmore, J
   Negri, J
   Hayden, P
   Mitsiades, N
   Jakubikova, J
   Maira, SM
   Garcia Echeverria, C
   Schlossman, R
   Munshi, NC
   Richardson, PG
   Anderson, KC
   Mitsiades, CS
AF McMillin, Douglas W.
   Ooi, Melissa
   Delmore, Jake
   Negri, Joseph
   Hayden, Patrick
   Mitsiades, Nicolas
   Jakubikova, Jana
   Maira, Sauveur Michel
   Garcia Echeverria, Carlos
   Schlossman, Robert
   Munshi, Nikhil C.
   Richardson, Paul G.
   Anderson, Kenneth C.
   Mitsiades, Constantine S.
TI Antimyeloma Activity of the Orally Bioavailable Dual
   Phosphatidylinositol 3 Kinase/Mammalian Target of Rapamycin Inhibitor
   NVP BEZ235
SO CANCER RESEARCH
LA English
DT Article
ID MULTIPLE MYELOMA CELLS; SET ENRICHMENT ANALYSIS; GENE EXPRESSION;
   THERAPEUTIC APPLICATIONS; IDENTIFICATION; SIGNATURE; GROWTH; CANCER;
   ACTIVATION; IDENTIFY
AB The phosphatidylinositol 3 kinase (PI3K) Akt mammalian target of rapamycin (mTOR) pathway mediates proliferation, survival, and drug resistance in multiple myeloma (MM) cells. Here, we tested the anti MM activity of NVP BEZ235 (BEZ235), which inhibits PI3K/Akt/mTOR signaling at the levels of PI3K and mTOR. 3 (4,5 Dimethylthiazol 2 yl) 2,5 diphenyltetrazolium bromide colorimetric survival assays showed that MM cell lines exhibited dose  and time dependent decreased viability after exposure to BEZ235 (IC50, 25 800 nmol/L or 48 hours). MM cells highly sensitive (IC50, <25 nmol/L) to BEZ235 (e.g., MM.1S, MM.1R, Dox40, and KMS 12 PE) included both lines sensitive and resistant to conventional (dexamethasone, cytotoxic chemotherapeutics) agents. Pharmacologically relevant BEZ235 concentrations (25 400 nmol/L,) induced rapid commitment to and induction of MM.1S and OPM 2 cell death. Furthermore, normal donor peripheral blood mononuclear cells were less sensitive (IC50, >800 nmol/L) than the majority of MM cell lines tested, suggesting a favorable therapeutic index. In addition, BEZ235 was able to target MM cells in the presence of exogenous interleukin 6, insulin like growth factor 1, stromal cells, or osteoclasts, which are known to protect against various anti MM agents. Molecular profiling revealed that BEZ235 treatment decreased the amplitude of transcriptional signatures previously associated with myc, ribosome, and proteasome function, as well as high risk MM and undifferentiated human embryonic stem cells. In vivo xenograft studies revealed significant reduction in tumor burden (P = 0.011) and survival (P = 0.028) in BEZ235 treated human MM tumor bearing mice. Combinations of BEZ235 with conventional (e.g., dexamethasone and doxorubicin) or novel (e.g., bortezomib) anti MM agents showed lack of antagonism. These results indicate that BEZ235 merits clinical testing, alone and in combination with other agents, in MM. [Cancer Res 2009;69(14):5835 42]
C1 [McMillin, Douglas W.; Ooi, Melissa; Delmore, Jake; Negri, Joseph; Hayden, Patrick; Mitsiades, Nicolas; Jakubikova, Jana; Schlossman, Robert; Munshi, Nikhil C.; Richardson, Paul G.; Anderson, Kenneth C.; Mitsiades, Constantine S.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA.
   [McMillin, Douglas W.; Ooi, Melissa; Delmore, Jake; Negri, Joseph; Hayden, Patrick; Mitsiades, Nicolas; Jakubikova, Jana; Anderson, Kenneth C.; Mitsiades, Constantine S.] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA.
   [Maira, Sauveur Michel; Garcia Echeverria, Carlos] Novartis Inst Biomed Res, Basel, Switzerland.
C3 Harvard University; Harvard Medical School; Harvard University Medical
   Affiliates; Dana Farber Cancer Institute; Harvard University; Harvard
   Medical School; Novartis
RP Mitsiades, CS (通讯作者)，Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr,Dept Med Oncol, 44 Binney St, Boston, MA 02115 USA.
EM Constantine_Mitsiades@dfci.harvard.edu
RI ; Anderson, Kenneth/ACP 5073 2022; Jakubikova, Jana/ABE 5761 2020;
   Munshi, Nikhil/ABE 2338 2021
OI Hayden, Patrick/0000 0003 1374 4503; Ooi, Melissa/0000 0002 7392 0655;
   Mitsiades, Nicholas/0000 0002 4659 476X; Jakubikova,
   Jana/0000 0003 2593 569X
FU "Dunkin Donuts Rising Stars" Program at the Dana Farber Cancer
   Institute; Chambers Medical Foundation; Cobb Family Fellowship; NIH
   [R01CA050947, PO 1 78378]
FX "Dunkin Donuts Rising Stars" Program at the Dana Farber Cancer Institute
   (C.S. Mitsiades), Chambers Medical Foundation (P.G. Richardson and C.S.
   Mitsiades), Cobb Family Fellowship (D.W. McMillin), and NIH grants
   R01CA050947 (K.C. Anderson and C.S. Mitsiades) and PO 1 78378 (K.C.
   Anderson).
CR Bhattacharya B, 2004, BLOOD, V103, P2956, DOI 10.1182/blood 2003 09 3314
   Ge NL, 2000, BLOOD, V96, P2856
   Hideshima T, 2001, ONCOGENE, V20, P5991, DOI 10.1038/sj.onc.1204833
   Hideshima T, 2007, NAT REV CANCER, V7, P585, DOI 10.1038/nrc2189
   Hu JT, 2005, ONCOGENE, V24, P1212, DOI 10.1038/sj.onc.1208242
   Ingram WJ, 2002, ONCOGENE, V21, P8196, DOI 10.1038/sj.onc.1205975
   Kannan K, 2001, ONCOGENE, V20, P2225, DOI 10.1038/sj.onc.1204319
   Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098
   Lindvall C, 2003, CANCER RES, V63, P1743
   Lu Yiling, 2003, Rev Clin Exp Hematol, V7, P205
   Maira SM, 2008, MOL CANCER THER, V7, P1851, DOI 10.1158/1535 7163.MCT 08 0017
   McMillin D, 2007, HAEMATOL HEMATOL J, V92, P65
   Mitsiades CS, 2001, BLOOD, V98, P795, DOI 10.1182/blood.V98.3.795
   Mitsiades CS, 2004, P NATL ACAD SCI USA, V101, P540, DOI 10.1073/pnas.2536759100
   Mitsiades CS, 2002, ONCOGENE, V21, P5673, DOI 10.1038/sj.onc.1205664
   Mitsiades N, 2002, P NATL ACAD SCI USA, V99, P14374, DOI 10.1073/pnas.202445099
   Mitsiades N, 2003, BLOOD, V101, P2377, DOI 10.1182/blood 2002 06 1768
   Nguyen BC, 2006, GENE DEV, V20, P1028, DOI 10.1101/gad.1406006
   Ramalho Santos M, 2002, SCIENCE, V298, P597, DOI 10.1126/science.1072530
   Schnell CR, 2008, CANCER RES, V68, P6598, DOI 10.1158/0008 5472.CAN 08 1044
   Serra V, 2008, CANCER RES, V68, P8022, DOI 10.1158/0008 5472.CAN 08 1385
   Shaffer AL, 2008, NATURE, V454, P226, DOI 10.1038/nature07064
   Shaughnessy JD, 2007, BLOOD, V109, P2276, DOI 10.1182/blood 2006 07 038430
   Shi YJ, 2005, MOL CANCER THER, V4, P1533, DOI 10.1158/1535 7163.MCT 05 0068
   Silvestris F, 2007, LEUKEMIA RES, V31, P129, DOI 10.1016/j.leukres.2006.04.014
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Subramanian A, 2007, BIOINFORMATICS, V23, P3251, DOI 10.1093/bioinformatics/btm369
   Thomas RK, 2007, NAT GENET, V39, P347, DOI 10.1038/ng1975
   Yap TA, 2008, CURR OPIN PHARMACOL, V8, P393, DOI 10.1016/j.coph.2008.08.004
   Yu DN, 2005, ANN NY ACAD SCI, V1059, P145, DOI 10.1196/annals.1339.047
   Zeller KI, 2003, GENOME BIOL, V4, DOI 10.1186/gb 2003 4 10 r69
NR 31
TC 115
Z9 130
U1 1
U2 9
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106 4404 USA
SN 0008 5472
EI 1538 7445
J9 CANCER RES
JI Cancer Res.
PD JUL 15
PY 2009
VL 69
IS 14
BP 5835
EP 5842
DI 10.1158/0008 5472.CAN 08 4285
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 475LJ
UT WOS:000268360300030
PM 19584292
OA Green Submitted
DA 2025 08 17
ER

PT J
AU Hu, ZB
   Gupta, J
   Zhang, ZW
   Gerseny, H
   Berg, A
   Chen, YJ
   Zhang, ZL
   Du, HY
   Brendler, CB
   Xiao, XH
   Pienta, KJ
   Guise, T
   Lee, C
   Stern, PH
   Stock, S
   Seth, P
AF Hu, Zebin
   Gupta, Janhavi
   Zhang, Zhenwei
   Gerseny, Helen
   Berg, Arthur
   Chen, Yun Ju
   Zhang, Zhiling
   Du, Hongyan
   Brendler, Charles B.
   Xiao, Xianghui
   Pienta, Kenneth J.
   Guise, Theresa
   Lee, Chung
   Stern, Paula H.
   Stock, Stuart
   Seth, Prem
TI Systemic Delivery of Oncolytic Adenoviruses Targeting Transforming
   Growth Factor β Inhibits Established Bone Metastasis in a Prostate
   Cancer Mouse Model
SO HUMAN GENE THERAPY
LA English
DT Article
ID TGF BETA; GENE THERAPY; CLINICAL TRIAL; RECEPTOR II; EXPRESSION;
   PROGRESS; ACTIVATION; CARCINOMA; PROMOTER; VECTORS
AB We have examined whether Ad.sT beta RFc and TAd.sT beta RFc, two oncolytic viruses expressing soluble transforming growth factor beta receptor II fused with human Fc (sTGF beta RIIFc), can be developed to treat bone metastasis of prostate cancer. Incubation of PC 3 and DU 145 prostate tumor cells with Ad.sT beta RFc and TAd.sT beta RFc produced sTGF beta RIIFc and viral replication; sTGF beta RIIFc caused inhibition of TGF beta mediated SMAD2 and SMAD3 phosphorylation. Ad(E1 ).sT beta RFc, an E1( ) adenovirus, produced sTGF beta RIIFc but failed to replicate in tumor cells. To examine the antitumor response of adenoviral vectors, PC 3 luc cells were injected into the left heart ventricle of nude mice. On day 9, mice were subjected to whole body bioluminescence imaging (BLI). Mice bearing hind limb tumors were administered viral vectors via the tail vein on days 10, 13, and 17 (2.5 x 10(10) viral particles per injection per mouse, each injection in a 0.1 ml volume), and subjected to BLI and X ray radiography weekly until day 53. Ad.sT beta RFc, TAd.sT beta RFc, and Ad(E1 ).sT beta RFc caused significant inhibition of tumor growth; however, Ad.sT beta RFc was the most effective among all the vectors. Only Ad.sT beta RFc and TAd.sT beta RFc inhibited tumor induced hypercalcemia. Histomorphometric and synchrotron micro computed tomographic analysis of isolated bones indicated that Ad.sT beta RFc induced significant reduction in tumor burden, osteoclast number, and trabecular and cortical bone destruction. These studies suggest that Ad.sT beta RFc and TAd.sT beta RFc can be developed as potential new therapies for prostate cancer bone metastasis.
C1 [Hu, Zebin; Gupta, Janhavi; Zhang, Zhenwei; Gerseny, Helen; Berg, Arthur; Chen, Yun Ju; Zhang, Zhiling; Seth, Prem] NorthShore Res Inst, Dept Med, Gene Therapy Program, Evanston, IL 60201 USA.
   [Du, Hongyan] NorthShore Res Inst, Ctr Clin & Res Informat, Evanston, IL 60201 USA.
   [Brendler, Charles B.] NorthShore Res Inst, Dept Surg, Evanston, IL 60201 USA.
   [Xiao, Xianghui] Argonne Natl Lab, Adv Photon Source, Argonne, IL 60439 USA.
   [Pienta, Kenneth J.] Univ Michigan, Dept Med & Urol, Ann Arbor, MI 48109 USA.
   [Guise, Theresa] Indiana Univ, Dept Med, Indianapolis, IN 46202 USA.
   [Lee, Chung] Northwestern Univ, Dept Urol, Chicago, IL 60611 USA.
   [Stern, Paula H.; Stock, Stuart] Northwestern Univ, Dept Mol Pharmacol & Biol Chem, Chicago, IL 60611 USA.
C3 NorthShore University Health System; NorthShore University Health
   System; NorthShore University Health System; United States Department of
   Energy (DOE); Argonne National Laboratory; University of Michigan
   System; University of Michigan; Indiana University System; Indiana
   University Indianapolis; Northwestern University; Northwestern
   University
RP Seth, P (通讯作者)，NorthShore Res Inst, Dept Med, Gene Therapy Program, 2650 Ridge Ave,Room B 652, Evanston, IL 60201 USA.
EM pseth@northshore.org
RI Zhang, Zhiling/GPS 8205 2022; Pienta, Kenneth/E 7679 2015; Hongyan,
   Du/IZD 6618 2023; Lee, Chung Hao/ABL 5350 2022; ZHANG,
   ZHENWEI/AAW 7973 2021
OI Berg, Arthur/0000 0002 4097 7348; Pienta, Kenneth/0000 0002 4138 2186;
   Stock, Stuart R./0000 0002 8886 4035; 
FU NIH [R01CA12738]; North Shore Foundation; U.S. Department of Energy,
   Office of Science, Office of Basic Energy Sciences [DE AC02 06CH11357]
FX This research was funded in part by NIH grant R01CA12738 (P.S.) and by
   an institutional grant from the North Shore Foundation (P.S.). Use of
   the Advanced Photon Source was supported by the U.S. Department of
   Energy, Office of Science, Office of Basic Energy Sciences, under
   contract DE AC02 06CH11357. The authors are thankful to the Kovler
   Family Foundation, Mr. and Mrs. Richard Hulina, Mr. Jimmie Alford and
   Ms. Maree Bullock, Maxine and James Farrell, the Carol Gollob
   Foundation, and an anonymous donor for their generous gifts. The authors
   are thankful to Janardan Khandekar, Theodore Mazzone, and Bruce
   Brockstein for continuous support. The authors thank Tamas Jilling for
   help in p SMAD quantification, and Rebecca Orr for tissue processing.
CR Adamson RE, 2012, HUM GENE THER, V23, P218, DOI 10.1089/hum.2011.021
   Ahi YS, 2011, CURR GENE THER, V11, P307
   Barrett JM, 2006, PROSTATE, V66, P632, DOI 10.1002/pros.20370
   Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373
   Bubendorf L, 2000, HUM PATHOL, V31, P578, DOI 10.1053/hp.2000.6698
   Cannata DH, 2012, J CLIN ENDOCR METAB, V97, P360, DOI 10.1210/jc.2011 2353
   Coleman RE, 2001, CANCER TREAT REV, V27, P165, DOI 10.1053/ctrv.2000.0210
   Coleman R, 2011, ANN NY ACAD SCI, V1218, P3, DOI 10.1111/j.1749 6632.2010.05766.x
   Coleman RE, 2010, CANCER TREAT REV, V36, P615, DOI 10.1016/j.ctrv.2010.04.003
   Cooper CR, 2003, CANCER AM CANCER SOC, V97, P739, DOI 10.1002/cncr.11181
   Damber JE, 2008, LANCET, V371, P1710, DOI 10.1016/S0140 6736(08)60729 1
   de Vrij J, 2010, HUM GENE THER, V21, P795, DOI 10.1089/hum.2009.203
   Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140 6736(10)62344 6
   Guise T, 2010, SEMIN ONCOL, V37, pS2, DOI 10.1053/j.seminoncol.2010.10.007
   Gupta J, 2011, CANCER BIOL THER, V11, P311, DOI 10.4161/cbt.11.3.14096
   Harris WP, 2009, NAT CLIN PRACT UROL, V6, P76, DOI 10.1038/ncpuro1296
   Howe JA, 2000, MOL THER, V2, P485, DOI 10.1006/mthe.2000.0206
   Hu Z, 2010, CANCER GENE THER, V17, P235, DOI 10.1038/cgt.2009.72
   Hu ZB, 2011, MOL THER, V19, P1609, DOI 10.1038/mt.2011.114
   Hu ZB, 2010, HUM GENE THER, V21, P1623, DOI 10.1089/hum.2010.018
   Iyer S, 2005, CANCER BIOL THER, V4, P261, DOI 10.4161/cbt.4.3.1566
   Jin JK, 2011, INT J CANCER, V128, P2545, DOI 10.1002/ijc.26024
   Jones E, 2009, EXPERT OPIN THER TAR, V13, P227, DOI [10.1517/14728220802705696 , 10.1517/14728220802705696]
   Juárez P, 2011, BONE, V48, P23, DOI 10.1016/j.bone.2010.08.004
   Katayose D, 1995, CLIN CANCER RES, V1, P889
   Kubo H, 2003, HUM GENE THER, V14, P227, DOI 10.1089/10430340360535788
   Lamfers MLM, 2006, MOL THER, V14, P779, DOI 10.1016/j.ymthe.2006.08.008
   Lee RJ, 2011, BONE, V48, P88, DOI 10.1016/j.bone.2010.05.038
   Liu TC, 2008, GENE THER, V15, P877, DOI 10.1038/gt.2008.72
   Loberg RD, 2005, J CLIN ONCOL, V23, P8232, DOI 10.1200/JCO.2005.03.0841
   Loberg RD, 2006, NEOPLASIA, V8, P69, DOI 10.1593/neo.05679
   Lu S, 2007, CLIN CANCER RES, V13, P5692, DOI 10.1158/1078 0432.CCR 07 1078
   Massagué J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001
   McLeod DG, 2003, UROLOGY, V61, P3, DOI 10.1016/S0090 4295(02)02393 2
   Mishra S, 2011, PROSTATE, V71, P1441, DOI 10.1002/pros.21361
   Morille M, 2008, BIOMATERIALS, V29, P3477, DOI 10.1016/j.biomaterials.2008.04.036
   Nguyen DX, 2009, NAT REV CANCER, V9, P274, DOI 10.1038/nrc2622
   Rauen KA, 2002, CANCER RES, V62, P3812
   Sato S, 2008, CANCER SCI, V99, P316, DOI 10.1111/j.1349 7006.2007.00690.x
   Schneider A, 2005, ENDOCRINOLOGY, V146, P1727, DOI 10.1210/en.2004 1211
   Schroten C, 2012, CANCER IMMUNOL IMMUN, V61, P905, DOI 10.1007/s00262 011 1159 3
   Seow Y, 2009, MOL THER, V17, P767, DOI 10.1038/mt.2009.41
   Seth P, 2006, HUM GENE THER, V17, P1152, DOI 10.1089/hum.2006.17.1152
   Shariat SF, 2001, J CLIN ONCOL, V19, P2856, DOI 10.1200/JCO.2001.19.11.2856
   Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959 8049(97)00062 2
   Shirakawa T, 2007, HUM GENE THER, V18, P1225, DOI 10.1089/hum.2007.074
   Stanford MM, 2010, CYTOKINE GROWTH F R, V21, P177, DOI 10.1016/j.cytogfr.2010.02.012
   Stock SR., 2008, MICROCOMPUTED TOMOGR
   Sturge J, 2011, NAT REV CLIN ONCOL, V8, P357, DOI 10.1038/nrclinonc.2011.67
   Tatem AJ, 2011, LANCET, V377, P30, DOI 10.1016/S0140 6736(11)61226 9
   Toth K, 2010, EXPERT OPIN BIOL TH, V10, P353, DOI 10.1517/14712590903559822
   Wang YX, 2001, REV SCI INSTRUM, V72, P2062, DOI 10.1063/1.1355270
   Zhang J, 2004, PROSTATE, V59, P360, DOI 10.1002/pros.20019
   Zhang ZW, 2011, HUM GENE THER, V22, P1137, DOI 10.1089/hum.2011.003
NR 54
TC 56
Z9 62
U1 2
U2 12
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1043 0342
EI 1557 7422
J9 HUM GENE THER
JI Hum. Gene Ther.
PD AUG
PY 2012
VL 23
IS 8
BP 871
EP 882
DI 10.1089/hum.2012.040
PG 12
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
   Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
   Experimental Medicine
GA 991EO
UT WOS:000307684500010
PM 22551458
OA Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU Fuerkaiti, SN
   Çakmak, AS
   Karaaslan, C
   Gümüsderelioglu, M
AF Fuerkaiti, Sumeyra Nur
   Cakmak, Anil Sera
   Karaaslan, Cagatay
   Gumusderelioglu, Menemse
TI Enhanced osteogenic effect in reduced BMP 2 doses with siNoggin
   transfected pre osteoblasts in 3D silk scaffolds
SO INTERNATIONAL JOURNAL OF PHARMACEUTICS
LA English
DT Article
DE siRNA; Noggin; BMP 2; Silk scaffold; Bone tissue engineering
ID BONE MORPHOGENETIC PROTEINS; IN VIVO; BIOMATERIAL SCAFFOLDS; RNA
   INTERFERENCE; SIRNA; DIFFERENTIATION; NOGGIN; DELIVERY; HYDROGELS;
   DEGRADATION
AB Bone morphogenetic proteins (BMPs), especially BMP 2, are being increasingly used in bone tissue engineering due to its osteo inductive effects. Although recombinant human BMP 2 (rhBMP 2) was approved by Food and Drug Administration (FDA) to use for bone repair, its high doses cause undesired side effects. In order to reduce the BMP 2 dose for enhanced osteogenic differentiation, in this study we decided to suppress the synthesis of Noggin protein, the primary antagonist of BMP 2, on the MC3T3 E1 cells using Noggin targeted small interfering RNA (siRNA). Unlike other studies, Noggin siRNA (siNoggin) transfected cells were seeded on silk scaffolds, and osteogenic differentiation was investigated for a long term period (21 days) with MTT, qPCR, SEM/EDS, and histological analysis. Besides, siNoggin transfected MC3T3 E1 cells were evaluated as a new cell source for tissue engineering studies. It was determined that Nog gene expression was suppressed in the siNoggin group and Ocn gene expression increased 5 fold compared to the control group (*p < 0.05). The osteogenic effect of BMP 2 was clearly observed in siNoggin transfected cells. According to the SEM/EDS analysis, the siNoggin group has mineral structures clustered on cells, which contain intense Ca and P elements. Histological staining showed that the siNoggin group has a more intense mineralized area than that of the control group. In conclusion, this study indicated that Noggin silencing by siRNA induces osteogenic differentiation in reduced BMP 2 doses for scaffold based bone regeneration. This non gene integration strategy has as a safe therapeutic potential to enhance tissue regeneration.
C1 [Fuerkaiti, Sumeyra Nur; Karaaslan, Cagatay; Gumusderelioglu, Menemse] Hacettepe Univ, Grad Sch Sci & Engn, Div Bioengn, TR 06800 Ankara, Turkey.
   [Cakmak, Anil Sera; Gumusderelioglu, Menemse] Hacettepe Univ, Dept Chem Engn, TR 06800 Ankara, Turkey.
   [Karaaslan, Cagatay] Hacettepe Univ, Dept Biol, TR 06800 Ankara, Turkey.
C3 Hacettepe University; Hacettepe University; Hacettepe University
RP Gümüsderelioglu, M (通讯作者)，Hacettepe Univ, Grad Sch Sci & Engn, Div Bioengn, TR 06800 Ankara, Turkey.
EM menemse@hacettepe.edu.tr
RI ; KARAASLAN, Cagatay/AAA 1621 2021
OI KARAASLAN, Cagatay/0000 0003 4857 0857; Fuerkaiti, Sumeyra
   Nur/0000 0001 7932 5972
FU Hacettepe University Scientific Research Projects Coordination Unit
   (BAP) [FYL 2018 17253]
FX This study was funded by Hacettepe University Scientific Research
   Projects Coordination Unit (BAP) graduate project (FYL 2018 17253) .
CR Bozo II, 2020, INT J BIOPRINTING, V6, DOI 10.18063/ijb.v6i3.275
   Bragdon B, 2011, CELL SIGNAL, V23, P609, DOI 10.1016/j.cellsig.2010.10.003
   Brazil DP, 2015, TRENDS CELL BIOL, V25, P249, DOI 10.1016/j.tcb.2014.12.004
   Çakmak S, 2016, MACROMOL BIOSCI, V16, P1212, DOI 10.1002/mabi.201600013
   Chambre L, 2020, ADV DRUG DELIVER REV, V160, P186, DOI 10.1016/j.addr.2020.10.008
   Chen C, 2012, J CELL BIOCHEM, V113, P3672, DOI 10.1002/jcb.24240
   Choi BY, 2015, J MATER CHEM B, V3, P6448, DOI 10.1039/c5tb00843c
   Cui ZK, 2017, ACTA BIOMATER, V58, P214, DOI 10.1016/j.actbio.2017.05.057
   Cui ZK, 2015, J CONTROL RELEASE, V217, P42, DOI 10.1016/j.jconrel.2015.08.031
   Devlin RD, 2003, ENDOCRINOLOGY, V144, P1972, DOI 10.1210/en.2002 220918
   Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107
   Ferreira AM, 2012, ACTA BIOMATER, V8, P3191, DOI 10.1016/j.actbio.2012.06.014
   Gazzerro E, 2006, REV ENDOCR METAB DIS, V7, P51, DOI 10.1007/s11154 006 9000 6
   Ghadakzadeh S, 2017, HELIYON, V3, DOI 10.1016/j.heliyon.2017.e00450
   Groppe J, 2003, J BONE JOINT SURG AM, V85A, P52, DOI 10.2106/00004623 200300003 00010
   Halloran D, 2020, J DEV BIOL, V8, DOI 10.3390/jdb8030019
   Holloway JL, 2014, J CONTROL RELEASE, V191, P63, DOI 10.1016/j.jconrel.2014.05.053
   Hsu MN, 2020, BIOMATERIALS, V252, DOI 10.1016/j.biomaterials.2020.120094
   Hu B, 2019, J GENE MED, V21, DOI 10.1002/jgm.3097
   Huang JS, 2018, ACS APPL MATER INTER, V10, P28471, DOI 10.1021/acsami.8b10521
   Huang MD, 2019, INT J NANOMED, V14, P4229, DOI 10.2147/IJN.S203540
   Inada T, 2018, BIOMATER SCI UK, V6, P440, DOI 10.1039/c7bm01100h
   Jung JI, 2018, DIFFERENTIATION, V101, P1, DOI 10.1016/j.diff.2018.03.001
   Jung SR, 2013, NUTR RES, V33, P162, DOI 10.1016/j.nutres.2012.11.006
   Kacarevic ZP, 2020, INT J ARTIF ORGANS, V43, P69, DOI 10.1177/0391398819876286
   Karageorgiou V, 2005, BIOMATERIALS, V26, P5474, DOI 10.1016/j.biomaterials.2005.02.002
   Kawasaki H, 2004, DIFFERENTIATION, V72, P58, DOI 10.1111/j.1432 0436.2004.07202006.x
   Kim UJ, 2005, BIOMATERIALS, V26, P2775, DOI 10.1016/j.biomaterials.2004.07.044
   Kowalczewski CJ, 2015, ACTA BIOMATER, V25, P109, DOI 10.1016/j.actbio.2015.07.045
   Kumar G, 2012, BIOMATERIALS, V33, P4022, DOI 10.1016/j.biomaterials.2012.02.048
   Leng QP, 2020, THERANOSTICS, V10, P3190, DOI 10.7150/thno.42640
   Li JJ, 2018, ADV HEALTHC MATER, V7, DOI 10.1002/adhm.201701061
   Liu B, 2019, J MATER SCI MATER M, V30, DOI 10.1007/s10856 018 6208 4
   Manaka T, 2011, BIOMATERIALS, V32, P9642, DOI 10.1016/j.biomaterials.2011.08.026
   Nazarov R, 2004, BIOMACROMOLECULES, V5, P718, DOI 10.1021/bm034327e
   Nguyen MK, 2018, ACTA BIOMATER, V75, P105, DOI 10.1016/j.actbio.2018.06.007
   Nguyen MK, 2014, BIOMATERIALS, V35, P6278, DOI 10.1016/j.biomaterials.2014.04.048
   Numata K, 2010, ADV DRUG DELIVER REV, V62, P1497, DOI 10.1016/j.addr.2010.03.009
   Panilaitis B, 2003, BIOMATERIALS, V24, P3079, DOI 10.1016/S0142 9612(03)00158 3
   Poon B, 2016, J PHARM PHARMACOL, V68, P139, DOI 10.1111/jphp.12506
   Ribeiro FO, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127722
   Rockwood DN, 2011, NAT PROTOC, V6, P1612, DOI 10.1038/nprot.2011.379
   Rossi M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20184502
   Rumpler M, 2008, J R SOC INTERFACE, V5, P1173, DOI 10.1098/rsif.2008.0064
   Salazar VS, 2016, NAT REV ENDOCRINOL, V12, P203, DOI 10.1038/nrendo.2016.12
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Shahbazi B, 2015, COLLOID SURFACE B, V136, P867, DOI 10.1016/j.colsurfb.2015.10.044
   Sharma U, 2014, INDIAN J CLIN BIOCHE, V29, P269, DOI 10.1007/s12291 013 0408 y
   Shin S, 2011, MOL BIOSYST, V7, P2110, DOI 10.1039/c1mb05054k
   Singh A, 2018, PROG ORTHOD, V19, DOI 10.1186/s40510 018 0216 2
   Sommer MR, 2017, J BIOMED MATER RES B, V105, P2074, DOI 10.1002/jbm.b.33737
   Sun XK, 2017, J MOL HISTOL, V48, P427, DOI 10.1007/s10735 017 9740 5
   Takayama K, 2009, J BONE MINER METAB, V27, P402, DOI 10.1007/s00774 009 0054 x
   Tomeh MA, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11100494
   Wan DC, 2007, J BIOL CHEM, V282, P26450, DOI 10.1074/jbc.M703282200
   Wang YZ, 2006, BIOMATERIALS, V27, P6064, DOI 10.1016/j.biomaterials.2006.07.008
   Wang YC, 2017, BIOMATERIALS, V139, P127, DOI 10.1016/j.biomaterials.2017.06.001
   Whitehead KA, 2009, NAT REV DRUG DISCOV, V8, P129, DOI 10.1038/nrd2742
   Wittrup A, 2015, NAT REV GENET, V16, P543, DOI 10.1038/nrg3978
   Wu XB, 2003, J CLIN INVEST, V112, P924, DOI 10.1172/JCI200315543
   Zoch ML, 2016, BONE, V82, P42, DOI 10.1016/j.bone.2015.05.046
   Zuckerman JE, 2015, NAT REV DRUG DISCOV, V14, P843, DOI 10.1038/nrd4685
NR 62
TC 10
Z9 11
U1 5
U2 23
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0378 5173
EI 1873 3476
J9 INT J PHARMACEUT
JI Int. J. Pharm.
PD JAN 25
PY 2022
VL 612
AR 121352
DI 10.1016/j.ijpharm.2021.121352
EA DEC 2021
PG 14
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA XY4RR
UT WOS:000736962200005
PM 34883207
DA 2025 08 17
ER

PT J
AU Mukai, T
   Akagi, T
   Asano, SH
   Tosa, I
   Ono, M
   Kittaka, M
   Ueki, Y
   Yahagi, A
   Iseki, M
   Oohashi, T
   Ishihara, K
   Morita, Y
AF Mukai, Tomoyuki
   Akagi, Takahiko
   Asano, Sumie Hiramatsu
   Tosa, Ikue
   Ono, Mitsuaki
   Kittaka, Mizuho
   Ueki, Yasuyoshi
   Yahagi, Ayano
   Iseki, Masanori
   Oohashi, Toshitaka
   Ishihara, Katsuhiko
   Morita, Yoshitaka
TI Imatinib has minimal effects on inflammatory and osteopenic phenotypes
   in a murine cherubism model
SO ORAL DISEASES
LA English
DT Article
DE cherubism; imatinib; inflammation; murine model; osteopenia; SH3BP2
ID ADAPTER PROTEIN 3BP2; SH3BP2 CHERUBISM; BONE LOSS; MICE; DESTRUCTION;
   INHIBITION; ACTIVATION; INDUCTION; RESPONSES; MESYLATE
AB Objective Cherubism is a genetic disorder characterised by bilateral jawbone deformation. The associated jawbone lesions regress after puberty, whereas severe cases require surgical treatment. Although several drugs have been tested, fundamental treatment strategies for cherubism have not been established. The effectiveness of imatinib has recently been reported; however, its pharmaceutical mechanism remains unclear. In this study, we tested the effects of imatinib using a cherubism mouse model. Methods We used Sh3bp2 P416R cherubism mutant mice, which exhibit systemic organ inflammation and osteopenia. The effects of imatinib were determined using primary bone marrow derived macrophages. Imatinib was administered intraperitoneally to the mice, and serum tumour necrosis factor alpha (TNF alpha), organ inflammation and bone properties were examined. Results The cherubism mutant macrophages produced higher levels of TNF alpha in response to lipopolysaccharide compared to wild type macrophages, and imatinib did not significantly suppress TNF alpha production. Although imatinib suppressed osteoclast formation in vitro, administering it in vivo did not suppress organ inflammation and osteopenia. Conclusion The in vivo administration of imatinib had a minimal therapeutic impact in cherubism mutant mice. To establish better pharmaceutical interventions, it is necessary to integrate new findings from murine models with clinical data from patients with a definitive diagnosis of cherubism.
C1 [Mukai, Tomoyuki; Yahagi, Ayano; Iseki, Masanori; Ishihara, Katsuhiko] Kawasaki Med Sch, Dept Immunol & Mol Genet, 577 Matsushima, Kurashiki, Okayama 7000965, Japan.
   [Mukai, Tomoyuki; Akagi, Takahiko; Asano, Sumie Hiramatsu; Morita, Yoshitaka] Kawasaki Med Sch, Dept Rheumatol, Kurashiki, Okayama, Japan.
   [Tosa, Ikue] Okayama Univ, Dept Oral Rehabil & Regenerat Med, Grad Sch Med Dent & Pharmaceut Sci, Okayama, Japan.
   [Ono, Mitsuaki; Oohashi, Toshitaka] Okayama Univ, Dept Mol Biol & Biochem, Grad Sch Med Dent & Pharmaceut Sci, Okayama, Japan.
   [Kittaka, Mizuho; Ueki, Yasuyoshi] Indiana Univ, Sch Dent, Dept Biomed Sci & Comprehens Care, Indianapolis, IN USA.
   [Kittaka, Mizuho; Ueki, Yasuyoshi] Indiana Univ Sch Med, Indiana Ctr Musculoskeletal Hlth, Indianapolis, IN 46202 USA.
C3 Kawasaki Medical School; Kawasaki Medical School; Okayama University;
   Okayama University; Indiana University System; Indiana University
   Indianapolis; Indiana University System; Indiana University Bloomington
RP Mukai, T (通讯作者)，Kawasaki Med Sch, Dept Immunol & Mol Genet, 577 Matsushima, Kurashiki, Okayama 7000965, Japan.
EM mukait@med.kawasaki m.ac.jp
RI Oohashi, Toshitaka/B 1599 2011; Kittaka, Mizuho/AAT 7398 2021; Mukai,
   Tomoyuki/AAP 5771 2021; YAHAGI, AYANO/ISR 9099 2023
OI Mukai, Tomoyuki/0000 0002 0103 1621; Oohashi,
   Toshitaka/0000 0002 9302 1913; Kittaka, Mizuho/0000 0002 3626 1638;
   Ueki, Yasuyoshi/0000 0002 8660 626X; 
FU National Institute of Health [R01DE025870, R01DE025870 06S1,
   R21DE030561]; Research Project Grants from Kawasaki Medical School
   [R02 B062, R02 B063, R03 B046]; Health Labour Sciences Research Grant
   [20FC1047]; Teraoka Foundation; UCB Japan; JSPS KAKENHI [18K08398,
   20K08814, 20K17442, 21K08484]; GSK Japan Research Grant; Mishima Kaiun
   foundation; Grants in Aid for Scientific Research [18K08398, 21K08484,
   20K21678, 20K17442, 20K08814] Funding Source: KAKEN
FX The National Institute of Health, Grant/Award Number: R01DE025870,
   R01DE025870 06S1 and R21DE030561; Research Project Grants from Kawasaki
   Medical School, Grant/Award Number: R02 B062, R02 B063 and R03 B046;
   Health Labour Sciences Research Grant, Grant/Award Number: 20FC1047;
   Teraoka Foundation; UCB Japan; JSPS KAKENHI, Grant/Award Number:
   18K08398, 20K08814, 20K17442 and 21K08484; GSK Japan Research Grant; the
   Mishima Kaiun foundation
CR Akagi T, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21114145
   Bader Meunier B, 2018, RHEUMATOLOGY, V57, P606, DOI 10.1093/rheumatology/kex306
   Battaglia A, 2000, OTOLARYNG HEAD NECK, V122, P573, DOI 10.1016/S0194 5998(00)70104 5
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Chrcanovic BR, 2021, INT J ORAL MAX SURG, V50, P43, DOI 10.1016/j.ijom.2020.05.021
   de la Fuente MA, 2006, MOL CELL BIOL, V26, P5214, DOI 10.1128/MCB.00087 06
   Demetri GD, 2002, NEW ENGL J MED, V347, P472, DOI 10.1056/NEJMoa020461
   Dimitriou ID, 2018, CELL REP, V24, P1123, DOI 10.1016/j.celrep.2018.06.075
   Druker BJ, 2006, NEW ENGL J MED, V355, P2408, DOI 10.1056/NEJMoa062867
   Eiden S, 2017, ROFO FORTSCHR RONTG, V189, P675, DOI 10.1055/s 0043 105074
   Foucault I, 2005, BLOOD, V105, P1106, DOI 10.1182/blood 2003 08 2965
   Fujita S, 2018, BONE, V106, P156, DOI 10.1016/j.bone.2017.10.017
   Gao YG, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22158182
   Gupta S, 2019, OR SURG OR MED OR PA, V128, pE191, DOI 10.1016/j.oooo.2019.01.082
   Hatani T, 2008, CURR MED CHEM, V15, P549
   Hero M, 2013, BONE, V52, P347, DOI 10.1016/j.bone.2012.10.003
   Hwang RF, 2003, CLIN CANCER RES, V9, P6534
   Kadlub N, 2015, J BONE MINER RES, V30, P878, DOI 10.1002/jbmr.2431
   Kantarjian H, 2002, NEW ENGL J MED, V346, P645, DOI 10.1056/NEJMoa011573
   Kawahara K, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22084169
   Kleiber GM, 2014, J ORAL MAXIL SURG, V72, P2186, DOI 10.1016/j.joms.2014.05.027
   Kueper J, 2022, INT J ORAL MAX SURG, V51, P54, DOI 10.1016/j.ijom.2021.04.001
   Kurebayashi J, 2006, CANCER CHEMOTH PHARM, V58, P460, DOI 10.1007/s00280 006 0185 x
   Levaot N, 2011, CELL, V147, P1324, DOI 10.1016/j.cell.2011.10.045
   Levaot N, 2011, J CLIN INVEST, V121, P3244, DOI 10.1172/JCI45843
   Morbach H, 2013, CLIN IMMUNOL, V147, P185, DOI 10.1016/j.clim.2012.12.012
   Mukai T, 2015, ARTHRITIS RHEUMATOL, V67, P656, DOI 10.1002/art.38975
   Mukai T, 2014, J BONE MINER RES, V29, P2618, DOI 10.1002/jbmr.2295
   Mukai T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105518
   Nagasu A, 2019, CELLS BASEL, V8, DOI 10.3390/cells8050402
   Papadaki ME, 2012, ORPHANET J RARE DIS, V7, DOI 10.1186/1750 1172 7 S1 S6
   Reichenberger EJ, 2012, ORPHANET J RARE DIS, V7, DOI 10.1186/1750 1172 7 S1 S5
   Ricalde P, 2019, J ORAL MAXIL SURG, V77, DOI 10.1016/j.joms.2019.02.021
   Schreuder WH, 2021, BONE, V149, DOI 10.1016/j.bone.2021.115935
   Serrano Candelas E, 2018, MOL ONCOL, V12, P1383, DOI 10.1002/1878 0261.12332
   Stern SM, 2013, RHEUM DIS CLIN N AM, V39, P735, DOI 10.1016/j.rdc.2013.05.002
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Tosa I, 2019, BIOCHEM BIOPH RES CO, V516, P1229, DOI 10.1016/j.bbrc.2019.07.014
   Ueki Y, 2001, NAT GENET, V28, P125, DOI 10.1038/88832
   Ueki Y, 2007, CELL, V128, P71, DOI 10.1016/j.cell.2006.10.047
   Yoshimoto T, 2018, J BONE MINER RES, V33, P1513, DOI 10.1002/jbmr.3449
   Yoshitaka T, 2014, CELL REP, V8, P1752, DOI 10.1016/j.celrep.2014.08.023
   Yoshitaka T, 2014, J BONE MINER RES, V29, P1170, DOI 10.1002/jbmr.2125
NR 43
TC 6
Z9 6
U1 0
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1354 523X
EI 1601 0825
J9 ORAL DIS
JI Oral Dis.
PD APR
PY 2023
VL 29
IS 3
BP 1089
EP 1101
DI 10.1111/odi.14073
EA NOV 2021
PG 13
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA A3UQ5
UT WOS:000721493700001
PM 34743383
OA Green Published, Green Accepted
DA 2025 08 17
ER

PT J
AU Francis, N
   Ayodele, BA
   O'Brien Simpson, NM
   Birchmeier, W
   Pike, RN
   Pagel, CN
   Mackie, EJ
AF Francis, Nidhish
   Ayodele, Babatunde A.
   O'Brien Simpson, Neil M.
   Birchmeier, Walter
   Pike, Robert N.
   Pagel, Charles N.
   Mackie, Eleanor J.
TI Keratinocyte specific ablation of protease activated receptor 2 prevents
   gingival inflammation and bone loss in a mouse model of periodontal
   disease
SO CELLULAR MICROBIOLOGY
LA English
DT Article
ID LIGATURE INDUCED PERIODONTITIS; NITRIC OXIDE SYNTHASE; HEPATOCYTE
   GROWTH FACTOR; MURINE LESION MODEL; PORPHYROMONAS GINGIVALIS;
   MAST CELLS; T CELLS; EXPRESSION; MICE; RGPA
AB Chronic periodontitis is characterised by gingival inflammation and alveolar bone loss. A major aetiological agent is Porphyromonas gingivalis, which secretes proteases that activate protease activated receptor 2 (PAR(2)). PAR(2) expressed on oral keratinocytes is activated by proteases released by P. gingivalis, inducing secretion of interleukin 6 (IL 6), and global knockout of PAR(2) prevents bone loss and inflammation in a periodontal disease model in mice. To test the hypothesis that PAR(2) expressed on gingival keratinocytes is required for periodontal disease pathology, keratinocyte specific PAR(2) null mice were generated using K14 Cre targeted deletion of the PAR(2) gene (F2rl1). These mice were subjected to a model of periodontitis involving placement of a ligature around a tooth, combined with P. gingivalis infection ("Lig+Inf"). The intervention caused a significant 44% decrease in alveolar bone volume (assessed by microcomputed tomography) in wildtype (K14 Cre:F2rl1(wt/wt)), but not littermate keratinocyte specific PAR(2) null (K14 Cre:F2rl1(fl/fl)) mice. Keratinocyte specific ablation of PAR(2) prevented the significant Lig + Inf induced increase (2.8 fold) in the number of osteoclasts in alveolar bone and the significant up regulation (2.4 4 fold) of the inflammatory markers IL 6, IL 1 beta, interferon gamma, myeloperoxidase, and CD11b in gingival tissue. These data suggest that PAR(2) expressed on oral epithelial cells is a critical regulator of periodontitis induced bone loss and will help in designing novel therapies with which to treat the disease.
C1 [Francis, Nidhish; Ayodele, Babatunde A.; Pagel, Charles N.] Univ Melbourne, Dept Vet Biosci, Melbourne Vet Sch, Parkville, Vic, Australia.
   [O'Brien Simpson, Neil M.] Univ Melbourne, Melbourne Dent Sch, Inst Bio21, Parkville, Vic, Australia.
   [Birchmeier, Walter] Max Delbruck Ctr Mol Med, Berlin, Germany.
   [Pike, Robert N.] La Trobe Univ, La Trobe Inst Mol Sci, Bundoora, Vic, Australia.
   [Francis, Nidhish] Charles Sturt Univ, Sch Anim & Vet Sci, Wagga Wagga, NSW 2650, Australia.
C3 University of Melbourne; University of Melbourne; Helmholtz Association;
   Max Delbruck Center for Molecular Medicine; La Trobe University; Charles
   Sturt University
RP Mackie, EJ (通讯作者)，Univ Melbourne, Dept Vet Biosci, Melbourne Vet Sch, Fac Vet & Agr Sci, Parkville, Vic 3010, Australia.
EM ejmackie@unimelb.edu.au
RI ; Pagel, Charles/A 8890 2014; O'Brien Simpson, Neil/B 2901 2009;
   Ayodele, Babatunde/AAA 7271 2022; Francis, Nidhish/AAX 3068 2020;
   Mackie, Eleanor/B 2045 2008
OI Ayodele, Babatunde/0000 0002 0308 1497; Pagel,
   Charles/0000 0002 7844 2242; Mackie, Eleanor/0000 0002 8057 5407;
   O'Brien Simpson, Neil/0000 0001 8462 5603; Francis,
   Nidhish/0000 0002 9475 2144
FU National Health and Medical Research Council [1044103]
FX National Health and Medical Research Council, Grant/Award Number:
   1044103
CR Abe T, 2013, J IMMUNOL METHODS, V394, P49, DOI 10.1016/j.jim.2013.05.002
   Abraham LA, 2000, BONE, V26, P7, DOI 10.1016/S8756 3282(99)00237 9
   Adams MN, 2011, PHARMACOL THERAPEUT, V130, P248, DOI 10.1016/j.pharmthera.2011.01.003
   Alshurafa Hashem N., 2004, BMC Pharmacology, V4, P12, DOI 10.1186/1471 2210 4 12
   Baker PJ, 2000, INFECT IMMUN, V68, P5864, DOI 10.1128/IAI.68.10.5864 5868.2000
   Bar Shavit R, 2002, IMMUNOLOGY, V105, P35, DOI 10.1046/j.0019 2805.2001.01351.x
   Belibasakis GN, 2010, CELL BIOL INT, V34, P287, DOI 10.1042/CBI20090290
   Bostanci N, 2012, FEMS MICROBIOL LETT, V333, P1, DOI 10.1111/j.1574 6968.2012.02579.x
   Campbell TM, 2003, CALCIFIED TISSUE INT, V73, P49, DOI 10.1007/s00223 002 2120 4
   Carvalho RFD, 2010, EXP DERMATOL, V19, P117, DOI 10.1111/j.1600 0625.2009.00998.x
   D'Aiuto F, 2004, J DENT RES, V83, P156, DOI 10.1177/154405910408300214
   D'Andrea MR, 2000, BIOTECH HISTOCHEM, V75, P85, DOI 10.3109/10520290009064152
   Fehlner Gardiner CC, 1999, DIFFERENTIATION, V65, P27, DOI 10.1046/j.1432 0436.1999.6510027.x
   Francis N, 2017, INT J BIOCHEM CELL B, V92, P95, DOI 10.1016/j.biocel.2017.09.015
   Georgy SR, 2010, CLIN EXP PHARMACOL P, V37, P328, DOI 10.1111/j.1440 1681.2009.05294.x
   Grenier D, 2006, ORAL MICROBIOL IMMUN, V21, P190, DOI 10.1111/j.1399 302X.2006.00278.x
   Gully N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100838
   Herrera BS, 2011, J PERIODONTOL, V82, P1608, DOI 10.1902/jop.2011.100768
   Holzhausen M, 2006, AM J PATHOL, V168, P1189, DOI 10.2353/ajpath.2006.050658
   Holzhausen M, 2005, J DENT RES, V84, P154, DOI 10.1177/154405910508400209
   Huelsken J, 2001, CELL, V105, P533, DOI 10.1016/S0092 8674(01)00336 1
   Kayal RA, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/639368
   Lappin DF, 2000, J PERIODONTAL RES, V35, P369, DOI 10.1034/j.1600 0765.2000.035006369.x
   Lichti U, 2008, NAT PROTOC, V3, P799, DOI 10.1038/nprot.2008.50
   Lin J, 2014, INFECT IMMUN, V82, P4127, DOI 10.1128/IAI.02084 14
   Lindner JR, 2000, J IMMUNOL, V165, P6504, DOI 10.4049/jimmunol.165.11.6504
   Liu Y, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 07465 5
   Lohinai Z, 1998, BRIT J PHARMACOL, V123, P353, DOI 10.1038/sj.bjp.0701604
   Loos BG, 2000, J PERIODONTOL, V71, P1528, DOI 10.1902/jop.2000.71.10.1528
   Lourbakos A, 1998, FEBS LETT, V435, P45, DOI 10.1016/S0014 5793(98)01036 9
   Lourbakos A, 2001, INFECT IMMUN, V69, P5121, DOI 10.1128/IAI.69.8.5121 5130.2001
   LUNDQVIST C, 1994, J IMMUNOL, V153, P2302
   Malcolm J, 2016, J DENT RES, V95, P704, DOI 10.1177/0022034516634630
   Moormann C, 2006, J INVEST DERMATOL, V126, P746, DOI 10.1038/sj.jid.5700169
   O'Brien Simpson NM, 2000, INFECT IMMUN, V68, P2704, DOI 10.1128/IAI.68.5.2704 2712.2000
   O'Brien Simpson NM, 2001, INFECT IMMUN, V69, P7527, DOI 10.1128/IAI.69.12.7527 7534.2001
   O'Brien Simpson NM, 2000, INFECT IMMUN, V68, P4055, DOI 10.1128/IAI.68.7.4055 4063.2000
   Pagel CN, 2003, BONE, V33, P733, DOI 10.1016/S8756 3282(03)00209 6
   Palm E, 2013, BMC MICROBIOL, V13, DOI 10.1186/1471 2180 13 155
   Pathirana RD, 2007, INFECT IMMUN, V75, P1436, DOI 10.1128/IAI.01627 06
   Pfaffl MW, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.9.e36
   Ramachandran R, 2011, J BIOL CHEM, V286, P24638, DOI 10.1074/jbc.M110.201988
   Shpacovitch VM, 2004, J LEUKOCYTE BIOL, V76, P388, DOI 10.1189/jlb.0503221
   Simon P, 2003, BIOINFORMATICS, V19, P1439, DOI 10.1093/bioinformatics/btg157
   Smith R, 2004, J BONE MINER RES, V19, P507, DOI 10.1359/JBMR.0301248
   Truett GE, 2000, BIOTECHNIQUES, V29, P52, DOI 10.2144/00291bm09
   Uehara A, 2005, J IMMUNOL, V175, P6076, DOI 10.4049/jimmunol.175.9.6076
   van't Hof RJ, 2000, P NATL ACAD SCI USA, V97, P7993, DOI 10.1073/pnas.130511497
   Wong DM, 2010, INFECT IMMUN, V78, P629, DOI 10.1128/IAI.01019 09
NR 49
TC 6
Z9 8
U1 1
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1462 5814
EI 1462 5822
J9 CELL MICROBIOL
JI Cell Microbiol.
PD NOV
PY 2018
VL 20
IS 11
AR e12891
DI 10.1111/cmi.12891
PG 13
WC Cell Biology; Microbiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Microbiology
GA GY8FU
UT WOS:000448858900008
PM 30009515
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Migliore, A
   Gigliucci, G
   Alekseeva, L
   Avasthi, S
   Bannuru, RR
   Chevalier, X
   Conrozier, T
   Crimaldi, S
   Damjanov, N
   de Campos, GC
   Diracoglu, D
   Herrero Beaumont, G
   Iolascon, G
   Ionescu, R
   Isailovic, N
   Jerosch, J
   Lains, J
   Maheu, E
   Makri, S
   Martusevich, N
   Cerinc, MM
   Micu, M
   Pavelka, K
   Petrella, RJ
   Tarantino, U
   Raman, R
AF Migliore, Alberto
   Gigliucci, Gianfranco
   Alekseeva, Liudmila
   Avasthi, Sachin
   Bannuru, Raveendhara R.
   Chevalier, Xavier
   Conrozier, Thierry
   Crimaldi, Sergio
   Damjanov, Nemanja
   de Campos, Gustavo Constantino
   Diracoglu, Demirhan
   Herrero Beaumont, Gabriel
   Iolascon, Giovanni
   Ionescu, Ruxandra
   Isailovic, Natasa
   Jerosch, Joerg
   Lains, Jorge
   Maheu, Emmanuel
   Makri, Souzi
   Martusevich, Natalia
   Cerinc, Marco Matucci
   Micu, Mihaela
   Pavelka, Karel
   Petrella, Robert J.
   Tarantino, Umberto
   Raman, Raghu
TI Treat to target strategy for knee osteoarthritis. International
   technical expert panel consensus and good clinical practice statements
SO THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE
LA English
DT Article
DE knee osteoarthritis; NSAIDs; osteoarthritis; outcome research; treatment
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; ACCEPTABLE SYMPTOM STATE;
   EVIDENCE BASED GUIDELINE; RHEUMATOID ARTHRITIS; HIP OSTEOARTHRITIS;
   METABOLIC SYNDROME; OBESE PATIENTS; RISK FACTORS; WEIGHT LOSS; BODY MASS
AB Background: In this work, we aimed to establish a clinical target in the management of knee osteoarthritis (KOA) and to propose good clinical practice (GCP) statements for carrying out a treat to target strategy. Methods: A steering committee of seven experts had formulated a provisional set of recommendations that were exposed for discussion and modification to a technical expert panel (TEP) of 25 multidisciplinary experts from Europe, North America, South America and Asia. The level of evidence and strength of each recommendation was discussed. The TEP formulated overarching principles and GCP statements based on the level of agreement for each item with a vote using a 10 point numerical scale. Results: Two overarching principles and 10 GCP statements were formulated by the TEP. These GCP statements suggest: treatment should achieve clinical improvement bringing the patient to the Patient Acceptable Symptom State (PASS); pharmacological and nonpharmacological treatment should begin as early as possible, with an early diagnosis of symptomatic KOA; the patient should be evaluated every 3 6 months; risk factors of KOA progression should be identified and managed with patients at the beginning of the treatment and monitored regularly; treatment should be adapted according to patient phenotype and disease severity; healthy lifestyle must be promoted and monitored. The level of agreement average ranged from 8.7 to 9.6 on scale. Conclusions: The proposed overarching principles and GCP statements have the aim of involving patients, general practitioners and multidisciplinary specialists in sharing a therapeutic treat to target strategy for KOA management based on the best evidence and expert opinions.
C1 [Isailovic, Natasa] Humanitas Res Hosp, Div Rheumatol & Clin Immunol, Via A Manzoni 56, I 20089 Milan, Italy.
   [Migliore, Alberto; Gigliucci, Gianfranco] San Pietro Fatebenefratelli Hosp, Rheumatol Unit, Rome, Italy.
   [Alekseeva, Liudmila] VA Nasonova Res Inst Rheumatol, Dept Metab Dis Bone & Joints, Moscow, Russia.
   [Avasthi, Sachin] Dr Ram Manohar Lohia Hosp, Dept Emergency Med, Lucknow, Uttar Pradesh, India.
   [Bannuru, Raveendhara R.] Tufts Med Ctr, Ctr Treatment Comparison & Integrat Anal, Div Rheumatol, Boston, MA 02111 USA.
   [Chevalier, Xavier] Henri Mondor Hosp, Unit Rheumatol, Creteil, France.
   [Conrozier, Thierry] Hop Nord Franche, Serv Rhumatol, Belfort, France.
   [Crimaldi, Sergio] Humanitas Res Hosp, Chirurg Ortoped Mininvas & Nuove Tecnol, Castellanza, Italy.
   [Damjanov, Nemanja] Univ Belgrade, Inst Rheumatol, Med Sch, Belgrade, Serbia.
   [de Campos, Gustavo Constantino] Univ Estadual Campinas, Dept Orthopaed & Traumatol, Sao Paulo, SP, Brazil.
   [Diracoglu, Demirhan] Istanbul Univ, Dept Phys Med & Rehabil, Div Pain Med, Istanbul, Turkey.
   [Herrero Beaumont, Gabriel] IIS Fdn Jimenez Diaz UAM, Joint & Bone Res Unit, Madrid, Spain.
   [Iolascon, Giovanni] Univ Campania LVanvitelli, Dept Med & Surg Specialties & Dent, Caserta, Italy.
   [Ionescu, Ruxandra] Univ Med & Pharm Carol Davila, Dept Internal Med & Rheumatol, Sf Maria Hosp, Bucharest, Romania.
   [Jerosch, Joerg] Johanna Etienne Hosp, Orthopaed Dept, Neuss, Germany.
   [Lains, Jorge] Rovisco Pais Med & Rehabil Ctr, Phys Rehabil Med Dept, Tocha, Portugal.
   [Maheu, Emmanuel] St Antoine Hosp, AP HP, Rheumatol Dept, Paris, France.
   [Makri, Souzi] EUPATI, Brussels, Belgium.
   [Martusevich, Natalia] Belorussian State Med Univ, Dept Rheumatol, Minsk, BELARUS.
   [Cerinc, Marco Matucci] Univ Florence, Dept Expt & Clin Med, Florence, Italy.
   [Micu, Mihaela] Rehabil Clin Hosp, Rehabil Dept 2, Cluj Napoca, Romania.
   [Pavelka, Karel] Inst Rheumatol, Prague, Czech Republic.
   [Petrella, Robert J.] Univ Western Ontario, Sch Kinesiol, Dept Family Med, London, ON, Canada.
   [Tarantino, Umberto] Policlin Tor Vergata Fdn, Dept Orthopaed & Traumatol, Rome, Italy.
   [Raman, Raghu] Hull & East Yorkshire NHS Trust, Acad Dept Orthopaed, Castle Hill Hosp, Cottingham, England.
C3 Tufts Medical Center; Assistance Publique Hopitaux Paris (APHP);
   Universite Paris Est Creteil Val de Marne (UPEC); Hopital Universitaire
   Henri Mondor   APHP; University of Belgrade; Universidade Estadual de
   Campinas; Istanbul University; Fundacion Jimenez Diaz; Carol Davila
   University of Medicine & Pharmacy; Assistance Publique Hopitaux Paris
   (APHP); Sorbonne Universite; Hopital Universitaire Saint Antoine   APHP;
   University of Florence; Institute of Rheumatology; Western University
   (University of Western Ontario); University of Hull
RP Isailovic, N (通讯作者)，Humanitas Res Hosp, Div Rheumatol & Clin Immunol, Via A Manzoni 56, I 20089 Milan, Italy.
EM natasa.isailovic@humanitasresearch.it
RI Lains, Jorge/HFZ 7626 2022; Alekseeva, Liudmila/I 7028 2017; Isailovic,
   Natasa/AAB 4047 2020; Bannuru, Raveendhara/G 2601 2011; Pavelka,
   Karel/E 6578 2017; Dıraçoğlu, Demirhan/AAE 3131 2020; Alberto,
   Migliore/AAX 9382 2020; Micu, Mihaela/AAP 2694 2020; Iolascon,
   Giovanni/T 6220 2017
OI Isailovic, Natasa/0000 0002 9819 8822; Lains, Jorge/0000 0002 8737 7569;
   Crimaldi, Sergio/0000 0002 8392 3745; Bannuru,
   Raveendhara/0000 0002 8069 5783; TARANTINO, Umberto/0000 0003 0330 2189;
   Pavelka, Karel/0000 0003 1952 8422; 
CR Arthritis Foundation/Centers for Disease Control and Prevention, 2010, NAT PUBL HLTH AG OST
   Bally M, 2018, PHARMACOEPIDEM DR S, V27, P69, DOI 10.1002/pds.4358
   Bannuru RR, 2019, OSTEOARTHR CARTILAGE, V27, P1578, DOI 10.1016/j.joca.2019.06.011
   Bastick AN, 2016, BRIT J GEN PRACT, V66, pE32, DOI 10.3399/bjgp15X688129
   Baudart P, 2017, RMD OPEN, V3, DOI 10.1136/rmdopen 2017 000442
   Bennell KL, 2011, J SCI MED SPORT, V14, P4, DOI 10.1016/j.jsams.2010.08.002
   Bhala N, 2013, LANCET, V382, P769, DOI 10.1016/S0140 6736(13)60900 9
   Brown GA, 2013, J AM ACAD ORTHOP SUR, V21, P577, DOI [10.5435/00124635 201309020 00009, 10.5435/JAAOS 21 09 577]
   Bruyère O, 2019, SEMIN ARTHRITIS RHEU, V49, P337, DOI 10.1016/j.semarthrit.2019.04.008
   Bruyère O, 2015, DRUG AGING, V32, P179, DOI 10.1007/s40266 015 0243 3
   Castañeda S, 2014, RHEUMATOLOGY, V53, P1, DOI 10.1093/rheumatology/ket247
   Christensen P, 2017, AM J CLIN NUTR, V106, P755, DOI 10.3945/ajcn.117.158543
   Christensen R, 2007, ANN RHEUM DIS, V66, P433, DOI 10.1136/ard.2006.065904
   Collins JE, 2014, OSTEOARTHR CARTILAGE, V22, P622, DOI 10.1016/j.joca.2014.03.009
   Conrozier T, 2018, CARTILAGE, V9, P370, DOI 10.1177/1947603517723072
   Cooper C, 2000, ARTHRITIS RHEUM, V43, P995, DOI 10.1002/1529 0131(200005)43:5<995::AID ANR6>3.0.CO;2 1
   Courties A, 2016, DIABETES RES CLIN PR, V122, P198, DOI 10.1016/j.diabres.2016.10.021
   Cross M, 2014, ANN RHEUM DIS, V73, P1323, DOI 10.1136/annrheumdis 2013 204763
   Dell'Isola A, 2016, BMC MUSCULOSKEL DIS, V17, DOI 10.1186/s12891 016 1286 2
   Deveza LA, 2017, OSTEOARTHR CARTILAGE, V25, P1926, DOI 10.1016/j.joca.2017.08.009
   Doherty M, 2011, ANN RHEUM DIS, V70, P1534, DOI 10.1136/ard.2011.154047
   Dougados M, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2118
   Driban JB, 2018, J ORTHOP RES, V36, P876, DOI 10.1002/jor.23675
   Duclos M, 2016, ANN PHYS REHABIL MED, V59, P157, DOI 10.1016/j.rehab.2016.04.002
   Eaton Charles B, 2004, Med Health R I, V87, P201
   Farr JN, 2010, PHYS THER, V90, P356, DOI 10.2522/ptj.20090041
   FELSON DT, 1988, ANN INTERN MED, V109, P18, DOI 10.7326/0003 4819 109 1 18
   Fernandes L, 2013, ANN RHEUM DIS, V72, P1125, DOI 10.1136/annrheumdis 2012 202745
   Fransen M, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004376.pub3
   Grotle M, 2008, BMC MUSCULOSKEL DIS, V9, DOI 10.1186/1471 2474 9 132
   Gudbergsen H, 2012, OSTEOARTHR CARTILAGE, V20, P495, DOI 10.1016/j.joca.2012.02.639
   Hall AJ, 2016, EUR J PREV CARDIOL, V23, P938, DOI 10.1177/2047487315610663
   Herrero Beaumont G, 2009, SEMIN ARTHRITIS RHEU, V39, P71, DOI 10.1016/j.semarthrit.2009.03.006
   Hochberg MC, 2012, ARTHRIT CARE RES, V64, P465, DOI 10.1002/acr.21596
   Hsu CC, 2015, HYPERTENSION, V66, P524, DOI 10.1161/HYPERTENSIONAHA.114.05105
   Iolascon G, 2017, EUR GERIATR MED, V8, P383, DOI 10.1016/j.eurger.2017.07.008
   Jevsevar DS, 2013, J AM ACAD ORTHOP SUR, V21, P571, DOI 10.5435/JAAOS 21 09 571
   Karsdal MA, 2015, OSTEOARTHR CARTILAGE, V23, P550, DOI 10.1016/j.joca.2014.12.024
   Khan M, 2018, CAN MED ASSOC J, V190, pE72, DOI 10.1503/cmaj.170696
   Kluzek S, 2016, ANN RHEUM DIS, V75, P1749, DOI 10.1136/annrheumdis 2015 208056
   Kulkarni K, 2016, MATURITAS, V89, P22, DOI 10.1016/j.maturitas.2016.04.006
   Langworthy MJ, 2014, MIL MED, V179, P815, DOI 10.7205/MILMED D 14 00052
   Li HX, 2016, ANN TRANSL MED, V4, DOI 10.21037/atm.2016.03.48
   Lo GH, 2009, OSTEOARTHR CARTILAGE, V17, P1562, DOI 10.1016/j.joca.2009.06.006
   Lohmander LS, 2009, ANN RHEUM DIS, V68, P490, DOI 10.1136/ard.2008.089748
   Louati K, 2015, RMD OPEN, V1, DOI 10.1136/rmdopen 2015 000077
   Maheu E, 2019, SEMIN ARTHRITIS RHEU, V48, P563, DOI 10.1016/j.semarthrit.2018.06.002
   Mahler EAM, 2018, J RHEUMATOL, V45, P122, DOI 10.3899/jrheum.170181
   McAlindon TE, 2015, OSTEOARTHR CARTILAGE, V23, P747, DOI 10.1016/j.joca.2015.03.005
   McAlindon TE, 2014, OSTEOARTHR CARTILAGE, V22, P363, DOI 10.1016/j.joca.2014.01.003
   Messier SP, 2013, JAMA J AM MED ASSOC, V310, P1263, DOI 10.1001/jama.2013.277669
   Migliore A, 2015, EUR REV MED PHARMACO, V19, P1124
   Migliore A, 2017, RHEUMATOL INT, V37, P1227, DOI 10.1007/s00296 017 3700 y
   Nelson Fred R T, 2018, Open Orthop J, V12, P105, DOI 10.2174/1874325001812010105
   Nguyen C, 2017, EXPERT OPIN DRUG SAF, V16, P897, DOI 10.1080/14740338.2017.1344211
   Nicholls AS, 2012, KNEE, V19, P316, DOI 10.1016/j.knee.2011.06.008
   Nielen JTH, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003739
   Nissen SE, 2016, NEW ENGL J MED, V375, P2519, DOI 10.1056/NEJMoa1611593
   Nüesch E, 2011, BMJ BRIT MED J, V342, DOI 10.1136/bmj.d1165
   Osthoff AKR, 2018, ANN RHEUM DIS, V77, P1251, DOI 10.1136/annrheumdis 2018 213585
   Pelletier JP, 2016, SEMIN ARTHRITIS RHEU, V45, pS22, DOI 10.1016/j.semarthrit.2015.11.009
   Puenpatom RA, 2009, POSTGRAD MED, V121, P9, DOI 10.3810/pgm.2009.11.2073
   Quintrec Jean Laurent Le, 2014, Open Rheumatol J, V8, P89, DOI 10.2174/1874312901408010089
   Raman R, 2018, CARTILAGE, V9, P263, DOI 10.1177/1947603517693043
   Reed GW, 2018, J AM COLL CARDIOL, V71, P1741, DOI 10.1016/j.jacc.2018.02.036
   Richette P, 2014, JOINT BONE SPINE, V81, P4, DOI 10.1016/j.jbspin.2013.11.010
   Richette P, 2011, ANN RHEUM DIS, V70, P139, DOI 10.1136/ard.2010.134015
   Roberts E, 2016, ANN RHEUM DIS, V75, P552, DOI 10.1136/annrheumdis 2014 206914
   Roman Blas JA, 2016, EXPERT OPIN PHARMACO, V17, P1745, DOI 10.1080/14656566.2016.1201070
   Schneider K, 2018, DRUG AGING, V35, P559, DOI 10.1007/s40266 018 0550 6
   Siemieniuk RAC, 2017, BMJ BRIT MED J, V357, DOI 10.1136/bmj.j1982
   Smolen JS, 2016, ANN RHEUM DIS, V75, P3, DOI 10.1136/annrheumdis 2015 207524
   Smolen JS, 2010, ANN RHEUM DIS, V69, P631, DOI 10.1136/ard.2009.123919
   Teichtahl AJ, 2008, OBESITY, V16, P232, DOI 10.1038/oby.2007.30
   Trelle S, 2011, BMJ BRIT MED J, V342, DOI 10.1136/bmj.c7086
   Tubach F, 2005, ANN RHEUM DIS, V64, P34, DOI 10.1136/ard.2004.023028
   Tubach F, 2012, ARTHRIT CARE RES, V64, P1699, DOI 10.1002/acr.21747
   van der Esch M, 2015, OSTEOARTHR CARTILAGE, V23, P544, DOI 10.1016/j.joca.2015.01.006
   Williams MF, 2016, J DIABETES COMPLICAT, V30, P944, DOI 10.1016/j.jdiacomp.2016.02.016
   Woolf AD, 2003, B WORLD HEALTH ORGAN, V81, P646
   Wylde V, 2007, KNEE, V14, P417, DOI 10.1016/j.knee.2007.06.001
   Yoshimura N, 2012, OSTEOARTHR CARTILAGE, V20, P1217, DOI 10.1016/j.joca.2012.06.006
   Zeng C, 2018, BRIT J SPORT MED, V52, P642, DOI 10.1136/bjsports 2017 098043
   Zhang W, 2010, OSTEOARTHR CARTILAGE, V18, P476, DOI 10.1016/j.joca.2010.01.013
   Zhang XY, 2017, BMC NEPHROL, V18, DOI 10.1186/s12882 017 0673 8
NR 85
TC 29
Z9 30
U1 1
U2 4
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1759 720X
EI 1759 7218
J9 THER ADV MUSCULOSKEL
JI Ther. Adv. Musculoskelet. Dis.
PD DEC
PY 2019
VL 11
AR 1759720X19893800
DI 10.1177/1759720X19893800
PG 15
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA JX5RY
UT WOS:000503793100001
PM 31903099
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Andersson, A
   Bernardi, AI
   Stubelius, A
   Nurkkala Karlsson, M
   Ohlsson, C
   Carlsten, H
   Islander, U
AF Andersson, Annica
   Bernardi, Angelina I.
   Stubelius, Alexandra
   Nurkkala Karlsson, Merja
   Ohlsson, Claes
   Carlsten, Hans
   Islander, Ulrika
TI Selective oestrogen receptor modulators lasofoxifene and bazedoxifene
   inhibit joint inflammation and osteoporosis in ovariectomised mice with
   collagen induced arthritis
SO RHEUMATOLOGY
LA English
DT Article
DE arthritis; selective oestrogen receptor modulators; oestrogen;
   osteoporosis
ID BONE MINERAL DENSITY; EXPERIMENTAL POSTMENOPAUSAL POLYARTHRITIS;
   OSTEOCLAST DIFFERENTIATION FACTOR; RHEUMATOID ARTHRITIS; VERTEBRAL
   FRACTURE; CELL DEVELOPMENT; II COLLAGEN; T CELLS; DISEASE; WOMEN
AB Objective. RA predominantly affects post menopausal women and is strongly associated with development of generalised osteoporosis. To find treatments that target both joint manifestations and osteoporosis in RA is desirable. The third generation of selective oestrogen receptor modulators (SERMs) [lasofoxifene (LAS) and bazedoxifene (BZA)] are new treatment options for post menopausal osteoporosis. The aim of this study was to investigate the effects of LAS and BZA on arthritic disease and inflammation associated bone loss using CIA in mice.
   Methods. Female DBA/1 mice were ovariectomised and subjected to CIA as a model of post menopausal RA. Mice received treatment with LAS, BZA, 17 beta estradiol (E2) as reference or vehicle. Arthritis development was assessed and BMD was determined by peripheral quantitative CT of the femurs. Serologic markers of inflammation and cartilage destruction were analysed. Immune cells in lymph nodes were studied by flow cytometry.
   Results. LAS and BZA reduced the clinical severity of arthritis as well as the grade of histologic synovitis and erosions on cartilage and bone. Moreover, SERMs protected against generalised bone loss in CIA by increasing trabecular BMD. Both SERMs decreasem marker of cd seruartilage destruction and LAS reduced serum IL 6 levels. SERMs did not alter Th17 cells in lymph nodes as E2 did.
   Conclusion. The anti osteoporotic drugs LAS and BZA were found to be potent inhibitors of joint inflammation and bone destruction in experimental arthritis. This study provides new important knowledge regarding the treatment regimen of post menopausal women with RA who suffer from increased risk for osteoporosis.
C1 [Andersson, Annica; Bernardi, Angelina I.; Stubelius, Alexandra; Nurkkala Karlsson, Merja; Carlsten, Hans; Islander, Ulrika] Univ Gothenburg, Sahlgrenska Acad, Inst Med, Ctr Bone & Arthrit Res,Dept Rheumatol & Inflammat, Gothenburg, Sweden.
   [Ohlsson, Claes] Univ Gothenburg, Sahlgrenska Acad, Inst Med, Ctr Bone & Arthrit Res,Dept Internal Med & Clin N, Gothenburg, Sweden.
C3 University of Gothenburg; University of Gothenburg
RP Andersson, A (通讯作者)，Univ Gothenburg, Dept Rheumatol & Inflammat Res, Box 480, S 40530 Gothenburg, Sweden.
EM annica.andersson@rheuma.gu.se
RI Islander, Ulrika/S 4824 2019; Ohlsson, Claes/AGP 3544 2022; Andersson,
   Annica/B 4424 2015; Ohlsson, Claes/HIR 6959 2022
OI Islander, Ulrika/0000 0002 8493 1739; Stubelius,
   Alexandra/0000 0003 4170 8892; Ohlsson, Claes/0000 0002 9633 2805
FU Gothenburg Medical Society, COMBINE; Swedish Research Council; King
   Gustav V's 80 years' Foundation; Association Against Rheumatism; Swedish
   Association for Medical Research; Sahlgrenska University Hospital;
   Swedish Society of Medicine; Wilhelm and Martina Lundgren Science
   Foundation; Lars Hierta Foundation; Magnus Bergvall Foundation; Family
   Tholens and Kristlers Foundation; Ragnar Soderberg Foundation; Ake
   Wiberg Foundation; Novo Nordisk Fonden [NNF14OC0010513, NNF13OC0005785]
   Funding Source: researchfish
FX This work was supported by the Gothenburg Medical Society, COMBINE, the
   Swedish Research Council, King Gustav V's 80 years' Foundation, the
   Association Against Rheumatism, the Swedish Association for Medical
   Research and Sahlgrenska University Hospital, the Swedish Society of
   Medicine, the Wilhelm and Martina Lundgren Science Foundation, the Lars
   Hierta Foundation, the Magnus Bergvall Foundation, the Family Tholens
   and Kristlers Foundation, the Ragnar Soderberg Foundation and the Ake
   Wiberg Foundation. The FACS Canto II instrument was bought thanks to
   generous support from the Inga Britt and Arne Lundberg Foundation.
   Lasofoxifene and bazedoxifene were kind gifts from Pfizer.
CR Alamanos Y, 2006, SEMIN ARTHRITIS RHEU, V36, P182, DOI 10.1016/j.semarthrit.2006.08.006
   Andersson A, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075 015 0548 y
   Bernardi AI, 2015, IMMUNOBIOLOGY, V220, P1122, DOI 10.1016/j.imbio.2015.05.009
   Bernardi AI, 2014, IMMUN INFLAMM DIS, V2, P214, DOI 10.1002/iid3.37
   Börjesson AE, 2013, J BONE MINER RES, V28, P1117, DOI 10.1002/jbmr.1842
   Cohen SB, 2008, ARTHRITIS RHEUM, V58, P1299, DOI 10.1002/art.23417
   Cook AD, 1996, ARTHRITIS RHEUM, V39, P1720, DOI 10.1002/art.1780391015
   Cummings SR, 2010, NEW ENGL J MED, V362, P686, DOI 10.1056/NEJMoa0808692
   D'Elia HF, 2003, J RHEUMATOL, V30, P1456
   d'Elia HF, 2003, ANN RHEUM DIS, V62, P617, DOI 10.1136/ard.62.7.617
   De Man YA, 2008, ARTHRIT RHEUM ARTHR, V59, P1241, DOI 10.1002/art.24003
   Eggelmeijer F, 1996, ARTHRITIS RHEUM, V39, P396, DOI 10.1002/art.1780390307
   Engdahl C, 2010, ARTHRITIS RHEUM US, V62, P524, DOI 10.1002/art.25055
   Ettinger B, 1999, JAMA J AM MED ASSOC, V282, P637, DOI 10.1001/jama.282.7.637
   Hegen M, 2008, ANN RHEUM DIS, V67, P1505, DOI 10.1136/ard.2007.076430
   Holmdahl R, 1989, Br J Rheumatol, V28 Suppl 1, P54
   Holmdahl R., 1989, BR J RHEUMATOL S1, V28, P69
   Horwood NJ, 1999, BIOCHEM BIOPH RES CO, V265, P144, DOI 10.1006/bbrc.1999.1623
   Humphreys JH, 2013, ANN RHEUM DIS, V72, P1315, DOI 10.1136/annrheumdis 2012 201960
   JANSSON L, 1994, J NEUROIMMUNOL, V53, P203, DOI 10.1016/0165 5728(94)90030 2
   Jochems C, 2008, CLIN EXP IMMUNOL, V152, P593, DOI 10.1111/j.1365 2249.2008.03660.x
   Jochems C, 2005, ARTHRITIS RES THER, V7, pR837, DOI 10.1186/ar1753
   Jochems C, 2007, ARTHRITIS RHEUM US, V56, P3261, DOI 10.1002/art.22873
   Kim JM, 2007, NAT IMMUNOL, V8, P191, DOI 10.1038/ni1428
   Kobayashi K, 2000, J EXP MED, V191, P275, DOI 10.1084/jem.191.2.275
   Kotake S, 1999, J CLIN INVEST, V103, P1345, DOI 10.1172/JCI5703
   Lubberts E, 2008, CYTOKINE, V41, P84, DOI 10.1016/j.cyto.2007.09.014
   Maldonado López R, 1999, J LEUKOCYTE BIOL, V66, P242, DOI 10.1002/jlb.66.2.242
   Manabe N, 2001, J IMMUNOL, V167, P2625, DOI 10.4049/jimmunol.167.5.2625
   McInnes IB, 2011, NEW ENGL J MED, V365, P2205, DOI 10.1056/NEJMra1004965
   Nalbandian G, 2005, IMMUNOL RES, V31, P91, DOI 10.1385/IR:31:2:091
   Nandakumar KS, 2003, AM J PATHOL, V163, P1827, DOI 10.1016/S0002 9440(10)63542 0
   O'Neill SK, 2007, J IMMUNOL, V179, P5109, DOI 10.4049/jimmunol.179.8.5109
   Oliver JE, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2825
   Pikwer M, 2012, ANN RHEUM DIS, V71, P378, DOI 10.1136/ard.2011.200059
   Quinn JMW, 1998, ENDOCRINOLOGY, V139, P4424, DOI 10.1210/endo.139.10.6331
   Reagan Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07 9574LSF
   Roggia C, 2001, P NATL ACAD SCI USA, V98, P13960, DOI 10.1073/pnas.251534698
   Scott DL, 2000, RHEUMATOLOGY, V39, P24, DOI 10.1093/oxfordjournals.rheumatology.a031490
   Silverman SL, 2012, OSTEOPOROSIS INT, V23, P1069, DOI 10.1007/s00198 011 1721 z
   Sinigaglia L, 2000, J RHEUMATOL, V27, P2582
   SPECTOR TD, 1993, BRIT MED J, V306, P558, DOI 10.1136/bmj.306.6877.558
   Stewart A, 2004, RHEUMATOLOGY, V43, P1561, DOI 10.1093/rheumatology/keh385
   Svensson L, 1998, CLIN EXP IMMUNOL, V111, P521
   van Staa TP, 2006, ARTHRITIS RHEUM US, V54, P3104, DOI 10.1002/art.22117
   Wilder RL, 1998, ANN NY ACAD SCI, V840, P45, DOI 10.1111/j.1749 6632.1998.tb09547.x
   Windahl SH, 1999, J CLIN INVEST, V104, P895, DOI 10.1172/JCI6730
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
NR 48
TC 23
Z9 30
U1 0
U2 13
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1462 0324
EI 1462 0332
J9 RHEUMATOLOGY
JI RHEUMATOLOGY
PD MAR
PY 2016
VL 55
IS 3
BP 553
EP 563
DI 10.1093/rheumatology/kev355
PG 11
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA DF7SL
UT WOS:000371557800021
PM 26424839
OA hybrid, Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU Yang, S
   Leslie, WD
   Morin, SN
   Majumdar, SR
   Lix, LM
AF Yang, S.
   Leslie, W. D.
   Morin, S. N.
   Majumdar, S. R.
   Lix, L. M.
TI Antiresorptive therapy and newly diagnosed diabetes in women: a
   historical cohort study
SO DIABETES OBESITY & METABOLISM
LA English
DT Article
DE antiresorptive therapy; diabetes; osteoporosis; women
ID POSTMENOPAUSAL WOMEN; ENERGY METABOLISM; UNDERCARBOXYLATED OSTEOCALCIN;
   GLUCOSE HOMEOSTASIS; BIOCHEMICAL MARKERS; DETECTION BIAS; BONE DENSITY;
   RISK; METAANALYSIS; OSTEOPOROSIS
AB Aims: Undercarboxylated osteocalcin (ucOC) promotes increased insulin sensitivity and increased secretion. Since antiresorptive therapy (AT) decreases ucOC levels, AT could increase the risk of diabetes and this would have serious clinical ramifications. We sought to test this hypothesis by examining the association between new use of AT and newly diagnosed diabetes.
   Methods: Using a bone mineral density (BMD) registry for Manitoba, Canada, we identified 33 640 women aged >= 50 years without diabetes at their first BMD test for 1998 2013. We linked these women to a province wide retail pharmacy database to identify new AT exposure each year for up to 5 years after a BMD test. Time dependent analysis was used to test the independent association between new use of AT and newly diagnosed diabetes.
   Results: This cohort had a mean age of 65 years, a mean body mass index of 26.8 kg/m(2), and 12% were receiving glucocorticoid and 13% hormone replacement therapy at BMD test. In the first year after BMD test, 29% of women started AT (bisphosphonates, 92%). Over a mean 4.2 years of follow up, 3.7% new AT users and 4.2% non users had diabetes (adjusted hazard ratio 1.01, 95% confidence interval 0.87 1.16). Sensitivity analyses using AT dose response gradients also found no significant associations with diabetes.
   Conclusions: Despite the plausible biological mechanisms related to ucOC, new use of AT was not a risk factor for diabetes in this cohort. The clinical implications of these findings are reassuring, as AT is widely prescribed for treating osteoporosis in older women who are also at high risk of developing diabetes.
C1 [Yang, S.; Leslie, W. D.] Univ Manitoba, Dept Internal Med, C5121 409 Tache Ave, Winnipeg, MB R2H 2A6, Canada.
   [Morin, S. N.] McGill Univ, Dept Med, Montreal, PQ, Canada.
   [Majumdar, S. R.] Univ Alberta, Dept Med, Edmonton, AB, Canada.
   [Lix, L. M.] Univ Manitoba, Dept Community Hlth Sci, Winnipeg, MB, Canada.
C3 University of Manitoba; McGill University; University of Alberta;
   University of Manitoba
RP Leslie, WD (通讯作者)，Univ Manitoba, Dept Internal Med, C5121 409 Tache Ave, Winnipeg, MB R2H 2A6, Canada.
EM bleslie@sbgh.mb.ca
RI ; Leslie, William/JKJ 1433 2023
OI Leslie, William/0000 0002 1056 1691; Morin, Suzanne/0000 0002 4317 492X
FU Manitoba Research Chair
FX S. R. M. holds the Endowed Chair in Patient Health Management (Faculties
   of Medicine and Dentistry and Pharmacy and Pharmaceutical Sciences,
   University of Alberta). L. M. L. is supported by a Manitoba Research
   Chair. S. N. M. is a clinician researcher scholar of Fonds de Recherche
   du Quebec en Sante.
CR Bell JA, 2014, OBES REV, V15, P504, DOI 10.1111/obr.12157
   Blanchard JF, 1996, DIABETES CARE, V19, P807, DOI 10.2337/diacare.19.8.807
   Bowker SL, 2011, DIABETES CARE, V34, P2542, DOI 10.2337/dc11 1199
   Chateau D, 2012, CAN J PUBLIC HEALTH, V103, pS23, DOI 10.1007/BF03403825
   Cooper C, 1999, OSTEOPOROSIS INT, V9, P2
   Ferron M, 2010, CELL, V142, P296, DOI 10.1016/j.cell.2010.06.003
   Fraser LA, 2011, OSTEOPOROSIS INT, V22, P829, DOI 10.1007/s00198 010 1465 1
   Harslof T, 2015, J CLIN ENDOCR METAB, V100, P2758, DOI 10.1210/jc.2015 1477
   Herman WH, 2007, DIABETES CARE, V30, P1912, DOI 10.2337/dc07 9924
   Ho PM, 2009, CIRCULATION, V119, P3028, DOI 10.1161/CIRCULATIONAHA.108.768986
   James Robert C, 2004, Chronic Dis Can, V25, P7
   Johnell O, 2002, J CLIN ENDOCR METAB, V87, P985, DOI 10.1210/jc.87.3.985
   Johnson JA, 2011, DIABETOLOGIA, V54, P2263, DOI 10.1007/s00125 011 2242 1
   Kozma CM, 2013, PATIENT PREFER ADHER, V7, P509, DOI 10.2147/PPA.S40736
   Kozyrskyj AL, 1998, ANN PHARMACOTHER, V32, P1152, DOI 10.1345/aph.18117
   Kumar R, 2010, AM J CLIN NUTR, V92, P1528, DOI 10.3945/ajcn.2010.30108
   Lee NK, 2007, CELL, V130, P456, DOI 10.1016/j.cell.2007.05.047
   Leslie WD, 2005, J CLIN DENSITOM, V8, P25, DOI 10.1385/JCD:8:1:025
   Leslie WD, 2003, J CLIN DENSITOM, V6, P275, DOI 10.1385/JCD:6:3:275
   Leslie WD, 2010, J BONE MINER RES, V25, P2350, DOI 10.1002/jbmr.123
   Leslie WD, 2010, J CLIN ENDOCR METAB, V95, P3272, DOI 10.1210/jc.2009 2794
   Lévesque LE, 2010, BRIT MED J, V340, DOI 10.1136/bmj.b5087
   Liu DM, 2015, OSTEOPOROSIS INT, V26, P2823, DOI 10.1007/s00198 015 3197 8
   Lix L., 2006, DEFINING VALIDATING
   Miller E, 1996, CAN MED ASSOC J, V154, P1855
   Public Health Agency of Canada, 2011, Facts & figures
   Raymond C., 2010, PHARM USE MANITOBA O
   Roos LL, 1999, J CLIN EPIDEMIOL, V52, P39, DOI 10.1016/S0895 4356(98)00126 7
   Roos LL, 2003, HEALTH SERV RES, V38, P1339, DOI 10.1111/1475 6773.00180
   Schafer AL, 2011, J CLIN ENDOCR METAB, V96, pE1982, DOI 10.1210/jc.2011 0587
   Schwartz AV, 2013, J BONE MINER RES, V28, P1348, DOI 10.1002/jbmr.1865
   Starup Linde J, 2014, OSTEOPOROSIS INT, V25, P1697, DOI 10.1007/s00198 014 2676 7
   Toulis KA, 2015, J CLIN ENDOCR METAB, V100, P1933, DOI 10.1210/jc.2014 3481
   van Buuren S, 2011, J STAT SOFTW, V45, P1
   Vestergaard P, 2007, OSTEOPOROSIS INT, V18, P427, DOI 10.1007/s00198 006 0253 4
   Vestergaard P, 2011, CALCIFIED TISSUE INT, V89, P265, DOI 10.1007/s00223 011 9515 z
   Yoshida M, 2008, DIABETES CARE, V31, P2092, DOI 10.2337/dc08 1204
NR 37
TC 13
Z9 14
U1 0
U2 4
PU WILEY BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1462 8902
EI 1463 1326
J9 DIABETES OBES METAB
JI Diabetes Obes. Metab.
PD SEP
PY 2016
VL 18
IS 9
BP 875
EP 881
DI 10.1111/dom.12678
PG 7
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA DT7JX
UT WOS:000381664000004
PM 27097832
DA 2025 08 17
ER

PT J
AU Fujikawa, K
   Kawakami, A
   Tanaka, F
   Iwamoto, N
   Tamai, M
   Eguchi, K
AF Fujikawa, K.
   Kawakami, A.
   Tanaka, F.
   Iwamoto, N.
   Tamai, M.
   Eguchi, K.
TI Calcium/calmodulin dependent protein kinase II (CaMKII) regulates tumour
   necrosis factor related apoptosis inducing ligand (TRAIL) mediated
   apoptosis of fibroblast like synovial cells (FLS) by phosphorylation of
   Akt
SO CLINICAL AND EXPERIMENTAL RHEUMATOLOGY
LA English
DT Article
DE Akt; calcium/calmodulin dependent protein kinase II; fibroblast like
   synovial cells; rheumatoid arthritis; tumour necrosis factor related
   apoptosis inducing ligand
ID RHEUMATOID ARTHRITIS; OSTEOCLAST DIFFERENTIATION; PATHWAY; INDUCTION;
   RECEPTOR; THERAPY
AB Objective
   We tried to determine whether calcium/calmodulin dependent protein kinase II (CaMKII) regulates tumour necrosis factor related apoptosis inducing ligand (TRAIL) mediated apoptosis of fibroblast like synovial cells (FLS).
   Methods
   CaMKII expression in FLS was studied by both western blotting and real time reverse transcription polymerase chain reaction (RT PCR). TRAIL mediated apoptosis of FLS was quantified by disruption of mitochondrial transmembrane potential (Delta Psi m), Leu Glu His Asp (IETD) ase activity and DNA degradation. Involvement of CaMKII and other kinases, including extracellular signal regulated kinase (ERK), p38, c Jun N terminal kinase (JNK) and Akt during TRAIL mediated apoptosis of FLS was estimated by the use of specific each kinase chemical inhibitor.
   Results
   Predominant expression of delta and gamma isoform, of CaMKII, especially delta isoform, was determined in cultured FLS. TRAIL rapidly induced apoptosis of FLS as well as the phosphorylation of extracellular signal regulated kinase (ERK), p38, c Jun N terminal kinase (JNK) and Akt. Chemical kinase inhibitor toward CaMKII and Akt significantly augmented TRAIL mediated apoptosis of FLS whereas those toward ERK, p38 and JNK did not. Notably, CaMKII chemical inhibitor abrogated TRAIL induced phosphorylation of Akt. Elevation of Leu Glu His Asp (IETD) ase activity was associated with the apoptotic phenomena, which was almost suppressed by IETD competitive peptides.
   Conclusion
   Our results suggest a first observation that CaMKII regulates TRAIL mediated apoptosis of FLS through Akt, standing an upstream of caspase 8 dependent cascades. Furthermore, CaMKII is suggested to be a new therapeutic target molecule of rheumatoid arthritis (RA).
C1 [Fujikawa, K.; Kawakami, A.; Iwamoto, N.; Tamai, M.; Eguchi, K.] Nagasaki Univ, Unit Translat Med, Dept Immunol & Rheumatol, Grad Sch Biomed Sci, Nagasaki 8528501, Japan.
   [Tanaka, F.] NHO Ureshino Med Ctr, Saga, Japan.
C3 Nagasaki University
RP Eguchi, K (通讯作者)，Nagasaki Univ, Unit Translat Med, Dept Immunol & Rheumatol, Grad Sch Biomed Sci, 1 7 1 Sakamoto, Nagasaki 8528501, Japan.
EM eguchi@net.nagasaki u.ac.jp
RI ; Kawakami, Atsushi/D 3785 2019
OI Tamai, Mami/0000 0002 2429 7553; 
CR Ang ESM, 2007, J CELL PHYSIOL, V212, P787, DOI 10.1002/jcp.21076
   Colbran RJ, 2004, CURR OPIN NEUROBIOL, V14, P318, DOI 10.1016/j.conb.2004.05.008
   Coury F, 2008, CLIN EXP RHEUMATOL, V26, P234
   Inaba M, 2008, CLIN EXP RHEUMATOL, V26, P52
   Kraan TCTMV, 2003, ARTHRITIS RHEUM US, V48, P2132, DOI 10.1002/art.11096
   Marganski WA, 2005, CIRC RES, V97, P541, DOI 10.1161/01.RES.0000182630.29093.0d
   Marino JH, 2003, J IMMUNOL METHODS, V283, P291, DOI 10.1016/S0022 1759(03)00103 0
   Miyamoto Hiroyuki, 2003, Mol Interv, V3, P404, DOI 10.1124/mi.3.7.404
   Miyashita T, 2004, CLIN EXP IMMUNOL, V137, P430, DOI 10.1111/j.1365 2249.2004.02534.x
   Sato K, 2006, NAT MED, V12, P1410, DOI 10.1038/nm1515
   Seales EC, 2006, J CELL BIOCHEM, V97, P45, DOI 10.1002/jcb.20659
   Tamai M, 2006, J LAB CLIN MED, V147, P182, DOI 10.1016/j.lab.2005.12.001
   Weinmann P, 2007, CLIN EXP RHEUMATOL, V25, P885
   Yamamoto Yamaguchi Y, 2001, EXP HEMATOL, V29, P582, DOI 10.1016/S0301 472X(01)00626 9
   Yamauchi T, 2005, BIOL PHARM BULL, V28, P1342, DOI 10.1248/bpb.28.1342
   Zayzafoon M, 2006, J CELL BIOCHEM, V97, P56, DOI 10.1002/jcb.20675
NR 16
TC 11
Z9 14
U1 0
U2 4
PU CLINICAL & EXPER RHEUMATOLOGY
PI PISA
PA VIA SANTA MARIA 31, 56126 PISA, ITALY
SN 0392 856X
EI 1593 098X
J9 CLIN EXP RHEUMATOL
JI Clin. Exp. Rheumatol.
PD NOV DEC
PY 2009
VL 27
IS 6
BP 952
EP 957
PG 6
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA 552CO
UT WOS:000274264700010
PM 20149311
DA 2025 08 17
ER

PT J
AU Peng, F
   Shi, JQ
   Cai, WS
   Zhou, SQ
   Zhang, YB
AF Peng, Fei
   Shi, Jiaqi
   Cai, Weisong
   Zhou, Siqi
   Zhang, Yubiao
TI Cryptochrome 1 Promotes Low Level Laser Irradiation Induced Bone Marrow
   Mesenchymal Stem Cells Proliferation and Differentiation
SO JOURNAL OF BIOMATERIALS AND TISSUE ENGINEERING
LA English
DT Article
DE Bone Marrow Mesenchymal Stem Cells; Proliferation; Differentiation;
   Low Level Laser Irradiation; Cryptochrome 1
ID CIRCADIAN CLOCK; ACTIVATION; OSTEOBLAST; GENETICS; CANCER
AB Mesenchymal stem cells (MSCs) are able to differentiate into diverse types of specialized cells, playing a critical role in cell based therapy in various medical fields. Cryptochrome 1 (Cry1) is a key clock gene of circadian rhythms, which control nearly all biological processes. The present study aims to investigate the effect of Cry1 on low level laser irradiation (LLLI) induced bone marrow MSCs (BMSCs) proliferation and differentiation. Our results showed that BMSCs responded to LLLI treatment (660 nm, 10 mW) in a dose  and time dependent manner. High cell growth and proliferation were observed when cells were irradiated with a dose of 1.0 J/cm(2) after 72 h. LLLI increased Cry1 protein expression, which was paralleled with the proliferation of BMSCs induced by LLLI. Overexpression of Cry1 potentiated LLLI induced cell growth and proliferation, accompanied by enhanced Cyclin D1, c myc and bcl 2 expressions. In contrast, Cry1 deficiency significantly suppressed cell viability, proliferation and the above cell cycle regulators expressions. Moreover, LLLI induced BMSCs osteogenic differentiation was augmented by Cry1 upregulation, but was inhibited after knockdown of Cry1. Mechanistically, Cry1 overexpression further increased ERK phosphorylation and RhoA activity under LLLI treatment, concomitantly with inhibition of cAMP level and PKA signaling However, inverse results were obtained in cells lacking of Cry1 These findings demonstrate that Cry increases the sensitivity of BMSCs to LLLI, indicating that forced Cry1 expression may be a novel approach for improving MSCs based therapy in clinic.
C1 [Peng, Fei; Shi, Jiaqi; Cai, Weisong; Zhou, Siqi; Zhang, Yubiao] Wuhan Univ, Dept Orthoped, Renmin Hosp, Wuhan 430060, Hubei, Peoples R China.
C3 Wuhan University
RP Peng, F (通讯作者)，Wuhan Univ, Dept Orthoped, Renmin Hosp, Wuhan 430060, Hubei, Peoples R China.
FU National Natural Science Foundation of China [631308110]
FX This study was supported by the National Natural Science Foundation of
   China (grant No. 631308110).
CR Azevedo LH, 2006, LASER MED SCI, V21, P86, DOI 10.1007/s10103 006 0379 9
   Boucher H, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146674
   Bouvet Gerbettaz S, 2009, LASER SURG MED, V41, P291, DOI 10.1002/lsm.20759
   Chen X, 2006, STEM CELLS, V24, P2052, DOI 10.1634/stemcells.2005 0591
   Chen YC, 2005, EXP BIOL MED, V230, P731, DOI 10.1177/153537020523001006
   Agnol MAD, 2009, LASER MED SCI, V24, P909, DOI 10.1007/s10103 009 0648 5
   Eduardo FD, 2008, LASER SURG MED, V40, P433, DOI 10.1002/lsm.20646
   Fu LN, 2005, CELL, V122, P803, DOI 10.1016/j.cell.2005.06.028
   Barboza CAG, 2014, EINSTEIN SAO PAULO, V12, P75, DOI 10.1590/S1679 45082014AO2824
   Gambardella A, 2011, J BONE MINER RES, V26, P811, DOI 10.1002/jbmr.266
   Gao XJ, 2009, J BIOMED SCI, V16, DOI 10.1186/1423 0127 16 4
   Ginani F, 2017, EINSTEIN SAO PAULO, V15, P334, DOI [10.1590/S1679 45082017AO3991, 10.1590/s1679 45082017ao3991]
   Green CB, 2008, CELL, V134, P728, DOI 10.1016/j.cell.2008.08.022
   Horvát Karajz K, 2009, LASER SURG MED, V41, P463, DOI 10.1002/lsm.20791
   Hou JF, 2008, LASER SURG MED, V40, P726, DOI 10.1002/lsm.20709
   Hunt T, 2007, CELL, V129, P461, DOI 10.1016/j.cell.2007.04.015
   Kume K, 1999, CELL, V98, P193, DOI 10.1016/S0092 8674(00)81014 4
   Kushibiki Toshihiro, 2008, Int J Med Sci, V5, P319
   Kushibiki T, 2009, PHOTOMED LASER SURG, V27, P493, DOI 10.1089/pho.2008.2343
   Langlotz F, 1997, Comput Aided Surg, V2, P317, DOI 10.1002/(SICI)1097 0150(1997)2:6<317::AID IGS1>3.0.CO;2 2
   Lévi F, 2007, COLD SPRING HARB SYM, V72, P465, DOI 10.1101/sqb.2007.72.030
   Matsuo T, 2003, SCIENCE, V302, P255, DOI 10.1126/science.1086271
   Maury E, 2010, CIRC RES, V106, P447, DOI 10.1161/CIRCRESAHA.109.208355
   Minguell JJ, 2001, EXP BIOL MED, V226, P507, DOI 10.1177/153537020122600603
   Miyata H, 2006, INT ENDOD J, V39, P238, DOI 10.1111/j.1365 2591.2006.01080.x
   Mvula B, 2008, LASER MED SCI, V23, P277, DOI 10.1007/s10103 007 0479 1
   Okamoto T, 2002, BIOCHEM BIOPH RES CO, V295, P354, DOI 10.1016/S0006 291X(02)00661 7
   Renno ACM, 2007, PHOTOMED LASER SURG, V25, P275, DOI 10.1089/pho.2007.2055
   Reppert SM, 2002, NATURE, V418, P935, DOI 10.1038/nature00965
   Schernhammer ES, 2003, JNCI J NATL CANCER I, V95, P825, DOI 10.1093/jnci/95.11.825
   Schibler U, 2002, CELL, V111, P919, DOI 10.1016/S0092 8674(02)01225 4
   Shefer G, 2001, J CELL PHYSIOL, V187, P73, DOI 10.1002/1097 4652(2001)9999:9999<::AID JCP1053>3.0.CO;2 9
   Stein E, 2008, WIEN KLIN WOCHENSCHR, V120, P112, DOI 10.1007/s00508 008 0932 6
   Taniguchi D, 2009, LASER SURG MED, V41, P232, DOI 10.1002/lsm.20750
   Uccelli A, 2008, NAT REV IMMUNOL, V8, P726, DOI 10.1038/nri2395
   Vitaterna MH, 1999, P NATL ACAD SCI USA, V96, P12114, DOI 10.1073/pnas.96.21.12114
   Wang Y, 2006, ONCOL REP, V16, P755
   Wu JY, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0044027, 10.1371/journal.pone.0046393]
   Yu HY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061679
   Yu XJ, 2004, P NATL ACAD SCI USA, V101, P11203, DOI 10.1073/pnas.0402532101
   Yuan Y, 2017, CELL PHYSIOL BIOCHEM, V43, P237, DOI 10.1159/000480344
   Zaidi S, 2017, CIRC RES, V120, P923, DOI 10.1161/CIRCRESAHA.116.309140
NR 42
TC 2
Z9 2
U1 0
U2 8
PU AMER SCIENTIFIC PUBLISHERS
PI VALENCIA
PA 26650 THE OLD RD, STE 208, VALENCIA, CA 91381 0751 USA
SN 2157 9083
EI 2157 9091
J9 J BIOMATER TISS ENG
JI J. Biomater. Tissue Eng.
PD MAR
PY 2018
VL 8
IS 3
BP 416
EP 425
DI 10.1166/jbt.2018.1751
PG 10
WC Cell & Tissue Engineering
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA GG9SO
UT WOS:000433041600016
DA 2025 08 17
ER

PT J
AU Herstad, KMV
   Vinje, H
   Skancke, E
   Næverdal, T
   Corral, F
   Llarena, AK
   Heilmann, RM
   Suchodolski, JS
   Steiner, JM
   Nyquist, NF
AF Herstad, Kristin M., V
   Vinje, Hilde
   Skancke, Ellen
   Naeverdal, Terese
   Corral, Francisca
   Llarena, Ann Katrin
   Heilmann, Romy M.
   Suchodolski, Jan S.
   Steiner, Joerg M.
   Nyquist, Nicole Frost
TI Effects of Canine Obtained Lactic Acid Bacteria on the Fecal Microbiota
   and Inflammatory Markers in Dogs Receiving Non Steroidal
   Anti Inflammatory Treatment
SO ANIMALS
LA English
DT Article
DE probiotics; NSAID induced enteropathy; intestinal dysbiosis;
   inflammatory biomarkers
ID S100A12 CONCENTRATION; NSAID ENTEROPATHY; DISEASE SEVERITY;
   DOUBLE BLIND; INDOMETHACIN; CALPROTECTIN; ASSOCIATION; PREVALENCE;
   VALIDATION; PROBIOTICS
AB Simple Summary The use of non steroidal anti inflammatory drugs (NSAIDs) has prolonged the longevity and well being of dogs with osteoarthritis and other painful conditions. However, this treatment is also associated with diarrhea in dogs, but the pathogenetic mechanisms and possible prevention strategies remain unknown. This study aimed to determine whether canine obtained lactic acid bacteria affect the frequency of diarrhea, fecal microbiota (dysbiosis index), and gastrointestinal inflammation (assessed by calprotectin and S100A12/Calgranulin C) in dogs receiving NSAIDs. Diarrhea occurred in 4/12 dogs (33%) receiving placebo and 1/10 dogs (10%) receiving canine obtained lactic acid bacteria (LAB), but this difference was not significant. The fecal dysbiosis index, calprotectin, and S100A12 were not significantly different between dogs receiving NSAIDs and LAB and dogs receiving NSAIDs and placebo. This study suggests that LAB is safe to use in NSAID treated dogs, but further studies are needed to determine its potential to ameliorate diarrhea and gastrointestinal inflammation in dogs receiving NSAIDs. Non steroidal anti inflammatory drugs (NSAIDs) may cause enteropathy in dogs and probiotics may be one option to prevent this. The objective of this study was to determine whether the administration of canine obtained lactic acid bacteria (LAB) has an effect on the frequency of diarrhea, the composition of the fecal microbiota, and/or markers of gastrointestinal inflammation in dogs receiving NSAIDs when compared to dogs given NSAIDs and a placebo. A total of 22 dogs treated with NSAIDs for various clinical indications were enrolled in a seven day randomized, double blinded placebo controlled interventional study. Dogs were randomized to receive either placebo or LAB, a product containing Limosilactobacillus fermentum, Lacticaseibacillus rhamnosus, and Lactiplantibacillus plantarum. Fecal samples were collected on days one and seven. The fecal microbiota was evaluated using the fecal dysbiosis index (DI) and individual bacterial taxa. Fecal calprotectin (CP) and S100A12/Calgranulin C concentrations were used as markers of gastrointestinal inflammation. There was a difference in frequency of diarrhea between groups, with it affecting 4/12 dogs (33%) in the placebo group and 1/10 dogs (10%) in the LAB group, but this difference did not reach statistical significance (p = 0.32). There was a correlation between S100A12 and CP (p < 0.001), and Clostridium perfringens correlated with S100A12 (p < 0.015). Neither treatment significantly affected S100A12 (p = 0.37), CP (p = 0.12), or fecal DI (p = 0.65). This study suggests that LAB is a safe supplement to use for short term treatment in NSAID treated dogs, but further studies are needed to determine its potential to prevent NSAID induced enteropathy in dogs.
C1 [Herstad, Kristin M., V; Skancke, Ellen; Corral, Francisca] Norwegian Univ Life Sci, Fac Vet Med, Dept Compan Anim Clin Sci, N 1433 As, Norway.
   [Vinje, Hilde] Norwegian Univ Life Sci, Fac Chem Biotechnol & Food Sci, N 1433 As, Norway.
   [Naeverdal, Terese] EMPET Skedsmo Dyresykehus, N 2007 Kjeller, Norway.
   [Llarena, Ann Katrin; Nyquist, Nicole Frost] Norwegian Univ Life Sci, Fac Vet Med, Dept Paraclin Sci, N 1433 As, Norway.
   [Heilmann, Romy M.] Univ Leipzig, Vet Teaching Hosp, Coll Vet Med, Dept Small Anim, D 04103 Leipzig, Germany.
   [Suchodolski, Jan S.; Steiner, Joerg M.] Texas A&M Univ, Coll Vet Med & Biomed Sci, Dept Small Anim Clin Sci, Gastrointestinal Lab, 4474 TAMU, College Stn, TX 77843 USA.
C3 Norwegian University of Life Sciences; Norwegian University of Life
   Sciences; Norwegian University of Life Sciences; Leipzig University;
   Texas A&M University System; Texas A&M University College Station
RP Herstad, KMV (通讯作者)，Norwegian Univ Life Sci, Fac Vet Med, Dept Compan Anim Clin Sci, N 1433 As, Norway.
EM kristin.herstad@nmbu.no
OI Vinje, Hilde/0000 0003 0318 0214; Heilmann, Romy/0000 0003 3485 5157;
   Llarena, Ann Katrin/0000 0001 5278 7253
FU Vetcare, Finland
FX The canine obtained lactic acid bacteria (LAB) product used in this
   study was provided by Vetcare, Finland. This product is commercially
   available as Canius (R).
CR AlShawaqfeh MK, 2017, FEMS MICROBIOL ECOL, V93, DOI 10.1093/femsec/fix136
   Aragon CL, 2007, JAVMA J AM VET MED A, V230, P514, DOI 10.2460/javma.230.4.514
   ARMSTRONG CP, 1987, GUT, V28, P527, DOI 10.1136/gut.28.5.527
   Beasley SS, 2006, J APPL MICROBIOL, V101, P131, DOI 10.1111/j.1365 2672.2006.02884.x
   Blake AB, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0224454
   Dial EJ, 2008, J GASTROEN HEPATOL, V23, pE384, DOI 10.1111/j.1440 1746.2007.05266.x
   Gómez Gallego C, 2016, VET MICROBIOL, V197, P122, DOI 10.1016/j.vetmic.2016.11.015
   Gotteland M, 2001, ALIMENT PHARM THER, V15, P11, DOI 10.1046/j.1365 2036.2001.00898.x
   Grützner N, 2014, ANAL BIOCHEM, V457, P65, DOI 10.1016/j.ab.2014.04.026
   Guard BC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127259
   Heilmann RM, 2019, VET IMMUNOL IMMUNOP, V211, P64, DOI 10.1016/j.vetimm.2019.04.003
   Heilmann RM, 2018, J VET INTERN MED, V32, P679, DOI 10.1111/jvim.15065
   Heilmann RM, 2016, VET CLIN PATH, V45, P135, DOI 10.1111/vcp.12320
   Heilmann RM, 2014, VET IMMUNOL IMMUNOP, V158, P156, DOI 10.1016/j.vetimm.2014.01.006
   Heilmann RM, 2011, VET IMMUNOL IMMUNOP, V144, P200, DOI 10.1016/j.vetimm.2011.09.011
   Heilmann RM, 2016, VET J, V215, P96, DOI 10.1016/j.tvjl.2016.03.001
   Herstad KMV, 2021, J VET INTERN MED, V35, P2177, DOI 10.1111/jvim.16201
   Herstad KMV, 2017, BMC VET RES, V13, DOI 10.1186/s12917 017 1073 9
   Hill C, 2014, NAT REV GASTRO HEPAT, V11, P506, DOI 10.1038/nrgastro.2014.66
   Hunt JR, 2015, VET J, V206, P183, DOI 10.1016/j.tvjl.2015.07.025
   Jones SM, 2020, J VET INTERN MED, V34, P1886, DOI 10.1111/jvim.15897
   Kaiser T, 2007, GUT, V56, P1706, DOI 10.1136/gut.2006.113431
   Kamil R, 2007, DIGEST DIS SCI, V52, P1247, DOI 10.1007/s10620 006 9443 3
   Lascelles BDX, 2005, VET THER, V6, P237
   Mabry K, 2021, J VET INTERN MED, V35, P853, DOI 10.1111/jvim.16057
   Mäkelä SM, 2021, BRIT J CLIN PHARMACO, V87, P4625, DOI 10.1111/bcp.14880
   Mäkivuokko H, 2010, BRIT J NUTR, V103, P227, DOI 10.1017/S0007114509991553
   Manninen TJK, 2006, APPL ENVIRON MICROB, V72, P6539, DOI 10.1128/AEM.02977 05
   Monteros MJM, 2021, SCI REP UK, V11, DOI 10.1038/s41598 020 80482 z
   Meling TR, 1996, SCAND J GASTROENTERO, V31, P339, DOI 10.3109/00365529609006407
   Minamoto Y, 2014, VET MICROBIOL, V174, P463, DOI 10.1016/j.vetmic.2014.10.005
   Montalto M, 2010, ALIMENT PHARM THER, V32, P209, DOI 10.1111/j.1365 2036.2010.04324.x
   Montalto M, 2013, J GASTROENTEROL, V48, P689, DOI 10.1007/s00535 012 0648 2
   Monteiro Steagall BP, 2013, J VET INTERN MED, V27, P1011, DOI 10.1111/jvim.12127
   Otani K, 2017, DIGESTION, V95, P22, DOI 10.1159/000452356
   Pilla R, 2021, VET CLIN N AM SMALL, V51, P605, DOI 10.1016/j.cvsm.2021.01.002
   Pilla R, 2020, J VET INTERN MED, V34, P1853, DOI 10.1111/jvim.15871
   Rogers MAM, 2016, CLIN MICROBIOL INFEC, V22, DOI 10.1016/j.cmi.2015.10.003
   Sandri M, 2017, BMC VET RES, V13, DOI 10.1186/s12917 017 0981 z
   Santiago López L, 2019, NUTRIENTS, V11, DOI 10.3390/nu11071610
   Shin SJ, 2017, INTEST RES, V15, P446, DOI 10.5217/ir.2017.15.4.446
   Sindern N, 2019, J VET INTERN MED, V33, P100, DOI 10.1111/jvim.15361
   Suchodolski JS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051907
   Sung CH, 2022, J FELINE MED SURG, V24, pE1, DOI 10.1177/1098612X221077876
   Tibble JA, 1999, GUT, V45, P362, DOI 10.1136/gut.45.3.362
   Uejima M, 1996, MICROBIOL IMMUNOL, V40, P553, DOI 10.1111/j.1348 0421.1996.tb01108.x
   Wang XL, 2021, FRONT CELL INFECT MI, V11, DOI 10.3389/fcimb.2021.679396
   Zhou Y, 2010, AM J PHYSIOL GASTR L, V298, pG722, DOI 10.1152/ajpgi.00387.2009
NR 48
TC 10
Z9 10
U1 1
U2 8
PU MDPI
PI BASEL
PA MDPI AG, Grosspeteranlage 5, CH 4052 BASEL, SWITZERLAND
SN 2076 2615
J9 ANIMALS BASEL
JI Animals
PD OCT
PY 2022
VL 12
IS 19
AR 2519
DI 10.3390/ani12192519
PG 12
WC Agriculture, Dairy & Animal Science; Veterinary Sciences; Zoology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Agriculture; Veterinary Sciences; Zoology
GA 5F9AF
UT WOS:000866602500001
PM 36230259
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Riester, SM
   Lin, Y
   Wang, W
   Cong, L
   Ali, AM
   Peck, SH
   Smith, LJ
   Currier, BL
   Clark, M
   Huddleston, P
   Krauss, W
   Yaszemski, MJ
   Morrey, ME
   Abdel, MP
   Bydon, M
   Qu, WC
   Larson, AN
   van Wijnen, AJ
   Nassr, A
AF Riester, Scott M.
   Lin, Yang
   Wang, Wei
   Cong, Lin
   Mohamed Ali, Abdel Moneim
   Peck, Sun H.
   Smith, Lachlan J.
   Currier, Bradford L.
   Clark, Michelle
   Huddleston, Paul
   Krauss, William
   Yaszemski, Michael J.
   Morrey, Mark E.
   Abdel, Matthew P.
   Bydon, Mohamad
   Qu, Wenchun
   Larson, Annalise N.
   van Wijnen, Andre J.
   Nassr, Ahmad
TI RNA sequencing identifies gene regulatory networks controlling
   extracellular matrix synthesis in intervertebral disk tissues
SO JOURNAL OF ORTHOPAEDIC RESEARCH
LA English
DT Article
DE RNA sequencing; nucleus pulposus; annulus fibrosus; intervertebral disk;
   extracellular matrix
ID NUCLEUS PULPOSUS CELLS; LUMBAR DISC; EXPRESSION; PHENOTYPE;
   DEGENERATION; CHONDROCYTES; HIF 1 ALPHA; MICROARRAY; PATHOLOGY; DISEASE
AB Degenerative disk disease of the spine is a major cause of back pain and disability. Optimization of regenerative medical therapies for degenerative disk disease requires a deep mechanistic understanding of the factors controlling the structural integrity of spinal tissues. In this investigation, we sought to identify candidate regulatory genes controlling extracellular matrix synthesis in spinal tissues. To achieve this goal we performed high throughput next generation RNA sequencing on 39 annulus fibrosus and 21 nucleus pulposus human tissue samples. Specimens were collected from patients undergoing surgical discectomy for the treatment of degenerative disk disease. Our studies identified associations between extracellular matrix genes, growth factors, and other important regulatory molecules. The fibrous matrix characteristic of annulus fibrosus was associated with expression of the growth factors platelet derived growth factor beta (PDGFB), vascular endothelial growth factor C (VEGFC), and fibroblast growth factor 9 (FGF9). Additionally we observed high expression of multiple signaling proteins involved in the NOTCH and WNT signaling cascades. Nucleus pulposus extracellular matrix related genes were associated with the expression of numerous diffusible growth factors largely associated with the transforming growth signaling cascade, including transforming factor alpha (TGFA), inhibin alpha (INHA), inhibin beta A (INHBA), bone morphogenetic proteins (BMP2, BMP6), and others. Clinical significance: this investigation provides important data on extracellular matrix gene regulatory networks in disk tissues. This information can be used to optimize pharmacologic, stem cell, and tissue engineering strategies for regeneration of the intervertebral disk and the treatment of back pain. (c) 2017 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 36:1356 1369, 2018.
C1 [Riester, Scott M.; Lin, Yang; Wang, Wei; Cong, Lin; Mohamed Ali, Abdel Moneim; Currier, Bradford L.; Huddleston, Paul; Yaszemski, Michael J.; Morrey, Mark E.; Abdel, Matthew P.; Larson, Annalise N.; van Wijnen, Andre J.; Nassr, Ahmad] Mayo Clin, Dept Orthoped Surg, 200 First St SW, Rochester, MN 55905 USA.
   [Riester, Scott M.] HealthPartners, Dept Occupat & Environm Med, Bloomington, MN USA.
   [Lin, Yang] Huazhong Univ Sci & Technol, Tongji Hosp, Dept Orthoped Surg, Tongji Med Coll, Wuhan, Hubei, Peoples R China.
   [Wang, Wei] Huazhong Univ Sci & Technol, Puai Hosp, Dept Orthoped Surg, Tongji Med Coll, Wuhan, Hubei, Peoples R China.
   [Cong, Lin] China Med Univ, Dept Orthoped Surg, Hosp 1, 155 Nanjing Bei St, Shenyang 110001, Liaoning, Peoples R China.
   [Peck, Sun H.; Smith, Lachlan J.] Univ Penn, Dept Neurosurg, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Peck, Sun H.; Smith, Lachlan J.] Univ Penn, Dept Orthopaed Surg, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Clark, Michelle; Krauss, William; Bydon, Mohamad] Mayo Clin, Dept Neurosurg, Rochester, MN USA.
   [Qu, Wenchun] Mayo Clin, Dept Phys Med & Rehabil, Rochester, MN USA.
   [Qu, Wenchun] Mayo Clin, Dept Anesthesiol, Div Pain Med, Rochester, MN USA.
   [Qu, Wenchun] Mayo Clin, Spine Ctr, Rochester, MN USA.
C3 Mayo Clinic; HealthPartners Institute for Education & Research; Huazhong
   University of Science & Technology; Huazhong University of Science &
   Technology; China Medical University; University of Pennsylvania;
   University of Pennsylvania; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo
   Clinic
RP van Wijnen, AJ; Nassr, A (通讯作者)，Mayo Clin, Dept Orthoped Surg, 200 First St SW, Rochester, MN 55905 USA.
EM vanwijnen.andre@mayo.edu; ahmad@mayo.edu
RI ; Peck, Sun/KLD 0171 2024; van Wijnen, Andre/AAG 3578 2019; Larson,
   A./AAC 7158 2019; Riester, Scott/K 7032 2015; Huddleston,
   Paul/ABI 6836 2020
OI Smith, Lachlan/0000 0001 5823 6073; Huddleston,
   Paul/0000 0002 8665 3787; Elomeiri, Moneim/0000 0002 5942 3476; van
   Wijnen, Andre J./0000 0002 4458 0946
FU Cervical Spine Research Society 21st Century grant; National Institutes
   of Health; National Institute of Arthritis and Musculoskeletal and Skin
   Diseases NIAMS [R03 AR066342, R01 AR049069]; National Center for
   Advancing Translational Sciences (NCATS) [UL1 TR000135]; Doctor Research
   Startup Fund' of Liaoning Province [201601114]
FX Grant sponsor: Cervical Spine Research Society 21st Century grant; Grant
   sponsor: National Institutes of Health; Grant sponsor: National
   Institute of Arthritis and Musculoskeletal and Skin Diseases NIAMS;
   Grant numbers: R03 AR066342, R01 AR049069; Grant sponsor: The National
   Center for Advancing Translational Sciences (NCATS); Grant number: UL1
   TR000135; Grant sponsor: Doctor Research Startup Fund' of Liaoning
   Province; Grant number: 201601114.
CR Agrawal A, 2007, AM J PHYSIOL CELL PH, V293, pC621, DOI 10.1152/ajpcell.00538.2006
   Agrawal A, 2008, ARTHRITIS RHEUM US, V58, P3798, DOI 10.1002/art.24073
   Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638
   BATTIE MC, 1991, SPINE, V16, P1015, DOI 10.1097/00007632 199109000 00001
   Camilleri ET, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287 016 0370 8
   CHELBERG MK, 1995, J ANAT, V186, P43
   Chen K, 2013, GENET MOL BIOL, V36, P448, DOI 10.1590/S1415 47572013000300021
   Driscoll T, 2014, ANN RHEUM DIS, V73, P975, DOI 10.1136/annrheumdis 2013 204631
   Dudakovic A, 2015, J BIOL CHEM, V290, P27604, DOI 10.1074/jbc.M115.672345
   Eirin A, 2014, GENE, V551, P55, DOI 10.1016/j.gene.2014.08.041
   Gilbert HTJ, 2013, CURR PAIN HEADACHE R, V17, DOI 10.1007/s11916 013 0377 0
   Gilson A, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar2931
   Gogate SS, 2011, ARTHRITIS RHEUM US, V63, P1950, DOI 10.1002/art.30342
   Gonzalez DM, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005189
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Kalari KR, 2014, BMC BIOINFORMATICS, V15, DOI 10.1186/1471 2105 15 224
   Kettler A, 2006, EUR SPINE J, V15, P705, DOI 10.1007/s00586 005 0954 y
   Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb 2013 14 4 r36
   Kim KW, 2003, SPINE, V28, P982, DOI 10.1097/00007632 200305150 00005
   LANE NE, 1993, J RHEUMATOL, V20, P1911
   Langfelder P, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471 2105 9 559
   Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb 2009 10 3 r25
   Lee CR, 2007, EUR SPINE J, V16, P2174, DOI 10.1007/s00586 007 0475 y
   Lin Y, 2016, J ORTHOP RES, V34, P1950, DOI 10.1002/jor.23209
   Minogue BM, 2010, ARTHRITIS RHEUM US, V62, P3695, DOI 10.1002/art.27710
   Minogue BM, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar2929
   Önnerfjord P, 2012, J BIOL CHEM, V287, P18913, DOI 10.1074/jbc.M111.298968
   PAZZAGLIA UE, 1989, J ROY SOC MED, V82, P413, DOI 10.1177/014107688908200714
   Peck SH, 2016, MOL GENET METAB, V118, P232, DOI 10.1016/j.ymgme.2016.06.002
   Peck SH, 2015, MOL GENET METAB, V116, P195, DOI 10.1016/j.ymgme.2015.09.008
   Power KA, 2011, ARTHRITIS RHEUM US, V63, P3876, DOI 10.1002/art.30607
   Risbud MV, 2015, J ORTHOP RES, V33, P283, DOI 10.1002/jor.22789
   Risbud MV, 2006, J CELL BIOCHEM, V98, P152, DOI 10.1002/jcb.20765
   Roberts S, 2006, J BONE JOINT SURG AM, V88A, P10, DOI 10.2106/JBJS.F.00019
   Rodriguez AG, 2012, J ORTHOP RES, V30, P280, DOI 10.1002/jor.21513
   Roughley PJ, 2002, BIOCHEM SOC T, V30, P869, DOI 10.1042/BST0300869
   Sakai D, 2009, SPINE, V34, P1448, DOI 10.1097/BRS.0b013e3181a55705
   Sanson B, 1996, NATURE, V383, P627, DOI 10.1038/383627a0
   Smith LJ, 2011, DIS MODEL MECH, V4, P31, DOI 10.1242/dmm.006403
   Smolders LA, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4157
   Sprinzak D, 2010, NATURE, V465, P86, DOI 10.1038/nature08959
   Tang YC, 2014, EXP THER MED, V7, P343, DOI 10.3892/etm.2013.1421
   Tong W, 2017, TRANSL RES, V181, P49, DOI 10.1016/j.trsl.2016.11.008
   VIDEMAN T, 1995, SPINE, V20, P699, DOI 10.1097/00007632 199503150 00011
   Vos T, 2015, LANCET, V386, P743, DOI 10.1016/S0140 6736(15)60692 4
   Yang F, 2009, J PATHOL, V218, P113, DOI 10.1002/path.2519
NR 46
TC 26
Z9 30
U1 0
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0736 0266
EI 1554 527X
J9 J ORTHOP RES
JI J. Orthop. Res.
PD MAY
PY 2018
VL 36
IS 5
BP 1356
EP 1369
DI 10.1002/jor.23834
PG 14
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA GI4SE
UT WOS:000434360700007
PM 29227558
OA Bronze, Green Accepted
DA 2025 08 17
ER

PT J
AU Luo, ZP
   Li, DW
   Luo, XB
   Li, LT
   Gu, SX
   Yu, L
   Ma, YZ
AF Luo, Zhanpeng
   Li, Dawei
   Luo, Xiaobo
   Li, Litao
   Gu, Suxi
   Yu, Long
   Ma, Yuanzheng
TI Decreased Expression of miR 548c 3p in Osteosarcoma Contributes to Cell
   Proliferation Via Targeting ITGAV
SO CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
LA English
DT Article
DE apoptosis; cell cycle; ITGAV; miR 548c 3p; osteosarcoma
ID INTEGRIN; MEDULLOBLASTOMA; MICRORNAS; THERAPY
AB The members of the integrin alpha v (ITGAV) family are widely expressed on many types of tumors and have been reported to be involved into angiogenesis, tumor metastases, and multicellular radioresistance. Osteosarcoma (OS) is the most common primary malignant bone tumor and the role of ITGAV in OS needs to be further elucidated. MicroRNAs are aberrantly expressed in a variety of cancers. Thus, the authors collected OS tissues (n = 15) and corresponding paracancerous tissues (n = 15) and found that the expression of miR 548c 3p was significantly downregulated in OS tissues and cell lines 143B, SaoS2, and HOS when compared to the corresponding paracancerous tissues and human osteoblast cell line hFOB (OB3), respectively. In addition, the authors identified that miR 548c 3p could directly target the 3' untranslated region of ITGAV, and miR 548c 3p overexpression inhibits the mRNA and protein levels of ITGAV, which were confirmed by the luciferase reporter assays. Interestingly, they also uncovered that miR 548c 3p overexpression or knockdown of ITGAV remarkably suppressed cell vitality and promoted apoptosis and G2/M cell cycle arrest, leading to abrogating the ability of colony formation. The results indicated that the miR 548c 3p, similar to the target agents against integrin av in clinical trials, could negatively regulate the ITGAV and be a promising tumor therapeutic target.
C1 [Luo, Zhanpeng; Li, Dawei; Ma, Yuanzheng] Southern Med Univ, Grad Sch, Guangzhou, Guangdong, Peoples R China.
   [Luo, Zhanpeng; Li, Dawei; Luo, Xiaobo; Li, Litao; Gu, Suxi; Yu, Long; Ma, Yuanzheng] Chinese PLA, Hosp 309, Dept Orthoped, 17 Heishanhu Rd, Beijing 100091, Peoples R China.
C3 Southern Medical University   China
RP Ma, YZ (通讯作者)，Chinese PLA, Hosp 309, Dept Orthoped, 17 Heishanhu Rd, Beijing 100091, Peoples R China.
EM myzdr@sina.com
RI Li, Dawei/G 5195 2012; gu, suxi/MBV 3551 2025
CR Bielack SS, 2002, J CLIN ONCOL, V20, P776, DOI 10.1200/JCO.20.3.776
   Cooper CR, 2002, NEOPLASIA, V4, P191, DOI 10.1038/sj.neo.7900224
   Curley GP, 1999, CELL MOL LIFE SCI, V56, P427, DOI 10.1007/s000180050443
   Duperret EK, 2015, J CELL SCI, V128, P3997, DOI 10.1242/jcs.175539
   Eliceiri BP, 2000, CANCER J, V6, pS245
   Garzon R, 2009, ANNU REV MED, V60, P167, DOI [10.1146/annurev.med.59.053006.104707, 10.1146/annurev.pathol.4.110807.092222]
   Ginsberg MH, 2005, CURR OPIN CELL BIOL, V17, P509, DOI 10.1016/j.ceb.2005.08.010
   Ha SY, 2014, J CLIN PATHOL, V67, P576, DOI 10.1136/jclinpath 2013 202163
   He JM, 2009, CANCER LETT, V284, P182, DOI 10.1016/j.canlet.2009.04.023
   Hood JD, 2002, NAT REV CANCER, V2, P91, DOI 10.1038/nrc727
   Humphries JD, 2006, J CELL SCI, V119, P3901, DOI 10.1242/jcs.03098
   Isakoff MS, 2015, J CLIN ONCOL, V33, P3029, DOI 10.1200/JCO.2014.59.4895
   Jansson MD, 2012, MOL ONCOL, V6, P590, DOI 10.1016/j.molonc.2012.09.006
   Jia JQ, 2013, ANTI CANCER DRUG, V24, P237, DOI 10.1097/CAD.0b013e32835d29fd
   Kaid C, 2015, CANCER SCI, V106, P1188, DOI 10.1111/cas.12733
   Melo SA, 2011, FEBS LETT, V585, P2087, DOI 10.1016/j.febslet.2010.08.009
   Mitjans F, 2000, INT J CANCER, V87, P716, DOI 10.1002/1097 0215(20000901)87:5<716::AID IJC14>3.0.CO;2 R
   Nemeth JA, 2007, CANCER INVEST, V25, P632, DOI 10.1080/07357900701522638
   Ou JJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038737
   Piriyapongsa J, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000203
   Sampson VB, 2015, FRONT PEDIATR, V3, DOI 10.3389/fped.2015.00069
   Schwickert A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143993
   Shi YF, 2015, BIOMED PHARMACOTHER, V75, P111, DOI 10.1016/j.biopha.2015.07.027
   Stucci S, 2015, CRIT REV ONCOL HEMAT, V96, P183, DOI 10.1016/j.critrevonc.2015.05.018
   Stupp R, 2014, LANCET ONCOL, V15, P1100, DOI 10.1016/S1470 2045(14)70379 1
   Sun XC, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046 016 0288 0
   TAYLOR WF, 1985, MAYO CLIN PROC, V60, P91, DOI 10.1016/S0025 6196(12)60293 6
   VanderGriend RA, 1996, ORTHOP CLIN N AM, V27, P575
   Yang SY, 2015, ONCOTARGET, V6, P43712, DOI 10.18632/oncotarget.6227
NR 29
TC 30
Z9 32
U1 0
U2 9
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1084 9785
EI 1557 8852
J9 CANCER BIOTHER RADIO
JI Cancer Biother. Radiopharm.
PD JUN
PY 2016
VL 31
IS 5
BP 153
EP 158
DI 10.1089/cbr.2016.1995
PG 6
WC Oncology; Medicine, Research & Experimental; Pharmacology & Pharmacy;
   Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Research & Experimental Medicine; Pharmacology & Pharmacy;
   Radiology, Nuclear Medicine & Medical Imaging
GA DO8RR
UT WOS:000378051700001
PM 27310302
DA 2025 08 17
ER

PT J
AU Allen, J
   Imbert, I
   Havelin, J
   Henderson, T
   Stevenson, G
   Liaw, L
   King, T
AF Allen, Joshua
   Imbert, Ian
   Havelin, Joshua
   Henderson, Terry
   Stevenson, Glenn
   Liaw, Lucy
   King, Tamara
TI Effects of Treadmill Exercise on Advanced Osteoarthritis Pain in Rats
SO ARTHRITIS & RHEUMATOLOGY
LA English
DT Article
ID ONGOING PAIN; KNEE OSTEOARTHRITIS; PHYSICAL EXERCISE; SUBCHONDRAL BONE;
   NEUROPATHIC PAIN; OPIOID ACTIVITY; UNITED STATES; MOUSE MODEL;
   HYPERALGESIA; ACTIVATION
AB Objective. Exercise is commonly recommended for patients with osteoarthritis (OA) pain. However, whether exercise is beneficial in ameliorating ongoing pain that is persistent, resistant to nonsteroidal antiinflammatory drugs (NSAIDs), and associated with advanced OA is unknown.
   Methods. Rats treated with intraarticular (IA) monosodium iodoacetate (MIA) or saline underwent tread mill exercise or remained sedentary starting 10 days postinjection. Tactile sensory thresholds and weight bearing were assessed, followed by radiography at weekly intervals. After 4 weeks of exercise, ongoing pain was assessed using conditioned place preference (CPP) to IA or rostral ventromedial medulla (RVM) administered lidocaine. The possible role of endogenous opioids in exercise induced pain relief was examined by systemic administration of naloxone. Knee joints were collected for micro computed tomography (micro CT) analysis to examine pathologic changes to subchondral bone andmetaphysis of the tibia.
   Results. Treadmill exercise for 4 weeks reversed MIA induced tactile hypersensitivity and weight asymmetry. Both IA and RVM lidocaine D35, administered post MIA, induced CPP in sedentary but not exercised MIA treated rats, indicating that exercise blocks MIA induced ongoing pain. Naloxone reestablished weight asymmetry in MIA treated rats undergoing exercise and induced conditioned place aversion, indicating that exercise induced pain relief is dependent on endogenous opioids. Exercise did not alter radiographic evidence of OA. However, micro CT analysis indicated that exercise did not block lateral subchondral bone loss or trabecular bone loss in the metaphysis, but did blockMIA induced medial bone loss.
   Conclusion. These findings support the conclusion that exercise induces pain relief in advanced, NSAID resistant OA, likely through increased endogenous opioid signaling. In addition, treadmill exercise blocked MIA induced bone loss in this model, indicating a potential bone stabilizing effect of exercise on the OA joint.
C1 [Allen, Joshua; Imbert, Ian; Havelin, Joshua; Stevenson, Glenn; King, Tamara] Univ New England, Biddeford, ME USA.
   [Henderson, Terry; Liaw, Lucy] Maine Med Ctr, Res Inst, Ctr Mol Med, Scarborough, ME USA.
C3 University of New England   Maine; Maine Medical Center
RP King, T (通讯作者)，Coll Osteopath Med, Dept Biomed Sci, Ctr Excellence Neurosci, 11 Hills Beach Rd, Biddeford, ME 04005 USA.
EM tking6@une.edu
FU NIH (National Institute of General Medical Sciences COBRE grant)
   [P20 GM 103643]; NIH [5P30 GM 103392]
FX Supported by the NIH (National Institute of General Medical Sciences
   COBRE grant P20 GM 103643 to Dr. King). Micro computed tomography was
   supported by the NIH (COBRE grant in vascular biology 5P30 GM 103392 to
   the Maine Medical Center Research Institute).
CR Almeida C, 2015, PAIN, V156, P504, DOI 10.1097/01.j.pain.0000460339.23976.12
   Arendt Nielsen L, 2010, PAIN, V149, P573, DOI 10.1016/j.pain.2010.04.003
   Bement MKH, 2005, ARCH PHYS MED REHAB, V86, P1736, DOI 10.1016/j.apmr.2005.03.029
   Bijlsma JWJ, 2011, LANCET, V377, P2115, DOI 10.1016/S0140 6736(11)60243 2
   BLAKE MJ, 1984, PEPTIDES, V5, P953, DOI 10.1016/0196 9781(84)90122 0
   Boudenot A, 2014, OSTEOARTHR CARTILAGE, V22, P1176, DOI 10.1016/j.joca.2014.05.020
   CHAPLAN SR, 1994, J NEUROSCI METH, V53, P55, DOI 10.1016/0165 0270(94)90144 9
   Chen YW, 2013, ANESTH ANALG, V116, P482, DOI 10.1213/ANE.0b013e318274e4a0
   COLT EWD, 1981, LIFE SCI, V28, P1637, DOI 10.1016/0024 3205(81)90319 2
   Cooper MA, 2016, FRONT NEUROSCI SWITZ, V10, DOI 10.3389/fnins.2016.00372
   Debruille C, 1999, PHYSIOL RES, V48, P129
   Dillon CF, 2006, J RHEUMATOL, V33, P2271
   Finnila MA, 2016, J ORTHOP RES
   Galois L, 2004, OSTEOARTHR CARTILAGE, V12, P779, DOI 10.1016/j.joca.2004.06.008
   Grace PM, 2016, PAIN, V157, P2012, DOI 10.1097/j.pain.0000000000000607
   Harvey VL, 2009, MOL PAIN, P5
   Havelin J, 2016, J PAIN, V17, P374, DOI 10.1016/j.jpain.2015.12.001
   Hawker GA, 2008, OSTEOARTHR CARTILAGE, V16, P415, DOI 10.1016/j.joca.2007.12.017
   Hill CL, 2007, ANN RHEUM DIS, V66, P1599, DOI 10.1136/ard.2006.067470
   Hugle Thomas, 2012, J Aging Res, V2012, P950192, DOI 10.1155/2012/950192
   Hunter DJ, 2008, RHEUM DIS CLIN N AM, V34, P623, DOI 10.1016/j.rdc.2008.05.004
   Kuphal KE, 2007, J PAIN, V8, P989, DOI 10.1016/j.jpain.2007.08.001
   Lane NE, 2011, OSTEOARTHR CARTILAGE, V19, P478, DOI 10.1016/j.joca.2010.09.013
   Leung A, 2016, PAIN, V157, P70, DOI 10.1097/j.pain.0000000000000312
   Liu A, 2014, OSTEOARTHR CARTILAGE, V22, P178, DOI 10.1016/j.joca.2013.11.012
   Liu P, 2011, NEUROSCI LETT, V493, P72, DOI 10.1016/j.neulet.2011.01.027
   Lu Y, 2008, EUR J NEUROSCI, V27, P1153, DOI 10.1111/j.1460 9568.2008.06076.x
   Maserejian NN, 2014, ARTHRIT CARE RES, V66, P147, DOI 10.1002/acr.22143
   McAlindon TE, 2014, OSTEOARTHR CARTILAGE, V22, P363, DOI 10.1016/j.joca.2014.01.003
   Minett MS, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9967
   Mobasheri A, 2016, ANN PHYS REHABIL MED, V59, P333, DOI 10.1016/j.rehab.2016.07.004
   Morenko BJ, 2004, CONTEMP TOP LAB ANIM, V43, P39
   Navratilova E, 2015, J NEUROSCI, V35, P7264, DOI 10.1523/JNEUROSCI.3862 14.2015
   Neogi T, 2013, RHEUM DIS CLIN N AM, V39, P1, DOI 10.1016/j.rdc.2012.10.004
   Okun A, 2012, PAIN, V153, P924, DOI 10.1016/j.pain.2012.01.022
   Ossipov MH, 2014, CURR OPIN SUPPORT PA, V8, P143, DOI 10.1097/SPC.0000000000000055
   Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix
   Pomonis JD, 2005, PAIN, V114, P339, DOI 10.1016/j.pain.2004.11.008
   Rahman W, 2009, MOL PAIN, V5, DOI 10.1186/1744 8069 5 45
   Ravi B, 2012, BEST PRACT RES CL RH, V26, P637, DOI 10.1016/j.berh.2012.07.014
   Sabharwal R, 2016, PAIN, V157, P387, DOI 10.1097/j.pain.0000000000000330
   Sagar DR, 2011, MOL PAIN, V7, DOI 10.1186/1744 8069 7 88
   Schaible HG, 2012, CURR RHEUMATOL REP, V14, P549, DOI 10.1007/s11926 012 0279 x
   Semanik PA, 2012, PM&R, V4, pS37, DOI 10.1016/j.pmrj.2012.02.015
   Shankarappa SA, 2011, J NEUROCHEM, V118, P224, DOI 10.1111/j.1471 4159.2011.07302.x
   Sluka KA, 2012, MED SCI SPORT EXER, V44, P420, DOI 10.1249/MSS.0b013e31822f490e
   Smith MA, 2003, PSYCHOPHARMACOLOGY, V168, P426, DOI 10.1007/s00213 003 1471 5
   Stagg NJ, 2011, ANESTHESIOLOGY, V114, P940, DOI 10.1097/ALN.0b013e318210f880
   Thakur M, 2014, NAT REV RHEUMATOL, V10, P374, DOI 10.1038/nrrheum.2014.47
   Thakur M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033730
   Timmins KA, 2017, AM J SPORT MED, V45, P1447, DOI 10.1177/0363546516657531
   Tsuda M, 2013, GLIA, V61, P55, DOI 10.1002/glia.22379
   Xie JY, 2014, PAIN, V155, P1659, DOI 10.1016/j.pain.2014.05.018
   Xie LQ, 2012, ARTHRITIS RHEUM US, V64, P1899, DOI 10.1002/art.34370
NR 54
TC 44
Z9 49
U1 1
U2 15
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 2326 5191
EI 2326 5205
J9 ARTHRITIS RHEUMATOL
JI Arthritis Rheumatol.
PD JUL
PY 2017
VL 69
IS 7
BP 1407
EP 1417
DI 10.1002/art.40101
PG 11
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA EY8NR
UT WOS:000404252200009
PM 28320059
OA Green Accepted, Bronze
DA 2025 08 17
ER

PT J
AU Plikus, MV
   Widelitz, RB
   Maxson, R
   Chuong, CM
AF Plikus, Maksim V.
   Widelitz, Randall B.
   Maxson, Rob
   Chuong, Cheng Ming
TI Analyses of regenerative wave patterns in adult hair follicle
   populations reveal macro environmental regulation of stem cell activity
SO INTERNATIONAL JOURNAL OF DEVELOPMENTAL BIOLOGY
LA English
DT Article
DE stem cell; hair cycle; biological rhythm; skin appendage; complexity;
   pattern formation
ID ALBINO RAT; SKIN; GROWTH; DIFFERENTIATION; MODULATION; ACTIVATION;
   INDUCTION; ANAGEN; INHIBITION; PELAGE
AB The control of hair growth in the adult mammalian coat is a fascinating topic which has just begun to be explored with molecular genetic tools. Complex hair cycle domains and regenerative hair waves are present in normal adult (> 2 month) mice, but more apparent in mutants with cyclic alopecia phenotypes. Each hair cycle domain consists of initiation site(s), a propagating wave and boundaries. By analyzing the dynamics of hair growth, time required for regeneration after plucking, in situ hybridization and reporter activity, we showed that there is oscillation of intra follicular Wnt signaling which is synchronous with hair cycling, and there is oscillation of dermal bone morphogenetic protein (BMP) signaling which is asynchronous with hair cycling. The interactions of these two rhythms lead to the recognition of refractory and competent phases in the telogen, and autonomous and propagating phases in the anagen. Boundaries form when propagating anagen waves reach follicles which are in refractory telogen. Experiments showed that Krt14 Nog mice have shortened refractory telogen and simplified wave dynamics. Krt14 Nog skin grafts exhibit non autonomous interactions with surrounding host skin. Implantation of BMP coated beads into competent telogen skin prevents hair wave propagation around the bead. Thus, we have developed a new molecular understanding of the classic early concepts of inhibitory "chalone", suggesting that stem cells within the hair follicle micro environment, or other organs, are subject to a higher level of macro environmental regulation. Such a novel understanding has important implications in the field of regenerative medicine. The unexpected links with Bmp2 expression in subcutaneous adipocytes has implications for systems biology and Evo Devo.
C1 [Plikus, Maksim V.; Widelitz, Randall B.; Chuong, Cheng Ming] Univ So Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90033 USA.
   [Maxson, Rob] Univ So Calif, Keck Sch Med, Dept Biochem & Mol Biol, Los Angeles, CA 90033 USA.
C3 University of Southern California; University of Southern California
RP Chuong, CM (通讯作者)，Univ So Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90033 USA.
EM cmchuong@usc.edu
RI ; Chen, Lan/ISB 4578 2023
OI Plikus, Maksim/0000 0002 8845 2559; 
FU NIAMS
FX We sincerely thank many colleagues for their very helpful discussions
   when we presented the work in progress in Montagna Symposium on the
   Biology of Skin in 2006 and in North American Hair Research Society
   meeting in 2007. This work would not have achieved its current status
   without their input. This study is supported by grants from NIAMS to CMC
   and RB W, and NIA to CMC. Plikus is a postdoctoral scholar of California
   Institute of Regenerative Medicine. We thank Dr. Baker, Maini, and all
   members of the Chuong Laboratory for discussion. We thank publishers for
   the kind to use the same or modified version of Figs. 2, 4, 5, 8, 11,
   12,13 (Nature) and Fig. 3. (J. Investigative Dermatology).
CR Andl T, 2004, DEVELOPMENT, V131, P2257, DOI 10.1242/dev.01125
   Blanpain C, 2004, CELL, V118, P635, DOI 10.1016/j.cell.2004.08.012
   Botchkarev VA, 2002, J INVEST DERMATOL, V118, P3, DOI 10.1046/j.1523 1747.2002.01645.x
   Botchkarev VA, 2004, DIFFERENTIATION, V72, P512, DOI 10.1111/j.1432 0436.2004.07209005.x
   Botchkarev VA, 2003, J INVEST DERMATOL, V120, P36, DOI 10.1046/j.1523 1747.2003.12002.x
   Botchkarev VA, 1999, NAT CELL BIOL, V1, P158, DOI 10.1038/11078
   Botchkarev VA, 2001, FASEB J, V15, P2205, DOI 10.1096/fj.01 0207com
   Brugger SM, 2004, DEVELOPMENT, V131, P5153, DOI 10.1242/dev.01390
   Butcher EO, 1936, ANAT RECORD, V64, P161, DOI 10.1002/ar.1090640204
   CHASE H, 1954, PHYSIOL REV, P113
   Collins HH, 1918, J EXP ZOOL, V27, P73, DOI 10.1002/jez.1400270106
   Cotsarelis G, 2006, J INVEST DERMATOL, V126, P1459, DOI 10.1038/sj.jid.5700376
   Craven AJ, 2006, J ENDOCRINOL, V191, P415, DOI 10.1677/joe.1.06685
   Deutsch A., 2005, CELLULAR AUTOMATON M
   DURWARD A, 1949, J ANAT, V83, P325
   EBLING FJ, 1961, J EMBRYOL EXP MORPH, V9, P285
   FRASER AS, 1953, AUST J BIOL SCI, V6, P645, DOI 10.1071/BI9530645
   Fuchs E, 2001, DEV CELL, V1, P13, DOI 10.1016/S1534 5807(01)00022 3
   Fuchs E, 2004, CELL, V116, P769, DOI 10.1016/S0092 8674(04)00255 7
   Guha U, 2004, AM J PATHOL, V165, P729, DOI 10.1016/S0002 9440(10)63336 6
   Jiang TX, 1999, DEVELOPMENT, V126, P4997
   JOHNSON E, 1958, J ENDOCRINOL, V16, P351, DOI 10.1677/joe.0.0160351
   JOHNSON E, 1958, J ENDOCRINOL, V16, P360, DOI 10.1677/joe.0.0160360
   Kobielak K, 2003, J CELL BIOL, V163, P609, DOI 10.1083/jcb.200309042
   Kulessa H, 2000, EMBO J, V19, P6664, DOI 10.1093/emboj/19.24.6664
   Ma L, 2003, DEVELOPMENT, V130, P379, DOI 10.1242/dev.00201
   Maurer M, 1997, AM J PATHOL, V150, P1433
   Militzer K, 2001, CELLS TISSUES ORGANS, V168, P285, DOI 10.1159/000047845
   Müller Röver S, 2001, J INVEST DERMATOL, V117, P3, DOI 10.1046/j.0022 202x.2001.01377.x
   Park YG, 2001, EXP ANIM TOKYO, V50, P179, DOI 10.1538/expanim.50.179
   Paus R, 2004, DIFFERENTIATION, V72, P489, DOI 10.1111/j.1432 0436.2004.07209004.x
   PAUS R, 1990, BRIT J DERMATOL, V122, P777, DOI 10.1111/j.1365 2133.1990.tb06266.x
   Paus Ralf, 1998, Journal of Dermatology (Tokyo), V25, P793
   Plikus M, 2004, AM J PATHOL, V164, P1099, DOI 10.1016/S0002 9440(10)63197 5
   Plikus MV, 2008, J INVEST DERMATOL, V128, P1071, DOI 10.1038/sj.jid.5701180
   Plikus MV, 2008, NATURE, V451, P340, DOI 10.1038/nature06457
   PLIKUS MV, 2006, MOUSE BIOMEDICAL RES, P691
   ROSE J, 1995, J EXP ZOOL, V271, P205, DOI 10.1002/jez.1402710307
   Stenn KS, 2001, PHYSIOL REV, V81, P449, DOI 10.1152/physrev.2001.81.1.449
   Suzuki N, 2003, P NATL ACAD SCI USA, V100, P9680, DOI 10.1073/pnas.1731184100
   Uyttendaele H, 2004, DIFFERENTIATION, V72, P396, DOI 10.1111/j.1432 0436.2004.07208006.x
   van Steensel MAM, 2000, P SOC EXP BIOL MED, V223, P1, DOI 10.1046/j.1525 1373.2000.22301.x
   Wolfram S., 2002, NEW KIND SCI
   Yuhki M, 2004, DEVELOPMENT, V131, P1825, DOI 10.1242/dev.01079
   Zhang JW, 2006, STEM CELLS, V24, P2826, DOI 10.1634/stemcells.2005 0544
NR 45
TC 57
Z9 71
U1 1
U2 11
PU UNIV BASQUE COUNTRY UPV EHU PRESS
PI BILBAO
PA PO BOX 1397, BILBAO, BIZKAIA E 48080, SPAIN
SN 0214 6282
EI 1696 3547
J9 INT J DEV BIOL
JI Int. J. Dev. Biol.
PY 2009
VL 53
IS 5 6
SI SI
BP 857
EP 868
DI 10.1387/ijdb.072564mp
PG 12
WC Developmental Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Developmental Biology
GA 483FW
UT WOS:000268949100022
PM 19378257
OA Green Accepted, Bronze
DA 2025 08 17
ER

PT J
AU Tölle, M
   Henkel, C
   Herrmann, J
   Daniel, C
   Babic, M
   Xia, MD
   Schulz, AM
   Amann, K
   van der Giet, M
   Schuchardt, M
AF Toelle, Markus
   Henkel, Cornelia
   Herrmann, Jaqueline
   Daniel, Christoph
   Babic, Milen
   Xia, Mengdi
   Schulz, Anna M.
   Amann, Kerstin
   van der Giet, Markus
   Schuchardt, Mirjam
TI Uremic mouse model to study vascular calcification and "inflamm aging"
SO JOURNAL OF MOLECULAR MEDICINE JMM
LA English
DT Article
DE Calcification; Cardiovascular; Chronic inflammation; Chronic renal
   insufficiency; Inflammation; Vascular calcification
ID ARTERIAL MEDIAL CALCIFICATION; C REACTIVE PROTEIN; CELLULAR SENESCENCE;
   HEMODIALYSIS; MICE; INTERLEUKIN 6; PHOSPHORUS; MORTALITY; UPSTREAM;
   ADENINE
AB Calcification and chronic inflammation of the vascular wall is a high risk factor for cardiovascular mortality, especially in patients with chronic uremia. For the reduction or prevention of rapid disease progression, no specific treatment options are currently available. This study aimed to evaluate an adenine based uremic mouse model for studying medial vessel calcification and senescence associated secretory phenotype (SASP) changes of aortic tissue to unravel molecular pathogenesis and provide a model for therapy testing. The dietary adenine administration induced a stable and similar degree of chronic uremia in DBA2/N mice with an increase of uremia blood markers such as blood urea nitrogen, calcium, creatinine, alkaline phosphatase, and parathyroid hormone. Also, renal fibrosis and crystal deposits were detected upon adenine feeding. The uremic condition is related to a moderate to severe medial vessel calcification and subsequent elastin disorganization. In addition, expression of osteogenic markers as Bmp 2 and its transcription factor Sox 9 as well as p21 as senescence marker were increased in uremic mice compared to controls. Pro inflammatory uremic proteins such as serum amyloid A, interleukin (I1) 1 beta, and I1 6 increased. This novel model of chronic uremia provides a simple method for investigation of signaling pathways in vascular inflammation and calcification and therefore offers an experimental basis for the development of potential therapeutic intervention studies.
C1 [Toelle, Markus; Henkel, Cornelia; Herrmann, Jaqueline; Babic, Milen; Xia, Mengdi; Schulz, Anna M.; van der Giet, Markus; Schuchardt, Mirjam] Charite Univ Med Berlin, Dept Nephrol & Med Intens Care, Hindenburgdamm 30, D 12203 Berlin, Germany.
   [Toelle, Markus; Henkel, Cornelia; Herrmann, Jaqueline; Babic, Milen; Xia, Mengdi; Schulz, Anna M.; van der Giet, Markus; Schuchardt, Mirjam] Free Univ Berlin, Hindenburgdamm 30, D 12203 Berlin, Germany.
   [Toelle, Markus; Henkel, Cornelia; Herrmann, Jaqueline; Babic, Milen; Xia, Mengdi; Schulz, Anna M.; van der Giet, Markus; Schuchardt, Mirjam] Humboldt Univ, Campus Benjamin Franklin, Hindenburgdamm 30, D 12203 Berlin, Germany.
   [Daniel, Christoph; Amann, Kerstin] Friedrich Alexander Univ Erlangen Nurnberg, Dept Nephropathol, Krankenhausstr 8 10, D 91054 Erlangen, Germany.
   [Xia, Mengdi] Nanchong Cent Hosp, Sichuan Med Coll, Dept Nephrol, Clin Med Inst North 2, Nanchong 63700, Sichuan, Peoples R China.
C3 Free University of Berlin; Humboldt University of Berlin; Charite
   Universitatsmedizin Berlin; Free University of Berlin; Free University
   of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin
   Berlin; University of Erlangen Nuremberg
RP van der Giet, M (通讯作者)，Charite Univ Med Berlin, Dept Nephrol & Med Intens Care, Hindenburgdamm 30, D 12203 Berlin, Germany.; van der Giet, M (通讯作者)，Free Univ Berlin, Hindenburgdamm 30, D 12203 Berlin, Germany.; van der Giet, M (通讯作者)，Humboldt Univ, Campus Benjamin Franklin, Hindenburgdamm 30, D 12203 Berlin, Germany.
EM Markus.vanderGiet@charite.de
RI ; Tölle, Markus/GPP 7157 2022; Daniel, Christoph/AAK 2136 2021;
   Schuchardt, Mirjam/AAS 3704 2021
OI van der Giet, Markus/0000 0003 3590 5451; Schuchardt,
   Mirjam/0000 0001 7388 9611; Daniel, Christoph/0000 0002 6803 4755;
   Herrmann, Jaqueline/0000 0003 1043 3945; Babic,
   Milen/0000 0001 6248 0570
FU Ernst und Berta Grimmke Stiftung; Berlin Institute of Health; Sonnenfeld
   Stiftung; DynAge Focus Area; Nanchong school science and technology
   strategic cooperation project [20SXQT0117]; Projekt DEAL
FX Open Access funding enabled and organized by Projekt DEAL. The financial
   support for this project was from the Ernst und Berta Grimmke Stiftung
   (M.S.), the Berlin Institute of Health (M.S.), the Sonnenfeld Stiftung
   (M.S., M.T., J.H.), a grant by the DynAge Focus Area (M.T., M.S.), and a
   research scholarship of the Nanchong school science and technology
   strategic cooperation project (M. X., grant number 20SXQT0117).
CR Barreto DV, 2010, KIDNEY INT, V77, P550, DOI 10.1038/ki.2009.503
   Burton DGA, 2009, EXP GERONTOL, V44, P659, DOI 10.1016/j.exger.2009.07.004
   Dai L, 2019, COMPUT STRUCT BIOTEC, V17, P721, DOI 10.1016/j.csbj.2019.06.015
   De Schutter TM, 2013, KIDNEY INT, V83, P1109, DOI 10.1038/ki.2013.34
   Du FY, 2000, J NUTR, V130, P514, DOI 10.1093/jn/130.3.514
   El Abbadi MM, 2009, KIDNEY INT, V75, P1297, DOI 10.1038/ki.2009.83
   Fang YF, 2014, KIDNEY INT, V85, P142, DOI 10.1038/ki.2013.271
   Feng H, 2019, ANTIOXID REDOX SIGN, V31, P75, DOI 10.1089/ars.2018.7620
   Freund A, 2010, TRENDS MOL MED, V16, P238, DOI 10.1016/j.molmed.2010.03.003
   Hegner B, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 30626 z
   Herrmann J, 2021, FRONT CARDIOVASC MED, V8, DOI 10.3389/fcvm.2021.752305
   Herrmann J, 2021, BIOLOGY BASEL, V10, DOI 10.3390/biology10060459
   Herrmann J, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21062204
   Lanzer P, 2021, J AM COLL CARDIOL, V78, P1145, DOI 10.1016/j.jacc.2021.06.049
   Lau WL, 2013, NEPHROL DIAL TRANSPL, V28, P62, DOI 10.1093/ndt/gfs333
   Lee CT, 2013, DIS MARKERS, V34, P229, DOI [10.1155/2013/846059, 10.3233/DMA 130965]
   Leopold JA, 2015, TRENDS CARDIOVAS MED, V25, P267, DOI 10.1016/j.tcm.2014.10.021
   Mazzaccara C, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003772
   Nakano Kurimoto R, 2009, AM J PHYSIOL HEART C, V297, pH1673, DOI 10.1152/ajpheart.00455.2009
   Nguyen Yamamoto L, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.126467
   Oe Y, 2021, AM J PATHOL, V191, P283, DOI 10.1016/j.ajpath.2020.10.012
   Orjalo AV, 2009, P NATL ACAD SCI USA, V106, P17031, DOI 10.1073/pnas.0905299106
   Pai A, 2011, AM J PATHOL, V178, P764, DOI 10.1016/j.ajpath.2010.10.006
   Price PA, 2006, KIDNEY INT, V70, P1577, DOI 10.1038/sj.ki.5001841
   Prüfer J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101709
   Ridker PM, 2016, CIRC RES, V118, P145, DOI 10.1161/CIRCRESAHA.115.306656
   Rodier F, 2009, NAT CELL BIOL, V11, P973, DOI 10.1038/ncb1909
   Sanchis P, 2019, KIDNEY INT, V95, P958, DOI 10.1016/j.kint.2018.12.014
   Santana AC, 2013, NEPHROL DIAL TRANSPL, V28, P1140, DOI 10.1093/ndt/gfs569
   Schuchardt M, 2012, KIDNEY INT, V81, P256, DOI 10.1038/ki.2011.326
   Shobeiri N, 2013, J HYPERTENS, V31, P160, DOI 10.1097/HJH.0b013e32835b15bb
   Simic Ogrizovic S, 2009, TOHOKU J EXP MED, V219, P121, DOI 10.1620/tjem.219.121
   Sperka T, 2012, NAT REV MOL CELL BIO, V13, P579, DOI 10.1038/nrm3420
   Tani T, 2020, J PATHOL, V250, P30, DOI 10.1002/path.5346
   Tani T, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 02351 6
   Tölle M, 2015, EUR J CLIN INVEST, V45, P976, DOI 10.1111/eci.12493
   Tölle M, 2012, CARDIOVASC RES, V94, P154, DOI 10.1093/cvr/cvs089
   Wen CY, 2013, INT J CARDIOL, V168, P2242, DOI 10.1016/j.ijcard.2013.01.211
   Yoshida T, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.117.007248
NR 39
TC 11
Z9 11
U1 1
U2 8
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D 69121 HEIDELBERG, GERMANY
SN 0946 2716
EI 1432 1440
J9 J MOL MED
JI J. Mol. Med.
PD SEP
PY 2022
VL 100
IS 9
BP 1321
EP 1330
DI 10.1007/s00109 022 02234 y
EA AUG 2022
PG 10
WC Genetics & Heredity; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Genetics & Heredity; Research & Experimental Medicine
GA 3Z1ZZ
UT WOS:000836373100001
PM 35916902
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Arnold, W
   Fullerton, DS
   Holder, S
   May, CS
AF Arnold, William
   Fullerton, Dwight S. 'Pete'
   Holder, Sharon
   May, Coral S.
TI Viscosupplementation: Managed care issues for osteoarthritis of the knee
SO JOURNAL OF MANAGED CARE PHARMACY
LA English
DT Article
DE cartilage degrading mechanisms; cost effectiveness; hyaluronan;
   haluronate; hylan; managed care; osteoarthritis; viscosupplementation
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; G F 20; DOUBLE BLIND;
   UNITED STATES; RHEUMATOID ARTHRITIS; HYALURONIC ACID; HYLAN G F 20;
   INTRAARTICULAR HYALURONAN; SYNOVIAL FLUID; INCREASED RISK
AB BACKGROUND: Osteoarthritis (OA) affects an estimated 49 million adults in North America, or nearly 1 of every 6 adults. More than 8 million North Americans have limited mobility to some extent because of OA. By 2030, an estimated 71 million North Americans will be diagnosed with OA, an increase of 45% over current figures. For one group model health maintenance organization (HMO), the average cost of care for patients with OA was $543 per member, a total annual cost to the HMO of $4,728,425. Of this total amount, 46% was for inpatient care, 32% was for medication, and 22% was for ambulatory care.
   OBJECTIVE: To determine the impact of OA on managed care and discuss treatment options available to those with OA, particularly of the knee.
   SUMMARY: OA represents an advanced stage of an active, progressive disease process. We know from medical research that OA is the endpoint of a progression in tissue degradation that results in loss of cartilage structure and function. Relief of pain and preservation of joint tissue must evolve to encompass treatments that interfere with cartilage degrading mechanisms that follow acute or chronic injury, restore normal cartilage and joint homeostasis, and arrest the progression of disease. Optimal future treatments will also reverse existing damage and restore normal cartilage structure and function.
   Viscosupplementation with an elastoviscous fluid containing polymers of hylan derivatives of the natural glycosaminoglycan hyaluronan is indicated for treating pain of OA of the knee that has not responded to or is contraindicated for conservative nonpharmacologic therapy and traditional analgesics. These analgesics include acetaminophen, nonsteroidal anti inflammatory drugs (NSAIDs), and cyclooxygenase 2 (COX 2) inhibitors.
   Clinicians in the managed care setting may consider using viscosupplementation in patients (1) who have persistent pain despite their use of conservative nonpharmacologic and pharmacologic therapy (e.g., exercise, weight loss, physician therapy, bracing/orthotics, NSAIDs, COX 2 inhibitors, and intra articular glucocorticoids); (2) who have compromised gastrointestinal (GI) function or who are at risk for GI bleeding due to the adverse events of NSAIDs; (3) who are taking concomitant anticoagulant therapy for any condition; (4) who have cardiovascular or renal risk factors that preclude use of COX 2 inhibitors; and (5) for whom surgery is not appropriate.
   Further study should be conducted with larger numbers of patients to help identify a subgroup of patients with OA in whom viscosupplementation may have even greater effects. Additional research should also concentrate on assessing the risks and benefits of extended treatments, because limited data are available concerning the effectiveness of multiple courses of therapy.
   CONCLUSION: OA is an important public health issue as the leading cause of disability in North America. As populations age, socioeconomic costs of OA will dramatically increase. Among available treatment options, viscosupplementation is a valuable alternative to more conservative therapy and has the benefit of circumventing the possible side effects of systemically administered pharmacologic agents. Viscosupplementation demonstrated efficacy in OA of the knee, and its use in the managed care arena may generate savings in hospitalizations and other costs.
C1 Illinoise Bone & Joint Inst Ltd, 9000 Waukegan Rd, Morton Grove, IL 60053 USA.
   Univ Washington, Pharmaceut Outcomes Res & Policy Program, Seattle, WA 98195 USA.
   Oschner Hlth Ctr, Baton Rouge, LA USA.
   e3 COMMUNICATION, Ft Worth, TX USA.
C3 University of Washington; University of Washington Seattle
RP Arnold, W (通讯作者)，Illinoise Bone & Joint Inst Ltd, 9000 Waukegan Rd, Morton Grove, IL 60053 USA.
EM billncele@comcast.net
CR ALTMAN R, 1986, ARTHRITIS RHEUM US, V29, P1039, DOI 10.1002/art.1780290816
   Altman RD, 1998, J RHEUMATOL, V25, P2203
   Altman RD, 2000, ARTHRITIS RHEUM US, V43, P1905
   *AM AC ORTH SURG, 2000, VISC TREATM OST
   *AM AC ORTH SURG, 2003, IMP OST KNEE
   *AM AC ORTH SURG, 2004, OST KNEE COMP EV BAS
   *AN THER INC, 2005, ORTH PRESCR INF
   Bagga H, 2006, J RHEUMATOL, V33, P946
   Baker CL, 2005, ORTHOPEDICS, V28, pS227
   BEERS MH, 2006, MERCK MANUAL DIAGNOS, P294
   BEL M, 1999, OSTEOARTHR CARTILAGE, V7, pS1
   Bellamy N, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005321.pub2
   Bellamy N, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005328
   Bjordal JM, 2004, BMJ BRIT MED J, V329, P1317, DOI 10.1136/bmj.38273.626655.63
   Bond GR, 1999, ACAD EMERG MED, V6, P1115, DOI 10.1111/j.1553 2712.1999.tb00113.x
   Buffum M, 2000, Pain Manag Nurs, V1, P40, DOI 10.1053/jpmn.2000.7779
   Burch F, 2004, OSTEOARTHR CARTILAGE, V12, P253, DOI 10.1016/j.joca.2003.10.007
   Clegg DO, 2006, NEW ENGL J MED, V354, P795, DOI 10.1056/NEJMoa052771
   Cooper C, 1998, OSTEOARTHRITIS, P237
   Creamer P, 2000, RHEUMATOLOGY, V39, P490, DOI 10.1093/rheumatology/39.5.490
   Dalgin Paul, 1997, Arthritis and Rheumatism, V40, pS86
   Dillon CF, 2006, J RHEUMATOL, V33, P2271
   Evanich JD, 2001, CLIN ORTHOP RELAT R, P173
   Fan ZY, 2006, ARTHRITIS RHEUM US, V54, P2471, DOI 10.1002/art.21961
   FELSON DT, 1987, ARTHRITIS RHEUM US, V30, P914, DOI 10.1002/art.1780300811
   Felson DT, 2000, ANN INTERN MED, V133, P635, DOI 10.7326/0003 4819 133 8 200010170 00016
   *FERR PHARM, 2006, EUFL PRESCR INF
   FORRESTER JV, 1980, IMMUNOLOGY, V40, P435
   GABRIEL PERE, 1995, HIST SOCIAL, P43
   Gammaitoni AR, 2004, CURR MED RES OPIN, V20, pS13, DOI 10.1185/030079904X12951
   Geba GP, 2002, JAMA J AM MED ASSOC, V287, P64, DOI 10.1001/jama.287.1.64
   *GENZ CORP, 2004, SYNV PRESCR INF
   Gomis A, 2004, ARTHRITIS RHEUM US, V50, P314, DOI 10.1002/art.11421
   Hamburger MI, 2003, SEMIN ARTHRITIS RHEU, V32, P296, DOI 10.1053/sarh.2002.50008
   Hannan MT, 2000, J RHEUMATOL, V27, P1513
   Hawkey C, 2000, ARTHRITIS RHEUM US, V43, P370, DOI 10.1002/1529 0131(200002)43:2<370::AID ANR17>3.0.CO;2 D
   Holmberg S, 2004, INT ARCH OCC ENV HEA, V77, P345, DOI 10.1007/s00420 004 0518 1
   Hylek EM, 1998, JAMA J AM MED ASSOC, V279, P657, DOI 10.1001/jama.279.9.657
   Jinks C, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471 2458 6 258
   KAIYAMA J, 2006, J IWATE MED ASS, V58, P9
   Karatosun V, 2006, RHEUMATOL INT, V26, P277, DOI 10.1007/s00296 005 0592 z
   Kelly Michael A, 2004, Am J Orthop (Belle Mead NJ), V33, P23
   Kemper F, 2005, CURR MED RES OPIN, V21, P1261, DOI 10.1185/030079905X56501
   Kirwan JR, 1997, BAILLIERE CLIN RHEUM, V11, P769, DOI 10.1016/S0950 3579(97)80009 X
   Kurtz S, 2005, J BONE JOINT SURG AM, V87A, P1487, DOI 10.2106/JBJS.D.02441
   Lanes SF, 1997, ARTHRITIS RHEUM US, V40, P1475, DOI 10.1002/art.1780400816
   Larson AM, 2005, HEPATOLOGY, V42, P1364, DOI 10.1002/hep.20948
   LAWRENCE RC, 1989, J RHEUMATOL, V16, P427
   Lohmander LS, 1996, ANN RHEUM DIS, V55, P424, DOI 10.1136/ard.55.7.424
   Lussier A, 1996, J RHEUMATOL, V23, P1579
   Mandelbaum B, 2005, ORTHOPEDICS, V28, pS207
   Marshall KW, 1998, J RHEUMATOL, V25, P2056
   MARSHALL KW, 1999, J BONE JOINT S BR S2, V81, pS123
   McCleane G, 2000, EUR J PAIN LONDON, V4, P355, DOI 10.1053/eujp.2000.0200
   Moskowitz Roland W, 2004, Am J Orthop (Belle Mead NJ), V33, P5
   Oliveria SA, 1996, EPIDEMIOLOGY, V7, P415, DOI 10.1097/00001648 199607000 00013
   Pagnano M, 2005, OSTEOARTHR CARTILAGE, V13, P751, DOI 10.1016/j.joca.2005.04.012
   Petrella RJ, 2002, ARCH INTERN MED, V162, P292, DOI 10.1001/archinte.162.3.292
   Pincus T, 2000, J RHEUMATOL, V27, P1020
   Pozo MA, 1997, EXP BRAIN RES, V116, P3, DOI 10.1007/PL00005742
   RAMAN R, 2006, OSTEOARTHRITIS CA SB, V14, pS162
   *SAN SYNTH INC, 2001, HYALG PRESCR INF
   SATO H, 1988, ARTHRITIS RHEUM US, V31, P63, DOI 10.1002/art.1780310110
   Schumacher HR, 2005, AM J MED, V118, P1208, DOI 10.1016/j.amjmed.2005.05.003
   *SEIK CORP, 2006, SUP PRESCR INF
   Snibbe JC, 2005, ORTHOPEDICS, V28, pS215, DOI 10.3928/0147 7447 20050202 06
   Sowers M, 2001, CURR OPIN RHEUMATOL, V13, P447, DOI 10.1097/00002281 200109000 00018
   Temple AR, 2006, CLIN THER, V28, P222, DOI 10.1016/j.clinthera.2006.02.004
   Thelin N, 2006, SCAND J MED SCI SPOR, V16, P329, DOI 10.1111/j.1600 0838.2005.00497.x
   TOBETTO K, 1993, CONNECT TISSUE RES, V29, P181, DOI 10.3109/03008209309016825
   Torrance GW, 2002, OSTEOARTHR CARTILAGE, V10, P518, DOI 10.1053/joca.2001.0513
   Towheed TE, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004257.pub2
   *US FDA, 2005, COX 2 SEL BEXTR CEL
   Vad VB, 2003, ARCH PHYS MED REHAB, V84, P634, DOI 10.1016/S0003 9993(03)04811 6
   Waddell D, 2001, AM J MANAG CARE, V7, P981
   Waddell DD, 2007, J MANAGE CARE PHARM, V13, P113, DOI 10.18553/jmcp.2007.13.2.113
   Waddell David D, 2005, J Knee Surg, V18, P7
   Wang CT, 2004, J BONE JOINT SURG AM, V86A, P538, DOI 10.2106/00004623 200403000 00012
   Watkins PB, 2006, JAMA J AM MED ASSOC, V296, P87, DOI 10.1001/jama.296.1.87
   Wobig M, 1998, CLIN THER, V20, P410, DOI 10.1016/S0149 2918(98)80052 0
   Wobig M, 1999, CLIN THER, V21, P1549, DOI 10.1016/S0149 2918(00)80010 7
   Wolfe F, 2000, ARTHRITIS RHEUM US, V43, P378, DOI 10.1002/1529 0131(200002)43:2<378::AID ANR18>3.0.CO;2 2
   Woolf CJ, 2004, ANN INTERN MED, V140, P441, DOI 10.7326/0003 4819 140 8 200404200 00010
   Zhang W, 2004, ANN RHEUM DIS, V63, P901, DOI 10.1136/ard.2003.018531
   Zhang YQ, 2001, ARTHRITIS RHEUM, V44, P2065, DOI 10.1002/1529 0131(200109)44:9<2065::AID ART356>3.0.CO;2 Z
NR 85
TC 26
Z9 32
U1 0
U2 7
PU ACAD MANAGED CARE PHARMACY
PI ALEXANDRIA
PA 100 N PITT ST, 400, ALEXANDRIA, VA 22314 3134 USA
SN 1083 4087
J9 J MANAGE CARE PHARM
JI J. Manag. Care Pharm.
PD MAY
PY 2007
VL 13
IS 4
SU S
BP S3
EP S19
PG 17
WC Health Care Sciences & Services; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Health Care Sciences & Services; Pharmacology & Pharmacy
GA 176LD
UT WOS:000247085700001
PM 23631049
DA 2025 08 17
ER

PT J
AU Zhang, LY
   Xue, HG
   Chen, JY
   Chai, W
   Ni, M
AF Zhang, Li Yan
   Xue, Hao Gang
   Chen, Ji Ying
   Chai, Wei
   Ni, Ming
TI Genistein induces adipogenic differentiation in human bone marrow
   mesenchymal stem cells and suppresses their osteogenic potential by
   upregulating PPARγ
SO EXPERIMENTAL AND THERAPEUTIC MEDICINE
LA English
DT Article
DE genistein; bone marrow mesenchymal stem cells; adipogenic; osteogenic;
   peroxisome proliferator activated receptor gamma
ID BREAST CANCER CELLS; STROMAL CELLS; ALZHEIMERS DISEASE; GENE EXPRESSION;
   PATHWAY; OSTEOBLASTS; LINEAGE; OSTEOPOROSIS; INHIBITION; APOPTOSIS
AB Genistein is a soy isoflavone that exists in the form of an aglycone. It is the primary active component in soy isoflavone and has a number of biological activities (anti inflammatory and anti oxidative). However, the specific effect of genistein on human bone marrow mesenchymal stem cells (BMSCs) remains unclear. In the present study, the mechanism underlying the effect of genistein on the suppression of BMSC adipogenic differentiation and the enhancement of osteogenic potential was investigated using an MTT assay. It was observed that genistein significantly increased BMSC cell proliferation in a time and dose dependent manner (P<0.01). In addition, reverse transcription quantitative polymerase chain reaction revealed that genistein significantly inhibited the expression of runt related transcription factor 2 (Runx2), type I collagen (Col I) and osteocalcin (OC; P<0.01). Furthermore, 20 mu m genistein significantly inhibited the activity of alkaline phosphatase (ALP) and increased the activity of triglycerides (TGs) increased (P<0.01) as determined by an enzyme linked immunosorbent assay. Finally, western blotting revealed that BMSC pretreatment with 20 mu m genistein significantly increased peroxisome proliferator activated receptor gamma (PPAR gamma) protein expression (P<0.01). This suggests that the downregulation of PPAR. may significantly reduce the effect of genistein on cell proliferation, suppress the expression of Runx2, Col I and OC mRNA, and reduce ALP and promote TG activity in BMSCs. Thus, the results of the present study conclude that genistein induces adipogenic differentiation in human BMSCs and suppresses their osteogenic potential by upregulating the expression of PPAR gamma. In conclusion, genistein may be a promising candidate drug for treatment against osteogenesis.
C1 [Zhang, Li Yan; Chen, Ji Ying; Chai, Wei; Ni, Ming] Gen Hosp Chinese Peoples Liberat Army, Dept Orthoped, 28 Fuxing Rd, Beijing 100853, Peoples R China.
   [Zhang, Li Yan; Xue, Hao Gang] Beihua Univ, Dept Orthoped 1, Affiliated Hosp, Jilin 132001, Jilin, Peoples R China.
C3 Beihua University
RP Chen, JY; Chai, W (通讯作者)，Gen Hosp Chinese Peoples Liberat Army, Dept Orthoped, 28 Fuxing Rd, Beijing 100853, Peoples R China.
EM chenjiying_301@yeah.net; 5170765@qq.com
FU National Natural Science Foundation of China [81301564]; Army Medical
   Science Youth Training Project [13QNP184]; 'Twelfth Five Year Plan'
   Science and Technology Research Project of Jilin Province Department of
   Education [141]; Jilin Province Science and Technology Department
   Project [20130624003JC]
FX The current study was supported by the National Natural Science
   Foundation of China subsidization project (no. 81301564), the Army
   Medical Science Youth Training Project (no. 13QNP184), the 'Twelfth
   Five Year Plan' Science and Technology Research Project of Jilin
   Province Department of Education (no. 141) and the Jilin Province
   Science and Technology Department Project (no. 20130624003JC).
CR Antoniou J, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar4113
   Arrigoni C, 2014, MOL CANCER, V13, DOI 10.1186/1476 4598 13 238
   Cao J, 2015, MOL CELL ENDOCRINOL, V410, P27, DOI 10.1016/j.mce.2015.01.045
   Chatterjee G, 2015, AGING DIS, V6, P456, DOI 10.14336/AD.2015.0327
   Chen J, 2015, FOOD FUNCT, V6, P995, DOI [10.1039/c4fo01141d, 10.1039/C4FO01141D]
   Chen YP, 2013, CELL PHYSIOL BIOCHEM, V32, P755, DOI 10.1159/000354477
   Choudhary S., 2015, J BIOL CHEM
   Dumont N, 2014, EXP HEMATOL, V42, P741, DOI 10.1016/j.exphem.2014.04.009
   Fan JF, 2015, MOL MED REP, V12, P4759, DOI 10.3892/mmr.2015.3996
   Hirayama Kazuhiro, 2011, Biosci Microflora, V30, P135, DOI 10.12938/bifidus.30.135
   Hu HM, 2013, INT J CLIN EXP PATHO, V6, P841
   Katsuda T, 2013, SCI REP UK, V3, DOI 10.1038/srep01197
   Kawai M, 2010, P NATL ACAD SCI USA, V107, P10508, DOI 10.1073/pnas.1000788107
   Kim Seung Hee, 2014, Lab Anim Res, V30, P143, DOI 10.5625/lar.2014.30.4.143
   Lee NJ, 2010, J BONE MINER RES, V25, P1736, DOI 10.1002/jbmr.61
   Lee S, 2014, BMC CELL BIOL, V15, DOI 10.1186/s12860 014 0042 4
   Liao MH, 2014, BRIT J NUTR, V111, P55, DOI 10.1017/S0007114513002043
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lu TF, 2014, APPL BIOCHEM BIOTECH, V172, P21, DOI 10.1007/s12010 013 0458 x
   Lv FH, 2013, EXP THER MED, V6, P184, DOI 10.3892/etm.2013.1076
   Menze ET, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117223
   Nagaraju GP, 2013, NUTR REV, V71, P562, DOI 10.1111/nure.12044
   Niagro FD, 2015, J ORAL IMPLANTOL
   Pauksch L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114740
   Relic B, 2009, LAB INVEST, V89, P811, DOI 10.1038/labinvest.2009.41
   Song MZ, 2015, INT J ONCOL, V46, P1131, DOI 10.3892/ijo.2015.2829
   Valles SL, 2010, BRAIN RES, V1312, P138, DOI 10.1016/j.brainres.2009.11.044
   Wang LF, 2012, J HUAZHONG U SCI MED, V32, P530, DOI 10.1007/s11596 012 0091 x
   Weivoda MM, 2012, BONE, V50, P467, DOI 10.1016/j.bone.2011.09.056
   Zeng XJ, 2012, STEM CELL RES, V8, P357, DOI 10.1016/j.scr.2011.12.004
   Zhou H, 2007, MOL CELL ENDOCRINOL, V270, P17, DOI 10.1016/j.mce.2007.01.017
   Zhou Y, 2009, MED HYPOTHESES, V73, P83, DOI 10.1016/j.mehy.2009.01.029
   Zhuang H., 2015, Curr Stem Cell Res Ther
NR 33
TC 28
Z9 31
U1 0
U2 17
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792 0981
EI 1792 1015
J9 EXP THER MED
JI Exp. Ther. Med.
PD MAY
PY 2016
VL 11
IS 5
BP 1853
EP 1858
DI 10.3892/etm.2016.3120
PG 6
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA DH3TR
UT WOS:000372710200049
PM 27168816
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Zhou, GQ
   Li, YF
   Ma, YY
   Liu, Z
   Cao, LL
   Wang, D
   Liu, SD
   Xu, WS
   Wang, WY
AF Zhou, Guoqiang
   Li, Yunfei
   Ma, Yanyan
   Liu, Zhu
   Cao, Lili
   Wang, Da
   Liu, Sudan
   Xu, Wenshi
   Wang, Wenying
TI Size dependent cytotoxicity of yttrium oxide nanoparticles on primary
   osteoblasts in vitro
SO JOURNAL OF NANOPARTICLE RESEARCH
LA English
DT Article
DE Yttrium oxide nanoparticles; Primary osteoblasts; Reactive oxygen
   species; Mitochondrial membrane potential; Oxidative stress; Toxicity;
   Environmental and health effects
ID TITANIUM DIOXIDE NANOPARTICLES; DOPED Y2O3 NANOPARTICLES; OXIDATIVE
   STRESS; SILVER NANOPARTICLES; CERIUM OXIDE; APOPTOSIS;
   PHOTOLUMINESCENCE; TOXICITY; HEPATOMA; DAMAGE
AB Yttrium oxide nanoparticles are an excellent host material for the rare earth metals and have high luminescence efficiency providing a potential application in photodynamic therapy and biological imaging. In this study, the effects of yttrium oxide nanoparticles with four different sizes were investigated using primary osteoblasts in vitro. The results demonstrated that the cytotoxicity generated by yttrium oxide nanoparticles depended on the particle size, and smaller particles possessed higher toxicological effects. For the purpose to elucidate the relationship between reactive oxygen species generation and cell damage, cytomembrane integrity, intracellular reactive oxygen species level, mitochondrial membrane potential, cell apoptosis rate, and activity of caspase 3 in cells were then measured. Increased reactive oxygen species level was also observed in a size dependent way. Thus, our data demonstrated that exposure to yttrium oxide nanoparticles resulted in a size dependent cytotoxicity in cultured primary osteoblasts, and reactive oxygen species generation should be one possible damage pathway for the toxicological effects produced by yttrium oxide particles. The results may provide useful information for more rational applications of yttrium oxide nanoparticles in the future.
C1 [Zhou, Guoqiang; Li, Yunfei; Ma, Yanyan; Liu, Zhu; Cao, Lili; Wang, Da; Liu, Sudan; Xu, Wenshi; Wang, Wenying] Hebei Univ, Coll Chem & Environm Sci, Key Lab Chem Biol Hebei Prov, Key Lab Med Chem & Mol Diag,Minist Educ, Baoding 071002, Peoples R China.
C3 Hebei University
RP Zhou, GQ (通讯作者)，Hebei Univ, Coll Chem & Environm Sci, Key Lab Chem Biol Hebei Prov, Key Lab Med Chem & Mol Diag,Minist Educ, Baoding 071002, Peoples R China.
EM zhougq1982@163.com
RI ; Li, Yunfei/F 1546 2015
OI li, yunfei/0000 0002 8413 0026; 
FU National Natural Science Foundation of China [21471044, 21001038]; Youth
   Talent Fund Project of Hebei Education Department [BJ2014007]; College
   Students Innovative Training Project of Hebei University [201410075072]
FX This work was supported by the National Natural Science Foundation of
   China (21471044 and 21001038), the Youth Talent Fund Project of Hebei
   Education Department (BJ2014007), and the College Students Innovative
   Training Project of Hebei University (201410075072).
CR Ali AG, 2014, PHYSICA B, V439, P181, DOI 10.1016/j.physb.2013.11.051
   Andelman T, 2010, NANOSCALE RES LETT, V5, P263, DOI 10.1007/s11671 009 9445 0
   Asare N, 2012, TOXICOLOGY, V291, P65, DOI 10.1016/j.tox.2011.10.022
   Avalos A, 2014, J APPL TOXICOL, V34, P413, DOI 10.1002/jat.2957
   Bai CL, 2012, NANO TODAY, V7, P258, DOI 10.1016/j.nantod.2012.05.002
   Balbus JM, 2007, ENVIRON HEALTH PERSP, V115, P1654, DOI [10.1289/ehp.10327, 10.1289/chp.10327]
   Botelho MC, 2014, BIOMED PHARMACOTHER, V68, P59, DOI 10.1016/j.biopha.2013.08.006
   Franco Molina MA, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756 9966 29 148
   Ghaznavi H, 2015, NEUROL RES, V37, P624, DOI 10.1179/1743132815Y.0000000037
   Hahn MA, 2011, ANAL BIOANAL CHEM, V399, P3, DOI 10.1007/s00216 010 4207 5
   Hilger I, 2013, INT J HYPERTHER, V29, P828, DOI 10.3109/02656736.2013.832815
   Hirst SM, 2013, ENVIRON TOXICOL, V28, P107, DOI 10.1002/tox.20704
   Hosseini A, 2013, HUM EXP TOXICOL, V32, P544, DOI 10.1177/0960327112468175
   Huerta García E, 2014, FREE RADICAL BIO MED, V73, P84, DOI 10.1016/j.freeradbiomed.2014.04.026
   Kabir M, 2014, CERAM INT, V40, P10877, DOI 10.1016/j.ceramint.2014.03.081
   Kim J, 2009, CHEM SOC REV, V38, P372, DOI 10.1039/b709883a
   Li TG, 2011, J MATER SCI, V46, P2882, DOI 10.1007/s10853 010 5162 4
   Li Y, 2011, TOXICOL IN VITRO, V25, P1343, DOI 10.1016/j.tiv.2011.05.003
   Liu HF, 2014, J NANOPART RES, V16, DOI 10.1007/s11051 014 2303 8
   Liu SC, 2010, TOXICOLOGY, V267, P172, DOI 10.1016/j.tox.2009.11.012
   Lojpur V, 2014, CERAM INT, V40, P16033, DOI 10.1016/j.ceramint.2014.07.139
   Marinkovic K, 2010, OPT MATER, V32, P1606, DOI 10.1016/j.optmat.2010.05.023
   Miethling Graff R, 2014, TOXICOL IN VITRO, V28, P1280, DOI 10.1016/j.tiv.2014.06.005
   Mitra RN, 2014, FREE RADICAL BIO MED, V75, P140, DOI 10.1016/j.freeradbiomed.2014.07.013
   Packiyaraj P, 2014, J LUMIN, V145, P997, DOI 10.1016/j.jlumin.2013.07.074
   Park EJ, 2008, TOXICOL LETT, V180, P222, DOI 10.1016/j.toxlet.2008.06.869
   Selvaraj V, 2014, INT J NANOMED, V9, P1379, DOI 10.2147/IJN.S52625
   Shi ZL, 2009, ACTA BIOMATER, V5, P338, DOI 10.1016/j.actbio.2008.07.023
   Shih SJ, 2012, J NANOSCI NANOTECHNO, V12, P7954, DOI 10.1166/jnn.2012.6592
   Shukla RK, 2011, TOXICOL IN VITRO, V25, P231, DOI 10.1016/j.tiv.2010.11.008
   Wang JL, 2012, CHEMSUSCHEM, V5, P1307, DOI 10.1002/cssc.201100596
   Wierzbicka Wieczorek M, 2015, J LUMIN, V168, P207, DOI 10.1016/j.jlumin.2015.08.004
   Xia GD, 2010, NANOTECHNOLOGY, V21, DOI 10.1088/0957 4484/21/34/345601
   Yang ER, 2015, J ALLOY COMPD, V647, P648, DOI 10.1016/j.jallcom.2015.06.016
   Yang KN, 2013, NANOSCALE, V5, P1205, DOI 10.1039/c2nr33575a
   Yokel RA, 2012, TOXICOL SCI, V127, P256, DOI 10.1093/toxsci/kfs067
   Yoshiura Y, 2015, J NANOPART RES, V17, DOI 10.1007/s11051 015 3054 x
   Zako T, 2015, BIOMATER SCI UK, V3, P59, DOI 10.1039/c4bm00232f
   Zhou GQ, 2014, MICRO NANO LETT, V9, P91, DOI 10.1049/mnl.2013.0586
   Zobeiri E, 2015, LUMINESCENCE, V30, P290, DOI 10.1002/bio.2727
NR 40
TC 35
Z9 37
U1 2
U2 53
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1388 0764
EI 1572 896X
J9 J NANOPART RES
JI J. Nanopart. Res.
PD MAY 18
PY 2016
VL 18
IS 5
AR 135
DI 10.1007/s11051 016 3447 5
PG 14
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science
GA DM5ZF
UT WOS:000376428400001
DA 2025 08 17
ER

PT J
AU Styner, M
   Sen, B
   Xie, ZH
   Case, N
   Rubin, J
AF Styner, Maya
   Sen, Buer
   Xie, Zhihui
   Case, Natasha
   Rubin, Janet
TI Indomethacin Promotes Adipogenesis of Mesenchymal Stem Cells Through a
   Cyclooxygenase Independent Mechanism
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE CYCLOOXYGENASE 2; NON STEROIDAL ANTI INFLAMMATORY DRUG; PROSTAGLANDIN
   E2; OSTEOBLAST; FRACTURE HEALING
ID ADIPOCYTE DIFFERENTIATION; BONE FORMATION; GENE EXPRESSION; RECEPTOR;
   MARROW; INDUCTION; FRACTURE; MICE; PROSTAGLANDIN E2; COMMITMENT
AB Regulation of mesenchymal stem cell (MSC) lineage selection is important for the generation of bone mass. Inhibition of cyclooxygenase 2 (COX2) may increase adipogenesis at the cost of decreasing osteoprogenitor output. Here we investigated the role of COX2 and its products during MSC differentiation. Indomethacin stimulated adipogenesis (increased aP2, adiponectin and lipid droplets) of CH310T1/2 stem cells as well as marrow derived MSCs to a degree similar to the PPAR gamma 2 ligand, rosiglitazone. Unlike rosiglitazone, indomethacin significantly upregulated PPAR gamma 2 expression. Indomethacin and the COX2 specific inhibitor celecoxib suppressed PGE2 production, but celecoxib did not induce adipogenesis. As well, addition of PGE2 failed to reverse indomethacin induced adipogenesis, indicating that indomethacin's effects were prostaglandin independent. In MSCs over expressing PPAR gamma 2 and RXR alpha, indomethacin did not increase PPAR induced transcription, while rosiglitazone and 15d PGJ2 did (1.7  and 1.3 fold, respectively, P < 0.001). We considered whether indomethacin might directly affect C/EBP beta proximally to PPAR gamma 2 induction. Indomethacin significantly increased C/EBP beta expression and protein within 24 h of addition. These results indicate that indomethacin promotes adipogenesis by increasing C/EBP beta and PPAR gamma 2 expression in a prostaglandin independent fashion. This effect of indomethacin is pertinent to potential deleterious effects of this commonly used anti inflammatory drug on bone remodeling and tissue healing. J. Cell. Biochem. 111: 1042 1050, 2010. (C) 2010 Wiley Liss, Inc.
C1 [Styner, Maya] Univ N Carolina, Sch Med, Div Endocrinol & Metab, Dept Med, Chapel Hill, NC 27599 USA.
C3 University of North Carolina; University of North Carolina Chapel Hill;
   University of North Carolina School of Medicine
RP Styner, M (通讯作者)，Univ N Carolina, Sch Med, Div Endocrinol & Metab, Dept Med, 5030 Burnett Womack, Chapel Hill, NC 27599 USA.
EM mstyner@med.unc.edu
RI Xie, Zhihui/G 8736 2013; Styner, Maya/I 2044 2019
OI Styner, Maya/0000 0001 9790 8645; 
FU NIH [DK007129, AR042360, AR52014]
FX Grant sponsor: NIH; Grant numbers: DK007129, AR042360, AR52014.
CR Abella E, 2002, AM J CLIN PATHOL, V118, P582, DOI 10.1309/2Y7X YDXK 006B XLT2
   ADOLPHSON P, 1993, ARCH ORTHOP TRAUM SU, V112, P127, DOI 10.1007/BF00449987
   Akune T, 2004, J CLIN INVEST, V113, P846, DOI 10.1172/JCI200419900
   Arikawa T, 2004, J CELL PHYSIOL, V200, P400, DOI 10.1002/jcp.20031
   Bowers RR, 2006, P NATL ACAD SCI USA, V103, P13022, DOI 10.1073/pnas.0605789103
   Burd TA, 2003, J BONE JOINT SURG BR, V85B, P700, DOI 10.1302/0301 620X.85B5.13970
   Case N, 2008, J BIOL CHEM, V283, P29196, DOI 10.1074/jbc.M801907200
   Case N, 2010, J ORTHOP RES, V28, P1531, DOI 10.1002/jor.21156
   Cheng MZ, 1997, J BONE MINER RES, V12, P1424, DOI 10.1359/jbmr.1997.12.9.1424
   Choudhary S, 2008, PROSTAG OTH LIPID M, V86, P35, DOI 10.1016/j.prostaglandins.2008.02.001
   CHOW JWM, 1994, AM J PHYSIOL, V267, pE287, DOI 10.1152/ajpendo.1994.267.2.E287
   Chuang HC, 2008, MOL CANCER, V7, DOI 10.1186/1476 4598 7 38
   Dennis JE, 1999, J BONE MINER RES, V14, P700, DOI 10.1359/jbmr.1999.14.5.700
   Farmer PK, 2000, AM J PHYSIOL ENDOC M, V279, pE213, DOI 10.1152/ajpendo.2000.279.1.E213
   Forwood MR, 1996, J BONE MINER RES, V11, pP210
   Fumoto T, 2007, J BIOCHEM, V141, P181, DOI 10.1093/jb/mvm018
   Goodman S, 2002, J ORTHOP RES, V20, P1164, DOI 10.1016/S0736 0266(02)00079 7
   Grey A, 2008, OSTEOPOROSIS INT, V19, P129, DOI 10.1007/s00198 007 0477 y
   Grösch S, 2001, FASEB J, V15, P2742, DOI 10.1096/fj.01 0299fje
   Huang HY, 2009, P NATL ACAD SCI USA, V106, P12670, DOI 10.1073/pnas.0906266106
   Kahn SE, 2006, NEW ENGL J MED, V355, P2427, DOI 10.1056/NEJMoa066224
   Kang HJ, 2000, BIOL PHARM BULL, V23, P815
   Kang S, 2007, J BIOL CHEM, V282, P14515, DOI 10.1074/jbc.M700030200
   Kelly KA, 1998, ENDOCRINOLOGY, V139, P2622, DOI 10.1210/en.139.5.2622
   KNIGHT DM, 1987, MOL ENDOCRINOL, V1, P36, DOI 10.1210/mend 1 1 36
   Kokoska ER, 1998, AM J PHYSIOL GASTR L, V275, pG322, DOI 10.1152/ajpgi.1998.275.2.G322
   LANGENBACH R, 1995, CELL, V83, P483, DOI 10.1016/0092 8674(95)90126 4
   Lehmann JM, 1997, J BIOL CHEM, V272, P3406, DOI 10.1074/jbc.272.6.3406
   Matsuda T, 2010, J CLIN INVEST, V120, P115, DOI 10.1172/JCI39721
   Moldes M, 2003, BIOCHEM J, V376, P607, DOI 10.1042/BJ20030426
   Naik AA, 2009, J BONE MINER RES, V24, P251, DOI [10.1359/jbmr.081002, 10.1359/JBMR.081002]
   Okada Y, 2000, J CLIN INVEST, V105, P823, DOI 10.1172/JCI8195
   Park BH, 2004, MOL CELL BIOL, V24, P8671, DOI 10.1128/MCB.24.19.8671 8680.2004
   Peister A, 2004, BLOOD, V103, P1662, DOI 10.1182/blood 2003 09 3070
   Robertson G, 2006, BONE, V39, P767, DOI 10.1016/j.bone.2006.04.006
   Sen B, 2008, ENDOCRINOLOGY, V149, P6065, DOI 10.1210/en.2008 0687
   Sen B, 2009, J BIOL CHEM, V284, P34607, DOI 10.1074/jbc.M109.039453
   Sha HB, 2009, CELL METAB, V9, P556, DOI 10.1016/j.cmet.2009.04.009
   Simon AM, 2002, J BONE MINER RES, V17, P963, DOI 10.1359/jbmr.2002.17.6.963
   Suponitzky I, 1998, J ENDOCRINOL, V156, P51, DOI 10.1677/joe.0.1560051
   Tang QQ, 2004, P NATL ACAD SCI USA, V101, P9607, DOI 10.1073/pnas.0403100101
   Tegeder I, 2001, FASEB J, V15, P2057, DOI 10.1096/fj.01 0390rev
   Tsutsumi S, 2004, CELL DEATH DIFFER, V11, P1009, DOI 10.1038/sj.cdd.4401436
   UENO K, 1985, BONE, V6, P79, DOI 10.1016/8756 3282(85)90311 4
   VERRANDO P, 1981, BIOCHIM BIOPHYS ACTA, V663, P255, DOI 10.1016/0005 2760(81)90212 5
   WILLIAMS IH, 1977, BIOCHEM BIOPH RES CO, V77, P175, DOI 10.1016/S0006 291X(77)80180 0
   Xie C, 2009, AM J PATHOL, V175, P772, DOI 10.2353/ajpath.2009.081099
   Yeung DKW, 2005, J MAGN RESON IMAGING, V22, P279, DOI 10.1002/jmri.20367
   Yoshida K, 2002, P NATL ACAD SCI USA, V99, P4580, DOI 10.1073/pnas.062053399
   Zhang JW, 2004, P NATL ACAD SCI USA, V101, P43, DOI 10.1073/pnas.0307229101
   Zhang XP, 2002, J CLIN INVEST, V109, P1405, DOI 10.1172/JCI200215681
NR 51
TC 59
Z9 71
U1 0
U2 23
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0730 2312
EI 1097 4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD NOV 1
PY 2010
VL 111
IS 4
BP 1042
EP 1050
DI 10.1002/jcb.22793
PG 9
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 677AA
UT WOS:000283960100029
PM 20672310
OA Green Published, Green Accepted
DA 2025 08 17
ER

PT J
AU Mo, JW
   Zheng, TS
   Lei, L
   Dai, P
   Liu, J
   He, HB
   Shi, J
   Chen, X
   Guo, TT
   Yuan, B
   Ji, GL
AF Mo, Jianwen
   Zheng, Tiansheng
   Lei, Li
   Dai, Peng
   Liu, Jun
   He, Huabin
   Shi, Jin
   Chen, Xi
   Guo, Tianting
   Yuan, Bin
   Ji, Guanglin
TI MicroRNA 1253 Suppresses Cell Proliferation Migration and Invasion of
   Osteosarcoma by Targeting MMP9
SO TECHNOLOGY IN CANCER RESEARCH & TREATMENT
LA English
DT Article
DE miR 1253; MMP9; proliferation; migration; invasion
ID METASTASIS; GROWTH; CANCER
AB Purpose: MicroRNAs play an important role in osteosarcoma (OS) development and progress. Although miR 1253 was considered as a tumor inhibitor in some cancers, it's function in the OS is not clear. Methods: In our study, we examined the expression of miR 1253 in OS cells and osteoblast cells using quantitative real time PCR. The proliferation of OS cells was measured by BrdU assay, and we performed transwell to detect migration and invasion of OS cells. Meanwhile, EMT proteins were tested by western blot. We used Bioinformatics to predict the target genes of miR 1253 and found out Matrix metalloproteinases9 (MMP9) was one of that. The direct combination between miR 1253 and MMP9 was verified by double luciferase reporting experiment. Quantitative real time PCR and western blot were used to detect the expression of MMP9. Results: We found that the expression level of miR 1253 in OS cells was significantly lower than that in osteoblast cells. Overexpression of miR 1253 could significantly inhibit OS cell proliferation, migration, invasion and EMT. And then, MMP9 was predicted as a downstream target of miR 1253 by Bioinformatics analysis. Further experiments showed that miR 1253 could reduce the protein level of MMP9 by directly binding to the 3' UTR of MMP9. Afterward, we performed a rescue experiment, in which both MMP9 and miR 1253 were overexpressed. Compared with the groups overexpressed miR 1253 alone, cell proliferation, migration and invasion in co overexpression groups were improved. Conclusions: In summary, these results suggested that miR 1253 downregulated in OS cells, and could suppress the proliferation, migration and invasion of OS cells. Its molecular regulatory mechanism was that inhibits the expression of the downstream target gene MMP9 by directly binding, thus affect OS cell functions. Therefore, miR 1253 has the potential to become a biomarker and therapeutic target for OS therapy.
C1 [Mo, Jianwen; Zheng, Tiansheng; Dai, Peng; Liu, Jun; He, Huabin; Shi, Jin; Chen, Xi; Guo, Tianting; Yuan, Bin; Ji, Guanglin] Gannan Med Univ, Affiliated Hosp 1, Dept Orthoped Surg, Ganzhou, Jiangxi, Peoples R China.
   [Lei, Li] Gannan Med Univ, Affiliated Hosp 1, Dept Dent, Ganzhou, Jiangxi, Peoples R China.
C3 Gannan Medical University; Gannan Medical University
RP Mo, JW; Ji, GL (通讯作者)，Gannan Med Univ, Affiliated Hosp 1, Dept Orthoped Surg, Ganzhou, Jiangxi, Peoples R China.
EM mojianwen33@sina.com; ganyiguke@163.com
RI Yuan, Bin/AAN 2031 2020; shi, jin/JCD 8826 2023; mo, jian/KLC 9208 2024
FU science and technology research project of education department of
   Jiangxi provincial [GJJ180811]; science and technology plan of health
   and family planning commission of Jiangxi provincial [20195375]
FX The author(s) disclosed receipt of the following financial support for
   the research, authorship, and/or publication of this article: This study
   was funded by the science and technology research project of education
   department of Jiangxi provincial (Project No. GJJ180811) and science and
   technology plan of health and family planning commission of Jiangxi
   provincial (Project No. 20195375).
CR Chen YB, 2019, GENE, V686, P37, DOI 10.1016/j.gene.2018.10.085
   Cho HJ, 2007, J BIOCHEM MOL BIOL, V40, P1069
   Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745
   GILL M, 1988, LANCET, V1, P689
   Han J, 2012, WORLD J SURG ONCOL, V10, DOI 10.1186/1477 7819 10 37
   Huang LP, 2018, BIOCHEM BIOPH RES CO, V500, P511, DOI 10.1016/j.bbrc.2018.04.131
   Isakoff MS, 2015, J CLIN ONCOL, V33, P3029, DOI 10.1200/JCO.2014.59.4895
   Jiang WW, 2016, FEBS LETT, V590, P2973, DOI 10.1002/1873 3468.12337
   Jin J, 2013, ASIAN PAC J CANCER P, V14, P3681, DOI 10.7314/APJCP.2013.14.6.3681
   Liao YY, 2016, ONCOTARGET, V7, P4310, DOI 10.18632/oncotarget.6708
   Liu MY, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 017 0218 x
   Osaki M, 2011, MOL THER, V19, P1123, DOI 10.1038/mt.2011.53
   Ottaviani G, 2009, CANCER TREAT RES, V152, P3, DOI 10.1007/978 1 4419 0284 9_1
   Sasaki R, 2019, CANCERS, V11, DOI 10.3390/cancers11040553
   Tabone MD, 1999, J CLIN ONCOL, V17, P2789, DOI 10.1200/JCO.1999.17.9.2789
   Wang Y, 2019, ARTIF CELL NANOMED B, V47, P1458, DOI 10.1080/21691401.2019.1601099
   Worku T, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18020333
   Xie YL, 2019, INT J BIOL MACROMOL, V133, P137, DOI 10.1016/j.ijbiomac.2019.04.016
   Xin M, 2016, ONCOTARGET, V7, P44252, DOI 10.18632/oncotarget.10020
   Xu Y, 2019, BIOCHEM BIOPH RES CO, V509, P138, DOI 10.1016/j.bbrc.2018.12.088
NR 20
TC 6
Z9 6
U1 0
U2 0
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1533 0346
EI 1533 0338
J9 TECHNOL CANCER RES T
JI Technol. Cancer Res. Treat.
PD OCT
PY 2021
VL 20
DI 10.1177/1533033821995278
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA VN0JH
UT WOS:001098833600001
PM 34036868
OA Green Published
DA 2025 08 17
ER

PT J
AU Staehlke, S
   Rebl, H
   Finke, B
   Mueller, P
   Gruening, M
   Nebe, JB
AF Staehlke, Susanne
   Rebl, Henrike
   Finke, Birgit
   Mueller, Petra
   Gruening, Martina
   Nebe, J. Barbara
TI Enhanced calcium ion mobilization in osteoblasts on amino group
   containing plasma polymer nanolayer
SO CELL AND BIOSCIENCE
LA English
DT Article
DE Chemical surface modifications; Titanium; Plasma polymer; Tissue culture
   plastic; Collagen type I; Human osteoblasts; Zeta potential; Cell
   viability; Signaling; Calcium ion dynamic
ID INTRACELLULAR CALCIUM; SURFACE CHEMISTRY; TITANIUM SURFACES; CONTACT
   GUIDANCE; CELL ADHESION; OSSEOINTEGRATION; PROLIFERATION; TOPOGRAPHY;
   IMPLANTS; COLLAGEN
AB Background: Biomaterial modifications chemical and topographical are of particular importance for the integration of materials in biosystems. Cells are known to sense these biomaterial characteristics, but it has remained unclear which physiological processes bio modifications trigger. Hence, the question arises of whether the dynamic of intracellular calcium ions is important for the characterization of the cell material interaction. In our prior research we could demonstrate that a defined geometrical surface topography affects the cell physiology; this was finally detectable in a reduced intracellular calcium mobilization after the addition of adenosine triphosphate (ATP).
   Results: This new contribution examines the cell physiology of human osteoblasts concerning the relative cell viability and the calcium ion dynamic on different chemical modifications of silicon titanium (Ti) substrates. Chemical modifications comprising the coating of Ti surfaces with a plasma polymerized allylamine (PPAAm) layer or with a thin layer of collagen type I were compared with a bare Ti substrate as well as tissue culture plastic. For this purpose, the human osteoblasts (MG 63 and primary osteoblasts) were seeded onto the surfaces for 24 h. The relative cell viability was determined by colorimetric measurements of the cell metabolism and relativized to the density of cells quantified using crystal violet staining. The calcium ion dynamic of osteoblasts was evaluated by the calcium imaging analysis of fluo 3 stained vital cells using a confocal laser scanning microscope. The positively charged nano PPAAm layer resulted in enhanced intracellular calcium ion mobilization after ATP stimulus and cell viability. This study underlines the importance of the calcium signaling for the manifestation of the cell physiology.
   Conclusions: Our current work provides new insights into the intracellular calcium dynamic caused by diverse chemical surface compositions. The calcium ion dynamic appears to be a sensitive parameter for the cell physiology and, thus, may represent a useful approach for evaluating a new biomaterial. In this regard, reliable in vitro tests of cell behavior at the interface to a material are crucial steps in securing the success of a new biomaterial in medicine.
C1 [Staehlke, Susanne; Rebl, Henrike; Mueller, Petra; Gruening, Martina; Nebe, J. Barbara] Univ Med Ctr Rostock, Dept Cell Biol, Schillingallee 69, D 18057 Rostock, Germany.
   [Finke, Birgit] Leibniz Inst Plasma Sci & Technol INP, Felix Hausdorff Str 2, D 17489 Greifswald, Germany.
C3 University of Rostock; Leibniz Institut fur Plasmaforschung und
   Technologie
RP Nebe, JB (通讯作者)，Univ Med Ctr Rostock, Dept Cell Biol, Schillingallee 69, D 18057 Rostock, Germany.
EM barbara.nebe@med.uni rostock.de
RI Rebl, Henrike/ABB 5332 2020
FU German Research Foundation (DFG) graduate school welisa [1505/2]; DFG
   ELAINE [1270/1]; KarriereWegeMentoring Programme of the University
   Medical Center Rostock (state of Mecklenburg Vorpommern)
   [ESF/14 SM A41 0005/15]; German Ministry of Education and Research
   (BMBF) [FKZ 13GW0109D]
FX We appreciate the financial support of the German Research Foundation
   (DFG) graduate school welisa (No. 1505/2) and the DFG ELAINE (No.
   1270/1). SS is grateful to the KarriereWegeMentoring Programme of the
   University Medical Center Rostock (European Social Fund for Germany and
   the state of Mecklenburg Vorpommern, ESF/14 SM A41 0005/15). HR is
   currently supported by the German Ministry of Education and Research
   (BMBF; FKZ 13GW0109D).
CR [Anonymous], 2007, LAB SLID SOL BIOMICR
   Anselme K, 2010, P I MECH ENG H, V224, P1487, DOI 10.1243/09544119JEIM901
   Avila G, 2009, IMPLANT DENT, V18, P17, DOI 10.1097/ID.0b013e318192cb7d
   Bacakova L, 2011, BIOTECHNOL ADV, V29, P739, DOI 10.1016/j.biotechadv.2011.06.004
   Berridge MJ, 2012, BIOCHEM SOC T, V40, P297, DOI 10.1042/BST20110766
   Czekanska EM, 2014, J BIOMED MATER RES A, V102, P2636, DOI 10.1002/jbm.a.34937
   Finke B, 2007, BIOMATERIALS, V28, P4521, DOI 10.1016/j.biomaterials.2007.06.028
   Finke B, 2014, LANGMUIR, V30, P13914, DOI 10.1021/la5019778
   Guo CL, 2013, CELL BIOSCI, V3, DOI 10.1186/2045 3701 3 25
   Ismail FSM, 2007, J MATER SCI MATER M, V18, P705, DOI 10.1007/s10856 006 0012 2
   Izquierdo JH, 2014, REUMATOL CLIN, V10, P43, DOI [10.1016/j.reumae.2013.11.004, 10.1016/j.reuma.2013.05.008]
   Kim JM, 2017, BIOMATERIALS, V127, P107, DOI 10.1016/j.biomaterials.2017.02.038
   Labelle D, 2007, CELL PROLIFERAT, V40, P866, DOI 10.1111/j.1365 2184.2007.00477.x
   Liedert A, 2006, BIOCHEM BIOPH RES CO, V349, P1, DOI 10.1016/j.bbrc.2006.07.214
   Moerke C, 2017, ACS APPL MATER INTER, V9, P10461, DOI 10.1021/acsami.6b16430
   Morra M, 2003, BIOMATERIALS, V24, P4639, DOI 10.1016/S0142 9612(03)00360 0
   Nebe B, 2007, BIOMOL ENG, V24, P447, DOI 10.1016/j.bioeng.2007.07.004
   Nebe J. Barbara, 2017, Materials Science Forum, V879, P78, DOI 10.4028/www.scientific.net/MSF.879.78
   Paredes RM, 2008, METHODS, V46, P143, DOI 10.1016/j.ymeth.2008.09.025
   Petrie TA, 2008, BIOMATERIALS, V29, P2849, DOI 10.1016/j.biomaterials.2008.03.036
   Pommerenke H, 2002, J BONE MINER RES, V17, P603, DOI 10.1359/jbmr.2002.17.4.603
   Ravenscroft Chang MS, 2010, BIOMATERIALS, V31, P602, DOI 10.1016/j.biomaterials.2009.09.084
   Rebl H, 2016, MAT SCI ENG C MATER, V69, P1116, DOI 10.1016/j.msec.2016.08.016
   Rebl H, 2010, ADV ENG MATER, V12, pB356, DOI 10.1002/adem.200980070
   Reyes CD, 2007, BIOMATERIALS, V28, P3228, DOI 10.1016/j.biomaterials.2007.04.003
   Sanz Herrera JA, 2011, INT J MOL SCI, V12, P8217, DOI 10.3390/ijms12118217
   Schulz MC, 2014, J MATER SCI MATER M, V25, P247, DOI 10.1007/s10856 013 5066 3
   Staehlke S, 2015, BIOMATERIALS, V46, P48, DOI 10.1016/j.biomaterials.2014.12.016
   Sverzut AT, 2012, BIOMED MATER, V7, DOI 10.1088/1748 6041/7/3/035007
   Takahashi A, 1999, PHYSIOL REV, V79, P1089, DOI 10.1152/physrev.1999.79.4.1089
   van Kooten TG, 1999, J BIOMED MATER RES, V46, P33, DOI 10.1002/(SICI)1097 4636(199907)46:1<33::AID JBM4>3.0.CO;2 K
   Whitaker M, 2006, CELL CALCIUM, V40, P585, DOI 10.1016/j.ceca.2006.08.018
NR 32
TC 25
Z9 25
U1 1
U2 12
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 2045 3701
J9 CELL BIOSCI
JI Cell Biosci.
PD MAR 21
PY 2018
VL 8
AR 22
DI 10.1186/s13578 018 0220 8
PG 11
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA GA3SE
UT WOS:000428249000001
PM 29588849
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Sharqawi, A
   Hewitt, K
   Alexander, C
   El Sakka, AI
   Lee, L
AF Sharqawi, Abdallah
   Hewitt, Kathryn
   Alexander, Cameron
   El Sakka, A., I
   Lee, L.
TI Improving bone health in prostate cancer patients starting androgen
   deprivation therapy: does Fracture Risk Assessment Tool (FRAX®) enhance
   stratification and targeted management?
SO ARCHIVES OF OSTEOPOROSIS
LA English
DT Article
DE FRAX (R) algorithm; ADT; Bone health; Cancer induced bone loss
AB .Summary Androgen deprivation therapy for prostate cancer can lead to osteoporosis and increased fracture risk. The Fracture Risk Assessment Tool (FRAX (R)) questionnaire can be used for risk stratification, and our study has demonstrated that the majority of men (91%) in our cohort commencing ADT for prostate cancer were considered low risk for future osteoporotic fracture.
   Purpose/introduction Long term use of androgen deprivation therapy (ADT) in prostate cancer patients results in increased bone turnover and decreased bone mineral density (BMD). Proper assessment of any existing osteoporotic fracture risk is crucial prior to starting treatment. However, this risk assessment is poorly performed in these patients in spite of available validated tools including the Fracture Risk Assessment Tool (FRAX (R)). The objective of this study was to assess the distribution of osteoporotic fracture risk in a cohort of men commencing ADT for prostate cancer using the FRAX (R) algorithm.
   Methods Between July 2020 and May 2022, 200 men filled in the FRAX (R) questionnaire just before ADT. They were stratified into the high risk (> 20% probability of a MOF over the next 10 years), intermediate , and low risk categories for fragility fractures. We also measured their serum vitamin D and calcium levels.
   Results The average age was 73.5 years (54 89). It took less than 10 min to complete the assessment. Only six patients were at high risk, were started on bisphosphonates immediately, and referred for a dual energy X ray absorptiometry (DEXA) scan. Twelve patients in the intermediate risk category were referred for DEXA scans for bone mineral density measurements. A total of 182 patients (91%), were in the low risk category and given lifestyle advice only. All had normal calcium levels but 134 (67%) patients, mostly in the low risk category, had reduced vitamin D levels (< 50 nmol/L).
   Conclusion The FRAX (R) questionnaire is simple and immediately identifies patients who are at risk of fragility fractures. Our study has demonstrated that the majority of men (91%) in our cohort commencing ADT for prostate cancer were considered low risk for future osteoporotic fracture. We were surprised that more than half of our patients had low vitamin D levels.
C1 [Sharqawi, Abdallah; Hewitt, Kathryn; Alexander, Cameron; Lee, L.] Royal Bolton Hosp, Urol Dept, Bolton, England.
   [Sharqawi, Abdallah; El Sakka, A., I] Suez Canal Univ, Fac Med, Urol Dept, Ismailia, Egypt.
C3 Royal Bolton Hospital; Egyptian Knowledge Bank (EKB); Suez Canal
   University
RP Sharqawi, A (通讯作者)，Royal Bolton Hosp, Urol Dept, Bolton, England.; Sharqawi, A (通讯作者)，Suez Canal Univ, Fac Med, Urol Dept, Ismailia, Egypt.
EM abdallah_elmagd@yahoo.com
CR Adler RA, 2010, OSTEOPOROSIS INT, V21, P647, DOI 10.1007/s00198 009 0984 0
   [Anonymous], 2012, INDIAN J UROL
   [Anonymous], 2009, UROL ONCOL SEMIN ORI
   Compston J, 2017, ARCH OSTEOPOROS, V12, DOI 10.1007/s11657 017 0324 5
   Cosman F, 2014, OSTEOPOROSIS INT, V25, P2359, DOI 10.1007/s00198 014 2794 2
   Hoff M, 2017, OSTEOPOROSIS INT, V28, P2935, DOI 10.1007/s00198 017 4134 9
   James H, 2014, UROLOGY, V84, P164, DOI 10.1016/j.urology.2013.12.071
   Kanis JA, 2016, ARCH OSTEOPOROS, V11, DOI 10.1007/s11657 016 0278 z
   Lowey H, 2021, PUBLIC HLTH ANN REPO
   Mottet N., 2016, EAU   ESTRO   SIOG Guidelines on Prostate Cancer
   NCCN Clinical Practice Guidelines in Oncology, 2020, PROSTATE CANC VERSIO, P46
   Neubecker K, 2011, J OSTEOPOROS, V2011, DOI 10.4061/2011/924595
   NICE, 2019, Prostate cancer diagnosis and management: NICE guideline (NG131)
   Resnick MJ, 2015, J CLIN ONCOL, V33, P1078, DOI 10.1200/JCO.2014.60.2557
   Ross AC, 2011, J CLIN ENDOCR METAB, V96, P53, DOI 10.1210/jc.2010 2704
   Saylor PJ, 2010, J UROLOGY, V183, P2200, DOI 10.1016/j.juro.2010.02.022
NR 16
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 1862 3522
EI 1862 3514
J9 ARCH OSTEOPOROS
JI Arch. Osteoporos.
PD DEC
PY 2022
VL 17
IS 1
AR 143
DI 10.1007/s11657 022 01185 8
PG 5
WC Endocrinology & Metabolism; Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Orthopedics
GA 6E4XN
UT WOS:000883384700002
PM 36376762
DA 2025 08 17
ER

PT J
AU Hounslow, AM
   Carran, J
   Brown, RJ
   Rejman, D
   Blackburn, GM
   Watts, DJ
AF Hounslow, Andrea M.
   Carran, John
   Brown, Richard J.
   Rejman, Dominik
   Blackburn, G. Michael
   Watts, Donald J.
TI Determination of the microscopic equilibrium dissociation constants for
   risedronate and its analogues reveals two distinct roles for the
   nitrogen atom in nitrogen containing bisphosphonate drugs
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID DICTYOSTELIUM DISCOIDEUM; BONE RESORPTION; GROWTH; ACIDS; INHIBITION;
   AMEBAS
AB Microscopic equilibrium dissociation constants, k(a)s, were determined for four nitrogen containing bisphosphonates (N BP): risedronate and its analogues 2 (2 aminophenyl) 1 hydroxyethylidene 1,1 bisphosphonate,NE 11807, and NE 97220. The proportion of each and of analogues 2 (3' (N ethyl)pyridinium)ethylidenebisphosphonate and 2 (3 piperinidyl)  1 hydroxyethylidene 1, 1 bisphosphonate, having a positively charged nitrogen and three negative charges on the bisphosphonate group ("carbocation analogue") at pH 7.5, was calculated. When set in order of increasing potency at inhibiting farnesyl diphosphate (FDP) synthase (their intracellular target), the N BPs are also ranked in order of decreasing mole fraction of carbocation analogue. However, only a weak correlation exists between potency for inhibiting FDP synthase and potency for inhibiting Dictyostelium discoideum growth. It is concluded that, although high potency for inhibiting FDP synthase is favored when the nitrogen atom in a N BP is uncharged, N BPs having a positively charged nitrogen can still be potent inhibitors of Dictyostelium growth owing to favorable interaction with a second, unidentified target.
C1 [Hounslow, Andrea M.; Brown, Richard J.; Watts, Donald J.] Univ Sheffield, Dept Mol Biol & Biotechnol, Sheffield S10 2TN, S Yorkshire, England.
   [Carran, John; Rejman, Dominik; Blackburn, G. Michael] Univ Sheffield, Dept Chem, Sheffield S3 7HF, S Yorkshire, England.
C3 University of Sheffield; University of Sheffield
RP Watts, DJ (通讯作者)，Univ Sheffield, Dept Mol Biol & Biotechnol, Firth Court, Sheffield S10 2TN, S Yorkshire, England.
EM d.j.watts@sheffield.ac.uk
RI ; Rejman, Dominik/D 6901 2011; Brown, Richard/HKV 8644 2023
OI Brown, Richard/0000 0001 8093 9779; 
FU Wellcome Trust Funding Source: Medline
CR Boduszek B, 1997, J CHEM SOC DALTON, P973, DOI 10.1039/a606086b
   BREITMAIER E, 1973, TETRAHEDRON, V29, P1145, DOI 10.1016/0040 4020(73)80075 4
   Ebrahimpour A, 1995, MINERAL SCALE FORMATION AND INHIBITION, P295
   Fleisch H., 1995, BISPHOSPHONATES BONE
   Ghosh S, 2004, J MED CHEM, V47, P175, DOI 10.1021/jm030084x
   Grove JE, 2000, J BONE MINER RES, V15, P971, DOI 10.1359/jbmr.2000.15.5.971
   Hägele G, 2000, HETEROATOM CHEM, V11, P562
   Hosfield DJ, 2004, J BIOL CHEM, V279, P8526, DOI 10.1074/jbc.C300511200
   Jencks W.P., 1976, HDB BIOCH MOL BIOL, P305
   Lecouvey M, 2001, TETRAHEDRON LETT, V42, P8475, DOI 10.1016/S0040 4039(01)01844 5
   Maniak M., 2001, ENDOCYTOSIS, P78
   Martin MB, 1999, BIOCHEM BIOPH RES CO, V263, P754, DOI 10.1006/bbrc.1999.1404
   Matczak Jon E, 2001, NEW J CHEM, V25, P1447, DOI 10.1039/b102282m
   PERRINS DD, 1965, DISSOCIATION CONSTAN, P145
   POULTER CD, 1978, ACCOUNTS CHEM RES, V11, P307, DOI 10.1021/ar50128a004
   RABENSTEIN DL, 1973, J AM CHEM SOC, V95, P2797, DOI 10.1021/ja00790a009
   Rogers MJ, 1997, PHARMACEUT RES, V14, P625, DOI 10.1023/A:1012157212793
   ROGERS MJ, 1994, J BONE MINER RES, V9, P1029
   ROGERS MJ, 1995, MOL PHARMACOL, V47, P398
   Russell RGG, 2006, ANN NY ACAD SCI, V1068, P367, DOI 10.1196/annals.1346.041
   SCHENK R, 1986, CALCIFIED TISSUE INT, V38, P342, DOI 10.1007/BF02555748
   Seelig A, 1998, EUR J BIOCHEM, V251, P252, DOI 10.1046/j.1432 1327.1998.2510252.x
   SIETSEMA WK, 1989, DRUG EXP CLIN RES, V15, P389
   Szakács Z, 2004, ANAL BIOANAL CHEM, V378, P1428, DOI 10.1007/s00216 003 2390 3
   TARSHIS LC, 1994, BIOCHEMISTRY US, V33, P10871, DOI 10.1021/bi00202a004
   Ullmann GM, 2003, J PHYS CHEM B, V107, P1263, DOI 10.1021/jp026454v
   WATTS D, UNPUB
   WATTS DJ, 1970, BIOCHEM J, V119, P171, DOI 10.1042/bj1190171
NR 28
TC 25
Z9 31
U1 0
U2 16
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022 2623
EI 1520 4804
J9 J MED CHEM
JI J. Med. Chem.
PD JUL 24
PY 2008
VL 51
IS 14
BP 4170
EP 4178
DI 10.1021/jm7015792
PG 9
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI EXPANDED); Index Chemicus (IC)
SC Pharmacology & Pharmacy
GA 327IA
UT WOS:000257721600011
PM 18590315
DA 2025 08 17
ER

PT J
AU Nie, MF
   Wu, SY
   Chen, YY
   Wu, YT
   Chen, RT
   Liu, Y
   Yue, MX
   Jiang, Y
   Qiu, DK
   Yang, M
   Wang, ZK
   Gao, JH
   Xiong, HL
   Qi, RY
   He, JH
   Zhang, JL
   Wang, YB
   Fang, MJ
   Que, YQ
   Yao, YL
   Li, SW
   Zhang, J
   Zhao, QJ
   Yuan, Q
   Zhang, TY
   Xia, NS
AF Nie, Meifeng
   Wu, Shuyu
   Chen, Yiyi
   Wu, Yangtao
   Chen, Ruitong
   Liu, Yue
   Yue, Mingxi
   Jiang, Yao
   Qiu, Dekui
   Yang, Man
   Wang, Zikang
   Gao, Jiahua
   Xiong, Hualong
   Qi, Ruoyao
   He, Jinhang
   Zhang, Jinlei
   Wang, Yingbin
   Fang, Mujin
   Que, Yuqiong
   Yao, Youliang
   Li, Shaowei
   Zhang, Jun
   Zhao, Qinjian
   Yuan, Quan
   Zhang, Tianying
   Xia, Ningshao
TI Micronanoparticled risedronate exhibits potent vaccine adjuvant effects
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article
DE Risedronate; Particulate adjuvant; Mechanism; Respiratory disease;
   Elderly population
ID ZOLEDRONIC ACID; BISPHOSPHONATES; MODULATION; RESPONSES; CELLS
AB Micro/Nano scale particles are widely used as vaccine adjuvants to enhance immune response and improve antigen stability. While aluminum salt is one of the most common adjuvants approved for human use, its immunostimulatory capacity is suboptimal. In this study, we modified risedronate, an immunostimulant and anti osteoporotic drug, to create zinc salt particle based risedronate (Zn RS), also termed particulate risedronate. Compared to soluble risedronate, micronanoparticled Zn RS adjuvant demonstrated increased recruitment of innate cells, enhanced antigen uptake locally, and a similar antigen depot effect as aluminum salt. Furthermore, Zn RS adjuvant directly and quickly stimulated immune cells, accelerated the formulation of germinal centers in lymph nodes, and facilitated the rapid production of antibodies. Importantly, Zn RS adjuvant exhibited superior performance in both young and aged mice, effectively protecting against respiratory diseases such as SARS CoV 2 challenge. Consequently, particulate risedronate showed great potential as an immune enhancing vaccine adjuvant, particularly beneficial for vaccines targeting the susceptible elderly.
C1 [Nie, Meifeng; Wu, Shuyu; Chen, Yiyi; Wu, Yangtao; Chen, Ruitong; Liu, Yue; Yue, Mingxi; Jiang, Yao; Qiu, Dekui; Yang, Man; Wang, Zikang; Gao, Jiahua; Xiong, Hualong; Qi, Ruoyao; He, Jinhang; Zhang, Jinlei; Wang, Yingbin; Fang, Mujin; Que, Yuqiong; Yao, Youliang; Li, Shaowei; Zhang, Jun; Yuan, Quan; Zhang, Tianying; Xia, Ningshao] Xiamen Univ, Sch Publ Hlth, State Key Lab Vaccines Infect Dis, Xiang An Biomed Lab, Xiamen 361102, Fujian, Peoples R China.
   [Nie, Meifeng; Wu, Shuyu; Chen, Yiyi; Wu, Yangtao; Chen, Ruitong; Liu, Yue; Yue, Mingxi; Jiang, Yao; Qiu, Dekui; Yang, Man; Wang, Zikang; Gao, Jiahua; Xiong, Hualong; Qi, Ruoyao; He, Jinhang; Zhang, Jinlei; Wang, Yingbin; Fang, Mujin; Que, Yuqiong; Yao, Youliang; Li, Shaowei; Zhang, Jun; Yuan, Quan; Zhang, Tianying; Xia, Ningshao] Xiamen Univ, Sch Life Sci, Xiamen 361102, Fujian, Peoples R China.
   [Nie, Meifeng; Wu, Shuyu; Chen, Yiyi; Wu, Yangtao; Chen, Ruitong; Liu, Yue; Yue, Mingxi; Jiang, Yao; Qiu, Dekui; Yang, Man; Wang, Zikang; Gao, Jiahua; Xiong, Hualong; Qi, Ruoyao; He, Jinhang; Zhang, Jinlei; Wang, Yingbin; Fang, Mujin; Que, Yuqiong; Yao, Youliang; Li, Shaowei; Zhang, Jun; Yuan, Quan; Zhang, Tianying; Xia, Ningshao] Xiamen Univ, State Key Lab Mol Vaccinol & Mol Diagnost, Natl Inst Diagnost & Vaccine Dev Infect Dis,NMPA K, Natl Innovat Platform Ind Educ Integrat Vaccine Re, Xiamen 361102, Fujian, Peoples R China.
   [Zhao, Qinjian] Chongqing Med Univ, Coll Pharm, Chongqing 400016, Peoples R China.
C3 Xiamen University; Xiamen University; Xiamen University; Chongqing
   Medical University
RP Li, SW; Zhang, J; Yuan, Q; Zhang, TY; Xia, NS (通讯作者)，Xiamen Univ, Sch Publ Hlth, State Key Lab Vaccines Infect Dis, Xiang An Biomed Lab, Xiamen 361102, Fujian, Peoples R China.; Li, SW; Zhang, J; Yuan, Q; Zhang, TY; Xia, NS (通讯作者)，Xiamen Univ, Sch Life Sci, Xiamen 361102, Fujian, Peoples R China.; Li, SW; Zhang, J; Yuan, Q; Zhang, TY; Xia, NS (通讯作者)，Xiamen Univ, State Key Lab Mol Vaccinol & Mol Diagnost, Natl Inst Diagnost & Vaccine Dev Infect Dis,NMPA K, Natl Innovat Platform Ind Educ Integrat Vaccine Re, Xiamen 361102, Fujian, Peoples R China.; Zhao, QJ (通讯作者)，Chongqing Med Univ, Coll Pharm, Chongqing 400016, Peoples R China.
EM shaowei@xmu.edu.cn; zhangj@xmu.edu.cn; zhaoqinjian@cqmu.edu.cn;
   yuanquan@xmu.edu.cn; zhangj@xmu.edu.cn; nsxia@xmu.edu.cn
RI Jin, Zhi/O 3281 2015; Wang, Yingbin/AGA 2216 2022; qi,
   ruoyao/HHZ 5200 2022; Xia, NS/G 4647 2010
OI Zhao, Qinjian/0000 0002 6297 9969; 
FU National Key Research and Development Program of China [82322027,
   81991495, U1905205, 32070925, 2022YFC0870800, 20720220003]; Fundamental
   Research Funds for the Central Universities;  [32170943];  [82341043]
FX This study was funded by National Natural Science Foundation of China
   grants 32170943 (to T.Y.Z.) , 82341043 (to T.Y.Z.) , 82322027 (to
   T.Y.Z.) , 81991495 (to T.Y.Z.) , U1905205 (to Q.Y.) , 32070925 (to Q.J.
   Z.) , National Key Research and Development Program of China
   2022YFC0870800 (to N.S.X.) , and the Fundamental Research Funds for the
   Central Universities (20720220003) .
CR Bachmann MF, 2010, NAT REV IMMUNOL, V10, P787, DOI 10.1038/nri2868
   Borriello F, 2022, CELL, V185, P614, DOI 10.1016/j.cell.2022.01.009
   Brufsky A, 2020, J TRANSL MED, V18, DOI 10.1186/s12967 020 02433 6
   Chen SY, 2019, EUR J PHARM BIOPHARM, V141, P221, DOI 10.1016/j.ejpb.2019.05.027
   Cheng KM, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 22308 8
   Cui YT, 2019, ADV HEALTHC MATER, V8, DOI 10.1002/adhm.201901073
   Drake MT, 2008, MAYO CLIN PROC, V83, P1032, DOI 10.4065/83.9.1032
   Fragni M, 2016, N S ARCH PHARMACOL, V389, P529, DOI 10.1007/s00210 016 1224 8
   Genito CJ, 2021, ADV NANOBIOMED RES, V1, DOI 10.1002/anbr.202000041
   Gridelli C, 2007, ONCOLOGIST, V12, P62, DOI 10.1634/theoncologist.12 1 62
   Kaneko J, 2018, INFLAMM REGEN, V38, DOI 10.1186/s41232 018 0074 9
   Lambert SL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051618
   Leng SY, 2019, J NATL COMPR CANC NE, V17, P22, DOI 10.6004/jnccn.2018.7079
   Li JX, 2021, NAT MED, V27, P1062, DOI 10.1038/s41591 021 01330 9
   Liao YH, 2023, PHARMACEUTICS, V15, DOI 10.3390/pharmaceutics15020576
   Liu D, 2022, RESP RES, V23, DOI 10.1186/s12931 022 02274 5
   Lu LT, 2021, VACCINES BASEL, V9, DOI 10.3390/vaccines9060563
   Mitchell DY, 2001, PHARMACEUT RES, V18, P166, DOI 10.1023/A:1011024200280
   Munoz MA, 2021, ELIFE, V10, DOI [10.7554/eLife.72430, 10.7554/eLife.72430.sa0, 10.7554/eLife.72430.sa1, 10.7554/eLife.72430.sa2]
   Nie MF, 2022, J PHARM SCI US, V111, P2397, DOI 10.1016/j.xphs.2022.05.015
   Noe SM, 2010, VACCINE, V28, P3588, DOI 10.1016/j.vaccine.2010.02.085
   Nussbaumer O, 2011, BLOOD, V118, P2743, DOI 10.1182/blood 2011 01 328526
   Orsini G, 2011, EXP BIOL MED, V236, P1420, DOI 10.1258/ebm.2011.011168
   Papapetrou PD, 2009, HORM INT J ENDOCRINO, V8, P96, DOI 10.14310/horm.2002.1226
   Park HM, 2016, VACCINE, V34, P1275, DOI 10.1016/j.vaccine.2016.01.026
   Pedersen GK, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.579761
   Peng S, 2020, ADV MATER, V32, DOI 10.1002/adma.202004210
   Rigau M, 2020, SCIENCE, V367, P642, DOI 10.1126/science.aay5516
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Tonti E, 2013, CELL REP, V5, P323, DOI 10.1016/j.celrep.2013.09.004
   Wang X, 2022, EMERG MICROBES INFEC, V11, P914, DOI 10.1080/22221751.2022.2050951
   Wu JX, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aba3458
   Wu TYH, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009980
   Wu YT, 2022, CELL HOST MICROBE, V30, P1732, DOI 10.1016/j.chom.2022.10.011
   Wu YT, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abg1143
   Xia Y, 2018, CELL, V175, P1059, DOI 10.1016/j.cell.2018.08.070
   Xiong HL, 2020, EMERG MICROBES INFEC, V9, P2105, DOI 10.1080/22221751.2020.1815589
   Xue WH, 2022, VIRUSES BASEL, V14, DOI 10.3390/v14081785
   Yang J, 2020, SMALL, V16, DOI 10.1002/smll.201906846
   Zhang KY, 2019, SMALL, V15, DOI 10.1002/smll.201900242
   Zhang QZ, 2015, J BONE MINER RES, V30, P2300, DOI 10.1002/jbmr.2577
   Zhang TY, 2020, GUT, V69, P343, DOI 10.1136/gutjnl 2018 317725
NR 42
TC 3
Z9 3
U1 9
U2 28
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0168 3659
EI 1873 4995
J9 J CONTROL RELEASE
JI J. Control. Release
PD JAN
PY 2024
VL 365
BP 369
EP 383
DI 10.1016/j.jconrel.2023.11.025
EA NOV 2023
PG 15
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Pharmacology & Pharmacy
GA CX2C6
UT WOS:001128457100001
PM 37972764
DA 2025 08 17
ER

PT J
AU Wen, J
   Li, JH
   Pan, HY
   Zhang, WJ
   Zeng, DL
   Xu, LY
   Wu, QJ
   Zhang, XL
   Liu, XY
   Jiang, XQ
AF Wen, Jin
   Li, Jinhua
   Pan, Hongya
   Zhang, Wenjie
   Zeng, Deliang
   Xu, Lianyi
   Wu, Qianju
   Zhang, Xiuli
   Liu, Xuanyong
   Jiang, Xinquan
TI Strontium delivery on topographical titanium to enhance bioactivity and
   osseointegration in osteoporotic rats
SO JOURNAL OF MATERIALS CHEMISTRY B
LA English
DT Article
ID OSTEOGENIC ACTIVITY; CERAMIC PARTICLES; FIBROUS SCAFFOLDS; CELL
   RESPONSE; THIN FILMS; SURFACE; TIO2; INTEGRATION; MECHANISMS; NANOTUBES
AB Osseointegration remains a major clinical challenge in osteoporotic patients. Strontium (Sr) has been shown to be a significant therapy to favor bone growth by both increasing new bone formation and reducing bone resorption. In this study, we attempt to chemically functionalize Ti implants by micro arc oxidation, alkali treatment and ion exchange. This functionalized Ti surface possessed a hierarchical topography with Sr incorporation, which can release Sr ions at a slow rate. To our knowledge, this work is the first to use this type of Sr doped Ti surface to address osteoporotic bone mesenchymal stem cells (BMSCs) in the dual directions of bone regeneration, bone formation and bone resorption. The modified surface was demonstrated to remarkably enhance the adhesion, spreading, and osteogenic differentiation of BMSCs in vitro. The effect of the wash out solution from various groups on osteoporotic BMSCs was also investigated. The Sr doped group can improve the ALP activity and osteogenic gene expression. Moreover, the Sr doped group and the wash out solution show the most inhibition in osteoclast formation and maturation. Furthermore, the increased bioactivity of the hierarchical structure was also confirmed with the ovariectomized rat femur model in vivo. The outcome of fluorescence labeling, histology and histomorphometric analysis demonstrated a significant promotion of osseointegration in ovariectomized rats. Altogether, the experimental data indicate that the fabrication of a Sr doped hierarchical Ti surface is a meaningful attempt to incorporate the Sr nutrient element into Ti based implants, and it is expected to be exploited in developing better osseointegration for osteoporotic patients.
C1 [Wen, Jin; Zhang, Wenjie; Zeng, Deliang; Xu, Lianyi; Wu, Qianju; Jiang, Xinquan] Shanghai Jiao Tong Univ, Peoples Hosp Affiliated 9, Sch Med, Dept Prosthodont, Shanghai 200011, Peoples R China.
   [Wen, Jin; Pan, Hongya; Zhang, Wenjie; Zeng, Deliang; Xu, Lianyi; Wu, Qianju; Zhang, Xiuli; Jiang, Xinquan] Shanghai Jiao Tong Univ, Peoples Hosp Affiliated 9, Sch Med, Shanghai Res Inst Stomatol,Oral Bioengn Lab, Shanghai 200011, Peoples R China.
   [Li, Jinhua; Liu, Xuanyong] Chinese Acad Sci, Shanghai Inst Ceram, State Key Lab High Performance Ceram & Superfine, Shanghai 200050, Peoples R China.
C3 Shanghai Jiao Tong University; Shanghai Jiao Tong University; Chinese
   Academy of Sciences; Shanghai Institute of Ceramics, CAS
RP Jiang, XQ (通讯作者)，Shanghai Jiao Tong Univ, Peoples Hosp Affiliated 9, Sch Med, Dept Prosthodont, 639 Zhizaoju Rd, Shanghai 200011, Peoples R China.
EM xyliu@mail.sic.ac.cn; xinquanj@aliyun.cn
RI Wen, Jin/AAI 1204 2019; Li, Jinhua/AAI 3716 2021; Liu,
   Xuanyong/J 2609 2018; Pan, Hongya/L 5684 2018; Xu, Lianyi/KBB 9332 2024;
   Zhang, Wenjie/O 5336 2014
OI Wen, Jin/0000 0001 5365 0179; Zhang, Wenjie/0000 0002 7753 695X; Wu,
   Qianju/0000 0002 9711 7058; Li, Jinhua/0000 0003 1110 7471; 
FU National Basic Research Program of China (973 Program) [2012CB933600];
   National Science Fund for Distinguished Young Scholars [81225006]; Chang
   Jiang Scholars Program; National Natural Science Foundation of China
   [81271704, 31370962]; Shanghai Science and Technology RD Fund
   [14XD1403900, 13441902400]
FX Joint financial support from the National Basic Research Program of
   China (973 Program, 2012CB933600), National Science Fund for
   Distinguished Young Scholars (81225006), Chang Jiang Scholars Program,
   National Natural Science Foundation of China (81271704, 31370962), and
   Shanghai Science and Technology R&D Fund (14XD1403900, 13441902400) is
   acknowledged.
CR Andersen OZ, 2013, BIOMATERIALS, V34, P5883, DOI 10.1016/j.biomaterials.2013.04.031
   BRANEMARK PI, 1995, CLIN ORAL IMPLAN RES, V6, P227, DOI 10.1034/j.1600 0501.1995.060405.x
   Brnemark P., 1985, TISSUE INTEGRATED PR, P11
   Bylski D, 2009, J BIOMED MATER RES A, V89A, P707, DOI 10.1002/jbm.a.31956
   Chug A., 2013, INT J ORAL MAXILLOF, V25, P1
   Chung CJ, 2011, ACTA BIOMATER, V7, P4081, DOI 10.1016/j.actbio.2011.07.004
   Dahl SG, 2001, BONE, V28, P446, DOI 10.1016/S8756 3282(01)00419 7
   Dupraz A, 1999, BIOMATERIALS, V20, P663, DOI 10.1016/S0142 9612(98)00222 1
   FEIST TP, 1992, J SOLID STATE CHEM, V101, P275, DOI 10.1016/0022 4596(92)90184 W
   Feng L, 2002, ADV MATER, V14, P1857, DOI 10.1002/adma.200290020
   Flecher X, 2009, J CLIN IMMUNOL, V29, P681, DOI 10.1007/s10875 009 9305 9
   Forsgren J, 2010, J MATER SCI MATER M, V21, P1605, DOI 10.1007/s10856 010 4022 8
   Gagnon C., 2009, F1000 Medicine Reports
   Gao H, 2014, J MATER CHEM B, V2, P1216, DOI 10.1039/c3tb21521k
   Geetha M, 2009, PROG MATER SCI, V54, P397, DOI 10.1016/j.pmatsci.2008.06.004
   Gentleman E, 2010, BIOMATERIALS, V31, P3949, DOI 10.1016/j.biomaterials.2010.01.121
   GRYNPAS MD, 1990, BONE, V11, P313, DOI 10.1016/8756 3282(90)90086 E
   Han Y, 2008, ACTA BIOMATER, V4, P1518, DOI 10.1016/j.actbio.2008.03.005
   Han Y, 2013, RSC ADV, V3, P11169, DOI 10.1039/c3ra23425h
   Huang Y, 2014, SCI REP UK, V4, DOI 10.1038/srep06172
   Jiang XQ, 2009, BIOMATERIALS, V30, P4522, DOI 10.1016/j.biomaterials.2009.05.021
   Kanis JA, 2002, OSTEOPOROSIS INT, V13, P527, DOI 10.1007/s001980200069
   KANIS JA, 1994, J BONE MINER RES, V9, P1137, DOI 10.1002/jbmr.5650090802
   Krzakala A, 2013, RSC ADV, V3, P19725, DOI 10.1039/c3ra43465f
   Kung KC, 2010, J ALLOY COMPD, V508, P384, DOI 10.1016/j.jallcom.2010.08.057
   Kurth AHA, 2005, BONE, V37, P204, DOI 10.1016/j.bone.2004.12.017
   Li JH, 2014, J COLLOID INTERF SCI, V436, P160, DOI 10.1016/j.jcis.2014.08.053
   Li JH, 2014, COLLOID SURFACE B, V113, P134, DOI 10.1016/j.colsurfb.2013.08.030
   Li JH, 2014, J MATER CHEM B, V2, P283, DOI 10.1039/c3tb21102a
   Li JH, 2013, RSC ADV, V3, P11214, DOI 10.1039/c3ra23252b
   Li X, 2014, NUCL INSTRUM METH B, V332, P321, DOI 10.1016/j.nimb.2014.02.087
   Li YF, 2010, BIOMATERIALS, V31, P9006, DOI 10.1016/j.biomaterials.2010.07.112
   Lin KL, 2013, BIOMATERIALS, V34, P10028, DOI 10.1016/j.biomaterials.2013.09.056
   Liu MX, 2013, J MATER CHEM B, V1, P2078, DOI 10.1039/c3tb20084a
   Liu XY, 2010, MAT SCI ENG R, V70, P275, DOI 10.1016/j.mser.2010.06.013
   Liu XY, 2004, MAT SCI ENG R, V47, P49, DOI 10.1016/j.mser.2004.11.001
   Lutolf MP, 2009, NATURE, V462, P433, DOI 10.1038/nature08602
   Ma RZ, 2004, J AM CHEM SOC, V126, P10382, DOI 10.1021/ja048855p
   Marie PJ, 2001, CALCIFIED TISSUE INT, V69, P121, DOI 10.1007/s002230010055
   MARIE PJ, 1985, MINER ELECTROL METAB, V11, P5
   Mendonça G, 2008, BIOMATERIALS, V29, P3822, DOI 10.1016/j.biomaterials.2008.05.012
   Meunier PJ, 2004, NEW ENGL J MED, V350, P459, DOI 10.1056/NEJMoa022436
   Miyauchi M, 2007, J PHYS CHEM C, V111, P12440, DOI 10.1021/jp073604z
   Nair AS, 2012, LANGMUIR, V28, P6202, DOI 10.1021/la301172g
   Ng R, 2012, RSC ADV, V2, P10110, DOI 10.1039/c2ra21085a
   Park JW, 2012, J BIOMED MATER RES A, V100A, P1477, DOI 10.1002/jbm.a.34085
   Peng SL, 2011, BONE, V49, P1290, DOI 10.1016/j.bone.2011.08.031
   Rani VVD, 2009, NANOTECHNOLOGY, V20, DOI 10.1088/0957 4484/20/19/195101
   Roy M, 2012, J BIOMED MATER RES A, V100A, P2450, DOI 10.1002/jbm.a.34181
   Sabareeswaran A, 2013, BIOMATERIALS, V34, P9278, DOI 10.1016/j.biomaterials.2013.08.070
   Saidak Z, 2012, PHARMACOL THERAPEUT, V136, P216, DOI 10.1016/j.pharmthera.2012.07.009
   Santos MI, 2008, BIOMATERIALS, V29, P4306, DOI 10.1016/j.biomaterials.2008.07.033
   Shen QP, 2013, J PHARM PHARMACOL, V65, P1005, DOI 10.1111/jphp.12054
   Sowmya S, 2013, PROG POLYM SCI, V38, P1748, DOI 10.1016/j.progpolymsci.2013.05.005
   Thormann U, 2013, BIOMATERIALS, V34, P8589, DOI 10.1016/j.biomaterials.2013.07.036
   Tokudome H, 2004, CHEM COMMUN, P958, DOI 10.1039/b316924c
   TURNER AS, 2001, EUR CELLS MATER, V1, P13
   Wu QJ, 2014, J MATER CHEM B, V2, P6738, DOI 10.1039/c4tb00923a
   Xie HX, 2013, CERAM INT, V39, P8945, DOI 10.1016/j.ceramint.2013.04.091
   Xin YC, 2009, ACS NANO, V3, P3228, DOI 10.1021/nn9007675
   Xiong JH, 2011, NAT MED, V17, P1235, DOI 10.1038/nm.2448
   Yong H., 2011, NANOTECHNOLOGY, V52, P22
   Yu B, 2014, NAT MED, V20, P1009, DOI 10.1038/nm.3586
   Zhang WJ, 2014, NANOMED NANOTECHNOL, V10, P1809, DOI 10.1016/j.nano.2014.07.002
   Zhang WJ, 2013, BIOMATERIALS, V34, P3184, DOI 10.1016/j.biomaterials.2013.01.008
   Zhao LZ, 2013, BIOMATERIALS, V34, P19, DOI 10.1016/j.biomaterials.2012.09.041
   Zreiqat H, 2010, BIOMATERIALS, V31, P3175, DOI 10.1016/j.biomaterials.2010.01.024
   Zuruzi AS, 2005, ADV FUNCT MATER, V15, P396, DOI 10.1002/adfm.200400135
NR 68
TC 35
Z9 39
U1 1
U2 118
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2050 750X
EI 2050 7518
J9 J MATER CHEM B
JI J. Mat. Chem. B
PY 2015
VL 3
IS 24
BP 4790
EP 4804
DI 10.1039/c5tb00128e
PG 15
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA CK1TC
UT WOS:000355989200004
PM 32262668
DA 2025 08 17
ER

PT J
AU Feng, SM
   Zhu, GC
   McConnell, M
   Deng, LF
   Zhao, Q
   Wu, MR
   Zhou, Q
   Wang, JS
   Qi, J
   Li, YP
   Chen, W
AF Feng, Shengmei
   Zhu, Guochun
   McConnell, Matthew
   Deng, Lianfu
   Zhao, Qiang
   Wu, Mengrui
   Zhou, Qi
   Wang, Jinshen
   Qi, Jin
   Li, Yi Ping
   Chen, Wei
TI Silencing of Atp6v1c1 Prevents Breast Cancer Growth and Bone Metastasis
SO INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES
LA English
DT Article
DE Atp6v1c1 (C1); V ATPase; breast cancer; lysosomal acidification; tumor
   bone metastasis
ID VACUOLAR H+ ATPASE; IN VIVO; MELANOMA CELLS; MATRIX METALLOPROTEINASE 9
   EXPRESSION; MULTISTAGE TUMORIGENESIS; PROTON PUMP; C SUBUNIT; PH;
   OSTEOCLASTS; GENE
AB Previous studies have shown that Atp6v1c1, a regulator of the assembly of the V0 and V1 domains of the V ATPase complex, is up regulated in metastatic oral tumors. Despite these studies, the function of Atp6v1c1 in tumor growth and metastasis is still unknown. Atp6v1c1's expression in metastatic oral squamous cell carcinoma indicates that Atp6v1c1 has an important function in cancer growth and metastasis. We hypothesized that elevated expression of Atp6v1c1 is essential to cancer growth and metastasis and that Atp6v1c1 promotes cancer growth and metastasis through activation of V ATPase activity. To test this hypothesis, a Lentivirus mediated RNAi knockdown approach was used to study the function of Atp6v1c1 in mouse 4T1 mammary tumor cell proliferation and migration in vitro and cancer growth and metastasis in vivo. Our data revealed that silencing of Atp6v1c1 in 4T1 cancer cells inhibited lysosomal acidification and severely impaired 4T1 cell growth, migration, and invasion through Matrigel in vitro. We also show that Atp6v1c1 knockdown with Lenti c1s3, a lentivirus targeting Atp6v1c1 for shRNA mediated knockdown, can significantly inhibit 4T1 xenograft tumor growth, metastasis, and osteolytic lesions in vivo. Our study demonstrates that Atp6v1c1 may promote breast cancer growth and bone metastasis through regulation of lysosomal V ATPase activity, indicating that Atp6v1c1 may be a viable target for breast cancer therapy and silencing of Atp6v1c1 may be an innovative therapeutic approach for the treatment and prevention of breast cancer growth and metastasis.
C1 [Feng, Shengmei; Deng, Lianfu; Zhao, Qiang; Zhou, Qi; Wang, Jinshen; Qi, Jin] Jiao Tong Univ, Shanghai Inst Traumatol & Orthopaed, Shanghai Key Lab Prevent & Treatment Bone & Joint, Ruijin Hosp,Sch Med, Shanghai 200030, Peoples R China.
   [Feng, Shengmei; Zhu, Guochun; McConnell, Matthew; Wu, Mengrui; Li, Yi Ping; Chen, Wei] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA.
C3 Shanghai Jiao Tong University; University of Alabama System; University
   of Alabama Birmingham
RP Li, YP (通讯作者)，Univ Alabama Birmingham, Dept Pathol, SHEL 810,1825 Univ Blvd, Birmingham, AL 35294 USA.
EM ypli@uab.edu; wechen@uab.edu
RI ; Zhao, Qiang/I 4287 2013; Li, Yi Ping/ABF 9245 2020
OI McConnell, Matthew/0000 0003 0194 5287; 
FU National Natural Science Foundation of China [30901525]; Shanghai
   Natural Science Foundation [09ZR1428900]; Shanghai Education Commission
   Foundation [10YZ39]; Talents Cultivation Plan of Shanghai Health System
   [XYQ2011050]; NIH [AR 055307, R01 AR 44741]
FX We thank Ms. Christie Paulson and Mr. Zach Nolen for their excellent
   assistance with this manuscript. We are grateful for the assistance of
   Small Animal Bone Phenotyping Core and Histomorphometry and Molecular
   Analyses Core and Neuroscience Image Core and Neuroscience Molecular
   Detection Core Laboratory at the University of Alabama at Birmingham
   (P30 NS0474666). This paper was supported by National Natural Science
   Foundation of China Grant 30901525, Shanghai Natural Science Foundation
   Grant 09ZR1428900, Shanghai Education Commission Foundation Grant
   10YZ39, and Talents Cultivation Plan of Shanghai Health System
   XYQ2011050 (all to S. M. F.). NIH grants AR 055307 (Y. P. L.) and
   R01 AR 44741(Y.P.L.).
CR Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296
   Chen W, 2013, P NATL ACAD SCI USA, V110, P7294, DOI 10.1073/pnas.1211383110
   Chirgwin JM, 2000, CRIT REV EUKAR GENE, V10, P159, DOI 10.1615/CritRevEukarGeneExpr.v10.i2.50
   Cicek M, 2007, CANCER RES, V67, P10106, DOI 10.1158/0008 5472.CAN 07 1362
   Day CP, 2009, PIGM CELL MELANOMA R, V22, P283, DOI 10.1111/j.1755 148X.2009.00545.x
   De Milito A, 2007, CANCER RES, V67, P5408, DOI 10.1158/0008 5472.CAN 06 4095
   Feng SM, 2009, BIOCHEM J, V417, P195, DOI 10.1042/BJ20081073
   Forgac M, 1999, J BIOL CHEM, V274, P12951, DOI 10.1074/jbc.274.19.12951
   Forgac M, 2007, NAT REV MOL CELL BIO, V8, P917, DOI 10.1038/nrm2272
   Gocheva V, 2006, GENE DEV, V20, P543, DOI 10.1101/gad.1407406
   Goligan LI, 1991, CURRENT PROTOCAL IMM, P4148
   Harhaji L, 2006, FREE RADICAL BIO MED, V40, P226, DOI 10.1016/j.freeradbiomed.2005.08.027
   Iwai K, 2007, J BONE MINER RES, V22, P1612, DOI 10.1359/JBMR.070612
   Joyce JA, 2004, CELL CYCLE, V3, P1516, DOI 10.4161/cc.3.12.1289
   Joyce JA, 2004, CANCER CELL, V5, P443, DOI 10.1016/S1535 6108(04)00111 4
   KANE PM, 1995, J BIOL CHEM, V270, P17025
   Kato Y, 2005, J BIOL CHEM, V280, P10938, DOI 10.1074/jbc.M411313200
   Kato Y, 2007, FEBS J, V274, P3171, DOI 10.1111/j.1742 4658.2007.05848.x
   Kim JM, 2007, INT J MOL MED, V19, P393
   Kissler S, 2006, NAT GENET, V38, P479, DOI 10.1038/ng1766
   Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404
   Lelekakis M, 1999, CLIN EXP METASTAS, V17, P163, DOI 10.1023/A:1006689719505
   Li YP, 1999, NAT GENET, V23, P447, DOI 10.1038/70563
   Lu YD, 2005, CANCER RES, V65, P6843, DOI 10.1158/0008 5472.CAN 04 3822
   Martí Renom MA, 2000, ANNU REV BIOPH BIOM, V29, P291, DOI 10.1146/annurev.biophys.29.1.291
   Martin TJ, 2000, ENDOCR RELAT CANCER, V7, P271, DOI 10.1677/erc.0.0070271
   Martínez Zaguilán R, 1998, J CELL PHYSIOL, V176, P196, DOI 10.1002/(SICI)1097 4652(199807)176:1<196::AID JCP21>3.0.CO;2 4
   Martínez Zaguilán R, 1999, BIOCHEM PHARMACOL, V57, P1037, DOI 10.1016/S0006 2952(99)00022 2
   MARTINEZZAGUILAN R, 1993, AM J PHYSIOL, V265, pC1015, DOI 10.1152/ajpcell.1993.265.4.C1015
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Nam JS, 2006, CANCER RES, V66, P6327, DOI 10.1158/0008 5472.CAN 06 0068
   Nishisho T, 2011, MOL CANCER RES, V9, P845, DOI 10.1158/1541 7786.MCR 10 0449
   Otero Rey EM, 2008, ORAL ONCOL, V44, P193, DOI 10.1016/j.oraloncology.2007.02.011
   Parra KJ, 2000, J BIOL CHEM, V275, P21761, DOI 10.1074/jbc.M002305200
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Sennoune SR, 2004, AM J PHYSIOL CELL PH, V286, pC1443, DOI 10.1152/ajpcell.00407.2003
   Stewart SA, 2003, RNA, V9, P493, DOI 10.1261/rna.2192803
   SUMNER JP, 1995, J BIOL CHEM, V270, P5649, DOI 10.1074/jbc.270.10.5649
   Sun Wada GH, 2003, J BIOL CHEM, V278, P44843, DOI 10.1074/jbc.M307197200
   Sun Wada GH, 2003, GENE, V302, P147, DOI 10.1016/S0378 1119(02)01099 5
   Taraboletti G, 2006, NEOPLASIA, V8, P96, DOI 10.1593/neo.05583
   Tehrani S, 2006, MOL BIOL CELL, V17, P2882, DOI 10.1091/mbc.E06 03 0187
   Tu QS, 2009, J CELL PHYSIOL, V218, P135, DOI 10.1002/jcp.21576
   von Schwarzenberg K, 2013, J BIOL CHEM, V288, P1385, DOI 10.1074/jbc.M112.412007
   Wu C, 2009, GENOME BIOL, V10, DOI 10.1186/gb 2009 10 11 r130
   Xu J, 2007, HISTOL HISTOPATHOL, V22, P443, DOI 10.14670/HH 22.443
   Xu T, 1999, J BIOL CHEM, V274, P28909, DOI 10.1074/jbc.274.41.28909
NR 47
TC 39
Z9 46
U1 1
U2 17
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1449 2288
J9 INT J BIOL SCI
JI Int. J. Biol. Sci.
PY 2013
VL 9
IS 8
BP 853
EP 862
DI 10.7150/ijbs.6030
PG 10
WC Biochemistry & Molecular Biology; Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine   Other
   Topics
GA 218FW
UT WOS:000324419200010
PM 24155661
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Bergqvist, AGC
   Schall, JI
   Stallings, VA
   Zemel, BS
AF Bergqvist, A. G. Christina
   Schall, Joan I.
   Stallings, Virginia A.
   Zemel, Babette S.
TI Progressive bone mineral content loss in children with intractable
   epilepsy treated with the ketogenic diet
SO AMERICAN JOURNAL OF CLINICAL NUTRITION
LA English
DT Article
ID ANTIEPILEPTIC DRUG MONOTHERAPY; CARBONIC ANHYDRASE INHIBITORS; VITAMIN D
   STATUS; APPENDICULAR SKELETONS; HEALTHY CHILDREN; HIGH FREQUENCY;
   KIDNEY STONES; DENSITY; GROWTH; EFFICACY
AB Background: The ketogenic diet (KD) is a high fat, low carbohydrate, and protein diet that effectively treats intractable epilepsy (IE).
   Objective: The purpose of this study was to measure the change in bone mineral content (BMC) in children with IE treated with the KD for 15 mo.
   Design: Prepubertal children >= 5 y of age with IE were eligible. A 4: 1 ketogenic diet was maintained for 15 mo, and whole body and spine BMCs were measured with dual energy X ray absorptiometry. Z scores were generated by comparing the children with IE with a cohort of 847 healthy children. Other measurements included demographics, anthropometry, serum 25 hydroxyvitamin D (25 OHD), intact parathyroid hormone, electrolytes, and dietary intake. All measurements were performed at baseline and at 3, 6, 12, and 15 mo. Longitudinal mixed effects models were used to analyze change in BMC over time.
   Results: Twenty five children (9 girls, 16 boys) with IE [age ((x) over bar +/  SD): 7.3 +/  1.9 y] participated. Growth and bone health status were suboptimal as were serum 25 OHD concentrations and dietary intake of calcium and vitamin D. Whole body and spine BMC for age both declined by 0.6 zscore/y and whole body and spine BMC for height declined 0.7 z score/y and 0.4 z score/y, respectively. Height declined 0.5 z score/y. Body mass index (BMI; in kg/m(2)) z score, age, and ambulation were positive predictors of BMC, which declined sharply over 15 mo of KD treatment.
   Conclusion: Bone health in children with IE was poor, particularly for younger nonambulatory children with low BMI status. The KD resulted in progressive loss of BMC. The mechanism is unclear. Further studies are needed. Am J Clin Nutr 2008; 88: 1678 84.
C1 [Bergqvist, A. G. Christina] Univ Penn, Sch Med, Dept Pediat & Neurol, Childrens Hosp Philadelphia,Div Neurol, Philadelphia, PA 19104 USA.
   [Schall, Joan I.; Stallings, Virginia A.; Zemel, Babette S.] Univ Penn, Sch Med, Dept Pediat & Neurol,Childrens Hosp Philadelphia, Div Gastroenterol Hepatol & Nutr, Philadelphia, PA 19104 USA.
C3 University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of
   Philadelphia; University of Pennsylvania; Pennsylvania Medicine;
   Childrens Hospital of Philadelphia
RP Bergqvist, AGC (通讯作者)，Univ Penn, Sch Med, Dept Pediat & Neurol, Childrens Hosp Philadelphia,Div Neurol, 34th & Civ Ctr Blvd,CHOP North,Room 1591, Philadelphia, PA 19104 USA.
EM bergqvist@email.chop.edu
RI Zemel, Babette/D 1117 2009
FU NIH [K 23 RR16074, UL1 RR 024134 NCRR]; Clinical Translational Science
   Award; Pediatric Regional Epilepsy Program; Catherine Brown Foundation;
   Nutrition Center
FX Supported by NIH (K 23 RR16074, UL1 RR 024134 NCRR), the Clinical
   Translational Science Award (Children's Hospital of Philadelphia and
   University of Pennsylvania), the Pediatric Regional Epilepsy Program,
   the Catherine Brown Foundation, and the Nutrition Center.
CR [Anonymous], 2005, Dietary Reference intakes for energy, carbohydrate, fiber, Fat, fatty acids, cholesterol, protein, and amino acids
   [Anonymous], 1975, Assessment of Skeletal Maturity and Prediction of Adult Height (TW2 method)
   [Anonymous], 2001, DIETARY REFERENCE IN, DOI DOI 10.1016/S0899 9007(00)00596 7
   [Anonymous], 1997, DIET REF INT CALC MA
   [Anonymous], 1991, Anthropometric standardization reference manual
   Bachrach LK, 1999, J CLIN ENDOCR METAB, V84, P4702, DOI 10.1210/jc.84.12.4702
   Bajpai A, 2005, INDIAN PEDIATR, V42, P321
   Beck BR, 2006, J BONE MINER METAB, V24, P505, DOI 10.1007/s00774 006 0717 9
   Bergqvist AGC, 2007, EPILEPSIA, V48, P66, DOI 10.1111/j.1528 1167.2006.00803.x
   Bergqvist AGC, 2005, EPILEPSIA, V46, P1810, DOI 10.1111/j.1528 1167.2005.00282.x
   Bertoli Simona, 2002, Recenti Progressi in Medicina, V93, P671
   Caulton JM, 2004, ARCH DIS CHILD, V89, P131, DOI 10.1136/adc.2002.009316
   Chang Chia Yau, 2002, Acta Paediatrica Taiwanica, V43, P334
   COLE TJ, 1992, STAT MED, V11, P1305, DOI 10.1002/sim.4780111005
   Couch SC, 1999, J AM DIET ASSOC, V99, P1573, DOI 10.1016/S0002 8223(99)00387 9
   Fitzpatrick LA, 2004, EPILEPSY BEHAV, V5, pS3, DOI 10.1016/j.yebeh.2003.11.026
   Fraser DA, 2000, CLIN EXP RHEUMATOL, V18, P209
   Freeman JM, 1996, The epilepsy diet treatment: An introduction to the ketogenic diet
   Gilsanz V, 1997, J CLIN ENDOCR METAB, V82, P1603, DOI 10.1210/jc.82.5.1603
   Gilsanz V, 1998, J CLIN ENDOCR METAB, V83, P1420, DOI 10.1210/jc.83.5.1420
   Gilsanz V, 2006, J BONE MINER RES, V21, P1464, DOI 10.1359/JBMR.060612
   Groesbeck DK, 2006, DEV MED CHILD NEUROL, V48, P978, DOI 10.1111/j.1469 8749.2006.tb01269.x
   HAHN TJ, 1979, CALCIFIED TISSUE INT, V28, P17, DOI 10.1007/BF02441213
   Heaney RP, 2003, AM J CLIN NUTR, V78, P350, DOI 10.1093/ajcn/78.2.350
   Henderson CB, 2006, J CHILD NEUROL, V21, P193, DOI 10.2310/7010.2006.00044
   HOLLIS BW, 1993, CLIN CHEM, V39, P529
   *I MED, 2001, DIET REF INT VIT A V
   Kim SH, 2007, EPILEPSY BEHAV, V10, P291, DOI 10.1016/j.yebeh.2006.11.007
   Kossoff EH, 2002, EPILEPSIA, V43, P1168, DOI 10.1046/j.1528 1157.2002.11302.x
   KUCZMARSKI RJ, 2000, CDC GROWTH CHARTS US
   Laron Z, 2001, J CLIN PATHOL MOL PA, V54, P311
   Lefevre F, 2000, PEDIATRICS, V105, DOI 10.1542/peds.105.4.e46
   Leonard MB, 1998, J BONE MINER RES, V13, P1687, DOI 10.1359/jbmr.1998.13.11.1687
   Parmar MS, 2003, EPILEPSIA, V44, P735
   PRENTICE A, 1994, AM J CLIN NUTR, V60, P837
   SCHWARTZ RH, 1989, DEV MED CHILD NEUROL, V31, P145
   Sheth RD, 2008, NEUROLOGY, V70, P170, DOI 10.1212/01.wnl.0000284595.45880.93
   Sheth RD, 2008, EPILEPSIA, V49, P125, DOI 10.1111/j.1528 1167.2007.01253.x
   TANNER JM, 1962, GROWTH ADOLESCENCE
   Tekgul H, 2006, J CHILD NEUROL, V21, P411, DOI 10.1177/08830738060210050101
   Tsukahara H, 2002, PEDIATR INT, V44, P247, DOI 10.1046/j.1442 200X.2002.01561.x
   Vining EPG, 2002, DEV MED CHILD NEUROL, V44, P796, DOI 10.1017/S0012162201002961
   Volpe SL, 2007, J AM DIET ASSOC, V107, P1014, DOI 10.1016/j.jada.2007.03.011
   Weng FL, 2007, AM J CLIN NUTR, V86, P150, DOI 10.1093/ajcn/86.1.150
   Williams S, 2002, J AM DIET ASSOC, V102, P405, DOI 10.1016/S0002 8223(02)90093 3
   Wilner A, 1999, EPILEPSIA, V40, P792, DOI 10.1111/j.1528 1157.1999.tb00781.x
NR 46
TC 136
Z9 150
U1 0
U2 23
PU AMER SOC CLINICAL NUTRITION
PI BETHESDA
PA 9650 ROCKVILLE PIKE, SUBSCRIPTIONS, RM L 3300, BETHESDA, MD 20814 3998
   USA
SN 0002 9165
J9 AM J CLIN NUTR
JI Am. J. Clin. Nutr.
PD DEC 1
PY 2008
VL 88
IS 6
BP 1678
EP 1684
DI 10.3945/ajcn.2008.26099
PG 7
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Nutrition & Dietetics
GA 380EO
UT WOS:000261449200029
PM 19064531
OA Bronze
DA 2025 08 17
ER

PT J
AU Zhou, YP
   Jia, XE
   Tan, L
   Xie, QJ
   Lei, LH
   Yao, SZ
AF Zhou, Yaping
   Jia, Xue'en
   Tan, Liang
   Xie, Qingji
   Lei, Lihong
   Yao, Shouzhuo
TI Magnetically enhanced cytotoxicity of paramagnetic selenium ferroferric
   oxide nanocomposites on human osteoblast like MG 63 cells
SO BIOSENSORS & BIOELECTRONICS
LA English
DT Article
DE Quartz crystal microbalance; Human osteoblast like MG 63 cells;
   Paramagnetic Se Fe3O4 nanocomposites; Cytotoxicity
ID QUARTZ CRYSTAL MICROBALANCE; DRUG TARGETING DELIVERY; IN VIVO; IMPEDANCE
   ANALYSIS; CANCER PREVENTION; NANOPARTICLES; BIOSENSOR; GROWTH; ADHESION;
   POLYMER
AB We use quartz crystal microbalance (QCM), 3 (4,5 dimethylthizaol 2 yl) 2,5 diphenyltetrazolium bromide (MTT) assay, and fluorescence/optical microscopic inspections to investigate the cytotoxicity of paramagnetic selenium ferroferric oxide (Se Fe3O4) nanocomposites on human osteoblast like MG 63 cells. The nearly spherical Se Fe3O4 nanocomposites of 40 50 nm diameter, as characterized by transmission electron microscopy (TEM), are synthesized through reduction of selenious acid by ascorbic acid in the presence of nanosized Fe3O4. The QCM technique is employed for the first time to monitor the toxicity of Se Fe3O4 on tumor cells in a real time manner. We find that the Se Fe3O4 nanocomposites are able to induce cell apoptosis in a dose dependent way, and an external magnetic field increases the cytotoxicity. The results obtained from MTT assay as well as fluorescence and inverted optical microscopy experiments are consistent with that from QCM experiments, indicating that the QCM technique as a simple, inexpensive and dynamic tool is promising in studying the magnetic effects of many paramagnetic drugs on the cells for better understanding of the relevant magneto chemotherapy processes. (C) 2009 Elsevier B.V. All rights reserved.
C1 [Zhou, Yaping; Jia, Xue'en; Tan, Liang; Xie, Qingji; Lei, Lihong; Yao, Shouzhuo] Hunan Normal Univ, Key Lab Chem Biol & Tradit Chinese Med Res, Minist Educ China, Coll Chem & Chem Engn, Changsha 410081, Hunan, Peoples R China.
C3 Hunan Normal University
RP Xie, QJ (通讯作者)，Hunan Normal Univ, Key Lab Chem Biol & Tradit Chinese Med Res, Minist Educ China, Coll Chem & Chem Engn, Changsha 410081, Hunan, Peoples R China.
EM xieqj@hunnu.edu.cn
RI zhou, yaping/KDP 3571 2024
FU National Natural Science Foundation of China [20675029, 90713018,
   20905025]; State Special Scientific Project on Water Treatment
   [2009ZX07212 001 06]; Foundation of the Hunan Provincial Education
   Department [05A036]; State Key Laboratory of Electroanalytical Chemistry
FX This work was supported by the National Natural Science Foundation of
   China (20675029, 90713018, 20905025), the State Special Scientific
   Project on Water Treatment (2009ZX07212 001 06), the Foundation of the
   Hunan Provincial Education Department (05A036), and the State Key
   Laboratory of Electroanalytical Chemistry.
CR Abdulah R, 2005, J TRACE ELEM MED BIO, V19, P141, DOI 10.1016/j.jtemb.2005.09.003
   [Anonymous], ADV FUNCT MAT
   Banerjee SS, 2007, CHEM MATER, V19, P6345, DOI 10.1021/cm702278u
   Cao XB, 2004, ADV MATER, V16, P649, DOI 10.1002/adma.200306317
   Carvalho KM, 2003, J AGR FOOD CHEM, V51, P704, DOI 10.1021/jf0258555
   Chen HM, 2009, ANAL BIOCHEM, V392, P1, DOI 10.1016/j.ab.2009.05.029
   Chen S, 2007, LANGMUIR, V23, P12669, DOI 10.1021/la702049d
   Cheng Y, 2008, J AM CHEM SOC, V130, P10643, DOI 10.1021/ja801631c
   DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022 1759(86)90368 6
   Elsom J, 2008, BIOSENS BIOELECTRON, V23, P1259, DOI 10.1016/j.bios.2007.11.020
   Hamilton SJ, 2004, SCI TOTAL ENVIRON, V326, P1, DOI 10.1016/j.scitotenv.2004.01.019
   Hiraoka K, 2001, J ORTHOP RES, V19, P809, DOI 10.1016/S0736 0266(00)00079 6
   Hu SH, 2008, ADV FUNCT MATER, V18, P2946, DOI 10.1002/adfm.200800428
   Jacobson GB, 2008, ANGEW CHEM INT EDIT, V47, P7880, DOI 10.1002/anie.200802260
   Jain D, 2008, J BIOMED MATER RES B, V86B, P105, DOI 10.1002/jbm.b.30994
   KANAZAWA KK, 1985, ANAL CHIM ACTA, V175, P99
   Kang HW, 2009, BIOSENS BIOELECTRON, V24, P1318, DOI 10.1016/j.bios.2008.07.038
   Kim JS, 2006, J VET SCI, V7, P321, DOI 10.4142/jvs.2006.7.4.321
   Kim S, 2008, J CEREAL SCI, V47, P1, DOI 10.1016/j.jcs.2007.08.004
   Kim TW, 2008, NANO LETT, V8, P3724, DOI 10.1021/nl801976m
   Lee C, 2008, ADV FUNCT MATER, V18, P1
   Lee JJ, 2008, ANN DERMATOL, V20, P1, DOI 10.5021/ad.2008.20.1.1
   Letavayová L, 2006, TOXICOLOGY, V227, P1, DOI 10.1016/j.tox.2006.07.017
   Li J, 2005, BIOSENS BIOELECTRON, V20, P1333, DOI 10.1016/j.bios.2004.05.004
   Li Q, 2006, CHEM COMMUN, P1006, DOI 10.1039/b515025f
   Liang HF, 2006, BIOCONJUGATE CHEM, V17, P291, DOI 10.1021/bc0502107
   Liong M, 2008, ACS NANO, V2, P889, DOI 10.1021/nn800072t
   Liu TY, 2008, LANGMUIR, V24, P13306, DOI 10.1021/la801451v
   Lord MS, 2008, BIOMATERIALS, V29, P2581, DOI 10.1016/j.biomaterials.2008.03.002
   MARTIN SJ, 1991, ANAL CHEM, V63, P2272, DOI 10.1021/ac00020a015
   Marx KA, 2001, BIOSENS BIOELECTRON, V16, P773, DOI 10.1016/S0956 5663(01)00219 6
   Marx KA, 2007, ANAL BIOCHEM, V361, P77, DOI 10.1016/j.ab.2006.09.023
   Mayers BT, 2003, CHEM MATER, V15, P3852, DOI 10.1021/cm034193b
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022 1759(83)90303 4
   Navarro Alarcon M, 2008, SCI TOTAL ENVIRON, V400, P115, DOI 10.1016/j.scitotenv.2008.06.024
   Park JH, 2008, ANGEW CHEM INT EDIT, V47, P7284, DOI 10.1002/anie.200801810
   SONG M, 2007, J BIOMED MATER RES A, P942
   Tan L, 2009, BIOSENS BIOELECTRON, V24, P2268, DOI 10.1016/j.bios.2008.10.030
   Tan L, 2009, BIOSENS BIOELECTRON, V24, P1603, DOI 10.1016/j.bios.2008.08.021
   Tu XM, 2005, J PHYS CHEM B, V109, P4053, DOI 10.1021/jp044731n
   Urbina MC, 2008, J PHYS CHEM C, V112, P11102, DOI 10.1021/jp711517d
   Wegener J, 1998, EUR BIOPHYS J BIOPHY, V28, P26, DOI 10.1007/s002490050180
   Xiao XL, 2008, BIOSENS BIOELECTRON, V24, P247, DOI 10.1016/j.bios.2008.03.041
   Xie QJ, 1999, ANAL CHEM, V71, P4649, DOI 10.1021/ac981390z
   Xu J, 2003, J AGR FOOD CHEM, V51, P1081, DOI 10.1021/jf020940y
   Xu J, 2007, J AGR FOOD CHEM, V55, P5349, DOI 10.1021/jf070568s
   Ye M, 2009, BIOSENS BIOELECTRON, V24, P2339, DOI 10.1016/j.bios.2008.12.002
   Yu MK, 2008, ANGEW CHEM INT EDIT, V47, P5362, DOI 10.1002/anie.200800857
   Zhang JL, 2007, LANGMUIR, V23, P6342, DOI 10.1021/la0636199
   Zhang L. W., 2008, ADV FUNCT MATER, V18, P1
   Zhang LY, 2007, ADV MATER, V19, P2988, DOI 10.1002/adma.200601817
   Zhu YJ, 1996, MATER LETT, V28, P119, DOI 10.1016/0167 577X(96)00046 8
NR 52
TC 20
Z9 23
U1 0
U2 45
PU ELSEVIER ADVANCED TECHNOLOGY
PI OXFORD
PA OXFORD FULFILLMENT CENTRE THE BOULEVARD, LANGFORD LANE, KIDLINGTON,
   OXFORD OX5 1GB, OXON, ENGLAND
SN 0956 5663
EI 1873 4235
J9 BIOSENS BIOELECTRON
JI Biosens. Bioelectron.
PD JAN 15
PY 2010
VL 25
IS 5
BP 1116
EP 1121
DI 10.1016/j.bios.2009.09.035
PG 6
WC Biophysics; Biotechnology & Applied Microbiology; Chemistry, Analytical;
   Electrochemistry; Nanoscience & Nanotechnology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biophysics; Biotechnology & Applied Microbiology; Chemistry;
   Electrochemistry; Science & Technology   Other Topics
GA 548FT
UT WOS:000273945800026
PM 19880305
DA 2025 08 17
ER

PT J
AU Ciavarella, S
   Laurenzana, A
   De Summa, S
   Pilato, B
   Chillà, A
   Lacalamita, R
   Minoia, C
   Margheri, F
   Iacobazzi, A
   Rana, A
   Merchionne, F
   Fibbi, G
   Del Rosso, M
   Guarini, A
   Tommasi, S
   Serratì, S
AF Ciavarella, S.
   Laurenzana, A.
   De Summa, S.
   Pilato, B.
   Chilla, A.
   Lacalamita, R.
   Minoia, C.
   Margheri, F.
   Iacobazzi, A.
   Rana, A.
   Merchionne, F.
   Fibbi, G.
   Del Rosso, M.
   Guarini, A.
   Tommasi, S.
   Serrati, S.
TI u PAR expression in cancer associated fibroblast: new acquisitions in
   multiple myeloma progression
SO BMC CANCER
LA English
DT Article
DE u PAR; Cancer associated fibroblasts (CAF); Fibroblast activation;
   Multiple myeloma microenvironment
ID PLASMINOGEN ACTIVATOR RECEPTOR; HEPATOCYTE GROWTH FACTOR; BONE MARROW;
   UROKINASE RECEPTOR; CELLS; UPAR; INVASION; ANGIOGENESIS; PATHOGENESIS;
   OSTEOBLASTS
AB Background: Multiple Myeloma (MM) is a B cell malignancy in which clonal plasma cells progressively expand within the bone marrow (BM) as effect of complex interactions with extracellular matrix and a number of microenvironmental cells. Among these, cancer associated fibroblasts (CAF) mediate crucial reciprocal signals with MM cells and are associated to aggressive disease and poor prognosis. A large body of evidence emphasizes the role of the urokinase plasminogen activator (u PA) and its receptor u PAR in potentiating the invasion capacity of tumor plasma cells, but little is known about their role in the biology of MM CAF. In this study, we investigated the u PA/u PAR axis in MM associated fibroblasts and explore additional mechanisms of tumor/stroma interplay in MM progression.
   Methods: CAF were purified from total BM stromal fraction of 64 patients including monoclonal gammopathy of undetermined significance, asymptomatic and symptomatic MM, as well as MM in post treatment remission. Flow cytometry, Real Time PCR and immunofluorescence were performed to investigate the u PA/u PAR system in relation to the level of activation of CAF at different stages of the disease. Moreover, proliferation and invasion assays coupled with silencing experiments were used to prove, at functional level, the function of u PAR in CAF.
   Results: We found higher activation level, along with increased expression of pro invasive molecules, including u PA, u PAR and metalloproteinases, in CAF from patients with symptomatic MM compared to the others stages of the disease. Consistently, CAF from active MM as well as U266 cell line under the influence of medium conditioned by active MM CAF, display higher proliferative rate and invasion potential, which were significantly restrained by u PAR gene expression inhibition.
   Conclusions: Our data suggest that the stimulation of u PA/u PAR system contributes to the activated phenotype and function of CAF during MM progression, providing a biological rationale for future targeted therapies against MM.
C1 [Ciavarella, S.; Minoia, C.; Iacobazzi, A.; Rana, A.; Merchionne, F.; Guarini, A.] IRCCS Giovanni Paolo II, Natl Inst Canc Res, I 70124 Milan, Italy.
   [Laurenzana, A.; Chilla, A.; Margheri, F.; Fibbi, G.; Del Rosso, M.] Univ Florence, Dept Expt & Clin Biomed Sci, Expt Pathol Sect & Oncol, Florence, Italy.
   [De Summa, S.; Pilato, B.; Lacalamita, R.; Tommasi, S.; Serrati, S.] IRCCS Giovanni Paolo II, Natl Inst Canc Res, Mol Genet Lab, Milan, Italy.
C3 University of Genoa; IRCCS AOU San Martino IST; University of Florence;
   University of Genoa; IRCCS AOU San Martino IST; Consiglio Nazionale
   delle Ricerche (CNR); Istituto di Genetica Molecolare (IGM CNR)
RP Serratì, S (通讯作者)，IRCCS Giovanni Paolo II, Natl Inst Canc Res, Nanotechnol Lab, Milan, Italy.
EM simonaserrati@hotmail.com
RI ; Serrati, Simona/B 2520 2013; Chillà, Anastasia/ABC 7402 2020; De
   Summa, Simona/K 2582 2018; CIAVARELLA, SABINO/K 3082 2018; Guarini,
   Attilio/AAK 3156 2020; Minoia, Carla/AAG 9823 2020; SERRATI,
   SIMONA/B 2520 2013; Iacobazzi, Angela/AAI 1184 2020; Lacalamita,
   Rosanna/AAB 9902 2019; Pilato, Brunella/AAH 7365 2020
OI guarini, attilio/0000 0002 9304 6651; De Summa,
   Simona/0000 0001 9607 3754; CIAVARELLA, SABINO/0000 0003 4414 3903;
   Lacalamita, Rosanna/0000 0003 4264 5619; pilato,
   brunella/0000 0001 6067 3977; minoia, carla/0000 0002 5707 0689;
   Iacobazzi, Angela/0000 0002 7269 8386; SERRATI,
   SIMONA/0000 0002 4015 5205; 
FU Italian Ministry of Health [RC2015 2016]
FX This work (in vitro experiments, collection and analyses of data) was
   supported by the grant "RC2015 2016" from the Italian Ministry of
   Health.
CR Andreasen PA, 2000, CELL MOL LIFE SCI, V57, P25, DOI 10.1007/s000180050497
   Béné MC, 2004, LEUKEMIA, V18, P394, DOI 10.1038/sj.leu.2403250
   Bianchi G, 2015, BLOOD, V125, P3049, DOI 10.1182/blood 2014 11 568881
   Daci E, 2003, J BONE MINER RES, V18, P1167, DOI 10.1359/jbmr.2003.18.7.1167
   De Veirman K, 2014, CANCERS, V6, P1363, DOI 10.3390/cancers6031363
   Fibbi G, 1998, LAB INVEST, V78, P1109
   Frassanito MA, 2014, LEUKEMIA, V28, P904, DOI 10.1038/leu.2013.254
   Ghobrial IM, 2012, BLOOD, V120, P20, DOI 10.1182/blood 2012 01 379024
   Hecht M, 2007, BRIT J HAEMATOL, V138, P446, DOI 10.1111/j.1365 2141.2007.06665.x
   Heissig B, 2015, CELL MOL LIFE SCI, V72, P4759, DOI 10.1007/s00018 015 2035 7
   Hideshima T, 2007, NAT REV CANCER, V7, P585, DOI 10.1038/nrc2189
   Hjertner O, 1999, BLOOD, V94, P3883
   Hjertner Ö, 2000, BRIT J HAEMATOL, V109, P815, DOI 10.1046/j.1365 2141.2000.02089.x
   Khan R, 2014, CLIN EXP METASTAS, V31, P585, DOI 10.1007/s10585 014 9652 7
   Margheri F, 2014, ONCOTARGET, V5, P1538, DOI 10.18632/oncotarget.1754
   Mazar AP, 2011, CURR PHARM DESIGN, V17, P1970
   Plesner T, 1997, STEM CELLS, V15, P398, DOI 10.1002/stem.150398
   QUATTRONE A, 1995, CANCER RES, V55, P90
   Raffaghello L, 2015, ONCOTARGET, V6, P2589, DOI 10.18632/oncotarget.2661
   Rigolin GM, 2003, BRIT J HAEMATOL, V120, P953, DOI 10.1046/j.1365 2141.2003.04176.x
   Sainz IM, 2006, CANCER IMMUNOL IMMUN, V55, P797, DOI 10.1007/s00262 005 0068 8
   Serrati S, 2008, J PATHOL, V214, P545, DOI 10.1002/path.2309
   Shen J, 2015, ONCOL LETT, V10, P2403, DOI 10.3892/ol.2015.3613
   Slany A, 2014, J PROTEOME RES, V13, P844, DOI 10.1021/pr400881p
   Yue J, 2004, J CELL PHYSIOL, V199, P284, DOI 10.1002/jcp.10469
NR 25
TC 22
Z9 22
U1 0
U2 6
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471 2407
J9 BMC CANCER
JI BMC Cancer
PD MAR 24
PY 2017
VL 17
AR 215
DI 10.1186/s12885 017 3183 y
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA EP5VS
UT WOS:000397447700001
PM 28340565
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Li, M
   Zhang, TX
   Jiang, JY
   Mao, YX
   Zhang, AQ
   Zhao, JY
AF Li, Mei
   Zhang, Tingxia
   Jiang, Jingyu
   Mao, Yuxing
   Zhang, Anqi
   Zhao, Jiyuan
TI ECM coating modification generated by optimized decellularization
   process improves functional behavior of BMSCs
SO MATERIALS SCIENCE AND ENGINEERING C MATERIALS FOR BIOLOGICAL
   APPLICATIONS
LA English
DT Article
DE Bone mesenchymal stem cells (BMSCs); Decellularization; Extracellular
   matrix (ECM); Sternness
ID MESENCHYMAL STEM CELLS; EXTRACELLULAR MATRIX; MECHANICAL PROPERTIES;
   SUBMUCOSA; DIFFERENTIATION; CULTURE; ICARIIN; SCAFFOLDS; EXPANSION;
   PROTEOME
AB Bone mesenchymal stem cells (BMSCs) have been widely applied in tissue engineering and regenerative medicine. However, small number of BMSCs and loss of stem cell characteristics after expansion in vitro limited clinical use of BMSCs. In the present study, osteoblasts were cultured to lay down extracellular matrix (ECM) and then the cells were removed (decellularization) to generate ECM coating substrates. The decellularization process was optimized to maximally remove cells and cellular components, along with integrated ECM retained which was demonstrated to be beneficial for BMSCs expansion in vitro. After decellularization, only less than 2% of residual DNA and cellular proteins were detected in TFFF ECM (decellularized by triton X 100 (T) and three freeze/thaw cycles (FFF)), which was much less than that in TN ECM generated by traditional decellularization method (triton X 100 (T) and NH4OH (N)). Meanwhile, ECM components and structure were preserved best after decellularization by TFFF method. More ECM proteins were detected, and structure proteins (fibronectin and collagen) exhibited as classic network fibers in TFFF ECM. Functionally, all kinds of decellularized ECM (dECM) were demonstrated to promote BMSCs proliferation and osteogenic differentiation capacity, thus maintain the stemness of BMSCs. Importantly, cells cultured on TFFF ECM grew faster than the cells on other kinds of dECM at early stage and TFFF ECM was beneficial to preserve stemness of BMSCs with high expression of OCT4 and NANOG when cultured in vitro. Proteomic analysis showed the proteins in ECM functioned in multiple biological activities and signaling pathways, which contributed to stemness maintenance of BMSC. Thus, the mild decellularization process optimized in this study enhanced the effectiveness of dECM for BMSCs culture in vitro and maybe further applied to BMSCs based tissue repair.
C1 [Li, Mei; Zhang, Tingxia; Jiang, Jingyu; Mao, Yuxing; Zhang, Anqi; Zhao, Jiyuan] Ningbo Univ, Zhejiang Key Lab Pathophysiol, Med Sch, Ningbo 315211, Zhejiang, Peoples R China.
   [Li, Mei] Ningbo Inst Med Sci, Ningbo 315020, Zhejiang, Peoples R China.
C3 Ningbo University
RP Zhao, JY (通讯作者)，Ningbo Univ, Med Sch, 818 Fenghua Rd, Ningbo 315211, Zhejiang, Peoples R China.
EM zhaojiyuan@nbu.edu.cn
RI Zhang, Tingxia/KIH 6473 2024; Li, Mei/JDD 8859 2023
OI Zhao, Jiyuan/0000 0002 1327 7119; 
FU Applied Research Project on Nonprofit Technology of Zhejiang Province
   [2017C33135]; National Natural Science Foundation of China [31300800,
   81702625]; Natural Science Foundation of Ningbo [2018A610202]; K.C. Wong
   Magna Fund in Ningbo University
FX This work was supported by the Applied Research Project on Nonprofit
   Technology of Zhejiang Province (No. 2017C33135), the National Natural
   Science Foundation of China (Grant No. 31300800 and 81702625), the
   Natural Science Foundation of Ningbo (Grant No. 2018A610202) and the
   K.C. Wong Magna Fund in Ningbo University.
CR Bignon A, 2003, J MATER SCI MATER M, V14, P1089, DOI 10.1023/B:JMSM.0000004006.90399.b4
   Bose S, 2012, TRENDS BIOTECHNOL, V30, P546, DOI 10.1016/j.tibtech.2012.07.005
   Chai YC, 2017, TISSUE ENG PT A, V23, P874, DOI 10.1089/ten.tea.2016.0432
   Chen XD, 2007, J BONE MINER RES, V22, P1943, DOI 10.1359/JBMR.070725
   Choi JS, 2015, BIOMATERIALS, V40, P98, DOI 10.1016/j.biomaterials.2014.11.028
   Farag A, 2018, ARCH ORAL BIOL, V88, P67, DOI 10.1016/j.archoralbio.2018.01.014
   Guneta V, 2017, BIOMATER SCI UK, V6, P168, DOI 10.1039/c7bm00695k
   Habibovic P, 2005, BIOMATERIALS, V26, P3565, DOI 10.1016/j.biomaterials.2004.09.056
   Hing KA, 2005, J MATER SCI MATER M, V16, P467, DOI 10.1007/s10856 005 6988 1
   Hsieh MK, 2018, MAT SCI ENG C MATER, V91, P806, DOI 10.1016/j.msec.2018.06.004
   Huang S, 2015, J ORTHOP TRANSL, V3, P26, DOI 10.1016/j.jot.2014.07.005
   Hussey GS, 2018, NAT REV MATER, V3, P159, DOI 10.1038/s41578 018 0023 x
   Kang KN, 2011, INT J PHARMACEUT, V420, P266, DOI 10.1016/j.ijpharm.2011.08.047
   Kim J, 2009, ARCH PHARM RES, V32, P117, DOI 10.1007/s12272 009 1125 1
   Kim YB, 2016, ACS APPL MATER INTER, V8, P32230, DOI 10.1021/acsami.6b11669
   Lai YL, 2010, STEM CELLS DEV, V19, P1095, DOI 10.1089/scd.2009.0217
   Le Nihouannen D, 2005, BONE, V36, P1086, DOI 10.1016/j.bone.2005.02.017
   Li M, 2018, TISSUE ENG PT A, V24, P1099, DOI [10.1089/ten.tea.2017.0407, 10.1089/ten.TEA.2017.0407]
   Li M, 2017, ANN BIOMED ENG, V45, P2673, DOI 10.1007/s10439 017 1900 y
   Li M, 2017, MAT SCI ENG C MATER, V75, P149, DOI 10.1016/j.msec.2017.02.042
   Li M, 2017, MAT SCI ENG C MATER, V71, P260, DOI 10.1016/j.msec.2016.10.016
   Li N, 2018, MAT SCI ENG C MATER, V93, P61, DOI 10.1016/j.msec.2018.07.061
   Liu XH, 2018, XENOTRANSPLANTATION, V25, DOI 10.1111/xen.12380
   Liu XZ, 2016, MAT SCI ENG C MATER, V61, P437, DOI 10.1016/j.msec.2015.12.090
   Martino MM, 2014, SCIENCE, V343, P885, DOI 10.1126/science.1247663
   Ouni E, 2019, MOL CELL PROTEOMICS, V18, pS159, DOI 10.1074/mcp.RA117.000469
   Pati F, 2015, BIOMATERIALS, V37, P230, DOI 10.1016/j.biomaterials.2014.10.012
   Prewitz MC, 2013, NAT METHODS, V10, P788, DOI [10.1038/nmeth.2523, 10.1038/NMETH.2523]
   Ragelle H, 2017, BIOMATERIALS, V128, P147, DOI 10.1016/j.biomaterials.2017.03.008
   Shakouri Motlagh A, 2017, ACTA BIOMATER, V55, P1, DOI 10.1016/j.actbio.2017.04.014
   Soleimani M, 2009, NAT PROTOC, V4, P102, DOI 10.1038/nprot.2008.221
   Wisniewski JR, 2009, NAT METHODS, V6, P359, DOI [10.1038/NMETH.1322, 10.1038/nmeth.1322]
   Woodard JR, 2007, BIOMATERIALS, V28, P45, DOI 10.1016/j.biomaterials.2006.08.021
   Xing Q, 2017, ACS BIOMATER SCI ENG, V3, P1462, DOI 10.1021/acsbiomaterials.6b00235
   Zhang C, 2018, MATER DESIGN, V154, P254, DOI 10.1016/j.matdes.2018.05.045
   Zhang C, 2017, REGEN MED, V12, P541, DOI 10.2217/rme 2017 0024
   Zhang L, 2018, MAT SCI ENG C MATER, V90, P159, DOI 10.1016/j.msec.2018.04.045
   Zhao JY, 2010, TISSUE ENG PT A, V16, P233, DOI [10.1089/ten.tea.2009.0165, 10.1089/ten.TEA.2009.0165]
NR 38
TC 36
Z9 37
U1 4
U2 76
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0928 4931
EI 1873 0191
J9 MAT SCI ENG C MATER
JI Mater. Sci. Eng. C Mater. Biol. Appl.
PD DEC
PY 2019
VL 105
AR 110039
DI 10.1016/j.msec.2019.110039
PG 10
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA JD5TG
UT WOS:000490044700026
PM 31546422
DA 2025 08 17
ER

PT J
AU Lee, HH
   Jang, JW
   Lee, JK
   Park, CK
AF Lee, Hye Hwa
   Jang, Jae Won
   Lee, Jung Kil
   Park, Choon Keun
TI Rutin Improves Bone Histomorphometric Values by Reduction of
   Osteoclastic Activity in Osteoporosis Mouse Model Induced by Bilateral
   Ovariectomy
SO JOURNAL OF KOREAN NEUROSURGICAL SOCIETY
LA English
DT Article
DE Histomorphometric values; Mice; Osteoclast; Osteoporosis; Rutin
ID TNF ALPHA; THERAPY; FRACTURES; CURCUMIN; FEMUR; WOMEN; BMD
AB Objective : Osteoporosis is a disease of unbalanced bone metabolism that results in low bone mineral density with increased bone fragility and propensity for fractures. The increased rate of bone fracture due to osteoporosis places a significant burden on public health care expenditures. Therefore, numerous studies have been designed and performed to identify the drugs or health foods that can improve the bone quality or quantity. This study was designed to evaluate and analyze the therapeutic effects of rutin on histomorphometric values of the spine and femur in an osteoporotic mouse model induced by bilateral ovariectomy.
   Methods : Thirty female ICR mice (8 weeks old) underwent either a sham operation (only abdominal incision, sham group, n=10) or bilateral ovariectomy (n=20). The ovariectomized (OVX) animals were randomly divided into two groups : untreated OVX group (OVX C, n=10), or rutin administered group (OVX R, n=10). The OVX C group received weight adjusted doses of saline vehicle and the OVX R group received 50 mg/kg of rutin intraperitoneally, starting 1 day after surgery. At 4 and 8 weeks after surgery, serum estrogen, osteocalcin, alkaline phosphatase (ALP), and the telopeptide fragment of type I collagen C terminus (CTX 1) were analyzed. Interleukin (IL) 1 beta, IL 6, IL 10, and tumor necrosis factor (TNF) alpha were also analyzed. Bone histomorphometric parameters of the 4th lumbar vertebra and femur were determined by micro computed tomography.
   Results : In OVX C group, ALP, osteocalcin, CTX 1, IL 1 beta, IL 6, and TNF alpha levels were significantly increased at 4 and 8 weeks compared to sham operation group. Rutin administration after OVX statistically significantly reduced ALP, CTX 1, IL 1 beta, IL 6, and TNF alpha levels at 4 and 8 weeks. Rutin administration also improves bone histomorphometric parameters including trabecular bone volume fraction, trabecular thickness, and trabecular number. Trabecular separation was also decreased in OVX R group compared to OVX C group.
   Conclusion : The present study demonstrated that rutin has therapeutic effects on improving bone histomorphometric values in an OVX mouse model. The improvement in histomorphometric values may be associated with the reduction of osteoclastic activity via inhibition of IL 1 beta, IL 6, and TNF alpha. In future studies, the mechanism for the effect of rutin on osteoporosis should be demonstrated more clearly to use rutin in human osteoporosis.
C1 [Lee, Hye Hwa; Jang, Jae Won; Lee, Jung Kil] Chonnam Natl Univ, Res Inst Med Sci, Gwangju, South Korea.
   [Jang, Jae Won; Park, Choon Keun] Leon Wiltse Mem Hosp, Dept Neurosurg, 437 Gyeongsu Dearo, Suwon 16480, South Korea.
   [Lee, Jung Kil] Chonnam Natl Univ Hosp, Dept Neurosurg, Gwangju, South Korea.
C3 Chonnam National University; Chonnam National University; Chonnam
   National University Hospital
RP Jang, JW (通讯作者)，Leon Wiltse Mem Hosp, Dept Neurosurg, 437 Gyeongsu Dearo, Suwon 16480, South Korea.
EM genius60@hanmail.net
RI ; Lee, Jeong Hoon/Q 1055 2018
OI Lee, Hye Hwa/0000 0002 1061 6023; 
FU Chonnam National University Hospital research institute of clinical
   medicine [2011 CURIMS DR012]
FX Chonnam National University Hospital research institute of clinical
   medicine provided financial support in the form of a grant
   (2011 CURIMS DR012) funding.
CR Adachi JD, 2001, OSTEOPOROSIS INT, V12, P903, DOI 10.1007/s001980170017
   Burge R, 2007, J BONE MINER RES, V22, P465, DOI [10.1359/jbmr.061113, 10.1359/JBMR.061113]
   Cho DC, 2012, ACTA NEUROCHIR, V154, P2215, DOI 10.1007/s00701 012 1516 9
   Ersan N, 2014, DENTOMAXILLOFAC RAD, V43, DOI 10.1259/dmfr.20130144
   Ferretti M, 2010, J ANAT, V217, P48, DOI 10.1111/j.1469 7580.2010.01242.x
   French DL, 2008, PHYTOMEDICINE, V15, P1069, DOI 10.1016/j.phymed.2008.06.007
   Giuliani N, 1998, Minerva Med, V89, P249
   Horcajada Molteni MN, 2000, J BONE MINER RES, V15, P2251, DOI 10.1359/jbmr.2000.15.11.2251
   Isai M, 2009, Mol Vis, V15, P2570
   KANIS JA, 1994, J BONE MINER RES, V9, P1137, DOI 10.1002/jbmr.5650090802
   Kaptoge S, 2008, J BONE MINER RES, V23, P1892, DOI [10.1359/jbmr.080802, 10.1359/JBMR.080802]
   Korkmaz A, 2010, J SURG RES, V164, P309, DOI 10.1016/j.jss.2009.03.022
   Kyung TW, 2008, EXP MOL MED, V40, P52, DOI 10.3858/emm.2008.40.1.52
   Lam J, 2000, J CLIN INVEST, V106, P1481, DOI 10.1172/JCI11176
   Lumachi F, 2010, MENOPAUSE, V17, P524, DOI 10.1097/gme.0b013e3181ca0c74
   Manach C, 1997, FEBS LETT, V409, P12, DOI 10.1016/S0014 5793(97)00467 5
   Middleton ET, 2010, J BONE MINER RES, V25, P455, DOI 10.1359/jbmr.090821
   OMI N, 1995, BONE, V17, pS163, DOI 10.1016/8756 3282(95)00329 C
   Pabon M, 2014, CELL MED, V6, P111, DOI 10.3727/215517913X672263
   Palumbo C, 2009, J BONE MINER METAB, V27, P538, DOI 10.1007/s00774 009 0070 x
   Pazianas M, 2011, BONE, V49, P103, DOI 10.1016/j.bone.2011.01.003
   Reszka Alfred A, 2003, Curr Osteoporos Rep, V1, P45, DOI 10.1007/s11914 003 0008 5
   Shin YH, 2012, J KOREAN NEUROSURG S, V52, P1, DOI 10.3340/jkns.2012.52.1.1
   Songpatanasilp T, 2014, SINGAP MED J, V55, P493, DOI 10.11622/smedj.2014120
   THOMPSON DD, 1995, BONE, V17, pS125, DOI 10.1016/8756 3282(95)00285 L
   Watts NB, 2000, MENOPAUSE, V7, P375, DOI 10.1097/00042192 200011000 00002
   Weber M, 2002, JCR J CLIN RHEUMATOL, V8, P166, DOI 10.1097/00124743 200206000 00010
   Yang MW, 2011, PHYTOMEDICINE, V18, P205, DOI 10.1016/j.phymed.2010.05.011
   Zhang Q, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/284836
NR 29
TC 22
Z9 23
U1 0
U2 13
PU KOREAN NEUROSURGICAL SOC
PI SEOUL
PA BLDG B, #402, 27, CHILPAE RO, JUNG GU, SEOUL, 04511, SOUTH KOREA
SN 2005 3711
EI 1598 7876
J9 J KOREAN NEUROSURG S
JI J. Korean. Neurosurg. Soc.
PD JUL
PY 2020
VL 63
IS 4
BP 433
EP 443
DI 10.3340/jkns.2019.0097
PG 11
WC Clinical Neurology; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Neurosciences & Neurology; Surgery
GA MG9LJ
UT WOS:000546353800004
PM 32172552
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Fong, CY
   Kong, AN
   Poh, BK
   Mohamed, AR
   Khoo, TB
   Ng, RL
   Noordin, M
   Nadarajaw, T
   Ong, LC
AF Fong, Choong Yi
   Kong, Ann Nie
   Poh, Bee Koon
   Mohamed, Ahmad Rithauddin
   Khoo, Teik Beng
   Ng, Rui Lun
   Noordin, Mazidah
   Nadarajaw, Thiyagar
   Ong, Lai Choo
TI Vitamin D deficiency and its risk factors in Malaysian children with
   epilepsy
SO EPILEPSIA
LA English
DT Article
DE Antiepileptic drug; Anticonvulsant; Bone health; Pediatric; Nutrition
ID PHYSICAL ACTIVITY QUESTIONNAIRE; BONE HEALTH; INTRACTABLE EPILEPSY;
   ANTIEPILEPTIC DRUGS; NUTRITIONAL STATUS; PREVALENCE; MANAGEMENT;
   CHILDHOOD; VALIDITY; DENSITY
AB Objective: Long term use of antiepileptic drugs (AEDs) is a significant risk factor for vitamin D deficiency in children with epilepsy. The aims of our study were to evaluate the prevalence and risk factors for vitamin D deficiency among Malaysian children with epilepsy.
   Methods: Cross sectional study of ambulant children with epilepsy on long term AEDs for >1 year seen in three tertiary hospitals in Malaysia from April 2014 to April 2015. Detailed assessment of pubertal status, skin pigmentation, sunshine exposure behavior, physical activity, dietary vitamin D and calcium intake, anthropometric measurements and bone health blood tests (vitamin D, alkaline phosphatase, calcium, phosphate, and parathyroid hormone levels) were obtained on all patients. Vitamin D deficiency was defined as 25 hydroxy vitamin D [25(OH) D] levels <= 35 nmol/L and insufficiency as 25(OH) D levels of 36 50 nmol/L.
   Results: A total of 244 children (146 male) participated in the study. Ages ranged between 3.7 and 18.8 years (mean 12.3 years). 25(OH) D levels ranged between 7.5 and 140.9 nmol/L (mean 53.9 nmol/L). Vitamin D deficiency was identified in 55 patients (22.5%), and a further 48 (19.7%) had vitamin D insufficiency. Multivariate logistic regression analysis identified polytherapy >1 AED (odds ratio [OR] 2.16, 95% confidence interval [CI] 1.07 4.36), age >12 years (OR 4.16, 95% CI 1.13 15.30), Indian ethnicity (OR 6.97, 95% CI 2.48 19.55), sun exposure time 30 60 min/day (OR 2.44, 95% CI 1.05 5.67), sun exposure time <30 min/day (OR 3.83, 95% CI 1.61 9.09), and female (OR 2.61, 95% CI 1.31 5.20) as statistically significant (p < 0.05) risk factors for vitamin Ddeficiency.
   Significance: Despite living in the tropics, a high proportion of Malaysian children with epilepsy are at risk of vitamin D deficiency. Targeted strategies including vitamin D supplementation and lifestyle advice of healthy sunlight exposure behavior should be implemented among children with epilepsy, particularly for those at high risk of having vitamin Ddeficiency.
C1 [Fong, Choong Yi; Kong, Ann Nie; Ng, Rui Lun; Noordin, Mazidah; Ong, Lai Choo] Univ Malaya, Div Pediat Neurol, Dept Pediat, Fac Med, Kuala Lumpur 50603, Malaysia.
   [Poh, Bee Koon] Univ Kebangsaan Malaysia, Nutr Sci Program, Fac Hlth Sci, Kuala Lumpur, Malaysia.
   [Mohamed, Ahmad Rithauddin; Khoo, Teik Beng] Hosp Kuala Lumpur, Inst Pediat, Pediat Neurol Unit, Kuala Lumpur, Malaysia.
   [Ng, Rui Lun; Nadarajaw, Thiyagar] Hosp Sultanah Bahiyah, Dept Pediat, Alor Setar, Kedah, Malaysia.
C3 Universiti Malaya; Universiti Kebangsaan Malaysia
RP Fong, CY (通讯作者)，Univ Malaya, Div Pediat Neurol, Dept Pediat, Fac Med, Kuala Lumpur 50603, Malaysia.
EM cyfong@ummc.edu.my
RI ; Ng, Rui/S 5738 2016; Poh, Bee Koon/LLL 3691 2024; Fong,
   Choong/A 4584 2015; Ong, Lai/G 6439 2011
OI Poh, Bee Koon/0000 0003 0713 5197; 
FU University of Malaya [UMRG 532 13HTM, P0026/2013A]
FX This research study received funding from the University of Malaya
   research grant (UMRG 532 13HTM and P0026/2013A). We gratefully thank all
   participating children and their parents for their full cooperation
   toward this study. We also acknowledge the support of specialists,
   clinical staff, and nurses of all the three participating clinics for
   their cooperation and assistance.
CR Aini JN, 2013, PEDIATR INT, V55, P223, DOI 10.1111/ped.12035
   [Anonymous], WHO GROWTH REF DAT 5
   [Anonymous], 2009, DRUG SAFETY UPDATE
   Barger Lux MJ, 2002, J CLIN ENDOCR METAB, V87, P4952, DOI 10.1210/jc.2002 020636
   Bener A, 2009, Minerva Pediatr, V61, P15
   Bergqvist AGC, 2007, EPILEPSIA, V48, P66, DOI 10.1111/j.1528 1167.2006.00803.x
   Bertoli S, 2006, NUTR J, V5, DOI 10.1186/1475 2891 5 14
   Bischoff Ferrari HA, 2010, ENDOCRIN METAB CLIN, V39, P347, DOI 10.1016/j.ecl.2010.02.009
   Cebeci AN, 2014, EXPERT REV NEUROTHER, V14, P481, DOI 10.1586/14737175.2014.905742
   Farrar MD, 2013, AM J CLIN NUTR, V97, P1210, DOI 10.3945/ajcn.112.052639
   FITZPATRICK TB, 1988, ARCH DERMATOL, V124, P869, DOI 10.1001/archderm.124.6.869
   Fong CY, 2014, J CHILD NEUROL, V29, P368, DOI 10.1177/0883073812472256
   Fong CY, 2011, EUR J PAEDIATR NEURO, V15, P417, DOI 10.1016/j.ejpn.2011.04.002
   HOLICK MF, 1995, AM J CLIN NUTR, V61, p638S, DOI 10.1093/ajcn/61.3.638S
   Kemper HCG, 2002, BONE, V30, P799, DOI 10.1016/S8756 3282(02)00709 3
   Khor GL, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471 2458 11 95
   Lee Seung Ho, 2015, Ann Pediatr Endocrinol Metab, V20, P198, DOI 10.6065/apem.2015.20.4.198
   Mansour Maha M H K, 2012, Indian J Endocrinol Metab, V16, P263, DOI 10.4103/2230 8210.93746
   Marwaha RK, 2005, AM J CLIN NUTR, V82, P477, DOI 10.1093/ajcn/82.2.477
   Menon B, 2010, NEUROL INDIA, V58, P209, DOI 10.4103/0028 3886.63793
   Misra M, 2008, PEDIATRICS, V122, P398, DOI 10.1542/peds.2007 1894
   National Coordinating Committee on Food and Nutrition, 2005, REC NUTR INT MAL REP
   Palermo NE, 2014, J PEDIATR REHAB MED, V7, P179, DOI 10.3233/PRM 140287
   Pearce SHS, 2010, BRIT MED J, V340, DOI 10.1136/bmj.b5664
   Poh BK, 2013, BRIT J NUTR, V110, pS21, DOI 10.1017/S0007114513002092
   Poh BK, 2015, ASIA PAC J CLIN NUTR
   Saggese G, 2015, EUR J PEDIATR, V174, P565, DOI 10.1007/s00431 015 2524 6
   Samaniego Edgar A, 2007, Semin Pediatr Neurol, V14, P196, DOI 10.1016/j.spen.2007.08.006
   Shahar S, 2000, Malays J Nutr, V6, P33
   Shellhaas RA, 2010, PEDIATR NEUROL, V42, P385, DOI 10.1016/j.pediatrneurol.2009.12.005
   Siong T. E., 1997, Nutrient composition of Malaysian foods, V4th
   Soghier L, 2014, REFERENCE RANGE VALU, P68
   TANNER JM, 1976, ARCH DIS CHILD, V51, P170, DOI 10.1136/adc.51.3.170
   Vestergaard P, 2015, PEDIATR DRUGS, V17, P141, DOI 10.1007/s40272 014 0115 z
   Volpe SL, 2007, J AM DIET ASSOC, V107, P1014, DOI 10.1016/j.jada.2007.03.011
   Wacker M, 2013, NUTRIENTS, V5, P111, DOI 10.3390/nu5010111
   WHO, 2006, WHO child growth standards: length/height for age, weight for age, weight for length, weight for height and body mass index for age, methods and development
   Winzenberg T, 2013, CALCIFIED TISSUE INT, V92, P140, DOI 10.1007/s00223 012 9615 4
   Winzenberg T, 2011, BMJ BRIT MED J, V342, DOI 10.1136/bmj.c7254
   Yang Zy, 2013, FOOD NUTR BULL, V34, pS81, DOI 10.1177/15648265130342S110
NR 40
TC 42
Z9 45
U1 0
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0013 9580
EI 1528 1167
J9 EPILEPSIA
JI Epilepsia
PD AUG
PY 2016
VL 57
IS 8
BP 1271
EP 1279
DI 10.1111/epi.13443
PG 9
WC Clinical Neurology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Neurosciences & Neurology
GA DS4KP
UT WOS:000380750300016
PM 27378185
OA Bronze
DA 2025 08 17
ER

PT J
AU Kumar, S
   Mahendra, G
   Ponnazhagan, S
AF Kumar, S
   Mahendra, G
   Ponnazhagan, S
TI Determination of osteoprogenitor specific promoter activity in mouse
   mesenchymal stem cells by recombinant adeno associated virus
   transduction
SO BIOCHIMICA ET BIOPHYSICA ACTA GENE STRUCTURE AND EXPRESSION
LA English
DT Article
DE adeno associated virus; mesenchymal stem cell; osteoprogenitor; promoter
   activity
ID BONE MORPHOGENETIC PROTEIN 2; OSTEOCALCIN GENE; IN VITRO; CHONDROCYTE
   DIFFERENTIATION; GROWTH FACTORS; EXPRESSION; MARROW; VIVO; THERAPY;
   SIALOPROTEIN
AB Towards utilizing gene targeted, repopulating mesenchymal stem cells (MSC) to increase osteogenesis, we evaluated the expression of bone specific promoters during MSC differentiation. Multi lineage potential of cultured MSC was confirmed by osteogenic, adipogenic and chondrogenic differentiation under controlled conditions. Recombinant adeno associated virus (rAAV) encoding luciferase under the human cytomegalovirus (CMV), mouse alkaline phosphatase (ALP), Runx 2/cbfa1 (RUNX), osteopontin (OPN), collagen type 1a (COL), and osteocalcin (OCN) promoters was used to transduce mouse MSC. Replicate cultures were maintained undifferentiated or differentiated to osteoblast lineage. Luciferase expression was determined oil days 1, 2, 3, 7, 14, or 21 as a measure of promoter activity. Expression of osteogenic markers and mineralization was determined as correlates of osteopoiesis. Results indicated expression from CMV promoter in undifferentiated and differentiated cultures at early stage. However, expression from COL and RUNX promoters was abundant only in differentiating cultures as early as 24 h but declined gradually. Expression from OPN and ALP promoters was evident 24 h following osteogenic differentiation and peaked gradually until 2 weeks before declining. Expression from OC promoter was evident only after 7 days of differentiation but remained until final analysis on day 21. That rAAV transduction of MSC does not induce differentiation was also confirmed by quantitative reverse transcription polymerase chain reaction (QRT PCR). The observed stage specific expression of analyzed promoters was not significant when the MSC were differentiated to adipocytes. Thus, the use of RUNX2 or COL promoter to stably express osteoinductive factors in MSC may allow both self renewal of modified MSC and enrichment of osteoblast commitment. (c) 2005 Elsevier B.V. All rights reserved.
C1 Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA.
C3 University of Alabama System; University of Alabama Birmingham
RP Ponnazhagan, S (通讯作者)，Univ Alabama Birmingham, Dept Pathol, LHRB 513,701,19th St South, Birmingham, AL 35294 USA.
EM sponnazh@path.uab.edu
CR Akiyama H, 2002, GENE DEV, V16, P2813, DOI 10.1101/gad.1017802
   ALDRICH WA, 2005, GENE THER
   Aubin Jane E., 1996, P51
   Banerjee C, 1996, P NATL ACAD SCI USA, V93, P4968, DOI 10.1073/pnas.93.10.4968
   Banerjee C, 2001, ENDOCRINOLOGY, V142, P4026, DOI 10.1210/en.142.9.4026
   BANERJEE U, 1997, LOOP TR RESTRUCT COM, V3, P1
   BELLOWS CG, 1986, CALCIFIED TISSUE INT, V38, P143, DOI 10.1007/BF02556874
   BIDWELL JP, 1994, CANCER RES, V54, P28
   Chaudhary LR, 2004, BONE, V34, P402, DOI 10.1016/j.bone.2003.11.014
   Cheng HW, 2003, J BONE JOINT SURG AM, V85A, P1544, DOI 10.2106/00004623 200308000 00017
   Date T, 2004, J ORTHOP SCI, V9, P503, DOI 10.1007/s00776 004 0815 2
   DUCY P, 1995, MOL CELL BIOL, V15, P1858
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Hauck B, 2004, J VIROL, V78, P13678, DOI 10.1128/JVI.78.24.13678 13686.2004
   Inada M, 1999, DEV DYNAM, V214, P279, DOI 10.1002/(SICI)1097 0177(199904)214:4<279::AID AJA1>3.0.CO;2 W
   Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870
   Kalajzic I, 2003, J CELL BIOCHEM, V88, P1168, DOI 10.1002/jcb.10459
   Kumar S, 2004, HUM GENE THER, V15, P1197, DOI 10.1089/hum.2004.15.1197
   Kumar S, 2004, CURR GENE THER, V4, P287
   Lee KS, 2000, MOL CELL BIOL, V20, P8783, DOI 10.1128/MCB.20.23.8783 8792.2000
   Lengner CJ, 2002, MECH DEVELOP, V114, P167, DOI 10.1016/S0925 4773(02)00050 3
   Liu F, 2003, J CELL SCI, V116, P1787, DOI 10.1242/jcs.00376
   LONG MW, 1995, J CLIN INVEST, V95, P881, DOI 10.1172/JCI117738
   Long MW, 2001, BLOOD CELL MOL DIS, V27, P677, DOI 10.1006/bcmd.2001.0431
   Madras N, 2002, STEM CELLS, V20, P230, DOI 10.1634/stemcells.20 3 230
   MERRIMAN HL, 1995, BIOCHEMISTRY US, V34, P13125, DOI 10.1021/bi00040a025
   MINTZ KP, 1993, J BONE MINER RES, V8, P985
   OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859
   OLDBERG A, 1988, J BIOL CHEM, V263, P19430
   Ponnazhagan S, 2004, CANCER RES, V64, P1781, DOI 10.1158/0008 5472.CAN 03 1786
   Ponnazhagan S, 2001, J VIROL, V75, P9493, DOI 10.1128/JVI.75.19.9493 9501.2001
   Pratap J, 2003, CANCER RES, V63, P5357
   Puleo DA, 1997, J CELL PHYSIOL, V173, P93, DOI 10.1002/(SICI)1097 4652(199710)173:1<93::AID JCP11>3.0.CO;2 O
   Ren C, 2005, HUM GENE THER, V16, P1047, DOI 10.1089/hum.2005.16.1047
   Ryoo HM, 1997, J CELL BIOCHEM, V64, P106, DOI 10.1002/(SICI)1097 4644(199701)64:1<106::AID JCB13>3.0.CO;2 J
   Sammons J, 2004, STEM CELLS DEV, V13, P273, DOI 10.1089/154732804323099208
   SAMULSKI RJ, 1987, J VIROL, V61, P3096, DOI 10.1128/JVI.61.10.3096 3101.1987
   Stein Gary S., 2000, Cancer, V88, P2899, DOI 10.1002/1097 0142(20000615)88:12+<2899::AID CNCR3>3.0.CO;2 O
   Stewart M, 1997, P NATL ACAD SCI USA, V94, P8646, DOI 10.1073/pnas.94.16.8646
   Stricker S, 2002, DEV BIOL, V245, P95, DOI 10.1006/dbio.2002.0640
   Sun SK, 2003, STEM CELLS, V21, P527, DOI 10.1634/stemcells.21 5 527
   Suzawa M, 1999, ENDOCRINOLOGY, V140, P2125, DOI 10.1210/en.140.5.2125
   URIST MR, 1983, SCIENCE, V220, P680, DOI 10.1126/science.6403986
   Vaillant F, 1999, ONCOGENE, V18, P7124, DOI 10.1038/sj.onc.1203202
   Winter A, 2003, ARTHRITIS RHEUM US, V48, P418, DOI 10.1002/art.10767
   Yang JS, 1999, J VIROL, V73, P9468, DOI 10.1128/JVI.73.11.9468 9477.1999
   Zolotukhin S, 1999, GENE THER, V6, P973, DOI 10.1038/sj.gt.3300938
NR 47
TC 23
Z9 51
U1 0
U2 5
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0167 4781
J9 BBA GENE STRUCT EXPR
JI Biochim. Biophys. Acta Gene Struct. Expression
PD NOV 10
PY 2005
VL 1731
IS 2
BP 95
EP 103
DI 10.1016/j.bbaexp.2005.08.007
PG 9
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 993HK
UT WOS:000233945000004
PM 16225939
DA 2025 08 17
ER

PT J
AU Rosenberg, JE
   Astor, BC
   Deluca, HF
   Yevzlin, AS
AF Rosenberg, Joel E.
   Astor, Brad C.
   Deluca, Hector F.
   Yevzlin, Alexander S.
TI The association of mineral metabolism with vascular access patency
SO JOURNAL OF VASCULAR ACCESS
LA English
DT Article
DE End stage renal disease; Mineral homeostasis; Mineral metabolism;
   Vascular access; Vascular access patency; Vitamin D
ID STAGE RENAL DISEASE; HEMODIALYSIS PATIENTS; MORTALITY; PHOSPHATE;
   DIALYSIS; OUTCOMES; DEFICIENCY; CALCIUM; RISK
AB Background: Declining kidney function leads to progressively dysregulated mineral homeostasis and contributes to vascular calcification and a pro inflammatory milieu, both of which play a critical role in loss of dialysis vascular access patency. We designed this study to examine the relationship between markers of bone and mineral metabolism, vitamin D replacement medications, and vascular access outcomes. We hypothesized that higher levels of calcium, phosphorous, parathyroid hormone (PTH), and albumin are independently associated with vascular access patency and that vitamin D supplementation is associated with lower risk of access failure.
   Methodology: We abstracted data on 204 consecutive patients referred for angiographic evaluation of their permanent arteriovenous access over a 25 month period. We followed patients from the time of access salvage until subsequent referral for access failure.
   Results: The incidence of vascular access failure did not differ by serum phosphorus, PTH, calcium, calciumphosphorus product or albumin level. Patients receiving any vitamin D replacement therapy, however, had a lower incidence of access failure compared to those receiving no therapy. Those receiving vitamin D3 therapy with or without paricalcitol (Zemplar, Abbot Laboratories, Abbot Park, IL) or calcitriol had an adjusted HR = 0.18 compared to those receiving no vitamin D therapy.
   Conclusions: This study suggests a relationship between vitamin D3 usage and better vascular access patency, independent of the effect of vitamin D on PTH. Though this relationship needs more rigorous investigation prior to clinical application, the known differences in the pro and anti inflammatory effects of various vitamin D metabolites provide a potential mechanism for these clinical observations.
C1 [Rosenberg, Joel E.; Astor, Brad C.; Yevzlin, Alexander S.] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Div Nephrol, Madison, WI USA.
   [Deluca, Hector F.] Univ Wisconsin, Dept Biochem, 420 Henry Mall, Madison, WI 53705 USA.
C3 University of Wisconsin System; University of Wisconsin Madison;
   University of Wisconsin System; University of Wisconsin Madison
RP Yevzlin, AS (通讯作者)，Univ Wisconsin, 5148 MFCB 1685 Highland Ave, Madison, WI 53705 USA.
EM asy@medicine.wisc.edu
RI Rosenberg, Jonathan/JOZ 9416 2023
FU UW Madison Hilldale Undergraduate/Faculty
FX A grant from the UW Madison Hilldale Undergraduate/Faculty supported
   this study.
CR Aoshima Y, 2012, NEPHROL DIAL TRANSPL, V27, P1800, DOI 10.1093/ndt/gfr758
   Banerjee T, 2014, AM J KIDNEY DIS, V64, P954, DOI 10.1053/j.ajkd.2014.07.010
   Block GA, 1998, AM J KIDNEY DIS, V31, P607, DOI 10.1053/ajkd.1998.v31.pm9531176
   Feldman HI, 1996, J AM SOC NEPHROL, V7, P523
   Gutiérrez OM, 2008, NEW ENGL J MED, V359, P584, DOI 10.1056/NEJMoa0706130
   London GM, 2007, J AM SOC NEPHROL, V18, P613, DOI 10.1681/ASN.2006060573
   Melamed ML, 2006, KIDNEY INT, V70, P351, DOI 10.1038/sj.ki.5001542
   Melamed ML, 2012, CLIN J AM SOC NEPHRO, V7, P358, DOI 10.2215/CJN.04040411
   Melamed ML, 2009, J AM SOC NEPHROL, V20, P2631, DOI 10.1681/ASN.2009030283
   Rayner HC, 2004, NEPHROL DIAL TRANSPL, V19, P108, DOI 10.1093/ndt/gfg483
   Sato T, 2016, J VASC ACCESS, V17, P72, DOI 10.5301/jva.5000469
   Scialla JJ, 2015, AM J NEPHROL, V42, P25, DOI 10.1159/000438999
   Treiber G, 2015, CLIN IMMUNOL, V161, P217, DOI 10.1016/j.clim.2015.08.002
   Walker JP, 2014, J VASC SURG, V60, P176, DOI 10.1016/j.jvs.2014.01.037
   Yevzlin AS, 2010, TRANSL RES, V156, P216, DOI 10.1016/j.trsl.2010.07.004
NR 15
TC 5
Z9 5
U1 0
U2 6
PU WICHTIG PUBLISHING
PI MILAN
PA 72/74 VIA FRIULI, 20135 MILAN, ITALY
SN 1129 7298
EI 1724 6032
J9 J VASC ACCESS
JI J. Vasc. Access
PD SEP OCT
PY 2016
VL 17
IS 5
BP 392
EP 396
DI 10.5301/jva.5000584
PG 5
WC Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cardiovascular System & Cardiology
GA EJ8YG
UT WOS:000393512600008
PM 27470251
DA 2025 08 17
ER

PT J
AU Aderibigbe, BA
   Ndwabu, S
AF Aderibigbe, B. A.
   Ndwabu, S.
TI Evaluation of whey protein isolate graft carbopol polyacrylamide
   pH sensitive composites for controlled release of pamidronate
SO POLYMER BULLETIN
LA English
DT Article
DE Pamidronate; Osteoporosis; Whey protein isolate; Hydrogel composites;
   Polyacrylamide
ID SWELLING BEHAVIOR; IN VITRO; HYDROGELS; BISPHOSPHONATES; SCAFFOLDS
AB Whey protein isolate graft carbopol polyacrylamide pH sensitive hydrogel composites were prepared by simultaneous redox cross linked polymerization of whey protein isolate, acrylamide and carbopol. The hydrogel composites were characterized by SEM, FTIR, XRD and swelling analysis was performed on the hydrogels. The hydrogels were pH sensitive, degradable and protected the entrapped drug in the matrix. The aforementioned factors were influenced by the grafting of whey protein isolate onto the composite networks. The release of pamidronate from the hydrogel followed a super case 2 transport suggesting that the release mechanism was a combination of erosion and diffusion at pH 7.4. At pH 1.2, the release mechanism of pamidronate from the hydrogels was a quasi Fickian diffusion. The SEM images of the hydrogels after drug release indicated degradability of the hydrogels. The results obtained suggested that whey protein isolate is a potential biopolymer for controlled drug delivery systems with enhanced drug bioavailability.
C1 [Aderibigbe, B. A.; Ndwabu, S.] Univ Ft Hare, Dept Chem, Alice Campus, Alice, Eastern Cape, South Africa.
C3 University of Fort Hare
RP Aderibigbe, BA (通讯作者)，Univ Ft Hare, Dept Chem, Alice Campus, Alice, Eastern Cape, South Africa.
EM blessingaderibigbe@gmail.com
RI Aderibigbe, Blessing/ITV 6685 2023
OI Aderibigbe, Blessing/0000 0003 1157 7481
FU Medical Research Council; National Research Foundation, South Africa
FX The financial assistance of the Medical Research Council (Self Initiated
   Research) and National Research Foundation, South Africa towards this
   research are hereby acknowledged. The views and opinions expressed in
   this manuscript are those of the authors and not of MRC or NRF.
CR Asti A, 2014, INT J ARTIF ORGANS, V37, P187, DOI [10.5301/ijao.5000307, 10.530/ijao.5000307]
   Awad RA, 2015, INT J FOOD NUTR SCI, V4, P125
   Betz M, 2012, FOOD RES INT, V47, P51, DOI 10.1016/j.foodres.2012.01.010
   Betz M, 2012, SOFT MATTER, V8, P2477, DOI 10.1039/c2sm06976h
   Chou J, 2009, J TISSUE ENG REGEN M, V3, P92, DOI 10.1002/term.142
   Drake MT, 2008, MAYO CLIN PROC, V83, P1032, DOI 10.4065/83.9.1032
   Gunasekaran S, 2006, J APPL POLYM SCI, V99, P2470, DOI 10.1002/app.22838
   Gunasekaran S, 2007, J FOOD ENG, V83, P31, DOI 10.1016/j.jfoodeng.2006.11.001
   James HP, 2014, ACTA PHARM SIN B, V4, P120, DOI 10.1016/j.apsb.2014.02.005
   Jayaramudu T, 2013, CARBOHYD POLYM, V92, P2193, DOI 10.1016/j.carbpol.2012.12.006
   Kieczykowski GR, 1995, J ORG CHEM, V60, P8310, DOI 10.1021/jo00130a036
   Kuljanin J, 2002, J PHARMACEUT BIOMED, V28, P1215, DOI 10.1016/S0731 7085(02)00021 3
   Kulkarni RV, 2012, J COLLOID INTERF SCI, V367, P509, DOI 10.1016/j.jcis.2011.10.025
   Li H, 2016, INT J BIOL MACROMOL, V83, P152, DOI 10.1016/j.ijbiomac.2015.11.018
   Liu LS, 2012, POLYMERS BASEL, V4, P997, DOI 10.3390/polym4020997
   Lubrizol, 2011, LUBR PHARM B
   Mostovoy SO, 2014, J EXP INTEGR MED, V4, P81
   Muhamad12 I.I., 2014, Nanomedicine, V287, P287
   Omidian H, 2012, ADV DEL SCI TECHNOL, P75, DOI 10.1007/978 1 4614 0881 9_4
   Pasqui D, 2012, POLYMERS BASEL, V4, P1517, DOI 10.3390/polym4031517
   Qasim S, 2011, J APP PHARM, V4, P438
   Remondetto GE, 2004, J AGR FOOD CHEM, V52, P8137, DOI 10.1021/jf040286h
   RITGER P L, 1987, Journal of Controlled Release, V5, P23, DOI 10.1016/0168 3659(87)90034 4
   Singh B, 2007, CARBOHYD POLYM, V67, P190, DOI 10.1016/j.carbpol.2006.05.006
   Tanvetyanon T, 2006, ANN ONCOL, V17, P897, DOI 10.1093/annonc/mdj105
   Thakur A, 2011, CHEM BIOCHEM ENG Q, V25, P181
   Weinstein SM., 2001, Plumer's Principles Practice of Intravenous Therapy, V7th
   Woo SB, 2006, ANN INTERN MED, V144, P753, DOI 10.7326/0003 4819 144 10 200605160 00009
   Xiao L, 2003, 3 INT S FOOD RHEOL S
   Yoon DM, 2009, BIOMEDICAL MATERIALS, P415, DOI 10.1007/978 0 387 84872 3_15
   Zhu JM, 2011, EXPERT REV MED DEVIC, V8, P607, DOI [10.1586/erd.11.27, 10.1586/ERD.11.27]
NR 31
TC 6
Z9 6
U1 0
U2 39
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0170 0839
EI 1436 2449
J9 POLYM BULL
JI Polym. Bull.
PD DEC
PY 2017
VL 74
IS 12
BP 5129
EP 5144
DI 10.1007/s00289 017 2008 0
PG 16
WC Polymer Science
WE Science Citation Index Expanded (SCI EXPANDED)
SC Polymer Science
GA FJ9QP
UT WOS:000413115200021
DA 2025 08 17
ER

PT J
AU Hawkey, CJ
   Weinstein, WM
   Smalley, W
   Gitton, X
   Sallstig, P
   Stricker, K
   Krammer, G
   Mellein, B
   Richard, D
   Matchaba, P
AF Hawkey, Christopher J.
   Weinstein, Wilfred M.
   Smalley, Walter
   Gitton, Xavier
   Sallstig, Peter
   Stricker, Kirstin
   Krammer, Gerhard
   Mellein, Bernhard
   Richard, Dominik
   Matchaba, Patrice
TI Effect of risk factors on complicated and uncomplicated ulcers in the
   TARGET lumiracoxib outcomes study
SO GASTROENTEROLOGY
LA English
DT Article
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; THERAPEUTIC ARTHRITIS RESEARCH;
   GASTROINTESTINAL EVENT TRIAL; LOW DOSE ASPIRIN; RHEUMATOID ARTHRITIS;
   OSTEOARTHRITIS; PHARMACOLOGY; MANAGEMENT; TOXICITY; NAPROXEN
AB Background & Aims: Selective cyclooxygenase 2 inhibitors were developed to reduce the gastrointestinal risk associated with nonsteroidal anti inflammatory drugs (NSAIDs). The Therapeutic Arthritis Research and Gastrointestinal Event Trial was the largest study to evaluate primarily the gastrointestinal safety outcomes of selective cyclooxygenase 2 inhibitors. Data from the Therapeutic Arthritis Research and Gastrointestinal Event Trial were used to identify risk factors and investigate the safety of lumiracoxib in subgroups. Methods: Patients with osteoarthritis (age, >= 50 y) were randomized to receive lumiracoxib 400 mg once daily, naproxen 500 mg twice daily, or ibuprofen 800 mg 3 times daily for 12 months. Events were categorized by a blinded adjudication committee. The primary end point was all definite or probable ulcer complications. Results: For patients taking NSAIDs, factors associated with an increased risk of ulcer complications were age 65 years or older (hazard ratio [HR], 2.30; 95% confidence interval [CI], 1.48 3.59), previous history of gastrointestinal bleed or ulcer (HR, 3.61; 95% CI, 1.86 7.00), non Caucasian racial origin (HR, 2.10; 95% Cl, 1.35 3.27), and male sex (HR, 1.70; 95% CI, 1.08 2.68). With lumiracoxib, significant risk factors were age 65 years or older (HR, 3.18; 95% CI, 1.40 7.20), male sex (HR, 2.60; 95% CI, 1.25 5.40), non Caucasian racial origin (HR, 2.16; 95% CI, 1.02 4.59), and concomitant aspirin use (HR, 2.89; 95% CI, 1.40 5.97). Increased risks in patients age 65 years and older were increased further if other risk factors were present. Lumiracoxib maintained an advantage over NSAIDs across all subgroups except aspirin use. Conclusions: Lumiracoxib was associated with a reduced risk of ulcer complications compared with NSAIDs in all significant subgroups except aspirin users.
C1 Univ Nottingham Hosp, Wolfson Digest Dis Ctr, Nottingham NG7 2UH, England.
   Univ Calif Los Angeles, David Geffen Sch Med, Div Digest Dis, Los Angeles, CA USA.
   Vanderbilt Univ, Nashville, TN USA.
   Novartis Pharma AG, Basel, Switzerland.
   Novartis Pharmaceut, E Hanover, NJ USA.
C3 University of Nottingham; University of California System; University of
   California Los Angeles; University of California Los Angeles Medical
   Center; David Geffen School of Medicine at UCLA; Vanderbilt University;
   Novartis; Novartis; Novartis USA
RP Hawkey, CJ (通讯作者)，Univ Nottingham Hosp, Wolfson Digest Dis Ctr, Nottingham NG7 2UH, England.
EM cj.hawkey@nottingham.ac.uk
CR Altman RD, 2000, ARTHRITIS RHEUM US, V43, P1905
   Bombardier C, 2000, NEW ENGL J MED, V343, P1520, DOI 10.1056/NEJM200011233432103
   Esser R, 2005, BRIT J PHARMACOL, V144, P538, DOI 10.1038/sj.bjp.0706078
   Goldstein JL, 2006, ALIMENT PHARM THER, V23, P1489, DOI 10.1111/j.1365 2036.2006.02912.x
   Hansen JM, 1996, SCAND J GASTROENTERO, V31, P126, DOI 10.3109/00365529609031975
   Hawkey CJ, 2002, GUT, V51, P344, DOI 10.1136/gut.51.3.344
   Hawkey CJ, 2004, ALIMENT PHARM THER, V20, P51, DOI 10.1111/j.1365 2036.2004.02026.x
   Hawkey CJ, 2003, GUT, V52, P600, DOI 10.1136/gut.52.4.600
   Hawkey CJ, 2002, GUT, V51, P336, DOI 10.1136/gut.51.3.336
   Jackson LM, 2000, GUT, V47, P762, DOI 10.1136/gut.47.6.762
   Laine L, 2002, GASTROENTEROLOGY, V123, P1006, DOI 10.1053/gast.2002.36013
   Pendleton A, 2000, ANN RHEUM DIS, V59, P936, DOI 10.1136/ard.59.12.936
   Poonam D, 2005, EUR J PHARMACOL, V519, P277, DOI 10.1016/j.ejphar.2005.06.055
   Rahme E, 2007, RHEUMATOLOGY, V46, P265, DOI 10.1093/rheumatology/kel223
   RODRIGUEZ LAG, 1994, LANCET, V343, P769, DOI 10.1016/S0140 6736(94)91843 0
   Rordorf CM, 2005, CLIN PHARMACOKINET, V44, P1247, DOI 10.2165/00003088 200544120 00004
   Schnitzer TJ, 2004, LANCET, V364, P665, DOI 10.1016/S0140 6736(04)16893 1
   Scott G, 2004, CLIN PHARMACOKINET, V43, P467, DOI 10.2165/00003088 200443070 00003
   Silverstein FE, 2000, JAMA J AM MED ASSOC, V284, P1247, DOI 10.1001/jama.284.10.1247
   Singh G, 1996, ARCH INTERN MED, V156, P1530, DOI 10.1001/archinte.156.14.1530
   Weaver ML, 2003, ANN RHEUM DIS, V62, P378
NR 21
TC 19
Z9 20
U1 0
U2 0
PU W B SAUNDERS CO ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103 2899 USA
SN 0016 5085
EI 1528 0012
J9 GASTROENTEROLOGY
JI Gastroenterology
PD JUL
PY 2007
VL 133
IS 1
BP 57
EP 64
DI 10.1053/j.gastro.2007.04.045
PG 8
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Gastroenterology & Hepatology
GA 190JP
UT WOS:000248055400012
PM 17631131
DA 2025 08 17
ER

PT J
AU van der Heide, HJL
   Rijnberg, WJ
   van Sorge, A
   van Kampen, A
   Schreurs, BW
AF van der Heide, Huub J. L.
   Rijnberg, Willard J.
   van Sorge, Adriaan
   van Kampen, Albert
   Schreurs, B. Willem
TI Similar effects of rofecoxib and indomethacin on the incidence of
   heterotopic ossification after hip arthroplasty
SO ACTA ORTHOPAEDICA
LA English
DT Article
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; GASTROINTESTINAL TOXICITY;
   CYCLOOXYGENASE 2 INHIBITORS; RHEUMATOID ARTHRITIS; COX INHIBITORS;
   BONE FORMATION; PREVENTION; MELOXICAM; OSTEOARTHRITIS; PROPHYLAXIS
AB Background Although indomethacin is effective in preventing heterotopic ossification (HO) after primary total hip arthroplasty, side effects are frequently observed. In the last decade a new class of drugs the COX 2 selective nonsteroidal anti inflammatory drugs has been developed. To investigate the effect of these COX 2 selective NSAIDs on heterotopic ossification (HO) after primary total hip arthroplasty (TRA), we conducted a randomized controlled trial using either indomethacin or rofecoxib for 7 days.
   Methods 186 patients received either indomethacin 3 times daily, or rofecoxib twice, and 1 placebo, daily for 7 days. HO was graded according to the 1 year postoperative radiographs according to the Brooker classification.
   Results 12 of the 186 patients included discontinued their medication before the end of the trial due to side effects. The remaining 174 patients were included in the analysis. In the indomethacin group (n = 89),77 patients (87%) showed no HO, 9 showed HO of grade 1 and 3 showed HO of grade 2 according to the Brooker classification. In the rofecoxib group (n = 85) 73 patients (86%) showed no ossification, 9 showed grade 1, and 3 showed grade 2.
   Interpretation The prophylactic effect of rofecoxib for 7 days in preventing heteropic ossification after primary total hip arthroplasty is comparable to the effect of indomethacin given for 7 days. These results indicate that the development of HO follows a COX 2 pathway.
C1 Radboud Univ Nijmegen, Nijmegen Med Ctr, Dept Orthopaed Surg, Nijmegen, Netherlands.
   Rijnstate Hosp, Dept Orthopaed Surg, Arnhem, Netherlands.
   Rijnstate Hosp, Dept Clin Pharmacol, Arnhem, Netherlands.
C3 Radboud University Nijmegen; Rijnstate Hospital; Rijnstate Hospital
RP Schreurs, BW (通讯作者)，Radboud Univ Nijmegen, Nijmegen Med Ctr, Dept Orthopaed Surg, Nijmegen, Netherlands.
EM b.schreurs@orthop.umcn.nl
RI van Kampen, A./H 8056 2014; Schreurs, B.W./L 4639 2015
OI van der Heide, Huub JL/0000 0003 3910 5048; 
CR Aspenberg P, 2005, ACTA ORTHOP, V76, P741, DOI 10.1080/17453670510045318
   Aspenberg P, 2005, ACTA ORTHOP, V76, P733, DOI 10.1080/17453670510045291
   Aspenberg P, 2002, ACTA ORTHOP SCAND, V73, P489, DOI 10.1080/000164702321022730
   Banovac K, 2004, SPINAL CORD, V42, P707, DOI 10.1038/sj.sc.3101628
   Barthel T, 2002, ACTA ORTHOP SCAND, V73, P611, DOI 10.3109/17453670209178023
   Bischoff R, 1994, J Arthroplasty, V9, P641, DOI 10.1016/0883 5403(94)90118 X
   Bombardier C, 2000, NEW ENGL J MED, V343, P1520, DOI 10.1056/NEJM200011233432103
   BROOKER AF, 1973, J BONE JOINT SURG AM, VA 55, P1629, DOI 10.2106/00004623 197355080 00006
   Burd TA, 2003, J BONE JOINT SURG BR, V85B, P700, DOI 10.1302/0301 620X.85B5.13970
   Cella J P, 1988, J Arthroplasty, V3, P229
   Couzin J, 2004, SCIENCE, V306, P384, DOI 10.1126/science.306.5695.384
   Dahners LE, 2004, J AM ACAD ORTHOP SUR, V12, P139, DOI 10.5435/00124635 200405000 00001
   Degner F, 1998, DRUG TODAY, V34, P1
   Dequeker J, 1998, BRIT J RHEUMATOL, V37, P946
   Dieppe PA, 2004, BRIT MED J, V329, P867, DOI 10.1136/bmj.329.7471.867
   Dorn U, 1998, ACTA ORTHOP SCAND, V69, P107, DOI 10.3109/17453679809117607
   Eggli S, 2001, ARCH ORTHOP TRAUM SU, V121, P531, DOI 10.1007/s004020100287
   Feldman M, 2000, ANN INTERN MED, V132, P134, DOI 10.7326/0003 4819 132 2 200001180 00008
   Gajraj NM, 2003, ANESTH ANALG, V96, P1720, DOI 10.1213/01.ANE.0000061461.55712.C5
   Grohs JG, 2007, ACTA ORTHOP, V78, P95, DOI 10.1080/17453670610013484
   Hawkey C, 1998, BRIT J RHEUMATOL, V37, P937
   Knelles D, 1997, J BONE JOINT SURG BR, V79B, P596, DOI 10.1302/0301 620X.79B4.6829
   KRISTENSEN SS, 1990, J BONE JOINT SURG BR, V72, P447, DOI 10.1302/0301 620X.72B3.2111327
   Laine L, 2002, SEMIN ARTHRITIS RHEU, V32, P25, DOI 10.1053/sarh.2002.37217
   Legenstein R, 2003, ARCH ORTHOP TRAUM SU, V123, P91, DOI 10.1007/s00402 003 0487 y
   Neal BC, 2000, ACTA ORTHOP SCAND, V71, P122, DOI 10.1080/000164700317413076
   Romanò CL, 2004, J ARTHROPLASTY, V19, P14, DOI 10.1016/S0883 5403(03)00279 1
   Schoenfeld P., 1999, The American journal of medicine, V107, P48
   Silverstein FE, 2000, JAMA J AM MED ASSOC, V284, P1247, DOI 10.1001/jama.284.10.1247
   van der Heide HJL, 1999, J ARTHROPLASTY, V14, P796, DOI 10.1016/S0883 5403(99)90027 X
   van der Heide Huub J L, 2004, Acta Orthop Belg, V70, P240
   Weber EWG, 2003, EUR J ANAESTH, V20, P963, DOI 10.1097/00003643 200312000 00005
NR 32
TC 37
Z9 37
U1 0
U2 2
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1745 3674
EI 1745 3682
J9 ACTA ORTHOP
JI Acta Orthop.
PD FEB
PY 2007
VL 78
IS 1
BP 90
EP 94
DI 10.1080/17453670610013475
PG 5
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA 150TX
UT WOS:000245243600014
PM 17453398
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Ueno, T
   Yamada, M
   Igarashi, Y
   Ogawa, T
AF Ueno, T.
   Yamada, M.
   Igarashi, Y.
   Ogawa, T.
TI N acetyl cysteine protects osteoblastic function from oxidative
   stress
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A
LA English
DT Article
DE antioxidant; hydrogen peroxide; glutathione; reactive oxygen species
   (ROS); bone
ID FREE RADICALS; BONE MARROW; GLUTATHIONE STATUS; SURGICAL STRESS;
   MC3T3 E1 CELLS; DNA DAMAGE; DIFFERENTIATION; ACETYLCYSTEINE; MECHANISMS;
   OXIDANTS
AB We tested the protective potential of an antioxidant amino acid derivative, N acetyl cysteine (NAC), in controlling oxidative stress against osteoblasts. Osteoblastic cells extracted from rat bone marrow were cultured. Oxidative stress was induced by adding 100 mu M H(2)O(2) into the culture media. Then, some H(2)O(2) treated cultures were cotreated with 2.5 or 5 mM NAC. Addition of H(2)O(2) decreased the number of cells to 50% of untreated cultures at days 2. Addition of 5 mM NAC into H(2)O(2) cultures resulted in a dose dependent increase in the number of cells, with the cell number being 50% greater than that in the 100 mu M H(2)O(2) culture. The gene expression levels of type I collagen, osteopontin, and osteocalcin were downregulated threefold by H(2)O(2) on day 7. The H(2)O(2) suppressed gene expression was fully recovered by NAC cotreatment. The mineralizing capability, assessed by Von Kossa staining on day 15, were approximately 1.8 times greater in the NAC + H(2)O(2) cotreated group than in the culture with H(2)O(2) alone. These NAC mediated restorations were associated with an NAC dose dependent increase of intracellular glutathione and a NAC dose dependent decrease of intracellular reactive oxygen species. In conclusion, oxidative stress induced by H(2)O(2) substantially impairs the proliferation, differentiation, and mineralization of osteoblasts. More importantly, the addition of NAC into the culture was found to restore these damages to a near normal level due to the improved redox balance, warranting further in vivo studies to test its therapeutic potential as a local antioxidative stress drug. (C) 2011 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 99A: 523 531, 2011.
C1 [Ueno, T.; Yamada, M.; Ogawa, T.] Univ Calif Los Angeles, Sch Dent, Div Adv Prosthodont Biomat & Hosp Dent,LBIS, Jane & Jerry Weintraub Ctr Reconstruct Biotechnol, Los Angeles, CA 90024 USA.
   [Ueno, T.; Igarashi, Y.] Tokyo Med & Dent Univ, Bunkyo Ku, Tokyo 1138549, Japan.
C3 University of California System; University of California Los Angeles;
   Institute of Science Tokyo; Tokyo Medical & Dental University (TMDU)
RP Ueno, T (通讯作者)，Univ Calif Los Angeles, Sch Dent, Div Adv Prosthodont Biomat & Hosp Dent,LBIS, Jane & Jerry Weintraub Ctr Reconstruct Biotechnol, Los Angeles, CA 90024 USA.
EM t.ueno.rpro@tmd.ac.jp
RI ; Yamada, Masahiro/AAC 7864 2019; Ueno, Takeshi/AAG 7638 2020
OI Ueno, Takeshi/0000 0001 6476 1632; Yamada, Masahiro/0000 0002 6316 7866;
   
FU Grants in Aid for Scientific Research [22791923] Funding Source: KAKEN
CR Aita H, 2010, J BIOMED MATER RES A, V92A, P285, DOI 10.1002/jbm.a.32336
   Anup R, 1999, SURGERY, V125, P560, DOI 10.1067/msy.1999.98045
   Arai M, 2007, IUBMB LIFE, V59, P27, DOI 10.1080/15216540601156188
   Bai XC, 2004, BIOCHEM BIOPH RES CO, V314, P197, DOI 10.1016/j.bbrc.2003.12.073
   Basu S, 2001, BIOCHEM BIOPH RES CO, V288, P275, DOI 10.1006/bbrc.2001.5747
   Bertram C, 2008, BIOL CHEM, V389, P211, DOI 10.1515/BC.2008.031
   Eckhardt A, 2009, BIOMATERIALS, V30, P2006, DOI 10.1016/j.biomaterials.2008.12.045
   Fatokun AA, 2006, BONE, V39, P542, DOI 10.1016/j.bone.2006.02.062
   FIALKOW L, 1994, J BIOL CHEM, V269, P31234
   Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687
   GARRETT IR, 1990, J CLIN INVEST, V85, P632, DOI 10.1172/JCI114485
   Hecquet CM, 2009, THROMB HAEMOSTASIS, V101, P619, DOI 10.1160/TH08 10 0641
   Henrotin YE, 2003, OSTEOARTHR CARTILAGE, V11, P747, DOI 10.1016/S1063 4584(03)00150 X
   Hiran TS, 1997, FREE RADICAL BIO MED, V23, P736, DOI 10.1016/S0891 5849(97)00054 3
   Jun JH, 2008, J CELL BIOCHEM, V103, P1246, DOI 10.1002/jcb.21508
   Kim JM, 2004, BIOCHEM BIOPH RES CO, V325, P101, DOI 10.1016/j.bbrc.2004.09.220
   Kovacic P, 2001, CURR MED CHEM, V8, P773, DOI 10.2174/0929867013373084
   Lee DH, 2006, CELL BIOL TOXICOL, V22, P39, DOI 10.1007/s10565 006 0018 z
   Maggio D, 2003, J CLIN ENDOCR METAB, V88, P1523, DOI 10.1210/jc.2002 021496
   MANIATOPOULOS C, 1988, CELL TISSUE RES, V254, P317
   MANOLAGAS SC, 1995, NEW ENGL J MED, V332, P305, DOI 10.1056/NEJM199502023320506
   MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431
   Mody N, 2001, FREE RADICAL BIO MED, V31, P509, DOI 10.1016/S0891 5849(01)00610 4
   Okamoto H, 2008, FEBS J, V275, P4463, DOI 10.1111/j.1742 4658.2008.06582.x
   Prabhu R, 2000, J SURG RES, V94, P178, DOI 10.1006/jsre.2000.6007
   Sato N, 2009, DENT MATER, V25, P1532, DOI 10.1016/j.dental.2009.07.006
   Schweikl H, 2006, J DENT RES, V85, P870, DOI 10.1177/154405910608501001
   Smith SS, 2009, TOXICOL IN VITRO, V23, P60, DOI 10.1016/j.tiv.2008.10.011
   Son MJ, 2010, J BIOCHEM MOL TOXIC, V24, P313, DOI 10.1002/jbt.20340
   Therond P, 2000, FREE RADICAL BIO MED, V28, P585, DOI 10.1016/S0891 5849(99)00265 8
   Tsukimura N, 2009, BIOMATERIALS, V30, P3378, DOI 10.1016/j.biomaterials.2009.02.043
   Valko M, 2006, CHEM BIOL INTERACT, V160, P1, DOI 10.1016/j.cbi.2005.12.009
   Valko M, 2001, BBA GEN SUBJECTS, V1527, P161, DOI 10.1016/S0304 4165(01)00163 5
   Van de Bittner GC, 2010, P NATL ACAD SCI USA, V107, P21316, DOI 10.1073/pnas.1012864107
   WEISS SJ, 1983, SCIENCE, V222, P625, DOI 10.1126/science.6635660
   Yamada M, 2010, J DENT RES, V89, P411, DOI 10.1177/0022034510363243
   ZIMENT I, 1986, RESPIRATION, V50, P26, DOI 10.1159/000195085
NR 37
TC 51
Z9 58
U1 1
U2 7
PU WILEY BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1549 3296
J9 J BIOMED MATER RES A
JI J. Biomed. Mater. Res. Part A
PD DEC
PY 2011
VL 99A
IS 4
BP 523
EP 531
DI 10.1002/jbm.a.33211
PG 9
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA 848AR
UT WOS:000297019200003
PM 21913320
DA 2025 08 17
ER

PT J
AU Prévost, V
   Anselme, K
   Gallet, O
   Hindié, M
   Petithory, T
   Valentin, J
   Veuillet, M
   Ploux, L
AF Prevost, Victor
   Anselme, Karine
   Gallet, Olivier
   Hindie, Mathilde
   Petithory, Tatiana
   Valentin, Jules
   Veuillet, Mathieu
   Ploux, Lydie
TI Real Time Imaging of Bacteria/Osteoblast Dynamic Coculture on Bone
   Implant Material in an in Vitro Postoperative Contamination Model
SO ACS BIOMATERIALS SCIENCE & ENGINEERING
LA English
DT Article
DE real time imaging; bacteria/eukaryotic cells coculture; biomaterials;
   confocal fluorescence microscopy; fibronectin
ID MICROBIAL BIOFILM GROWTH; MAMMALIAN CELL GROWTH; ESCHERICHIA COLI;
   TISSUE INTEGRATION; BACTERIAL ADHESION; 2 HYDROXYETHYL METHACRYLATE;
   STAPHYLOCOCCUS AUREUS; SURFACE CHEMISTRY; TITANIUM SURFACE; FIBRONECTIN
AB Biomedical implants are an important part of evolving modern medicine but have a potential drawback in the form of postoperative pathogenic infection. Accordingly, the "race for surface" combat between invasive bacteria and host cells determines the fate of implants. Hence, proper in vitro systems are required to assess effective strategies to avoid infection. In this study, we developed a real time observation model, mimicking postoperative contamination, designed to follow E. coli proliferation on a titanium surface occupied by human osteoblastic progenitor cells (STRO). This model allowed us to monitor E. coli invasion of human cells on titanium surfaces coated and uncoated with fibronectin. We showed that the surface colonization of bacteria is significantly enhanced on fibronectin coated surfaces irrespective of whether areas were uncovered or covered with human cells. We further revealed that bacterial colonization of the titanium surfaces is enhanced in coculture with STRO cells. Finally, this coculture system provides a comprehensive system to describe in vitro and in situ bacterial and human cells and their localization but also to target biological mechanisms involved in adhesion as well as in interactions with surfaces, thanks to fluorescent labeling. This system is thus an efficient method for studies related to the design and function of new biomaterials.
C1 [Prevost, Victor; Anselme, Karine; Petithory, Tatiana; Valentin, Jules; Veuillet, Mathieu; Ploux, Lydie] Univ Haute Alsace, CNRS, UMR 7361 IS2M, F 68100 Mulhouse, France.
   [Prevost, Victor; Anselme, Karine; Petithory, Tatiana; Valentin, Jules; Veuillet, Mathieu; Ploux, Lydie] Univ Strasbourg, F 67000 Strasbourg, France.
   [Ploux, Lydie] Univ Strasbourg, INSERM, BIOMAT U1121, F 67000 Strasbourg, France.
   [Prevost, Victor; Gallet, Olivier; Hindie, Mathilde] Univ Cergy Pontoise, ERRMECe, F 95000 Neuville Sur Oise, France.
C3 Universites de Strasbourg Etablissements Associes; Universite de
   Haute Alsace (UHA); Centre National de la Recherche Scientifique (CNRS);
   Universites de Strasbourg Etablissements Associes; Universite de
   Strasbourg; Institut National de la Sante et de la Recherche Medicale
   (Inserm); Universite de Lorraine; Universites de Strasbourg
   Etablissements Associes; Universite de Strasbourg; CY Cergy Paris
   Universite
RP Ploux, L (通讯作者)，Univ Haute Alsace, CNRS, UMR 7361 IS2M, F 68100 Mulhouse, France.; Ploux, L (通讯作者)，Univ Strasbourg, F 67000 Strasbourg, France.; Ploux, L (通讯作者)，Univ Strasbourg, INSERM, BIOMAT U1121, F 67000 Strasbourg, France.
EM ploux@unistra.fr
RI Hindie, Mathilde/LNQ 9558 2024
OI Anselme, Karine/0000 0002 6669 205X; Ploux, Lydie/0000 0003 0410 693X;
   Hindie, Mathilde/0000 0001 7681 7517; Valentin,
   Jules/0000 0001 6799 6664
FU CNRS (the French National Center for Scientific Research); ANR (the
   French National Research Agency)
FX The authors thank CNRS (the French National Center for Scientific
   Research) and ANR (the French National Research Agency) for their
   financial support. The authors acknowledge N. T. Wakhloo for English
   revision of the manuscript.
CR Amable PR, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt442
   Anagnostou F, 2006, BIOMATERIALS, V27, P3912, DOI 10.1016/j.biomaterials.2006.03.004
   Anselme K, 2010, P I MECH ENG H, V224, P1487, DOI 10.1243/09544119JEIM901
   Anselme K, 2010, ACTA BIOMATER, V6, P3824, DOI 10.1016/j.actbio.2010.04.001
   Ba OM, 2015, COLLOID SURFACE B, V134, P73, DOI 10.1016/j.colsurfb.2015.06.009
   Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453
   Böhmler J, 2015, ACS BIOMATER SCI ENG, V1, P693, DOI 10.1021/acsbiomaterials.5b00151
   Boysen A, 2015, J MICROBIOL METH, V116, P66, DOI 10.1016/j.mimet.2015.06.015
   Burton EA, 2009, LANGMUIR, V25, P1547, DOI 10.1021/la803261b
   Busscher HJ, 2006, CLIN MICROBIOL REV, V19, P127, DOI 10.1128/CMR.19.1.127 141.2006
   Cataldi A, 2016, J MATER SCI MATER M, V27, DOI 10.1007/s10856 016 5701 x
   Cottenye N, 2012, ADV FUNCT MATER, V22, P4891, DOI 10.1002/adfm.201200988
   Dapunt U, 2016, BMC MUSCULOSKEL DIS, V17, DOI 10.1186/s12891 016 1091 y
   Di Giulio M, 2012, APMIS, V120, P139, DOI 10.1111/j.1600 0463.2011.02828.x
   Di Martino P, 2002, CAN J MICROBIOL, V48, P132, DOI 10.1139/W02 001
   Egea L, 2007, INT J BIOCHEM CELL B, V39, P1190, DOI 10.1016/j.biocel.2007.03.008
   Engelsman AF, 2010, BIOFOULING, V26, P761, DOI 10.1080/08927014.2010.515027
   Fernández ICS, 2011, BIOMATERIALS, V32, P979, DOI 10.1016/j.biomaterials.2010.10.011
   Foss BL, 2015, COLLOID SURFACE B, V134, P370, DOI 10.1016/j.colsurfb.2015.07.014
   Franková J, 2013, J BIOMED MATER RES A, V101, P2915, DOI 10.1002/jbm.a.34598
   Fritton SP, 2009, ANNU REV FLUID MECH, V41, P347, DOI 10.1146/annurev.fluid.010908.165136
   Gallorini M, 2016, J MATER SCI MATER M, V27, DOI 10.1007/s10856 016 5803 5
   Gophna U, 2002, FEMS MICROBIOL LETT, V212, P55, DOI 10.1111/j.1574 6968.2002.tb11244.x
   Grainger DW, 2013, BIOMATERIALS, V34, P9237, DOI 10.1016/j.biomaterials.2013.08.043
   GRISTINA AG, 1987, SCIENCE, V237, P1588, DOI 10.1126/science.3629258
   Harshey RM, 2003, ANNU REV MICROBIOL, V57, P249, DOI 10.1146/annurev.micro.57.030502.091014
   Henderson B, 2013, CURR TOP MICROBIOL, V358, P155, DOI 10.1007/82_2011_188
   Heydorn A, 2000, MICROBIOL UK, V146, P2409, DOI 10.1099/00221287 146 10 2409
   Hindié M, 2017, ADV EXP MED BIOL, V973, P17, DOI 10.1007/5584_2016_41
   Hirsh SL, 2013, COLLOID SURFACE B, V103, P395, DOI 10.1016/j.colsurfb.2012.10.039
   HOEPELMAN AIM, 1992, INFECT IMMUN, V60, P1729, DOI 10.1128/IAI.60.5.1729 1733.1992
   Josse J, 2015, FRONT CELL INFECT MI, V5, DOI 10.3389/fcimb.2015.00085
   Kendall MM, 2016, MBIO, V7, DOI 10.1128/mBio.01748 15
   Le Guéhennec L, 2007, DENT MATER, V23, P844, DOI 10.1016/j.dental.2006.06.025
   Lee JH, 2011, TISSUE ENG PART C ME, V17, P39, DOI 10.1089/ten.TEC.2010.0285
   Lee JH, 2010, ACTA BIOMATER, V6, P4422, DOI 10.1016/j.actbio.2010.05.021
   Leonhardt Å, 1999, CLIN ORAL IMPLAN RES, V10, P339, DOI 10.1034/j.1600 0501.1999.100501.x
   Lorenzetti M, 2015, ACS APPL MATER INTER, V7, P1644, DOI 10.1021/am507148n
   March JC, 2003, APPL MICROBIOL BIOT, V62, P303, DOI 10.1007/s00253 003 1339 y
   Miao H, 2009, J MICROBIOL METH, V76, P111, DOI 10.1016/j.mimet.2008.09.015
   Ploux L, 2009, LANGMUIR, V25, P8161, DOI 10.1021/la900457f
   Poulouin L, 1999, PROTEIN EXPRES PURIF, V17, P146, DOI 10.1006/prep.1999.1103
   Rasband, 1997, IMAGEJ
   Reisner A, 2003, MOL MICROBIOL, V48, P933, DOI 10.1046/j.1365 2958.2003.03490.x
   Ren L, 2015, J MECH BEHAV BIOMED, V50, P104, DOI 10.1016/j.jmbbm.2015.04.021
   Ribet D, 2015, MICROBES INFECT, V17, P173, DOI 10.1016/j.micinf.2015.01.004
   Rico P, 2009, TISSUE ENG PT A, V15, P3271, DOI 10.1089/ten.TEA.2009.0141
   Riquelme MA, 2015, J BIOL CHEM, V290, P28321, DOI 10.1074/jbc.M115.683417
   Rochford ETJ, 2014, J BIOMED MATER RES A, V102, P4427, DOI 10.1002/jbm.a.35130
   SCHERRER B., 2007, BIOSTATISTIQUE
   Stephens DJ, 2003, SCIENCE, V300, P82, DOI 10.1126/science.1082160
   Sternberg C, 2014, METHODS MOL BIOL, V1147, P3, DOI 10.1007/978 1 4939 0467 9_1
   Stones DH, 2016, BIOCHEM SOC T, V44, P1571, DOI 10.1042/BST20160186
   Subbiahdoss G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024827
   Subbiahdoss G, 2010, MICROBIOL SGM, V156, P3073, DOI 10.1099/mic.0.040378 0
   Subbiahdoss G, 2010, J BIOMED MATER RES A, V94A, P533, DOI 10.1002/jbm.a.32731
   Subbiahdoss G, 2010, EUR CELLS MATER, V19, P205, DOI 10.22203/eCM.v019a20
   Subbiahdoss G, 2009, ACTA BIOMATER, V5, P1399, DOI 10.1016/j.actbio.2008.12.011
   Vasilev K, 2010, NANO LETT, V10, P202, DOI 10.1021/nl903274q
   Velve Casquillas G, 2010, NANO TODAY, V5, P28, DOI 10.1016/j.nantod.2009.12.001
   Wang Y, 2012, BIOFOULING, V28, P1011, DOI 10.1080/08927014.2012.725471
   Wang YX, 2008, ANNU REV BIOMED ENG, V10, P1, DOI 10.1146/annurev.bioeng.010308.161731
   Waters JC, 2009, J CELL BIOL, V185, P1135, DOI 10.1083/jcb.200903097
   Wu Y, 2011, BIOMATERIALS, V32, P951, DOI 10.1016/j.biomaterials.2010.10.001
   Yáñez D, 2016, FRONT CELL INFECT MI, V6, DOI 10.3389/fcimb.2016.00166
   Yeo IS, 2012, INT J ARTIF ORGANS, V35, P762, DOI 10.5301/ijao.5000154
   Yue CX, 2014, BIOMATERIALS, V35, P2580, DOI 10.1016/j.biomaterials.2013.12.036
   Zaatreh S, 2017, MOL MED REP, V15, P1624, DOI 10.3892/mmr.2017.6218
   Zaatreh S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151534
   Zara S, 2011, INT ENDOD J, V44, P1145, DOI 10.1111/j.1365 2591.2011.01935.x
   Zhao BR, 2015, INT J ORAL SCI, V7, P250, DOI 10.1038/ijos.2015.45
   Zhao B, 2014, DENT MATER, V30, P716, DOI 10.1016/j.dental.2014.04.001
   Zheng XY, 2006, BIOTECHNOL PROGR, V22, P1294, DOI 10.1021/bp060121o
   Zulfakar SS, 2012, INT J FOOD MICROBIOL, V157, P210, DOI 10.1016/j.ijfoodmicro.2012.05.007
NR 74
TC 4
Z9 4
U1 0
U2 33
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 2373 9878
J9 ACS BIOMATER SCI ENG
JI ACS Biomater. Sci. Eng.
PD JUL
PY 2019
VL 5
IS 7
BP 3260
EP 3269
DI 10.1021/acsbiomaterials.9b00050
PG 19
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA IH9FP
UT WOS:000474812300010
PM 33405569
OA Green Submitted
DA 2025 08 17
ER

PT J
AU McConeghy, KW
   Zullo, AR
   Lary, CW
   Zhang, T
   Lee, Y
   Daiello, L
   Kiel, DP
   Berry, S
AF McConeghy, Kevin W.
   Zullo, Andrew R.
   Lary, Christine W.
   Zhang, Tingting
   Lee, Yoojin
   Daiello, Lori
   Kiel, Douglas P.
   Berry, Sarah
TI Association Between Bisphosphonates and Hospitalized Clostridioides
   difficile Infection Among Frail Older Adults
SO JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION
LA English
DT Article
DE Bisphosphonate; Clostridioides difficile; nursing home; adverse drug
   reaction
ID TERM CARE FACILITIES; BURDEN
AB Objectives: Clostridioides difficile infection is a major source of morbidity and mortality among frail older adults, especially those in nursing homes (NHs). Safety reports have signaled that bisphosphonate use may be a contributing cause. We therefore evaluated the risk of C difficile hospitalization associated with oral bisphosphonate use in the NH.
   Design: Observational, retrospective new user cohort study.
   Setting: The cohort included US NH residents aged >= 65 years who became a long stay resident (>100 days in the NH) between January 1, 2008 and December 31, 2009.
   Methods: We conducted a study of NH residents using linked Medicare claims and Minimum Data Set records. Residents were new users of an oral bisphosphonate 1:1 matched to new calcitonin users ("active" comparator) on propensity scores controlling for more than 100 covariates. The outcome was risk of hospitalization for C difficile infection in a Cox proportional hazards model adjusted for previous antibiotic and proton pump inhibitor use.
   Results: Our final analytical cohort included 17,753 bisphosphonate and 5348 calcitonin users. In the matched cohort, 84/5209 (1.6%) vs 71/5209 (1.4%) C difficile related hospitalizations occurred in bisphosphonate and calcitonin users, respectively. We observed no significant difference in the risk of hospitalization among bisphosphonate users (hazard ratio: 1.11, 95% confidence interval: 0.80 1.51). Antibiotic and proton pump inhibitor exposure before and after osteoporosis treatment was also similar between bisphosphonate and calcitonin users.
   Conclusions and Implications: C difficile infection should not be a consideration when prescribing bisphosphonates to frail older adults given the lack of a significant association. (C) 2019 Published by Elsevier Inc. on behalf of AMDA   The Society for Post Acute and Long Term Care Medicine.
C1 [McConeghy, Kevin W.; Zullo, Andrew R.; Zhang, Tingting; Lee, Yoojin] Providence VA Med Ctr, Ctr Innovat Long Term Serv & Support, Providence, RI 02908 USA.
   [McConeghy, Kevin W.; Zullo, Andrew R.; Zhang, Tingting; Lee, Yoojin; Daiello, Lori] Brown Univ, Sch Publ Hlth, Providence, RI 02912 USA.
   [McConeghy, Kevin W.] Univ Rhode Isl, Coll Pharm, Kingston, RI 02881 USA.
   [Lary, Christine W.] Maine Med Ctr Outcomes Res & Evaluat, Portland, ME USA.
   [Kiel, Douglas P.; Berry, Sarah] Hinda & Arthur Marcus Inst Aging Res, Hebrew SeniorLife, Boston, MA USA.
   [Kiel, Douglas P.; Berry, Sarah] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
   [Kiel, Douglas P.; Berry, Sarah] Harvard Med Sch, Boston, MA 02215 USA.
C3 US Department of Veterans Affairs; Veterans Health Administration (VHA);
   Providence VA Medical Center; Brown University; University of Rhode
   Island; Harvard University; Harvard University Medical Affiliates;
   Hebrew SeniorLife; Harvard University; Harvard University Medical
   Affiliates; Beth Israel Deaconess Medical Center; Harvard University;
   Harvard Medical School
RP McConeghy, KW (通讯作者)，Providence VA Med Ctr, Ctr Innovat Long Term Serv & Support, Providence, RI 02908 USA.
EM Kevin.mcconeghy@va.gov
RI ; Zullo, Andrew R/C 6088 2017; Zullo, Andrew/C 6088 2017
OI Lee, Yoojin/0000 0002 3373 310X; Zullo, Andrew R/0000 0003 1673 4570;
   Kiel, Douglas/0000 0001 8474 0310; 
FU National Institute of Health, National Institute on Aging [R101AG045441,
   5P01AG027296 05]
FX This work was supported by the National Institute of Health, National
   Institute on Aging (grant nos. R101AG045441 and 5P01AG027296 05).
CR [Anonymous], FOS AL
   Berry SD, 2018, J GERONTOL A BIOL, V73, P763, DOI 10.1093/gerona/glx147
   Dubberke ER, 2006, EMERG INFECT DIS, V12, P1576, DOI 10.3201/eid1210.060016
   HAWES C, 1995, GERONTOLOGIST, V35, P172, DOI 10.1093/geront/35.2.172
   Karanika S, 2017, J AM GERIATR SOC, V65, P1733, DOI 10.1111/jgs.14863
   Kee VR, 2012, AM J GERIATR PHARMAC, V10, P14, DOI 10.1016/j.amjopharm.2011.12.004
   Kim JH, 2011, INFECT CONT HOSP EP, V32, P656, DOI 10.1086/660767
   Kruszewska Hanna, 2002, Acta Pol Pharm, V59, P436
   McConeghy KW, 2016, PHARMACOTHERAPY, V36, P1095, DOI 10.1002/phar.1832
   Menezes AMA, 2005, J PERIODONTOL, V76, P1901, DOI 10.1902/jop.2005.76.11.1901
   Pawar D, 2012, INFECT CONT HOSP EP, V33, P1107, DOI 10.1086/668031
   Rogers TL, 2011, J TRANSL MED, V9, DOI 10.1186/1479 5876 9 177
   Ziakas PD, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004187
   Ziakas PD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117195
   Zullo AR, 2019, J AM GERIATR SOC, V67, P768, DOI 10.1111/jgs.15725
NR 15
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1525 8610
EI 1538 9375
J9 J AM MED DIR ASSOC
JI J. Am. Med. Dir. Assoc.
PD MAY
PY 2020
VL 21
IS 5
BP 688
EP 691
DI 10.1016/j.jamda.2019.11.016
PG 4
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI EXPANDED); Social Science Citation Index (SSCI)
SC Geriatrics & Gerontology
GA LL4UN
UT WOS:000531552200020
PM 31932139
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Kurpinski, K
   Jang, DJ
   Bhattacharya, S
   Rydberg, B
   Chu, J
   So, J
   Wyrobek, A
   Li, S
   Wang, DJ
AF Kurpinski, Kyle
   Jang, Deok Jin
   Bhattacharya, Sanchita
   Rydberg, Bjorn
   Chu, Julia
   So, Joanna
   Wyrobek, Andy
   Li, Song
   Wang, Daojing
TI DIFFERENTIAL EFFECTS OF X RAYS AND HIGH ENERGY <SUP>56</SUP>Fe IONS ON
   HUMAN MESENCHYMAL STEM CELLS
SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
LA English
DT Article
DE Radioresponse; High LET; Cell cycle; Osteogenic differentiation;
   Transcriptomics
ID BONE MARROW TRANSPLANTATION; NORMAL HUMAN FIBROBLASTS;
   IONIZING RADIATION; GENOMIC INSTABILITY; SPACE EXPLORATION; LET
   RADIATION; DNA DAMAGE; EXPOSURE; CANCER; ARREST
AB Purpose: Stem cells hold great potential for regenerative medicine, but they have also been implicated in cancer and aging. How different kinds of ionizing radiation affect stem cell biology remains unexplored. This study was designed to compare the biological effects of X rays and of high linear energy transfer (LET) Fe 56 ions on human mesenchymal stem cells (hMSC).
   Methods and Materials: A multi functional comparison was carried out to investigate the differential effects of X rays and Fe 56 ions on hMSC. The end points included modulation of key markers such as p53, cell cycle progression, osteogenic differentiation, and pathway and networks through transcriptomic profiling and bioinformatics analysis.
   Results: X rays and Fe 56 ions differentially inhibited the cell cycle progression of hMSC in a p53 dependent manner without impairing their in vitro osteogenic differentiation process. Pathway and network analyses revealed that cytoskeleton and receptor signaling were uniquely enriched for low dose (0.1 Gy) X rays. In contrast, DNA/RNA metabolism and cell cycle regulation were enriched for high dose (1 Gy) X rays and Fe 56 ions, with more significant effects from Fe 56 ions. Specifically, DNA replication, DNA strand elongation, and DNA binding/transferase activity were perturbed more severely by 1 Gy Fe 56 ions than by 1 Gy X rays, consistent with the significant G2/M arrest for the former while not for the latter.
   Conclusions: Fe 56 ions exert more significant effects on hMSC than X rays. Since hMSC are the progenitors of osteoblasts in vivo, this study provides new mechanistic understandings of the relative health risks associated with low  and high dose X rays and high LET space radiation. (C) 2009 Elsevier Inc.
C1 [Jang, Deok Jin; Bhattacharya, Sanchita; Rydberg, Bjorn; Wyrobek, Andy; Wang, Daojing] Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA.
   [Kurpinski, Kyle; Chu, Julia; So, Joanna; Li, Song] Univ Calif Berkeley, Dept Bioengn, Berkeley, CA 94720 USA.
C3 United States Department of Energy (DOE); Lawrence Berkeley National
   Laboratory; University of California System; University of California
   Berkeley; University of California System; University of California
   Berkeley
RP Wang, DJ (通讯作者)，Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, 1 Cyclotron Rd,MS 977 225A, Berkeley, CA 94720 USA.
EM djwang@lbl.gov
RI ; Li, Song/NLO 4200 2025
OI Li, Song/0000 0002 4760 8828; Wyrobek, Andrew/0000 0002 5921 5298
FU NHLBI NIH HHS [HL079419] Funding Source: Medline
CR Baumann P, 1998, TRENDS BIOCHEM SCI, V23, P247, DOI 10.1016/S0968 0004(98)01232 8
   Beausejour CM, 2006, NATURE, V443, P404, DOI 10.1038/nature05221
   Birrell GW, 2002, P NATL ACAD SCI USA, V99, P8778, DOI 10.1073/pnas.132275199
   Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497
   Chen MF, 2006, INT J RADIAT ONCOL, V66, P244, DOI 10.1016/j.ijrobp.2006.03.062
   Cucinotta FA, 2006, LANCET ONCOL, V7, P431, DOI 10.1016/S1470 2045(06)70695 7
   Dickhut A, 2005, ANN HEMATOL, V84, P722, DOI 10.1007/s00277 005 1067 8
   Ding LH, 2005, RADIAT RES, V164, P17, DOI 10.1667/RR3354
   Ducy P, 2000, DEV DYNAM, V219, P461, DOI 10.1002/1097 0177(2000)9999:9999<::AID DVDY1074>3.0.CO;2 C
   Fei PW, 2003, ONCOGENE, V22, P5774, DOI 10.1038/sj.onc.1206677
   Franceschi RT, 2003, J CELL BIOCHEM, V88, P446, DOI 10.1002/jcb.10369
   Groesser T, 2007, RADIAT RES, V168, P675, DOI 10.1667/RR0967.1
   Grove JE, 2004, STEM CELLS, V22, P487, DOI 10.1634/stemcells.22 4 487
   Hall EJ, 2003, ONCOGENE, V22, P7034, DOI 10.1038/sj.onc.1206900
   Hamilton SA, 2006, J APPL PHYSIOL, V101, P789, DOI 10.1152/japplphysiol.01078.2005
   Koshurnikova NA, 2000, RADIAT RES, V154, P237, DOI 10.1667/0033 7587(2000)154[0237:BCIMW]2.0.CO;2
   Kurpinski K, 2006, P NATL ACAD SCI USA, V103, P16095, DOI 10.1073/pnas.0604182103
   Lengner CJ, 2006, J CELL BIOL, V172, P909, DOI 10.1083/jcb.200508130
   LUCKEHUHLE C, 1979, RADIAT RES, V79, P97, DOI 10.2307/3575025
   Maiorano D, 2006, CURR OPIN CELL BIOL, V18, P130, DOI 10.1016/j.ceb.2006.02.006
   Matsuoka S, 2007, SCIENCE, V316, P1160, DOI 10.1126/science.1140321
   Morgan WF, 2003, ONCOGENE, V22, P7094, DOI 10.1038/sj.onc.1206992
   Nelson Gregory A, 2003, Gravit Space Biol Bull, V16, P29
   Oghiso Y, 2003, J RADIAT RES, V44, P125, DOI 10.1269/jrr.44.125
   Pruitt SC, 2007, STEM CELLS, V25, P3121, DOI 10.1634/stemcells.2007 0483
   Rieger K, 2005, EXP HEMATOL, V33, P605, DOI 10.1016/j.exphem.2005.02.004
   Rosemann M, 2002, RADIAT RES, V157, P426, DOI 10.1667/0033 7587(2002)157[0426:BTIBAP]2.0.CO;2
   Rubio D, 2005, CANCER RES, V65, P3035, DOI 10.1158/0008 5472.CAN 04 4194
   Rydberg B, 2005, RADIAT RES, V163, P526, DOI 10.1667/RR3346
   Schimmerling W, 2003, ADV SPACE RES, V31, P27, DOI 10.1016/S0273 1177(02)00653 1
   Serakinci N, 2004, ONCOGENE, V23, P5095, DOI 10.1038/sj.onc.1207651
   Sokolov MV, 2006, GENE, V382, P47, DOI 10.1016/j.gene.2006.06.008
   Virtanen A, 2006, INT J CANCER, V118, P1017, DOI 10.1002/ijc.21456
   WALDMAN T, 1995, CANCER RES, V55, P5187
   Wang DJ, 2004, J BIOL CHEM, V279, P43725, DOI 10.1074/jbc.M407368200
   Willey JS, 2008, RADIAT RES, V170, P201, DOI 10.1667/RR0832.1
   XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0
   Yin E, 2003, INT J RADIAT BIOL, V79, P759, DOI 10.1080/09553000310001610961
   Zeitlin C, 1998, RADIAT RES, V149, P560, DOI 10.2307/3579902
NR 39
TC 41
Z9 46
U1 0
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 0360 3016
J9 INT J RADIAT ONCOL
JI Int. J. Radiat. Oncol. Biol. Phys.
PD MAR 1
PY 2009
VL 73
IS 3
BP 869
EP 877
DI 10.1016/j.ijrobp.2008.10.002
PG 9
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA 408NE
UT WOS:000263440900034
PM 19101095
DA 2025 08 17
ER

PT J
AU Shankhwar, N
   Kothiyal, GP
   Srinivasan, A
AF Shankhwar, Nisha
   Kothiyal, G. P.
   Srinivasan, A.
TI Influence of phosphate precursors on the structure, crystallization
   behaviour and bioactivity of sol gel derived 45S5 bioglass
SO RSC ADVANCES
LA English
DT Article
ID IN VITRO; GLASS; OSTEOBLASTS; MECHANISM; COATINGS
AB Obtaining bioglass composition 45S5 (R) in completely amorphous form without crystalline inclusion by the sol gel route has remained a challenge so far. Here, we demonstrate that with appropriate phosphate precursor and by controlling the polymerization and gelation reactions by adjusting the pH of the reactants, one can overcome this challenge. As synthesized glass was heat treated to understand the devitrification behaviour of the sol gel derived glass and to obtain bioglass ceramics. As synthesized and heat treated glasses were characterized using powder X ray diffraction, transmission electron microscope, differential scanning calorimeter and differential thermal analyzer. For assessing the in vitro bioactivity of sol gel derived glass and glass ceramic powders, we tested the apatite forming ability on their surface upon immersion in simulated body fluid. Properties of sol derived 45S5 glass are then compared with the bulk counterpart obtained by conventional melt quenching method. This study reveals a procedure to prepare completely amorphous sol gel derived 45S5 glass which can be used as a bioactive material for bone implant, tooth coating, bone tissue engineering and drug delivery applications.
C1 [Shankhwar, Nisha; Srinivasan, A.] Indian Inst Technol Guwahati, Dept Phys, Gauhati 781039, India.
   [Kothiyal, G. P.] Bhabha Atom Res Ctr, Glass & Adv Ceram Div, Bombay 400085, Maharashtra, India.
C3 Indian Institute of Technology System (IIT System); Indian Institute of
   Technology (IIT)   Guwahati; Bhabha Atomic Research Center (BARC)
RP Srinivasan, A (通讯作者)，Indian Inst Technol Guwahati, Dept Phys, Gauhati 781039, India.
EM asrini@iitg.ernet.in
RI Shankhwar, Nisha/AAQ 5453 2021; SHANKHWAR, Dr NISHA/AAQ 5453 2021
OI Srinivasan, Ananthakrishnan/0000 0003 3729 2572; SHANKHWAR, Dr
   NISHA/0000 0002 8371 5057
FU Department of Atomic Energy, Government of India [2010/34/54/BRNS]
FX We are grateful to Department of Atomic Energy (2010/34/54/BRNS),
   Government of India, for financially supporting this work. High end
   instrument support received from Central Instruments Facility, IIT
   Guwahati is gratefully acknowledged.
CR ANDERSSON OH, 1991, J NON CRYST SOLIDS, V129, P145, DOI 10.1016/0022 3093(91)90090 S
   Bretcanu O, 2009, J EUR CERAM SOC, V29, P3299, DOI 10.1016/j.jeurceramsoc.2009.06.035
   Brinker CJ, 2013, SOL GEL SCI PHYS CHE, DOI 10.1016/C2009 0 22386 5
   Cacciotti I, 2012, J MATER SCI MATER M, V23, P1849, DOI 10.1007/s10856 012 4667 6
   Catteaux R, 2013, CHEM ENG RES DES, V91, P2420, DOI 10.1016/j.cherd.2013.05.017
   Chen QZ, 2011, ACTA BIOMATER, V7, P3616, DOI 10.1016/j.actbio.2011.06.005
   Clupper DC, 2003, J NON CRYST SOLIDS, V318, P43, DOI 10.1016/S0022 3093(02)01857 4
   El Kady AM, 2010, MAT SCI ENG C MATER, V30, P120, DOI 10.1016/j.msec.2009.09.008
   Eqtesadi S, 2014, J EUR CERAM SOC, V34, P113, DOI 10.1016/j.jeurceramsoc.2013.08.003
   Essien E. R., 2013, J BIOMED SCI ENG, V6, P258
   Fan JP, 2014, MAT SCI ENG C MATER, V36, P206, DOI 10.1016/j.msec.2013.12.009
   Fraczyk A., 2011, Technol Sci, V14, P93
   Hench L. L., 1980, SCIENCE, V80, P208
   Hench LL, 2006, J MATER SCI MATER M, V17, P967, DOI 10.1007/s10856 006 0432 z
   HENCH LL, 1991, J AM CERAM SOC, V74, P1487, DOI 10.1111/j.1151 2916.1991.tb07132.x
   Hench LL, 1998, J AM CERAM SOC, V81, P1705
   Jones R.W., 1990, Fundamental Principles of Sol  Gel Technology
   Kokubo T, 2006, BIOMATERIALS, V27, P2907, DOI 10.1016/j.biomaterials.2006.01.017
   Lucas Girot A, 2011, J NON CRYST SOLIDS, V357, P3322, DOI 10.1016/j.jnoncrysol.2011.06.002
   Massera J, 2012, J AM CERAM SOC, V95, P607, DOI 10.1111/j.1551 2916.2011.05012.x
   Milea C.A., 2011, UniTBv Eng. Sci, V4, P59, DOI DOI 10.3390/MA14071788
   Nassar E. J., 2001, BIOMATERIALS SCI ENG
   OHTSUKI C, 1992, J NON CRYST SOLIDS, V143, P84, DOI 10.1016/S0022 3093(05)80556 3
   Padilla S, 2005, BIOMATERIALS, V26, P475, DOI 10.1016/j.biomaterials.2004.02.054
   Pirayesh H, 2013, J AM CERAM SOC, V96, P1643, DOI 10.1111/jace.12190
   Pourhashem S, 2014, CERAM INT, V40, P993, DOI 10.1016/j.ceramint.2013.06.096
   Rámila A, 2002, CHEM MATER, V14, P542, DOI 10.1021/cm0110876
   Rau JV, 2012, MATER RES BULL, V47, P1130, DOI 10.1016/j.materresbull.2012.02.011
   Shankhwar N, 2013, AIP CONF PROC, V1536, P209, DOI 10.1063/1.4810174
   Silver IA, 2001, BIOMATERIALS, V22, P175, DOI 10.1016/S0142 9612(00)00173 3
   Siqueira RL, 2013, J MATER SCI MATER M, V24, P365, DOI 10.1007/s10856 012 4797 x
   WILLIAMSON GK, 1953, ACTA METALL MATER, V1, P22, DOI 10.1016/0001 6160(53)90006 6
   Young S.K., 2002, OVERVIEW SOL GEL SCI
   ZANOTTO ED, 1992, J NON CRYST SOLIDS, V147, P820, DOI 10.1016/S0022 3093(05)80723 9
NR 34
TC 19
Z9 19
U1 0
U2 27
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
EI 2046 2069
J9 RSC ADV
JI RSC Adv.
PY 2015
VL 5
IS 122
BP 100762
EP 100768
DI 10.1039/c5ra19184j
PG 7
WC Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry
GA CX3FN
UT WOS:000365581700045
DA 2025 08 17
ER

PT J
AU Ji, XJ
   Gao, L
   Liu, JC
   Jiang, RZ
   Sun, FY
   Cui, LY
   Li, SQ
   Zhi, KQ
   Zeng, RC
   Wang, ZL
AF Ji, Xiao Jing
   Gao, Ling
   Liu, Jia Cheng
   Jiang, Run Zheng
   Sun, Feng Yu
   Cui, Lan Yue
   Li, Shuo Qi
   Zhi, Ke Qian
   Zeng, Rong Chang
   Wang, Zhen Lin
TI Corrosion resistance and antibacterial activity of hydroxyapatite
   coating induced by ciprofloxacin loaded polymeric multilayers on
   magnesium alloy
SO PROGRESS IN ORGANIC COATINGS
LA English
DT Article
DE Magnesium alloy; Corrosion resistance; Antibacterial performance;
   Hydroxyapatite coating; Drug release; Layer by layer assembly
ID STRONTIUM PHOSPHATE COATINGS; IN VITRO CORROSION; HYDROTHERMAL
   TREATMENT; FORMATION MECHANISM; MG 1LI 1CA ALLOY; CYTOCOMPATIBILITY;
   BIODEGRADATION; FABRICATION; ADSORPTION; DEPOSITION
AB Magnesium (Mg) alloys have received increasing interest as innovative orthopedic implants, while the extremely rapid degradation rate and the susceptibility to the infection have limited their medical applications. In this study, a novel hydroxyapatite (HAp) coating induced by ciprofloxacin (CIP) loaded polymeric multilayers was prepared on Mg alloy via the combination of layer by layer (LbL) assembly and hydrothermal treatment. The coated substrates were subjected to various characterization techniques such as X ray diffraction (XRD), scanning electron microscopy (SEM), X ray photoelectron spectroscopy (XPS) and Fourier transform infrared spectroscopy (FT IR) techniques. The corrosion resistance was evaluated by electrochemical and immersion tests. The antibacterial activity was investigated via plate counting method against Staphylococcus aureus (S. aureus) and Escherichia coll. (E. coli). Besides, the cytocompatibility was assessed via an indirect extraction test for MC3T3 E1 pre osteoblasts. The results revealed that the as prepared HAp coating with a compact topography showed favorable corrosion resistance, antibacterial activity and cell compatibility together with a prolonged release profile of CIP.
C1 [Ji, Xiao Jing; Jiang, Run Zheng; Sun, Feng Yu; Cui, Lan Yue; Li, Shuo Qi; Zeng, Rong Chang] Shandong Univ Sci & Technol, Coll Mat Sci & Engn, Qingdao 266590, Shandong, Peoples R China.
   [Gao, Ling; Liu, Jia Cheng; Zhi, Ke Qian] Qingdao Univ, Dept Oral & Maxillofacial Surg, Affiliated Hosp, Qingdao 266000, Shandong, Peoples R China.
   [Gao, Ling; Liu, Jia Cheng; Zhi, Ke Qian] Qingdao Univ, Key Lab Oral Clin Med, Affiliated Hosp, Qingdao 266000, Shandong, Peoples R China.
   [Liu, Jia Cheng] Qingdao Univ, Sch Stomatol, Qingdao 266071, Shandong, Peoples R China.
   [Wang, Zhen Lin] Chongqing Univ Technol, Coll Mat Sci & Engn, Chongqing 400065, Peoples R China.
C3 Shandong University of Science & Technology; Qingdao University; Qingdao
   University; Qingdao University; Chongqing University of Technology
RP Li, SQ; Zeng, RC (通讯作者)，Shandong Univ Sci & Technol, Coll Mat Sci & Engn, Qingdao 266590, Shandong, Peoples R China.; Zhi, KQ (通讯作者)，Qingdao Univ, Dept Oral & Maxillofacial Surg, Affiliated Hosp, Qingdao 266000, Shandong, Peoples R China.
EM lishuoqi@sdust.edu.cn; zhikeqian@sina.com; rczeng@foxmail.com
RI Zeng, Rong Chang/H 4154 2011; Lanyue, Cui/F 3065 2019; Li,
   Shuoqi/K 8932 2012; 李, 硕琦/K 8932 2012; Liu, Jiacheng/GNW 5828 2022
OI Zeng, Rong Chang/0000 0002 5945 3851; Li, Shuoqi/0000 0001 7138 3713; 
FU National Natural Science Foundation of China [51571134]; Shandong
   University of Science and Technology (SDUST) Research Fund
   [2014TDJH104]; Shandong Provincial Natural Science Foundation
   [ZR2017BEM002]
FX This work was supported by the National Natural Science Foundation of
   China (No. 51571134), the Shandong University of Science and Technology
   (SDUST) Research Fund (No. 2014TDJH104) and the Shandong Provincial
   Natural Science Foundation (No. ZR2017BEM002).
CR Arunnellaiappan T, 2018, CERAM INT, V44, P874, DOI 10.1016/j.ceramint.2017.10.014
   Berhane TM, 2016, APPL CLAY SCI, V132, P518, DOI 10.1016/j.clay.2016.07.023
   Chotitumnavee J, 2019, J DENT SCI, V14, P7, DOI 10.1016/j.jds.2018.08.010
   Cui LY, 2019, J MATER SCI TECHNOL, V35, P254, DOI 10.1016/j.jmst.2018.09.052
   Cui LY, 2017, J ALLOY COMPD, V695, P2464, DOI 10.1016/j.jallcom.2016.11.146
   Cui XJ, 2015, CORROS SCI, V90, P402, DOI 10.1016/j.corsci.2014.10.041
   Cui ZY, 2013, CORROS SCI, V76, P243, DOI 10.1016/j.corsci.2013.06.047
   Ding ZY, 2018, J ALLOY COMPD, V764, P250, DOI 10.1016/j.jallcom.2018.06.073
   Elahi MF, 2014, MATERIALS, V7, P2956, DOI 10.3390/ma7042956
   Fang WC, 2016, CRYST GROWTH DES, V16, P1247, DOI 10.1021/acs.cgd.5b01235
   Feng WC, 2016, MAT SCI ENG C MATER, V62, P105, DOI 10.1016/j.msec.2016.01.046
   Palomec Garfias AF, 2018, COLLOID SURFACE A, V549, P13, DOI 10.1016/j.colsurfa.2018.03.070
   Gu XN, 2011, ACTA BIOMATER, V7, P1880, DOI 10.1016/j.actbio.2010.11.034
   HOFFKEN G, 1985, ANTIMICROB AGENTS CH, V27, P375, DOI 10.1128/AAC.27.3.375
   Jayaraj J, 2016, CORROS SCI, V113, P104, DOI 10.1016/j.corsci.2016.10.010
   Ji XJ, 2019, COLLOID SURFACE B, V179, P429, DOI 10.1016/j.colsurfb.2019.04.029
   Kavitha RJ, 2018, J ALLOY COMPD, V745, P725, DOI 10.1016/j.jallcom.2018.02.200
   Kawamoto Y, 1999, J FLUORINE CHEM, V96, P135, DOI 10.1016/S0022 1139(99)00068 8
   Ke C, 2019, CORROS SCI, V151, P143, DOI 10.1016/j.corsci.2019.02.024
   Kim IS, 2004, MAT SCI ENG B SOLID, V111, P232, DOI 10.1016/j.mseb.2004.04.011
   Kumar GS, 2014, J MATER CHEM B, V2, P5052, DOI 10.1039/c4tb00339j
   Li DY, 2017, SURF COAT TECH, V330, P87, DOI 10.1016/j.surfcoat.2017.09.085
   Li LY, 2019, APPL SURF SCI, V465, P1066, DOI 10.1016/j.apsusc.2018.09.203
   Li LY, 2018, ACTA BIOMATER, V79, P23, DOI 10.1016/j.actbio.2018.08.030
   Li Y, 2008, BIOMATERIALS, V29, P2025, DOI 10.1016/j.biomaterials.2008.01.009
   Mao ZW, 2005, J CONTROL RELEASE, V104, P193, DOI 10.1016/j.jconrel.2005.02.005
   Masadeh MM, 2015, CURR THER RES CLIN E, V77, P14, DOI 10.1016/j.curtheres.2014.11.001
   Mhaede M, 2015, MAT SCI ENG C MATER, V50, P24, DOI 10.1016/j.msec.2015.01.093
   Misra DN, 1996, J COLLOID INTERF SCI, V181, P289, DOI 10.1006/jcis.1996.0380
   Sangeetha K, 2017, MAT SCI ENG C MATER, V78, P1046, DOI 10.1016/j.msec.2017.04.154
   Shi ZM, 2011, CORROS SCI, V53, P226, DOI 10.1016/j.corsci.2010.09.016
   Song MS, 2019, J MATER SCI TECHNOL, V35, P535, DOI 10.1016/j.jmst.2018.10.008
   Song Y, 2010, ACTA BIOMATER, V6, P1736, DOI 10.1016/j.actbio.2009.12.020
   Thomas MB, 2016, ELECTROCHIM ACTA, V222, P355, DOI 10.1016/j.electacta.2016.10.186
   Tian P, 2015, COLLOID SURFACE B, V128, P44, DOI 10.1016/j.colsurfb.2015.02.011
   Tomozawa M, 2011, ACTA MATER, V59, P355, DOI 10.1016/j.actamat.2010.09.041
   Xia LG, 2018, CHEM ENG J, V347, P711, DOI 10.1016/j.cej.2018.04.045
   Xu QW, 2017, NANOSCALE, V9, P19245, DOI 10.1039/c7nr07106j
   Yang HW, 2016, J ALLOY COMPD, V672, P366, DOI 10.1016/j.jallcom.2016.02.156
   Yang HW, 2015, INT J MOL SCI, V16, P6113, DOI 10.3390/ijms16036113
   Yang X, 2017, COLLOID SURFACE B, V160, P136, DOI 10.1016/j.colsurfb.2017.09.006
   Yu C, 2018, SURF COAT TECH, V344, P1, DOI 10.1016/j.surfcoat.2018.03.007
   Zeng RC, 2016, ACS APPL MATER INTER, V8, P10014, DOI 10.1021/acsami.6b00527
   Zhang X, 2016, CORROS SCI, V111, P216, DOI 10.1016/j.corsci.2016.05.012
   Zhang YF, 2016, CORROS SCI, V111, P334, DOI 10.1016/j.corsci.2016.05.023
NR 45
TC 59
Z9 63
U1 7
U2 141
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 0300 9440
J9 PROG ORG COAT
JI Prog. Org. Coat.
PD OCT
PY 2019
VL 135
BP 465
EP 474
DI 10.1016/j.porgcoat.2019.06.048
PG 10
WC Chemistry, Applied; Materials Science, Coatings & Films
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Materials Science
GA JX8NZ
UT WOS:000503986800049
DA 2025 08 17
ER

PT J
AU Azim, HA
   Peccatori, FA
   Brohée, S
   Branstetter, D
   Loi, S
   Viale, G
   Piccart, M
   Dougall, WC
   Pruneri, G
   Sotiriou, C
AF Azim, Hatem A., Jr.
   Peccatori, Fedro A.
   Brohee, Sylvain
   Branstetter, Daniel
   Loi, Sherene
   Viale, Giuseppe
   Piccart, Martine
   Dougall, William C.
   Pruneri, Giancarlo
   Sotiriou, Christos
TI RANK ligand (RANKL) expression in young breast cancer patients and
   during pregnancy
SO BREAST CANCER RESEARCH
LA English
DT Article
ID PROLIFERATION; PROGNOSIS; PATHWAYS; BIOLOGY; TUMORIGENESIS; DENOSUMAB;
   CELLS; WOMEN
AB Introduction: RANKL is important in mammary gland development during pregnancy and mediates the initiation and progression of progesterone induced breast cancer. No clinical data are available on the effect of pregnancy on RANK/RANKL expression in young breast cancer patients.
   Methods: We used our previously published dataset of 65 pregnant and 130 matched young breast cancer patients with full clinical, pathological, and survival information. 85% of patients had available transcriptomic data as well. RANK/RANKL expression by immunohistochemistry using H score on the primary tumor and adjacent normal tissue was performed. We examined the difference in expression of RANK/RANKL between pregnant and non pregnant patients and their association with clinicopathological features and prognosis. We also evaluated genes and pathways associated with RANK/RANKL expression on primary tumors.
   Results: RANKL but not RANK expression was more prevalent in the pregnant group, both on the tumor and adjacent normal tissue, independent of other clinicopathological factors (both P < 0.001). 18.7% of pregnant and 5.3% of non pregnant patients had tumors showing >= 10% of cells with 3+ RANKL expression. RANKL expression was significantly higher in progesterone receptor positive, and luminal A like tumors, with negative correlation with Ki 67 (all P < 0.001). On the contrary, RANK expression was higher in triple negative tumors (P < 0.001). Using false discovery rate <0.05, 151 and 1,207 genes were significantly correlated with tumor expressed RANKL and RANK expression by immunohistochemistry, respectively. High RANKL expression within primary tumor was associated with pathways related to mammary gland development, bone resorption, T cell proliferation and regulation of chemotaxis, while RANK expression was associated with immune response and proliferation pathways. At a median follow up of 65 months, neither RANK nor RANKL expression within tumor was associated with disease free survival in pregnant or non pregnant group.
   Conclusions: Pregnancy increases RANKL expression both in normal breast and primary tumors. These results could guide further development of RANKL targeted therapy.
C1 [Azim, Hatem A., Jr.; Brohee, Sylvain; Sotiriou, Christos] Univ Libre Bruxelles, Inst Jules Bordet, Breast Canc Translat Res Lab BCTL JC Heuson, BE 1000 Brussels, Belgium.
   [Azim, Hatem A., Jr.] Univ Libre Bruxelles, Inst Jules Bordet, Dept Med, BrEAST Data Ctr, Brussels 1, Belgium.
   [Peccatori, Fedro A.] European Inst Oncol, Dept Gynecol Oncol, Fertil & Procreat Unit, I 20141 Milan, Italy.
   [Branstetter, Daniel] Amgen Inc, Dept Pathol, Seattle, WA 98119 USA.
   [Loi, Sherene] Peter MacCallum Canc Ctr, Canc Therapeut Program, Translat Breast Canc Genom Lab, East Melbourne, Vic 3002, Australia.
   [Viale, Giuseppe; Pruneri, Giancarlo] European Inst Oncol, Dept Pathol, I 20141 Milan, Italy.
   [Viale, Giuseppe; Pruneri, Giancarlo] Univ Milan, I 20141 Milan, Italy.
   [Piccart, Martine; Sotiriou, Christos] Univ Libre Bruxelles, Inst Jules Bordet, Dept Med Oncol, Brussels 1, Belgium.
   [Dougall, William C.] Amgen Inc, Therapeut Innovat Unit, Seattle, WA 98119 USA.
C3 Universite Libre de Bruxelles; Institut Jules Bordet; Institut Jules
   Bordet; IRCCS European Institute of Oncology (IEO); Amgen; Peter
   Maccallum Cancer Center; IRCCS European Institute of Oncology (IEO);
   University of Milan; Institut Jules Bordet; Amgen
RP Azim, HA (通讯作者)，Univ Libre Bruxelles, Inst Jules Bordet, Breast Canc Translat Res Lab BCTL JC Heuson, Blvd Waterloo 121, BE 1000 Brussels, Belgium.
EM hatem.azim@bordet.be
RI Peccatori, Fedro/AAP 7058 2020; Loi, Sherene/ITT 3863 2023; peccatori,
   fedro/AAP 7058 2020; Viale, Giuseppe/AAE 8921 2019; Loi,
   Sherene/H 1979 2016; Pruneri, Giancarlo/AAC 7767 2022
OI peccatori, fedro/0000 0001 8227 8740; Loi, Sherene/0000 0001 6137 9171;
   Dougall, William/0000 0001 9487 251X; Pruneri,
   Giancarlo/0000 0002 7963 7172
FU IEO
FX Amgen performed RANK and RANKL testing by immunohistochemistry and
   funded the transport of tissue samples from IEO to their laboratories.
   No other funding was provided. Amgen provided input in the
   interpretation of the data, and review of the manuscript.
CR Albrektsen G, 2005, BRIT J CANCER, V92, P167, DOI 10.1038/sj.bjc.6602302
   Andre F, 2013, CLIN CANCER RES, V19, P28, DOI 10.1158/1078 0432.CCR 11 2701
   Asselin Labat ML, 2010, NATURE, V465, P798, DOI 10.1038/nature09027
   Azim H, 2013, EXPERT REV ANTICANC, V13, P195, DOI [10.1586/era.12.177, 10.1586/ERA.12.177]
   Azim HA, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058 014 0427 5
   Azim HA, 2014, ENDOCR RELAT CANCER, V21, P545, DOI 10.1530/ERC 14 0111
   Azim HA, 2012, CANCER TREAT REV, V38, P834, DOI 10.1016/j.ctrv.2012.06.004
   Azim HA, 2012, ACTA ONCOL, V51, P653, DOI 10.3109/0284186X.2011.636069
   Azim HA, 2012, CLIN CANCER RES, V18, P1341, DOI 10.1158/1078 0432.CCR 11 2599
   BENJAMINI Y, 1995, J ROY STAT SOC B, V57, P289, DOI 10.1111/j.2517 6161.1995.tb02031.x
   Brohée S, 2008, NAT PROTOC, V3, P1616, DOI 10.1038/nprot.2008.100
   Cheng ML, 2014, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00329
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Dougall WC, 2012, CLIN CANCER RES, V18, P326, DOI 10.1158/1078 0432.CCR 10 2507
   Gonzalez Suarez E, 2010, NATURE, V468, P103, DOI 10.1038/nature09495
   Haynes BP, 2014, BREAST CANCER RES TR, V148, P327, DOI 10.1007/s10549 014 3181 6
   Hu H, 2014, BREAST CANCER RES TR, V146, P515, DOI 10.1007/s10549 014 3049 9
   Palafox M, 2012, CANCER RES, V72, P2879, DOI 10.1158/0008 5472.CAN 12 0044
   Pfitzner BM, 2014, BREAST CANCER RES TR, V145, P307, DOI 10.1007/s10549 014 2955 1
   Schramek D, 2010, NATURE, V468, P98, DOI 10.1038/nature09387
   Stopeck AT, 2010, J CLIN ONCOL, V28, P5132, DOI 10.1200/JCO.2010.29.7101
   Tan W, 2011, NATURE, V470, P548, DOI 10.1038/nature09707
   Wood CE, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3456
NR 23
TC 148
Z9 153
U1 0
U2 11
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1465 5411
EI 1465 542X
J9 BREAST CANCER RES
JI Breast Cancer Res.
PD FEB 21
PY 2015
VL 17
AR 24
DI 10.1186/s13058 015 0538 7
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA CE3LN
UT WOS:000351727900003
PM 25849336
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Favot, CL
   Forster, C
   Glogauer, M
AF Favot, C. L.
   Forster, C.
   Glogauer, M.
TI The effect of bisphosphonate therapy on neutrophil function: a potential
   biomarker
SO INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY
LA English
DT Article
DE biphosphonates; osteonecrosis; neutrophils; NADPH oxidase; chemotaxis
ID HUMAN POLYMORPHONUCLEAR LEUKOCYTES; LONG TERM EXTENSION;
   RANDOMIZED TRIAL; CIGARETTE SMOKE; OSTEONECROSIS; ALENDRONATE;
   CHEMOTAXIS; JAW; DISCONTINUATION; PERIODONTITIS
AB Bisphosphonate related osteonecrosis of the jaws (BRONJ) occurs subsequent to intravenous and oral bisphosphonate exposure in a small subset of patients. The identification of the pathophysiologic mechanisms has not been fully elucidated. Evidence of concurrent bacterial colonization at sites of bone necrosis, previous reports of neutrophil related complications in some patients taking some bisphosphonates, along with perturbed neutrophil function in bisphosphonate treated mice, suggest an innate immune role in the development of BRONJ. This study investigated neutrophil function in BRONJ patients to determine if neutrophil functional defects may serve as a potential biomarker for BRONJ susceptibility. Two populations were studied: patients with BRONJ and those beginning intravenous pamidronate. Healthy control patients were used for comparison. Twenty three patients with BRONJ and five patients who were beginning pamidronate therapy provided neutrophil samples from the mouth (oral rinses) and from blood. Neutrophils from the population of patients with BRONJ and from those post pamidronate treatment showed lower reactive oxygen species production and impaired chemotaxis relative to controls. These data suggest that a compromise in neutrophil function may be a potential biomarker for BRONJ susceptibility.
C1 [Favot, C. L.] Univ Toronto, Dept Oral & Maxillofacial Surg & Anaesthesia, Toronto, ON M5S 3E2, Canada.
   [Favot, C. L.] Mt Sinai Hosp, Div Oral & Maxillofacial Surg, Toronto, ON M5G 1X5, Canada.
   [Forster, C.; Glogauer, M.] Univ Toronto, Matrix Dynam Grp, Toronto, ON M5S 3E2, Canada.
   [Forster, C.; Glogauer, M.] Univ Toronto, Dept Periodontol, Toronto, ON M5S 3E2, Canada.
   [Glogauer, M.] Univ Toronto, Dent Res Inst, Toronto, ON M5S 3E2, Canada.
   [Glogauer, M.] Univ Toronto, Fac Dent, Toronto, ON M5S 3E2, Canada.
C3 University of Toronto; University of Toronto; Sinai Health System
   Toronto; University of Toronto; University of Toronto; University of
   Toronto; University of Toronto
RP Glogauer, M (通讯作者)，Univ Toronto, Matrix Dynam Grp, Toronto, ON M5S 3E2, Canada.
EM michael.glogauer@utoronto.ca
RI ; Glogauer, Michael/D 2504 2011
OI Glogauer, Michael/0000 0002 6248 5977; 
FU Foundation for Continuing Education and Research (Canadian Association
   of Oral and Maxillofacial Surgeons); Canadian Institutes of Health
   Research
FX This investigation was supported by a Research Grant Award from the
   Foundation for Continuing Education and Research (Canadian Association
   of Oral and Maxillofacial Surgeons) and by a Canadian Institutes of
   Health Research Bone Team Grant (to MG).
CR AMIN D, 1992, J LIPID RES, V33, P1657
   Bamias A, 2005, J CLIN ONCOL, V23, P8580, DOI 10.1200/JCO.2005.02.8670
   Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264 6021:3480241
   Black DM, 2006, JAMA J AM MED ASSOC, V296, P2927, DOI 10.1001/jama.296.24.2927
   BRIDGES RB, 1986, J LEUKOCYTE BIOL, V40, P73, DOI 10.1002/jlb.40.1.73
   Cheretakis C, 2005, BONE MARROW TRANSPL, V36, P227, DOI 10.1038/sj.bmt.1705025
   Colella G, 2009, J ORAL MAXIL SURG, V67, P2698, DOI 10.1016/j.joms.2009.07.097
   CORBERAND J, 1980, INFECT IMMUN, V30, P649
   Ebetino FH, 2011, BONE, V49, P20, DOI 10.1016/j.bone.2011.03.774
   Ensrud KE, 2004, J BONE MINER RES, V19, P1259, DOI 10.1359/JBMR.040326
   Grant BT, 2008, J ORAL MAXIL SURG, V66, P223, DOI 10.1016/j.joms.2007.09.019
   Johnstone AM, 2007, J PERIODONTOL, V78, P1788, DOI 10.1902/jop.2007.070107
   Kantarci A, 2003, J PERIODONTOL, V74, P66, DOI 10.1902/jop.2003.74.1.66
   KENNEY EB, 1977, J PERIODONTAL RES, V12, P227, DOI 10.1111/j.1600 0765.1977.tb00126.x
   Kos M, 2011, MED HYPOTHESES, V77, P214, DOI 10.1016/j.mehy.2011.04.015
   Kuiper JWP, 2012, BRIT J PHARMACOL, V165, P532, DOI 10.1111/j.1476 5381.2011.01592.x
   NIWA Y, 1989, LIFE SCI, V44, P1655, DOI 10.1016/0024 3205(89)90482 7
   NOBES CD, 1995, BIOCHEM SOC T, V23, P456, DOI 10.1042/bst0230456
   Premack BA, 1996, NAT MED, V2, P1174, DOI 10.1038/nm1196 1174
   SASAGAWA S, 1985, J LEUKOCYTE BIOL, V37, P493, DOI 10.1002/jlb.37.5.493
   SCULLY C, 1982, J DENT RES, V61, P636, DOI 10.1177/00220345820610050301
   Sedghizadeh PP, 2009, J AM DENT ASSOC, V140, P61, DOI 10.14219/jada.archive.2009.0019
   Stock JL, 1997, AM J MED, V103, P291, DOI 10.1016/S0002 9343(97)00130 7
   Traidl Hoffmann C, 2002, J ALLERGY CLIN IMMUN, V109, P831, DOI 10.1067/mai.2002.124655
   Witko Sarsat V, 2000, LAB INVEST, V80, P617, DOI 10.1038/labinvest.3780067
   Woo SB, 2006, ANN INTERN MED, V144, P753, DOI 10.7326/0003 4819 144 10 200605160 00009
   Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506
NR 27
TC 20
Z9 25
U1 0
U2 10
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1 3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0901 5027
J9 INT J ORAL MAX SURG
JI Int. J. Oral Maxillofac. Surg.
PD MAY
PY 2013
VL 42
IS 5
BP 619
EP 626
DI 10.1016/j.ijom.2012.12.011
PG 8
WC Dentistry, Oral Surgery & Medicine; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine; Surgery
GA 133IR
UT WOS:000318132600012
PM 23578802
DA 2025 08 17
ER

PT J
AU Pajares Chamorro, N
   Wagley, Y
   Hammer, N
   Hankenson, K
   Chatzistavrou, X
AF Pajares Chamorro, Natalia
   Wagley, Yadav
   Hammer, Neal
   Hankenson, Kurt
   Chatzistavrou, Xanthippi
TI Bioactive glass particles as multi functional therapeutic carriers
   against antibiotic resistant bacteria
SO JOURNAL OF THE AMERICAN CERAMIC SOCIETY
LA English
DT Article
DE antibacterial properties; antibiotic resistance; cell viability; drug
   delivery; methicillin resistant Staphylococcus aureus; silver doped
   bioactive glass; synergism; vancomycin
ID GEL BASED FABRICATION; STAPHYLOCOCCUS AUREUS; ANTIMICROBIAL ACTIVITY;
   MOLECULAR MECHANISMS; BONE; ANTIBACTERIAL; COMPOSITES; VANCOMYCIN;
   DIFFERENTIATION; SUSCEPTIBILITY
AB The development of antibiotic resistance in pathogenic bacteria like Staphylococcus aureus calls for novel approaches to cope with the limited availability of effective antibacterial options. This work aims to develop a site specific drug delivery multifunctional vehicle with the ability to clear resistant bacteria while promoting the healing of the surrounding damaged tissue. The use of silver doped microparticles (Ag BG) is proposed as a platform to deliver vancomycin against MRSA, which under growth arrested conditions exhibits resistance to vancomycin. Ag BG caged vancomycin within the Ca P deposits resulted from the ion exchange between surface and medium, with a loading efficiency higher than 50% after 6 h of uptake. The drug was always released above the minimum inhibitory concentration against MRSA. The Ag BG@vanc conjugate presented strong antibacterial properties against metabolically impaired bacteria, which can tolerate high concentrations of vancomycin. Ag BG@vanc was more lethal for MRSA than Ag BG alone, due to its capability to synergize with antibiotics. The presence of Ca P deposits and antibiotics at the Ag BG surface did not compromise its biological properties since the Ag BG@vanc conjugate still promoted the cell proliferation of human pre osteoblast cells. These properties of multifunctional Ag BG@vanc can provide new hope to fight antibiotic resistance and simultaneously promote bone regeneration holding great potential.
C1 [Pajares Chamorro, Natalia; Chatzistavrou, Xanthippi] Michigan State Univ, Coll Engn, Dept Chem Engn & Mat Sci, E Lansing, MI 48824 USA.
   [Wagley, Yadav; Hankenson, Kurt] Univ Michigan, Sch Med, Dept Orthopaed Surg, Ann Arbor, MI 48109 USA.
   [Hammer, Neal] Michigan State Univ, Dept Microbiol & Mol Genet, E Lansing, MI 48824 USA.
C3 Michigan State University; University of Michigan System; University of
   Michigan; Michigan State University
RP Chatzistavrou, X (通讯作者)，Dept Chem Engn & Mat Sci, Engn Bldg,428 S Shaw Lane, E Lansing, MI 48824 USA.
EM chatzist@msu.edu
RI ; Hankenson, Kurt/ABI 1547 2020
OI Chatzistavrou, Xanthippi/0000 0001 5340 0153; 
FU OPIP of the NIH [P40OD011050]
FX OPIP of the NIH, Grant/Award Number: P40OD011050
CR Allahverdiyev AM, 2011, EXPERT REV ANTI INFE, V9, P1035, DOI [10.1586/eri.11.121, 10.1586/ERI.11.121]
   Arciola CR, 2015, ADV EXP MED BIOL, V830, P29, DOI 10.1007/978 3 319 11038 7_2
   Barberán J, 2006, CLIN MICROBIOL INFEC, V12, P93, DOI 10.1111/j.1469 0691.2006.01400.x
   Bax R, 2001, CLIN MICROBIOL INFEC, V7, P316, DOI 10.1046/j.1198 743x.2001.00239.x
   Brady RA, 2008, FEMS IMMUNOL MED MIC, V52, P13, DOI 10.1111/j.1574 695X.2007.00357.x
   Breukink E, 1999, SCIENCE, V286, P2361, DOI 10.1126/science.286.5448.2361
   Brooks BD, 2014, ADV DRUG DELIVER REV, V78, P14, DOI 10.1016/j.addr.2014.10.027
   Campoccia D, 2006, BIOMATERIALS, V27, P2331, DOI 10.1016/j.biomaterials.2005.11.044
   Chakraborty SP, 2012, INT J PHARMACEUT, V436, P659, DOI 10.1016/j.ijpharm.2012.07.033
   Chambers HF, 2001, EMERG INFECT DIS, V7, P178, DOI 10.3201/eid0702.010204
   Chatzistavrou X, 2010, MAT SCI ENG C MATER, V30, P730, DOI 10.1016/j.msec.2010.03.005
   Chatzistavrou X., 2012, MRS Proc, V1417, DOI [DOI 10.1557/OPL.2012.743, DOI 10.1557/opl.2012.743]
   Chatzistavrou X, 2016, J NON CRYST SOLIDS, V432, P143, DOI 10.1016/j.jnoncrysol.2015.03.024
   Chatzistavrou X, 2014, ACTA BIOMATER, V10, P3723, DOI 10.1016/j.actbio.2014.04.030
   Chatzistavrou X, 2012, J EUR CERAM SOC, V32, P3051, DOI 10.1016/j.jeurceramsoc.2012.04.037
   Cunningham R, 1996, J MED MICROBIOL, V44, P157, DOI 10.1099/00222615 44 3 157
   D'Costa VM, 2006, SCIENCE, V311, P374, DOI 10.1126/science.1120800
   Davey ME, 2000, MICROBIOL MOL BIOL R, V64, P847, DOI 10.1128/MMBR.64.4.847 867.2000
   Davies D, 2003, NAT REV DRUG DISCOV, V2, P114, DOI 10.1038/nrd1008
   Desrousseaux C, 2013, J HOSP INFECT, V85, P87, DOI 10.1016/j.jhin.2013.06.015
   Detsch R, 2015, J TISSUE ENG REGEN M, V9, P1133, DOI 10.1002/term.1851
   Dibrov P, 2002, ANTIMICROB AGENTS CH, V46, P2668, DOI 10.1128/AAC.46.8.2668 2670.2002
   Dongari Bagtzoglou A, 2008, EXPERT REV ANTI INFE, V6, P201, DOI 10.1586/14787210.6.2.201
   Dufrane D, 2003, J MATER SCI MATER M, V14, P33, DOI 10.1023/A:1021545302732
   Edwards R, 2004, CURR OPIN INFECT DIS, V17, P91, DOI 10.1097/00001432 200404000 00004
   Eriksen EF, 2010, REV ENDOCR METAB DIS, V11, P219, DOI 10.1007/s11154 010 9153 1
   Fey PD, 2013, MBIO, V4, DOI 10.1128/mBio.00537 12
   Fischbach MA, 2011, CURR OPIN MICROBIOL, V14, P519, DOI 10.1016/j.mib.2011.08.003
   Foster TJ, 2017, FEMS MICROBIOL REV, V41, P430, DOI 10.1093/femsre/fux007
   Geng Z, 2021, BIOACT MATER, V6, P905, DOI 10.1016/j.bioactmat.2020.09.024
   He YF, 2013, BIOL TRACE ELEM RES, V152, P292, DOI 10.1007/s12011 013 9605 z
   Hench LL, 2004, J BIOMAT SCI POLYM E, V15, P543, DOI 10.1163/156856204323005352
   Hiramatsu K, 1998, DRUG RESIST UPDATE, V1, P135, DOI 10.1016/S1368 7646(98)80029 0
   Howden BP, 2010, CLIN MICROBIOL REV, V23, P99, DOI 10.1128/CMR.00042 09
   Huang DQ, 2020, REGEN BIOMATER, V7, P303, DOI 10.1093/rb/rbaa004
   Jia P, 2012, J ORTHOP RES, V30, P1843, DOI 10.1002/jor.22133
   Jo JH, 2009, J BIOMED MATER RES B, V91B, P213, DOI 10.1002/jbm.b.31392
   Jones ME, 1999, ANTIMICROB AGENTS CH, V43, P421, DOI 10.1128/AAC.43.2.421
   Klomparens KarenL., 1986, PROCEDURES TRANSMISS
   Labruère R, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01121
   Lok CN, 2006, J PROTEOME RES, V5, P916, DOI 10.1021/pr0504079
   Lowy FD, 1998, NEW ENGL J MED, V339, P520, DOI 10.1056/NEJM199808203390806
   Lu HH, 2000, J BIOMED MATER RES, V51, P80, DOI 10.1002/(SICI)1097 4636(200007)51:1<80::AID JBM11>3.0.CO;2 6
   Maeno S, 2005, BIOMATERIALS, V26, P4847, DOI 10.1016/j.biomaterials.2005.01.006
   Magill SS, 2014, NEW ENGL J MED, V370, P1198, DOI 10.1056/NEJMoa1306801
   Marsh AC, 2019, WOODH PUBL SER BIOM, P379, DOI 10.1016/B978 0 08 102451 5.00015 9
   Matsumura Y, 2003, APPL ENVIRON MICROB, V69, P4278, DOI 10.1128/AEM.69.7.4278 4281.2003
   Miola M, 2013, J BIOMATER APPL, V28, P308, DOI 10.1177/0885328212447665
   Misra SK, 2010, J R SOC INTERFACE, V7, P453, DOI 10.1098/rsif.2009.0255
   Morones JR, 2005, NANOTECHNOLOGY, V16, P2346, DOI 10.1088/0957 4484/16/10/059
   Olson ME, 2002, CAN J VET RES, V66, P86
   Ovington L.G., 2004, OSTOMY WOUND MANAGE, V50, p1S
   Pajares Chamorro N, 2021, MAT SCI ENG C MATER, V120, DOI 10.1016/j.msec.2020.111693
   Pajares Chamorro N, 2019, ACTA BIOMATER, V96, P537, DOI 10.1016/j.actbio.2019.07.012
   Raggatt LJ, 2010, J BIOL CHEM, V285, P25103, DOI 10.1074/jbc.R109.041087
   Reffitt DM, 2003, BONE, V32, P127, DOI 10.1016/S8756 3282(02)00950 X
   Reidy B, 2013, MATERIALS, V6, P2295, DOI 10.3390/ma6062295
   REYNOLDS PE, 1989, EUR J CLIN MICROBIOL, V8, P943, DOI 10.1007/BF01967563
   Rivadeneira J, 2014, J APPL MICROBIOL, V116, P1438, DOI 10.1111/jam.12476
   Rivadeneira J., 2015, Biomed. Glas, V1, DOI [10.1515/bglass 2015 0012, DOI 10.1515/BGLASS 2015 0012]
   Morones Ramirez JR, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006276
   Saravanapavan P, 2004, KEY ENG MATER, V254 2, P1087, DOI 10.4028/www.scientific.net/KEM.254 256.1087
   Sepulveda P, 2001, J BIOMED MATER RES, V58, P734, DOI 10.1002/jbm.10026
   Shahverdi AR, 2007, NANOMED NANOTECHNOL, V3, P168, DOI 10.1016/j.nano.2007.02.001
   Sieradzki R, 1999, J BIOL CHEM, V274, P18942, DOI 10.1074/jbc.274.27.18942
   Soundrapandian C, 2014, J MECH BEHAV BIOMED, V40, P1, DOI 10.1016/j.jmbbm.2014.08.007
   Stigter M, 2004, J CONTROL RELEASE, V99, P127, DOI 10.1016/j.jconrel.2004.06.011
   Vallet Regí M, 2011, ADV MATER, V23, P5177, DOI 10.1002/adma.201101586
   van Gestel NAP, 2019, J MATER SCI MATER M, V30, DOI 10.1007/s10856 019 6295 x
   Walsh C, 2000, NATURE, V406, P775, DOI 10.1038/35021219
   World Health Organisation, 2017, WORLD HEAL ORGAN, V1
   Wu CT, 2014, J CONTROL RELEASE, V193, P282, DOI 10.1016/j.jconrel.2014.04.026
   ZAIDI M, 1993, EXP PHYSIOL, V78, P721, DOI 10.1113/expphysiol.1993.sp003721
NR 73
TC 8
Z9 9
U1 0
U2 13
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0002 7820
EI 1551 2916
J9 J AM CERAM SOC
JI J. Am. Ceram. Soc.
PD MAR
PY 2022
VL 105
IS 3
BP 1778
EP 1789
DI 10.1111/jace.17923
EA JUN 2021
PG 12
WC Materials Science, Ceramics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA YD0ZM
UT WOS:000659471900001
OA Green Published
DA 2025 08 17
ER

PT J
AU Lakkireddy, C
   Vishwakarma, SK
   Bardia, A
   Raju, N
   Ahmed, SI
   Fathima, SM
   Annamaneni, S
   Khan, AA
AF Lakkireddy, Chandrakala
   Vishwakarma, Sandeep Kumar
   Bardia, Avinash
   Raju, Nagarapu
   Ahmed, Shaik Iqbal
   Fathima, Syeda Maliha
   Annamaneni, Sandhya
   Khan, Aleem Ahmed
TI Biofabrication of allogenic bone grafts using cellularized amniotic
   scaffolds for application in efficient bone healing
SO TISSUE & CELL
LA English
DT Article
DE Bone healing; Mesenchymal stem cells; Osteoblasts; Decellularized
   amniotic scaffolds; Allogenic bone grafts
ID STEM CELLS; MEMBRANE SCAFFOLD; MATRIX; THERAPY; DECELLULARIZATION;
   ALLOGRAFTS; CYTOKINES; COLLAGEN; ORIGIN; GROWTH
AB Introduction: The reconstruction/regeneration of human bone injuries/defects represents a crucial challenge due to the lack of suitable bio/immune compatible and implantable biological grafts. The available strategies represent implications of several types of grafting materials in the form of metals, synthetic, and various kinds of biological scaffolds; however, the lack of appropriate biological components required for activating and enhancing repair mechanisms at the lesion site limits their wider applicability. Methods: In this study, a unique approach for generating human osteogenic implantable grafts was developed using biofabrication technology. Using a gradient change of detergents and continuous agitation, developed a unique technique to generate completely cell free amnion and chorion scaffolds. The absence of cellular components and integrity of biological and mechanical cues within decellularized human amnion (D HAM) and chorion (D HCM) were evaluated and compared with fresh membranes. Allogenic bone grafts were prepared through induction of human mesenchymal stem cells (hMSCs) into osteogenic cells on D HAM and D HCM and evaluated for their comparative behavior at the cellular, histological and molecular levels. Results: The common decellularization process resulted in an efficient way to generate D HAM and D HCM while retaining their intact gross anatomical architecture, surface morphology, extracellular matrix components, and mechanical properties. Both these scaffolds supported better growth of human umbilical cord blood derived MSCs as well as osteogenic differentiation. Comparative investigation revealed better growth rate and differentiation on D HCM compared to D HAM and control conditions. Conclusion: D HCM could be used as a better choice for producing suitable allogenic bone grafts for efficient bone healing applications.
C1 [Lakkireddy, Chandrakala; Vishwakarma, Sandeep Kumar; Bardia, Avinash; Raju, Nagarapu; Ahmed, Shaik Iqbal; Khan, Aleem Ahmed] Deccan Coll Med Sci, Ctr Liver Res & Diagnost, Cent Lab Stem Cell Res & Translat Med, Hyderabad 500058, Telangana, India.
   [Fathima, Syeda Maliha] Deccan Coll Med Sci, Dept Gynecol, Hyderabad 500058, Telangana, India.
   [Annamaneni, Sandhya] Osmania Univ, Dept Genet, Hyderabad 500007, Telangana, India.
C3 Osmania University
RP Khan, AA (通讯作者)，Deccan Coll Med Sci, Ctr Liver Res & Diagnost, Cent Lab Stem Cell Res & Translat Med, Hyderabad 500058, Telangana, India.
EM aleem_a_khan@rediffmail.com
RI ANNAMANENI, SANDHYA/AFL 5108 2022; Vishwakarma, Dr. Sandeep
   Kumar/ADU 4497 2022
OI Nagarapu, Raju/0000 0001 9264 007X; Annamaneni,
   Sandhya/0000 0001 9420 5952
CR Badylak SF, 2011, ANNU REV BIOMED ENG, V13, P27, DOI 10.1146/annurev bioeng 071910 124743
   Baldwin P, 2019, J ORTHOP TRAUMA, V33, P203, DOI 10.1097/BOT.0000000000001420
   Barrientos S, 2008, WOUND REPAIR REGEN, V16, P585, DOI 10.1111/j.1524 475X.2008.00410.x
   Bloom W., 1986, Textbook of histology
   Bozzola J.J., 1998, Electron Microscopy Principles and Techniques for Biologists, V3nd
   Bracey DN, 2018, J FUNCT BIOMATER, V9, DOI 10.3390/jfb9030045
   Castro Silva II, 2011, EINSTEIN SAO PAULO, V9, P449, DOI [10.1590/S1679 45082011AO2196, 10.1590/s1679 45082011ao2196]
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Dobreva MP, 2010, INT J DEV BIOL, V54, P761, DOI 10.1387/ijdb.092935md
   Efron PA, 2004, J BURN CARE REHABIL, V25, P149, DOI 10.1097/01.BCR.0000111766.97335.34
   Francisco JC, 2016, TRANSPL P, V48, P2845, DOI 10.1016/j.transproceed.2016.07.026
   Fukuda K, 1999, CORNEA, V18, P73, DOI 10.1097/00003226 199901000 00013
   Garoufalis M, 2018, J AM PODIAT MED ASSN, V108, P84, DOI 10.7547/17 039
   Gholipourmalekabadi M, 2015, ADV HEALTHC MATER, V4, P918, DOI 10.1002/adhm.201400704
   Greco SJ, 2007, STEM CELLS, V25, P3143, DOI 10.1634/stemcells.2007 0351
   Guo QC, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/306083
   Hasan Osamah, 2019, Case Rep Obstet Gynecol, V2019, P1920430, DOI 10.1155/2019/1920430
   Ho Shui Ling A, 2018, BIOMATERIALS, V180, P143, DOI 10.1016/j.biomaterials.2018.07.017
   Jeon HJ, 2020, STEM CELL REV REP, V16, P596, DOI 10.1007/s12015 020 09958 9
   Jie J, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 24694 4
   Kannaiyan J., 2016, International Journal of Research in Medical Sciences, V4, P3654, DOI [DOI 10.18203/2320 6012.IJRMS, 10.18203/2320 6012.ijrms20162206, DOI 10.18203/2320 6012.IJRMS20162206]
   Khalil S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167116
   Koob TJ, 2013, INT WOUND J, V10, P493, DOI 10.1111/iwj.12140
   Krishnamurithy G, 2011, J BIOMED MATER RES A, V99A, P500, DOI 10.1002/jbm.a.33184
   Lei J, 2017, TECH ORTHOP, V32, P149, DOI 10.1097/BTO.0000000000000229
   Li JJ, 2018, ADV HEALTHC MATER, V7, DOI 10.1002/adhm.201701061
   Liu JB, 2010, EXPERT REV OPHTHALMO, V5, P645, DOI 10.1586/EOP.10.63
   Lyons Alexis B, 2018, JAAD Case Rep, V4, P688, DOI 10.1016/j.jdcr.2018.03.015
   MALAK TM, 1993, PLACENTA, V14, P385, DOI 10.1016/S0143 4004(05)80460 6
   Mansour A, 2017, TISSUE ENG PT A, V23, P1436, DOI [10.1089/ten.tea.2017.0026, 10.1089/ten.TEA.2017.0026]
   Maraldi T, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt203
   Martínez ME, 1999, CALCIFIED TISSUE INT, V64, P280, DOI 10.1007/s002239900619
   Mendibil U, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21155447
   Niknejad H, 2008, EUR CELLS MATER, V15, P88
   Orciani M, 2017, FRONT BIOENG BIOTECH, V5, DOI 10.3389/fbioe.2017.00017
   Oryan A, 2014, J ORTHOP SURG RES, V9, DOI 10.1186/1749 799X 9 18
   Pak JY, 2019, OSTEOARTHR CARTILAGE, V27, pS511, DOI 10.1016/j.joca.2019.02.581
   Pati F, 2015, BIOMATERIALS, V37, P230, DOI 10.1016/j.biomaterials.2014.10.012
   Portal Núñez S, 2012, HISTOL HISTOPATHOL, V27, P559, DOI 10.14670/HH 27.559
   Qin L, 2015, BIOMATERIALS, V59, P125, DOI 10.1016/j.biomaterials.2015.04.038
   Riboh JC, 2016, AM J SPORT MED, V44, P2425, DOI 10.1177/0363546515612750
   Sabapathy V, 2016, J BIOMATER TISS ENG, V6, P549, DOI 10.1166/jbt.2016.1480
   Saghazadeh S, 2018, ADV DRUG DELIVER REV, V127, P138, DOI 10.1016/j.addr.2018.04.008
   Saghizadeh M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079632
   Sanluis Verdes A, 2015, CELL TISSUE BANK, V16, P411, DOI 10.1007/s10561 014 9485 2
   Schemitsch EH, 2017, J ORTHOP TRAUMA, V31, pS20, DOI 10.1097/BOT.0000000000000978
   Schneider KH, 2016, ACTA BIOMATER, V29, P125, DOI 10.1016/j.actbio.2015.09.038
   Shao HG, 2015, BIOMATERIALS, V60, P92, DOI 10.1016/j.biomaterials.2015.04.048
   Tenenhaus M, 2017, ANN PLAS SURG, V78, pS11, DOI 10.1097/SAP.0000000000000983
   Ballesteros ACV, 2020, POLYMERS BASEL, V12, DOI 10.3390/polym12030590
   Vishwakarma SK, 2020, TISSUE CELL, V67, DOI 10.1016/j.tice.2020.101443
   Vishwakarma SK, 2019, CELL MOL BIOENG, V12, P569, DOI 10.1007/s12195 019 00586 z
   Vishwakarma SK, 2019, MAT SCI ENG C MATER, V98, P861, DOI 10.1016/j.msec.2019.01.045
   Vishwakarma SK, 2018, FRONT BIOENG BIOTECH, V6, DOI 10.3389/fbioe.2018.00150
   Wang WH, 2017, BIOACT MATER, V2, P224, DOI 10.1016/j.bioactmat.2017.05.007
   Wilshaw SP, 2006, TISSUE ENG, V12, P2117, DOI 10.1089/ten.2006.12.2117
   Wu JJ, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287 016 0437 6
   You HJ, 2015, CYTOTHERAPY, V17, P1506, DOI 10.1016/j.jcyt.2015.06.011
   Zelen C.M., 2014, Wound Med, V4, P1, DOI [10.1016/j.wndm.2013.10.008, DOI 10.1016/J.WNDM.2013.10.008]
   ZHANG L, 2016, SCI REP UK, V6, P1, DOI DOI 10.1038/S41598 016 0001 8
NR 60
TC 4
Z9 5
U1 0
U2 6
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1 3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0040 8166
J9 TISSUE CELL
JI Tissue Cell
PD DEC
PY 2021
VL 73
AR 101631
DI 10.1016/j.tice.2021.101631
EA AUG 2021
PG 12
WC Anatomy & Morphology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Anatomy & Morphology; Cell Biology
GA XT1VE
UT WOS:000733382500002
PM 34461569
DA 2025 08 17
ER

PT J
AU Yu, Z
   Sanders, AJ
   Owen, S
   Cheng, S
   Yang, XM
   Jiang, WG
AF Yu, Zhen
   Sanders, Andrew J.
   Owen, Sioned
   Cheng, Shan
   Yang, Xiaomei
   Jiang, Wen G.
TI Expression of Osteoprotegrin Is Enhanced in Lung Cancer Tissues and
   Promotes Aggressive Cellular Traits in H3122 Lung Cancer Cells
SO ANTICANCER RESEARCH
LA English
DT Article; Proceedings Paper
CT China United Kingdom Cancer (CUKC) Conference
CY APR 22 23, 2017
CL Beijing Friendship Hosp, Beijing, PEOPLES R CHINA
SP Capital Med Univ, Peking Univ, Cardiff Univ, Royal Soc Med
HO Beijing Friendship Hosp
DE OPG; lung cancer; H3122; cell function
ID HUMAN PROSTATE CANCER; INDUCED APOPTOSIS; SURVIVAL FACTOR;
   BREAST CANCER; RANK LIGAND; OPG; RECEPTORS; MARKERS
AB Background: Osteoprotegrin (OPG), a secreted protein and a member of the tumor necrosis factor receptor superfamily has been well characterized and is an important regulator of bone remodeling by blocking osteoclast maturation thus preventing osteolysis. In recent years, OPG has been reported to have an association with the malignant capacity of various cancer types and cancer associated bone metastasis, although the mechanisms of this are not clearly understood. Materials and Methods: In this study, OPG expression was analyzed in human lung cancer tissue and normal tissue based on the dataset of The Cancer Genome Atlas and Oncomine. The in vitro effect of OPG on H3122 lung cancer cells was also assessed by characterizing cell function following knock down and forced overexpression in this cell line. Results: The expression of OPG was significantly increased in lung cancer tissues compared to the normal control group and OPG promoted the malignant phenotypes of H3122 cells in in vitro models. Conclusion: OPG may be a potential driver of lung cancer cells and therefore might have potential in therapy and diagnostics.
C1 [Yu, Zhen; Cheng, Shan; Yang, Xiaomei; Jiang, Wen G.] Capital Med Univ, Dept Biochem & Mol Biol, Sch Basic Med Sci, Beijing, Peoples R China.
   [Yu, Zhen; Cheng, Shan; Yang, Xiaomei; Jiang, Wen G.] Capital Med Univ, Beijing Key Lab Canc & Metastasis Res, Beijing 100069, Peoples R China.
   [Yu, Zhen; Sanders, Andrew J.; Owen, Sioned; Jiang, Wen G.] Cardiff Univ, Sch Med, Cardiff China Med Res Collaborat, Heath Pk, Cardiff CF14 4XN, S Glam, Wales.
C3 Capital Medical University; Capital Medical University; Cardiff
   University
RP Yang, XM (通讯作者)，Capital Med Univ, Beijing Key Lab Canc & Metastasis Res, Beijing 100069, Peoples R China.; Jiang, WG (通讯作者)，Cardiff Univ, Sch Med, Cardiff China Med Res Collaborat, Heath Pk, Cardiff CF14 4XN, S Glam, Wales.
EM XMYang126@126.com; jiangw@cf.ac.uk
RI Jiang, Wen G./B 1293 2010; , firhill/HGE 6886 2022; Jiang,
   Wen/AAF 1876 2020
OI Jiang, Wen G./0000 0002 3283 1111; Sanders, Andrew/0000 0002 7997 5286; 
FU Capital Medical University; Cancer Research Wales; Cardiff University
   China Medical Scholarship
FX The Authors wish to express their heartfelt gratitude to Capital Medical
   University; Cancer Research Wales and Cardiff University China Medical
   Scholarship for supporting this work.
CR Baud'huin M, 2013, CYTOKINE GROWTH F R, V24, P401, DOI 10.1016/j.cytogfr.2013.06.001
   Benslimane Ahmim Z, 2017, CANCER LETT, V395, P11, DOI 10.1016/j.canlet.2017.02.032
   Brown JM, 2001, UROLOGY, V57, P611, DOI 10.1016/S0090 4295(00)01122 5
   Bucay N, 1998, GENE DEV, V12, P1260, DOI 10.1101/gad.12.9.1260
   Chen G, 2006, CANCER AM CANCER SOC, V107, P289, DOI 10.1002/cncr.21978
   De Toni EN, 2008, CLIN CANCER RES, V14, P4713, DOI 10.1158/1078 0432.CCR 07 5019
   Eaton CL, 2004, PROSTATE, V59, P304, DOI 10.1002/pros.20016
   Higgs JT, 2015, MOL CANCER RES, V13, P819, DOI 10.1158/1541 7786.MCR 14 0492
   Holen I, 2002, CANCER RES, V62, P1619
   Holen I, 2006, CLIN SCI, V110, P279, DOI 10.1042/CS20050175
   Jung K, 2004, INT J CANCER, V111, P783, DOI 10.1002/ijc.20314
   Khosla S, 2001, ENDOCRINOLOGY, V142, P5050, DOI 10.1210/en.142.12.5050
   Kobayashi Sakamoto M, 2008, MICROVASC RES, V76, P139, DOI 10.1016/j.mvr.2008.06.004
   Kobayashi Sakamoto M, 2010, EUR J HAEMATOL, V85, P26, DOI 10.1111/j.1600 0609.2010.01446.x
   Lane D, 2012, J OVARIAN RES, V5, DOI 10.1186/1757 2215 5 34
   Lu CJ, 2016, ONCOL LETT, V11, P2261, DOI 10.3892/ol.2016.4166
   Maginn EN, 2011, BRIT J CANCER, V104, P281, DOI 10.1038/sj.bjc.6606035
   Malyankar UM, 2000, J BIOL CHEM, V275, P20959, DOI 10.1074/jbc.C000290200
   Neville Webbe HL, 2004, BREAST CANCER RES TR, V86, P269
   Owen S, 2016, INT J ONCOL, V48, P919, DOI 10.3892/ijo.2016.3339
   Popper HH, 2016, CANCER METAST REV, V35, P75, DOI 10.1007/s10555 016 9618 0
   Reck M, 2013, LANCET, V382, P709, DOI 10.1016/S0140 6736(13)61502 0
   Reid P, 2009, EUR J CELL BIOL, V88, P1, DOI 10.1016/j.ejcb.2008.06.004
   Schoppet M, 2002, ARTERIOSCL THROM VAS, V22, P549, DOI 10.1161/01.ATV.0000012303.37971.DA
   Shi WC, 2014, BIOSCI TRENDS, V8, P322, DOI 10.5582/bst.2014.01092
   Truneh A, 2000, J BIOL CHEM, V275, P23319, DOI 10.1074/jbc.M910438199
   Wang SL, 2003, ONCOGENE, V22, P8628, DOI 10.1038/sj.onc.1207232
   Weichhaus M, 2015, MOL CANCER, V14, DOI 10.1186/s12943 015 0390 5
   Zang LY, 2015, SCI REP UK, V5, DOI 10.1038/srep18324
NR 29
TC 5
Z9 6
U1 0
U2 8
PU INT INST ANTICANCER RESEARCH
PI ATHENS
PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU KALAMOU RD KAPANDRITI, PO BOX 22,
   ATHENS 19014, GREECE
SN 0250 7005
EI 1791 7530
J9 ANTICANCER RES
JI Anticancer Res.
PD AUG
PY 2017
VL 37
IS 8
BP 4277
EP 4283
DI 10.21873/anticanres.11820
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC Oncology
GA FJ2SF
UT WOS:000412579000038
PM 28739719
OA Bronze, Green Accepted
DA 2025 08 17
ER

PT J
AU Sheen, CR
   Kuss, P
   Narisawa, S
   Yadav, MC
   Nigro, J
   Wang, W
   Chhea, TN
   Sergienko, EA
   Kapoor, K
   Jackson, MR
   Hoylaerts, MF
   Pinkerton, AB
   O'Neill, WC
   Millán, JL
AF Sheen, Campbell R.
   Kuss, Pia
   Narisawa, Sonoko
   Yadav, Manisha C.
   Nigro, Jessica
   Wang, Wei
   Chhea, T. Nicole
   Sergienko, Eduard A.
   Kapoor, Kapil
   Jackson, Michael R.
   Hoylaerts, Marc F.
   Pinkerton, Anthony B.
   O'Neill, W. Charles
   Millan, Jose Luis
TI Pathophysiological Role of Vascular Smooth Muscle Alkaline Phosphatase
   in Medial Artery Calcification
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE GENETIC ANIMAL MODELS; PRECLINICAL STUDIES; MATRIX MINERALIZATION;
   THERAPEUTICS
ID ENZYME REPLACEMENT THERAPY; EXTRACELLULAR PYROPHOSPHATE METABOLISM; CELL
   MEMBRANE GLYCOPROTEIN 1; AORTIC CALCIFICATION; INFANTILE
   HYPOPHOSPHATASIA; INORGANIC PYROPHOSPHATE; BONE; PLASMA; MINERALIZATION;
   GENES
AB Medial vascular calcification (MVC) is a pathological phenomenon that causes vascular stiffening and can lead to heart failure; it is common to a variety of conditions, including aging, chronic kidney disease, diabetes, obesity, and a variety of rare genetic diseases. These conditions share the common feature of tissue nonspecific alkaline phosphatase (TNAP) upregulation in the vasculature. To evaluate the role of TNAP in MVC, we developed a mouse model that overexpresses human TNAP in vascular smooth muscle cells in an X linked manner. Hemizygous overexpressor male mice (Tagln Cre(+/ ); Hprt(ALPL/Y) or TNAP OE) show extensive vascular calcification, high blood pressure, and cardiac hypertrophy, and have a median age of death of 44 days, whereas the cardiovascular phenotype is much less pronounced and life expectancy is longer in heterozygous (Tagln Cre(+/ ); Hprt(ALPL/ )) female TNAP OE mice. Gene expression analysis showed upregulation of osteoblast and chondrocyte markers and decreased expression of vascular smooth muscle markers in the aortas of TNAP OE mice. Through medicinal chemistry efforts, we developed inhibitors of TNAP with drug like pharmacokinetic characteristics. TNAP OE mice were treated with the prototypical TNAP inhibitor SBI 425 or vehicle to evaluate the feasibility of TNAP inhibition in vivo. Treatment with this inhibitor significantly reduced aortic calcification and cardiac hypertrophy, and extended lifespan over vehicle treated controls, in the absence of secondary effects on the skeleton. This study shows that TNAP in the vasculature contributes to the pathology of MVC and that it is a druggable target. (c) 2015 American Society for Bone and Mineral Research.
C1 [Sheen, Campbell R.; Kuss, Pia; Narisawa, Sonoko; Yadav, Manisha C.; Wang, Wei; Chhea, T. Nicole; Millan, Jose Luis] Sanford Burnham Med Res Inst, Sanford Childrens Hlth Res Ctr, La Jolla, CA 92037 USA.
   [Nigro, Jessica; Kapoor, Kapil] Sanford Burnham Med Res Inst Lake Nona, Cardiometab Phenotyping Core, Orlando, FL USA.
   [Sergienko, Eduard A.; Jackson, Michael R.; Pinkerton, Anthony B.] Sanford Burnham Med Res Inst, Conrad Prebys Ctr Chem Genom, La Jolla, CA 92037 USA.
   [Hoylaerts, Marc F.] Univ Leuven, Dept Cardiovasc Sci, Ctr Mol & Vasc Biol, Leuven, Belgium.
   [O'Neill, W. Charles] Emory Univ, Sch Med, Div Renal, Atlanta, GA 30322 USA.
C3 Sanford Burnham Prebys Medical Discovery Institute; Sanford Burnham
   Prebys Medical Discovery Institute; Sanford Burnham Prebys Medical
   Discovery Institute; KU Leuven; Emory University
RP Millán, JL (通讯作者)，Sanford Burnham Med Res Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.
EM millan@sanfordburnham.org
RI ; Millan, Jose Luis/LXU 4378 2024
OI Pinkerton, Anthony/0000 0003 4571 152X; Hoylaerts,
   Marc/0000 0002 6474 3933
FU NIH [X01MH077602, RC1HL101899, DE012889, AG045933]; American Heart
   Association Postdoctoral Fellowship; German Research Foundation (DFG)
FX This work was supported in part by grants from the NIH (X01MH077602,
   RC1HL101899, DE012889, and AG045933). CRS is the recipient of an
   American Heart Association Postdoctoral Fellowship. PK is the recipient
   of a Research Fellowship from the German Research Foundation (DFG). We
   thank Diana Sandoval from the Animal Facility at SBMRI La Jolla for her
   help with animal breeding and injections. We also thank John Shelley of
   the Histology Core Facility at SBMRI Lake Nona, and the staff of the
   Histopathology Core Facility at SBMRI La Jolla for their help with the
   embedding and sectioning of specimens.
CR Blacher J, 2001, HYPERTENSION, V38, P938, DOI 10.1161/hy1001.096358
   Coburn SP, 1998, J CLIN ENDOCR METAB, V83, P3951, DOI 10.1210/jc.83.11.3951
   Dahl R, 2009, J MED CHEM, V52, P6919, DOI 10.1021/jm900383s
   El Maadawy S, 2003, CONNECT TISSUE RES, V44, P272, DOI 10.1080/03008200390181762
   Fedde KN, 1999, J BONE MINER RES, V14, P2015, DOI 10.1359/jbmr.1999.14.12.2015
   Hessle L, 2002, P NATL ACAD SCI USA, V99, P9445, DOI 10.1073/pnas.142063399
   Holtwick R, 2002, P NATL ACAD SCI USA, V99, P7142, DOI 10.1073/pnas.102650499
   Johnson K, 1999, ARTHRITIS RHEUM US, V42, P1986, DOI 10.1002/1529 0131(199909)42:9<1986::AID ANR26>3.0.CO;2 O
   Johnson K, 2005, ARTERIOSCL THROM VAS, V25, P686, DOI 10.1161/01.ATV.0000154774.71187.f0
   JUNG A, 1970, AM J PHYSIOL, V218, P1757, DOI 10.1152/ajplegacy.1970.218.6.1757
   Lehto S, 1996, ARTERIOSCL THROM VAS, V16, P978, DOI 10.1161/01.ATV.16.8.978
   Leroux Berger M, 2011, J BONE MINER RES, V26, P1543, DOI 10.1002/jbmr.382
   Li L, 1996, CIRC RES, V78, P188, DOI 10.1161/01.RES.78.2.188
   Li L, 2006, J CELL BIOCHEM, V99, P1553, DOI 10.1002/jcb.20993
   Lomashvili KA, 2008, KIDNEY INT, V73, P1024, DOI 10.1038/ki.2008.26
   Lomashvili KA, 2009, KIDNEY INT, V75, P617, DOI 10.1038/ki.2008.646
   London GM, 2003, NEPHROL DIAL TRANSPL, V18, P1731, DOI 10.1093/ndt/gfg414
   London GM, 2001, J AM SOC NEPHROL, V12, P2759, DOI 10.1681/ASN.V12122759
   McEniery CM, 2009, HYPERTENSION, V53, P524, DOI 10.1161/HYPERTENSIONAHA.108.126615
   MEYER JL, 1984, ARCH BIOCHEM BIOPHYS, V231, P1, DOI 10.1016/0003 9861(84)90356 4
   Millán JL, 2008, J BONE MINER RES, V23, P777, DOI 10.1359/JBMR.071213
   Moe SM, 2003, KIDNEY INT, V63, P1003, DOI 10.1046/j.1523 1755.2003.00820.x
   MOOREHEAD WR, 1974, CLIN CHEM, V20, P1458
   Murshed M, 2005, GENE DEV, V19, P1093, DOI 10.1101/gad.1276205
   Narisawa S, 1997, DEV DYNAM, V208, P432, DOI 10.1002/(SICI)1097 0177(199703)208:3<432::AID AJA13>3.0.CO;2 1
   NARISAWA S, 1992, DEVELOPMENT, V116, P159
   Narisawa S, 2007, J BONE MINER RES, V22, P1700, DOI 10.1359/JBMR.070714
   Narisawa S, 2013, J BONE MINER RES, V28, P1587, DOI 10.1002/jbmr.1901
   Nitschke Yvonne, 2012, Frontiers in Genetics, V3, P302, DOI 10.3389/fgene.2012.00302
   O'Neill WC, 2008, KIDNEY INT, V74, P1376, DOI 10.1038/ki.2008.502
   O'Neill WC, 2011, KIDNEY INT, V79, P512, DOI 10.1038/ki.2010.461
   Otero JE, 2013, J BONE MINER RES, V28, P419, DOI 10.1002/jbmr.1752
   Persy VP, 2011, KIDNEY INT, V79, P490, DOI 10.1038/ki.2010.478
   Pinkerton AB, 2013, CNY World patent, Patent No. [WO 2013/126608, 2013126608]
   Proudfoot D, 2011, KIDNEY INT, V79, P379, DOI 10.1038/ki.2010.455
   Ren X, 2012, J ENDOCRINOL INVEST, V35, P497, DOI 10.3275/7865
   Rutsch F, 2001, AM J PATHOL, V158, P543, DOI 10.1016/S0002 9440(10)63996 X
   Rutsch F, 2003, NAT GENET, V34, P379, DOI 10.1038/ng1221
   Rutsch F, 2008, CIRC CARDIOVASC GENE, V1, P133, DOI 10.1161/CIRCGENETICS.108.797704
   Sage AP, 2011, KIDNEY INT, V79, P414, DOI 10.1038/ki.2010.390
   Sallam T, 2013, CELL MOL LIFE SCI, V70, P3187, DOI 10.1007/s00018 012 1231 y
   Schäfer C, 2003, J CLIN INVEST, V112, P357, DOI [10.1172/JCI17202, 10.1172/JCI200317202]
   Sergienko E, 2009, J BIOMOL SCREEN, V14, P824, DOI 10.1177/1087057109338517
   Shanahan CM, 1999, CIRCULATION, V100, P2168, DOI 10.1161/01.CIR.100.21.2168
   Shroff RC, 2008, CIRCULATION, V118, P1748, DOI 10.1161/CIRCULATIONAHA.108.783738
   Speer MY, 2010, J CELL BIOCHEM, V110, P935, DOI 10.1002/jcb.22607
   St Hilaire C, 2011, NEW ENGL J MED, V364, P432, DOI 10.1056/NEJMoa0912923
   Sutliff RL, 2011, AM J PHYSIOL RENAL, V301, pF78, DOI 10.1152/ajprenal.00533.2010
   Toussaint ND, 2009, CLIN J AM SOC NEPHRO, V4, P221, DOI 10.2215/CJN.02550508
   Towler D.a., 2008, IBMS BONEKEY, V5, P41
   Towler DA, 2005, ARTERIOSCL THROM VAS, V25, P651, DOI 10.1161/01.ATV.0000158943.79580.9d
   Towler DA, 2011, CIRC RES, V108, P1378, DOI 10.1161/CIRCRESAHA.110.234419
   Villa Bellosta R, 2013, CIRCULATION, V127, P2442, DOI 10.1161/CIRCULATIONAHA.112.000571
   Villa Bellosta R, 2011, AM J PHYSIOL HEART C, V301, pH61, DOI 10.1152/ajpheart.01020.2010
   Villa Bellosta R, 2011, AM J PHYSIOL CELL PH, V300, pC210, DOI 10.1152/ajpcell.00229.2010
   Whyte MP, 2012, NEW ENGL J MED, V366, P904, DOI 10.1056/NEJMoa1106173
   WHYTE MP, 1984, J PEDIATR US, V105, P926, DOI 10.1016/S0022 3476(84)80079 7
   WHYTE MP, 1982, J PEDIATR US, V101, P379, DOI 10.1016/S0022 3476(82)80061 9
   WITTEMAN JCM, 1986, LANCET, V2, P1120
   Yadav MC, 2014, J BONE MINER RES, V29, P2369, DOI 10.1002/jbmr.2281
NR 60
TC 169
Z9 184
U1 2
U2 19
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD MAY
PY 2015
VL 30
IS 5
BP 824
EP 836
DI 10.1002/jbmr.2420
PG 13
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA CG2JQ
UT WOS:000353101100008
PM 25428889
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Larsson, S
   Procter, P
AF Larsson, Sune
   Procter, Philip
TI Optimising implant anchorage (augmentation) during fixation of
   osteoporotic fractures: Is there a role for bone graft substitutes?
SO INJURY INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED
LA English
DT Article
DE Screws; Augmentation; PMMA; Bone substitutes
ID CALCIUM PHOSPHATE CEMENT; PEDICLE SCREW FIXATION; CANCELLOUS BONE;
   IN VIVO; INTERTROCHANTERIC FRACTURES; INTERNAL FIXATION; FEMORAL
   FRACTURES; HOLDING STRENGTH; COMPOSITE GRAFT; MINERAL PHASE
AB When stabilising a fracture the contact between the screw and the surrounding bone is crucial for mechanical strength. Through development of screws with new thread designs, as well as optimisation of other properties, improved screw purchase has been gained. Other alternatives to improve screw fixation in osteoporotic bone, as well as normal bone if needed, includes the use of various coatings on the screw that will induce a bonding between the implant surface and the bone implant, as well as application of drugs such as bisphosphonates locally in the screw hole to induce improved screw anchorage through their anticatabolic effect on the bone tissue. As failure of internal fixation of fractures in osteoporotic bone typically occurs through breakage of the bone that surrounds the implant, rather than the implant itself, an alternative strategy in osteoporotic bone can include augmentation of the bone around the screw. This is useful when screws alone are being used for fixation, as it will increase pull out resistance, but also when conventional plates and screws are used. In angularly stable plate screw systems, screw back out is not a problem if the locking mechanism between the screws and the plate works. However, augmentation that will strengthen the bone around the screws can also be useful in conjunction with angle stable plate screw systems, as the augmentation will provide valuable support when subjected to loading that might cause cut out. For many years conventional bone cement, polymethylmethacrylate (PMMA), has been used for augmentation, but due to side effects   including great difficulties if removal becomes necessary   the use of PMMA has never gained wide acceptance. With the introduction of bone substitutes, such as calcium phosphate cement, it has been shown that augmentation around screws can be achieved without the drawbacks seen with PMMA. When dealing with fixation of fractures in osteoporotic bone where screw stability might be inadequate, it therefore seems an attractive option to include bone substitutes for augmentation around screws as part of the armamentarium. Clinical studies now are needed to determine the indications in which bone augmentation with bone graft substitutes (BGSs) would merit clinical usage. (C) 2011 Published by Elsevier Ltd.
C1 [Larsson, Sune] Uppsala Univ, Dept Orthoped, S 75185 Uppsala, Sweden.
   [Procter, Philip] Stryker Osteosynth, Zurich, Switzerland.
   [Procter, Philip] Brunel Univ, Sch Engn & Design, Uxbridge UB8 3PH, Middx, England.
C3 Uppsala University; Brunel University
RP Larsson, S (通讯作者)，Uppsala Univ, Dept Orthoped, S 75185 Uppsala, Sweden.
EM sune.larsson@ortopedi.uu.se
RI ; Procter, Philip/N 4714 2019
OI Procter, Philip/0000 0002 3219 1177; 
CR Andersson T, 2010, J MATER SCI MATER M, V21, P3029, DOI 10.1007/s10856 010 4154 x
   Andreassen GS, 2004, ARCH ORTHOP TRAUM SU, V124, P161, DOI 10.1007/s00402 004 0642 0
   Asnis SE, 1996, J ORTHOP TRAUMA, V10, P462, DOI 10.1097/00005131 199610000 00003
   BARTUCCI EJ, 1985, J BONE JOINT SURG AM, V67A, P1094, DOI 10.2106/00004623 198567070 00014
   BENUM P, 1977, ACTA ORTHOP SCAND, V48, P52, DOI 10.3109/17453677708985111
   CAMERON HU, 1975, J BONE JOINT SURG AM, V57, P655, DOI 10.2106/00004623 197557050 00013
   Chapman JR, 1996, J BIOMECH ENG T ASME, V118, P391, DOI 10.1115/1.2796022
   CONSTANTZ BR, 1995, SCIENCE, V267, P1796, DOI 10.1126/science.7892603
   Constantz BR, 1998, J BIOMED MATER RES, V43, P451, DOI 10.1002/(SICI)1097 4636(199824)43:4<451::AID JBM13>3.3.CO;2 H
   Dall'Oca C, 2010, INJURY, V41, P1150, DOI 10.1016/j.injury.2010.09.026
   DeCoster T A, 1990, J Orthop Trauma, V4, P169, DOI 10.1097/00005131 199004020 00012
   Eriksson F, 2002, J ORTHOP TRAUMA, V16, P302, DOI 10.1097/00005131 200205000 00003
   Eriksson F, 2000, ANN CHIR GYNAECOL FE, V89, P119
   Hasegawa K, 1998, ARCH ORTHOP TRAUM SU, V117, P175, DOI 10.1007/s004020050223
   Hearn T C, 1993, J Orthop Trauma, V7, P138, DOI 10.1097/00005131 199304000 00006
   Kawagoe K, 2000, J BIOMED MATER RES, V53, P678, DOI 10.1002/1097 4636(2000)53:6<678::AID JBM10>3.0.CO;2 E
   Kelly CM, 2004, ORTHOPEDICS, V27, pS131
   LEGGON R, 1993, J ORTHOP TRAUMA, V7, P450, DOI 10.1097/00005131 199310000 00008
   Mattsson P, 2003, Scand J Surg, V92, P215
   McKoy BE, 2001, J ORTHOPAED RES, V19, P545, DOI 10.1016/S0736 0266(00)00052 8
   McKoy BE, 2000, J BIOMED MATER RES, V53, P216, DOI 10.1002/(SICI)1097 4636(2000)53:3<216::AID JBM5>3.0.CO;2 O
   Moore DC, 1997, SPINE, V22, P1696, DOI 10.1097/00007632 199708010 00003
   Moroni A, 2002, J ORTHOP TRAUMA, V16, P257, DOI 10.1097/00005131 200204000 00007
   Moroni A, 1996, J ORTHOP TRAUMA, V10, P236, DOI 10.1097/00005131 199605000 00003
   Moroni A, 2008, J BIOMED MATER RES B, V86B, P417, DOI 10.1002/jbm.b.31036
   Moroni A, 2007, J BONE JOINT SURG AM, V89A, P96, DOI 10.2106/JBJS.F.00484
   MUHR G, 1979, CLIN ORTHOP RELAT R, P41
   Nilsson M, 2003, J MATER SCI MATER M, V14, P399, DOI 10.1023/A:1023254632704
   Panchbhavi VK, 2008, FOOT ANKLE INT, V29, P593, DOI 10.3113/FAI.2008.0593
   PFEIFER BA, 1994, SPINE, V19, P350, DOI 10.1097/00007632 199402000 00017
   Renner SM, 2004, SPINE, V29, pE212, DOI 10.1097/00007632 200406010 00020
   Ricci JL, 2001, USE CALCIUM SULFATE, P13
   Sandén B, 2001, SPINE, V26, P2673, DOI 10.1097/00007632 200112150 00008
   Sandén B, 2002, J BONE JOINT SURG BR, V84B, P387, DOI 10.1302/0301 620X.84B3.12388
   Sandén B, 2000, EUR SPINE J, V9, P534, DOI 10.1007/s005860000180
   Shane E, 2010, J BONE MINER RES, V25, P2267, DOI 10.1002/jbmr.253
   Skoglund B, 2004, J ORTHOP RES, V22, P1108, DOI 10.1016/j.orthres.2003.12.015
   SOSHI S, 1991, SPINE, V16, P1335, DOI 10.1097/00007632 199111000 00015
   Stadelmann VA, 2010, J BIOMECH, V43, P2869, DOI 10.1016/j.jbiomech.2010.07.025
   TAMURA J, 1995, J BIOMED MATER RES, V29, P551, DOI 10.1002/jbm.820290502
   Tay BKB, 1999, ORTHOP CLIN N AM, V30, P615, DOI 10.1016/S0030 5898(05)70114 0
   Tengvall P, 2004, BIOMATERIALS, V25, P2133, DOI 10.1016/j.biomaterials.2003.08.049
   Urban RM, 2007, CLIN ORTHOP RELAT R, P110, DOI 10.1097/BLO.0b013e318059b902
   Van Landuyt P, 1999, BONE, V25, p95S, DOI 10.1016/S8756 3282(99)00142 8
   Wermelin K, 2008, J BIOMED MATER RES A, V86A, P220, DOI 10.1002/jbm.a.31583
   Yi XD, 2008, SPINE, V33, P2503, DOI 10.1097/BRS.0b013e318184e750
   ZINDRICK MR, 1986, CLIN ORTHOP RELAT R, P99
NR 47
TC 14
Z9 15
U1 0
U2 11
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0020 1383
EI 1879 0267
J9 INJURY
JI Injury Int. J. Care Inj.
PD SEP
PY 2011
VL 42
SU 2
BP S72
EP S76
DI 10.1016/j.injury.2011.06.019
PG 5
WC Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery
GA 824PB
UT WOS:000295213300012
PM 21839441
DA 2025 08 17
ER

PT J
AU Yu, LK
   Lin, RL
   Han, Y
   Fan, DH
   Zhou, GQ
   Zhang, JC
   Jia, G
   Ge, K
AF Yu, Linkang
   Lin, Runlian
   Han, Yu
   Fan, Dehui
   Zhou, Guoqiang
   Zhang, Jinchao
   Jia, Guang
   Ge, Kun
TI La(OH)3 nanorods with different sizes enhanced osteogenic
   differentiation on mice bone marrow mesenchymal stem cells
SO JOURNAL OF NANOPARTICLE RESEARCH
LA English
DT Article
DE La(OH)(3) nanorods; BMSCs; Osteogenic differentiation; Degradation
ID STROMAL CELLS; OSTEOBLAST DIFFERENTIATION; RARE EARTH; NANOPARTICLES;
   LYSOSOME; NECROSIS
AB With the wide use of rare earth nanomaterials in industry, environmental control, and medicine with their unique properties, it has focused on the exposure of humans to the rare earth nanoparticles in recent years. Because of the similar properties of rare earth and calcium, rare earth nanoparticles can deposit in the bone and affect the osteogenic differentiation of bone mesenchymal stem cells (BMSCs). La(OH)(3) nanoparticles are widely used in the catalysis, sensor, electrode, and luminescent materials. However, there are few reports about the bioactivity of La(OH)(3) nanoparticles on the bone metabolism. In this work, three La(OH)(3) nanorods have been got by hydrothermal method, Long , Medium , and Short La(OH)(3) nanorods, the lengths of which were of similar to 640, 255, and 80 nm, and the diameters of which were of similar to 85, 40, and 35 nm, respectively. All the La(OH)(3) nanorods showed no effect on BMSCs viability and the blood compatibility. But the osteogenic differentiation showed a significant difference in La(OH)(3) nanorods, in which Short La(OH)(3) nanorods showed the highest promoting effect on osteogenic differentiation. The potential mechanism in the osteogenic differentiation caused by three La(OH)(3) nanorods was correlated with the different uptake efficiency in BMSCs and degradation in lysosome to form LaPO4. This work on La(OH)(3) nanorods provides the basic data for the development of lanthanum based nanoparticles.
C1 [Yu, Linkang; Lin, Runlian; Han, Yu; Fan, Dehui; Zhou, Guoqiang; Zhang, Jinchao; Jia, Guang; Ge, Kun] Hebei Univ, Coll Chem & Environm Sci, Key Lab Med Chem & Mol Diag, Key Lab Chem Biol Hebei Prov,Minist Educ, Baoding 071002, Peoples R China.
   [Ge, Kun] Hebei Univ, Hebei Key Lab Chron Kidney Dis & Bone Metab, Affiliated Hosp, Baoding 071000, Peoples R China.
C3 Hebei University; Hebei University
RP Jia, G; Ge, K (通讯作者)，Hebei Univ, Coll Chem & Environm Sci, Key Lab Med Chem & Mol Diag, Key Lab Chem Biol Hebei Prov,Minist Educ, Baoding 071002, Peoples R China.; Ge, K (通讯作者)，Hebei Univ, Hebei Key Lab Chron Kidney Dis & Bone Metab, Affiliated Hosp, Baoding 071000, Peoples R China.
EM jiaguang_2001@163.com; kaqikun@163.com
RI Han, Yu/GZA 9220 2022
OI Jia, Guang/0000 0001 6906 4027; Ge, Kun/0000 0001 8972 837X
FU National Natural Science Foundations of China [21807023, 21271059];
   Natural Science Foundation of Hebei Province [B2019201449, H2019201466,
   B2020201020, E2020201033]; Science and Technology Project of Hebei
   Education Department [QN2018010, ZD2020150]; Priority Strategy Project
   of the Key Laboratory of Medicinal Chemistry and Molecular Diagnosis of
   the Ministry of Education [ts2019005]; Excellent Youth Scientific
   Research and Innovation Team of Hebei University [605020521003]
FX This work was supported by the National Natural Science Foundations of
   China (Nos. 21807023, 21271059), Natural Science Foundation of Hebei
   Province (Nos. B2019201449, H2019201466, B2020201020, E2020201033),
   Science and Technology Project of Hebei Education Department (Nos.
   QN2018010, ZD2020150), the Priority Strategy Project of the Key
   Laboratory of Medicinal Chemistry and Molecular Diagnosis of the
   Ministry of Education (ts2019005), and Excellent Youth Scientific
   Research and Innovation Team of Hebei University (605020521003).
CR Aragón J, 2018, J COLLOID INTERF SCI, V531, P126, DOI 10.1016/j.jcis.2018.07.029
   Bai J, 2018, BIOMETALS, V31, P771, DOI 10.1007/s10534 018 0121 7
   Elsafadi M, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/6913594
   Ferby VA, 2020, J AUST CERAM SOC, V56, P711, DOI 10.1007/s41779 019 00389 5
   Figueiredo BR, 2016, MICROPOR MESOPOR MAT, V234, P73, DOI 10.1016/j.micromeso.2016.07.004
   Gao CY, 2019, ACS NANO, V13, P313, DOI 10.1021/acsnano.8b06211
   Ge K, 2016, RSC ADV, V6, P21725, DOI 10.1039/c6ra01625a
   Ge K, 2015, ACS APPL MATER INTER, V7, P10905, DOI 10.1021/acsami.5b02146
   Harini D, 2014, J RARE EARTH, V32, P1080, DOI 10.1016/S1002 0721(14)60186 1
   Harini D, 2015, J MATER SCI MATER M, V26, DOI 10.1007/s10856 015 5378 6
   Hu HR, 2018, J NANOBIOTECHNOL, V16, DOI 10.1186/s12951 018 0411 9
   Jia G, 2009, EUR J INORG CHEM, P3721, DOI 10.1002/ejic.200900495
   Jin Y, 2015, J INORG BIOCHEM, V146, P28, DOI 10.1016/j.jinorgbio.2015.02.006
   Jing H, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 017 0231 0
   Li Rongchang, 2003, Beijing Da Xue Xue Bao Yi Xue Ban, V35, P622
   Li RB, 2014, ACS NANO, V8, P10280, DOI 10.1021/nn505002w
   Li RB, 2014, ACS NANO, V8, P1771, DOI 10.1021/nn406166n
   Li XY, 2020, ACTA BIOMATER, V101, P554, DOI 10.1016/j.actbio.2019.10.044
   Liu DD, 2010, ACS NANO, V4, P2185, DOI 10.1021/nn901479w
   Liu HF, 2017, ACS APPL MATER INTER, V9, P5784, DOI 10.1021/acsami.6b14682
   Liu XZ, 2017, EUR J PHARMACOL, V810, P156, DOI 10.1016/j.ejphar.2017.07.013
   Patel KD, 2020, ACTA BIOMATER, V108, P97, DOI 10.1016/j.actbio.2020.03.012
   Peng XY, 2019, BIOMATER SCI UK, V7, P1565, DOI 10.1039/c8bm01498a
   Rejman J, 2016, J COLLOID INTERF SCI, V482, P260, DOI 10.1016/j.jcis.2016.07.065
   Ren ZY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120087
   Wang JX, 2006, BIOCHEM PHARMACOL, V71, P872, DOI 10.1016/j.bcp.2005.12.001
   Wang LM, 2011, NANO LETT, V11, P772, DOI 10.1021/nl103992v
   Wang QW, 2017, NANO RES, V10, P626, DOI 10.1007/s12274 016 1322 4
   Wang QW, 2016, BIOMATERIALS, V86, P11, DOI 10.1016/j.biomaterials.2016.02.004
   Wang X, 2008, J CELL BIOCHEM, V105, P1307, DOI 10.1002/jcb.21932
   Yang KN, 2013, NANOSCALE, V5, P1205, DOI 10.1039/c2nr33575a
   Yu CX, 2017, J ENVIRON SCI CHINA, V51, P88, DOI 10.1016/j.jes.2016.06.029
   Yu LK, 2021, J LUMIN, V229, DOI 10.1016/j.jlumin.2020.117663
   Zhang JC, 2012, J RARE EARTH, V30, P90, DOI 10.1016/S1002 0721(10)60645 X
   Zhang JC, 2009, PROG CHEM, V21, P919
   Zhang Q, 2014, J NANOPART RES, V16, DOI 10.1007/s11051 014 2697 3
NR 36
TC 3
Z9 3
U1 2
U2 40
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1388 0764
EI 1572 896X
J9 J NANOPART RES
JI J. Nanopart. Res.
PD JUL
PY 2021
VL 23
IS 7
AR 137
DI 10.1007/s11051 021 05253 x
PG 14
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science
GA TB8CK
UT WOS:000668173900001
DA 2025 08 17
ER

PT J
AU Iafisco, M
   Palazzo, B
   Falini, G
   Di Foggia, M
   Bonora, S
   Nicolis, S
   Casella, L
   Roveri, N
AF Iafisco, Michele
   Palazzo, Barbara
   Falini, Giuseppe
   Di Foggia, Michele
   Bonora, Sergio
   Nicolis, Stefania
   Casella, Luigi
   Roveri, Norberto
TI Adsorption and conformational change of myoglobin on biomimetic
   hydroxyapatite nanocrystals functionalized with alendronate
SO LANGMUIR
LA English
DT Article
ID CATALYTIC ACTIVITY; RAMAN SCATTERING; PROTEINS; PARTICLES; MOLECULES;
   BEHAVIOR; SILVER
AB The chemical conjugation of bisphosphonates (BP's), specifically alendronate, to hydroxyapatite could be an effective means to impart to it fine tuned bioactivity. Horse heart myoglobin (Mb), a well characterized protein, has been adsorbed onto biomimetic hydroxyapatite nanocrystals (nHA) and onto the nHA/alendronate conjugate powdered samples. The obtained materials have potential use in bone implantation and as prospective drug delivery devices. The kinetic absorption of Mb onto nHA is dramatically affected by its functionalization with alendronate. The covering of the nHA surface by alendronate inhibits the adsorption of myoglobin. The adsorption mechanisms of the protein were studied by spectroscopic techniques (UV vis and surface enhanced Raman spectroscopy). The results indicate that the protein changes conformation upon adsorption on the inorganic substrate. In particular, the interaction with nHA alters the coordination state of the iron in the heme through the formation of a hexacoordinated low spin Mb heme, possibly involving the distal histidine. Instead, the covering of the nHA surface by alendronate does not adsorb the protein but preserves the coordination state of the heme moiety. This study could be of significance either in the field of biomaterials science, in particular, to fine tune a bone specific drug delivery device and to test nHA as a new support for heterogeneous catalysis, improving the understating of enzyme immobilization.
C1 [Iafisco, Michele; Palazzo, Barbara; Falini, Giuseppe; Roveri, Norberto] Univ Bologna, Alma Mater Studiorum, Dipartimento Chim G Ciamician, I 40126 Bologna, Italy.
   [Di Foggia, Michele; Bonora, Sergio] Univ Bologna, Alma Mater Studiorum, Dipartimento Biochim, I 40126 Bologna, Italy.
   [Nicolis, Stefania; Casella, Luigi] Univ Pavia, Dipartimento Chim Gen, I 27100 Pavia, Italy.
C3 University of Bologna; University of Bologna; University of Pavia
RP Roveri, N (通讯作者)，Univ Bologna, Alma Mater Studiorum, Dipartimento Chim G Ciamician, Via Selmi 2, I 40126 Bologna, Italy.
EM norberto.roveri@unibo.it
RI Di Foggia, Michele/B 1230 2010; Iafisco, Michele/B 4597 2010; Di Foggia,
   Michele/R 8936 2018; Iafisco, Michele/ABF 7752 2020
OI Iafisco, Michele/0000 0002 7813 8347; Di Foggia,
   Michele/0000 0002 0591 0105; Palazzo, Barbara/0000 0001 5645 3779; 
CR AKAWA T, 1999, J CHROMATOGR A, V863, P217
   AlDuri B, 1997, J MOL CATAL B ENZYM, V3, P177, DOI 10.1016/S1381 1177(96)00052 5
   Bajpai AK, 2005, POLYM INT, V54, P304, DOI 10.1002/pi.1673
   Barroug A, 1997, J COLLOID INTERF SCI, V189, P37, DOI 10.1006/jcis.1997.4787
   Bellezza F, 2004, LANGMUIR, V20, P5019, DOI 10.1021/la0496791
   Bellezza F, 2006, LANGMUIR, V22, P5064, DOI 10.1021/la0531897
   Bizzarri AR, 2002, APPL SPECTROSC, V56, P1531, DOI 10.1366/000370202321115977
   Boix T, 2005, J INORG BIOCHEM, V99, P1043, DOI 10.1016/j.jinorgbio.2005.01.011
   Brunauer S, 1938, J AM CHEM SOC, V60, P309, DOI 10.1021/ja01269a023
   CREIGHTON JA, 1979, J CHEM SOC FARAD T 2, V75, P790, DOI 10.1039/f29797500790
   Droghetti E, 2005, J BIOL INORG CHEM, V10, P696, DOI 10.1007/s00775 005 0027 z
   Feng ML, 2001, J AM CHEM SOC, V123, P3013, DOI 10.1021/ja003088p
   Gray JJ, 2004, CURR OPIN STRUC BIOL, V14, P110, DOI 10.1016/j.sbi.2003.12.001
   Hughes Wassell Diana T., 1995, Biomaterials, V16, P697
   IOZZI L, 2001, SOIL BIOL BIOCHEM, V33, P1021
   Jäger C, 2006, MAGN RESON CHEM, V44, P573, DOI 10.1002/mrc.1774
   Kandori K, 2000, PHYS CHEM CHEM PHYS, V2, P2015, DOI 10.1039/a909396f
   Kandori K, 2005, CALCIFIED TISSUE INT, V76, P194, DOI 10.1007/s00223 004 0102 4
   Kitagawa T, 1978, Adv Biophys, V11, P153
   Kondo A, 1996, J COLLOID INTERF SCI, V177, P214, DOI 10.1006/jcis.1996.0023
   Leopold N, 2003, J PHYS CHEM B, V107, P5723, DOI 10.1021/jp027460u
   Lu HY, 2006, J PHYS CHEM B, V110, P23710, DOI 10.1021/jp063550d
   MORENO EC, 1984, CALCIFIED TISSUE INT, V36, P48, DOI 10.1007/BF02405293
   NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407
   OUIZAT S, 1999, MAT RES B, V34, P2279, DOI DOI 10.1016/S0025 5408(00)00167 7
   Palazzo B, 2007, ADV FUNCT MATER, V17, P2180, DOI 10.1002/adfm.200600361
   Roat Malone R. M., 2002, Bioinorganic Chemistry
   Roncone R, 2005, J BIOL INORG CHEM, V10, P11, DOI 10.1007/s00775 004 0606 4
   Roveri N., 2006, TISSUE CELL ORGAN EN, V9, P283
   Sharma S, 2001, J COLLOID INTERF SCI, V243, P61, DOI 10.1006/jcis.2001.7846
   SPIRO TG, 1979, J AM CHEM SOC, V101, P2648, DOI 10.1021/ja00504a027
   Taha EA, 2003, CHEM PHARM BULL, V51, P1444, DOI 10.1248/cpb.51.1444
   TANAKA T, 2007, J MAT SCI ENG C, V27, P817
   Tofani L, 2004, BIOPHYS J, V87, P1186, DOI 10.1529/biophysj.104.041731
   Vallet Regí M, 2004, PROG SOLID STATE CH, V32, P1, DOI 10.1016/j.progsolidstchem.2004.07.001
   Wright JEI, 2006, BIOMATERIALS, V27, P769, DOI 10.1016/j.biomaterials.2005.06.012
   Xu T, 2007, MAT SCI ENG C BIO S, V27, P579, DOI 10.1016/j.msec.2006.05.029
NR 37
TC 77
Z9 85
U1 1
U2 58
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0743 7463
J9 LANGMUIR
JI Langmuir
PD MAY 6
PY 2008
VL 24
IS 9
BP 4924
EP 4930
DI 10.1021/la703381h
PG 7
WC Chemistry, Multidisciplinary; Chemistry, Physical; Materials Science,
   Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Materials Science
GA 294UP
UT WOS:000255432000075
PM 18373380
DA 2025 08 17
ER

PT J
AU Hao, LL
   Li, LL
   Wang, P
   Wang, ZL
   Shi, XC
   Guo, M
   Zhang, PB
AF Hao, Lili
   Li, Linlong
   Wang, Peng
   Wang, Zongliang
   Shi, Xincui
   Guo, Min
   Zhang, Peibiao
TI Synergistic osteogenesis promoted by magnetically actuated
   nano mechanical stimuli
SO NANOSCALE
LA English
DT Article
ID BONE; DIFFERENTIATION; FIELDS; NANOPARTICLES; SCAFFOLDS; CELLS;
   NANOFIBERS; COMPOSITE; CHANNELS; PIEZO2
AB Functional biomaterials with magnetic properties are considerably useful for regulating cell behavior and promoting bone regeneration. And the combination of such biomaterials with physical environmental cues (such as magnetic fields and mechanical stress) might be more favorable for the regulation of cell function. This study is aimed at investigating the combined effects of magnetically responsive materials and a static magnetic field (SMF) on the osteogenic differentiation of osteoblasts and the potential mechanism involved. In this study, oleic acid modified iron oxide nanoparticles (IO OA NPs) were utilized to generate homogeneous magnetic nanocomposites with poly(lactide co glycolide) (PLGA) used as the base and to enhance the mechanical properties of the composites. In vitro experimental results show that in the presence of an external SMF, cell attachment and osteogenic differentiation were significantly improved using the IO OA/PLGA composites, as indicated by enhanced alkaline phosphatase (ALP) activity, increased mineralized nodule formation, and upregulated bone associated gene expression (ALP, OCN, and BMP2), in a dose  and time dependent manner. Furthermore, the upregulated expression levels of piezo type mechanosensitive ion channel component 1 (Piezo1), a key receptor for sensing mechanical stimuli, implied that the synergistically enhanced osteogenic differentiation was mainly caused as a result of the mechanical stimuli. Such magnetically actuated mechanical stimuli were induced through the nano deformation of the magnetic substrate under a SMF, which was directly characterized via in situ scanning using atomic force microscopy (AFM). This study demonstrates that magnetically actuated nano mechanical stimuli may underpin the synergistic effects of magnetic composites and magnetic stimuli to enhance osteogenic differentiation, and they could form the basis of a potential strategy to accelerate bone formation for bone tissue engineering and regenerative medicine applications.
C1 [Hao, Lili; Li, Linlong; Wang, Peng; Wang, Zongliang; Shi, Xincui; Guo, Min; Zhang, Peibiao] Chinese Acad Sci, Changchun Inst Appl Chem, Key Lab Polymer Ecomat, 5625 Renmin St, Changchun 130022, Peoples R China.
   [Hao, Lili; Wang, Peng; Zhang, Peibiao] Univ Sci & Technol China, Sch Appl Chem & Engn, 96 Jinzhai Rd, Hefei 230026, Anhui, Peoples R China.
   [Li, Linlong] Univ Chinese Acad Sci, Beijing 100039, Peoples R China.
C3 Chinese Academy of Sciences; Changchun Institute of Applied Chemistry,
   CAS; Chinese Academy of Sciences; University of Science & Technology of
   China, CAS; Chinese Academy of Sciences; University of Chinese Academy
   of Sciences, CAS
RP Guo, M; Zhang, PB (通讯作者)，Chinese Acad Sci, Changchun Inst Appl Chem, Key Lab Polymer Ecomat, 5625 Renmin St, Changchun 130022, Peoples R China.; Zhang, PB (通讯作者)，Univ Sci & Technol China, Sch Appl Chem & Engn, 96 Jinzhai Rd, Hefei 230026, Anhui, Peoples R China.
EM guomin@ciac.ac.cn; zhangpb@ciac.ac.cn
RI ; Pengjie, Wang/J 5250 2014; Wang, Zongliang/L 8740 2019
OI Li, Linlong/0000 0001 5927 6712; Wang, Zongliang/0000 0001 6101 8317
FU National Natural Science Foundation of China [51673186, 51473164]; Japan
   Society for the Promotion of Science [GJHZ1519]; Chinese Academy of
   Sciences [GJHZ1519, 2017SYHZ0021]; Jilin Province [2017SYHZ0021]
FX This study was financially supported by the National Natural Science
   Foundation of China (Projects 51673186 and 51473164), the joint funded
   program of the Chinese Academy of Sciences and Japan Society for the
   Promotion of Science (GJHZ1519), and the Special Fund for
   Industrialization of Science and Technology Cooperation between Jilin
   Province and the Chinese Academy of Sciences (2017SYHZ0021).
CR Amanda J. G., 2015, NEUROSCIENCE, V4, P12088
   Ba XL, 2011, BIOMATERIALS, V32, P7831, DOI 10.1016/j.biomaterials.2011.06.053
   Beech DJ, 2018, J PHYSIOL LONDON, V596, P965, DOI 10.1113/JP274395
   Benoit DSW, 2008, NAT MATER, V7, P816, DOI 10.1038/nmat2269
   Bhushan B, 2004, MICROSYST TECHNOL, V10, P633, DOI 10.1007/s00542 004 0489 x
   Bock N, 2010, ACTA BIOMATER, V6, P786, DOI 10.1016/j.actbio.2009.09.017
   Boda SK, 2015, J MATER CHEM B, V3, P3150, DOI 10.1039/c5tb00118h
   Cai Q, 2015, MAT SCI ENG C MATER, V55, P166, DOI 10.1016/j.msec.2015.05.002
   Chiu KH, 2007, ANN BIOMED ENG, V35, P1932, DOI 10.1007/s10439 007 9370 2
   Chung HJ, 2007, ADV DRUG DELIVER REV, V59, P249, DOI 10.1016/j.addr.2007.03.015
   COEY JMD, 1971, PHYS REV LETT, V27, P1140, DOI 10.1103/PhysRevLett.27.1140
   Coste B, 2010, SCIENCE, V330, P55, DOI 10.1126/science.1193270
   Dobson J, 2008, NAT NANOTECHNOL, V3, P139, DOI 10.1038/nnano.2008.39
   Guo YP, 2014, J MATER CHEM B, V2, P2899, DOI 10.1039/c3tb21829e
   He Y, 2019, FASEB J, V33, P6069, DOI 10.1096/fj.201802195R
   Hoang QQ, 2003, NATURE, V425, P977, DOI 10.1038/nature02079
   Huang G, 2009, J MATER CHEM, V19, P6367, DOI 10.1039/b902358e
   Huang HM, 2006, CLIN ORTHOP RELAT R, P201, DOI 10.1097/01.blo.0000203464.35561.be
   Jiang PF, 2016, ACTA BIOMATER, V46, P141, DOI 10.1016/j.actbio.2016.09.020
   Kim EC, 2015, BIOELECTROMAGNETICS, V36, P267, DOI 10.1002/bem.21903
   Kim JJ, 2014, RSC ADV, V4, P17325, DOI 10.1039/c4ra00040d
   LANG SB, 1966, NATURE, V212, P705
   LANGER R, 1993, SCIENCE, V260, P920, DOI 10.1126/science.8493529
   Lee W, 2014, P NATL ACAD SCI USA, V111, pE5114, DOI 10.1073/pnas.1414298111
   Li J, 2014, NATURE, V515, P279, DOI 10.1038/nature13701
   Li YF, 2019, J ANAL APPL PYROL, V141, DOI 10.1016/j.jaap.2019.104636
   Lin TC, 2012, ACTA BIOMATER, V8, P2704, DOI 10.1016/j.actbio.2012.03.045
   Ma PX, 2004, MATER TODAY, V7, P30, DOI 10.1016/S1369 7021(04)00233 0
   Maity D, 2007, J MAGN MAGN MATER, V308, P46, DOI 10.1016/j.jmmm.2006.05.001
   Meng J, 2010, NANOSCALE, V2, P2565, DOI 10.1039/c0nr00178c
   Mollon B, 2008, J BONE JOINT SURG AM, V90A, P2322, DOI 10.2106/JBJS.H.00111
   Park J, 2004, NAT MATER, V3, P891, DOI 10.1038/nmat1251
   Perez RA, 2015, RSC ADV, V5, P13411, DOI 10.1039/c4ra12640h
   Rode B, 2017, NAT COMMUN, V8, DOI 10.1038/s41467 017 00429 3
   Shan DY, 2013, MAT SCI ENG C MATER, V33, P3498, DOI 10.1016/j.msec.2013.04.040
   Singh RS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109265
   Sugimoto A, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 18089 0
   Sun SH, 2004, J AM CHEM SOC, V126, P273, DOI 10.1021/ja0380852
   Sun WJ, 2019, ELIFE, V8, DOI 10.7554/eLife.47454
   Tampieri A, 2011, NANOTECHNOLOGY, V22, DOI 10.1088/0957 4484/22/1/015104
   Tanase M, 2001, NANO LETT, V1, P155, DOI 10.1021/nl005532s
   Thrivikraman G, 2014, BIOMATERIALS, V35, P6219, DOI 10.1016/j.biomaterials.2014.04.018
   TURNER CH, 1994, J BONE MINER RES, V9, P87
   Wang ZL, 2016, ACS APPL MATER INTER, V8, P26559, DOI 10.1021/acsami.6b08733
   Wen XT, 2008, CURR APPL PHYS, V8, P535, DOI 10.1016/j.cap.2007.09.003
   Wu J, 2017, TRENDS BIOCHEM SCI, V42, P57, DOI 10.1016/j.tibs.2016.09.004
   Xiao R, 2010, CURR BIOL, V20, pR936, DOI 10.1016/j.cub.2010.09.053
   Yamamoto Y, 2003, J DENT RES, V82, P962, DOI 10.1177/154405910308201205
   Yuan ZY, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 33455 2
   Yun HM, 2016, BIOMATERIALS, V85, P88, DOI 10.1016/j.biomaterials.2016.01.035
   Zafari J, 2015, ELECTROMAGN BIOL MED, V34, P216, DOI 10.3109/15368378.2015.1076452
   Zhuang JJ, 2018, ACTA BIOMATER, V71, P49, DOI 10.1016/j.actbio.2018.03.009
NR 52
TC 66
Z9 68
U1 5
U2 161
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2040 3364
EI 2040 3372
J9 NANOSCALE
JI Nanoscale
PD DEC 28
PY 2019
VL 11
IS 48
BP 23423
EP 23437
DI 10.1039/c9nr07170a
PG 15
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary; Physics, Applied
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science;
   Physics
GA KC0NA
UT WOS:000506883100034
PM 31799540
DA 2025 08 17
ER

PT J
AU Kearney, EM
   Farrell, E
   Prendergast, PJ
   Campbell, VA
AF Kearney, E. M.
   Farrell, E.
   Prendergast, P. J.
   Campbell, V. A.
TI Tensile Strain as a Regulator of Mesenchymal Stem Cell Osteogenesis
SO ANNALS OF BIOMEDICAL ENGINEERING
LA English
DT Article
DE Mesenchymal stem cells; Mechanical strain; Osteogenic differentiation;
   Proliferation; Stretch activated cation channels; Mitogen activated
   protein kinase; PI3 kinase
ID BONE MORPHOGENETIC PROTEIN 2; OSTEOBLAST DIFFERENTIATION; MECHANICAL
   STRAIN; CYCLIC STRAIN; GROWTH FACTOR; IN VITRO; TRANSCRIPTION FACTOR;
   SKELETAL DEVELOPMENT; PROGENITOR CELLS; STROMAL CELLS
AB A role for mechanical stimulation in the control of cell fate has been proposed and mechanical conditioning of mesenchymal stem cells (MSCs) is of interest in directing MSC behavior for tissue engineering applications. This study investigates strain induced differentiation and proliferation of MSCs, and investigates the cellular mechanisms of mechanotransduction. MSCs were seeded onto a collagen coated silicone substrate and exposed to cyclic tensile mechanical strain of 2.5% at 0.17 Hz for 1 14 days. To examine mechanotransduction, cells were strained in the presence of the stretch activated cation channel (SACC) blocker, gadolinium chloride (GdCl3); the extracellular regulated kinase (ERK) inhibitor, U0126; the p38 inhibitor, SB203580; and the phosphatidylinosito1 3 kinase (PI3 kinase) inhibitor, LY294002. Following exposure to strain, the osteogenic markers Cbf alpha 1, collagen type I, osteocalcin, and BMP2 were temporally expressed. Exposure to strain in the presence of GdCl3 (10 mu M) reduced the induction of collagen I expression, thus identifying a role for SACC, at least in part, as mechanosensors in strain induced MSC differentiation. The strain induced synthesis of BMP2 was found to be reduced by inhibitors of the kinases, ERK, p38, and PI3 kinase. Additionally, mechanical strain reduced the rate of MSC proliferation. The identification of the mechanical control of MSC proliferation and the molecular link between mechanical stimulation and osteogenic differentiation has consequences for regenerative medicine through the development of a functional tissue engineering approach.
C1 [Campbell, V. A.] Univ Dublin Trinity Coll, Sch Med, Dept Physiol, Dublin 2, Ireland.
   [Kearney, E. M.; Farrell, E.; Prendergast, P. J.; Campbell, V. A.] Univ Dublin Trinity Coll, Sch Engn, Trinity Ctr Bioengn, Dublin 2, Ireland.
C3 Trinity College Dublin; Trinity College Dublin
RP Campbell, VA (通讯作者)，Univ Dublin Trinity Coll, Sch Med, Dept Physiol, Dublin 2, Ireland.
EM vacmpbll@tcd.ie
RI ; Farrell, Eric/J 9379 2012
OI Farrell, Eric/0000 0001 6886 6693; 
FU Program for Research in Third Level Institutions (PRTLI)
FX This study was supported by a grant under the Program for Research in
   Third Level Institutions (PRTLI) to the Trinity Centre for
   Bioengineering.
CR Altman GH, 2001, FASEB J, V15, P270, DOI 10.1096/fj.01 0656fje
   Bae JS, 2007, J CELL BIOCHEM, V100, P434, DOI 10.1002/jcb.21039
   BRIGHTON CT, 1991, J BONE JOINT SURG AM, V73A, P320, DOI 10.2106/00004623 199173030 00002
   BRUDER SP, 1994, J CELL BIOCHEM, V56, P283, DOI 10.1002/jcb.240560303
   Caetano Lopes J, 2007, ACTA REUMATOL PORT, V32, P103
   CAPLAN AI, 1987, BIOESSAYS, V6, P171, DOI 10.1002/bies.950060406
   Chao Edmund Y S, 2003, Eur Cell Mater, V6, P72
   CHAO EY, 2003, EUR CELLS MATER, V6, P84
   Charras GT, 2004, BIOPHYS J, V87, P2870, DOI 10.1529/biophysj.104.040436
   Danciu TE, 2003, FEBS LETT, V536, P193, DOI 10.1016/S0014 5793(03)00055 3
   Ducy P, 1996, NATURE, V382, P448, DOI 10.1038/382448a0
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Farrell E, 2006, TISSUE ENG, V12, P459, DOI 10.1089/ten.2006.12.459
   Franceschi RT, 2003, J CELL BIOCHEM, V88, P446, DOI 10.1002/jcb.10369
   Friedl G, 2007, OSTEOARTHR CARTILAGE, V15, P1293, DOI 10.1016/j.joca.2007.04.002
   Gallea S, 2001, BONE, V28, P491, DOI 10.1016/S8756 3282(01)00415 X
   Ge CX, 2007, J CELL BIOL, V176, P709, DOI 10.1083/jcb.200610046
   Ghazanfari S, 2009, BIOCHEM BIOPH RES CO, V388, P601, DOI 10.1016/j.bbrc.2009.08.072
   Ghosh Choudhury N, 2002, J BIOL CHEM, V277, P33361, DOI 10.1074/jbc.M205053200
   Gross TS, 2004, EXERC SPORT SCI REV, V32, P9, DOI 10.1097/00003677 200401000 00003
   Hall BK, 2000, BIOESSAYS, V22, P138, DOI 10.1002/(SICI)1521 1878(200002)22:2<138::AID BIES5>3.0.CO;2 4
   Hamilton DW, 2004, TISSUE ENG, V10, P361, DOI 10.1089/107632704323061726
   Hipskind R.A., 1998, FRONT BIOSCI, V3, P804, DOI [10.2741/A323, DOI 10.2741/A323]
   Jagodzinski M, 2004, Eur Cell Mater, V7, P35
   Jaiswal RK, 2000, J BIOL CHEM, V275, P9645, DOI 10.1074/jbc.275.13.9645
   Jansen JHW, 2004, J CELL BIOCHEM, V93, P542, DOI 10.1002/jcb.20162
   Karsenty G, 2003, NATURE, V423, P316, DOI 10.1038/nature01654
   Kaspar D, 2002, J BIOMECH, V35, P873, DOI 10.1016/S0021 9290(02)00058 1
   Kawarizadeh A, 2005, J DENT RES, V84, P902, DOI 10.1177/154405910508401006
   Kearney EM, 2008, J BIOMECH ENG T ASME, V130, DOI 10.1115/1.2979870
   KENT RL, 1989, CIRC RES, V64, P74, DOI 10.1161/01.RES.64.1.74
   KIM YJ, 1988, ANAL BIOCHEM, V174, P168, DOI 10.1016/0003 2697(88)90532 5
   Kostenuik PJ, 1997, AM J PHYSIOL ENDOC M, V273, pE1133
   Lai CF, 2002, J BIOL CHEM, V277, P15514, DOI 10.1074/jbc.M200794200
   Lee KS, 2000, MOL CELL BIOL, V20, P8783, DOI 10.1128/MCB.20.23.8783 8792.2000
   Lee WCC, 2007, BIOMECH MODEL MECHAN, V6, P265, DOI 10.1007/s10237 006 0053 y
   Mackie EJ, 2003, INT J BIOCHEM CELL B, V35, P1301, DOI 10.1016/S1357 2725(03)00107 9
   Moretti M, 2004, J MATER SCI MATER M, V15, P1159, DOI 10.1023/B:JMSM.0000046400.18607.72
   MOREY ER, 1978, SCIENCE, V201, P1138, DOI 10.1126/science.150643
   Müller GB, 2003, EVOL DEV, V5, P56, DOI 10.1046/j.1525 142X.2003.03009.x
   Nieponice A, 2007, J BIOMED MATER RES A, V81A, P523, DOI 10.1002/jbm.a.31041
   Nohe A, 2002, J BIOL CHEM, V277, P5330, DOI 10.1074/jbc.M102750200
   OWEN TA, 1990, J CELL PHYSIOL, V143, P420, DOI 10.1002/jcp.1041430304
   Park SA, 2004, BIOMATERIALS, V25, P527, DOI 10.1016/S0142 9612(03)00553 2
   Petroff MGV, 2001, NAT CELL BIOL, V3, P867, DOI 10.1038/ncb1001 867
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Pratap J, 2003, CANCER RES, V63, P5357
   Prendergast PJ, 1997, J BIOMECH, V30, P539, DOI 10.1016/S0021 9290(96)00140 6
   ROBEY PG, 1985, CALCIFIED TISSUE INT, V37, P453, DOI 10.1007/BF02557826
   Robling AG, 2002, J BONE MINER RES, V17, P1545, DOI 10.1359/jbmr.2002.17.8.1545
   Robling AG, 2001, J EXP BIOL, V204, P3389
   Rochefort GY, 2005, RESP RES, V6, DOI 10.1186/1465 9921 6 125
   Rubin J, 2002, J BONE MINER RES, V17, P1452, DOI 10.1359/jbmr.2002.17.8.1452
   Sebastine I M, 2006, Conf Proc IEEE Eng Med Biol Soc, V2006, P3648
   Shea JE, 2003, J APPL PHYSIOL, V95, P631, DOI 10.1152/japplphysiol.01049.2002
   Simmons CA, 2003, J BIOMECH, V36, P1087, DOI 10.1016/S0021 9290(03)00110 6
   Song GB, 2007, COLLOID SURFACE B, V58, P271, DOI 10.1016/j.colsurfb.2007.04.001
   Srinivasan S, 2002, J BONE MINER RES, V17, P1613, DOI 10.1359/jbmr.2002.17.9.1613
   Suzawa M, 2003, NAT CELL BIOL, V5, P224, DOI 10.1038/ncb942
   Suzuma K, 2000, J BIOL CHEM, V275, P40725, DOI 10.1074/jbc.M006509200
   Turner CH, 1998, BONE, V23, P399, DOI 10.1016/S8756 3282(98)00118 5
   van Griensven M, 2005, TOPICS TISSUE ENG
   Wang FS, 2002, J BIOL CHEM, V277, P10931, DOI 10.1074/jbc.M104587200
   Ward Donald F. Jr., 2007, Molecular & Cellular Biomechanics, V4, P177
   Yamaguchi A, 2000, ENDOCR REV, V21, P393, DOI 10.1210/er.21.4.393
   Ziros PG, 2002, J BIOL CHEM, V277, P23934, DOI 10.1074/jbc.M109881200
NR 66
TC 98
Z9 125
U1 1
U2 46
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0090 6964
EI 1573 9686
J9 ANN BIOMED ENG
JI Ann. Biomed. Eng.
PD MAY
PY 2010
VL 38
IS 5
BP 1767
EP 1779
DI 10.1007/s10439 010 9979 4
PG 13
WC Engineering, Biomedical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering
GA 577EK
UT WOS:000276204600006
PM 20217480
DA 2025 08 17
ER

PT J
AU Ohba, S
   Ikeda, T
   Kugimiya, F
   Yano, F
   Lichtler, AC
   Nakamura, K
   Takato, T
   Kawaguchi, H
   Chung, UI
AF Ohba, Shinsuke
   Ikeda, Toshiyuki
   Kugimiya, Fumitaka
   Yano, Fumiko
   Lichtler, Alexander C.
   Nakamura, Kozo
   Takato, Tsuyoshi
   Kawaguchi, Hiroshi
   Chung, Ung il
TI Identification of a potent combination of osteogenic genes for bone
   regeneration using embryonic stem (ES) cell based sensor
SO FASEB JOURNAL
LA English
DT Article
DE osteogenesis; screening; biosensor; cell sheet
ID IN VITRO; OSTEOBLAST DIFFERENTIATION; TRANSCRIPTION FACTOR; BETA
   INTERACTS; RUNX2; OVEREXPRESSION; MARROW; GROWTH; REPAIR; MECHANISMS
AB To identify potent bioactive factors for in vivo tissue regeneration by comprehensive screening remains a challenge for regenerative medicine. Here we report the development of an ES cell based monitoring system for osteogenic differentiation, the identification of a potent combination of osteogenic genes using such a system, and an evaluation of its therapeutic potentials. ES cells were isolated from mice carrying a transgene expressing GFP driven by the 2.3 kb fragment of rat type I collagen alpha( 1) promoter. Using these cells engineered to fluoresce on osteogenic differentiation, we screened cDNA libraries and combinations of major osteogenesis related genes. Among them, the combination of constitutively active activin receptorlike kinase 6 (caALK6) and runt related transcription factor 2 ( Runx2) was the minimal unit that induced fluorescence. The combination efficiently induced osteogenic differentiation in various cell types, including terminally differentiated nonosteogenic cells. The cooperative action of the combination occurred through protein stabilization of core binding factor beta (Cbfb), induction of Runx2 Cbfb complex formation, and its DNA binding. Furthermore, transplantation of a monolayer sheet of fibroblasts transduced with the combination achieved bone regeneration within 4 wk in mouse calvarial bone defects. Thus, we successfully identified the potent combination of genes for bone regeneration, which helped broaden cell sources. Ohba, S., Ikeda, T., Kugimiya, F., Yano, F., Lichtler, A. C., Nakamura, K., Takato, T., Kawaguchi, H., Chung, U. I. Identification of a potent combination of osteogenic genes for bone regeneration using embryonic stem ( ES) cell based sensor.
C1 Univ Tokyo, Fac Med, Ctr Dis Biol & Integrat Med, Bunkyo Ku, Tokyo 1130033, Japan.
   Univ Connecticut, Ctr Hlth, Dept Genet & Dev Biol, Farmington, CT 06032 USA.
   Univ Tokyo, Fac Med, Div Sensory & Motor Syst Med, Bunkyo Ku, Tokyo 1130033, Japan.
   Japan Soc Promot Sci, Chiyoda Ku, Tokyo, Japan.
C3 University of Tokyo; University of Connecticut; University of Tokyo;
   Japan Society for the Promotion of Science
RP Chung, UI (通讯作者)，Univ Tokyo, Fac Med, Ctr Dis Biol & Integrat Med, Bunkyo Ku, 7 3 1 Hongo, Tokyo 1130033, Japan.
EM uichung tky@umin.ac.jp
RI Ikeda, Toshiyuki/GVS 5588 2022
OI Ohba, Shinsuke/0000 0002 6874 8539
CR Altaba ARI, 1999, DEVELOPMENT, V126, P3205
   Balint E, 2003, J CELL BIOCHEM, V89, P401, DOI 10.1002/jcb.10515
   Bauer TW, 2002, CLIN ORTHOP RELAT R, P11
   BEE JS, 2006, IN PRESS J CELL BIOC
   Bradley A., 1987, TERATOCARCINOMAS EMB, P113
   Bridwell KH, 2004, J BONE JOINT SURG AM, V86A, P1587, DOI 10.2106/00004623 200407000 00033
   Bruder SP., 2000, PRINCIPLES TISSUE EN, V2nd, P683
   Buttery LDK, 2001, TISSUE ENG, V7, P89, DOI 10.1089/107632700300003323
   Byers BA, 2004, TISSUE ENG, V10, P1757, DOI 10.1089/ten.2004.10.1757
   Byers BA, 2002, J BONE MINER RES, V17, P1931, DOI 10.1359/jbmr.2002.17.11.1931
   Cowan CM, 2004, NAT BIOTECHNOL, V22, P560, DOI 10.1038/nbt958
   Franceschi RT, 2000, J CELL BIOCHEM, V78, P476, DOI 10.1002/1097 4644(20000901)78:3<476::AID JCB12>3.0.CO;2 5
   Geesink RGT, 1999, J BONE JOINT SURG BR, V81B, P710, DOI 10.1302/0301 620X.81B4.9311
   GEY GO, 1952, CANCER RES, V12, P264
   Hirata K, 2003, BONE, V32, P502, DOI 10.1016/S8756 3282(03)00054 1
   Huang G, 2001, EMBO J, V20, P723, DOI 10.1093/emboj/20.4.723
   JAINCHIL.JL, 1969, J VIROL, V4, P549, DOI 10.1128/JVI.4.5.549 553.1969
   Jayme D W, 1985, Adv Biotechnol Processes, V5, P1
   Jiang YH, 2002, EXP HEMATOL, V30, P896, DOI 10.1016/S0301 472X(02)00869 X
   Kalajzic I, 2002, J BONE MINER RES, V17, P15, DOI 10.1359/jbmr.2002.17.1.15
   Katagiri T, 2002, ORAL DIS, V8, P147, DOI 10.1034/j.1601 0825.2002.01829.x
   KAUFMAN M, 1994, ATLAS MOUSE DEV, P495
   Kojima H, 2005, J BIOL CHEM, V280, P2944, DOI 10.1074/jbc.M311598200
   Komori T, 2003, J BONE MINER METAB, V21, P193, DOI 10.1007/s00774 002 0408 0
   Krebsbach PH, 2000, HUM GENE THER, V11, P1201, DOI 10.1089/10430340050015248
   Kronenberg HM, 2003, NATURE, V423, P332, DOI 10.1038/nature01657
   Kugimiya F, 2005, J BIOL CHEM, V280, P35704, DOI 10.1074/jbc.M505166200
   Kundu M, 2002, NAT GENET, V32, P639, DOI 10.1038/ng1050
   LANGER R, 1993, SCIENCE, V260, P920, DOI 10.1126/science.8493529
   Lieberman JR, 2002, J BONE JOINT SURG AM, V84A, P1032, DOI 10.2106/00004623 200206000 00022
   Long FX, 2004, DEVELOPMENT, V131, P1309, DOI 10.1242/dev.01006
   Long FX, 2001, DEVELOPMENT, V128, P5099
   Nakashima K, 2003, TRENDS GENET, V19, P458, DOI 10.1016/S0168 9525(03)00176 8
   Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092 8674(02)00654 2
   Ogasawara T, 2004, MOL CELL BIOL, V24, P6560, DOI 10.1128/mcb.24.15.6560 6568.2004
   Ogata N, 2000, J CLIN INVEST, V105, P935, DOI 10.1172/JCI9017
   Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014 5793(97)00313 X
   Otto WR, 2004, CELL PROLIFERAT, V37, P97, DOI 10.1111/j.1365 2184.2004.00303.x
   Patel MS, 2002, NEW ENGL J MED, V346, P1572, DOI 10.1056/NEJM200205163462011
   Phimphilai M, 2006, J BONE MINER RES, V21, P637, DOI 10.1359/JBMR.060109
   Salgado AJ, 2005, BIODEGRADABLE SYSTEMS IN TISSUE ENGINEERING AND REGENERATIVE MEDICINE, P457
   Sekiya I, 2002, P NATL ACAD SCI USA, V99, P4397, DOI 10.1073/pnas.052716199
   Shi ST, 2002, NAT BIOTECHNOL, V20, P587, DOI 10.1038/nbt0602 587
   VERBRUGGEN LA, 1980, ARCH DERMATOL RES, V269, P111, DOI 10.1007/BF00406531
   Vleminckx K, 1999, MECH DEVELOP, V81, P65, DOI 10.1016/S0925 4773(98)00225 1
   Yamato M, 2002, BIOMATERIALS, V23, P561, DOI 10.1016/S0142 9612(01)00138 7
   Yang SY, 2003, J BONE MINER RES, V18, P705, DOI 10.1359/jbmr.2003.18.4.705
   Yano F, 2005, BIOCHEM BIOPH RES CO, V333, P1300, DOI 10.1016/j.bbrc.2005.06.041
   Yoshida CA, 2002, NAT GENET, V32, P633, DOI 10.1038/ng1015
   zur Nieden NI, 2003, DIFFERENTIATION, V71, P18, DOI 10.1046/j.1432 0436.2003.700602.x
NR 50
TC 25
Z9 25
U1 0
U2 13
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0892 6638
EI 1530 6860
J9 FASEB J
JI Faseb J.
PD JUN
PY 2007
VL 21
IS 8
BP 1777
EP 1787
DI 10.1096/fj.06 7571com
PG 11
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine   Other
   Topics; Cell Biology
GA 173IK
UT WOS:000246866500020
PM 17317722
DA 2025 08 17
ER

PT J
AU Kim, MO
   Jung, H
   Kim, SC
   Park, JK
   Seo, YK
AF Kim, Min Ok
   Jung, Hyun
   Kim, Soo Chan
   Park, Jung Keug
   Seo, Young Kwon
TI Electromagnetic fields and nanomagnetic particles increase the
   osteogenic differentiation of human bone marrow derived mesenchymal stem
   cells
SO INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
LA English
DT Article
DE electromagnetic fields; osteogenic differentiation; nanomagnetic
   particles; human bone marrow derived mesenchymal stem cells
ID OSTEOBLAST DIFFERENTIATION; PROLIFERATION; EXPRESSION; GENE;
   OSTEOCALCIN; PATHWAYS; CBFA1
AB Human bone marrow derived mesenchymal stem cells (hBM MSCs) are widely used in a number of cell therapies and have osteogenic differentiation capacity. Exposure to electromagnetic fields (EMFs) increases the osteogenic differentiation of hBM MSCs. Nanomagnetic particles (MPs) also promote the differentiation potential of stem cells. In the present study, we investigated the effects of EMFs and MPs on the osteogenic differentiation of hBM MSCs. hBM MSCs were treated with 50 g/ml of Fe3O4 MPs or exposed to a frequency of 45 Hz and an intensity of 1 mT EMF twice every 8 h per day for 7 days. MP incorporation, EMF exposure and MP incorporation with exposure to EMFs did not induce cytotoxic effects. A strong expression of osteogenic markers (osteocalcin, osteopontin and osteonectin) and von Kossa staining intensity was observed in the cells treated with MPs, the cells exposed to EMFs and in the cells treated with MPs and exposed to EMFs compared with the control group, as shown by immunohistochemical staining. Quantitative RT PCR revealed that the mRNA expression levels of osteoblast markers [osteocalcin, osteopontin, osteonectin, collagen I, collagen III, bone morphogenetic protein 2 (BMP 2), bone sialoprotein (BSP) and runt related transcription factor 2 (Runx 2)] were markedly increased in the cells treated with MPs and exposed to EMFs. Furthermore, the mRNA expression of calcium channels (CACNA1C, CACNA1E, CACNA1G and CACNA1I) was activated during osteogenic differentiation. The expression levels of osteogenesis related proteins (BSP, BMP 2, osteopontin and osteonectin) and phosphorylated extracellular signal regulated kinase (p ERK) were increased in the cells treated with MPs, those exposed to EMFs and in the cells treated with MPs and exposed to EMFs compared with the control group, as shown by western blot analysis. Fluorescence activated cell sorting (FACS) analysis was performed for the hBM MSC markers, CD73, CD90 and CD105. The expression levels of hBM MSC surface antigens were decreased in the cells treated with MPs, those exposed to EMFs and in the cells treated with MPs and exposed to EMFs compared with the control group. The cell numbers were determined to be approximately 3.4x10(5) cells in the control group, 3.7x10(5) cells in the MP treated group, 3.1x10(5) cells in the group exposed to EMFs and 3.9x10(5) cells in the group treated with MPs and exposed to EMFs. The cell mitochondrial activity among the 4 experimental groups was similar. The hBM MSCs treated with MPs and exposed to EMFs showed an increase in alkaline phosphatase (ALP) activity. Taken together, these results suggest that the treatment of hBM MSCs with MPs or exposure to EMFs increases osteogenic differentiation, and that treatment with MPs in conjunction with EMF exposure is more effective in increasing osteogenic differentiation.
C1 [Kim, Min Ok; Park, Jung Keug; Seo, Young Kwon] Dongguk Univ, Dept Med Biotechnol, Seoul 100715, South Korea.
   [Jung, Hyun] Dongguk Univ, Dept Chem, Seoul 100715, South Korea.
   [Kim, Soo Chan] Hankyong Natl Univ, Grad Sch Bio & Informat Technol, Anseong 456749, Kyonggi Do, South Korea.
C3 Dongguk University; Dongguk University; Hankyong National University
RP Seo, YK (通讯作者)，Dongguk Univ, Dept Med Biotechnol, Pil Dong 3 Ga, Seoul 100715, South Korea.
EM bioseo@dongguk.edu
RI JUNG, Hyun/AAQ 7463 2021
FU Pioneer Research Center Program through the National Research Foundation
   of Korea   Ministry of Science, ICT and Future Planning, Republic of
   Korea [2009 0082941]
FX The present study was supported by the Pioneer Research Center Program
   through the National Research Foundation of Korea funded by the Ministry
   of Science, ICT and Future Planning, Republic of Korea (grant number
   2009 0082941).
CR Azuma N, 2000, J VASC SURG, V32, P789, DOI 10.1067/mva.2000.107989
   Barry FP, 2004, INT J BIOCHEM CELL B, V36, P568, DOI 10.1016/j.biocel.2003.11.001
   BASSETT CA, 1964, NATURE, V204, P652, DOI 10.1038/204652a0
   Bielby R, 2007, INJURY, V38, pS26, DOI 10.1016/j.injury.2007.02.007
   BILLS CE, 1971, JOHNS HOPKINS MED J, V128, P194
   Bobis S, 2007, FOLIA HISTOCHEM CYTO, V44, P215
   Cartmell Sarah H, 2002, IEEE Trans Nanobioscience, V1, P92, DOI 10.1109/TNB.2002.806945
   Cho H, 2013, BIOTECHNOL APPL BIOC, V60, P596, DOI 10.1002/bab.1109
   Ducy P, 1996, NATURE, V382, P448, DOI 10.1038/382448a0
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Ferraro JT, 2004, AM J PHYSIOL CELL PH, V286, pC831, DOI 10.1152/ajpcell.00224.2003
   FUKADA E, 1957, J PHYS SOC JPN, V12, P1158, DOI 10.1143/JPSJ.12.1158
   Gundberg CM, 2002, BONE, V31, P703, DOI 10.1016/S8756 3282(02)00902 X
   Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870
   Kapur S, 2003, BONE, V32, P241, DOI 10.1016/S8756 3282(02)00979 1
   KELM RJ, 1992, BLOOD, V80, P3112
   Klar RM, 2013, J CELL MOL MED, V17, P1444, DOI 10.1111/jcmm.12125
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Komori T, 2010, CELL TISSUE RES, V339, P189, DOI 10.1007/s00441 009 0832 8
   Lai CF, 2001, J BIOL CHEM, V276, P14443, DOI 10.1074/jbc.M010021200
   MELOAN S N, 1985, Journal of Histotechnology, V8, P11
   Mitchell D.B., 1980, Journal of tissue culture methods, V6, P113, DOI DOI 10.1007/BF02082861
   MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431
   OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262
   Oldenhof AD, 2002, AM J PHYSIOL CELL PH, V283, pC1530, DOI 10.1152/ajpcell.00607.2001
   Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092 8674(00)80259 7
   Pankhurst QA, 2003, J PHYS D APPL PHYS, V36, pR167, DOI 10.1088/0022 3727/36/13/201
   PUCHTLER H, 1985, HISTOCHEMISTRY, V82, P201, DOI 10.1007/BF00501395
   Sadan O, 2009, EXPERT OPIN BIOL TH, V9, P1487, DOI 10.1517/14712590903321439
   Schieker M, 2007, J ANAT, V210, P592, DOI 10.1111/j.1469 7580.2007.00716.x
   Schwartz Z, 2008, J ORTHOP RES, V26, P1250, DOI 10.1002/jor.20591
   Schwartz Z, 1999, Adv Dent Res, V13, P38
   Sodek J, 2000, CRIT REV ORAL BIOL M, V11, P279, DOI 10.1177/10454411000110030101
   Sun LY, 2010, BIOELECTROMAGNETICS, V31, P209, DOI 10.1002/bem.20550
   Tsai MT, 2009, J ORTHOP RES, V27, P1169, DOI 10.1002/jor.20862
   von Kóssa J, 1901, BEITR PATHOL ANAT AL, V29, P163
   Wen L, 2012, BIOCHEM BIOPH RES CO, V424, P439, DOI 10.1016/j.bbrc.2012.06.128
NR 37
TC 50
Z9 56
U1 0
U2 30
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1107 3756
EI 1791 244X
J9 INT J MOL MED
JI Int. J. Mol. Med.
PD JAN
PY 2015
VL 35
IS 1
BP 153
EP 160
DI 10.3892/ijmm.2014.1978
PG 8
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA AX0MW
UT WOS:000346647300018
PM 25352086
OA Bronze
DA 2025 08 17
ER

PT J
AU Zhang, YF
   Miron, RJ
   Li, S
   Shi, B
   Sculean, A
   Cheng, XR
AF Zhang, Yufeng
   Miron, Richard J.
   Li, Sue
   Shi, Bin
   Sculean, Anton
   Cheng, Xiangrong
TI Novel MesoPorous BioGlass/silk scaffold containing adPDGF B and adBMP7
   for the repair of periodontal defects in beagle dogs
SO JOURNAL OF CLINICAL PERIODONTOLOGY
LA English
DT Article
DE gene therapy; growth factors; intrabony defect; osteoinduction;
   periodontal defect
ID RANDOMIZED CLINICAL TRIAL; BETA TRICALCIUM PHOSPHATE; GROWTH FACTOR;
   GENE THERAPY; RHPDGF BB; RIDGE AUGMENTATION; BONE REGENERATION; EXHIBITS
   SAFETY; PDGF B; ADENOVIRUS
AB Aim: The local delivery of growth factors via gene therapy has gained tremendous awareness in recent years due to their sustained growth factor delivery to target tissues. The aim of this study was to fabricate and investigate a scaffold able to release growth factors via gene therapy for the repair of periodontal tissues.
   Materials and Methods: Novel mesoporous bioglass (MBG)/silk fibrin scaffold combined with BMP7 and/or PDGF B adenovirus was fabricated and tested in vitro for cell migration, proliferation and differentiation. Furthermore, acute type buccal dehiscence periodontal defects (mesiodistal width 9 depth: 5 9 5 mm) were created on the buccal portion of the maxillary premolars in five normal male beagle dogs (12 months old, 15.0 +/  2.0 kg) and histologically examined for periodontal regeneration following implantation of the following five groups: (1) no scaffold, (2) MBG/silk scaffold alone, (3) scaffold + adPDGF B, (4) scaffold + adBMP7, (5) scaffold + adPDGF b + adBMP7.
   Results: In vitro findings demonstrated that adPDGF B was able to rapidly recruit periodontal ligament (PDL) cells over sixfold more effectively than adBMP7, whereas adBMP7 was more able to induce osteoblast differentiation of PDL cells. In vivo findings demonstrate that scaffolds loaded with adPDGF B were able to partially regenerate the periodontal ligament while adBMP7 scaffolds primarily improved new bone formation. The combination of both adPDGF B and adBMP7 synergistically promoted periodontal regeneration by allowing up to two times greater regeneration of the periodontal ligament, alveolar bone and cementum when compared to each adenovirus used alone.
   Conclusions: Although both PDGF B and BMP7 are individually capable of promoting periodontal regeneration to some degree, their combination synergistically promotes wound healing in acute type buccal dehiscence periodontal defects when
C1 [Zhang, Yufeng; Miron, Richard J.; Li, Sue; Shi, Bin; Cheng, Xiangrong] Wuhan Univ, Sch & Hosp Stomatol, State Key Lab Breeding Base Basic Sci Stomatol Hu, Minist Educ, Wuhan 430079, Peoples R China.
   [Zhang, Yufeng; Miron, Richard J.; Li, Sue; Shi, Bin; Cheng, Xiangrong] Wuhan Univ, Sch & Hosp Stomatol, Key Lab Oral Biomed, Minist Educ, Wuhan 430079, Peoples R China.
   [Zhang, Yufeng; Shi, Bin] Wuhan Univ, Dept Oral Implantol, Sch Stomatol, Wuhan 430079, Peoples R China.
   [Miron, Richard J.; Sculean, Anton] Univ Bern, Sch Dent Med, Dept Periodontol, Bern, Switzerland.
C3 Wuhan University; Wuhan University; Wuhan University; University of Bern
RP Zhang, YF (通讯作者)，Wuhan Univ, Sch & Hosp Stomatol, State Key Lab Breeding Base Basic Sci Stomatol Hu, Minist Educ, 237 Luoyu Rd, Wuhan 430079, Peoples R China.
EM zyf@whu.edu.cn
RI Zhang, Yufeng/GZL 1973 2022; Miron, Richard/J 4995 2012
OI Zhang, Yufeng/0000 0001 8702 5291
FU ITI Foundation for the Promotion of Implantology, Basel, Switzerland;
   National Natural Science Foundation of China [81271108]
FX The authors report no conflict of interest for this study. This work was
   financially supported by the funds of the ITI Foundation for the
   Promotion of Implantology, Basel, Switzerland, and funds of the National
   Natural Science Foundation of China (81271108).
CR Anusaksathien Orasa, 2002, Current Pharmaceutical Biotechnology, V3, P129, DOI 10.2174/1389201023378391
   Bersenev A, 2012, REGEN MED, V7, P50, DOI [10.2217/rme.12.71, 10.2217/RME.12.71]
   Camelo M, 2003, INT J PERIODONT REST, V23, P213
   Cha JK, 2014, J CLIN PERIODONTOL, V41, P86, DOI 10.1111/jcpe.12174
   Chang PC, 2010, GENE THER, V17, P95, DOI 10.1038/gt.2009.117
   Chang PC, 2009, HUM GENE THER, V20, P486, DOI 10.1089/hum.2008.114
   Chaudhari A, 2012, J CLIN PERIODONTOL, V39, P1206, DOI 10.1111/jcpe.12005
   Chen FM, 2010, BIOMATERIALS, V31, P6279, DOI 10.1016/j.biomaterials.2010.04.053
   Cochran DL, 1999, PERIODONTOL 2000, V19, P40, DOI 10.1111/j.1600 0757.1999.tb00146.x
   de Freitas RM, 2013, J CLIN PERIODONTOL, V40, P968, DOI 10.1111/jcpe.12148
   Emerton KB, 2011, J DENT RES, V90, P1416, DOI 10.1177/0022034511423665
   Evans C, 2011, INJURY, V42, P599, DOI 10.1016/j.injury.2011.03.032
   Fang JM, 1996, P NATL ACAD SCI USA, V93, P5753, DOI 10.1073/pnas.93.12.5753
   Fiedler J, 2002, J CELL BIOCHEM, V87, P305, DOI 10.1002/jcb.10309
   Ghosh SS, 2006, APPL BIOCHEM BIOTECH, V133, P9, DOI 10.1385/ABAB:133:1:9
   Govender S, 2002, J BONE JOINT SURG AM, V84A, P2123, DOI 10.2106/00004623 200212000 00001
   Grzesik WJ, 2002, CRIT REV ORAL BIOL M, V13, P474, DOI 10.1177/154411130201300605
   Gu DL, 2004, MOL THER, V9, P699, DOI 10.1016/j.ymthe.2004.02.018
   Gugala Z, 2007, BIOMATERIALS, V28, P4469, DOI 10.1016/j.biomaterials.2007.07.007
   Habisch HJ, 2008, CYTOTHERAPY, V10, P824, DOI 10.1080/14653240802474331
   Ilic D, 2013, REGEN MED, V8, P9
   Jayakumar A, 2011, J CLIN PERIODONTOL, V38, P163, DOI 10.1111/j.1600 051X.2010.01639.x
   Jiang XQ, 2009, BIOMATERIALS, V30, P4522, DOI 10.1016/j.biomaterials.2009.05.021
   Jung RE, 2008, J CLIN PERIODONTOL, V35, P255, DOI 10.1111/j.1600 051X.2008.01270.x
   Kamimura Kenya, 2011, Pharmaceut Med, V25, P293
   KAPLAN DR, 1979, BLOOD, V53, P1043
   Kimelman N, 2006, REGEN MED, V1, P549, DOI 10.2217/17460751.1.4.549
   Lissenberg Thunnissen SN, 2011, INT ORTHOP, V35, P1271, DOI 10.1007/s00264 011 1301 z
   Miron RJ, 2012, J DENT RES, V91, P736, DOI 10.1177/0022034511435260
   Miron RJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071008
   Miron RJ, 2013, CLIN ORAL INVEST, V17, P405, DOI 10.1007/s00784 012 0742 0
   Mishra A, 2013, J CLIN PERIODONTOL, V40, P172, DOI 10.1111/jcpe.12030
   Phillips JE, 2007, BIOMATERIALS, V28, P211, DOI 10.1016/j.biomaterials.2006.07.032
   Ramseier Christoph A, 2006, Dent Clin North Am, V50, P245, DOI 10.1016/j.cden.2005.12.001
   Ramseier CA, 2012, PERIODONTOL 2000, V59, P185, DOI 10.1111/j.1600 0757.2011.00432.x
   Rios HF, 2011, J PERIODONTOL, V82, P1223, DOI 10.1902/jop.2011.100710
   Sarment DP, 2006, J CLIN PERIODONTOL, V33, P135, DOI 10.1111/j.1600 051X.2005.00870.x
   Steed DL, 1996, J AM COLL SURGEONS, V183, P61
   Wang HL, 2005, J PERIODONTOL, V76, P1601
   Wang JX, 2012, J CLIN PERIODONTOL, V39, P98, DOI 10.1111/j.1600 051X.2011.01807.x
   White AP, 2007, INT ORTHOP, V31, P735, DOI 10.1007/s00264 007 0422 x
   Wieman TJ, 1998, DIABETES CARE, V21, P822, DOI 10.2337/diacare.21.5.822
   Wikesjö UME, 1999, PERIODONTOL 2000, V19, P21, DOI 10.1111/j.1600 0757.1999.tb00145.x
   Wu CT, 2011, BIOMATERIALS, V32, P7068, DOI 10.1016/j.biomaterials.2011.06.009
   Wu CT, 2011, ACTA BIOMATER, V7, P2229, DOI 10.1016/j.actbio.2010.12.019
   Zhang YF, 2012, BONE, V51, P704, DOI 10.1016/j.bone.2012.06.029
   Zhang YF, 2012, BIOMATERIALS, V33, P6698, DOI 10.1016/j.biomaterials.2012.06.021
   Zhang YF, 2010, BIOMATERIALS, V31, P2848, DOI 10.1016/j.biomaterials.2009.12.049
NR 48
TC 36
Z9 40
U1 2
U2 42
PU WILEY BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0303 6979
EI 1600 051X
J9 J CLIN PERIODONTOL
JI J. Clin. Periodontol.
PD MAR
PY 2015
VL 42
IS 3
BP 262
EP 271
DI 10.1111/jcpe.12364
PG 10
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA CD7VR
UT WOS:000351303600006
PM 25580515
DA 2025 08 17
ER

PT J
AU Chen, GY
   Wang, QY
   Yang, QW
   Li, ZY
   Du, ZW
   Ren, M
   Zhao, HY
   Song, Y
   Zhang, GZ
AF Chen, Gaoyang
   Wang, Qingyu
   Yang, Qiwei
   Li, Zhaoyan
   Du, Zhenwu
   Ren, Ming
   Zhao, Haiyue
   Song, Yang
   Zhang, Guizhen
TI Circular RNAs hsa_circ_0032462, hsa_circ_0028173, hsa_circ_0005909 are
   predicted to promote CADM1 expression by functioning as miRNAs sponge in
   human osteosarcoma
SO PLOS ONE
LA English
DT Article
ID MOLECULAR PATHOGENESIS; CANCER; GENES; CELLS; DIFFERENTIATION;
   PROLIFERATION; CARCINOMA; INVASION; PLAYS
AB Background
   Osteosarcoma (OS) is a primary malignant bone tumor with a high fatality rate. Many circRNAs have been proved to play important roles in the pathogenesis of some diseases. However, the occurrence of circRNAs in OS remains little known.
   Methods
   The circular RNA (circRNA) expression file GSE96964 dataset, which included seven osteosarcoma cell lines and one control sample (osteoblast cell line), was downloaded from the Gene Expression Omnibus (GEO) database to explore the potential function of circRNAs in osteosarcoma by competing endogenous RNA (ceRNA) analysis. Three gene expression profiles of OS were downloaded from GEO database and then used for the pathway enrichment analysis, Venn analysis and protein protein interaction (PPI) network analysis. Realtime qPCR validation and RNA interference were conducted to verify our prediction.
   Results
   Differentially expressed circRNAs between OS and control, including 8 up regulated and 102 down regulated circRNAs, were generated and ceRNA analysis for 5 most up regulated or 5 most down regulated circRNAs in OS were then performed. The pathway enrichment analysis of gene expression profiles indicated differentially expressed genes (DEGs) of three gene profiles significantly enriched in cell cycle pathway, cell adhesion molecules (CAMs) pathway, oxidative phosphorylation pathway, cytokine cytokine receptor interaction pathway, p53 signaling pathway and proteoglycans in cancer pathway, which were critical important pathways in the pathogenesis of OS. The Venn analysis showed that 2 (one is a pseudogene) up regulated and 39 down regulated DEGs were co expressed in all three gene profiles. Then PPI networks of 41 co expressed DEGs (up  and down regulated DEGs) were constructed to predict their functions using the GeneMANIA. The expression levels of these related RNAs also matched our predictions really well.
   Conclusion
   Ultimately, we found cell adhesion molecule 1 (CADM1) gene was not only a co expression mRNA of the three mRNA expression profiles of OS, but also are predicted to be regulated by hsa_circ_0032462, hsa_circ_0028173, hsa_circ_0005909 by functioning as miRNAs `Sponge' in human osteosarcoma. These over expressed circRNAs may result in the over expression of CADM1 which promote the development of OS. We envision this discovery of these important moleculars, incuding hsa_circ_0032462, hsa_circ_0028173, hsa_circ_0005909 and CADM1 may lead to further development of new concepts, thus allowing for more opportunities in diagnosis and therapy of OS.
C1 [Chen, Gaoyang; Wang, Qingyu; Li, Zhaoyan; Du, Zhenwu; Ren, Ming; Song, Yang; Zhang, Guizhen] Jilin Univ, Hosp 2, Dept Orthoped, Changchun, Jilin, Peoples R China.
   [Chen, Gaoyang; Wang, Qingyu; Yang, Qiwei; Du, Zhenwu; Zhao, Haiyue; Zhang, Guizhen] Jilin Univ, Hosp 2, Res Ctr, Changchun, Jilin, Peoples R China.
   [Chen, Gaoyang; Wang, Qingyu; Yang, Qiwei; Li, Zhaoyan; Du, Zhenwu; Ren, Ming; Zhao, Haiyue; Song, Yang; Zhang, Guizhen] Engn Res Ctr Mol Diag & Cell Treatment Metab Bone, Changchun, Jilin, Peoples R China.
C3 Jilin University; Jilin University
RP Song, Y; Zhang, GZ (通讯作者)，Jilin Univ, Hosp 2, Dept Orthoped, Changchun, Jilin, Peoples R China.; Zhang, GZ (通讯作者)，Jilin Univ, Hosp 2, Res Ctr, Changchun, Jilin, Peoples R China.; Song, Y; Zhang, GZ (通讯作者)，Engn Res Ctr Mol Diag & Cell Treatment Metab Bone, Changchun, Jilin, Peoples R China.
EM songyangjlu@foxmail.com; zhangguizhenjlu@163.com
RI Yang, Qiwei/HTS 3386 2023; Li, ZhuoYang/KXR 7635 2024; Zhang,
   Chunhong/T 9358 2019; Wang, Chenyu/G 3576 2019
OI Yang, Qiwei/0000 0003 0681 2184; Wang, Qingyu/0000 0002 6298 5357
FU National Natural Science Foundation of China [81702195]; project of
   application demonstration center of precision medicine for molecular
   diagnosis in Jilin Province (NDRC); Department of Science and Technology
   of Jilin Province, China [20180520125JH]; Education Department of Jilin
   Province, China [JJKH20170853KJ]; Bethune Youth Foundation of Jilin
   University, China [2015409]; Health Management Department of Jilin
   Province, China [20132003]
FX This work was supported by the Project supported by the National Natural
   Science Foundation of China (Grant No. 81702195), the project of
   application demonstration center of precision medicine for molecular
   diagnosis in Jilin Province (2016 2018, NDRC), the Department of Science
   and Technology of Jilin Province, China (Grant No. 20180520125JH), the
   Project of Education Department of Jilin Province, China (Grant No.
   JJKH20170853KJ), the Project of Bethune Youth Foundation of Jilin
   University, China (Grant No. 2015409), the Project of Health Management
   Department of Jilin Province, China (Grant No. 20132003).
CR Abarrategi A, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/3631764
   Bai XP, 2018, J CELL BIOCHEM, V119, P2179, DOI 10.1002/jcb.26379
   Barrett SP, 2016, DEVELOPMENT, V143, P1838, DOI 10.1242/dev.128074
   Biederer T, 2002, SCIENCE, V297, P1525, DOI 10.1126/science.1072356
   Cesana M, 2011, CELL, V147, P358, DOI 10.1016/j.cell.2011.09.028
   Chen L, 2017, ONCOGENE, V36, P4551, DOI 10.1038/onc.2017.89
   Chen P, 2012, J MOL HISTOL, V43, P63, DOI 10.1007/s10735 011 9370 2
   Chiappetta C, 2017, ONCOTARGET, V8, P80416, DOI 10.18632/oncotarget.19010
   CLEZARDIN P, 1993, CANCER RES, V53, P4695
   Dang HS, 2017, ONCOL RES, V25, P177, DOI 10.3727/096504016X14732772150343
   Coelho KMDA, 2017, PATHOL RES PRACT, V213, P1067, DOI 10.1016/j.prp.2017.07.028
   Deng NA, 2018, BIOCHEM BIOPH RES CO, V495, P189, DOI 10.1016/j.bbrc.2017.11.028
   Deng ZM, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/496193
   Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb 2003 4 9 r60
   Dhondge A, 2012, ENVIRON SCI POLLUT R, V19, P4030, DOI 10.1007/s11356 012 0879 z
   Duijvis NW, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185097
   Evola FR, 2017, FRONT PHARMACOL, V8, P1, DOI [10.3389/fphar.2017.00001, DOI 10.3389/FPHAR.2017.00001]
   Guan J, 2016, EXP THER MED, V12, P2815, DOI 10.3892/etm.2016.3713
   He JP, 2014, ASIAN PAC J CANCER P, V15, P5967, DOI 10.7314/APJCP.2014.15.15.5967
   Helvering LM, 2005, MOL PHARMACOL, V68, P1225, DOI 10.1124/mol.105.011478
   Howe JR, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177661
   Inoue T, 2013, LIFE SCI, V92, P91, DOI 10.1016/j.lfs.2012.10.021
   Islam F, 2018, EXP MOL PATHOL, V104, P98, DOI 10.1016/j.yexmp.2018.01.006
   Ito A, 2012, ISLETS, V4, DOI 10.4161/isl.18675
   Ito T, 2011, GENES CELLS, V16, P791, DOI 10.1111/j.1365 2443.2011.01525.x
   Jin X, 2016, ONCOTARGET, V7, P66455, DOI 10.18632/oncotarget.12186
   Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27
   Lin YH, 2017, TRENDS MOL MED, V23, P737, DOI 10.1016/j.molmed.2017.06.004
   Lindsey BA, 2017, RHEUMATOL THER, V4, P25, DOI 10.1007/s40744 016 0050 2
   Liu PT, 2017, ONCOL LETT, V14, P4779, DOI 10.3892/ol.2017.6747
   Liu Q, 2016, SCI REP UK, V6, DOI 10.1038/srep22572
   Liu WH, 2017, CELL PHYSIOL BIOCHEM, V43, P969, DOI 10.1159/000481650
   Liu Y, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 14088 3
   Meng G, 2015, TUMOR BIOL, V36, P3009, DOI 10.1007/s13277 014 2935 4
   Nikitovic D, 2008, CONNECT TISSUE RES, V49, P235, DOI 10.1080/03008200802147589
   Pahl JHW, 2013, CANCER IMMUNOL IMMUN, V62, P1235, DOI 10.1007/s00262 013 1406 x
   Palmini G, 2017, MOLECULES, V22, DOI 10.3390/molecules22030417
   Palorini R, 2014, J CELL BIOCHEM, V115, P368, DOI 10.1002/jcb.24671
   Patop IL, 2018, CURR OPIN GENET DEV, V48, P121, DOI 10.1016/j.gde.2017.11.007
   Perbal B, 2008, CLIN CANCER RES, V14, P701, DOI 10.1158/1078 0432.CCR 07 0806
   Rybak Wolf A, 2015, MOL CELL, V58, P870, DOI 10.1016/j.molcel.2015.03.027
   Salmena L, 2011, CELL, V146, P353, DOI 10.1016/j.cell.2011.07.014
   Selamat W, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129634
   Song YZ, 2018, BIOCHEM BIOPH RES CO, V495, P2369, DOI 10.1016/j.bbrc.2017.12.050
   Sun CH, 2017, ONCOTARGET, V8, P70271, DOI 10.18632/oncotarget.20082
   Tang YY, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317705745
   Yang JX, 2016, ONCOL LETT, V12, P3075, DOI 10.3892/ol.2016.5060
   Zhang W, 2016, HEPATOB PANCREAT DIS, V15, P289, DOI 10.1016/S1499 3872(16)60099 1
   Zhang ZH, 2017, ENVIRONMENTAL DATA ANALYSIS: METHODS AND APPLICATIONS, P1, DOI 10.1515/9783110424904 002
   Zhao MD, 2014, INT J MOL MED, V34, P1565, DOI 10.3892/ijmm.2014.1963
   Zhu KP, 2017, ONCOTARGET, V8, P71881, DOI 10.18632/oncotarget.17985
NR 51
TC 40
Z9 42
U1 0
U2 18
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD AUG 28
PY 2018
VL 13
IS 8
AR e0202896
DI 10.1371/journal.pone.0202896
PG 18
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA GR8TH
UT WOS:000443001700030
PM 30153287
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Leong, WF
   Chau, JFL
   Li, BJ
AF Leong, Wai Fook
   Chau, Jenny Fung Ling
   Li, Baojie
TI p53 Deficiency Leads to Compensatory Up Regulation of p16INK4a
SO MOLECULAR CANCER RESEARCH
LA English
DT Article
ID ETS TRANSCRIPTION FACTORS; P16(INK4A) EXPRESSION; WILD TYPE; CANCER;
   SENESCENCE; GENES; CELLS; MICE; PROLIFERATION; TUMORIGENESIS
AB p53 p21 cyclin dependent kinase and p16(INK4a) cyclin dependent kinase pathways have parallel functions in preventing tumorigenesis. In cancer patients, tumor suppressor p53 is frequently inactivated through mutations, whereas p16(INK4a) is silenced through promoter methylation. However, the interaction between these two pathways is less well understood. Here, we report that p53 controls p16(INK4a) expression in a unique way. p53 deficiency led to up regulation of p16(INK4a) in primary mouse embryonic fibroblasts, osteoblasts, and various mouse organs, and an increase in the p16(INK4a) promoter activity, without affecting the half life of p16(INK4a). Reconstitution of p53, but not mutant p53, restored the proper expression of p16(INK4a). These results indicate that p53 is necessary in repressing p16(INK4a) expression. However, up regulation of p53 in response to genotoxic stress or nutlin 3 treatment did not down regulate p16(INK4a). p53 did not repress the p16(INK4a) promoter activity either. These findings suggest that p53 has a necessary but not sufficient role in repressing p16(INK4a) expression. p16(INK4a) elevation in p53( / ) cells is, at least partially, mediated by Ets1, a known positive regulator of p16(INK4a), as p53 deficiency up regulated Etsl through protein stabilization and knockdown of Ets1 down regulated p16(INK4a) expression in p53( / ) mouse embryonic fibroblasts. These studies uncover a compensatory mechanism for the loss of p53 and provide a basis for targeting both p53 and p16(INK4a) in cancer therapy. (Mol Cancer Res 2009;7(3):354 60)
C1 [Leong, Wai Fook; Chau, Jenny Fung Ling; Li, Baojie] Agcy Sci Technol & Res, Canc & Dev Biol Div, Inst Mol & Cell Biol, Singapore 138673, Singapore.
C3 Agency for Science Technology & Research (A*STAR); A*STAR   Institute of
   Molecular & Cell Biology (IMCB)
RP Li, BJ (通讯作者)，Agcy Sci Technol & Res, Canc & Dev Biol Div, Inst Mol & Cell Biol, 61 Biopolis Dr, Singapore 138673, Singapore.
EM libj@imcb.a star.edu.sg
RI ; Leong, Wai Fook Peter/GXG 9911 2022
OI Leong, Wai Fook/0000 0002 2438 2715; 
FU Agency of Science, Technology, and Research of the Republic of Singapore
FX Grant support: Agency of Science, Technology, and Research of the
   Republic of Singapore.
CR Duursma A, 2005, MOL CELL BIOL, V25, P6937, DOI 10.1128/MCB.25.16.6937 6947.2005
   Gutierrez Hartmann A, 2007, TRENDS ENDOCRIN MET, V18, P150, DOI 10.1016/j.tem.2007.03.002
   Higuchi T, 2007, MOL CELL BIOL, V27, P3353, DOI 10.1128/MCB.01871 06
   Iotsova V, 1996, ONCOGENE, V13, P2331
   Karsai S, 2007, J PATHOL, V211, P314, DOI 10.1002/path.2100
   Lau WM, 2007, ONCOGENE, V26, P6050, DOI 10.1038/sj.onc.1210405
   Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008
   Molofsky AV, 2005, GENE DEV, V19, P1432, DOI 10.1101/gad.1299505
   Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131
   Pei XH, 2005, ONCOGENE, V24, P2787, DOI 10.1038/sj.onc.1208611
   Seike M, 2000, CLIN CANCER RES, V6, P4307
   Seth A, 2005, EUR J CANCER, V41, P2462, DOI 10.1016/j.ejca.2005.08.013
   Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592
   Sharpless NE, 2002, CANCER RES, V62, P2761
   Tang YF, 2006, CANCER RES, V66, P6139, DOI 10.1158/0008 5472.CAN 06 0772
   Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675
   Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087
   Vousden KH, 2007, NAT REV MOL CELL BIO, V8, P275, DOI 10.1038/nrm2147
   Wang XY, 2006, J CELL BIOL, V172, P115, DOI 10.1083/jcb.200507106
   Wang Y, 2003, CANCER RES, V63, P4389
   YOSHIDA S, 1995, CANCER RES, V55, P2756
   Zhang JM, 2006, CANCER RES, V66, P10325, DOI 10.1158/0008 5472.CAN 06 1594
NR 22
TC 47
Z9 53
U1 0
U2 8
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106 4404 USA
SN 1541 7786
EI 1557 3125
J9 MOL CANCER RES
JI Mol. Cancer Res.
PD MAR
PY 2009
VL 7
IS 3
BP 354
EP 360
DI 10.1158/1541 7786.MCR 08 0373
PG 7
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Cell Biology
GA 421ZE
UT WOS:000264396000007
PM 19240179
OA Bronze
DA 2025 08 17
ER

PT J
AU Wu, X
   Zhang, XB
   Feng, WJ
   Feng, HM
   Ding, ZY
   Zhao, QQ
   Li, XS
   Tang, N
   Zhang, P
   Li, J
   Wang, JL
AF Wu, Xin
   Zhang, Xiaobo
   Feng, Wanjiang
   Feng, Haoming
   Ding, Zhiyu
   Zhao, Qiangqiang
   Li, Xisheng
   Tang, Ning
   Zhang, Pan
   Li, Jian
   Wang, Jianlong
TI A Targeted Erythrocyte Membrane Encapsulated Drug Delivery System with
   Anti osteosarcoma and Anti osteolytic Effects
SO ACS APPLIED MATERIALS & INTERFACES
LA English
DT Article
DE zoledronic acid; VEGF; membrane nanovesicle; osteosarcoma;
   anti osteolytic
ID PRECLINICAL EVIDENCE; FUNCTIONALIZATION; BISPHOSPHONATES
AB Chemotherapy is one of the main treatment methods for osteosarcoma. However, conventional chemotherapy lacks targeting properties, and its long term and extensive use will have serious side effects on patients. For this reason, a multifunctional nanodrug system (V RZCD) targeting osteosarcoma was developed in this study. V RZCD consists of two parts: (1) the core (ZCD), wherein calcium ions (Ca2+) and zoledronic acid (ZA) form a metal organic framework for loading doxorubicin (DOX), and (2) the shell (V R), a vascular endothelial growth factor (VEGF) ligand modified red blood cell membrane nanovesicle. By targeting the VEGF, V RZCD can specifically bind to the VEGF receptors that are highly expressed on the surface of osteosarcoma cells. Importantly, compared with free ZA and DOX, V RZCD not only clearly inhibits the proliferation of osteosarcoma but also significantly inhibits osteolysis induced by osteosarcoma. In summary, V RZCD represents a new way to treat osteosarcoma.
C1 [Wu, Xin; Zhang, Xiaobo; Feng, Wanjiang; Feng, Haoming; Ding, Zhiyu; Wang, Jianlong] Cent South Univ, Xiangya Hosp 3, Dept Orthoped, Changsha 410013, Hunan, Peoples R China.
   [Zhao, Qiangqiang; Li, Jian] Cent South Univ, Xiangya Hosp 3, Dept Blood Transfus, Changsha 410013, Hunan, Peoples R China.
   [Li, Xisheng] Cent South Univ, Xiangya Hosp 3, Dept Lab Med, Changsha 410013, Hunan, Peoples R China.
   [Tang, Ning] Cent South Univ, Xiangya Hosp 2, Dept Orthoped, Changsha 410011, Hunan, Peoples R China.
   [Zhang, Pan] Cent South Univ, Xiangya Hosp 3, Dept Infect Dis, Changsha 410013, Hunan, Peoples R China.
C3 Central South University; Central South University; Central South
   University; Central South University; Central South University
RP Wang, JL (通讯作者)，Cent South Univ, Xiangya Hosp 3, Dept Orthoped, Changsha 410013, Hunan, Peoples R China.; Li, J (通讯作者)，Cent South Univ, Xiangya Hosp 3, Dept Blood Transfus, Changsha 410013, Hunan, Peoples R China.
EM 603196@csu.edu.cn; 13787073787@139.com
RI æ¬£, é‚¬/AAE 6331 2022; Wang, Jianlong/AAG 9425 2020; Liu,
   Xiaojuan/B 4947 2017; zhao, qiangq/LZG 5793 2025
OI Li, Jian/0000 0001 6562 6483; Dong, Yan/0000 0002 4018 3839; wu,
   xin/0000 0001 8641 0382; 
FU National Natural Science Foundation of China [82001165]; Changsha
   Municipal Natural Science Foundation [kq2007056]; Independent Innovation
   Projects of Postgraduates of Central South University [2020zzts896];
   Hunan Provincial Natural Science Foundation of China [2020JJ8050]
FX This work supported by the National Natural Science Foundation of China
   (grant no. 82001165), the Changsha Municipal Natural Science Foundation
   (grant no. kq2007056), the Independent Innovation Projects of
   Postgraduates of Central South University (grant no. 2020zzts896), and
   the Hunan Provincial Natural Science Foundation of China (grant no.
   2020JJ8050).
CR Biteau K, 2016, AM J CANCER RES, V6, P677
   Burns J, 2020, SEMIN CANCER BIOL, V61, P56, DOI 10.1016/j.semcancer.2019.11.003
   Cifuentes Rius A, 2017, ACS APPL MATER INTER, V9, P41159, DOI 10.1021/acsami.7b13100
   Corre I, 2020, CELLS BASEL, V9, DOI 10.3390/cells9040976
   Daroszewska A, 2018, DIS MODEL MECH, V11, DOI 10.1242/dmm.035576
   Fang RH, 2018, ADV MATER, V30, DOI 10.1002/adma.201706759
   Fang RH, 2014, NANO LETT, V14, P2181, DOI 10.1021/nl500618u
   Finianos A, 2019, EXPERT OPIN PHARMACO, V20, P657, DOI 10.1080/14656566.2019.1574754
   Gao CY, 2016, SMALL, V12, P4056, DOI 10.1002/smll.201600624
   Giarra S, 2018, PHARMACEUTICS, V10, DOI 10.3390/pharmaceutics10040180
   Hadji P, 2016, ANN ONCOL, V27, P379, DOI 10.1093/annonc/mdv617
   Han YJ, 2018, BONE RES, V6, DOI 10.1038/s41413 018 0019 6
   Heymann MF, 2020, BONE, V139, DOI 10.1016/j.bone.2020.115523
   Kroll AV, 2017, BIOCONJUGATE CHEM, V28, P23, DOI 10.1021/acs.bioconjchem.6b00569
   Li JH, 2020, ACS APPL MATER INTER, V12, P21231, DOI 10.1021/acsami.9b17747
   Li RX, 2019, NANO LETT, V19, P124, DOI 10.1021/acs.nanolett.8b03439
   Li TT, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.00371
   Linschoten M, 2020, LANCET HAEMATOL, V7, pE295, DOI 10.1016/S2352 3026(20)30031 4
   Lu KH, 2020, PHARMACOL THERAPEUT, V214, DOI 10.1016/j.pharmthera.2020.107611
   Ma MX, 2020, INT IMMUNOPHARMACOL, V83, DOI 10.1016/j.intimp.2020.106388
   Ma YF, 2016, SMALL, V12, P4936, DOI 10.1002/smll.201600635
   Mercatelli D, 2018, BIOMEDICINES, V6, DOI 10.3390/biomedicines6010019
   Mori K, 2007, J PATHOL, V211, P555, DOI 10.1002/path.2140
   Müller Buschbaum P, 2015, ACS APPL MATER INTER, V7, P12287, DOI 10.1021/acsami.5b04607
   Ohba T, 2014, J BONE MINER RES, V29, P1431, DOI 10.1002/jbmr.2182
   Ouyang ZX, 2018, CURR DRUG TARGETS, V19, P409, DOI 10.2174/1573399811666150615145409
   Oz Y, 2017, ACS APPL MATER INTER, V9, P34194, DOI 10.1021/acsami.7b08433
   Peña Blanco A, 2018, FEBS J, V285, P416, DOI 10.1111/febs.14186
   Picarda G, 2010, CLIN CANCER RES, V16, P2363, DOI 10.1158/1078 0432.CCR 09 1779
   Salvioni L, 2019, CANCERS, V11, DOI 10.3390/cancers11121855
   Sinha S., 2017, ACS APPL MATER INTER
   Travis WD, 2020, J THORAC ONCOL, V15, P709, DOI 10.1016/j.jtho.2020.01.005
   Turner JH, 2018, BRIT J RADIOL, V91, DOI 10.1259/bjr.20170893
   Valentin R, 2018, BLOOD, V132, P1248, DOI 10.1182/blood 2018 02 791350
   Velletri T, 2021, CELL DEATH DIFFER, V28, P156, DOI 10.1038/s41418 020 0590 4
   Wang X, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 14870 4
   Wei XL, 2018, ADV MATER, V30, DOI 10.1002/adma.201802233
   Wei XL, 2018, ACS NANO, V12, P109, DOI 10.1021/acsnano.7b07720
   Wu HZ, 2019, J ORTHOP SURG RES, V14, DOI 10.1186/s13018 019 1301 z
   Xu HY, 2020, ACS APPL MATER INTER, V12, P52319, DOI 10.1021/acsami.0c12971
   Yang H, 2016, NANOMED NANOTECHNOL, V12, P309, DOI 10.1016/j.nano.2015.11.012
   Zeng MY, 2017, ACS APPL MATER INTER, V9, P13029, DOI 10.1021/acsami.7b00936
   Zhang HJ, 2016, BIOMATER SCI UK, V4, P1024, DOI 10.1039/c6bm00072j
   Zhang KX, 2019, ACS APPL MATER INTER, V11, P46604, DOI 10.1021/acsami.9b18282
   Zhang PC, 2019, ADV MATER, V31, DOI 10.1002/adma.201904156
   Zhao QQ, 2020, ACS APPL MATER INTER, V12, P22687, DOI 10.1021/acsami.0c05763
   Zhou YM, 2018, CHEM ASIAN J, V13, P3333, DOI 10.1002/asia.201800149
NR 47
TC 34
Z9 37
U1 3
U2 81
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1944 8244
EI 1944 8252
J9 ACS APPL MATER INTER
JI ACS Appl. Mater. Interfaces
PD JUN 23
PY 2021
VL 13
IS 24
BP 27920
EP 27933
DI 10.1021/acsami.1c06059
EA JUN 2021
PG 14
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Materials Science
GA TB5IX
UT WOS:000667982100016
PM 34125517
DA 2025 08 17
ER

PT J
AU Nourissat, G
   Calò, M
   Montalvan, B
   Parier, J
AF Nourissat, Geoffroy
   Calo, Michel
   Montalvan, Bernard
   Parier, Jacques
TI Os Acromiale in Professional Tennis Players
SO ORTHOPAEDIC JOURNAL OF SPORTS MEDICINE
LA English
DT Article
DE os acromiale; athletes; tennis; conservative treatment; shoulder
ID SHOULDER PAIN; ANATOMY; ATHLETE
AB Background: Os acromiale is a rare condition mostly reported in the literature through case reports, imaging studies, or reports of surgical treatment. This condition is the result of nonunion of growth plates of the acromion during the natural developmental process that occurs between 15 and 25 years of age. Its incidence is low, and few studies are available in the literature on athletes with high functional demands, and particularly on athletes within a specific sport.
   Purpose: To collect epidemiological data and to report the amount of time out of play as well as the type of treatment and its efficiency in professional tennis players.
   Study Design: Case series; Level of evidence, 4.
   Methods: We performed a retrospective study using the medical data of athletes within our national tennis league who complained about their shoulder between 2011 and 2016. Nine professional tennis players (mean age, 20 years) with painful shoulders were diagnosed with os acromiale; 3 of them played at an international level, with the other 6 playing at a national level. The diagnosis was confirmed using radiography, including the axillary view, and magnetic resonance imaging (MRI). One female player had associated subacromial bursitis.
   Results: All cases of os acromiale were classified as involving the mesoacromion, following the Lieberson classification. No patient underwent surgery, and no patient was treated with local or subacromial infiltration. Patients stopped competition and training throughout the rehabilitation period. All patients received medical treatment with nonsteroidal anti inflammatory drugs (NSAIDs), ice, and physical therapy with a specific rehabilitation program. All athletes returned to their former level of play after a mean of 37 days. No patient suffered from recurrent pain. One patient underwent MRI after 2 years, showing a normal bone signal and complete healing of the acromion.
   Conclusion: Conservative treatment including NSAIDs, rest, ice, and physical therapy allowed for good recovery and return to the former level of play. Surgical treatment is usually not indicated for os acromiale in the professional tennis player.
C1 [Nourissat, Geoffroy; Parier, Jacques] Ramsay Gen Sante, Clin Maussins Nollet, 67 Rue Romainville, F 75019 Paris, France.
   [Calo, Michel] Univ Torino, Turin, Italy.
   [Montalvan, Bernard; Parier, Jacques] Ctr Natl Entrainement Federat Francaise Tennis, Paris, France.
C3 University of Turin
RP Nourissat, G (通讯作者)，Ramsay Gen Sante, Clin Maussins Nollet, 67 Rue Romainville, F 75019 Paris, France.
EM gnourissat@wanadoo.fr
CR Abrams GD, 2012, BRIT J SPORT MED, V46, P492, DOI 10.1136/bjsports 2012 091164
   [Anonymous], 1933, REV DORTHOP
   BURKHART SS, 1992, AM J SPORT MED, V20, P483, DOI 10.1177/036354659202000424
   EDELSON JG, 1993, J BONE JOINT SURG BR, V75, P551, DOI 10.1302/0301 620X.75B4.8331108
   Frizziero A, 2012, J SPORT SCI MED, V11, P352
   LEHMAN RC, 1988, CLIN SPORT MED, V7, P309
   Liberson F, 1937, J BONE JOINT SURG, V19, P683
   Neuman BJ, 2011, AM J SPORT MED, V39, P1883, DOI 10.1177/0363546511412317
   Nicholson G P, 1996, J Shoulder Elbow Surg, V5, P1, DOI 10.1016/S1058 2746(96)80024 3
   Perkins Robert H, 2006, Phys Med Rehabil Clin N Am, V17, P609, DOI 10.1016/j.pmr.2006.05.005
   Roedl JB, 2015, RADIOLOGY, V274, P201, DOI 10.1148/radiol.14140587
   Sammarco VJ, 2000, J BONE JOINT SURG AM, V82A, P394, DOI 10.2106/00004623 200003000 00010
   STIRLAND A, 1996, INT J OSTEOARCHAEOL, V6, P92
   van der Hoeven H, 2006, BRIT J SPORT MED, V40, P435, DOI 10.1136/bjsm.2005.023218
   Warner JJP, 1998, J BONE JOINT SURG AM, V80A, P1320, DOI 10.2106/00004623 199809000 00011
   Young SW, 2015, AM J SPORT MED, V43, P1989, DOI 10.1177/0363546515588177
NR 16
TC 1
Z9 1
U1 1
U2 5
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 2325 9671
J9 ORTHOP J SPORTS MED
JI Orthop. J. Sports Med.
PD MAY 29
PY 2018
VL 6
IS 5
AR 2325967118773723
DI 10.1177/2325967118773723
PG 5
WC Orthopedics; Sport Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics; Sport Sciences
GA GH6EY
UT WOS:000433537400001
PM 29872663
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Xu, NN
   Wang, YX
   Xu, YY
   Li, LS
   Chen, JQ
   Mai, XD
   Xu, J
   Zhang, Z
   Yang, R
   Sun, J
   Chen, H
   Chen, RP
AF Xu, Ningning
   Wang, Yaxian
   Xu, Yuying
   Li, Lishan
   Chen, Jiaqi
   Mai, Xudong
   Xu, Jie
   Zhang, Zhen
   Yang, Rui
   Sun, Jia
   Chen, Hong
   Chen, Rongping
TI Effect of subclinical hyperthyroidism on osteoporosis: A meta analysis
   of cohort studies
SO ENDOCRINE
LA English
DT Article
DE Bone health; Hyperthyroidism; Meta analysis; Osteoporosis; Fracture
   risk; Review
ID BONE MINERAL DENSITY; AMERICAN THYROID ASSOCIATION; FRACTURE RISK; HIP
   FRACTURE; OSTEOCLAST ACTIVATION; SUPPRESSIVE THERAPY; SERUM THYROTROPIN;
   DYSFUNCTION; WOMEN; DEHYDROEPIANDROSTERONE
AB Objective The effect of subclinical hyperthyroidism (SH) on bone mineral density (BMD) remains unclear, as do the linking mechanisms. This review aims to investigate the relationship between SH and bone loss in terms of the gender dependent effects of SH on BMD. Methods The PUBMED, EMBASE, OVID, MEDLINE, SINOMED and COCHRANE LIBRARY databases (inception to August 12, 2019) were searched for cohort studies investigating the effects of SH on BMD. Eligible studies were subjected to qualitative and quantitative analysis using a random effects model meta analysis with the Cochrane systematic evaluation method. Results Twelve cohort studies involving 275,086 participants who were followed for 3 months to 13 years were included based on predefined inclusion and exclusion criteria. The results indicated that SH did not affect lumbar spine BMD in females or males. However, a significant reduction in femoral neck BMD was observed in females, but not in males. Further, there was a significant increase in hip fractures events in both females and males with SH. Conclusions The present findings indicate that SH is significantly associated with hip fracture risk, and therefore, it is important to assess the risk of fractures in patients with SH. Future studies should focus on methods for accurately determining this risk in patients with SH and providing them with timely and efficient diagnosis and treatment.
C1 [Xu, Ningning; Wang, Yaxian; Xu, Yuying; Li, Lishan; Chen, Jiaqi; Mai, Xudong; Xu, Jie; Zhang, Zhen; Yang, Rui; Sun, Jia; Chen, Hong; Chen, Rongping] Southern Med Univ, Zhujiang Hosp, Dept Endocrinol, Guangzhou, Peoples R China.
C3 Southern Medical University   China
RP Chen, H; Chen, RP (通讯作者)，Southern Med Univ, Zhujiang Hosp, Dept Endocrinol, Guangzhou, Peoples R China.
EM chenhong123@smu.edu.cn; 62782333@163.com
RI wang, yuyan/HNC 3272 2023
FU Science and Technology Planning Project of Guangdong Province, China
   [2014A020212177]; National Natural Science Foundation of China
   [81500623, 81770804]
FX This work was supported by the Science and Technology Planning Project
   of Guangdong Province, China (Grant no. 2014A020212177) and the National
   Natural Science Foundation of China (Grant no. 81500623 and 81770804).
CR Abrahamsen B, 2014, J BONE MINER RES, V29, P2040, DOI 10.1002/jbmr.2244
   [Anonymous], 2011, The Newcastle OttawaScale (NOS) for assessing the quality of non randomized studies in meta analyses
   Bahn RS, 2011, THYROID, V21, P593, DOI 10.1089/thy.2010.0417
   Baliram R, 2012, J CLIN INVEST, V122, P3737, DOI 10.1172/JCI63948
   Bauer DC, 2001, ANN INTERN MED, V134, P561, DOI 10.7326/0003 4819 134 7 200104030 00009
   Biondi B, 2008, ENDOCR REV, V29, P76, DOI 10.1210/er.2006 0043
   Blum MR, 2015, JAMA J AM MED ASSOC, V313, P2055, DOI 10.1001/jama.2015.5161
   Cooper DS, 2012, LANCET, V379, P1142, DOI 10.1016/S0140 6736(11)60276 6
   Cormier C, 2001, JOINT BONE SPINE, V68, P588, DOI 10.1016/S1297 319X(01)00327 X
   Coughlan T, 2014, CLIN MED, V14, P187, DOI 10.7861/clinmedicine.14 2 187
   Dhanwal DK, 2011, INDIAN J ORTHOP, V45, P15, DOI 10.4103/0019 5413.73656
   Drake MT, 2015, CLIN THER, V37, P1837, DOI 10.1016/j.clinthera.2015.06.006
   Emkey GR, 2014, BEST PRACT RES CL EN, V28, P911, DOI 10.1016/j.beem.2014.07.002
   Faber J, 1998, CLIN ENDOCRINOL, V48, P285
   Flynn RW, 2010, J CLIN ENDOCR METAB, V95, P186, DOI 10.1210/jc.2009 1625
   FOLDES J, 1993, CLIN ENDOCRINOL, V39, P521, DOI 10.1111/j.1365 2265.1993.tb02403.x
   Foldes J, 1997, EUR J ENDOCRINOL, V136, P277, DOI 10.1530/eje.0.1360277
   Garin MC, 2014, J CLIN ENDOCR METAB, V99, P2657, DOI 10.1210/jc.2014 1051
   Gharib H, 2005, J CLIN ENDOCR METAB, V90, P581, DOI 10.1210/jc.2004 1231
   Glaser DL, 1997, SPINE, V22, p12S, DOI 10.1097/00007632 199712151 00003
   Gordon CM, 1999, ENDOCRINE, V11, P1, DOI 10.1385/ENDO:11:1:1
   Gürlek A, 1999, THYROID, V9, P539, DOI 10.1089/thy.1999.9.539
   Kanis JA, 2005, OSTEOPOROSIS INT, V16, P229, DOI 10.1007/s00198 004 1811 2
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   Lane NE, 2006, AM J OBSTET GYNECOL, V194, pS3, DOI 10.1016/j.ajog.2005.08.047
   Leader A, 2014, J CLIN ENDOCR METAB, V99, P2665, DOI 10.1210/jc.2013 2474
   Lee JS, 2010, ARCH INTERN MED, V170, P1876, DOI 10.1001/archinternmed.2010.424
   Lee WY, 2006, ARCH MED RES, V37, P511, DOI 10.1016/j.arcmed.2005.09.009
   Liu SQ, 2005, CANCER RES, V65, P2269, DOI 10.1158/0008 5472.CAN 04 3079
   Marcocci C, 1997, J BONE MINER RES, V12, P72, DOI 10.1359/jbmr.1997.12.1.72
   Miyamoto Takeshi, 2015, Keio Journal of Medicine, V64, P44, DOI 10.2302/kjm.2015 0003 RE
   Miyauchi Y, 2013, P NATL ACAD SCI USA, V110, P16568, DOI 10.1073/pnas.1308755110
   MUDDE AH, 1994, CLIN ENDOCRINOL, V41, P421, DOI 10.1111/j.1365 2265.1994.tb02571.x
   Noh HM, 2015, OSTEOPOROSIS INT, V26, P997, DOI 10.1007/s00198 014 2906 z
   Ray NF, 1997, J BONE MINER RES, V12, P24, DOI 10.1359/jbmr.1997.12.1.24
   Reverter JL, 2005, ENDOCR RELAT CANCER, V12, P973, DOI 10.1677/erc.1.01072
   RIGGS BL, 1995, BONE, V17, pS505, DOI 10.1016/8756 3282(95)00258 4
   ROSS DS, 1987, AM J MED, V82, P1167, DOI 10.1016/0002 9343(87)90219 1
   Saler T, 2014, HIPPOKRATIA, V18, P240
   Segna D, 2018, J INTERN MED, V283, P56, DOI 10.1111/joim.12688
   Siru R, 2018, CLIN ENDOCRINOL, V89, P93, DOI 10.1111/cen.13615
   Srivastava M, 2002, CLIN GERIATR MED, V18, P529, DOI 10.1016/S0749 0690(02)00022 8
   Stewart LA, 2015, JAMA J AM MED ASSOC, V313, P1657, DOI 10.1001/jama.2015.3656
   Sugitani I, 2011, SURGERY, V150, P1250, DOI 10.1016/j.surg.2011.09.013
   Surks MI, 2004, JAMA J AM MED ASSOC, V291, P228, DOI 10.1001/jama.291.2.228
   Svare A, 2013, EUR J ENDOCRINOL, V169, P845, DOI 10.1530/EJE 13 0546
   Vadiveloo T, 2011, J CLIN ENDOCR METAB, V96, P1344, DOI 10.1210/jc.2010 2693
   Vestergaard P, 2003, THYROID, V13, P585, DOI 10.1089/105072503322238854
   Wang LY, 2015, THYROID, V25, P300, DOI 10.1089/thy.2014.0287
   Waring AC, 2013, J BONE MINER RES, V28, P472, DOI 10.1002/jbmr.1774
   Wirth CD, 2014, ANN INTERN MED, V161, P189, DOI 10.7326/M14 0125
   Zhou SH, 2018, VITAM HORM, V108, P251, DOI 10.1016/bs.vh.2018.01.005
NR 52
TC 11
Z9 15
U1 1
U2 13
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1355 008X
EI 1559 0100
J9 ENDOCRINE
JI Endocrine
PD JUL
PY 2020
VL 69
IS 1
BP 39
EP 48
DI 10.1007/s12020 020 02259 8
EA MAR 2020
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA MH4LB
UT WOS:000521689900001
PM 32207036
DA 2025 08 17
ER

PT J
AU Gilani, N
   Bitarafan, F
   Ozaslan, M
   Åsheim, S
   Heidari, M
   Garshasbi, M
AF Gilani, Naser
   Bitarafan, Fatemeh
   Ozaslan, Mehmet
   Asheim, Sarah
   Heidari, Morteza
   Garshasbi, Masoud
TI Homozygous TREM2 c.549del; p.(Leu184Serfs*5) variant causing
   Nasu Hakola disease in three siblings in a consanguineous Iraqi family:
   Case report and review of literature
SO MOLECULAR GENETICS & GENOMIC MEDICINE
LA English
DT Article
DE disease associated microglia (DAM); genetic variations; Nasu Hakola
   disease (NHD); neurodegenerative disorders; TREM2; whole exome
   sequencing (WES)
ID MUTATIONS; ALZHEIMERS; DEMENTIA; GENES; DAP12
AB BackgroundThe Triggering Receptor Expressed on Myeloid Cells 2 protein (TREM2) plays a crucial role in various biological processes, including osteoclast differentiation, and disease associated microglia (DAM) activation to regulate neuroinflammation, and phagocytosis in the brain. Genetic variations in TREM2 are implicated in neurodegenerative disorders, such as Nasu hakola disease (NHD), characterized by bone lesions, neuropsychiatric disorders, and early onset dementia. MethodsWe studied 3 siblings with suspected NHD. Whole exome sequencing was conducted on the proband to identify the possible genetic cause(s) and by Sanger sequencing to validate the identified variants in the two other affected siblings, a healthy sister, and the parents. ResultsWe identified a novel homozygous deletion (c.549del; p.(Leu184Serfs*5)) in TREM2. Our literature review reveals 16 TREM2 mutations causing early onset dementia and bone lesions. ConclusionThese findings, alongside previous research, elucidate the clinical spectrum of TREM2 related diseases, aiding accurate diagnosis and patient care. This knowledge is vital for understanding TREM2 dependent DAM and its involvement in the pathogenesis of neurodevelopmental disorders which can help to develop targeted therapies and improve outcomes for TREM2 affected individuals.
C1 [Gilani, Naser; Ozaslan, Mehmet] Gaziantep Univ, Dept Biol, Gaziantep, Turkiye.
   [Gilani, Naser] Farabi Mol Lab, Irbil, Iraq.
   [Bitarafan, Fatemeh; Asheim, Sarah] Oslo Univ Hosp, Dept Med Genet, Oslo, Norway.
   [Bitarafan, Fatemeh; Asheim, Sarah] Univ Oslo, Oslo, Norway.
   [Heidari, Morteza] Univ Tehran Med Sci, Childrens Med Ctr, Pediat Ctr Excellence, Myelin Disorders Clin,Dept Pediat Neurol, Tehran, Iran.
   [Garshasbi, Masoud] Tarbiat Modares Univ, Fac Med Sci, Dept Med Genet, Tehran, Iran.
C3 Gaziantep University; University of Oslo; University of Oslo; Tehran
   University of Medical Sciences; Tarbiat Modares University
RP Gilani, N (通讯作者)，Gaziantep Univ, Dept Biol, Gaziantep, Turkiye.; Garshasbi, M (通讯作者)，Tarbiat Modares Univ, Fac Med Sci, Dept Med Genet, Tehran, Iran.
EM nasergilani55@gmail.com; masoud.garshasbi@modares.ac.ir
RI OZASLAN, Mehmet/T 5549 2018; Heidari, morteza/AAI 6656 2020; Bitarafan,
   Fatemeh/AAW 3196 2020; Ozaslan, Mehmet/J 5494 2018
OI Bitarafan, Fatemeh/0000 0002 4489 2923; Ozaslan,
   Mehmet/0000 0001 9380 4902
FX We would like to thank the family; for their participation that made
   this work possible. We sincerely appreciate the staff of DeNA laboratory
   for helping us in this research.
CR Bonham LW, 2017, NEUROCASE, V23, P65, DOI 10.1080/13554794.2017.1294182
   Borroni B, 2014, NEUROBIOL AGING, V35, DOI 10.1016/j.neurobiolaging.2013.09.017
   Buthut M, 2023, NEUROL SCI, V44, P2581, DOI 10.1007/s10072 023 06726 8
   Dardiotis E, 2017, NEUROBIOL AGING, V53, DOI 10.1016/j.neurobiolaging.2017.01.015
   Deczkowska A, 2018, CELL, V173, P1073, DOI 10.1016/j.cell.2018.05.003
   Doragna D, 2003, J NEUROL NEUROSUR PS, V74, P825, DOI 10.1136/jnnp.74.6.825 a
   Ghezzi L, 2017, NEUROLOGY, V89, P2503, DOI 10.1212/WNL.0000000000004747
   Guerreiro R, 2013, NEUROBIOL AGING, V34, DOI 10.1016/j.neurobiolaging.2013.06.005
   Guerreiro R, 2013, NEW ENGL J MED, V368, P117, DOI 10.1056/NEJMoa1211851
   Guerreiro RJ, 2013, JAMA NEUROL, V70, P78, DOI 10.1001/jamaneurol.2013.579
   Karch CM, 2015, BIOL PSYCHIAT, V77, P43, DOI 10.1016/j.biopsych.2014.05.006
   Kleinberger G, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009093
   Klünemann HH, 2005, NEUROLOGY, V64, P1502, DOI 10.1212/01.WNL.0000160304.00003.CA
   Kober DL, 2016, ELIFE, V5, DOI 10.7554/eLife.20391
   Köseoglu E, 2018, NOROPSIKIYATRI ARS, V55, P98, DOI 10.5152/npa.2017.19484
   Kulkarni B, 2021, MOL NEUROBIOL, V58, P5239, DOI 10.1007/s12035 021 02477 9
   Le Ber I, 2014, NEUROBIOL AGING, V35, DOI 10.1016/j.neurobiolaging.2014.04.010
   Li XT, 2020, NEUROBIOL AGING, V86, DOI 10.1016/j.neurobiolaging.2019.01.009
   Montalbetti L, 2005, FUNCT NEUROL, V20, P71
   Numasawa Y, 2011, EUR J NEUROL, V18, P1179, DOI 10.1111/j.1468 1331.2010.03311.x
   Paloneva J, 2003, J EXP MED, V198, P669, DOI 10.1084/jem.20030027
   Paloneva J, 2002, AM J HUM GENET, V71, P656, DOI 10.1086/342259
   Park JS, 2015, TRAFFIC, V16, P510, DOI 10.1111/tra.12264
   Redaelli V, 2018, J ALZHEIMERS DIS, V63, P195, DOI 10.3233/JAD 180018
   Samanci B, 2021, EUR J NEUROL, V28, P2603, DOI 10.1111/ene.14908
   Sasaki A, 2015, NEUROGENETICS, V16, P265, DOI 10.1007/s10048 015 0451 3
   Sirkis DW, 2017, MOL BIOL CELL, V28, P2723, DOI 10.1091/mbc.E17 06 0423
   Sobue A, 2021, ACTA NEUROPATHOL COM, V9, DOI 10.1186/s40478 020 01099 x
   Swain PS, 2023, J MOL MODEL, V29, DOI 10.1007/s00894 023 05770 7
   Thelen M, 2014, NEUROBIOL AGING, V35, DOI 10.1016/j.neurobiolaging.2014.06.018
   Xing JJ, 2015, RES REP BIOCHEM, V5, P89, DOI 10.2147/RRBC.S58057
   Xu YJ, 2022, FRONT AGING NEUROSCI, V14, DOI 10.3389/fnagi.2022.896852
   Xue F, 2021, CELLS BASEL, V10, DOI 10.3390/cells10020321
   Yao HL, 2019, FRONT CELL NEUROSCI, V13, DOI 10.3389/fncel.2019.00457
NR 34
TC 1
Z9 1
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 2324 9269
J9 MOL GENET GENOM MED
JI Mol. Genet. Genom. Med.
PD JUN
PY 2024
VL 12
IS 6
AR e2476
DI 10.1002/mgg3.2476
PG 15
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Genetics & Heredity
GA WA8R2
UT WOS:001252243800001
PM 38888203
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Sun, P
   Xue, Y
AF Sun, Peng
   Xue, Yuan
TI Silence of TANK binding kinase 1 (TBK1) regulates extracellular matrix
   degradation of chondrocyte in osteoarthritis by janus kinase
   (JAK) signal transducer of activators of transcription (STAT) signaling
SO BIOENGINEERED
LA English
DT Article
DE Osteoarthritis; TBK1; extracellular matrix; chondrocyte; JAK; STAT
   signaling
ID KNEE; INSTABILITY; EXPRESSION; THERAPY; HAND; HIP
AB TANK binding kinase 1 (TBK1) was previously reported to be critical for the regulation of osteoclast differentiation. However, its function in osteoarthritis (OA) has not yet been determined. This study aims to reveal the role of TBK1 in the extracellular matrix (ECM) degradation in OA. C57BL/6 J mice were subjected to anterior cruciate ligament transection (ACLT) surgery to establish an OA animal model. ATDC5 cells were treated with IL 1 beta to construct a cell model of OA. Changes in the expression of TBK1 were analyzed by qRT PCR, Western blotting, and immunohistochemistry. Safranin O fast green staining, ELISA, and Western blotting were performed to evaluate the ECM degradation. By searching GSE75181 and GSE6119 datasets, TBK1 was found to be highly expressed in the OA model. Its upregulation was also confirmed in ACLT mice and in a cell model of OA. Silencing of TBK1 reduced cartilage degradation, OARSI score, and serum levels of CTX II and COMP. Silencing of TBK1 attenuated ECM degradation, as ADAMTS 4, MMP3, and MMP13 were downregulated, whilst SOX9, collagen II, and aggrecan were upregulated. Furthermore, TBK1 activates the JAK/STAT signaling pathway. Transfection of cells with the STAT3 overexpression plasmid blocked the beneficial effects of TBK1 silencing. In conclusion, TBK1 is highly expressed in OA. Silencing of TBK1 inhibited ECM degradation.
C1 [Sun, Peng; Xue, Yuan] Tianjin Med Univ, Gen Hosp, Dept Orthopaed Surg, 154 Anshan Rd, Tianjin 300052, Peoples R China.
   [Sun, Peng] Jining Med Univ, Affiliated Hosp, Dept Orthopaed, Jining, Shandong, Peoples R China.
C3 Tianjin Medical University; Jining Medical University
RP Xue, Y (通讯作者)，Tianjin Med Univ, Gen Hosp, Dept Orthopaed Surg, 154 Anshan Rd, Tianjin 300052, Peoples R China.
EM yuanxue3321@126.com
RI Sun, Peng/KDO 4243 2024; Xue, Yuan/AFT 1587 2022
CR Ali A, 2017, PAIN MED, V18, P1168, DOI 10.1093/pm/pnw217
   Banerjee S, 2017, DRUGS, V77, P521, DOI 10.1007/s40265 017 0701 9
   Barnes EV, 2005, SOUTH MED J, V98, P205, DOI 10.1097/01.SMJ.0000153116.71823.24
   Clément JF, 2008, CELL RES, V18, P889, DOI 10.1038/cr.2008.273
   Dahaghin S, 2005, ANN RHEUM DIS, V64, P682, DOI 10.1136/ard.2004.023564
   Gerwin N, 2010, OSTEOARTHR CARTILAGE, V18, pS24, DOI 10.1016/j.joca.2010.05.030
   Glyn Jones S, 2015, LANCET, V386, P376, DOI 10.1016/S0140 6736(14)60802 3
   Guilak F, 2018, MATRIX BIOL, V71 72, P40, DOI 10.1016/j.matbio.2018.05.008
   Jenei Lanzl Z, 2019, CELL SIGNAL, V53, P212, DOI 10.1016/j.cellsig.2018.10.005
   Kawai T, 2007, TRENDS MOL MED, V13, P460, DOI 10.1016/j.molmed.2007.09.002
   Lefebvre V, 2017, CONNECT TISSUE RES, V58, P2, DOI 10.1080/03008207.2016.1183667
   Lim H, 2011, ARCH PHARM RES, V34, P109, DOI 10.1007/s12272 011 0113 4
   Lin S, 2021, IMMUNOL CELL BIOL, V99, P223, DOI 10.1111/imcb.12401
   Long H, 2021, BIOENGINEERED, V12, P3148, DOI 10.1080/21655979.2021.1945362
   Louis C, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00434
   Malemud CJ, 2017, PROG MOL BIOL TRANSL, V148, P305, DOI 10.1016/bs.pmbts.2017.03.003
   Malemud CJ, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18030484
   March L, 2002, J RHEUMATOL, V29, P1006
   OLIVERIA SA, 1995, ARTHRITIS RHEUM, V38, P1134, DOI 10.1002/art.1780380817
   Pritchett J, 2011, TRENDS MOL MED, V17, P166, DOI 10.1016/j.molmed.2010.12.001
   Ren YM, 2021, BIOENGINEERED, V12, P7694, DOI 10.1080/21655979.2021.1982309
   Roskoski R, 2016, PHARMACOL RES, V111, P784, DOI 10.1016/j.phrs.2016.07.038
   Sharma S, 2020, HUM VACC IMMUNOTHER, V16, P2196, DOI 10.1080/21645515.2020.1765621
   Singh P, 2019, ANN NY ACAD SCI, V1442, P17, DOI 10.1111/nyas.13930
   Skou ST, 2019, CLIN EXP RHEUMATOL, V37, P112
   Tang YH, 2021, BIOENGINEERED, V12, P2984, DOI 10.1080/21655979.2021.1943602
   Thomis DC, 1997, J EXP MED, V185, P197, DOI 10.1084/jem.185.2.197
   Wang YD, 2019, CELL COMMUN SIGNAL, V17, DOI 10.1186/s12964 019 0411 x
   WILLIAMS JM, 1982, J ANAT, V134, P103
   Yang KM, 2013, CANCER RES, V73, P6679, DOI 10.1158/0008 5472.CAN 13 0891
NR 30
TC 12
Z9 13
U1 0
U2 8
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 2165 5979
EI 2165 5987
J9 BIOENGINEERED
JI Bioengineered
PD JAN 1
PY 2022
VL 13
IS 1
BP 1872
EP 1879
DI 10.1080/21655979.2021.2018976
PG 8
WC Biotechnology & Applied Microbiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology
GA YU4ZY
UT WOS:000752054300001
PM 35129065
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Musso, N
   Caruso, G
   Bongiorno, D
   Grasso, M
   Bivona, DA
   Campanile, F
   Caraci, F
   Stefani, S
AF Musso, Nicolo
   Caruso, Giuseppe
   Bongiorno, Dafne
   Grasso, Margherita
   Bivona, Dalida A.
   Campanile, Floriana
   Caraci, Filippo
   Stefani, Stefania
TI Different Modulatory Effects of Four Methicillin Resistant
   Staphylococcus aureus Clones on MG 63 Osteoblast Like Cells
SO BIOMOLECULES
LA English
DT Article
DE Staphylococcus aureus; osteoblast like cells; internalization;
   inflammation; immune system; eukaryotic host&#173; &#8211; pathogen
   interaction; cytokines
AB Staphylococcus aureus is a Gram positive bacterium responsible for a variety of mild to life threatening infections including bone infections such as osteomyelitis. This bacterium is able to invade and persist within non professional phagocytic cells such as osteoblasts. In the present study, four different S. aureus strains, namely, 2SA ST239 III (ST239), 5SA ST5 II (ST5), 10SA ST228 I (ST228), and 14SA ST22 IVh (ST22), were tested for their ability to modulate cell viability in MG 63 osteoblast like cells following successful invasion and persistence. Methicillin sensitive S. aureus (MSSA) ATCC 12598 ST30 (ST30) was used as control strain. Despite being proven that ST30, ST239, and ST22 have a similar ability to internalize and persist in MG 63 osteoblast like cells under our experimental conditions, we demonstrated that the observed decrease in cell viability was due to the different behavior of the considered strains, rather than the number of intracellular bacteria. We focused our attention on different biochemical cell functions related to inflammation, cell metabolism, and oxidative stress during osteoblast infections. We were able to show the following: (1) ST30 and ST239 were the only two clones able to persist and maintain their number in the hostile environment of the cell during the entire period of infection; (2) ST239 was the only clone able to significantly increase gene expression (3 and 24 h post infection (p.i.)) and protein secretion (24 h p.i.) of both interleukin 6 (IL 6) and tumor necrosis factor alpha (TNF alpha) in MG 63 osteoblast like cells; (3) the same clone determined a significant up regulation of the transforming growth factorbeta 1 (TGF beta 1) and of the metabolic marker glyceraldehyde 3 phosphate dehydrogenase (GAPDH) mRNAs at 24 h p.i.; and (4) neither the MSSA nor the four methicillin resistant S. aureus (MRSA) strains induced oxidative stress phenomena in MG 63 cells, although a high degree of variability was observed for the different clones with regard to the expression pattern of nuclear factor E2 related factor 2 (Nrf2) and its downstream gene heme oxygenase 1 (HO 1) activation. Our results may pave the way for an approach to S. aureus induced damage, moving towards individualized therapeutic strategies that take into account the differences between MSSA and MRSA as well as the distinctive features of the different clones. This approach is based on a change of paradigm in antibiotic therapy involving a case based use of molecules able to counteract pro inflammatory cytokines activity such as selective cytokine signaling inhibitors (IL 6, TNF alpha).
C1 [Musso, Nicolo; Bongiorno, Dafne; Bivona, Dalida A.; Campanile, Floriana; Stefani, Stefania] Univ Catania, Dept Biomed & Biotechnol Sci BIOMETEC, I 95125 Catania, Italy.
   [Caruso, Giuseppe; Grasso, Margherita; Caraci, Filippo] Oasi Res Inst IRCCS, Via Conte Ruggero,73, I 94018 Troina, Italy.
   [Caruso, Giuseppe; Grasso, Margherita; Caraci, Filippo] Univ Catania, Dept Drug Sci, I 95125 Catania, Italy.
C3 University of Catania; IRCCS   Oasi Research Institute; University of
   Catania
RP Caraci, F (通讯作者)，Oasi Res Inst IRCCS, Via Conte Ruggero,73, I 94018 Troina, Italy.; Caraci, F (通讯作者)，Univ Catania, Dept Drug Sci, I 95125 Catania, Italy.
EM nmusso@unict.it; forgiuseppecaruso@gmail.com; dbongio@unict.it;
   grassomargherita940@gmail.com; dalidabivona@gmail.com;
   f.campanile@unict.it; carafil@hotmail.com; stefanis@unict.it
RI ; STEFANI, STEFANIA/K 8075 2016; Stefani, Stefania/K 8075 2016; MUSSO,
   Nicolo'/CAH 2950 2022; Caruso, Giuseppe/C 1435 2018; Caraci,
   Filippo/K 2262 2016; Campanile, Floriana/I 8831 2012; Grasso,
   Margherita/AAB 6242 2019
OI CAMPANILE, Floriana Rosa Maria/0000 0002 8405 5425; STEFANI,
   STEFANIA/0000 0003 1594 7427; Caruso, Giuseppe/0000 0003 1571 5327;
   Bivona, Dalida/0000 0002 2448 0227; MUSSO, Nicolo'/0000 0003 2451 1158;
   Caraci, Filippo/0000 0002 9867 6054; Grasso,
   Margherita/0000 0003 4458 5226
FU Italian Ministry of Health Research Program 2018 [RC: 2635256]; research
   grant entitled "Identification of cancer driver genes for novel
   diagnostics and therapeutic strategies Piano per la ricerca
   2016 2018 Linea di intervento 2 University of Catania, Dept. of
   Biomedical and Biotechnological Sciences";  [2017SFBFER]
FX G.C. and Fi.C. received support from the Italian Ministry of Health
   Research Program 2018, grant number RC: 2635256. S.S. received support
   from Minister of research, grant number 2017SFBFER. Fl.C. received
   support from the research grant entitled "Identification of cancer
   driver genes for novel diagnostics and therapeutic strategies Piano per
   la ricerca 2016 2018 Linea di intervento 2 University of Catania, Dept.
   of Biomedical and Biotechnological Sciences".
CR Alva Murillo N, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/538546
   Bachtiar Boy M, 2017, BMC Res Notes, V10, P401, DOI 10.1186/s13104 017 2740 4
   Baldan R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043153
   Bauché D, 2017, CLIN TRANSL IMMUNOL, V6, DOI 10.1038/cti.2017.9
   Bongiorno D, 2020, MICROBIOLOGYOPEN, V9, DOI 10.1002/mbo3.1017
   Bongiorno D, 2018, MICROB DRUG RESIST, V24, P732, DOI 10.1089/mdr.2017.0299
   Campanile F, 2012, EUR J CLIN MICROBIOL, V31, P739, DOI 10.1007/s10096 011 1367 y
   Campanile F, 2015, J GLOB ANTIMICROB RE, V3, P247, DOI 10.1016/j.jgar.2015.06.006
   Campoccia D, 2018, MATERIALS, V11, DOI 10.3390/ma11040550
   Caruso G, 2019, CURR PHARM DESIGN, V25, P4771, DOI 10.2174/1381612825666191209115431
   Caruso G, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00995
   Caruso G, 2019, ANTIOXIDANTS BASEL, V8, DOI 10.3390/antiox8080281
   Caruso G, 2020, CURR MED CHEM, V27, P1782, DOI 10.2174/0929867326666190712091515
   Caruso G, 2019, CELLS BASEL, V8, DOI 10.3390/cells8010064
   Caruso G, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113659
   Caruso G, 2017, MOL CELL BIOCHEM, V425, P85, DOI 10.1007/s11010 016 2864 1
   Chamon RC, 2017, BRAZ J INFECT DIS, V21, P185, DOI 10.1016/j.bjid.2016.09.015
   CLOVER J, 1994, BONE, V15, P585, DOI 10.1016/8756 3282(94)90305 0
   Cosgrove SE, 2003, CLIN INFECT DIS, V36, P53, DOI 10.1086/345476
   Delpino MV, 2009, INFECT IMMUN, V77, P984, DOI 10.1128/IAI.01259 08
   Deramaudt TB, 2013, MED MALADIES INFECT, V43, P100, DOI 10.1016/j.medmal.2013.02.004
   Di Domenico EG, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 27421 1
   Dupieux C, 2017, J ANTIMICROB CHEMOTH, V72, P3353, DOI 10.1093/jac/dkx314
   Engemann JJ, 2003, CLIN INFECT DIS, V36, P592, DOI 10.1086/367653
   Evans CAW, 1998, J INFECT DIS, V177, P1582, DOI 10.1086/515313
   Faulkner L, 2005, J IMMUNOL, V175, P6870, DOI 10.4049/jimmunol.175.10.6870
   Ferreira GF, 2012, MEM I OSWALDO CRUZ, V107, P348, DOI 10.1590/S0074 02762012000300009
   FRANCESCHI RT, 1990, J BONE MINER RES, V5, P1157
   Fresta CG, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21030776
   Gao JY, 2014, J ZHEJIANG UNIV SC B, V15, P776, DOI 10.1631/jzus.B1400023
   Gastmeier P, 2005, INFECTION, V33, P50, DOI 10.1007/s15010 005 3186 5
   Gaupp R, 2012, FRONT CELL INFECT MI, V2, DOI 10.3389/fcimb.2012.00033
   Ghasemzadeh Moghaddam H, 2018, EUR J CLIN MICROBIOL, V37, P255, DOI 10.1007/s10096 017 3124 3
   Gould IM, 2011, INT J ANTIMICROB AG, V37, P202, DOI 10.1016/j.ijantimicag.2010.10.030
   Hjerpe E, 2013, BMC CLIN PATHOL, V13, DOI 10.1186/1472 6890 13 30
   Holub M, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/190145
   Horn J, 2018, INT J MED MICROBIOL, V308, P607, DOI 10.1016/j.ijmm.2017.11.009
   Imanishi J, 2000, J BIOCHEM TOKYO, V127, P525, DOI 10.1093/oxfordjournals.jbchem.a022636
   Jain S, 2019, ANN CLIN MICROB ANTI, V18, DOI 10.1186/s12941 019 0307 z
   Ji T, 2016, ONCOTARGET, V7, P66635, DOI 10.18632/oncotarget.11365
   Josse J, 2015, FRONT CELL INFECT MI, V5, DOI 10.3389/fcimb.2015.00085
   Kasagi S, 2013, CELL BIOSCI, V3, DOI 10.1186/2045 3701 3 4
   LAJEUNESSE D, 1990, J BONE MINER RES, V5, P915, DOI 10.1002/jbmr.5650050904
   Landskron G, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/149185
   Li MO, 2006, ANNU REV IMMUNOL, V24, P99, DOI 10.1146/annurev.immunol.24.021605.090737
   Li ZG, 2017, J IMMUNOL, V198, P1865, DOI 10.4049/jimmunol.1601336
   Lopalco G, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001858
   Lüthje FL, 2020, APMIS, V128, P275, DOI 10.1111/apm.13027
   Ma J, 2017, CELL PHYSIOL BIOCHEM, V43, P2170, DOI 10.1159/000484296
   Marriott I, 2004, AM J PATHOL, V164, P1399, DOI 10.1016/S0002 9440(10)63226 9
   McNicholas S, 2014, BMC INFECT DIS, V14, DOI 10.1186/s12879 014 0580 6
   McPherson JC, 2008, COMPARATIVE MED, V58, P369
   Mitchell G, 2017, CELL HOST MICROBE, V22, P166, DOI 10.1016/j.chom.2017.07.005
   Moldovan A, 2019, CELL MICROBIOL, V21, DOI 10.1111/cmi.12997
   Monecke S, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.01436
   Nahlik KW, 2003, ACTA BIOCHIM POL, V50, P667
   Navarro JF, 2006, THESCIENTIFICWORLDJO, V6, P908, DOI 10.1100/tsw.2006.179
   Botelho MMN, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.00082
   Popko K, 2010, EUR J MED RES, V15, P120
   Rasigade JP, 2014, INFECT GENET EVOL, V21, P510, DOI 10.1016/j.meegid.2013.08.018
   Reed SD, 2005, INFECT CONT HOSP EP, V26, P175, DOI 10.1086/502523
   Sawada M, 2006, J NEURAL TRANSM SUPP, P373
   Selan L, 2017, INT J IMMUNOPATH PH, V30, P423, DOI 10.1177/0394632017745762
   Shi SF, 2012, EXP THER MED, V3, P367, DOI 10.3892/etm.2011.423
   Sriram S, 2013, INVEST OPHTH VIS SCI, V54, P8214, DOI 10.1167/iovs.13 12758
   Stefani S, 2012, INT J ANTIMICROB AG, V39, P273, DOI 10.1016/j.ijantimicag.2011.09.030
   TAKEUCHI Y, 1995, J CELL PHYSIOL, V162, P315, DOI 10.1002/jcp.1041620303
   Thakur A, 2019, J IMMUNOL RES, V2019, DOI 10.1155/2019/1356540
   Torrisi SA, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00693
   Tuchscherr L, 2016, CURR GENET, V62, P15, DOI 10.1007/s00294 015 0503 0
   Valour F, 2015, Clin Microbiol Infect, V21, DOI 10.1016/j.cmi.2015.01.026
   Valour F, 2015, ANTIMICROB AGENTS CH, V59, P2029, DOI 10.1128/AAC.04359 14
   Verkaik NJ, 2010, EUR J CLIN MICROBIOL, V29, P509, DOI 10.1007/s10096 010 0888 0
   Verrecchia F, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00133
   Wang P, 2016, EXP THER MED, V12, P2102, DOI 10.3892/etm.2016.3591
   Wright JA, 2010, INT J MED MICROBIOL, V300, P193, DOI 10.1016/j.ijmm.2009.10.003
   Xiao ZB, 2013, ADV SKIN WOUND CARE, V26, P266, DOI 10.1097/01.ASW.0000429705.02588.f5
   Yoshii T, 2002, CYTOKINE, V19, P59, DOI 10.1006/cyto.2002.1039
NR 78
TC 17
Z9 17
U1 1
U2 6
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2218 273X
J9 BIOMOLECULES
JI Biomolecules
PD JAN
PY 2021
VL 11
IS 1
AR 72
DI 10.3390/biom11010072
PG 18
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA PV3AM
UT WOS:000609863400001
PM 33430251
OA Green Submitted, gold, Green Published
DA 2025 08 17
ER

PT J
AU Zhang, CF
   Liu, ZP
AF Zhang, Can Fei
   Liu, Zhao Peng
TI Recent Developments of 2 Substituted Analogs of
   1,25(OH)2D3
SO CURRENT MEDICINAL CHEMISTRY
LA English
DT Article
DE 1,25(OH)(2)D 3; 2 substituted vitamin D 3; structure activity
   relationships; VDR; HL 60 cell differentiation; transactivation; bone
   mineral density
ID VITAMIN D RECEPTOR; A RING DIASTEREOMERS; 1 ALPHA,25 DIHYDROXYVITAMIN
   D 3 26,23 LACTONE ANALOGS; INHIBITS OSTEOCLAST FORMATION; CARBOXYLIC
   ESTER ANTAGONISTS; BONE MINERAL LOSS; BIOLOGICAL EVALUATION;
   2 METHYL 1 ALPHA,25 DIHYDROXYVITAMIN D 3; 2 METHYL 1,25 DIHYDROXYVITAMIN
   D 3; MOLECULAR MECHANISM
AB The plethora of biological activities of 1,25(OH)(2)D 3 and its analogs suggests an enormous potential for vitamin D therapy in the treatment of hyperproliferative diseases (cancer, psoriasis), endocrine dysfunction (hyperparathyroidism), immune disorders (autoimmune diseases, transplant rejection), bone disorders (osteoporosis, Paget's bone disease). However, the therapeutic limitation of 1,25(OH)(2)D 3 is its calcemic and phosphatemic activities, since it can cause serious side effects such as hypercalcemia and hyperphosphatemia at super physiological levels. Therefore, numerous efforts have been made to find the new vitamin D analogs, that retain the therapeutically important properties of 1,25(OH) 2D3, but with greater selectivity, which allows more effective intervention with fewer toxic side effects. This review will focus on the biological activities of the 2 substituted analogs of 1,25(OH)(2)D 3. They were classified as 2 alpha , 2 beta , 2,2 disubstituted analogs, and those with modifications in both the A ring at the 2 position and the side chains. Their structure activity relationships and binding features with the vitamin D receptor (VDR) were discussed.
C1 [Zhang, Can Fei; Liu, Zhao Peng] Shandong Univ, Sch Pharmaceut Sci, Minist Educ, Key Lab Chem Biol,Dept Organ Chem, Jinan 250012, Peoples R China.
C3 Shandong University
RP Liu, ZP (通讯作者)，Shandong Univ, Sch Pharmaceut Sci, Minist Educ, Key Lab Chem Biol,Dept Organ Chem, Jinan 250012, Peoples R China.
EM liuzhaop@sdu.edu.cn
FU Shandong Provincial Natural Science Foundation [ZR2011CZ001]
FX This work was supported by Shandong Provincial Natural Science
   Foundation (key project, ZR2011CZ001).
CR Abe D, 2005, DRUG METAB DISPOS, V33, P778, DOI 10.1124/dmd.104.003038
   [Anonymous], LANDSCOPE
   Antony P, 2010, J MED CHEM, V53, P1159, DOI 10.1021/jm9014636
   BINDERUP L, 1991, BIOCHEM PHARMACOL, V42, P1569, DOI 10.1016/0006 2952(91)90426 6
   Bouillon R, 2008, ENDOCR REV, V29, P726, DOI 10.1210/er.2008 0004
   Bury Y, 2000, MOL PHARMACOL, V58, P1067, DOI 10.1124/mol.58.5.1067
   Carlberg C, 2004, J STEROID BIOCHEM, V89 90, P227, DOI 10.1016/j.jsbmb.2004.03.112
   Chiang KC, 2013, ANTI CANCER AGENT ME, V13, P126, DOI 10.2174/187152013804487443
   Choi M, 2009, EXPERT OPIN THER PAT, V19, P593, DOI 10.1517/13543770902877717
   Deeb KK, 2007, NAT REV CANCER, V7, P684, DOI 10.1038/nrc2196
   Di Rosa M, 2011, IMMUNOLOGY, V134, P123, DOI 10.1111/j.1365 2567.2011.03482.x
   DILWORTH FJ, 1994, BIOCHEM PHARMACOL, V47, P987
   Endo Itsuro, 2012, Clin Calcium, V22, P870, DOI CliCa1206870876
   Endo Itsuro, 2011, Clin Calcium, V21, P103, DOI CliCa111116871694
   Fujishima T, 2004, J STEROID BIOCHEM, V89 90, P89, DOI 10.1016/j.jsbmb.2004.03.053
   Fujishima T, 2003, BIOORGAN MED CHEM, V11, P3621, DOI 10.1016/S0968 0896(03)00371 7
   Fujishima T, 2003, ORG BIOMOL CHEM, V1, P1863, DOI 10.1039/b302017g
   Fujishima T, 1998, BIOORG MED CHEM LETT, V8, P2145, DOI 10.1016/S0960 894X(98)00363 1
   Fujishima T, 2000, BIOORGAN MED CHEM, V8, P123, DOI 10.1016/S0968 0896(99)00262 X
   Fujishima T, 2001, CHEM BIOL, V8, P1011, DOI 10.1016/S1074 5521(01)00062 X
   Fujishima T, 2001, BIOORGAN MED CHEM, V9, P525, DOI 10.1016/S0968 0896(00)00267 4
   Fujishima T, 2006, ANTICANCER RES, V26, P2633
   Hagino Hiroshi, 2011, Clin Calcium, V21, P111, DOI CliCa111116951702
   Harada Suguru, 2011, Clin Calcium, V21, P91, DOI CliCa111116751682
   Hatakeyama S, 2001, STEROIDS, V66, P267, DOI 10.1016/S0039 128X(00)00149 5
   Hatakeyama S, 2010, J STEROID BIOCHEM, V121, P25, DOI 10.1016/j.jsbmb.2010.03.041
   Herdick M, 2000, CHEM BIOL, V7, P885, DOI 10.1016/S1074 5521(00)00036 3
   Herdick M, 2000, J BIOL CHEM, V275, P16506, DOI 10.1074/jbc.M910000199
   Honzawa S, 2005, TETRAHEDRON, V61, P11253, DOI 10.1016/j.tet.2005.08.116
   Honzawa S, 2003, BIOORG MED CHEM LETT, V13, P3503, DOI 10.1016/S0960 894X(03)00739 X
   Hourai S, 2008, CHEM BIOL, V15, P383, DOI 10.1016/j.chembiol.2008.03.016
   Hourai S, 2006, J MED CHEM, V49, P5199, DOI 10.1021/jm0604070
   Ishizuka S, 2000, ARCH BIOCHEM BIOPHYS, V380, P92, DOI 10.1006/abbi.2000.1902
   Ishizuka S, 2005, ENDOCRINOLOGY, V146, P2023, DOI 10.1210/en.2004 1140
   Ishizuka S, 2004, J STEROID BIOCHEM, V89 90, P331, DOI 10.1016/j.jsbmb.2004.03.025
   Ishizuka S, 2001, STEROIDS, V66, P227, DOI 10.1016/S0039 128X(00)00146 X
   Ishizuka S, 2001, ENDOCRINOLOGY, V142, P59, DOI 10.1210/en.142.1.59
   Khoo AL, 2012, CRIT REV MICROBIOL, V38, P122, DOI 10.3109/1040841X.2011.622716
   Kittaka A, 2003, CHEM PHARM BULL, V51, P357
   Kittaka A, 2000, ORG LETT, V2, P2619, DOI 10.1021/ol006222j
   Konno K, 2000, J MED CHEM, V43, P4247, DOI 10.1021/jm000261j
   Konno K, 1998, BIOORG MED CHEM LETT, V8, P151, DOI 10.1016/S0960 894X(97)10204 9
   Krishnan AV, 2011, ANNU REV PHARMACOL, V51, P311, DOI 10.1146/annurev pharmtox 010510 100611
   Kubodera N, 2012, ANTICANCER RES, V32, P303
   Liu C., 2013, CURR ORG SY IN PRESS
   Masuno H, 2002, J MED CHEM, V45, P1825, DOI 10.1021/jm0105631
   Miura D, 1999, FEBS LETT, V460, P297, DOI 10.1016/S0014 5793(99)01347 2
   Miura D, 1999, J BIOL CHEM, V274, P16392, DOI 10.1074/jbc.274.23.16392
   Miura D, 2005, J STEROID BIOCHEM, V94, P469, DOI 10.1016/j.jsbmb.2005.01.025
   Mizwicki MT, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.275re4
   Nakagawa K, 2000, BIOCHEM PHARMACOL, V59, P691, DOI 10.1016/S0006 2952(99)00357 3
   Nakagawa K, 2000, BIOCHEM PHARMACOL, V60, P1937, DOI 10.1016/S0006 2952(00)00486 X
   Nishii Y, 2001, STEROIDS, V66, P137, DOI 10.1016/S0039 128X(00)00227 0
   Norman AW, 2000, J MED CHEM, V43, P2719, DOI 10.1021/jm0000160
   Ochiai E, 2005, MOL ENDOCRINOL, V19, P1147, DOI 10.1210/me.2004 0234
   Ono Y, 1997, CHEM PHARM BULL, V45, P1626, DOI 10.1248/cpb.45.1626
   Ono Y, 1998, BIOORGAN MED CHEM, V6, P2517, DOI 10.1016/S0968 0896(98)80025 4
   Ozono K, 1999, J BIOL CHEM, V274, P32376, DOI 10.1074/jbc.274.45.32376
   Peräkylä M, 2004, CHEM BIOL, V11, P1147, DOI 10.1016/j.chembiol.2004.05.023
   Pilz S, 2013, ANTI CANCER AGENT ME, V13, P107, DOI 10.2174/187152013804487407
   Pinette KV, 2003, MINI REV MED CHEM, V3, P193, DOI 10.2174/1389557033488204
   Plum LA, 2010, NAT REV DRUG DISCOV, V9, P941, DOI 10.1038/nrd3318
   POSNER GH, 1995, J ORG CHEM, V60, P4617, DOI 10.1021/jo00119a045
   Posner GH, 2002, BIOORGAN MED CHEM, V10, P2353, DOI 10.1016/S0968 0896(02)00058 5
   Reddy S V, 2001, Rev Endocr Metab Disord, V2, P195
   Reddy SV, 2004, J CELL BIOCHEM, V93, P688, DOI 10.1002/jcb.20256
   Rochel N, 2000, MOL CELL, V5, P173, DOI 10.1016/S1097 2765(00)80413 X
   Roodman GD, 2005, J CLIN INVEST, V115, P200, DOI 10.1172/JCI200524281
   Saito N, 2006, HETEROCYCLES, V67, P311
   Saito N, 2005, SYNTHESIS STUTTGART, P2533, DOI 10.1055/s 2005 872075
   Saito N, 2004, J ORG CHEM, V69, P7463, DOI 10.1021/jo0491051
   Saito N, 2004, TETRAHEDRON, V60, P7951, DOI 10.1016/j.tet.2004.05.113
   Saito N, 2003, ORG BIOMOL CHEM, V1, P4396, DOI 10.1039/b311107e
   Saito N, 2003, ORG LETT, V5, P4859, DOI 10.1021/ol035922w
   Saito N, 2006, J MED CHEM, V49, P7063, DOI 10.1021/jm060797q
   Saito N, 2009, BIOORGAN MED CHEM, V17, P4296, DOI 10.1016/j.bmc.2009.05.032
   Saitoh H, 2011, ORG BIOMOL CHEM, V9, P3954, DOI 10.1039/c1ob05142c
   Sanford M, 2011, DRUGS, V71, P1755, DOI 10.2165/11206790 000000000 00000
   Scheddin D, 1998, STEROIDS, V63, P633, DOI 10.1016/S0039 128X(98)00072 5
   Souberbielle JC, 2010, AUTOIMMUN REV, V9, P709, DOI 10.1016/j.autrev.2010.06.009
   Suhara Y, 2002, BIOORG MED CHEM LETT, V12, P3255, DOI 10.1016/S0960 894X(02)00722 9
   Suhara Y, 2001, J ORG CHEM, V66, P8760, DOI 10.1021/jo010375i
   Suhara Y, 2000, BIOORG MED CHEM LETT, V10, P1129, DOI 10.1016/S0960 894X(00)00189 X
   Takahashi E, 2006, BIOL PHARM BULL, V29, P2246, DOI 10.1248/bpb.29.2246
   Takayama H, 2001, STEROIDS, V66, P277, DOI 10.1016/S0039 128X(00)00141 0
   Takenouchi K, 2004, J STEROID BIOCHEM, V89 90, P31, DOI 10.1016/j.jsbmb.2004.03.046
   Teegarden D, 2009, NUTR RES REV, V22, P82, DOI 10.1017/S0954422409389301
   Toell A, 2001, MOL PHARMACOL, V59, P1478, DOI 10.1124/mol.59.6.1478
   Tsugawa N, 2000, BIOL PHARM BULL, V23, P66
   Tsugawa N, 1999, BIOL PHARM BULL, V22, P371
   Verstuyf A, 2010, KIDNEY INT, V78, P140, DOI 10.1038/ki.2010.17
   Yin YZ, 2011, CURR ORG SYNTH, V8, P374, DOI 10.2174/157017911795529074
NR 92
TC 9
Z9 9
U1 0
U2 11
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y 2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 0929 8673
EI 1875 533X
J9 CURR MED CHEM
JI Curr. Med. Chem.
PD MAY
PY 2013
VL 20
IS 16
BP 2080
EP 2095
DI 10.2174/0929867311320160003
PG 16
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Pharmacology &
   Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA 126ZM
UT WOS:000317662200003
PM 23514414
DA 2025 08 17
ER

PT J
AU Zhao, Q
   Chen, JQ
   Tang, JJ
   Lei, XY
   Zhang, JZ
   Zhang, YL
   Li, JD
   Zuo, Y
   Li, YB
AF Zhao, Qing
   Chen, Jieqiong
   Tang, Jiajing
   Lei, Xiaoyu
   Zhang, Jinzheng
   Zhang, Yinglong
   Li, Jidong
   Zuo, Yi
   Li, Yubao
TI Self Activating Phosphorus Rich Substrate Import Enzyme Catalytic
   Domains for Bone Regeneration
SO ADVANCED FUNCTIONAL MATERIALS
LA English
DT Article
DE calcified symbiotic state; chemical potential; early osteoinductivity
   and angiogenesis; enzyme catalytic domain; phosphorus rich fibrous
   polyurethane
ID ALKALINE PHOSPHATASE; MATRIX VESICLES; IN VITRO; CALCIUM;
   MINERALIZATION; SCAFFOLD; OSTEOBLASTS; PREVENTION; HYDROGELS; IONS
AB Enzymes play a key role in natural mineralization, but their function is disabling in bone metabolism when patients suffer severe degenerations like hypophosphatasia. To regulate bone homeostasis, a self activating phosphorus rich system is proposed on calcium glycerophosphate (CaGP) modified polyurethane (PU) fibrous substrate, wherein ample enzyme catalytic domains are imported with intestinal alkaline phosphatase (IALP) chelating and activating by calcium in situ that is testified by chemical potential evaluation. Therefore, Ca bonding IALP catalyzes organophosphate to phosphate locally to achieve a calcified symbiotic state, regulating mineralization and accelerating osteoinduction in vitro and in vivo. The self activating enzyme system promotes early osteogenic differentiation and angiogenesis, resulting in rapid healing of cranial defect with a "long tail" effect compared to an enzyme assisted system. Transcriptomic and metabolomic analyses demonstrate positive associations with neovascularization and calcium/phosphorus metabolism, specifically upregulated glycerophospholipids and calcium ions in favor of osteogenic differentiation under cytokine free conditions. These results provide a potential enzyme activating therapy in bone homeostasis and regeneration.
   Inspired by natural bone mineralization, a self activating phosphorus rich system is proposed on calcium glycerophosphate (CaGP) modified polyurethane (PU) fibrous substrate, wherein ample enzyme catalytic domains are imported with intestinal alkaline phosphatase (IALP). Multi omics analysis reveals the mechanism of osteogenesis in vitro. In a rat ectopic bone formation and a rat skull defect model, PU CaGP@IALP exhibits excellent osteogenesis, osteoinductivity, and angiogenesis. image
C1 [Zhao, Qing; Chen, Jieqiong; Tang, Jiajing; Lei, Xiaoyu; Zhang, Jinzheng; Zhang, Yinglong; Li, Jidong; Zuo, Yi; Li, Yubao] Sichuan Univ, Res Ctr Nanobiomaterials, Analyt & Testing Ctr, Chengdu 610064, Peoples R China.
C3 Sichuan University
RP Zuo, Y; Li, YB (通讯作者)，Sichuan Univ, Res Ctr Nanobiomaterials, Analyt & Testing Ctr, Chengdu 610064, Peoples R China.
EM zoae@vip.sina.com; nic7504@scu.edu.cn
RI ; Li, Jidong/E 2767 2012; Tang, Jiajing/GYD 8435 2022; Zuo,
   Yi/C 4328 2016
OI Tang, Jiajing/0000 0001 9928 7918; zhang, ying long/0000 0002 6446 5662;
   Lei, Xiaoyu/0000 0001 7467 7776; Zhao, Qing/0000 0002 3523 2763; Zhao,
   Qing/0009 0003 7438 0106; Li, Jidong/0000 0002 0483 3304; Zuo,
   Yi/0000 0003 2301 9786
FU Fundamental Research Funds for the Central Universities; National
   Natural Science Foundation of China [32171338]; National Key Research
   and Development Program of China [2021YFA1201304]; Sichuan International
   Science and Technology Innovation Cooperation Project [2021YFH0122]
FX This work was supported by the National Natural Science Foundation of
   China (No. 32171338), the National Key Research and Development Program
   of China (2021YFA1201304), Sichuan International Science and Technology
   Innovation Cooperation Project (No. 2021YFH0122), and the Fundamental
   Research Funds for the Central Universities. The authors would like to
   thank Li Chen (Analytical & Testing Center of Sichuan University) for
   her help with Micro CT testing, Shuguang Yan (Analytical & Testing
   Center of Sichuan University) for his help with XPS spectra, and Shanlin
   Wang (Analytical & Testing Center of Sichuan University) for her help of
   TEM images.
CR Awasthi H, 2018, MED RES REV, V38, P2024, DOI 10.1002/med.21504
   Boffito M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0199896
   Bottini M, 2018, BBA GEN SUBJECTS, V1862, P532, DOI 10.1016/j.bbagen.2017.11.005
   Camargo WA, 2017, ACTA BIOMATER, V57, P511, DOI 10.1016/j.actbio.2017.05.016
   Chen GD, 2022, ADV FUNCT MATER, V32, DOI 10.1002/adfm.202113262
   Chen L, 2019, ACS BIOMATER SCI ENG, V5, P1405, DOI 10.1021/acsbiomaterials.8b01197
   Chen YQ, 2022, ACS APPL MATER INTER, V14, P7592, DOI 10.1021/acsami.1c21260
   Cheng WX, 2021, J ORTHOP TRANSL, V31, P41, DOI 10.1016/j.jot.2021.10.002
   Ciancaglini P, 2010, J BONE MINER RES, V25, P716, DOI 10.1359/jbmr.091023
   Colaço E, 2020, NANOSCALE, V12, P10051, DOI 10.1039/d0nr01638a
   Colaço E, 2020, J COLLOID INTERF SCI, V565, P43, DOI 10.1016/j.jcis.2019.12.097
   Colaço E, 2021, BIOMACROMOLECULES, V22, P3460, DOI 10.1021/acs.biomac.1c00565
   Danoux CBSS, 2015, ACTA BIOMATER, V17, P1, DOI 10.1016/j.actbio.2015.02.003
   Fang W, 2021, MACROMOL RAPID COMM, V42, DOI 10.1002/marc.202100125
   Franklin Renty B, 2014, Open Bone J, V6, P1
   FREW JE, 1989, J ELECTROANAL CHEM, V266, P309, DOI 10.1016/0022 0728(89)85077 6
   George MN, 2020, J BIOMED MATER RES A, V108, P515, DOI 10.1002/jbm.a.36832
   Germaini MM, 2022, PROG MATER SCI, V130, DOI 10.1016/j.pmatsci.2022.100963
   Guibert C, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms222312957
   Guo J, 2022, ACTA BIOMATER, V149, P220, DOI 10.1016/j.actbio.2022.06.008
   Han JP, 2024, ADV MATER, V36, DOI 10.1002/adma.202209778
   Hasegawa T, 2018, HISTOCHEM CELL BIOL, V149, P289, DOI 10.1007/s00418 018 1646 0
   Hoeben A, 2004, PHARMACOL REV, V56, P549, DOI 10.1124/pr.56.4.3
   Hou W, 2022, MATER DESIGN, V219, DOI 10.1016/j.matdes.2022.110767
   Jaroszewicz J, 2019, MAT SCI ENG C MATER, V96, P319, DOI 10.1016/j.msec.2018.11.027
   Kavanaugh TE, 2016, J MATER SCI MATER M, V27, DOI 10.1007/s10856 015 5654 5
   Kawai S, 2019, NAT BIOMED ENG, V3, P558, DOI 10.1038/s41551 019 0410 7
   Khoshniat S, 2011, BONE, V48, P894, DOI 10.1016/j.bone.2010.12.002
   KOKUBO T, 1991, BIOMATERIALS, V12, P155, DOI 10.1016/0142 9612(91)90194 F
   Komori T, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23105776
   Leone FA, 1997, J INORG BIOCHEM, V68, P123, DOI 10.1016/S0162 0134(97)00047 0
   Li LM, 2015, ACS APPL MATER INTER, V7, P22618, DOI 10.1021/acsami.5b07327
   Liang YX, 2021, J PERIODONTAL RES, V56, P982, DOI 10.1111/jre.12911
   Lin CY, 2013, BIOMATERIALS, V34, P9401, DOI 10.1016/j.biomaterials.2013.08.051
   Liu HD, 2023, SCI ADV, V9, DOI 10.1126/sciadv.adg0731
   Lopez Heredia MA, 2017, MATER LETT, V190, P13, DOI 10.1016/j.matlet.2016.12.122
   Lu GG, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 022 30243 5
   MACLENNAN DH, 1975, ANNU REV BIOPHYS BIO, V4, P377, DOI 10.1146/annurev.bb.04.060175.002113
   Migliorati CA, 2006, LANCET ONCOL, V7, P508, DOI 10.1016/S1470 2045(06)70726 4
   Mikhaylin S, 2016, ADV COLLOID INTERFAC, V229, P34, DOI 10.1016/j.cis.2015.12.006
   Mornet E, 2015, SUBCELL BIOCHEM, V76, P25, DOI 10.1007/978 94 017 7197 9_2
   Nath AS, 2022, CELL REP, V38, DOI 10.1016/j.celrep.2022.110433
   Nizet A, 2020, CLIN CHIM ACTA, V501, P198, DOI 10.1016/j.cca.2019.11.012
   Pinto V, 2020, CANCERS, V12, DOI 10.3390/cancers12020407
   Rauner N, 2017, NATURE, V543, P407, DOI 10.1038/nature21392
   Reznikov N, 2020, BONE, V138, DOI 10.1016/j.bone.2020.115447
   Seeman E, 2019, NAT REV RHEUMATOL, V15, P225, DOI 10.1038/s41584 019 0172 3
   Sekaran S, 2021, BIOMOLECULES, V11, DOI 10.3390/biom11111564
   Singh A, 2018, PROG ORTHOD, V19, DOI 10.1186/s40510 018 0216 2
   Skwarczynska A, 2018, J APPL POLYM SCI, V135, DOI 10.1002/app.46459
   Spoerke ED, 2009, ADV MATER, V21, P425, DOI 10.1002/adma.200802242
   Tanaka K, 2010, MACROMOLECULES, V43, P6180, DOI 10.1021/ma1009066
   Tian TR, 2017, ACS APPL MATER INTER, V9, P30437, DOI 10.1021/acsami.7b09176
   Toscani D, 2021, APPL SCI BASEL, V11, DOI 10.3390/app11104642
   TOWNSHEND A, 1970, TALANTA, V17, P289, DOI 10.1016/0039 9140(70)80215 6
   Vimalraj S, 2020, GENE, V754, DOI 10.1016/j.gene.2020.144855
   von Moos R, 2019, CANCER TREAT REV, V76, P57, DOI 10.1016/j.ctrv.2019.05.003
   Wang D, 2020, ADV MATER, V32, DOI 10.1002/adma.202002080
   Wawrzyniak A, 2022, ANIMALS BASEL, V12, DOI 10.3390/ani12151946
   Wu CW, 2022, CHEM ENG J, V443, DOI 10.1016/j.cej.2022.136508
   Wu MH, 2020, INT J BIOL MACROMOL, V162, P1627, DOI 10.1016/j.ijbiomac.2020.08.029
   Yamauchi K, 2004, BIOMATERIALS, V25, P5481, DOI 10.1016/j.biomaterials.2003.12.057
   Yao JJ, 2020, BIOMACROMOLECULES, V21, P2176, DOI 10.1021/acs.biomac.0c00160
   Yu P, 2022, ADV MATER, V34, DOI 10.1002/adma.202107922
   Yu YT, 2023, NAT COMMUN, V14, DOI 10.1038/s41467 023 39833 3
   Zhang H, 2021, ADV FUNCT MATER, V31, DOI 10.1002/adfm.202006697
   Zhang YA, 2023, ADV MATER, V35, DOI 10.1002/adma.202210517
   Zhou Z, 2022, ACS APPL MATER INTER, V14, P36315, DOI 10.1021/acsami.2c05794
   Zou ZL, 2020, CELL BIOSCI, V10, DOI 10.1186/s13578 020 00396 1
NR 69
TC 4
Z9 4
U1 18
U2 54
PU WILEY V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1616 301X
EI 1616 3028
J9 ADV FUNCT MATER
JI Adv. Funct. Mater.
PD JUN
PY 2024
VL 34
IS 25
DI 10.1002/adfm.202316428
EA FEB 2024
PG 20
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
   Physics, Condensed Matter
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science;
   Physics
GA WC1S3
UT WOS:001157725900001
DA 2025 08 17
ER

PT J
AU Umar, S
   Palasiewicz, K
   Van Raemdonck, K
   Volin, MV
   Romay, B
   Ahmad, I
   Tetali, C
   Sweiss, N
   Amin, MA
   Zomorrodi, RK
   Shahrara, S
AF Umar, Sadiq
   Palasiewicz, Karol
   Van Raemdonck, Katrien
   Volin, Michael V.
   Romay, Bianca
   Ahmad, Imran
   Tetali, Chandana
   Sweiss, Nadera
   Amin, M. Asif
   Zomorrodi, Ryan K.
   Shahrara, Shiva
TI CCL25 and CCR9 is a unique pathway that potentiates pannus formation by
   remodeling RA macrophages into mature osteoclasts
SO EUROPEAN JOURNAL OF IMMUNOLOGY
LA English
DT Article
DE CCL25; CCR9; Macrophages; Fibroblasts; RA
AB This study elucidates the mechanism of CCL25 and CCR9 in rheumatoid arthritis (RA). RA synovial fluid (SF) expresses elevated levels of CCL25 compared to OA SF and plasma from RA and normal. CCL25 was released into RA SF by fibroblasts (FLS) and macrophages (M phi s) stimulated with IL 1 beta and IL 6. CCR9 is also presented on IL 1 beta and IL 6 activated RA FLS and differentiated M phi s. Conversely, in RA PBMCs neither CCL25 nor CCR9 are impacted by 3 month longitudinal TNF inhibitor therapy. CCL25 amplifies RA FLS and monocyte infiltration via p38 and ERK phosphorylation. CCL25 stimulated RA FLS secrete potentiated levels of IL 8 which is disrupted by p38 and ERK inhibitors. CCL25 polarizes RA monocytes into nontraditional M1 M phi s that produce IL 8 and CCL2. Activation of p38 and ERK cascades are also responsible for the CCL25 induced M1 M phi development. Unexpectedly, CCL25 was unable to polarize RA PBMCs into effector Th1/Th17 cells. Consistently, lymphokine like RANKL was uninvolved in CCL25 induced osteoclastogenesis; however, this manifestation was regulated by osteoclastic factors such as RANK, cathepsin K (CTSK), and TNF alpha. In short, we reveal that CCL25/CCR9 manipulates RA FLS and M phi migration and inflammatory phenotype in addition to osteoclast formation via p38 and ERK activation.
C1 [Umar, Sadiq; Palasiewicz, Karol; Van Raemdonck, Katrien; Shahrara, Shiva] Jesse Brown VA Med Ctr, Chicago, IL USA.
   [Umar, Sadiq; Palasiewicz, Karol; Van Raemdonck, Katrien; Romay, Bianca; Ahmad, Imran; Tetali, Chandana; Sweiss, Nadera; Zomorrodi, Ryan K.; Shahrara, Shiva] Univ Illinois, Dept Med, Div Rheumatol, 840 S Wood St,CSB Suite 1114, Chicago, IL 60612 USA.
   [Volin, Michael V.] Midwestern Univ, Dept Microbiol & Immunol, Downers Grove, IL 60515 USA.
   [Amin, M. Asif] Univ Michigan, Div Rheumatol, Ann Arbor, MI 48109 USA.
   [Amin, M. Asif] Univ Michigan, Clin Autoimmun Ctr Excellence, Ann Arbor, MI 48109 USA.
C3 US Department of Veterans Affairs; Veterans Health Administration (VHA);
   Jesse Brown VA Medical Center; University of Illinois System; University
   of Illinois Chicago; University of Illinois Chicago Hospital; Midwestern
   University; Midwestern University   Downers Grove; University of
   Michigan System; University of Michigan; University of Michigan System;
   University of Michigan
RP Shahrara, S (通讯作者)，Univ Illinois, Dept Med, Div Rheumatol, 840 S Wood St,CSB Suite 1114, Chicago, IL 60612 USA.
EM shahrara@uic.edu
RI Ahmad, Imran/GRJ 0536 2022; Umar, Sadiq/H 3769 2019
OI Shahrara, Shiva/0000 0002 6698 8491; Palasiewicz,
   Karol/0000 0002 2894 6047; Umar, Sadiq/0000 0002 4733 5751; Zomorrodi,
   Ryan/0009 0003 6417 5985
FU Department of Veteran's Affairs MERIT Award [BX002286]; National
   Institutes of Health NIH [AI147697, AR056099, AR065778]; National
   Psoriasis Foundation (NPF); Pfizer Investigator Initiated Research (IIR)
   Program; Chicago Biomedical Consortium (CBC) Accelerator Award; National
   Institute of Allergy and Infectious Diseases [R41AI147697] Funding
   Source: NIH RePORTER
FX This work was supported in part by awards from the Department of
   Veteran's Affairs MERIT Award BX002286, the National Institutes of
   Health NIH AI147697, AR056099, and AR065778 and the National Psoriasis
   Foundation (NPF), Pfizer Investigator Initiated Research (IIR) Program,
   and Chicago Biomedical Consortium (CBC) Accelerator Award.
CR Amersi FF, 2008, CLIN CANCER RES, V14, P638, DOI 10.1158/1078 0432.CCR 07 2025
   ARNETT FC, 1988, ARTHRITIS RHEUM US, V31, P315, DOI 10.1002/art.1780310302
   Blokland SLM, 2017, ARTHRITIS RHEUMATOL, V69, P2038, DOI 10.1002/art.40182
   Brennan FM, 2008, J CLIN INVEST, V118, P3537, DOI 10.1172/JCI36389
   Chamberlain ND, 2012, J IMMUNOL, V189, P475, DOI 10.4049/jimmunol.1102977
   Chen HJ, 2012, J CLIN INVEST, V122, P3184, DOI 10.1172/JCI62110
   Chu PS, 2013, HEPATOLOGY, V58, P337, DOI 10.1002/hep.26351
   Elshabrawy H, 2018, ANGIOGENESIS, V21, P215, DOI 10.1007/s10456 017 9589 y
   Endres M, 2010, OSTEOARTHR CARTILAGE, V18, P1458, DOI 10.1016/j.joca.2010.08.003
   Heinrich EL, 2013, CANCER MICROENVIRON, V6, P241, DOI 10.1007/s12307 013 0130 6
   Huang Y, 2016, SCI REP UK, V6, DOI 10.1038/srep32660
   Igaki K, 2018, INT IMMUNOPHARMACOL, V60, P160, DOI 10.1016/j.intimp.2018.04.049
   Johnson Holiday C, 2011, WORLD J SURG ONCOL, V9, DOI 10.1186/1477 7819 9 46
   Kim SJ, 2020, CELL MOL IMMUNOL, V17, P728, DOI 10.1038/s41423 019 0235 z
   Kim SJ, 2014, J IMMUNOL, V193, P3902, DOI 10.4049/jimmunol.1302998
   Kunkel EJ, 2003, MICROCIRCULATION, V10, P313, DOI 10.1038/sj.mn.7800196
   Li BJ, 2015, MED ONCOL, V32, DOI 10.1007/s12032 015 0531 0
   McGrory K, 2004, BIOCHEM BIOPH RES CO, V324, P317, DOI 10.1016/j.bbrc.2004.09.056
   Mizukami T, 2012, IMMUNOL LETT, V147, P75, DOI 10.1016/j.imlet.2012.06.006
   Morgan R, 2015, ARTHRITIS RHEUMATOL, V67, P74, DOI 10.1002/art.38878
   Nakamoto N, 2012, GASTROENTEROLOGY, V142, P366, DOI 10.1053/j.gastro.2011.10.039
   Ohoka Y, 2011, J IMMUNOL, V186, P733, DOI 10.4049/jimmunol.1000913
   Omland SH, 2017, BMC CANCER, V17, DOI 10.1186/s12885 017 3663 0
   Otten K, 2003, BIOCHEM BIOPH RES CO, V304, P36, DOI 10.1016/S0006 291X(03)00533 3
   Papadakis KA, 2000, J IMMUNOL, V165, P5069, DOI 10.4049/jimmunol.165.9.5069
   Papadakis KA, 2001, GASTROENTEROLOGY, V121, P246, DOI 10.1053/gast.2001.27154
   Park C, 2019, J IMMUNOL, V203, P3427, DOI 10.4049/jimmunol.1900082
   Pickens SR, 2011, ARTHRITIS RHEUM US, V63, P914, DOI 10.1002/art.30232
   Pickens SR, 2011, ARTHRITIS RHEUM US, V63, P2884, DOI 10.1002/art.30493
   Saruta M, 2007, J IMMUNOL, V178, P3293, DOI 10.4049/jimmunol.178.5.3293
   Schmutz C, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3120
   Sharma PK, 2010, INT J CANCER, V127, P2020, DOI 10.1002/ijc.25219
   Singh R, 2011, INT J ONCOL, V39, P373, DOI 10.3892/ijo.2011.1059
   Stenstad H, 2007, P NATL ACAD SCI USA, V104, P10122, DOI 10.1073/pnas.0700269104
   Svensson M, 2002, J CLIN INVEST, V110, P1113, DOI 10.1172/JCI200215988
   Trivedi PJ, 2016, J AUTOIMMUN, V68, P98, DOI 10.1016/j.jaut.2016.01.001
   Tu ZB, 2016, J HEMATOL ONCOL, V9, DOI 10.1186/s13045 016 0236 7
   Underhill DM, 2003, J ENDOTOXIN RES, V9, P176, DOI 10.1179/096805103125001586
   Van Raemdonck K, 2020, CELL MOL LIFE SCI, V77, P1387, DOI 10.1007/s00018 019 03235 w
   Weissmann G, 2006, BULL HOSP JT DIS, V64, P12
   Wendland M, 2007, P NATL ACAD SCI USA, V104, P6347, DOI 10.1073/pnas.0609180104
   Wurbel MA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016442
   Yokoyama W, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/s13075 014 0445 9
   Zabel BA, 1999, J EXP MED, V190, P1241, DOI 10.1084/jem.190.9.1241
   Zhang QP, 2004, CANCER RES, V64, P7579, DOI 10.1158/0008 5472.CAN 04 0641
   Zhang QP, 2003, CANCER RES, V63, P6469
   Zhang Y, 2019, J NEUROIMMUNE PHARM, V14, P493, DOI 10.1007/s11481 019 09854 1
   Zheng L, 2013, EUR J MICROBIOL IMMU, V3, P11, DOI 10.1556/EuJMI.3.2013.1.2
   Zhou BB, 2010, LEUKEMIA RES, V34, P769, DOI 10.1016/j.leukres.2009.11.025
NR 49
TC 17
Z9 17
U1 1
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0014 2980
EI 1521 4141
J9 EUR J IMMUNOL
JI Eur. J. Immunol.
PD APR
PY 2021
VL 51
IS 4
BP 903
EP 914
DI 10.1002/eji.202048681
EA JAN 2021
PG 12
WC Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology
GA RN8KA
UT WOS:000611108900001
PM 33347617
OA Green Accepted, Green Published
DA 2025 08 17
ER

PT J
AU Soen, S
   Fujiwara, S
   Takayanagi, R
   Kajimoto, K
   Tsujimoto, M
   Kimura, S
   Sato, M
   Krege, JH
   Enomoto, H
AF Soen, Satoshi
   Fujiwara, Saeko
   Takayanagi, Ryoichi
   Kajimoto, Kenta
   Tsujimoto, Mika
   Kimura, Shuichi
   Sato, Masayo
   Krege, John H.
   Enomoto, Hiroyuki
TI Real world effectiveness of daily teriparatide in Japanese patients with
   osteoporosis at high risk for fracture: final results from the 24 month
   Japan Fracture Observational Study (JFOS)
SO CURRENT MEDICAL RESEARCH AND OPINION
LA English
DT Article
DE Daily teriparatide; osteoporosis; clinical fractures; observational
   study; Japan
ID BONE MINERAL DENSITY; PARATHYROID HORMONE 1 34; POST HOC ANALYSIS;
   QUALITY OF LIFE; POSTMENOPAUSAL WOMEN; NONVERTEBRAL FRACTURES; HIP
   FRACTURE; PERSISTENCE; ADHERENCE; OUTCOMES
AB Objective: The Japan Fracture Observational Study (JFOS), a prospective observational study, investigated the real world effectiveness of daily teriparatide to reduce clinical fracture risk in osteoporotic patients.Methods: In routine clinical practice, Japanese patients initiated on teriparatide 20g/day by subcutaneous injection were enrolled. The primary end point was the rate of clinical fractures at 6 month intervals over 24 months. Bone mineral density (BMD), procollagen type 1 aminoterminal propeptide (P1NP), back pain, and health related quality of life (HRQoL) information was collected.Results: Of 1,996 patients at baseline, 90.1% were female, and mean age was 76.9 years. Teriparatide persistence at 12 and 24 months was 68.0% and 51.6%, respectively. Compared to the first 6 month treatment interval, the odds ratio of fractures decreased by 56.4% during 6 12 months, 51.6% during 12 18 months, and 58.8% during 18 24 months (all p<.01). After 24 months, BMD increased by 17.2% (lumbar spine) and 7.9% (total hip). After 6 months, P1NP levels increased by 259.3%. A reduction in back pain (100mm visual analog scale) of 16.1mm at 3 months was maintained through 24 months. HRQoL (pain, daily living activities, general health) improved by 10% at each post baseline time point. Of 279 (14.6%) patients with 1 adverse event (AE), 71 (3.7%) experienced 1 drug related AE (investigator assessed), including nausea (0.7%), dizziness (0.4%), and decreased appetite (0.3%). Osteosarcoma was not reported; there were no new safety signals.Conclusions: JFOS demonstrated effectiveness of teriparatide 20g/day to reduce the risk of clinical fractures in Japanese patients in a real world setting.
C1 [Soen, Satoshi] Kindai Univ, Nara Hosp, Dept Orthopaed Surg & Rheumatol, Ikoma City, Japan.
   [Fujiwara, Saeko] Hiroshima Atom Bomb Casualty Council, Hlth Management & Promot Ctr, Hiroshima, Japan.
   [Takayanagi, Ryoichi] Fukuoka Sanno Hosp, Ctr Prevent Med, Fukuoka, Japan.
   [Takayanagi, Ryoichi] Int Univ Hlth & Welf, Fukuoka, Japan.
   [Kajimoto, Kenta; Tsujimoto, Mika; Kimura, Shuichi; Sato, Masayo; Enomoto, Hiroyuki] Eli Lilly Japan KK, Med Dev Unit Japan, Kobe, Hyogo, Japan.
   [Krege, John H.] Eli Lilly & Co, Biomed Core Team, Indianapolis, IN 46285 USA.
C3 International University of Health & Welfare; Eli Lilly; Eli Lilly
RP Enomoto, H (通讯作者)，4 15 1 13F Akasaka,Minato Ku, Tokyo 1070052, Japan.
EM enomoto_hiroyuki@lilly.com
OI Soen, Satoshi/0000 0002 0955 2747
FU Eli Lilly Japan K.K.
FX The study was sponsored by Eli Lilly Japan K.K.
CR Becker DJ, 2010, J GERONTOL A BIOL, V65, P1012, DOI 10.1093/gerona/glq093
   Bonnick SL, 2010, MENOPAUSE, V17, P25, DOI [10.1097/gme.0b013e3181c617e6, 10.1097/gme.0b013e3181e617e6]
   Burden AM, 2012, OSTEOPOROSIS INT, V23, P1075, DOI 10.1007/s00198 011 1645 7
   Burge R, 2016, J BONE MINER METAB, V34, P692, DOI 10.1007/s00774 015 0720 0
   Canalis E, 2007, NEW ENGL J MED, V357, P905, DOI 10.1056/NEJMra067395
   Chan DC, 2016, OSTEOPOROSIS INT, V27, P2855, DOI 10.1007/s00198 016 3611 x
   Cramer JA, 2005, CURR MED RES OPIN, V21, P1453, DOI 10.1185/030079905X61875
   Dowd R, 2000, OSTEOPOROSIS INT, V11, P533, DOI 10.1007/s001980070097
   Eriksen EF, 2014, BONE, V67, P246, DOI 10.1016/j.bone.2014.07.014
   Herdman M, 2011, QUAL LIFE RES, V20, P1727, DOI 10.1007/s11136 011 9903 x
   Hui SL, 1997, J BONE MINER RES, V12, P1463, DOI 10.1359/jbmr.1997.12.9.1463
   Jiang YB, 2003, J BONE MINER RES, V18, P1932, DOI 10.1359/jbmr.2003.18.11.1932
   Kumamoto K, 2010, J BONE MINER METAB, V28, P1, DOI 10.1007/s00774 009 0125 z
   Ladova K, 2014, J EVAL CLIN PRACT, V20, P111, DOI 10.1111/jep.12095
   Langdahl BL, 2016, CALCIFIED TISSUE INT, V99, P259, DOI 10.1007/s00223 016 0143 5
   Langdahl BL, 2009, CALCIFIED TISSUE INT, V85, P484, DOI 10.1007/s00223 009 9299 6
   LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13
   Lindsay R, 2016, OSTEOPOROSIS INT, V27, P2395, DOI 10.1007/s00198 016 3534 6
   Lindsay R, 2009, OSTEOPOROSIS INT, V20, P943, DOI 10.1007/s00198 008 0766 0
   Lips P, 2005, OSTEOPOROSIS INT, V16, P447, DOI 10.1007/s00198 004 1762 7
   Ljunggren Ö, 2013, BMC MUSCULOSKEL DIS, V14, DOI 10.1186/1471 2474 14 251
   Lu Y, 2001, OSTEOPOROSIS INT, V12, P438, DOI 10.1007/s001980170087
   Mithal Ambrish, 2014, Indian J Endocrinol Metab, V18, P449, DOI 10.4103/2230 8210.137485
   Miyauchi A, 2010, BONE, V47, P493, DOI 10.1016/j.bone.2010.05.022
   Moriwaki K, 2013, J BONE MINER RES, V28, P395, DOI 10.1002/jbmr.1755
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Nishikawa A, 2016, CLIN INTERV AGING, V11, P1653, DOI 10.2147/CIA.S120175
   Nishikawa A, 2016, CLIN INTERV AGING, V11, P913, DOI 10.2147/CIA.S107285
   Nishizawa Y, 2013, J BONE MINER METAB, V31, P1, DOI 10.1007/s00774 012 0392 y
   Nomura Y, 2013, J BONE MINER METAB, V31, P644, DOI 10.1007/s00774 013 0460 y
   Ohta H, 2017, J BONE MINER METAB, V35, P351, DOI 10.1007/s00774 016 0760 0
   Prevrhal S, 2009, CURR MED RES OPIN, V25, P921, DOI 10.1185/03007990902790993 
   ROGERS AS, 1987, DRUG INTEL CLIN PHAR, V21, P915
   Sakamoto K, 2006, J ORTHOP SCI, V11, P127, DOI 10.1007/s00776 005 0998 1
   Salomon JA, 2012, LANCET, V380, P2144, DOI 10.1016/S0140 6736(12)61690 0
   Silverman S, 2013, OSTEOPOROSIS INT, V24, P2309, DOI 10.1007/s00198 013 2284 y
   Siris ES, 2006, MAYO CLIN PROC, V81, P1013, DOI 10.4065/81.8.1013
   Soen S, 2015, CURR MED RES OPIN, V31, P1771, DOI 10.1185/03007995.2015.1074063
   Soen S, 2013, J BONE MINER METAB, V31, P247, DOI [CliCa1403323329, 10.1007/s00774 013 0447 8]
   Tajeu GS, 2014, J GERONTOL A BIOL, V69, P346, DOI 10.1093/gerona/glt105
   Wang XF, 2012, OSTEOPOROSIS INT, V23, P411, DOI 10.1007/s00198 011 1739 2
   Weycker D, 2007, OSTEOPOROSIS INT, V18, P271, DOI 10.1007/s00198 006 0230 y
   Yoshiki F, 2017, J ORTHOP SCI, V22, P330, DOI 10.1016/j.jos.2016.11.022
   Yu S, 2012, OSTEOPOROSIS INT, V23, P1103, DOI 10.1007/s00198 011 1843 3
NR 44
TC 28
Z9 28
U1 0
U2 2
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0300 7995
EI 1473 4877
J9 CURR MED RES OPIN
JI Curr. Med. Res. Opin.
PY 2017
VL 33
IS 11
BP 2049
EP 2056
DI 10.1080/03007995.2017.1354826
PG 8
WC Medicine, General & Internal; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED); Social Science Citation Index (SSCI)
SC General & Internal Medicine; Research & Experimental Medicine
GA FK9TR
UT WOS:000413854200017
PM 28699789
DA 2025 08 17
ER

PT J
AU Karaboyas, A
   Muenz, D
   Fuller, DS
   Desai, P
   Lin, TC
   Robinson, BM
   Rossetti, S
   Pisoni, RL
AF Karaboyas, Angelo
   Muenz, Daniel
   Fuller, Douglas S.
   Desai, Pooja
   Lin, Tzu Chieh
   Robinson, Bruce M.
   Rossetti, Sandro
   Pisoni, Ronald L.
TI Etelcalcetide Utilization, Dosing Titration, and Chronic Kidney
   Disease Mineral and Bone Disease (CKD MBD) Marker Responses in US
   Hemodialysis Patients
SO AMERICAN JOURNAL OF KIDNEY DISEASES
LA English
DT Article
ID PATIENTS RECEIVING HEMODIALYSIS; SERUM PARATHYROID HORMONE; DOPPS
   PRACTICE MONITOR; SECONDARY HYPERPARATHYROIDISM; DIALYSIS OUTCOMES;
   PRACTICE PATTERNS; CINACALCET; ASSOCIATION; METABOLISM; MORTALITY
AB Rationale & Objective: Clinical trial data have demonstrated the efficacy of etelcalcetide for reducing parathyroid hormone (PTH) levels in hemodialysis (HD) patients. We provide a real world summary of etelcalcetide utilization, dosing, effectiveness, and discontinuation since its US introduction in April 2017.
   Study Design: New user design within prospective cohort.
   Setting & Participants: 2,596 new users of etelcalcetide from April 2017 through August 2019 in a national sample of adult maintenance HD patients in the US Dialysis Outcomes and Practice Patterns Study (DOPPS).
   Predictors: Baseline PTH, prior cinacalcet use, initial etelcalcetide dose.
   Outcome: Trajectories of etelcalcetide dose, chronic kidney disease mineral and bone disease (CKD MBD) medications, and levels of PTH, serum calcium, and phosphorus in the 12 months after etelcalcetide initiation.
   Analytical Approach: Cumulative incidence methods for etelcalcetide discontinuation and linear generalized estimating equations for trajectory analyses.
   Results: By August 2019, etelcalcetide prescriptions increased to 6% of HD patients from their first use in April 2017. Starting etelcalcetide dose was 15 mg/wk in 70% of patients and 7.5 mg/wk in 27% of patients; 49% of new users were prescribed cinacalcet in the prior 3 months. Etelcalcetide discontinuation was 9%, 17%, and 27% by 3, 6, and 12 months after initiation. One year after etelcalcetide initiation, mean PTH levels declined by 40%, from 948 to 566 pg/mL, and the proportion of patients with PTH within target (150 599 pg/mL) increased from 33% to 64% overall, from 0 to 60% among patients with baseline PTH >= 600 pg/mL, and from 30% to 63% among patients with prior cinacalcet use. The proportion of patients with serum phosphorus 5.5 mg/dL decreased from 55% to 45%, while the prevalence of albumin corrected serum calcium < 7.5 mg/dL remained at 1% 2%. There were increases in use of active vitamin D (from 77% to 87%) and calcium based phosphate binders (from 41% to 50%) in the 12 months after etelcalcetide initiation.
   Limitations: Data are unavailable for provider dosing protocols, dose holds, or reasons for discontinuation.
   Conclusions: In the 12 months after etelcalcetide initiation, patients had large and sustained reductions in PTH levels. These results support the utility of etelcalcetide as an effective therapy to achieve the KDIGO recommended guidelines for CKD MBD markers in HD patients.
C1 [Karaboyas, Angelo; Muenz, Daniel; Fuller, Douglas S.; Robinson, Bruce M.; Pisoni, Ronald L.] Arbor Res Collaborat Hlth, 3700 Earhart Rd, Ann Arbor, MI 48105 USA.
   [Desai, Pooja; Lin, Tzu Chieh; Rossetti, Sandro] Amgen Inc, Thousand Oaks, CA 91320 USA.
C3 Arbor Research Collaborative for Health; Amgen
RP Karaboyas, A (通讯作者)，Arbor Res Collaborat Hlth, 3700 Earhart Rd, Ann Arbor, MI 48105 USA.
EM angelo.karaboyas@arborresearch.org
RI Desai, Pooja/JZT 8280 2024
FU Arbor Research Collaborative for Health
FX Drs Karaboyas, Muenz, Robinson, and Pisoni are employees, and Mr Fuller
   is a former employee, of Arbor Research Collaborative for Health, which
   administers the DOPPS. All funds are made to Arbor Research
   Collaborative for Health and not directly to the authors. Drs Desai,
   Lin, and Rossetti are Amgen employees and stockholders.
CR [Anonymous], 2017, PARS ET INJ INTR US
   Arbor Research Collaborative for Health, 2016, DIAL AKTUELL, DOI DOI 10.1055/S 0042 110411
   Bikbov B, 2017, HEMODIAL INT, V21, P393, DOI 10.1111/hdi.12503
   Block GA, 2004, J AM SOC NEPHROL, V15, P2208, DOI 10.1097/01.ASN.0000133041.27682.A2
   Block GA, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0213774
   Block GA, 2017, JAMA J AM MED ASSOC, V317, P146, DOI 10.1001/jama.2016.19456
   Block GA, 2017, JAMA J AM MED ASSOC, V317, P156, DOI 10.1001/jama.2016.19468
   Bushinsky DA, 2020, NEPHROL DIAL TRANSPL, V35, P1642, DOI 10.1093/ndt/gfz110
   Bushinsky DA, 2020, NEPHROL DIAL TRANSPL, V35, P1769, DOI 10.1093/ndt/gfz039
   Chertow GM, 2012, NEW ENGL J MED, V367, P2482, DOI 10.1056/NEJMoa1205624
   CLEVELAND WS, 1979, J AM STAT ASSOC, V74, P829, DOI 10.2307/2286407
   Covic A, 2009, NEPHROL DIAL TRANSPL, V24, P1506, DOI 10.1093/ndt/gfn613
   Cunningham J, 2019, KIDNEY INT REP, V4, P987, DOI 10.1016/j.ekir.2019.04.010
   Cunningham J, 2011, CLIN J AM SOC NEPHRO, V6, P913, DOI 10.2215/CJN.06040710
   Cunningham J, 2008, CLIN KIDNEY J, V1, pI29, DOI 10.1093/ndtplus/sfm042
   Arenas MD, 2021, CLIN KIDNEY J, V14, P840, DOI 10.1093/ckj/sfaa005
   Eknoyan G, 2002, AM J KIDNEY DIS, V39, pS14, DOI 10.1053/ajkd.2002.30939
   Friedl C, 2018, DRUG DES DEV THER, V12, P1589, DOI 10.2147/DDDT.S134103
   Fuller DS, 2019, BMC NEPHROL, V20, DOI 10.1186/s12882 019 1355 5
   Fuller DS, 2019, CLIN J AM SOC NEPHRO, V14, P241, DOI 10.2215/CJN.09550818
   Goodman WG, 2008, KIDNEY INT, V74, P276, DOI 10.1038/sj.ki.5002287
   Hedgeman E, 2015, INT J NEPHROL, V2015, DOI 10.1155/2015/184321
   Kalantar Zadeh K, 2006, KIDNEY INT, V70, P771, DOI 10.1038/sj.ki.5001514
   Kidney Dis Improving Global, 2017, KIDNEY INT SUPPL, V7, P1, DOI 10.1016/j.kisu.2017.04.001
   Kidney Disease: Improving Global Outcomes (KDIGO) CKD MBD Work Group, 2009, Kidney Int Suppl, pS1, DOI 10.1038/ki.2009.188
   Kilpatrick RD, 2013, AM J NEPHROL, V37, P389, DOI 10.1159/000350213
   Lee Andrew, 2011, J Med Econ, V14, P798, DOI 10.3111/13696998.2011.627404
   Nemeth EF, 2004, J PHARMACOL EXP THER, V308, P627, DOI 10.1124/jpet.103.057273
   Newsome BB, 2013, AM J NEPHROL, V38, P104, DOI 10.1159/000353298
   Palmer SC, 2020, AM J KIDNEY DIS, V76, P321, DOI 10.1053/j.ajkd.2020.02.439
   Peter WLS, 2009, CLIN J AM SOC NEPHRO, V4, P354, DOI 10.2215/CJN.05241008
   Pisoni RL, 2004, AM J KIDNEY DIS, V44, pS7, DOI 10.1053/j.ajkd.2004.08.005
   Reams BD, 2015, BMC NEPHROL, V16, DOI 10.1186/s12882 015 0174 6
   Robinson B, 2011, AM J KIDNEY DIS, V57, P822, DOI 10.1053/j.ajkd.2011.03.001
   Roggeri A, 2020, DRUGS CONTEXT, V9
   Rottembourg J, 2019, CLIN KIDNEY J, V12, P871, DOI 10.1093/ckj/sfz021
   Russo D, 2019, J CLIN MED, V8, DOI 10.3390/jcm8071066
   Seaman SR, 2013, STAT METHODS MED RES, V22, P278, DOI 10.1177/0962280210395740
   Tentori F, 2008, AM J KIDNEY DIS, V52, P519, DOI 10.1053/j.ajkd.2008.03.020
   Tentori F, 2015, CLIN J AM SOC NEPHRO, V10, P98, DOI 10.2215/CJN.12941213
   Tentori F, 2014, AM J KIDNEY DIS, V63, P851, DOI 10.1053/j.ajkd.2014.02.003
   Valle C, 2008, J AM SOC NEPHROL, V19, P2430, DOI 10.1681/ASN.2007121320
   Xipell M, 2019, BLOOD PURIFICAT, V48, P106, DOI 10.1159/000496562
   Young EW, 2000, KIDNEY INT, V57, pS74, DOI 10.1046/j.1523 1755.2000.07413.x
   Young EW, 2005, KIDNEY INT, V67, P1179, DOI 10.1111/j.1523 1755.2005.00185.x
NR 45
TC 18
Z9 20
U1 0
U2 4
PU W B SAUNDERS CO ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103 2899 USA
SN 0272 6386
EI 1523 6838
J9 AM J KIDNEY DIS
JI Am. J. Kidney Dis.
PD MAR
PY 2022
VL 79
IS 3
BP 362
EP 373
DI 10.1053/j.ajkd.2021.05.020
EA FEB 2022
PG 12
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Urology & Nephrology
GA ZG9KG
UT WOS:000760569000008
PM 34273436
OA hybrid
DA 2025 08 17
ER

PT J
AU Arai, Y
   Choi, B
   Kim, BJ
   Park, S
   Park, H
   Moon, JJ
   Lee, SH
AF Arai, Yoshie
   Choi, Bogyu
   Kim, Byoung Ju
   Park, Sunghyun
   Park, Hyoeun
   Moon, James J.
   Lee, Soo Hong
TI Cryptic ligand on collagen matrix unveiled by MMP13 accelerates bone
   tissue regeneration via MMP13/Integrin α3/RUNX2 feedback loop
SO ACTA BIOMATERIALIA
LA English
DT Article
DE Matrix metalloproteinases; ECM remodeling; Bond tissue regeneration;
   Self healing; Mesenchymal stem cells
ID MESENCHYMAL STEM CELLS; REAL TIME DETECTION; OSTEOGENIC DIFFERENTIATION;
   EXTRACELLULAR MATRIX; I COLLAGEN; OSTEOBLAST DIFFERENTIATION;
   GENE EXPRESSION; INTEGRINS; METALLOPROTEINASE 13; IDENTIFICATION
AB Extracellular matrix (ECM) remodeling is necessary for the development and self healing of tissue, and the process is tissue specific. Matrix metalloproteinases (MMPs) play a role in ECM remodeling by unwinding and cleaving ECM. We hypothesized that ECM remodeling by MMPs is involved in the differentiation of stem cells into specific lineages during self healing. To prove the hypothesis, we investigated which MMPs are involved in the osteogenic differentiation of human mesenchymal stem cells (hMSCs) grown on a type I collagen (Col I) matrix, and we found that specifically high expression of MMP13 in hMSCs grown on a Col I matirx during osteogenic differentiation. Moreover, knocking down of MMP13 decreased the osteogenic differentiation of hMSCs grown on a Col I matrix. In addition, pre treatment of recombinant human MMP13 lead to remodeling of Col I matrix and increased the osteogenic differentiation of hMSCs and in vivo bone formation following the upregulation of the expression of runt related transcription factor 2 (RUNX2), integrin alpha 3 (ITGA3), and focal adhesion kinase. Furthermore, the transcription factor RUNX2 bound to the MMP13 promoter. These results suggest that growth on a remodeled Col I matrix by MMP13 stimulates osteogenic differentiation of hMSCs and self healing of bone tissue via an MMP13/ITGA3/RUNX2 positive feedback loop.
   Statement of significance Self healing of tissue could be the key to treating diseases that cannot be overcome by present technology. We investigated the mechanism underlying the self healing of tissue and we found that the osteogenic differentiation was increased in hMSCs grown on a remodeled Col I matrix by the optimized concentration of MMP13 not in hMSCs grown on a Col I fragments cleaved by a high concentration of MMP13. In addition, we found the remodeled Col I matrix by MMP13 increased the osteogenic capacity through a MMP13/integrin alpha 3/RUNX2 positive feedback loop. This result would be able to not only provide a strategy for bone tissue specific functional materials following strong evidence about the self healing mechanism of bone through the interaction between stem cells and the ECM matrix. As such, we strongly believe our finding will be of interest to researchers studying biomaterials, stem cell biology and matrix interaction for regenerative medicine and therapy. (C) 2021 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
C1 [Arai, Yoshie; Kim, Byoung Ju; Park, Hyoeun; Lee, Soo Hong] Dongguk Univ, Dept Med Biotechnol, Seoul 04620, South Korea.
   [Choi, Bogyu; Park, Sunghyun] CHA Univ, Dept Biomed Sci, CHA Biocomplex 335, Seongnam Si 13488, Gyeonggi Do, South Korea.
   [Moon, James J.] Univ Michigan, Dept Pharmaceut Sci, Dept Biomed Engn, Ann Arbor, MI 48109 USA.
   [Moon, James J.] Univ Michigan, Biointerfaces Inst, Ann Arbor, MI 48109 USA.
C3 Dongguk University; Pochon Cha University; University of Michigan
   System; University of Michigan; University of Michigan System;
   University of Michigan
RP Lee, SH (通讯作者)，Dongguk Univ, Dept Med Biotechnol, Seoul 04620, South Korea.
EM soohong@dongguk.edu
RI LEE, SOO/AAR 9112 2020; Kim, Jung/L 9791 2019; Arai,
   Yoshie/IST 8485 2023; Moon, James/ABE 4429 2021
OI Moon, James/0000 0003 2238 2372
FU Korean government (MSIT) [NRF 2019R1A2B5B03069690, NRF 2019M3A9H1032376,
   NRF 2020R1I1A1A01074331, NRF 2020H1D3A1A02078382]; Korean government
   (MOE) [NRF 2019R1A2B5B03069690, NRF 2019M3A9H1032376,
   NRF 2020R1I1A1A01074331, NRF 2020H1D3A1A02078382]; Dongguk University
   Research Fund
FX This work was funded by the Korean government (MSIT and MOE)
   (NRF 2019R1A2B5B03069690, NRF 2019M3A9H1032376, NRF 2020R1I1A1A01074331,
   and NRF 2020H1D3A1A02078382) and supported by the Dongguk University
   Research Fund of 2018.
CR Barthelemi S, 2012, J CELL BIOCHEM, V113, P760, DOI 10.1002/jcb.23401
   Behonick DJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001150
   Bernhardt A, 2008, J MATER SCI MATER M, V19, P269, DOI 10.1007/s10856 006 0059 0
   Bi YM, 2007, NAT MED, V13, P1219, DOI 10.1038/nm1630
   Bonnans C, 2014, NAT REV MOL CELL BIO, V15, P786, DOI 10.1038/nrm3904
   BRUDER SP, 1994, J CELL BIOCHEM, V56, P283, DOI 10.1002/jcb.240560303
   Corradetti B., 2015, RESIDENT STEM CELLS
   Daley WP, 2008, J CELL SCI, V121, P255, DOI 10.1242/jcs.006064
   Di Benedetto A, 2015, STEM CELL RES, V15, P618, DOI 10.1016/j.scr.2015.09.011
   Einhorn TA, 2015, NAT REV RHEUMATOL, V11, P45, DOI 10.1038/nrrheum.2014.164
   Fowlkes JL, 2012, J DIABETES METAB, V3, DOI 10.4172/2155 6156.S1 003
   Gentili C, 2009, CURR PHARM DESIGN, V15, P1334, DOI 10.2174/138161209787846739
   Gong T, 2015, BONE RES, V3, DOI 10.1038/boneres.2015.29
   GULLBERG D, 1992, EMBO J, V11, P3865, DOI 10.1002/j.1460 2075.1992.tb05479.x
   Hamidouche Z, 2009, P NATL ACAD SCI USA, V106, P18587, DOI 10.1073/pnas.0812334106
   Heino J, 2007, BIOESSAYS, V29, P1001, DOI 10.1002/bies.20636
   Henkel J, 2013, BONE RES, V1, P216, DOI 10.4248/BR201303002
   Howes JM, 2014, J BIOL CHEM, V289, P24091, DOI 10.1074/jbc.M114.583443
   Jokinen J, 2004, J BIOL CHEM, V279, P31956, DOI 10.1074/jbc.M401409200
   Klees RF, 2005, MOL BIOL CELL, V16, P881, DOI 10.1091/mbc.e04 08 0695
   Kosaki N, 2007, BIOCHEM BIOPH RES CO, V354, P846, DOI 10.1016/j.bbrc.2006.12.234
   Lane SW, 2014, NAT BIOTECHNOL, V32, P795, DOI 10.1038/nbt.2978
   Liacini A, 2005, ARTHRITIS RES THER, V7, pR777, DOI 10.1186/ar1735
   Lu PF, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a005058
   MATTOT V, 1995, J CELL SCI, V108, P529
   Mauney JR, 2006, J BIOMED MATER RES A, V79A, P464, DOI 10.1002/jbm.a.30876
   Messent AJ, 1998, J CELL SCI, V111, P1127
   Pankov R, 2002, J CELL SCI, V115, P3861, DOI 10.1242/jcs.00059
   Popov C, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.71
   Rahman MS, 2015, BONE RES, V3, DOI 10.1038/boneres.2015.5
   Rennert RC, 2012, REGEN MED, V7, P833, DOI [10.2217/RME.12.82, 10.2217/rme.12.82]
   ROBEY PG, 1993, J BONE MINER RES, V8, pS483
   Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697
   Saidak Z, 2015, J BIOL CHEM, V290, P6903, DOI 10.1074/jbc.M114.621219
   Selvamurugan N, 2009, FEBS LETT, V583, P1141, DOI 10.1016/j.febslet.2009.02.040
   Shimizu E, 2014, J BIOL CHEM, V289, P21340, DOI 10.1074/jbc.M114.550699
   Paiva KBS, 2014, ARCH BIOCHEM BIOPHYS, V561, P74, DOI 10.1016/j.abb.2014.07.034
   Tang SY, 2012, J BONE MINER RES, V27, P1936, DOI 10.1002/jbmr.1646
   Tang Y, 2013, DEV CELL, V25, P402, DOI 10.1016/j.devcel.2013.04.011
   Taubenberger AV, 2010, BIOMATERIALS, V31, P2827, DOI 10.1016/j.biomaterials.2009.12.051
   Tsai KS, 2010, J BIOMED MATER RES A, V94A, P673, DOI 10.1002/jbm.a.32693
   Wang KP, 2020, NANOSCALE, V12, P10106, DOI 10.1039/d0nr00872a
   Wang XB, 2004, OSTEOARTHR CARTILAGE, V12, P963, DOI 10.1016/j.joca.2004.08.008
   Witkowska Zimny M, 2014, FOLIA HISTOCHEM CYTO, V52, P297, DOI 10.5603/FHC.a2014.0031
   Wu Q, 2020, J MATER CHEM B, V8, P3016, DOI 10.1039/c9tb02899d
   Yue J, 2012, CANCER MICROENVIRON, V5, P275, DOI 10.1007/s12307 012 0101 3
   Zaragoza C, 2006, J CELL SCI, V119, P1896, DOI 10.1242/jcs.02895
NR 47
TC 36
Z9 39
U1 2
U2 23
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1742 7061
EI 1878 7568
J9 ACTA BIOMATER
JI Acta Biomater.
PD APR 15
PY 2021
VL 125
BP 219
EP 230
DI 10.1016/j.actbio.2021.02.042
EA APR 2021
PG 12
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA RN9XI
UT WOS:000640705500004
PM 33677160
DA 2025 08 17
ER

PT J
AU Niemann, S
   Nguyen, MT
   Eble, JA
   Chasan, AI
   Mrakovcic, M
   Böttcher, RT
   Preissner, KT
   Rosslenbroich, S
   Peters, G
   Herrmann, M
AF Niemann, Silke
   Minh Thu Nguyen
   Eble, Johannes A.
   Chasan, Achmet, I
   Mrakovcic, Maria
   Bottcher, Ralph T.
   Preissner, Klaus T.
   Rosslenbroich, Steffen
   Peters, Georg
   Herrmann, Mathias
TI More Is Not Always Better the Double Headed Role of Fibronectin in
   Staphylococcus aureus Host Cell Invasion
SO MBIO
LA English
DT Article
DE Staphylococcus; epithelial cells; fibronectin; host cell invasion;
   host pathogen interactions; osteoblasts
ID EXTRACELLULAR ADHERENCE PROTEIN; SURFACE FIBRONECTIN; MATRIX;
   INTERNALIZATION; INFECTION; FRAGMENT
AB While Staphylococcus aureus has classically been considered an extracellular pathogen, these bacteria are also capable of being taken up by host cells, including nonprofessional phagocytes such as endothelial cells, epithelial cells, or osteoblasts. The intracellular S. aureus lifestyle contributes to infection development. The predominant recognition and internalization pathway appears to be the binding of the bacteria via a fibronectin bridge to the alpha 5 beta 1 integrin on the host cell membrane, followed by phagocytosis. Although osteoblasts showed high expression of alpha 5 beta 1 integrin and fibronectin, and bacteria adhered to osteoblasts to a high proportion, here we demonstrate by internalization assays and immunofluorescence microscopy that S. aureus was less engulfed in osteoblasts than in epithelial cells. The addition of exogenous fibronectin during the infection of cells with S. aureus resulted in an increased uptake by epithelial cells but not by osteoblasts. This contrasts with the previous conception of the uptake mechanism, where high expression of integrin and fibronectin would promote the bacterial uptake into host cells. Extracellular fibronectin surrounding osteoblasts, but not epithelial cells, is organized in a fibrillary network. The inhibition of fibril formation, the short interfering RNA mediated reduction of fibronectin expression, and the disruption of the fibronectin fibril meshwork all resulted in a significant increase in S. aureus uptake by osteoblasts. Thus, the network of fibronectin fibrils appears to strongly reduce the uptake of S. aureus into a given host cell, indicating that the supramolecular structure of fibronectin determines the capacity of particular host cells to internalize the pathogen.
   IMPORTANCE Traditionally, Staphylococcus aureus has been considered an extracellular pathogen. However, among other factors, the frequent failure of antimicrobial therapy and the ability of the pathogen to cause recurrent disease have established the concept of eukaryotic invasion of the pathogen, thereby evading the host's immune system. In the current model of host cell invasion, bacteria initially bind to alpha 5 beta 1 integrin on the host cell side via a fibronectin bridge, which eventually leads to phagocytosis of S. aureus by host cells. However, in this study, we demonstrate that not the crude amount but the supramolecular structure of fibronectin molecules deposited on the eukaryotic cell surface plays an essential role in bacterial uptake by host cells. Our findings explain the large differences of S. aureus uptake efficacy in different host cell types as well as in vivo differences between courses of bacterial infections and the localization of bacteria in different clinical settings.
C1 [Niemann, Silke; Minh Thu Nguyen; Mrakovcic, Maria; Peters, Georg; Herrmann, Mathias] Univ Hosp Munster, Inst Med Microbiol, Munster, Germany.
   [Eble, Johannes A.] Univ Munster, Inst Physiol Chem & Pathobiochem, Munster, Germany.
   [Chasan, Achmet, I] Univ Munster, Inst Immunol, Munster, Germany.
   [Bottcher, Ralph T.] Max Planck Inst Biochem, Dept Mol Med, Martinsried, Germany.
   [Preissner, Klaus T.] Justus Liebig Univ, Med Sch, Kerckhoff Herzforschungsinst, Dept Cardiol, Giessen, Germany.
   [Rosslenbroich, Steffen] Univ Hosp Munster, Dept Trauma Hand & Reconstruct Surg, Munster, Germany.
   [Mrakovcic, Maria] Univ Munster, Inst Infectiol, Munster, Germany.
C3 University of Munster; University of Munster; University of Munster; Max
   Planck Society; Justus Liebig University Giessen; University of Munster;
   University of Munster
RP Niemann, S (通讯作者)，Univ Hosp Munster, Inst Med Microbiol, Munster, Germany.
EM Silke.Niemann@uni muenster.de
RI ; Nguyen, Minh Thu/HJY 2560 2023; Rosslenbroich, Steffen/AIB 3974 2022;
   Nguyen, Minh Thu/A 3964 2019; Herrmann, Mathias/B 6475 2013
OI Imam Chasan, Achmet/0000 0001 5137 6890; Nguyen,
   Minh Thu/0000 0001 6510 0684; Niemann, Silke/0000 0002 9807 2541
FU Deutsche Forschungsgemeinschaft (DFG; German Research Foundation)
   [194468054 SFB 1009]
FX This work was funded by the Deutsche Forschungsgemeinschaft (DFG; German
   Research Foundation), Project ID 194468054 SFB 1009, projects A09, B01,
   and Z02.
CR Abu Humaidan AH, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00396
   Agerer F, 2005, J CELL SCI, V118, P2189, DOI 10.1242/jcs.02328
   Agerer F, 2003, J BIOL CHEM, V278, P42524, DOI 10.1074/jbc.M302096200
   Bascetin R, 2017, INT J BIOL MACROMOL, V97, P733, DOI 10.1016/j.ijbiomac.2017.01.061
   Bascetin R, 2018, EXP CELL RES, V371, P104, DOI 10.1016/j.yexcr.2018.07.047
   Benito Jardón M, 2017, ELIFE, V6, DOI 10.7554/eLife.22264
   Bongiorno D, 2020, MICROBIOLOGYOPEN, V9, DOI 10.1002/mbo3.1017
   Bosse MJ, 2005, J BONE JOINT SURG AM, V87A, P1343, DOI 10.2106/JBJS.D.02649
   Bur S, 2013, J INVEST DERMATOL, V133, P2004, DOI 10.1038/jid.2013.87
   Chabria M, 2010, NAT COMMUN, V1, DOI 10.1038/ncomms1135
   Dallas SL, 2005, J BIOL CHEM, V280, P18871, DOI 10.1074/jbc.M410762200
   Edwards AM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018899
   Fraunholz M, 2013, GENOME ANNOUNCEMENTS, V1, DOI 10.1128/genomeA.00775 13
   Grinnell F, 1996, J INVEST DERMATOL, V106, P335, DOI 10.1111/1523 1747.ep12342990
   Haggar A, 2003, INFECT IMMUN, V71, P2310, DOI 10.1128/IAI.71.5.2310 2317.2003
   Hammerschmidt S, 2019, MICROBIOL SPECTR, V7, DOI 10.1128/microbiolspec.GPP3 0041 2018
   Hamza T, 2013, EUR CELLS MATER, V25, P341, DOI 10.22203/eCM.v025a24
   Hauck CR, 2006, EUR J CELL BIOL, V85, P235, DOI 10.1016/j.ejcb.2005.08.002
   Hirschhausen N, 2010, CELL MICROBIOL, V12, P1746, DOI 10.1111/j.1462 5822.2010.01506.x
   HYNES RO, 1979, J SUPRAMOL STR CELL, V11, P95, DOI 10.1002/jss.400110110
   Ji ZG, 2020, CELL MICROBIOL, V22, DOI 10.1111/cmi.13240
   Josse J, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.02433
   Kusubata M, 1999, J INVEST DERMATOL, V113, P906, DOI 10.1046/j.1523 1747.1999.00802.x
   Lemanska Perek A, 2019, ADV CLIN EXP MED, V28, P1561, DOI 10.17219/acem/104531
   Liang Xiaowen, 2016, PLoS One, V11, pe0159118, DOI 10.1371/journal.pone.0159118
   Libring S, 2020, CANCERS, V12, DOI 10.3390/cancers12051270
   Liesenborghs L, 2020, J THROMB HAEMOST, V18, P995, DOI 10.1111/jth.14736
   Löffler B, 2014, INT J MED MICROBIOL, V304, P170, DOI 10.1016/j.ijmm.2013.11.011
   Lowy FD, 2000, TRENDS MICROBIOL, V8, P341, DOI 10.1016/S0966 842X(00)01803 5
   Mao Y, 2005, MATRIX BIOL, V24, P389, DOI 10.1016/j.matbio.2005.06.008
   Maurer LM, 2016, CRIT REV BIOCHEM MOL, V51, P213, DOI 10.1080/10409238.2016.1184224
   MCKEOWNLONGO PJ, 1985, J CELL BIOL, V100, P364, DOI 10.1083/jcb.100.2.364
   Nguyen MT, 2018, INFECT IMMUN, V86, DOI 10.1128/IAI.00343 18
   Moretti FA, 2007, J BIOL CHEM, V282, P28057, DOI 10.1074/jbc.M611315200
   Niemann S, 2012, J INFECT DIS, V206, P1138, DOI 10.1093/infdis/jis468
   Ou J, 2016, INT FORUM ALLERGY RH, V6, P792, DOI 10.1002/alr.21758
   Pietrocola G, 2020, J BIOL CHEM, V295, P10008, DOI 10.1074/jbc.RA120.013510
   Prystopiuk V, 2018, ACS NANO, V12, P3609, DOI 10.1021/acsnano.8b00716
   Que YA, 2005, J EXP MED, V201, P1627, DOI 10.1084/jem.20050125
   ROBEY PG, 1985, CALCIFIED TISSUE INT, V37, P453, DOI 10.1007/BF02557826
   Rosenstein R, 2009, APPL ENVIRON MICROB, V75, P811, DOI 10.1128/AEM.01982 08
   Schlesier T, 2020, INT J MED MICROBIOL, V310, DOI 10.1016/j.ijmm.2020.151463
   Schwarz Linek U, 2004, MOL MICROBIOL, V52, P631, DOI 10.1111/j.1365 2958.2004.04027.x
   Singh P, 2010, ANNU REV CELL DEV BI, V26, P397, DOI 10.1146/annurev cellbio 100109 104020
   Sinha B, 1999, CELL MICROBIOL, V1, P101, DOI 10.1046/j.1462 5822.1999.00011.x
   Sinha B, 2000, INFECT IMMUN, V68, P6871, DOI 10.1128/IAI.68.12.6871 6878.2000
   Strobel M, 2016, CLIN MICROBIOL INFEC, V22, P799, DOI 10.1016/j.cmi.2016.06.020
   Surewaard BGJ, 2016, J EXP MED, V213, P1141, DOI 10.1084/jem.20160334
   Tomasini Johansson BR, 2006, MATRIX BIOL, V25, P282, DOI 10.1016/j.matbio.2006.02.002
   Tribelli PM, 2020, CELL MICROBIOL, V22, DOI 10.1111/cmi.13111
   Tuchscherr L, 2010, J INFECT DIS, V202, P1031, DOI 10.1086/656047
   VANN JM, 1987, INFECT IMMUN, V55, P2155, DOI 10.1128/IAI.55.9.2155 2163.1987
   Wen QQ, 2020, INT J MED SCI, V17, P1327, DOI 10.7150/ijms.45960
   Wierzbicka Patynowski I, 2003, J CELL SCI, V116, P3269, DOI 10.1242/jcs.00670
   Wierzbicka Patynowski Iwona, 2004, Curr Protoc Cell Biol, VChapter 10, DOI 10.1002/0471143030.cb1012s25
   Yasir S, 2021, AM J SURG PATHOL, V45, P205, DOI 10.1097/PAS.0000000000001585
   Zautner AE, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009452
NR 57
TC 21
Z9 23
U1 1
U2 19
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036 2904 USA
SN 2150 7511
J9 MBIO
JI mBio
PD SEP OCT
PY 2021
VL 12
IS 5
AR e01062 21
DI 10.1128/mBio.01062 21
PG 18
WC Microbiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Microbiology
GA XV8TQ
UT WOS:000735207700009
PM 34663090
OA Green Published
DA 2025 08 17
ER

PT J
AU Morrison, LS
   Tobias, JH
AF Morrison, LS
   Tobias, JH
TI Effect of a case finding strategy for osteoporosis on bisphosphonate
   prescribing in primary care
SO OSTEOPOROSIS INTERNATIONAL
LA English
DT Article
DE bisphosphonates; DXA scans; primary care
ID FRACTURE; WOMEN; SERVICE; MEN
AB Case selection strategies have been advocated for identifying patients who would benefit from primary care to prevent osteoporosis. However, the effectiveness of this approach is unclear. To address this question., we performed a randomized control trial to determine whether a case selection strategy to identify patients with clinical risk factors for osteoporosis.. combined with open access to dual X ray absorptometry (DXA) scans, influences bisphosphonate prescribing in ten GP practices in Avon. Practices were randomized to two groups: the first identified women aged 45 75 years at high risk of osteoporosis and provided open access to DXA scans for 12 months; the second had no case finding strategy and no DXA scan access. Bisphosphonate prescribing was ascertained by searching computerized patient records every 3 months during the intervention and a subsequent 6 month follow up period. Overall., the number of subjects in each practice who were prescribed bisphosphonates increased by 50% (p<0.001),. and the proportion of bisphosphonates prescribed as aminobisphosphonates increased 3 fold (p<0.001). The magnitude of these changes was similar in both groups. However, of the patients prescribed bisphosphonates, approximately twice as many in group 1, as compared with group 2, had a previously documented low trauma fracture, as assessed at the end of the 12 month intervention period (p=0.01). Furthermore, at study's end, of the 30 patients in group I receiving bisphosphonates who had received DXA scans, 80% had osteoporosis as defined by t score <  2.5. We conclude that use of a case selection strategy for osteoporosis in primary care, combined with open access to DXA scans, appears to target bisphosphonate therapy to those at high risk of osteoporotic fractures. In contrast. the overall rate of bisphosphonate prescribing is unaffected by this intervention.
C1 Univ Bristol, Rheumatol Unit, Bristol BS8 1TH, Avon, England.
   Bristol Royal Infirm & Gen Hosp, Rheumatol Unit, Bristol BS2 8HW, Avon, England.
C3 University of Bristol; Bristol Royal Infirmary
RP Bristol Royal Infirm & Gen Hosp, Rheumatol Unit, Bristol BS2 8HW, Avon, England.
EM Jon.Tobias@bristol.ac.uk
RI Tobias, Jon/E 2832 2014
OI Tobias, Jon/0000 0002 7475 3932
CR Bland M., 1995, INTRO MED STAT, V2nd
   Chantler IW, 2003, ANN RHEUM DIS, V62, P350, DOI 10.1136/ard.62.4.350
   COMPSTON J, 2000, OSTEOPOROSIS CLIN GU
   Cranney A, 2002, ENDOCR REV, V23, P570, DOI 10.1210/er.2001 9002
   de Lusignan S, 2003, PUBLIC HEALTH, V117, P438, DOI 10.1016/S0033 3506(03)00129 X
   Fitt NS, 2001, CAN MED ASSOC J, V164, P777
   Haentjens P, 2003, J BONE JOINT SURG AM, V85A, P1936, DOI 10.2106/00004623 200310000 00011
   Kanis J A, 2002, Health Technol Assess, V6, P1
   O'Neill TW, 2001, OSTEOPOROSIS INT, V12, P555, DOI 10.1007/s001980170076
   ROSS PD, 1991, ANN INTERN MED, V114, P919, DOI 10.7326/0003 4819 114 11 919
   Sahota O, 2000, J PUBLIC HEALTH MED, V22, P466, DOI 10.1093/pubmed/22.4.466
   Siris ES, 2003, J CLIN ENDOCR METAB, V88, P3482, DOI 10.1210/jc.2003 030568
   Torgerson DJ, 1998, ANN RHEUM DIS, V57, P378, DOI 10.1136/ard.57.6.378
   Torgerson DJ, 1996, J ROY SOC MED, V89, P457, DOI 10.1177/014107689608900810
   TOWNSEND P, 1988, HLTH DEPRIVATION
NR 15
TC 9
Z9 10
U1 0
U2 0
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0937 941X
EI 1433 2965
J9 OSTEOPOROSIS INT
JI Osteoporosis Int.
PD JAN
PY 2005
VL 16
IS 1
BP 71
EP 77
DI 10.1007/s00198 004 1644 z
PG 7
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 887DG
UT WOS:000226284900009
PM 15175847
DA 2025 08 17
ER

PT J
AU Hu, RY
   Li, B
   Sun, L
   Xu, FB
   Yang, XT
   Luo, R
   Tian, XB
   Zhao, JM
AF Hu, Ru Yin
   Li, Bo
   Sun, Li
   Xu, Fu Ben
   Yang, Xian Teng
   Luo, Rui
   Tian, Xiao Bin
   Zhao, Jin Min
TI Taraxasterol as a proliferation enhancing agent to enhance osteogenic
   differentiation of rat osteoblastic cells
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE
LA English
DT Article
DE Osteoporosis; taraxasterol; rat osteoblastic cells;
   proliferation enhancing; differentiation
ID BONE MORPHOGENETIC PROTEINS; INFLAMMATORY RESPONSES; OXIDATIVE STRESS;
   STEM CELLS; RECRUITMENT; SCAFFOLD; LIPOPOLYSACCHARIDE; HEALTH
AB Osteoporosis is a disease characterized by decreased bone strength, decreased bone mass, and bone deterioration. The proliferation and osteogenic capacity of osteoblastic cells needs to be improved, for their use in cell based therapy, and in the treatment of osteoporosis. Taraxasterol, the main constituent of the traditional Chinese medicinal herb Taraxacum, has been demonstrated to have anti inflammatory, cholesterol lowering, antirheumatic, anti cancer, and protective effects. However, the protective effects of taraxasterol, on osteoblastic cells and osteogenic differentiation, have not been reported. Based on the hypothesis that taraxasterol may have an effect on osteoblastic cell growth and differentiation, we studied the effect of taraxasterol on rat osteoblastic cells by detecting cell proliferation, alkaline phosphatase (ALP) activity, and the expression of relevant osteogenic markers. Various concentrations of taraxasterol (0 mu M, 6.25 mu M, 12.5 mu M, and 25 mu M) were used for treatment of rat osteoblastic cells, with the cell proliferation to be detected. Bone morphogenetic protein 2 (BMP 2), runt related transcription factor 2 (RUNX2), alkaline phosphatase (ALP), bone sialoprotein (BSP), type I collagen (COL I), and osteocalcin (OCN) expression levels were evaluated by reverse transcription polymerase chain reaction (RT PCR) using isolated RNA. Our results demonstrated that taraxasterol has a strong stimulatory effect on osteoblastic cell proliferation/ enhancement, and on maintaining the phenotype. Taraxasterol also regulated osteoblast differentiation through the upregulation of ALP expression in rat osteoblastic cells. Also, treatment with taraxasterol enhanced the transcript levels of BMP 2, RUNX2, ALP, BSP, COL I, and OCN. The underlying mechanism might be associated with taraxasterol's antioxidative effect, leading to favorable amounts of reactive oxygen species in the cellular environment. Thus, our study indicated that taraxasterol can be used as an osteogenic proliferation enhancing agent for the therapy of osteoporosis.
C1 [Hu, Ru Yin; Zhao, Jin Min] Guangxi Med Univ, 22 Shuangyong St, Nanning 530021, Peoples R China.
   [Hu, Ru Yin; Li, Bo; Sun, Li; Yang, Xian Teng; Luo, Rui; Tian, Xiao Bin] Guizhou Prov Peoples Hosp, Dept Orthoped, 83 East Zhongshan Rd, Guiyang 550002, Guizhou, Peoples R China.
   [Zhao, Jin Min] Guangxi Med Univ, Affiliated Hosp 1, Nanning 530021, Peoples R China.
   [Xu, Fu Ben] Maternal & Child Hlth Hosp Guangxi Zhuang Autonom, Nanning 530003, Peoples R China.
C3 Guangxi Medical University; Guangxi Medical University
RP Zhao, JM (通讯作者)，Guangxi Med Univ, 22 Shuangyong St, Nanning 530021, Peoples R China.; Zhao, JM (通讯作者)，Guizhou Prov Peoples Hosp, Dept Orthoped, 83 East Zhongshan Rd, Guiyang 550002, Guizhou, Peoples R China.
EM txb6@vip.163.com
RI zhao, jin/LBH 0351 2024
FU Project of Administration of Traditional Chinese Medicine of Guizhou
   Province of China [QZYY 2016 074]; National Natural Science Foundation
   of China [81560356]
FX This study was supported by the Project of Administration of Traditional
   Chinese Medicine of Guizhou Province of China (QZYY 2016 074) and the
   National Natural Science Foundation of China (No. 81560356).
CR Almeida M, 2013, J GERONTOL A BIOL, V68, P1197, DOI 10.1093/gerona/glt079
   Aubin J E, 2001, Rev Endocr Metab Disord, V2, P81, DOI 10.1023/A:1010011209064
   Aubin JE, 1998, BIOCHEM CELL BIOL, V76, P899, DOI 10.1139/bcb 76 6 899
   Axelrad TW, 2009, CYTOKINE GROWTH F R, V20, P481, DOI 10.1016/j.cytogfr.2009.10.003
   Ben Mordechai T, 2013, J AM COLL CARDIOL, V62, P1890, DOI 10.1016/j.jacc.2013.07.057
   Bishop GB, 2007, INT ORTHOP, V31, P721, DOI 10.1007/s00264 007 0424 8
   Boehler RM, 2011, BIOTECHNIQUES, V51, P239, DOI 10.2144/000113754
   Brown BN, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00510
   Crupi A, 2015, EUR J IMMUNOL, V45, P3222, DOI 10.1002/eji.201545818
   Farea M, 2014, ARCH ORAL BIOL, V59, P1400, DOI 10.1016/j.archoralbio.2014.08.015
   Gersbach CA, 2004, EXP CELL RES, V300, P406, DOI 10.1016/j.yexcr.2004.07.031
   Haidar ZS, 2009, BIOTECHNOL LETT, V31, P1825, DOI 10.1007/s10529 009 0100 8
   Haigis MC, 2010, MOL CELL, V40, P333, DOI 10.1016/j.molcel.2010.10.002
   Hassan MQ, 2004, MOL CELL BIOL, V24, P9248, DOI 10.1128/MCB.24.20.9248 9261.2004
   Huang Q, 2002, TISSUE ENG, V8, P469, DOI 10.1089/107632702760184727
   Jilka RL, 2010, AGING CELL, V9, P851, DOI 10.1111/j.1474 9726.2010.00616.x
   Jimbo R, 2007, BIOMATERIALS, V28, P3469, DOI 10.1016/j.biomaterials.2007.04.029
   Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534 5807(02)00157 0
   Kolaczkowska E, 2013, NAT REV IMMUNOL, V13, P159, DOI 10.1038/nri3399
   Komori T, 2006, J CELL BIOCHEM, V99, P1233, DOI 10.1002/jcb.20958
   Lee DH, 2006, TISSUE ENG, V12, P1577, DOI 10.1089/ten.2006.12.1577
   Lee HY, 2016, BMC COMPLEM ALTERN M, V16, DOI 10.1186/s12906 016 1274 y
   Likhitpanichkul M, 2016, J BIOMECH, V49, P1214, DOI 10.1016/j.jbiomech.2016.02.029
   Liu XSBJ, 2016, EUR J PHARMACOL, V789, P301, DOI 10.1016/j.ejphar.2016.07.047
   Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119
   Mills CD, 2012, CRIT REV IMMUNOL, V32, P463, DOI 10.1615/CritRevImmunol.v32.i6.10
   Nauth A, 2009, INJURY, V40, P27
   Ni PY, 2011, INT J NANOMED, V6, P3065, DOI 10.2147/IJN.S25297
   Niu LN, 2014, J DENT, V42, P839, DOI 10.1016/j.jdent.2014.03.016
   Piao TK, 2015, EUR J PHARMACOL, V756, P38, DOI 10.1016/j.ejphar.2015.03.012
   Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071
   Sambrook P, 2006, LANCET, V367, P2010, DOI 10.1016/S0140 6736(06)68891 0
   San ZH, 2014, INT IMMUNOPHARMACOL, V19, P342, DOI 10.1016/j.intimp.2014.01.031
   Sharma K, 2016, PLANT PHYSIOL BIOCH, V103, P24, DOI 10.1016/j.plaphy.2016.02.029
   Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643
   Sun JL, 2017, BIOMATERIALS, V113, P203, DOI 10.1016/j.biomaterials.2016.10.050
   Xiong HZ, 2014, J ETHNOPHARMACOL, V155, P753, DOI 10.1016/j.jep.2014.06.023
   Zhang XM, 2014, IMMUNOPHARM IMMUNOT, V36, P11, DOI 10.3109/08923973.2013.861482
   Zhang XM, 2012, J ETHNOPHARMACOL, V141, P206, DOI 10.1016/j.jep.2012.02.020
   Zhao HH, 2014, J CELL MOL MED, V18, P283, DOI 10.1111/jcmm.12186
NR 40
TC 3
Z9 3
U1 0
U2 8
PU E CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1940 5901
J9 INT J CLIN EXP MED
JI Int. J. Clin. Exp. Med.
PY 2018
VL 11
IS 2
BP 528
EP 538
PG 11
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA FZ2OH
UT WOS:000427417600012
DA 2025 08 17
ER

PT J
AU Shao, YW
   Wood, GA
   Lu, JC
   Tang, QL
   Liu, J
   Molyneux, S
   Chen, Y
   Fang, H
   Adissu, H
   McKee, T
   Waterhouse, P
   Khokha, R
AF Shao, Yang W.
   Wood, Geoffrey A.
   Lu, Jinchang
   Tang, Qing Lian
   Liu, Jonathan
   Molyneux, Sam
   Chen, Yan
   Fang, Hui
   Adissu, Hibret
   McKee, Trevor
   Waterhouse, Paul
   Khokha, Rama
TI Cross species genomics identifies DLG2 as a tumor suppressor in
   osteosarcoma
SO ONCOGENE
LA English
DT Article
ID GENE EXPRESSION; COPY NUMBER; G PROTEINS; HYBRIDIZATION; REARRANGEMENT;
   POLARITY; GTPASES; CANCER; CANINE; EVENT
AB Leveraging the conserved cancer genomes across mammals has the potential to transform driver gene discovery in orphan cancers. Here, we combine cross species genomics with validation across human dog mouse systems to uncover a new bone tumor suppressor gene. Comparative genomics of spontaneous human and dog osteosarcomas (OS) expose Disks Large Homolog 2 (DLG2) as a tumor suppressor candidate. DLG2 copy number loss occurs in 42% of human and 56% of canine OS. Functional validation through pertinent human and canine OS DLG2 deficient cell lines identifies a regulatory role of DLG2 in cell division, migration and tumorigenesis. Moreover, osteoblast specific deletion of Dlg2 in a clinically relevant genetically engineered mouse model leads to acceleration of OS development, establishing DLG2 as a critical determinant of OS. This widely applicable cross species approach serves as a platform to expedite the search of cancer drivers in rare human malignancies, offering new targets for cancer therapy.
C1 [Shao, Yang W.; Lu, Jinchang; Tang, Qing Lian; Molyneux, Sam; Chen, Yan; Fang, Hui; McKee, Trevor; Waterhouse, Paul; Khokha, Rama] Univ Toronto, Princess Margaret Canc Ctr, Toronto, ON M5G 1L7, Canada.
   [Wood, Geoffrey A.; Liu, Jonathan; Adissu, Hibret] Univ Guelph, Ontario Vet Coll, Dept Pathobiol, Guelph, ON N1G 2W1, Canada.
   [Lu, Jinchang; Tang, Qing Lian] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Orthoped Oncol, Guangzhou 510080, Guangdong, Peoples R China.
C3 University of Toronto; University Health Network Toronto; Princess
   Margaret Cancer Centre; University of Guelph; Sun Yat Sen University
RP Khokha, R (通讯作者)，Univ Toronto, Princess Margaret Canc Ctr, Toronto, ON M5G 1L7, Canada.
EM rama.khokha@utoronto.ca
RI adissu, hibret/R 3282 2018; McKee, Trevor/N 4992 2016; Wood,
   Geoffrey/ABB 2052 2021
OI Wood, Geoffrey/0000 0003 1756 8607; Waterhouse, Paul/0000 0001 8745 5224
FU Canadian Institutes of Health Research (CIHR); Ontario Institute for
   Cancer Research (OICR); Global Leadership Round in Genomics and Life
   Sciences (GL2); OVC Pet Trust; National Natural Science Foundation of
   China [81702665]; National Postdoctoral Program for Innovative Talents
   [BX201600196]; China Postdoctoral Science Foundation [2017M610571]
FX This study is supported by funding from the Canadian Institutes of
   Health Research (CIHR), Ontario Institute for Cancer Research (OICR),
   and Global Leadership Round in Genomics and Life Sciences (GL2) to RK
   and the OVC Pet Trust to GW. J. Lu is also supported by National Natural
   Science Foundation of China (81702665), National Postdoctoral Program
   for Innovative Talents (BX201600196) and China Postdoctoral Science
   Foundation (2017M610571).
CR Aguiar SD, 2007, CANCER GENET CYTOGEN, V175, P35, DOI 10.1016/j.cancergencyto.2007.01.007
   Aljubran AH, 2009, ANN ONCOL, V20, P1136, DOI 10.1093/annonc/mdn731
   Angstadt AY, 2012, CANCER GENET NY, V205, P572, DOI 10.1016/j.cancergen.2012.09.005
   Angstadt AY, 2011, GENE CHROMOSOME CANC, V50, P859, DOI 10.1002/gcc.20908
   Beroukhim R, 2007, P NATL ACAD SCI USA, V104, P20007, DOI 10.1073/pnas.0710052104
   Chen X, 2014, CELL REP, V7, P104, DOI 10.1016/j.celrep.2014.03.003
   Chen X, 2014, CELL, V158, P1187, DOI 10.1016/j.cell.2014.07.034
   Chen Y, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aad0295
   Coleman ML, 2004, NAT REV MOL CELL BIO, V5, P355, DOI 10.1038/nrm1365
   Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092 8674(00)81179 4
   Dunn HA, 2015, MOL PHARMACOL, V88, P624, DOI 10.1124/mol.115.098509
   Forbes SA, 2015, NUCLEIC ACIDS RES, V43, pD805, DOI 10.1093/nar/gku1075
   Freeman SS, 2008, CANCER AM CANCER SOC, V113, P1453, DOI 10.1002/cncr.23782
   Hooks SB, 2003, J BIOL CHEM, V278, P10087, DOI 10.1074/jbc.M211382200
   Hupé P, 2004, BIOINFORMATICS, V20, P3413, DOI 10.1093/bioinformatics/bth418
   Kuijjer ML, 2012, GENE CHROMOSOME CANC, V51, P696, DOI 10.1002/gcc.21956
   Mohseny AB, 2010, GENE CHROMOSOME CANC, V49, P1095, DOI 10.1002/gcc.20817
   Nathrath MH, 2002, ONCOGENE, V21, P5975, DOI 10.1038/sj.onc.1205764
   Ray P, 2004, CANCER RES, V64, P1323, DOI 10.1158/0008 5472.CAN 03 1816
   Roberts S, 2012, FEBS J, V279, P3549, DOI 10.1111/j.1742 4658.2012.08729.x
   Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795
   Scott MC, 2011, BONE, V49, P356, DOI 10.1016/j.bone.2011.05.008
   Shimizu T, 2010, ONCOGENE, V29, P5687, DOI 10.1038/onc.2010.312
   Stephens PJ, 2011, CELL, V144, P27, DOI 10.1016/j.cell.2010.11.055
   Stramer B, 2005, J CELL BIOL, V168, P567, DOI 10.1083/jcb.200405120
   TOGUCHIDA J, 1989, NATURE, V338, P156, DOI 10.1038/338156a0
   Tsai PC, 2012, AM J VET RES, V73, P1335, DOI 10.2460/ajvr.73.9.1335
   van Dam Teunis J P, 2011, Small GTPases, V2, P4
   Venkatraman ES, 2007, BIOINFORMATICS, V23, P657, DOI 10.1093/bioinformatics/btl646
   Walkley CR, 2008, GENE DEV, V22, P1662, DOI 10.1101/gad.1656808
   Woods DF, 1996, J CELL BIOL, V134, P1469, DOI 10.1083/jcb.134.6.1469
NR 31
TC 60
Z9 67
U1 0
U2 11
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950 9232
EI 1476 5594
J9 ONCOGENE
JI Oncogene
PD JAN 10
PY 2019
VL 38
IS 2
BP 291
EP 298
DI 10.1038/s41388 018 0444 4
PG 8
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA HG9XX
UT WOS:000455366700010
PM 30093633
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Chongsatientam, A
   Yimlamai, T
AF Chongsatientam, Areeya
   Yimlamai, Tossaporn
TI THERAPEUTIC PULSED ULTRASOUND PROMOTES REVASCULARIZATION AND FUNCTIONAL
   RECOVERY OF RAT SKELETAL MUSCLE AFTER CONTUSION INJURY
SO ULTRASOUND IN MEDICINE AND BIOLOGY
LA English
DT Article
DE Therapeutic pulsed ultrasound; Muscle regeneration; Injury;
   Angiogenesis; Vascular endothelial growth factor
ID ENDOTHELIAL GROWTH FACTOR; NITRIC OXIDE; INFLAMMATORY RESPONSE; HUMAN
   OSTEOBLASTS; SATELLITE CELLS; RABBIT MODEL; IN VIVO; REGENERATION;
   ANGIOGENESIS; VEGF
AB The mechanism by which therapeutic pulsed ultrasound (TPU) promotes the repair of damaged gastrocnemius muscle was investigated. Male Wistar rats were divided into uninjured, sham treated injured and TPU treated injured (TPU) groups. Injury was induced by mass drop technique. TPU was applied to the injured muscle for 5 min, daily, started at day 1 post injury and continuing for 3, 7 and 14 d. For 3 d postinjury, a significant reduction in muscle force was observed in both the sham treated injured and TPU groups. TPU treatment significantly increased recovery force of the injured muscle after day 7 post injury. This effect of TPU is associated with increased centronucleated fibers and cross sectional area, mRNA expression of the vascular endothelial growth factor and capillary density of the regenerated fibers, but not with mRNA expression of nitric oxide synthase. We conclude that TPU hastens muscle recovery, at least in part, by upregulating angiogenesis. (E mail: tossaporn.yim@mahidol.ac.th) (C) 2016 World Federation for Ultrasound in Medicine & Biology.
C1 [Chongsatientam, Areeya; Yimlamai, Tossaporn] Mahidol Univ, Dept Physiol, Fac Sci, 272 Rama VI Rd, Bangkok 10400, Thailand.
C3 Mahidol University
RP Yimlamai, T (通讯作者)，Mahidol Univ, Dept Physiol, Fac Sci, 272 Rama VI Rd, Bangkok 10400, Thailand.
EM tossaporn.yim@mahidol.ac.th
RI ; Yimlamai, Tossaporn/ABI 7968 2020
OI Yimlamai, Tossaporn/0000 0003 0861 7075; 
FU Huachiew Chalermprakiet University Affairs
FX The authors gratefully acknowledge Dr. Chumpol Pholpramol and Dr. Anuwat
   Dinudom for critical reading of the article and Dr. Suparerk
   Borwornpinyo for technical advice and support. We are thankful to Dr.
   Ratchakrit Srikuea's provision of chemicals and technical assistance. We
   are also grateful to the Olympus Bioimaging Center, Faculty of Science,
   Mahidol University, for technical support. This work was supported by a
   research grant from Huachiew Chalermprakiet University Affairs (to
   A.C.).
CR Arsic N, 2004, MOL THER, V10, P844, DOI 10.1016/j.ymthe.2004.08.007
   Piedade MCB, 2008, ULTRASONICS, V48, P403, DOI 10.1016/j.ultras.2008.01.009
   Borselli C, 2010, P NATL ACAD SCI USA, V107, P3287, DOI 10.1073/pnas.0903875106
   Cebasek V, 2004, EUR J HISTOCHEM, V48, P151
   Chan YS, 2010, ULTRASOUND MED BIOL, V36, P743, DOI 10.1016/j.ultrasmedbio.2010.02.010
   Claes L, 2007, PROG BIOPHYS MOL BIO, V93, P384, DOI 10.1016/j.pbiomolbio.2006.07.021
   Clapp C, 2009, PHYSIOL REV, V89, P1177, DOI 10.1152/physrev.00024.2009
   DINNO MA, 1989, PHYS MED BIOL, V34, P1543, DOI 10.1088/0031 9155/34/11/003
   Dyson M, 1973, Physiotherapy, V59, P284
   Dyson M, 1974, Ultrasound Med Biol, V1, P133, DOI 10.1016/0301 5629(74)90003 9
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003 0027
   Filippin LI, 2011, INFLAMM RES, V60, P347, DOI 10.1007/s00011 010 0277 2
   Frey SP, 2012, CLIN ORTHOP RELAT R, V470, P3607, DOI 10.1007/s11999 012 2456 7
   Gavin TP, 2000, J APPL PHYSIOL, V88, P1192, DOI 10.1152/jappl.2000.88.4.1192
   Handolin L, 2005, J ORTHOP SCI, V10, P391, DOI 10.1007/s00776 005 0901 0
   Huard J, 2002, J BONE JOINT SURG AM, V84A, P822, DOI 10.2106/00004623 200205000 00022
   Ito M, 2000, ULTRASOUND MED BIOL, V26, P161, DOI 10.1016/S0301 5629(99)00110 6
   Järvinen TAHJ, 2005, AM J SPORT MED, V33, P745, DOI 10.1177/0363546505274714
   Jozkowicz A, 2001, CARDIOVASC RES, V51, P773, DOI 10.1016/S0008 6363(01)00344 3
   Kami K, 2002, J HISTOCHEM CYTOCHEM, V50, P1579, DOI 10.1177/002215540205001202
   Karalaki M, 2009, IN VIVO, V23, P779
   Kasemkijwattana C, 1998, CELL TRANSPLANT, V7, P585, DOI 10.1016/S0963 6897(98)00037 2
   Kitchen S., 2004, ELECTROTHERAPY EVIDE, P211
   Li HY, 2013, INT J SPORTS MED, V34, P789, DOI 10.1055/s 0032 1333284
   Markert CD, 2005, ARCH PHYS MED REHAB, V86, P1304, DOI 10.1016/j.apmr.2004.12.037
   MAURO A, 1961, J BIOPHYS BIOCHEM CY, V9, P493, DOI 10.1083/jcb.9.2.493
   Milkiewicz M, 2005, AM J PHYSIOL HEART C, V289, pH336, DOI 10.1152/ajpheart.01105.2004
   Minamoto VB, 1999, ANAT REC, V254, P281
   Montalti CS, 2013, BRAZ J PHYS THER, V17, P343, DOI 10.1590/S1413 35552012005000101
   Murohara T, 2002, ANTIOXID REDOX SIGN, V4, P825, DOI 10.1089/152308602760598981
   Nagata K, 2013, ANN BIOMED ENG, V41, P1095, DOI 10.1007/s10439 013 0757 y
   Nakamura T, 2011, ANN BIOMED ENG, V39, P2964, DOI 10.1007/s10439 011 0408 0
   Nakamura T, 2010, ANN BIOMED ENG, V38, P3363, DOI 10.1007/s10439 010 0104 5
   Nematollahi S, 2009, BIOMED PAP, V153, P125, DOI 10.5507/bp.2009.021
   Ochoa O, 2007, AM J PHYSIOL REG I, V293, pR651, DOI 10.1152/ajpregu.00069.2007
   Ota S, 2011, AM J SPORT MED, V39, P1912, DOI 10.1177/0363546511415239
   Pounder NM, 2008, ULTRASONICS, V48, P330, DOI 10.1016/j.ultras.2008.02.005
   Rangel R, 2007, P NATL ACAD SCI USA, V104, P4588, DOI 10.1073/pnas.0611653104
   Rantanen J, 1999, AM J SPORT MED, V27, P54, DOI 10.1177/03635465990270011701
   Reher P, 2002, BONE, V31, P236, DOI 10.1016/S8756 3282(02)00789 5
   Reher P, 1999, CYTOKINE, V11, P416, DOI 10.1006/cyto.1998.0444
   Shu B, 2012, CELL BIOCHEM BIOPHYS, V62, P329, DOI 10.1007/s12013 011 9310 5
   Smith C, 2008, SPORTS MED, V38, P947, DOI 10.2165/00007256 200838110 00005
   Sparrow KJ, 2005, AM J SPORT MED, V33, P1048, DOI 10.1177/0363546504267356
   St Pierre BA, 1985, J APPL PHYSIOL, V77, P290
   Suzuki A, 2009, ACTA BIOCH BIOPH SIN, V41, P108, DOI 10.1093/abbs/gmn012
   Tang CH, 2007, J BIOL CHEM, V282, P25406, DOI 10.1074/jbc.M701001200
   Tang CH, 2006, MOL PHARMACOL, V69, P2047, DOI 10.1124/mol.105.022160
   Tidball JG, 2010, AM J PHYSIOL REG I, V298, pR1173, DOI 10.1152/ajpregu.00735.2009
   Tidball JG, 2005, AM J PHYSIOL REG I, V288, pR345, DOI 10.1152/ajpregu.00454.2004
   Wagatsuma A, 2007, MOL CELL BIOCHEM, V298, P151, DOI 10.1007/s11010 006 9361 x
   Wagers AJ, 2005, CELL, V122, P659, DOI 10.1016/j.cell.2005.08.021
   Wang FS, 2004, BONE, V35, P114, DOI 10.1016/j.bone.2004.02.012
   Warden SJ, 2006, AM J SPORT MED, V34, P1094, DOI 10.1177/0363546505286139
   Wilkin LD, 2004, INT J SPORTS MED, V25, P73
   YOUNG SR, 1990, ULTRASOUND MED BIOL, V16, P261, DOI 10.1016/0301 5629(90)90005 W
   Zammit PS, 2006, J CELL SCI, V119, P1824, DOI 10.1242/jcs.02908
   Zhao X, 2002, AM J PHYSIOL HEART C, V283, pH2371, DOI 10.1152/ajpheart.00383.2002
NR 58
TC 12
Z9 17
U1 0
U2 16
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 0301 5629
EI 1879 291X
J9 ULTRASOUND MED BIOL
JI Ultrasound Med. Biol.
PD DEC
PY 2016
VL 42
IS 12
BP 2938
EP 2949
DI 10.1016/j.ultrasmedbio.2016.08.004
PG 12
WC Acoustics; Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI EXPANDED)
SC Acoustics; Radiology, Nuclear Medicine & Medical Imaging
GA EE4CK
UT WOS:000389549300022
PM 27665217
DA 2025 08 17
ER

PT J
AU Tarafder, S
   Bose, S
AF Tarafder, Solaiman
   Bose, Susmita
TI Polycaprolactone Coated 3D Printed Tricalcium Phosphate Scaffolds for
   Bone Tissue Engineering: In Vitro Alendronate Release Behavior
   and Local Delivery Effect on In Vivo Osteogenesis
SO ACS APPLIED MATERIALS & INTERFACES
LA English
DT Article
DE tricalcium phosphate (TCP); 3D printing (3DP); in vitro alendronate
   release; polycaprolactone (PCL) coating; in vivo osteogenesis
ID CONTROLLED DRUG RELEASE; BIOLOGICAL PROPERTIES; RESORBABLE CERAMICS;
   BISPHOSPHONATES; MGO; ZOLEDRONATE; MECHANISM; COATINGS; MATRICES;
   CARRIERS
AB The aim of this work was to evaluate the effect of in vitro alendronate (AD) release behavior through polycaprolactone (PCL) coating on in vivo bone formation using PCL coated 3D printed interconnected porous tricalcium phosphate (TCP) scaffolds. Higher AD and Ca2+ ion release was observed at lower pH (5.0) than that at higher pH (7.4). AD and Ca2+ release, surface morphology, and phase analysis after release indicated a matrix degradation dominated AD release caused by TCP dissolution. PCL coating showed its effectiveness for controlled and sustained AD release. Six different scaffold compositions, namely, (i) TCP (bare TCP), (ii) TCP + AD (AD coated TCP), (iii) TCP + PCL (PCL coated TCP), (iv) TCP + PCL + AD, (v) TCP + AD + PCL, and (vi) TCP + AD + PCL + AD were tested in the distal femoral defect of Sprague Dawley rats for 6 and 10 weeks. An excellent bone formation inside the micro and macro pores of the scaffolds was observed from histomorphology. Histomorphometric analysis revealed maximum new bone formation in TCP + AD + PCL scaffolds after 6 weeks. No adverse effect of PCL on bioactivity of TCP and in vivo bone formation was observed. All scaffolds with AD showed higher bone formation and reduced TRAP (tartrate resistant acid phosphatase) positive cells activity compared to bare TCP and TCP coated with only PCL. Bare TCP scaffolds showed the highest TRAP positive cells activity followed by TCP + PCL scaffolds, whereas TCP + AD scaffolds showed the lowest TRAP activity. A higher TRAP positive cells activity was observed in TCP + AD + PCL compared to TCP + AD scaffolds after 6 weeks. Our results show that in vivo local AD delivery from PCL coated 3DP TCP scaffolds could further induce increased early bone formation.
C1 [Tarafder, Solaiman; Bose, Susmita] Washington State Univ, Sch Mech & Mat Engn, WM Keck Biomed Mat Res Lab, Pullman, WA 99164 USA.
C3 Washington State University
RP Bose, S (通讯作者)，Washington State Univ, Sch Mech & Mat Engn, WM Keck Biomed Mat Res Lab, Pullman, WA 99164 USA.
EM sbose@wsu.edu
RI ; Tarafder, Solaiman/F 4335 2011
OI Tarafder, Solaiman/0000 0001 9659 690X; 
FU National Institutes of Health, NIBIB [NIH R01 EB 007351]
FX National Institutes of Health, NIBIB (Grant # NIH R01 EB 007351).
CR Acharya G, 2006, ADV DRUG DELIVER REV, V58, P387, DOI 10.1016/j.addr.2006.01.016
   Bandyopadhyay A, 2006, J AM CERAM SOC, V89, P2675, DOI 10.1111/j.1551 2916.2006.01207.x
   Banerjee SS, 2010, ACTA BIOMATER, V6, P4167, DOI 10.1016/j.actbio.2010.05.012
   Banerjee SS, 2010, ADV ENG MATER, V12, pB148, DOI 10.1002/adem.200980072
   Bölgen N, 2008, TISSUE ENG PT A, V14, P1743, DOI 10.1089/ten.tea.2007.0277
   Bose S, 2012, TRENDS BIOTECHNOL, V30, P546, DOI 10.1016/j.tibtech.2012.07.005
   Bose S, 2012, ACTA BIOMATER, V8, P1401, DOI 10.1016/j.actbio.2011.11.017
   Bose S, 2011, BONE, V48, P1282, DOI 10.1016/j.bone.2011.03.685
   Butscher A, 2011, ACTA BIOMATER, V7, P907, DOI 10.1016/j.actbio.2010.09.039
   Carrodeguas RG, 2011, ACTA BIOMATER, V7, P3536, DOI 10.1016/j.actbio.2011.06.019
   Coombes AGA, 2004, BIOMATERIALS, V25, P315, DOI 10.1016/S0142 9612(03)00535 0
   Coxon FP, 2006, CURR OPIN PHARMACOL, V6, P307, DOI 10.1016/j.coph.2006.03.005
   Dasgupta S, 2009, ACTA BIOMATER, V5, P3112, DOI 10.1016/j.actbio.2009.04.031
   Ezra A, 2000, ADV DRUG DELIVER REV, V42, P175, DOI 10.1016/S0169 409X(00)00061 2
   Fernández E, 1999, J MATER SCI MATER M, V10, P223, DOI 10.1023/A:1008958112257
   Fielding GA, 2012, DENT MATER, V28, P113, DOI 10.1016/j.dental.2011.09.010
   Frommelt L, 2006, INJURY, V37, P87, DOI 10.1016/j.injury.2006.04.014
   Garbuz DS, 2008, J BONE JOINT SURG AM, V90A, P1090, DOI 10.2106/JBJS.G.00415
   Giger EV, 2013, J CONTROL RELEASE, V167, P175, DOI 10.1016/j.jconrel.2013.01.032
   Ginebra MP, 2006, BIOMATERIALS, V27, P2171, DOI 10.1016/j.biomaterials.2005.11.023
   Habraken WJEM, 2007, ADV DRUG DELIVER REV, V59, P234, DOI 10.1016/j.addr.2007.03.011
   Hing KA, 2005, J MATER SCI MATER M, V16, P467, DOI 10.1007/s10856 005 6988 1
   Jiang X, 2005, J HISTOCHEM CYTOCHEM, V53, P593, DOI 10.1369/jhc.4A6401.2005
   Kim CW, 2010, J CONTROL RELEASE, V147, P45, DOI 10.1016/j.jconrel.2010.06.016
   Kim HW, 2005, J MATER SCI MATER M, V16, P189, DOI 10.1007/s10856 005 6679 y
   Kim HW, 2004, BIOMATERIALS, V25, P1279, DOI 10.1016/j.biomaterials.2003.07.003
   Kumar G, 2012, BIOMATERIALS, V33, P4022, DOI 10.1016/j.biomaterials.2012.02.048
   Kumar G, 2011, BIOMATERIALS, V32, P9188, DOI 10.1016/j.biomaterials.2011.08.054
   Levengood SKL, 2010, BIOMATERIALS, V31, P3552, DOI 10.1016/j.biomaterials.2010.01.052
   LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201
   Lin JH, 1996, BONE, V18, P75, DOI 10.1016/8756 3282(95)00445 9
   Manzano M, 2012, PROG SOLID STATE CH, V40, P17, DOI 10.1016/j.progsolidstchem.2012.05.001
   Mattanavee W, 2009, ACS APPL MATER INTER, V1, P1076, DOI 10.1021/am900048t
   Moioli EK, 2007, ADV DRUG DELIVER REV, V59, P308, DOI 10.1016/j.addr.2007.03.019
   Nancollas GH, 2006, BONE, V38, P617, DOI 10.1016/j.bone.2005.05.003
   Peter B, 2005, BONE, V36, P52, DOI 10.1016/j.bone.2004.10.004
   Radin S, 1997, BIOMATERIALS, V18, P777, DOI 10.1016/S0142 9612(96)00190 1
   Reszka Alfred A, 2003, Curr Osteoporos Rep, V1, P45, DOI 10.1007/s11914 003 0008 5
   Rodan Gideon A., 2002, Current Molecular Medicine (Hilversum), V2, P571, DOI 10.2174/1566524023362104
   Roelofs AJ, 2006, CLIN CANCER RES, V12, p6222S, DOI 10.1158/1078 0432.CCR 06 0843
   Rogers Michael J., 2000, Cancer, V88, P2961, DOI 10.1002/1097 0142(20000615)88:12+<2961::AID CNCR12>3.0.CO;2 L
   Roussiere H, 2008, CHEM MATER, V20, P182, DOI 10.1021/cm702584d
   Sachlos E., 2003, European Cells & Materials, V5, P29
   Saylor DM, 2009, J PHARM SCI US, V98, P169, DOI 10.1002/jps.21416
   Seeley Z, 2008, MAT SCI ENG C BIO S, V28, P11, DOI 10.1016/j.msec.2006.12.010
   Tarafder S, 2013, J TISSUE ENG REGEN M, V7, P631, DOI 10.1002/term.555
   Tarafder S, 2013, MAT SCI ENG C MATER, V33, P3121, DOI 10.1016/j.msec.2013.02.049
   Tarafder S, 2010, LANGMUIR, V26, P16625, DOI 10.1021/la101851f
   van Beek E, 1999, J BONE MINER RES, V14, P722, DOI 10.1359/jbmr.1999.14.5.722
   Webster TJ, 2001, BIOMATERIALS, V22, P1327, DOI 10.1016/S0142 9612(00)00285 4
   Xue WC, 2009, J BIOMED MATER RES B, V91B, P831, DOI 10.1002/jbm.b.31464
   Yoshinari M, 2007, DENT MATER J, V26, P451, DOI 10.4012/dmj.26.451
NR 52
TC 177
Z9 195
U1 3
U2 190
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1944 8244
EI 1944 8252
J9 ACS APPL MATER INTER
JI ACS Appl. Mater. Interfaces
PD JUL 9
PY 2014
VL 6
IS 13
BP 9955
EP 9965
DI 10.1021/am501048n
PG 11
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Materials Science
GA AL2UB
UT WOS:000338979900009
PM 24826838
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Maleeva, EE
   Palikova, YA
   Palikov, VA
   Kazakov, VA
   Simonova, MA
   Logashina, YA
   Tarasova, NV
   Dyachenko, IA
   Andreev, YA
AF Maleeva, Ekaterina E.
   Palikova, Yulia A.
   Palikov, Viktor A.
   Kazakov, Vitaly A.
   Simonova, Maria A.
   Logashina, Yulia A.
   Tarasova, Nadezhda V.
   Dyachenko, Igor A.
   Andreev, Yaroslav A.
TI Potentiating TRPA1 by Sea Anemone Peptide Ms 9a 1 Reduces Pain and
   Inflammation in a Model of Osteoarthritis
SO MARINE DRUGS
LA English
DT Article
DE arthritis; TRPA1; TRPV1; peptide; Ms9a 1; inflammation; osteoarthritis;
   non steroidal anti inflammatory drugs; sea anemone; Metridium senile
ID ONGOING PAIN; VANILLOID 1; TRPV1; CHANNELS; MODULATION; MUSCLE; MICE
AB Progressive articular surface degradation during arthritis causes ongoing pain and hyperalgesia that lead to the development of functional disability. TRPA1 channel significantly contributes to the activation of sensory neurons that initiate neurogenic inflammation and mediates pain signal transduction to the central nervous system. Peptide Ms 9a 1 from the sea anemone Metridium senile is a positive allosteric modulator of TRPA1 and shows significant anti inflammatory and analgesic activity in different models of pain. We used a model of monosodium iodoacetate (MIA) induced osteoarthritis to evaluate the anti inflammatory properties of Ms 9a 1 in comparison with APHC3 (a polypeptide modulator of TRPV1 channel) and non steroidal anti inflammatory drugs (NSAIDs) such as meloxicam and ibuprofen. Administration of Ms 9a 1 (0.1 mg/kg, subcutaneously) significantly reversed joint swelling, disability, thermal and mechanical hypersensitivity, and grip strength impairment. The effect of Ms 9a 1 was equal to or better than that of reference drugs. Post treatment histological analysis revealed that long term administration of Ms9a 1 could reduce inflammatory changes in joints and prevent the progression of cartilage and bone destruction at the same level as meloxicam. Peptide Ms 9a 1 showed significant analgesic and anti inflammatory effects in the model of MIA induced OA, and therefore positive allosteric modulators could be considered for the alleviation of OA symptoms.
C1 [Maleeva, Ekaterina E.; Simonova, Maria A.; Logashina, Yulia A.; Andreev, Yaroslav A.] Russian Acad Sci, Shemyakin Ovchinnikov Inst Bioorgan Chem, Ul Miklukho Maklaya 16 10, Moscow 117997, Russia.
   [Palikova, Yulia A.; Palikov, Viktor A.; Kazakov, Vitaly A.; Dyachenko, Igor A.] Russian Acad Sci, Branch Shemyakin Ovchinnikov Inst Bioorgan Chem, Prospekt Nauki 6, Pushchino 142290, Russia.
   [Tarasova, Nadezhda V.; Andreev, Yaroslav A.] Sechenov First Moscow State Med Univ, Inst Mol Med, Trubetskaya Str 8,Bld 2, Moscow 119991, Russia.
C3 Russian Academy of Sciences; Pushchino Scientific Center for Biological
   Research (PSCBI) of the Russian Academy of Sciences; Institute of
   Bioorganic Chemistry of the Russian Academy of Sciences; Russian Academy
   of Sciences; Pushchino Scientific Center for Biological Research (PSCBI)
   of the Russian Academy of Sciences; Institute of Bioorganic Chemistry of
   the Russian Academy of Sciences; Sechenov First Moscow State Medical
   University
RP Andreev, YA (通讯作者)，Russian Acad Sci, Shemyakin Ovchinnikov Inst Bioorgan Chem, Ul Miklukho Maklaya 16 10, Moscow 117997, Russia.; Andreev, YA (通讯作者)，Sechenov First Moscow State Med Univ, Inst Mol Med, Trubetskaya Str 8,Bld 2, Moscow 119991, Russia.
EM yuliyapalikova@bibch.ru; vpalikov@bibch.ru; vitalij.tomsk@list.ru;
   marisimonova@gmail.com; yulia.logashina@gmail.com; compasstar@gmail.com;
   dyachenko@bibch.ru; aya@ibch.ru
RI Kazakov, Vitaly/AAO 7177 2021; Simonova, Maria/E 6081 2014; Palikov,
   Viktor/AIE 3992 2022; Tarasova, Nadezhda/I 9892 2016; DI Igor,
   Dyachenko/K 9060 2017; Logashina, Yulia/AEC 7225 2022; Andreev,
   Yaroslav/C 6627 2012; Palikova, Yuliya/Y 4228 2018
OI Andreev, Yaroslav/0000 0002 7628 0980; Palikov,
   Victor/0000 0003 2989 4477; Palikova, Yuliya/0000 0001 9547 0686
FU Russian Science Foundation
FX No Statement Available
CR Abramson SB, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2655
   Andersson DA, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1559
   Andreev YA, 2013, MAR DRUGS, V11, P5100, DOI 10.3390/md11125100
   Andrei SR, 2016, CHANNELS, V10, P395, DOI 10.1080/19336950.2016.1185579
   Aspden RM, 2001, LANCET, V357, P1118, DOI 10.1016/S0140 6736(00)04264 1
   Bautista DM, 2006, CELL, V124, P1269, DOI 10.1016/j.cell.2006.02.023
   Bessac BF, 2008, PHYSIOLOGY, V23, P360, DOI 10.1152/physiol.00026.2008
   Chen Y, 2011, NEUROSCIENCE, V193, P440, DOI 10.1016/j.neuroscience.2011.06.085
   Ciotu CI, 2020, NEUROTHERAPEUTICS, V17, P784, DOI 10.1007/s13311 020 00937 z
   da Costa BR, 2016, LANCET, V387, P2093, DOI 10.1016/S0140 6736(16)30002 2
   Desclaux S, 2020, FASEB J, V34, DOI 10.1096/fasebj.2020.34.s1.01838
   Galindo T, 2018, PHARMACEUTICALS BASE, V11, DOI 10.3390/ph11040105
   Garcia MM, 2019, EUR J PHARMACOL, V854, P109, DOI 10.1016/j.ejphar.2019.04.011
   Garrison SR, 2014, ARTHRITIS RHEUMATOL, V66, P2380, DOI 10.1002/art.38724
   Halonen L, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms241210057
   Hatano N, 2012, J BIOL CHEM, V287, P31962, DOI 10.1074/jbc.M112.361139
   Horváth A, 2016, ARTHRITIS RES THER, V18, DOI 10.1186/s13075 015 0904 y
   Hunter DJ, 2019, LANCET, V393, P1745, DOI 10.1016/S0140 6736(19)30417 9
   Kojima R, 2014, EUR J PHARMACOL, V723, P288, DOI 10.1016/j.ejphar.2013.11.020
   Krupkova O, 2017, EUR CELLS MATER, V34, P180, DOI 10.22203/eCM.v034a12
   Lee LY, 2015, PULM PHARMACOL THER, V35, P87, DOI 10.1016/j.pupt.2015.08.003
   Liu P, 2011, NEUROSCI LETT, V493, P72, DOI 10.1016/j.neulet.2011.01.027
   Liu Bryan R, 2015, NAT REV RHEUMATOL, V11, P35, DOI 10.1038/nrrheum.2014.162
   Logashina YA, 2019, BIOCHEMISTRY MOSCOW+, V84, P101, DOI 10.1134/S0006297919020020
   Logashina YA, 2022, MAR DRUGS, V20, DOI 10.3390/md20070465
   Logashina YA, 2021, MAR DRUGS, V19, DOI 10.3390/md19010039
   Logashina YA, 2017, TOXINS, V9, DOI 10.3390/toxins9050154
   Logashina YA, 2017, J BIOL CHEM, V292, P2992, DOI 10.1074/jbc.M116.757369
   Luostarinen S, 2021, PULM PHARMACOL THER, V70, DOI 10.1016/j.pupt.2021.102059
   Mann PC, 2012, TOXICOL PATHOL, V40, P7, DOI 10.1177/0192623312438738
   Materazzi S, 2013, PAIN, V154, P2750, DOI 10.1016/j.pain.2013.08.002
   Matta C, 2023, AM J PHYSIOL CELL PH, V325, pC257, DOI 10.1152/ajpcell.00040.2023
   McGaraughty S, 2010, MOL PAIN, V6, DOI 10.1186/1744 8069 6 14
   Moilanen LJ, 2015, OSTEOARTHR CARTILAGE, V23, P2017, DOI 10.1016/j.joca.2015.09.008
   Moore RA, 2010, ANN RHEUM DIS, V69, P374, DOI 10.1136/ard.2009.107805
   Neogi T, 2013, OSTEOARTHR CARTILAGE, V21, P1145, DOI 10.1016/j.joca.2013.03.018
   Niibori M, 2020, HELIYON, V6, DOI 10.1016/j.heliyon.2020.e03963
   Nikolaev MV, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177077
   Nummenmaa E, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22010087
   Nummenmaa E, 2017, RMD OPEN, V3, DOI 10.1136/rmdopen 2017 000556
   Nummenmaa E, 2016, ARTHRITIS RES THER, V18, DOI 10.1186/s13075 016 1080 4
   Okun A, 2012, PAIN, V153, P924, DOI 10.1016/j.pain.2012.01.022
   Philyppov IB, 2012, LIFE SCI, V91, P912, DOI 10.1016/j.lfs.2012.09.001
   Pitcher T, 2016, JOVE J VIS EXP, DOI 10.3791/53746
   Rao PNP, 2008, J PHARM PHARM SCI, V11, P81, DOI 10.18433/J3T886
   Rios JL, 2022, CURR PROTOC, V2, DOI 10.1002/cpz1.596
   Risbud MV, 2014, NAT REV RHEUMATOL, V10, P44, DOI 10.1038/nrrheum.2013.160
   Spahn V, 2014, MOL PHARMACOL, V85, P335, DOI 10.1124/mol.113.088997
   Tamai H, 2023, BIOCHEM BIOPHYS REP, V34, DOI 10.1016/j.bbrep.2023.101470
   Thakur M, 2014, NAT REV RHEUMATOL, V10, P374, DOI 10.1038/nrrheum.2014.47
   Vincent TL, 2020, PAIN, V161, pS138, DOI 10.1097/j.pain.0000000000001923
   Weng YQ, 2012, MOL PAIN, V8, DOI 10.1186/1744 8069 8 75
   Yao KF, 2023, FRONT PHYSIOL, V14, DOI 10.3389/fphys.2023.1093925
   Yin SJ, 2018, J INFLAMM LOND, V15, DOI 10.1186/s12950 018 0204 9
   Yocum D, 2000, ARCH INTERN MED, V160, P2947, DOI 10.1001/archinte.160.19.2947
   Yu H, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23094642
NR 56
TC 4
Z9 4
U1 1
U2 5
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1660 3397
J9 MAR DRUGS
JI Mar. Drugs
PD DEC
PY 2023
VL 21
IS 12
AR 617
DI 10.3390/md21120617
PG 19
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA DM8I8
UT WOS:001132549100001
PM 38132938
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU An, JY
   Ma, XN
   Wen, HL
   Hu, HD
AF An, Jin yu
   Ma, Xing na
   Wen, Hui long
   Hu, Hui dong
TI Identification of key genes and long non coding RNA expression profiles
   in osteoporosis with rheumatoid arthritis based on bioinformatics
   analysis
SO BMC MUSCULOSKELETAL DISORDERS
LA English
DT Article
DE Osteoporosis; Rheumatoid arthritis; lncRNA; Differentially expressed
   genes; Protein protein interaction network; Co expression network
ID MEAN PLATELET VOLUME; OSTEOCLAST; INFLAMMATION; PATHWAYS
AB BackgroundAlthough rheumatoid arthritis (RA) is a chronic systemic tissue disease often accompanied by osteoporosis (OP), the molecular mechanisms underlying this association remain unclear. This study aimed to elucidate the pathogenesis of RA and OP by identifying differentially expressed mRNAs (DEmRNAs) and long non coding RNAs (lncRNAs) using a bioinformatics approach.MethodsExpression profiles of individuals diagnosed with OP and RA were retrieved from the Gene Expression Omnibus database. Differential expression analysis was conducted. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes pathway (KEGG) pathway enrichment analyses were performed to gain insights into the functional categories and molecular/biochemical pathways associated with DEmRNAs. We identified the intersection of common DEmRNAs and lncRNAs and constructed a protein protein interaction (PPI) network. Correlation analysis between the common DEmRNAs and lncRNAs facilitated the construction of a coding non coding network. Lastly, serum peripheral blood mononuclear cells (PBMCs) from patients with RA and OP, as well as healthy controls, were obtained for TRAP staining and qRT PCR to validate the findings obtained from the online dataset assessments.ResultsA total of 28 DEmRNAs and 2 DElncRNAs were identified in individuals with both RA and OP. Chromosomal distribution analysis of the consensus DEmRNAs revealed that chromosome 1 had the highest number of differential expression genes. GO and KEGG analyses indicated that these DEmRNAs were primarily associated with " platelets (PLTs) degranulation", "platelet alpha granules", "platelet activation", "tight junctions" and "leukocyte transendothelial migration", with many genes functionally related to PLTs. In the PPI network, MT ATP6 and PTGS1 emerged as potential hub genes, with MT ATP6 originating from mitochondrial DNA. Co expression analysis identified two key lncRNA mRNA pairs: RP11   815J21.2 with MT   ATP6 and RP11   815J21.2 with PTGS1. Experimental validation confirmed significant differential expression of RP11 815J21.2, MT ATP6 and PTGS1 between the healthy controls and the RA + OP groups. Notably, knockdown of RP11 815J21.2 attenuated TNF + IL 6 induced osteoclastogenesis.ConclusionsThis study successfully identified shared dysregulated genes and potential therapeutic targets in individuals with RA and OP, highlighting their molecular similarities. These findings provide new insights into the pathogenesis of RA and OP and suggest potential avenues for further research and targeted therapies.
C1 [An, Jin yu; Wen, Hui long; Hu, Hui dong] Changzhou Fourth Peoples Hosp, Dept Orthoped, Changzhou 213000, Peoples R China.
   [Ma, Xing na] Changzhou Fourth Peoples Hosp, Dept Pediat, Changzhou, Peoples R China.
RP An, JY (通讯作者)，Changzhou Fourth Peoples Hosp, Dept Orthoped, Changzhou 213000, Peoples R China.
EM ajy_428@126.com
CR Akbal A, 2014, OSTEOPOROSIS INT, V25, P2291, DOI 10.1007/s00198 014 2764 8
   Aken BL, 2016, DATABASE OXFORD, DOI 10.1093/database/baw093
   Bar Shavit Z, 2007, J CELL BIOCHEM, V102, P1130, DOI 10.1002/jcb.21553
   Barik RR, 2021, RHEUMATOL INT, V41, P2047, DOI 10.1007/s00296 021 04951 y
   Boilard E, 2010, SCIENCE, V327, P580, DOI 10.1126/science.1181928
   Cafaro G, 2019, EXPERT REV CLIN IMMU, V15, P1, DOI 10.1080/1744666X.2019.1544071
   Chen H, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471 2105 12 35
   Chen RM, 2022, INT J GEN MED, V15, P7817, DOI 10.2147/IJGM.S380197
   Chen XF, 2018, AM J HUM GENET, V102, P776, DOI 10.1016/j.ajhg.2018.03.001
   Cho HW, 2021, GENES BASEL, V12, DOI 10.3390/genes12030378
   Ciovacco WA, 2010, J CELL BIOCHEM, V109, P774, DOI 10.1002/jcb.22456
   Collins LV, 2004, J LEUKOCYTE BIOL, V75, P995, DOI 10.1189/jlb.0703328
   Doncheva NT, 2019, J PROTEOME RES, V18, P623, DOI 10.1021/acs.jproteome.8b00702
   Du JP, 2020, RHEUMATOLOGY, V59, P2982, DOI 10.1093/rheumatology/keaa063
   Eroglu S, 2019, SAUDI MED J, V40, P360, DOI 10.15537/smj.2019.4.24009
   Feng X, 2013, BONE RES, V1, DOI 10.4248/BR201301003
   Flad HD, 2010, CELL MOL LIFE SCI, V67, P2363, DOI 10.1007/s00018 010 0306 x
   Gao XP, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419 021 03993 1
   Gawaz M, 2005, J CLIN INVEST, V115, P3378, DOI 10.1172/JCI27196
   Jang HY, 2021, ARCH ORAL BIOL, V122, DOI 10.1016/j.archoralbio.2020.105029
   Khan FA, 2017, J INT SOC PREV COMMU, V7, pS55, DOI 10.4103/jispcd.JISPCD_284_17
   Kim SY, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3107
   Korotkova M, 2014, NAT REV RHEUMATOL, V10, P229, DOI 10.1038/nrrheum.2014.1
   Laki J, 2012, ARTHRITIS RHEUM US, V64, P2078, DOI 10.1002/art.34421
   Li M, 2020, EXP THER MED, V20, P461, DOI 10.3892/etm.2020.8681
   Li XS, 2012, J BONE MINER METAB, V30, P660, DOI 10.1007/s00774 012 0362 4
   Herráez DL, 2013, ARTHRITIS RHEUM US, V65, P1457, DOI 10.1002/art.37923
   Maruotti N, 2014, REUMATISMO, V66, P125, DOI 10.4081/reumatismo.2014.785
   Mattick JS, 2023, NAT REV MOL CELL BIO, V24, P430, DOI 10.1038/s41580 022 00566 8
   Miyazaki T, 2012, J BIOL CHEM, V287, DOI 10.1074/jbc.M112.385369
   Moshayedi S, 2022, SCI REP UK, V12, DOI 10.1038/s41598 022 20016 x
   Naidu VGM, 2013, CHEM BIOL INTERACT, V203, P467, DOI 10.1016/j.cbi.2012.12.016
   Papaioannou A, 2009, OSTEOPOROSIS INT, V20, P703, DOI 10.1007/s00198 008 0743 7
   Park JH, 2017, BMC MUSCULOSKEL DIS, V18, DOI 10.1186/s12891 017 1514 4
   Raterman HG, 2020, EXPERT OPIN PHARMACO, V21, P1725, DOI 10.1080/14656566.2020.1787381
   Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Sharif Pooneh Salari, 2010, Inflammation & Allergy Drug Targets, V9, P393
   Smolen JS, 2016, LANCET, V388, P2023, DOI 10.1016/S0140 6736(16)30173 8
   Szklarczyk D, 2021, NUCLEIC ACIDS RES, V49, pD605, DOI 10.1093/nar/gkaa1074
   Teng ZW, 2020, FRONT GENET, V11, DOI 10.3389/fgene.2020.566959
   van Dijk FS, 2013, NEW ENGL J MED, V369, P1529, DOI 10.1056/NEJMoa1308223
   Wang YJ, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1167 3
   Wegierska Malgorzata, 2016, Reumatologia (Warsaw), V54, P29, DOI 10.5114/reum.2016.58759
   Yao ZQ, 2017, J BIOL CHEM, V292, P10169, DOI 10.1074/jbc.M116.771816
   Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118
   Zhang HE, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471 2105 14 244
   Zhao LL, 2019, ENZYMES, V45, P311, DOI 10.1016/bs.enz.2019.08.004
   Zhu DL, 2018, J BONE MINER RES, V33, P1335, DOI 10.1002/jbmr.3419
   Zhu NQ, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000010997
NR 50
TC 1
Z9 1
U1 1
U2 3
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471 2474
J9 BMC MUSCULOSKEL DIS
JI BMC Musculoskelet. Disord.
PD AUG 8
PY 2024
VL 25
IS 1
AR 634
DI 10.1186/s12891 024 07738 x
PG 14
WC Orthopedics; Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics; Rheumatology
GA C2C6E
UT WOS:001287491100002
PM 39118036
OA Green Accepted, gold
DA 2025 08 17
ER

PT J
AU Wen, MT
   Li, JC
   Lu, BW
   Shao, HR
   Ling, PX
   Liu, F
   Li, G
   Luo, D
AF Wen, Ming Tao
   Li, Jia Cheng
   Lu, Bo Wen
   Shao, Hua Rong
   Ling, Pei Xue
   Liu, Fei
   Li, Gang
   Luo, Di
TI Indications and adverse events of teriparatide: based on FDA adverse
   event reporting system (FAERS)
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE teriparatide; osteoporosis; FAERS; adverse events; pharmacovigilance
ID PARATHYROID HORMONE 1 34; BONE MINERAL DENSITY; POSTMENOPAUSAL WOMEN;
   OSTEOPOROSIS; RATS
AB Background Teriparatide is approved for osteoporosis. Post marketing surveillance is critical given its widespread use.Objective To investigate adverse events (AEs) associated with teriparatide using the FAERS database, compare association strengths for key AEs, and explore potential applications to provide clinical reference.Methods FAERS data from 2004 to 2023 were analyzed. Reports where teriparatide was the primary suspect drug were included. Adverse events were mapped to System Organ Classes and Preferred Terms. Disproportionality analysis using ROR, PRR, BCPNN and EBGM algorithms was conducted to detect safety signals.Results Out of 107,123 reports with teriparatide as the primary suspect, key AEs identified included pain in extremity (PRR: 4.54), muscle spasms (PRR: 5.11), fractures (PRR range: 17.67 552.95), and increased calcium levels (PRR: 50.73). Teriparatide exhibited a stronger association with increased calcium levels (PRR: 50.73) compared to fractures (PRR range: 17.67 552.95). Notably, only 10.86% of AE reports were submitted by physicians and another 10% by other health professionals. Subset analyses showed a higher consistency of reported AEs from health professionals compared to the general dataset. Off label uses were noted in conditions such as arthritis (0.57%) and cancer (0.12%). For osteoporosis, main AEs were pain (18.2%), fractures (12.4%), muscle spasms (7.7%), and nausea (6.5%), while glucocorticoid induced osteoporosis AEs included fractures (24.1%), pain (13.2%), decreased bone density (9.8%), and nausea (5.1%).Conclusion Our findings provide real world safety data on teriparatide, revealing key AEs and their association strengths. The low proportion of reports by healthcare professionals suggests the need for cautious interpretation. Continuous vigilance and further research are imperative to guide teriparatide's clinical use.
C1 [Wen, Ming Tao; Li, Jia Cheng; Lu, Bo Wen; Liu, Fei; Li, Gang; Luo, Di] Shandong Univ Tradit Chinese Med, Clin Med Sch 1, Jinan, Shandong, Peoples R China.
   [Li, Jia Cheng; Li, Gang; Luo, Di] Shandong Univ Tradit Chinese Med, Orthopaed, Affiliated Hosp, Jinan, Shandong, Peoples R China.
   [Shao, Hua Rong; Ling, Pei Xue; Liu, Fei] Shandong Acad Pharmaceut Sci, Key Lab Biopharmaceut, Jinan, Shandong, Peoples R China.
C3 Shandong University of Traditional Chinese Medicine; Shandong University
   of Traditional Chinese Medicine
RP Li, G; Luo, D (通讯作者)，Shandong Univ Tradit Chinese Med, Clin Med Sch 1, Jinan, Shandong, Peoples R China.; Li, G; Luo, D (通讯作者)，Shandong Univ Tradit Chinese Med, Orthopaed, Affiliated Hosp, Jinan, Shandong, Peoples R China.
EM sdszylg@163.com; topld22@163.com
FU Key Technology Research and Development Program of Shandong
   Province10.13039/100014103
FX No Statement Available
CR Arceo Mendoza R, 2021, ENDOCRIN METAB CLIN, V50, P167, DOI 10.1016/j.ecl.2021.03.009
   Bate A, 1998, EUR J CLIN PHARMACOL, V54, P315, DOI 10.1007/s002280050466
   Blick SKA, 2009, BIODRUGS, V23, P197, DOI 10.2165/00063030 200923030 00006
   Blick SKA, 2008, DRUGS, V68, P2709, DOI 10.2165/0003495 200868180 00012
   Brixen KT, 2004, BASIC CLIN PHARMACOL, V94, P260
   Chiba K, 2022, BONE, V160, DOI 10.1016/j.bone.2022.116416
   Dhodapkar MM, 2022, BMJ BRIT MED J, V379, DOI 10.1136/bmj 2022 071752
   DuMouchel W, 1999, AM STAT, V53, P177, DOI 10.2307/2686093
   Evans SJW, 2001, PHARMACOEPIDEM DR S, V10, P483, DOI 10.1002/pds.677
   Gallagher JC, 2006, BONE, V39, P1268, DOI 10.1016/j.bone.2006.06.007
   Hajime M, 2014, J BONE MINER METAB, V32, P601, DOI 10.1007/s00774 014 0564 z
   Hauser B, 2021, J CLIN MED, V10, DOI 10.3390/jcm10071403
   Hodsman AB, 2005, ENDOCR REV, V26, P688, DOI 10.1210/er.2004 0006
   Jiang Y, 2024, J AFFECT DISORDERS, V346, P223, DOI 10.1016/j.jad.2023.11.025
   Johnston CB, 2020, MED CLIN N AM, V104, P873, DOI 10.1016/j.mcna.2020.06.004
   Karatoprak C, 2012, INDIAN J PHARMACOL, V44, P270, DOI 10.4103/0253 7613.93869
   Khan M, 2017, ENDOCRIN METAB CLIN, V46, P181, DOI 10.1016/j.ecl.2016.09.009
   Khosla S, 2017, LANCET DIABETES ENDO, V5, P898, DOI 10.1016/S2213 8587(17)30188 2
   Lindsay R, 2016, OSTEOPOROSIS INT, V27, P2395, DOI 10.1007/s00198 016 3534 6
   Minisola S, 2019, THER ADV MUSCULOSKEL, V11, DOI 10.1177/1759720X19877994
   Oswald AJ, 2019, CALCIFIED TISSUE INT, V105, P148, DOI 10.1007/s00223 019 00563 8
   Reid IR, 2022, LANCET, V399, P1080, DOI 10.1016/S0140 6736(21)02646 5
   Reid IR, 2020, NAT REV ENDOCRINOL, V16, P333, DOI 10.1038/s41574 020 0339 7
   Rojas GA, 2021, INT J CANCER, V149, P1044, DOI 10.1002/ijc.33673
   Rossini M, 2016, EXPERT OPIN DRUG SAF, V15, P321, DOI 10.1517/14740338.2016.1136287
   Rothman KJ, 2004, PHARMACOEPIDEM DR S, V13, P519, DOI 10.1002/pds.1001
   Sánchez Riera L, 2017, BEST PRACT RES CL RH, V31, P169, DOI 10.1016/j.berh.2017.10.001
   Sethi B K, 2008, J Assoc Physicians India, V56, P418
   Shane E, 2022, J CLIN ENDOCR METAB, V107, pE1528, DOI 10.1210/clinem/dgab850
   Vahle JL, 2002, TOXICOL PATHOL, V30, P312, DOI 10.1080/01926230252929882
   Vahle JL, 2004, TOXICOL PATHOL, V32, P426, DOI 10.1080/01926230490462138
NR 31
TC 8
Z9 8
U1 4
U2 11
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
EI 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD AUG 7
PY 2024
VL 15
AR 1391356
DI 10.3389/fphar.2024.1391356
PG 11
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA D2H0D
UT WOS:001294435200001
PM 39170708
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Sun, RL
   Zhu, GY
   Wang, JP
   Tong, L
   Zhai, JL
AF Sun, Ruilian
   Zhu, Guoying
   Wang, Jianping
   Tong, Ling
   Zhai, Jianglong
TI Indirect effects of X irradiation on proliferation and osteogenic
   potential of bone marrow mesenchymal stem cells in a local irradiated
   rat model
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE local irradiation; bone mesenchymal stem cells; osteogenesis; indirect
   effect; rat model
ID LEVEL LASER IRRADIATION; TOTAL BODY IRRADIATION; MINERAL DENSITY; CANCER
   PATIENTS; PELVIC FRACTURES; CANCELLOUS BONE; DIFFERENTIATION; MICE;
   RADIOTHERAPY; THERAPY
AB Cancer survivors after radiotherapy may suffer a variety of bone related adverse side effects, including radioactive osteoporosis and fractures. Localized irradiation is a common treatment modality for malignancies. Recently, a series of reactions and injuries called indirect effects (remote changes in bone when other parts of the body are irradiated) have been reported on the indirect irradiated area of bone tissue after radiotherapy. To address this issue, we developed a rat localized irradiation model. Rats were irradiated with a single dose of X rays to the left hind limbs, and bone marrow mesenchymal stem cells (BMMSCs) were isolated from bone marrow of the left (direct irradiated) and right (indirect irradiated) hind limbs 3, 7 and 14 days after irradiation, and assayed for the proliferation ability and osteogenic potential by alkaline phosphatase (ALP) activity, mineralization assay, RT PCR and western blot analysis. The results showed that there were significant morphology changes in the BMMSCs from direct and indirect irradiated bone tissue with bigger cell bodies and increased granules. The proliferation of BMMSCs decreased both in the direct irradiated and non irradiated bone tissue. The ALP expression and activities of BMMSCs from direct irradiated bone was consistently defected following a transient enhancement, the mRNA levels of RUNX2 and OCN, the protein expression of RUNX2, and the mineralization ability also showed the same trend. Simultaneously, in indirect irradiated group, the osteogenic potential indicators of BMMSCs decreased in the early stage of post irradiation and were still impaired 14 days after irradiation. Our data demonstrate that localized irradiation may have both direct and indirect adverse effects on BMMSCs' proliferation and osteogenic potential into osteoblast, which may be the mechanism of radiation induced abscopal impairment to the skeleton in the cancer radiotherapy induced bone loss.
C1 [Sun, Ruilian; Zhu, Guoying; Wang, Jianping; Tong, Ling; Zhai, Jianglong] Fudan Univ, Inst Radiat Med, Dept Radiat Protect, 2094 Xie Tu Rd, Shanghai 200032, Peoples R China.
C3 Fudan University
RP Zhu, GY (通讯作者)，Fudan Univ, Inst Radiat Med, Dept Radiat Protect, 2094 Xie Tu Rd, Shanghai 200032, Peoples R China.
EM zhugy@shmu.edu.cn
RI Sun, Ruilian/G 5632 2012
FU Shanghai Natural Science Fund [14ZR1401600]; Shanghai Municipal
   Commission of Health [2013ZYJB0801, 20154Y0202]
FX The present study was sponsored by the Shanghai Natural Science Fund
   (grant no. 14ZR1401600) and Shanghai Municipal Commission of Health
   (grant nos. 2013ZYJB0801 and 20154Y0202).
CR Baxter NN, 2005, JAMA J AM MED ASSOC, V294, P2587, DOI 10.1001/jama.294.20.2587
   Bonyadi M, 2003, P NATL ACAD SCI USA, V100, P5840, DOI 10.1073/pnas.1036475100
   Cao X, 2011, P NATL ACAD SCI USA, V108, P1609, DOI 10.1073/pnas.1015350108
   Caplan AI, 2001, TRENDS MOL MED, V7, P259, DOI 10.1016/S1471 4914(01)02016 0
   Choo R, 2013, INT J RADIAT ONCOL, V85, P1239, DOI 10.1016/j.ijrobp.2012.11.007
   Choong PF, 2007, CYTOTHERAPY, V9, P170, DOI 10.1080/14653240701196829
   Chuang SC, 2015, BIOCHEM PHARMACOL, V98, P453, DOI 10.1016/j.bcp.2015.09.018
   Deng ZZ, 2017, NEUROCHEM RES, V42, P625, DOI 10.1007/s11064 016 2118 3
   Fernandez Palomo C, 2015, PHYS MEDICA, V31, P584, DOI 10.1016/j.ejmp.2015.03.004
   Filip S, 2003, FOLIA BIOL PRAGUE, V49, P9
   Galotto M, 1999, EXP HEMATOL, V27, P1460, DOI 10.1016/S0301 472X(99)00076 4
   Green DE, 2012, J BONE MINER RES, V27, P749, DOI 10.1002/jbmr.1505
   GRIGSBY PW, 1995, INT J RADIAT ONCOL, V32, P63, DOI 10.1016/0360 3016(95)00546 B
   Guo CJ, 2016, SCI REP UK, V6, DOI 10.1038/srep31318
   Hamilton SA, 2006, J APPL PHYSIOL, V101, P789, DOI 10.1152/japplphysiol.01078.2005
   HARRISON DE, 1978, J EXP MED, V147, P1526, DOI 10.1084/jem.147.5.1526
   HARRISON DE, 1982, J EXP MED, V156, P1767, DOI 10.1084/jem.156.6.1767
   Hopewell JW, 2003, MED PEDIATR ONCOL, V41, P208, DOI 10.1002/mpo.10338
   Hou JF, 2008, LASER SURG MED, V40, P726, DOI 10.1002/lsm.20709
   Hwang JH, 2010, MENOPAUSE, V17, P416, DOI 10.1097/gme.0b013e3181b9b11f
   Islam MS, 2015, J RADIAT RES, V56, P269, DOI 10.1093/jrr/rru098
   Jia D, 2011, RADIAT RES, V176, P624, DOI 10.1667/RR2505.1
   Johansson S, 2000, INT J RADIAT ONCOL, V48, P745, DOI 10.1016/S0360 3016(00)00674 X
   Khadra M, 2005, BIOMATERIALS, V26, P3503, DOI 10.1016/j.biomaterials.2004.09.033
   Kleibeuker EA, 2016, ONCOTARGET, V7, P76613, DOI 10.18632/oncotarget.12814
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Kondo H, 2010, J APPL PHYSIOL, V108, P152, DOI 10.1152/japplphysiol.00294.2009
   Kondo H, 2009, RADIAT RES, V171, P283, DOI 10.1667/RR1463.1
   Luo XJ, 2008, LAB INVEST, V88, P1264, DOI 10.1038/labinvest.2008.98
   Ma J, 2007, HAEMATOLOGICA, V92, P889, DOI 10.3324/haematol.11106
   Meirelles LD, 2009, CYTOKINE GROWTH F R, V20, P419, DOI 10.1016/j.cytogfr.2009.10.002
   Morgan WF, 2015, CANCER LETT, V356, P17, DOI 10.1016/j.canlet.2013.09.009
   Mori Satoshi, 2016, Clin Calcium, V26, P17, DOI CliCa16011727
   Nambu A, 2013, BMC CANCER, V13, DOI 10.1186/1471 2407 13 68
   Okonogi N, 2013, INT J RADIAT ONCOL, V87, P968, DOI 10.1016/j.ijrobp.2013.08.036
   OVERGAARD M, 1988, ACTA ONCOL, V27, P117, DOI 10.3109/02841868809090331
   OWEN TA, 1990, J CELL PHYSIOL, V143, P420, DOI 10.1002/jcp.1041430304
   Ozawa Y, 1998, BONE, V22, P347, DOI 10.1016/S8756 3282(97)00294 9
   Piao HY, 2017, J PHYSIOL SCI, V67, P141, DOI 10.1007/s12576 016 0447 2
   QUARLES LD, 1992, J BONE MINER RES, V7, P683
   Rades D, 2016, IN VIVO, V30, P917, DOI 10.21873/invivo.11013
   Schmeler KM, 2010, CANCER AM CANCER SOC, V116, P625, DOI 10.1002/cncr.24811
   Soleimani M, 2012, LASER MED SCI, V27, P423, DOI 10.1007/s10103 011 0930 1
   Wagner J, 2009, CURR OPIN BIOTECH, V20, P531, DOI 10.1016/j.copbio.2009.08.009
   Wang Y, 2016, MOL MED REP, V13, P213, DOI 10.3892/mmr.2015.4539
   WERTS ED, 1980, RADIAT RES, V81, P20, DOI 10.2307/3575360
   Willey JS, 2008, RADIAT RES, V170, P388, DOI 10.1667/RR1388.1
   Willey JS, 2010, BONE, V46, P101, DOI 10.1016/j.bone.2009.09.002
   Williams HJ, 2006, EUR RADIOL, V16, P619, DOI 10.1007/s00330 005 0010 7
   Zhu L, 2013, BIOCHEM BIOPH RES CO, V432, P612, DOI 10.1016/j.bbrc.2013.02.036
   Zwahlen DR, 2016, RADIAT ONCOL, V11, DOI 10.1186/s13014 016 0723 6
NR 51
TC 9
Z9 10
U1 0
U2 4
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791 2997
EI 1791 3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD JUN
PY 2017
VL 15
IS 6
BP 3706
EP 3714
DI 10.3892/mmr.2017.6464
PG 9
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Research & Experimental Medicine
GA EU5LA
UT WOS:000401071600035
PM 28440500
OA hybrid, Green Submitted, Green Published
DA 2025 08 17
ER

PT J
AU Zhu, C
   Bao, NR
   Chen, S
   Zhao, JN
AF Zhu, Chen
   Bao, Nirong
   Chen, Shuo
   Zhao, Jianning
TI Dioscin enhances osteoblastic cell differentiation and proliferation by
   inhibiting cell autophagy via the ASPP2/NF κβ pathway
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE dioscin; osteoblastic differentiation; autophagy; apoptosis stimulated
   protein of p53 2; nuclear factor kappa beta
ID CANCER CELLS; CARDIOVASCULAR DISEASE; DNA DAMAGE; ASPP2; APOPTOSIS;
   SAPONINS; ACTIVATION; MECHANISM; INJURY; DEATH
AB Dioscin, a typical steroid saponin, has been reported to promote osteoblastic cell differentiation. However, the underling mechanisms remain to be elucidated. In the present study, it was identified that dioscin (0.5, 1, 5, 10 and 25 mu g/ml) promoted MC3T3 E1 cell proliferation and differentiation in a dose dependent manner. Western blot analysis showed that dioscin regulated autophagy associated protein expression in MC3T3 E1 cells; it promoted the expression of apoptosis stimulated protein of p53 2 (ASPP2), and inhibited the expression of nuclear factor (NF) kappa beta and microtubule associated protein 1 light chain 3 beta, in a concentration dependent manner. Caffeic acid phenethyl ester (CAPE) was used to inhibit the activation of NF kappa B and examine the effect of the ASPP2/NF kappa beta pathway on osteoblastic cell differentiation, proliferation and autophagy. It was identified that CAPE reversed the regulation of dioscin on osteoblastic cell differentiation, proliferation and autophagy. In conclusion, the present study revealed that dioscin promoted osteoblast proliferation and differentiation by inhibiting cell autophagy via the ASPP2/NF kappa beta pathway. These results are the first, to the best of our knowledge, to reveal the involvement of autophagy in the effects of dioscin on the prevention and therapy of osteoporosis.
C1 [Zhu, Chen; Bao, Nirong; Chen, Shuo; Zhao, Jianning] Nanjing Univ, Sch Med, Jinling Hosp, Dept Orthopaed Surg, 305 East Zhongshan Rd, Nanjing 210002, Jiangsu, Peoples R China.
C3 Nanjing University
RP Zhao, JN (通讯作者)，Nanjing Univ, Sch Med, Jinling Hosp, Dept Orthopaed Surg, 305 East Zhongshan Rd, Nanjing 210002, Jiangsu, Peoples R China.
EM zhaojianning00207@163.com
RI Zhu, Chen/GXN 0330 2022
FU National Natural Science Foundation of China [81401815]; China
   Postdoctoral Science Foundation [2015M582900]; Jiangsu Postdoctoral
   Science Foundation [1501146C]
FX This study was supported by the National Natural Science Foundation of
   China (grant no. 81401815), the China Postdoctoral Science Foundation
   (grant no. 2015M582900) and the Jiangsu Postdoctoral Science Foundation
   (grant no. 1501146C).
CR [Anonymous], CELL DEATH DIS
   Aumsuwan P, 2016, ARCH BIOCHEM BIOPHYS, V591, P98, DOI 10.1016/j.abb.2015.12.001
   Barile E, 2005, PLANTA MED, V71, P1010, DOI 10.1055/s 2005 873134
   Bartolomé A, 2013, BIOCHEM J, V455, P329, DOI 10.1042/BJ20130562
   Benyamini H, 2009, PROTEINS, V77, P602, DOI 10.1002/prot.22473
   Gao LL, 2011, ASIAN PAC J CANCER P, V12, P1361
   Ha SW, 2014, ACS NANO, V8, P5898, DOI 10.1021/nn5009879
   Hou HP, 2014, TURK NEUROSURG, V24, P369, DOI 10.5137/1019 5149.JTN.8623 13.0
   Li H, 2010, FITOTERAPIA, V81, P1147, DOI 10.1016/j.fitote.2010.07.016
   Lu BN, 2012, ENVIRON TOXICOL PHAR, V34, P127, DOI 10.1016/j.etap.2012.03.010
   Lv LL, 2013, FOOD CHEM TOXICOL, V59, P657, DOI 10.1016/j.fct.2013.07.012
   Lv XH, 2015, TOXICOL LETT, V239, P131, DOI 10.1016/j.toxlet.2015.09.014
   Nyhan MJ, 2016, BMC CANCER, V16, DOI 10.1186/s12885 016 2123 6
   Orogo AM, 2015, CIRC RES, V116, P489, DOI 10.1161/CIRCRESAHA.116.303791
   Pan HM, 2016, ONCOTARGET, V7, P21235, DOI 10.18632/oncotarget.6908
   Schiattarella GG, 2016, J MOL CELL CARDIOL, V95, P86, DOI 10.1016/j.yjmcc.2015.11.019
   Shi Y, 2015, J CELL MOL MED, V19, P535, DOI 10.1111/jcmm.12435
   Song B, 2015, MOL CANCER, V14, DOI 10.1186/s12943 015 0447 5
   Takahashi A, 1996, J BIOL CHEM, V271, P32487, DOI 10.1074/jbc.271.51.32487
   Wang YH, 2012, P NATL ACAD SCI USA, V109, P13325, DOI 10.1073/pnas.1120193109
   Wei YL, 2013, FOOD CHEM TOXICOL, V59, P118, DOI 10.1016/j.fct.2013.05.054
   Xie F, 2015, J CELL MOL MED, V19, P155, DOI 10.1111/jcmm.12364
   Yu H, 2015, PHYTOTHER RES, V29, P228, DOI 10.1002/ptr.5243
   Zhang CF, 2014, J BIOMED SCI, V21, DOI 10.1186/1423 0127 21 30
NR 24
TC 11
Z9 13
U1 1
U2 16
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791 2997
EI 1791 3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD OCT
PY 2017
VL 16
IS 4
BP 4922
EP 4926
DI 10.3892/mmr.2017.7206
PG 5
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Research & Experimental Medicine
GA FG9JA
UT WOS:000410753800160
PM 28849197
OA Bronze
DA 2025 08 17
ER

PT J
AU Ohlsson, C
   Nilsson, KH
   Henning, P
   Wu, JY
   Gustafsson, KL
   Poutanen, M
   Lerner, UH
   Movérare Skrtic, S
AF Ohlsson, Claes
   Nilsson, Karin H.
   Henning, Petra
   Wu, Jianyao
   Gustafsson, Karin L.
   Poutanen, Matti
   Lerner, Ulf H.
   Moverare Skrtic, Sofia
TI WNT16 overexpression partly protects against glucocorticoid induced bone
   loss
SO AMERICAN JOURNAL OF PHYSIOLOGY ENDOCRINOLOGY AND METABOLISM
LA English
DT Article
DE glucocorticoids; secondary osteoporosis; transgenic mice; WNT
ID INDUCED OSTEOPOROSIS; OSTEOBLAST DIFFERENTIATION; RECEPTOR BETA;
   CORTICOSTEROID THERAPY; VERTEBRAL FRACTURE; MINERAL DENSITY;
   MESSENGER RNA; EXPRESSION; GROWTH; CELLS
AB Therapeutic use of glucocorticoids (GCs) is a major cause of secondary osteoporosis, but the molecular mechanisms responsible for the deleterious effects of GCs in bone are only partially understood. WNT16 is a crucial physiological regulator of bone mass and fracture susceptibility, and we hypothesize that disturbed WNT16 activity might be involved in the deleterious effects of GC in bone. Twelve week old female Obl Wnt16 mice (WNT16 expression driven by the rat procollagen type I alpha 1 promoter) and wild type (WT) littermates were treated with prednisolone (7.6 mg.kg( 1).day( 1)) or vehicle for 4 wk. We first observed that GC treatment decreased the Wnt16 mRNA levels in bone of female mice ( 56.4 +/  6.1% compared with vehicle, P < 0.001). We next evaluated if WNT16 overexpression protects against GC induced bone loss. Dual energy X ray absorptiometry analyses revealed that GC treatment decreased total body bone mineral density in WT mice ( 3.9 +/  1.2%, P = 0.028) but not in Obl Wnt16 mice (+1.3 +/  1.4%, nonsignificant). Microcomputed tomography analyses showed that GC treatment decreased trabecular bone volume fraction (BV/TV) of the femur in WT mice (P = 0.019) but not in Obl Wnt16 mice. Serum levels of the bone formation marker procollagen type I N terminal propeptide were substantially reduced by GC treatment in WT mice ( 50.3 +/  7.0%, P = 0.008) but not in Obl Wnt16 mice ( 3.8 +/  21.2%, nonsignificant). However, the cortical bone thickness in femur was reduced by GC treatment in both WT mice and Obl Wnt16 mice. In conclusion. GC treatment decreases Wnt16 mRNA levels in bone and WNT16 overexpression partly protects against GC induced bone loss.
C1 [Ohlsson, Claes; Nilsson, Karin H.; Henning, Petra; Wu, Jianyao; Gustafsson, Karin L.; Poutanen, Matti; Lerner, Ulf H.; Moverare Skrtic, Sofia] Univ Gothenburg, Ctr Bone & Arthrit Res, Inst Med, Sahlgrenska Acad, Gothenburg, Sweden.
   [Poutanen, Matti] Univ Turku, Inst Biomed, Turku, Finland.
   [Poutanen, Matti] Univ Turku, Turku Ctr Dis Modeling, Turku, Finland.
C3 University of Gothenburg; University of Turku; University of Turku
RP Ohlsson, C (通讯作者)，Sahlgrens Univ Hosp, Ctr Bone & Anhritis Res, Vita Straket 11, S 41345 Gothenburg, Sweden.
EM claes.ohlsson@medic.gu.se
RI Henning, Petra/KIL 4650 2024; Horkeby, Karin/IUN 8177 2023; Skrtic,
   Sofia/AAQ 1585 2020; Ohlsson, Claes/HIR 6959 2022; Poutanen,
   Matti/I 1700 2018; Ohlsson, Claes/AGP 3544 2022
OI Lerner, Ulf/0000 0002 3579 1960; Ohlsson, Claes/0000 0002 9633 2805;
   Henning, Petra/0000 0002 9330 6265; Poutanen, Matti/0000 0002 8953 1734;
   
FU Swedish Research Council; Swedish Foundation for Strategic Research;
   Avtal om lakarutbildning och forskning (ALF) research grant from
   Sahlgrenska University Hospital; European Calcified Tissue Society;
   Lundberg Foundation; Torsten and Ragnar Soderberg's Foundation; Knut and
   Alice Wallenberg Foundation; Novo Nordisk Foundation; Novo Nordisk
   Fonden [NNF15OC0015080, NNF14OC0010513, NNF13OC0005785] Funding Source:
   researchfish
FX This study is supported by the Swedish Research Council, Swedish
   Foundation for Strategic Research, Avtal om lakarutbildning och
   forskning (ALF) research grant from Sahlgrenska University Hospital,
   European Calcified Tissue Society, Lundberg Foundation, Torsten and
   Ragnar Soderberg's Foundation, Knut and Alice Wallenberg Foundation, and
   Novo Nordisk Foundation.
CR Alam I, 2016, ENDOCRINOLOGY, V157, P722, DOI 10.1210/en.2015 1281
   Almeida M, 2011, J BIOL CHEM, V286, P44326, DOI 10.1074/jbc.M111.283481
   Angeli A, 2006, BONE, V39, P253, DOI 10.1016/j.bone.2006.02.005
   BAMBERGER CM, 1995, J CLIN INVEST, V95, P2435, DOI 10.1172/JCI117943
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Baron R, 2012, J CLIN ENDOCR METAB, V97, P311, DOI 10.1210/jc.2011 2332
   Bultink IEM, 2013, EXPERT OPIN PHARMACO, V14, P185, DOI 10.1517/14656566.2013.761975
   Canalis E, 2007, OSTEOPOROSIS INT, V18, P1319, DOI 10.1007/s00198 007 0394 0
   CANALIS E, 1984, CALCIFIED TISSUE INT, V36, P158, DOI 10.1007/BF02405312
   Canalis Ernesto, 2005, Curr Osteoporos Rep, V3, P98, DOI 10.1007/s11914 005 0017 7
   Cheng SL, 1998, J CELL BIOCHEM, V71, P449, DOI 10.1002/(SICI)1097 4644(19981201)71:3<449::AID JCB13>3.0.CO;2 D
   Compston J, 2010, NAT REV RHEUMATOL, V6, P82, DOI 10.1038/nrrheum.2009.259
   Conaway HH, 2016, BONE, V93, P43, DOI 10.1016/j.bone.2016.08.024
   COOPER C, 1995, ANN RHEUM DIS, V54, P49, DOI 10.1136/ard.54.1.49
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Eijken M, 2006, MOL CELL ENDOCRINOL, V248, P87, DOI 10.1016/j.mce.2005.11.034
   Estrada K, 2012, NAT GENET, V44, P491, DOI 10.1038/ng.2249
   Frenkel B, 2015, ADV EXP MED BIOL, V872, P179, DOI 10.1007/978 1 4939 2895 8_8
   Hinds TD, 2010, MOL ENDOCRINOL, V24, P1715, DOI 10.1210/me.2009 0411
   Humphrey EL, 2006, BONE, V38, P652, DOI 10.1016/j.bone.2005.10.004
   Hurson CJ, 2007, BMC MUSCULOSKEL DIS, V8, DOI 10.1186/1471 2474 8 12
   Jensen PR, 2015, BONE, V73, P16, DOI 10.1016/j.bone.2014.12.004
   Kalak R, 2009, BONE, V45, P61, DOI 10.1016/j.bone.2009.03.673
   Kassel O, 2007, MOL CELL ENDOCRINOL, V275, P13, DOI 10.1016/j.mce.2007.07.003
   Kiper POS, 2016, NEW ENGL J MED, V374, P2553, DOI 10.1056/NEJMoa1509342
   Lerner UH, 2015, J INTERN MED, V277, P630, DOI 10.1111/joim.12368
   Mak W, 2009, CALCIFIED TISSUE INT, V85, P538, DOI 10.1007/s00223 009 9303 1
   Maresova KB, 2013, CALCIFIED TISSUE INT, V92, P354, DOI 10.1007/s00223 012 9684 4
   Medina Gomez C, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002718
   Moutsatsou P, 2012, TRENDS MOL MED, V18, P348, DOI 10.1016/j.molmed.2012.04.005
   Movérare Skrtic S, 2015, P NATL ACAD SCI USA, V112, P14972, DOI 10.1073/pnas.1520408112
   Movérare Skrtic S, 2014, NAT MED, V20, P1279, DOI 10.1038/nm.3654
   Naganathan V, 2000, ARCH INTERN MED, V160, P2917, DOI 10.1001/archinte.160.19.2917
   O'Brien CA, 2004, ENDOCRINOLOGY, V145, P1835, DOI 10.1210/en.2003 0990
   Oakley RH, 2013, J ALLERGY CLIN IMMUN, V132, P1033, DOI 10.1016/j.jaci.2013.09.007
   Ohlsson C, 2009, ENDOCR REV, V30, P494, DOI 10.1210/er.2009 0010
   Ohnaka K, 2005, BIOCHEM BIOPH RES CO, V329, P177, DOI 10.1016/j.bbrc.2005.01.117
   Ohnaka K, 2004, BIOCHEM BIOPH RES CO, V318, P259, DOI 10.1016/j.bbrc.2004.04.025
   Rauch A, 2010, CELL METAB, V11, P517, DOI 10.1016/j.cmet.2010.05.005
   Sato AY, 2016, J BONE MINER RES, V31, P1791, DOI 10.1002/jbmr.2869
   Sher LB, 2006, CALCIFIED TISSUE INT, V79, P118, DOI 10.1007/s00223 005 0297 z
   Sher LB, 2004, ENDOCRINOLOGY, V145, P922, DOI 10.1210/en.2003 0655
   Smith E, 2002, J BIOL CHEM, V277, P18191, DOI 10.1074/jbc.M109708200
   Soe K, 2010, J BONE MINER RES, V25, P2184, DOI 10.1002/jbmr.113
   Strickland I, 2001, J EXP MED, V193, P585, DOI 10.1084/jem.193.5.585
   Swanson C, 2006, ENDOCRINOLOGY, V147, P3613, DOI 10.1210/en.2005 0717
   Swolin D, 1996, J ENDOCRINOL, V149, P397, DOI 10.1677/joe.0.1490397
   Thiele Sylvia, 2014, Bonekey Rep, V3, P552, DOI 10.1038/bonekey.2014.47
   Thiele S, 2012, J BONE MINER RES, V27, P2242, DOI 10.1002/jbmr.1688
   Van Staa TP, 2003, ARTHRITIS RHEUM, V48, P3224, DOI 10.1002/art.11283
   van Staa TP, 2002, OSTEOPOROSIS INT, V13, P777, DOI 10.1007/s001980200108
   Vidal NOA, 1998, J ENDOCRINOL, V159, P191, DOI 10.1677/joe.0.1590191
   Wang FS, 2008, ENDOCRINOLOGY, V149, P1793, DOI 10.1210/en.2007 0910
   Weinstein RS, 2012, ENDOCRIN METAB CLIN, V41, P595, DOI 10.1016/j.ecl.2012.04.004
   Wergedal JE, 2015, ENDOCRINOLOGY, V156, P1023, DOI 10.1210/en.2014 1702
   Wood CL, 2018, J ENDOCRINOL, V236, pR69, DOI 10.1530/JOE 17 0361
   Yao W, 2008, ARTHRITIS RHEUM, V58, P1674, DOI 10.1002/art.23454
   Zheng HF, 2015, NATURE, V526, P112, DOI 10.1038/nature14878
   Zheng HF, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002745
   Zhong ZD, 2012, P NATL ACAD SCI USA, V109, pE2197, DOI 10.1073/pnas.1120407109
NR 60
TC 21
Z9 24
U1 0
U2 6
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0193 1849
EI 1522 1555
J9 AM J PHYSIOL ENDOC M
JI Am. J. Physiol. Endocrinol. Metab.
PD JUN
PY 2018
VL 314
IS 6
BP E597
EP E604
DI 10.1152/ajpendo.00292.2017
PG 8
WC Endocrinology & Metabolism; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Physiology
GA GP8OP
UT WOS:000441171500007
PM 29406783
OA Bronze
DA 2025 08 17
ER

PT J
AU Han, NR
   Kim, HY
   Yang, WM
   Jeong, HJ
   Kim, HM
AF Han, Na Ra
   Kim, Hee Yun
   Yang, Woong Mo
   Jeong, Hyun Ja
   Kim, Hyung Min
TI Glutamic acid ameliorates estrogen deficiency induced menopausal like
   symptoms in ovariectomized mice
SO NUTRITION RESEARCH
LA English
DT Article
DE Glutamic acid; Microcomputed tomography; Alkaline phosphatase; Estrogen
   receptor beta; Estrogen response element; Extracellular signal regulated
   kinase phosphorylation
ID RECEPTOR ALPHA; IN VITRO; MCF 7 CELLS; BODY WEIGHT; PROLIFERATION; BONE;
   ACTIVATION; GENISTEIN; ESTRADIOL; BETA
AB Some amino acids are considered alternative therapies for improving menopausal symptoms. Glutamic acid (GA), which is abundant in meats, fish, and protein rich plant foods, is known to be a neurotransmitter or precursor of gamma aminobutyric acid. Although it is unclear if GA functions in menopausal symptoms, we hypothesized that GA would attenuate estrogen deficiency induced menopausal symptoms. The objective to test our hypothesis was to examine an estrogenic effect of GA in ovariectomized (OVX) mice, estrogen receptor (ER) positive human osteoblast like MG 63 cells, and ER positive human breast cancer MCF 7 cells. The results demonstrated that administration with GA to mice suppressed body weight gain and vaginal atrophy when compared with the OVX mice. A microcomputed tomographic analysis of the trabecular bone showed increases in bone mineral density, trabecular number, and connectivity density as well as a significant decrease in total porosity of the OVX mice treated with GA. In addition, GA increased serum levels of alkaline phosphatase and estrogen compared with the OVX mice. Furthermore, GA induced proliferation and increased ER beta messenger RNA (mRNA) expression, estrogen response element (ERE) activity, extracellular signal regulated kinase phosphorylation, and alkaline phosphatase activity in MG 63 cells. In MCF 7 cells, GA also increased proliferation, Ki 67 mRNA expression, ER beta mRNA expression, and ERE activity. Estrogen response element activity increased by GA was inhibited by an estrogen antagonist. Taken together, our data demonstrated that GA has estrogenic and osteogenic activities in OVX mice, MG 63 cells, and MCF 7 cells. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Han, Na Ra; Kim, Hee Yun; Kim, Hyung Min] Kyung Hee Univ, Dept Pharmacol, Coll Korean Med, Seoul 130701, South Korea.
   [Yang, Woong Mo] Kyung Hee Univ, Coll Korean Med, Seoul 130701, South Korea.
   [Yang, Woong Mo] Kyung Hee Univ, Inst Korean Med, Seoul 130701, South Korea.
   [Jeong, Hyun Ja] Hoseo Univ, Dept Food Technol, Asan 336795, Chungcheongnam, South Korea.
   [Jeong, Hyun Ja] Hoseo Univ, Inflammatory Dis Res Ctr, Asan 336795, Chungcheongnam, South Korea.
C3 Kyung Hee University; Kyung Hee University; Kyung Hee University; Hoseo
   University; Hoseo University
RP Jeong, HJ (通讯作者)，Hoseo Univ, Dept Food Technol, Asan 336795, Chungcheongnam, South Korea.
EM hjjeong@hoseo.edu; hmkim@khu.ac.kr
RI ; Park, Mi Kyung/J 9643 2017; Yang, Woong/AAH 9185 2020
OI Yang, Woong Mo/0000 0001 5308 2386; 
FU Ministry of Trade, Industry and Energy, Korea
FX This research was supported by the Ministry of Trade, Industry and
   Energy, Korea, through the Education Support program for Creative and
   Industrial Convergence.
CR Abdallah HM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098559
   Al Zaubai N, 2014, J PHARMACOL EXP THER, V351, P172, DOI 10.1124/jpet.114.214403
   Amato P, 2002, MENOPAUSE, V9, P145, DOI 10.1097/00042192 200203000 00010
   An JP, 2001, J BIOL CHEM, V276, P17808, DOI 10.1074/jbc.M100953200
   [Anonymous], 2014, CHEM MAT RES
   Archer DF, 2015, MENOPAUSE, V22, P786, DOI 10.1097/GME.0000000000000365
   Ariazi EA, 2002, CANCER RES, V62, P6510
   Auro K, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5708
   Balakrishnan B, 2014, J OSTEOPOROS, V2014, DOI 10.1155/2014/348189
   Basha ME, 2013, J SEX MED, V10, P1219, DOI 10.1111/jsm.12088
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Camporez JPG, 2013, ENDOCRINOLOGY, V154, P1021, DOI 10.1210/en.2012 1989
   Chanawong A, 2015, DRUG METAB DISPOS, V43, P889, DOI 10.1124/dmd.114.062935
   Chen J, 2011, CANCER LETT, V308, P144, DOI 10.1016/j.canlet.2011.04.022
   CIVITELLI R, 1992, NUTRITION, V8, P400
   Ediz L, 2010, MED HYPOTHESES, V75, P319, DOI 10.1016/j.mehy.2010.03.012
   Fahlén M, 2013, EUR J CANCER, V49, P52, DOI 10.1016/j.ejca.2012.07.003
   Galea GL, 2013, J BIOL CHEM, V288, P9035, DOI 10.1074/jbc.M112.405456
   Gao QG, 2012, EUR J PHARMACOL, V677, P39, DOI 10.1016/j.ejphar.2011.12.032
   Giguère V, 1998, STEROIDS, V63, P335, DOI 10.1016/S0039 128X(98)00024 5
   Greger JG, 2006, STEROIDS, V71, P317, DOI 10.1016/j.steroids.2005.09.016
   Hall JM, 2001, J BIOL CHEM, V276, P36869, DOI 10.1074/jbc.R100029200
   Han NR, 2014, J INVEST DERMATOL, V134, P2521, DOI 10.1038/jid.2014.198
   Han NR, 2013, NUTRITION, V29, P1381, DOI 10.1016/j.nut.2013.04.016
   Helle J, 2014, MOL CELL ENDOCRINOL, V392, P125, DOI 10.1016/j.mce.2014.05.014
   Henriques HN, 2011, INT J EXP PATHOL, V92, P266, DOI 10.1111/j.1365 2613.2011.00774.x
   Hong GoEun Hong GoEun, 2014, Asian Journal of Animal and Veterinary Advances, V9, P556
   Hsieh CY, 1998, CANCER RES, V58, P3833
   Hu XJ, 2014, ARCH TOXICOL, V88, P625, DOI 10.1007/s00204 013 1184 4
   Jaroenporn S, 2014, J REPROD DEVELOP, V60, P238, DOI 10.1262/jrd.2013 144
   Kameda Y, 2015, BONE, V71, P217, DOI 10.1016/j.bone.2014.10.027
   Kanaya N, 2010, NUTR RES, V30, P714, DOI 10.1016/j.nutres.2010.09.001
   KASPERK C, 1995, J CLIN ENDOCR METAB, V80, P2511, DOI 10.1210/jc.80.8.2511
   Kato M, 2010, OSTEOARTHR CARTILAGE, V18, P934, DOI 10.1016/j.joca.2010.03.008
   Kee N, 2002, J NEUROSCI METH, V115, P97, DOI 10.1016/S0165 0270(02)00007 9
   Le Donne M, 2011, ARCH GYNECOL OBSTET, V283, P1319, DOI 10.1007/s00404 010 1545 7
   Lee CG, 2009, J CLIN ENDOCR METAB, V94, P1104, DOI 10.1210/jc.2008 0701
   Lee EJ, 2014, PHYTOMEDICINE, V21, P1208, DOI 10.1016/j.phymed.2014.04.002
   Lizcano F, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/757461
   Luo XH, 2003, ENDOCR RES, V29, P343, DOI 10.1081/ERC 120025041
   Matsubara M, 2004, PEPTIDES, V25, P289, DOI 10.1016/j.peptides.2003.12.020
   Mödder UIL, 2004, EUR J ENDOCRINOL, V151, P503, DOI 10.1530/eje.0.1510503
   Mpalaris V, 2015, OBES REV, V16, P225, DOI 10.1111/obr.12244
   Nedrow A, 2006, ARCH INTERN MED, V166, P1453, DOI 10.1001/archinte.166.14.1453
   Nilsen J, 2002, NEUROREPORT, V13, P825, DOI 10.1097/00001756 200205070 00018
   Park SB, 2010, J KOREAN NEUROSURG S, V48, P309, DOI 10.3340/jkns.2010.48.4.309
   Pastore LM, 2004, MATURITAS, V49, P292, DOI 10.1016/j.maturitas.2004.06.019
   김민호, 2014, [CELLMED, 셀메드], V4, P14, DOI 10.5667/tang.2014.0020
   Prins HJ, 2014, STEM CELL RES, V12, P428, DOI 10.1016/j.scr.2013.12.001
   Prouillet C, 2004, BIOCHEM PHARMACOL, V67, P1307, DOI 10.1016/j.bcp.2003.11.009
   Qu N, 2013, INT J NEUROPSYCHOPH, V16, P1071, DOI 10.1017/S1461145712000958
   Reeds PJ, 2000, J NUTR, V130, p978S, DOI 10.1093/jn/130.4.978S
   Roman Blas JA, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2791
   Rucci N, 2009, J CELL BIOL, V187, P669, DOI 10.1083/jcb.200906014
   Sabry L., 2013, LIFE SCI J, V10, P177
   Song LG, 2013, EUR J PHARMACOL, V714, P15, DOI 10.1016/j.ejphar.2013.05.039
   Sundar SN, 2008, CARCINOGENESIS, V29, P2252, DOI 10.1093/carcin/bgn214
   Takao T, 2005, J ENDOCRINOL, V184, P191, DOI 10.1677/joe.1.05914
   Takuma K, 2012, J PHARMACOL SCI, V120, P89, DOI 10.1254/jphs.12115FP
   Tang XL, 2008, ENDOCRINE, V34, P29, DOI 10.1007/s12020 008 9099 1
   Tuomikoski P, 2012, CLIMACTERIC, V15, P153, DOI 10.3109/13697137.2011.597894
   Uyar Y, 2008, ARCH GYNECOL OBSTET, V278, P107, DOI 10.1007/s00404 007 0534 y
   Wang XL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118184
   Xu Y, 2014, INT J MOL SCI, V15, P7827, DOI 10.3390/ijms15057827
   Yang LC, 2008, BIOSCI BIOTECH BIOCH, V72, P3084, DOI 10.1271/bbb.80024
   Yener T, 2007, ANAT HISTOL EMBRYOL, V36, P75, DOI 10.1111/j.1439 0264.2006.00743.x
   Zhao YY, 2009, EXP MOL MED, V41, P478, DOI 10.3858/emm.2009.41.7.053
   Zhou H, 2001, J BONE MINER RES, V16, P1300, DOI 10.1359/jbmr.2001.16.7.1300
   Zhou Y, 2015, FASEB J, V29, P1635, DOI 10.1096/fj.14 260844
NR 69
TC 17
Z9 19
U1 1
U2 27
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0271 5317
J9 NUTR RES
JI Nutr. Res.
PD SEP
PY 2015
VL 35
IS 9
BP 774
EP 783
DI 10.1016/j.nutres.2015.06.006
PG 10
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Nutrition & Dietetics
GA CR5XE
UT WOS:000361416900004
PM 26144993
DA 2025 08 17
ER

PT J
AU Lv, SM
   Zhang, Y
   Yan, M
   Mao, HJ
   Pan, CL
   Gan, MX
   Fan, JW
   Wang, GX
AF Lv, Shumin
   Zhang, Yun
   Yan, Ming
   Mao, Hongjiao
   Pan, Cailing
   Gan, Mingxiao
   Fan, Jiawen
   Wang, Guoxia
TI Inhibition of osteolysis after local administration of osthole in a TCP
   particles induced osteolysis model
SO INTERNATIONAL ORTHOPAEDICS
LA English
DT Article
DE TCP particles; Osteolysis; Osthole; ER stress
ID ENDOPLASMIC RETICULUM STRESS; TITANIUM PARTICLES; GENE EXPRESSION;
   DIFFERENTIATION; SUPPLEMENTATION; OSTEOCLASTS; ACTIVATION; INDUCTION
AB Purpose Wear debris induced osteolysis and aseptic loosening are the most frequent late complications of total joint arthroplasty leading to revision of the prosthesis. However, no effective measures for the prevention and treatment of particles induced osteolysis currently exist. Here, we investigated the efficacy of local administration of osthole on tricalcium phosphate (TCP) particles induced osteolysis in a murine calvarial model.
   Methods TCP particles were implanted over the calvaria of ICR mice, and established TCP particles induced osteolysis model. On days one, four, seven, ten and thirteen post surgery, osthole (10 mg/kg) or phosphate buffer saline (PBS) were subcutaneously injected into the calvaria of TCP particles implanted or sham operated mice. Two weeks later, blood, the periosteum and the calvaria were collected and processed for bone turnover markers, pro inflammatory cytokine, histomorphometric and molecular analysis.
   Results Osthole (10 mg/kg) markedly prevented TCP particles induced osteoclastogenesis and bone resorption in a mouse calvarial model. Osthole also inhibited the decrease of serum osteocalcin level and calvarial alkaline phosphatase (ALP) activity, and prevented the increase in the activity of tartrate resistant acid phosphatase (TRAP) and cathepsin K in the mouse calvaria. Furthermore, osthole obviously reduced the release of tumor necrosis factor alpha (TNF alpha) and interleukin 6 (IL 6) into the periosteum. Western blotting demonstrated TCP particles caused a remarkable endoplasmic reticulum (ER) stress response in the mouse calvaria, which was obviously blocked by osthole treatment.
   Conclusion These results suggest that local administration of osthole inhibits TCP particles induced osteolysis in the mouse calvarial in vivo, which may be mediated by inhibition of the ER stress signaling pathway, and it will be developed as a new drug in the prevention and treatment of destructive diseases caused by prosthetic wear particles.
C1 [Lv, Shumin; Zhang, Yun; Mao, Hongjiao; Pan, Cailing; Gan, Mingxiao; Fan, Jiawen; Wang, Guoxia] Shaoxing Univ, Coll Med, Huancheng West Rd 508, Shaoxing 312000, Peoples R China.
   [Yan, Ming] Hangzhou Dianzi Univ, Coll Life Informat Sci & Instrument Engn, Hangzhou 310018, Zhejiang, Peoples R China.
C3 Shaoxing University; Hangzhou Dianzi University
RP Zhang, Y (通讯作者)，Shaoxing Univ, Coll Med, Huancheng West Rd 508, Shaoxing 312000, Peoples R China.
EM zhangyunbme@126.com
FU Zhejiang Provincial Natural Science Foundation of China [LY13H060003,
   LY15H180012]; Scientific Research Foundation of Traditional Chinese
   Medicine in Zhejiang Province [2012ZB161]; Science & Technology
   Innovation Project of College Students in Zhejiang Province
   [2013R426025]
FX This work was supported by Zhejiang Provincial Natural Science
   Foundation of China (No. LY13H060003 and No. LY15H180012), Scientific
   Research Foundation of Traditional Chinese Medicine in Zhejiang Province
   (No.2012ZB161) and Science & Technology Innovation Project of College
   Students in Zhejiang Province (No. 2013R426025).
CR Cardozo AK, 2005, DIABETES, V54, P452, DOI 10.2337/diabetes.54.2.452
   Dankbar B, 2015, NAT MED, V21, P1085, DOI 10.1038/nm.3917
   Ding Y, 2012, BIOMED MATER, V7, DOI 10.1088/1748 6041/7/4/045019
   Fu CF, 2014, INT ORTHOP, V38, P1091, DOI 10.1007/s00264 013 2190 0
   Harris WH, 2001, CLIN ORTHOP RELAT R, P66
   Iitsuka N, 2013, EUR J PHARMACOL, V714, P41, DOI 10.1016/j.ejphar.2013.05.020
   Kandel Kfir M, 2015, J HEPATOL, V63, P926, DOI 10.1016/j.jhep.2015.05.012
   Katsuyama E, 2015, J BIOL CHEM, V290, P716, DOI 10.1074/jbc.M114.568360
   Kim JA, 2015, INT ORTHOP, V39, P173, DOI 10.1007/s00264 014 2596 3
   Kim S, 2015, J IMMUNOL, V194, P4498, DOI 10.4049/jimmunol.1401399
   Li XX, 2002, BIOL PHARM BULL, V25, P738, DOI 10.1248/bpb.25.738
   Li ZP, 2014, INT IMMUNOPHARMACOL, V20, P33, DOI 10.1016/j.intimp.2014.02.013
   Liu G, 2015, CELL TISSUE RES, V2015
   Liu Jianxin, 2005, Zhong Yao Cai, V28, P1002
   Meng F, 2004, PHARMAZIE, V59, P643
   Ming Lei guo, 2012, Yaoxue Xuebao, V47, P174
   Ming LG, 2011, PHARMACOLOGY, V88, P33, DOI 10.1159/000328776
   Obando Pereda GA, 2014, LIFE SCI, V97, P96, DOI 10.1016/j.lfs.2013.11.008
   Rao AJ, 2013, INT ORTHOP, V37, P1393, DOI 10.1007/s00264 013 1887 4
   Smith BJ, 2014, BONE, V58, P151, DOI 10.1016/j.bone.2013.10.005
   Sundfeldt M, 2006, ACTA ORTHOP, V77, P177, DOI 10.1080/17453670610045902
   Tang DZ, 2010, J BONE MINER RES, V25, P1234, DOI 10.1002/jbmr.21
   Tian B, 2014, BIOMATERIALS, V35, P8937, DOI 10.1016/j.biomaterials.2014.06.055
   Vallés G, 2013, ACTA BIOMATER, V9, P4916, DOI 10.1016/j.actbio.2012.08.027
   Wang R, 2013, BIOMATERIALS, V34, P2611, DOI 10.1016/j.biomaterials.2013.01.025
   Wang XM, 2015, THEORETICAL AND METHODOLOGICAL APPROACHES TO SOCIAL SCIENCE, ECONOMICS AND MANAGEMENT SCIENCE, P37
   Wu SJ, 2015, J MED FOOD, V18, P972, DOI 10.1089/jmf.2014.3314
   Zheng Y, 2013, UROL INT, V91, P350, DOI 10.1159/000347191
NR 28
TC 19
Z9 27
U1 0
U2 13
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0341 2695
EI 1432 5195
J9 INT ORTHOP
JI Int. Orthop.
PD JUL
PY 2016
VL 40
IS 7
BP 1545
EP 1552
DI 10.1007/s00264 015 3021 2
PG 8
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA DQ2JP
UT WOS:000379028900028
PM 26498175
DA 2025 08 17
ER

PT J
AU Yu, XY
   Wang, HY
   Liu, S
   Zhang, XM
   Guida, P
   Hu, BC
   Wang, Y
AF Yu, Xiaoyan
   Wang, Hongyan
   Liu, Shuang
   Zhang, Xiangming
   Guida, Peter
   Hu, Baocheng
   Wang, Ya
TI A small peptide mimicking the key domain of MEPE/OF45 interacting with
   CHK1 protects human cells from radiation induced killing
SO CELL CYCLE
LA English
DT Article
DE MEPE/OF45; CHK1; ionizing radiation
ID HOMOLOGOUS RECOMBINATION REPAIR; ENERGY TRANSFER RADIATION; S PHASE
   CELLS; IONIZING RADIATION; CHECKPOINT RESPONSE; ATR/CHK1 PATHWAY; BONE;
   GENE; ATR; RADIOSENSITIVITY
AB Checkpoint activation benefits DNA homologous recombination repair and; therefore, protects cells from ionizing radiation (IR) induced killing. CHK1 is one of the most important checkpoint regulators in mammalian cells. We recently reported that matrix extracellular phosphoglycoprotein/osteoblast factor 45 (MEPE/OF45) stabilizes CHK1 through interacting with CHK1, thus protecting cells from IR induced killing. The purpose of this study is to investigate whether a small peptide that mimics the key domain of MEPE/OF45 could interact with CHK1 and protect cells from IR induced killing. We showed here that the synthesized peptide with 18 amino acids (aa) could enter human transformed lymphoblasts when it is linked to fatty acid CH 3 (CH 2) 8 CO. After the 18 aa peptide entered the human cells, it interacted with CHK1, increased the CHK1 level and induced a stronger G 2 arrest in the cells following IR. More importantly, the 18 aa peptide could protect the cells from IR induced killing. Our data indicate that the 18 aa peptide, similar to MEPE/OF45, reduces CHK1 degradation and protects cells from IR induced killing. We believe that these results provide useful information for drug development in two directions: protect cells from IR induced damage and sensitize cells to radiation therapy.
C1 [Yu, Xiaoyan; Wang, Hongyan; Liu, Shuang; Zhang, Xiangming; Wang, Ya] Emory Univ, Winship Canc Inst, Dept Radiat Oncol, Atlanta, GA 30322 USA.
   [Yu, Xiaoyan] Jilin Univ, Sch Pharm, Dept Expt Pharmacol & Toxicol, Changchun 130023, Peoples R China.
   [Guida, Peter] Brookhaven Natl Lab, NSRL, Med Dept Liaison Scientist, Upton, NY 11973 USA.
   [Liu, Shuang] Jiamusi Univ, Coll Med, Dept Genet, Jiamusi, Peoples R China.
   [Hu, Baocheng] Beijing Inst Biotechnol, Beijing, Peoples R China.
C3 Emory University; Jilin University; United States Department of Energy
   (DOE); Brookhaven National Laboratory; Jiamusi University
RP Wang, Y (通讯作者)，Emory Univ, Winship Canc Inst, Dept Radiat Oncol, Atlanta, GA 30322 USA.
EM yawang@radonc.emory.org
FU National Basic Research Program of China [2005CB522506, 2007CB914604];
   National Natural Science Foundation of China [30770651, 30670616,
   30370441]; National Institutes of Health; National Aeronautics and Space
   Administration USA [GM080771, NNX07AT40G]
FX We thank Drs. Levine and Lavin for providing the cell lines. We thank
   Brookhaven National Laboratory support group for helping with high LET
   irradiation. We thank Doreen Theune for editing this manuscript. This
   work is supported by grants from the National Basic Research Program of
   China (2005CB522506 and 2007CB914604 to B. H.), the National Natural
   Science Foundation of China (30770651, 30670616 and 30370441 to B. H.),
   and the grants from the National Institutes of Health and from National
   Aeronautics and Space Administration USA (GM080771 and NNX07AT40G to
   Y.W.).
CR Argiro L, 2001, GENOMICS, V74, P342, DOI 10.1006/geno.2001.6553
   Brown EJ, 2003, GENE DEV, V17, P615, DOI 10.1101/gad.1067403
   Hu BC, 2005, CANCER RES, V65, P8613, DOI 10.1158/0008 5472.CAN 05 1966
   Hu BC, 2005, J CELL PHYSIOL, V202, P518, DOI 10.1002/jcp.20139
   Hu BC, 2001, J BIOL CHEM, V276, P17693, DOI 10.1074/jbc.M009340200
   Liu QH, 2000, GENE DEV, V14, P1448
   Liu S, 2009, NUCLEIC ACIDS RES, V37, P7447, DOI 10.1093/nar/gkp768
   MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151
   Petersen DN, 2000, J BIOL CHEM, V275, P36172, DOI 10.1074/jbc.M003622200
   Rowe PSN, 2000, GENOMICS, V67, P54, DOI 10.1006/geno.2000.6235
   Sorensen CS, 2005, NAT CELL BIOL, V7, P195, DOI 10.1038/ncb1212
   Wang HC, 2003, RADIAT RES, V159, P420, DOI 10.1667/0033 7587(2003)159[0420:CCNESH]2.0.CO;2
   Wang HY, 2008, CELL CYCLE, V7, P2444, DOI 10.4161/cc.6552
   Wang HY, 2008, DNA REPAIR, V7, P725, DOI 10.1016/j.dnarep.2008.01.010
   Wang HY, 2009, INT J RADIAT ONCOL, V74, P1236, DOI 10.1016/j.ijrobp.2008.12.089
   Wang HY, 2009, CELL CYCLE, V8, P1451, DOI 10.4161/cc.8.9.8241
   Wang HY, 2005, CELL CYCLE, V4, P300
   Wang HY, 2004, CANCER RES, V64, P7139, DOI 10.1158/0008 5472.CAN 04 1289
   Wang JL, 2002, CELL CYCLE, V1, P267, DOI 10.4161/cc.1.4.137
   Wang JL, 2000, CANCER RES, V60, P1498
   Wang X, 2003, J BIOL CHEM, V278, P30869, DOI 10.1074/jbc.M301876200
   ZHANG P, 2010, BR J CANC
   Zhao H, 2002, P NATL ACAD SCI USA, V99, P14795, DOI 10.1073/pnas.182557299
   Zhou XY, 2002, CANCER RES, V62, P1598
NR 24
TC 3
Z9 5
U1 0
U2 14
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA
SN 1538 4101
J9 CELL CYCLE
JI Cell Cycle
PD MAY 15
PY 2010
VL 9
IS 10
BP 1981
EP 1985
DI 10.4161/cc.9.10.11651
PG 5
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA 600VB
UT WOS:000278015900026
PM 20436300
OA Bronze, Green Accepted
DA 2025 08 17
ER

PT J
AU Honig, A
   Rieger, L
   Kapp, M
   Krockenberger, M
   Eck, M
   Dietl, J
   Kämmerer, U
AF Honig, A.
   Rieger, L.
   Kapp, M.
   Krockenberger, M.
   Eck, M.
   Dietl, J.
   Kaemmerer, U.
TI Increased tartrate resistant acid phosphatase (TRAP) expression in
   malignant breast, ovarian and melanoma tissue:: an investigational study
SO BMC CANCER
LA English
DT Article
ID SERUM MARKER; CANCER PATIENTS; BONE; 5B; LOCALIZATION; DISEASE;
   OSTEOPETROSIS; METASTASIS; CELLS
AB Background: Tartrate resistant acid phosphatase (TRAP) is a metalloprotein enzyme that belongs to the acid phosphatases and is known to be expressed by osteoclasts. It has already been investigated as a marker of bone metastases in cancer patients. In this study, which examined the value of serum TRAP concentrations as a marker of bone disease in breast cancer patients, we observed high concentrations of TRAP even in patients without bone metastases. To elucidate this phenomenon, we examined the expression of TRAP in breast cancer cells and the cells of several other malignancies.
   Methods: TRAP concentrations in the serum of tumor patients were determined by ELISA. The expression of TRAP in breast, ovarian, and cervical cancer and malignant melanoma was analyzed by immunohistochemistry. RT PCR and immunocytology were used to evaluate TRAP expression in cultured tumor cells.
   Results: A marked increase in serum TRAP concentrations was observed in patients with breast and ovarian cancer, regardless of the presence or absence of bone disease. TRAP expression was found in breast and ovarian cancers and malignant melanoma, while cervical cancer showed only minimal expression of TRAP. Expression of TRAP was absent in benign tissue or was much less marked than in the corresponding malignant tissue. TRAP expression was also demonstrated in cultured primary cancer cells and in commercially available cell lines.
   Conclusion: Overexpression of TRAP was detected in the cells of various different tumors. TRAP might be useful as a marker of progression of malignant disease. It could also be a potential target for future cancer therapies.
C1 Univ Wurzburg, Dept Obstet & Gynecol, D 97070 Wurzburg, Germany.
   Univ Wurzburg, Dept Pathol, D 97070 Wurzburg, Germany.
C3 University of Wurzburg; University of Wurzburg
RP Honig, A (通讯作者)，Univ Wurzburg, Dept Obstet & Gynecol, D 97070 Wurzburg, Germany.
EM arnd_hoenig@hotmail.com; lrieger@gmx.de; M.Kapp@mail.uni wuerzburg.de;
   matze.krock@web.de; Matth.Eck@gmx.de;
   frauenklinik@mail.uni wuerzburg.de; FRAK057@mail.UNI wuerzburg.de
CR Alatalo SL, 2004, CLIN CHEM, V50, P883, DOI 10.1373/clinchem.2003.029355
   Bull H, 2002, J CLIN PATHOL MOL PA, V55, P65
   Cabera Salazar MA, 2004, CLIN CHIM ACTA, V344, P101, DOI 10.1016/j.cccn.2004.02.018
   CALVO F, 1984, CANCER RES, V44, P4553
   Chao TY, 2005, CLIN CANCER RES, V11, P544
   Chen CJ, 2004, J PEDIAT HEMATOL ONC, V26, P5, DOI 10.1097/00043426 200401000 00003
   Halleen JM, 2001, CLIN CHEM, V47, P597
   Hayman AR, 2000, J HISTOCHEM CYTOCHEM, V48, P219, DOI 10.1177/002215540004800207
   Janckila AJ, 2005, J LEUKOCYTE BIOL, V77, P209, DOI 10.1189/jlb.0504287
   Janckila AJ, 2003, J BONE MINER RES, V18, P1916, DOI 10.1359/jbmr.2003.18.10.1916
   Janckila AJ, 1996, HISTOCHEM J, V28, P195, DOI 10.1007/BF02331443
   Koizumi M, 2002, ANN NUCL MED, V16, P161, DOI 10.1007/BF02996296
   Mose S, 2003, ANTICANCER RES, V23, P2783
   Nakano Y, 2004, J HISTOCHEM CYTOCHEM, V52, P1475, DOI 10.1369/jhc.4A6378.2004
   NGUYEN M, 1991, ANTICANCER RES, V11, P831
   Terpos E, 2003, INT J CANCER, V106, P455, DOI 10.1002/ijc.11247
   Yam LT, 2003, J BONE MINER RES, V18, P1894, DOI 10.1359/jbmr.2003.18.10.1894
NR 17
TC 26
Z9 30
U1 0
U2 4
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471 2407
J9 BMC CANCER
JI BMC Cancer
PD JUL 25
PY 2006
VL 6
AR 199
DI 10.1186/1471 2407 6 199
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 074XA
UT WOS:000239843900001
PM 16869970
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Petropoulou, K
   Platania, V
   Chatzinikolaidou, M
   Mitraki, A
AF Petropoulou, Katerina
   Platania, Varvara
   Chatzinikolaidou, Maria
   Mitraki, Anna
TI A Doubly Fmoc Protected Aspartic Acid Self Assembles into Hydrogels
   Suitable for Bone Tissue Engineering
SO MATERIALS
LA English
DT Article
DE fluorenyl methoxycarbonyl (Fmoc); self assembly; amyloid fibrils;
   injectable hydrogel; composite; calcium ion binding; building block;
   single amino acid; osteogenesis; biomineralization
ID OSTEOBLAST DIFFERENTIATION; OSTEOGENIC DIFFERENTIATION; AMINO ACIDS;
   IN VIVO; SCAFFOLDS; BIOMATERIALS; PEPTIDES; MATRIX; HYDROXYAPATITE;
   IMMOBILIZATION
AB Hydrogels have been used as scaffolds for biomineralization in tissue engineering and regenerative medicine for the repair and treatment of many tissue types. In the present work, we studied an amino acid based material that is attached to protecting groups and self assembles into biocompatible and stable nanostructures that are suitable for tissue engineering applications. Specifically, the doubly protected aspartic residue (Asp) with fluorenyl methoxycarbonyl (Fmoc) protecting groups have been shown to lead to the formation of well ordered fibrous structures. Many amino acids and small peptides which are modified with protecting groups display relatively fast self assembly and exhibit remarkable physicochemical properties leading to three dimensional (3D) networks, the trapping of solvent molecules, and forming hydrogels. In this study, the self assembling fibrous structures are targeted toward calcium binding and act as nucleation points for the binding of the available phosphate groups. The cell viability, proliferation, and osteogenic differentiation of pre osteoblastic cells cultured on the formed hydrogel under various conditions demonstrate that hydrogel formation in CaCl2 and CaCl2 Na2HPO4 solutions lead to calcium ion binding onto the hydrogels and enrichment with phosphate groups, respectively, rendering these mechanically stable hydrogels osteoinductive scaffolds for bone tissue engineering.
C1 [Petropoulou, Katerina] Univ Crete, Dept Biol, Iraklion 70013, Greece.
   [Platania, Varvara; Chatzinikolaidou, Maria; Mitraki, Anna] Univ Crete, Dept Mat Sci & Technol, Iraklion 70013, Greece.
   [Chatzinikolaidou, Maria; Mitraki, Anna] Fdn Res & Technol Hellas FORTH, Inst Elect Struct & Laser IESL, Iraklion 70013, Greece.
C3 University of Crete; University of Crete
RP Chatzinikolaidou, M; Mitraki, A (通讯作者)，Univ Crete, Dept Mat Sci & Technol, Iraklion 70013, Greece.; Chatzinikolaidou, M; Mitraki, A (通讯作者)，Fdn Res & Technol Hellas FORTH, Inst Elect Struct & Laser IESL, Iraklion 70013, Greece.
EM mchatzin@materials.uoc.gr; mitraki@materials.uoc.gr
RI Chatzinikolaidou, Maria/H 1061 2014
OI Chatzinikolaidou, Maria/0000 0002 2749 2506; Platania,
   Varvara/0000 0002 8273 4619
CR Adams DJ, 2010, SOFT MATTER, V6, P1971, DOI 10.1039/b921863g
   Alshehri S, 2021, BIOMACROMOLECULES, V22, P2094, DOI 10.1021/acs.biomac.1c00205
   Amosi N, 2012, ACTA BIOMATER, V8, P2466, DOI 10.1016/j.actbio.2012.04.003
   Blair HC, 2017, TISSUE ENG PART B RE, V23, P268, DOI [10.1089/ten.teb.2016.0454, 10.1089/ten.TEB.2016.0454]
   Bongiovanni MN, 2011, BIOMATERIALS, V32, P6099, DOI 10.1016/j.biomaterials.2011.05.021
   Bradshaw A D., 2020, Principles of Tissue Engineering, V5, P205, DOI [10.1016/B978 0 12 818422 6.00013 7, DOI 10.1016/B978 0 12 818422 6.00013 7]
   Chakraborty P, 2018, CHEMNANOMAT, V4, P730, DOI 10.1002/cnma.201800147
   Chang SA, 2022, GELS BASEL, V8, DOI 10.3390/gels8110745
   Chao L, 2021, FRONT BIOENG BIOTECH, V9, DOI 10.3389/fbioe.2021.779854
   Das S, 2018, BIOMACROMOLECULES, V19, P1826, DOI 10.1021/acs.biomac.8b00279
   El Boujaady H., 2016, J. Mater. Environ. Sci, V7, P4049
   Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044
   Florencio Silva R, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/421746
   Franz Odendaal TA, 2006, DEV DYNAM, V235, P176, DOI 10.1002/dvdy.20603
   Ghosh M, 2019, NANOMATERIALS BASEL, V9, DOI 10.3390/nano9040497
   Ghosh M, 2017, BIOMACROMOLECULES, V18, P3541, DOI 10.1021/acs.biomac.7b00876
   Gitelman A, 2014, LANGMUIR, V30, P4716, DOI 10.1021/la500310n
   Gras SL, 2008, BIOMATERIALS, V29, P1553, DOI 10.1016/j.biomaterials.2007.11.028
   Gruening M, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.01016
   Guilak F, 2005, ANN BIOMED ENG, V33, P1312, DOI 10.1007/s10439 005 4479 7
   Halperin Sternfeld M, 2023, J CLIN PERIODONTOL, V50, P200, DOI 10.1111/jcpe.13725
   Hartgerink JD, 2002, P NATL ACAD SCI USA, V99, P5133, DOI 10.1073/pnas.072699999
   Jafari M, 2020, INT J PHARMACEUT, V576, DOI 10.1016/j.ijpharm.2019.118959
   Jayawarna V, 2006, ADV MATER, V18, P611, DOI 10.1002/adma.200501522
   Kavasi RM, 2021, NANOMATERIALS BASEL, V11, DOI 10.3390/nano11051152
   Khanarian NT, 2012, TISSUE ENG PT A, V18, P533, DOI [10.1089/ten.tea.2011.0279, 10.1089/ten.TEA.2011.0279]
   Kim SE, 2008, J MATER CHEM, V18, P4994, DOI 10.1039/b810328c
   Kim S, 2015, SMALL, V11, P3623, DOI 10.1002/smll.201500169
   Kirkham J, 2007, J DENT RES, V86, P426, DOI 10.1177/154405910708600507
   Lee EJ, 2014, ANN BIOMED ENG, V42, P323, DOI 10.1007/s10439 013 0859 6
   Li JL, 2019, SOFT MATTER, V15, P1704, DOI 10.1039/c8sm02573h
   Loo Y, 2015, ADV HEALTHC MATER, V4, P2557, DOI 10.1002/adhm.201500402
   Mahler A, 2006, ADV MATER, V18, P1365, DOI 10.1002/adma.200501765
   Maidaniuc A, 2018, APPL SURF SCI, V438, P158, DOI 10.1016/j.apsusc.2017.07.074
   Makvandi P, 2020, MAT SCI ENG C MATER, V107, DOI 10.1016/j.msec.2019.110195
   Miculescu F, 2018, APPL SURF SCI, V438, P147, DOI 10.1016/j.apsusc.2017.07.144
   Morris A., 2016, MEASUREMENT INSTRUME, P45
   Orbach R, 2012, LANGMUIR, V28, P2015, DOI 10.1021/la204426q
   Orbach R, 2009, BIOMACROMOLECULES, V10, P2646, DOI 10.1021/bm900584m
   Osathanon T, 2009, BIOMATERIALS, V30, P4513, DOI 10.1016/j.biomaterials.2009.05.022
   Parkatzidis K, 2019, ACS BIOMATER SCI ENG, V5, P6161, DOI 10.1021/acsbiomaterials.9b01300
   Phogat K, 2023, J APPL POLYM SCI, V140, DOI 10.1002/app.53362
   Qu HW, 2019, RSC ADV, V9, P26252, DOI 10.1039/c9ra05214c
   Racquel Z., 1991, MONOGR ORAL SCI, V15, P88
   Reynolds NP, 2014, BIOMACROMOLECULES, V15, P599, DOI 10.1021/bm401646x
   Rougerie P, 2021, APPL SCI BASEL, V11, DOI 10.3390/app11041791
   Ruhé PQ, 2005, J CONTROL RELEASE, V106, P162, DOI 10.1016/j.jconrel.2005.04.018
   Rutkovskiy A, 2016, MED SCI MONIT BASIC, V22, P95, DOI 10.12659/MSMBR.901142
   Ryan DM, 2012, POLYM CHEM UK, V3, P18, DOI 10.1039/c1py00335f
   Sarker B, 2017, ACS BIOMATER SCI ENG, V3, P1730, DOI 10.1021/acsbiomaterials.7b00188
   Scanlon S, 2008, NANO TODAY, V3, P22, DOI 10.1016/S1748 0132(08)70041 0
   Segman Magidovich S, 2008, ADV MATER, V20, P2156, DOI 10.1002/adma.200702125
   Siffert R. S., 1951, Journal of Experimental Medicine, V93, P415, DOI 10.1084/jem.93.5.415
   Spalazzi JP, 2008, J BIOMED MATER RES A, V86A, P1, DOI 10.1002/jbm.a.32073
   Stolz M, 2009, NAT NANOTECHNOL, V4, P186, DOI [10.1038/NNANO.2008.410, 10.1038/nnano.2008.410]
   Stupp SI, 2005, MRS BULL, V30, P546, DOI 10.1557/mrs2005.148
   Tao K, 2016, CHEM SOC REV, V45, P3935, DOI 10.1039/c5cs00889a
   Terzaki K, 2013, BIOFABRICATION, V5, DOI 10.1088/1758 5082/5/4/045002
   Veis A, 2013, CALCIFIED TISSUE INT, V93, P307, DOI 10.1007/s00223 012 9678 2
   Wasupalli GK, 2020, MAT SCI ENG C MATER, V107, DOI 10.1016/j.msec.2019.110343
   Winkler T, 2018, BONE JOINT RES, V7, P232, DOI 10.1302/2046 3758.73.BJR 2017 0270.R1
   Wu XC, 2021, ADV HEALTHC MATER, V10, DOI 10.1002/adhm.202001101
   Zhang K, 2018, BONE RES, V6, DOI 10.1038/s41413 018 0032 9
   Zhao FL, 2015, NANOMATERIALS BASEL, V5, P2054, DOI 10.3390/nano5042054
NR 64
TC 4
Z9 4
U1 0
U2 16
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1996 1944
J9 MATERIALS
JI Materials
PD DEC
PY 2022
VL 15
IS 24
AR 8928
DI 10.3390/ma15248928
PG 17
WC Chemistry, Physical; Materials Science, Multidisciplinary; Metallurgy &
   Metallurgical Engineering; Physics, Applied; Physics, Condensed Matter
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Materials Science; Metallurgy & Metallurgical Engineering;
   Physics
GA 7H2TX
UT WOS:000903060700001
PM 36556733
OA Green Accepted, gold
DA 2025 08 17
ER

PT J
AU Wang, J
   Song, SJ
   Shi, L
   Zhu, Q
   Ma, CC
   Tan, XQ
   Ding, Y
   Niu, ZY
AF Wang, Jing
   Song, Shujun
   Shi, Liang
   Zhu, Qiang
   Ma, Chuanchuan
   Tan, Xiaoqing
   Ding, Yin
   Niu, Zhongying
TI Temporal Expression of Pelp1 during Proliferation and Osteogenic
   Differentiation of Rat Bone Marrow Mesenchymal Stem Cells
SO PLOS ONE
LA English
DT Article
ID ESTROGEN RECEPTOR; BREAST CANCER; ER ALPHA; GENE EXPRESSION;
   OSTEOBLASTS; PROTEIN; BETA; MNAR; ACTIVATION; RESISTANCE
AB Background: Osteogenic induction and bone formation are heavily affected by environmental factors, including estrogen, estrogen receptors, and coregulatory proteins, such as the recently reported proline , glutamic acid , and leucine rich protein 1(Pelp1).
   Objective: To investigate Pelp1 expression in rat bone mesenchymal stem cells (rBMSCs) during cell proliferation and osteogenic differentiation.
   Methods: rBMSCs were cultured in routine and osteogenic differentiation media. Cell proliferation was assessed at days 1, 3, 5, 7, 9, 11, 14, and 21. Pelp1 protein expression in the nucleus and cytoplasm were detected by immunocytochemical analysis. Real time RT PCR and western blot were used to detect mRNA and protein expressions of Pelp1, osteocalcin (OCN), and alkaline phosphatase (ALP).
   Results: Over 21 days, rBMSCs in routine culture exhibited a 1 2 day lag phase and exponential growth from day 3 to 9, plateauing at day 9, and correlated with temporal mRNA expression of Pelp1, which almost reached baseline levels at day 21. In osteogenic induction cultures, Pelp1 mRNA levels rose at day 9 and steadily increased until day 21, reaching 6.8 fold greater value compared with day 1. Interestingly, Pelp1 mRNA expression in osteogenic cultures exhibited a trend similar to that of OCN expression. Pelp1 knockdown by siRNA transfection inhibited undifferentiated rBMSC proliferation, and bone markers OCN and ALP expressions in rBMSCs cultured in routine and osteogenic differentiation media.
   Conclusions: Pelp1 may be a key player in BMSCs proliferation and osteogenic differentiation, meriting further consideration as a target for development of therapies for pathological bone loss conditions, such as menopausal bone loss.
C1 [Wang, Jing; Ding, Yin] Forth Mil Med Univ, Coll Stomatol, Dept Orthodont, Xian, Peoples R China.
   [Song, Shujun; Tan, Xiaoqing] 306 Hosp PLA, Dept Pathol & Expt Med, Beijing, Peoples R China.
   [Shi, Liang; Ma, Chuanchuan; Niu, Zhongying] 306 Hosp PLA, Dept Stomatol, Beijing, Peoples R China.
   [Zhu, Qiang] Gen Hosp Peoples Liberat Army, Dept Urol, Beijing, Peoples R China.
C3 Air Force Medical University
RP Ding, Y (通讯作者)，Forth Mil Med Univ, Coll Stomatol, Dept Orthodont, Xian, Peoples R China.
EM dingyin.fmmu@gmail.com; zhongying.niu@gmail.com
RI Tan, Xiaoqing/H 8470 2015
FU 306th Hospital of the People's Liberation Army (PLA)
FX The authors gratefully acknowledge the support of the 306th Hospital of
   the People's Liberation Army (PLA). We thank the staff in the Center of
   Pathology and Experimental Medicine of the 306th Hospital of PLA for
   their skills, knowledge, and advice.
CR Asumda FZ, 2011, BMC CELL BIOL, V12, DOI 10.1186/1471 2121 12 44
   Barletta F, 2004, MOL ENDOCRINOL, V18, P1096, DOI 10.1210/me.2003 0335
   Bennani Baiti IM, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3249
   Bord S, 2003, BONE, V32, P136, DOI 10.1016/S8756 3282(02)00953 5
   Bowring C E, 2011, Menopause Int, V17, P63, DOI 10.1258/mi.2011.011012
   Brann DW, 2008, MOL CELL ENDOCRINOL, V290, P2, DOI 10.1016/j.mce.2008.04.019
   Brennan O, 2012, HORM METAB RES, V44, P47, DOI 10.1055/s 0031 1291358
   Centrella M, 2012, STEROIDS, V77, P174, DOI 10.1016/j.steroids.2011.10.016
   Cheskis BJ, 2008, STEROIDS, V73, P901, DOI 10.1016/j.steroids.2007.12.028
   Chimutengwende Gordon M, 2012, CURR STEM CELL RES T, V7, P122, DOI 10.2174/157488812799219036
   Delorme B, 2008, BLOOD, V111, P2631, DOI 10.1182/blood 2007 07 099622
   Derubeis AR, 2004, ANN BIOMED ENG, V32, P160, DOI 10.1023/B:ABME.0000007800.89194.95
   Dobrzycka KM, 2003, ENDOCR RELAT CANCER, V10, P517, DOI 10.1677/erc.0.0100517
   Grivas PD, 2009, CELL ONCOL, V31, P235, DOI 10.3233/CLO 2009 0467
   Hongo Hiromi, 2011, Clin Calcium, V21, P63, DOI CliCa111116471654
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Meyer MR, 2009, MOL CELL ENDOCRINOL, V308, P9, DOI 10.1016/j.mce.2009.03.009
   Mishra SK, 2004, GENE, V330, P115, DOI 10.1016/j.gene.2004.01.011
   Pawlak J, 2005, CELL TISSUE RES, V320, P545, DOI 10.1007/s00441 005 1090 z
   Shi H, 2010, ANAL CHEM, V82, P2213, DOI 10.1021/ac902417s
   Smuc T, 2009, MOL CELL ENDOCRINOL, V301, P59, DOI 10.1016/j.mce.2008.07.020
   Song RXD, 2005, TRENDS ENDOCRIN MET, V16, P347, DOI 10.1016/j.tem.2005.06.010
   Toran Allerand CD, 2004, EXP GERONTOL, V39, P1579, DOI 10.1016/j.exger.2004.05.006
   Vadlamudi RK, 2005, HUM PATHOL, V36, P670, DOI 10.1016/j.humpath.2005.03.016
   Vadlamudi RK, 2007, NUCL RECEPT SIGNAL, V5
   Wang N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043768
   Xiao Y, 2010, INT J ORAL SCI, V2, P127, DOI 10.4248/IJOS10045
   Yildirim M, 2011, BRAIN RES, V1379, P98, DOI 10.1016/j.brainres.2010.07.053
   Zilli M, 2009, BBA REV CANCER, V1795, P62, DOI 10.1016/j.bbcan.2008.08.003
NR 29
TC 8
Z9 11
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD OCT 16
PY 2013
VL 8
IS 10
AR e75477
DI 10.1371/journal.pone.0075477
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 239JR
UT WOS:000326019400007
PM 24146754
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

EF